FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Zhou, RP
   Lin, SJ
   Wan, WB
   Zuo, HL
   Yao, FF
   Ruan, HB
   Xu, J
   Song, W
   Zhou, YC
   Wen, SY
   Dai, JH
   Zhu, ML
   Luo, J
AF Zhou, Rong Ping
   Lin, Si Jian
   Wan, Wen Bing
   Zuo, Hui Ling
   Yao, Fen Fen
   Ruan, Hui Bing
   Xu, Jin
   Song, Wei
   Zhou, Yi Cheng
   Wen, Shi Yao
   Dai, Jiang Hua
   Zhu, Mei Lan
   Luo, Jun
TI Chlorogenic Acid Prevents Osteoporosis by Shp2/PI3K/Akt Pathway in
   Ovariectomized Rats
SO PLOS ONE
LA English
DT Article
ID EUCOMMIA ULMOIDES OLIV.; OVX INDUCED OSTEOPOROSIS; BONE LOSS;
   ANTIOXIDANT ACTIVITY; POSTMENOPAUSAL OSTEOPOROSIS; PHENOLIC COMPOUNDS;
   TISSUE METABOLISM; OXIDATIVE STRESS; CONTROLLED TRIAL; ESTROGEN
AB Cortex Eucommiae is used worldwide in traditional medicine, various constituents of Cortex Eucommiae, such as chlorogenic acid (CGA), has been reported to exert anti osteoporosis activity in China, but the mechanism about their contribution to the overall activity is limited. The aims of this study were to determine whether chlorogenic acid can prevent estrogen deficiency induced osteoporosis and to analyze the mechanism of CGA bioactivity. The effect of CGA on estrogen deficiency induced osteoporosis was performed in vivo. Sixty female Sprague Dawley rats were divided randomly among a sham operated group and five ovariectomy (OVX) plus treatment subgroups: saline vehicle, 17 alpha ethinylestradiol (E2), or CGA at 9, 27, or 45 mg/kg/d. The rats' femoral metaphyses were evaluated by microcomputed tomography (mu CT). The mechanism of CGA bioactivity was investigated in vitro. Bone mesenchymal stem cells (BMSCs) were treated with CGA, with or without phosphoinositide 3 kinase (PI3K) inhibitor LY294002. BMSCs proliferation and osteoblast differentiation were assessed with 3 (4,5 dimethyl 2 thiazolyl) 2,5 diphenyl 2 H tetrazolium bromide (MTT) and alkaline phosphatase, with or without Shp2 interfering RNA (RNAi). The results display that CGA at 27 and 45 mg/kg/day inhibited the decrease of bone mineral density (BMD) that induced by OVX in femur (p<0.01), significantly promoted the levels of bone turnover markers, and prevented bone volume fraction (BV/TV), connectivity density (CoonD), trabecular number (Tb. N), trabecular thickness (Tb. Th) (all p<0.01) to decrease and prevented the trabecular separation (Tb. Sp), structure model index (SMI)(both p<0.01) to increase. CGA at 1 or 10 mu M enhanced BMSC proliferation in a dose dependent manner. CGA at 0.1 to 10 mu M increased phosphorylated Akt (p Akt) and cyclin D1. These effects were reversed by LY294002. CGA at 1 or 10 mu M increased BMSC differentiation to osteoblasts (p<0.01), Shp2 RNAi suppressed CGA induced osteoblast differentiation by decreasing Shp2, p Akt, and cyclin D1. This study found that CGA improved the BMD and trabecular micro architecture for the OVX induced osteoporosis. Therefore, CGA might be an effective alternative treatment for postmenopausal osteoporosis. CGA promoted proliferation of osteoblast precursors and osteoblastic differentiation of BMSCs via the Shp2/PI3K/ Akt/cyclin D1 pathway.
C1 [Zhou, Rong Ping; Wan, Wen Bing; Ruan, Hui Bing; Xu, Jin; Song, Wei; Zhou, Yi Cheng; Wen, Shi Yao] NanChang Univ, Affiliated Hosp 2, Dept Orthopaed, Nanchang, Jiangxi, Peoples R China.
   [Zhou, Rong Ping; Lin, Si Jian; Dai, Jiang Hua; Zhu, Mei Lan; Luo, Jun] Regenerat & Rehabil Engn Res Inst Bone & Nerve Ji, Nanchang, Jiangxi, Peoples R China.
   [Zhou, Rong Ping; Wan, Wen Bing; Ruan, Hui Bing; Xu, Jin; Song, Wei; Zhou, Yi Cheng; Wen, Shi Yao; Luo, Jun] NanChuang Univ, Orthopaed Res Inst Jiangxi, Nanchang, Jiangxi, Peoples R China.
   [Lin, Si Jian; Zuo, Hui Ling; Yao, Fen Fen; Dai, Jiang Hua; Zhu, Mei Lan; Luo, Jun] NanChang Univ, Affiliated Hosp 2, Rehabil Dept, Nanchang, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University
RP Zhou, RP (通讯作者)，NanChang Univ, Affiliated Hosp 2, Dept Orthopaed, Nanchang, Jiangxi, Peoples R China.; Zhou, RP; Luo, J (通讯作者)，Regenerat & Rehabil Engn Res Inst Bone & Nerve Ji, Nanchang, Jiangxi, Peoples R China.; Zhou, RP; Luo, J (通讯作者)，NanChuang Univ, Orthopaed Res Inst Jiangxi, Nanchang, Jiangxi, Peoples R China.; Luo, J (通讯作者)，NanChang Univ, Affiliated Hosp 2, Rehabil Dept, Nanchang, Jiangxi, Peoples R China.
EM rong8618241@126.com; Luojun1786@163.com
RI zhou, yicheng/MGW 2971 2025
FU National Natural Science Foundation of China [81160508, 81260401,
   81460342]; Natural Science Foundation of Jiangxi Province [GZY0170]
FX This work was supported by National Natural Science Foundation of China
   (No: 81160508, 81260401, 81460342) and the Natural Science Foundation of
   Jiangxi Province (No: GZY0170).
CR Allen AJ, 2002, J CLIN PSYCHIAT, V63, P44
   Andia DC, 2008, HISTOL HISTOPATHOL, V23, P1177, DOI 10.14670/HH 23.1177
   [Anonymous], 2014, J BOT
   Arjmandi BH, 1998, AM J CLIN NUTR, V68, p1364S, DOI 10.1093/ajcn/68.6.1364S
   AVIOLI LV, 1965, J CLIN ENDOCR METAB, V25, P912, DOI 10.1210/jcem 25 7 912
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Brezinski A., 1999, EUR J OBSTET GYN R B, V85, P47, DOI DOI 10.1016/S0301 2115(98)00281 4
   Bunin DI, 2013, RADIAT RES, V179, P171, DOI 10.1667/RR3115.1
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Castelo Branco C, 2013, GYNECOL ENDOCRINOL, V29, P735, DOI 10.3109/09513590.2013.801441
   Chang KL, 2013, NUTRITION, V29, P250, DOI 10.1016/j.nut.2012.03.009
   Cheng XG, 2007, J CLIN DENSITOM, V10, P276, DOI 10.1016/j.jocd.2007.05.004
   Dang ZC, 2002, J BONE MINER RES, V17, P394, DOI 10.1359/jbmr.2002.17.3.394
   Eklund PC, 2005, ORG BIOMOL CHEM, V3, P3336, DOI 10.1039/b506739a
   FERRETTI JL, 1990, BONE MINER, V11, P111, DOI 10.1016/0169 6009(90)90020 G
   Gatti D, 2011, J CLIN ENDOCR METAB, V96, P1555, DOI 10.1210/jc.2010 2552
   Geng WX, 2013, BIOCHEM BIOPH RES CO, V434, P280, DOI 10.1016/j.bbrc.2013.02.116
   Hassan HA, 2013, CYTOTECHNOLOGY, V65, P609, DOI 10.1007/s10616 012 9514 6
   Ho SC, 2007, MENOPAUSE, V14, P905, DOI 10.1097/gme.0b013e318032b2d3
   Horcajada Molteni MN, 2000, J BONE MINER RES, V15, P2251, DOI 10.1359/jbmr.2000.15.11.2251
   Hsieh CL, 2000, LIFE SCI, V66, P1387, DOI 10.1016/S0024 3205(00)00450 1
   Huber Florian, 2003, Clin Lab, V49, P203
   Hunyadi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050619
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Iolascon G, 2013, CLIN CASES MINER BON, V10, P47, DOI 10.11138/ccmbm/2013.10.1.047
   Jilka RL, 1998, J CLIN INVEST, V101, P1942, DOI 10.1172/JCI1039
   Alonso Castro AJ, 2015, J ETHNOPHARMACOL, V175, P335, DOI 10.1016/j.jep.2015.09.029
   Kähkönen MP, 1999, J AGR FOOD CHEM, V47, P3954, DOI 10.1021/jf990146l
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kamiyama M, 2015, J AGR FOOD CHEM, V63, P1996, DOI 10.1021/jf5060563
   Khajuria DK, 2014, J ORTHOP SCI, V19, P646, DOI 10.1007/s00776 014 0557 8
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim MK, 2002, CLIN ENDOCRINOL, V56, P321, DOI 10.1046/j.1365 2265.2002.01470.x
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Lee MK, 2007, BIOL PHARM BULL, V30, P814, DOI 10.1248/bpb.30.814
   Lee MK, 2005, J MED FOOD, V8, P86, DOI 10.1089/jmf.2005.8.86
   Li BJ, 2011, J CELL BIOCHEM, V112, P1229, DOI 10.1002/jcb.23049
   LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003 4819 117 1 1
   Luo JY, 2009, J ENZYM INHIB MED CH, V24, P1280, DOI 10.3109/14756360902829741
   Mattsson C, 2007, CURR MED CHEM, V14, P2918, DOI 10.2174/092986707782359972
   Medical Advisory Secretariat, 2006, Ont Health Technol Assess Ser, V6, P1
   MEYERSABELLEK W, 1988, J CHROMATOGR BIOMED, V429, P419, DOI 10.1016/S0378 4347(00)83881 5
   Omsland TK, 2014, OSTEOPOROSIS INT, V25, P2493, DOI 10.1007/s00198 014 2781 7
   Rachidi Mouna, 2008, Journal de la Societe de Biologie, V202, P265, DOI 10.1051/jbio:2008035
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rakshit S, 2010, BIOCHEM PHARMACOL, V80, P1662, DOI 10.1016/j.bcp.2010.08.013
   Rendina E, 2012, J NUTR BIOCHEM, V23, P60, DOI 10.1016/j.jnutbio.2010.10.010
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Ro SC, 2007, MENOPAUSE, V14, P489, DOI 10.1097/gme.0b013e31802v4f4f
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Rufus P, 2013, CURR DRUG TARGETS, V14, P1689, DOI 10.2174/1389450114666131220160357
   Seidlova Wuttke D, 2008, BONE, V43, P849, DOI 10.1016/j.bone.2008.07.237
   Sontakke A, 2002, CLIN CHIM ACTA, V318, P145, DOI 10.1016/S0009 8981(01)00766 5
   Tchernof A, 1998, OBES RES, V6, P246, DOI 10.1002/j.1550 8528.1998.tb00344.x
   Teixeira S, 2005, FREE RADICAL BIO MED, V39, P1099, DOI 10.1016/j.freeradbiomed.2005.05.028
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   WRONSKI TJ, 1989, ENDOCRINOLOGY, V125, P810, DOI 10.1210/endo 125 2 810
   Wu CJ, 2001, ONCOGENE, V20, P6018, DOI 10.1038/sj.onc.1204699
   Xu ZS, 2010, J AGR FOOD CHEM, V58, P7289, DOI 10.1021/jf100304t
   Yin J, 2006, PHYTOMEDICINE, V13, P37, DOI 10.1016/j.phymed.2004.06.017
   Zhang G, 2006, BONE, V38, P818, DOI 10.1016/j.bone.2005.11.019
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
   Zhao Q, 2013, CALCIFIED TISSUE INT, V93, P172, DOI 10.1007/s00223 013 9739 1
   Zheng J, 2012, INDIAN J EXP BIOL, V50, P875
   Zhu HM, 2012, MOLECULES, V17, P8001, DOI 10.3390/molecules17078001
   Zito CI, 2004, J CELL PHYSIOL, V199, P227, DOI 10.1002/jcp.10446
NR 66
TC 69
Z9 80
U1 1
U2 46
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 29
PY 2016
VL 11
IS 12
AR e0166751
DI 10.1371/journal.pone.0166751
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EG7KQ
UT WOS:000391226900007
PM 28033335
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Sohn, HM
   Ko, Y
   Park, M
   Kim, B
   Park, JE
   Kim, D
   Moon, YL
   Lim, W
AF Sohn, Hong Moon
   Ko, Youngjong
   Park, Mineon
   Kim, Bora
   Park, Jung Eun
   Kim, Donghwi
   Moon, Young Lae
   Lim, Wonbong
TI Comparison of the alendronate and irradiation with a light emitting
   diode (LED) on murine osteoclastogenesis
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Osteoporosis; LED; ROS; Osteoclastogenesis
ID LEVEL LASER THERAPY; BONE RESORPTION; OXIDATIVE STRESS; IN VITRO;
   DIFFERENTIATION; CELLS; ACTIVATION; PROLIFERATION; INHIBITION; DISORDERS
AB Photomodulation therapy (PBMT) using light emitting diode (LED) has been proposed as an alternative to conventional osteoporosis therapies. Our aim was to determine the effect of irradiation with a light emitting diode on receptor activator of NF kappa B ligand (RANKL) mediated differentiation of mouse bone marrow macrophages into osteoclasts and compare it to alendronate treatment. The cells were irradiated with LED at 635 +/  10 nm, 9 cm spot size, 5 mW/cm(2), and 18 J for 60 min/day in a CO2 incubator. The differentiation of irradiated and untreated RANKL stimulated bone marrow macrophages into osteoclasts was evaluated by tartrate resistant acid phosphatase (TRAP) staining and by molecular methods. These included assessing messenger RNA (mRNA) expression of osteoclastic markers such as TRAP, c Fos, Atp6v0d2, DC STAMP, NFATc1, cathepsin K, MMP9 and OSCAR; phosphorylation of various MAPKs, including extracellular signal regulated kinase ERK1/2, P38, and JNK; NF kappa B translocation; and resorption pit formation. Results were compared to those obtained with sodium alendronate. Production of reactive oxygen species was measured by a 2',7' dihydrodichlorofluorescein diacetate assay. LED irradiation and alendronate inhibited mRNA expression of osteoclast related genes, such as TRAP, c Fos, and NFATc1, and reduced the osteoclast activity of RANKL stimulated bone marrow macrophages. LED irradiation, but not alendronate, also inhibited the production of reactive oxygen species (ROS); phosphorylation of ERK, P38, and I kappa B; and NF kappa B translocation. These findings suggest that LED irradiation downregulates osteoclastogenesis by ROS production; this effect could lead to reduced bone loss and may offer a new therapeutic tool for managing osteoporosis.
C1 [Sohn, Hong Moon; Ko, Youngjong; Park, Mineon; Kim, Bora; Kim, Donghwi; Moon, Young Lae; Lim, Wonbong] Chosun Univ Hosp, Dept Orthopaed Surg, Gwangju, South Korea.
   [Park, Jung Eun] Chosun Univ, Dept Biomed Sci, Plus Res Team Bioact Control BK21, Gwangju, South Korea.
   [Lim, Wonbong] Chosun Univ, Dept Premed Sci, Coll Med, 309 Pilmun Daero, Gwangju 61452, South Korea.
C3 Chosun University; Chosun University; Chosun University
RP Lim, W (通讯作者)，Chosun Univ Hosp, Dept Orthopaed Surg, Gwangju, South Korea.; Lim, W (通讯作者)，Chosun Univ, Dept Premed Sci, Coll Med, 309 Pilmun Daero, Gwangju 61452, South Korea.
EM wonbong@chosun.ac.kr
RI Kim, Joonghee/C 9811 2014
FU Chosun University
FX This study was supported by research funds from Chosun University
   (2014).
CR Amid R, 2014, J LASERS MED SCI, V5, P163
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   Bjordal JM, 2003, AUST J PHYSIOTHER, V49, P107, DOI 10.1016/S0004 9514(14)60127 6
   Bouvet Gerbettaz S, 2009, LASER SURG MED, V41, P291, DOI 10.1002/lsm.20759
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Grassi FR, 2011, J BIOL REG HOMEOS AG, V25, P603
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Hopkins JT, 2004, J ATHL TRAINING, V39, P223
   Hussein AJ, 2011, N AM J MED SCI, V3, P193, DOI 10.4297/najms.2011.3193
   Ishizuka H, 2011, J BONE MINER RES, V26, P169, DOI 10.1002/jbmr.199
   Isomura H, 2004, TOXICOLOGY, V197, P93, DOI 10.1016/j.tox.2003.12.006
   Jiang F, 2011, PHARMACOL REV, V63, P218, DOI 10.1124/pr.110.002980
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Lim HJ, 2014, LASER MED SCI, V29, P659, DOI 10.1007/s10103 013 1363 9
   Lim WB, 2011, LASER SURG MED, V43, P344, DOI 10.1002/lsm.21038
   Lim W, 2007, LASER SURG MED, V39, P614, DOI 10.1002/lsm.20533
   Lubart R, 2006, PHOTOMED LASER SURG, V24, P179, DOI 10.1089/pho.2006.24.179
   Pinheiro Antonio Luiz Barbosa, 2003, Braz. Dent. J., V14, P177, DOI 10.1590/S0103 64402003000300007
   Pretel H, 2007, LASER SURG MED, V39, P788, DOI 10.1002/lsm.20585
   Rao LG, 2007, OSTEOPOROSIS INT, V18, P109, DOI 10.1007/s00198 006 0205 z
   Shakouri SK, 2010, LASER MED SCI, V25, P73, DOI 10.1007/s10103 009 0670 7
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Ueda Y, 2003, J CLIN LASER MED SUR, V21, P271, DOI 10.1089/104454703322564479
   Zhuo Y, 2014, BONE, V67, P269, DOI 10.1016/j.bone.2014.07.013
NR 31
TC 9
Z9 9
U1 1
U2 14
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD JAN
PY 2017
VL 32
IS 1
BP 189
EP 200
DI 10.1007/s10103 016 2101 x
PG 12
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA EH9HH
UT WOS:000392081900023
PM 27807651
DA 2025 08 17
ER

PT J
AU Engelholm, LH
   Melander, MC
   Hald, A
   Persson, M
   Madsen, DH
   Jürgensen, HJ
   Johansson, K
   Nielsen, C
   Norregaard, KS
   Ingvarsen, SZ
   Kjær, A
   Trovik, CS
   Lærum, OD
   Bugge, TH
   Eide, J
   Behrendt, N
AF Engelholm, Lars H.
   Melander, Maria C.
   Hald, Andreas
   Persson, Morten
   Madsen, Daniel H.
   Jurgensen, Henrik J.
   Johansson, Kristina
   Nielsen, Christoffer
   Norregaard, Kirstine S.
   Ingvarsen, Signe Z.
   Kjaer, Andreas
   Trovik, Clement S.
   Laerum, Ole D.
   Bugge, Thomas H.
   Eide, Johan
   Behrendt, Niels
TI Targeting a novel bone degradation pathway in primary bone cancer by
   inactivation of the collagen receptor uPARAP/Endo180
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE bone cancer; collagen; matrix metalloprotease; matrix degradation;
   osteosarcoma; uPARAP/Endo180
ID PLASMINOGEN ACTIVATOR RECEPTOR; BREAST CANCER; MONOCLONAL ANTIBODIES;
   ENDOCYTIC RECEPTOR; MANNOSE RECEPTOR; MATRIX TURNOVER; ENDO180;
   EXPRESSION; OSTEOSARCOMA; PROTEIN
AB In osteosarcoma, a primary mesenchymal bone cancer occurring predominantly in younger patients, invasive tumour growth leads to extensive bone destruction. This process is insufficiently understood, cannot be efficiently counteracted and calls for novel means of treatment. The endocytic collagen receptor, uPARAP/Endo180, is expressed on various mesenchymal cell types and is involved in bone matrix turnover during normal bone growth. Human osteosarcoma specimens showed strong expression of this receptor on tumour cells, along with the collagenolytic metalloprotease, MT1 MMP. In advanced tumours with ongoing bone degeneration, sarcoma cells positive for these proteins formed a contiguous layer aligned with the degradation zones. Remarkably, osteoclasts were scarce or absent from these regions and quantitative analysis revealed that this scarcity marked a strong contrast between osteosarcoma and bone metastases of carcinoma origin. This opened the possibility that sarcoma cells might directly mediate bone degeneration. To examine this question, we utilized a syngeneic, osteolytic bone tumour model with transplanted NCTC 2472 sarcoma cells in mice. When analysed in vitro, these cells were capable of degrading the protein component of surface labelled bone slices in a process dependent on MMP activity and uPARAP/Endo180. Systemic treatment of the sarcoma inoculated mice with a mouse monoclonal antibody that blocks murine uPARAP/Endo180 led to a strong reduction of bone destruction. Our findings identify sarcoma cell resident uPARAP/Endo180 as a central player in the bone degeneration of advanced tumours, possibly following an osteoclast mediated attack on bone in the early tumour stage. This points to uPARAP/Endo180 as a promising therapeutic target in osteosarcoma, with particular prospects for improved neoadjuvant therapy. Copyright (c) 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Engelholm, Lars H.; Melander, Maria C.; Hald, Andreas; Jurgensen, Henrik J.; Johansson, Kristina; Nielsen, Christoffer; Norregaard, Kirstine S.; Ingvarsen, Signe Z.; Laerum, Ole D.; Behrendt, Niels] Rigshosp, BRIC, Finsen Lab, Copenhagen, Denmark.
   [Engelholm, Lars H.; Melander, Maria C.; Hald, Andreas; Persson, Morten; Jurgensen, Henrik J.; Johansson, Kristina; Nielsen, Christoffer; Norregaard, Kirstine S.; Ingvarsen, Signe Z.; Kjaer, Andreas; Laerum, Ole D.; Behrendt, Niels] Univ Copenhagen, DK 2200 Copenhagen, Denmark.
   [Persson, Morten; Kjaer, Andreas] Rigshosp, Dept Clin Physiol Nucl Med & PET, Copenhagen, Denmark.
   [Persson, Morten; Kjaer, Andreas] Rigshosp, Cluster Mol Imaging, Copenhagen, Denmark.
   [Madsen, Daniel H.; Bugge, Thomas H.] NIH, Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodelling Sect, Bethesda, MD 20892 USA.
   [Trovik, Clement S.] Haukeland Hosp, Dept Oncol Orthopaed, N 5021 Bergen, Norway.
   [Laerum, Ole D.] Univ Bergen, Gade Lab Pathol, Dept Clin Med, N 5020 Bergen, Norway.
   [Eide, Johan] Haukeland Hosp, Dept Pathol, N 5021 Bergen, Norway.
C3 Rigshospitalet; University of Copenhagen; Copenhagen University
   Hospital; University of Copenhagen; Rigshospitalet; University of
   Copenhagen; Copenhagen University Hospital; Rigshospitalet; University
   of Copenhagen; Copenhagen University Hospital; National Institutes of
   Health (NIH)   USA; NIH National Institute of Dental & Craniofacial
   Research (NIDCR); University of Bergen; Haukeland University Hospital;
   University of Bergen; University of Bergen; Haukeland University
   Hospital
RP Behrendt, N (通讯作者)，Univ Copenhagen, Rigshosp, BRIC, Finsen Lab, Ole Maaloes Vej 5, DK 2200 Copenhagen N, Denmark.
EM niels.behrendt@finsenlab.dk
RI Ingvarsen, Signe/AAT 3296 2020; Behrendt, Niels/HKM 9295 2023;
   Engelholm, Lars/J 4735 2013; Kjaer, Andreas/E 8932 2015
OI Engelholm, Lars/0000 0002 6616 1232; Norregaard, Kirstine
   Sandal/0000 0002 1299 0991; Madsen, Daniel Hargboel/0000 0002 3183 6201;
   Kjaer, Andreas/0000 0002 2706 5547; Behrendt, Niels/0000 0003 1833 3922;
   Johansson, Kristina/0000 0001 7330 2665; Ingvarsen, Signe
   Ziir/0000 0001 7800 6443
FU Danish Cancer Society; Danish Medical Research Council; Danish National
   Advanced Technology Foundation; Danish Cancer Research Foundation;
   Lundbeck Foundation; Novo Nordisk Foundation; AP Moller Foundation;
   Danish National Research Foundation (Danish Chinese Centre for Proteases
   and Cancer); Intramural Research Programme of the National Institutes of
   Health (NIH), NIDCR, USA; European Community's Seventh Framework
   Programme FP7 [201279]; Grosserer Alfred Nielsen og Hustrus Foundation;
   Copenhagen University Hospital; Lundbeck Foundation [R118 2012 11578]
   Funding Source: researchfish; Novo Nordisk Fonden [NNF13OC0007149,
   NNF12OC0002353] Funding Source: researchfish
FX The excellent technical assistance of Katharina H Stegmann, Lotte B
   Frederiksen, Lene K Callesen and Bendik Nordanger is gratefully
   acknowledged. Dr Sanjiv S Gambhir is thanked for the generous gift of
   the pFU L2T vector. Senior Statistician Ib Jarle Christensen is thanked
   for data evaluation and statistical advice. This study was supported by
   the Danish Cancer Society, the Danish Medical Research Council, the
   Danish National Advanced Technology Foundation, the Danish Cancer
   Research Foundation, the Lundbeck Foundation, the Novo Nordisk
   Foundation, the AP Moller Foundation, the Danish National Research
   Foundation (Danish Chinese Centre for Proteases and Cancer), the
   Intramural Research Programme of the National Institutes of Health
   (NIH), NIDCR, USA, the European Community's Seventh Framework Programme
   FP7/2007 2011 (Grant No. 201279) and the Grosserer Alfred Nielsen og
   Hustrus Foundation. DHM and HJJ received personal fellowship grants from
   Copenhagen University Hospital.
CR Abdelgawad ME, 2014, BONE, V67, P181, DOI 10.1016/j.bone.2014.07.012
   Almholt K, 2008, MOL CANCER THER, V7, P2758, DOI 10.1158/1535 7163.MCT 08 0251
   ATHANASOU NA, 1991, J CLIN PATHOL, V44, P664, DOI 10.1136/jcp.44.8.664
   Atkinson SM, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3867
   Behrendt N, 2004, BIOL CHEM, V385, P103, DOI 10.1515/BC.2004.031
   Behrendt N, 2000, J BIOL CHEM, V275, P1993, DOI 10.1074/jbc.275.3.1993
   Brown JE, 2012, CLIN CANCER RES, V18, P6348, DOI 10.1158/1078 0432.CCR 12 1397
   Caley MP, 2012, J PATHOL, V226, P775, DOI 10.1002/path.3958
   Clohisy DR, 1998, J ORTHOPAED RES, V16, P660, DOI 10.1002/jor.1100160606
   Clohisy DR, 1995, J ORTHOPAED RES, V13, P892, DOI 10.1002/jor.1100130613
   Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100
   Curino AC, 2005, J CELL BIOL, V169, P977, DOI 10.1083/jcb.200411153
   Dai XM, 2004, J BONE MINER RES, V19, P1441, DOI 10.1359/JBMR.040514
   East L, 2003, EMBO REP, V4, P710, DOI 10.1038/sj.embor.embor882
   Endo Munoz L, 2010, BRIT J CANCER, V103, P73, DOI 10.1038/sj.bjc.6605723
   Endo Munoz L, 2012, BBA REV CANCER, V1826, P434, DOI 10.1016/j.bbcan.2012.07.003
   Engelholm LH, 2009, FRONT BIOSCI LANDMRK, V14, P2103, DOI 10.2741/3365
   Engelholm LH, 2003, J CELL BIOL, V160, P1009, DOI 10.1083/jcb.200211091
   Engelholm LH, 2001, LAB INVEST, V81, P1403, DOI 10.1038/labinvest.3780354
   Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77
   Fasquelle C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000666
   Ferrari S, 2005, J CLIN ONCOL, V23, P8845, DOI 10.1200/JCO.2004.00.5785
   Fletcher C DM., 2002, WHO classification of tumours editorial board: soft tissue and bone tumours, V3rd
   Flores JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100757
   Gill J, 2013, PHARMACOL THERAPEUT, V137, P89, DOI 10.1016/j.pharmthera.2012.09.003
   Goldsby RE, 2013, EUR J CANCER, V49, P2384, DOI 10.1016/j.ejca.2013.03.018
   Gu XP, 2010, MOL PAIN, V6, DOI 10.1186/1744 8069 6 64
   Hald A, 2009, INT J CANCER, V125, P1177, DOI 10.1002/ijc.24436
   Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092 8674(00)80064 1
   Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092 8674(03)00513 0
   Jögi A, 2007, J THROMB HAEMOST, V5, P1936, DOI 10.1111/j.1538 7836.2007.02653.x
   Jürgensen HJ, 2014, J BIOL CHEM, V289, P7935, DOI 10.1074/jbc.M113.512780
   JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772
   Jürgensen HJ, 2011, J BIOL CHEM, V286, P32736, DOI 10.1074/jbc.M111.266692
   Kato Y, 2013, CANCER CELL INT, V13, DOI 10.1186/1475 2867 13 89
   Kjoller L, 2004, EXP CELL RES, V293, P106, DOI 10.1016/j.yexcr.2003.10.008
   Kogianni G, 2009, EUR J CANCER, V45, P685, DOI 10.1016/j.ejca.2008.11.023
   Korpal M, 2009, NAT MED, V15, P960, DOI 10.1038/nm.1943
   Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107
   Madsen DH, 2007, J BIOL CHEM, V282, P27037, DOI 10.1074/jbc.M701088200
   Madsen DH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071261
   Madsen DH, 2012, J PATHOL, V227, P94, DOI 10.1002/path.3981
   Madsen DH, 2011, J BIOL CHEM, V286, P26996, DOI 10.1074/jbc.M110.208033
   Melander MC, 2015, INT J ONCOL
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266
   Nielsen BS, 2002, INT J CANCER, V98, P656, DOI 10.1002/ijc.10227
   Ohba T, 2014, J BONE MINER RES, V29, P1431, DOI 10.1002/jbmr.2182
   Rodriguez Teja M, 2015, MOL CANCER RES, V13, P538, DOI 10.1158/1541 7786.MCR 14 0344 T
   Rodriguez Teja M, 2015, J PATHOL, V235, P581, DOI 10.1002/path.4485
   Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097 4652(200003)182:3<311::AID JCP1>3.0.CO;2 9
   Sheikh H, 2000, J CELL SCI, V113, P1021
   Sturge J, 2006, J CELL BIOL, V175, P337, DOI 10.1083/jcb.200602125
   Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67
   Sulek J, 2007, J HISTOCHEM CYTOCHEM, V55, P347, DOI 10.1369/jhc.6A7133.2006
   Têtu B, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1503
   Wagenaar Miller RA, 2007, MOL CELL BIOL, V27, P6309, DOI 10.1128/MCB.00291 07
   Wienke D, 2003, MOL BIOL CELL, V14, P3592, DOI 10.1091/mbc.E02 12 0814
   Wilson C, 2012, CANCER TREAT REV, V38, P877, DOI 10.1016/j.ctrv.2012.02.007
NR 60
TC 28
Z9 34
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3417
EI 1096 9896
J9 J PATHOL
JI J. Pathol.
PD JAN
PY 2016
VL 238
IS 1
BP 120
EP 133
DI 10.1002/path.4661
PG 14
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA CZ7QW
UT WOS:000367295800013
PM 26466547
DA 2025 08 17
ER

PT J
AU Yanagi, T
   Kajiya, H
   Fujisaki, S
   Maeshiba, M
   Yanagi S, A
   Yamamoto M, N
   Kakura, K
   Kido, H
   Ohno, J
AF Yanagi, Tsukasa
   Kajiya, Hiroshi
   Fujisaki, Seiichi
   Maeshiba, Munehisa
   Yanagi S, Ayako
   Yamamoto M, Nana
   Kakura, Kae
   Kido, Hirofumi
   Ohno, Jun
TI Three dimensional spheroids of dedifferentiated fat cells enhance bone
   regeneration
SO REGENERATIVE THERAPY
LA English
DT Article
DE Bone regeneration; Dedifferentiated fat cells; Cell transplantation;
   Calvarial bone defect
ID MESENCHYMAL STEM CELLS; STROMAL CELLS; DIFFERENTIATION; TRANSPLANTATION;
   OSTEOGENESIS; SCAFFOLDS; CULTURE; INJURY
AB Introduction: Mesenchymal stromal/stem cells (MSCs) are multipotent, self renewing cells that are extensively used in tissue engineering. Dedifferentiated fat (DFAT) cells are derived from adipose tissues and are similar to MSCs. Three dimensional (3D) spheroid cultures comprising MSCs mimic the biological microenvironment more accurately than two dimensional cultures; however, it remains unclear whether DFAT cells in 3D spheroids possess high osteogenerative ability. Furthermore, it is unclear whether DFAT cells from 3D spheroids transplanted into calvarial bone defects are as effective as those from two dimensional ( 2D) monolayers in promoting bone regeneration.
   Methods: We compared the in vitro osteogenic potential of rat DFAT cells cultured under osteogenic conditions in 3D spheroids with that in 2D monolayers. Furthermore, to elucidate the ability of 3D spheroid DFAT cells to promote bone healing, we examined the in vivo osteogenic potential of transplanting DFAT cells from 3D spheroids or 2D monolayers into a rat calvarial defect model.
   Results: Osteoblast differentiation stimulated by bone morphogenetic protein 2 (BMP 2) or osteogenesis inducing medium upregulated osteogenesis related molecules in 3D spheroid DFAT cells compared with 2D monolayer DFAT cells. BMP 2 activated phosphorylation in the canonical Smad 1/5 pathways in 3D spheroid DFAT cells but phosphorylated ERK1/2 and Smad2 in 2D monolayer DFAT cells. Regardless of osteogenic stimulation, the transplantation of 3D DFAT spheroid cells into rat calvarial defects promoted new bone formation at a greater extent than that of 2D DFAT cells.
   Conclusions: Compared with 2D DFAT cells, 3D DFAT spheroid cells promote osteoblast differentiation and new bone formation via canonical Smad 1/5 signaling pathways. These results indicate that transplantation of DFAT cells from 3D spheroids, but not 2D monolayers, accelerates bone healing. (C) 2021, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.
C1 [Yanagi, Tsukasa; Kajiya, Hiroshi; Fujisaki, Seiichi; Maeshiba, Munehisa; Ohno, Jun] Fukuoka Dent Coll, Oral Med Res Ctr, 2 15 1Tamura, Fukuoka, Japan.
   [Yanagi, Tsukasa; Fujisaki, Seiichi; Maeshiba, Munehisa; Yanagi S, Ayako; Kakura, Kae; Kido, Hirofumi] Fukuoka Dent Coll, Dept Oral Rehabil, 2 15 1Tamura, Fukuoka, Japan.
   [Kajiya, Hiroshi] Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, 2 15 1Tamura, Fukuoka 8140193, Japan.
   [Yamamoto M, Nana] Fukuoka Dent Coll, Dept Odontol, 2 15 1Tamura, Fukuoka, Japan.
C3 Fukuoka Dental College (FDC); Fukuoka Dental College (FDC); Fukuoka
   Dental College (FDC); Fukuoka Dental College (FDC)
RP Kajiya, H (通讯作者)，Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, 2 15 1Tamura, Fukuoka 8140193, Japan.
EM kajiya@college.fdcnet.ac.jp
OI Kajiya, Hiroshi/0000 0003 3275 3632
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [21K21052, 15K11062]; Private University Research Branding Project of
   Fukuoka Dental College; Grants in Aid for Scientific Research [20K18622,
   15K11062, 21K09990, 21K09948, 21K21052] Funding Source: KAKEN
FX The authors would like to thank Professor Matsumoto (Nihon University)
   for the technical guidance and suggestion in isolation and culture of
   DFAT cells. The authors also would like to thank Enago (Academic
   Proofreading Service; www.enago.jp) for the English language review.
   This work was supported by Grants inAid for Scientific Research from the
   Ministry of Education, Culture, Sports, Science and Technology of Japan
   (21K21052 to SF and 15K11062 to HK) and the Private University Research
   Branding Project of Fukuoka Dental College.
CR Ader M, 2014, CURR OPIN CELL BIOL, V31, P23, DOI 10.1016/j.ceb.2014.06.013
   Akita D, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00050
   Aldahmash A, 2012, ANN SAUDI MED, V32, P68, DOI 10.5144/0256 4947.2012.68
   Baraniak PR, 2012, CELL TISSUE RES, V347, P701, DOI 10.1007/s00441 011 1215 5
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Bartosh TJ, 2013, STEM CELLS, V31, P2443, DOI 10.1002/stem.1499
   Cesarz Z, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9176357
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   English K, 2010, CELL STEM CELL, V7, P431, DOI 10.1016/j.stem.2010.09.009
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Guo L, 2014, STEM CELLS DEV, V23, P978, DOI 10.1089/scd.2013.0338
   Hamada K, 2008, J BIOMED MATER RES A, V84A, P128, DOI 10.1002/jbm.a.31439
   Huang GS, 2013, EUR CELLS MATER, V26, P179, DOI 10.22203/eCM.v026a13
   Imamura A, 2020, BIOCHEM BIOPH RES CO, V523, P458, DOI 10.1016/j.bbrc.2019.12.066
   Kapur SK, 2012, BIOFABRICATION, V4, DOI 10.1088/1758 5082/4/2/025004
   Katsumata Y, 2015, BIOCHEM BIOPH RES CO, V468, P622, DOI 10.1016/j.bbrc.2015.10.172
   Kikuta S, 2013, TISSUE ENG PT A, V19, P1792, DOI [10.1089/ten.tea.2012.0380, 10.1089/ten.TEA.2012.0380]
   Kishimoto N, 2018, ORAL DIS, V24, P1161, DOI 10.1111/odi.12832
   Li Y, 2017, J CELL PHYSIOL, V232, P2427, DOI 10.1002/jcp.25517
   Matsumoto T, 2008, J CELL PHYSIOL, V215, P210, DOI 10.1002/jcp.21304
   Nickel J, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121579
   Ohta Y, 2008, CELL TRANSPLANT, V17, P877, DOI 10.3727/096368908786576516
   Sakuma T, 2009, J UROLOGY, V182, P355, DOI 10.1016/j.juro.2009.02.103
   Shi YF, 2012, TRENDS IMMUNOL, V33, P136, DOI 10.1016/j.it.2011.11.004
   Shimizu K, 2007, J BIOSCI BIOENG, V104, P171, DOI 10.1263/jbb.104.171
   Sugawara A, 2014, HUM CELL, V27, P12, DOI 10.1007/s13577 013 0075 6
   Suzuki D, 2017, J ORAL SCI, V59, P611, DOI 10.2334/josnusd.16 0878
   Wang WJ, 2009, BIOMATERIALS, V30, P2705, DOI 10.1016/j.biomaterials.2009.01.030
   Yagi K, 2004, BIOCHEM BIOPH RES CO, V321, P967, DOI 10.1016/j.bbrc.2004.07.055
   Yin XL, 2016, CELL STEM CELL, V18, P25, DOI 10.1016/j.stem.2015.12.005
   Zhang ZY, 2012, BIOMATERIALS, V33, P2656, DOI 10.1016/j.biomaterials.2011.12.025
   Zhou Z, 2010, DEV CELL, V19, P90, DOI 10.1016/j.devcel.2010.06.016
NR 32
TC 18
Z9 18
U1 1
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD DEC
PY 2021
VL 18
BP 472
EP 479
DI 10.1016/j.reth.2021.10.004
PG 8
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA WX1SV
UT WOS:000718384700001
PM 34853808
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cheng, YH
   Hooker, RA
   Nguyen, K
   Gerard O'Riley, R
   Waning, DL
   Chitteti, BR
   Meijome, TE
   Chua, HL
   Plett, AP
   Orschell, CM
   Srour, EF
   Mayo, LD
   Pavalko, FM
   Bruzzaniti, A
   Kacena, MA
AF Cheng, Ying Hua
   Hooker, R. Adam
   Nguyen, Khanh
   Gerard O'Riley, Rita
   Waning, David L.
   Chitteti, Brahmananda R.
   Meijome, Tomas E.
   Chua, Hui Lin
   Plett, Artur P.
   Orschell, Christie M.
   Srour, Edward F.
   Mayo, Lindsey D.
   Pavalko, Fredrick M.
   Bruzzaniti, Angela
   Kacena, Melissa A.
TI Pyk2 regulates megakaryocyte induced increases in osteoblast number and
   bone formation
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE PYK2; MEGAKARYOCYTE; OSTEOBLASTS; BONE FORMATION
ID TRANSCRIPTION FACTOR GATA 1; STEM CELL FACTOR; MYELOPROLIFERATIVE
   SYNDROME; TYROSINE KINASE 2; MASS PHENOTYPE; EXPRESSION; MICE;
   DIFFERENTIATION; THROMBOPOIETIN; MARROW
AB Preclinical and clinical evidence from megakaryocyte (MK) related diseases suggests that MKs play a significant role in maintaining bone homeostasis. Findings from our laboratories reveal that MKs significantly increase osteoblast (OB) number through direct MK OB contact and the activation of integrins. We, therefore, examined the role of Pyk2, a tyrosine kinase known to be regulated downstream of integrins, in the MK mediated enhancement of OBs. When OBs were co cultured with MKs, total Pyk2 levels in OBs were significantly enhanced primarily because of increased Pyk2 gene transcription. Additionally, p53 and Mdm2 were both decreased in OBs upon MK stimulation, which would be permissive of cell cycle entry. We then demonstrated that OB number was markedly reduced when Pyk2/ OBs, as opposed to wild type (WT) OBs, were co cultured with MKs. We also determined that MKs inhibit OB differentiation in the presence and absence of Pyk2 expression. Finally, given that MK replete spleen cells from GATA 1deficient mice can robustly stimulate OB proliferation and bone formation in WT mice, we adoptively transferred spleen cells from these mice into Pyk2/ recipient mice. Importantly, GATA 1deficient spleen cells failed to stimulate an increase in bone formation in Pyk2/ mice, suggesting in vivo the important role of Pyk2 in the MK induced increase in bone volume. Further understanding of the signaling pathways involved in the MK mediated enhancement of OB number and bone formation will facilitate the development of novel anabolic therapies to treat bone loss diseases.
C1 [Cheng, Ying Hua; Hooker, R. Adam; Nguyen, Khanh; Meijome, Tomas E.; Kacena, Melissa A.] Indiana Univ Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46202 USA.
   [Gerard O'Riley, Rita; Pavalko, Fredrick M.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA.
   [Waning, David L.; Srour, Edward F.; Mayo, Lindsey D.] Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA.
   [Chitteti, Brahmananda R.; Chua, Hui Lin; Plett, Artur P.; Orschell, Christie M.; Srour, Edward F.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
   [Srour, Edward F.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.
   [Mayo, Lindsey D.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
   [Bruzzaniti, Angela; Kacena, Melissa A.] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   [Bruzzaniti, Angela] Indiana Univ, Sch Dent, Dept Oral Biol, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington; Indiana University System; Indiana
   University Bloomington; Indiana University System; Indiana University
   Bloomington; Indiana University System; Indiana University Bloomington;
   Indiana University System; Indiana University Indianapolis
RP Kacena, MA (通讯作者)，Indiana Univ Sch Med, Dept Orthopaed Surg, 1120 South Dr,FH 115, Indianapolis, IN 46202 USA.
EM abruzzan@iupui.edu; mkacena@iupui.edu
RI Bruzzaniti, Angela/AAP 2225 2020
FU Department of Orthopaedic Surgery at Indiana University School of
   Medicine; Department of Oral Biology at Indiana University School of
   Dentistry; Indiana University School of Medicine; NIH [R03 AR055269, R01
   AR060332, R01 HL55716, R01 AR052682, R01 CA109262];  [P30 CA082709]
FX This work was sponsored in part by the Department of Orthopaedic Surgery
   at Indiana University School of Medicine, the Department of Oral Biology
   at Indiana University School of Dentistry, a Biomedical Research Grant
   and Pilot Funding for Research Use of Core Facilities Award both from
   Indiana University School of Medicine (MAK), and by the following NIH
   grants: R03 AR055269 (MAK), R01 AR060332 (MAK, AB), R01 HL55716 (EFS),
   R01 AR052682 (FMP), and R01 CA109262 (LDM). We sincerely thank Dr.
   Charles H Turner (posthumously) for helpful discussions and Pfizer for
   providing us with the Pyk2 deficient mice. We also thank Drs. Stuart
   Orkin and Ramesh Shivdasani for providing us with the GATA 1 deficient
   mice. We are thankful to Dr. Matthew Allen for training us in mu CT
   analyses. Finally, we thank the operators of the Indiana University
   Melvin and Bren Simon Cancer Center Flow Cytometry Resource Facility for
   their technical help and support. The FCRF is partially funded by P30
   CA082709.
CR Arai F, 2008, EXP HEMATOL, V36, pS25
   Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898 6568(99)00076 5
   Blair HC, 1999, VIRCHOWS ARCH, V435, P50, DOI 10.1007/s004280050394
   Blair HC, 1999, BIOCHEM BIOPH RES CO, V255, P778, DOI 10.1006/bbrc.1999.0260
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Bruzzaniti A, 2009, MOL CELL BIOL, V29, P3644, DOI 10.1128/MCB.00851 08
   Buckbinder L, 2007, P NATL ACAD SCI USA, V104, P10619, DOI 10.1073/pnas.0701421104
   Chagraoui H, 2006, BEST PRACT RES CL HA, V19, P399, DOI 10.1016/j.beha.2005.07.002
   Cheng YH, 2011, J BONE MINER RES, V26, P1111, DOI 10.1002/jbmr.302
   Ciovacco WA, 2010, J CELL BIOCHEM, V109, P774, DOI 10.1002/jcb.22456
   Ciovacco WA, 2009, BONE, V44, P80, DOI 10.1016/j.bone.2008.08.117
   Dominici M, 2009, BLOOD, V114, P2333, DOI 10.1182/blood 2008 10 183459
   Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483
   Duong Le T., 1998, Frontiers in Bioscience, V3, pD757
   Duong LT, 2001, J BIOL CHEM, V276, P7484, DOI 10.1074/jbc.M008368200
   Frey BM, 1998, SCHWEIZ MED WSCHR, V128, P1587
   Frey BM, 1998, J IMMUNOL, V160, P691
   Gil Henn H, 2007, J CELL BIOL, V178, P1053, DOI 10.1083/jcb.200701148
   HOROWITZ MC, 1994, ENDOCRINOLOGY, V135, P1032, DOI 10.1210/en.135.3.1032
   HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349
   JILKA RL, 1981, ENDOCRINOLOGY, V109, P743, DOI 10.1210/endo 109 3 743
   Kacena MA, 2005, BONE, V36, P215, DOI 10.1016/j.bone.2004.09.024
   Kacena MA, 2004, J BONE MINER RES, V19, P652, DOI 10.1359/JBMR.0301254
   Kacena MA, 2006, BONE, V39, P991, DOI 10.1016/j.bone.2006.05.004
   Kacena MA, 2012, J BIOL CHEM, V287, P17257, DOI 10.1074/jbc.M111.309880
   Kacena MA, 2010, ADV EXP MED BIOL, V658, P31, DOI 10.1007/978 1 4419 1050 9_4
   Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200
   Lemieux JM, 2010, J CELL BIOCHEM, V109, P927, DOI 10.1002/jcb.22468
   LENNERT K, 1975, CLIN HAEMATOL, V4, P331
   Mayack SR, 2008, BLOOD, V112, P519, DOI 10.1182/blood 2008 01 133710
   McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781
   Miao D, 2004, TISSUE ENG, V10, P807, DOI 10.1089/1076327041348473
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Schick P K, 1996, Stem Cells, V14 Suppl 1, P212
   Schick PK, 1997, ARTERIOSCL THROM VAS, V17, P797, DOI 10.1161/01.ATV.17.4.797
   Schick PK, 1996, BLOOD, V87, P1817
   Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965
   SIMMONS DJ, 1982, CALCIFIED TISSUE INT, V34, P291, DOI 10.1007/BF02411253
   STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420
   Suva LJ, 2008, AM J PATHOL, V172, P430, DOI 10.2353/ajpath.2008.070417
   Thiele J, 1999, ANN HEMATOL, V78, P495, DOI 10.1007/s002770050546
   Towler DA, 2002, PRINCIPLES BONE BIOL, V2, P1503
   Villeval JL, 1997, BLOOD, V90, P4369
   Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036
   WONG GL, 1975, P NATL ACAD SCI USA, V72, P3167, DOI 10.1073/pnas.72.8.3167
   Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529
   YAN XQ, 1995, BLOOD, V86, P4025, DOI 10.1182/blood.V86.11.4025.bloodjournal86114025
   Yan XQ, 1996, BLOOD, V88, P402, DOI 10.1182/blood.V88.2.402.bloodjournal882402
NR 48
TC 24
Z9 29
U1 1
U2 9
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2013
VL 28
IS 6
BP 1434
EP 1445
DI 10.1002/jbmr.1876
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 149VS
UT WOS:000319350100021
PM 23362087
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Kurabayashi, A
   Inoue, K
   Fukuhara, H
   Karashima, T
   Fukata, S
   Kawada, C
   Shuin, T
   Furihata, M
AF Kurabayashi, Atsushi
   Inoue, Keiji
   Fukuhara, Hideo
   Karashima, Takashi
   Fukata, Satoshi
   Kawada, Chiaki
   Shuin, Taro
   Furihata, Mutsuo
TI Combination with third generation bisphosphonate (YM529) and
   interferon alpha can inhibit the progression of established bone renal
   cell carcinoma
SO CANCER SCIENCE
LA English
DT Article
DE Angiogenesis; bisphosphonate; interferon alpha; osteoclasts; renal cell
   carcinoma
ID ANGIOGENESIS RELATED GENES; INDUCE APOPTOSIS; IN VITRO; SURVIVAL;
   CANCER; THERAPY; METASTASES; EXPRESSION; PROTEINS; LINES
AB The aim of this study was to investigate whether the third generation nitrogen containing bisphosphonate (YM529) can inhibit the progression of established bone renal cell carcinoma (RCC) and to elucidate its mechanism. Antiproliferative effect and apoptosis induction of RCC cells and mouse osteoclasts by YM529 and/or interferon alpha (IFN ) were evaluated invitro using cell counting and invivo using soft X ray, the TUNEL method and tartrate resistant acid phosphatase stain. For the invivo study, male athymic BALB/cA Jc1 nu nude mice bearing human RCC cell line RBM1 IT4 cells were treated with YM529 and/or IFN . The biological activity of osteoclasts was evaluated using the pit formation assay. The antiangiogenetic effect by YM529 and/or IFN  was analyzed using micro vessel density and insitu mRNA hybridization. Osteoclast number in bone tumors was decreased in YM529 treated mouse. YM529 also inhibited osteoclast activity and proliferation invitro, whereas basic fibroblast growth factor expressions and micro vessel density within tumors were inhibited by IFN . Neither YM529 nor IFN  alone significantly inhibited the growth of established bone metastatic tumors. Combined treatment with YM529 and IFN  may be beneficial in patients with human RCC bone metastasis. Their effects are mediated by osteoclast recruitment inhibition and inactivation by YM529 and antiangiogenesis by IFN .
C1 [Kurabayashi, Atsushi; Furihata, Mutsuo] Kochi Med Sch, Dept Pathol, Nankoku, Kochi 7838505, Japan.
   [Inoue, Keiji; Fukuhara, Hideo; Karashima, Takashi; Fukata, Satoshi; Kawada, Chiaki; Shuin, Taro] Kochi Med Sch, Dept Urol, Nankoku, Kochi 7838505, Japan.
C3 Kochi University; Kochi University
RP Inoue, K (通讯作者)，Kochi Med Sch, Dept Urol, Nankoku, Kochi 7838505, Japan.
EM keiji@kochi u.ac.jp
CR AOKI J, 1988, CANCER AM CANCER SOC, V62, P98, DOI 10.1002/1097 0142(19880701)62:1<98::AID CNCR2820620118>3.0.CO;2 8
   Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Callander NS, 2001, SEMIN HEMATOL, V38, P276, DOI 10.1053/shem.2001.26007
   Caraglia M, 2004, AMINO ACIDS, V26, P409, DOI 10.1007/s00726 004 0085 5
   Chow WH, 1999, JAMA J AM MED ASSOC, V281, P1628, DOI 10.1001/jama.281.17.1628
   Fukata S, 2005, CANCER AM CANCER SOC, V103, P931, DOI 10.1002/cncr.20887
   Inoue K, 2005, CLIN CANCER RES, V11, P6669, DOI 10.1158/1078 0432.CCR 05 1010
   Kobayashi H, 2007, CANCER IMMUNOL IMMUN, V56, P469, DOI 10.1007/s00262 006 0199 6
   Kurabayashi A, 2001, MODERN PATHOL, V14, P741, DOI 10.1038/modpathol.3880383
   Motzer RJ, 1999, J CLIN ONCOL, V17, P2530, DOI 10.1200/JCO.1999.17.8.2530
   Motzer RJ, 2002, J CLIN ONCOL, V20, P2376, DOI 10.1200/JCO.2002.11.123
   Motzer RJ, 2000, J CLIN ONCOL, V18, P1928, DOI 10.1200/JCO.2000.18.9.1928
   Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.2002.20.1.289
   Motzer RJ, 2004, J CLIN ONCOL, V22, P454, DOI 10.1200/JCO.2004.06.132
   Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293
   Mundy GR, 2001, SEMIN ONCOL, V28, P35, DOI 10.1053/sonc.2001.24158
   Naito S, 2010, EUR UROL, V57, P317, DOI 10.1016/j.eururo.2008.12.026
   Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375
   Sakai I, 2014, INT J CLIN ONCOL, V19, P674, DOI 10.1007/s10147 013 0612 z
   Sasaki A, 1998, INT J CANCER, V77, P279, DOI 10.1002/(SICI)1097 0215(19980717)77:2<279::AID IJC18>3.0.CO;2 6
   Schilbach K, 2001, BLOOD, V97, P2917, DOI 10.1182/blood.V97.9.2917
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shinohara N, 2013, UROL ONCOL SEMIN ORI, V31, P1276, DOI 10.1016/j.urolonc.2011.08.009
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Slaton JW, 1999, CLIN CANCER RES, V5, P2726
   STREWLER GJ, 1987, J CLIN INVEST, V80, P1803, DOI 10.1172/JCI113275
   Usumi T, 1994, J CHROMATOGR, V652, P67
   Wada Y, 2012, INT J UROL, V19, P284, DOI 10.1111/j.1442 2042.2012.02962.x
   Woodward E, 2011, BONE, V48, P160, DOI 10.1016/j.bone.2010.09.008
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yuasa T, 2005, CLIN CANCER RES, V11, P853
NR 32
TC 3
Z9 4
U1 0
U2 4
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1347 9032
EI 1349 7006
J9 CANCER SCI
JI Cancer Sci.
PD AUG
PY 2015
VL 106
IS 8
BP 1092
EP 1099
DI 10.1111/cas.12711
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CP4QI
UT WOS:000359867000019
PM 26041278
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ruvolo, PP
AF Ruvolo, Peter P.
TI Role of protein phosphatases in the cancer microenvironment
SO BIOCHIMICA ET BIOPHYSICA ACTA MOLECULAR CELL RESEARCH
LA English
DT Article
DE PP2A; PP1; PTPN11; DUSP; Tumor microenvironment; Immune surveillance;
   Metastasis
ID MESENCHYMAL STEM CELLS; ACUTE MYELOID LEUKEMIA; TGF BETA; IN VIVO;
   BONE MARROW; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTOMIC ANALYSIS;
   TYROSINE PHOSPHATASES; T308 PHOSPHORYLATION; MOLECULAR MECHANISM
AB Cancer cells depend on a supportive niche (the tumor microenvironment) that promotes tumor cell survival while protecting the malignant cells from therapeutic challenges and the host's defense systems. Cancer cells and the support cells in the tumor microenvironment communicate via cytokines/chemokines, cell:cell contact, or alterations in the metabolic state of the niche (e.g. hypoxia) that promote growth and survival of the tumor cell, influence metastasis, and defeat immune surveillance. These signaling pathways involve dysregulation of not only protein kinases but also protein phosphatases as normal signal transduction processes require both activation and deactivation. For instance, aberrant receptor signaling can result from constitutive activation of a tyrosine kinase such as FLT3 or inactivation of a tyrosine protein phosphatase such as SHP 2 (PTPN11). Activation of serine/threonine kinases such as AKT and ERK are often observed during the development of drug resistance while genomic and non genomic suppression of serine/threonine protein phosphatases such as PP2A achieve similar results. It is fairly clear that the various protein phosphatases will impact processes that support drug resistance. Of growing interest is the emerging model whereby the support cells in the tumor micro environment actually serve as drivers of tumorigenesis. This phenomenon has been most prominently observed in osteoblast cells in leukemic niches. At least one protein phosphatase, PTPN11, has emerged as a critical driver of this process in juvenile myelomonocytic leukemia. This review will cover the role of various serine/threonine and tyrosine protein phosphatases in processes that are central to tumor microenvironment function.
C1 [Ruvolo, Peter P.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center
RP Ruvolo, PP (通讯作者)，Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 0425, Houston, TX 77030 USA.
EM pruvolo@mdanderson.org
CR Ali AK, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00355
   Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089
   Alonso A, 2016, METHODS MOL BIOL, V1447, P1, DOI 10.1007/978 1 4939 3746 2_1
   [Anonymous], BIOCH BIOPHYS ACTA
   [Anonymous], CELL IMMUNOL
   [Anonymous], CELL REP
   Apostolidis SA, 2016, NAT IMMUNOL, V17, P556, DOI 10.1038/ni.3390
   Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200
   Barcellos de Souza P, 2013, BBA REV CANCER, V1836, P321, DOI 10.1016/j.bbcan.2013.10.004
   Battula VL, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90036
   Batut J, 2008, DEVELOPMENT, V135, P2927, DOI 10.1242/dev.020842
   Belle L, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005547
   Belli C, 2018, CANCER TREAT REV, V65, P22, DOI 10.1016/j.ctrv.2018.02.004
   Bendall SC, 2012, NAT BIOTECHNOL, V30, P639, DOI 10.1038/nbt.2283
   Brenner AK, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00106
   Breuer R, 2014, J BIOL CHEM, V289, P14996, DOI 10.1074/jbc.M113.533547
   Brownlie RJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01427 1
   Burger JA, 2011, HEMATOL AM SOC HEMAT, P96, DOI 10.1182/asheducation 2011.1.96
   Campioni D, 2003, CYTOTHERAPY, V5, P66, DOI 10.1080/14653240310000092
   Chen L, 2015, LEUKEMIA, V29, P1290, DOI 10.1038/leu.2015.18
   Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497
   Cohen PTW, 2002, J CELL SCI, V115, P241
   Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008
   Côme C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152996
   Dennison JB, 2016, CLIN CANCER RES, V22, P5068, DOI 10.1158/1078 0432.CCR 16 0171
   Deynoux M, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00041
   DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523
   Dong L, 2017, BLOOD, V130, P1471, DOI 10.1182/blood 2017 06 791103
   Dong L, 2016, NATURE, V539, P304, DOI 10.1038/nature20131
   Droujinine IA, 2013, ONCOTARGET, V4, P651, DOI 10.18632/oncotarget.1040
   Du ZF, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0782 4
   Eitelhuber AC, 2011, EMBO J, V30, P594, DOI 10.1038/emboj.2010.331
   Etet PFS, 2012, CELL SIGNAL, V24, P1433, DOI 10.1016/j.cellsig.2012.03.008
   Evans AG, 2015, ANN NY ACAD SCI, V1335, P63, DOI 10.1111/nyas.12562
   Fan DP, 2016, J BIOMED MATER RES A, V104, P1871, DOI 10.1002/jbm.a.35718
   Guo LL, 2016, TUMOR BIOL, V37, P115, DOI 10.1007/s13277 015 4374 2
   Hales EC, 2014, CELL SIGNAL, V26, P149, DOI 10.1016/j.cellsig.2013.09.021
   Hales EC, 2013, J BIOL CHEM, V288, P22836, DOI 10.1074/jbc.M113.451625
   Han LN, 2015, CYTOM PART A, V87A, P346, DOI 10.1002/cyto.a.22628
   Han YL, 2015, TUMOR BIOL, V36, P1385, DOI 10.1007/s13277 015 3230 8
   Heijman J, 2013, J MOL CELL CARDIOL, V64, P90, DOI 10.1016/j.yjmcc.2013.09.006
   Heikkinen PT, 2010, J BIOL CHEM, V285, P3740, DOI 10.1074/jbc.M109.042978
   Hendriks WJAJ, 2013, BBA MOL BASIS DIS, V1832, P1673, DOI 10.1016/j.bbadis.2013.05.022
   Hendriks WJAJ, 2013, FEBS J, V280, P708, DOI 10.1111/febs.12000
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hofstetter CP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030059
   Hou PC, 2017, CANCER RES, V77, P4305, DOI 10.1158/0008 5472.CAN 16 2990
   Icard P, 2014, BBA REV CANCER, V1846, P216, DOI 10.1016/j.bbcan.2014.06.002
   Kauko O, 2018, INT J BIOCHEM CELL B, V96, P157, DOI 10.1016/j.biocel.2018.01.005
   Kfoury Y, 2015, CELL STEM CELL, V16, P239, DOI 10.1016/j.stem.2015.02.019
   Kidd S, 2008, CYTOTHERAPY, V10, P657, DOI 10.1080/14653240802486517
   Kitamura H, 2017, CANCER SCI, V108, P1947, DOI 10.1111/cas.13332
   Klco JM, 2014, CANCER CELL, V25, P379, DOI 10.1016/j.ccr.2014.01.031
   Kode A, 2016, LEUKEMIA, V30, P1, DOI 10.1038/leu.2015.161
   Kode A, 2014, NATURE, V506, P240, DOI 10.1038/nature12883
   Konopleva M, 2013, ANN HEMATOL, V92, pS45
   Konopleva MY, 2011, J CLIN ONCOL, V29, P591, DOI 10.1200/JCO.2010.31.0904
   Kornblau SM, 2018, HAEMATOLOGICA, V103, P810, DOI 10.3324/haematol.2017.172429
   Krevvata M, 2014, BLOOD, V124, P2834, DOI 10.1182/blood 2013 07 517219
   Krtolica A, 1998, ONCOGENE, V17, P2295, DOI 10.1038/sj.onc.1202159
   Krucher NA, 2006, EXP CELL RES, V312, P2757, DOI 10.1016/j.yexcr.2006.05.002
   Labbé DP, 2012, PROG MOL BIOL TRANSL, V106, P253, DOI 10.1016/B978 0 12 396456 4.00009 2
   Lambrecht C, 2013, METHODS MOL BIOL, V1053, P283, DOI 10.1007/978 1 62703 562 0_17
   Lamprecht S, 2018, CANCERS, V10, DOI 10.3390/cancers10030061
   Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008 5472.CAN 14 3362
   Lennon DP, 2001, J CELL PHYSIOL, V187, P345, DOI 10.1002/jcp.1081
   Levitin HM, 2018, TRENDS CANCER, V4, P264, DOI 10.1016/j.trecan.2018.02.003
   Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689
   Liebermann DA, 2003, BLOOD CELL MOL DIS, V31, P213, DOI 10.1016/S1079 9796(03)00160 8
   Lim WA, 2010, CELL, V142, P661, DOI 10.1016/j.cell.2010.08.023
   Liu Q, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.118
   LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377
   LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823
   Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270
   McCubrey JA, 2014, LEUKEMIA, V28, P15, DOI 10.1038/leu.2013.184
   Medinger M, 2017, BRIT J HAEMATOL, V179, P530, DOI 10.1111/bjh.14823
   Mercadante ER, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00193
   Mitsumori T, 2014, EXP HEMATOL, V42, P783, DOI 10.1016/j.exphem.2014.05.007
   Mittendorf EA, 2014, CANCER IMMUNOL RES, V2, P361, DOI 10.1158/2326 6066.CIR 13 0127
   Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205
   MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673
   Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052
   Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807
   Neuzillet C, 2014, ONCOTARGET, V5, P78, DOI 10.18632/oncotarget.1569
   Nirschl CJ, 2017, CELL, V170, P127, DOI 10.1016/j.cell.2017.06.016
   Noman MZ, 2012, CANCER RES, V72, P4629, DOI 10.1158/0008 5472.CAN 12 1383
   Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011
   Nunes Xavier CE, 2013, BBA REV CANCER, V1836, P211, DOI 10.1016/j.bbcan.2013.06.001
   Oaks J, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00388
   Okamura H, 2017, J CLIN MED, V6, DOI 10.3390/jcm6030023
   Okamura H, 2013, J CELL PHYSIOL, V228, P1031, DOI 10.1002/jcp.24250
   Okamura H, 2011, BONE, V49, P368, DOI 10.1016/j.bone.2011.06.004
   Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543 9553.2005
   Patterson KI, 2009, BIOCHEM J, V418, P475, DOI 10.1042/BJ20082234
   Pereira ER, 2015, SEMIN CELL DEV BIOL, V38, P98, DOI 10.1016/j.semcdb.2015.01.008
   Peti W, 2013, FEBS J, V280, P596, DOI 10.1111/j.1742 4658.2012.08509.x
   Petrova V, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389 017 0011 9
   Pin E, 2016, MOL ONCOL, V10, P1585, DOI 10.1016/j.molonc.2016.09.007
   Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015
   Poggi A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00262
   Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044
   Qian YY, 2015, CANCER RES, V75, P5070, DOI 10.1158/0008 5472.CAN 15 0898
   Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851
   Rebelo S, 2015, CELL SIGNAL, V27, P2589, DOI 10.1016/j.cellsig.2015.08.007
   Roberts AE, 2013, LANCET, V381, P333, DOI 10.1016/S0140 6736(12)61023 X
   Russnes HG, 2011, J CLIN INVEST, V121, P3810, DOI 10.1172/JCI57088
   Ruvolo PP, 2011, LEUKEMIA, V25, P1711, DOI 10.1038/leu.2011.146
   Ruvolo PP, 2018, BBA MOL CELL RES, V1865, P959, DOI 10.1016/j.bbamcr.2018.04.005
   Ruvolo Peter P., 2017, Advances in Biological Regulation, V65, P26, DOI 10.1016/j.jbior.2017.05.001
   Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200
   Sablina AA, 2010, CANCER RES, V70, P10474, DOI 10.1158/0008 5472.CAN 10 2855
   Sallman DA, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00264
   Sano R, 2013, BBA MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Sebestyén A, 2015, CYTOKINE, V73, P219, DOI 10.1016/j.cyto.2015.02.024
   Semenza GL, 2016, BBA MOL CELL RES, V1863, P382, DOI 10.1016/j.bbamcr.2015.05.036
   Serguienko A, 2017, STEM CELLS DEV, V26, P1375, DOI 10.1089/scd.2017.0129
   Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030
   Sharma P, 2011, NAT REV CANCER, V11, P805, DOI 10.1038/nrc3153
   Shlush LI, 2014, NATURE, V506, P328, DOI 10.1038/nature13038
   Shouse G, 2016, ONCOTARGET, V7, P61081, DOI 10.18632/oncotarget.11209
   Spitzer MH, 2016, CELL, V165, P780, DOI 10.1016/j.cell.2016.04.019
   Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898
   SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666
   Suprynowicz FA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180897
   Takai M, 2015, CANCER BIOL THER, V16, P325, DOI 10.1080/15384047.2014.1002362
   Takakura N, 2012, CANCER SCI, V103, P1177, DOI 10.1111/j.1349 7006.2012.02270.x
   Terrak M, 2004, NATURE, V429, P780, DOI 10.1038/nature02582
   Thompson JJ, 2018, GENES BASEL, V9, DOI 10.3390/genes9030121
   Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001
   Trotta R, 2007, J EXP MED, V204, P2397, DOI 10.1084/jem.20070419
   Trotta R, 2011, BLOOD, V117, P2378, DOI 10.1182/blood 2010 05 285130
   Udho E, 2002, BIOCHEM BIOPH RES CO, V297, P463, DOI 10.1016/S0006 291X(02)02236 2
   Venteicher AS, 2017, SCIENCE, V355, DOI 10.1126/science.aai8478
   Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02 09 0577
   Wadham C, 2000, J CELL SCI, V113, P3117
   Wang MN, 2017, J CANCER, V8, P761, DOI 10.7150/jca.17648
   Wei S, 2009, P NATL ACAD SCI USA, V106, P12974, DOI 10.1073/pnas.0811267106
   Wohlfert EA, 2007, TRENDS IMMUNOL, V28, P154, DOI 10.1016/j.it.2007.02.003
   Wyatt L, 2008, CELL CYCLE, V7, P2290, DOI 10.4161/cc.6443
   Wyatt L, 2007, J CELL BIOL, V178, P1223, DOI 10.1083/jcb.200705035
   Yang D, 2018, CELL BIOL INT, V42, P403, DOI 10.1002/cbin.10902
   Ye J, 2014, TUMOR BIOL, V35, P3945, DOI 10.1007/s13277 013 1561 x
   Yoshida K, 2018, MOL CELL ENDOCRINOL, V470, P251, DOI 10.1016/j.mce.2017.11.005
   Zeng ZH, 2017, METHODS MOL BIOL, V1633, P75, DOI 10.1007/978 1 4939 7142 8_5
   Zhang Q, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00094
   Zhao ZG, 2007, STEM CELLS DEV, V16, P637, DOI 10.1089/scd.2007.0008
   Zhou PH, 2014, NATURE, V506, P52, DOI 10.1038/nature12988
   Zhu SL, 2017, NUCLEIC ACIDS RES, V45, P10583, DOI 10.1093/nar/gkx686
   Ziani L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00414
   Zou LJ, 2006, ADV EXP MED BIOL, V585, P431
   Zuo CL, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0013 z
NR 151
TC 45
Z9 51
U1 0
U2 25
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167 4889
EI 1879 2596
J9 BBA MOL CELL RES
JI Biochim. Biophys. Acta Mol. Cell Res.
PD JAN
PY 2019
VL 1866
IS 1
SI SI
BP 144
EP 152
DI 10.1016/j.bbamcr.2018.07.006
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HD5MC
UT WOS:000452573500013
PM 30026077
DA 2025 08 17
ER

PT J
AU Berger, MB
   Cohen, DJ
   Olivares Navarrete, R
   Williams, JK
   Cochran, DL
   Boyan, BD
   Schwartz, Z
AF Berger, Michael B.
   Cohen, David J.
   Olivares Navarrete, Rene
   Williams, Joseph K.
   Cochran, David L.
   Boyan, Barbara D.
   Schwartz, Zvi
TI Human osteoblasts exhibit sexual dimorphism in their response to
   estrogen on microstructured titanium surfaces
SO BIOLOGY OF SEX DIFFERENCES
LA English
DT Article
DE Human osteoblasts; Sex specific responses; Hormones; Estradiol;
   1,25 Dihydroxy vitamin D3; Titanium surface roughness
ID IMPLANT SURFACES; DENTAL IMPLANTS; CELL RESPONSE; STEM CELLS; BONE MASS;
   IN VITRO; ROUGHNESS; ENERGY; WOMEN; AGE
AB Background: Osseointegration is dependent on the implant surface, surrounding bone quality, and the systemic host environment, which can differ in male and female patients. Titanium (Ti) implants with microstructured surfaces exhibit greater pullout strength when compared to smooth surfaced implants and exhibit enhanced osteogenic cellular responses in vitro. Previous studies showed that 1a,25 dihydroxyvitamin D3 [1a,25(OH)(2)D 3] has a greater effect on rat osteoblast differentiation on microstructured Ti compared to smooth Ti surfaces and tissue culture polystyrene (TCPS). The stimulatory effect of 17 beta estradiol (E 2 ) on differentiation is observed in female osteoblasts on micro rough Ti, but it is not known if male osteoblasts behave similarly in response to E 2 and microtopography. This study assessed whether human male and female osteoblasts exhibit sex specific differences in response to E 2 and 1a,25(OH)(2)D 3 when cultured on microstructured Ti surfaces.
   Methods: Osteoblasts from three male and three female human donors were cultured on Ti discs with varying surface profiles: a smooth pretreatment (PT), a coarse grit blasted/acid etched (SLA), and an SLA surface having undergone modification in a nitrogen environment and stored in saline to maintain hydrophilicity (modSLA). Cells cultured on these surfaces were treated with E 2 or 1a,25(OH)(2)D 3.
   Results: Male and female human osteoblasts responded similarly to microstructure although there were donor specific differences; cell number decreased, and osteocalcin (OCN), osteoprotegerin (OPG), and latent and active transforming growth factor 1 increased on SLA and modSLA compared to TCPS. Female osteoblasts had higher alkaline phosphatase activity and OCN production than male counterparts but produced less OPG. Both sexes responded similarly to 1a,25(OH)(2)D 3. E 2 treatment reduced cell number and increased osteoblast differentiation and factor production only in female cells.
   Conclusions: Male and female human osteoblasts respond similarly to microstructure and 1a,25(OH)(2)D 3 but exhibit sexual dimorphism in substrate dependent responses to E 2. E 2 affected female osteoblasts, suggesting that signaling is sex specific and surface dependent. Donor osteoblasts varied in response, demonstrating the need to test multiple donors when examining human samples. Understanding how male and female cells respond to orthopedic biomaterials will enable greater predictability post implantation as well as therapies that are more patient specific.
C1 [Berger, Michael B.; Cohen, David J.; Olivares Navarrete, Rene; Boyan, Barbara D.; Schwartz, Zvi] Virginia Commonwealth Univ, Coll Engn, Dept Biomed Engn, 601 West Main St, Richmond, VA 23284 USA.
   [Williams, Joseph K.] Childrens Healthcare Atlanta, Atlanta, GA 30332 USA.
   [Cochran, David L.; Schwartz, Zvi] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA.
   [Boyan, Barbara D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA.
C3 Virginia Commonwealth University; Children's Healthcare of Atlanta
   (CHOA); University System of Georgia; Georgia Institute of Technology;
   University of Texas System; University of Texas Health Science Center at
   San Antonio
RP Boyan, BD (通讯作者)，Virginia Commonwealth Univ, Coll Engn, Dept Biomed Engn, 601 West Main St, Richmond, VA 23284 USA.; Boyan, BD (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA.
EM bboyan@vcu.edu
OI Olivares Navarrete, Rene/0000 0003 1232 9164; Boyan, Barbara
   D./0000 0002 9642 0311; Berger, Michael/0000 0002 3908 7612
FU Institut Straumann AG; US PHS [1 R01 AR052102]
FX This study was funded in part by Institut Straumann AG. Institut
   Straumann AG was not involved in the design, collection, analysis, or
   interpretation of the data for this study or writing of the manuscript.
   Titanium disks were provided by Institut Straumann AG as a gift. This
   research was also funded by US PHS Grant 1 R01 AR052102.
CR Armen TA, 2000, J CELL BIOCHEM, V79, P620, DOI 10.1002/1097 4644(20001215)79:4<620::AID JCB110>3.0.CO;2 H
   Bellahcene A, 2008, NAT REV CANCER, V8, P212, DOI 10.1038/nrc2345
   BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874
   Bessho K, 1999, CLIN ORAL IMPLAN RES, V10, P212, DOI 10.1034/j.1600 0501.1999.100304.x
   Bodnar LM, 2007, J NUTR, V137, P447, DOI 10.1093/jn/137.2.447
   Boyan B. D., 2003, European Cells & Materials, V6, P22
   Boyan BD, 1998, J BIOMED MATER RES, V39, P77, DOI 10.1002/(SICI)1097 4636(199801)39:1<77::AID JBM10>3.0.CO;2 L
   Boyan BD, 2003, J ORTHOP RES, V21, P638, DOI 10.1016/S0736 0266(02)00261 9
   Boyan BD, 2002, CALCIFIED TISSUE INT, V71, P519, DOI 10.1007/s00223 001 1114 y
   Boyan BD, 2001, J BIOMED MATER RES, V55, P350, DOI 10.1002/1097 4636(20010605)55:3<350::AID JBM1023>3.0.CO;2 M
   BUSER D, 1991, J BIOMED MATER RES, V25, P889, DOI 10.1002/jbm.820250708
   Christodoulou S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/396541
   D'Amelio P, 2008, CONNECT TISSUE RES, V49, P99, DOI 10.1080/03008200801913940
   Deligianni DD, 2001, BIOMATERIALS, V22, P1241, DOI 10.1016/S0142 9612(00)00274 X
   Doroudi M, 2014, STEROIDS, V81, P81, DOI 10.1016/j.steroids.2013.10.019
   Erdman CP, 2012, J TISSUE ENG REGEN M, V6, ps34, DOI 10.1002/term.513
   FRANK GR, 1995, ACTA PAEDIATR, V84, P627, DOI 10.1111/j.1651 2227.1995.tb13714.x
   GASPERINO J, 1995, CLIN ORTHOP RELAT R, P278
   Hotchkiss KM, 2017, CLIN ORAL IMPLAN RES, V28, P414, DOI 10.1111/clr.12814
   Kinney RC, 2005, OSTEOARTHR CARTILAGE, V13, P330, DOI 10.1016/j.joca.2004.12.003
   Lai M, 2015, J BIOMED MATER RES A, V103, P564, DOI 10.1002/jbm.a.35185
   Lapauw BM, 2009, J BONE MINER RES, V24, P1075, DOI [10.1359/JBMR.081260, 10.1359/jbmr.081260]
   Le Guéhennec L, 2007, DENT MATER, V23, P844, DOI 10.1016/j.dental.2006.06.025
   LeBoff MS, 2008, OSTEOPOROSIS INT, V19, P1283, DOI 10.1007/s00198 008 0582 6
   LIEBERHERR M, 1993, J BONE MINER RES, V8, P1365
   Lohmann CH, 2000, J BONE MINER RES, V15, P1169, DOI 10.1359/jbmr.2000.15.6.1169
   Lohmann CH, 2002, J BIOMED MATER RES, V62, P204, DOI 10.1002/jbm.10290
   Lotz EM, 2018, ACTA BIOMATER, V68, P296, DOI 10.1016/j.actbio.2017.12.039
   Lotz EM, 2016, J BIOMED MATER RES A, V104, P3137, DOI 10.1002/jbm.a.35852
   MARTIN RB, 1988, J BONE JOINT SURG AM, V70A, P540, DOI 10.2106/00004623 198870040 00010
   Matsumoto T, 2008, ARTHRITIS RHEUM US, V58, P3809, DOI 10.1002/art.24125
   NASATZKY E, 1994, CONNECT TISSUE RES, V30, P277, DOI 10.3109/03008209409015043
   Olivares Navarrete R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/365014
   Olivares Navarrete R, 2014, ANN BIOMED ENG, V42, P2551, DOI 10.1007/s10439 014 1108 3
   Olivares Navarrete R, 2011, BIOMATERIALS, V32, P6399, DOI 10.1016/j.biomaterials.2011.05.036
   Olivares Navarrete Rene, 2010, Biol Sex Differ, V1, P4, DOI 10.1186/2042 6410 1 4
   Olivares Navarrete R, 2010, BIOMATERIALS, V31, P2728, DOI 10.1016/j.biomaterials.2009.12.029
   Pan JL, 2000, J ORAL MAXIL SURG, V58, P877, DOI 10.1053/joms.2000.8212
   Rathbun AM, 2016, ARCH OSTEOPOROS, V11, DOI 10.1007/s11657 016 0263 6
   Raz P, 2004, J BIOMED MATER RES A, V71A, P217, DOI 10.1002/jbm.a.30134
   Rupp F, 2006, J BIOMED MATER RES A, V76A, P323, DOI 10.1002/jbm.a.30518
   Saggese G, 2002, BEST PRACT RES CL EN, V16, P53, DOI 10.1053/beem.2001.0180
   Schoenau E, 2002, CALCIFIED TISSUE INT, V70, P405, DOI 10.1007/s00223 001 0048 8
   Schwartz Z, 2001, J BIOMED MATER RES, V56, P417, DOI 10.1002/1097 4636(20010905)56:3<417::AID JBM1111>3.0.CO;2 K
   Schwartz Z, 2001, BIOMATERIALS, V22, P731, DOI 10.1016/S0142 9612(00)00241 6
   Schwartz Z, 2008, J BONE JOINT SURG AM, V90A, P2485, DOI 10.2106/JBJS.G.00499
   Schwartz Z, 2007, J STEROID BIOCHEM, V103, P606, DOI 10.1016/j.jsbmb.2006.12.083
   Schwartz Z, 2009, BIOMATERIALS, V30, P3390, DOI 10.1016/j.biomaterials.2009.03.047
   Schwarz F, 2009, J BIOMED MATER RES B, V88B, P544, DOI 10.1002/jbm.b.31233
   Somjen D, 2013, J ENDOCRINOL INVEST, V36, P118, DOI 10.1007/BF03346746
   Taha W, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.5.e79
   Tosi LL, 2005, J BONE JOINT SURG AM, V87A, P1631, DOI 10.2106/JBJS.E.00218
   Vashishth D, 2005, ANAT REC PART A, V282A, P157, DOI 10.1002/ar.a.20146
   Visser M, 2006, AM J CLIN NUTR, V84, P616, DOI 10.1093/ajcn/84.3.616
   Wang LP, 2006, BIOMATERIALS, V27, P3716, DOI 10.1016/j.biomaterials.2006.02.022
   Wennerberg A, 1998, CLIN ORAL IMPLAN RES, V9, P11, DOI 10.1034/j.1600 0501.1998.090102.x
   Zhao G, 2007, BIOMATERIALS, V28, P2821, DOI 10.1016/j.biomaterials.2007.02.024
   Zhao G, 2006, CLIN ORAL IMPLAN RES, V17, P258, DOI 10.1111/j.1600 0501.2005.01195.x
   Zhao G, 2005, J BIOMED MATER RES A, V74A, P49, DOI 10.1002/jbm.a.30320
   Zinger O, 2005, BIOMATERIALS, V26, P1837, DOI 10.1016/j.biomaterials.2004.06.035
NR 60
TC 19
Z9 21
U1 0
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2042 6410
J9 BIOL SEX DIFFER
JI Biol. Sex Differ.
PD JUL 3
PY 2018
VL 9
AR 30
DI 10.1186/s13293 018 0190 x
PG 10
WC Endocrinology & Metabolism; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity
GA GL6SM
UT WOS:000437320800001
PM 29970177
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Albulescu, DM
   Preda, AS
   Camen, A
   Ionovici, N
AF Albulescu, Dana Maria
   Preda, Adelina Smaranda
   Camen, Adrian
   Ionovici, Nina
TI Ibandronat in the Therapy of Osteoporosis in Turner Syndrome
SO REVISTA DE CHIMIE
LA English
DT Article
DE ibandronat; osteoporosis; Turner syndrome
ID DISEASE FREE MARGINS; BONE TURNOVER; BISPHOSPHONATES; MECHANISMS;
   FRACTURES; EFFICACY; MARKERS; BLUE
AB Turner syndrome represents a condition that associates diverse pathology with somatic, metabolic (diabetes), cardio vascular, digestive, respiratory and bone involvement along with chromosomal abnormalities. In our study we have analyzed the bone pathology that occurs in Turner syndrome and the response in the therapy with ibandronat. The decrease in value of the bone turn over biomarkers and the decrease of the T score after the administration of ibandronate p.o. in a monthly dosage demonstrates the efficiency of this bisphosphonate in the treatment of the osteoporosis secondary to sexual hormone deficiency in Turner syndrome.
C1 [Albulescu, Dana Maria] Univ Med & Pharm Craiova, Dept Anat, 2 Petru Rares Str, Craiova, Romania.
   [Preda, Adelina Smaranda] Univ Med & Pharm Craiova, 2 Petru Rares Str, Craiova, Romania.
   [Camen, Adrian] Univ Med & Pharm Craiova, Dept Oromaxilofacial Surg, 2 Petru Rares Str, Craiova, Romania.
   [Ionovici, Nina] Univ Med & Pharm Craiova, Res Ctr Microscop Morphol & Immunol, 2 Petru Rares Str, Craiova, Romania.
C3 University of Medicine & Pharmacy of Craiova; University of Medicine &
   Pharmacy of Craiova; University of Medicine & Pharmacy of Craiova;
   University of Medicine & Pharmacy of Craiova
RP Camen, A (通讯作者)，Univ Med & Pharm Craiova, Dept Oromaxilofacial Surg, 2 Petru Rares Str, Craiova, Romania.
EM adycamen@icloud.com
RI Adelina Preda, A.S.Preda/AAV 2081 2020; albulescu, dana/AAS 9895 2020;
   Camen, Adrian/KJM 6006 2024
CR Bauss F, 2004, OSTEOPOROSIS INT, V15, P423, DOI 10.1007/s00198 004 1612 7
   Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367
   BONDARI S, 2015, OST INT OTH MET BON, V26, P216
   Bonnick SL, 2010, MENOPAUSE, V17, P25, DOI [10.1097/gme.0b013e3181c617e6, 10.1097/gme.0b013e3181e617e6]
   Boonen S, 2005, OSTEOPOROSIS INT, V16, P1291, DOI 10.1007/s00198 005 1945 x
   Delmas PD, 2000, OSTEOPOROSIS INT, V11, P66
   Delmas PD, 2000, OSTEOPOROSIS INT, V11, P2, DOI 10.1007/s001980070002
   Donescu OS, 2006, OSTEOPOROSIS INT, V17, pS18
   Dragoi D, 2010, ROM J MORPHOL EMBRYO, V51, P707
   Ebetino FH, 1998, REV CONTEMP PHARMACO, V9, P233
   Gravholt CH, 2003, CLIN ENDOCRINOL, V59, P89, DOI 10.1046/j.1365 2265.2003.01807.x
   Holroyd CR, 2010, OSTEOPOROSIS INT, V21, P2093, DOI 10.1007/s00198 010 1170 0
   Ionovici N, 2009, ROM J MORPHOL EMBRYO, V50, P79
   Lazar AC, 2017, REV CHIM BUCHAREST, V68, P246
   Levitsky LL, 2015, CURR OPIN ENDOCRINOL, V22, P65, DOI 10.1097/MED.0000000000000128
   Nechita AM, 2016, FARMACIA, V64, P348
   Papapoulos SE, 2007, ANN RHEUM DIS, V66, P853, DOI 10.1136/ard.2006.064931
   Pituru TS, 2016, J CRANIO MAXILL SURG, V44, P500, DOI 10.1016/j.jcms.2016.01.002
   PREDA S.A., 2016, WORLD C OST OST M S1, V27, P293
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell R.G.G., 1970, Calcif. Tissue Res, V6, P83
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Stefanescu DC, 2016, REV CHIM BUCHAREST, V67, P1327
   Stefanescu DC, 2016, REV CHIM BUCHAREST, V67, P1255
   Tankó LB, 2004, J BONE MINER RES, V19, P1531, DOI 10.1359/JBMR.040715
   TRIPATHY D, 2002, ANN ONCOL, V13, P168
NR 26
TC 6
Z9 6
U1 0
U2 6
PU CHIMINFORM DATA S A
PI BUCHAREST
PA CALEA PLEVNEI NR 139, SECTOR 6, BUCHAREST R 77131, ROMANIA
SN 0034 7752
J9 REV CHIM BUCHAREST
JI Rev. Chim.
PD JUL
PY 2018
VL 69
IS 7
BP 1692
EP 1694
PG 3
WC Chemistry, Multidisciplinary; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Engineering
GA GT6BP
UT WOS:000444595700018
DA 2025 08 17
ER

PT J
AU Pierfelice, TV
   D'Amico, E
   D'Ercole, S
   Lepore, S
   Piattelli, A
   Barone, A
   Iezzi, G
   Petrini, M
AF Pierfelice, Tania Vanessa
   D'Amico, Emira
   D'Ercole, Simonetta
   Lepore, Stefania
   Piattelli, Adriano
   Barone, Antonio
   Iezzi, Giovanna
   Petrini, Morena
TI Functionalization of a Cortical Membrane with a Photodynamic Protocol
SO JOURNAL OF FUNCTIONAL BIOMATERIALS
LA English
DT Article
DE lamina cortical membrane; photodynamic therapy; osteoblasts;
   5 aminolevulinic acid; LED; ALP; calcium deposition; GBR
ID GUIDED BONE REGENERATION; PROTOPORPHYRIN IX; FERROCHELATASE; MECHANISMS;
   THERAPY; ACCUMULATION
AB Guided bone regeneration (GBR) comprehends the application of membranes to drive bone healing and to exclude non osteogenic tissues from interfering with bone regeneration. However, the membranes may be exposed to bacterial attack, with the risk of failure of the GBR. Recently, an antibacterial photodynamic protocol (ALAD PDT) based on a gel with 5% 5 aminolevulinic acid incubated for 45 min and irradiated for 7 min by a LED light at 630 nm, also showed a pro proliferative effect on human fibroblasts and osteoblasts. The present study hypothesized that the functionalization of a porcine cortical membrane (soft curved lamina, OsteoBiol) with ALAD PDT might promote its osteoconductive properties. TEST 1 aimed to verify the response of osteoblasts seeded on lamina with respect to the plate surface (CTRL). TEST 2 aimed to investigate the effects of ALAD PDT on the osteoblasts cultured on the lamina. SEM analyses were performed to study the topographical characteristics of the membrane surface, the adhesion, and the morphology of cells at 3 days. The viability was assessed at 3 days, the ALP activity at 7 days, and calcium deposition at 14 days. Results showed the porous surface of the lamina and the increase in cell attachment of osteoblasts with respect to controls. The proliferation, the ALP, and bone mineralization activity of osteoblasts seeded on lamina resulted in being significantly higher (p < 0.0001) than controls. Results also showed an additional significative enhancement (p < 0.0001) in the proliferative rate in ALP and calcium deposition after applying ALAD PDT. In conclusion, the functionalization of the cortical membranes cultured with osteoblasts with the ALAD PDT improved their osteoconductive properties.
C1 [Pierfelice, Tania Vanessa; D'Amico, Emira; D'Ercole, Simonetta; Lepore, Stefania; Iezzi, Giovanna; Petrini, Morena] Univ G Annunzio Chieti Pescara, Dept Med Oral & Biotechnol Sci, Via Vestini 31, I 66013 Chieti, Italy.
   [Piattelli, Adriano] St Camillus Int Univ Hlth & Med Sci, Sch Dent, Via St Alessandro 8, I 00131 Rome, Italy.
   [Piattelli, Adriano] UCAM Univ Catol San Antonio Murcia, Fac Med, Murcia 30107, Spain.
   [Barone, Antonio] Univ Pisa, Sch Dent, Dept Surg Med Mol Pathol & Crit Needs, I 56100 Pisa, Italy.
   [Barone, Antonio] Univ Hosp Pisa, Complex Unit Stomatol & Oral Surg, I 56100 Pisa, Italy.
   [Barone, Antonio] Univ Geneva, Univ Hosp Geneva, Unit Oral Surg & Implantol, CH 1205 Geneva, Switzerland.
C3 G d'Annunzio University of Chieti Pescara; University of Pisa;
   University of Pisa; Azienda Ospedaliero Universitaria Pisana; University
   of Geneva
RP D'Ercole, S (通讯作者)，Univ G Annunzio Chieti Pescara, Dept Med Oral & Biotechnol Sci, Via Vestini 31, I 66013 Chieti, Italy.
EM simonetta.dercole@unich.it
RI ; Petrini, Morena/AAA 8334 2019; D'Ercole, Simonetta/ACP 1645 2022;
   Barone, Antonio/O 2738 2013
OI Pierfelice, Tania Vanessa/0000 0002 5886 2186; Ramamurthy,
   Poornima/0000 0002 9096 1889; Petrini, Morena/0000 0002 3849 4304;
   D'AMICO, EMIRA/0000 0003 2414 7130; D'Ercole,
   Simonetta/0000 0002 4797 4019
FU G.I. and M.P. FAR GRANT University of Chieti Pescara Fund
FX This work was supported by G.I. and M.P. FAR GRANT University of
   Chieti Pescara Fund.
CR Azaripour A, 2018, CLIN LAB, V64, P1225, DOI 10.7754/Clin.Lab.2018.180220
   Aziz B, 2023, BIOMEDICINES, V11, DOI 10.3390/biomedicines11010224
   Becerra J, 2022, J MATER SCI MATER M, V33, DOI 10.1007/s10856 022 06643 w
   Chang HI, 2011, REGENERATIVE MEDICINE AND TISSUE ENGINEERING   CELLS AND BIOMATERIALS, P569
   D'Ercole S, 2022, GELS BASEL, V8, DOI 10.3390/gels8110697
   de Carvalho GG, 2020, PHOTODIAGN PHOTODYN, V30, DOI 10.1016/j.pdpdt.2020.101705
   Di Carlo R, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9040604
   Di Lodovico S, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23136942
   Elgali I, 2017, EUR J ORAL SCI, V125, P315, DOI 10.1111/eos.12364
   Fontana F, 2011, INT J PERIODONT REST, V31, P265
   Fukuhara H, 2013, PHOTODIAGN PHOTODYN, V10, P399, DOI 10.1016/j.pdpdt.2013.03.003
   Gallardo Villagrán M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133339
   Gholami L, 2023, FRONT MICROBIOL, V13, DOI 10.3389/fmicb.2022.1020995
   Jin JQ, 2019, PHOTODIAGN PHOTODYN, V26, P134, DOI 10.1016/j.pdpdt.2019.03.011
   Kou JY, 2017, ONCOTARGET, V8, P81591, DOI 10.18632/oncotarget.20189
   Kwiatkowski S, 2018, BIOMED PHARMACOTHER, V106, P1098, DOI 10.1016/j.biopha.2018.07.049
   Lan MH, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201900132
   Lauritano D, 2022, APPL SCI BASEL, V12, DOI 10.3390/app12063102
   Li X, 2013, J SURG RES, V184, P1013, DOI 10.1016/j.jss.2013.03.094
   Liu QM, 2021, BEHAV RES METHODS, V53, P264, DOI 10.3758/s13428 020 01407 2
   Nakai Y, 2016, PHOTODIAGN PHOTODYN, V13, P225, DOI 10.1016/j.pdpdt.2015.07.174
   O'Brien FJ, 2005, BIOMATERIALS, V26, P433, DOI 10.1016/j.biomaterials.2004.02.052
   Ohgari Y, 2005, BIOCHEM PHARMACOL, V71, P42, DOI 10.1016/j.bcp.2005.10.019
   Ou JL, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 13497 3
   Petrini M, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10030572
   Petrini M, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19053048
   Pierfelice TV, 2022, LASER MED SCI, V37, P3671, DOI 10.1007/s10103 022 03651 8
   Pierfelice TV, 2022, GELS BASEL, V8, DOI 10.3390/gels8080491
   Qian Y, 2023, BIOMATER SCI UK, V11, P704, DOI 10.1039/d2bm01384c
   Radunovic M, 2020, J PHOTOCH PHOTOBIO B, V205, DOI 10.1016/j.jphotobiol.2020.111826
   Ramos UD, 2017, CLIN ORAL IMPLAN RES, V28, P1388, DOI 10.1111/clr.12998
   Rossi R, 2022, ANTIBIOTICS BASEL, V11, DOI 10.3390/antibiotics11091267
   Sachar M, 2016, J PHARMACOL EXP THER, V356, P267, DOI 10.1124/jpet.115.228130
   Stájer A, 2020, DENT J BASEL, V8, DOI 10.3390/dj8020043
   Wachtel H, 2013, INT J PERIODONT REST, V33, P491, DOI 10.11607/prd.1248
   Wu ZZ, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.752506
NR 36
TC 2
Z9 2
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2079 4983
J9 J FUNCT BIOMATER
JI J. Func. Biomater.
PD MAR
PY 2023
VL 14
IS 3
AR 133
DI 10.3390/jfb14030133
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA A8YG0
UT WOS:000957912300001
PM 36976057
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kelly, NH
   Schimenti, JC
   Ross, FP
   van der Meulen, MCH
AF Kelly, Natalie H.
   Schimenti, John C.
   Ross, F. Patrick
   van der Meulen, Marjolein C. H.
TI Transcriptional profiling of cortical versus cancellous bone from
   mechanically loaded murine tibiae reveals differential gene expression
SO BONE
LA English
DT Article
DE Osteoporosis; Animal models; Mechanical loading; Transcriptome;
   Cancellous bone; Cortical bone
ID ESTROGEN RECEPTOR ALPHA; RANDOMIZED CONTROLLED TRIAL; MINERAL DENSITY;
   FEMALE MICE; IN VIVO; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN;
   SCLEROSTIN ANTIBODY; SOST GENE; STRENGTH
AB Mechanical loading is an anabolic stimulus that increases bone mass, and thus a promising method to counteract osteoporosis related bone loss. The mechanism of this anabolism remains unclear, and needs to be established for both cortical and cancellous envelopes individually. We hypothesized that cortical and cancellous bone display different gene expression profiles at baseline and in response to mechanical loading. To test this hypothesis, the left tibiae of 10 week old female C57B16 mice were subjected to one session of axial tibial compression (9 N, 1200 cycles, 4 Hz riangle waveform) and euthanized 3 and 24 h following loading. The right limb served as the contralateral control. We performed RNA seq on marrow free metaphyseal samples from the cortical shell and the cancellous core to determine differential gene expression at baseline (control limb) and in response to load. Differential expression was verified with qPCR. Cortical and cancellous bone exhibited distinctly different transcriptional profiles basally and in response to mechanical loading. More genes were differentially expressed with loading at 24 h with more genes downregulated at 24 h than at 3 h in both tissues. Enhanced Wnt signaling dominated the response in cortical bone at 3 and 24 h, but in cancellous bone only at 3 h. In cancellous bone at 24 h many muscle related genes were downregulated. These findings reveal key differences between cortical and cancellous genetic regulation in response to mechanical loading. Future studies at different time points and multiple loading sessions will add to our knowledge of cortical and cancellous mechanotransduction with the potential to identify new targets for mouse genetic knockout studies and drugs to treat osteoporosis. ( C) 2016 Elsevier Inc. All rights reserved.
C1 [Kelly, Natalie H.; van der Meulen, Marjolein C. H.] Cornell Univ, Sibley Sch Mech & Aerosp Engn, 105 Upson Hall, Ithaca, NY 14853 USA.
   [Kelly, Natalie H.; van der Meulen, Marjolein C. H.] Cornell Univ, Nancy E & Peter C Meinig Sch Biomed Engn, 101 Weill Hall, Ithaca, NY 14853 USA.
   [Schimenti, John C.] Cornell Univ, Coll Vet Med, Ithaca, NY 14853 USA.
   [Ross, F. Patrick; van der Meulen, Marjolein C. H.] Hosp Special Surg, Div Res, 541 East 71st St, New York, NY 10021 USA.
C3 Cornell University; Cornell University; Cornell University
RP van der Meulen, MCH (通讯作者)，Cornell Univ, Sibley Sch Mech & Aerosp Engn, 219 Upson Hall, Ithaca, NY 14853 USA.
EM nhk28@cornell.edu; jcs92@comell.edu; RossF@hss.edu; mcv3@cornell.edu
RI van der Meulen, Marjolein/D 1549 2010; van der Meulen, Marjolein
   Christine Hermance/D 1549 2010
OI van der Meulen, Marjolein Christine Hermance/0000 0001 6637 9808
FU National Institutes of Health [R01 AG028664, R21 AR064034]; NSF GRF
FX National Institutes of Health Grants R01 AG028664 (MCHM) and
   R21 AR064034 (MCHM), NSF GRF (NHK).
CR Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200
   Ayturk UM, 2013, J BONE MINER RES, V28, P2081, DOI 10.1002/jbmr.1946
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   BILEZIKIAN JP, 1994, JAMA J AM MED ASSOC, V272, P1942, DOI 10.1001/jama.1994.03520240070044
   Bonnet N, 2009, J BIOL CHEM, V284, P35939, DOI 10.1074/jbc.M109.060335
   Brodt MD, 1999, J BONE MINER RES, V14, P2159, DOI 10.1359/jbmr.1999.14.12.2159
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Fritton JC, 2005, BONE, V36, P1030, DOI 10.1016/j.bone.2005.02.013
   Fuchs RK, 2001, J BONE MINER RES, V16, P148, DOI 10.1359/jbmr.2001.16.1.148
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   Grimston SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044222
   Holguin N, 2013, CALCIFIED TISSUE INT, V93, P211, DOI 10.1007/s00223 013 9744 4
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Isaac J, 2014, CELL DEATH DIFFER, V21, P1365, DOI 10.1038/cdd.2014.82
   Jacobsen CM., 2014, J Bone Miner Res
   Kedlaya R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006627
   Kelly NH., 2014, Bone
   Kondoh S, 2014, BONE, V60, P68, DOI 10.1016/j.bone.2013.12.005
   Kontulainen S, 2003, J BONE MINER RES, V18, P352, DOI 10.1359/jbmr.2003.18.2.352
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lara Castillo N, 2015, BONE, V76, P58, DOI 10.1016/j.bone.2015.03.019
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lynch ME, 2011, BONE, V49, P439, DOI 10.1016/j.bone.2011.05.017
   Lynch ME, 2010, J APPL PHYSIOL, V109, P685, DOI 10.1152/japplphysiol.00210.2010
   Macias BR, 2013, BONE, V53, P515, DOI 10.1016/j.bone.2013.01.018
   Main RP, 2014, J EXP BIOL, V217, P1775, DOI 10.1242/jeb.085522
   Main RP, 2010, J BIOMECH, V43, P2689, DOI 10.1016/j.jbiomech.2010.06.019
   Martin Millan M, 2010, MOL ENDOCRINOL, V24, P323, DOI 10.1210/me.2009 0354
   McBride SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096862
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Melville KM, 2015, J BONE MINER RES, V30, P1468, DOI 10.1002/jbmr.2488
   Melville KM, 2014, J BONE MINER RES, V29, P370, DOI 10.1002/jbmr.2082
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Paic F, 2009, BONE, V45, P682, DOI 10.1016/j.bone.2009.06.010
   Poulet B, 2012, ARTHRITIS RHEUM US, V64, P3256, DOI 10.1002/art.34572
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rolfe RA, 2014, BMC GENOMICS, V15, DOI 10.1186/1471 2164 15 48
   Roosa SMM, 2011, J BONE MINER RES, V26, P100, DOI 10.1002/jbmr.193
   Silva MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034980
   Sugiyama T, 2010, BONE, V46, P314, DOI 10.1016/j.bone.2009.08.054
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Vainionpää A, 2005, OSTEOPOROSIS INT, V16, P191, DOI 10.1007/s00198 004 1659 5
   Wasserman E, 2013, BONE, V53, P14, DOI 10.1016/j.bone.2012.11.017
   Windahl SH, 2013, P NATL ACAD SCI USA, V110, P2294, DOI 10.1073/pnas.1220811110
   Winters Stone KM, 2006, BONE, V39, P1203, DOI 10.1016/j.bone.2006.06.005
   Xing WR, 2005, J CELL BIOCHEM, V96, P1049, DOI 10.1002/jcb.20606
   Yang L, 2014, P NATL ACAD SCI USA, V111, P12097, DOI 10.1073/pnas.1302703111
   Zaman G, 2010, BONE, V46, P628, DOI 10.1016/j.bone.2009.10.021
   Zheng HF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002745
   Zhou X, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004820
NR 58
TC 55
Z9 76
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2016
VL 86
BP 22
EP 29
DI 10.1016/j.bone.2016.02.007
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DJ9CX
UT WOS:000374512700003
PM 26876048
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Zhang, N
   Wei, QS
   Dong, YP
   Liu, YW
   Yuan, Q
   He, W
   Jing, ZH
   Hong, ZN
   Zhang, LL
   Wang, HB
   Li, WY
AF Zhang, Ying
   Zhang, Ning
   Wei, Qiushi
   Dong, Yipping
   Liu, Youwen
   Yuan, Qiang
   He, Wei
   Jing, Zhenhao
   Hong, Zhinan
   Zhang, Leilei
   Wang, Haibin
   Li, Wuyin
TI MiRNA 320a 5p contributes to the homeostasis of osteogenesis and
   adipogenesis in bone marrow mesenchymal stem cell
SO REGENERATIVE THERAPY
LA English
DT Article
DE TIONFH; miRNA 320a; RUNX2; Osteoblast differentiation; Adipocyte
   differentiation
ID FEMORAL HEAD NECROSIS; NONTRAUMATIC OSTEONECROSIS; DIFFERENTIATION;
   MICRORNAS; IDENTIFICATION; MECHANISM; TARGET; GROWTH; RUNX2
AB Objective: A number of miRNAs and their targets were dragged in the differentiation of bone marrow mesenchymal stem cells (BMSCs). We aimed to elaborate the underlying molecular mechanisms of miRNA 320a in the osteoblast and adipocyte differentiation. Methods: Trauma induced osteonecrosis of the femoral head (TIONFH) and normal control samples (n 1/4 10 for each group) were collected, followed by miRNA chip analysis to identify the differentially expressed miRNAs. H&E staining was used to observe the pathological development of TIONFH. Lentiviral vector was used for overexpression and inhibition of miRNA 320a in vitro. Quantitative real time PCR (qPCR), Western blotting and immunohistochemistry staining were employed to determine the expression of interested genes at mRNA or protein level. Luciferase report assay was employed to determine the binding of miRNA 320a and RUNX2. Alkaline phosphatase (ALP) and Alizarin red staining were performed to observe the osteogenesis and Oil red O staining were conducted to visualize the adipogenesis. Results: Expression of miRNA 320a was up regulated while RUNX2 expression was down regulated in TIONFH than Normal control. Luciferase report assay confirmed that miRNA 320a directly targeted to the 30UTR of RUNX2. miRNA 320a overexpression significantly declined the expressions of osteogenesisrelated markers: RUNX2, OSTERIX, Collagen I, Osteocalcin and Osteopontin. ALP and Alizarin red staining confirmed the inhibition function of miRNA 320a in osteogenesis of BMSCs. miRNA 320a inhibition significantly decreased the expression of adipogenesis related markers: AP2, C/EBPa, FABP4 and PPARg. Oil Red O staining confirmed the miRNA 320a inhibition reduced adipogenesis of BMSCs. Conclusions: miRNA 320a inhibits osteoblast differentiation via targeting RUNX2 and promotes adipocyte differentiation of BMSCs. (c) 2022, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.
C1 [Zhang, Ying; Liu, Youwen; Zhang, Leilei; Li, Wuyin] Orthoped Hosp Henan Prov, Luoyang Orthoped Traumatol Hosp, Med Ctr Hip, 82 Qiming South Rd, Luoyang 471002, Henan, Peoples R China.
   [Zhang, Ying; Wang, Haibin] Guangzhou Univ Tradit Chinese Med, Guangzhou 510405, Guangdong, Peoples R China.
   [Zhang, Ning] Hunan Univ Tradit Chinese Med, Changsha 410208, Hunan, Peoples R China.
   [Wei, Qiushi; He, Wei; Hong, Zhinan] Guangzhou Univ Tradit Chinese Med, Inst Orthopaed, Guangzhou 510240, Peoples R China.
   [Wei, Qiushi; He, Wei; Hong, Zhinan] Guangzhou Univ Tradit Chine, Affiliated Hosp 3, Guangzhou 510240, Peoples R China.
   [Dong, Yipping; Yuan, Qiang; Jing, Zhenhao] Henan Univ Tradit Chinese Med, Zhengzhou 450046, Henan, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Hunan University of Chinese
   Medicine; Guangzhou University of Chinese Medicine; Henan University of
   Traditional Chinese Medicine
RP Li, WY (通讯作者)，Orthoped Hosp Henan Prov, Luoyang Orthoped Traumatol Hosp, Med Ctr Hip, 82 Qiming South Rd, Luoyang 471002, Henan, Peoples R China.; Wang, HB (通讯作者)，Guangzhou Univ Tradit Chinese Med, Guangzhou 510405, Guangdong, Peoples R China.
EM hipknee@163.com; liwuyin2000@163.com
RI Liu, Youwen/AAE 7833 2019; Zhang, Ning/S 8849 2019; Yuan,
   Qiang/S 1556 2016
FU National Science Foundation of China [81774348, 81874477]; Science and
   Technology Project of Henan Province [212102310365]
FX This work was supported by National Science Foundation of China (grant
   number 81774348 and 81874477) ; and Science and Technology Project of
   Henan Province (grant number 212102310365) .
CR Balla B, 2011, DIS MARKERS, V31, P25, DOI [10.1155/2011/196021, 10.3233/DMA 2011 0797]
   Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Chen LL, 2017, J ORTHOP TRANSL, V11, P62, DOI 10.1016/j.jot.2016.11.002
   Chen SB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120234
   Cooke PS, 2004, EXP BIOL MED, V229, P1127, DOI 10.1177/153537020422901107
   Cui QJ, 2000, CONNECT TISSUE RES, V41, P45
   Gu CG, 2016, SCI REP UK, V6, DOI [10.1038/srep21412, 10.1038/srep36054]
   Güclü A, 2016, RENAL FAILURE, V38, P1468, DOI 10.1080/0886022X.2016.1227915
   Hamam D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.462
   Hao C, 2016, SCI REP UK, V6, DOI 10.1038/srep22599
   Hassan MQ, 2007, MOL CELL BIOL, V27, P3337, DOI 10.1128/MCB.01544 06
   Houdek MT, 2016, J ARTHROPLASTY, V31, P893, DOI 10.1016/j.arth.2015.08.017
   Huang JH, 2016, CELL PHYSIOL BIOCHEM, V38, P40, DOI 10.1159/000438607
   Huang L, 2018, J BIOCHEM, V163, P243, DOI 10.1093/jb/mvx076
   Kang H, 2015, BMB REP, V48, P319, DOI 10.5483/BMBRep.2015.48.6.206
   Kuroda Y, 2019, BONE JOINT RES, V8, P451, DOI 10.1302/2046 3758.810.BJR 2019 0022.R1
   Lee H, 2019, EXP THER MED, V17, P3548, DOI 10.3892/etm.2019.7369
   Lespasio MJ., 2018, The Permanenete Journal, V22, P17, DOI DOI 10.7812/TPP/17 084
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Li T, 2016, INT J BIOCHEM CELL B, V72, P55, DOI 10.1016/j.biocel.2016.01.004
   Li Y, ARTHRITIS RES THER, V23, P21
   Lieb V., 2018, ONCOTARGET, V9, P10402, DOI DOI 10.18632/ONCOTARGET.23781
   Lin ZY, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12688
   Mont MA, 2015, J BONE JOINT SURG AM, V97A, P1604, DOI 10.2106/JBJS.O.00071
   Moya Angeler J, 2015, WORLD J ORTHOP, V6, P590, DOI 10.5312/wjo.v6.i8.590
   Narayanan A, 2019, LIFE SCI, V232, DOI 10.1016/j.lfs.2019.116676
   Ng KS, 2015, CELL METAB, V22, P541, DOI 10.1016/j.cmet.2015.09.019
   Petek D, 2019, EFORT OPEN REV, V4, P85, DOI 10.1302/2058 5241.4.180036
   Piuzzi NS, 2017, J ARTHROPLASTY, V32, P1698, DOI 10.1016/j.arth.2016.12.049
   Sepramaniam S, 2010, J BIOL CHEM, V285, P29223, DOI 10.1074/jbc.M110.144576
   Sheng Hui H, 2007, J Orthop Surg Res, V2, P15, DOI 10.1186/1749 799X 2 15
   Su T, 2019, ACS NANO, V13, P2450, DOI 10.1021/acsnano.8b09375
   Sun J, 2014, J TRANSL MED, V12, P1
   Sun MY, 2018, INT J MED SCI, V15, P257, DOI 10.7150/ijms.21620
   Tang Y, 2018, J CELL MOL MED, V22, P2162, DOI 10.1111/jcmm.13490
   Teplyuk NM, 2008, J BIOL CHEM, V283, P27585, DOI 10.1074/jbc.M802453200
   Tomlinson JJ, 2006, ENDOCRINOLOGY, V147, P5284, DOI 10.1210/en.2006 0267
   Wan C, SCI REP UK, V11, P183
   WANG GJ, 1977, J BONE JOINT SURG AM, V59, P729, DOI 10.2106/00004623 197759060 00003
   Wang XJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 9 r65
   Wang YS, 2003, CLIN ORTHOP RELAT R, P213, DOI 10.1097/01.blo.0000063602.67412.83
   Wu XJ, 2015, GENE, V565, P22, DOI 10.1016/j.gene.2015.03.072
   Wysokinski D, 2015, DNA CELL BIOL, V34, P305, DOI 10.1089/dna.2014.2688
   Xiang S, 2020, INT J MOL MED, V45, P805, DOI 10.3892/ijmm.2020.4455
   Yang ZH, 2016, J EXP MED, V213, P2349, DOI 10.1084/jem.20160185
   Yeh CH, 2009, CLIN ORTHOP RELAT R, V467, P2159, DOI 10.1007/s11999 009 0803 0
   Yin N, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658 019 0177 6
   Zhang L, FRONT ONCOL, V11
   Zhang Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182678
   Zhao DW, 2020, J ORTHOP TRANSL, V21, P100, DOI 10.1016/j.jot.2019.12.004
   Zhao RB, 2016, BIOCHEM BIOPH RES CO, V477, P749, DOI 10.1016/j.bbrc.2016.06.130
   Zhu WW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2496 y
NR 54
TC 7
Z9 8
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD JUN
PY 2022
VL 20
BP 32
EP 40
DI 10.1016/j.reth.2022.03.001
EA MAR 2022
PG 9
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA 0Z6QR
UT WOS:000791201100003
PM 35402661
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, L
   Liu, DH
AF Zhang, Li
   Liu, Dahua
TI The mechanism by which AFDR promotes osteogenic differentiation of rat
   genetically modified myoblasts through the P38/ERK MAPK signaling
   pathways
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Assemble flavone of rhizome drynaria; myoblasts; osteoblast
   differentiation; signal pathway
ID WNT/BETA CATENIN; CELLS; EXPRESSION; MSCS
AB This study aimed to explore the underlying mechanism by which Assemble flavone of rhizomadrynariae (AFDR) promotes osteogenic differentiation of genetically modified myoblasts through the P38/ERK mitogen activated protein kinase (MAPK) signaling pathways. Transfected ciliary neurotrophic factor (CNTF) myoblasts exposed to osteogenesis inducers were treated with blank serum, AFDR drug serum, p38 pathway inhibitor SB203580, and extracellular signal regulated kinase (ERK) pathway inhibitor PD98059. Osteogenic differentiation indexes, namely core binding factor A1 (Cbfa1) and Alkalische phosphatase (ALP) mRNA levels, in the groups were measured using RT PCR; and the protein phosphorylation levels of the p38 and ERK1/2 MAPK signal pathways in each group were measured using western blot. RT PCR results showed that the expression of osteogenesis related factors Cbfa1 and ALP mRNA was highest in the AFDR group. The expression of Cbfa1 and ALP mRNA was significantly lower than that in the AFDR group after the addition of SB203580 or PD98059. The phosphorylation levels of the p38 and ERK1/2 proteins varied among the different inhibitor groups. Western blot showed that the p38 protein phosphorylation levels were lower in the AFDR group (P < 0.01) than in the blank serum group, while there was no obvious difference in ERK1/2 protein phosphorylation levels (P > 0.05). These data suggest that AFDR promotes osteogenic differentiation of transfected CNTF myoblasts primarily via activation of the P38 and ERK MAPK signaling pathways, and that the increased expression of the osteogenesis related genes Cbfa1 and ALP. AFDR is largely influenced by the ERK pathway of the MAPK pathway.
C1 [Zhang, Li] Minist Civil Affairs, Natl Res Ctr Rehabil Tech Aids, Beijing Key Lab Rehabil TechnicalAids Old Age Dis, Key Lab Intelligent Control & Rehabil Technol, Beijing 100176, Peoples R China.
   [Zhang, Li] Jinzhou Cent Hosp, Expt Ctr, Jinzhou 121000, Peoples R China.
   [Liu, Dahua] Jinzhou Med Univ, Biol Anthropol Inst, 40 Songpo Rd, Linghe Dist 121000, Jinzhou, Peoples R China.
C3 Jinzhou Medical University
RP Liu, DH (通讯作者)，Jinzhou Med Univ, Biol Anthropol Inst, 40 Songpo Rd, Linghe Dist 121000, Jinzhou, Peoples R China.
EM cnzdoc@163.com
RI LIU, DAHUA/IUP 2960 2023
FU Liaoning province natural science funds [2015020556]; Key laboratory and
   engineering technology research center in rehabilitation field of the
   Ministry of Civil Affairs
FX This study was supported by Liaoning province natural science funds
   (2015020556) and it was also funded by the project of Key laboratory and
   engineering technology research center in rehabilitation field of the
   Ministry of Civil Affairs.
CR [Anonymous], CHINESE J TISSUE ENG
   [Anonymous], GUID TREATM LAB AN
   [Anonymous], J LOGISTICS U CAPF
   Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031 10
   Chung SH, 2018, NEUROSCIENCE, V386, P175, DOI 10.1016/j.neuroscience.2018.06.037
   Deng B, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/381904
   Hu HY, 2016, CELL PHYSIOL BIOCHEM, V38, P2375, DOI 10.1159/000445590
   Jo H, 2017, ACTA BIOMATER, V48, P100, DOI 10.1016/j.actbio.2016.10.035
   Jung JI, 2018, DIFFERENTIATION, V101, P1, DOI 10.1016/j.diff.2018.03.001
   Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200
   Lee CY, 2018, CHINESE J PHYSIOL, V61, P171, DOI 10.4077/CJP.2018.BAG562
   Li Zhang, 2007, Neural Regeneration Research, V2, P1
   Maruotti N, 2017, J CELL PHYSIOL, V232, P2957, DOI 10.1002/jcp.25969
   McClure MJ, 2016, ACTA BIOMATER, V39, P44, DOI 10.1016/j.actbio.2016.04.046
   Neef K, 2012, J THORAC CARDIOV SUR, V144, P1176, DOI 10.1016/j.jtcvs.2012.07.036
   Owston H, 2016, INJURY, V47, pS3, DOI 10.1016/S0020 1383(16)30834 8
   Paduano F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102140
   Ramachandran R, 2017, MAT SCI ENG C MATER, V73, P674, DOI 10.1016/j.msec.2016.12.110
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Son M, 2019, EUR J NUTR, V58, P1961, DOI 10.1007/s00394 018 1753 7
   Thouverey C, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.80
   Treskes P, 2015, J THORAC CARDIOV SUR, V149, P348, DOI 10.1016/j.jtcvs.2014.09.034
   Xu Q, 2018, BIOCHEM BIOPH RES CO, V498, P32, DOI 10.1016/j.bbrc.2018.02.144
   Yang HP, 2018, ORGANOGENESIS, V14, P36, DOI 10.1080/15476278.2018.1455010
   [张力 Zhang Li], 2011, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V15, P7791
   [张力 ZHANG Li], 2007, [军事医学科学院院刊, Bulletin of the Academy of Military Medical Sciences], V31, P62
   [张玉强 ZHANG Yu Qiang], 2009, [军事医学科学院院刊, Bulletin of the Academy of Military Medical Sciences], V33, P14
   Zhang YX, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0042 7
NR 28
TC 0
Z9 0
U1 0
U2 0
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940 5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2019
VL 12
IS 12
BP 13659
EP 13665
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA JZ4CP
UT WOS:000505049200054
DA 2025 08 17
ER

PT J
AU Yang, K
   Tang, XD
   Guo, W
   Xu, XL
   Ren, TT
   Ren, CM
   Wang, SD
   Bao, X
   Zhang, F
   Sun, KK
AF Yang, Kang
   Tang, Xiao Dong
   Guo, Wei
   Xu, Xiao Long
   Ren, Ting Ting
   Ren, Cong Min
   Wang, Shi Dong
   Bao, Xing
   Zhang, Fan
   Sun, Kun Kun
TI BMPR2 pSMAD1/5 signaling pathway regulates RUNX2 expression and impacts
   the progression of dedifferentiated chondrosarcoma
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Dedifferentiated chondrosarcoma; conventional chondrosarcoma; BMPR2;
   RUNX2; p Smad1/5; progression
ID BONE MORPHOGENETIC PROTEINS; STEM LIKE CELLS; OSTEOBLAST
   DIFFERENTIATION; KINASE; BMP 2; ACTIVATION; GROWTH; BMPR2; SMAD5; BETA
AB Bone morphogenetic protein receptors (BMPRs) are multifunctional proteins; they have indispensible roles in the process of BMP signaling. However, their function in dedifferentiated chondrosarcoma is uncertain. It has been reported that BMPR2 is associated with chondrosarcoma. Moreover, the detection of BMPR2 is more frequent in dedifferentiated chondrosarcomas (DDCS) than in conventional chondrosarcomas (CCS). BMPR2, phosphoSMAD1/5 (pSMAD1/5), and runt related transcription factor 2 (RUNX2) expressions were found to be associated with the pathological grades of chondrosarcoma and could be a promising target of treatment outcome. Moreover, BMPR2 was found to induce the RUNX2 expression via pSmad1/5. Knockdown of BMPR2 and pSmad1/5 results in the downregulation of RUNX2 expression in DDCS cells, while the upregulation of BMPR2 and Smad1/5 in CCS cells leads to increased RUNX2 expression. The luciferase reporter gene assay suggested that BMPR2 can induce the RUNX2 expression at the transcriptional level. By chromatin immunoprecipitation (ChIP) and electrophoresis mobility shift assay (EMSA), it was found that pSmad1/5 combined directly to RUNX2. The in vivo tumorigenicity assay in mice showed that the inhibition of BMPR2 or Smad1/5 in DDCS cell line reduced tumor growth, while the upregulation of BMPR2 or Smad1/5 in CCS cell line increased tumor growth. Furthermore, a BMPR signaling inhibitor, LDN 193189, was introduced to investigate its role as a potential drug to treat DDCS. Taken together, the present study results suggest that BMPR2 pSmad1/5 signaling pathway has an important role in regulating not only the RUNX2 expression but also the tumorigenesis of DDCS.
C1 [Yang, Kang; Tang, Xiao Dong; Guo, Wei; Xu, Xiao Long; Ren, Ting Ting; Ren, Cong Min; Wang, Shi Dong; Bao, Xing; Zhang, Fan] Peking Univ, Peoples Hosp, Beijing Key Lab Musculoskeletal Tumor, Musculoskeletal Tumor Ctr, Beijing 100044, Peoples R China.
   [Sun, Kun Kun] Peking Univ, Peoples Hosp, Dept Pathol, Beijing 100044, Peoples R China.
C3 Peking University; Peking University
RP Tang, XD; Guo, W (通讯作者)，Peking Univ, Peoples Hosp, Musculoskeletal Tumor Ctr, 11 Xizhimen South St, Beijing 100044, Peoples R China.
EM Tang15877@163.com; bonetumor@163.com
FU Program for New Century Excellent Talents in University [NCET 12 0007];
   Natural Science Foundation of China [81172544]
FX The NDCS 1 and HCS2/8 cell line were generous gifts from Dr. Akira Ogose
   (Niigata University Graduate School of Medical and Dental Sciences
   Niigata Japan) and Dr. Takigawa (Osaka University Faculty of Dentistry,
   Japan), respectively. This work was supported by the Program for New
   Century Excellent Talents in University (NCET 12 0007) and the Natural
   Science Foundation of China (No. 81172544).
CR Alarmo EL, 2007, BREAST CANCER RES TR, V103, P239, DOI 10.1007/s10549 006 9362 1
   Bharath Gangadhara, 2015, Asian Cardiovasc Thorac Ann, V23, P221, DOI 10.1177/0218492314522253
   Boeuf S, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 488
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   DAHLIN DC, 1971, CANCER, V28, P461, DOI 10.1002/1097 0142(197108)28:2<461::AID CNCR2820280227>3.0.CO;2 U
   Davies Simon R, 2008, J Exp Ther Oncol, V7, P327
   Deng L, 2014, CANCER RES, V74, P6648, DOI 10.1158/0008 5472.CAN 13 3710
   Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Gangopahyay A, 2011, J BIOL CHEM, V286, P33134, DOI 10.1074/jbc.M111.274100
   Groeneveld EHJ, 2000, EUR J ENDOCRINOL, V142, P9, DOI 10.1530/eje.0.1420009
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Guo W, 1999, CLIN ORTHOP RELAT R, P175
   Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919
   Jiao G, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.540
   Kim IY, 2004, ONCOGENE, V23, P7651, DOI 10.1038/sj.onc.1207924
   Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840
   Kozawa O, 2002, J CELL BIOCHEM, V84, P583, DOI 10.1002/jcb.10056.abs
   Kudo N, 2007, VIRCHOWS ARCH, V451, P691, DOI 10.1007/s00428 007 0426 3
   Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200
   Matsumoto Y, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477 7819 11 32
   Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200
   Owens P, 2012, P NATL ACAD SCI USA, V109, P2814, DOI 10.1073/pnas.1101139108
   Park JH, 2002, MOL CELL ENDOCRINOL, V192, P197, DOI 10.1016/S0303 7207(02)00036 9
   Pouliot F, 2003, CANCER RES, V63, P277
   Sakamoto A, 2014, INDIAN J ORTHOP, V48, P262, DOI 10.4103/0019 5413.132506
   Tang XD, 2010, EUR J CANCER PREV, V19, P466, DOI 10.1097/CEJ.0b013e32833d942f
   Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796 343
   von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388
   Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325
   Yokota K, 2012, J ORTHOP SURG RES, V7, DOI 10.1186/1749 799X 7 38
NR 33
TC 15
Z9 18
U1 1
U2 10
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156 6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2016
VL 6
IS 6
BP 1302
EP +
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DQ8GX
UT WOS:000379448200008
PM 27429845
DA 2025 08 17
ER

PT J
AU Kim, MK
   Lee, HN
   Jenjob, R
   Lee, J
   Yang, SG
AF Kim, Min Kyoung
   Lee, Ha Neul
   Jenjob, Ratchapol
   Lee, Junghan
   Yang, Su Geun
TI Calcium Triggered Pulsatile Delivery of Parathyroid Hormone from
   Microbeads for Osteoporosis Treatment
SO BIOMACROMOLECULES
LA English
DT Article
ID BONE; INTERMITTENT; FRACTURES; COMPLEX; TISSUE
AB Recombinant human parathyroid hormone 1 34 (rhPTH 1 34) is the most potent anabolic drug recommended for patients with osteoporosis who do not respond to conventional treatment. However, subcutaneous intermittent injection is the only effective regimen due to its unusual action of mechanism. This regimen is inconvenient and is a big hurdle in clinical applications. In this study, we designed polyelectrolyte microbeads that can deliver rhPTH 1 34 in response to Cat(2+) concentration, which indicates the osteoporotic status. Dextran photopolymer was synthesized, mixed with anionic monoacrylate, and photopolymerized by passing through capillary microfluidics to obtain the microbeads. The anionic property of microbeads was confirmed by toluidine blue staining. One microbead, loaded with a 1 day dose of rhPTH 1 34 (23.4 +/  0.9 mu g), released rhPTH 1 34 in a triggered manner following the addition of Ca2+ ion. In vitro cell study demonstrated that rhPTH 1 34 released in a pulsatile manner from the microbeads induced osteogenic markers (ALP, RUNX2, and OPN) and precipitated mineral disposition more effectively.
C1 [Kim, Min Kyoung; Lee, Ha Neul; Jenjob, Ratchapol; Lee, Junghan; Yang, Su Geun] Inha Univ, Coll Med, Dept New Drug Dev, WCSL, B 308 Chungsuk Bldg,366 Seohae Daero, Incheon 22332, South Korea.
C3 Inha University
RP Yang, SG (通讯作者)，Inha Univ, Coll Med, Dept New Drug Dev, WCSL, B 308 Chungsuk Bldg,366 Seohae Daero, Incheon 22332, South Korea.
EM sugeun.yang@inha.ac.kr
RI Kim, Min/ACN 6827 2022
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Science, ICT, and Future Planning
   [NRF 2017R1A2A2A07001272]; WCSL (World Class Smart Lab) research grant
   from Inha University
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Science, ICT, and Future Planning (NRF 2017R1A2A2A07001272) as well
   as by WCSL (World Class Smart Lab) research grant from Inha University.
CR Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Chen FM, 2008, J BIOMED MATER RES A, V84A, P568, DOI 10.1002/jbm.a.31252
   Chiang CY, 2013, BONE, V52, P360, DOI 10.1016/j.bone.2012.10.006
   Costa RR, 2014, CHEM SOC REV, V43, P3453, DOI 10.1039/c3cs60393h
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   ESTEBANEZ P, 1992, J ACQ IMMUN DEF SYND, V5, P316
   Farra R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003276
   He W, 2015, BIOMACROMOLECULES, V16, P2282, DOI 10.1021/acs.biomac.5b00500
   Khemtong C, 2009, CANCER RES, V69, P1651, DOI 10.1158/0008 5472.CAN 08 3231
   Kurinomaru T, 2017, INT J BIOL MACROMOL, V100, P11, DOI 10.1016/j.ijbiomac.2016.06.016
   Lévesque SG, 2005, BIOMATERIALS, V26, P7436, DOI 10.1016/j.biomaterials.2005.05.054
   Locklin RM, 2003, J CELL BIOCHEM, V89, P180, DOI 10.1002/jcb.10490
   Meng XX, 2017, ACS MACRO LETT, V6, P505, DOI 10.1021/acsmacrolett.7b00173
   MICHAELS AS, 1961, J PHYS CHEM US, V65, P1765, DOI 10.1021/j100827a020
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ratanajanchai M, 2014, J COLLOID INTERF SCI, V415, P70, DOI 10.1016/j.jcis.2013.09.049
   Schanze KS, 2009, LANGMUIR, V25, P13698, DOI 10.1021/la903785g
   Serra VV, 2016, COLLOID SURFACE B, V146, P127, DOI 10.1016/j.colsurfb.2016.05.047
   Shukla P, 2010, EXPERT OPIN DRUG DEL, V7, P993, DOI 10.1517/17425247.2010.510830
   Wainwright M, 2003, BIOTECH HISTOCHEM, V78, P147, DOI 10.1080/10520290310001602404
   Wang BL, 2016, BIOCONJUGATE CHEM, V27, P1305, DOI 10.1021/acs.bioconjchem.6b00118
   ZANELLI JM, 1983, J CHROMATOGR, V276, P55, DOI 10.1016/S0378 4347(00)85065 3
NR 22
TC 6
Z9 6
U1 0
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525 7797
EI 1526 4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD OCT
PY 2017
VL 18
IS 10
BP 3099
EP 3105
DI 10.1021/acs.biomac.7b00750
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA FJ6JU
UT WOS:000412864900009
PM 28850775
DA 2025 08 17
ER

PT J
AU Chung, YS
   Langdahl, B
   Plebanski, R
   Czerwinski, E
   Dokoupilova, E
   Supronik, J
   Rosa, J
   Mydlak, A
   Sapula, R
   Rowinska Osuch, A
   Baek, KH
   Urboniene, A
   Mordaka, R
   Ahn, S
   Rho, YH
   Ban, J
   Eastell, R
AF Chung, Yoon Sok
   Langdahl, Bente
   Plebanski, Rafal
   Czerwinski, Edward
   Dokoupilova, Eva
   Supronik, Jerzy
   Rosa, Jan
   Mydlak, Andrzej
   Sapula, Rafal
   Rowinska Osuch, Anna
   Baek, Ki Hyun
   Urboniene, Audrone
   Mordaka, Robert
   Ahn, Sohui
   Rho, Young Hee
   Ban, Jisuk
   Eastell, Richard
TI SB16 versus reference denosumab in postmenopausal women with
   osteoporosis: 18 month outcomes of a phase III randomized clinical trial
SO BONE
LA English
DT Article
DE Biosimilar; Bone mineral density; Denosumab; Clinical trials;
   Postmenopausal osteoporosis; SB16
ID BIOSIMILARS
AB Purpose: This study evaluated the efficacy, safety, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of SB16 versus reference denosumab (DEN) up to 18 months in postmenopausal osteoporosis (PMO) patients, and assessed outcomes after switching from DEN to SB16 compared to those who continued with DEN or SB16. Methods: 457 PMO patients were initially randomized, with 407 re randomized at Month 12 to either continue DEN (DEN+DEN), switch to SB16 (DEN+SB16), or continue SB16 (SB16 + SB16) through Month 18. Efficacy was assessed by the percent change from baseline in bone mineral density (BMD) at the lumbar spine, total hip, and femoral neck. Safety, PD, PK, and immunogenicity were evaluated throughout the study period. Results: Mean percent changes from baseline in lumbar spine, total hip, and femoral neck BMD at Month 18 were comparable across treatment groups, indicating comparable efficacy between SB16 and DEN. The mean percent change in lumbar spine BMD was 6.8 % (SB16 + SB16), 6.2 % (DEN+SB16), and 6.8 % (DEN+DEN). Total hip BMD increased by 4.4 %, 3.5 %, and 4.0 %, and femoral neck BMD by 3.4 %, 3.1 %, and 2.7 % for SB16 + SB16, DEN+SB16, and DEN+DEN, respectively. Safety profiles were similar among groups, with no new safety concerns identified after switching. Only one patient in the DEN+SB16 group developed non neutralizing anti drug antibodies by Month 18, indicating a low immunogenicity risk for SB16.
C1 [Chung, Yoon Sok] Ajou Univ, Sch Med, Dept Endocrinol & Metab, Suwon, South Korea.
   [Chung, Yoon Sok] Ajou Univ, Inst Aging, Med Ctr, Suwon, South Korea.
   [Langdahl, Bente] Aarhus Univ, Aarhus Univ Hosp, Dept Endocrinol, Aarhus, Denmark.
   [Langdahl, Bente] Aarhus Univ, Dept Clin Med, Aarhus, Denmark.
   [Plebanski, Rafal] Klin Zdrowej Kosci, Lodz, Poland.
   [Czerwinski, Edward] Krakowskie Ctr Medyczne Sp Zoo, Krakow, Poland.
   [Dokoupilova, Eva] Med PLUS Sro, Uherske Hradiste, Czech Republic.
   [Dokoupilova, Eva] Masaryk Univ, Fac Pharm, Dept Pharmaceut Technol, Brno, Czech Republic.
   [Supronik, Jerzy] OsteoMed Sc A Racewicz J Supron, Bialystok, Poland.
   [Rosa, Jan] Affidea Praha Sro, Prague, Czech Republic.
   [Mydlak, Andrzej] ETG Siedlce, Siedlce, Poland.
   [Sapula, Rafal] Acad Zamosc, Zamosc Rehabil Clin, Zamosc, Poland.
   [Rowinska Osuch, Anna] ETG Warszawa, Warsaw, Poland.
   [Baek, Ki Hyun] Catholic Univ Korea, Yeouido St Marys Hosp, Coll Med, Dept Internal Med,Div Endocrinol & Metab, Seoul, South Korea.
   [Urboniene, Audrone] JSC Saules Seimos Med Centras, Kaunas, Lithuania.
   [Mordaka, Robert] Santa Sp Zoo, Lodz, Poland.
   [Ahn, Sohui; Rho, Young Hee; Ban, Jisuk] Samsung Bioepis Co Ltd, Incheon, South Korea.
   [Eastell, Richard] Univ Sheffield, Sheffield, England.
C3 Ajou University; Ajou University; Aarhus University; Aarhus University;
   Masaryk University Brno; Catholic University of Korea; University of
   Sheffield
RP Eastell, R (通讯作者)，Univ Sheffield, Mellanby Ctr Musculoskeletal Res, Sch Med & Populat Hlth, Med Sch,Div Clin Med, EU38,Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM yschung@ajou.ac.kr; bente.langdahl@aarhus.rm.dk;
   edward.czerwinski@futuremeds.com; a.urboniene@ssmc.ltaffidea praha.cz;
   a.mydlak@etg network.com; r.sapula@etg network.com;
   a.rowinskaosuch@etg network.com; a.urboniene@ssmc.lt;
   robert.mordaka@swietarodzina.com.pl; sohui.ahn@samsung.com;
   younghee.rho@samsung.com; jisuk.ban@samsung.com;
   r.eastell@sheffield.ac.uk
FU Samsung Bioepis Co., Ltd.
FX Medical writing support was provided by Jack Cronk, PhD, on behalf of
   SFL Regulatory Affairs and Scientific Communications Ltd., and funded by
   Samsung Bioepis Co., Ltd.
CR [Anonymous], 8. US. Food and Drug Administration. Accessed August 1, 2023$4. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
   [Anonymous], US FOOD DRUG ADM
   [Anonymous], Kineret | European Medicines Agency (no date). Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/kineret (Accessed: 18 May 2023).
   Barbier L, 2020, CLIN PHARMACOL THER, V108, P734, DOI 10.1002/cpt.1836
   Bennett CL, 2020, LANCET ONCOL, V21, pE575, DOI 10.1016/S1470 2045(20)30485 X
   Bhatnagar A, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.29367
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dylst P, 2014, PHARMACOECONOMICS, V32, P681, DOI 10.1007/s40273 014 0163 9
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Ebbers HC, 2019, DRUG DISCOV TODAY, V24, P1963, DOI 10.1016/j.drudis.2019.06.016
   European Medicines Agency, 2019, BIOS EU INF GUID HEA
   Herndon TM, 2023, PLOS ONE, V18, DOI 10.1371/journal.pone.0292231
   Huang HY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.572569
   Jeka S, 2024, J BONE MINER RES, V39, P202, DOI 10.1093/jbmr/zjae016
   Kendler DL, 2022, ADV THER, V39, P58, DOI 10.1007/s12325 021 01936 y
   Kim H, 2020, DRUGS, V80, P99, DOI 10.1007/s40265 020 01256 5
   Kvien TK, 2022, SEMIN ARTHRITIS RHEU, V52, DOI 10.1016/j.semarthrit.2021.11.009
   Langdahl B, 2025, J CLIN ENDOCR METAB, V110, pe1951, DOI 10.1210/clinem/dgae611
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Reginster JY, 2024, OSTEOPOROSIS INT, V35, P1919, DOI 10.1007/s00198 024 07161 x
   Ruiz Esteves KN, 2022, MATURITAS, V156, P25, DOI 10.1016/j.maturitas.2021.10.010
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Smolen JS, 2021, RMD OPEN, V7, DOI 10.1136/rmdopen 2021 001637
   US Food and Drug Administration, 2023, Prolia Highlights of Prescribing Information
   van Overbeeke E, 2017, BIODRUGS, V31, P447, DOI 10.1007/s40259 017 0244 3
NR 25
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2025
VL 192
AR 117371
DI 10.1016/j.bone.2024.117371
EA DEC 2024
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA R6V1T
UT WOS:001392794100001
PM 39674388
OA hybrid
DA 2025 08 17
ER

PT J
AU Yu, J
   Hang, YL
   Sun, WN
   Wang, GQ
   Xiong, ZQ
   Ai, LZ
   Xia, YJ
AF Yu, Jing
   Hang, Yiling
   Sun, Wenni
   Wang, Guangqiang
   Xiong, Zhiqiang
   Ai, Lianzhong
   Xia, Yongjun
TI Anti Osteoporotic Effect of Lactobacillus brevis AR281 in an
   Ovariectomized Mouse Model Mediated by Inhibition of Osteoclast
   Differentiation
SO BIOLOGY BASEL
LA English
DT Article
DE gut microbiota; osteoporosis; Lactobacillus brevis; osteoclastogenesis;
   osteoclast differentiation
ID NECROSIS FACTOR ALPHA; BONE; INFLAMMATION; THERAPY; DENSITY; FEMUR; AGE
AB Simple Summary Osteoporosis related fractures are among the most common complications found in postmenopausal adults, which results in considerable economic impacts. Most treatments for osteoporosis increase bone formation or decrease bone resorption. While estrogen replacement therapy may be the gold standard for the treatment of osteoporosis, it also carries an increased risk of cardiac events and strokes in women. Thus, it is important to seek a safe and effective treatment method. Gut homeostasis is demonstrably linked to bone health. Probiotics are widely known to modulate gut microbiota, but with large strain differences. Our findings showed a strain of Lactobacillus brevis AR281 with an anti osteoporotic property in ovariectomized mice, which may provide a new way to prevent osteoporosis. Osteoporosis is a global disease characterized by weakened bone microarchitecture, leading to osteoporotic fractures. Estrogen replacement therapy is the traditional treatment for osteoporosis but carries with it an increased risk of cardiac events. In search of a safe and effective treatment, we used Lactobacillus brevis AR281, which has anti inflammatory properties, to conduct a 7 week experiment, investigating its inhibitory effects on osteoporosis in an ovariectomized (ovx) mouse model. The results demonstrated that AR281 significantly improved bone microarchitecture and biomechanical strength in ovx mice by attenuating bone resorption. AR281 significantly decreased the critical osteoclast activator, the ratio of the receptor activator for nuclear factor kappa B (NF kappa B) ligand (RANKL) to osteoprotegerin, and pro inflammatory osteoclastogenic mediators, such as IL 1, IL 6, and IL 17, which can increase the RANKL expression. Moreover, AR281 modulated intestinal microbiota in ovx mice increased the abundance of Akkermansia, which is responsible for the improvement of gut epithelial barrier integrity. In an in vitro trial, AR281 suppressed the number of osteoclasts differentiated from the osteoclast precursor RAW264.7 cells caused by RANKL through the tumor necrosis factor (TNF) receptor associated factor 6 (TRAF6)/NF kappa B/nuclear factor of activated T cells c1 (NFATc1) pathway. Therefore, AR281 may be a natural alternative for combating osteoporosis.
C1 [Yu, Jing; Hang, Yiling; Sun, Wenni; Wang, Guangqiang; Xiong, Zhiqiang; Ai, Lianzhong; Xia, Yongjun] Univ Shanghai Sci & Technol, Sch Hlth Sci & Engn, Shanghai 200093, Peoples R China.
C3 University of Shanghai for Science & Technology
RP Xia, YJ (通讯作者)，Univ Shanghai Sci & Technol, Sch Hlth Sci & Engn, Shanghai 200093, Peoples R China.
EM joyceyu26@126.com; 18851572933@163.com; 15720509860@163.com;
   1015wanggq@163.com; xiongzq@hotmail.com; ailianzhong1@126.com;
   dreamup@126.com
RI Wang, Guangqiang/B 2632 2014
OI Wang, Guangqiang/0000 0002 3966 044X; Xia, Yongjun/0000 0002 2727 2730;
   Xiong, Zhi Qiang/0000 0002 7984 3662
FU Shanghai Engineering Research Center of Food Microbiology Program
   [19DZ2281100]; Shanghai Agriculture Applied Technology Development
   Program of China [2019 02 08 00 07 F01152]; National Key R&D Program of
   China [2018YFC1604305]; Natural Science Foundation of China [3177195]
FX Shanghai Engineering Research Center of Food Microbiology Program
   (19DZ2281100); Shanghai Agriculture Applied Technology Development
   Program of China (Grant No. 2019 02 08 00 07 F01152); National Key R&D
   Program of China (Grant No. 2018YFC1604305); Natural Science Foundation
   of China (Grant No. 3177195).
CR Abrahamsen B, 2012, BONE, V50, P1196, DOI 10.1016/j.bone.2012.02.009
   Alpízar Rodríguez D, 2021, NUTRIENTS, V13, DOI 10.3390/nu13010096
   Ansari MA, 2021, MOLECULES, V26, DOI 10.3390/molecules26071839
   Aron Wisnewsky J, 2021, GASTROENTEROLOGY, V160, P573, DOI 10.1053/j.gastro.2020.10.057
   Becken B, 2021, MBIO, V12, DOI 10.1128/mBio.00478 21
   Bruunsgaard H, 2002, EUR CYTOKINE NETW, V13, P389
   Brüünsgaard H, 2003, IMMUNOL ALLERGY CLIN, V23, P15, DOI 10.1016/S0889 8561(02)00056 5
   Chedid VG, 2020, J CLIN DENSITOM, V23, P182, DOI 10.1016/j.jocd.2019.07.009
   Chiodini RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134382
   Di Donato V, 2020, ONCOLOGY BASEL, V98, P195, DOI 10.1159/000505427
   Fang J, 2018, CELL REP, V22, P1250, DOI 10.1016/j.celrep.2018.01.013
   Feyereisen M, 2019, VIRUSES BASEL, V11, DOI 10.3390/v11050393
   Gennari L, 2011, EXPERT OPIN DRUG DIS, V6, P205, DOI 10.1517/17460441.2011.547188
   Giehler F., 2022, RES SQ, V1, DOI [10.21203/rs.3.rs 1295699/v1, DOI 10.21203/RS.3.RS 1295699/V1]
   Goel R, 2015, GUT, V64, pA435, DOI 10.1136/gutjnl 2015 309861.955
   Greendale GA, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10480
   Grondin J., 2020, J CAN ASS GASTROENTE, V3, P93, DOI [10.1093/jcag/gwz047.218, DOI 10.1093/JCAG/GWZ047.218]
   Hang Y., 2018, IND MICROBIOL, V48, P12
   Hu J., 2013, Inflammatory Bowel Diseases, V19, pS119
   Jämsä T, 1998, BONE, V23, P155, DOI 10.1016/S8756 3282(98)00076 3
   Kim I, 2021, BMB REP, V54, P482, DOI 10.5483/BMBRep.2021.54.9.070
   Kim JY, 2021, HEALTHCARE BASEL, V9, DOI 10.3390/healthcare9060729
   Kim MH, 2021, PHYTOMEDICINE, V80, DOI 10.1016/j.phymed.2020.153397
   Lee CS, 2021, J APPL MICROBIOL, V130, P2041, DOI 10.1111/jam.14852
   Lee YM, 2019, BIOMED RES INT UK, V2019, DOI 10.1155/2019/5073085
   Li JY, 2016, J CLIN INVEST, V126, P2049, DOI 10.1172/JCI86062
   Li N, 2021, INFLAMM BOWEL DIS, V27, P1525, DOI 10.1093/ibd/izaa342
   LINDSAY R, 1980, LANCET, V2, P1151
   Liu H, 2019, THER ADV CHRONIC DIS, V10, DOI 10.1177/2040622319860653
   Lorenzo J, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI146619
   Luo JS, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20192317
   Maekawa T, 2014, J PERIODONTAL RES, V49, P785, DOI 10.1111/jre.12164
   Masip E, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 021 00945 2
   Mccabe LR, 2013, J CELL PHYSIOL, V228, P1793, DOI 10.1002/jcp.24340
   Moller AMJ, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0102 7
   Mun H, 2021, OSTEOPOROSIS INT, V32, P425, DOI 10.1007/s00198 020 05623 6
   Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378 1119(03)00841 2
   Rinonapoli G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042105
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   Rönkä E, 2003, INT J FOOD MICROBIOL, V83, P63, DOI 10.1016/S0168 1605(02)00315 X
   Rossouw JE, 2007, JAMA J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465
   Sorbera LA, 2003, DRUG FUTURE, V28, P328, DOI 10.1358/dof.2003.028.04.726503
   Takauji S, 2021, DIGEST DIS SCI, V66, P3872, DOI 10.1007/s10620 020 06747 9
   Ueta M, 2019, MOL MED REP, V20, P4331, DOI 10.3892/mmr.2019.10662
   Vinogradova Y, 2020, BMJ BRIT MED J, V371, DOI 10.1136/bmj.m3873
   Weitzmann MN, 2016, NAT REV ENDOCRINOL, V12, P518, DOI 10.1038/nrendo.2016.91
   Xi ML, 2020, FOOD RES INT, V137, DOI 10.1016/j.foodres.2020.109288
   Yang YJ, 2019, NEUROPSYCHOPHARMACOL, V44, P2054, DOI 10.1038/s41386 019 0437 1
   Yasuda H, 2021, J BONE MINER METAB, V39, P2, DOI 10.1007/s00774 020 01175 1
   Yu J, 2021, J FUNCT FOODS, V87, DOI 10.1016/j.jff.2021.104762
   Yue Li, 2011, Proceedings of the 2011 International Conference on Remote Sensing, Environment and Transportation Engineering (RSETE 2011), P8065, DOI 10.1109/RSETE.2011.5964025
   Zaiss MM, 2015, IMMUNITY, V43, P998, DOI 10.1016/j.immuni.2015.09.012
   Zhai R, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00239
   Zhao XH, 2021, J ETHNOPHARMACOL, V266, DOI 10.1016/j.jep.2020.113402
NR 54
TC 14
Z9 15
U1 1
U2 25
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2079 7737
J9 BIOLOGY BASEL
JI Biology Basel
PD MAR
PY 2022
VL 11
IS 3
AR 359
DI 10.3390/biology11030359
PG 16
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA 0D3TT
UT WOS:000775922200001
PM 35336732
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Abe, T
   Sato, T
   Yoda, T
   Hoshi, K
AF Abe, Takahiro
   Sato, Tomoya
   Yoda, Tetsuya
   Hoshi, Kazuto
TI The period circadian clock 2 gene responds to glucocorticoids and
   regulates osteogenic capacity
SO REGENERATIVE THERAPY
LA English
DT Article
DE Circadian rhythm; Glucocorticoids; Period circadian clock 2 gene; Second
   messenger
ID BONE RESORPTION; ZOLEDRONIC ACID; EXPRESSION; DIFFERENTIATION;
   MECHANISM; SLEEP; MICE; LINE
AB Introduction: The central regulatory system that generates biological rhythms is regulated by circadian clock genes expressed by cells in the suprachiasmatic nucleus. Signals from this system are converted to adrenocortical hormones through the sympathetic nervous system and transmitted to peripheral organs. Another system releases glucocorticoids (GCs) in response to stress through the HPA axis. Here we investigated the second messenger GC, which is shared by these systems and influences the expression of circadian clock genes of cells of the musculoskeletal system and in viable bone tissue.
   Methods: We used mouse derived cell lines, which differentiate into osteoblasts (MC3T3 E1, C2C12, and 10T1/2) as well as primary cultures of mouse osteoblasts to determine the expression levels of circadian clock genes that respond to GC. Mice (mPer2(m)(/m)) with an inactivating mutation in the period circadian clock 2 gene (Per2) exhibit marked dysrhythmia. Here we compared the bone morphologies of mPer2(m/m) mice with those of wild type (WT) mice.
   Results: The expression of major circadian clock genes was detected in each cell line, and their responsiveness to GC was confirmed. We focused on Per2, a negative regulator of the circadian clock and found that a Per2 loss of function mutation increased the proliferative capacity of osteoblasts. Treatment of mutant mice with slow release GC and bisphosphonate affected the maturation of bone tissue, which reflects a tendency to retard calcification.
   Conclusion: Our investigations of the mechanisms that regulate circadian rhythm function in tissues of the musculoskeletal system that respond to the stress hormone GC, reveal that Per2 is required for the maturation of bone tissue. Thus, the influences of the systems that control circadian rhythms and the responses to stress by regenerating tissue used for regenerative medicine must be considered and studied in greater detail. (C) 2019, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.
C1 [Abe, Takahiro; Hoshi, Kazuto] Univ Tokyo, Grad Sch Med, Dept Sensory & Motor Syst Med, Oral & Maxillofacial Surg, Tokyo, Japan.
   [Sato, Tomoya] Saitama Med Univ, Dept Plast & Reconstruct Surg, Saitama, Japan.
   [Yoda, Tetsuya] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Maxillofacial Surg, Tokyo, Japan.
C3 University of Tokyo; Saitama Medical University; Institute of Science
   Tokyo; Tokyo Medical & Dental University (TMDU)
RP Abe, T (通讯作者)，Univ Tokyo, Bunkyo Ku, 7 3 1 Hongo, Tokyo 1138655, Japan.
EM abetakahiro.dream@gmail.com
FU JSPS KAKENHI [JP17791488]
FX We thank Professor Shigenobu Shibata atWaseda University for providing
   Per2 knockout mice, and Dr. Naoko Hori for assistance. This work was
   supported by JSPS KAKENHI Grant Number JP17791488.
CR Abe T, 2016, CYTOKINE, V83, P1, DOI 10.1016/j.cyto.2016.03.012
   Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092 8674(02)00961 3
   Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Hinoi E, 2006, J BIOL CHEM, V281, P23632, DOI 10.1074/jbc.M512362200
   Hori H, 2011, J PSYCHIATR RES, V45, P1257, DOI 10.1016/j.jpsychires.2011.04.001
   Hori N, 2016, DATA BRIEF, V7, P1486, DOI 10.1016/j.dib.2016.04.041
   Ishida A, 2005, CELL METAB, V2, P297, DOI 10.1016/j.cmet.2005.09.009
   Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092 8674(00)80959 9
   Katamune C, 2016, J BIOL CHEM, V291, P10541, DOI 10.1074/jbc.M115.706481
   Keenan DM, 2004, AM J PHYSIOL ENDOC M, V287, pE652, DOI 10.1152/ajpendo.00167.2004
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Koyanagi S, 2006, MOL ENDOCRINOL, V20, P573, DOI 10.1210/me.2005 0165
   Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586
   Nakamura Y, 2011, J ALLERGY CLIN IMMUN, V127, P1038, DOI 10.1016/j.jaci.2011.02.006
   Ohba S, 2016, J DEV BIOL, V4, DOI 10.3390/jdb4020020
   REZNIKOFF CA, 1973, CANCER RES, V33, P3231
   Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013
   Suarez Bregua P, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00526
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Sun Q, 2017, J BIOL CHEM, V292, P12679, DOI 10.1074/jbc.M117.783985
   Swanson CM, 2018, METABOLISM, V84, P28, DOI 10.1016/j.metabol.2017.12.002
   Takarada T, 2017, J BONE MINER RES, V32, P872, DOI 10.1002/jbmr.3053
   Takarada T, 2012, J BIOL CHEM, V287, P36081, DOI 10.1074/jbc.M112.408963
   Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499
   Tronche F, 1998, CURR OPIN GENET DEV, V8, P532, DOI 10.1016/S0959 437X(98)80007 5
   Xu C, 2016, J BONE MINER RES, V31, P1344, DOI 10.1002/jbmr.2803
   YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0
   Yang ST, 2009, ENDOCRINOLOGY, V150, P2153, DOI 10.1210/en.2008 0705
   Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118
   Zhou X, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12470
   Zhuo HY, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3407821
NR 34
TC 8
Z9 11
U1 5
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD DEC 1
PY 2019
VL 11
BP 199
EP 206
DI 10.1016/j.reth.2019.07.006
PG 8
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA JQ6OW
UT WOS:000499063400029
PM 31489343
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Shi, J
   Chen, Y
   Zhao, W
   Chen, Y
   Yang, Q
   Zhao, Z
   Wang, H
   Zhou, W
   Sun, W
AF Shi, J.
   Chen, Y.
   Zhao, W.
   Chen, Y.
   Yang, Q.
   Zhao, Z.
   Wang, H.
   Zhou, W.
   Sun, W.
TI Galectin 8 involves in arthritic condylar bone loss via
   podoplanin/AKT/ERK axis mediated inflammatory lymphangiogenesis
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Condylar bone loss; Galectin 8; Lymphangiogenesis; Lymphatic endothelial
   cell; Osteoclast
ID ENDOTHELIAL CELLS; THIODIGALACTOSIDE; CARTILAGE; NETWORK; DAMAGE;
   TISSUE; CD44; LUNG
AB Objective: The lymphatic system plays a crucial role in the maintenance of tissue fluid homeostasis and the immunological response to inflammation. Galectin 8 (Gal 8) regulates pathological lymphangiogenesis but the effects of which on inflammation related condylar bone loss in temporomandibular joint (TMJ) have not been well studied.Design: We used TNFa transgenic (TNFTG) mice and their wildtype (WT) littermates to compare their inflammatory phenotype in TMJs. Next, lymphatic endothelial cells (LECs) were used to examine the effects of which on osteoclast formation, pro inflammatory factor expression, and inflammatory lymphangiogenesis with or without thiodigalactoside (TDG, a Gal 8 inhibitor) treatment. At last, two murine models (TNFTG arthritic model and forced mouth opening model) were used to explore TDG as a potential drug for the treatment of inflammation related condylar bone loss.Results: In comparison to WT mice, lymphatic areas of lymphatic vessel endothelial receptor 1 (LYVE1)+/ podoplanin (PDPN)+ and Gal 8+/PDPN+, TRAP positive osteoclast number, and condylar bone loss are increased in TNFTG mice. Inhibition of Gal 8 in LECs by TDG, reduces TNFa induced osteoclast formation, pro inflammatory factor expression, and inflammatory lymphangiogenesis. In addition, Gal 8 promotes TNFa activated AKT/ERK/NF kB pathways by binding to PDPN. Finally, the administration of TDG attenuates inflammatory lymphangiogenesis, inhibits osteoclast activity, and reduces condylar bone loss in TNFTG arthritic mice and forced mouth opening mice.Conclusions: Our findings reveal the important role of Gal 8 promoted pathological lymphangiogenesis in inflammation related condylar bone loss.(c) 2023 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Shi, J.; Chen, Y.; Zhao, W.; Chen, Y.; Yang, Q.; Zhao, Z.; Wang, H.; Sun, W.] Nanjing Med Univ, Affiliated Stomatol Hosp, Dept Basic Sci Stomatol, Nanjing, Peoples R China.
   [Shi, J.; Chen, Y.; Zhao, W.; Chen, Y.; Yang, Q.; Zhao, Z.; Wang, H.; Zhou, W.; Sun, W.] Jiangsu Prov Key Lab Oral Dis, Nanjing, Peoples R China.
   [Shi, J.; Chen, Y.; Zhao, W.; Chen, Y.; Yang, Q.; Zhao, Z.; Wang, H.; Zhou, W.; Sun, W.] Jiangsu Prov Engn Res Ctr Stomatol Translat Med, Nanjing, Peoples R China.
   [Shi, J.; Zhou, W.] Nanjing Med Univ, Affiliated Stomatol Hosp, Dept Temporomandibular Joint & Maxillofacial Pain, Nanjing, Peoples R China.
   [Sun, W.] Nanjing Med Univ, Affiliated Hosp Stomatol, Dept Basic Stomatol, Nanjing 210029, Peoples R China.
   [Zhou, W.] Nanjing Med Univ, Affiliated Hosp Stomatol, Dept Temporomandibular Joint & Maxillofacial Pain, Nanjing 210029, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University; Nanjing Medical University
RP Sun, W (通讯作者)，Nanjing Med Univ, Affiliated Hosp Stomatol, Dept Basic Stomatol, Nanjing 210029, Peoples R China.; Zhou, W (通讯作者)，Nanjing Med Univ, Affiliated Hosp Stomatol, Dept Temporomandibular Joint & Maxillofacial Pain, Nanjing 210029, Peoples R China.
EM 2077019352@qq.com; 277915923@qq.com; 925793210@qq.com; xydzcy@126.com;
   510688676@qq.com; 441774770@qq.com; huawang@njmu.edu.cn;
   weina119@126.com; wensun@njmu.edu.cn
FU National Natural Science Foundation of China [82071086, 81970961];
   National Key Research and Development Program of China [2018YFA0800804];
   Project of Priority Academic Program Development of Jiangsu Higher
   Education Institutions (PAPD) [2018 87]; Natural Science Foundation of
   Jiangsu Province [BK20190648]
FX Role of the funding source The research was supported by grants from the
   National Natural Science Foundation of China (82071086, 81970961) , and
   from the National Key Research and Development Program of China
   (2018YFA0800804) . This work was also supported by the Project of
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD, 2018 87) and the Natural Science Foundation of
   Jiangsu Province (grant number BK20190648) . The study sponsors had no
   involvement in the study design, collection, analysis, and
   interpretation of data; in the writing of the manu  script; and in the
   decision to submit the manuscript for publication.
CR Arbel Goren R, 2005, J BIOL CHEM, V280, P19105, DOI 10.1074/jbc.M502060200
   Bell SL, 2021, MBIO, V12, DOI 10.1128/mBio.01871 20
   Bieniasz Krzywiec P, 2019, CELL METAB, V30, P917, DOI 10.1016/j.cmet.2019.07.015
   Bouta EM, 2018, NAT REV RHEUMATOL, V14, P94, DOI 10.1038/nrrheum.2017.205
   Carabelli J, 2017, J LEUKOCYTE BIOL, V102, P1237, DOI [10.1189/jlb.3A0816 357RR, 10.1189/jlb.3a0816 357rr]
   Chen WS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11302
   Cueni LN, 2009, EXP CELL RES, V315, P1715, DOI 10.1016/j.yexcr.2009.02.021
   Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111
   Delaine T, 2016, CHEMBIOCHEM, V17, P1759, DOI 10.1002/cbic.201600285
   Delaine T, 2008, J MED CHEM, V51, P8109, DOI 10.1021/jm801077j
   Deng Y, 2013, J CLIN INVEST, V123, P1202, DOI 10.1172/JCI63034
   Dobsak T, 2017, J CLIN PERIODONTOL, V44, P1226, DOI 10.1111/jcpe.12799
   Fang LL, 2021, ANN NY ACAD SCI, V1503, P72, DOI 10.1111/nyas.14606
   Gallotta S, 2017, WORLD J GASTROENTERO, V23, P103, DOI 10.3748/wjg.v23.i1.103
   Gerner MY, 2015, IMMUNITY, V42, P172, DOI 10.1016/j.immuni.2014.12.024
   Gucciardo E, 2018, J PATHOL, V245, P172, DOI 10.1002/path.5070
   Huggenberger R, 2011, BLOOD, V117, P4667, DOI 10.1182/blood 2010 10 316356
   Hwang SD, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1436 1
   Kany S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236008
   Kuo P, 2014, CLIN CANCER RES, V20, P5558, DOI 10.1158/1078 0432.CCR 14 1138
   Martín Villar E, 2010, MOL BIOL CELL, V21, P4387, DOI 10.1091/mbc.E10 06 0489
   Miao DS, 2002, J HISTOCHEM CYTOCHEM, V50, P333, DOI 10.1177/002215540205000305
   Miwa HE, 2013, GLYCOBIOLOGY, V23, P1477, DOI 10.1093/glycob/cwt075
   Noda Y, 2010, ACTA HISTOCHEM CYTOC, V43, P61, DOI 10.1267/ahc.10008
   Ohrbach R, 2016, J DENT RES, V95, P1093, DOI 10.1177/0022034516653922
   Ouanounou A, 2017, J CAN DENT ASSOC, V83
   Papadakou P, 2017, J DENT RES, V96, P467, DOI 10.1177/0022034516681762
   Parray HA, 2015, INT J MOL SCI, V16, P14441, DOI 10.3390/ijms160714441
   Pedica F, 2008, VIRCHOWS ARCH, V452, P57, DOI 10.1007/s00428 007 0540 2
   Peterziel H, 2012, NEURO ONCOLOGY, V14, P426, DOI 10.1093/neuonc/nos055
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Saharinen P, 2004, TRENDS IMMUNOL, V25, P387, DOI 10.1016/j.it.2004.05.003
   Schiffman E, 2014, J ORAL FACIAL PAIN H, V28, P6, DOI 10.11607/jop.1151
   Schwager S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00308
   Sebban LE, 2007, J IMMUNOL, V179, P1225, DOI 10.4049/jimmunol.179.2.1225
   Sikorska J, 2019, BMC CANCER, V19, DOI 10.1186/s12885 018 5239 z
   Smith PC, 2020, J PERIODONTAL RES, V55, P724, DOI 10.1111/jre.12761
   Sobue T, 2011, J DENT RES, V90, P512, DOI 10.1177/0022034510390810
   Sun W, 2017, J BONE MINER RES, V32, P1469, DOI 10.1002/jbmr.3117
   Tammela T, 2007, NAT MED, V13, P1458, DOI 10.1038/nm1689
   Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015
   Trevaskis NL, 2015, NAT REV DRUG DISCOV, V14, P781, DOI 10.1038/nrd4608
   Tribulatti MV, 2020, GLYCOBIOLOGY, V30, P134, DOI 10.1093/glycob/cwz077
   Utreja A, 2016, OSTEOARTHR CARTILAGE, V24, P335, DOI 10.1016/j.joca.2015.08.010
   Vinik Y, 2018, FASEB J, V32, P2366, DOI 10.1096/fj.201700716R
   Vinik Y, 2015, ELIFE, V4, DOI 10.7554/eLife.05914
   Voisin MB, 2019, J PATHOL, V247, P662, DOI 10.1002/path.5227
   Wang H, 2020, J PATHOL, V251, P323, DOI 10.1002/path.5456
   Wang WS, 2017, J BONE MINER RES, V32, P939, DOI 10.1002/jbmr.3077
   Weinmann D, 2018, CELL MOL LIFE SCI, V75, P4187, DOI 10.1007/s00018 018 2856 2
   Zhou F, 2010, AM J PATHOL, V177, P2124, DOI 10.2353/ajpath.2010.091301
   Zhou Q, 2011, ARTHRITIS RHEUM US, V63, P2318, DOI 10.1002/art.30421
NR 52
TC 5
Z9 5
U1 4
U2 50
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD JUN
PY 2023
VL 31
IS 6
BP 753
EP 765
DI 10.1016/j.joca.2023.01.008
EA MAY 2023
PG 13
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA I3HX3
UT WOS:001001734300001
PM 36702375
OA Bronze
DA 2025 08 17
ER

PT J
AU Hsu, SL
   Cheng, JH
   Wang, CJ
   Ko, JY
   Hsu, CH
AF Hsu, Shan Ling
   Cheng, Jai Hong
   Wang, Ching Jen
   Ko, Jih Yang
   Hsu, Chih Hsiang
TI Extracorporeal Shockwave Therapy Enhances Expression of Pdia 3 Which Is
   a Key Factor of the 1α,25 Dihydroxyvitamin D 3 Rapid Membrane Signaling
   Pathway in Treatment of Early Osteoarthritis of the Knee
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE protein disulfide isomerase associated 3; osteoarthritis; extracorporeal
   shockwave therapy; 1 alpha,25 Dihydroxyvitamin D3 signaling pathway; two
   dimensional electrophoresis
ID GROWTH PLATE CHONDROCYTES; ALKALINE PHOSPHATASE; BONE FORMATION; WAVE
   THERAPY; CARTILAGE DESTRUCTION; ARTICULAR CARTILAGE; ACTIVATING PROTEIN;
   PROTEOMIC ANALYSIS; RECEPTOR COMPLEX; 1 ALPHA,25(OH)(2)D 3
AB The goal of our research was demonstrated that multiple molecules in microenvironments of the early osteoarthritis (OA) joint tissue may be actively responded to extracorporeal shockwave therapy (ESWT) treatment, which potentially regulated biological function of chondrocytes and synovial cells in early OA knee. We demonstrated that shockwave treatment induced the expression of protein disulfide isomerase associated 3 (Pdia 3) which was a significant mediator of the 1 alpha,25 Dihydroxyvitamin D 3 (1 alpha,25(OH)2D3) rapid signaling pathway, using two dimensional electrophoresis, histological analysis and quantitative polymerase chain reaction (qPCR). We observed that the expression of Pdia 3 at 2 weeks was significantly higher than that of other group at 4, 8, and 12 weeks post shockwave treatment in early OA rat knee model. The other factors of the rapid membrane signaling pathway, including extracellular signal regulated protein kinases 1 (ERK1), osteopontin (OPG), alkaline phosphatase (ALP), and matrix metallopeptidase 13 (MMP13) were examined and were found to be significantly increased at 2 weeks post shockwave treatment by qPCR in early OA of the knee. Our proteomic data revealed significant Pdia 3 expression in microenvironments of OA joint tissue that could be actively responded to ESWT, which may potentially regulate the biological functions of chondrocytes and osteoblasts in the treatment of the early OA of the knee.
C1 [Hsu, Shan Ling; Cheng, Jai Hong; Wang, Ching Jen; Ko, Jih Yang] Kaohsiung Chang Gung Mem Hosp, Ctr Shockwave Med & Tissue Engn, 123 Tai Pei Rd, Kaohsiung 833, Taiwan.
   [Hsu, Shan Ling; Wang, Ching Jen; Ko, Jih Yang; Hsu, Chih Hsiang] Kaohsiung Chang Gung Mem Hosp, Dept Orthoped Surg, 123 Tai Pei Rd, Kaohsiung 833, Taiwan.
   [Cheng, Jai Hong] Kaohsiung Chang Gung Mem Hosp, Med Res, Kaohsiung, Taiwan.
   [Cheng, Jai Hong] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung
   Memorial Hospital; Chang Gung University
RP Hsu, SL; Cheng, JH (通讯作者)，Kaohsiung Chang Gung Mem Hosp, Ctr Shockwave Med & Tissue Engn, 123 Tai Pei Rd, Kaohsiung 833, Taiwan.; Hsu, SL (通讯作者)，Kaohsiung Chang Gung Mem Hosp, Dept Orthoped Surg, 123 Tai Pei Rd, Kaohsiung 833, Taiwan.
EM cjh1106@cgmh.org.tw; cjh1106@cgmh.org.tw
RI Cheng, Jai Hong/ISV 0466 2023
OI Cheng, Jai Hong/0000 0003 3667 2741
FU Kaohsiung Chang Gung Memorial Hospital; Chang Gung Medical Foundation
   [CMRPG8B1311, CMRPG8B1312]
FX We are grateful to Kaohsiung Chang Gung Memorial Hospital for the
   supporting of this work. Funds are received support for the research
   study presented in this article. The funding sources are from Chang Gung
   Medical Foundation (No: CMRPG8B1311 and CMRPG8B1312).
CR Avbersek Luznik I, 2007, CLIN CHEM LAB MED, V45, P1014, DOI 10.1515/CCLM.2007.186
   Blom AB, 2007, ARTHRITIS RHEUM, V56, P147, DOI 10.1002/art.22337
   Bondeson J, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2099
   Boyan BD, 2006, J BONE MINER RES, V21, P1637, DOI 10.1359/JBMR.060713
   Boyan BD, 2012, STEROIDS, V77, P892, DOI 10.1016/j.steroids.2012.04.018
   Chen JX, 2013, CELL SIGNAL, V25, P2362, DOI 10.1016/j.cellsig.2013.07.020
   Chen JX, 2013, MOL ENDOCRINOL, V27, P1065, DOI 10.1210/me.2012 1277
   Chen YJ, 2004, BONE, V34, P466, DOI 10.1016/j.bone.2003.11.013
   Dahlberg J, 2005, VET COMP ORTHOPAED, V18, P147
   Doroudi M, 2015, J STEROID BIOCHEM, V152, P84, DOI 10.1016/j.jsbmb.2015.04.002
   Doroudi M, 2014, BBA MOL CELL RES, V1843, P2365, DOI 10.1016/j.bbamcr.2014.06.006
   Doroudi M, 2014, CONNECT TISSUE RES, V55, P125, DOI 10.3109/03008207.2014.923882
   Doroudi M, 2012, J STEROID BIOCHEM, V132, P48, DOI 10.1016/j.jsbmb.2012.03.001
   Dufield DR, 2010, ANAL BIOCHEM, V406, P113, DOI 10.1016/j.ab.2010.06.044
   Fraser A, 2003, ARTHRITIS RHEUM, V48, P3085, DOI 10.1002/art.11331
   Frisbie DD, 2009, AM J VET RES, V70, P449, DOI 10.2460/ajvr.70.4.449
   Hashimoto S, 1997, ARTHRITIS RHEUM US, V40, P1749, DOI 10.1002/art.1780401004
   Hayami T, 2006, BONE, V38, P234, DOI 10.1016/j.bone.2005.08.007
   Hayami T, 2008, MATRIX BIOL, V27, P682, DOI 10.1016/j.matbio.2008.07.005
   Haywood L, 2003, ARTHRITIS RHEUM, V48, P2173, DOI 10.1002/art.11094
   Johnson K, 2004, ARTHRITIS RHEUM US, V50, P1216, DOI 10.1002/art.20149
   Kaspar D, 2003, J ORTHOP RES, V21, P320, DOI 10.1016/S0736 0266(02)00134 1
   Kim HA, 2000, J RHEUMATOL, V27, P455
   Kurz B, 2005, ANN ANAT, V187, P473, DOI 10.1016/j.aanat.2005.07.003
   Liao WX, 2015, INT J CLIN EXP PATHO, V8, P9975
   Liu W, 2016, MOL MED REPORTS
   MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623 197153030 00009
   Min JL, 2007, EUR J HUM GENET, V15, P791, DOI 10.1038/sj.ejhg.5201829
   Mueller M, 2007, VET REC, V160, P762, DOI 10.1136/vr.160.22.762
   Ochiai N, 2007, OSTEOARTHR CARTILAGE, V15, P1093, DOI 10.1016/j.joca.2007.03.011
   Revenaugh MS, 2005, VET CLIN N AM EQUINE, V21, P609, DOI 10.1016/j.cveq.2005.09.001
   Ruiz Romero C, 2009, CURR DRUG TARGETS, V10, P543, DOI 10.2174/138945009788488404
   Schwartz Z, 2005, J CELL PHYSIOL, V203, P54, DOI 10.1002/jcp.20212
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sylvia VL, 2001, J CELL BIOCHEM, P32
   Tanaka H, 2011, BIOCHEM BIOPH RES CO, V411, P690, DOI 10.1016/j.bbrc.2011.07.001
   Taniguchi T, 2003, INJURY, V34, P477, DOI 10.1016/S0020 1383(02)00380 7
   Theis KA, 2007, ARTHRIT RHEUM ARTHR, V57, P355, DOI 10.1002/art.22622
   Tuckermann JP, 2000, J BONE MINER RES, V15, P1257, DOI 10.1359/jbmr.2000.15.7.1257
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   VANSTRAALEN JP, 1991, CLIN CHIM ACTA, V201, P27, DOI 10.1016/0009 8981(91)90021 4
   Wang CJ, 2012, J SURG RES, V178, P196, DOI 10.1016/j.jss.2012.01.010
   Wang CJ, 2011, DIABETES RES CLIN PR, V94, P105, DOI 10.1016/j.diabres.2011.06.016
   Wang CJ, 2011, ARCH ORTHOP TRAUM SU, V131, P1153, DOI 10.1007/s00402 011 1289 2
   Wang FS, 2002, J BIOL CHEM, V277, P10931, DOI 10.1074/jbc.M104587200
   Yang MY, 2014, PLAST RECONSTR SURG, V133, P59, DOI 10.1097/01.prs.0000439050.08733.cf
   Yudoh K, 2005, ARTHRITIS RES THER, V7, pR380, DOI 10.1186/ar1499
NR 47
TC 9
Z9 11
U1 0
U2 2
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2017
VL 14
IS 12
BP 1220
EP 1230
DI 10.7150/ijms.20303
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA FL6DY
UT WOS:000414336600007
PM 29104478
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Zhao, G
   Luo, WD
   Yuan, Y
   Lin, F
   Guo, LM
   Ma, JJ
   Chen, HB
   Tang, H
   Shu, J
AF Zhao, Gang
   Luo, Wen Dong
   Yuan, Yong
   Lin, Feng
   Guo, Li Min
   Ma, Jing Jing
   Chen, Han Bo
   Tang, Huang
   Shu, Jun
TI LINC02381, a sponge of miR 21, weakens osteogenic differentiation of
   hUC MSCs through KLF12 mediated Wnt4 transcriptional repression
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Osteoporosis; hUS MSCs; LINC02381; miR 21; KLF12
ID MESENCHYMAL STEM CELLS; BONE REPAIR; OSTEOPOROSIS; INHIBITION;
   INDUCTION; THERAPY
AB Introduction Human umbilical cord blood derived MSCs (hUC MSCs) have the potential to differentiate into osteoblasts. This study investigated the function and potential mechanisms of a novel lncRNA LINC02381 in hUC MSC osteogenic differentiation. Materials and methods hUC MSCs were maintained in osteogenic differentiation medium. RT qPCR assay was performed to assess LINC02381 expression. Alizarin Red S (ARS) and alkaline phosphatase (ALP) staining were performed to evaluate osteogenic differentiation. The interaction between miR 21 and LINC0238/KLF12 was determined by luciferase reporter and RNA immunoprecipitation (RIP) assays. Chromatin immunoprecipitation (ChIP) assay was used to confirm the transcriptional regulation of KLF12 on Wnt4 promoter. The nuclear translocation of beta catenin was evaluated using immunofluorescence. hUC MSCs seeded on Bio Oss Collagen scaffolds were transplanted into nude mice to assess in vivo osteogenesis. Bone formation was observed by H&E and Masson's trichrome staining. OSX and OPN levels were assessed by immunohistochemistry. Results LINC02381 was up regulated in the clinical samples of osteoporotic patients. However, LINC02381 expression was reduced during osteogenic differentiation of hUC MSCs. Enforced expression of LINC02381 suppressed the osteogenic differentiation of hUC MSCs. Mechanistically, LINC02381 sponged miR 21 to enhance KLF12 expression, which led to the inactivation of Wnt/beta catenin signaling pathway. Furthermore, miR 21 mimics or KLF12 silencing counteracted LINC02381 induced inhibition of osteogenic differentiation, whereas IWP 4 (an inhibitor of Wnt pathway) abolished this effect. Conclusion In summary, LINC02381 repressed osteogenic differentiation of hUS MSCs through sponging miR 21 to enhance KLF12 mediated inactivation of Wnt/beta catenin pathway, indicating that LINC02381 might be a therapeutic target for osteoporosis.
C1 [Zhao, Gang; Luo, Wen Dong; Yuan, Yong; Lin, Feng; Guo, Li Min; Ma, Jing Jing; Chen, Han Bo; Tang, Huang; Shu, Jun] Kunming Med Univ, Dept Emergency Surg, Yunnan Trauma Surg Res Ctr, Affiliated Hosp 2,Yunnan Osteoporosis Res Ctr, Kunming 650101, Yunnan, Peoples R China.
C3 Kunming Medical University
RP Shu, J (通讯作者)，Kunming Med Univ, Dept Emergency Surg, Yunnan Trauma Surg Res Ctr, Affiliated Hosp 2,Yunnan Osteoporosis Res Ctr, Kunming 650101, Yunnan, Peoples R China.
EM shujunsj496@163.com
FU Yunnan Provincial Department of Science and Technology Kunming Medical
   University Applied Basic Research Joint Special Fund Project
   [2017FE468( 060)]
FX This work was supported by Yunnan Provincial Department of Science and
   Technology Kunming Medical University Applied Basic Research Joint
   Special Fund Project [2017FE468( 060)]
CR Antebi B, 2014, CURR OSTEOPOROS REP, V12, P41, DOI 10.1007/s11914 013 0184 x
   Bougioukli S, 2019, HUM GENE THER, V30, P906, DOI 10.1089/hum.2018.054
   Cao LH, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12814
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Chen XH, 2020, CANCER MANAG RES, V12, P3971, DOI 10.2147/CMAR.S237285
   Feng L, 2020, MOL THER NUCL ACIDS, V21, P1017, DOI 10.1016/j.omtn.2020.07.018
   Xiaoling GL, 2020, BMC MED GENET, V21, DOI 10.1186/s12881 020 0948 y
   Griffin M, 2011, J BONE JOINT SURG BR, V93B, P427, DOI 10.1302/0301 620X.93B4.25249
   Han YY, 2019, INT IMMUNOPHARMACOL, V76, DOI 10.1016/j.intimp.2019.105878
   Hong Boohwi, 2018, Osteoporos Sarcopenia, V4, P95, DOI 10.1016/j.afos.2018.08.003
   Huang YX, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110365
   Jafarzadeh M, 2020, BIOCHIMIE, V171, P63, DOI 10.1016/j.biochi.2020.02.009
   Jin CY, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 02813 2
   Ko NY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144886
   Liu J, 2020, INT J MOL MED, V46, P1029, DOI 10.3892/ijmm.2020.4672
   Meng YB, 2015, J ORTHOP RES, V33, P957, DOI 10.1002/jor.22884
   Mi BB, 2020, MOL THER NUCL ACIDS, V21, P814, DOI 10.1016/j.omtn.2020.07.023
   Mora Raimundo P, 2019, ACS NANO, V13, P5451, DOI 10.1021/acsnano.9b00241
   Shen JJ, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02487 3
   Sun XL, 2020, J ORTHOP TRANSL, V24, P76, DOI 10.1016/j.jot.2020.04.007
   Takai H, 2019, J ORAL SCI, V61, P313, DOI 10.2334/josnusd.18 0224
   Tang PF, 2014, RNA BIOL, V11, P1355, DOI 10.1080/15476286.2014.996462
   Vescini F, 2016, J ENDOCRINOL INVEST, V39, P807, DOI 10.1007/s40618 016 0434 8
   Wang YF, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/2971413
   Wei FL, 2015, STEM CELLS DEV, V24, P312, DOI 10.1089/scd.2014.0191
   Wu D, 2020, ARCH ORAL BIOL, V117, DOI 10.1016/j.archoralbio.2020.104814
   Wu TY, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00843
   Xiao TF, 2021, STEM CELL REP, V16, P1006, DOI 10.1016/j.stemcr.2021.03.024
   Xu Q, 2021, J CELL MOL MED, V25, P7294, DOI 10.1111/jcmm.16758
   Yan Q, 2019, BIOL REPROD, V100, P1395, DOI 10.1093/biolre/ioz026
   Yang CL, 2020, LAB INVEST, V100, P1494, DOI 10.1038/s41374 020 0451 2
   Yang L, 2019, MOL THER, V27, P394, DOI 10.1016/j.ymthe.2018.11.019
   Yang SE, 2004, CYTOTHERAPY, V6, P476, DOI 10.1080/14653240410005041
   Zhang J, 2019, J PHYSIOL BIOCHEM, V75, P443, DOI 10.1007/s13105 019 00688 2
   Zhang L, 2020, J BONE MINER METAB, V38, P794, DOI 10.1007/s00774 020 01123 z
NR 35
TC 16
Z9 17
U1 0
U2 11
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JAN
PY 2022
VL 40
IS 1
BP 66
EP 80
DI 10.1007/s00774 021 01277 4
EA NOV 2021
PG 15
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA YH3DF
UT WOS:000718258500001
PM 34778905
DA 2025 08 17
ER

PT J
AU Tao, CH
   Chen, TD
   Liu, H
   Su, SS
AF Tao, Caihong
   Chen, Tiandi
   Liu, Hui
   Su, Sisi
TI Design of biocompatible Fe3O4@MPDA mesoporous
   core shell nanospheres for drug delivery
SO MICROPOROUS AND MESOPOROUS MATERIALS
LA English
DT Article
DE Mesoporous; Polydopamine; Magnetic particles; Adsorption performance;
   Drug delivery
ID POLYDOPAMINE NANOPARTICLES; SILICA NANOPARTICLES; FE3O4 NANOPARTICLES;
   ADSORPTION; MICROSPHERES; NANOCARRIERS; REMOVAL; SUPPORT; CARRIER
AB The magnetically core shell Fe3O4@mesoporous polydopamine (Fe3O4@MPDA) nanospheres were prepared by a facile and efficient self assembly approach, the key mechanism for generating the mesoporous structure of PDA is the pi pi stacking interactions between dopamine molecules and 1,3,5 trimethylbenzene (TMB) molecules. Because of the mesoporous structure of the surface, the Fe3O4@MPDA particles exhibited a large specific surface area of 17.27 m(2)/g and total pore volumes of 0.057 cm(3)/g. Besides, it maintained good magnetic properties. The adsorption properties and mechanism of organic dyes methylene blue (MB) and rhodamine B (RhB) on Fe3O4@MPDA nanoparticles were studied. And a model anticancer drug of doxorubicin hydrochloride (DOX) was used as a target drug to research the delivery and sustained release properties of theFe(3)O(4)@MPDA particles. The average loading capacities toward DOX could reach 295.2 mg/g, and the release amounts were about 41% within 60 h. Meanwhile, the in vitro cytotoxicity of the DOX loadedFe(3)O(4)@MPDA nanoparticles against hela cells and osteoblast cells were also being researched. The DOX loaded Fe3O4@MPDA nanoparticles showed greater toxicity than Fe3O4 nanoparticles and Fe3O4@MPDA nanoparticles, even than free DOX. Compared with osteoblasts, the inhibitory effect on hella cells was more obvious. The above properties are of great significance for its application in the field of biological medicine, especially the target drug carriers.
C1 [Tao, Caihong; Chen, Tiandi; Liu, Hui; Su, Sisi] Lanzhou Jiaotong Univ, Sch Chem & Biol Engn, Lanzhou 730070, Gansu, Peoples R China.
C3 Lanzhou Jiaotong University
RP Tao, CH (通讯作者)，Lanzhou Jiaotong Univ, Sch Chem & Biol Engn, Lanzhou 730070, Gansu, Peoples R China.
EM taoch@mail.lzjtu.cn
FU Natural science fund project of Gansu province [18JR3RA109]; Foundation
   of a Hundred Youth Talents Training Program of Lanzhou Jiaotong
   University
FX We acknowledge the financial support from the Natural science fund
   project of Gansu province (18JR3RA109) and the Foundation of a Hundred
   Youth Talents Training Program of Lanzhou Jiaotong University.
CR Alver E, 2012, CHEM ENG J, V200, P59, DOI 10.1016/j.cej.2012.06.038
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   Byeon JH, 2014, ACS MACRO LETT, V3, P369, DOI 10.1021/mz500142e
   Chang BS, 2011, J MATER CHEM, V21, P9239, DOI 10.1039/c1jm10631g
   Chen F, 2016, LANGMUIR, V32, P12119, DOI 10.1021/acs.langmuir.6b03294
   Chen GY, 2016, CHEM REV, V116, P2826, DOI 10.1021/acs.chemrev.5b00148
   Chen M, 2014, ADV MATER, V26, P8210, DOI 10.1002/adma.201404013
   Chen ZW, 2013, BIOMATERIALS, V34, P1364, DOI 10.1016/j.biomaterials.2012.10.060
   Cheng W, 2017, ACS APPL MATER INTER, V9, P18462, DOI 10.1021/acsami.7b02457
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Costa HPD, 2021, J WATER PROCESS ENG, V40, DOI 10.1016/j.jwpe.2021.101925
   Deng H, 2005, ANGEW CHEM INT EDIT, V44, P2782, DOI 10.1002/anie.200462551
   Du X, 2015, SMALL, V11, P392, DOI 10.1002/smll.201401201
   Dutta B, 2018, COLLOID SURFACE B, V162, P163, DOI 10.1016/j.colsurfb.2017.11.054
   Freundlich H, 1906, Z PHYS CHEM STOCH VE, V57, P385
   Gan Q, 2011, BIOMATERIALS, V32, P1932, DOI 10.1016/j.biomaterials.2010.11.020
   Ganivada MN, 2014, MACROMOLECULES, V47, P2703, DOI 10.1021/ma500384m
   Ge R, 2016, ACS APPL MATER INTER, V8, P22942, DOI 10.1021/acsami.6b07997
   Hao R, 2010, ADV MATER, V22, P2729, DOI 10.1002/adma.201000260
   Hu H, 2013, J MATER SCI, V48, P7686, DOI 10.1007/s10853 013 7588 y
   Kong G, 1999, INT J HYPERTHER, V15, P345, DOI 10.1080/026567399285558
   Lagergren S., 1898, Kungliga svenska vetenskapsakademiens. Handlingar, DOI DOI 10.1007/BF01501332
   Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004
   Li J, 2017, SCI TECHNOL ADV MAT, V18, P3, DOI 10.1080/14686996.2016.1246941
   Li YH, 2017, ACS APPL MATER INTER, V9, P2123, DOI 10.1021/acsami.6b13876
   Lim C, 2016, ANGEW CHEM INT EDIT, V55, P3342, DOI 10.1002/anie.201510319
   Liu B, 2011, J PHYS CHEM C, V115, P15875, DOI 10.1021/jp204976y
   Liu F, 2014, BIOMACROMOLECULES, V15, P968, DOI 10.1021/bm4018484
   Liu R, 2013, ACS APPL MATER INTER, V5, P9167, DOI 10.1021/am402585y
   Liu XC, 2013, J MATER CHEM A, V1, P3945, DOI 10.1039/c3ta00527e
   Liu YL, 2014, CHEM REV, V114, P5057, DOI 10.1021/cr400407a
   Loo C, 2004, TECHNOL CANCER RES T, V3, P33, DOI 10.1177/153303460400300104
   Ma M, 2013, MATER LETT, V105, P36, DOI 10.1016/j.matlet.2013.04.020
   Maier GP, 2015, SCIENCE, V349, P628, DOI 10.1126/science.aab0556
   Manchanda AS, 2016, LANGMUIR, V32, P900, DOI 10.1021/acs.langmuir.5b04284
   Mathew A, 2014, MICROPOR MESOPOR MAT, V200, P124, DOI 10.1016/j.micromeso.2014.08.033
   Minati L, 2010, J PHYS CHEM C, V114, P11068, DOI 10.1021/jp101868s
   Mustapic M, 2016, MICROPOR MESOPOR MAT, V226, P243, DOI 10.1016/j.micromeso.2015.12.032
   Nasrallah GK, 2018, MICROPOR MESOPOR MAT, V265, P195, DOI 10.1016/j.micromeso.2018.02.008
   Noonan O, 2016, J MATER CHEM A, V4, P9063, DOI 10.1039/c6ta02265k
   Qian LW, 2017, TALANTA, V168, P174, DOI 10.1016/j.talanta.2017.03.044
   Seo WS, 2006, NAT MATER, V5, P971, DOI 10.1038/nmat1775
   Su FF, 2019, MICROPOR MESOPOR MAT, V275, P152, DOI 10.1016/j.micromeso.2018.08.026
   Sun ZK, 2016, NANO TODAY, V11, P464, DOI 10.1016/j.nantod.2016.07.003
   Vieira EFS, 2008, BIOMACROMOLECULES, V9, P1195, DOI 10.1021/bm7011983
   Wang BD, 2008, J AM CHEM SOC, V130, P14436, DOI 10.1021/ja806519m
   Wang JX, 2015, J IND ENG CHEM, V25, P321, DOI 10.1016/j.jiec.2014.11.011
   Wang WC, 2012, J COLLOID INTERF SCI, V368, P241, DOI 10.1016/j.jcis.2011.10.047
   Xing YX, 2017, NANOSCALE, V9, P8781, DOI 10.1039/c7nr01857f
   Xiong L, 2016, SMALL, V12, P4735, DOI 10.1002/smll.201600531
   Yang XY, 2011, J MATER CHEM, V21, P3448, DOI 10.1039/c0jm02494e
   You LJ, 2014, ACS APPL MATER INTER, V6, P15179, DOI 10.1021/am503421z
   Zhang L, 2009, MATER LETT, V63, P272, DOI 10.1016/j.matlet.2008.10.015
   Zhu YF, 2010, J PHYS CHEM C, V114, P16382, DOI 10.1021/jp106685q
NR 58
TC 31
Z9 31
U1 8
U2 178
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29a, 1043 NX AMSTERDAM, NETHERLANDS
SN 1387 1811
EI 1873 3093
J9 MICROPOR MESOPOR MAT
JI Microporous Mesoporous Mat.
PD FEB
PY 2020
VL 293
AR 109823
DI 10.1016/j.micromeso.2019.109823
PG 10
WC Chemistry, Applied; Chemistry, Physical; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA JY6EJ
UT WOS:000504505500046
DA 2025 08 17
ER

PT J
AU Feldman, F
AF Feldman, Frieda
TI Atypical diaphyseal femoral fractures new aspects
SO SKELETAL RADIOLOGY
LA English
DT Article
DE Atypical femoral fractures; Bisphosphonate fractures; Diaphyseal
   fractures
ID SUPPRESSED BONE TURNOVER; INSUFFICIENCY FRACTURES; ALENDRONATE THERAPY;
   STRESS FRACTURES; WOMEN; CALCIFICATION; COMPLICATION
AB Post menopausal osteoporotic fractures are a major public health concern worldwide with oral bisphosphonates favored for their prevention and treatment. Recent interest has centered on clinically observed, unusually sited femoral diaphyseal fractures, particularly attributed to alendronate. Their imaging presentations on routine radiographs, alternate imaging modalities, and associated pitfalls in nine fractures in six patients are selectively illustrated by seven fractures in four patients that serve to emphasize the following: (1) Bisphosphonates other than alendronate have been used for treating various bone diseases in children and men as well as osteoporotic women. (2) Effects may differ with each bisphosphonate's route of administration and prolongation of activity, despite discontinuation. Prior investigations and theoretical mechanisms of bisphosphonates as a class rather than with a specific alendronate association are reviewed to provide a broader basis for evaluating their recently observed clinical and radiographic complications.
C1 NY Presbyterian Med Ctr, New York, NY 10032 USA.
RP Feldman, F (通讯作者)，NY Presbyterian Med Ctr, 622 W 168 St,Harkness Pavil 3rd floor, New York, NY 10032 USA.
EM ff2@columbia.edu
CR Bagger YZ, 2003, BONE, V33, P301, DOI 10.1016/S8756 3282(03)00112 1
   Bilezikian JP, 2009, AM J MED, V122, P14, DOI 10.1016/j.amjmed.2008.12.003
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Burr DB, 1997, J BONE MINER RES, V12, P6, DOI 10.1359/jbmr.1997.12.1.6
   BUSH LA, 2009, RADIOL CASE REP, V4, P1
   Chan SS, 2010, AM J ROENTGENOL, V194, P1581, DOI 10.2214/AJR.09.3588
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   FLEISCH H, 1962, AM J PHYSIOL, V203, P671, DOI 10.1152/ajplegacy.1962.203.4.671
   FLEISCH H, 2002, PRINCIPLES BONE BIOL, V2, P1361
   FLEISH H, 1961, AM J PHYSIOL, V200, P1296, DOI 10.1152/ajplegacy.1961.200.6.1296
   Goh SK, 2007, J BONE JOINT SURG BR, V89B, P349, DOI 10.1302/0301 620X.89B3.18146
   Kwek EBK, 2008, INJURY, V39, P224, DOI 10.1016/j.injury.2007.08.036
   LAVELLE DG, 2002, CAMPBELLS OPERATIVE, V3, P2873
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P1897, DOI 10.1210/jc.2005 0057
   Pauwels F, 1948, ANAT EMBRYOL, V114, P1
   Porrino JA, 2010, AM J ROENTGENOL, V194, P1061, DOI 10.2214/AJR.09.3383
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Schilcher J, 2009, ACTA ORTHOP, V80, P413, DOI 10.3109/17453670903139914
   Shane E, 2010, NEW ENGL J MED, V362, P1825, DOI 10.1056/NEJMe1003064
   Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109
   Visekruna M, 2008, J CLIN ENDOCR METAB, V93, P2948, DOI 10.1210/jc.2007 2803
   WEINSTEIN RS, N ENGL J MED, V360, P53
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
NR 28
TC 6
Z9 6
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0364 2348
EI 1432 2161
J9 SKELETAL RADIOL
JI Skeletal Radiol.
PD JAN
PY 2012
VL 41
IS 1
BP 75
EP 81
DI 10.1007/s00256 011 1130 6
PG 7
WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
GA 855DK
UT WOS:000297543700009
PM 21369720
DA 2025 08 17
ER

PT J
AU Liu, S
   Kiyoi, T
   Takemasa, E
   Maeyama, K
AF Liu, Shuang
   Kiyoi, Takeshi
   Takemasa, Erika
   Maeyama, Kazutaka
TI Intra articular lentivirus mediated gene therapy targeting CRACM1 for
   the treatment of collagen induced arthritis
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Intra articular injection; Lentivirus; Gene silencing; Calcium
   release activated calcium channel 1; Collagen induced arthritis
ID OPERATED CA2+ ENTRY; CD4(+) T CELLS; RHEUMATOID ARTHRITIS; VIVO
AB Abnormal store operated calcium uptake has been observed in peripheral T lymphocytes of rheumatoid arthritis (RA) patients, and sustained intracellular calcium signalling is known to mediate the functions of many types of immune cells. Thus, it is hypothesized that regulating calcium entry through CRACM1 (the pore forming subunit of calcium release activated calcium (CRAC) channels; also known as ORAI1) may be beneficial for the management of RA. Localized CRACM1 knockdown in the joints and draining lymph nodes (DLNs) of mice with collagen induced arthritis (CIA) was achieved via lentiviral based delivery of shRNA targeting mouse CRACM1. Consistent with CRACM1 knockdown, calcium influx in synovial cells and the histopathological features of CIA were reduced. These effects were also associated with reduced levels of several notable inflammatory cytokines, such as IL 6, IL 17A, and IFN gamma, in the joints. Additionally, CRACM1 shRNA reduced the number of bone marrow derived osteoclasts in vitro as well as osteoclasts in CIA joints, which was associated with reduced RANKL levels in the serum and joints. In summary, inhibiting calcium entry by CRACM1 knockdown suppressed arthritis development and may be therapeutically beneficial for RA patients. (C) 2017 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/4.0/).
C1 [Liu, Shuang; Takemasa, Erika; Maeyama, Kazutaka] Ehime Univ, Grad Sch Med, Dept Pharmacol, Toon, Ehime 7910295, Japan.
   [Kiyoi, Takeshi] Ehime Univ, Integrated Ctr Sci, Dept Biosci, Toon, Ehime 7910295, Japan.
C3 Ehime University; Ehime University
RP Liu, S (通讯作者)，Ehime Univ, Grad Sch Med, Dept Pharmacol, Toon, Ehime 7910295, Japan.
EM liussmzk@m.ehime u.ac.jp
RI Shuang, Liu/AAW 2695 2020
FU Japan Society for the Promotion of Science (JSPS) (KAKENHI Grant)
   [15K19575]; Grants in Aid for Scientific Research [15K19575] Funding
   Source: KAKEN
FX This work was supported by the Japan Society for the Promotion of
   Science (JSPS) (KAKENHI Grant Number 15K19575).
CR Cato MH, 2011, NAT PROTOC, V6, P953, DOI 10.1038/nprot.2011.344
   Evans CH, 2013, TRANSL RES, V161, P205, DOI 10.1016/j.trsl.2013.01.002
   Guo HT, 2014, J BIOL CHEM, V289, P21716, DOI 10.1074/jbc.M114.566620
   Hueber AJ, 2010, J IMMUNOL, V184, P3336, DOI 10.4049/jimmunol.0903566
   Kay J, 2004, RHEUMATOLOGY, V43, P2, DOI 10.1093/rheumatology/keh201
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   Liu S, 2016, SCI REP UK, V6, DOI 10.1038/srep28133
   Liu S, 2015, J IMMUNOL, V194, P76, DOI 10.4049/jimmunol.1401976
   Liu S, 2014, IMMUNOL CELL BIOL, V92, P752, DOI 10.1038/icb.2014.45
   Liu XD, 2016, J PHARMACOL SCI, V130, P204, DOI 10.1016/j.jphs.2016.02.001
   Ma HT, 2009, CRIT REV IMMUNOL, V29, P155, DOI 10.1615/CritRevImmunol.v29.i2.40
   Mandema JW, 2011, CLIN PHARMACOL THER, V90, P828, DOI 10.1038/clpt.2011.256
   Ohga K, 2008, INT IMMUNOPHARMACOL, V8, P1787, DOI 10.1016/j.intimp.2008.08.016
   Parekh AB, 2010, NAT REV DRUG DISCOV, V9, P399, DOI 10.1038/nrd3136
   Prakriya M, 2013, CURR TOP MEMBR, V71, P1, DOI 10.1016/B978 0 12 407870 3.00001 9
   Rothe M, 2014, CURR GENE THER, V14, P429, DOI 10.2174/1566523214666140918110905
   Saitoh T, 2012, CELL HOST MICROBE, V12, P109, DOI 10.1016/j.chom.2012.05.015
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Tagishi K, 2016, J PHARMACOL SCI, V132, P205, DOI 10.1016/j.jphs.2016.10.007
   Venkatesha SH, 2015, INT J MOL SCI, V16, P887, DOI 10.3390/ijms16010887
NR 20
TC 22
Z9 22
U1 0
U2 6
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
EI 1347 8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD MAR
PY 2017
VL 133
IS 3
BP 130
EP 138
DI 10.1016/j.jphs.2017.02.001
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA ER7UM
UT WOS:000399019400003
PM 28258822
OA gold
DA 2025 08 17
ER

PT J
AU Chi, MH
   Chao, J
   Ko, CY
   Huang, SS
AF Chi, Min Han
   Chao, Jung
   Ko, Chien Yu
   Huang, Shyh Shyun
TI An Ethnopharmaceutical Study on the Hypolipidemic Formulae in Taiwan
   Issued by Traditional Chinese Medicine Pharmacies
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE hyperlipidemia; hypolipidemic; traditional Chinese medicine; pharmacies;
   drug combination
ID NF KAPPA B; METABOLIC SYNDROME; GUT MICROBIOTA; IN VITRO; OSTEOCLAST
   DIFFERENTIATION; ANTIOXIDANT ACTIVITIES; HYDROXYSAFFLOR YELLOW;
   CHAENOMELES SPECIOSA; DIABETIC RATS; POLYSACCHARIDE
AB Globally, approximately one third of ischemic heart diseases are due to hyperlipidemia, which has been shown to cause various metabolic disorders. This study was aimed to disassemble and analyze hypolipidemic formulae sold by traditional Chinese medicine (TCM) pharmacies. Using commonly used statistical parameters in ethnopharmacology, we identified the core drug combination of the hypolipidemic formulae, thereby exploring the strategy by which the Taiwanese people select hypolipidemic drugs. Most important of all, we preserved the inherited knowledge of TCM. We visited 116 TCM pharmacies in Taiwan and collected 91 TCM formulae. The formulae were mainly disassembled by macroscopical identification, and the medicinal materials with a relative frequency of citation (RFC) >0.2 were defined as commonly used medicinal materials. Subsequently, we sorted the information of medicinal materials recorded in the Pharmacopeia, searched for modern pharmacological research on commonly used medicinal materials using PubMed database, and visualized data based on the statistical results. Finally, the core hypolipidemic medicinal materials used in folk medicine were obtained. Of the 91 TCM formulae collected in this study, 80 traditional Chinese medicinal materials were used, belonging to 43 families, predominantly Lamiaceae. Roots were the most commonly used part as a medicinal material. There were 17 commonly used medicinal materials. Based on medicinal records in Pharmacopeia, most flavors and properties were warm and pungent, the majority traditional effects were "tonifying and replenishing" and "blood regulating." Besides, the targeted diseases searching from modern pharmacological studies were diabetes mellitus and dyslipidemia. The core medicinal materials consisted of Astragalus mongholicus Bunge and Crataegus pinnatifida Bunge, and the core formulae were Bu Yang Huan Wu Tang and Xie Fu Zhu Yu Tang. In addition, 7 groups of folk misused medicinal materials were found. Although these TCMs have been used for a long period of time, their hypolipidemic mechanisms remain unclear, and further studies are needed to validate their safety and efficacy.
C1 [Chi, Min Han; Ko, Chien Yu; Huang, Shyh Shyun] China Med Univ, Sch Pharm, Taichung, Taiwan.
   [Chao, Jung] China Med Univ, Chinese Med Res Ctr, Dept Chinese Pharmaceut Sci & Chinese Med Resource, Master Program Food & Drug Safety, Taichung, Taiwan.
   [Huang, Shyh Shyun] Asia Univ, Dept Food Nutr & Hlth Biotechnol, Taichung, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; Asia
   University Taiwan
RP Huang, SS (通讯作者)，China Med Univ, Sch Pharm, Taichung, Taiwan.; Huang, SS (通讯作者)，Asia Univ, Dept Food Nutr & Hlth Biotechnol, Taichung, Taiwan.
EM sshuang@mail.cmu.edu.tw
CR Abd Rashed A, 2021, MOLECULES, V26, DOI 10.3390/molecules26103042
   Agiannitopoulos K, 2016, J CLIN LAB ANAL, V30, P204, DOI 10.1002/jcla.21837
   Ahmad KS, 2017, J ETHNOBIOL ETHNOMED, V13, DOI 10.1186/s13002 017 0196 1
   Aierken A, 2017, J SCI FOOD AGR, V97, P4557, DOI 10.1002/jsfa.8323
   Al Aubaidy HA, 2021, NUTRIENTS, V13, DOI 10.3390/nu13041133
   Alam F, 2019, PHYTOTHER RES, V33, P41, DOI 10.1002/ptr.6211
   Ali MY, 2020, BIOORG CHEM, V102, DOI 10.1016/j.bioorg.2020.104061
   Alwan A, 2011, GLOBAL STATUS REPORT ON NONCOMMUNICABLE DISEASES 2010, P1
   Alzahrani S, 2020, INT IMMUNOPHARMACOL, V87, DOI 10.1016/j.intimp.2020.106813
   An T, 2019, PEERJ, V7, DOI 10.7717/peerj.6506
   Athyros VG, 2018, HORM INT J ENDOCRINO, V17, P61, DOI 10.1007/s42000 018 0014 8
   Baek SY, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030437
   Bai L, 2019, AM J CHINESE MED, V47, P933, DOI 10.1142/S0192415X19500496
   Behl T, 2017, J PHARM PHARMACOL, V69, P223, DOI 10.1111/jphp.12683
   Byeon JH, 2019, J ETHNOPHARMACOL, V233, P190, DOI 10.1016/j.jep.2019.01.006
   Cao H, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00445
   Cao YM, 2017, PHARMACOGN MAG, V13, P693, DOI 10.4103/pm.pm_560_16
   Carnovali M, 2020, J PHARMACOL SCI, V143, P300, DOI 10.1016/j.jphs.2020.06.001
   Carnovali M, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051042
   Castro MA, 2020, NUTR METAB CARDIOVAS, V30, P1590, DOI 10.1016/j.numecd.2020.04.033
   Chao J, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.625869
   Chen G, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 017 2016 5
   Chen LD, 2019, BIOCHEM BIOPH RES CO, V520, P580, DOI 10.1016/j.bbrc.2019.09.106
   Chen Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030752
   Chen ZW, 2019, EXP THER MED, V18, P3741, DOI 10.3892/etm.2019.8047
   Cheng CF, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003 019 0624 y
   Cheng X, 2020, CARBOHYD POLYM, V236, DOI 10.1016/j.carbpol.2020.116065
   Cheng XL, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2019.109702
   Chinese Pharmacopoeia Commission, 2020, Pharmacopoeia of the People's Republic of China, Vfirst
   Choi JH, 2017, PHYTOMEDICINE, V34, P6, DOI 10.1016/j.phymed.2017.07.006
   Chu SM, 2015, J ETHNOPHARMACOL, V168, P129, DOI 10.1016/j.jep.2015.03.047
   Dehghani S, 2019, IRAN J BASIC MED SCI, V22, P460, DOI 10.22038/IJBMS.2019.31964.7678
   Deng YJ, 2020, INT J BIOL MACROMOL, V153, P755, DOI 10.1016/j.ijbiomac.2020.03.057
   Dhuique Mayer C, 2020, FOOD FUNCT, V11, P9263, DOI 10.1039/d0fo02430a
   Di Giantomasso D, 2002, INTENS CARE MED, V28, P1804, DOI 10.1007/s00134 002 1444 x
   Dincer Y, 2021, NUTRITION, V84, DOI 10.1016/j.nut.2020.111119
   Dong XL, 2020, AM J CHINESE MED, V48, P463, DOI 10.1142/S0192415X2050024X
   Du GH, 2020, ADV PHARMACOL, V87, P1, DOI 10.1016/bs.apha.2019.12.004
   Fan HJ, 2018, J ETHNOPHARMACOL, V212, P67, DOI 10.1016/j.jep.2017.10.017
   Fan JR, 2020, J NAT PROD, V83, P814, DOI 10.1021/acs.jnatprod.9b00262
   Feng HB, 2019, MOLECULES, V24, DOI 10.3390/molecules24224150
   Feng HB, 2017, MOLECULES, V22, DOI 10.3390/molecules22010106
   Feng SH, 2021, DRUG DES DEV THER, V15, P705, DOI 10.2147/DDDT.S293046
   Fernandez ML, 2018, CURR PHARM DESIGN, V24, P1905, DOI 10.2174/1381612824666180316114832
   Figarska SM, 2014, PHYSIOL GENOMICS, V46, P411, DOI 10.1152/physiolgenomics.00178.2013
   Fürstenau CR, 2019, NEUROTOX RES, V36, P491, DOI 10.1007/s12640 019 00091 1
   Gandhi GR, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102907
   Gao J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00989
   Gao K, 2018, PHARMACOL RES, V130, P93, DOI 10.1016/j.phrs.2018.01.011
   Ge HF, 2018, FOOD CHEM TOXICOL, V119, P417, DOI 10.1016/j.fct.2017.12.035
   Grundy SM, 2019, J AM COLL CARDIOL, V73, pE285, DOI 10.1016/j.jacc.2018.11.003
   Guan YH, 2021, MED SCI MONITOR, V27, DOI 10.12659/MSM.928153
   Guo JJ, 2020, BIOCHEM BIOPH RES CO, V529, P277, DOI 10.1016/j.bbrc.2020.05.212
   Guo M, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/163036
   Guo Y, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000023843
   Hager MR, 2017, REV ENDOCR METAB DIS, V18, P29, DOI 10.1007/s11154 016 9402 z
   Han D, 2016, SCI REP UK, V6, DOI 10.1038/srep35319
   Hao XL, 2020, J ADV RES, V23, P1, DOI 10.1016/j.jare.2020.01.012
   Hassan S, 2020, J ETHNOPHARMACOL, V254, DOI 10.1016/j.jep.2020.112710
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   He KQ, 2018, INT J MOL MED, V41, P1078, DOI 10.3892/ijmm.2017.3265
   Health Promotion Administration, 2020, PREV MET DIS TAIW
   Hendrich AB, 2020, ADV CLIN EXP MED, V29, P215, DOI 10.17219/acem/115086
   HOEKSTRA JW, 1990, RESUSCITATION, V19, P227, DOI 10.1016/0300 9572(90)90104 M
   Hu FP, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240311
   Hu HM, 2017, MED SCI MONITOR, V23, P3412, DOI 10.12659/MSM.905544
   Hu YZ, 2019, J THROMB THROMBOLYS, V48, P491, DOI 10.1007/s11239 019 01945 3
   Hua YL, 2019, BIOMED CHROMATOGR, V33, DOI 10.1002/bmc.4402
   Huang Feng, 2018, Zhongguo Zhen Jiu, V38, P969, DOI 10.13703/j.0255 2930.2018.09.017
   Huang WC, 2021, ENVIRON TOXICOL, V36, P1932, DOI 10.1002/tox.23313
   Huang WF, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/9591845
   Hussain A, 2021, MOLECULES, V26, DOI 10.3390/molecules26020302
   Igarashi Y, 2021, BIOMED PHARMACOTHER, V140, DOI 10.1016/j.biopha.2021.111714
   Jia N, 2019, INT J BIOL MACROMOL, V132, P213, DOI 10.1016/j.ijbiomac.2019.03.196
   Jia QQ, 2019, PHYTOMEDICINE, V58, DOI 10.1016/j.phymed.2019.152871
   Jin J, 2019, CELL CYCLE, V18, P3125, DOI 10.1080/15384101.2019.1669986
   Jung HA, 2017, MOLECULES, V22, DOI 10.3390/molecules22010028
   Jung HA, 2017, ARCH PHARM RES, V40, P37, DOI 10.1007/s12272 016 0852 3
   Kambalachenu HR, 2018, REV RECENT CLIN TRIA, V13, P69, DOI 10.2174/1574887112666171120094539
   Karr S, 2017, AM J MANAG CARE, V23, pS139
   Ko CY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.736370
   Ko E, 2020, AM J CHINESE MED, V48, P615, DOI 10.1142/S0192415X20500317
   Kong FS, 2020, J ETHNOPHARMACOL, V262, DOI 10.1016/j.jep.2020.113178
   Kopin L, 2017, ANN INTERN MED, V167, pITC81, DOI 10.7326/AITC201712050
   Kumar Ravindra, 2021, Cardiovascular & Hematological Agents in Medicinal Chemistry, V19, P175, DOI 10.2174/1871525718666201217102638
   Lee CL, 2013, J AGR FOOD CHEM, V61, P143, DOI 10.1021/jf304346r
   Lee EJ, 2018, J AGR FOOD CHEM, V66, P10447, DOI 10.1021/acs.jafc.8b04080
   Lee HE, 2018, BIOCHEM BIOPH RES CO, V503, P2117, DOI 10.1016/j.bbrc.2018.07.168
   Lee MS, 2020, DIABET METAB SYND OB, V13, P1097, DOI 10.2147/DMSO.S246381
   Lee M, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7805393
   Lee SR, 2020, J ETHNOPHARMACOL, V258, DOI 10.1016/j.jep.2020.112874
   Lee YH, 2016, MOLECULES, V21, DOI 10.3390/molecules21111424
   Leng B, 2018, LIFE SCI, V209, P111, DOI 10.1016/j.lfs.2018.07.053
   Li AL, 2021, J FOOD BIOCHEM, V45, DOI 10.1111/jfbc.13541
   Li CL, 2020, J MOL CELL CARDIOL, V139, P98, DOI 10.1016/j.yjmcc.2020.01.009
   Li D, 2017, CHINESE MED J PEKING, V130, P2829, DOI 10.4103/0366 6999.219143
   Li NY, 2018, CHINESE MED J PEKING, V131, P516, DOI 10.4103/0366 6999.226077
   Li X, 2020, FOOD CHEM TOXICOL, V146, DOI 10.1016/j.fct.2020.111801
   Li YP, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/2462039
   Liao Feng, 2019, Hua Xi Kou Qiang Yi Xue Za Zhi, V37, P193, DOI 10.7518/hxkq.2019.02.012
   Liao WT, 2019, J ETHNOPHARMACOL, V243, DOI 10.1016/j.jep.2019.112091
   Lien ASY, 2016, J ETHNOPHARMACOL, V191, P324, DOI 10.1016/j.jep.2016.06.051
   Lin CH, 2017, FOOD FUNCT, V8, P2102, DOI 10.1039/c7fo00406k
   Liu CH, 2012, NUTR DIET, V69, P64, DOI 10.1111/j.1747 0080.2011.01565.x
   Liu J, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.598744
   Liu J, 2018, PHARMACOL RES, V134, P40, DOI 10.1016/j.phrs.2018.05.012
   Liu JQ, 2021, PHYTOMEDICINE, V86, DOI 10.1016/j.phymed.2019.153077
   Liu L, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6762146
   Liu SY, 2018, INT J MOL MED, V41, P2059, DOI 10.3892/ijmm.2018.3414
   Liu YQ, 2008, AM J CHINESE MED, V36, P771, DOI 10.1142/S0192415X08006223
   Liu Y, 2019, J ETHNOPHARMACOL, V236, P1, DOI 10.1016/j.jep.2019.02.038
   Lu HL, 2020, COMPLEMENT THER MED, V49, DOI 10.1016/j.ctim.2020.102332
   Lu JF, 2020, FASEB J, V34, P12053, DOI 10.1096/fj.201903102RR
   Luo ZH, 2019, J CHROMATOGR B, V1114, P134, DOI 10.1016/j.jchromb.2019.01.026
   Ma Jing, 2019, Zhejiang Da Xue Xue Bao Yi Xue Ban, V48, P289
   Ma L, 2019, BIOCHEM BIOPH RES CO, V514, P861, DOI 10.1016/j.bbrc.2019.05.056
   Ma QX, 2020, MOLECULES, V25, DOI 10.3390/molecules25051089
   Meephat S, 2021, FOOD FUNCT, V12, P1469, DOI [10.1039/D0FO02744H, 10.1039/d0fo02744h]
   Meng XQ, 2019, INT J BIOL MACROMOL, V132, P1057, DOI 10.1016/j.ijbiomac.2019.04.018
   Meng YQ, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110574
   Meng YQ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00667
   Miao J, 2017, J FOOD SCI TECH MYS, V54, P2758, DOI 10.1007/s13197 017 2712 7
   Ministry of Health and Welfare, 2021, ADM PHARM AFF
   Mofo EPM, 2020, BASIC CLIN PHARMACOL, V127, P211, DOI 10.1111/bcpt.13407
   Naeini F, 2021, ADV NUTR, V12, P413, DOI 10.1093/advances/nmaa106
   National Administration of Traditional Chinese Medicine, 1999, CHINESE MAT MED
   National Center for Complementary and Integrative Health, 2019, TRADITIONAL CHINESE
   Nie T, 2018, BRIT J PHARMACOL, V175, P1439, DOI 10.1111/bph.14139
   Nimrouzi M, 2020, J ETHNOPHARMACOL, V254, DOI 10.1016/j.jep.2020.112721
   Noest XH, 2019, MOLECULES, V24, DOI 10.3390/molecules24173116
   Nowicka P, 2018, PLANT FOOD HUM NUTR, V73, P314, DOI 10.1007/s11130 018 0688 8
   Nozaki Tomoko, 2017, Okajimas Folia Anat Jpn, V93, P111, DOI 10.2535/ofaj.93.111
   O'Brien KA, 2010, CHOLESTEROL, DOI 10.1155/2010/723289
   Orgah JO, 2020, PHARMACOL RES, V153, DOI 10.1016/j.phrs.2020.104654
   Patrono C, 2016, BRIT J CLIN PHARMACO, V82, P957, DOI 10.1111/bcp.13048
   Qin TY, 2020, J ETHNOPHARMACOL, V246, DOI 10.1016/j.jep.2019.112128
   Rai U, 2019, LIFE SCI, V236, DOI 10.1016/j.lfs.2019.116836
   Rani R, 2017, EUR J PHARM SCI, V106, P220, DOI 10.1016/j.ejps.2017.05.068
   Raslova K., 2016, VNITR LEK, V62, P908
   Reiter Brennan C, 2020, CLEV CLIN J MED, V87, P231, DOI 10.3949/ccjm.87a.19078
   Ren DD, 2017, CHIN J NAT MEDICINES, V15, P847, DOI 10.1016/S1875 5364(18)30018 9
   Rho TW, 2017, AM J CHINESE MED, V45, P283, DOI [10.1142/S0192415X17500185, 10.1142/s0192415x17500185]
   Royal Botanic Gardens K. Garden M.B., 2021, WORLD FLOR ONL
   Ryuk JA, 2017, COMPLEMENT THER MED, V33, P6, DOI 10.1016/j.ctim.2017.05.004
   Sham TT, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/925302
   Shi H.X., 2007, J MED FORUM, V28, P123
   Shi M, 2019, CRIT REV FOOD SCI, V59, P953, DOI 10.1080/10408398.2018.1474170
   Shi ZQ, 2021, J CHROMATOGR B, V1176, DOI 10.1016/j.jchromb.2021.122737
   Sil R, 2016, PHYTOTHER RES, V30, P1503, DOI 10.1002/ptr.5654
   Singh S, 2020, DRUG RES, V70, P298, DOI 10.1055/a 1148 3950
   Sirtori CR, 2014, PHARMACOL RES, V88, P3, DOI 10.1016/j.phrs.2014.03.002
   Soliman AM, 2019, MINI REV MED CHEM, V19, P381, DOI 10.2174/1389557518666181025155204
   Song M, 2020, PHARM BIOL, V58, P845, DOI 10.1080/13880209.2020.1803369
   Song T, 2020, INVEST NEW DRUG, V38, P1743, DOI 10.1007/s10637 020 00979 2
   Stefanie N, 2017, J PHARMACEUT BIOMED, V145, P219, DOI 10.1016/j.jpba.2017.03.049
   Su KH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.746777
   Subash Babu P, 2018, BIOMED PHARMACOTHER, V99, P375, DOI 10.1016/j.biopha.2018.01.084
   Sui Y, 2019, PHYTOTHER RES, V33, P818, DOI 10.1002/ptr.6275
   Sun CJ, 2020, PHYTOTHER RES, V34, P1704, DOI 10.1002/ptr.6652
   Sun HH, 2021, J ETHNOPHARMACOL, V265, DOI 10.1016/j.jep.2020.113324
   Sun J, 2019, J MOL ENDOCRINOL, V63, P77, DOI 10.1530/JME 19 0035
   Sun NY, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2020.11657
   Sun RL, 2021, J PHARMACEUT BIOMED, V193, DOI 10.1016/j.jpba.2020.113708
   Sun SQ, 2019, J ETHNOPHARMACOL, V238, DOI 10.1016/j.jep.2019.111857
   Sun XX, 2017, PHYSIOL BEHAV, V174, P162, DOI 10.1016/j.physbeh.2017.03.020
   [孙玉平 Sun Yuping], 2015, [中草药, Chinese Traditional and Herbal Drugs], V46, P785
   Taiwan Herbal Pharmacopeia 4th Edition Committee, 2021, TAIWAN HERBAL PHARMA, V4
   Tang Y, 2018, MOL MED REP, V18, P3011, DOI 10.3892/mmr.2018.9251
   Testai L, 2021, PHYTOTHER RES, V35, P4324, DOI 10.1002/ptr.7128
   Thompson PD, 2016, J AM COLL CARDIOL, V67, P2395, DOI 10.1016/j.jacc.2016.02.071
   Turkiewicz IP, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9010060
   Wang HJ, 2018, J ETHNOPHARMACOL, V213, P101, DOI 10.1016/j.jep.2017.10.032
   Wang KP, 2016, FOOD FUNCT, V7, P4889, DOI [10.1039/c6fo01196a, 10.1039/C6FO01196A]
   Wang MY, 2021, COMPR REV FOOD SCI F, V20, P225, DOI 10.1111/1541 4337.12652
   Wang Peng, 2014, Zhongguo Zhong Xi Yi Jie He Za Zhi, V34, P1365
   Wang QY, 2019, J ETHNOPHARMACOL, V239, DOI 10.1016/j.jep.2019.111904
   Wang S, 2019, COMPLEMENT THER MED, V43, P218, DOI 10.1016/j.ctim.2019.02.008
   Wang W, 2020, DIABETES METAB J, V44, P336, DOI 10.4093/dmj.2019.0042
   Wang YT, 2017, INT J BIOL MACROMOL, V98, P379, DOI 10.1016/j.ijbiomac.2017.01.085
   Wang ZJ, 2021, J AGR FOOD CHEM, V69, P4686, DOI 10.1021/acs.jafc.1c00298
   World Health Organization, 2021, NONC DIS THEM
   World Health Organization (WHO), 2021, WHO REV LEAD CAUS DE
   World Health Organization (WHO), 2021, The top 10 causes of death
   Wu Guo tai, 2016, Zhong Yao Cai, V39, P2102
   Wu L, 2018, J MASS SPECTROM, V53, P99, DOI 10.1002/jms.4041
   Xia LL, 2017, PHARM BIOL, V55, P2178, DOI 10.1080/13880209.2017.1390589
   Xie X, 2019, BONE JOINT RES, V8, P323, DOI [10.1302/2046 3758.87.BJR 2018 0223.R2, 10.1302/2046 3758.87BJR 2018 0223.R2]
   Xie XF, 2016, INT J BIOL MACROMOL, V92, P702, DOI 10.1016/j.ijbiomac.2016.07.086
   Xiong ZX, 2019, FOOD CHEM TOXICOL, V131, DOI 10.1016/j.fct.2019.110585
   Xu XY, 2020, J ETHNOPHARMACOL, V262, DOI 10.1016/j.jep.2020.113129
   Xu YY, 2018, J BIOMOL STRUCT DYN, V36, P830, DOI 10.1080/07391102.2017.1300544
   Yamashita Y, 2019, INT J FOOD SCI NUTR, V70, P294, DOI 10.1080/09637486.2018.1508425
   Yang AL, 2020, PANCREATOLOGY, V20, P795, DOI 10.1016/j.pan.2020.06.005
   Yang B, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.925087
   Yang DS, 2020, BIOCHEM BIOPH RES CO, V533, P510, DOI 10.1016/j.bbrc.2020.09.054
   Yang F, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 43518 7
   Yang F, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110479
   Yang L, 2020, J ETHNOPHARMACOL, V263, DOI 10.1016/j.jep.2020.113216
   Yang M, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104840
   Yang WJ, 2018, J ETHNOPHARMACOL, V227, P166, DOI 10.1016/j.jep.2018.08.037
   Ye TY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123977
   Yin Xiang jun, 2015, Zhongguo Zhong Yao Za Zhi, V40, P550
   Yin ZQ, 2021, CURR MOL PHARMACOL, V14, P960, DOI 10.2174/1874467214999210111222918
   You Liang Zhen, 2017, Zhongguo Zhong Yao Za Zhi, V42, P4700, DOI 10.19540/j.cnki.cjcmm.20171010.007
   Yu JN, 2000, PRIMARY CARE, V27, P541, DOI 10.1016/S0095 4543(05)70164 0
   Zhai RN, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/1602892
   Zhang Bin, 2020, Zhongguo Zhong Yao Za Zhi, V45, P2595, DOI 10.19540/j.cnki.cjcmm.20200418.401
   Zhang EX, 2016, SCI REP UK, V6, DOI 10.1038/srep38138
   Zhang JJ, 2020, PHARM BIOL, V58, P219, DOI 10.1080/13880209.2020.1738502
   [张静雅 Zhang Jingya], 2016, [中草药, Chinese Traditional and Herbal Drugs], V47, P533
   Zhang N, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/7564207
   Zhang RX, 2018, MOLECULES, V23, DOI 10.3390/molecules23102711
   Zhang RX, 2020, CAN J PHYSIOL PHARM, V98, P466, DOI 10.1139/cjpp 2019 0548
   Zhang Ruixue, 2019, Reprod Biol Endocrinol, V17, P77, DOI 10.1186/s12958 019 0522 7
   [张铁军 Zhang Tiejun], 2015, [中草药, Chinese Traditional and Herbal Drugs], V46, P1
   Zhang WN, 2018, J PHARMACEUT BIOMED, V158, P128, DOI 10.1016/j.jpba.2018.05.045
   Zhang XT, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/4642018
   Zhang YX, 2021, J ETHNOPHARMACOL, V266, DOI 10.1016/j.jep.2020.113436
   Zhang Y, 2016, BIOMED PHARMACOTHER, V84, P1337, DOI 10.1016/j.biopha.2016.10.036
   Zhang YD, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9542165
   Zhao JJ, 2017, EXP THER MED, V14, P5395, DOI 10.3892/etm.2017.5218
   Zhao WW, 2019, FOOD CHEM TOXICOL, V129, P97, DOI 10.1016/j.fct.2019.04.018
   Zheng JP, 2020, J ETHNOPHARMACOL, V258, DOI 10.1016/j.jep.2020.112928
   Zheng JP, 2020, J ETHNOPHARMACOL, V248, DOI 10.1016/j.jep.2019.112330
   Zheng XW, 2018, FRONT NEUROSCI SWITZ, V12, DOI 10.3389/fnins.2018.00911
   Zheng X, 2018, MOLECULES, V23, DOI 10.3390/molecules23102518
   Zhong LJ, 2017, CHIN J NAT MEDICINES, V15, P210, DOI 10.1016/S1875 5364(17)30037 7
   Zhou DR, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/8318792
   Zhou J, 2020, J ETHNOPHARMACOL, V262, DOI 10.1016/j.jep.2020.113208
   Zhou Q, 2020, TOXICOL IN VITRO, V65, DOI 10.1016/j.tiv.2020.104817
   Zhou X, 2021, J ETHNOPHARMACOL, V268, DOI 10.1016/j.jep.2020.113556
   Zhu QJ, 2016, INT UROL NEPHROL, V48, P1873, DOI 10.1007/s11255 016 1345 5
NR 232
TC 1
Z9 1
U1 0
U2 22
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 15
PY 2022
VL 13
AR 900693
DI 10.3389/fphar.2022.900693
PG 21
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 4Z3IA
UT WOS:000862105800001
PM 36188612
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sun, Y
   Zhou, QR
   Du, YW
   Sun, J
   Bi, W
   Liu, WJ
   Li, RX
   Wu, XW
   Yang, F
   Song, L
   Li, N
   Cui, WG
   Yu, YC
AF Sun, Yang
   Zhou, Qianrong
   Du, Yawei
   Sun, Jian
   Bi, Wei
   Liu, Wenjuan
   Li, Ruixue
   Wu, Xingwen
   Yang, Fei
   Song, Liang
   Li, Ni
   Cui, Wenguo
   Yu, Youcheng
TI Dual Biosignal Functional Injectable Microspheres for Remodeling
   Osteogenic Microenvironment
SO SMALL
LA English
DT Article
DE dual signals; IL 4; Ls; PLLA microspheres; microenvironment;
   osteogenesis; regenerative medicine
ID DIFFERENTIATION; BIOMATERIALS; ELEVATION; STRATEGY; FRACTURE; PROMOTE;
   SURFACE; REPAIR
AB Bone defect regeneration depends on the population and lifespan of M2 macrophages, which are regulated by dual signals generated by the "physical" spatial configuration of biological tissues and "molecular" chemokines. Herein, inspired by the reprogramming of macrophages, immunoengineered porous microspheres are constructed to accelerate bone repair through the regulation of both "physical" and "molecular" signals. The porous structure of injectable poly (l lactic acid) (PLLA) microspheres prepared by the microfluidic technique provides a "physical signal" for osteogenic differentiation. Additionally, interleukin (IL) 4 loaded liposomes (Ls) are modified on PLLA microspheres through amide bonds to produce IL 4/Ls/PLLA microspheres, providing a "molecular signal" in stimulating the differentiation of macrophages to M2 type. It is confirmed that IL 4/Ls/PLLA microspheres could induce M2 macrophages polarization and potentiate osteoblast proliferation and differentiation while coculturing with macrophages and osteoblasts in vitro. Besides, IL 4/Ls/PLLA microspheres are proved to promote bone defect regeneration by inducing the conversion of M1 macrophages to M2 through dual biosignal functional regulation in both the calvaria defect and maxillary sinus defect models. Overall, the immuno reprogrammed IL 4/Ls/PLLA microspheres achieve the precise immuno reprogramming of macrophages by dual biosignal functional regulation. This immune reengineering strategy paves a way for clinical bone defect treatment.
C1 [Sun, Yang; Zhou, Qianrong; Sun, Jian; Bi, Wei; Li, Ruixue; Wu, Xingwen; Yang, Fei; Song, Liang; Li, Ni; Yu, Youcheng] Fudan Univ, Zhongshan Hosp, Dept Stomatol, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
   [Du, Yawei; Cui, Wenguo] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp,Dept Orthopaed, Shanghai Inst Traumatol & Orthopaed,Shanghai Key, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.
   [Liu, Wenjuan] Xuhui Cent Hosp, Dept Stomatol, 996 Huaihaizhong Rd, Shanghai 200031, Peoples R China.
C3 Fudan University; Shanghai Jiao Tong University
RP Yu, YC (通讯作者)，Fudan Univ, Zhongshan Hosp, Dept Stomatol, 180 Fenglin Rd, Shanghai 200032, Peoples R China.; Cui, WG (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp,Dept Orthopaed, Shanghai Inst Traumatol & Orthopaed,Shanghai Key, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.
EM wgcui80@hotmail.com; yu.youcheng@zs hospital.sh.cn
RI MENG, Lingshuo/JED 8649 2023; Yawei, Du/GPF 7398 2022; Wu,
   Xingwen/AGR 8092 2022; Du, Yawei/F 7154 2015
OI Du, Yawei/0000 0002 0829 1901; sun, yang/0000 0002 4016 753X
FU National Key Research and Development Program of China [2020YFA0908200];
   National Natural Science Foundation of China [81870793, 82170990];
   Shanghai Science Commission Project [201409006100, 19411950103,
   19ZR1409300, SHDC2020CR2042B, SHDC2020CR5015]
FX Y.S., Q.Z., and Y.D. contributed equally to this work. This study was
   supported by National Key Research and Development Program of China
   (Grant No. 2020YFA0908200), National Natural Science Foundation of China
   (Grant Nos. 81870793 and 82170990), Shanghai Science Commission Project
   (Grant Nos. 201409006100, 19411950103, 19ZR1409300, SHDC2020CR2042B, and
   SHDC2020CR5015).
CR Cai ZW, 2021, BIOACT MATER, V6, P4506, DOI 10.1016/j.bioactmat.2021.04.039
   Chen L, 2021, BIOACT MATER, V6, P3218, DOI 10.1016/j.bioactmat.2021.02.022
   Chen W, 2020, ADV SCI, V7, DOI 10.1002/advs.201902099
   Chen ZT, 2017, NANOSCALE, V9, P18129, DOI 10.1039/c7nr05913b
   Chen ZH, 2020, J MATER CHEM B, V8, P2951, DOI 10.1039/c9tb02271f
   Cheng RY, 2020, BIOMATERIALS, V232, DOI 10.1016/j.biomaterials.2019.119706
   Franz S, 2011, BIOMATERIALS, V32, P6692, DOI 10.1016/j.biomaterials.2011.05.078
   García Sánchez D, 2019, WORLD J STEM CELLS, V11, P748, DOI 10.4252/wjsc.v11.i10.748
   Hachim D, 2017, BIOMATERIALS, V112, P95, DOI 10.1016/j.biomaterials.2016.10.019
   Hatano N, 2007, CLIN IMPLANT DENT R, V9, P150, DOI 10.1111/j.1708 8208.2007.00043.x
   He NN, 2015, SCI REP UK, V5, DOI 10.1038/srep10902
   Julier Z, 2017, ACTA BIOMATER, V53, P13, DOI 10.1016/j.actbio.2017.01.056
   Kankala RK, 2019, SMALL, V15, DOI 10.1002/smll.201901397
   Kim H, 2019, ADV SCI, V6, DOI 10.1002/advs.201900513
   Li MT, 2020, MAT SCI ENG C MATER, V109, DOI 10.1016/j.msec.2019.110508
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Lu YH, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03800 x
   Lundgren Stefan, 2004, Clin Implant Dent Relat Res, V6, P165, DOI 10.1111/j.1708 8208.2004.tb00224.x
   Ma DY, 2011, STEM CELLS DEV, V20, P989, DOI 10.1089/scd.2010.0348
   Mahon OR, 2020, BIOMATERIALS, V239, DOI 10.1016/j.biomaterials.2020.119833
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   Pajarinen J, 2019, BIOMATERIALS, V196, P80, DOI 10.1016/j.biomaterials.2017.12.025
   Paterson TE, 2018, APL BIOENG, V2, DOI 10.1063/1.5008556
   Potapova IA, 2008, J BIOL CHEM, V283, P13100, DOI 10.1074/jbc.M800184200
   Raghoebar GM, 2006, CLIN ORAL IMPLAN RES, V17, P288, DOI 10.1111/j.1600 0501.2005.01200.x
   Scala A, 2010, CLIN ORAL IMPLAN RES, V21, P1320, DOI 10.1111/j.1600 0501.2010.01964.x
   Serpooshan V, 2015, ADV FUNCT MATER, V25, P4379, DOI 10.1002/adfm.201500875
   Sharifiaghdam M, 2021, NANOSCALE, V13, P15445, DOI 10.1039/d1nr03830c
   Sobacchi C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103150
   Suenaga H, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5591 3
   Vi L, 2015, J BONE MINER RES, V30, P1090, DOI 10.1002/jbmr.2422
   Wang ML, 2018, J MATER CHEM B, V6, P4765, DOI 10.1039/c8tb01201f
   Wang XH, 2015, J MATER CHEM B, V3, P7334, DOI 10.1039/c5tb01506e
   Waqas SFH, 2019, METHODS MOL BIOL, V1966, P211, DOI 10.1007/978 1 4939 9195 2_17
   Wei DX, 2018, ADV MATER, V30, DOI 10.1002/adma.201802273
   Wei F, 2018, ADV EXP MED BIOL, V1077, P69, DOI 10.1007/978 981 13 0947 2_5
   Wei Y, 2020, J MATER CHEM B, V8, P6322, DOI 10.1039/d0tb01129k
   Wu P, 2020, J BIOMATER APPL, V35, P59, DOI 10.1177/0885328220911598
   Xi K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18265 3
   Xia LG, 2014, BIOMATERIALS, V35, P8514, DOI 10.1016/j.biomaterials.2014.06.028
   Xia LG, 2013, J MATER CHEM B, V1, P5403, DOI 10.1039/c3tb20945h
   Xie YJ, 2020, REGEN BIOMATER, V7, P233, DOI 10.1093/rb/rbaa006
   Xu YC, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202006333
   Yang C., 2021, ENG REGEN, V2, P171, DOI DOI 10.1016/J.ENGREG.2021.09.006
   Yang HC, 2018, ADV EXP MED BIOL, V1064, P197, DOI 10.1007/978 981 13 0445 3_12
   Zhang F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11911 5
   Zhang Y, 2017, CELL TISSUE RES, V369, P273, DOI 10.1007/s00441 017 2598 8
   Zhao CC, 2015, J MATER CHEM B, V3, P968, DOI 10.1039/c4tb01838a
   Zheng ZW, 2018, THERANOSTICS, V8, P5482, DOI 10.7150/thno.28315
   Zhou R, 2014, COLLOID SURFACE B, V123, P236, DOI 10.1016/j.colsurfb.2014.09.021
   Zhu Y, 2013, RSC ADV, V3, P2509, DOI 10.1039/c2ra22358a
NR 51
TC 27
Z9 28
U1 7
U2 167
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613 6810
EI 1613 6829
J9 SMALL
JI Small
PD SEP
PY 2022
VL 18
IS 36
SI SI
AR 2201656
DI 10.1002/smll.202201656
EA APR 2022
PG 19
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA 4J4AM
UT WOS:000782347700001
PM 35419952
DA 2025 08 17
ER

PT J
AU Sun, DH
   Junger, WG
   Yuan, CJ
   Zhang, WY
   Bao, Y
   Qin, DM
   Wang, CX
   Tan, L
   Qi, BC
   Zhu, D
   Zhang, XZ
   Yu, TC
AF Sun, Dahui
   Junger, Wolfgang G.
   Yuan, Changji
   Zhang, Wenyan
   Bao, Yi
   Qin, Daming
   Wang, Chengxue
   Tan, Lei
   Qi, Baochang
   Zhu, Dong
   Zhang, Xizheng
   Yu, Tiecheng
TI Shockwaves Induce Osteogenic Differentiation of Human Mesenchymal Stem
   Cells Through ATP Release and Activation of P2X7 Receptors
SO STEM CELLS
LA English
DT Article
DE Shockwaves; Human mesenchymal stem cells; Osteogenic differentiation;
   ATP; p38 MAPK; c Fos; c Jun
ID MARROW STROMAL CELLS; EXTRACELLULAR ATP; PROTEIN KINASE; BONE FORMATION;
   AP 1 SUBUNITS; EXPRESSION; WAVES; PROLIFERATION; OSTEOBLASTS; PATHWAY
AB Shockwave treatment promotes bone healing of nonunion fractures. In this study, we investigated whether this effect could be due to adenosine 5' triphosphate (ATP) release induced differentiation of human mesenchymal stem cells (hMSCs) into osteoprogenitor cells. Cultured bone marrow derived hMSCs were subjected to shockwave treatment and ATP release was assessed. Osteogenic differentiation and mineralization of hMSCs were evaluated by examining alkaline phosphatase activity, osteocalcin production, and calcium nodule formation. Expression of P2X7 receptors and c fos and c jun mRNA was determined with real time reverse transcription polymerase chain reaction and Western blotting. P2X7 siRNA, apyrase, P2 receptor antagonists, and p38 MAPK inhibitors were used to evaluate the roles of ATP release, P2X7 receptors, and p38 MAPK signaling in shockwave induced osteogenic hMSCs differentiation. Shockwave treatment released significant amounts (similar to 7 mu M) of ATP from hMSCs. Shockwaves and exogenous ATP induced c fos and c jun mRNA transcription, p38 MAPK activation, and hMSC differentiation. Removal of ATP with apyrase, targeting of P2X7 receptors with P2X7 siRNA or selective antagonists, or blockade of p38 MAPK with SB203580 prevented osteogenic differentiation of hMSCs. Our findings indicate that shockwaves release cellular ATP that activates P2X7 receptors and downstream signaling events that caused osteogenic differentiation of hMSCs. We conclude that shockwave therapy promotes bone healing through P2X7 receptor signaling, which contributes to hMSC differentiation.
C1 [Sun, Dahui; Qin, Daming; Wang, Chengxue; Tan, Lei; Qi, Baochang; Zhu, Dong; Yu, Tiecheng] Jilin Univ, Norman Bethune Hosp 1, Dept Orthoped, Changchun 130021, Peoples R China.
   [Yuan, Changji] Jilin Univ, Norman Bethune Hosp 1, Dept Hematol, Changchun 130021, Peoples R China.
   [Zhang, Wenyan] Jilin Univ, Norman Bethune Hosp 1, Inst Virol & AIDS Res, Changchun 130021, Peoples R China.
   [Junger, Wolfgang G.; Bao, Yi] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg, Boston, MA 02215 USA.
   [Junger, Wolfgang G.] Ludwig Boltzmann Inst Expt & Clin Traumatol, Vienna, Austria.
   [Zhang, Xizheng] PLA, Mil Med Sci Acad, Inst Med Equipment, Tianjin, Peoples R China.
C3 Jilin University; Jilin University; Jilin University; Harvard
   University; Harvard Medical School; Harvard University Medical
   Affiliates; Beth Israel Deaconess Medical Center; Ludwig Boltzmann
   Institute; Ludwig Boltzmann Institute for Experimental & Clinical
   Traumatology
RP Yu, TC (通讯作者)，Jilin Univ, Norman Bethune Hosp 1, Dept Orthoped, Changchun 130021, Peoples R China.
EM tiechengyu@163.com
RI Junger, Wolfgang/I 1932 2013; Zhu, Dong/AAE 5951 2019; Bao,
   Yi/J 5418 2013; Zhang, Xi/KPY 2115 2024
OI Bao, Yi/0000 0003 0748 1575; 
FU National Natural Science Foundation of China [81172183, 30500132,
   31270202, 10832012, 11272134]
FX We thank Hang Gao, Dept. of Pathology, Jilin University, for assistance
   with the cell culture experiments. We are also grateful to Suna Dong of
   the Lithotripsy Center of the First Hospital of Jilin University for the
   kind support with our experiments. This study was supported in part by
   grants 81172183 (Tiecheng Yu), 30500132 (Tiecheng Yu), 31270202 (Wenyan
   Zhang), 10832012 (Xizheng Zhang), and 11272134 (Dong Zhu) from the
   National Natural Science Foundation of China.
CR Ammoun S, 2006, J BIOL CHEM, V281, P834, DOI 10.1074/jbc.M508603200
   Bara T, 2000, Ortop Traumatol Rehabil, V2, P54
   Burnstock G, 2012, BIOESSAYS, V34, P218, DOI 10.1002/bies.201100130
   Chen Y, 2006, AM J PHYSIOL CELL PH, V290, pC1051, DOI 10.1152/ajpcell.00216.2005
   Chen Y, 2006, SCIENCE, V314, P1792, DOI 10.1126/science.1132559
   Coppi E, 2007, STEM CELLS, V25, P1840, DOI 10.1634/stemcells.2006 0669
   Coss D, 2007, MOL ENDOCRINOL, V21, P3071, DOI 10.1210/me.2007 0247
   de Freitas PHL, 2009, J BONE MINER RES, V24, P1586, DOI [10.1359/JBMR.090413, 10.1359/jbmr.090413]
   Delarasse C, 2009, J NEUROCHEM, V109, P846, DOI 10.1111/j.1471 4159.2009.06008.x
   Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587
   Dorotka R, 2003, ARCH ORTHOP TRAUM SU, V123, P345, DOI 10.1007/s00402 003 0551 7
   Forte G, 2006, STEM CELLS, V24, P23, DOI 10.1634/stemcells.2004 0176
   GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Grol MW, 2009, PURINERG SIGNAL, V5, P205, DOI 10.1007/s11302 009 9139 1
   Gunosewoyo H, 2007, CURR MED CHEM, V14, P1505, DOI 10.2174/092986707780831023
   Hammoud M, 2012, J CELL PHYSIOL, V227, P2750, DOI 10.1002/jcp.23019
   Haupt G, 1997, J UROLOGY, V158, P4, DOI 10.1097/00005392 199707000 00003
   Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589
   Ihara H, 2005, BIOCHEM BIOPH RES CO, V326, P329, DOI 10.1016/j.bbrc.2004.11.037
   Junger WG, 2011, NAT REV IMMUNOL, V11, P201, DOI 10.1038/nri2938
   Katz S, 2006, INT J BIOCHEM CELL B, V38, P2082, DOI 10.1016/j.biocel.2006.05.018
   Kawano S, 2006, CELL CALCIUM, V39, P313, DOI 10.1016/j.ceca.2005.11.008
   Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003 0021
   Lenertz LY, 2011, IMMUNOL RES, V50, P22, DOI 10.1007/s12026 011 8203 4
   Li JL, 2009, CALCIFIED TISSUE INT, V84, P405, DOI 10.1007/s00223 009 9237 7
   Li JL, 2005, J BIOL CHEM, V280, P42952, DOI 10.1074/jbc.M506415200
   Liu CM, 2009, CELL TISSUE RES, V336, P465, DOI 10.1007/s00441 009 0780 3
   Liu WH, 2010, J CELL PHYSIOL, V224, P775, DOI 10.1002/jcp.22180
   Loomis WH, 2003, J BIOL CHEM, V278, P4590, DOI 10.1074/jbc.M207868200
   Ma HZ, 2008, ACTA ORTHOP, V79, P98, DOI 10.1080/17453670710014833
   Neub A, 2007, J INVEST DERMATOL, V127, P2453, DOI 10.1038/sj.jid.5700864
   Odabas S, 2008, J CHROMATOGR B, V861, P74, DOI 10.1016/j.jchromb.2007.11.017
   Ohlendorff SD, 2007, PHARMACOGENET GENOM, V17, P555, DOI 10.1097/FPC.0b013e3280951625
   Panupinthu N, 2008, J CELL BIOL, V181, P859, DOI 10.1083/jcb.200708037
   Panupinthu N, 2007, J BIOL CHEM, V282, P3403, DOI 10.1074/jbc.M605620200
   Penolazzi L, 2005, J BIOMED SCI, V12, P1013, DOI 10.1007/s11373 005 9029 7
   Pham DT, 2010, OPTIMIZATION, V59, P1, DOI 10.1080/02331930903500233
   Poulsom R, 2007, KIDNEY INT, V72, P389, DOI 10.1038/sj.ki.5002398
   Powell JR, 2009, P NATL ACAD SCI USA, V106, P2782, DOI 10.1073/pnas.0813048106
   SCHLEBERGER R, 1992, ARCH ORTHOP TRAUM SU, V111, P224, DOI 10.1007/BF00571482
   Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735
   Tanaka S, 2004, J BONE MINER RES, V19, P1813, DOI 10.1359/JBMR.040808
   Thompson BAN, 2012, CELL SIGNAL, V24, P770, DOI 10.1016/j.cellsig.2011.11.012
   Trivedi P, 2007, EXP HEMATOL, V35, P146, DOI 10.1016/j.exphem.2006.09.003
   Uspenskaya Yu A., 2007, Eksperimental'naya i Klinicheskaya Farmakologiya, V70, P52
   van der Jagt OP, 2011, J BONE JOINT SURG AM, V93A, P38, DOI 10.2106/JBJS.I.01535
   Wang CJ, 2005, J BONE JOINT SURG AM, V87A, P2380, DOI 10.2106/JBJS.E.00174
   Wang CJ, 2001, CLIN ORTHOP RELAT R, P95
   Wang FS, 2002, J BONE JOINT SURG BR, V84B, P457, DOI 10.1302/0301 620X.84B3.11609
   Wang FS, 2001, BIOCHEM BIOPH RES CO, V287, P648, DOI 10.1006/bbrc.2001.5654
   Wu JB, 2008, EUR J PHARMACOL, V588, P333, DOI 10.1016/j.ejphar.2008.04.030
   Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771
   Yew TL, 2011, CELL TRANSPLANT, V20, P693, DOI 10.3727/096368910X550198
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   Yip L, 2009, FASEB J, V23, P1685, DOI 10.1096/fj.08 126458
   Yu TC, 2010, AM J PHYSIOL CELL PH, V298, pC457, DOI 10.1152/ajpcell.00342.2009
   Zannettino ACW, 2007, HAEMATOLOGICA, V92, P1707, DOI 10.3324/haematol.11691
   ZIGANSHIN AU, 1995, PFLUG ARCH EUR J PHY, V429, P412, DOI 10.1007/BF00374157
NR 59
TC 116
Z9 129
U1 0
U2 36
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD JUN
PY 2013
VL 31
IS 6
BP 1170
EP 1180
DI 10.1002/stem.1356
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 149QD
UT WOS:000319335200014
PM 23404811
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Shimozaki, S
   Yamamoto, N
   Domoto, T
   Nishida, H
   Hayashi, K
   Kimura, H
   Takeuchi, A
   Miwa, S
   Igarashi, K
   Kato, T
   Aoki, Y
   Higuchi, T
   Hirose, M
   Hoffman, RM
   Minamoto, T
   Tsuchiya, H
AF Shimozaki, Shingo
   Yamamoto, Norio
   Domoto, Takahiro
   Nishida, Hideji
   Hayashi, Katsuhiro
   Kimura, Hiroaki
   Takeuchi, Akihiko
   Miwa, Shinji
   Igarashi, Kentaro
   Kato, Takashi
   Aoki, Yu
   Higuchi, Takashi
   Hirose, Mayumi
   Hoffman, Robert M.
   Minamoto, Toshinari
   Tsuchiya, Hiroyuki
TI Efficacy of glycogen synthase kinase 3β targeting against osteosarcoma
   via activation of β catenin
SO ONCOTARGET
LA English
DT Article
DE glycogen synthase kinase 3 beta; molecular target; treatment;
   osteosarcoma; orthotopic nude mice
ID KINASE 3 BETA INHIBITION; CELLS IN VITRO; PANCREATIC CANCER; LUNG
   METASTASIS; STEM CELLS; BONE MASS; NUDE MICE; SURVIVAL; GSK3 BETA;
   CHEMOTHERAPY
AB Development of innovative more effective therapy is required for refractory osteosarcoma patients. We previously established that glycogen synthase kinase 3 beta (GSK 3 beta) is a therapeutic target in various cancer types. In the present study, we explored the therapeutic efficacy of GSK 3 beta inhibition against osteosarcoma and the underlying molecular mechanisms in an orthotopic mouse model. Expression and phosphorylation of GSK 3 beta in osteosarcoma and normal osteoblast cell lines was examined, together with efficacy of GSK 3 beta inhibition on cell survival, proliferation and apoptosis and on the growth of orthotopically transplanted human osteosarcoma in nude mice. We also investigated changes in expression, phosphorylation and co transcriptional activity of beta catenin in osteosarcoma cells following GSK 3 beta inhibition. Expression of the active form of GSK 3 beta (tyrosine 216 phosphorylated) was higher in osteosarcoma than osteoblast cells. Inhibition of GSK 3 beta activity by pharmacological inhibitors or of its expression by RNA interference suppressed proliferation of osteosarcoma cells and induced apoptosis. Treatment with GSK 3 beta specific inhibitors attenuated the growth of orthotopic osteosaroma in mice. Inhibition of GSK 3 beta reduced phosphorylation at GSK 3 beta phospho acceptor sites in beta catenin and increased beta catenin expression, nuclear localization and co transcriptional activity. These results suggest the efficacy of GSK 3 beta inhibitors is associated with activation of beta catenin, a putative tumor suppressor in bone and soft tissue sarcoma and an important component of osteogenesis. Our study thereby demonstrates a critical role for GSK 3 beta in sustaining survival and proliferation of osteosarcoma cells, and identifies this kinase as a potential therapeutic target against osteosarcoma.
C1 [Shimozaki, Shingo; Yamamoto, Norio; Nishida, Hideji; Hayashi, Katsuhiro; Kimura, Hiroaki; Takeuchi, Akihiko; Miwa, Shinji; Igarashi, Kentaro; Kato, Takashi; Aoki, Yu; Higuchi, Takashi; Tsuchiya, Hiroyuki] Kanazawa Univ, Grad Sch Med Sci, Dept Orthoped Surg, Kanazawa, Ishikawa, Japan.
   [Hoffman, Robert M.] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA.
   [Miwa, Shinji; Hoffman, Robert M.] AntiCancer Inc, San Diego, CA 92111 USA.
   [Shimozaki, Shingo; Domoto, Takahiro; Miwa, Shinji; Hirose, Mayumi; Minamoto, Toshinari] Kanazawa Univ, Canc Res Inst, Div Translat & Clin Oncol, Kanazawa, Ishikawa, Japan.
C3 Kanazawa University; University of California System; University of
   California San Diego; AntiCancer, Inc.; Kanazawa University
RP Yamamoto, N (通讯作者)，Kanazawa Univ, Grad Sch Med Sci, Dept Orthoped Surg, Kanazawa, Ishikawa, Japan.; Hoffman, RM (通讯作者)，Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA.; Hoffman, RM (通讯作者)，AntiCancer Inc, San Diego, CA 92111 USA.
EM norinori@med.kanazawa u.ac.jp; all@anticancer.com
RI Kimura, Hiroaki/E 3224 2010; Minamoto, Toshinari/D 8442 2015; DOMOTO,
   Takahiro/D 8425 2015; Miwa, Shinji/AAI 9309 2020; TSUCHIYA,
   HIROYUKI/C 5142 2015; Hayashi, K/C 4685 2015; Takeuchi,
   Akihiko/AAJ 1563 2020
OI Takeuchi, Akihiko/0000 0002 4071 5620; Higuchi,
   Takashi/0000 0002 7489 1657; Igarashi, Kentaro/0000 0003 2278 1736;
   Hayashi, Katsuhiro/0000 0001 8665 2154; 
FU Grants in Aid for Scientific Research [15H04928, 16K20042, 15K15493,
   26293333, 16K15658] Funding Source: KAKEN
CR Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   [Anonymous], 2012, Spacecraft Recovery & Remote Sensing
   Apontes P, 2011, ONCOTARGET, V2, P222, DOI 10.18632/oncotarget.248
   Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200
   Blagosklonny MV, 2006, LEUKEMIA, V20, P385, DOI 10.1038/sj.leu.2404075
   Blagosklonny MV, 2005, CELL CYCLE, V4, P1518, DOI 10.4161/cc.4.11.2208
   Blagosklonny MV, 2003, DRUG DISCOV TODAY, V8, P1104, DOI 10.1016/S1359 6446(03)02806 X
   Blagosklonny MV, 2003, BRIT J CANCER, V89, P1147, DOI 10.1038/sj.bjc.6601256
   Blagosklonny MV, 2001, LEUKEMIA, V15, P936, DOI 10.1038/sj.leu.2402127
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Botter SM, 2014, CURR OPIN PHARMACOL, V16, P15, DOI 10.1016/j.coph.2014.02.002
   Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628
   Chen EY, 2014, P NATL ACAD SCI USA, V111, P5349, DOI 10.1073/pnas.1317731111
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074 5521(00)00025 9
   Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384
   Faes S, 2015, INT J MOL SCI, V16, P21138, DOI 10.3390/ijms160921138
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   Hayashi K, 2009, CELL CYCLE, V8, P870, DOI 10.4161/cc.8.6.7891
   Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574
   Holmes T, 2008, CURR MED CHEM, V15, P1493, DOI 10.2174/092986708784638834
   Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064 006 9128 5
   Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Khanna C, 2014, CLIN CANCER RES, V20, P4200, DOI 10.1158/1078 0432.CCR 13 2574
   Kimura H, 2012, INT J CANCER, V131, P2027, DOI 10.1002/ijc.27475
   Kitano A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055289
   Korur S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007443
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kunnimalaiyaan M, 2007, MOL CANCER THER, V6, P1151, DOI 10.1158/1535 7163.MCT 06 0665
   Le Guellec S, 2013, HUM PATHOL, V44, P2149, DOI 10.1016/j.humpath.2013.03.020
   Li X, 2015, CYTOGENET GENOME RES, V146, P124, DOI 10.1159/000437379
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045
   Ma YL, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046 015 0232 8
   Mai W, 2009, CLIN CANCER RES, V15, P6810, DOI 10.1158/1078 0432.CCR 09 0973
   Mamaghani S, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 132
   Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377
   McCubrey JA, 2014, ONCOTARGET, V5, P2881, DOI 10.18632/oncotarget.2037
   MEXT LifeScience Portalsite, TOKY JAP FUND GUID P
   Miwa S, 2014, J ORTHOP RES, V32, P1596, DOI 10.1002/jor.22706
   Miyashita K, 2009, ANTI CANCER AGENT ME, V9, P1114, DOI 10.2174/187152009789734982
   Miyashita K, 2009, CLIN CANCER RES, V15, P887, DOI 10.1158/1078 0432.CCR 08 0760
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Ougolkov AV, 2005, CANCER RES, V65, P2076, DOI 10.1158/0008 5472.CAN 04 3642
   Pakos EE, 2009, EUR J CANCER, V45, P2367, DOI 10.1016/j.ejca.2009.03.005
   Phukan S, 2010, BRIT J PHARMACOL, V160, P1, DOI 10.1111/j.1476 5381.2010.00661.x
   Pyko IV, 2013, CARCINOGENESIS, V34, P2206, DOI 10.1093/carcin/bgt182
   Ralston SH, 2006, GENE DEV, V20, P2492, DOI 10.1101/gad.1449506
   Ryves WJ, 2002, BIOCHEM BIOPH RES CO, V290, P967, DOI 10.1006/bbrc.2001.6305
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Savu D, 2015, MUTAT RES FUND MOL M, V771, P13, DOI 10.1016/j.mrfmmm.2014.11.005
   Shakoori A, 2005, BIOCHEM BIOPH RES CO, V334, P1365, DOI 10.1016/j.bbrc.2005.07.041
   Shakoori A, 2007, CANCER SCI, V98, P1388, DOI 10.1111/j.1349 7006.2007.00545.x
   Shimasaki T, 2012, J GASTROENTEROL, V47, P321, DOI 10.1007/s00535 011 0484 9
   Starha P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136338
   Sun FX, 2003, CANCER RES, V63, P80
   Tang QL, 2012, JNCI J NATL CANCER I, V104, P749, DOI 10.1093/jnci/djs210
   The Office of Laboratory Animal Welfare National Institutes of Health Department of Health and Human Services [Internet], GUIDE CARE USE LAB A
   Thomas DM, 2010, J PATHOL, V220, P1, DOI 10.1002/path.2635
   Tome Y, 2013, ANTICANCER RES, V33, P3623
   Tome Y, 2013, ANTICANCER RES, V33, P3021
   Trowbridge JJ, 2006, NAT MED, V12, P89, DOI 10.1038/nm1339
   Tsuchiya H, 1998, ANTICANCER RES, V18, P657
   Uehara F, 2014, J CELL BIOCHEM, V115, P1490, DOI 10.1002/jcb.24799
   Uehara F, 2013, ANTICANCER RES, V33, P1361
   Whelan J, 2012, INT J CANCER, V131, pE508, DOI 10.1002/ijc.26426
   Yang JL, 2013, CURR OPIN ONCOL, V25, P398, DOI 10.1097/CCO.0b013e3283622c1b
   Zeng FY, 2010, BIOCHEM BIOPH RES CO, V391, P1049, DOI 10.1016/j.bbrc.2009.12.017
NR 69
TC 25
Z9 28
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 22
PY 2016
VL 7
IS 47
BP 77038
EP 77051
DI 10.18632/oncotarget.12781
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA EE5GK
UT WOS:000389633400057
PM 27780915
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Cheng, ZH
   Biechele, T
   Wei, ZY
   Morrone, S
   Moon, RT
   Wang, LG
   Xu, WQ
AF Cheng, Zhihong
   Biechele, Travis
   Wei, Zhiyi
   Morrone, Seamus
   Moon, Randall T.
   Wang, Liguo
   Xu, Wenqing
TI Crystal structures of the extracellular domain of LRP6 and its complex
   with DKK1
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Article
ID RECEPTOR RELATED PROTEIN 5; HIGH BONE DENSITY; DICKKOPF PROTEINS; WNT
   PROTEINS; LDL; CATENIN; BINDING; LIGAND; INHIBITION; MASS
AB Low density lipoprotein (LDL) receptor related proteins 5 and 6 (LRP5/6) are Wnt co receptors essential for Wnt/beta catenin signaling. Dickkopf 1 (DKK1) inhibits Wnt signaling by interacting with the extracellular domains of LRP5/6 and is a drug target for multiple diseases. Here we present the crystal structures of a human LRP6 E3E4 DKK1 complex and the first and second halves of human LRP6's four propeller epidermal growth factor (EGF) pairs (LRP6 E1E2 and LRP6 E3E4). Combined with EM analysis, these data demonstrate that LRP6 E1E2 and LRP6 E3E4 form two rigid structural blocks, with a short intervening hinge that restrains their relative orientation. The C terminal domain of DKK1 (DKK1c) interacts with the top surface of the LRP6 E3 YWTD propeller and given their structural similarity, probably also that of the LRP6 E1 propeller, through conserved hydrophobic patches buttressed by a network of salt bridges and hydrogen bonds. Our work provides key insights for understanding LRP5/6 structure and the interaction of LRP5/6 with DKK, as well as for drug discovery.
C1 [Cheng, Zhihong; Wei, Zhiyi; Morrone, Seamus; Wang, Liguo; Xu, Wenqing] Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA.
   [Biechele, Travis; Moon, Randall T.] Univ Washington, Sch Med, Dept Pharmacol, Howard Hughes Med Inst, Seattle, WA 98195 USA.
   [Biechele, Travis; Moon, Randall T.] Univ Washington, Sch Med, Inst Stem Cell & Regenerat Med, Seattle, WA USA.
C3 University of Washington; University of Washington Seattle; Howard
   Hughes Medical Institute; University of Washington; University of
   Washington Seattle; University of Washington; University of Washington
   Seattle
RP Xu, WQ (通讯作者)，Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA.
EM wxu@u.washington.edu
RI ; Wei, Zhiyi/N 9995 2019; Moon, Randall/M 5605 2019; Xu,
   Wenqing/K 2873 2018; Moon, Randall/B 1743 2014; Cheng,
   Zhihong/F 8933 2011
OI Morrone, Seamus/0000 0001 6454 8970; Xu, Wenqing/0000 0002 2884 3101;
   Wei, Zhiyi/0000 0002 4446 6502; Moon, Randall/0000 0002 9352 1408; 
FU US National Institutes of Health (NIH) [CA90351]; Howard Hughes Medical
   Institute; NIH/National Institute of Arthritis and Musculoskeletal and
   Skin [T32AR056969]
FX We are grateful to the staff at ALS beamlines BL 8.2.1 and 8.2.2 for
   assistance with synchrotron data collection. We thank G. Bu (Washington
   University) for human LRP6 cDNA. This work was supported by US National
   Institutes of Health (NIH) grants CA90351 to W.X. R.T.M. is funded by
   the Howard Hughes Medical Institute. T.B. was supported by a Training
   Grant from NIH/National Institute of Arthritis and Musculoskeletal and
   Skin (T32AR056969).
CR Ai M, 2005, MOL CELL BIOL, V25, P4946, DOI 10.1128/MCB.25.12.4946 4955.2005
   Aravind L, 1998, CURR BIOL, V8, pR477, DOI 10.1016/S0960 9822(98)70309 4
   Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081
   BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112
   Balemans W, 2008, CALCIFIED TISSUE INT, V82, P445, DOI 10.1007/s00223 008 9130 9
   Baron R, 2006, CURR TOP DEV BIOL, V76, P103, DOI 10.1016/S0070 2153(06)76004 5
   Bilechele Travis L., 2008, V468, P99, DOI 10.1007/978 1 59745 249 6_8
   Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065
   Bourhis E, 2010, J BIOL CHEM, V285, P9172, DOI 10.1074/jbc.M109.092130
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100 6110.2002
   Chen LJ, 2008, J BIOL CHEM, V283, P23364, DOI 10.1074/jbc.M802375200
   Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Ellwanger K, 2008, MOL CELL BIOL, V28, P4875, DOI 10.1128/MCB.00222 08
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Ettenberg SA, 2010, P NATL ACAD SCI USA, V107, P15473, DOI 10.1073/pnas.1007428107
   Gong Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012682
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Jeon H, 2005, ANNU REV BIOCHEM, V74, P535, DOI 10.1146/annurev.biochem.74.082803.133354
   Jeon H, 2001, NAT STRUCT BIOL, V8, P499, DOI 10.1038/88556
   Johnson ML, 2005, CRIT REV EUKAR GENE, V15, P229, DOI 10.1615/CritRevEukarGeneExpr.v15.i3.50
   Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13
   Lee N, 2007, BRIT J CANCER, V97, P1552, DOI 10.1038/sj.bjc.6604069
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Liu CC, 2009, J BIOL CHEM, V284, P15299, DOI 10.1074/jbc.M807285200
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370
   Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Murrills RJ, 2009, J CELL BIOCHEM, V108, P1066, DOI 10.1002/jcb.22335
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054
   Niehrs C, 2010, CELL MOL LIFE SCI, V67, P2551, DOI 10.1007/s00018 010 0329 3
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076 6879(97)76066 X
   Petersen CP, 2009, CELL, V139, P1056, DOI 10.1016/j.cell.2009.11.035
   Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Semënov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960 9822(01)00290 1
   Springer TA, 1998, J MOL BIOL, V283, P837, DOI 10.1006/jmbi.1998.2115
   Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117
   Wang K, 2008, J BIOL CHEM, V283, P23371, DOI 10.1074/jbc.M802376200
   Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110
   Weidauer SE, 2009, BIOCHEM BIOPH RES CO, V380, P160, DOI 10.1016/j.bbrc.2009.01.062
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Williams BO, 2009, J BONE MINER RES, V24, P171, DOI [10.1359/JBMR.081235, 10.1359/jbmr.081235]
   Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076 6879(03)74014 2
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
NR 55
TC 163
Z9 185
U1 0
U2 31
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1545 9993
EI 1545 9985
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
PD NOV
PY 2011
VL 18
IS 11
BP 1204
EP U44
DI 10.1038/nsmb.2139
PG 8
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 844FX
UT WOS:000296734200006
PM 21984209
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Xu, H
   Wang, L
   Zhu, XP
   Zhang, HG
   Chen, HW
   Zhang, H
AF Xu, Hui
   Wang, Lin
   Zhu, Xunpeng
   Zhang, Haigang
   Chen, Hongwei
   Zhang, Hui
TI Jintiange capsule ameliorates glucocorticoid induced osteonecrosis of
   the femoral head in rats by regulating the activity and differentiation
   of BMSCs
SO JOURNAL OF TRADITIONAL AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE Osteonecrosis of the femoral head (ONFH); Glucocorticoids (GCs); Bone
   mesenchymal stem cells (BMSCs); Jintiange (JTG); Differentiation
ID MESENCHYMAL STEM CELLS; PLATELET RICH PLASMA; OSTEOGENIC
   DIFFERENTIATION; ANGIOGENESIS; APOPTOSIS; PREVENTS; DELIVERY; THERAPY;
   SUBTYPE; PATHWAY
AB Background and aim: A surplus of glucocorticoids (GC) is a main cause of non traumatic osteonecrosis of the femoral head (ONFH), and Jintiange (JTG), as one of the traditional Chinese medicines (TCM), also plays an instrumental role in the alleviation of bone loss simultaneously. Therefore, JTG was thought to be able to reverse GC induced ONFH (GC ONFH) to a certain extent. Experimental procedure: In vivo, the effect of JTG on trabeculae in the subchondral bone of the femoral head was investigated using micro computed tomography (micro CT), TdT mediated dUTP nick end labeling (TUNEL) and histological staining; in vitro, proliferation, viability, apoptosis, and senescence of purified bone mesenchymal stem cells (BMSCs) were examined to demonstrate the direct impact of JTG on these cells. Meanwhile after using a series of interventions, the function of JTG on BMSC differentiation could be assessed by measuring of osteogenic and adipogenic markers at levels of protein and mRNA. Results: Our final results demonstrated that with the involvement of Wnt/beta catenin pathway, JTG was able to significantly promote osteogenesis, restrain adipogenesis, delay senescence in BMSCs, reduce osteoclast number, weaken apoptosis, and enhance proliferation of osteocytes, all of which could mitigate the progression of subchondral osteonecrosis. Conclusion: According to the results of experiments in vitro and vivo, JTG was deemed to relieve the early GC ONFH using the prevention of destruction of subchondral bone, which was contributed to regulating the differentiation of BMSCs and the number of osteoclasts.
C1 [Xu, Hui; Wang, Lin; Zhu, Xunpeng; Zhang, Haigang; Chen, Hongwei; Zhang, Hui] Anhui Med Univ, Affiliated Hosp 1, Dept Orthoped, 218 JiXi Rd, Hefei 230022, Anhui, Peoples R China.
C3 Anhui Medical University
RP Zhang, H (通讯作者)，Anhui Med Univ, Affiliated Hosp 1, Dept Orthoped, 218 JiXi Rd, Hefei 230022, Anhui, Peoples R China.
EM zhanghui@ahmu.edu.cn
RI zhang, hui/LUZ 6545 2024; Zhang, Haigang/A 7099 2019; chen,
   hongwei/GRO 4858 2022
OI Wang, Lin/0009 0005 6580 3677; 
FU University Natural Science Research Project of Anhui Province
   [KJ2018A0662]; Scientific Research Funding of Anhui Medical University
   [2022xkj163]
FX This work was supported by the University Natural Science Research
   Project of Anhui Province (No. KJ2018A0662) and Scientific Research
   Funding of Anhui Medical University (No. 2022xkj163) .
CR Bai HB, 2019, J BIOCHEM, V166, P475, DOI 10.1093/jb/mvz060
   Balla B, 2019, J STEROID BIOCHEM, V188, P185, DOI 10.1016/j.jsbmb.2019.01.012
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Buttgereit F, 2020, NAT REV RHEUMATOL, V16, P239, DOI 10.1038/s41584 020 0370 z
   Cao F, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/1624074
   Chen K, 2020, INT J BIOL SCI, V16, P1888, DOI 10.7150/ijbs.40917
   Chen XJ, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108746
   Chia WK, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2572 3
   Cohen Rosenblum A, 2019, ORTHOP CLIN N AM, V50, P139, DOI 10.1016/j.ocl.2018.10.001
   Cui DP, 2018, INT J BIOL MACROMOL, V116, P106, DOI 10.1016/j.ijbiomac.2018.04.181
   Fang B, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 018 1112 x
   Gao FQ, 2020, ANN PALLIAT MED, V9, P1497, DOI 10.21037/apm 20 121
   Gao YC, 2020, INT J BIOL SCI, V16, P543, DOI 10.7150/ijbs.35256
   Gao YC, 2018, AM J PHYSIOL CELL PH, V315, pC300, DOI 10.1152/ajpcell.00009.2018
   Garavaglia B., 2022, Biomedicines, P10
   Haumer A, 2018, ADV DRUG DELIVER REV, V129, P285, DOI 10.1016/j.addr.2018.01.010
   He HP, 2021, CYTOKINE, V143, DOI 10.1016/j.cyto.2021.155488
   Hu N, 2015, INT J MOL SCI, V16, P10491, DOI 10.3390/ijms160510491
   Huang C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.777697
   Huang ZF, 2018, CELL PHYSIOL BIOCHEM, V47, P694, DOI 10.1159/000490023
   Jiang YN, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/315850
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lane Nancy E, 2018, Bone Rep, V9, P181, DOI 10.1016/j.bonr.2018.10.003
   Li CG, 2017, CHIN J INTEGR MED, V23, P183, DOI 10.1007/s11655 016 2407 3
   Li LJ, 2019, ACTA BIOMATER, V96, P674, DOI 10.1016/j.actbio.2019.07.007
   Llorente Pelayo S, 2020, NUTRIENTS, V12, DOI 10.3390/nu12123854
   Mao LH, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01956 5
   Montaigne D, 2021, NAT REV CARDIOL, V18, P809, DOI 10.1038/s41569 021 00569 6
   Ngo D, 2013, ARTHRITIS RHEUM US, V65, P1203, DOI 10.1002/art.37858
   Peng XY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.767243
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   Rauch A, 2019, NAT GENET, V51, P716, DOI 10.1038/s41588 019 0359 1
   Reggio A, 2020, CELL DEATH DIFFER, V27, P2921, DOI 10.1038/s41418 020 0551 y
   Ren YL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.571535
   Shen Y, 2022, CHIN MED UK, V17, DOI 10.1186/s13020 022 00627 2
   Shu LJ, 2022, ORTHOP SURG, V14, P427, DOI 10.1111/os.13121
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Sun J, 2019, ORTHOP SURG, V11, P176, DOI 10.1111/os.12439
   Suntornsaratoon P, 2018, J SCI FOOD AGR, V98, P2027, DOI 10.1002/jsfa.8688
   Tao SC, 2017, THERANOSTICS, V7, P733, DOI 10.7150/thno.17450
   Venkatesh B, 2018, NEW ENGL J MED, V378, P797, DOI 10.1056/NEJMoa1705835
   Vidoni C, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0414 7
   Wang G, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02278 w
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wang TS, 2017, EXP THER MED, V13, P669, DOI 10.3892/etm.2016.3991
   Wei X, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 017 1617 3
   Xu HH, 2021, PLATELETS, V32, P950, DOI 10.1080/09537104.2020.1810221
   Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591 018 0020 z
   Xu W, 2015, DRUG DELIV, V22, P258, DOI 10.3109/10717544.2014.892545
   Xu YX, 2020, REGEN THER, V15, P295, DOI 10.1016/j.reth.2020.11.003
   Yan ZJ, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/7908429
   Yang QH, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109486
   Yeh YA, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/5870179
   Yokoi Y, 2021, MATERIALS, V14, DOI 10.3390/ma14164414
   Yu HP, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12871
   Yu HP, 2020, J CELL MOL MED, V24, P4439, DOI 10.1111/jcmm.15103
   Yu ZF, 2015, INT J MOL MED, V36, P1264, DOI 10.3892/ijmm.2015.2340
   Zhang C, 2018, OSTEOARTHR CARTILAGE, V26, P824, DOI 10.1016/j.joca.2018.03.002
   Zhang QW, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000012196, 10.1097/md.0000000000012196]
   Zhang XL, 2018, EUR REV MED PHARMACO, V22, P2143, DOI 10.26355/eurrev_201804_14748
   Zhang YL, 2016, INT J BIOL SCI, V12, P347, DOI 10.7150/ijbs.13269
   Zhao DW, 2020, J ORTHOP TRANSL, V21, P100, DOI 10.1016/j.jot.2019.12.004
   Zhao J, 2017, J BONE MINER RES, V32, P319, DOI 10.1002/jbmr.2992
   Zhao JL, 2021, COMPLEMENT THER CLIN, V44, DOI 10.1016/j.ctcp.2021.101419
   Zhao SJ, 2020, THERANOSTICS, V10, P17, DOI 10.7150/thno.36930
   Zheng LZ, 2020, BIOMATERIALS, V238, DOI 10.1016/j.biomaterials.2020.119828
   Zheng LZ, 2018, J ORTHOP TRANSL, V13, P13, DOI 10.1016/j.jot.2018.01.003
   Zhou D, 2018, INT J MOL MED, V41, P3433, DOI 10.3892/ijmm.2018.3534
   Zhou ML, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02249 1
   Zhou P, 2019, J CELL PHYSIOL, V234, P13799, DOI 10.1002/jcp.28060
   Zhu B, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12709
   Zhuang CY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.762543
NR 73
TC 2
Z9 2
U1 3
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2225 4110
J9 J TRADIT COMPL MED
JI J. Tradit. Complement. Med.
PD SEP
PY 2024
VL 14
IS 5
BP 568
EP 580
DI 10.1016/j.jtcme.2024.03.013
EA AUG 2024
PG 13
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA D9U0V
UT WOS:001299547300001
PM 39262662
OA gold
DA 2025 08 17
ER

PT J
AU Peng, CH
   Lin, WY
   Li, CY
   Dharini, KK
   Chang, CY
   Hong, JT
   Lin, MD
AF Peng, Cheng Huan
   Lin, Wen Ying
   Li, Chia Ying
   Dharini, Kameshwara Kumar
   Chang, Chih Yu
   Hong, Jo Ting
   Lin, Ming Der
TI Gu Sui Bu (Drynaria fortunei J. Sm.) antagonizes
   glucocorticoid induced mineralization reduction in zebrafish larvae by
   modulating the activity of osteoblasts and osteoclasts
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Drynaria fortunei J; Sm; Glucocorticoid induced osteoporosis; Gu Sui Bu;
   Naringin; Zebrafish model
ID OSTEOGENIC DIFFERENTIATION; BONE; EXPRESSION; ACTIVATOR; NARINGIN;
   IMPROVES; CELLS; MODEL; MICE; MASS
AB Ethnopharmacological relevance: Gu Sui Bu (GSB), the dried rhizome of Drynaria fortunei J. Sm., is widely used in traditional Chinese medicine for treating fractures and osteoporosis. Although glucocorticoids are widely pre scribed in modern medicine, the efficacy of GSB in treating glucocorticoid induced osteoporosis (GIOP) remains unclear.Aim of the study: GIOP is one of the most prevalent forms of osteoporosis and increases the risk of fracture, which can cause severe complications in elderly people. Safe, efficacious, and cost effective treatment options for GIOP are thus warranted. The present study investigated the efficacy and mechanism of GSB for treating GIOP.Materials and methods: We established an efficient and robust in vivo GIOP model by optimizing zebrafish larvae rearing conditions and the dose and duration of dexamethasone treatment. Bone calcification was evaluated through calcein staining. To quantify the degree of vertebral mineralization in the larvae, we developed a scoring system based on the rate of vertebral calcification; this system reduced quantification errors among individual zebrafish caused by inconsistencies in staining or imaging parameters. Quantitative real time polymerase chain reaction was used to access the expression levels of genes essential to the differentiation and function of bone cells. High performance liquid chromatography was employed to identify naringin in the GSB extract. Results: GSB significantly reversed the dexamethasone induced calcification delay in zebrafish larvae. GSB enhanced osteoblast activity by increasing the expression of collagen I, osteopontin, and osteonectin and repressed bone resorption by decreasing the expression of matrix metalloproteinases (mmps), including mmp9 and mmp13a. We also identified naringin as one of the constituents of GSB responsible for the herbal extract's anti GIOP activity.Conclusions: Using the in vivo zebrafish GIOP model that we established, the efficacy of traditional Chinese medicines in treating GIOP could be systematically investigated. GSB has an osteogenic effect and may thus be an efficacious and cost effective treatment option for GIOP. Notably, bone resorption activity was found to be retained after GSB treatment, which would be beneficial for maintaining normal bone remodeling.
C1 [Peng, Cheng Huan; Lin, Wen Ying] Hualien Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Orthoped, Hualien 97002, Taiwan.
   [Peng, Cheng Huan; Dharini, Kameshwara Kumar; Lin, Ming Der] Tzu Chi Univ, Inst Med Sci, Hualien 97004, Taiwan.
   [Peng, Cheng Huan] Tzu Chi Univ, Sch Med, Hualien 97004, Taiwan.
   [Li, Chia Ying] Natl Pingtung Univ, Dept Appl Chem, Pingtung 90003, Taiwan.
   [Chang, Chih Yu; Hong, Jo Ting; Lin, Ming Der] Tzu Chi Univ, Dept Mol Biol & Human Genet, Hualien 97004, Taiwan.
   [Lin, Ming Der] Hualien Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Integrat Ctr Tradit Chinese & Modern Med, Hualien 97002, Taiwan.
   [Lin, Ming Der] Tzu Chi Univ, Dept Mol Biol & Human Genet, 701 Zhongyang Rd, Sec 3, Hualien 97004, Taiwan.
C3 Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Tzu Chi
   University; Tzu Chi University; National Pingtung University; Tzu Chi
   University; Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital;
   Tzu Chi University
RP Lin, MD (通讯作者)，Tzu Chi Univ, Dept Mol Biol & Human Genet, 701 Zhongyang Rd, Sec 3, Hualien 97004, Taiwan.
EM mingder@gms.tcu.edu.tw
RI Lin, Ming Der/AAL 5302 2020; Chen, Xiao Dong/ADG 8612 2022
OI Li, Chia Ying/0000 0002 8319 5768; Lin, Ming Der/0000 0003 3411 5685; 
FU Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan;
   Tzu Chi University;  [TCRD109 53];  [TCRD110 36];  [610400239 11]
FX Acknowledgments This work was supported by the Hualien Tzu Chi Hospital,
   Buddhist Tzu Chi Medical Foundation, Taiwan (Grant No. TCRD109 53 and
   TCRD110 36) to C.H.P. and Tzu Chi University (Grant No. 610400239 11) to
   M.D.L.
CR Ballanti P, 1997, OSTEOPOROSIS INT, V7, P39, DOI 10.1007/BF01623458
   Barrett Ruth, 2006, Biotechnology Journal, V1, P651, DOI 10.1002/biot.200600043
   Bruneel B, 2015, CONNECT TISSUE RES, V56, P161, DOI 10.3109/03008207.2015.1013193
   Cackowski FC, 2010, BLOOD, V115, P140, DOI 10.1182/blood 2009 08 237628
   Caesar LK, 2019, NAT PROD REP, V36, P869, DOI 10.1039/c9np00011a
   Charles JF, 2017, BONE, V101, P162, DOI 10.1016/j.bone.2017.05.001
   Chen Z. Q, 2002, BEN CAO SHI YI JI SH
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Cotti S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155429
   Depalle B, 2021, ACTA BIOMATER, V120, P194, DOI 10.1016/j.actbio.2020.04.040
   Dietrich K, 2021, J BONE MINER RES, V36, P436, DOI 10.1002/jbmr.4256
   du Plessis A, 2017, GIGASCIENCE, V6, DOI 10.1093/gigascience/gix027
   Du SJ, 2001, DEV BIOL, V238, P239, DOI 10.1006/dbio.2001.0390
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fardet L, 2011, RHEUMATOLOGY, V50, P1982, DOI 10.1093/rheumatology/ker017
   Favus MJ, 2010, NEW ENGL J MED, V363, P2027, DOI 10.1056/NEJMct1004903
   Fisher S, 2003, DEV BIOL, V264, P64, DOI 10.1016/S0012 1606(03)00399 3
   Han YP, 2007, J BIOL CHEM, V282, P12928, DOI 10.1074/jbc.M700554200
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Hernandez RE, 2018, ZEBRAFISH, V15, P515, DOI 10.1089/zeb.2018.1579
   Huo L, 2018, BIOL OPEN, V7, DOI 10.1242/bio.029405
   Kim KS, 2012, RHEUMATOL INT, V32, P3069, DOI 10.1007/s00296 011 2095 4
   Kiviranta R, 2005, BONE, V36, P159, DOI 10.1016/j.bone.2004.09.020
   Krane SM, 2008, BONE, V43, P7, DOI 10.1016/j.bone.2008.03.020
   Lee YE, 2014, J ETHNOPHARMACOL, V158, P94, DOI 10.1016/j.jep.2014.10.016
   Li LN, 2011, PHYTOMEDICINE, V18, P985, DOI 10.1016/j.phymed.2011.03.002
   Li NH, 2013, J ORTHOP SCI, V18, P478, DOI 10.1007/s00776 013 0362 9
   Lin FX, 2016, AM J TRANSL RES, V8, P5098
   Luo SY, 2016, J ORTHOP TRANSL, V4, P35, DOI 10.1016/j.jot.2015.07.002
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379
   Pang WY, 2010, BRIT J PHARMACOL, V159, P1693, DOI 10.1111/j.1476 5381.2010.00664.x
   Peng CH, 2021, TZU CHI MED J, V33, P212, DOI 10.4103/tcmj.tcmj_233_20
   Peng Zhang, 2009, EUR J PHARMACOL, V607, P1, DOI 10.1016/j.ejphar.2009.01.035
   Qiao X, 2014, PLANTA MED, V80, P330, DOI 10.1055/s 0033 1360362
   Rosset EM, 2016, MATRIX BIOL, V52 54, P78, DOI 10.1016/j.matbio.2016.02.001
   Schreiber AM, 2006, J EXP BIOL, V209, P610, DOI 10.1242/jeb.02056
   Shih WT, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/752837
   Si JY, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.919159
   Song SH, 2017, MOLECULES, V22, DOI 10.3390/molecules22071033
   Tokuhara CK, 2019, J APPL ORAL SCI, V27
   Tonelli F, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00489
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   WEINER S, 1986, FEBS LETT, V206, P262, DOI 10.1016/0014 5793(86)80993 0
   Wong KC, 2013, BRIT J NUTR, V110, P475, DOI 10.1017/S0007114512005405
   Zhang C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050525
   Zhang YH, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006481
   Zhao Y, 2020, DRUG DES DEV THER, V14, P195, DOI 10.2147/DDDT.S225516
   Zhao Z., 2017, Altern. Complement. Integr. Med, V3, P45, DOI [10.24966/ACIM 7562/100045, DOI 10.24966/ACIM 7562/100045]
   Zhao ZZ, 2018, CHIN MED UK, V13, DOI 10.1186/s13020 018 0176 y
NR 50
TC 13
Z9 15
U1 5
U2 36
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD OCT 28
PY 2022
VL 297
AR 115565
DI 10.1016/j.jep.2022.115565
EA AUG 2022
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 6Q0FV
UT WOS:000891298500002
PM 35863613
DA 2025 08 17
ER

PT J
AU Webster, R
   Sheriff, S
   Faroqui, R
   Siddiqui, F
   Hawse, JR
   Amlal, H
AF Webster, Rose
   Sheriff, Sulaiman
   Faroqui, Rashma
   Siddiqui, Faraaz
   Hawse, John R.
   Amlal, Hassane
TI Klotho/fibroblast growth factor 23 and PTH independent estrogen
   receptor α mediated direct downregulation of NaPi IIa by estrogen in the
   mouse kidney
SO AMERICAN JOURNAL OF PHYSIOLOGY RENAL PHYSIOLOGY
LA English
DT Article
DE inorganic phosphate; hyperphosphatemia; sex steroids; proximal tubule;
   hypophosphatemia; parathyroid hormone; estrogen
ID COTRANSPORTER GENE EXPRESSION; MESSENGER RNA; BONE LOSS; ER ALPHA;
   PHOSPHATE REABSORPTION; OVARIECTOMIZED RATS; REPLACEMENT THERAPY;
   METABOLIC ACIDOSIS; MINERAL METABOLISM; PROXIMAL TUBULE
AB Estrogen treatment causes renal phosphate (P i) wasting and hypophosphatemia in rats and humans; however, the signaling mechanisms mediating this effect are still poorly understood. To determine the specific roles of estrogen receptor isoforms (ER alpha and ER beta) and the Klotho pathway in mediating these effects, we studied the effects of estrogen on renal P i handling in female mice with null mutations of ER alpha or ER beta or Klotho and their wild type (WT) using balance studies in metabolic cages. Estrogen treatment of WT and ER beta knockout (KO) mice caused a significant reduction in food intake along with increased renal phosphate wasting. The latter resulted from a significant downregulation of NaPi IIa and NaPi IIc protein abundance. The mRNA expression levels of both transporters were unchanged in estrogen treated mice. These effects on both food intake and renal P i handling were absent in ER alpha KO mice. Estrogen treatment of Klotho KO mice or parathyroid hormone (PTH) depleted thyroparathyroidectomized mice exhibited a significant downregulation of NaPi IIa with no change in the abundance of NaPi IIc. Estrogen treatment of a cell line (U20S) stably coexpressing both ER alpha and ER beta caused a significant downregulation of NaPi IIa protein when transiently transfected with a plasmid containing full length or open reading frame (ORF) 3' untranslated region (UTR) but not 5' UTR ORF of mouse NaPi IIa transcript. In conclusion, estrogen causes phosphaturia and hypophosphatemia in mice. These effects result from downregulation of NaPi IIa and NaPi IIc proteins in the proximal tubule through the activation of ER alpha. The downregulation of NaPi IIa by estrogen involves 3' UTR of its mRNA and is independent of Klotho/fibroblast growth factor 23 and PTH signaling pathways.
C1 [Webster, Rose; Faroqui, Rashma; Siddiqui, Faraaz; Amlal, Hassane] Univ Cincinnati, Dept Med, Div Nephrol & Hypertens, Cincinnati, OH USA.
   [Sheriff, Sulaiman] Univ Cincinnati, Dept Surg, 231 Bethesda Ave, Cincinnati, OH 45267 USA.
   [Hawse, John R.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN USA.
C3 University System of Ohio; University of Cincinnati; University System
   of Ohio; University of Cincinnati; Mayo Clinic
RP Amlal, H (通讯作者)，Div Nephrol & Hypertens, 231 Albert Sabin Way,MSB Rm G 259, Cincinnati, OH 45267 USA.
EM Amlalh@uc.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases
   [RO1 DK 083582]
FX These studies were supported by National Institute of Diabetes and
   Digestive and Kidney Diseases Grant RO1 DK 083582 to H. Amlal.
CR Abu Hossain S, 2011, AM J PHYSIOL RENAL, V301, pF969, DOI 10.1152/ajprenal.00010.2011
   ADAMI S, 1992, OSTEOPOROSIS INT, V2, P180, DOI 10.1007/BF01623924
   Balkovetz DF, 2009, AM J PHYSIOL RENAL, V297, pF604, DOI 10.1152/ajprenal.00043.2009
   Beck L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/pnas.95.9.5372
   Beers KW, 1996, BIOCHEM BIOPH RES CO, V221, P442, DOI 10.1006/bbrc.1996.0614
   Bergwitz C, 2010, ANNU REV MED, V61, P91, DOI 10.1146/annurev.med.051308.111339
   Berndt T., 1992, KIDNEY PHYSL PATHOPH, P2511
   Biber J, 2009, PFLUG ARCH EUR J PHY, V458, P39, DOI 10.1007/s00424 008 0580 8
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Burris D, 2015, AM J PHYSIOL RENAL, V308, pF522, DOI 10.1152/ajprenal.00386.2014
   Carrillo López N, 2009, J AM SOC NEPHROL, V20, P2009, DOI 10.1681/ASN.2008121258
   CASTELOBRANCO C, 1992, EUR J OBSTET GYN R B, V44, P131, DOI 10.1016/0028 2243(92)90058 7
   Cheema MU, 2015, AM J PHYSIOL RENAL, V309, pF305, DOI 10.1152/ajprenal.00685.2014
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   CHURCH GM, 1984, P NATL ACAD SCI BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991
   CITRIN DL, 1984, AM J MED, V76, P787, DOI 10.1016/0002 9343(84)90987 2
   Danisi G., 1991, Handbook of Physiology. The Gastrointestinal System. Intestinal Absorption and Secretion, V6, P323
   DAVIDOFF M, 1980, HISTOCHEMISTRY, V69, P39, DOI 10.1007/BF00508365
   DEMPSTER DW, 1993, LANCET, V341, P797, DOI 10.1016/0140 6736(93)90570 7
   Dennis VW, 1992, HDB PHYSL RENAL PH 8, VII, P1785
   Doherty TM, 2002, FASEB J, V16, DOI 10.1096/fj.01 0898hyp
   Edwards DP, 2005, ANNU REV PHYSIOL, V67, P335, DOI 10.1146/annurev.physiol.67.040403.120151
   Faroqui S, 2008, KIDNEY INT, V73, P1141, DOI 10.1038/ki.2008.33
   Forster IC, 2006, KIDNEY INT, V70, P1548, DOI 10.1038/sj.ki.5001813
   Geary N, 2001, ENDOCRINOLOGY, V142, P4751, DOI 10.1210/en.142.11.4751
   Hajarnis S, 2005, J BIOL CHEM, V280, P28272, DOI 10.1074/jbc.M501204200
   Hoag HM, 1999, J CLIN INVEST, V104, P679, DOI 10.1172/JCI7103
   Irsik DL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070926
   Karim Z, 2003, J AM SOC NEPHROL, V14, P2229, DOI 10.1097/01.ASN.0000085023.73801.4A
   Khosla S, 2010, J CLIN ENDOCR METAB, V95, P3569, DOI 10.1210/jc.2010 0856
   Kiel DP, 2001, CALCIFIED TISSUE INT, V68, P271, DOI 10.1007/BF02390833
   Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Lundquist P, 2007, CELL PHYSIOL BIOCHEM, V19, P43, DOI 10.1159/000099191
   Manson JE, 2007, NEW ENGL J MED, V356, P2591, DOI 10.1056/NEJMoa071513
   Monroe DG, 2004, ADV MOL CEL, V34, P39, DOI 10.1016/S1569 2558(03)34003 2
   Monroe DG, 2005, MOL ENDOCRINOL, V19, P1555, DOI 10.1210/me.2004 0381
   MONROE DG, 2004, PRIMER METABOLIC BON, P32
   Murer H, 2004, PFLUG ARCH EUR J PHY, V447, P763, DOI 10.1007/s00424 003 1072 5
   Murer H, 2000, PHYSIOL REV, V80, P1373, DOI 10.1152/physrev.2000.80.4.1373
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   Santollo J, 2007, AM J PHYSIOL REG I, V293, pR2194, DOI 10.1152/ajpregu.00385.2007
   Schroeder JM, 2003, AM J PHYSIOL RENAL, V285, pF258, DOI 10.1152/ajprenal.00422.2002
   Segawa H, 2002, J BIOL CHEM, V277, P19665, DOI 10.1074/jbc.M200943200
   Segawa H, 2009, J AM SOC NEPHROL, V20, P104, DOI 10.1681/ASN.2008020177
   Solbu TT, 2005, J AM SOC NEPHROL, V16, P869, DOI 10.1681/ASN.2004060433
   STOCK JL, 1985, J CLIN ENDOCR METAB, V61, P595, DOI 10.1210/jcem 61 4 595
   Thammacharoen S, 2009, BRAIN RES, V1268, P88, DOI 10.1016/j.brainres.2009.02.067
   Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353
   Tsujikawa H, 2003, MOL ENDOCRINOL, V17, P2393, DOI 10.1210/me.2003 0048
   Uemura H, 2000, J CLIN ENDOCR METAB, V85, P1215, DOI 10.1210/jc.85.3.1215
   Van Abel M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022423.34922.2A
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Wells Corinne C, 2005, Gend Med, V2, P227, DOI 10.1016/S1550 8579(05)80052 X
   Xu H, 2003, AM J PHYSIOL GASTR L, V285, pG1317, DOI 10.1152/ajpgi.00172.2003
   Yoshida T, 2002, ENDOCRINOLOGY, V143, P683, DOI 10.1210/en.143.2.683
NR 56
TC 19
Z9 21
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931 857X
EI 1522 1466
J9 AM J PHYSIOL RENAL
JI Am. J. Physiol. Renal Physiol.
PD AUG 1
PY 2016
VL 311
IS 2
BP F249
EP F259
DI 10.1152/ajprenal.00542.2015
PG 11
WC Physiology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Urology & Nephrology
GA DY3FP
UT WOS:000384976500002
PM 27194721
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Zhao, N
   Tsuda, H
   Murofushi, T
   Imai, K
   Ochiai, K
   Yang, PS
   Suzuki, N
AF Zhao, Ning
   Tsuda, Hiromasa
   Murofushi, Takahisa
   Imai, Kenichi
   Ochiai, Kuniyasu
   Yang, Pishan
   Suzuki, Naoto
TI Chaetocin inhibits RANKL induced osteoclast differentiation through
   reduction of Blimp1 in Raw264.7 cells
SO LIFE SCIENCES
LA English
DT Article
DE Chaetocin; Osteoclast differentiation; Cell growth; Blimp1;
   Transcriptional repressors
ID HISTONE METHYLTRANSFERASE SUV39H1; BREAST CANCER; TRANSCRIPTION;
   REPRESSION; METHYLATION; ACTIVATION; INDUCTION; APOPTOSIS; PROTEIN; AXIS
AB Aims: Periodontitis is one of the most common bone destructive diseases. Osteoclast is differentiated from hematopoietic macrophage like cells through receptor activator of NF kappa B ligand (RANKL) RANK signaling system, and the reduction in osteoclast formation may result in prevention of bone resorptive diseases. Chaetocin is a compound isolated from fungal cultures and has been reported as a potent and selective inhibitor of suppressor of variegation 3 9 homolog 1 (Suv39h1), which catalyzes histone methylation on histone H3 lysine 9 (H3K9) residues. However, the effect of chaetocin on osteoclast differentiation is uncertain. In this study, we examine the effect of chaetocin on RANKL induced osteoclast differentiation and cell growth.
   Main methods: Mouse macrophage like Raw264.7 cells were treated with RANKL in the presence or absence of chaetocin, and tartrate resistant acid phosphatase (TRAP) staining was performed. Cell growth was measured as the amount of DNA stained with SYTOX Green dye. Expression and production of osteoclast differentiation markers, anti osteoclastogenic genes, B lymphocyte induced maturation protein 1 (Blimp1), and cell growth suppressors were examined by qRT PCR or/and Western blot analysis.
   Key findings: Here we show that chaetocin dose dependently reduced RANKL induced osteoclast differentiation and cell growth via Blimp1 downregulation which results in the upregulation of osteoclast differentiation inhibitors and cell growth suppressors. These effects were not derived from the chaetocin's inhibitory effect of Suv39h1.
   Significance: These results suggest that chaetocin suppresses RANKL induced osteoclastogenesis and cell growth through blimp1 downregulation, followed by induction of anti osteoclastogenic genes and cell growth suppressors, without inhibition of Suv39h1. Thus, chaetocin might be a drug candidate for the prevention of bone resorption in bone destructive diseases. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Zhao, Ning; Tsuda, Hiromasa; Murofushi, Takahisa; Suzuki, Naoto] Nihon Univ, Dept Biochem, Sch Dent, Chiyoda Ku, Tokyo 1018310, Japan.
   [Imai, Kenichi; Ochiai, Kuniyasu] Nihon Univ, Sch Dent, Dept Oral Microbiol, Chiyoda Ku, Tokyo 1018310, Japan.
   [Zhao, Ning] Shandong Univ, Sch Dent, Dept Endodont, Jinan 250012, Shandong, Peoples R China.
   [Tsuda, Hiromasa; Suzuki, Naoto] Nihon Univ, Dent Res Ctr, Sch Dent, Div Funct Morphol,Chiyoda Ku, Tokyo 1018310, Japan.
   [Imai, Kenichi; Ochiai, Kuniyasu] Nihon Univ, Dent Res Ctr, Sch Dent, Div Immunol & Pathobiol,Chiyoda Ku, Tokyo 1018310, Japan.
   [Yang, Pishan] Shandong Univ, Sch Dent, Dept Periodont, Jinan 250012, Shandong, Peoples R China.
C3 Nihon University; Nihon University; Shandong University; Nihon
   University; Nihon University; Shandong University
RP Tsuda, H (通讯作者)，Nihon Univ, Dept Biochem, Sch Dent, Chiyoda Ku, 1 8 13 Kanda Surugadai, Tokyo 1018310, Japan.
EM tsuda.hiromasa@nihon u.ac.jp
OI TSUDA, HIROMASA/0000 0002 2047 2262
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [C23593104, C23592714]; Dental Research Center, Nihon University School
   of Dentistry; Strategic Research Base Development Program for Private
   Universities from Ministry of Education, Culture, Sports, Science and
   Technology of Japan [S1001024]; Nihon University
FX This work was supported by a Grant in Aid for Scientific Research
   (C23593104 and C23592714) from the Ministry of Education, Culture,
   Sports, Science and Technology of Japan; Grant from Dental Research
   Center, Nihon University School of Dentistry (H.T. 2011); a Strategic
   Research Base Development Program for Private Universities from Ministry
   of Education, Culture, Sports, Science and Technology of Japan,
   2010 2014 (S1001024); and a Nihon University Joint Research Grant (Y.M.
   2012). The authors declare no conflict of interest associated with this
   manuscript.
CR Bartold PM, 2010, PERIODONTOL 2000, V53, P55, DOI 10.1111/j.1600 0757.2010.00347.x
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Bernhard W, 2011, FEBS LETT, V585, P3549, DOI 10.1016/j.febslet.2011.10.018
   Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Carbone R, 2006, MOL CELL BIOL, V26, P1288, DOI 10.1128/MCB.26.4.1288 1296.2006
   Chaib H, 2012, LEUKEMIA, V26, P662, DOI 10.1038/leu.2011.271
   Chiba T., 2014, INT J CANC
   Clézardin P, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2835
   Dixit D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.179
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092 8674(93)90500 P
   Greiner D, 2005, NAT CHEM BIOL, V1, P143, DOI 10.1038/nchembio721
   HAUSER D, 1970, HELV CHIM ACTA, V53, P1061, DOI 10.1002/hlca.19700530521
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Imai K, 2014, FEBS J, V281, P2148, DOI 10.1111/febs.12768
   Isham CR, 2007, BLOOD, V109, P2579, DOI 10.1182/blood 2006 07 027326
   Jenuwein T, 2006, FEBS J, V273, P3121, DOI 10.1111/j.1742 4658.2006.05343.x
   Ji Y, 2011, NAT IMMUNOL, V12, P1230, DOI 10.1038/ni.2153
   Ke XX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106962
   Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood 2006 09 048249
   Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017
   Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004 0008
   Lee J, 2006, BLOOD, V107, P2686, DOI 10.1182/blood 2005 07 2798
   Mal AK, 2006, EMBO J, V25, P3323, DOI 10.1038/sj.emboj.7601229
   Miyauchi Y, 2010, J EXP MED, V207, P751, DOI 10.1084/jem.20091957
   Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092 8674(02)00654 2
   Nishikaw K, 2010, P NATL ACAD SCI USA, V107, P3117, DOI 10.1073/pnas.0912779107
   Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304 3835(01)00847 3
   Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422
   Shiozawa S, 2011, ARCH IMMUNOL THER EX, V59, P89, DOI 10.1007/s00005 011 0116 3
   Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tsuda H, 2013, BOSNIAN J BASIC MED, V13, P271, DOI 10.17305/bjbms.2013.2339
   Väänänen HK, 2008, ARCH BIOCHEM BIOPHYS, V473, P132, DOI 10.1016/j.abb.2008.03.037
   Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e
   Yan JL, 2007, P NATL ACAD SCI USA, V104, P1841, DOI 10.1073/pnas.0605562104
   Yasui T., 2011, J BONE MINER RES
NR 38
TC 12
Z9 15
U1 0
U2 16
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD DEC 15
PY 2015
VL 143
BP 1
EP 7
DI 10.1016/j.lfs.2015.10.027
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CZ2TD
UT WOS:000366956600001
PM 26514304
DA 2025 08 17
ER

PT J
AU Cucu, A
   Shreder, K
   Kraft, D
   Rühle, PF
   Klein, G
   Thiel, G
   Frey, B
   Gaipl, US
   Fournier, C
AF Cucu, Aljona
   Shreder, Kateryna
   Kraft, Daniela
   Ruhle, Paul Friedrich
   Klein, Gerhart
   Thiel, Gerhard
   Frey, Benjamin
   Gaipl, Udo S.
   Fournier, Claudia
TI Decrease of Markers related to Bone erosion in serum of Patients with
   Musculoskeletal Disorders after serial low Dose radon spa Therapy
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE chronic inflammatory diseases; degenerative musculoskeletal disorders;
   bone metabolism; osteoblasts; osteoclasts; adipokines; Treg; Th17 cells;
   radon spa treatment
ID RANDOMIZED CONTROLLED TRIAL; KAPPA B LIGAND; RHEUMATOID ARTHRITIS;
   ANKYLOSING SPONDYLITIS; CARTILAGE DEGRADATION; RECEPTOR ACTIVATOR;
   EXERCISE THERAPY; IMMUNE SYSTEM; OSTEOARTHRITIS; ADIPOKINES
AB Musculoskeletal disorders (MSDs) are the most frequent cause of disability in Europe. Reduced mobility and quality of life of the patients are often associated with pain due to chronic inflammation. The inflammatory process, accompanied by a destruction of the cartilage and bone tissue, is discussed as a result of (A) the infiltration of immune cells into the joints, (B) an altered homeostasis of the joint cavity (synovium) with a critical role of bone remodeling cells, and (C) release of inflammatory factors including adipokines in the arthritic joint. In addition to the classical medication, low dose radiation therapy using photons or radon spa treatments has shown to reduce pain and improve the mobility of the patients. However, the cellular and molecular mechanisms of anti inflammatory effects of radon are yet poorly understood. We analyzed blood and serum samples from 32 patients, suffering from MSDs, who had been treated in the radon spa in Bad Steben (Germany). Before and after therapy, we measured the levels of markers related to bone metabolism (collagen fragments type 1, cartilage oligomeric matrix protein, receptor activator of NF kappa B ligand, and osteoprotegerin) in the serum of patients. In addition, adipokines related to inflammation (visfatin, leptin, resistin, and adiponectin) were analyzed. Some of these factors are known to correlate with disease activity. Since T cells play an important role in the progression of the disease, we further analyzed in blood samples the frequency of pro and anti inflammatory T cell subpopulations (CD4(+)IL17(+) T cells and CD4(+)FoxP3(+) regulatory T cells). Overall, we found a decrease of collagen fragments (CTX I), indicating decreased bone resorption, presumably by osteoclasts, in the serum of MSD patients. We also observed reduced levels of visfatin and a consistent trend toward an increase of regulatory T cells in the peripheral blood, both indicating attenuation of inflammation. However, key proteins of bone metabolism were unchanged on a systemic level, suggesting that these factors act locally after radon spa therapy of patients with MSDs.
C1 [Cucu, Aljona; Shreder, Kateryna; Kraft, Daniela; Fournier, Claudia] GSI Helmholtz Ctr Heavy Ion Res, Dept Biophys, Darmstadt, Germany.
   [Ruhle, Paul Friedrich; Frey, Benjamin; Gaipl, Udo S.] Friedrich Alexander Univ Erlangen Numberg, Univ Klinikum Erlangen, Dept Radiat Oncol, Erlangen, Germany.
   [Klein, Gerhart] Assoc Spa Res & Med Practice Cardiol, Bad Steben, Germany.
   [Thiel, Gerhard] Tech Univ Darmstadt, Membrane Biophys Grp, Dept Biol, Darmstadt, Germany.
C3 Helmholtz Association; GSI Helmholtz Center for Heavy Ion Research;
   University of Erlangen Nuremberg; Technical University of Darmstadt
RP Fournier, C (通讯作者)，GSI Helmholtz Ctr Heavy Ion Res, Dept Biophys, Darmstadt, Germany.
EM c.fournier@gsi.de
RI Gaipl, Udo/AAE 1060 2020; Frey, Benjamin/D 9565 2017
OI Thiel, Gerhard/0000 0002 2335 1351; 
FU German Federal Ministry of Education and Research [02NUK017A, 02NUK017G,
   GREWIS]; Landesamt fur Gesundheit und Lebensmittelsicherheit Bayern
   (LDL); Bayrisches Staatsbad Bad Steben GmbH; HGS HIRe (Helmholtz
   Graduate School for Hadron and Ion Research)
FX This work was supported by the German Federal Ministry of Education and
   Research (grant no. 02NUK017A and 02NUK017G, GREWIS), by Landesamt fur
   Gesundheit und Lebensmittelsicherheit Bayern (LDL), and by Bayrisches
   Staatsbad Bad Steben GmbH and HGS HIRe (Helmholtz Graduate School for
   Hadron and Ion Research).
CR Annegret F, 2013, RHEUMATOL INT, V33, P2839, DOI 10.1007/s00296 013 2819 8
   Bas S, 2014, INT ORTHOP, V38, P2577, DOI 10.1007/s00264 014 2416 9
   Benito MJ, 2005, ANN RHEUM DIS, V64, P1263, DOI 10.1136/ard.2004.025270
   Bhattaram P, 2017, SEMIN CELL DEV BIOL, V62, P86, DOI 10.1016/j.semcdb.2016.05.009
   Burmester GR, 2014, NAT REV RHEUMATOL, V10, P77, DOI 10.1038/nrrheum.2013.168
   Chopin F, 2008, ANN RHEUM DIS, V67, P353, DOI 10.1136/ard.2007.076604
   Conaghan PG, 2012, RHEUMATOL INT, V32, P1491, DOI 10.1007/s00296 011 2263 6
   Curatolo M, 2001, CLIN J PAIN, V17, P25, DOI 10.1097/00002508 200103000 00005
   de Lange Brokaar BJE, 2012, OSTEOARTHR CARTILAGE, V20, P1484, DOI 10.1016/j.joca.2012.08.027
   Deetjen P, 2005, INDIKATIONEN KONTROL
   Eekman DA, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 167
   Falkenbach A, 2005, RHEUMATOL INT, V25, P205, DOI 10.1007/s00296 003 0419 8
   Francin PJ, 2014, OSTEOARTHR CARTILAGE, V22, P519, DOI 10.1016/j.joca.2014.01.002
   Franke A, 2000, RHEUMATOLOGY, V39, P894, DOI 10.1093/rheumatology/39.8.894
   Franke A, 2007, RHEUMATOL INT, V27, P703, DOI 10.1007/s00296 006 0293 2
   Gengenbacher M, 2008, ANN RHEUM DIS, V67, P620, DOI 10.1136/ard.2007.076711
   Gómez R, 2011, NAT REV RHEUMATOL, V7, P528, DOI 10.1038/nrrheum.2011.107
   Gribi R, 2001, MOL CELL ENDOCRINOL, V180, P163, DOI 10.1016/S0303 7207(01)00517 2
   Hofbauer LC, 2001, ARTHRITIS RHEUM US, V44, P253, DOI 10.1002/1529 0131(200102)44:2<253::AID ANR41>3.0.CO;2 S
   Kim KS, 2014, MOL MED REP, V9, P255, DOI 10.3892/mmr.2013.1764
   La Cava A, 2004, NAT REV IMMUNOL, V4, P371, DOI 10.1038/nri1350
   Labelle H, 1997, ARCH FAM MED, V6, P257, DOI 10.1001/archfami.6.3.257
   Laiguillon MC, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4467
   Lange U, 2016, CLIN RHEUMATOL, V35, P2783, DOI 10.1007/s10067 016 3236 7
   Lind  Albrecht G., 2004, HERBSTTAGUNG ARBEISG
   Lurati A, 2015, OPEN ACCESS RHEUMATO, V7, P63, DOI 10.2147/OARRR.S81905
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Messent EA, 2007, OSTEOARTHR CARTILAGE, V15, P179, DOI 10.1016/j.joca.2006.06.020
   Moder A., 2013, HYPERTHERMIA, P185
   Moder Angelika, 2010, International Journal of Low Radiation, V7, P423, DOI 10.1504/IJLR.2010.037663
   Moulin DE, 1996, LANCET, V347, P143, DOI 10.1016/S0140 6736(96)90339 6
   Munn DH, 2016, TRENDS IMMUNOL, V37, P193, DOI 10.1016/j.it.2016.01.002
   Neumann E, 2014, Z RHEUMATOL, V73, P556, DOI 10.1007/s00393 013 1325 4
   Neumann E, 2016, NAT REV RHEUMATOL, V12, P296, DOI 10.1038/nrrheum.2016.49
   NUSSBAUM E, 1957, SCIENCE, V125, P552, DOI 10.1126/science.125.3247.552
   Poonpet T, 2014, WORLD J ORTHOP, V5, P319, DOI 10.5312/wjo.v5.i3.319
   Popa C, 2009, J RHEUMATOL, V36, P724, DOI 10.3899/jrheum.080626
   Procaccini C, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00332
   REYNOLDS DL, 1992, J RHEUMATOL, V19, P1020
   Rho YH, 2009, ARTHRITIS RHEUM US, V60, P1906, DOI 10.1002/art.24626
   Rousseau JC, 2007, NAT CLIN PRACT RHEUM, V3, P346, DOI 10.1038/ncprheum0508
   Rühle PF, 2017, AUTOIMMUNITY, V50, P133, DOI 10.1080/08916934.2017.1284819
   Schett G, 2005, NAT CLIN PRACT RHEUM, V1, P47, DOI 10.1038/ncprheum0036
   Scott DL, 2006, NEW ENGL J MED, V355, P704, DOI 10.1056/NEJMct055183
   Seegenschmiedt MH, 2015, BRIT J RADIOL, V88, DOI 10.1259/bjr.20150080
   Sglunda O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103495
   Skoumal M, 2005, RHEUMATOL INT, V26, P63, DOI 10.1007/s00296 004 0579 1
   Sokolove J, 2013, THER ADV MUSCULOSKEL, V5, P77, DOI 10.1177/1759720X12467868
   SOTO J, 1997, RADON KURORTMEDIZIN, P103
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   Udagawa N, 2002, ARTHRITIS RES, V4, P281, DOI 10.1186/ar431
   Van Tubergen A, 2002, ARTHRIT RHEUM ARTHR, V47, P459, DOI 10.1002/art.10658
   Van Tubergen A, 2001, ARTHRIT RHEUM ARTHR, V45, P430, DOI 10.1002/1529 0131(200110)45:5<430::AID ART362>3.0.CO;2 F
   van Tuyl LHD, 2010, ANN RHEUM DIS, V69, P1623, DOI 10.1136/ard.2009.121764
   Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198 010 1501 1
   Wenham CYJ, 2013, AGE AGEING, V42, P272, DOI 10.1093/ageing/aft043
   Winklmayr M, 2015, RADIAT ENVIRON BIOPH, V54, P123, DOI 10.1007/s00411 014 0568 z
NR 58
TC 31
Z9 32
U1 0
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 25
PY 2017
VL 8
AR 882
DI 10.3389/fimmu.2017.00882
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA FB6BX
UT WOS:000406227400001
PM 28791026
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Yeo, H
   Beck, LH
   McDonald, JM
   Zayzafoon, M
AF Yeo, Hyeonju
   Beck, Lauren H.
   McDonald, Jay M.
   Zayzafoon, Majd
TI Cyclosporin A elicits dose dependent biphasic effects on osteoblast
   differentiation and bone formation
SO BONE
LA English
DT Article
DE NFAT; osteoblasts; bone; AP 1; Fra 2; calcineurin; cyclosporin;
   transplantation
ID ACTIVATED T CELLS; C FOS; IN VITRO; TRANSCRIPTIONAL REGULATION; NUCLEAR
   FACTORS; GROWTH FACTOR; CALCINEURIN; NFAT; EXPRESSION; RAT
AB Cyclosporin A (CsA) is thought to prevent immune reactions after organ transplantation by inhibiting calcineurin (Cn) and its substrate, the Nuclear Factor of Activated T Cells (NFAT). A dichotomy exists in describing the effects of CsA on bone formation. The concept that the suppression of Cn/NFAT signaling by CsA inhibits bone formation is not entirely supported by many clinical reports and laboratory animal studies. Gender, dosage and basal inflammatory activity have all been suggested as explanations for these seemingly contradictory reports. Here we examine the effects of varying concentrations of CsA on bone formation and osteoblast differentiation and elucidate the role of NFATc I in this response. We show that low concentrations of CsA (< 1 mu M in vitro and 35.5 nM in vivo) are anabolic as they increase bone formation, osteoblast differentiation, and bone mass, while high concentrations (> 1 mu M in vitro and in vivo) elicit an opposite and catabolic response. The overexpression of constitutively active NFATc1 inhibits osteoblast differentiation, and treatment with low concentrations of CsA does not ameliorate this inhibition. Treating osteoblasts with low concentrations of CsA (< 1 mu M) increases fra 2 gene expression and protein levels in a dose dependent manner as well as AP 1 DNA binding activity. Finally, NFATc1 silencing with siRNA increases Fra 2 expression, whereas NFATc1 overexpression inhibits Fra 2 expression. Therefore, NFATc1 negatively regulates osteoblast differentiation, and its specific inhibition may represent a viable anabolic therapy for osteoporosis. (c) 2007 Elsevier Inc. All rights reserved.
C1 Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   Vet Adm Med Ctr, Birmingham, AL 35233 USA.
C3 University of Alabama System; University of Alabama Birmingham; US
   Department of Veterans Affairs; Veterans Health Administration (VHA)
RP Zayzafoon, M (通讯作者)，Univ Alabama Birmingham, Dept Pathol, 813 Shelby Biomed Res Bldg,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM mzayzafo@path.uab.edu
FU NCI NIH HHS [R01 CA109119, P01 CA098912, P01 CA098912] Funding Source:
   Medline; NIAMS NIH HHS [R01 AR050235, P30 AR046031, P30 AR46031,
   R01 AR050235] Funding Source: Medline; NIDDK NIH HHS [P30 DK56336, P30
   DK056336] Funding Source: Medline
CR ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304 419X(91)90011 9
   ARAMBURU J, 1995, J EXP MED, V182, P801, DOI 10.1084/jem.182.3.801
   Aroldi A, 1997, TRANSPLANTATION, V63, P380, DOI 10.1097/00007890 199702150 00009
   Arzate H, 2005, J PERIODONTAL RES, V40, P218, DOI 10.1111/j.1600 0765.2005.00797.x
   Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<73::AID JCB11>3.0.CO;2 L
   Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092 8674(02)00699 2
   D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Epstein Sol, 1995, Current Opinion in Rheumatology, V7, P255, DOI 10.1097/00002281 199505000 00018
   Erben RG, 1998, J BONE MINER RES, V13, P79, DOI 10.1359/jbmr.1998.13.1.79
   Furuke K, 1999, J IMMUNOL, V162, P1988
   Gilbert LC, 2005, AM J PHYSIOL ENDOC M, V288, pE1011, DOI 10.1152/ajpendo.00534.2004
   GLOBUS RK, 1988, ENDOCRINOLOGY, V123, P98, DOI 10.1210/endo 123 1 98
   GOMEZ DA, 2000, J BIOL CHEM, V275, P13872
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073
   JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0
   KATZ IA, 1992, J BONE MINER RES, V7, P123
   Khanna A, 1997, TRANSPLANTATION, V63, P1037, DOI 10.1097/00007890 199704150 00026
   Kodras K, 2006, EUR J CLIN INVEST, V36, P63, DOI 10.1111/j.1365 2362.2006.01662.x
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Kreideweiss S, 1999, EUR J BIOCHEM, V265, P1075, DOI 10.1046/j.1432 1327.1999.00830.x
   LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092 8674(91)90124 H
   LUKERT BP, 1994, RHEUM DIS CLIN N AM, V20, P629
   Macián F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386
   Matsuda S, 2000, IMMUNOPHARMACOLOGY, V47, P119, DOI 10.1016/S0162 3109(00)00192 2
   MAZANEC DJ, 1989, CLEV CLIN J MED, V56, P297, DOI 10.3949/ccjm.56.3.297
   McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398
   MCDONALD JA, 1991, HEPATOLOGY, V14, P613, DOI 10.1016/0270 9139(91)90047 Y
   MOVSOWITZ C, 1989, J BONE MINER RES, V4, P393
   MOVSOWITZ C, 1988, ENDOCRINOLOGY, V123, P2571, DOI 10.1210/endo 123 5 2571
   Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200
   Ogawa K, 2002, CLIN EXP IMMUNOL, V130, P475, DOI 10.1046/j.1365 2249.2002.01994.x
   Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097 2765(00)00053 8
   ORCEL P, 1989, J BONE MINER RES, V4, P387
   ORCEL P, 1991, ENDOCRINOLOGY, V128, P1638, DOI 10.1210/endo 128 3 1638
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Parsons SA, 2003, MOL CELL BIOL, V23, P4331, DOI 10.1128/MCB.23.12.4331 4343.2003
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707
   RICH GM, 1992, J HEART LUNG TRANSPL, V11, P950
   Rodino MA, 1998, AM J MED, V104, P459, DOI 10.1016/S0002 9343(98)00081 3
   SCHLITT HJ, 1991, TRANSPLANT INT, V4, P38, DOI 10.1111/j.1432 2277.1991.tb01943.x
   SCHUG J, 1997, CBILTR19971001V00
   Selvamurugan N, 2004, J BIOL CHEM, V279, P27764, DOI 10.1074/jbc.M312870200
   SHANE E, 1993, AM J MED, V94, P257, DOI 10.1016/0002 9343(93)90057 V
   Shane E, 1997, J CLIN ENDOCR METAB, V82, P1497, DOI 10.1210/jc.82.5.1497
   Stern PH, 2006, MOL INTERV, V6, P193, DOI 10.1124/mi.6.4.4
   Stolzing A, 2006, AGING CELL, V5, P213, DOI 10.1111/j.1474 9726.2006.00213.x
   Sun L, 2005, P NATL ACAD SCI USA, V102, P17130, DOI 10.1073/pnas.0508480102
   Sunters A, 2004, J BIOL CHEM, V279, P9882, DOI 10.1074/jbc.M310184200
   SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537
   Tang L, 2002, CELL BIOL INT, V26, P75, DOI 10.1006/cbir.2001.0812
   Wagner EF, 2002, ANN RHEUM DIS, V61, P40, DOI 10.1136/ard.61.suppl_2.ii40
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Yeo H, 2006, J BONE MINER RES, V21, pS123
   YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zayzafoon M, 2005, J BIOL CHEM, V280, P7049, DOI 10.1074/jbc.M412680200
   Zayzafoon M, 2004, J BIOL CHEM, V279, P3662, DOI 10.1074/jbc.M308158200
   Zayzafoon M, 2002, J BIOL CHEM, V277, P37212, DOI 10.1074/jbc.M200129200
   Zayzafoon M, 2000, J CELL BIOCHEM, V79, P301, DOI 10.1002/1097 4644(20001101)79:2<301::AID JCB130>3.0.CO;2 0
   Zhang W, 1996, J EXP MED, V183, P413, DOI 10.1084/jem.183.2.413
NR 66
TC 79
Z9 89
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2007
VL 40
IS 6
BP 1502
EP 1516
DI 10.1016/j.bone.2007.02.017
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 181FX
UT WOS:000247423600008
PM 17392048
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Dong, GC
   Ma, TY
   Li, CH
   Chi, CY
   Su, CM
   Huang, CL
   Wang, YH
   Lee, TM
AF Dong, Guo Chung
   Ma, Tzn Yuan
   Li, Chi Han
   Chi, Chih Ying
   Su, Chao Ming
   Huang, Chih Ling
   Wang, Yan Hsiung
   Lee, Tzer Ming
TI A study of Drynaria fortunei in modulation of BMP 2 signalling by
   bone tissue engineering
SO TURKISH JOURNAL OF MEDICAL SCIENCES
LA English
DT Article; Proceedings Paper
CT Taiwan Turkey Science Summit on Translation of Cells, Nanomaterials and
   Signaling Molecules into Regenerative Medicine
CY APR 01 03, 2018
CL Ankara, TURKEY
DE BMPR 1A; naringin; bone tissue engineering
ID CHINESE HERBAL MEDICINE; DIFFERENTIATION; OSTEOBLAST; NARINGIN; EXTRACT;
   CELLS; SM
AB Background/aim: Drynaria fortunei (Gusuibu; GSB) is a popular traditional Chinese medicine used for bone repair. An increasing number of studies have reported that GSB induces osteogenic differentiation in bone marrow mesenchymal stem cells (BMSCs). These results provide insight into the application of GSB for bone tissue engineering techniques used to repair large bone defects. However, few studies have described the molecular mechanisms of GSB.
   Materials and methods: In the present study, the effects of GSB and naringin, a marker compound, on the binding of BMP 2 to BMPR and BMP 2 derived signal transduction were investigated using surface plasmon resonance (SPR) and coculturing with BMPR expressed cell line, C 2 C 12, respectively. Furthermore, naringin was also used to prepare naringin contained scaffolds for bone tissue engineering. The physical and chemical properties of these scaffolds were analysed using scanning electron microscopy (SEM) and highperfonnance liquid chromatography (HPLC). These scaffolds were cocultured with rabbit BMSCs in vitro and implanted into rabbit calvarial defects for bone repair assessment.
   Results: The results showed that GSB and naringin affect the binding of BMP and BMPR in SPR experiments. GSB is a subtle BMP modulator that simultaneously inhibits the binding of BMP 2 to BM PR IA and enhances its binding to BM PR 1B. In contrast, naringin inhibited BMP 2 binding to BMPR 1A. In vitro studies involving the phosphorylation of signals downstream of BMPR and Smad showed that GSB and naringin affected stem cell differentiation by inhibiting BMPR 1A signalling. When using GSB for bone tissue engineering, naringin exhibited a higher capacity for slow and gradual release from the scaffold, which promotes bone formation via osteoinduction. Moreover, control and naringin scaffolds were implanted into rabbit calvarial defects for 4 weeks, and naringin enhanced bone regeneration in vivo significantly.
   Conclusion: GSB and its marker compound (naringin) could inhibit the binding of BMP 2 and BMPR 1A to control cell differentiation by blocked BMPR 1A signalling and enhanced BMPR 1B signalling. GSB and naringin could be good natural BMP regulators for bone tissue engineering.
C1 [Dong, Guo Chung; Ma, Tzn Yuan; Li, Chi Han; Chi, Chih Ying; Su, Chao Ming] Natl Hlth Res Inst, Inst Biomed Engn & Nanomed, Zhunan Township, Miaoli County, Taiwan.
   [Huang, Chih Ling] Kaohsiung Med Univ, Ctr Fundamental Sci, Kaohsiung, Taiwan.
   [Wang, Yan Hsiung; Lee, Tzer Ming] Kaohsiung Med Univ, Coll Dent Med, Sch Dent, Kaohsiung, Taiwan.
C3 National Health Research Institutes   Taiwan; Kaohsiung Medical
   University; Kaohsiung Medical University
RP Dong, GC (通讯作者)，Natl Hlth Res Inst, Inst Biomed Engn & Nanomed, Zhunan Township, Miaoli County, Taiwan.
EM gcdong@nhri.org.tw
RI ; Lee, Tzer Min/G 3713 2011; Wang, Yan Hsiung/ABD 4004 2020; Dong,
   Guo Chung/E 3950 2010
OI Su, Chao Ming/0000 0002 3463 287X; LEE, Tzer Min/0000 0002 1873 9685;
   Wang, Yan Hsiung/0000 0001 8161 7472; Dong,
   Guo Chung/0000 0003 1159 1718; Huang, Chih Ling/0000 0002 7323 4954
FU National Health Research Institutes, Taiwan [01A1 MEPP09 014]; Kaohsiung
   Medical University [KMU KI109004]
FX This project was financially supported through a grant from the National
   Health Research Institutes, Taiwan (01A1 MEPP09 014) and Kaohsiung
   Medical University (KMU KI109004). The authors would like to thank the
   Taiwan Mouse Clinic for assistance with the X ray imaging experiments.
CR Altundal H, 2005, TURK J MED SCI, V35, P209, DOI DOI 10.1520/M0N062013002304
   Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295
   Chen KY, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/283941
   Chen KY, 2013, J BIOMED MATER RES A, V101, P954, DOI 10.1002/jbm.a.34397
   Chen X, 2003, ANTIMICROB AGENTS CH, V47, P2810, DOI 10.1128/AAC.47.9.2810 2816.2003
   Ding Ye, 2009, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V17, P137
   Dokuyucu R, 2014, TURK J MED SCI, V44, P576, DOI 10.3906/sag 1307 100
   Gaoli Xu, 2017, Hua Xi Kou Qiang Yi Xue Za Zhi, V35, P275, DOI 10.7518/hxkq.2017.03.009
   Günay M, 2013, TURK J MED SCI, V43, P733, DOI 10.3906/sag 1209 44
   Guo WJ, 2019, MED SCI MONITOR, V25, P3133, DOI 10.12659/MSM.914568
   Lin FH, 2003, BIOMATERIALS, V24, P2413, DOI 10.1016/S0142 9612(03)00031 0
   Liu HC, 2001, J FORMOS MED ASSOC, V100, P383
   Liu YH, 2011, XENOBIOTICA, V41, P259, DOI 10.3109/00498254.2010.537395
   Lowery JW, 2015, J CELL SCI, V128, P1308, DOI 10.1242/jcs.156737
   Min Kim Sang, 2018, [The Journal of Pediatrics of Korean Medicine, 대한한방소아과학회지], V32, P30, DOI 10.7778/jpkm.2018.32.1.030
   Moseychuk O, 2013, J CELL COMMUN SIGNAL, V7, P265, DOI 10.1007/s12079 013 0199 1
   Mukwaya E, 2014, PHARM BIOL, V52, P1223, DOI 10.3109/13880209.2014.884606
   Peng Zhang, 2009, EUR J PHARMACOL, V607, P1, DOI 10.1016/j.ejphar.2009.01.035
   Shao R, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00412
   Singhuber J, 2012, PHYTOMEDICINE, V19, P334, DOI 10.1016/j.phymed.2011.10.009
   Siu WS, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/9795806
   Sun JS, 2003, BIOMATERIALS, V24, P873, DOI 10.1016/S0142 9612(02)00372 1
   Sun JS, 2002, BIOMATERIALS, V23, P3377, DOI 10.1016/S0142 9612(02)00038 8
   Wang LL, 2016, CURR PHARM DESIGN, V22, P328, DOI 10.2174/1381612822666151112145907
   Wang SQ, 2013, IERI PROC, V4, P2, DOI 10.1016/j.ieri.2013.11.002
   Wang W, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/518609
   Wang WL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131999
   Wang XL, 2013, J ORTHOP RES, V31, P164, DOI 10.1002/jor.22188
   Wei M, 2007, AM J CHINESE MED, V35, P663, DOI 10.1142/S0192415X07005156
   Wei ZZ, 2018, DESTECH TRANS ENVIR
   Wong RWK, 2006, J ORAL MAXIL SURG, V64, P770, DOI 10.1016/j.joms.2006.01.008
   Wu JB, 2008, EUR J PHARMACOL, V588, P333, DOI 10.1016/j.ejphar.2008.04.030
   Yang AF, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/5747298
   Yang BY, 2019, POLYMERS BASEL, V11, DOI 10.3390/polym11111745
   Yu GY, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7130653
   Zhu Yingxia, 2012, Zhongguo Zhong Yao Za Zhi, V37, P1152
NR 36
TC 12
Z9 16
U1 0
U2 17
PU Tubitak Scientific & Technological Research Council Turkey
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, TR 06100 ANKARA, TURKIYE
SN 1300 0144
EI 1303 6165
J9 TURK J MED SCI
JI Turk. J. Med. Sci.
PY 2020
VL 50
IS 5
BP 1444
EP 1453
DI 10.3906/sag 2001 148
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC General & Internal Medicine
GA NK1JN
UT WOS:000566495700035
PM 32252500
OA Green Published
DA 2025 08 17
ER

PT J
AU Li, MY
   Sun, J
   Zhao, D
   Zhang, W
   Xu, QA
AF Li, Mengya
   Sun, Jian
   Zhao, Dong
   Zhang, Wen
   Xu, Qingan
TI Inhibitory impact of a mesoporous silica nanoparticle based drug
   delivery system on Porphyromonas gingivalis induced bone
   resorption
SO JOURNAL OF MATERIALS SCIENCE MATERIALS IN MEDICINE
LA English
DT Article
ID IN VITRO; TETRACYCLINE HYDROCHLORIDE; ORAL BIOAVAILABILITY; MINERAL
   DENSITY; PORE SIZE; ISOLIQUIRITIGENIN; ANTIMICROBIALS; PREVENTS;
   CARRIERS
AB Controlling and reducing plaque formation plays a pivotal role in preventing and treating periodontal disease, often utilizing antibacterial drugs to enhance therapeutic outcomes. Mesoporous silica nanoparticles (MSN), an FDA approved inorganic nanomaterial, possess robust physical and chemical properties, such as adjustable pore size and pore capacity, easy surface modification, and high biosafety. Numerous studies have exploited MSN to regulate drug release and facilitate targeted delivery. This study aimed to synthesize an MSN tetracycline (MSN TC) complex and investigate its inhibitory potential on Porphyromonas gingivalis (P. gingivalis) induced bone resorption. The antibacterial efficacy of MSN TC was evaluated through bacterial culture experiments. A P. gingivalis induced bone resorption model was constructed by subcutaneously injecting P. gingivalis around the cranial bone of rats. Micro computed tomography was employed to assess the inhibitory impact of MSN and MSN TC on bone resorption. Furthermore, the influence of MSN and MSN TC on osteoclast differentiation was examined in vitro. The MSN exhibited optimal pore size and particle dimensions for effective loading and gradual release of TC. MSN TC demonstrated significant bacteriostatic activity against P. gingivalis. MSN TC treated rats showed significantly reduced cranial bone tissue destruction compared to MSN or TC treated rats. Additionally, both MSN and MSN TC exhibited inhibitory effects on the receptor activator of nuclear factor kappa Beta ligand mediated osteoclast differentiation. The MSN TC complex synthesized in this study demonstrated dual efficacy by exerting antibacterial effects on P. gingivalis and by resisting osteoclast differentiation, thereby mitigating bone resorption induced by P. gingivalis.
C1 [Li, Mengya; Zhang, Wen; Xu, Qingan] Jianghan Univ, Sch Med, Wuhan, Peoples R China.
   [Sun, Jian; Xu, Qingan] Wuhan First Stomatol Hosp, Dept Conservat Dent & Endodont, Wuhan, Peoples R China.
   [Zhao, Dong] Jianghan Univ, Sch Optoelect Mat & Technol, Wuhan, Peoples R China.
C3 Jianghan University; Jianghan University
RP Xu, QA (通讯作者)，Jianghan Univ, Sch Med, Wuhan, Peoples R China.; Xu, QA (通讯作者)，Wuhan First Stomatol Hosp, Dept Conservat Dent & Endodont, Wuhan, Peoples R China.
EM xuqingan1977@163.com
RI Zhang, Wen/HGC 1106 2022
FU Guiding Project of the Hubei Provincial Health and Wellness Committee
   [WJ2023F040]
FX This study was funded by the Guiding Project of the Hubei Provincial
   Health and Wellness Committee (Grant No. WJ2023F040)
CR Addy M, 2003, ORAL DIS, V9, P38, DOI 10.1034/j.1601 0825.9.s1.7.x
   Andrews JM, 2001, J ANTIMICROB CHEMOTH, V48, P5, DOI 10.1093/jac/48.suppl_1.5
   Beck GR, 2012, NANOMED NANOTECHNOL, V8, P793, DOI 10.1016/j.nano.2011.11.003
   Biswas N, 2017, EUR J PHARM SCI, V99, P152, DOI 10.1016/j.ejps.2016.12.015
   Butler KS, 2016, SMALL, V12, P2173, DOI 10.1002/smll.201502119
   Cai X, 2020, J PERIODONTAL RES, V55, P410, DOI 10.1111/jre.12725
   Chen L, 2019, WIRES NANOMED NANOBI, V11, DOI 10.1002/wnan.1573
   Chopra I, 2001, MICROBIOL MOL BIOL R, V65, P232, DOI 10.1128/MMBR.65.2.232 260.2001
   Franco GCN, 2011, EXP CELL RES, V317, P1454, DOI 10.1016/j.yexcr.2011.03.014
   Hashemikia S, 2015, J COLLOID INTERF SCI, V443, P105, DOI 10.1016/j.jcis.2014.11.020
   Herrera D, 2002, J CLIN PERIODONTOL, V29, P136, DOI 10.1034/j.1600 051X.29.s3.8.x
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Hu YC, 2011, J COLLOID INTERF SCI, V363, P410, DOI 10.1016/j.jcis.2011.07.022
   Jia LJ, 2013, INT J PHARMACEUT, V445, P12, DOI 10.1016/j.ijpharm.2013.01.058
   Jia LJ, 2012, INT J PHARMACEUT, V439, P81, DOI 10.1016/j.ijpharm.2012.10.011
   Jin SH, 2014, J SURG RES, V192, pE1, DOI 10.1016/j.jss.2014.08.054
   Jones DS, 2000, J CONTROL RELEASE, V67, P357, DOI 10.1016/S0168 3659(00)00231 5
   Juneja R, 2020, ACS APPL MATER INTER, V12, P38873, DOI 10.1021/acsami.0c07106
   Khademi Abbass Ali, 2015, Dent Res J (Isfahan), V12, P157
   Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38
   Koo H, 2013, J DENT RES, V92, P1065, DOI 10.1177/0022034513504218
   Li L, 2016, EUR J PHARMACOL, V777, P17, DOI 10.1016/j.ejphar.2016.02.057
   Li ZF, 2016, ARCH ORAL BIOL, V72, P146, DOI 10.1016/j.archoralbio.2016.08.029
   Li Z, 2019, EXPERT OPIN DRUG DEL, V16, P219, DOI 10.1080/17425247.2019.1575806
   Lin CX, 2009, MICROPOR MESOPOR MAT, V117, P213, DOI 10.1016/j.micromeso.2008.06.023
   Liu S, 2016, BIOCHEM PHARMACOL, V106, P82, DOI 10.1016/j.bcp.2016.03.002
   Lu MM, 2018, INT J NANOMED, V13, P7697, DOI 10.2147/IJN.S181168
   Magnusson C, 2021, J BIOMED MATER RES A, V109, P1967, DOI 10.1002/jbm.a.37189
   Miller CS, 2009, J AM DENT ASSOC, V140, P56, DOI 10.14219/jada.archive.2009.0018
   Nelson ML, 2011, Antimicrobial therapeutics reviews: antibiotics that target the ribosome
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Rajeshwari HR, 2019, J CONTROL RELEASE, V307, P393, DOI 10.1016/j.jconrel.2019.06.038
   Rakhshaei R, 2017, MAT SCI ENG C MATER, V73, P456, DOI 10.1016/j.msec.2016.12.097
   Ranjbar Mohammadi M, 2016, MAT SCI ENG C MATER, V58, P521, DOI 10.1016/j.msec.2015.08.066
   Rasool N, 2023, ACS BIOMATER SCI ENG, V9, P3535, DOI 10.1021/acsbiomaterials.3c00479
   Reddy NS, 2014, BBA GEN SUBJECTS, V1840, P2080, DOI 10.1016/j.bbagen.2014.02.007
   Rosan B, 2000, MICROBES INFECT, V2, P1599, DOI 10.1016/S1286 4579(00)01316 2
   Sanz M, 2020, J CLIN PERIODONTOL, V47, P4, DOI 10.1111/jcpe.13290
   Shen Yeqi, 2021, Zhejiang Da Xue Xue Bao Yi Xue Ban, V50, P162, DOI 10.3724/zdxbyxb 2021 0099
   Slots J, 2017, PERIODONTOL 2000, V75, P7, DOI 10.1111/prd.12221
   Song YX, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2019.109561
   Sun XY, 2019, THERANOSTICS, V9, P5183, DOI 10.7150/thno.33376
   Tevlin R., 2014, J Vis Exp, V93
   Thomas MJK, 2010, INT J PHARMACEUT, V387, P272, DOI 10.1016/j.ijpharm.2009.12.023
   Wang DD, 2018, INT J NANOMED, V13, P187, DOI 10.2147/IJN.S150610
   Wang XB, 2018, PHARM RES DORDR, V35, DOI 10.1007/s11095 018 2444 z
   Williams S, 1996, BONE, V19, P637, DOI 10.1016/S8756 3282(96)00302 X
   Wright J, 2013, MED CLIN N AM, V97, P667, DOI 10.1016/j.mcna.2013.02.006
   Xiao CJ, 2018, HEAD FACE MED, V14, DOI 10.1186/s13005 018 0169 1
   Yang J, 2020, THERANOSTICS, V10, P615, DOI 10.7150/thno.40066
   Yu X, 2017, J PERIODONTAL RES, V52, P1011, DOI 10.1111/jre.12472
   Zhang YZ, 2012, MOL PHARMACEUT, V9, P505, DOI 10.1021/mp200287c
   Zhou YX, 2018, ACTA PHARM SIN B, V8, P165, DOI 10.1016/j.apsb.2018.01.007
NR 54
TC 0
Z9 0
U1 4
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957 4530
EI 1573 4838
J9 J MATER SCI MATER M
JI J. Mater. Sci. Mater. Med.
PD SEP 30
PY 2024
VL 35
IS 1
AR 56
DI 10.1007/s10856 024 06827 6
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA H8G6T
UT WOS:001325773700002
PM 39347836
OA gold
DA 2025 08 17
ER

PT J
AU Paoletta, M
   Moretti, A
   Liguori, S
   Bertone, M
   Toro, G
   Iolascon, G
AF Paoletta, Marco
   Moretti, Antimo
   Liguori, Sara
   Bertone, Matteo
   Toro, Giuseppe
   Iolascon, Giovanni
TI Transient osteoporosis of the hip and subclinical hypothyroidism: an
   unusual dangerous duet? Case report and pathogenetic hypothesis
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Case report; Transient osteoporosis of the hip; Hypothyroidism;
   Diphosphonates; Rehabilitation
ID BONE MARROW EDEMA; PULSED ELECTROMAGNETIC FIELDS; SYNDROME TYPE I;
   TRANSITORY DEMINERALIZATION; BIOPHYSICAL STIMULATION; TRABECULAR BONE;
   CLODRONATE; BISPHOSPHONATES; PAIN; PREGNANCY
AB Background Transient osteoporosis of the hip (TOH) is a rare and temporary clinical condition characterised by bone marrow edema (BME), severe pain, and functional limitation. It commonly occurs in middle aged men or in women in the last trimester of pregnancy. TOH usually resolves with conservative therapy but may predispose to hip fracture or progression to avascular necrosis (AVN). Etiology is still unclear, although several pathophysiological mechanisms underpinning this condition has been proposed. We describe the management of an unusual case of TOH occurred in a patient with subclinical hypothyroidism. Case presentation A clinical case of a 46 year old man with severe pain in the left anterior thigh is presented. After a comprehensive clinical and radiological approach, a TOH was diagnosed. Moreover, biochemical assessment suggested the presence of subclinical hypothyroidism. After 3 months of treatment with clodronate, physical therapy and hormone replacement therapy (HRT) a significant improvement of clinical and radiological outcomes was observed. Conclusion Several pathological conditions have been related to development of TOH. In our case, we suggested for the first time a role of subclinical hypothyroidism as novel contributory factor for the onset of this condition, providing pathophysiological mechanisms and a scientific rationale for pharmacological treatment.
C1 [Paoletta, Marco; Moretti, Antimo; Liguori, Sara; Bertone, Matteo; Toro, Giuseppe; Iolascon, Giovanni] Univ Campania Luigi Vanvitelli, Dept Med & Surg Specialties & Dent, Via De Crecchio 4, I 80138 Naples, Italy.
C3 Universita della Campania Vanvitelli
RP Moretti, A (通讯作者)，Univ Campania Luigi Vanvitelli, Dept Med & Surg Specialties & Dent, Via De Crecchio 4, I 80138 Naples, Italy.
EM antimo.moretti@unicampania.it
RI ; Iolascon, Giovanni/T 6220 2017; Paoletta, Marco/KHT 2720 2024;
   Moretti, Antimo/T 8571 2017; Toro, Giuseppe/AAE 3721 2020
OI Toro, Giuseppe/0000 0002 8560 721X; Iolascon,
   Giovanni/0000 0002 0976 925X; Moretti, Antimo/0000 0002 4598 2891;
   liguori, sara/0000 0002 8707 2482; Paoletta, Marco/0000 0002 3291 9738;
   Bertone, Matteo/0000 0001 9221 1355; 
FU Vanvitelli per la Ricerca (VALERE) program
FX The authors would like to acknowledge the Vanvitelli per la Ricerca
   (VALERE) program for the allocation of funding that aims to publish
   University of Campania "Luigi Vanvitelli" research products.
CR Abe Y, 2015, J BONE MINER METAB, V33, P125, DOI 10.1007/s00774 014 0574 x
   Albright F, 1938, J BONE JOINT SURG, V20, P764
   Arnstein RA, 1972, ORTHOP CLIN N AM, V3, P585
   Asadipooya K, 2017, OSTEOPOROSIS INT, V28, P1805, DOI 10.1007/s00198 017 3952 0
   AXELROD AR, 1951, BLOOD, V6, P436, DOI 10.1182/blood.V6.5.436.436
   Bonabello A, 2001, PAIN, V91, P269, DOI 10.1016/S0304 3959(00)00447 4
   BRAY ST, 1979, J NUCL MED, V20, P1268
   CURTISS PH, 1959, J BONE JOINT SURG AM, V41, P1327, DOI 10.2106/00004623 195941070 00014
   Emad Y, 2012, CLIN RHEUMATOL, V31, P1641, DOI 10.1007/s10067 012 2060 y
   ERIKSEN EF, 1986, ENDOCR REV, V7, P379, DOI 10.1210/edrv 7 4 379
   ERIKSEN EF, 1986, BONE, V7, P101, DOI 10.1016/8756 3282(86)90681 2
   Eriksen EF, 2012, RHEUMATOL INT, V32, P575, DOI 10.1007/s00296 011 2141 2
   Frediani B, 2018, MINERVA MED, V109, P300, DOI 10.23736/S0026 4806.18.05688 4
   Frediani B, 2015, CLIN CASES MINER BON, V12, P97, DOI 10.11138/ccmbm/2015.12.2.097
   FROST HM, 1992, BONE MINER, V19, P257, DOI 10.1016/0169 6009(92)90875 E
   Gaus K, 2003, HIROSHIMA J MED SCI, V52, P43
   Ghinoi Valentina, 2002, Expert Opin Pharmacother, V3, P1643, DOI 10.1517/14656566.3.11.1643
   Guardiano SA, 2004, JCR J CLIN RHEUMATOL, V10, P269, DOI 10.1097/01.rhu.0000141509.18395.3c
   HOFMANN S, 1993, J BONE JOINT SURG BR, V75, P210, DOI 10.1302/0301 620X.75B2.8444939
   Ji QH, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014812
   Klontzas ME, 2017, HIP INT, V27, P329, DOI 10.5301/hipint.5000527
   Klontzas ME, 2015, AM J ROENTGENOL, V205, P353, DOI 10.2214/AJR.14.13689
   Klontzas ME, 2015, EUR J RADIOL, V84, P431, DOI 10.1016/j.ejrad.2014.11.022
   Kon E, 2016, KNEE SURG SPORT TR A, V24, P1797, DOI 10.1007/s00167 016 4113 2
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Leo M, 2009, INDIAN J ORTHOP, V43, P17, DOI 10.4103/0019 5413.45319
   Makkonen N, 1999, EUR J PHARM SCI, V8, P109, DOI 10.1016/S0928 0987(98)00065 7
   Martinelli N, 2015, J AM PODIAT MED ASSN, V105, P27, DOI 10.7547/8750 7315 105.1.27
   Massari L, 2006, J BONE JOINT SURG AM, V88A, P56, DOI 10.2106/JBJS.F.00536
   MCLEAN RM, 1995, SEMIN ARTHRITIS RHEU, V24, P282, DOI 10.1016/S0049 0172(95)80038 7
   Mepani JB, 2009, J CLIN ENDOCR METAB, V94, P1068, DOI 10.1210/jc.2008 1523
   Moriyama Y, 2018, TRENDS PHARMACOL SCI, V39, P13, DOI 10.1016/j.tips.2017.10.007
   MOSEKILDE L, 1990, ENDOCRIN METAB CLIN, V19, P35, DOI 10.1016/S0889 8529(18)30338 4
   O'Sullivan SM, 2006, OSTEOPOROSIS INT, V17, P1008, DOI 10.1007/s00198 006 0112 3
   Ohtori S, 2010, J CLIN NEUROSCI, V17, P209, DOI 10.1016/j.jocn.2009.06.013
   Pagani S, 2017, PAIN PHYSICIAN, V20, pE806
   Patel S, 2014, RHEUMATOLOGY, V53, P785, DOI 10.1093/rheumatology/ket324
   Righetti M, 2018, JOINT BONE SPINE, V85, P365, DOI 10.1016/j.jbspin.2017.12.001
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   ROSEN RA, 1970, RADIOLOGY, V94, P509, DOI 10.1148/94.3.509
   Schapira D, 2003, CLIN EXP RHEUMATOL, V21, P107
   Shima K, 2016, BIOL PHARM BULL, V39, P770, DOI 10.1248/bpb.b15 00882
   Trevisan C, 2002, CLIN RHEUMATOL, V21, P418, DOI 10.1007/s100670200112
   Van Offel JF, 2001, CLIN EXP RHEUMATOL, V19, P13
   Varenna M, 1996, CLIN RHEUMATOL, V15, P169, DOI 10.1007/BF02230335
   Varenna M, 2000, J RHEUMATOL, V27, P1477
   Varenna M, 2014, CLIN EXP RHEUMATOL, V32, P451
   WEISSBEIN AS, 1959, ARCH INTERN MED, V104, P643, DOI 10.1001/archinte.1959.00270100129023
   Zanetti M, 2000, RADIOLOGY, V215, P835, DOI 10.1148/radiology.215.3.r00jn05835
NR 49
TC 12
Z9 13
U1 2
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD AUG 13
PY 2020
VL 21
IS 1
AR 543
DI 10.1186/s12891 020 03574 x
PG 6
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA NF6TV
UT WOS:000563429300001
PM 32791961
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lindström, E
   Rizoska, B
   Henderson, I
   Terelius, Y
   Jerling, M
   Edenius, C
   Grabowska, U
AF Lindstrom, Erik
   Rizoska, Biljana
   Henderson, Ian
   Terelius, Ylva
   Jerling, Markus
   Edenius, Charlotte
   Grabowska, Urszula
TI Nonclinical and clinical pharmacological characterization of the potent
   and selective cathepsin K inhibitor MIV 711
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Cathepsin K; Osteoarthritis; CTX I; NTX I; CTX II; Subchondral bone;
   Cartilage
ID BONE TURNOVER; KNEE OSTEOARTHRITIS; POSTMENOPAUSAL OSTEOPOROSIS;
   BIOCHEMICAL MARKERS; CONTROLLED TRIAL; DOUBLE BLIND; COLLAGEN;
   EXPRESSION; BIOMARKERS; CARTILAGE
AB Background: Cathepsin K is an attractive therapeutic target for diseases in which bone resorption is excessive such as osteoporosis and osteoarthritis (OA). The current paper characterized the pharmacological profile of the potent and selective cathepsin K inhibitor, MIV 711, in vitro and in cynomolgus monkeys, and assessed translation to human based on a single dose clinical study in man.
   Methods: The potency and selectivity of MIV 711 were assessed in vitro using recombinant enzyme assays and differentiated human osteoclasts. MIV 711 was administered to healthy cynomolgus monkeys (3 30 mu mol/kg, p.o.). Plasma levels of MIV 711 and the bone resorption biomarker CTX I were measured after single dose experiments, and urine levels of CTX I, NTX I and CTX II biomarkers were measured after repeat dose experiments. The safety, pharmacokinetics and pharmacodynamics (serum CTX I) of MIV 711 were assessed in human healthy subjects after single ascending doses from 20 to 600 mg.
   Results: MIV 711 was a potent inhibitor of human cathepsin K (K i: 0.98 nmol/L) with > 1300 fold selectivity towards other human cathepsins. MIV 711 inhibited human osteoclast mediated bone resorption with an IC50 value of 43 nmol/L. Single oral doses of MIV 711 to monkeys reduced plasma levels of CTX I in a dose dependent fashion by up to 57% at trough. The effect on CTX I was linearly correlated to the plasma exposure of MIV 711, while the efficacy duration outlasted plasma exposure. Repeat oral dosing with MIV 711 also reduced urinary levels of the bone resorption biomarkers CTX I (by 93%) and NTX I (by 71%) and the cartilage degradation biomarker CTX II (by 71%). MIV 711 was safe and well tolerated when given as single ascending doses to healthy subjects. MIV 711 reduced serum CTX I levels in a dose dependent manner by up to 79% at trough. The relationship between MIV 711 exposure and effects on these biomarkers in humans was virtually identical when compared to the corresponding monkey data.
   Conclusions: MIV 711 is a potent and selective cathepsin K inhibitor with dose dependent effects on biomarkers of bone and cartilage degradation in monkey and human. Taken together, MIV 711 shows promise for the treatment of bone and cartilage related disorders in humans, such as OA.
C1 [Lindstrom, Erik; Rizoska, Biljana; Henderson, Ian; Terelius, Ylva; Jerling, Markus; Edenius, Charlotte; Grabowska, Urszula] Medivir AB, Box 1086, S 14122 Huddinge, Sweden.
C3 Medivir
RP Rizoska, B (通讯作者)，Medivir AB, Box 1086, S 14122 Huddinge, Sweden.
EM miv711@medivir.com
CR Atley LM, 2000, BONE, V26, P241, DOI 10.1016/S8756 3282(99)00270 7
   Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Chapurlat R, 2016, JOINT BONE SPINE, V83, P254, DOI 10.1016/j.jbspin.2015.09.008
   Conaghan PG, 2017, AM COLL RHEUM ANN M
   Connor JR, 2009, OSTEOARTHR CARTILAGE, V17, P1236, DOI 10.1016/j.joca.2009.03.015
   Dejica VM, 2008, AM J PATHOL, V173, P161, DOI 10.2353/ajpath.2008.070494
   Dodds RA, 1999, ARTHRITIS RHEUM, V42, P1588, DOI 10.1002/1529 0131(199908)42:8<1588::AID ANR4>3.0.CO;2 S
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Eastell R, 2014, J BONE MINER RES, V29, P458, DOI 10.1002/jbmr.2047
   Eastell R, 2011, J BONE MINER RES, V26, P1303, DOI 10.1002/jbmr.341
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Falgueyret JP, 2005, J MED CHEM, V48, P7535, DOI 10.1021/jm0504961
   Fuller K, 2010, BONE, V46, P1400, DOI 10.1016/j.bone.2010.01.374
   Garnero P, 2003, J BONE MINER RES, V18, P859, DOI 10.1359/jbmr.2003.18.5.859
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Grabowska U, 2014, BONE ABSTRACTS, V3, P6
   Grabowska U, 2013, J BONE MINER RES, V28
   Hayami T, 2012, BONE, V50, P1250, DOI 10.1016/j.bone.2012.03.025
   Herrero Beaumont G, 2013, NAT REV RHEUMATOL, V9, P448, DOI 10.1038/nrrheum.2013.113
   Hou WS, 2002, ARTHRITIS RHEUM, V46, P663, DOI 10.1002/art.10114
   Jerome C, 2011, OSTEOPOROSIS INT, V22, P3001, DOI 10.1007/s00198 011 1529 x
   Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727
   Karsdal MA, 2014, ANN RHEUM DIS, V73, P336, DOI 10.1136/annrheumdis 2013 204111
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kraus VB, 2011, OSTEOARTHR CARTILAGE, V19, P515, DOI 10.1016/j.joca.2010.08.019
   Kraus VB, 2017, ANN RHEUM DIS, V76, P186, DOI 10.1136/annrheumdis 2016 209252
   Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015
   Lindström E, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 018 1425 7
   Manicourt DH, 2006, ARTHRITIS RHEUM, V54, P3205, DOI 10.1002/art.22075
   Masarachia PJ, 2012, J BONE MINER RES, V27, P509, DOI 10.1002/jbmr.1475
   McDougall JJ, 2010, OSTEOARTHR CARTILAGE, V18, P1355, DOI 10.1016/j.joca.2010.07.014
   McQueney MS, 1998, PROTEIN EXPRES PURIF, V14, P387, DOI 10.1006/prep.1998.0965
   MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201
   Nagase S, 2012, J CLIN PHARMACOL, V52, P306, DOI 10.1177/0091270011399080
   Ochi Y, 2011, BONE, V49, P1351, DOI 10.1016/j.bone.2011.09.041
   Oestergaard S, 2006, OSTEOARTHR CARTILAGE, V14, P670, DOI 10.1016/j.joca.2006.01.004
   Pennypacker BL, 2014, J BONE MINER RES, V29, P1847, DOI 10.1002/jbmr.2211
   Qvist P, 2002, BONE, V31, P57, DOI 10.1016/S8756 3282(02)00791 3
   Reginster JY, 2013, ANN RHEUM DIS, V72, P179, DOI 10.1136/annrheumdis 2012 202231
   Rünger TM, 2012, J AM ACAD DERMATOL, V66, pE89, DOI 10.1016/j.jaad.2010.11.033
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Spector TD, 2005, ARTHRITIS RES THER, V7, pR625, DOI 10.1186/ar1716
   Stoch SA, 2009, CLIN PHARMACOL THER, V86, P175, DOI 10.1038/clpt.2009.60
   Stoch SA, 2013, BRIT J CLIN PHARMACO, V75, P1240, DOI 10.1111/j.1365 2125.2012.04471.x
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Wijkmans J, 2011, EXPERT OPIN THER PAT, V21, P1611, DOI 10.1517/13543776.2011.616283
NR 47
TC 30
Z9 33
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1479 5876
J9 J TRANSL MED
JI J. Transl. Med.
PD MAY 9
PY 2018
VL 16
AR 125
DI 10.1186/s12967 018 1497 4
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GF9KF
UT WOS:000432294900003
PM 29743078
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lin, YS
   Park, J
   De Schutter, JW
   Huang, XF
   Berghuis, AM
   Sebag, M
   Tsantrizos, YS
AF Lin, Yih Shyan
   Park, Jaeok
   De Schutter, Joris W.
   Huang, Xian Fang
   Berghuis, Albert M.
   Sebag, Michael
   Tsantrizos, Youla S.
TI Design and Synthesis of Active Site Inhibitors of the Human Farnesyl
   Pyrophosphate Synthase: Apoptosis and Inhibition of ERK Phosphorylation
   in Multiple Myeloma Cells
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID NITROGEN CONTAINING BISPHOSPHONATES; TIME DEPENDENT INHIBITION;
   DIPHOSPHATE SYNTHASE; IN VIVO; BIOLOGICAL EVALUATION; ACCURATE DOCKING;
   X RAY; ANALOGS; GLIDE; MODEL
AB Human farnesyl pyrophosphate synthase (hFPPS) controls intracellular levels of FPP and post translational prenylation of small GTPase proteins, which are essential for cell signaling and cell proliferation. Clinical investigations provide evidence that N BP inhibitors of hFPPS are disease modifying agents that improve survival of multiple myeloma (MM) patients via mechanisms unrelated to their skeletal effects. A new series of N BPs was designed that interact with a larger portion of the GPP subpocket, as compared to the current therapeutic drugs, and rigidify the (KRRK367) K 364 tail of hFPPS in the closed conformation in the absence of IPP. An analogue of this series was used to demonstrate inhibition of the intended biological target, resulting in apoptosis and down regulation of ERK phosphorylation in human MM cell lines.
C1 [Park, Jaeok; Berghuis, Albert M.; Tsantrizos, Youla S.] McGill Univ, Dept Biochem, Montreal, PQ H3G 0B1, Canada.
   [Lin, Yih Shyan; De Schutter, Joris W.; Tsantrizos, Youla S.] McGill Univ, Dept Chem, Montreal, PQ H3A 0B8, Canada.
   [Huang, Xian Fang; Sebag, Michael] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Haematol, Montreal, PQ H3A 1A1, Canada.
C3 McGill University; McGill University; McGill University; Royal Victoria
   Hospital
RP Tsantrizos, YS (通讯作者)，McGill Univ, Dept Biochem, 3649 Promenade Sir William Osler, Montreal, PQ H3G 0B1, Canada.
EM Youla.tsantrizos@mcgill.ca
RI Berghuis, Albert/A 6495 2008; Park, Jaeok/U 6904 2019
OI Berghuis, Albert/0000 0002 2663 025X; Park, Jaeok/0000 0002 8180 3950
FU Natural Sciences and Engineering Research Council of Canada (NSERC);
   Canada Foundation for Innovation (CFI); Quebec ministere de la recherche
   en science et technologie (FQRNT); McGill University; NSERC; FQRNT
FX We are grateful to Dr. Tara Sprules for assistance with the setup of the
   <SUP>1</SUP>H NMR line broadening experiments, which were acquired on a
   500 MHz NMR instrument at the Quebec/Eastern Canada High Field NMR
   Facility, supported by the Natural Sciences and Engineering Research
   Council of Canada (NSERC), the Canada Foundation for Innovation (CFI),
   the Quebec ministere de la recherche en science et technologie (FQRNT),
   and McGill University. Financial support for this work was provided by
   McGill University, NSERC and FQRNT (to Y.S.T.). We also thank the
   Canadian Institute of Health Research (CIHR; to Y. S.L. and J.W.D.S.),
   the Ministry of Education of Taiwan (to Y. S.L.), and the Groupe de
   Recherche Axe sur la Structure des Proteines (GRASP; to J.W.D.S.).
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151
   Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837
   De Schutter JW, 2010, BIOORG MED CHEM LETT, V20, P5781, DOI 10.1016/j.bmcl.2010.07.133
   Dunford JE, 2010, CURR PHARM DESIGN, V16, P2961
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Ezra A, 2000, J MED CHEM, V43, P3641, DOI 10.1021/jm980645y
   Fleckenstein CA, 2008, CHEM EUR J, V14, P4267, DOI 10.1002/chem.200701877
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Guram AS, 2007, J ORG CHEM, V72, P5104, DOI 10.1021/jo070341w
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Heim R, 2008, J MED CHEM, V51, P5064, DOI 10.1021/jm800377h
   Jahnke W, 2010, NAT CHEM BIOL, V6, P660, DOI [10.1038/NCHEMBIO.421, 10.1038/nchembio.421]
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kavanagh KL, 2006, J BIOL CHEM, V281, P22004, DOI 10.1074/jbc.M602603200
   Lolli ML, 2010, BIOORGAN MED CHEM, V18, P2428, DOI 10.1016/j.bmc.2010.02.058
   Marma MS, 2007, J MED CHEM, V50, P5967, DOI 10.1021/jm0702884
   Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404
   Matczak Jon E, 2006, J MOL STRUCT, V782, P81, DOI 10.1016/j.molstruc.2005.07.004
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Mitrofan LM, 2009, BONE, V45, P1153, DOI 10.1016/j.bone.2009.08.010
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Morita CT, 2007, IMMUNOL REV, V215, P59, DOI 10.1111/j.1600 065X.2006.00479.x
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076 6879(97)76066 X
   Räikkönen J, 2011, BIOCHEM BIOPH RES CO, V407, P663, DOI 10.1016/j.bbrc.2011.03.070
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Shmeeda H, 2010, J CONTROL RELEASE, V146, P76, DOI 10.1016/j.jconrel.2010.04.028
   Simoni D, 2008, J MED CHEM, V51, P6800, DOI 10.1021/jm801003y
   SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044
   Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018
   Vagin AA, 2004, ACTA CRYSTALLOGR D, V60, P2184, DOI 10.1107/S0907444904023510
   Wasko BM, 2011, J LIPID RES, V52, P1957, DOI 10.1194/jlr.M016089
   Wiemer AJ, 2007, BIOCHEM BIOPH RES CO, V353, P921, DOI 10.1016/j.bbrc.2006.12.094
   Zhang Y, 2006, J MED CHEM, V49, P5804, DOI 10.1021/jm060280e
   Zhang YH, 2010, ANGEW CHEM INT EDIT, V49, P1136, DOI 10.1002/anie.200905933
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 40
TC 48
Z9 55
U1 1
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD APR 12
PY 2012
VL 55
IS 7
BP 3201
EP 3215
DI 10.1021/jm201657x
PG 15
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 923AT
UT WOS:000302591100030
PM 22390415
DA 2025 08 17
ER

PT J
AU Ghosh, M
   Gupta, PK
   Jena, S
   Rana, S
AF Ghosh, Manaswini
   Gupta, Pulkit Kr.
   Jena, Shobhan
   Rana, Soumendra
TI The interaction of methotrexate with the human C5a and its potential
   therapeutic implications
SO COMPUTATIONAL BIOLOGY AND CHEMISTRY
LA English
DT Article
DE C5a; Methotrexate; Inflammation; Receptors; Drug repurposing; Molecular
   dynamics
ID DIHYDROFOLATE REDUCTASE; RHEUMATOID ARTHRITIS; DOSE METHOTREXATE; ADULT
   PATIENTS; DRUG; MECHANISM; TERMINUS; VARIANTS; DYNAMICS; COMPLEX
AB Methotrexate (MTX) is an antimetabolite drug that mimics folate and inhibits dihydrofolic acid reductase, resulting in the impairment of malignant growth in actively proliferating tissues. MTX is approved by the FDA for primarily treating non Hodgkin lymphoma, lymphoblastic leukemia, and osteosarcoma. In addition, MTX is also prescribed as a preferred anti rheumatic medication for the management of rheumatoid arthritis, including psoriasis, indicating that MTX has a multipronged mechanism of action. MTX is also known to exert antiinflammatory effects, and interestingly, the role of C5a, a pro inflammatory glycoprotein of the complement system, is well established in several chronic inflammatory diseases, including rheumatoid arthritis and psoriasis, through the recruitment of C5a receptors (C5aR1/C5aR2) expressed in both immune and non immune cells. Notably, through drug repurposing studies, we have earlier shown that non steroidal anti inflammatory drugs (NSAIDS) can potentially neutralize the function of C5a. Though MTX binds to serum albumin and can affect the immune system, whether its interaction with C5a could be therapeutically beneficial due to the downregulation of both extracellular and intracellular signaling of C5a is not yet established in the literature. In the current study, we have hypothesized and provided preliminary evidence through computational studies that MTX can strongly bind to the hotspot regions on C5a involved in the interactions with its receptors, which is likely to alter the downstream signaling of C5a and contribute to the overall therapeutic efficacy of MTX.
C1 [Ghosh, Manaswini; Gupta, Pulkit Kr.; Jena, Shobhan; Rana, Soumendra] Indian Inst Technol, Sch Basic Sci, Chem Biol Lab, Bhubaneswar 752050, Odisha, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Bhubaneswar
RP Rana, S (通讯作者)，Indian Inst Technol, Sch Basic Sci, Chem Biol Lab, Bhubaneswar 752050, Odisha, India.
EM soumendra@iitbbs.ac.in
RI ; Rana, Soumendra/MDT 8928 2025
OI Gupta, Pulkit Kumar/0009 0002 7940 5088; Rana,
   Soumendra/0000 0003 4878 9066; 
FU UGC, New Delhi
FX The usage of computational facility of CDAC, Pune is highly
   acknowledged. PKG acknowledges the receipt of the fellowship from UGC,
   New Delhi.
CR [Anonymous], 2023, Med Lett Drugs Ther, V65, P86, DOI 10.58347/tml.2023.1677d
   [Anonymous], 2007, Happy accidents: Serendipity in modern medical breakthroughs
   Barrett CD, 2018, CLIN EXP IMMUNOL, V194, P103, DOI 10.1111/cei.13166
   Bedoui Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205023
   Bugnon M, 2023, J CHEM INF MODEL, V63, P6469, DOI 10.1021/acs.jcim.3c01053
   Carvelli J, 2020, NATURE, V588, P146, DOI 10.1038/s41586 020 2600 6
   CAYLEY PJ, 1981, BIOCHEMISTRY US, V20, P874, DOI 10.1021/bi00507a034
   Chan ESL, 2010, NAT REV RHEUMATOL, V6, P175, DOI 10.1038/nrrheum.2010.5
   Chen J, 2024, PLOS ONE, V19, DOI 10.1371/journal.pone.0301701
   Cipriani P, 2014, EXPERT REV CLIN IMMU, V10, P1519, DOI 10.1586/1744666X.2014.962996
   Cody V, 2005, ACTA CRYSTALLOGR D, V61, P147, DOI 10.1107/S0907444904030422
   Comandone A, 2005, ACTA ONCOL, V44, P406, DOI 10.1080/02841860510029770
   Cronstein BN, 2020, NAT REV RHEUMATOL, V16, P145, DOI 10.1038/s41584 020 0373 9
   Czarnecka Operacz M, 2014, POSTEP DERM ALERGOL, V31, P392, DOI 10.5114/pdia.2014.47121
   Das A, 2022, J CELL BIOCHEM, V123, P1841, DOI 10.1002/jcb.30320
   Das A, 2021, COMPUT BIOL CHEM, V92, DOI 10.1016/j.compbiolchem.2021.107482
   Ding PP, 2022, CELL REP, V39, DOI 10.1016/j.celrep.2022.110851
   Dmytrijuk A, 2008, ONCOLOGIST, V13, P993, DOI 10.1634/theoncologist.2008 0086
   Komi DEA, 2020, ALLERGY, V75, P2818, DOI 10.1111/all.14413
   FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301
   Feng YY, 2023, CELL RES, V33, P312, DOI 10.1038/s41422 023 00779 2
   Genestier L, 2000, IMMUNOPHARMACOLOGY, V47, P247, DOI 10.1016/S0162 3109(00)00189 2
   Ghosh M, 2024, PROTEINS, V92, P449, DOI 10.1002/prot.26637
   Ghosh M, 2023, INT IMMUNOPHARMACOL, V118, DOI 10.1016/j.intimp.2023.110081
   Gray O., 2004, Cochrane Database Syst Rev
   Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835
   Guo Z, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27184 w
   Gupta PK, 2025, J BIOMOL STRUCT DYN, V43, P4885, DOI 10.1080/07391102.2024.2305698
   Gupta PK, 2024, J BIOMOL STRUCT DYN, V42, P7190, DOI 10.1080/07391102.2023.2239927
   HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148
   He Y, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00828 5
   Herfarth HH, 2016, INFLAMM BOWEL DIS, V22, P224, DOI 10.1097/MIB.0000000000000589
   Herman S, 2005, INFLAMM RES, V54, P273, DOI 10.1007/s00011 005 1355 8
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hobl EL, 2011, CLIN EXP RHEUMATOL, V29, P963
   Hobl EL, 2012, CLIN THER, V34, P1195, DOI 10.1016/j.clinthera.2012.03.059
   Honorato RV, 2024, NAT PROTOC, V19, DOI 10.1038/s41596 024 01011 0
   Honorato RV, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.729513
   Hsu NY, 2012, INDOOR AIR, V22, P186, DOI 10.1111/j.1600 0668.2011.00753.x
   Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354
   Huff S, 2022, J MED CHEM, V65, P10920, DOI 10.1021/acs.jmedchem.1c02075
   Kolev M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.931273
   Lawrence MC, 2008, CELL RES, V18, P436, DOI 10.1038/cr.2008.37
   Lee A, 2022, DRUGS, V82, P79, DOI 10.1007/s40265 021 01643 6
   Lee H, 2008, IMMUNOL CELL BIOL, V86, P153, DOI 10.1038/sj.icb.7100166
   Liu H, 2018, NAT STRUCT MOL BIOL, V25, P472, DOI 10.1038/s41594 018 0067 z
   Mahmudpour M, 2020, CYTOKINE, V133, DOI 10.1016/j.cyto.2020.155151
   Manna MS, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 23191 z
   Markiewski MM, 2008, NAT IMMUNOL, V9, P1225, DOI 10.1038/ni.1655
   Mishra R, 2021, J BIOMOL STRUCT DYN, V39, P1766, DOI 10.1080/07391102.2020.1738958
   Mishra R, 2019, BIOORGAN MED CHEM, V27, DOI 10.1016/j.bmc.2019.115052
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   O'Brien RM, 2023, BRIT J CANCER, V128, P165, DOI 10.1038/s41416 022 02116 7
   Pettersen EF, 2021, PROTEIN SCI, V30, P70, DOI 10.1002/pro.3943
   Polshakov VI, 1999, PROTEIN SCI, V8, P467
   Portilla D, 2021, BRIT J PHARMACOL, V178, P2880, DOI 10.1111/bph.15408
   Pouw RB, 2021, SEMIN IMMUNOPATHOL, V43, P757, DOI 10.1007/s00281 021 00892 7
   Prescott JA, 2021, BIOCHEM J, V478, P2619, DOI 10.1042/BCJ20210139
   Rajagopalan PTR, 2002, P NATL ACAD SCI USA, V99, P13481, DOI 10.1073/pnas.172501499
   Rana S, 2016, J BIOMOL STRUCT DYN, V34, P1201, DOI 10.1080/07391102.2015.1073634
   Rana S, 2016, MOL BIOSYST, V12, P1586, DOI 10.1039/c6mb00031b
   Rana S, 2010, J BIOL CHEM, V285, P31472, DOI 10.1074/jbc.M110.129213
   Rosanò L, 2019, INT REV CEL MOL BIO, V346, P129, DOI 10.1016/bs.ircmb.2019.03.002
   ROTHENBERG RJ, 1988, ARTHRITIS RHEUM US, V31, P612, DOI 10.1002/art.1780310505
   Sahoo AR, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21290 4
   Sawaya MR, 1997, BIOCHEMISTRY US, V36, P586, DOI 10.1021/bi962337c
   Secker E, 2009, INT J HUM RIGHTS, V13, P697, DOI 10.1080/13642980802533190
   SEEGER DR, 1949, J AM CHEM SOC, V71, P1753, DOI 10.1021/ja01173a061
   Socié G, 2019, BRIT J HAEMATOL, V185, P297, DOI 10.1111/bjh.15790
   Sokka T, 2002, J RHEUMATOL, V29, P2521
   STEELE WH, 1981, CANCER CHEMOTH PHARM, V7, P61
   TERNOWITZ T, 1987, J INVEST DERMATOL, V89, P192, DOI 10.1111/1523 1747.ep12470559
   Toksvang LN, 2022, LEUKEMIA, V36, P1749, DOI 10.1038/s41375 022 01591 4
   Usman AR, 1996, J RHEUMATOL, V23, P1095
   Valdés Tresanco MS, 2021, J CHEM THEORY COMPUT, V17, P6281, DOI 10.1021/acs.jctc.1c00645
   Wang Y, 2009, BIOL BLOOD MARROW TR, V15, P505, DOI 10.1016/j.bbmt.2008.12.493
   Wang Y, 2023, NAT CHEM BIOL, V19, P1351, DOI 10.1038/s41589 023 01339 w
   West EE, 2023, NAT REV NEPHROL, V19, P426, DOI 10.1038/s41581 023 00704 1
   Xu H, 2015, MOL MED REP, V11, P489, DOI 10.3892/mmr.2014.2767
   Zhang XL, 1997, PROTEINS, V28, P261, DOI 10.1002/(SICI)1097 0134(199706)28:2<261::AID PROT13>3.0.CO;2 G
   Zhao ZX, 2022, BIOMED PHARMACOTHER, V150, DOI 10.1016/j.biopha.2022.113074
NR 81
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1476 9271
EI 1476 928X
J9 COMPUT BIOL CHEM
JI Comput. Biol. Chem.
PD FEB
PY 2025
VL 114
AR 108283
DI 10.1016/j.compbiolchem.2024.108283
EA NOV 2024
PG 9
WC Biology; Computer Science, Interdisciplinary Applications
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Computer Science
GA N3W1A
UT WOS:001363670300001
PM 39579472
DA 2025 08 17
ER

PT J
AU Ahluwalia, A
   Hoa, N
   Ge, LS
   Blumberg, B
   Levin, ER
AF Ahluwalia, Amrita
   Hoa, Neil
   Ge, Lisheng
   Blumberg, Bruce
   Levin, Ellis R.
TI Mechanisms by Which Membrane and Nuclear ER Alpha Inhibit Adipogenesis
   in Cells Isolated From Female Mice
SO ENDOCRINOLOGY
LA English
DT Article
DE estrogen receptor; stem cells; adipogenesis; co repressors; signal
   transduction
ID ESTROGEN RECEPTOR ALPHA; BODY FAT DISTRIBUTION; ADIPOSE TISSUE;
   PPAR GAMMA; OSTEOBLAST DIFFERENTIATION; REPLACEMENT THERAPY; BETA;
   PHOSPHORYLATION; BONE; GENE
AB Mesenchymal stem cells can differentiate into mature chondrocytes, osteoblasts, and adipocytes. Excessive and dysfunctional visceral adipocytes increase upon menopause and importantly contribute to altered metabolism in postmenopausal women. We previously showed both plasma membrane and nuclear estrogen receptors alpha (ER alpha) with endogenous estrogen are required to suppress adipogenesis in vivo. Here we determined mechanisms by which these liganded ER pools collaborate to inhibit the peroxisome proliferator activated gamma (PPAR gamma) gene and subsequent progenitor differentiation. In 3T3 L1 pre adipocytes and adipose derived stem cells (ADSC), membrane ER alpha signaled through phosphatidylinositol 3 kinase (PI3K) protein kinase B (AKT) to enhance ER alpha nuclear localization, importantly at the PPAR gamma gene promoter. AKT also increased overall abundance and recruitment of co repressors GATA3, beta catenin, and TCF4 to the PPAR gamma promoter. Membrane ER alpha signaling additionally enhanced wingless integrated (Wnt)1 and 10b expression. The components of the repressor complex were required for estrogen to inhibit rosiglitazone induced differentiation of ADSC and 3T3 L1 cells to mature adipocytes. These mechanisms whereby ER cellular pools collaborate to inhibit gene expression limit progenitor differentiation to mature adipocytes.
C1 [Ahluwalia, Amrita; Hoa, Neil; Ge, Lisheng; Levin, Ellis R.] Dept Vet Affairs Med Ctr, Div Endocrinol, Long Beach, CA 90822 USA.
   [Blumberg, Bruce] Univ Calif Irvine, Dept Dev Biol, Irvine, CA 92717 USA.
   [Blumberg, Bruce] Univ Calif Irvine, Dept Pharmaceut Sci, Irvine, CA 92717 USA.
   [Levin, Ellis R.] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA.
   [Levin, Ellis R.] Univ Calif Irvine, Dept Biochem, Irvine, CA 92717 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Long Beach Healthcare System; University of California System;
   University of California Irvine; University of California System;
   University of California Irvine; University of California System;
   University of California Irvine; University of California System;
   University of California Irvine
RP Levin, ER (通讯作者)，Vet Affairs Med Ctr Res 09 151, 5901 East 7th St, Long Beach, CA 90822 USA.
EM ellis.levin@va.gov
RI ; Ge, Li/T 3955 2018
OI Levin, Ellis/0000 0003 3015 4177; Blumberg, Bruce/0000 0002 8016 8414
FU United States (U.S.) Department of Veterans Affairs Biomedical
   Laboratory Research and Development Service [I01 BX002316 07]
FX This work was supported by Merit Review Award #I01 BX002316 07 from the
   United States (U.S.) Department of Veterans Affairs Biomedical
   Laboratory Research and Development Service to Ellis R Levin.
CR Anbalagan M, 2015, MOL CELL ENDOCRINOL, V418, P264, DOI 10.1016/j.mce.2015.01.016
   Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200
   Benvenuti S, 2007, J ENDOCRINOL INVEST, V30, pRC26, DOI 10.1007/BF03350807
   Cawthorn WP, 2007, CELL DEATH DIFFER, V14, P1361, DOI 10.1038/sj.cdd.4402127
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Davis KE, 2013, MOL METAB, V2, P227, DOI 10.1016/j.molmet.2013.05.006
   Gambacciani M, 1997, J CLIN ENDOCR METAB, V82, P414, DOI 10.1210/jc.82.2.414
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Ge CX, 2016, J CELL PHYSIOL, V231, P587, DOI 10.1002/jcp.25102
   HAARBO J, 1991, METABOLISM, V40, P1323, DOI 10.1016/0026 0495(91)90037 W
   Heim M, 2004, ENDOCRINOLOGY, V145, P848, DOI 10.1210/en.2003 1014
   Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729
   Hoa N, 2018, MOL CELL ENDOCRINOL, V470, P240, DOI 10.1016/j.mce.2017.11.004
   Hosokawa H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11289
   Kalyanaraman H, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004911
   Kirchner S, 2010, MOL ENDOCRINOL, V24, P526, DOI 10.1210/me.2009 0261
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925
   Kumar A, 2012, ENDOCRINOLOGY, V153, P254, DOI 10.1210/en.2011 1169
   Kwok S, 2012, CLIN ENDOCRINOL, V77, P828, DOI 10.1111/j.1365 2265.2012.04331.x
   Lapid K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6196
   Lee MJ, 2013, J CELL MOL MED, V17, P1188, DOI 10.1111/jcmm.12098
   Lefterova MI, 2014, TRENDS ENDOCRIN MET, V25, P293, DOI 10.1016/j.tem.2014.04.001
   Levin ER, 2016, NAT REV MOL CELL BIO, V17, DOI 10.1038/nrm.2016.122
   Li PP, 2011, CELL, V147, P815, DOI 10.1016/j.cell.2011.09.050
   Louwen F, 2018, OBES REV, V19, P888, DOI 10.1111/obr.12679
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426
   Muncan V, 2006, MOL CELL BIOL, V26, P8418, DOI 10.1128/MCB.00821 06
   Okazaki R, 2002, ENDOCRINOLOGY, V143, P2349, DOI 10.1210/en.143.6.2349
   Okura T, 2003, INT J OBESITY, V27, P1020, DOI 10.1038/sj.ijo.0802378
   Pae M, 2018, J NUTR BIOCHEM, V57, P93, DOI 10.1016/j.jnutbio.2018.03.011
   Palmisano BT, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00044
   Pedram A, 2005, J BIOL CHEM, V280, P26339, DOI 10.1074/jbc.M414409200
   Pedram A, 2016, FASEB J, V30, P230, DOI 10.1096/fj.15 274878
   Pedram A, 2014, DEV CELL, V29, P482, DOI 10.1016/j.devcel.2014.04.016
   Pedram A, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004013
   Pedram A, 2012, MOL BIOL CELL, V23, P188, DOI 10.1091/mbc.E11 07 0638
   Pedram A, 2009, J BIOL CHEM, V284, P3488, DOI 10.1074/jbc.M806249200
   Peppa M, 2013, EUR J INTERN MED, V24, P824, DOI 10.1016/j.ejim.2013.07.001
   Raghav SK, 2012, MOL CELL, V46, P335, DOI 10.1016/j.molcel.2012.03.017
   Rauch A, 2019, NAT GENET, V51, P716, DOI 10.1038/s41588 019 0359 1
   Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307
   Roforth MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095987
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Samarasinghe RA, 2011, P NATL ACAD SCI USA, V108, P16657, DOI 10.1073/pnas.1102821108
   Seidlova Wuttke D, 2008, BONE, V43, P849, DOI 10.1016/j.bone.2008.07.237
   Thomas RS, 2008, J MOL ENDOCRINOL, V40, P173, DOI 10.1677/JME 07 0165
   Toth MJ, 2000, ANN NY ACAD SCI, V904, P502
   UTIAN WH, 1987, AM J OBSTET GYNECOL, V156, P1280, DOI 10.1016/0002 9378(87)90164 5
   Wang L, 2015, J BIOL CHEM, V290, P19458, DOI 10.1074/jbc.M115.641332
   Wang LF, 2010, P NATL ACAD SCI USA, V107, P7317, DOI 10.1073/pnas.1000031107
   Xu CY, 2016, CURR STEM CELL RES T, V11, P247, DOI 10.2174/1574888X10666150723145707
   Xu Y, 2011, CELL METAB, V14, P453, DOI 10.1016/j.cmet.2011.08.009
   Yochum GS, 2010, P NATL ACAD SCI USA, V107, P145, DOI 10.1073/pnas.0912294107
NR 57
TC 11
Z9 11
U1 0
U2 2
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD NOV 1
PY 2020
VL 161
IS 11
AR bqaa175
DI 10.1210/endocr/bqaa175
PG 18
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA VK7VS
UT WOS:000754315400012
PM 32976570
OA hybrid
DA 2025 08 17
ER

PT J
AU Tong, XS
   Yu, GS
   Liu, QY
   Zhang, XQ
   Bian, JC
   Liu, ZP
   Gu, JH
AF Tong, Xishuai
   Yu, Gengsheng
   Liu, Qingyang
   Zhang, Xueqing
   Bian, Jianchun
   Liu, Zongping
   Gu, Jianhong
TI Puerarin alleviates cadmium induced oxidative damage to bone by reducing
   autophagy in rats
SO ENVIRONMENTAL TOXICOLOGY
LA English
DT Article
DE autophagy; bone; cadmium; osteoclastogenesis; puerarin
ID PAGETS DISEASE; DIFFERENTIATION; CELLS; OSTEOPOROSIS; OSTEOCLAST;
   EXPOSURE; STRESS; MICE; INHIBITION; ACTIVATION
AB Autophagy is a regulatory mechanism involved in cadmium (Cd) induced bone toxicity and is suppressed by various stimuli, including oxidative stress. Puerarin is an isoflavonoid compound isolated from Pueraria, a plant used in traditional Chinese medicine. The underlying mechanisms of action of puerarin remain unclear. The objective of this study was to explore the mitigating effects of puerarin on cadmium induced oxidative damage in the bones of rats. Cadmium exposure increased oxidative damage in rat bones; this was markedly decreased by puerarin treatment, as demonstrated by changes in the activity of antioxidative enzymes. Cadmium induced blockage of the expression of key bone regulatory proteins, autophagy related markers, and signaling molecules was also alleviated by puerarin treatment. Additionally, cadmium reduced expression of the autophagic protein Rab7 and of late endosomal/lysosomal adaptor and MAPK and mTOR activator 1 (LAMTOR1); the decrease in these proteins was not restored by puerarin treatment. We speculate that puerarin relieves the inhibition of fusion of autophagosomes with lysosomes that is induced by cadmium; however, this specific effect of puerarin and downstream effects on bone regulatory mechanisms require further investigation. In conclusion, puerarin alleviates cadmium induced oxidative damage in the bones of rats by attenuating autophagy, which is likely associated with the antioxidant activity of puerarin.
C1 [Tong, Xishuai; Liu, Zongping; Gu, Jianhong] Yangzhou Univ, Minist Educ China, Joint Int Res Lab Agr & Agriprod Safety, Inst Agr Sci, Yangzhou, Jiangsu, Peoples R China.
   [Tong, Xishuai; Liu, Zongping; Gu, Jianhong] Yangzhou Univ, Minist Educ China, Joint Int Res Lab Agr & Agriprod Safety, Inst Technol Dev, Yangzhou, Jiangsu, Peoples R China.
   [Tong, Xishuai; Yu, Gengsheng; Liu, Qingyang; Zhang, Xueqing; Bian, Jianchun; Liu, Zongping; Gu, Jianhong] Yangzhou Univ, Coll Vet Med, Yangzhou 225009, Jiangsu, Peoples R China.
   [Tong, Xishuai; Yu, Gengsheng; Liu, Qingyang; Zhang, Xueqing; Bian, Jianchun; Liu, Zongping; Gu, Jianhong] Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou, Jiangsu, Peoples R China.
   [Tong, Xishuai; Bian, Jianchun; Liu, Zongping; Gu, Jianhong] Jiangsu Key Lab Zoonosis, Yangzhou, Jiangsu, Peoples R China.
C3 Yangzhou University; Yangzhou University; Yangzhou University; Yangzhou
   University
RP Gu, JH (通讯作者)，Yangzhou Univ, Coll Vet Med, Yangzhou 225009, Jiangsu, Peoples R China.
EM jhgu@yzu.edu.cn
RI Gu, Jianhong/B 5316 2011
OI Bian, Jianchun/0000 0001 8023 0751
FU National Natural Science Foundation of China [32102732, 31872534,
   31872533, 31802260]; Natural Science Foundation of Jiangsu Province
   [BK20210806, BK20180917, BK20181452]; Open Project Program of the Joint
   International Research Laboratory of Agriculture and Agri Product
   Safety; Ministry of Education of China, Yangzhou University
   [JILAR KF202110]; Priority Academic Program Development of Jiangsu
   Higher Education Institutions (PAPD)
FX This work was financially supported by the National Natural Science
   Foundation of China (32102732, 31872534, 31872533, and 31802260), the
   Natural Science Foundation of Jiangsu Province (BK20210806, BK20180917,
   and BK20181452), the Open Project Program of the Joint International
   Research Laboratory of Agriculture and Agri Product Safety, the Ministry
   of Education of China, Yangzhou University (JILAR KF202110), and a
   Project Funded by the Priority Academic Program Development of Jiangsu
   Higher Education Institutions (PAPD).
CR Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   Arai A, 2019, J BONE MINER RES, V34, P1753, DOI 10.1002/jbmr.3756
   Bebrevska L, 2010, J ETHNOPHARMACOL, V127, P112, DOI 10.1016/j.jep.2009.09.039
   Bonnet N, 2017, J BONE MINER RES, V32, P1432, DOI 10.1002/jbmr.3136
   Buha A, 2019, ENVIRON RES, V176, DOI 10.1016/j.envres.2019.108539
   Cervellati C, 2013, CLIN CHEM LAB MED, V51, P333, DOI 10.1515/cclm 2012 0095
   Dai R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00433
   Daroszewska A, 2011, HUM MOL GENET, V20, P2734, DOI 10.1093/hmg/ddr172
   Feng Q, 2020, EXP THER MED, V19, P883, DOI 10.3892/etm.2019.8291
   Genchi G, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17113782
   Graniel Amador MA, 2021, BIOMETALS, V34, P87, DOI 10.1007/s10534 020 00265 x
   Gu JH, 2015, J STEROID BIOCHEM, V152, P25, DOI 10.1016/j.jsbmb.2015.04.003
   Huang DH, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/7126914
   James KA, 2013, INT J PUBLIC HEALTH, V58, P737, DOI 10.1007/s00038 013 0488 8
   Jiang PD, 2015, METHODS, V75, P13, DOI 10.1016/j.ymeth.2014.11.021
   Kalyanaraman H, 2018, DIABETES, V67, P607, DOI 10.2337/db17 0965
   Kawane T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31853 0
   Kazantzis G, 2004, BIOMETALS, V17, P493, DOI 10.1023/B:BIOM.0000045727.76054.f3
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lee JW, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00134 w
   Li BB, 2014, BIOL PHARM BULL, V37, P1919, DOI 10.1248/bpb.b14 00513
   Li B, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110923
   Li M, 2018, ACTA BIOMATER, V71, P118, DOI 10.1016/j.actbio.2018.03.003
   Li RF, 2014, J HISTOCHEM CYTOCHEM, V62, P879, DOI 10.1369/0022155414551367
   Li WJ, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000026049
   Li XM, 2020, FOOD CHEM TOXICOL, V144, DOI 10.1016/j.fct.2020.111644
   Li X, 2020, AGEING RES REV, V62, DOI 10.1016/j.arr.2020.101098
   Li Y, 2018, INT J MOL MED, V41, P2535, DOI 10.3892/ijmm.2018.3498
   Ling M, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578 017 0154 6
   Lippai M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/832704
   Liu W, 2016, SCI REP UK, V6, DOI 10.1038/srep20404
   Lu HK, 2014, INT J CLIN EXP PATHO, V7, P640
   Lv HH, 2015, MOL MED REP, V12, P2283, DOI 10.3892/mmr.2015.3647
   Lv YJ, 2019, ENVIRON POLLUT, V249, P620, DOI 10.1016/j.envpol.2019.03.027
   McManus Stephen, 2012, J Mol Signal, V7, P1, DOI 10.1186/1750 2187 7 1
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Monteiro C, 2018, J TOXICOL ENV HEAL A, V81, P705, DOI 10.1080/15287394.2018.1485122
   Nair AR, 2013, INT J MOL SCI, V14, P6116, DOI 10.3390/ijms14036116
   Nawrot TS, 2015, CANCER CAUSE CONTROL, V26, P1281, DOI 10.1007/s10552 015 0621 5
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pi HF, 2019, AUTOPHAGY, V15, P565, DOI 10.1080/15548627.2018.1531198
   Ralston SH, 2013, NEW ENGL J MED, V368, P644, DOI 10.1056/NEJMcp1204713
   Ran D, 2020, TOXICOLOGY, V442, DOI 10.1016/j.tox.2020.152538
   Satarug S, 2018, TOXICS, V6, DOI 10.3390/toxics6010015
   Sheu SY, 2012, CHINESE MED J PEKING, V125, P3646, DOI 10.3760/cma.j.issn.0366 6999.2012.20.009
   Smith SS, 2009, TOXICOL IN VITRO, V23, P60, DOI 10.1016/j.tiv.2008.10.011
   Takayanagi H, 2021, J BONE MINER METAB, V39, P13, DOI 10.1007/s00774 020 01191 1
   Thiab NR, 2015, MOL CELL BIOCHEM, V408, P253, DOI 10.1007/s11010 015 2503 2
   Thimmuri D, 2021, IMMUNOL LETT, V231, P35, DOI 10.1016/j.imlet.2021.01.003
   Tong XS, 2021, J CELL MOL MED, V25, P937, DOI 10.1111/jcmm.16152
   Tong XS, 2020, DIFFERENTIATION, V114, P58, DOI 10.1016/j.diff.2020.06.002
   Tong XS, 2020, BIOL CELL, V112, P251, DOI 10.1111/boc.202000008
   Tong XS, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12714
   Vidoni C, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0414 7
   Wang PP, 2012, J ASIAN NAT PROD RES, V14, P897, DOI 10.1080/10286020.2012.702757
   Wang T, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.632825
   Wang XY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.475
   Wong R, 2007, OSTEOARTHR CARTILAGE, V15, P894, DOI 10.1016/j.joca.2007.02.009
   Xiao C, 2011, EUR J PHARMACOL, V666, P242, DOI 10.1016/j.ejphar.2011.05.061
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Yang C, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01113
   Yang X, 2017, CURR MOL MED, V17, P488, DOI 10.2174/1566524018666171219101142
   Yin X, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0058 7
   Yuan SY, 2016, CHIN J NAT MEDICINES, V14, P265, DOI 10.1016/S1875 5364(16)30026 7
   Zhang GY, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906 019 2691 5
   Zhang MY, 2012, CHIN J INTEGR MED, V18, P276, DOI 10.1007/s11655 012 1056 4
   Zhang WY, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13058
   Zhang Y, 2007, PLANTA MED, V73, P341, DOI 10.1055/s 2007 967168
   Zhao Y, 2021, ECOTOX ENVIRON SAFE, V208, DOI 10.1016/j.ecoenv.2020.111743
   Zhou YX, 2014, PHYTOTHER RES, V28, P961, DOI 10.1002/ptr.5083
NR 71
TC 21
Z9 22
U1 1
U2 42
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1520 4081
EI 1522 7278
J9 ENVIRON TOXICOL
JI Environ. Toxicol.
PD APR
PY 2022
VL 37
IS 4
BP 720
EP 729
DI 10.1002/tox.23437
EA DEC 2021
PG 10
WC Environmental Sciences; Toxicology; Water Resources
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Toxicology; Water Resources
GA ZU1IZ
UT WOS:000729480600001
PM 34897960
DA 2025 08 17
ER

PT J
AU Sultanli, S
   Ghumnani, S
   Ashma, R
   Kubatzky, KF
AF Sultanli, Sevinj
   Ghumnani, Soni
   Ashma, Richa
   Kubatzky, Katharina F.
TI Plumbagin, a Biomolecule with (Anti)Osteoclastic Properties
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteoclast; plumbagin; mTOR; translation; ROS; phytotherapy
ID FACTOR KAPPA B; BONE METASTASIS; OSTEOCLAST; DISEASE; INFLAMMATION;
   INHIBITION; METABOLISM; MACROPHAGE; IMMUNE; DAMAGE
AB Plumbagin is a plant derived naphthoquinone that is widely used in traditional Asian medicine due to its anti inflammatory and anti microbial properties. Additionally, plumbagin is cytotoxic for cancer cells due to its ability to trigger reactive oxygen species (ROS) formation and subsequent apoptosis. Since it was reported that plumbagin may inhibit the differentiation of bone resorbing osteoclasts in cancer related models, we wanted to elucidate whether plumbagin interferes with cytokine induced osteoclastogenesis. Using C57BL/6 mice, we unexpectedly found that plumbagin treatment enhanced osteoclast formation and that this effect was most pronounced when cells were pre treated for 24 h with plumbagin before subsequent M CSF/RANKL stimulation. Plumbagin caused a fast induction of NFATc1 signalling and mTOR dependent activation of p70S6 kinase which resulted in the initiation of protein translation. In line with this finding, we observed an increase in RANK surface expression after Plumbagin stimulation that enhanced the responsiveness for subsequent RANKL treatment. However, in Balb/c mice and Balb/c derived RAW264.7 macrophages, these findings could not be corroborated and osteoclastogenesis was inhibited. Our results suggest that the effects of plumbagin depend on the model system used and can therefore either trigger or inhibit osteoclast formation.
C1 [Sultanli, Sevinj; Kubatzky, Katharina F.] Univ Klinikum Heidelberg, Zentrum Infektiol Med Mikrobiol & Hyg, Neuenheimer Feld 324, D 69120 Heidelberg, Germany.
   [Ghumnani, Soni; Ashma, Richa] Savitribai Phule Pune Univ, Dept Zool, Pune 411007, Maharashtra, India.
C3 Ruprecht Karls University Heidelberg; Savitribai Phule Pune University
RP Kubatzky, KF (通讯作者)，Univ Klinikum Heidelberg, Zentrum Infektiol Med Mikrobiol & Hyg, Neuenheimer Feld 324, D 69120 Heidelberg, Germany.
EM sevinj.sultanli@med.uni heidelberg.de; soniighumnani04@gmail.com;
   richaashma@unipune.ac.in; kubatzky@uni heidelberg.de
RI ; Ashma, Richa/ABG 3750 2021
OI GHUMNANI, SONI/0000 0002 4804 1296; Kubatzky, Katharina
   F./0000 0003 3739 9329; Ashma, Richa/0000 0002 0099 9497
FU DAAD (German Exchange Service)
FX This research was funded by a Ph.D. fellowship to S.S. by the DAAD
   (German Exchange Service).
CR ABDUL KM, 1995, IMMUNOPHARMACOLOGY, V30, P231, DOI 10.1016/0162 3109(95)00027 Q
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Chakraborty S, 2017, IMMUNOBIOLOGY, V223, P142, DOI 10.1016/j.imbio.2017.09.001
   Chakraborty S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00185
   Checker R, 2014, INFLAMMATION, V37, P542, DOI 10.1007/s10753 013 9768 y
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Davies LC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02092 0
   Di Ceglie I, 2019, FASEB J, V33, P10104, DOI 10.1096/fj.201802691RR
   Efferth T, 2011, CURR DRUG TARGETS, V12, P122, DOI 10.2174/138945011793591626
   Gan ZY, 2015, EUR J HAEMATOL, V94, P343, DOI 10.1111/ejh.12436
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Hazra B, 2002, PHYTOTHER RES, V16, P133, DOI 10.1002/ptr.867
   Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95
   Khaw AK, 2015, MUTAT RES GEN TOX EN, V793, P86, DOI 10.1016/j.mrgentox.2015.06.004
   Klotz LO, 2014, MOLECULES, V19, P14902, DOI 10.3390/molecules190914902
   Kubatzky KF, 2018, CYTOKINE, V112, P102, DOI 10.1016/j.cyto.2018.06.013
   Le Pape F, 2016, J BONE ONCOL, V5, P93, DOI 10.1016/j.jbo.2016.02.008
   Li Z, 2012, CURR MOL MED, V12, P967, DOI 10.2174/156652412802480871
   Luo P, 2010, J PHARMACOL EXP THER, V335, P735, DOI 10.1124/jpet.110.170852
   Matsuike R, 2018, LIFE SCI, V201, P30, DOI 10.1016/j.lfs.2018.03.038
   Mbaveng AT, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00343
   Messeha SS, 2017, J NEUROIMMUNOL, V313, P129, DOI 10.1016/j.jneuroim.2017.09.007
   MOLL H, 1990, EUR J IMMUNOL, V20, P2067, DOI 10.1002/eji.1830200927
   Morita M, 2015, CELL CYCLE, V14, P473, DOI 10.4161/15384101.2014.991572
   Naik E, 2011, J EXP MED, V208, P417, DOI 10.1084/jem.20110367
   Nguyen GT, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00373
   Perillo B, 2020, EXP MOL MED, V52, P192, DOI 10.1038/s12276 020 0384 2
   Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068
   Seca AML, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010263
   Srinivas P, 2004, MOL CARCINOGEN, V40, P201, DOI 10.1002/mc.20031
   Sung B, 2012, MOL CANCER THER, V11, P350, DOI 10.1158/1535 7163.MCT 11 0731
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tiedemann K, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00054
   Tripathi SK, 2019, FOOD CHEM TOXICOL, V125, P566, DOI 10.1016/j.fct.2019.01.018
   Turpin A, 2020, TRANSL ONCOL, V13, P308, DOI 10.1016/j.tranon.2019.10.012
   Wang CQ, 2018, BIOCHEM CELL BIOL, V96, P627, DOI 10.1139/bcb 2017 0243
   Wang TY, 2014, FOOD CHEM TOXICOL, V64, P177, DOI 10.1016/j.fct.2013.11.027
   Watanabe H, 2004, SHOCK, V22, P460, DOI 10.1097/01.shk.0000142249.08135.e9
   Weaver BA, 2014, MOL BIOL CELL, V25, P2677, DOI 10.1091/mbc.E14 04 0916
   Yin ZH, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6940953
   Zeng R, 2015, J BONE MINER RES, V30, P2287, DOI 10.1002/jbmr.2584
   Zhang ZX, 2016, MOL MED, V22, DOI 10.2119/molmed.2015.00250
   Zhou R, 2019, ENVIRON TOXICOL PHAR, V70, DOI 10.1016/j.etap.2019.103200
NR 43
TC 14
Z9 16
U1 1
U2 8
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2021
VL 22
IS 5
AR 2779
DI 10.3390/ijms22052779
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA QV8VV
UT WOS:000628243000001
PM 33803472
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wood, C
   González, EA
   Martin, KJ
AF Wood, C
   González, EA
   Martin, KJ
TI Challenges in the therapy of secondary hyperparathyroidism
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article
DE hyperparathyroidism; parathyroid hormone; renal bone disease; renal
   osteodystrophy
ID SUPPRESSES PARATHYROID HORMONE; CHRONIC RENAL FAILURE;
   HEMODIALYSIS PATIENTS; DIALYSIS PATIENTS; 1 ALPHA HYDROXYVITAMIN D 2;
   UREMIC RATS; PHOSPHORUS; CALCIUM; DISEASE; ASSAYS
AB Derangements in mineral metabolism are known to occur early in the course of chronic kidney disease (CKD). Recent clinical practice guidelines are designed to focus on the problem early in the course of kidney disease, when it is recommended to evaluate the levels of parathyroid hormone (PTH) and to try to intervene early if the levels are elevated. To begin early intervention for hyperparathyroidism in chronic kidney disease will require involvement of primary care physicians and other subspecialty groups to identify the patients at risk and begin to intervene with measures to control hyperparathyroidism and its consequences on mineral metabolism. It has recently been demonstrated that chronic kidney disease is a significant risk factor for vitamin D deficiency and since abnormalities in vitamin D metabolism are important in the generation of hyperparathyroidism, this is an issue that needs direct attention. Studies are needed to assess the effects of correcting this vitamin D deficiency in early CKD. As kidney disease progresses, efforts to control hyperparathyroidism will likely need to be intensified and several therapeutic options are available, such as phosphate binders, repletion of vitamin D, the use of active vitamin D sterols, or the use of vitamin D analogs. In addition, it is important to define the appropriate PTH values that need to be achieved to minimize complications on bone. Such studies are in progress at the present time to validate the current more specific PTH assays. Strict guidelines have been proposed for the management of bone and mineral metabolism in patients with CKD stage V on dialysis, and although these challenging recommendations were initially opinion based, there is mounting evidence which provides confirmation of these targets as relevant. Treatment options for patients on dialysis involve the full spectrum of agents which include phosphate binders, active vitamin D sterols (often given parenterally), the use of calcimimetic agents, surgical parathyroidectomy, and evaluation of appropriate levels of dialysate calcium. Similar to early stages of CKD, studies are in progress to refine the PTH targets with the newer PTH assays. With increased focus on the complications of bone and mineral metabolism as part of the continuum of chronic kidney disease, and with a variety of new therapies available, it is anticipated that improved patient outcomes should be achievable in this patient group.
C1 St Louis Univ, Div Nephrol, St Louis, MO 63110 USA.
C3 Saint Louis University
RP St Louis Univ, Div Nephrol, 3635 Vista Ave, St Louis, MO 63110 USA.
EM martinkj@slu.edu
RI Martin, Kevin/AAA 3212 2021
CR Akiba T, 1998, AM J KIDNEY DIS, V32, P238, DOI 10.1053/ajkd.1998.v32.pm9708607
   ALY ZA, 2004, AM J NEPHROL, V24, P422
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2000, AM J KIDNEY DIS, V35, P1226, DOI 10.1016/S0272 6386(00)70064 3
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Chertow GM, 2000, NEPHROL DIAL TRANSPL, V15, P559, DOI 10.1093/oxfordjournals.ndt.a027950
   Chertow GM, 1997, AM J KIDNEY DIS, V29, P66, DOI 10.1016/S0272 6386(97)90009 3
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   Coen G, 1996, NEPHROL DIAL TRANSPL, V11, P813, DOI 10.1093/oxfordjournals.ndt.a027404
   EKNOYAN G, 2003, AM J KIDNEY DIS S, V42, P1
   Gao P, 2001, J BONE MINER RES, V16, P605, DOI 10.1359/jbmr.2001.16.4.605
   González EA, 2004, AM J NEPHROL, V24, P503, DOI 10.1159/000081023
   Goodman WG, 2002, NEPHROL DIAL TRANSPL, V17, P204, DOI 10.1093/ndt/17.2.204
   Goodman WG, 2003, KIDNEY INT, V63, P1, DOI 10.1046/j.1523 1755.2003.00700.x
   Hirata M, 2003, NEPHROL DIAL TRANSPL, V18, P1770, DOI 10.1093/ndt/gfg296
   Kurokawa K, 1996, NEPHROL DIAL TRANSPL, V11, P121, DOI 10.1093/ndt/11.supp3.121
   London GM, 2004, J AM SOC NEPHROL, V15, P1943, DOI 10.1097/01.asn.0000129337.50739.48
   MALLUCHE HH, 1976, KIDNEY INT, V9, P355, DOI 10.1038/ki.1976.42
   Martin KJ, 2004, SEMIN NEPHROL, V24, P456, DOI 10.1016/j.semnephrol.2004.06.013
   Martin KJ, 2004, SEMIN NEPHROL, V24, P3, DOI 10.1053/j.semnephrol.2003.08.019
   Martin KJ, 2001, CURR OPIN NEPHROL HY, V10, P569, DOI 10.1097/00041552 200109000 00004
   MARTIN KJ, 2004, KIDNEY, V2, P2255
   Martinez I, 1997, AM J KIDNEY DIS, V29, P496, DOI 10.1016/S0272 6386(97)90330 9
   Maung HM, 2001, AM J KIDNEY DIS, V37, P532
   RAMIREZ JA, 1986, KIDNEY INT, V30, P753, DOI 10.1038/ki.1986.252
   SLATOPOLSKY E, 1995, AM J KIDNEY DIS, V26, P852, DOI 10.1016/0272 6386(95)90455 7
   Slatopolsky E, 2002, KIDNEY INT, V62, P1277, DOI 10.1111/j.1523 1755.2002.kid573.x
   Slatopolsky E, 2001, AM J KIDNEY DIS, V37, pS54, DOI 10.1053/ajkd.2001.20740
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
NR 29
TC 15
Z9 18
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1744 9979
EI 1744 9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
PD FEB
PY 2005
VL 9
IS 1
BP 4
EP 8
DI 10.1111/j.1774 9987.2005.00208.x
PG 5
WC Hematology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Urology & Nephrology
GA 916RN
UT WOS:000228403600002
PM 15828898
DA 2025 08 17
ER

PT J
AU Wan, QQ
   Cho, E
   Yokota, H
   Na, S
AF Wan, Qiaoqiao
   Cho, Eunhye
   Yokota, Hiroki
   Na, Sungsoo
TI Rac1 and Cdc42 GTPases regulate shear stress driven β catenin signaling
   in osteoblasts
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Fluorescence resonance energy transfer (FRET); MC3T3 E1; Mechanical
   loading; Mechanotransduction; Rho family GTPases; TCF/LEF
ID LIVING CELLS; RHO GTPASES; ACTIVATION; MECHANOTRANSDUCTION; RESPONSES;
   ADHESION
AB Beta catenin dependent TCF/LEF (T cell factor/lymphocyte enhancing factor) is known to be mechanosensitive and an important regulator for promoting bone formation. However, the functional connection between TCF/LEF activity and Rho family GTPases is not well understood in osteoblasts. Herein we investigated the molecular mechanisms underlying oscillatory shear stress induced TCF/LEF activity in MC3T3 E1 osteoblast cells using live cell imaging. We employed fluorescence resonance energy transfer (FRET) based and green fluorescent protein (GFP) based biosensors, which allowed us to monitor signal transduction in living cells in real time. Oscillatory (1 Hz) shear stress (10 dynes/cm(2)) increased TCF/LEF activity and stimulated translocation of beta catenin to the nucleus with the distinct activity patterns of Rac1 and Cdc42. The shear stress induced TCF/LEF activity was blocked by the inhibition of Rac1 and Cdc42 with their dominant negative mutants or selective drugs, but not by a dominant negative mutant of RhoA. In contrast, constitutively active Rac1 and Cdc42 mutants caused a significant enhancement of TCF/LEF activity. Moreover, activation of Rac1 and Cdc42 increased the basal level of TCF/LEF activity, while their inhibition decreased the basal level. Interestingly, disruption of cytoskeletal structures or inhibition of myosin activity did not significantly affect shear stress induced TCF/LEF activity. Although Rac1 is reported to be involved in beta catenin in cancer cells, the involvement of Cdc42 in beta catenin signaling in osteoblasts has not been identified. Our findings in this study demonstrate that both Rac1 and Cdc42 GTPases are critical regulators in shear stress driven beta catenin signaling in osteoblasts. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Wan, Qiaoqiao; Cho, Eunhye; Yokota, Hiroki; Na, Sungsoo] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
   [Yokota, Hiroki] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
C3 Purdue University System; Purdue University; Purdue University in
   Indianapolis; Indiana University System; Indiana University Bloomington
RP Na, S (通讯作者)，Indiana Univ Purdue Univ, Dept Biomed Engn, 723 West Michigan St,SL220, Indianapolis, IN 46202 USA.
EM sungna@iupui.edu
RI Wan, Qiaoqiao/N 6562 2017
FU Indiana University; National Institutes of Health [AR052144]
FX We thank Dr. M. Matsuda (Kyoto University, Japan) and Dr. J. Miyazaki
   (Osaka University, Japan) for the gift of the GTPase biosensors, Dr. E.
   Schuman (California Institute of Technology, Pasadena, CA, USA) for the
   EGFP beta catenin; Dr. Y. Wang (University of Illinois,
   Urbana Champaign, IL, USA) for the RhoA mutant, and Dr. A. Hall
   (Memorial Sloan Kettering Cancer Center, New York, NY, USA) for the Rac1
   and Cdc42 mutants. This work was supported by Indiana University (S.N.),
   and National Institutes of Health Grant AR052144 (H.Y.).
CR Arnsdorf EJ, 2009, J CELL SCI, V122, P546, DOI 10.1242/jcs.036293
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Case N, 2008, J BIOL CHEM, V283, P29196, DOI 10.1074/jbc.M801907200
   Chellaiah MA, 2003, J BIOL CHEM, V278, P29086, DOI 10.1074/jbc.M211074200
   Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168 9525(97)01305 X
   Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007
   Etienne Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101
   Hamamura K, 2012, CONNECT TISSUE RES, V53, P398, DOI 10.3109/03008207.2012.671398
   Huang CY, 2010, FASEB J, V24, P3625, DOI 10.1096/fj.10 157370
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Ito Y, 2010, J CLIN INVEST, V120, P1981, DOI 10.1172/JCI39650
   Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582 6591.2002
   Kamel MA, 2010, BONE, V47, P872, DOI 10.1016/j.bone.2010.08.007
   Lane SW, 2012, BLOOD, V119, P736, DOI 10.1182/blood 2011 07 368753
   Lang T, 2004, J BONE MINER RES, V19, P1006, DOI 10.1359/JBMR.040307
   Li S, 1999, J CLIN INVEST, V103, P1141, DOI 10.1172/JCI5367
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   Murase S, 2002, NEURON, V35, P91, DOI 10.1016/S0896 6273(02)00764 X
   Na S, 2008, P NATL ACAD SCI USA, V105, P6626, DOI 10.1073/pnas.0711704105
   Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235
   NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092 8674(95)90370 4
   Norvell SM, 2004, CALCIFIED TISSUE INT, V75, P396, DOI 10.1007/s00223 004 0213 y
   Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449
   Poh YC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007886
   Razzouk S, 1999, EUR J CELL BIOL, V78, P249, DOI 10.1016/S0171 9335(99)80058 2
   Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623 198466030 00012
   Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968 0004(00)01605 4
   Surviladze Z., 2010, PROBE REPORTS NIH MO
   Tzima E, 2006, CIRC RES, V98, P176, DOI 10.1161/01.RES.0000200162.94463.d7
   WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021 9290(94)90010 8
   Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052
   Yokota Hiroki, 2011, Curr Osteoporos Rep, V9, P237, DOI 10.1007/s11914 011 0067 y
   Yoshizaki H, 2003, J CELL BIOL, V162, P223, DOI 10.1083/jcb.200212049
NR 36
TC 31
Z9 38
U1 0
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 19
PY 2013
VL 433
IS 4
BP 502
EP 507
DI 10.1016/j.bbrc.2013.03.020
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 135AT
UT WOS:000318259100025
PM 23524265
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Rivadeneira, J
   Di Virgilio, AL
   Barrio, DA
   Muglia, CI
   Bruzzone, L
   Etcheverry, SB
AF Rivadeneira, J.
   Di Virgilio, A. L.
   Barrio, D. A.
   Muglia, C. I.
   Bruzzone, L.
   Etcheverry, S. B.
TI Cytotoxicity of a Vanadyl(IV) Complex with a Multidentate Oxygen Donor
   in Osteoblast Cell Lines in Culture
SO MEDICINAL CHEMISTRY
LA English
DT Article
DE Vanadium cytotoxicity; chelating ligands; osteoblasts; cellular
   morphology; oxidative stress; mitochondria membrane potential; GSH/GSSG
   ratio; ERK phopsphorylation
ID VANADIUM COMPOUNDS; HYDROGEN PEROXIDE; PHOSPHATIDYLINOSITOL 3 KINASE;
   MORPHOLOGICAL TRANSFORMATION; DIHYDRORHODAMINE 123; SPERMICIDAL
   ACTIVITY; OXIDATIVE STRESS; GROWTH FACTOR; ACTIVATION; APOPTOSIS
AB Strong chelating ligands as oxodiacetate (oda) are model systems to study the process of metal trapping by living organisms. Vanadium compounds display interesting biological and pharmacological actions. In vertebrates, vanadium is stored mainly in bones. In the present study we report the effects of the complex of oda with vanadyl(IV) cation, VO(oda), on two osteoblast cell lines, one normal (MC3T3 E1) and the other tumoral (UMR106). VO(oda) exerted cytotoxic actions in osteoblasts as it was determined through a dose dependent decrease in cell proliferation, and morphological and actin alterations. The putative mechanisms underlying VO(oda) deleterious effects were also investigated. The complex increased the level of ROS which correlated with a decreased in GSH/GSSG ratio. Besides, VO(oda) induced a dissipation of the mitochondria membrane potential (MMP) and promoted an increase in ERK cascade phosphorylation, which is involved in the regulation of cellular death and survival. All the effects were more pronounced in MC3T3 E1 than in UMR106 cells. ERK activation was inhibited by PD98059, Wortmanin and the ROS scavenger NAC (N acetyl cysteine). These results suggest that VO(oda) stimulated ERKs phosphorylation by induction of free radicals involving kinases upstream of ERK pathway. The inhibitory effect of the complex on cell proliferation was partially reversed in both cell lines by NAC. Moreover, PD98059 and Wortmanin also partially reversed the inhibition of cell proliferation in the tumoral osteoblasts. The use of specific inhibitors and ROS scavengers suggested the involvement of oxidative stress, MMP alterations and ERK pathway in the apoptotic actions of this complex.
C1 [Rivadeneira, J.; Di Virgilio, A. L.; Barrio, D. A.; Muglia, C. I.; Etcheverry, S. B.] Natl Univ La Plata, Fac Ciencias Exactas, Catedra Bioquim Patol, RA 1900 La Plata, Argentina.
   [Rivadeneira, J.; Etcheverry, S. B.] Natl Univ La Plata, Fac Ciencias Exactas, CEQUINOR, CONICET, RA 1900 La Plata, Argentina.
   [Bruzzone, L.] Natl Univ La Plata, Fac Ciencias Exactas, Div Quim Analit, RA 1900 La Plata, Argentina.
C3 National University of La Plata; National University of La Plata;
   National University of La Plata
RP Etcheverry, SB (通讯作者)，Natl Univ La Plata, Fac Ciencias Exactas, Catedra Bioquim Patol, RA 1900 La Plata, Argentina.
EM etcheverry@biol.unlp.edu.ar
RI ; Barrio, Daniel/AAG 6938 2019
OI Bruzzone, Liliana/0000 0001 7960 0145; 
FU UNLP; CONICET, Argentina [PIP 1125]
FX This work was supported by UNLP and CONICET (PIP 1125). ALDV, DAB, CIM
   and SBE are members of the Carrera del Investigador, CONICET, Argentina.
   JR is a postdoctoral fellowship from CONICET, Argentina.
CR Altamirano Lozano M, 1998, Invest Clin, V39 Suppl 1, P39
   Baggio R, 2003, ACTA CRYSTALLOGR C, V59, pM175, DOI 10.1107/S010827010300595X
   Baran E. J., 1996, ANAL ACAD NAC CS FIS, V46, P35
   Barrio DA, 2003, J BIOL INORG CHEM, V8, P459, DOI 10.1007/s00775 002 0438 z
   Barrio DA, 2006, CAN J PHYSIOL PHARM, V84, P765, DOI 10.1139/Y06 021
   Blázquez C, 2000, FASEB J, V14, P2315, DOI 10.1096/fj.00 0122com
   Borenfreund E., 1984, Journal of Tissue Culture Methods, V9, P7, DOI [10.1007/BF01666038, DOI 10.1007/BF01666038]
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Capella MAM, 2007, CELL BIOL TOXICOL, V23, P413, DOI 10.1007/s10565 007 9003 4
   CHAO J, 2003, INORG CHEM COMMUN, V6, P706
   Chen F, 2001, MOL CELL BIOCHEM, V222, P183, DOI 10.1023/A:1017970330982
   COHEN MD, 1988, J LEUKOCYTE BIOL, V44, P122, DOI 10.1002/jlb.44.2.122
   Cortizo AM, 2000, TOXICOLOGY, V147, P89, DOI 10.1016/S0300 483X(00)00181 5
   CORTIZO AM, 1995, MOL CELL BIOCHEM, V145, P97, DOI 10.1007/BF00935481
   CORTIZO AM, 2000, METAL IONS BIOL MED, V6, P714
   Cortizo AM, 2006, INT J BIOCHEM CELL B, V38, P1171, DOI 10.1016/j.biocel.2005.12.007
   Costas M, 2004, CHEM REV, V104, P939, DOI 10.1021/cr020628n
   D'Cruz OJ, 1998, MOL HUM REPROD, V4, P683
   D'Cruz OJ, 1999, BIOL REPROD, V60, P435, DOI 10.1095/biolreprod60.2.435
   DARZYNKIEWICZ Z, 1982, CANCER RES, V42, P799
   Dayeh VR, 2009, ATLA ALTERN LAB ANIM, V37, P77, DOI 10.1177/026119290903700111
   del Río D, 2003, DALTON T, P1813, DOI 10.1039/b300914a
   del Río D, 2000, INORG CHEM COMMUN, V3, P32, DOI 10.1016/S1387 7003(99)00180 X
   DJORDJEVIC C, 1995, MET IONS BIOL SYST, V31, P595
   Domingo JL, 1996, REPROD TOXICOL, V10, P175, DOI 10.1016/0890 6238(96)00019 6
   DONOFRIO F, 1994, FEBS LETT, V340, P269, DOI 10.1016/0014 5793(94)80152 5
   Etcheverry SB, 1997, ARCH BIOCHEM BIOPHYS, V338, P7, DOI 10.1006/abbi.1996.9778
   Etcheverry SB, 2007, BIOORGAN MED CHEM, V15, P6418, DOI 10.1016/j.bmc.2007.06.056
   Etcheverry SB, 2007, ACS SYM SER, V974, P204
   Etcheverry SB, 2008, J BIOL INORG CHEM, V13, P435, DOI 10.1007/s00775 007 0332 9
   Evangelou AM, 2002, CRIT REV ONCOL HEMAT, V42, P249, DOI 10.1016/S1040 8428(01)00221 9
   Fu Y, 2008, J BIOL INORG CHEM, V13, P1001, DOI 10.1007/s00775 008 0387 2
   Giovannini C, 2008, J NUTR BIOCHEM, V19, P118, DOI 10.1016/j.jnutbio.2007.01.010
   Grebenová D, 2003, J PHOTOCH PHOTOBIO B, V69, P71, DOI 10.1016/S1011 1344(02)00410 4
   Gresser M.J., 1990, Vanadium in Biological Systems, P63
   Häcker G, 2000, CELL TISSUE RES, V301, P5, DOI 10.1007/s004410000193
   HARDING CJ, 1993, ANGEW CHEM INT EDIT, V32, P570, DOI 10.1002/anie.199305701
   Harding MM, 2000, CURR MED CHEM, V7, P1289, DOI 10.2174/0929867003374066
   Hasenknopf B, 2005, FRONT BIOSCI LANDMRK, V10, P275, DOI 10.2741/1527
   Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603
   HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003 2697(76)90326 2
   Holko P, 2008, POL J PATHOL, V59, P3
   Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200
   HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409
   Ivancsits S, 2002, MUTAT RES GEN TOX EN, V519, P25, DOI 10.1016/S1383 5718(02)00138 9
   Jelikic Stankov M, 2007, J TRACE ELEM MED BIO, V21, P8, DOI 10.1016/j.jtemb.2006.11.004
   Jones DP, 2000, FREE RADICAL BIO MED, V28, P625, DOI 10.1016/S0891 5849(99)00275 0
   Kim R, 2002, CANCER CHEMOTH PHARM, V50, P343, DOI 10.1007/s00280 002 0522 7
   Kordowiak Anna M., 2007, Polish Journal of Pathology, V58, P51
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lefcort H, 2008, ECOHEALTH, V5, P10, DOI 10.1007/s10393 008 0158 0
   LIPPARD SJ, 1994, PRINCIPLES BIOINORGA
   LOPEZMEDIAVILLA C, 1995, BBA BIOENERGETICS, V1232, P27, DOI 10.1016/0005 2728(95)00105 8
   Luber B, 2000, CELL ADHES COMMUN, V7, P391, DOI 10.3109/15419060009109021
   Mayer B, 2003, NEWS PHYSIOL SCI, V18, P89, DOI 10.1152/nips.01433.2002
   MOHAMADIN AM, 1996, BASIC CLIN PHARMACOL, V100, P84
   Molinuevo MS, 2008, CANCER CHEMOTH PHARM, V61, P767, DOI 10.1007/s00280 007 0532 6
   Molinuevo MS, 2005, TOXICOLOGY, V210, P205, DOI 10.1016/j.tox.2005.02.016
   Molinuevo MS, 2004, CANCER CHEMOTH PHARM, V53, P163, DOI 10.1007/s00280 003 0708 7
   Morinville A, 1998, TRENDS PHARMACOL SCI, V19, P452, DOI 10.1016/S0165 6147(98)01257 7
   Narla RK, 2001, CLIN CANCER RES, V7, P1094
   NIELSEN FH, 1995, MET IONS BIOL SYST, V31, P543
   OHKUMA S, 1981, J CELL BIOL, V90, P656, DOI 10.1083/jcb.90.3.656
   OKAJIMA T, 1992, ENDOCRINOLOGY, V130, P2201, DOI 10.1210/en.130.4.2201
   OLIVIER P, 1995, TOXICOL IN VITRO, V9, P133, DOI 10.1016/0887 2333(94)00209 D
   Osinska Królicka I, 2004, J INORG BIOCHEM, V98, P2087, DOI 10.1016/j.jinorgbio.2004.09.013
   Pandey SK, 1999, BIOCHEMISTRY US, V38, P14667, DOI 10.1021/bi9911886
   Perez Benito JF, 2006, J TRACE ELEM MED BIO, V20, P161, DOI 10.1016/j.jtemb.2006.04.001
   Qin Y, 2008, CELL BIOL INT, V32, P224, DOI 10.1016/j.cellbi.2007.08.028
   Reed DJ., 1984, PHARMACOL REV, V36, P25
   Rivadeneira J, 2007, BIOL TRACE ELEM RES, V118, P159, DOI 10.1007/s12011 007 0025 9
   Rivadeneira J, 2009, J INORG BIOCHEM, V103, P633, DOI 10.1016/j.jinorgbio.2008.11.009
   ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222
   Rumora L, 2004, CELL BIOL TOXICOL, V20, P293, DOI 10.1007/s10565 004 5104 5
   SABBIONI E, 1993, CARCINOGENESIS, V14, P2565, DOI 10.1093/carcin/14.12.2565
   SAKURAI H, 1994, ENVIRON HEALTH PERSP, V102, P35, DOI 10.1289/ehp.94102s335
   Sálice VC, 1999, MOL CELL BIOCHEM, V198, P119, DOI 10.1023/A:1006997830346
   SCHEDLE A, 1995, J DENT RES, V74, P1513, DOI 10.1177/00220345950740081301
   Schmidt CM, 2004, TOXICOL IND HEALTH, V20, P57, DOI 10.1191/0748233704th192oa
   Shang XJ, 2009, J ANDROL, V30, P122, DOI 10.2164/jandrol.108.005629
   Soares SS, 2008, CHEM RES TOXICOL, V21, P607, DOI 10.1021/tx700204r
   Stebbing ARD, 2002, MAR ENVIRON RES, V54, P805, DOI 10.1016/S0141 1136(02)00119 8
   STOSSEL TP, 1989, J BIOL CHEM, V264, P18261
   Théberge JF, 2003, ARCH BIOCHEM BIOPHYS, V420, P9, DOI 10.1016/j.abb.2003.09.010
   Thompson KH, 1999, CHEM REV, V99, P2561, DOI 10.1021/cr980427c
   Upreti RK, 1995, MOL CELL BIOCHEM, V153, P167, DOI 10.1007/BF01075934
   Valko M, 2006, CHEM BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   Wang YZ, 2000, AM J RESP CELL MOL, V22, P590, DOI 10.1165/ajrcmb.22.5.3882
   Yamazaki Y, 2000, EXP CELL RES, V259, P64, DOI 10.1006/excr.2000.4970
   Yang XG, 2004, PHARM RES DORDR, V21, P1026, DOI 10.1023/B:PHAM.0000029293.89113.d5
   Ye JP, 1999, MOL CELL BIOCHEM, V202, P9, DOI 10.1023/A:1007078915585
   Ye JP, 1999, MOL CELL BIOCHEM, V198, P193, DOI 10.1023/A:1006969008056
   Yuan BZ, 2007, EXP CELL RES, V313, P3868, DOI 10.1016/j.yexcr.2007.08.009
   Zhang Z, 2001, ARCH BIOCHEM BIOPHYS, V392, P311, DOI 10.1006/abbi.2001.2464
NR 94
TC 32
Z9 34
U1 0
U2 7
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573 4064
EI 1875 6638
J9 MED CHEM
JI Med. Chem.
PD JAN
PY 2010
VL 6
IS 1
BP 9
EP 23
DI 10.2174/157340610791208754
PG 15
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 579VW
UT WOS:000276405800003
PM 20402656
OA Green Published
DA 2025 08 17
ER

PT J
AU Chea, C
   Haing, S
   Miyauchi, M
   Shrestha, M
   Imanaka, H
   Takata, T
AF Chea, Chanbora
   Haing, Sivmeng
   Miyauchi, Mutsumi
   Shrestha, Madhu
   Imanaka, Hiromichi
   Takata, Takashi
TI Molecular mechanisms underlying the inhibitory effects of bovine
   lactoferrin on osteosarcoma
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Bovine lactoferrin; Osteosarcoma; Osteoblast; IL 1 beta; IL 6; RANKL;
   Osteoclastogenesis
ID BONE; CANCER
AB Osteosarcoma (OS) is one the most common primary malignancies of the bone in children and young adults with high metastasis. The use of non toxic naturally derived compounds is one of present strategies in OS therapy to reduce secondary effects and chemo resistance. Lactoferrin (LF), a transferrin protein derived from milk, currently appears to be an anticancer agent. However, its suppressive effects on OS have not been fully investigated. Therefore, we aimed to examine the molecular mechanism underlying the inhibitory effects of bovine LF (bLF) on OS. OS cell lines (NOS1, U2OS, MG63, and 143B) and an osteoblastic (ST2) were treated with bLF. Effects of bLF on OS cell proliferation and migration were examined by proliferation and wound healing assays. Expression levels of low density lipoprotein receptor related protein 1 (LRP1) and cytokines including interleukin 1 beta (IL 1 beta), IL 6, and receptor activator of nuclear factor kappa B ligand (RANKL) were measured using western blotting. Osteoclast formation was examined by co culture of 1438, ST2, and bone marrow cells. We found that bLF down regulated IL 1 beta, IL 6, and RANKL expression and suppressed phosphorylation of nuclear factor kappa light chain enhancer of activated B cells (NF kappa B) p65 in 143B cells; bLF also drastically suppressed 143B activated RANKL production in ST2 cells. This may have contributed to the reduction in the number of differentiated osteoclasts. Taken together, these data reveal that bLF down regulates NF kappa B to attenuate proliferation, migration, and bone resorption in OS and the OS microenvironment. This study provides new findings and the precise underlying mechanisms of the inhibitory effects of bLF on OS. bLF can be a possible therapeutic agent for OS patients. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Chea, Chanbora; Haing, Sivmeng; Miyauchi, Mutsumi; Shrestha, Madhu; Takata, Takashi] Hiroshima Univ, Dept Oral & Maxillofacial Pathobiol, Grad Sch Biomed & Hlth Sci, Minami Ku, 1 2 3 Kasumi, Hiroshima 7348553, Japan.
   [Haing, Sivmeng] Univ Hlth Sci, Dept Oral Pathobiol, Fac Odontostomatol, 73 Preah Monivong Blvd, Phnom Penh 12201, Cambodia.
   [Imanaka, Hiromichi] Sunstar Inc, R&D Dept, Osaka 5691195, Japan.
C3 Hiroshima University
RP Chea, C; Miyauchi, M; Takata, T (通讯作者)，Hiroshima Univ, Dept Oral & Maxillofacial Pathobiol, Grad Sch Biomed & Hlth Sci, Minami Ku, 1 2 3 Kasumi, Hiroshima 7348553, Japan.
EM cheachanbora@yahoo.com; mmiya@hiroshima u.ac.jp;
   ttakata@hiroshima u.ac.jp
RI Miyauchi, Mutsumi/G 5268 2019; Shrestha, Madhu/HHC 3819 2022
OI Chea, Chanbora/0000 0002 3109 4527; SHRESTHA, MADHU/0000 0003 1904 3265
FU JSPS KAKENHI [25293373]; Grants in Aid for Scientific Research
   [25293373] Funding Source: KAKEN
FX This research was supported by JSPS KAKENHI, Grants in Aid for
   Scientific Research (B), project number: 25293373.
CR Ara T, 2010, EUR J CANCER, V46, P1223, DOI 10.1016/j.ejca.2010.02.026
   Beristain AG, 2012, J CELL SCI, V125, P943, DOI 10.1242/jcs.094029
   Chea C., 2018, PLOS ONE, V1
   Chen Y, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0295
   Durfee RA, 2016, RHEUMATOL THER, V3, P221, DOI 10.1007/s40744 016 0046 y
   Guillen C, 2000, ARTHRITIS RHEUM, V43, P2073, DOI 10.1002/1529 0131(200009)43:9<2073::AID ANR19>3.0.CO;2 U
   Hirata I, 2007, WORLD J GASTROENTERO, V13, P1569, DOI 10.3748/wjg.v13.i10.1569
   Hofbauer LC, 1998, BIOCHEM BIOPH RES CO, V250, P776, DOI 10.1006/bbrc.1998.9394
   Inubushi T, 2012, J BIOL CHEM, V287, P23527, DOI 10.1074/jbc.M111.324673
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Kinpara K, 2000, J IMMUNOASSAY, V21, P327, DOI 10.1080/01971520009349540
   Lamora A, 2016, J CLIN MED, V5, DOI 10.3390/jcm5110096
   MACHNICKI M, 1993, INT J EXP PATHOL, V74, P433
   Masera RG, 2000, Z RHEUMATOL, V59, P103, DOI 10.1007/s003930070003
   MOTOYAMA T, 1993, VIRCHOWS ARCH B, V63, P277, DOI 10.1007/BF02899273
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Scheller J, 2011, BBA MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034
   Shapovalov Y, 2011, J BIOL CHEM, V286, P22331, DOI 10.1074/jbc.M111.250092
   Siebert PD, 1997, P NATL ACAD SCI USA, V94, P2198, DOI 10.1073/pnas.94.6.2198
   Steeve KT, 2004, CYTOKINE GROWTH F R, V15, P49, DOI 10.1016/j.cytogfr.2003.10.005
   Tanaka S, 2007, AM J NEPHROL, V27, P466, DOI 10.1159/000106484
   Tang QL, 2012, JNCI J NATL CANCER I, V104, P749, DOI 10.1093/jnci/djs210
   Tu B, 2012, CANCER LETT, V325, P80, DOI 10.1016/j.canlet.2012.06.006
   van Driel M, 2014, ARCH BIOCHEM BIOPHYS, V561, P159, DOI 10.1016/j.abb.2014.07.013
   Vesce F, 2014, GYNECOL OBSTET INVES, V77, P245, DOI 10.1159/000358877
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Yamano E, 2010, LAB INVEST, V90, P1236, DOI 10.1038/labinvest.2010.80
NR 27
TC 12
Z9 14
U1 1
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 15
PY 2019
VL 508
IS 3
BP 946
EP 952
DI 10.1016/j.bbrc.2018.11.204
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HI5KX
UT WOS:000456492000044
PM 30545626
DA 2025 08 17
ER

PT J
AU Sousa, BL
   Barroso Neto, IL
   Oliveira, EF
   Fonseca, E
   Lima Neto, P
   Ladeira, LO
   Freire, VN
AF Sousa, Bruno L.
   Barroso Neto, Ito L.
   Oliveira, Evanildo F.
   Fonseca, Emerson
   Lima Neto, Pedro
   Ladeira, Luiz O.
   Freire, Valder N.
TI Explaining RANKL inhibition by OPG through quantum biochemistry
   computations and insights into peptide design for the treatment of
   osteoporosis
SO RSC ADVANCES
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION FACTOR; BONE LOSS; RECEPTOR ACTIVATOR;
   MOLECULAR DYNAMICS; CRYSTAL STRUCTURE; PROTEIN; OSTEOPROTEGERIN;
   BINDING; LIGAND; DISEASE
AB Osteoporosis is a degenerative disease associated with excessive bone resorption, a natural process performed by osteoclasts. In turn, osteoclast maturation is critically regulated by the receptor activator of nuclear factor kB ligand (RANKL), its signalling receptor (RANK), and its decoy receptor osteoprotegerin (OPG). The critical role of the protein triad, RANK RANKL OPG, in osteoclastogenesis has made their binding an important target for the rational development of drugs against osteoporosis. Based on this, we have performed a quantum biochemistry investigation of the binding between RANKL and its decoy receptor, OPG, in order to analyse the individual contributions of all amino acid residues involved in the complex formation, providing a deeper understanding of the inhibition process. The role of specific residues in the RANKL OPG binding was evaluated through quantum biochemistry computations performed within the molecular fractionation with conjugate caps (MFCC) methodology, and inter residue binding energies were calculated within the framework of density functional theory (DFT). Our simulations, considering water effects (implicit and explicit) and the role of the dielectric constant background, attested the major importance of site II, when compared to site I, over OPG binding and functionality, mainly through interactions performed by the tripeptide OPG core, I94 E95 F96. The obtained results also explain (i) the impact of a specific OPG mutation (F96L) on Paget's disease development; (ii) how some pioneers proposed that peptides efficiently inhibit the RANKL OPG complex, acting as promising drugs for the treatment of osteoporosis. In conclusion, our quantum biochemistry approach provides a solid base that allows important insights into peptide and drug design for the treatment of osteoporosis based on RANKL OPG binding inhibition.
C1 [Sousa, Bruno L.; Oliveira, Evanildo F.; Freire, Valder N.] Univ Fed Ceara, Dept Fis, BR 60455760 Fortaleza, Ceara, Brazil.
   [Barroso Neto, Ito L.; Lima Neto, Pedro] Univ Fed Ceara, Dept Quim Anal & Fis Quim, BR 60455760 Fortaleza, Ceara, Brazil.
   [Fonseca, Emerson; Ladeira, Luiz O.] Univ Fed Minas Gerais, Dept Fis, Belo Horizonte, MG, Brazil.
C3 Universidade Federal do Ceara; Universidade Federal do Ceara;
   Universidade Federal de Minas Gerais
RP Sousa, BL (通讯作者)，Univ Fed Ceara, Dept Fis, BR 60455760 Fortaleza, Ceara, Brazil.
EM brunolopesdesousa@gmail.com
RI Barroso Neto, Ito Liberato/J 1436 2016; De Lima Neto, Pedro/F 2440 2012;
   Barroso Neto, Ito/J 1436 2016; Freire, Valder/D 1136 2013; Ladeira,
   Luiz/AAJ 4918 2021; Fonseca, Emerson/AAI 3637 2021
OI Barroso Neto, Ito Liberato/0000 0001 7820 8053; Ladeira, Luiz
   Orlando/0000 0002 4935 6070; Sousa, Bruno/0000 0002 0689 0898; Freire,
   Valder/0000 0001 7867 3908; Fonseca, Emerson/0000 0002 7971 1686
FU Fundacao de Amparo a Pesquisa do Estado de Minas Gerais
   (PRONEX/FAPEMIG Brazil); Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)
FX This study was partially supported by Fundacao de Amparo a Pesquisa do
   Estado de Minas Gerais (PRONEX/FAPEMIG Brazil), Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), and Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES).
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   [Anonymous], 2012, Proteomics Bioinf.
   Antony J, 2012, J COMPUT CHEM, V33, P1730, DOI 10.1002/jcc.23004
   Barroso Neto IL, 2012, J PHYS CHEM B, V116, P3270, DOI 10.1021/jp206397z
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Chen XH, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1897382
   Cheng X, 2004, J BIOL CHEM, V279, P8269, DOI 10.1074/jbc.M309690200
   Clarke MV, 2015, ENDOCRINOLOGY, V156, P3203, DOI 10.1210/en.2015 1345
   Craik DJ, 2013, CHEM BIOL DRUG DES, V81, P136, DOI 10.1111/cbdd.12055
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   da Costa RF, 2012, PHYS CHEM CHEM PHYS, V14, P1389, DOI 10.1039/c1cp22824b
   Ribeiro TCD, 2014, NEW J CHEM, V38, P2946, DOI 10.1039/c3nj01453c
   Dantas DS, 2015, RSC ADV, V5, P49439, DOI 10.1039/c5ra04395f
   Delley B, 2000, J CHEM PHYS, V113, P7756, DOI 10.1063/1.1316015
   ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Fosgerau K, 2015, DRUG DISCOV TODAY, V20, P122, DOI 10.1016/j.drudis.2014.10.003
   Geppert T, 2011, CHEM BIOL, V18, P344, DOI 10.1016/j.chembiol.2011.01.005
   Gordon MS, 2012, CHEM REV, V112, P632, DOI 10.1021/cr200093j
   Gurban CV, 2011, ROM J MORPHOL EMBRYO, V52, P1113
   Hafner J, 2010, NAT MATER, V9, P690, DOI 10.1038/nmat2838
   Hanada R, 2009, NATURE, V462, P505, DOI 10.1038/nature08596
   He X, 2010, J CHEM THEORY COMPUT, V6, P405, DOI 10.1021/ct9006635
   Heymann D, 2012, J BONE ONCOL, V1, P2, DOI 10.1016/j.jbo.2012.03.001
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRevB.7.1912
   Hruby VJ, 2013, ANNU REV PHARMACOL, V53, P557, DOI 10.1146/annurev pharmtox 010510 100456
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263 7855(96)00018 5
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Jorgensen WL, 2004, SCIENCE, V303, P1813, DOI 10.1126/science.1096361
   Khosla S, 2013, J GERONTOL A BIOL, V68, P1226, DOI 10.1093/gerona/gls163
   KLAMT A, 1993, J CHEM SOC PERK T 2, P799, DOI 10.1039/p29930000799
   KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Neto JXL, 2015, PHYS CHEM CHEM PHYS, V17, P13092, DOI 10.1039/c4cp05630b
   Liu CZ, 2015, SCI REP UK, V5, DOI 10.1038/srep14150
   Liu CZ, 2010, J IMMUNOL, V184, P6910, DOI 10.4049/jimmunol.0904033
   London N, 2010, STRUCTURE, V18, P188, DOI 10.1016/j.str.2009.11.012
   Luan XD, 2012, J IMMUNOL, V189, P245, DOI 10.4049/jimmunol.1103387
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Ma B, 2012, ACTA PHARMACOL SIN, V33, P479, DOI 10.1038/aps.2011.177
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Martins ACV, 2016, BIOELECTROCHEMISTRY, V108, P46, DOI 10.1016/j.bioelechem.2015.12.004
   Martins ACV, 2013, RSC ADV, V3, P14988, DOI 10.1039/c3ra42149j
   Milroy LG, 2014, CHEM REV, V114, P4695, DOI 10.1021/cr400698c
   Mohammadpour Amir Hooshang, 2012, Thrombosis, V2012, P306263, DOI 10.1155/2012/306263
   Monari A, 2013, ACCOUNTS CHEM RES, V46, P596, DOI 10.1021/ar300278j
   Naidu VGM, 2013, CHEM BIOL INTERACT, V203, P467, DOI 10.1016/j.cbi.2012.12.016
   Nelson CA, 2012, STRUCTURE, V20, P1971, DOI 10.1016/j.str.2012.08.030
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   Orwoll ES, 2014, J CLIN INVEST, V124, P491, DOI 10.1172/JCI71101
   Patargias GN, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3430628
   Pelay Gimeno M., 2015, ANGEW CHEM INT EDIT, V54, P2
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Rehman Q, 2001, ARTHRITIS RES, V3, P221, DOI 10.1186/ar305
   Rezacova P, 2008, PROTEINS, V70, P311, DOI 10.1002/prot.21511
   Rodrigues CRF, 2013, CHEM PHYS LETT, V559, P88, DOI 10.1016/j.cplett.2012.12.061
   Roodman GD, 2005, J CLIN INVEST, V115, P200, DOI 10.1172/JCI200524281
   Rossi SW, 2007, J EXP MED, V204, P1267, DOI 10.1084/jem.20062497
   Rupp M, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.058301
   Schneeweis LA, 2005, J BIOL CHEM, V280, P41155, DOI 10.1074/jbc.M506366200
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Schutz C.N., 2001, Proteins Structure Function and Genetics, V417, P400
   Siar CH, 2015, OR SURG OR MED OR PA, V119, P83, DOI 10.1016/j.oooo.2014.09.017
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Subbiah V, 2010, OSTEOPOROSIS INT, V21, P1041, DOI 10.1007/s00198 009 1004 0
   Takasaki W, 1997, NAT BIOTECHNOL, V15, P1266, DOI 10.1038/nbt1197 1266
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Téletchéa S, 2014, J BONE MINER RES, V29, P1466, DOI 10.1002/jbmr.2170
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   van der Kamp MW, 2013, BIOCHEMISTRY US, V52, P2708, DOI 10.1021/bi400215w
   Vicatos S, 2009, PROTEINS, V77, P670, DOI 10.1002/prot.22481
   Vlieghe P, 2010, DRUG DISCOV TODAY, V15, P40, DOI 10.1016/j.drudis.2009.10.009
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   WARSHEL A, 1984, P NATL ACAD SCI BIOL, V81, P4785, DOI 10.1073/pnas.81.15.4785
   Warshel A, 2006, BBA PROTEINS PROTEOM, V1764, P1647, DOI 10.1016/j.bbapap.2006.08.007
   Weitzmann MN, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/125705
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Wu EL, 2007, BIOPHYS J, V92, P4244, DOI 10.1529/biophysj.106.099150
   Wuyts W, 2001, BONE, V28, P104, DOI 10.1016/S8756 3282(00)00411 7
   Xie JP, 2011, J MANAGE CARE PHARM, V17, P621, DOI 10.18553/jmcp.2011.17.8.621
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zanatta G, 2014, ACS CHEM NEUROSCI, V5, P1041, DOI 10.1021/cn500111e
   Zhang DW, 2003, J CHEM PHYS, V119, P3599, DOI 10.1063/1.1591727
   Zhou T, 2010, CURR TOP MED CHEM, V10, P33, DOI 10.2174/156802610790232242
NR 90
TC 7
Z9 7
U1 1
U2 10
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046 2069
J9 RSC ADV
JI RSC Adv.
PY 2016
VL 6
IS 88
BP 84926
EP 84942
DI 10.1039/c6ra16712h
PG 17
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA DX1PI
UT WOS:000384139000044
OA Green Published
DA 2025 08 17
ER

PT J
AU Zhang, SY
   Dong, KF
   Zeng, XJ
   Wang, F
   Lu, M
AF Zhang, Shenyao
   Dong, Kefang
   Zeng, Xiangjing
   Wang, Fan
   Lu, Min
TI Astragalus polysaccharide ameliorates steroid induced osteonecrosis of
   the femoral head by regulating miR 200b 3p mediated
   Wnt/β catenin signaling pathway via inhibiting SP1
   expression Astragalus polysaccharide regulates SONFH via SP1
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Astragalus polysaccharide; miR 200b 3p; SP1; Steroid induced
   osteonecrosis of the femoral head; Wnt/beta catenin
ID BONE
AB Background Steroid induced osteonecrosis of the femoral head (SONFH) is the necrosis of the femur bone caused by prolonged and massive use of corticosteroids. The present study probed into the significance of Astragalus polysaccharide (APS) in SONFH progression.
   Methods SONFH cell model was constructed using murine long bone osteocyte Y4 (MLO Y4) cells and then treated with APS. mRNA microarray analysis selected differentially expressed genes between control group and SONFH group. RT qPCR determined SP1 and miR 200b 3p expression. Levels of SP1, beta catenin, autophagy related proteins (LC3II/LC3I, Beclin1, p62) and apoptosis related proteins (Bax, C caspase3, C caspase9, Bcl 2) were tested by Western blot. ChIP and luciferase reporter assays confirmed relationship between SP1 and miR 200b 3p. Fluorescence intensity of LC3 in cells was detected by immunofluorescence. Flow cytometry assessed cell apoptosis. Osteonecrosis tissues from SONFH mice were examined by HE and TRAP staining.
   Results APS induced autophagy and suppressed apoptosis in SONFH cell model. APS inhibited SP1 expression and SP1 overexpression reversed effects of APS on SONFH cell model. Mechanistically, SP1 targeted miR 200b 3p to inhibit Wnt/beta catenin pathway. MiR 200b 3p depletion rescued the promoting effect of SP1 on SONFH cell model by activating Wnt/beta catenin pathway. HE staining showed that APS treatment reduced the empty lacunae and alleviated inflammation in trabecular bone of SONFH mice. TRAP staining revealed decreased osteoclasts number in SONFH mice after APS treatment.
   Conclusion APS regulated osteocyte autophagy and apoptosis via SP1/miR 200b 3p axis and activated Wnt/beta catenin signaling, thereby alleviating SONFH, shedding new insights for therapy of SONFH.
C1 [Zhang, Shenyao; Dong, Kefang; Zeng, Xiangjing; Wang, Fan] Hunan Univ Chinese Med, Orthoped Dept, Affiliated Hosp 2, Changsha, Peoples R China.
   [Lu, Min] Hunan Univ Chinese Med, Orthoped Dept, Affiliated Hosp 1, Changsha, Peoples R China.
C3 Hunan University of Chinese Medicine; Hunan University of Chinese
   Medicine
RP Lu, M (通讯作者)，Hunan Univ Chinese Med, Orthoped Dept, Affiliated Hosp 1, Changsha, Peoples R China.
EM lumin00222@126.com
FU Provincial Natural Science Foundation of Hunan,Youth Foundation
   [2022JJ40328]
FX The authors gratefully acknowledge the financial supports of Provincial
   Natural Science Foundation of Hunan, Youth Foundation: Mechanism of
   astragalus polysaccharide ameliorating steroid induced osteonecrosis of
   femoral head via regulation of osteocyte autophagy and apoptosis through
   down regulating miR 206 (No. 2022JJ40328).
CR Birla Vikas, 2021, J Clin Orthop Trauma, V23, P101643, DOI 10.1016/j.jcot.2021.101643
   Chang C, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2020.102460
   Chen DL, 2021, AM J TRANSL RES, V13, P7574
   Chen LJ, 2018, MOL MED REP, V18, P2571, DOI 10.3892/mmr.2018.9287
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Duan PP, 2016, INT J BIOCHEM CELL B, V77, P23, DOI 10.1016/j.biocel.2016.05.015
   Duttenhoefer F, 2014, INT J ORAL MAX IMPL, V29, pE107, DOI 10.11607/jomi.te49
   Fu WM, 2019, INT ORTHOP, V43, P1083, DOI 10.1007/s00264 018 4011 y
   Han LZ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.606289
   Han LZ, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1498 0
   Huo J, 2016, Genet Mol Res, V15, DOI 10.4238/gmr15049169
   Jing L, 2020, FOOD NUTR RES, P64
   Koizume S, 2016, CANCERS, V8, DOI 10.3390/cancers8010002
   Kong FM, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.737674
   Li CX, 2022, ARCH PHARM RES, V45, P367, DOI 10.1007/s12272 022 01393 3
   Li LS, 2019, BIOCHEM BIOPH RES CO, V517, P103, DOI 10.1016/j.bbrc.2019.07.025
   Lin TY, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02464 9
   Luo P, 2018, INT ORTHOP, V42, P1747, DOI 10.1007/s00264 018 3994 8
   Ou L, 2019, ACTA CIR BRAS, V34, DOI 10.1590/s0102 865020190050000002
   Peng Y, 2017, ONCOTARGET, V8, P14089, DOI 10.18632/oncotarget.12923
   Shen GY, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102626
   Shi W, 2022, CARTILAGE, V13, DOI 10.1177/19476035221074000
   Stacey SK, 2021, AM FAM PHYSICIAN, V103, P337
   Tan YY, 2020, INT J BIOL MACROMOL, V153, P349, DOI 10.1016/j.ijbiomac.2020.02.282
   Tutar L, 2015, DRUG DEVELOP RES, V76, P382, DOI 10.1002/ddr.21273
   Wang A, 2018, GENE, V671, P103, DOI 10.1016/j.gene.2018.05.091
   Xia CP, 2020, MOL CELL PROBE, V50, DOI 10.1016/j.mcp.2019.101504
   Xie WG, 2015, MED SCI MONITOR, V21, P1333, DOI 10.12659/MSM.894111
   Yang M, 2010, J ETHNOPHARMACOL, V127, P242, DOI 10.1016/j.jep.2009.11.013
   Zhang LS, 2017, BIOCHEM BIOPH RES CO, V485, P736, DOI 10.1016/j.bbrc.2017.02.118
   Zhang SY, 2021, KAOHSIUNG J MED SCI, V37, P1089, DOI 10.1002/kjm2.12426
   Zhang YM, 2020, CELL CYCLE, V19, P3195, DOI 10.1080/15384101.2020.1838793
   Zheng YJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00349
   Zhu L, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.903432
NR 34
TC 6
Z9 10
U1 4
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD MAY 10
PY 2023
VL 24
IS 1
AR 369
DI 10.1186/s12891 023 06447 1
PG 12
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA G1CN4
UT WOS:000986621400002
PM 37165386
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jiang, T
   Yu, XH
   Carbone, EJ
   Nelson, C
   Kan, HM
   Lo, KWH
AF Jiang, Tao
   Yu, Xiaohua
   Carbone, Erica J.
   Nelson, Clarke
   Kan, Ho Man
   Lo, Kevin W.  H.
TI Poly aspartic acid peptide linked PLGA based nanoscale particles:
   Potential for bone targeting drug delivery applications
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Nanoparticles; Targeted drug delivery; Peptides; Bone diseases
ID GENE THERAPY; IN VITRO; CLINICAL APPLICATIONS; SMALL MOLECULES;
   LUNG CANCER; NANOPARTICLES; SYSTEM; POLY(LACTIDE CO GLYCOLIDE);
   OLIGOPEPTIDE; OSTEOPOROSIS
AB Delivering drugs specifically to bone tissue is very challenging due to the architecture and structure of bone tissue. Poly(lactic co glycolic acid) (PLGA) based nanoparticles (NPs) hold great promise for the delivery of therapeutics to bone tissue. The goal of the present research was to formulate a PLGA based NP drug delivery system for bone tissue exclusively. Since poly aspartic acids (poly Asp) peptide sequence has been shown to bind to hydroxyapatite (HA), and has been suggested as a molecular tool for bone targeting applications, we fabricated PLGA based NPs linked with poly Asp peptide sequence. Nanoparticles made of methoxy   poly(ethylene glycol) (PEG) PLGA and maleimide PEG PLGA were prepared using a water in oil in water double emulsion and solvent evaporation method. Fluorescein isothiocyanate (FITC) tagged poly Asp peptide was conjugated to the surface of the nanoparticles via the alkylation reaction between the sulfhydryl groups at the N terminal of the peptide and the C C double bond of maleimide at one end of the polymer chain to form thioether bonds. The conjugation of FITC tagged poly Asp peptide to PLGA NPs was confirmed by NMR analysis and fluorescent microscopy. The developed nanoparticle system is highly aqueous dispersible with an average particle size of similar to 80 nm. In vitro binding analyses demonstrated that FITC poly Asp NPs were able to bind to HA gel as well as to mineralized matrices produced by human mesenchymal stem cells and mouse bone marrow stromal cells. Using a confocal microscopy technique, an ex vivo binding study of mouse major organ ground sections revealed that the FITC poly Asp NPs were able to bind specifically to the bone tissue. In addition, proliferation studies indicated that our FITC poly Asp NPs did not induce cytotoxicity to human osteoblast like MG63 cell lines. Altogether, these promising results indicated that this nanoscale targeting system was able to bind to bone tissue specifically and might have a great potential for bone disease therapy in clinical applications. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Jiang, Tao; Yu, Xiaohua; Carbone, Erica J.; Nelson, Clarke; Kan, Ho Man; Lo, Kevin W.  H.] Univ Connecticut, Ctr Hlth, Sch Med, Inst Regenerat Engn, Farmington, CT 06030 USA.
   [Jiang, Tao; Yu, Xiaohua; Carbone, Erica J.; Nelson, Clarke; Kan, Ho Man; Lo, Kevin W.  H.] Univ Connecticut, Ctr Hlth, Sch Med, Raymond & Beverly Sackler Ctr Biomed Biol Phys &, Farmington, CT 06030 USA.
   [Jiang, Tao; Carbone, Erica J.; Lo, Kevin W.  H.] Univ Connecticut, Ctr Hlth, Sch Med, Dept Med,Div Endocrinol, Farmington, CT 06030 USA.
   [Lo, Kevin W.  H.] Univ Connecticut, Sch Engn, Dept Biomed Engn, Storrs, CT 06268 USA.
   [Yu, Xiaohua; Kan, Ho Man] Univ Connecticut, Ctr Hlth, Sch Med, Dept Orthoped Surg, Farmington, CT 06030 USA.
C3 University of Connecticut; University of Connecticut; University of
   Connecticut; University of Connecticut; University of Connecticut
RP Lo, KWH (通讯作者)，Univ Connecticut, Ctr Hlth, Sch Med, Farmington, CT 06030 USA.
EM wlo@uchc.edu
RI Yu, Xiaohua/J 9903 2014
FU Connecticut Stem Cell Research Foundation [13 SCA UCHC 01]; Raymond;
   Beverly Sackler Center for Biomedical, Biological, Physical and
   Engineering Sciences Foundation
FX The work was partly supported by the Connecticut Stem Cell Research
   Foundation grant (13 SCA UCHC 01) to Dr. Kevin Lo. We would like to
   thank Dr. Cato T. Laurencin, the Director of the Institute for
   Regenerative Engineering (IRE) and the University Professor of the
   University of Connecticut, for his excellent leadership. We wish to
   thank the Raymond and Beverly Sackler Center for Biomedical, Biological,
   Physical and Engineering Sciences Foundation for supporting our
   Institute. The authors would also like to thank Dr. Ewa Folta Stogniew
   at the Keck Biotechnology Resource Laboratory of Yale University School
   of Medicine for her technical assistance on the dynamic light scattering
   experiments. Finally, we wish to thank all members of the IRE, past and
   present, and numerous colleagues and friends for their helpful
   discussions.
CR [Anonymous], J TISSUE ENG REGEN M
   Aoki K, 2012, ADV DRUG DELIVER REV, V64, P1220, DOI 10.1016/j.addr.2012.05.017
   Baltzer AWA, 2001, GENE THER, V8, P1770, DOI 10.1038/sj.gt.3301594
   Bivas Benita M, 2004, EUR J PHARM BIOPHARM, V58, P1, DOI 10.1016/j.ejpb.2004.03.008
   Buescher JM, 2007, CRIT REV BIOTECHNOL, V27, P1, DOI 10.1080/07388550601166458
   Cao Z., 2010, Angewandte Chemie, V122, P3859, DOI DOI 10.1002/ANGE.V122:22
   Capriani C, 2012, J BONE MINER RES, V27, P2419, DOI 10.1002/jbmr.1800
   Chen HY, 2012, BIOCONJUGATE CHEM, V23, P1915, DOI 10.1021/bc3003088
   Chen Z, 2010, TRENDS MOL MED, V16, P594, DOI 10.1016/j.molmed.2010.08.001
   Cheng WW, 2010, EXPERT OPIN DRUG DEL, V7, P461, DOI 10.1517/17425240903579963
   Croll TI, 2004, BIOMACROMOLECULES, V5, P463, DOI 10.1021/bm0343040
   de Miguel L, 2014, INT J PHARMACEUT, V460, P73, DOI 10.1016/j.ijpharm.2013.10.048
   Egermann M, 2005, OSTEOPOROSIS INT, V16, pS120, DOI 10.1007/s00198 004 1817 9
   FUJISAWA R, 1991, BIOCHIM BIOPHYS ACTA, V1075, P56
   Genevaux P, 2002, GENETICS, V162, P1045
   Goldenberg NM, 2010, CANCER RES, V70, P1277, DOI 10.1158/0008 5472.CAN 09 2905
   GORSKI JP, 1992, CALCIFIED TISSUE INT, V50, P391, DOI 10.1007/BF00296767
   Gu WY, 2013, INT J NANOMED, V8, DOI 10.2147/IJN.S44393
   Jain R, 1998, DRUG DEV IND PHARM, V24, P703, DOI 10.3109/03639049809082719
   Jain RA, 2000, BIOMATERIALS, V21, P2475, DOI 10.1016/S0142 9612(00)00115 0
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   Laurencin CT, 2014, DRUG DISCOV TODAY, V19, P794, DOI 10.1016/j.drudis.2014.01.012
   Lee TY, 2007, CANCER RES, V67, P10958, DOI 10.1158/0008 5472.CAN 07 2233
   Liang GF, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556 276X 6 447
   Lin ZY, 2010, J CONTROL RELEASE, V144, P190, DOI 10.1016/j.jconrel.2010.02.016
   Lo KWH, 2012, J TISSUE ENG REGEN M, V6, P40, DOI 10.1002/term.395
   Lo KWH, 2012, REGEN MED, V7, P535, DOI [10.2217/rme.12.33, 10.2217/RME.12.33]
   Lu RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066128
   Lü JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI 10.1586/ERM.09.15
   Luhmann T, 2012, J CONTROL RELEASE, V161, P198, DOI 10.1016/j.jconrel.2011.10.001
   Luo GP, 2010, INT J PHARMACEUT, V385, P150, DOI 10.1016/j.ijpharm.2009.10.014
   Malich G, 1997, TOXICOLOGY, V124, P179, DOI 10.1016/S0300 483X(97)00151 0
   Mooney DT, 1996, BIOMATERIALS, V17, P115, DOI 10.1016/0142 9612(96)85756 5
   Murphy MB, 2007, BIOMACROMOLECULES, V8, P2237, DOI 10.1021/bm070121s
   Nam YS, 2003, BIOMATERIALS, V24, P2053, DOI 10.1016/S0142 9612(02)00641 5
   Ogawa K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084335
   OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819
   OLDBERG A, 1988, J BIOL CHEM, V263, P19430
   Ouyang L, 2009, SYNTHETIC COMMUN, V39, P4039, DOI 10.1080/00397910902883660
   Maia FR, 2013, ACTA BIOMATER, V9, P8773, DOI 10.1016/j.actbio.2013.08.004
   Rizzoli R., 2013, EXPERT REV CLIN PHAR, V4, P593
   Sabir MI, 2009, J MATER SCI, V44, P5713, DOI 10.1007/s10853 009 3770 7
   Sarig S, 2004, BONE, V35, P108, DOI 10.1016/j.bone.2004.02.020
   Tautzenberger A, 2012, INT J NANOMED, V7, P4545, DOI 10.2147/IJN.S34127
   Vert M, 1998, J CONTROL RELEASE, V53, P85, DOI 10.1016/S0168 3659(97)00240 X
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang YQ, 2004, BIOMATERIALS, V25, P4777, DOI 10.1016/j.biomaterials.2003.11.051
   Xiao RZ, 2010, INT J NANOMED, V5, P1057, DOI [10.2147/ijn.S14912, 10.2147/IJN.S14912]
   Yokogawa K, 2001, ENDOCRINOLOGY, V142, P1228, DOI 10.1210/en.142.3.1228
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang N, 2008, BIOCONJUGATE CHEM, V19, P145, DOI 10.1021/bc700227z
   Zhao J, 2005, MACROMOL BIOSCI, V5, P636, DOI 10.1002/mabi.200500043
   Zou WW, 2009, INT J PHARMACEUT, V370, P187, DOI 10.1016/j.ijpharm.2008.11.016
NR 53
TC 81
Z9 92
U1 4
U2 118
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD NOV 20
PY 2014
VL 475
IS 1 2
BP 547
EP 557
DI 10.1016/j.ijpharm.2014.08.067
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AU0FR
UT WOS:000345299500057
PM 25194353
DA 2025 08 17
ER

PT J
AU Delorme, B
   Ringe, J
   Pontikoglou, C
   Gaillard, J
   Langonné, A
   Sensebé, L
   Noël, D
   Jorgensen, C
   Häupl, T
   Charbord, P
AF Delorme, Bruno
   Ringe, Jochen
   Pontikoglou, Charalampos
   Gaillard, Julien
   Langonné, Alain
   Sensebe, Luc
   Noel, Daniele
   Jorgensen, Christian
   Haeupl, Thomas
   Charbord, Pierre
TI Specific Lineage Priming of Bone Marrow Mesenchymal Stem Cells Provides
   the Molecular Framework for Their Plasticity
SO STEM CELLS
LA English
DT Article
DE Differentiation; Osteoblast; Chondrocyte; Adipocyte; Muscle; Neuron;
   Hepatocyte; Endothelium
ID MULTILINEAGE GENE EXPRESSION; STROMAL CELLS; IN VITRO; HEMATOPOIETIC
   MICROENVIRONMENT; GROWTH FACTOR; DIFFERENTIATION; PHENOTYPE; CULTURE;
   REPAIR; TRANSDIFFERENTIATION
AB Lineage priming is a molecular model of stem cell (SC) differentiation in which proliferating SCs express a subset of genes associated to the differentiation pathways to which they can commit. This concept has been developed for hematopoietic SCs, but has been poorly studied for other SC populations. Because the differentiation potential of human bone marrow mesenchymal stem cells (BM MSCs) remains controversial, we have explored the theory of lineage priming applied to these cells. We show that proliferating primary layers and clones of BM MSCs have precise priming to the osteoblastic (O), chondrocytic (C), adipocytic (A), and the vascular smooth muscle (V) lineages, but not to skeletal muscle, cardiac muscle, hematopoietic, hepatocytic, or neural lineages. Priming was shown both at the mRNA (300 transcripts were evaluated) and the protein level. In particular, the master transactivator proteins PPARG, RUNX2, and SOX9 were coexpressed before differentiation induction in all cells from incipient clones. We further show that MSCs cultured in the presence of inducers differentiate into the lineages for which they are primed. Our data point out to a number of signaling pathways that might be activated in proliferating MSCs and would be responsible for the differentiation and proliferation potential of these cells. Our results extend the notion of lineage priming and provide the molecular framework for inter A,  O,  C,  V plasticity of BM MSCs. Our data highlight the use of BM MSCs for the cell therapy of skeletal or vascular disorders, but provide a word of caution about their use in other clinical indications. STEM CELLS 2009;27:1142 1151
C1 [Charbord, Pierre] Hop Paul Brousse, INSERM, U972, F 94807 Villejuif, France.
   [Delorme, Bruno; Pontikoglou, Charalampos; Gaillard, Julien; Langonné, Alain; Sensebe, Luc; Charbord, Pierre] Univ Tours, INSERM, Equipe ESPRI EA 3855, Fac Med, Tours, France.
   [Ringe, Jochen; Haeupl, Thomas] Charite, Dept Rheumatol & Clin Immunol, Lab Tissue Engn, D 13353 Berlin, Germany.
   [Delorme, Bruno] MacoPharma, Tourcoing, France.
   [Gaillard, Julien; Langonné, Alain; Sensebe, Luc] Etab Francais Sang Ctr Atlantique, Tours, France.
   [Noel, Daniele; Jorgensen, Christian] Lapeyronie Hosp, INSERM, U844, Montpellier, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Paul Brousse   APHP; Universite de Tours; Institut National de la Sante
   et de la Recherche Medicale (Inserm); Free University of Berlin;
   Humboldt University of Berlin; Charite Universitatsmedizin Berlin;
   Universite de Montpellier; CHU de Montpellier; Institut National de la
   Sante et de la Recherche Medicale (Inserm)
RP Charbord, P (通讯作者)，Hop Paul Brousse, INSERM, U972, Batiment Lavoisier,14 16 Av Paul Vaillant Couturi, F 94807 Villejuif, France.
EM pcharbord@noos.fr
RI ; Noel, Daniele/E 5719 2016
OI charbord, pierre/0000 0002 2254 3300; Noel, Daniele/0000 0002 3498 3776
FU European Community [503161]; INSERM [A04069FS]; German Federal Ministry
   of Education and Research [01GS0413]
FX This work is supported by the European Community (Key action 1.2.4 3
   Integrated Project Genostem, contract No. 503161), by a grant from
   INSERM (Contract ProA No. A04069FS), and by the (national genome
   research network in Germany (German Federal Ministry of Education and
   Research, grant 01GS0413).
CR Anjos Afonso F, 2007, BLOOD, V109, P1298, DOI 10.1182/blood 2006 06 030551
   Ball SG, 2007, J CELL BIOL, V177, P489, DOI 10.1083/jcb.200608093
   BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092 8674(82)90027 7
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Breitbach M, 2007, BLOOD, V110, P1362, DOI 10.1182/blood 2006 12 063412
   Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886
   Chateauvieux S, 2007, PHYSIOL GENOMICS, V29, P128, DOI 10.1152/physiolgenomics.00197.2006
   Delorme Bruno, 2007, V140, P67
   Delorme B, 2008, BLOOD, V111, P2631, DOI 10.1182/blood 2007 07 099622
   Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364
   Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Even Ram S, 2006, CELL, V126, P645, DOI 10.1016/j.cell.2006.08.008
   GALMICHE MC, 1993, BLOOD, V82, P66, DOI 10.1182/blood.V82.1.66.bloodjournal82166
   Graf T, 2002, BLOOD, V99, P3089, DOI 10.1182/blood.V99.9.3089
   Hatzfeld A, 2007, LEUKEMIA, V21, P714, DOI 10.1038/sj.leu.2404589
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kaltz N, 2008, STEM CELLS, V26, P2419, DOI 10.1634/stemcells.2008 0304
   Loose M, 2006, CURR OPIN HEMATOL, V13, P229, DOI 10.1097/01.moh.0000231419.15654.7f
   Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298
   Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007 1122
   Minguell JJ, 2005, STEM CELLS DEV, V14, P408, DOI 10.1089/scd.2005.14.408
   Muguruma Y, 2006, BLOOD, V107, P1878, DOI 10.1182/blood 2005 06 2211
   Oswald J, 2004, STEM CELLS, V22, P377, DOI 10.1634/stemcells.22 3 377
   Park SR, 1999, BONE, V24, P549, DOI 10.1016/S8756 3282(99)00084 8
   Peterkin T, 2005, SEMIN CELL DEV BIOL, V16, P83, DOI 10.1016/j.semcdb.2004.10.003
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pontikoglou C, 2008, REGEN MED, V3, P731, DOI 10.2217/17460751.3.5.731
   Pri Chen S, 1998, BONE, V23, P111, DOI 10.1016/S8756 3282(98)00087 8
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Satomura K, 2000, J CELL BIOCHEM, V78, P391
   Seshi B, 2003, BLOOD CELL MOL DIS, V31, P268, DOI 10.1016/S1079 9796(03)00150 5
   Solchaga LA, 2005, J CELL PHYSIOL, V203, P398, DOI 10.1002/jcp.20238
   Song L, 2004, FASEB J, V18, P980, DOI 10.1096/fj.03 1100fje
   Song L, 2006, STEM CELLS, V24, P1707, DOI 10.1634/stemcells.2005 0604
   Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207
   Tremain N, 2001, STEM CELLS, V19, P408, DOI 10.1634/stemcells.19 5 408
   Vilquin JT, 2006, REGEN MED, V1, P589, DOI 10.2217/17460751.1.4.589
   Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365
   Zipori D, 2004, NAT REV GENET, V5, P873, DOI 10.1038/nrg1475
NR 44
TC 104
Z9 122
U1 0
U2 6
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1066 5099
J9 STEM CELLS
JI Stem Cells
PY 2009
VL 27
IS 5
BP 1142
EP 1151
DI 10.1002/stem.34
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 447GL
UT WOS:000266179500017
PM 19418444
OA Bronze
DA 2025 08 17
ER

PT J
AU Sandoval Usme, MC
   Umaña Pérez, A
   Guerra, B
   Hernández Perera, O
   García Castellano, JM
   Fernández Pérez, L
   Sánchez Gómez, M
AF Claudia Sandoval Usme, Maria
   Umana Perez, Adriana
   Guerra, Borja
   Hernandez Perera, Orlando
   Manuel Garcia Castellano, Jose
   Fernandez Perez, Leandro
   Sanchez Gomez, Myriam
TI Simvastatin Impairs Growth Hormone Activated Signal Transducer and
   Activator of Transcription (STAT) Signaling Pathway in UMR 106
   Osteosarcoma Cells
SO PLOS ONE
LA English
DT Article
ID OSTEOBLAST LIKE CELLS; COLORECTAL CANCER; MELANOMA CELLS; GH;
   PHOSPHORYLATION; INHIBITORS; EXPRESSION; METASTASIS; MECHANISMS;
   LOVASTATIN
AB Recent studies have demonstrated that statins reduce cell viability and induce apoptosis in various types of cancer cells. The molecular mechanisms underlying these effects are poorly understood. The JAK/STAT pathway plays an important role in the regulation of proliferation and apoptosis in many tissues, and its deregulation is believed to be involved in tumorigenesis and cancer. The physiological activation of STAT proteins by GH is rapid but transient in nature and its inactivation is regulated mainly by the expression of SOCS proteins. UMR 106 osteosarcoma cells express a GH responsive JAK2/STAT5 signaling pathway, providing an experimental model to study the influence of statins on this system. In this study we investigated the actions of simvastatin on cell proliferation, migration, and invasion on UMR 106 cells and examined whether alterations in GH stimulated JAK/STAT/SOCS signaling may be observed. Results showed that treatment of osteosarcoma cells with simvastatin at 3 to 10 mu M doses decreases cell proliferation, migration, and invasion in a time and dose dependent manner. At the molecular level, although the mechanisms used by simvastatin are not entirely clear, the effect of the statin on the reduction of JAK2 and STAT5 phosphorylation levels may partially explain the decrease in the GH stimulated STAT5 transcriptional activity. This effect correlated with a time and dose dependent increase of SOCS 3 expression levels in cells treated with simvastatin, a regulatory role that has not been previously described. Furthermore, the finding that simvastatin is capable of inducing SOCS 3 and CIS genes expression shows the potential of the JAK/STAT pathway as a therapeutic target, reinforcing the efficacy of simvastatin as chemotherapeutic drug for the treatment of osteosarcoma.
C1 [Claudia Sandoval Usme, Maria; Umana Perez, Adriana; Sanchez Gomez, Myriam] Univ Nacl Colombia, Hormone Lab, Dept Chem, Bogota, Colombia.
   [Guerra, Borja; Fernandez Perez, Leandro] Univ Las Palmas Gran Canaria, Dept Clin Sci, Mol & Translat Endocrinol Grp, Canc Res Inst Canary Isl ICIC, Las Palmas Gran Canaria, Spain.
   [Guerra, Borja; Fernandez Perez, Leandro] CSIC, Associated Biomed Unit, ULPGC IIBM Alberto Sols, Las Palmas Gran Canaria, Spain.
   [Hernandez Perera, Orlando; Manuel Garcia Castellano, Jose] CHUIMI, Mol Oncol Lab, Res Unit, Las Palmas Gran Canaria, Spain.
C3 Universidad Nacional de Colombia; Universidad de Las Palmas de Gran
   Canaria; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC  
   Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)
RP Sandoval Usme, MC (通讯作者)，Univ Nacl Colombia, Hormone Lab, Dept Chem, Bogota, Colombia.
EM mysanchezd@unal.edu.co
RI Guerra, Borja/G 9739 2015; Umana Perez, Adriana/MSW 0703 2025;
   Fernandez Perez, Leandro/H 1493 2015
OI Guerra, Borja/0000 0003 4355 5682; Umana Perez,
   Adriana/0000 0001 9262 2699; Fernandez Perez,
   Leandro/0000 0001 7802 465X; Sanchez Gomez, Myriam/0000 0002 9481 7534
FU Spanish Ministry of Science and Innovation; European Regional
   Development Fund European Social Fund [SAF2003 02117, SAF2006 07824];
   National University of Colombia Research Council (DIB) [10879, 12243,
   14233, 16056]
FX This work was supported by grants in aid to LF P from the Spanish
   Ministry of Science and Innovation with the funding of European Regional
   Development Fund European Social Fund (SAF2003 02117 and SAF2006 07824)
   and grants to M.S. G. from the National University of Colombia Research
   Council (DIB Grants 10879, 12243, 14233 and 16056). The excellent
   technical assistance of C. Mateos Diaz is greatly appreciated. The
   funders had no role in the study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ahmed SF, 2010, J ENDOCRINOL, V206, P249, DOI 10.1677/JOE 10 0045
   Babon JJ, 2008, J MOL BIOL, V381, P928, DOI 10.1016/j.jmb.2008.06.038
   BARNARD R, 1991, ENDOCRINOLOGY, V128, P1459, DOI 10.1210/endo 128 3 1459
   Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527
   Cabrera Benitez NE, 2008, PAPEL INHIBIDORES 3
   CARMICHAEL J, 1987, CANCER RES, V47, P936
   Collisson EA, 2003, MOL CANCER THER, V2, P941
   Cooper JC, 2010, INT J ONCOL, V36, P1201, DOI 10.3892/ijo_00000603
   Deng JY, 2010, WORLD J GASTROENTERO, V16, P5380, DOI 10.3748/wjg.v16.i42.5380
   Fernández L, 1998, ENDOCRINOLOGY, V139, P1815, DOI 10.1210/en.139.4.1815
   Fromigué O, 2008, J PHARMACOL EXP THER, V325, P595, DOI 10.1124/jpet.108.136127
   Gallagher EJ, 2011, CELL METAB, V13, P355, DOI 10.1016/j.cmet.2011.03.003
   Gbelcová H, 2008, INT J CANCER, V122, P1214, DOI 10.1002/ijc.23242
   Glynn SA, 2008, BMC CANCER, V8, DOI 10.1186/1471 2407 8 9
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Huang KC, 2003, FEBS LETT, V555, P385, DOI 10.1016/S0014 5793(03)01297 3
   Jougasaki M, 2010, BRIT J PHARMACOL, V159, P1294, DOI 10.1111/j.1476 5381.2009.00612.x
   Karlsson R, 2009, BBA REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003
   Kodach LL, 2007, GASTROENTEROLOGY, V133, P1272, DOI 10.1053/j.gastro.2007.08.021
   Koyuturk M, 2007, CANCER LETT, V250, P220, DOI 10.1016/j.canlet.2006.10.009
   Lima GAB, 2006, J ENDOCRINOL INVEST, V29, P1006, DOI 10.1007/BF03349215
   Liu J, 2008, LIFE SCI, V82, P991, DOI 10.1016/j.lfs.2008.02.012
   Mantha AJ, 2003, J CANCER RES CLIN, V129, P631, DOI 10.1007/s00432 003 0490 2
   Mitra A, 2012, J BIOL CHEM, V287, P16596, DOI 10.1074/jbc.M111.319756
   Morales O, 2000, J BONE MINER RES, V15, P2284, DOI 10.1359/jbmr.2000.15.11.2284
   Morales O, 2002, J BIOL CHEM, V277, P34879, DOI 10.1074/jbc.M204819200
   Nagy ZS, 2002, J LEUKOCYTE BIOL, V72, P819
   Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219
   Ohlsson C, 1998, ENDOCR REV, V19, P55, DOI 10.1210/er.19.1.55
   Oliveira KAP, 2008, J BIOENERG BIOMEMBR, V40, P307, DOI 10.1007/s10863 008 9155 9
   Park SH, 2001, MOL ENDOCRINOL, V15, P2157, DOI 10.1210/me.15.12.2157
   Parsons RB, 2006, BIOCHEM J, V399, P205, DOI 10.1042/BJ20060655
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553
   Robles Valero J, 2010, BLOOD, V115, P4174, DOI 10.1182/blood 2009 12 256222
   Sandoval Usme María Claudia, 2011, Rev. acad. colomb. cienc. exact. fis. nat., V35, P287
   Smirnova OV, 2007, WORLD J GASTROENTERO, V13, P6478, DOI 10.3748/wjg.13.6478
   Solly K, 2004, ASSAY DRUG DEV TECHN, V2, P363, DOI 10.1089/adt.2004.2.363
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   Spano JP, 2006, EUR J CANCER, V42, P2668, DOI 10.1016/j.ejca.2006.07.006
   Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206
   Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200
   Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218
   Zhang X, 2008, J IMMUNOL, V180, P6988, DOI 10.4049/jimmunol.180.10.6988
NR 44
TC 19
Z9 27
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JAN 29
PY 2014
VL 9
IS 1
AR e87769
DI 10.1371/journal.pone.0087769
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 301ZC
UT WOS:000330570000176
PM 24489959
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Carrier, JL
   Javadi, P
   Bourrier, E
   Camus, C
   Ségal Bendirdjian, E
   Karniguian, A
AF Carrier, Jean Luc
   Javadi, Pasha
   Bourrier, Emilie
   Camus, Celine
   Segal Bendirdjian, Evelyne
   Karniguian, Aida
TI cFos Mediates cAMP Dependent Generation of ROS and Rescue of Maturation
   Program in Retinoid Resistant Acute Promyelocytic Leukemia Cell Line
   NB4 LR1
SO PLOS ONE
LA English
DT Article
ID ACUTE MYELOID LEUKEMIA; OSTEOCLAST DIFFERENTIATION; CROSS TALK; CD44
   GENE; C FOS; NB4; ACTIVATION; EXPRESSION; PHOSPHORYLATION; MECHANISMS
AB A determining role has been assigned to cAMP in the signaling pathways that relieve resistance to anti leukemia differentiation therapy. However, the underlying mechanisms have not been elucidated yet. Here, we identify cFos as a critical cAMP effector, able to regulate the re expression and splicing of epigenetically silenced genes associated with maturation (CD44) in retinoid  resistant NB4 LR1 leukemia cells. Furthermore, using RNA interference approach, we show that cFos mediates cAMP induced ROS generation, a critical mediator of neutrophil maturation, and in fine differentiation. This study highlights some of the mechanisms by which cAMP acts to overcome resistance, and reveals a new alternative cFos dependent pathway which, though nonexistent in retinoid  sensitive NB4 cells, is essential to rescue the maturation program of resistant cells.
C1 [Carrier, Jean Luc; Javadi, Pasha; Bourrier, Emilie; Camus, Celine; Segal Bendirdjian, Evelyne; Karniguian, Aida] INSERM, UMR S 1007, Paris, France.
   [Carrier, Jean Luc; Javadi, Pasha; Bourrier, Emilie; Camus, Celine; Segal Bendirdjian, Evelyne; Karniguian, Aida] Univ Paris 05, Paris, France.
C3 Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite Paris Cite
RP Karniguian, A (通讯作者)，INSERM, UMR S 1007, Paris, France.
EM aida.karniguian@inserm.fr
RI ; Karniguian, Aida/M 3136 2018; Segal bendirdjian, evelyne/JRW 5286 2023
OI Segal Bendirdjian, Evelyne/0000 0001 9813 4880; Karniguian,
   Aida/0000 0002 2308 6236; 
FU Institut National de la Sante et de la Recherche Medicale (INSERM);
   Ligue Nationale Contre le Cancer (Comite de Paris)
FX This work was supported by grants from the Institut National de la Sante
   et de la Recherche Medicale (INSERM, www.inserm.fr/) and the Ligue
   Nationale Contre le Cancer (Comite de Paris,
   http://www.ligue cancer.net/). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abecassis I, 2008, LEUKEMIA, V22, P511, DOI 10.1038/sj.leu.2405071
   Altucci L, 2005, CANCER RES, V65, P8754, DOI 10.1158/0008 5472.CAN 04 3569
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bemmo A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011981
   Bendall LJ, 2000, LEUKEMIA, V14, P1239, DOI 10.1038/sj.leu.2401830
   Benoit G, 2001, ONCOGENE, V20, P7161, DOI 10.1038/sj.onc.1204760
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   de Thé H, 2010, NAT REV CANCER, V10, P775, DOI 10.1038/nrc2943
   Duprez E, 1996, ONCOGENE, V12, P2451
   DUPREZ E, 1992, LEUKEMIA, V6, P1281
   Goodison S, 1998, AM J PATHOL, V153, P1221, DOI 10.1016/S0002 9440(10)65666 0
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Guillemin MC, 2002, J EXP MED, V196, P1373, DOI 10.1084/jem.20021129
   Han BS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036941
   Hayes GM, 2004, CANCER GENE THER, V11, P797, DOI 10.1038/sj.cgt.7700759
   Jack GD, 2009, BLOOD, V114, P2172, DOI 10.1182/blood 2008 11 191536
   Kamashev D, 2004, J EXP MED, V199, P1163, DOI 10.1084/jem.20032226
   Lai HC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028280
   LANOTTE M, 1991, BLOOD, V77, P1080
   Legras S, 1998, BLOOD, V91, P3401, DOI 10.1182/blood.V91.9.3401.3401_3401_3413
   Lo Coco F, 1999, HAEMATOLOGICA, V84, P961
   LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841
   Mullenbrock S, 2011, J BIOL CHEM, V286, P45131, DOI 10.1074/jbc.M111.274076
   Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007
   Ohkubo Y, 2005, J IMMUNOL, V174, P7703, DOI 10.4049/jimmunol.174.12.7703
   Roussel MJS, 2001, ONCOGENE, V20, P7287, DOI 10.1038/sj.onc.1204863
   RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428
   Shafarenko M, 2004, BLOOD, V103, P4259, DOI 10.1182/blood 2002 09 2704
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097 2765(01)00404 X
   Vela E, 2006, BIOCHEM BIOPH RES CO, V343, P167, DOI 10.1016/j.bbrc.2006.02.128
   Yu Q, 1996, J BIOL CHEM, V271, P20603, DOI 10.1074/jbc.271.34.20603
NR 32
TC 4
Z9 5
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD NOV 28
PY 2012
VL 7
IS 11
AR e50408
DI 10.1371/journal.pone.0050408
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 057YW
UT WOS:000312601700068
PM 23209736
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Casarrubios, L
   Cicuéndez, M
   Polo Montalvo, A
   Feito, MJ
   Martínez del Pozo, A
   Arcos, D
   Duarte, IF
   Portoles, MT
AF Casarrubios, Laura
   Cicuendez, Monica
   Polo Montalvo, Alberto
   Feito, Maria Jose
   Martinez del Pozo, Alvaro
   Arcos, Daniel
   Duarte, Iola F.
   Portoles, Maria Teresa
TI Metabolomic characterization of MC3T3 E1pre osteoblast differentiation
   induced by ipriflavone loaded mesoporous nanospheres
SO BIOMATERIALS ADVANCES
LA English
DT Article
ID LIVER PLASMA MEMBRANES; SILICA NANOPARTICLES; OSTEOBLAST
   DIFFERENTIATION; DEGRADATION BEHAVIOR; OXIDATIVE STRESS; BONE;
   MICROVISCOSITY; STRATEGY; FLUIDITY; FUTURE
AB This study reports on the metabolic changes accompanying the differentiation of MC3T3 E1 osteoprogenitor cells induced by mesoporous bioactive glass nanospheres (nMBG) loaded with ipriflavone (nMBG IP). Ipriflavone (IP) is a synthetic isoflavone known for inhibiting bone resorption, maintaining bone density, and preventing osteoporosis. Delivering IP intracellularly is a promising strategy to modulate bone remodeling at significantly lower doses compared to free drug administration. Our results demonstrate that nMBG are efficiently internalized by pre osteoblasts and, when loaded with IP, induce their differentiation. This differentiation process is accompanied by pronounced metabolic alterations, as monitored by NMR analysis of medium supernatants and cell extracts (exo  and endo metabolomics, respectively). The main effects include an early stage intensification of glycolysis and changes in several metabolic pathways, such as nucleobase metabolism, osmoregulatory and antioxidant pathways, and lipid metabolism. Notably, the metabolic impacts of nMBG IP and free IP were very similar, whereas nMBG alone induced only mild changes in the intracellular metabolic profile without affecting the cells' consumption/secretion patterns or lipid composition. This finding indicates that the observed effects are primarily related to IP induced differentiation and that nMBG nanospheres serve as convenient carriers with both efficient internalization and minimal metabolic impact. Furthermore, the observed link between pre osteoblast differentiation and metabolism underscores the potential of utilizing metabolites and metabolic reprogramming as strategies to modulate the osteogenic process, for instance, in the context of osteoporosis and other bone diseases.
C1 [Casarrubios, Laura; Feito, Maria Jose; Martinez del Pozo, Alvaro; Portoles, Maria Teresa] Univ Complutense Madrid, Fac Ciencias Quim, Dept Bioquim & Biol Mol, Madrid 28040, Spain.
   [Casarrubios, Laura; Cicuendez, Monica; Polo Montalvo, Alberto; Feito, Maria Jose; Portoles, Maria Teresa] Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Madrid 28040, Spain.
   [Cicuendez, Monica; Polo Montalvo, Alberto; Arcos, Daniel] Univ Complutense Madrid, Fac Farm, Dept Quim Ciencias Farmaceut, Madrid 28040, Spain.
   [Arcos, Daniel] Inst Invest Sanitaria Hosp 12 Octubre i 12, Plaza Ramon & Cajal S N, Madrid 28040, Spain.
   [Arcos, Daniel; Portoles, Maria Teresa] ISCIII, CIBER Bioingn Biomat & Nanomed, Madrid 28040, Spain.
   [Duarte, Iola F.] Univ Aveiro, Aveiro Inst Mat, Dept Chem, CICECO, P 3810193 Aveiro, Portugal.
C3 Complutense University of Madrid; Complutense University of Madrid;
   Hospital Universitario 12 de Octubre; CIBER   Centro de Investigacion
   Biomedica en Red; CIBERBBN; Instituto de Salud Carlos III; Universidade
   de Aveiro
RP Portoles, MT (通讯作者)，Univ Complutense Madrid, Fac Ciencias Quim, Dept Bioquim & Biol Mol, Madrid 28040, Spain.; Duarte, IF (通讯作者)，Univ Aveiro, Aveiro Inst Mat, Dept Chem, CICECO, P 3810193 Aveiro, Portugal.
EM portoles@quim.ucm.es
RI Feito, Maria/AAE 7813 2020; Martinez del Pozo, Alvaro/L 8556 2014;
   Portolés, María/U 1678 2017; PORTOLES PEREZ, MARIA TERESA/U 1678 2017;
   Duarte, Iola/H 5505 2013
OI FEITO CASTELLANO, MARIA JOSE/0000 0001 8623 4913; PORTOLES PEREZ, MARIA
   TERESA/0000 0002 9681 0184; Duarte, Iola/0000 0003 4289 9256
FU Ministerio de Ciencia e Innovacion, Spain [MAT2016 75611 R,
   PID2020 117091RB I00]; CICECO Aveiro Institute of Materials
   [UIDB/50011/2020, UIDP/50011/2020, LA/P/0006/2020]; National funds
   through the FCT/MCTES (PIDDAC); Infrastructure Project [022161]; FEDER
   through COMPETE 2020; POCI [022161]; PORL; FCT [CEE CIND/02387/2018];
   FCT through PIDDAC
FX This work was developed in the scope of the projects MAT2016 75611 R and
   PID2020 117091RB I00 (financed by Ministerio de Ciencia e Innovacion,
   Spain) and CICECO Aveiro Institute of Materials, UIDB/50011/2020 (DOI
   10.54499/UIDB/50011/2020) , UIDP/50011/2020 (DOI
   10.54499/UIDP/50011/2020) & LA/P/0006/2020 (DOI 10.54499/LA/P/0006/2020)
   , financed by national funds through the FCT/MCTES (PIDDAC) . The NMR
   spectrometer is part of the National NMR Network (PTNMR) , partially
   supported by Infrastructure Project No 022161 (co financed by FEDER
   through COMPETE 2020, POCI, and PORL and FCT through PIDDAC) . I.F.D.
   acknowledges FCT for the research contract under the Scientific
   Employment Stimulus (CEE CIND/02387/2018) . The authors wish to thank
   the staff of the ICTS Centro Nacional de Microscopia Electronica (Spain)
   and the Centro de Citometria y Microscopia de Fluorescencia of the
   Universidad Complutense de Madrid (Spain) for assistance with the
   electron microscopy, flow cytometry and confocal microscopy studies,
   respectively. The authors would like to thank Mireia Gomez Duro for her
   participation in preliminary metabolomics studies.
CR Abshirini M, 2021, PROG LIPID RES, V83, DOI 10.1016/j.plipres.2021.101113
   Addison WN, 2015, BONE, V71, P244, DOI 10.1016/j.bone.2014.11.003
   Arcos D, 2022, ACTA BIOMATER, V151, P501, DOI 10.1016/j.actbio.2022.07.067
   Arcos D, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043249
   Bispo DSC, 2022, CELLS BASEL, V11, DOI 10.3390/cells11233745
   Bispo DSC, 2022, CELLS BASEL, V11, DOI 10.3390/cells11081257
   Bispo DSC, 2022, J PROTEOME RES, V21, P654, DOI 10.1021/acs.jproteome.1c00832
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Carrola J, 2016, ARCH BIOCHEM BIOPHYS, V589, P53, DOI 10.1016/j.abb.2015.08.022
   Casarrubios L, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10122573
   Casarrubios L, 2018, EUR J PHARM BIOPHARM, V133, P258, DOI 10.1016/j.ejpb.2018.10.019
   Cazzola R, 2004, J LIPID RES, V45, P1846, DOI 10.1194/jlr.M300509 JLR200
   Chen GT, 2015, J BIOMED NANOTECHNOL, V11, P722, DOI 10.1166/jbn.2015.2072
   Croissant JG, 2017, ADV MATER, V29, DOI 10.1002/adma.201604634
   Cuperlovic Culf M, 2010, DRUG DISCOV TODAY, V15, P610, DOI 10.1016/j.drudis.2010.06.012
   de la Haba C, 2013, BBA BIOMEMBRANES, V1828, P357, DOI 10.1016/j.bbamem.2012.08.013
   do Canto AMTM, 2016, BBA BIOMEMBRANES, V1858, P2647, DOI 10.1016/j.bbamem.2016.07.013
   Duarte IF, 2009, BIOANALYSIS, V1, P1597, DOI [10.4155/bio.09.151, 10.4155/BIO.09.151]
   Fan JZ, 2021, METABOLITES, V11, DOI 10.3390/metabo11070434
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Gao J, 2018, CELL DEATH DIFFER, V25, P229, DOI 10.1038/cdd.2017.144
   Gowda GAN, 2021, ADV EXP MED BIOL, V1280, P19, DOI 10.1007/978 3 030 51652 9_2
   Guijas C, 2018, NAT BIOTECHNOL, V36, P316, DOI 10.1038/nbt.4101
   Guntur AR, 2014, ENDOCRINOLOGY, V155, P1589, DOI 10.1210/en.2013 1974
   Halama A, 2014, ARCH BIOCHEM BIOPHYS, V564, P100, DOI 10.1016/j.abb.2014.09.002
   Hao XH, 2015, ACS NANO, V9, P9614, DOI 10.1021/nn507485j
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hermansson M, 2011, PROG LIPID RES, V50, P240, DOI 10.1016/j.plipres.2011.02.004
   Hishikawa D, 2014, J LIPID RES, V55, P799, DOI 10.1194/jlr.R046094
   Huang FL, 2023, BIOENGINEERING BASEL, V10, DOI 10.3390/bioengineering10050535
   Kempen PJ, 2015, THERANOSTICS, V5, P631, DOI 10.7150/thno.11389
   Kielkopf Clara L, 2020, Cold Spring Harb Protoc, V2020, P102269, DOI 10.1101/pdb.prot102269
   Kushwaha P, 2018, BONE, V115, P8, DOI 10.1016/j.bone.2017.08.024
   Lee JM, 2017, MAX PLAST RECONSTR S, V39
   Lee WC, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108108
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Levental KR, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao1193
   Li X, 2007, MICROPOR MESOPOR MAT, V102, P151, DOI 10.1016/j.micromeso.2006.12.048
   Ma CY, 2019, ADV SCI, V6, DOI 10.1002/advs.201900819
   Mackie EJ, 2003, INT J BIOCHEM CELL B, V35, P1301, DOI 10.1016/S1357 2725(03)00107 9
   Markley JL, 2017, CURR OPIN BIOTECH, V43, P34, DOI 10.1016/j.copbio.2016.08.001
   Mohamad NV, 2020, ENDOCR METAB IMMUNE, V20, P1478, DOI 10.2174/1871530320666200604160614
   Nakamura A, 2009, TISSUE ENG PART C ME, V15, P169, DOI 10.1089/ten.tec.2007.0334
   Nandy A, 2023, BONE RES, V11, DOI 10.1038/s41413 023 00297 2
   PAGANI R, 1984, BIOCHEM J, V218, P125, DOI 10.1042/bj2180125
   Parfitt AM, 2002, BONE, V30, P5, DOI 10.1016/S8756 3282(01)00642 1
   PORTOLES MT, 1987, CELL BIOCHEM FUNCT, V5, P55, DOI 10.1002/cbf.290050107
   Prinetti A, 2001, J BIOL CHEM, V276, P21136, DOI 10.1074/jbc.M010666200
   Qin A, 2012, INT J BIOCHEM CELL B, V44, P1422, DOI 10.1016/j.biocel.2012.05.014
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   REDDI AH, 1972, P SOC EXP BIOL MED, V140, P807
   Redondo Morata L, 2012, LANGMUIR, V28, P12851, DOI 10.1021/la302620t
   REGINSTER JYL, 1993, BONE MINER, V23, P223, DOI 10.1016/S0169 6009(08)80099 2
   Shin TH, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9101475
   Smith P, 2021, BIOPHYS J, V120, P1746, DOI 10.1016/j.bpj.2021.02.046
   Tarantili PA, 2008, EUR POLYM J, V44, P444, DOI 10.1016/j.eurpolymj.2007.11.014
   Watkins BA, 2003, PROSTAG LEUKOTR ESS, V68, P387, DOI 10.1016/S0952 3278(03)00063 2
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Wei XR, 2022, SCI TOTAL ENVIRON, V838, DOI 10.1016/j.scitotenv.2022.156552
   Xiao ZM, 2013, EUR J PHARMACOL, V721, P286, DOI 10.1016/j.ejphar.2013.09.023
   Xie Y, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.746
   Yamada H, 2012, CHEM MATER, V24, P1462, DOI 10.1021/cm3001688
   Ye ML, 2020, FOOD FUNCT, V11, P1498, DOI [10.1039/c9fo01944h, 10.1039/C9FO01944H]
   Zhai WY, 2012, J BIOMED MATER RES B, V100B, P1397, DOI 10.1002/jbm.b.32711
NR 64
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2772 9508
J9 BIOMATER ADV
JI Biomater. Adv.
PD JAN
PY 2025
VL 166
AR 214085
DI 10.1016/j.bioadv.2024.214085
EA OCT 2024
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA K8T0W
UT WOS:001346555400001
PM 39490191
OA hybrid
DA 2025 08 17
ER

PT J
AU Viggers, R
   Al Mashhadi, Z
   Starup Linde, J
   Vestergaard, P
AF Viggers, Rikke
   Al Mashhadi, Zheer
   Starup Linde, Jakob
   Vestergaard, Peter
TI The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic
   Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish
   Retrospective Cohort Study
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE diabetes; fracture; alendronate; denosumab; osteoporosis; bone
ID BONE MINERAL DENSITY; REPORTED MEDICATION USE; POSTMENOPAUSAL WOMEN;
   BIOCHEMICAL MARKERS; TURNOVER; GLUCOSE; POPULATION; THERAPY;
   COMPLICATIONS; EPIDEMIOLOGY
AB ObjectivePatients with diabetes mellitus have an increased risk of fractures; however, the underlying mechanism is largely unknown. We aimed to investigate whether the risk of major osteoporotic fractures in diabetes patients differs between subjects initiated with alendronate and denosumab, respectively. Methods and Research DesignWe conducted a retrospective nationwide cohort study through access to all discharge diagnoses (ICD 10 system) from the National Danish Patient Registry along with all redeemed drug prescriptions (ATC classification system) from the Health Service Prescription Registry. We identified all subjects with a diabetes diagnosis between 2000 and 2018 and collected data on the first new prescription of anti osteoporotic treatment between 2011 and 2018. Exposure was defined as either alendronate or denosumab treatment initiated after diabetes diagnosis. Outcome information was collected by identification of all major osteoporotic fracture (MOF) diagnoses, i.e., hip, spine, forearm, and humerus, from exposure until 2018 or censoring by emigration or death. The risk of fracture was calculated as hazard ratios (HR) using multiply adjusted Cox proportional models with death as a competing risk. ResultsWe included 8,745 subjects initiated with either alendronate (n = 8,255) or denosumab (n = 490). The cohort consisted of subjects with a mean age of 73.62 (SD +/  9.27) years, primarily females (69%) and suffering mainly from type 2 diabetes (98.22%) with a median diabetes duration at baseline of 5.45 years (IQR 2.41 9.19). Those in the denosumab group were older (mean 75.60 [SD +/  9.72] versus 73.51 [SD +/  9.23] years), had a higher proportion of women (81% versus 68%, RR 1.18 [95% CI 1.13 1.24], and were more comorbid (mean CCI 2.68 [95% CI 2.47 2.88] versus 1.98 [95% CI 1.93 2.02]) compared to alendronate initiators. In addition, denosumab users had a higher prevalence of previous fractures (64% versus 46%, RR 1.38 [95% CI 1.28 1.48]). The adjusted HR for any MOF after treatment initiation with denosumab was 0.89 (95% CI 0.78 1.02) compared to initiation with alendronate. ConclusionThe risk of incident MOF among subjects with diabetes was similar between those initially treated with alendronate and denosumab. These findings indicate that the two treatment strategies are equally effective in preventing osteoporotic fractures in subjects with diabetes.
C1 [Viggers, Rikke; Vestergaard, Peter] Aalborg Univ Hosp, Steno Diabet Ctr North Jutland, Dept Endocrinol, Aalborg, Denmark.
   [Viggers, Rikke; Vestergaard, Peter] Aalborg Univ, Dept Clin Med, Aalborg, Denmark.
   [Al Mashhadi, Zheer; Starup Linde, Jakob] Aarhus Univ Hosp, Steno Diabet Ctr Aarhus, Aarhus, Denmark.
   [Al Mashhadi, Zheer] Aarhus Univ, Dept Clin Med, Aarhus, Denmark.
   [Starup Linde, Jakob] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Aarhus, Denmark.
C3 Steno Diabetes Center; Aalborg University; Aalborg University Hospital;
   Aalborg University; Aarhus University; Aarhus University; Aarhus
   University
RP Viggers, R (通讯作者)，Aalborg Univ Hosp, Steno Diabet Ctr North Jutland, Dept Endocrinol, Aalborg, Denmark.; Viggers, R (通讯作者)，Aalborg Univ, Dept Clin Med, Aalborg, Denmark.
EM rikke.viggers@rn.dk
RI ; Al Mashhadi, Zheer/ABA 2607 2020; Viggers, Rikke/JNT 4337 2023
OI Kejlberg Al Mashhadi, Zheer/0000 0003 1201 199X; Vestergaard,
   Peter/0000 0002 9046 2967; Viggers, Rikke/0000 0002 0742 9788; Linde,
   Jakob Starup/0000 0002 4325 8023
FU Steno Collaborative grant, Novo Nordisk Foundation, Denmark
   [NNF18OC0052064]
FX This work was supported by a Steno Collaborative grant, Novo Nordisk
   Foundation, Denmark (Grant no. NNF18OC0052064).
CR Abrahamsen B, 2010, CALCIFIED TISSUE INT, V86, P421, DOI 10.1007/s00223 010 9364 1
   agenciaandaluzadelaenergia, TAT 2020
   Al Hariri M, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/6969040
   Allin S, 2013, HEALTH REP, V24, P3
   Anagnostis P, 2018, ENDOCRINE, V60, P373, DOI 10.1007/s12020 018 1548 x
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Benjamin Biju, 2016, Osteoporos Sarcopenia, V2, P77, DOI 10.1016/j.afos.2016.03.003
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Bonnet N, 2019, J CLIN INVEST, V129, P3214, DOI 10.1172/JCI125915
   Bouxsein ML, 2019, J BONE MINER RES, V34, P632, DOI 10.1002/jbmr.3641
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Briot K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083436
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Chan DC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123279
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021 9681(87)90171 8
   Cui M, 2019, EXP CLIN ENDOCR DIAB, V127, P68, DOI 10.1055/s 0042 105282
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Delmas PD, 2008, J CLIN DENSITOM, V11, P325, DOI 10.1016/j.jocd.2008.02.002
   Fard MK, 2019, J DIABETES INVEST, V10, P731, DOI 10.1111/jdi.12944
   Ferrari SL, 2018, OSTEOPOROSIS INT, V29, P2585, DOI 10.1007/s00198 018 4650 2
   Ferrari S, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115268
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Forsén L, 1999, DIABETOLOGIA, V42, P920, DOI 10.1007/s001250051248
   Frank L, 2000, SCIENCE, V287, P2398, DOI 10.1126/science.287.5462.2398
   Hansen L, 2018, OSTEOPOROSIS INT, V29, P2243, DOI 10.1007/s00198 018 4603 9
   Hygum K, 2017, EUR J ENDOCRINOL, V176, pR137, DOI 10.1530/EJE 16 0652
   Jensen MH, 2020, DIABETES CARE, V43, P1209, DOI 10.2337/dc19 2535
   Jensen MH, 2020, ACTA DIABETOL, V57, P549, DOI 10.1007/s00592 019 01447 x
   Jensen MH, 2020, DIABETES METAB RES, V36, DOI 10.1002/dmrr.3225
   Johannesdottir Sigrun Alba, 2012, Clin Epidemiol, V4, P303, DOI 10.2147/CLEP.S37587
   Kähm K, 2018, DIABETES CARE, V41, P971, DOI 10.2337/dc17 1763
   Keegan THM, 2004, DIABETES CARE, V27, P1547, DOI 10.2337/diacare.27.7.1547
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717
   Koromani F, 2020, DIABETES CARE, V43, P137, DOI 10.2337/dc19 0925
   Kristensen JK, 2001, DAN MED BULL, V48, P33
   Lee YS, 2018, SPINE J, V18, P1877, DOI 10.1016/j.spinee.2018.05.020
   Lin T, 2012, INT J CLIN PRACT, V66, P399, DOI 10.1111/j.1742 1241.2011.02806.x
   Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   Maugeri D, 2002, ARCH GERONTOL GERIAT, V34, P117, DOI 10.1016/S0167 4943(01)00202 3
   Miyoshi A, 2021, J DIABETES INVEST, V12, P1293, DOI 10.1111/jdi.13458
   Mosbech J, 1995, Ugeskr Laeger, V157, P3741
   Mosekilde L, 2000, MATURITAS, V36, P181, DOI 10.1016/S0378 5122(00)00158 4
   Nielsen G L, 1997, Int J Risk Saf Med, V10, P203, DOI 10.3233/JRS 1997 10309
   Nyström T, 2017, DIABETES RES CLIN PR, V123, P199, DOI 10.1016/j.diabres.2016.12.004
   Oei L, 2013, DIABETES CARE, V36, P1619, DOI 10.2337/dc12 1188
   PECK WA, 1993, AM J MED, V94, P646
   Pedersen AB, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2416
   Persson S, 2020, DIABETES OBES METAB, V22, P1586, DOI 10.1111/dom.14070
   Rasmussen NH, 2019, CURR OSTEOPOROS REP, V17, P147, DOI 10.1007/s11914 019 00513 1
   Roux C, 2014, BONE, V58, P48, DOI 10.1016/j.bone.2013.10.006
   Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125
   Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654 014 9930 3
   Schuit SCE, 2004, BONE, V34, P195, DOI 10.1016/j.bone.2003.10.001
   Schwartz AV, 2013, J BONE MINER RES, V28, P1348, DOI 10.1002/jbmr.1865
   Sediq R, 2018, CLIN EPIDEMIOL, V10, P981, DOI 10.2147/CLEP.S163037
   Shetty Sahana, 2016, Indian J Endocrinol Metab, V20, P846
   Starup Linde J, 2014, OSTEOPOROSIS INT, V25, P1697, DOI 10.1007/s00198 014 2676 7
   Starup Linde J, 2016, BONE, V82, P69, DOI 10.1016/j.bone.2015.02.019
   Thygesen SK, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471 2288 11 83
   Toulis KA, 2015, J CLIN ENDOCR METAB, V100, P1933, DOI 10.1210/jc.2014 3481
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198 006 0253 4
   Vestergaard P, 2011, CALCIFIED TISSUE INT, V89, P265, DOI 10.1007/s00223 011 9515 z
   Vestergaard P, 2011, CALCIFIED TISSUE INT, V88, P209, DOI 10.1007/s00223 010 9450 4
   Viggers R, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.771426
   Viggers R, 2021, DIABETES CARE, V44, P2045, DOI 10.2337/dc21 0333
   Vilaca T, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115457
   von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013
NR 71
TC 8
Z9 8
U1 3
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD JAN 26
PY 2022
VL 12
AR 826997
DI 10.3389/fendo.2021.826997
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA YV6GZ
UT WOS:000752826100001
PM 35154013
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Grigoriadis, AE
   Kennedy, M
   Bozec, A
   Brunton, F
   Stenbeck, G
   Park, IH
   Wagner, EF
   Keller, GM
AF Grigoriadis, Agamemnon E.
   Kennedy, Marion
   Bozec, Aline
   Brunton, Fiona
   Stenbeck, Gudrun
   Park, In Hyun
   Wagner, Erwin F.
   Keller, Gordon M.
TI Directed differentiation of hematopoietic precursors and functional
   osteoclasts from human ES and iPS cells
SO BLOOD
LA English
DT Article
ID EMBRYONIC STEM CELLS; HUMAN BLASTOCYSTS; IN VITRO; BONE; LINES;
   OSTEOPETROSIS; PROGENITORS; COMMUNICATION; PLURIPOTENCY; OSTEOPOROSIS
AB The directed differentiation of human pluripotent stem cells offers the unique opportunity to generate a broad spectrum of human cell types and tissues for transplantation, drug discovery, and studying disease mechanisms. Here, we report the stepwise generation of bone resorbing osteoclasts from human embryonic and induced pluripotent stem cells. Generation of a primitive streak like population in embryoid bodies, followed by specification to hematopoiesis and myelopoiesis by vascular endothelial growth factor and hematopoietic cytokines in serum free media, yielded a precursor population enriched for cells expressing the monocyte macrophage lineage markers CD14, CD18, CD11b, and CD115. When plated in monolayer culture in the presence of macrophage colony stimulating factor and receptor activator of nuclear factor kappa B ligand (RANKL), these precursors formed large, multinucleated osteoclasts that expressed tartrate resistant acid phosphatase and were capable of resorption. No tartrate resistant acid phosphatase positive multinucleated cells or resorption pits were observed in the absence of RANKL. Molecular analyses confirmed the expression of the osteoclast marker genes NFATc1, cathepsin K, and calcitonin receptor in a RANKL dependent manner, and confocal microscopy demonstrated the coexpression of the alpha v beta 3 integrin, cathepsin K and F actin rings characteristic of active osteoclasts. Generating hematopoietic and osteoclast populations from human embryonic and induced pluripotent stem cells will be invaluable for understanding embryonic bone development and postnatal bone disease. (Blood. 2010; 115(14): 2769 2776)
C1 [Grigoriadis, Agamemnon E.; Brunton, Fiona] Kings Coll London, Guys Hosp, Dept Craniofacial Dev, London SE1 9RT, England.
   [Grigoriadis, Agamemnon E.; Brunton, Fiona] Kings Coll London, Guys Hosp, Dept Orthodont, London SE1 9RT, England.
   [Kennedy, Marion; Keller, Gordon M.] Univ Hlth Network, McEwen Ctr Regenerat Med, Toronto, ON, Canada.
   [Bozec, Aline; Wagner, Erwin F.] Spanish Natl Canc Res Ctr CNIO, Madrid, Spain.
   [Stenbeck, Gudrun] Brunel Univ, Uxbridge UB8 3PH, Middx, England.
   [Park, In Hyun] Harvard Univ, Sch Med, Dept Pediat Hematol Oncol, Boston, MA USA.
C3 Guy's & St Thomas' NHS Foundation Trust; University of London; King's
   College London; Guy's & St Thomas' NHS Foundation Trust; University of
   London; King's College London; University of Toronto; University Health
   Network Toronto; Centro Nacional de Investigaciones Oncologicas (CNIO);
   Brunel University; Harvard University; Harvard Medical School
RP Grigoriadis, AE (通讯作者)，Kings Coll London, Guys Hosp, Dept Craniofacial Dev, Tower Floor 27, London SE1 9RT, England.
EM agi.grigoriadis@kcl.ac.uk
RI ; Bozec, Aline/M 6942 2015
OI Wagner, Erwin F/0000 0001 7872 0196; Keller, Gordon/0000 0001 9309 9297;
   
FU Nuffield Foundation; Arthritis Research Campaign (ARC) [18197]; National
   Institutes of Health [R01 HL080627, P20 GM075019]; Austrian Science Fund
   (FWF); Anabonos EU [FP7]; MRC [G9800001] Funding Source: UKRI; Medical
   Research Council [G9800001] Funding Source: researchfish
FX We thank Staci Schwantz and Sunita D'Souza for expert technical
   assistance, Prof G. Q. Daley (Harvard Medical School) for the MSC iPS1
   cells, and Prof T. R. Arnett and Dr G. Charras (University College
   London) for microscopy.This study was supported (in part) by research
   funding from the Nuffield Foundation Oliver Bird Rheumatism Program to
   A. E. G., Arthritis Research Campaign (ARC ref 18197) to G. S., National
   Institutes of Health grants R01 HL080627 and P20 GM075019 to G. M. K.,
   and Austrian Science Fund (FWF) and Anabonos EU FP7 to E.F.W.
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bhatia M, 2007, ANN NY ACAD SCI, V1106, P219, DOI 10.1196/annals.1392.007
   Blank U, 2008, BLOOD, V111, P492, DOI 10.1182/blood 2007 07 075168
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bozec A, 2008, NATURE, V454, P221, DOI 10.1038/nature07019
   Campbell C, 2008, CURR OPIN HEMATOL, V15, P319, DOI 10.1097/MOH.0b013e328303b9df
   Chang KH, 2008, EXP CELL RES, V314, P2930, DOI 10.1016/j.yexcr.2008.07.019
   Choi KD, 2009, J CLIN INVEST, V119, P2818, DOI 10.1172/JCI38591
   Choi KD, 2009, STEM CELLS, V27, P559, DOI 10.1634/stemcells.2008 0922
   Deal C, 2009, CURR OPIN RHEUMATOL, V21, P380, DOI 10.1097/BOR.0b013e32832cbc2a
   Duplomb L, 2007, STEM CELLS, V25, P544, DOI 10.1634/stemcells.2006 0395
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Guerrini MM, 2008, AM J HUM GENET, V83, P64, DOI 10.1016/j.ajhg.2008.06.015
   Henriksen K, 2009, BONE, V44, P1026, DOI 10.1016/j.bone.2009.03.671
   Husheem M, 2005, CALCIFIED TISSUE INT, V76, P222, DOI 10.1007/s00223 004 0123 z
   Irion S, 2008, COLD SH Q B, V73, P101, DOI 10.1101/sqb.2008.73.065
   Kanawaty A, 2009, BIOESSAYS, V31, P134, DOI 10.1002/bies.200800204
   Karlsson KR, 2008, EXP HEMATOL, V36, P1167, DOI 10.1016/j.exphem.2008.04.009
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kennedy M, 2007, BLOOD, V109, P2679, DOI 10.1182/blood 2006 09 047704
   Kirstein B, 2006, J TRANSL MED, V4, DOI 10.1186/1479 5876 4 45
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Ledran MH, 2008, CELL STEM CELL, V3, P85, DOI 10.1016/j.stem.2008.06.001
   Loh YH, 2009, BLOOD, V113, P5476, DOI 10.1182/blood 2009 02 204800
   Martin TJ, 2009, CRIT REV EUKAR GENE, V19, P73, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.40
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   McDevitt TC, 2008, CURR OPIN BIOTECH, V19, P527, DOI 10.1016/j.copbio.2008.08.005
   Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008
   Okuyama H, 2003, STEM CELLS, V21, P670, DOI 10.1634/stemcells.21 6 670
   Osafune K, 2008, NAT BIOTECHNOL, V26, P313, DOI 10.1038/nbt1383
   Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]
   Pick M, 2007, STEM CELLS, V25, P2206, DOI 10.1634/stemcells.2006 0713
   Raya A, 2009, NATURE, V460, P53, DOI 10.1038/nature08129
   Reid IR, 2008, SEMIN CELL DEV BIOL, V19, P473, DOI 10.1016/j.semcdb.2008.08.002
   Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447
   Shalhoub V, 2000, BRIT J HAEMATOL, V111, P501, DOI 10.1046/j.1365 2141.2000.02379.x
   Slukvin II, 2006, J IMMUNOL, V176, P2924, DOI 10.4049/jimmunol.176.5.2924
   Sorensen MG, 2007, J BONE MINER METAB, V25, P36, DOI 10.1007/s00774 006 0725 9
   Stenbeck G, 2000, J CELL SCI, V113, P1577
   Susa Mira, 2004, J Transl Med, V2, P6, DOI 10.1186/1479 5876 2 6
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Trounson A, 2006, ENDOCR REV, V27, P208, DOI 10.1210/er.2005 0016
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wang Y, 2005, P NATL ACAD SCI USA, V102, P19081, DOI 10.1073/pnas.0506127102
   Welstead GG, 2008, CURR OPIN GENET DEV, V18, P123, DOI 10.1016/j.gde.2008.01.013
   Yang L, 2008, NATURE, V453, P524, DOI 10.1038/nature06894
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 50
TC 115
Z9 141
U1 0
U2 24
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006 4971
J9 BLOOD
JI Blood
PD APR 8
PY 2010
VL 115
IS 14
BP 2769
EP 2776
DI 10.1182/blood 2009 07 234690
PG 8
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 580MY
UT WOS:000276454600010
PM 20065292
OA Bronze, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Angle, SR
   Sena, K
   Sumner, DR
   Virdi, AS
AF Angle, S. R.
   Sena, K.
   Sumner, D. R.
   Virdi, A. S.
TI Osteogenic differentiation of rat bone marrow stromal cells by various
   intensities of low intensity pulsed ultrasound
SO ULTRASONICS
LA English
DT Article
DE Low intensity pulsed ultrasound; Fracture healing; Bone marrow derived
   stromal cells; Osteogenesis
ID ACTIVATED PROTEIN KINASE; HUMAN OSTEOBLASTIC CELLS; GENE EXPRESSION;
   IN VITRO; DISTRACTION OSTEOGENESIS; MATRIX MINERALIZATION;
   MOLECULAR MECHANISMS; SIGNAL TRANSDUCTION; ORGANIC PHOSPHATE; FRACTURE
   MODEL
AB Bone growth and repair are under the control of biochemical and mechanical signals. Low intensity pulsed ultrasound (LIPUS) stimulation at 30 mW/cm(2) is an established, widely used and FDA approved intervention for accelerating bone healing in fractures and non unions. Although this LIPUS signal accelerates mineralization and bone regeneration, the actual intensity experienced by the cells at the target site might be lower, due to the possible attenuation caused by the overlying soft tissue. The aim of this study was to investigate whether LIPUS intensities below 30 mW/cm(2) are able to provoke phenotypic responses in bone cells. Rat bone marrow stromal cells were cultured under defined conditions and the effect of 2, 15, 30 mW/cm(2) and sham treatments were studied at early (cell activation), middle (differentiation into osteogenic cells) and late (biological mineralization) stages of osteogenic differentiation. We observed that not only 30 mW/cm(2) but also 2 and 15 mW/cm(2), modulated ERK1/2 and p38 intracellular signaling pathways as compared to the sham treatment. After 5 days with daily treatments of 2, 15 and 30 mW/cm(2), alkaline phosphatase activity, an early indicator of osteoblast differentiation, increased by 79%, 147% and 209%, respectively, compared to sham, indicating that various intensities of LIPUS were able to initiate osteogenic differentiation. While all LIPUS treatments showed higher mineralization, interestingly, the highest increase of 225% was observed in cells treated with 2 mW/cm(2). As the intensity increased to 15 and 30 mW/cm(2), the increase in the level of mineralization dropped to 120% and 82%. Our data show that LIPUS intensities lower than the current clinical standard have a positive effect on osteogenic differentiation of rat bone marrow stromal cells. Although Exogen (TM) at 30 mW/cm(2) continues to be effective and should be used as a clinical therapy for fracture healing, if confirmed in vivo, the increased mineralization at lower intensities might be the first step towards redefining the most effective LIPUS intensity for clinical use. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Angle, S. R.; Sena, K.; Sumner, D. R.; Virdi, A. S.] Rush Univ, Med Ctr, Dept Anat & Cell Biol, Chicago, IL 60612 USA.
   [Angle, S. R.; Sumner, D. R.; Virdi, A. S.] Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA.
C3 Rush University; University of Illinois System; University of Illinois
   Chicago; University of Illinois Chicago Hospital
RP Virdi, AS (通讯作者)，Rush Univ, Med Ctr, Dept Anat & Cell Biol, Chicago, IL 60612 USA.
EM amarjit_virdi@rush.edu
RI ; Sena, Kotaro/A 8033 2013
OI Sumner, Dale/0000 0001 9575 3862; Sena, Kotaro/0000 0003 0612 1826; 
CR AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Bandow K, 2007, J CELL PHYSIOL, V211, P392, DOI 10.1002/jcp.20944
   Barnett SB, 1997, ULTRASOUND MED BIOL, V23, P805, DOI 10.1016/S0301 5629(97)00027 6
   BELLOWS CG, 1991, BONE MINER, V14, P27, DOI 10.1016/0169 6009(91)90100 E
   BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165
   Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018
   Cook SD, 1997, CLIN ORTHOP RELAT R, P198
   Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220
   Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264
   Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701
   DUARTE LR, 1983, ARCH ORTHOP TRAUM SU, V101, P153, DOI 10.1007/BF00436764
   ECAROTCHARRIER B, 1983, J CELL BIOL, V96, P639, DOI 10.1083/jcb.96.3.639
   Fratzl Zelman N, 1998, BONE, V23, P511, DOI 10.1016/S8756 3282(98)00139 2
   Gebauer D, 2005, ULTRASOUND MED BIOL, V31, P1391, DOI 10.1016/j.ultrasmedbio.2005.06.002
   Gebken J, 1999, J BIOCHEM, V126, P676, DOI 10.1093/oxfordjournals.jbchem.a022502
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Guo XY, 2007, J BIOMED MATER RES A, V82A, P1022, DOI 10.1002/jbm.a.31200
   Hadjiargyrou M, 1998, CLIN ORTHOP RELAT R, pS216, DOI 10.1097/00003086 199810001 00022
   Harle J, 2001, ULTRASOUND MED BIOL, V27, P579, DOI 10.1016/S0301 5629(00)00326 4
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   Heng NHM, 2007, J PERIODONTOL, V78, P2369, DOI 10.1902/jop.2007.070130
   Heybeli N, 2002, J ULTRAS MED, V21, P1357, DOI 10.7863/jum.2002.21.12.1357
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   IBARAKI K, 1992, J BONE MINER RES, V7, P743
   Ikeda K, 2006, LIFE SCI, V79, P1936, DOI 10.1016/j.lfs.2006.06.029
   Iwashina T, 2006, BIOMATERIALS, V27, P354, DOI 10.1016/j.biomaterials.2005.06.031
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577
   KLUG W, 1986, EUR J NUCL MED, V11, P494
   Kristiansen TK, 1997, J BONE JOINT SURG AM, V79A, P961, DOI 10.2106/00004623 199707000 00002
   Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Liu F, 2003, J CELL SCI, V116, P1787, DOI 10.1242/jcs.00376
   Maddi A, 2006, BONE, V39, P283, DOI 10.1016/j.bone.2006.01.162
   Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849
   Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151
   McCormick SM, 2006, ANN BIOMED ENG, V34, P436, DOI 10.1007/s10439 005 9057 5
   Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200
   Nanci A, 1996, MICROSC RES TECHNIQ, V33, P214
   Naruse K, 2000, BIOCHEM BIOPH RES CO, V268, P216, DOI 10.1006/bbrc.2000.2094
   Naruse K, 2004, BONE, V35, P850, DOI 10.1016/j.bone.2004.05.006
   Nolte PA, 2001, J TRAUMA, V51, P693, DOI 10.1097/00005373 200110000 00012
   RAISZ LG, 1993, OSTEOPOROSIS INT, V3, pS136
   RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022
   Saito M, 2004, CALCIFIED TISSUE INT, V75, P384, DOI 10.1007/s00223 004 0292 9
   Sant'Anna EF, 2005, J ORTHOP RES, V23, P646, DOI 10.1016/j.orthres.2004.09.007
   Sato W, 1999, J ULTRAS MED, V18, P699
   Sena K, 2005, ULTRASOUND MED BIOL, V31, P703, DOI 10.1016/j.ultrasmedbio.2005.01.013
   Shimazaki A, 2000, J BONE JOINT SURG BR, V82B, P1077, DOI 10.1302/0301 620X.82B7.9948
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838
   Sun JS, 2001, J BIOMED MATER RES, V57, P449, DOI 10.1002/1097 4636(20011205)57:3<449::AID JBM1188>3.0.CO;2 0
   Takayama T, 2007, LIFE SCI, V80, P965, DOI 10.1016/j.lfs.2006.11.037
   Takikawa S, 2001, J ULTRAS MED, V20, P197, DOI 10.7863/jum.2001.20.3.197
   Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160
   Tanzer M, 1996, J ORTHOPAED RES, V14, P901, DOI 10.1002/jor.1100140609
   TENENBAUM HC, 1981, J DENT RES, V60, P1586, DOI 10.1177/002203458106000308011
   Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677
   Uglow MG, 2003, CLIN ORTHOP RELAT R, P303, DOI 10.1097/01.blo.0000093043.56370.5a
   Unsworth J, 2007, ULTRASOUND MED BIOL, V33, P1468, DOI 10.1016/j.ultrasmedbio.2006.12.003
   Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233
   Wadhwa S, 2002, BIOCHEM BIOPH RES CO, V297, P46, DOI 10.1016/S0006 291X(02)02124 1
   Wang JHC, 2006, BIOMECH MODEL MECHAN, V5, P1, DOI 10.1007/s10237 005 0012 z
   Warden SJ, 2001, BIOCHEM BIOPH RES CO, V286, P443, DOI 10.1006/bbrc.2001.5412
   Yang KH, 1996, J ORTHOP RES, V14, P802, DOI 10.1002/jor.1100140518
   Zhang ZJ, 2003, ULTRASOUND MED BIOL, V29, P1645, DOI 10.1016/j.ultrasmedbio.2003.08.011
   Zhou SX, 2004, J BIOL CHEM, V279, P54463, DOI 10.1074/jbc.M404786200
NR 68
TC 117
Z9 139
U1 0
U2 42
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0041 624X
EI 1874 9968
J9 ULTRASONICS
JI Ultrasonics
PD APR
PY 2011
VL 51
IS 3
BP 281
EP 288
DI 10.1016/j.ultras.2010.09.004
PG 8
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA 702TS
UT WOS:000285919400006
PM 20965537
DA 2025 08 17
ER

PT J
AU Hosogane, N
   Huang, ZP
   Rawlins, BA
   Liu, X
   Boachie Adjei, O
   Boskey, AL
   Zhu, W
AF Hosogane, Naobumi
   Huang, Zhiping
   Rawlins, Bernard A.
   Liu, Xia
   Boachie Adjei, Oheneba
   Boskey, Adele L.
   Zhu, Wei
TI Stromal derived factor 1 regulates bone morphogenetic protein 2 induced
   osteogenic differentiation of primary mesenchymal stem cells
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Bone morphogenetic protein 2; CXC chemokine receptor 4; Mesenchymal stem
   cell; Osteogenic differentiation; Stromal derived factor 1
ID CHEMOKINE RECEPTOR CXCR4; OSTEOBLAST DIFFERENTIATION; PROGENITOR CELLS;
   CD34(+) CELLS; SDF 1 CXCL12; C2C12 CELLS; HIV 1 ENTRY; MARROW;
   MIGRATION; VITRO
AB Stromal derived factor 1 (SDF 1) is a chemokine signaling molecule that binds to its transmembrane receptor CXC chemokine receptor 4 (CXCR4). While we previously detected that SDF 1 was co required with bone morphogenetic protein 2 (BMP2) for differentiating mesenchymal C2C12 cells into osteoblastic cells, it is unknown whether SDF 1 is similarly involved in the osteogenic differentiation of mesenchymal stem cells (MSCs). Therefore, here we examined the role of SDF 1 signaling during BMP2 induced osteogenic differentiation of primary MSCs that were derived from human and mouse bone marrow. Our data showed that blocking of the SDF 1/CXCR4 signal axis or adding SDF 1 protein to MSCs significantly affected BMP2 induced alkaline phosphatase (ALP) activity and osteocalcin (OCN) synthesis, markers of preosteoblasts and mature osteoblasts, respectively. Moreover, disrupting the SDF 1 signaling impaired bone nodule mineralization during terminal differentiation of MSCs. Furthermore, we detected that blocking of the SDF 1 signaling inhibited the BMP2 induced early expression of Runt related factor 2 (Runx2) and osterix (Osx), two "master" regulators of osteogenesis, and the SDF 1 effect was mediated via intracellular Smad and Erk activation. In conclusion, our results demonstrated a regulatory role of SDF 1 in BMP2 induced osteogenic differentiation of MSCs, as perturbing the SDF 1 signaling affected the differentiation of MSCs towards osteoblastic cells in response to BMP2 stimulation. These data provide novel insights into molecular mechanisms underlying MSC osteogenesis, and will contribute to the development of MSC therapies for enhancing bone formation and regeneration in broad orthopaedic situations. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Hosogane, Naobumi; Huang, Zhiping; Liu, Xia; Boskey, Adele L.; Zhu, Wei] Hosp Special Surg, Musculoskeletal Integr Program, New York, NY 10021 USA.
   [Rawlins, Bernard A.; Boachie Adjei, Oheneba] Hosp Special Surg, Spinal Deform Serv, Dept Orthopaed Surg, New York, NY 10021 USA.
   [Boskey, Adele L.; Zhu, Wei] Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
C3 Cornell University; Weill Cornell Medicine
RP Zhu, W (通讯作者)，Hosp Special Surg, Musculoskeletal Integr Program, Room 624,6th Floor,Caspary Res Bldg,535 E 70th St, New York, NY 10021 USA.
EM zhuw@hss.edu
RI Huang, Zhiping/MTD 4734 2025
OI Boskey, Adele/0000 0002 6181 2219
FU Arthritis Foundation; Beatrice and Samuel A. Seaver Foundation
FX This work was supported by grants from Arthritis Foundation and Beatrice
   and Samuel A. Seaver Foundation.
CR Aiuti A, 1999, EUR J IMMUNOL, V29, P1823, DOI 10.1002/(SICI)1521 4141(199906)29:06<1823::AID IMMU1823>3.0.CO;2 B
   Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340
   Baribaud F, 2001, J VIROL, V75, P8957, DOI 10.1128/JVI.75.19.8957 8967.2001
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   Bruder SP, 1998, J BONE JOINT SURG AM, V80A, P985, DOI 10.2106/00004623 199807000 00007
   Cei S, 2006, J PERIODONTOL, V77, P699, DOI 10.1902/jop.2006.050155
   Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729
   Dar A, 2006, EXP HEMATOL, V34, P967, DOI 10.1016/j.exphem.2006.04.002
   Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198 072
   Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801
   Gronthos S, 2001, BONE, V28, P174, DOI 10.1016/S8756 3282(00)00424 5
   Gu K, 2004, CELLS TISSUES ORGANS, V176, P28, DOI 10.1159/000075025
   Guo ZK, 2006, STEM CELLS, V24, P992, DOI 10.1634/stemcells.2005 0224
   Hartmann TN, 2008, J LEUKOCYTE BIOL, V84, P1130, DOI 10.1189/jlb.0208088
   Hatch Heather M., 2002, Cloning and Stem Cells, V4, P339, DOI 10.1089/153623002321025014
   Hatse S, 2005, BIOCHEM PHARMACOL, V70, P752, DOI 10.1016/j.bcp.2005.05.035
   Hill WD, 2004, J NEUROPATH EXP NEUR, V63, P84, DOI 10.1093/jnen/63.1.84
   Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22 3 415
   Jung Y, 2006, BONE, V38, P497, DOI 10.1016/j.bone.2005.10.003
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kitaori T, 2009, ARTHRITIS RHEUM US, V60, P813, DOI 10.1002/art.24330
   Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361
   Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood 2004 11 4349
   Lataillade JJ, 2000, BLOOD, V95, P756, DOI 10.1182/blood.V95.3.756
   Levoye A, 2009, BLOOD, V113, P6085, DOI 10.1182/blood 2008 12 196618
   Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448
   Majka M, 2000, STEM CELLS, V18, P128, DOI 10.1634/stemcells.18 2 128
   Marcacci M, 2007, TISSUE ENG, V13, P947, DOI 10.1089/ten.2006.0271
   Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Otsuru S, 2008, STEM CELLS, V26, P223, DOI 10.1634/stemcells.2007 0515
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296
   Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813
   Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329
   Ratajczak MZ, 2003, STEM CELLS, V21, P363, DOI 10.1634/stemcells.21 3 363
   Salvucci O, 2002, BLOOD, V99, P2703, DOI 10.1182/blood.V99.8.2703
   Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383
   SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180
   Strizki JM, 1997, J VIROL, V71, P5678, DOI 10.1128/JVI.71.7.5678 5683.1997
   Tögel F, 2005, KIDNEY INT, V67, P1772, DOI 10.1111/j.1523 1755.2005.00275.x
   Trubiani O, 2008, J CELL PHYSIOL, V214, P706, DOI 10.1002/jcp.21266
   Wong D, 2008, CLIN CANCER RES, V14, P7975, DOI 10.1158/1078 0432.CCR 07 4846
   Yeh LCC, 2002, J CELL BIOCHEM, V87, P292, DOI 10.1002/jcb.10315
   Yu L, 2006, GENE, V374, P174, DOI 10.1016/j.gene.2006.02.001
   Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404
   Zachos TA, 2006, J ORTHOP RES, V24, P1279, DOI 10.1002/jor.20068
   Zhu W, 2007, J BIOL CHEM, V282, P18676, DOI 10.1074/jbc.M610232200
   Zhu W, 2006, BONE, V39, P61, DOI 10.1016/j.bone.2005.12.018
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074 7613(00)80165 X
   Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269
NR 53
TC 114
Z9 135
U1 1
U2 23
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357 2725
EI 1878 5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD JUL
PY 2010
VL 42
IS 7
BP 1132
EP 1141
DI 10.1016/j.biocel.2010.03.020
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 619FA
UT WOS:000279413400011
PM 20362069
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Poon, M
   Zeng, L
   Zhang, L
   Lam, H
   Emmenegger, U
   Wong, E
   Bedard, G
   Lao, N
   Chow, R
   Chow, E
AF Poon, M.
   Zeng, L.
   Zhang, L.
   Lam, H.
   Emmenegger, U.
   Wong, E.
   Bedard, G.
   Lao, N.
   Chow, R.
   Chow, E.
TI Incidence of Skeletal related Events Over Time from Solid Tumour Bone
   Metastases Reported in Randomised Trials Using Bone modifying Agents
SO CLINICAL ONCOLOGY
LA English
DT Article
DE Bisphosphonates; bone metastases; orthopaedic surgery; palliative
   radiation; pathological fracture; skeletal related events
ID PLACEBO CONTROLLED TRIAL; ADVANCED BREAST CANCER; ZOLEDRONIC ACID;
   DOUBLE BLIND; PROSTATE CANCER; COMPLICATIONS; PAMIDRONATE; CARCINOMA;
   WOMEN; MANAGEMENT
AB Aims: Skeletal related events (SREs) in patients with bone metastases decrease a patient's quality of life and functional status. Although bone modifying agents have been found to reduce the time to first on trial SRE and decrease the total incidence of SREs in randomised clinical trials, standard practice in the management of bone metastases has changed concurrently. The purpose of this study was to investigate if advances in bone targeted therapies have decreased the incidence of individual types of SREs and to delineate the trend of SREs.
   Materials and methods: A literature review was conducted in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials to identify phase III, randomised bisphosphonate and other bone targeted therapy trials from 1980 to September 2011. For all studies, a mean year of enrolment ([start of enrolment + end of enrolment]/2) was calculated. The incidences of SREs were tabulated and expressed as percentages of on trial patients. Generalised linear mixed models were used to search for the trends of SREs over time for all placebo and intervention arms. Regression coefficients were interpreted as the odds ratio, which was calculated using the exponential of the slope. Ninety five per cent confidence intervals were also calculated.
   Results: In total, 20 eligible studies were identified that reported SRE data from phase III trials, of which 11 were suitable for the quantitative analysis. Most of the articles included patients with breast cancer and the remaining involved patients with prostate, renal cell, bladder and lung cancer or other solid tumours. Enrolment periods for all included data ranged from 1990 to 2009. Statistically significant overall downward trends in pathological fractures and the need for surgery were seen over time. Also significant differences between intervention and placebo were seen with all SREs.
   Conclusion: The decrease in SREs over time may not only be a result of the development of new generation bone targeted agents, but also due to better systemic management and awareness of events associated with bone metastases. (C) 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
C1 [Poon, M.; Zeng, L.; Zhang, L.; Lam, H.; Emmenegger, U.; Wong, E.; Bedard, G.; Lao, N.; Chow, R.; Chow, E.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada.
C3 University of Toronto; Sunnybrook Research Institute; Sunnybrook Health
   Science Center
RP Chow, E (通讯作者)，Sunnybrook Hlth Sci Ctr, Dept Radiat Oncol, Odette Canc Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
EM edward.chow@sunnybrook.ca
RI Chow, Ronald/V 3117 2019
CR Bundred NJ, 2008, CANCER AM CANCER SOC, V112, P1001, DOI 10.1002/cncr.23259
   Carteni G, 2006, ONCOLOGIST, V11, P841, DOI 10.1634/theoncologist.11 7 841
   Costa L, 2009, NAT CLIN PRACT ONCOL, V6, P163, DOI 10.1038/ncponc1323
   Dearnaley DP, 2003, J NATL CANCER I, V95, P1300, DOI 10.1093/jnci/djg038
   Delea T, 2004, ONCOLOGY BASEL, V67, P390, DOI 10.1159/000082923
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Harrington KD, 1997, CANCER, V80, P1614
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Higginson IJ, 2002, J PAIN SYMPTOM MANAG, V23, P96, DOI 10.1016/S0885 3924(01)00406 7
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Khan L, 2012, SUPPORT CARE CANCER, V20, P549, DOI 10.1007/s00520 011 1120 1
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Lagman R, 2005, SEMIN ONCOL, V32, P134, DOI 10.1053/j.seminoncol.2004.11.015
   Lipton A, 2003, CANCER, V98, P962, DOI 10.1002/cncr.11571
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Plunkett TA, 2000, EUR J CANCER, V36, P476, DOI 10.1016/S0959 8049(99)00331 7
   Polascik TJ, 2008, DRUG DES DEV THER, V3, P27
   Ristevski B, 2009, CAN J SURG, V52, P302
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2007, CLIN GENITOURIN CANC, V5, P390, DOI 10.3816/CGC.2007.n.022
   SHERRY MM, 1986, CANCER AM CANCER SOC, V58, P178, DOI 10.1002/1097 0142(19860701)58:1<178::AID CNCR2820580130>3.0.CO;2 T
   Shiue K, 2010, EXPERT REV ANTICANC, V10, P697, DOI 10.1586/ERA.10.47
   Small EJ, 2003, J CLIN ONCOL, V21, P4277, DOI 10.1200/JCO.2003.05.147
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   Zeng L, 2012, SUPPORT CARE CANCER, V20, P3307, DOI 10.1007/s00520 012 1484 x
NR 27
TC 26
Z9 27
U1 0
U2 4
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0936 6555
EI 1433 2981
J9 CLIN ONCOL UK
JI Clin. Oncol.
PD JUL
PY 2013
VL 25
IS 7
BP 435
EP 444
DI 10.1016/j.clon.2013.03.003
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 171FU
UT WOS:000320911300006
PM 23582277
DA 2025 08 17
ER

PT J
AU Chen, JS
   Xu, WK
   Song, KY
   Da, LT
   Zhang, X
   Lin, MY
   Hong, XW
   Zhang, S
   Guo, F
AF Chen, Junsong
   Xu, Wenke
   Song, Kaiyuan
   Da, Lin Tai
   Zhang, Xin
   Lin, Mengyao
   Hong, Xiaowu
   Zhang, Sheng
   Guo, Fang
TI Legumain inhibitor prevents breast cancer bone metastasis by attenuating
   osteoclast differentiation and function
SO BONE
LA English
DT Article
DE Asparagine endopeptidase; Epithelial mesenchymal transition; Breast
   cancer; Bone metastasis; Osteoclast
ID ASPARAGINE ENDOPEPTIDASE; E CADHERIN; IN VITRO; CYSTEINE; PROGRESSION;
   MODEL
AB Breast cancer is the main lethal disease among females, and metastasis to lung and bone poses a serious threat to patients' life. Therefore, identification of novel molecular mediators that can potentially be exploited as thera peutic targets for treating osteolytic bone metastases is needed. A murine model of breast cancer bone metastasis was developed by injection of 4 T1.2 cells into the left ventricle and hence directly into the arterial system leading to bone. AEP (Asparagine endopeptidase) inhibitor combined with epirubicin or epirubicin alone was administered by intraperitoneal injection into animal model. The presence of bone metastatic and osteolytic lesions in bone were assessed by bioluminescent imaging and X rays analysis. The expression of EMT (Epithelial Mesenchymal Transition) relevant genes were examined by Western blotting. Cell migration and invasion were investigated with a transwell assay. Compound BIC 113, small molecule inhibitors of AEP, inhibited AEP enzymatic activity in breast cancer cell lines, and affected invasion and migration of cancer cells, but had no effect on cell growth. In animal model of breast cancer bone metastasis, compound BIC 113 combined with epirubicin inhibited breast cancer bone metastasis and attenuated breast cancer osteolytic lesions in bone by inhibiting osteoclast differentiation and EMT. These results indicate that compound BIC 113 combined with epirubicin has the potential to be used in breast cancer therapy by preventing bone metastasis via improving E cadherin expression and inhibition of osteoclast formation.
C1 [Chen, Junsong; Xu, Wenke; Song, Kaiyuan; Da, Lin Tai; Zhang, Xin; Lin, Mengyao; Guo, Fang] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Key Lab Syst Biomed, Minist Educ, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.
   [Hong, Xiaowu] Fudan Univ, Sch basic Med Sci, Dept Immunol, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.
   [Zhang, Sheng] Fujian Med Univ, Affiliated Hosp 1, Dept Pathol, Chazhong Rd, Fuzhou 350000, Peoples R China.
C3 Shanghai Jiao Tong University; Fudan University; Fujian Medical
   University
RP Guo, F (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Key Lab Syst Biomed, Minist Educ, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.; Zhang, S (通讯作者)，Fujian Med Univ, Affiliated Hosp 1, Dept Pathol, Chazhong Rd, Fuzhou 350000, Peoples R China.
EM zhgshg@fjmu.edu.cn; fguo@sjtu.edu.cn
RI Song, KaiYuan/NDR 9418 2025; Guo, Fang/L 2273 2017
FU Special Fund for Basic Scientific Research of Central Colleges, Shanghai
   Jiaotong University for Nationalities' [17X100040081]; National Key
   Technologies R&D Program of China [2018ZX10732202 002 009]; Special
   Clinical Research Project of Shanghai Health Commission [202040315];
   Medical Research Project of Shanghai Hongkou District Health Commission
   (Hongwei2002 11) [Hongwei2002 11]
FX This study was funded by The Special Fund for Basic Scientific Research
   of Central Colleges, Shanghai Jiaotong University for Nationalities'
   (grant number: 17X100040081) , National Key Technologies R & D Program
   of China (2018ZX10732202 002 009) , Special Clinical Research Project of
   Shanghai Health Commission (202040315) and Medical Research Project of
   Shanghai Hongkou District Health Commission (Hongwei2002 11) .
CR ARGUELLO F, 1988, CANCER RES, V48, P6876
   Brage M, 2004, BONE, V34, P412, DOI 10.1016/j.bone.2003.11.018
   Brage M, 2005, CALCIFIED TISSUE INT, V76, P439, DOI 10.1007/s00223 004 0043 y
   Chen JM, 2001, BIOL CHEM, V382, P777, DOI 10.1515/BC.2001.093
   Clézardin P, 2021, PHYSIOL REV, V101, P797, DOI 10.1152/physrev.00012.2019
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   Corso G, 2020, J CELL MOL MED, V24, P5930, DOI 10.1111/jcmm.15140
   Cui YH, 2016, ONCOTARGET, V7, P34356, DOI 10.18632/oncotarget.8879
   Fiorino C, 2016, BONE, V86, P106, DOI 10.1016/j.bone.2016.03.004
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Fornetti J, 2018, J BONE MINER RES, V33, P2099, DOI 10.1002/jbmr.3618
   Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406
   Gu R, 2020, METHODS MOL BIOL, V2080, P135, DOI 10.1007/978 1 4939 9936 1_12
   Khasraw M, 2012, BREAST, V21, P142, DOI 10.1016/j.breast.2011.12.012
   Landrum G., RDKit: Open Source Cheminformatics Software
   Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505
   Li N, 2013, MED ONCOL, V30, DOI 10.1007/s12032 013 0621 9
   Lin YY, 2020, JNCI J NATL CANCER I, V112, P343, DOI 10.1093/jnci/djz155
   Lin YY, 2014, JNCI J NATL CANCER I, V106, DOI 10.1093/jnci/dju012
   Liu Y, 2012, MOL PHARMACEUT, V9, P168, DOI 10.1021/mp200434n
   Lukasiewicz S, 2021, CANCERS, V13, DOI 10.3390/cancers13174287
   Mai CW, 2017, CURR DRUG TARGETS, V18, P1259, DOI 10.2174/1389450117666161216125344
   Martin TJ, 2021, BRIT J PHARMACOL, V178, P1923, DOI 10.1111/bph.14709
   Patel N, 2015, J ORTHOP RES, V33, P1474, DOI 10.1002/jor.22795
   Qi Q, 2017, J MED CHEM, V60, P7244, DOI 10.1021/acs.jmedchem.7b00228
   Reddy BD, 2021, CURR PHARM DESIGN, V27, P3337, DOI 10.2174/1381612826666201125111625
   Riquelme MA, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.567844
   Simmons JK, 2015, VET PATHOL, V52, P827, DOI 10.1177/0300985815586223
   Strålberg F, 2013, FASEB J, V27, P2687, DOI 10.1096/fj.12 211748
   Tahara RK, 2019, ADV EXP MED BIOL, V1152, P105, DOI 10.1007/978 3 030 20301 6_7
   Tarragona M, 2012, J BIOL CHEM, V287, P21346, DOI 10.1074/jbc.M112.355834
   Toss MS, 2019, MODERN PATHOL, V32, P639, DOI 10.1038/s41379 018 0180 x
   Wang HB, 2020, INT J BIOL SCI, V16, P172, DOI 10.7150/ijbs.36467
   Weivoda MM, 2016, J BONE MINER RES, V31, P65, DOI 10.1002/jbmr.2599
   Wu HJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020636
   Zhang WR, 2021, CELLS BASEL, V10, DOI 10.3390/cells10051153
   Zhang YH, 2019, CELL DEATH DIFFER, V26, P565, DOI 10.1038/s41418 018 0147 y
   Zhao T, 2021, INVEST NEW DRUG, V39, P337, DOI 10.1007/s10637 020 01011 3
NR 38
TC 10
Z9 10
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2023
VL 169
AR 116680
DI 10.1016/j.bone.2023.116680
EA FEB 2023
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 9A3FM
UT WOS:000933946700001
PM 36702335
DA 2025 08 17
ER

PT J
AU Wei, SJ
   Zhang, Q
   Xiang, YJ
   Peng, LY
   Peng, W
   Ren, Q
   Gao, YX
AF Wei, Shu jun
   Zhang, Qing
   Xiang, Yong jing
   Peng, Lan yu
   Peng, Wei
   Ren, Qiang
   Gao, Yong xiang
TI Guizhi Shaoyao Zhimu decoction attenuates bone erosion in rats
   that have collagen induced arthritis via modulating NF κB signalling to
   suppress osteoclastogenesis
SO PHARMACEUTICAL BIOLOGY
LA English
DT Article
DE Rheumatoid arthritis; osteoclast; RANKL; osteoprotegerin
AB Context
   Guizhi Shaoyao Zhimu decoction (GSZD) is commonly used to treat rheumatoid arthritis (RA), but its mechanism is unclear.
   Objective
   To investigate the effect of GSZD on bone erosion in type II collagen (CII) induced arthritis (CIA) in rats and to identify the underlying mechanism.
   Materials and methods
   The CIA model was prepared in male Wistar rats by two subcutaneous injections of CII, 1 mg/mL. Fifty CIA rats were randomized equally into the control group given saline daily, the positive group given saline daily and methotrexate 0.75 mg/kg once a week, and three GSZD treated groups gavaged daily with 800, 1600 and 3200 mg/kg of GSZD for 21 days. GSZD effects were assessed by paw volume, arthritic severity index and histopathology. Cytokine levels were determined by ELISA. The effects of GSZD on RAW264.7 cells were evaluated by receptor activator of NF kappa B ligand (RANKL) induced osteoclastogenesis and bone resorption assay. Expression of I kappa B alpha and p65 was measured by Western blotting. Major components of GSZD were identified by HPLC.
   Results
   Arthritis index score, paw volume and bone destruction score showed that GSZD improved inflammatory symptoms and reduced joint tissue erosion (p < 0.01). GSZD decreased RANKL, and the number of osteoclasts (OCs) in joint tissues (p < 0.01) and increased osteoprotegerin levels (p < 0.01). GSZD inhibited RANKL induced RAW264.7 differentiation and reduced bone resorption by OCs. GSZD upregulated I kappa B (p < 0.01) and p65 (p < 0.01) in the cytoplasm and downregulated p65 (p < 0.01) in the cell nucleus.
   Conclusions
   Guizhi Shaoyao Zhimu decoction has an anti RA effect, suggesting its possible use as a supplement and alternative drug therapy for RA.
C1 [Wei, Shu jun; Xiang, Yong jing; Gao, Yong xiang] Chengdu Univ Tradit Chinese Med, Sch Basic Med, Chengdu, Peoples R China.
   [Zhang, Qing; Peng, Wei] Chengdu Univ Tradit Chinese Med, Sch Pharm, 1166 Liu Tai Rd, Chengdu 611130, Peoples R China.
   [Peng, Lan yu; Ren, Qiang] Univ Tradit Chinese Med, Hosp Chengdu, 39 Shi Er Qiao Rd, Chengdu 610072, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University
   of Traditional Chinese Medicine
RP Peng, W (通讯作者)，Chengdu Univ Tradit Chinese Med, Sch Pharm, 1166 Liu Tai Rd, Chengdu 611130, Peoples R China.; Ren, Q (通讯作者)，Univ Tradit Chinese Med, Hosp Chengdu, 39 Shi Er Qiao Rd, Chengdu 610072, Peoples R China.; Gao, YX (通讯作者)，Chengdu Univ Tradit Chinese Med, Int Educ Coll, 37 Shi Er Qiao Rd, Chengdu 610075, Peoples R China.
EM pengwei@cdutcm.edu.cn; 401627406@qq.com; drgaoyx@cdutcm.edu.cn
RI ; Zhang, Qing/ABG 4263 2021; Peng, Wei/ABD 2833 2021
OI wei, Shujun/0000 0002 2343 8107; 
FU National Science and Technology Major Project of the Ministry of Science
   and Technology of China [2018ZX09721004 009 002]; Sichuan Science and
   Technology Program [2019JDRC0074]; Xinglin Scholar Discipline Promotion
   Talent Program of Chengdu University of Traditional Chinese Medicine
   [BSH2018006]
FX This work was supported by the National Science and Technology Major
   Project of the Ministry of Science and Technology of China [No.
   2018ZX09721004 009 002], Sichuan Science and Technology Program [No.
   2019JDRC0074] and Xinglin Scholar Discipline Promotion Talent Program of
   Chengdu University of Traditional Chinese Medicine [No. BSH2018006].
CR Adamopoulos IE, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2936
   Aletaha D, 2018, JAMA J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103
   Atkins GJ, 2006, J BONE MINER RES, V21, P1339, DOI 10.1359/JBMR.060604
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   Bridges SL, 2018, ARTHRITIS RHEUMATOL, V70, P334, DOI 10.1002/art.40388
   Brzustewicz E, 2015, CYTOKINE, V76, P527, DOI 10.1016/j.cyto.2015.08.260
   Chambers TJ, 2000, J PATHOL, V192, P4
   Chen Z, 2013, INT IMMUNOPHARMACOL, V15, P474, DOI 10.1016/j.intimp.2013.01.021
   Chingcuanco F, 2016, ANN INTERN MED, V165, P565, DOI 10.7326/M16 0428
   Cross M, 2014, ANN RHEUM DIS, V73, P1316, DOI 10.1136/annrheumdis 2013 204627
   Daily JW, 2017, J ALTERN COMPLEM MED, V23, P756, DOI 10.1089/acm.2017.0098
   Dekkers JS, 2017, ANN RHEUM DIS, V76, P458, DOI 10.1136/annrheumdis 2016 209830
   Edwards JR, 2012, DISCOV MED, V13, P201
   Fardellone P, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/484280
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Gravallese EM, 2003, J CLIN INVEST, V112, P147, DOI 10.1172/JCI200310109
   Guo QY, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 016 0921 x
   Huang RY, 2019, PHYTOMEDICINE, V57, P403, DOI 10.1016/j.phymed.2018.12.030
   Jia XY, 2014, INT IMMUNOPHARMACOL, V18, P1, DOI 10.1016/j.intimp.2013.09.007
   Jin S, 2018, OSTEOPOROSIS INT, V29, P1263, DOI 10.1007/s00198 018 4473 1
   Kim JH, 2009, J IMMUNOL, V183, P1862, DOI 10.4049/jimmunol.0803007
   Komatsu N, 2015, INT J BIOCHEM CELL B, V58, P92, DOI 10.1016/j.biocel.2014.11.008
   Liu WW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02228
   McInnes IB, 2016, NAT REV RHEUMATOL, V12, P63, DOI 10.1038/nrrheum.2015.171
   Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173
   Papadaki M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00097
   Qin Yi, 2019, Zhongguo Zhong Yao Za Zhi, V44, P3042, DOI 10.19540/j.cnki.cjcmm.20190410.305
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Singh JA, 2016, ARTHRITIS RHEUMATOL, V68, P1, DOI 10.1002/art.39480
   Sinigaglia L, 2006, RHEUM DIS CLIN N AM, V32, P631, DOI 10.1016/j.rdc.2006.07.002
   Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis 2016 210715
   Sparks JA, 2019, ANN INTERN MED, V170, pITC1, DOI 10.7326/AITC201901010
   Tsuboi H, 2003, ANN RHEUM DIS, V62, P196, DOI 10.1136/ard.62.3.196
   Vanderborght A, 2004, J RHEUMATOL, V31, P1483
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Walsh NC, 2010, IMMUNOL REV, V233, P301, DOI 10.1111/j.0105 2896.2009.00857.x
   Wang ML, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01051
   Wu MR, 2012, INT J BIOL SCI, V8, P1398, DOI 10.7150/ijbs.5079
   Xiang N, 2015, INT IMMUNOPHARMACOL, V28, P802, DOI 10.1016/j.intimp.2015.08.008
   Xu SQ, 2012, RHEUMATOL INT, V32, P3397, DOI 10.1007/s00296 011 2175 5
   Yang CLH, 2013, CLIN REV ALLERG IMMU, V44, P284, DOI 10.1007/s12016 012 8329 8
   Zhang Q, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109367
NR 46
TC 17
Z9 19
U1 1
U2 38
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1388 0209
EI 1744 5116
J9 PHARM BIOL
JI Pharm. Biol.
PD JAN 1
PY 2021
VL 59
IS 1
BP 262
EP 274
DI 10.1080/13880209.2021.1876100
PG 13
WC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
GA QL6RR
UT WOS:000621212300001
PM 33626293
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Li, TT
   Xiao, PP
   Qiu, DB
   Yang, AP
   Chen, QJ
   Lin, JF
   Liu, Y
   Chen, JM
   Zeng, ZY
AF Li, Tingting
   Xiao, Pingping
   Qiu, Dongbiao
   Yang, Apeng
   Chen, Qingjiao
   Lin, Junfang
   Liu, Yao
   Chen, Junmin
   Zeng, Zhiyong
TI NCX1/Ca<SUP>2+</SUP> promotes autophagy and decreases bortezomib
   activity in multiple myeloma through non canonical NFκB signaling
   pathway
SO CELL COMMUNICATION AND SIGNALING
LA English
DT Article
DE Sodium calcium exchanger 1; Calcium; Bortezomib; Autophagy; NF kappa B
ID NA+/CA2+ EXCHANGER 1; PROTEASOME INHIBITOR; RESISTANCE; PROLIFERATION;
   APOPTOSIS; DIAGNOSIS; SURVIVAL; SYSTEM; CELLS
AB Although bortezomib (BTZ) is the cornerstone of anti multiple myeloma (MM) therapy, the inevitable primary and secondary drug resistance still seriously affects the prognosis of patients. New treatment strategies are in need. Sodium calcium exchanger 1 (NCX1) is a calcium permeable ion transporter on the membrane, and our previous studies showed that low NCX1 confers inferior viability in MM cells and suppressed osteoclast differentiation. However, the effect of NCX1 on BTZ sensitivity of MM and its possible mechanism remain unclear. In this study, we investigated the effect of NCX1 on BTZ sensitivity in MM, focusing on cellular processes of autophagy and cell viability. Our results provide evidence that NCX1 expression correlates with MM disease progression and low NCX1 expression increases BTZ sensitivity. NCX1/Ca2+ triggered autophagic flux through non canonical NF kappa B pathway in MM cells, leading to attenuated the sensitivity of BTZ. Knockdown or inhibition of NCX1 could potentiate the anti MM activity of BTZ in vitro and vivo, and inhibition of autophagy sensitized NCX1 overexpressing MM cells to BTZ. In general, this work implicates NCX1 as a potential therapeutic target in MM with BTZ resistance and provides novel mechanistic insights into its vital role in combating BTZ resistance.
C1 [Li, Tingting; Xiao, Pingping; Yang, Apeng; Chen, Qingjiao; Lin, Junfang; Chen, Junmin; Zeng, Zhiyong] Fujian Med Univ, Affiliated Hosp 1, Dept Hematol, Fuzhou, Peoples R China.
   [Qiu, Dongbiao] Fujian Med Univ, Affiliated Hosp 1, Dept Blood Transfus, Fuzhou, Peoples R China.
   [Li, Tingting; Yang, Apeng; Chen, Qingjiao; Lin, Junfang; Chen, Junmin; Zeng, Zhiyong] Fujian Key Lab, Lab Med, Fuzhou, Peoples R China.
   [Li, Tingting; Yang, Apeng; Chen, Qingjiao; Lin, Junfang; Chen, Junmin; Zeng, Zhiyong] Fujian Med Univ, Affiliated Hosp 1, Natl Reg Med Ctr, Dept Hematol, Binhai Campus, Fuzhou, Peoples R China.
   [Li, Tingting; Liu, Yao] Chongqing Univ, Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis & I, Dept Hematol Oncol, Chongqing, Peoples R China.
C3 Fujian Medical University; Fujian Medical University; Fujian Medical
   University; Chongqing University
RP Chen, JM; Zeng, ZY (通讯作者)，Fujian Med Univ, Affiliated Hosp 1, Dept Hematol, Fuzhou, Peoples R China.; Chen, JM; Zeng, ZY (通讯作者)，Fujian Key Lab, Lab Med, Fuzhou, Peoples R China.; Chen, JM; Zeng, ZY (通讯作者)，Fujian Med Univ, Affiliated Hosp 1, Natl Reg Med Ctr, Dept Hematol, Binhai Campus, Fuzhou, Peoples R China.; Liu, Y (通讯作者)，Chongqing Univ, Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis & I, Dept Hematol Oncol, Chongqing, Peoples R China.
EM liuyao77@cqu.edu.cn; drjunminchen@fjmu.edu.cn; zengzhiyong049@163.com
RI ; Yao, Liu/LJM 3304 2024; Lin, Junfanng/AGT 8705 2022
OI Liu, Yao/0000 0003 1782 7322; 
FU Sailing Fund of Fujian Medical University
FX Not applicable.
CR Beider K, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045 020 00993 0
   Berry CT, 2018, CELL CALCIUM, V74, P131, DOI 10.1016/j.ceca.2018.07.003
   Brandalise F, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241612673
   Cai Z, 2022, Zhonghua Nei Ke Za Zhi, V61, P469, DOI 10.3760/cma.j.cn112138 20220414 00278
   Cao BR, 2019, J CELL PHYSIOL, V234, P6831, DOI 10.1002/jcp.27432
   Chhabra S, 2017, PHARMACEUTICALS BASE, V10, DOI 10.3390/ph10020040
   Chovancova B, 2020, BIOCHEM PHARMACOL, V171, DOI 10.1016/j.bcp.2019.113695
   Cowan AJ, 2022, JAMA J AM MED ASSOC, V327, P464, DOI 10.1001/jama.2022.0003
   Dai HB, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.585286
   Di Lernia G, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020552
   Egan JB, 2012, BLOOD, V120, P1060, DOI 10.1182/blood 2012 01 405977
   Escalante AM, 2013, CANCER CHEMOTH PHARM, V71, P1567, DOI 10.1007/s00280 013 2156 3
   Feinman Rena, 2004, Clin Adv Hematol Oncol, V2, P162
   Fitzwalter Brent E, 2018, Oncotarget, V9, P25384, DOI 10.18632/oncotarget.25366
   Gerkau NJ, 2018, CEREB CORTEX, V28, P4264, DOI 10.1093/cercor/bhx280
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008 5472.CAN 13 2966
   Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242
   Gu CY, 2021, MOL CANCER, V20, DOI 10.1186/s12943 021 01380 0
   Hu HJ, 2019, BRIT J PHARMACOL, V176, P2691, DOI 10.1111/bph.14692
   Hui B, 2012, CANCER AM CANCER SOC, V118, P5560, DOI 10.1002/cncr.27586
   Jaganathan S, 2014, ONCOTARGET, V5, P12358, DOI 10.18632/oncotarget.2590
   Jia L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032584
   Kania E, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/352794
   Kocaturk NM, 2019, EUR J PHARM SCI, V134, P116, DOI 10.1016/j.ejps.2019.04.011
   Lawson MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9983
   Li N, 2022, CLIN TRANSL IMMUNOL, V11, DOI 10.1002/cti2.1386
   Li TT, 2023, CLIN EXP MED, V23, P1581, DOI 10.1007/s10238 022 00905 1
   Liao QS, 2019, WORLD J GASTROENTERO, V25, P287, DOI 10.3748/wjg.v25.i3.287
   Lim SK, 2022, Leukemia, V23, P901
   Liu ZK, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020901
   Long Z, 2016, ONCOTARGET, V7, P42059, DOI 10.18632/oncotarget.9806
   Milan E, 2016, J CLIN IMMUNOL, V36, pS18, DOI 10.1007/s10875 016 0254 9
   Milan E, 2015, AUTOPHAGY, V11, P1161, DOI 10.1080/15548627.2015.1052928
   Murdaca G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22169039
   Niewerth D, 2015, DRUG RESIST UPDATE, V18, P18, DOI 10.1016/j.drup.2014.12.001
   Pang XN, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11020135
   Pérez Pérez ME, 2021, J EXP BOT, V72, P3340, DOI 10.1093/jxb/erab063
   Rahman MA, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10030408
   Roy M, 2016, THERANOSTICS, V6, P2209, DOI 10.7150/thno.15584
   Song IS, 2013, INT J CANCER, V133, P1357, DOI 10.1002/ijc.28149
   Sonneveld P, 2016, HAEMATOLOGICA, V101, P396, DOI 10.3324/haematol.2015.129189
   Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264
   Wallington Beddoe CT, 2018, BRIT J HAEMATOL, V182, P11, DOI 10.1111/bjh.15210
   Wan HX, 2022, ONCOGENE, V41, P4169, DOI 10.1038/s41388 022 02412 9
   Wang JZ, 2021, INT J MOL MED, V47, P643, DOI 10.3892/ijmm.2020.4831
   Wen JX, 2016, ONCOTARGET, V7, P63816, DOI 10.18632/oncotarget.11695
   Wu XH, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/6096391
   Xia JL, 2020, MOL ONCOL, V14, P763, DOI 10.1002/1878 0261.12641
   Xu JY, 2016, CARCINOGENESIS, V37, P290, DOI 10.1093/carcin/bgw004
   Yanamandra N, 2011, J PHARMACOL EXP THER, V337, P636, DOI 10.1124/jpet.110.172809
   Yao F, 2012, MOL MED REP, V5, P84, DOI 10.3892/mmr.2011.590
   Yerlikaya A, 2016, ONCOL LETT, V12, P323, DOI 10.3892/ol.2016.4597
   Yi H, 2021, CANCER LETT, V520, P307, DOI 10.1016/j.canlet.2021.08.009
   Zang XY, 2022, LEUKEMIA RES, V123, DOI 10.1016/j.leukres.2022.106967
   Zhang H, 2016, CANCER RES, V76, P6410, DOI 10.1158/0008 5472.CAN 16 0595
   Zhang HM, 2018, ONCOL RES, V26, P421, DOI 10.3727/096504017X15049221237147
   Zhao YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127334
NR 57
TC 4
Z9 4
U1 2
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1478 811X
J9 CELL COMMUN SIGNAL
JI Cell Commun. Signal.
PD MAY 6
PY 2024
VL 22
IS 1
AR 258
DI 10.1186/s12964 024 01628 4
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA PO2F7
UT WOS:001214947300002
PM 38711131
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Leon, A
   Liu, L
   Yang, Y
   Hudock, MP
   Hall, P
   Yin, FL
   Studer, D
   Puan, KJ
   Morita, CT
   Oldfield, E
AF Leon, Annette
   Liu, Lei
   Yang, Yan
   Hudock, Michael P.
   Hall, Patrick
   Yin, Fenglin
   Studer, Danielle
   Puan, Kia Joo
   Morita, Craig T.
   Oldfield, Eric
TI Isoprenoid biosynthesis as a drug target:: Bisphosphonate inhibition of
   Escherichia coli K12 growth and synergistic effects of
   fosmidomycin
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID TRYPANOSOMA CRUZI; IN VITRO; PYROPHOSPHATE SYNTHASE;
   PLASMODIUM FALCIPARUM; MEVALONATE PATHWAY; GENE CLUSTER; EXPRESSION;
   BRUCEI; ANTIBACTERIAL; DISCOVERY
AB We screened a library of 117 bisphosphonates for antibacterial activity against Escherichia coli. The most potent growth inhibitors where the N [methyl(4 phenylalkyl)] 3 aminopropyl 1 hydroxy 1,1 bisphosphonates, known potent bone resorption inhibitors, and there was a generally good correlation between cell growth inhibition and E. coli farnesyl diphosphate synthase (FPPS) inhibition. However, some potent FPPS inhibitors had no activity in cell growth inhibition, and based on the result of Catalyst pharmacophore modeling, this could be attributed to the requirement of a large hydrophobic feature for cellular activity (due most likely to transport). The activity of the most potent compound, N [methyl(4 phenylbutyl)] 3 aminopropyl 1 hydroxy1,1 bisphosphonate (13), was strongly potentiated by the drug fosmidomycin. The transcription profiles for 13 or fosmidomycin alone were different from those found with carbenicillin or ciprofloxacin alone, but there were many similarities between the combination (13 fosmidomycin) and carbenicillin or ciprofloxacin, reflecting the more potent bactericidal activity of the drug combination on bacterial growth.
C1 Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
   Univ Illinois, Ctr Biostat & Computat Biol, Urbana, IL 61801 USA.
   Univ Illinois, WM Keck Ctr Comparat & Funct Genom, Urbana, IL 61801 USA.
   Univ Illinois, Dept Stat, Urbana, IL 61820 USA.
   Univ Illinois, Sch Mol & Cellular Biol, Urbana, IL 61801 USA.
   Univ Iowa, Coll Med, Dept Internal Med, Div Rheumatol, Iowa City, IA 52242 USA.
   Univ Iowa, Coll Med, Interdisciplinary Grp Immunol, Iowa City, IA 52242 USA.
C3 University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign;
   University of Iowa; University of Iowa
RP Oldfield, E (通讯作者)，Univ Illinois, Dept Chem, 600 S Mathews Ave, Urbana, IL 61801 USA.
EM eo@chad.scs.uiuc.edu
RI Morita, Craig/C 1365 2011; Puan, Kia Joo/JGE 3146 2023; Hudock,
   Michael/B 3781 2009
OI Morita, Craig/0000 0001 8496 8294
FU NIAMS NIH HHS [AR45504, R01 AR045504] Funding Source: Medline; NIGMS NIH
   HHS [GM073216 26, R01 GM073216, GM 08276] Funding Source: Medline
CR *AFF INC, 2002, GEN E COL ANT GEN AR
   [Anonymous], MTT CELL PROL ASS
   Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483 492.1999
   BAUER AW, 1966, AM J CLIN PATHOL, V45, P493
   Benaim G, 2006, J MED CHEM, V49, P892, DOI 10.1021/jm050691f
   BERENBAUM MC, 1989, PHARMACOL REV, V41, P93
   Borrmann S, 2005, ANTIMICROB AGENTS CH, V49, P3749, DOI 10.1128/AAC.49.9.3749 3754.2005
   Buckner FS, 2001, ANTIMICROB AGENTS CH, V45, P1210, DOI 10.1128/AAC.45.4.1210 1215.2001
   Chu TM, 2002, MATH BIOSCI, V176, P35, DOI 10.1016/S0025 5564(01)00107 9
   Eliopolous G.M., 1998, Antibiotics in Laboratory Medicine, P330
   EUCAST, 2000, CLIN MICROBIOL INFEC, V6, P570
   Fujisaki S, 2005, J BIOCHEM, V137, P395, DOI 10.1093/jb/mvi049
   Ghosh S, 2004, J MED CHEM, V47, P175, DOI 10.1021/jm030084x
   Hahn FM, 1999, J BACTERIOL, V181, P4499, DOI 10.1128/JB.181.15.4499 4504.1999
   Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573
   Kaneda K, 2001, P NATL ACAD SCI USA, V98, P932, DOI 10.1073/pnas.020472198
   Kato JI, 1999, J BACTERIOL, V181, P2733, DOI 10.1128/JB.181.9.2733 2738.1999
   Kotsikorou E, 2005, J MED CHEM, V48, P6128, DOI 10.1021/jm058220g
   Kotsikorou E, 2003, J MED CHEM, V46, P2932, DOI 10.1021/jm030054u
   Kuntz L, 2005, BIOCHEM J, V386, P127, DOI 10.1042/BJ20041378
   Li H, 2003, J BIOMOL SCREEN, V8, P712, DOI 10.1177/1087057103258185
   Ling Y, 2005, J MED CHEM, V48, P3130, DOI 10.1021/jm040132t
   Liu GY, 2005, J EXP MED, V202, P209, DOI 10.1084/jem.20050846
   Liu GY, 2004, P NATL ACAD SCI USA, V101, P14491, DOI 10.1073/pnas.0406143101
   Martin MB, 2002, J MED CHEM, V45, P2904, DOI 10.1021/jm0102809
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   Montalvetti A, 2001, J BIOL CHEM, V276, P33930, DOI 10.1074/jbc.M103950200
   *NAT COMM CLIN LAB, 2000, M7A5 NCCLS
   NEU HC, 1982, ANTIMICROB AGENTS CH, V22, P560, DOI 10.1128/AAC.22.4.560
   Projan SJ, 2004, CLIN MICROBIOL INFEC, V10, P18, DOI 10.1111/j.1465 0691.2004.1006.x
   Rieger CE, 1997, ANAL BIOCHEM, V246, P86, DOI 10.1006/abio.1996.9962
   Rohmer M, 1999, NAT PROD REP, V16, P565, DOI 10.1039/a709175c
   Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb 2001 2 2 reviews3004
   Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788
   Sanders JM, 2004, J MED CHEM, V47, P375, DOI 10.1021/jm0303709
   Sanders JM, 2003, J MED CHEM, V46, P5171, DOI 10.1021/jm0302344
   Shaw KJ, 2003, J MOL MICROB BIOTECH, V5, P105, DOI 10.1159/000069981
   Singh PK, 2000, AM J PHYSIOL LUNG C, V279, pL799, DOI 10.1152/ajplung.2000.279.5.L799
   SUHNEL J, 1992, ARZNEIMITTEL FORSCH, V42 2, P1251
   Szabo CM, 2002, J MED CHEM, V45, P2185, DOI 10.1021/jm010412y
   Takagi M, 2000, J BACTERIOL, V182, P4153, DOI 10.1128/JB.182.15.4153 4157.2000
   Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879
   *TEL TEST INC, 2004, RNA STAT 60 TOT RNA
   URBINA JA, 1993, ANTIMICROB AGENTS CH, V37, P580, DOI 10.1128/AAC.37.3.580
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Wiesner J, 2002, ANTIMICROB AGENTS CH, V46, P2889, DOI 10.1128/AAC.46.9.2889 2894.2002
   Wilding EI, 2000, J BACTERIOL, V182, P5147, DOI 10.1128/JB.182.18.5147 5152.2000
NR 47
TC 56
Z9 84
U1 0
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD DEC 14
PY 2006
VL 49
IS 25
BP 7331
EP 7341
DI 10.1021/jm060492b
PG 11
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 113VJ
UT WOS:000242625800009
PM 17149863
DA 2025 08 17
ER

PT J
AU Zheng, NY
   Xu, JK
   Ruan, YC
   Chang, L
   Wang, XL
   Yao, H
   Wang, JL
   Zhang, R
   Xue, QY
   Tang, N
   Ong, TY
   Schilcher, J
   O'Keefe, RJ
   Qin, L
AF Zheng, Nianye
   Xu, Jiankun
   Ruan, Ye Chun
   Chang, Liang
   Wang, Xinluan
   Yao, Hao
   Wang, Jiali
   Zhang, Ri
   Xue, Qingyun
   Tang, Ning
   Ong, Tim yun
   Schilcher, Joerg
   O'Keefe, Regis J.
   Qin, Ling
TI Magnesium facilitates the healing of atypical femoral fractures: A
   single cell transcriptomic study
SO MATERIALS TODAY
LA English
DT Article
DE Atypical femoral fractures (AFFs); Bisphosphonates (BPs); Calcitonin
   gene related peptide (CGRP); Magne sium (Mg); Single cell RNA sequencing
ID ZOLEDRONIC ACID; NERVE FIBERS; BONE MARROW; IN VITRO; FIBROSIS;
   BISPHOSPHONATES; ANGIOGENESIS; GROWTH; MICE; CGRP
AB Bisphosphonates (BPs) associated atypical femoral fractures (AFFs) present with impaired fracture healing, yet the underlying mechanism is unclear, which prevents the development of effective therapy. Peripheral sensory nerve has been shown to regulate fracture healing via releasing neuropeptides. Here we show that long term BPs pre treatment leads to fracture non union in rats, characterized by reduced expression of calcitonin gene related peptide (CGRP, a predominant type of neuropeptides) and abundant fibrous tissues in the non bridged fracture gap, mimicking clinical AFFs. By using single cell RNA sequencing, long term BPs treatment was identified to promote transition of progenitor cells into a specific cluster of fibroblasts that actively deposit dense extracellular matrix (ECM) to prevent fracture callus bridging. Administration of exogenous CGRP at early stages of fracture repair, in contrast, eliminates the ECM secreting fibroblast cluster, attenuates fibrogenesis, and facilitates callus bridging, suggesting CGRP is a promising agent to facilitate AFF healing. Accordingly, we have developed an innovative magnesium (Mg) containing hybrid intramedullary nail fixation system (Mg IMN) to effectively rescue BPs impaired fracture healing via elevating CGRP synthesis and release. Such device optimizes the fracture healing in BPs pretreated rats, comparable to direct administration of CGRP. These findings address the indispensable role of CGRP in advancing the healing of AFFs and develop translational strategies to accelerate AFF healing by taking advantage of the CGRP stimulating effect of Mg based biodegradable orthopedic implant. The study also indicates fibrosis could be targeted by augmenting CGRP expression to accelerate fracture healing even under challenging scenarios where fibroblasts are aberrantly activated.
C1 [Zheng, Nianye; Xu, Jiankun; Chang, Liang; Yao, Hao; Zhang, Ri; Tang, Ning; Ong, Tim yun; Qin, Ling] Chinese Univ Hong Kong, Fac Med, Musculoskeletal Res Lab, Dept Orthoped & Traumatol, Hong Kong, Peoples R China.
   [Zheng, Nianye; Xu, Jiankun; Chang, Liang; Yao, Hao; Zhang, Ri; Qin, Ling] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Innovat Orthoped Biomat & Drug Translat Res Lab, Hong Kong, Peoples R China.
   [Zheng, Nianye; O'Keefe, Regis J.] Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO 63110 USA.
   [Ruan, Ye Chun] Hong Kong Polytech Univ, Fac Engn, Dept Biomed Engn, Hong Kong, Peoples R China.
   [Wang, Xinluan; Qin, Ling] Chinese Acad Sci, Translat Med R&D Ctr, Inst Biomed & Hlth Engn, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China.
   [Wang, Jiali] Sun Yat Sen Univ, Sch Biomed Engn, Guangzhou, Peoples R China.
   [Xue, Qingyun] Beijing Hosp, Dept Orthoped Surg, Beijing, Peoples R China.
   [Schilcher, Joerg] Univ Hosp Linkoping, Dept Orthoped Surg, Linkoping, Sweden.
   [Schilcher, Joerg] Linkoping Univ, Wallenberg Ctr Mol Med, Linkoping, Sweden.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong;
   Washington University (WUSTL); Hong Kong Polytechnic University; Chinese
   Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS; Sun
   Yat Sen University; Beijing Hospital; Linkoping University; Linkoping
   University
RP Qin, L (通讯作者)，Chinese Univ Hong Kong, Fac Med, Musculoskeletal Res Lab, Dept Orthoped & Traumatol, Hong Kong, Peoples R China.; Qin, L (通讯作者)，Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Innovat Orthoped Biomat & Drug Translat Res Lab, Hong Kong, Peoples R China.; O'Keefe, RJ (通讯作者)，Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO 63110 USA.; Qin, L (通讯作者)，Chinese Acad Sci, Translat Med R&D Ctr, Inst Biomed & Hlth Engn, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China.
EM rokeefe@wustl.edu; qin@ort.cuhk.edu.hk
RI RUAN, Ye Chun/T 5919 2017; Ong, Michael/ADU 9207 2022; Wang,
   Jiali/IQU 4490 2023; Ruan, Ye Chun/T 5919 2017; Ong, Michael Tim
   Yun/ADU 9207 2022; qin, ling/KIB 1029 2024
OI Ruan, Ye Chun/0000 0002 4266 6789; Ong, Michael Tim
   Yun/0000 0002 4460 9286; 
FU Research Grants Council of Hong Kong SAR [T13 402/17 N]; Research Grants
   Council of Hong Kong SAR grants [14121918, 14173917]; Innovation and
   Technology Commission Funding [ITS/208/18FX]; National Natural Science
   Foundation of China [81802152, 81702165]; Natural Science Fund of
   Guangdong province [2019A1515012224, 2019A1515011404]; Health and
   Medical Research Fund of Hong Kong [18190481]; Early Career Scheme of
   Hong Kong [24104517]
FX We thank the laboratory members and Li Ka Shing Institute of Health
   Sciences (LiHS) for providing a harmonious working envi ronment.
   Funding: Theme based Research Scheme T13 402/17 N, Research Grants
   Council of Hong Kong SAR grants (L.Q.) ; General Research Funds 14121918
   and 14173917, Research Grants Council of Hong Kong SAR grants (L.Q.,
   J.X., N.Z.) ; Inno vation and Technology Commission Funding ITS/208/18FX
   (L. Q.) ; National Natural Science Foundation of China 81802152 and
   81702165 (J.X.) ; Natural Science Fund of Guangdong pro vince
   2019A1515012224 and 2019A1515011404 (J.X.) ; Health and Medical Research
   Fund of Hong Kong 18190481 (J.X.) ; Early Career Scheme of Hong Kong
   24104517 (Y.C.R.)
CR Amanat N, 2007, J BONE MINER RES, V22, P867, DOI 10.1359/JBMR.070318
   AOKI M, 1994, INT ORTHOP, V18, P317
   Bogl H.P., 2017, OSTEOPOROS INT, P1
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Brazill JM, 2019, J BONE MINER RES, V34, P1393, DOI 10.1002/jbmr.3822
   Chen SH, 2014, J ORTHOP TRANSL, V2, P91, DOI 10.1016/j.jot.2014.01.002
   Colnot C, 2009, J BONE MINER RES, V24, P274, DOI 10.1359/JBMR.081003
   Croft AP, 2019, NATURE, V570, P246, DOI 10.1038/s41586 019 1263 7
   Dang HX, 2017, INT J MOL MED, V40, P209, DOI 10.3892/ijmm.2017.3002
   De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274
   Debnath S, 2018, NATURE, V562, P133, DOI 10.1038/s41586 018 0554 8
   Dell RM, 2012, J BONE MINER RES, V27, P2544, DOI 10.1002/jbmr.1719
   Denu RA, 2016, ACTA HAEMATOL BASEL, V136, P85, DOI 10.1159/000445096
   Desai VD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086865
   Edwards BJ, 2016, J BONE MINER RES, V31, P1569, DOI 10.1002/jbmr.2818
   Fournier P, 2002, CANCER RES, V62, P6538
   Frolova EG, 2012, FASEB J, V26, P2363, DOI 10.1096/fj.11 190728
   Gasse P, 2007, J CLIN INVEST, V117, P3786, DOI 10.1172/JCI32285
   Ge XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101207
   Gibon E, 2017, J ORTHOP TRANSL, V10, P28, DOI 10.1016/j.jot.2017.04.002
   Gómez Barrena E, 2015, BONE, V70, P93, DOI 10.1016/j.bone.2014.07.033
   Grässel S, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0485 1
   Guerrero Juarez CF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08247 x
   Hagelauer N, 2015, CLIN ORAL INVEST, V19, P139, DOI 10.1007/s00784 014 1219 0
   Han HS, 2020, ADV SCI, V7, DOI 10.1002/advs.202000800
   HaraIrie F, 1996, BONE, V18, P29, DOI 10.1016/8756 3282(95)00425 4
   Hu JJ, 2016, SCI REP UK, V6, DOI 10.1038/srep23521
   Huang S, 2015, J ORTHOP TRANSL, V3, P26, DOI 10.1016/j.jot.2014.07.005
   HUKKANEN M, 1993, NEUROSCIENCE, V54, P969, DOI 10.1016/0306 4522(93)90588 7
   Jia YY, 2018, CHINESE MED J PEKING, V131, P2089, DOI 10.4103/0366 6999.239301
   Julien A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22842 5
   Kaji K, 2014, J GASTROENTEROL, V49, P481, DOI 10.1007/s00535 013 0783 4
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lai YS, 2019, GERIATR ORTHOP SURG, V10, DOI 10.1177/2151459319864736
   Lee KJ, 2017, INJURY, V48, P941, DOI 10.1016/j.injury.2017.02.036
   Lesclous P, 2009, BONE, V45, P843, DOI 10.1016/j.bone.2009.07.011
   Li XW, 2016, CAN J PHYSIOL PHARM, V94, P1315, DOI 10.1139/cjpp 2015 0602
   Li YT, 2015, OSTEOPOROSIS INT, V26, P431, DOI 10.1007/s00198 014 2903 2
   Lim SJ, 2018, OSTEOPOROSIS INT, V29, P2427, DOI 10.1007/s00198 018 4640 4
   Lindtner RA, 2014, OSTEOPOROSIS INT, V25, P1151, DOI 10.1007/s00198 013 2494 3
   Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0
   McDonald MM, 2008, BONE, V43, P653, DOI 10.1016/j.bone.2008.05.019
   McDonald MM, 2011, J ORTHOP RES, V29, P726, DOI 10.1002/jor.21293
   Mi J, 2021, TISSUE ENG PT A, V27, P87, DOI [10.1089/ten.TEA.2020.0009, 10.1089/ten.tea.2020.0009]
   Min HS, 2014, LAB INVEST, V94, P598, DOI 10.1038/labinvest.2014.50
   Morry J, 2015, BIOMATERIALS, V66, P41, DOI 10.1016/j.biomaterials.2015.07.005
   Nagy MT, 2021, INJURY, V52, P582, DOI 10.1016/j.injury.2020.09.051
   Nakagawa T., 2015, ANN RHEUM DIS, V74
   Ochoa AC, 2007, CLIN CANCER RES, V13, p721S, DOI 10.1158/1078 0432.CCR 06 2197
   Orita S, 2010, SPINE, V35, P1974, DOI 10.1097/BRS.0b013e3181d5959e
   Panagiotis M, 2005, INJURY, V36, pS30, DOI 10.1016/j.injury.2005.10.008
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   Rinkevich Y, 2015, SCIENCE, V348, DOI 10.1126/science.aaa2151
   Schilcher J, 2014, NEW ENGL J MED, V371, P974, DOI 10.1056/NEJMc1403799
   Schilcher J, 2014, ACTA ORTHOP, V85, P280, DOI 10.3109/17453674.2014.916488
   Schilcher J, 2013, BONE, V52, P389, DOI 10.1016/j.bone.2012.10.016
   Schinke T, 2004, J BONE MINER RES, V19, P2049, DOI 10.1359/JBMR.040915
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Siris ES, 2011, J BONE MINER RES, V26, P3, DOI 10.1002/jbmr.189
   Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009
   Tai T. W., 2017, SCI REP UK, V7, P1
   Unger S, 2013, AM J HUM GENET, V92, P990, DOI 10.1016/j.ajhg.2013.04.020
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099
   Wang JL, 2020, ADV SCI, V7, DOI 10.1002/advs.201902443
   Wang LQ, 2019, J BONE MINER RES, V34, P520, DOI 10.1002/jbmr.3626
   Wei HJ, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108252
   Xanthos DN, 2014, NAT REV NEUROSCI, V15, P43, DOI 10.1038/nrn3617
   Xie K, 2021, J ORTHOP TRANSL, V27, P96, DOI 10.1016/j.jot.2020.11.007
   Xu JF, 2012, AM J RESP CRIT CARE, V185, P547, DOI 10.1164/rccm.201108 1574OC
   Yamashita J, 2011, CLIN CANCER RES, V17, P1405, DOI 10.1158/1078 0432.CCR 10 1614
   Yu D., 2013, PLOS ONE, V8
   Yu YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031771
   Zhang QZ, 2015, J BONE MINER RES, V30, P2300, DOI 10.1002/jbmr.2577
   Zhang XP, 2005, J BONE MINER RES, V20, P2124, DOI 10.1359/JBMR.050806
   Zhang YF, 2016, NAT MED, V22, P1160, DOI 10.1038/nm.4162
   Zheng NY, 2016, J ORTHOP TRANSL, V7, P7, DOI 10.1016/j.jot.2016.06.029
   Zheng S., 2010, AM J PHYSIOL CELL PH, V299, pC1485
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
NR 79
TC 31
Z9 34
U1 7
U2 65
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1369 7021
EI 1873 4103
J9 MATER TODAY
JI Mater. Today
PD JAN FEB
PY 2022
VL 52
BP 43
EP 62
DI 10.1016/j.mattod.2021.11.028
PG 20
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 3T5PK
UT WOS:000840325900007
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Krieg, MA
   Aubry Rozier, B
   Hans, D
   Leslie, WD
AF Krieg, M. A.
   Aubry Rozier, B.
   Hans, D.
   Leslie, W. D.
CA Manitoba Bone Density Program
TI Effects of anti resorptive agents on trabecular bone score (TBS) in
   older women
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Anti resorptive therapy; Bisphosphonates; Bone mineral density; Fracture
   risk; Osteoporosis; Trabecular bone score
ID OSTEOPOROTIC FRACTURES; CAUCASIAN WOMEN; MINERAL DENSITY; HIP FRACTURE;
   MICROARCHITECTURE; ACQUISITION; MECHANISMS; STRENGTH; ODDS; BMD
AB We evaluated the longitudinal effects of anti resorptive agents (534 treated women vs. 1,150 untreated) on lumbar spine bone mineral density (BMD) and trabecular bone score (TBS). TBS was responsive to treatment in women over age 50. The treatment related increase in TBS was less than the increase in BMD, which is consistent with bone texture preservation.
   In addition to inducing an increase in BMD, anti resorptive agents also help to preserve bone architecture. TBS, a new gray level texture measurement, correlates with 3D parameters of bone micro architecture independent of BMD. Our objective was to evaluate the longitudinal effects of anti resorptive agents on lumbar spine BMD and TBS.
   Women (a parts per thousand yen50 years), from the BMD program database for the province of Manitoba, Canada, who had not received any anti resorptive drug prior to their initial dual X ray absorptiometry (DXA) exam were divided into two groups: untreated, those without any anti resorptive drug over the course of follow up, and treated, those with a non estrogen anti resorptive drug (86 % bisphosphonates, 10 % raloxifene, and 4 % calcitonin). Lumbar spine TBS was calculated for each lumbar spine DXA examination. Changes in TBS and BMD between baseline and follow up (mean follow up 3.7 years), expressed in percentage per year, were compared between the two groups.
   A total of 1,150 untreated women and 534 treated women met the inclusion criteria. Only a weak correlation was seen between BMD and TBS in either group. Significant intergroup differences in BMD change and TBS change were observed over the course of follow up (p < 0.001). Similar mean decreases in BMD and TBS ( 0.36 %/year and  0.31 %/year, respectively) were seen for untreated subjects (both p < 0.001). Conversely, treated subjects exhibited a significant mean increase in BMD (+1.86 %/year, p < 0.002) and TBS (+0.20 %/year, p < 0.001).
   TBS is responsive to treatment with non estrogen anti resorptive drug therapy in women over age 50. The treatment related increase in TBS is less than the increase in BMD, which is consistent with bone texture preservation.
C1 [Krieg, M. A.; Aubry Rozier, B.; Hans, D.] Univ Lausanne Hosp, DAL, Bone Dis Unit, CH 1011 Lausanne, Switzerland.
   [Leslie, W. D.] Univ Manitoba, Fac Med, Winnipeg, MB, Canada.
C3 University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV);
   University of Manitoba
RP Hans, D (通讯作者)，Univ Lausanne Hosp, DAL, Bone Dis Unit, Ave Pierre Decker 4, CH 1011 Lausanne, Switzerland.
EM didier.hans@ascendys.ch
RI ; Leslie, William/JKJ 1433 2023; Hans, Didier/B 3208 2018
OI Leslie, William/0000 0002 1056 1691; 
CR ALEXEEVA L, 1994, WHO TECH REP SER, V843, P1
   [Anonymous], J CLIN DENSITOM
   [Anonymous], OSTEOPOROSIS INT S2
   [Anonymous], OSTEOPOROS INT
   Binkley N, 2005, J BONE MINER RES, V20, P195, DOI 10.1359/JBMR.041115
   Boudousq V, 2005, OSTEOPOROSIS INT, V16, P813, DOI 10.1007/s00198 004 1751 x
   BOUTROY S, 2010, J BONE MINER RES, V25, P89
   Breban S, 2010, ANN M AM SOC BON MIN
   Browner WS, 1996, ARCH INTERN MED, V156, P1521, DOI 10.1001/archinte.156.14.1521
   Carbonare LD, 2004, J ENDOCRINOL INVEST, V27, P99, DOI 10.1007/BF03350919
   Colson F, 2011, ISCD ANN M APR 6 9 M
   Czerwinski Edward, 2007, Ortop Traumatol Rehabil, V9, P337
   Faulkner KG, 2006, OSTEOPOROSIS INT, V17, P593, DOI 10.1007/s00198 005 0019 4
   GLUER CC, 1995, OSTEOPOROSIS INT, V5, P262, DOI 10.1007/BF01774016
   Hadji P, 2012, OSTEOPOROSIS INT S2, V23, pS85
   Hannan EL, 2001, JAMA J AM MED ASSOC, V285, P2736, DOI 10.1001/jama.285.21.2736
   Hans D, 2011, J BONE MINER RES, V26, P2762, DOI 10.1002/jbmr.499
   Hans D, 2011, J CLIN DENSITOM, V14, P302, DOI 10.1016/j.jocd.2011.05.005
   Hordon LD, 2000, BONE, V27, P271, DOI 10.1016/S8756 3282(00)00329 X
   Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kanis JA, 2008, BONE, V42, P467, DOI 10.1016/j.bone.2007.11.001
   Leslie WD, 2009, OSTEOPOROSIS INT, V20, P1767, DOI 10.1007/s00198 009 0874 5
   Leslie WD, 2006, BONE, V39, P361, DOI 10.1016/j.bone.2006.02.002
   Leslie WD, 2005, J CLIN DENSITOM, V8, P25, DOI 10.1385/JCD:8:1:025
   Leslie WD, 2003, J CLIN DENSITOM, V6, P275, DOI 10.1385/JCD:6:3:275
   Link Thomas M, 2004, Curr Osteoporos Rep, V2, P47, DOI 10.1007/s11914 004 0003 5
   Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761
   Popp AW, 2012, OSTEOPOROSIS INT S2, V23, p[S85, P599]
   Popp AW, 2012, IOF ECCEO12 EUR C OS, pP598
   Pothuaud L, 2008, BONE, V42, P775, DOI 10.1016/j.bone.2007.11.018
   Pothuaud L, 2009, J CLIN DENSITOM, V12, P170, DOI 10.1016/j.jocd.2008.11.006
   Rabier B, 2010, BONE, V46, P176, DOI 10.1016/j.bone.2009.06.032
   Rizzoli R, 2012, OSTEOPOROSIS INT, V23, P305, DOI 10.1007/s00198 011 1758 z
   Roos NP, 1999, MED CARE, V37, pJS10, DOI 10.1097/00005650 199906001 00005
   Rubin CD, 2005, CURR MED RES OPIN, V21, P1049, DOI 10.1185/030079905X50525
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Winzenrieth R, 2012, OSTEOPOROSI IN PRESS
   Winzenrieth R, 2010, CALCIFIED TISSUE INT, V86, P104, DOI 10.1007/s00223 009 9322 y
NR 40
TC 73
Z9 75
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAR
PY 2013
VL 24
IS 3
BP 1073
EP 1078
DI 10.1007/s00198 012 2155 y
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 089DH
UT WOS:000314889100034
PM 23052939
DA 2025 08 17
ER

PT J
AU Hwang, JH
   Park, YS
   Kim, HS
   Dong ha Kim
   Lee, SH
   Lee, CH
   Lee, SH
   Kim, JE
   Lee, S
   Kim, HM
   Kim, HW
   Kim, J
   Seo, W
   Kwon, HJ
   Song, BJ
   Kim, DK
   Baek, MC
   Cho, YE
AF Hwang, Jin Hyeon
   Park, Yu Seong
   Kim, Hyuk Soon
   Dong ha Kim
   Lee, Sang Hoon
   Lee, Chan Hyeong
   Lee, Seung Hoon
   Kim, Jung Eun
   Lee, Sangkyu
   Kim, Ho Min
   Kim, Hyun Woo
   Kim, Jihoon
   Seo, Wonhyo
   Kwon, Hyo Jung
   Song, Byoung Joon
   Kim, Do Kyun
   Baek, Moon Chang
   Cho, Young Eun
TI Yam derived exosome like nanovesicles stimulate osteoblast formation and
   prevent osteoporosis in mice
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Exosome like nanovesicles; Yam  derived nanovesicles; Bone mineral
   density; Osteoporosis
ID ALKALINE PHOSPHATASE ACTIVITY; ACTIVATED PROTEIN KINASE; DRUG DELIVERY;
   EXTRACELLULAR VESICLES; CELL DIFFERENTIATION; COLLAGEN SYNTHESIS;
   BONE FORMATION; PROLIFERATION; GROWTH; IDENTIFICATION
AB Plants releasing exosome like nanovesicles (PENs) contain miRNA, bioactive lipids, mRNAs, and proteins to exert antioxidant, anti inflammatory, and regenerative activity. Substances extracted from yams have been reported to promote osteoblast growth in bone regeneration, which prevent weak and brittle bones in osteoporosis. Herein, we describe the beneficial effects of yam derived exosome like nanovesicles (YNVs) on promoting differentiation and mineralization of osteoblasts for bone regeneration in ovariectomized (OVX) induced osteoporotic mice. YNVs were successfully isolated and characterized. YNVs stimulate the proliferation, differentiation, and mineralization of osteoblasts with increased bone differentiation markers (OPN, ALP, and COL I). Interestingly, YNVs do not contain saponins including diosgenin and dioscin known to mainly exert osteogenic activity of yams. Instead, the osteogenic activity of YNVs was revealed to be resulted from activation of the BMP 2/p p38 dependent Runx2 pathway. As a result, YNVs promote longitudinal bone growth and mineral density of the tibia in the OVX induced osteoporotic mice in vivo, and these results positively correlate the significant increases in osteoblast related parameters. In addition, the orally administered YNVs were transported through the GI tract and absorbed through the small intestine. These results showed an excellent systemic biosafety determined by histological analysis and liver/kidney toxicity tests. Taken together, YNVs can serve as a safe and orally effective agent in the treatment of osteoporosis.
C1 [Hwang, Jin Hyeon; Park, Yu Seong; Dong ha Kim; Lee, Sang Hoon; Cho, Young Eun] Andong Natl Univ, Dept Food & Nutr, Andong 36729, South Korea.
   [Hwang, Jin Hyeon; Kim, Hyun Woo; Kim, Do Kyun] Jeonbuk Natl Univ, Korea Zoonosis Res Inst, Iksan 54531, South Korea.
   [Park, Yu Seong; Dong ha Kim; Lee, Chan Hyeong; Lee, Seung Hoon; Kim, Jung Eun; Baek, Moon Chang] Kyungpook Natl Univ, Sch Med, Dept Mol Med, CMRI, Daegu, South Korea.
   [Kim, Hyuk Soon] Dong A Univ, Dept Biomed Sci, Coll Nat Sci, Grad Sch, Busan 49315, South Korea.
   [Kim, Hyuk Soon] Dong A Univ, Dept Hlth Sci, Grad Sch, Busan 49315, South Korea.
   [Lee, Sangkyu; Kim, Ho Min] Inst Basic Sci IBS, Ctr Biomol & Cellular Struct, Daejeon 34126, South Korea.
   [Kim, Jihoon] Yonsei Univ, Div Biol Sci & Technol, Wonju 26493, South Korea.
   [Seo, Wonhyo] Ewha Womans Univ, Coll Pharm, Grad Sch Pharmaceut Sci, Seoul 03760, South Korea.
   [Kwon, Hyo Jung] Chungnam Natl Univ, Coll Vet Med, Dept Vet Pathol, 99 Daehak Ro, Daejeon 34134, South Korea.
   [Song, Byoung Joon] NIAAA, Sect Mol Pharmacol & Toxicol, NIH, Bethesda, MD 20892 USA.
C3 Gyeongkuk National University; Jeonbuk National University; Kyungpook
   National University (KNU); Dong A University; Dong A University;
   Institute for Basic Science   Korea (IBS); Yonsei University; Ewha
   Womans University; Chungnam National University; National Institutes of
   Health (NIH)   USA; NIH National Institute on Alcohol Abuse & Alcoholism
   (NIAAA)
RP Cho, YE (通讯作者)，Andong Natl Univ, Dept Food & Nutr, Andong 36729, South Korea.; Kim, DK (通讯作者)，Jeonbuk Natl Univ, Korea Zoonosis Res Inst, Iksan 54531, South Korea.; Baek, MC (通讯作者)，Kyungpook Natl Univ, Sch Med, Dept Mol Med, CMRI, Daegu, South Korea.
EM dkkim714@jbnu.ac.kr; mcbaek@knu.ac.kr; yecho@anu.ac.kr
RI Kim, Hyuk Soon/IQW 9348 2023; Wang, Xiaolin/ADQ 6971 2022; kim,
   david/AAA 4537 2020; Kim, Jihoon/GQP 4563 2022; Lee,
   Sangkyu/AAM 2198 2021
OI Kim, Jihoon/0000 0001 7091 8050; 
FU National Research Foundation of Korea (NRF)   Korea government (MSIT)
   [2021R1C1C1008117, 2021R1A5A2021614, 2022R1C1C1006334,
   2021R1A4A1033078]; Intramural Research Fund of National Institute of
   Alcohol Abuse and Alcoholism
FX This work was supported by National Research Foundation of Korea (NRF)
   grant funded by Korea government (MSIT) (No.2021R1C1C1008117,
   2021R1A5A2021614, 2022R1C1C1006334, 2021R1A4A1033078) . This work was
   also supported in part (via B.J.S.) by the Intramural Research Fund of
   National Institute of Alcohol Abuse and Alcoholism.
CR Alcantara EH, 2011, J NUTR BIOCHEM, V22, P1055, DOI 10.1016/j.jnutbio.2010.09.003
   Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307
   Cai Q, 2018, SCIENCE, V360, P1126, DOI 10.1126/science.aar4142
   Carbonare LD, 2010, DRUG HEALTHC PATIENT, V2, P121, DOI 10.2147/DHPS.S6285
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chen XY, 2019, MOL PHARMACEUT, V16, P2690, DOI 10.1021/acs.molpharmaceut.9b00246
   Cho YE, 2021, HEPATOLOGY, V73, P2180, DOI 10.1002/hep.30652
   Cho YE, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34309 7
   Cho YE, 2018, PHARMACOL THERAPEUT, V187, P180, DOI 10.1016/j.pharmthera.2018.03.009
   Cho YE, 2017, HEPATOL COMMUN, V1, P675, DOI 10.1002/hep4.1066
   Cho YE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172463
   Cranney A, 2005, DRUG SAFETY, V28, P721, DOI 10.2165/00002018 200528080 00006
   Datta NS, 2010, CELL SIGNAL, V22, P457, DOI 10.1016/j.cellsig.2009.10.017
   Deng ZB, 2017, MOL THER, V25, P1641, DOI 10.1016/j.ymthe.2017.01.025
   Di Gioia S, 2020, OPEN MED WARSAW, V15, P1096, DOI 10.1515/med 2020 0160
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Im EJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09387 4
   Jeyaram A, 2018, AAPS J, V20, DOI 10.1208/s12248 017 0160 y
   Jia TL, 2003, BIOCHEM PHARMACOL, V65, P709, DOI 10.1016/S0006 2952(02)01585 X
   Ju SW, 2013, MOL THER, V21, P1345, DOI 10.1038/mt.2013.64
   Kim D.Y., 2021, ANTIOXIDANTS BASEL, V10
   Kim DK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22754 4
   Kim DK, 2018, P NATL ACAD SCI USA, V115, pE10692, DOI 10.1073/pnas.1809938115
   Kwun IS, 2010, BONE, V46, P732, DOI 10.1016/j.bone.2009.11.003
   Lee JE, 2016, J PROTEOMICS, V131, P17, DOI 10.1016/j.jprot.2015.10.005
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Lee SR, 2020, J ETHNOPHARMACOL, V258, DOI 10.1016/j.jep.2020.112874
   Liu L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00228
   Martiniakova M, 2020, J PHYSIOL PHARMACOL, V71, P307, DOI 10.26402/jpp.2020.3.01
   Moon PG, 2016, ONCOTARGET, V7, P40189, DOI 10.18632/oncotarget.9561
   Moon PG, 2016, CLIN CANCER RES, V22, P1757, DOI 10.1158/1078 0432.CCR 15 0654
   Mu JY, 2014, MOL NUTR FOOD RES, V58, P1561, DOI 10.1002/mnfr.201300729
   Niu YB, 2015, MOL MED REP, V11, P4468, DOI 10.3892/mmr.2015.3249
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   PARFITT AM, 1982, METAB BONE DIS RELAT, V4, P1, DOI 10.1016/0221 8747(82)90002 9
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raimondo S, 2015, ONCOTARGET, V6, P19514, DOI 10.18632/oncotarget.4004
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   RIGGS BL, 1991, WESTERN J MED, V154, P63
   Rome S, 2019, FOOD FUNCT, V10, P529, DOI [10.1039/c8fo02295j, 10.1039/C8FO02295J]
   Ryu JK, 2017, IMMUNITY, V46, P38, DOI 10.1016/j.immuni.2016.11.007
   Sakai S, 2008, J TISSUE ENG REGEN M, V2, P164, DOI 10.1002/term.72
   Seo HJ, 2010, NUTR RES PRACT, V4, P356, DOI 10.4162/nrp.2010.4.5.356
   Seo W, 2019, J HEPATOL, V71, P1000, DOI 10.1016/j.jhep.2019.06.018
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Sykaras Nikitas, 2003, J Oral Sci, V45, P57
   TAKUWA Y, 1991, BIOCHEM BIOPH RES CO, V174, P96, DOI 10.1016/0006 291X(91)90490 X
   Wang BM, 2014, MOL THER, V22, P522, DOI 10.1038/mt.2013.190
   Wang QL, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2886
   Wu ZD, 2017, BIOMED PHARMACOTHER, V94, P1, DOI 10.1016/j.biopha.2017.07.071
   Zhang CF, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 30
   Zhang MZ, 2017, NANOMEDICINE UK, V12, P1927, DOI 10.2217/nnm 2017 0196
   Zhang MZ, 2016, MOL THER, V24, P1783, DOI 10.1038/mt.2016.159
   Zhang ZG, 2014, INT J MOL SCI, V15, P17130, DOI 10.3390/ijms150917130
   Zhuang XY, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.28713
NR 61
TC 123
Z9 131
U1 58
U2 351
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAR
PY 2023
VL 355
BP 184
EP 198
DI 10.1016/j.jconrel.2023.01.071
EA FEB 2023
PG 15
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 9C0UH
UT WOS:000935142300001
PM 36736431
DA 2025 08 17
ER

PT J
AU Zhang, ZW
   Ji, CH
   Wang, YN
   Liu, SY
   Wang, MS
   Xu, X
   Zhang, DJ
AF Zhang, Zhanwei
   Ji, Chonghao
   Wang, Ya Nan
   Liu, Shiyue
   Wang, Maoshan
   Xu, Xin
   Zhang, Dongjiao
TI Maresin1 Suppresses High Glucose Induced Ferroptosis in Osteoblasts via
   NRF2 Activation in Type 2 Diabetic Osteoporosis
SO CELLS
LA English
DT Article
DE maresin1; diabetic osteoporosis; NRF2; ferroptosis; glutathione
   peroxidase 4
ID POLYUNSATURATED FATTY ACIDS; PRO RESOLVING MEDIATORS; BONE REGENERATION;
   IRON OVERLOAD; RESOLUTION; MELLITUS; MODEL; INFLAMMATION; METABOLISM;
   MECHANISMS
AB Maresin1 (MaR1) is an endogenous pro resolving lipid mediator produced from polyunsaturated fatty acids and is believed to have antioxidant and anti inflammatory properties. The objective of this study was to estimate MaR1 ' s impact on type 2 diabetic osteoporosis (T2DOP) and its pharmacological mode of action. An in vitro high glucose model of the osteoblast cell line MC3T3 E1 was constructed and stimulated with MaR1. Type 2 diabetic rats were used to establish in vivo models of calvarial defects and were treated in situ with MaR1. The results revealed that, aside from preventing mortality and promoting the osteogenic capacity of MC3T3 E1 cells, MaR1 increased nuclear factor erythroid 2 related factor 2 (NRF2) signaling as well as the activity of glutathione peroxidase 4 (GPX4) and cystine glutamate antiporter (SLC7A11) and caused the restraint of ferroptosis under hyperglycemic stimulation. However, the therapeutic impact of MaR1 was significantly diminished due to NRF2 siRNA interference and the ferroptosis activator Erastin. Meanwhile, these results were validated through in vivo experiments. These findings imply that MaR1 activated the NRF2 pathway in vivo and in vitro to alleviate high glucose induced ferroptosis greatly. More crucially, MaR1 might effectively reduce the risk of T2DOP.
C1 [Zhang, Zhanwei; Ji, Chonghao; Wang, Ya Nan; Wang, Maoshan; Xu, Xin; Zhang, Dongjiao] Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Dept Implantol, 44 1 Wenhua Rd West, Jinan 250012, Peoples R China.
   [Zhang, Zhanwei; Ji, Chonghao; Wang, Ya Nan; Liu, Shiyue; Wang, Maoshan; Xu, Xin; Zhang, Dongjiao] Shandong Key Lab Oral Tissue Regenerat, 44 1 Wenhua Rd West, Jinan 250012, Peoples R China.
   [Zhang, Zhanwei; Ji, Chonghao; Wang, Ya Nan; Liu, Shiyue; Wang, Maoshan; Xu, Xin; Zhang, Dongjiao] Shandong Engn Lab Dent Mat & Oral Tissue Regenera, 44 1 Wenhua Rd West, Jinan 250012, Peoples R China.
   [Liu, Shiyue] Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Dept Periodontol, 44 1 Wenhua Rd West, Jinan 250012, Peoples R China.
C3 Shandong University; Shandong University
RP Xu, X; Zhang, DJ (通讯作者)，Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Dept Implantol, 44 1 Wenhua Rd West, Jinan 250012, Peoples R China.; Xu, X; Zhang, DJ (通讯作者)，Shandong Key Lab Oral Tissue Regenerat, 44 1 Wenhua Rd West, Jinan 250012, Peoples R China.; Xu, X; Zhang, DJ (通讯作者)，Shandong Engn Lab Dent Mat & Oral Tissue Regenera, 44 1 Wenhua Rd West, Jinan 250012, Peoples R China.
EM xinxu@sdu.edu.cn; djzhang1109@sdu.edu.cn
FU National Natural Science Foundation of China [82071148]; Natural Science
   Foundation of Shandong Province [ZR2021MH092]; Natural Science
   Foundation of Jiangsu Province [BK20210111]
FX This research was funded by the National Natural Science Foundation of
   China, grant no. 82071148; the Natural Science Foundation of Shandong
   Province, grant no. ZR2021MH092; and the Natural Science Foundation of
   Jiangsu Province, grant no. BK20210111. The APC was funded by the
   National Natural Science Foundation of China, grant no. 82071148.
CR Barden AE, 2016, PROSTAG LEUKOTR ESS, V107, P24, DOI 10.1016/j.plefa.2016.03.004
   Battaglia AM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9061505
   Bebber CM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22336 4
   Cao ZH, 2022, CLIN CHIM ACTA, V531, P188, DOI 10.1016/j.cca.2022.04.011
   Çolakoglu M, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12472
   Compston J, 2018, J INTERN MED, V283, P140, DOI 10.1111/joim.12725
   Cuadrado A, 2019, NAT REV DRUG DISCOV, V18, P295, DOI 10.1038/s41573 018 0008 x
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   Das UN, 2011, NUTRITION, V27, P21, DOI 10.1016/j.nut.2010.04.003
   de Oliveira PGFP, 2020, TRENDS ENDOCRIN MET, V31, P596, DOI 10.1016/j.tem.2020.05.005
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Dodson M, 2019, REDOX BIOL, V23, DOI 10.1016/j.redox.2019.101107
   Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/NCHEMBIO.2239, 10.1038/nchembio.2239]
   Ferrari SL, 2018, OSTEOPOROSIS INT, V29, P2585, DOI 10.1007/s00198 018 4650 2
   Francos Quijorna I, 2017, J NEUROSCI, V37, P11731, DOI 10.1523/JNEUROSCI.1395 17.2017
   Gan BY, 2021, J CELL BIOL, V220, DOI 10.1083/jcb.202105043
   Gao S, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.932886
   Gao YG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158182
   Gheibi S, 2017, BIOMED PHARMACOTHER, V95, P605, DOI 10.1016/j.biopha.2017.08.098
   Gomes PS, 2011, LAB ANIM UK, V45, P14, DOI 10.1258/la.2010.010085
   Hamann C, 2012, NAT REV ENDOCRINOL, V8, P297, DOI 10.1038/nrendo.2011.233
   He YF, 2013, BIOL TRACE ELEM RES, V152, P292, DOI 10.1007/s12011 013 9605 z
   Hu ZA, 2018, ACS APPL MATER INTER, V10, P2377, DOI 10.1021/acsami.7b18458
   Huang R, 2020, FASEB J, V34, P13521, DOI 10.1096/fj.202001145R
   Jang S, 2021, REDOX BIOL, V45, DOI 10.1016/j.redox.2021.102021
   Javed F, 2019, PERIODONTOL 2000, V81, P57, DOI 10.1111/prd.12283
   Jia T., 2021, OXID MED CELL LONGEV, V2021, P5552530, DOI [10.1155/2021/5552530, DOI 10.1155/2021/5552530]
   Jia TT, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109216
   Jing XZ, 2019, J CELL PHYSIOL, V234, P10123, DOI 10.1002/jcp.27678
   Kagan VE, 2017, NAT CHEM BIOL, V13, P81, DOI [10.1038/nchembio.2238, 10.1038/NCHEMBIO.2238]
   Khosla S, 2021, NAT REV ENDOCRINOL, V17, P685, DOI 10.1038/s41574 021 00555 5
   Krishnamoorthy N, 2015, J IMMUNOL, V194, P863, DOI 10.4049/jimmunol.1402534
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Levy BD, 2014, ANNU REV PHYSIOL, V76, P467, DOI 10.1146/annurev physiol 021113 170408
   Li D, 2021, LIFE SCI, V277, DOI 10.1016/j.lfs.2021.119467
   Li QF, 2020, EUR REV MED PHARMACO, V24, P7442, DOI 10.26355/eurrev_202007_21913
   Li YH, 2020, J BONE MINER METAB, V38, P607, DOI 10.1007/s00774 020 01101 5
   Lin YF, 2022, FASEB J, V36, DOI 10.1096/fj.202101610R
   Liu P, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/2634431
   Liu YP, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117459
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma HD, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9067610
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev pharmtox 011112 140320
   Mohsin S, 2019, EXPERT OPIN BIOL TH, V19, P937, DOI 10.1080/14712598.2019.1618266
   Napoli N, 2017, NAT REV ENDOCRINOL, V13, P208, DOI 10.1038/nrendo.2016.153
   Pasupuleti VR, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/8878172
   Pillai R, 2022, CANCER DISCOV, V12, P625, DOI 10.1158/2159 8290.CD 21 0922
   Qiu SJ, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.106018
   Qiu Y, 2019, DRUG DES DEV THER, V13, P739, DOI 10.2147/DDDT.S188654
   Saito M, 2010, OSTEOPOROSIS INT, V21, P195, DOI 10.1007/s00198 009 1066 z
   Saito Sasaki N, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031367
   Serhan CN, 2012, FASEB J, V26, P1755, DOI 10.1096/fj.11 201442
   Serhan CN, 2009, J EXP MED, V206, P15, DOI 10.1084/jem.20081880
   Sha WX, 2021, J DIABETES RES, V2021, DOI 10.1155/2021/9999612
   Sheu A, 2022, TRENDS ENDOCRIN MET, V33, P333, DOI 10.1016/j.tem.2022.02.006
   Shintoku R, 2017, CANCER SCI, V108, P2187, DOI 10.1111/cas.13380
   Skovso S, 2014, J DIABETES INVEST, V5, P349, DOI 10.1111/jdi.12235
   Soto G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020540
   Sparvero LJ, 2021, ANGEW CHEM INT EDIT, V60, P11784, DOI 10.1002/anie.202102001
   Stockwell BR, 2020, TRENDS CELL BIOL, V30, P478, DOI 10.1016/j.tcb.2020.02.009
   Suzuki T, 2015, FREE RADICAL BIO MED, V88, P93, DOI 10.1016/j.freeradbiomed.2015.06.006
   Tang DL, 2021, CELL RES, V31, P107, DOI 10.1038/s41422 020 00441 1
   Tang S, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/2438247
   Tao WW, 2022, ACS APPL MATER INTER, V14, P6404, DOI 10.1021/acsami.1c22861
   Tsay J, 2010, BLOOD, V116, P2582, DOI 10.1182/blood 2009 12 260083
   Tu WJ, 2019, AGING DIS, V10, P637, DOI 10.14336/AD.2018.0513
   Ulasov AV, 2022, LIFE SCI, V291, DOI 10.1016/j.lfs.2021.120111
   Vajgel A, 2014, CLIN ORAL IMPLAN RES, V25, P879, DOI 10.1111/clr.12194
   Veronese N, 2019, SEMIN ARTHRITIS RHEU, V49, P9, DOI 10.1016/j.semarthrit.2019.01.005
   Vestergaard P, 2009, CURR OPIN ENDOCRINOL, V16, P125, DOI 10.1097/MED.0b013e328325d155
   Wang CW, 2020, J DENT RES, V99, P930, DOI 10.1177/0022034520917903
   Wang XD, 2022, BIOL TRACE ELEM RES, V200, P298, DOI 10.1007/s12011 021 02627 z
   Wang YN, 2021, J DENT RES, V100, P658, DOI 10.1177/0022034520983245
   Yamagishi S, 2011, CURR DRUG TARGETS, V12, P2096, DOI 10.2174/138945011798829456
   Yang T, 2019, BRIT J ANAESTH, V122, P350, DOI 10.1016/j.bja.2018.10.062
   Yang WS, 2016, P NATL ACAD SCI USA, V113, pE4966, DOI 10.1073/pnas.1603244113
   Yang WC, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.865689
   Zhang QL, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9281481
NR 78
TC 33
Z9 46
U1 7
U2 51
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD AUG
PY 2022
VL 11
IS 16
AR 2560
DI 10.3390/cells11162560
PG 27
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 4D2PW
UT WOS:000846989200001
PM 36010637
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Bambini, F
   Santarelli, A
   Putignano, A
   Procaccini, M
   Orsini, G
   Di Iorio, D
   Memè, L
   Sartini, D
   Emanuelli, M
   Lo Muzio, L
AF Bambini, F.
   Santarelli, A.
   Putignano, A.
   Procaccini, M.
   Orsini, G.
   Di Iorio, D.
   Meme, L.
   Sartini, D.
   Emanuelli, M.
   Lo Muzio, L.
TI USE OF SUPERCHARGED COVER SCREW AS STATIC MAGNETIC FIELD GENERATOR FOR
   BONE HEALING, 2nd PART: IN VIVO ENHANCEMENT OF BONE REGENERATION
   IN RABBITS
SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
LA English
DT Article
DE static magnetic fields; MG63; osseointegration; dental implant; cover
   screw; permanent magnets; rabbit
ID PULSED ELECTROMAGNETIC FIELDS; STIMULATION; OSTEOBLASTS
AB In 1979, Pulsed electromagnetic fields (PEMFs) were approved by the Food and Drug Administration as an effective method in the treatment of non unions. As well as PEMFs, also static magnetic fields (SMFs) have been widely investigated in orthopaedic studies. Even if the exact mechanism of action is not well understood, a large number of studies showed specific effects both at cellular and tissue levels. As bone fracture healing and osseointegration share the same biological events, the application of magnetic field stimulation in order to facilitate the osseointegration process has been suggested. In this study we investigated BIC and newly formed bone volume around dental implants inserted in the tibia of New Zealand rabbits after SMF stimulation, generated by a small customized cover screw shaped neodymium iron bore magnet placed in the inner cavity of dental implants. As a result, we found that the SMF field generated around dental implants enhanced bone healing in the animal model. Our findings represent, to our knowledge, the first ready clinical technique for dental implants showing the ability of SMF to promote the osteogenesis process in vivo.
C1 [Bambini, F.; Santarelli, A.; Putignano, A.; Procaccini, M.; Orsini, G.; Meme, L.; Sartini, D.; Emanuelli, M.] Marche Polytech Univ, Dept Specialist & Stomatol Clin Sci, Ancona, Italy.
   [Di Iorio, D.] Chieti Univ, Dept Med Oral & Biotechnol Sci, Chieti, Italy.
   [Lo Muzio, L.] Foggia Univ, Dept Clin & Expt Med, Foggia, Italy.
C3 Marche Polytechnic University; G d'Annunzio University of
   Chieti Pescara; University of Foggia
RP Lo Muzio, L (通讯作者)，Clin Odontoiatr, Via Rovelli 50, I 71122 Foggia, Italy.
EM lorenzo.lomuzio@unifg.it
RI ; Muzio, Lorenzo/C 8533 2011; Meme', Lucia/HGC 8816 2022; MEME',
   LUCIA/HGC 8816 2022; Orsini, Giovanna/B 5470 2016; Lo Muzio,
   Lorenzo/C 8533 2011; Santarelli, Andrea/P 6310 2014
OI SARTINI, Davide/0000 0003 3879 8647; PUTIGNANO,
   Angelo/0000 0001 6205 2613; MEME', LUCIA/0000 0002 0441 3596; Lo Muzio,
   Lorenzo/0000 0003 4633 4893; Santarelli, Andrea/0000 0003 4218 3354
CR Aaron RK, 2004, CLIN ORTHOP RELAT R, P30, DOI 10.1097/01.blo.0000118698.46535.83
   Chiu KH, 2007, ANN BIOMED ENG, V35, P1932, DOI 10.1007/s10439 007 9370 2
   De Mattei M, 2005, BIOELECTROMAGNETICS, V26, P207, DOI 10.1002/bem.20068
   Fini M, 2006, J BONE JOINT SURG BR, V88B, P123, DOI 10.1302/0301 620X.88B1.16496
   Kotani H, 2002, J BONE MINER RES, V17, P1814, DOI 10.1359/jbmr.2002.17.10.1814
   Li JKJ, 2007, ELECTROMAGN BIOL MED, V26, P153, DOI 10.1080/15368370701572837
   MAMMI GI, 1993, CLIN ORTHOP RELAT R, P246
   Matsumoto H, 2000, CLIN ORAL IMPLAN RES, V11, P354, DOI 10.1034/j.1600 0501.2000.011004354.x
   Puricelli Edela, 2006, Head Face Med, V2, P43, DOI 10.1186/1746 160X 2 43
   SHIMIZU T, 1988, J ORTHOP RES, V6, P248, DOI 10.1002/jor.1100060212
   Singh P, 2006, INDIAN J BIOCHEM BIO, V43, P167
   SOBALLE K, 1993, ACTA ORTHOP SCAND, V64, pR1
   Zhang XJ, 2007, ELECTROMAGN BIOL MED, V26, P167, DOI 10.1080/15368370701580756
NR 13
TC 20
Z9 20
U1 0
U2 8
PU BIOLIFE SAS
PI SILVA MARINA (TE)
PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY
SN 0393 974X
EI 1724 6083
J9 J BIOL REG HOMEOS AG
JI J. Biol. Regul. Homeost. Agents
PD APR JUN
PY 2017
VL 31
IS 2
BP 481
EP 485
PG 5
WC Endocrinology & Metabolism; Immunology; Medicine, Research &
   Experimental; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Immunology; Research & Experimental
   Medicine; Physiology
GA FA7QO
UT WOS:000405642200032
PM 28685556
DA 2025 08 17
ER

PT J
AU Ma, S
   Choi, J
   Jin, X
   Kim, HY
   Yun, JH
   Lee, W
   Choi, KY
   No, KT
AF Ma, Songling
   Choi, Jiwon
   Jin, Xuemei
   Kim, Hyun Yi
   Yun, Ji Hye
   Lee, Weontae
   Choi, Kang Yell
   No, Kyoung Tai
TI Discovery of a small molecule inhibitor of Dvl CXXC5 interaction by
   computational approaches
SO JOURNAL OF COMPUTER AIDED MOLECULAR DESIGN
LA English
DT Article
DE Wnt/beta catenin signaling pathway; Dvl CXXC5 interaction;
   Pharmacophore; Virtual screening; Molecular dynamics simulation; Nuclear
   magnetic resonance
ID DISHEVELLED PDZ DOMAIN; DYNAMICS; IDENTIFICATION; PATHWAY; DISEASE;
   CXXC5
AB The Wnt/beta catenin signaling pathway plays a significant role in the control of osteoblastogenesis and bone formation. CXXC finger protein 5 (CXXC5) has been recently identified as a negative feedback regulator of osteoblast differentiation through a specific interaction with Dishevelled (Dvl) protein. It was reported that targeting the Dvl CXXC5 interaction could be a novel anabolic therapeutic target for osteoporosis. In this study, complex structure of Dvl PDZ domain and CXXC5 peptide was simulated with molecular dynamics (MD). Based on the structural analysis of binding modes of MD simulated Dvl PDZ domain with CXXC5 peptide and crystal Dvl PDZ domain with synthetic peptide ligands, we generated two different pharmacophore models and applied pharmacophore based virtual screening to discover potent inhibitors of the Dvl CXXC5 interaction for the anabolic therapy of osteoporosis. Analysis of 16 compounds selected by means of a virtual screening protocol yielded four compounds that effectively disrupted the Dvl CXXC5 interaction in the fluorescence polarization assay. Potential compounds were validated by fluorescence spectroscopy and nuclear magnetic resonance. We successfully identified a highly potent inhibitor, BMD4722, which directly binds to the Dvl PDZ domain and disrupts the Dvl CXXC5 interaction. Overall, CXXC5 Dvl PDZ domain complex based pharmacophore combined with various traditional and simple computational methods is a promising approach for the development of modulators targeting the Dvl CXXC5 interaction, and the potent inhibitor BMD4722 could serve as a starting point to discover or design more potent and specific the Dvl CXXC5 interaction disruptors.
C1 [Ma, Songling; Jin, Xuemei; No, Kyoung Tai] Yonsei Univ, Dept Biotechnol, Coll Life Sci & Biotechnol, Seoul 03722, South Korea.
   [Ma, Songling; Choi, Jiwon; No, Kyoung Tai] Yonsei Univ, Bioinformat & Mol Design Res Ctr, Seoul 03722, South Korea.
   [Kim, Hyun Yi; Choi, Kang Yell] Yonsei Univ, Translat Res Ctr Prot Funct Control, Seoul 03722, South Korea.
   [Yun, Ji Hye; Lee, Weontae] Yonsei Univ, Dept Biochem, Coll Life Sci & Biotechnol, Seoul 03722, South Korea.
C3 Yonsei University; Yonsei University; Yonsei University; Yonsei
   University
RP No, KT (通讯作者)，Yonsei Univ, Dept Biotechnol, Coll Life Sci & Biotechnol, Seoul 03722, South Korea.; No, KT (通讯作者)，Yonsei Univ, Bioinformat & Mol Design Res Ctr, Seoul 03722, South Korea.
EM ktno@bmdrc.org
RI LEE, WEON/AAQ 9088 2021; No, Kyoung/P 1644 2015; Kim,
   Jong Yeup/ISA 2120 2023
OI Lee, Weontae/0000 0003 2347 1262; Ma, Songling/0009 0001 4900 4200
FU Ministry of Knowledge Economy through Korea Research Institute of
   Chemical Technology [SI 1205, SI 1304, SI 1404]; Basic Science Research
   Program through the National Research Foundation of Korea (NRF)  
   Ministry of Education [NRF 2016R1A6A3A04010213]
FX This work was supported by the Ministry of Knowledge Economy through
   Korea Research Institute of Chemical Technology (SI 1205, SI 1304,
   SI 1404), and Basic Science Research Program through the National
   Research Foundation of Korea (NRF) funded by the Ministry of Education
   (NRF 2016R1A6A3A04010213).
CR Andersson T, 2009, J BIOL CHEM, V284, P3672, DOI 10.1074/jbc.M808119200
   Berwick DC, 2012, BIOCHEM SOC T, V40, P1123, DOI 10.1042/BST20120122
   Choi J, 2016, BIOORGAN MED CHEM, V24, P3259, DOI 10.1016/j.bmc.2016.03.026
   Dees C, 2013, EXP DERMATOL, V22, P710, DOI 10.1111/exd.12255
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fujii N, 2007, CANCER RES, V67, P573, DOI 10.1158/0008 5472.CAN 06 2726
   Grandy D, 2009, J BIOL CHEM, V284, P16256, DOI 10.1074/jbc.M109.009647
   Gregersen B.A., P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Guo ZJ, 2010, CHEM BIOL DRUG DES, V75, P348, DOI 10.1111/j.1747 0285.2010.00951.x
   HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695
   HUMPHREYS DD, 1994, J PHYS CHEM US, V98, P6885, DOI 10.1021/j100078a035
   Inestrosa NC, 2012, J NEUROIMMUNE PHARM, V7, P788, DOI 10.1007/s11481 012 9417 5
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kim HY, 2015, CELL DEATH DIFFER, V22, P912, DOI 10.1038/cdd.2014.238
   Kim HY, 2016, EMBO MOL MED, V8, P375, DOI 10.15252/emmm.201505714
   Kim MS, 2010, J BIOL CHEM, V285, P14585, DOI 10.1074/jbc.M109.094334
   Knappskog S, 2011, ANN ONCOL, V22, P2208, DOI 10.1093/annonc/mdq737
   Lee HJ, 2009, ANGEW CHEM INT EDIT, V48, P6448, DOI 10.1002/anie.200902981
   LLC S., 2010, PYMOL MOL GRAPHICS S
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Regard JB, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007997
   Schinner S, 2009, HORM METAB RES, V41, P159, DOI 10.1055/s 0028 1119408
   Shan JF, 2005, BIOCHEMISTRY US, V44, P15495, DOI 10.1021/bi0512602
   Shan JF, 2009, J COMPUT AID MOL DES, V23, P37, DOI 10.1007/s10822 008 9236 1
   Shivakumar D, 2010, J CHEM THEORY COMPUT, V6, P1509, DOI 10.1021/ct900587b
NR 28
TC 16
Z9 16
U1 1
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920 654X
EI 1573 4951
J9 J COMPUT AID MOL DES
JI J. Comput. Aided Mol. Des.
PD MAY
PY 2018
VL 32
IS 5
BP 643
EP 655
DI 10.1007/s10822 018 0118 x
PG 13
WC Biochemistry & Molecular Biology; Biophysics; Computer Science,
   Interdisciplinary Applications
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Computer Science
GA GE2IJ
UT WOS:000431038500006
PM 29627878
DA 2025 08 17
ER

PT J
AU Wang, JW
   Yeh, CB
   Chou, SJ
   Lu, KC
   Chu, TH
   Chen, WY
   Chien, JL
   Yen, MH
   Chen, TH
   Shyu, JF
AF Wang, Jin Wen
   Yeh, Chin Bin
   Chou, Shao Jiun
   Lu, Kuo Cheng
   Chu, Tzu Hui
   Chen, Wei Yu
   Chien, Jui Lin
   Yen, Mao Hsiung
   Chen, Tien Hua
   Shyu, Jia Fwu
TI YC 1 alleviates bone loss in ovariectomized rats by inhibiting bone
   resorption and inducing extrinsic apoptosis in osteoclasts
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE YC 1; Osteoclasts; Antiresorptive; Osteoporosis
ID SOLUBLE GUANYLATE CYCLASE; NITRIC OXIDE; OSTEOPOROSIS; ESTROGEN; MODEL;
   OSTEOPENIA; MOTILITY; CALPAIN; FUTURE
AB Osteoporosis is a major health problem in postmenopausal women and the elderly that leads to fractures associated with substantial morbidity and mortality. Current osteoporosis therapies have significant drawbacks, and the risk of fragility fractures has not yet been eliminated. There remains an unmet need for a broader range of therapeutics. Previous studies have shown that YC 1 has important regulatory functions in the cardiovascular and nervous systems. Many of the YC 1 effector molecules in platelets, smooth muscle cells and neurons, such as cGMP and mu calpain, also have important functions in osteoclasts. In this study, we explored the effects of YC 1 on bone remodeling and determined the potential of YC 1 as a treatment for postmenopausal osteoporosis. Micro computed tomography of lumbar vertebrae showed that YC 1 significantly improved E trabecular bone microarchitecture in ovariectomized rats compared with sham operated rats. YC 1 also significantly reversed the increases in serum bone resorption and formation in these rats, as measured by enzyme immunoassays for serum CTX 1 and P1NP, respectively. Actin ring and pit formation assays and TRAP staining analysis showed that YC 1 inhibited osteoclast activity and survival. YC 1 induced extrinsic apoptosis in osteoclasts by activating caspase 3 and caspase 8. In osteoclasts, YC 1 stimulated mu calpain activity and inhibited Src activity. Our findings provide proof of concept for YC 1 as a novel antiresorptive treatment strategy for postmenopausal osteoporosis, confirming an important role of nitric oxide/cGMP/protein kinase G signaling in bone.
C1 [Wang, Jin Wen] Chiali Hosp, Chi Mei Med Ctr, Dept Orthoped, Chiali, Taiwan.
   [Yeh, Chin Bin] Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Psychiat, Taipei, Taiwan.
   [Chou, Shao Jiun] Fu Jen Catholic Univ, Sch Med, Cardinal Tien Hosp, Dept Gen Surg, New Taipei, Taiwan.
   [Lu, Kuo Cheng] Fu Jen Catholic Univ, Sch Med, Cardinal Tien Hosp, Dept Med, New Taipei, Taiwan.
   [Chu, Tzu Hui; Chen, Wei Yu; Chien, Jui Lin; Shyu, Jia Fwu] Natl Def Med Ctr, Dept Biol & Anat, 161 Ming Chuan E,Rd Sect 6, Taipei 114, Taiwan.
   [Yen, Mao Hsiung] Natl Def Med Ctr, Dept Pharmacol, Taipei, Taiwan.
   [Chen, Tien Hua] Natl Yang Ming Univ, Sch Med, Inst Anat & Cell Biol, Taipei, Taiwan.
C3 Chi Mei Hospital; National Defense Medical University; Tri Service
   General Hospital; Fu Jen Catholic University; Fu Jen Catholic
   University; National Defense Medical University; National Defense
   Medical University; National Yang Ming Chiao Tung University
RP Shyu, JF (通讯作者)，Natl Def Med Ctr, Dept Biol & Anat, 161 Ming Chuan E,Rd Sect 6, Taipei 114, Taiwan.
EM shyujeff@ndmctsgh.edu.tw
RI chen, weiyu/M 5972 2018
FU Ministry of Science and Technology [MOST 104 2320 B 016 008]; National
   Defense Medical Center [MAB 105 059]; Tri Service General Hospital
   [TSGH C105 129]; Chi Mei Medical Center [CMNDMC10503]
FX This research was supported by research grants from the Ministry of
   Science and Technology (MOST 104 2320 B 016 008), National Defense
   Medical Center (MAB 105 059), Tri Service General Hospital
   (TSGH C105 129), and Chi Mei Medical Center (CMNDMC10503) to JF Shyu.
   The authors acknowledge the technical support provided by the Instrument
   Center of the National Defense Medical Center.
CR Balci H, 2005, MATURITAS, V50, P289, DOI 10.1016/j.maturitas.2004.07.002
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Baron R, 2012, NAT REV ENDOCRINOL, V8, P76, DOI 10.1038/nrendo.2011.207
   Black DM, 2016, NEW ENGL J MED, V374, P2096, DOI 10.1056/NEJMc1602599
   Buys E, 2014, CURR OPIN NEPHROL HY, V23, P135, DOI 10.1097/01.mnh.0000441048.91041.3a
   Chae HJ, 1997, J PHARM PHARMACOL, V49, P897, DOI 10.1111/j.2042 7158.1997.tb06132.x
   Evans DM, 1996, J BONE MINER RES, V11, P300
   Ghofrani HA, 2013, NEW ENGL J MED, V369, P330, DOI 10.1056/NEJMoa1209655
   GUY JA, 1993, CALCIFIED TISSUE INT, V53, P283, DOI 10.1007/BF01320915
   Hukkanen M, 2003, BONE, V32, P142, DOI 10.1016/S8756 3282(02)00955 9
   Joshua J, 2014, ENDOCRINOLOGY, V155, P4720, DOI 10.1210/en.2014 1343
   Kharode Yogendra P., 2008, V455, P111, DOI 10.1007/978 1 59745 104 8_8
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   KO FN, 1994, BLOOD, V84, P4226, DOI 10.1182/blood.V84.12.4226.bloodjournal84124226
   Kuo YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040272
   LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817
   Lam KK, 2013, EUR J PHARMACOL, V699, P67, DOI 10.1016/j.ejphar.2012.11.044
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Liu XM, 2009, MOL PHARMACOL, V75, P208, DOI 10.1124/mol.108.048314
   Marathe N, 2012, J BIOL CHEM, V287, P978, DOI 10.1074/jbc.M111.294959
   Marzia M, 2006, J BIOL CHEM, V281, P9745, DOI 10.1074/jbc.M513516200
   Müller R, 1998, BONE, V23, P59, DOI 10.1016/S8756 3282(98)00068 4
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reginster JY, 2014, BEST PRACT RES CL EN, V28, P809, DOI 10.1016/j.beem.2014.09.003
   Seeman E, 2015, J BONE MINER RES, V30, P753, DOI 10.1002/jbmr.2496
   Soriano R, 2014, BEST PRACT RES CL EN, V28, P885, DOI 10.1016/j.beem.2014.09.004
   Stacey E, 1998, J CLIN ENDOCR METAB, V83, P3056, DOI 10.1210/jc.83.9.3056
   Stasch JP, 2015, CURR OPIN PHARMACOL, V21, P95, DOI 10.1016/j.coph.2014.12.014
   Suzuki K, 2002, J BONE MINER RES, V17, P1486, DOI 10.1359/jbmr.2002.17.8.1486
   Tsai YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069320
   Wu CH, 2004, J PHARMACOL SCI, V94, P252, DOI 10.1254/jphs.94.252
   Yaroslavskiy BB, 2005, J CELL SCI, V118, P5479, DOI 10.1242/jcs.02655
   Yaroslavskiy BB, 2004, J CELL BIOCHEM, V91, P962, DOI 10.1002/jcb.20009
   Yaroslavskiy BB, 2007, J CELL SCI, V120, P2884, DOI 10.1242/jcs.004184
NR 36
TC 9
Z9 10
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3 8 1 NISHI KANDA, CHIYODA KU, TOKYO, 101 0065,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD SEP
PY 2018
VL 36
IS 5
BP 508
EP 518
DI 10.1007/s00774 017 0866 z
PG 11
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA GR7FV
UT WOS:000442855100002
PM 28983668
DA 2025 08 17
ER

PT J
AU Yin, YX
   Chen, ZQ
   Liu, ZJ
   Ma, QJ
   Dang, GT
AF Yin Yiao xue
   Chen Zhong qiang
   Liu Zhong jun
   Ma Qing jun
   Dang Geng ting
TI Icariine stimulates proliferation and differentiation of human
   osteoblasts by increasing production of bone morphogenetic protein 2
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE Icariine; osteoblasts; cell proliferation; cell differentiation; bone
   morphogenetic protein
ID CELLS
AB Background lcariine is a flavonoid isolated from a traditional Chinese medicine Epimedium pubescens and is the main active compound of it. Recently, Epimedium pubescens was found to have a therapeutic effect on osteoporosis. But the mechanism is unclear. The aim of the study was to research the effect of Icariine on the proliferation and differentiation of human osteoblasts.
   Methods Human osteoblasts were obtained by inducing human marrow mesenchymal stem cells (hMSCs) directionally and were cultured in the presence of various concentrations of Icariine. 3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide (MTT) test was used to observe the effect of lcariine on cell proliferation. The activity of alkaline phosphatase (ALP) and the amount of calcified nodules were assayed to observe the effect on cell differentiation. The expression of bone morphogenetic protein 2 (BMP 2) mRNA was detected by reverse transcriptase polymerase chain reaction (RT PCR).
   Results Icariine (20 mu g/ml) increased significantly the proliferation of human osteoblasts. And, Icariine (10 mu g/ml and 20 mu g/ml) increased the activity of ALP and the amount of calcified nodules of human osteoblasts significantly (P < 0.05). BMP 2 mRNA synthesis was elevated significantly in response to Icariine (20 mu g/ml).
   Conclusions Icariine has a direct stimulatory effect on the proliferation and differentiation of cultured human osteoblast cells in vitro, which may be mediated by increasing production of BMP 2 in osteoblasts.
C1 Peking Univ Third Hosp, Dept Orthopaed, Beijing 100083, Peoples R China.
C3 Peking University
RP Chen, ZQ (通讯作者)，Peking Univ Third Hosp, Dept Orthopaed, Beijing 100083, Peoples R China.
EM luckyemail2008@sina.com
CR Cai ManLing Cai ManLing, 2004, Chinese Journal of Natural Medicines, V2, P235
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   HUANG HJ, 2004, ZHEJIANG J TRAUMA SU, V9, P9
   Ikegame M, 2001, J BONE MINER RES, V16, P24, DOI 10.1359/jbmr.2001.16.1.24
   JI H, 2001, CHIN J OSTEOPOROSIS, V7, P4
   JI H, 2000, J CHINA PHARM U, V31, P222
   Lecanda F, 1997, J CELL BIOCHEM, V67, P386, DOI 10.1002/(SICI)1097 4644(19971201)67:3<386::AID JCB10>3.3.CO;2 5
   Li Jingjing, 2002, Zhonghua Kou Qiang Yi Xue Za Zhi, V37, P391
   Li Y, 2002, J CHIN PHARM U, V33, P48
   MA Z, 1999, CHIN J OBSTET GYNECO, V34, P82
   Meng FH, 2005, PHYTOMEDICINE, V12, P189, DOI 10.1016/j.phymed.2004.03.007
   SAMPATH TK, 1992, J BIOL CHEM, V267, P20352
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0
   Wang BL, 2000, CHIN J OBSTET GYNECO, V35, P724
   WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   [雪原 Xue Yuan], 2005, [中华骨科杂志, Chinese Journal of Orthopedics], V25, P119
   Yin XX, 2004, BIOCHEM BIOPH RES CO, V315, P643, DOI 10.1016/j.bbrc.2003.01.102
   YIN XX, 2005, CHIN J CLIN REHABILI, V9, P72
   YIN XX, 2004, CHIN J REPARAT RECON, V18, P98
   Yu S, 1999, Chin J Dent Res, V2, P7
NR 23
TC 54
Z9 77
U1 0
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0366 6999
EI 2542 5641
J9 CHINESE MED J PEKING
JI Chin. Med. J.
PD FEB 5
PY 2007
VL 120
IS 3
BP 204
EP 210
DI 10.1097/00029330 200702010 00006
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 136KY
UT WOS:000244222200006
PM 17355822
OA gold
DA 2025 08 17
ER

PT J
AU Campopiano, MC
   Fogli, A
   Michelucci, A
   Mazoni, L
   Longo, A
   Borsari, S
   Pardi, E
   Benelli, E
   Sardella, C
   Pierotti, L
   Dinoi, E
   Marcocci, C
   Cetani, F
AF Campopiano, Maria Cristina
   Fogli, Antonella
   Michelucci, Angela
   Mazoni, Laura
   Longo, Antonella
   Borsari, Simona
   Pardi, Elena
   Benelli, Elena
   Sardella, Chiara
   Pierotti, Laura
   Dinoi, Elisa
   Marcocci, Claudio
   Cetani, Filomena
TI Case report: Early onset osteoporosis in a patient carrying a novel
   heterozygous variant of the WNT1 gene
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE Wnt signaling; fracture; teriparatide; osteogenesis imperfecta
ID RECESSIVE OSTEOGENESIS IMPERFECTA; SKELETAL CHARACTERISTICS; CHINESE
   FAMILIES; MUTATIONS; DIAGNOSIS; CHILDREN; TERIPARATIDE; PREGNANCY;
   FORMS; ASSOCIATION
AB The WNT1 gene is crucial for bone development and homeostasis. Homozygous mutations in WNT1 cause severe bone fragility known as osteogenesis imperfecta type XV. Moreover, heterozygous WNT1 mutations have been found in adults with early onset osteoporosis. We identified a 35 year old Caucasian woman who experienced multiple vertebral fractures two months after her second pregnancy. There was no history of risk factors for secondary osteoporosis or family history of osteoporosis. Dual energy X ray absorptiometry confirmed a marked reduction of bone mineral density (BMD) at the lumbar spine (0.734 g/cm(2), Z score  2.8), femoral neck (0.48 g/cm(2), Z score  3.5), and total hip (0.589 g/cm(2), Z score  3.0). Blood tests excluded secondary causes of bone fragility. Genetic analysis revealed a heterozygous missense mutation (p.Leu370Val) in the WNT1 gene. Varsome classified it as a variant of uncertain significance. However, the fact that the Leucine residue at position 370 is highly conserved among vertebrate species and the variant has a very low allelic frequency in the general population would exclude the possibility of a polymorphism. The patient was treated for two years with teriparatide therapy associated with calcium and vitamin D supplements. During the follow up period she did not report further clinical fractures. After 24 months of teriparatide, BMD increased at lumbar spine (+14.6%), femoral neck (+8.3%) and total hip (+4.9%) compared to baseline. We confirm that the heterozygous WNT1 mutation could cause a variable bone fragility and low turnover osteoporosis. We suggest that teriparatide is one of the most appropriate available therapies for this case.
C1 [Campopiano, Maria Cristina; Mazoni, Laura; Borsari, Simona; Pardi, Elena; Benelli, Elena; Pierotti, Laura; Dinoi, Elisa; Marcocci, Claudio] Univ Pisa, Dept Clin & Expt Med, Unit Endocrinol, Pisa, Italy.
   [Fogli, Antonella; Michelucci, Angela] Univ Hosp Pisa, Lab Mol Genet, Pisa, Italy.
   [Longo, Antonella] Univ North Texas, Dept Biol Sci, Denton, TX USA.
   [Longo, Antonella] Univ North Texas, BioDiscovery Inst, Denton, TX USA.
   [Sardella, Chiara; Marcocci, Claudio; Cetani, Filomena] Univ Hosp Pisa, Unit Endocrinol, Pisa, Italy.
C3 University of Pisa; University of Pisa; Azienda Ospedaliero
   Universitaria Pisana; University of North Texas System; University of
   North Texas Denton; University of North Texas System; University of
   North Texas Denton; University of Pisa; Azienda Ospedaliero
   Universitaria Pisana
RP Cetani, F (通讯作者)，Univ Hosp Pisa, Unit Endocrinol, Pisa, Italy.
EM cetani@endoc.med.unipi.it
RI ; Pardi, Elena/GQQ 0531 2022
OI Longo, Antonella/0000 0003 3815 4374; 
CR Agostino M, 2020, BIOCHEM SOC T, V48, P1765, DOI 10.1042/BST20200243
   Aldinger KA, 2016, J MED GENET, V53, P427, DOI 10.1136/jmedgenet 2015 103476
   Alhamdi S, 2018, AM J MED GENET A, V176, P2419, DOI 10.1002/ajmg.a.40347
   Ang Kathleen, 2018, Bone Rep, V9, P154, DOI 10.1016/j.bonr.2018.09.001
   Bardai G, 2017, OSTEOPOROSIS INT, V28, P2095, DOI 10.1007/s00198 017 4031 2
   Bardai G, 2016, OSTEOPOROSIS INT, V27, P3607, DOI 10.1007/s00198 016 3709 1
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Blumsohn A, 2011, OSTEOPOROSIS INT, V22, P1935, DOI 10.1007/s00198 010 1379 y
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Butscheidt S, 2018, OSTEOPOROSIS INT, V29, P1643, DOI 10.1007/s00198 018 4499 4
   Byers PH, 2012, ANNU REV GENET, V46, P475, DOI 10.1146/annurev genet 110711 155608
   Cao YJ, 2019, ENDOCR PRACT, V25, P230, DOI 10.4158/EP 2018 0443
   Caparros Martin JA, 2017, MOL GENET GENOM MED, V5, P28, DOI 10.1002/mgg3.257
   Chen P, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1350
   Cohen A, 2013, J CLIN ENDOCR METAB, V98, P1971, DOI 10.1210/jc.2013 1172
   CUMMINGS SR, 1987, AM J EPIDEMIOL, V126, P796, DOI 10.1093/oxfordjournals.aje.a114716
   DUNNE F, 1993, CLIN ENDOCRINOL, V39, P487, DOI 10.1111/j.1365 2265.1993.tb02398.x
   Fahiminiya S, 2013, J MED GENET, V50, P345, DOI 10.1136/jmedgenet 2013 101567
   Faqeih E, 2013, J MED GENET, V50, P491, DOI 10.1136/jmedgenet 2013 101750
   Forlino A, 2016, LANCET, V387, P1657, DOI 10.1016/S0140 6736(15)00728 X
   Forlino A, 2011, NAT REV ENDOCRINOL, V7, P540, DOI 10.1038/nrendo.2011.81
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gori F, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.36
   Hadji P, 2017, OSTEOPOROSIS INT, V28, P1393, DOI 10.1007/s00198 016 3897 8
   Hirai H, 2019, NAT STRUCT MOL BIOL, V26, P372, DOI 10.1038/s41594 019 0216 z
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Kämpe AJ, 2015, HORM RES PAEDIAT, V84, P361, DOI 10.1159/000439566
   Kantaputra PN, 2019, J HUM GENET, V64, P291, DOI 10.1038/s10038 019 0565 9
   Kausar M, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929 018 0481 x
   Keupp K, 2013, AM J HUM GENET, V92, P565, DOI 10.1016/j.ajhg.2013.02.010
   Kopanos C, 2019, BIOINFORMATICS, V35, P1978, DOI 10.1093/bioinformatics/bty897
   Kovacs CS, 2015, OSTEOPOROSIS INT, V26, P2223, DOI 10.1007/s00198 015 3149 3
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Kuptanon C, 2018, BMC MED GENET, V19, DOI 10.1186/s12881 018 0639 0
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Li S, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00984
   Liu Y, 2016, CLIN CHIM ACTA, V461, P172, DOI 10.1016/j.cca.2016.07.012
   Lu YQ, 2018, BONE, V114, P144, DOI 10.1016/j.bone.2018.06.018
   Lu YQ, 2018, INTRACTABLE RARE DIS, V7, P19, DOI 10.5582/irdr.2018.01014
   Mäkitie RE, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00070
   Mäkitie RE, 2016, J BONE MINER RES, V31, P1734, DOI 10.1002/jbmr.2841
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Mrosk J, 2018, BONE, V110, P368, DOI 10.1016/j.bone.2018.02.029
   Nampoothiri S, 2019, AM J MED GENET A, V179, P908, DOI 10.1002/ajmg.a.61119
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Palomo T, 2014, BONE, V67, P63, DOI 10.1016/j.bone.2014.06.041
   Pyott SM, 2013, AM J HUM GENET, V92, P590, DOI 10.1016/j.ajhg.2013.02.009
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Stephen J, 2015, EUR J MED GENET, V58, P21, DOI 10.1016/j.ejmg.2014.10.001
   Trejo P, 2016, OSTEOPOROSIS INT, V27, P3427, DOI 10.1007/s00198 016 3723 3
   Välimäki VV, 2017, J CLIN ENDOCR METAB, V102, P535, DOI 10.1210/jc.2016 2423
   Vignali E, 2009, J CLIN ENDOCR METAB, V94, P2306, DOI 10.1210/jc.2008 2006
   Witte F, 2009, GENE EXPR PATTERNS, V9, P215, DOI 10.1016/j.gep.2008.12.009
   Won JY, 2017, EUR J MED GENET, V60, P411, DOI 10.1016/j.ejmg.2017.05.002
   Zheng HF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002745
NR 55
TC 5
Z9 5
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD AUG 8
PY 2022
VL 13
AR 918682
DI 10.3389/fendo.2022.918682
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 6P1ZD
UT WOS:000890731900001
PM 36004351
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Etschmaier, V
   Üçal, M
   Lohberger, B
   Weinberg, A
   Schäfer, U
AF Etschmaier, Vanessa
   Uecal, Muammer
   Lohberger, Birgit
   Weinberg, Annelie
   Schafer, Ute
TI Ex vivo organotypic bone slice culture reveals preferential
   chondrogenesis after sustained growth plate injury
SO CELLS & DEVELOPMENT
LA English
DT Article
DE Growth plate injury; Endochondral ossification; Organotypic culture
ID BRIDGE FORMATION
AB Postnatal bone growth primarily relies on chondrocyte proliferation and osteogenic differentiation within the growth plate (GP) via endochondral ossification. Despite its importance, the GP is vulnerable to injuries, affecting 15 30 % of bone fractures. These injuries may lead to growth discrepancies, influence bone length and shape, and negatively affecting the patient's quality of life. This study aimed to investigate the molecular and cellular physiological and pathophysiological regeneration following sustained growth plate injury (GPI) in an ex vivo rat femur organotypic culture (OTC) model. Specifically, focusing on postnatal endochondral ossification process. 300 mu m thick ex vivo bone cultures with a 2 mm long horizontal GPI was utilized. After 15 days of cultivation, gene expression analysis, histological and immunohistochemistry staining's were conducted to analyze key markers of endochondral ossification. In our OTCs we observed a significant increase in Sox9 expression due to GPI at day 15. The Ihh PTHrP feedback loop was affected, favoring chondrocyte proliferation and maturation. Ihh levels increased significantly on day 7 and day 15, while PTHrP was downregulated on day 7. GPI had no impact on osteoclast number and activity, but gene expression analysis indicated OTCs' efforts to inhibit osteoclast differentiation and activation, thereby reducing bone resorption. In conclusion, our study provides novel insights into the molecular and cellular mechanisms underlying postnatal bone growth and regeneration following growth plate injury (GPI). We demonstrate that chondrocyte proliferation and differentiation play pivotal roles in the regeneration process, with the Ihh PTHrP feedback loop modulating these processes. Importantly, our ex vivo rat femur organotypic culture model allows for the detailed investigation of these processes, providing a valuable tool for future research in the field of skeletal biology and regenerative medicine.
C1 [Etschmaier, Vanessa; Lohberger, Birgit; Weinberg, Annelie] Med Univ Graz, Dept Orthopaed & Trauma, Auenbruggerplatz 5, A 8036 Graz, Austria.
   [Uecal, Muammer; Schafer, Ute] Med Univ Graz, Dept Neurosurg, Res Unit Expt Neurotraumatol, A 8036 Graz, Austria.
   [Uecal, Muammer] BioTech Med Graz, Graz, Austria.
C3 Medical University of Graz; Medical University of Graz
RP Lohberger, B (通讯作者)，Med Univ Graz, Dept Orthopaed & Trauma, Auenbruggerplatz 5, A 8036 Graz, Austria.
EM vanessa.etschmaier@medunigraz.at; muammer.uecal@medunigraz.at;
   birgit.lohberger@medunigraz.at; anneliemartina.weinberg@medunigraz.at;
   ute.schaefer@medunigraz.at
RI Üçal, Muammer/AFS 9448 2022
OI Lohberger, Birgit/0000 0002 3156 7902
FU CAMed (COMET) [871132]; Austrian Federal Ministry of Transport,
   Innovation and Technology (BMVIT); Austrian Federal Ministry for Digital
   and Economic Affairs (BMDW); Styrian Business Promotion Agency (SFG);
   LOGOS TBI (Zukunftskollegs Project)   Austrian Science Fond (FWF)
   [ZK 17]
FX This work was supported by CAMed (COMET Project 871132) which is funded
   by the Austrian Federal Ministry of Transport, Innovation and Technology
   (BMVIT) and the Austrian Federal Ministry for Digital and Economic
   Affairs (BMDW) and the Styrian Business Promotion Agency (SFG) . Muammer
   UEral was supported by LOGOS TBI (Zukunftskollegs Project, ZK 17) funded
   by Austrian Science Fond (FWF) .
CR Baht GS, 2018, CURR OSTEOPOROS REP, V16, P138, DOI 10.1007/s11914 018 0423 2
   Blumer MJF, 2021, ANN ANAT, V235, DOI 10.1016/j.aanat.2021.151704
   Bucher CH, 2022, EXP MOL MED, V54, P1262, DOI 10.1038/s12276 022 00834 9
   Chung Rosa, 2011, Front Biosci (Schol Ed), V3, P117, DOI 10.2741/s137
   Coleman RM, 2010, BONE, V46, P1555, DOI 10.1016/j.bone.2010.02.017
   D'Angelo F, 2017, INJURY, V48, pS7, DOI 10.1016/S0020 1383(17)30650 2
   Drenkard LMM, 2017, J BIOMECH ENG T ASME, V139, DOI 10.1115/1.4036686
   Ehnert S, 2021, WORLD J STEM CELLS, V13, P1667, DOI 10.4252/wjsc.v13.i11.1667
   Erickson CB, 2017, JOVE J VIS EXP, DOI 10.3791/55571
   Etschmaier V, 2023, CELLS BASEL, V12, DOI 10.3390/cells12131687
   Haseeb A, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2019152118
   HUNZIKER EB, 1994, MICROSC RES TECHNIQ, V28, P505, DOI 10.1002/jemt.1070280606
   James CG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008693
   Kozhemyakina E, 2015, DEVELOPMENT, V142, P817, DOI 10.1242/dev.105536
   Kronenberg H M, 2001, Novartis Found Symp, V232, P144
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Loreto C, 2009, HISTOL HISTOPATHOL, V24, P293, DOI 10.14670/HH 24.293
   Macsai CE, 2011, BONE, V49, P904, DOI 10.1016/j.bone.2011.07.024
   Martin EA, 2003, BONE, V32, P261, DOI 10.1016/S8756 3282(02)00983 3
   Mizuhashi K, 2018, NATURE, V563, P254, DOI 10.1038/s41586 018 0662 5
   Musumeci G, 2014, EUR J HISTOCHEM, V58, P107, DOI 10.4081/ejh.2014.2371
   Pichler K, 2014, INT ORTHOP, V38, P881, DOI 10.1007/s00264 013 2163 3
   Pichler K, 2013, CONNECT TISSUE RES, V54, P408, DOI 10.3109/03008207.2013.828715
   Rad EB, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 18044 z
   SALTER RB, 1963, J BONE JOINT SURG AM, V45, P587, DOI 10.2106/00004623 196345030 00019
   Srinivasaiah S, 2019, TISSUE ENG PART C ME, V25, P197, DOI [10.1089/ten.tec.2018.0368, 10.1089/ten.TEC.2018.0368]
   Su YW, 2021, BONE, V145, DOI 10.1016/j.bone.2021.115874
   Tao DK, 2023, INT J ORAL SCI, V15, DOI 10.1038/s41368 023 00223 6
   Tsukasaki M, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 31592 x
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
NR 30
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2667 2901
J9 CELLS DEV
JI Cells Dev.
PD SEP
PY 2024
VL 179
AR 203927
DI 10.1016/j.cdev.2024.203927
EA AUG 2024
PG 7
WC Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Developmental Biology
GA E0W5H
UT WOS:001300296000001
PM 38740089
OA hybrid
DA 2025 08 17
ER

PT J
AU Blanch Rubió, J
   Soldevila Domenech, N
   Tio, L
   Llorente Onaindia, J
   Ciria Recasens, M
   Polino, L
   Gurt, A
   de la Torre, R
   Maldonado, R
   Monfort, J
AF Blanch Rubio, Josep
   Soldevila Domenech, Natalia
   Tio, Laura
   Llorente Onaindia, Jone
   Ciria Recasens, Manuel
   Polino, Luciano
   Gurt, Alba
   de la Torre, Rafael
   Maldonado, Rafael
   Monfort, Jordi
CA Covidmar Study Grp
TI Influence of anti osteoporosis treatments on the incidence of COVID 19
   in patients with non inflammatory rheumatic conditions
SO AGING US
LA English
DT Article
DE denosumab; zoledronate; calcium; vitamin D; anti resorptive drugs;
   COVID 19
ID IMMUNE RESPONSES; ZOLEDRONIC ACID; MORTALITY; PREGABALIN; MECHANISM;
   DISEASES; CALCIUM
AB Coronavirus disease 19 (COVID 19) is currently a global pandemic that affects patients with other pathologies. Here, we investigated the influence of treatments for osteoporosis and other non inflammatory rheumatic conditions, such as osteoarthritis and fibromyalgia, on COVID 19 incidence. To this end, we conducted a cross sectional study of 2,102 patients being treated at the Rheumatology Service of Hospital del Mar (Barcelona, Spain). In our cohort, COVID 19 cumulative incidence from March 1 to May 3, 2020 was compared to population estimates for the same city. We used Poisson regression models to determine the adjusted relative risk ratios for COVID 19 associated with different treatments and comorbidities. Denosumab, zoledronate and calcium were negatively associated with COVID 19 incidence. Some analgesics, particularly pregabalin and most of the studied antidepressants, were positively associated with COVID 19 incidence, whereas duloxetine presented a negative association. Oral bisphosphonates, vitamin D, thiazide diuretics, anti hypertensive drugs and chronic nonsteroidal anti inflammatory drugs had no effect on COVID 19 incidence in the studied population. Our results provide novel evidence to support the maintenance of the main anti osteoporosis treatments in COVID 19 patients, which may be of particular relevance to elderly patients affected by the SARS CoV 2 pandemic.
C1 [Blanch Rubio, Josep; Ciria Recasens, Manuel; Monfort, Jordi] Hosp del Mar, Rheumatol Serv, Barcelona 08003, Spain.
   [Blanch Rubio, Josep; Tio, Laura; Llorente Onaindia, Jone; Ciria Recasens, Manuel; Polino, Luciano; Maldonado, Rafael; Monfort, Jordi] IMIM Hosp del Mar, PRBB, Med Res Inst, Barcelona 08003, Spain.
   [Soldevila Domenech, Natalia; de la Torre, Rafael] IMIM Inst Hosp Mar Invest Med, PRBB, Neurosci Res Program, Integrat Pharmacol & Syst Neurosci Res Grp, Barcelona 08003, Spain.
   [Maldonado, Rafael] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Lab Neuropharmacol, PRBB, Barcelona 08003, Spain.
   [Gurt, Alba] CAP Vila Olimp, Parc Sanitari Pere Virgili, Barcelona 08003, Spain.
   [de la Torre, Rafael] Inst Salud Carlos III ISCIII, Spanish Biomed Res Ctr Physiopathol Obes & Nutr C, Madrid 28029, Spain.
   [Soldevila Domenech, Natalia; de la Torre, Rafael] Univ Pompeu Fabra, Dept Expt & Hlth Sci, PRBB, Barcelona 08003, Spain.
C3 Hospital del Mar Research Institute; Hospital del Mar; Pompeu Fabra
   University; Barcelona Biomedical Research Park; Hospital del Mar
   Research Institute; Hospital del Mar; Hospital del Mar Research
   Institute; Pompeu Fabra University; Barcelona Biomedical Research Park;
   Pompeu Fabra University; Barcelona Biomedical Research Park; Pompeu
   Fabra University; Barcelona Biomedical Research Park
RP Maldonado, R (通讯作者)，IMIM Hosp del Mar, PRBB, Med Res Inst, Barcelona 08003, Spain.; Maldonado, R (通讯作者)，Univ Pompeu Fabra, Dept Expt & Hlth Sci, Lab Neuropharmacol, PRBB, Barcelona 08003, Spain.
EM rafael.maldonado@upf.edu
RI ; Torre, Riccardo/N 9558 2014; Martin Garcia, Elena/H 5406 2013
OI Polino, Luciano/0000 0002 9586 1377; Soldevila Domenech,
   Natalia/0000 0001 6024 8508; Tio Barrera, Laura/0000 0003 1408 7381;
   Pros, Ana/0000 0003 0266 0531; Puig, Maria Victoria/0000 0002 1490 4153;
   Perez Garcia, Carolina/0000 0002 6695 6406; Ojeda Morillo, Fabiola
   Alejandra/0000 0002 6734 9288; Martin Garcia, Elena/0000 0002 4487 3028;
   Ciria Recasens, Manuel/0000 0002 4527 377X; Vilchez Oya,
   Francisco/0000 0002 0304 7993
FU Hospital del Mar; Ministerio de Ciencia, Innovacion y Universidades
   [AEI SAF2017 84060 R, DPI2016 80283 C2 2 R]; Ministerio de Sanidad,
   Servicios Sociales e Igualdad [RD16/0017/0020, PNSD 2017I068,
   PI18/00059]; Generalitat de Catalunya [2017 SGR 669, ICREA Academia
   2015, 2017 SGR 138]; DIUE AGAUR of the "Generalitat de Catalunya"
   [2019 DI 47]
FX This study was supported by Hospital del Mar. Authors funding includes
   "Ministerio de Ciencia, Innovacion y Universidades"
   (#AEI SAF2017 84060 R FEDER to R.M., #DPI2016 80283 C2 2 R), "Ministerio
   de Sanidad, Servicios Sociales e Igualdad" (#RD16/0017/0020 &
   #PNSD 2017I068 to R.M., #PI18/00059 to TCS M) and "Generalitat de
   Catalunya" (#2017 SGR 669 & #ICREA Academia 2015 to R.M., #2017 SGR 138
   to R.D.L.T.). N.S.D. is recipient of predoctoral fellowship #2019 DI 47
   from the DIUE AGAUR of the "Generalitat de Catalunya".
CR Abu rish EY, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 61006 1
   Agencia de Salut Publica de Barcelona, 2020, Pla Director Integral de Sanejament de la Ciutat de Barcelona (PDISBA)
   Amrhein V, 2019, NATURE, V567, P305, DOI 10.1038/d41586 019 00857 9
   [Anonymous], 2020, ANN RHEUM DIS, DOI DOI 10.1136/annrheumdis 2020 217877
   [Anonymous], 2020, American ACR manual on MR safety, P1
   [Anonymous], 2020, ASBMR WEBINAR PANEL
   [Anonymous], 2015, INTEGRATIVE MOL MED
   [Anonymous], XGEV DEN
   Awwad ZM, 2020, CARDIOVASC TOXICOL, V20, P301, DOI 10.1007/s12012 019 09553 6
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bergman J, 2019, OSTEOPOROSIS INT, V30, P1973, DOI 10.1007/s00198 019 05097 1
   Brufsky A, 2020, J TRANSL MED, V18, DOI 10.1186/s12967 020 02433 6
   Brunton L.L., 2018, Goodman Gilman the pharmacological basis of therapeutics, V13th
   Buschmann HH, 2007, Spain, Patent No. [EP 1 787 679 A1, 1787679]
   Cao ZH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234764
   Cappellini F, 2020, CLIN CHEM LAB MED, V58, pE171, DOI 10.1515/cclm 2020 0611
   Cheng ML, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00329
   Chiu YG, 2017, EXPERT OPIN BIOL TH, V17, P119, DOI 10.1080/14712598.2017.1263614
   Colón Emeric CS, 2010, J BONE MINER RES, V25, P91, DOI 10.1359/jbmr.090704
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   El Kurdi B, 2020, GASTROENTEROLOGY, V159, P1015, DOI 10.1053/j.gastro.2020.05.057
   Gianfrancesco M, ANN RHEUM
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586 020 2286 9
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140 6736(20)30183 5
   Johns Hopkins University, 2020, COVID 19 DASHB
   Kanis JA, 2019, CALCIFIED TISSUE INT, V104, P235, DOI 10.1007/s00223 018 00512 x
   Khan F, 2020, SYSTEMATIC REV ANAKI, DOI DOI 10.1101/2020.04.23.20076612V1?%253FCOLLECTION=1
   Lee K, 2010, BMC NEUROL, V10, DOI 10.1186/1471 2377 10 44
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Martino M, 2012, CURR NEUROPHARMACOL, V10, P97, DOI 10.2174/157015912800604542
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577 020 0331 4
   Michelena X, 2020, SEMIN ARTHRITIS RHEU, V50, P564, DOI 10.1016/j.semarthrit.2020.05.001
   Okamoto S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.475
   Ortuño MJ, 2016, NAT MED, V22, P1170, DOI 10.1038/nm.4166
   PECK WA, 1993, AM J MED, V94, P646
   Poccia F, 2006, J INFECT DIS, V193, P1244, DOI 10.1086/502975
   Santos RAS, 2018, PHYSIOL REV, V98, P505, DOI 10.1152/physrev.00023.2016
   Taylor CP, 2007, EPILEPSY RES, V73, P137, DOI 10.1016/j.eplepsyres.2006.09.008
   Vaeth M, 2016, IMMUNITY, V44, P1350, DOI 10.1016/j.immuni.2016.04.013
   Wasserstein RL, 2019, AM STAT, V73, P1, DOI 10.1080/00031305.2019.1583913
   World Health Organization. World Health Organization, 2020, 32 WHO
   Yu EW, 2020, J BONE MINER RES, V35, P1009, DOI 10.1002/jbmr.4049
   Zhang X, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104927
NR 45
TC 36
Z9 39
U1 0
U2 13
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD OCT 31
PY 2020
VL 12
IS 20
BP 19923
EP 19937
DI 10.18632/aging.104117
PG 15
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA OJ3AX
UT WOS:000583838700010
PM 33080571
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Vassiliou, V
   Andreopoulos, D
   Frangos, S
   Tselis, N
   Giannopoulou, E
   Lutz, S
AF Vassiliou, V.
   Andreopoulos, D.
   Frangos, S.
   Tselis, N.
   Giannopoulou, E.
   Lutz, S.
TI Bone Metastases: Assessment of Therapeutic Response through Radiological
   and Nuclear Medicine Imaging Modalities
SO CLINICAL ONCOLOGY
LA English
DT Article
DE Bisphosphonates; bone metastases; chemotherapy; Imaging; radiotherapy;
   therapeutic response
ID X RAY ABSORPTIOMETRY; QUALITY OF LIFE; BREAST CANCER PATIENTS; SKELETAL
   METASTASES; DISODIUM PAMIDRONATE; OSSEOUS METASTASES; PROCESSING
   TECHNIQUES; CLINICAL EVALUATION; ZOLEDRONIC ACID; TUMOR RESPONSE
AB Radiological and nuclear medicine imaging modalities used for assessing bone metastases treatment response include plain and digitalised radiography (XR), skeletal scintigraphy (SS), dual energy X ray absorptiometry (DEXA), computed tomography (CT), magnetic resonance imaging (MRI), [F 18] fluorodeoxyglucose positron emission tomography (FDG PET) and PET/CT. Here we discuss the advantages and disadvantages of these assessment modalities as evident through different clinical trials. Additionally, we present the more established response criteria of the International Union Against Cancer and the World Health Organization and compare them with newer MD Anderson criteria. Even though serial XR and SS have been used to assess the therapeutic response for decades, several months are required before changes are evident Newer techniques, such as MRI or PET, may allow an earlier evaluation of response that may be quantified through monitoring changes in signal intensity and standard uptake value, respectively. Moreover, the application of PET/CT, which can follow both morphological and metabolic changes, has yielded interesting and promising results that give a new insight into the natural history of metastatic bone disease. However, only a few studies have investigated the application of these newer techniques and further clinical trials are needed to corroborate their promising results and establish the most suitable imaging parameters and evaluation time points. Last, but not least, there is an absolute need to adopt uniform response criteria for bone metastases through an international consensus in order to better assess treatment response in terms of accuracy and objectivity. (C)2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
C1 [Vassiliou, V.; Andreopoulos, D.] Bank Cyprus Oncol Ctr, Dept Radiat Oncol, Nicosia, Cyprus.
   [Andreopoulos, D.] Bank Cyprus Oncol Ctr, Dept Radiol, Nicosia, Cyprus.
   [Frangos, S.] Bank Cyprus Oncol Ctr, Dept Nucl Med, Nicosia, Cyprus.
   [Tselis, N.] Klinikum Offenbach, Dept Radiat Oncol, Offenbach, Germany.
   [Giannopoulou, E.] Univ Patras, Sch Med, Dept Med Oncol, GR 26110 Patras, Greece.
C3 Sana Klinikum Offenbach; University of Patras
RP Vassiliou, V (通讯作者)，Bank Cyprus Oncol Ctr, Dept Radiat Oncol, Nicosia, Cyprus.
EM vvassilios@yahoo.gr
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Berruti A, 2000, ONCOL REP, V7, P777
   Body JJ, 2004, BRIT J CANCER, V90, P1133, DOI 10.1038/sj.bjc.6601663
   Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367
   BODY JJ, 1992, BONE, V13, pS57, DOI 10.1016/S8756 3282(09)80011 2
   Body JJ, 2004, PAIN, V111, P306, DOI 10.1016/j.pain.2004.07.011
   Bristow AR, 2008, BREAST, V17, P98, DOI 10.1016/j.breast.2007.07.042
   Brown AL, 1998, CLIN RADIOL, V53, P935, DOI 10.1016/S0009 9260(98)80235 3
   BROWN HK, 2001, CANC PRINCIPLES PRAC, P2713
   Brown JE, 2004, ENDOCR RELAT CANCER, V11, P207, DOI 10.1677/erc.0.0110207
   Byun WM, 2002, AM J NEURORADIOL, V23, P906
   Chavdarova L, 2006, J BUON, V11, P499
   Chow E, 2002, RADIOTHER ONCOL, V64, P275, DOI 10.1016/S0167 8140(02)00170 6
   Chow E, 2007, J CLIN ONCOL, V25, P1423, DOI 10.1200/JCO.2006.09.5281
   Çiray I, 2001, ACTA RADIOL, V42, P198, DOI 10.1080/028418501127346503
   CITRIN DL, 1981, CANCER AM CANCER SOC, V47, P680, DOI 10.1002/1097 0142(19810215)47:4<680::AID CNCR2820470410>3.0.CO;2 W
   Clamp A, 2004, LANCET ONCOL, V5, P607, DOI 10.1016/S1470 2045(04)01596 7
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Cook Gary J. R., 2000, Cancer, V88, P2927, DOI 10.1002/1097 0142(20000615)88:12+<2927::AID CNCR8>3.0.CO;2 V
   Cook GJ, 1998, J CLIN ONCOL, V16, P3375, DOI 10.1200/JCO.1998.16.10.3375
   Cook GJR, 2001, SEMIN NUCL MED, V31, P206, DOI 10.1053/snuc.2001.23527
   Dehdashti F, 1999, EUR J NUCL MED, V26, P51, DOI 10.1007/s002590050359
   Diel IJ, 2004, EUR J CANCER, V40, P1704, DOI 10.1016/j.ejca.2004.03.025
   DIET IJ, 2007, SUPPORT CARE CANCER, V15, P1243
   Du Y, 2007, J CLIN ONCOL, V25, P3440, DOI 10.1200/JCO.2007.11.2854
   Finlay OG, 2005, LANCET ONCOL, V6, P392, DOI 10.1016/S1470 2045(05)70206 0
   Fizazi K, 2009, J CLIN ONCOL, V27, P2429, DOI 10.1200/JCO.2008.18.9811
   Freedman O, 2009, CANCER METAST BIOL T, V12, P345, DOI 10.1007/978 1 4020 9819 2_17
   GALASKO CSB, 1995, CLIN ORTHOP RELAT R, P64
   GALASKO CSB, 1984, RADIONUCLIDE SCINTIG, P34
   Ghanem N, 2002, EUR J RADIOL, V43, P256, DOI 10.1016/S0720 048X(01)00477 6
   Gralow J, 2007, J PAIN SYMPTOM MANAG, V33, P462, DOI 10.1016/j.jpainsymman.2007.01.001
   GRANT VB, 2005, EJC SUPPL, pS33
   GRONEMUNZEBROCK W, 1988, RONTGENBLATTER, V41, P223
   Gwak HS, 2006, MINIM INVAS NEUROSUR, V49, P127, DOI 10.1055/s 2006 932181
   Hamaoka T, 2004, J CLIN ONCOL, V22, P2942, DOI 10.1200/jco.2004.08.181
   Hamaoka T, 2010, BRIT J CANCER, V102, P651, DOI 10.1038/sj.bjc.6605546
   HAYWARD JL, 1977, BRIT J CANCER, V35, P292, DOI 10.1038/bjc.1977.42
   HELLER M, 1988, FORTSCHR RONTG NEUEN, V149, P121
   HORTOBAGYI GN, 1984, CANCER AM CANCER SOC, V53, P577, DOI 10.1002/1097 0142(19840201)53:3<577::AID CNCR2820530335>3.0.CO;2 U
   Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038, DOI 10.1200/JCO.1998.16.6.2038
   HOSKIN PJ, 1988, CANCER SURV, V7, P69
   Huber S, 2002, ANTICANCER RES, V22, P1279
   INOKA T, 2010, SPINE, V35, P86
   JANICEK MJ, 1994, RADIOLOGY, V192, P201, DOI 10.1148/radiology.192.1.8208938
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Koswig S, 1999, STRAHLENTHER ONKOL, V175, P500, DOI 10.1007/s000660050061
   Kouloulias EV, 2003, STRAHLENTHER ONKOL, V179, P471, DOI 10.1007/s00066 003 0978 3
   Kouloulias V, 2003, INT J RADIAT ONCOL, V57, P143, DOI 10.1016/S0360 3016(03)00525 X
   Kouloulias V, 2001, PHYS MEDICA, V17, P17
   Kouloulias VE, 2002, ACTA ONCOL, V41, P169, DOI 10.1080/028418602753669553
   Krempien R, 2005, EXPERT REV ANTICANC, V5, P295, DOI 10.1586/14737140.5.2.295
   Lam MGEH, 2008, EUR J NUCL MED MOL I, V35, P756, DOI 10.1007/s00259 007 0659 z
   Lewington VJ, 2005, J NUCL MED, V46, p38S
   Lindholm P, 2009, NUCL MED COMMUN, V30, P30, DOI 10.1097/MNM.0b013e328313b7bc
   LOKICH JJ, 1978, ONCOLOGY BASEL, V35, P274, DOI 10.1159/000225304
   Lutz S, 2009, CLIN ONCOL UK, V21, P659, DOI 10.1016/j.clon.2009.07.013
   Montemurro F, 2004, ACTA RADIOL, V45, P71, DOI 10.1080/02841850410003374
   Morris MJ, 2009, J CLIN ONCOL, V27, P2436, DOI 10.1200/JCO.2008.20.4164
   Ohta M, 2001, NUCL MED COMMUN, V22, P875, DOI 10.1097/00006231 200108000 00005
   PAVLAKIS N, 2002, COCHRANE LIB
   RAFII M, 1986, SEMIN ULTRASOUND CT, V7, P371
   REINBOLD WD, 1989, SKELETAL RADIOL, V18, P517, DOI 10.1007/BF00351751
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   ROSSLEIGH MA, 1984, AUST NZ J MED, V14, P19, DOI 10.1111/j.1445 5994.1984.tb03578.x
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   Sabbatini P, 1999, J CLIN ONCOL, V17, P948, DOI 10.1200/JCO.1999.17.3.948
   Saip P, 1999, CANCER INVEST, V17, P575, DOI 10.3109/07357909909032842
   Scher HI, 2003, CANCER AM CANCER SOC, V97, P758, DOI 10.1002/cncr.11151
   Shapiro CL, 1999, CANCER INVEST, V17, P566, DOI 10.3109/07357909909032841
   Shreve PD, 1996, RADIOLOGY, V199, P751, DOI 10.1148/radiology.199.3.8638000
   Smith GL, 2001, CLIN EXP METASTAS, V18, P385
   Southard TE, 1996, IEEE T BIO MED ENG, V43, P123, DOI 10.1109/10.481981
   Stafford SE, 2002, ACAD RADIOL, V9, P913, DOI 10.1016/S1076 6332(03)80461 0
   Storto G, 2006, BONE, V39, P35, DOI 10.1016/j.bone.2005.12.004
   Sze WM, 2003, CLIN ONCOL UK, V15, P345, DOI 10.1016/S0936 6555(03)00113 4
   Tateishi U, 2008, RADIOLOGY, V247, P189, DOI 10.1148/radiol.2471070567
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Tombal B, 2005, PROSTATE, V65, P178, DOI 10.1002/pros.20280
   Vassiliou V, 2008, RADIOL MED, V113, P771, DOI 10.1007/s11547 008 0310 5
   Vassiliou V, 2010, BRIT J CANCER, V103, P925, DOI 10.1038/sj.bjc.6605825
   Vassiliou V, 2009, CLIN ONCOL UK, V21, P665, DOI 10.1016/j.clon.2009.07.011
   Vassiliou V, 2009, ANTI CANCER AGENT ME, V9, P326, DOI 10.2174/1871520610909030326
   Vassiliou V, 2007, CLIN EXP METASTAS, V24, P169, DOI 10.1007/s10585 007 9066 x
   Vassiliou V, 2007, INT J RADIAT ONCOL, V67, P264, DOI 10.1016/j.ijrobp.2006.08.022
   Vassiliou V, 2010, BREAST J, V16, P92, DOI 10.1111/j.1524 4741.2009.00867.x
   Vassiliou V, 2009, BJU INT, V104, P417, DOI 10.1111/j.1464 410X.2009.08767_3.x
   VOGEL CL, 1995, J CLIN ONCOL, V13, P1123, DOI 10.1200/JCO.1995.13.5.1123
   Wachenfeld I., 1996, Strahlentherapie und Onkologie, V172, P332
   Whitlock JPL, 2001, CLIN ONCOL UK, V13, P181, DOI 10.1007/s001740170072
   *WHO, 1979, HDB REP RES CANC TRE
   Wu HC, 2002, J CANCER RES CLIN, V128, P503, DOI 10.1007/s00432 002 0370 1
   Yahara J, 2003, BJU INT, V92, P379, DOI 10.1046/j.1464 410X.2003.04362.x
NR 94
TC 28
Z9 34
U1 0
U2 6
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0936 6555
EI 1433 2981
J9 CLIN ONCOL UK
JI Clin. Oncol.
PD NOV
PY 2011
VL 23
IS 9
BP 632
EP 645
DI 10.1016/j.clon.2011.03.010
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 840BO
UT WOS:000296413500009
PM 21530193
DA 2025 08 17
ER

PT J
AU Hamilton, SM
   Bayer, CR
   Stevens, DL
   Lieber, RL
   Bryant, AE
AF Hamilton, Stephanie M.
   Bayer, Clifford R.
   Stevens, Dennis L.
   Lieber, Richard L.
   Bryant, Amy E.
TI Muscle Injury, Vimentin Expression, and Nonsteroidal Anti inflammatory
   Drugs Predispose to Cryptic Group A Streptococcal Necrotizing Infection
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT Pacific Division Regional Meeting of the
   American Academy for the Advancement of Science
CY JUN 17 21, 2007
CL Boise, ID
SP Amer Acad Advancement Sci, Pacific Div
ID REGENERATING SKELETAL MUSCLE; FILAMENT PROTEIN NESTIN;
   TOXIC SHOCK SYNDROME; ECCENTRIC CONTRACTIONS; PRIMARY VARICELLA;
   IN VIVO; FASCIITIS; PYOGENES; BINDING; DESMIN
AB Background. Myonecrosis due to group A streptococci (GAS) often develops at sites of nonpenetrating muscle injury, and nonsteroidal anti inflammatory drugs (NSAIDs) may increase the severity of these cryptic infections. We have previously shown that GAS bind to vimentin on injured skeletal muscles in vitro. The present study investigated whether vimentin up regulation in injured muscles in vivo is associated with homing of circulating GAS to the injured site and whether NSAIDs facilitate this process.
   Methods. M type 3 GAS were delivered intravenously 48 h after eccentric contraction (EC) induced injury of murine hind limb muscles. Vimentin gene expression and homing of GAS were followed by real time reverse transcriptase polymerase chain reaction and quantitative bacteriology of muscle homogenates, respectively. In separate experiments, ketorolac tromethamine (Toradol) was given 1 h before GAS infusion.
   Results. Vimentin was up regulated similar to 8 fold 48 h after EC. Significantly more GAS were found in moderately injured muscles than in noninjured controls. NSAIDs greatly augmented the number of GAS in injured muscles.
   Conclusions. Vimentin may tether circulating GAS to injured muscle, and NSAIDs enhance this process. Strategies targeting the vimentin GAS interaction may prevent or attenuate GAS myonecrosis. Use of NSAIDs should increase suspicion of cryptic GAS infection in patients with increasing pain at sites of nonpenetrating muscle injury.
C1 [Hamilton, Stephanie M.; Bayer, Clifford R.; Stevens, Dennis L.; Bryant, Amy E.] Vet Affairs Med Ctr, Infect Dis Sect, Boise, ID 83702 USA.
   [Hamilton, Stephanie M.; Bryant, Amy E.] Univ Idaho, Moscow, ID 83843 USA.
   [Stevens, Dennis L.; Bryant, Amy E.] Univ Washington, Sch Med, Seattle, WA USA.
   [Lieber, Richard L.] Vet Affairs Med Ctr, San Diego, CA 92161 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   University of Idaho; University of Washington; University of Washington
   Seattle; US Department of Veterans Affairs; Veterans Health
   Administration (VHA)
RP Bryant, AE (通讯作者)，Vet Affairs Med Ctr, Infect Dis Sect, Bldg 45,500 W Ft St, Boise, ID 83702 USA.
EM amy.bryant@mindspring.com
OI Lieber, Richard/0000 0002 7203 4520
CR ADAMS EM, 1985, ARCH INTERN MED, V145, P1020, DOI 10.1001/archinte.145.6.1020
   Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075
   Aronoff DM, 2003, MEDICINE, V82, P225, DOI 10.1097/00005792 200307000 00001
   Barash IA, 2004, AM J PHYSIOL CELL PH, V286, pC355, DOI 10.1152/ajpcell.00211.2003
   Barnham MRD, 2002, CLIN MICROBIOL INFEC, V8, P174, DOI 10.1046/j.1469 0691.2002.00396.x
   Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407
   Bondesen BA, 2004, AM J PHYSIOL CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004
   BORNEMANN A, 1992, MUSCLE NERVE, V15, P14, DOI 10.1002/mus.880150104
   Bryant AE, 2006, J INFECT DIS, V193, P1685, DOI 10.1086/504261
   Courtney HS, 2002, ANN MED, V34, P77, DOI 10.1080/07853890252953464
   Hentzen ER, 2006, J PHYSIOL LONDON, V570, P157, DOI 10.1113/jphysiol.2005.093005
   Lamagni TL, 2008, EMERG INFECT DIS, V14, P202, DOI 10.3201/eid1402.070888
   Lesko SM, 2001, PEDIATRICS, V107, P1108, DOI 10.1542/peds.107.5.1108
   Lluís F, 2001, BLOOD, V97, P1703, DOI 10.1182/blood.V97.6.1703
   Lovering RM, 2004, AM J PHYSIOL CELL PH, V286, pC230, DOI 10.1152/ajpcell.00199.2003
   Mackey AL, 2004, J APPL PHYSIOL, V97, P197, DOI 10.1152/japplphysiol.01174.2003
   NATANSON S, 1995, J INFECT DIS, V171, P871, DOI 10.1093/infdis/171.4.871
   Nuwayhid ZB, 2007, ANN EPIDEMIOL, V17, P878, DOI 10.1016/j.annepidem.2007.05.011
   Peters D, 2003, J PHYSIOL LONDON, V553, P947, DOI 10.1113/jphysiol.2003.048462
   Schurr M, 1998, AM J SURG, V175, P213, DOI 10.1016/S0002 9610(97)00297 3
   STEVENS DL, 1995, CLIN INFECT DIS, V21, P977, DOI 10.1093/clinids/21.4.977
   STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101
   Taylor FB, 1999, CLIN INFECT DIS, V29, P167, DOI 10.1086/520147
   Tidball JG, 2005, AM J PHYSIOL REG I, V288, pR345, DOI 10.1152/ajpregu.00454.2004
   Vaittinen S, 1999, AM J PATHOL, V154, P591, DOI 10.1016/S0002 9440(10)65304 7
   Vaittinen S, 2001, J NEUROPATH EXP NEUR, V60, P588, DOI 10.1093/jnen/60.6.588
   VATER R, 1994, HISTOCHEM J, V26, P916
   Zerr DM, 1999, PEDIATRICS, V103, P783, DOI 10.1542/peds.103.4.783
NR 28
TC 36
Z9 41
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022 1899
EI 1537 6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 1
PY 2008
VL 198
IS 11
BP 1692
EP 1698
DI 10.1086/593016
PG 7
WC Immunology; Infectious Diseases; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Immunology; Infectious Diseases; Microbiology
GA 374NY
UT WOS:000261052200016
PM 18939933
OA Bronze
DA 2025 08 17
ER

PT J
AU Mercatali, L
   La Manna, F
   Miserocchi, G
   Liverani, C
   De Vita, A
   Spadazzi, C
   Bongiovanni, A
   Recine, F
   Amadori, D
   Ghetti, M
   Ibrahim, T
AF Mercatali, Laura
   La Manna, Federico
   Miserocchi, Giacomo
   Liverani, Chiara
   De Vita, Alessandro
   Spadazzi, Chiara
   Bongiovanni, Alberto
   Recine, Federica
   Amadori, Dino
   Ghetti, Martina
   Ibrahim, Toni
TI Tumor Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of
   a Breast Cancer Cell Line in a Co Culture System and the Role of EGFR
   Inhibition
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE breast cancer; co culture; osteoclasts; mesenchymal stromal cells;
   non canonical osteoclastogenesis
ID TYROSINE KINASE INHIBITOR; MESENCHYMAL STEM CELLS; PHASE II; ZD1839
   IRESSA; TREFOIL FACTOR 1; PROSTATE CANCER; ZOLEDRONIC ACID; FOLLOW UP;
   METASTASIS; GEFITINIB
AB Although bone metastases represent a major challenge in the natural history of breast cancer (BC), the complex interactions involved have hindered the development of robust in vitro models. The aim of this work is the development of a preclinical model of cancer and bone stromal cells to mimic the bone microenvironment. We studied the effects on osteoclastogenesis of BC cells and Mesenchymal stem cells (MSC) cultured alone or in combination. We also analyzed: (a) whether the blockade of the Epithelial Growth Factor Receptor (EGFR) pathway modified their influence on monocytes towards differentiation, and (b) the efficacy of bone targeted therapy on osteoclasts. We evaluated the osteoclastogenesis modulation of human peripheral blood monocytes (PBMC) indirectly induced by the conditioned medium (CM) of the human BC cell line SCP2, cultured singly or with MSC. Osteoclastogenesis was evaluated by TRAP analysis. The effect of the EGFR blockade was assessed by treating the cells with gefitinib, and analyzed with the 3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide (MTT) assay and Western Blot (WB). We observed that SCP2 co cultured with MSC increased the differentiation of PBMC. This effect was underpinned upon pre treatment of the co culture with gefitinib. Co culture of SCP2 with MSC increased the expression of both the bone related marker Receptor Activator of Nuclear Factor B (RANK) and EGFR in BC cells. These upregulations were not affected by the EGFR blockade. The effects of the CM obtained by the cells treated with gefitinib in combination with the treatment of the preosteoclasts with the bone targeted agents and everolimus enhanced the inhibition of the osteoclastogenesis. Finally, we developed a fully human co culture system of BC cells and bone progenitor cells. We observed that the interaction of MSC with cancer cells induced in the latter molecular changes and a higher power of inducing osteoclastogenesis. We found that blocking EGFR signaling could be an efficacious strategy for breaking the interactions between cancer and bone cells in order to inhibit bone metastasis.
C1 [Mercatali, Laura; La Manna, Federico; Miserocchi, Giacomo; Liverani, Chiara; De Vita, Alessandro; Spadazzi, Chiara; Bongiovanni, Alberto; Recine, Federica; Amadori, Dino; Ghetti, Martina; Ibrahim, Toni] IRCCS, Osteoncol & Rare Tumors Ctr, Ist Sci Romagnolo Studio & Cura Tumori IRST, I 47014 Meldola, Italy.
   [Ghetti, Martina] Univ Bologna, Biomed & Neuromotor Sci Dept, I 40123 Bologna, Italy.
C3 IRCCS Meldola (IRST); University of Bologna
RP Mercatali, L (通讯作者)，IRCCS, Osteoncol & Rare Tumors Ctr, Ist Sci Romagnolo Studio & Cura Tumori IRST, I 47014 Meldola, Italy.
EM laura.mercatali@irst.emr.it; federico.lamanna@lumc.nl;
   giacomo.miserocchi@irst.emr.it; chiara.liverani@irst.emr.it;
   alessandro.devita@irst.emr.it; chiara.spadazzi@irst.emr.it;
   alberto.bongiovanni@irst.emr.it; federica.recine@irst.emr.it;
   editing@irst.emr.it; martina.ghetti@irst.emr.it;
   toni.ibrahim@irst.emr.it
RI Spadazzi, Chiara/AAB 5917 2021; Miserocchi, Giacomo/AAA 7159 2021;
   Liverani, Chiara/K 3913 2016; Ghetti, Martina/AAC 4173 2022; Mercatali,
   Laura/J 9154 2016; Bongiovanni, Alberto/J 9802 2018; Ibrahim,
   Toni/IQR 9219 2023; De Vita, Alessandro/K 1534 2016
OI Spadazzi, Chiara/0000 0001 6710 5980; Liverani,
   Chiara/0000 0002 4279 1926; Ghetti, Martina/0000 0002 8156 3694; La
   Manna, Federico/0000 0003 3644 8395; Bongiovanni,
   Alberto/0000 0002 3845 4687; De Vita, Alessandro/0000 0002 1677 5797
CR Albain K, 2002, BREAST CANCER RES TR, V76, pS33
   [Anonymous], 2016, Clinical Practice Guidelines in Oncology
   Anthony BA, 2014, TRENDS IMMUNOL, V35, P32, DOI 10.1016/j.it.2013.10.002
   Awolaran O, 2016, BREAST, V30, P156, DOI 10.1016/j.breast.2016.09.017
   Barcellos de Souza P, 2013, BBA REV CANCER, V1836, P321, DOI 10.1016/j.bbcan.2013.10.004
   Baselga J, 2005, J CLIN ONCOL, V23, P5323, DOI 10.1200/JCO.2005.08.326
   Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653
   Blake ML, 2014, CLIN EXP METASTAS, V31, P233, DOI 10.1007/s10585 013 9624 3
   Borghese C, 2013, J CELL BIOCHEM, V114, P1135, DOI 10.1002/jcb.24456
   Bougen NM, 2013, CANCER LETT, V332, P19, DOI 10.1016/j.canlet.2012.12.012
   Chaturvedi P, 2013, J CLIN INVEST, V123, P189, DOI 10.1172/JCI64993
   Ciardiello F, 2001, CLIN CANCER RES, V7, P1459
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Coleman RE, 2011, BONE, V49, P71, DOI 10.1016/j.bone.2011.02.003
   Conti A, 2014, CLIN EXP METASTAS, V31, P15, DOI 10.1007/s10585 013 9605 6
   Foley John, 2010, Semin Cell Dev Biol, V21, P951, DOI 10.1016/j.semcdb.2010.08.009
   Gnant M, 2013, JNCI J NATL CANCER I, V105, P654, DOI 10.1093/jnci/djt026
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Ibrahim T, 2013, ONCOL LETT, V6, P306, DOI 10.3892/ol.2013.1372
   Ibrahim T, 2011, CLIN BREAST CANCER, V11, P369, DOI 10.1016/j.clbc.2011.05.001
   Ibrahim T, 2010, CANCER AM CANCER SOC, V116, P1406, DOI 10.1002/cncr.24896
   Joensuu G, 2012, ACTA ONCOL, V51, P130, DOI 10.3109/0284186X.2011.617387
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Kawaida R, 2003, J EXP MED, V197, P1029, DOI 10.1084/jem.20021321
   Liverani C, 2014, BONE, V66, P214, DOI 10.1016/j.bone.2014.06.017
   LoRusso PM, 2003, SEMIN ONCOL, V30, P21, DOI 10.1053/sonc.2003.50029
   Lu X, 2010, BRIT J CANCER, V102, P457, DOI 10.1038/sj.bjc.6605490
   Lu X, 2009, GENE DEV, V23, P1882, DOI 10.1101/gad.1824809
   Markicevic M, 2014, INT J MED SCI, V11, P663, DOI 10.7150/ijms.8194
   Mercatali L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111827
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320
   Moasser MM, 2001, CANCER RES, V61, P7184
   Normanno N, 2006, J CELL PHYSIOL, V207, P420, DOI 10.1002/jcp.20588
   Normanno N, 2006, ENDOCR RELAT CANCER, V13, P3, DOI 10.1677/erc.1.01185
   Normanno N, 2005, ENDOCR RELAT CANCER, V12, P471, DOI 10.1677/erc.1.00956
   Osborne CK, 2011, CLIN CANCER RES, V17, P1147, DOI 10.1158/1078 0432.CCR 10 1869
   Phinney DG, 2013, CYTOTHERAPY, V15, P140, DOI 10.1016/j.jcyt.2012.11.005
   Plotkin LI, 2015, CURR OSTEOPOROS REP, V13, P67, DOI 10.1007/s11914 015 0255 2
   Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100
   Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002
   Santini D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019234
   Smid M, 2006, J CLIN ONCOL, V24, P2261, DOI 10.1200/JCO.2005.03.8802
   Somlo G, 2012, BREAST CANCER RES TR, V131, P899, DOI 10.1007/s10549 011 1850 2
   Stickeler E, 2014, BREAST CARE, V9, P161, DOI 10.1159/000365129
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   von Minckwitz G, 2005, BREAST CANCER RES TR, V89, P165, DOI 10.1007/s10549 004 1720 2
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Zampa G, 2008, LUNG CANCER, V60, P452, DOI 10.1016/j.lungcan.2007.11.002
   Zukawa M, 2008, ASIAN SPINE J, V2, P109, DOI 10.4184/asj.2008.2.2.109
NR 50
TC 24
Z9 24
U1 0
U2 11
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2017
VL 18
IS 8
AR 1655
DI 10.3390/ijms18081655
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FF4HB
UT WOS:000408897400056
PM 28758931
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Sanfilippo, KM
   Keller, J
   Gage, BF
   Luo, SH
   Wang, TF
   Moskowitz, G
   Gumbel, J
   Blue, B
   O'Brian, K
   Carson, KR
AF Sanfilippo, Kristen Marie
   Keller, Jesse
   Gage, Brian F.
   Luo, Suhong
   Wang, Tzu Fei
   Moskowitz, Gerald
   Gumbel, Jason
   Blue, Brandon
   O'Brian, Katiuscia
   Carson, Kenneth R.
TI Statins Are Associated With Reduced Mortality in Multiple Myeloma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID COA REDUCTASE INHIBITOR; ZOLEDRONIC ACID; DRUG RESISTANCE; BONE DISEASE;
   SURVIVAL; GERANYLGERANYLATION; CELLS; BISPHOSPHONATES; SIMVASTATIN;
   APOPTOSIS
AB Purpose
   The 3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors (statins) have activity in one of the pathways influenced by nitrogen containing bisphosphonates, which are associated with improved survival in multiple myeloma (MM). To understand the benefit of statins in MM, we evaluated the association between statin use and mortality in a large cohort of patients with MM.
   Patients and Methods
   From the Veterans Administration Central Cancer Registry, we identified patients diagnosed with MMbetween 1999 and 2013. We defined statin use as the presence of any prescription for a statin within 3 months before or any time after MM diagnosis. Cox proportional hazards regression assessed the association of statin use with mortality, while controlling for known MM prognostic factors.
   Results
   We identified a cohort of 4,957 patients, of whom 2,294 received statin therapy. Statin use was associated with a 21% decrease in all cause mortality (adjusted hazard ratio, 0.79; 95% CI, 0.73 to 0.86; P,. 001) as well as a 24% decrease in MM specific mortality (adjusted hazard ratio, 0.76; 95% CI, 0.67 to 0.86; P,.001). This association remained significant across all sensitivity analyses. In addition to reductions in mortality, statin use was associated with a 31% decreased risk of developing a skeletal related event.
   Conclusion
   In this cohort study of US veterans with MM, statin therapy was associated with a reduced risk of both all cause and MM specific mortality. Our findings suggest a potential role for statin therapy in patients with MM. The putative benefit of statin therapy in MM should be corroborated in prospective studies. (C) 2016 by American Society of Clinical Oncology
C1 [Sanfilippo, Kristen Marie; Luo, Suhong; Gumbel, Jason; Carson, Kenneth R.] St Louis Vet Hlth Adm Med Ctr, St Louis, MO USA.
   [Sanfilippo, Kristen Marie; Keller, Jesse; Gage, Brian F.; Moskowitz, Gerald; O'Brian, Katiuscia; Carson, Kenneth R.] Washington Univ, Sch Med, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.
   [Blue, Brandon] St Louis Univ, St Louis, MO 63103 USA.
   [Wang, Tzu Fei] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Washington University (WUSTL); Saint Louis University; University System
   of Ohio; Ohio State University; James Cancer Hospital & Solove Research
   Institute
RP Sanfilippo, KM (通讯作者)，Washington Univ, Sch Med, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.
EM ksanfilippo@wustl.edu
RI ; Sanfilippo, Kristen/X 8251 2019; Wang, Tzu Fei/F 2519 2016
OI Gumbel, Jason/0000 0002 2302 3657; Gage, Brian/0000 0002 4727 8742
FU National Institutes of Health, National Heart, Lung, and Blood Institute
   [5K12HL087107, U54 HL112303]; Barnes Jewish Foundation; American Cancer
   Society Institutional Research [58 010 52]
FX Supported by National Institutes of Health, National Heart, Lung, and
   Blood Institute Grants No. 5K12HL087107 and U54 HL112303; the Barnes
   Jewish Foundation; and the American Cancer Society Institutional
   Research Grant No. 58 010 52.
CR ANDERSON JR, 1983, J CLIN ONCOL, V1, P710, DOI 10.1200/JCO.1983.1.11.710
   Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786
   Berenson JR, 2002, J CLIN ONCOL, V20, P3719, DOI 10.1200/JCO.2002.06.037
   Chubak J, 2013, JNCI J NATL CANCER I, V105, P1456, DOI 10.1093/jnci/djt211
   Dai Y, 2007, BLOOD, V109, P4415, DOI 10.1182/blood 2006 09 047076
   Giobbie Hurder A, 2013, J CLIN ONCOL, V31, P2963, DOI 10.1200/JCO.2013.49.5283
   Guenther A, 2010, INT J CANCER, V126, P239, DOI 10.1002/ijc.24758
   Hamadani M, 2008, BIOL BLOOD MARROW TR, V14, P351, DOI 10.1016/j.bbmt.2007.12.489
   Hus M, 2011, ANN HEMATOL, V90, P1161, DOI 10.1007/s00277 011 1276 2
   Jánosi J, 2004, ANTICANCER RES, V24, P1817
   KORT WJ, 1989, CLIN EXP METASTAS, V7, P517, DOI 10.1007/BF01753812
   Krupski TL, 2007, J UROLOGY, V178, P1423, DOI 10.1016/j.juro.2007.05.135
   Kutner JS, 2015, JAMA INTERN MED, V175, P691, DOI 10.1001/jamainternmed.2015.0289
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003 4819 150 9 200905050 00006
   MANTEL N, 1974, J AM STAT ASSOC, V69, P81, DOI 10.2307/2285503
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Otsuki T, 2004, ONCOL REP, V11, P1053
   Park HJ, 2002, CIRC RES, V91, P143, DOI 10.1161/01.RES.0000028149.15986.4C
   PRENTICE RL, 1978, BIOMETRICS, V34, P541, DOI 10.2307/2530374
   ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1085, DOI 10.1016/0895 4356(93)90106 B
   ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895 4356(93)90103 8
   ROTHMAN KJ, 1981, AM J EPIDEMIOL, V114, P253, DOI 10.1093/oxfordjournals.aje.a113189
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   Sanfilippo KM, 2015, LEUKEMIA LYMPHOMA, V56, P615, DOI 10.3109/10428194.2014.924117
   Savas LS, 2009, MED CARE, V47, P125, DOI 10.1097/MLR.0b013e3181809125
   Schmidmaier R, 2004, BLOOD, V104, P1825, DOI 10.1182/blood 2003 12 4218
   Schmidmaier R, 2007, EUR J HAEMATOL, V79, P240, DOI 10.1111/j.1600 0609.2007.00902.x
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Sohn Min Woong, 2006, Popul Health Metr, V4, P2, DOI 10.1186/1478 7954 4 2
   Stancu C, 2001, J CELL MOL MED, V5, P378, DOI 10.1111/j.1582 4934.2001.tb00172.x
   Terpos E, 2013, J CLIN ONCOL, V31, P2347, DOI 10.1200/JCO.2012.47.7901
   van de Donk NWCJ, 2003, BLOOD, V102, P3354, DOI 10.1182/blood 2003 03 0970
   Velde NV, 2011, PROSTATE CANCER P D, V14, P79, DOI 10.1038/pcan.2010.49
   WHO Collaborating Centre for Drug Statistics Methodology (WHOCC), DDD DEF GEN CONS
   Wong BM, 2001, J LEUKOCYTE BIOL, V69, P959
NR 37
TC 71
Z9 79
U1 0
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732 183X
EI 1527 7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD NOV 20
PY 2016
VL 34
IS 33
BP 4008
EP U115
DI 10.1200/JCO.2016.68.3482
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA ED5XU
UT WOS:000388927700010
PM 27646948
OA Green Published
DA 2025 08 17
ER

PT J
AU Virk, MS
   Alaee, F
   Petrigliano, FA
   Sugiyama, O
   Chatziioannou, AF
   Stout, D
   Dougall, WC
   Lieberman, JR
AF Virk, Mandeep S.
   Alaee, Farhang
   Petrigliano, Frank A.
   Sugiyama, Osamu
   Chatziioannou, Arion F.
   Stout, David
   Dougall, William C.
   Lieberman, Jay R.
TI Combined inhibition of the BMP pathway and the RANK RANKL axis in a
   mixed lytic/blastic prostate cancer lesion
SO BONE
LA English
DT Article
DE Prostate cancer; Bone metastasis; RANK Fc; Bone morphogenetic proteins;
   Intratibial injection model of bone metastasis; Mixed
   osteolytic/osteoblastic skeletal lesion
ID BONE MORPHOGENETIC PROTEIN 7; KAPPA B LIGAND; METASTATIC PROSTATE;
   RECEPTOR ACTIVATOR; OSTEOCLAST DIFFERENTIATION; OSTEOLYTIC LESIONS;
   TUMOR BURDEN; MODEL; EXPRESSION; CELLS
AB The purpose of this study was to investigate the influence of combined inhibition of receptor activator of nuclear factor kappa B ligand (RANKL) and bone morphogenetic protein (BMP) activity in a mixed lytic/blastic prostate cancer lesion in bone. Human prostate cancer cells (C4 2b) were injected into immunocompromised mice using an intratibial injection model to create mixed lytic/blastic lesions. RANK Fc, a recombinant RANKL antagonist, was injected subcutaneously three times a week (10 mg/kg) to inhibit RANKL and subsequent formation, function and survival of osteoclasts. Inhibition of BMP activity was achieved by transducing prostate cancer cells ex vivo with a retroviral vector expressing noggin (retronoggin; RN). There were three treatment groups (RANK Fc treatment, RN treatment and combined RN and RANK Fc treatment) and two control groups (untreated control and empty vector control for the RN treatment group). The progression of bone lesion and tumor growth was evaluated using plain radiographs, hindlimb tumor size, F 18 Fluorodeoxyglucose and F 18 fluoride micro PET CT, histology and histomorphometry. Treatment with RANK Fc alone inhibited osteolysis and transformed a mixed lytic/blastic lesion into an osteoblastic phenotype. Treatment with RN alone inhibited the osteoblastic component in a mixed lytic/blastic lesion and resulted in formation of smaller osteolytic bone lesion with smaller soft tissue size. The animals treated with both RN and RANK Fc demonstrated delayed development of bone lesions, inhibition of osteolysis, small soft tissue tumors and preservation of bone architecture with less tumor induced new bone formation. This study suggests that combined inhibition of the RANKL and the BMP pathway may be an effective biologic therapy to inhibit the progression of established mixed lytic/blastic prostate cancer lesions in bone. Published by Elsevier Inc.
C1 [Virk, Mandeep S.; Alaee, Farhang; Sugiyama, Osamu; Lieberman, Jay R.] Univ Connecticut, Ctr Hlth, New England Musculoskeletal Inst, Dept Orthopaed Surg, Farmington, CT 06030 USA.
   [Petrigliano, Frank A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthopaed Surg, Ctr Hlth Sci 76 134, Los Angeles, CA 90095 USA.
   [Chatziioannou, Arion F.; Stout, David] Univ Calif Los Angeles, Crump Inst Mol Imaging, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
   [Dougall, William C.] Dept Hematol & Oncol Res, Seattle, WA 98119 USA.
C3 University of Connecticut; University of California System; University
   of California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles
RP Lieberman, JR (通讯作者)，Univ Connecticut, Ctr Hlth, New England Musculoskeletal Inst, Dept Orthopaed Surg, 263 Farmington Ave, Farmington, CT 06030 USA.
EM jlieberman@uchc.edu
RI ; Virk, Mandeep/AAW 9319 2020
OI Dougall, William/0000 0001 9487 251X; Virk, Mandeep/0000 0001 6294 2771
FU National Institute of Health [RO1 CA103039]
FX This work was supported by a research grant from the National Institute
   of Health (RO1 CA103039 to JRL). RANK Fc was generously provided by
   Amgen Inc.
CR [Anonymous], J NUCL MED
   Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658
   Berger F, 2002, EUR J NUCL MED MOL I, V29, P1225, DOI 10.1007/s00259 002 0850 1
   Bobinac D, 2005, CROAT MED J, V46, P389
   Body JJ, 2010, J BONE MINER RES, V25, P440, DOI 10.1359/jbmr.090810
   Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679
   Canon J, 2010, BONE, V46, P1613, DOI 10.1016/j.bone.2010.03.001
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chirgwin J. M., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P308
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008 5472.CAN 05 1891
   Dougall WC, 2006, CANCER METAST REV, V25, P541, DOI 10.1007/s10555 006 9021 3
   Eaton CL, 2003, CANCER TREAT REV, V29, P189, DOI 10.1016/S0305 7372(03)00071 9
   Feeley BT, 2006, J BONE MINER RES, V21, P1571, DOI 10.1359/JBMR.060706
   Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015
   Feeley BT, 2005, J BONE MINER RES, V20, P2189, DOI 10.1359/JBMR.050802
   Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245
   Guise TA, 2003, CANCER AM CANCER SOC, V97, P779, DOI 10.1002/cncr.11129
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   HARRIS SE, 1994, PROSTATE, V24, P204, DOI 10.1002/pros.2990240406
   Hatoum HT, 2008, CANCER, V113, P1438, DOI 10.1002/cncr.23775
   HAWKINS RA, 1992, J NUCL MED, V33, P633
   Higano CS, 2004, UROL CLIN N AM, V31, P331, DOI 10.1016/j.ucl.2004.01.001
   Hofbauer LC, 2001, CANCER AM CANCER SOC, V92, P460, DOI 10.1002/1097 0142(20010801)92:3<460::AID CNCR1344>3.0.CO;2 D
   Holland PM, 2010, CANCER BIOL THER, V9, P539, DOI 10.4161/cbt.9.7.11266
   Ide H, 1997, CANCER RES, V57, P5022
   Ignatoski KMW, 2008, PROSTATE, V68, P820, DOI 10.1002/pros.20744
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Keller ET, 2002, DRUG TODAY, V38, P91, DOI 10.1358/dot.2002.38.2.820105
   Kitazawa S, 2002, J PATHOL, V198, P228, DOI 10.1002/path.1199
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee Y, 2003, J ORTHOP RES, V21, P62, DOI 10.1016/S0736 0266(02)00095 5
   Lee YP, 2002, CANCER RES, V62, P5564
   Li XL, 2006, ANN NY ACAD SCI, V1068, P26, DOI 10.1196/annals.1346.006
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Loberg RD, 2005, J CELL BIOCHEM, V96, P439, DOI 10.1002/jcb.20522
   Masuda H, 2003, PROSTATE, V54, P268, DOI 10.1002/pros.10193
   Michigami T, 2001, CANCER RES, V61, P1637
   Miller RE, 2008, MOL CANCER THER, V7, P2160, DOI 10.1158/1535 7163.MCT 08 0046
   Morrissey C, 2010, NEOPLASIA, V12, P192, DOI 10.1593/neo.91836
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Peng HR, 2001, MOL THER, V4, P95, DOI 10.1006/mthe.2001.0423
   Roodman GD, 2008, CANCER TREAT REV, V34, P92, DOI 10.1016/j.ctrv.2007.09.002
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen V, 2006, ANN NY ACAD SCI, V1068, P19, DOI 10.1196/annals.1346.005
   Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140
   Saad F, 2006, EUR UROL, V49, P429, DOI 10.1016/j.eururo.2005.12.045
   Saad Fred, 2005, Clin Prostate Cancer, V4, P31, DOI 10.3816/CGC.2005.n.009
   Schwaninger R, 2007, AM J PATHOL, V170, P160, DOI 10.2353/ajpath.2007.051276
   Thalmann GN, 2000, PROSTATE, V44, P91
   Vessella RL, 2006, CLIN CANCER RES, V12, p6285S, DOI 10.1158/1078 0432.CCR 06 0813
   Virk MS, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2169
   Virk MS, 2009, BONE, V44, P160, DOI 10.1016/j.bone.2008.09.009
   Whang PG, 2005, J ORTHOP RES, V23, P1475, DOI 10.1016/j.orthres.2005.05.004
   Yang SX, 2005, CANCER RES, V65, P5769, DOI 10.1158/0008 5472.CAN 05 0289
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Ye L, 2007, HISTOL HISTOPATHOL, V22, P1129, DOI 10.14670/HH 22.1129
   Ye L, 2009, J UROLOGY, V181, P2749, DOI 10.1016/j.juro.2009.01.098
   Zhang J, 2003, CANCER RES, V63, P7883
NR 60
TC 15
Z9 16
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR 1
PY 2011
VL 48
IS 3
BP 578
EP 587
DI 10.1016/j.bone.2010.11.003
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 740EG
UT WOS:000288773800020
PM 21073986
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wu, Q
   Lai, XL
   Zhu, ZY
   Hong, ZY
   Dong, X
   Wang, TY
   Wang, HY
   Lou, ZY
   Lin, QS
   Guo, ZY
   Chai, YF
AF Wu, Qiong
   Lai, Xueli
   Zhu, Zhenyu
   Hong, Zhanying
   Dong, Xin
   Wang, Tieyun
   Wang, Haiyan
   Lou, Ziyang
   Lin, Qishan
   Guo, Zhiyong
   Chai, Yifeng
TI Evidence for Chronic Kidney Disease Mineral and Bone Disorder Associated
   With Metabolic Pathway Changes
SO MEDICINE
LA English
DT Article
ID MECHANISM; PLASMA; SYSTEM; CELLS
AB Abnormalities in the levels of calcium, phosphorus, and parathyroid hormone (PTH) in serum are typical for patients with chronic kidney disease (CKD). They are used routinely to predict the onset of CKD mineral and bone disorder (MBD). However, CKD MBD associated with metabolic pathway imbalance is not well understood.The objective of the study was to identify endogenous metabolic signatures in patients with intact PTH using mass spectrometry based metabolomics. This study was a cross sectional study. Ultra performance liquid chromatography Quadrupole Time of Flight/mass spectrometry based metabolic profiling was employed to analyze serum samples from 19 disease controls (DCs) (intact parathyroid hormone [iPTH] 150 300pg/mL) and 19 secondary hyperparathyroidism (SHPT) patients (iPTH >300pg/mL) (the training data set) to identify metabolic biomarkers for CKD MBD. Then, another set of samples including 19 DCs (iPTH 150 300pg/mL) and 19 SHPT patients (iPTH >300pg/mL) (the test data set) were used to validate the potential biomarkers identified.Metabolic profiling analyses revealed different patterns of endogenous metabolites between the SHPT and the DC groups. A total of 32 unique metabolites were identified and 30 metabolites were elevated in the iPTH compared with control serum pools. Cytidine and l phenylalanine were downregulated in the SHPT patients. The metabolic signatures identified were assessed respectively by an internal 10 fold cross validation with an accuracy of 91.4% and an external validation with an accuracy of 71.1%, a sensitivity of 73.7%, and a specificity of 68.4%.Mass spectrometry based metabolomic analyses for SHPT patients promises immense potential for early diagnosis and therapy monitoring. Our results indicated that the onset of CKD MBD is associated with pathway changes of protein synthesis and metabolism, amino acid metabolism, energy metabolism, and steroid hormone metabolism, with obvious promise for better understanding the pathogenesis of this disease. Several metabolic biomarkers were identified, which warrant further development.
C1 [Wu, Qiong; Lai, Xueli; Zhu, Zhenyu; Hong, Zhanying; Dong, Xin; Wang, Tieyun; Wang, Haiyan; Lou, Ziyang; Guo, Zhiyong; Chai, Yifeng] Second Mil Med Univ, Sch Pharm, Dept Nephrol, Changhai Hosp, Shanghai 200433, Peoples R China.
   [Lin, Qishan] SUNY Albany, Ctr Funct Genom, Prote Mass Spectrometry Facil, Rensselaer, NY USA.
C3 Naval Medical University; State University of New York (SUNY) System;
   University at Albany, SUNY
RP Chai, YF (通讯作者)，Second Mil Med Univ, Dept Pharm, 325 Guohe Rd, Shanghai 200433, Peoples R China.
EM chguozhiyong@126.com; yfchai1234@163.com
RI Hong, Zhanying/AAQ 6770 2021; Liang, Yang/JFK 8602 2023
FU National Natural Science Foundation of China [81273472]; Science and
   Technology Commission of Shanghai, China [12401900802]; China
   Postdoctoral Science Foundation [2014M562591]; Scientific Program from
   Changhai Hospital [CH125520301]
FX Portions of this research were supported by the National Natural Science
   Foundation of China (no. 81273472), the Science and Technology
   Commission of Shanghai, China (no. 12401900802), China Postdoctoral
   Science Foundation Grant (2014M562591), and the Scientific Program from
   Changhai Hospital (CH125520301).
CR Arlt W, 2011, J CLIN ENDOCR METAB, V96, P3775, DOI 10.1210/jc.2011 1565
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Berndt TJ, 1999, J LAB CLIN MED, V134, P616, DOI 10.1016/S0022 2143(99)90102 6
   Bliziotes M., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P291
   Cherney DZI, 2007, AM J PHYSIOL RENAL, V293, pF1539, DOI 10.1152/ajprenal.00351.2007
   Hossein nezhad A, 2011, J BONE MINER METAB, V29, P186, DOI 10.1007/s00774 010 0205 0
   Huang DX, 2013, J PHARMACEUT BIOMED, V76, P200, DOI 10.1016/j.jpba.2012.12.022
   Ivorra C, 2012, J TRANSL MED, V10, DOI 10.1186/1479 5876 10 142
   Jin H, 2014, J PROTEOME RES, V13, P4091, DOI 10.1021/pr500483z
   Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05
   Lee HJ, 2007, BIOCHEM J, V404, P141, DOI 10.1042/BJ20061826
   Levin A, 2007, KIDNEY INT, V71, P31, DOI 10.1038/sj.ki.5002009
   Liang QL, 2012, J TRANSL MED, V10, DOI 10.1186/1479 5876 10 26
   Mathew S, 2014, J TRANSL MED, V12, DOI 10.1186/1479 5876 12 161
   Nagai J, 1997, AM J PHYSIOL RENAL, V273, pF674, DOI 10.1152/ajprenal.1997.273.5.F674
   Pérez Enciso M, 2003, HUM GENET, V112, P581, DOI 10.1007/s00439 003 0921 9
   Poschke I, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 290
   Sheikh Ali M, 2010, NUTRITION, V26, P1146, DOI 10.1016/j.nut.2009.08.019
   Wen T, 2013, MOL BIOSYST, V9, P2370, DOI 10.1039/c3mb70138g
   Yonova D, 2007, Hippokratia, V11, P199
   Zhou JB, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0304 0
NR 21
TC 14
Z9 16
U1 0
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD AUG
PY 2015
VL 94
IS 32
AR e1273
DI 10.1097/MD.0000000000001273
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA CS6PD
UT WOS:000362201900001
PM 26266360
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yang, L
   Li, MM
   Liu, YC
   Bai, Y
   Yin, TY
   Chen, YY
   Jiang, JH
   Liu, S
AF Yang, Long
   Li, Miaomiao
   Liu, Yucheng
   Bai, Yang
   Yin, Tianyu
   Chen, Yangyang
   Jiang, Jinhong
   Liu, Su
TI MOTS c is an effective target for treating cancer induced bone pain
   through the induction of AMPK mediated mitochondrial biogenesis
SO ACTA BIOCHIMICA ET BIOPHYSICA SINICA
LA English
DT Article
DE MOTS c; AMPK; bone cancer pain; mitochondrial; osteoclast
ID OXIDATIVE STRESS; INJURY
AB Bone cancer pain (BCP), due to cancer bone metastasis and bone destruction, is a common symptom of tumors, including breast, prostate, and lung tumors. Patients often experience severe pain without effective treatment. Here, using a mouse model of bone cancer, we report that MOTS c, a novel mitochondrial derived peptide, confers remarkable protection against cancer pain and bone destruction. Briefly, we find that the plasma level of endogenous MOTS c is significantly lower in the BCP group than in the sham group. Accordingly, intraperitoneal administration of MOTS c robustly attenuates bone cancer induced pain. These effects are blocked by compound C, an AMPK inhibitor. Furthermore, MOTS c treatment significantly enhances AMPK alpha 1/2 phosphorylation. Interestingly, mechanical studies indicate that at the spinal cord level, MOTS c relieves pain by restoring mitochondrial biogenesis, suppressing microglial activation, and decreasing the production of inflammatory factors, which directly contribute to neuronal modulation. However, in the periphery, MOTS c protects against local bone destruction by modulating osteoclast and immune cell function in the tumor microenvironment, providing long term relief from cancer pain. Additionally, we find that chronic administration of MOTS c has little effect on liver, renal, lipid or cardiac function in mice. In conclusion, MOTS c improves BCP through peripheral and central synergistic effects on nociceptors, immune cells, and osteoclasts, providing a pharmacological and biological rationale for the development of mitochondrial peptide based therapeutic agents for cancer induced pain.
C1 [Yang, Long; Li, Miaomiao; Bai, Yang; Jiang, Jinhong] Xuzhou Med Univ, Jiangsu Prov Key Lab Anesthesiol, Jiangsu Prov Key Lab Anesthesia & Analgesia Applic, NMPA Key Lab Res & Evaluat Narcot & Psychotrop Dru, Xuzhou 221004, Peoples R China.
   [Liu, Yucheng; Yin, Tianyu; Chen, Yangyang; Liu, Su] Xuzhou Med Univ, Affiliated Hosp, Dept Anesthesiol, Xuzhou 221018, Peoples R China.
C3 Xuzhou Medical University; Xuzhou Medical University
RP Jiang, JH (通讯作者)，Xuzhou Med Univ, Jiangsu Prov Key Lab Anesthesiol, Jiangsu Prov Key Lab Anesthesia & Analgesia Applic, NMPA Key Lab Res & Evaluat Narcot & Psychotrop Dru, Xuzhou 221004, Peoples R China.; Liu, S (通讯作者)，Xuzhou Med Univ, Affiliated Hosp, Dept Anesthesiol, Xuzhou 221018, Peoples R China.
EM 150040009@qq.com; 100002019018@xzhmu.edu.cn
FU National Natural Science Foundation of China [82201385]; Natural Science
   Research Fund of Higher Education Institutions in Jiangsu Province
   [22KJA320007]; Science and Technology Project of Xuzhou Health
   Commission [XWKYHT20230056]
FX Funding This work was supported by the grants from the National Natural
   Science Foundation of China (No. 82201385) , the Natural Science
   Research Fund of Higher Education Institutions in Jiangsu Province (No.
   22KJA320007) , and the Science and Technology Project of Xuzhou Health
   Commission (No. XWKYHT20230056) .
CR Amaya F, 2013, CURR NEUROPHARMACOL, V11, P592, DOI 10.2174/1570159X11311060003
   Asiedu MN, 2016, EXPERIENTIA SUPPL, V107, P257, DOI 10.1007/978 3 319 43589 3_11
   Baeza Flores GD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.558474
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165 0270(94)90144 9
   Che N, 2019, EUR REV MED PHARMACO, V23, P3183, DOI 10.26355/eurrev_201904_17676
   Christofides A, 2022, NAT IMMUNOL, V23, P1148, DOI 10.1038/s41590 022 01267 2
   Dai RC, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046 022 02520 0
   Dharshini LCP, 2023, APPL BIOCHEM BIOTECH, V195, P2893, DOI 10.1007/s12010 022 04266 z
   Forman HJ, 2021, NAT REV DRUG DISCOV, V20, P689, DOI 10.1038/s41573 021 00233 1
   Gallaway MS, 2020, PREV CHRONIC DIS, V17, DOI 10.5888/pcd17.190367
   Hanc P, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1127571
   Jiang JH, 2023, ACS CHEM NEUROSCI, V14, P2362, DOI 10.1021/acschemneuro.3c00140
   Jiang JH, 2023, EUR J PHARMACOL, V939, DOI 10.1016/j.ejphar.2022.175469
   Jiang JH, 2021, ACS CHEM NEUROSCI, V12, P1506, DOI 10.1021/acschemneuro.0c00782
   Jiang W, 2023, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1087648
   Kapoor R, 2021, MED ONCOL, V38, DOI 10.1007/s12032 021 01587 7
   Kim SJ, 2021, GEROSCIENCE, V43, P1113, DOI 10.1007/s11357 020 00262 5
   Kong BS, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109724
   Lee C, 2015, CELL METAB, V21, P443, DOI 10.1016/j.cmet.2015.02.009
   Li X, 2022, FRONT MOL NEUROSCI, V15, DOI 10.3389/fnmol.2022.1026593
   Liu XN, 2014, MOL CANCER THER, V13, P596, DOI 10.1158/1535 7163.MCT 13 0579
   Long H, 2020, CANCER MANAG RES, V12, P10929, DOI 10.2147/CMAR.S263177
   Lu HY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102456
   Luan YW, 2020, P NATL ACAD SCI USA, V117, P10045, DOI 10.1073/pnas.1916263117
   Mantyh PW, 2014, CURR OPIN SUPPORT PA, V8, P83, DOI 10.1097/SPC.0000000000000048
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   Melemedjian OK, 2011, MOL PAIN, V7, DOI 10.1186/1744 8069 7 70
   Mestdagh F, 2023, CURR ONCOL, V30, P6838, DOI 10.3390/curroncol30070500
   Volpe CMO, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0135 z
   Price TJ, 2013, NEUROSCI LETT, V557, P9, DOI 10.1016/j.neulet.2013.06.060
   Rao Xiayu, 2013, Biostat Bioinforma Biomath, V3, P71
   Suter MR, 2016, CURR OPIN ANESTHESIO, V29, P584, DOI 10.1097/ACO.0000000000000373
   Tang DL, 2021, ACTA PHARMACOL SIN, V42, P189, DOI 10.1038/s41401 020 0433 3
   Tarng DG, 2000, AM J KIDNEY DIS, V36, P934, DOI 10.1053/ajkd.2000.19086
   Tseng WC, 2023, CANCERS, V15, DOI 10.3390/cancers15030739
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Udit S, 2022, NAT REV NEUROSCI, V23, P157, DOI 10.1038/s41583 021 00555 4
   Wang KY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 24867 2
   Wang P, 2019, J CELL PHYSIOL, V234, P10588, DOI 10.1002/jcp.27734
   Wang Z, 2024, NEUROL RES, V46, P165, DOI 10.1080/01616412.2023.2258584
   Wei M, 2016, BIOCHEM BIOPH RES CO, V476, P412, DOI 10.1016/j.bbrc.2016.05.135
   Wu JQ, 2023, ACTA BIOCH BIOPH SIN, V55, P285, DOI 10.3724/abbs.2023006
   Yan Z, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104381
   Yang HY, 2023, ACTA BIOCH BIOPH SIN, V55, P460, DOI 10.3724/abbs.2023039
   Yang L, 2023, NEUROPHARMACOLOGY, V237, DOI 10.1016/j.neuropharm.2023.109641
   Yin XQ, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2019.106174
   Yin YD, 2022, PHARMACOL RES, V175, DOI 10.1016/j.phrs.2021.105987
   Yoon TK, 2022, DIABETES METAB J, V46, P402, DOI 10.4093/dmj.2022.0092
   Zhao JJ, 2023, INT J MOL MED, V51, DOI 10.3892/ijmm.2023.5245
   Zheng XQ, 2022, J ADV RES, V35, P117, DOI 10.1016/j.jare.2021.06.006
   Zheng YJ, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1120533
   Zhou YQ, 2016, EXPERT OPIN THER TAR, V20, P1365, DOI 10.1080/14728222.2016.1214716
NR 52
TC 4
Z9 4
U1 10
U2 13
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, 100009,
   PEOPLES R CHINA
SN 1672 9145
EI 1745 7270
J9 ACTA BIOCH BIOPH SIN
JI Acta Biochim. Biophys. Sin.
PD SEP
PY 2024
VL 56
IS 9
BP 1323
EP 1339
DI 10.3724/abbs.2024048
PG 17
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA M3Q5Y
UT WOS:001356725800001
PM 38716540
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jagannath, S
AF Jagannath, Sundar
TI Pathophysiological underpinnings of multiple myeloma progression
SO JOURNAL OF MANAGED CARE PHARMACY
LA English
DT Article
ID BONE MARROW; SOCIETY
AB BACKGROUND: Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in the bone marrow. Myeloma is characterized by skeletal destruction, renal failure, hypercalcemia, and anemia. Currently, there is no cure, though recent understanding of the bone marrow micro environment and the cytogenetics involved in MM are leading to improved and individualized treatment strategies, leading to longer periods of remission and improved survival rates.
   OBJECTIVE: To review MM pathophysiology, genetic issues, other risk factors, and the steps of disease progression. This section will address diagnosis, staging, classification, and disease complications, as well as the roles of cytogenetic abnormalities and the bone marrow milieu.
   SUMMARY: In MM, malignant plasma cells in the in the bone marrow produce large quantities of monoclonal protein (M protein) leading to stimulation of osteoclasts. This increase in osteoclast activity leads to bone resorption and destruction, causing painful bone lesions and hypercalcemia. Myeloma cells also crowd out other normal bone marrow cells, which leads to a plethora of complications, including renal insufficiency, anemia, infection, and clotting disorders.
   Updated standards of diagnosis, staging, and classification of MM have recently been developed. The International Staging System (ISS) categorizes myeloma patients into 1 of 3 groups based on serum albumin and beta2 microglobulin blood tests.
   Genetic mutations leading to chromosomal translocations and deletions play a key role in the progression to active, malignant MM. Cytogenetic testing allows physicians to appropriately diagnose and treat patients specific to their unique presentation of disease.
   CONCLUSION: The future of treating the myeloma patient is progressing at a fast and positive pace. Identification and treatment of comorbid conditions are leading to improvements in quality of life. Identification of potential therapeutic targets in the bone marrow microenvironment is leading to the development of therapies that are changing the standard of care for MM patients.
C1 [Jagannath, Sundar] New York Med Coll, New York, NY 10011 USA.
   [Jagannath, Sundar] St Vincents Comprehens Canc Ctr, Transplant Program, New York, NY 10011 USA.
C3 New York Medical College; Saint Vincents Hospital Manhattan
RP Jagannath, S (通讯作者)，New York Med Coll, New York, NY 10011 USA.
EM sjagannath@aptiumoncology.com
CR Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Auwerda JJA, 2007, HAEMATOLOGICA, V92, P279, DOI 10.3324/haematol.10454
   Barosi G, 2004, HAEMATOLOGICA, V89, P717
   Chen L. J., 2007, Experimental Oncology, V29, P116
   DIMOPOULOS MA, 2008, LEUKEMIA, P1
   Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   *INT MYL FDN, MULT MYEL REN INV MU
   JOSHUA D, 2007, 11 INT MYEL WORKSH J
   Katzel JA, 2007, CA CANCER J CLIN, V57, P301, DOI 10.3322/CA.57.5.301
   Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746
   Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875
   Lentzsch S, 2007, HEMATOL ONCOL CLIN N, V21, P1035, DOI 10.1016/j.hoc.2007.08.009
   Lyman GH, 2007, J CLIN ONCOL, V25, P5490, DOI 10.1200/JCO.2007.14.1283
   *MULT MYEL RES FDN, 2006, MULT MYEL DIS OV
   Orlowski Robert Z, 2006, Hematology Am Soc Hematol Educ Program, P338
   SCHWARTZBERG I, 2007, MANAGED CARE ONC SPR, P47
   SCHWARTZBERG I, 2007, MANAGED CARE ONC SPR, P14
   Zhan F, 2006, LEUKEMIA, V20, P1484, DOI 10.1038/sj.leu.2404330
NR 19
TC 14
Z9 14
U1 0
U2 3
PU ACAD MANAGED CARE PHARMACY
PI ALEXANDRIA
PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314 3134 USA
SN 1083 4087
J9 J MANAGE CARE PHARM
JI J. Manag. Care Pharm.
PD SEP
PY 2008
VL 14
IS 7
SU S
BP S7
EP S11
DI 10.18553/jmcp.2008.14.S7 A.7
PG 5
WC Health Care Sciences & Services; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Health Care Sciences & Services; Pharmacology & Pharmacy
GA 354LN
UT WOS:000259641200002
PM 18774880
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Guo, XJ
   Wei, SL
   Lu, MM
   Shao, ZW
   Lu, JY
   Xia, LG
   Lin, KL
   Zou, DR
AF Guo, Xiaojing
   Wei, Silong
   Lu, Mengmeng
   Shao, Zhengwei
   Lu, Jiayu
   Xia, Lunguo
   Lin, Kaili
   Zou, Derong
TI RNA Seq investigation and in vivo study the effect of strontium
   ranelate on ovariectomized rat via the involvement of ROCK1
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
DE Strontium ranelate; ROCK 1; osteogenesis; angiogenesis; local delivery
ID MESENCHYMAL STEM CELLS; PROMOTES OSTEOGENIC DIFFERENTIATION; DOPED
   CALCIUM POLYPHOSPHATE; BONE MARROW; OSTEOPOROTIC BONE; DELIVERY SYSTEM;
   ANGIOGENESIS; REGENERATION; REPLICATION; ACTIVATION
AB Strontium ranelate (SrR) is an anti osteoporosis drug with excellent osteogenic and angiogenic capacity. In this study, we aimed to investigate the osteogenesis and angiogenesis effects of SrR and the underlying mechanism involved. RNA Seq was conducted to examine the effects of SrR on gene expression in ovariectomy rat bone marrow mesenchymal stem cells (OVX rBMSCs). To validate the different expressed gene in vitro, the effects of gene interference and overexpression in osteogenic induction environment of OVX rBMSCs and in primary osteoblasts were studied. RNA Seq showed that ROCK1 significantly increased after SrR treatment in OVX rBMSCs, and further validated by real time PCR and western blotting. Overexpression of ROCK1 promoted osteogenic differentiation of OVX rBMSCs and induced cell viability and inhibited apoptosis of primary osteoblasts, which was reversed by inhibition of ROCK1 by RNA interference or ROCK1 inhibitor (Y 27632) after SrR treatment. Furthermore, the SrR was loaded on nano structured hydroxyapatite (nano HAp) particulates to promote osteogenesis and angiogenesis in repairing of the femoral condyle bone defect using ovariectomy rat model. Taken together, ROCK1 is one of the targets that SrR promotes the osteogenic differentiation of OVX rBMSCs and cell viability of primary osteoblasts, the nano HAp particles could act as carriers for SrR to repair bone defects.
C1 [Guo, Xiaojing; Lu, Mengmeng; Shao, Zhengwei; Lu, Jiayu; Zou, Derong] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Stomatol, Shanghai, Peoples R China.
   [Guo, Xiaojing; Lu, Mengmeng] Shanghai Stomatol Hosp, Shanghai, Peoples R China.
   [Wei, Silong; Xia, Lunguo] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Oral & Craniomaxillofacial Sci, Sch Med, Shanghai, Peoples R China.
   [Lin, Kaili] Tongji Univ, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Sch & Hosp Stomatol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Tongji
   University
RP Zou, DR (通讯作者)，Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Stomatol, Shanghai, Peoples R China.; Lin, KL (通讯作者)，Tongji Univ, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Sch & Hosp Stomatol, Shanghai, Peoples R China.
EM linkaili@tongji.edu.cn; drzou@sjtu.edu.cn
OI Lin, Kaili/0000 0002 1900 9641; guo, xiao jing/0000 0002 6516 0019; Lu,
   Jiayu/0000 0001 9841 978X; Zou, Derong/0000 0002 4550 9092; Shao,
   Zhengwei/0000 0003 0396 1176
FU National Natural Science Foundation of China [81470714, 31400825,
   81672134]; Science and Technology Commission of Shanghai Municipality
   [15410722600, 16140903900, 15441905300, 17510710800]; Research Project
   of Shanghai Stomatological Hospital [SSDC 2017 01]; Fund of Shanghai
   Municipal Commission of Health and Family Planning [201540369]; Shanghai
   Pujiang Program [17PJD030]; Advanced Research Program of Shanghai Jiao
   Tong University Affiliated Sixth People's Hospital [LYZY 0082];
   Innovation Fund of Translational Medicine of Medicine School of Shanghai
   Jiao Tong University [15ZH2012]
FX The authors gratefully acknowledge the support of the National Natural
   Science Foundation of China (No. 81470714, 31400825, 81672134), Science
   and Technology Commission of Shanghai Municipality (No. 15410722600,
   16140903900, 15441905300, 17510710800), the Research Project of Shanghai
   Stomatological Hospital (SSDC 2017 01) and the Fund of Shanghai
   Municipal Commission of Health and Family Planning (No. 201540369),
   Shanghai Pujiang Program (17PJD030), the Advanced Research Program of
   Shanghai Jiao Tong University Affiliated Sixth People's Hospital
   (LYZY 0082), and Innovation Fund of Translational Medicine of Medicine
   School of Shanghai Jiao Tong University (15ZH2012).
CR Atkins GJ, 2009, OSTEOPOROSIS INT, V20, P653, DOI 10.1007/s00198 008 0728 6
   Bain SD, 2009, OSTEOPOROSIS INT, V20, P1417, DOI 10.1007/s00198 008 0815 8
   Brennan TC, 2009, BRIT J PHARMACOL, V157, P1291, DOI 10.1111/j.1476 5381.2009.00305.x
   Cao X, 2014, HYPERTENS RES, V37, P803, DOI 10.1038/hr.2014.90
   Caverzasio J, 2008, BONE, V42, P1131, DOI 10.1016/j.bone.2008.02.010
   Chang CS, 1999, J BIOMED MATER RES, V48, P411, DOI 10.1002/(SICI)1097 4636(1999)48:4<411::AID JBM3>3.0.CO;2 H
   Chen YW, 2008, J MATER SCI MATER M, V19, P2655, DOI 10.1007/s10856 007 3350 9
   Cianferotti L, 2013, THER ADV MUSCULOSKEL, V5, P127, DOI 10.1177/1759720X13483187
   Curtis Elizabeth M, 2015, Clin Med (Lond), V15 Suppl 6, ps92, DOI 10.7861/clinmedicine.15 6 s92
   Devlin H, 2007, BONE, V40, P835, DOI 10.1016/j.bone.2006.10.024
   Du XF, 2017, ARTIF CELL NANOMED B, V45, P1710, DOI 10.1080/21691401.2017.1282499
   Fromigué O, 2010, J BIOL CHEM, V285, P25251, DOI 10.1074/jbc.M110.110502
   Fromigué O, 2009, J CELL MOL MED, V13, P2189, DOI 10.1111/j.1582 4934.2009.00673.x
   Gu ZP, 2013, J MATER SCI MATER M, V24, P1251, DOI 10.1007/s10856 013 4891 8
   Guo XJ, 2016, INT J BIOL SCI, V12, P1511, DOI 10.7150/ijbs.16499
   Han TY, 2017, ARTIF CELL NANOMED B, V45, P108, DOI 10.3109/21691401.2015.1129629
   Ishizaki T, 2000, MOL PHARMACOL, V57, P976
   [靳思思 Jin Sisi], 2014, [中国病理生理杂志, Chinese Journal of Pathophysiology], V30, P159
   Khatiwala CB, 2009, J BONE MINER RES, V24, P886, DOI [10.1359/jbmr.081240, 10.1359/JBMR.081240]
   Lin KL, 2013, BIOMATERIALS, V34, P10028, DOI 10.1016/j.biomaterials.2013.09.056
   Lin KL, 2013, ACS APPL MATER INTER, V5, P8008, DOI 10.1021/am402089w
   Lin KL, 2013, CHEM ENG J, V222, P49, DOI 10.1016/j.cej.2013.02.037
   Liu F, 2011, J MATER SCI MATER M, V22, P683, DOI 10.1007/s10856 011 4247 1
   Lv Huizhen, 2013, Nan Fang Yi Ke Da Xue Xue Bao, V33, P376
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Meunier PJ, 2009, OSTEOPOROSIS INT, V20, P1663, DOI 10.1007/s00198 008 0825 6
   Okada M, 2012, SCI TECHNOL ADV MAT, V13, DOI 10.1088/1468 6996/13/6/064103
   Oviedo PJ, 2011, MOL CELL ENDOCRINOL, V335, P96, DOI 10.1016/j.mce.2010.06.020
   Peng SL, 2009, CELL PHYSIOL BIOCHEM, V23, P165, DOI 10.1159/000204105
   Pezzatini S, 2006, J BIOMED MATER RES A, V76A, P656, DOI 10.1002/jbm.a.30524
   Shen QP, 2013, J PHARM PHARMACOL, V65, P1005, DOI 10.1111/jphp.12054
   Tewari D, 2015, STEM CELL REV REP, V11, P309, DOI 10.1007/s12015 014 9573 5
   Torricelli P, 2003, ARTIF CELL BLOOD SUB, V31, P263, DOI 10.1081/BIO 120023157
   Toung JM, 2011, GENOME RES, V21, P991, DOI 10.1101/gr.116335.110
   Wang YK, 2012, STEM CELLS DEV, V21, P1176, DOI 10.1089/scd.2011.0293
   Wu YQ, 2015, J MATER CHEM B, V3, P4871, DOI 10.1039/c5tb00621j
   Xia LG, 2014, BIOMATERIALS, V35, P8514, DOI 10.1016/j.biomaterials.2014.06.028
   Yamaguchi M, 2012, MOL CELL BIOCHEM, V359, P399, DOI 10.1007/s11010 011 1034 8
   Zhou YN, 2017, J MATER CHEM B, V5, P612, DOI 10.1039/c6tb02312f
NR 39
TC 10
Z9 11
U1 2
U2 25
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2169 1401
EI 2169 141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PY 2018
VL 46
SU 1
BP S629
EP S641
DI 10.1080/21691401.2018.1433188
PG 13
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA HJ3DI
UT WOS:000457049400059
PM 29381089
DA 2025 08 17
ER

PT J
AU Wang, L
   Zhao, X
   Wei, BY
   Liu, Y
   Ma, XY
   Wang, J
   Cao, PC
   Zhang, Y
   Yan, YB
   Lei, W
   Feng, YF
AF Wang, Lin
   Zhao, Xiong
   Wei, Bo yuan
   Liu, Yi
   Ma, Xiang yu
   Wang, Jian
   Cao, Peng chong
   Zhang, Yang
   Yan, Ya bo
   Lei, Wei
   Feng, Ya fei
TI Insulin improves osteogenesis of titanium implants under diabetic
   conditions by inhibiting reactive oxygen species overproduction via the
   PI3K Akt pathway
SO BIOCHIMIE
LA English
DT Article
DE Insulin; Titanium implant; Diabetes; Reactive oxygen species; PI3K Akt
ID OXIDATIVE STRESS; BONE FORMATION; METABOLIC CONTROL; OSSEOINTEGRATION;
   CELLS; THERAPY; OSTEOBLASTS; EXPRESSION; MELLITUS; H2O2
AB Clinical evidence indicates that insulin therapy improves implant survival rates in diabetic patients; however, the mechanisms responsible for this effect are unknown. Here, we test if insulin exerts antioxidative effects, thereby improving diabetes associated impaired osteoblast behavior on titanium implants. To test this hypothesis, we cultured primary rabbit osteoblasts in the presence of titanium implants and studied the impact of treatment with normal serum (NS), diabetic serum (DS), DS + insulin, DS + tempol (a superoxide dismutase mimetic), DS + insulin + tempol, and DS + insulin + wortmannin. We analyzed cell function, apoptosis, and reactive oxygen species (ROS) production in osteoblasts following the various treatments. Treatment with DS induced osteoblast dysfunction, evidenced by impaired cell attachment and morphology, decreased cell proliferation and ALP activity, and decreased expression of osteogenesis related genes. We also observed a significant increase in apoptosis. Importantly, treatment with DS resulted in increased production of ROS in osteoblasts. In contrast, treatment with insulin inhibited ROS production, alleviated cell dysfunction, and decreased apoptosis of osteoblasts on the implants. Scavenging ROS with tempol also attenuated cell dysfunction. Compared to insulin treatment alone, the combination of insulin and tempol failed to further improve osteoblast functional recovery. Moreover, the anti oxidative and pro osteogenic effects afforded by insulin were almost completely abolished by the phosphatidylinositol 3 kinase (PI3K) inhibitor wortmannin. These results demonstrate, for the first time, that insulin treatment alleviates the impaired osteogenesis of titanium implants under diabetic conditions by inhibiting ROS overproduction via a PI3K/Akt dependent mechanism. Both the anti oxidative and metabolic properties of insulin should make it a viable therapeutic option to combat diabetic implant failure. (C) 2014 Published by Elsevier B.V.
C1 [Wang, Lin; Zhao, Xiong; Wei, Bo yuan; Ma, Xiang yu; Wang, Jian; Cao, Peng chong; Zhang, Yang; Yan, Ya bo; Lei, Wei; Feng, Ya fei] Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Peoples R China.
   [Liu, Yi] Fourth Mil Med Univ, Sch Stomatol, Dept Implant Dent, Xian 710032, Peoples R China.
C3 Air Force Medical University; Air Force Medical University
RP Lei, W (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Peoples R China.
EM leiwei@fmmu.edu.cn; fengyafei2005@163.edu.cn
RI ; MA, XIANGYU/AAS 6485 2021; wang, jian/HRB 9588 2023; Wang,
   Lin/J 8805 2018; Cao, Peng/GQP 3834 2022
OI Lei, Wei/0000 0002 7346 6915; Wang, Lin/0000 0002 5995 8446; Wang,
   Lin/0000 0001 5937 6318; 
FU Research Fund for the National Natural Science Foundation of China
   [81371933, 31170913]; Ming Zhutui Project [XJZT13M08]
FX We appreciate the assistance of Guo xian Pei from the Department of
   Orthopedics, Xijing Hospital, for providing language help. This work was
   supported by the Research Fund for the National Natural Science
   Foundation of China (No. 81371933) to Lin Wang, Ming Zhutui Project
   (XJZT13M08) to Ya Fei Feng, and the Research Fund for the National
   Natural Science Foundation of China (No. 31170913) to Wei Lei.
CR Atsuta I, 2013, ARCH ORAL BIOL, V58, P1696, DOI 10.1016/j.archoralbio.2013.07.013
   Cao XY, 2006, BIOMED MATER, V1, pL16, DOI 10.1088/1748 6041/1/4/L02
   Chen T, 2012, MOL CELL BIOCHEM, V369, P167, DOI 10.1007/s11010 012 1379 7
   Cheng ZY, 2010, TRENDS ENDOCRIN MET, V21, P589, DOI 10.1016/j.tem.2010.06.005
   Dandona P, 2013, AM J PHYSIOL ENDOC M, V304, pE810, DOI 10.1152/ajpendo.00566.2012
   de Molon RS, 2013, CLIN ORAL IMPLAN RES, V24, P831, DOI 10.1111/j.1600 0501.2012.02467.x
   Feng YF, 2013, BIOMATERIALS, V34, P2234, DOI 10.1016/j.biomaterials.2012.12.023
   Feng YF, 2013, CRIT CARE MED, V41, pE74, DOI 10.1097/CCM.0b013e318278b6e7
   Fiorellini JP, 2000, INT J PERIODONT REST, V20, P367
   Fiorellini JP, 1999, CLIN ORAL IMPLAN RES, V10, P362, DOI 10.1111/j.1600 0501.1999.tb00011.x
   Follak N, 2004, BONE, V35, P144, DOI 10.1016/j.bone.2004.03.011
   Hasegawa H, 2008, INT J ORAL MAX IMPL, V23, P237
   Hou CJ, 2012, INT J ORAL MAX SURG, V41, P400, DOI 10.1016/j.ijom.2011.10.004
   Ji LL, 2010, AM J PHYSIOL ENDOC M, V298, pE871, DOI 10.1152/ajpendo.00623.2009
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Klein GL, 2014, WORLD J DIABETES, V5, P14, DOI 10.4239/wjd.v5.i1.14
   Kotsovilis S, 2006, CLIN ORAL IMPLAN RES, V17, P587, DOI 10.1111/j.1600 0501.2005.01245.X
   Kwon PT, 2005, J PERIODONTOL, V76, P621, DOI 10.1902/jop.2005.76.4.621
   Langston W, 2008, FREE RADICAL BIO MED, V45, P1591, DOI 10.1016/j.freeradbiomed.2008.09.013
   Le Nga N, 2011, J Diabetes Sci Technol, V5, P605
   Lee YH, 2010, CELL BIOCHEM FUNCT, V28, P678, DOI 10.1002/cbf.1708
   Li CJ, 2010, BIOCHEM PHARMACOL, V79, P926, DOI 10.1016/j.bcp.2009.10.019
   Li X, 2009, MATER LETT, V63, P403, DOI 10.1016/j.matlet.2008.10.065
   Liang D, 2012, BIOL TRACE ELEM RES, V148, P420, DOI 10.1007/s12011 012 9387 8
   Malekzadeh B, 2013, J BIOMED MATER RES A, V101, P132, DOI 10.1002/jbm.a.34313
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Margonar Rogerio, 2003, Implant Dent, V12, P333, DOI 10.1097/01.ID.0000086482.65273.B7
   McGonnell Imelda M, 2012, Front Endocrinol (Lausanne), V3, P88, DOI 10.3389/fendo.2012.00088
   Moreira P I, 2006, Med Chem, V2, P299, DOI 10.2174/157340606776930754
   Moy PK, 2005, INT J ORAL MAX IMPL, V20, P569
   Muller AP, 2013, EXP NEUROL, V247, P66, DOI 10.1016/j.expneurol.2013.03.007
   de Morais JAND, 2009, CLIN ORAL IMPLAN RES, V20, P796, DOI 10.1111/j.1600 0501.2009.01716.x
   Oates TW, 2013, CLIN ORAL IMPLAN RES, V24, P117, DOI 10.1111/j.1600 0501.2011.02374.x
   Pan J, 1998, J BIOMED MATER RES, V40, P244, DOI 10.1002/(SICI)1097 4636(199805)40:2<244::AID JBM9>3.0.CO;2 L
   Papaiahgari S, 2006, ANTIOXID REDOX SIGN, V8, P43, DOI 10.1089/ars.2006.8.43
   Ramalingam M, 2014, FREE RADICAL RES, V48, P347, DOI 10.3109/10715762.2013.869588
   Ramalingam M., 2014, J RECEPT SIGNAL TRAN
   Retzepi M, 2010, CLIN ORAL IMPLAN RES, V21, P71, DOI 10.1111/j.1600 0501.2009.01805.x
   Tsaryk R, 2007, BIOMATERIALS, V28, P806, DOI 10.1016/j.biomaterials.2006.09.033
   Waddington RJ, 2011, CELLS TISSUES ORGANS, V194, P307, DOI 10.1159/000324251
   Wang BG, 2011, BRIT J ORAL MAX SURG, V49, P225, DOI 10.1016/j.bjoms.2010.03.006
   Wang W, 2013, BIOMATERIALS, V34, P631, DOI 10.1016/j.biomaterials.2012.10.021
   Wang X, 2012, BIOCHIMIE, V94, P1705, DOI 10.1016/j.biochi.2012.03.024
   Wang X, 2012, MOL CELL ENDOCRINOL, V349, P111, DOI 10.1016/j.mce.2011.08.019
   Yu M, 2011, BONE, V49, P387, DOI 10.1016/j.bone.2011.05.025
   Zupnik J, 2011, J PERIODONTOL, V82, P1390, DOI 10.1902/jop.2011.100685
NR 46
TC 27
Z9 29
U1 0
U2 35
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0300 9084
EI 1638 6183
J9 BIOCHIMIE
JI Biochimie
PD JAN
PY 2015
VL 108
BP 85
EP 93
DI 10.1016/j.biochi.2014.10.004
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA CA5PD
UT WOS:000348959400012
PM 25308835
DA 2025 08 17
ER

PT J
AU Chu, ZM
   Li, HB
   Sun, SX
   Jiang, YC
   Wang, B
   Dong, YF
AF Chu, Z.  M.
   Li, H.  B.
   Sun, S.  X.
   Jiang, Y.  C.
   Wang, B.
   Dong, Y.  F.
TI Melatonin promotes osteoblast differentiation of bone marrow mesenchymal
   stem cells in aged rats
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Melatonin; Osteoporosis; Micro CT; Osteoblast differentiation;
   Adipogenic differentiation
ID QUALITY OF LIFE; VERTEBRAL FRACTURES; OSTEOPOROSIS; WOMEN; EXPRESSION;
   PREVENTION; RECEPTORS; STRENGTH; THERAPY; HEALTH
AB OBJECTIVE: The current study was to explore the effect of melatonin on osteoporosis and relevant mechanisms.
   MATERIALS AND METHODS: We performed micro CT to detect bone microstructure and ELI SA to detect the contents of osteocalcin (OCN) and bone alkaline phosphatase (BAP) in serum. Double fluorescence labeling of calcein and tetracycline and toluidine blue staining were used to determine morphological indexes of bone tissues. Alizarin red staining and Oil Red O staining were performed to recognize bone cells and adipocytes. RT PCR was performed to determine the expression of osteoblast differentiation related genes.
   RESULTS: In the current study, data from micro CT indicated that melatonin significantly increased the bone mass density (BMD), bone volume/tissue volume (BV/TV), trabecular number (Tb.N) and trabecular thickness (Tb.Th), and decreased the Structure Model Index (SMI) and trabecular Separation/Spacing (Tb.Sp) in elderly rats. Melatonin reduced calcium and phosphorus losses in urine and increased BAP and OCN levels in serum in elderly rats and increased bone formation rate (BFR) and bone mineralization rate (MAR) in elderly rats. Melatonin increased the number of osteoblasts in bone marrow and reduced the number of adipocytes in elderly rats. Melatonin also promoted the expression of osteogenic differentiation genes and suppressed the expression of adipogenic differentiation genes.
   CONCLUSIONS: WE suggest that melatonin could alleviate osteoporosis in aged rats' models probably by promoting osteoblast differentiation.
C1 [Chu, Z.  M.; Dong, Y.  F.] First Peoples Hosp Lianyungang, Dept Orthoped, Lianyungang, Jiangsu, Peoples R China.
   [Chu, Z.  M.; Li, H.  B.; Sun, S.  X.; Jiang, Y.  C.; Wang, B.] Nanjing Med Univ, Dept Orthoped, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Dong, YF (通讯作者)，First Peoples Hosp Lianyungang, Dept Orthoped, Lianyungang, Jiangsu, Peoples R China.
EM dongyuefu@163.com
CR Cardinali DP, 2003, J PINEAL RES, V34, P81, DOI 10.1034/j.1600 079X.2003.00028.x
   Colombo J, 2016, ONCOL LETT, V12, P231, DOI 10.3892/ol.2016.4605
   COOK DJ, 1993, ARTHRITIS RHEUM, V36, P750, DOI 10.1002/art.1780360603
   Cutando A, 2011, ARCH ORAL BIOL, V56, P944, DOI 10.1016/j.archoralbio.2011.03.004
   Duque G, 2008, CURR OPIN RHEUMATOL, V20, P429, DOI 10.1097/BOR.0b013e3283025e9c
   Egermann M, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 271
   Fjelldal PG, 2004, J PINEAL RES, V36, P132, DOI 10.1046/j.1600 079X.2003.00109.x
   Fonseca H, 2014, SPORTS MED, V44, P37, DOI 10.1007/s40279 013 0100 7
   Gold DT, 1996, BONE, V18, pS185, DOI 10.1016/8756 3282(95)00500 5
   HAKANSON DO, 1987, PEDIATR RES, V22, P414, DOI 10.1203/00006450 198710000 00010
   HAKANSON DO, 1981, SCIENCE, V214, P807, DOI 10.1126/science.6895262
   Hardeland R, 2012, J PINEAL RES, V52, P139, DOI 10.1111/j.1600 079X.2011.00934.x
   Kado DM, 2003, OSTEOPOROSIS INT, V14, P589, DOI 10.1007/s00198 003 1412 5
   Liu J, 2013, INT J MOL SCI, V14, P10063, DOI 10.3390/ijms140510063
   Roth JA, 1999, J BIOL CHEM, V274, P22041, DOI 10.1074/jbc.274.31.22041
   Satomura K, 2007, J PINEAL RES, V42, P231, DOI 10.1111/j.1600 079X.2006.00410.x
   Stolzing A, 2006, AGING CELL, V5, P213, DOI 10.1111/j.1474 9726.2006.00213.x
   Toffol E, 2014, MENOPAUSE, V21, P493, DOI 10.1097/GME.0b013e3182a6c8f3
   Witt Enderby PA, 2006, J PINEAL RES, V41, P297, DOI 10.1111/j.1600 079X.2006.00369.x
   Wu J, 2016, BIOMED REP, V5, P233, DOI 10.3892/br.2016.697
   Yang L, 2016, CELL PHYSIOL BIOCHEM, V38, P809, DOI 10.1159/000443036
   Zhang Y, 2016, EUR REV MED PHARMACO, V20, P433
NR 22
TC 28
Z9 35
U1 0
U2 1
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD OCT
PY 2017
VL 21
IS 19
BP 4446
EP 4456
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FM6HP
UT WOS:000415151500029
PM 29077147
DA 2025 08 17
ER

PT J
AU Chen, Y
   Wang, XX
   Zhao, BJ
   Bu, J
   Su, YR
   Zhang, J
AF Chen, Yun
   Wang, Xu Xia
   Zhao, Bing Jie
   Bu, Jie
   Su, Yu Ran
   Zhang, Jun
TI Effects of icariin on orthodontic tooth movement in rats
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Icariin; traditional Chinese medicine (TCM); orthodontic tooth movement
   (OTM); bone remodeling
ID COLONY STIMULATING FACTOR; BONE RESORPTION; IN VITRO; OSTEOGENIC
   DIFFERENTIATION; OSTEOCLAST DIFFERENTIATION; ACTIVATION; CELLS; TISSUES;
   EXPRESSION; RANKL
AB Purpose: Orthodontic tooth movement (OTM) is achieved through bone remodeling of the alveolar bone. Icariin, the active ingredient isolated from Herba Epimedii which is a traditional Chinese medicine (TCM) commonly used for osteoporosis treatment in China. The purpose of the study is to explore the effect of icariin on OTM in rats, and analyze the possible mechanism involved. Methods: 48 rats were selected and divided into 2 groups: the control group and the experimental group. Rats in the experimental group were given 20 mg/kg/day icariin by intragastric administration, while the control group received the same volume solvent. All rats were placed a closed coil spring between their upper first molar and incisor, exerting a force of about 40 g to establish animal models of OTM. As the first molar moved mesially, a space between the first and second molar was created. The rats were sacrificed in batch on the 7th, 14th, 21st and 28th days after orthodontic treatment. The amount of tooth movement was measured, and histomorphometric analysis based on slices from periodontium adjacent to the maxillary first molars were used to observe new bone formation, bone resorption and quantify osteoclasts. Key results: Icariin increased OTM (P<0.05) by 65.2%, 35.3%, 11.7% and 16.7% on day 7, 14, 21, 28 respectively compared with the control group. The number of osteoclasts in the icariin group showed a transient but sudden increase and then a persistent decrease. Conclusions: Icariin could accelerate OTM in rats through promoting bone remodeling of alveolar bone.
C1 [Chen, Yun; Su, Yu Ran; Zhang, Jun] Shandong Univ, Sch Stomatol, Dept Orthodont, Jinan 250012, Shandong, Peoples R China.
   [Wang, Xu Xia; Zhao, Bing Jie] Shandong Univ, Sch Stomatol, Dept Oral & Maxillofacial Surg, Jinan 250012, Shandong, Peoples R China.
   [Bu, Jie] Jining Med Univ, Sch Stomatol, Dept Orthodont, Jining, Shandong, Peoples R China.
C3 Shandong University; Shandong University; Jining Medical University
RP Zhang, J (通讯作者)，Shandong Univ, Sch Stomatol, Dept Orthodont, 44 1 Wenhua West Rd, Jinan 250012, Shandong, Peoples R China.
EM zhangj@sdu.edu.cn
FU National Science Fund (China) [81371180]
FX The study were supported by the National Science Fund (81371180, China).
   The authors thank to Shandong Provincial Key Laboratory of Oral
   Biomedicine and Shandong University Experimental Animal Center, Jinan,
   China.
CR An SJ, 2000, CHIN J OSTEOPOROSIS, V6, P55
   Bao Jia rong, 2005, Wei Sheng Yan Jiu, V34, P191
   Bartzela T, 2009, AM J ORTHOD DENTOFAC, V135, P16, DOI 10.1016/j.ajodo.2008.08.016
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BRIDGES T, 1988, AM J ORTHOD DENTOFAC, V93, P245, DOI 10.1016/S0889 5406(88)80010 6
   Cai WJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028835
   Chen KM, 2007, PHARMAZIE, V62, P388, DOI 10.1691/ph.2007.5.6682
   Chen KM, 2005, PHARMAZIE, V60, P939
   Cheng S, 2007, J SEP SCI, V30, P1307, DOI 10.1002/jssc.200600313
   [CPCoHMoPR C Industry C], 2000, CHINESE PHARMACOPOEI, VI, P267
   Fields H PW., 2007, CONT ORTHODONTICS, P331
   Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222 6233.2002
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Huang J, 2007, LIFE SCI, V81, P832, DOI 10.1016/j.lfs.2007.07.015
   Huang J, 2007, CHINESE SCI BULL, V52, P890, DOI 10.1007/s11434 007 0121 4
   Kale S, 2004, AM J ORTHOD DENTOFAC, V125, P607, DOI 10.1016/j.ajodo.2003.06.002
   KING GJ, 1991, AM J ORTHOD DENTOFAC, V99, P456, DOI 10.1016/S0889 5406(05)81579 3
   LEIKER BJ, 1995, AM J ORTHOD DENTOFAC, V108, P380, DOI 10.1016/S0889 5406(95)70035 8
   Liu Chang Geng, 2006, Hua Xi Kou Qiang Yi Xue Za Zhi, V24, P458
   Mok SK, 2010, BRIT J PHARMACOL, V159, P939, DOI 10.1111/j.1476 5381.2009.00593.x
   Noxon SJ, 2001, AM J ORTHOD DENTOFAC, V120, P466, DOI 10.1067/mod.2001.117912
   Proff P, 2009, CLIN ORAL INVEST, V13, P355, DOI 10.1007/s00784 009 0268 2
   Qin L, 2005, J BONE MINER METAB, V23, P55, DOI 10.1007/BF03026324
   Rody WJ, 2001, AM J ORTHOD DENTOFAC, V120, P477, DOI 10.1067/mod.2001.118623
   RYGH P, 1986, AM J ORTHOD DENTOFAC, V89, P453, DOI 10.1016/0002 9416(86)90001 1
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   STOREY E, 1973, AM J ORTHOD DENTOFAC, V63, P292, DOI 10.1016/0002 9416(73)90353 9
   Sze SCW, 2010, MOLECULES, V15, P7861, DOI 10.3390/molecules15117861
   Taweechaisupapong S, 2005, ANGLE ORTHOD, V75, P356
   Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756 3282(99)00210 0
   VAES G, 1988, CLIN ORTHOP RELAT R, P239
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang Y, 2012, J ETHNOPHARMACOL, V141, P642, DOI 10.1016/j.jep.2011.09.003
   Xie F, 2005, EVID BASED COMPL ALT, V2, P353, DOI 10.1093/ecam/neh101
   Xue LM, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/241416
   Yamaguchi M, 2009, ORTHOD CRANIOFAC RES, V12, P113, DOI 10.1111/j.1601 6343.2009.01444.x
   Yin YX, 2007, CHINESE MED J PEKING, V120, P204, DOI 10.1097/00029330 200702010 00006
   Zhang DW, 2012, BIOCHIMIE, V94, P2514, DOI 10.1016/j.biochi.2012.06.033
   Zhao J, 2008, BIOCHEM BIOPH RES CO, V369, P444, DOI 10.1016/j.bbrc.2008.02.054
NR 39
TC 8
Z9 10
U1 0
U2 10
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940 5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 6
BP 8608
EP 8616
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA CO6VS
UT WOS:000359295600030
PM 26309512
DA 2025 08 17
ER

PT J
AU Brüning, J
   Petereit, AC
   Alig, E
   Bolte, M
   Dressman, JB
   Schmidt, MU
AF Bruening, Juergen
   Petereit, Anna Christine
   Alig, Edith
   Bolte, Michael
   Dressman, Jennifer B.
   Schmidt, Martin U.
TI Characterization of a New Solvate of Risedronate
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE risedronate; bisphosphonates; osteoporosis; polymorphism; crystal
   structure; crystallization; hydrates/solvates; X ray diffractometry;
   dissolution
ID MEVALONATE PATHWAY; BISPHOSPHONATES; ABSORPTION; DIPHOSPHONATES;
   PYROPHOSPHATE; DISSOLUTION; OSTEOCLASTS; CALCIUM
AB Three new forms of the osteoporosis drug sodium risedronate, sodium [1 hydroxy 2 (3 pyridinyl)ethylidene]bisphosphonate, were identified and designated as the J, K, and M phases. Form J is an acetic acid disolvate with the chemical composition Na+ [C7H10NO7P2]( )center dot 2CH(3)COOH, as determined by single crystal structure analysis. This novel solvate is easily formed by the recrystallization of sodium risedronate from acetic acid. Dissolution of the new disolvate was characterized in distilled water, a compendial buffer, simulated gastric fluid sine pepsin (pH 1.2), and a biorelevant buffer system FaSSIF V2 (pH 6.8). It was demonstrated that solubility of the disolvate in physiological buffers differed significantly from that of the original molecule, with delayed dissolution under simulated esophageal and gastric conditions, but rapid and complete dissolution under simulated intestinal conditions. These studies suggest that through the generation of novel solvates, the biopharmaceutical properties of poorly soluble drug candidates can be improved. (C) 2010 Wiley Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:863 873, 2011
C1 [Petereit, Anna Christine; Dressman, Jennifer B.] Goethe Univ Frankfurt, Inst Pharmaceut Technol, D 60438 Frankfurt, Germany.
   [Bruening, Juergen; Alig, Edith; Bolte, Michael; Schmidt, Martin U.] Goethe Univ Frankfurt, Inst Inorgan & Analyt Chem, D 60438 Frankfurt, Germany.
C3 Goethe University Frankfurt; Goethe University Frankfurt
RP Dressman, JB (通讯作者)，Goethe Univ Frankfurt, Inst Pharmaceut Technol, Max von Laue Str 9, D 60438 Frankfurt, Germany.
EM dressman@em.uni frankfurt.de; m.schmidt@chemie.uni frankfurt.de
FU ratiopharm GmbH, Ulm, Germany
FX We thank ratiopharm GmbH, Ulm, Germany for supply of the sodium
   risedronate hemi pentahydrate and for financial support.
CR ARONHIME J, 2003, Patent No. 2480764
   BASSETT CAL, 1969, LANCET, V2, P845
   BRUNING J, 2007, Patent No. 102007030370
   CAWTHON PM, 2006, IOF WORLD C OST, pS24
   CAZER FD, 2001, Patent No. 1252170
   DANSEREAU RJ, 2006, Patent No. 20060110452
   Diez Perez A, 2002, MATURITAS, V43, pS19
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   FLEISCH H, 1968, CALC TISS RES, VS  2, P10, DOI 10.1007/BF02065192
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   Gossman WL, 2003, ACTA CRYSTALLOGR C, V59, pM33, DOI 10.1107/S0108270102021996
   Illum L, 1996, J DRUG TARGET, V3, P427, DOI 10.3109/10611869609015963
   Ito M, 1999, BONE, V25, P447, DOI 10.1016/S8756 3282(99)00197 0
   JANNER M, 1991, CALCIFIED TISSUE INT, V49, P280, DOI 10.1007/BF02556218
   Jantratid E, 2008, PHARM RES DORDR, V25, P1663, DOI 10.1007/s11095 008 9569 4
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Menschutkin N., 1865, ANN CHEM PHARM, V133, P317
   MONKKONEN J, 1990, EUR J DRUG METAB PH, V15, P239
   Nguyen TNP, 2008, INT J PHARMACEUT, V364, P1, DOI 10.1016/j.ijpharm.2008.05.037
   Ogura Y, 2004, J BONE MINER METAB, V22, P120, DOI 10.1007/s00774 003 0459 x
   Paulekuhn GS, 2007, J MED CHEM, V50, P6665, DOI 10.1021/jm701032y
   Redman Furey N, 2005, J PHARM SCI US, V94, P893, DOI 10.1002/jps.20308
   RODEN GA, 1998, ANN REV PHARM TOXICO, V38, P375
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   SATO M, 1990, J BONE MINER RES, V5, P31, DOI 10.1002/jbmr.5650050107
   SHELDRICK GM, 1997, SHELXS97 SHELXL97
   SHREWSBURY RP, 1985, J PHARM PHARMACOL, V37, P440, DOI 10.1111/j.2042 7158.1985.tb03034.x
   Spek AL, 2003, J APPL CRYSTALLOGR, V36, P7, DOI 10.1107/S0021889802022112
   *STOE CIE, 2000, IPDSII SINGL CRYST D
   *STOE CIE, 1988, STADI P FAST POWD DI
   *STOE CIE, 2001, XAREA XSTEP PROGR DA
   Sweetman S.C., 2009, MARTINDALE COMPLETE
   Tucker KL, 2006, AM J CLIN NUTR, V84, P936, DOI 10.1093/ajcn/84.4.936
   *USPC INC, 2008, US PHARM USPANF USPA
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   VANHOOGDALEM EJ, 1989, J PHARM PHARMACOL, V41, P339
   Von Baeyer H., 1897, BEITR DTSCH CHEM GES, V30, P1973, DOI [10.1002/CBER.189703002157, DOI 10.1002/CBER.189703002157]
NR 39
TC 10
Z9 10
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0022 3549
EI 1520 6017
J9 J PHARM SCI US
JI J. Pharm. Sci.
PD MAR
PY 2011
VL 100
IS 3
BP 863
EP 873
DI 10.1002/jps.22327
PG 11
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA 729JZ
UT WOS:000287947100009
PM 20967794
DA 2025 08 17
ER

PT J
AU Li, WF
   Yu, B
   Li, MM
   Sun, DM
   Hu, YJ
   Zhao, M
   Cui, CB
   Hou, SX
AF Li, Wenfeng
   Yu, Bin
   Li, Mengmeng
   Sun, Daming
   Hu, Yanjun
   Zhao, Ming
   Cui, Cai Bin
   Hou, Shuxun
TI NEMO binding domain peptide promotes osteoblast differentiation impaired
   by tumor necrosis factor alpha
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Osteoblast differentiation; Nuclear factor kappaB; Smad1; BMP 2;
   TNF alpha; NEMO binding domain
ID BONE MORPHOGENETIC PROTEIN; NF KAPPA B; TNF ALPHA; INFLAMMATION;
   INHIBITION; TRANSCRIPTION; REGULATORS; PATHWAY; SURGERY; BLOCKS
AB Osteogenesis associated with persistent inflammation or infection exists in a broad range of conditions including rheumatoid arthritis and traumatic bone fracture. The poor outcomes of these conditions will benefit from more effective treatments. Here we investigated the molecular mechanisms and tested NEMO binding domain peptide as a new approach of circumventing TNF alpha. inhibition of osteoblast differentiation. Our results showed: TNF alpha markedly decreased BMP 2 induced alkaline phosphatase activity in the multipotent myoblast C2C12 cells in a dose dependent manner; stepwise experiments demonstrated that BMP 2 induced Smad1 activity was abrogated by addition of exogenous TNF alpha or overexpression of NF kappa B, and it was significantly elevated by overexpression of I kappa B alpha, an inhibitor of NF kappa B; Western blotting showed that TNF alpha markedly decreased the amount of phospho Smad1 in BMP 2 activated C2C12 cells, but it did not alter Smad1 mRNA abundance as measured by real time PCR; addition of a functional cell permeable NEMO binding domain (NBD) peptide antagonized NF kappa B activity and ameliorated TNF alpha inhibition of osteoblast differentiation. Taken together, our study reveals for the first time that NF kappa B activation inhibits osteoblast differentiation by attenuating Smad1 activity and application of NBD peptide ameliorates this inhibitory effect. This could lead to new therapeutic drugs that circumvent the inflammatory inhibition of osteogenesis for treatment of traumatic open fractures with infection, rheumatoid arthritis and other bone loss disorders. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Li, Wenfeng; Yu, Bin; Hu, Yanjun] So Med Univ, Nanfang Hosp, Dept Orthoped Trauma, Guangzhou 510515, Guangdong, Peoples R China.
   [Li, Wenfeng; Li, Mengmeng; Sun, Daming; Hou, Shuxun] Gen Hosp Peoples Liberat Army, Affiliated Hosp 1, Dept Orthoped, Beijing 100037, Peoples R China.
   [Zhao, Ming] Vanderbilt Univ, Ctr Bone Biol, Nashville, TN 37232 USA.
   [Cui, Cai Bin] Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA.
C3 Southern Medical University   China; Vanderbilt University; University
   of North Carolina; University of North Carolina Chapel Hill
RP Yu, B (通讯作者)，So Med Univ, Nanfang Hosp, Dept Orthoped Trauma, Guangzhou 510515, Guangdong, Peoples R China.
EM yubin0001@gmail.com
RI hu, yanjun/ISA 0125 2023; Sun, Daming/K 3298 2013; Li,
   Wenfeng/KRQ 8098 2024
FU NSFC [30672133]
FX We thank Dr. Ruiyun Peng and Dr. Changyong Wang for helpful discussions.
   We also thank Ms. Yabing Gao and Dr. Hongyan Zuo for technical help.
   This work was supported by a research grant from NSFC (No. 30672133).
   The authors declare there was no conflict of interest related to the
   work.
CR Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200
   Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hiyama A, 2008, BIOCHEM BIOPH RES CO, V369, P679, DOI 10.1016/j.bbrc.2008.02.087
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   KATAGIRI T, 1995, J CELL BIOL, V128, pU8
   May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550
   Mukai T, 2007, BIOCHEM BIOPH RES CO, V356, P1004, DOI 10.1016/j.bbrc.2007.03.099
   Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Pande V, 2005, CURR MED CHEM, V12, P357, DOI 10.2174/0929867053363180
   Rihn JA, 2008, J BONE JOINT SURG AM, V90A, P2014
   Smith DM, 2008, J CRANIOFAC SURG, V19, P1244, DOI 10.1097/SCS.0b013e3181843312
   Strickland I, 2006, ANN RHEUM DIS, V65, P75, DOI 10.1136/ard.2006.058438
   Tsialogiannis E, 2009, EXPERT OPIN THER TAR, V13, P123, DOI 10.1517/14728220802637725 
   Wozney JM, 1998, EUR J ORAL SCI, V106, P160, DOI 10.1111/j.1600 0722.1998.tb02170.x
   Xiao YT, 2007, BIOCHEM BIOPH RES CO, V362, P550, DOI 10.1016/j.bbrc.2007.08.045
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Yamashita M, 2008, J ENDOCRINOL, V196, P601, DOI 10.1677/JOE 07 0532
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
   Zhu NL, 2007, GENE, V393, P70, DOI 10.1016/j.gene.2007.01.016
NR 24
TC 34
Z9 43
U1 1
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 8
PY 2010
VL 391
IS 2
BP 1228
EP 1233
DI 10.1016/j.bbrc.2009.12.048
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 548FI
UT WOS:000273944700015
PM 20006586
DA 2025 08 17
ER

PT J
AU Chen, HH
   Liu, NY
   Hu, SQ
   Li, X
   He, FZ
   Chen, LB
   Xu, XJ
AF Chen, Huanhuan
   Liu, Ningyue
   Hu, Shuqian
   Li, Xuan
   He, Fangzhou
   Chen, Liaobin
   Xu, Xiaojuan
TI Yeast β glucan based nanoparticles loading methotrexate promotes
   osteogenesis of hDPSCs and periodontal bone regeneration under the
   inflammatory microenvironment
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Yeast beta glucan based nanoparticles; Periodontitis; Macrophage
   transformation; Human dental pulp stem cells; Osteogenic differentiation
ID BAKERS YEAST; DIFFERENTIATION; DECTIN 1; LIPOPOLYSACCHARIDE;
   PROLIFERATION; MACROPHAGES; OSTEOCLAST; ACTIVATION; EXPRESSION; RECEPTOR
AB The regeneration of absorbed alveolar bone and reconstruction of periodontal support tissue are huge challenges in the clinical treatment of periodontitis due to the limited regenerative capacity of alveolar bone. It is essential to regulate inflammatory reaction and periodontal cell differentiation. Based on the anti inflammatory effect of baker's yeast beta glucan (BYG) with biosafety by targeting macrophages, the BYG based nanoparticles loading methotrexate (cBPM) were fabricated from polyethylene glycol grafted BYG through chemical crosslinking for treatment of periodontitis. In our findings, cBPM promoted osteogenesis of human dental pulp stem cells (hDPSCs) under inflammatory microenvironment, characterized by the enhanced expression of osteogenesisrelated Runx2 and activation of mitogen activated protein kinase/extracellular signal regulated protein kinase (MAPK/Erk) pathway in vitro. Animal experiments further demonstrate that cBPM effectively promoted periodontal bone regeneration and achieved in a better effect of recovery indicated by 19.2 % increase in tissue volume, 7.1 % decrease in trabecular separation, and a significant increase in percent bone volume and trabecular thickness, compared with the model group. Additionally, cBPM inhibited inflammation and repaired alveolar bone by transforming macrophage phenotype from inflammatory M1 to anti inflammatory M2. This work provides an alternative strategy for the clinical treatment of periodontitis through BYG based delivery nanoplatform of anti inflammatory drugs.
C1 [Chen, Huanhuan; Liu, Ningyue; Hu, Shuqian; Li, Xuan; He, Fangzhou; Chen, Liaobin; Xu, Xiaojuan] Wuhan Univ, Zhongnan Hosp, Coll Chem & Mol Sci, Dept Orthopaed Surg,Div Joint Surg & Sports Med, Wuhan 430072, Peoples R China.
   [Chen, Huanhuan] Wuhan Business Univ, Coll Food Sci & Technol, Wuhan 430056, Peoples R China.
C3 Wuhan University; Wuhan Business University
RP Chen, LB; Xu, XJ (通讯作者)，Wuhan Univ, Zhongnan Hosp, Coll Chem & Mol Sci, Dept Orthopaed Surg,Div Joint Surg & Sports Med, Wuhan 430072, Peoples R China.
EM liaobinchen@163.com; xuxj@whu.edu.cn
FU National Natural Science Foundation of China [21875167, 22075213,
   21574102]; Key R&D Program of Hubei Province [2020BCA079]; Doctoral
   Foundation Program of Wuhan Business University [2023KB002]
FX This work was financially supported by the National Natural Science
   Foundation of China (21875167, 22075213, and 21574102) , Key R&D Program
   of Hubei Province (2020BCA079) and Doctoral Foundation Program of Wuhan
   Business University (2023KB002) . The authors thank their laboratory
   members for their generous help and gratefully acknowledge the help of
   Ningyue Liu, Shuqian Hu, Fangzhou He and Xuan Li at College of Chemistry
   and Molecular Sciences of Wuhan University.
CR Bai JY, 2019, TRENDS FOOD SCI TECH, V88, P57, DOI 10.1016/j.tifs.2019.03.023
   Basha RY, 2020, MAT SCI ENG C MATER, V108, DOI 10.1016/j.msec.2019.110379
   Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Breivik T, 2005, J CLIN PERIODONTOL, V32, P347, DOI 10.1111/j.1600 051X.2005.00672.x
   Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470
   Castro ED, 2021, MOL NUTR FOOD RES, V65, DOI 10.1002/mnfr.201901071
   Cen X., 2021, Stem Cell Research & Therapy, V13, P1
   Chen FM, 2010, BIOMATERIALS, V31, P7892, DOI 10.1016/j.biomaterials.2010.07.019
   Chen HH, 2022, CARBOHYD POLYM, V284, DOI 10.1016/j.carbpol.2022.119183
   Chen ZT, 2014, BIOMATERIALS, V35, P8553, DOI 10.1016/j.biomaterials.2014.06.038
   Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742 2094 11 98
   Cochran DL, 2008, J PERIODONTOL, V79, P1569, DOI 10.1902/jop.2008.080233
   de Arruda AA, 2022, ANAEROBE, V75, DOI 10.1016/j.anaerobe.2022.102577
   Dominy SS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau3333
   Dumitrescu AL, 2004, J CLIN PERIODONTOL, V31, P596, DOI 10.1111/j.1600 051X.2004.00528.x
   Eleuterio E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071101
   Gan JJ, 2018, BIOMATERIALS, V178, P95, DOI 10.1016/j.biomaterials.2018.06.015
   Genco RJ, 2020, PERIODONTOL 2000, V83, P7, DOI 10.1111/prd.12344
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Hara S, 2021, J CELL PHYSIOL, V236, P5098, DOI 10.1002/jcp.30217
   Hou FS, 2022, CHEM ENG J, V427, DOI 10.1016/j.cej.2021.132000
   Huang R, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.19
   Jensen ED, 2010, BIOFACTORS, V36, P25, DOI 10.1002/biof.72
   Jia LL, 2017, INT J MED SCI, V14, P1118, DOI 10.7150/ijms.19814
   Kassebaum NJ, 2014, J DENT RES, V93, P1045, DOI 10.1177/0022034514552491
   Kayal RA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/639368
   Khayat A, 2017, J DENT RES, V96, P192, DOI 10.1177/0022034516682005
   Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400
   Kim HS, 2016, INT IMMUNOPHARMACOL, V39, P71, DOI 10.1016/j.intimp.2016.07.013
   Könönen E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081135
   Li DH, 2022, CHEM ENG J, V435, DOI 10.1016/j.cej.2022.134991
   Liu M, 2015, J IMMUNOL, V195, P5055, DOI 10.4049/jimmunol.1501158
   Liu YS, 2010, AMINO ACIDS, V38, P763, DOI 10.1007/s00726 009 0281 4
   Lübcke PM, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44512 9
   Luke AM, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2019.e03054
   Moentadj R, 2021, ANN RHEUM DIS, V80, P573, DOI 10.1136/annrheumdis 2020 219009
   Ni C, 2019, BIOMATERIALS, V206, P115, DOI 10.1016/j.biomaterials.2019.03.039
   Ping ZH, 2016, J MATER CHEM B, V4, P4565, DOI 10.1039/c6tb01299j
   Ren CX, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202100196
   Ren DP, 2015, J CELL PHYSIOL, V230, P2426, DOI 10.1002/jcp.24972
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Silva VD, 2017, NUTRIENTS, V9, DOI 10.3390/nu9091016
   Silva VD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134742
   Spagnuolo G, 2023, DENT MATER, V39, P485, DOI 10.1016/j.dental.2023.03.017
   Sun Y, 2019, CARBOHYD POLYM, V207, P371, DOI 10.1016/j.carbpol.2018.11.087
   Wang QY, 2022, INT J NANOMED, V17, P443, DOI 10.2147/IJN.S349238
   Welte Jzyk C, 2024, BMC ORAL HEALTH, V24, DOI 10.1186/s12903 024 04092 1
   Xiao CY, 2019, IUBMB LIFE, V71, P854, DOI 10.1002/iub.2016
   Xie G., 2008, Chinese Journal of Comparative Medicine, V18, P60
   Xing LP, 2005, BIOCHEM BIOPH RES CO, V328, P709, DOI 10.1016/j.bbrc.2004.11.072
   Yang YX, 2007, MOL IMMUNOL, V44, P984, DOI 10.1016/j.molimm.2006.03.013
   Yu M, 2023, CHEM ENG J, V454, DOI 10.1016/j.cej.2022.140141
   Zhai F, 2017, MOL MED REP, V16, P4127, DOI 10.3892/mmr.2017.7088
   Zhang S, 2024, CHEM SOC REV, V53, DOI 10.1039/d3cs00894k
   Zhang SJ, 2022, J NANOMATER, V2022, DOI 10.1155/2022/2063265
   Zhang WB, 2006, BIOMATERIALS, V27, P5658, DOI 10.1016/j.biomaterials.2006.07.013
   Zheng X, 2016, CARBOHYD POLYM, V148, P61, DOI 10.1016/j.carbpol.2016.04.044
NR 57
TC 6
Z9 6
U1 13
U2 31
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0144 8617
EI 1879 1344
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD OCT 15
PY 2024
VL 342
AR 122401
DI 10.1016/j.carbpol.2024.122401
EA JUN 2024
PG 12
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Polymer Science
GA K8N0E
UT WOS:001346395000001
PM 39048236
DA 2025 08 17
ER

PT J
AU Li, CJ
   Chang, JK
   Chou, CH
   Wang, GJ
   Ho, ML
AF Li, Ching Ju
   Chang, Je Ken
   Chou, Chia Hsuan
   Wang, Gwo Jaw
   Ho, Mei Ling
TI The PI3K/Akt/FOXO3a/p27<SUP>Kip1</SUP> signaling contributes to
   anti inflammatory drug suppressed proliferation of human osteoblasts
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Anti inflammatory drugs; Human osteoblasts; PI3K/Akt signal
   transduction; Forkhead box O (FOXO); p27(Kip1); Proliferation
ID CELL CYCLE ARREST; REGULATES P27(KIP1) EXPRESSION; FOXO TRANSCRIPTION
   FACTORS; PROSTATE CANCER CELLS; RHEUMATOID ARTHRITIS; CYCLOOXYGENASE 2
   INHIBITOR; CORTICOSTEROID THERAPY; ENDOTHELIAL CELLS; TUMOR SUPPRESSOR;
   GENE EXPRESSION
AB Akt has been reported to suppress p27(Kip1) promoter activity through Forkhead box O (FOXO) in different kinds of cells. Previous studies indicated that anti inflammatory drugs up regulated p27(Kip1), and this effect might play an important role in anti inflammatory drug induced cell cycle arrest of human osteoblasts (hOBs). In this study, we hypothesized that these drugs might increase p27(Kip1) expression in hOBs by altering the Akt/FOXO signaling. We tested this hypothesis by examining the influences of three anti inflammatory drugs on the levels and/or activities of Akt, FOXO and p27(Kip1) as well as the relationship between these factors and proliferation of hOBs. We tested the effects of indomethacin (10( 5) and 10( 4) M), celecoxib(10( 6) and 10( 5) M), and dexamethasone (10( 7) and 10( 6) M) using PI3K inhibitor, LY294002 (10( 5) M) as the basis of comparison. The three drugs suppressed the canonical level of phosphorylated Akt in hOBs. This was accompanied by elevated FOXO3a level and increased promoter activity, mRNA expression and protein level of p27(Kip1). Furthermore, the anti inflammatory drugs suppressed the EGF induced increases in proliferation, phosphorylation, and nucleus translocation of Akt. Simultaneously, they suppressed EGF induced decreases of FOXO3a nucleus accumulation and p27(Kip1) mRNA expression. On the other hand, FOXO silencing significantly attenuated the drug induced up regulation of p27(Kip1) and suppression of proliferation in hOBs. To the best of our knowledge, this study represents the first to demonstrate that Akt/FOXO3a/p27(Kip1) pathway contributes to suppression of hOB proliferation by anti inflammatory drugs. We suggest that anti inflammatory drugs suppress hOB proliferation, at least partly, through inactivating Akt, activating FOXO3a, and eventually up regulating p27(Kip1) expression. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Li, Ching Ju; Ho, Mei Ling] Kaohsiung Med Univ, Coll Med, Dept Physiol, Fac Med, Kaohsiung 807, Taiwan.
   [Chang, Je Ken; Wang, Gwo Jaw] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Orthopaed, Kaohsiung 807, Taiwan.
   [Li, Ching Ju; Ho, Mei Ling] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan.
   [Li, Ching Ju; Chang, Je Ken; Chou, Chia Hsuan; Wang, Gwo Jaw; Ho, Mei Ling] Kaohsiung Med Univ, Coll Med, Orthopaed Res Ctr, Kaohsiung 807, Taiwan.
   [Chang, Je Ken; Wang, Gwo Jaw] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Orthopaed, Kaohsiung 807, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Medical
   University; Kaohsiung Medical University Hospital
RP Ho, ML (通讯作者)，Kaohsiung Med Univ, Coll Med, Dept Physiol, Fac Med, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.
EM homelin@cc.kmu.edu.tw
RI Chang, Je Ken/A 1315 2010; Ho, Mei Ling/D 5515 2009
OI Ho, Mei Ling/0000 0001 8064 8488; 
FU Taiwan's National Health Research Institutes [NHRI EX96 98 9615EP];
   Technology Development Program for Academia in Taiwan
   [97 99 EC 17 A 17 S1 041]
FX We thank Dr. Sakai for providing the wild type and deleted
   p27<SUP>Kip1</SUP> promoter reporter constructs. This study was
   supported by a grant from Taiwan's National Health Research Institutes
   (NHRI EX96 98 9615EP) and the Technology Development Program for
   Academia in Taiwan (97 99 EC 17 A 17 S1 041).
CR Adachi M, 2007, GASTROENTEROLOGY, V132, P1434, DOI 10.1053/j.gastro.2007.01.033
   Ali F, 2007, J THROMB HAEMOST, V5, P2537, DOI 10.1111/j.1538 7836.2007.02787.x
   Arden KC, 2006, EXP GERONTOL, V41, P709, DOI 10.1016/j.exger.2006.05.015
   Basu GD, 2005, BREAST CANCER RES, V7, pR422, DOI 10.1186/bcr1019
   Boursinos LA, 2009, J MUSCULOSKEL NEURON, V9, P44
   Brenkman AB, 2008, CANCER RES, V68, P7597, DOI 10.1158/0008 5472.CAN 08 1059
   Chang JK, 2007, BIOCHEM PHARMACOL, V74, P1371, DOI 10.1016/j.bcp.2007.06.047
   Chang JK, 2009, TOXICOLOGY, V258, P148, DOI 10.1016/j.tox.2009.01.016
   Chang JK, 2005, CONNECT TISSUE RES, V46, P200, DOI 10.1080/03008200500344025
   Chrysis D, 2005, ENDOCRINOLOGY, V146, P1391, DOI 10.1210/en.2004 1152
   Chua CC, 2003, BBA MOL CELL RES, V1642, P79, DOI 10.1016/S0167 4889(03)00100 9
   Clemett D, 2000, DRUGS, V59, P957, DOI 10.2165/00003495 200059040 00017
   Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200
   COOPER C, 1995, ANN RHEUM DIS, V54, P49, DOI 10.1136/ard.54.1.49
   Corroyer S, 2002, PEDIATR RES, V51, P169, DOI 10.1203/00006450 200202000 00008
   Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138 9148.2000
   Drissi H, 1999, CANCER RES, V59, P3705
   Failor KL, 2007, MOL ENDOCRINOL, V21, P2403, DOI 10.1210/me.2007 0143
   Fernandes D, 1999, AM J RESP CELL MOL, V21, P77, DOI 10.1165/ajrcmb.21.1.3396
   Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24
   Fujita T, 2004, J CELL BIOCHEM, V93, P374, DOI 10.1002/jcb.20192
   Goldberg Y, 1996, ONCOGENE, V12, P893
   Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086
   Grösch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01 0299fje
   HO ML, 1995, CLIN ORTHOP RELAT R, P270
   Ho ML, 1999, BIOCHEM PHARMACOL, V58, P983, DOI 10.1016/S0006 2952(99)00186 0
   Ho ML, 1998, PHARMACOLOGY, V57, P148, DOI 10.1159/000028236
   Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397
   Hu YY, 2005, MOL BIOL CELL, V16, P3705, DOI 10.1091/mbc.E05 04 0301
   Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309
   Kim KJ, 2008, J BIOL CHEM, V283, P14032, DOI 10.1074/jbc.M800859200
   Kovarik JM, 1998, PHARMACOTHERAPY, V18, P1230
   Kucab JE, 2005, BREAST CANCER RES, V7, pR796, DOI 10.1186/bcr1294
   Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378 1119(96)00416 7
   LEES SJ, 2008, AM J PHYSL CELL PHYS
   Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433
   Lin HP, 2004, MOL CANCER THER, V3, P1671
   Liu B, 2008, CELL BIOL INT, V32, P494, DOI 10.1016/j.cellbi.2007.10.008
   Liu XS, 2008, NEOPLASIA, V10, P828, DOI 10.1593/neo.08408
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lynch RL, 2005, MOL CANCER RES, V3, P163, DOI 10.1158/1541 7786.MCR 04 0163
   Marinovic AC, 2002, J BIOL CHEM, V277, P16673, DOI 10.1074/jbc.M200501200
   Marinovic AC, 2007, AM J PHYSIOL RENAL, V292, pF660, DOI 10.1152/ajprenal.00178.2006
   Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115
   Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014 5793(97)00660 1
   Morrison TB, 1998, BIOTECHNIQUES, V24, P954
   Motti ML, 2005, AM J PATHOL, V166, P737, DOI 10.1016/S0002 9440(10)62295 X
   Nakao T, 2008, CELL CYCLE, V7, P257, DOI 10.4161/cc.7.2.5148
   Newton R, 1998, J BIOL CHEM, V273, P32312, DOI 10.1074/jbc.273.48.32312
   O'Connor JP, 2008, DRUG TODAY, V44, P693, DOI 10.1358/dot.2008.44.9.1251573
   OBERBAUER R, 1993, CLIN PHARMACOKINET, V24, P428, DOI 10.2165/00003088 199324050 00007
   Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd
   Otsubo T, 2008, BRIT J CANCER, V98, P824, DOI 10.1038/sj.bjc.6604193
   Piazza GA, 1997, CANCER RES, V57, P2452
   Reagan Shaw S, 2006, CANCER RES, V66, P1062, DOI 10.1158/0008 5472.CAN 05 1018
   SAAG KG, 1994, AM J MED, V96, P115, DOI 10.1016/0002 9343(94)90131 7
   Sakurai K, 2008, J NEUROSCI, V28, P4604, DOI 10.1523/JNEUROSCI.5074 07.2008
   Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023
   Sue YM, 2009, AM J PHYSIOL CELL PH, V297, pC321, DOI 10.1152/ajpcell.00069.2009
   Suzuki N, 2003, LIFE SCI, V73, P2237, DOI 10.1016/S0024 3205(03)00603 9
   Tan AG, 2007, FREE RADICAL RES, V41, P861, DOI 10.1080/10715760701199618
   Tang XY, 2008, J IMMUNOL, V180, P4793, DOI 10.4049/jimmunol.180.7.4793
   Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187
   Tsatsanis C, 2006, INT J BIOCHEM CELL B, V38, P1654, DOI 10.1016/j.biocel.2006.03.021
   VERSTRAETEN A, 1986, ANN RHEUM DIS, V45, P852, DOI 10.1136/ard.45.10.852
   Viereck V, 2003, J CLIN ENDOCR METAB, V88, P4206, DOI 10.1210/jc.2002 021877
   Vuolteenaho K, 2008, BASIC CLIN PHARMACOL, V102, P10, DOI 10.1111/j.1742 7843.2007.00149.x
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Wang XN, 2007, AM J PHYSIOL CELL PH, V292, pC1874, DOI 10.1152/ajpcell.00617.2006
   Wang YH, 2009, MOL THER, V17, P302, DOI 10.1038/mt.2008.267
   Wei Q, 2003, MOL CELL BIOL, V23, P4035, DOI 10.1128/MCB.23.12.4035 4045.2003
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wu T, 2004, MOL CANCER THER, V3, P299
   Yasumaru M, 2003, CANCER RES, V63, P6726
   Zhang GS, 2000, LEUKEMIA RES, V24, P385, DOI 10.1016/S0145 2126(99)00198 8
NR 76
TC 41
Z9 46
U1 0
U2 6
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAR 15
PY 2010
VL 79
IS 6
BP 926
EP 937
DI 10.1016/j.bcp.2009.10.019
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 550WZ
UT WOS:000274165500014
PM 19883628
DA 2025 08 17
ER

PT J
AU Jiang, T
   Gong, YH
   Zhang, WK
   Qiu, JX
   Zheng, XH
   Li, Z
   Yang, GY
   Hong, ZH
AF Jiang, Ting
   Gong, Yuhang
   Zhang, Wekang
   Qiu, Jianxin
   Zheng, Xiaohang
   Li, Ze
   Yang, Guangyong
   Hong, Zhenghua
TI PD0325901, an ERK inhibitor, attenuates RANKL induced osteoclast
   formation and mitigates cartilage inflammation by inhibiting the NF ?B
   and MAPK pathways
SO BIOORGANIC CHEMISTRY
LA English
DT Article
DE Osteoarthritis; Osteoclasts; Cartilage; IL 1?; PD0325901
ID ARTICULAR CARTILAGE; OSTEOARTHRITIS; APOPTOSIS; COLLAGEN; BONE
AB Osteoarthritis (OA), a degenerative disease affecting the joint, is characterized by degradation of the joint edge, cartilage injury, and subchondral bone hyperplasia. Treatment of early subchondral bone loss in OA can inhibit subsequent articular degeneration and improve the prognosis of OA. PD0325901, a specific inhibitor of ERK, is widely used in oncology and has potential as a therapeutic agent for osteoarthritis In this study, we investigated the biological function of PD0325901 in bone marrow monocytes/macrophages (BMMs)treated with RANKL and found that it inhibited osteoclast differentiation in vitro in a time  and dose dependent manner. PD0325901 restrained the expression of osteoclast marker genes, such as c Fos and NFATc1 induced by RANKL. We tested the biological effects of PD035901 on ATDC5 cells stimulated by IL 1 beta and found that it had protective effects on ATDC5 cells. In animal studies, we used a destabilization of the medial meniscus (DMM) model and injected 5 mg/kg or 10 mg/kg of PD0325901 compound into each experimental group of mice. We found that PD0325901 significantly reduced osteochondral pathological changes in post OA subchondral bone destruction.Finally, we found that PD0325901 down regulated the pyroptosis level in chondrocytes to rescue cartilage degeneration. Therefore, PD0325901 is expected to be a new generation alternative therapy for OA.
C1 [Yang, Guangyong; Hong, Zhenghua] Wenzhou Med Univ, Dept Orthoped, Taizhou Hosp, Linhai, Zhejiang, Peoples R China.
   Taizhou Hosp Zhejiang Prov, Bone Dev & Metab Res Ctr, Linhai, Zhejiang, Peoples R China.
C3 Wenzhou Medical University
RP Yang, GY; Hong, ZH (通讯作者)，Wenzhou Med Univ, Dept Orthoped, Taizhou Hosp, Linhai, Zhejiang, Peoples R China.
EM yanggy7689@enzemed.com; 0001hzh@163.com
RI Zhang, Hailiang/AAF 4937 2020
FU Basic Public Welfare Research Project of Zhejiang Province
   [LGF19H060004]; Medical Science and Technology Project of Zhejiang
   Province [2020KY347]; Science and Technology Planning Program of Taizhou
   City [1802KY04]
FX This research was partly supported by the Basic Public Welfare Research
   Project of Zhejiang Province (LGF19H060004) , Medical Science and
   Technology Project of Zhejiang Province (2020KY347) and Science and
   Technology Planning Program of Taizhou City (1802KY04) .
CR An SB, 2020, AGING DIS, V11, P1146, DOI 10.14336/AD.2019.1127
   Bai H, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6116890
   Bondeson J, 2008, CLIN EXP RHEUMATOL, V26, P139
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Carr AJ, 1999, OSTEOARTHR CARTILAGE, V7, P230, DOI 10.1053/joca.1998.0154
   Chen D, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.44
   Chen L, 2021, INT J BIOL SCI, V17, P4140, DOI 10.7150/ijbs.64152
   El Hoss J, 2014, BONE, V59, P151, DOI 10.1016/j.bone.2013.11.013
   Englund M, 2012, NAT REV RHEUMATOL, V8, P412, DOI 10.1038/nrrheum.2012.69
   Fan K, 2021, PEERJ, V9, DOI 10.7717/peerj.11609
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470 2045(05)70168 6
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Goldring MB, 2010, ANN NY ACAD SCI, V1192, P230, DOI 10.1111/j.1749 6632.2009.05240.x
   Guilak F, 2018, MATRIX BIOL, V71 72, P40, DOI 10.1016/j.matbio.2018.05.008
   Horton WE Jr, 1998, MATRIX BIOL, V17, P107, DOI 10.1016/S0945 053X(98)90024 5
   Hu Y, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00147 z
   Jenei Lanzl Z, 2019, CELL SIGNAL, V53, P212, DOI 10.1016/j.cellsig.2018.10.005
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Li SS, 2019, LAB INVEST, V99, P1321, DOI 10.1038/s41374 019 0252 7
   Li ZC, 2022, J INFLAMM RES, V15, P723, DOI 10.2147/JIR.S348491
   Mehana ESE, 2019, LIFE SCI, V234, DOI 10.1016/j.lfs.2019.116786
   Roux C, 2018, NAT REV RHEUMATOL, V14, P67, DOI 10.1038/nrrheum.2017.218
   Rucci N, 2016, MATRIX BIOL, V52 54, P176, DOI 10.1016/j.matbio.2016.02.009
   Schulze Tanzil G, 2019, CELLS BASEL, V8, DOI 10.3390/cells8090990
   Smida M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13701
   Starlinger J, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 01673 w
   Thummuri D, 2015, PHARMACOL RES, V99, P63, DOI 10.1016/j.phrs.2015.05.006
   Tiku ML, 2016, AGEING RES REV, V28, P62, DOI 10.1016/j.arr.2016.04.011
   Uehara Y, 2014, OSTEOARTHR CARTILAGE, V22, P1007, DOI 10.1016/j.joca.2014.04.025
   Varela Eirin M, 2018, AGEING RES REV, V42, P56, DOI 10.1016/j.arr.2017.12.006
   Wan YC, 2020, CURR MED CHEM, V27, P3753, DOI 10.2174/0929867326666181217153118
   Wang ZY, 2018, EXPERIENTIA SUPPL, V108, P281, DOI 10.1007/978 3 319 89390 7_12
   Yong HY, 2009, EXPERT OPIN INV DRUG, V18, P1893, DOI 10.1517/13543780903321490
   Yoshioka NK, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 13062 y
NR 34
TC 30
Z9 33
U1 0
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0045 2068
EI 1090 2120
J9 BIOORG CHEM
JI Bioorganic Chem.
PD MAR
PY 2023
VL 132
AR 106321
DI 10.1016/j.bioorg.2022.106321
EA JAN 2023
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 8H5PN
UT WOS:000921085400001
PM 36642020
OA hybrid
DA 2025 08 17
ER

PT J
AU Hao, YQ
   Lu, C
   Zhang, BG
   Xu, ZC
   Guo, H
   Zhang, GK
AF Hao, Yangquan
   Lu, Chao
   Zhang, Baogang
   Xu, Zhaochen
   Guo, Hao
   Zhang, Gaokui
TI CircPVT1 up regulation attenuates steroid induced osteonecrosis of the
   femoral head through regulating miR 21 5p mediated Smad7/TGFβ signalling
   pathway
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE ceRNA; circPVT1; miR&#8208; 21&#8208; 5p; osteonecrosis; steroid
ID CIRCULAR RNA; OSTEOGENIC DIFFERENTIATION; CELLS; BMSCS; PROLIFERATION;
   OSTEOBLASTS; SUPPRESSES; APOPTOSIS; CARTILAGE; NECROSIS
AB Steroid induced osteonecrosis of the femoral head (SIONFH) has been a common disease following corticosteroid therapy. Presently, we aim to explore the functions of circular RNA (circ) PVT1 in SIONFH rats and the underlying mechanism. Glucocorticoid (GC) was used to treat SD rats and bone marrow derived mesenchymal stem cells (BMSCs) to construct SIONFH model in vitro and in vivo, respectively. The pathological injury of the femoral head in the SIONFH rats was detected via haematoxylin eosin (HE) staining and immunohistochemistry (IHC). The osteogenic differentiation, proliferation and apoptosis of BMSCs were detected. Western blot was used to detect Smad7, Bax, Bcl2 and Smad2/3. The potential targets of circPVT1 and miR 21 5p were validated through luciferase reporter gene assay and RNA pull down assay, respectively. We found that CircPVT1 was decreased in the femoral head of SIONFH rats and GC treated BMSCs, while miR 21 5p was markedly up regulated. Overexpressed circPVT1 attenuated the apoptosis and cell viability inhibition of BMSCs induced by GC, while miR 21 5p up regulation had the opposite effects. What's more, the in vivo experiments confirmed that up regulating circPVT1 repressed osteonecrosis in SIONFH rats through repressing apoptosis. Mechanistically, circPVT1 functioned as a ceRNA of miR 21 5p, which targeted at the 3'untranslated region of Smad7. CircPVT1 enhancing Smad7 and mitigating GC activated TGF beta/Smad2/3 pathway through inhibiting miR 21 5p. In conclusion, CircPVT1 exerts protective effects against SIONFH via modulating miR 21 5p mediated Smad7/TGF beta pathway.
C1 [Hao, Yangquan; Lu, Chao; Zhang, Baogang; Xu, Zhaochen; Guo, Hao] Xi An Jiao Tong Univ, Hlth Sci Ctr, Honghui Hosp, Dept Osteonecrosis & Joint Reconstruct, 555 Youyi East Rd, Xian 710068, Peoples R China.
   [Zhang, Gaokui] Shaanxi Univ Chinese Med, Xian, Peoples R China.
C3 Xi'an Jiaotong University; Shaanxi University of Chinese Medicine
RP Hao, YQ (通讯作者)，Xi An Jiao Tong Univ, Hlth Sci Ctr, Honghui Hosp, Dept Osteonecrosis & Joint Reconstruct, 555 Youyi East Rd, Xian 710068, Peoples R China.
EM haoyangquan87@163.com
FU Shaanxi Provincial Department of Science and Technology [2020SF 287]
FX This work was supported by Shaanxi Provincial Department of Science and
   Technology (2020SF 287).
CR Bai YM, 2019, INT J MOL MED, V43, P850, DOI 10.3892/ijmm.2018.4007
   Che N, 2019, EUR REV MED PHARMACO, V23, P3183, DOI 10.26355/eurrev_201904_17676
   Chen CJ, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117924
   Chen GY, 2020, BONE, V133, DOI 10.1016/j.bone.2020.115258
   Chen WH, 2012, CHIN J INTEGR MED, V18, P378, DOI 10.1007/s11655 012 1086 y
   Chi GN, 2020, ARTIF CELL NANOMED B, V48, P188, DOI 10.1080/21691401.2019.1699825
   Chia WK, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2572 3
   Cui HM, 2019, MOL THER NUCL ACIDS, V14, P114, DOI 10.1016/j.omtn.2018.11.006
   Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555 012 9375 7
   Felten R, 2014, ANN INTERN MED, V161, P763, DOI 10.7326/L14 5026
   Gao X, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2530 0
   Grieco Giuseppina E., 2018, Non Coding RNA, V4, P37, DOI 10.3390/ncrna4040037
   Gu CX, 2016, SCI REP UK, V6, DOI 10.1038/srep38491
   Guerado E, 2016, INJURY, V47, pS16, DOI 10.1016/S0020 1383(16)30835 X
   Hao YQ, 2021, J CELL MOL MED, V25, P4608, DOI 10.1111/jcmm.16294
   He GS, 2019, EXP THER MED, V18, P312, DOI 10.3892/etm.2019.7570
   Hsiao KY, 2017, EXP BIOL MED, V242, P1136, DOI 10.1177/1535370217708978
   Jiang YN, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0334 7
   Jin D, 2018, AM J TRANSL RES, V10, P1498
   Kong LC, 2020, INT J BIOL SCI, V16, P655, DOI 10.7150/ijbs.38713
   Li Y, 2020, CLIN EXP PHARMACOL P, V47, P1291, DOI 10.1111/1440 1681.13273
   Lian F, 2018, CELL BIOL INT, V42, P931, DOI 10.1002/cbin.10957
   Liu BY, 2019, MAT SCI ENG C MATER, V99, P1123, DOI 10.1016/j.msec.2019.02.072
   Lukas D, 2017, P NATL ACAD SCI USA, V114, pE1480, DOI 10.1073/pnas.1615065114
   Ma SX, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 2145 y
   Macias MJ, 2015, TRENDS BIOCHEM SCI, V40, P296, DOI 10.1016/j.tibs.2015.03.012
   Mont MA, 2015, J BONE JOINT SURG AM, V97A, P1604, DOI 10.2106/JBJS.O.00071
   Moriya M, 2012, INT ORTHOP, V36, P2041, DOI 10.1007/s00264 012 1612 8
   Ouyang QQ, 2017, CELL PHYSIOL BIOCHEM, V42, P651, DOI 10.1159/000477883
   Piuzzi NS, 2019, CLEV CLIN J MED, V86, P511, DOI 10.3949/ccjm.86a.19004
   Shen SY, 2019, ANN RHEUM DIS, V78, P826, DOI 10.1136/annrheumdis 2018 214786
   Smieszek A, 2020, CELLS BASEL, V9, DOI 10.3390/cells9020479
   Wang A, 2018, GENE, V671, P103, DOI 10.1016/j.gene.2018.05.091
   Wang XB, 2019, MOL MED REP, V20, P2851, DOI 10.3892/mmr.2019.10497
   Wei QS, 2019, J ORTHOP TRANSL, V18, P65, DOI 10.1016/j.jot.2018.11.002
   Xiong YY, 2020, TRANSL RES, V215, P1, DOI 10.1016/j.trsl.2019.07.013
   Yan M, 2020, J CELL MOL MED, V24, P5593, DOI 10.1111/jcmm.15215
   Yan XH, 2009, ACTA BIOCH BIOPH SIN, V41, P263, DOI 10.1093/abbs/gmp018
   Zhang A, 2020, BONE JOINT RES, V9, P689, DOI 10.1302/2046 3758.910.BJR 2020 0140.R1
   Zheng FS, 2020, BIOMED PHARMACOTHER, V124, DOI 10.1016/j.biopha.2020.109828
   Zhu CY, 2019, BIOCHEM BIOPH RES CO, V516, P645, DOI 10.1016/j.bbrc.2019.06.073
   Zhu HM, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2447 7
   Zhu KP, 2018, INT J BIOL SCI, V14, P321, DOI 10.7150/ijbs.24360
   Zhu ZX, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/8759642
NR 44
TC 27
Z9 29
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD MAY
PY 2021
VL 25
IS 10
BP 4608
EP 4622
DI 10.1111/jcmm.16294
EA MAR 2021
PG 15
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA RZ2KW
UT WOS:000629874500001
PM 33733589
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Baertschi, S
   Baur, N
   Lueders Lefevre, V
   Voshol, J
   Keller, H
AF Baertschi, Stefan
   Baur, Nina
   Lueders Lefevre, Valerie
   Voshol, Johannes
   Keller, Hansjoerg
TI Class I and IIa Histone Deacetylases Have Opposite Effects on Sclerostin
   Gene Regulation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID CONTROLS CHONDROCYTE HYPERTROPHY; MEF2 TRANSCRIPTION FACTORS; MYOCYTE
   ENHANCER FACTOR 2; NUCLEAR EXPORT; PARATHYROID HORMONE; TRICHOSTATIN A;
   BONE FORMATION; INHIBITORS; DIFFERENTIATION; SOST
AB Adult bone mass is controlled by the bone formation repressor sclerostin (SOST). Previously, we have shown that intermittent parathyroid hormone (PTH) bone anabolic therapy involves SOST expression reduction by inhibiting myocyte enhancer factor 2 (MEF2), which activates a distant bone enhancer. Here, we extended our SOST gene regulation studies by analyzing a role of class I and IIa histone deacetylases (HDACs), which are known regulators of MEF2s. Expression analysis using quantitative PCR (qPCR) showed high expression of HDACs 1 and 2, lower amounts of HDACs 3, 5, and 7, low amounts of HDAC4, and no expression of HDACs 8 and 9 in constitutively SOST expressing UMR106 osteocytic cells. PTH induced Sost suppression was associated with specific rapid nuclear accumulation of HDAC5 and co localization with MEF2s in nuclear speckles requiring serine residues 259 and 498, whose phosphorylations control nucleocytoplasmic shuttling. Increasing nuclear levels of HDAC5 in UMR106 by blocking nuclear export with leptomycin B (LepB) or overexpression in transient transfection assays inhibited endogenous Sost transcription and reporter gene expression, respectively. This repressor effect of HDAC5 did not require catalytic activity using specific HDAC inhibitors. In contrast, inhibition of class I HDAC activities and expression using RNA interference suppressed constitutive Sost expression in UMR106 cells. An unbiased comprehensive search for involved HDAC targets using an acetylome analysis revealed several non histone proteins as candidates. These findings suggest that PTH mediated Sost repression involves nuclear accumulation of HDAC inhibiting the MEF2 dependent Sost bone enhancer, and class I HDACs are required for constitutive Sost expression in osteocytes.
C1 [Baertschi, Stefan; Lueders Lefevre, Valerie; Keller, Hansjoerg] Novartis Inst BioMed Res, Musculoskeletal Dis Area, CH 4056 Basel, Switzerland.
   [Baur, Nina; Voshol, Johannes] Novartis Inst BioMed Res, CH 4056 Basel, Switzerland.
C3 Novartis; Novartis
RP Keller, H (通讯作者)，WSJ 360 6 05, CH 4056 Basel, Switzerland.
EM hansjoerg.keller@novartis.com
CR Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bradner JE, 2010, NAT CHEM BIOL, V6, P238, DOI 10.1038/NCHEMBIO.313
   Buglio D, 2010, BRIT J HAEMATOL, V151, P387, DOI 10.1111/j.1365 2141.2010.08342.x
   Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Escaffit F, 2007, MOL CELL BIOL, V27, P554, DOI 10.1128/MCB.00869 06
   Fournel M, 2008, MOL CANCER THER, V7, P759, DOI 10.1158/1535 7163.MCT 07 2026
   Gao ZG, 2006, J BIOL CHEM, V281, P4540, DOI 10.1074/jbc.M507784200
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Glass DA, 2007, ENDOCRINOLOGY, V148, P2630, DOI 10.1210/en.2006 1372
   Grégoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273 2287.2005
   Grégoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882 06
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Harrison BC, 2004, MOL CELL BIOL, V24, P10636, DOI 10.1128/MCB.24.24.10636 10649.2004
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Huber K, 2011, J BIOL CHEM, V286, P22211, DOI 10.1074/jbc.M110.180224
   Johnson ML, 2007, CURR OPIN RHEUMATOL, V19, P376, DOI 10.1097/BOR.0b013e32816e06f9
   Jung HM, 2010, BIOMATERIALS, V31, P29, DOI 10.1016/j.biomaterials.2009.09.019
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779
   Kim HN, 2009, EUR J PHARMACOL, V623, P22, DOI 10.1016/j.ejphar.2009.09.025
   Kozhemyakina E, 2009, MOL CELL BIOL, V29, P5751, DOI 10.1128/MCB.00415 09
   Kramer I, 2010, TRENDS ENDOCRIN MET, V21, P237, DOI 10.1016/j.tem.2009.12.002
   Kramer I, 2010, J BONE MINER RES, V25, P178, DOI 10.1359/jbmr.090730
   Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136
   Kwon YJ, 2007, J BIOMOL SCREEN, V12, P621, DOI 10.1177/1087057107301319
   Pham L, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.216853
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Longworth MS, 2006, ONCOGENE, V25, P4495, DOI 10.1038/sj.onc.1209473
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Ma KW, 2005, MOL CELL BIOL, V25, P3575, DOI 10.1128/MCB.25.9.3575 3582.2005
   McGee Lawrence ME, 2011, GENE, V474, P1, DOI 10.1016/j.gene.2010.12.003
   McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593
   McKinsey TA, 2005, J CLIN INVEST, V115, P538, DOI 10.1172/JCI200524144
   McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968 0004(01)02031 X
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Nakamura T, 2005, J IMMUNOL, V175, P5809, DOI 10.4049/jimmunol.175.9.5809
   Nishino TG, 2008, BIOCHEM BIOPH RES CO, V377, P852, DOI 10.1016/j.bbrc.2008.10.079
   Ontoria JM, 2009, J MED CHEM, V52, P6782, DOI 10.1021/jm900555u
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Parra M, 2010, CURR OPIN PHARMACOL, V10, P454, DOI 10.1016/j.coph.2010.04.004
   Potthoff MJ, 2007, DEVELOPMENT, V134, P4131, DOI 10.1242/dev.008367
   Rahman MM, 2003, BLOOD, V101, P3451, DOI 10.1182/blood 2002 08 2622
   Rivadeneira F, 2009, NAT GENET, V41, P1199, DOI 10.1038/ng.446
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Soragni E, 2012, J CHILD NEUROL, V27, P1164, DOI 10.1177/0883073812448533
   Thomas EA, 2014, PHARMACEUTICALS, V7, P634, DOI 10.3390/ph7060634
   Urbich C, 2009, BLOOD, V113, P5669, DOI 10.1182/blood 2009 01 196485
   Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024
   Walkinshaw DR, 2008, J CELL BIOCHEM, V104, P1541, DOI 10.1002/jcb.21746
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Wu XY, 2001, J BIOL CHEM, V276, P24177, DOI 10.1074/jbc.M100412200
   Xu XA, 2010, J BIOL CHEM, V285, P18139, DOI 10.1074/jbc.C110.131599
   Yi T, 2007, EXP MOL MED, V39, P213, DOI 10.1038/emm.2007.24
   Zanella F, 2007, ASSAY DRUG DEV TECHN, V5, P333, DOI 10.1089/adt.2007.058
NR 58
TC 34
Z9 41
U1 1
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
SN 0021 9258
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 5
PY 2014
VL 289
IS 36
BP 24995
EP 25009
DI 10.1074/jbc.M114.564997
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA AP3OH
UT WOS:000341985300024
PM 25012661
OA Green Published
DA 2025 08 17
ER

PT J
AU Lee, HJ
   Wu, Q
   Li, H
   Bae, GU
   Kim, AK
   Ryu, JH
AF Lee, Hwa Jin
   Wu, Qian
   Li, Hua
   Bae, Gyu Un
   Kim, An Keun
   Ryu, Jae Ha
TI A sesquiterpene lactone from Siegesbeckia glabrescens suppresses
   Hedgehog/Gli mediated transcription in pancreatic cancer cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE Siegesbeckia glabrescens; compositae; sesquiterpene lactone; pancreatic
   cancer; Gli; Hedgehog pathway
ID SMALL MOLECULE INHIBITORS; SONIC HEDGEHOG; SIGNALING PATHWAY; OSTEOGENIC
   DIFFERENTIATION; IN VITRO; GLI1; GENES; GROWTH; COMBINATION; ACTIVATION
AB Pancreatic cancer is aggressive and therefore difficult to treat; however, continued efforts have been made with the aim of developing an effective therapy against the disease. The Hedgehog (Hh) signaling pathway is reportedly involved in the proliferation and survival of pancreatic cancer cells. The transcription factor glioma associated oncogene (Gli) is a key component of the Hh signaling pathway and the primary effector of pancreatic cancer development. Inhibiting Gli is a proven therapeutic strategy for this disease. The present study examined the regulation of Gli and the expression of its target genes to identify an inhibitor of the Sonic Hh (Shh) pathway. A germacranolide sesquiterpene lactone (GSL) was isolated from Siegesbeckia glabrescens as an inhibitor of Gli mediated transcription. The results demonstrated that GSL inhibited Shh induced osteoblast differentiation and Gli homolog 1 (Gli1) mediated transcriptional activity in mesenchymal C3H10T1/2 stem cells. Furthermore, GSL suppressed Gli mediated transcriptional activity in human pancreatic cancer PANC 1 and AsPC 1 cells, which resulted in reduced cancer cell proliferation and downregulated expression of the Gli target genes, Gli1 and cyclin D1. A sesquiterpene lactone from S. glabrescens may therefore serve as a candidate for the treatment of Hh/Gli dependent pancreatic cancer.
C1 [Lee, Hwa Jin] Semyung Univ, Dept Nat Med Resources, Jecheon 390711, Chungcheongbuk, South Korea.
   [Wu, Qian; Li, Hua; Bae, Gyu Un; Kim, An Keun; Ryu, Jae Ha] Sookmyung Womens Univ, Res Ctr Cell Fate Control, 52 Hyochangwon Gil, Seoul 140742, South Korea.
   [Wu, Qian; Li, Hua; Bae, Gyu Un; Kim, An Keun; Ryu, Jae Ha] Sookmyung Womens Univ, Coll Pharm, 52 Hyochangwon Gil, Seoul 140742, South Korea.
C3 Semyung University; Sookmyung Women's University; Sookmyung Women's
   University
RP Ryu, JH (通讯作者)，Sookmyung Womens Univ, Res Ctr Cell Fate Control, 52 Hyochangwon Gil, Seoul 140742, South Korea.; Ryu, JH (通讯作者)，Sookmyung Womens Univ, Coll Pharm, 52 Hyochangwon Gil, Seoul 140742, South Korea.
EM ryuha@sookmyung.ac.kr
FU National Research Foundation of Korea   Korean Government (MSIP)
   [2011 0030074, 2012R1A1A3013645]
FX The present study was supported by grants from the National Research
   Foundation of Korea funded by the Korean Government (MSIP) (nos.
   2011 0030074 and 2012R1A1A3013645).
CR Ailles L, 2011, CLIN CANCER RES, V17, P2071, DOI 10.1158/1078 0432.CCR 11 0211
   Akiyama H, 1997, BIOCHEM BIOPH RES CO, V235, P142, DOI 10.1006/bbrc.1997.6750
   Bahra M, 2012, PANCREAS, V41, P222, DOI 10.1097/MPA.0b013e31822896dd
   Bai CYB, 2001, DEVELOPMENT, V128, P5161
   Bisht S, 2010, CURR OPIN INVEST DR, V11, P1387
   Bosetti C, 2012, MOL CARCINOGEN, V51, P3, DOI 10.1002/mc.20785
   Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899
   Cho YR, 2013, ONCOL REP, V30, P221, DOI 10.3892/or.2013.2468
   Di Magno L, 2015, BBA REV CANCER, V1856, P62, DOI 10.1016/j.bbcan.2015.06.003
   Fendrich V, 2011, NEOPLASIA, V13, P923, DOI 10.1593/neo.11088
   Gill PS, 2006, CELL CYCLE, V5, P1426, DOI 10.4161/cc.5.13.2928
   Guo JF, 2013, CANCER LETT, V339, P185, DOI 10.1016/j.canlet.2013.06.010
   Hao K, 2013, ONCOL REP, V29, P1124, DOI 10.3892/or.2012.2210
   Hosoya T, 2008, CHEMBIOCHEM, V9, P1082, DOI 10.1002/cbic.200700511
   Hu MC, 2006, DEVELOPMENT, V133, P569, DOI 10.1242/dev.02220
   Hu WG, 2007, ACTA PHARMACOL SIN, V28, P1224, DOI 10.1111/j.1745 7254.2007.00620.x
   Hyman JM, 2009, P NATL ACAD SCI USA, V106, P14132, DOI 10.1073/pnas.0907134106
   Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601
   Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039
   Katoh Y, 2009, CURR MOL MED, V9, P873, DOI 10.2174/156652409789105570
   Katoh Y, 2006, INT J MOL MED, V18, P1019
   Kelleher FC, 2011, CARCINOGENESIS, V32, P445, DOI 10.1093/carcin/bgq280
   Kim WK, 2010, J CELL BIOCHEM, V111, P1199, DOI 10.1002/jcb.22846
   Kimura H, 2005, ONCOGENE, V24, P4026, DOI 10.1038/sj.onc.1208567
   Lauth M, 2007, CELL CYCLE, V6, P2458, DOI 10.4161/cc.6.20.4808
   Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104
   Lauth M, 2011, ADV CANCER RES, V110, P1, DOI 10.1016/B978 0 12 386469 7.00001 3
   Lee ST, 2014, J AGR FOOD CHEM, V62, P7355, DOI 10.1021/jf5005622
   Lee Y, 2007, ONCOGENE, V26, P6442, DOI 10.1038/sj.onc.1210467
   Li H, 2011, PHYTOTHER RES, V25, P1323, DOI 10.1002/ptr.3420
   LoRusso PM, 2011, CLIN CANCER RES, V17, P2502, DOI 10.1158/1078 0432.CCR 10 2745
   Mazumdar T, 2011, CANCER RES, V71, P5904, DOI 10.1158/0008 5472.CAN 10 4173
   Morton JP, 2007, P NATL ACAD SCI USA, V104, P5103, DOI 10.1073/pnas.0701158104
   Nakamura T, 1997, BIOCHEM BIOPH RES CO, V237, P465, DOI 10.1006/bbrc.1997.7156
   Onishi H, 2014, WORLD J GASTROENTERO, V20, P2335, DOI 10.3748/wjg.v20.i9.2335
   Park HL, 2000, DEVELOPMENT, V127, P1593
   Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365 2133.2005.06353.X
   Riobó NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103
   Schnidar H, 2009, CANCER RES, V69, P1284, DOI 10.1158/0008 5472.CAN 08 2331
   Stanton BZ, 2010, MOL BIOSYST, V6, P44, DOI 10.1039/b910196a
   Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0
   Tang JY, 2011, SEMIN CUTAN MED SURG, V30, pS14, DOI 10.1016/j.sder.2011.11.002
   Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009
   Thiyagarajan S, 2007, CANCER RES, V67, P10642, DOI 10.1158/0008 5472.CAN 07 2015
   Wang XD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054415
   Xie JW, 2013, ONCOTARGETS THER, V6, P1425, DOI 10.2147/OTT.S34678
   Xu XF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096441
   Zahreddine HA, 2014, NATURE, V511, P90, DOI 10.1038/nature13283
NR 48
TC 16
Z9 22
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD OCT
PY 2016
VL 12
IS 4
BP 2912
EP 2917
DI 10.3892/ol.2016.4994
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DZ1DN
UT WOS:000385579200104
PM 27698879
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, RH
   Su, S
   Xing, J
   Liu, K
   Zhao, YW
   Stangis, M
   Jacho, DP
   Yildirim Ayan, ED
   Gatto Weis, CM
   Chen, B
   Li, XH
AF Liu, Ruihua
   Su, Shang
   Xing, Jing
   Liu, Ke
   Zhao, Yawei
   Stangis, Mary
   Jacho, Diego P.
   Yildirim Ayan, Eda D.
   Gatto Weis, Cara M.
   Chen, Bin
   Li, Xiaohong
TI Tumor removal limits prostate cancer cell dissemination in bone and
   osteoblasts induce cancer cell dormancy through focal adhesion kinase
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE Prostate cancer; Bone metastases; tumor removal; Dormancy; Osteoblasts;
   Mitochondria; FAK
ID CARCINOMA CELLS; FAK INHIBITOR; MARROW; PHOSPHORYLATION; MECHANISMS;
   EXPRESSION; VIABILITY; APOPTOSIS; SURVIVAL; DISEASE
AB BackgroundDisseminated tumor cells (DTCs) can enter a dormant state and cause no symptoms in cancer patients. On the other hand, the dormant DTCs can reactivate and cause metastases progression and lethal relapses. In prostate cancer (PCa), relapse can happen after curative treatments such as primary tumor removal. The impact of surgical removal on PCa dissemination and dormancy remains elusive. Furthermore, as dormant DTCs are asymptomatic, dormancy induction can be an operational cure for preventing metastases and relapse of PCa patients.MethodsWe used a PCa subcutaneous xenograft model and species specific PCR to survey the DTCs in various organs at different time points of tumor growth and in response to tumor removal. We developed in vitro 2D and 3D co culture models to recapitulate the dormant DTCs in the bone microenvironment. Proliferation assays, fluorescent cell cycle reporter, qRT PCR, and Western Blot were used to characterize the dormancy phenotype. We performed RNA sequencing to determine the dormancy signature of PCa. A drug repurposing algorithm was applied to predict dormancy inducing drugs and a top candidate was validated for the efficacy and the mechanism of dormancy induction.ResultsWe found DTCs in almost all mouse organs examined, including bones, at week 2 post tumor cell injections. Surgical removal of the primary tumor reduced the overall DTC abundance, but the DTCs were enriched only in the bones. We found that osteoblasts, but not other cells of the bones, induced PCa cell dormancy. RNA Seq revealed the suppression of mitochondrial related biological processes in osteoblast induced dormant PCa cells. Importantly, the mitochondrial related biological processes were found up regulated in both circulating tumor cells and bone metastases from PCa patients' data. We predicted and validated the dormancy mimicking effect of PF 562,271 (PF 271), an inhibitor of focal adhesion kinase (FAK) in vitro. Decreased FAK phosphorylation and increased nuclear translocation were found in both co cultured and PF 271 treated C4 2B cells, suggesting that FAK plays a key role in osteoblast induced PCa dormancy.ConclusionsOur study provides the first insights into how primary tumor removal enriches PCa cell dissemination in the bones, defines a unique osteoblast induced PCa dormancy signature, and identifies FAK as a PCa cell dormancy gatekeeper.
C1 [Liu, Ruihua; Su, Shang; Zhao, Yawei; Stangis, Mary; Li, Xiaohong] Univ Toledo, Coll Med & Life Sci, Dept Cell & Canc Biol, 3000 Transverse Dr, Toledo, OH 43614 USA.
   [Xing, Jing; Liu, Ke; Chen, Bin] Michigan State Univ, Coll Human Med, Dept Pediat & Human Dev, Grand Rapids, MI 49503 USA.
   [Jacho, Diego P.; Yildirim Ayan, Eda D.] Univ Toledo, Bioengn Dept, Toledo, OH 43606 USA.
   [Gatto Weis, Cara M.] Univ Toledo, Coll Med & Life Sci, Dept Pathol, Toledo, OH 43614 USA.
   [Chen, Bin] Michigan State Univ, Dept Pharmacol & Toxicol, Grand Rapids, MI 49503 USA.
C3 University System of Ohio; University of Toledo; Michigan State
   University; Michigan State University College of Human Medicine;
   University System of Ohio; University of Toledo; University System of
   Ohio; University of Toledo; Michigan State University
RP Li, XH (通讯作者)，Univ Toledo, Coll Med & Life Sci, Dept Cell & Canc Biol, 3000 Transverse Dr, Toledo, OH 43614 USA.; Chen, B (通讯作者)，Michigan State Univ, Coll Human Med, Dept Pediat & Human Dev, Grand Rapids, MI 49503 USA.; Chen, B (通讯作者)，Michigan State Univ, Dept Pharmacol & Toxicol, Grand Rapids, MI 49503 USA.
EM chenbi12@msu.edu; xiaohong.li@utoledo.edu
RI Liu, Ruihua/JJC 9572 2023
OI Stangis, Mary/0000 0003 4139 0861
FU We thank Dr. Songpeng Zu from the University of California, San Diego,
   for his advice on statistical analyses and Mr. Shubhra Kanti Dey and Mr.
   Augustine Kwabil from the University of Toledo for technical support.
FX We thank Dr. Songpeng Zu from the University of California, San Diego,
   for his advice on statistical analyses and Mr. Shubhra Kanti Dey and Mr.
   Augustine Kwabil from the University of Toledo for technical support.
CR Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116
   Aguirre Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   Aguirre Ghiso JA, 2018, SCIENCE, V361, P1314, DOI 10.1126/science.aav0191
   Al Moraissi EA, 2017, J CRANIO MAXILL SURG, V45, P131, DOI 10.1016/j.jcms.2016.10.013
   Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227
   Bagi CM, 2008, CANCER AM CANCER SOC, V112, P2313, DOI 10.1002/cncr.23429
   Baylan N, 2013, BIOMED MATER, V8, DOI 10.1088/1748 6041/8/4/045011
   Becker M, 2002, BRIT J CANCER, V87, P1328, DOI 10.1038/sj.bjc.6600573
   Berruti A, 2000, J UROLOGY, V164, P1248, DOI 10.1016/S0022 5347(05)67149 2
   Boire A, 2019, TRENDS CANCER, V5, P762, DOI 10.1016/j.trecan.2019.10.010
   Borgen E, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058 018 1049 0
   Bray NL, 2016, NAT BIOTECHNOL, V34, P525, DOI 10.1038/nbt.3519
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Cackowski FC, 2017, J CELL BIOCHEM, V118, P891, DOI 10.1002/jcb.25768
   Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666
   Chéry L, 2014, ONCOTARGET, V5, P9939, DOI 10.18632/oncotarget.2480
   Conway T, 2012, BIOINFORMATICS, V28, pI172, DOI 10.1093/bioinformatics/bts236
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092 8674(00)80405 5
   Demicheli R, 2008, ANN ONCOL, V19, P1821, DOI 10.1093/annonc/mdn386
   Elsaadany M, 2017, BIOMECH MODEL MECHAN, V16, P1049, DOI 10.1007/s10237 017 0872 z
   Elsaadany M, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3609703
   Fares J, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 0134 x
   Federer Gsponer JR, 2020, PROSTATE, V80, P1108, DOI 10.1002/pros.24039
   Frankish A, 2021, NUCLEIC ACIDS RES, V49, pD916, DOI 10.1093/nar/gkaa1087
   Gao XL, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 5925 5
   Ge SX, 2020, BIOINFORMATICS, V36, P2628, DOI 10.1093/bioinformatics/btz931
   Ghiso JAA, 2002, ONCOGENE, V21, P2513, DOI 10.1038/sj/onc/1205342
   Giancotti FG, 2013, CELL, V155, P750, DOI 10.1016/j.cell.2013.10.029
   González Gualda E, 2021, FEBS J, V288, P56, DOI 10.1111/febs.15570
   Grant GD, 2018, CELL CYCLE, V17, P2496, DOI 10.1080/15384101.2018.1547001
   Greenbaum A, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah6518
   Hernandez Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001
   Huang SJ, 2022, AM J CANCER RES, V12, P1102
   Ivey NS, 2009, J NEUROVIROL, V15, P312, DOI 10.1080/13550280902998413
   Jakob M, 2021, STRAHLENTHER ONKOL, V197, P231, DOI 10.1007/s00066 020 01653 5
   Jung Y, 2021, NEOPLASIA, V23, P102, DOI 10.1016/j.neo.2020.11.009
   Khalil BD, 2022, J Exp Med, P219
   Khoo WH, 2019, BLOOD, V134, P30, DOI 10.1182/blood.2018880930
   Kim D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/s41587 019 0201 4
   Kluin RJC, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859 018 2353 5
   Köllermann J, 1999, INT J CANCER, V84, P145
   Kurppa KJ, 2020, CANCER CELL, V37, P104, DOI 10.1016/j.ccell.2019.12.006
   Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Lin HM, 2018, PROSTATE, V78, P308, DOI 10.1002/pros.23476
   Linxweiler J, 2022, Cancers (Basel), P14
   Manna F, 2019, Cold Spring Harb Perspect Med, P9
   Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917
   Molina JR, 2018, NAT MED, V24, P1036, DOI 10.1038/s41591 018 0052 4
   Muñoz F, 2001, FEBS LETT, V492, P156, DOI 10.1016/S0014 5793(01)02247 5
   Murray NP, 2012, INT J MOL MED, V30, P896, DOI 10.3892/ijmm.2012.1071
   Murray NP, 2020, TURK J UROL, V46, P360, DOI 10.5152/tud.2020.20147
   Murray NP, 2020, UROL J, V17, P262, DOI 10.22037/uj.v0i0.5174
   Murray NP, 2018, BIOL RES, V51
   Murray Nigel P, 2018, Asian Pac J Cancer Prev, V19, P229
   O'Brien S, 2014, ONCOTARGET, V5, P7945, DOI 10.18632/oncotarget.2381
   Owen KL, 2020, EMBO REP, V21, DOI 10.15252/embr.202050162
   Paschalis EP, 2003, J BONE MINER RES, V18, P1942, DOI 10.1359/jbmr.2003.18.11.1942
   Pfitzenmaier J, 2006, BJU INT, V97, P1309, DOI 10.1111/j.1464 410X.2006.06194.x
   Phan TG, 2020, NAT REV CANCER, V20, P398, DOI 10.1038/s41568 020 0263 0
   Quayle LA, 2021, Cancers (Basel), P13
   Rashid OM, 2013, SURGERY, V153, P771, DOI 10.1016/j.surg.2013.02.002
   Ren QH, 2022, BREAST CANCER RES, V24, DOI 10.1186/s13058 022 01503 5
   Risson E, 2020, NAT CANCER, V1, P672, DOI 10.1038/s43018 020 0088 5
   Roberts WG, 2008, CANCER RES, V68, P1935, DOI 10.1158/0008 5472.CAN 07 5155
   Ruppender NS, 2013, CANCER METAST REV, V32, P501, DOI 10.1007/s10555 013 9422 z
   Sartor O, 2018, NEW ENGL J MED, V378, P1653, DOI 10.1056/NEJMc1803343
   Sharma S, 2021, ONCOGENE, V40, P1012, DOI 10.1038/s41388 020 01565 9
   Shen W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163962
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Siegel RL, 2023, CA CANCER J CLIN, V73, P17, DOI [10.3322/caac.21763, 10.3322/caac.21820]
   Sosa MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7170
   Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793
   Sow Y, 2019, RES REP UROL, V11, P137, DOI 10.2147/RRU.S204507
   Stensland KD, 2022, J CLIN ONCOL, V40
   Su S, 2022, CANCER LETT, V525, P170, DOI 10.1016/j.canlet.2021.10.042
   Subramanian G, 2017, BIOTECHNOL BIOENG, V114, P1878, DOI 10.1002/bit.26304
   Sun HH, 2010, CANCER BIOL THER, V10, P38, DOI 10.4161/cbt.10.1.11993
   Thomas C, 2009, BJU INT, V104, P29, DOI 10.1111/j.1464 410X.2008.08298.x
   Thomsen MK, 2010, CANCER RES, V70, P979, DOI 10.1158/0008 5472.CAN 09 2370
   Troyano A, 2003, CELL DEATH DIFFER, V10, P889, DOI 10.1038/sj.cdd.4401249
   Tzaphlidou M, 2008, J BIOL PHYS, V34, P39, DOI 10.1007/s10867 008 9115 y
   Uhra JW, 2011, P NATL ACAD SCI USA, V108, P12396, DOI 10.1073/pnas.1106613108
   Vashist YK, 2012, ANN SURG, V255, P1105, DOI 10.1097/SLA.0b013e3182565b0b
   Venegas V, 2012, METHODS MOL BIOL, V837, P327, DOI 10.1007/978 1 61779 504 6_22
   Vera Ramirez L, 2020, SEMIN CANCER BIOL, V60, P28, DOI 10.1016/j.semcancer.2019.07.027
   Wang L, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/fpubh.2022.811044
   Weckermann D, 2001, J UROLOGY, V166, P699, DOI 10.1016/S0022 5347(05)66046 6
   Weckermann D, 2009, J CLIN ONCOL, V27, P1549, DOI 10.1200/JCO.2008.17.0563
   Whitburn J, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abf9096
   Xie ZR, 2021, CURR PROTOC, V1, DOI 10.1002/cpz1.90
   Yu Lee LY, 2018, CANCER RES, V78, P2911, DOI 10.1158/0008 5472.CAN 17 1051
   Yumoto K, 2016, SCI REP UK, V6, DOI 10.1038/srep36520
   Zeng B, 2021, NAT PROTOC, V16, DOI 10.1038/s41596 020 00430 z
NR 94
TC 10
Z9 10
U1 2
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756 9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD OCT 11
PY 2023
VL 42
IS 1
AR 264
DI 10.1186/s13046 023 02849 0
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA U3SZ9
UT WOS:001084042400002
PM 37821954
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liang, XN
   He, MW
   Zhu, B
   Zhu, YJ
   He, XX
   Liu, DC
   Wei, QJ
AF Liang, Xiaonan
   He, Mingwei
   Zhu, Bo
   Zhu, Yongjia
   He, Xixi
   Liu, Dachang
   Wei, Qingjun
TI TMT Based Proteomic Explores the Influence of DHEA on the Osteogenic
   Differentiation of hBMSCs
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE hBMSCs; DHEA; osteogenic differentiation; TMT; bioinformatic analysis
ID MESENCHYMAL STEM CELL; OSTEOBLAST DIFFERENTIATION; BONE; OSTEOPOROSIS;
   METABOLISM; EXPRESSION
AB Dehydroepiandrosterone (DHEA) has been revealed to implicate in facilitating osteoblast differentiation of human bone marrow mesenchymal stem cells (hBMSCs) and inhibiting osteoporosis (OP). However, the underlying molecular mechanism remains largely unknown. Here, we induced osteogenic differentiation of hBMSCs derived from elders using an osteogenic induction medium with or without DHEA. The results showed that osteogenic induction medium (OIM) with DHEA could significantly promote the proliferation and osteogenic differentiation of hBMSCs than OIM alone. By using a Tandem Mass Tag (TMT) labeling and liquid chromatography tandem mass spectrometry (LC MS/MS) technology, we screened out 604 differentially expressed proteins (DEPs) with at least one unique peptide were identified [524: OIM vs. complete medium (CM), and 547: OIM+DHEA vs. CM], among these proteins, 467 DEPs were shared in these two different comparative groups. Bioinformatic analysis revealed these DEPs are mainly enriched in metabolic pathways. Interestingly, the expression levels of the DEPs in the metabolic pathways showed a more noticeable change in the OIM+DHEA vs. CM group than OIM vs. CM group. Moreover, the protein protein interaction (PPI) network analysis revealed that three potential proteins, ATP5B, MT CYB, and MT ATP6, involved in energy metabolism, might play a key role in osteogenic differentiation induced by OIM+DHEA. These findings offer a valuable clue for us to better understand the underlying mechanisms involved in osteoblast differentiation of hBMSCs caused by DHEA and assist in applying DHEA in hBMSCs based therapy for osteogenic regeneration.</p>
C1 [Liang, Xiaonan; He, Xixi; Liu, Dachang; Wei, Qingjun] Guangxi Med Univ, Affiliated Hosp 1, Dept Orthoped Trauma & Hand Surg, Nanning, Peoples R China.
   [He, Mingwei] Guangxi Med Univ, Guangxi Collaborat Innovat Ctr Biomed, Nanning, Peoples R China.
   [Zhu, Bo] Guangxi Med Univ, Affiliated Hosp 1, Guangxi Engn Ctr Biomed Mat Tissue & Organ Regene, Nanning, Peoples R China.
   [Zhu, Yongjia] Guangxi Med Univ, Affiliated Hosp 1, Nanning Peoples Hosp 2, Nanning, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; Guangxi Medical University
RP Wei, QJ (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Dept Orthoped Trauma & Hand Surg, Nanning, Peoples R China.
EM weiqingjungxnn@163.com
RI He, Mingwei/AAV 7700 2020
FU National Natural Science Foundation of China [81560371]; Guangxi Key RD
   Program [GuiKeAB17292073]; Guangxi Natural Science Foundation of China
   [2019GXNSFAA245072]
FX This study was financially supported by the National Natural Science
   Foundation of China (Grant No. 81560371), the Guangxi Key R&D Program
   (Grant No. GuiKeAB17292073), and the Guangxi Natural Science Foundation
   of China (Grant No. 2019GXNSFAA245072).
CR Allolio B, 2002, TRENDS ENDOCRIN MET, V13, P288, DOI 10.1016/S1043 2760(02)00617 3
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Annamalai RT, 2019, BIOMATERIALS, V208, P32, DOI 10.1016/j.biomaterials.2019.04.001
   Çelebi B, 2009, J PROTEOME RES, V8, P2164, DOI 10.1021/pr800590g
   Chen XH, 2019, EUR REV MED PHARMACO, V23, P6352, DOI 10.26355/eurrev_201907_18459
   Ciapetti G, 2006, BIOMATERIALS, V27, P6150, DOI 10.1016/j.biomaterials.2006.08.025
   Demir D, 2014, J CLIN RES PEDIATR E, V6, P209, DOI [10.4274/Jcrpe.1601, 10.4274/jcrpe.1601]
   Dirckx N, 2019, NAT REV ENDOCRINOL, V15, P651, DOI 10.1038/s41574 019 0246 y
   Formoso G, 2006, MOL ENDOCRINOL, V20, P1153, DOI 10.1210/me.2005 0266
   Foster LJ, 2005, STEM CELLS, V23, P1367, DOI 10.1634/stemcells.2004 0372
   Franco Trepat E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081178
   Ginaldi Lia, 2005, Immun Ageing, V2, P14, DOI 10.1186/1742 4933 2 14
   Guntur AR, 2014, ENDOCRINOLOGY, V155, P1589, DOI 10.1210/en.2013 1974
   Ismail IT, 2019, METABOLITES, V9, DOI 10.3390/metabo9100242
   Kurpinski K, 2009, CELL MOL BIOENG, V2, P606, DOI 10.1007/s12195 009 0090 6
   Liang XN, 2016, J CELL BIOCHEM, V117, P1769, DOI 10.1002/jcb.25475
   Liu YW, 2019, BIOMATERIALS, V218, DOI 10.1016/j.biomaterials.2019.119336
   Lynn HS, 2005, OSTEOPOROSIS INT, V16, P1663, DOI 10.1007/s00198 005 1899 z
   Ma K, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951 020 00708 0
   Malik AK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013566
   Meleshina AV, 2016, SCI REP UK, V6, DOI 10.1038/srep21853
   Motyl KJ, 2017, TOXICOL PATHOL, V45, P887, DOI 10.1177/0192623317737065
   Moulder R, 2018, MASS SPECTROM REV, V37, P583, DOI 10.1002/mas.21550
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qiu XM, 2015, BIOSCI TRENDS, V9, P307, DOI 10.5582/bst.2015.01073
   Scheven BAA, 1997, LIFE SCI, V62, P59, DOI 10.1016/S0024 3205(97)01038 2
   Shen WC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10197 x
   Smith CO, 2021, STEM CELLS DEV, V30, P149, DOI 10.1089/scd.2020.0141
   Sze SK, 2007, MOL CELL PROTEOMICS, V6, P1680, DOI 10.1074/mcp.M600393 MCP200
   Tan FZ, 2019, EUR REV MED PHARMACO, V23, P81, DOI 10.26355/eurrev_201908_18633
   Thompson A, 2003, ANAL CHEM, V75, P1895, DOI 10.1021/ac0262560
   Voss PJ, 2018, ODONTOLOGY, V106, P469, DOI 10.1007/s10266 018 0362 5
   Wang DJ, 2004, J BIOL CHEM, V279, P43725, DOI 10.1074/jbc.M407368200
   Wang L, 2009, OSTEOPOROSIS INT, V20, P79, DOI 10.1007/s00198 008 0631 1
   Wang L, 2007, J MOL ENDOCRINOL, V38, P467, DOI 10.1677/jme.1.02173
   Wilson DF, 2017, J PHYSIOL LONDON, V595, P7023, DOI 10.1113/JP273839
   Wu QY, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00587
   Xie XY, 2017, SCI REP UK, V7, DOI 10.1038/srep42672
   Zhang C, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.658040
   Zhang LC, 2017, METHODS MOL BIOL, V1550, P185, DOI 10.1007/978 1 4939 6747 6_14
   Zhou Q, 2019, OSTEOPOROSIS INT, V30, P1089, DOI 10.1007/s00198 019 04884 0
   Zhou SH, 2017, ANN NY ACAD SCI, V1402, P43, DOI 10.1111/nyas.13464
NR 43
TC 4
Z9 4
U1 1
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD AUG 17
PY 2021
VL 9
AR 726549
DI 10.3389/fcell.2021.726549
PG 13
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA UM0QN
UT WOS:000693045400001
PM 34490274
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ding, WH
   Ji, RQ
   Yao, S
   Ruan, PF
   Ye, F
   Lou, XL
   Ni, LP
   Ji, YC
   Chen, J
   Ji, WF
AF Ding, WeiHang
   Ji, RuiQing
   Yao, Sai
   Ruan, PengFei
   Ye, Fei
   Lou, XiuLong
   Ni, LiPing
   Ji, YuChi
   Chen, Jie
   Ji, WeiFeng
TI Hu'po Anshen decoction promotes fracture healing in mice with traumatic
   brain injury through BMP2 COX2 ATF4 signaling pathway
SO FASEB JOURNAL
LA English
DT Article
DE bone morphogenetic protein 2; cyclooxygenase 2; fracture healing; Hu'po
   Anshen decoction; traumatic brain injury
ID GENE RELATED PEPTIDE; ATF4; CYCLOOXYGENASE 2; PHOSPHORYLATION;
   OSTEOBLASTS; CELLS; MODEL
AB Hu'po Anshen decoction (HPASD), a traditional Chinese medicine used to treat concussion and fracture, could regulate the expression of bone morphogenetic protein 2 (BMP2). However, whether HPASD affects the fracture healing of traumatic brain injury (TBI) combined with a fracture through BMP2 and its downstream signals remains obscure. The chondrocyte specific BMP2 conditional knockout mice and chondrocyte specific cyclooxygenase 2 (COX2) overexpression mice were generated. BMP2 conditional knockout mice were treated with fracture surgery, fracture combined with TBI, or fracture combined with TBI followed by different doses of HPASD (2.4, 4.8, and 9.6 g/kg), respectively. TBI was induced by Feeney's weight drop technique. The fracture callus formation and fracture sites were determined by X ray, micro CT, and histological analyses. The expressions of chondrocyte , osteoblast , and BMP2/COX2 signal related targets were determined by quantitative reverse transcription polymerase chain reaction (qRT PCR) and western blot assays. The specific absence of BMP2 in chondrocytes led to the prolonged formation of cartilage callus, a delay in the osteogenesis initiation and the downregulation of RUNX2, Smad1/5/9, EP4, ERK1/2, RSK2, ATF4. Overexpression of COX2 partially reverses the effects of chondrocyte specific BMP2 knockout mice. HPASD promoted cartilage callus formation and osteogenesis initiation, as accompanied by upregulated expression levels of RUNX2, Smad1/5/9, EP4, ERK1/2, RSK2, and ATF4 in a time dependent and concentration dependent manner in chondrocyte specific BMP2 knockout mice. Overall, our findings demonstrated that HPASD induced COX2 transcription through the BMP2 Smad1/5/9 RUNX2 axis, and then affected fracture healing through the COX2 mediated EP4 ERK1/2 RSK2 ATF4 axis.
C1 [Ding, WeiHang; Ruan, PengFei; Ye, Fei; Lou, XiuLong; Chen, Jie; Ji, WeiFeng] Zhejiang Chinese Med Univ, Dept Orthoped, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China.
   [Ji, RuiQing] Wenzhou Med Univ, Dept Anaesthesia, Clin Med Coll 2, Wenzhou, Peoples R China.
   [Yao, Sai] Zhejiang Chinese Med Univ, Dept Orthoped & Traumatol Tradit Chinese Med, Hangzhou, Zhejiang, Peoples R China.
   [Ni, LiPing] Hangzhou Womens Hosp, Dept Gynaecol & Obstet, Hangzhou, Zhejiang, Peoples R China.
   [Ji, YuChi] Guang xi Univ Chinese Med, Tradit Chinese Med, Fac Chinese Med Sci, Guangxi, Peoples R China.
   [Chen, Jie; Ji, WeiFeng] Zhejiang Chinese Med Univ, Dept Orthoped, Affiliated Hosp 1, 54, Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University; Wenzhou Medical University;
   Zhejiang Chinese Medical University; Zhejiang Chinese Medical University
RP Chen, J; Ji, WF (通讯作者)，Zhejiang Chinese Med Univ, Dept Orthoped, Affiliated Hosp 1, 54, Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.
EM zjszchenjie@163.com; jiweifeng1230@163.com
RI Zhang, Wei/JKI 3565 2023; ruan, pengfei/MCX 7230 2025; Ni,
   Liping/HZL 2258 2023
FU National Natural Science of China [81974576]
FX National Natural Science of China, Grant/Award Number: 81974576
CR Bratton A, 2018, J ORTHOP TRAUMA, V32, P288, DOI 10.1097/BOT.0000000000001160
   Chikazu D, 2002, J BONE MINER RES, V17, P1430, DOI 10.1359/jbmr.2002.17.8.1430
   Tam DNH, 2021, CURR NEUROPHARMACOL, V19, P193, DOI 10.2174/1570159X18666200507081531
   Dong YM, 2022, SPINE J, V22, P857, DOI 10.1016/j.spinee.2021.12.007
   Fu WJ, 2017, J ETHNOPHARMACOL, V195, P118, DOI 10.1016/j.jep.2016.11.015
   Huang SX, 2018, NEUROCHEM RES, V43, P1814, DOI 10.1007/s11064 018 2597 5
   Jeong YH, 2021, NUTRIENTS, V13, DOI 10.3390/nu13113690
   Joh B, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/379268
   Kim H, 2021, J BONE JOINT SURG AM, V103, P1402, DOI 10.2106/JBJS.20.01663
   Kim SA, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/6975646
   Lau KHW, 2013, BONE, V53, P369, DOI 10.1016/j.bone.2013.01.003
   Li TF, 2014, OSTEOARTHR CARTILAGE, V22, P481, DOI 10.1016/j.joca.2013.12.020
   Liu CY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01239
   Liu Fei, 2016, Nan Fang Yi Ke Da Xue Xue Bao, V36, P997
   Liu J, 2018, J ETHNOPHARMACOL, V210, P340, DOI 10.1016/j.jep.2017.08.037
   Liu YB, 2018, CELL CYCLE, V17, P2411, DOI 10.1080/15384101.2018.1526603
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luo YN, 2022, MOLECULES, V27, DOI 10.3390/molecules27061817
   Ma J, 2018, MED SCI MONITOR, V24, P2045, DOI 10.12659/MSM.905703
   Makowski AJ, 2014, BONE, V62, P1, DOI 10.1016/j.bone.2014.01.021
   McBride Gagyi SH, 2015, BONE, V81, P533, DOI 10.1016/j.bone.2015.09.003
   Mecollari V, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00328
   Mi M, 2013, GENE, V512, P211, DOI 10.1016/j.gene.2012.09.130
   Mollahosseini M, 2021, J MOL NEUROSCI, V71, P162, DOI 10.1007/s12031 020 01640 6
   Morioka K, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 48126 z
   Peng H, 2018, EUR REV MED PHARMACO, V22, P2519, DOI 10.26355/eurrev_201805_14914
   Qiu WX, 2020, J CELL MOL MED, V24, P317, DOI 10.1111/jcmm.14729
   Shen J, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.952696
   Song Y, 2017, EUR REV MED PHARMACO, V21, P1522
   Song Y, 2012, MOL MED REP, V5, P432, DOI 10.3892/mmr.2011.645
   Sum SW, 2019, J TRADIT CHIN MED, V39, P853
   Sun WP, 2021, BIOMED PHARMACOTHER, V138, DOI 10.1016/j.biopha.2021.111480
   Susperregui ARG, 2011, MOL ENDOCRINOL, V25, P1006, DOI 10.1210/me.2010 0515
   Toosi S, 2020, BIOFACTORS, V46, P326, DOI 10.1002/biof.1598
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Wang D, 2018, NEURAL REGEN RES, V13, P819, DOI 10.4103/1673 5374.232529
   Wang P, 2017, INT J BIOL SCI, V13, P996, DOI 10.7150/ijbs.19986
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wu J, 2021, PEERJ, V9, DOI 10.7717/peerj.10693
   Xia Z, 2020, ASN NEURO, V12, DOI 10.1177/1759091420910957
   Xu JK, 2022, BIOACT MATER, V8, P95, DOI 10.1016/j.bioactmat.2021.06.034
   Yuan HW, 2020, J ETHNOPHARMACOL, V261, DOI 10.1016/j.jep.2020.113043
   Zhang Chong, 2017, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V31, P885, DOI 10.7507/1002 1892.201612048
   Zhu ZH, 2019, MOLECULES, V24, DOI 10.3390/molecules24030460
NR 44
TC 5
Z9 6
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD JUN
PY 2023
VL 37
IS 6
AR e22952
DI 10.1096/fj.202201552RR
PG 18
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA F9SC7
UT WOS:000985663200001
PM 37159303
DA 2025 08 17
ER

PT J
AU Jiao, Y
   Mi, SC
   Li, XY
   Liu, YT
   Han, NN
   Xu, JJ
   Liu, Y
   Li, S
   Guo, LJ
AF Jiao, Yao
   Mi, Sicong
   Li, Xiaoyan
   Liu, Yitong
   Han, Nannan
   Xu, Junji
   Liu, Yi
   Li, Song
   Guo, Lijia
TI MicroRNA 155 targets SOCS1 to inhibit osteoclast differentiation during
   orthodontic tooth movement
SO BMC ORAL HEALTH
LA English
DT Article
DE MicroRNA 155; Osteoclast; Orthodontics; Monocyte
ID LASER THERAPY; MIR 155; CELLS
AB BackgroundMicroRNA 155 (miR 155) is a multifunctional miRNA whose expression is known to be involved in a range of physiological and pathological processes. Its association with several oral diseases has been established. However, the specific role of miR 155 in orthodontic tooth movement remains unclear. In this study, we investigated the impact of miR 155 on osteoclast differentiation and orthodontic tooth movement models, aiming to explore the underlying mechanisms.MethodsIn this experiment, we utilized various agents including miR 155 mimic, miR 155 inhibitor, as well as non specific sequences (NC mimic & NC inhibitor) to treat murine BMMNCs. Subsequently, osteoclast induction (OC) was carried out to examine the changes in the differentiation ability of monocytes under different conditions. To assess these changes, we employed RT PCR, Western blotting, and TRAP staining techniques. For the orthodontic tooth movement model in mice, the subjects were divided into two groups: the NaCl group (injected with saline solution) and the miR 155 inhibitor group (injected with AntagomiR 155). We observed the impact of orthodontic tooth movement using stereoscopic microscopy, micro CT, and HE staining. Furthermore, we performed RT PCR and Western blotting analyses on the tissues surrounding the moving teeth. Additionally, we employed TargetScan to predict potential target genes of miR 155.ResultsDuring osteoclast induction of BMMNCs, the expression of miR 155 exhibited an inverse correlation with osteoclast related markers. Overexpression of miR 155 led to a decrease in osteoclast related indexes, whereas underexpression of miR 155 increased those indexes. In the mouse orthodontic tooth movement model, the rate of tooth movement was enhanced following injection of the miR 155 inhibitor, leading to heightened osteoclast activity. TargetScan analysis identified SOCS1 as a target gene of miR 155.ConclusionsOur results suggest that miR 155 functions as an inhibitor of osteoclast differentiation, and it appears to regulate osteoclasts during orthodontic tooth movement. The regulatory mechanism of miR 155 in this process involves the targeting of SOCS1.
C1 [Jiao, Yao; Li, Xiaoyan; Liu, Yitong; Han, Nannan; Xu, Junji; Liu, Yi] Capital Med Univ, Sch Stomatol, Dept Periodont, Tian Tan Xi Li 4, Beijing 100050, Peoples R China.
   [Mi, Sicong] Fourth Mil Med Univ, Air Force Med Ctr, Dept Stomatol, PLA, Beijing 100142, Peoples R China.
   [Li, Xiaoyan; Liu, Yitong; Han, Nannan; Xu, Junji; Liu, Yi] Capital Med Univ, Lab Tissue Regenerat & Immunol, Beijing Key Lab Tooth Regenerat & Funct Reconstruc, Dept Periodont,Sch Stomatol, Beijing 100050, Peoples R China.
   [Li, Song] Capital Med Univ, Sch Stomatol, Dept Orthodont, Tian Tan Xi Li 4, Beijing 100050, Peoples R China.
   [Guo, Lijia] Capital Med Univ, Sch Stomatol, Dept Orthodont WangFuJing Campus, Scylla Alley 11, Beijing 100006, Peoples R China.
C3 Capital Medical University; Air Force Medical University; Capital
   Medical University; Capital Medical University; Capital Medical
   University
RP Li, S (通讯作者)，Capital Med Univ, Sch Stomatol, Dept Orthodont, Tian Tan Xi Li 4, Beijing 100050, Peoples R China.; Guo, LJ (通讯作者)，Capital Med Univ, Sch Stomatol, Dept Orthodont WangFuJing Campus, Scylla Alley 11, Beijing 100006, Peoples R China.
EM dentistli@263.net; drguolijia@163.com
RI Xu, Junji/K 5691 2013
FU National Key R&D Program of China [2022YFC2504201]; Beijing Municipal
   Administration of Hospitals Incubating Program [PX2023054]; Innovation
   Foundation of Beijing Stomatological Hospital, Capital Medical
   University [21 09 18]
FX This work was supported by grants from National Key R & D Program of
   China (Grant NO. 2022YFC2504201 to Lijia Guo), the Beijing Municipal
   Administration of Hospitals Incubating Program (PX2023054 to Lijia Guo),
   the Innovation Foundation of Beijing Stomatological Hospital, Capital
   Medical University (21 09 18 to Lijia Guo).
CR Alghamdi B, 2023, CURR OSTEOPOROS REP, V21, P128, DOI 10.1007/s11914 023 00774 x
   Alsino HI, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.24985
   Ambros V, 2007, DEVELOPMENT, V134, P1635, DOI 10.1242/dev.002006
   Bayraktar R, 2018, CANCER METAST REV, V37, P33, DOI 10.1007/s10555 017 9724 7
   Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590
   Cao H, 2014, J DENT RES, V93, P1163, DOI 10.1177/0022034514551769
   Chang JH, 2020, EUR J ORTHODONT, V42, P317, DOI 10.1093/ejo/cjz027
   Cirillo F, 2020, HORM RES PAEDIAT, V93, P7, DOI 10.1159/000504669
   Cruz DR, 2004, LASER SURG MED, V35, P117, DOI 10.1002/lsm.20076
   Elton TS, 2013, GENE, V532, P1, DOI 10.1016/j.gene.2012.12.009
   Emami N, 2020, J KOR ASSOC ORAL MAX, V46, P341, DOI 10.5125/jkaoms.2020.46.5.341
   Fini MB, 2020, J LASERS MED SCI, V11, P204, DOI 10.34172/jlms.2020.34
   Guo HD, 2022, ADV SCI, V9, DOI 10.1002/advs.202200978
   Husain A, 2017, CURR OSTEOPOROS REP, V15, P450, DOI 10.1007/s11914 017 0391 y
   Jiang HT, 2021, J PERIODONTAL RES, V56, P761, DOI 10.1111/jre.12875
   Kapoor P, 2021, PROG ORTHOD, V22, DOI 10.1186/s40510 021 00377 1
   Keser E, 2022, MAX PLAST RECONSTR S, V44
   Lee Y, 2011, BIOMOL THER, V19, P141, DOI 10.4062/biomolther.2011.19.2.141
   Li XY, 2017, BIOCHEM BIOPH RES CO, V493, P928, DOI 10.1016/j.bbrc.2017.09.119
   Li Y, 2021, INT J ORAL SCI, V13, DOI 10.1038/s41368 021 00125 5
   Liu HX, 2018, INT J MOL MED, V41, P3379, DOI 10.3892/ijmm.2018.3526
   Nie M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.165
   Nimeri G, 2013, PROG ORTHOD, V14, DOI 10.1186/2196 1042 14 42
   Ohishi M, 2005, J IMMUNOL, V174, P3024, DOI 10.4049/jimmunol.174.5.3024
   Olmedo Hernández OL, 2022, LASER MED SCI, V37, P2323, DOI 10.1007/s10103 022 03538 8
   Pepin Genevieve, 2016, Microrna, V5, P167
   Simonson B, 2015, MINI REV MED CHEM, V15, P467, DOI 10.2174/1389557515666150324123208
   Tsichlaki A, 2016, AM J ORTHOD DENTOFAC, V149, P308, DOI 10.1016/j.ajodo.2015.09.020
   Wang Y., 2018, Biosci Rep, V38
   Wienholds E, 2005, FEBS LETT, V579, P5911, DOI 10.1016/j.febslet.2005.07.070
   Wu P, 2021, AM J TRANSL RES, V13, P6670
   Xin P, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2020.106210
   Zhang J, 2012, FEBS LETT, V586, P3255, DOI 10.1016/j.febslet.2012.06.047
NR 33
TC 1
Z9 1
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472 6831
J9 BMC ORAL HEALTH
JI BMC Oral Health
PD DEC 1
PY 2023
VL 23
IS 1
AR 955
DI 10.1186/s12903 023 03443 8
PG 14
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA Z5VP0
UT WOS:001112751300002
PM 38041017
OA gold
DA 2025 08 17
ER

PT J
AU Wang, YP
   Yang, X
   Gu, ZP
   Qin, HH
   Li, L
   Liu, JW
   Yu, XX
AF Wang, Yaping
   Yang, Xu
   Gu, Zhipeng
   Qin, Huanhuan
   Li, Li
   Liu, Jingwang
   Yu, Xixun
TI In vitro study on the degradation of lithium doped hydroxyapatite for
   bone tissue engineering scaffold
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Li doped hydroxyapatite (LiHA) scaffolds; In vitro solution mediated
   degradation; In vitro osteoblast mediated degradation; Bioactivity; Bone
   tissue engineering
ID BIOACTIVE GLASS; TRICALCIUM PHOSPHATE; DRUG DELIVERY; BIOMATERIALS
AB Li doped hydroxyapatite (LiHA) which is prepared through introducing low dose of Li into hydroxyapatite (HA) has been increasingly studied as a bone tissue engineered scaffold. The degradation properties play a crucial role in the success of long term implantation of a bone tissue engineered construct. Herein, the in vitro degradation behaviors of LiHA scaffolds via two approaches were investigated in this study: solution mediated degradation and osteoblast mediated degradation. In solution mediated degradation, after being immersed in simulated body fluid (SBF) for some time, some characteristics of these scaffolds (such as release of ionized lithium and phosphate, pH change, mechanical properties, cytocompatibility and SEM surface characterization) were systematically tested. A similar procedure was also employed to research the degradation behaviors of LiHA scaffolds in osteoblast mediated degradation. The results suggested that the degradation in SBF and degradation in culture medium with cell existed distinguishing mechanisms. LiHA scaffolds were degraded via a hydrolytic mechanism when they were soaked in SBF. Upon degradation, an apatite precipitation (layer) was formed on the surfaces of scaffolds. While a biological mechanism was presented for the degradation of scaffolds in cell mediated degradation. Compared with pure HA, LiHA scaffolds had a better effect on the growth of osteoblast cells, meanwhile, the release amount of PO43  in a degradation medium indicated that osteoblasts could accelerate the degradation of LiHA due to the more physiological activities of osteoblast. According to the results from compressive strength test, doping Li into HA could enhance the strength of HA. Moreover, the results from MIT assay and SEM observation showed that the degradation products of LiHA scaffolds were beneficial to the proliferation of osteoblasts. The results of this research can provide the theoretical basis for the clinical application of LiHA scaffolds. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Wang, Yaping; Yang, Xu; Gu, Zhipeng; Qin, Huanhuan; Liu, Jingwang; Yu, Xixun] Sichuan Univ, Coll Polymer Sci & Engn, Chengdu 610065, Peoples R China.
   [Li, Li] 452 Hosp Chinese PIA, Dept Oncol, Chengdu 610021, Sichuan, Peoples R China.
C3 Sichuan University
RP Yu, XX (通讯作者)，Sichuan Univ, Coll Polymer Sci & Engn, Chengdu 610065, Peoples R China.
EM yuxixun@163.com
RI Gu, Zhipeng/E 5108 2013; Gu, Zhi peng/E 5108 2013
OI Yu, Xixun/0000 0002 2301 8727; Gu, Zhi peng/0000 0003 4533 6539
FU Scientific and Technological Project of Sichuan Province [2012SZ0015];
   Scientific and Technological Project of Chengdu [2014 HM01 00207 SF];
   Sichuan University Luzhou Strategic Partnership Scientific and
   Technological Cooperation Projects [2014CDLZ S27]
FX The authors would like to thank the Scientific and Technological Project
   of Sichuan Province (No. 2012SZ0015), the Scientific and Technological
   Project of Chengdu (No. 2014 HM01 00207 SF) and Sichuan
   University Luzhou Strategic Partnership Scientific and Technological
   Cooperation Projects (No. 2014CDLZ S27).
CR Abd Al Hay A, 2014, CHEM ENG J, V254, P612, DOI 10.1016/j.cej.2014.05.118
   Barralet J, 2002, J MATER SCI MATER M, V13, P529, DOI 10.1023/A:1015175108668
   Barralet J, 1998, J BIOMED MATER RES, V41, P79, DOI 10.1002/(SICI)1097 4636(199807)41:1<79::AID JBM10>3.0.CO;2 C
   Basu B, 2013, RSC ADV, V3, P14622, DOI 10.1039/c3ra42369g
   Boccaccini AR, 2003, J BIOMED MATER RES B, V67B, P618, DOI 10.1002/jbm.b.10047
   Chen JD, 2011, MATER LETT, V65, P1923, DOI 10.1016/j.matlet.2011.03.076
   Chen QZ, 2012, PROG BIOMATER, V1, DOI 10.1186/2194 0517 1 2
   Dorozhkin SV, 2013, MATERIALS, V6, P3840, DOI 10.3390/ma6093840
   Fanovich MA, 1998, MATER LETT, V33, P269, DOI 10.1016/S0167 577X(97)00115 8
   Fathi MH, 2008, J MATER PROCESS TECH, V202, P536, DOI 10.1016/j.jmatprotec.2007.10.004
   Fu QA, 2010, J BIOMED MATER RES A, V95A, P164, DOI 10.1002/jbm.a.32824
   Gerhardt LC, 2010, MATERIALS, V3, P3867, DOI 10.3390/ma3073867
   Gibson IR, 2002, J BIOMED MATER RES, V59, P697, DOI 10.1002/jbm.10044
   Gough JE, 2004, J BIOMED MATER RES A, V68A, P640, DOI 10.1002/jbm.a.20075
   Gu ZP, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/6/065007
   HASSAN AR, 2013, INT J CURR ENG TECHN, V3, P1600
   HENCH LL, 1979, BIOMATER ARTIF CELL, V7, P339, DOI 10.3109/10731197909117590
   Holy CE, 1999, BIOMATERIALS, V20, P1177, DOI 10.1016/S0142 9612(98)00256 7
   Kailasanathan C, 2012, CERAM INT, V38, P571, DOI 10.1016/j.ceramint.2011.07.045
   Kamitakahara M, 2008, J BIOMATER APPL, V23, P197, DOI 10.1177/0885328208096798
   Kaygili O, 2013, POWDER TECHNOL, V245, P1, DOI 10.1016/j.powtec.2013.04.012
   KOKUBO T, 1990, J NON CRYST SOLIDS, V120, P138, DOI 10.1016/0022 3093(90)90199 V
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Kolmas J, 2011, J MOL STRUCT, V987, P40, DOI 10.1016/j.molstruc.2010.11.058
   KOUTSOUKOS PG, 1986, COLLOID SURFACE, V17, P361, DOI 10.1016/0166 6622(86)80259 1
   LeGeros R.Z., 1970, DEV APPL SPECTROSCOP, V7B, P3
   Lei Y, 2007, MAT SCI ENG C BIO S, V27, P293, DOI 10.1016/j.msec.2006.05.006
   Liu F, 2011, J MATER SCI MATER M, V22, P683, DOI 10.1007/s10856 011 4247 1
   Matsumoto N, 2009, MATER RES BULL, V44, P1889, DOI 10.1016/j.materresbull.2009.05.012
   MAYER I, 1986, CALCIFIED TISSUE INT, V38, P293, DOI 10.1007/BF02556609
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Mohammad NF, 2014, REV ADV MATER SCI, V38, P138
   Mostafa NY, 2011, J AM CERAM SOC, V94, P1584, DOI 10.1111/j.1551 2916.2010.04282.x
   Mouriño V, 2010, J R SOC INTERFACE, V7, P209, DOI 10.1098/rsif.2009.0379
   Natalie S., 2000, SKELETAL GROWTH FACT, P1
   Navarro M, 2008, J R SOC INTERFACE, V5, P1137, DOI 10.1098/rsif.2008.0151
   Nimkerdphol AR, 2014, J MECH BEHAV BIOMED, V36, P98, DOI 10.1016/j.jmbbm.2014.04.007
   Oktar FN, 1999, ARTIF CELL BLOOD SUB, V27, P367, DOI 10.3109/10731199909117706
   Padmanabhan SK, 2009, PARTICUOLOGY, V7, P466, DOI 10.1016/j.partic.2009.06.008
   Palmer LC, 2008, CHEM REV, V108, P4754, DOI 10.1021/cr8004422
   Rajabi Zamani AH, 2008, MAT SCI ENG C BIO S, V28, P1326, DOI 10.1016/j.msec.2008.02.001
   Satija NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055769
   Shainberg APM, 2012, ADV MATER SCI ENG, V2012, DOI 10.1155/2012/650574
   Sopyan I, 2011, MATER MANUF PROCESS, V26, P908, DOI 10.1080/10426914.2011.557285
   Sun F, 2011, ACTA BIOMATER, V7, P3813, DOI 10.1016/j.actbio.2011.07.002
   Tang GH, 2011, J DENT RES, V90, P336, DOI 10.1177/0022034510389180
   Tavakol S, 2014, J NANOPART RES, V16, DOI 10.1007/s11051 014 2622 9
   Thamaraiselvi T.V., 2004, TRENDS BIOMATER ARTI, V18, P9, DOI DOI 10.1.1.470.4214
   Wang QB, 2011, CERAM SILIKATY, V55, P43
NR 49
TC 79
Z9 84
U1 1
U2 103
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD SEP 1
PY 2016
VL 66
BP 185
EP 192
DI 10.1016/j.msec.2016.04.065
PG 8
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA DO4FK
UT WOS:000377737000022
PM 27207053
DA 2025 08 17
ER

PT J
AU Liu, Y
   Wang, ZH
   Ju, MY
   Zhao, YX
   Jing, YQ
   Li, JC
   Shao, CY
   Fu, T
   Lv, Z
   Li, G
AF Liu, Yi
   Wang, Zihan
   Ju, Mingyan
   Zhao, Yuxia
   Jing, Yaqing
   Li, Jiaci
   Shao, Chenyi
   Fu, Ting
   Lv, Zhe
   Li, Guang
TI Modification of COL1A1 in Autologous Adipose Tissue Derived
   Progenitor Cells Rescues the Bone Phenotype in a Mouse Model of
   Osteogenesis Imperfecta
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ADIPOSE&#8208; DERIVED MESENCHYMAL STEM CELLS; GENE MODIFICATION; HIPPO;
   YAP; OSTEOGENESIS IMPERFECTA; OSTEOGENIC DIFFERENTIATION
ID MESENCHYMAL STEM CELLS; MARROW STROMAL CELLS; ORGAN SIZE CONTROL; HIPPO
   PATHWAY; TRANSPLANTATION; YAP; DIFFERENTIATION; TURNOVER; CHILDREN;
   YAP/TAZ
AB Osteogenesis imperfecta (OI) is a congenital genetic disorder mainly manifested as bone fragility and recurrent fracture. Mutation of COL1A1/COL1A2 genes encoding the type I collagen are most responsible for the clinical patients. Allogenic mesenchymal stem cells (MSCs) provide the potential to treat OI through differentiation into osteoblasts. Autologous defective MSCs have not been utilized in OI treatment mainly because of their impaired osteogenesis, but the latent mechanism has not been well understood. Here, the relative signaling abnormality of adipose derived mesenchymal stem cells (ADSCs) isolated from OI type I mice (Col1a1(+/ 365) mice) was explored. Autologous ADSCs transfected by retrovirus carrying human COL1A1 gene was first utilized in OI therapy. The results showed that decreased activity of Yes associated protein (YAP) due to hyperactive upstream Hippo kinases greatly contributed to the weakened bone forming capacity of defective ADSCs. Recovered collagen synthesis of autologous ADSCs by COL1A1 gene modification normalized Hippo/YAP signaling and effectively rescued YAP mediated osteogenesis. And the COL1A1 gene engineered autologous ADSCs efficaciously improved the microstructure, enhanced the mechanical properties and promoted bone formation of Col1a1(+/ 365) mice after femoral bone marrow cavity delivery and might serve as an alternative source of stem cells in OI treatment. (c) 2021 American Society for Bone and Mineral Research. (c) 2021 American Society for Bone and Mineral Research (ASBMR).
C1 [Liu, Yi; Wang, Zihan; Ju, Mingyan; Zhao, Yuxia; Jing, Yaqing; Li, Jiaci; Shao, Chenyi; Fu, Ting; Lv, Zhe; Li, Guang] Tianjin Med Univ, Sch Basic Med Sci, Dept Genet, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.
C3 Tianjin Medical University
RP Li, G (通讯作者)，Tianjin Med Univ, Sch Basic Med Sci, Dept Genet, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.
EM lig@tmu.edu.cn
RI ; Zhang, Yunjiao/AAG 4482 2020; Wang, Zihan/EZP 6684 2022
OI wang, zi han/0000 0001 8193 7054; Li, Guang/0000 0002 9608 0820; 
FU National Key R&D Program of China [2017YFC1001900, 2017YFC1001904];
   Tianjin Science and Technology Support Program [16YFZCSY00900]; National
   Natural Science Foundation of China for Young Scholars [81501386];
   National College Students' Innovative Entrepreneurial Training Plan
   Program [201810062013]
FX The present work was supported by grants from National Key R&D Program
   of China (2017YFC1001900 and 2017YFC1001904), Tianjin Science and
   Technology Support Program (16YFZCSY00900), National Natural Science
   Foundation of China for Young Scholars (81501386), and National College
   Students' Innovative Entrepreneurial Training Plan Program
   (201810062013).
CR Bionaz M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137644
   Byun MR, 2014, BONE, V58, P72, DOI 10.1016/j.bone.2013.09.024
   Castelein RM, 2019, J CHILD ORTHOP, V13, P22, DOI 10.1302/1863 2548.13.180185
   Chamberlain JR, 2004, SCIENCE, V303, P1198, DOI 10.1126/science.1088757
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Constantino CS, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10216
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Forlino A, 2016, LANCET, V387, P1657, DOI 10.1016/S0140 6736(15)00728 X
   Gioia R, 2012, STEM CELLS, V30, P1465, DOI 10.1002/stem.1107
   Golshani Kayvon R, 2016, Del Med J, V88, P178
   Götherström C, 2020, CURR OSTEOPOROS REP, V18, P337, DOI 10.1007/s11914 020 00594 3
   Götherström C, 2014, STEM CELL TRANSL MED, V3, P255, DOI 10.5966/sctm.2013 0090
   Grompe Markus, NATURE REPORTS STEM, DOI [10.1038/stemcells.2007.100, DOI 10.1038/STEMCELLS.2007.100]
   Guillot P, 2008, J PATHOL, V214, P627, DOI 10.1002/path.2325
   Guillot PV, 2008, BLOOD, V111, P1717, DOI 10.1182/blood 2007 08 105809
   Holloway L, 2007, BRIT J NUTR, V97, P365, DOI 10.1017/S000711450733674X
   Horwitz EM, 2001, BLOOD, V97, P1227, DOI 10.1182/blood.V97.5.1227
   Kaneto CM, 2017, EUR J MED GENET, V60, P326, DOI 10.1016/j.ejmg.2017.04.003
   Komatsu N, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1085 9
   Li F, 2007, STEM CELLS, V25, P3183, DOI 10.1634/stemcells.2007 0466
   Lindroos B, 2011, STEM CELL REV REP, V7, P269, DOI 10.1007/s12015 010 9193 7
   Liu PY, 2005, J CLIN ENDOCR METAB, V90, P1953, DOI 10.1210/jc.2004 1583
   Liu XL, 2018, BIOCHIMIE, V150, P110, DOI 10.1016/j.biochi.2018.05.005
   Liu Y, 2019, BONE, V127, P646, DOI 10.1016/j.bone.2019.07.021
   Marini JC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.52
   Mo JS, 2017, BMB REP, V50, P71, DOI 10.5483/BMBRep.2017.50.2.199
   Morello R, 2018, MATRIX BIOL, V71 72, P294, DOI 10.1016/j.matbio.2018.03.010
   Nair AK, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2720
   Niemeyer P, 2007, TISSUE ENG, V13, P111, DOI 10.1089/ten.2006.0114
   Niklason LE, 2018, CELL STEM CELL, V22, P302, DOI 10.1016/j.stem.2018.02.001
   Otsuru S, 2012, BLOOD, V120, P1933, DOI 10.1182/blood 2011 12 400085
   Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007
   Pan JX, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0018 7
   Pochampally RR, 2005, GENE THER, V12, P1119, DOI 10.1038/sj.gt.3302514
   Rijks EBG, 2015, HORM RES PAEDIAT, V84, P26, DOI 10.1159/000381713
   Si ZZ, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108765
   Sillence D O, 1979, Birth Defects Orig Artic Ser, V15, P113
   Silver FH, 2011, CONNECT TISSUE RES, V52, P242, DOI 10.3109/03008207.2010.551567
   Solomon LM, 2008, GENDER MED, V5, P3, DOI 10.1016/S1550 8579(08)80003 4
   TJELLESEN L, 1984, ACTA MED SCAND, V215, P411
   Tournis S, 2018, METABOLISM, V80, P27, DOI 10.1016/j.metabol.2017.06.001
   Trejo P, 2017, J BONE MINER RES, V32, P1034, DOI 10.1002/jbmr.3071
   Vanleene M, 2011, BLOOD, V117, P1053, DOI 10.1182/blood 2010 05 287565
   Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376
   Wang S, 2017, NAT IMMUNOL, V18, P733, DOI 10.1038/ni.3744
   Wittkowske C, 2016, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00087
   Xiong JH, 2018, BONE, V112, P1, DOI 10.1016/j.bone.2018.04.001
   Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044
   Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303
NR 49
TC 15
Z9 17
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2021
VL 36
IS 8
BP 1521
EP 1534
DI 10.1002/jbmr.4326
EA MAY 2021
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA TU3UB
UT WOS:000651557100001
PM 33950576
OA Bronze
DA 2025 08 17
ER

PT J
AU Wazen, RM
   Moffatt, P
   Zalzal, SF
   Daniel, NG
   Westerman, KA
   Nanci, A
AF Wazen, R. M.
   Moffatt, P.
   Zalzal, S. F.
   Daniel, N. G.
   Westerman, K. A.
   Nanci, A.
TI Local gene transfer to calcified tissue cells using prolonged infusion
   of a lentiviral vector
SO GENE THERAPY
LA English
DT Article
DE ameloblastin; bone; osteogenic cell culture; gene transfer; green
   fluorescent protein; lentiviral vector
ID BONE MORPHOGENETIC PROTEIN; TRANSGENE EXPRESSION; FRACTURE REPAIR; RAT
   INCISORS; IN VITRO; THERAPY; DELIVERY; OSTEOGENESIS; SYNOVIUM
AB Gene transfer using viral vectors offers the potential for the sustained expression of proteins in specific target tissues. However, in the case of calcified tissues, in vivo delivery remains problematic because of limited accessibility. The aim of this study was to test the efficiency of lentiviral vectors (LVs) on osteogenic cells in vitro, and determine the feasibility of directly transducing resident bone cells in vivo. LVs encoding for green fluorescent protein (GFP) and ameloblastin (AMBN), a protein associated with mineralization not reported in bone, were generated. The transduction efficiency of the LVs was evaluated using the MC3T3 cell line and primary calvaria derived osteogenic cells. For in vivo delivery, the LVs were infused using osmotic minipumps through holes created in the bone of the rat hemimandible and tibia. The production of GFP and AMBN in vitro and in vivo was monitored using fluorescence microscopy. Both transgenes were expressed in MC3T3 and primary osteogenic cells. In vivo, GFP was detected at the infusion site and fibroblast like cells, osteoblasts, osteocytes and osteoclasts expressed AMBN. Our data demonstrate, for the first time, that primary osteogenic cells are efficiently transduced with LVs and that their infusion is advantageous for locally delivering DNA to bone cells.
C1 Univ Montreal, Fac Dent, Dept Stomatol, Lab Study Calcified Tissues & Biomat, Montreal, PQ H3C 3J7, Canada.
   Univ Laval, Hosp Ctr, Hop Enfants Jesus, Ste Foy, PQ G1K 7P4, Canada.
   Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesia Res, Boston, MA 02115 USA.
C3 Universite de Montreal; Laval University; Harvard University; Harvard
   University Medical Affiliates; Brigham & Women's Hospital; Harvard
   Medical School
RP Nanci, A (通讯作者)，Univ Montreal, Fac Dent, Dept Stomatol, Lab Study Calcified Tissues & Biomat, POB 6128,Stn Ctr Ville, Montreal, PQ H3C 3J7, Canada.
EM antonio.nanci@umontreal.ca
RI Wazen, Rima/ABE 1878 2020
OI Moffatt, Pierre/0000 0002 5793 1944; Wazen, Rima M./0000 0002 7477 4979;
   Nanci, Antonio/0000 0003 0616 843X
CR Alden TD, 2000, J CRANIOFAC SURG, V11, P24, DOI 10.1097/00001665 200011010 00005
   [Anonymous], LENTIVIRUS GENE ENG
   Ashinoff RL, 2004, ANN PLAS SURG, V52, P585, DOI 10.1097/01.sap.0000123023.28874.1e
   Baltzer AWA, 2000, GENE THER, V7, P734, DOI 10.1038/sj.gt.3301166
   Baltzer AWA, 2000, CLIN ORTHOP RELAT R, pS120
   CHEN WY, 1995, CALCIFIED TISSUE INT, V57, P145, DOI 10.1007/BF00298435
   Chen Y, 2003, GENE THER, V10, P1345, DOI 10.1038/sj.gt.3301999
   Dai J, 2004, CURR GENE THER, V4, P469
   de Oliveira PT, 2003, J HISTOCHEM CYTOCHEM, V51, P633, DOI 10.1177/002215540305100509
   Evans CH, 2004, CLIN ORTHOP RELAT R, P316, DOI 10.1097/01.blo.0000148854.14399.ec
   Fincham AG, 1999, J STRUCT BIOL, V126, P270, DOI 10.1006/jsbi.1999.4130
   Franceschi RT, 2005, J DENT RES, V84, P1093, DOI 10.1177/154405910508401204
   Ghazizadeh S, 2004, J INVEST DERM SYMP P, V9, P269, DOI 10.1111/j.1087 0024.2004.09302.x
   Gouze E, 2003, MOL THER, V7, P460, DOI 10.1016/S1525 0016(03)00024 8
   Gouze E, 2002, MOL THER, V5, P397, DOI 10.1006/mthe.2002.0562
   Helm GA, 2000, J NEUROSURG, V92, P191, DOI 10.3171/spi.2000.92.2.0191
   Hiltunen MO, 2003, FASEB J, V17, P1147, DOI 10.1096/fj.02 0514fje
   Irie K, 1998, ANAT RECORD, V252, P554
   Jin QM, 2003, J PERIODONTOL, V74, P202, DOI 10.1902/jop.2003.74.2.202
   Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197 314
   Kanerva A, 2005, ANN MED, V37, P33, DOI 10.1080/07853890410018934
   Katsube K, 2005, J ORTHOP RES, V23, P469, DOI 10.1016/j.orthres.2004.08.013
   Kofron MD, 2005, CURR GENE THER, V5, P37
   Kootstra NA, 2003, ANNU REV PHARMACOL, V43, P413, DOI 10.1146/annurev.pharmtox.43.100901.140257
   Kostenuik PJ, 2004, BONE, V34, P656, DOI 10.1016/j.bone.2003.12.006
   Krebsbach PH, 1996, J BIOL CHEM, V271, P4431
   Krebsbach PH, 2000, HUM GENE THER, V11, P1201, DOI 10.1089/10430340050015248
   Kuboki T, 1999, ARCH ORAL BIOL, V44, P701, DOI 10.1016/S0003 9969(99)00069 2
   Kyrkanides S, 2004, J DENT RES, V83, P65, DOI 10.1177/154405910408300113
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Li MQ, 2004, MICROSC RES TECHNIQ, V64, P330, DOI 10.1002/jemt.20088
   Lieberman JR, 1999, J BONE JOINT SURG AM, V81A, P905, DOI 10.2106/00004623 199907000 00002
   Luk KDK, 2003, BIOCHEM BIOPH RES CO, V308, P636, DOI 10.1016/S0006 291X(03)01429 3
   Luo J, 2005, CURR GENE THER, V5, P167, DOI 10.2174/1566523053544218
   Mason JM, 1998, GENE THER, V5, P1098, DOI 10.1038/sj.gt.3300703
   Musgrave DS, 1999, BONE, V24, P541, DOI 10.1016/S8756 3282(99)00086 1
   Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382
   Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263
   Nanci A, 1996, MICROSC RES TECHNIQ, V33, P214
   Nanci A, 2004, J HISTOCHEM CYTOCHEM, V52, P1591, DOI 10.1369/jhc.4A6452.2004
   Newman KD, 1995, J CLIN INVEST, V96, P2955, DOI 10.1172/JCI118367
   Orsini G, 2001, J HISTOCHEM CYTOCHEM, V49, P165, DOI 10.1177/002215540104900204
   Partridge KA, 2004, TISSUE ENG, V10, P295, DOI 10.1089/107632704322791934
   Robbins PD, 2003, GENE THER, V10, P902, DOI 10.1038/sj.gt.3302040
   Rundle CH, 2003, BONE, V32, P591, DOI 10.1016/S8756 3282(03)00096 6
   Schwarz EM, 2000, CLIN ORTHOP RELAT R, pS31, DOI 10.1097/00003086 200010001 00005
   Shai E, 2005, MOL THER, V12, P137, DOI 10.1016/j.ymthe.2005.02.022
   SMITH CE, 1975, ANAT RECORD, V183, P523, DOI 10.1002/ar.1091830405
   SMITH CE, 1989, ANAT RECORD, V225, P257, DOI 10.1002/ar.1092250312
   Sugiyama O, 2005, MOL THER, V11, P390, DOI 10.1016/j.ymthe.2004.10.019
   Ulrich Vinther M, 2002, J BONE JOINT SURG AM, V84A, P1405, DOI 10.2106/00004623 200208000 00017
   Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637
   Vu DD, 1999, J HISTOCHEM CYTOCHEM, V47, P323, DOI 10.1177/002215549904700306
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   WARSHAWSKY H, 1967, J HISTOCHEM CYTOCHEM, V15, P542, DOI 10.1177/15.9.542
   Watanabe S, 2000, MOL THER, V2, P147, DOI 10.1006/mthe.2000.0111
   Ylä Herttuala S, 2000, LANCET, V355, P213, DOI 10.1016/S0140 6736(99)04180 X
   Zhang XY, 2002, MOL THER, V5, P555, DOI 10.1006/mthe.2002.0585
NR 58
TC 15
Z9 18
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969 7128
EI 1476 5462
J9 GENE THER
JI Gene Ther.
PD NOV
PY 2006
VL 13
IS 22
BP 1595
EP 1602
DI 10.1038/sj.gt.3302824
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 102ND
UT WOS:000241818000006
PM 16855616
DA 2025 08 17
ER

PT J
AU Roberts, ES
   Van Lare, KA
   Marable, BR
   Salminen, WF
AF Roberts, E. S.
   Van Lare, K. A.
   Marable, B. R.
   Salminen, W. F.
TI Safety and tolerability of 3 week and 6 month dosing of
   Deramaxx<SUP>®</SUP> (Deracoxib) chewable tablets in dogs
SO JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RENAL PAPILLARY NECROSIS;
   VETERINARY MEDICINE; INHIBITION; COX 2
AB Although non steroidal anti inflammatory drugs (NSAIDs) are effective in reducing pain and inflammation, these agents have adverse effects. Selective inhibitors of COX 2 are an alternative to traditional NSAIDs. Deramaxx((R)) [Novartis Animal Health US, Inc. (NAH), Greensboro, NC, USA] contains the selective COX 2 inhibitor, deracoxib, and is approved for the relief of pain and inflammation associated with orthopedic surgery and osteoarthritis in dogs. The safety of Deramaxx was evaluated in two target animal safety studies: 40 dogs (four dogs/sex/group) received 0, 4, 6, 8, or 10 mg/kg/day deracoxib once daily for 21 days; and 60 dogs (five dogs/sex/group) received 0, 2, 4, 6, 8, or 10 mg/kg/day deracoxib once daily for 6 months. There was a dose dependent trend towards increased blood urea nitrogen (BUN) in treated dogs, however mean BUN values remained within the reference range at the labeled doses. In both trials, histopathology revealed focal renal tubular degeneration/regeneration in some dogs receiving >= 6 mg/kg/day deracoxib. Focal renal papillary necrosis was seen in one dog treated with 8 mg/kg/day and in three dogs receiving 10 mg/kg/day deracoxib on the 6 month study. No other parameters of renal function were adversely affected for either study. Results show that Deramaxx is safe and well tolerated in dogs when administered as directed.
C1 [Roberts, E. S.; Van Lare, K. A.; Marable, B. R.; Salminen, W. F.] Novartis Anim Hlth US Inc, Greensboro, NC 27408 USA.
C3 Novartis; Novartis USA
RP Roberts, ES (通讯作者)，Novartis Anim Hlth US Inc, 3200 Northline Ave,Suite 300, Greensboro, NC 27408 USA.
EM elizabeth.roberts@novartis.com
OI Salminen, William/0000 0002 1693 9448
CR Adams R. H., 2001, VET PHARM THERAPEUTI, P403
   Bergh MS, 2005, J VET INTERN MED, V19, P633, DOI 10.1892/0891 6640(2005)19[633:TCNPCA]2.0.CO;2
   Bertolini A, 2001, PHARMACOL RES, V44, P437, DOI 10.1006/phrs.2001.0872
   Bertolini A, 2002, CURR MED CHEM, V9, P1033, DOI 10.2174/0929867024606650
   Blikslager AT, 1999, AM J PHYSIOL GASTR L, V276, pG28, DOI 10.1152/ajpgi.1999.276.1.G28
   Botting RM, 2006, J PHYSIOL PHARMACOL, V57, P113
   BURKE A., 2006, Goodman Gilman's the Pharmaceutical Basis of Therapeutics, P671
   Cheng HF, 2005, CURR PHARM DESIGN, V11, P1795, DOI 10.2174/1381612053764922
   COLLINS LG, 1985, AM J VET RES, V46, P1605
   Coruzzi Gabriella, 2007, Acta Biomed, V78, P96
   Curry SL, 2005, J AM ANIM HOSP ASSOC, V41, P298, DOI 10.5326/0410298
   Duncan B, 2007, VET ANAESTH ANALG, V34, P228, DOI 10.1111/j.1467 2995.2006.00322.x
   Hampshire VA, 2004, JAVMA J AM VET MED A, V225, P533, DOI 10.2460/javma.2004.225.533
   Hinz B, 2004, CURR OPIN RHEUMATOL, V16, P628, DOI 10.1097/01.hco.0000136130.95746.14
   JONES RD, 1992, J AM VET MED ASSOC, V217, P721
   Lathers CM, 2003, NAT REV DRUG DISCOV, V2, P915, DOI 10.1038/nrd1229
   Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903
   MCCORMACK K, 1994, PAIN, V59, P9, DOI 10.1016/0304 3959(94)90045 0
   MCMANN ME, 2004, AM J VET RES, V65, P503
   *NAT RES COUNC, 1996, GUID CAR US LAB AN
   Renberg WC, 2005, VET CLIN N AM SMALL, V35, P1073, DOI 10.1016/j.cvsm.2005.05.005
   Sellers RS, 2004, DRUG CHEM TOXICOL, V27, P111, DOI 10.1081/DCT 120030726
   Silverman LR, 1999, TOXICOL PATHOL, V27, P244, DOI 10.1177/019262339902700213
   Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157
   Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271
   Tsuchiya Y, 2005, TOXICOL PATHOL, V33, P561, DOI 10.1080/01926230500222593
   Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97
   Wooten JG, 2008, AM J VET RES, V69, P457, DOI 10.2460/ajvr.69.4.457
NR 28
TC 25
Z9 27
U1 0
U2 4
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0140 7783
J9 J VET PHARMACOL THER
JI J. Vet. Pharmacol. Ther.
PD AUG
PY 2009
VL 32
IS 4
BP 329
EP 337
DI 10.1111/j.1365 2885.2008.01043.x
PG 9
WC Pharmacology & Pharmacy; Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Veterinary Sciences
GA 468PU
UT WOS:000267832700003
PM 19614837
DA 2025 08 17
ER

PT J
AU Sahana, H
   Khajuria, DK
   Razdan, R
   Mahapatra, DR
   Bhat, MR
   Suresh, S
   Rao, RR
   Mariappan, L
AF Sahana, H.
   Khajuria, Deepak Kumar
   Razdan, Rema
   Mahapatra, D. Roy
   Bhat, M. R.
   Suresh, Sarasija
   Rao, R. Ramachandra
   Mariappan, L.
TI Improvement in Bone Properties by Using Risedronate Adsorbed
   Hydroxyapatite Novel Nanoparticle Based Formulation in a Rat Model of
   Osteoporosis
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE Rat; Ovariectomy; Osteoporosis; Risedronate; Hydroxyapatite
   Nanoparticles; Biomechanical Properties; Bone Density; Bone Porosity
ID DRUG DELIVERY; OVARIECTOMIZED RATS; HIGH AFFINITY; BISPHOSPHONATES;
   ALENDRONATE; NANOCRYSTALS; SUBSTITUTES; MECHANISMS; STRENGTH; CELLS
AB A superior drug formulation capable of achieving efficient osteogenesis is in imperative demand for the treatment of osteoporosis. In the present study we investigated the potential of using novel risedronate hydroxyapatite (HA) nanoparticle based formulation in an animal model of established osteoporosis. Nanoparticles of HA loaded with risedronate (NHLR) of various sizes (80 130 nm) were generated for bone targeted drug delivery. Three months after ovariectomy, 36 ovariectomized (OVX) rats were divided into 6 equal groups and treated with various doses of NHLR (500,350 and 250 mu g/kg intravenous single dose) and sodium risedronate (500 mu g/kg, intravenous single dose). Untreated OVX and sham OVX served as controls. One month after drug administration, the left tibia and femur were tested for bone mechanical properties and histology, respectively. In the right femur, bone density was measured by method based on Archimedes principle and bone porosity analyses were performed using X ray imaging. NHLR (250 mu g/kg) showed a significant increase in bone density and reduced bone porosity when compared with OVX control. Moreover, NHLR (250 mu g/kg) significantly increased bone mechanical properties and bone quality when compared with OVX control. The results strongly suggest that the NHLR, which is a novel nanoparticle based formulation, has a therapeutic advantage over risedronate sodium monotherapy for the treatment of osteoporosis in a rat model of postmenopausal osteoporosis.
C1 [Sahana, H.; Khajuria, Deepak Kumar; Razdan, Rema] Al Ameen Coll Pharm, Dept Pharmacol, Bangalore 560027, Karnataka, India.
   [Khajuria, Deepak Kumar; Mahapatra, D. Roy; Bhat, M. R.] Indian Inst Sci, Dept Aerosp Engn, Bangalore 560012, Karnataka, India.
   [Suresh, Sarasija] Al Ameen Coll Pharm, Dept Pharmaceut, Bangalore 560027, Karnataka, India.
   [Rao, R. Ramachandra; Mariappan, L.] Natl Aeronaut Labs, Bangalore 560017, Karnataka, India.
C3 Indian Institute of Science (IISC)   Bangalore; Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   National Aerospace
   Laboratories (NAL)
RP Khajuria, DK (通讯作者)，Al Ameen Coll Pharm, Dept Pharmacol, Bangalore 560027, Karnataka, India.
RI ; Khajuria, Deepak Kumar/A 5993 2019; Khajuria, Deepak/A 5993 2019; Roy
   Mahapatra, Debiprosad/HJH 4305 2023
OI Roy Mahapatra, Debiprosad/0000 0001 7657 2302; Khajuria, Deepak
   Kumar/0000 0002 3737 8504; 
CR Abdel Gawad EI., 2010, Nat. Sci, V8, P60
   Bitto A, 2008, BRIT J PHARMACOL, V155, P896, DOI 10.1038/bjp.2008.305
   Boanini E, 2008, BIOMATERIALS, V29, P790, DOI 10.1016/j.biomaterials.2007.10.040
   Boanini E, 2007, ADV MATER, V19, P2499, DOI 10.1002/adma.200602497
   Brunton L. L., 2005, GOODMAN GILMANS PHAR, P1662
   Cai YR, 2007, J MATER CHEM, V17, P3780, DOI 10.1039/b705129h
   Dixon H. B. F., U.S. Patent, Patent No. [6, 214, 812, 6214812]
   EINHORN TA, 1992, CALCIFIED TISSUE INT, V51, P333, DOI 10.1007/BF00316875
   Fathi MH, 2008, J MATER PROCESS TECH, V202, P536, DOI 10.1016/j.jmatprotec.2007.10.004
   Gomes AJ, 2007, INT J PHARMACEUT, V332, P153, DOI 10.1016/j.ijpharm.2006.09.035
   Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148
   Hengst V, 2007, INT J PHARMACEUT, V331, P224, DOI 10.1016/j.ijpharm.2006.11.024
   Keenan MJ, 1997, J BONE MINER RES, V12, P1903, DOI 10.1359/jbmr.1997.12.11.1903
   Khajuria DK, 2012, REV BRAS REUMATOL, V52, P462
   Khajuria DK, 2011, REV BRAS REUMATOL, V51, P365
   Kumar PTS, 2011, INT J BIOL MACROMOL, V49, P20, DOI 10.1016/j.ijbiomac.2011.03.006
   Liu TY, 2005, J CONTROL RELEASE, V107, P112, DOI 10.1016/j.jconrel.2005.05.025
   Ogawa K, 2006, J NUCL MED, V47, P2042
   Ong HT, 2008, J NANOPART RES, V10, P141, DOI 10.1007/s11051 007 9239 1
   Palazzo B, 2007, ADV FUNCT MATER, V17, P2180, DOI 10.1002/adfm.200600361
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Power RA, 2004, OSTEOPOROSIS INT, V15, P716, DOI 10.1007/s00198 004 1595 4
   Rang H. P., 2007, PHARMACOLOGY, P461
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756 3282(99)00070 8
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Saikia KC, 2008, INDIAN J ORTHOP, V42, P169, DOI 10.4103/0019 5413.39588
   Su K, 2011, EXPERT OPIN DRUG DEL, V8, P113, DOI 10.1517/17425247.2011.541438
   Taha EA, 2003, CHEM PHARM BULL, V51, P1444, DOI 10.1248/cpb.51.1444
   Tripathi K. D., 2008, ESSENTIALS MED PHARM, P293
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Uludag H, 2002, CURR PHARM DESIGN, V8, P1929, DOI 10.2174/1381612023393585
   Yao W, 2007, BONE, V41, P804, DOI 10.1016/j.bone.2007.06.021
   Ye F, 2010, ACTA BIOMATER, V6, P2212, DOI 10.1016/j.actbio.2009.12.014
NR 34
TC 78
Z9 81
U1 0
U2 43
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 1550 7033
EI 1550 7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD FEB
PY 2013
VL 9
IS 2
BP 193
EP 201
DI 10.1166/jbn.2013.1482
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA 079SH
UT WOS:000314192000005
PM 23627045
DA 2025 08 17
ER

PT J
AU Liao, CH
   Lin, LP
   Yu, TY
   Hsu, CC
   Pang, JHS
   Tsai, WC
AF Liao, Chih Hao
   Lin, Li Ping
   Yu, Tung Yang
   Hsu, Chih Chin
   Pang, Jong Hwei S.
   Tsai, Wen Chung
TI Ibuprofen inhibited migration of skeletal muscle cells in association
   with downregulation of p130cas and CrkII expressions
SO SKELETAL MUSCLE
LA English
DT Article
DE Ibuprofen; Skeletal muscle; Cell migration; Sport injury
ID SATELLITE CELLS; PAXILLIN; INJURIES; PHOSPHORYLATION; SRC
AB Background Nonsteroidal anti inflammatory drugs (NSAIDs) are commonly used to treat sports related muscle injuries. However, NSAIDs were recently shown to impede the muscle healing process after acute injury. Migration of skeletal muscle cells is a crucial step during the muscle healing process. The present study was performed to investigate the effect and molecular mechanisms of action of ibuprofen, a commonly used NSAID, on the migration of skeletal muscle cells. Methods Skeletal muscle cells isolated from the gastrocnemius muscle of Sprague Dawley rats were treated with ibuprofen. MTT assay (3 [4,5 dimethylthiazol 2 yl] 2,5 diphenyltetrazolium bromide) was used to evaluate cell viability, and cell apoptosis was evaluated by TUNEL assay, after ibuprofen treatment. Skeletal muscle cell migration and spreading were evaluated using the transwell filter migration assay and F actin staining, respectively. The protein expression of p130cas and CrkII, which are cell migration facilitating genes, was determined by western blot analysis. The overexpression of p130cas of muscle cells was achieved by p130cas vector transfection. Results The results demonstrated that ibuprofen did not have a significant negative effect on cell viability and apoptosis. Ibuprofen inhibited the migration and spreading of skeletal muscle cells in a dose dependent manner. Ibuprofen also dose dependently decreased the protein expression of p130cas and CrkII. Furthermore, overexpression of p130cas resulted in the promotion of cell migration and spreading and counteracted ibuprofen mediated inhibition. Conclusion This study suggested that ibuprofen exerts a potentially adverse effect on the migration of skeletal muscle cells by downregulating protein expression of p130cas and CrkII. These results indicate a possible mechanism underlying the possible negative effect of NSAIDs on muscle regeneration.
C1 [Liao, Chih Hao; Lin, Li Ping; Yu, Tung Yang; Pang, Jong Hwei S.; Tsai, Wen Chung] Chang Gung Mem Hosp, Dept Phys Med & Rehabil, 123 Dinghu Rd, Taoyuan 333, Taiwan.
   [Lin, Li Ping; Pang, Jong Hwei S.] Chang Gung Univ, Grad Inst Clin Med Sci, Taoyuan, Taiwan.
   [Hsu, Chih Chin; Tsai, Wen Chung] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
   [Hsu, Chih Chin] Chang Gung Mem Hosp, Dept Phys Med & Rehabil, Keelung, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University; Chang Gung
   University; Chang Gung Memorial Hospital
RP Tsai, WC (通讯作者)，Chang Gung Mem Hosp, Dept Phys Med & Rehabil, 123 Dinghu Rd, Taoyuan 333, Taiwan.; Tsai, WC (通讯作者)，Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
EM tsaiwc@cgmh.org.tw
RI lin, liping/HGE 0871 2022
FU Chang Gung Memorial Hospital, Taiwan [CMRPG5I0031]
FX We would like to thank Chang Gung Memorial Hospital, Taiwan, for
   financially supporting this research (CMRPG5I0031)
CR Alderton JM, 2000, TRENDS CARDIOVAS MED, V10, P268, DOI 10.1016/S1050 1738(00)00075 X
   ALMEKINDERS LC, 1986, AM J SPORT MED, V14, P303, DOI 10.1177/036354658601400411
   Baoge L, 2012, ISRN Orthop, V2012, P689012, DOI 10.5402/2012/689012
   Barrett A, 2013, CELL SIGNAL, V25, P766, DOI 10.1016/j.cellsig.2012.12.019
   Cantini M, 2002, NEUROL SCI, V23, P189, DOI 10.1007/s100720200060
   Casanova I, 2006, INT J CANCER, V118, P2381, DOI 10.1002/ijc.21662
   Casanova I, 2008, INT J CANCER, V123, P217, DOI 10.1002/ijc.23516
   Chen CH, 2013, CARDIOVASC RES, V100, P461, DOI 10.1093/cvr/cvt207
   Chodniewicz D, 2004, BBA MOL CELL RES, V1692, P63, DOI 10.1016/j.bbamcr.2004.03.006
   Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721
   Cunningham Edmondson AC, 2009, BREAST CANCER TARGET, V1, P39
   Delos D, 2013, SPORTS HEALTH, V5, P346, DOI 10.1177/1941738113480934
   Deng B, 2014, ONCOL LETT, V8, P454, DOI 10.3892/ol.2014.2123
   Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901 1041
   Ekstrand J, 2011, AM J SPORT MED, V39, P1226, DOI 10.1177/0363546510395879
   Grounds MD, 2014, INT J BIOCHEM CELL B, V56, P56, DOI 10.1016/j.biocel.2014.09.010
   Halevy O, 2004, DEV DYNAM, V231, P489, DOI 10.1002/dvdy.20151
   Hamer PW, 2002, J ANAT, V200, P69, DOI 10.1046/j.0021 8782.2001.00008.x
   Hindi SM, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003832
   Ho ATV, 2017, P NATL ACAD SCI USA, V114, P6675, DOI 10.1073/pnas.1705420114
   Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446
   JANSSEN GME, 1985, J INT MED RES, V13, P68, DOI 10.1177/030006058501300110
   Järvinen TAHJ, 2005, AM J SPORT MED, V33, P745, DOI 10.1177/0363546505274714
   Kawauchi K, 2012, BIOCHEM J, V445, P323, DOI 10.1042/BJ20112169
   Kim MC, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002926
   Kratimenos P, 2014, EXPERT OPIN THER TAR, V18, P1395, DOI 10.1517/14728222.2014.952280
   Lamorte L, 2003, MOL BIOL CELL, V14, P2818, DOI 10.1091/mbc.E02 08 0497
   MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0
   Merly F, 1999, MUSCLE NERVE, V22, P724, DOI 10.1002/(SICI)1097 4598(199906)22:6<724::AID MUS9>3.0.CO;2 O
   MISHRA DK, 1995, J BONE JOINT SURG AM, V77, P1510, DOI 10.2106/00004623 199510000 00005
   Mueller Wohlfahrt HW, 2013, BRIT J SPORT MED, V47, P342, DOI 10.1136/bjsports 2012 091448
   Oakes PW, 2014, CURR OPIN CELL BIOL, V30, P68, DOI 10.1016/j.ceb.2014.06.003
   OBREMSKY WT, 1994, AM J SPORT MED, V22, P558, DOI 10.1177/036354659402200420
   ORIMO S, 1991, MUSCLE NERVE, V14, P515, DOI 10.1002/mus.880140605
   Panetti TS, 2002, FRONT BIOSCI LANDMRK, V7, pD143, DOI 10.2741/panetti
   Paoloni JA, 2009, BRIT J SPORT MED, V43, P863, DOI 10.1136/bjsm.2009.059980
   Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957
   SCHULTZ E, 1985, MUSCLE NERVE, V8, P217, DOI 10.1002/mus.880080307
   Shen W, 2005, AM J PATHOL, V167, P1105, DOI 10.1016/S0002 9440(10)61199 6
   Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803
   Tidball JG, 1998, AM J PHYSIOL CELL PH, V275, pC260, DOI 10.1152/ajpcell.1998.275.1.C260
   TIDBALL JG, 1995, MED SCI SPORT EXER, V27, P1022, DOI 10.1249/00005768 199507000 00011
   Tsai WC, 2006, J ORTHOP RES, V24, P551, DOI 10.1002/jor.20069
   Tsai WC, 2016, PROBL POST COMMUNISM, P1
   Yamada M, 2008, INT J BIOCHEM CELL B, V40, P2183, DOI 10.1016/j.biocel.2008.02.017
   Yamada S, 2011, CANCER LETT, V303, P84, DOI 10.1016/j.canlet.2011.01.004
   Yin H, 2013, PHYSIOL REV, V93, P23, DOI 10.1152/physrev.00043.2011
   Zammit PS, 2004, J CELL BIOL, V166, P347, DOI 10.1083/jcb.200312007
NR 48
TC 11
Z9 14
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2044 5040
J9 SKELET MUSCLE
JI Skeletal Muscle
PD AUG 29
PY 2019
VL 9
IS 1
AR 23
DI 10.1186/s13395 019 0208 z
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA IU7QN
UT WOS:000483778500001
PM 31464636
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yu, XJ
   Wang, YX
   Liu, XL
   Ge, YW
   Zhang, SY
AF Yu, Xijiao
   Wang, Yuxuan
   Liu, Xiaoliang
   Ge, Yuwei
   Zhang, Shanyong
TI Ursolic Acid Loaded Mesoporous Hydroxylapatite/Chitosan Therapeutic
   Scaffolds Regulate Bone Regeneration Ability by Promoting the M2 Type
   Polarization of Macrophages
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE mesoporous hydroxylapatite; polarization; bone regeneration; ursolic
   acid; drug delivery
ID OSTEOBLAST DIFFERENTIATION; SIGNALING PATHWAY; IN VITRO; COMPOSITE;
   DELIVERY
AB Purpose: Mesoporous hydroxylapatite (MHAP) might be important for bone regeneration, and ursolic acid (UA) has anti inflammatory effects. Accordingly, we developed, for the first time, ursolic acid loaded MHAP chitosan (MHAP CS UA) scaffolds to treat bone defects.
   Methods: In vitro, we synthesize biomaterial scaffolds. By SEM, XRD, EDS and FTIR, we test the performance of the hybrid scaffolds. By drug release, flow cytometry, immunofluorescence, alizarin red staining, and Western blotting, we test the anti inflammatory and osteoinductive properties of scaffolds. In vivo, we verify osseointegration ability and bone regeneration.
   Results: The MHAP is a rod shaped structure with a length of 100 similar to 300nm and a diameter of 40 similar to 60nm. The critical structure gives the micro scaffold a property of control release due to the pore sizes of 1.6 similar to 4.3 nm in hydroxyapatite and the hydrogen bonding between the scaffolds and UA drugs. The released UA drugs could notably inhibit the polarization of macrophages to pro inflammatory macrophages (M1 type) and promote the expression of osteogenic related genes (COL1, ALP and OPG) and osteogenic related proteins (BMP 2, RUNX2 and COL1).
   Conclusion: The MHAP CS UA scaffolds have good anti inflammatory, osseointegration, osteo inductivity and bone regeneration. And they will be the novel and promising candidates to cure the bone disease.
C1 [Yu, Xijiao; Zhang, Shanyong] Shanghai Jiao Tong Univ, Peoples Hosp 9, Coll Stomatol, Dept Oral Surg,Sch Med, Shanghai, Peoples R China.
   [Yu, Xijiao; Zhang, Shanyong] Shanghai Res Inst Stomatol, Shanghai, Peoples R China.
   [Yu, Xijiao] Jinan Stomatol Hosp, Dept Endodont, Cent Lab, Jinan, Shandong, Peoples R China.
   [Wang, Yuxuan; Liu, Xiaoliang; Ge, Yuwei] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthoped Surg, Shanghai Key Lab Orthoped Implants,Sch Med, Shanghai, Peoples R China.
   [Ge, Yuwei] Shanghai Jiao Tong Univ, Dept Orthoped Surg, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Zhang, SY (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 9, Coll Stomatol, Dept Oral Surg,Sch Med, Shanghai, Peoples R China.; Zhang, SY (通讯作者)，Shanghai Res Inst Stomatol, Shanghai, Peoples R China.; Ge, YW (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthoped Surg, Shanghai Key Lab Orthoped Implants,Sch Med, Shanghai, Peoples R China.; Ge, YW (通讯作者)，Shanghai Jiao Tong Univ, Dept Orthoped Surg, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China.
EM geyw2000@163.com; zhangshanyong@126.com
RI YU, XIJIAO/KFA 3924 2024
FU Dean's Research Fund of Jinan Stomatological Hospital [202102]
FX This work was supported by the Dean's Research Fund of Jinan
   Stomatological Hospital (202102) .
CR Aghaloo TL, 2010, J DENT RES, V89, P1293, DOI 10.1177/0022034510378427
   Ahn YJ, 2020, J NUTR BIOCHEM, V86, DOI 10.1016/j.jnutbio.2020.108483
   Ansari Z, 2020, MATERIALS, V13, DOI 10.3390/ma13173772
   Bai X, 2017, CARBOHYD POLYM, V175, P557, DOI 10.1016/j.carbpol.2017.08.020
   Chen Y, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.202000724
   Déciga Campos M, 2014, PLANTA MED, V80, P139, DOI 10.1055/s 0033 1360220
   Gashtasbi F, 2020, XENOTRANSPLANTATION, V27, DOI 10.1111/xen.12628
   Ge YW, 2019, NANOMED NANOTECHNOL, V18, P336, DOI 10.1016/j.nano.2018.10.010
   Gronbach L, 2020, BIOMATERIALS, V258, DOI 10.1016/j.biomaterials.2020.120277
   He F, 2019, BIOMATERIALS, V224, DOI 10.1016/j.biomaterials.2019.119489
   Henkel K O, 2002, Mund Kiefer Gesichtschir, V6, P59
   Hou LT, 2003, CELL TRANSPLANT, V12, P787, DOI 10.3727/000000003108747262
   Jiang C, 2015, BIOCHIMIE, V111, P107, DOI 10.1016/j.biochi.2015.02.002
   Lastra ML, 2020, COLLOID SURFACE B, V196, DOI 10.1016/j.colsurfb.2020.111322
   Lavanya K, 2020, MAT SCI ENG C MATER, V111, DOI 10.1016/j.msec.2020.110862
   Lee SU, 2008, PHARMACOL RES, V58, P290, DOI 10.1016/j.phrs.2008.08.008
   Li C, 2020, SAUDI J BIOL SCI, V27, P2143, DOI 10.1016/j.sjbs.2020.05.029
   Li Q, 2015, J ETHNOPHARMACOL, V170, P88, DOI 10.1016/j.jep.2015.05.013
   Li YG, 2020, ACTA BIOMATER, V115, P29, DOI 10.1016/j.actbio.2020.08.018
   Liu DD, 2013, J CELL BIOCHEM, V114, P1105, DOI 10.1002/jcb.24451
   Liu L, 2020, ACTA BIOMATER, V103, P281, DOI 10.1016/j.actbio.2019.12.022
   Lu Y, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800013
   Nie HM, 2007, J CONTROL RELEASE, V120, P111, DOI 10.1016/j.jconrel.2007.03.018
   Peng MZ, 2018, MOL PHARMACEUT, V15, P5244, DOI 10.1021/acs.molpharmaceut.8b00747
   Pitaloka DAE, 2020, INFECT DIS REP, V12, P5, DOI 10.4081/idr.2020.8717
   Porwal K, 2017, J NUTR BIOCHEM, V44, P22, DOI 10.1016/j.jnutbio.2017.02.011
   Qian WD, 2020, J BIOSCI BIOENG, V129, P528, DOI 10.1016/j.jbiosc.2019.11.008
   Radwan NH, 2020, CARBOHYD POLYM, V244, DOI 10.1016/j.carbpol.2020.116482
   Sadeghianmaryan A, 2020, INT J BIOL MACROMOL, V164, P3179, DOI 10.1016/j.ijbiomac.2020.08.180
   Sumathra M, 2018, ACS OMEGA, V3, P14620, DOI 10.1021/acsomega.8b02090
   Szewczyk A, 2020, INT J PHARMACEUT, V588, DOI 10.1016/j.ijpharm.2020.119718
   Tan H, 2019, J AGR FOOD CHEM, V67, P3333, DOI 10.1021/acs.jafc.8b06954
   Tao J, 2020, INT J NANOMED, V15, P5855, DOI 10.2147/IJN.S247088
   Toledano M, 2020, POLYMERS BASEL, V12
   Vasconcelos RC, 2020, AM J TRANSL RES, V12, P2439
   Wang CL, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110568
   Zhang ML, 2020, BIOMATERIALS, V260, DOI 10.1016/j.biomaterials.2020.120334
NR 37
TC 14
Z9 14
U1 3
U2 40
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2021
VL 16
BP 5301
EP 5315
DI 10.2147/IJN.S323033
PG 15
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA TV5BX
UT WOS:000681739500001
PM 34393482
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, B
   Yang, Q
   Cheng, Y
   Liu, M
   Ji, QF
   Zhang, BL
   Yang, ZF
   Zhou, SY
   Liu, DZ
AF Liu, Bao
   Yang, Qian
   Cheng, Ying
   Liu, Miao
   Ji, Qifeng
   Zhang, Bangle
   Yang, Zhifu
   Zhou, Siyuan
   Liu, Daozhou
TI Calcium phosphate hybrid micelles inhibit orthotopic bone metastasis
   from triple negative breast cancer by simultaneously killing cancer
   cells and reprogramming the microenvironment of bone resorption and
   immunosuppression
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Bone metastasis; Triple negative breast cancer; Bone resorption;
   Immunosuppression; Docetaxel; Zoledronate
ID CO DELIVERY; PROSTATE; DOXORUBICIN; PACLITAXEL; DOCETAXEL; TARGET
AB Triple negative breast cancer (TNBC) is prone to develop drug resistance and metastasis. Bone is the most common distant metastasis site of breast cancer cell. Patients with bone metastasis from TNBC suffer from unbearable pain due to the growth of bone metastasis and bone destruction. Simultaneously blocking the growth of bone metastasis and reprogramming the microenvironment of bone resorption and immunosuppression is a promising strategy to treat bone metastasis from TNBC. Herein, we prepared a pH and redox responsive drug delivery system, named DZ@CPH, by encapsulating docetaxel (DTX) with hyaluronic acid polylactic acid micelle then reinforcing with calcium phosphate and zoledronate for targeting to bone metastasis from TNBC. DZ@CPH reduced the activation of osteoclast and inhibited bone resorption by decreasing the expression of nuclear factor & kappa;B receptor ligand and increasing the expression of osteoprotegerin in drug resistant bone metastasis tissue. At the same time, DZ@CPH inhibited the invasion of bone metastatic TNBC cells by regulating the apoptosis related and invasion related protein expression. It also increased the sensitivity of orthotopic drug resistant bone metastasis to DTX by inhibiting the expression of P glycoprotein, Bcl 2 and transforming growth factor & beta; in tissue of drug resistant bone metastasis. Moreover, the ratio between M1 type macrophage to M2 type macrophage in bone metastasis tissue was increased by DZ@CPH. In a word, DZ@CPH blocked the growth of bone metastasis from drug resistant TNBC through inducing the apoptosis of drug resistant TNBC cells and reprogramming the microenvironment of bone resorption and immunosuppression. DZ@CPH has a great potential in clinical application for the treatment of bone metastasis from drug resistant TNBC.Statement of significanceTriple negative breast cancer (TNBC) is prone to develop bone metastasis. Now bone metastasis is still an intractable disease. In this study, docetaxel and zoledronate co loaded calcium phosphate hybrid micelles (DZ@CPH) were prepared. DZ@CPH reduced the activation of osteoclasts and inhibited bone resorption. At the same time, DZ@CPH inhibited the invasion of bone metastatic TNBC cells by regulating the expression of apoptosis and invasion related protein in bone metastasis tissue. Moreover, the ratio between M1 type macrophages to M2 type macrophages in bone metastases tissue was increased by DZ@CPH. In a word, DZ@CPH blocked vicious cycle between the growth of bone metastasis and bone resorption, which greatly improved the therapeutic effect on bone metastasis from drug resistant TNBC.& COPY; 2023 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Liu, Bao; Cheng, Ying; Liu, Miao; Ji, Qifeng; Zhang, Bangle; Zhou, Siyuan; Liu, Daozhou] Air Force Med Univ, Sch Pharm, Dept Pharmaceut, Xian 710032, Peoples R China.
   [Yang, Qian] Shaanxi Energy Inst, Sch Med, Dept Pharm, Xianyang 712000, Peoples R China.
   [Yang, Zhifu] Air Force Med Univ, Xijing Hosp, Dept Pharm, Xian 710032, Peoples R China.
   [Zhou, Siyuan] Air Force Med Univ, Sch Pharm, Key Lab Gastrointestinal Pharmacol Chinese Mat Med, Dept Pharmacol,State Adm Tradit Chinese Med, Xian 710032, Peoples R China.
   [Yang, Zhifu; Zhou, Siyuan; Liu, Daozhou] Changle West Rd 169, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University
RP Zhou, SY; Liu, DZ (通讯作者)，Air Force Med Univ, Sch Pharm, Dept Pharmaceut, Xian 710032, Peoples R China.; Yang, ZF; Zhou, SY; Liu, DZ (通讯作者)，Changle West Rd 169, Xian 710032, Shaanxi, Peoples R China.
EM yangtian_1973@163.com; zhousy@fmmu.edu.cn; ldzhhnxh@163.com
FU National Nature Sci ence Foundation [82073775, 81872803]; Shaanxi
   Province Key Re search and Development Projects [2021ZDLSF03 08,
   2023 YBSF 221, 2022SF 161]; Shaanxi Province Nature Science Foundation
   [2023 JC QN 0988]; Shaanxi Province Traditional Chinese Medicine Talents
   Project [2023 ZQNY 0 02]
FX This research was supported by the National Nature Sci ence Foundation
   (82073775, 81872803) , Shaanxi Province Key Re search and Development
   Projects (2021ZDLSF03 08, 2023 YBSF 221, 2022SF 161) . Shaanxi Province
   Nature Science Foundation (2023 JC QN 0988) . Shaanxi Province
   Traditional Chinese Medicine Talents Project (2023 ZQNY 0 02) .
CR Atehortua C, 2021, J BIOMED NANOTECHNOL, V17, P1184, DOI 10.1166/jbn.2021.3087
   Bai SB, 2019, NANOMED NANOTECHNOL, V21, DOI 10.1016/j.nano.2019.102054
   Cai Z, 2020, RSC ADV, V10, P4251, DOI 10.1039/c9ra07894k
   Chaudhari VS, 2020, J PHARMACEUT BIOMED, V186, DOI 10.1016/j.jpba.2020.113325
   Curtin P, 2012, BIOMATERIALS, V33, P1065, DOI 10.1016/j.biomaterials.2011.10.046
   de Vasquez MGV, 2021, J PHYS CHEM B, V125, P11308, DOI 10.1021/acs.jpcb.1c06108
   Deng B, 2017, MOL PHARMACEUT, V14, P1938, DOI 10.1021/acs.molpharmaceut.7b00025
   Draffin JE, 2004, CANCER RES, V64, P5702, DOI 10.1158/0008 5472.CAN 04 0389
   Ge XF, 2020, ENVIRON SCI TECHNOL, V54, P207, DOI 10.1021/acs.est.9b05145
   Ghafouri Fard S, 2021, BIOMED PHARMACOTHER, V142, DOI 10.1016/j.biopha.2021.112112
   Grigoreva T, 2021, CHEM BIOL INTERACT, V344, DOI 10.1016/j.cbi.2021.109510
   Hu KL, 2015, NANOSCALE, V7, P8607, DOI 10.1039/c5nr01084e
   Huang H, 2018, SENSORS BASEL, V18, DOI 10.3390/s18103249
   Huang JB, 2014, BIOMATERIALS, V35, P550, DOI 10.1016/j.biomaterials.2013.09.089
   Huang JS, 2021, J CONTROL RELEASE, V340, P259, DOI 10.1016/j.jconrel.2021.10.030
   Junankar S, 2015, CANCER DISCOV, V5, P35, DOI 10.1158/2159 8290.CD 14 0621
   Kameda Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041889
   Ke XZ, 2017, DRUG DELIV, V24, P1680, DOI 10.1080/10717544.2017.1396384
   Lee K, 2021, CARBOHYD POLYM, V260, DOI 10.1016/j.carbpol.2021.117817
   Liu DZ, 2022, ACS NANO, V16, P7409, DOI 10.1021/acsnano.1c09794
   Liu Z., 2021, INT J ONCOL, V58, P1
   Luo C, 2016, NANO LETT, V16, P5401, DOI 10.1021/acs.nanolett.6b01632
   Majidpoor J, 2021, MED ONCOL, V38, DOI 10.1007/s12032 020 01447 w
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Mierke CT, 2019, REP PROG PHYS, V82, DOI 10.1088/1361 6633/ab1628
   Misra S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00201
   Mitrofan LM, 2009, BONE, V45, P1153, DOI 10.1016/j.bone.2009.08.010
   Pan YX, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm 21 4052
   Pan YY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583084
   Pibuel MA, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420 021 00672 0
   Ponzetti M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21114124
   Qiang HP, 2022, TRANSL LUNG CANCER R, V11, P87, DOI 10.21037/tlcr 21 1033
   Qiao S, 2021, J CONTROL RELEASE, V336, P54, DOI 10.1016/j.jconrel.2021.06.015
   Quan YJ, 2021, INT J BIOL SCI, V17, P3288, DOI 10.7150/ijbs.63300
   Sethuraman V, 2021, EUR J PHARM SCI, V158, DOI 10.1016/j.ejps.2020.105657
   Shash LS, 2021, APPL IMMUNOHISTO M M, V29, P657, DOI 10.1097/PAI.0000000000000940
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tahara RK, 2019, ADV EXP MED BIOL, V1152, P105, DOI 10.1007/978 3 030 20301 6_7
   Tu DY, 2021, CELL BIOL INT, V45, P831, DOI 10.1002/cbin.11528
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wang BL, 2022, ADV SCI, V9, DOI 10.1002/advs.202201451
   Wang KL, 2018, MOL PHARMACEUT, V15, P2764, DOI 10.1021/acs.molpharmaceut.8b00266
   Wang KY, 2020, J CLIN INVEST, V130, P3603, DOI 10.1172/JCI133334
   Wang KF, 2021, ACS APPL MATER INTER, V13, P49519, DOI 10.1021/acsami.1c15393
   Wang X, 2021, ACS APPL MATER INTER, V13, P39112, DOI 10.1021/acsami.1c11583
   Wong SK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102587
   Wu CY, 2019, J ETHNOPHARMACOL, V232, P145, DOI 10.1016/j.jep.2018.12.023
   Xu HT, 2021, PHARM RES DORDR, V38, P1209, DOI 10.1007/s11095 021 03072 2
   Yang Q, 2021, J PHARM SCI US, V110, P876, DOI 10.1016/j.xphs.2020.11.005
   Yang X, 2020, J CONTROL RELEASE, V326, P615, DOI 10.1016/j.jconrel.2020.07.029
   Yousefi H, 2021, ONCOGENE, V40, P1043, DOI 10.1038/s41388 020 01588 2
   Zhang BT, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21976 w
   Zheng X, 2018, INT J MOL MED, V41, P3137, DOI 10.3892/ijmm.2018.3515
   Zheng Y, 2013, J BONE ONCOL, V2, P47, DOI 10.1016/j.jbo.2012.11.002
   Zhou L, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880 018 0327 7
   Zhou R, 2020, RSC ADV, V10, P7708, DOI 10.1039/c9ra09385k
NR 56
TC 7
Z9 7
U1 3
U2 41
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD AUG
PY 2023
VL 166
BP 640
EP 654
DI 10.1016/j.actbio.2023.05.038
EA JUN 2023
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA M3CG3
UT WOS:001028984800001
PM 37236576
DA 2025 08 17
ER

PT J
AU Kim, K
   Kong, SY
   Fulciniti, M
   Li, XF
   Song, WH
   Nahar, S
   Burger, P
   Rumizen, MJ
   Podar, K
   Chauhan, D
   Hideshima, T
   Munshi, NC
   Richardson, P
   Clark, A
   Ogden, J
   Goutopoulos, A
   Rastelli, L
   Anderson, KC
   Tai, YT
AF Kim, Kihyun
   Kong, Sun Young
   Fulciniti, Mariateresa
   Li, Xianfeng
   Song, Weihua
   Nahar, Sabikun
   Burger, Peter
   Rumizen, Mathew J.
   Podar, Klaus
   Chauhan, Dharminder
   Hideshima, Teru
   Munshi, Nikhil C.
   Richardson, Paul
   Clark, Ann
   Ogden, Janet
   Goutopoulos, Andreas
   Rastelli, Luca
   Anderson, Kenneth C.
   Tai, Yu Tzu
TI Blockade of the MEK/ERK signalling cascade by AS703026, a novel
   selective MEK1/2 inhibitor, induces pleiotropic anti myeloma activity
   in vitro and in vivo
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE multiple myeloma (MM); MEK1; 2 inhibitor; bone marrow stromal cells
   (BMSCs); novel kinase inhibitor therapy
ID ACTIVATING RAS MUTATIONS; PROTEIN KINASE CASCADE; MULTIPLE MYELOMA;
   BONE MARROW; N RAS; VEGF SECRETION; GENE MUTATIONS; CELL ADHESION;
   ONCOGENIC RAS; BRAF GENE
AB P>This study investigated the cytotoxicity and mechanism of action of AS703026, a novel, selective, orally bioavailable MEK1/2 inhibitor, in human multiple myeloma (MM). AS703026 inhibited growth and survival of MM cells and cytokine induced osteoclast differentiation more potently (9  to 10 fold) than AZD6244. Inhibition of proliferation induced by AS703026 was mediated by G(0) G(1) cell cycle arrest and was accompanied by reduction of MAF oncogene expression. AS703026 further induced apoptosis via caspase 3 and Poly ADP ribose polymerase (PARP) cleavage in MM cells, both in the presence or absence of bone marrow stromal cells (BMSCs). Importantly, AS703026 sensitized MM cells to a broad spectrum of conventional (dexamethasone, melphalan), novel or emerging (lenalidomide, perifosine, bortezomib, rapamycin) anti MM therapies. Significant tumour growth reduction in AS703026  vs. vehicle treated mice bearing H929 MM xenograft tumours correlated with downregulated pERK1/2, induced PARP cleavage, and decreased microvessels in vivo. Moreover, AS703026 (< 200 nmol/l) was cytotoxic against the majority of tumour cells tested from patients with relapsed and refractory MM (84%), regardless of mutational status of RAS and BRAF genes. Importantly, BMSC induced viability of MM patient cells was similarly blocked within the same dose range. Our results therefore support clinical evaluation of AS703026, alone or in combination with other anti MM agents, to improve patient outcome.
C1 [Kim, Kihyun; Kong, Sun Young; Fulciniti, Mariateresa; Li, Xianfeng; Song, Weihua; Nahar, Sabikun; Burger, Peter; Rumizen, Mathew J.; Podar, Klaus; Chauhan, Dharminder; Hideshima, Teru; Munshi, Nikhil C.; Richardson, Paul; Anderson, Kenneth C.; Tai, Yu Tzu] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
   [Kim, Kihyun; Kong, Sun Young; Fulciniti, Mariateresa; Li, Xianfeng; Song, Weihua; Nahar, Sabikun; Burger, Peter; Rumizen, Mathew J.; Podar, Klaus; Chauhan, Dharminder; Hideshima, Teru; Munshi, Nikhil C.; Richardson, Paul; Anderson, Kenneth C.; Tai, Yu Tzu] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
   [Kim, Kihyun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Haematol Oncol, Seoul, South Korea.
   [Clark, Ann; Ogden, Janet; Goutopoulos, Andreas; Rastelli, Luca] EMD Serono Res Inst, Rockland, MA USA.
C3 Harvard University; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute; Harvard Medical School; Harvard University; Harvard
   University Medical Affiliates; Dana Farber Cancer Institute; Harvard
   Medical School; Sungkyunkwan University (SKKU); Samsung Medical Center
RP Tai, YT (通讯作者)，Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,LeBow Inst Myeloma Therapeut, M551,44 Binney St, Boston, MA 02115 USA.
EM yu tzu_tai@dfci.harvard.edu
RI Kim, Kihyun/D 5175 2013; Anderson, Kenneth/ACP 5073 2022; Podar,
   Klaus/ABD 1112 2020; Kong, Sun Young/ABB 7914 2021; li,
   xianfeng/GYD 5825 2022; Munshi, Nikhil/ABE 2338 2021
OI Kim, Kihyun/0000 0002 5878 8895; Podar, Klaus/0000 0002 7414 3632
FU Multiple Myeloma Research Consortium; National Institutes of Health
   [RO 1 50947, PO1 78378]; SPORE [P50CA100707]; Lebow Fund
FX We thank Dr. William Dalton at Lee Moffitt Cancer Center, Tampa, FL; Dr.
   Steven Rosen at Northwestern University, Chicago, IL; Dr. Takemi Otsuki
   at Kawasaki Medical School, Okayama, Japan; Dr. Steven Rosen at
   Northwestern University, Chicago, IL; Dr. Renate Burger at University of
   Erlangen Nuernberg, Erlangen, Germany; Dr. Megumu Ogawa at Osaka
   University, Osaka, Japan for MM lines used in the study. The authors
   thank Dr Ender Soydan, Giovanni Tonon, and Sophia Adamia for help and
   suggestions on animal work, RAS gene mutation, and microphotography. We
   thank the nursing staff and clinical research coordinators of the LeBow
   Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma
   Center of Dana Farber Cancer Institute for their constant help in
   providing primary tumour specimens for this study. Multiple Myeloma
   Research Consortium (Y. T.Tai); National Institutes of Health Grants
   RO 1 50947, PO1 78378 and SPORE P50CA100707; and the Lebow Fund to Cure
   Myeloma (K.C.A.).
CR Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956
   Bezieau S, 2002, BLOOD, V100, P1101, DOI 10.1182/blood 2002 03 0795
   BILLADEAU D, 1995, CANCER RES, V55, P3640
   Bonello L, 2003, LEUKEMIA, V17, P2238, DOI 10.1038/sj.leu.2403116
   Burger R, 2001, Hematol J, V2, P42, DOI 10.1038/sj.thj.6200075
   Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729
   Chng WJ, 2008, LEUKEMIA, V22, P2280, DOI 10.1038/leu.2008.142
   Chou TC, 2008, LEUKEMIA LYMPHOMA, V49, P2059, DOI 10.1080/10428190802353591
   CLARK AM, 2009, P 100 ANN M AM ASS C
   CORRADINI P, 1993, BLOOD, V81, P2708
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Friday BB, 2008, CLIN CANCER RES, V14, P342, DOI 10.1158/1078 0432.CCR 07 4790
   Giuliani N, 2004, LEUKEMIA, V18, P628, DOI 10.1038/sj.leu.2403269
   GOUTOPOULOS A, 2009, P 100 ANN M AM ASS C
   Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood 2004 01 0037
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Hideshima T, 2006, BLOOD, V107, P4053, DOI 10.1182/blood 2005 08 3434
   Hoang B, 2006, BLOOD, V107, P4484, DOI 10.1182/blood 2005 09 3926
   Hu LP, 2003, BLOOD, V101, P3126, DOI 10.1182/blood 2002 08 2640
   Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535 6108(04)00019 4
   Intini D, 2007, HEMATOL ONCOL, V25, P6, DOI 10.1002/hon.801
   Kalakonda N, 2001, BLOOD, V98, P1555, DOI 10.1182/blood.V98.5.1555
   Liu PC, 1996, BLOOD, V88, P2699, DOI 10.1182/blood.V88.7.2699.bloodjournal8872699
   MACHL AW, 2009, P 100 ANN M AM ASS C
   Menu E, 2004, BRIT J CANCER, V90, P1076, DOI 10.1038/sj.bjc.6601613
   PORTIER M, 1992, ONCOGENE, V7, P2539
   Pratilas CA, 2007, REV RECENT CLIN TRIA, V2, P121, DOI 10.2174/157488707780599393
   Rasmussen T, 2005, BLOOD, V105, P317, DOI 10.1182/blood 2004 03 0833
   Richardson P, 2006, J CLIN ONCOL, V24, P334, DOI 10.1200/JCO.2005.03.8851
   Richardson P, 2009, BLOOD, V114, P772, DOI 10.1182/blood 2008 12 196238
   Sebolt Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503
   Shain KH, 2009, CANCER RES, V69, P1009, DOI 10.1158/0008 5472.CAN 08 2419
   Smalley KSM, 2009, ONCOGENE, V28, P85, DOI 10.1038/onc.2008.362
   Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304
   Tai YT, 2005, CANCER RES, V65, P5898, DOI 10.1158/0008 5472.CAN 04 4125
   Tai YT, 2004, CANCER RES, V64, P2846, DOI 10.1158/0008 5472.CAN 03 3630
   Tai YT, 2003, CANCER RES, V63, P5850
   Tai YT, 2008, BLOOD, V112, P1329, DOI 10.1182/blood 2007 08 107292
   Tai YT, 2007, BLOOD, V110, P1656, DOI 10.1182/blood 2007 03 081240
   Tai YT, 2009, BLOOD, V113, P4309, DOI 10.1182/blood 2008 10 183772
   Tiedemann RE, 2008, LEUKEMIA, V22, P1044, DOI 10.1038/leu.2008.4
NR 41
TC 85
Z9 94
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1048
EI 1365 2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD MAY
PY 2010
VL 149
IS 4
BP 537
EP 549
DI 10.1111/j.1365 2141.2010.08127.x
PG 13
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 588BI
UT WOS:000277040700008
PM 20331454
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Huang, M
   Li, XP
   Li, G
AF Huang, Meng
   Li, Xiaopeng
   Li, Guo
TI Mesenchyme homeobox 1 mediated promotion of osteoblastic differentiation
   is negatively regulated by mir 3064 5p
SO DIFFERENTIATION
LA English
DT Article
DE Human mesenchymal stem cells; Osteogenesis; Osteoporosis; Meox1;
   miR 3064 5p
ID OSTEOGENIC DIFFERENTIATION; TUMOR PROGRESSION; STEM CELLS; BONE; RUNX2
AB Human mesenchymal stem cells (hMSCs) are multipotent cells that can be differentiated into different cell types including osteoblasts. Herein we aimed to assess the regulation of transcription factor mesenchyme homeobox 1 (Meox1) in the osteogenic differentiation of hMSCs and to determine the microRNA which targets on Meox1. Total RNA was extracted from the isolated ligamentum flavum tissue samples and cultured hMSCs, and the expression of Meox1 was assessed by RT PCR and Western blot assays. Cultured hMSCs were induced towards osteoblastic differentiation, and the osteoblast phenotype was determined by alkaline phosphatase activity and alizarin red staining. The microRNA targeting on the 3 ' UTR of Meox1was predicted using bioinformatics tool, and the binding was validated by luciferase and RNA pulldown assays. The osteoblastic differentiation of hMSCs was checked with the knockdown of Meox1 and microRNA inhibitors. Higher expression of Meox1, and lower expression of miR 3064 5p in ossified ligamentum flavum (OLF) tissues were identified. In addition, increased expression along with the osteoblastic differentiation of hMSCs was found. Further research revealed that Meox was a direct target of miR 3064 5p, when the former promoted the differentiation of hMSCs into osteoblasts, the latter significantly suppressed the osteogenesis. The expression of Meox1 increased gradually with the osteoblastic differentiation of hMSCs, during which miR 3064 5p decreased. Meox1 is a direct target of miR 3064 5p, and they both play important roles in the osteogenesis. These findings provide potential target for the development of therapeutic drugs for skeletal system diseases.
C1 [Huang, Meng; Li, Xiaopeng] Qingdao Univ, Dept Clin Lab, Affiliated Hosp, 59 Haier Rd, Qingdao 266000, Shandong, Peoples R China.
   [Li, Guo] Qingdao Univ, Dept Resp & Crit Care Med, Affiliated Hosp, 59 Haier Rd, Qingdao 266000, Shandong, Peoples R China.
C3 Qingdao University; Qingdao University
RP Li, G (通讯作者)，Qingdao Univ, Dept Resp & Crit Care Med, Affiliated Hosp, 59 Haier Rd, Qingdao 266000, Shandong, Peoples R China.
EM liguo88@aliyun.com
RI Li, Xiaopeng/AAN 3868 2021
CR Ahn DK, 2014, ASIAN SPINE J, V8, P89, DOI 10.4184/asj.2014.8.1.89
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   Carbonare LD, 2012, STEM CELL REV REP, V8, P891, DOI 10.1007/s12015 011 9337 4
   Chen YT, 2011, SPINE, V36, pE1193, DOI 10.1097/BRS.0b013e3182053f58
   Chiang CW, 2015, INT J MOL SCI, V16, P23318, DOI 10.3390/ijms161023318
   Dauer MVP, 2018, J ANAT, V233, P687, DOI 10.1111/joa.12890
   Deng Y, 2013, STEM CELLS DEV, V22, P2278, DOI 10.1089/scd.2012.0686
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Farina NH, 2016, ONCOTARGET, V7, P70462, DOI 10.18632/oncotarget.11992
   Fu C., 2020, STEMEDICINE, V1, pE57, DOI DOI 10.37175/STEMEDICINE.V1I4.57
   Geber J, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 27522 x
   GLOWACKI J, 1991, J CELL BIOCHEM, V45, P292, DOI 10.1002/jcb.240450312
   Gu CX, 2016, SCI REP UK, V6, DOI 10.1038/srep38491
   Kajimura D, 2011, J EXP MED, V208, P841, DOI 10.1084/jem.20102608
   Kolf CM, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0223 x
   Li X, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154677
   Mizuno M, 2000, CALCIFIED TISSUE INT, V66, P388, DOI 10.1007/s002230010078
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Pisani P, 2016, WORLD J ORTHOP, V7, P171, DOI 10.5312/wjo.v7.i3.171
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Sera SR, 2017, CURR OSTEOPOROS REP, V15, P353, DOI 10.1007/s11914 017 0379 7
   Skuntz S, 2009, DEV BIOL, V332, P383, DOI 10.1016/j.ydbio.2009.06.006
   Sun LC, 2019, INT J MED SCI, V16, P68, DOI 10.7150/ijms.27595
   Sun XL, 2019, BIOCHEM BIOPH RES CO, V515, P16, DOI 10.1016/j.bbrc.2019.05.079
   Tuan RS, 2003, ARTHRITIS RES THER, V5, P32, DOI 10.1186/ar614
   Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166
   Wang CC, 2016, J CLIN INVEST, V126, P1471, DOI 10.1172/JCI80672
   Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057
   Xu Z., 2020, STEMEDICINE, V2, pe67, DOI [10.37175/stemedicine.v2i5.67, DOI 10.37175/STEMEDICINE.V2I5.67]
   Yamamoto K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137887
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
NR 33
TC 8
Z9 8
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0301 4681
EI 1432 0436
J9 DIFFERENTIATION
JI Differentiation
PD JUL AUG
PY 2021
VL 120
BP 19
EP 27
DI 10.1016/j.diff.2021.05.002
EA JUN 2021
PG 9
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA TQ8RA
UT WOS:000678544100003
PM 34130045
DA 2025 08 17
ER

PT J
AU Li, LL
   Li, HL
   Wang, Q
   Xue, YT
   Dai, Y
   Dong, YH
   Shao, MH
   Lyu, FZ
AF Li, Linli
   Li, Hailong
   Wang, Qi
   Xue, Yitong
   Dai, Yuan
   Dong, Youhai
   Shao, Minghao
   Lyu, Feizhou
TI Hydroxyapatite Nanoparticles Promote the Development of Bone
   Microtissues for Accelerated Bone Regeneration by Activating the FAK/Akt
   Pathway
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE bone organoid; bone microtissues; hydroxyapatitenanoparticle; osteogenic
   differentiation; bone regeneration; FAK/Akt pathway
ID OSTEOBLAST; MINERALIZATION; BIOMATERIALS; YAP/TAZ
AB Scaffold free bone microtissues differentiated from mesenchymal stem cell (MSC) spheroids offer great potential for bottom up bone tissue engineering as a direct supply of cells and osteogenic signals. Many biomaterials or biomolecules have been incorporated into bone microtissues to enhance their osteogenic abilities, but these materials are far from clinical approval. Here, we aimed to incorporate hydroxyapatite (HAP) nanoparticles, an essential component of bone matrix, into MSC spheroids to instruct their osteogenic differentiation into bone microtissues and further self organization into bone organoids with a trabecular structure. Furthermore, the biological interaction between HAP nanoparticles and MSCs and the potential molecular mechanisms in the bone development of MSC spheroids were investigated by both in vitro and in vivo studies. As a result, improved cell viability and osteogenic abilities were observed for the MSC spheroids incorporated with HAP nanoparticles at a concentration of 30 mu g/mL. HAP nanoparticles could promote the sequential expression of osteogenic markers (Runx2, Osterix, Sclerostin), promote the expression of bone matrix proteins (OPN, OCN, and Collagen I), promote the mineralization of the bone matrix, and thus promote the bone development of MSC spheroids. The differentiated bone microtissues could further self organize into linear, lamellar, and spatial bone organoids with trabecular structures. More importantly, adding FAK or Akt inhibitors could decrease the level of HAP induced osteogenic differentiation of bone microtissues. Finally, excellent new bone regeneration was achieved after injecting bone microtissues into cranial bone defect models, which could also be eliminated by the Akt inhibitor. In conclusion, HAP nanoparticles could promote the development of bone microtissues by promoting the osteogenic differentiation of MSCs and the formation and mineralization of the bone matrix via the FAK/Akt pathway. The bone microtissues could act as individual ossification centers and self organize into macroscale bone organoids, and in this meaning, the bone microtissues could be called microscale bone organoids. Furthermore, the bone microtissues revealed excellent clinical perspectives for injectable cellular therapies for bone defects.
C1 [Li, Linli; Wang, Qi; Xue, Yitong; Dai, Yuan; Shao, Minghao; Lyu, Feizhou] Fudan Univ, Huashan Hosp, Dept Orthoped, Shanghai 200040, Peoples R China.
   [Li, Linli; Li, Hailong; Dong, Youhai; Lyu, Feizhou] Fudan Univ, Shanghai Peoples Hosp 5, Dept Orthoped, Shanghai 200240, Peoples R China.
C3 Fudan University; Fudan University
RP Shao, MH; Lyu, FZ (通讯作者)，Fudan Univ, Huashan Hosp, Dept Orthoped, Shanghai 200040, Peoples R China.; Lyu, FZ (通讯作者)，Fudan Univ, Shanghai Peoples Hosp 5, Dept Orthoped, Shanghai 200240, Peoples R China.
EM shao_minghao@126.com; lufeizhou@hotmail.com
RI ; 黎, 林丽/ABC 1632 2021; SHAO, MINGHAO/LIF 9804 2024
OI Li, Linli/0000 0002 2095 5635; Dai, Yuan/0000 0002 9068 6813; 
FU National Natural Science Foundation of China [82202678]; National
   Natural Science Foundation of China [22YF1434200]; Shanghai Rising Star
   Program
FX This study was funded by the National Natural Science Foundation of
   China (No. 82202678) and the Shanghai Rising Star Program (No.
   22YF1434200).
CR Ahmad T, 2020, BIOMATERIALS, V230, DOI 10.1016/j.biomaterials.2019.119652
   Akiva A, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202010524
   Armiento AR, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909874
   Bratt Leal AM, 2011, BIOMATERIALS, V32, P48, DOI 10.1016/j.biomaterials.2010.08.113
   Burdis R, 2021, ACTA BIOMATER, V126, P1, DOI 10.1016/j.actbio.2021.03.016
   Campi G, 2017, NANOSCALE, V9, P17274, DOI 10.1039/c7nr05013e
   Campi G, 2015, ACTA BIOMATER, V23, P309, DOI 10.1016/j.actbio.2015.05.033
   Campi G, 2012, ACTA BIOMATER, V8, P3411, DOI 10.1016/j.actbio.2012.05.034
   Capulli M, 2014, ARCH BIOCHEM BIOPHYS, V561, P3, DOI 10.1016/j.abb.2014.05.003
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chen SS, 2022, BIOACT MATER, V18, P15, DOI 10.1016/j.bioactmat.2022.01.048
   De Witte TM, 2018, REGEN BIOMATER, V5, P197, DOI 10.1093/rb/rby013
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Dupont S, 2016, EXP CELL RES, V343, P42, DOI 10.1016/j.yexcr.2015.10.034
   Ebrahimi Z, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 15602 y
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Gieroba B, 2021, MAT SCI ENG C MATER, V119, DOI 10.1016/j.msec.2020.111634
   Gionet Gonzales MA, 2018, BIOMED MATER, V13, DOI 10.1088/1748 605X/aab0b3
   Ha SW, 2015, BIOMATERIALS, V65, P32, DOI 10.1016/j.biomaterials.2015.06.039
   Hu C, 2019, BIOMATERIALS, V219, DOI 10.1016/j.biomaterials.2019.119366
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Iordachescu A, 2021, NPJ MICROGRAVITY, V7, DOI 10.1038/s41526 021 00146 8
   Koons GL, 2020, NAT REV MATER, V5, P584, DOI 10.1038/s41578 020 0204 2
   Lee BY, 2015, PHARMACOL THERAPEUT, V146, P132, DOI 10.1016/j.pharmthera.2014.10.001
   Li LL, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00164 w
   Li LL, 2021, MAT SCI ENG C MATER, V121, DOI 10.1016/j.msec.2020.111812
   Lin HS, 2017, BIOFABRICATION, V9, DOI 10.1088/1758 5090/aa663b
   Liu S, 2024, ADV FUNCT MATER, V34, DOI 10.1002/adfm.202306534
   Liu XF, 2022, ACS NANO, V16, P2741, DOI 10.1021/acsnano.1c09688
   Matsuguchi T, 2009, J BONE MINER RES, V24, P398, DOI 10.1359/JBMR.081107
   Hall GN, 2021, BIOFABRICATION, V13, DOI 10.1088/1758 5090/ac2208
   Ogueri KS, 2020, ACS NANO, V14, P9347, DOI 10.1021/acsnano.0c03981
   Oryan A, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 18
   Park Y, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd6495
   Pini J, 2018, J BONE MINER RES, V33, P1826, DOI 10.1002/jbmr.3474
   Sun K, 2020, OSTEOARTHR CARTILAGE, V28, P400, DOI 10.1016/j.joca.2020.02.027
   Totaro A, 2018, NAT CELL BIOL, V20, P888, DOI 10.1038/s41556 018 0142 z
   Wang C, 2020, BIOACT MATER, V5, P82, DOI 10.1016/j.bioactmat.2020.01.004
   Wen Y, 2023, ADV SCI, V10, DOI 10.1002/advs.202301833
   Winkler T, 2018, BONE JOINT RES, V7, P232, DOI 10.1302/2046 3758.73.BJR 2017 0270.R1
   Wu B, 2023, NAT CELL BIOL, V25, P415, DOI 10.1038/s41556 023 01092 1
   Xu ZL, 2012, J APPL TOXICOL, V32, P429, DOI 10.1002/jat.1745
   Zhang Q, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202204182
   Zhang RJ, 2016, ADV FUNCT MATER, V26, P7965, DOI 10.1002/adfm.201602088
   Zhao D, 2024, ADV HEALTHC MATER, V13, DOI 10.1002/adhm.202302088
   Zhao ZY, 2021, ACS NANO, V15, P13041, DOI 10.1021/acsnano.1c02147
NR 46
TC 7
Z9 7
U1 11
U2 39
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD JUN 7
PY 2024
VL 10
IS 7
BP 4463
EP 4479
DI 10.1021/acsbiomaterials.4c00574
EA JUN 2024
PG 17
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA XW6J1
UT WOS:001242698500001
PM 38848471
DA 2025 08 17
ER

PT J
AU Smidt Hansen, T
   Folkmar, TB
   Fode, K
   Agerbaek, M
   Donskov, F
AF Smidt Hansen, Torben
   Folkmar, Troels B.
   Fode, Kirsten
   Agerbaek, Mads
   Donskov, Frede
TI Combination of Zoledronic Acid and Targeted Therapy Is Active But May
   Induce Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell
   Carcinoma
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID SKELETAL RELATED EVENTS; CANCER PATIENTS; BISPHOSPHONATES; SURVIVAL;
   SUNITINIB; BREAST; PROGRESSION; PROSTATE; ADHESION; NECROSIS
AB Purpose: To investigate the efficacy and safety of zoledronic acid (ZA) combined with targeted therapy (TT).
   Materials and Methods: A retrospective study was performed in patients with metastatic renal cell carcinoma treated with ZA and TT.
   Results: Twenty one patients received ZA and TT to prevent skeletal related events and no pretherapy oral and maxillofacial (OM) examination (cohort A). Six patients (29%) developed osteonecrosis of the jaw (ONJ), which was observed only in patients receiving sunitinib and ZA. Sixteen patients received TT and ZA for hypercalcemia and no pretherapy OM examination (cohort B). In these patients, no ONJ was observed. Nine patients received ZA and TT and pretherapy OM examination (cohort C). One patient (11%) developed ONJ during sunitinib and ZA treatment. Mean skeletal morbidity rates were 0.8 for cohort A and 1.2 for cohort C. In the combined cohort (A plus C; n = 30), 47% developed skeletal related events, 7% pathologic fracture, 7% medullary compression, and 37% progression of bone metastases. Patients who developed ONJ had a significantly improved median survival of 31.6 months compared with 14.5 months in patients without ONJ (P = .039).
   Conclusion: The combination of ZA and TT resulted in high, clinically meaningful activity. ONJ may be exacerbated by concomitant ZA and sunitinib. Regular OM examinations before and during treatment are recommended. (C) 2013 American Association of Oral and Maxillofacial Surgeons
C1 [Smidt Hansen, Torben; Fode, Kirsten; Agerbaek, Mads; Donskov, Frede] Aarhus Univ Hosp, Dept Oncol, DK 8000 Aarhus C, Denmark.
   [Folkmar, Troels B.] Aarhus Univ Hosp, Dept Oral & Maxillofacial Surg, DK 8000 Aarhus C, Denmark.
C3 Aarhus University; Aarhus University
RP Smidt Hansen, T (通讯作者)，Aarhus Univ Hosp, Dept Oncol, Norrebrogade 44, DK 8000 Aarhus C, Denmark.
EM torhan@rm.dk
OI Donskov, Frede/0000 0002 8449 863X; Agerbaek, Mads/0000 0003 3923 6136
FU Danish Medical Association Research Fund; Department of Oncology,
   Institute for Clinical Medicine, Aarhus University Hospital; Region Midt
   Research Fund; Novartis; Roche
FX This work was supported by the Danish Medical Association Research Fund;
   the Department of Oncology Research Fund, Institute for Clinical
   Medicine, Aarhus University Hospital; and the Region Midt Research Fund.
   Dr Donskov has received research grants from Novartis and Roche.
CR Agrillo A, 2012, EUR REV MED PHARMACO, V16, P952
   Ayllon J, 2009, ANN ONCOL, V20, P600, DOI 10.1093/annonc/mdn788
   Beuselinck B, 2012, BRIT J CANCER, V107, P1665, DOI 10.1038/bjc.2012.385
   Beuselinck B, 2011, ANN ONCOL, V22, P794, DOI 10.1093/annonc/mdq554
   Beuselinck BL, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.7_suppl.388
   Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200
   Boissier S, 2000, CANCER RES, V60, P2949
   Boissier S, 1997, CANCER RES, V57, P3890
   Bozas G, 2010, ONKOLOGIE, V33, P321, DOI 10.1159/000313680
   Brunello A, 2009, BONE, V44, P173, DOI 10.1016/j.bone.2008.08.132
   Christodoulou C, 2009, ONCOLOGY BASEL, V76, P209, DOI 10.1159/000201931
   Derenne S, 1999, J BONE MINER RES, V14, P2048, DOI 10.1359/jbmr.1999.14.12.2048
   Dieli F, 2003, BLOOD, V102, P2310, DOI 10.1182/blood 2003 05 1655
   Filleul O, 2010, J CANCER RES CLIN, V136, P1117, DOI 10.1007/s00432 010 0907 7
   Fleissig Y, 2012, OR SURG OR MED OR PA, V113, pE1, DOI 10.1016/j.tripleo.2011.06.023
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Haidar A, 2009, SCAND J UROL NEPHROL, V43, P442, DOI 10.3109/00365590903295193
   Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Hoefert S, 2010, ORAL SURG ORAL MED O, V110, P463, DOI 10.1016/j.tripleo.2010.04.049
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Keizman D, 2012, EUR J CANCER, V48, P1031, DOI 10.1016/j.ejca.2012.02.050
   Khosla S, 2007, CRIT REV ONCOL HEMAT, V22, P1479
   Koch FP, 2011, ORAL MAXILLOFAC SURG, V15, P63, DOI 10.1007/s10006 010 0224 y
   Lipton A, 2003, CANCER, V98, P962, DOI 10.1002/cncr.11571
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   MANI S, 1995, J UROLOGY, V154, P35, DOI 10.1016/S0022 5347(01)67218 5
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Motzer RJ, 1999, J CLIN ONCOL, V17, P2530, DOI 10.1200/JCO.1999.17.8.2530
   Pandha H, 2006, J UROLOGY, V176, P2255, DOI 10.1016/j.juro.2006.07.053
   Reid IR, 2009, SKELETAL RADIOL, V38, P5, DOI 10.1007/s00256 008 0549 x
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Ruggiero SL, 2009, AUST ENDOD J, V35, P119, DOI 10.1111/j.1747 4477.2009.00213.x
   Saad F, 2010, SEMIN ONCOL, V37, pS38, DOI 10.1053/j.seminoncol.2010.06.001
   Santini D, 2007, CLIN CANCER RES, V13, P4482, DOI 10.1158/1078 0432.CCR 07 0551
   Vincenzi B, 2005, J INTERF CYTOK RES, V25, P144, DOI 10.1089/jir.2005.25.144
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Wood SL, 2012, CANCER TREAT REV, V38, P284, DOI 10.1016/j.ctrv.2011.06.011
   Woodward E, 2011, BONE, V48, P160, DOI 10.1016/j.bone.2010.09.008
   Yuasa T, 2012, INT J CLIN ONCOL, DOI DOI 10.1007/S10147 012 0472 Y;2012
NR 40
TC 47
Z9 52
U1 0
U2 7
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0278 2391
EI 1531 5053
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD SEP
PY 2013
VL 71
IS 9
BP 1532
EP 1540
DI 10.1016/j.joms.2013.03.019
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 207NS
UT WOS:000323608900009
PM 23642545
DA 2025 08 17
ER

PT J
AU Fregnani, A
   Saggin, L
   Gianesin, K
   Tubi, LQ
   Carraro, M
   Barilà, G
   Scapinello, G
   Bonetto, G
   Pesavento, M
   Berno, T
   Branca, A
   Gurrieri, C
   Zambello, R
   Semenzato, G
   Trentin, L
   Manni, S
   Piazza, F
AF Fregnani, Anna
   Saggin, Lara
   Gianesin, Ketty
   Tubi, Laura Quotti
   Carraro, Marco
   Barila, Gregorio
   Scapinello, Greta
   Bonetto, Giorgia
   Pesavento, Maria
   Berno, Tamara
   Branca, Antonio
   Gurrieri, Carmela
   Zambello, Renato
   Semenzato, Gianpietro
   Trentin, Livio
   Manni, Sabrina
   Piazza, Francesco
TI CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic
   Target in Multiple Myeloma
SO CANCERS
LA English
DT Article
DE multiple myeloma; bone marrow microenvironment; CK1 alpha; RUNX2; target
   therapy
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; LENALIDOMIDE; RUNX2;
   OSTEOCLASTOGENESIS; RUNX2/CBFA1; CBFA1/RUNX2; THALIDOMIDE; RESORPTION;
   EXPRESSION
AB Multiple myeloma (MM) is a malignant plasma cell (PC) neoplasm, which also displays pathological bone involvement. Clonal expansion of MM cells in the bone marrow causes a perturbation of bone homeostasis that culminates in MM associated bone disease (MMABD). We previously demonstrated that the S/T kinase CK1 alpha sustains MM cell survival through the activation of AKT and beta catenin signaling. CK1 alpha is a negative regulator of the Wnt/beta catenin cascade, the activation of which promotes osteogenesis by directly stimulating the expression of RUNX2, the master gene regulator of osteoblastogenesis. In this study, we investigated the role of CK1 alpha in the osteoblastogenic potential of mesenchymal stromal cells (MSCs) and its involvement in MM MSC cross talk. We found that CK1 alpha silencing in in vitro co cultures of MMs and MSCs modulated RUNX2 expression differently in PCs and in MSCs, mainly through the regulation of Wnt/beta catenin signaling. Our findings suggest that the CK1 alpha/RUNX2 axis could be a potential therapeutic target for constraining malignant PC expansion and supporting the osteoblastic transcriptional program of MSCs, with potential for ameliorating MMABD. Moreover, considering that Lenalidomide treatment leads to MM cell death through Ikaros, Aiolos and CK1 alpha proteasomal degradation, we examined its effects on the osteoblastogenic potential of MSC compartments.
C1 [Fregnani, Anna; Saggin, Lara; Gianesin, Ketty; Tubi, Laura Quotti; Carraro, Marco; Barila, Gregorio; Scapinello, Greta; Bonetto, Giorgia; Pesavento, Maria; Berno, Tamara; Branca, Antonio; Gurrieri, Carmela; Zambello, Renato; Semenzato, Gianpietro; Trentin, Livio; Manni, Sabrina; Piazza, Francesco] Univ Padua, Dept Med, Hematol & Clin Immunol Branch, I 35128 Padua, Italy.
   [Fregnani, Anna; Saggin, Lara; Gianesin, Ketty; Tubi, Laura Quotti; Barila, Gregorio; Pesavento, Maria; Zambello, Renato; Semenzato, Gianpietro; Trentin, Livio; Manni, Sabrina; Piazza, Francesco] Veneto Inst Mol Med VIMM, Lab Myeloma & Lymphoma Pathobiol, I 35129 Padua, Italy.
C3 University of Padua
RP Manni, S; Piazza, F (通讯作者)，Univ Padua, Dept Med, Hematol & Clin Immunol Branch, I 35128 Padua, Italy.; Manni, S; Piazza, F (通讯作者)，Veneto Inst Mol Med VIMM, Lab Myeloma & Lymphoma Pathobiol, I 35129 Padua, Italy.
EM sabrina.manni@unipd.it; francesco.piazza@unipd.it
RI SEMENZATO, GIANPIETRO/J 7727 2016; TRENTIN, LIVIO/J 7676 2016; Zambello,
   Renato/AAB 5280 2022; Manni, Sabrina/AAE 9182 2021; Piazza,
   Francesco/K 6695 2016; Barilà, Gregorio/KLY 9482 2024; Branca,
   Antonio/ADK 9593 2022; gurrieri, carmela/AAA 5365 2022; Scapinello,
   Greta/IAR 6907 2023
OI TRENTIN, LIVIO/0000 0003 1222 6149; Barila,
   Gregorio/0000 0003 3430 6115; MANNI, SABRINA/0000 0001 6804 0680; 
FU Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 18387, IG
   25024]; PRIN (Progetti di rilevante interesse nazionale) MIUR
   [2017ZXT5WR]
FX This work was supported by grants from the Associazione Italiana per la
   Ricerca sul Cancro (AIRC) to F.P. (IG 18387) and L.T. (IG 25024), PRIN
   (Progetti di rilevante interesse nazionale) MIUR Prot. 2017ZXT5WR to
   S.M. and Ricerca per Credere nella vita (R.C.V.) ODV to L.T.
CR Abramson HN, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155192
   Artigas N, 2017, CELL DEATH DIFFER, V24, P2022, DOI 10.1038/cdd.2017.113
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bingham N, 2017, CURR HEMATOL MALIG R, V12, P109, DOI 10.1007/s11899 017 0370 5
   Bolomsky A, 2014, EXP HEMATOL, V42, P516, DOI 10.1016/j.exphem.2014.03.005
   Bolzoni M, 2013, EXP HEMATOL, V41, P387, DOI 10.1016/j.exphem.2012.11.005
   Breitkreutz I, 2008, LEUKEMIA, V22, P1925, DOI 10.1038/leu.2008.174
   Brigle K, 2017, SEMIN ONCOL NURS, V33, P225, DOI 10.1016/j.soncn.2017.05.012
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Caetano Lopes J, 2007, ACTA REUMATOL PORT, V32, P103
   Carrino M, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420 019 0179 1
   Castaneda Omar, 2019, Acta Med Acad, V48, P57, DOI 10.5644/ama2006 124.242
   Caverzasio J, 2007, ENDOCRINOLOGY, V148, P5323, DOI 10.1210/en.2007 0520
   Cohen Solal KA, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0404 3
   Colla S, 2005, LEUKEMIA, V19, P2166, DOI 10.1038/sj.leu.2403976
   Corre J, 2015, BLOOD, V125, P1870, DOI 10.1182/blood 2014 10 567370
   Costa F, 2017, ONCOTARGET, V8, P53053, DOI 10.18632/oncotarget.18085
   Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097 4652(200009)184:3<341::AID JCP8>3.3.CO;2 Q
   Du JS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073389
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Eijken M, 2008, J CELL BIOCHEM, V104, P568, DOI 10.1002/jcb.21651
   Fink EC, 2015, BLOOD, V126, P2366, DOI 10.1182/blood 2015 07 567958
   García Ortiz A, 2021, CANCERS, V13, DOI 10.3390/cancers13020217
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222 6233.2002
   Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Giuliani N, 2002, BLOOD, V100, P4615, DOI 10.1182/blood 2002 04 1121
   Giuliani N, 2009, EXP HEMATOL, V37, P879, DOI 10.1016/j.exphem.2009.04.004
   Haxaire C, 2016, AM J PATHOL, V186, P1598, DOI 10.1016/j.ajpath.2016.01.016
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Hu Y, 2015, LEUKEMIA, V29, P474, DOI 10.1038/leu.2014.202
   James MJ, 2006, J BONE MINER RES, V21, P1034, DOI 10.1359/JBMR.060413
   Janovská P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239026
   Jiang SJ, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964 018 0236 z
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130
   Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200
   Liao NN, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249894
   Liu X, 2020, ONCOGENE, V39, P176, DOI 10.1038/s41388 019 0979 z
   Lonial S, 2020, LANCET ONCOL, V21, P207, DOI 10.1016/S1470 2045(19)30788 0
   Manni S, 2014, LEUKEMIA, V28, P2094, DOI 10.1038/leu.2014.178
   Manni S, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.733848
   Manni S, 2017, ONCOTARGET, V8, P14604, DOI [10.18632/oncotarget.14678, 10.18632/oncotarget.14654]
   Manni S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075280
   Marino S, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031286
   Mazziotta C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052362
   Mihara K, 2003, BRIT J HAEMATOL, V120, P846, DOI 10.1046/j.1365 2141.2003.04217.x
   Munemasa S, 2008, INT J ONCOL, V33, P129
   Nierste BA, 2014, AM J BLOOD RES, V4, P73
   Panaroni C, 2017, CURR OSTEOPOROS REP, V15, P483, DOI 10.1007/s11914 017 0397 5
   Piazza F, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 526
   Rajkumar SV, 2020, AM J HEMATOL, V95, P548, DOI 10.1002/ajh.25791
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   ROECKLEIN BA, 1995, BLOOD, V85, P997, DOI 10.1182/blood.V85.4.997.bloodjournal854997
   Schneider RK, 2014, CANCER CELL, V26, P509, DOI 10.1016/j.ccr.2014.08.001
   Scullen T, 2013, LEUKEMIA, V27, P1715, DOI 10.1038/leu.2013.50
   Shen C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165940
   Spinello Z, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073716
   Storti P, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092864
   Sweeney K, 2020, MOL CELLS, V43, P188, DOI 10.14348/molcells.2019.0310
   Tai YT, 2014, BLOOD, V123, P3128, DOI 10.1182/blood 2013 10 535088
   TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607
   Trotter TN, 2015, BLOOD, V125, P3598, DOI 10.1182/blood 2014 12 613968
   Venerando A, 2010, CELL MOL LIFE SCI, V67, P1105, DOI 10.1007/s00018 009 0236 7
   Wobus M, 2012, EXP HEMATOL, V40, P867, DOI 10.1016/j.exphem.2012.06.004
   Yavropoulou Maria P, 2007, Hormones (Athens), V6, P279
   Zhang PP, 2020, LEUKEMIA RES, V92, DOI 10.1016/j.leukres.2020.106340
   Zhang Y, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045 020 00990 3
NR 70
TC 5
Z9 6
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD SEP
PY 2022
VL 14
IS 17
AR 4173
DI 10.3390/cancers14174173
PG 22
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 4J1WR
UT WOS:000851061500001
PM 36077711
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, SY
   Ma, QL
   Xie, Z
   Shen, Y
   Zheng, BJ
   Jiang, C
   Yuan, PT
   An, Q
   Fan, SW
   Jie, ZW
AF Wang, Shiyu
   Ma, Qingliang
   Xie, Ziang
   Shen, Yang
   Zheng, Bingjie
   Jiang, Chao
   Yuan, Putao
   An, Qin
   Fan, Shunwu
   Jie, Zhiwei
TI An Antioxidant Sesquiterpene Inhibits Osteoclastogenesis Via Blocking
   IPMK/TRAF6 and Counteracts OVX Induced Osteoporosis in Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPOROSIS; OSTEOCLASTOGENESIS; TRAF6; IPMK; CURCUMENOL; ANTIOXIDANT
ID NF KAPPA B; INOSITOL POLYPHOSPHATE MULTIKINASE; INDUCED BONE LOSS;
   TRANSCRIPTIONAL REGULATION; TRAF6; UBIQUITIN; ACTIVATION; KINASE; RANK;
   PROLIFERATION
AB Excessive bone resorption induced by increased osteoclast activity in postmenopausal women often causes osteoporosis. Although the pharmacological treatment of osteoporosis has been extensively developed, a safer and more effective treatment is still needed. Here, we found that curcumenol (CUL), an antioxidant sesquiterpene isolated from Curcuma zedoaria, impaired receptor activator of nuclear factor kappa B (NF kappa B) ligand (RANKL) induced osteoclastogenesis in vitro, whereas the osteoblastogenesis of MC3T3 E1 cells was not affected. We further demonstrated that CUL treatment during RANKL induced osteoclastogenesis promotes proteasomal degradation of TRAF6 by increasing its K48 linked polyubiquitination, leading to suppression of mitogen activated protein kinases (MAPKs) and NF kappa B pathways and the production of reactive oxygen species (ROS). We also showed that inositol polyphosphate multikinase (IPMK) binds with TRAF6 to reduce its K48 linked polyubiquitination under RANKL stimulation. Concurrently, IPMK deficiency inhibits osteoclast differentiation. The binding between IPMK and TRAF6 blocked by CUL treatment was found in our study. Finally, we confirmed that CUL treatment prevented ovariectomy (OVX) induced bone loss in mice. In summary, our study demonstrates that CUL could impair the stability of TRAF6 enhanced by IPMK and suppress excessive osteoclast activity in estrogen deficient mice to treat osteoporosis. (c) 2021 American Society for Bone and Mineral Research. (c) 2021 American Society for Bone and Mineral Research (ASBMR).
C1 [Wang, Shiyu; Ma, Qingliang; Xie, Ziang; Shen, Yang; Zheng, Bingjie; Jiang, Chao; Yuan, Putao; Fan, Shunwu; Jie, Zhiwei] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Orthopaed Surg, Hangzhou, Peoples R China.
   [Wang, Shiyu; Ma, Qingliang; Xie, Ziang; Shen, Yang; Zheng, Bingjie; Jiang, Chao; Yuan, Putao; Fan, Shunwu; Jie, Zhiwei] Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou, Peoples R China.
   [An, Qin] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthopaed, Sch Med,Shanghai Key Lab Orthopaed Implant, Shanghai, Peoples R China.
C3 Zhejiang University; Shanghai Jiao Tong University
RP Fan, SW; Jie, ZW (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Orthopaed, 3 East Qingchun Rd, Hangzhou 310000, Peoples R China.
EM 0099203@zju.edu.cn; jiezhiwei@zju.edu.cn
RI ; Shen, Yang/LRC 0895 2024
OI Jie, Zhiwei/0000 0002 9469 4490; 
FU National Nature Science Fund of China [82002334, 81972089]; Natural
   Science Fund of Zhejiang Province [Q20H060042]
FX This work was supported in part by grants from National Nature Science
   Fund of China (82002334, 81972089) and Natural Science Fund of Zhejiang
   Province (Q20H060042). Authors' roles: SF, ZJ, AQ, and SW designed the
   study. SW, QM, ZJ, and ZX performed all experiments. SW, YS, BZ, CJ, and
   PY analyzed data. SF, ZJ, and SW interpreted results of experiments. YS,
   BZ, and XZ prepared the figures. SW and ZJ wrote the manuscript. All
   authors reviewed and approved the manuscript.
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cevik MO, 2008, BIOCHEM BIOPH RES CO, V374, P351, DOI 10.1016/j.bbrc.2008.07.027
   Chen S, 2015, SCI REP UK, V5, DOI 10.1038/srep12853
   Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805 758
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fukuda A, 2005, J BONE MINER RES, V20, P2245, DOI 10.1359/JBMR.050816
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Grabowski P, 2009, ENDOCR DEV, V16, P32, DOI 10.1159/000223687
   Guha P, 2019, CELL REP, V26, P2692, DOI 10.1016/j.celrep.2019.02.013
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   He X, 2013, J MOL CELL BIOL, V5, P39, DOI 10.1093/jmcb/mjs024
   Hu B., 2019, FASEB J, V33, p2574
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Kim E, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1602296
   Kim E, 2013, P NATL ACAD SCI USA, V110, P19938, DOI 10.1073/pnas.1320171110
   Kim S, 2011, CELL METAB, V13, P215, DOI 10.1016/j.cmet.2011.01.007
   Knopp Sihota JA, 2013, BMC GERIATR, V13, DOI 10.1186/1471 2318 13 36
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lamothe B, 2008, J BIOL CHEM, V283, P24871, DOI 10.1074/jbc.M802749200
   Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630
   Lin XW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067633
   Lo JY, 2015, FOOD FUNCT, V6, P3550, DOI 10.1039/c5fo00607d
   Lobo R, 2009, J PHARM PHARMACOL, V61, P13, DOI 10.1211/jpp/61.01.0003
   Malabanan MM, 2016, BIOCHEM SOC T, V44, P279, DOI 10.1042/BST20150225
   Manea A, 2008, ARTERIOSCL THROM VAS, V28, P878, DOI 10.1161/ATVBAHA.108.163592
   Mattiroli F, 2014, NAT STRUCT MOL BIOL, V21, P308, DOI 10.1038/nsmb.2792
   Min Y, 2018, AUTOPHAGY, V14, P1347, DOI 10.1080/15548627.2018.1474995
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Ning N, 2020, J CANCER, V11, P1679, DOI 10.7150/jca.38624
   Ohtake F, 2016, MOL CELL, V64, P251, DOI 10.1016/j.molcel.2016.09.014
   Panda S, 2015, IMMUNITY, V43, P647, DOI 10.1016/j.immuni.2015.09.010
   Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Shang YF, 2006, NAT REV CANCER, V6, P360, DOI 10.1038/nrc1879
   Tan EM, 2017, J BONE MINER RES, V32, P846, DOI 10.1002/jbmr.3031
   Tao XF, 2016, PHARMACOL RES, V108, P90, DOI 10.1016/j.phrs.2016.05.003
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Valente AJ, 2012, AM J PHYSIOL HEART C, V303, pH282, DOI 10.1152/ajpheart.00231.2012
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Walsh MC, 2015, IMMUNOL REV, V266, P72, DOI 10.1111/imr.12302
   Walsh MC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004064
   Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597
   Wu CL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02073 3
   Yan K, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12778
   Yin X, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0058 7
   Yoshida H, 2005, J BIOL CHEM, V280, P41111, DOI 10.1074/jbc.M509526200
   Zhang B, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01412
   Zhang JX, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4350965
   Zhao W, 2012, J IMMUNOL, V188, P2567, DOI 10.4049/jimmunol.1103255
NR 53
TC 25
Z9 27
U1 2
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD SEP
PY 2021
VL 36
IS 9
BP 1850
EP 1865
DI 10.1002/jbmr.4328
EA MAY 2021
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA UQ3LN
UT WOS:000651558000001
PM 33956362
OA Bronze
DA 2025 08 17
ER

PT J
AU Zheng, YL
   Nishikawa, M
   Ikemura, M
   Yamashita, F
   Hashida, M
AF Zheng, Yunlong
   Nishikawa, Makiya
   Ikemura, Mai
   Yamashita, Fumiyoshi
   Hashida, Mitsuru
TI Development of bone targeted catalase derivatives for inhibition of bone
   metastasis of tumor cells in mice
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE cancer; conjugation; PEGylation; protein delivery; targeted drug
   delivery
ID CHEMICAL MODIFICATION; DELIVERY; BISPHOSPHONATES; GROWTH; ANTIOXIDANT;
   DESIGN; AGENTS
AB Removal of hydrogen peroxide by delivering catalase to the vicinity of metastasizing tumor cells is a promising approach for inhibiting tumor metastasis. To inhibit bone metastasis, catalase was conjugated with 3,5 di(ethylamino 2,2 bisphosphono)benzoic acid (Bip), a derivative of bone seeking bisphosphonates, polyethylene glycol (PEG), or both. Bip conjugated catalase derivatives, that is, catalaseBip and PEGcatalaseBip, exhibited a higher affinity for bone matrix as compared with their counterparts without Bip. The tissue distribution of 111In labeled catalase derivatives indicated that the accumulation of radioactivity in bones was increased by conjugation of either Bip or PEG with catalase. An experimental bone metastasis model was developed by injecting male C57BL/6 mice with murine melanoma B16BL6/Luc cells, which stably express firefly luciferase into left ventricle. Repeated injections of catalase to tumor bearing mice had no significant effect on the number of melanoma cells in tibiae and femurs, whereas injections of catalaseBip, PEGcatalase, or PEGcatalaseBip significantly reduced the number. These results indicate that targeted delivery of catalase to the bones can be achieved by conjugating the enzyme with either Bip or PEG, and this delivery is effective in inhibiting the bone metastasis of tumor cells. (C) 2011 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 101:552557, 2012
C1 [Nishikawa, Makiya] Kyoto Univ, Dept Biopharmaceut & Drug Metab, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan.
   [Zheng, Yunlong; Ikemura, Mai; Yamashita, Fumiyoshi; Hashida, Mitsuru] Kyoto Univ, Dept Drug Delivery Res, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan.
   [Hashida, Mitsuru] Kyoto Univ, Inst Integrated Cell Mat Sci, Sakyo Ku, Kyoto 6068302, Japan.
C3 Kyoto University; Kyoto University; Kyoto University
RP Nishikawa, M (通讯作者)，Kyoto Univ, Dept Biopharmaceut & Drug Metab, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan.
EM makiya@pharm.kyoto u.ac.jp
RI Hashida, Masaki/O 2968 2016; Yamashita, Fumiyoshi/ITV 5450 2023; 山下,
   富義/ITV 5450 2023; 郑, 云龙/AAB 6477 2021
OI Yamashita, Fumiyoshi/0000 0002 3503 8696; hashida,
   mitsuru/0000 0001 7383 8080
FU Japan Society for the Promotion of Science
FX This work was supported in parts by a Grant in aid for Scientific
   Research (B) from the Japan Society for the Promotion of Science. The
   authors would like to thank Drs. Hideki Hirabayashi and Satoshi Yonishi,
   Astellas Pharma Inc., Tokyo, Japan, for their generous advice.
CR Ames B.N, 1966, Meth. Enzymol, P115, DOI DOI 10.1016/0076 6879(66)08014 5
   Bansal G, 2004, J PHARM SCI US, V93, P2788, DOI 10.1002/jps.20186
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Costa L, 2009, NAT CLIN PRACT ONCOL, V6, P163, DOI 10.1038/ncponc1323
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   Doschak MR, 2009, MOL PHARMACEUT, V6, P634, DOI 10.1021/mp8002368
   Dröge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Hyoudou K, 2004, CLIN CANCER RES, V10, P7685, DOI 10.1158/1078 0432.CCR 04 1020
   Hyoudou K, 2007, J CONTROL RELEASE, V119, P121, DOI 10.1016/j.jconrel.2007.02.007
   Hyoudou K, 2006, FREE RADICAL BIO MED, V41, P1449, DOI 10.1016/j.freeradbiomed.2006.08.004
   Ma SF, 2006, J CONTROL RELEASE, V110, P273, DOI 10.1016/j.jconrel.2005.10.016
   Marcus Y, 2008, J MED CHEM, V51, P4300, DOI 10.1021/jm8002558
   Morioka M, 2010, BIOORGAN MED CHEM, V18, P1143, DOI 10.1016/j.bmc.2009.12.041
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nishikawa M, 2005, J CONTROL RELEASE, V109, P101, DOI 10.1016/j.jconrel.2005.09.017
   Nishikawa M, 2008, CANCER LETT, V266, P53, DOI 10.1016/j.canlet.2008.02.031
   Nishikawa M, 2009, ADV DRUG DELIVER REV, V61, P319, DOI 10.1016/j.addr.2009.01.001
   Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688
   Suzuki K, 2006, J PHARMACOL SCI, V100, P189, DOI 10.1254/jphs.FMJ05004X2
   Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891 5849(96)00275 4
   TALMAGE RV, 1970, AM J ANAT, V129, P467, DOI 10.1002/aja.1001290408
   Wu Shenhong, 2007, Acta Oncol, V46, P581
   Yabe Y, 1999, FREE RADICAL RES, V30, P265, DOI 10.1080/10715769900300291
   Yabe Y, 1999, J PHARMACOL EXP THER, V289, P1176
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
NR 26
TC 11
Z9 12
U1 0
U2 10
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0022 3549
J9 J PHARM SCI US
JI J. Pharm. Sci.
PD FEB
PY 2012
VL 101
IS 2
BP 552
EP 557
DI 10.1002/jps.22773
PG 6
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA 867SV
UT WOS:000298475400012
PM 21953593
DA 2025 08 17
ER

PT S
AU van Dam, PA
   Verhoeven, Y
   Trinh, XB
AF van Dam, Peter A.
   Verhoeven, Yannick
   Trinh, Xuan B.
BE Birbrair, A
TI The Non Bone Related Role of RANK/RANKL Signaling in Cancer
SO TUMOR MICROENVIRONMENT: MOLECULAR PLAYERS, PT B
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
DE RANK; RANKL; Osteoprotegerin; Microenvironment; Cancer; Bone health;
   Immunomodulation; PFD L1; CTLA 4; Immune response; Inflammation; Immune
   tolerance; Angiogenesis
ID MESSENGER RNA EXPRESSION; TUMOR NECROSIS FACTOR; BREAST CANCER;
   RECEPTOR ACTIVATOR; RANK LIGAND; ENDOTHELIAL CELLS; ESTROGEN RECEPTOR;
   PROGNOSTIC VALUE; LUNG CANCER; T CELLS
AB RANK ligand (RANKL) is a member of the tumor necrosis factor alpha superfamily of cytokines. It is the only known ligand binding to a membrane receptor named receptor activator of nuclear factor kappa B (RANK), thereby triggering recruitment of TNF receptor associated factor (TRAF) adaptor proteins and activation of downstream pathways. RANK/RANKL signaling is controlled by a decoy receptor, osteoprotegerin (OPG), but also has additional more complex levels of regulation. It is crucial for the differentiation of bone resorbing osteoclasts and is deregulated in disease processes such as osteoporosis and cancer bone metastasis. Cells expressing RANK and RANKL are commonly found in the tumor environment. In many tumor types, the RANK/RANKL pathway is overexpressed, and this is in most cases correlated with poor prognosis. RANK signaling plays an important role in the innate and adaptive immune response, generates regulatory T (Treg) cells, and increases the production of cytokines. It is also involved in chemo resistance in vitro. Recent evidence suggests that RANKL blockade improves the efficacy of anti CTLA 4 antibodies against solid tumors and experimental metastasis. Therefore, there is increasing interest to use RANKL inhibition as an immunomodulatory strategy in an attempt to make immune resistant tumor responsive to immune therapy.
C1 [van Dam, Peter A.; Verhoeven, Yannick; Trinh, Xuan B.] Antwerp Univ Hosp, Multidisciplinary Oncol Ctr Antwerp MOCA, Edegem, Belgium.
   [van Dam, Peter A.; Verhoeven, Yannick; Trinh, Xuan B.] Univ Antwerp, Ctr Oncol Res CORE, Antwerp, Belgium.
C3 University of Antwerp; University of Antwerp
RP van Dam, PA (通讯作者)，Antwerp Univ Hosp, Multidisciplinary Oncol Ctr Antwerp MOCA, Edegem, Belgium.; van Dam, PA (通讯作者)，Univ Antwerp, Ctr Oncol Res CORE, Antwerp, Belgium.
EM peter.vandam@uza.be
RI ; Verhoeven, Yannick/O 7194 2019
OI Verhoeven, Yannick/0000 0002 4168 8222; 
CR Afzal MZ, 2018, MELANOMA RES, V28, P341, DOI 10.1097/CMR.0000000000000459
   Ahern E, 2017, CLIN CANCER RES, V23, P5789, DOI 10.1158/1078 0432.CCR 17 0606
   Aspeslagh S, 2018, ANN ONCOL, V29, P812, DOI 10.1093/annonc/mdy050
   Bakhru P, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93265
   Birbrair A, 2014, AM J PHYSIOL CELL PH, V307, pC25, DOI 10.1152/ajpcell.00084.2014
   Casey SC, 2015, SEMIN CANCER BIOL, V35, pS199, DOI 10.1016/j.semcancer.2015.02.007
   Castellano D, 2011, ONCOLOGIST, V16, P136, DOI 10.1634/theoncologist.2010 0154
   Christoph F, 2018, WORLD J UROL, V36, P187, DOI 10.1007/s00345 017 2145 y
   Chu GCY, 2014, CANCER METAST REV, V33, P497, DOI 10.1007/s10555 013 9488 7
   Coleman RE, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.501
   Cross SS, 2006, J CLIN PATHOL, V59, P716, DOI 10.1136/jcp.2005.030031
   De Castro J, 2015, CLIN LUNG CANCER, V16, P431, DOI 10.1016/j.cllc.2015.06.004
   de Groot AF, 2018, CANCER TREAT REV, V62, P18, DOI 10.1016/j.ctrv.2017.10.010
   Gnant M, 2018, J CLIN ONCOL, V36
   González Suárez E, 2016, FEBS J, V283, P2018, DOI 10.1111/febs.13645
   Gonzalez Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495
   Goswami S, 2016, ONCOTARGET, V7, P42777, DOI 10.18632/oncotarget.8658
   Heymann MF, 2008, REGUL PEPTIDES, V148, P46, DOI 10.1016/j.regpep.2008.02.004
   Ikeda T, 2001, ENDOCRINOLOGY, V142, P1419, DOI 10.1210/en.142.4.1419
   Li HY, 2010, BLOOD, V116, P210, DOI 10.1182/blood 2009 11 255026
   Liu Y, 2016, ONCOTARGET, V7, P25328, DOI 10.18632/oncotarget.8291
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Ma D, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15979 1
   Millán MM, 2015, CLIN REV BONE MINER, V13, P105, DOI 10.1007/s12018 015 9188 7
   Min JK, 2003, J BIOL CHEM, V278, P39548, DOI 10.1074/jbc.M300539200
   Mizutani Y, 2004, CANCER AM CANCER SOC, V101, P1794, DOI 10.1002/cncr.20550
   Naumnik W, 2018, ADV EXP MED BIOL, V1047, P1, DOI 10.1007/5584_2017_111
   Nguyen B, 2018, CANC RES, V78
   Palafox M, 2012, CANCER RES, V72, P2678
   Papanastasiou A. D, 2018, J CANC GENET BIOMARK, V216 217, P61, DOI [10.1016/j.cancergen.2017.07.004, DOI 10.1016/J.CANCERGEN.2017.07.004]
   Papanastasiou AD, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3234
   Park HR, 2003, J KOREAN MED SCI, V18, P541, DOI 10.3346/jkms.2003.18.4.541
   Pasquale P, 2013, STEM CELLS, V31, P1954, DOI 10.1002/stem.1454
   Peters S, 2018, ANN ONCOL S8, V29, DOI DOI 10.1093/annonc/mdy292.008
   Reid PE, 2009, MOL CANCER, V8, DOI 10.1186/1476 4598 8 49
   Renema N, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160150
   Rochette L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030705
   Sarink D, 2017, CANCER PREV RES, V10, P525, DOI 10.1158/1940 6207.CAPR 17 0125
   Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b
   Schneeweis LA, 2005, J BIOL CHEM, V280, P41155, DOI 10.1074/jbc.M506366200
   Schultz MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087204
   Shang WQ, 2015, ONCOL REP, V34, P3007, DOI 10.3892/or.2015.4303
   Sigl V, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160230
   Smyth MJ, 2016, J CLIN ONCOL, V34, pE104, DOI 10.1200/JCO.2013.51.3572
   Song FN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108507
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Tang ZN, 2011, BIOCHEM BIOPH RES CO, V408, P411, DOI 10.1016/j.bbrc.2011.04.035
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Tilborghs S, 2017, CRIT REV ONCOL HEMAT, V120, P141, DOI 10.1016/j.critrevonc.2017.11.001
   Timotheadou E, 2017, TRANSL ONCOL, V10, P589, DOI 10.1016/j.tranon.2017.05.006
   Tsubaki M, 2016, TUMOR BIOL, V37, P9099, DOI 10.1007/s13277 015 4761 8
   van Dam PA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092183
   van Dam PA, 2019, CRIT REV ONCOL HEMAT, V133, P85, DOI 10.1016/j.critrevonc.2018.10.011
   van Dam PA, 2016, ONCOTARGET, V7, P2780, DOI 10.18632/oncotarget.6667
   Vinay DS, 2015, SEMIN CANCER BIOL, V35, pS185, DOI 10.1016/j.semcancer.2015.03.004
   Wang J, 2015, ONCOL REP, V33, P799, DOI 10.3892/or.2014.3651
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Yamada T, 2011, AM J PATHOL, V178, P2845, DOI 10.1016/j.ajpath.2011.02.003
   Zhang LY, 2015, ONCOTARGET, V6, P22918, DOI 10.18632/oncotarget.4382
   Zhang X, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414 431X20176265, 10.1590/1414 431x20176265]
NR 60
TC 5
Z9 5
U1 0
U2 5
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH 6330, SWITZERLAND
SN 0065 2598
EI 2214 8019
BN 978 3 030 50224 9; 978 3 030 50223 2
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2020
VL 1277
BP 53
EP 62
DI 10.1007/978 3 030 50224 9_3
D2 10.1007/978 3 030 50224 9
PG 10
WC Biochemistry & Molecular Biology; Oncology
WE Book Citation Index– Science (BKCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA BQ5AA
UT WOS:000595856800004
PM 33119864
DA 2025 08 17
ER

PT J
AU Niu, S
   Cao, XR
   Zhang, Y
   Zhu, QS
   Zhu, JY
AF Niu, Shun
   Cao, Xiaorui
   Zhang, Yan
   Zhu, Qingsheng
   Zhu, Jinyu
TI The inhibitory effect of alendronate hydroxyapatite composite coating on
   wear debris induced peri implant high bone turnover
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE Aseptic loosening; Bisphosphonates; Bone turnover; Composite coating;
   Drug release; Revision
ID IN VITRO; POLYETHYLENE PARTICLES; OVARIECTOMIZED RATS; HIP ARTHROPLASTY;
   ZOLEDRONIC ACID; BISPHOSPHONATES; FIXATION; OSTEOLYSIS; RESORPTION;
   PRESSURE
AB Background: Bisphosphonate (BP) has been confirmed as the most potent drug for enhancing implant stability. There have been few studies focused on BP hydroxyapatite (HA) composite coatings, and the mechanisms through which BPs inhibit wear debris induced high bone turnover have not been comprehensively discussed.
   Materials and methods: Thirty rabbits were divided into three groups. HA coated implants were inserted into the proximal region of the medullary cavity of the left tibia. In groups II and III, particles were injected around the implant and into the knee joint during implantation. Low dose alendronate (ALN) was combined with the HA coating in group III. The efficacy of the composite coating was evaluated using several parameters, including the intra articular pressure, histology of the synovial membranes and bone implant interfaces, bone histomorphometry and mineralization, implant stability, osteolysis related cytokine levels, and the duration of ALN release in vitro.
   Results: The results indicate that the ALN HA composite coating reduces peri implant high bone turnover; improves bone implant integration, bone quality, and implant stability; and inhibits particle migration. In vitro results suggest that the ALN HA composite coating can afford long release duration.
   Conclusions: This study may help us further realize the mechanisms through which BPs enhance bone implant integration in a state of peri implant high bone turnover. BP HA composite coatings are promising materials, particularly in revision surgeries. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Niu, Shun; Cao, Xiaorui; Zhu, Qingsheng; Zhu, Jinyu] Fourth Mil Med Univ, Xi Jing Hosp, Dept Orthopaed, Xian 710032, Shaanxi, Peoples R China.
   [Zhang, Yan] Fourth Mil Med Univ, Xi Jing Hosp, Dept Digest Dis, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Medical University; Air Force Medical University
RP Zhu, QS (通讯作者)，Fourth Mil Med Univ, Xi Jing Hosp, Dept Orthopaed, ChangLe W Rd 15, Xian 710032, Shaanxi, Peoples R China.
EM xijingbone@yahoo.com.cn
OI ZHU, JINYU/0000 0002 7811 752X
CR Boanini E, 2008, BIOMATERIALS, V29, P790, DOI 10.1016/j.biomaterials.2007.10.040
   Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756 3282(00)00376 8
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   DHERT WJA, 1992, J BIOMED MATER RES, V26, P119, DOI 10.1002/jbm.820260111
   Diab T, 2009, OSTEOPOROSIS INT, V20, P647, DOI 10.1007/s00198 008 0717 9
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Ebetino FH, 1998, REV CONTEMP PHARMACO, V9, P233
   Faucheux C, 2009, J BIOMED MATER RES A, V89A, P46, DOI 10.1002/jbm.a.31989
   Ferrier GM, 2000, J BONE JOINT SURG BR, V82B, P755, DOI 10.1302/0301 620X.82B5.9561
   Gao Y, 2009, BIOMATERIALS, V30, P1790, DOI 10.1016/j.biomaterials.2008.12.025
   Gao Y, 2009, BONE, V44, P225, DOI 10.1016/j.bone.2008.10.054
   Gonnelli S, 1999, CALCIFIED TISSUE INT, V65, P359, DOI 10.1007/s002239900713
   Ishiguro N, 1996, J BIOMED MATER RES, V32, P611, DOI 10.1002/(SICI)1097 4636(199612)32:4<611::AID JBM14>3.0.CO;2 G
   Iwase M, 2002, J ORTHOPAED RES, V20, P499, DOI 10.1016/S0736 0266(01)00155 3
   Jakobsen T, 2007, J ORTHOP RES, V25, P432, DOI 10.1002/jor.20276
   Kuljanin J, 2002, J PHARMACEUT BIOMED, V28, P1215, DOI 10.1016/S0731 7085(02)00021 3
   Legay F, 2002, J PHARMACEUT BIOMED, V30, P897, DOI 10.1016/S0731 7085(02)00218 2
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Millett PJ, 2002, J BONE JOINT SURG AM, V84A, P236, DOI 10.2106/00004623 200202000 00011
   Perilli E, 2010, OSTEOPOROSIS INT, V21, P1371, DOI 10.1007/s00198 009 1082 z
   Peter B, 2005, BONE, V36, P52, DOI 10.1016/j.bone.2004.10.004
   Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456
   Rahbek O, 2001, J BONE JOINT SURG BR, V83B, P441, DOI 10.1302/0301 620X.83B3.10667
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Santini D, 2004, BIODRUGS, V18, P269, DOI 10.2165/00063030 200418040 00004
   Sato T, 1998, J DENT RES, V77, P387, DOI 10.1177/00220345980770020701
   Schmalzried TP, 1997, J BONE JOINT SURG AM, V79A, P447, DOI 10.2106/00004623 199703000 00021
   Stadelmann VA, 2008, EUR CELLS MATER, V16, P10, DOI 10.22203/eCM.v016a02
   Suratwala SJ, 2008, J BONE JOINT SURG AM, V90A, P2189, DOI 10.2106/JBJS.G.00409
   Tanzer M, 2005, CLIN ORTHOP RELAT R, P30, DOI 10.1097/01.blo.0000194728.62996.2d
   van der Vis HM, 1998, ACTA ORTHOP SCAND, V69, P5, DOI 10.3109/17453679809002345
   von Knoch F, 2007, BIOMATERIALS, V28, P3549, DOI 10.1016/j.biomaterials.2007.04.024
   von Knoch M, 2004, Z ORTHOP GRENZGEB, V142, P366, DOI 10.1055/s 2004 822589
   Wang CZ, 2010, BIOMATERIALS, V31, P8674, DOI 10.1016/j.biomaterials.2010.07.096
   Wermelin K, 2008, BONE, V42, P365, DOI 10.1016/j.bone.2007.10.013
   Wermelin K, 2007, ACTA ORTHOP, V78, P385, DOI 10.1080/17453670710013979
   Wise LM, 2005, CALCIFIED TISSUE INT, V77, P367, DOI 10.1007/s00223 005 0062 3
   Yun MH, 2006, J PHARMACEUT BIOMED, V40, P168, DOI 10.1016/j.jpba.2005.06.025
NR 38
TC 19
Z9 21
U1 1
U2 34
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0022 4804
J9 J SURG RES
JI J. Surg. Res.
PD JAN
PY 2013
VL 179
IS 1
BP E107
EP E115
DI 10.1016/j.jss.2012.02.003
PG 9
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 051LW
UT WOS:000312129700014
PM 22498026
DA 2025 08 17
ER

PT J
AU Hioki, T
   Matsushima Nishiwaki, R
   Tokuda, H
   Kozawa, O
AF Hioki, Tomoyuki
   Matsushima Nishiwaki, Rie
   Tokuda, Haruhiko
   Kozawa, Osamu
TI Selective estrogen receptor modulators, acting as agonists of estrogen
   receptor α in osteoblasts, reduce the TGF β induced synthesis of
   macrophage colony stimulating factor via inhibition of JNK signaling
   pathway
SO BIOMEDICAL RESEARCH TOKYO
LA English
DT Article
ID CYCLIC AMP; APOPTOSIS; STRESS; SERMS
AB Selective estrogen receptor modulator (SERM) binds to estrogen receptors (ERs) and acts as both an agonist or an antagonist, depending on the target tissue. Raloxifene and bazedoxifene as SERMs are currently used hormone replacement medicines for postmenopausal osteoporosis. Macrophage colony stimulating factor (M CSF) secreted from osteoblasts promotes osteoclastogenesis. We have previously demonstrated that transforming growth factor (TGF) beta induces the synthesis of M CSF via SMAD2/3, p38 mitogen activated protein kinase (MAPK), p44/p42 MAPK and c Jun N terminal kinase (JNK) in osteoblast like MC3T3 E1 cells. In the present study, we investigated whether SERM affects the M CSF synthesis by TGF beta in MC3T3 E1 cells. Raloxifene and bazedoxifene significantly suppressed the synthesis of M CSF. PPT, an ER alpha agonist, but not ERB041, an ER beta agonist, inhibited the release of M CSF. MPP, an ER alpha antagonist, reversed the suppression by raloxifene of the M CSF release. Raloxifene attenuated the TGF beta induced phosphorylation of JNK but not SMAD3, p42 MAPK and p38 MAPK. Bazedoxifene and PPT also inhibited the phosphorylation of JNK. Furthermore, MPP, an ER alpha antagonist, reversed the suppression by both raloxifene and bazedoxifene of the phosphorylation of JNK. Our results strongly indicate that raloxifene and bazedoxifene, SERMs, suppress the TGF beta induced synthesis of M CSF through ER alpha mediated inhibition of JNK pathway in osteoblasts.
C1 [Hioki, Tomoyuki; Matsushima Nishiwaki, Rie; Tokuda, Haruhiko; Kozawa, Osamu] Gifu Univ, Dept Pharmacol, Grad Sch Med, Gifu 5011194, Japan.
   [Hioki, Tomoyuki] Cent Japan Int Med Ctr, Dept Dermatol, Minokamo 5058510, Japan.
   [Tokuda, Haruhiko; Kozawa, Osamu] Natl Ctr Geriatr & Gerontol, Dept Metab Res, Obu 4748511, Japan.
   [Tokuda, Haruhiko] Natl Ctr Geriatr & Gerontol, Dept Clin Lab, Med Genome Ctr, Obu 4748511, Japan.
C3 Gifu University; National Center for Geriatrics & Gerontology; National
   Center for Geriatrics & Gerontology
RP Kozawa, O (通讯作者)，Gifu Univ, Dept Pharmacol, Grad Sch Med, Gifu 5011194, Japan.
EM okkasugai@yahoo.co.jp
OI Matsushima Nishiwaki, Rie/0009 0003 7496 737X
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [26462289, 15K10487]; National Center for Geriatrics and Gerontology,
   Japan [20 12, 21 1]
FX This study was supported in part by a Grant in Aid for Scientific
   Research from the Ministry of Education, Culture, Sports, Science and
   Technology of Japan [grant numbers 26462289, 15K10487]; the Research
   Funding for Longevity Sciences from the National Center for Geriatrics
   and Gerontology, Japan [grant number 20 12, 21 1]. We are very grateful
   to Mrs. Yumiko Kurokawa for her skillful technical assistance.
CR Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   An KC, 2016, ASIAN SPINE J, V10, P787, DOI 10.4184/asj.2016.10.4.787
   Doi T, 2022, BIOMED RES TOKYO, V43, P41, DOI 10.2220/biomedres.43.41
   Fixe P, 1998, CYTOKINE, V10, P32, DOI 10.1006/cyto.1997.0249
   Harris HA, 2003, ENDOCRINOLOGY, V144, P4241, DOI 10.1210/en.2003 0550
   Kanazawa I, 2017, CALCIFIED TISSUE INT, V100, P286, DOI 10.1007/s00223 016 0211 x
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kato K, 1996, J NEUROCHEM, V66, P946
   Khalid AB, 2016, BONE, V87, P130, DOI 10.1016/j.bone.2016.03.016
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   KOZAWA O, 1992, EXP CELL RES, V198, P130, DOI 10.1016/0014 4827(92)90158 5
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Martinkovich S, 2014, CLIN INTERV AGING, V9, P1437, DOI 10.2147/CIA.S66690
   Maximov PY, 2013, CURR CLIN PHARMACOL, V8, P135, DOI 10.2174/1574884711308020006
   Morikawa M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021873
   Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554
   Olivier S, 2005, BIOCHEM PHARMACOL, V69, P891, DOI 10.1016/j.bcp.2004.11.030
   Pinkerton JV, 2014, J STEROID BIOCHEM, V142, P142, DOI 10.1016/j.jsbmb.2013.12.011
   Sinder BP, 2015, J BONE MINER RES, V30, P2140, DOI 10.1002/jbmr.2735
   Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Sun J, 2002, ENDOCRINOLOGY, V143, P941, DOI 10.1210/en.143.3.941
   TAKAISHI T, 1994, AM J PHYSIOL, V267, pC25, DOI 10.1152/ajpcell.1994.267.1.C25
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wang GQ, 2021, J BIOMED NANOTECHNOL, V17, P932, DOI 10.1166/jbn.2021.3068
   Xu BB, 2017, J DIABETES COMPLICAT, V31, P773, DOI 10.1016/j.jdiacomp.2016.12.010
   Zuo C, 2012, OSTEOPOROSIS INT, V23, P1653, DOI 10.1007/s00198 012 1909 x
NR 31
TC 2
Z9 2
U1 3
U2 5
PU BIOMEDICAL RESEARCH PRESS LTD
PI SAPPORO
PA HOKKAIDO UNIV, LAB HISTOLOGY & CYTOLOGY, C/O TOSHIHIKO IWANAGA, KITA
   15 NISHI 7, SAPPORO, 060 8638, JAPAN
SN 0388 6107
EI 1880 313X
J9 BIOMED RES TOKYO
JI Biomed. Res.
PY 2022
VL 43
IS 6
BP 211
EP 221
DI 10.2220/biomedres.43.211
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 8L2ZK
UT WOS:000923655000003
PM 36517023
OA gold
DA 2025 08 17
ER

PT J
AU Souza, ATP
   Freitas, GP
   Lopes, HB
   Totoli, GGC
   Tarone, AG
   Marostica, MR
   Rosa, AL
   Beloti, MM
AF Souza, Alann Thaffarell Portilho
   Freitas, Gileade Pereira
   Lopes, Helena Bacha
   Totoli, Gabriela Guaraldo Campos
   Tarone, Adriana Gadioli
   Marostica Junior, Mario Roberto
   Rosa, Adalberto Luiz
   Beloti, Marcio Mateus
TI Jabuticaba peel extract modulates adipocyte and osteoblast
   differentiation of MSCs from healthy and osteoporotic rats
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Adipocyte; Jabuticaba; Mesenchymal stromal cell; Osteoblast;
   Osteoporosis
ID JABOTICABA PEEL; FATE DECISION; CELLS; MECHANISMS; THERAPY
AB Introduction The jabuticaba peel extract (JPE) contains bioactive compounds that regulate fat metabolism. Because the negative correlation between fat accumulation and bone formation in bone marrow, we hypothesized that JPE inhibits adipocyte as well as favors osteoblast differentiation of mesenchymal stromal cells (MSCs) under healthy and osteoporotic conditions, a disease that display an imbalance between adipocyte and osteoblast differentiation resulting in reduced bone mass. Material and methods To test these hypotheses, bone marrow MSCs were harvested from healthy and osteoporotic rats and cultured in adipogenic and osteogenic media with three concentrations of JPE, 0.25, 5 and 10 mu g/ml, and vehicle (control). After selecting the most efficient concentrations of JPE, we used them to evaluate adipocyte and osteoblast differentiation of MSCs from both sources. Results We observed that, in general, JPE inhibited adipocyte differentiation of MSCs with more pronounced effects in cells from healthy than osteoporotic rats. In addition, JPE increased osteoblast differentiation, exhibiting a slightly higher osteogenic potential on MSCs from osteoporotic compared to healthy condition. Conclusion Our results demonstrated that JPE drives MSCs to inhibit adipocyte differentiation and toward osteoblast differentiation under healthy and osteoporotic conditions. These findings pave the way for further translational studies to investigate the therapeutic possibilities of JPE in both prevention and treatment of osteoporosis.
C1 [Souza, Alann Thaffarell Portilho; Freitas, Gileade Pereira; Lopes, Helena Bacha; Totoli, Gabriela Guaraldo Campos; Rosa, Adalberto Luiz; Beloti, Marcio Mateus] Univ Sao Paulo, Sch Dent Ribeirao Preto, Bone Res Lab, Av Cafe S N, BR 14040904 Ribeirao Preto, SP, Brazil.
   [Tarone, Adriana Gadioli; Marostica Junior, Mario Roberto] Univ Estadual Campinas, Sch Food Engn, Rua Monteiro Lobato 80, BR 13083862 Campinas, SP, Brazil.
C3 Universidade de Sao Paulo; Universidade Estadual de Campinas
RP Beloti, MM (通讯作者)，Univ Sao Paulo, Sch Dent Ribeirao Preto, Bone Res Lab, Av Cafe S N, BR 14040904 Ribeirao Preto, SP, Brazil.
EM mmbeloti@usp.br
RI Marostica Junior, Mario Roberto/P 5936 2018; Marostica,
   Mario/P 5936 2018; Lopes, Helena/G 8090 2016; Rosa, Adalberto
   Luiz/A 6314 2008; Souza, Alann/E 4194 2018; Guaraldo,
   Gabriela/AAF 1538 2021; Tarone, Adriana/ADM 8405 2022; Freitas,
   Gileade/G 8468 2016; Pereira Freitas, Gileade/G 8468 2016; Portilho de
   Souza, Alann Thaffarell/E 4194 2018; Beloti, Marcio/AAX 4014 2020;
   Beloti, Marcio/E 7473 2012; Rosa, Adalberto/A 6314 2008
OI Marostica Junior, Mario Roberto/0000 0001 8877 3160; Guaraldo,
   Gabriela/0000 0002 4472 0291; Gadioli Tarone,
   Adriana/0000 0002 3812 6472; Rosa, Adalberto Luiz/0000 0002 6495 2778;
   Pereira Freitas, Gileade/0000 0002 1674 4667; Bacha Lopes,
   Helena/0000 0002 6998 5296; Portilho de Souza, Alann
   Thaffarell/0000 0001 7344 5420; Reis, AlessanRSS/0000 0001 8486 7469;
   Beloti, Marcio/0000 0003 0149 7189; 
FU State of Sao Paulo Research Foundation (FAPESP, Brazil) [2015/50333 1,
   2017/12622 7, 2017/20349 9, 2018/11069 5, 2015/13320 9]; National
   Council for Scientific and Technological Development (CNPq, Brazil)
   [303464/2016 0, 403328/2016 0, 301496/2019 6, 140942/2016 5];
   Coordination of Improvement of Higher Education Personnel (CAPES,
   Brazil) [001]; Red Iberomericana de Alimentos Autoctonos Subutilizados
   (ALSUB CYTED) [118RT0543]
FX The authors would like to thank Adriana L. G. Almeida, Fabiola S.
   Oliveira and Roger R. Fernandes for technical assistance. This study was
   supported by the State of Sao Paulo Research Foundation (FAPESP, Brazil,
   # 2015/50333 1, 2017/12622 7, 2017/20349 9, 2018/11069 5, 2015/13320 9),
   National Council for Scientific and Technological Development (CNPq,
   Brazil, # 303464/2016 0, 403328/2016 0, 301496/2019 6 and
   140942/2016 5), Coordination of Improvement of Higher Education
   Personnel (Finance Code 001, CAPES, Brazil) and Red Iberomericana de
   Alimentos Autoctonos Subutilizados (ALSUB CYTED, 118RT0543).
CR Abuna RPF, 2016, J CELL PHYSIOL, V231, P204, DOI 10.1002/jcp.25073
   Albuquerque BR, 2020, FOOD CHEM, V309, DOI 10.1016/j.foodchem.2019.125735
   de Paula FJA, 2018, COMPR PHYSIOL, V8, P315, DOI 10.1002/cphy.c170010
   Araújo CRR, 2014, J MED FOOD, V17, P262, DOI 10.1089/jmf.2012.0256
   Ardawi MSM, 2016, BONE, V83, P127, DOI 10.1016/j.bone.2015.10.017
   Cawthorn WP, 2008, FEBS LETT, V582, P117, DOI 10.1016/j.febslet.2007.11.051
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Deal C, 2009, NAT CLIN PRACT RHEUM, V5, P20, DOI 10.1038/ncprheum0977
   Domazetovic V, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9020125
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Friesen JB, 2015, J NAT PROD, V78, P1765, DOI 10.1021/np501065h
   Giusti MM, 2016, HDB FOOD ANAL CHEM, P19
   Almeida ALG, 2019, BRAZ ORAL RES, V33, DOI [10.1590/1807 3107BOR 2019.vol33.0079, 10.1590/1807 3107bor 2019.vol33.0079]
   Hamadeh IS, 2015, CANCER TREAT REV, V41, P455, DOI 10.1016/j.ctrv.2015.04.007
   He N, 2015, BIOSCI BIOTECH BIOCH, V79, P1779, DOI 10.1080/09168451.2015.1062712
   Hou TT, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109205
   Hough FS, 2014, SAMJ S AFR MED J, V104, P279, DOI 10.7196/SAMJ.7505
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Iimura Y, 2015, J BONE MINER METAB, V33, P270, DOI 10.1007/s00774 014 0596 4
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Jiang M, 2011, PLANTA MED, V77, P873, DOI 10.1055/s 0030 1270983
   KALU DN, 1984, ENDOCRINOLOGY, V115, P507, DOI 10.1210/endo 115 2 507
   Khan M, 2017, ENDOCRIN METAB CLIN, V46, P181, DOI 10.1016/j.ecl.2016.09.009
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Kraus NA, 2016, ADIPOCYTE, V5, P351, DOI 10.1080/21623945.2016.1240137
   Lamas CA, 2018, J FUNCT FOODS, V47, P434, DOI 10.1016/j.jff.2018.06.005
   Leite Legatti AV, 2012, FOOD RES INT, V49, P596, DOI 10.1016/j.foodres.2012.07.044
   Lenquiste SA, 2015, FOOD RES INT, V77, P162, DOI 10.1016/j.foodres.2015.07.023
   Lenquiste SA, 2012, FOOD RES INT, V49, P153, DOI 10.1016/j.foodres.2012.07.052
   Luna Vital D, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201700362
   Mackinnon ES, 2011, OSTEOPOROSIS INT, V22, P1091, DOI 10.1007/s00198 010 1308 0
   Minisola S, 2017, INTERN EMERG MED, V12, P915, DOI 10.1007/s11739 017 1719 4
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Nepal AK, 2021, J ORTHOP RES, V39, P42, DOI 10.1002/jor.24775
   Oliveira GR, 2019, J BONE MINER METAB, V37, P658, DOI 10.1007/s00774 018 0970 8
   Pitz HD, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3403586
   Plaza M, 2016, FOOD CHEM, V211, P185, DOI 10.1016/j.foodchem.2016.04.142
   Reynertson KA, 2008, FOOD CHEM, V109, P883, DOI 10.1016/j.foodchem.2008.01.021
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Sgarbossa A, 2015, NUTRIENTS, V7, P5764, DOI 10.3390/nu7075246
   Solomon DH, 2005, ARCH INTERN MED, V165, P2414, DOI 10.1001/archinte.165.20.2414
   Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694
   SUZUKI T, 2017, NUTRIENTS, V9
   Swain T., 1959, Journal of the Science of Food and Agriculture, V10, P63, DOI 10.1002/jsfa.2740100110
   Tasadduq R, 2017, J CELL PHYSIOL, V232, P540, DOI 10.1002/jcp.25449
   Tu Kristie N, 2018, P T, V43, P92
   Udalamaththa VL, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0366 4
   Wang W, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/518609
   WRONSKI TJ, 1989, BONE, V10, P295, DOI 10.1016/8756 3282(89)90067 7
   Xu Hong, 2004, J Tradit Chin Med, V24, P224
   ZIOMEK CA, 1990, J HISTOCHEM CYTOCHEM, V38, P437, DOI 10.1177/38.3.1689343
NR 53
TC 6
Z9 6
U1 0
U2 9
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAR
PY 2021
VL 39
IS 2
BP 163
EP 173
DI 10.1007/s00774 020 01152 8
EA SEP 2020
PG 11
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA QT9BJ
UT WOS:000566318000003
PM 32889573
DA 2025 08 17
ER

PT J
AU Perpétuo, IP
   Caetano Lopes, J
   Vieira Sousa, E
   Campanilho Marques, R
   Ponte, C
   Khmelinskii, N
   Canhao, H
   Ainola, M
   Fonseca, JE
AF Perpetuo, Ines P.
   Caetano Lopes, Joana
   Vieira Sousa, Elsa
   Campanilho Marques, Raquel
   Ponte, Cristina
   Khmelinskii, Nikita
   Canhao, Helena
   Ainola, Mari
   Fonseca, Joao E.
TI Ankylosing Spondylitis Patients Have Impaired Osteoclast Gene Expression
   in Circulating Osteoclast Precursors
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE monocytes; osteoclasts; ankylosing spondylitis; CSF1R; RANK; NFATc1;
   gene expression; humans
ID RHEUMATOID ARTHRITIS; DISEASE ACTIVITY; BONE RESORPTION; BIOCHEMICAL
   MARKERS; UP REGULATION; TNF ALPHA; RANKL; INFLAMMATION; MECHANISMS;
   CYTOKINES
AB Introduction: Ankylosing spondylitis (AS) is typically characterized by focal bone over growth and also by systemic bone loss. We hypothesize that the increased osteoproliferation found in AS might be partially due to reduced ability of osteoclast precursors (OCPs) to differentiate into osteoclasts (OCs). Therefore, our aim was to characterize bone remodeling and pro osteoclastogenesis inflammatory environment, monocytes' phenotype, and in vitro osteoclast differentiation in AS patients.
   Methods: Patients with active AS without any ongoing therapy and age and gender matched healthy donors were recruited. Receptor activator of nuclear factor K13 (RANKL) surface expression on circulating leukocytes and frequency and phenotype of monocyte subpopulations were assessed. Quantification of serum levels of bone turnover markers and cytokines, in vitro OC differentiation assay and quantitative reverse transcription real time PCR for OC specific genes were performed.
   Results: Pro and anti inflammatory cytokine serum levels were higher in AS patients than in controls. RANKL neutrophil expression was higher in AS patients when compared to healthy donors, but CD51/CD61 expression was lower in the classical monocyte subpopulation. Concerning osteoclastogenesis, we found no differences in the in vitro osteoclast differentiating potential of these cells when compared to healthy donors. However, we observed low expression of CSF1R, RANK, and NFATc1 in AS OCPs.
   Conclusion: Despite the high levels of pro inflammatory cytokines present in AS patients, no differences in the number of OC or resorbed area were found between AS patients and healthy donors. Moreover, we observed that OCPs have low OC specific gene expression. These findings support our hypothesis of an impaired response of OCPs to pro osteoclastogenic stimuli in vivo in AS patients.
C1 [Perpetuo, Ines P.; Caetano Lopes, Joana; Vieira Sousa, Elsa; Campanilho Marques, Raquel; Ponte, Cristina; Fonseca, Joao E.] Univ Lisbon, Inst Med Mol, Rheumatol Res Unit, Fac Med, Lisbon, Portugal.
   [Vieira Sousa, Elsa; Campanilho Marques, Raquel; Ponte, Cristina; Khmelinskii, Nikita; Fonseca, Joao E.] Lisbon Acad Med Ctr, Hosp Santa Maria, Rheumatol Dept, Ctr Hosp Lisboa Norte,EPE, Lisbon, Portugal.
   [Canhao, Helena] Univ Nova Lisboa, NOVA Med Sch, EpiDoC Unit, Chron Dis Res Ctr CEDOC, Lisbon, Portugal.
   [Ainola, Mari] Univ Helsinki, Inst Clin Med, Musculoskeletal Dis & Inflammat Res Grp, Biomedicum Helsinki 1,Fac Med, Helsinki, Finland.
C3 Universidade de Lisboa; Universidade de Lisboa; Hospital Santa Maria;
   Universidade Nova de Lisboa; University of Helsinki
RP Perpétuo, IP (通讯作者)，Univ Lisbon, Inst Med Mol, Rheumatol Res Unit, Fac Med, Lisbon, Portugal.
EM ines.perpetuo@gmail.com
RI Fonseca, Joao/KHW 7048 2024; Ainola, Mari Mia/T 8035 2017; Ponte,
   Cristina/AEU 0624 2022; Vieira Sousa, Elsa/I 8319 2015; Canhao,
   Helena/C 9611 2018; Perpétuo, Inês/F 3643 2011; Ainola,
   Mari/T 8035 2017; Caetano Lopes, Joana/J 9345 2012
OI Khmelinskii, Nikita/0000 0001 6358 7388; Ponte,
   Cristina/0000 0002 3989 1192; Fonseca, Joao/0000 0003 1432 3671;
   Caetano Lopes, Joana/0000 0003 0310 4641; Marques Ruivo,
   Raquel/0000 0002 1894 8516; Canhao, Helena/0000 0003 1894 4870; Ainola,
   Mari/0000 0003 2853 5851; 
FU Fundacao para a Ciencia e Tecnologia [SFRH/BD/70533/2010];
   Investigator Initiated Studies Program of Merck Sharp and Dohme Corp.
   [Merck_P08574]; Fundação para a Ciência e a Tecnologia
   [SFRH/BD/70533/2010] Funding Source: FCT
FX This work was supported by Fundacao para a Ciencia e Tecnologia
   (SFRH/BD/70533/2010) and by a research grant front
   Investigator Initiated Studies Program of Merck Sharp and Dohme Corp.
   (Merck_P08574). The opinions expressed in this paper are those of the
   authors and do not necessarily represent those of Merck Sharp and Dohme
   Corp. The funding agencies had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Abdulghani S, 2009, AUTOIMMUN REV, V8, P668, DOI 10.1016/j.autrev.2009.02.021
   Abeles D, 2012, CYTOM PART A, V81A, P823, DOI 10.1002/cyto.a.22104
   Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   Appel H, 2009, CLIN EXP RHEUMATOL, V27, pS15
   Appel H, 2009, ARTHRITIS RHEUM US, V60, P3257, DOI 10.1002/art.24888
   Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883
   BIASI D, 1995, CLIN EXP RHEUMATOL, V13, P623
   Boyraz I, 2014, INT J CLIN EXP MED, V7, P2912
   Caetano Lopes J, 2009, AUTOIMMUN REV, V8, P250, DOI 10.1016/j.autrev.2008.07.038
   Caetano Lopes J, 2014, CLIN REV ALLERG IMMU, V47, P38, DOI 10.1007/s12016 013 8366 y
   CALIN A, 1994, J RHEUMATOL, V21, P2281
   Chakravarti A, 2009, BLOOD, V114, P1633, DOI 10.1182/blood 2008 09 178301
   Chen CH, 2010, CLIN RHEUMATOL, V29, P1155, DOI 10.1007/s10067 010 1543 y
   Coiffier G, 2013, JOINT BONE SPINE, V80, P250, DOI 10.1016/j.jbspin.2012.08.004
   Costa Rodrigues J, 2011, CELL PROLIFERAT, V44, P410, DOI 10.1111/j.1365 2184.2011.00768.x
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   DONNELLY S, 1994, ANN RHEUM DIS, V53, P117, DOI 10.1136/ard.53.2.117
   Fonseca JE, 2005, CLIN EXP RHEUMATOL, V23, P185
   GARRETT S, 1994, J RHEUMATOL, V21, P2286
   Gengenbacher M, 2008, ANN RHEUM DIS, V67, P620, DOI 10.1136/ard.2007.076711
   Gökmen F, 2015, J CLIN LAB ANAL, V29, P294, DOI 10.1002/jcla.21768
   GRATACOS J, 1994, BRIT J RHEUMATOL, V33, P927
   Hannon R, 2000, OSTEOPOROSIS INT, V11, P30, DOI 10.1007/s001980070004
   Hart SM, 1999, CURR OPIN NEPHROL HY, V8, P421, DOI 10.1097/00041552 199907000 00005
   Holloway WR, 2002, J BONE MINER RES, V17, P200, DOI 10.1359/jbmr.2002.17.2.200
   Husheem M, 2005, CALCIFIED TISSUE INT, V76, P222, DOI 10.1007/s00223 004 0123 z
   Klingberg E, 2014, J RHEUMATOL, V41, P1349, DOI 10.3899/jrheum.131199
   Limón Camacho L, 2012, J RHEUMATOL, V39, P830, DOI 10.3899/jrheum.110862
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Machado P, 2011, ANN RHEUM DIS, V70, P47, DOI 10.1136/ard.2010.138594
   McGonagle D, 2008, ARTHRITIS RHEUM, V58, P2694, DOI 10.1002/art.23755
   Mei Y, 2011, CLIN RHEUMATOL, V30, P269, DOI 10.1007/s10067 010 1647 4
   Mercan R, 2016, J CLIN LAB ANAL, V30, P597, DOI 10.1002/jcla.21908
   Miceli Richard C, 2010, ARTHRITIS RHEUM S10, V62, P548, DOI [10.1002/art.28317, DOI 10.1002/ART.28317]
   Perpétuo IP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144655
   Poubelle PE, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2137
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Schett G, 2005, NAT CLIN PRACT RHEUM, V1, P47, DOI 10.1038/ncprheum0036
   Schett G, 2011, EUR J CLIN INVEST, V41, P1361, DOI 10.1111/j.1365 2362.2011.02545.x
   Schett G, 2011, ARTHRITIS RES THER, V13, DOI [10.1186/1478 6354 13 S1 S4, 10.1186/ar3095]
   Sieper J, 2008, ARTHRITIS RHEUM US, V58, P649, DOI 10.1002/art.23260
   Sveaas SH, 2015, SCAND J RHEUMATOL, V44, P118, DOI 10.3109/03009742.2014.956142
   Takuma A, 2003, J BIOL CHEM, V278, P44667, DOI 10.1074/jbc.M300213200
   Taylan A, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 191
   Taylan A, 2012, RHEUMATOL INT, V32, P2511, DOI 10.1007/s00296 011 1995 7
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
   Vosse D, 2009, CLIN EXP RHEUMATOL, V27, pS62
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang Qing wen, 2012, Beijing Da Xue Xue Bao Yi Xue Ban, V44, P244
   Wong KL, 2012, IMMUNOL RES, V53, P41, DOI 10.1007/s12026 012 8297 3
   Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01
   Yago T, 2009, J CELL BIOCHEM, V108, P947, DOI 10.1002/jcb.22326
   Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200
   Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471 2105 13 134
NR 55
TC 17
Z9 18
U1 0
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 2296 858X
J9 FRONT MED LAUSANNE
JI Front. Med.
PD JAN 27
PY 2017
VL 4
AR 5
DI 10.3389/fmed.2017.00005
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA FC8HE
UT WOS:000407081600001
PM 28191455
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Bove Fenderson, E
   Mannstadt, M
AF Bove Fenderson, Erin
   Mannstadt, Michael
TI Hypocalcemic disorders
SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE parathyroid hormone; hypocalcemia; hypoparathyroidism; vitamin D;
   pseudohypoparathyroidism
ID CALCIUM SENSING RECEPTOR; AUTOSOMAL DOMINANT HYPOCALCEMIA; VITAMIN D
   DEFICIENCY; PARATHYROID HORMONE 1 34; FAMILIAL ISOLATED
   HYPOPARATHYROIDISM; ALBRIGHT HEREDITARY OSTEODYSTROPHY;
   PSEUDOHYPOPARATHYROIDISM TYPE IA; SIGNAL SEQUENCE MUTATION; BONE MINERAL
   DENSITY; REPLACEMENT THERAPY
AB Calcium is vital for life, and extracellular calcium concentrations must constantly be maintained within a precise concentration range. Low serum calcium (hypocalcemia) occurs in conjunction with multiple disorders and can be life threatening if severe. Symptoms of acute hypocalcemia include neuromuscular irritability, tetany, and seizures, which are rapidly resolved with intravenous administration of calcium gluconate. However, disorders that lead to chronic hypocalcemia often have more subtle manifestations. Hypoparathyroidism, characterized by impaired secretion of parathyroid hormone (PTH), a key regulatory hormone for maintaining calcium homeostasis, is a classic cause of chronic hypocalcemia. Disorders that disrupt the metabolism of vitamin D can also lead to chronic hypocalcemia, as vitamin D is responsible for increasing the gut absorption of dietary calcium. Treatment and management options for chronic hypocalcemia vary depending on the underlying disorder. For example, in patients with hypoparathyroidism, calcium and vitamin D supplementation must be carefully titrated to avoid symptoms of hypocalcemia while keeping serum calcium in the low normal range to minimize hypercalciuria, which can lead to renal dysfunction. Management of chronic hypocalcemia requires knowledge of the factors that influence the complex regulatory axes of calcium homeostasis in a given disorder. This chapter discusses common and rare disorders of hypocalcemia, symptoms and workup, and management options including replacement of PTH in hypoparathyroidism. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Mannstadt, Michael] Massachusetts Gen Hosp, Endocrine Unit, Thier 1101,50 Blossom St, Boston, MA 02114 USA.
   Harvard Med Sch, Thier 1101,50 Blossom St, Boston, MA 02114 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard Medical School
RP Mannstadt, M (通讯作者)，Massachusetts Gen Hosp, Endocrine Unit, Thier 1101,50 Blossom St, Boston, MA 02114 USA.
EM mannstadt@mgh.harvard.edu
RI Mannstadt, Michael/AAO 1124 2020
CR Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297 399
   Akirav EM, 2011, NAT REV ENDOCRINOL, V7, P25, DOI 10.1038/nrendo.2010.200
   Al Haggar M, 2009, CLIN EXP NEPHROL, V13, P288, DOI 10.1007/s10157 008 0126 6
   ALBRIGHT F, 1952, T ASSOC AM PHYSICIAN, V65, P337
   Albright F, 1942, ENDOCRINOLOGY, V30, P922
   ANAST CS, 1972, SCIENCE, V177, P606, DOI 10.1126/science.177.4049.606
   Arlt W, 2002, EUR J ENDOCRINOL, V146, P215, DOI 10.1530/eje.0.1460215
   ARNOLD A, 1990, J CLIN INVEST, V86, P1084, DOI 10.1172/JCI114811
   Babinsky VN, 2016, J BIOL CHEM, V291, P10876, DOI 10.1074/jbc.M115.696401
   Basha B, 2000, AM J MED, V108, P296, DOI 10.1016/S0002 9343(99)00460 X
   Bastepe M, 2005, HORM RES, V63, P65, DOI 10.1159/000083895
   Bastepe M, 2008, ADV EXP MED BIOL, V626, P27
   Baumber L, 2005, J MED GENET, V42, P443, DOI 10.1136/jmg.2004.026898
   Bilezikian JP, 2016, J CLIN ENDOCR METAB, V101, P2313, DOI 10.1210/jc.2015 3910
   Bowl MR, 2005, J CLIN INVEST, V115, P2822, DOI 10.1172/JCI24156
   Brown EM, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P101, DOI 10.1016/B978 0 12 397166 1.00006 0
   Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239
   BROWN EM, 1984, METABOLISM, V33, P171, DOI 10.1016/0026 0495(84)90131 8
   Buckley MS, 2010, CRIT CARE MED, V38, pS253, DOI 10.1097/CCM.0b013e3181dda0be
   Bushinsky DA, 1998, LANCET, V352, P306, DOI 10.1016/S0140 6736(97)12331 5
   CAFFEY J, 1967, AMER J ROENTGENOL RA, V100, P1
   Caltabiano S, 2013, BONE, V56, P154, DOI 10.1016/j.bone.2013.05.021
   Chan FKW, 2003, J CLIN ENDOCR METAB, V88, P3155, DOI 10.1210/jc.2002 021388
   CHASE LR, 1969, J CLIN INVEST, V48, P1832, DOI 10.1172/JCI106149
   Chawla H, 2017, J CLIN ENDOCR METAB, V102, P251, DOI 10.1210/jc.2016 3292
   Cho JN, 2016, INT J SURG, V34, P47, DOI 10.1016/j.ijsu.2016.08.019
   CHOLST IN, 1984, NEW ENGL J MED, V310, P1221, DOI 10.1056/NEJM198405103101904
   Christakos Sylvia, 2014, Bonekey Rep, V3, P496, DOI 10.1038/bonekey.2013.230
   Cianferotti L, 2015, PARATHYROIDS, P719
   Cinque L, 2017, J CLIN ENDOCR METAB, V102, P3961, DOI 10.1210/jc.2017 00250
   Clarke BL, 2016, J CLIN ENDOCR METAB, V101, P2284, DOI 10.1210/jc.2015 3908
   Clarke BL, 2014, CLIN THER, V36, P722, DOI 10.1016/j.clinthera.2014.04.001
   Cooper MS, 2008, BRIT MED J, V336, P1298, DOI 10.1136/bmj.39582.589433.BE
   Cusano NE, 2016, J BONE MINER RES, V31, P308, DOI 10.1002/jbmr.2609
   Cusano NE, 2015, EXPERT REV ENDOCRINO, V10, P5, DOI 10.1586/17446651.2015.971755
   D'Souza Li L, 2002, J CLIN ENDOCR METAB, V87, P1309, DOI 10.1210/jc.87.3.1309
   Damiani FM, 2015, OSTEOPOROSIS INT, V26, P1819, DOI 10.1007/s00198 015 3076 3
   Datta R, 2007, P NATL ACAD SCI USA, V104, P19989, DOI 10.1073/pnas.0708725104
   Dave V, 2015, AM J NEPHROL, V41, P129, DOI 10.1159/000380960
   de Sanctis L, 2003, PEDIATR RES, V53, P749, DOI 10.1203/01.PDR.0000059752.07086.A2
   Dedivitis RA, 2017, CURR OPIN OTOLARYNGO, V25, P142, DOI 10.1097/MOO.0000000000000346
   DELVIN EE, 1981, J PEDIATR US, V99, P26, DOI 10.1016/S0022 3476(81)80952 3
   DESAI TK, 1988, AM J MED, V84, P209, DOI 10.1016/0002 9343(88)90415 9
   Ding CL, 2001, J CLIN INVEST, V108, P1215, DOI 10.1172/JCI13180
   Dong BZ, 2015, J BONE MINER RES, V30, P1980, DOI 10.1002/jbmr.2551
   Edafe O, 2017, GLAND SURG, V6, pS59, DOI 10.21037/gs.2017.09.03
   Elli FM, 2013, HUM MUTAT, V34, P411, DOI 10.1002/humu.22265
   Ertl DA, 2012, BONE, V51, P629, DOI 10.1016/j.bone.2012.06.009
   Falco J, 2016, J AM COLL SURGEONS, V223, P374, DOI 10.1016/j.jamcollsurg.2016.04.049
   FELDMAN D, 1982, J CLIN ENDOCR METAB, V55, P1020, DOI 10.1210/jcem 55 5 1020
   Feldman D, 2014, BoneKEy Rep, V3
   FITCH N, 1982, AM J MED GENET, V11, P11, DOI 10.1002/ajmg.1320110104
   Forrest KYZ, 2011, NUTR RES, V31, P48, DOI 10.1016/j.nutres.2010.12.001
   FRAME B, 1978, ANN INTERN MED, V89, P966, DOI 10.7326/0003 4819 89 6 966
   Fu GK, 1997, MOL ENDOCRINOL, V11, P1961, DOI 10.1210/me.11.13.1961
   FUJIYAMA K, 1995, J CLIN ENDOCR METAB, V80, P2135, DOI 10.1210/jc.80.7.2135
   Gardella TJ, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P65, DOI 10.1016/B978 0 12 397166 1.00004 7
   Geng Y, 2016, ELIFE, V5, DOI 10.7554/eLife.13662
   Glorieux F.H., 2014, BONEKEY REP, V3
   Goldstein D.A., 1990, Clinical Methods: The History, Physical, and Laboratory Examinations
   Gorvin CM, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91103
   Goswami R, 2012, CLIN ENDOCRINOL, V77, P200, DOI 10.1111/j.1365 2265.2012.04353.x
   HAHN TJ, 1972, NEW ENGL J MED, V287, P900, DOI 10.1056/NEJM197211022871803
   Hampson G, 2008, BMC NEPHROL, V9, DOI 10.1186/1471 2369 9 12
   Hannan FM, 2015, ENDOCRINOLOGY, V156, P3114, DOI 10.1210/en.2015 1269
   Hannan FM, 2013, BMJ BRIT MED J, V346, DOI 10.1136/bmj.f2213
   Henry HL, 2011, BEST PRACT RES CL EN, V25, P531, DOI 10.1016/j.beem.2011.05.003
   Hicks G, 2017, GLAND SURG, V6, pS75, DOI 10.21037/gs.2017.09.15
   HOCHBERG Z, 1992, J PEDIATR US, V121, P803, DOI 10.1016/S0022 3476(05)81919 5
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Isojima T, 2014, J BONE MINER RES, V29, P992, DOI 10.1002/jbmr.2091
   Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193
   Kahramangil B, 2017, J SURG ONCOL, V115, P848, DOI 10.1002/jso.24583
   KENNY FM, 1966, AM J DIS CHILD, V111, P201, DOI 10.1001/archpedi.1966.02090050133013
   Kim CJ, 2007, J CLIN ENDOCR METAB, V92, P3177, DOI 10.1210/jc.2006 2664
   Kinoshita Y, 2014, J CLIN ENDOCR METAB, V99, pE363, DOI 10.1210/jc.2013 3430
   Klein GL, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P697, DOI 10.1016/B978 0 12 397166 1.00048 5
   Konrad M, 2014, NEPHROL DIAL TRANSPL, V29, P63, DOI 10.1093/ndt/gfu198
   Koontz SL, 2004, AM J OBSTET GYNECOL, V190, P1773, DOI 10.1016/j.ajog.2004.02.050
   KRUSE K, 1987, EUR J PEDIATR, V146, P373, DOI 10.1007/BF00444941
   KRUSE K, 1989, EUR J PEDIATR, V148, P535, DOI 10.1007/BF00441552
   Laway BA, 2006, CLIN ENDOCRINOL, V64, P405, DOI 10.1111/j.1365 2265.2006.02479.x
   Lemos MC, 2015, HUM MUTAT, V36, P11, DOI 10.1002/humu.22696
   Letz S, 2010, J CLIN ENDOCR METAB, V95, pE229, DOI 10.1210/jc.2010 0651
   Levine MA, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P781, DOI 10.1016/B978 0 12 397166 1.00055 2
   Li D, 2014, J CLIN ENDOCR METAB, V99, pE1774, DOI 10.1210/jc.2014 1029
   Lienhardt A, 2001, J CLIN ENDOCR METAB, V86, P5313, DOI 10.1210/jc.86.11.5313
   Linglart A, 2005, AM J HUM GENET, V76, P804, DOI 10.1086/429932
   Makras P, 2015, METABOLISM, V64, P1199, DOI 10.1016/j.metabol.2015.07.011
   Malloy PJ, 2010, ENDOCRIN METAB CLIN, V39, P333, DOI 10.1016/j.ecl.2010.02.004
   MALLOY PJ, 1990, J CLIN INVEST, V86, P2071, DOI 10.1172/JCI114944
   Mannstadt M, 2008, J CLIN ENDOCR METAB, V93, P3568, DOI 10.1210/jc.2007 2167
   Mannstadt M, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.55
   Mannstadt M, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P37, DOI 10.1016/B978 0 12 397166 1.00002 3
   Mannstadt M, 2013, LANCET DIABETES ENDO, V1, P275, DOI 10.1016/S2213 8587(13)70106 2
   Mannstadt M, 2013, NEW ENGL J MED, V368, P2532, DOI 10.1056/NEJMc1300278
   McCollum EV, 1922, J BIOL CHEM, V53, pE8
   McDonald McGinn DM, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.71
   McGonigle R J, 1984, Magnesium, V3, P1
   Minisola S, 2002, OSTEOPOROSIS INT, V13, P171, DOI 10.1007/s001980200009
   Mirczuk SM, 2010, J CLIN ENDOCR METAB, V95, P3512, DOI 10.1210/jc.2009 2532
   Mitchell DM, 2012, J CLIN ENDOCR METAB, V97, P4507, DOI 10.1210/jc.2012 1808
   MIZUNASHI K, 1990, CALCIFIED TISSUE INT, V46, P227, DOI 10.1007/BF02555000
   Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297 393
   Nakamoto JM, 1998, AM J MED GENET, V77, P261
   Navarro JF, 1999, PERITON DIALYSIS INT, V19, P455
   Nesbit MA, 2013, NEW ENGL J MED, V368, P2476, DOI 10.1056/NEJMoa1300253
   Nitta K, 2017, INTERNAL MED, V56, P3271, DOI 10.2169/internalmedicine.8618 16
   Obi Y, 2015, DIS MARKERS, V2015, P1, DOI 10.1155/2015/868961
   Papadopoulou A, 2017, HORM INT J ENDOCRINO, V16, P200, DOI 10.14310/horm.2002.1734
   PAPAPOULOS SE, 1980, LANCET, V2, P612
   PARKINSON DB, 1992, NAT GENET, V1, P149, DOI 10.1038/ng0592 149
   Parvari R, 2002, NAT GENET, V32, P448, DOI 10.1038/ng1012
   PAYNE RB, 1979, J CLIN PATHOL, V32, P56, DOI 10.1136/jcp.32.1.56
   Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505
   Pike JW, 2010, ENDOCRIN METAB CLIN, V39, P255, DOI 10.1016/j.ecl.2010.02.007
   Piret SE, 2016, J BONE MINER RES, V31, P1207, DOI 10.1002/jbmr.2797
   Pittman K, 2017, ASIA PAC J CLIN ONCO, V13, P266, DOI 10.1111/ajco.12517
   Poradosu S., 2016, BMJ Case Rep, V2016, pbcr2016214673
   PORTER RH, 1978, NEW ENGL J MED, V298, P577, DOI 10.1056/NEJM197803162981101
   Powers J, 2013, J BONE MINER RES, V28, P2570, DOI 10.1002/jbmr.2004
   PRICE PA, 1980, J CLIN INVEST, V66, P878, DOI 10.1172/JCI109954
   Quitterer U, 2001, J BIOL CHEM, V276, P6763, DOI 10.1074/jbc.M007727200
   Rahman MZ, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P807, DOI 10.1016/B978 0 12 397166 1.00056 4
   Ramnitz M, 2015, J BONE MINER RES, V30, P51
   Raue F, 2011, CLIN ENDOCRINOL, V75, P760, DOI 10.1111/j.1365 2265.2011.04142.x
   Riccardi D, 2010, AM J PHYSIOL RENAL, V298, pF485, DOI 10.1152/ajprenal.00608.2009
   Richard N, 2012, J CLIN ENDOCR METAB, V97, pE863, DOI 10.1210/jc.2011 2804
   Robien K, 2013, NUTR CLIN PRACT, V28, P194, DOI 10.1177/0884533612467824
   Rodríguez Ortiz ME, 2014, NEPHROL DIAL TRANSPL, V29, P282, DOI 10.1093/ndt/gft400
   Roszko KL, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91079
   Roszko KL, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00458
   Rubin MR, 2016, J CLIN ENDOCR METAB, V101, P2742, DOI 10.1210/jc.2015 4135
   Rubin MR, 2016, J BONE MINER RES, V31, P1082, DOI 10.1002/jbmr.2777
   Rubin MR, 2011, J BONE MINER RES, V26, P2727, DOI 10.1002/jbmr.452
   Rubin MR, 2010, BONE, V46, P190, DOI 10.1016/j.bone.2009.09.020
   Rubin MR, 2008, J BONE MINER RES, V23, P2018, DOI 10.1359/JBMR.080803
   RUDE RK, 1976, CLIN ENDOCRINOL, V5, P209, DOI 10.1111/j.1365 2265.1976.tb01947.x
   RuDusky BM, 2001, CHEST, V119, P668, DOI 10.1378/chest.119.2.668 a
   Sabbagh Y, 2005, P NATL ACAD SCI USA, V102, P9637, DOI 10.1073/pnas.0502249102
   Sato K, 2002, J CLIN ENDOCR METAB, V87, P3068, DOI 10.1210/jc.87.7.3068
   Schafer A.L., 2000, Endotext
   Schlingmann KP, 2005, J AM SOC NEPHROL, V16, P3061, DOI 10.1681/ASN.2004110989
   Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889
   SCRIVER CR, 1978, NEW ENGL J MED, V299, P976, DOI 10.1056/NEJM197811022991803
   Shaker JL., 2000, ENDOTEXT
   Shaw NJ, 2013, ARCH DIS CHILD, V98, P363, DOI 10.1136/archdischild 2011 301264
   Shoback D, 2008, NEW ENGL J MED, V359, P391, DOI 10.1056/NEJMcp0803050
   Shoback DM, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P687, DOI 10.1016/B978 0 12 397166 1.00047 3
   Sikjaer T, 2012, J BONE MINER RES, V27, P781, DOI 10.1002/jbmr.1493
   Sikjaer T, 2011, J BONE MINER RES, V26, P2358, DOI 10.1002/jbmr.470
   Silva BC, 2017, OSTEOPOROSIS INT, V28, P463, DOI 10.1007/s00198 016 3750 0
   STONE MD, 1993, BONE, V14, P727, DOI 10.1016/8756 3282(93)90204 N
   Sunthornthepvarakul T, 1999, J CLIN ENDOCR METAB, V84, P3792, DOI 10.1210/jc.84.10.3792
   Takamura Y, 2013, WORLD J SURG, V37, P2860, DOI 10.1007/s00268 013 2207 2
   Tenhola S, 2016, EUR J ENDOCRINOL, V175, P211, DOI 10.1530/EJE 16 0109
   Thomée C, 2005, J CLIN ENDOCR METAB, V90, P2487, DOI 10.1210/jc.2004 2450
   TOLMAN KG, 1975, PEDIATRICS, V56, P45
   Turer CB, 2013, PEDIATRICS, V131, pE152, DOI 10.1542/peds.2012 1711
   Underbjerg L, 2018, J BONE MINER RES, V33, P467, DOI 10.1002/jbmr.3328
   Underbjerg L, 2015, J BONE MINER RES, V30, P1738, DOI 10.1002/jbmr.2501
   Underbjerg L, 2014, J BONE MINER RES, V29, P2504, DOI 10.1002/jbmr.2273
   Underbjerg L, 2013, J BONE MINER RES, V28, P2277, DOI 10.1002/jbmr.1979
   Urbano FL, 2000, Hosp Physician, P43
   Van Esch H, 2000, NATURE, V406, P419, DOI 10.1038/35019088
   Viering DHHM, 2017, PEDIATR NEPHROL, V32, P1123, DOI 10.1007/s00467 016 3416 3
   Villarroya Marquina I, 2018, EUR J ENDOCRINOL, V178, P103, DOI 10.1530/EJE 17 0589
   VLOT M, 2014, BMJ CASE REP, V2014
   Vokes TJ, 2018, J CLIN ENDOCR METAB, V103, P722, DOI 10.1210/jc.2017 01471
   Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901
   Wani AI, 2013, J PEDIATR ENDOCR MET, V26, P373, DOI 10.1515/jpem 2012 0201
   Ward DT, 2004, CELL CALCIUM, V35, P217, DOI 10.1016/j.ceca.2003.10.017
   Weber S, 2001, J AM SOC NEPHROL, V12, P1872, DOI 10.1681/ASN.V1291872
   Wein MN, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031237
   Wettschureck N, 2007, MOL ENDOCRINOL, V21, P274, DOI 10.1210/me.2006 0110
   WHANG R, 1984, ARCH INTERN MED, V144, P1794, DOI 10.1001/archinte.144.9.1794
   Winer KK, 2014, J PEDIATR US, V165, P556, DOI 10.1016/j.jpeds.2014.04.060
   Winer KK, 2012, J CLIN ENDOCR METAB, V97, P391, DOI 10.1210/jc.2011 1908
   Winer KK, 2003, J CLIN ENDOCR METAB, V88, P4214, DOI 10.1210/jc.2002 021736
   Winer KK, 1998, J CLIN ENDOCR METAB, V83, P3480, DOI 10.1210/jc.83.10.3480
   Winer KK, 1996, JAMA J AM MED ASSOC, V276, P631, DOI 10.1001/jama.276.8.631
   Yagi H, 2003, LANCET, V362, P1366, DOI 10.1016/S0140 6736(03)14632 6
   Yamaguti PM, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882 015 0079 4
   Yuan T, 2015, CALCIFIED TISSUE INT, V96, P265, DOI 10.1007/s00223 014 9951 7
   ZALOGA GP, 1987, ANN INTERN MED, V107, P36, DOI 10.7326/0003 4819 107 1 36
   Zhang C, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00441
   Zivin JR, 2001, AM J KIDNEY DIS, V37, P689, DOI 10.1016/S0272 6386(01)80116 5
NR 187
TC 36
Z9 39
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521 690X
EI 1532 1908
J9 BEST PRACT RES CL EN
JI Best Pract. Res. Clin. Endoc. Metab.
PD OCT
PY 2018
VL 32
IS 5
BP 639
EP 656
DI 10.1016/j.beem.2018.05.006
PG 18
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HC0NP
UT WOS:000451495400004
PM 30449546
DA 2025 08 17
ER

PT J
AU Minegaki, T
   Fukushima, S
   Morioka, C
   Takanashi, H
   Uno, J
   Tsuji, S
   Yamamoto, S
   Watanabe, A
   Tsujimoto, M
   Nishiguchi, K
AF Minegaki, T.
   Fukushima, S.
   Morioka, C.
   Takanashi, H.
   Uno, J.
   Tsuji, S.
   Yamamoto, S.
   Watanabe, A.
   Tsujimoto, M.
   Nishiguchi, K.
TI Effects of bisphosphonates on human esophageal squamous cell carcinoma
   cell survival
SO DISEASES OF THE ESOPHAGUS
LA English
DT Article
DE bisphosphonate; esophageal cancer; mevalonate pathway
ID S PHASE ARREST; ZOLEDRONIC ACID; INDUCE APOPTOSIS; ANTICANCER DRUGS;
   DNA DAMAGE; CANCER; PATHWAY; RAS; INHIBITION; ACTIVATION
AB Esophageal squamous cell carcinoma (ESCC) is one of the most malignant cancers in Japan. Anticancer chemotherapy has been useful for ESCC treatment. However, therapeutic options are limited. Recently, bisphosphonates (BPs), which are osteoporosis drugs, have shown anticancer effects in several cancer cell lines, but the effects against ESCC cell lines are unknown. In this study, we examined the cytotoxic effects of BPs and their mechanisms of cytotoxicity in human ESCC cell lines. A first generation BP (etidronate), two second generation BPs (alendronate and pamidronate), and two third generation BPs (risedronate and zoledronate) were used in this study. All BPs, except etidronate, were cytotoxic, as indicated by increased caspase 3/7 activity and numbers of Annexin fluorescein isothiocyanate positive cells in ESCC cell lines. From cell cycle analysis, G0/G1 phase arrest was observed upon treatment with second and third generation BPs. In addition, Cyclin D1 protein expression levels were decreased by second and third generation BP treatment. Although squalene and trans, trans farnesol minimally affected BP cytotoxicity, treatment with geranylgeraniol inhibited BP cytotoxicity almost completely. We concluded that second and third generation BPs are cytotoxic to ESCC cell lines as they induce apoptosis and inhibit the cell cycle through mevalonate pathway inhibition. Therefore, BP treatment may be a beneficial therapy in ESCC patients.
C1 [Minegaki, T.; Fukushima, S.; Morioka, C.; Takanashi, H.; Uno, J.; Tsuji, S.; Yamamoto, S.; Watanabe, A.; Tsujimoto, M.; Nishiguchi, K.] Kyoto Pharmaceut Univ, Fac Pharmaceut Sci, Dept Clin Pharm, Kyoto, Japan.
C3 Kyoto Pharmaceutical University
RP Minegaki, T (通讯作者)，Kyoto Pharmaceut Univ, Fac Pharmaceut Sci, Dept Clin Pharm, Yamashina Ku, 5 Nakauchi Cho, Kyoto 6078414, Japan.
EM t minegaki@mb.kyoto phu.ac.jp
FU Ministry of Education, Culture, Sport, Science, and Technology of Japan;
   JSPS KAKENHI grant [25460230]; Grants in Aid for Scientific Research
   [25460230] Funding Source: KAKEN
FX This study was supported in part by a Grant aided Project for Private
   Universities from Ministry of Education, Culture, Sport, Science, and
   Technology of Japan and JSPS KAKENHI grant number 25460230.
CR Advani SH, 2010, INDIAN J MED PAEDIAT, V31, P132, DOI 10.4103/0971 5851.76197
   [Anonymous], CANC STAT JAP 2013
   Chuah C, 2005, LEUKEMIA, V19, P1896, DOI 10.1038/sj.leu.2403949
   Crick DC, 1997, BIOCHEM BIOPH RES CO, V237, P483, DOI 10.1006/bbrc.1997.7145
   Di Salvatore M, 2011, CELL PROLIFERAT, V44, P139, DOI 10.1111/j.1365 2184.2011.00745.x
   Fujita M, 2012, ONCOL REP, V27, P1371, DOI 10.3892/or.2012.1683
   Goffinet M, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 60
   Guo RT, 2007, P NATL ACAD SCI USA, V104, P10022, DOI 10.1073/pnas.0702254104
   Ho CL, 2014, BIOMED PHARMACOTHER, V68, P1007, DOI 10.1016/j.biopha.2014.09.008
   Holstein SA, 2002, BIOCHEMISTRY US, V41, P13698, DOI 10.1021/bi026251x
   Iguchi T, 2007, INT J ONCOL, V31, P285
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Koto K, 2013, INT J ONCOL, V42, P525, DOI 10.3892/ijo.2012.1735
   Kubista B, 2006, J ORTHOP RES, V24, P1145, DOI 10.1002/jor.20129
   Kuroda J, 2004, CANCER SCI, V95, P186, DOI 10.1111/j.1349 7006.2004.tb03202.x
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608
   Li Shaojuan, 2011, Cancers (Basel), V3, P662, DOI 10.3390/cancers3010662
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Murayama T, 2008, ANTICANCER RES, V28, P2147
   Nogawa M, 2005, ONCOL RES, V15, P1
   Ohnuki H, 2012, ARCH ORAL BIOL, V57, P906, DOI 10.1016/j.archoralbio.2011.11.015
   Romani AA, 2009, BIOCHEM PHARMACOL, V78, P133, DOI 10.1016/j.bcp.2009.04.004
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097 0142(19920115)69:2<277::AID CNCR2820690202>3.0.CO;2 C
   Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968 0004(03)00087 2
   Takara K, 2002, BIOL PHARM BULL, V25, P771, DOI 10.1248/bpb.25.771
   Thallinger CMR, 2011, J CLIN ONCOL, V29, P4709, DOI 10.1200/JCO.2011.36.7599
   Tsubaki M, 2013, BIOCHEM PHARMACOL, V85, P163, DOI 10.1016/j.bcp.2012.10.009
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Verdijk R, 2007, CANCER LETT, V246, P308, DOI 10.1016/j.canlet.2006.03.011
NR 33
TC 7
Z9 8
U1 0
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1120 8694
EI 1442 2050
J9 DIS ESOPHAGUS
JI Dis. Esophagus
PD AUG SEP
PY 2016
VL 29
IS 6
BP 656
EP 662
DI 10.1111/dote.12370
PG 7
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology
GA DW4PT
UT WOS:000383626200023
PM 25894100
DA 2025 08 17
ER

PT J
AU Günaldi, M
   Afsar, CU
   Duman, BB
   Kara, IO
   Tatli, U
   Sahin, B
AF Gunaldi, Meral
   Afsar, Cigdem Usul
   Duman, Berna Bozkurt
   Kara, Ismail Oguz
   Tatli, Ufuk
   Sahin, Berksoy
TI Effect of the cumulative dose of zoledronic acid on the pathogenesis of
   osteonecrosis of the jaws
SO ONCOLOGY LETTERS
LA English
DT Article
DE zoledronic acid; cumulative dose; jaw; osteonecrosis; risk factors
ID BISPHOSPHONATE RELATED OSTEONECROSIS; RENAL CELL CARCINOMA;
   RISK FACTORS; INTRAVENOUS BISPHOSPHONATES; MULTIPLE MYELOMA;
   CANCER PATIENTS; OSTEOCLASTS; THERAPY; ALENDRONATE; MECHANISMS
AB Bisphosphonate related osteonecrosis of the jaws (BRONJ) is a severe bone disease for which the pathogenetic mechanisms and risk factors are not fully understood. The present study evaluated the data of 652 patients with bone metastasis that had undergone treatment with biphosphonates. Subsequently, 24 patients with BRONJ and 20 control patients without BRONJ that were treated with zoledronic acid were enrolled. It was found that BRONJ occurred in 3.6% of patients. The mean age and the administration of dental treatment were found to be significantly associated with BRONJ development (P=0.049 and P=0.013, respectively). The cumulative dose median in the BRONJ group was found to be significantly higher compared with the cumulative dose average in the control group (P=0.037). In addition, at the time of BRONJ development, improvement in the disease was determined to be better in the BRONJ group than in the control group (P=0.031). The present study determined that age, the existence of dental extraction and the cumulative dose of zoledronate were all important risk factors in BRONJ development.
C1 [Gunaldi, Meral] Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Med Oncol, TR 34147 Istanbul, Turkey.
   [Afsar, Cigdem Usul; Kara, Ismail Oguz; Sahin, Berksoy] Cukurova Univ, Dept Med Oncol, Sch Med, Adana, Turkey.
   [Duman, Berna Bozkurt] Cukurova Univ, Dept Med Oncol, Adana Res & Training Hosp, Adana, Turkey.
   [Tatli, Ufuk] Cukurova Univ, Fac Dent, Adana, Turkey.
C3 Bakirkoy Dr. Sadi Konuk Research & Training Hospital; Cukurova
   University; Cukurova University; Adana Numune Training & Research
   Hospital; Cukurova University
RP Günaldi, M (通讯作者)，Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Med Oncol, 11 Tevfik Saglam St, TR 34147 Istanbul, Turkey.
EM meralgunaldi@gmail.com
RI Afsar, Cigdem/C 3436 2015; Duman, B./AAV 5237 2021; Tatli,
   Ufuk/K 3762 2018; Gunaldi, Meral/Z 1463 2018; Usul Afsar,
   Cigdem/C 3436 2015
OI Usul Afsar, Cigdem/0000 0002 3764 7639
CR Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Berenson JR, 2002, J CLIN ONCOL, V20, P3719, DOI 10.1200/JCO.2002.06.037
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Boonyapakorn T, 2008, ORAL ONCOL, V44, P857, DOI 10.1016/j.oraloncology.2007.11.012
   Brufsky AM, 2013, BREAST J, V19, P504, DOI 10.1111/tbj.12152
   Diel Ingo J., 2000, Cancer, V88, P3080, DOI 10.1002/1097 0142(20000615)88:12+<3080::AID CNCR27>3.0.CO;2 W
   Ferlito S, 2012, BRIT J ORAL MAX SURG, V50, P425, DOI 10.1016/j.bjoms.2011.08.004
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Fusco V, 2014, CLIN GENITOURIN 1209
   Green J, 2010, SEMIN ONCOL, V37, pS3, DOI 10.1053/j.seminoncol.2010.06.003
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Janovska Zuzana, 2012, Acta Medica (Hradec Kralove), V55, P111
   Kos M, 2010, J CRANIO MAXILL SURG, V38, P255, DOI 10.1016/j.jcms.2009.06.005
   Ledoux D, 2006, ANTI CANCER DRUG, V17, P479, DOI 10.1097/01.cad.0000198909.52701.0f
   Lescaille G, 2014, BONE, V58, P103, DOI 10.1016/j.bone.2013.10.002
   LOWIK CWGM, 1988, J BONE MINER RES, V3, P185
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   McArthur HL, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.9588
   McKay RR, 2014, EUR UROL, V66, P502, DOI 10.1016/j.eururo.2014.02.040
   McLeod NMH, 2012, SURG J R COLL SURG E, V10, P36, DOI 10.1016/j.surge.2011.09.002
   Molcho S, 2013, J CLIN ENDOCR METAB, V98, pE1807, DOI 10.1210/jc.2013 2434
   Pietschmann P, 1998, CALCIFIED TISSUE INT, V63, P325, DOI 10.1007/s002239900535
   PIPER K, 1994, CALCIFIED TISSUE INT, V54, P56, DOI 10.1007/BF00316291
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Ruggiero SL, 2009, AUST ENDOD J, V35, P119, DOI 10.1111/j.1747 4477.2009.00213.x
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   Smidt Hansen T, 2013, J ORAL MAXIL SURG, V71, P1532, DOI 10.1016/j.joms.2013.03.019
   Thumbigere Math V, 2012, AM J CLIN ONCOL CANC, V35, P386, DOI 10.1097/COC.0b013e3182155fcb
   Tubiana Hulin M, 2009, CRIT REV ONCOL HEMAT, V71, P12, DOI 10.1016/j.critrevonc.2008.10.009
   Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584
   Vescovi P, 2011, ORAL ONCOL, V47, P191, DOI 10.1016/j.oraloncology.2010.11.007
   Wessel JH, 2008, J ORAL MAXIL SURG, V66, P625, DOI 10.1016/j.joms.2007.11.032
NR 34
TC 12
Z9 15
U1 1
U2 14
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JUL
PY 2015
VL 10
IS 1
BP 439
EP 442
DI 10.3892/ol.2015.3156
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CN0WD
UT WOS:000358133800080
PM 26171047
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Li, KC
   Chang, YH
   Hsu, MN
   Lo, SC
   Li, WH
   Hu, YC
AF Li, Kuei Chang
   Chang, Yu Han
   Hsu, Mu Nung
   Lo, Shih Chun
   Li, Wan Hua
   Hu, Yu Chen
TI Baculovirus Mediated miR 214 Knockdown Shifts Osteoporotic ASCs
   Differentiation and Improves Osteoporotic Bone Defects Repair
SO SCIENTIFIC REPORTS
LA English
DT Article
ID STEM CELLS; OSTEOGENIC DIFFERENTIATION; BETA CATENIN; OSTEOBLAST
   DIFFERENTIATION; CALVARIAL DEFECTS; WNT; ADIPOGENESIS; DELIVERY; MSCS;
   SCAFFOLDS
AB Osteoporotic patients often suffer from bone fracture but its healing is compromised due to impaired osteogenesis potential of bone marrow derived mesenchymal stem cells (BMSCs). Here we aimed to exploit adipose derived stem cells from ovariectomized rats (OVX ASCs) for bone healing. We unraveled that OVX ASCs highly expressed miR 214 and identified 2 miR 214 targets: CTNNB1 (beta catenin) and TAB2. We demonstrated that miR 214 targeting of these two genes blocked the Wnt pathway, led to preferable adipogenesis and hindered osteogenesis. As a result, OVX ASCs implantation into OVX rats failed to heal critical size metaphyseal bone defects. We further engineered the OVX ASCs with a novel Cre/loxP based hybrid baculovirus vector that conferred prolonged expression of miR 214 sponge. Gene delivery for miR 214 sponge expression successfully downregulated miR 214 levels, activated the Wnt pathway, upregulated osteogenic factors beta catenin/Runx2, downregulated adipogenic factors PPAR gamma and C/EBP alpha, shifted the differentiation propensity towards osteogenic lineage, enhanced the osteogenesis of co cultured OVX BMSCs, elevated BMP7/osteoprotegerin secretion and hindered exosomal miR 214/osteopontin release. Consequently, implanting the miR 214 sponge expressing OVX ASCs tremendously improved bone healing in OVX rats. Co expression of miR 214 sponge and BMP2 further synergized the OVX ASCs mediated bone regeneration in OVX rats. This study implicates the potential of suppressing miR 214 by baculovirus mediated gene delivery in osteoporotic ASCs for regenerative medicine.
C1 [Li, Kuei Chang; Hsu, Mu Nung; Lo, Shih Chun; Li, Wan Hua; Hu, Yu Chen] Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu 300, Taiwan.
   [Chang, Yu Han] Chang Gung Mem Hosp, Ctr Tissue Engn, Taoyuan 333, Taiwan.
   [Chang, Yu Han] Chang Gung Mem Hosp, Dept Orthopaed, Taoyuan 333, Taiwan.
C3 National Tsing Hua University; Chang Gung Memorial Hospital; Chang Gung
   Memorial Hospital
RP Hu, YC (通讯作者)，Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu 300, Taiwan.
EM yuchen@che.nthu.edu.tw
RI Hu, Yu Chen/E 7825 2012; Yeh, Chun Hung/JDM 9927 2023
FU National Tsing Hua University [106N526CE1, 105N526CE1]; NTHU CGMH Joint
   Research Program [CMRPG3D0591, 103N2758E1]; CGMH Intramural Project
   [CRRPG3E0172, CMRPG3E0441, CMRPG3E0061, CMRPG3B1542, CMRPG3B1541];
   Ministry of Science and Technology, Taiwan [105 2923 E 007 002 MY3,
   104 2221 E 007 088 MY3, 103 2221 E 007 093 MY3]
FX This work was supported by the National Tsing Hua University (Toward
   World Class University Project 106N526CE1, 105N526CE1 and NTHU CGMH
   Joint Research Program CMRPG3D0591, 103N2758E1), CGMH Intramural Project
   (CRRPG3E0172, CMRPG3E0441, CMRPG3E0061, CMRPG3B1542, CMRPG3B1541) and
   Ministry of Science and Technology (105 2923 E 007 002 MY3,
   104 2221 E 007 088 MY3, 103 2221 E 007 093 MY3), Taiwan.
CR Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Cao L, 2012, BIOMATERIALS, V33, P5076, DOI 10.1016/j.biomaterials.2012.03.069
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Christodoulides C, 2009, TRENDS ENDOCRIN MET, V20, P16, DOI 10.1016/j.tem.2008.09.002
   Deal C, 2009, NAT CLIN PRACT RHEUM, V5, P20, DOI 10.1038/ncprheum0977
   Desiderio V, 2014, INT J BIOCHEM CELL B, V51, P75, DOI 10.1016/j.biocel.2014.03.025
   Ekström K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075227
   Fan JB, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0072474, 10.1371/journal.pone.0076701]
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Huang CC, 2016, BIOMATERIALS, V111, P103, DOI 10.1016/j.biomaterials.2016.09.029
   Jing H, 2016, MOL THER, V24, P217, DOI 10.1038/mt.2015.152
   Kennell JA, 2005, J BIOL CHEM, V280, P24004, DOI 10.1074/jbc.M501080200
   Kushwaha P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.350
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li K. C., 2016, J TISSUE ENG REGENER
   Li KC, 2016, BIOMATERIALS, V74, P155, DOI 10.1016/j.biomaterials.2015.09.046
   Li KC, 2015, TISSUE ENG PT A, V21, P1471, DOI [10.1089/ten.tea.2014.0465, 10.1089/ten.TEA.2014.0465]
   Li M, 2010, J BIOL CHEM, V285, P13397, DOI 10.1074/jbc.M109.083246
   Liao L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.130
   Liao YH, 2014, BIOMATERIALS, V35, P4901, DOI 10.1016/j.biomaterials.2014.02.055
   Lin CY, 2013, BIOMATERIALS, V34, P9401, DOI 10.1016/j.biomaterials.2013.08.051
   Lin CY, 2012, BIOMATERIALS, V33, P7422, DOI 10.1016/j.biomaterials.2012.06.083
   Lin CY, 2012, BIOMATERIALS, V33, P3682, DOI 10.1016/j.biomaterials.2012.02.007
   Liu HY, 2012, BIOMATERIALS, V33, P6105, DOI 10.1016/j.biomaterials.2012.05.024
   Liu JM, 2017, EXP CELL RES, V351, P157, DOI 10.1016/j.yexcr.2017.01.006
   Lo SC, 2017, BIOMATERIALS, V124, P1, DOI 10.1016/j.biomaterials.2017.01.033
   Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253
   Mirsaidi A, 2014, BIOMATERIALS, V35, P7326, DOI 10.1016/j.biomaterials.2014.05.016
   Niemeyer P, 2010, BIOMATERIALS, V31, P3572, DOI 10.1016/j.biomaterials.2010.01.085
   Orso F, 2016, CANCER RES, V76, P5151, DOI 10.1158/0008 5472.CAN 15 1322
   Pei M, 2015, BONE, V78, P1, DOI 10.1016/j.bone.2015.04.040
   Peng B, 2015, ADV DRUG DELIVER REV, V88, P108, DOI 10.1016/j.addr.2015.05.014
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Shi KK, 2013, BONE, V55, P487, DOI 10.1016/j.bone.2013.04.002
   Sung LY, 2014, NAT PROTOC, V9, P1882, DOI 10.1038/nprot.2014.130
   Sung LY, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt442
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Tang D, 2016, BIOMATERIALS, V83, P363, DOI 10.1016/j.biomaterials.2016.01.024
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Zhang HM, 2015, BIOMATERIALS, V39, P145, DOI 10.1016/j.biomaterials.2014.11.007
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhang YF, 2012, BIOMATERIALS, V33, P6698, DOI 10.1016/j.biomaterials.2012.06.021
NR 45
TC 28
Z9 31
U1 0
U2 9
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD NOV 24
PY 2017
VL 7
AR 16225
DI 10.1038/s41598 017 16547 3
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FN6OL
UT WOS:000416135000024
PM 29176755
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Luppen, CA
   Chandler, RL
   Noh, T
   Mortlock, DP
   Frenkel, B
AF Luppen, Cynthia A.
   Chandler, Ronald L.
   Noh, Tommy
   Mortlock, Douglas P.
   Frenkel, Baruch
TI BMP 2 vs. BMP 4 expression and activity in glucocorticoid arrested
   MCM E1 osteoblasts: Smad signaling, not alkaline phosphatase activity,
   predicts rescue of mineralization
SO GROWTH FACTORS
LA English
DT Article
DE osteoblast; BMP; Smad; alkaline phosphatase; glucocorticoids
ID BONE MORPHOGENETIC PROTEIN 2; GROWTH FACTOR BETA; IN VITRO; INDUCED
   OSTEOPOROSIS; GENE; DIFFERENTIATION; TRANSCRIPTION; STIMULATION;
   APOPTOSIS; KINASE
AB Pharmacological glucocorticoids (GCs) inhibit bone formation, leading to osteoporosis. GCs inhibit bone morphogenetic protein 2 (Bmp2) expression, and rhBMP 2 restores mineralization in GC arrested osteoblast cultures. To better understand how GCs regulate BMPs, we investigated Bmp transcription, as well as rhBMP induced Smad and alkaline phosphatase (ALP) activity. Bmp2 cis regulatory regions were analyzed by reporter plasmids and LacZ containing bacterial artificial chromosomes. We found that GCs inhibited Bmp2 via a domain > 50 kb downstream of the coding sequence. Bmp expression was evaluated by RT PCR; whereas GCs strongly inhibited Bmp2, Bmp4 was abundantly expressed and resistant to GCs. Both rhBMP 2 and rhBMP 4 restored mineralization in GC arrested cultures; rhBMP 2 was 5 fold more effective when dosing was based on ALP activation, however, the rhBMPs were equipotent when dosing was based on Smad transactivation. In conclusion, GCs regulate Bmp2 via a far downstream domain, and activation of Smad, not ALP, best predicts the pro mineralization potential of rhBMPs.
C1 [Luppen, Cynthia A.; Noh, Tommy; Frenkel, Baruch] Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA.
   [Chandler, Ronald L.; Mortlock, Douglas P.] Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37212 USA.
   [Chandler, Ronald L.; Mortlock, Douglas P.] Vanderbilt Univ, Sch Med, Ctr Human Genet Res, Nashville, TN 37212 USA.
   [Frenkel, Baruch] Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Orthopaed Surg, Los Angeles, CA 90033 USA.
C3 University of Southern California; Vanderbilt University; Vanderbilt
   University; University of Southern California
RP Frenkel, B (通讯作者)，Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Biochem & Mol Biol, 2250 Alcazar St,CSC IGM240, Los Angeles, CA 90033 USA.
EM frenkel@usc.edu
RI Mortlock, Douglas/C 9981 2010
FU Arthritis Foundation; NIH [AR047052, HD47880 01, DE07211, HD07502];
   NIH/NCRR [C06 (RR10600 01, CA62528 01, RR14514 01)]
FX The authors thank Drs Ming Zhao and Stephen Harris (University of Texas
   Health Sciences Center, San Antonio, TX) for Bmp2 promoterluciferase
   constructs and the BMP Smad reporter "(GCCG)<INF>12</INF> luciferase";
   Wyeth Pharmaceuticals (Cambridge, MA) for rhBMP 2; and Drs Johnny Huard
   (University of Pittsburgh) and Wei Zhu (Hospital for Special Surgery,
   New York, NY, USA) for helpful discussions. This study was supported by
   grants from the Arthritis Foundation (Atlanta, Georgia, to BF) and the
   NIH (AR047052 to BF and HD47880 01 to DPM) and by the J. Harold and Edna
   L. LaBriola Chair in Genetic Orthopaedics at the University of Southern
   California (held by BF). CAL and RLC were supported by NIH training
   grants DE07211 and HD07502, respectively. The experiments were conducted
   in a facility constructed with support from Research Facilities
   Improvement Program Grant Number C06 (RR10600 01, CA62528 01,
   RR14514 01) from the NIH/NCRR.
CR Abzhanov A, 2004, SCIENCE, V305, P1462, DOI 10.1126/science.1098095
   Boden SD, 1996, ENDOCRINOLOGY, V137, P3401, DOI 10.1210/en.137.8.3401
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843
   Centrella M, 1997, J CELL BIOCHEM, V67, P528, DOI 10.1002/(SICI)1097 4644(19971215)67:4<528::AID JCB10>3.0.CO;2 5
   Chandler RL, 2007, MOL CELL BIOL, V27, P2934, DOI 10.1128/MCB.01609 06
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Cooper MS, 1999, J ENDOCRINOL, V163, P159, DOI 10.1677/joe.0.1630159
   Dempster DW, 1997, J ENDOCRINOL, V154, P397, DOI 10.1677/joe.0.1540397
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   DiLeone RJ, 1998, GENETICS, V148, P401
   Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018
   Fritz DT, 2004, J BIOL CHEM, V279, P48950, DOI 10.1074/jbc.M409620200
   GODSCHALK MF, 1988, J BONE MINER RES, V3, P113
   Greenwald J, 2004, MOL CELL, V15, P485, DOI 10.1016/j.molcel.2004.07.011
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Harrison CA, 2004, J BIOL CHEM, V279, P28036, DOI 10.1074/jbc.M402782200
   Heller LC, 1999, J BIOL CHEM, V274, P1394, DOI 10.1074/jbc.274.3.1394
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kirsch T, 2000, NAT STRUCT BIOL, V7, P492
   Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555
   Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200
   Leclerc N, 2004, J MOL ENDOCRINOL, V33, P175, DOI 10.1677/jme.0.0330175
   Lian JB, 1997, ENDOCRINOLOGY, V138, P2117, DOI 10.1210/en.138.5.2117
   Liu W, 2005, DEV BIOL, V283, P282, DOI 10.1016/j.ydbio.2005.04.019
   Liu YS, 2004, BONE, V35, P673, DOI 10.1016/j.bone.2004.04.017
   Luppen CA, 2003, J BIOL CHEM, V278, P44995, DOI 10.1074/jbc.M306730200
   Luppen CA, 2003, J BONE MINER RES, V18, P1186, DOI 10.1359/jbmr.2003.18.7.1186
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356
   Mortlock DP, 2003, GENOME RES, V13, P2069, DOI 10.1101/gr.1306003
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Ohkawara B, 2002, CURR BIOL, V12, P205, DOI 10.1016/S0960 9822(01)00684 4
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Pearce G, 1998, J CLIN ENDOCR METAB, V83, P801, DOI 10.1210/jc.83.3.801
   Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708
   PRUMMEL MF, 1991, J CLIN ENDOCR METAB, V72, P382, DOI 10.1210/jcem 72 2 382
   Qiao B, 2005, J BIOL CHEM, V280, P17562, DOI 10.1074/jbc.M500646200
   Sears KE, 2006, P NATL ACAD SCI USA, V103, P6581, DOI 10.1073/pnas.0509716103
   Sebald W, 2004, BIOL CHEM, V385, P697, DOI 10.1515/BC.2004.086
   SMITH E, 1999, J BIOL CHEM, V275, P2
   Styrkarsdottir U, 2003, PLOS BIOL, V1, P351, DOI 10.1371/journal.pbio.0000069
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wu P, 2004, SCIENCE, V305, P1465, DOI 10.1126/science.1098109
   Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366
   Zalavras C, 2003, CRIT REV EUKAR GENE, V13, P221, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.140
   Zhao M, 2005, J CELL BIOCHEM, V95, P1, DOI 10.1002/jcb.20411
   Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012
   Zhou SH, 2003, MOL ENDOCRINOL, V17, P56, DOI 10.1210/me.2002 0210
   Zhu W, 2006, BONE, V39, P61, DOI 10.1016/j.bone.2005.12.018
NR 59
TC 33
Z9 41
U1 0
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0897 7194
EI 1029 2292
J9 GROWTH FACTORS
JI Growth Factors
PD AUG
PY 2008
VL 26
IS 4
BP 226
EP 237
DI 10.1080/08977190802277880
PG 12
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 342FG
UT WOS:000258769400007
PM 19021035
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Cho, E
   Cheon, S
   Ding, M
   Lim, K
   Park, SW
   Park, C
   Lee, TH
AF Cho, Eunjin
   Cheon, Seongmin
   Ding, Mina
   Lim, Kayeong
   Park, Sang Wook
   Park, Chungoo
   Lee, Tae Hoon
TI Identification of Novel Genes for Cell Fusion during Osteoclast
   Formation
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteoclast; fusion; Calcrl; Marco; Ube3a; CRISPR Cas9
ID MACROPHAGE POLARIZATION; DIFFERENTIATION; MICE
AB Osteoclasts are derived from hematopoietic stem cells. Monocyte preosteoclasts obtain resorbing activity via cell cell fusion to generate multinucleated cells. However, the mechanisms and molecules involved in the fusion process are poorly understood. In this study, we performed RNA sequencing with single nucleated cells (SNCs) and multinucleated cells (MNCs) to identify the fusion specific genes. The SNCs and MNCs were isolated under the same conditions during osteoclastogenesis with the receptor activator of nuclear factor kappa B ligand (RANKL) administration. Based on this analysis, the expression of seven genes was found to be significantly increased in MNCs but decreased in SNCs, compared to that in bone marrow derived macrophages (BMMs). We then generated knockout macrophage cell lines using a CRISPR Cas9 genome editing tool to examine their function during osteoclastogenesis. Calcrl , Marco , or Ube3a deficient cells could not develop multinucleated giant osteoclasts upon RANKL stimulation. However, Tmem26 deficient cells fused more efficiently than control cells. Our findings demonstrate that Calcrl, Marco, and Ube3a are novel determinants of osteoclastogenesis, especially with respect to cell fusion, and highlight potential targets for osteoporosis therapy.
C1 [Cho, Eunjin; Park, Sang Wook; Lee, Tae Hoon] Chonnam Natl Univ, Sch Dent, Dent Sci Res Inst, Dept Oral Biochem, Gwangju 61186, South Korea.
   [Cheon, Seongmin; Park, Chungoo] Chonnam Natl Univ, Sch Biol Sci & Technol, Gwangju 61186, South Korea.
   [Cheon, Seongmin] Seoul Natl Univ Hosp, Biomed Res Inst, Prote Core Facil, Seoul 03080, South Korea.
   [Ding, Mina] Chonnam Natl Univ, Sch Med, Biomed Sci Grad Program, Gwangju 61186, South Korea.
   [Lim, Kayeong] Ctr Genome Engn, Inst Basic Sci, Daejeon 34126, South Korea.
C3 Chonnam National University; Chonnam National University; Seoul National
   University (SNU); Seoul National University Hospital; Chonnam National
   University; Institute for Basic Science   Korea (IBS)
RP Lee, TH (通讯作者)，Chonnam Natl Univ, Sch Dent, Dent Sci Res Inst, Dept Oral Biochem, Gwangju 61186, South Korea.
EM ag8414@gmail.com; s.cheon1995@gmail.com; minading1021@gmail.com;
   limka@snu.ac.kr; swpark@chonnam.ac.kr; chungoo.park@gmail.com;
   thlee83@chonnam.ac.kr
RI ; Lee, Tae Hoon/AAR 3708 2021; Park, Sang Wook/LEM 5116 2024
OI Lee, Tae Hoon/0000 0003 0105 1750; Cho, Eunjin/0000 0003 0276 4728;
   Ding, Mina/0000 0002 7114 738X; 
FU Korea Mouse Phenotyping Project of the Ministry of Science and ICT
   through the National Research Foundation [2014M3A9D5A01073658];
   Commercializations Promotion Agency for R&D Outcomes (COMPA)   Korean
   government (MSIT) [2021C200]
FX This work was supported by the KoreaMouse Phenotyping Project
   (2014M3A9D5A01073658) of the Ministry of Science and ICT through the
   National Research Foundation and by the Commercializations Promotion
   Agency for R&D Outcomes (COMPA) grant funded by the Korean government
   (MSIT) (2021C200).
CR Aguilar PS, 2013, TRENDS GENET, V29, P427, DOI 10.1016/j.tig.2013.01.011
   Ahn SH, 2018, MOLECULES, V23, DOI 10.3390/molecules23123139
   Alexander KA, 2011, J BONE MINER RES, V26, P1517, DOI 10.1002/jbmr.354
   An E, 2014, MOL CELL PROTEOMICS, V13, P2687, DOI 10.1074/mcp.M113.034371
   Angenendt L, 2019, LEUKEMIA, V33, P2830, DOI 10.1038/s41375 019 0505 x
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Bollag AE, 2019, J ENDOCRINOL, V243, P15, DOI 10.1530/JOE 18 0691
   Buttitta LA, 2007, CURR OPIN CELL BIOL, V19, P697, DOI 10.1016/j.ceb.2007.10.004
   Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Cho E, 2021, BONE, V142, DOI 10.1016/j.bone.2020.115707
   Cho E, 2019, MOLECULES, V24, DOI 10.3390/molecules24183346
   Da WCL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.675385
   Dou C, 2016, SCI REP UK, V6, DOI 10.1038/srep21499
   Fierro FA, 2017, STEM CELLS, V35, P1461, DOI 10.1002/stem.2625
   Gao F, 2017, MOL MED REP, V15, P3969, DOI 10.3892/mmr.2017.6544
   Gluexam T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235826
   Godwin JW, 2013, P NATL ACAD SCI USA, V110, P9415, DOI 10.1073/pnas.1300290110
   Hobolt Pedersen AS, 2014, CALCIFIED TISSUE INT, V95, P73, DOI 10.1007/s00223 014 9864 5
   Huang R, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.19
   Ivashkiv LB, 2013, TRENDS IMMUNOL, V34, P216, DOI 10.1016/j.it.2012.11.001
   Jann J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207597
   Jeganathan S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104498
   Jiang M, 2019, J BONE MINER RES, V34, P361, DOI 10.1002/jbmr.3604
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kodama J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165685
   Komine H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067795
   Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Leroy H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249644
   Lv Y, 2016, J BIOL CHEM, V291, P23390, DOI 10.1074/jbc.M116.735563
   Madel MB, 2020, ELIFE, V9, DOI 10.7554/eLife.54493
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Miyamoto H, 2012, J BONE MINER RES, V27, P1289, DOI 10.1002/jbmr.1575
   Moller AMJ, 2017, J CELL PHYSIOL, V232, P1396, DOI 10.1002/jcp.25633
   Moon YJ, 2019, CELL DEATH DIFFER, V26, P2358, DOI 10.1038/s41418 019 0306 9
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   Nagy V, 2015, GERONTOLOGY, V61, P534, DOI 10.1159/000371845
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Park J, 2017, BIOINFORMATICS, V33, P286, DOI 10.1093/bioinformatics/btw561
   Pereira M, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216267
   Petrany MJ, 2019, TRENDS CELL BIOL, V29, P964, DOI 10.1016/j.tcb.2019.09.002
   Qiu YF, 2014, CELL, V157, P1292, DOI 10.1016/j.cell.2014.03.066
   Rahman MM, 2015, BONE, V81, P392, DOI 10.1016/j.bone.2015.08.008
   Russell FA, 2014, PHYSIOL REV, V94, P1099, DOI 10.1152/physrev.00034.2013
   Sankar U, 2004, J BONE MINER RES, V19, P1339, DOI 10.1359/JBMR.040321
   Soe K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207717
   Suekane A, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 36796 0
   Suryawanshi H, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aau4788
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tiedemann K, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00054
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Upadhyay A, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00151
   Vi L, 2015, J BONE MINER RES, V30, P1090, DOI 10.1002/jbmr.2422
   Wang ZN, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108472
   Xiao Y, 2019, J INT MED RES, V47, P5787, DOI 10.1177/0300060519876796
   Xu JT, 2017, J IMMUNOL, V198, P3548, DOI 10.4049/jimmunol.1700057
   Xue F, 2021, ELIFE, V10, DOI 10.7554/eLife.64872
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664871
   Zampeta FI, 2020, HUM MOL GENET, V29, P3032, DOI 10.1093/hmg/ddaa194
NR 63
TC 3
Z9 7
U1 0
U2 9
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2022
VL 23
IS 12
AR 6421
DI 10.3390/ijms23126421
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 2O5CY
UT WOS:000819077200001
PM 35742859
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, JW
   Li, R
   Liao, XW
   Hu, BL
   Yu, J
AF Liu, Jianwei
   Li, Rong
   Liao, Xiwen
   Hu, Bangli
   Yu, Jia
TI Comprehensive investigation of the clinical significance and molecular
   mechanisms of plasmacytoma variant translocation 1 in sarcoma using
   genome wide RNA sequencing data
SO JOURNAL OF CANCER
LA English
DT Article
DE sarcoma; plasmacytoma variant translocation 1; RNA sequencing; The
   Cancer Genome Atlas; molecular mechanism
ID LONG NONCODING RNA; FALSE DISCOVERY RATE; SQUAMOUS CELL CARCINOMA;
   LNCRNA PVT1; PROGNOSTIC SIGNIFICANCE; INTERACTION NETWORKS; CANCER
   PROGRESSION; TRANSCRIPTOME DATA; CONNECTIVITY MAP; EXPRESSION
AB Objective: The present study aims to identify the potential clinical application and molecular mechanism of plasmacytoma variant translocation 1 (PVT1) in patients with sarcomas by mining an RNA sequencing dataset from The Cancer Genome Atlas (TCGA) through multiple genome wide analysis approaches.
   Methods: A genome wide RNA sequencing dataset was downloaded from TCGA, survival analysis was used to evaluate the prognostic value of PVT1 in sarcoma. The potential mechanism was investigated by multiple tools: Database for Annotation, Visualization, and Integrated Discovery v6.8, gene set enrichment analysis (GSEA), and Connectivity Map (CMap).
   Results: Comprehensive survival analysis indicated that overexpression of PVT1 was significantly associated with poor prognosis in patients with sarcoma, and nomogram demonstrated that PVT1 contributed more than other traditional clinical parameters in sarcoma survival prediction. Weighted gene co expression network analysis identified ten hub differentially expressed genes (DEGs) between sarcoma tissues with low and overexpression of PVT1, and substantiated that these DEGs have a complex co expression network relationship. CMap analysis has identified that antipyrine, ondansetron, and econazole may be candidate targeted drugs for sarcoma patients with PVT1 overexpression. GSEA revealed that overexpression of PVT1 may be involved in the post transcriptional regulation of gene expression, tumor invasiveness and metastasis, osteoblast differentiation and development, apoptosis, nuclear factor kappa B, Wnt, and apoptotic related signaling pathways.
   Conclusions: Our findings indicate that PVT1 may serve as a prognostic indicator in patients with sarcoma. Its underlying mechanism is revealed by GSEA, and CMap offers three candidate drugs for the individualized targeted therapy of sarcoma patients with overexpression of PVT1.
C1 [Liu, Jianwei; Yu, Jia] Guangxi Med Univ, Dept Osteol, Affiliated Hosp 3, Dan Cun Rd 13, Nanning 530031, Guangxi Zhuang, Peoples R China.
   [Li, Rong] Guangxi Med Univ, Affiliated Hosp 3, Dept Reprod Ctr, Nanning 530031, Guangxi Zhuang, Peoples R China.
   [Liao, Xiwen] Guangxi Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Nanning 530021, Guangxi Zhuang, Peoples R China.
   [Hu, Bangli] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Res, Nanning 530021, Guangxi Zhuang, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; Guangxi Medical University
RP Liu, JW (通讯作者)，Guangxi Med Univ, Dept Osteol, Affiliated Hosp 3, Dan Cun Rd 13, Nanning 530031, Guangxi Zhuang, Peoples R China.
EM liujianwei@stu.gxmu.edu.cn
OI Liu, Jianwei/0000 0002 9975 1562; Liu, Jianwei/0000 0001 6680 4659
FU Youth Science and Technology Innovation and Entrepreneurship Talent
   Cultivation Project of Nanning [RC20180107]; Innovation Project of
   Guangxi Graduate Education [YCBZ2018034]; Scientific Project of Guangxi
   Health and Family Planning Commission [Z20170107]
FX This work was supported in part by Youth Science and Technology
   Innovation and Entrepreneurship Talent Cultivation Project of Nanning
   (RC20180107), the Innovation Project of Guangxi Graduate Education
   (Grant/Award Number: YCBZ2018034); Scientific Project of Guangxi Health
   and Family Planning Commission (Grant/Award Number: Z20170107). The
   authors thank the contributors of The Cancer Genome Atlas
   (https://cancergenome.nih.gov/) for sharing the sarcoma dataset on open
   access. In addition, we would like to acknowledge the helpful comments
   on this article received from our reviewers.
CR Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb 2010 11 10 r106
   [Anonymous], ONCOTARGET
   [Anonymous], 2017, CANC BIOMARKERS A
   [Anonymous], TUMOUR BIOL J INT SO
   [Anonymous], INT J BIOL MARKERS
   [Anonymous], 2003, GENOME BIOL
   Barsotti AM, 2012, J BIOL CHEM, V287, P2509, DOI 10.1074/jbc.M111.322875
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166 4328(01)00297 2
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Chen J, 2017, CANCER LETT, V388, P208, DOI 10.1016/j.canlet.2016.12.006
   Chen XJ, 2017, BIOMED RES INT UK, V2017, DOI 10.1155/2017/7038579
   Chen XL, 2018, CANCER MANAG RES, V10, P2711, DOI 10.2147/CMAR.S166260
   Chen Y, 2018, CANCER BIOL MED, V15, P238, DOI 10.20892/j.issn.2095 3941.2017.0174
   Cormier JN, 2004, CA CANCER J CLIN, V54, P94, DOI 10.3322/canjclin.54.2.94
   Filippov Levy N, 2018, GYNECOL ONCOL, V148, P559, DOI 10.1016/j.ygyno.2018.01.004
   Guo D, 2018, EXP CELL RES, V362, P172, DOI 10.1016/j.yexcr.2017.11.014
   Guo JP, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935 018 0582 3
   He RQ, 2018, CELL PHYSIOL BIOCHEM, V46, P591, DOI 10.1159/000488627
   He Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0265 y
   Heagerty PJ, 2005, BIOMETRICS, V61, P92, DOI 10.1111/j.0006 341X.2005.030814.x
   Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168
   Huang CS, 2016, AM J TRANSL RES, V8, P5025
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang FT, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0845 6
   Iden M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156274
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Kong R, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0355 8
   Kuhn M, 2008, NUCLEIC ACIDS RES, V36, pD684, DOI 10.1093/nar/gkm795
   Kuhn M, 2010, NUCLEIC ACIDS RES, V38, pD552, DOI 10.1093/nar/gkp937
   Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471 2105 9 559
   Lazar AJ, 2017, CELL, V171, P950, DOI 10.1016/j.cell.2017.10.014
   Li PD, 2017, ONCOTARGET, V8, P34164, DOI 10.18632/oncotarget.15878
   Li WC, 2018, ONCOL LETT, V15, P7855, DOI 10.3892/ol.2018.8315
   Liao XW, 2017, ONCOTARGETS THER, V10, P4493, DOI 10.2147/OTT.S142557
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Liu FT, 2017, CELL PHYSIOL BIOCHEM, V43, P1077, DOI 10.1159/000481719
   Liu ZY, 2017, ONCOTARGET, V8, P64273, DOI 10.18632/oncotarget.19604
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Mostafavi S, 2008, GENOME BIOL, V9, DOI 10.1186/gb 2008 9 s1 s4
   Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Song JY, 2017, BIOCHEM BIOPH RES CO, V490, P217, DOI 10.1016/j.bbrc.2017.06.024
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Szklarczyk D, 2016, NUCLEIC ACIDS RES, V44, pD380, DOI 10.1093/nar/gkv1277
   Takahashi Y, 2014, BRIT J CANCER, V110, P164, DOI 10.1038/bjc.2013.698
   Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136
   Verduci L, 2017, GENOME BIOL, V18, DOI 10.1186/s13059 017 1368 y
   von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034
   Wang YL, 2017, NUCLEIC ACIDS RES, V45, pD955, DOI 10.1093/nar/gkw1118
   Warde Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
   Xiao MZ, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12519
   Xu HM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189675
   Xu MD, 2017, CLIN CANCER RES, V23, P2071, DOI 10.1158/1078 0432.CCR 16 0742
   Xu X, 2017, ONCOTARGET, V8, P87773, DOI 10.18632/oncotarget.21206
   Yang J, 2017, BIOSCI BIOTECH BIOCH, V81, P2301, DOI 10.1080/09168451.2017.1387048
   Yang YR, 2014, INT J CLIN EXP PATHO, V7, P6929
   Yu CY, 2018, J CANCER, V9, P3593, DOI 10.7150/jca.26465
   Yu JY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004436
   Yuan CL, 2016, NEOPLASMA, V63, P442, DOI 10.4149/314_150825N45
   Zeng YH, 2017, ONCOTARGET, V8, P75455, DOI 10.18632/oncotarget.20634
   Zhang SR, 2016, APMIS, V124, P649, DOI 10.1111/apm.12555
   Zhang Y, 2018, CELL PHYSIOL BIOCHEM, V47, P2216, DOI 10.1159/000491534
   Zhang Y, 2018, ONCOL REP, V40, P226, DOI 10.3892/or.2018.6410
   Zhao J, 2018, ONCOGENE, V37, P4094, DOI 10.1038/s41388 018 0250 z
   Zheng JF, 2018, INT J MOL MED, V42, P489, DOI 10.3892/ijmm.2018.3595
   Zhou Q, 2016, ONCOTARGET, V7, P82620, DOI 10.18632/oncotarget.13012
   Zhuang CL, 2015, ONCOTARGET, V6, P41194, DOI 10.18632/oncotarget.5880
NR 71
TC 10
Z9 10
U1 1
U2 6
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837 9664
J9 J CANCER
JI J. Cancer
PY 2019
VL 10
IS 20
BP 4961
EP 4977
DI 10.7150/jca.31675
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA IV2MQ
UT WOS:000484111700026
PM 31598169
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Schneider, MGM
   Azcona, P
   Campelo, A
   Massheimer, V
   Agotegaray, M
   Lassalle, V
AF Schneider, Maria Gabriela Montiel
   Azcona, Pamela
   Campelo, Adrian
   Massheimer, Virginia
   Agotegaray, Mariela
   Lassalle, Veronica
TI Magnetic Nanoplatform With Novel Potential for the Treatment of Bone
   Pathologies: Drug Loading and Biocompatibility on Blood and Bone Cells
SO IEEE TRANSACTIONS ON NANOBIOSCIENCE
LA English
DT Article
DE Drugs; Bones; Iron; Dispersion; Adsorption; Temperature measurement;
   Magnetic separation; Biocompatibility; blood; bone; iron oxide
   nanoparticles; raloxifen; curcumin methylene blue
ID IRON OXIDE NANOPARTICLES; RALOXIFENE HYDROCHLORIDE; GOLD NANOPARTICLES;
   ENDOTHELIAL CELLS; CURCUMIN; NANOTHERANOSTICS; OPTIMIZATION;
   FORMULATION; ADSORPTION; STABILITY
AB Magnetic iron oxide nanoparticles (MNPs) coated with citric acid (MG@CA) are proposed as raw materials for the treatment of bone diseases. Citric acid (CA) was selected as coating due to its role in the stabilization of apatite nanocrystals and as a signaling agent for osteoblast activation. Raloxifene (Ral), curcumine (Cur) and methylene blue (MB) were employed as model drugs as therapeutic agents for bone diseases. Characterization of raw and drug loaded nanosystems was conducted in order to elucidate the mechanisms governing interactions between therapeutics and the magnetic platform. Biocompatibility studies were performed on red blood cells (RBCs) from peripheral human blood. Cytotoxicity was evaluated on endothelial cells (ECs); and viability was studied for bone cells exposed at concentrations of 1, 10 and 100 $\mu \text{g}$ /mL of the magnetic nano platform. MG@CA exhibited proper physicochemical properties for the applications intended within this work. It presented satisfactory biocompatibility on peripheral red blood cells. Only doses of 100 $\mu \text{g}$ /mL induced a decrease in metabolic activity of ECs and MC3T3 E1 cells. Drug adsorption efficiency was estimated as 62.0, 15.0 and 54.0 % for Ral, Cur and MB and drug loading capability of 12.0, 20.0 and 13.6%, respectively.
C1 [Schneider, Maria Gabriela Montiel; Azcona, Pamela; Agotegaray, Mariela; Lassalle, Veronica] Univ Nacl, Dept Quim, Inst Quim INQUISUR, UNS,CONICET, 8000FTN, Bahia Blanca, Argentina.
   [Campelo, Adrian; Massheimer, Virginia] Univ Nacl, Dept Biol Bioquim & Farm, Inst Invest Biol & Biomed INBIOSUR, CONICET,UNS, 8000FTN, Bahia Blanca, Argentina.
C3 National University of the South; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET); Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET); National University of the South
RP Agotegaray, M (通讯作者)，Univ Nacl, Dept Quim, Inst Quim INQUISUR, UNS,CONICET, 8000FTN, Bahia Blanca, Argentina.
EM magotegaray@uns.edu.ar
RI ; Montiel Schneider, María Gabriela/ABE 6009 2021
OI Montiel Schneider, Maria Gabriela/0000 0002 3701 7266; MASSHEIMER,
   VIRGINIA/0000 0002 2613 8142
FU Universidad Nacional del Sur (UNS) Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET)
FX This work was supported by the Universidad Nacional del Sur
   (UNS) Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET).
CR Alonso Geli Yamirka, 2015, Rev Cub Quim, V27, P110
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Azcona P, 2018, COLLOID SURFACE A, V537, P185, DOI 10.1016/j.colsurfa.2017.10.025
   Beaty R., 1993, CONCEPTS INSTRUMENTA
   Benson E. S., 1964, POSTGRADUATE MED, V36
   Borenfreund E., 1984, Journal of Tissue Culture Methods, V9, P7, DOI [10.1007/BF01666038, DOI 10.1007/BF01666038]
   Bukhari SNA, 2019, J INTEGR MED JIM, V17, P38, DOI 10.1016/j.joim.2018.08.003
   Chen SF, 2004, BIOTECHNIQUES, V37, P84, DOI 10.2144/04371ST05
   Corrons V., 2006, MANUAL TECNICAS LAB
   Dadfar SM, 2019, ADV DRUG DELIVER REV, V138, P302, DOI 10.1016/j.addr.2019.01.005
   Danafar H, 2017, DRUG RES, V67, P698, DOI 10.1055/s 0043 115905
   Elsheikh MA, 2012, INT J NANOMED, V7, P3787, DOI 10.2147/IJN.S33186
   Evangelista RA, 1996, ELECTROPHORESIS, V17, P347, DOI 10.1002/elps.1150170210
   Farzin A, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201901058
   Feng JT, 2015, CHEM ENG J, V269, P316, DOI 10.1016/j.cej.2015.01.109
   Gupta SC, 2013, AAPS J, V15, P195, DOI 10.1208/s12248 012 9432 8
   Hajdú A, 2009, COLLOID SURFACE A, V347, P104, DOI 10.1016/j.colsurfa.2008.12.039
   Hall JE., 2021, Guyton and Hall textbook of medical physiology, V14th
   Hatefi M, 2018, WORLD NEUROSURG, V114, pE785, DOI 10.1016/j.wneu.2018.03.081
   Hu YY, 2010, P NATL ACAD SCI USA, V107, P22425, DOI 10.1073/pnas.1009219107
   Karim AH, 2012, J COLLOID INTERF SCI, V386, P307, DOI 10.1016/j.jcis.2012.07.043
   Kurniawan A, 2017, INT J PHARMACEUT, V516, P158, DOI 10.1016/j.ijpharm.2016.10.067
   Li XY, 2018, EXP THER MED, V15, P3856, DOI 10.3892/etm.2018.5918
   Azcona PL, 2019, NEW J CHEM, V43, P2126, DOI 10.1039/c8nj05289a
   Liu C, 1999, SOIL SCI SOC AM J, V63, P65, DOI 10.2136/sssaj1999.03615995006300010011x
   Liu J, 2009, ANGEW CHEM INT EDIT, V48, P5875, DOI 10.1002/anie.200901566
   Michiels C, 2003, J CELL PHYSIOL, V196, P430, DOI 10.1002/jcp.10333
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Naqvi S, 2010, INT J NANOMED, V5, P983, DOI 10.2147/IJN.S13244
   Nicolás P, 2013, ACTA BIOMATER, V9, P4754, DOI 10.1016/j.actbio.2012.09.040
   Nosrati H, 2019, ACS BIOMATER SCI ENG, V5, P1677, DOI 10.1021/acsbiomaterials.8b01420
   Priyadarsini KI, 2014, MOLECULES, V19, P20091, DOI 10.3390/molecules191220091
   Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75
   Rohanizadeh R, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.20
   Rudenko SV, 2010, BBA BIOMEMBRANES, V1798, P1767, DOI 10.1016/j.bbamem.2010.05.010
   Saini D, 2015, DRUG DELIV, V22, P823, DOI 10.3109/10717544.2014.900153
   Shanmugam MK, 2015, MOLECULES, V20, P2728, DOI 10.3390/molecules20022728
   Shehzad A, 2013, BIOFACTORS, V39, P69, DOI 10.1002/biof.1066
   Silambarasi T, 2012, INT J PHARM SCI RES, V3, P1393, DOI 10.13040/IJPSR.0975 8232.3(5).1393 00
   Sutka A, 2015, MATER CHEM PHYS, V149, P473, DOI 10.1016/j.matchemphys.2014.10.048
   Teeter JS, 2002, ENVIRON TOXICOL CHEM, V21, P729, DOI 10.1897/1551 5028(2002)021<0729:EFACOR>2.0.CO;2
   Trontelj J, 2005, PHARMACOL RES, V52, P334, DOI 10.1016/j.phrs.2005.05.007
   Vargas AMM, 2011, CHEM ENG J, V168, P722, DOI 10.1016/j.cej.2011.01.067
   Villasenor A, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 38154 6
   WESTERGREN A, 1957, Triangle, V3, P20
   Yeh YC, 2002, ATHEROSCLEROSIS, V161, P95, DOI 10.1016/S0021 9150(01)00642 6
   Zhang L, 2004, ANAL SCI, V20, P445, DOI 10.2116/analsci.20.445
   Zhou YH, 2016, MATER CHEM PHYS, V170, P83, DOI 10.1016/j.matchemphys.2015.12.022
   Zsila F, 2003, BIOCHEM BIOPH RES CO, V301, P776, DOI 10.1016/S0006 291X(03)00030 5
NR 49
TC 4
Z9 4
U1 0
U2 3
PU IEEE INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855 4141 USA
SN 1536 1241
EI 1558 2639
J9 IEEE T NANOBIOSCI
JI IEEE Trans. Nanobiosci.
PD JAN
PY 2023
VL 22
IS 1
BP 11
EP 18
DI 10.1109/TNB.2021.3136525
PG 8
WC Biochemical Research Methods; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Science & Technology   Other Topics
GA 8O5MW
UT WOS:000925880000003
PM 34928800
DA 2025 08 17
ER

PT J
AU Shen, Q
   Stanton, ML
   Feng, W
   Rodriguez, ME
   Ramondetta, L
   Chen, L
   Brown, RE
   Duan, XZ
AF Shen, Qi
   Stanton, Melissa L.
   Feng, Wei
   Rodriguez, Michelle E.
   Ramondetta, Lois
   Chen, Lei
   Brown, Robert E.
   Duan, Xiuzhen
TI Morphoproteomic analysis reveals an overexpressed and constitutively
   activated phospholipase D1 mTORC2 pathway in endometrial carcinoma
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE morphoproteomics; phospholipase D1; mTORC2; endometrial carcinoma
ID GROWTH FACTOR I; RECEPTOR SUBSTRATE 1 PHOSPHORYLATION; HYPOXIA INDUCIBLE
   FACTOR 2 ALPHA; OSTEOBLAST LIKE CELLS; MAMMALIAN TARGET; RENAL CANCER;
   EARLY EVENT; MTOR; INSULIN; EXPRESSION
AB The mammalian target of rapamycin (mTOR) assembles into two distinct complexes: mTOR complex 1 (mTORC1) is predominantly cytoplasmic and highly responsive to rapamycin, whereas mTOR complex 2 (mTORC2) is both cytoplasmic and nuclear, and relatively resistant to rapamycin. mTORC1 and mTORC2 phosphorylatively regulate their respective downstream effectors p70S6K/4EBP1, and Akt. The resulting activated mTOR pathways stimulate protein synthesis, cellular proliferation, and cell survival. Moreover, phospholipase D (PLD) and its product, phosphatidic acid (PA) have been implicated as one of the upstream activators of mTOR signaling. In this study, we investigated the activation status as well as the subcellular distribution of mTOR, and its upstream regulators and downstream effectors in endometrial carcinomas (ECa) and non neoplastic endometrial control tissue. Our data show that the mTORC2 activity is selectively elevated in endometrial cancers as evidenced by a predominant nuclear localization of the activated form of mTOR (p mTOR at Ser2448) in malignant epithelium, accompanied by overexpression of nuclear p Akt (Ser473), as well as overexpression of vascular endothelial growth factor (VEGF) A isoform, the latter a resultant of target gene activation by mTORC2 signaling via hypoxia inducible factor (HIF) 2alpha. In addition, expression of PLD1, one of the two major isoforms of PLD in human, is increased in tumor epithelium. In summary, we demonstrate that the PLD1/PA mTORC2 signal pathway is overactivated in endometrial carcinomas. This suggests that the rapamycin insensitive mTORC2 pathway plays a major role in endometrial tumorigenesis and that therapies designed to target the phospholipase D pathway and components of the mTORC2 pathway should be efficacious against ECa.
C1 [Shen, Qi; Feng, Wei; Chen, Lei; Brown, Robert E.; Duan, Xiuzhen] Univ Texas Med Sch Houston, Dept Pathol & Lab Med, Houston, TX USA.
   [Stanton, Melissa L.; Rodriguez, Michelle E.] Univ Texas MD Anderson Canc Ctr, Dept Pathol & Lab Med, Houston, TX 77030 USA.
   [Ramondetta, Lois] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA.
C3 University of Texas System; University of Texas Health Science Center
   Houston; University of Texas System; UTMD Anderson Cancer Center;
   University of Texas System; UTMD Anderson Cancer Center
RP Brown, RE (通讯作者)，Univ Texas Hlth Sci Ctr Med Sch Houston, Dept Pathol & Lab Med, 6431 Fannin St,MSB 2 286, Houston, TX 77030 USA.
EM Robert.Brown@uth.tmc.edu
RI Rodriguez, Michelle/KIA 9175 2024
CR Akeno N, 2002, ENDOCRINOLOGY, V143, P420, DOI 10.1210/en.143.2.420
   Akeno N, 2001, ENDOCRINOLOGY, V142, P959, DOI 10.1210/en.142.2.959
   Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140 6736(05)67063 8
   Berker B, 2004, GYNECOL ENDOCRINOL, V19, P125, DOI 10.1080/09513590400007309
   Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020
   Brown RE, 2009, ARCH PATHOL LAB MED, V133, P568, DOI 10.1043/1543 2165 133.4.568
   Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535 6108(03)00187 9
   Cantrell LA, 2010, GYNECOL ONCOL, V116, P92, DOI 10.1016/j.ygyno.2009.09.024
   Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008 5472.CAN 05 2519
   Darb Esfahani S, 2009, J CANCER RES CLIN, V135, P933, DOI 10.1007/s00432 008 0529 5
   Delmonte A, 2008, CURR OPIN ONCOL, V20, P554, DOI 10.1097/CCO.0b013e32830b0deb
   Exton JH, 1999, BBA MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388 1981(99)00089 X
   Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015
   Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024
   Kaku T, 1997, CANCER, V80, P741, DOI 10.1002/(SICI)1097 0142(19970815)80:4<741::AID CNCR13>3.0.CO;2 T
   Lehman N, 2007, FASEB J, V21, P1075, DOI 10.1096/fj.06 6652com
   Lin F, 2006, ANN CLIN LAB SCI, V36, P283
   Lu KH, 2008, CLIN CANCER RES, V14, P2543, DOI 10.1158/1078 0432.CCR 07 0321
   Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161
   McCampbell AS, 2010, CELL CYCLE, V9, P2698, DOI 10.4161/cc.9.14.12618
   McCampbell AS, 2010, CANCER PREV RES, V3, P290, DOI 10.1158/1940 6207.CAPR 09 0199
   Pectasides D, 2007, CANCER TREAT REV, V33, P177, DOI 10.1016/j.ctrv.2006.10.007
   Rosner M, 2008, HUM MOL GENET, V17, P2934, DOI 10.1093/hmg/ddn192
   Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974
   Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869
   Singh BK, 2010, METAB SYNDR RELAT D, V8, P355, DOI 10.1089/met.2010.0011
   Slomovitz B.M., 2010, CANCER
   Sorosky JI, 2008, OBSTET GYNECOL, V111, P436, DOI 10.1097/AOG.0b013e318162f690
   Sun HZ, 2003, MOL ENDOCRINOL, V17, P472, DOI 10.1210/me.2002 0276
   Toschi A, 2008, ONCOGENE, V27, P2746, DOI 10.1038/sj.onc.1210927
   Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782 08
   Treins C, 2006, BIOCHEM BIOPH RES CO, V342, P1197, DOI 10.1016/j.bbrc.2006.02.088
   Tzatsos A, 2009, J BIOL CHEM, V284, P22525, DOI 10.1074/jbc.M109.027748
   Vazquez Martin A, 2009, CELL CYCLE, V8, P88, DOI 10.4161/cc.8.1.7499
   Wanninger J, 2008, BBA MOL CELL BIOL L, V1781, P321, DOI 10.1016/j.bbalip.2008.04.012
   Zakikhani M, 2010, BREAST CANCER RES TR, V123, P271, DOI 10.1007/s10549 010 0763 9
   Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719
NR 37
TC 30
Z9 35
U1 0
U2 3
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936 2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2011
VL 4
IS 1
BP 13
EP 21
PG 9
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA 802KL
UT WOS:000293509500002
PM 21228924
DA 2025 08 17
ER

PT J
AU Rubin, MR
   Cusano, N
   Yin, SM
   Tokareva, E
   Ayodele, O
   Finkelman, RD
AF Rubin, Mishaela R.
   Cusano, Natalie
   Yin, Shaoming
   Tokareva, Elena
   Ayodele, Olulade
   Finkelman, Richard D.
TI Extended Treatment With Recombinant Human Parathyroid Hormone (1 84) in
   Adult Patients With Chronic Hypoparathyroidism
SO ENDOCRINE PRACTICE
LA English
DT Article
DE hypoparathyroidism; rhPTH(1 84); quality of life; long term exposure
ID QUALITY OF LIFE; PTH(1 84); EFFICACY; CALCIUM; MANAGEMENT; THERAPY;
   SAFETY
AB Objective: Recombinant human parathyroid hormone (1 84) (rhPTH[1 84]) is efficacious in patients with hypoparathyroidism but additional data supporting its prolonged use are needed. We evaluated whether efficacy, safety, and tolerability are maintained during long term rhPTH(1 84) treatment of patients with chronic hypoparathyroidism. Methods: This was a phase 4, single  center, open label, single  arm, 3  year extension (NCT02910466) of the phase 3 Hypo Extended (HEXT) study (NCT01199614). Patients self administered rhPTH(1 84) once daily by subcutaneous injection, with doses individualized based on clinical parameters. Albumin adjusted serum calcium levels (primary outcome measure), other disease biomarkers, healthrelated quality of life, and safety of rhPTH(1 84) were assessed using descriptive statistics. Results: All patients (n 1/4 39) had been exposed to rhPTH(1 84) (mean exposure [SD] 8.5 [3.5] years) before the start of the study, resulting in a mean exposure of 10.8 years including the present study. Mean patient age was 51.9 years, 79.5% were female, and 97.4% were White. Mean albumin adjusted serum calcium concentrations were within the target range, and mean serum phosphate, serum calciumphosphate product, and 24  hour urinary calcium excretion levels were within reference ranges at end of treatment. Mean doses of supplemental calcium and active vitamin D were maintained throughout the study. Bone turnover marker levels were maintained from baseline to end of treatment. No clinically relevant changes in bone mineral density were observed. Patient reported health related quality of life scores were generally maintained throughout the study. Four adverse events were considered treatment related and no new safety signals were identified. Conclusion: The effects of rhPTH(1 84) on biochemical, skeletal, and health related quality of life parameters did not wane with extended use. (c) 2023 AACE. Published by Elsevier Inc. This is an open access article under the CC BY  NC  ND license (http://creativecommons.org/licenses/by nc nd/4.0/).
C1 [Rubin, Mishaela R.] Columbia Univ, Irving Med Ctr, Dept Endocrinol, New York, NY USA.
   [Cusano, Natalie] Lenox Hill Hosp, Div Endocrinol, New York, NY USA.
   [Yin, Shaoming; Tokareva, Elena; Ayodele, Olulade] Takeda Dev Ctr Amer Inc, Lexington, MA USA.
   [Finkelman, Richard D.] Takeda Pharmaceut USA Inc, Cambridge, MA USA.
C3 NewYork Presbyterian Hospital; Columbia University; Northwell Health;
   Takeda Pharmaceutical Company Ltd; Takeda Development Center Americas,
   Inc.; Takeda Pharmaceutical Company Ltd; Takeda Pharmaceuticals USA Inc.
   (TPUSA)
RP Rubin, MR (通讯作者)，Columbia Univ, Irving Med Ctr, 180 Ft Washington Ave, New York, NY 10032 USA.
EM mrr6@cumc.columbia.edu
FU Shire Human Genetic Therapies, Inc; Takeda company, Lexington, MA, USA;
   Takeda Development Center Americas Inc.
FX This study was funded by Shire Human Genetic Therapies, Inc, a Takeda
   company, Lexington, MA, USA. Medical writing support was provided by
   Valentina Bart, PhD of Pharma Genesis Cardiff, Cardiff, UK and sponsored
   by Takeda Development Center Americas Inc. Data from this study have
   been presented in a poster at the European Congress of Endocrinology in
   2022.
CR Agarwal S, 2023, J BONE MINER RES, V38, P480, DOI 10.1002/jbmr.4780
   [Anonymous], Takeda issues US recall of NATPARA (parathyroid hormone) for injection due to the potential for rubber particulate _ FDA.pdf
   [Anonymous], Natpar summary of product characteristics Takeda Pharmaceuticals International AG
   [Anonymous], ?About us"
   Arlt W, 2002, EUR J ENDOCRINOL, V146, P215, DOI 10.1530/eje.0.1460215
   Astor MC, 2016, J CLIN ENDOCR METAB, V101, P3045, DOI 10.1210/jc.2016 1477
   Berg J, 2011, ANN CLIN BIOCHEM, V48, P195, DOI 10.1258/acb.2011.011078
   Bilezikian JP, 2017, CLIN THER, V39, P2096, DOI 10.1016/j.clinthera.2017.08.011
   Bilezikian JP, 2016, J CLIN ENDOCR METAB, V101, P2313, DOI 10.1210/jc.2015 3910
   Bollerslev J, 2015, EUR J ENDOCRINOL, V173, pEG1, DOI 10.1530/EJE 15 0628
   Chan FKW, 2003, J CLIN ENDOCR METAB, V88, P3155, DOI 10.1210/jc.2002 021388
   COE FL, 1982, AM J MED, V72, P25, DOI 10.1016/0002 9343(82)90567 8
   Coles T, 2019, PATIENT RELAT OUTCOM, V10, P25, DOI 10.2147/PROM.S179310
   Goltzman D, 2018, FRONT HORM RES, V50, P1, DOI 10.1159/000486060
   Gosmanova EO, 2021, ADV THER, V38, P1876, DOI 10.1007/s12325 021 01658 1
   Hadker N, 2014, ENDOCR PRACT, V20, P671, DOI 10.4158/EP13328.OR
   Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305
   Hays RD, 2001, ANN MED, V33, P350, DOI 10.3109/07853890109002089
   Ketteler M, 2021, ADV THER, V38, P1946, DOI 10.1007/s12325 021 01649 2
   Mannstadt M, 2019, J CLIN ENDOCR METAB, V104, P5133, DOI 10.1210/jc.2019 01010
   Mannstadt M, 2013, LANCET DIABETES ENDO, V1, P275, DOI 10.1016/S2213 8587(13)70106 2
   Natpara prescribing information, ABOUT US
   Rejnmark L, 2023, CLIN ENDOCRINOL, V98, P496, DOI 10.1111/cen.14813
   Rubin MR, 2010, OSTEOPOROSIS INT, V21, P1927, DOI 10.1007/s00198 009 1149 x
   Rubin MR, 2016, J CLIN ENDOCR METAB, V101, P2742, DOI 10.1210/jc.2015 4135
   Rubin MR, 2011, J BONE MINER RES, V26, P2727, DOI 10.1002/jbmr.452
   Rubin MR, 2010, ARQ BRAS ENDOCRINOL, V54, P220, DOI 10.1590/S0004 27302010000200019
   Shoback D, 2008, NEW ENGL J MED, V359, P391, DOI 10.1056/NEJMcp0803050
   Sikjaer T, 2016, J BONE MINER RES, V31, P1440, DOI 10.1002/jbmr.2812
   Sikjaer T, 2011, J BONE MINER RES, V26, P2358, DOI 10.1002/jbmr.470
   Tay YKD, 2019, J CLIN ENDOCR METAB, V104, P5601, DOI 10.1210/jc.2019 00893
   Vokes TJ, 2018, J CLIN ENDOCR METAB, V103, P722, DOI 10.1210/jc.2017 01471
   Wagner LI., 2009, J SUPPORT ONCOL, V7, pW32
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650 199206000 00002
   Webster Kimberly, 2003, Health Qual Life Outcomes, V1, P79, DOI 10.1186/1477 7525 1 79
   Yokum D, 2008, J RENAL NUTR, V18, P521, DOI 10.1053/j.jrn.2008.05.003
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600 0447.1983.tb09716.x
NR 37
TC 2
Z9 2
U1 11
U2 11
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 1530 891X
EI 1934 2403
J9 ENDOCR PRACT
JI Endocr. Pract.
PD MAR
PY 2024
VL 30
IS 3
BP 200
EP 208
DI 10.1016/j.eprac.2023.12.001
EA MAR 2024
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA OU0O5
UT WOS:001209679300001
PM 38086524
OA hybrid
DA 2025 08 17
ER

PT J
AU Xie, SD
   Zeng, DM
   Luo, HW
   Zhong, P
   Wang, Y
   Xu, ZQ
   Zhang, PB
AF Xie, Shaodong
   Zeng, Deming
   Luo, Hanwen
   Zhong, Ping
   Wang, Yu
   Xu, Zhiqiang
   Zhang, Peibiao
TI Bone morphogenetic protein 2 and pulsed electrical stimulation
   synergistically promoted osteogenic differentiation on MC 3T3 E1 cells
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Biophysical stimuli; Pulsed electrical stimulation; BMP 2; Osteogenic
   differentiation; Bone repair
ID BMP 2; KINASE; PHOSPHORYLATION; ACTIVATION; EXPRESSION; SCAFFOLDS;
   REPAIR; MAPK
AB Electrical stimulation (ES) plays an important role in regulating cell osteoblast differentiation. As a noninvasive rehabilitation therapy method, Es has a unique role in postoperative recovery. Bone morphogenetic protein 2 (BMP 2) is the most commonly used bioactive molecule in in situ tissue engineering scaffolds, and it plays an important regulatory role in the whole process of bone injury repair. In this study, the osteogenic regulation of MC 3T3 E1 cells was studied by combining pulsed electrical stimulation (PES) and different concentrations of BMP 2. The results showed that PES and BMP 2 could synergically promote the proliferation of MC 3T3 E1 cells. The qPCR results of osteoblast related genes showed that PES was synergistic with BMP 2 to promote osteoblast differentiation mainly through the regulation of the Smad/BMP and insulin like growth factor 1 (IGF1) signaling pathways. The expression level of alkaline phosphatase (ALP) and alizarin red staining further demonstrated the synergistic effect of PES and BMP 2 on promoting osteogenic differentiation and mineralization of cells. PES and BMP 2 could also synergically promote cell proliferation, expression of collagen I (COL I) and ALP, and cell mineralization on the 3D printed polylactic acid scaffold. These results suggest that the use of PES can enhance the osteogenic effect of in situ bone repair scaffolds containing BMP 2, reduce the dose of BMP 2 alone, and reduce the possible side effects of high dose BMP 2 in vivo.
C1 [Xie, Shaodong; Zeng, Deming; Luo, Hanwen; Zhong, Ping; Xu, Zhiqiang] Foshan Hosp Tradit Chinese Med, Dept Rehabil Med, Foshan 528000, Peoples R China.
   [Wang, Yu; Zhang, Peibiao] Chinese Acad Sci, Key Lab Polymer Ecomat, Changchun Inst Appl Chem, Changchun 130022, Peoples R China.
C3 Chinese Academy of Sciences; Changchun Institute of Applied Chemistry,
   CAS
RP Xu, ZQ (通讯作者)，Foshan Hosp Tradit Chinese Med, Dept Rehabil Med, Foshan 528000, Peoples R China.; Wang, Y (通讯作者)，Chinese Acad Sci, Key Lab Polymer Ecomat, Changchun Inst Appl Chem, Changchun 130022, Peoples R China.
EM wydna@ciac.ac.cn; xuzq@fshtcm.com.cn
RI Ping, Zhong/AAC 6088 2022
FU Dengfeng Project of Foshan Hospital of Development Program
FX No Statement Available
CR Bouteraa Y, 2020, IND ROBOT, V47, P489, DOI 10.1108/IR 02 2020 0041
   BRIGHTON CT, 1985, J BONE JOINT SURG AM, V67A, P577, DOI 10.2106/00004623 198567040 00012
   Cao SJ, 2020, COMPOS PART B ENG, V202, DOI 10.1016/j.compositesb.2020.108445
   Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200
   Cerqueira Telma Cristina Fontes, 2019, Int. J. Cardiovasc. Sci., V32, P483, DOI 10.5935/2359 4802.20190028
   Chen JD, 2015, COLLOID SURFACE B, V135, P581, DOI 10.1016/j.colsurfb.2015.08.019
   Chen L, 2019, RSC ADV, V9, P10494, DOI 10.1039/c8ra08788a
   Chen SS, 2022, BIOACT MATER, V18, P15, DOI 10.1016/j.bioactmat.2022.01.048
   Coronado RA, 2020, PAIN REP, V5, DOI 10.1097/PR9.0000000000000847
   deVet Taylor, 2021, Crit Rev Biomed Eng, V49, P1, DOI 10.1615/CritRevBiomedEng.2021035327
   Durham EL, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 018 1697 y
   Elsner B, 2021, STROKE, V52, pE358, DOI 10.1161/STROKEAHA.120.033757
   FRIEDENBERG ZB, 1971, J TRAUM, V11, P883, DOI 10.1097/00005373 197110000 00010
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Guillot Ferriols M, 2022, BIOMATER ADV, V138, DOI 10.1016/j.bioadv.2022.212918
   Hao ZW, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.790050
   Hendron E, 2002, MOL BIOL CELL, V13, P3042, DOI 10.1091/mbc.E02 05 0260
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   Kim HY, 2016, BIOMACROMOLECULES, V17, P1633, DOI 10.1021/acs.biomac.6b00009
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Lee W, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221810167
   Li L, 2019, MAT SCI ENG C MATER, V98, P1241, DOI 10.1016/j.msec.2019.01.075
   Liu HH, 2013, BIOMATERIALS, V34, P4404, DOI 10.1016/j.biomaterials.2013.02.048
   Martini F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062104
   Pettersen E, 2022, J NEUROENG REHABIL, V19, DOI 10.1186/s12984 022 01005 7
   Ravikumar K, 2017, BIOELECTROCHEMISTRY, V116, P52, DOI 10.1016/j.bioelechem.2017.03.004
   Robinson PG, 2020, OPER TECHN SPORT MED, V28, DOI 10.1016/j.otsm.2020.150780
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Wang Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154924
   Yan HH, 2020, ACS BIOMATER SCI ENG, V6, P634, DOI 10.1021/acsbiomaterials.9b01601
   Yang ZY, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.854693
   Yeh LCC, 1997, ENDOCRINOLOGY, V138, P4181, DOI 10.1210/en.138.10.4181
   Yeh LCC, 2015, ENDOCRINOLOGY, V156, P2872, DOI 10.1210/en.2014 1945
   Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105
   Zhu SL, 1997, BIOCHEM J, V323, P637, DOI 10.1042/bj3230637
   Zhuang WD, 2022, BIOMATER ADV, V133, DOI 10.1016/j.msec.2021.112619
NR 38
TC 6
Z9 6
U1 3
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300 8177
EI 1573 4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD NOV
PY 2024
VL 479
IS 11
BP 3107
EP 3118
DI 10.1007/s11010 023 04916 8
EA JAN 2024
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA I8E2B
UT WOS:001150933100002
PM 38228982
DA 2025 08 17
ER

PT J
AU Yang, QJ
   Zhou, LY
   Mu, YQ
   Zhou, QX
   Luo, JY
   Cheng, L
   Deng, ZL
   He, TC
   Haydon, RC
   He, BC
AF Yang, Qiu Jun
   Zhou, Long Yang
   Mu, Yu Qin
   Zhou, Qi Xin
   Luo, Jin Yong
   Cheng, Lang
   Deng, Zhong Liang
   He, Tong Chuan
   Haydon, Rex C.
   He, Bai Cheng
TI All trans retinoic acid inhibits tumor growth of human osteosarcoma by
   activating Smad signaling induced osteogenic differentiation
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE all trans retinoic acid; osteosarcoma; proliferation inhibition;
   osteogenic differentiation; Smad signaling
ID ACUTE PROMYELOCYTIC LEUKEMIA; BONE MORPHOGENETIC PROTEINS; STEM CELL
   DIFFERENTIATION; 2ND PRIMARY NEOPLASMS; OSTEOBLAST DIFFERENTIATION;
   CANCER; RECEPTORS; RETINOBLASTOMA; CHEMOTHERAPY; MECHANISMS
AB Osteosarcoma (OS) is one of the most common malignant bone tumors. Despite the advancement of diagnosis and treatment for OS, the prognosis remains poor. We investigated the proliferation inhibitory effect of all trans retinoic acid (ATRA) for human OS and the possible mechanism underlying this effect. We examined the proliferation inhibition and apoptosis inducing effects of ATRA in 143B OS cells. We validated this effect by exogenously expressing the retinoic acid receptor alpha (RAR alpha) in 143B OS cells and injecting the cells into nude mice. We explored the possible mechanism for the proliferation inhibitory effect of ATRA on OS cells and multipotential progenitor cells by detecting osteogenic markers. We demonstrated that the endogenous retinoic acid receptor and retinoid X receptor are all detectable in the commercially available OS cell lines and in primary osteosarcoma cells. ATRA inhibits the proliferation of OS cells in a concentration dependent manner, as well as induces apoptosis in 143B OS cells. The exogenous expression of RARa inhibits the tumor growth and cell proliferation in vivo. The alkaline phosphatase activity, protein levels of osteopontin (OPN) and osteocalcin (OCN) are all promoted by ATRA in OS cells and mouse embryonic fibroblasts (MEFs), at least by activating the Smad signaling pathway. Collectively, our results strongly indicate that ATRA can inhibit the tumor growth of OS by promoting osteogenic differentiation in OS cells, which is mediated in part by activating Smad signaling. Therefore, combination of ATRA with other current chemotherapy agents may be a promising therapy strategy for OS treatment.
C1 [Yang, Qiu Jun; Zhou, Long Yang; Mu, Yu Qin; Luo, Jin Yong; He, Tong Chuan; He, Bai Cheng] Chongqing Med Univ, Key Lab Diagnost Med Designated, Chinese Minist Educ, Affiliated Hosp 2, Chongqing 400016, Peoples R China.
   [Yang, Qiu Jun; Zhou, Long Yang; Mu, Yu Qin; Zhou, Qi Xin; He, Bai Cheng] Chongqing Med Univ, Dept Pharmacol, Affiliated Hosp 2, Chongqing 400016, Peoples R China.
   [Cheng, Lang; Deng, Zhong Liang] Chongqing Med Univ, Dept Orthoped, Affiliated Hosp 2, Chongqing 400016, Peoples R China.
   [Haydon, Rex C.] Univ Chicago, Med Ctr, Dept Surg, Mol Oncol Lab, Chicago, IL 60637 USA.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; University of Chicago; University of Chicago Medical
   Center
RP He, BC (通讯作者)，Chongqing Med Univ, Dept Diagnost Med, Sch Pharm, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
EM hebaicheng99@yahoo.com
FU Natural Science Foundation of China; Chongqing Science & Technology
   Commission of China; National Basic Research Program of China [NSFC
   81071462, CSTC 2011BB5129, 2011CB70790]
FX We thank Dr Di Chen of University of Rochester Medical Center for his
   kind provision of the p12XSBE Luc plasmids. This study was supported in
   part by research grants from Natural Science Foundation of China,
   Chongqing Science & Technology Commission of China, the National Basic
   Research Program of China (NSFC 81071462, CSTC 2011BB5129, 2011CB70790).
CR Akiyama T, 2008, MOL CANCER THER, V7, P3461, DOI 10.1158/1535 7163.MCT 08 0530
   Altucci L, 2007, NAT REV DRUG DISCOV, V6, P793, DOI 10.1038/nrd2397
   Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110
   Dutta A, 2009, J ONCOL, V2009, DOI 10.1155/2009/627840
   Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936
   Garattini E, 2004, CURR PHARM DESIGN, V10, P433, DOI 10.2174/1381612043453351
   Geller David S, 2010, Clin Adv Hematol Oncol, V8, P705
   Haydon RC, 2002, CLIN CANCER RES, V8, P1288
   Haydon RC, 2007, CLIN ORTHOP RELAT R, P237, DOI 10.1097/BLO.0b013e31802b683c
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Kambhampati S, 2004, LEUKEMIA LYMPHOMA, V45, P2175, DOI 10.1080/10428190410001722053
   Kamimura T, 2011, CANCER SCI, V102, P1929, DOI 10.1111/j.1349 7006.2011.02045.x
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188
   Karsy M, 2010, ANTICANCER RES, V30, P4915
   Kneissel M, 2005, BONE, V36, P202, DOI 10.1016/j.bone.2004.11.006
   Krishnan A, 2007, CURR MOL MED, V7, P532, DOI 10.2174/156652407781695765
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   Luo XJ, 2008, CLIN ORTHOP RELAT R, V466, P2060, DOI 10.1007/s11999 008 0361 x
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585 005 0365 9
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   Mercader J, 2010, OBESITY, V18, P655, DOI 10.1038/oby.2009.330
   Monzillo E, 2011, EXPLORE NY, V7, P44, DOI 10.1016/j.explore.2010.10.001
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Park BH, 2001, CURR OPIN ONCOL, V13, P78, DOI 10.1097/00001622 200101000 00015
   Park JH, 2011, EXPERT REV HEMATOL, V4, P427, DOI [10.1586/EHM.11.42, 10.1586/ehm.11.42]
   Sandberg AA, 2003, CANCER GENET CYTOGEN, V145, P1, DOI 10.1016/S0165 4608(03)00105 5
   Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Su YX, 2009, CLIN EXP METASTAS, V26, P599, DOI 10.1007/s10585 009 9259 6
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Tang XH, 2011, ANNU REV PATHOL MECH, V6, P345, DOI 10.1146/annurev pathol 011110 130303
   Tateishi U, 2003, AM J ROENTGENOL, V181, P879, DOI 10.2214/ajr.181.3.1810879
   Thomas D, 2006, J CELL BIOCHEM, V98, P757, DOI 10.1002/jcb.20850
   Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187
   Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027
   TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002
   van Deursen JM, 2007, CANCER CELL, V11, P1, DOI 10.1016/j.ccr.2006.12.006
   Wan DC, 2006, P NATL ACAD SCI USA, V103, P12335, DOI 10.1073/pnas.0604849103
   Yao ZY, 2011, J ORAL PATHOL MED, V40, P433, DOI 10.1111/j.1600 0714.2010.00994.x
   Yeny CT, 2005, CANCER RES, V65, P8698, DOI 10.1158/0008 5472.CAN 05 1704
   Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58
   Yu ZL, 2006, BIOCHEM BIOPH RES CO, V340, P929, DOI 10.1016/j.bbrc.2005.12.100
   Zhang WL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011917
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
NR 53
TC 30
Z9 37
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019 6439
EI 1791 2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD JUL
PY 2012
VL 41
IS 1
BP 153
EP 160
DI 10.3892/ijo.2012.1426
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 949LX
UT WOS:000304578800020
PM 22485251
OA Bronze
DA 2025 08 17
ER

PT J
AU Riedl, CA
   Rosner, A
   Harringer, S
   Salomon, P
   Hejl, M
   Jakupec, MA
   Kandioller, W
   Keppler, BK
AF Riedl, Christoph A.
   Rosner, Alexander
   Harringer, Sophia
   Salomon, Philipp
   Hejl, Michaela
   Jakupec, Michael A.
   Kandioller, Wolfgang
   Keppler, Bernhard K.
TI Water soluble trithiolato bridged dinuclear ruthenium(II) and osmium(II)
   arene complexes with bisphosphonate functionalized ligands as anticancer
   organometallics
SO JOURNAL OF INORGANIC BIOCHEMISTRY
LA English
DT Article
DE Organometallics; Ruthenium; Bisphosphonates; Targeting complexes;
   Anticancer; Hydroxy apatite binding
ID IN VITRO; STRUCTURAL CHARACTERIZATION; CYTOTOXICITY; NKP 1339; CYMENE;
   BONE
AB Trithiolato bridged dinuclear ruthenium(II) complexes [Ru2(p cym)2(SR)3]Cl (p cym = p cymene, R = benzyl derivatives) are regarded as the most cytotoxically potent metal(II) arene antineoplastics, but are oftentimes limited by their poor solubility in aqueous media. Thus, we designed bisphosphonate functionalized ligands for use in a modular two step complexation process to synthesize six trithiolato bridged dinuclear ruthenium(II) and osmium(II) arene complexes bearing one to three bisphosphonate benzylmercaptane derived ligands. In addition to improved aqueous solubility the high affinity of bisphosphonates towards apatite structures found in bone and bone metastases may grant selective targeting properties to functionalized organometallics. The complex stabilities and hydroxyapatite binding behavior were determined by UV/Vis spectroscopy. The bisphosphonate functionalization decreases antiproliferative activity in vitro, which was correlated to lower cellular accumulation, due to the different lipophilic profiles of the drug candidates.
C1 [Riedl, Christoph A.; Rosner, Alexander; Harringer, Sophia; Salomon, Philipp; Hejl, Michaela; Jakupec, Michael A.; Kandioller, Wolfgang; Keppler, Bernhard K.] Univ Vienna, Fac Chem, Inst Inorgan Chem, Vienna, Austria.
   [Riedl, Christoph A.; Jakupec, Michael A.; Kandioller, Wolfgang; Keppler, Bernhard K.] Res Cluster Translat Canc Therapy Res, Waehringer Str 42, A 1090 Vienna, Austria.
C3 University of Vienna
RP Riedl, CA; Kandioller, W (通讯作者)，Univ Vienna, Fac Chem, Inst Inorgan Chem, Vienna, Austria.
EM christoph.riedl@univie.ac.at; wolfgang.kandioller@univie.ac.at
RI ; Kandioller, Wolfgang/AAD 9304 2020
OI Salomon, Philipp/0009 0000 7355 4141; Keppler,
   Bernhard/0000 0003 0877 1822; Jakupec, Michael/0000 0001 7945 1426
FU University of Vienna
FX We thank the University of Vienna for financial support and Sophie
   Neumayer (Departement of Analytical Chemistry, University of Vienna) for
   ICP MS measurements.
CR Aird RE, 2002, BRIT J CANCER, V86, P1652, DOI 10.1038/sj.bjc.6600290
   [Anonymous], 1980, INORGANIC CHEM BIOL, DOI [DOI 10.1021/BK 1980 0140.CH010, 10.1021/bk 1980 0140.ch010]
   BENNETT MA, 1974, J CHEM SOC DALTON, P233, DOI 10.1039/dt9740000233
   Bennett MA, 2004, J ORGANOMET CHEM, V689, P4463, DOI 10.1016/j.jorganchem.2004.07.027
   Choudhury AR, 2013, ADV SYNTH CATAL, V355, P1989, DOI 10.1002/adsc.201300281
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Ferrer Casal M, 2013, SYNTHESIS STUTTGART, V45, P2397, DOI 10.1055/s 0033 1338498
   Fong J, 2015, PHOTOCH PHOTOBIO SCI, V14, P2014, DOI 10.1039/c4pp00438h
   Fulmer GR, 2010, ORGANOMETALLICS, V29, P2176, DOI 10.1021/om100106e
   Furrer J, 2016, COORDIN CHEM REV, V309, P36, DOI 10.1016/j.ccr.2015.10.007
   Galanski M, 2003, J MED CHEM, V46, P4946, DOI 10.1021/jm0308040
   Giannini F, 2015, MEDCHEMCOMM, V6, P347, DOI 10.1039/c4md00433g
   Giannini F, 2013, J ORGANOMET CHEM, V744, P41, DOI 10.1016/j.jorganchem.2013.04.049
   Giannini F, 2012, J BIOL INORG CHEM, V17, P951, DOI 10.1007/s00775 012 0911 2
   Gras M, 2010, DALTON T, V39, P10305, DOI 10.1039/c0dt00887g
   Gupta G, 2014, INORG CHIM ACTA, V423, P524, DOI 10.1016/j.ica.2014.09.013
   Gupta G, 2014, INORG CHIM ACTA, V423, P31, DOI 10.1016/j.ica.2014.07.050
   Hartinger CG, 2006, J INORG BIOCHEM, V100, P891, DOI 10.1016/j.jinorgbio.2006.02.013
   Iafisco M, 2012, NANOSCALE, V4, P206, DOI 10.1039/c1nr11147g
   Ibao AF, 2012, EUR J INORG CHEM, P1531, DOI 10.1002/ejic.201101057
   Kilpin KJ, 2013, CHEM SCI, V4, P1410, DOI 10.1039/c3sc22349c
   Klein EA, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.5_suppl.7
   KLENNER T, 1990, CANCER TREAT REV, V17, P253, DOI 10.1016/0305 7372(90)90056 L
   Korch C, 2012, GYNECOL ONCOL, V127, P241, DOI 10.1016/j.ygyno.2012.06.017
   Kuhn PS, 2015, DALTON T, V44, P659, DOI 10.1039/c4dt01645a
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   MASHIMA K, 1992, CHEM LETT, P1795, DOI 10.1246/cl.1992.1795
   McKenna C.E., 1977, TETRAHEDRON LETT, V18, P155, DOI [10.1016/S0040 4039(01)92575 4, DOI 10.1016/S0040 4039(01)92575 4]
   Monro S, 2019, CHEM REV, V119, P797, DOI 10.1021/acs.chemrev.8b00211
   Papapoulos SE, 2006, BONE, V38, P613, DOI 10.1016/j.bone.2006.01.141
   Pichler V, 2011, DALTON T, V40, P8187, DOI 10.1039/c1dt10301f
   SCHACHT HT, 1992, INORG CHEM, V31, P1728, DOI 10.1021/ic00035a042
   Scolaro C, 2005, J MED CHEM, V48, P4161, DOI 10.1021/jm050015d
   Scolaro C, 2008, J INORG BIOCHEM, V102, P1743, DOI 10.1016/j.jinorgbio.2008.05.004
   Sienkiewicz Gromiuk J, 2016, J MOL STRUCT, V1110, P65, DOI 10.1016/j.molstruc.2016.01.016
   Stíbal D, 2016, J BIOL INORG CHEM, V21, P443, DOI 10.1007/s00775 016 1353 z
   Stíbal D, 2014, EUR J INORG CHEM, P5925, DOI 10.1002/ejic.201402754
   Sun YY, 2017, CHEM BIODIVERS, V14, DOI 10.1002/cbdv.201700348
   Trondl R, 2014, CHEM SCI, V5, P2925, DOI 10.1039/c3sc53243g
   Wang FY, 2005, P NATL ACAD SCI USA, V102, P18269, DOI 10.1073/pnas.0505798102
   WERNER H, 1988, J ORGANOMET CHEM, V345, P151, DOI 10.1016/0022 328X(88)80244 4
   Xue ZQ, 2010, CHEM COMMUN, V46, P1212, DOI 10.1039/b922222g
   Zhang ZQ, 2018, INORG CHEM, V57, P3315, DOI 10.1021/acs.inorgchem.7b03261
   Zielinska M, 2021, J PHARM ANAL, V11, P364, DOI 10.1016/j.jpha.2020.07.011
NR 44
TC 2
Z9 2
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0162 0134
EI 1873 3344
J9 J INORG BIOCHEM
JI J. Inorg. Biochem.
PD DEC
PY 2021
VL 225
AR 111618
DI 10.1016/j.jinorgbio.2021.111618
EA OCT 2021
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA WG7UO
UT WOS:000707200400005
PM 34607124
DA 2025 08 17
ER

PT J
AU Zhang, JC
   Song, ZC
   Xia, YR
   Shu, R
AF Zhang, Ji Chun
   Song, Zhong Chen
   Xia, Yi Ru
   Shu, Rong
TI Extracellular matrix derived from periodontal ligament cells maintains
   their stemness and enhances redifferentiation via the wnt pathway
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE extracellular matrix (ECM); cell expansion; stemness; Wnt signaling
   pathway; human periodontal ligament cells (PDLCs)
ID TREATED DENTIN MATRIX; OSTEOGENIC DIFFERENTIATION; BONE MARROW;
   SIGNALING PATHWAY; PROGENITOR CELLS; EX VIVO; REGENERATION; EXPANSION;
   SHEETS; PROLIFERATION
AB Large numbers of viable cells cannot be obtained from periodontal ligament tissues of patients with periodontitis. Therefore, it is imperative to establish an ex vivo environment that can support cell proliferation and delay senescence. Here, we have successfully reconstructed a native extracellular matrix (ECM), derived from early passage human periodontal ligament cells (PDLCs) using the NH4OH/Triton X 100 protocol. The ECM was investigated by scanning electron microscopy and immunostaining for specific ECM proteins (collagen I and fibronectin). Late passage ECM expanded PDLCs exhibited a much higher proliferation index and lower levels of reactive oxygen species (ROS), confirmed by the increased expression of pluripotent markers and enhanced osteogenic capacity. Interestingly, the Wnt pathway was suppressed during the ECM expansion mediated increase in pluripotency, but was activated in an osteogenic differentiation environment, as confirmed by treatment with the XAV 939 beta catenin inhibitor or the SP600125 c Jun Nterminal kinase (JNK) inhibitor. Cell sheets formed by ECM expanded PDLCs exhibited an enhanced periodontal tissue regeneration capacity compared to those formed on tissue culture polystyrene (TCP) surfaces in vivo. Taken together, the cell free ECM provides a tissue specific cell niche for the ex vivo expansion of PDLCs while retaining stemness and osteogenic potential, partially via the Wnt pathway. This represents a promising matrix for future applications in periodontal tissue regeneration therapy. (C) 2017 Wiley Periodicals, Inc.
C1 [Zhang, Ji Chun; Song, Zhong Chen; Xia, Yi Ru; Shu, Rong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Stomatol, Dept Periodontol,Peoples Hosp 9, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University
RP Shu, R (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Stomatol, Dept Periodontol,Peoples Hosp 9, Shanghai 200011, Peoples R China.
EM shurong1977@163.com
FU National Natural Science Foundation of China [81570977]; Shanghai Summit
   & Plateau Disciplines
FX Contract grant sponsor: National Natural Science Foundation of China;
   contract grant number: 81570977Contract grant sponsor: Shanghai Summit &
   Plateau Disciplines
CR Angbohang A, 2016, STEM CELLS DEV, V25, P1, DOI 10.1089/scd.2015.0262
   Barnouin K, 2002, J BIOL CHEM, V277, P13761, DOI 10.1074/jbc.M111123200
   Bukowska J, 2015, STEM CELLS DEV, V24, P2873, DOI 10.1089/scd.2015.0078
   Chatterjee SS, 2015, J CELL BIOL, V211, P39, DOI 10.1083/jcb.201503017
   Chen XD, 2007, J BONE MINER RES, V22, P1943, DOI 10.1359/JBMR.070725
   Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260
   Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912
   Damianova R, 2008, CELL BIOL INT, V32, P229, DOI 10.1016/j.cellbi.2007.08.029
   Dan HX, 2014, BIOMATERIALS, V35, P113, DOI 10.1016/j.biomaterials.2013.09.074
   Davidson KC, 2012, P NATL ACAD SCI USA, V109, P4485, DOI 10.1073/pnas.1118777109
   Farag A, 2014, J DENT RES, V93, P1313, DOI 10.1177/0022034514547762
   Feng F, 2010, ORAL DIS, V16, P20, DOI 10.1111/j.1601 0825.2009.01593.x
   Hajishengallis G, 2014, J ORAL BIOSCI, V56, P30, DOI 10.1016/j.job.2013.09.001
   He F, 2009, TISSUE ENG PT A, V15, P3809, DOI 10.1089/ten.TEA.2009.0188
   He F, 2013, J TISSUE ENG REGEN M, V7, P73, DOI 10.1002/term.505
   Heo JS, 2010, MOL CELLS, V30, P449, DOI 10.1007/s10059 010 0139 3
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Hwang JI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141728
   Igishi T, 1999, J BIOL CHEM, V274, P30738, DOI 10.1074/jbc.274.43.30738
   Iwata T, 2009, BIOMATERIALS, V30, P2716, DOI 10.1016/j.biomaterials.2009.01.032
   Ji BH, 2015, TISSUE ENG PT A, V21, P26, DOI 10.1089/ten.tea.2014.0043
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381
   Kong XW, 2013, BBA GEN SUBJECTS, V1830, P5119, DOI 10.1016/j.bbagen.2013.07.027
   Lai YL, 2010, STEM CELLS DEV, V19, P1095, DOI 10.1089/scd.2009.0217
   Li JT, 2014, BIOMATERIALS, V35, P642, DOI 10.1016/j.biomaterials.2013.09.099
   Li R, 2011, BIOMATERIALS, V32, P4525, DOI 10.1016/j.biomaterials.2011.03.008
   Lim WH, 2014, J PERIODONTAL RES, V49, P751, DOI 10.1111/jre.12158
   Lin NH, 2009, PERIODONTOL 2000, V51, P239, DOI 10.1111/j.1600 0757.2009.00303.x
   Liu AR, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0090229, 10.1371/journal.pone.0083736]
   Liu QS, 2015, EARTH PLANETS SPACE, V67, P1, DOI 10.1186/s40623 015 0237 8
   Liu W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.65
   Liu WJ, 2014, BBA GEN SUBJECTS, V1840, P1125, DOI 10.1016/j.bbagen.2013.11.003
   Lu H, 2013, CELL TRANSPLANT, V22, P205, DOI 10.3727/096368912X656171
   Lu HX, 2012, J BIOMED MATER RES A, V100A, P2507, DOI 10.1002/jbm.a.34150
   MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092 8674(95)90401 8
   Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542
   Ng CP, 2014, BIOMATERIALS, V35, P4046, DOI 10.1016/j.biomaterials.2014.01.081
   Pei M, 2013, TISSUE ENG PT A, V19, P1144, DOI [10.1089/ten.tea.2012.0351, 10.1089/ten.TEA.2012.0351]
   Pei M, 2012, J CELL PHYSIOL, V227, P2163, DOI 10.1002/jcp.22950
   Pei M, 2011, TISSUE ENG PT A, V17, P3067, DOI [10.1089/ten.tea.2011.0158, 10.1089/ten.TEA.2011.0158]
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Syedain ZH, 2013, TISSUE ENG PT A, V19, P759, DOI [10.1089/ten.tea.2012.0365, 10.1089/ten.TEA.2012.0365]
   Tsumanuma Y, 2011, BIOMATERIALS, V32, P5819, DOI 10.1016/j.biomaterials.2011.04.071
   Wu RX, 2015, ACTA BIOMATER, V22, P70, DOI 10.1016/j.actbio.2015.04.024
   Xing Q, 2015, TISSUE ENG PART C ME, V21, P77, DOI [10.1089/ten.TEC.2013.0666, 10.1089/ten.tec.2013.0666]
   Yi F, 2011, NAT CELL BIOL, V13, P762, DOI 10.1038/ncb2283
   Yoshida T, 2012, INT J DENT, V2012, DOI 10.1155/2012/307024
   Yu Y, 2012, HISTOCHEM CELL BIOL, V137, P513, DOI 10.1007/s00418 011 0908 x
   Zhang J, 2012, BIOMATERIALS, V33, P6974, DOI 10.1016/j.biomaterials.2012.06.032
   Zhang WB, 2009, METHODS, V47, P122, DOI 10.1016/j.ymeth.2008.09.004
NR 51
TC 11
Z9 11
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD JAN
PY 2018
VL 106
IS 1
BP 272
EP 284
DI 10.1002/jbm.a.36227
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA GB0MS
UT WOS:000428741100027
PM 28884507
DA 2025 08 17
ER

PT J
AU Ling, Y
   Sahota, G
   Odeh, S
   Chan, JMW
   Araujo, FG
   Moreno, SNJ
   Oldfield, E
AF Ling, Y
   Sahota, G
   Odeh, S
   Chan, JMW
   Araujo, FG
   Moreno, SNJ
   Oldfield, E
TI Bisphosphonate inhibitors of Toxoplasma gondi growth:: In vitro,
   QSAR, and in vivo investigations
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID FARNESYL PYROPHOSPHATE SYNTHASE; DELTA T CELLS; NITROGEN CONTAINING
   BISPHOSPHONATES; DIPHOSPHATE SYNTHASE; ISOPRENOID BIOSYNTHESIS;
   TRYPANOSOMA BRUCEI; LEISHMANIA DONOVANI; POTENTIAL ROUTE; RISEDRONATE;
   CRUZI
AB We have investigated the activity of 60 bisphosphonates against the replication of Toxoplasma gondii in vitro and of three of the most active compounds, in vivo. The two most active compounds found were n alkyl bisphosphonates containing long (n = 9 or 10) hydrocarbon chains, not the nitrogen containing species used in bone resorption therapy. The target of all of the most active bisphosphonates appears to be the isoprene biosynthesis pathway enzyme farnesyl pyrophosphate synthase (FPPS), as indicated by the correlations between T. gondii growth inhibition and FPPS (human and Leishmania major) enzyme inhibition and by the fact that a T. gondii. strain engineered to overexpress FPPS required considerably higher levels of bisphosphonates to achieve 50% growth inhibition, while the IC50 for atovaquone (which does not inhibit FPPS) remained the same in the overexpressing strain. The phosphonate inhibitor of the non mevalonate pathway, fosmidomycin, which inhibits the enzyme 1 deoxy xylulose 5 phosphate reductoisomerase, had no effect on T. gondii growth. To investigate structure activity relationships (SARs) in more detail, we used two three dimensional quantitative SAR methods: comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA), to investigate all 60 bisphosphonates. Both the CoMFA and CoMSIA models indicated a 60 70% contribution from steric interactions and a 30 40% contribution from electrostatic interactions and using four N = 55 training sets for each method, we found on average between a factor of 2 and 3 error in IC50 prediction. The three most active compounds found in vitro were tested in vivo in a Smith Webster mouse model and the two most active bisphosphonates were found to provide up to an 80% protection from death, a considerable improvement over that found previously with nitrogen containing bisphosphonates. This effect may originate in the much higher therapeutic indices of these alkyl bisphosphonates, as deduced from in vitro assays using LD50 values for growth inhibition of a human cell line. Overall, these results indicate that alkyl bisphosphonates are promising compounds for further development as agents against Toxoplasma gondii growth, in vivo.
C1 Univ Illinois, Mol Parasitol Lab, Dept Pathobiol, Urbana, IL 61802 USA.
   Univ Illinois, Ctr Zoonoses Res, Urbana, IL 61802 USA.
   Univ Illinois, Dept Biophys, Urbana, IL 61801 USA.
   Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
   Palo Alto Med Fdn, Dept Infect Dis, Palo Alto, CA 94301 USA.
C3 University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign;
   Palo Alto Medical Foundation Research Institute
RP Univ Illinois, Mol Parasitol Lab, Dept Pathobiol, 2001 S Lincoln Ave, Urbana, IL 61802 USA.
EM eo@chad.ses.uiuc.edu
RI Chan, Julian/AAT 6244 2021; Chan, Julian/D 3448 2013
OI Chan, Julian/0000 0002 2734 6496
FU NIGMS NIH HHS [GM 65307, GM 08276] Funding Source: Medline
CR Altincicek B, 2000, FEMS MICROBIOL LETT, V190, P329, DOI 10.1016/S0378 1097(00)00357 8
   Araujo FG, 1997, ANTIMICROB AGENTS CH, V41, P2137, DOI 10.1128/AAC.41.10.2137
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   BUSH BL, 1993, J COMPUT AID MOL DES, V7, P587, DOI 10.1007/BF00124364
   CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804
   Cramer R D 3rd, 1989, Prog Clin Biol Res, V291, P161
   Das H, 2001, BLOOD, V98, P1616, DOI 10.1182/blood.V98.5.1616
   Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092 8674(00)81071 5
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Eberl M, 2003, FEBS LETT, V544, P4, DOI 10.1016/S0014 5793(03)00483 6
   Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P273, DOI 10.1016/j.ijantimicag.2003.07.020
   Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P286, DOI 10.1016/j.ijantimicag.2003.07.019
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040 4020(80)80168 2
   Ghosh S, 2004, J MED CHEM, V47, P175, DOI 10.1021/jm030084x
   Grove JE, 2000, J BONE MINER RES, V15, P971, DOI 10.1359/jbmr.2000.15.5.971
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573
   Kato Y, 2001, J IMMUNOL, V167, P5092, DOI 10.4049/jimmunol.167.9.5092
   Keller RK, 1999, BIOCHEM BIOPH RES CO, V266, P560, DOI 10.1006/bbrc.1999.1849
   KHANNA SC, 1994, Patent No. 5344825
   KLEBE G, 1994, J MED CHEM, V37, P4130, DOI 10.1021/jm00050a010
   Kotsikorou E, 2003, J MED CHEM, V46, P2932, DOI 10.1021/jm030054u
   Kunzmann V, 2000, BLOOD, V96, P384
   Martin MB, 2002, J MED CHEM, V45, P2904, DOI 10.1021/jm0102809
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   McFadden DC, 2000, MOL BIOCHEM PARASIT, V108, P1, DOI 10.1016/S0166 6851(00)00184 5
   Montalvetti A, 2001, J BIOL CHEM, V276, P33930, DOI 10.1074/jbc.M103950200
   Montalvetti A, 2003, J BIOL CHEM, V278, P17075, DOI 10.1074/jbc.M210467200
   Moreno B, 2001, BIOCHEM BIOPH RES CO, V284, P632, DOI 10.1006/bbrc.2001.5009
   NEU HC, 1981, ANTIMICROB AGENTS CH, V19, P1013, DOI 10.1128/AAC.19.6.1013
   POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790
   Press W.H., 1988, NUMERICAL RECIPES C, P324
   Rodriguez N, 2002, J INFECT DIS, V186, P138, DOI 10.1086/341074
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Sanders JM, 2004, J MED CHEM, V47, P375, DOI 10.1021/jm0303709
   Sanders JM, 2003, J MED CHEM, V46, P5171, DOI 10.1021/jm0302344
   SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986
   *SPSS INC, SIGM PLOT 5 0
   Szabo CM, 2002, J MED CHEM, V45, P2185, DOI 10.1021/jm010412y
   Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018
   Testa C. A., 2003, Current Pharmaceutical Biotechnology, V4, P248, DOI 10.2174/1389201033489784
   *TRIP INC, SYBYL 6 9
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Wang LS, 2001, J CLIN INVEST, V108, P1349, DOI 10.1172/JCI200113584
   Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood 2002 12 3665
   Yardley V, 2002, ANTIMICROB AGENTS CH, V46, P929, DOI 10.1128/AAC.46.3.929 931.2002
NR 46
TC 93
Z9 104
U1 0
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD MAY 5
PY 2005
VL 48
IS 9
BP 3130
EP 3140
DI 10.1021/jm040132t
PG 11
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 922WX
UT WOS:000228871700010
PM 15857119
DA 2025 08 17
ER

PT J
AU Zhao, N
   Shi, JC
   Li, M
   Xu, PC
   Wang, XF
   Li, XX
AF Zhao, Ning
   Shi, Jiaci
   Li, Ming
   Xu, Pengcheng
   Wang, Xuefeng
   Li, Xinxin
TI Alkaline Phosphatase Electrochemical Micro Sensor Based on 3D Graphene
   Networks for the Monitoring of Osteoblast Activity
SO BIOSENSORS BASEL
LA English
DT Article
DE alkaline phosphatase (ALP); electrochemical sensor; three dimensional
   graphene networks; osteoblast cells; screen printed electrode
ID FUNCTIONALIZED GRAPHENE; IN VITRO; BIOMARKER; CALCIUM; ASSAY; OXIDE
AB Alkaline phosphatase (ALP) is a significant biomarker that indicates osteoblast activity and skeletal growth. Efficient ALP detection methods are essential in drug development and clinical diagnosis. In this work, we developed an in situ synthesized three dimensional graphene networks (3DGNs) based electrochemical sensor to determine ALP activity. The sensor employs an ALP enzymatic conversion of non electroactive substrate to electroactive product and presents the ALP activity as an electrochemical signal. With 3DGNs as the catalyst and signal amplifier, a sample consumption of 5 mu L and an incubation time of 2 min are enough for the sensor to detect a wide ALP activity range from 10 to 10,000 U/L, with a limit of detection of 5.70 U/L. This facile fabricated sensor provides a quick response, cost effective and non destructive approach for monitoring living adherent osteoblast cell activity and holds promise for ALP quantification in other biological systems and clinical samples.
C1 [Zhao, Ning] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Coll Stomatol,Dept Orthodont,Natl Ctr Stomatol,Nat, Shanghai 200011, Peoples R China.
   [Shi, Jiaci] Shanghai Normal Univ, Coll Chem & Mat Sci, Shanghai 200234, Peoples R China.
   [Shi, Jiaci; Li, Ming; Xu, Pengcheng; Wang, Xuefeng; Li, Xinxin] Chinese Acad Sci, Shanghai Inst Microsyst & Informat Technol, State Key Lab Transducer Technol, Shanghai 200050, Peoples R China.
   [Li, Ming; Xu, Pengcheng; Wang, Xuefeng; Li, Xinxin] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Normal University; Chinese
   Academy of Sciences; Shanghai Institute of Microsystem & Information
   Technology, CAS; Chinese Academy of Sciences; University of Chinese
   Academy of Sciences, CAS
RP Wang, XF; Li, XX (通讯作者)，Chinese Acad Sci, Shanghai Inst Microsyst & Informat Technol, State Key Lab Transducer Technol, Shanghai 200050, Peoples R China.; Wang, XF; Li, XX (通讯作者)，Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
EM zhaon1995@126.com; 1000495035@smail.shnu.edu.cn;
   liming01@mail.sim.ac.cn; xpc@mail.sim.ac.cn; wangxuefeng@mail.sim.ac.cn;
   xxli@mail.sim.ac.cn
RI Xu, Pengcheng/J 1429 2012; Li, Mingguang/A 7028 2015
OI Wang, Xuefeng/0000 0002 0158 5990; Xu, Pengcheng/0000 0001 8651 208X; 
FU National Key R&D Program of China [2021YFB3200800]; National Natural
   Science Foundation of China [82171011, 61974155, 61874130, 61831021,
   62171275, 62104241]; Key Research Program of Frontier Sciences of
   Chinese Academy of Sciences [QYZDJ SSW JSC001]; Shanghai JiaoTong
   University School of Medicine [JYJC202108]; Shanghai "Road and Belt"
   International Young Scientist Exchange Program [19510744600]; Shanghai
   Pujiang Program [20PJ1415600]; Innovation Team and Talents Cultivation
   Program of National Administration of Traditional Chinese Medicine
   [ZYYCXTD D 202002, ZYYCXTD D 202003]
FX This research was funded by the National Key R&D Program of China
   (2021YFB3200800), National Natural Science Foundation of China
   (82171011, 61974155, 61874130, 61831021, 62171275, 62104241), Key
   Research Program of Frontier Sciences of Chinese Academy of Sciences
   (QYZDJ SSW JSC001), Cross disciplinary Research Fund of Shanghai Ninth
   People's Hospital, Shanghai JiaoTong University School of Medicine
   (JYJC202108), Shanghai "Road and Belt" International Young Scientist
   Exchange Program (19510744600), Shanghai Pujiang Program (20PJ1415600),
   and Innovation Team and Talents Cultivation Program of National
   Administration of Traditional Chinese Medicine (ZYYCXTD D 202002,
   ZYYCXTD D 202003).
CR Abdallah EAA, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004837
   Baig N, 2018, MICROCHIM ACTA, V185, DOI 10.1007/s00604 018 2809 3
   Balbaied T, 2019, BIOSENSORS BASEL, V9, DOI 10.3390/bios9030102
   Boulanger N, 2020, ACS APPL MATER INTER, V12, P45122, DOI 10.1021/acsami.0c11122
   Dong L, 2015, ANAL CHEM, V87, P6475, DOI 10.1021/acs.analchem.5b01657
   Du WX, 2014, J CANCER RES THER, V10, pC140, DOI 10.4103/0973 1482.145842
   Grote Koska D, 2017, CLIN CHEM LAB MED, V55, pE146, DOI 10.1515/cclm 2016 0771
   HAUSAMEN TU, 1967, CLIN CHIM ACTA, V15, P241, DOI 10.1016/0009 8981(67)90060 5
   Hayat A, 2013, ANAL CHEM, V85, P10028, DOI 10.1021/ac4020963
   Huang H, 2019, J MATER CHEM B, V7, P6508, DOI 10.1039/c9tb01390c
   Kanno Y, 2022, ELECTROANAL, V34, P161, DOI 10.1002/elan.202100294
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Lu HF, 2018, SENSOR ACTUAT B CHEM, V258, P461, DOI 10.1016/j.snb.2017.11.122
   Ma CJ, 2014, SENSOR ACTUAT B CHEM, V202, P683, DOI 10.1016/j.snb.2014.06.007
   Ma YF, 2015, NATL SCI REV, V2, P40, DOI 10.1093/nsr/nwu072
   Mahato K, 2020, BIOSENS BIOELECTRON, V148, DOI 10.1016/j.bios.2019.111815
   Mahato K, 2019, BIOSENS BIOELECTRON, V128, P9, DOI 10.1016/j.bios.2018.12.006
   McAllister MJ, 2007, CHEM MATER, V19, P4396, DOI 10.1021/cm0630800
   Montes Navajas P, 2013, LANGMUIR, V29, P13443, DOI 10.1021/la4029904
   Niu XH, 2019, ANAL CHIM ACTA, V1086, P29, DOI 10.1016/j.aca.2019.07.068
   Nizet A, 2020, CLIN CHIM ACTA, V501, P198, DOI 10.1016/j.cca.2019.11.012
   Pang YH, 2020, ELECTROANAL, V32, P1459, DOI 10.1002/elan.201900692
   Pang YH, 2016, J ELECTROANAL CHEM, V769, P89, DOI 10.1016/j.jelechem.2016.03.023
   Peng J, 2015, ANAL CHIM ACTA, V878, P87, DOI 10.1016/j.aca.2015.03.052
   Sappia L, 2019, SENSOR ACTUAT B CHEM, V281, P221, DOI 10.1016/j.snb.2018.10.105
   Song L, 2017, ADV CLIN CHEM, V82, P1, DOI 10.1016/bs.acc.2017.06.005
   Sun D, 2020, ACS SENSORS, V5, P1758, DOI 10.1021/acssensors.0c00428
   Sun D, 2019, LAB CHIP, V19, P335, DOI 10.1039/c8lc01006d
   Sun ZX, 2020, CHEM REV, V120, P10336, DOI 10.1021/acs.chemrev.0c00083
   Tabish TA, 2022, BIOSENSORS BASEL, V12, DOI 10.3390/bios12020077
   Tanabe Y, 2016, ADV MATER, V28, P10304, DOI 10.1002/adma.201601067
   Wang W, 2021, ANAL CHIM ACTA, V1183, DOI 10.1016/j.aca.2021.338989
   Wei H, 2008, ANAL CHEM, V80, P7051, DOI 10.1021/ac801144t
   Wu T, 2013, J MATER CHEM A, V1, P7612, DOI 10.1039/c3ta10989e
   Wu Z, 2016, ANAL CHEM, V88, P9166, DOI 10.1021/acs.analchem.6b02284
   Xia XH, 2014, NANO TODAY, V9, P785, DOI 10.1016/j.nantod.2014.12.001
   Xu YX, 2013, ADV MATER, V25, P5779, DOI 10.1002/adma.201301928
   Xue Q, 2018, MICROCHIM ACTA, V185, DOI 10.1007/s00604 018 2769 7
   Yeung MCL, 2013, CHEM SCI, V4, P2928, DOI 10.1039/c3sc50383f
   Zahanich I, 2005, J BONE MINER RES, V20, P1637, DOI 10.1359/JBMR.050521
   Zhao H, 2021, SENSORS BASEL, V21, DOI 10.3390/s21030674
   Zhao WA, 2007, CHEM COMMUN, P3729, DOI 10.1039/b705335e
NR 42
TC 7
Z9 7
U1 2
U2 44
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2079 6374
J9 BIOSENSORS BASEL
JI Biosensors Basel
PD JUN
PY 2022
VL 12
IS 6
AR 406
DI 10.3390/bios12060406
PG 10
WC Chemistry, Analytical; Nanoscience & Nanotechnology; Instruments &
   Instrumentation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Instruments &
   Instrumentation
GA 8Z3IC
UT WOS:000933275400001
PM 35735554
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Francesca, S
   Veronica, B
   Silvia, B
   Gianluca, G
   Annapaola, P
   Simona, C
   Matteo, C
   Lucia, M
   Antonio, M
   Milena, F
AF Francesca, Salamanna
   Veronica, Borsari
   Silvia, Brogini
   Gianluca, Giavaresi
   Annapaola, Parrilli
   Simona, Cepollaro
   Matteo, Cadossi
   Lucia, Martini
   Antonio, Mazzotti
   Milena, Fini
TI An in vitro 3D bone metastasis model by using a human bone tissue
   culture and human sex related cancer cells
SO ONCOTARGET
LA English
DT Article
DE 3D model; cancer bone metastasis model; human bone tissue; human
   sex related cancer cells
ID BREAST CANCER; OSTEOCLAST DIFFERENTIATION; VIVO; OSTEOBLASTS;
   CHALLENGES; RESORPTION; SCAFFOLDS; CYTOKINES; SYSTEM; GROWTH
AB One of the main limitations, when studying cancer bone metastasis, is the complex nature of the native bone environment and the lack of reliable, simple, inexpensive models that closely mimic the biological processes occurring in patients and allowing the correct translation of results. To enhance the understanding of the mechanisms underlying human bone metastases and in order to find new therapies, we developed an in vitro three dimensional (3D) cancer bone metastasis model by culturing human breast or prostate cancer cells with human bone tissue isolated from female and male patients, respectively. Bone tissue discarded from total hip replacement surgery was cultured in a rolling apparatus system in a normoxic or hypoxic environment. Gene expression profile, protein levels, histological, immunohistochemical and four dimensional (4D) micro CT analyses showed a noticeable specificity of breast and prostate cancer cells for bone colonization and ingrowth, thus highlighting the species specific and sex specific osteotropism and the need to widen the current knowledge on cancer bone metastasis spread in human bone tissues. The results of this study support the application of this model in preclinical studies on bone metastases and also follow the 3R principles, the guiding principles, aimed at replacing/reducing/refining (3R) animal use and their suffering for scientific purposes.
C1 [Francesca, Salamanna; Veronica, Borsari; Gianluca, Giavaresi; Annapaola, Parrilli; Lucia, Martini; Milena, Fini] Rizzoli Orthoped Inst, Rizzoli RIT, Lab Biocompatibil Technol Innovat & Adv Therapy, Bologna, Italy.
   [Francesca, Salamanna; Silvia, Brogini; Simona, Cepollaro; Lucia, Martini; Milena, Fini] Rizzoli Orthopaed Inst, Lab Preclin & Surg Studies, Bologna, Italy.
   [Gianluca, Giavaresi] Rizzoli Orthoped Inst, Lab Tissue Engn Innovat Technol Platforms Tissue, Palermo, Italy.
   [Simona, Cepollaro] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy.
   [Matteo, Cadossi; Antonio, Mazzotti] Rizzoli Orthopaed Inst, Orthopaed & Trauma Clin 1, Bologna, Italy.
   [Matteo, Cadossi; Antonio, Mazzotti] Univ Bologna, Bologna, Italy.
C3 IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto Ortopedico Rizzoli;
   IRCCS Istituto Ortopedico Rizzoli; University of Bologna; IRCCS Istituto
   Ortopedico Rizzoli; University of Bologna
RP Veronica, B (通讯作者)，Rizzoli Orthoped Inst, Rizzoli RIT, Lab Biocompatibil Technol Innovat & Adv Therapy, Bologna, Italy.
EM veronica.borsari@ior.it
RI Mazzotti, Antonio/ABI 2083 2020; mazzotti, antonio/D 2163 2019;
   Parrilli, Annapaola/C 7008 2019; Borsari, Veronica/AAC 9501 2021; Fini,
   Milena/J 4808 2016; Salamanna, Francesca/J 6032 2016; Giavaresi,
   Gianluca/J 5583 2016; Brogini, Silvia/C 6884 2019
OI mazzotti, antonio/0000 0001 9974 4787; Parrilli,
   Annapaola/0000 0003 0251 5094; CEPOLLARO, SIMONA/0000 0003 4780 7250;
   Borsari, Veronica/0000 0002 6327 4653; Salamanna,
   Francesca/0000 0001 7402 4054; Brogini, Silvia/0000 0002 1229 9367
FU Rizzoli Orthopedic Institute (Ricerca Corrente); 5 x 1000 Project
   "Sviluppo e validazione di modelli alternativi e complementari in vitro
   (intelligent testing strategy) in ortopedia e traumatologia";
   Operational Programme ERDF in the region Emilia Romagna: Activity The
   1.1 "Creation of technology centers for Industrial research and
   technological transfer"; Project: "Tumor microenvironment: potential
   role of osteoporosis in the development of bone metastases. In vitro and
   in vivo studies", programma di ricerca Regione Universita Area 1 "Bando
   Giovani Ricercatori"
FX This work was partially supported by grants from Rizzoli Orthopedic
   Institute (Ricerca Corrente), 5 x 1000 2013 Project "Sviluppo e
   validazione di modelli alternativi e complementari in vitro (intelligent
   testing strategy) in ortopedia e traumatologia", the Operational
   Programme ERDF 2007 2013 in the region Emilia Romagna: Activity The 1.1
   "Creation of technology centers for Industrial research and
   technological transfer" and by the Project: "Tumor microenvironment:
   potential role of osteoporosis in the development of bone metastases. In
   vitro and in vivo studies", programma di ricerca Regione Universita
   2010 2012 Area 1 "Bando Giovani Ricercatori".
CR Alsberg E, 2001, J DENT RES, V80, P2025, DOI 10.1177/00220345010800111501
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bussard KM, 2010, CLIN EXP METASTAS, V27, P331, DOI 10.1007/s10585 010 9330 3
   Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200
   Cicek M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017522
   Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007
   Contag CH, 2014, MOL IMAGING BIOL, V16, P158, DOI 10.1007/s11307 013 0685 0
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Curtin P, 2012, BIOMATERIALS, V33, P1065, DOI 10.1016/j.biomaterials.2011.10.046
   Doroudinia A, 2015, CLIN NUCL MED, V40, P647, DOI 10.1097/RLU.0000000000000860
   Ell B, 2013, TRENDS CELL BIOL, V23, P603, DOI 10.1016/j.tcb.2013.06.001
   Fischbach C, 2007, NAT METHODS, V4, P855, DOI 10.1038/NMETH1085
   Foerster R, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014 015 0368 x
   Glowacki J, 2008, BIOPOLYMERS, V89, P338, DOI 10.1002/bip.20871
   Griffith LG, 2002, SCIENCE, V295, P1009, DOI 10.1126/science.1069210
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hicks KO, 2006, JNCI J NATL CANCER I, V98, P1118, DOI 10.1093/jnci/djj306
   Hirao M, 2007, J BONE MINER METAB, V25, P266, DOI 10.1007/s00774 007 0765 9
   Holen I, 2015, CLIN EXP METASTAS, V32, P689, DOI 10.1007/s10585 015 9737 y
   Jung K, 2014, BBA REV CANCER, V1846, P425, DOI 10.1016/j.bbcan.2014.09.001
   Kang JH, 2014, J DENT RES, V93, P1116, DOI 10.1177/0022034514552677
   Kim JB, 2005, SEMIN CANCER BIOL, V15, P365, DOI 10.1016/j.semcancer.2005.05.002
   Kuperwasser C, 2005, CANCER RES, V65, P6130, DOI 10.1158/0008 5472.CAN 04 1408
   Lee YM, 2010, INT IMMUNOL, V22, P805, DOI 10.1093/intimm/dxq431
   Mercier NR, 2004, ANN BIOMED ENG, V32, P418, DOI 10.1023/B:ABME.0000017547.84146.fd
   Miyaura C, 2000, J BIOL CHEM, V275, P19819, DOI 10.1074/jbc.M002079200
   Nordstrand A, 2009, CLIN EXP METASTAS, V26, P945, DOI 10.1007/s10585 009 9285 4
   Nyga A, 2011, J CELL COMMUN SIGNAL, V5, P239, DOI 10.1007/s12079 011 0132 4
   Pagani S, 2015, BONE, V79, P176, DOI 10.1016/j.bone.2015.06.002
   Sabino MAC, 2002, CANCER RES, V62, P7343
   Salamanna F, 2015, HISTOL HISTOPATHOL
   Salamanna F, 2013, ACTA HISTOCHEM, V115, P76, DOI 10.1016/j.acthis.2012.05.005
   Schiller KR, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 45
   Schulze J, 2012, CANCER LETT, V317, P106, DOI 10.1016/j.canlet.2011.11.016
   Sosnoski DM, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/160265
   Sottnik JL, 2013, CURR MOL MED, V13, P626
   Tagliaferri P, 2012, CURR CANCER DRUG TAR, V12, P838, DOI 10.2174/156800912802429355
   Thein Han WW, 2009, ACTA BIOMATER, V5, P1182, DOI 10.1016/j.actbio.2008.11.025
   Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0
   Trebec Reynolds DP, 2010, J CELL BIOCHEM, V109, P975, DOI 10.1002/jcb.22476
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Xu F, 2007, CYTOTECHNOLOGY, V54, P135, DOI 10.1007/s10616 007 9065 4
   Zhang Q, 2008, J BIOL CHEM, V283, P13491, DOI 10.1074/jbc.M708055200
NR 43
TC 23
Z9 23
U1 0
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 22
PY 2016
VL 7
IS 47
BP 76966
EP 76983
DI 10.18632/oncotarget.12763
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA EE5GK
UT WOS:000389633400052
PM 27765913
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Yan, Y
   Zeng, WF
   Song, SJ
   Zhang, FY
   He, WX
   Liang, W
   Niu, ZY
AF Yan, Yan
   Zeng, Wenfeng
   Song, Shujun
   Zhang, Fayun
   He, Wenxi
   Liang, Wei
   Niu, Zhongying
TI Vitamin C induces periodontal ligament progenitor cell differentiation
   via activation of ERK pathway mediated by PELP1
SO PROTEIN & CELL
LA English
DT Article
DE periodontal ligament progenitor cells; Vitamin C; PELP1; ERK signaling
   pathway; osteogenic differentiation
ID L ASCORBIC ACID; STEM CELLS; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC
   DIFFERENTIATION; ALKALINE PHOSPHATASE; TRANSCRIPTION FACTOR;
   COLLAGEN SYNTHESIS; GENE EXPRESSION; RECEPTOR ALPHA; MAPK PATHWAYS
AB The differentiation of periodontal ligament (PDL) progenitor cells is important for maintaining the homeostasis of PDL tissue and alveolar bone. Vitamin C (VC), a water soluble nutrient that cannot be biosynthesized by humans, is vital for mesenchymal stem cells differentiation and plays an important role in bone remodeling. Therefore, the objective of this study was to determine the function and mechanism of VC in PDL progenitor cells osteogenic differentiation at the molecular level. We demonstrated that VC could induce the osteogenic differentiation and maturation of PDL progenitor cell without other osteogenic agents. During the process, VC preferentially activated ERK1/2 but did not affect JNK or p38. Co treatment with ERK inhibitor effectively decreased the Vitamin C induced expression of Runx2. ERK inhibitor also abrogated Vitamin C induced the minimized nodules formation. PELP1, a nuclear receptor co regulator, was up regulated under VC treatment. PELP1 knockdown inhibited ERK phosphorylation. The overexpression of PELP1 had a positive relationship with Runx2 expression. Taken together, we could make a conclude that VC induces the osteogenic differentiation of PDL progenitor cells via PELP1 ERK axis. Our finding implies that VC may have a potential in the regeneration medicine and application to periodontitis treatment.
C1 [Yan, Yan; He, Wenxi; Niu, Zhongying] Fourth Mil Med Univ, Sch Stomatol, Dept Endodont, Xian 710032, Peoples R China.
   [Zeng, Wenfeng; Zhang, Fayun; Liang, Wei] Chinese Acad Sci, Inst Biophys, Prot & Peptide Pharmaceut Lab, Beijing 100101, Peoples R China.
   [Yan, Yan; Niu, Zhongying] 306th Hosp Peoples Liberat Army, Treatment Ctr Oral Dis, Beijing 100101, Peoples R China.
   [Song, Shujun] 306th Hosp Peoples Liberat Army, Dept Pathol & Expt Med, Beijing 100101, Peoples R China.
C3 Air Force Medical University; Chinese Academy of Sciences; Institute of
   Biophysics, CAS
RP Liang, W (通讯作者)，Chinese Acad Sci, Inst Biophys, Prot & Peptide Pharmaceut Lab, Beijing 100101, Peoples R China.
EM weixx@sun5.ibp.ac.cn; nzhongying@gmail.com
RI ; Ye, Jianxiong/JFK 8186 2023
OI Zeng, Wenfeng/0000 0002 4725 9541; liang, wei/0000 0002 0739 6648; 
FU National Basic Research Program (973 Program) [2011CB707705]; National
   Natural Science Foundation of China [11202229]
FX This work is supported by grants: the National Basic Research Program
   (973 Program) (No. 2011CB707705), National Natural Science Foundation of
   China (Grant No. 11202229).
CR Cao N, 2012, CELL RES, V22, P219, DOI 10.1038/cr.2011.195
   Choi KM, 2008, J BIOSCI BIOENG, V105, P586, DOI 10.1263/jbb.105.586
   Desvarieux M, 2003, STROKE, V34, P2120, DOI 10.1161/01.STR.0000085086.50957.22
   Ding G, 2010, STEM CELLS, V28, P1829, DOI 10.1002/stem.512
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   EKLUND SA, 1994, J PUBLIC HEALTH DENT, V54, P5, DOI 10.1111/j.1752 7325.1994.tb01173.x
   Esteban MA, 2010, CELL STEM CELL, V6, P71, DOI 10.1016/j.stem.2009.12.001
   Franceschi RT, 2007, ANN NY ACAD SCI, V1116, P196, DOI 10.1196/annals.1402.081
   FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gordon JAR, 2007, BONE, V41, P462, DOI 10.1016/j.bone.2007.04.191
   Haas D, 2005, MOL ENDOCRINOL, V19, P2035, DOI 10.1210/me.2004 0531
   Kanno T, 2007, J CELL BIOCHEM, V101, P1266, DOI 10.1002/jcb.21249
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2008, FRONT BIOSCI LANDMRK, V13, P898, DOI 10.2741/2730
   Kunath T, 2007, DEVELOPMENT, V134, P2895, DOI 10.1242/dev.02880
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   LEBOY PS, 1989, J BIOL CHEM, V264, P17281
   Liu Y, 2008, STEM CELLS, V26, P1065, DOI 10.1634/stemcells.2007 0734
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mao JJ, 2006, J DENT RES, V85, P966, DOI 10.1177/154405910608501101
   Mekala NK, 2013, CURR STEM CELL RES T, V8, P156
   MITOMA C, 1960, J BIOL CHEM, V235, P426
   Park S, 2005, CELL SIGNAL, V17, P111, DOI 10.1016/j.cellsig.2004.06.006
   PETERKOFSKY B, 1991, AM J CLIN NUTR, V54, pS1135, DOI 10.1093/ajcn/54.6.1135s
   Petersen PE, 2005, B WORLD HEALTH ORGAN, V83, P661
   Rayala SK, 2006, J BIOL CHEM, V281, P4395, DOI 10.1074/jbc.M510368200
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shiga M, 2003, J BONE MINER RES, V18, P67, DOI 10.1359/jbmr.2003.18.1.67
   Singh RR, 2006, J BIOL CHEM, V281, P15394, DOI 10.1074/jbc.M601593200
   Sonoyama W, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000079
   Vadlamudi RK, 2005, CANCER RES, V65, P7724, DOI 10.1158/0008 5472.CAN 05 0614
   Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272
   VAN ROBERTSON W B, 1959, J Biol Chem, V234, P105
   Wang YZ, 2006, BIOMATERIALS, V27, P3265, DOI 10.1016/j.biomaterials.2006.01.036
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Yu Y, 2012, HISTOCHEM CELL BIOL, V137, P513, DOI 10.1007/s00418 011 0908 x
NR 40
TC 32
Z9 32
U1 1
U2 27
PU HIGHER EDUCATION PRESS
PI BEIJING
PA SHATANHOU ST 55, BEIJING 100009, PEOPLES R CHINA
SN 1674 800X
J9 PROTEIN CELL
JI Protein Cell
PD AUG
PY 2013
VL 4
IS 8
BP 620
EP 627
DI 10.1007/s13238 013 3030 0
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 191DZ
UT WOS:000322394300009
PM 23836152
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Zuckerman, LM
   Frames, WL
   Elsissy, JG
   Shields, TG
   De Necochea Campion, R
   Mirshahidi, HR
   Williams, NL
   Mirshahidi, S
AF Zuckerman, L. M.
   Frames, W. L.
   Elsissy, J. G.
   Shields, T. G.
   De Necochea Campion, R.
   Mirshahidi, H. R.
   Williams, N. L.
   Mirshahidi, S.
TI The effect of non steroidal anti inflammatory drugs on osteosarcoma
   cells
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Osteosarcoma; Non Steroidal Anti Inflammatory Drugs (NSAIDs); Ketorolac;
   Indomethacin; Apoptosis
ID CYCLOOXYGENASE 2 EXPRESSION; NEOADJUVANT CHEMOTHERAPY; IN VITRO;
   APOPTOSIS; INDOMETHACIN; MIGRATION; INVASION; PROLIFERATION; KETOROLAC;
   SURVIVIN
AB OBJECTIVE: Osteosarcoma (OS), an aggressive malignancy, is the most common primary bone tumor in children. Nonsteroidal anti  inflammatory drugs (NSAIDs) are widely used to reduce pain and inflammation. NSAIDs have shown to be toxic to certain malignancies such as colorectal, breast, and pancreatic cancers, but are not well studied in OS. The purpose of this study is to assess whether ketorolac induces apoptosis in OS cells, compare this to indomethacin, which has been shown to inhibit OS proliferation, and explore the underlying mechanism.
   MATERIALS AND METHODS: A rat OS cell line (UMR 108) was exposed to various concentrations of ketorolac and indomethacin. Cell viability, cytotoxicity, apoptosis induction, DNA fragmentation and the expression of apoptosis  related markers were examined by MTT assay, colony formation assay, flow cytometry, agarose gel electrophoresis, and Western blot respectively.
   RESULTS: The results indicated that ketorolac and indomethacin could induce apoptosis of rat OS cells in a dose and time dependent manner. Apoptosis was confirmed by cell morphology and annexin positivity. The molecular data showed that NSAIDs affected expression of Bcl 2, survivin, and Poly (ADP ribose) polymerase 1 (PARP).
   CONCLUSIONS: These findings demonstrated that NSAIDs induced apoptosis in rat OS cells in vitro. Further research focusing on the potential cytotoxicity of NSAIDs in vivo is needed.
C1 [Zuckerman, L. M.; Frames, W. L.; Elsissy, J. G.; Shields, T. G.; Williams, N. L.] Loma Linda Univ, Med Ctr, Dept Orthopaed Surg, Loma Linda, CA 92350 USA.
   [Mirshahidi, H. R.] Loma Linda Univ, Sch Med, Div Hematol Oncol, Loma Linda, CA USA.
   [De Necochea Campion, R.; Mirshahidi, S.] Loma Linda Univ, Med Ctr, Loma Linda Canc Ctr Biospecimen Lab, Loma Linda, CA USA.
C3 Loma Linda University; Loma Linda University; Loma Linda University
RP Frames, WL (通讯作者)，Loma Linda Univ, Med Ctr, Dept Orthopaed Surg, Loma Linda, CA 92350 USA.
EM wframes@llu.edu
RI Zuckerman, Lee/I 6570 2019
CR Ackerstaff E, 2007, NEOPLASIA, V9, P222, DOI 10.1593/neo.06673
   Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968
   [Anonymous], 2007, TOXICOL PATHOL, DOI DOI 10.1080/01926230701320337
   Arndt CAS, 2012, MAYO CLIN PROC, V87, P475, DOI 10.1016/j.mayocp.2012.01.015
   Axelsson H, 2010, INT J ONCOL, V37, P1143, DOI 10.3892/ijo_00000766
   Bacci G, 2000, ONCOL REP, V7, P1129
   Bai XM, 2009, ONCOL REP, V21, P129, DOI 10.3892/or_00000199
   Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478 811X 8 31
   Chen X, 2015, CANCER GENE THER, V22, P380, DOI 10.1038/cgt.2015.30
   DAHLIN DC, 1967, J BONE JOINT SURG AM, VA 49, P101, DOI 10.2106/00004623 196749010 00008
   Díaz Rodríguez L, 2012, BIOL RES NURS, V14, P98, DOI 10.1177/1099800411398933
   Dickens DS, 2002, PEDIATR DEVEL PATHOL, V5, P356, DOI 10.1007/s10024 002 0005 1
   Ferrari S, 2005, J CLIN ONCOL, V23, P8845, DOI 10.1200/JCO.2004.00.5785
   Forget P, 2014, BRIT J ANAESTH, V113, P82, DOI 10.1093/bja/aet464
   Forget P, 2010, ANESTH ANALG, V110, P1630, DOI 10.1213/ANE.0b013e3181d2ad07
   Fox MG, 2013, SEMIN MUSCULOSKEL R, V17, P123, DOI 10.1055/s 0033 1342969
   Guo YN, 2015, CLIN CANCER RES, V21, P5064, DOI 10.1158/1078 0432.CCR 15 0461
   Gurpinar E, 2014, CLIN CANCER RES, V20, P1104, DOI 10.1158/1078 0432.CCR 13 1573
   Hull MA, 2003, CANCER TREAT REV, V29, P309, DOI 10.1016/S0305 7372(03)00014 8
   Indran IR, 2011, BBA BIOENERGETICS, V1807, P735, DOI 10.1016/j.bbabio.2011.03.010
   Jaffe N, 1976, CA Cancer J Clin, V26, P351, DOI 10.3322/canjclin.26.6.351
   Jelinek GA, 2000, BRIT MED J, V321, P1236, DOI 10.1136/bmj.321.7271.1236
   Kato T, 2011, BIOCHEM PHARMACOL, V82, P1781, DOI 10.1016/j.bcp.2011.07.096
   Lee EJ, 2007, EXP MOL MED, V39, P469, DOI 10.1038/emm.2007.51
   Li YH, 2004, WORLD J GASTROENTERO, V10, P1984
   Liu B, 2008, CELL BIOL INT, V32, P494, DOI 10.1016/j.cellbi.2007.10.008
   LUNDHOLM K, 1994, CANCER RES, V54, P5602
   Maki RG, 2012, J CLIN ONCOL, V30, P2033, DOI 10.1200/JCO.2012.42.3285
   McIlwain DR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008656
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Naruse T, 2006, CARCINOGENESIS, V27, P584, DOI 10.1093/carcin/bgi240
   Obiedat H, 2018, BMC MED GENET, V19, DOI 10.1186/s12881 018 0627 4
   Onizuka S, 2012, J ANESTH, V26, P45, DOI 10.1007/s00540 011 1257 6
   Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750 1172 2 6
   Saadat YR, 2015, BIOIMPACTS, V5, P25, DOI 10.15171/bi.2015.01
   Smith CE, 2017, CELL CHEM BIOL, V24, P281, DOI 10.1016/j.chembiol.2017.02.003
   Sobolewski Cyril, 2010, Int J Cell Biol, V2010, P215158, DOI 10.1155/2010/215158
   Sutton KM, 2004, ONCOLOGY BASEL, V66, P275, DOI 10.1159/000078327
   Vacha Mary E, 2015, Hosp Pharm, V50, P108, DOI 10.1310/hpj5002 108
   Vane JR, 1998, INFLAMM RES, V47, pS78
   Vanegas H, 2010, PHARMACEUTICALS, V3, P1335, DOI 10.3390/ph3051335
   Wang W, 2017, CELL PHYSIOL BIOCHEM, V43, P320, DOI 10.1159/000480412
   Xu Z, 2006, CANCER RES, V66, P6657, DOI 10.1158/0008 5472.CAN 05 3624
   Zhou DY, 2013, CARCINOGENESIS, V34, P943, DOI 10.1093/carcin/bgs394
   Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192
NR 45
TC 6
Z9 6
U1 0
U2 4
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD MAR
PY 2019
VL 23
IS 6
BP 2681
EP 2690
DI 10.26355/eurrev_201903_17416
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HS6VQ
UT WOS:000464009800044
PM 30964195
DA 2025 08 17
ER

PT J
AU Xu, DH
   Gao, Y
   Hu, N
   Wu, LH
   Chen, Q
AF Xu, Daohua
   Gao, Yun
   Hu, Nan
   Wu, Longhuo
   Chen, Qian
TI miR 365 Ameliorates Dexamethasone Induced Suppression of Osteogenesis in
   MC3T3 E1 Cells by Targeting HDAC4
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE miR 365; glucocorticoid; osteoporosis; histone deacetylase 4
ID HISTONE DEACETYLASE 4; GLUCOCORTICOID INDUCED OSTEOPOROSIS; OSTEOBLAST
   DIFFERENTIATION; BONE FORMATION; TRANSCRIPTION; DISEASE; INHIBITION;
   MATURATION; REPRESSION; THERAPY
AB Glucocorticoid administration is the leading cause of secondary osteoporosis. In this study, we tested the hypotheses that histone deacetylase 4 (HDAC4) is associated with glucocorticoid induced bone loss and that HDAC4 dependent bone loss can be ameliorated by miRNA 365. Our previous studies showed that miR 365 mediates mechanical stimulation of chondrocyte proliferation and differentiation by targeting HDAC4. However, it is not clear whether miR 365 has an effect on glucocorticoid induced osteoporosis. We have shown that, in MC3T3 E1 osteoblasts, dexamethasone (DEX) treatment decreased the expression of miR 365, which is accompanied by the decrease of cell viability in a dose dependent manner. Transfection of miR 365 ameliorated DEX induced inhibition of MC3T3 E1 cell viability and alkaline phosphatase activity, and attenuated the suppressive effect of DEX on runt related transcription factor 2 (Runx2), osteopontin (OPN), and collagen 1a1 (Col1a1) osteogenic gene expression. In addition, miR 365 decreased the expression of HDAC4 mRNA and protein by direct targeting the 3 ' untranslated regions (3 ' UTR) of HDAC4 mRNA in osteoblasts. MiR 365 increased Runx2 expression and such stimulatory effect could be reversed by HDAC4 over expression in osteoblasts. Collectively, our findings indicate that miR 365 ameliorates DEX induced suppression of cell viability and osteogenesis by regulating the expression of HDAC4 in osteoblasts, suggesting miR 365 might be a novel therapeutic agent for treatment of glucocorticoid induced osteoporosis.
C1 [Xu, Daohua] Guangdong Med Univ, Dept Pharmacol, Dongguan 523808, Peoples R China.
   [Xu, Daohua; Gao, Yun; Hu, Nan; Wu, Longhuo; Chen, Qian] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Dept Orthopaed, Providence, RI 02903 USA.
   [Hu, Nan] Xi An Jiao Tong Univ, Dept Rheumatol, Affiliated Hosp 1, Xian 710061, Peoples R China.
   [Wu, Longhuo] Gannan Med Univ, Coll Pharm, Ganzhou 341000, Peoples R China.
   [Chen, Qian] Xi An Jiao Tong Univ, Bone & Joint Res Ctr, Affiliated Hosp 1, Xian 710061, Peoples R China.
   [Chen, Qian] Xi An Jiao Tong Univ, Frontier Inst Sci & Technol, Xian 710061, Peoples R China.
C3 Guangdong Medical University; Lifespan Health Rhode Island; Rhode Island
   Hospital; Brown University; Xi'an Jiaotong University; Gannan Medical
   University; Xi'an Jiaotong University; Xi'an Jiaotong University
RP Chen, Q (通讯作者)，Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Dept Orthopaed, Providence, RI 02903 USA.; Chen, Q (通讯作者)，Xi An Jiao Tong Univ, Bone & Joint Res Ctr, Affiliated Hosp 1, Xian 710061, Peoples R China.; Chen, Q (通讯作者)，Xi An Jiao Tong Univ, Frontier Inst Sci & Technol, Xian 710061, Peoples R China.
EM daohuaxu@gdmu.edu.com; yun_gao@brown.edu; nan_hu@brown.edu;
   fjwlhwlh@hqu.edu.cn; qian_chen@brown.edu
RI Chen, Qian/C 4354 2011; hu, nan/KHE 4563 2024
FU National Institutes of Health [P20GM104937]; Natural Science Foundation
   of Guangdong Province [2014A030313534]; China Scholarship Council
FX The project was financially supported by National Institutes of Health
   (P20GM104937), Natural Science Foundation of Guangdong Province
   (2014A030313534), and China Scholarship Council.
CR Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674
   Cao K, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0491 3
   Desiderio V, 2014, INT J BIOCHEM CELL B, V51, P75, DOI 10.1016/j.biocel.2014.03.025
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Dudakovic A, 2013, J BIOL CHEM, V288, P28783, DOI 10.1074/jbc.M113.489732
   Gordon JAR, 2015, BONE, V81, P739, DOI 10.1016/j.bone.2015.03.011
   Guan YJ, 2011, FASEB J, V25, P4457, DOI 10.1096/fj.11 185132
   Guo Q, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.22
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729
   Ko JY, 2013, BONE, V57, P468, DOI 10.1016/j.bone.2013.09.019
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Liu YZ, 2015, CLIN INTERV AGING, V10, P1245, DOI 10.2147/CIA.S85225
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rizzoli R, 2015, NAT REV RHEUMATOL, V11, P98, DOI 10.1038/nrrheum.2014.188
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Shimizu E, 2010, J BIOL CHEM, V285, P9616, DOI 10.1074/jbc.M109.094862
   Smith SS, 2013, ENDOCRINOLOGY, V154, P253, DOI 10.1210/en.2012 1476
   Takahashi M, 2010, LIFE SCI, V86, P24, DOI 10.1016/j.lfs.2009.10.020
   Teitelbaum SL, 2012, NAT REV ENDOCRINOL, V8, P451, DOI 10.1038/nrendo.2012.89
   van der Goes MC, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4686
   Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024
   Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Yang X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040436
   Zhao WG, 2015, MOL CELL BIOCHEM, V405, P125, DOI 10.1007/s11010 015 2404 4
   Zhao WG, 2015, INT J MOL SCI, V16, P11699, DOI 10.3390/ijms160511699
   Zhao ZR, 2005, MOL THER, V12, P247, DOI 10.1016/j.ymthe.2005.03.009
NR 30
TC 12
Z9 13
U1 1
U2 10
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2017
VL 18
IS 5
AR 977
DI 10.3390/ijms18050977
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EY6SQ
UT WOS:000404113900084
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Hu, Y
   Li, JC
   Zhu, XJ
   Li, YH
   Zhang, S
   Chen, XJ
   Gao, YH
   Li, FY
AF Hu, Yan
   Li, Jiachang
   Zhu, Xingjun
   Li, Yuhao
   Zhang, Shuang
   Chen, Xiaojing
   Gao, Yanhong
   Li, Fuyou
TI 17β Estradiol Loaded PEGlyated Upconversion Nanoparticles as a
   Bone Targeted Drug Nanocarrier
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE PEGlyated upconversion nanoparticles; 17 beta estradiol; drug delivery;
   imaging; osteoporosis; osteoblast
ID HORMONE REPLACEMENT THERAPY; LUMINESCENCE; CELLS; DELIVERY;
   DIFFERENTIATION; NANOPHOSPHORS; MICROSPHERES; EXPRESSION; FRACTURES;
   APOPTOSIS
AB Hormone replacement therapy (HRT) plays an important role in the treatment and prevention of osteoporosis. Here, 17 beta estradiol (E2) loaded PEGlyated upconversion nanoparticles (E2 UCNP@pPEG) were synthesized that retained E2 bioactivity and improved delivery efficiency over a relatively long time period. E2 UCNP@pPEG was synthesized and characterized using transmission electron microscopy (TEM), X ray diffraction (XRD), and Fourier transform infrared (FTIR), among other methods. The loading efficiency of E2 was determined to be 14.5 wt %, and the nanocarrier effectively facilitated sustained release. Confocal upconversion luminescence (UCL) imaging using the OAT 980 nm laser as excitation resource revealed significant interactions of E2 UCNP@ pPEG with preosteoblasts. E2 UCNP@pPEG treatment of preosteoblasts induced positive effects on differentiation, matrix maturation, and mineralization. Moreover, in situ and ex vivo UCL imaging studies disclosed that E2 encapsulated in the nanocomposite was passively delivered to bone. Our results collectively suggest that this nanoreservoir provides an effective drug loading system for hormonelike drug delivery and support its considerable potential as a therapeutic agent for osteoporosis.
C1 [Hu, Yan; Zhang, Shuang; Chen, Xiaojing; Gao, Yanhong] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Geriatr, Shanghai 200092, Peoples R China.
   [Li, Jiachang; Zhu, Xingjun; Li, Yuhao; Li, Fuyou] Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
   [Li, Jiachang; Zhu, Xingjun; Li, Yuhao; Li, Fuyou] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China.
   [Li, Jiachang; Zhu, Xingjun; Li, Yuhao; Li, Fuyou] Fudan Univ, Adv Mat Lab, Shanghai 200433, Peoples R China.
C3 Shanghai Jiao Tong University; Fudan University; Fudan University; Fudan
   University
RP Gao, YH (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Geriatr, Shanghai 200092, Peoples R China.
EM yhgao2010@yahoo.com; fyli@fudan.edu.cn
RI 李, 富友/ISB 0234 2023; Li, Yuhao/O 6260 2015
OI Li, Fuyou/0000 0001 8729 1979; Li, Yuhao/0000 0001 7146 8645; 
FU State Key Basic Research Program of China [2015CB931800]; National
   Science Foundation of China [81101360, 21231004]; Shanghai Science and
   Technology Commission [13NM1401101]; CAS/SAFEA International Partnership
   Program for Creative Research Teams
FX We thank the State Key Basic Research Program of China (2015CB931800),
   National Science Foundation of China (81101360 and 21231004), Shanghai
   Science and Technology Commission (13NM1401101), and the CAS/SAFEA
   International Partnership Program for Creative Research Teams for
   financial support.
CR Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chen GY, 2010, ACS NANO, V4, P3163, DOI 10.1021/nn100457j
   Dai YL, 2012, BIOMATERIALS, V33, P8704, DOI 10.1016/j.biomaterials.2012.08.029
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Gray S, 2003, LANCET, V362, P1332, DOI 10.1016/S0140 6736(03)14598 9
   Guo HC, 2011, LANGMUIR, V27, P2854, DOI 10.1021/la102872v
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Hou ZY, 2013, LANGMUIR, V29, P9473, DOI 10.1021/la402080y
   Jokerst JV, 2011, NANOMEDICINE UK, V6, P715, DOI [10.2217/NNM.11.19, 10.2217/nnm.11.19]
   Kim H, 2015, J BONE MINER METAB, V33, P30, DOI 10.1007/s00774 014 0567 9
   Lacey JV, 2002, JAMA J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334
   Liu JN, 2014, ANGEW CHEM INT EDIT, V53, P4551, DOI 10.1002/anie.201400900
   Liu Q, 2013, NAT PROTOC, V8, P2033, DOI 10.1038/nprot.2013.114
   MOGHIMI SM, 1993, BIOCHIM BIOPHYS ACTA, V1157, P233, DOI 10.1016/0304 4165(93)90105 H
   Mueck AO, 2012, CLIMACTERIC, V15, P11, DOI 10.3109/13697137.2012.669624
   Mura S, 2013, NAT MATER, V12, P991, DOI [10.1038/NMAT3776, 10.1038/nmat3776]
   PARFITT AM, 1984, CALCIFIED TISSUE INT, V36, pS37, DOI 10.1007/BF02406132
   Poenaru DV, 2014, INT ORTHOP, V38, P2329, DOI 10.1007/s00264 014 2407 x
   PORTER CJH, 1992, FEBS LETT, V305, P62, DOI 10.1016/0014 5793(92)80655 Z
   Prencipe G, 2009, J AM CHEM SOC, V131, P4783, DOI 10.1021/ja809086q
   Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756 3282(97)00276 7
   Rickard DJ, 1999, J CELL BIOCHEM, P123
   Riggs BL, 2002, J BONE MINER RES, V17, P11, DOI 10.1359/jbmr.2002.17.1.11
   Shang ZZ, 2014, INT J ORAL SCI, V6, P142, DOI 10.1038/ijos.2014.2
   Tessmar JK, 2007, MACROMOL BIOSCI, V7, P23, DOI 10.1002/mabi.200600096
   Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128
   Wang C, 2011, BIOMATERIALS, V32, P1110, DOI 10.1016/j.biomaterials.2010.09.069
   Wang F, 2010, ANALYST, V135, P1839, DOI 10.1039/c0an00144a
   Wang F, 2011, NAT MATER, V10, P968, DOI [10.1038/nmat3149, 10.1038/NMAT3149]
   Wang F, 2010, ANGEW CHEM INT EDIT, V49, P7456, DOI 10.1002/anie.201003959
   Wang Y, 2009, OSTEOPOROSIS INT, V20, P1651, DOI 10.1007/s00198 009 0925 y
   Welsher K, 2009, NAT NANOTECHNOL, V4, P773, DOI [10.1038/nnano.2009.294, 10.1038/NNANO.2009.294]
   Yang DM, 2013, BIOMATERIALS, V34, P1601, DOI 10.1016/j.biomaterials.2012.11.004
   Yao LM, 2012, ADV FUNCT MATER, V22, P2667, DOI 10.1002/adfm.201102981
   Yu MX, 2009, ANAL CHEM, V81, P930, DOI 10.1021/ac802072d
   Zhou J, 2015, CHEM REV, V115, P395, DOI 10.1021/cr400478f
   Zhou J, 2012, CHEM SOC REV, V41, P1323, DOI 10.1039/c1cs15187h
   Zhou S, 2001, J CELL BIOCHEM, P144
   Zhu XJ, 2014, RSC ADV, V4, P23580, DOI 10.1039/c4ra01815j
NR 39
TC 27
Z9 29
U1 1
U2 114
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD JUL 29
PY 2015
VL 7
IS 29
BP 15803
EP 15811
DI 10.1021/acsami.5b02831
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA CO1ES
UT WOS:000358897200014
PM 26133323
DA 2025 08 17
ER

PT J
AU Li, Y
   Yu, C
   Shen, GS
   Li, GF
   Shen, JK
   Xu, YJ
   Gong, JP
AF Li, Yong
   Yu, Chen
   Shen, Guangsi
   Li, Guangfei
   Shen, Junkang
   Xu, Youjia
   Gong, Jianping
TI Sirt3 MnSOD axis represses nicotine induced mitochondrial oxidative
   stress and mtDNA damage in osteoblasts
SO ACTA BIOCHIMICA ET BIOPHYSICA SINICA
LA English
DT Article
DE nicotine; osteoblasts; mitochondrial oxidative stress; mtDNA damage;
   MnSOD; Sirt3
ID MESENCHYMAL STEM CELLS; POSTMENOPAUSAL OSTEOPOROSIS; HYDROGEN PEROXIDE;
   BETA CATENIN; IN VITRO; BONE; DIFFERENTIATION; AUTOPHAGY; ARTHRITIS;
   PATHWAY
AB Increasing evidence has suggested an important role played by reactive oxygen species in the pathogenesis of osteoporosis. Tobacco smoking is an important risk factor for the development of osteoporosis, and nicotine is one of the major components in tobacco. However, the mechanism by which nicotine promotes osteoporosis is not fully understood. Here, in this study, we found that nicotine induced mitochondrial oxidative stress and mitochondrial DNA (mtDNA) damage in osteoblasts differentiated from mouse mesenchymal stem cell. The activity of MnSOD, one of the mitochondrial anti oxidative enzymes, was significantly reduced by nicotine due to the reduced level of Sirt3. More over, it was also found that Sirt3 could promote MnSOD activity by deacetylating MnSOD. Finally, Mn(III) tetrakis (4 benzoic acid) porphyrin (MnTBAP, a MnSOD mimetic) was found to markedly reduce the effect of nicotine on osteoblasts. In summary, Sirt3 MnSOD axis was identified as a negative component in nicotine induced mitochondrial oxidative stress and mtDNA damage, and MnTBAP may serve as a potential therapeutic drug for osteoporosis.
C1 [Li, Yong; Shen, Junkang; Gong, Jianping] Soochow Univ, Dept Radiol, Affiliated Hosp 2, Suzhou 215004, Peoples R China.
   [Yu, Chen; Shen, Guangsi; Li, Guangfei; Xu, Youjia] Soochow Univ, Dept Orthopaed, Affiliated Hosp 2, Suzhou 215004, Peoples R China.
C3 Soochow University   China; Soochow University   China
RP Gong, JP (通讯作者)，Soochow Univ, Dept Radiol, Affiliated Hosp 2, Suzhou 215004, Peoples R China.
EM unionlab@yeah.net; jianping_gonggong@126.com
RI Li, Guangfei/AAA 2948 2020
FU National Natural Science Foundation of China [81273090, 81302438];
   Natural Science Foundation of Jiangsu Province [BK2012608]; Research and
   Innovation Project for College Graduates of Jiangsu Province
   [CX10B_053Z]; Foundation Program of Suzhou Key Laboratory of High
   Technology [SZS201208]
FX This work was supported by the grants from the National Natural Science
   Foundation of China (Nos. 81273090 and 81302438), the Natural Science
   Foundation of Jiangsu Province (No. BK2012608), Research and Innovation
   Project for College Graduates of Jiangsu Province (No. CX10B_053Z), and
   the Foundation Program of Suzhou Key Laboratory of High Technology (No.
   SZS201208).
CR Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Bartolomé A, 2013, BIOCHEM J, V455, P329, DOI 10.1042/BJ20130562
   Bause AS, 2013, EXP GERONTOL, V48, P634, DOI 10.1016/j.exger.2012.08.007
   Bruin JE, 2008, FREE RADICAL BIO MED, V44, P1919, DOI 10.1016/j.freeradbiomed.2008.02.010
   BUI LM, 1995, TOXICOLOGY, V98, P57, DOI 10.1016/0300 483X(95)91102 U
   Cervellati C, 2013, CLIN CHEM LAB MED, V51, P333, DOI 10.1515/cclm 2012 0095
   Choi EM, 2014, PHYTOTHER RES, V28, P880, DOI 10.1002/ptr.5071
   Cuzzocrea S, 1999, BRIT J PHARMACOL, V128, P1241, DOI 10.1038/sj.bjp.0702826
   Dolev E, 1997, Harefuah, V132, P511
   Dölle C, 2013, FEBS J, V280, P3530, DOI 10.1111/febs.12304
   Engler A, 2014, J MOL MED, V92, P757, DOI 10.1007/s00109 014 1139 0
   Han C, 2013, EXP GERONTOL, V48, P1091, DOI 10.1016/j.exger.2013.02.014
   Huang W, 2012, ACTA PHARMACOL SIN, V33, P668, DOI 10.1038/aps.2011.189
   Kallala R, 2013, EXPERT OPIN DRUG SAF, V12, P209, DOI 10.1517/14740338.2013.770471
   Kim BS, 2012, LIFE SCI, V90, P109, DOI 10.1016/j.lfs.2011.10.019
   Kim DH, 2013, J BONE MINER METAB, V31, P44, DOI 10.1007/s00774 012 0382 0
   Kim SJ, 2014, J BIOL CHEM, V289, P6165, DOI 10.1074/jbc.M113.515130
   Krum SA, 2008, EMBO J, V27, P535, DOI 10.1038/sj.emboj.7601984
   Lin JT, 2013, BIOCHEM BIOPH RES CO, V441, P897, DOI 10.1016/j.bbrc.2013.10.153
   Ma L, 2011, CLIN ORAL IMPLAN RES, V22, P338, DOI 10.1111/j.1600 0501.2010.02088.x
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Qandil R, 1997, J Can Dent Assoc, V63, P187
   Qandil R, 1997, J CAN DENT ASSOC, V63, P94
   She F, 2014, MOL MED REP, V9, P493, DOI 10.3892/mmr.2013.1832
   Simic P, 2013, EMBO MOL MED, V5, P430, DOI 10.1002/emmm.201201606
   Srivastava S, 2012, MOL CELL ENDOCRINOL, V361, P153, DOI 10.1016/j.mce.2012.04.002
   Talaulikar VS, 2012, J OBSTET GYNAECOL RE, V38, P253, DOI 10.1111/j.1447 0756.2011.01629.x
   Tang XQ, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00175
   Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013
   Wei W, 2011, MOL CELL BIOL, V31, P4692, DOI 10.1128/MCB.05979 11
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Yang YH, 2014, FREE RADICAL BIO MED, V77, P10, DOI 10.1016/j.freeradbiomed.2014.08.028
NR 32
TC 38
Z9 42
U1 2
U2 28
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1672 9145
EI 1745 7270
J9 ACTA BIOCH BIOPH SIN
JI Acta Biochim. Biophys. Sin.
PD APR
PY 2015
VL 47
IS 4
DI 10.1093/abbs/gmv013
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CH1XT
UT WOS:000353817500010
PM 25757953
DA 2025 08 17
ER

PT J
AU Zhou, HJ
   Wei, J
   Wu, XH
   Shi, JL
   Liu, CS
   Jia, JF
   Dai, CL
   Gan, Q
AF Zhou, Huanjun
   Wei, Jie
   Wu, Xiaohui
   Shi, Jianlin
   Liu, Changsheng
   Jia, Junfeng
   Dai, Chenglong
   Gan, Qi
TI The bio functional role of calcium in mesoporous silica xerogels on the
   responses of osteoblasts in vitro
SO JOURNAL OF MATERIALS SCIENCE MATERIALS IN MEDICINE
LA English
DT Article
ID NITRIC OXIDE SYNTHASE; CONTROLLED RELEASE; BIOACTIVE GLASSES; OSTEOGENIC
   DIFFERENTIATION; EXTRACELLULAR CALCIUM; BONE FORMATION; EXPRESSION;
   CELLS; PROLIFERATION; ADHESION
AB Mesoporous silica xerogels with various amount of calcium (0, 5, 10 and 15%, named m SXC0, m SXC5, m SXC10 and m SXC15, respectively) were synthesized by template sol gel methods, and cell responses to m SXCs were studied using murine pre osteoblast MC3T3 E1 in vitro. The results showed that cell morphology was not affected by m SXCs indicating good biocompatibility. Furthermore, cell proliferation ratio on the m SXCs increased over time, among which m SXC10 was highest. NO production obviously rose with the increase of Ca content in m SXCs. ALP activity and PGE(2) level on m SXC5 significantly improved compared with m SXC0 while decreased with the increase of Ca content for m SXC10 and m SXC15. No obvious discrepancy on osteopontin mRNA expressions was observed among m SXCs. The collagen I and osteocalcin mRNA expression on m SXC5 were up regulated, while decreased on m SXC15 evidently. The phosphorylation level of ERK 1/2 for the m SXC10 was highest after 7 days. In conclusion, calcium in m SXCs plays an important role in osteoblast activity, which indicates mesoporous silica xerogel containing appropriate calcium could stimulate osteoblast proliferation, differentiation, gene expression via the activation of ERK 1/2 signaling pathway, and shows great prospects in bone regeneration field using as a drug controlled release filler.
C1 [Zhou, Huanjun; Wei, Jie; Wu, Xiaohui; Shi, Jianlin; Liu, Changsheng; Jia, Junfeng; Dai, Chenglong; Gan, Qi] E China Univ Sci & Technol, Ctr Biomed Mat, Key Lab Ultrafine Mat Minist Educ & Engn, Minist Educ, Shanghai 200237, Peoples R China.
C3 East China University of Science & Technology
RP Liu, CS (通讯作者)，E China Univ Sci & Technol, Ctr Biomed Mat, Key Lab Ultrafine Mat Minist Educ & Engn, Minist Educ, Shanghai 200237, Peoples R China.
EM liucs@ecust.edu.cn
RI , jianlin Shi/HTM 8889 2023; Wu, Xiao'Hui/MNO 3883 2025
FU National Natural Science Foundation of China [30670568, 50732002];
   Program of Shanghai Subject Chief Scientist [07XD14008]; Shanghai
   Nanotechnology Special Foundation [0852nm02700]; Program for Changjiang
   Scholars and Innovative Research Team in University
FX The authors are indebted to the financial support from the National
   Natural Science Foundation of China (No. 30670568, 50732002), Program of
   Shanghai Subject Chief Scientist (No. 07XD14008), and Shanghai
   Nanotechnology Special Foundation (No. 0852nm02700), Major Program of
   National Natural Science Foundation of China (No. 50732002), Program for
   Changjiang Scholars and Innovative Research Team in University.
CR Bernhardt A, 2008, J MATER SCI MATER M, V19, P269, DOI 10.1007/s10856 006 0059 0
   Bosetti M, 2003, J BIOMED MATER RES A, V64A, P189, DOI 10.1002/jbm.a.10415
   Choudhary S, 2003, J BONE MINER RES, V18, P1813, DOI 10.1359/jbmr.2003.18.10.1813
   Conconi MT, 2002, INT J MOL MED, V10, P451
   Costa Pinto AR, 2009, BIOMACROMOLECULES, V10, P2067, DOI 10.1021/bm9000102
   Czarnobaj K, 2008, DRUG DELIV, V15, P485, DOI 10.1080/10717540802321495 
   Czarnobaj K, 2008, J BIOMED MATER RES B, V87B, P114, DOI 10.1002/jbm.b.31076
   Czarnobaj K, 2007, J MATER SCI MATER M, V18, P2041, DOI 10.1007/s10856 007 3139 x
   De Benedittis A, 1999, INT J ARTIF ORGANS, V22, P516, DOI 10.1177/039139889902200711
   Giannoudis PV, 2005, INJURY, V36, P20, DOI 10.1016/j.injury.2005.07.029
   Hoinkis E, 2005, LANGMUIR, V21, P7366, DOI 10.1021/la050580j
   Huang ZM, 2001, J BIOL CHEM, V276, P21351, DOI 10.1074/jbc.M010921200
   HUKKANEN M, 1995, ENDOCRINOLOGY, V136, P5445, DOI 10.1210/en.136.12.5445
   Jäger M, 2008, J ORTHOP RES, V26, P1440, DOI 10.1002/jor.20565
   Khoshniat S, 2008, BONE, V42, pS24, DOI 10.1016/j.bone.2007.12.027
   Koller G, 2007, J MATER SCI MATER M, V18, P2291, DOI 10.1007/s10856 007 3137 z
   Lam V, 2003, BLOOD, V102, P1405, DOI 10.1182/blood 2002 10 3176
   Lazáry A, 2007, BIOMATERIALS, V28, P393, DOI 10.1016/j.biomaterials.2006.09.002
   Lee EJ, 2009, BIOMATERIALS, V30, P743, DOI 10.1016/j.biomaterials.2008.10.025
   Lefebvre L, 2008, ACTA BIOMATER, V4, P1894, DOI 10.1016/j.actbio.2008.05.019
   Li XS, 2008, J INORG MATER, V23, P327, DOI 10.3724/SP.J.1077.2008.00327
   López Alvarez M, 2009, J MATER SCI MATER M, V20, P1131, DOI 10.1007/s10856 008 3658 0
   Lossdörfer S, 2004, BIOMATERIALS, V25, P2547, DOI 10.1016/j.biomaterials.2003.09.094
   MacPherson H, 1999, BONE, V24, P179, DOI 10.1016/S8756 3282(98)00173 2
   Matsuoka H, 1999, J BIOMED MATER RES, V47, P176, DOI 10.1002/(SICI)1097 4636(199911)47:2<176::AID JBM7>3.0.CO;2 Z
   Prokopowicz M, 2007, J PHARM PHARMACOL, V59, P1365, DOI 10.1211/jpp.59.10.0006
   Prokopowicz M, 2009, ACTA BIOMATER, V5, P193, DOI 10.1016/j.actbio.2008.07.027
   Quarles LD, 1997, J BONE MINER RES, V12, P393, DOI 10.1359/jbmr.1997.12.3.393
   Radin S, 2005, BIOMATERIALS, V26, P1043, DOI 10.1016/j.biomaterials.2004.04.004
   Radin S, 2002, BIOMATERIALS, V23, P3113, DOI 10.1016/S0142 9612(02)00051 0
   RIANCHO JA, 1995, J BONE MINER RES, V10, P439
   Santos EM, 1998, J BIOMED MATER RES, V41, P87, DOI 10.1002/(SICI)1097 4636(199807)41:1<87::AID JBM11>3.0.CO;2 E
   Sepulveda P, 2002, J BIOMED MATER RES, V61, P301, DOI 10.1002/jbm.10207
   Silver IA, 2001, BIOMATERIALS, V22, P175, DOI 10.1016/S0142 9612(00)00173 3
   Sowa H, 2002, J BONE MINER RES, V17, P1190, DOI 10.1359/jbmr.2002.17.7.1190
   Tan YF, 2007, J MATER SCI MATER M, V18, P2237, DOI 10.1007/s10856 006 0058 1
   Vallet Regí M, 2007, ANGEW CHEM INT EDIT, V46, P7548, DOI 10.1002/anie.200604488
   Walsh MF, 2003, CELL PHYSIOL BIOCHEM, V13, P135, DOI 10.1159/000071864
   Wang JW, 2009, J BIOMED MATER RES A, V90A, P664, DOI 10.1002/jbm.a.32128
   Wang Q, 1998, CLIN ORTHOP RELAT R, P259
   Xynos ID, 2000, CALCIFIED TISSUE INT, V67, P321, DOI 10.1007/s002230001134
   Xynos ID, 2000, BIOCHEM BIOPH RES CO, V276, P461, DOI 10.1006/bbrc.2000.3503
   Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257
NR 43
TC 29
Z9 33
U1 0
U2 31
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957 4530
EI 1573 4838
J9 J MATER SCI MATER M
JI J. Mater. Sci. Mater. Med.
PD JUL
PY 2010
VL 21
IS 7
BP 2175
EP 2185
DI 10.1007/s10856 010 4083 8
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 621PH
UT WOS:000279592600019
PM 20411307
DA 2025 08 17
ER

PT J
AU Pöllinger, B
   Junt, T
   Metzler, B
   Walker, UA
   Tyndall, A
   Allard, C
   Bay, S
   Keller, R
   Raulf, F
   Di Padova, F
   O'Reilly, T
   Horwood, NJ
   Patel, DD
   Littlewood Evans, A
AF Poellinger, Bernadette
   Junt, Tobias
   Metzler, Barbara
   Walker, Ulrich A.
   Tyndall, Alan
   Allard, Cyril
   Bay, Serkan
   Keller, Roland
   Raulf, Friedrich
   Di Padova, Franco
   O'Reilly, Terrence
   Horwood, Nicole J.
   Patel, Dhavalkumar D.
   Littlewood Evans, Amanda
TI Th17 Cells, Not IL 17<SUP>+</SUP> γδ T Cells, Drive Arthritic Bone
   Destruction in Mice and Humans
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID COLLAGEN INDUCED ARTHRITIS; RHEUMATOID ARTHRITIS; AUTOIMMUNE
   INFLAMMATION; MONOCLONAL ANTIBODY; JOINT INFLAMMATION; DIFFERENTIATION
   FACTOR; IL 23 RECEPTOR; CUTTING EDGE; DOUBLE BLIND; II COLLAGEN
AB The mechanism whereby IL 17 drives rheumatoid arthritis remains incompletely understood. We demonstrate that anti IL 17 therapy in collagen induced arthritis ameliorates bone damage by reducing the number of osteoclasts in joints. We found equal numbers of CD4(+) Th17 and IL 17 producing gamma delta T cells in the joints of arthritic mice, and in vitro, both populations similarly induced osteoclastogenesis. However, individual depletion and adoptive transfer studies revealed that in vivo, Th17 cells dominated with regard to bone destruction. Unlike gamma delta T cells, Th17 cells were found in apposition to tartrate resistant acid phosphatase positive osteoclasts in subchondral areas of inflamed joints, a pattern reproduced in patient biopsies. This localization was caused by Ag specific retention, because OVA primed Th17 cells showed a gamma delta T cell like diffuse distribution. Because IL 23, as produced by osteoclasts, enhanced T cell mediated osteoclastogenesis, we propose that Ag specific juxtaposition is key to foster the molecular cross talk of Th17 cells and osteoclasts, thus driving arthritic bone destruction. The Journal of Immunology, 2011, 186: 2602 2612.
C1 [Poellinger, Bernadette; Junt, Tobias; Metzler, Barbara; Allard, Cyril; Bay, Serkan; Keller, Roland; Raulf, Friedrich; Di Padova, Franco; Patel, Dhavalkumar D.; Littlewood Evans, Amanda] Novartis Inst BioMed Res, Dept Autoimmun Transplantat & Inflammat, Forum 1 Novartis Campus, CH 4002 Basel, Switzerland.
   [Walker, Ulrich A.; Tyndall, Alan] Univ Basel, Felix Platter Hosp, Dept Rheumatol, CH 4012 Basel, Switzerland.
   [O'Reilly, Terrence] Novartis Inst BioMed Res, Dept Oncol, CH 4002 Basel, Switzerland.
   [Horwood, Nicole J.] Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol, London W6 8LH, England.
C3 Novartis; University of Basel; Novartis; University of Oxford; Kennedy
   Institute for Rheumatology; Imperial College London
RP Littlewood Evans, A (通讯作者)，Novartis Inst BioMed Res, Dept Autoimmun Transplantat & Inflammat, Forum 1 Novartis Campus, CH 4002 Basel, Switzerland.
EM amanda.littlewood evans@novartis.com
RI Walker, Ulrich/KMA 2190 2024; Horwood, Nicole/B 4351 2009; Junt,
   Tobias/AAE 4389 2021
OI Horwood, Nicole/0000 0002 6344 1677; 
FU Medical Research Council [G0900160] Funding Source: researchfish;
   Medical Research Council [G0900160] Funding Source: Medline; MRC
   [G0900160] Funding Source: UKRI
CR Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200
   Awasthi A, 2009, J IMMUNOL, V182, P5904, DOI 10.4049/jimmunol.0900732
   Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949
   Bush KA, 2002, ARTHRITIS RHEUM US, V46, P802, DOI 10.1002/art.10173
   Chabaud M, 1999, ARTHRITIS RHEUM US, V42, P963, DOI 10.1002/1529 0131(199905)42:5<963::AID ANR15>3.0.CO;2 E
   Corthay A, 1999, INT IMMUNOL, V11, P1065, DOI 10.1093/intimm/11.7.1065
   Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355
   Emery P, 2008, RHEUMATOLOGY, V47, pII16
   Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593
   Genant HK, 2008, ANN RHEUM DIS, V67, P1084, DOI 10.1136/ard.2007.085084
   Genovese MC, 2010, ARTHRITIS RHEUM US, V62, P929, DOI 10.1002/art.27334
   GOLDSCHMIDT TJ, 1990, IMMUNOLOGY, V69, P508
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   HOM JT, 1986, J IMMUNOL, V136, P769
   HORNEFF G, 1991, ARTHRITIS RHEUM, V34, P129, DOI 10.1002/art.1780340202
   Ito Y, 2009, ARTHRITIS RHEUM US, V60, P2294, DOI 10.1002/art.24687
   Jones CE, 2002, AM J RESP CELL MOL, V26, P748, DOI 10.1165/ajrcmb.26.6.4757
   Keystone E, 2002, ANN RHEUM DIS, V61, P43
   Kim HR, 2007, RHEUMATOLOGY, V46, P57, DOI 10.1093/rheumatology/kel159
   Kim HR, 2007, SCAND J RHEUMATOL, V36, P259, DOI 10.1080/03009740701286813
   Kirkham BW, 2006, ARTHRITIS RHEUM, V54, P1122, DOI 10.1002/art.21749
   Koenders MI, 2005, AM J PATHOL, V167, P141, DOI 10.1016/S0002 9440(10)62961 6
   Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018
   Korhonen R, 2009, BASIC CLIN PHARMACOL, V104, P276, DOI 10.1111/j.1742 7843.2009.00375.x
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Kremer JM, 2008, ARTHRITIS RHEUM, V58, P953, DOI 10.1002/art.23397
   Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257
   Li HY, 2010, BLOOD, V116, P210, DOI 10.1182/blood 2009 11 255026
   Lochner M, 2008, J EXP MED, V205, P1381, DOI 10.1084/jem.20080034
   Lubberts E, 2004, ARTHRITIS RHEUM US, V50, P650, DOI 10.1002/art.20001
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Miossec P, 2007, ARTHRITIS RHEUM US, V56, P2111, DOI 10.1002/art.22733
   Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896
   MYERS LK, 1993, J IMMUNOL, V151, P500
   Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173
   PETERMAN GM, 1993, J IMMUNOL, V151, P6546
   Quinn JMW, 2008, J IMMUNOL, V181, P5720, DOI 10.4049/jimmunol.181.8.5720
   Rachitskaya AV, 2008, J IMMUNOL, V180, P5167, DOI 10.4049/jimmunol.180.8.5167
   Roark CL, 2007, J IMMUNOL, V179, P5576, DOI 10.4049/jimmunol.179.8.5576
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Shibata K, 2007, J IMMUNOL, V178, P4466, DOI 10.4049/jimmunol.178.7.4466
   Stark MA, 2005, IMMUNITY, V22, P285, DOI 10.1016/j.immuni.2005.01.011
   Tak P. P., 2009, ARTHRITIS RHEUM S10, V21
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   TARTAKOVSKY B, 1989, J IMMUNOL, V142, P2695
   TARTAKOVSKY B, 1986, J IMMUNOL, V137, P160
   Tesmer LA, 2008, IMMUNOL REV, V223, P87, DOI 10.1111/j.1600 065X.2008.00628.x
   VANDERLUBBE PA, 1995, ARTHRITIS RHEUM, V38, P1097, DOI 10.1002/art.1780380812
   WANO Y, 1987, J CLIN INVEST, V80, P911, DOI 10.1172/JCI113152
   Wegner N, 2010, IMMUNOL REV, V233, P34, DOI 10.1111/j.0105 2896.2009.00850.x
   Yago T, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2297
   Yago T, 2009, J CELL BIOCHEM, V108, P947, DOI 10.1002/jcb.22326
NR 53
TC 104
Z9 112
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022 1767
EI 1550 6606
J9 J IMMUNOL
JI J. Immunol.
PD FEB 15
PY 2011
VL 186
IS 4
BP 2602
EP 2612
DI 10.4049/jimmunol.1003370
PG 11
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 715KF
UT WOS:000286882700081
PM 21217016
DA 2025 08 17
ER

PT J
AU Kanis, JA
   McCloskey, E
   Branco, J
   Brandi, ML
   Dennison, E
   Devogelaer, JP
   Ferrari, S
   Kaufman, JM
   Papapoulos, S
   Reginster, JY
   Rizzoli, R
AF Kanis, J. A.
   McCloskey, E.
   Branco, J.
   Brandi, M.  L.
   Dennison, E.
   Devogelaer, J.  P.
   Ferrari, S.
   Kaufman, J.  M.
   Papapoulos, S.
   Reginster, J.  Y.
   Rizzoli, R.
TI Goal directed treatment of osteoporosis in Europe
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE BMD; Bone marker; FRAX; Management strategy; Osteoporosis;
   Target to treat; Treat to target
ID BONE MINERAL DENSITY; VERTEBRAL FRACTURE RISK;
   AMERICAN DIABETES ASSOCIATION; PARATHYROID HORMONE 1 34; POSTMENOPAUSAL
   WOMEN; RHEUMATOID ARTHRITIS; HIP FRACTURE; RALOXIFENE TREATMENT;
   STRONTIUM RANELATE; BLOOD PRESSURE
AB Despite the proven predictive ability of bone mineral density, Fracture Risk Assessment Tool (FRAXA (R)), bone turnover markers, and fracture for osteoporotic fracture, their use as targets for treatment of osteoporosis is limited.
   Treat to target is a strategy applied in several fields of medicine and has recently become an area of interest in the management of osteoporosis. Its role in this setting remains controversial. This article was prepared following a European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group meeting convened under the auspices of the International Osteoporosis Foundation (IOF) to discuss the feasibility of applying such a strategy in osteoporosis in Europe.
   Potential targets range from the absence of an incident fracture to fixed levels of bone mineral density (BMD), a desired FRAXA (R) score, a specified level of bone turnover markers or indeed changes in any one or a combination of these parameters.
   Despite the proven predictive ability of all of these variables for fracture (particularly BMD and FRAX), their use as targets remains limited due to low sensitivity, the influence of confounders and current lack of evidence that targets can be consistently reached.
   ESCEO considers that it is not currently feasible to apply a treat to target strategy in osteoporosis, though it did identify a need to continue to improve the targeting of treatment to those at higher risk (target to treat strategy) and a number of issues for the research agenda. These include international consensus on intervention thresholds and definition of treatment failure, further exploration of the relationship between fracture and BMD, and FRAX and treatment efficacy and investigation of the potential of short term targets to improve adherence.
C1 [Kanis, J. A.; McCloskey, E.] Univ Sheffield Med Sch, Ctr Metab Bone Dis, Sheffield S10 2RX, S Yorkshire, England.
   [Branco, J.] Univ Novade Lisboa, Hosp Egas Moniz, Dept Rheumatol, Fac Ciencias Med,CEDOC,CHLO,EPE, Lisbon, Portugal.
   [Brandi, M.  L.] Univ Florence, Dept Internal Med, Bone Metab Unit, Florence, Italy.
   [Dennison, E.] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England.
   [Devogelaer, J.  P.] Catholic Univ Louvain, Dept Rheumatol, St Luc Univ Hosp, B 1200 Brussels, Belgium.
   [Ferrari, S.; Rizzoli, R.] Univ Hosp Geneva, Div Bone Dis, Fac Med, Geneva, Switzerland.
   [Kaufman, J.  M.] Ghent Univ Hosp, Ghent, Belgium.
   [Papapoulos, S.] Leiden Univ Med Ctr, Ctr Bone Qual, Leiden, Netherlands.
   [Reginster, J.  Y.] Univ Liege, Dept Publ Hlth Epidemiol & Hlth Econ, Liege, Belgium.
   [Dennison, E.] Univ Southampton, NIHR Nutr Biomed Res Ctr, Southampton, Hants, England.
C3 University of Sheffield; Egas Moniz Hospital; Universidade Nova de
   Lisboa; Centro Hospitalar de Lisboa Ocidental, EPE; University of
   Florence; University of Southampton; Universite Catholique Louvain;
   Cliniques Universitaires Saint Luc; University of Geneva; Ghent
   University; Ghent University Hospital; Leiden University; Leiden
   University Medical Center (LUMC); University of Liege; University of
   Southampton
RP Kanis, JA (通讯作者)，Univ Sheffield Med Sch, Ctr Metab Bone Dis, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM w.j.pontefract@sheffield.ac.uk
RI McCloskey, Eugene/T 5197 2019; Reginster, Jean Yves/AGC 6097 2022;
   Ferrari, Serge/ABD 2730 2020
OI ferrari, serge/0000 0002 1372 4417; brandi, maria
   luisa/0000 0002 8741 0592; Branco, Jaime/0000 0001 7024 4375; 
FU Active Signal; Alliance for Better Bone Health; Amgen; Bayer; Consilient
   Healthcare; GE Lunar; Hologic; Internis Pharma; Lilly; MSD; Novartis;
   Pfizer; Roche; Servier; Tethys; UCB; Univadis; Eli Lilly; Merck Sharp
   Dohme; Spa; Stroder; NPS; GSK; Bioiberica; GlaxoSmithKline; Merck;
   Procter Gamble; Sanofi Aventis; Warner Chilcott; Axsome;
   GlaxoSmithKlein; Negma; Wyeth; Merckle; Nycomed; Theramex; Merck Sharp
   and Dohme; Rottapharm; IBSA; Genevrier; Teijin; Teva; Ebewee Pharma;
   Zodiac; Analis; Novo Nordisk; Takeda; Danone
FX JA Kanis has received consulting fees, advisory board fees, lecture fees
   and/or grant support from the majority of companies concerned with
   skeletal metabolism. E McCloskey has received consultancy, lecture fees,
   research grant support and/or honoraria from Active Signal, Alliance for
   Better Bone Health, Amgen, Bayer, Consilient Healthcare, GE Lunar,
   Hologic, Internis Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Servier,
   Tethys, UCB and Univadis. ML Brandi has received consulting fees, paid
   advisory boards, lecture fees and/or grant support from Amgen, Eli
   Lilly, Merck Sharp & Dohme, Novartis, Servier, Spa, Stroder and NPS. E
   Dennison declares lecture fees from Lilly. S Ferrari has received
   consulting fees, advisory board fees, lecture fees and/or grant support
   from Amgen, GSK, MSD, Eli Lilly, Novartis and Bioiberica. J M Kauffman
   has received consulting fees, paid advisory boards, lecture fees and/or
   grant support from Amgen, Eli Lilly, GlaxoSmithKline, Merck, Novartis,
   Procter & Gamble, Roche, Sanofi Aventis, Servier and Warner Chilcott. S
   Papapoulos has received consulting/speaking fees from Axsome, Amgen, Eli
   Lilly, GlaxoSmithKlein, Merck, Novartis and Roche. J Y Reginster on
   behalf of the Department of Public Health, Epidemiology and Health
   Economics of the University of Liege, Liege, Belgium, received
   consulting fees or paid advisory boards from Servier, Novartis, Negma,
   Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS,
   Theramex, UCB. Lecture fees when speaking at the invitation of a
   commercial sponsor: Merck Sharp and Dohme, Lilly, Rottapharm, IBSA,
   Genevrier, Novartis, Servier, Roche, GlaxoSmithKline, Teijin, Teva,
   Ebewee Pharma, Zodiac, Analis, Theramex, Nycomed, Novo Nordisk. R
   Rizzoli received lecture fee and paid advisory boards from Merck Sharp
   and Dohme, Eli Lilly, Amgen, Servier, Takeda and Danone. JC Branco and
   JP Devogelaer have no conflict of interest.
CR Åkesson K, 2013, OSTEOPOROSIS INT, V24, P2135, DOI 10.1007/s00198 013 2348 z
   [Anonymous], J BONE MINER RES
   [Anonymous], 2011, HYPERT CLIN MAN PRI
   [Anonymous], POOLED COHORT EQUATI
   [Anonymous], J BONE MINER RES
   [Anonymous], ABSTR J BONE MINER R
   [Anonymous], 2007, ASSESSMENT OSTEOPORO
   [Anonymous], GLOB GUID TYP 2 DIAB
   [Anonymous], 2006, HYP MAN HYP AD PRIM
   [Anonymous], 2014, J AM COLL CARDIOL, DOI DOI 10.1016/J.JACC.2013.11.002
   [Anonymous], 2013, CIRCULATION
   Arlot M, 2005, J BONE MINER RES, V20, P1244, DOI 10.1359/JBMR.050309
   Arlot ME, 2008, J BONE MINER RES, V23, P215, DOI 10.1359/JBMR.071012
   Austin M, 2012, J BONE MINER RES, V27, P687, DOI 10.1002/jbmr.1472
   Bauer DC, 2004, J BONE MINER RES, V19, P1250, DOI 10.1359/JBMR.040512
   Bergmann P, 2009, INT J CLIN PRACT, V63, P19, DOI 10.1111/j.1742 1241.2008.01911.x
   Bjarnason NH, 2001, OSTEOPOROSIS INT, V12, P922, DOI 10.1007/s001980170020
   Bruyere O, 2007, J CLIN ENDOCR METAB, V92, P3076, DOI 10.1210/jc.2006 2758
   Cannon CP, 2005, JAMA J AM MED ASSOC, V294, P2492, DOI 10.1001/jama.294.19.2492
   Canoui Poitrine F, 2010, BONE, V47, P790, DOI 10.1016/j.bone.2010.06.026
   Catapano AL, 2011, ATHEROSCLEROSIS, V217, P1, DOI 10.1016/j.atherosclerosis.2011.06.011
   Chen PQ, 2007, J BONE MINER RES, V22, P1173, DOI 10.1359/JBMR.070413
   Cummings SR, 2013, J BONE MINER RES, V28, P433, DOI 10.1002/jbmr.1854
   Diez Perez A, 2012, OSTEOPOROSIS INT, V23, P2769, DOI 10.1007/s00198 012 2093 8
   Donaldson MG, 2012, J BONE MINER RES, V27, P1804, DOI 10.1002/jbmr.1625
   Eastell R, 2003, J BONE MINER RES, V18, P1051, DOI 10.1359/jbmr.2003.18.6.1051
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939
   Garnero P, 1996, J BONE MINER RES, V11, P1531
   Grigor C, 2004, LANCET, V364, P263, DOI 10.1016/S0140 6736(04)16676 2
   Hayward RA, 2012, CIRC CARDIOVASC QUAL, V5, P2, DOI 10.1161/CIRCOUTCOMES.111.964676
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Hochberg MC, 2002, J CLIN ENDOCR METAB, V87, P1586, DOI 10.1210/jc.87.4.1586
   Inzucchi SE, 2012, DIABETOLOGIA, V55, P1577, DOI 10.1007/s00125 012 2534 0
   Jacques RM, 2012, J BONE MINER RES, V27, P1627, DOI 10.1002/jbmr.1644
   Jennings LA, 2010, J AM GERIATR SOC, V58, P650, DOI 10.1111/j.1532 5415.2010.02769.x
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Johansson H, 2014, CALCIFIED TISSUE INT, V94, P560, DOI 10.1007/s00223 014 9842 y
   Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304
   Kanis JA, 2007, OSTEOPOROSIS INT, V18, P1033, DOI 10.1007/s00198 007 0343 y
   Kanis JA, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0144 1
   Kanis JA, 2013, OSTEOPOROSIS INT, V24, P23, DOI 10.1007/s00198 012 2074 y
   Kanis JA, 2012, OSTEOPOROSIS INT, V23, P2239, DOI 10.1007/s00198 012 1964 3
   Kanis JA, 2011, OSTEOPOROSIS INT, V22, P2395, DOI 10.1007/s00198 011 1713 z
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P737, DOI 10.1007/s00198 004 1734 y
   Kanis JA, 2001, OSTEOPOROSIS INT, V12, P989, DOI 10.1007/s001980170006
   Kanis JA, 2000, OSTEOPOROSIS INT, V11, P120, DOI 10.1007/PL00004173
   Kanis JA, 2010, BONE, V47, P729, DOI 10.1016/j.bone.2010.06.009
   Kanis JA, 2009, BONE, V44, P1049, DOI 10.1016/j.bone.2009.02.014
   Keaveny TM, 2008, J BONE MINER RES, V23, P1541, DOI [10.1359/jbmr.080406, 10.1359/JBMR.080406]
   Keaveny TM, 2007, J BONE MINER RES, V22, P149, DOI 10.1359/JBMR.061011
   Kopperdahl DL, 2014, J BONE MINER RES, V29, P570, DOI 10.1002/jbmr.2069
   Krumholz HM, 2013, BMJ BRIT MED J, V347, DOI 10.1136/bmj.f7110
   Ledford H, 2013, NATURE, V494, P410, DOI 10.1038/494410a
   Leslie WD, 2014, J BONE MINER RES, V29, P1074, DOI 10.1002/jbmr.2151
   Leslie WD, 2012, J BONE MINER RES, V27, P1243, DOI 10.1002/jbmr.1582
   Lewiecki EM, 2013, J CLIN ENDOCR METAB, V98, P946, DOI 10.1210/jc.2012 3680
   Li ZQ, 2001, STAT MED, V20, P3175, DOI 10.1002/sim.984
   Mancia G, 2013, EUR HEART J, V34, P2159, DOI 10.1093/eurheartj/eht151
   Marcus R, 2003, J BONE MINER RES, V18, P18, DOI 10.1359/jbmr.2003.18.1.18
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   McAlister FA, 2007, PLOS MED, V4, P1325, DOI 10.1371/journal.pmed.0040250
   McCloskey E, 2013, J BONE MINER RES, V28, P439, DOI 10.1002/jbmr.1859
   McCloskey EV, 2012, J BONE MINER RES, V27, P1480, DOI 10.1002/jbmr.1606
   Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08 9025
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   PECK WA, 1993, AM J MED, V94, P646
   Reginster JY, 2004, BONE, V34, P344, DOI 10.1016/j.bone.2003.10.004
   REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502
   Rizzoli R, 2012, OSTEOPOROSIS INT, V23, P305, DOI 10.1007/s00198 011 1758 z
   Rizzoli R, 2010, RHEUMATOL INT, V30, P1341, DOI 10.1007/s00296 010 1542 y
   Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Sarkar S, 2002, J BONE MINER RES, V17, P1, DOI 10.1359/jbmr.2002.17.1.1
   Schoels M, 2010, ANN RHEUM DIS, V69, P995, DOI 10.1136/ard.2009.126714
   Silva BC, 2014, J BONE MINER RES, V29, P518, DOI 10.1002/jbmr.2176
   Smolen JS, 2010, ANN RHEUM DIS, V69, P631, DOI 10.1136/ard.2009.123919
   Staessen JA, 2001, LANCET, V358, P1305, DOI 10.1016/S0140 6736(01)06411 X
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140 6736(98)07019 6
   Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198 010 1501 1
   Zanchetti A, 2009, J HYPERTENS, V27, P923, DOI 10.1097/HJH.0b013e32832aa6b5
NR 81
TC 50
Z9 55
U1 0
U2 10
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD NOV
PY 2014
VL 25
IS 11
BP 2533
EP 2543
DI 10.1007/s00198 014 2787 1
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AS3HE
UT WOS:000344167500003
PM 25199574
DA 2025 08 17
ER

PT J
AU Velev, M
   Dalban, C
   Chevreau, C
   Gravis, G
   Negrier, S
   Laguerre, B
   Gross Goupil, M
   Ladoire, S
   Borchiellini, D
   Geoffrois, L
   Joly, F
   Priou, F
   Barthelemy, P
   Laramas, M
   Narciso, B
   Thiery Vuillemin, A
   Berdah, JF
   Ferrari, V
   Thomas, QD
   Mione, C
   Curcio, H
   Oudard, S
   Tantot, F
   Escudier, B
   Chabaud, S
   Albiges, L
   Thibault, C
AF Velev, Maud
   Dalban, Cecile
   Chevreau, Christine
   Gravis, Gwenaelle
   Negrier, Sylvie
   Laguerre, Brigitte
   Gross Goupil, Marine
   Ladoire, Sylvain
   Borchiellini, Delphine
   Geoffrois, Lionnel
   Joly, Florence
   Priou, Frank
   Barthelemy, Philippe
   Laramas, Mathieu
   Narciso, Berangere
   Thiery Vuillemin, Antoine
   Berdah, Jean Francois
   Ferrari, Victoria
   Thomas, Quentin Dominique
   Mione, Cecile
   Curcio, Hubert
   Oudard, Stephane
   Tantot, Florence
   Escudier, Bernard
   Chabaud, Sylvie
   Albiges, Laurence
   Thibault, Constance
TI Efficacy and safety of nivolumab in bone metastases from renal cell
   carcinoma: Results of the GETUG AFU26 NIVOREN multicentre phase II study
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Metastatic renal cell carcinoma; Bone metastases; Nivolumab;
   Skeletal related events; Bone targeting agent; Immune checkpoint
   inhibitors; Survival analyses; Denosumab
ID SKELETAL COMPLICATIONS; EVEROLIMUS; SURVIVAL; THERAPY; CANCER; SITES;
   CARE
AB Introduction: Bone metastases (BM) in renal cell carcinoma (RCC) are associated with a poor prognosis based on retrospective studies evaluating antiangiogenic agents. Few data are available regarding immune checkpoint inhibitors (ICI) in patients with bone meta static RCC. NIVOREN is a multicentre prospective study in which patients were treated with nivolumab after the failure of antiangiogenic agents. We aim to assess the impact of BM on prognosis, and the efficacy and safety of nivolumab in patients enrolled in the NIVOREN trial.Materials and methods: All patients with BM at inclusion were included in our study. The pri mary endpoint was overall survival (OS). Secondary endpoints were progression free survival (PFS), objective response rate (ORR), safety, and skeletal related events (SRE). Results: Among 720 patients treated with nivolumab, 194 presented BM at inclusion. The me dian follow up was 23.9 months. Median OS was 17.9 months in patients with BM versus 26.1 months in patients without BM (p = 0.0023). The difference was not statistically significant after adjustment (p = 0.0707). The median PFS was shorter in patients with BM even after adjustment (2.8 versus 4.6 months, p = 0.0045), as well as the ORR (14.8% versus 23.3%). SRE occurred for 36% of patients with BM. A post hoc analysis evaluating the impact of bone targeting agents (BTA) on SRE incidence showed a significant benefit of BTA on the incidence of SRE (OR = 0.367, CI95% [0.151 0.895]).Conclusion: Nivolumab is associated with shorter PFS, and lower ORR in RCC patients with BM. Our study suggests that BTA in association with immunotherapy decreases the incidence of SRE. 2023 Elsevier Ltd. All rights reserved.
C1 [Velev, Maud] Univ Paris Cite, Hop Europeen Georges Pompidou, Inst Canc Paris CARPEM, APHP Ctr,Serv Oncol Med, 20 Rue Leblanc, F 75015 Paris, France.
   [Dalban, Cecile] Ctr Leon Berard Direct Rech Clin & Innovat, 28 Prom Lea & Napoleon Bullukian, F 69008 Lyon, France.
   [Chevreau, Christine] Inst Univ Canc Toulouse Oncopole, Serv Oncol Med, 1 Ave Irene Joliot Curie, F 31100 Toulouse, France.
   [Gravis, Gwenaelle] Inst Paoli Calmettes, Serv Oncol Med, 232 Bd Sainte Marguer, F 13009 Marseille, France.
   [Negrier, Sylvie] Univ Lyon 1, Ctr Leon Berard, Serv Oncol Med, 28 Prom Lea & Napoleon Bullukian, F 69008 Lyon, France.
   [Laguerre, Brigitte] Serv Oncol Med, Ctr Eugene Marquis, Ave Bataille Flandres Dunkerque,CS 44229, F 35000 Rennes, France.
   [Gross Goupil, Marine] Bordeaux Univ Hosp, Hop Pellegrin, Serv Oncol Med, Pl Amelie Raba Leon, F 33000 Bordeaux, France.
   [Negrier, Sylvie] Ctr Georges Francois Leclerc, Serv Oncol Med, 1 Rue Prof Mar, F 21000 Dijon, France.
   [Borchiellini, Delphine] Univ Cote Azur, Ctr Antoine Lacassagne, Serv Oncol Med, 33 Ave Valombrose, F 06100 Nice, France.
   [Geoffrois, Lionnel; Curcio, Hubert] Inst Cancerol Lorraine, Serv Oncol Med, 6 Ave Bourgogne, F 54519 Nancy, France.
   [Joly, Florence] Ctr Francois Baclesse, Serv Oncol Med, 3 Ave Gen Harris, F 14000 Caen, France.
   [Priou, Frank] Ctr Hosp Vendee, Serv Oncol Med, Bd Stephane Moreau, F 85000 La Roche Sur Yon, France.
   [Barthelemy, Philippe] Inst Cancerol Strasbourg Europe, Serv Oncol Med, 17 Rue Albert Calmette, F 67200 Strasbourg, France.
   [Laramas, Mathieu] Grenoble Alpes Univ Hosp, Serv Oncol Med, Ave Maquis Gresivaudan, F 38700 Latronche, France.
   [Narciso, Berangere] Tours Univ Hosp, Serv Oncol Med, 2 Bd Tonnelle, F 37000 Tours, France.
   [Thiery Vuillemin, Antoine] Hop Jean Minjoz, Serv Oncol medicale, 3 Bd Alexandre Fleming, F 25000 Besancon, France.
   [Berdah, Jean Francois] Ctr Hosp Ajaccio, Ctr Hosp Hyeres, Serv Oncol Med, 27 Ave Imperatrice Eugenie, F 20000 Ajaccio, France.
   [Thomas, Quentin Dominique] Montpellier Univ, Inst Canc Montpellier, Dept Med Oncol, Serv Oncol Med, 208 Ave Apothicaires, F 34090 Montpellier, France.
   [Mione, Cecile] Univ Clermont Ferrand, 28 Pl Henri Dunant, F 63000 Clermont Ferrand, France.
   [Oudard, Stephane] Univ Paris Cite, Hop Europeen Georges Pompidou, Ctr APHP, Inst Canc Paris CARPEM, 20 Rue Leblanc, F 75015 Paris, France.
   [Tantot, Florence] Unicanc, GETUG Grp, 101 Rue Tolbiac, Paris, France.
   [Escudier, Bernard; Albiges, Laurence] Univ Paris Saclay, Serv Oncol medicale, Gustave Roussy Canc Campus, 114 Rue Edouard Vaillant, F 94805 Villejuif, France.
   [Chabaud, Sylvie] Ctr Leon Berard, Lyon, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Europeen Georges Pompidou   APHP; UNICANCER;
   Institut Paoli Calmette (IPC); Universite Claude Bernard Lyon 1;
   UNICANCER; Centre Leon Berard; UNICANCER; Centre Eugene Marquis;
   Universite de Bordeaux; CHU Bordeaux; UNICANCER; Universite Bourgogne
   Europe; Centre Georges Francois Leclerc; Universite Cote d'Azur;
   UNICANCER; Centre Antoine Lacassagne; UNICANCER; Centre Francois
   Baclesse; CHD Vendee; Communaute Universite Grenoble Alpes; Universite
   Grenoble Alpes (UGA); CHU Grenoble Alpes; CHU Tours; Universite Marie et
   Louis Pasteur; CHU Besancon; Universite de Montpellier; UNICANCER;
   Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM);
   Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Europeen Georges Pompidou   APHP; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UNICANCER;
   UNICANCER; Gustave Roussy; Universite Paris Saclay; UNICANCER; Centre
   Leon Berard
RP Velev, M (通讯作者)，Hop Europeen Georges Pompidou, Serv Cancerol Med, 20 Rue Leblanc, F 75015 Paris, France.
EM md.velev@gmail.com; Cecile.DALBAN@lyon.unicancer.fr;
   chevreau.christine@iuct oncopole.fr; gravisg@ipc.unicancer.fr;
   sylvie.negrier@lyon.unicancer.fr; b.laguerre@rennes.unicancer.fr;
   marine.gross goupil@chu bordeaux.fr; sladoire@cgfl.fr;
   delphine.borchiellini@nice.unicancer.fr; l.geoffrois@nancy.unicancer.fr;
   f.joly@baclesse.unicancer.fr; frank.priou@chd vendee.fr;
   p.barthelemy@icans.eu; mlaramas@chu grenoble.fr;
   berengere.narciso@univ tours.fr;
   antoine.thieryvuillemin@oncologyfc2.onmicrosoft.com;
   jf.berdah@wanadoo.fr; Victoria.FERRARI@nice.unicancer.fr;
   Quentin.Thomas@icm.unicancer.fr; cecile.mione@clermont.unicancer.fr;
   stephane.oudard@aphp.fr; f tantot@unicancer.fr;
   Bernard.escudier@gustaveroussy.fr; Laurence.ALBIGES@gustaveroussy.fr;
   constance.thibault@aphp.fr
RI Escudier, Bernard/AES 5186 2022; BARTHELEMY, Philippe/AAE 4758 2019;
   thomas, quentin/GLT 1206 2022; Chevreau, Christine/A 5565 2015; Gravis,
   Gwenaelle/CAG 3019 2022; Borchiellini, Delphine/JGD 0323 2023; Albiges,
   Laurence/JOZ 9308 2023; joly, florence/AAF 9191 2020
OI Gravis, Gwenaelle/0000 0002 3127 1554; VELEV, Maud/0000 0002 3617 7698;
   ALBIGES, Laurence/0000 0002 5734 3480
FU UNICANCER; Bristol Myers Squibb
FX Our study was funded by UNICANCER. The NIVO REN study was funded by a
   grant from Bristol Myers Squibb, but no specific funding from
   Bristol Myers Squibb was obtained for the analysis reported here.
CR Albiges L, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.6_suppl.577
   Antczak C, 2014, J UROLOGY, V191, P1678, DOI 10.1016/j.juro.2013.12.042
   Beuselinck B, 2011, ANN ONCOL, V22, P794, DOI 10.1093/annonc/mdq554
   Bianchi M, 2012, ANN ONCOL, V23, P973, DOI 10.1093/annonc/mdr362
   Escudier B, 2017, EUR UROL, V72, P962, DOI 10.1016/j.eururo.2017.02.010
   Escudier B, 2018, J CLIN ONCOL, V36, P765, DOI 10.1200/JCO.2017.74.7352
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Grassi P, 2014, FUTURE ONCOL, V10, P1361, DOI [10.2217/fon.14.69, 10.2217/FON.14.69]
   Guillot A, 2019, CLIN GENITOURIN CANC, V17, pE38, DOI 10.1016/j.clgc.2018.08.006
   Huang ZX, 2019, EJSO EUR J SURG ONC, V45, P1246, DOI 10.1016/j.ejso.2019.01.221
   Hutchinson Lisa, 2015, Nat Rev Clin Oncol, V12, P503, DOI 10.1038/nrclinonc.2015.138
   Isla D, 2013, EXPERT REV ANTICANC, V13, P421, DOI [10.1586/ERA.13.15, 10.1586/era.13.15]
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   McKay RR, 2014, EUR UROL, V66, P502, DOI 10.1016/j.eururo.2014.02.040
   Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665
   Motzer RJ, 2013, BRIT J CANCER, V108, P2470, DOI 10.1038/bjc.2013.236
   Omae K, 2017, ONCOTARGET, V8, P68890, DOI 10.18632/oncotarget.20323
   Oprea Lager DE, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.772530
   Ruatta F, 2019, EUR J CANCER, V107, P79, DOI 10.1016/j.ejca.2018.10.023
   Saad Fred, 2002, Clin Prostate Cancer, V1, P145, DOI 10.3816/CGC.2002.n.016
   Santini D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083026
   Seymour L, 2017, LANCET ONCOL, V18, pE143, DOI 10.1016/S1470 2045(17)30074 8
   Siegel RL, 2021, CA CANCER J CLIN, V71, DOI [10.3322/ caac.21654.77 33, DOI 10.3322/ CAAC.21654.77 33]
   Woodward E, 2011, BONE, V48, P160, DOI 10.1016/j.bone.2010.09.008
NR 24
TC 8
Z9 9
U1 1
U2 2
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0959 8049
EI 1879 0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD MAR
PY 2023
VL 182
BP 66
EP 76
DI 10.1016/j.ejca.2022.12.028
EA FEB 2023
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 9E1QW
UT WOS:000936568700001
PM 36746010
OA Bronze
DA 2025 08 17
ER

PT J
AU Malek, N
   Starowicz, K
AF Malek, Natalia
   Starowicz, Katarzyna
TI Joint problems arising from lack of repair mechanisms: can cannabinoids
   help?
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article; Proceedings Paper
CT 8th European Workshop on Cannabinoid Research
CY SEP, 2017
CL Roehampton, ENGLAND
ID RHEUMATOID ARTHRITIS; SUBCHONDRAL BONE; CONCISE GUIDE; ENDOCANNABINOID
   SYSTEM; ARTICULAR CHONDROCYTES; SYNOVIAL FIBROBLASTS; OSTEOCLAST
   FUNCTION; RECEPTOR; OSTEOARTHRITIS; EXPRESSION
AB Osteoarthritis (OA) is the most common disease of joints, which are complex organs where cartilage, bone and synovium cooperate to allow a range of movements. During progression of the disease, the function of all three main components is jeopardized. Nevertheless, the involvement of each tissue in OA development is still not established and is the topic of the present review. The OA therapies available are symptomatic, largely targeting pain management rather than disease progression. The strong need to develop a treatment for cartilage degeneration, bone deformation and synovial inflammation has led to research on the involvement of the endocannabinoid system in the development of OA. The current review discusses the research on this topic to date and notes the advantages of exploiting endocannabinoid system modulation for cartilage, bone and synovium homeostasis, which could prevent the further progression of OA.
C1 [Malek, Natalia] Univ Wroclaw, Fac Biotechnol, Dept Cell Pathophysiol, PL 50383 Wroclaw, Poland.
   [Starowicz, Katarzyna] Polish Acad Sci, Inst Pharmacol, Dept Neurochem, Smetna12 St, PL 31343 Krakow, Poland.
C3 University of Wroclaw; Polish Academy of Sciences
RP Starowicz, K (通讯作者)，Polish Acad Sci, Inst Pharmacol, Dept Neurochem, Smetna12 St, PL 31343 Krakow, Poland.
EM starow@if pan.krakow.pl
RI ; Starowicz, Katarzyna/AAB 8595 2022; Malek, Natalia/AAF 2857 2019
OI Starowicz, Katarzyna/0000 0003 0091 0066; Malek,
   Natalia/0000 0003 3602 5122; 
FU National Science Centre, Krakow, Poland [2014/13/B/NZ7/02311]; Ministry
   of Science and Higher Education, Warsaw, Poland [0044/DIA/2013/42];
   START scholarship   Foundation for Polish Science
FX This work was supported by the National Science Centre, Krakow, Poland,
   by grant 2014/13/B/NZ7/02311, and by the Ministry of Science and Higher
   Education, Warsaw, Poland, by grant 0044/DIA/2013/42 from and statutory
   funds. N.M. is a recipient of a START scholarship funded by the
   Foundation for Polish Science. The Authors express their gratitude to
   Magdalena Kostrzewa and Agnieszka Pajk who contributed to the
   intellectual design of 2014/13/B/NZ7/02311.
CR Aigner T, 2004, CLIN ORTHOP RELAT R, pS138, DOI 10.1097/01.blo.0000143838.53434.b8
   Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS272, DOI [10.1111/bph.13882, 10.1111/bph.13877]
   Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS17, DOI 10.1111/bph.13878
   Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS160, DOI 10.1111/bph.13884
   Alvarez P, 2014, J PAIN, V15, P726, DOI 10.1016/j.jpain.2014.04.002
   [Anonymous], 2017, JOINTS
   [Anonymous], ARTHRITIS RES THER
   Buckwalter JA, 1998, ARTHRITIS RHEUM US, V41, P1331, DOI 10.1002/1529 0131(199808)41:8<1331::AID ART2>3.0.CO;2 J
   Dunn SL, 2014, OSTEOARTHR CARTILAGE, V22, P133, DOI 10.1016/j.joca.2013.10.016
   Dunn SL, 2016, CANNABIS CANNABINOID, V1, P3, DOI 10.1089/can.2015.0001
   Dunn SL, 2012, FUTURE MED CHEM, V4, P713, DOI [10.4155/fmc.12.20, 10.4155/FMC.12.20]
   Fukuda S, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 275
   Funck Brentano T, 2015, CURR OPIN RHEUMATOL, V27, P420, DOI 10.1097/BOR.0000000000000181
   Gavenis K, 2009, MOL CELL BIOCHEM, V321, P135, DOI 10.1007/s11010 008 9927 x
   Goldring M B, 2000, Curr Rheumatol Rep, V2, P459, DOI 10.1007/s11926 000 0021 y
   Goldring MB, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2592
   Goldring MB, 2000, ARTHRITIS RHEUM US, V43, P1916, DOI 10.1002/1529 0131(200009)43:9<1916::AID ANR2>3.0.CO;2 I
   Gómez R, 2014, J ORTHOP RES, V32, P1137, DOI 10.1002/jor.22660
   Gui H, 2014, RHEUMATOLOGY, V53, P802, DOI 10.1093/rheumatology/ket447
   Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121
   Huggins JP, 2012, PAIN, V153, P1837, DOI 10.1016/j.pain.2012.04.020
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Idris Aymen I, 2012, Front Endocrinol (Lausanne), V3, P136, DOI 10.3389/fendo.2012.00136
   Idris AI, 2009, CELL METAB, V10, P139, DOI 10.1016/j.cmet.2009.07.006
   Kraus VB, 2015, OSTEOARTHR CARTILAGE, V23, P1233, DOI 10.1016/j.joca.2015.03.036
   Krustev E, 2015, CURR OSTEOPOROS REP, V13, P216, DOI 10.1007/s11914 015 0275 y
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Lories Rik J U, 2012, Bonekey Rep, V1, P136, DOI 10.1038/bonekey.2012.136
   Lowin T, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0845 5
   Lubberts E, 1998, CYTOKINE, V10, P361, DOI 10.1006/cyto.1997.0298
   Malek N, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00257
   Malek N, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/130639
   Malfait AM, 1998, CLIN EXP IMMUNOL, V111, P377
   Malfait AM, 2000, P NATL ACAD SCI USA, V97, P9561, DOI 10.1073/pnas.160105897
   MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0
   Mbvundula EC, 2006, J PHARM PHARMACOL, V58, P351, DOI 10.1211/jpp.58.3.0009
   Mbvundula EC, 2005, BIOCHEM PHARMACOL, V69, P635, DOI 10.1016/j.bcp.2004.11.018
   McDougall JJ, 2008, BRIT J PHARMACOL, V153, P358, DOI 10.1038/sj.bjp.0707565
   McDougall JJ, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1313 1
   McPartland JM, 2008, J BODYW MOV THER, V12, P169, DOI 10.1016/j.jbmt.2008.01.004
   Milner Jennifer M., 2005, Current Drug Targets   Inflammation and Allergy, V4, P363, DOI 10.2174/1568010054022141
   Moore BA, 2000, BBA MOL BASIS DIS, V1502, P307, DOI 10.1016/S0925 4439(00)00056 9
   MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Richardson D, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2401
   Robinson WH, 2016, NAT REV RHEUMATOL, V12, P580, DOI 10.1038/nrrheum.2016.136
   Rossi F, 2009, BONE, V44, P476, DOI 10.1016/j.bone.2008.10.056
   Russo EB, 2016, TRENDS PHARMACOL SCI, V37, P594, DOI 10.1016/j.tips.2016.04.005
   Sanchez C, 2005, OSTEOARTHR CARTILAGE, V13, P988, DOI 10.1016/j.joca.2005.07.012
   Sarzi Puttini P, 2005, SEMIN ARTHRITIS RHEU, V35, P1, DOI 10.1016/j.semarthrit.2005.01.013
   Schlaak JF, 1996, CLIN EXP RHEUMATOL, V14, P155
   Schuelert N, 2011, PAIN, V152, P975, DOI 10.1016/j.pain.2010.11.025
   Schuelert N, 2009, NEUROSCI LETT, V465, P184, DOI 10.1016/j.neulet.2009.08.063
   Sharma AR, 2013, INT J MOL SCI, V14, P19805, DOI 10.3390/ijms141019805
   Smith MD, 1997, J RHEUMATOL, V24, P365
   Sofat Nidhi, 2014, Int J Clin Rheumtol, V9, P197
   Sophocleous A, 2015, OSTEOARTHR CARTILAGE, V23, P1586, DOI 10.1016/j.joca.2015.04.020
   SOREN A, 1976, CLIN ORTHOP RELAT R, P191
   Tam J, 2006, MOL PHARMACOL, V70, P786, DOI 10.1124/mol.106.026435
   Valverde O, 2005, HANDB EXP PHARMACOL, V168, P117
   Wei B, 2017, EXP THER MED, V13, P2161, DOI 10.3892/etm.2017.4238
   Whyte LS, 2012, BRIT J PHARMACOL, V165, P2584, DOI 10.1111/j.1476 5381.2011.01519.x
NR 63
TC 13
Z9 13
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD MAY
PY 2019
VL 176
IS 10
SI SI
BP 1412
EP 1420
DI 10.1111/bph.14204
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Pharmacology & Pharmacy
GA HW8VH
UT WOS:000466968400006
PM 29574720
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Yemisci, OU
   Yalbuzdag, SA
   Karatas, M
AF Yemisci, Oya Umit
   Yalbuzdag, Seniz Akcay
   Karatas, Metin
TI Risedronate Induced Arthritis
SO JCR JOURNAL OF CLINICAL RHEUMATOLOGY
LA English
DT Article
DE risedronate; arthritis; side effect; acute phase reaction
ID ACUTE PHASE RESPONSE; AMINOBISPHOSPHONATES; BISPHOSPHONATES;
   IBANDRONATE; ALENDRONATE; ACTIVATION
AB In most cases bisphosphonates are the first choice therapy for osteoporosis. We present a case of acute arthritis associated with once weekly risedronate in a 58 year old woman with osteoporosis. She developed arthritis 48 hours after the second dose of oral risedronate with elevated serum acute phase reactants. There was no evidence of rheumatoid arthritis or seronegative arthritis. Her symptoms resolved rapidly with rest, however, recurred after the patient was rechallenged with the same drug 1 week later. Although the mechanism of this potential side effect remains speculative, it is thought to be as a result of the proinflammatory properties of aminobisphosphonates. With the increasing use of bisphosphonates in the treatment and prevention of osteoporosis, physicians should be well aware of this possible side effect of these drugs.
C1 [Yemisci, Oya Umit; Yalbuzdag, Seniz Akcay; Karatas, Metin] Baskent Univ, Dept Phys Med & Rehabil, TR 06490 Ankara, Turkey.
C3 Baskent University
RP Yemisci, OU (通讯作者)，Baskent Univ, Dept Phys Med & Rehabil, Fevzi Cakmak Cad 5,Sok 48, TR 06490 Ankara, Turkey.
EM oyaumit@hotmail.com
RI Akcay, Seniz/DMD 2288 2022; Umit Yemisci, Oya/AAJ 8820 2021
OI Umit Yemisci, Oya/0000 0002 0501 5127
CR Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Diaz Borjon A, 2006, JCR J CLIN RHEUMATOL, V12, P131, DOI 10.1097/01.rhu.0000221796.06383.4e
   Frederiksen Louise, 2007, Ugeskr Laeger, V169, P1583
   Gerster JC, 2004, J RHEUMATOL, V31, P829
   Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365 2249.2005.02665.x
   Jones DPG, 2008, J RHEUMATOL, V35, P537
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Nakamura M, 1996, BRIT J PHARMACOL, V119, P205, DOI 10.1111/j.1476 5381.1996.tb15972.x
   Reginster JY, 2006, ANN RHEUM DIS, V65, P654, DOI 10.1136/ard.2005.044958
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   SCHWEITZER DH, 1995, J BONE MINER RES, V10, P956
   Strampel W, 2007, DRUG SAFETY, V30, P755, DOI 10.2165/00002018 200730090 00003
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   Zysk SP, 2003, INFLAMM RES, V52, P221, DOI 10.1007/s000110300075
NR 14
TC 5
Z9 5
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1076 1608
EI 1536 7355
J9 JCR J CLIN RHEUMATOL
JI JCR J. Clin. Rheumatol.
PD JUN 10
PY 2010
VL 16
IS 4
BP 168
EP 169
DI 10.1097/RHU.0b013e3181dfbb15
PG 2
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 602SP
UT WOS:000278159400004
PM 20414126
DA 2025 08 17
ER

PT J
AU Hughes, JM
   Petit, MA
AF Hughes, J. M.
   Petit, M. A.
TI Biological underpinnings of Frost's mechanostat thresholds: The
   important role of osteocytes
SO JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS
LA English
DT Article
DE Mechanostat; Osteocytes; Modeling; Remodeling; Mechanical Loading
ID PERIOSTEAL BONE FORMATION; IN VIVO; CORTICAL BONE; LOW MAGNITUDE;
   NITRIC OXIDE; FLUID FLOW; RAT BONE; APOPTOSIS; DIFFERENTIATION;
   OSTEOBLAST
AB Harold Frost first proposed the existence of several mechanical thresholds in bone, two of which determine whether bone is added to, or lost from, the skeleton. Recent evidence from bone biology helps elucidate the role of osteocytes in determining these mechanical thresholds. Specifically, when mechanical stimuli fall below the resorption threshold, osteocyte apoptosis occurs, followed by bone resorption. Conversely, mechanical loading maintains osteocytes viability, and consequently, no bone is lost. With a greater than customary mechanical stimulus, osteocytes perturbation from pulsatile fluid flow results in release of anabolic factors and subsequent bone formation. Osteocytes also play a pivotal role in bone remodeling in response to alterations in the mechanical environment. In particular, osteocyte apoptosis results in bone turnover in disuse as well as in response to greater than customary mechanical stimuli due to microdamage accumulation. Given the important role of osteocytes in bone modeling and remodeling, these cells provide an ideal target for both drug therapies and exercise to prevent bone fragility.
C1 [Hughes, J. M.; Petit, M. A.] Univ Minnesota, Sch Kinesiol, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities
RP Petit, MA (通讯作者)，Univ Minnesota, Sch Kinesiol, Cooke Hall,1900 Univ Ave, Minneapolis, MN 55455 USA.
EM mpetit@umn.edu
RI ; Hughes, Julie/AAJ 9791 2021
OI Hughes, Julie/0000 0001 5802 6711; 
CR Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   Ajubi NE, 1999, AM J PHYSIOL ENDOC M, V276, pE171, DOI 10.1152/ajpendo.1999.276.1.E171
   Allen MR., 2007, IBMS BoneKEy, V4, P49, DOI [10.1138/20060248, DOI 10.1138/20060248]
   Bakker A, 2004, BIOCHEM BIOPH RES CO, V320, P1163, DOI 10.1016/j.bbrc.2004.06.056
   Bentolila V, 1998, BONE, V23, P275, DOI 10.1016/S8756 3282(98)00104 5
   Bilezikian JP, 2009, J BONE MINER RES, V24, P373, DOI [10.1359/JBMR.090105, 10.1359/jbmr.090105]
   Bonewald L., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P331
   Bonewald Lynda F, 2006, Bonekey Osteovision, V3, P7
   Boutahar N, 2004, J BIOL CHEM, V279, P30588, DOI 10.1074/jbc.M313244200
   Chow JWM, 1998, J BONE MINER RES, V13, P1039, DOI 10.1359/jbmr.1998.13.6.1039
   Cowin S., 2007, TISSUE MECH
   David V, 2006, AM J PHYSIOL ENDOC M, V290, pE440, DOI 10.1152/ajpendo.00293.2004
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dufour C, 2007, EXP CELL RES, V313, P394, DOI 10.1016/j.yexcr.2006.10.021
   Fan M, 2006, J CELL PHYSIOL, V207, P454, DOI 10.1002/jcp.20581
   Forwood MR, 1996, J BONE MINER RES, V11, P1688
   FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104
   Frost HM, 2003, ANAT REC PART A, V275A, P1081, DOI 10.1002/ar.a.10119
   Glass DA, 2006, CURR TOP DEV BIOL, V73, P43, DOI 10.1016/S0070 2153(05)73002 7
   Gross TS, 1997, J BONE MINER RES, V12, P982, DOI 10.1359/jbmr.1997.12.6.982
   HATTNER R, 1965, NATURE, V206, P489, DOI 10.1038/206489a0
   Heaney RP, 2003, BONE, V33, P457, DOI 10.1016/S8756 3282(03)00236 9
   Isaksson H, 2009, EXP GERONTOL, V44, P708, DOI 10.1016/j.exger.2009.08.005
   Judex S, 2003, ANN BIOMED ENG, V31, P12, DOI 10.1114/1.1535414
   Keila S, 2001, J ENDOCRINOL, V168, P131, DOI 10.1677/joe.0.1680131
   Kurata K, 2006, J BONE MINER RES, V21, P616, DOI 10.1359/JBMR.060106
   LANYON LE, 1984, J BIOMECH, V17, P897, DOI 10.1016/0021 9290(84)90003 4
   LeBlanc A. D., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P33
   Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223 001 1025 y
   Li J., 2004, Osteogenesis after mechanical loading requires the P2X7 nucleotide receptor, V19
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Martin RB., 1998, Skeletal tissue mechanics
   Mashiba T, 2005, J BONE MINER METAB, V23, P36, DOI 10.1007/BF03026321
   Menuki K, 2008, BONE, V43, P613, DOI 10.1016/j.bone.2008.04.022
   Noble BS, 2003, AM J PHYSIOL CELL PH, V284, pC934, DOI 10.1152/ajpcell.00234.2002
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   PARFITT AM, 1994, OSTEOPOROSIS INT, V4, P382, DOI 10.1007/BF01622201
   Parfitt AM, 2002, BONE, V30, P5, DOI 10.1016/S8756 3282(01)00642 1
   Patel MJ, 2009, J CELL BIOCHEM, V106, P306, DOI 10.1002/jcb.22007
   RITTWEGER J, 2006, J PHYSL, V557, P331
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Scott A, 2008, SPORTS MED, V38, P139, DOI 10.2165/00007256 200838020 00004
   Skerry T. M., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P122
   Srinivasan S, 2003, BONE, V33, P946, DOI 10.1016/j.bone.2003.07.009
   Tan SD, 2008, BIOCHEM BIOPH RES CO, V369, P1150, DOI 10.1016/j.bbrc.2008.03.007
   Tate MLK, 1998, BONE, V22, P107
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Taylor D, 2001, J ORTHOPAED RES, V19, P919, DOI 10.1016/S0736 0266(01)00009 2
   Turner CH, 1996, AM J PHYSIOL ENDOC M, V270, pE634, DOI 10.1152/ajpendo.1996.270.4.E634
   Turner CH., 2004, BoneKEy Osteovision, V1, P15
   UHTHOFF HK, 1978, J BONE JOINT SURG BR, V60, P420, DOI 10.1302/0301 620X.60B3.681422
   Verborgt O, 2000, J BONE MINER RES, V15, P60, DOI 10.1359/jbmr.2000.15.1.60
   Verborgt O, 2002, J BONE MINER RES, V17, P907, DOI 10.1359/jbmr.2002.17.5.907
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
NR 57
TC 64
Z9 80
U1 0
U2 12
PU JMNI
PI NAFPLION
PA 7 SPILIADOU SQ, NAFPLION, 21 100, GREECE
SN 1108 7161
J9 J MUSCULOSKEL NEURON
JI J. Musculoskelet. Neuronal Interact.
PD JUN
PY 2010
VL 10
IS 2
BP 128
EP 135
PG 8
WC Neurosciences; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Physiology
GA 606ZD
UT WOS:000278466900002
PM 20516629
DA 2025 08 17
ER

PT J
AU Zanaty, MI
   Abdel Moneim, A
   Kitani, Y
   Sekiguchi, T
   Suzuki, N
AF Zanaty, Mohamed I.
   Abdel Moneim, Adel
   Kitani, Yoichiro
   Sekiguchi, Toshio
   Suzuki, Nobuo
TI Effect of Omeprazole on Osteoblasts and Osteoclasts in vivo and
   in the in vitro Model Using Fish Scales
SO BIOCHEMISTRY MOSCOW
LA English
DT Article
DE omeprazole; fish scales; transcription genes; osteoclastic genes
ID PROTON PUMP INHIBITORS; GOLDFISH SCALE; BONE; CALCIUM; RANKL; RISK;
   DIFFERENTIATION; EXPRESSION; WOMEN; OPG
AB Omeprazole suppresses excessive secretion of gastric acid via irreversible inhibition of H+/K+ ATPase in the gastric parietal cells. Recent meta analysis of data revealed an association between the use of proton pump inhibitors (PPIs) and increased risk of bone fractures, but the underlying molecular mechanism of PPI action remains unclear. In this study, we demonstrated that omeprazole directly influences bone metabolism using a unique in vitro bioassay system with teleost scales, as well as the in vivo model. The in vitro study showed that omeprazole significantly increased the activities of alkaline phosphatase and tartrate resistant acid phosphatase after 6 h of incubation with this PPI. Expression of mRNAs for several osteoclastic markers was upregulated after 3 h incubation of fish scales with 10( 7) M omeprazole. The in vivo experiments revealed that the plasma calcium levels significantly increased in the omeprazole treated group. The results of in vitro and in vivo studies suggest that omeprazole affects bone cells by increasing bone resorption by upregulating expression of osteoclastic genes and promoting calcium release to the circulation. The suggested in vitro bioassay in fish scales is a practical model that can be used to study the effects of drugs on bone metabolism.
C1 [Zanaty, Mohamed I.] Beni Suef Univ, Fac Postgrad Studies Adv Sci, Biotechnol & Life Sci Dept, Bani Suwayf 62511, Egypt.
   [Abdel Moneim, Adel] Beni Suef Univ, Mol Physiol Div, Fac Sci, Bani Suwayf 62511, Egypt.
   [Kitani, Yoichiro; Sekiguchi, Toshio; Suzuki, Nobuo] Kanazawa Univ, Inst Nat & Environm Technol, Div Marine Environm Studies, Noto Marine Lab, Noto Cho, Kanazawa, Ishikawa 9270553, Japan.
C3 Egyptian Knowledge Bank (EKB); Beni Suef University; Egyptian Knowledge
   Bank (EKB); Beni Suef University; Kanazawa University
RP Abdel Moneim, A (通讯作者)，Beni Suef Univ, Mol Physiol Div, Fac Sci, Bani Suwayf 62511, Egypt.
EM zanaty012@psas.bsu.edu.eg; adel_men2020@yahoo.com;
   yki@se.kanazawa u.ac.jp; t sekiguchi@se.kanazawa u.ac.jp;
   nobuos@staff.kanazawa u.ac.jp
RI zanaty, mohamed/JXN 6417 2024; SUZUKI, Nobuo/J 8420 2015; Suzuki,
   Nobuo/J 8420 2015
OI Suzuki, Nobuo/0000 0003 0283 9910
CR Al Subaie A, 2016, J CLIN PERIODONTOL, V43, P193, DOI 10.1111/jcpe.12506
   Andersen TL, 2009, AM J PATHOL, V174, P239, DOI 10.2353/ajpath.2009.080627
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Briganti SI, 2021, INT J ENDOCRINOL, V2021, DOI 10.1155/2021/8902367
   Chiu YH, 2016, J CELL PHYSIOL, V231, P2402, DOI 10.1002/jcp.25389
   Corley DA, 2010, GASTROENTEROLOGY, V139, P93, DOI 10.1053/j.gastro.2010.03.055
   Costa Rodrigues J, 2013, FEBS J, V280, P5052, DOI 10.1111/febs.12478
   FDA Drug Safety Communication, 2011, Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Goltzman D, 2018, FRONT HORM RES, V50, P1, DOI 10.1159/000486060
   Herroon MK, 2013, ONCOGENE, V32, P1580, DOI 10.1038/onc.2012.166
   Hutchings G, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010139
   Hyun JJ, 2010, INT J MOL MED, V26, P877, DOI 10.3892/ijmm_00000537
   Kinoshita Y, 2018, J NEUROGASTROENTEROL, V24, P182
   Kobayashi Y, 2009, CRIT REV EUKAR GENE, V19, P61, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.30
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lee JU, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02747
   Liu W, 2015, MOL MED REP, V11, P3212, DOI 10.3892/mmr.2015.3152
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Minisola S, 2015, BMJ BRIT MED J, V350, DOI 10.1136/bmj.h2723
   Moe SM, 2008, PRIMARY CARE, V35, P215, DOI 10.1016/j.pop.2008.01.007
   Nassar Yousef, 2018, J Bone Metab, V25, P141
   O'Connell MB, 2005, AM J MED, V118, P778, DOI 10.1016/j.amjmed.2005.02.007
   Park JH, 2017, MOL CELLS, V40, P706
   Podgorski I, 2009, AM J PATHOL, V175, P1255, DOI 10.2353/ajpath.2009.080906
   Prause M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/413097
   Prause M, 2014, INJURY, V45, P1156, DOI 10.1016/j.injury.2014.05.005
   Price Charles T, 2012, Open Orthop J, V6, P143, DOI 10.2174/1874325001206010143
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Romdhane Hayfa, 2018, Tunis Med, V96, P193
   Shetty Sahana, 2016, Indian J Endocrinol Metab, V20, P846
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Suzuki N, 2000, PEPTIDES, V21, P115, DOI 10.1016/S0196 9781(99)00181 3
   Suzuki N, 2007, ADV SPACE RES, V40, P1711, DOI 10.1016/j.asr.2007.04.104
   Suzuki N, 2016, ENDOCRINE, V54, P575, DOI 10.1007/s12020 016 1153 9
   Suzuki N, 2011, BONE, V48, P1186, DOI 10.1016/j.bone.2011.02.004
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tal Haim, 2012, BONE REGENERATION, DOI [10.5772/38292, DOI 10.5772/38292]
   Thaler HW, 2016, J NUTR HEALTH AGING, V20, P77, DOI 10.1007/s12603 015 0512 1
   Thamamongood TA, 2012, BONE, V50, P1240, DOI 10.1016/j.bone.2012.03.021
   Thong BKS, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16091571
   Tian H, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6374374
   Walsh MC, 2015, IMMUNOL REV, V266, P72, DOI 10.1111/imr.12302
   Wang LW, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05552 1
   Wu X, 2017, CLIN IMPLANT DENT R, V19, P222, DOI 10.1111/cid.12455
   Yanagihara Gabriela Rezende, 2015, Rev. bras. ortop., V50, P232, DOI 10.1016/j.rboe.2015.03.002
   Ye XF, 2011, EUR J GASTROEN HEPAT, V23, P794, DOI 10.1097/MEG.0b013e328348a56a
NR 47
TC 3
Z9 3
U1 0
U2 4
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 1578 USA
SN 0006 2979
EI 1608 3040
J9 BIOCHEMISTRY MOSCOW+
JI Biochem. Moscow
PD OCT
PY 2021
VL 86
IS 10
BP 1192
EP 1200
DI 10.1134/S0006297921100035
EA SEP 2021
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA WJ9OK
UT WOS:000692456400003
PM 34903151
DA 2025 08 17
ER

PT J
AU Liu, S
   Sahid, MNA
   Takemasa, E
   Maeyama, K
   Mogi, M
AF Liu, Shuang
   Sahid, Muhammad N. A.
   Takemasa, Erika
   Maeyama, Kazutaka
   Mogi, Masaki
TI Zoledronate modulates intracellular vesicle trafficking in mast cells
   via disturbing the interaction of myosinVa/Rab3a and sytaxin4/VAMP7
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Nitrogen containing bisphosphonate; Mast cell; Exocytosis; Velocity;
   Membrane fusion
ID T CELLS; MYOSIN V; TRANSPORT; RESPONSES; DEGRANULATION; MECHANISMS;
   SYNTAXIN4; PROTEINS; CANCER; ACID
AB Nitrogen containing bisphosphonates (NBPs) have been widely used as bone anti resorptive drugs for the treatment of osteoclast dependent bone disorders. Zoledronate is currently the most potent NBP, and has potential as an inhibitor of farnesyl pyrophosphate synthase. The present study was undertaken to elucidate the possible effects of zoledronate on Fc epsilon RI dependent mast cell activity in vitro, which is essential for in maintaining homeostasis of the gastrointestinal mucosa. Treatment with zoledronate significantly diminished exocytosis of mast cells, which was reflected by a decrease of FceRI dependent histamine release compared to that in vehicle treated mast cells. Our single vesicle monitoring and biochemical results suggested that zoledronate modulates intracellular formation of the myosinVa/Rab3a complex and syntaxin4/VAMP7 complex, which are critical in vesicle motility, and therefore disturbs exocytosis via suppression of the velocity of intracellular vesicles and inhibition of membrane fusion. Our findings imply that oral administration of zoledronate could modulate mucosal immune function by blocking mast cell function, and this risk should be of concern in the clinical usage of NBPs.
C1 [Liu, Shuang; Sahid, Muhammad N. A.; Takemasa, Erika; Maeyama, Kazutaka; Mogi, Masaki] Ehime Univ, Grad Sch Med, Dept Pharmacol, Toon, Ehime 7910295, Japan.
   [Sahid, Muhammad N. A.] Univ Gadjah Mada, Fac Pharm, Dept Pharmaceut Chem, Yogyakarta 55281, Indonesia.
C3 Ehime University; Gadjah Mada University
RP Liu, S (通讯作者)，Ehime Univ, Grad Sch Med, Dept Pharmacol, Toon, Ehime 7910295, Japan.
EM liussmzk@ehime u.ac.jp
RI Mogi, Masaki/ABH 2011 2020; Shuang, Liu/AAW 2695 2020
FU Japan Society for the Promotion of Science, KAKENHI [25462220,
   15K19575]; Grants in Aid for Scientific Research [15K19575] Funding
   Source: KAKEN
FX M.M's work was funded by the Japan Society for the Promotion of Science,
   KAKENHI Grant 25462220. S.L. was supported by the Japan Society for the
   Promotion of Science, KAKENHI Grant 15K19575.
CR Castella B, 2011, J IMMUNOL, V187, P1578, DOI 10.4049/jimmunol.1002514
   Silva PGD, 2017, INT ENDOD J, V50, P1067, DOI 10.1111/iej.12734
   Silva PGD, 2016, ORAL DIS, V22, P649, DOI 10.1111/odi.12513
   Efergan A, 2016, J IMMUNOL, V196, P1091, DOI 10.4049/jimmunol.1500731
   Fowler DW, 2014, IMMUNOLOGY, V143, P539, DOI 10.1111/imm.12331
   Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158
   Galli SJ, 2016, AM J PATHOL, V186, P212, DOI 10.1016/j.ajpath.2015.07.025
   Grimbaldeston MA, 2007, NAT IMMUNOL, V8, P1095, DOI 10.1038/ni1503
   Higashio H, 2016, SCI REP UK, V6, DOI 10.1038/srep22539
   Hu G, 2013, ACS CHEM BIOL, V8, P1947, DOI 10.1021/cb400259n
   Kolawole EM, 2016, J IMMUNOL, V196, P1461, DOI 10.4049/jimmunol.1501932
   Liu S, 2016, SCI REP UK, V6, DOI 10.1038/srep28133
   Liu S, 2012, IMMUNOL CELL BIOL, V90, P337, DOI 10.1038/icb.2011.41
   McTaggart SJ, 2006, CELL MOL LIFE SCI, V63, P255, DOI 10.1007/s00018 005 5298 6
   Miyagawa F, 2001, J IMMUNOL, V166, P5508, DOI 10.4049/jimmunol.166.9.5508
   Moon TC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00569
   Morita CT, 2007, IMMUNOL REV, V215, P59, DOI 10.1111/j.1600 065X.2006.00479.x
   Norton JT, 2012, J IMMUNOL, V188, P2977, DOI 10.4049/jimmunol.1100830
   Nussbaumer O, 2013, J IMMUNOL, V191, P1346, DOI 10.4049/jimmunol.1300603
   Rizzi A, 2016, IMMUNOL LETT, V177, P16, DOI 10.1016/j.imlet.2016.07.002
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Sahid MNA, 2017, EUR J PHARMACOL, V814, P255, DOI 10.1016/j.ejphar.2017.08.026
   Sbalzarini IF, 2005, J STRUCT BIOL, V151, P182, DOI 10.1016/j.jsb.2005.06.002
   Schott DH, 2002, J CELL BIOL, V156, P35, DOI 10.1083/jcb.200110086
   Singh R. K., 2010, FEBS J, V280, P244
   Stenton GR, 1998, ANN ALLERG ASTHMA IM, V81, P1, DOI 10.1016/S1081 1206(10)63105 5
   Tabb JS, 1998, J CELL SCI, V111, P3221
   Thurnher M, 2013, BBA MOL CELL BIOL L, V1831, P1009, DOI 10.1016/j.bbalip.2013.03.003
   Wöllert T, 2011, J BIOL CHEM, V286, P14352, DOI 10.1074/jbc.M110.187286
   Yamaguchi Y, 2016, ANTICANCER RES, V36, P2307
NR 30
TC 7
Z9 8
U1 0
U2 4
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAY
PY 2018
VL 151
BP 18
EP 25
DI 10.1016/j.bcp.2018.02.013
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GE3FO
UT WOS:000431099400003
PM 29454616
DA 2025 08 17
ER

PT J
AU Yu, H
   Li, Q
   Herbert, B
   Zinna, R
   Martin, K
   Junior, CR
   Kirkwood, KL
AF Yu, H.
   Li, Q.
   Herbert, B.
   Zinna, R.
   Martin, K.
   Junior, C. R.
   Kirkwood, K. L.
TI Anti inflammatory effect of MAPK phosphatase 1 local gene transfer in
   inflammatory bone loss
SO GENE THERAPY
LA English
DT Article
DE MKP 1; cytokine; osteoclastogenesis; periodontal disease
ID INNATE IMMUNE RESPONSES; KINASE PHOSPHATASE 1; OSTEOCLAST
   DIFFERENTIATION; PROTEIN PHOSPHATASES; P38 MAPK; LIPOPOLYSACCHARIDE;
   RESORPTION; DESTRUCTION; CELLS; MECHANISMS
AB Alveolar bone loss associated with periodontal diseases is the result of osteoclastogenesis induced by bacterial pathogens. The mitogen activated protein kinase (MAPK) phosphatase 1 (MKP 1) is a critical negative regulator of immune response as a key phosphatase capable of dephosphorylating activated MAPKs. In this study, rat macrophages transduced with recombinant adenovirus (Ad.) MKP 1 specifically dephosphorylated activated MAPKs induced by lipopolysaccharide (LPS) compared with control cells. Bone marrow macrophages from MKP 1 knockout (KO) mice exhibited higher interleukin (IL) 6, IL 10, tumor necrosis factor (TNF) alpha, and select chemokine compared with wild type (WT) mice when stimulated by LPS. In addition, bone marrow cultures from MKP 1 KO mice exhibited significantly more osteoclastogenesis induced by LPS than when compared with WT mice. Importantly, MKP 1 gene transfer in bone marrow cells of MKP 1 KO mice significantly decreased IL 6, IL 10, TNF alpha and chemokine levels, and formed fewer osteoclasts induced by LPS than compared with control group of cells. Furthermore, MKP 1 gene transfer in an experimental periodontal disease model attenuated bone resorption induced by LPS. Histological analysis confirmed that periodontal tissues transduced with Ad. MKP 1 exhibited less infiltrated inflammatory cells, less osteoclasts and less IL 6 than compared with rats of control groups. These studies indicate that MKP 1 is a key therapeutic target to control of inflammation induced bone loss. Gene Therapy (2011) 18, 344 353; doi:10.1038/gt.2010.139; published online 11 November 2010
C1 [Kirkwood, K. L.] Med Univ S Carolina, Dept Craniofacial Biol, DDS, PhD, Charleston, SC 29425 USA.
   [Yu, H.; Zinna, R.; Martin, K.; Junior, C. R.; Kirkwood, K. L.] Med Univ S Carolina, Ctr Oral Hlth Res, Charleston, SC 29425 USA.
   [Kirkwood, K. L.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
   [Herbert, B.] Coll Charleston, Dept Biol, Charleston, SC 29424 USA.
C3 Medical University of South Carolina; Medical University of South
   Carolina; Medical University of South Carolina; College of Charleston
RP Kirkwood, KL (通讯作者)，Med Univ S Carolina, Dept Craniofacial Biol, DDS, PhD, 173 Ashley Ave BSB 449, Charleston, SC 29425 USA.
EM klkirk@musc.edu
RI Kirkwood, Keith/L 4728 2018; Rossa Jr, Carlos/D 8328 2012
OI Rossa Jr, Carlos/0000 0003 1705 5481; Kirkwood,
   Keith/0000 0003 4519 8973
FU University of Michigan Orthopedic Research Labs; Muscloskeletal Core for
   the microcomputed tomography; NIH [1R01DE018290, 2P20 RR017696]; NIH,
   National Center for Research Resources [C06 RR015455]
FX We acknowledge the continued support of the University of Michigan
   Orthopedic Research Labs and the Muscloskeletal Core for the
   microcomputed tomography. This study is supported by NIH 1R01DE018290
   and 2P20 RR017696. This study was conducted in a facility constructed
   with support from the NIH C06 RR015455 from the Extramural Research
   Facilities Program of the National Center for Research Resources.
CR Brown L J, 1993, Periodontol 2000, V2, P57
   Carlson J, 2009, AM J PATHOL, V175, P1564, DOI 10.2353/ajpath.2009.090035
   Chen PL, 2002, J IMMUNOL, V169, P6408, DOI 10.4049/jimmunol.169.11.6408
   Chi HB, 2006, P NATL ACAD SCI USA, V103, P2274, DOI 10.1073/pnas.0510965103
   Hall TJ, 1996, INFLAMM RES, V45, P1, DOI 10.1007/BF02263497
   HANAZAWA S, 1987, CALCIFIED TISSUE INT, V41, P31, DOI 10.1007/BF02555128
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Jiang YL, 2002, INFECT IMMUN, V70, P3143, DOI 10.1128/IAI.70.6.3143 3148.2002
   Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955 0674(99)00075 7
   Kim MS, 2006, J CELL BIOCHEM, V97, P512, DOI 10.1002/jcb.20649
   Kirkwood KL, 2007, J PHARMACOL EXP THER, V320, P56, DOI 10.1124/jpet.106.112466
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   MARIE PJ, 1995, CALCIFIED TISSUE INT, V56, pS13, DOI 10.1007/BF03354642
   Miyamoto Takeshi, 2003, Keio J Med, V52, P1
   MUNDY GR, 1991, J PERIODONTAL RES, V26, P213, DOI 10.1111/j.1600 0765.1991.tb01647.x
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Nishida E, 2001, J PERIODONTAL RES, V36, P1, DOI 10.1034/j.1600 0765.2001.00637.x
   ORCEL P, 1993, AM J PHYSIOL, V264, pE391, DOI 10.1152/ajpendo.1993.264.3.E391
   Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412
   Ozaki Y, 2009, BONE, V44, P1169, DOI 10.1016/j.bone.2009.01.375
   Patil CS, 2008, MOL THER, V16, P1657, DOI 10.1038/mt.2008.163
   PILOT T, 1991, J CLIN PERIODONTOL, V18, P353, DOI 10.1111/j.1600 051X.1991.tb02300.x
   Reddy SV, 2004, CRIT REV EUKAR GENE, V14, P255, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.20
   Rogers JE, 2007, J PERIODONTOL, V78, P1992, DOI 10.1902/jop.2007.070101
   Salojin KV, 2006, J IMMUNOL, V176, P1899, DOI 10.4049/jimmunol.176.3.1899
   Sartori R, 2009, J DENT RES, V88, P1125, DOI 10.1177/0022034509349306
   Taubman MA, 2005, J PERIODONTOL, V76, P2033, DOI 10.1902/jop.2005.76.11 S.2033
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Wang XX, 2007, CELL SIGNAL, V19, P1372, DOI 10.1016/j.cellsig.2007.03.013
   Whitmarsh AJ, 2007, BBA MOL CELL RES, V1773, P1285, DOI 10.1016/j.bbamcr.2006.11.011
   WILSON ME, 1992, INFECT IMMUN, V60, P1806, DOI 10.1128/IAI.60.5.1806 1812.1992
   Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378 1119(03)00816 3
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Zhao Q, 2006, J EXP MED, V203, P131, DOI 10.1084/jem.20051794
   Zhuang L, 2007, LARYNGOSCOPE, V117, P841, DOI 10.1097/MLG.0b013e318033783a
   Zou W, 2002, J BONE MINER RES, V17, P1211, DOI 10.1359/jbmr.2002.17.7.1211
   Zwerina J, 2006, ARTHRITIS RHEUM US, V54, P463, DOI 10.1002/art.21626
NR 37
TC 45
Z9 49
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969 7128
EI 1476 5462
J9 GENE THER
JI Gene Ther.
PD APR
PY 2011
VL 18
IS 4
BP 344
EP 353
DI 10.1038/gt.2010.139
PG 10
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 769YE
UT WOS:000291053400004
PM 21068780
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Hu, NC
   Yu, T
   Chen, JL
   Zheng, SR
   Yan, H
   Duan, JA
AF Hu, Nianchun
   Yu, Ting
   Chen, Jingli
   Zheng, Shirong
   Yan, Hong
   Duan, Ji'an
TI Oxycodone stimulates normal and malignant hematopoietic progenitors via
   opioid receptor independent β catenin activation
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Oxycodone; Hematopoietic stem/progenitors; Wnt; Opioids receptor
ID MORPHINE; STEM; CANCER; PROLIFERATION; APOPTOSIS; MOLECULES; LEUKEMIA;
   IMPACT; CELLS
AB Oxycodone is a common type of opioid used for the treatment of moderate to severe pain. Besides its analgesic effects on neuron cells, the effects of oxycodone on other cell types are yet to be elucidated. We previously demonstrated that oxycodone displayed both proand anti cancer effects on bulk cancer cells. This work further investigated the effects of oxycodone on normal and malignant hematopoietic stem cells. Using hematopoietic CD34thorn cells isolated from normal bone marrow (NBM) or patients with acute myeloid leukemia (AML), we showed that oxycodone activates hematopoietic cells regardless of cell development stage and malignant status. Oxycodone dose dependently increases colony formation and self renewal capacity of NBM and AML stem/progenitor cells, and promotes proliferation of AML bulk cells. NBM stem/progenitor cells are more sensitive to oxycodone than AML counterparts. In addition, oxycodone alleviates chemotherapy drug induced toxicity in AML stem/progenitor cells. Mechanism studies demonstrate that oxycodone acts on hematopoietic cells in an opioid receptor independent manner. Oxycodone did not affect epithelial growth factor receptor (EGFR) signaling neither but stimulated Wnt/b catenin signaling. Rescue studies via depleting b catenin using genetic and pharmacological approaches confirmed that b catenin was required for the activation of hematopoietic cells induced by oxycodone. Our work demonstrates 1) the protective role of oxycodone in malignant hematopoietic cells from chemotherapy; 2) stimulatory effects of oxycodone in normal hematopoietic stem cells; and 3) ability of oxycodone in Wnt signaling activation. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Hu, Nianchun; Yu, Ting; Chen, Jingli; Yan, Hong; Duan, Ji'an] Huazhong Univ Sci & Technol, Wuhan Cent Hosp, Tongji Med Coll, Dept Anesthesiol, Wuhan, Hubei, Peoples R China.
   [Zheng, Shirong] Wuhan Iron & Steel Grp Corp, Dept Paediat, Staff Hosp 2, Wuhan, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology; China Baowu Steel Group
RP Duan, JA (通讯作者)，Wuhan Cent Hosp, Dept Anesthesiol, Shengli St 26, Wuhan 430014, Hubei, Peoples R China.
EM dr_duanjian@163.com
FU Wuhan Medical Research [WZ18Z06]
FX This work was supported by a research grant provided by Wuhan Medical
   Research (Grant No. WZ18Z06).
CR [Anonymous], 2016, THESCIENTIFICWORLDJO
   Bimonte S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/161508
   Bock TA, 1997, STEM CELLS, V15, P185, DOI 10.1002/stem.5530150824
   Boland JW, 2014, BMJ SUPPORT PALLIAT, V4, P357, DOI 10.1136/bmjspcare 2013 000573
   Carli M, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104938
   Chen YH, 2017, BIOL PHARM BULL, V40, P1686, DOI 10.1248/bpb.b17 00215
   Cui JH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007519
   Curseen KA, 2020, MED CLIN N AM, V104, P415, DOI 10.1016/j.mcna.2020.01.005
   Droney Joanne, 2009, J Pain Res, V2, P135
   Eisenstein TK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02904
   Gallego AO, 2007, CLIN TRANSL ONCOL, V9, P298, DOI 10.1007/s12094 007 0057 9
   Grigson ER, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117693
   Harper P., 2018, Experimental Oncology, V40, P190
   Luis TC, 2012, LEUKEMIA, V26, P414, DOI 10.1038/leu.2011.387
   Ma YB, 2017, RENAL FAILURE, V39, P258, DOI 10.1080/0886022X.2016.1256322
   Nishiwada T, 2019, J ANESTH, V33, P408, DOI 10.1007/s00540 019 02645 1
   Niu DG, 2015, ONCOTARGET, V6, P3963, DOI 10.18632/oncotarget.2894
   Ondrovics M, 2017, ONCOTARGET, V8, P25783, DOI 10.18632/oncotarget.15419
   Quek L, 2016, J EXP MED, V213, P1513, DOI 10.1084/jem.20151775
   Richter J, 2017, CRIT REV BIOCHEM MOL, V52, P414, DOI 10.1080/10409238.2017.1325828
   Rozenfeld Granot G, 2002, EXP HEMATOL, V30, P473, DOI 10.1016/S0301 472X(02)00786 5
   Scheidel B, 2017, INT J CLIN PHARM TH, V55, P881, DOI 10.5414/CP203005
   Schugar RC, 2008, GENE THER, V15, P126, DOI 10.1038/sj.gt.3303062
   Stein C, 2016, ANNU REV MED, V67, P433, DOI 10.1146/annurev med 062613 093100
   Tian M, 2016, EXP THER MED, V12, P559, DOI 10.3892/etm.2016.3346
   Xu C, 2016, CELL MOL LIFE SCI, V73, P327, DOI 10.1007/s00018 015 2067 z
   Yamamizu K, 2015, BRIT J PHARMACOL, V172, P268, DOI 10.1111/bph.12573
   Yu YQ, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20193524
   Zakrzewski W, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1165 5
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhang Y, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1275 0
   Zhao Jun, 2015, Journal of the Medical Association of Thailand, V98, P568
   Zhou Z, 2019, BIOCHEM BIOPH RES CO, V520, P560, DOI 10.1016/j.bbrc.2019.10.067
NR 33
TC 6
Z9 6
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 17
PY 2020
VL 533
IS 4
BP 1457
EP 1463
DI 10.1016/j.bbrc.2020.10.031
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA PG4CR
UT WOS:000599685100005
PM 33268026
DA 2025 08 17
ER

PT J
AU Wu, B
   Chen, ML
   Meng, L
   Tian, QY
   Dong, ZF
AF Wu, Bin
   Chen, Mulan
   Meng, Ling
   Tian, Qiuyun
   Dong, Zhifang
TI Osteoclasts Link Dysregulated Peripheral Degradation Processes and
   Accelerated Progression in Alzheimer's Disease
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Alzheimer's disease; amyloid beta burden; monocyte; osteoclast;
   osteoporosis
ID AMYLOID BETA PEPTIDE; ACID PHOSPHATASE 5B; BONE RESORPTION; TRANSGENIC
   MICE; HIP FRACTURE; CELLS; INHIBITION; MARKER; INFLAMMATION;
   OSTEOPOROSIS
AB Background: The amyloid beta (A beta) enhances the number and activity of blood monocyte derived osteoclasts (OCs). Individuals with osteoporosis (OP) face an increased risk of developing dementia or Alzheimer's disease (AD). Despite this association, the contribution of bone resorbing OCs to the progression of AD pathology remains unclear.
   Objective: Our objective was to investigate the potential impacts of OCs on the development of AD pathology.
   Methods: We conducted targeted analysis of publicly available whole blood transcriptomes from patients with AD to characterize the blood molecular signatures and pathways associated with hyperactive OCs. In addition, we used APP23 transgenic (APP23 TG) AD mouse model to assess the effects of OCs pharmacological blockade on AD pathology and behavior.
   Results: Patients withADexhibited increased osteoclastogenesis signature in their blood cells, which appears to be positively correlated with dysfunction of peripheral clearance of A beta mediated by immune cells. Long term anti resorptive intervention with Alendronate inhibited OC activity in APP23 mice, leading to improvements in peripheral monocyte A beta degrading enzyme expression, A beta deposition, and memory decline.
   Conclusions: Our findings suggest that OCs have a disease promoting role in the development and progression of AD, possibly linked to their modulation of peripheral immunity. These findings guide future research to further elucidate the connection between OP and AD pathogenesis, highlighting the potential benefits of preventing OP in alleviating cognitive burden.
C1 [Wu, Bin; Chen, Mulan; Tian, Qiuyun; Dong, Zhifang] Chongqing Med Univ, Pediat Res Ins,Chongqing Key Lab Child Neurodev &, Growth Dev & Mental Hlth Children & Adolescence,C, Minist Edu,Key Lab Child Dev & Disorders,Natl Cli, Chongqing 400014, Peoples R China.
   [Meng, Ling] Chongqing Med Univ, Sch Basic Med Sci, Dept Cell Biol & Genet, Lab Dev Biol, Chongqing, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University
RP Dong, ZF (通讯作者)，Chongqing Med Univ, Pediat Res Ins,Chongqing Key Lab Child Neurodev &, Growth Dev & Mental Hlth Children & Adolescence,C, Minist Edu,Key Lab Child Dev & Disorders,Natl Cli, Chongqing 400014, Peoples R China.
EM zfdong@cqmu.edu.cn
RI Dong, Zhifang/M 3752 2017; Wu, Bin/KQU 2529 2024
OI Dong, Zhifang/0000 0002 3411 7923; 
FU National Natural Science Foundation of China [32371030, 82071395]; CQMU
   Program for Youth Innovation in Future Medicine [W0044]
FX This work was supported by grants from the National Natural Science
   Foundation of China (32371030 and 82071395) and the CQMU Program for
   Youth Innovation in Future Medicine (W0044).
CR Amouzougan A, 2017, JOINT BONE SPINE, V84, P611, DOI 10.1016/j.jbspin.2016.08.002
   An G, 2016, BLOOD, V128, P1590, DOI 10.1182/blood 2016 03 707547
   Baecker N, 2003, J APPL PHYSIOL, V95, P977, DOI 10.1152/japplphysiol.00264.2003
   Baëhl S, 2016, GERONTOLOGY, V62, P477, DOI 10.1159/000443142
   Baker NL, 2011, AGE AGEING, V40, P49, DOI 10.1093/ageing/afq146
   Barth C, 2023, LANCET DIABETES ENDO, V11, P926, DOI 10.1016/S2213 8587(23)00224 3
   Baruch K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8967
   Bradshaw EM, 2013, NAT NEUROSCI, V16, P848, DOI 10.1038/nn.3435
   Britschgi M, 2007, NAT MED, V13, P408, DOI 10.1038/nm0407 408
   Chen SH, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398 020 01113 9
   Compston JE, 2001, PHYSIOL REV, V81, P419, DOI 10.1152/physrev.2001.81.1.419
   Cox SR, 2018, NEUROBIOL AGING, V69, P274, DOI 10.1016/j.neurobiolaging.2018.05.029
   Cui S, 2011, J BONE MINER RES, V26, P1084, DOI 10.1002/jbmr.299
   DeMarshall Cassandra A, 2016, Alzheimers Dement (Amst), V3, P51, DOI 10.1016/j.dadm.2016.03.002
   Dong Y, 2018, ANN NEUROL, V83, P387, DOI 10.1002/ana.25159
   Dong ZF, 2015, J CLIN INVEST, V125, P234, DOI 10.1172/JCI77888
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Fu JP, 2021, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.624304
   Gu BJ, 2016, ACTA NEUROPATHOL, V132, P377, DOI 10.1007/s00401 016 1596 3
   Hänzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 7
   Halleen JM, 2006, CLIN LAB, V52, P499
   Hansen DV, 2018, J CELL BIOL, V217, P459, DOI 10.1083/jcb.201709069
   Henriksen K, 2007, OSTEOPOROSIS INT, V18, P751, DOI 10.1007/s00198 006 0298 4
   Holmes C, 2009, NEUROLOGY, V73, P768, DOI 10.1212/WNL.0b013e3181b6bb95
   Ibáñez L, 2016, J BONE MINER RES, V31, P1899, DOI 10.1002/jbmr.2868
   Jin ZX, 2014, CELL METAB, V20, P483, DOI 10.1016/j.cmet.2014.07.011
   Kivimäki M, 2019, BMJ BRIT MED J, V365, DOI 10.1136/bmj.l1495
   Kostev K, 2018, J ALZHEIMERS DIS, V65, P401, DOI 10.3233/JAD 180569
   Kuo YM, 2001, MOL MED, V7, P609, DOI 10.1007/BF03401867
   Lebson L, 2010, J NEUROSCI, V30, P9651, DOI 10.1523/JNEUROSCI.0329 10.2010
   Li HY, 2014, J BONE MINER RES, V29, P2666, DOI 10.1002/jbmr.2294
   Li SF, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101683
   Liu YZ, 2005, J BIOL CHEM, V280, P29011, DOI 10.1074/jbc.M501164200
   Madel MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01408
   McGee Lawrence ME, 2008, AM J PHYSIOL REG I, V295, pR1999, DOI 10.1152/ajpregu.90648.2008
   Miyamoto Takeshi, 2003, Keio J Med, V52, P1
   Mohaupt P, 2022, ALZHEIMERS RES THER, V14, DOI 10.1186/s13195 022 01125 1
   Monsonego A, 2001, P NATL ACAD SCI USA, V98, P10273, DOI 10.1073/pnas.191118298
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nordengen K, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974 019 1399 2
   Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202 06.2006
   Park Min KH, 2022, BONE, V165, DOI 10.1016/j.bone.2022.116576
   Park Min KH, 2019, SEMIN IMMUNOPATHOL, V41, P565, DOI 10.1007/s00281 019 00757 0
   Pereira JB, 2021, BRAIN, V144, P3505, DOI 10.1093/brain/awab223
   Pereira M, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216267
   Peskind ER, 2001, NEUROCHEM INT, V39, P409, DOI 10.1016/S0197 0186(01)00048 1
   Preische O, 2019, NAT MED, V25, P277, DOI 10.1038/s41591 018 0304 3
   Purton LE, 1996, BLOOD, V87, P1802
   Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730
   Rissanen JP, 2008, CALCIFIED TISSUE INT, V82, P108, DOI 10.1007/s00223 007 9091 4
   Saresella M, 2010, J ALZHEIMERS DIS, V21, P927, DOI 10.3233/JAD 2010 091696
   Scarmeas N, 2011, AM J GERIAT PSYCHIAT, V19, P471, DOI 10.1097/JGP.0b013e3181eb00a9
   Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022
   Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401 009 0619 8
   Swardfager W, 2010, BIOL PSYCHIAT, V68, P930, DOI 10.1016/j.biopsych.2010.06.012
   Tournier BB, 2020, J ALZHEIMERS DIS, V77, P1043, DOI 10.3233/JAD 200136
   Van Hulle C, 2024, TRANSL PSYCHIAT, V14, DOI 10.1038/s41398 023 02706 w
   Wang JH, 2018, J ALZHEIMERS DIS, V63, P773, DOI 10.3233/JAD 170786
   Weng YT, 2021, REDOX BIOL, V40, DOI 10.1016/j.redox.2020.101849
   Xiao T, 2023, NEUROLOGY, V100, pE2125, DOI 10.1212/WNL.0000000000207220
   Yamamoto M, 2008, J IMMUNOL, V181, P3877, DOI 10.4049/jimmunol.181.6.3877
   Yan P, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI152565
   Yang B, 2020, FASEB J, V34, P3583, DOI 10.1096/fj.201901550R
   Yano A, 2008, P NATL ACAD SCI USA, V105, P15541, DOI 10.1073/pnas.0805354105
   Yu ZY, 2022, AGING CELL, V21, DOI 10.1111/acel.13533
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
   Zhou Y, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19196 2
NR 67
TC 1
Z9 1
U1 1
U2 3
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387 2877
EI 1875 8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2024
VL 99
IS 2
BP 773
EP 785
DI 10.3233/JAD 240096
PG 13
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA RQ8W7
UT WOS:001229228900028
PM 38701149
DA 2025 08 17
ER

PT J
AU Gal Moscovici, A
   Popovtzer, MM
AF Gal Moscovici, A
   Popovtzer, MM
TI New worldwide trends in presentation of renal osteodystrophy and its
   relationship to parathyroid hormone levels
SO CLINICAL NEPHROLOGY
LA English
DT Article
DE renal osteodystrophy; histomorphometry; PTH; dialysis; adynamic bone
   disease
ID BONE TURNOVER; DIALYSIS PATIENTS; PERITONEAL DIALYSIS;
   PEDIATRIC PATIENTS; PREDICTIVE VALUE; PTH FRAGMENTS; DISEASE; ASSAY;
   FAILURE; HISTOMORPHOMETRY
AB Aims. Abnormal mineral metabolism in chronic renal disease is associated with bone disease and extraskeletal calcifications. High turnover, hyperparathyroid bone disease, the most common form of renal osteodystrophy, has been the target for aggressive therapy. More recently, an increasing occurrence of low turnover bone disease has been reported. The present study was undertaken to evaluate the current prevalence of different forms of bone disease in a large Population on chronic hemodialysis and its relationship to parathyroid hormone (PTH) levels. Methods: Ninety six chronic hemodialysis patients underwent double tetracycline labeled bone biopsy. Serum PTH levels were obtained in 52 patients at the time of biopsy. Bone formation rate (BFR/BS) was plotted vs. PTH levels in all patients and in subgroups with PTH ranges between 0   150, 150   500 and 500   1,200 pg/ml. Results. The histomorphometric data showed that 40% of all patients were affected by osteitis fibrosa cystica (OFC). In the remaining 60%, various forms of low turnover bone disease were observed. There was no correlation between PTH and BFR/BS in all patients (r = 0.28) and in subgroups whose PTH levels ranged between 150   500 and 500   1,200 pg/ml (r = 0.027, r = 0.21), respectively. A close correlation between PTH and BFR/BS (r = 0.84, p < 0.05) was found only in the subgroup with a PTH level ranging low turnover bone disease. The predictive between 0   150 pg/ml. Conclusions: The histomorphometric findings present a wide spectrum of renal osteodystrophy with a shift towardsvalue of PTH is limited as high turnover osteodystrophy may present with low PTH levels and that with low turnover may occur with high PTH levels. In the latter parathyroidectomy should be avoided. We share the view that bone biopsy remains the "gold standard" diagnostic tool for renal osteodystrophy.
C1 Hadassah Univ Hosp, Serv Nephrol, IL 91120 Jerusalem, Israel.
   Hadassah Univ Hosp, Hypertens Serv, IL 91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Hospital; Hebrew
   University of Jerusalem; Hadassah University Hospital
RP Hadassah Univ Hosp, Serv Nephrol, POB 12000, IL 91120 Jerusalem, Israel.
EM galanca@hadassah.org.il
CR ANDRESS DL, 1989, NEW ENGL J MED, V321, P274, DOI 10.1056/NEJM198908033210502
   ANDRESS DL, 1986, J CLIN ENDOCR METAB, V63, P1163, DOI 10.1210/jcem 63 5 1163
   Avram MM, 2001, AM J KIDNEY DIS, V38, P1351, DOI 10.1053/ajkd.2001.29254
   Brossard JH, 1996, J CLIN ENDOCR METAB, V81, P3923, DOI 10.1210/jc.81.11.3923
   COBURN JW, 1991, CONTRIB NEPHROL, V90, P166
   Coco M, 2000, AM J KIDNEY DIS, V36, P1115, DOI 10.1053/ajkd.2000.19812
   Coen G, 2002, AM J KIDNEY DIS, V40, P348, DOI 10.1053/ajkd.2002.34519
   Gao P, 2001, J BONE MINER RES, V16, P605, DOI 10.1359/jbmr.2001.16.4.605
   Goodman WG, 2003, KIDNEY INT, V64, pS120, DOI 10.1046/j.1523 1755.64.s87.18.x
   GOODMAN WG, 1994, KIDNEY INT, V46, P1160, DOI 10.1038/ki.1994.380
   John MR, 1999, J CLIN ENDOCR METAB, V84, P4287, DOI 10.1210/jc.84.11.4287
   Lepage R, 1998, CLIN CHEM, V44, P805
   MALLUCHE H, 1990, KIDNEY INT, V38, P193, DOI 10.1038/ki.1990.187
   Monier Faugere MC, 2001, KIDNEY INT, V60, P1460, DOI 10.1046/j.1523 1755.2001.00949.x
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   QI QL, 1995, AM J KIDNEY DIS, V26, P622, DOI 10.1016/0272 6386(95)90599 5
   QUARLES LD, 1992, J CLIN ENDOCR METAB, V75, P145, DOI 10.1210/jc.75.1.145
   RASMUSSEN H, 1987, PHYSL BASIS METABOLI, P56
   Reichel H, 2003, NEPHROL DIAL TRANSPL, V18, P759, DOI 10.1093/ndt/gfg144
   Salusky IB, 2003, KIDNEY INT, V63, P1801, DOI 10.1046/j.1523 1755.2003.00915.x
   SALUSKY IB, 1988, KIDNEY INT, V33, P975, DOI 10.1038/ki.1988.96
   Sawaya BP, 2003, KIDNEY INT, V64, P737, DOI 10.1046/j.1523 1755.2003.00129.x
   SHERRARD DJ, 1993, KIDNEY INT, V56, P89
   TEITELBAUM SL, 1984, HUM PATHOL, V15, P306, DOI 10.1016/S0046 8177(84)80028 3
   VEDI S, 1983, Metabolic Bone Disease and Related Research, V5, P69
   WANG M, 1995, AM J KIDNEY DIS, V26, P836, DOI 10.1016/0272 6386(95)90453 0
NR 26
TC 51
Z9 55
U1 0
U2 3
PU DUSTRI VERLAG DR KARL FEISTLE
PI DEISENHOFEN MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D 82032 DEISENHOFEN MUENCHEN, GERMANY
SN 0301 0430
J9 CLIN NEPHROL
JI Clin. Nephrol.
PD APR
PY 2005
VL 63
IS 4
BP 284
EP 289
PG 6
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 915AJ
UT WOS:000228269700006
PM 15847255
DA 2025 08 17
ER

PT J
AU Toker, H
   Yuce, HB
   Yildirim, A
   Tekin, MB
   Gevrek, F
AF Toker, Hulya
   Yuce, Hatice Balci
   Yildirim, Ali
   Tekin, Mehmet Bugrul
   Gevrek, Fikret
TI The effect of colchicine on alveolar bone loss in ligature induced
   periodontitis
SO BRAZILIAN ORAL RESEARCH
LA English
DT Article
DE Periodontitis; Alveolar Bone Loss; Colchicine
ID FAMILIAL MEDITERRANEAN FEVER; CREVICULAR FLUID LEVELS; MATRIX
   METALLOPROTEINASE 1; TISSUE INHIBITOR; MINERAL DENSITY; RAT; THERAPY;
   DISEASE; GOUT; EXPRESSION
AB Colchicine is widely used in the treatment of several inflammatory diseases due to its anti inflammatory effect, but effects on bone metabolism are unclear. The aim of this study was to evaluate the effects of systemically administered colchicine on healthy periodontium and experimentally induced periodontitis. In total, 42 male Wistar rats were included in this study. A non ligated group constituting the negative control group (Control, C, n = 6) and a ligature only group forming the positive control group (LO, n = 12) were created separately. Twelve rats were treated with 0.4 mg/kg colchicine and another 12 with 1 mg/kg colchicine. In the colchicine administered groups, right mandibles constituted the ligated groups (1 mgC L or 0.4 mgC L) and left mandibles formed the corresponding non ligated controls (1mgC or 0.4mgC). Silk ligatures were placed at the gingival margin of the lower first molars. The animals were euthanized at different time points of healing (11 or 30 days). Alveolar bone loss was clinically measured and TRAP+ osteoclasts, osteoblastic activity, and MMP 1 expression were examined histologically. There was no increase in alveolar bone loss with either colchicine dose in healthy periodontium (p > 0.05) and the highest level of alveolar bone loss, TRAP+ osteoclast number, and MMP 1 expression were measured in the LO group (p < 0.05). The 0.4 mgC L group showed less alveolar bone loss at 11 days (p < 0.05), but greater loss at 30 days. The 1 mgC L group showed higher osteoblast number than the other ligated groups (p < 0.05) at both time points. In summary, colchicine did not increase alveolar bone loss in healthy periodontium and also may tend to reduce periodontitis progression. However, further extensive study is necessary to understand the mechanism of colchicine action on alveolar bone loss in periodontitis.
C1 [Toker, Hulya; Yildirim, Ali; Tekin, Mehmet Bugrul] Cumhuriyet Univ, Sch Dent, Dept Periodontol, Sivas, Turkey.
   [Yuce, Hatice Balci] Gaziosmanpasa Univ, Sch Dent, Dept Periodontol, Tokat, Turkey.
   [Gevrek, Fikret] Gaziosmanpasa Univ, Sch Med, Dept Histol & Embryol, Tokat, Turkey.
C3 Cumhuriyet University; Tokat Gaziosmanpasa University; Tokat
   Gaziosmanpasa University
RP Toker, H (通讯作者)，Cumhuriyet Univ, Sch Dent, Dept Periodontol, Sivas, Turkey.
EM tokerhulya@gmail.com
RI TOKER, Hulya/JVZ 8756 2024; Yüce, Hatice/AAH 8205 2019; Gevrek,
   Fikret/LNP 4862 2024
OI Gevrek, Fikret/0000 0002 3722 2542; 
CR Al Subaie AE, 2016, J CLIN PERIODONTOL, V43, P1160, DOI 10.1111/jcpe.12632
   ARAI N, 1995, J BONE MINER RES, V10, P1209
   Balli U, 2016, J PERIODONTAL IMPLAN, V46, P84, DOI 10.5051/jpis.2016.46.2.84
   Ben Chetrit E, 2006, RHEUMATOLOGY, V45, P274, DOI 10.1093/rheumatology/kei140
   Bhattacharyya B, 2008, MED RES REV, V28, P155, DOI 10.1002/med.20097
   Bostanci V, 2014, QUINTESSENCE INT, V45, P743, DOI 10.3290/j.qi.a32442
   Cai X, 2008, J PERIODONTAL RES, V43, P14, DOI 10.1111/j.1600 0765.2007.00989.x
   Caton J, 1998, J DENT RES, V77, P1001
   Das D, 2000, BBA MOL BASIS DIS, V1502, P351, DOI 10.1016/S0925 4439(00)00059 4
   de Almeida JM, 2007, J PERIODONTOL, V78, P566, DOI 10.1902/jop.2007.060214
   de Souza DM, 2010, J APPL ORAL SCI, V18, P493, DOI 10.1590/S1678 77572010000500011
   Dudkiewicz I, 2005, J ORTHOP RES, V23, P877, DOI 10.1016/j.orthres.2004.11.014
   Ford PJ, 2010, PERIODONTOL 2000, V53, P111, DOI 10.1111/j.1600 0757.2010.00349.x
   Hajishengallis G, 2014, MOL ORAL MICROBIOL, V29, P248, DOI 10.1111/omi.12065
   HARTUNG EF, 1954, ANN RHEUM DIS, V13, P190, DOI 10.1136/ard.13.3.190
   Hernández M, 2011, J DENT RES, V90, P1164, DOI 10.1177/0022034511401405
   HOLTROP ME, 1974, J CELL BIOL, V60, P346, DOI 10.1083/jcb.60.2.346
   Hoult JRS, 1996, GEN PHARMACOL VASC S, V27, P713, DOI 10.1016/0306 3623(95)02112 4
   Koga T, 2016, MOD RHEUMATOL, V26, P637, DOI 10.3109/14397595.2016.1162261
   Leong NL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035980
   Lima V, 2004, J PERIODONTOL, V75, P162, DOI 10.1902/jop.2004.75.1.162
   Liu HM, 2018, J ETHNOPHARMACOL, V210, P232, DOI 10.1016/j.jep.2017.08.029
   Marcaccini AM, 2010, J CLIN PERIODONTOL, V37, P180, DOI 10.1111/j.1600 051X.2009.01512.x
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Misawa T, 2013, NAT IMMUNOL, V14, P454, DOI 10.1038/ni.2550
   Molad Yair, 2002, Curr Rheumatol Rep, V4, P252, DOI 10.1007/s11926 002 0073 2
   Moll JM, 1973, PSORIATIC ARTHRITIS
   MOLLINEDO F, 1989, MOL PHARMACOL, V36, P547
   Muriel P, 2005, BASIC CLIN PHARMACOL, V96, P375, DOI 10.1111/j.1742 7843.2005.pto_06.x
   Nahm DS, 2004, EUR J ORTHODONT, V26, P129, DOI 10.1093/ejo/26.2.129
   Nuki George, 2008, Curr Rheumatol Rep, V10, P218
   Pascual E, 2017, JOINT BONE SPINE, V84, P541, DOI 10.1016/j.jbspin.2016.10.004
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   REIBMAN J, 1991, J IMMUNOL, V146, P988
   Salai M, 2001, J BONE JOINT SURG BR, V83B, P912, DOI 10.1302/0301 620X.83B6.10949
   Siverekli NB, 2012, RHEUMATOL INT, V32, P2453, DOI 10.1007/s00296 011 1980 1
   Suyani E, 2008, CLIN RHEUMATOL, V27, P1171, DOI 10.1007/s10067 008 0930 0
   Toker H, 2018, J PERIODONTAL RES, V53, P478, DOI 10.1111/jre.12536
   Toker H, 2008, J PERIODONTOL, V79, P1089, DOI [10.1902/jop.2008.070462, 10.1902/jop.2008.070462 ]
   Tüter G, 2002, J PERIODONTOL, V73, P487, DOI 10.1902/jop.2002.73.5.487
   Wang L, 2017, AM J MED SCI, V354, P252, DOI 10.1016/j.amjms.2017.05.009
   Wang LR, 2016, IRAN J BASIC MED SCI, V19, P670
   Xu BB, 2014, PHARMAZIE, V69, P43, DOI 10.1691/ph.2014.3773
NR 43
TC 13
Z9 13
U1 0
U2 6
PU SOCIEDADE BRASILEIRA DE PESQUISA ODONTOLOGICA
PI SAO PAULO
PA CIDADE UNIV, AV PROF LINEU PRESTES, ARMANDO SALLE OLIVEIRA, AVENIDA
   LINEU PRESTES, 2227, CP 8216, SAO PAULO, SP 05508 900, BRAZIL
SN 1807 3107
J9 BRAZ ORAL RES
JI Braz. Oral Res.
PY 2019
VL 33
AR 0001
DI 10.1590/1807 3107bor 2019.vol33.0001
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA HY7UA
UT WOS:000468340500001
PM 30758401
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Zou, JL
   Du, JY
   Tu, HL
   Chen, HJ
   Cong, K
   Bi, ZG
   Sun, JB
AF Zou, Jilong
   Du, Jianyang
   Tu, Hualei
   Chen, Hongjun
   Cong, Kai
   Bi, Zhenggang
   Sun, Jiabing
TI Resveratrol benefits the lineage commitment of bone marrow mesenchymal
   stem cells into osteoblasts via miR 320c by targeting Runx2
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE Adipogenic differentiation; BMSCs; MicroRNAs; Osteogenic
   differentiation; Resveratrol
AB Bone marrow mesenchymal stem cells (BMSCs) are a potential source of osteoblasts and have been widely used in clinical therapies due to their pluripotency. Recent publications have found that resveratrol (RSVL) played a crucial role in the proliferation and differentiation of BMSCs; however, the underlying molecular mechanism of RSVL induced BMSCs osteogenic differentiation needs to be fully elucidated. The objective of this study was to explore functions of miRNAs in the RSVL treated BMSCs and its effects on the differentiation potentials of BMSCs. The findings demonstrated that RSVL enhanced the osteogenesis and suppressed the adipogenesis of BMSCs in a dose dependent manner. Besides, a novel regulatory axis containing miR 320c, and its target Runx2 was found during the differentiation process of BMSCs under RSVL treatment. Increase of miR 320c reduced the osteogenic potential of BMSCs, while knockdown of miR 320c played a positive role in the osteogenesis of BMSCs. In contrast, overexpression of miR 320c accelerated the adipogenic differentiation, while knockdown of miR 320c restrained the adipogenic differentiation of BMSCs. The results confirmed that Runx2 might be the direct target of miR 320c in RSVL promoted osteogenic differentiation of BMSCs. This study revealed that RSVL might be used for the treatment of bone loss related diseases and miR 320c could be regarded as a novel and potential target to regulate the biological functions of BMSCs.
C1 [Zou, Jilong; Chen, Hongjun; Cong, Kai; Bi, Zhenggang; Sun, Jiabing] Harbin Med Univ, Affiliated Hosp 1, Dept Orthopaed, Harbin 150001, Peoples R China.
   [Du, Jianyang] Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin, Peoples R China.
   [Tu, Hualei] Fifth Hosp Harbin, Dept Burn, Harbin, Peoples R China.
C3 Harbin Medical University; Harbin Medical University
RP Sun, JB (通讯作者)，Harbin Med Univ, Affiliated Hosp 1, Dept Orthopaed, Harbin 150001, Peoples R China.
EM sunjiabing@live.cn
RI ; chen, hongjun/IZD 4640 2023
OI Zou, Jilong/0000 0002 8037 5077; Du, Jianyang/0000 0001 9682 4183; 
FU Natural Science Foundation of Heilongjiang Province [H2015064];
   Foundation of Heilongjiang Health Committee [2019 012]; Innovation
   Foundation of the First Affiliated Hospital of Harbin Medical University
   [2019B15]; Harbin Medical University Innovation Research Fund
   [2020 KYYWF 1437]
FX Natural Science Foundation of Heilongjiang Province, Grant/Award Number:
   H2015064; Foundation of Heilongjiang Health Committee, Grant/Award
   Number: 2019 012; Innovation Foundation of the First Affiliated Hospital
   of Harbin Medical University, Grant/Award Number: 2019B15; Harbin
   Medical University Innovation Research Fund, Grant/Award Number:
   2020 KYYWF 1437
CR Alkhalaf M, 2006, FREE RADICAL BIO MED, V41, P318, DOI 10.1016/j.freeradbiomed.2006.04.019
   Cai HZ, 2019, MOL THER NUCL ACIDS, V18, P787, DOI 10.1016/j.omtn.2019.09.023
   Cao X, 2014, HYPERTENS RES, V37, P803, DOI 10.1038/hr.2014.90
   Chakraborty S, 2013, BMC STRUCT BIOL, V13, DOI 10.1186/1472 6807 13 27
   Chaudhary Z, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00225
   Chen XH, 2019, EUR REV MED PHARMACO, V23, P6352, DOI 10.26355/eurrev_201907_18459
   Colbath AC, 2020, STEM CELLS DEV, V29, P110, DOI 10.1089/scd.2019.0202
   De Ugarte L, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920 015 0149 2
   Deng L, 2018, J BONE MINER METAB, V36, P648, DOI 10.1007/s00774 017 0886 8
   Deng Y, 2013, STEM CELLS DEV, V22, P2278, DOI 10.1089/scd.2012.0686
   Domazetovic V, 2017, CHEM BIOL INTERACT, V275, P13, DOI 10.1016/j.cbi.2017.07.015
   García Quiroz J, 2019, CANCERS, V11, DOI 10.3390/cancers11111739
   Hamam D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.462
   He J, 2020, BIOMED MATER, V15, DOI 10.1088/1748 605X/ab597f
   Hu N, 2015, INT J MOL SCI, V16, P10491, DOI 10.3390/ijms160510491
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Huang YQ, 2019, MOL MED REP, V20, P3746, DOI 10.3892/mmr.2019.10613
   Inoue K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06446 0
   Iwagami Y, 2013, BRIT J CANCER, V109, P502, DOI 10.1038/bjc.2013.320
   Jeandet P, 2020, BIOTECHNOL ADV, V39, DOI 10.1016/j.biotechadv.2019.107461
   Ji Q, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1119 y
   Jiang ZW, 2017, ACS APPL MATER INTER, V9, P34674, DOI 10.1021/acsami.7b10184
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Li J, 2019, J CELL BIOCHEM, V120, P16634, DOI 10.1002/jcb.28922
   Li KC, 2016, BIOMATERIALS, V74, P155, DOI 10.1016/j.biomaterials.2015.09.046
   Li Y, 2019, MOL THER NUCL ACIDS, V17, P590, DOI 10.1016/j.omtn.2019.06.023
   Liao L, 2018, FASEB J, V32, P1982, DOI 10.1096/fj.201700885R
   Liu H, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1285 y
   Liu J, 2015, BIOMATERIALS, V52, P148, DOI 10.1016/j.biomaterials.2015.02.007
   Luo ZW, 2019, NANOSCALE, V11, P20884, DOI 10.1039/c9nr02791b
   Lv YJ, 2018, THERANOSTICS, V8, P2387, DOI 10.7150/thno.23620
   Maruyama Z, 2007, DEV DYNAM, V236, P1876, DOI 10.1002/dvdy.21187
   Mirsaidi A, 2012, J TISSUE ENG REGEN M, V6, P378, DOI 10.1002/term.440
   Osman AMM, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935 014 0152 2
   Öztürk E, 2017, BIOMED PHARMACOTHER, V95, P230, DOI 10.1016/j.biopha.2017.08.070
   Peng H, 2018, EUR REV MED PHARMACO, V22, P2519, DOI 10.26355/eurrev_201805_14914
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Shou KQ, 2018, J TISSUE ENG REGEN M, V12, pE867, DOI 10.1002/term.2400
   Song H, 2019, NANO LETT, V19, P3040, DOI 10.1021/acs.nanolett.9b00287
   Sui L, 2018, BIOMATERIALS, V177, P88, DOI 10.1016/j.biomaterials.2018.05.038
   Tang Q, 2019, THERANOSTICS, V9, P1125, DOI 10.7150/thno.29566
   Timmers S, 2011, CELL METAB, V14, P612, DOI 10.1016/j.cmet.2011.10.002
   Wang X, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046 014 0069 6
   Wang ZT, 2020, J CELL PHYSIOL, V235, P5182, DOI 10.1002/jcp.29395
   Wilkesmann S, 2020, J BIOMED MATER RES A, V108, P663, DOI 10.1002/jbm.a.36846
   Lee GW, 2020, J CELL BIOCHEM, V121, P3642, DOI 10.1002/jcb.29657
   Wu XW, 2017, J TISSUE ENG REGEN M, V11, P542, DOI 10.1002/term.2076
   Xie Q, 2014, BIOCHEM BIOPH RES CO, V446, P98, DOI 10.1016/j.bbrc.2014.02.058
   Yang F, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12422
   Yang F, 2016, CELL PHYSIOL BIOCHEM, V39, P1369, DOI 10.1159/000447841
   Zhan FL, 2018, J CELL BIOCHEM, V119, P536, DOI 10.1002/jcb.26212
   Zhang XJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10376
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
   Zhao L, 2015, J NUTR BIOCHEM, V26, P1174, DOI 10.1016/j.jnutbio.2015.05.009
   Zheng LL, 2017, J CELL PHYSIOL, V232, P182, DOI 10.1002/jcp.25406
   Zhou T, 2019, REDOX REP, V24, P62, DOI 10.1080/13510002.2019.1658376
   Zhu YL, 2017, MOL MED REP, V15, P3271, DOI 10.3892/mmr.2017.6349
   Zou JL, 2017, CELL PHYSIOL BIOCHEM, V42, P1812, DOI 10.1159/000479537
NR 58
TC 15
Z9 16
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD APR
PY 2021
VL 15
IS 4
BP 347
EP 360
DI 10.1002/term.3176
EA FEB 2021
PG 14
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA RG4BO
UT WOS:000621960400001
PM 33481337
OA gold
DA 2025 08 17
ER

PT J
AU Dong, L
   Yu, WM
   Zheng, H
   Loh, ML
   Bunting, ST
   Pauly, M
   Huang, G
   Zhou, MX
   Broxmeyer, HE
   Scadden, DT
   Qu, CK
AF Dong, Lei
   Yu, Wen Mei
   Zheng, Hong
   Loh, Mignon L.
   Bunting, Silvia T.
   Pauly, Melinda
   Huang, Gang
   Zhou, Muxiang
   Broxmeyer, Hal E.
   Scadden, David T.
   Qu, Cheng Kui
TI Leukaemogenic effects of Ptpn11 activating mutations in the stem
   cell microenvironment
SO NATURE
LA English
DT Article
ID BONE MARROW NICHE; CHRONIC MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM;
   NOONAN SYNDROME; RECEPTOR GENE; SHP2 PTPN11; MOUSE MODEL; MAINTENANCE;
   PROGENITORS; REGENERATION
AB Germline activating mutations of the protein tyrosine phosphatase SHP2 (encoded by PTPN11), a positive regulator of the RAS signalling pathway(1), are found in 50% of patients with Noonan syndrome(2). These patients have an increased risk of developing leukaemia(3), especially juvenile myelomonocytic leukaemia (JMML), a childhood myeloproliferative neoplasm (MPN). Previous studies have demonstrated that mutations in Ptpn11 induce a JMML like MPN through cell autonomous mechanisms that are dependent on Shp2 catalytic activity(4 7). However, the effect of these mutations in the bone marrow microenvironment remains unclear. Here we report that Ptpn11 activating mutations in the mouse bone marrow microenvironment promote the development and progression of MPN through profound detrimental effects on haematopoietic stem cells (HSCs). Ptpn11 mutations in mesenchymal stem/progenitor cells and osteoprogenitors, but not in differentiated osteoblasts or endothelial cells, cause excessive production of the CC chemokine CCL3 (also known as MIP 1 alpha), which recruits monocytes to the area in which HSCs also reside. Consequently, HSCs are hyperactivated by interleukin 1 beta and possibly other proinflammatory cytokines produced by monocytes, leading to exacerbated MPN and to donor cell derived MPN following stem cell transplantation. Remarkably, administration of CCL3 receptor antagonists effectively reverses MPN development induced by the Ptpn11 mutated bone marrow microenvironment. This study reveals the critical contribution of Ptpn11 mutations in the bone marrow microenvironment to leukaemogenesis and identifies CCL3 as a potential therapeutic target for controlling leukaemic progression in Noonan syndrome and for improving stem cell transplantation therapy in Noonansyndrome associated leukaemias.
C1 [Dong, Lei; Yu, Wen Mei; Zheng, Hong; Pauly, Melinda; Zhou, Muxiang; Qu, Cheng Kui] Emory Univ, Sch Med, Div Hematol Oncol,Dept Pediat, Aflac Canc & Blood Disorders Ctr,Childrens Health, Atlanta, GA 30322 USA.
   [Loh, Mignon L.] Univ Calif San Francisco, Div Pediat Hematol Oncol, Dept Pediat, San Francisco, CA 94122 USA.
   [Bunting, Silvia T.] Emory Univ, Childrens Healthcare Atlanta, Dept Pathol, Atlanta, GA 30322 USA.
   [Huang, Gang] Univ Cincinnati, Cincinnati Childrens Hosp, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA.
   [Broxmeyer, Hal E.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.
   [Scadden, David T.] Harvard Univ, Ctr Regenerat Med, Boston, MA 02114 USA.
   [Scadden, David T.] Harvard Univ, MGH Canc Ctr, Massachusetts Gen Hosp, Dept Stem Cell & Regenerat Biol, Boston, MA 02114 USA.
   [Scadden, David T.] Harvard Univ, Harvard Stem Cell Inst, Boston, MA 02114 USA.
C3 Children's Healthcare of Atlanta (CHOA); Emory University; University of
   California System; University of California San Francisco; Children's
   Healthcare of Atlanta (CHOA); Emory University; University System of
   Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical
   Center; Indiana University System; Indiana University Bloomington;
   Harvard University; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Harvard University
RP Qu, CK (通讯作者)，Emory Univ, Sch Med, Div Hematol Oncol,Dept Pediat, Aflac Canc & Blood Disorders Ctr,Childrens Health, Atlanta, GA 30322 USA.
EM cheng kui.qu@emory.edu
RI dong, lei/O 9654 2016; Bunting, Silvia/AAH 1296 2019
OI dong, lei/0000 0001 7530 7427; 
FU National Institutes of Health [HL130995, DK092722]
FX This work was supported by The National Institutes of Health grants
   HL130995 and DK092722 (to C.K.Q.).
CR Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084
   Bruns I, 2014, NAT MED, V20, P1315, DOI 10.1038/nm.3707
   Chan G, 2009, BLOOD, V113, P4414, DOI 10.1182/blood 2008 10 182626
   DeFalco J, 2001, SCIENCE, V291, P2608, DOI 10.1126/science.1056602
   Ding L, 2013, NATURE, V495, P231, DOI 10.1038/nature11885
   Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783
   Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926
   Kfoury Y, 2015, CELL STEM CELL, V16, P239, DOI 10.1016/j.stem.2015.02.019
   Khokha R, 2013, NAT REV IMMUNOL, V13, P649, DOI 10.1038/nri3499
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125
   Kunisaki Y, 2013, NATURE, V502, P637, DOI 10.1038/nature12612
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Mendelson A, 2014, NAT MED, V20, P833, DOI 10.1038/nm.3647
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Mizoguchi T, 2014, DEV CELL, V29, P340, DOI 10.1016/j.devcel.2014.03.013
   Mohi MG, 2007, CURR OPIN GENET DEV, V17, P23, DOI 10.1016/j.gde.2006.12.011
   Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010
   Monvoisin A, 2006, DEV DYNAM, V235, P3413, DOI 10.1002/dvdy.20982
   Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046
   Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Reynaud D, 2011, CANCER CELL, V20, P661, DOI 10.1016/j.ccr.2011.10.012
   Roberts AE, 2013, LANCET, V381, P333, DOI 10.1016/S0140 6736(12)61023 X
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Schepers K, 2013, CELL STEM CELL, V13, P285, DOI 10.1016/j.stem.2013.06.009
   Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070
   Stadtfeld M, 2005, DEVELOPMENT, V132, P203, DOI 10.1242/dev.01558
   Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772
   Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703
   Walkley CR, 2007, CELL, V129, P1081, DOI 10.1016/j.cell.2007.03.055
   Walkley CR, 2007, CELL, V129, P1097, DOI 10.1016/j.cell.2007.05.014
   Wang L, 2014, CELL STEM CELL, V15, P51, DOI 10.1016/j.stem.2014.04.021
   Xu D, 2011, J EXP MED, V208, P1977, DOI 10.1084/jem.20110450
   Youn BS, 2000, IMMUNOL REV, V177, P150, DOI 10.1034/j.1600 065X.2000.17701.x
   Yu WM, 2013, CELL STEM CELL, V12, P62, DOI 10.1016/j.stem.2012.11.022
   Zhang B, 2012, CANCER CELL, V21, P577, DOI 10.1016/j.ccr.2012.02.018
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhao M, 2014, NAT MED, V20, P1321, DOI 10.1038/nm.3706
NR 39
TC 204
Z9 234
U1 1
U2 37
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028 0836
EI 1476 4687
J9 NATURE
JI Nature
PD NOV 10
PY 2016
VL 539
IS 7628
BP 304
EP +
DI 10.1038/nature20131
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EB4CZ
UT WOS:000387318500048
PM 27783593
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Carbonare, LD
   Innamorati, G
   Valenti, MT
AF Carbonare, Luca Dalle
   Innamorati, Giulio
   Valenti, Maria Teresa
TI Transcription Factor Runx2 and its Application to Bone Tissue
   Engineering
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article
DE Bone; Osteogenic differentiation; Regenerative medicine; Runx2
ID MESENCHYMAL STEM CELLS; MARROW STROMAL CELLS; HUMAN CBFA1 GENE;
   MORPHOGENETIC PROTEIN 2; IN VITRO; OSTEOBLASTIC DIFFERENTIATION;
   EXPRESSION; RUNX2/CBFA1; REGENERATION; ACTIVATION
AB Cbfa1/Runx2 is a bone transcription factor homologous to the Drosophila protein, Runt. Runx2 is a master gene that encodes for a protein involved in the osteogenic differentiation process from mesenchymal precursors. It is known that in Cbfa1 deficient mice (Cbfa1( / )) the lack of mature osteoblasts is associated to incomplete bone mineralization. An important aim of modern biology is the development of new molecular tools for identification of therapeutic approaches. Recent discoveries in cell and molecular biology enabled researchers in the bone tissue engineering field to develop new strategies for gene and cell based therapies. This review summarizes the process of osteogenic differentiation from mesenchymal stem cells and the importance of bone regeneration is discussed. In particular, given the increasing interest in the study of the transcription factor Runx2, this review highlights the role of this target gene and addresses recent strategies using Runx2 for bone regeneration.
C1 [Carbonare, Luca Dalle; Valenti, Maria Teresa] Univ Verona, Clin Internal Med, Dept Med, Sect D, I 37134 Verona, Italy.
   [Carbonare, Luca Dalle; Innamorati, Giulio; Valenti, Maria Teresa] Univ Verona, LURM Univ Lab Med Res, I 37134 Verona, Italy.
C3 University of Verona; University of Verona
RP Valenti, MT (通讯作者)，Univ Verona, Clin Internal Med, Dept Med, Sect D, Piazzale Scuro 10, I 37134 Verona, Italy.
EM mariateresa.valenti@univr.it
RI Innamorati, Giulio/AAR 6314 2020; Carbonare, Luca/E 5720 2011; Valenti,
   Maria/F 4712 2011
OI Valenti, Maria Teresa/0000 0003 1166 8033; Innamorati,
   Giulio/0000 0003 0123 8777; Dalle Carbonare, Luca/0000 0003 3263 6671
CR Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067
   Bae S., 2008, U.S. Patent, Patent No. 20080219962
   Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026
   Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534 5807(04)00058 9
   Buckley CT, 2010, J BIOMED MATER RES B, V93B, P459, DOI 10.1002/jbm.b.31603
   Byers BA, 2004, TISSUE ENG, V10, P1757, DOI 10.1089/ten.2004.10.1757
   Caetano Lopes J, 2007, ACTA REUMATOL PORT, V32, P103
   Cai X, 2009, ACTA BIOMATER, V5, P2693, DOI 10.1016/j.actbio.2009.03.005
   Cartmell SH, 2003, TISSUE ENG, V9, P1197, DOI 10.1089/10763270360728107
   Charbord P, 2010, HUM GENE THER, V21, P1045, DOI 10.1089/hum.2010.115
   Cohen MM, 2009, AM J MED GENET A, V149A, P2629, DOI 10.1002/ajmg.a.33021
   De Bari C, 2001, ARTHRITIS RHEUM US, V44, P1928, DOI 10.1002/1529 0131(200108)44:8<1928::AID ART331>3.0.CO;2 P
   De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935
   Doll B., 2003, U.S. Patent, Patent No. 20030235564
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Donna SD, 2006, US Patent, Patent No. [7,741,113, 7741113]
   Drissi H, 2002, EXP CELL RES, V274, P323, DOI 10.1006/excr.2002.5474
   Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695
   Fang JM, 1996, P NATL ACAD SCI USA, V93, P5753, DOI 10.1073/pnas.93.12.5753
   Foster LJ, 2005, STEM CELLS, V23, P1367, DOI 10.1634/stemcells.2004 0372
   Franceschi RT, 2007, ANN NY ACAD SCI, V1116, P196, DOI 10.1196/annals.1402.081
   Franceschi RT, 2005, J DENT RES, V84, P1093, DOI 10.1177/154405910508401204
   Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980
   Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679
   Gillissen A, 1997, RESP MED, V91, P159, DOI 10.1016/S0954 6111(97)90052 4
   Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972
   Himburg HA, 2010, NAT MED, V16, P475, DOI 10.1038/nm.2119
   Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197 36
   Hu R, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176099
   Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033 1043.2004
   Ishaug Riley SL, 1998, BIOMATERIALS, V19, P1405, DOI 10.1016/S0142 9612(98)00021 0
   Ishihara A, 2010, GENE THER, V17, P733, DOI 10.1038/gt.2010.13
   Janatova J, 2000, ASAIO J, V46, pS53, DOI 10.1097/00002480 200011000 00038
   Janicki P, 2011, EUR CELLS MATER, V21, P488, DOI 10.22203/eCM.v021a37
   Jensen ED, 2008, J BONE MINER RES, V23, P361, DOI 10.1359/JBMR.071104
   Jensen ED, 2010, BIOFACTORS, V36, P25, DOI 10.1002/biof.72
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Jeong JH, 2008, J CELL PHYSIOL, V217, P511, DOI 10.1002/jcp.21524
   Jilka RL, 2010, J BONE MINER RES, V25, P2427, DOI 10.1002/jbmr.145
   Jose MV, 2009, ACTA BIOMATER, V5, P305, DOI 10.1016/j.actbio.2008.07.019
   Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037
   Kretlow JD, 2008, AICHE J, V54, P3048, DOI 10.1002/aic.11610
   Laurencin CT, 1999, ANNU REV BIOMED ENG, V1, P19, DOI 10.1146/annurev.bioeng.1.1.19
   Legeros Racquel Z., 1993, Clinical Materials, V14, P65, DOI 10.1016/0267 6605(93)90049 D
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Lucas N, 2008, CHEMOSPHERE, V73, P429, DOI 10.1016/j.chemosphere.2008.06.064
   Luk JM, 2005, J IMMUNOL METHODS, V305, P39, DOI 10.1016/j.jim.2005.07.006
   LURIA EA, 1971, TRANSFUSION, V11, P345, DOI 10.1111/j.1537 2995.1971.tb04426.x
   Marie P, 2000, JOINT BONE SPINE, V67, P150
   Meyer U, 2005, Eur Cell Mater, V9, P39
   Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   NOJIRI C, 1992, J BIOMAT SCI POLYM E, V4, P75
   OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859
   Ogawa T., 2009, U.S. Patent, Patent No. 20090324669
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491
   Park MH, 2001, J BONE MINER RES, V16, P885, DOI 10.1359/jbmr.2001.16.5.885
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   Quarto N, 2010, TISSUE ENG PT A, V16, P3185, DOI 10.1089/ten.tea.2010.0133
   Roca H, 2005, J BIOL CHEM, V280, P30845, DOI 10.1074/jbc.M503942200
   Rosada C, 2003, CALCIFIED TISSUE INT, V72, P135, DOI 10.1007/s00223 002 2002 9
   Shen Q, 2005, J BIOL CHEM, V280, P40589, DOI 10.1074/jbc.M504166200
   Shui CX, 2003, J BONE MINER RES, V18, P213, DOI 10.1359/jbmr.2003.18.2.213
   SOBALLE K, 1992, J ORTHOPAED RES, V10, P285, DOI 10.1002/jor.1100100216
   Sreejalekshmi KG, 2011, J BIOMED MATER RES A, V96A, P477, DOI 10.1002/jbm.a.32980
   Sudhakar S, 2001, BIOCHEM BIOPH RES CO, V289, P616, DOI 10.1006/bbrc.2001.6033
   Tou LQ, 2001, MOL CELL ENDOCRINOL, V183, P71, DOI 10.1016/S0303 7207(01)00594 9
   Tsaryk R, 2007, BIOMATERIALS, V28, P806, DOI 10.1016/j.biomaterials.2006.09.033
   Valenti MT, 2008, BONE, V43, P1084, DOI 10.1016/j.bone.2008.07.252
   Vallés G, 2006, BIOMATERIALS, V27, P5199, DOI 10.1016/j.biomaterials.2006.05.045
   Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003
   Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Ylönen R, 2005, J BONE MINER RES, V20, P1381, DOI 10.1359/JBMR.050319
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
NR 80
TC 111
Z9 118
U1 0
U2 22
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629 3269
EI 2629 3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
PD SEP
PY 2012
VL 8
IS 3
BP 891
EP 897
DI 10.1007/s12015 011 9337 4
PG 7
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 986HQ
UT WOS:000307333100023
PM 22139789
DA 2025 08 17
ER

PT J
AU Leguizamón, ND
   de Molo, RS
   Coletto Nunes, G
   Nogueira, AVB
   Rocha, S
   Neo Justino, DM
   Soares Costa, A
   Cerri, PS
   Lerner, UH
   Souza, PPC
   Cirelli, JA
AF Leguizamon, N. Da Ponte
   de Molo, R. S.
   Coletto Nunes, G.
   Nogueira, A. V. B.
   Rocha, S., V
   Neo Justino, D. M.
   Soares Costa, A.
   Cerri, P. S.
   Lerner, U. H.
   Souza, P. P. C.
   Cirelli, J. A.
TI Phytocystatin CsinCPI 2 Reduces Osteoclastogenesis and Alveolar Bone
   Loss
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE periodontal diseases; periodontitis; bone resorption; osteoclasts;
   inflammation; cystatins
ID RESORPTION IN VITRO; FACTOR KAPPA B; PERIODONTAL DISEASE; CYSTATIN C;
   SUGARCANE CYSTATIN; OSTEOIMMUNOLOGY; OSTEONECROSIS; ACTIVATION;
   EXPRESSION; CYTOKINES
AB Periodontal disease (PD) is a polymicrobial chronic inflammatory condition of the supporting tissues around the teeth, leading to the destruction of surrounding connective tissue. During the progression of PD, osteoclasts play a crucial role in the resorption of alveolar bone that eventually leads to the loss of teeth if the PD is left untreated. Therefore, the development of antiresorptive therapies targeting bone resorbing cells will significantly benefit the treatment of PD. Here, we demonstrate the inhibitory effect of CsinCPI 2, a novel cysteine peptidase inhibitor from the orange tree, on periodontitis induced inflammation, alveolar bone loss, and osteoclast differentiation. Using the ligature induced periodontitis model in mice, we show that treatment with CsinCPI 2 (0.8 mu g/g of body weight) significantly reduced inflammatory cell infiltrate in the connective tissue and prevented the loss of alveolar bone mass (BV/TV) caused by PD, effects associated with diminished numbers of TRAP positive multinucleated cells. Furthermore, CsinCPI 2 significantly downregulated the numbers of inflammatory cells expressing CD3, CD45, MAC387, and IL 1 beta. In vitro, CsinCPI 2 inhibited RANKL induced TRAP+ multinucleated osteoclast formation in mouse bone marrow macrophage cultures in a concentration dependent manner. This effect was not due to cytotoxicity, as demonstrated by the MTT assay. CsinCPI 2 inhibited RANKL induced mRNA expression of Acp5, Calcr, and Ctsk, as well as the RANKL induced upregulation of Nfatc1, a crucial transcription factor for osteoclast differentiation. Based on our findings, CsinCPI 2 prevents bone loss induced by PD by controlling the inflammatory process and acting directly on osteoclastogenesis, suggesting an interesting potential for CsinCPI 2 in the strategy for PD treatment.
C1 [Leguizamon, N. Da Ponte; de Molo, R. S.; Coletto Nunes, G.; Cirelli, J. A.] Sao Paulo State Univ UNESP, Sch Dent, Dept Diag & Surg, Rua Humaita 1680, BR 14801903 Araraquara, SP, Brazil.
   [Nogueira, A. V. B.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Periodontol & Operat Dent, Mainz, Germany.
   [Rocha, S., V; Neo Justino, D. M.; Soares Costa, A.] Univ Fed Sao Carlos, Dept Genet & Evolut, Sao Carlos, Brazil.
   [Cerri, P. S.] Sao Paulo State Univ UNESP, Dept Morphol Genet Orthodont & Pediat Dent, Araraquara, SP, Brazil.
   [Lerner, U. H.] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Bone & Arthrit Res,Dept Internal Med & Clin N, Gothenburg, Sweden.
   [Souza, P. P. C.] Univ Fed Goias, Fac Dent, Innovat Biomat Lab, Av Univ Esq 1a Ave S N, BR 74605220 Goiania, Go, Brazil.
C3 Universidade Estadual Paulista; Johannes Gutenberg University of Mainz;
   Universidade Federal de Sao Carlos; Universidade Estadual Paulista;
   University of Gothenburg; Universidade Federal de Goias
RP Cirelli, JA (通讯作者)，Sao Paulo State Univ UNESP, Sch Dent, Dept Diag & Surg, Rua Humaita 1680, BR 14801903 Araraquara, SP, Brazil.; Souza, PPC (通讯作者)，Univ Fed Goias, Fac Dent, Innovat Biomat Lab, Av Univ Esq 1a Ave S N, BR 74605220 Goiania, Go, Brazil.
EM pedrosouza@ufg.br; joni.cirelli@unesp.br
RI Cerri, Paulo/AAC 5797 2019; Rocha, Sâmara/AAP 1944 2020; Soares Costa,
   Andrea/D 8270 2012; Nogueira, Andressa/H 3987 2014; Chaves de Souza,
   Pedro Paulo/G 3801 2011; Cirelli, Joni/AAG 7785 2019; Nogueira, Andressa
   V. B./H 3987 2014; Justino, Daniela/ABK 5590 2022; de Molon, Rafael
   Scaf/D 6633 2012; de Souza, Pedro/G 3801 2011
OI Soares Costa, Andrea/0000 0002 7379 1136; Chaves de Souza, Pedro
   Paulo/0000 0001 7266 6061; Nogueira, Andressa V. B./0000 0002 2756 5947;
   Morilha Neo Justino, Daniela/0000 0003 1588 0226; Lerner,
   Ulf/0000 0002 3579 1960; Rocha, Samara/0000 0001 7014 012X; de Molon,
   Rafael Scaf/0000 0003 1110 6233
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brasil
   (CAPES) [001]; Becal (Don Carlos Antonio Lopez, Paraguay Programme)
   [118/2017]; FAPESP [2014/05283 3, 2015/21697 5, 2016/09876 4,
   2018/10728 5, 2018/10727 9]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This study was
   financed by the Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior Brasil (CAPES; finance code 001), by Becal (Don Carlos Antonio
   Lopez, Paraguay Programme, grant 118/2017) to N. Da Ponte Leguizamon,
   and by FAPESP (grants 2014/05283 3; 2015/21697 5, 2016/09876 4;
   2018/10728 5 and 2018/10727 9).
CR Aral K, 2020, J PERIODONTAL RES, V55, P473, DOI 10.1111/jre.12733
   Bäcklund A, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3298
   Nogueira AVB, 2017, J CLIN PERIODONTOL, V44, P31, DOI 10.1111/jcpe.12636
   Bokarewa M, 2007, J RHEUMATOL, V34, P1293
   Brage M, 2004, BONE, V34, P412, DOI 10.1016/j.bone.2003.11.018
   Brandao DD, 2019, J PERIODONTOL, V90, P535, DOI 10.1002/JPER.18 0392
   Chen B, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/731039
   de Molon RS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184541
   de Molon RS, 2016, J BONE MINER RES, V31, P1596, DOI 10.1002/jbmr.2827
   de Molon RS, 2014, BONE, V68, P11, DOI 10.1016/j.bone.2014.07.027
   de Molon RS, 2014, J PERIODONTOL, V85, P465, DOI 10.1902/jop.2013.130225
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Elburki MS, 2017, INFLAMMATION, V40, P1436, DOI 10.1007/s10753 017 0587 4
   Gianotti A, 2008, BIOL CHEM, V389, P447, DOI 10.1515/BC.2008.035
   Guimaraes MR, 2011, J PERIODONTAL RES, V46, P269, DOI 10.1111/j.1600 0765.2010.01342.x
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Johansson L, 2000, BONE, V26, P451, DOI 10.1016/S8756 3282(00)00261 1
   Kim YG, 2020, J PERIODONTOL, V91, P809, DOI 10.1002/JPER.19 0228
   Kinane DF., 2017, NAT REV DIS PRIM, V3, P1, DOI DOI 10.1038/NRDP.2017.38
   Kuo PJ, 2019, J PERIODONTOL, V90, P271, DOI 10.1002/JPER.16 0708
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Leguizamón ND, 2019, CYTOKINE, V123, DOI 10.1016/j.cyto.2019.154760
   Lerner U.H., 2020, ENCY BONE BIOL, P67
   LERNER UH, 1992, J BONE MINER RES, V7, P433
   Lerner UH., 2020, ENCY BONE, P45
   Lerner UH., 2020, ENCY BONE, P88
   Liu D, 2003, INT J MOL MED, V11, P17
   Liu YCG, 2010, PERIODONTOL 2000, V52, P163, DOI 10.1111/j.1600 0757.2009.00321.x
   Nakashima T, 2009, J CLIN IMMUNOL, V29, P555, DOI 10.1007/s10875 009 9316 6
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Santiago AC, 2017, J DENT RES, V96, P1051, DOI 10.1177/0022034517712981
   Schett G, 2011, EUR J CLIN INVEST, V41, P1361, DOI 10.1111/j.1365 2362.2011.02545.x
   Soares Costa A, 2002, BIOCHEM BIOPH RES CO, V296, P1194, DOI 10.1016/S0006 291X(02)02046 6
   Souza PPC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01663
   Souza PPC, 2013, IMMUNOL INVEST, V42, P555, DOI 10.3109/08820139.2013.822766
   Stralberg F, 2017, J LEUKOCYTE BIOL, V101, P1233, DOI 10.1189/jlb.3A1016 433R
   Strålberg F, 2013, FASEB J, V27, P2687, DOI 10.1096/fj.12 211748
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tompkins KA, 2016, CONNECT TISSUE RES, V57, P69, DOI 10.3109/03008207.2016.1140152
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
NR 41
TC 10
Z9 10
U1 0
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD FEB
PY 2022
VL 101
IS 2
BP 216
EP 225
AR 00220345211027811
DI 10.1177/00220345211027811
EA JUL 2021
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA YR0OZ
UT WOS:000681099300001
PM 34328027
DA 2025 08 17
ER

PT J
AU Moradi, F
   Aghamaali, M
   Hadavi, M
AF Moradi, Fatemeh
   Aghamaali, Mahmoudreza
   Hadavi, Mahvash
TI Osteogenic differentiation of human amniotic mesenchymal stem cells by
   phycocyanin and phycoerythrin pigments isolated from Spirulina
   platensis and Gracilaria gracilis algae
SO TISSUE & CELL
LA English
DT Article
DE hAMCs; Osteogenic differentiation; Phycocyanin; Phycoerythrin; Algae
ID SIGNALING PATHWAYS; BONE; MINERALIZATION; ACTIVATION; EXTRACTION;
   CULTURE
AB Bone regeneration is a multistep and regular physiological process that occurs normally in fracture repair and bone defects. However, some factors such as aging, particular diseases and some drugs prevent or slowdown bone natural healing. Cell therapy using stem cells and differentiation activating factors is an effective treatment method for bone regeneration triggering in unusual conditions. Therefore, in the present study the effect of phycocyanin and phycoerythrin pigments which isolated from Spirulina platensis and Gracilaria gracilis algae was investigate on osteogenic differentiation potency of human Amniotic Mesenchymal Stem Cells (hAMSCs). For this purpose, hAMSCs were exposed to 300, 500, and 700 mu g/ml concentrations of phycocyanin and phycoerythrin pigments and then the cells viability was measured with MTT assay in 48 and 72 h after treatment. The osteo differentiation level of cells was studied by measuring ALP activity using calorimetric method and Alizarin red staining for calcium deposition in 7 and 21 days after treatment. Also, total RNA of cells was extracted in different time periods and then cDNA synthesized with specific primers, and relative expression of Runx2, beta catenin and Osteocalcin genes were investigated using SYBR Green RT qPCR technique. Osteogenic differentiation of hAMSCs that treated with pigments was confirmed by mineral deposits staining and increased level of ALP activity. Furthermore, these pigments elevated significantly the expression of osteogenic marker genes compared to control samples and caused hAMSCs to differentiate into osteoblast cells. According to these results, phycocyanin and phycoerythrin may suggest as suitable osteogenic supplements with low toxicity, low cost and high efficiency, although the molecular mechanism of its efficacy is not available yet.
C1 [Moradi, Fatemeh; Aghamaali, Mahmoudreza] Univ Guilan, Fac Sci, Dept Biol, Biochem Lab, Rasht, Iran.
   [Hadavi, Mahvash] Univ Guilan, Fac Sci, Dept Biol, Tissue Engn Lab, Rasht, Iran.
C3 University of Guilan; University of Guilan
RP Aghamaali, M (通讯作者)，Univ Guilan, Fac Sci, Dept Biol, Biochem Lab, Rasht, Iran.
EM aghamaali@guilan.ac.ir
FU Iran National Science Foundation (INSF) [99027769]
FX the Iran National Science Foundation (INSF) with project code 99027769
   from the Vice President of Science and Technology of Iran.
CR Abdel Moneim AME, 2022, SAUDI J BIOL SCI, V29, P1197, DOI 10.1016/j.sjbs.2021.09.046
   Anderson JM, 2011, ACTA BIOMATER, V7, P675, DOI 10.1016/j.actbio.2010.08.016
   Aneiros A, 2004, J CHROMATOGR B, V803, P41, DOI 10.1016/j.jchromb.2003.11.005
   Arvidson K, 2011, J CELL MOL MED, V15, P718, DOI 10.1111/j.1582 4934.2010.01224.x
   Augello A, 2010, EUR CELLS MATER, V20, P121
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   BENNETT A, 1973, J CELL BIOL, V58, P419, DOI 10.1083/jcb.58.2.419
   Bharathiraja S, 2016, MOLECULES, V21, DOI 10.3390/molecules21111470
   Chen XJ, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108746
   CRAIG IW, 1968, BIOCHEM J, V106, P361, DOI 10.1042/bj1060361
   Deng RX, 2018, J FUNCT FOODS, V40, P229, DOI 10.1016/j.jff.2017.10.044
   Dranseikiene D, 2022, PLANTS BASEL, V11, DOI 10.3390/plants11091249
   Francavilla M, 2015, BIORESOURCE TECHNOL, V184, P305, DOI 10.1016/j.biortech.2014.10.147
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Hadavi M, 2018, ARTIF CELL NANOMED B, V46, pS559, DOI 10.1080/21691401.2018.1431649
   Huo Shuang zhi, 2010, Chinese Medical Sciences Journal, V25, P211, DOI 10.1016/S1001 9294(11)60004 7
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Kim SC, 2023, MATER TODAY COMMUN, V36, DOI 10.1016/j.mtcomm.2023.106852
   Kirankumar S, 2022, EXP BIOL MED, V247, P433, DOI 10.1177/15353702211052927
   Littler M.M., 1978, Marine algae of California
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Luo Y., 2023, Modulation of mesenchymal stem cells protection against senescence during long term expansion by the PI3K/Akt signaling
   Meesuk L, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 24160 2
   Molagoda IMN, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110711
   Narisawa S, 2013, J BONE MINER RES, V28, P1587, DOI 10.1002/jbmr.1901
   Nguyen M.H.T., 2011, Advances in Food and Nutrition Research, P429
   Ohmes J, 2022, MAR DRUGS, V20, DOI 10.3390/md20060402
   Ohyashiki T, 1999, BBA BIOMEMBRANES, V1421, P131, DOI 10.1016/S0005 2736(99)00119 4
   Pan DJ, 2022, MAR DRUGS, V20, DOI 10.3390/md20040260
   PRICE PA, 1980, P NATL ACAD SCI BIOL, V77, P2234, DOI 10.1073/pnas.77.4.2234
   Ryu B, 2015, J FUNCT FOODS, V19, P505, DOI 10.1016/j.jff.2015.09.022
   Saud B, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/7513404
   Shen FY, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.809918
   Tate MLK, 2004, INT J BIOCHEM CELL B, V36, P1, DOI 10.1016/S1357 2725(03)00241 3
   Thoisen C, 2017, METHODSX, V4, P209, DOI 10.1016/j.mex.2017.06.002
   Titushkin I, 2007, BIOPHYS J, V93, P3693, DOI 10.1529/biophysj.107.107797
   Wijesekara I, 2011, CARBOHYD POLYM, V84, P14, DOI 10.1016/j.carbpol.2010.10.062
   Xiang X, 2022, J BIOPHOTONICS, V15, DOI 10.1002/jbio.202100333
   Yu LY, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00184 2
   Zamurovic N, 2004, J BIOL CHEM, V279, P37704, DOI 10.1074/jbc.M403813200
   Zhang LT, 2019, LIFE SCI, V232, DOI 10.1016/j.lfs.2019.116669
NR 41
TC 2
Z9 2
U1 3
U2 14
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0040 8166
J9 TISSUE CELL
JI Tissue Cell
PD DEC
PY 2023
VL 85
AR 102216
DI 10.1016/j.tice.2023.102216
EA SEP 2023
PG 8
WC Anatomy & Morphology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology; Cell Biology
GA U7FM0
UT WOS:001086424600001
PM 37774523
DA 2025 08 17
ER

PT J
AU Shrivats, AR
   Hsu, E
   Averick, S
   Klimak, M
   Watt, ACS
   DeMaio, M
   Matyjaszewski, K
   Hollinger, JO
AF Shrivats, Arun R.
   Hsu, Eric
   Averick, Saadyah
   Klimak, Molly
   Watt, April C. S.
   DeMaio, Marlene
   Matyjaszewski, Krzysztof
   Hollinger, Jeffrey O.
TI Cationic Nanogel mediated Runx2 and Osterix siRNA Delivery Decreases
   Mineralization in MC3T3 Cells
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID TRANSFER RADICAL POLYMERIZATION; TRAUMATIC BRAIN INJURY; MESENCHYMAL
   STEM CELLS; SPINAL CORD INJURY; HETEROTOPIC OSSIFICATION;
   TRANSCRIPTIONAL REGULATION; RISK FACTORS; RADIATION PROPHYLAXIS; EARLY
   EXCISION; BONE FORMATION
AB Heterotopic ossification (HO) may occur after musculoskeletal trauma, traumatic brain injury, and total joint arthroplasty. As such, HO is a compelling clinical concern in both military and civilian medicine. A possible etiology of HO involves dysregulated signals in the bone morphogenetic protein osteogenic cascade. Contemporary treatment options for HO (ie, nonsteroidal antiinflammatory drugs and radiation therapy) have adverse effects associated with their use and are not biologically engineered to abrogate the molecular mechanisms that govern osteogenic differentiation.
   We hypothesized that (1) nanogel mediated short interfering RNA (siRNA) delivery against Runt related transcription factor 2 (Runx2) and osterix (Osx) genes will decrease messenger RNA expression; (2) inhibit activity of the osteogenic marker alkaline phosphatase (ALP); and (3) inhibit hydroxyapatite (HA) deposition in osteoblast cell cultures.
   Nanogel nanostructured polymers delivered siRNA in 48 hour treatment cycles against master osteogenic regulators, Runx2 and Osx, in murine calvarial preosteoblasts (MC3T3 E1.4) stimulated for osteogenic differentiation by recombinant human bone morphogenetic protein (rhBMP 2). The efficacy of RNA interference (RNAi) therapeutics was determined by quantitation of messenger RNA knockdown (by quantitative reverse transcription polymerase chain reaction), downstream protein knockdown (determined ALP enzymatic activity assay), and HA deposition (determined by OsteoImage (TM) assay).
   Gene expression assays demonstrated that nanogel based RNAi treatments at 1:1 and 5:1 nanogel:short interfering RNA weight ratios reduced Runx2 expression by 48.59% +/  A 19.53% (p < 0.001) and 43.22% +/  A 18.01% (both p < 0.001). The same 1:1 and 5:1 treatments against both Runx2 and Osx reduced expression of Osx by 51.65% +/  A 10.85% and 47.65% +/  A 9.80% (both p < 0.001). Moreover, repeated 48 hour RNAi treatment cycles against Runx2 and Osx rhBMP 2 administration reduced ALP activity after 4 and 7 days. ALP reductions after 4 days in culture by nanogel 5:1 and 10:1 RNAi treatments were 32.4% +/  A 12.0% and 33.6% +/  A 13.8% (both p < 0.001). After 7 days in culture, nanogel 1:1 and 5:1 RNAi treatments produced 35.9% +/  A 14.0% and 47.7% +/  A 3.2% reductions in ALP activity. Osteoblast mineralization data after 21 days suggested that nanogel 1:1, 5:1, and 10:1 RNAi treatments decreased mineralization (ie, HA deposition) from cultures treated only with rhBMP 2 (p < 0.001). However, despite RNAi attack on Runx2 and Osx, HA deposition levels remained greater than non rhBMP 2 treated cell cultures.
   Although mRNA and protein knockdown were confirmed as a result of RNAi treatments against Runx2 and Osx, complete elimination of mineralization processes was not achieved. RNAi targeting mid  and late stage osteoblast differentiation markers such as ALP, osteocalcin, osteopontin, and bone sialoprotein) may produce the desired RNAi nanogel nanostructured polymer HO prophylaxis.
   Successful HO prophylaxis should target and silence osteogenic markers critical for heterotopic bone formation processes. The identification of such markers, beyond RUNX2 and OSX, may enhance the effectiveness of RNAi prophylaxes for HO.
C1 [Shrivats, Arun R.; Hsu, Eric; Klimak, Molly; Watt, April C. S.; Hollinger, Jeffrey O.] Carnegie Mellon Univ, Dept Biomed Engn, Pittsburgh, PA 15219 USA.
   [Averick, Saadyah; Matyjaszewski, Krzysztof] Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA.
   [DeMaio, Marlene] Naval Med Ctr Portsmouth, Dept Orthopaed Surg, Portsmouth, VA 23708 USA.
C3 Carnegie Mellon University; Carnegie Mellon University; United States
   Department of Defense; United States Navy
RP Hollinger, JO (通讯作者)，Carnegie Mellon Univ, Dept Biomed Engn, 700 Technol Dr, Pittsburgh, PA 15219 USA.
EM hollinge@cs.cmu.edu
RI Averick, Saadyah/A 9999 2015; Matyjaszewski, Krzysztof/A 2508 2008
OI Averick, Saadyah/0000 0003 4775 2317; Matyjaszewski,
   Krzysztof/0000 0003 1960 3402; Klimak, Molly/0000 0003 4673 9540
FU DoD   Defense Medical Research and Development Program [W81XWH1120073,
   DMR09 69301]; U.S. Department of Defense (DOD) [W81XWH1120073] Funding
   Source: U.S. Department of Defense (DOD); Direct For Mathematical &
   Physical Scien; Division Of Materials Research [0969301] Funding Source:
   National Science Foundation
FX Two of the authors (ARS, EH) contributed equally. All institutions in
   this study, during the study period, received funding from DoD Grant
   W81XWH1120073, which was awarded by the Defense Medical Research and
   Development Program, and DMR09 69301.
CR AHRENGART L, 1991, CLIN ORTHOP RELAT R, P49
   Alfieri KA, 2012, BONE JOINT RES, V1, P174, DOI 10.1302/2046 3758.18.2000102
   Arikawa T, 2004, J CELL PHYSIOL, V200, P400, DOI 10.1002/jcp.20031
   Aubut JAL, 2011, NEUROREHABILITATION, V28, P151, DOI 10.3233/NRE 2011 0643
   Averick S, 2012, ACS MACRO LETT, V1, P6, DOI 10.1021/mz200020c
   Averick SE, 2012, BIOMACROMOLECULES, V13, P3445, DOI 10.1021/bm301166s
   Bal BS, 2010, J ARTHROPLASTY, V25, P538, DOI 10.1016/j.arth.2009.04.019
   Banovac K, 2004, SPINAL CORD, V42, P707, DOI 10.1038/sj.sc.3101628
   Banovac K, 2001, SPINAL CORD, V39, P370, DOI 10.1038/sj.sc.3101166
   BROOKE MM, 1991, ARCH PHYS MED REHAB, V72, P425
   Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200
   Celil AB, 2005, J CELL BIOCHEM, V95, P518, DOI 10.1002/jcb.20429
   Chalidis B, 2007, J NEUROTRAUM, V24, P1675, DOI 10.1089/neu.2007.0342
   CHALMERS J, 1975, J BONE JOINT SURG BR, VB 57, P36, DOI 10.1302/0301 620X.57B1.36
   Chen D, 1997, CALCIFIED TISSUE INT, V60, P283, DOI 10.1007/s002239900230
   Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513
   Dizdar D, 2013, BRAIN INJURY, V27, P807, DOI 10.3109/02699052.2013.775490
   Dokka S, 2000, PHARMACEUT RES, V17, P521, DOI 10.1023/A:1007504613351
   Dykxhoorn DM, 2006, GENE THER, V13, P541, DOI 10.1038/sj.gt.3302703
   Farris MK, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748 717X 7 140
   Forsberg Jonathan Agner, 2010, J Surg Orthop Adv, V19, P54
   Gersbach CA, 2004, EXP CELL RES, V300, P406, DOI 10.1016/j.yexcr.2004.07.031
   Gurkan UA, 2010, TISSUE ENG PT A, V16, P2295, DOI [10.1089/ten.tea.2009.0565, 10.1089/ten.TEA.2009.0565]
   Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870
   Hassan MQ, 2006, J BIOL CHEM, V281, P40515, DOI 10.1074/jbc.M604508200
   Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248 9261.2004
   Haversath M, 2012, CAN J PHYSIOL PHARM, V90, P1434, DOI 10.1139/y2012 123
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   Hsu EW, 2014, J BIOMED NANOTECHNOL, V10, P1130, DOI 10.1166/jbn.2014.1823
   Huang WB, 2004, BONE, V34, P799, DOI 10.1016/j.bone.2003.11.027
   Javed A, 2008, J BIOL CHEM, V283, P8412, DOI 10.1074/jbc.M705578200
   Kan LX, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/309287
   Kaplan FS, 2004, J AM ACAD ORTHOP SUR, V12, P116, DOI 10.5435/00124635 200403000 00007
   Lin L, 2006, BIOCHEM BIOPH RES CO, V349, P564, DOI 10.1016/j.bbrc.2006.08.089
   Matyjaszewski K, 2014, J AM CHEM SOC, V136, P6513, DOI 10.1021/ja408069v
   Matyjaszewski K, 2012, MACROMOLECULES, V45, P4015, DOI 10.1021/ma3001719
   McCarthy TL, 2000, J BIOL CHEM, V275, P21746, DOI 10.1074/jbc.M002291200
   McCarthy TL, 2003, J BIOL CHEM, V278, P43121, DOI 10.1074/jbc.M306531200
   Medina A, 2014, J BURN CARE RES, V35, P251, DOI 10.1097/BCR.0b013e3182957768
   Melcer T, 2011, J REHABIL RES DEV, V48, P1, DOI 10.1682/JRRD.2010.03.0033
   Minghetti L, 2004, J NEUROPATH EXP NEUR, V63, P901, DOI 10.1093/jnen/63.9.901
   Mishra S, 2012, INTEGR BIOL UK, V4, P1498, DOI 10.1039/c2ib20200j
   Nelson ER, 2012, J BURN CARE RES, V33, P463, DOI 10.1097/BCR.0b013e31825af547
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Oh JK, 2006, J AM CHEM SOC, V128, P5578, DOI 10.1021/ja060586a
   Oh JK, 2008, PROG POLYM SCI, V33, P448, DOI 10.1016/j.progpolymsci.2008.01.002
   Oh JK, 2007, BIOMACROMOLECULES, V8, P3326, DOI 10.1021/bm070381+
   Oh JK, 2007, J AM CHEM SOC, V129, P5939, DOI 10.1021/ja069150l
   Oh JK, 2009, POLYMER, V50, P4407, DOI 10.1016/j.polymer.2009.06.045
   Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708
   Potter Benjamin K, 2006, J Am Acad Orthop Surg, V14, pS191
   Potter BK, 2007, J BONE JOINT SURG AM, V89A, P476, DOI 10.2106/JBJS.F.00412
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Sakellariou VI, 2012, J MUSCULOSKEL NEURON, V12, P230
   Schmitt JM, 1999, J ORTHOPAED RES, V17, P269, DOI 10.1002/jor.1100170217
   Seegenschmiedt MH, 2001, INT J RADIAT ONCOL, V51, P756, DOI 10.1016/S0360 3016(01)01640 6
   SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013
   Shea CM, 2003, J CELL BIOCHEM, V90, P1112, DOI 10.1002/jcb.10734
   Shea LD, 2000, TISSUE ENG, V6, P605, DOI 10.1089/10763270050199550
   Shehab D, 2002, J NUCL MED, V43, P346
   Shrivats A. R., 2013, BIOMIMETICS STEM CEL
   Shrivats AR, 2014, PRINCIPLES OF TISSUE ENGINEERING, 4TH EDITION, P1201, DOI 10.1016/B978 0 12 398358 9.00055 0
   Simakova A, 2012, MACROMOLECULES, V45, P6371, DOI 10.1021/ma301303b
   Tsionos I, 2004, J BONE JOINT SURG BR, V86B, P396, DOI 10.1302/0301 620X.86B3.14480
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Wang YH, 2006, BIOTECHNOL PROGR, V22, P1697, DOI 10.1021/bp060274b
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
   Zhu B, 2011, J TISSUE ENG REGEN M
NR 70
TC 19
Z9 23
U1 0
U2 35
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009 921X
EI 1528 1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD JUN
PY 2015
VL 473
IS 6
BP 2139
EP 2149
DI 10.1007/s11999 014 4073 0
PG 11
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA CH6FX
UT WOS:000354133000043
PM 25448327
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Gorsline, RT
   Kaeding, CC
AF Gorsline, RT
   Kaeding, CC
TI The use of NSAIDs and nutritional supplements in athletes with
   osteoarthritis: Prevalence, benefits, and consequences
SO CLINICS IN SPORTS MEDICINE
LA English
DT Article
ID CYCLOOXYGENASE 2; CHONDROITIN SULFATE; CLINICAL EFFICACY;
   CONTROLLED TRIALS; SPORTS INJURIES; GLUCOSAMINE; SAFETY; MANAGEMENT;
   INHIBITOR; SC 58635
AB The use of nonsteroidal antiinflammatory medications (NSAIDs) and nutraceuticals, such as glucosamine and chondroitin, is common among athletes at all ages and levels of participation. The use of these drugs has significant effects on pain and swelling associated with injury; however, this use does have significant risks to the gastrointestinal, hepatic, and renal organ systems. In the athlete with degenerative changes in the joints, the use of these medications can become chronic and lead to an increased risk of adverse effects. The purpose of this article is to examine the incidence of injury in sports, the prevalence of osteoarthritis in athletes, and the use of common over the counter medications and supplements. In addition, the mechanism of action, adverse side effects, and behavioral patterns for use of these medications will be analyzed.
C1 Ohio State Univ, Med Ctr, Dept Orthopaed, Columbus, OH 43221 USA.
C3 University System of Ohio; Ohio State University
RP Ohio State Univ, Med Ctr, Dept Orthopaed, 2050 Kenny Rd, Columbus, OH 43221 USA.
EM Kaeding 1@medctr.osu.edu
CR ABRAMSON S, 1989, CLIN EXP RHEUMATOL, V7, pS163
   Adebowale AO CD., 2000, J AM NUTRACEUTICAL A, V3, P37
   Anderson MA, 1999, PREV VET MED, V38, P65, DOI 10.1016/S0167 5877(98)00105 6
   [Anonymous], MED SCI SPORTS EXERC
   BASSLEER C, 1992, INT J TISSUE REACT, V14, P231
   Buckwalter JA, 1997, AM J SPORT MED, V25, P873, DOI 10.1177/036354659702500624
   CANALE ST, 1981, AM J SPORT MED, V9, P384, DOI 10.1177/036354658100900608
   Cannon GW, 2000, ARTHRITIS RHEUM US, V43, P978, DOI 10.1002/1529 0131(200005)43:5<978::AID ANR4>3.0.CO;2 0
   ENGSTROM B, 1991, AM J SPORT MED, V19, P372, DOI 10.1177/036354659101900408
   Felson DT, 2000, ARTHRIT CARE RES, V13, P179, DOI 10.1002/1529 0131(200008)13:4<179::AID ANR1>3.0.CO;2 X
   Goldberg Steven H, 2002, Am J Orthop (Belle Mead NJ), V31, P673
   Hanson R R, 2001, Vet Ther, V2, P148
   Hersh EV, 2000, CLIN THER, V22, P500, DOI 10.1016/S0149 2918(00)80043 0
   Hughes R, 2002, RHEUMATOLOGY, V41, P279, DOI 10.1093/rheumatology/41.3.279
   Hungerford DS, 2003, J ARTHROPLASTY, V18, P5, DOI 10.1054/arth.2003.50067
   Kaplan Machlis B, 1999, ANN PHARMACOTHER, V33, P979, DOI 10.1345/aph.18415
   Kohl HW, 2001, MED SCI SPORT EXER, V33, pS472, DOI 10.1097/00005768 200106001 00017
   KONRADSEN L, 1990, AM J SPORT MED, V18, P379, DOI 10.1177/036354659001800408
   Kujala UM, 2003, SPORTS MED, V33, P553, DOI 10.2165/00007256 200333080 00001
   LANE NE, 1986, JAMA J AM MED ASSOC, V255, P1147
   LANE NE, 1993, RHEUM DIS CLIN N AM, V19, P617
   LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140 6736(94)90185 6
   LANZA FL, 1984, AM J MED, V77, P19, DOI 10.1016/S0002 9343(84)80014 5
   LINDBERG H, 1993, ACTA ORTHOP SCAND, V64, P165, DOI 10.3109/17453679308994561
   McAlindon T, 2003, RHEUM DIS CLIN N AM, V29, P789, DOI 10.1016/S0889 857X(03)00064 4
   McAlindon TE, 2000, JAMA J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469
   MengleGaw L, 1997, ARTHRITIS RHEUM, V40, P374
   Rangger C, 1997, SPORTS MED, V23, P61, DOI 10.2165/00007256 199723010 00006
   Saxon L, 1999, SPORTS MED, V28, P123, DOI 10.2165/00007256 199928020 00005
   Schafer Andrew I., 1999, American Journal of Medicine, V106, p25S, DOI 10.1016/S0002 9343(99)00114 X
   Schwenk TL, 2002, AM J SPORT MED, V30, P907, DOI 10.1177/03635465020300062701
   SETNIKAR I, 1986, ARZNEIMITTELFORSCH, V36 1, P729
   Siegle I, 1998, ARTHRITIS RHEUM US, V41, P122, DOI 10.1002/1529 0131(199801)41:1<122::AID ART15>3.3.CO;2 #
   Simon LS, 1998, ARTHRITIS RHEUM US, V41, P1591, DOI 10.1002/1529 0131(199809)41:9<1591::AID ART9>3.0.CO;2 J
   Spector TD, 1996, ARTHRITIS RHEUM, V39, P988, DOI 10.1002/art.1780390616
   Stanley KL, 1998, CLIN SPORT MED, V17, P375, DOI 10.1016/S0278 5919(05)70087 9
   THEODOSAKIS J, 1997, ARTHRITIS CURE MED M
   Towheed T E, 2001, Cochrane Database Syst Rev, pCD002946
   Towheed TE, 1997, J RHEUMATOL, V24, P349
   Towheed TE, 2003, ARTHRIT RHEUM ARTHR, V49, P601, DOI 10.1002/art.11183
   Uebelhart D, 1998, OSTEOARTHR CARTILAGE, V6, P39, DOI 10.1016/S1063 4584(98)80011 3
   VANCE DE, 1991, BIOCH LIPIDS LIPOPRO, P297
   Vane JR, 1998, INFLAMM RES, V47, pS78
   Warner DC, 2002, J ADOLESCENT HEALTH, V30, P150, DOI 10.1016/S1054 139X(01)00325 1
   WATSON AWS, 1993, AM J SPORT MED, V21, P137, DOI 10.1177/036354659302100123
   WHELTON A, 1995, J CLIN PHARMACOL, V35, P454, DOI 10.1002/j.1552 4604.1995.tb04088.x
NR 46
TC 32
Z9 36
U1 0
U2 11
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0278 5919
EI 1556 228X
J9 CLIN SPORT MED
JI Clin. Sports Med.
PD JAN
PY 2005
VL 24
IS 1
BP 71
EP +
DI 10.1016/j.csm.2004.08.003
PG 13
WC Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Sport Sciences
GA 891OD
UT WOS:000226589500008
PM 15636778
DA 2025 08 17
ER

PT J
AU Sun, RX
   Liang, C
   Sun, YJ
   Xu, YF
   Geng, W
   Li, J
AF Sun, Rongxin
   Liang, Chao
   Sun, Yujie
   Xu, Yifan
   Geng, Wei
   Li, Jun
TI Effects of metformin on the osteogenesis of alveolar BMSCs from diabetic
   patients and implant osseointegration in rats
SO ORAL DISEASES
LA English
DT Article
DE bone marrow mesenchymal stem cells (BMSCs); dental implants; metformin;
   osseointegration; osteogenic differentiation; type&#8208; 2 diabetes
ID ACTIVATED PROTEIN KINASE; ANTIDIABETIC DRUG METFORMIN; BONE;
   DIFFERENTIATION; GLUCOSE; OSTEOBLASTS; SURVIVAL; MELLITUS; SUCCESS;
   MUSCLE
AB Objectives This study aimed to explore the effects of metformin on osteogenic differentiation of alveolar bone marrow mesenchymal stem cells (BMSCs) from type 2 diabetes mellitus (T2DM) patients (DM BMSCs) and implant osseointegration in rats, screen the optimal concentration, and investigate whether metformin could protect against the adverse impact of T2DM on BMSC osteogenic capacity.
   Subjects and methods Different concentrations of metformin were administered to human derived BMSCs and Wistar rats receiving implants. ALP detection, alizarin red staining, real time RT PCR and Western blotting were performed to detect osteogenesis and investigate the mechanism. Toluidine blue staining was performed to analyse bone implant contact in rats.
   Results Metformin increased implant osseointegration in a rat model and promoted the osteogenic capacity of DM BMSCs via the AMPK/BMP/Smad signalling pathway, and 125 mu M was the optimal concentration; however, concentrations over 200 mu M, metformin showed an inhibitory effect on DM BMSCs. Additionally, metformin at the optimal concentration (125 mu M) identified in this study could compensate for the negative impacts of T2DM on the osteogenic differentiation of BMSCs.
   Conclusions Metformin can promote the osteogenesis of BMSCs from T2DM patients and osseointegration in rats, and it might be an effective drug for increasing the success rate of T2DM associated implants.
C1 [Sun, Rongxin; Liang, Chao; Sun, Yujie; Xu, Yifan; Geng, Wei; Li, Jun] Capital Med Univ, Beijing Stomatol Hosp, Dept Dent Implant Ctr, Sch Stomatol, 4 Tian Tan Xi Li, Beijing 100050, Peoples R China.
   [Li, Jun] Capital Med Univ, Sch Stomatol, Beijing Key Lab Tooth Regenerat & Funct Reconstru, Beijing, Peoples R China.
C3 Capital Medical University; Capital Medical University
RP Li, J (通讯作者)，Capital Med Univ, Beijing Stomatol Hosp, Dept Dent Implant Ctr, Sch Stomatol, 4 Tian Tan Xi Li, Beijing 100050, Peoples R China.
EM lijun3021@aliyun.com
RI Geng, Wei/KYQ 4201 2024; Sun, Yujie/HHZ 7619 2022
FU National Natural Science Foundation of China [81371115]
FX National Natural Science Foundation of China, Grant/Award Number:
   81371115
CR Akintoye SO, 2018, ORAL DIS, V24, P49, DOI 10.1111/odi.12761
   Annibali S, 2016, IMPLANT DENT, V25, P663, DOI 10.1097/ID.0000000000000478
   Bak EJ, 2010, J PERIODONTOL, V81, P412, DOI 10.1902/jop.2009.090414
   Boutayeb Abdesslam, 2005, Int J Equity Health, V4, P2, DOI 10.1186/1475 9276 4 2
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   De Angelis F, 2017, EUR REV MED PHARMACO, V21, P433
   Dowell S, 2007, J AM DENT ASSOC, V138, P355, DOI 10.14219/jada.archive.2007.0168
   Fiorellini JP, 2000, INT J PERIODONT REST, V20, P367
   Fujii N, 2004, P NUTR SOC, V63, P205, DOI 10.1079/PNS2004340
   Gao Y, 2010, EUR J PHARMACOL, V635, P231, DOI 10.1016/j.ejphar.2010.02.051
   Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432 1033.1997.00259.x
   Inouye KAS, 2014, IMPLANT DENT, V23, P319, DOI 10.1097/ID.0000000000000069
   Jang WG, 2011, BIOCHEM BIOPH RES CO, V404, P1004, DOI 10.1016/j.bbrc.2010.12.099
   Jiao L.V., 2008, CHINESE J GERIATRIC, V6, P47
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   KRAKAUER JC, 1995, DIABETES, V44, P775, DOI 10.2337/diabetes.44.7.775
   Liang C, 2017, ORAL DIS, V23, P1099, DOI 10.1111/odi.12704
   Liang C, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7626215
   Luo L, 2018, INT J MOL MED, V41, P51, DOI 10.3892/ijmm.2017.3226
   Mai QG, 2011, J CELL BIOCHEM, V112, P2902, DOI 10.1002/jcb.23206
   Maiorana C, 2020, MATERIALS, V13, DOI 10.3390/ma13102389
   Markowicz Piasecka M, 2020, PHARMACEUTICALS BASE, V13, DOI 10.3390/ph13100323
   Michaud DS, 2017, EPIDEMIOL REV, V39, P49, DOI 10.1093/epirev/mxx006
   Mombelli A, 2006, CLIN ORAL IMPLAN RES, V17, P97, DOI 10.1111/j.1600 0501.2006.01354.x
   Moy PK, 2005, INT J ORAL MAX IMPL, V20, P569
   Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074
   Nascimento GG, 2018, ACTA DIABETOL, V55, P653, DOI 10.1007/s00592 018 1120 4
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Sanchez Rangel E, 2017, DIABETOLOGIA, V60, P1586, DOI 10.1007/s00125 017 4336 x
   Serrao CR, 2017, INT J ORAL MAX IMPL, V32, P547, DOI 10.11607/jomi.5754
   Molinuevo MS, 2010, J BONE MINER RES, V25, P211, DOI 10.1359/jbmr.090732
   Sun R., 2021, ORAL DIS, P1
   Sun YJ, 2019, ACS APPL MATER INTER, V11, P36449, DOI 10.1021/acsami.9b14572
   Takatani T, 2011, MOL CELL ENDOCRINOL, V339, P114, DOI 10.1016/j.mce.2011.04.003
   Xu L, 2016, CLIN IMPLANT DENT R, V18, P241, DOI 10.1111/cid.12259
   Zhang P, 2020, AGING US, V12, P2084, DOI 10.18632/aging.102723
   Zhen DH, 2010, J DIABETES COMPLICAT, V24, P334, DOI 10.1016/j.jdiacomp.2009.05.002
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
NR 40
TC 27
Z9 30
U1 3
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1354 523X
EI 1601 0825
J9 ORAL DIS
JI Oral Dis.
PD MAY
PY 2022
VL 28
IS 4
BP 1170
EP 1180
DI 10.1111/odi.13808
EA MAR 2021
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 0U7ND
UT WOS:000626532900001
PM 33606350
DA 2025 08 17
ER

PT J
AU Bu, YH
   Peng, D
   Zhou, HD
   Huang, QX
   Liu, W
   Luo, XB
   Tang, LL
   Tang, AG
AF Bu, Y.  H.
   Peng, D.
   Zhou, H.  D
   Huang, Q.  X
   Liu, W.
   Luo, X.  B
   Tang, L.  L
   Tang, A.  G
TI Insulin receptor substrate 2 plays important roles in
   17β estradiol induced bone formation
SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
LA English
DT Article
DE 17 beta Estradiol; insulin receptor substrate 2; osteoblast
ID OVARIECTOMIZED RATS; BREAST CANCER; ESTROGEN; WOMEN; OSTEOPOROSIS;
   MECHANISMS; APOPTOSIS; PROTEINS; THERAPY
AB Background: Discovering the mechanisms of the estrogen effects on the osteoblasts is very important for the development of new agents which have the clear cut beneficial effects of estrogen while free of adverse effect. Aim: The aim of this study was to investigate the differential gene expression of 17 beta estracliol (E 2) treated osteoblast like cells, and the effect of E 2 on the insulin receptor substrate 2 (IRS 2) expression in human cultured osteoblast like cells and the osteoblasts of ovariectornized (OVX) rats. Material and methods: The differential gene expression of E 2 treated osteoblast like cells was analyzed by cytokine expression array and validated by RT PCR and Western blot analysis. The protein expression and phosphorylation of one of the differentially expressed gene, IRS 2, treated at different times with E 2 were analyzed. The Sprague Dawley rats were ovariectomized and then treated with E 2, the IRS 2 expression was analyzed by immunohistochemistry analysis. Results: E 2 upregulated the mRNA expression of IRS 2, bone morphogenetic protein 9, and connective tissue growth factor expression, down regulated the mRNA expression of matrix metalloproteinase 15 and some tumor suppressor genes. Peak expression of IRS 2 was observed at 12 24 h of treatment by 10( 8)M E 2. E 2 can also increase the phosphorylation of IRS 2. The IRS 2 expression was down regulated in the osteoblasts and bone marrow cells of the OVX rats, which had lower bone mineral density (BMD) than the normal rats. However, both BMD and IRS 2 expression can be rescued by 10 8M E 2 in the OVX rats. Conclusion: IRS 2 in osteoblast is up regulated by E 2 and plays important roles in the estrogen induced bone formation. (J. Endocrinol. Invest. 32: 682 689, 2009) (C) 2009, Editrice Kurtis
C1 [Bu, Y.  H.; Luo, X.  B; Tang, L.  L; Tang, A.  G] Second Xiang Ya Hosp Cent S Univ, Dept Clin Lab, Changsha 410011, Hunan, Peoples R China.
   [Peng, D.] Second Xiang Ya Hosp Cent S Univ, Dept Orthopaed, Changsha 410011, Hunan, Peoples R China.
   [Zhou, H.  D; Huang, Q.  X; Liu, W.] Second Xiang Ya Hosp Cent S Univ, Inst Endocrinol & Metab, Changsha 410011, Hunan, Peoples R China.
RP Tang, AG (通讯作者)，Second Xiang Ya Hosp Cent S Univ, Dept Clin Lab, Changsha 410011, Hunan, Peoples R China.
EM aiguotang@yahoo.com.cn
OI Zhou, Hou De/0000 0001 9131 4141
FU National Natural Scientific Foundation of China [30400218, 30872617]
FX This work was supported by Grants 30400218 and 30872617 from National
   Natural Scientific Foundation of China.
CR Akune T, 2002, J CELL BIOL, V159, P147, DOI 10.1083/jcb.200204046
   Berger C, 2009, J BONE MINER RES, V24, P361, DOI 10.1359/JBMR.081004
   Burks DJ, 2001, DIABETES, V50, pS140, DOI 10.2337/diabetes.50.2007.S140
   Claus S, 2008, J INVEST DERMATOL, V128, P1442, DOI 10.1038/sj.jid.5701211
   Conner P, 2008, CLIN OBSTET GYNECOL, V51, P592, DOI 10.1097/GRF.0b013e318180b8ed
   Franchi M, 2007, THESCIENTIFICWORLDJO, V7, P404, DOI 10.1100/TSW.2007.92
   Gardner Michael J, 2006, HSS J, V2, P62, DOI 10.1007/s11420 005 0137 8
   Hawse JR, 2008, J CELL BIOCHEM, V103, P383, DOI 10.1002/jcb.21425
   He HB, 2004, ENDOCRINOLOGY, V145, P447, DOI 10.1210/en.2003 1239
   Hernandez CJ, 2003, BONE, V32, P357, DOI 10.1016/S8756 3282(03)00037 1
   Koricanac G, 2008, J STEROID BIOCHEM, V108, P109, DOI 10.1016/j.jsbmb.2007.06.001
   Krum SA, 2008, CELL CYCLE, V7, P1348, DOI 10.4161/cc.7.10.5892
   Laroche M, 2008, AM J MED, V121, P744, DOI 10.1016/j.amjmed.2008.03.048
   Lee Nicola J, 2008, Curr Osteoporos Rep, V6, P62, DOI 10.1007/s11914 008 0011 y
   Liu Shi ping, 2001, Hunan Yike Daxue Xuebao, V26, P111
   Matsuguchi T, 2009, J BONE MINER RES, V24, P398, DOI 10.1359/JBMR.081107
   Morelli C, 2003, ONCOGENE, V22, P4007, DOI 10.1038/sj.onc.1206436
   Musi N, 2006, ENDOCRINE, V29, P73, DOI 10.1385/ENDO:29:1:73
   Nordin BEC, 2008, CALCIFIED TISSUE INT, V83, P365, DOI 10.1007/s00223 008 9186 6
   Papapoulos S, 2008, NAT CLIN PRACT ENDOC, V4, P514, DOI 10.1038/ncpendmet0941
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Rageh MAE, 2001, J CLIN PATHOL MOL PA, V54, P338, DOI 10.1136/mp.54.5.338
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rao LG, 2003, BIOL PHARM BULL, V26, P936, DOI 10.1248/bpb.26.936
   Reid IR, 2008, SEMIN CELL DEV BIOL, V19, P473, DOI 10.1016/j.semcdb.2008.08.002
   Robey PG, 1996, CONNECT TISSUE RES, V35, P131, DOI 10.3109/03008209609029183
   Robinson JG, 2008, AM J CARDIOL, V102, P693, DOI 10.1016/j.amjcard.2007.12.044
   Saller A, 2008, AGING CLIN EXP RES, V20, P280
   Simic P, 2006, J BIOL CHEM, V281, P25509, DOI 10.1074/jbc.M513276200
   Sims NA, 2005, J BONE MINER RES, V20, P1093, DOI 10.1359/JBMR.050209
   Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097
   Syed FA, 2008, OSTEOPOROSIS INT, V19, P1323, DOI 10.1007/s00198 008 0574 6
   Thrailkill KM, 2005, AM J PHYSIOL ENDOC M, V289, pE735, DOI 10.1152/ajpendo.00159.2005
   Vedi S, 2003, BONE, V33, P330, DOI 10.1016/S8756 3282(03)00114 5
   Waddington R. J., 2003, European Cells & Materials, V6, P12
   Wang WM, 2006, BIOCHEM J, V398, P515, DOI 10.1042/BJ20060630
NR 36
TC 4
Z9 7
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0391 4097
EI 1720 8386
J9 J ENDOCRINOL INVEST
JI J. Endocrinol. Invest.
PD SEP
PY 2009
VL 32
IS 8
BP 682
EP 689
DI 10.1007/BF03345741
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 529MI
UT WOS:000272521000009
PM 19509476
DA 2025 08 17
ER

PT J
AU Su, WP
   Liu, GQ
   Mohajer, B
   Wang, JK
   Shen, A
   Zhang, WX
   Liu, B
   Guermazi, A
   Gao, PS
   Cao, X
   Demehri, S
   Wan, M
AF Su, Weiping
   Liu, Guanqiao
   Mohajer, Bahram
   Wang, Jiekang
   Shen, Alena
   Zhang, Weixin
   Liu, Bin
   Guermazi, Ali
   Gao, Peisong
   Cao, Xu
   Demehri, Shadpour
   Wan, Mei
TI Senescent preosteoclast secretome promotes metabolic syndrome associated
   osteoarthritis through cyclooxygenase 2
SO ELIFE
LA English
DT Article
ID KNEE OSTEOARTHRITIS; CELLULAR SENESCENCE; POSTTRAUMATIC OSTEOARTHRITIS;
   OSTEOCHONDRAL JUNCTION; SUBCHONDRAL BONE; WESTERN ONTARIO; STR/ORT
   MOUSE; GROWTH FACTOR; PDGF BB; CELLS
AB Background: Metabolic syndrome associated osteoarthritis (MetS OA) is a distinct osteoarthritis phenotype defined by the coexistence of MetS or its individual components. Despite the high prevalence of MetS OA, its pathogenic mechanisms are unclear. The aim of this study was to determine the role of cellular senescence in the development of MetS OA.
   Methods: Analysis of the human osteoarthritis initiative (OAI) dataset was conducted to investigate the MRI subchondral bone features of MetS human OA participants. Joint phenotype and senescent cells were evaluated in two MetS OA mouse models: high fat diet (HFD) challenged mice and STR/ Ort mice. In addition, the molecular mechanisms by which preosteoclasts become senescent as well as how the senescent preosteoclasts impair subchondral bone microenvironment were characterized using in vitro preosteoclast culture system.
   Results: Humans and mice with MetS are more likely to develop osteoarthritis related subchondral bone alterations than those without MetS. MetS OA mice exhibited a rapid increase in joint subchondral bone plate and trabecular thickness before articular cartilage degeneration. Subchondral preosteoclasts undergo senescence at the pre  or early osteoarthritis stage and acquire a unique secretome to stimulate osteoblast differentiation and inhibit osteoclast differentiation. Antagonizing preosteoclast senescence markedly mitigates pathological subchondral alterations and osteoarthritis progression in MetS OA mice. At the molecular level, preosteoclast secretome activates COX2 PGE2, resulting in stimulated differentiation of osteoblast progenitors for subchondral bone formation. Administration of a selective COX2 inhibitor attenuated subchondral bone alteration and osteoarthritis progression in MetS OA mice. Longitudinal analyses of the human Osteoarthritis Initiative (OAI) cohort dataset also revealed that COX2 inhibitor use, relative to non selective nonsteroidal antiinflammatory drug use, is associated with less progression of osteoarthritis and subchondral bone marrow lesion worsening in participants with MetS OA.
   Conclusions: Our findings suggest a central role of a senescent preosteoclast secretome COX2/PGE2 axis in the pathogenesis of MetS OA, in which selective COX2 inhibitors may have disease modifying potential.
C1 [Su, Weiping; Liu, Guanqiao; Wang, Jiekang; Zhang, Weixin; Liu, Bin; Cao, Xu; Wan, Mei] Johns Hopkins Univ, Dept Orthopaed Surg, Russell H Morgan Dept Radiol & Radiol Sci, Sch Med, Baltimore, MD 21218 USA.
   [Su, Weiping] Cent South Univ, Dept Orthopaed Surg, Xiangya Hosp 3, Changsha, Peoples R China.
   [Liu, Guanqiao] Southern Med Univ, Dept Orthopaed, Div Orthopaed & Traumatol, Nanfang Hosp, Guangzhou, Peoples R China.
   [Mohajer, Bahram; Demehri, Shadpour] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Musculoskeletal Radiol, Sch Med, Baltimore, MD 21218 USA.
   [Shen, Alena] Univ Southern Calif, Dornsife Coll Letters Arts & Sci, Los Angeles, CA USA.
   [Guermazi, Ali] Boston Univ, Dept Radiol, Sch Med, Boston, MA USA.
   [Gao, Peisong] Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA.
C3 Johns Hopkins University; Central South University; Southern Medical
   University   China; Johns Hopkins University; University of Southern
   California; Boston University; Johns Hopkins University; Johns Hopkins
   Medicine
RP Wan, M (通讯作者)，Johns Hopkins Univ, Dept Orthopaed Surg, Russell H Morgan Dept Radiol & Radiol Sci, Sch Med, Baltimore, MD 21218 USA.; Demehri, S (通讯作者)，Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Musculoskeletal Radiol, Sch Med, Baltimore, MD 21218 USA.
EM sdemehr1@jh.edu; mwan4@jhmi.edu
RI ; Wang, Jiekang/JLM 9356 2023; Guermazi, Ali/F 6014 2013; Mohajer,
   Bahram/I 9529 2019
OI Wang, Jiekang/0000 0002 1896 9552; Shen, Alena/0000 0003 3834 0927; ,
   Weixin/0000 0002 1009 101X; Su, Weiping/0000 0002 6261 8661
FU National Institutes of Health [R01AG068226, R01AG072090, R01AR079620,
   P01AG066603]
FX National Institutes of Health R01AG068226 Mei Wan National Institutes of
   Health R01AG072090 Mei Wan National Institutes of Health R01AR079620
   Shadpour Demehri National Institutes of Health P01AG066603 Xu Cao The
   funders had no role in study design, data collection and interpretation,
   or the decision to submit the work for publication.
CR Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464 5491.2006.01858.x
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Angst F, 2005, J RHEUMATOL, V32, P1324
   Banks LN., 2013, OA MUSCULOSKELETAL M, V1, P872, DOI [10.13172/2052 9287 1 3 872, DOI 10.13172/2052 9287 1 3 872]
   Basisty N, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000599
   Brown TD, 2006, J ORTHOP TRAUMA, V20, P739, DOI 10.1097/01.bot.0000246468.80635.ef
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Burr David B., 1998, Current Opinion in Rheumatology, V10, P256, DOI 10.1097/00002281 199805000 00017
   Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev physiol 030212 183653
   CERHAN JR, 1995, AM J EPIDEMIOL, V141, P225, DOI 10.1093/oxfordjournals.aje.a117424
   Chang AC, 2018, CANCER LETT, V426, P47, DOI 10.1016/j.canlet.2018.03.050
   Chen D, 2020, J ORTHOP TRANSL, V23, P132, DOI 10.1016/j.jot.2019.11.008
   Chen LZ, 2020, ANN RHEUM DIS, V79, P811, DOI 10.1136/annrheumdis 2020 216942
   Chien MH, 2009, CARCINOGENESIS, V30, P2005, DOI 10.1093/carcin/bgp244
   CHRISTENSEN E, 1987, HEPATOLOGY, V7, P1346, DOI 10.1002/hep.1840070628
   Collins JE, 2016, ARTHRITIS RHEUMATOL, V68, P2422, DOI 10.1002/art.39731
   Collins KH, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00112
   Coppé JP, 2010, ANNU REV PATHOL MECH, V5, P99, DOI 10.1146/annurev pathol 121808 102144
   D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097 0258(19981015)17:19<2265::AID SIM918>3.0.CO;2 B
   Danaei G, 2013, STAT METHODS MED RES, V22, P70, DOI 10.1177/0962280211403603
   Danaei G, 2012, AM J EPIDEMIOL, V175, P250, DOI 10.1093/aje/kwr301
   Davalos AR, 2013, J CELL BIOL, V201, P613, DOI 10.1083/jcb.201206006
   DeFrate LE, 2019, OSTEOARTHR CARTILAGE, V27, P392, DOI 10.1016/j.joca.2018.12.011
   Di Micco R, 2021, NAT REV MOL CELL BIO, V22, P75, DOI 10.1038/s41580 020 00314 w
   Diekman BO, 2018, AGING CELL, V17, DOI 10.1111/acel.12771
   Dieppe PA, 2005, LANCET, V365, P965, DOI 10.1016/S0140 6736(05)71086 2
   Englesbe MJ, 2004, J VASC SURG, V39, P1091, DOI 10.1016/j.jvs.2004.01.041
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Farr JN, 2016, J BONE MINER RES, V31, P1920, DOI 10.1002/jbmr.2892
   Felson DT, 2011, ANN RHEUM DIS, V70, P1884, DOI 10.1136/ard.2011.155119
   Findlay DM, 2014, CURR OSTEOPOROS REP, V12, P127, DOI 10.1007/s11914 014 0192 5
   Francisco V, 2018, J ORTHOP RES, V36, P594, DOI 10.1002/jor.23788
   Freund A, 2012, MOL BIOL CELL, V23, P2066, DOI 10.1091/mbc.E11 10 0884
   Gallou Kabani C, 2007, OBESITY, V15, P1996, DOI 10.1038/oby.2007.238
   Gandek B, 2015, ARTHRIT CARE RES, V67, P216, DOI 10.1002/acr.22415
   Geba GP, 2002, JAMA J AM MED ASSOC, V287, P64, DOI 10.1001/jama.287.1.64
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   Gómez Santos B, 2020, AGING CELL, V19, DOI 10.1111/acel.13183
   Haara MM, 2003, ANN RHEUM DIS, V62, P151, DOI 10.1136/ard.62.2.151
   Haj Mirzaian A, 2018, OSTEOARTHR CARTILAGE, V26, P564, DOI 10.1016/j.joca.2018.01.005
   Haj Mirzaian A, 2019, RADIOLOGY, V293, P396, DOI 10.1148/radiol.2019190557
   Hamzic N, 2013, J NEUROENDOCRINOL, V25, P271, DOI 10.1111/jne.12000
   Heijink A, 2012, KNEE SURG SPORT TR A, V20, P423, DOI 10.1007/s00167 011 1818 0
   Hernandez Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001
   Holvoet P, 2008, JAMA J AM MED ASSOC, V299, P2287, DOI 10.1001/jama.299.19.2287
   Hu B, 2020, J CLIN INVEST, V130, P3483, DOI 10.1172/JCI131554
   Hunter DJ, 2011, OSTEOARTHR CARTILAGE, V19, P990, DOI 10.1016/j.joca.2011.05.004
   Hurtado Roca Y, 2017, DIABETES, V66, P474, DOI 10.2337/db16 0933
   Jain S, 2006, CANCER RES, V66, P6638, DOI 10.1158/0008 5472.CAN 06 0661
   Jeon OH, 2018, J CLIN INVEST, V128, P1229, DOI 10.1172/JCI95147
   Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324
   Johnson ES, 2013, PHARMACOEPIDEM DR S, V22, P1, DOI 10.1002/pds.3334
   Kim SP, 2019, J BIOL CHEM, V294, P6899, DOI 10.1074/jbc.RA118.006769
   Kim SP, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92704
   Li CJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01509 0
   Li GY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4405
   Li YK, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0839 7
   Liu JY, 2019, P NATL ACAD SCI USA, V116, P2603, DOI 10.1073/pnas.1818313116
   Liu XN, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22131 1
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Mason RM, 2001, OSTEOARTHR CARTILAGE, V9, P85, DOI 10.1053/joca.2000.0363
   Mazur CM, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0070 y
   McHugh D, 2018, J CELL BIOL, V217, P65, DOI 10.1083/jcb.201708092
   Misra D, 2019, ARTHRITIS RHEUMATOL, V71, P232, DOI 10.1002/art.40692
   Misra D, 2015, J GERONTOL A BIOL, V70, P337, DOI 10.1093/gerona/glu102
   Mohajer B, 2021, J RHEUMATOL, V48, P1608, DOI 10.3899/jrheum.210189
   Mosteiro L, 2016, SCIENCE, V354, DOI 10.1126/science.aaf4445
   Muratovic D, 2019, OSTEOARTHR CARTILAGE, V27, P1653, DOI 10.1016/j.joca.2019.07.004
   nih, OVERVIEW DESCRIPTION
   Panagopoulos V, 2017, INT J ONCOL, V50, P1191, DOI 10.3892/ijo.2017.3883
   Peterfy CG, 2008, OSTEOARTHR CARTILAGE, V16, P1433, DOI 10.1016/j.joca.2008.06.016
   Philbin E F, 1996, J Cardiovasc Risk, V3, P529, DOI 10.1097/00043798 199612000 00008
   Pilbeam C, 2020, HANDB EXP PHARMACOL, V262, P157, DOI 10.1007/164_2019_332
   Puenpatom RA, 2009, POSTGRAD MED, V121, P9, DOI 10.3810/pgm.2009.11.2073
   Qiu WL, 2011, ONCOTARGET, V2, P862
   Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231
   Reijman M, 2007, ANN RHEUM DIS, V66, P158, DOI 10.1136/ard.2006.053538
   Resseguier N, 2011, EPIDEMIOLOGY, V22, P282, DOI 10.1097/EDE.0b013e318209dec7
   Rose John S, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028415
   Ruscitti P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/782382
   Saleh AS, 2007, OSTEOARTHR CARTILAGE, V15, P357, DOI 10.1016/j.joca.2006.09.008
   Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566
   Sansone V, 2019, BONE JOINT RES, V8, P582, DOI 10.1302/2046 3758.812.BJR 2019 0038.R1
   Schisterman EF, 2009, EPIDEMIOLOGY, V20, P488, DOI 10.1097/EDE.0b013e3181a819a1
   Shang DS, 2020, AGING CELL, V19, DOI 10.1111/acel.13145
   Staines KA, 2017, OSTEOARTHR CARTILAGE, V25, P802, DOI 10.1016/j.joca.2016.12.014
   Sterne JAC, 2009, BMJ BRIT MED J, V339, DOI 10.1136/bmj.b2393
   Su WP, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135446
   Su YP, 2017, J CELL PHYSIOL, V232, P1448, DOI 10.1002/jcp.25644
   Sun Q, 2021, ELIFE, V10, DOI 10.7554/eLife.66532
   Suri S, 2007, ANN RHEUM DIS, V66, P1423, DOI 10.1136/ard.2006.063354
   Tat SK, 2010, BEST PRACT RES CL RH, V24, P51, DOI 10.1016/j.berh.2009.08.004
   Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098
   Tilstra JS, 2012, J CLIN INVEST, V122, P2601, DOI 10.1172/JCI45785
   Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531 5565(00)00180 7
   Tubach F, 2005, ANN RHEUM DIS, V64, P34, DOI 10.1136/ard.2004.023028
   Veronese N, 2017, PAIN MED, V18, P414, DOI 10.1093/pm/pnw163
   Walsh DA, 2010, RHEUMATOLOGY, V49, P1852, DOI 10.1093/rheumatology/keq188
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Zhang J, 2010, INFLAMMATION, V33, P25, DOI 10.1007/s10753 009 9155 x
   Zhang YQ, 2010, CLIN GERIATR MED, V26, P355, DOI [10.1016/j.rdc.2012.10.004, 10.1016/j.cger.2010.03.001]
   Zhao XL, 2021, J BONE MINER RES, V36, P591, DOI 10.1002/jbmr.4215
   Zhen GH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21948 0
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
   Zhuo Q, 2012, NAT REV RHEUMATOL, V8, P729, DOI 10.1038/nrrheum.2012.135
   Zou W, 2016, NAT MED, V22, P1203, DOI 10.1038/nm.4208
   Zweers MC, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3437
NR 109
TC 27
Z9 28
U1 1
U2 28
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD JUL 26
PY 2022
VL 11
AR e79773
DI 10.7554/eLife.79773
PG 35
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA 5I4IX
UT WOS:000868323500001
PM 35881544
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Paul, S
   Choudhury, M
   Son, S
   Basak, P
AF Paul, Samrat
   Choudhury, Mahima
   Son, Sohini
   Basak, Piyali
TI Ginseng used for bone tissue scaffold
SO INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS
LA English
DT Article
DE Ginseng scaffold; Honeycomb scaffold; Regenarative therapy; MC3T3 E1cell
AB The scaffold based tissue engineering materialized for bone tissue therapy. Gelatin glutaraldehyde cross linked scaffold was prepared by solvent casting porogen leaching method. It was characterized by FTIR and SEM microphotograph analysis. Absence of peak at waves no. 1625 cm( 1) in ATR FTIR indicated formation of cross linking. FE SEM micrograph showed honeycomb pad like structure with high porosity. Methanolic extract of Withania somnifera (Ashwagandha) root extract induced MC3T3 E1 osteoblast cell adhesion and proliferation on porous gelatin scaffold. GC MS analysis pointed out presence of 4 amino 2 ethyl 3 methylquinoline, an active phyto chemicals having tissue regeneration potential. High anti oxidant capacity down regulates cell death mechanism by scavenging free radical. The biocompatible gelatin scaffold has RGD moiety that attune the MC3T3 E1 osteoblast cell adhesion. Withania somnifera root extract may boost up cell proliferation on scaffold. Therefore treatment with Withania somnifera root extract may be the new approaches for designing bone tissue scaffold for bone tissue therapy.
C1 [Paul, Samrat; Son, Sohini] Brainware Univ, Dept Biotechnol, Kolkata 700125, W Bengal, India.
   [Choudhury, Mahima] Heritage Inst Technol, Dept Biotechnol, Kolkata 700107, W Bengal, India.
   [Paul, Samrat; Basak, Piyali] Jadavpur Univ, Sch Biosci & Engn, Kolkata 700032, W Bengal, India.
C3 Heritage Institute of Technology (HITK); Jadavpur University
RP Basak, P (通讯作者)，Jadavpur Univ, Sch Biosci & Engn, Kolkata 700032, W Bengal, India.
EM piyalibasak@gmail.com
CR Denisa BK, 2020, FRONT CELL NEUROSCI, P14
   Dutta R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215310
   Joyce K, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00512 8
   Kemençe N, 2017, J TISSUE ENG REGEN M, V11, P20, DOI 10.1002/term.1813
   Mishra Debendranath, 2020, Biomedical & Pharmacology Journal, V13, P71, DOI 10.13005/bpj/1862
   Paul S, THESIS JADAVPUR U W
   Paul S, 2019, J PLANT BIOCHEM BIOT, V28, P1
   Paul S, 2019, ANTI CANCER AGENT ME, V19, P677, DOI 10.2174/1871520619666190206164137
   Sen S, 2021, RSC ADV, V11, P19265, DOI 10.1039/d0ra08538c
   Wang PJ, 2021, BIOACT MATER, V6, P1283, DOI 10.1016/j.bioactmat.2020.10.014
   Wang W, 2020, MATER DESIGN, V189, DOI 10.1016/j.matdes.2020.108514
NR 11
TC 0
Z9 0
U1 0
U2 6
PU NATL INST SCIENCE COMMUNICATION NISCAIR
PI NEW DELHI
PA DR K S KRISHNAN MARG, PUSA CAMPUS, NEW DELHI 110 012, INDIA
SN 0301 1208
EI 0975 0959
J9 INDIAN J BIOCHEM BIO
JI Indian J. Biochem. Biophys.
PD JUN
PY 2022
VL 59
IS 6
BP 696
EP 701
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 4H1ZN
UT WOS:000849680700008
DA 2025 08 17
ER

PT J
AU Csaki, C
   Matis, U
   Mobasheri, A
   Shakibaei, M
AF Csaki, C.
   Matis, U.
   Mobasheri, A.
   Shakibaei, M.
TI Co culture of canine mesenchymal stem cells with primary bone derived
   osteoblasts promotes osteogenic differentiation
SO HISTOCHEMISTRY AND CELL BIOLOGY
LA English
DT Article
DE Co culture; Mesenchymal stem cell (MSC); Osteoblast; Osteogenesis;
   Ultrastructure; Canine
ID CHONDROCYTES IN VITRO; INTEGRIN EXPRESSION; OSTEOCHONDRAL ALLOGRAFTS;
   CARTILAGE; CHONDROGENESIS; OSTEONECROSIS; CULTURE; TRANSPLANTATION;
   ACTIVATION; INHIBITION
AB Tissue engineering of bone grafts with osteogenic progenitor cells such as adult mesenchymal stem cells (MSC) represents a promising strategy for the treatment of large bone defects. The aim of this experimental study was to evaluate the osteogenic potential of primary osteoblasts on MSCs in co culture at different ratios. The co cultures were treated with or without a specific osteogenic induction medium in monolayer and high density cultures. In monolayer co cultures, MSCs and osteoblasts actively searched for cell cell contact leading to cell proliferation and only in treated monolayer co cultures osteogenesis was observed. Ultrastructural evaluation of high density co cultures using electron microscopy demonstrated osteogenesis with no significant difference between treated or untreated co cultures. Immunoblotting confirmed expression of collagen type I, beta 1 Integrin, the osteogenic specific transcription factor Cbfa 1 and induction of the MAPKinase pathway (Shc, Erk1/2) in both treated and untreated co cultures. Although treatment with the induction medium enhanced osteogenesis in the co cultures compared to untreated co cultures, the quality of osteogenesis was proportional to the quantity of osteoblasts in the co cultures. Fifty percent osteoblasts in the co cultures markedly increased osteogenesis; even the presence of ten percent osteoblasts in the co culture strongly promoted osteogenesis. This data leads us to conclude that co culture of MSCs with osteoblasts combined with the three dimensional environment of the high density culture strongly promotes osteogenesis and stabilizes the osteogenic potential of MSCs. This approach may prove to be of practical benefit in future tissue engineering and regenerative medicine research.
C1 [Csaki, C.; Shakibaei, M.] Univ Munich, Musculoskeletal Res Grp, Inst Anat, D 80336 Munich, Germany.
   [Matis, U.] Univ Munich, Clin Vet Surg, D 80336 Munich, Germany.
   [Mobasheri, A.] Univ Nottingham, Div Vet Med, Sch Vet Med & Sci, Loughborough LE12 5RD, Leics, England.
C3 University of Munich; University of Munich; University of Nottingham
RP Shakibaei, M (通讯作者)，Univ Munich, Musculoskeletal Res Grp, Inst Anat, Pettenkoferstr 11, D 80336 Munich, Germany.
EM mehdi.shakibaei@med.uni muenchen.de
RI ; Shakibaei, Prof. Dr. Mehdi/AAA 7004 2020; Mobasheri, Ali/D 5770 2011
OI Buhrmann, Constanze/0000 0002 0786 0463; Shakibaei, Prof. Dr.
   Mehdi/0000 0002 6304 7506; Mobasheri, Ali/0000 0001 6261 1286
FU Friedrich Bauer Stiftung, Munich, Germany
FX The authors would like to thank Ms. Karoline Fischer for her excellent
   technical assistance. The additional support of Ms. Simone Nebrich is
   also acknowledged. This work was supported in part by the Friedrich
   Bauer Stiftung, Munich, Germany.
CR AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871
   Alexanian AR, 2003, NEUROSCIENCE, V118, P1, DOI 10.1016/S0306 4522(02)00994 6
   Ball SG, 2004, INT J BIOCHEM CELL B, V36, P714, DOI 10.1016/j.biocel.2003.10.015
   Beris AE, 2005, INJURY, V36, pS14, DOI 10.1016/j.injury.2005.10.007
   Csaki C, 2007, HISTOCHEM CELL BIOL, V128, P507, DOI 10.1007/s00418 007 0337 z
   CZITROM AA, 1986, CLIN ORTHOP RELAT R, P141
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ducy P, 1996, CONNECT TISSUE RES, V35, P7, DOI 10.3109/03008209609029169
   Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1074>3.0.CO;2 C
   Gangji V, 2005, EXPERT OPIN BIOL TH, V5, P437, DOI 10.1517/14712598.5.4.437
   Gangji Valerie, 2005, J Bone Joint Surg Am, V87 Suppl 1, P106, DOI 10.2106/JBJS.D.02662
   Gerstenfeld LC, 2003, CONNECT TISSUE RES, V44, P85, DOI 10.1080/03008200390152142
   Gerstenfeld LC, 2002, J BONE MINER RES, V17, P221, DOI 10.1359/jbmr.2002.17.2.221
   Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436
   Hangody L, 2003, J BONE JOINT SURG AM, V85A, P25, DOI 10.2106/00004623 200300002 00004
   Heino TJ, 2004, EXP CELL RES, V294, P458, DOI 10.1016/j.yexcr.2003.11.016
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Kadiyala S, 1997, CELL TRANSPLANT, V6, P125, DOI 10.1016/S0963 6897(96)00279 5
   Kajiwara R, 2005, J ORTHOP RES, V23, P909, DOI 10.1016/j.orthres.2004.12.003
   Kanno T, 2007, J CELL BIOCHEM, V101, P1266, DOI 10.1002/jcb.21249
   KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006 291X(05)80208 6
   Kim H, 2003, YONSEI MED J, V44, P187, DOI 10.3349/ymj.2003.44.2.187
   Krampera M, 2006, BONE, V39, P678, DOI 10.1016/j.bone.2006.04.020
   Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395
   LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851
   Mackenzie TC, 2001, CYTOTHERAPY, V3, P403, DOI 10.1080/146532401753277571
   Mackenzie TC, 2001, BLOOD CELL MOL DIS, V27, P601, DOI 10.1006/bcmd.2001.0424
   MARCO F, 1993, INT ORTHOP, V17, P104, DOI 10.1007/BF00183551
   McPherron AC, 1999, NAT GENET, V22, P260, DOI 10.1038/10320
   MEYERS MH, 1983, CLIN ORTHOP RELAT R, P107
   MIKIC B, 1995, BONE, V16, P445
   Moioli EK, 2008, BONE, V42, P332, DOI 10.1016/j.bone.2007.10.004
   Nöth U, 2002, J ORTHOP RES, V20, P1060, DOI 10.1016/S0736 0266(02)00018 9
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qu CQ, 2007, IN VITRO CELL DEV AN, V43, P95, DOI 10.1007/s11626 006 9008 y
   Richardson SM, 2006, STEM CELLS, V24, P707, DOI 10.1634/stemcells.2005 0205
   RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548
   Ross N, 2000, BRIT J NEUROSURG, V14, P476
   Schulze Tanzil G, 2004, OSTEOARTHR CARTILAGE, V12, P448, DOI 10.1016/j.joca.2004.02.007
   Schulze Tanzil G, 2001, HISTOL HISTOPATHOL, V16, P1081, DOI 10.14670/HH 16.1081
   Shakibaei M, 1997, CELL BIOL INT, V21, P115, DOI 10.1006/cbir.1996.0118
   Shakibaei M, 1998, EXP CELL RES, V240, P95, DOI 10.1006/excr.1998.3933
   Shakibaei M, 1999, BIOCHEM J, V342, P615, DOI 10.1042/0264 6021:3420615
   SHAKIBAEI M, 1993, HISTOL HISTOPATHOL, V8, P463
   SHAKIBAEI M, 1995, HISTOL HISTOPATHOL, V10, P339
   Shakibaei M, 2001, J BIOL CHEM, V276, P13289, DOI 10.1074/jbc.M010859200
   SHAKIBAEI M, 1995, J HISTOCHEM CYTOCHEM, V43, P1061, DOI 10.1177/43.10.7560884
   Shakibaei M, 2006, BIOCHEM PHARMACOL, V72, P1382, DOI 10.1016/j.bcp.2006.08.022
   Silber JS, 2003, SPINE, V28, P134, DOI 10.1097/00007632 200301150 00008
   Smith SM, 2006, BIOCHEM BIOPH RES CO, V342, P909, DOI 10.1016/j.bbrc.2006.02.058
   Song L, 2005, STEM CELLS DEV, V14, P712, DOI 10.1089/scd.2005.14.712
   Sottile V, 2002, BONE, V30, P699, DOI 10.1016/S8756 3282(02)00674 9
   Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092 8674(00)81392 6
   Yamamoto N, 2007, J DERMATOL SCI, V48, P43, DOI 10.1016/j.jdermsci.2007.05.015
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 57
TC 85
Z9 94
U1 0
U2 25
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0948 6143
EI 1432 119X
J9 HISTOCHEM CELL BIOL
JI Histochem. Cell Biol.
PD FEB
PY 2009
VL 131
IS 2
BP 251
EP 266
DI 10.1007/s00418 008 0524 6
PG 16
WC Cell Biology; Microscopy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Microscopy
GA 392PU
UT WOS:000262315500009
PM 18941769
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Stein, NC
   Kreutzmann, C
   Zimmermann, SP
   Niebergall, U
   Hellmeyer, L
   Goettsch, C
   Schoppet, M
   Hofbauer, LC
AF Stein, Nicola C.
   Kreutzmann, Carmen
   Zimmermann, Sara Pia
   Niebergall, Ute
   Hellmeyer, Lars
   Goettsch, Claudia
   Schoppet, Michael
   Hofbauer, Lorenz C.
TI Interleukin 4 and interleukin 13 stimulate the osteoclast inhibitor
   osteoprotegerin by human endothelial cells through the STAT6 pathway
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE endothelial cells; interleukin 4; osteoporosis; osteoprotegerin; STAT6
ID NF KAPPA B; POSTMENOPAUSAL WOMEN; BONE RESORPTION; DEFICIENT MICE;
   GENE THERAPY; IL 4; CALCIFICATION; OSTEOPOROSIS; LIGAND; EXPRESSION
AB Introduction: Endothelial cells of the bone vasculature modulate development, remodeling, and repair of bone by secreting osteotropic cytokines and hormones, which can act on osteoblastic and osteoclastic lineage cells. RANKL is the essential factor for differentiation, activation, and survival of osteoclasts, whereas osteoprotegerin (OPG) is a soluble decoy receptor and inhibitor for RANKL.
   Materials and Methods: In this study, we analyzed the regulation of OPG by T helper 2 (Th2) cytokines interleukin (IL) 4 and the closely related IL 13 in human umbilical vein endothelial cells (HUVECs), the underlying signaling pathway, and its functional relevance on osteoclastic resorption.
   Results: IL 4 and IL 13 induced OPG mRNA levels and protein secretion in HUVEC by up to 4 fold in a dose  and time dependent fashion (maximum effect after 48 h and at 10 ng/ml). Activation of the transcription factor STAT6 preceded IL 4 induced OPG expression, and blockade of IL 4 induced STAT6 activation by the phospholipase, C specific inhibitor D609 decreased OPG expression. Soluble IL 4 receptor (sIL 4R) dose dependently abolished both IL 4 induced STAT6 phosphorylation and OPG expression. RANKL stimulated the activity of osteoclasts, which was antagonized by HUVEC derived supernatant containing OPG. The inhibitory effect on osteoclastogenesis was completely and specifically abrogated by a neutralizing OPG antibody in unstimulated HUVEC supernatant and partially in IL 4 stimulated HUVEC supernatant.
   Conclusions: In summary, IL 4 and IL 13 induced OPG expression through activation of STAT6 in endothelial cells, and HUVEC derived CPG is an 11 4/IL 13 induced inhibitor of osteoclastic resorption. These data underline the impact of Th2 cytokines on bone resorption through modulation of endothelial cell derived cytokines.
C1 [Stein, Nicola C.; Kreutzmann, Carmen; Zimmermann, Sara Pia; Niebergall, Ute; Hellmeyer, Lars; Schoppet, Michael; Hofbauer, Lorenz C.] Univ Marburg, Dept Med, Marburg, Germany.
   [Stein, Nicola C.; Goettsch, Claudia; Hofbauer, Lorenz C.] Tech Univ Dresden, Dept Med, Dresden, Germany.
   [Zimmermann, Sara Pia; Hellmeyer, Lars] Univ Marburg, Dept Gynecol & Obstet, Marburg, Germany.
C3 Philipps University Marburg; Technische Universitat Dresden; Philipps
   University Marburg
RP Stein, NC (通讯作者)，Univ Marburg, Dept Med, Marburg, Germany.
RI Niebergall, Ute/E 8885 2017; Hofbauer, Lorenz C./G 2490 2010; Hofbauer,
   Lorenz/G 2490 2010; Goettsch, Claudia/AAD 9658 2019
OI Hofbauer, Lorenz C./0000 0002 8691 8423; Goettsch,
   Claudia/0000 0002 7973 1329
CR Abu Amer Y, 2001, J CLIN INVEST, V107, P1375, DOI 10.1172/JCI10530
   Alayan J, 2007, J PERIODONTAL RES, V42, P97, DOI 10.1111/j.1600 0765.2006.00920.x
   Bendixen AC, 2001, P NATL ACAD SCI USA, V98, P2443, DOI 10.1073/pnas.041493198
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Collin Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200
   Davenport P, 2003, AM J PATHOL, V163, P1117, DOI 10.1016/S0002 9440(10)63471 2
   Finkelman FD, 2004, IMMUNOL REV, V201, P139, DOI 10.1111/j.0105 2896.2004.00192.x
   George J, 2000, ATHEROSCLEROSIS, V153, P403, DOI 10.1016/S0021 9150(00)00418 4
   Grehan JF, 2005, J IMMUNOL, V175, P1903, DOI 10.4049/jimmunol.175.3.1903
   Haraldsen G, 1996, J IMMUNOL, V156, P2558
   Hofbauer LC, 2006, THROMB HAEMOSTASIS, V95, P708, DOI 10.1160/TH05 12 0800
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Iribarren C, 2000, JAMA J AM MED ASSOC, V283, P2810, DOI 10.1001/jama.283.21.2810
   KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681
   Kelly Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458
   King VL, 2002, ARTERIOSCL THROM VAS, V22, P456, DOI 10.1161/hq0302.104905
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kong YY, 2000, IMMUNOL TODAY, V21, P495, DOI 10.1016/S0167 5699(00)01718 7
   Kotowicz K, 1996, INT IMMUNOL, V8, P1915, DOI 10.1093/intimm/8.12.1915
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee YW, 2003, AM J PHYSIOL HEART C, V284, pH185, DOI 10.1152/ajpheart.00524.2002
   Lubberts E, 2000, J CLIN INVEST, V105, P1697, DOI 10.1172/JCI7739
   Malyankar UM, 2000, J BIOL CHEM, V275, P20959, DOI 10.1074/jbc.C000290200
   Mangashetti LS, 2005, J IMMUNOL, V175, P917, DOI 10.4049/jimmunol.175.2.917
   Min H, 2000, J EXP MED, V192, P463, DOI 10.1084/jem.192.4.463
   Moreno JL, 2003, BLOOD, V102, P1078, DOI 10.1182/blood 2002 11 3437
   PalmerCrocker RL, 1996, J CLIN INVEST, V98, P604, DOI 10.1172/JCI118829
   Palmqvist P, 2006, J BIOL CHEM, V281, P2414, DOI 10.1074/jbc.M510160200
   PAUL WE, 1991, BLOOD, V77, P1859
   Rogers A, 2002, J CLIN ENDOCR METAB, V87, P4470, DOI 10.1210/jc.2002 020396
   Saidenberg Kermanac'h N, 2004, J CLIN IMMUNOL, V24, P370, DOI 10.1023/B:JOCI.0000029116.12371.bf
   Schoppet M, 2002, ARTERIOSCL THROM VAS, V22, P549, DOI 10.1161/01.ATV.0000012303.37971.DA
   Schulz E, 2004, J CLIN ENDOCR METAB, V89, P4246, DOI 10.1210/jc.2003 030964
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Tankó LB, 2005, J BONE MINER RES, V20, P1912, DOI 10.1359/JBMR.050711
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200
   Yano K, 1999, J BONE MINER RES, V14, P518, DOI 10.1359/jbmr.1999.14.4.518
   Yao LB, 1996, J EXP MED, V184, P81, DOI 10.1084/jem.184.1.81
   Zannettino ACW, 2005, J CELL PHYSIOL, V204, P714, DOI 10.1002/jcp.20354
NR 40
TC 65
Z9 74
U1 0
U2 4
PU AMER SOC BONE & MINERAL RES
PI WASHINGTON
PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036 3309 USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2008
VL 23
IS 5
BP 750
EP 758
DI 10.1359/JBMR.080203
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 291NC
UT WOS:000255203100018
PM 18251702
DA 2025 08 17
ER

PT J
AU Mitch, WE
AF Mitch, William E.
TI Metabolic and clinical consequences of metabolic acidosis
SO JOURNAL OF NEPHROLOGY
LA English
DT Article
DE acidosis; protein metabolism; amino acid metabolism; bone metabolism
ID CHRONIC RENAL FAILURE; BODY PROTEIN DEGRADATION; HEMODIALYSIS PATIENTS;
   SODIUM BICARBONATE; PARATHYROID HORMONE; DIALYSIS PATIENTS; ALBUMIN
   SYNTHESIS; CALCIUM BALANCE; ENDOCRINE AXIS; ALKALI THERAPY
AB Acid base balance is precisely regulated by pulmonary and renal responses while body buffers help to control pH. When its regulation becomes abnormal, accumulation of hydrogen ions cause metabolic acidosis and several responses are activated. These responses interfere with the metabolism of bones and muscle. Metabolic acidosis induces abnormalities in the release and function of several hormones including defects in growth hormone, IGF 1, insulin, glucocorticoids, thyroid hormone, parathyroid hormone and vitamin D. Clinical consequences of these abnormal metabolic responses include impaired growth of infants and children and loss of bone and muscle mass in adults. Notably, abnormalities in bone and muscle metabolism can be present even when there is little or no decrease in the plasma bicarbonate concentration. The abnormalities can be corrected by treatment with NaHCO3. In patients with chronic kidney disease, many abnormalities in bone and muscle metabolism can be directly linked to the presence of metabolic acidosis and these abnormalities can be largely corrected by treating acidosis with NaHCO3. Recent insights indicate that several consequences of metabolic acidosis including the development of insulin resistance can stimulate muscle protein degradation by activating proteolytic mechanisms. To avoid abnormalities in metabolism and the loss of bone and muscle, metabolic acidosis must be corrected in normal adults and in patients with kidney disease.
C1 Baylor Coll Med, Div Nephrol, Houston, TX 77030 USA.
C3 Baylor College of Medicine
RP Mitch, WE (通讯作者)，Baylor Coll Med, Div Nephrol, M S,BCM 285,1 Baylor Plaza,Alkek N 520, Houston, TX 77030 USA.
EM mitch@bcm.edu
CR Alpern RJ, 1997, AM J KIDNEY DIS, V29, P291, DOI 10.1016/S0272 6386(97)90045 7
   BALLMER PE, 1995, J CLIN INVEST, V95, P39, DOI 10.1172/JCI117668
   Bereket A, 1996, ENDOCRINOLOGY, V137, P2238, DOI 10.1210/en.137.6.2238
   BERGSTROM J, 1995, AM J KIDNEY DIS, V26, P229, DOI 10.1016/0272 6386(95)90178 7
   Boirie Y, 2000, KIDNEY INT, V58, P236, DOI 10.1046/j.1523 1755.2000.00158.x
   Brungger M, 1997, KIDNEY INT, V51, P216, DOI 10.1038/ki.1997.26
   Brungger M, 1997, AM J PHYSIOL RENAL, V272, pF648, DOI 10.1152/ajprenal.1997.272.5.F648
   Bushinsky DA, 1995, AM J PHYSIOL CELL PH, V269, pC1364, DOI 10.1152/ajpcell.1995.269.6.C1364
   BUSHINSKY DA, 1993, AM J PHYSIOL, V265, pF530, DOI 10.1152/ajprenal.1993.265.4.F530
   CHALLA A, 1993, AM J PHYSIOL, V265, pE547, DOI 10.1152/ajpendo.1993.265.4.E547
   DEFRONZO RA, 1979, AM J PHYSIOL, V236, pE328, DOI 10.1152/ajpendo.1979.236.4.E328
   Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330
   ENGLAND BK, 1995, AM J PHYSIOL CELL PH, V268, pC1395, DOI 10.1152/ajpcell.1995.268.6.C1395
   GARIBOTTO G, 1994, KIDNEY INT, V45, P1432, DOI 10.1038/ki.1994.187
   GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531
   GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095
   Graham KA, 1997, J AM SOC NEPHROL, V8, P627
   Graham KA, 1996, KIDNEY INT, V49, P1396, DOI 10.1038/ki.1996.196
   Graham KA, 1997, J AM SOC NEPHROL, V8, P632
   Green J, 2000, KIDNEY INT, V57, P2258, DOI 10.1046/j.1523 1755.2000.00086.x
   Kalhoff H, 1997, ACTA PAEDIATR, V86, P96, DOI 10.1111/j.1651 2227.1997.tb08840.x
   Kaysen GA, 2004, KIDNEY INT, V65, P1408, DOI 10.1111/j.1523 1755.2004.00520.x
   Kirschbaum B, 2000, AM J KIDNEY DIS, V35, P1068, DOI 10.1016/S0272 6386(00)70041 2
   Kobayashi S, 2005, AM J KIDNEY DIS, V45, P275, DOI 10.1053/j.ajkd.2004.09.034
   KOPPLE JD, 1973, MEDICINE, V52, P597, DOI 10.1097/00005792 197311000 00005
   KRAPF R, 1992, J CLIN INVEST, V90, P2456, DOI 10.1172/JCI116137
   Kuemmerle N, 1997, KIDNEY INT, pS102
   LEFEBVRE A, 1989, KIDNEY INT, V36, P1112, DOI 10.1038/ki.1989.309
   LITZOW JR, 1967, J CLIN INVEST, V46, P280, DOI 10.1172/JCI105530
   LUTZ J, 1984, AM J CLIN NUTR, V39, P281, DOI 10.1093/ajcn/39.2.281
   Mak RHK, 1998, KIDNEY INT, V54, P603, DOI 10.1046/j.1523 1755.1998.00023.x
   MCSHERRY E, 1978, J CLIN INVEST, V61, P509, DOI 10.1172/JCI108962
   Mitch WE, 2002, J CLIN INVEST, V110, P437, DOI 10.1172/JCI200216494
   Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507
   Movilli E, 2001, NEPHRON, V87, P257, DOI 10.1159/000045923
   Movilli E, 1998, NEPHROL DIAL TRANSPL, V13, P1719, DOI 10.1093/ndt/13.7.1719
   PAPADOYANNAKIS NJ, 1984, AM J CLIN NUTR, V40, P623, DOI 10.1093/ajcn/40.3.623
   Pickering WP, 2002, KIDNEY INT, V61, P1286, DOI 10.1046/j.1523 1755.2002.00276.x
   REAICH D, 1992, AM J PHYSIOL, V263, pE735, DOI 10.1152/ajpendo.1992.263.4.E735
   REAICH D, 1993, AM J PHYSIOL, V265, pE230, DOI 10.1152/ajpendo.1993.265.2.E230
   Roberts RG, 2002, EUR J CLIN INVEST, V32, P488, DOI 10.1046/j.1365 2362.2002.01008.x
   SCHAMBELAN M, 1987, AM J PHYSIOL, V252, pE454, DOI 10.1152/ajpendo.1987.252.4.E454
   SEBASTIAN A, 1994, NEW ENGL J MED, V330, P1776, DOI 10.1056/NEJM199406233302502
   SEYFFART G, 1987, KIDNEY INT, V32, pS174
   Stein A, 1997, KIDNEY INT, V52, P1089, DOI 10.1038/ki.1997.433
   Szeto CC, 2003, J AM SOC NEPHROL, V14, P2119, DOI 10.1097/01.ASN.0000080316.37254.7A
   Uribarri J, 1999, AM J KIDNEY DIS, V34, P493, DOI 10.1016/S0272 6386(99)70077 6
   Wiederkehr MR, 2004, NEPHROL DIAL TRANSPL, V19, P1190, DOI 10.1093/ndt/gfh096
   WILLIAMS B, 1991, KIDNEY INT, V40, P779, DOI 10.1038/ki.1991.275
NR 49
TC 51
Z9 53
U1 0
U2 9
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1121 8428
EI 1724 6059
J9 J NEPHROL
JI J. Nephrol.
PD MAR APR
PY 2006
VL 19
SU 9
BP S70
EP S75
PG 6
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 098EP
UT WOS:000241504100011
PM 16736444
DA 2025 08 17
ER

PT J
AU Guo, M
   Liu, N
   Guo, ZJ
AF Guo, Min
   Liu, Na
   Guo, Zhanjun
TI MiR 221 5p/Smad3 axis in osteoclastogenesis and its function: Potential
   therapeutic target for osteoporosis
SO STEROIDS
LA English
DT Article
DE MiR 221 5p; Smad3; Osteoclast; Postmenopausal osteoporosis
ID POSTMENOPAUSAL OSTEOPOROSIS
AB Objective: To probe the role of miR 221 5p in osteoclastogenesis and the underlying mechanism. Methods: Serum from patients with postmenopausal osteoporosis and healthy controls was collected for determination of miR 221 5p expression. For in vitro experiment, RAW264.7 macrophages, in which the expression of miR 221 5p and/or Smad3 was altered, were induced by RANKL to differentiate into osteoclasts. For in vivo experiment, ovariectomy was performed to construct osteoporosis mouse models, followed by tail vein injection of miR 221 5p agomir. qRT PCR and/or western blot were applied to measure the expression of miR 221 5p, Smad3, and osteoclastogenesis related genes (NFATc1 and TRAF6). TRAP staining was utilized for assessment of osteoclast formation, MTT assay for assessment of osteoclast viability, and H&E staining for observation of histomorphological changes. The targeting relationship between miR 221 5p and Smad3 was verified by dualluciferase reporter gene assay. Results: Compared with healthy controls, patients with postmenopausal osteoporosis had decreased miR 221 5p expression and lower lumbar vertebra bone mineral density. MiR 221 5p expression was decreased and Smad3 level was increased during osteoclastogenesis. The osteoclastogenesis was suppressed by miR 221 5p and promoted by Smad3, as evidenced by diminished number and viability of osteoclasts following overexpression of miR 221 5p or knockdown of Smad3. MiR 221 5p negatively mediated Smad3 expression. Smad3 suppression nullified the pro osteoclastogenesis effect of miR 221 5p inhibition. Consistent results were observed in osteoporosis mouse models. Conclusion: MiR 221 5p may alleviate postmenopausal osteoporosis through suppressing osteoclastogenesis via Smad3, which provides new ideas for molecule targeted therapy of osteoporosis.
C1 [Guo, Min; Liu, Na; Guo, Zhanjun] Cent South Univ, Xiangya Hosp, Dept Endocrinol, Changsha 410008, Hunan, Peoples R China.
C3 Central South University
RP Guo, M (通讯作者)，Cent South Univ, Xiangya Hosp, Dept Endocrinol, Changsha 410008, Hunan, Peoples R China.
EM xyguom@hotmail.com
RI Guo, Zhanjun/M 4666 2018
CR Bandeira L, 2017, ENDOCRIN METAB CLIN, V46, P207, DOI [10.1016/j.ec1.2016.11.001, 10.1016/j.ecl.2016.11.001]
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Budi EH, 2017, TRENDS CELL BIOL, V27, P658, DOI 10.1016/j.tcb.2017.04.005
   Burja B, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00056
   Cheng F, 2019, EUR REV MED PHARMACO, V23, P7766, DOI 10.26355/eurrev_201909_18986
   Cosman F, 2018, CURR OPIN RHEUMATOL, V30, P420, DOI 10.1097/BOR.0000000000000509
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Fan FY, 2019, ONCOL LETT, V18, P6536, DOI 10.3892/ol.2019.10992
   Fennen M, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1187 7
   Fu LG, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01688 5
   Fu Y, 2020, REJUV RES, V23, P313, DOI 10.1089/rej.2019.2239
   Ji X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030349
   Jiang XM, 2020, ONCOTARGETS THER, V13, P2333, DOI 10.2147/OTT.S232953
   Khajuria DK, 2012, REV BRAS REUMATOL, V52, P462
   Khan M, 2017, ENDOCRIN METAB CLIN, V46, P181, DOI 10.1016/j.ecl.2016.09.009
   Li ZQ, 2018, ACTA BIOCH BIOPH SIN, V50, P273, DOI 10.1093/abbs/gmy006
   Liu SW, 2019, BIOMED PHARMACOTHER, V119, DOI 10.1016/j.biopha.2019.109406
   Mei LW, 2018, J CELL PHYSIOL, V233, P9724, DOI 10.1002/jcp.26914
   Mizoguchi F, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4282
   Shao N, 2018, BMC UROL, V18, DOI 10.1186/s12894 018 0325 8
   Sun L, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658 019 0146 0
   Wang C, 2020, J BONE MINER RES, V35, P776, DOI 10.1002/jbmr.3927
   Watts NB, 2018, J WOMENS HEALTH, V27, P1093, DOI 10.1089/jwh.2017.6706
   Xu Z, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14570
   Yu FY, 2018, LIFE SCI, V202, P11, DOI 10.1016/j.lfs.2018.03.042
   Zhang YQ, 2017, AM J TRANSL RES, V9, P126
NR 26
TC 7
Z9 8
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039 128X
EI 1878 5867
J9 STEROIDS
JI Steroids
PD SEP
PY 2022
VL 185
AR 109063
DI 10.1016/j.steroids.2022.109063
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 2Z4NT
UT WOS:000826557600006
PM 35700796
DA 2025 08 17
ER

PT J
AU Li, L
   Zhu, ZM
   Huang, CP
   Chen, WC
AF Li, Lei
   Zhu, Zhimin
   Huang, Chunpeng
   Chen, Wenchuan
TI Ultrasound: A potential technique to improve osseointegration of dental
   implants
SO MEDICAL HYPOTHESES
LA English
DT Article
ID INTENSITY PULSED ULTRASOUND; PROSTAGLANDIN E 2 PRODUCTION;
   BONE FORMATION; HUMAN OSTEOBLASTS; NITRIC OXIDE; GROWTH; RATS;
   STIMULATION; EXPRESSION; INTERFACE
AB Dental implants have been widely used in clinic for the restoration of lost teeth in recent decades, but there still remains a great challenge for even a higher success rate and a shorter rehabilitation time. The osseointegration between dental implant and alveolar bone tissue is crucial for a successful implantation. Ultrasound has been proved to be an effective treatment for bone fracture heating. The underlying mechanism of the mechanotransduction pathway involved in cellular responses to ultrasound is still not clear, however, numerous studies have confirmed its ability to enhance osteogenesis and therefore facilitate bone regeneration. In this paper, we hypothesize that this kind of wave might have an ability to strengthen and accelerate osseointegration of dental implants, and thus a potential usage in dental therapy. (c) 2008 Elsevier Ltd. All rights reserved.
C1 [Li, Lei; Zhu, Zhimin; Huang, Chunpeng; Chen, Wenchuan] Sichuan Univ, W China Stomatol Hosp, Dept Prosthet Dent, State Key Lab Oral Dis,W China Coll Stomatol, Chengdu 610041, Peoples R China.
C3 Sichuan University
RP Zhu, ZM (通讯作者)，Sichuan Univ, W China Stomatol Hosp, Dept Prosthet Dent, State Key Lab Oral Dis,W China Coll Stomatol, 14 3rd Sect S Renmin Rood, Chengdu 610041, Peoples R China.
EM geraldleelei@163.com; li982307@ sina.com
OI chen, wenchuan/0000 0002 6145 7878
CR ADELL R, 1990, International Journal of Oral and Maxillofacial Implants, V5, P347
   Berglundh T, 2003, CLIN ORAL IMPLAN RES, V14, P251, DOI 10.1034/j.1600 0501.2003.00972.x
   Chang WHS, 2002, BIOELECTROMAGNETICS, V23, P256, DOI 10.1002/bem.10009
   Chikazu D, 2007, INT J ORAL MAX SURG, V36, P441, DOI 10.1016/j.ijom.2006.11.011
   Cooper LF, 1998, J PROSTHET DENT, V80, P439, DOI 10.1016/S0022 3913(98)70009 5
   DUARTE LR, 1983, ARCH ORTHOP TRAUM SU, V101, P153, DOI 10.1007/BF00436764
   Esposito Marco, 2005, Eur J Prosthodont Restor Dent, V13, P15
   Franchi Marco, 2004, ScientificWorldJournal, V4, P1083
   Gapski R, 2003, CLIN ORAL IMPLAN RES, V14, P515, DOI 10.1034/j.1600 0501.2003.00950.x
   GREENLEAF JF, AIUM ANN M 2003 MONT
   Gross TS, 1997, J BONE MINER RES, V12, P982, DOI 10.1359/jbmr.1997.12.6.982
   Han DQ, 2006, MED HYPOTHESES, V67, P75, DOI 10.1016/j.mehy.2006.01.014
   Hausman MR, 2001, BONE, V29, P560, DOI 10.1016/S8756 3282(01)00608 1
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   Jeffcoat M K, 1993, Adv Dent Res, V7, P196
   Kokubu T, 1999, BIOCHEM BIOPH RES CO, V256, P284, DOI 10.1006/bbrc.1999.0318
   Kristiansen TK, 1997, J BONE JOINT SURG AM, V79A, P961, DOI 10.2106/00004623 199707000 00002
   Le Guéhennec L, 2007, DENT MATER, V23, P844, DOI 10.1016/j.dental.2006.06.025
   Leung KS, 2004, ULTRASOUND MED BIOL, V30, P389, DOI 10.1016/j.ultrasmedbio.2003.11.008
   Li JGR, 2002, ULTRASOUND MED BIOL, V28, P683, DOI 10.1016/S0301 5629(02)00485 4
   Meyer U, 2004, BIOMATERIALS, V25, P1959, DOI 10.1016/j.biomaterials.2003.08.070
   Murai K, 1996, J BIOMED MATER RES, V30, P523, DOI 10.1002/(SICI)1097 4636(199604)30:4<523::AID JBM11>3.3.CO;2 6
   Nelson Fred R T, 2003, J Am Acad Orthop Surg, V11, P344
   Pilla A A, 1990, J Orthop Trauma, V4, P246, DOI 10.1097/00005131 199004030 00002
   Puleo David A, 2006, Dent Clin North Am, V50, P323, DOI 10.1016/j.cden.2006.03.001
   Rawool NM, 2003, J ULTRAS MED, V22, P145, DOI 10.7863/jum.2003.22.2.145
   Reher P, 2002, BONE, V31, P236, DOI 10.1016/S8756 3282(02)00789 5
   Spadaro JA, 1998, ULTRASOUND MED BIOL, V24, P567, DOI 10.1016/S0301 5629(98)00006 4
   Wang FS, 2004, BONE, V35, P114, DOI 10.1016/j.bone.2004.02.012
   WU JR, 1990, ULTRASOUND MED BIOL, V16, P489, DOI 10.1016/0301 5629(90)90171 8
   Yang RS, 2005, BONE, V36, P276, DOI 10.1016/j.bone.2004.10.009
NR 31
TC 16
Z9 17
U1 0
U2 13
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2008
VL 71
IS 4
BP 568
EP 571
DI 10.1016/j.mehy.2008.05.013
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 361RW
UT WOS:000260145800015
PM 18599220
DA 2025 08 17
ER

PT J
AU Barry, E
   Taylor, T
   Patel, J
   Hamid, U
   Bryant, C
AF Barry, Elizabeth
   Taylor, Talli
   Patel, Jashme
   Hamid, Umar
   Bryant, Cathy
TI The incidence of medication related osteonecrosis of the jaw following
   tooth extraction in patients prescribed oral bisphosphonates
SO BRITISH DENTAL JOURNAL
LA English
DT Article; Early Access
ID OSTEOPOROTIC PATIENTS; RISK FACTORS; ASSOCIATION; PREVENTION; FREQUENCY
AB Aims To determine the incidence of medication related osteonecrosis of the jaw in patients prescribed oral bisphosphonate medication following dental extraction in a dedicated clinic within the Department of Oral Surgery of King's College Hospital. The effect of factors such as sex, duration of therapy, medical comorbidities and site of extraction, which have previously been reported to significantly affect the risk of developing osteonecrosis of the jaw, was also examined. Materials and methods Data were gathered from the dental records of patients who had extractions over an eight year period and were included in this retrospective study. Patients with previous or current exposure to intravenous bisphosphonates, denosumab, novel targeted chemotherapies used in the oncology setting or radiotherapy to the head and neck were excluded from this study. Results The incidence of medication related osteonecrosis of the jaw following tooth extraction in this group of 652 was 0.8%. A significantly increased risk of developing medication related osteonecrosis of the jaw was evident in patients prescribed oral bisphosphonates for four years or more (p = 0.02), with an incidence in this group of 1.6%. Conclusion This study demonstrates that, following dental extraction, patients who are prescribed oral bisphosphonates are at risk of developing medication related osteonecrosis of the jaw and that this risk increases significantly when the patient has been taking the bisphosphonate for four years or more.
C1 [Barry, Elizabeth; Taylor, Talli; Patel, Jashme; Hamid, Umar; Bryant, Cathy] Kings Coll Hosp London, Oral Surg, London SE5 9RS, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital
RP Barry, E (通讯作者)，Kings Coll Hosp London, Oral Surg, London SE5 9RS, England.
EM elizabeth.barry@nhs.net
CR Bagan JV, 2006, ORAL ONCOL, V42, P327, DOI 10.1016/j.oraloncology.2005.08.001
   Bermudez Bejarano Elena Beatriz, 2017, J Clin Exp Dent, V9, pe141, DOI 10.4317/jced.53372
   Beth Tasdogan NH, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012432.pub2
   Chiu WY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196419
   Dodson TB, 2015, ORAL MAXIL SURG CLIN, V27, P509, DOI 10.1016/j.coms.2015.06.003
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   European Medicines Agency, 2011, ASS REP BISPH CONT
   Fleisher KE, 2016, ANTIRESORPTIVE DRUG
   Gaudin E, 2015, J CLIN PERIODONTOL, V42, P922, DOI 10.1111/jcpe.12455
   Hasegawa T, 2017, OSTEOPOROSIS INT, V28, P2465, DOI 10.1007/s00198 017 4063 7
   Hellstein JW, 2011, J AM DENT ASSOC, V142, P1243, DOI 10.14219/jada.archive.2011.0108
   Jeong HG, 2017, IMAGNG SCI DENT, V47, P41, DOI 10.5624/isd.2017.47.1.45
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   King R, 2020, BRIT DENT J, V228, P415, DOI 10.1038/s41415 020 1365 5
   Kunchur R, 2009, J ORAL MAXIL SURG, V67, P1167, DOI 10.1016/j.joms.2009.02.004
   Lo JC, 2010, J ORAL MAXIL SURG, V68, P243, DOI 10.1016/j.joms.2009.03.050
   Mavrokokki T, 2007, J ORAL MAXIL SURG, V65, P415, DOI 10.1016/j.joms.2006.10.061
   McGowan K, 2019, CLIN ORAL INVEST, V23, P3967, DOI 10.1007/s00784 019 02828 w
   Medicines and Healthcare products Regulatory Agency, 2014, BISPH ATYP FEM FRA
   Medicines and Healthcare products Regulatory Agency, 2015, BISPH VER RAR REP OS
   Medicines and Healthcare products Regulatory Agency, 2014, BISPH US SAF
   Mozzati M, 2013, OSTEOPOROSIS INT, V24, P1707, DOI 10.1007/s00198 012 2239 8
   National Institute for Health and Care Excellence, 2017, EARL BREAST CANC PRE
   Nicolatou Galitis O, 2019, OR SURG OR MED OR PA, V127, P117, DOI 10.1016/j.oooo.2018.09.008
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Schiodt M, 2019, ORAL DIS, V25, P1815, DOI 10.1111/odi.13160
   Scottish Dental Clinical Effectiveness Programme, 2017, ORAL HLTH MANAGEMENT
   Shudo A, 2018, OSTEOPOROSIS INT, V29, P2315, DOI 10.1007/s00198 018 4621 7
   Tanna N, 2017, BRIT DENT J, V222, P121, DOI 10.1038/sj.bdj.2017.79
   Taylor T, 2013, BRIT DENT J, V214, DOI 10.1038/sj.bdj.2013.327
   Ulmner M, 2014, J ORAL MAXIL SURG, V72, P76, DOI 10.1016/j.joms.2013.06.221
   Watts NB, 2003, CLIN GERIATR MED, V19, P395, DOI 10.1016/S0749 0690(02)00069 1
NR 33
TC 2
Z9 2
U1 1
U2 7
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0007 0610
EI 1476 5373
J9 BRIT DENT J
JI Br. Dent. J.
PD 2021 NOV 23
PY 2021
DI 10.1038/s41415 021 3620 9
EA NOV 2021
PG 5
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA XB9PW
UT WOS:000721653600001
PM 34815482
DA 2025 08 17
ER

PT J
AU Mizoshiri, N
   Kishida, T
   Yamamoto, K
   Shirai, T
   Terauchi, R
   Tsuchida, S
   Mori, Y
   Ejima, A
   Sato, Y
   Arai, Y
   Fujiwara, H
   Yamamoto, T
   Kanamura, N
   Mazda, O
   Kubo, T
AF Mizoshiri, N.
   Kishida, T.
   Yamamoto, K.
   Shirai, T.
   Terauchi, R.
   Tsuchida, S.
   Mori, Y.
   Ejima, A.
   Sato, Y.
   Arai, Y.
   Fujiwara, H.
   Yamamoto, T.
   Kanamura, N.
   Mazda, O.
   Kubo, T.
TI Transduction of Oct6 or Oct9 gene concomitant with Myc family gene
   induced osteoblast like phenotypic conversion in normal human
   fibroblasts
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Osteoblast; Direct reprogramming; Oct9; N Myc
ID STEM CELLS; EXPRESSION; DIFFERENTIATION
AB Introduction: Osteoblasts play essential roles in bone formation and regeneration, while they have low proliferation potential. Recently we established a procedure to directly convert human fibroblasts into osteoblasts (dOBs). Transduction of Runx2 (R), Osterix (X), Oct3/4 (O) and L myc (L) genes followed by culturing under osteogenic conditions induced normal human fibroblasts to express osteoblast specific genes and produce calcified bone matrix both in vitro and in vivo Intriguingly, a combination of only two factors, Oct3/4 and L myc, significantly induced osteoblast like phenotype in fibroblasts, but the mechanisms underlying the direct conversion remains to be unveiled.
   Materials and Methods: We examined which Oct family genes and Myc family genes are capable of inducing osteoblast like phenotypic conversion.
   Results: As result Oct3/4, Oct6 and Oct9, among other Oct family members, had the capability, while N myc was the most effective Myc family gene. The Oct9 plus N myc was the best combination to induce direct conversion of human fibroblasts into osteoblast like cells.
   Discussion: The present findings may greatly contribute to the elucidation of the roles of the Oct and Myc proteins in osteoblast direct reprogramming. The results may also lead to establishment of novel regenerative therapy for various bone resorption diseases. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Mizoshiri, N.; Kishida, T.; Yamamoto, K.; Mori, Y.; Ejima, A.; Sato, Y.; Mazda, O.] Kyoto Prefectural Univ Med, Dept Immunol, Kyoto 6028566, Japan.
   [Mizoshiri, N.; Shirai, T.; Terauchi, R.; Tsuchida, S.; Mori, Y.; Arai, Y.; Fujiwara, H.; Kubo, T.] Kyoto Prefectural Univ Med, Dept Orthopaed, Kyoto 6028566, Japan.
   [Yamamoto, K.; Sato, Y.; Yamamoto, T.; Kanamura, N.] Kyoto Prefectural Univ Med, Dept Dent Med, Kyoto 6028566, Japan.
C3 Kyoto Prefectural University of Medicine; Kyoto Prefectural University
   of Medicine; Kyoto Prefectural University of Medicine
RP Mazda, O (通讯作者)，Kyoto Prefectural Univ Med, Kamikyo Ku, Kyoto 6028566, Japan.
EM mazda@koto.kpu m.ac.jp
OI Mizoshiri, Naoki/0000 0002 8216 2673; Yamamoto,
   Kenta/0000 0003 0203 8603; Mori, Yuki/0000 0002 0259 4768
FU Japan Science and Technology Agency [AS262Z02511P]; Japanese Ministry of
   Education, Culture, Sports, Science and Technology [26293340, 26861679];
   Grants in Aid for Scientific Research [26861679, 26293340] Funding
   Source: KAKEN
FX This work was supported by grants from the Japan Science and Technology
   Agency AS262Z02511P, and the Japanese Ministry of Education, Culture,
   Sports, Science and Technology 26293340 and 26861679.
CR Andersen B, 1997, GENE DEV, V11, P1873, DOI 10.1101/gad.11.14.1873
   Arrington ED, 1996, CLIN ORTHOP RELAT R, P300, DOI 10.1097/00003086 199608000 00037
   Bandyopadhyay A, 2006, PLOS GENET, V2, P2116, DOI 10.1371/journal.pgen.0020216
   Bellantuono I, 2009, BBA MOL BASIS DIS, V1792, P364, DOI 10.1016/j.bbadis.2009.01.008
   Beltran H, 2014, MOL CANCER RES, V12, P815, DOI 10.1158/1541 7786.MCR 13 0536
   Bonilla Claudio M, 2012, DEVELOPMENT, V139, P709, DOI 10.1242/dev.073197
   Braunstein EM, 2008, JARO J ASSOC RES OTO, V9, P33, DOI 10.1007/s10162 008 0110 6
   Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408
   Esch D, 2013, NAT CELL BIOL, V15, P295, DOI 10.1038/ncb2680
   FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263
   Hagen A., 2012, GMS HLTH TECHNOL ASS
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Hiramatsu K, 2011, J CLIN INVEST, V121, P640, DOI 10.1172/JCI44605
   Huang PY, 2011, NATURE, V475, P386, DOI 10.1038/nature10116
   Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Jin TR, 1999, INT J CANCER, V81, P104, DOI 10.1002/(SICI)1097 0215(19990331)81:1<104::AID IJC18>3.0.CO;2 Q
   Komori T, 2013, CELL TISSUE RES, V352, P191, DOI 10.1007/s00441 012 1546 x
   Komori T, 2011, J CELL BIOCHEM, V112, P750, DOI 10.1002/jcb.22994
   MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Nakagawa M, 2010, P NATL ACAD SCI USA, V107, P14152, DOI 10.1073/pnas.1009374107
   Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168 9525(03)00176 8
   Outani H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077365
   Pesce M, 2000, MOL REPROD DEV, V55, P452, DOI 10.1002/(SICI)1098 2795(200004)55:4<452::AID MRD14>3.0.CO;2 S
   Sekiya S, 2011, NATURE, V475, P390, DOI 10.1038/nature10263
   Shafiee A, 2011, BIOTECHNOL LETT, V33, P1257, DOI 10.1007/s10529 011 0541 8
   SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460 2075.1990.tb07585.x
   Tan XF, 2010, CELL BIOL INT, V34, P877, DOI 10.1042/CBI20100214
   Tantin D, 2013, DEVELOPMENT, V140, P2857, DOI 10.1242/dev.095927
   Vierbuchen T, 2010, NATURE, V463, P1035, DOI 10.1038/nature08797
   Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015
   Wang PX, 2003, BIOCHEM J, V375, P199, DOI 10.1042/BJ20030579
   Xiao ZS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114198
   Yamamoto K, 2015, P NATL ACAD SCI USA, V112, P6152, DOI 10.1073/pnas.1420713112
NR 35
TC 16
Z9 20
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 27
PY 2015
VL 467
IS 4
BP 1110
EP 1116
DI 10.1016/j.bbrc.2015.10.098
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CW6YV
UT WOS:000365145300078
PM 26499074
OA Bronze
DA 2025 08 17
ER

PT J
AU Shor, S
   Fadl Alla, BA
   Pondenis, HC
   Zhang, X
   Wycislo, KL
   Lezmi, S
   Fan, TM
AF Shor, S.
   Fadl Alla, B. A.
   Pondenis, H. C.
   Zhang, X.
   Wycislo, K. L.
   Lezmi, S.
   Fan, T. M.
TI Expression of Nociceptive Ligands in Canine Osteosarcoma
SO JOURNAL OF VETERINARY INTERNAL MEDICINE
LA English
DT Article
DE Nociception; Osteoblast cytokines; Painful malignant osteolysis
ID TRANSITIONAL CELL CARCINOMA; URINARY BLADDER; CLINICAL TRIAL; URETHRAL
   TUMORS; DOGS; PIROXICAM; CISPLATIN; MODEL; COMBINATION; MANAGEMENT
AB Background: Canine osteosarcoma ( OS) is associated with localized pain as a result of tissue injury from tumor infiltration and peritumoral inflammation. Malignant bone pain is caused by stimulation of peripheral pain receptors, termed nociceptors, which reside in the localized tumor microenvironment, including the periosteal and intramedullary bone cavities. Several nociceptive ligands have been determined to participate directly or indirectly in generating bone pain associated with diverse skeletal abnormalities. Hypothesis: Canine OS cells actively produce nociceptive ligands with the capacity to directly or indirectly activate peripheral pain receptors residing in the bone tumor microenvironment. Animals: Ten dogs with appendicular OS. Methods: Expression of nerve growth factor, endothelin  1, and microsomal prostaglandin E synthase  1 was characterized in OS cell lines and naturally occurring OS samples. In 10 dogs with OS, circulating concentrations of nociceptive ligands were quantified and correlated with subjective pain scores and tumor volume in patients treated with standardized palliative therapies. Results: Canine OS cells express and secrete nerve growth factor, endothelin  1, and prostaglandin E2. Naturally occurring OS samples uniformly express nociceptive ligands. In a subset of OS  bearing dogs, circulating nociceptive ligand concentrations were detectable but failed to correlate with pain status. Localized foci of nerve terminal proliferation were identified in a minority of primary bone tumor samples. Conclusions and Clinical Importance: Canine OS cells express nociceptive ligands, potentially permitting active participation of OS cells in the generation of malignant bone pain. Specific inhibitors of nociceptive ligand signaling pathways might improve pain control in dogs with OS.
C1 [Shor, S.; Fadl Alla, B. A.; Pondenis, H. C.; Fan, T. M.] Univ Illinois, Dept Vet Clin Med, Urbana, IL 61802 USA.
   [Zhang, X.; Wycislo, K. L.; Lezmi, S.] Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA.
C3 University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign
RP Fan, TM (通讯作者)，Univ Illinois, Dept Vet Clin Med, 1008 West Hazelwood Dr, Urbana, IL 61802 USA.
EM t fan@illinois.edu
RI Wycislo, Kathryn/AAN 3317 2021
OI Wycislo, Kathryn/0000 0002 3074 6044; Lezmi,
   Stephane/0000 0002 3412 4058; Fan, Timothy/0000 0003 2510 7050; Shor,
   Sharon/0000 0002 1348 4409; Pondenis, Holly/0000 0003 1708 3570
CR Abbo AH, 2010, J VET INTERN MED, V24, P1124, DOI 10.1111/j.1939 1676.2010.0569.x
   Arnold EJ, 2011, J VET INTERN MED, V25, P1385, DOI 10.1111/j.1939 1676.2011.00796.x
   Boria P A, 2005, Vet Comp Oncol, V3, P73, DOI 10.1111/j.1476 5810.2005.00070.x
   Chun R, 1996, J AM VET MED ASSOC, V209, P1588
   Chun R, 1997, J VET INTERN MED, V11, P279, DOI 10.1111/j.1939 1676.1997.tb00465.x
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Greene SN, 2007, JAVMA J AM VET MED A, V231, P1056, DOI 10.2460/javma.231.7.1056
   Henry CJ, 2003, CLIN CANCER RES, V9, P906
   Hume C, 2010, VET COMP ONCOL, V8, P122, DOI 10.1111/j.1476 5829.2010.00212.x
   Knapp DW, 2013, J VET INTERN MED, V27, P126, DOI 10.1111/jvim.12013
   Knapp D.W., 2006, TXB BLADDER CANC, P171
   Knapp DW, 2000, UROL ONCOL, V5, P47, DOI 10.1016/S1078 1439(99)00006 X
   KNAPP DW, 1994, J VET INTERN MED, V8, P273, DOI 10.1111/j.1939 1676.1994.tb03232.x
   Knapp DW, 2000, CANCER CHEMOTH PHARM, V46, P221, DOI 10.1007/s002800000147
   Marconato L, 2011, JAVMA J AM VET MED A, V238, P1004, DOI 10.2460/javma.238.8.1004
   McMillan SK, 2012, JAVMA J AM VET MED A, V241, P1627, DOI 10.2460/javma.241.12.1627
   McMillan SK, 2011, JAVMA J AM VET MED A, V239, P1084, DOI 10.2460/javma.239.8.1084
   Molnár T, 2012, ACTA VET HUNG, V60, P55, DOI 10.1556/AVet.2012.005
   Mutsaers AJ, 2003, J VET INTERN MED, V17, P136, DOI 10.1892/0891 6640(2003)017<0136:CTCC>2.3.CO;2
   Naughton JE, 2012, AM J VET RES, V73, P1919, DOI 10.2460/ajvr.73.12.1919
   Nguyen SM, 2015, VET COMP ONCOL, V13, P176, DOI 10.1111/vco.12032
   Nieset JR, 2011, VET RADIOL ULTRASOUN, V52, P580, DOI 10.1111/j.1740 8261.2011.01838.x
   NORRIS AM, 1992, J VET INTERN MED, V6, P145, DOI 10.1111/j.1939 1676.1992.tb00330.x
   Priester W A, 1980, Natl Cancer Inst Monogr, P1
   Robat C, 2013, J SMALL ANIM PRACT, V54, P67, DOI 10.1111/jsap.12009
   Santos M, 2007, VET REC, V160, P557, DOI 10.1136/vr.160.16.557
   Schrempp DR, 2013, JAVMA J AM VET MED A, V242, P1534, DOI 10.2460/javma.242.11.1534
   TARVIN G, 1978, J AM VET MED ASSOC, V172, P931
   Therasse P, 2006, EUR J CANCER, V42, P1031, DOI 10.1016/j.ejca.2006.01.026
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   VALLI VE, 1995, J COMP PATHOL, V113, P113, DOI 10.1016/S0021 9975(05)80027 1
   Veterinary Co operative Oncology Group (VCOG), 2004, Vet Comp Oncol, V2, P195, DOI 10.1111/j.1476 5810.2004.0053b.x
   Weisse C, 2006, JAVMA J AM VET MED A, V229, P226, DOI 10.2460/javma.229.2.226
NR 33
TC 12
Z9 15
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0891 6640
EI 1939 1676
J9 J VET INTERN MED
JI J. Vet. Intern. Med.
PD JAN FEB
PY 2015
VL 29
IS 1
BP 268
EP 275
DI 10.1111/jvim.12511
PG 8
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA CA1HS
UT WOS:000348664000038
PM 25572473
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Smoum, R
   Baraghithy, S
   Chourasia, M
   Breuer, A
   Mussai, N
   Attar Namdar, M
   Kogan, NM
   Raphael, B
   Bolognini, D
   Cascio, MG
   Marini, P
   Pertwee, RG
   Shurki, A
   Mechoulam, R
   Bab, I
AF Smoum, Reem
   Baraghithy, Saja
   Chourasia, Mukesh
   Breuer, Aviva
   Mussai, Naama
   Attar Namdar, Malka
   Kogan, Natalya M.
   Raphael, Bitya
   Bolognini, Daniele
   Cascio, Maria G.
   Marini, Pietro
   Pertwee, Roger G.
   Shurki, Avital
   Mechoulam, Raphael
   Bab, Itai
TI CB2 cannabinoid receptor agonist enantiomers HU 433 and HU 308: An
   inverse relationship between binding affinity and biological potency
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE endocannabinoids; osteoporosis; enantiomers; pose occupancy
ID LIGAND; CELLS
AB Activation of the CB2 receptor is apparently an endogenous protective mechanism. Thus, it restrains inflammation and protects the skeleton against age related bone loss. However, the endogenous cannabinoids, as well as Delta(9) tetrahydrocannabinol, the main plant psychoactive constituent, activate both cannabinoid receptors, CB1 and CB2. HU 308 was among the first synthetic, selective CB2 agonists. HU 308 is antiosteoporotic and antiinflammatory. Here we show that the HU 308 enantiomer, designated HU 433, is 3 4 orders of magnitude more potent in osteoblast proliferation and osteoclast differentiation culture systems, as well as in mouse models, for the rescue of ovariectomy induced bone loss and ear inflammation. HU 433 retains the HU 308 specificity for CB2, as shown by its failure to bind to the CB1 cannabinoid receptor, and has no activity in CB2 deficient cells and animals. Surprisingly, the CB2 binding affinity of HU 433 in terms of [H 3] CP55,940 displacement and its effect on [S 35]GTP gamma S accumulation is substantially lower compared with HU 308. A molecular modeling analysis suggests that HU 433 and  308 have two different binding conformations within CB2, with one of them possibly responsible for the affinity difference, involving [35S] GTP gamma S and cAMP synthesis. Hence, different ligands may have different orientations relative to the same binding site. This situation questions the usefulness of universal radioligands for comparative binding studies. Moreover, orientation targeted ligands have promising potential for the pharmacological activation of distinct processes.
C1 [Smoum, Reem; Chourasia, Mukesh; Breuer, Aviva; Shurki, Avital; Mechoulam, Raphael] Hebrew Univ Jerusalem, Inst Drug Res, IL 91120 Jerusalem, Israel.
   [Baraghithy, Saja; Mussai, Naama; Attar Namdar, Malka; Kogan, Natalya M.; Raphael, Bitya; Bab, Itai] Hebrew Univ Jerusalem, Bone Lab, IL 91120 Jerusalem, Israel.
   [Chourasia, Mukesh; Shurki, Avital] Hebrew Univ Jerusalem, Lise Meitner Minerva Ctr Computat Quantum Chem, IL 91120 Jerusalem, Israel.
   [Bolognini, Daniele; Cascio, Maria G.; Marini, Pietro; Pertwee, Roger G.] Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.
   [Bolognini, Daniele] Univ Glasgow, Coll Med Vet & Life Sci, Inst Mol Cell & Syst Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland.
C3 Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew
   University of Jerusalem; University of Aberdeen; University of Glasgow
RP Mechoulam, R (通讯作者)，Hebrew Univ Jerusalem, Inst Drug Res, IL 91120 Jerusalem, Israel.
EM raphaelm@ekmd.huji.ac.il
RI Chourasia, Mukesh/S 3976 2016; Kogan, Natalya M./KHT 6734 2024;
   Chourasia, Mukesh/ABI 6012 2020; Pertwee, Roger/E 1312 2011; Bolognini,
   Daniele/AAF 7892 2020; Raphael Mizrahi, Bitya/GLR 8221 2022; Marini,
   Pietro/C 5746 2013
OI Chourasia, Mukesh/0000 0002 4565 5348; Kogan, Natalya
   M./0000 0002 6792 3841; Raphael Mizrahi, Bitya/0000 0001 8629 1088;
   Pertwee, Roger/0000 0003 3227 2783; Marini, Pietro/0000 0002 8456 4473
FU Kessler Family Foundation; National Institute on Drug Abuse Grant
   [DA 9789]
FX Research in the R.M. laboratory was supported by the Kessler Family
   Foundation and by National Institute on Drug Abuse Grant DA 9789.
CR ARIENS EJ, 1984, EUR J CLIN PHARMACOL, V26, P663, DOI 10.1007/BF00541922
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bab I, 2008, J NEUROENDOCRINOL, V20, P69, DOI 10.1111/j.1365 2826.2008.01675.x
   Bajayo A, 2005, P NATL ACAD SCI USA, V102, P12956, DOI 10.1073/pnas.0502562102
   Basu S, 2011, J IMMUNOL, V187, P5720, DOI 10.4049/jimmunol.1102195
   Bolognini D, 2012, BRIT J PHARMACOL, V165, P2561, DOI 10.1111/j.1476 5381.2011.01503.x
   Cabral GA, 2008, BRIT J PHARMACOL, V153, P240, DOI 10.1038/sj.bjp.0707584
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   Choi G, 2002, J PEPT RES, V60, P169, DOI 10.1034/j.1399 3011.2002.21012.x
   Dundas J, 2006, NUCLEIC ACIDS RES, V34, pW116, DOI 10.1093/nar/gkl282
   Elphick MR, 2001, PHILOS T R SOC B, V356, P381, DOI 10.1098/rstb.2000.0787
   GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432 1033.1995.tb20780.x
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040 4020(80)80168 2
   Han S, 2013, J MED CHEM, V56, P8224, DOI 10.1021/jm4005626
   Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228
   Horváth B, 2012, BRIT J PHARMACOL, V165, P2462, DOI 10.1111/j.1476 5381.2011.01381.x
   Huffman JW, 1999, BIOORGAN MED CHEM, V7, P2905, DOI 10.1016/S0968 0896(99)00219 9
   Hurst DP, 2010, J BIOL CHEM, V285, P17954, DOI 10.1074/jbc.M109.041590
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Klauke AL, 2014, EUR NEUROPSYCHOPHARM, V24, P608, DOI 10.1016/j.euroneuro.2013.10.008
   Kou JP, 2005, BIOL PHARM BULL, V28, P1234, DOI 10.1248/bpb.28.1234
   KURIHARA N, 1989, BLOOD, V74, P1295
   Magrane M, 2011, DATABASE OXFORD, DOI 10.1093/database/bar009
   Mimura T, 2012, LIFE SCI, V90, P862, DOI 10.1016/j.lfs.2012.04.005
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Ofek O, 2011, J BONE MINER RES, V26, P308, DOI 10.1002/jbmr.228
   Pacher P, 2011, PROG LIPID RES, V50, P193, DOI 10.1016/j.plipres.2011.01.001
   Pacher P, 2013, FEBS J, V280, P1918, DOI 10.1111/febs.12260
   Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pertwee RG, 2006, BRIT J PHARMACOL, V147, pS163, DOI 10.1038/sj.bjp.0706406
   Poso A, 2008, BRIT J PHARMACOL, V153, P335, DOI 10.1038/sj.bjp.0707567
   Prussin Calman, 2003, Journal of Allergy and Clinical Immunology, V111, pS486, DOI 10.1016/j.jaci.2009.11.017
   Rajesh M, 2007, J LEUKOCYTE BIOL, V82, P1382, DOI 10.1189/jlb.0307180
   Rega N., 2016, Gaussian 16
   Ross RA, 1999, BRIT J PHARMACOL, V126, P665, DOI 10.1038/sj.bjp.0702351
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Sulcova E, 1998, PHARMACOL BIOCHEM BE, V59, P347, DOI 10.1016/S0091 3057(97)00422 X
   TAMURA T, 1993, J BONE MINER RES, V8, P953
   Thomas A, 2005, BRIT J PHARMACOL, V146, P917, DOI 10.1038/sj.bjp.0706414
   Toguri JT, 2014, BRIT J PHARMACOL, V171, P1448, DOI 10.1111/bph.12545
   Wang J, 1999, PROTEINS, V36, P1
   WLODARSKI KH, 1990, CLIN ORTHOP RELAT R, P276
   Xie XQ, 2003, PROTEINS, V53, P307, DOI 10.1002/prot.10511
   Yirmiya R, 2006, P NATL ACAD SCI USA, V103, P16876, DOI 10.1073/pnas.0604234103
   Zaidi M, 2004, BIOL REV, V79, P79, DOI 10.1017/S1464793103006262
   Zhang R, 2012, ACTA PHARMACOL SIN, V33, P372, DOI 10.1038/aps.2011.173
   Zhang YX, 2011, INT IMMUNOPHARMACOL, V11, P1303, DOI 10.1016/j.intimp.2011.04.013
NR 49
TC 50
Z9 61
U1 0
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 14
PY 2015
VL 112
IS 28
BP 8774
EP 8779
DI 10.1073/pnas.1503395112
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CM7MU
UT WOS:000357878700069
PM 26124120
OA Green Published
DA 2025 08 17
ER

PT J
AU Yu, YF
   Song, ZB
   Yang, SF
   Yang, XH
   Zhang, J
   Lu, S
AF Yu, Yongfeng
   Song, Zhengbo
   Yang, Shunfang
   Yang, Xiaohua
   Zhang, Jie
   Lu, Shun
TI Everolimus and zoledronic acid a potential synergistic treatment for
   lung adenocarcinoma bone metastasis
SO ACTA BIOCHIMICA ET BIOPHYSICA SINICA
LA English
DT Article
DE zoledronic acid; everolimus; lung adenocarcinoma; bone metastasis
ID HORMONE RELATED PROTEIN; MULTIPLE MYELOMA CELLS; BREAST CANCER;
   PHASE II; PROSTATE CANCER; MAMMALIAN TARGET; ADVANCED NSCLC; SCID MICE;
   IN VITRO; BISPHOSPHONATES
AB Non small cell lung cancer (NSCLC) frequently metasta sizes to bone. It is known that zoledronic acid is cytostatic to tumors, and everolimus, the inhibitor for mammalian target of the rapamycin, could inhibit many types of cancer. Herein, we evaluated the effect of zoledronic acid alone and in combination with everolimus on treating lung adenocarcinoma bone metastasis in vitro and in vivo. Mice treated with zoledronic acid in combination with everolimus had more apoptotic lung cancer cells and more cells were arrested in the G1/G0 phase. The phosphorylation of p70S6K was inhibited in the combination treatment group. Lung cancer cell invasion was also significantly inhibited in the group with combination treatment in vitro. Bone nuclear scans revealed more metastatic lesions in controls compared with those in the combination treatment group. Bone scans and radiographic images indicated that combination therapy significantly reduced bone metastasis. The moderate survival rate suggested that the drug combination was synergistic, which can. delay NSCLC bone metastasis and prolong survival in vivo.
C1 [Yu, Yongfeng; Yang, Xiaohua; Lu, Shun] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai 200030, Peoples R China.
   [Song, Zhengbo] Zhejiang Canc Hosp, Dept Chemotherapy, Hangzhou 310022, Zhejiang, Peoples R China.
   [Yang, Shunfang] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Nucl Med, Shanghai 200030, Peoples R China.
   [Zhang, Jie] Fudan Univ, Shanghai Canc Hosp, Dept Thorac Surg, Shanghai 200032, Peoples R China.
C3 Shanghai Jiao Tong University; Zhejiang Cancer Hospital; Shanghai Jiao
   Tong University; Fudan University
RP Lu, S (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai 200030, Peoples R China.
EM lushun1964@126.com
RI Lu, Shun/ABF 8341 2021
FU Wu Jie Ping Roche Medical Special Foundation [320.6750.1388];
   International Cooperation Projects by the Chinese Ministry of Science
   and Technology [2012DFG31320]; National High Technology Research and
   Development Program of China [2012AA02A502]
FX This work was support by the grants from the Wu Jie Ping Roche Medical
   Special Foundation (320.6750.1388), the International Cooperation
   Projects by the Chinese Ministry of Science and Technology
   (2012DFG31320), and National High Technology Research and Development
   Program of China (2012AA02A502).
CR Angtuaco EJC, 2004, RADIOLOGY, V231, P11, DOI 10.1148/radiol.2311020452
   Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892
   Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362
   Boissier S, 2000, CANCER RES, V60, P2949
   Chan S, 2005, J CLIN ONCOL, V23, P5314, DOI 10.1200/JCO.2005.66.130
   Derenne S, 1999, J BONE MINER RES, V14, P2048, DOI 10.1359/jbmr.1999.14.12.2048
   Duran I, 2006, BRIT J CANCER, V95, P1148, DOI 10.1038/sj.bjc.6603419
   ENG CP, 1984, J ANTIBIOT, V37, P1231, DOI 10.7164/antibiotics.37.1231
   EVANS CE, 1994, BONE MINER, V26, P95, DOI 10.1016/S0169 6009(08)80055 4
   Even Sapir E, 2005, J NUCL MED, V46, P1356
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   GREEN JR, 1994, J BONE MINER RES, V9, P745
   Gridelli C, 2008, ONCOLOGIST, V13, P139, DOI 10.1634/theoncologist.2007 0171
   Grünwald V, 2002, CANCER RES, V62, P6141
   Hamaoka T, 2004, J CLIN ONCOL, V22, P2942, DOI 10.1200/jco.2004.08.181
   Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
   Iguchi H, 1996, CANCER RES, V56, P4040
   Iguchi H, 2001, INT J CANCER, V94, P24, DOI 10.1002/ijc.1425
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Lu B, 2013, ACTA BIOCH BIOPH SIN, V45, P683, DOI 10.1093/abbs/gmt054
   Lu S, 2008, ONCOL REP, V20, P581, DOI 10.3892/or_00000045
   Mabuchi S, 2007, CLIN CANCER RES, V13, P4261, DOI 10.1158/1078 0432.CCR 06 2770
   Margolin K, 2005, CANCER AM CANCER SOC, V104, P1045, DOI 10.1002/cncr.21265
   Melisi D, 2005, ENDOCR RELAT CANCER, V12, P1051, DOI 10.1677/erc.1.01061
   Miki T, 2004, INT J CANCER, V108, P511, DOI 10.1002/ijc.11586
   Mondesire WH, 2004, CLIN CANCER RES, V10, P7031, DOI 10.1158/1078 0432.CCR 04 0361
   Morgan TM, 2008, PROSTATE, V68, P861, DOI 10.1002/pros.20752
   Moriceau G, 2010, CANCER RES, V70, P10329, DOI 10.1158/0008 5472.CAN 10 0578
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Mundy GR, 2001, SEMIN ONCOL, V28, P35, DOI 10.1053/sonc.2001.24158
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008 5472.CAN 05 2925
   Paterson AHG, 2006, ONCOLOGIST, V11, P13, DOI 10.1634/theoncologist.11 90001 13
   Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003
   Reungwetwattana T, 2012, J THORAC ONCOL, V7, P919, DOI 10.1097/JTO.0b013e31824de0d6
   Rizzieri DA, 2008, CLIN CANCER RES, V14, P2756, DOI 10.1158/1078 0432.CCR 07 1372
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   SHULTZ LD, 1995, J IMMUNOL, V154, P180
   Soria JC, 2009, ANN ONCOL, V20, P1674, DOI 10.1093/annonc/mdp060
   Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337
   Yang Shunfang, 2009, Zhongguo Fei Ai Za Zhi, V12, P1055, DOI 10.3779/j.issn.1009 3419.2009.10.01
   Yang Shunfang, 2009, Zhongguo Fei Ai Za Zhi, V12, P753, DOI 10.3779/j.issn.1009 3419.2009.07.020
   Yang SF, 2009, NUCL MED BIOL, V36, P313, DOI 10.1016/j.nucmedbio.2008.12.007
   Zhou ZC, 2005, CANCER AM CANCER SOC, V104, P1713, DOI 10.1002/cncr.21383
NR 43
TC 12
Z9 12
U1 1
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1672 9145
EI 1745 7270
J9 ACTA BIOCH BIOPH SIN
JI Acta Biochim. Biophys. Sin.
PD SEP
PY 2014
VL 46
IS 9
BP 792
EP 801
DI 10.1093/abbs/gmu069
PG 10
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AQ1KF
UT WOS:000342539600008
PM 25098623
DA 2025 08 17
ER

PT J
AU Liu, YN
   Liu, Y
   Zheng, CP
   Huang, N
   Chen, X
   Zhu, XF
   Zhao, YY
   Yu, QQ
   Liu, J
AF Liu, Yanan
   Liu, Ying
   Zheng, Chuping
   Huang, Na
   Chen, Xu
   Zhu, Xufeng
   Zhao, Yingyu
   Yu, Qianqian
   Liu, Jie
TI Ru nanoparticles coated with γ Fe2O3 promoting and
   monitoring the differentiation of human mesenchymal stem cells via MRI
   tracking
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Mesenchymal stem cells; Osteogenic differentiation; Bone morphogenetic
   protein; Ru nanoparticles
ID MARROW STROMAL CELLS; HUMAN ADIPOSE TISSUE; OSTEOGENIC DIFFERENTIATION;
   IN VITRO; PATHWAY; CANCER; SYSTEM
AB Human mesenchymal stem cells (MSCs) can be successively passaged and can differentiate into multiple lineages. These attributes are important in tissue engineering, which has a great deal of attention in stem cell therapy. However, the effective labelling and tracking of MSCs in vivo remain major unresolved issues. Based on the use of iron oxides to label stem cells for magnetic resonance imaging (MRI), we synthesized nanoparticle (NPs) containing ruthenium (RuNPs), gamma Fe2O3@Ru (Fe2O3@Ru), and gamma Fe2O3@selenium (Fe2O3@Se) to label MSCs and promote osteogenic differentiation. Fe2O3@Ru and Fe2O3@Se could be used as T 2 weighted MRI contrast agents. Fe2O3@Ru more effectively diffused in the cytoplasm and localized in the nuclei of MSCs, compared with Fe2O3@Se. RuNPs, Fe2O3@Ru, and Fe2O3@Se induced MSCs to differentiate into osteoblasts. Fe2O3@Ru, in particular, was a potent osteoinductive agent. Fe2O3@Ru also inhibited adipocytic differentiation. Promotion of the osteogenic differentiation of MSCs may be regulated by a Smad dependent bone morphogenetic protein signaling pathway with reduced expression of CD44, CD73, and CD105. MSCs treated with Fe2O3@ Ru NPs expressing osteoblast surface markers.
C1 [Liu, Yanan; Liu, Ying; Zheng, Chuping; Huang, Na; Chen, Xu; Zhu, Xufeng; Zhao, Yingyu; Yu, Qianqian; Liu, Jie] Jinan Univ, Dept Chem, Guangzhou 510632, Guangdong, Peoples R China.
C3 Jinan University
RP Liu, J (通讯作者)，Jinan Univ, Dept Chem, Guangzhou 510632, Guangdong, Peoples R China.
EM tliuliu@jnu.edu.cn
RI ; liu, ying/GXF 4294 2022
OI Yu, Qianqian/0000 0001 5731 3356; Chen, Xu/0000 0002 2603 102X
FU National Natural Science Foundation of China [21171070, 21371075]; China
   Postdoctoral Science Foundation [55350207]; Natural Science Foundation
   of Guangdong Province [2014A030311025]; Planned Item of Science and
   Technology of Guangdong Province [2016A020217011]
FX This work was supported by the National Natural Science Foundation of
   China (21171070, 21371075), the China Postdoctoral Science Foundation
   (55350207), the Natural Science Foundation of Guangdong Province
   (2014A030311025) and the Planned Item of Science and Technology of
   Guangdong Province (2016A020217011).
CR Alzhavan O, 2013, CARBON, V59, P200, DOI 10.1016/j.carbon.2013.03.010
   [Anonymous], 2007, ANGEW CHEM
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Corr SA, 2006, CHEM COMMUN, P4474, DOI 10.1039/b610746j
   Debika M. I. T. R. A., 2017, BIOMATERIALS, V146, P29
   Goldsborough AS, 2011, J MED CHEM, V54, P4987, DOI 10.1021/jm2001663
   Hackenberg S, 2013, J BIOMED NANOTECHNOL, V9, P86, DOI 10.1166/jbn.2013.1473
   Hoogduijn MJ, 2017, TRANSPLANTATION, V101, P30, DOI 10.1097/TP.0000000000001534
   Hu FQ, 2006, ADV MATER, V18, P2553, DOI 10.1002/adma.200600385
   Huang DM, 2005, FASEB J, V19, P2014, DOI 10.1096/fj.05 4288fje
   Janssens S, 2006, LANCET, V367, P113, DOI 10.1016/S0140 6736(05)67861 0
   Joshua M. Hare, 2017, J AM COLL CARDIOL, V69, P526
   Kang HJ, 2007, AM HEART J, V153, DOI 10.1016/j.ahj.2006.11.004
   Kaur G, 2010, BIOMATERIALS, V31, P5813, DOI 10.1016/j.biomaterials.2010.04.017
   Kaur G, 2010, BIOMATERIALS, V31, P1732, DOI 10.1016/j.biomaterials.2009.11.041
   Kim T, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201604213
   Kuo JHS, 2007, J CONTROL RELEASE, V120, P51, DOI 10.1016/j.jconrel.2007.03.019
   Lee KW, 2010, STEM CELLS DEV, V19, P557, DOI 10.1089/scd.2009.0147
   Lee WC, 2011, ACS NANO, V5, P7334, DOI 10.1021/nn202190c
   Liu CM, 2009, CELL TISSUE RES, V336, P465, DOI 10.1007/s00441 009 0780 3
   Liu Z, 2011, BIOMATERIALS, V32, P4683, DOI 10.1016/j.biomaterials.2011.03.038
   Nikukar H, 2013, ACS NANO, V7, P2758, DOI 10.1021/nn400202j
   Oliveira JM, 2009, BIOMATERIALS, V30, P804, DOI 10.1016/j.biomaterials.2008.10.024
   Park KS, 2010, NANOMED NANOTECHNOL, V6, P263, DOI 10.1016/j.nano.2009.07.005
   Park YI, 2009, ADV MATER, V21, P4467, DOI 10.1002/adma.200901356
   Poulsom R, 2007, KIDNEY INT, V72, P389, DOI 10.1038/sj.ki.5002398
   Prabhakaran MP, 2009, BIOMATERIALS, V30, P4996, DOI 10.1016/j.biomaterials.2009.05.057
   Ruckh TT, 2010, ACTA BIOMATER, V6, P2949, DOI 10.1016/j.actbio.2010.02.006
   Samberg M, 2012, NANOMEDICINE UK, V7, P1197, DOI [10.2217/NNM.12.18, 10.2217/nnm.12.18]
   Shang QX, 2001, J CRANIOFAC SURG, V12, P586, DOI 10.1097/00001665 200111000 00017
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Sumanasinghe RD, 2006, TISSUE ENG, V12, P3459, DOI 10.1089/ten.2006.12.3459
   Sun DH, 2013, STEM CELLS, V31, P1170, DOI 10.1002/stem.1356
   Sun DD, 2013, BIOMATERIALS, V34, P171, DOI 10.1016/j.biomaterials.2012.09.031
   Tian QW, 2014, SMALL, V10, P1063, DOI 10.1002/smll.201302042
   Wan J, 2007, CHEM COMMUN, P5004, DOI 10.1039/b712795b
   Wang XQ, 2013, BIOMATERIALS, V34, P1155, DOI 10.1016/j.biomaterials.2012.10.063
   Wijesinghe SJ, 2017, J CELL PHYSIOL, V232, P566, DOI 10.1002/jcp.25454
   Xia W, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957 4484/18/13/135601
   Yang KN, 2013, NANOSCALE, V5, P1205, DOI 10.1039/c2nr33575a
   Yang LC, 2014, J MATER CHEM B, V2, P1977, DOI 10.1039/c3tb21586e
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   Yi PW, 2013, BIOMATERIALS, V34, P3010, DOI 10.1016/j.biomaterials.2013.01.022
   Zhao F, 2005, BIOTECHNOL BIOENG, V91, P482, DOI 10.1002/bit.20532
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 46
TC 12
Z9 12
U1 0
U2 67
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD OCT 1
PY 2018
VL 170
BP 701
EP 711
DI 10.1016/j.colsurfb.2018.05.041
PG 11
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA GV3JE
UT WOS:000445989400082
PM 29986267
DA 2025 08 17
ER

PT J
AU Meng, XL
   Cui, JW
   Wang, YS
   Zhang, XN
   Li, DY
   Hai, Y
   Du, HW
AF Meng, Xianglong
   Cui, Jiawen
   Wang, Yunsheng
   Zhang, Xinuo
   Li, Dongyue
   Hai, Yong
   Du, Hongwu
TI Heterogeneous nuclear ribonucleoprotein A1 interacts with microRNA 34a
   to promote chondrogenic differentiation of mesenchymal stem cells
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE degenerative disc disease; heterogeneous nuclear ribonucleoprotein A1;
   miR 34a; Wnt signaling; chondrogenic differentiation; mesenchymal stem
   cell
ID DEGENERATIVE DISC DISEASE; MESSENGER RNA; HNRNP A1; IN VIVO; BINDING;
   EXPRESSION; GENE; OSTEOARTHRITIS; MODEL
AB The mesenchymal stem cell (MSC) shows potential in degenerative disc disease (DDD) treatment. However, little is known about the function of heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) in modulating the chondrogenic differentiation of MSCs. This study aimed to investigate the role of hnRNPA1 in the chondrogenic differentiation of MSCs and potential mechanisms. Mouse MSCs C3H10 and chondrogenic ATDC5 cells were used to quantify hnRNPA1 expression. The hnRNPA1 overexpression vectors were transfected into C3H10 cells, cell viability and chondrogenic factors expressions were assessed by MTT assay, qPCR and Western blot, respectively. After microRNA 34a (miR 34a) inhibitor transfection, expressions of chondrogenic factors and the Wnt signaling were detected. RNA binding protein immunoprecipitation (RIP) was performed to reveal the interaction between hnRNPA1 and miR 34a. Results showed that hnRNPA1 was significantly down regulated in C3H10 compared to ATDC5. Overexpression of hnRNPA1 markedly promoted C3H10 cell viability and expressions of chondrogenic factors SRY box 9 (SOX9), collagen II, hyaluronan synthase 2 (HAS2) and aggrecan, without significant influence on adipogenic factors. miR 34a inhibitor suppressed chondrogenic factors expressions. RIP results showed the interaction between miR 34a and hnRNPA1. Besides, hnRNPA1 promoted expressions of Wnt family member 3A (WNT3A), WNT5A and beta catenin, and these effects were abrogated by miR 34a inhibitor. We fund the promotive effect of hnRNPA1 on chondrogenic factors, which might require the interaction with miR 34a and the regulation of the Wnt signaling. Thus hnRNPA1 might induce the chondrogenic differentiation of MSCs that facilitate the MSC therapy for DDD.
C1 [Meng, Xianglong; Wang, Yunsheng; Zhang, Xinuo; Li, Dongyue; Hai, Yong] Capital Med Univ, Beijing Chao Yang Hosp, Dept Orthoped, 8,Gongtinan Rd, Beijing 100020, Peoples R China.
   [Cui, Jiawen; Du, Hongwu] Univ Sci & Technol Beijing, Sch Chem & Biol Engn, Lab 112, 30,Xueyuan Rd, Beijing 100083, Peoples R China.
C3 Capital Medical University; University of Science & Technology Beijing
RP Hai, Y (通讯作者)，Capital Med Univ, Beijing Chao Yang Hosp, Dept Orthoped, 8,Gongtinan Rd, Beijing 100020, Peoples R China.; Du, HW (通讯作者)，Univ Sci & Technol Beijing, Sch Chem & Biol Engn, Lab 112, 30,Xueyuan Rd, Beijing 100083, Peoples R China.
EM haiyong020@126.com; duhongwu086@126.com
RI Hai, Yong/L 2679 2019; Zhang, Xinuo/GSI 7593 2022; Meng,
   Xiang Long/GXV 5867 2022
OI Hai, Yong/0000 0002 7206 325X; 
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Anderson JT, 2015, SPINE, V40, P1775, DOI 10.1097/BRS.0000000000001054
   Ankrum J, 2010, TRENDS MOL MED, V16, P203, DOI 10.1016/j.molmed.2010.02.005
   Avery Rhonda Marie, 2012, Int J Ther Massage Bodywork, V5, P41
   Charytonowicz E, 2012, J CLIN INVEST, V122, P886, DOI 10.1172/JCI60015
   David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697
   Dimar JR, 2007, SPINE J, V7, P332, DOI 10.1016/j.spinee.2006.03.008
   Feng GJ, 2011, J NEUROSURG SPINE, V14, P322, DOI 10.3171/2010.11.SPINE10285
   Georgi N, 2013, OSTEOARTHR CARTILAGE, V21, pS31, DOI 10.1016/j.joca.2013.02.085
   Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250
   Han Y, 2008, MOL CELL BIOL, V28, P4999, DOI 10.1128/MCB.00695 08
   Haudenschild AK, 2009, ANN BIOMED ENG, V37, P492, DOI 10.1007/s10439 008 9629 2
   Holmes B, 2016, CARBON, V97, P1, DOI 10.1016/j.carbon.2014.12.035
   Huang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047496
   Huang Y, 2013, STEM CELLS, V31, P906, DOI 10.1002/stem.1324
   Ikegawa S, 2013, ANNU REV GENOM HUM G, V14, P245, DOI 10.1146/annurev genom 091212 153427
   Jin EJ, 2006, INT J BIOCHEM CELL B, V38, P183, DOI 10.1016/j.biocel.2005.08.013
   Kim D, 2011, BIOCHEM BIOPH RES CO, V415, P551, DOI 10.1016/j.bbrc.2011.10.087
   Kim NH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001744
   Krinner A, 2009, CELL PROLIFERAT, V42, P471, DOI 10.1111/j.1365 2184.2009.00621.x
   Lemieux B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126654
   Luo SM, 2013, BIOMED PHARMACOTHER, V67, P819, DOI 10.1016/j.biopha.2013.03.008
   MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092 8674(92)90477 T
   Mishra A, 2009, TISSUE ENG PART C ME, V15, P431, DOI 10.1089/ten.tec.2008.0534
   Naito M, 2015, HISTOCHEM CELL BIOL, V144, P261, DOI 10.1007/s00418 015 1334 2
   Papadimitriou N, 2014, STEM CELLS DEV, V23, P2568, DOI 10.1089/scd.2014.0153
   Peletti Figueiró Manuela, 2013, Coluna/Columna, V12, P61
   Si WT, 2016, AM J MED SCI, V352, P191, DOI 10.1016/j.amjms.2016.05.002
   Siculella L, 2016, BBA MOL CELL BIOL L, V1861, P471, DOI 10.1016/j.bbalip.2016.02.003
   Spiker WR, 2011, INT J CLIN RHEUMATOL, V6, P495
   Trzeciak T, 2014, CURR GENOMICS, V15, P481, DOI 10.2174/1389202915666141024212506
   Zhang YJ, 2008, AM J PHYS MED REHAB, V87, P694, DOI 10.1097/PHM.0b013e31817c1945
   Zheng L, 2010, J BIOMED MATER RES A, V93A, P783, DOI 10.1002/jbm.a.32588
   Zuo Y, 2006, J BIOL CHEM, V281, P7960, DOI 10.1074/jbc.M510682200
NR 34
TC 6
Z9 7
U1 3
U2 10
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2017
VL 9
IS 4
BP 1774
EP 1782
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA ET7OZ
UT WOS:000400487800018
PM 28469782
DA 2025 08 17
ER

PT J
AU Pramanik, C
   Sood, P
   Niu, LN
   Yuan, H
   Ghoshal, S
   Henderson, W
   Liu, YD
   Jang, SS
   Kumar, S
   Pashley, DH
   Tay, FR
AF Pramanik, Chandrani
   Sood, Parveen
   Niu, Li na
   Yuan, He
   Ghoshal, Sushanta
   Henderson, Walter
   Liu, Yaodong
   Jang, Seung Soon
   Kumar, Satish
   Pashley, David H.
   Tay, Franklin R.
TI A mechanistic study of the interaction of water soluble borate glass
   with apatite bound heterocyclic nitrogen containing bisphosphonates
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Bisphosphonate; Borate bioactive glass; Density functional theory; Ionic
   cocktail
ID BIOACTIVE GLASS; DRUG DELIVERY; BONE; OSTEONECROSIS; JAW; MICROFIBERS;
   ADSORPTION; RAMAN
AB Long term oral and intravenous use of nitrogen containing bisphosphonates (N BPs) is associated with osteonecrosis of the jaw. Although N BPs bind strongly to bone surfaces via non covalent bonds, it is possible for extrinsic ions to dissociate bound N BPs from mineralized bone by competitive desorption. Here, we investigate the effects and mechanism of using an ionic cocktail derived from borate bioactive glass for sequestration of heterocyclic N BPs bound to apatite. By employing solid state and solution state analytical techniques, we confirmed that sequestration of N BPs from bisphosphonate bound apatite occurs in the presence of the borate containing ionic cocktail. Simulations by density functional theory computations indicate that magnesium cation and borate anion are well within the extent of the risedronate or zoledronate anion to form precipitate complexes. The sequestration mechanism is due to the borate anion competing with bisphosphonates for similar electron deficient sites on the apatite surface for binding. Thus, application of the borate containing ionic cocktail represents a new topical lavage approach for removing apatite bound heterocyclic N BPs from exposed necrotic bone in bisphosphonate related osteonecrosis of the jaw.
   Statement of significance
   Long term oral consumption and injections of nitrogen containing bisphosphonates (N BPs) may result in death of the jaw bone when there is traumatic injury to the bone tissues. To date, there is no effective treatment for such a condition. This work reported the use of an ionic cocktail derived from water soluble borate glass microfibers to displace the most potent type of N BPs that are bound strongly to the mineral component on bone surfaces. The mechanism responsible for such an effect has been identified to be cation mediated complexation of borate anions with negatively charged N BPs, allowing them to be released from the mineral surface. This borate containing cocktail may be developed into a novel topical rinse for removing mineral bound N BPs from exposed dead bone. (C) 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Pramanik, Chandrani; Sood, Parveen; Ghoshal, Sushanta; Liu, Yaodong; Jang, Seung Soon; Kumar, Satish] Georgia Inst Technol, Sch Mat Sci & Engn, Atlanta, GA 30332 USA.
   [Niu, Li na] Fourth Mil Med Univ, Sch Stomatol, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.
   [Yuan, He] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610064, Peoples R China.
   [Henderson, Walter] Georgia Inst Technol, Inst Elect & Nanotechnol, Atlanta, GA 30332 USA.
   [Pashley, David H.; Tay, Franklin R.] Augusta Univ, Coll Grad Studies, Augusta, GA 30912 USA.
C3 University System of Georgia; Georgia Institute of Technology; Air Force
   Medical University; Sichuan University; University System of Georgia;
   Georgia Institute of Technology; University System of Georgia; Augusta
   University
RP Tay, FR (通讯作者)，Augusta Univ, Coll Grad Studies, Augusta, GA 30912 USA.
EM SeungSoon.Jang@mse.gatech.edu; satish.kumar@gatech.edu; ftay@gru.edu
RI ; Kumar, Satish/F 7308 2011; niu, lina/GWR 3585 2022; liu,
   yaodong/HZH 8626 2023; Jang, Seung Soon/C 6847 2008; Ghoshal, Dr.
   Sushanta/D 6784 2013; Ghoshal, Sushanta/D 6784 2013
OI Henderson, Walter/0000 0002 7999 3388; Kumar,
   Satish/0000 0002 3415 170X; Tay, Franklin/0000 0003 3769 0626; Ghoshal,
   Sushanta/0000 0003 2064 2214
FU Georgia Institute of Technology (GIT); Georgia Regents University (GRU)
   for collaborative materials science research; seed funding program
FX This work was supported by a seed funding program co sponsored by
   Georgia Institute of Technology (GIT) and Georgia Regents University
   (GRU) for collaborative materials science research between the School of
   Materials Science and Engineering at GIT and the College of Dental
   Medicine at GRU. The authors thank Dr. Johannes Leisen, School of
   Chemistry and Biochemistry, Georgia Institute of Technology for advice
   on performing solid state NMR.
CR Abe K, 2012, INT J MOL MED, V29, P1007, DOI 10.3892/ijmm.2012.952
   Coxon FP, 2003, CALCIFIED TISSUE INT, V72, P80, DOI 10.1007/s00223 002 2017 2
   Dannemann C, 2007, BONE, V40, P828, DOI 10.1016/j.bone.2006.11.023
   DELLEY B, 1990, J CHEM PHYS, V92, P508, DOI 10.1063/1.458452
   Delley B, 2000, J CHEM PHYS, V113, P7756, DOI 10.1063/1.1316015
   Devirian TA, 2003, CRIT REV FOOD SCI, V43, P219, DOI 10.1080/10408690390826491
   DOLG M, 1987, J CHEM PHYS, V86, P866, DOI 10.1063/1.452288
   Errassifi F, 2014, J COLLOID INTERF SCI, V420, P101, DOI 10.1016/j.jcis.2014.01.017
   Ironside MS, 2010, EUR J PHARM BIOPHARM, V76, P120, DOI 10.1016/j.ejpb.2010.05.013
   Jahnke W, 2010, CHEMMEDCHEM, V5, P770, DOI 10.1002/cmdc.201000016
   Juillard A, 2010, BONE, V47, P895, DOI 10.1016/j.bone.2010.07.018
   Katsarelis H, 2015, J DENT RES, V94, P534, DOI 10.1177/0022034515572021
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   KLAMT A, 1993, J CHEM SOC PERK T 2, P799, DOI 10.1039/p29930000799
   Koilraj P, 2011, IND ENG CHEM RES, V50, P6943, DOI 10.1021/ie102395m
   Kos M, 2015, ARCH MED SCI, V11, P319, DOI 10.5114/aoms.2015.50964
   Lin YN, 2014, J BIOMED MATER RES A, V102, P4491, DOI 10.1002/jbm.a.35120
   Liu X, 2013, J MATER SCI MATER M, V24, P583, DOI 10.1007/s10856 012 4831 z
   Luque Caballero G, 2014, J CHEM PHYS, V140, DOI 10.1063/1.4872263
   MAYO SL, 1990, J PHYS CHEM US, V94, P8897, DOI 10.1021/j100389a010
   Modglin VC, 2013, J MATER SCI MATER M, V24, P1191, DOI 10.1007/s10856 013 4875 8
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Otto S, 2015, J CRANIO MAXILL SURG, V43, P847, DOI 10.1016/j.jcms.2015.03.039
   Pascaud P, 2014, J MATER SCI MATER M, V25, P2373, DOI 10.1007/s10856 014 5218 0
   Perdew JP, 1997, PHYS REV LETT, V78, P1396, DOI 10.1103/PhysRevLett.77.3865
   Pramanik C, 2015, J MATER CHEM B, V3, P959, DOI 10.1039/c4tb02035a
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Tasli PN, 2013, BIOL TRACE ELEM RES, V153, P419, DOI 10.1007/s12011 013 9657 0
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Ying XZ, 2011, BIOL TRACE ELEM RES, V144, P306, DOI 10.1007/s12011 011 9094 x
   Zhao SC, 2015, BIOMATERIALS, V53, P379, DOI 10.1016/j.biomaterials.2015.02.112
NR 33
TC 5
Z9 5
U1 0
U2 44
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD FEB
PY 2016
VL 31
BP 339
EP 347
DI 10.1016/j.actbio.2015.12.008
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA DD7EI
UT WOS:000370086100030
PM 26675128
DA 2025 08 17
ER

PT J
AU Minichsdorfer, C
   Fuereder, T
   Leutner, M
   Singer, CF
   Kacerovsky Strobl, S
   Egle, D
   Greil, R
   Balic, M
   Fitzal, F
   Pfeiler, G
   Frantal, S
   Bartsch, R
   Gnant, M
AF Minichsdorfer, C.
   Fuereder, T.
   Leutner, M.
   Singer, C. F.
   Kacerovsky Strobl, S.
   Egle, D.
   Greil, R.
   Balic, M.
   Fitzal, F.
   Pfeiler, G.
   Frantal, S.
   Bartsch, R.
   Gnant, M.
TI Effect of concomitant statin treatment in postmenopausal patients with
   hormone receptor positive early stage breast cancer receiving adjuvant
   denosumab or placebo: a post hoc analysis of ABCSG 18
SO ESMO OPEN
LA English
DT Article
DE breast cancer; hormone receptor positive; postmenopausal osteoporosis;
   statins; disease free survival; ABCSG 18
ID BONE MINERAL DENSITY; MEVALONATE PATHWAY; RISK; SIMVASTATIN; RECURRENCE;
   TAMOXIFEN; PROLIFERATION; INHIBITION; LOVASTATIN; MORTALITY
AB Background: Statins are cholesterol lowering drugs prescribed for the prevention and treatment of cardiovascular disease. Moreover, statins may possess anticancer properties and interact with receptor activator of nuclear factor kB ligand expression. We aimed at evaluating a hypothetical synergistic effect of statins with denosumab in early stage breast cancer (BC) patients from the Austrian Breast and Colorectal Cancer Study Group (ABCSG) trial 18.
   Patients and methods: ABCSG 18 (NCT00556374) is a prospective, randomized, double blind, phase III study; postmenopausal patients with hormone receptor positive BC receiving a nonsteroidal aromatase inhibitor were randomly assigned to denosumab or placebo. In this post hoc analysis, we investigated the effects of concomitant statin therapy on recurrence risk (RR) of BC, fracture risk and bone mineral density (BMD).
   Results: In the study population (n = 3420), statin therapy (n = 824) was associated with worse disease free survival (DFS) [hazard ratio (HR) 1.35, 95% confidence interval (CI) 1.04 1.75; P = 0.023]. While no significant effect of lipophilic statins (n = 710) on RR was observed (HR 1.30, 95% CI 0.99 1.72; P = 0.062), patients on hydrophilic statins (n = 87) had worse DFS compared with patients not receiving any statins (HR 2.00, 95% CI 1.09 3.66; P = 0.026). This finding was mainly driven by the effect of hydrophilic statins on DFS in the denosumab arm (HR 2.63, 95% CI 1.21 5.68; P = 0.014). However, this effect subsided after correction for confounders in the sensitivity analysis. No association between statin use and fracture risk or osteoporosis was observed.
   Conclusion: According to this analysis, hydrophilic statins showed a detrimental effect on DFS in the main model, which was attenuated after correction for confounders. Our data need to be interpreted with caution due to their retrospective nature and the low number of patients receiving hydrophilic statins.
C1 [Minichsdorfer, C.; Fuereder, T.; Bartsch, R.] Med Univ Vienna, Dept Med 1, Clin Div Oncol, Wahringer Gurtel 18 20, A 1090 Vienna, Austria.
   [Leutner, M.] Med Univ Vienna, Dept Med 3, Clin Div Endocrinol, Vienna, Austria.
   [Singer, C. F.; Pfeiler, G.] Med Univ Vienna, Dept Gynaecol, Vienna, Austria.
   [Kacerovsky Strobl, S.; Fitzal, F.] Med Univ Vienna, Dept Gen Surg, Vienna, Austria.
   [Egle, D.] Med Univ Innsbruck, Dept Gynaecol, Innsbruck, Austria.
   [Greil, R.] Paracelsus Univ Salzburg, Salzburg Canc Res Inst CCCIT, Canc Cluster Salzburg, Dept Med 3, Salzburg, Austria.
   [Balic, M.] Med Univ Graz, Dept Med, Clin Div Oncol, Graz, Austria.
   [Frantal, S.; Gnant, M.] Austrian Breast & Colorectal Canc Study Grp, Vienna, Austria.
   [Gnant, M.] Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna; Medical University of Vienna; Medical University
   of Innsbruck; Paracelsus Private Medical University; Medical University
   of Graz; Medical University of Vienna
RP Bartsch, R (通讯作者)，Med Univ Vienna, Dept Med 1, Clin Div Oncol, Wahringer Gurtel 18 20, A 1090 Vienna, Austria.
EM rupert.bartsch@meduniwien.ac.at
RI Gnant, Michael/AAN 7054 2020; Greil, Richard/C 7673 2017; Balic,
   Marija/LPQ 3522 2024; Minichsdorfer, Christoph/ABF 3532 2021
OI Kacerovsky Strobl, Stephanie/0000 0001 6278 6633
CR Ahern TP, 2011, JNCI J NATL CANCER I, V103, P1461, DOI 10.1093/jnci/djr291
   Ahn KS, 2008, INT J CANCER, V123, P1733, DOI 10.1002/ijc.23745
   Alonso DF, 1998, BREAST CANCER RES TR, V50, P83, DOI 10.1023/A:1006058409974
   An T, 2017, OSTEOPOROSIS INT, V28, P47, DOI 10.1007/s00198 016 3844 8
   Borgquist S, 2008, INT J CANCER, V123, P1146, DOI 10.1002/ijc.23597
   Borgquist S, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2146
   Burstein HJ, 2021, ANN ONCOL, V32, P1216, DOI 10.1016/j.annonc.2021.06.023
   Cheng KC, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017476
   Coleman RE, 2007, LANCET ONCOL, V8, P119, DOI 10.1016/S1470 2045(07)70003 7
   Delmas PD, 2008, J CLIN DENSITOM, V11, P325, DOI 10.1016/j.jocd.2008.02.002
   Desai P, 2015, CANCER CAUSE CONTROL, V26, P529, DOI 10.1007/s10552 015 0530 7
   Desai P, 2013, CANCER EPIDEM BIOMAR, V22, P1868, DOI 10.1158/1055 9965.EPI 13 0562
   Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140 6736(15)61074 1
   Egerdie RB, 2012, PROSTATE CANCER P D, V15, P308, DOI 10.1038/pcan.2012.18
   Gnant M, 2019, LANCET ONCOL, V20, P339, DOI 10.1016/S1470 2045(18)30862 3
   Gnant M, 2015, LANCET, V386, P433, DOI 10.1016/S0140 6736(15)60995 3
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Gopalan A, 2013, CANCER LETT, V329, P9, DOI 10.1016/j.canlet.2012.08.031
   Gopalan A, 2013, CANCER LETT, V328, P285, DOI 10.1016/j.canlet.2012.10.003
   Goss PE, 2005, JNCI J NATL CANCER I, V97, P1262, DOI 10.1093/jnci/dji250
   Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140 6736(04)17666 6
   Jakobsen M, 2021, BMC CANCER, V21, DOI 10.1186/s12885 021 08716 5
   Kiderlen M, 2013, ANN ONCOL, V24, P3011, DOI 10.1093/annonc/mdt367
   Kim JY, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4018
   Kumar AS, 2008, CANCER EPIDEM BIOMAR, V17, P1028, DOI 10.1158/1055 9965.EPI 07 0726
   Kwan ML, 2008, BREAST CANCER RES TR, V109, P573, DOI 10.1007/s10549 007 9683 8
   Leutner M, 2019, ANN RHEUM DIS, V78, P1706, DOI 10.1136/annrheumdis 2019 215714
   Lin SM, 2018, J CLIN ENDOCR METAB, V103, P3439, DOI 10.1210/jc.2018 00652
   Lin TK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196713
   Lin TK, 2018, CLIN EPIDEMIOL, V10, P159, DOI 10.2147/CLEP.S145311
   Mandal CC, 2011, J BIOL CHEM, V286, P11314, DOI 10.1074/jbc.M110.193714
   Mansourian M, 2016, J PHARM PHARM SCI, V19, P72, DOI 10.18433/J3202B
   Manthravadi S, 2016, INT J CANCER, V139, P1281, DOI 10.1002/ijc.30185
   Mück AO, 2004, INT J CLIN PHARM TH, V42, P695
   Mueck AO, 2003, MENOPAUSE, V10, P332, DOI 10.1097/01.GME.0000055485.06076.00
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Peña JM, 2015, JAMA INTERN MED, V175, P171, DOI 10.1001/jamainternmed.2014.6388
   Seeger H, 2003, EXP CLIN ENDOCR DIAB, V111, P47, DOI 10.1055/s 2003 37501
   Shellman YG, 2005, MELANOMA RES, V15, P83, DOI 10.1097/00008390 200504000 00001
   Shibata MA, 2004, CARCINOGENESIS, V25, P1887, DOI 10.1093/carcin/bgh201
   Sivaprasad U, 2006, MOL CANCER THER, V5, P2310, DOI 10.1158/1535 7163.MCT 06 0175
   Sun L, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000011220, 10.1097/md.0000000000011220]
   Thürlimann B, 2005, NEW ENGL J MED, V353, P2747
   van Staa TP, 2001, JAMA J AM MED ASSOC, V285, P1850, DOI 10.1001/jama.285.14.1850
   Woditschka S, 2010, CANCER EPIDEM BIOMAR, V19, P2479, DOI 10.1158/1055 9965.EPI 10 0524
   Yamashita M, 2008, J ENDOCRINOL, V196, P601, DOI 10.1677/JOE 07 0532
   Yamashita M, 2010, REGUL PEPTIDES, V162, P99, DOI 10.1016/j.regpep.2010.03.003
   Zhao XB, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005602
NR 48
TC 8
Z9 8
U1 1
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2059 7029
J9 ESMO OPEN
JI ESMO Open
PD APR
PY 2022
VL 7
IS 2
DI 10.1016/j.esmoop.2022.100426
EA MAR 2022
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 1J4MJ
UT WOS:000797892800019
PM 35334418
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Szulc, P
   Seeman, E
   Duboeuf, F
   Sornay Rendu, E
   Delmas, PD
AF Szulc, Pawel
   Seeman, Ego
   Duboeuf, Francois
   Sornay Rendu, Elisabeth
   Delmas, Pierre D.
TI Bone fragility: Failure of periosteal apposition to compensate for
   increased endocortical resorption in postmenopausal women
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE periosteal apposition; fracture risk; menopause
ID SEX DIFFERENCES; PARATHYROID HORMONE; AGE; STRENGTH; SIZE; GEOMETRY;
   FRACTURE; GROWTH; MASS; MEN
AB The increase in bone fragility after menopause results from reduced periosteal bone formation and increased endocortical resorption. Women with highest remodeling had greatest loss of bone mass and estimated bone strength, whereas those with low remodeling lost less bone and maintained estimated bone strength.
   Introduction: Bone loss from the inner (endocortical) surface contributes to bone fragility, whereas deposition of bone on the outer (periosteal) surface is believed to be an adaptive response to maintain resistance to bending.
   Materials and Methods: To test this hypothesis, changes in bone mass and estimated indices of bone geometry and strength of the one third distal radius, bone turnover markers, and fracture incidence were measured annually in 821 women 30 89 years of age for 7.1 +/  2.5 years. The analyses were made in 151 premenopausal women, 33 perimenopausal women, 279 postmenopausal women, and 72 postmenopausal women receiving hormone replacement therapy (HRT).
   Results: In premenopausal women, periosteal apposition increased the radius width, partly offsetting endocortical resorption; therefore, the estimated cortical thickness decreased. Outward displacement of the thinner cortex maintained bone mass and cortical area and increased estimated bending strength. Estimated endocortical resorption accelerated during perimenopause, whereas periosteal apposition decreased. Further cortical thinning occurred, but estimated bending strength was maintained by modest outward cortical displacement. Endocortical resorption accelerated further during the postmenopausal years, whereas periosteal apposition declined further; cortices thinned, but because outward displacement was minimal, estimated cortical area and bending strength now decreased. Women with highest remodeling had the greatest loss of bone mass and strength. Women with low remodeling lost less bone and maintained estimated bone strength. In HRT treated women, loss of bone strength was partly prevented. These structural indices predicted incident fractures; a 1 SD lower section modulus doubled fracture risk.
   Conclusions: Periosteal apposition does not increase after menopause to compensate for bone loss; it decreases. Bone fragility of osteoporosis is a consequence of reduced periosteal bone formation and increased endocortical resorption. Understanding the mechanisms of the age related decline in periosteal apposition will identify new therapeutic targets. On the basis of our results, it may be speculated that the stimulation of periosteal apposition will increase bone width and improve skeletal strength.
C1 Hop Edouard Herriot, INSERM 403 Res Unit, F 69437 Lyon, France.
   Univ Lyon 1, Lyon, France.
   Univ Melbourne, Dept Endocrinol, Melbourne, Vic, Australia.
C3 CHU Lyon; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite Claude Bernard Lyon 1; University of Melbourne
RP Szulc, P (通讯作者)，Hop Edouard Herriot, INSERM 403 Res Unit, Pavillon F, F 69437 Lyon, France.
EM szulc@lyon.inserm.fr
RI ; Seeman, Ego/AAC 3656 2019; Sornay Rendu, Elisabeth/AAP 6999 2020;
   Szulc, Pawel/N 5238 2018
OI francois, duboeuf/0000 0002 7819 0153; Sornay Rendu,
   Elisabeth/0000 0002 2573 5316; Seeman, Ego/0000 0002 9692 048X; Szulc,
   Pawel/0000 0003 4168 6697; 
CR Ahlborg HG, 2003, NEW ENGL J MED, V349, P327, DOI 10.1056/NEJMoa022464
   Albright F, 1941, J AMER MED ASSOC, V116, P2465, DOI 10.1001/jama.1941.02820220007002
   Arlot ME, 1997, J BONE MINER RES, V12, P683, DOI 10.1359/jbmr.1997.12.4.683
   Atkinson J, 2005, J BONE MINER RES, V20, pS294
   BALENA R, 1992, J BONE MINER RES, V7, P1475
   Beck T, 2003, OSTEOPOROSIS INT, V14, pS81, DOI 10.1007/s00198 003 1478 0
   Boivin G, 2002, CALCIFIED TISSUE INT, V70, P503, DOI 10.1007/s00223 001 2048 0
   Bousson V, 2001, J BONE MINER RES, V16, P1308, DOI 10.1359/jbmr.2001.16.7.1308
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Delmas PD, 2000, OSTEOPOROSIS INT, V11, P2, DOI 10.1007/s001980070002
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   GARN SM, 1992, AM J HUM BIOL, V4, P57, DOI 10.1002/ajhb.1310040109
   GARNERO P, 1994, J BONE MINER RES, V9, P255
   Greenspan SL, 2005, J BONE MINER RES, V20, P1525, DOI 10.1359/JBMR.050508
   HAYES WC, 1982, SCIENCE, V217, P945, DOI 10.1126/science.7112107
   Hirano T, 2000, CALCIFIED TISSUE INT, V66, P456, DOI 10.1007/s002230010091
   Ito M, 2005, J BONE MINER RES, V20, P1828, DOI 10.1359/JBMR.050610
   KANNUS P, 1995, ANN INTERN MED, V123, P27, DOI 10.7326/0003 4819 123 1 199507010 00003
   Kaptoge S, 2003, BONE, V32, P561, DOI 10.1016/S8756 3282(03)00055 3
   Koller DL, 2001, J BONE MINER RES, V16, P985, DOI 10.1359/jbmr.2001.16.6.985
   Kontulainen S, 2002, J BONE MINER RES, V17, P2281, DOI 10.1359/jbmr.2002.17.12.2281
   Kumar S, 2005, J BONE MINER RES, V20, pS80
   LIPS P, 1978, CALC TISS RES, V26, P13, DOI 10.1007/BF02013227
   Liu P, 2005, J BONE MINER RES, V20, pS17
   Livshits G, 2003, BONE, V32, P191, DOI 10.1016/S8756 3282(02)00954 7
   Mayhew PM, 2005, LANCET, V366, P129, DOI 10.1016/S0140 6736(05)66870 5
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Neu CM, 2001, OSTEOPOROSIS INT, V12, P538, DOI 10.1007/s001980170074
   PARFITT AM, 1994, OSTEOPOROSIS INT, V4, P382, DOI 10.1007/BF01622201
   Riggs BL, 2004, J BONE MINER RES, V19, P1945, DOI 10.1359/JBMR.040916
   Rosenquist C, 1998, CLIN CHEM, V44, P2281
   RUFF CB, 1988, J ORTHOP RES, V6, P886, DOI 10.1002/jor.1100060613
   Russo CR, 2006, BONE, V38, P112, DOI 10.1016/j.bone.2005.07.025
   Sato M, 2002, ENDOCRINOLOGY, V143, P3230, DOI 10.1210/en.2002 220149
   Seeman E, 2003, NEW ENGL J MED, V349, P320, DOI 10.1056/NEJMp038101
   Seeman E, 2004, CALCIFIED TISSUE INT, V75, P100, DOI 10.1007/s00223 004 0289 4
   Seeman E, 1997, J BONE MINER RES, V12, P509, DOI 10.1359/jbmr.1997.12.4.509
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Smith BB, 2003, INT J TOXICOL, V22, P403, DOI 10.1080/713936670
   Stroup G, 2005, J BONE MINER RES, V20, pS80
   Szulc P, 2006, BONE, V38, P595, DOI 10.1016/j.bone.2005.09.004
   Szulc P, 2004, OSTEOPOROSIS INT, V15, P909, DOI 10.1007/s00198 004 1635 0
   Wang XF, 2005, BONE, V36, P978, DOI 10.1016/j.bone.2004.11.015
   Zanchetta JR, 2003, J BONE MINER RES, V18, P539, DOI 10.1359/jbmr.2003.18.3.539
NR 44
TC 178
Z9 196
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC
PY 2006
VL 21
IS 12
BP 1856
EP 1863
DI 10.1359/JBMR.060904
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 108ZY
UT WOS:000242278900006
PM 17002580
OA Bronze
DA 2025 08 17
ER

PT J
AU Pujari Palmer, M
   Pujari Palmer, S
   Engqvist, H
   Ott, MK
AF Pujari Palmer, Michael
   Pujari Palmer, Shiuli
   Engqvist, Hakan
   Ott, Marjam Karlsson
TI Rebamipide Delivered by Brushite Cement Enhances Osteoblast and
   Macrophage Proliferation
SO PLOS ONE
LA English
DT Article
ID WATER SOLUBLE DRUGS; MC3T3 E1 CELLS; MECHANICAL PROPERTIES; BONE CEMENT;
   RAT MODEL; PHOSPHATE; DIFFERENTIATION; RELEASE; RECEPTOR; ACTIVATION
AB Many of the bioactive agents capable of stimulating osseous regeneration, such as bone morphogenetic protein 2 (BMP 2) or prostaglandin E2 (PGE2), are limited by rapid degradation, a short bioactive half life at the target site in vivo, or are prohibitively expensive to obtain in large quantities. Rebamipide, an amino acid modified hydroxylquinoline, can alter the expression of key mediators of bone anabolism, cyclo oxygenase 2 (COX 2), BMP 2 and vascular endothelial growth factor (VEGF), in diverse cell types such as mucosal and endothelial cells or chondrocytes. The present study investigates whether Rebamipide enhances proliferation and differentiation of osteoblasts when delivered from brushite cement. The reactive oxygen species (ROS) quenching ability of Rebampide was tested in macrophages as a measure of bioactivity following drug release incubation times, up to 14 days. Rebamipide release from brushite occurrs via non fickian diffusion, with a rapid linear release of 9.70%+/  0.37% of drug per day for the first 5 days, and an average of 0.5% 1% per day thereafter for 30 days. Rebamipide slows the initial and final cement setting time by up to 3 and 1 minute, respectively, but does not significantly reduce the mechanical strength below 4% (weight percentage). Pre osteoblast proliferation increases by 24% upon exposure to 0.4uM Rebamipide, and by up to 73% when Rebamipide is delivered via brushite cement. Low doses of Rebamipide do not adversely affect peak alkaline phosphatase activity in differentiating pre osteoblasts. Rebamipide weakly stimulates proliferation in macrophages at low concentrations (118 +/  7.4% at 1uM), and quenches ROS by 40 60%. This is the first investigation of Rebamipide in osteoblasts.
C1 [Pujari Palmer, Michael; Pujari Palmer, Shiuli; Engqvist, Hakan; Ott, Marjam Karlsson] Uppsala Univ, Dept Engn Sci, Div Appl Mat Sci, Uppsala, Sweden.
C3 Uppsala University
RP Ott, MK (通讯作者)，Uppsala Univ, Dept Engn Sci, Div Appl Mat Sci, Uppsala, Sweden.
EM marjam.ott@angstrom.uu.se
RI Pujari Palmer, michael/W 4362 2018
OI Pujari Palmer, michael/0000 0001 7004 2853
FU Swedish research council [GA 621 2011 3399]
FX This work was supported by the Swedish research council GA 621 2011 3399
   HE MP EU 7th framework project: Biodesign HE MP. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Åberg J, 2013, J MATER SCI MATER M, V24, P829, DOI 10.1007/s10856 013 4855 z
   [Anonymous], 2014, PLOS ONE
   [Anonymous], 1999, AM PHYSL SOC
   Arakawa T, 1996, J BIOL CHEM, V271, P29569, DOI 10.1074/jbc.271.47.29569
   Bamba H, 2003, ALIMENT PHARM THER, V18, P113, DOI 10.1046/j.1365 2036.18.s1.13.x
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   Bohner M LJ, 1996, J PHARM SCEINCES, V86, P565
   Bohner M, 2012, J EUR CERAM SOC, V32, P2663, DOI 10.1016/j.jeurceramsoc.2012.02.028
   Bramono DS, 2012, BONE, V50, P954, DOI 10.1016/j.bone.2011.12.013
   BROXMEYER HE, 1977, CANCER RES, V37, P3578
   Canal C, 2013, ACTA BIOMATER, V9, P8403, DOI 10.1016/j.actbio.2013.05.016
   Chen WC, 2012, TISSUE ENG PT A, V18, P816, DOI [10.1089/ten.tea.2011.0267, 10.1089/ten.TEA.2011.0267]
   Chou J, 2013, ADV HEALTHC MATER, V2, P678, DOI 10.1002/adhm.201200342
   Choudhary S, 2004, BIOCHEM BIOPH RES CO, V322, P395, DOI 10.1016/j.bbrc.2004.07.129
   Clarkin CE, 2008, J CELL PHYSIOL, V214, P537, DOI 10.1002/jcp.21234
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   Dvorak MM, 2004, CELL CALCIUM, V35, P249, DOI 10.1016/j.ceca.2003.10.014
   Engstrand J, 2014, J MECH BEHAV BIOMED, V29, P81, DOI 10.1016/j.jmbbm.2013.08.024
   Engstrand J, 2013, MAT SCI ENG C MATER, V33, P527, DOI 10.1016/j.msec.2012.09.026
   Ghanaati S, 2011, BIOMATERIALS, V32, P8150, DOI 10.1016/j.biomaterials.2011.07.041
   Grover LM, 2003, BIOMATERIALS, V24, P4133, DOI 10.1016/S0142 9612(03)00293 X
   Hamanishi C, 1996, J BIOMED MATER RES, V33, P139, DOI 10.1002/(SICI)1097 4636(199623)33:3<139::AID JBM3>3.0.CO;2 R
   Harland AG R.S., 1988, DRUG POLYM MATRIX SW, V5, P488
   Hayashi K, 2005, J BONE JOINT SURG BR, V87B, P1150, DOI 10.1302/0301 620X.87B8.15886
   Hofmann MP, 2009, ACTA BIOMATER, V5, P43, DOI 10.1016/j.actbio.2008.08.005
   Hong WS, 2001, PHARMACOL RES, V44, P293, DOI 10.1006/phrs.2001.0839
   Ishihara T, 2010, BIOCHEM PHARMACOL, V79, P1622, DOI 10.1016/j.bcp.2010.01.030
   Itoh F, 2003, EUR J PHARMACOL, V477, P9, DOI 10.1016/j.ejphar.2003.08.011
   Kamolratanakul P, 2011, ARTHRITIS RHEUM US, V63, P1021, DOI 10.1002/art.30151
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kang DW, 2010, EXP MOL MED, V42, P555, DOI 10.3858/emm.2010.42.8.056
   Kim JS, 2003, ALIMENTARY PHARM THE, V2003
   Kodama H.A., 1981, J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899
   KUU WY, 1989, INT J PHARMACEUT, V55, P77, DOI 10.1016/0378 5173(89)90279 2
   KYEYUNENYOMBI E, 1995, CALCIFIED TISSUE INT, V56, P154, DOI 10.1007/BF00296348
   Liu WE, 2011, BIOMATERIALS, V32, P1796, DOI 10.1016/j.biomaterials.2010.11.029
   Lubeck DP, 2003, BEST PRACT RES CL RH, V17, P529, DOI 10.1016/S1521 6942(03)00023 8
   Monrad SU, 2011, CURR REV MUSCULOSKE, V4, P91, DOI 10.1007/s12178 011 9083 x
   Montazerolghaem M, 2014, J BIOMED MATER RES A, V102, P340, DOI 10.1002/jbm.a.34702
   Moon SJ, 2012, OSTEOARTHR CARTILAGE, V20, P1426, DOI 10.1016/j.joca.2012.08.002
   Mulye N. TS, 1996, DRUG DEV IND PHARM, V22, P2621
   Mulye NV, 1996, DRUG DEV IND PHARM, V22, P673, DOI 10.3109/03639049609063223
   MULYE NV, 1995, DRUG DEV IND PHARM, V21, P943, DOI 10.3109/03639049509026658
   Nishiya Y, 2002, CALCIFIED TISSUE INT, V70, P30, DOI 10.1007/s00223 001 1010 5
   Pradhan R, 2014, ARCH PHARM RES
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168 3659(87)90034 4
   SCHOENFELD CM, 1974, MED BIOL ENG, V12, P313, DOI 10.1007/BF02477797
   Seeherman HJ, 2004, J BONE JOINT SURG AM, V86A, P1961, DOI 10.2106/00004623 200409000 00015
   Shamir D KS, 1994, BONE, V34, P157
   Shields LB RG, 2006, SPINE, V31
   Suda M, 2000, CALCIFIED TISSUE INT, V66, P217, DOI 10.1007/s002230010043
   Suetsugu H, 2000, J LAB CLIN MED, V136, P50, DOI 10.1067/mlc.2000.107303
   Tarnawski AS, 2004, DIGEST DIS SCI, V49, P202, DOI 10.1023/B:DDAS.0000017439.60943.5c
   Temizel N, 2011, MAT SCI ENG C MATER, V31, P1136, DOI 10.1016/j.msec.2011.04.009
   Tran RT, 2012, GASTROINTEST ENDOSC, V75, P1092, DOI 10.1016/j.gie.2011.12.009
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Vorndran E, 2013, ACTA BIOMATER, V9, P9558, DOI 10.1016/j.actbio.2013.08.009
   Wu X, 2007, CELL DEATH DIFFER, V14, P1792, DOI 10.1038/sj.cdd.4402190
   Xiaobin ZH Q, 2011, BIOACTIVE MAT MED DE
   Zhang WB, 2012, J ORTHOP SCI, V17, P289, DOI 10.1007/s00776 012 0206 z
   Zhong X, 2011, ACTA PHARMACOL SIN, V32, P591, DOI 10.1038/aps.2011.15
NR 61
TC 6
Z9 7
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 29
PY 2015
VL 10
IS 5
AR e0128324
DI 10.1371/journal.pone.0128324
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CJ2MQ
UT WOS:000355319400083
PM 26023912
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Liu, MM
   Li, Y
   Yang, ST
AF Liu, Meimei
   Li, Yan
   Yang, Shang Tian
TI Curculigoside Improves Osteogenesis of Human Amniotic Fluid Derived Stem
   Cells
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; BETA CATENIN; WNT; OSTEOPOROSIS;
   PROLIFERATION; ORCHIOIDES; GENE
AB Curculigoside, a phenolic glycoside, is the main active compound of Curculigo orchioides (Amaryllidaceae, rhizome). C. orchioides is a traditional Chinese herbal medicine and has been commonly used to treat orthopedic disorders and bone healing in Asia. This study evaluated the effect of curculigoside on osteogenic differentiation of human amniotic fluid derived stem cells (hAFSCs). The results showed that curculigoside stimulated alkaline phosphatase activity and calcium deposition of hAFSCs during osteogenic differentiation in a dose dependent manner (1 100g/mL), while the effects were reduced at the higher concentration of 200g/mL. From reverse transcriptase polymerase chain reaction analysis, the osteogenic genes osteopontin (OPN) and Collagen I were upregulated with curculigoside treatment (1 100g/mL). Concurrently, the ratio of osteoprotegerin (OPG) to receptor activator of nuclear factor kappa B ligand (RANKL) was increased, indicating the inhibition of osteoclastogenesis by curculigoside. Moreover, the role of Wnt/ catenin signaling during curculigoside treatment was revealed by the upregulation of  catenin and Cyclin D1. In summary, curculigoside improved osteogenesis and inhibited osteoclastogenesis of hAFSCs, suggesting its potential use to regulate hAFSC osteogenic differentiation for treating bone disorders.
C1 [Liu, Meimei; Yang, Shang Tian] Ohio State Univ, William G Lowrie Dept Chem & Biomol Engn, Columbus, OH 43210 USA.
   [Li, Yan] Florida State Univ, Dept Chem & Biomed Engn, FAMU FSU Coll Engn, Tallahassee, FL 32306 USA.
C3 University System of Ohio; Ohio State University; State University
   System of Florida; Florida State University; Florida A&M University
RP Yang, ST (通讯作者)，Ohio State Univ, William G Lowrie Dept Chem & Biomol Engn, 140 W 19th Ave, Columbus, OH 43210 USA.
EM yang.15@osu.edu
RI Yang, Shang Tian/A 7892 2009; Liu, Meimei/I 5650 2017
FU Ohio State University
FX This work was supported, in part, by the Alumni Grants for Graduate
   Research and Scholarship (AGGRS) of The Ohio State University. We would
   like to acknowledge Dr. Anthony Atala and Dr. James Yoo of the Wake
   Forest Institute for Regenerative Medicine (Winston Salem, NC) for
   kindly providing hAFSCs used in this study. We also would like to
   acknowledge Dr. Sebastien Sart for the assistance in ImageJ analysis.
CR [Anonymous], 2008, FOR AN DIS FOR EM DI
   Arum SM, 2008, CURR OPIN ENDOCRINOL, V15, P508, DOI 10.1097/MED.0b013e3283184017
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Cao DP, 2008, MATURITAS, V59, P373, DOI 10.1016/j.maturitas.2008.03.010
   Cooper C, 1999, OSTEOPOROSIS INT, V9, P2
   Curtis JR, 2012, DRUG AGING, V29, P549, DOI 10.2165/11599620 000000000 00000
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hamidouche Z, 2008, FASEB J, V22, P3813, DOI 10.1096/fj.08 106302
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Jiao L, 2009, PHYTOMEDICINE, V16, P874, DOI 10.1016/j.phymed.2009.01.005
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Li D, 2013, BIOTECHNOL PROGR, V29, P738, DOI 10.1002/btpr.1731
   Li D, 2013, PROCESS BIOCHEM, V48, P517, DOI 10.1016/j.procbio.2013.02.005
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   Liu Y., 2012, Clinical and experimental medicine
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Ma CJ, 2011, PHYTOTHER RES, V25, P922, DOI 10.1002/ptr.3449
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Rotella DP, 2002, CURR OPIN DRUG DISC, V5, P477
   Roubelakis MG, 2007, STEM CELLS DEV, V16, P931, DOI 10.1089/scd.2007.0036
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Shen QP, 2013, J PHARM PHARMACOL, V65, P1005, DOI 10.1111/jphp.12054
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Teede HJ, 2003, BEST PRACT RES CL EN, V17, P73, DOI 10.1016/S1521 690X(02)00083 0
   Trohatou O, 2013, CURR STEM CELL RES T, V8, P125, DOI 10.2174/1574888X11308020003
   Wang Y, 2012, ACTA BIOCH BIOPH SIN, V44, P431, DOI 10.1093/abbs/gms014
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Yeh YC, 2010, TISSUE ENG PT A, V16, P1925, DOI [10.1089/ten.tea.2009.0728, 10.1089/ten.TEA.2009.0728]
   Yoon BS, 2010, STEM CELLS DEV, V19, P887, DOI 10.1089/scd.2009.0138
   Zhang JF, 2010, MOL CELL ENDOCRINOL, V314, P70, DOI 10.1016/j.mce.2009.08.012
   Zhang JF, 2009, PHYTOMEDICINE, V16, P521, DOI 10.1016/j.phymed.2009.01.003
NR 43
TC 23
Z9 29
U1 1
U2 24
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD JAN 15
PY 2014
VL 23
IS 2
BP 146
EP 154
DI 10.1089/scd.2013.0261
PG 9
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 284XY
UT WOS:000329356800007
PM 24007307
DA 2025 08 17
ER

PT J
AU Liu, SY
   Bi, WZ
   Li, X
   Chen, XL
   Qu, LB
   Zhao, YF
AF Liu, Shuyun
   Bi, Wenzhu
   Li, Xu
   Chen, Xiaolan
   Qu, Lingbo
   Zhao, Yufen
TI A PRACTICAL METHOD TO SYNTHESIZE 1,2,3 TRIAZOLE AMINO BISPHOSPHONATE
   DERIVATIVES
SO PHOSPHORUS SULFUR AND SILICON AND THE RELATED ELEMENTS
LA English
DT Article
DE Michael addition reaction; 1; 3 dipolar cycloaddition; ultrasound; 1; 2;
   3 triazole amino bisphosphonates
ID DELIVERY SYSTEM ODDS; BISPHOSPHONIC PRODRUG; OSTEOTROPIC
   CARBOXYFLUORESCEIN; TERMINAL ALKYNES; BONE RESORPTION; IN VITRO; DRUG;
   GERANYLGERANYLATION; PHARMACOKINETICS; LOCALIZATION
AB A practical and efficient method for the synthesis of 1,2,3 triazole amino bisphosphonates derivatives was developed through two steps: The Michael addition reaction of propargyl amine with vinylidene bisphosphonate, and the 1,3 dipolar click cycloaddition assisted by ultrasound irradiation. This approach has significant advantages in terms of experimental simplicity, mild reaction condition, and can be easily scaled up. The target compounds were characterized by H 1 , P 31 , C 13 NMR spectroscopy and high resolution mass spectral analyses.
C1 [Liu, Shuyun; Bi, Wenzhu; Li, Xu; Chen, Xiaolan; Qu, Lingbo; Zhao, Yufen] Zhengzhou Univ, Dept Chem, Key Lab Organ Chem & Chem Biol, Zhengzhou 450052, Henan Province, Peoples R China.
   [Qu, Lingbo] Henan Univ Technol, Chem & Chem Engn Sch, Zhengzhou, Henan Province, Peoples R China.
   [Zhao, Yufen] Xiamen Univ, Dept Chem, Xiamen 361005, Peoples R China.
C3 Zhengzhou University; Henan University of Technology; Xiamen University
RP Chen, XL (通讯作者)，Zhengzhou Univ, Dept Chem, Key Lab Organ Chem & Chem Biol, Zhengzhou 450052, Henan Province, Peoples R China.
EM chenxl@zzu.edu.cn
FU National Natural Science Foundation of China [21072178]; Innovation
   Specialist Projects of Henan Province [114200510023]; Technology and
   Science Talent Cultivation Project in Zhengzhou City [112PLJRC359];
   Special Fund for the Doctoral Program of Higher Education
   [20124101110003]; Foundational and Frontier Technology Research
   Foundation of Henan Province
FX Financial support from The National Natural Science Foundation of China
   (No. 21072178), Innovation Specialist Projects of Henan Province (No.
   114200510023), Technology and Science Talent Cultivation Project in
   Zhengzhou City (No. 112PLJRC359), the Special Fund for the Doctoral
   Program of Higher Education (No. 20124101110003), and Foundational and
   Frontier Technology Research Foundation of Henan Province for their
   financial support.
CR ADAZAMLI IK, 1989, J MED CHEM, V32, P139, DOI 10.1021/jm00121a026
   ALVAREZ R, 1994, J MED CHEM, V37, P4185, DOI 10.1021/jm00050a015
   Bansal G, 2005, ANGEW CHEM INT EDIT, V44, P3710, DOI 10.1002/anie.200500350
   Brockunier LL, 2000, BIOORG MED CHEM LETT, V10, P2111, DOI 10.1016/S0960 894X(00)00422 4
   BUCKLE DR, 1984, J MED CHEM, V27, P223, DOI 10.1021/jm00368a021
   Chaleix V, 2007, TETRAHEDRON LETT, V48, P703, DOI 10.1016/j.tetlet.2006.11.094
   Coxon FP, 2005, BONE, V37, P349, DOI 10.1016/j.bone.2005.04.021
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Dalvie DK, 2002, CHEM RES TOXICOL, V15, P269, DOI 10.1021/tx015574b
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Fujisaki J, 1996, J DRUG TARGET, V4, P117, DOI 10.3109/10611869609046270
   Fujisaki J, 1995, J DRUG TARGET, V3, P273, DOI 10.3109/10611869509015956
   Genin MJ, 2000, J MED CHEM, V43, P953, DOI 10.1021/jm990373e
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968 0896(99)00045 0
   Hirabayashi H, 2002, BIOPHARM DRUG DISPOS, V23, P307, DOI 10.1002/bdd.323
   Hirabayashi H, 2001, J CONTROL RELEASE, V70, P183, DOI 10.1016/S0168 3659(00)00355 2
   HUTCHINSON DW, 1988, J ORGANOMET CHEM, V346, P341, DOI 10.1016/0022 328X(88)80134 7
   Kubek V., 2005, J AM CHEM SOC, V127, P16477
   Maarseveen J. H., 2004, J AM CHEM SOC, V126, P15366
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Ogawa K, 2005, BIOCONJUGATE CHEM, V16, P751, DOI 10.1021/bc040249w
   Page PCB, 2001, J ORG CHEM, V66, P3704, DOI 10.1021/jo001489h
   Prasad A., 2004, ORG LETT, V6, P4223
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521 3773(20020715)41:14<2596::AID ANIE2596>3.0.CO;2 4
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Sanders JM, 2005, J MED CHEM, V48, P2957, DOI 10.1021/jm040209d
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Skarpos H, 2007, ORG BIOMOL CHEM, V5, P2361, DOI 10.1039/b705510b
   Sturtz G., 1991, SYNTHESIS STUTTGART, V27, P661
   Tornoe CW, 2002, J ORG CHEM, V67, P3057, DOI 10.1021/jo011148j
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wright JEI, 2006, BIOMATERIALS, V27, P769, DOI 10.1016/j.biomaterials.2005.06.012
NR 34
TC 7
Z9 7
U1 0
U2 22
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1042 6507
EI 1563 5325
J9 PHOSPHORUS SULFUR
JI Phosphorus Sulfur Silicon Relat. Elem.
PD NOV 2
PY 2015
VL 190
IS 11
BP 1735
EP 1742
DI 10.1080/10426507.2015.1012200
PG 8
WC Chemistry, Inorganic & Nuclear; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Chemistry
GA CX4ZU
UT WOS:000365710500002
DA 2025 08 17
ER

PT J
AU McCully, M
   Conde, J
   Baptista, PV
   Mullin, M
   Dalby, MJ
   Berry, CC
AF McCully, Mark
   Conde, Joao
   Baptista, Pedro V.
   Mullin, Margaret
   Dalby, Matthew J.
   Berry, Catherine C.
TI Nanoparticle antagomiR based targeting of miR 31 to induce osterix and
   osteocalcin expression in mesenchymal stem cells
SO PLOS ONE
LA English
DT Article
ID OSTEOGENIC DIFFERENTIATION; BONE MARROW; OSTEOBLAST DIFFERENTIATION;
   MICRORNA EXPRESSION; SATB2; PROLIFERATION; MECHANISMS; PHENOTYPE;
   INSIGHTS; RUNX2
AB Mesenchymal stem cells are multipotent adult stem cells capable of generating bone, cartilage and fat, and are thus currently being exploited for regenerative medicine. When considering osteogenesis, developments have been made with regards to chemical induction (e.g. differentiation media) and physical induction (e.g. material stiffness, nanotopography), targeting established early transcription factors or regulators such as runx2 or bone morphogenic proteins and promoting increased numbers of cells committing to osteo specific differentiation. Recent research highlighted the involvement of microRNAs in lineage commitment and terminal differentiation. Herein, gold nanoparticles that confer stability to short single stranded RNAs were used to deliver MiR 31 antagomiRs to both pre osteoblastic cells and primary human MSCs in vitro. Results showed that blocking miR 31 led to an increase in osterix protein in both cell types at day 7, with an increase in osteocalcin at day 21, suggesting MSC osteogenesis. In addition, it was noted that antagomiR sequence direction was important, with the 5 prime reading direction proving more effective than the 3 prime. This study highlights the potential that miRNA antagomiR tagged nanoparticles offer as novel therapeutics in regenerative medicine.
C1 [McCully, Mark; Dalby, Matthew J.; Berry, Catherine C.] Univ Glasgow, Ctr Cell Engn, Glasgow, Lanark, Scotland.
   [Conde, Joao] Harvard MIT, Div Hlth Sci & Technol, Inst Med Engn & Sci, MIT, Cambridge, MA USA.
   [Baptista, Pedro V.] Univ Nova Lisboa, UCIBIO, DCV, Fac Ciencias & Tecnol, Campus Caparica, Caparica, Portugal.
   [Mullin, Margaret] Univ Glasgow, Electron Microscopy Unit, Glasgow, Lanark, Scotland.
C3 University of Glasgow; Harvard University; Massachusetts Institute of
   Technology (MIT); Universidade Nova de Lisboa; University of Glasgow
RP McCully, M; Berry, CC (通讯作者)，Univ Glasgow, Ctr Cell Engn, Glasgow, Lanark, Scotland.
EM markamccully@gmail.com; Catherine.berry@glasgow.ac.uk
RI Berry, Catherine/AAE 4493 2021; Baptista, Pedro/A 1237 2009; Conde,
   João/F 2231 2011; McCully, Mark/D 3192 2018; Conde, Joao/F 2231 2011;
   Dalby, Matthew/G 2426 2012
OI Baptista, Pedro/0000 0001 5255 7095; Conde, Joao/0000 0001 8422 6792;
   Dalby, Matthew/0000 0002 0528 3359; 
FU Biotechnology and Biological Sciences Research Council (BBSRC)
   [BB/L008661/1]; Unidade de Ciencias Biomoleculares Aplicadas UCIBIO  
   national funds from Fundacao para a Ciencia e a Tecnologia / Ministerio
   da Educacao e Ciencia (FCT/MEC) [UID/Multi/04378/2013]; European
   Regional Development Fund (ERDF) [POCI 01 0145 FEDER 007728]; 
   [PD/BD/105734/2014]; Biotechnology and Biological Sciences Research
   Council [BB/G008868/1, JF20604, BB/L008661/1, BB/L023814/1] Funding
   Source: researchfish; Fundação para a Ciência e a Tecnologia
   [PD/BD/105734/2014] Funding Source: FCT; BBSRC [BB/L008661/1,
   BB/G008868/1, BB/L023814/1] Funding Source: UKRI
FX The author CCB wishes to acknowledge funding from the Biotechnology and
   Biological Sciences Research Council (BBSRC); BB/L008661/1.
   (https://www.bbsrc.ac.uk/); PVB was supported by the Unidade de Ciencias
   Biomoleculares Aplicadas UCIBIO, which is financed by national funds
   from Fundacao para a Ciencia e a Tecnologia / Ministerio da Educacao e
   Ciencia (FCT/MEC) (https://www.fct.pt/) (UID/Multi/04378/2013) and
   co financed by the European Regional Development Fund (ERDF)
   (http://ec.europa.eu/regional_policy/en/funding/erdf/) under the PT2020
   Partnership Agreement (POCI 01 0145 FEDER 007728); PP for
   PD/BD/105734/2014. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Baglìo SR, 2013, GENE, V527, P321, DOI 10.1016/j.gene.2013.06.021
   Bhushan R, 2013, INT J BIOCHEM CELL B, V45, P696, DOI 10.1016/j.biocel.2012.12.008
   Chan YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054130
   Chang KW, 2013, ORAL ONCOL, V49, P27, DOI 10.1016/j.oraloncology.2012.07.003
   Child HW, 2015, NANOMEDICINE UK, V10, P2513, DOI 10.2217/NNM.15.95
   Conde J, 2012, ACS NANO, V6, P8316, DOI 10.1021/nn3030223
   Demontiero O, 2012, THER ADV MUSCULOSKEL, V4, P61, DOI 10.1177/1759720X11430858
   Deng Y, 2013, STEM CELLS DEV, V22, P2278, DOI 10.1089/scd.2012.0686
   Deng Y, 2013, BIOMATERIALS, V34, P6717, DOI 10.1016/j.biomaterials.2013.05.042
   Dong WJ, 2015, J CELL PHYSIOL, V230, P680, DOI 10.1002/jcp.24792
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Gao J, 2011, J CELL BIOCHEM, V112, P1844, DOI 10.1002/jcb.23106
   Grigsby CL, 2010, J R SOC INTERFACE, V7, pS67, DOI 10.1098/rsif.2009.0260
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   Heggebö J, 2014, ORTHOP REV, V6, P65, DOI 10.4081/or.2014.5242
   Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312
   Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Liu LH, 2011, BIOCHEM BIOPH RES CO, V416, P31, DOI 10.1016/j.bbrc.2011.10.117
   McCully M, 2015, NANO RES, V8, P3281, DOI 10.1007/s12274 015 0828 5
   McMurray RJ, 2011, NAT MATER, V10, P637, DOI [10.1038/NMAT3058, 10.1038/nmat3058]
   McNamara LE, 2010, J TISSUE ENG, V1, DOI 10.4061/2010/120623
   Nombela Arrieta C, 2011, NAT REV MOL CELL BIO, V12, P126, DOI 10.1038/nrm3049
   Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604
   RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022
   Sibley CR, 2010, MOL THER, V18, P466, DOI 10.1038/mt.2009.306
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Sun FY, 2009, BIOCHEM BIOPH RES CO, V380, P660, DOI 10.1016/j.bbrc.2009.01.161
   Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185
   Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002
   Weilner S, 2016, AGING CELL, V15, P744, DOI 10.1111/acel.12484
   Xie Q, 2014, BIOCHEM BIOPH RES CO, V446, P98, DOI 10.1016/j.bbrc.2014.02.058
   Xu CY, 2016, CURR STEM CELL RES T, V11, P247, DOI 10.2174/1574888X10666150723145707
   Yang JL, 2014, ACS NANO, V8, P9941, DOI 10.1021/nn504767g
NR 36
TC 20
Z9 21
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD FEB 14
PY 2018
VL 13
IS 2
AR e0192562
DI 10.1371/journal.pone.0192562
PG 21
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FW3CM
UT WOS:000425183500072
PM 29444183
OA Green Submitted, Green Published, Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Lee, S
   Cho, HY
   Bui, HTT
   Kang, D
AF Lee, Sooho
   Cho, Hee Yeon
   Hang Thi Thuy Bui
   Kang, Dongchul
TI The osteogenic or adipogenic lineage commitment of human mesenchymal
   stem cells is determined by protein kinase C delta
SO BMC CELL BIOLOGY
LA English
DT Article
DE hBMSCs; Osteogenic differentiation; Signal transduction; PKC delta; AMPK
ID PKC DELTA; OSTEOBLASTIC DIFFERENTIATION; THERAPEUTIC TARGET; BONE;
   EXPRESSION; ACTIVATION; OSTEOPOROSIS; RUNX2; FAT; METABOLISM
AB Background: Mesenchymal stem cells (MSCs) have the potential to differentiate into specialized cell lineages such as osteoblasts and adipocytes in vitro. There exists a reciprocal relationship between osteogenic and adipogenic differentiation of MSCs that an osteogenic phenotype occurs at the expense of an adipogenic phenotype and vice versa, which in turn influence one another's phenotype through negative feedback loops. Thus, it is important to understand what signaling molecules modulate the lineage commitment of MSCs. Protein kinase C (PKC) plays a central role in cellular signal transduction for mediating diverse biological functions, and dysregulation of PKC activity is involved in various metabolic diseases including cancer, diabetes, and heart disease. Although the role of individual PKC isoforms has been investigated in various fields, the potential role of PKC in bone metabolism is not completely understood. In this study, we investigated the potential role of PKCd in osteogenic lineage commitment of human bone marrow derived mesenchymal stem cells (hBMSCs).
   Results: We observed that expression and phosphorylation of PKC delta were increased during osteogenic differentiation of hBMSCs. Pharmacological inhibition and genetic ablation of PKC delta in hBMSCs resulted in a significant attenuation of osteogenic differentiation as evidenced by reduced ALP activity and ECM mineralization, as well as down regulation of the expression of osteoblast specific genes. These effects were also accompanied by induction of adipogenic differentiation and up regulation of the expression of adipocyte specific genes involved in lipid synthesis in osteogenic induction of hBMSCs. Additionally, the activation of AMPK, which is a key cellular energy sensor, induced osteogenesis of hBMSCs. However, the inhibition of AMPK activity by compound C did not affect the activation of PKCd at all, indicating that there is no direct correlation between AMPK and PKCd in osteogenesis of hBMSCs.
   Conclusions: These results suggest that PKCd is a critical regulator for the balance between osteogenesis and adipogenesis of hBMSCs and thus has a potential novel therapeutic target for the treatment of metabolic bone diseases.
C1 [Lee, Sooho; Cho, Hee Yeon; Hang Thi Thuy Bui; Kang, Dongchul] Hallym Univ, Ilsong Inst Life Sci, Anyang 431060, Gyeonggi Do, South Korea.
   [Cho, Hee Yeon; Hang Thi Thuy Bui; Kang, Dongchul] Hallym Univ, Grad Sch, Dept Biomed Gerontol, Chunchon 200702, Gangwon Do, South Korea.
C3 Hallym University; Hallym University
RP Kang, D (通讯作者)，Hallym Univ, Ilsong Inst Life Sci, Anyang 431060, Gyeonggi Do, South Korea.
EM dckang@hallym.ac.kr
OI Gander Bui, Hang Thi Thuy/0000 0002 9463 4543
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education, Science and Technology
   [2011 0025290]
FX This work was supported by Basic Science Research Program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Education, Science and Technology (No. 2011 0025290).
CR Arvidson K, 2011, J CELL MOL MED, V15, P718, DOI 10.1111/j.1582 4934.2010.01224.x
   Bair AM, 2009, J BIOL CHEM, V284, P563, DOI 10.1074/jbc.M803984200
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Chen HQ, 2014, AGEING RES REV, V13, P55, DOI 10.1016/j.arr.2013.12.002
   Duque G, 2008, CURR OPIN RHEUMATOL, V20, P429, DOI 10.1097/BOR.0b013e3283025e9c
   Geraldes P, 2010, CIRC RES, V106, P1319, DOI 10.1161/CIRCRESAHA.110.217117
   Giordano A, 2007, J CELL PHYSIOL, V211, P27, DOI 10.1002/jcp.20959
   Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Jeyabalan J, 2012, J ENDOCRINOL, V212, P277, DOI 10.1530/JOE 11 0306
   Jonason JH, 2009, J DENT RES, V88, P693, DOI 10.1177/0022034509341629
   Khor EC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070815
   Kim BG, 2006, PROTEOMICS, V6, P1166, DOI 10.1002/pmic.200500289
   Kim EK, 2012, J CELL PHYSIOL, V227, P1680, DOI 10.1002/jcp.22892
   Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200
   Kutner RH, 2009, NAT PROTOC, V4, P495, DOI 10.1038/nprot.2009.22
   Lampasso JD, 2006, INT J MOL MED, V17, P1125
   Lima F, 2009, MOL BIOL CELL, V20, P2697, DOI 10.1091/mbc.E08 10 1079
   Liu J, 2010, J TISSUE ENG REGEN M, V4, P329, DOI 10.1002/term.242
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Mehla R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011160
   Mochly Rosen D, 2012, NAT REV DRUG DISCOV, V11, P937, DOI 10.1038/nrd3871
   Murakami M, 2002, J BIOL CHEM, V277, P20367, DOI 10.1074/jbc.M202501200
   Nakura A, 2011, BONE, V48, P476, DOI 10.1016/j.bone.2010.09.238
   Pantovic A, 2013, BONE, V52, P524, DOI 10.1016/j.bone.2012.10.024
   Papachroni KK, 2009, TRENDS MOL MED, V15, P208, DOI 10.1016/j.molmed.2009.03.001
   Park KH, 2010, BIOCHEM BIOPH RES CO, V403, P7, DOI 10.1016/j.bbrc.2010.10.074
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Rosen CJ, 2009, AM J MED, V122, P409, DOI 10.1016/j.amjmed.2008.11.027
   Rosse C, 2010, NAT REV MOL CELL BIO, V11, P103, DOI 10.1038/nrm2847
   Rossi F, 1996, EMBO J, V15, P1894, DOI 10.1002/j.1460 2075.1996.tb00540.x
   Sanders JL, 1996, J BONE MINER RES, V11, P1862
   Schmitz Peiffer C, 2013, FEBS J, V280, P5371, DOI 10.1111/febs.12285
   Shui CX, 2003, J BONE MINER RES, V18, P213, DOI 10.1359/jbmr.2003.18.2.213
   Soltoff SP, 2007, TRENDS PHARMACOL SCI, V28, P453, DOI 10.1016/j.tips.2007.07.003
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Teicher BA, 2006, CLIN CANCER RES, V12, P5336, DOI 10.1158/1078 0432.CCR 06 0945
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Zhao LJ, 2008, J BONE MINER RES, V23, P17, DOI 10.1359/JBMR.070813
   Zhou YR, 2006, INT J BIOCHEM CELL B, V38, P2151, DOI 10.1016/j.biocel.2006.06.009
NR 43
TC 26
Z9 31
U1 0
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2121
J9 BMC CELL BIOL
JI BMC Cell Biol.
PD NOV 25
PY 2014
VL 15
AR 42
DI 10.1186/s12860 014 0042 4
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA AW5HC
UT WOS:000346305600001
PM 25420887
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chen, Y
   Wang, MY
   Chen, DM
   Wang, J
   Kang, N
AF Chen, Yi
   Wang, Mengyuan
   Chen, Demeng
   Wang, Jun
   Kang, Ning
TI Chromatin remodeling enzyme CHD7 is necessary for osteogenesis of human
   mesenchymal stem cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE MSC; Osteogenesis; CHD7; SMAD1; Enhancer
ID CHARGE SYNDROME; OSTEOBLAST DIFFERENTIATION; BONE FORMATION; MICE
AB Mesenchymal stem cells (MSCs) have great therapeutic potential due to their abilities to self renewal and their potential for differentiating into a variety of cell lineages. However, how to improve the differentiation efficiency of MSC into osteoblast remains a big challenge in the field of bone regenerative medicine. In current study, we identified a role of CHD7 in osteogenic differentiation of MSC. We showed that CHD7 expression in MSC could be induced by BMP2 or osteogenic induction medium. Depletion of CHD7 in MSC via siRNA knockdown resulted in inhibition of key osteogenic transcription factors and impaired osteogenic capability of MSC. Complementarily, overexpression of CHD7 in MSC led to increased osteogenic ability. Mechanistically, we demonstrated that CHD7 interacted with SMAD1, downstream factor of BMP signaling. BMP2 stimulated the binding of CHD7 to the enhancer region of SP7. Finally, CHD7 silencing MSC showed comprised osteogenic ability when cultured with scaffold in vivo. Overall, our study established a new epigenetic regulation of MSC osteogenic differentiation and provided a potential target for controlling MSC osteogenesis. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Chen, Yi; Wang, Mengyuan; Wang, Jun; Kang, Ning] Sichuan Univ, West China Sch Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
   [Chen, Demeng] Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Los Angeles, CA 90095 USA.
   [Wang, Jun] Sichuan Univ, West China Sch Stomatol, Dept Orthodont, Chengdu 610041, Peoples R China.
   [Kang, Ning] Sichuan Univ, West China Sch Stomatol, Dent Implant Ctr, Chengdu 610041, Peoples R China.
C3 Sichuan University; University of California System; University of
   California Los Angeles; Sichuan University; Sichuan University
RP Wang, J (通讯作者)，Sichuan Univ, West China Sch Stomatol, Dept Orthodont, Chengdu 610041, Peoples R China.; Kang, N (通讯作者)，Sichuan Univ, West China Sch Stomatol, Dent Implant Ctr, Chengdu 610041, Peoples R China.
EM wangjunv@scu.edu.cn; ningakang20088@163.com
RI Chen, Demeng/M 3694 2016
FU National Natural Science Foundation of China [81271718]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81271718). The authors declare no potential
   conflicts of interest with respect to the authorship and/or publication
   of this article.
CR [Anonymous], ONCOTARGET
   Bajpai R, 2010, NATURE, V463, P958, DOI 10.1038/nature08733
   Beederman M., 2013, J BIOMEDICAL SCI ENG, V6, P32, DOI DOI 10.4236/JBISE.2013.68A1004
   Budnick I, 2016, GENESIS
   Chen D. M., 2015, Journal of Tissue Science Engineering, V06, P1, DOI DOI 10.4172/2157 7552.1000154
   Chen DM, 2012, DEVELOPMENT, V139, P1522, DOI 10.1242/dev.076463
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Eslaminejad MB, 2013, CELL J, V15, P1
   Fujita K, 2014, MECH DEVELOP, V133, P126, DOI 10.1016/j.mod.2014.05.001
   He DY, 2016, NAT NEUROSCI, V19, P678, DOI 10.1038/nn.4258
   Liang Y, 2016, SCI REP UK, V6, DOI 10.1038/srep29479
   Liu YL, 2014, HUM MOL GENET, V23, P2145, DOI 10.1093/hmg/ddt610
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Pei M, 2009, DIFFERENTIATION, V78, P260, DOI 10.1016/j.diff.2009.08.001
   Schnetz MP, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001023
   Sharma S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147507
   Sperry ED, 2014, DEV DYNAM, V243, P1055, DOI [10.1002/dvdy.24156, 10.1002/DVDY.24156]
   van de Laar I, 2007, AM J MED GENET A, V143A, P2712, DOI 10.1002/ajmg.a.32008
   Wang M, 2011, OSTEOARTHR CARTILAGE, V19, P751, DOI 10.1016/j.joca.2011.03.004
   Yuan Q, 2014, J BONE MINER RES, V29, P693, DOI 10.1002/jbmr.2079
   Zentner GE, 2010, AM J MED GENET A, V152A, P674, DOI 10.1002/ajmg.a.33323
NR 21
TC 14
Z9 16
U1 0
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 30
PY 2016
VL 478
IS 4
BP 1588
EP 1593
DI 10.1016/j.bbrc.2016.08.161
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DX4ZS
UT WOS:000384390200016
PM 27586276
DA 2025 08 17
ER

PT J
AU Ye, ML
   Zhang, CH
   Zhu, LY
   Jia, W
   Shen, QS
AF Ye, Mengliang
   Zhang, Chunhui
   Zhu, Lingyu
   Jia, Wei
   Shen, Qingshan
TI Yak (Bos grunniens) bones collagen derived peptides stimulate
   osteoblastic proliferation and differentiation via the activation of
   Wnt/β catenin signaling pathway
SO JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE
LA English
DT Article
DE bioactive peptides; osteogenic; Wnt/beta catenin; EGFR; cross talk; yak
   bones
ID EPIDERMAL GROWTH FACTOR; CACO 2 CELL MONOLAYERS; GASTROINTESTINAL
   DIGESTION; TRANSEPITHELIAL TRANSPORT; ANTIHYPERTENSIVE PEPTIDE;
   INHIBITORY PEPTIDES; ANTIOXIDANT; CASEIN; STABILITY; PRO
AB BACKGROUND As the world's population is transitioning gradually to an ageing stage, the incidence of osteoporosis is increasing annually. Yak bone is one of the major components of Tibetan medicine and it has mainly been associated with an improvement in bone health, for example against osteoporosis. However, the functional bioactive ingredients and the underlying mechanisms are still unclear.
   RESULTS Sequential purification of yak bone hydrolysates was achieved by ultrafiltration, size exclusion chromatography, and semi preparative reverse phase high performance liquid chromatography. After this, 35 novel peptides were identified by mass spectrometry analysis, of which peptide GPAGPPGPIGNV (GP 12) displayed the highest osteoblast proliferation promoting activity, with an increase of 42.7% in cell growth. An in vitro stability study demonstrated that GP 12 was digested into smaller peptides (GP 9, GV 9, AV 10 and GP 11) after simulated gastrointestinal digestion and absorption (Caco 2 cell monolayers) experiments. However, some of them still can be absorbed intact through the (Caco 2 cell monolayers by a paracellular route (Papp: 5.36 +/  0.34 cm s( 1)). Flow cytometry results indicated that GP 12 enhanced osteoblastic proliferation by inducing the alteration of the cell cycle progression both from the G0/G1 to the S phase and from the S to the G2/M phase. Quantitative real time polymerase chain reaction (PCR) and western blot results revealed that GP 12 induced osteoblastic proliferation and differentiation in a dose response manner through the activation of a Wnt/beta catenin signaling pathway.
   CONCLUSION These findings highlighted that such peptides hold the promise of discovering candidates for functional and health promoting foods, which could be potentially used for the treatment of osteoporosis.
C1 [Ye, Mengliang; Zhang, Chunhui; Zhu, Lingyu; Jia, Wei; Shen, Qingshan] Chinese Acad Agr Sci, Inst Food Sci & Technol, 2 Yuan Ming Yuan West Rd, Beijing 100193, Peoples R China.
   [Zhu, Lingyu] Anhui Agr Univ, Sch Tea & Food Sci & Technol, Hefei, Peoples R China.
C3 Chinese Academy of Agricultural Sciences; Institute of Food Science &
   Technology, CAAS; Anhui Agricultural University
RP Zhang, CH (通讯作者)，Chinese Acad Agr Sci, Inst Food Sci & Technol, 2 Yuan Ming Yuan West Rd, Beijing 100193, Peoples R China.
EM dr_zch@163.com
RI Ye, Mengliang/AAB 4643 2020
OI Ye, Mengliang/0000 0001 9511 9757
FU Science and Technology Special Project of Tibet Autonomous Region
   (Characteristic Agro products Processing Technologies and Product
   Development Program) [XZ201801NA04]; Ten Thousand Experts Plan; National
   Agricultural Science and Technology Innovation Program; Yuandu Industry
   Leading Talent Program
FX This work was financially supported by the Science and Technology
   Special Project of Tibet Autonomous Region (Characteristic Agro products
   Processing Technologies and Product Development Program) (XZ201801NA04),
   the Ten Thousand Experts Plan, Yuandu Industry Leading Talent Program,
   and the National Agricultural Science and Technology Innovation Program.
CR Aaseth J, 2012, J TRACE ELEM MED BIO, V26, P149, DOI 10.1016/j.jtemb.2012.03.017
   Ao J, 2013, FOOD RES INT, V52, P334, DOI 10.1016/j.foodres.2013.03.036
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Chen X, 2017, MOL MED REP, V15, P2890, DOI 10.3892/mmr.2017.6327
   Del Angel Mosqueda C, 2015, HEAD FACE MED, V11, DOI 10.1186/s13005 015 0086 5
   Ding L, 2015, J AGR FOOD CHEM, V63, P8143, DOI 10.1021/acs.jafc.5b01824
   Fan FJ, 2017, J AGR FOOD CHEM, V65, P7179, DOI 10.1021/acs.jafc.7b02067
   Guturi KKN, 2012, J BIOL CHEM, V287, P18287, DOI 10.1074/jbc.M111.324798
   Hong J, 2014, J FUNCT FOODS, V10, P144, DOI 10.1016/j.jff.2014.05.014
   Hwang JH, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.115
   Jia HL, 2018, J CELL BIOCHEM, V2018, P1
   Jin Y, 2016, J PROTEOMICS, V141, P24, DOI 10.1016/j.jprot.2016.04.010
   Kim M, 2014, BMB REP, V47, P540, DOI 10.5483/BMBRep.2014.47.10.177
   Kwak JH, 2013, INT IMMUNOPHARMACOL, V17, P704, DOI 10.1016/j.intimp.2013.08.015
   Lee CH, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 64
   Li B, 2016, BIOMED PHARMACOTHER, V83, P1335, DOI 10.1016/j.biopha.2016.07.033
   Li KJ, 2018, BIOMED PHARMACOTHER, V99, P319, DOI 10.1016/j.biopha.2018.01.040
   Li L, 2017, SCI REP UK, V7, DOI 10.1038/srep45204
   Lin K, 2017, J FUNCT FOODS, V32, P266, DOI 10.1016/j.jff.2017.03.008
   Liu M, 2018, INT J BIOL MACROMOL, V107, P137, DOI 10.1016/j.ijbiomac.2017.08.151
   Martineau X, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180711
   Miguel M, 2008, MOL NUTR FOOD RES, V52, P1507, DOI 10.1002/mnfr.200700503
   Nongonierma AB, 2017, TRENDS FOOD SCI TECH, V69, P289, DOI 10.1016/j.tifs.2017.03.003
   Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092 8674(02)00963 7
   Ottewell PD, 2016, J BONE ONCOL, V5, P124, DOI 10.1016/j.jbo.2016.03.007
   Pan L, 2014, TOXICOL LETT, V225, P34, DOI 10.1016/j.toxlet.2013.11.029
   Pepe G, 2016, J FUNCT FOODS, V26, P494, DOI 10.1016/j.jff.2016.08.021
   Pigossi SC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111885
   Plonka AB, 2017, GENE THER, V24, P31, DOI 10.1038/gt.2016.73
   Quirós A, 2008, INT DAIRY J, V18, P279, DOI 10.1016/j.idairyj.2007.09.006
   Regazzo D, 2010, MOL NUTR FOOD RES, V54, P1428, DOI 10.1002/mnfr.200900443
   Sakata T, 2011, CHEM SOC REV, V40, P4318, DOI 10.1039/c1cs15019g
   Sangsawad P, 2018, FOOD CHEM, V251, P77, DOI 10.1016/j.foodchem.2018.01.047
   Sarmadi BH, 2010, PEPTIDES, V31, P1949, DOI 10.1016/j.peptides.2010.06.020
   Segura Campos M, 2011, FOOD REV INT, V27, P213, DOI 10.1080/87559129.2011.563395
   Shimizu K, 2010, J AGR FOOD CHEM, V58, P6960, DOI 10.1021/jf100388w
   Sun HY, 2009, BIOSCI BIOTECH BIOCH, V73, P293, DOI 10.1271/bbb.80473
   Xie NN, 2014, EUR FOOD RES TECHNOL, V239, P577, DOI 10.1007/s00217 014 2253 5
   Xu Z, 2019, J AGR FOOD CHEM, V67, P1572, DOI 10.1021/acs.jafc.8b06530
   Ye ML, 2019, RSC ADV, V9, P14627, DOI 10.1039/c9ra00945k
   Yin XH, 2015, EXP CELL RES, V335, P107, DOI 10.1016/j.yexcr.2015.04.020
   Zhang C, 2017, J FUNCT FOODS, V35, P224, DOI 10.1016/j.jff.2017.05.032
   [张鹤 Zhang He], 2011, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V27, P76
   Zhang XR, 2013, J BIOL CHEM, V288, P32229, DOI 10.1074/jbc.M113.463554
   Zhang YF, 2018, GENE, V650, P41, DOI 10.1016/j.gene.2018.01.054
   Zhou L, 2018, LIFE SCI, V212, P129, DOI 10.1016/j.lfs.2018.09.053
NR 46
TC 27
Z9 31
U1 7
U2 113
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 5142
EI 1097 0010
J9 J SCI FOOD AGR
JI J. Sci. Food Agric.
PD APR
PY 2020
VL 100
IS 6
BP 2600
EP 2609
DI 10.1002/jsfa.10286
EA FEB 2020
PG 10
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA LA0NT
UT WOS:000512828100001
PM 31975417
DA 2025 08 17
ER

PT J
AU Lee, WS
   Jeong, JH
   Lee, EG
   Choi, Y
   Kim, JH
   Kim, HR
   Yoo, WH
AF Lee, Won Seok
   Jeong, Ji Hyeon
   Lee, Eun Gyeong
   Choi, Yunjung
   Kim, Jin Hee
   Kim, Hang Rae
   Yoo, Wan Hee
TI Tacrolimus regulates endoplasmic reticulum stress mediated
   osteoclastogenesis and inflammation: In vitro and collagen induced
   arthritis mouse model
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE Endoplasmic reticulum stress; inflammation; osteoclastogenesis;
   rheumatoid arthritis; tacrolimus
ID RHEUMATOID ARTHRITIS; SYNOVIAL FIBROBLASTS; CYCLOSPORINE A; FK506;
   DIFFERENTIATION; ACTIVATION; PATHWAY; SAFETY; THAPSIGARGIN; MECHANISMS
AB Tacrolimus is an immunosuppressive drug that inhibits the release of inflammatory cytokines involved in rheumatoid arthritis development by blocking T cell activation. Endoplasmic reticulum stress, an imbalance between protein folding load and capacity leading to the accumulation of unfolded proteins in the endoplasmic reticulum lumen, has been implicated in rheumatoid arthritis and other inflammatory and metabolic diseases. We aimed to investigate the effect of tacrolimus on endoplasmic reticulum stress mediated osteoclastogenesis and inflammation and elucidate the underlying mechanisms. In vitro studies were performed using mouse bone marrow cells that were cultured with or without interleukin 1, thapsigargin, or tacrolimus to induce osteoclast differentiation. A mouse model of arthritis was established by immunizing mice with bovine type II collagen. Tacrolimus was orally administered to mice from day 20 to 45 following the initial immunization, and histopathological changes and expression of specific biomarkers of endoplasmic reticulum stress mediated inflammatory signaling pathways were examined. In vitro, tacrolimus inhibited receptor activator of nuclear factor B ligand mediated osteoclast formation augmented by interleukin 1, thapsigargin, or both. Furthermore, tacrolimus inhibited glucose regulated protein (GRP78), protein kinase R like endoplasmic reticulum kinase, inositol requiring enzyme 1 (IRE 1), and activating transcription factor 6 (ATF6) augmented by interleukin 1, thapsigargin, or both. Tacrolimus significantly ameliorated osteolysis and endoplasmic reticulum stress intensity in mice. Simultaneously, it reduced inflammatory cell infiltration, osteoclastogenesis, and inflammatory responses by inhibiting GRP78, IRE 1, and ATF6. These findings suggest that tacrolimus exhibits an anti inflammation effect in rheumatoid arthritis and might inhibit joint damage progression by inhibiting endoplasmic reticulum stress.
C1 [Lee, Won Seok; Jeong, Ji Hyeon; Lee, Eun Gyeong; Choi, Yunjung; Yoo, Wan Hee] Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Dept Internal Med, Biomed Res Inst,Res Inst,Clin Med,Div Rheumatol, Jeonju, South Korea.
   [Kim, Jin Hee] Seoul Natl Univ, Dept Anat & Cell Biol, Coll Med, Seoul, South Korea.
   [Kim, Jin Hee] Cheongju Univ, Dept Biomed Lab Sci, Coll Hlth Sci, Cheongu, South Korea.
   [Kim, Hang Rae] Seoul Natl Univ, Coll Med, Dept Anat & Cell Biol, Seoul, South Korea.
   [Kim, Hang Rae] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.
C3 Jeonbuk National University; Jeonbuk National University Hospital; Seoul
   National University (SNU); Cheongju University; Seoul National
   University (SNU); Seoul National University (SNU)
RP Yoo, WH (通讯作者)，Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Dept Internal Med, Biomed Res Inst,Res Inst,Clin Med,Div Rheumatol, Jeonju, South Korea.
EM ywhim@jbnu.ac.kr
RI choi, yunjung/LRC 4601 2024; Kim, Juhee/KFS 3069 2024; Kim,
   Hang Rae/J 5448 2012
OI Kim, Hang Rae/0000 0002 3983 6193; 
FU Chonbuk National University; Korean National Research Foundation
   [2015R1A2A2A01006120]
FX This paper was supported by the Korean National Research Foundation
   (2015R1A2A2A01006120) and research grants from Chonbuk National
   University awarded in 2014.
CR Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Choe JY, 2012, JOINT BONE SPINE, V79, P137, DOI 10.1016/j.jbspin.2011.03.018
   Gravallese EM, 2000, ARTHRITIS RHEUM US, V43, P2143, DOI 10.1002/1529 0131(200010)43:10<2143::AID ANR1>3.3.CO;2 J
   Han MK, 2003, J LEUKOCYTE BIOL, V73, P525, DOI 10.1189/jlb.0502256
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034
   Igarashi K, 2004, BONE, V35, P47, DOI 10.1016/j.bone.2004.02.009
   Jeong BC, 2010, BONE, V46, P479, DOI 10.1016/j.bone.2009.09.019
   Kawai S, 2006, RHEUMATOLOGY, V45, P441, DOI 10.1093/rheumatology/kei172
   KINO T, 1987, J ANTIBIOT, V40, P1256, DOI 10.7164/antibiotics.40.1256
   Kitahara K, 2012, INFLAMM RES, V61, P1385, DOI 10.1007/s00011 012 0541 8
   Kremer JM, 2003, ARTHRITIS RHEUM, V48, P2763, DOI 10.1002/art.11257
   Lau CS, 2015, INT J RHEUM DIS, V18, P685, DOI 10.1111/1756 185X.12754
   Lee EG, 2014, JOINT BONE SPINE, V81, P520, DOI 10.1016/j.jbspin.2014.04.012
   Lee WS, 2016, KOREAN J INTERN MED, V31, P779, DOI 10.3904/kjim.2015.066
   Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782
   MCDIARMID SV, 1993, TRANSPLANTATION, V55, P1328, DOI 10.1097/00007890 199306000 00022
   Miyata S, 2005, INFLAMM RES, V54, P1, DOI 10.1007/s00011 004 1318 5
   Miyazaki M, 2007, CLIN RHEUMATOL, V26, P231, DOI 10.1007/s10067 006 0287 1
   Murdoch C, 2005, J IMMUNOL, V175, P6257, DOI 10.4049/jimmunol.175.10.6257
   Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575 2585.2002
   Odegård S, 2006, ARTHRITIS RHEUM, V54, P68, DOI 10.1002/art.21548
   Park YJ, 2014, J KOREAN MED SCI, V29, P2, DOI 10.3346/jkms.2014.29.1.2
   Rogers TB, 1995, BIOSCIENCE REP, V15, P341, DOI 10.1007/BF01788366
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Schröder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   Scott DL, 2000, RHEUMATOLOGY, V39, P122, DOI 10.1093/rheumatology/39.2.122
   Scriven P, 2007, J MOL MED, V85, P331, DOI 10.1007/s00109 006 0150 5
   Shin YJ, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2921
   Singh JA, 2016, ARTHRITIS RHEUMATOL, V68, P1, DOI 10.1002/art.39480
   Smolen JS, 2014, ANN RHEUM DIS, V73, P492, DOI 10.1136/annrheumdis 2013 204573
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tang L, 2002, CELL BIOL INT, V26, P75, DOI 10.1006/cbir.2001.0812
   THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466
   Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347
   Welsing PMJ, 2001, ARTHRITIS RHEUM, V44, P2009, DOI 10.1002/1529 0131(200109)44:9<2009::AID ART349>3.0.CO;2 L
   Yamasaki S, 2005, ARTHRITIS RES THER, V7, P181, DOI 10.1186/ar1808
   Yocum DE, 2004, RHEUMATOLOGY, V43, P992, DOI 10.1093/rheumatology/keh155
   Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203
NR 39
TC 19
Z9 22
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1065 6995
EI 1095 8355
J9 CELL BIOL INT
JI Cell Biol. Int.
PD APR
PY 2018
VL 42
IS 4
BP 393
EP 402
DI 10.1002/cbin.10861
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA FZ0DI
UT WOS:000427236900002
PM 28833755
DA 2025 08 17
ER

PT J
AU Ban, YF
   Wang, Y
   Qiao, LM
   Zhang, CZ
   Wang, HR
   He, XH
   Jia, D
   Zheng, CJ
AF Ban, Yanfei
   Wang, Yang
   Qiao, Liming
   Zhang, Chengzhong
   Wang, Hongrui
   He, Xuhui
   Jia, Dan
   Zheng, Chengjian
TI Total lignans from Vitex negundo seeds attenuate osteoarthritis
   and their main component vitedoin A alleviates osteoclast
   differentiation by suppressing ERK/NFATc1 signaling
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE osteoarthritis; osteoclast; pharmacokinetic study; total lignans;
   vitedoin A; Vitex negundo seeds
ID VON FREY; PAIN; REPRODUCIBILITY; DIAGNOSIS; CARTILAGE; MODEL
AB The seeds of Vitex negundo have been used for inflammation related disease treatment in traditional medicine. This study focused on the anti osteoarthritis (OA) effects of the total lignans of V. negundo seeds (TOV) in monosodium iodoacetate induced osteoarthritis rats and its pharmacokinetic properties, as well as the effects and potential mechanism of its main components VN1 (6 hydroxy 4 (4 hydroxy 3 methoxy phenyl) 3 hydro xymethyl 7 methoxy 3,4 dihydro 2 naphthaldehydeb) and VN2 (vitedoin A) on receptor activator of NF kappa B ligand (RANKL) induced osteoclast differentiation in bone marrow macrophages (BMMs). TOV significantly attenuated osteoarthritis, leading to an increase in pain thresholds, improvement of knee articular cartilages and chondrocytes loss, and decreased total joint scores and serum levels of TNF alpha, interleukin 1 beta (IL 1 beta), and prostaglandin E2 (PGE2) in osteoarthritis rats. The half time (T 1/2) was 2.82 h and 1.33 h, and the bioavailability was 15.34% 21.89% and 16.29% 22.11%, for VN1 and VN2, respectively. VN2, rather than VN1, remarkably inhibited tartrate resistant acid phosphatase (TRAP) activity, reduced the number of TRAP positive multinuclear cells, diminished the formation of actin ring, and decreased mRNA levels of cathepsin K (CTSK), TRAP, nuclear factor of activated T cell 1 (NFATc1), and osteoclast associated receptor, as well as downregulated protein levels of p ERK (phosphorylated extracellular signal regulated kinase), TRAP, CTSK and NFATc1 in BMMs. These findings suggest TOV has promising therapeutic potential for OA treatment and VN2, in particular, attenuates osteoclast differentiation by suppressing ERK/NFATc1 signaling and actin ring, mainly accounting for the anti OA efficacy of TOV.
C1 [Ban, Yanfei; Zhang, Chengzhong; Wang, Hongrui; He, Xuhui; Jia, Dan; Zheng, Chengjian] Second Mil Med Univ, Naval Med Univ, Fac Pharm, Shanghai, Peoples R China.
   [Wang, Yang] Zhejiang Intlmed Co Ltd, Hangzhou, Peoples R China.
   [Qiao, Liming] Shanghai Changhai Hosp, Shanghai, Peoples R China.
   [Jia, Dan; Zheng, Chengjian] Second Mil Med Univ, Naval Med Univ, Fac Pharm, Shanghai 200433, Peoples R China.
C3 Naval Medical University; Naval Medical University; Naval Medical
   University
RP Jia, D; Zheng, CJ (通讯作者)，Second Mil Med Univ, Naval Med Univ, Fac Pharm, Shanghai 200433, Peoples R China.
EM jiadansmmu@163.com; cjzheng1984@126.com
RI Zheng, Chengjian/CAI 2262 2022; Zhang, Zhao/I 1162 2019
FU National Natural Science Foundation of China [82174081, 82004002];
   Shanghai Pujiang Program [21PJD082]
FX ACKNOWLEDGMENTS This work was supported by the National Natural Science
   Foundation of China (Grant Numbers: 82174081, 82004002) and the Shanghai
   Pujiang Program (Grant Number: 21PJD082).
CR Abramoff B, 2020, MED CLIN N AM, V104, P293, DOI 10.1016/j.mcna.2019.10.007
   Cui QH, 2020, MOLECULES, V25, DOI 10.3390/molecules25010183
   FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607
   GERECZSIMON EM, 1989, CLIN RHEUMATOL, V8, P467, DOI 10.1007/BF02032098
   Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917
   Hu D, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/721721
   Jing R, 2019, PHYTOMEDICINE, V58, DOI 10.1016/j.phymed.2019.152825
   Jüngel A, 2007, ARTHRITIS RHEUM, V56, P3564, DOI 10.1002/art.22980
   Kakadia N, 2019, J TRADIT COMPL MED, V9, P336, DOI 10.1016/j.jtcme.2018.03.001
   Katz JN, 2021, JAMA J AM MED ASSOC, V325, P568, DOI 10.1001/jama.2020.22171
   Lambert GA, 2009, J NEUROSCI METH, V177, P420, DOI 10.1016/j.jneumeth.2008.10.033
   Latourte A, 2020, NAT REV RHEUMATOL, V16, P673, DOI 10.1038/s41584 020 00518 6
   Lee SH, 2008, J BIOL CHEM, V283, P11526, DOI 10.1074/jbc.M708935200
   Li CL, 2018, MOLECULES, V23, DOI 10.3390/molecules23010173
   [李月婷 Li Yueting], 2017, [中草药, Chinese Traditional and Herbal Drugs], V48, P5117
   Linna Wang P. H., 2017, J HUBEI U MED, V36, P411, DOI [DOI 10.13819/J.ISSN.1006 9674.2017.05.006, 10.13819/j.issn.1006 9674.2017.05.006]
   Marker CL, 2012, METHODS MOL BIOL, V851, P239, DOI 10.1007/978 1 61779 561 9_18
   Moody HR, 2012, J ANAT, V221, P47, DOI 10.1111/j.1469 7580.2012.01513.x
   Neogi T, 2013, OSTEOARTHR CARTILAGE, V21, P1145, DOI 10.1016/j.joca.2013.03.018
   Ostergaard K, 1997, ARTHRITIS RHEUM, V40, P1766, DOI 10.1002/art.1780401007
   Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016
   Quicke JG, 2022, OSTEOARTHR CARTILAGE, V30, P196, DOI 10.1016/j.joca.2021.10.003
   RAGHOW G, 1981, J PHARM SCI US, V70, P1166, DOI 10.1002/jps.2600701022
   Saleem M, 2005, NAT PROD REP, V22, P696, DOI 10.1039/b514045p
   Tena B, 2012, CLIN J PAIN, V28, P318, DOI 10.1097/AJP.0b013e31822f0092
   Tsai HC, 2018, J PAIN RES, V11, P41, DOI 10.2147/JPR.S154038
   Wajed J, 2012, INT J RHEUMATOL, V2012, DOI 10.1155/2012/703138
   Wang YJ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.723988
   Xu MJ, 2008, J ETHNOPHARMACOL, V115, P483, DOI 10.1016/j.jep.2007.10.016
   Zheng CJ, 2015, PHYTOTHER RES, V29, P633, DOI 10.1002/ptr.5303
NR 30
TC 4
Z9 4
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD APR
PY 2023
VL 37
IS 4
BP 1422
EP 1434
DI 10.1002/ptr.7750
EA FEB 2023
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA D5KZ9
UT WOS:000928486200001
PM 36737044
DA 2025 08 17
ER

PT J
AU Rainsford, KD
AF Rainsford, K. D.
CA Consensus Report Grp Nimesulide
TI Nimesulide   a multifactorial approach to inflammation and pain:
   scientific and clinical consensus
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Article
DE analgesic; anti inflammatory; nimesulide; NSAID; side effects;
   sulphonanilide
ID DOUBLE BLIND; IN VITRO; EFFICACY; OSTEOARTHRITIS; INHIBITION;
   DICLOFENAC; NSAIDS; TRIAL; COX 2
AB Background: This paper summarises the outcome from a consensus meeting, held in Rome on 5 October 2005, that aimed to review the state of the art regarding the non steroidal anti inflammatory drug ( NSAID) nimesulide, with inflammatory reference to its chemical, pharmacokinetic, pharmacological and clinical characteristics.
   Scope: The meeting aimed to provide a continuous and up to date evaluation of the clinical and safety profile of nimesulide, and of its role in the treatment of inflammatory pain, in light of existing therapeutic alternatives, through a revision and critical discussion on the information available on the drug among authoritative experts in different fields of medical science.
   Findings: The members of the Consensus Report Group on Nimesulide ( CRGN) recognised that nimesulide is an NSAID which exerts its analgesic, anti inflammatory and anti pyretic activities thanks to unique chemical pyretic and pharmacokinetic characteristics, and to a multifactorial mechanism of action, which goes beyond its preferential inhibitory activity on the COX 2 enzyme. Nimesulide was found to be at least as effective, or superior, to placebo and other NSAIDs, with a particularly fast onset of analgesic action. The safety profile is in line with that expected from the class, with evidence of a better gastrointestinal safety profile.
   Conclusions: Based on the available evidence, the CRGN concluded that nimesulide remains an effective and safe therapeutic choice for the treatment of various painful inflammatory conditions, with a rapid onset of analgesic activity and an overall positive benefit/risk profile.
C1 Sheffield Hallam Univ, Ctr Biomed Res, Sheffield S1 1WB, S Yorkshire, England.
C3 Sheffield Hallam University
RP Rainsford, KD (通讯作者)，Sheffield Hallam Univ, Ctr Biomed Res, Howard St, Sheffield S1 1WB, S Yorkshire, England.
EM k.d.rainsford@shu.ac.uk
CR *AM COLL RHEM, 2005, ARTHRITIS RHEUM, V43, P1905
   Barracchini A, 1998, J PHARM PHARMACOL, V50, P1417, DOI 10.1111/j.2042 7158.1998.tb03369.x
   Bennett A, 2000, Expert Opin Pharmacother, V1, P277, DOI 10.1517/14656566.1.2.277
   Bennett A., 2001, Therapeutic Roles of COX 2 Inhibitors (Vane JR and Botting RM eds), P524
   Bernareggi A, 2005, NIMESULIDE   ACTIONS AND USES, P63, DOI 10.1007/3 7643 7410 1_2
   Bernareggi A, 1998, CLIN PHARMACOKINET, V35, P247, DOI 10.2165/00003088 199835040 00001
   Bevilacqua M, 2004, INT J CLIN PRACT, V58, P13, DOI 10.1111/j.1742 1241.2004.013_c.x
   Bianchi M, 2005, NIMESULIDE   ACTIONS AND USES, P245, DOI 10.1007/3 7643 7410 1_5
   Bianchi M, 2003, DRUGS, V63, P37, DOI 10.2165/00003495 200363001 00006
   Bianchi M, 2002, INT J CLIN PRACT, P11
   Bjarnason I, 2005, NIMESULIDE   ACTIONS AND USES, P315, DOI 10.1007/3 7643 7410 1_6
   Boelsterli UA, 2002, INT J CLIN PRACT, P30
   Conforti A, 2001, DRUG SAFETY, V24, P1081, DOI 10.2165/00002018 200124140 00006
   *EUR MED EV AG, CPMP172404
   Facchinetti F, 2001, DRUG TODAY, V37, P39
   Ferreira S H, 1993, Drugs, V46 Suppl 1, P1
   Huskisson EC, 1999, CURR THER RES CLIN E, V60, P253, DOI 10.1016/S0011 393X(99)80002 2
   JENOURE P, 1998, J CLIN RES, V1, P343
   Kriegel W, 2001, INT J CLIN PRACT, V55, P510
   Laporte JR, 2004, DRUG SAFETY, V27, P411, DOI 10.2165/00002018 200427060 00005
   Maroni A, 2005, NIMESULIDE   ACTIONS AND USES, P121, DOI 10.1007/3 7643 7410 1_3
   Pohjolainen T, 2000, SPINE, V25, P1579, DOI 10.1097/00007632 200006150 00019
   Pulkkinen MO, 2001, DRUG TODAY, V37, P31
   Rainsford KD, 2005, NIMESULIDE   ACTIONS AND USES, P1, DOI 10.1007/3 7643 7410 1_1
   Rainsford KD, 2005, NIMESULIDE   ACTIONS AND USES, P133, DOI 10.1007/3 7643 7410 1_4
   Sandrini G, 2001, DRUGS TODAY, V37, P21
   Shah AA, 2001, GUT, V48, P339, DOI 10.1136/gut.48.3.339
   Swingle K., 1985, ANTIINFLAMMATORY ANT, V3, P105
   Traversa G, 2003, BMJ BRIT MED J, V327, P18, DOI 10.1136/bmj.327.7405.18
   Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563
   Wober W, 1999, RHEUMATOLOGY, V38, P33, DOI 10.1093/rheumatology/38.suppl_1.33
NR 31
TC 56
Z9 63
U1 1
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300 7995
EI 1473 4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD JUN
PY 2006
VL 22
IS 6
BP 1161
EP 1170
DI 10.1185/030079906X104849
PG 10
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 062PP
UT WOS:000238957300015
PM 16846549
DA 2025 08 17
ER

PT J
AU Wei, F
   Neal, CJ
   Sakthivel, TS
   Fu, YF
   Omer, M
   Adhikary, A
   Ward, S
   Ta, KM
   Moxon, S
   Molinari, M
   Asiatico, J
   Kinzel, M
   Yarmolenko, SN
   Cheong, VS
   Orlovskaya, N
   Ghosh, R
   Seal, S
   Coathup, M
AF Wei, Fei
   Neal, Craig J.
   Sakthivel, Tamil Selvan
   Fu, Yifei
   Omer, Mahmoud
   Adhikary, Amitava
   Ward, Samuel
   Ta, Khoa Minh
   Moxon, Samuel
   Molinari, Marco
   Asiatico, Jackson
   Kinzel, Michael
   Yarmolenko, Sergey N.
   Cheong, Vee San
   Orlovskaya, Nina
   Ghosh, Ranajay
   Seal, Sudipta
   Coathup, Melanie
TI A novel approach for the prevention of ionizing radiation induced bone
   loss using a designer multifunctional cerium oxide nanozyme
SO BIOACTIVE MATERIALS
LA English
DT Article
DE Ionizing radiation; Osteoporosis; Nanozyme; Cerium oxide; Bone strength;
   Bone resorption
ID SUPEROXIDE DISMUTASE MNSOD; RADIOPROTECTIVE GENE THERAPY; LENS
   EPITHELIAL CELLS; FACTOR KAPPA B; OXIDATIVE STRESS; PLASMID/LIPOSOMES
   PROTECTS; FREE RADICALS; UP REGULATION; IN VIVO; IRRADIATION
AB The disability, mortality and costs due to ionizing radiation (IR) induced osteoporotic bone fractures are sub stantial and no effective therapy exists. Ionizing radiation increases cellular oxidative damage, causing an imbalance in bone turnover that is primarily driven via heightened activity of the bone resorbing osteoclast. We demonstrate that rats exposed to sublethal levels of IR develop fragile, osteoporotic bone. At reactive surface sites, cerium ions have the ability to easily undergo redox cycling: drastically adjusting their electronic con figurations and versatile catalytic activities. These properties make cerium oxide nanomaterials fascinating. We show that an engineered artificial nanozyme composed of cerium oxide, and designed to possess a higher fraction of trivalent (Ce3+) surface sites, mitigates the IR induced loss in bone area, bone architecture, and strength. These investigations also demonstrate that our nanozyme furnishes several mechanistic avenues of protection and selectively targets highly damaging reactive oxygen species, protecting the rats against IR induced DNA damage, cellular senescence, and elevated osteoclastic activity in vitro and in vivo. Further, we reveal that our nanozyme is a previously unreported key regulator of osteoclast formation derived from macrophages while also directly targeting bone progenitor cells, favoring new bone formation despite its exposure to harmful levels of IR in vitro. These findings open a new approach for the specific prevention of IR induced bone loss using synthesis  mediated designer multifunctional nanomaterials.
C1 [Wei, Fei; Omer, Mahmoud; Seal, Sudipta; Coathup, Melanie] Univ Cent Florida, Coll Med, Dept Internal Med, Biionix Cluster, Orlando, FL 32816 USA.
   [Neal, Craig J.; Fu, Yifei; Seal, Sudipta] Univ Cent Florida, Coll Med, Nanosci Technol Ctr NSTC, Adv Mat Proc & Anal Ctr,Mat Sci & Engn, Orlando, FL USA.
   [Sakthivel, Tamil Selvan] CMC Mat, 870 North Commons Dr, Aurora, IL USA.
   [Adhikary, Amitava; Ward, Samuel] Oakland Univ, Dept Chem, Rochester, MI USA.
   [Ta, Khoa Minh; Moxon, Samuel; Molinari, Marco] Univ Huddersfield, Sch Appl Sci, Dept Chem Sci, Huddersfield, England.
   [Asiatico, Jackson; Kinzel, Michael; Orlovskaya, Nina; Ghosh, Ranajay] Univ Cent Florida, Dept Mech & Aerosp Engn, Orlando, FL USA.
   [Yarmolenko, Sergey N.] North Carolina A&T Univ, Engn Res Ctr Revolutionizing Biomat, Greensboro, NC USA.
   [Cheong, Vee San] Univ Sheffield, Insigneo Inst In Sil Med, Dept Automatic Control & Syst Engn, Sheffield S1 3JD, England.
C3 State University System of Florida; University of Central Florida; State
   University System of Florida; University of Central Florida; Oakland
   University; University of Huddersfield; State University System of
   Florida; University of Central Florida; University of North Carolina;
   North Carolina A&T State University; University of Sheffield
RP Coathup, M (通讯作者)，Univ Cent Florida, Coll Med, Dept Internal Med, Biionix Cluster, Orlando, FL 32816 USA.
EM fei.wei@ucf.edu; melanie.coathup@ucf.edu
RI Seal, Sudipta/A 7698 2012; Molinari, Marco/O 3405 2015; Mermer,
   Omer/AAR 8964 2021; Neal, Craig/JRX 7870 2023; molinari,
   marco/O 3405 2015; Wei, Fei/ITZ 4717 2023
OI Ta, Khoa Minh/0000 0002 8070 2891; Adhikary,
   Amitava/0000 0001 9024 9579; ghosh, ranajay/0000 0002 8419 9621; Neal,
   Craig/0000 0001 7288 4229; Moxon, Samuel/0000 0002 2972 5975; molinari,
   marco/0000 0001 7144 6075; 
FU University of Central Florida (ER Award) [25089A06]; National Science
   Foundation (NSF) Major Research Instrumentation (MRI) Program
   [EP/R513234/1]; University of Huddersfield (UoH) EPSRC DTP competition
   2018 19 [EP/R513234/1]; Vice Chancellor's Scholarship Scheme; NIH NCI
   [R01CA045424]; Research Excellence Fund (REF); Center for Biomedical
   Research; National Science Foundation (NSF) instrumentation award
   [CHE 1920110]; National Aeronautics and Space Administration
   [80NSSC21M0309]; EPSRC [2117565, EP/R029431/1] Funding Source: UKRI
FX The authors acknowledge funding from the University of Central Florida
   (ER Award: #25089A06). We would also like to acknowledge the National
   Science Foundation (NSF) Major Research Instrumentation (MRI) Program
   (Grant ID: ECCS:1726636) for the XPS measurements presented in this
   manuscript. MM acknowledges the University of Huddersfield (UoH)
   EPSRC DTP competition 2018 19 (EP/R513234/1) for funding SM, and the
   Vice Chancellor's Scholarship Scheme for funding KMT. Analysis was
   performed on the Orion computing facility at the UoH. Calculations were
   run on the ARCHER and ARCHER2 UK National Supercomputing Services via
   our membership of the UK HEC Materials Chemistry Consortium (MCC; EPSRC
   EP/L000202, EP/R029431). AA acknowledges NIH NCI (Grant R01CA045424),
   Research Excellence Fund (REF), and Center for Biomedical Research for
   support. AA also acknowledges the National Science Foundation (NSF)
   instrumentation award (CHE 1920110). JA's work was supported by the
   National Aeronautics and Space Administration [grant No. 80NSSC21M0309]
   issued through the NASA Office of STEM Engagement.
CR Alwood JS, 2015, J INTERF CYTOK RES, V35, P480, DOI 10.1089/jir.2014.0152
   Aoki M, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014 015 0406 8
   Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321
   Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012
   Barkam S, 2017, J PHYS CHEM C, V121, P20039, DOI 10.1021/acs.jpcc.7b05725
   Barr T., QUANTITIVE SURFACE A, P19428
   BIELSKI BHJ, 1985, J PHYS CHEM REF DATA, V14, P1041, DOI 10.1063/1.555739
   BLOCHL PE, 1994, PHYS REV B, V50, P17953, DOI 10.1103/PhysRevB.50.17953
   Blomlie V, 1996, AM J ROENTGENOL, V167, P1205, DOI 10.2214/ajr.167.5.8911181
   Borek C, 2004, J NUTR, V134, p3207S, DOI 10.1093/jn/134.11.3207S
   Bozec A, 2017, PFLUG ARCH EUR J PHY, V469, P517, DOI 10.1007/s00424 017 1952 8
   Brambila C, 2021, J PHYS CHEM C, V125, P10077, DOI 10.1021/acs.jpcc.1c01221
   Buonanno M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021540
   Buonanno M, 2011, RADIAT RES, V175, P405, DOI 10.1667/RR2461.1
   Cao X, 2011, P NATL ACAD SCI USA, V108, P1609, DOI 10.1073/pnas.1015350108
   Carpenter M, 2005, GENE THER, V12, P685, DOI 10.1038/sj.gt.3302468
   Celardo I, 2011, NANOSCALE, V3, P1411, DOI 10.1039/c0nr00875c
   Chatgilialoglu C, 2021, FREE RADICAL RES, V55, P384, DOI 10.1080/10715762.2021.1876855
   Coates P, 2008, J PATHOL, V214, P610, DOI 10.1002/path.2321
   Colon J, 2010, NANOMED NANOTECHNOL, V6, P698, DOI 10.1016/j.nano.2010.01.010
   Culotta VC, 2006, BBA MOL CELL RES, V1763, P747, DOI 10.1016/j.bbamcr.2006.05.003
   Curi MM, 2016, J ORAL MAXIL SURG, V74, P190, DOI 10.1016/j.joms.2015.07.009
   Das S, 2018, NANOSCALE, V10, P21069, DOI 10.1039/c8nr04640a
   Das S, 2012, BIOMATERIALS, V33, P7746, DOI 10.1016/j.biomaterials.2012.07.019
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Donaubauer AJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176377
   Donneys A, 2016, BONE, V84, P245, DOI 10.1016/j.bone.2015.12.051
   Dorr RT, 1998, SEMIN RADIAT ONCOL, V8, P10
   Dou C, 2021, BIOACT MATER, V6, P4697, DOI 10.1016/j.bioactmat.2021.04.038
   Drager J, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.4
   Dudarev SL, 1998, PHYS REV B, V57, P1505, DOI 10.1103/PhysRevB.57.1505
   Epperly MW, 2002, RADIAT RES, V157, P568, DOI 10.1667/0033 7587(2002)157[0568:MSDSIR]2.0.CO;2
   Epperly MW, 2001, RADIAT RES, V155, P2, DOI 10.1667/0033 7587(2001)155[0002:MORICE]2.0.CO;2
   Epperly MW, 2000, GENE THER, V7, P1011, DOI 10.1038/sj.gt.3301207
   Epperly MW, 2005, IN VIVO, V19, P997
   Epperly MW, 2004, IN VIVO, V18, P401
   Epperly MW, 2001, INT J CANCER, V96, P11, DOI 10.1002/1097 0215(20010220)96:1<11::AID IJC2>3.0.CO;2 R
   Epperly MW, 1999, RADIAT ONCOL INVESTI, V7, P331, DOI 10.1002/(SICI)1520 6823(1999)7:6<331::AID ROI3>3.0.CO;2 M
   Fan LH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/239356
   Fan M, 2007, CANCER RES, V67, P3220, DOI 10.1158/0008 5472.CAN 06 2728
   Fekete N, 2015, TISSUE ENG PART C ME, V21, P112, DOI [10.1089/ten.TEC.2013.0766, 10.1089/ten.tec.2013.0766]
   Filippi A, 2019, RSC ADV, V9, P11077, DOI 10.1039/c9ra00642g
   Gal TJ, 2000, ARCH OTOLARYNGOL, V126, P1124, DOI 10.1001/archotol.126.9.1124
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Soares CBG, 2019, REV ASSOC MED BRAS, V65, P902, DOI 10.1590/1806 9282.65.6.902
   Grdina D J, 2000, Drug Metabol Drug Interact, V16, P237
   Guo HL, 2003, RADIAT RES, V159, P361, DOI 10.1667/0033 7587(2003)159[0361:PORIOC]2.0.CO;2
   Gurina T.S., 2021, HISTOLOGY STAINING
   Hall EJ., 2019, Radiobiology for the radiologist, VEighth edition
   Halliwell B, 2015, FREE RADICAL BIO MED
   Halliwell B, 2021, CHEM SOC REV, V50, P8355, DOI 10.1039/d1cs00044f
   He JB, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.645140
   Heckert EG, 2008, BIOMATERIALS, V29, P2705, DOI 10.1016/j.biomaterials.2008.03.014
   Henglein A., 1991, BER BUNSEN PHYS CHEM, V95, P451, DOI DOI 10.1002/BBPC.19910950346
   Hirst SM, 2009, SMALL, V5, P2848, DOI 10.1002/smll.200901048
   Ighodaro OM, 2018, ALEX J MED, V54, P287, DOI 10.1016/j.ajme.2017.09.001
   Kadivar F, 2020, REP PRACT ONCOL RADI, V25, P206, DOI 10.1016/j.rpor.2019.12.023
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Ke XX, 2019, ONCOL LETT, V18, P5871, DOI 10.3892/ol.2019.10956
   KEY LL, 1994, BONE, V15, P431, DOI 10.1016/8756 3282(94)90821 4
   Kim H, 2017, J BONE MINER RES, V32, P397, DOI 10.1002/jbmr.2974
   Kim HJ, 2012, INT J RADIAT ONCOL, V84, P694, DOI 10.1016/j.ijrobp.2012.01.021
   Klug F, 2013, CANCER CELL, V24, P589, DOI 10.1016/j.ccr.2013.09.014
   KOONG AC, 1994, CANCER RES, V54, P1425
   Korsvik C, 2007, CHEM COMMUN, P1056, DOI 10.1039/b615134e
   Kouvaris JR, 2007, ONCOLOGIST, V12, P738, DOI 10.1634/theoncologist.12 6 738
   KRESSE G, 1994, PHYS REV B, V49, P14251, DOI 10.1103/PhysRevB.49.14251
   Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169
   Kresse G, 1999, PHYS REV B, V59, P1758, DOI 10.1103/PhysRevB.59.1758
   Lee JH, 2001, BBA GEN SUBJECTS, V1526, P191, DOI 10.1016/S0304 4165(01)00126 X
   Leger AJ, 2010, J BONE MINER METAB, V28, P510, DOI 10.1007/s00774 010 0171 6
   Li J, 2007, PEDIATR TRANSPLANT, V11, P379, DOI 10.1111/j.1399 3046.2006.00663.x
   Li JH, 2018, ADV SCI, V5, DOI 10.1002/advs.201700678
   Liechtenstein, 1995, Phys Rev B Condens Matter, V52, pR5467, DOI 10.1103/PhysRevB.52.R5467
   Liochev SI, 2000, J BIOL CHEM, V275, P38482, DOI 10.1074/jbc.M007891200
   Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903
   Lu B, 2019, BIOFABRICATION, V11, DOI 10.1088/1758 5090/ab0676
   Luo JC, 2023, BIOL TRACE ELEM RES, V201, P865, DOI 10.1007/s12011 022 03168 9
   Ma J., 2020, ACTUAL CHIMIQUE, V450
   McHugh D, 2018, J CELL BIOL, V217, P65, DOI 10.1083/jcb.201708092
   Meziani L, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1494488
   Meziani L, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02120 2017
   Molinari M, 2019, ACS APPL BIO MATER, V2, P1098, DOI 10.1021/acsabm.8b00709
   Molinari M, 2012, J PHYS CHEM C, V116, P7073, DOI 10.1021/jp300576b
   Monson LA, 2016, ANN PLAS SURG, V77, P164, DOI 10.1097/SAP.0000000000000276
   Muroya Y, 2006, RADIAT RES, V165, P485, DOI 10.1667/RR3540.1
   Niu JL, 2011, J PHARMACOL EXP THER, V338, P53, DOI 10.1124/jpet.111.179978
   Nojiri H, 2011, J BONE MINER RES, V26, P2682, DOI 10.1002/jbmr.489
   Oh D, 2014, RADIAT ONCOL J, V32, P213, DOI 10.3857/roj.2014.32.4.213
   OLIVER PM, 1993, MODEL SIMUL MATER SC, V1, P755, DOI 10.1088/0965 0393/1/5/015
   Perdew JP, 1997, PHYS REV LETT, V78, P1396, DOI 10.1103/PhysRevLett.77.3865
   Perullini M., 2013, Nanomaterials: A Danger or a Promise, P307, DOI DOI 10.1007/978 1 4471 4213 3_12
   Peyssonnaux C, 2007, J IMMUNOL, V178, P7516, DOI 10.4049/jimmunol.178.12.7516
   Pinto AT, 2016, SCI REP UK, V6, DOI 10.1038/srep18765
   Pirmohamed T, 2010, CHEM COMMUN, V46, P2736, DOI 10.1039/b922024k
   Poli G., 1993, FREE RADICALS BASIC
   REDDAN JR, 1993, EXP EYE RES, V56, P543, DOI 10.1006/exer.1993.1068
   Reddan JR, 2003, EXP EYE RES, V76, P49, DOI 10.1016/S0014 4835(02)00256 7
   Regan JN, 2014, P NATL ACAD SCI USA, V111, P8673, DOI 10.1073/pnas.1324290111
   Regulski MJ, 2017, WOUNDS, V29, P168
   RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041
   RUBIN P, 1995, INT J RADIAT ONCOL, V33, P99, DOI 10.1016/0360 3016(95)00095 G
   Ryan SV, 1996, J CLIN PHARMACOL, V36, P365, DOI 10.1002/j.1552 4604.1996.tb04214.x
   Sakurai T, 2007, J RADIAT RES, V48, P515, DOI 10.1269/jrr.07012
   Salvetti A, 2020, MAT SCI ENG C MATER, V115, DOI 10.1016/j.msec.2020.111113
   Sayle TXT, 2013, NANOSCALE, V5, P6063, DOI 10.1039/c3nr00917c
   Scharpfenecker M, 2012, RADIOTHER ONCOL, V105, P313, DOI 10.1016/j.radonc.2012.08.021
   Selvaraj V, 2015, BIOMATERIALS, V59, P160, DOI 10.1016/j.biomaterials.2015.04.025
   Seminko V, 2021, J PHYS CHEM C, V125, P4743, DOI 10.1021/acs.jpcc.1c00382
   Shao J, 2015, IN VITRO CELL DEV AN, V51, P808, DOI 10.1007/s11626 015 9895 x
   SIMS JR, 1976, HIGH TEMP SCI, V8, P99
   Singh VK, 2019, EXPERT OPIN DRUG SAF, V18, P1077, DOI 10.1080/14740338.2019.1666104
   Song GC, 2021, CATALYSTS, V11, DOI 10.3390/catal11091123
   Southgate TD, 2006, J GENE MED, V8, P557, DOI 10.1002/jgm.890
   Spitz DR, 2004, CANCER METAST REV, V23, P311, DOI 10.1023/B:CANC.0000031769.14728.bc
   Suzuki T, 2001, J AM CERAM SOC, V84, P2007, DOI 10.1111/j.1151 2916.2001.tb00950.x
   Symington AR, 2020, J PHYS CHEM C, V124, P23210, DOI 10.1021/acs.jpcc.0c07437
   Symington AR, 2020, J PHYS CHEM C, V124, P3577, DOI 10.1021/acs.jpcc.9b09046
   Tchanque Fossuo CN, 2018, ANN PLAS SURG, V80, P176, DOI 10.1097/SAP.0000000000001209
   TRAVIS EL, 1980, INT J RADIAT ONCOL, V6, P345, DOI 10.1016/0360 3016(80)90145 5
   Turrens JF, 2003, J PHYSIOL LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478
   TURRISI AT, 1986, CANCER TREAT REP, V70, P1389
   UMEGAKI K, 1995, FREE RADICAL BIO MED, V19, P493, DOI 10.1016/0891 5849(95)00033 T
   Urlaub KM, 2018, J ORAL MAXIL SURG, V76, P2660, DOI 10.1016/j.joms.2018.05.013
   van Uden P, 2008, BIOCHEM J, V412, P477, DOI 10.1042/BJ20080476
   van Uden P, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001285
   Vignery A, 2000, INT J EXP PATHOL, V81, P291, DOI 10.1046/j.1365 2613.2000.00164.x
   Vujaskovic Z, 2012, INT J RADIAT ONCOL, V84, pS683, DOI 10.1016/j.ijrobp.2012.07.1824
   Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105 2896.2005.00338.x
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Wang YY, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4909
   Watson GW, 1996, J CHEM SOC FARADAY T, V92, P433, DOI 10.1039/ft9969200433
   Wei F, 2021, MAT SCI ENG C MATER, V126, DOI 10.1016/j.msec.2021.112145
   Wei F, 2021, MAT SCI ENG C MATER, V124, DOI 10.1016/j.msec.2021.112041
   Willey JS, 2011, CLIN REV BONE MINER, V9, P54, DOI 10.1007/s12018 011 9092 8
   Wissing MD, 2015, CURR OSTEOPOROS REP, V13, P140, DOI 10.1007/s11914 015 0266 z
   Xu C, 2014, NPG ASIA MATER, V6, DOI 10.1038/am.2013.88
   Xue Y, 2011, J PHYS CHEM C, V115, P4433, DOI 10.1021/jp109819u
   Yahara Y, 2020, NAT CELL BIOL, V22, P49, DOI 10.1038/s41556 019 0437 8
   Yasui K, 2006, INFLAMM RES, V55, P359, DOI 10.1007/s00011 006 5195 y
   Yu ZZ, 2020, CHEM COMMUN, V56, P15513, DOI 10.1039/d0cc05427e
   Yuan K, 2020, INT J NANOMED, V15, P6355, DOI 10.2147/IJN.S257741
   Zhang Z, 2020, SCI ADV MATER, V12, P93, DOI 10.1166/sam.2020.3594
NR 143
TC 58
Z9 59
U1 11
U2 153
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, DONGCHENG
   DISTRICT 100009, PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD MAR
PY 2023
VL 21
BP 547
EP 565
DI 10.1016/j.bioactmat.2022.09.011
PG 19
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 6M1BH
UT WOS:000888611400001
PM 36185749
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tauro, M
   Laghezza, A
   Loiodice, F
   Agamennone, M
   Campestre, C
   Tortorella, P
AF Tauro, Marilena
   Laghezza, Antonio
   Loiodice, Fulvio
   Agamennone, Mariangela
   Campestre, Cristina
   Tortorella, Paolo
TI Arylamino methylene bisphosphonate derivatives as bone seeking matrix
   metalloproteinase inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Matrix metalloproteinase inhibitors; Zinc binding group; Bone targeting;
   Bisphosphonates
ID DRUG LIKE MOLECULES; BIOLOGICAL EVALUATION; BINDING AFFINITIES; POTENT
   INHIBITORS; ACCURATE DOCKING; IN VITRO; DESIGN; METASTASIS; RESORPTION;
   GLIDE
AB The complexity of matrix metalloproteinase inhibitors (MMPIs) design derives from the difficulty in carefully addressing their inhibitory activity towards the MMP isoforms involved in many pathological conditions. In particular, specific metalloproteinases, such as MMP 2 and MMP 9, are key regulators of the 'vicious cycle' occurring between tumor metastases growth and bone remodeling. In an attempt to devise new approaches to selective inhibitor derivatives, we describe novel bisphosphonate bone seeking MMP inhibitors (BP MMPIs), capable to be selectively targeted and to overcome undesired side effects of broad spectrum MMPIs.
   In vitro activity (IC50 values) for each inhibitor was determined against MMP 2,  8,  9 and  14, because of their relevant role in skeletal development and renewal. The results show that BP MMPIs reached IC50 values of enzymatic inhibition in the low micromolar range. Computational studies, used to rationalize some trends in the observed inhibitory profiles, suggest a possible differential binding mode in MMP 2 that explains the selective inhibition of this isoform.
   In addition, survival assay was conducted on J774 cell line, a well known model system used to evaluate the structure activity relationship of BPs for inhibiting bone resorption. The resulting data, confirming the specific activity of BP MMPIs, and their additional proved propensity to bind hydroxyapatite powder in vitro, suggest a potential use of BP MMPIs in skeletal malignancies. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Tauro, Marilena; Laghezza, Antonio; Loiodice, Fulvio; Tortorella, Paolo] Univ Aldo Moro Bari, Dipartimento Farm Sci Farmaco, I 70126 Bari, Italy.
   [Agamennone, Mariangela; Campestre, Cristina] Univ G DAnnunzio, Dipartimento Farm, I 66013 Chieti, Italy.
C3 Universita degli Studi di Bari Aldo Moro; G d'Annunzio University of
   Chieti Pescara
RP Tortorella, P (通讯作者)，Univ Aldo Moro Bari, Dipartimento Farm Sci Farmaco, Via Orabona 4, I 70126 Bari, Italy.
EM paolo.tortorella@uniba.it
RI Laghezza, Antonio/F 7420 2014; Agamennone, Mariangela/J 2916 2012
OI CAMPESTRE, Cristina/0000 0001 5870 7509; Agamennone,
   Mariangela/0000 0001 5198 0051; Laghezza, Antonio/0000 0001 6221 6155
FU Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)
   [JERJPC_003]
FX The authors are grateful to Dr. Maria Teresa Rubino for preliminary
   experiments. This work was accomplished thanks to the financial support
   of the Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR
   2007 JERJPC_003).
CR Agamennone M, 2005, EUR J MED CHEM, V40, P271, DOI 10.1016/j.ejmech.2004.10.013
   [Anonymous], 2012, MAESTR V 9 3 5 EP V
   Balakrishna A, 2011, EUR J MED CHEM, V46, P1798, DOI 10.1016/j.ejmech.2011.02.038
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Biasone A, 2007, BIOORGAN MED CHEM, V15, P791, DOI 10.1016/j.bmc.2006.10.047
   Cai J, 2012, EUR J MED CHEM, V55, P409, DOI 10.1016/j.ejmech.2012.07.053
   Campestre C, 2006, BIOORG MED CHEM LETT, V16, P20, DOI 10.1016/j.bmcl.2005.09.057
   Clezardin P, 2007, CLIN EXP METASTAS, V24, P599, DOI 10.1007/s10585 007 9112 8
   Folgueras AR, 2008, J BIOL CHEM, V283, P9465, DOI 10.1074/jbc.M709522200
   Forlani G, 2008, J AGR FOOD CHEM, V56, P3193, DOI 10.1021/jf800029t
   Frant J, 2011, CHEMMEDCHEM, V6, P1471, DOI 10.1002/cmdc.201100153
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Greenwood JR, 2010, J COMPUT AID MOL DES, V24, P591, DOI 10.1007/s10822 010 9349 1
   Greig IR, 2006, J MED CHEM, V49, P7487, DOI 10.1021/jm051236m
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Jacobsen FE, 2007, CHEMMEDCHEM, V2, P152, DOI 10.1002/cmdc.200600204
   Jahnke W, 2010, CHEMMEDCHEM, V5, P770, DOI 10.1002/cmdc.201000016
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Kotsikorou E, 2005, J MED CHEM, V48, P6128, DOI 10.1021/jm058220g
   Lenevich S, 2011, ANAL BIOCHEM, V408, P316, DOI 10.1016/j.ab.2010.08.030
   Leu CT, 2006, BONE, V38, P628, DOI 10.1016/j.bone.2005.07.023
   Lin YS, 2012, J MED CHEM, V55, P3201, DOI 10.1021/jm201657x
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Lynch CC, 2011, BONE, V48, P44, DOI 10.1016/j.bone.2010.06.007
   MURAKAMI H, 1995, BONE, V17, P137, DOI 10.1016/S8756 3282(95)00150 6
   MURPHY G, 1995, METHOD ENZYMOL, V248, P470
   Nemeth JA, 2002, J NATL CANCER I, V94, P17
   Nicolotti O, 2012, EUR J MED CHEM, V58, P368, DOI 10.1016/j.ejmech.2012.09.036
   Pochetti G, 2006, J MED CHEM, V49, P923, DOI 10.1021/jm050787+
   Rao BG, 2005, CURR PHARM DESIGN, V11, P295, DOI 10.2174/1381612053382115
   Rubino MT, 2011, ARCH PHARM, V344, P557, DOI 10.1002/ardp.201000350
   Rubino MT, 2011, CHEMMEDCHEM, V6, P1258, DOI 10.1002/cmdc.201000540
   Rubino MT, 2009, CHEMMEDCHEM, V4, P352, DOI 10.1002/cmdc.200800324
   Russell R. G. G., 2010, J BIOMED MATER RES B, V92B, P149
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822 007 9133 z
   Skiles JW, 2001, CURR MED CHEM, V8, P425, DOI 10.2174/0929867013373417
   Topliss J. G., 1983, J MED CHEM
   Varghese S, 2006, FRONT BIOSCI LANDMRK, V11, P2949, DOI 10.2741/2024
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Wu MS, 2004, SYNTHETIC COMMUN, V34, P1393, DOI 10.1081/SCC 120030688
   Yadav RK, 2011, CURR MED CHEM, V18, P1704, DOI 10.2174/092986711795471329
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
NR 44
TC 38
Z9 41
U1 0
U2 22
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968 0896
EI 1464 3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD NOV 1
PY 2013
VL 21
IS 21
BP 6456
EP 6465
DI 10.1016/j.bmc.2013.08.054
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 228DC
UT WOS:000325164500020
PM 24071448
DA 2025 08 17
ER

PT J
AU Bousson, V
   Leturcq, T
   Ea, HK
   Hauger, O
   Mehsen Cetre, N
   Hamzé, B
   Parlier Cuau, C
   Laredo, JD
   Schaeverbeke, T
   Orcel, P
AF Bousson, Valerie
   Leturcq, Tifenn
   Ea, Hang Korng
   Hauger, Olivier
   Mehsen Cetre, Nadia
   Hamze, Bassam
   Parlier Cuau, Caroline
   Laredo, Jean Denis
   Schaeverbeke, Thierry
   Orcel, Philippe
TI An open label, prospective, observational study of the efficacy of
   bisphosphonate therapy for painful osteoid osteoma
SO EUROPEAN RADIOLOGY
LA English
DT Article
DE Osteoid osteoma; Pain; Bisphosphonate; CT; MRI
ID INTRAVENOUS ZOLEDRONIC ACID; MEDICAL MANAGEMENT; LASER ABLATION;
   BONE TUMORS; FOLLOW UP; PAMIDRONATE; CHILDREN; SAFETY
AB To assess the efficacy of bisphosphonate therapy on bone pain in patients with osteoid osteoma (OO) (main objective), and to describe bisphosphonate induced changes in nidus mineralisation and regional bone marrow oedema (BMO).
   A prospective, observational study was conducted from 2011 to 2014. Patients with risk factors for complications of percutaneous or surgical ablation or recurrence after ablation, were offered once monthly intravenous bisphosphonate treatment until significant pain alleviation was achieved.
   We included 23 patients. The first two patients received pamidronate and the next 21 zoledronic acid (mean, 2.95 infusions per patient). Bisphosphonate therapy was successful in 19 patients (83%), whose mean pain visual analogue scale score decreased by 76.7%; this pain relieving effect persisted in 17 patients (74%) with a mean follow up time of 36 months. Computed tomography (CT) demonstrated a mean nidus density increase of 177.7% (p = 0.001). By magnetic resonance imaging (MRI), mean decreases were 38.4% for BMO surface area and 30.3% for signal intensity (p = 0.001 and p = 0.000, respectively).
   In 17/23 patients with painful OO managed conservatively with bisphosphonates, long term final success was achieved. Bisphosphonates may accelerate the spontaneous healing of OO.
   aEuro cent 19/23 patients with OO managed with bisphosphonates experienced significant pain relief
   aEuro cent Pain relief was sustained in 17/23 patients, mean follow up of 36 months
   aEuro cent CT demonstrated a significant increase in nidus mineralisation
   aEuro cent MRI demonstrated a significant decrease in bone marrow oedema
   aEuro cent Bisphosphonate therapy may accelerate the spontaneous healing of OO.
C1 [Bousson, Valerie; Hamze, Bassam; Parlier Cuau, Caroline; Laredo, Jean Denis] Hop Lariboisiere, AP HP, Serv Radiol Osteoarticulaire, 2 Rue Ambroise Pare, F 75010 Paris, France.
   [Bousson, Valerie; Leturcq, Tifenn; Ea, Hang Korng; Parlier Cuau, Caroline; Laredo, Jean Denis; Orcel, Philippe] Univ Paris Diderot, Sorbonne Paris Cite, F 75205 Paris, France.
   [Leturcq, Tifenn; Ea, Hang Korng; Orcel, Philippe] Hop Lariboisiere, AP HP, Serv Rhumatol, 2 Rue Ambroise Pare, F 75010 Paris, France.
   [Hauger, Olivier] CHU Pellegrin Bordeaux, Serv Imagerie Diagnost & Therapeut Adulte, Pl Amelie Raba Leon, F 33076 Bordeaux, France.
   [Mehsen Cetre, Nadia; Schaeverbeke, Thierry] CHU Pellegrin Bordeaux, Serv Rhumatol, Pl Amelie Raba Leon, F 33076 Bordeaux, France.
C3 Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Lariboisiere Fernand Widal   APHP; Universite
   Paris Cite; Universite Paris Cite; Assistance Publique Hopitaux Paris
   (APHP); Hopital Universitaire Lariboisiere Fernand Widal   APHP; CHU
   Bordeaux; CHU Bordeaux
RP Bousson, V (通讯作者)，Hop Lariboisiere, AP HP, Serv Radiol Osteoarticulaire, 2 Rue Ambroise Pare, F 75010 Paris, France.; Bousson, V (通讯作者)，Univ Paris Diderot, Sorbonne Paris Cite, F 75205 Paris, France.
EM valerie.bousson@lrb.aphp.fr
RI ; Ea, HK/P 5527 2016
OI ORCEL, Philippe/0000 0001 7028 1133; Ea, HK/0000 0002 2393 7475
CR Aiba H, 2014, ANTICANCER RES, V34, P3721
   Arzoo K, 2001, NEW ENGL J MED, V345, P225, DOI 10.1056/NEJM200107193450318
   BOONEKAMP PM, 1986, BONE MINER, V1, P27
   Brown JJ, 2009, J PEDIATR ENDOCR MET, V22, P55
   Chapurlat RD, 1997, J BONE MINER RES, V12, P1746, DOI 10.1359/jbmr.1997.12.10.1746
   Coleman RE, 2011, BONE, V49, P71, DOI 10.1016/j.bone.2011.02.003
   Cornelis F, 2014, BONE, V58, P11, DOI 10.1016/j.bone.2013.10.004
   Coulier B, 2005, JBR BTR, V88, P43
   de Chadarévian JP, 2007, PEDIATR DEVEL PATHOL, V10, P358, DOI 10.2350/06 07 0133.1
   DEBERG JC, 1995, LANCET, V346, P350, DOI 10.1016/S0140 6736(95)92228 8
   Fournier PG, 2010, NEOPLASIA, V12, P571, DOI 10.1593/neo.10282
   Fuchs S, 2014, EUR J RADIOL, V83, P696, DOI 10.1016/j.ejrad.2013.12.018
   Gangi A, 2007, RADIOLOGY, V242, P293, DOI 10.1148/radiol.2421041404
   Goto T, 2011, ARCH ORTHOP TRAUM SU, V131, P619, DOI 10.1007/s00402 010 1179 z
   Hogler W, 2004, J PEDIATR US, V145, P701, DOI 10.1016/j.jpeds.2004.06.066
   Igarashi K, 1997, PROSTAG LEUKOTR ESS, V56, P121, DOI 10.1016/S0952 3278(97)90508 1
   Ilyas I, 2002, CAN J SURG, V45, P435
   Jaffe HL, 1935, ARCH SURG CHICAGO, V31, P709, DOI 10.1001/archsurg.1935.01180170034003
   Jayakumar P, 2007, SKELET RADIOL S1, V36, P72
   Klein M J., 2002, Pathology and genetics of tumours of soft tissue and bone, V5, P260
   KLEIN MH, 1992, SKELETAL RADIOL, V21, P23
   KNEISL JS, 1992, J BONE JOINT SURG AM, V74A, P179, DOI 10.2106/00004623 199274020 00004
   MAKLEY JT, 1982, LANCET, V2, P42
   Mungo DV, 2002, J ORTHOP RES, V20, P159, DOI 10.1016/S0736 0266(01)00065 1
   Munns CF, 2007, BONE, V41, P366, DOI 10.1016/j.bone.2007.05.002
   Rybak LD, 2010, AM J ROENTGENOL, V195, pW293, DOI 10.2214/AJR.10.4192
   Touraine S, 2014, RADIOLOGY, V271, P795, DOI 10.1148/radiol.14131629
   VICKERS CW, 1959, J BONE JOINT SURG AM, V41, P357, DOI 10.2106/00004623 195941020 00018
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Yanagawa T, 2001, CLIN RADIOL, V56, P877, DOI 10.1053/crad.2001.0795
   Yokouchi M, 2014, PEDIATRIC REP, V6, P16, DOI 10.4081/pr.2014.5311
NR 31
TC 15
Z9 15
U1 1
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0938 7994
EI 1432 1084
J9 EUR RADIOL
JI Eur. Radiol.
PD FEB
PY 2018
VL 28
IS 2
BP 478
EP 486
DI 10.1007/s00330 017 5019 1
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA FQ7XH
UT WOS:000418576300004
PM 28884296
DA 2025 08 17
ER

PT J
AU Leskelä, HV
   Olkku, A
   Lehtonen, S
   Mahonen, A
   Koivunen, J
   Turpeinen, M
   Uusitalo, J
   Pelkonen, O
   Kangas, L
   Selander, K
   Lehenkari, P
AF Leskelä, Hannu Ville
   Olkku, Anu
   Lehtonen, Siri
   Mahonen, Anitta
   Koivunen, Jussi
   Turpeinen, Miia
   Uusitalo, Jouko
   Pelkonen, Olavi
   Kangas, Lauri
   Selander, Katri
   Lehenkari, Petri
TI Estrogen receptor alpha genotype confers interindividual variability of
   response to estrogen and testosterone in mesenchymal stem cell derived
   osteoblasts
SO BONE
LA English
DT Article
DE mesenchymal stem cells; osteoblasts; estrogen receptor alpha; sex
   steroids; polymorphism
ID HORMONE REPLACEMENT THERAPY; BONE MINERAL DENSITY; EARLY POSTMENOPAUSAL
   WOMEN; SEX STEROIDS; GENE POLYMORPHISM; FRACTURE RISK; DIFFERENTIATION;
   OSTEOPOROSIS; EXPRESSION; MASS
AB Hormone replacement therapy is effectively used to prevent postmenopausal bone loss. Variation in response to the therapy is, however, frequently seen. In addition, the direct effects of sex steroids on isolated human bone marrow stromal cells have been reported to vary depending on the donor, but the biological mechanisms are not understood. The aim of this study was to investigate the effects of 17 beta estradiol (E2) and testosterone in human bone marrow derived mesenchymal stem cell (MSC) cultures from both female and male donors of various ages. The osteoblast differentiation capacity and activity of the MSCs were quantified in vitro by measuring alkaline phosphatase activity and calcium deposition. We show here that also the osteoblast responses of MSCs to sex hormones vary widely depending on the donor. When the results from all donors were analyzed together, treatment with E2 increased calcium deposition significantly by MSCs of both sexes but ALP activity only in the male MSCs. Testosterone had no effect on ALP activity nor calcium deposition in either sex. To further characterize the individual variation, we investigated estrogen receptor alpha PvuII restriction site polymorphism with PCR. Restriction fragment length polymorphism was assigned as P or non P, P signifying the absence of the restriction site. Our results indicate that higher basal osteoblast differentiation capacity of MSCs is associated with the presence of the P allele in females, whereas higher response to sex steroids treatment is associated with the non P allele. These results could help explain the contradictory effects of E2 on osteoblasts in vitro and might also provide new insights to understanding the differences in responses to hormone replacement therapy. (C) 2006 Elsevier Inc. All rights reserved.
C1 Univ Oulu, Dept Surg, Clin Res Ctr, FI 90014 Oulu, Finland.
   Univ Oulu, Dept Anat & Cell Biol, Oulu, Finland.
   Univ Oulu, Dept Pharmacol & Toxicol, Oulu, Finland.
   Univ Oulu, Dept Chem, Oulu, Finland.
   Univ Kuopio, Dept Med Biochem, FIN 70211 Kuopio, Finland.
   Hormos Med Ltd, Turku, Finland.
   Univ Alabama, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA.
C3 University of Oulu; University of Oulu; University of Oulu; University
   of Oulu; University of Eastern Finland; University of Alabama System;
   University of Alabama Birmingham
RP Leskelä, HV (通讯作者)，Univ Oulu, Dept Surg, Clin Res Ctr, FI 90014 Oulu, Finland.
EM haleskel@paju.oulu.fi
RI ; Lehenkari, Petri/O 3009 2016; Pelkonen, Olavi/F 7740 2012; Selander,
   Katri/GWM 8685 2022
OI Koivunen, Jussi/0000 0001 6425 1640; Turpeinen,
   Miia/0000 0002 1420 4632; Lehenkari, Petri/0000 0002 0055 5183;
   Lehtonen, Siri/0000 0002 5578 8232
CR Arts J, 1997, ENDOCRINOLOGY, V138, P5067, DOI 10.1210/en.138.11.5067
   Behre HM, 1997, J CLIN ENDOCR METAB, V82, P2386, DOI 10.1210/jc.82.8.2386
   Bord S, 2000, BONE, V27, P397, DOI 10.1016/S8756 3282(00)00336 7
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   CASTAGNOLI A, 1987, NUCLEIC ACIDS RES, V15, P866, DOI 10.1093/nar/15.2.866
   Compston JE, 2001, PHYSIOL REV, V81, P419, DOI 10.1152/physrev.2001.81.1.419
   Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358
   Delaveyne Bitbol R, 1999, J BONE MINER RES, V14, P376, DOI 10.1359/jbmr.1999.14.3.376
   Deng HW, 1998, HUM GENET, V103, P576, DOI 10.1007/s004390050872
   ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003 4819 102 3 319
   HANSEN MA, 1991, BMJ BRIT MED J, V303, P961, DOI 10.1136/bmj.303.6808.961
   Herrington DM, 2002, CIRCULATION, V105, P1879, DOI 10.1161/01.CIR.0000016173.98826.88
   Holzer G, 2002, J ORTHOP RES, V20, P281, DOI 10.1016/S0736 0266(01)00092 4
   Ioannidis JPA, 2004, JAMA J AM MED ASSOC, V292, P2105, DOI 10.1001/jama.292.17.2105
   Ioannidis JPA, 2002, J BONE MINER RES, V17, P2048, DOI 10.1359/jbmr.2002.17.11.2048
   Ireland DC, 2002, J CELL BIOCHEM, V86, P251, DOI 10.1002/jcb.10228
   Katzburg S, 1999, BONE, V25, P667, DOI 10.1016/S8756 3282(99)00225 2
   KEETING PE, 1991, J BONE MINER RES, V6, P297
   Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043 2760(01)00377 0
   Khosla S, 2004, J CLIN ENDOCR METAB, V89, P1808, DOI 10.1210/jc.2003 031448
   Komulainen M, 2000, OSTEOPOROSIS INT, V11, P211, DOI 10.1007/s001980050283
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261
   LAURIE CC, 1994, GENETICS, V138, P379
   Leskelä HV, 2003, BIOCHEM BIOPH RES CO, V311, P1008, DOI 10.1016/j.bbrc.2003.10.095
   LINDSAY R, 1976, LANCET, V1, P1038
   O'Neil JP, 1998, MUTAT RES REV MUTAT, V411, P179, DOI 10.1016/S1383 5742(98)00013 1
   Ongphiphadhanakul B, 2000, CLIN ENDOCRINOL, V52, P581, DOI 10.1046/j.1365 2265.2000.00979.x
   Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756 3282(97)00276 7
   Rao LG, 2003, BIOL PHARM BULL, V26, P936, DOI 10.1248/bpb.26.936
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Riggs BL, 2003, OSTEOPOROSIS INT, V14, P728, DOI 10.1007/s00198 003 1437 9
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Salmén T, 2000, J BONE MINER RES, V15, P2479, DOI 10.1359/jbmr.2000.15.12.2479
   Salmén T, 2000, J BONE MINER RES, V15, P315, DOI 10.1359/jbmr.2000.15.2.315
   SCHEVEN BAA, 1992, BIOCHEM BIOPH RES CO, V186, P54, DOI 10.1016/S0006 291X(05)80774 0
   Sims NA, 2002, BONE, V30, P18, DOI 10.1016/S8756 3282(01)00643 3
   SLEMENDA C, 1987, J CLIN INVEST, V80, P1261, DOI 10.1172/JCI113201
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Solomon KR, 2000, J BONE MINER RES, V15, P2391, DOI 10.1359/jbmr.2000.15.12.2391
   Syed FA, 2005, J BONE MINER RES, V20, P1992, DOI 10.1359/JBMR.050713
   Waters KM, 2001, J CELL BIOCHEM, V83, P448, DOI 10.1002/jcb.1242
   Wiren KM, 2002, J ENDOCRINOL, V175, P683, DOI 10.1677/joe.0.1750683
NR 43
TC 50
Z9 58
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD NOV
PY 2006
VL 39
IS 5
BP 1026
EP 1034
DI 10.1016/j.bone.2006.05.003
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 099HP
UT WOS:000241584500008
PM 16782420
DA 2025 08 17
ER

PT J
AU Yoshida, A
   Fujiwara, T
   Uotani, K
   Morita, T
   Kiyono, M
   Yokoo, S
   Hasei, J
   Nakata, E
   Kunisada, T
   Ozaki, T
AF Yoshida, Aki
   Fujiwara, Tomohiro
   Uotani, Koji
   Morita, Takuya
   Kiyono, Masahiro
   Yokoo, Suguru
   Hasei, Joe
   Nakata, Eiji
   Kunisada, Toshiyuki
   Ozaki, Toshifumi
TI Clinical and Functional Significance of Intracellular and Extracellular
   microRNA 25 3p in Osteosarcoma
SO ACTA MEDICA OKAYAMA
LA English
DT Article
DE microRNA; circulating microRNA; osteosarcoma; prognosis
ID EXOSOME MEDIATED TRANSFER; BREAST CANCER; PROGNOSTIC BIOMARKER;
   COLORECTAL CANCER; STEM CELLS; METASTASIS; INVASION; BIOGENESIS;
   MECHANISM; RELEVANCE
AB Although there is considerable evidence indicating that the dysregulation of microRNAs (miRNAs) in malignant tumors plays a role in tumor development, the overall function of miRNAs and their clinicopathological significance are not well understood. In this retrospective analysis of 45 biopsy specimens from osteosarcoma (OS) patients, we investigated the functional and clinical significance of miR 25 3p in OS, which we previously identified as a highly expressed miRNA in OS patients' serum. We observed that miR 25 3p dysregulation in human OS tissues was negatively correlated with the clinical prognosis, whereas the expression level of its target gene, Dickkopf WNT Signaling Pathway Inhibitor 3 (DKK3), was positively correlated with the clinical prognosis. Endogenous miR 25 3p upregulation promoted tumor growth, invasion, and drug resistance, which was consistent with DKK3 silencing in OS cells. In addition, secretory miR 25 3p was embedded in tumor derived exosomes, where it promoted capillary formation and the invasion of vascular endothelial cells. Overall, our results show that miR 25 3p has intracellular and extracellular oncogenic functions as well as clinicopathological relevance in OS, indicating its potential as a novel diagnostic and therapeutic tool for the clinical management of this disease.
C1 [Yoshida, Aki; Fujiwara, Tomohiro; Uotani, Koji; Morita, Takuya; Kiyono, Masahiro; Yokoo, Suguru; Hasei, Joe; Nakata, Eiji; Kunisada, Toshiyuki; Ozaki, Toshifumi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Orthopaed Surg, Okayama 7008558, Japan.
   [Kunisada, Toshiyuki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Med Mat Musculoskeletal Reconstruct, Okayama 7008558, Japan.
C3 Okayama University; Okayama University
RP Fujiwara, T (通讯作者)，Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Orthopaed Surg, Okayama 7008558, Japan.
EM tomomedvn@gmail.com
RI Hasei, Joe/LDE 8424 2024
OI Hasei, Joe/0000 0002 4028 0786
FU Japan Orthopaedics and Traumatology Research Foundation [311]; Uehara
   Memorial Foundation; JSPS KAKENHI [16K20054, 16H05449]; Grants in Aid
   for Scientific Research [16K20054, 16H05449] Funding Source: KAKEN
FX We thank the member of the Central Research Laboratory of the Okayama
   University Medical School for the technical support for the isolation
   and validation of exosomes and histological analysis. The authors are
   supported by the Japan Orthopaedics and Traumatology Research Foundation
   (Grant no. 311), the Uehara Memorial Foundation, and JSPS KAKENHI Grants
   nos. 16K20054 and 16H05449.
CR Allison Daniel C., 2012, Sarcoma, V2012, P704872, DOI 10.1155/2012/704872
   Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304
   Cortez MA, 2011, NAT REV CLIN ONCOL, V8, P467, DOI 10.1038/nrclinonc.2011.76
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Esquela Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fujiwara T, 2017, ONCOTARGET, V8, P33375, DOI 10.18632/oncotarget.16498
   Fujiwara T, 2014, STEM CELLS, V32, P959, DOI 10.1002/stem.1618
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Kosaka N, 2010, CANCER SCI, V101, P2087, DOI 10.1111/j.1349 7006.2010.01650.x
   Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821
   Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359
   LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502
   Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Schwarzenbach H, 2014, NAT REV CLIN ONCOL, V11, P145, DOI 10.1038/nrclinonc.2014.5
   Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066
   Singh R, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 256
   Toiyama Y, 2013, JNCI J NATL CANCER I, V105, P849, DOI 10.1093/jnci/djt101
   Tominaga N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7716
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376
NR 27
TC 49
Z9 51
U1 0
U2 2
PU OKAYAMA UNIV MED SCHOOL
PI OKAYAMA
PA EDITORIAL OFFICE, ACTA MEDICA OKAYAMA OKAYAMA UNIVERSITY MEDICAL SCHOOL
   2 5 1 SHIKATA CHO, KITA KU, OKAYAMA, 700 8558, JAPAN
SN 0386 300X
J9 ACTA MED OKAYAMA
JI Acta Med. Okayama
PD APR
PY 2018
VL 72
IS 2
BP 165
EP 174
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GK1MK
UT WOS:000435880900009
PM 29674765
DA 2025 08 17
ER

PT J
AU Wu, PH
   Lin, MY
   Huang, TH
   Lee, TC
   Lin, SY
   Chen, CH
   Kuo, MC
   Chiu, YW
   Chang, JM
   Hwang, SJ
AF Wu, Ping Hsun
   Lin, Ming Yen
   Huang, Teng Hui
   Lee, Tien Ching
   Lin, Sung Yen
   Chen, Chung Hwan
   Kuo, Mei Chuan
   Chiu, Yi Wen
   Chang, Jer Ming
   Hwang, Shang Jyh
TI Kidney Function Change and All Cause Mortality in Denosumab Users with
   and without Chronic Kidney Disease
SO JOURNAL OF PERSONALIZED MEDICINE
LA English
DT Article
DE denosumab; adherence; mortality; renal function; chronic kidney disease
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; HIP FRACTURE; FRAGILITY
   FRACTURES; OSTEOPOROSIS; PERSISTENCE; THERAPY; PREVENTION; DIALYSIS;
   DISCONTINUATION
AB Denosumab is approved for osteoporosis treatment in subjects with and without chronic kidney disease (CKD). Confirmation is required for its safety, treatment adherence, renal function effect, and mortality in patients with CKD. A retrospective cohort study was conducted to compare new users of denosumab in terms of their two year drug adherence in all participants (overall cohort) and CKD participants (CKD subcohort), which was defined as baseline estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m(2). The eGFR was calculated using the 2021 CKD EPI (Chronic Kidney Disease Epidemiology Collaboration) equation. We defined high adherence (HA) users as receiving three or four doses and low adherence (LA) users as receiving one or two doses. All cause mortality was analyzed using Kaplan Meier curves and Cox regression models. In total, there were 1142 subjects in the overall cohort and 500 subjects in the CKD subcohort. HA users had better renal function status at baseline than LD users in the overall cohort. A decline in renal function was only observed among LD users in the overall cohort. In the CKD subcohort, no baseline renal function difference or renal function decline was demonstrated. The all cause mortality rate of HA users was lower than LA users in both the overall cohort and CKD. A randomized control trial is warranted to target this unique population to confirm our observations.
C1 [Wu, Ping Hsun; Lin, Ming Yen; Huang, Teng Hui; Kuo, Mei Chuan; Chiu, Yi Wen; Chang, Jer Ming; Hwang, Shang Jyh] Kaohsiung Med Univ Hosp, Div Nephrol, Dept Internal Med, Kaohsiung 80756, Taiwan.
   [Wu, Ping Hsun; Chiu, Yi Wen; Chang, Jer Ming; Hwang, Shang Jyh] Kaohsiung Med Univ, Coll Med, Fac Med, Kaohsiung 80708, Taiwan.
   [Lee, Tien Ching; Lin, Sung Yen; Chen, Chung Hwan] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Orthoped, Kaohsiung 80756, Taiwan.
   [Lee, Tien Ching; Lin, Sung Yen; Chen, Chung Hwan] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Coll Med, Orthopaed Res Ctr, Kaohsiung 80708, Taiwan.
   [Lee, Tien Ching; Lin, Sung Yen; Chen, Chung Hwan] Kaohsiung Med Univ, Regenerat Med & Cell Therapy Res Ctr, Kaohsiung 80708, Taiwan.
   [Lee, Tien Ching; Lin, Sung Yen; Chen, Chung Hwan] Kaohsiung Med Univ, Dept Orthoped, Coll Med, Kaohsiung 80708, Taiwan.
   [Lee, Tien Ching; Lin, Sung Yen; Chen, Chung Hwan] Kaohsiung Municipal Tatung Hosp, Dept Orthoped, Kaohsiung 80145, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University Hospital;
   Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University Hospital; Kaohsiung Medical University; Kaohsiung
   Medical University Hospital; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Municipal
   Ta Tung Hospital
RP Lee, TC (通讯作者)，Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Orthoped, Kaohsiung 80756, Taiwan.; Lee, TC (通讯作者)，Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Coll Med, Orthopaed Res Ctr, Kaohsiung 80708, Taiwan.; Lee, TC (通讯作者)，Kaohsiung Med Univ, Regenerat Med & Cell Therapy Res Ctr, Kaohsiung 80708, Taiwan.; Lee, TC (通讯作者)，Kaohsiung Med Univ, Dept Orthoped, Coll Med, Kaohsiung 80708, Taiwan.; Lee, TC (通讯作者)，Kaohsiung Municipal Tatung Hosp, Dept Orthoped, Kaohsiung 80145, Taiwan.
EM 970392@kmuh.org.tw; mingyenlin3@gmail.com; sfestg3329@gmail.com;
   tn916943@gmail.com; tony8501031@gmail.com; hwan@kmu.edu.tw;
   mechku@kmu.edu.tw; chiuyiwen@kmu.edu.tw; jemich@kmu.edu.tw;
   sjhwang@kmu.edu.tw
RI Lin, Ming/A 8637 2010; Hwang, Shang Jyh/C 7270 2009; Chen,
   Chung Hwan/D 4036 2009; Wu, Ping Hsun/S 8746 2017; Lee,
   Tien Ching/ABF 4544 2021; Chiu, Yi Wen/D 5041 2009
OI Lee, Tien Ching/0000 0002 1510 8079; Lin, Ming Yen/0000 0002 8194 4833;
   Lin, Sung Yen/0000 0002 4191 2183; Chang, Jer Ming/0000 0003 0071 1710;
   Chen, Chung Hwan/0000 0001 8941 4792; Wu, Ping Hsun/0000 0003 1021 8161;
   Kuo, Mei Chuan/0000 0003 0244 7685; 
FU Ministry of Science and Technology, Taiwan [MOST 109 2314 B 037 088];
   Kaohsiung Municipal Ta Tung Hospital, Taiwan [kmtth 109 R006]; Kaohsiung
   Medical University Hospital, Taiwan [KMUH DK(B)110003 1, KMUH110 0M13,
   KMUH110 0M12, KMUH109 9R16, KMUH108 8M11, KMUH106 6T03, KMU DK(B)110003,
   KMU Q108024];  [KMU TC108B04];  [KMUTC111IFSP0]
FX FundingThe funding sources did not play any role in the design and
   conduct of the study, collection, management, analysis, and
   interpretation of the data, and preparation, review, or approval of the
   manuscript. The study was funded by grants from the Ministry of Science
   and Technology, Taiwan (MOST 109 2314 B 037 088), Kaohsiung Municipal
   Ta Tung Hospital, Taiwan (kmtth 109 R006), Kaohsiung Medical University
   Hospital, Taiwan (KMUH DK(B)110003 1, KMUH110 0M13, KMUH110 0M12,
   KMUH109 9R16, KMUH108 8M11, and KMUH106 6T03), and Kaohsiung Medical
   University (KMU DK(B)110003 and KMU Q108024).
CR Alem AM, 2000, KIDNEY INT, V58, P396, DOI 10.1046/j.1523 1755.2000.00178.x
   Behanova M, 2019, CALCIFIED TISSUE INT, V105, P630, DOI 10.1007/s00223 019 00611 3
   Bolland MJ, 2010, J CLIN ENDOCR METAB, V95, P1174, DOI 10.1210/jc.2009 0852
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Broadwell A, 2021, J CLIN ENDOCR METAB, V106, P397, DOI 10.1210/clinem/dgaa851
   Chen CL, 2020, OSTEOPOROSIS INT, V31, P1507, DOI 10.1007/s00198 020 05391 3
   Colón Emeric CS, 2010, J BONE MINER RES, V25, P91, DOI 10.1359/jbmr.090704
   Cummings SR, 2018, J BONE MINER RES, V33, P190, DOI 10.1002/jbmr.3337
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Durden E, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0316 5
   Fahrleitner Pammer A, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0351 2
   Goldenstein PT, 2015, CURR OPIN NEPHROL HY, V24, P317, DOI 10.1097/MNH.0000000000000131
   Hadji P, 2015, OSTEOPOROSIS INT, V26, P2479, DOI 10.1007/s00198 015 3164 4
   Hsu CY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186846
   Jamal SA, 2011, J BONE MINER RES, V26, P1829, DOI 10.1002/jbmr.403
   Kazama JJ, 2017, CLIN EXP NEPHROL, V21, P46, DOI 10.1007/s10157 016 1368 3
   Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001
   Kim SM, 2016, J BONE MINER RES, V31, P1803, DOI 10.1002/jbmr.2862
   Klawansky S, 2003, OSTEOPOROSIS INT, V14, P570, DOI 10.1007/s00198 003 1435 y
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kobayashi K, 2020, ASIAN SPINE J, V14, P453, DOI 10.31616/asj.2019.0230
   Kunizawa K, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 59143 8
   Migliaccio S, 2017, J ENDOCRINOL INVEST, V40, P1321, DOI 10.1007/s40618 017 0701 3
   Miller PD, 2008, CLIN J AM SOC NEPHRO, V3, pS140, DOI 10.2215/CJN.02430508
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Miller PD, 2009, CLEV CLIN J MED, V76, P715, DOI 10.3949/ccjm.76a.08108
   Morizio P, 2018, ANN PHARMACOTHER, V52, P1031, DOI 10.1177/1060028018768808
   Najar MS, 2017, SAUDI J KIDNEY DIS T, V28, P538, DOI 10.4103/1319 2442.206439
   Nickolas TL, 2006, J AM SOC NEPHROL, V17, P3223, DOI 10.1681/ASN.2005111194
   Papapoulos S, 2015, OSTEOPOROSIS INT, V26, P2773, DOI 10.1007/s00198 015 3234 7
   Pimentel A, 2017, KIDNEY INT, V92, P1343, DOI 10.1016/j.kint.2017.07.021
   Sidibé A, 2019, JBMR PLUS, V3, P45, DOI 10.1002/jbm4.10067
   Silverman SL, 2015, OSTEOPOROSIS INT, V26, P361, DOI 10.1007/s00198 014 2871 6
   Silverman SL, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0491 z
   Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   Yu SF, 2019, BMC GERIATR, V19, DOI 10.1186/s12877 019 1278 9
NR 38
TC 3
Z9 3
U1 2
U2 6
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2075 4426
J9 J PERS MED
JI J. Pers. Med.
PD FEB
PY 2022
VL 12
IS 2
AR 185
DI 10.3390/jpm12020185
PG 11
WC Health Care Sciences & Services; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine
GA ZK5WM
UT WOS:000763058500001
PM 35207673
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tang, H
   Du, YX
   Tan, ZJ
   Li, DP
   Xie, J
AF Tang, Hao
   Du, Yuxuan
   Tan, Zejiu
   Li, Dongpeng
   Xie, Jiang
TI METTL14 mediated HOXA5 m<SUP>6</SUP>A modification alleviates
   osteoporosis via promoting WNK1 transcription to suppress
   NLRP3 dependent macrophage pyroptosis
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE HOXA5; METTL14; NLRP3; Osteoporosis; WNK1
ID OSTEOCLAST FORMATION; NLRP3 INFLAMMASOME; DIFFERENTIATION; CELLS
AB Background: Osteoporosis is a commonly diagnosed metabolic bone disease. NLRP3 inflammasome activation and pyroptosis are observed during osteoporosis. However, the mechanism by which NLRP3 mediated pyroptosis contributes to osteoporosis remains largely undefined. Methods: Ovariectomized (OVX) mice were employed as an in vivo model of osteoclastogenesis. H&E staining and micro CT detected the histological changes and bone parameters in the femur tissues. RANKL treated macrophages were used as the in vitro model of osteoclastogenesis, and LPS/ATP treatment was used as the macrophage pyroptosis model. The cytotoxicity, cytokine secretion and caspase 1 activity were assessed by LDH release assay, ELISA and flow cytometry, respectively. The osteoclast formation ability was detected by TRAP staining. qRTPCR, IHC and Western blotting detected the expression and localization of METTL14, pyroptosis related or osteoclast specific molecules in femur tissues or macrophages. Mechanistically, MeRIP assessed the m6A modification of HOXA5. Luciferase and ChIP assays were employed to detect the direct association between HOXA5 and WNK1 promoter in macrophages. Results: METTL14, HOXA5 and WNK1 were decreased in OVX mice, which was associated with pyroptosis. METTL14 or HOXA5 overexpression suppressed macrophage osteoclast differentiation and pyroptosis, along with the upregulation of WNK1. METTL14 mediated m6A modification stabilized HOXA5 mRNA and increased its expression, and HOXA5 regulated WNK1 expression via direct binding to its promoter. Functional studies showed that WNK1 knockdown counteracted METTL14  or HOXA5 suppressed pyroptosis and macrophageosteoclast differentiation. In OVX mice, overexpression of METTL14 or HOXA5 alleviated osteoporosis via suppressing WNK1 dependent NLRP3 signaling. Conclusion: METTL14 mediated HOXA5 m6A modification increased its expression, thereby inducing WNK1 expression and suppressing NLRP3 dependent pyroptosis to alleviate osteoporosis. The combination of METTL14 or HOXA5 agonist with pyroptosis targeted therapy may be a promising therapeutic approach for osteoporosis. The Translational Potential of this Article & sdot;:
C1 [Tang, Hao; Du, Yuxuan; Tan, Zejiu; Li, Dongpeng; Xie, Jiang] Cent South Univ, Xiangya Hosp, Dept Spine Surg & Orthopaed, Changsha 410008, Hunan, Peoples R China.
   [Tang, Hao; Du, Yuxuan; Tan, Zejiu; Li, Dongpeng; Xie, Jiang] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha 410008, Hunan, Peoples R China.
C3 Central South University; Central South University
RP Xie, J (通讯作者)，Dept Spine Surg & Orthopaed, Xiangya Rd, Changsha 410008, Hunan, Peoples R China.; Xie, J (通讯作者)，Natl Clin Res Ctr Geriatr Disorders, Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
EM xj809902077@163.com
FU Fundamental Research Funds for the Central Universities of Central South
   University
FX This study was supported by the Fundamental Research Funds for the
   Central Universities of Central South University.
CR Akkawi Ibrahim, 2018, Joints, V6, P122, DOI 10.1055/s 0038 1660790
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Bujnicki JM, 2002, J MOL EVOL, V55, P431, DOI 10.1007/s00239 002 2339 8
   Cao WN, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00647
   Chen D, 2023, J ORTHOP TRANSL, V39, P163, DOI 10.1016/j.jot.2023.02.004
   Chen HX, 2005, J BIOL CHEM, V280, P19373, DOI 10.1074/jbc.M413528200
   Chen SJ, 2020, AGING DIS, V11, P1058, DOI 10.14336/AD.2019.0724
   Chen XJ, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00911
   Chen Y, 2023, J ORTHOP TRANSL, V39, P1, DOI 10.1016/j.jot.2022.11.002
   Clynes MA, 2020, BRIT MED BULL, V133, P105, DOI 10.1093/bmb/ldaa005
   Coker H, 2019, BBA GENE REGUL MECH, V1862, P310, DOI 10.1016/j.bbagrm.2018.12.002
   Dai SM, 2004, ANN RHEUM DIS, V63, P1379, DOI 10.1136/ard.2003.018481
   Deng MS, 2023, ENVIRON TOXICOL, V38, P2057, DOI 10.1002/tox.23829
   Godfrey TC, 2018, J BIOL CHEM, V293, P17646, DOI 10.1074/jbc.RA118.003052
   Hassan MQ, 2007, MOL CELL BIOL, V27, P3337, DOI 10.1128/MCB.01544 06
   He MY, 2022, STEM CELL TRANSL MED, V11, P987, DOI 10.1093/stcltm/szac049
   Horwood NJ, 2001, J IMMUNOL, V166, P4915, DOI 10.4049/jimmunol.166.8.4915
   Hu YB, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10358
   Huang M, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.783322
   Jiang N, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.752546
   Li XY, 2023, APOPTOSIS, V28, P293, DOI 10.1007/s10495 022 01807 z
   Liu SS, 2020, J MOL HISTOL, V51, P221, DOI 10.1007/s10735 020 09874 9
   Mao CY, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.204
   Mayes Hopfinger L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 24784 4
   Meng LP, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 021 04484 z
   Minisola S, 2017, INTERN EMERG MED, V12, P915, DOI 10.1007/s11739 017 1719 4
   Nakamura I, 2006, VITAM HORM, V74, P357, DOI 10.1016/S0083 6729(06)74015 8
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ruscitti P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/782382
   Rux DR, 2017, DEV DYNAM, V246, P310, DOI 10.1002/dvdy.24482
   Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Sun ZY, 2021, AGING CELL, V20, DOI 10.1111/acel.13298
   Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577 019 0165 0
   Tao ZB, 2021, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.548812
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   Trautmann A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.256pe6
   Wang CS, 2023, BONE, V168, DOI 10.1016/j.bone.2022.116652
   Wang P, 2016, MOL CELL, V63, P306, DOI 10.1016/j.molcel.2016.05.041
   Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080
   Xiao P, 2008, J BONE MINER RES, V23, P644, DOI 10.1359/JBMR.080105
   Xie Q, 2014, INT J MOL MED, V34, P341, DOI 10.3892/ijmm.2014.1755
   Xu LJ, 2018, CALCIFIED TISSUE INT, V103, P400, DOI 10.1007/s00223 018 0428 y
   Yang JG, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419 023 06263 4
   Yuan XQ, 2021, MOL MED, V27, DOI 10.1186/s10020 021 00355 7
   Zhou YM, 2020, J BONE MINER RES, V35, P978, DOI 10.1002/jbmr.3957
NR 46
TC 5
Z9 6
U1 2
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD SEP
PY 2024
VL 48
BP 190
EP 203
DI 10.1016/j.jot.2024.08.008
EA AUG 2024
PG 14
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA E3S5P
UT WOS:001302239000001
PM 39280633
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Di Pietro, L
   Barba, M
   Prampolini, C
   Ceccariglia, S
   Frassanito, P
   Vita, A
   Guadagni, E
   Bonvissuto, D
   Massimi, L
   Tamburrini, G
   Parolini, O
   Lattanzi, W
AF Di Pietro, Lorena
   Barba, Marta
   Prampolini, Chiara
   Ceccariglia, Sabrina
   Frassanito, Paolo
   Vita, Alessia
   Guadagni, Enrico
   Bonvissuto, Davide
   Massimi, Luca
   Tamburrini, Gianpiero
   Parolini, Ornella
   Lattanzi, Wanda
TI GLI1 and AXIN2 Are Distinctive Markers of Human Calvarial Mesenchymal
   Stromal Cells in Nonsyndromic Craniosynostosis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE mesenchymal stromal cells; stem cell niche; GLI1; AXIN2; osteogenesis;
   bone development; nonsyndromic craniosynostosis; cranial suture;
   regenerative medicine; personalised medicine
ID BONE MARROW; STEM CELLS; OSTEOBLAST DIFFERENTIATION; EXPRESSION;
   REGULATOR; PRECURSOR; PATHWAYS; SUTURES; PROTEIN; NICHE
AB All skeletal bones house osteogenic stem cell niches, in which mesenchymal stromal cells (MSC) provide progenitors for tissue growth and regeneration. They have been widely studied in long bones formed through endochondral ossification. Limited information is available on the composition of the osteogenic niche in flat bones (i.e., skull vault bones) that develop through direct membranous ossification. Craniosynostosis (CS) is a congenital craniofacial defect due to the excessive and premature ossification of skull vault sutures. This study aimed at analysing the expression of GLI1, AXIN2 and THY1 in the context of the human skull vault, using nonsyndromic forms of CS (NCS) as a model to test their functional implication in the aberrant osteogenic process. The expression of selected markers was studied in NCS patients' calvarial bone specimens, to assess the in vivo location of cells, and in MSC isolated thereof. The marker expression profile was analysed during in vitro osteogenic differentiation to validate the functional implication. Our results show that GLI1 and AXIN2 are expressed in periosteal and endosteal locations within the osteogenic niche of human calvarial bones. Their expression is higher in MSC isolated from calvarial bones than in those isolated from long bones and tends to decrease upon osteogenic commitment and differentiation. In particular, AXIN2 expression was lower in cells isolated from prematurely fused sutures than in those derived from patent sutures of NCS patients. This suggests that AXIN2 could reasonably represent a marker for the stem cell population that undergoes depletion during the premature ossification process occurring in CS.
C1 [Di Pietro, Lorena; Barba, Marta; Ceccariglia, Sabrina; Vita, Alessia; Guadagni, Enrico; Parolini, Ornella; Lattanzi, Wanda] Univ Cattolica Sacro Cuore, Dipartimento Sci Vita & Sanita Pubbl, I 00168 Rome, Italy.
   [Barba, Marta; Ceccariglia, Sabrina; Frassanito, Paolo; Guadagni, Enrico; Bonvissuto, Davide; Massimi, Luca; Tamburrini, Gianpiero; Parolini, Ornella; Lattanzi, Wanda] Fdn Policlin Univ A Gemelli IRCCS, I 00168 Rome, Italy.
   [Prampolini, Chiara] Univ Cattolica Sacro Cuore, Dipartimento Testa Collo & Organi Senso, I 00168 Rome, Italy.
   [Bonvissuto, Davide; Massimi, Luca; Tamburrini, Gianpiero; Lattanzi, Wanda] Univ Cattolica Sacro Cuore, Dipartimento Neurosci, I 00168 Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli
RP Lattanzi, W (通讯作者)，Univ Cattolica Sacro Cuore, Dipartimento Sci Vita & Sanita Pubbl, I 00168 Rome, Italy.; Lattanzi, W (通讯作者)，Fdn Policlin Univ A Gemelli IRCCS, I 00168 Rome, Italy.
EM lorena.dipietro@unicatt.it; marta.barba@unicatt.it;
   chiara.prampolini@unicatt.it; sabrina.ceccariglia@unicatt.it;
   paolo.frassanito@policlinicogemelli.it; alessiavita89@gmail.com;
   enrico.guadagni@unicatt.it; davide.bonvissuto@unicatt.it;
   luca.massimi@policlinicogemelli.it; gianpiero.tamburrini@unicatt.it;
   ornella.parolini@unicatt.it; wanda.lattanzi@unicatt.it
RI Lattanzi, Wanda/K 5978 2016; FRASSANITO, PAOLO/K 4099 2018; lattanzi,
   wanda/K 5978 2016; Tamburrini, Gianpiero/K 4521 2018; PAROLINI,
   ORNELLA/ABI 7862 2020; Barba, Marta/ABD 6985 2020; Parolini,
   Ornella/ABI 7862 2020; tamburrini, gianpiero/K 4521 2018; Di Pietro,
   Lorena/Z 3179 2019; Massimi, Luca/JRW 2578 2023
OI FRASSANITO, PAOLO/0000 0003 0071 3126; lattanzi,
   wanda/0000 0003 3092 4936; Barba, Marta/0000 0001 6084 7666; Di Pietro,
   Lorena/0000 0001 5723 2169; massimi, luca/0000 0003 3088 0822;
   Tamburrini, Gianpiero/0000 0002 8017 4830; Parolini,
   Ornella/0000 0002 5211 6430; 
FU Federazione GENE non profit organization; Region Latium "LazioInnova"  
   Key Enabling Technologies [G13675]; Universita Cattolica del Sacro Cuore
FX This research was supported by Federazione GENE non profit organization
   (research funds to W.L.), by Region Latium "LazioInnova"   Key Enabling
   Technologies Call for Grant (ID #G13675, 11/21/2016 POR FESR LAZIO
   2014 2020, grant to W.L.), and by Universita Cattolica del Sacro Cuore
   ("linea D1 2018" to W.L. and "linea D1 2017" to O.P.).
CR Aghaloo TL, 2010, J DENT RES, V89, P1293, DOI 10.1177/0022034510378427
   Barba M, 2018, BONE, V112, P58, DOI 10.1016/j.bone.2018.04.013
   Barreto S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11801 0
   Behr B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070240
   Carinci P, 2007, EUR J HISTOCHEM, V51, P105
   Chai Y, 2006, DEV DYNAM, V235, P2353, DOI 10.1002/dvdy.20833
   Chan CKF, 2013, P NATL ACAD SCI USA, V110, P12643, DOI 10.1073/pnas.1310212110
   Cohen M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7709
   Coussens AK, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 458
   Cuellar A, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115395
   Cyprus GN, 2018, J NEUROSURG PEDIATR, V22, P620, DOI 10.3171/2018.6.PEDS18229
   Doro DH, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00956
   Eppley BL, 1997, J CRANIOFAC SURG, V8, P452
   Flaherty K, 2016, WIRES DEV BIOL, V5, P429, DOI 10.1002/wdev.227
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890 196803000 00009
   Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521 1878(200002)22:2<138::AID BIES5>3.0.CO;2 4
   Hunenko O, 2001, ANN PLAS SURG, V46, P546, DOI 10.1097/00000637 200105000 00015
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Justice CM, 2020, HUM GENET, V139, P1077, DOI 10.1007/s00439 020 02157 z
   Kim SD, 2014, CLEFT PALATE CRAN J, V51, P115, DOI 10.1597/12 136
   Kim WK, 2010, J CELL BIOCHEM, V111, P1199, DOI 10.1002/jcb.22846
   LAJEUNIE E, 1995, AM J MED GENET, V55, P500, DOI 10.1002/ajmg.1320550422
   Lana Elola E, 2007, DEV BIOL, V311, P335, DOI 10.1016/j.ydbio.2007.08.028
   Lattanzi W, 2017, AM J MED GENET A, V173, P1406, DOI 10.1002/ajmg.a.38159
   Lattanzi W, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3389/fncel.2015.00504, 10.3389/fncel.2015.00455]
   Lattanzi W, 2013, BONE, V52, P474, DOI 10.1016/j.bone.2012.09.004
   Lattanzi W, 2012, CHILD NERV SYST, V28, P1301, DOI 10.1007/s00381 012 1781 1
   Lee E, 2018, GENET MED, V20, P1061, DOI 10.1038/gim.2017.214
   Liu B, 2007, DEV BIOL, V301, P298, DOI 10.1016/j.ydbio.2006.10.018
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu XH, 2011, J BONE MINER RES, V26, P209, DOI 10.1002/jbmr.203
   Maruyama T, 2017, J BONE MINER RES, V32, P1816, DOI 10.1002/jbmr.3171
   Maruyama T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000727
   Massimi L, 2012, CHILD NERV SYST, V28, P1341, DOI 10.1007/s00381 012 1799 4
   Matsubara T, 2005, J BONE MINER RES, V20, P399, DOI 10.1359/JBMR.041117
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Mohammad K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092158
   Morrison SJ, 2015, NATURE, V505, P327, DOI DOI 10.1038/nature12984
   Opperman LA, 2000, DEV DYNAM, V219, P472, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1073>3.0.CO;2 F
   Pan A, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00061
   Plaisant M, 2009, STEM CELLS, V27, P703, DOI 10.1634/stemcells.2008 0888
   Potter Amiee B, 2015, Eplasty, V15, pe12
   Ratisoontorn C, 2005, BONE, V36, P627, DOI 10.1016/j.bone.2005.01.010
   Robbins DJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002906
   Senarath Yapa K, 2012, ORGANOGENESIS, V8, P103, DOI 10.4161/org.23307
   Shevde NK, 2001, CLEFT PALATE CRAN J, V38, P606, DOI 10.1597/1545 1569(2001)038<0606:EAOODF>2.0.CO;2
   Simpson Andrew, 2017, Ann Plast Surg, V78, P103
   Song DZ, 2020, PLAST RECONSTR SURG, V145, p552E, DOI 10.1097/PRS.0000000000006597
   Tamburrini G, 2012, CHILD NERV SYST, V28, P1511, DOI 10.1007/s00381 012 1819 4
   TAVASSOLI M, 1968, SCIENCE, V161, P54, DOI 10.1126/science.161.3836.54
   Twigg SRF, 2015, AM J HUM GENET, V97, P359, DOI 10.1016/j.ajhg.2015.07.006
   Wilk K, 2017, STEM CELL REP, V8, P933, DOI 10.1016/j.stemcr.2017.03.002
   Wilkie AOM, 2017, CURR OPIN PEDIATR, V29, P622, DOI 10.1097/MOP.0000000000000542
   Yilmaz E, 2018, AM J MED GENET A, V176, P1976, DOI 10.1002/ajmg.a.40373
   Yu HMI, 2005, DEVELOPMENT, V132, P1995, DOI 10.1242/dev.01786
   Zhao H, 2015, NAT CELL BIOL, V17, P386, DOI 10.1038/ncb3139
NR 56
TC 24
Z9 26
U1 3
U2 13
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2020
VL 21
IS 12
AR 4356
DI 10.3390/ijms21124356
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA MM4QC
UT WOS:000550142100001
PM 32575385
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pan, DY
   Benkato, KG
   Han, XQ
   Zheng, JJ
   Kumar, V
   Wan, M
   Zheng, JY
   Cao, X
AF Pan, Dayu
   Benkato, Kheiria Gamal
   Han, Xuequan
   Zheng, Jinjian
   Kumar, Vijay
   Wan, Mei
   Zheng, Junying
   Cao, Xu
TI Senescence of endplate osteoclasts induces sensory innervation and
   spinal pain
SO ELIFE
LA English
DT Article
DE low back pain; senescence; osteoclast; sensory nerve; endplate; H type
   vessle; Mouse
ID LOW BACK PAIN; INTERVERTEBRAL DISC DEGENERATION; SYSTEMATIC ANALYSIS;
   GLOBAL BURDEN; AXON GUIDANCE; STEM CELLS; TERIPARATIDE; NETRIN 1;
   OSTEOSARCOMA; CLEARANCE
AB Spinal pain affects individuals of all ages and is the most common musculoskeletal problem globally. Its clinical management remains a challenge as the underlying mechanisms leading to it are still unclear. Here, we report that significantly increased numbers of senescent osteoclasts (SnOCs) are observed in mouse models of spinal hypersensitivity, like lumbar spine instability (LSI) or aging, compared to controls. The larger population of SnOCs is associated with induced sensory nerve innervation, as well as the growth of H type vessels, in the porous endplate. We show that deletion of senescent cells by administration of the senolytic drug Navitoclax (ABT263) results in significantly less spinal hypersensitivity, spinal degeneration, porosity of the endplate, sensory nerve innervation, and H type vessel growth in the endplate. We also show that there is significantly increased SnOC mediated secretion of Netrin 1 and NGF, two well established sensory nerve growth factors, compared to non senescent OCs. These findings suggest that pharmacological elimination of SnOCs may be a potent therapy to treat spinal pain.
C1 [Pan, Dayu; Benkato, Kheiria Gamal; Han, Xuequan; Zheng, Jinjian; Kumar, Vijay; Wan, Mei; Zheng, Junying; Cao, Xu] Johns Hopkins Univ, Sch Med, Dept Orthoped Surg, Baltimore, MD 21218 USA.
   Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins University
RP Cao, X (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Orthoped Surg, Baltimore, MD 21218 USA.
EM xcao11@jhmi.edu
RI ; PAN, DAYU/ABB 6617 2021; Kumar, Vijay/B 6213 2018
OI Pan, Dayu/0000 0003 0284 9350; Han, Xuequan/0000 0001 5629 5918; Wan,
   Mei/0000 0001 9404 540X
FU National Institutes of Health [R01AG068997, P01AG066603, R01AG076783,
   R01AR071432]; United States NIH National Institute on Aging
FX This research was supported by the United States NIH National Institute
   on Aging under award numbers R01AG068997, P01AG066603, R01AG076783,
   R01AR071432 (to XC).
CR Andrews EB, 2012, J BONE MINER RES, V27, P2429, DOI 10.1002/jbmr.1768
   Ariga K, 2001, SPINE, V26, P2414, DOI 10.1097/00007632 200111150 00004
   Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932
   Bernstein IA, 2017, BMJ BRIT MED J, V356, DOI 10.1136/bmj.i6748
   Bian Q, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.8
   Bian Q, 2016, SCI REP UK, V6, DOI 10.1038/srep27093
   Boos N, 2002, SPINE, V27, P2631, DOI 10.1097/00007632 200212010 00002
   Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010
   Chen S, 2022, J ORTHOP TRANSL, V32, P49, DOI 10.1016/j.jot.2021.07.005
   Chen ZP, 2021, ANN PALLIAT MED, V10, P4000, DOI 10.21037/apm 20 2333
   Cherif H, 2020, ELIFE, V9, DOI 10.7554/eLife.54693
   Childs BG, 2016, SCIENCE, V354, P472, DOI 10.1126/science.aaf6659
   Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003 4819 147 7 200710020 00006
   Cobos EJ, 2012, PAIN, V153, P876, DOI 10.1016/j.pain.2012.01.016
   DEYO RA, 1991, ANNU REV PUBL HEALTH, V12, P141, DOI 10.1146/annurev.pu.12.050191.001041
   Deyo RA, 2015, BMJ BRIT MED J, V350, DOI 10.1136/bmj.g6380
   Di Micco R, 2021, NAT REV MOL CELL BIO, V22, P75, DOI 10.1038/s41580 020 00314 w
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Fields AJ, 2014, SPINE J, V14, P513, DOI 10.1016/j.spinee.2013.06.075
   Forcet C, 2002, NATURE, V417, P443, DOI 10.1038/nature748
   Goldberg H, 2015, JAMA J AM MED ASSOC, V313, P1915, DOI 10.1001/jama.2015.4468
   Gorissen B, 2019, J CELL PHYSIOL, V234, P414, DOI 10.1002/jcp.26511
   Hand RA, 2017, NEURON, V94, P691, DOI 10.1016/j.neuron.2017.05.012
   Harper KD, 2007, J BONE MINER RES, V22, P334, DOI 10.1359/JBMR.061111
   Hartvigsen J, 2018, LANCET, V391, P2356, DOI 10.1016/S0140 6736(18)30480 X
   He SH, 2017, CELL, V169, P1000, DOI 10.1016/j.cell.2017.05.015
   Hoy D, 2012, ARTHRITIS RHEUM US, V64, P2028, DOI 10.1002/art.34347
   James SL, 2018, LANCET, V392, P1789, DOI [10.1016/s0140 6736(18)32335 3, 10.1016/S0140 6736(18)32335 3]
   Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324
   Kallewaard JW, 2010, PAIN PRACT, V10, P560, DOI 10.1111/j.1533 2500.2010.00408.x
   Kamei H, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 13217 x
   Krishnamurthy J, 2006, NATURE, V443, P453, DOI 10.1038/nature05092
   Kwak HB, 2005, BLOOD, V105, P2963, DOI 10.1182/blood 2004 07 2534
   Lee CH, 2017, SPINE J, V17, P1770, DOI 10.1016/j.spinee.2017.05.006
   Liao ZW, 2019, THERANOSTICS, V9, P4084, DOI 10.7150/thno.33638
   Lim S, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202101483
   López Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Maas ET, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008572.pub2
   Maher C, 2017, LANCET, V389, P736, DOI 10.1016/S0140 6736(16)30970 9
   MARTIN TJ, 1976, NATURE, V260, P436, DOI 10.1038/260436a0
   Masuda K, 2005, SPINE, V30, P5, DOI 10.1097/01.brs.0000148152.04401.20
   MIYAMOTO S, 1991, SPINE, V16, pS495, DOI 10.1097/00007632 199110001 00008
   Mizoguchi T, 2009, J CELL BIOL, V184, P541, DOI 10.1083/jcb.200806139
   Moore SW, 2012, J NEUROSCI, V32, P11574, DOI 10.1523/JNEUROSCI.0999 12.2012
   Muralidharan A, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI151817
   Nevitt MC, 2006, OSTEOPOROSIS INT, V17, P273, DOI 10.1007/s00198 005 2013 2
   Ni SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 13476 9
   Papadakis Michael, 2011, Open Orthop J, V5, P335, DOI 10.2174/1874325001105010335
   Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16 2367
   Roclofs PDDM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000396.pub3
   Rodriguez AG, 2012, J ORTHOP RES, V30, P280, DOI 10.1002/jor.21513
   Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092 8674(00)81795 X
   Shaheed CA, 2016, JAMA INTERN MED, V176, P958, DOI 10.1001/jamainternmed.2016.1251
   Sheyn D, 2019, THERANOSTICS, V9, P7506, DOI 10.7150/thno.34898
   Shu TZ, 2000, J COMP NEUROL, V416, P201, DOI 10.1002/(SICI)1096 9861(20000110)416:2<201::AID CNE6>3.0.CO;2 Z
   Taher F, 2012, ADV ORTHOP, V2012, DOI 10.1155/2012/970752
   Tomlinson RE, 2017, P NATL ACAD SCI USA, V114, pE3632, DOI 10.1073/pnas.1701054114
   Wang F, 2016, OSTEOARTHR CARTILAGE, V24, P398, DOI 10.1016/j.joca.2015.09.019
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xue P, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00155 z
   Zhen GH, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00217 w
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
NR 62
TC 2
Z9 2
U1 2
U2 6
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA 95 Regent Street, CAMBRIDGE, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD JUN 19
PY 2024
VL 12
AR RP92889
DI 10.7554/eLife.92889
PG 17
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA UW9B0
UT WOS:001251208100001
PM 38896465
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Terpos, E
   Ntanasis Stathopoulos, I
   Katodritou, E
   Kyrtsonis, MC
   Douka, V
   Spanoudakis, E
   Papatheodorou, A
   Eleutherakis Papaiakovou, E
   Kanellias, N
   Gavriatopoulou, M
   Makras, P
   Kastritis, E
   Dimopoulos, MA
AF Terpos, Evangelos
   Ntanasis Stathopoulos, Ioannis
   Katodritou, Eirini
   Kyrtsonis, Marie Christine
   Douka, Vassiliki
   Spanoudakis, Emmanouil
   Papatheodorou, Athanasios
   Eleutherakis Papaiakovou, Evangelos
   Kanellias, Nikolaos
   Gavriatopoulou, Maria
   Makras, Polyzois
   Kastritis, Efstathios
   Dimopoulos, Meletios A.
TI Carfilzomib Improves Bone Metabolism in Patients with Advanced
   Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study
SO CANCERS
LA English
DT Article
DE multiple myeloma; carfilzomib; skeletal related events; bone disease;
   bone metabolism; osteocalcin; procollagen type I N propeptide (PINP);
   C telopeptide of collagen type 1 (CTX); tartrate resistant acid
   phosphatase 5b (TRACP 5B); nuclear factor kappa B ligand (RANKL)
ID NEWLY DIAGNOSED PATIENTS; BIOCHEMICAL MARKERS; RECEPTOR ACTIVATOR;
   ACTIVIN A; DISEASE; SCLEROSTIN; BORTEZOMIB; SURVIVAL; DICKKOPF 1;
   DEXAMETHASONE
AB Simple Summary
   Carfilzomib with dexamethasone is an important therapeutic option for patients with relapsed/refractory multiple myeloma. We sought to evaluate the effect of this regimen on the bone related outcomes, which are associated with both quality of life and survival. Among 25 patients, less than one third experienced a new skeletal related event during treatment, even in the absence of any bone targeted agent. Interestingly, there was a significant decrease in serum biomarkers of bone resorption, which was at least partially due to the sRANKL/OPG ratio reduction. Furthermore, Kd produced an increase in markers of bone formation. Importantly, these changes were independent of myeloma response to treatment. Therefore, the combination of carfilzomib and dexamethasone improves bone metabolism and bone health in patients with advanced multiple myeloma.
   Carfilzomib with dexamethasone (Kd) is a well established regimen for the treatment of relapsed/refractory multiple myeloma (RRMM). There is limited information for the effects of Kd on myeloma related bone disease. This non interventional study aimed to assess skeletal related events (SREs) and bone metabolism in patients with RRMM receiving Kd, in the absence of any bone targeted agent. Twenty five patients were enrolled with a median of three prior lines of therapy; 72% of them had evidence of osteolytic bone disease at study entry. During Kd treatment, the rate of new SREs was 28%. Kd produced a clinically relevant (>= 30%) decrease in C telopeptide of collagen type 1 (p = 0.048) and of tartrate resistant acid phosphatase 5b (p = 0.002) at 2 months. This reduction was at least partially due to the reduction in the osteoclast regulator RANKL/osteoprotegerin ratio, at 2 months (p = 0.026). Regarding bone formation, there was a clinically relevant increase in osteocalcin at 6 months (p = 0.03) and in procollagen type I N propeptide at 8 months post Kd initiation. Importantly, these bone metabolism changes were independent of myeloma response to treatment. In conclusion, Kd resulted in a low rate of SREs among RRMM patients, along with an early, sustained and clinically relevant decrease in bone resorption, which was accompanied by an increase in bone formation, independently of myeloma response and in the absence of any bone targeted agent use.
C1 [Terpos, Evangelos; Ntanasis Stathopoulos, Ioannis; Eleutherakis Papaiakovou, Evangelos; Kanellias, Nikolaos; Gavriatopoulou, Maria; Kastritis, Efstathios; Dimopoulos, Meletios A.] Natl & Kapodistrian Univ Athens, Alexandra Gen Hosp, Sch Med, Dept Clin Therapeut, Athens 11528, Greece.
   [Katodritou, Eirini] Theagenio Canc Hosp, Dept Hematol, Thessaloniki 54639, Greece.
   [Kyrtsonis, Marie Christine] Natl & Kapodistrian Univ Athens, Sch Med, Dept Propedeut Internal Med 1, Athens 11528, Greece.
   [Douka, Vassiliki] Gen Hosp G Papanikolaou, Dept Hematol, Thessaloniki 57010, Greece.
   [Douka, Vassiliki] Gen Hosp G Papanikolaou, Bone Marrow Transplantat Unit, Thessaloniki 57010, Greece.
   [Spanoudakis, Emmanouil] Democritus Univ Thrace, Fac Med, Dept Hematol, Alexandroupolis 68131, Greece.
   [Papatheodorou, Athanasios; Makras, Polyzois] 251 Gen Air Force Hosp, Dept Med Res, Athens 11525, Greece.
C3 Alexandra Hospital; National & Kapodistrian University of Athens;
   National & Kapodistrian University of Athens; Democritus University of
   Thrace
RP Terpos, E (通讯作者)，Natl & Kapodistrian Univ Athens, Alexandra Gen Hosp, Sch Med, Dept Clin Therapeut, Athens 11528, Greece.
EM eterpos@med.uoa.gr; johnntanasis@med.uoa.gr; eirinikatodritou@gmail.com;
   kyrtsoni@med.uoa.gr; vassiliki.douka@gmail.com;
   emmanouilspanoudakis@yahoo.com; atpapath@med.uoa.gr;
   mdeleutherakis@gmail.com; nick.kanellias@gmail.com;
   mariagabria@gmail.com; makras@internet.gr; ekastritis@gmail.com;
   mdimop@med.uoa.gr
RI Eleutherakis Papaiakovou, Evangelos/AAA 7055 2020; Gavriatopoulou,
   Maria/AAD 3698 2019; Kastritis, Efstathios/AAD 3656 2019; Dimopoulos,
   Meletios/AAD 4130 2019; Terpos, Evangelos/AAD 3667 2019; Makras,
   Polyzois/AAF 5871 2020; Ntanasis Stathopoulos, Ioannis/AAD 3692 2019
OI Terpos, Evangelos/0000 0001 5133 1422; Makras,
   Polyzois/0000 0002 3231 3357; Spanoudakis,
   Emmanouil/0000 0003 4985 5862; Kastritis,
   Efstathios/0000 0001 8191 5832; Eleutherakis Papaiakovou,
   Evangelos/0000 0003 3407 5994; Dimopoulos, Meletios/0000 0001 8990 3254
FU Amgen
FX The study was supported by Amgen.
CR Accardi F, 2015, BIOMED RES INT UK, V2015, DOI 10.1155/2015/172458
   Brunetti G, 2011, ANN NY ACAD SCI, V1237, P19, DOI 10.1111/j.1749 6632.2011.06196.x
   Burch J, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18110
   Coleman R, 2020, ANN ONCOL, V31, P1650, DOI 10.1016/j.annonc.2020.07.019
   Colucci S, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.22
   Delforge M, 2011, EUR J HAEMATOL, V86, P372, DOI 10.1111/j.1600 0609.2011.01599.x
   Delgado Calle J, 2017, BONE, V96, P29, DOI 10.1016/j.bone.2016.10.007
   Dimopoulos MA, 2021, HEMASPHERE, V5, DOI 10.1097/HS9.0000000000000528
   Dimopoulos MA, 2016, LANCET ONCOL, V17, P27, DOI 10.1016/S1470 2045(15)00464 7
   Eda H, 2014, LEUKEMIA, V28, P1892, DOI 10.1038/leu.2014.69
   Eda H, 2016, J BONE MINER RES, V31, P1225, DOI 10.1002/jbmr.2789
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Gavriatopoulou M, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408 020 0297 2
   Gavriatopoulou M, 2009, EXPERT OPIN THER TAR, V13, P839, DOI 10.1517/14728220903025770
   Hu B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074191
   Hurchla MA, 2013, LEUKEMIA, V27, P430, DOI 10.1038/leu.2012.183
   Jiang ZF, 2020, BONE REP, V12, DOI 10.1016/j.bonr.2020.100272
   Kim C, 2019, J BONE ONCOL, V14, DOI 10.1016/j.jbo.2018.100215
   Kleber M, 2019, EXPERT REV HEMATOL, V12, P651, DOI 10.1080/17474086.2019.1640115
   Kortuem KM, 2013, BLOOD, V121, P893, DOI 10.1182/blood 2012 10 459883
   Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470 2045(16)30206 6
   Li YL, 2014, LEUKEMIA RES, V38, P970, DOI 10.1016/j.leukres.2014.05.022
   Mateos MV, 2020, BMC CANCER, V20, DOI 10.1186/s12885 020 6596 y
   McDonald MM, 2017, BLOOD, V129, P3452, DOI 10.1182/blood 2017 03 773341
   Mohty M, 2014, CANCER AM CANCER SOC, V120, P618, DOI 10.1002/cncr.28481
   Ntanasis Stathopoulos I, 2021, CL LYMPH MYELOM LEUK, V21, P379, DOI 10.1016/j.clml.2021.01.018
   Ntanasis Stathopoulos I, 2020, ADV EXP MED BIOL, V1231, P13, DOI 10.1007/978 3 030 36667 4_2
   Politou MC, 2006, INT J CANCER, V119, P1728, DOI 10.1002/ijc.22033
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470 2045(18)30072 X
   Roussou M, 2009, LEUKEMIA, V23, P2177, DOI 10.1038/leu.2009.130
   Sarkar S, 2004, J BONE MINER RES, V19, P394, DOI 10.1359/JBMR.0301243
   Suvannasankha A, 2017, BLOOD, V130
   Takito J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040984
   Terpos E, 2007, LEUKEMIA, V21, P1875, DOI 10.1038/sj.leu.2404843
   Terpos E, 2014, LEUKEMIA, V28, P928, DOI 10.1038/leu.2013.267
   Terpos E, 2012, ANN ONCOL, V23, P2681, DOI 10.1093/annonc/mds068
   Terpos E, 2003, BRIT J HAEMATOL, V123, P106, DOI 10.1046/j.1365 2141.2003.04561.x
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Terpos E, 2010, LEUKEMIA, V24, P1700, DOI 10.1038/leu.2010.173
   Terpos E, 2010, LEUKEMIA, V24, P1043, DOI 10.1038/leu.2010.62
   Terpos E, 2008, LEUKEMIA, V22, P2247, DOI 10.1038/leu.2008.235
   Terpos E., LANCET ONCOL, V2021, DOI [10.1016/S1470 2045(20)30559, DOI 10.1016/S1470 2045(20)30559]
   Terpos E, 2007, BLOOD, V110, P1098, DOI 10.1182/blood 2007 03 067710
   Terpos E, 2006, BRIT J HAEMATOL, V135, P688, DOI 10.1111/j.1365 2141.2006.06356.x
   Terpos E, 2019, BLOOD, V133, P1534, DOI 10.1182/blood 2018 11 852459
   Terpos E, 2019, INT J CANCER, V145, P559, DOI 10.1002/ijc.32125
   Terpos E, 2019, AM J HEMATOL, V94, P400, DOI 10.1002/ajh.25392
   Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 018 0075 6
   Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 017 0037 4
   Terpos E, 2012, INT J CANCER, V131, P1466, DOI 10.1002/ijc.27342
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Vallet S, 2011, LEUKEMIA, V25, P1174, DOI 10.1038/leu.2011.43
   Vallet S, 2010, P NATL ACAD SCI USA, V107, P5124, DOI 10.1073/pnas.0911929107
   Yang YM, 2015, J BIOL CHEM, V290, P16918, DOI 10.1074/jbc.M115.663963
   Zangari M, 2016, BONE, V86, P131, DOI 10.1016/j.bone.2016.02.019
   Zangari M, 2012, CANCER TREAT REV, V38, P968, DOI 10.1016/j.ctrv.2011.12.007
   Zangari M, 2011, EUR J HAEMATOL, V86, P484, DOI 10.1111/j.1600 0609.2011.01602.x
   Zangari M, 2011, HAEMATOL HEMATOL J, V96, P333, DOI 10.3324/haematol.2010.031302
   Zhang D, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02037 3
NR 59
TC 10
Z9 10
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD MAR
PY 2021
VL 13
IS 6
AR 1257
DI 10.3390/cancers13061257
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA RE7SS
UT WOS:000634349500001
PM 33809268
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Philbrick, KA
   Martin, SA
   Colagiovanni, AR
   Branscum, AJ
   Turner, RT
   Iwaniec, UT
AF Philbrick, Kenneth A.
   Martin, Stephen A.
   Colagiovanni, Amy R.
   Branscum, Adam J.
   Turner, Russell T.
   Iwaniec, Urszula T.
TI Effects of hypothalamic leptin gene therapy on osteopetrosis in
   leptin deficient mice
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
DE bone formation and resorption; cartilage; histology; ob/ob; osteoclast
ID INCREASES BONE FORMATION; OBESE MOUSE GENOTYPE; OB/OB MICE; MINERAL
   DENSITY; BODY WEIGHT; ENDOCHONDRAL OSSIFICATION; SKELETAL ABNORMALITIES;
   TRANSGENE EXPRESSION; INSULIN; GROWTH
AB Impaired resorption of cartilage matrix deposited during endochondral ossification is a defining feature of juvenile osteopetrosis. Growing, leptin deficient ob/ob mice exhibit a mild form of osteopetrosis. However, the extent to which the disease is (1) self limiting and (2) reversible by leptin treatment is unknown. We addressed the first question by performing histomorphometric analysis of femurs in rapidly growing (2 month old), slowly growing (4 month old) and skeletally mature (6 month old) wild type (WT) and ob/ob male mice. Absent by 6 months of age in WT mice, cartilage matrix persisted to varying extents in distal femur epiphysis, metaphysis and diaphysis in ob/ob mice, suggesting that the osteopetrotic phenotype is not entirely self limiting. To address the second question, we employed hypothalamic recombinant ade no associated virus (rAAV) gene therapy to restore leptin signaling in ob/ob mice. Two month old mice were randomized to one of the three groups: (1) untreated control, (2) rAAV Leptin or (3) control vector rAAV green fluorescent protein and vectors injected intracerebroventricularly. Seven months later, rAAV leptin treated mice exhibited no cartilage in the metaphysis and greatly reduced cartilage in the epiphysis and diaphysis. At the cellular level, the reduction in cartilage was associated with increased bone turnover. These findings (1) support the concept that leptin is important for normal replacement of cartilage by bone, and (2) demonstrate that osteopetrosis in ob/ob mice is bone compartment specific and reversible by leptin at skeletal sites capable of undergoing robust bone turnover.
C1 [Philbrick, Kenneth A.; Martin, Stephen A.; Colagiovanni, Amy R.; Turner, Russell T.; Iwaniec, Urszula T.] Oregon State Univ, Sch Biol & Populat Hlth Sci, Skeletal Biol Lab, Corvallis, OR 97331 USA.
   [Branscum, Adam J.] Oregon State Univ, Sch Biol & Populat Hlth Sci, Biostat Program, Corvallis, OR 97331 USA.
   [Turner, Russell T.; Iwaniec, Urszula T.] Oregon State Univ, Ctr Hlth Aging Res, Corvallis, OR 97331 USA.
C3 Oregon State University; Oregon State University; Oregon State
   University
RP Iwaniec, UT (通讯作者)，Oregon State Univ, Sch Biol & Populat Hlth Sci, Skeletal Biol Lab, Corvallis, OR 97331 USA.; Iwaniec, UT (通讯作者)，Oregon State Univ, Ctr Hlth Aging Res, Corvallis, OR 97331 USA.
EM urszula.iwaniec@oregonstate.edu
FU NIH [AR 054609]; NASA [NNX12AL24]; USDA [38420 17804]
FX This work was supported by grants from the NIH (AR 054609), NASA
   (NNX12AL24) and USDA (38420 17804).
CR Arruda M, 2016, J BONE MINER RES, V31, P657, DOI 10.1002/jbmr.2715
   Bartell SM, 2011, J BONE MINER RES, V26, P1710, DOI 10.1002/jbmr.406
   BATT RAL, 1992, INT J OBESITY, V16, P29
   BATT RAL, 1978, INT J OBESITY, V2, P457
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Beretta E, 2002, PEDIATR RES, V52, DOI 10.1203/00006450 200208000 00010
   Boghossian S, 2007, NEUROBIOL AGING, V28, P1594, DOI 10.1016/j.neurobiolaging.2006.08.010
   Boghossian S, 2006, PEPTIDES, V27, P3245, DOI 10.1016/j.peptides.2006.07.022
   CIELINSKI MJ, 1994, BONE, V15, P707, DOI 10.1016/8756 3282(94)90321 2
   Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503
   Del Fattore A, 2008, BONE, V42, P19, DOI 10.1016/j.bone.2007.08.029
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Ealey KN, 2006, REGUL PEPTIDES, V136, P9, DOI 10.1016/j.regpep.2006.04.013
   Gat Yablonski G, 2004, ENDOCRINOLOGY, V145, P343, DOI 10.1210/en.2003 0910
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   Hamrick MW, 2005, J BONE MINER RES, V20, P994, DOI 10.1359/JBMR.050103
   Hamrick MW, 2004, J BONE MINER RES, V19, P1607, DOI 10.1359/JBMR.040712
   Hamrick MW, 2004, BONE, V34, P376, DOI 10.1016/j.bone.2003.11.020
   Henriksen K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027482
   Hoshi K, 2004, J BONE MINER RES, V19, P214, DOI 10.1359/JBMR.0301221
   ISHIDA H, 1988, ENDOCRINOLOGY, V122, P2436, DOI 10.1210/endo 122 6 2436
   Iwaniec UT, 2009, BONE, V44, P404, DOI 10.1016/j.bone.2008.10.058
   Iwaniec UT, 2007, PEPTIDES, V28, P1012, DOI 10.1016/j.peptides.2007.02.001
   Iwaniec Urszula T., 2008, V447, P325, DOI 10.1007/978 1 59745 242 7_21
   Kalra SP, 2009, PEPTIDES, V30, P967, DOI 10.1016/j.peptides.2009.01.020
   Kishida Y, 2005, BONE, V37, P607, DOI 10.1016/j.bone.2005.05.009
   Kocher Mininder S, 2003, Am J Orthop (Belle Mead NJ), V32, P222
   Kondo T, 2004, J BIOL CHEM, V279, P37997, DOI 10.1074/jbc.M401339200
   Koskinen A, 2011, CLIN EXP RHEUMATOL, V29, P57
   Lee HS, 2008, CLIN EXP OTORHINOLAR, V1, P211, DOI 10.3342/ceo.2008.1.4.211
   Lindenmaier LB, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00110
   Mackie EJ, 2011, J ENDOCRINOL, V211, P109, DOI 10.1530/JOE 11 0048
   Martin EA, 2003, BONE, V32, P261, DOI 10.1016/S8756 3282(02)00983 3
   Odgren PR, 2016, CONNECT TISSUE RES, V57, P161, DOI 10.3109/03008207.2016.1140752
   Ozata M, 1999, J CLIN ENDOCR METAB, V84, P3686, DOI 10.1210/jc.84.10.3686
   Philbrick KA, 2017, J ENDOCRINOL, V232, P461, DOI 10.1530/JOE 16 0484
   Philbrick KA, 2015, ANAT REC, V298, P2018, DOI 10.1002/ar.23267
   Schroeter MR, 2012, CARDIOVASC RES, V93, P170, DOI 10.1093/cvr/cvr275
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Steppan CM, 2000, REGUL PEPTIDES, V92, P73, DOI 10.1016/S0167 0115(00)00152 X
   Turner RT, 2017, J ENDOCRINOL, V233, P357, DOI 10.1530/JOE 17 0103
   Turner RT, 2015, J ENDOCRINOL, V227, P129, DOI 10.1530/JOE 15 0280
   Turner RT, 2014, J ENDOCRINOL, V223, pM1, DOI 10.1530/JOE 14 0224
   Turner RT, 2013, J BONE MINER RES, V28, P22, DOI 10.1002/jbmr.1734
   Tuukkanen J, 2000, J BONE MINER RES, V15, P1905, DOI 10.1359/jbmr.2000.15.10.1905
   Ueno N, 2004, ENDOCRINOLOGY, V145, P4176, DOI 10.1210/en.2004 0262
   Ueno N, 2006, PEPTIDES, V27, P2332, DOI 10.1016/j.peptides.2006.03.006
   Unnanuntana A, 2011, CLIN ORTHOP RELAT R, V469, P2194, DOI 10.1007/s11999 010 1694 9
   WELCH BL, 1951, BIOMETRIKA, V38, P330, DOI 10.2307/2332579
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Williams GA, 2011, J BONE MINER RES, V26, P1698, DOI 10.1002/jbmr.367
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0
NR 54
TC 16
Z9 17
U1 0
U2 3
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0022 0795
EI 1479 6805
J9 J ENDOCRINOL
JI J. Endocrinol.
PD FEB
PY 2018
VL 236
IS 2
BP 57
EP 68
DI 10.1530/JOE 17 0524
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FU7OF
UT WOS:000424040800004
PM 29191939
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Gu, JQ
   Yang, WW
   Lin, S
   Ying, DQ
AF Gu, Junqing
   Yang, Wenwei
   Lin, Shun
   Ying, Danqing
TI Identification of co expressed genes and immune infiltration features
   related to the progression of atherosclerosis
SO JOURNAL OF APPLIED GENETICS
LA English
DT Article
DE Atherosclerosis; Gene co expression modules; WGCNA; Immune cell
   infiltration; Therapeutic targets
AB Atherosclerosis is a chronic inflammatory disease that affects arterial walls and is a leading cause of cardiovascular disease. Gene co expression modules can provide insight into the molecular mechanisms underlying atherosclerosis progression. In this study, gene co expression network analysis (WGCNA) was done to identify gene co expression modules associated with atherosclerosis progression. Before conducting WGCNA, preprocessing and soft power selection were performed on the GSE28829, GSE100927, GSE43292, GSE10334, and GSE16134 datasets (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi). Co expression modules were identified using dynamic tree cuts, and their correlations and trait associations were visualized. Enrichment analysis was performed on the blue and magenta modules to identify biological processes (BP) and pathways related to atherosclerosis. The CIBERSORT algorithm was used to predict immune cell infiltration in early and advanced atherosclerotic plaques. We identified 12 co expression modules, in which blue and magenta were most highly correlated with atherosclerosis progression. The blue module was enriched for inflammation  and immune related BP and pathways, including phagosome, lysosome, osteoclast differentiation, chemokine signaling pathway, platelet activation, NF kappa B signaling pathway, Fc gamma R mediated phagocytosis, lipid and atherosclerosis, autophagy, and apoptosis. The magenta module was significantly enriched for vascular permeability regulation, positive and negative regulation of epithelial to mesenchymal transition, and lamellipodium. Additionally, the CIBERSORT algorithm predicted less abundance of T regulatory cells and monocytes in advanced compared to early atherosclerotic plaques. The enrichment analysis of BP, cellular components, molecular functions, and atherosclerosis related pathways in the blue and magenta modules showed that inflammation and immune response played a key role in the progression of atherosclerosis. Our study provides insights into the molecular mechanisms underlying atherosclerosis progression and identifies potential therapeutic targets for the treatment of atherosclerosis. The identification of immune cell subtypes associated with atherosclerosis could lead to the development of immunomodulatory therapies to prevent or treat atherosclerosis.
C1 [Gu, Junqing] Yuyao Municipal Peoples Hosp, Yuyao, Peoples R China.
   [Yang, Wenwei] Longshan Hosp, Yuyao, Peoples R China.
   [Lin, Shun] Linhai City First Peoples Hosp, Yuyao, Peoples R China.
   [Ying, Danqing] Yuyao City Lanjiang St Community Hlth Serv Ctr, Yuyao, Peoples R China.
RP Ying, DQ (通讯作者)，Yuyao City Lanjiang St Community Hlth Serv Ctr, Yuyao, Peoples R China.
EM 13819574773@163.com
RI Gu, Junqing/GQP 5268 2022
CR Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978 1 4939 7493 1_12
   Chen MY, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.601952
   Feng SW, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.951582
   Fruchart JC, 2019, CARDIOVASC DIABETOL, V18, DOI 10.1186/s12933 019 0864 7
   Gimbrone MA, 2016, CIRC RES, V118, P620, DOI 10.1161/CIRCRESAHA.115.306301
   Herrington W, 2016, CIRC RES, V118, P535, DOI 10.1161/CIRCRESAHA.115.307611
   Kobiyama K, 2018, CIRC RES, V123, P1118, DOI 10.1161/CIRCRESAHA.118.313816
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471 2105 9 559
   Liang WW, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/4178639
   Libby P, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572 019 0106 z, 10.1038/s41572 019 0116 x]
   Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914
   Tardif JC, 2019, NEW ENGL J MED, V381, P2497, DOI 10.1056/NEJMoa1912388
   Winkels H, 2018, CIRC RES, V122, P1675, DOI 10.1161/CIRCRESAHA.117.312513
   Wolf D, 2019, CIRC RES, V124, P315, DOI 10.1161/CIRCRESAHA.118.313591
   Wu TZ, 2021, INNOVATION AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100141
   Zhang TT, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/9918498
   Zhang XK, 2022, TRANSL RES, V247, P19, DOI 10.1016/j.trsl.2022.04.001
   Zhao W, 2010, J BIOPHARM STAT, V20, P281, DOI 10.1080/10543400903572753
   Zhu F, 2021, BMC CARDIOVASC DISOR, V21, DOI 10.1186/s12872 021 02323 9
NR 19
TC 2
Z9 2
U1 1
U2 6
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1234 1983
EI 2190 3883
J9 J APPL GENET
JI J. Appl. Genetics
PD MAY
PY 2024
VL 65
IS 2
BP 331
EP 339
DI 10.1007/s13353 023 00801 8
EA NOV 2023
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA NH2Y9
UT WOS:001105681400001
PM 37996696
DA 2025 08 17
ER

PT J
AU Liu, MZ
   Zhou, DC
   Liu, Q
   Xie, FL
   Xiang, DX
   Tang, GY
   Luo, SL
AF Liu, Min zhen
   Zhou, Dong Chu
   Liu, Qiang
   Xie, Fu li
   Xiang, Da xiong
   Tang, Gen yun
   Luo, Shi Lin
TI Osteogenesis activity of isocoumarin a through the activation of the
   PI3K Akt/Erk cascade activated BMP/RUNX2 signaling pathway
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Isocoumarin A; Osteogenesis activity; Akt; Erk; BMP/RUNX2
ID OSTEOBLAST DIFFERENTIATION; VAR. SINENSE; IN VIVO; BONE; EXPRESSION;
   MAPK; ERK; MINERALIZATION; OSTEOPOROSIS; GROWTH
AB Bone formation refers to a series of complex events related to the activities of osteoblasts. In this study, we evaluated the osteogenesis activity of a natural compound named isocoumarin A that was isolated from the rhizomes of Polygonum amplexicaule on the non transformed preosteoblastic cell line MC3T3 E1 for an in vitro study, and the results revealed that it increased the proliferation and promoted the mineralization of the extracellular matrix of MC3T3 E1 cells after treatment for 3 d in a dose dependent manner. The cell metabolic activity peaked at 169% at 10 mu M, and the activity of alkaline phosphatase (ALP) tripled to 15.94 U/mg compared with the control group. The protein levels of morphogenetic protein 2 (BMP 2), runt related transcription factor 2 (RUNX2), ALP, and the mRNA levels of ALP, type I collagen (COL 1), and osteocalcin (OCN) were also upregulated after isocoumarin A administration. The mechanism investigation revealed that these effects were associated with the activation of the p Akt/p Erk1/2 activated BMP/RUNX2 signaling pathway. Subsequently, the in vivo investigation on the zebrafish embryos model demonstrated that isocoumarin A (0.30 mM) increased the number of vertebrae (5.38 +/  2.07 pcs) and the vertebral area (433.25 +/  111.77 mu m(2)) in the development process of zebrafish embryos after a 7 day postfertilization (dpf) culture compared with the control group (2.50 +/  1.16 pcs and 209.75 +/  86.40 mu m(2)). Together, these results indicated that isocoumarin A could be viewed as a promising candidate in early drug discovery and development to promote the healing of fractures and postmenopausal osteoporosis.
C1 [Liu, Min zhen; Zhou, Dong Chu; Xiang, Da xiong; Luo, Shi Lin] Cent South Univ, Xiangya Hosp 2, Dept Pharm, Changsha 410011, Hunan, Peoples R China.
   [Liu, Min zhen; Zhou, Dong Chu; Xiang, Da xiong; Luo, Shi Lin] Cent South Univ, Xiangya Hosp 2, Inst Clin Pharm, Changsha 410011, Hunan, Peoples R China.
   [Liu, Qiang] Yiyang Cent Hosp, Dept Pharm, Yiyang 41300, Peoples R China.
   [Xie, Fu li; Tang, Gen yun] Hunan Univ Med, Hunan Prov Key Lab Dong Med, Sch Med Sci, Huaihua 418000, Peoples R China.
C3 Central South University; Central South University; Hunan University of
   Medicine
RP Luo, SL (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Pharm, Changsha 410011, Hunan, Peoples R China.
EM shilin_luo@csu.edu.cn
RI Xiang, Da Xiong/ABD 3898 2021
OI Luo, shilin/0000 0002 6773 7790
FU National Natural Science Foundation of China [81503358]; Health and
   Family Planning Commission of Hunan Province, China [B20180328]
FX The authors gratefully acknowledge the financial support received from
   National Natural Science Foundation of China (No. 81503358, S. L.) and
   Health and Family Planning Commission of Hunan Province, China (No.
   B20180328, D. Z.). We thank Ji Chun Zhang (Jinan University, China) for
   polishing the manuscript.
CR Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   BELLOWS CG, 1991, BONE MINER, V14, P27, DOI 10.1016/0169 6009(91)90100 E
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Dirckx N, 2013, BIRTH DEFECTS RES C, V99, P170, DOI 10.1002/bdrc.21047
   Du SJ, 2001, DEV BIOL, V238, P239, DOI 10.1006/dbio.2001.0390
   El Hawary SS, 2016, J PHARM PHARMACOL, V68, P834, DOI 10.1111/jphp.12566
   Feng JQ, 2003, J BIOL CHEM, V278, P29130, DOI 10.1074/jbc.M212296200
   Fleming A, 2005, J BIOMOL SCREEN, V10, P823, DOI 10.1177/1087057105279952
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Ghosh Choudhury N, 2007, J BIOL CHEM, V282, P4983, DOI 10.1074/jbc.M606706200
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Jia TL, 2003, BIOCHEM PHARMACOL, V65, P709, DOI 10.1016/S0006 2952(02)01585 X
   Knopf F, 2011, DEV CELL, V20, P713, DOI 10.1016/j.devcel.2011.04.014
   Lee CH, 2011, EUR J PHARMACOL, V668, P383, DOI 10.1016/j.ejphar.2011.06.059
   Lee SU, 2008, INT IMMUNOPHARMACOL, V8, P741, DOI 10.1016/j.intimp.2008.01.027
   Lee YY, 2005, PLANTA MED, V71, P776, DOI 10.1055/s 2005 864189
   Li BQ, 2018, COMPUT STRUCT BIOTEC, V16, P600, DOI 10.1016/j.csbj.2018.11.002
   Li CH, 2018, EUR J PHARMACOL, V825, P107, DOI 10.1016/j.ejphar.2018.02.035
   Majors AK, 1997, J ORTHOPAED RES, V15, P546, DOI 10.1002/jor.1100150410
   Morin Kensicki EM, 2002, DEVELOPMENT, V129, P3851
   Orija IB, 2003, CLIN ENDOCRINOL, V59, P657, DOI 10.1046/j.1365 2265.2003.01833.x
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Proff P, 2009, CLIN ORAL INVEST, V13, P355, DOI 10.1007/s00784 009 0268 2
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sanchez A, 2009, INT J PLANT SCI, V170, P1044, DOI 10.1086/605121
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Wang D., 1995, CHIN J ETHNOMED ETHN, V15, P37
   Wang XY, 2011, J BONE MINER RES, V26, P1964, DOI 10.1002/jbmr.394
   Winter JN, 2011, AM J PHYSIOL CELL PH, V300, pC1172, DOI 10.1152/ajpcell.00504.2010
   Xiang MX, 2011, PHARM BIOL, V49, P1091, DOI 10.3109/13880209.2011.568507
   Xiang MX, 2011, MOLECULES, V16, P728, DOI 10.3390/molecules16010728
   Yodthong T, 2018, MOLECULES, V23, DOI 10.3390/molecules23123086
   Zhang J, 2014, BIOMATERIALS, V35, P9322, DOI 10.1016/j.biomaterials.2014.07.056
NR 34
TC 29
Z9 29
U1 1
U2 36
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 5
PY 2019
VL 858
AR 172480
DI 10.1016/j.ejphar.2019.172480
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA IM0SI
UT WOS:000477699100034
PM 31228453
DA 2025 08 17
ER

PT J
AU Xu, YD
   Huang, SX
   Li, ZC
   Dai, LB
   Wu, H
   Wang, PG
   Yao, XG
   Luo, W
   Liu, YM
   Yang, WC
   Feng, Y
   Miao, HX
   Xu, JK
   Ye, DP
AF Xu, Yude
   Huang, Suixiang
   Li, Zhencong
   Dai, Libing
   Wu, Hao
   Wang, Peigeng
   Yao, Xiguan
   Luo, Wei
   Liu, Yiming
   Yang, Weichao
   Feng, Yi
   Miao, Haixiong
   Xu, Jiake
   Ye, Dongping
TI Single cell RNA landscape of osteoimmune microenvironment in
   osteoporotic vertebral compression fracture and Kümmell's disease
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE osteoimmunology; osteoporosis; osteoporotic vertebral compression
   fracture; Kummell's disease; single cell RNA sequencing
AB Background: Single cell RNA sequencing (scRNA seq) enables specific analysis of cell populations at single cell resolution; however, there is still a lack of single cell level studies to characterize the dynamic and complex interactions between osteoporotic vertebral compression fractures (OVCFs) and Kummell's disease (KD) in the osteoimmune microenvironment. In this study, we used scRNA seq analysis to investigate the osteoimmune microenvironment and cellular composition in OVCFs and KD.Methods: ScRNA seq was used to perform analysis of fractured vertebral bone tissues from one OVCF and one KD patients, and a total of 8,741 single cells were captured for single cell transcriptomic analysis. The cellularity of human vertebral bone tissue was further analyzed using uniform manifold approximation and projection. Pseudo time analysis and gene enrichment analysis revealed the biological function of cell fate and its counterparts. CellphoneDB was used to identify the interactions between bone cells and immune cells in the osteoimmune microenvironment of human vertebral bone tissue and their potential functions.Results: A cellular profile of the osteoimmune microenvironment of human vertebral bone tissue was established, including mesenchymal stem cells (MSCs), pericytes, myofibroblasts, fibroblasts, chondrocytes, endothelial cells (ECs), granulocytes, monocytes, T cells, B cells, plasma cells, mast cells, and early erythrocytes. MSCs play an immunoregulatory function and mediate osteogenic differentiation and cell proliferation. The differentiation trajectory of osteoclasts in human vertebral bone tissue was also revealed. In addition, ECs actively participate in inflammatory infiltration and coupling with bone cells. T and B cells actively participate in regulating bone homeostasis. Finally, by identifying the interaction of ligand receptor pairs, we found that immune cells and osteoclasts have bidirectional regulatory characteristics, have the effects of regulating bone resorption by osteoclasts and promoting bone formation, and are essential for bone homeostasis. It is also highlighted that CD8 TEM cells and osteoclasts might crosstalk via CD160 TNFRSF14 ligand receptor interaction.Conclusion: Our analysis reveals a differential landscape of molecular pathways, population composition, and cell cell interactions during OVCF development into KD. OVCFs exhibit a higher osteogenic differentiation capacity, owing to abundant immune cells. Conversely, KD results in greater bone resorption than bone formation due to depletion of MSCs and a relatively suppressed immune system, and this immune imbalance eventually leads to vertebral avascular necrosis. The site of action between immune cells and osteoclasts is expected to be a new therapeutic target, and these results may accelerate mechanistic and functional studies of osteoimmune cell types and specific gene action in vertebral avascular necrosis and pathological bone loss diseases, paving the way for drug discovery.
C1 [Xu, Yude; Dai, Libing; Wu, Hao; Wang, Peigeng; Yao, Xiguan; Luo, Wei; Liu, Yiming; Yang, Weichao; Miao, Haixiong; Ye, Dongping] Jinan Univ, Guangzhou Red Cross Hosp, Guangzhou, Peoples R China.
   [Huang, Suixiang] Jinan Univ, Guangzhou Red Cross Hosp, Dept Pain Med, Guangzhou, Peoples R China.
   [Li, Zhencong] Guangdong Med Univ, Dept Spinal Degenerat & Deform Surg, Affiliated Hosp, Zhanjiang, Peoples R China.
   [Feng, Yi] Jinan Univ, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
   [Xu, Jiake] Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China.
C3 Jinan University; Jinan University; Guangdong Medical University; Jinan
   University; University of Western Australia; Chinese Academy of
   Sciences; Shenzhen Institute of Advanced Technology, CAS
RP Miao, HX; Ye, DP (通讯作者)，Jinan Univ, Guangzhou Red Cross Hosp, Guangzhou, Peoples R China.; Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.; Xu, JK (通讯作者)，Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China.
EM yedongping927@126.com; jiake.xu@uwa.edu.au; miaohaixiong@163.com
RI Li, Zhencong/JAI 9720 2023; Wu, Hao/H 3899 2017; Liu,
   yiming/GSD 2483 2022; Feng, Yi/AAT 5071 2020
FU Guangzhou Science and Technology Planning Project [202102010111];
   Guangzhou Medical and Health Project [20201A011021]; Guangdong Science
   and Technology Planning Project [B2019064]
FX The authors acknowledge NovelBio Bio Pharm Technology Co., Ltd., for
   providing single cell sequencing services with their NovelBrain Cloud
   Analysis Platform (http://www.novelbio.com/).r The authors declare that
   financial support was received for the research, authorship, and/or
   publication of this article. This work was supported by the Guangzhou
   Science and Technology Planning Project (202102010111): The Fluid Shear
   Stress Induces Normal Human Nucleus Pulposus Cells Pyroptosis by
   Activating the NLRP3 Inflammasome Pathway; Guangzhou Medical and Health
   Project (20201A011021): The Fluid Shear Stress Induces Normal Human
   Nucleus Pulposus Cells Pyroptosis by Activating the NLRP3 Inflammasome
   Pathway; and Guangdong Science and Technology Planning Project
   (B2019064): The Fluid Shear Stress Induces Normal Human Nucleus Pulposus
   Cells Pyroptosis by Activating the NLRP3 Inflammasome Pathway.
CR Adamska O, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122584
   Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]
   Aoki K, 2021, BRIT J HAEMATOL, V193, P659, DOI 10.1111/bjh.17396
   Arceo Mendoza R, 2021, ENDOCRIN METAB CLIN, V50, P167, DOI 10.1016/j.ecl.2021.03.009
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Arthur A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.598612
   Avin KG, 2023, J ORTHOP RES, V41, P1060, DOI 10.1002/jor.25452
   Bai HB, 2019, J BIOCHEM, V166, P475, DOI 10.1093/jb/mvz060
   BROWER AC, 1981, RADIOLOGY, V141, P363, DOI 10.1148/radiology.141.2.7291557
   BURKHARDT R, 1987, BONE, V8, P157, DOI 10.1016/8756 3282(87)90015 9
   Cao JY, 2019, NATURE, V566, P496, DOI 10.1038/s41586 019 0969 x
   Chen GD, 2015, PAIN PHYSICIAN, V18, pE1021
   Chen SF, 2018, BIOINFORMATICS, V34, P884, DOI 10.1093/bioinformatics/bty560
   Chen Y, 2022, THERANOSTICS, V12, P1074, DOI 10.7150/thno.65694
   Chen ZZ, 2021, ORTHOP SURG, V13, P1979, DOI 10.1111/os.13025
   Cheung TC, 2009, J IMMUNOL, V183, P7286, DOI 10.4049/jimmunol.0902490
   Chiba N, 2022, FEBS LETT, V596, P1720, DOI 10.1002/1873 3468.14407
   Chim SM, 2013, CYTOKINE GROWTH F R, V24, P297, DOI 10.1016/j.cytogfr.2013.03.008
   Dar HY, 2018, FRONT BIOSCI LANDMRK, V23, P464, DOI 10.2741/4600
   David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dostert C, 2019, PHYSIOL REV, V99, P115, DOI 10.1152/physrev.00045.2017
   Edidin A., 2011, Spine J, V11, pS109, DOI [10.1016/j.spinee.2011.08.272, DOI 10.1016/J.SPINEE.2011.08.272]
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Glorie L, 2016, BONE, V92, P37, DOI 10.1016/j.bone.2016.08.009
   Gou PG, 2023, ORTHOP SURG, V15, P366, DOI 10.1111/os.13559
   He DW, 2016, EXP THER MED, V12, P879, DOI 10.3892/etm.2016.3369
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Huang YJ, 2020, EXP THER MED, V20, P736, DOI 10.3892/etm.2020.8774
   Jia J, 2016, MICROVASC RES, V105, P103, DOI 10.1016/j.mvr.2016.02.004
   Karimi L, 2019, CLIN EXP ALLERGY, V49, P1429, DOI 10.1111/cea.13460
   Karmakar A, 2017, J CLIN DIAGN RES, V11, pRC7, DOI 10.7860/JCDR/2017/25886.10461
   Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood 2006 09 048249
   Komatsu N, 2022, NAT REV RHEUMATOL, V18, P415, DOI 10.1038/s41584 022 00793 5
   Komori T, 2020, MOL CELLS, V43, P168, DOI 10.14348/molcells.2019.0244
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lee SH, 2011, J CLIN NEUROSCI, V18, P509, DOI 10.1016/j.jocn.2010.07.139
   Li CH, 2012, BIOCHEM BIOPH RES CO, V429, P156, DOI 10.1016/j.bbrc.2012.10.122
   Li XM, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2020.11708
   Liang B, 2022, CELL MOL BIOL LETT, V27, DOI 10.1186/s11658 022 00371 3
   Liao GB, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964 018 0266 6
   Lim J, 2018, J KOREAN NEUROSURG S, V61, P1, DOI 10.3340/jkns.2017.0505.010
   Lin Q, 2022, EUR J PHARMACOL, V936, DOI 10.1016/j.ejphar.2022.175347
   Liu ML, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10134 y
   Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Schebesta A, 2007, IMMUNITY, V27, P49, DOI 10.1016/j.immuni.2007.05.019
   Sedy J, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016279
   Shao Y, 2020, ARTERIOSCL THROM VAS, V40, pE138, DOI 10.1161/ATVBAHA.120.314330
   Shui JW, 2011, J LEUKOCYTE BIOL, V89, P517, DOI 10.1189/jlb.0910528
   Smith T, 2017, GENOME RES, V27, P491, DOI 10.1101/gr.209601.116
   Sperandio S, 2009, MOL CARCINOGEN, V48, P38, DOI 10.1002/mc.20454
   Stiffel V, 2014, J BONE MINER RES, V29, P804, DOI 10.1002/jbmr.2084
   Swartz K, 2008, SPINE, V33, pE152, DOI 10.1097/BRS.0b013e3181657f31
   Tan JY, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/9919024
   Tang PF, 2014, RNA BIOL, V11, P1355, DOI 10.1080/15476286.2014.996462
   Tian J, 2014, INT J SURG, V12, P1249, DOI 10.1016/j.ijsu.2014.10.027
   Tuckermann J, 2021, NAT REV RHEUMATOL, V17, P608, DOI 10.1038/s41584 021 00682 3
   Vento Tormo R, 2018, NATURE, V563, P347, DOI 10.1038/s41586 018 0698 6
   Wang YX, 2022, INT IMMUNOPHARMACOL, V113, DOI 10.1016/j.intimp.2022.109302
   Wang Z, 2021, INT J BIOL SCI, V17, P4192, DOI 10.7150/ijbs.61950
   Wu T, 2004, CYTOKINE, V25, P11, DOI 10.1016/j.cyto.2003.08.013
   Xia YH, 2018, EXP THER MED, V16, P3617, DOI 10.3892/etm.2018.6628
   Xie ZY, 2022, EXP MOL MED, V54, P483, DOI 10.1038/s12276 022 00749 5
   Yaari G, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt660
   Yan SF, 2006, J AM COLL CARDIOL, V48, pA47, DOI 10.1016/j.jacc.2006.05.063
   Yoshitake F, 2008, J BIOL CHEM, V283, P11535, DOI 10.1074/jbc.M607999200
   Zhang JY, 2020, NAT IMMUNOL, V21, P1107, DOI 10.1038/s41590 020 0762 x
   Zhang J, 2020, REGEN MED, V15, P2129, DOI 10.2217/rme 2019 0080
   Zhang L, 2018, NATURE, V564, P268, DOI 10.1038/s41586 018 0694 x
   Zhang XS, 2016, SPINE, V41, pE923, DOI 10.1097/BRS.0000000000001467
   Zhu SP, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00203 2
   Zhu SP, 2020, THERANOSTICS, V10, P5957, DOI 10.7150/thno.45422
   Zhu YW, 2016, J EXP MED, V213, P167, DOI 10.1084/jem.20150785
NR 75
TC 7
Z9 7
U1 6
U2 18
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD DEC 15
PY 2023
VL 11
AR 1276098
DI 10.3389/fcell.2023.1276098
PG 17
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA DP3F1
UT WOS:001133213100001
PM 38161331
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kim, HJ
   Kim, BK
   Ohk, B
   Yoon, HJ
   Kang, WY
   Cho, S
   Seong, SJ
   Lee, HW
   Yoon, YR
AF Kim, Hyun Ju
   Kim, Bo Kyung
   Ohk, Boram
   Yoon, Hye Jin
   Kang, Woo Youl
   Cho, Seungil
   Seong, Sook Jin
   Lee, Hae Won
   Yoon, Young Ran
TI Estrogen related receptor γ negatively regulates osteoclastogenesis and
   protects against inflammatory bone loss
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE ERR gamma; NFATc1; NF kappa B; osteoclastogenesis
ID NF KAPPA B; INDEPENDENT TRANSCRIPTIONAL ACTIVATION; LOOP HELIX PROTEINS;
   LACKING C FOS; NUCLEAR FACTOR; DIFFERENTIATION; ORPHAN; ALPHA; RANKL;
   IDENTIFICATION
AB Estrogen related receptor gamma (ERR gamma) is an orphan nuclear receptor that plays an important role in various metabolic processes under physiological and pathophysiological conditions. Here, we report that ERR gamma functions as a negative regulator in receptor activator of nuclear factor kappa Beta ligand (RANKL) induced osteoclast differentiation. We observed that ERR gamma was strongly expressed in osteoclast precursors, bone marrow derived macrophages (BMMs) while its expression was significantly reduced by RANKL during osteoclastogenesis. Overexpression of ERR gamma in BMMs suppressed the formation of multinucleated osteoclasts and attenuated the induction of c Fos and nuclear factor of activated T cells c1, which are critical modulators in osteoclastogenesis. Similarly, the treatment of ERR gamma agonists, N (4 (diethylaminobenzylidenyl) N' (4 hydroxybenzoyl) hydrazine (DY131) or GSK4716, also inhibited osteoclast generation and the expression of these key modulators. On the other hand, shRNA mediated knockdown of ERR gamma accelerated the formation of bone resorbing cells and the expression of osteoclastogenic markers. Forced expression of ERR gamma blocked RANKL stimulated phosphorylation of the nuclear factor kappa B (NF kappa B) inhibitor I kappa B alpha and suppressed NF kappa B transcriptional activity induced by RANKL or the NF kappa B subunit p65. Furthermore, by employing a pharmacological approach, we showed that the ERR gamma agonist DY131 protected against inflammatory bone loss induced by lipopolysaccharide in vivo. Together, our findings reveal that ERR gamma is a pivotal regulator in RANKL mediated osteoclastogenesis and suggest that ERR gamma may have potential as a therapeutic target for pathological bone loss.
C1 [Kim, Hyun Ju; Kim, Bo Kyung; Ohk, Boram; Yoon, Young Ran] Kyungpook Natl Univ, Sch Med, Plus KNU Biomed Convergence Program BK21, Dept Mol Med,Cell & Matrix Res Inst, Daegu, South Korea.
   [Kim, Hyun Ju; Kim, Bo Kyung; Ohk, Boram; Yoon, Hye Jin; Kang, Woo Youl; Cho, Seungil; Seong, Sook Jin; Lee, Hae Won; Yoon, Young Ran] Kyungpook Natl Univ Hosp, Clin Trial Ctr, Daegu, South Korea.
C3 Kyungpook National University (KNU); Kyungpook National University
   (KNU); Kyungpook National University Hospital (KNUH)
RP Kim, HJ (通讯作者)，Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Plus KNU Biomed Convergence Program BK21, Clin Trial Ctr,Sch Med,Dept Mol Med,Cell & Matrix, Daegu 41944, South Korea.; Yoon, YR (通讯作者)，Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Plus KNU Biomed Convergence Program BK21,Sch Med, Dept Mol Med,Cell & Matrix Res Inst,Clin Trial Ct, Daegu 41944, South Korea.
EM biohjk@knu.ac.kr; yry@knu.ac.kr
RI Yoon, Young Ran/GLT 0172 2022; Kim, Bo Kyung/JMC 2134 2023
OI Cho, Seungil/0000 0003 4216 7805; Kim, Hyun Ju/0000 0002 5836 5841
FU National Research Foundation (NRF)   Ministry of Education, Science, and
   Technology, Republic of Korea [NRF 2015R1D1A1A01056666]; Ministry of
   Health & Welfare, Republic of Korea [HI14C2750, HI15C0001]
FX National Research Foundation (NRF) funded by the Ministry of Education,
   Science, and Technology, Republic of Korea, Grant/Award Number:
   NRF 2015R1D1A1A01056666; Ministry of Health & Welfare, Republic of
   Korea, Grant/Award Numbers: HI14C2750, HI15C0001
CR Audet Walsh É, 2015, ACTA PHARMACOL SIN, V36, P51, DOI 10.1038/aps.2014.121
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Bonnelye E, 2013, J BONE MINER RES, V28, P225, DOI 10.1002/jbmr.1836
   Bonnelye E, 2010, J MOL ENDOCRINOL, V45, P365, DOI 10.1677/JME 10 0024
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bruzzaniti A, 2006, REV ENDOCR METAB DIS, V7, P123, DOI 10.1007/s11154 006 9009 x
   Cardelli M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109592
   Cardelli M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081511
   Carnesecchi J, 2016, MOL CELL ENDOCRINOL, V432, P47, DOI 10.1016/j.mce.2015.07.019
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gallet M, 2010, TRENDS ENDOCRIN MET, V21, P637, DOI 10.1016/j.tem.2010.06.008
   GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0
   Giguère V, 2008, ENDOCR REV, V29, P677, DOI 10.1210/er.2008 0017
   Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097 2765(02)00444 6
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jeong BC, 2009, J BIOL CHEM, V284, P14211, DOI 10.1074/jbc.M808345200
   JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092 8674(92)90592 Z
   Kallen J, 2004, J BIOL CHEM, V279, P49330, DOI 10.1074/jbc.M407999200
   Kim HJ, 2016, CELL SIGNAL, V28, P1137, DOI 10.1016/j.cellsig.2016.05.018
   Kim HJ, 2016, J CELL PHYSIOL, V231, P844, DOI 10.1002/jcp.25133
   Kim HJ, 2012, BONE, V51, P643, DOI 10.1016/j.bone.2012.07.015
   Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood 2006 09 048249
   Lee J, 2006, BLOOD, V107, P2686, DOI 10.1182/blood 2005 07 2798
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Misra J, 2017, TRENDS ENDOCRIN MET, V28, P261, DOI 10.1016/j.tem.2016.12.005
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Park JW, 2018, J CELL PHYSIOL, V233, P1481, DOI 10.1002/jcp.26035
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Son YO, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01868 8
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Zhang L, 2016, CELL MOL LIFE SCI, V73, P3781, DOI 10.1007/s00018 016 2328 5
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
NR 44
TC 12
Z9 14
U1 1
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD FEB
PY 2019
VL 234
IS 2
BP 1659
EP 1670
DI 10.1002/jcp.27035
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA HA9HQ
UT WOS:000450611300058
PM 30076703
DA 2025 08 17
ER

PT J
AU Patrocínio Silva, TL
   de Souza, AMF
   Goulart, RL
   Pegorari, CF
   Oliveira, JR
   Fernandes, K
   Magri, A
   Pereira, RMR
   Araki, DR
   Nagaoka, MR
   Parizotto, NA
   Rennó, ACM
AF Patrocinio Silva, Tatiane Lopes
   Fogaca de Souza, Andre Moreira
   Goulart, Raul Loppi
   Pegorari, Carolina Fuirini
   Oliveira, Jussan Rodrigues
   Fernandes, Kelly
   Magri, Angela
   Rodrigues Pereira, Rosa Maria
   Araki, Daniel Ribeiro
   Nagaoka, Marcia Regina
   Parizotto, Nivaldo Antonio
   Muniz Renno, Ana Claudia
TI The effects of low level laser irradiation on bone tissue in diabetic
   rats
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Diabetes mellitus; Bone tissue; Low level laser therapy
ID MECHANICAL PROPERTIES; PARTIAL OSTEOTOMY; THERAPY; DEFECTS; INSULIN;
   TIBIA; PHOTOSTIMULATION; APOPTOSIS; DIAGNOSIS; MELLITUS
AB Diabetes mellitus (DM) leads to a decrease in bone mass and increase the risk of osteoporosis and in this context, many treatments have shown to accelerate bone metabolism. It seems that low level laser therapy (LLLT) is able of stimulating osteoblast activity and produced increased biomechanical properties. However, its effects on bone in diabetic rats are not fully elucidated. The aim of this study was to evaluate the effects of LLLT on bone formation, immunoexpression of osteogenic factors, biomechanical properties and densitometric parameters in diabetic rats. Thirty male Wistar rats were randomly distributed into three experimental groups: control group, diabetic group, and laser treated diabetic group. DM was induced by streptozotocin (STZ) and after 1 week laser treatment started. An 830 nm laser was used, performed for 18 sessions, during 6 weeks. At the end of the experiment, animals were euthanized and tibias and femurs were defleshed for analysis. Extensive resorptive areas as a result of osteoclasts activity were noticed in DG when compared to control. Laser treated animals showed an increased cortical area. The immunohistochemical analysis revealed that LLLT produced an increased RUNX 2 expression compared to other groups. Similar RANK L immunoexpression was observed for all experimental groups. In addition, laser irradiation produced a statistically increase in fracture force, bone mineral content (BMC) and bone mineral density compared to DG. The results of this study indicate that the STZ model was efficient in inducing DM 1 and producing a decrease in cortical diameter, biomechanical properties and in densitometric variables. In addition, it seems that LLLT stimulated bone metabolism, decreased resorptive areas, increased RUNX 2 expression, cortical area, fracture force, BMD, and BMC. Further studies should be developed to provide additional information concerning the mechanisms of action of laser therapy in diabetic bone in experimental and clinical trials.
C1 [Patrocinio Silva, Tatiane Lopes; Parizotto, Nivaldo Antonio] Univ Fed Sao Carlos, Dept Biotechnol, BR 13565902 Sao Paulo, Brazil.
   [Fogaca de Souza, Andre Moreira; Goulart, Raul Loppi; Pegorari, Carolina Fuirini; Oliveira, Jussan Rodrigues; Fernandes, Kelly; Magri, Angela] Univ Fed Sao Paulo, Dept Physiotherapy, BR 11050240 Sao Paulo, Brazil.
   [Rodrigues Pereira, Rosa Maria] Univ Sao Paulo, Dept Med, BR 01246903 Sao Paulo, Brazil.
   [Araki, Daniel Ribeiro; Nagaoka, Marcia Regina; Muniz Renno, Ana Claudia] Univ Fed Sao Paulo, Dept Biosci, BR 11050240 Sao Paulo, Brazil.
C3 Universidade Federal de Sao Carlos; Universidade Federal de Sao Paulo
   (UNIFESP); Universidade de Sao Paulo; Universidade Federal de Sao Paulo
   (UNIFESP)
RP Rennó, ACM (通讯作者)，Univ Fed Sao Paulo, Dept Biosci, Av Ana Costa,95,Vila Mathias, BR 11050240 Sao Paulo, Brazil.
EM a.renno@unifesp.br
RI Pereira, Rosa Maria Rodrigues/C 5192 2012; PARIZOTTO, NIVALDO
   ANTONIO/D 5347 2014; Pereira, Rosa/C 5192 2012; Nagaoka,
   Marcia/C 2086 2012; Parizotto, Nivaldo/D 5347 2014; Paiva Magri, Angela
   Maria/J 9323 2016; Renno, Ana/C 1266 2015; Magri, Angela/J 9323 2016
OI Pereira, Rosa Maria Rodrigues/0000 0002 3723 5028; PARIZOTTO, NIVALDO
   ANTONIO/0000 0003 1774 9053; Renno, Ana/0000 0003 2358 0514; Nagaoka,
   Marcia/0000 0003 1403 3738; Paiva Magri, Angela
   Maria/0000 0001 5901 7227; 
CR Abdi S, 2009, PHOTOMED LASER SURG, V27, P907, DOI 10.1089/pho.2008.2421
   Akyol UK, 2010, PHOTOMED LASER SURG, V28, P411, DOI 10.1089/pho.2008.2478
   Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096 9136(199807)15:7<539::AID DIA668>3.0.CO;2 S
   Anandarajah AP, 2009, TRENDS ENDOCRIN MET, V20, P88, DOI 10.1016/j.tem.2008.10.007
   Bashardoust Tajali S, 2003, OSTEO TRAUMA CARE, V11, P17
   Bayat M, 2009, PHOTOMED LASER SURG, V27, P703, DOI 10.1089/pho.2008.2351
   Blakytny R, 2011, INT J LOW EXTR WOUND, V10, P16, DOI 10.1177/1534734611400256
   Bossini PS, 2012, EXP GERONTOL, V47, P136, DOI 10.1016/j.exger.2011.11.005
   Coombe A R, 2001, Clin Orthod Res, V4, P3, DOI 10.1034/j.1600 0544.2001.040102.x
   Cornish J, 1996, CALCIFIED TISSUE INT, V59, P492, DOI 10.1007/BF00369216
   EINHORN TA, 1988, J ORTHOP RES, V6, P317, DOI 10.1002/jor.1100060303
   Fávaro Pípi E, 2010, LASER MED SCI, V25, P727, DOI 10.1007/s10103 010 0772 2
   Fernandes KR, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.3.038002
   Freitas IGF, 2000, APPL SURF SCI, V154, P548, DOI 10.1016/S0169 4332(99)00431 6
   Garavello Freltas I, 2003, J PHOTOCH PHOTOBIO B, V70, P81, DOI 10.1016/S1011 1344(03)00058 7
   Genuth S, 2003, DIABETES CARE, V26, P3160
   He HB, 2004, ENDOCRINOLOGY, V145, P447, DOI 10.1210/en.2003 1239
   Higgins TF, 2010, J ORTHOP RES, V28, P125, DOI 10.1002/jor.20942
   Huang S, 2010, BONE, V46, P1138, DOI 10.1016/j.bone.2009.12.020
   Javadieh F, 2009, PHOTOMED LASER SURG, V27, P641, DOI 10.1089/pho.2008.2370
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Khadra M, 2004, ORAL SURG ORAL MED O, V97, P693, DOI 10.1016/j.tripleo.2003.11.008
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Lozano D, 2011, BRIT J PHARMACOL, V162, P1424, DOI 10.1111/j.1476 5381.2010.01155.x
   Luger EJ, 1998, LASER SURG MED, V22, P97, DOI 10.1002/(SICI)1096 9101(1998)22:2<97::AID LSM5>3.3.CO;2 E
   MATHIASSEN B, 1990, Journal of Diabetic Complications, V4, P145, DOI 10.1016/0891 6632(90)90012 T
   Medalha CC, 2010, PHOTOMED LASER SURG, V28, P669, DOI 10.1089/pho.2009.2691
   Renno ACM, 2006, PHOTOMED LASER SURG, V24, P642, DOI 10.1089/pho.2006.24.642
   Nissan J, 2006, J ORAL REHABIL, V33, P619, DOI 10.1111/j.1365 2842.2006.01601.x
   Nyman JS, 2011, BONE, V48, P733, DOI 10.1016/j.bone.2010.12.016
   Oliveira DAAP, 2008, PHOTOMED LASER SURG, V26, P401, DOI 10.1089/pho.2007.2101
   Petersen M, 2003, DIABETES CARE, V26, P917
   Reddy GK, 2001, WOUND REPAIR REGEN, V9, P248, DOI 10.1046/j.1524 475x.2001.00248.x
   Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161
   Suzuki K, 2003, BONE, V33, P108, DOI 10.1016/S8756 3282(03)00169 8
   Tajali SB, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 1
   Thrailkill KM, 2005, AM J PHYSIOL ENDOC M, V289, pE735, DOI 10.1152/ajpendo.00159.2005
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Wongdee K, 2011, WORLD J DIABETES, V2, P41, DOI 10.4239/wjd.v2.i3.41
   Yaoita H, 2000, J BONE MINER METAB, V18, P63, DOI 10.1007/s007740050013
   Yu W, 1997, LASER SURG MED, V20, P56, DOI 10.1002/(SICI)1096 9101(1997)20:1<56::AID LSM9>3.0.CO;2 Y
NR 41
TC 25
Z9 25
U1 0
U2 5
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD JUL
PY 2014
VL 29
IS 4
BP 1357
EP 1364
DI 10.1007/s10103 013 1418 y
PG 8
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA AK7ZB
UT WOS:000338645800006
PM 23990218
DA 2025 08 17
ER

PT J
AU George, B
   Pillai, PM
   Paul, AM
   Amjesh, R
   Leitzel, K
   Ali, SM
   Sandiford, O
   Lipton, A
   Rameshwar, P
   Hortobagyi, GN
   Pillai, MR
   Kumar, R
AF George, Bijesh
   Pillai, P. Mukundan
   Paul, Aswathy Mary
   Amjesh, Revikumar
   Leitzel, Kim
   Ali, Suhail M.
   Sandiford, Oleta
   Lipton, Allan
   Rameshwar, Pranela
   Hortobagyi, Gabriel N.
   Pillai, Madhavan Radhakrishna
   Kumar, Rakesh
TI Cellular Fitness Phenotypes of Cancer Target Genes from Oncobiology to
   Cancer Therapeutics
SO CELLS
LA English
DT Article
DE cancer fitness genes; breast cancer hard to treat cancers; Mevalonate
   and Purine biosynthesis; oncology drugs; repurposing
ID NEGATIVE BREAST CANCER; ADJUVANT ZOLEDRONIC ACID; 1ST LINE TREATMENT;
   SINGLE AGENT; SUBTYPES; GENOMICS; REVEALS; BONE; TRASTUZUMAB; PROFILES
AB To define the growing significance of cellular targets and/or effectors of cancer drugs, we examined the fitness dependency of cellular targets and effectors of cancer drug targets across human cancer cells from 19 cancer types. We observed that the deletion of 35 out of 47 cellular effectors and/or targets of oncology drugs did not result in the expected loss of cell fitness in appropriate cancer types for which drugs targeting or utilizing these molecules for their actions were approved. Additionally, our analysis recognized 43 cellular molecules as fitness genes in several cancer types in which these drugs were not approved, and thus, providing clues for repurposing certain approved oncology drugs in such cancer types. For example, we found a widespread upregulation and fitness dependency of several components of the mevalonate and purine biosynthesis pathways (currently targeted by bisphosphonates, statins, and pemetrexed in certain cancers) and an association between the overexpression of these molecules and reduction in the overall survival duration of patients with breast and other hard to treat cancers, for which such drugs are not approved. In brief, the present analysis raised cautions about off target and undesirable effects of certain oncology drugs in a subset of cancers where the intended cellular effectors of drug might not be good fitness genes and that this study offers a potential rationale for repurposing certain approved oncology drugs for targeted therapeutics in additional cancer types.
C1 [George, Bijesh; Pillai, P. Mukundan; Paul, Aswathy Mary; Amjesh, Revikumar; Pillai, Madhavan Radhakrishna; Kumar, Rakesh] Rajiv Gandhi Ctr Biotechnol, Canc Res Program, Trivandrum 695014, Kerala, India.
   [George, Bijesh; Paul, Aswathy Mary] Manipal Acad Higher Educ, Grad Degree Program, Manipal 576104, India.
   [Leitzel, Kim; Lipton, Allan] Penn State Univ, Sch Med, Dept Med, Hematol Oncol, Hershey, PA 17033 USA.
   [Ali, Suhail M.; Kumar, Rakesh] Lebanon Vet Affairs Med Ctr, Lebanon, PA 17042 USA.
   [Sandiford, Oleta; Rameshwar, Pranela] Rutgers New Jersey Med Sch, Div Hematol & Oncol, Dept Med, Newark, NJ 07103 USA.
   [Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA.
   [Kumar, Rakesh] Virginia Commonwealth Univ, Med Ctr, Dept Human & Mol Genet, Richmond, VA 23298 USA.
C3 Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for
   Biotechnology (RGCB); Manipal Academy of Higher Education (MAHE);
   Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Rutgers University
   System; Rutgers University New Brunswick; Rutgers University Biomedical
   & Health Sciences; University of Texas System; UTMD Anderson Cancer
   Center; Virginia Commonwealth University
RP Pillai, MR; Kumar, R (通讯作者)，Rajiv Gandhi Ctr Biotechnol, Canc Res Program, Trivandrum 695014, Kerala, India.; Kumar, R (通讯作者)，Lebanon Vet Affairs Med Ctr, Lebanon, PA 17042 USA.; Kumar, R (通讯作者)，Virginia Commonwealth Univ, Med Ctr, Dept Human & Mol Genet, Richmond, VA 23298 USA.
EM bijeshgeorge@rgcb.res.in; mukundan@rgcb.res.in; aswathym@rgcb.res.in;
   amjeshr@rgcb.res.in; kleitzel@pennstatehealth.psu.edu;
   Suhail.Ali@med.va.gov; oas26@njms.rutgers.edu;
   alipton@pennstatehealth.psu.edu; Rameshwa@njms.rutgers.edu;
   ghortoba@mdanderson.org; mrpillai@rgcb.res.in; rakeshkumar@rgcb.res.in
OI Rameshwar, Pranela/0000 0003 0434 9034; Hortobagyi,
   Gabriel/0000 0002 4873 4412; R, Amjesh/0000 0003 0036 6582
FU Department of Science & Technology, Government of India
   [VI D&P/535/2015 16/TDT(G)]
FX We acknowledge funding from the Department of Science & Technology,
   Government of India to M.R.P. (Sanction Number:
   VI D&P/535/2015 16/TDT(G)).
CR Aguirre Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250
   Alexandre L, 2014, GASTROENTEROLOGY, V146, P661, DOI 10.1053/j.gastro.2013.11.046
   ARMAND JP, 1990, FUNDAM CLIN PHARM, V4, pS197, DOI 10.1111/j.1472 8206.1990.tb00079.x
   Bang YJ, 2010, LANCET, V376, P1302
   Behan FM, 2019, NATURE, V568, P511, DOI 10.1038/s41586 019 1103 9
   Bogdanovich S, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.1
   Borgquist S, 2019, BMC CANCER, V19, DOI 10.1186/s12885 018 5263 z
   Burstein MD, 2015, CLIN CANCER RES, V21, P1688, DOI 10.1158/1078 0432.CCR 14 0432
   Cabrera Galeana P, 2018, ONCOLOGIST, V23, P670, DOI 10.1634/theoncologist.2017 0396
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159 8290.CD 12 0095
   Choi J, 2019, NUCLEIC ACIDS RES, V47, pD841, DOI 10.1093/nar/gky1064
   Choi J, 2019, NUCLEIC ACIDS RES, V47, pD780, DOI 10.1093/nar/gky1020
   Coleman R, 2017, LANCET ONCOL, V18, P1543, DOI 10.1016/S1470 2045(17)30603 4
   Costa L, 2017, LANCET ONCOL, V18, P1437, DOI 10.1016/S1470 2045(17)30695 2
   Crocamo S, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919853971
   de Fonseka D, 2018, TRIALS, V19, DOI 10.1186/s13063 018 2851 9
   den Hollander P, 2016, CANCER RES, V76, P1942, DOI 10.1158/0008 5472.CAN 14 0673
   Deng HY, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016480
   Diel IJ, 2008, ANN ONCOL, V19, P2007, DOI 10.1093/annonc/mdn429
   Dy GK, 2019, BMC MED INFORM DECIS, V19, DOI 10.1186/s12911 019 0743 x
   El Refai SM, 2017, JCO CLIN CANCER INFO, V1, DOI 10.1200/CCI.17.00010
   Elsayed M, 2016, BIOL PHARM BULL, V39, P1238, DOI 10.1248/bpb.b15 00746
   Feizi A, 2015, DATABASE OXFORD, DOI 10.1093/database/bav051
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Garraway LA, 2013, J CLIN ONCOL, V31, P1806, DOI 10.1200/JCO.2012.46.8934
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   Goldman Mary, 2018, bioRxiv, V2018, DOI DOI 10.1101/326470
   Hantschel O, 2015, ACS CHEM BIOL, V10, P234, DOI 10.1021/cb500886n
   Harney AS, 2015, CANCER DISCOV, V5, P932, DOI 10.1158/2159 8290.CD 15 0012
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   Jézéquel P, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058 019 1148 6
   Jézéquel P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058 015 0550 y
   Kaelin WG, 2017, NAT REV CANCER, V17, P441, DOI 10.1038/nrc.2017.32
   Karaayvaz M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06052 0
   Karagiannis GS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0026
   Karn T, 2014, GENOM DATA, V2, P354, DOI 10.1016/j.gdata.2014.09.014
   Karn T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028403
   Karn T, 2012, EUR J CANCER, V48, P12, DOI 10.1016/j.ejca.2011.06.025
   Keklikoglou I, 2019, NAT CELL BIOL, V21, P190, DOI 10.1038/s41556 018 0256 3
   Kimbung S, 2016, ONCOTARGET, V7, P59640, DOI 10.18632/oncotarget.10746
   Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126
   Kumar R, 2019, CANCER RES, V79, P4315, DOI 10.1158/0008 5472.CAN 19 0989
   Lacouture M, 2018, AM J CLIN DERMATOL, V19, P31, DOI 10.1007/s40257 018 0384 3
   Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068
   Li YR, 2019, BREAST CANCER RES TR, V176, P669, DOI 10.1007/s10549 019 05267 z
   Lin A, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw8412
   Lipton A, 2011, EXPERT REV ANTICANC, V11, P999, DOI [10.1586/ERA.11.71, 10.1586/era.11.71]
   Liu YR, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058 016 0690 8
   Lonard DM, 2010, MOL ENDOCRINOL, V24, P279, DOI 10.1210/me.2009 0276
   Mendelsohn J, 2000, Trans Am Clin Climatol Assoc, V111, P95
   Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003
   Middleton JD, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113333
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   O'Carrigan B, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub4
   Onishi T, 2010, NAT REV CLIN ONCOL, V7, P641, DOI 10.1038/nrclinonc.2010.134
   Pandyra AA, 2015, ONCOTARGET, V6, P26909, DOI 10.18632/oncotarget.4817
   Pavlovic M, 2015, JNCI J NATL CANCER I, V107, DOI 10.1093/jnci/djv256
   Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476 5586(04)80047 2
   Roche M, 2018, ONCOL REV, V12, P8, DOI 10.4081/oncol.2018.346
   Rody A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3035
   Rozenblum AB, 2017, J THORAC ONCOL, V12, P258, DOI 10.1016/j.jtho.2016.10.021
   Santos R, 2017, NAT REV DRUG DISCOV, V16, P19, DOI 10.1038/nrd.2016.230
   Sastre J, 2011, CRIT REV ONCOL HEMAT, V77, P79, DOI 10.1016/j.critrevonc.2009.11.005
   Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095
   Seshacharyulu P, 2019, ONCOGENE, V38, P5265, DOI 10.1038/s41388 019 0791 9
   Swain SM, 2015, NEW ENGL J MED, V372, P724, DOI 10.1056/NEJMoa1413513
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Vallianou NG, 2014, ANTI CANCER AGENT ME, V14, P706, DOI 10.2174/1871520613666131129105035
   van der Meer D, 2019, NUCLEIC ACIDS RES, V47, pD923, DOI 10.1093/nar/gky872
   Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719
   Wang Z, 2018, LANCET RESP MED, V6, pE50
   Widakowich C, 2007, ONCOLOGIST, V12, P1443, DOI 10.1634/theoncologist.12 12 1443
   Winkler GC, 2014, REGUL TOXICOL PHARM, V70, P46, DOI 10.1016/j.yrtph.2014.06.012
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
NR 78
TC 5
Z9 5
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD FEB
PY 2021
VL 10
IS 2
AR 433
DI 10.3390/cells10020433
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA QN3QV
UT WOS:000622379400001
PM 33670680
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liang, N
   Zhang, QW
   He, B
AF Liang, Ning
   Zhang, Qiwen
   He, Bin
TI 被撤回的出版物: Depth Vision Based Assessment of Bone Marrow Mesenchymal Stem
   Cell Differentiation Capacity in Patients with Congenital Scoliosis
   (Retracted Article)
SO JOURNAL OF HEALTHCARE ENGINEERING
LA English
DT Article; Retracted Publication
AB Congenital scoliosis (CS) is a lateral curvature of one or more segments of the spine due to spinal dysplasia during fetal life. CS is clinically defined as a curvature of the spine >10 degrees due to structural abnormalities of the vertebrae during the embryonic period. Its etiology is unknown, but recent studies suggest that it may be closely related to genetic factors, environmental factors, and developmental abnormalities. The induction methods and modern applications of bone marrow MSCs provide a reference for in depth human research on the induction of differentiation of bone marrow MSCs into osteoblasts. In this paper, by reviewing and organizing the literature on bone marrow MSCs, we summarized and analyzed the biological properties and preparation of bone marrow MSCs, the methods of inducing osteoblasts, the applications in tissue engineering bone, the problems faced, and the future research directions and proposed a method to assess the differentiation ability of bone marrow MSCs in patients with congenital scoliosis based on depth visual characteristics and the change of the method. The method reveals and evaluates the multidirectional differentiation potential of bone marrow MSCs, which can be induced to differentiate into osteoblasts in vitro and can be used to construct bone tissue engineering scaffolds in vitro using tissue engineering techniques. Based on the properties of bone marrow MSCs, their application in congenital scoliosis patients for trauma repair, cell replacement therapy, hematopoietic support, and gene therapy is quite promising. It is necessary to carry out research on the mechanism of osteogenic differentiation of bone marrow MSCs to provide guidance and reference value for their induced differentiation into osteoblasts.
C1 [Liang, Ning; Zhang, Qiwen; He, Bin] Zunyi Med Univ, Affiliated Hosp 3, Zunyi Peoples Hosp 1, Zunyi 563000, Guizhou, Peoples R China.
C3 Zunyi Medical University
RP He, B (通讯作者)，Zunyi Med Univ, Affiliated Hosp 3, Zunyi Peoples Hosp 1, Zunyi 563000, Guizhou, Peoples R China.
EM 171847206@masu.edu.cn
RI ; Zhao, Wensi/JDW 1266 2023
OI He, Bin/0000 0002 5212 3737; 
FU Guizhou Provincial Department of Science and Technology [[2018] 2756]
FX This work was sponsored in part by Fund Project approved by Guizhou
   Provincial Department of Science and Technology ([2018] 2756).
CR Ahuja K, 2021, EUR SPINE J, V30, P599, DOI 10.1007/s00586 020 06662 7
   Cho W, 2018, EUR SPINE J, V27, pS533, DOI 10.1007/s00586 018 5604 2
   Gao P, 2018, LECT NOTES COMPUT SC, V11205, P485, DOI 10.1007/978 3 030 01246 5_29
   Guo YH, 2019, AAAI CONF ARTIF INTE, P8368
   Hou DP, 2018, INT ORTHOP, V42, P575, DOI 10.1007/s00264 018 3805 2
   Li PX, 2018, PATTERN RECOGN, V76, P323, DOI 10.1016/j.patcog.2017.11.007
   Li QJ, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011701
   Liu JQ, 2019, GENET MED, V21, P1548, DOI 10.1038/s41436 018 0377 x
   Luo M, 2019, CLIN ORTHOP RELAT R, V477, P1904, DOI 10.1097/CORR.0000000000000739
   Mackel CE, 2018, CHILD NERV SYST, V34, P2155, DOI 10.1007/s00381 018 3915 6
   Mohamed Ahmed S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0914 1
   Sun Q, 2019, J CELL MOL MED, V23, P7592, DOI 10.1111/jcmm.14632
   Takeda K, 2018, MOL GENET GENOM MED, V6, P966, DOI 10.1002/mgg3.466
   Wang B, 2019, J CELL PHYSIOL, V234, P1008, DOI 10.1002/jcp.27090
   Wei YW, 2019, PROCEEDINGS OF THE 27TH ACM INTERNATIONAL CONFERENCE ON MULTIMEDIA (MM'19), P1437, DOI 10.1145/3343031.3351034
   Wu L, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2708 8
   Xue F, 2019, PROC CVPR IEEE, P8567, DOI 10.1109/CVPR.2019.00877
   Yang J, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019095
   Yu HL, 2020, ACTA BIOMATER, V106, P328, DOI 10.1016/j.actbio.2020.01.051
   Zhang L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 1562 9
   Zhao QH, 2019, J NEUROSURG SPINE, V31, P40, DOI 10.3171/2019.1.SPINE181205
   Zhou BL, 2019, IEEE T PATTERN ANAL, V41, P2131, DOI 10.1109/TPAMI.2018.2858759
NR 22
TC 0
Z9 0
U1 1
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2040 2295
EI 2040 2309
J9 J HEALTHC ENG
JI J. Healthc. Eng.
PD APR 12
PY 2022
VL 2022
AR 4890008
DI 10.1155/2022/4890008
PG 11
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI EXPANDED)
SC Health Care Sciences & Services
GA 1Z1GW
UT WOS:000808582500010
PM 35449851
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Li, ZC
   Zhang, B
   Shang, JM
   Wang, YA
   Jia, LL
   She, X
   Xu, X
   Zhang, DJ
   Guo, J
   Zhang, F
AF Li, Zechuan
   Zhang, Bing
   Shang, Jiaming
   Wang, Yanan
   Jia, Linglu
   She, Xiao
   Xu, Xin
   Zhang, Dongjiao
   Guo, Jing
   Zhang, Fan
TI Diabetic and nondiabetic BMSC derived exosomes affect bone regeneration
   via regulating miR 17 5p/SMAD7 axis
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Diabetes mellitus; Diabetic bone disease; Exosomes; microRNA; SMAD7;
   Osteogenesis
ID OSTEOGENIC DIFFERENTIATION; EXTRACELLULAR VESICLES; ANTI INFLAMMATION;
   EXPRESSION; HYDROGEL; DELIVERY; CELLS
AB Diabetic bone disease (DBD) is a complication of diabetes mellitus (DM) and is characterized by impaired osteocyte function and delayed bone remodeling due to high blood glucose levels and sustained release of inflammatory factors. Recent studies show that the regulation of osteoblasts (OBs) by bone marrow stromal cells (BMSCs) is an important mechanism in alleviating DBD and that exosomes are recognized as the key medium. Mesenchymal stem cell derived exosome (MSC Exos) therapy is a promising approach to facilitate tissue repair. However, the influence of exosomes from diabetic conditioned BMSCs on OBs and bone regeneration, as well as the underlying mechanism, are still elusive. Here, we used high glucose medium to mimic diabetic conditions and normal glucose medium as control to mimic nondiabetic conditions in vitro and found that microRNA 17 (miR 17) was downregulated in diabetic conditioned BMSC derived exosomes (HG Exos), HG Exo co cultured osteoblasts, and the skull of rats with type 2 diabetes mellitus (T2DM). Further experiment concluded that nondiabetic conditioned BMSC Exos (NG Exos) promoted the osteogenesis of OBs and bone regeneration of rats with T2DM via upregulation of miR 17. Compare with NG Exos, HG Exos impeded osteogenesis of OBs in vitro and bone regeneration of rats in vivo by downregulation of miR 17. Moreover, miR 17 promoted bone regeneration by targeting SMAD7, which was further proved to have a negative effect on osteogenesis. Taken together, nondiabetic BMSC derived exosomes greatly foster bone regeneration, whereas diabetic BMSC derived exosomes undermine the promotion effect of MSC Exos by regulating the miR 17/SMAD7 axis. These findings provide support for the miR 17 5p/SMAD7 axis as a promising therapeutic target to treat DBD.
C1 [Li, Zechuan; Wang, Yanan; She, Xiao; Xu, Xin; Zhang, Dongjiao] Shandong Univ, Cheeloo Coll Med, Sch & Hosp Stomatol, Dept Implantol, 44 1 Wenhua Rd West, Jinan 250012, Shandong, Peoples R China.
   [Li, Zechuan; Zhang, Bing; Shang, Jiaming; Wang, Yanan; Jia, Linglu; She, Xiao; Xu, Xin; Zhang, Dongjiao; Zhang, Fan] Shandong Engn Res Ctr Dent Mat & Oral Tissue Regen, Shandong Prov Clin Res Ctr Oral Dis, Shandong Key Lab Oral Tissue Regenerat, 44 1 Wenhua Rd West, Jinan 250012, Shandong, Peoples R China.
   [Zhang, Bing] Shandong Univ, Dept Health Care, Cheeloo Coll Med, Sch & Hosp Stomatol, 44 1 Wenhua Rd West, Jinan 250012, Shandong, Peoples R China.
   [Shang, Jiaming; Jia, Linglu] Shandong Univ, Cheeloo Coll Med, Sch & Hosp Stomatol, Dept Prosthodont, 44 1 Wenhua Rd West, Jinan 250012, Shandong, Peoples R China.
   [Guo, Jing] Ningbo Stomatol Hosp, Engn Lab Biomat & Tissue Regenerat, 435 Xinxing Rd, Ningbo 310051, Zhejiang, Peoples R China.
   [Guo, Jing] Hangzhou Med Coll, Savaid Stomatol Sch, 1 Pinghai Rd, Hangzhou 310051, Zhejiang, Peoples R China.
   [Zhang, Fan] Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Dept Orthodont, 44 1 Wenhua Rd West, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University; Shandong University; Shandong University; Hangzhou
   Medical College; Shandong University
RP Zhang, F (通讯作者)，Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Dept Orthodont, 44 1 Wenhua Rd West, Jinan 250012, Shandong, Peoples R China.
EM zhfan@sdu.edu.cn
RI ; LINGLU, JIA/HGA 3173 2022; Zhang, Bing/LZI 1642 2025
OI Jia, Linglu/0000 0002 7074 8861; Li, Zechuan/0000 0002 4427 4017; Shang,
   Jiaming/0009 0002 1916 6548; 
FU National Natural Science Foundation of China [82071148, 82201101];
   Ningbo Science and Technology Planning Project [2022S053]
FX This work was supported by grants from the National Natural Science
   Foundation of China, grant Nos. 82071148 and 82201101; Ningbo Science
   and Technology Planning Project, grant No. 2022S053.
CR Abdelhamid AM, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.754098
   Bai XD, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9450240
   Balint E, 2001, BONE, V28, P21, DOI 10.1016/S8756 3282(00)00426 9
   Behera Jyotirmaya, 2018, Oncoscience, V5, P181, DOI 10.18632/oncoscience.421
   Cassidy FC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072476
   Ding ML, 2021, HUM CELL, V34, P1398, DOI 10.1007/s13577 021 00567 3
   Gong YM, 2014, MOL CELL BIOCHEM, V387, P227, DOI 10.1007/s11010 013 1888 z
   Gu C, 2022, COMPUT MATH METHOD M, V2022, DOI 10.1155/2022/3864863
   Guo SY, 2021, THERANOSTICS, V11, P8379, DOI 10.7150/thno.58052
   Hu HX, 2022, INT J NANOMED, V17, P6201, DOI [10.2147/IJN.S389471DovePress, 10.2147/IJN.S389471]
   Hu YK, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6324912
   Jia J, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.43
   Jiao HL, 2015, CURR OSTEOPOROS REP, V13, P327, DOI 10.1007/s11914 015 0286 8
   Kasperk C, 2017, EXP CLIN ENDOCR DIAB, V125, P213, DOI 10.1055/s 0042 123036
   Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097 2765(00)00134 9
   Kim DK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22754 4
   Kitaura H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126578
   Li HL, 2013, STEM CELL RES, V10, P313, DOI 10.1016/j.scr.2012.11.007
   Li J, 2020, FASEB J, V34, P14234, DOI 10.1096/fj.202000970RR
   Li W, 2021, J ENDOCRINOL INVEST, V44, P1193, DOI 10.1007/s40618 020 01405 3
   Liao W, 2019, CLIN SCI, V133, P1955, DOI 10.1042/CS20181064
   Liao XY, 2019, CALCIFIED TISSUE INT, V105, P670, DOI 10.1007/s00223 019 00608 y
   Liu L, 2019, BIOMATERIALS, V192, P523, DOI 10.1016/j.biomaterials.2018.11.007
   Liu XL, 2017, INT J BIOL SCI, V13, P232, DOI 10.7150/ijbs.16951
   Lou GH, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046 019 1512 5
   Man KY, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020832
   Mohan S, 2015, PHYSIOL GENOMICS, V47, P33, DOI 10.1152/physiolgenomics.00107.2014
   Musolino C, 2018, ANN HEMATOL, V97, P1259, DOI 10.1007/s00277 018 3296 7
   Pomatto M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22083851
   Ponzetti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136651
   Shao HL, 2018, CHEM REV, V118, P1917, DOI 10.1021/acs.chemrev.7b00534
   Tang YY, 2018, INT J MOL MED, V41, P1595, DOI 10.3892/ijmm.2018.3373
   Tian T, 2021, THERANOSTICS, V11, P6507, DOI 10.7150/thno.56367
   Tian T, 2018, BIOMATERIALS, V150, P137, DOI 10.1016/j.biomaterials.2017.10.012
   Wan S, 2018, CURR DRUG TARGETS, V19, P191, DOI 10.2174/1389450118666171117125319
   Wan Shan, 2017, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V31, P870, DOI 10.7507/1002 1892.201701068
   Wang K, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2574 1
   Wang M, 2022, BIOENGINEERED, V13, P684, DOI 10.1080/21655979.2021.2012618
   Wang N, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01267 2
   Wang W, 2019, J CELL MOL MED, V23, P5486, DOI 10.1111/jcmm.14432
   Wang XQ, 2021, BASIC CLIN PHARMACOL, V128, P18, DOI 10.1111/bcpt.13478
   Wang YX, 2022, ACTA BIOMATER, V147, P342, DOI 10.1016/j.actbio.2022.05.018
   Wei BF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169097
   Wu KL, 2021, INT J NANOMED, V16, P7831, DOI 10.2147/IJN.S334194
   Wu SL, 2014, MAT SCI ENG R, V80, P1, DOI 10.1016/j.mser.2014.04.001
   Yang ZJ, 2023, J NANOBIOTECHNOL, V21, DOI 10.1186/s12951 023 01871 w
   Yano M, 2012, ENDOCR J, V59, P653, DOI 10.1507/endocrj.EJ12 0022
   Yavropoulou MP, 2018, J MUSCULOSKEL NEURON, V18, P18
   Yu FJ, 2015, LAB INVEST, V95, P781, DOI 10.1038/labinvest.2015.58
   Yue K, 2015, BIOMATERIALS, V73, P254, DOI 10.1016/j.biomaterials.2015.08.045
   Zhang C, 2018, BIOMED PHARMACOTHER, V100, P448, DOI 10.1016/j.biopha.2018.02.012
   Zhang D, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00964 8
   Zhang ZJ, 2012, J CELL BIOCHEM, V113, P888, DOI 10.1002/jcb.23418
   Zhao T, 2019, CURR STEM CELL RES T, V14, P482, DOI 10.2174/1574888X14666190228103230
   Zhou ML, 2014, ENDOCRINE, V45, P302, DOI 10.1007/s12020 013 9986 y
   Zhu Y, 2019, STEM CELL TRANSL MED, V8, P593, DOI 10.1002/sctm.18 0199
NR 56
TC 11
Z9 12
U1 6
U2 28
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD DEC
PY 2023
VL 125
AR 111190
DI 10.1016/j.intimp.2023.111190
EA NOV 2023
PN B
PG 16
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA AG6H3
UT WOS:001117347200001
PM 37976598
DA 2025 08 17
ER

PT J
AU Qaseem, A
   Forciea, MA
   McLean, RM
   Denberg, TD
AF Qaseem, Amir
   Forciea, Mary Ann
   McLean, Robert M.
   Denberg, Thomas D.
CA Clinical Guidelines Comm Amer Coll
TI Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in
   Men and Women: A Clinical Practice Guideline Update From the American
   College of Physicians
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
AB Description: This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians.
   Methods: The ACP Clinical Guidelines Committee based these recommendations on a systematic review of randomized controlled trials; systematic reviews; large observational studies (for adverse events); and case reports (for rare events) that were published between 2 January 2005 and 3 June 2011. The review was updated to July 2016 by using a machine learning method, and a limited update to October 2016 was done. Clinical outcomes evaluated were fractures and adverse events. This guideline focuses on the comparative benefits and risks of short and long term pharmacologic treatments for low bone density, including pharmaceutical prescriptions, calcium, vitamin D, and estrogen. Evidence was graded according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.
   Target Audience and Patient Population: The target audience for this guideline includes all clinicians. The target patient population includes men and women with low bone density and osteoporosis.
   Recommendation 1: ACP recommends that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis. (Grade: strong recommendation; high quality evidence)
   Recommendation 2: ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 years. (Grade: weak recommendation; low quality evidence)
   Recommendation 3: ACP recommends that clinicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized osteoporosis. (Grade: weak recommendation; low quality evidence)
   Recommendation 4: ACP recommends against bone density monitoring during the 5 year pharmacologic treatment period for osteoporosis in women. (Grade: weak recommendation; low quality evidence)
   Recommendation 5: ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women. (Grade: strong recommendation; moderate quality evidence)
   Recommendation 6: ACP recommends that clinicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications. (Grade: weak recommendation; low quality evidence)
C1 [Qaseem, Amir] Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA.
   [Forciea, Mary Ann] Univ Penn Hlth Syst, 3615 Chestnut St, Philadelphia, PA 19104 USA.
   [McLean, Robert M.] Yale Sch Med, 46 Prince St,Suite 302, New Haven, CT 06519 USA.
   [Denberg, Thomas D.] 7480 East 5th Ave, Denver, CO 80230 USA.
C3 American College of Physicians; University of Pennsylvania; Yale
   University
RP Qaseem, A (通讯作者)，Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA.
EM aqaseem@acponline.org
RI Schunemann, Holger/LRB 7016 2024
OI Schunemann, Holger/0000 0003 3211 8479
FU ACP operating budget
FX Financial support for the development of this guideline comes
   exclusively from the ACP operating budget.
CR 2002, BONE, V30, P836
NR 1
TC 508
Z9 550
U1 1
U2 131
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106 1572 USA
SN 0003 4819
EI 1539 3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JUN 6
PY 2017
VL 166
IS 11
BP 818
EP +
DI 10.7326/M15 1361
PG 28
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA EW7NJ
UT WOS:000402700200009
PM 28492856
DA 2025 08 17
ER

PT J
AU Hagiwara, Y
   Dyment, NA
   Jiang, X
   Ping, HJ
   Ackert Bicknell, C
   Adams, DJ
   Rowe, DW
AF Hagiwara, Yusuke
   Dyment, Nathaniel A.
   Jiang, Xi
   Ping, Huang Jiang
   Ackert Bicknell, Cheryl
   Adams, Douglas J.
   Rowe, David W.
TI Fixation stability dictates the differentiation pathway of periosteal
   progenitor cells in fracture repair
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE external and internal fracture fixation; closed tibial fracture; GFP
   reporter mice; cryohistology of non decalcified bone
ID DISTRACTION OSTEOGENESIS; PHOSPHATASE TRAP; OSTEOTOMY MODEL; BONE; MICE;
   EXPRESSION; ANIMALS; LINEAGE; TISSUES; PROTEIN
AB This study compared fracture repair stabilized by intramedullary pin (IMP) or external fixation (EF) in GFP reporter mice. A modified IMP was used as control while EF utilized six needles inserted transversely through the tibia and into a segment of a syringe barrel. X rays taken at days 0, 14, and 35 showed that IMP resulted in significant three dimensional deformity with a large callus while EF showed minimal deformity and callus formation. Cryohistological analysis of IMP at day 14 confirmed a large ColX RFPchry+ callus surrounded by woven bone (Col3.6 GFPcyan) and TRAP+ osteoclasts with mature bone (hOC GFPtpz) at the base. By day 35, cartilaginous components had been resorbed and an outer cortical shell (OCS) showed evidence of inward modeling. In contrast, the EF at day 14 showed no evidence of cartilage formation. Instead, periosteal derived osteoblasts (Col3.6 GFPcyan) entered the fracture cleft and formed woven bone that spanned the marrow space. By day 35, mature bone had formed that was contiguous with the opposing cortical bone. Fracture site stability greatly affects the cellular response during repair and must be considered in the preclinical models that test therapies for improving fracture healing. (c) 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 33:948 956, 2015.
C1 [Hagiwara, Yusuke] Nippon Med Coll Hosp, Dept Orthoped Surg, Tokyo 113, Japan.
   [Dyment, Nathaniel A.; Jiang, Xi; Ping, Huang Jiang; Rowe, David W.] Univ Rochester, Sch Dent Med, Ctr Regenerat Med & Skeletal Dev, Sch Med, Rochester, NY 14642 USA.
   [Ackert Bicknell, Cheryl] Univ Rochester, Dept Orthopaed & Rehabil, Ctr Musculoskeletal Res, Sch Med, Rochester, NY 14642 USA.
   [Adams, Douglas J.] Univ Connecticut, New England Musculoskeletal Inst, Dept Orthopaed Surg, Ctr Hlth, Farmington, CT 06030 USA.
C3 Nippon Medical School; University of Rochester; University of Rochester;
   University of Connecticut
RP Hagiwara, Y (通讯作者)，Nippon Med Coll Hosp, Dept Orthoped Surg, Tokyo 113, Japan.
EM ysk@nms.ac.jp; drowe@uchc.edu
RI Adams, David/GMW 8541 2022; Ackert Bicknell, Cheryl/AAC 6833 2019;
   Hagiwara, Yusuke/JBJ 0337 2023; Dyment, Nathaniel/AAD 6747 2021; ping,
   huang/GYD 3580 2022
OI Ackert Bicknell, Cheryl/0000 0003 4253 4775; Dyment,
   Nathaniel/0000 0001 8708 112X; 
FU Department of Defense [W81XWH 11 1 0262]; USPHS [R01 AR052374]
FX Grant sponsor: Department of Defense; Grant number: W81XWH 11 1 0262;
   Grant sponsor: USPHS; Grant number: R01 AR052374.
CR Alaee F, 2014, GENE THER, V21, P139, DOI 10.1038/gt.2013.66
   Bilic Curcic I, 2005, GENESIS, V43, P87, DOI 10.1002/gene.20156
   Blaber EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061372
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Carvalho RS, 2004, BONE, V34, P849, DOI 10.1016/j.bone.2003.12.027
   Chaubey A, 2013, J ORTHOP TRAUMATOL, V14, P247, DOI 10.1007/s10195 013 0269 4
   Connolly CK, 2003, J ORTHOPAED RES, V21, P843, DOI 10.1016/S0736 0266(03)00041 X
   Ender J., 1970, Acta Chir. Austriaca, V1, P40, DOI 10.1007/BF02600735
   Filgueira L, 2004, J HISTOCHEM CYTOCHEM, V52, P411, DOI 10.1177/002215540405200312
   Gamo K, 2014, J PEDIATR ORTHOP B, V23, P277, DOI 10.1097/BPB.0000000000000042
   Garcia P, 2008, J BIOMECH, V41, P1689, DOI 10.1016/j.jbiomech.2008.03.010
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Gröngröft I, 2009, J BIOMECH, V42, P2089, DOI 10.1016/j.jbiomech.2009.06.004
   HILTUNEN A, 1993, J ORTHOP RES, V11, P305, DOI 10.1002/jor.1100110219
   Histing T, 2011, BONE, V49, P591, DOI 10.1016/j.bone.2011.07.007
   Hong Seung Hyun, 2012, J Tissue Sci Eng, VSuppl 1, P004
   ILIZAROV GA, 1989, CLIN ORTHOP RELAT R, P249, DOI 10.1097/00003086 198901000 00038
   Jiang X, 2005, J HISTOCHEM CYTOCHEM, V53, P593, DOI 10.1369/jhc.4A6401.2005
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123
   Matthews BG, 2014, J BONE MINER RES, V29, P1283, DOI 10.1002/jbmr.2140
   Maye P, 2011, GENESIS, V49, P410, DOI 10.1002/dvg.20733
   McDonald MM, 2008, BONE, V43, P653, DOI 10.1016/j.bone.2008.05.019
   Nakano Y, 2004, J HISTOCHEM CYTOCHEM, V52, P1475, DOI 10.1369/jhc.4A6378.2004
   Qing H, 2012, J BONE MINER RES, V27, P1018, DOI 10.1002/jbmr.1567
   Röntgen V, 2010, J ORTHOP RES, V28, P1456, DOI 10.1002/jor.21148
   Tay BKB, 1998, J ORTHOP RES, V16, P636, DOI 10.1002/jor.1100160518
   Thompson Z, 2002, J ORTHOPAED RES, V20, P1091, DOI 10.1016/S0736 0266(02)00017 7
   Ushiku C, 2010, J ORTHOP RES, V28, P1338, DOI 10.1002/jor.21105
   Vincelette J, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2331
   Willie BM, 2011, CLIN ORTHOP RELAT R, V469, P3094, DOI 10.1007/s11999 011 1866 2
   Yu Nicole Y C, 2012, Front Biosci (Elite Ed), V4, P2647
NR 32
TC 21
Z9 23
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD JUL
PY 2015
VL 33
IS 7
BP 948
EP 956
DI 10.1002/jor.22816
PG 9
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA CJ2SA
UT WOS:000355333600002
PM 25639792
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Langley, E
   Velazquez Cruz, R
   Parra Torres, A
   Enríquez, J
AF Langley, Elizabeth
   Velazquez Cruz, Rafael
   Parra Torres, Alma
   Enriquez, Juana
TI The Non Aromatic Δ5 Androstenediol Derivative of Dehydroepiandrosterone
   Acts as an Estrogen Agonist in Neonatal Rat Osteoblasts through an
   Estrogen Receptor α related Mechanism
SO ENDOCRINE RESEARCH
LA English
DT Article
DE Estrogen receptors; androgen receptors; bone; dehydroepiandrosterone;
   Delta 5 androstenediol
ID PHYSIOLOGICAL CONCENTRATIONS; REPLACEMENT THERAPY; EXPRESSION; STEROIDS;
   BONE; POSTMENOPAUSAL; BINDING; GROWTH; DHEA;
   5 ANDROSTENE 3 BETA,17 BETA DIOL
AB Purpose: It has been proposed that DHEA influences bone formation through, bioconversion to 17 beta estradiol; however, DHEA is converted to Delta 5 androstenediol (Delta 5 Adiol), a metabolite with estrogenic potential involved in diverse biological process. To gain new insight into the role of Delta 5 Adiol in bone cells, we examined DHEA and Delta 5 Adiol effects in neonatal rat and human hFOB1.19 osteoblasts. Methods: Osteoblast activity was assessed by analyzing proliferation, alkaline phosphatase activity, and expression of OSX and ALPL. We also examined binding affinities for osteoblast ER and transcriptional activation of human (h)ER alpha, hER beta or hAR in U2 OS cells. Results: The most striking finding was that Delta 5 Adiol had greater stimulatory effect than DHEA on rat osteoblast proliferation and differentiation, as well as ALPL expression in human osteoblasts. Interestingly, the Delta 5 Adiol or DHEA induced effects were not precluded with letrozole or trilostane, consistent with bioconversion of DHEA to Delta 5 Adiol due to elevated expression of Hsd17b1 in neonatal rat osteoblasts, suggesting a high level of 17 beta hydroxysteroid dehydrogenase type 1 activity. Conversely, Delta 5 Adiol and DHEA induced proliferative effects were inhibited with ICI 182780 alone or combined with trilostane, which correlates with the higher binding affinity of Delta 5 Adiol for ER compared to DHEA. Furthermore, Delta 5 Adiol showed a greater relative agonist activity for hER alpha than for hER beta or hAR. Conclusion: This study is the first to show that a bioactive DHEA derivative stimulates E 2 dependent osteoblast activities, including proliferation and differentiation in rat and human osteoblasts, through ER alpha related mechanisms.
C1 [Langley, Elizabeth] Inst Nacl Cancerol, Dept Invest Basica, Mexico City, DF, Mexico.
   [Velazquez Cruz, Rafael; Parra Torres, Alma] Inst Nacl Med Genom, Lab Genom Metab Oseo, Mexico City, DF, Mexico.
   [Enriquez, Juana] INCMNSZ, Dept Biol Reprod Carlos Gual Castro, Mexico City, DF, Mexico.
C3 Instituto Nacional de Cancerologia (INCAN); Instituto Nacional de
   Medicina Genomica
RP Enríquez, J (通讯作者)，Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Biol Reprod Carlos Gual Castro, Vasco Quiroga 15,Secc 16, Ciudad De Mexico 14080, Mexico.
EM juanaenriquez@yahoo.com.mx
RI Velazquez Cruz, Rafael/AAC 3710 2021
OI Langley, Elizabeth/0000 0001 6180 8036
FU Departamento de Biologia de la Reproduccion Carlos Gual Castro, INCMNSZ;
   Departamento de Investigacion Basica, Instituto Nacional de Cancerologia
FX This study was supported by grants of the Departamento de Biologia de la
   Reproduccion Carlos Gual Castro, INCMNSZ and the Departamento de
   Investigacion Basica, Instituto Nacional de Cancerologia.
CR ADAMS J, 1981, CANCER RES, V41, P4720
   Arzate H, 1998, J PERIODONTAL RES, V33, P249, DOI 10.1111/j.1600 0765.1998.tb02197.x
   BOCCUZZI G, 1992, ANTICANCER RES, V12, P799
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Chen J, 2013, J STEROID BIOCHEM, V137, P316, DOI 10.1016/j.jsbmb.2013.01.012
   Diamond P, 1996, J ENDOCRINOL, V150, pS43
   Engdahl C, 2014, ENDOCRINOLOGY, V155, P889, DOI 10.1210/en.2013 1561
   Enríquez J, 2007, J ENDOCRINOL, V193, P493, DOI 10.1677/JOE 06 0038
   Eyre LJ, 1998, J BONE MINER RES, V13, P996, DOI 10.1359/jbmr.1998.13.6.996
   HUGGINS C, 1954, J EXP MED, V100, P225, DOI 10.1084/jem.100.3.225
   Ishida Y, 2002, OSTEOPOROSIS INT, V13, P235, DOI 10.1007/s001980200020
   KAPLOW LS, 1955, BLOOD, V10, P1023, DOI 10.1182/blood.V10.10.1023.1023
   Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863
   Labrie F, 1997, J CLIN ENDOCR METAB, V82, P2403, DOI 10.1210/jc.82.8.2403
   Labrie F, 2001, FRONT NEUROENDOCRIN, V22, P185, DOI 10.1006/frne.2001.0216
   Labrie F, 1997, J CLIN ENDOCR METAB, V82, P3498, DOI 10.1210/jc.82.10.3498
   Lemus AE, 2009, J ENDOCRINOL, V200, P199, DOI 10.1677/JOE 08 0166
   LOWRY OH, 1954, J BIOL CHEM, V207, P19
   MAJESKA RJ, 1994, J BONE JOINT SURG AM, V76A, P713, DOI 10.2106/00004623 199405000 00013
   Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P11083, DOI 10.1073/pnas.95.19.11083
   Papierska L, 2012, ADV MED SCI POLAND, V57, P51, DOI 10.2478/v10039 011 0060 9
   Qiu XM, 2015, BIOSCI TRENDS, V9, P307, DOI 10.5582/bst.2015.01073
   REEL JR, 1979, FERTIL STERIL, V31, P552
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   SEYMOURMUNN K, 1983, ENDOCRINOLOGY, V112, P486, DOI 10.1210/endo 112 2 486
   SIMARD J, 1988, MOL CELL ENDOCRINOL, V55, P233, DOI 10.1016/0303 7207(88)90138 4
   SIMARD J, 1987, J STEROID BIOCHEM, V26, P539, DOI 10.1016/0022 4731(87)90005 7
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   Sun HZ, 2011, ENDOCRINOLOGY, V152, P1423, DOI 10.1210/en.2010 0920
   TURNER RT, 1990, AM J PHYSIOL, V258, pE673, DOI 10.1152/ajpendo.1990.258.4.E673
   van der Eerden BCJ, 2004, J ENDOCRINOL, V180, P457, DOI 10.1677/joe.0.1800457
   Wang Ling, 2006, Fen Zi Xi Bao Sheng Wu Xue Bao, V39, P365
   Wang YD, 2012, CHINESE MED J PEKING, V125, P1230, DOI 10.3760/cma.j.issn.0366 6999.2012.07.008
   Wang YD, 2006, CELL MOL IMMUNOL, V3, P41
NR 34
TC 4
Z9 4
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0743 5800
EI 1532 4206
J9 ENDOCR RES
JI Endocr. Res.
PY 2019
VL 44
IS 3
BP 87
EP 102
DI 10.1080/07435800.2018.1559185
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA II8JZ
UT WOS:000475439600003
PM 30580653
DA 2025 08 17
ER

PT J
AU Li, Y
   Jacox, LA
   Coats, S
   Kwon, J
   Xue, P
   Tang, N
   Rui, Z
   Wang, XY
   Kim, YI
   Wu, TJ
   Lee, YT
   Wong, SW
   Chien, CH
   Cheng, CW
   Gross, R
   Lin, FC
   Tseng, H
   Martinez, J
   Ko, CC
AF Li, Yina
   Jacox, Laura Anne
   Coats, Shannon
   Kwon, Jane
   Xue, Peng
   Tang, Na
   Rui, Zou
   Wang, Xiaoyu
   Kim, Yong Il
   Wu, Te Ju
   Lee, Yan Ting
   Wong, Sing Wai
   Chien, Chia Hui
   Cheng, Chih Wen
   Gross, Ryan
   Lin, Feng Chang
   Tseng, Henry
   Martinez, Jennifer
   Ko, Ching Chang
TI Roles of autophagy in orthodontic tooth movement
SO AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS
LA English
DT Article
ID PERIODONTAL LIGAMENT; SUBSTANCE P; EXPRESSION; FORCE; FIBROBLASTS;
   CYTOKINES; PATHWAY
AB Introduction: Orthodontic tooth movement (OTM) relies on efficient remodeling of alveolar bone. While a well controlled inflammatory response is essential during OTM, the mechanism regulating inflammation is unknown. Autophagy, a conserved catabolic pathway, has been shown to protect cells from excess inflammation in disease states. We hypothesize that autophagy plays a role in regulating inflammation during OTM. Methods: A split mouth design was used to force load molars in adult male mice, carrying a GFP LC3 transgene for in vivo detection of autophagy. Confocal microscopy, Western blot, and quantitative polymerase chain reaction analyses were used to evaluate autophagy activation in tissues of loaded and control molars at time points after force application. Rapamycin, a Food and Drug Administration approved immunosuppressant, was injected to evaluate induction of autophagy. Results: Autophagy activity increases shortly after loading, primarily on the compression side of the tooth, and is closely associated with inflammatory cytokine expression and osteoclast recruitment. Daily administration of rapamycin, an autophagy activator, led to reduced tooth movement and osteoclast recruitment, suggesting that autophagy downregulates the inflammatory response and bone turnover during OTM. Conclusions: This is the first demonstration that shows that autophagy is induced by orthodontic loading and plays a role during OTM, likely via negative regulation of inflammatory response and bone turnover. Exploring roles of autophagy in OTM holds great promise, as aberrant autophagy is associated with periodontal disease and its related systemic inflammatory disorders.
C1 [Li, Yina; Jacox, Laura Anne; Xue, Peng; Gross, Ryan; Ko, Ching Chang] Univ N Carolina, Sch Dent, Dept Orthodont, Chapel Hill, NC 27515 USA.
   [Coats, Shannon; Tseng, Henry] Duke Univ, Med Ctr Greenspace, Durham, NC USA.
   [Kwon, Jane; Tang, Na; Rui, Zou; Wang, Xiaoyu; Kim, Yong Il; Wu, Te Ju; Lee, Yan Ting; Chien, Chia Hui; Cheng, Chih Wen] Univ N Carolina, Sch Dent, Oral & Craniofacial Hlth Sci, Chapel Hill, NC 27515 USA.
   [Tang, Na] Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Dept Oral Med, Chengdu, Sichuan, Peoples R China.
   [Rui, Zou] Xi An Jiao Tong Univ, Stomatol Hosp, Dept Orthodont, Xian, Shaanxi, Peoples R China.
   [Wang, Xiaoyu] Capital Med Univ, Dept Dent, Beijing Tiantan Hosp, Beijing, Peoples R China.
   [Kim, Yong Il] Pusan Natl Univ, Dept Orthodont, Sch Dent, Yangsan, South Korea.
   [Wu, Te Ju] Chang Gung Mem Hosp, Dept Orthodont, Kaohsiung, Taiwan.
   [Wong, Sing Wai] Univ N Carolina, Sch Dent, Dept Periodontol, Chapel Hill, NC 27515 USA.
   [Chien, Chia Hui; Cheng, Chih Wen] Dept Dent, Div Prosthodont, Tainan, Taiwan.
   [Lin, Feng Chang] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC 27515 USA.
   [Tseng, Henry] Duke Eye Ctr, Glaucoma Div, Durham, NC USA.
   [Martinez, Jennifer] NIH, Bethesda, MD USA.
   [Martinez, Jennifer] NIEHS, Res Triangle Pk, NC USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   Duke University; University of North Carolina; University of North
   Carolina Chapel Hill; Sichuan Provincial People's Hospital; Xi'an
   Jiaotong University; Capital Medical University; Pusan National
   University; Pusan National University Hospital; Chang Gung Memorial
   Hospital; University of North Carolina; University of North Carolina
   Chapel Hill; University of North Carolina; University of North Carolina
   Chapel Hill; Duke University; National Institutes of Health (NIH)   USA;
   National Institutes of Health (NIH)   USA; NIH National Institute of
   Environmental Health Sciences (NIEHS)
RP Ko, CC (通讯作者)，Ohio State Univ, Div Orthodont, Coll Dent, 4088A Postle Hall, Columbus, OH 43210 USA.
EM Ko.367@osu.edu
RI Lin, Feng Chang/ABE 9659 2020; xue, peng/K 4159 2015
OI Wang, Xiaoyu/0000 0002 2086 4979; Kim, Yong Il/0000 0003 3889 2545
FU National Institutes of Health [R01DE022816]; UNC Hale Professorship
   fund; American Association of Orthodontics Foundation Martin 'Bud'
   Schulman Postdoctoral Fellowship; Graduate School Masters Merit
   Assistantship for study in Dentistry   UNC Graduate School; Southern
   Association of Orthodontics research awards; Masters Research Support
   Grants   Office of the Associate Dean for Research at UNC School of
   Dentistry; Dental Foundation of North Carolina; National Institute of
   Environmental Health Sciences [ZIAES103286] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health [grant
   #R01DE022816] and the UNC Hale Professorship fund. This work was also
   supported by the American Association of Orthodontics Foundation Martin
   'Bud' Schulman Postdoctoral Fellowship awarded to Dr. Jacox. Drs. Li and
   Jacox were supported by the Graduate School Masters Merit Assistantship
   for study in Dentistry awarded by the UNC Graduate School, the Southern
   Association of Orthodontics research awards, and the Masters Research
   Support Grants awarded by the Office of the Associate Dean for Research
   at UNC School of Dentistry and the Dental Foundation of North Carolina.
CR Andrade I, 2007, J DENT RES, V86, P1089, DOI 10.1177/154405910708601113
   Apelo SIA, 2016, AGING CELL, V15, P28, DOI 10.1111/acel.12405
   Bullon P, 2012, BMC MED, V10, DOI 10.1186/1741 7015 10 122
   Couve E, 2013, J DENT RES, V92, P765, DOI 10.1177/0022034513495874
   Crisan TO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018666
   Taddei SRD, 2012, J BIOMECH, V45, P2729, DOI 10.1016/j.jbiomech.2012.09.006
   Diercke K, 2012, J OROFAC ORTHOP, V73, P397, DOI 10.1007/s00056 012 0095 y
   Garlet TP, 2007, EUR J ORAL SCI, V115, P355, DOI 10.1111/j.1600 0722.2007.00469.x
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Harris J, 2011, CYTOKINE, V56, P140, DOI 10.1016/j.cyto.2011.08.022
   Huang H, 2014, AM J ORTHOD DENTOFAC, V146, P620, DOI 10.1016/j.ajodo.2014.07.007
   Jiang X, 2005, J HISTOCHEM CYTOCHEM, V53, P593, DOI 10.1369/jhc.4A6401.2005
   Kenney DL, 2015, NEUROLOGY, V85, P634, DOI 10.1212/WNL.0000000000001860
   Koyama Y, 2008, ARCH ORAL BIOL, V53, P488, DOI 10.1016/j.archoralbio.2007.12.004
   Krishnan V, 2009, J DENT RES, V88, P597, DOI 10.1177/0022034509338914
   Krishnan V., 2006, AM J ORTHOD DENTOFAC, V129, p469., DOI [10.1016/j.ajodo.2005.10.007, DOI 10.1016/J.AJODO.2005.10.007]
   Lapaquette P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/398483
   Lee Brian, 2007, Aust Orthod J, V23, P155
   Lin NY, 2013, ANN RHEUM DIS, V72, P761, DOI 10.1136/annrheumdis 2012 201671
   Liu WJ, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658 016 0031 z
   Maeda A, 2007, J DENT RES, V86, P629, DOI 10.1177/154405910708600709
   Martinez J, 2016, NATURE, V533, P115, DOI 10.1038/nature17950
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03 09 0704
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev cellbio 092910 154005
   Mizushima N, 2009, METHOD ENZYMOL, V452, P13, DOI 10.1016/S0076 6879(08)03602 1
   Nakao K, 2007, J DENT RES, V86, P623, DOI 10.1177/154405910708600708
   Netea Maier RT, 2016, AUTOPHAGY, V12, P245, DOI 10.1080/15548627.2015.1071759
   Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Proffit W. R., 2019, Contemporary orthodontics, V6th ed.
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Sambandam Y, 2014, BONE, V61, P125, DOI 10.1016/j.bone.2014.01.004
   Tan YQ, 2017, AUTOPHAGY, V13, P225, DOI 10.1080/15548627.2016.1234563
   Tyrovola JB, 2015, J CELL BIOCHEM, V116, P2724, DOI 10.1002/jcb.25265
   Woodrum C, 2010, J TRANSL MED, V8, DOI 10.1186/1479 5876 8 14
   Xiao WM, 2016, FRONT ORAL BIOL, V18, P17, DOI 10.1159/000351896
   Yamaguchi M, 2009, ORTHOD CRANIOFAC RES, V12, P113, DOI 10.1111/j.1601 6343.2009.01444.x
   Yamaguchi M, 2008, AM J ORTHOD DENTOFAC, V133, P690, DOI 10.1016/j.ajodo.2006.03.043
   Yamaguchi M, 2006, EUR J ORTHODONT, V28, P241, DOI 10.1093/ejo/cji100
   Yang JW, 2013, HISTOCHEM CELL BIOL, V139, P109, DOI 10.1007/s00418 012 1016 2
   Yang JW, 2013, J MOL HISTOL, V44, P619, DOI 10.1007/s10735 013 9518 3
   Yang Z, 2015, J MOL MED, V93, P707, DOI 10.1007/s00109 015 1297 8
   Zhuang H, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.24
   Zhuang H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.103
NR 44
TC 16
Z9 18
U1 0
U2 25
PU MOSBY ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0889 5406
EI 1097 6752
J9 AM J ORTHOD DENTOFAC
JI Am. J. Orthod. Dentofac. Orthop.
PD MAY
PY 2021
VL 159
IS 5
BP 582
EP 593
DI 10.1016/j.ajodo.2020.01.027
EA APR 2021
PG 12
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA RW2TN
UT WOS:000646380700020
PM 33771430
DA 2025 08 17
ER

PT J
AU Jiang, YF
   Mu, HR
   Jiang, WY
   Xue, LH
   Tian, K
   Wang, GY
   Wang, ZY
   Han, J
   Yang, MK
   Tang, YJ
   Hua, YQ
   Cai, ZD
AF Jiang Yafei
   Mu Haoran
   Jiang Wenyan
   Xue Linghang
   Tian Kai
   Wang Gangyang
   Wang Zhuoying
   Han Jing
   Yang Mengkai
   Tang Yujie
   Hua Yingqi
   Cai Zhengdong
TI Personalized medicine modality based on patient derived xenografts from
   a malignant transformed GCTB harboring H3F3A G34W mutation
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE Malignant giant cell tumor of bone; Drug screening; Patient derived
   xenograft; Histone deacetylase inhibitor
ID GIANT CELL TUMOR; BONE; ONCOHISTONES; DENOSUMAB
AB Background: The function of H3F3A G43W mutation, which has been observed in almost all GCTB, remains poorly characterized. Breakthrough in malignant GCTB has been trapped by the lack of clinical available drugs, limited canonical patient samples and paucity of fidelity preclinical models.
   Methods: Tumor samples obtained from a malignant GCTB was implanted in immunodeficient mice for the generation of PDX. Histological examination and short tandem repeat (STR) were used for inherited features analyses. An epigenetic/transcriptional targeted compound library was selected for drug screening. The in vivo effects of selected drug were validated in PDX model.
   Results: We established the PDX model with recurrent malignant GCTB specimens, histological examination and STR analyses revealed that PDX and their corresponding parental patients shared the same STRs and histologic features, suggesting common origins. ITF 2357 was the most significant compound with an IC50 lower than 0.1 uM. The results of the drug screening and in vivo PDX validation demonstrated that ITF 2357 might be a promising drug targeted H3F3A G34W mutation MGCTBs.
   Conclusion: Our study demonstrates that PDX model maintained the same histologic and genetic features as those in the original patient. targeting HDAC through ITF 2357 effectively overcomes malignant GCTB progression in vitro and in vivo.
   Translational potential statement: As PDX retain the principal histologic and genetic characteristics of the primary tumors, mad it a valuable research tool in predictive clinical efficacy. In this study, we first established a malignant GCTB PDX model, which might further accelerate the progress of drug development in malignant GCTB.
C1 [Jiang Yafei; Mu Haoran; Xue Linghang; Tian Kai; Wang Gangyang; Wang Zhuoying; Han Jing; Yang Mengkai; Hua Yingqi; Cai Zhengdong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Orthopaed, Sch Med, Shanghai 200080, Peoples R China.
   [Jiang Yafei; Mu Haoran; Xue Linghang; Tian Kai; Wang Gangyang; Wang Zhuoying; Han Jing; Yang Mengkai; Hua Yingqi; Cai Zhengdong] Shanghai Bone Tumor Inst, Shanghai 201620, Peoples R China.
   [Jiang Wenyan; Tang Yujie] Shanghai Jiao Tong Univ, Dept Pathophysiol, Key Lab Cell Differentiat & Apoptosis, Natl Minist Educ,Sch Med, Shanghai 200025, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Hua, YQ; Cai, ZD (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Orthopaed, Sch Med, Shanghai 200080, Peoples R China.
EM hua_yingqi@163.com; caizhengdong@sjtu.edu.cn
RI Tang, Yujie/KWU 9594 2024; Mu, Haoran/AFM 0882 2022; Jiang,
   Yafei/NZO 2042 2025
FU NSFC [81972512, 81872177, 82072968]; Shanghai Hospital Development
   Center [SHDC2020CR2037B]; Medical engineering cross research project of
   Shanghai JiaoTong University [YG2019QNB37]
FX This study was supported by NSFC (81972512, 81872177 and 82072968) .
   Shanghai Hospital Development Center (SHDC2020CR2037B) , and Medical
   engineering cross research project of Shanghai JiaoTong University
   (YG2019QNB37) .
CR Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   Bertoni F, 2003, CANCER, V97, P2520, DOI 10.1002/cncr.11359
   Chawla S, 2019, LANCET ONCOL, V20, P1719, DOI 10.1016/S1470 2045(19)30663 1
   Cheng WX, 2020, J ORTHOP TRANSL, V22, P92, DOI 10.1016/j.jot.2019.07.007
   Cleven AHG, 2015, AM J SURG PATHOL, V39, P1576, DOI 10.1097/PAS.0000000000000512
   De Souza C, 2015, RECENT PAT ANTI CANC, V10, P145
   Dreyer CH, 2020, J ORTHOP TRANSL, V24, P46, DOI 10.1016/j.jot.2020.05.005
   Fletcher CDM, 2013, ORG WH WHO CLASSIFIC, P319
   Fleuren EDG, 2011, CLIN CANCER RES, V17, P7693, DOI 10.1158/1078 0432.CCR 11 1488
   Gong LH, 2012, VIRCHOWS ARCH, V460, P327, DOI 10.1007/s00428 012 1198 y
   Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159 8290.CD 14 0001
   Lipplaa A, 2019, CURR OPIN ONCOL, V31, P329, DOI 10.1097/CCO.0000000000000529
   Lüke J, 2017, HISTOPATHOLOGY, V71, P125, DOI 10.1111/his.13190
   Mohammad F, 2017, GENE DEV, V31, P2313, DOI 10.1101/gad.309013.117
   Nacev BA, 2019, NATURE, V567, P473, DOI 10.1038/s41586 019 1038 1
   Nanni P, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 48634 y
   Niu XH, 2019, J ORTHOP TRANSL, V18, P100, DOI 10.1016/j.jot.2018.10.003
   Qiu L, 2018, J GENET GENOMICS, V45, P227, DOI 10.1016/j.jgg.2018.04.004
   Rosario M, 2017, J SURG ONCOL, V116, P907, DOI 10.1002/jso.24739
   Sarthy JF, 2019, CANCER DISCOV, V9, P1346, DOI 10.1158/2159 8290.CD 19 0839
   Skubitz KM, 2014, CURR TREAT OPTION ON, V15, P507, DOI 10.1007/s11864 014 0289 1
   Wong RMY, 2020, J ORTHOP TRANSL, V23, P8, DOI 10.1016/j.jot.2020.03.002
   Zou CY, 2019, J BONE ONCOL, V14, DOI 10.1016/j.jbo.2018.100211
NR 24
TC 10
Z9 10
U1 0
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD JUL
PY 2021
VL 29
BP 106
EP 112
DI 10.1016/j.jot.2021.04.004
EA JUN 2021
PG 7
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA TZ6EE
UT WOS:000684563000014
PM 34136349
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wawrzyniak, A
   Skrzypczak Zielinska, M
   Krela Kazmierczak, I
   Michalak, M
   Marszalek, D
   Marcinkowska, M
   Zakerska Banaszak, O
   Slomski, R
AF Wawrzyniak, Anna
   Skrzypczak Zielinska, Marzena
   Krela Kazmierczak, Iwona
   Michalak, Michal
   Marszalek, Daria
   Marcinkowska, Michalina
   Zakerska Banaszak, Oliwia
   Slomski, Ryszard
TI Analysis of the tumor necrosis factor superfamily member 11 gene
   polymorphism with bone mineral density and bone fracture frequency in
   patients with postmenopausal osteoporosis
SO ADVANCES IN MEDICAL SCIENCES
LA English
DT Article
DE BMD; TNFSF11 gene; Polymorphism; Postmenopausal osteoporosis
ID PROMOTER POLYMORPHISMS; ASSOCIATION; RANKL; OSTEOPROTEGERIN; DIAGNOSIS;
   DENOSUMAB; RISK; LOCI
AB Purpose: We aimed to examine the polymorphism of the promoter and exon 5 of the TNFSF11 gene and their impact on bone mineral density (BMD) and the frequency of bone fractures. TNFSF11 encodes the receptor activator of the NF kB ligand (RANKL), a key regulator of bone metabolism and osteoporosis drug targets. BMD is an essential measure in diagnosing osteoporosis and assessing the risk of fractures. In vivo, RANKL expression research suggests that promoter TNFSF11 variants influence BMD. Moreover, exon 5 polymorphism of a linear epitope sequence for a denosumab could be related to the effectiveness of biological therapy.
   Patients and methods: The study included 114 postmenopausal osteoporosis patients. BMD was measured in the lumbar spine and the femoral neck. Genetic analysis was performed using Sanger sequencing. Genotypes data for 263 female European population group were obtained from the 1000Genomes database.
   Results: We identified six promoter polymorphisms (rs9525641, rs9533155, rs9533156, rs11839112, rs28926171, rs183599708) and one silent TNFSF11 variant in exon 5 (rs9562415). Three of the sequence variants detected (rs9525641, rs9533155, rs9533156) proved to be polymorphic, whereas the others four occurred at a frequency below 2%. The statistical analysis demonstrated no significant differences between polymorphisms and BMD, and bone fractures. However, variant rs9533156 was relevant with the lumbar spine T score (p = 0.0273), and no association with BMD was of borderline significance (p = 0.0529).
   Conclusions: Variant rs9533156 may contribute to the genetic regulation of BMD in Polish postmenopausal osteoporosis, while the exon 5 sequence of the TNFSF11 gene is very conservative.
C1 [Wawrzyniak, Anna; Marcinkowska, Michalina] Poznan Univ Med Sci, Dept Family Med, Poznan, Poland.
   [Skrzypczak Zielinska, Marzena; Marszalek, Daria; Zakerska Banaszak, Oliwia; Slomski, Ryszard] Polish Acad Sci, Inst Human Genet, Strzeszynska 32, PL 479 Poznan, Poland.
   [Krela Kazmierczak, Iwona] Poznan Univ Med Sci, Dept Gastroenterol Dietet & Internal Dis, Poznan, Poland.
   [Michalak, Michal] Poznan Univ Med Sci, Dept Comp Sci & Stat, Poznan, Poland.
C3 Poznan University of Medical Sciences; Polish Academy of Sciences;
   Poznan University of Medical Sciences; Poznan University of Medical
   Sciences
RP Skrzypczak Zielinska, M (通讯作者)，Polish Acad Sci, Inst Human Genet, Strzeszynska 32, PL 479 Poznan, Poland.
EM marzena.skrzypczak zielinska@igcz.poznan.pl
RI Wawrzyniak, Anna/IZP 8311 2023; Slomski, Ryszard/AGR 6196 2022;
   SkrzypczakZielinska, Marzena/KEE 6458 2024; Michalak,
   Michał/I 4215 2016; Michalak, Michal/I 4215 2016
OI Skrzypczak Zielinska, Marzena/0000 0001 5313 107X; Zakerska Banaszak,
   Oliwia/0000 0002 2223 3767; Slomski, Ryszard/0000 0001 5601 7002;
   Michalak, Michal/0000 0002 2852 3984
FU Foundation for the Development of Biotechnology and Genetics POLBIOGEN
FX The language editing of the manuscript was supported by the Foundation
   for the Development of Biotechnology and Genetics POLBIOGEN.
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Boron D, 2014, ANN ACAD MED SILES, V6, P415
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Clark GR, 2015, BRIT MED BULL, V113, P73, DOI 10.1093/bmb/ldu042
   Dong SS, 2009, CALCIFIED TISSUE INT, V85, P104, DOI 10.1007/s00223 009 9255 5
   Duncan EL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001372
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   Ferrari S, 1998, J CLIN ENDOCR METAB, V83, P358, DOI 10.1210/jc.83.2.358
   Ferrari S, 2008, BEST PRACT RES CL EN, V22, P723, DOI 10.1016/j.beem.2008.08.007
   Gregson CL, 2018, BONE, V114, P62, DOI 10.1016/j.bone.2018.06.001
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Kanis JA, 1997, OSTEOPOROSIS INT, V7, P390, DOI 10.1007/BF01623782
   Kanis JA, 2000, OSTEOPOROSIS INT, V11, P192, DOI 10.1007/s001980050281
   Kanis JA, 2000, BONE, V27, P585, DOI 10.1016/S8756 3282(00)00381 1
   Karasik D, 2016, NAT REV RHEUMATOL, V12, P496, DOI 10.1038/nrrheum.2016.118
   Lewiecki EM, 2018, THER ADV MUSCULOSKEL, V10, P209, DOI 10.1177/1759720X18805759
   Mencej S, 2008, J MOL ENDOCRINOL, V40, P273, DOI 10.1677/JME 08 0003
   Mencej S, 2006, MATURITAS, V55, P219, DOI 10.1016/j.maturitas.2006.03.004
   Meng XH, 2018, BONE, V113, P41, DOI 10.1016/j.bone.2018.05.012
   Mo XB, 2018, OSTEOPOROSIS INT, V29, P2029, DOI 10.1007/s00198 018 4573 y
   Qiu C, 2018, INT J GENOMICS, V2018, DOI 10.1155/2018/6407257
   Richards JB, 2008, LANCET, V371, P1505, DOI 10.1016/S0140 6736(08)60599 1
   Rocha Braz MGM, 2016, ARCH ENDOCRIN METAB, V60, P391, DOI 10.1590/2359 3997000000178
   Sassi R, 2017, CLIMACTERIC, V20, P374, DOI 10.1080/13697137.2017.1315088
   Schieferdecker A, 2014, ONCOTARGET, V5, P6647, DOI 10.18632/oncotarget.2160
   Shang M, 2013, CLIN BIOCHEM, V46, P1493, DOI 10.1016/j.clinbiochem.2013.03.011
   Styrkarsdottir U, 2008, NEW ENGL J MED, V358, P2355, DOI 10.1056/NEJMoa0801197
   Takács I, 2010, EUR J ENDOCRINOL, V162, P423, DOI 10.1530/EJE 09 0617
   Techapatiphandee M, 2018, BIOMED REP, V9, P350, DOI 10.3892/br.2018.1137
   Wright HL, 2009, CURR REV MUSCULOSKE, V2, P56, DOI 10.1007/s12178 009 9046 7
   Zhu DL, 2018, J BONE MINER RES, V33, P1335, DOI 10.1002/jbmr.3419
NR 32
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER URBAN & PARTNER SP Z O O
PI WROCLAW
PA UL MIGDALOWA 4, LOK 59, WROCLAW, 02 796, POLAND
SN 1896 1126
EI 1898 4002
J9 ADV MED SCI POLAND
JI Adv. Med. Sci.
PD SEP
PY 2020
VL 65
IS 2
BP 291
EP 297
DI 10.1016/j.advms.2020.05.001
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA QA5SP
UT WOS:000613505100007
PM 32446200
OA hybrid
DA 2025 08 17
ER

PT J
AU Lei, W
   Duan, R
   Li, JB
   Liu, X
   Huston, A
   Boyce, BF
   Yao, ZQ
AF Lei, Wei
   Duan, Rong
   Li, Jinbo
   Liu, Xin
   Huston, Alissa
   Boyce, Brendan F.
   Yao, Zhenqiang
TI The IAP Antagonist SM 164 Eliminates Triple Negative Breast Cancer
   Metastasis to Bone and Lung in Mice
SO SCIENTIFIC REPORTS
LA English
DT Article
ID TUMOR NECROSIS FACTOR; SMAC MIMETIC BIRINAPANT; APOPTOSIS PROTEINS;
   MULTIDRUG RESISTANCE; PHASE I; OSTEOBLAST DIFFERENTIATION;
   MOLECULAR MECHANISM; INHIBITOR; CELLS; RANKL
AB The most challenging issue for breast cancer (BC) patients is metastasis to other organs because current therapies do not prevent or eliminate metastatic BC. Here, we show that SM 164, a small molecule inhibitor, which degrades inhibitor of apoptosis proteins (IAPs), eliminated early stage metastases and reduced progression of advanced BC metastasis from MDA MB 231 BC cells in bones and lungs of nude mice. Mechanistically, SM 164 induced BC cell death is TNF alpha  dependent, with TNF alpha produced by IL 4 polarized macrophages triggering MDA MB 231 cell apoptosis in combination with SM 164. SM 164 also inhibited expression of RANKL, which mediates interactions between metastatic BC and host microenvironment cells and induces osteoclast mediated osteolysis. SM 164 did not kill adriamycin resistant BC cells, while adriamycin inhibited SM 164 resistant BC cell growth, similar to parental cells. We conclude that SM 164 is a promising therapeutic agent for early stage bone and lung metastasis from triple negative breast cancer that should be given prior to conventional chemotherapy.
C1 [Lei, Wei; Duan, Rong; Li, Jinbo; Liu, Xin; Boyce, Brendan F.; Yao, Zhenqiang] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, 601 Elmwood Ave, Rochester, NY 14642 USA.
   [Lei, Wei; Duan, Rong; Li, Jinbo; Liu, Xin; Boyce, Brendan F.; Yao, Zhenqiang] Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, 601 Elmwood Ave, Rochester, NY 14642 USA.
   [Lei, Wei] Henan Univ, Affiliated Hosp 1, Dept Med Imaging, 357 Ximen St, Kaifeng 475001, Henan, Peoples R China.
   [Huston, Alissa] Univ Rochester, Med Ctr, Dept Med, Hematol Oncol, Rochester, NY 14642 USA.
C3 University of Rochester; University of Rochester; Henan University;
   University of Rochester
RP Yao, ZQ (通讯作者)，Univ Rochester, Med Ctr, Dept Pathol & Lab Med, 601 Elmwood Ave, Rochester, NY 14642 USA.; Yao, ZQ (通讯作者)，Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, 601 Elmwood Ave, Rochester, NY 14642 USA.
EM zhenqiang_yao@urmc.rochester.edu
RI ; LEI, WEI/IYJ 1029 2023
OI Li, Jinbo/0000 0003 1279 9000; Yao, Zhenqiang/0000 0002 4664 3648
FU Breast Cancer Coalition of Rochester New York; New York State Department
   of Health Peter T. Rowley Breast Cancer Scientific Research Projects
   [C34928GG]; NIA, National Institutes of Health [R01AG049994]; NIAMS,
   National Institutes of Health [R01AR43510]
FX The research was supported by Breast Cancer Coalition of Rochester New
   York (to ZY) and New York State Department of Health Peter T. Rowley
   Breast Cancer Scientific Research Projects #C34928GG (to ZY); NIA,
   National Institutes of Health Grant R01AG049994 (to BFB and ZY); and
   NIAMS, National Institutes of Health Grant R01AR43510 (to BFB).
CR Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140 6736(05)66544 0
   Amaravadi RK, 2015, MOL CANCER THER, V14, P2569, DOI 10.1158/1535 7163.MCT 15 0475
   BOORSMA C, 2015, EUR RESPIR J S59, V46, DOI DOI 10.1183/13993003
   Brunckhorst MK, 2012, CANCER BIOL THER, V13, P804, DOI 10.4161/cbt.20563
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Clancy Thompson E, 2018, CANCER IMMUNOL RES, V6, P25, DOI 10.1158/2326 6066.CIR 17 0490
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Deveraux Q L, 1998, EMBO J, V17, P2215
   DiPersio JF, 2015, CL LYMPH MYELOM LEUK, V15, P443, DOI 10.1016/j.clml.2015.02.020
   Dougan M, 2010, J EXP MED, V207, P2195, DOI 10.1084/jem.20101123
   Erdogan B, 2014, ASIAN PAC J CANCER P, V15, P1503, DOI 10.7314/APJCP.2014.15.4.1503
   Flygare JA, 2012, J MED CHEM, V55, P4101, DOI 10.1021/jm300060k
   Fulda S, 2014, CLIN CANCER RES, V20, P289, DOI 10.1158/1078 0432.CCR 13 0227
   Genovese I, 2017, DRUG RESIST UPDATE, V32, P23, DOI 10.1016/j.drup.2017.10.003
   Gomis RR, 2017, MOL ONCOL, V11, P62, DOI 10.1016/j.molonc.2016.09.009
   He JQ, 2007, J BIOL CHEM, V282, P3688, DOI 10.1074/jbc.M610271200
   Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778
   Hofbauer LC, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1848
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Hurwitz HI, 2015, CANCER CHEMOTH PHARM, V75, P851, DOI 10.1007/s00280 015 2709 8
   Infante JR, 2014, J CLIN ONCOL, V32, P3103, DOI 10.1200/JCO.2013.52.3993
   Jobke B, 2014, BONE, V59, P37, DOI 10.1016/j.bone.2013.10.024
   Lawson MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9983
   LENK H, 1989, CANCER CHEMOTH PHARM, V24, P391
   Leong SPL, 2014, CA CANCER J CLIN, V64, P196, DOI 10.3322/caac.21217
   Li JB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10677 0
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Li WY, 2011, J THORAC ONCOL, V6, P1801, DOI 10.1097/JTO.0b013e318226b4a6
   Lian N, 2012, J BIOL CHEM, V287, P35975, DOI 10.1074/jbc.M112.372458
   Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200
   Lu JF, 2008, CANCER RES, V68, P9384, DOI 10.1158/0008 5472.CAN 08 2655
   Lu JF, 2011, MOL CANCER THER, V10, P902, DOI 10.1158/1535 7163.MCT 10 0864
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471 4906(02)02302 5
   MCCAULEY LK, 1995, J BONE MINER RES, V10, P1243, DOI 10.1002/jbmr.5650100815
   McComb S, 2012, CELL DEATH DIFFER, V19, P1791, DOI 10.1038/cdd.2012.59
   Mechetner E, 1998, CLIN CANCER RES, V4, P389
   Michie J, 2019, CANCER IMMUNOL RES, V7, P183, DOI 10.1158/2326 6066.CIR 18 0428
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Noonan AM, 2016, CANCER AM CANCER SOC, V122, P588, DOI 10.1002/cncr.29783
   Price TT, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad4059
   Richert MM, 2005, BREAST CANCER RES, V7, pR819, DOI 10.1186/bcr1292
   Rolfo C, 2014, EXPERT OPIN BIOL TH, V14, P15, DOI 10.1517/14712598.2013.843667
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Shen F, 2008, J PHARMACOL EXP THER, V324, P95, DOI 10.1124/jpet.107.127704
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Siegel RL, 2019, CA CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Sun HY, 2007, J AM CHEM SOC, V129, P15279, DOI 10.1021/ja074725f
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678
   Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037
   Wang X, 2008, ACTA PHARMACOL SIN, V29, P1275, DOI 10.1111/j.1745 7254.2008.00889.x
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   WHITEHEAD RP, 1990, J BIOL RESP MODIF, V9, P588
   Wong H, 2013, DRUG METAB DISPOS, V41, P2104, DOI 10.1124/dmd.113.053926
   Wright LE, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.31
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang C, 2013, CANCER DISCOV, V3, P212, DOI 10.1158/2159 8290.CD 12 0271
   Yao ZQ, 2017, J BIOL CHEM, V292, P10169, DOI 10.1074/jbc.M116.771816
   Yao ZQ, 2014, J BONE MINER RES, V29, P866, DOI 10.1002/jbmr.2108
   Yao ZQ, 2009, J CLIN INVEST, V119, P3024, DOI 10.1172/JCI38716
   Yu PF, 2017, ONCOGENE, V36, P840, DOI 10.1038/onc.2016.252
NR 63
TC 16
Z9 18
U1 0
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD APR 24
PY 2020
VL 10
IS 1
AR 7004
DI 10.1038/s41598 020 64018 z
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA NA4ET
UT WOS:000559769400009
PM 32332865
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kitazoe, K
   Abe, M
   Hiasa, M
   Oda, A
   Amou, H
   Harada, T
   Nakano, A
   Takeuchi, K
   Hashimoto, T
   Ozaki, S
   Matsumoto, T
AF Kitazoe, Ken ichi
   Abe, Masahiro
   Hiasa, Masahiro
   Oda, Asuka
   Amou, Hiroe
   Harada, Takeshi
   Nakano, Ayako
   Takeuchi, Kyoko
   Hashimoto, Toshihiro
   Ozaki, Shuji
   Matsumoto, Toshio
TI Valproic acid exerts anti tumor as well as anti angiogenic effects on
   myeloma
SO INTERNATIONAL JOURNAL OF HEMATOLOGY
LA English
DT Article
DE Valproic acid; Myeloma; Osteoclast; Angiogenesis; Apoptosis
ID HISTONE DEACETYLASE INHIBITOR; SUBEROYLANILIDE HYDROXAMIC ACID;
   TRANS RETINOIC ACID; MULTIPLE MYELOMA; BONE DESTRUCTION; CELL GROWTH;
   ANTIEPILEPTIC DRUGS; OSTEOLYTIC LESIONS; HDAC INHIBITORS; MURINE MODEL
AB Multiple myeloma is still an incurable disease, most commonly occurring in the elderly. The myeloma induced bone marrow microenvironment protects myeloma cells from drug induced apoptosis. Therefore, the development of novel and tolerable therapeutic alternatives to overcome the drug resistance is an important clinical issue. Valproic acid (VPA), a safe and widely used anti epileptic agent, is revisited as a class I  and IIa specific histone deacetylase inhibitor. In the present study, we evaluated the effect as well as a mechanism of actions of VPA on myeloma cell growth and survival, with special reference to the myeloma induced bone marrow microenvironment. VPA at therapeutic concentrations for epilepsy induced cell death in primary CD138 positive myeloma cells as well as myeloma cell lines, but not in CD138 negative bone marrow cells. VPA suppressed osteoclastogenesis as well as osteoclast mediated myeloma cell growth. VPA also inhibited vascular tubule formation enhanced by co cultures of myeloma cells and osteoclasts in concert with thalidomide. In addition, VPA induced both caspase dependent and  independent cell death in myeloma cells, and potentiated the anti myeloma effects of melphalan and dexamethasone. Collectively, VPA is suggested to exert multi factorial anti myeloma actions, and may serve as a safe adjuvant to be included in conventional chemotherapies against myeloma.
C1 [Kitazoe, Ken ichi; Abe, Masahiro; Oda, Asuka; Amou, Hiroe; Harada, Takeshi; Nakano, Ayako; Takeuchi, Kyoko; Hashimoto, Toshihiro; Matsumoto, Toshio] Univ Tokushima, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Tokushima 7708503, Japan.
   [Hiasa, Masahiro] Univ Tokushima, Grad Sch Dent Sci, Dept Orthodont, Tokushima 7708503, Japan.
   [Ozaki, Shuji] Tokushima Univ Hosp, Div Transfus Med, Tokushima, Japan.
C3 Tokushima University; Tokushima University; Tokushima University
RP Abe, M (通讯作者)，Univ Tokushima, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, 3 18 15 Kuramoto Cho, Tokushima 7708503, Japan.
EM masabe@clin.med.tokushima u.ac.jp
RI Abe, Masahiro/AAJ 3032 2021; 日浅, 雅博/S 1537 2019
OI HIASA, MASAHIRO/0000 0002 4830 6274; 
FU Ministry of Education, Culture, Science and Sports of Japan; Ministry of
   Health, Labour and Welfare of Japan
FX This work was supported in part by Grants in Aid for Scientific Research
   awarded to T. M. (A) and M. A. (C), the 21st Century Center of
   Excellence Program of the Ministry of Education, Culture, Science and
   Sports of Japan, and a Grant in Aid for Cancer Research (17 16) awarded
   to M. A. from the Ministry of Health, Labour and Welfare of Japan.
CR Abdul M, 2001, ANTICANCER RES, V21, P2045
   Abe M, 2006, LEUKEMIA, V20, P1313, DOI 10.1038/sj.leu.2404228
   Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Blaheta RA, 2005, MED RES REV, V25, P383, DOI 10.1002/med.20027
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Byrd JC, 2005, BLOOD, V105, P959, DOI 10.1182/blood 2004 05 1693
   Catley L, 2003, BLOOD, V102, P2615, DOI 10.1182/blood 2003 01 0233
   Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340
   Cho HH, 2005, J CELL BIOCHEM, V96, P533, DOI 10.1002/jcb.20544
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   D'Amato RJ, 2001, SEMIN ONCOL, V28, P597, DOI 10.1053/sonc.2001.28601
   Dallas SL, 1999, BLOOD, V93, P1697, DOI 10.1182/blood.V93.5.1697.405a17_1697_1706
   Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194
   Garrett IR, 1997, BONE, V20, P515, DOI 10.1016/S8756 3282(97)00056 2
   Gazitt Y, 1998, INT J ONCOL, V13, P397
   Göttlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008 5472.CAN 03 0799
   Inoue S, 2006, CANCER RES, V66, P6785, DOI 10.1158/0008 5472.CAN 05 4563
   Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160
   Kaiser M, 2006, HAEMATOL HEMATOL J, V91, P248
   Kawagoe R, 2002, LEUKEMIA RES, V26, P495, DOI 10.1016/S0145 2126(01)00151 5
   Knüpfer MM, 1998, ANTICANCER RES, V18, P3585
   Kuendgen A, 2006, CANCER AM CANCER SOC, V106, P112, DOI 10.1002/cncr.21552
   Kumar S, 2006, EUR J CANCER, V42, P1612, DOI 10.1016/j.ejca.2006.04.004
   Lavelle D, 2001, AM J HEMATOL, V68, P170, DOI 10.1002/ajh.1174
   Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895
   Maiso P, 2006, CANCER RES, V66, P5781, DOI 10.1158/0008 5472.CAN 05 4186
   Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272
   Matsumoto T, 2006, ANN NY ACAD SCI, V1068, P319, DOI 10.1196/annals.1346.035
   Michaelis M, 2004, MOL PHARMACOL, V65, P520, DOI 10.1124/mol.65.3.520
   Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100
   Mitsiades N, 2003, BLOOD, V101, P4055, DOI 10.1182/blood 2002 11 3514
   Mori Y, 2004, BLOOD, V104, P2149, DOI 10.1182/blood 2004 01 0236
   Nakamura T, 2005, J IMMUNOL, V175, P5809, DOI 10.4049/jimmunol.175.9.5809
   Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161
   O'Connor OA, 2006, J CLIN ONCOL, V24, P166, DOI 10.1200/JCO.2005.01.9679
   Olsen CM, 2004, MOL CELL ENDOCRINOL, V213, P173, DOI 10.1016/j.mce.2003.10.032
   Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood 2004 12 4940
   Palumbo A, 2004, BLOOD, V104, P3052, DOI 10.1182/blood 2004 02 0408
   Palumbo A, 2006, LANCET, V367, P825, DOI 10.1016/S0140 6736(06)68338 4
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   Rogawski MA, 2004, NAT REV NEUROSCI, V5, P553, DOI 10.1038/nrn1430
   Sabokbar A, 2003, METH MOLEC MED, V80, P101
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Schwartz C, 2007, INT J ONCOL, V30, P573
   Takada Y, 2006, J BIOL CHEM, V281, P5612, DOI 10.1074/jbc.M507213200
   Tanaka Y, 2007, CLIN CANCER RES, V13, P816, DOI 10.1158/1078 0432.CCR 06 2258
   TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006 291X(92)90832 6
   TITTLE TV, 1992, EPILEPSIA, V33, P729, DOI 10.1111/j.1528 1157.1992.tb02354.x
   Trus MR, 2005, LEUKEMIA, V19, P1161, DOI 10.1038/sj.leu.2403773
   Yaccoby S, 2006, HAEMATOL HEMATOL J, V91, P192
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
NR 53
TC 25
Z9 27
U1 0
U2 6
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0925 5710
EI 1865 3774
J9 INT J HEMATOL
JI Int. J. Hematol.
PD JAN
PY 2009
VL 89
IS 1
BP 45
EP 57
DI 10.1007/s12185 008 0226 9
PG 13
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 394ZB
UT WOS:000262490600007
PM 19093163
DA 2025 08 17
ER

PT J
AU Park, KR
   Leem, HH
   Cho, M
   Kang, SW
   Yun, HM
AF Park, Kyung Ran
   Leem, Hyun Hee
   Cho, MyoungLae
   Kang, Sang Wook
   Yun, Hyung Mun
TI Effects of the amide alkaloid piperyline on apoptosis, autophagy, and
   differentiation of pre osteoblasts
SO PHYTOMEDICINE
LA English
DT Article
DE Phytomedicine; Piper nigrum L; piperyline; osteoblast; Src
ID FOCAL ADHESION KINASE; ALKALINE PHOSPHATASE; PIPERINE; MINERALIZATION;
   PIPERAMIDES; BLACK
AB Background: Amide alkaloidsare typical constituents in plants of the Piperaceae family. Most of the pharmacological properties of Piper nigrum L. are attributed to the major amide alkaloid, piperine. Piperyline (PIPE) is a further amide alkaloid that has been isolated from P. nigrum.
   Hypothesis/Purpose: This study was performed to examine the biological effects of PIPE on pre osteoblasts and elucidate the underlying mechanisms.
   Study Design: We investigated the effects of PIPE in MC3T3E 1 cells, which are widely used for studying osteoblast behavior in in vitro cell systems.
   Results: We found that at concentrations ranging from 1 to 30 mu M, PIPE inhibited cell growth and induced apoptosis in pre osteoblasts, which was accompanied by the upregulation of apoptotic proteins but downregulation of anti apoptotic proteins. In contrast, PIPE had no appreciable effect on the autophagy pathway. Nevertheless, PIPE reduced cell adhesion and migration via the inactivation of non receptor tyrosine kinase (Src)/focal adhesion kinase (FAK) and mitogen activated protein kinases, and also promoted the downregulation of matrix metalloproteinase 2 and 9 levels. Furthermore, at concentrations of 10 and 30 mu M, PIPE suppressed osteoblast differentiation, as indicated by reductions in alkaline phosphatase staining and activity. In addition, PIPE reduced the protein levels of phospho Smad1/5/8 and runt related transcription factor 2, and the mRNA levels of osteopontin, alkaline phosphatase, and osteocalcin.
   Conclusion: The findings of this study indicate that PIPE has biological effects associated with cell adhesion, migration, proliferation, and osteoblast differentiation, and suggest a potential role for this alkaloid in the treatment of bone diseases.
C1 [Park, Kyung Ran; Kang, Sang Wook; Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, 26 Kyungheedae Ro, Seoul 02453, South Korea.
   [Leem, Hyun Hee; Cho, MyoungLae] Natl Dev Inst Korean Med, Gyongsan 38540, South Korea.
C3 Kyung Hee University
RP Kang, SW; Yun, HM (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, 26 Kyungheedae Ro, Seoul 02453, South Korea.
EM pathemis@khu.ac.kr; yunhm@khu.ac.kr
RI ; Kang, Sang/AAY 5970 2021
OI Kang, Sang Wook/0000 0002 0358 2304; Yun, Hyung Mun/0000 0001 6504 1610
FU Kyung Hee University [KHU 20201216]
FX This work was supported by a grant from Kyung Hee University in 2020
   (KHU 20201216).
CR Grinevicius VMAD, 2016, J ETHNOPHARMACOL, V189, P139, DOI 10.1016/j.jep.2016.05.020
   Canel M, 2008, BRIT J CANCER, V98, P1274, DOI 10.1038/sj.bjc.6604286
   Chang YM, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep131
   Chen YY, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/378415
   Deepak V, 2015, BIOFACTORS, V41, P403, DOI 10.1002/biof.1241
   Friedman M, 2008, J AGR FOOD CHEM, V56, P3028, DOI 10.1021/jf703711z
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980
   GOLUB EE, 1992, BONE MINER, V17, P273, DOI 10.1016/0169 6009(92)90750 8
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   Guo KK, 2018, J SEP SCI, V41, DOI 10.1002/jssc.201800360
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Iguchi M, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/3979606
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kim DY, 2018, BIOCHEM BIOPH RES CO, V495, P1497, DOI 10.1016/j.bbrc.2017.11.200
   KIUCHI F, 1988, CHEM PHARM BULL, V36, P2452
   Liao XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042709
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Numan MS, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S88845
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Parim B, 2015, PHARM BIOL, V53, P1318, DOI 10.3109/13880209.2014.980585
   Park K.R., 2020, **DROPPED REF**, V21
   Park KR, 2020, INT J BIOL SCI, V16, P330, DOI 10.7150/ijbs.37781
   Park KR, 2019, TOXICOLOGY, V422, P95, DOI 10.1016/j.tox.2019.05.010
   Park KR, 2018, THERANOSTICS, V8, P3087, DOI 10.7150/thno.24426
   Park KR, 2017, ARCH PHARM RES, V40, P933, DOI 10.1007/s12272 017 0932 z
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Ngo QMT, 2018, NAT PROD COMMUN, V13, P1467
   Regasini LO, 2009, AFR J BIOTECHNOL, V8, P2866
   Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097 4644(199701)64:1<50::AID JCB8>3.0.CO;2 Z
   Srinivasan K, 2007, CRIT REV FOOD SCI, V47, P735, DOI 10.1080/10408390601062054
   Tang DL, 2019, CELL RES, V29, P347, DOI 10.1038/s41422 019 0164 5
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113 8133.2004
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Yun HM, 2016, SCI REP UK, V6, DOI 10.1038/srep30985
   Zheng XG, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414 431X20187574, 10.1590/1414 431x20187574]
NR 39
TC 18
Z9 20
U1 1
U2 22
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD DEC
PY 2020
VL 79
AR 153347
DI 10.1016/j.phymed.2020.153347
PG 8
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA OG0BW
UT WOS:000581562000023
PM 32992084
DA 2025 08 17
ER

PT J
AU Seefried, L
   Genest, F
   Baumann, J
   Heidemeier, A
   Meffert, R
   Jakob, F
AF Seefried, Lothar
   Genest, Franca
   Baumann, Jasmin
   Heidemeier, Anke
   Meffert, Rainer
   Jakob, Franz
TI Efficacy of Zoledronic Acid in the Treatment of Nonmalignant Painful
   Bone Marrow Lesions: A Triple Blind, Randomized, Placebo Controlled
   Phase III Clinical Trial (ZoMARS)
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BONE BIOLOGY; OSTEOPOROSIS; BONE MARROW LESION; EDEMA; BISPHOSPHONATES;
   ZOLEDRONIC ACID
ID TRANSIENT OSTEOPOROSIS; EDEMA SYNDROME; BISPHOSPHONATES; TERIPARATIDE
AB Bone marrow lesions (BML) represent areas of deteriorated bone structure and metabolism characterized by pronounced water equivalent signaling within the trabecular bone on magnetic resonance imaging (MRI). BML are associated with repair mechanisms subsequent to various clinical conditions associated with inflammatory and non inflammatory injury to the bone. There is no approved treatment for this condition. Bisphosphonates are known to improve bone stability in osteoporosis and other bone disorders and have been used off label to treat BML. A randomized, triple blind, placebo controlled phase III trial was conducted to assess efficacy and safety of single dose zoledronic acid (ZOL) 5 mg iv with vitamin D 1000 IU/d as opposed to placebo with vitamin D 1000 IU/d in 48 patients (randomized 2:1) with BML. Primary efficacy endpoint was reduction of edema volume 6 weeks after treatment as assessed by MRI. After treatment, mean BML volume decreased by 64.53% (+/  41.92%) in patients receiving zoledronic acid and increased by 14.43% (+/  150.46%) in the placebo group (p = 0.007). A decrease in BML volume was observed in 76.5% of patients receiving ZOL and in 50% of the patients receiving placebo. Pain level (visual analogue scale [VAS]) and all categories of the pain disability index (PDI) improved with ZOL versus placebo after 6 weeks but reconciled after 6 additional weeks of follow up. Six serious adverse events occurred in 5 patients, none of which were classified as related to the study drug. No cases of osteonecrosis or fractures occurred. Therefore, single dose zoledronic acid 5 mg iv together with vitamin D may enhance resolution of bone marrow lesions over 6 weeks along with reduction of pain compared with vitamin D supplementation only. (c) 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
C1 [Seefried, Lothar; Genest, Franca; Baumann, Jasmin; Jakob, Franz] Univ Wurzburg, Orthoped Ctr Musculoskeletal Res, Orthoped Dept, Wurzburg, Germany.
   [Heidemeier, Anke] Univ Hosp Wuerzburg, Dept Diagnost & Intervent Radiol, Wurzburg, Germany.
   [Meffert, Rainer] Univ Hosp Wuerzburg, Dept Trauma Plast Reconstruct & Hand Surg, Wurzburg, Germany.
C3 University of Wurzburg; University of Wurzburg; University of Wurzburg
RP Seefried, L (通讯作者)，Univ Wurzburg, Orthoped Dept, Clin Trial Unit, Brettreichstr 11, D 97074 Wurzburg, Germany.
EM l seefried.klh@uni wuerzburg.de
RI Genest, Franca/HDO 6905 2022; Seefried, Lothar/AAU 2169 2021
FU Projekt DEAL; Novartis
FX The authors thank Dr Nils Pollak, Central Pharmacy, University Hospital
   Wuerzburg, for the highly reliable and diligent collaboration regarding
   provision of the IMP, and CROLLL Ltd., namely Sabine Hofling and Marcos
   Schulte, for excellent support with data monitoring and completing the
   study report. The authors acknowledge Guilia Zarid and Antonio Cagnazzo
   (CROSNT) for statistical support. The authors thank Prof Kathryn Dahir
   (Vanderbilt University, Nashville, TN, USA) for critically reading the
   manuscript. The authors thank Novartis for financial support of this
   trial. Authors' roles: LS designed and conducted the trial, contributed
   to acquisition and analysis of data, and wrote the manuscript. FG
   contributed to acquisition, analysis, and interpretation of data and
   revised the manuscript. JB contributed to acquisition and analysis of
   data and manuscript preparation. AH contributed to acquisition,
   analysis, and interpretation of data and revised the manuscript. RM
   contributed to conception and design of the study and analysis and
   interpretation of data and revised the manuscript. FJ initiated the
   study and contributed to conception and design of the study,
   interpretation of data, and revised the manuscript. Open access funding
   enabled and organized by Projekt DEAL.
CR Adam C, 2018, BONE, V111, P49, DOI 10.1016/j.bone.2018.03.020
   Allen MR, 2008, CLIN REV BONE MINER, V6, P24, DOI 10.1007/s12018 008 9015 5
   Asadipooya K, 2017, OSTEOPOROSIS INT, V28, P1805, DOI 10.1007/s00198 017 3952 0
   Baier C, 2013, RHEUMATOL INT, V33, P1397, DOI 10.1007/s00296 012 2584 0
   Bartl C, 2012, ARCH ORTHOP TRAUM SU, V132, P1781, DOI 10.1007/s00402 012 1617 1
   Baumbach SF, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020551
   Bischoff Ferrari HA, 2004, AM J CLIN NUTR, V80, P752
   Bonadio MB, 2017, MAGN RESON INSIGHTS, V10, P1, DOI 10.1177/1178623X17703382
   Bugatti S, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4115
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   CHIBNALL JT, 1994, ARCH PHYS MED REHAB, V75, P1082, DOI 10.1016/0003 9993(94)90082 5
   Cui PP, 2018, HISTOL HISTOPATHOL, V33, P89, DOI 10.14670/HH 11 893
   Dempster DW, 2016, J BONE MINER RES, V31, P1527, DOI 10.1002/jbmr.2825
   Dempster DW, 2016, J BONE MINER RES, V31, P1429, DOI 10.1002/jbmr.2804
   Dhillon S, 2016, DRUGS, V76, P1683, DOI 10.1007/s40265 016 0662 4
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Emad Y, 2012, CLIN RHEUMATOL, V31, P1641, DOI 10.1007/s10067 012 2060 y
   Eriksen EF, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.124
   Ghasemi RA, 2019, ORTHOP CLIN N AM, V50, P131, DOI 10.1016/j.ocl.2018.08.008
   Flores Robles BJ, 2017, J PAIN PALLIAT CARE, V31, P52, DOI 10.1080/15360288.2016.1276993
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Lips P, 2010, OSTEOPOROSIS INT, V21, P61, DOI 10.1007/s00198 009 0946 6
   Matheny JB, 2017, J BIOMECH, V64, P258, DOI 10.1016/j.jbiomech.2017.09.020
   Patel S, 2014, RHEUMATOLOGY, V53, P785, DOI 10.1093/rheumatology/ket324
   Ringe JD, 2007, CLIN EXP RHEUMATOL, V25, P766
   Ringe JD, 2005, OSTEOPOROSIS INT, V16, P2063, DOI 10.1007/s00198 005 2001 6
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2015, CURR OPIN PHARMACOL, V22, P115, DOI 10.1016/j.coph.2015.05.005
   Shabestari M, 2016, OSTEOARTHR CARTILAGE, V24, P1745, DOI 10.1016/j.joca.2016.05.009
   Shin Young Ho, 2020, J Bone Metab, V27, P15, DOI 10.11005/jbm.2020.27.1.15
   Simon MJK, 2014, INJURY, V45, P981, DOI 10.1016/j.injury.2014.01.023
   Singh Dishan, 2016, Foot Ankle Spec, V9, P218, DOI 10.1177/1938640015609986
   Zafar S, 2020, J ORAL SCI, V62, P79, DOI 10.2334/josnusd.19 0130
   Zhou DY, 2017, ONCOL LETT, V14, P4078, DOI 10.3892/ol.2017.6717
NR 34
TC 13
Z9 14
U1 1
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2022
VL 37
IS 3
BP 420
EP 427
DI 10.1002/jbmr.4493
EA JAN 2022
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ZW0AY
UT WOS:000742207900001
PM 34954857
OA Green Published
DA 2025 08 17
ER

PT J
AU Rennert, G
   Pinchev, M
   Gronich, N
   Saliba, W
   Flugelman, A
   Lavi, I
   Goldberg, H
   Fried, G
   Steiner, M
   Bitterman, A
   Landsman, K
   Rennert, HS
AF Rennert, Gad
   Pinchev, Mila
   Gronich, Naomi
   Saliba, Walid
   Flugelman, Anath
   Lavi, Idit
   Goldberg, Hadassah
   Fried, Georgeta
   Steiner, Mariana
   Bitterman, Arie
   Landsman, Keren
   Rennert, Hedy S.
TI Oral Bisphosphonates and Improved Survival of Breast Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID PLUS ZOLEDRONIC ACID; ADJUVANT BISPHOSPHONATES; ANTITUMOR ACTIVITY;
   RISK; THERAPY; BONE; WOMEN; ALENDRONATE; MECHANISMS; PREVENTION
AB Purpose: Bisphosphonates are used for treatment or prevention of osteoporosis and of bone metastases. The use of oral bisphosphonates was suggested to be associated with reduced risk of developing breast cancer, and their positive influence on breast cancer survival was only demonstrated with third generation bisphosphonates. We studied the association of use of oral bisphosphonates after breast cancer diagnosis on overall and breast cancer survival.
   Experimental Design: A nested case control analysis was performed using data from the population based Breast Cancer in Northern Israel Study (BCINIS). Participants were postmenopausal women with newly diagnosed breast cancer insured by Clalit. Use of second generation bisphosphonates (alendronate and/or risedronate) was identified using computerized prescription records. The analysis was restricted to women who did not use bisphosphonates prior to diagnosis.
   Results: In a cohort of 3,731 postmenopausal women with breast cancer, followed up for an average of 70 months, there were 799 cases of death which were matched to 15,915 control periods of living breast cancer cases. Use of bisphosphonates after diagnosis for at least 18 months was significantly more common among survivors than among their matched controls who died, adjusted for tumor stage/grade (overall survival: OR = 0.63, 0.410.96, P = 0.03; breast cancer specific survival: OR = 0.28, 0.090.91, P = 0.035). A similar advantageous effect, but statistically underpowered, was found in estrogen receptor (ER) positive, ERnegative, and HER2neu positive tumors.
   Conclusions: The use of oral bisphosphonates, by postmenopausal, probably osteoporotic, women initiated after diagnosis of breast cancer was associated with a significant improvement in overall and breast specific odds of survival.
C1 [Rennert, Gad; Pinchev, Mila; Gronich, Naomi; Saliba, Walid; Flugelman, Anath; Lavi, Idit; Landsman, Keren; Rennert, Hedy S.] Technion Israel Inst Technol, Carmel Med Ctr, Dept Community Med & Epidemiol, Haifa, Israel.
   [Goldberg, Hadassah] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Haifa, Israel.
   [Goldberg, Hadassah] Clalit Natl Canc Control Ctr, Haifa, Israel.
   [Goldberg, Hadassah] Western Galilee Hosp, Inst Oncol, Nahariyya, Israel.
   [Fried, Georgeta] Rambam Med Ctr, Inst Oncol, Haifa, Israel.
   [Steiner, Mariana] Lynn Med Ctr, Clalit Hlth Serv, Haifa, Israel.
   [Bitterman, Arie] A Carmel Med Ctr, Dept Surg, Haifa, Israel.
C3 Clalit Health Services; Carmel Medical Center; Technion Israel Institute
   of Technology; Technion Israel Institute of Technology; Rappaport
   Faculty of Medicine; Western Galilee Hospital; Rambam Health Care
   Campus; Clalit Health Services; Clalit Health Services; Carmel Medical
   Center
RP Rennert, HS (通讯作者)，Carmel Hosp, Dept Community Med & Epidemiol, 7 Michal St, IL 34362 Haifa, Israel.
EM rennert@tx.technion.ac.il
OI Gronich, Naomi/0000 0003 4369 6813; Rennert, Gad/0000 0002 8512 068X
FU Breast Cancer Research Foundation (BCRF), New York
FX Funding for this study was provided in part by a grant from the Breast
   Cancer Research Foundation (BCRF), New York.
CR Amoroso V, 2015, FUTURE ONCOL, V11, P2853, DOI 10.2217/fon.15.210
   Avilés A, 2007, MED ONCOL, V24, P227, DOI 10.1007/BF02698044
   Boudreau DM, 2010, EXPERT OPIN DRUG SAF, V9, P603, DOI 10.1517/14740331003662620
   Cardwell CR, 2012, INT J CANCER, V131, pE717, DOI 10.1002/ijc.27389
   Chlebowski RT, 2010, J CLIN ONCOL, V28, P3582, DOI 10.1200/JCO.2010.28.2095
   Clézardin P, 2012, ANTI CANCER AGENT ME, V12, P102, DOI 10.2174/187152012799014977
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Coscia M, 2010, J CELL MOL MED, V14, P2803, DOI 10.1111/j.1582 4934.2009.00926.x
   de Boer R, 2011, P 34 ANN CTRCAACR SA
   Gnant M, 2011, P 34 ANN CTRC AACR S
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Hadji P, 2016, ANN ONCOL, V27, P379, DOI 10.1093/annonc/mdv617
   Holen I, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2769
   Hue TF, 2014, JAMA INTERN MED, V174, P1550, DOI 10.1001/jamainternmed.2014.3634
   Jacobs C, 2015, J BONE ONCOL, V4, P54, DOI 10.1016/j.jbo.2015.06.001
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Monsees GM, 2011, J NATL CANCER I, V103, P1752, DOI 10.1093/jnci/djr399
   Mystakidou K, 2005, MED ONCOL, V22, P195, DOI 10.1385/MO:22:2:195
   Newcomb PA, 2010, BRIT J CANCER, V102, P799, DOI 10.1038/sj.bjc.6605555
   Powles T, 2006, CLIN CANCER RES, V12, p6301S, DOI 10.1158/1078 0432.CCR 06 1211
   Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792
   Rachner TD, 2010, CANCER LETT, V287, P109, DOI 10.1016/j.canlet.2009.06.003
   Rennert G, 2011, J NATL CANCER I, V103, P1728, DOI 10.1093/jnci/djr441
   Rennert G, 2011, J CLIN ONCOL, V29, P1146, DOI 10.1200/JCO.2010.33.7485
   Rennert G, 2010, J CLIN ONCOL, V28, P3577, DOI 10.1200/JCO.2010.28.1113
   Richardson DB, 2004, OCCUP ENVIRON MED, V61, DOI 10.1136/oem.2004.014472
   Rosen CJ, 2005, NEW ENGL J MED, V353, P595, DOI 10.1056/NEJMcp043801
   Rothman KJ., 2008, Modern Epidemiology
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Santini D, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058 015 0634 8
   SASAKI A, 1995, CANCER RES, V55, P3551
   Singh H, 2012, CANCER AM CANCER SOC, V118, P1236, DOI 10.1002/cncr.26395
   Siris ES, 2011, J BONE MINER RES, V26, P3, DOI 10.1002/jbmr.189
   Strobl S, 2016, ANNU REV MED, V67, P1, DOI 10.1146/annurev med 053014 103600
   Tanimori Y, 2010, CLIN EXP METASTAS, V27, P529, DOI 10.1007/s10585 010 9342 z
   Tuomela JM, 2008, BMC CANCER, V8, DOI 10.1186/1471 2407 8 81
   Van Acker HH, 2016, PHARMACOL THERAPEUT, V158, P24, DOI 10.1016/j.pharmthera.2015.11.008
   Van Poznak CH, 2011, J CLIN ONCOL, V29, P1221, DOI 10.1200/JCO.2010.32.5209
   Wiemer AJ, 2009, ANTI CANCER AGENT ME, V9, P526, DOI 10.2174/187152009788451860
   Winter MC, 2008, CANCER TREAT REV, V34, P453, DOI 10.1016/j.ctrv.2008.02.004
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Zaghloul MS, 2010, INT J CLIN ONCOL, V15, P382, DOI 10.1007/s10147 010 0074 5
   Zarogoulidis K, 2009, INT J CANCER, V125, P1705, DOI 10.1002/ijc.24470
NR 47
TC 31
Z9 33
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 1
PY 2017
VL 23
IS 7
BP 1684
EP 1689
DI 10.1158/1078 0432.CCR 16 0547
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA EQ7KK
UT WOS:000398262700009
PM 27683176
DA 2025 08 17
ER

PT J
AU Chen, YX
   Zhu, R
   Ke, QF
   Gao, YS
   Zhang, CQ
   Guo, YP
AF Chen, Yi Xuan
   Zhu, Rong
   Ke, Qin Fei
   Gao, You Shui
   Zhang, Chang Qing
   Guo, Ya Ping
TI MgAl layered double hydroxide/chitosan porous scaffolds loaded with PFTα
   to promote bone regeneration
SO NANOSCALE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; INHIBITOR PIFITHRIN ALPHA; RELEASE RATE
   MODULATION; BINARY POLYMER SYSTEM; OSTEOGENIC DIFFERENTIATION; IN VITRO;
   OSTEOBLAST DIFFERENTIATION; BIOLOGICAL PROPERTIES; NANO HYDROXYAPATITE;
   SIGNALING PATHWAY
AB Poor bone formation remains a key risk factor associated with acellular scaffolds that occurs in some bone defects, particularly in patients with metabolic bone disorders and local osteoporosis. We herein fabricated for the first time layered double hydroxide chitosan porous scaffolds loaded with PFT alpha (LDH CS PFT alpha scaffolds) as therapeutic bone scaffolds for the controlled release of PFT alpha to enhance stem cell osteogenic differentiation and bone regeneration. The LDH CS scaffolds had three dimensional interconnected macropores, and plate like LDH nanoparticles were uniformly dispersed within or on the CS films. The LDH CS scaffolds exhibited appropriate PFT alpha drug delivery due to hydrogen bonding among LDH, CS and PFT alpha. In vitro functional studies demonstrated that the PFT alpha molecules exhibited potent ability to induce osteogenesis of hBMSCs via the GSK3 beta/beta catenin pathway, and the LDH CS PFT alpha scaffolds significantly enhanced the osteogenic differentiation of hBMSCs. In vivo studies revealed significantly increased repair and regeneration of bone tissue in cranial defect model rats compared to control rats at 12 weeks post implantation. In conclusion, the LDH CS PFT alpha scaffolds exhibited excellent osteogenic differentiation and bone regeneration capability and hold great potential for applications in defined local bone regeneration.
C1 [Chen, Yi Xuan; Gao, You Shui; Zhang, Chang Qing] Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Orthoped Surg, Shanghai 200233, Peoples R China.
   [Zhu, Rong; Ke, Qin Fei; Guo, Ya Ping] Shanghai Normal Univ, Educ Minist, Key Lab Resource Chem, Shanghai 200234, Peoples R China.
   [Zhu, Rong; Ke, Qin Fei; Guo, Ya Ping] Shanghai Normal Univ, Shanghai Key Lab Rare Earth Funct Mat, Shanghai 200234, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Normal University; Shanghai
   Normal University
RP Zhang, CQ (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Orthoped Surg, Shanghai 200233, Peoples R China.; Guo, YP (通讯作者)，Shanghai Normal Univ, Educ Minist, Key Lab Resource Chem, Shanghai 200234, Peoples R China.; Guo, YP (通讯作者)，Shanghai Normal Univ, Shanghai Key Lab Rare Earth Funct Mat, Shanghai 200234, Peoples R China.
EM zhangcq@sjtu.edu.cn; ypguo@shnu.edu.cn
RI GAO, YOUSHUI/U 8349 2019; chen, yixuan/KVC 2060 2024
OI chen, yixuan/0000 0001 7390 0622; Guo, Ya Ping/0000 0002 5450 2968;
   zhang, changqing/0000 0002 7408 4126
FU Natural Science Foundation of China [51372152, 81472066]; Innovation
   Foundation of Shanghai Education Committee [14ZZ124]; Key Disciplines of
   Shanghai Municipal Education Commission [J50206]; National High
   Technology Research and Development Program of China [2012AA020506];
   "Priority Among Priorities" Clinical Medical Centre Construction Project
   of the Shanghai Municipal, Science and Technology Commission of Shanghai
   Municipality [12JC1405600]
FX This research was supported by the Natural Science Foundation of China
   (no. 51372152 and 81472066), the Innovation Foundation of Shanghai
   Education Committee (no. 14ZZ124), Key Disciplines of Shanghai Municipal
   Education Commission (no. J50206), the National High Technology Research
   and Development Program of China (2012AA020506), and the "Priority Among
   Priorities" Clinical Medical Centre Construction Project of the Shanghai
   Municipal, Science and Technology Commission of Shanghai Municipality
   (no. 12JC1405600).
CR Abdolmohammad Zadeh H, 2011, TALANTA, V84, P368, DOI 10.1016/j.talanta.2011.01.026
   Aliramaji S, 2017, MAT SCI ENG C MATER, V70, P736, DOI 10.1016/j.msec.2016.09.039
   Bandara N, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0442 9
   Bayraktar S, 2018, J TISSUE ENG REGEN M, V12, P114, DOI 10.1002/term.2375
   Begum RA, 2002, BIOMED SCI INSTRUM, V38, P41
   Bose S, 2012, TRENDS BIOTECHNOL, V30, P546, DOI 10.1016/j.tibtech.2012.07.005
   Cabraja M, 2012, J NEUROSURG SCI, V56, P87
   Calabrese G, 2016, SCI REP UK, V6, DOI 10.1038/srep36399
   Chen H, 2012, CHEM ENG J, V185, P358, DOI 10.1016/j.cej.2011.12.096
   Craciunescu O, 2011, CENT EUR J BIOL, V6, P301, DOI 10.2478/s11535 011 0012 1
   Cunniffe GM, 2016, ACS APPL MATER INTER, V8, P23477, DOI 10.1021/acsami.6b06596
   D'Elía NL, 2015, NANOSCALE, V7, P18751, DOI 10.1039/c5nr04850h
   Dallari D, 2012, BIOMATERIALS, V33, P72, DOI 10.1016/j.biomaterials.2011.09.029
   Dang M, 2017, BIOMATERIALS, V114, P1, DOI 10.1016/j.biomaterials.2016.10.049
   El Fiqi A, 2012, NANOSCALE, V4, P7475, DOI 10.1039/c2nr31775c
   El Gibaly AM, 2004, HEPATOLOGY, V39, P1553, DOI 10.1002/hep.20243
   Fibbe WE, 2002, ANN RHEUM DIS, V61, P29
   Friedlaender GE, 2013, CURR PHARM DESIGN, V19, P3384, DOI 10.2174/1381612811319190005
   Guo XX, 2010, CHEM COMMUN, V46, P5197, DOI 10.1039/c0cc00313a
   Guo YP, 2015, J MATER CHEM B, V3, P4679, DOI 10.1039/c5tb00175g
   He YL, 2015, STEM CELLS, V33, P1304, DOI 10.1002/stem.1925
   Hild N, 2011, NANOSCALE, V3, P401, DOI 10.1039/c0nr00615g
   Hochgreb Hägele T, 2015, DEV BIOL, V400, P23, DOI 10.1016/j.ydbio.2015.01.011
   Hu C, 2016, INT J BIOL MACROMOL, V92, P1191, DOI 10.1016/j.ijbiomac.2016.08.007
   Huang W, 2011, AICHE J, V57, P1936, DOI 10.1002/aic.12379
   Hunziker EB, 2012, BONE, V51, P98, DOI 10.1016/j.bone.2012.04.004
   Jiang H, 2013, ACS APPL MATER INTER, V5, P12036, DOI 10.1021/am4038432
   Kapusetti G, 2013, J MATER CHEM B, V1, P2275, DOI 10.1039/c3tb00004d
   Kesireddy V, 2016, J MATER CHEM B, V4, P6773, DOI [10.1039/c6tb00783j, 10.1039/C6TB00783J]
   Kim H, 1997, J PHARM SCI, V86, P323, DOI 10.1021/js960307p
   Kim H, 1997, J PHARM SCI US, V86, P316, DOI 10.1021/js960302s
   Kim MH, 2016, ADV HEALTHC MATER, V5, P2765, DOI 10.1002/adhm.201600761
   Kim TH, 2016, NANOSCALE, V8, P8300, DOI 10.1039/c5nr07933k
   Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200
   Laurencin CT, 2014, DRUG DISCOV TODAY, V19, P794, DOI 10.1016/j.drudis.2014.01.012
   Lei Y, 2015, RSC ADV, V5, P25462, DOI 10.1039/c5ra01628b
   Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130
   Leonova KI, 2010, CELL CYCLE, V9, P1434, DOI 10.4161/cc.9.7.11508
   Lin YY, 2014, BONE, V64, P147, DOI 10.1016/j.bone.2014.03.051
   Liu WJ, 2015, AGING US, V7, P205, DOI 10.18632/aging.100728
   Liu XW, 2004, AM J PHYSIOL HEART C, V286, pH933, DOI 10.1152/ajpheart.00759.2003
   Liu Y, 2016, SMALL, V12, P4611, DOI 10.1002/smll.201600626
   Luca L, 2010, J CONTROL RELEASE, V147, P38, DOI 10.1016/j.jconrel.2010.06.011
   Ma G, 2017, J ORAL MAXIL SURG, V75, P92, DOI 10.1016/j.joms.2016.08.014
   Masaoka Tomokazu, 2016, Open Biomed Eng J, V10, P2, DOI 10.2174/1874120701610010002
   Nijboer CH, 2011, ANN NEUROL, V70, P255, DOI 10.1002/ana.22413
   Pavlaki K, 2014, STEM CELLS DEV, V23, P1568, DOI 10.1089/scd.2013.0283
   Peng X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097283
   Quinlan E, 2015, BIOMATERIALS, V52, P358, DOI 10.1016/j.biomaterials.2015.02.006
   Radha G, 2017, MAT SCI ENG C MATER, V73, P164, DOI 10.1016/j.msec.2016.11.098
   Rudnicki MA, 2015, BONE, V80, P60, DOI 10.1016/j.bone.2015.02.009
   Sabbieti MG, 2009, J CELL BIOCHEM, V107, P316, DOI 10.1002/jcb.22127
   Sakai A, 2002, J BONE MINER RES, V17, P119, DOI 10.1359/jbmr.2002.17.1.119
   Shen XF, 2016, BIOMATERIALS, V106, P205, DOI 10.1016/j.biomaterials.2016.08.023
   Shen YL, 2016, AM J TRANSL RES, V8, P4040
   SING KSW, 1982, PURE APPL CHEM, V54, P2201, DOI 10.1351/pac198254112201
   Sommer AE, 2011, POLYM ADVAN TECHNOL, V22, P2638, DOI 10.1002/pat.1667
   Stokols S, 2006, BIOMATERIALS, V27, P443, DOI 10.1016/j.biomaterials.2005.06.039
   Sun JL, 2015, SCI REP UK, V5, DOI 10.1038/srep18572
   Tabata Y, 1998, BIOMATERIALS, V19, P807, DOI 10.1016/S0142 9612(98)00233 6
   Tang S, 2014, SURF COAT TECH, V251, P210, DOI 10.1016/j.surfcoat.2014.04.028
   Tao K, 2016, TOXICOL LETT, V240, P68, DOI 10.1016/j.toxlet.2015.10.007
   Tao YF, 2011, J COLLOID INTERF SCI, V358, P554, DOI 10.1016/j.jcis.2011.02.070
   Teotia AK, 2016, ACS APPL MATER INTER, V8, P10775, DOI 10.1021/acsami.6b02145
   Wang F, 2015, J BIOMATER TISS ENG, V5, P557, DOI 10.1166/jbt.2015.1348
   Wang XY, 2006, J CELL BIOL, V172, P115, DOI 10.1083/jcb.200507106
   Xie XY, 2015, NANOSCALE, V7, P7992, DOI 10.1039/c5nr01107h
   Xu R, 2001, CHEM MATER, V13, P297, DOI 10.1021/cm000526i
   Xu ZP, 2011, J NANOPART RES, V13, P1253, DOI 10.1007/s11051 010 0118 9
   Yan XB, 2011, MOL CELL BIOCHEM, V354, P21, DOI 10.1007/s11010 011 0801 x
   Yang GJ, 2017, NANOSCALE, V9, P5794, DOI 10.1039/c7nr00347a
   Yang LY, 2016, NEUROBIOL DIS, V96, P216, DOI 10.1016/j.nbd.2016.08.012
   Yang TI, 2014, CURR NANOSCI, V10, P194, DOI 10.2174/1573413709666131129000432
   Yin Z, 2016, STEM CELL TRANSL MED, V5, P1106, DOI 10.5966/sctm.2015 0215
   Zanin H, 2015, NANOSCALE, V7, P10218, DOI 10.1039/c4nr07317g
   Zeimaran E, 2016, MATER DESIGN, V109, P434, DOI 10.1016/j.matdes.2016.07.096
   Zhang P, 2016, SCI REP UK, V6, DOI 10.1038/srep26295
NR 77
TC 61
Z9 62
U1 3
U2 180
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040 3364
EI 2040 3372
J9 NANOSCALE
JI Nanoscale
PD MAY 28
PY 2017
VL 9
IS 20
BP 6765
EP 6776
DI 10.1039/c7nr00601b
PG 12
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA EV8MI
UT WOS:000402034400020
PM 28489093
DA 2025 08 17
ER

PT J
AU Genova, T
   Petrillo, S
   Zicola, E
   Roato, I
   Ferracini, R
   Tolosano, E
   Altruda, F
   Carossa, S
   Mussano, F
   Munaron, L
AF Genova, Tullio
   Petrillo, Sara
   Zicola, Elisa
   Roato, Ilaria
   Ferracini, Riccardo
   Tolosano, Emanuela
   Altruda, Fiorella
   Carossa, Stefano
   Mussano, Federico
   Munaron, Luca
TI The Crosstalk Between Osteodifferentiating Stem Cells and Endothelial
   Cells Promotes Angiogenesis and Bone Formation
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE mesenchymal stem cells; adipose derived stem cells; bone
   vascularization; endothelial cells; co culture; 3D cultures
ID HUMAN ADIPOSE TISSUE; IN VITRO; STROMAL CELLS; PLASMA; DEXAMETHASONE;
   OSTEOBLASTS; EXPRESSION; INDUCTION; EXPANSION; THERAPY
AB The synergistic crosstalk between osteodifferentiating stem cells and endothelial cells (ECs) gained the deserved consideration, shedding light on the role of angiogenesis for bone formation and healing. A deep understanding of the molecular basis underlying the mutual influence of mesenchymal stem cells (MSCs) and ECs in the osteogenic process may help improve greatly bone regeneration. Here, the authors demonstrated that osteodifferentiating MSCs co cultured with ECs promote angiogenesis and ECs recruitment. Moreover, through the use of 3D co culture systems, we showed that ECs are in turn able to further stimulate the osteodifferentiation of MSCs, thus enhancing bone production. These findings highlighted the existence of a virtuous loop between MSCs and ECs that is central to the osteogenic process. Unraveling the molecular mechanisms governing the functional interaction MSCs and ECs holds great potential in the field of regenerative medicine.
C1 [Genova, Tullio; Munaron, Luca] UNITO, Dept Life Sci & Syst Biol, Turin, Italy.
   [Genova, Tullio; Carossa, Stefano; Mussano, Federico] UNITO, Dept Surg Sci, CIR Dent Sch, Turin, Italy.
   [Petrillo, Sara; Tolosano, Emanuela; Altruda, Fiorella] UNITO, Dept Mol Biotechnol & Hlth Sci, Turin, Italy.
   [Zicola, Elisa] UNITO, Dept Clin & Biol Sci, Orbassano, Italy.
   [Roato, Ilaria] AOU Citta Salute & Sci, Ctr Res & Med Studies, Turin, Italy.
   [Ferracini, Riccardo] Orthopaed Clin IRCCS AOU San Martino, Dept Surg Sci DISC, Genoa, Italy.
C3 University of Turin; University of Turin; A.O.U. Citta della Salute e
   della Scienza di Torino; University of Turin; A.O.U. Citta della Salute
   e della Scienza di Torino
RP Genova, T (通讯作者)，UNITO, Dept Life Sci & Syst Biol, Turin, Italy.; Genova, T (通讯作者)，UNITO, Dept Surg Sci, CIR Dent Sch, Turin, Italy.
EM tullio.genova@unito.it
RI Roato, Ilaria/ACF 6827 2022; Ferracini, Riccardo/AAL 4622 2020; Genova,
   Tullio/S 2674 2018; Tolosano, Emanuela/L 8080 2019; Petrillo,
   Sara/AAE 7656 2019
OI Mussano, Federico/0000 0001 5800 0749; Zicola,
   Elisa/0000 0002 2347 8299; 
CR Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Avanzato D, 2016, SCI REP UK, V6, DOI 10.1038/srep32602
   Basilico N, 2015, TOXICOL APPL PHARM, V288, P330, DOI 10.1016/j.taap.2015.08.005
   Beneduce E, 2019, AM J HEMATOL, V94, P10, DOI 10.1002/ajh.25295
   Cacopardo L, 2019, BIOSENS BIOELECTRON, V140, P145, DOI 10.1016/j.bios.2019.111340
   Cai XX, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.48
   Canullo L, 2016, J DENT RES, V95, P566, DOI 10.1177/0022034516629119
   Canullo L, 2017, INT J ORAL MAX IMPL, V32, P1315, DOI 10.11607/jomi.5777
   Canullo L, 2017, INT J PERIODONT REST, V37, P541, DOI 10.11607/prd.2916
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Chen MK, 2019, BIOTECHNOL LETT, V41, P305, DOI 10.1007/s10529 019 02649 7
   Clark D, 2015, J BIOMED MATER RES A, V103, P639, DOI 10.1002/jbm.a.35215
   Correia C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028352
   Correia SI, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0784
   CUNNINGHAM NS, 1992, P NATL ACAD SCI USA, V89, P11740, DOI 10.1073/pnas.89.24.11740
   Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545
   Derubeis AR, 2004, ANN BIOMED ENG, V32, P160, DOI 10.1023/B:ABME.0000007800.89194.95
   Dufrane D, 2017, CELL TRANSPLANT, V26, P1496, DOI 10.1177/0963689717721203
   Genova T, 2016, J BIOMATER APPL, V30, P940, DOI 10.1177/0885328215616749
   Genova T, 2017, J CELL BIOL, V216, P2107, DOI 10.1083/jcb.201506024
   Griffith LG, 2002, SCIENCE, V295, P1009, DOI 10.1126/science.1069210
   Guillotin B, 2004, CELL PHYSIOL BIOCHEM, V14, P325, DOI 10.1159/000080342
   Hankenson KD, 2011, INJURY, V42, P556, DOI 10.1016/j.injury.2011.03.035
   Hanley PJ, 2014, CYTOTHERAPY, V16, P1048, DOI 10.1016/j.jcyt.2014.01.417
   HEFFERNAN JT, 1978, INVEST OPHTH VIS SCI, V17, P565
   Ingoglia G, 2017, DATA BRIEF, V13, P69, DOI 10.1016/j.dib.2017.05.026
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603 685
   Kim KI, 2014, BIOMATERIALS, V35, P4792, DOI 10.1016/j.biomaterials.2014.02.048
   Leszczynska J, 2013, TISSUE ENG PT A, V19, P393, DOI [10.1089/ten.tea.2011.0710, 10.1089/ten.TEA.2011.0710]
   Liu YC, 2013, TISSUE ENG PT A, V19, P893, DOI [10.1089/ten.tea.2012.0187, 10.1089/ten.TEA.2012.0187]
   Mirabelli P, 2014, EXP EYE RES, V125, P118, DOI 10.1016/j.exer.2014.06.006
   Moutsatsos IK, 2001, MOL THER, V3, P449, DOI 10.1006/mthe.2001.0291
   Mussano F, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/6202783
   Mussano F, 2017, APPL SURF SCI, V409, P314, DOI 10.1016/j.apsusc.2017.02.035
   Mussano F, 2017, J MATER SCI, V52, P467, DOI 10.1007/s10853 016 0346 1
   Mussano F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051454
   Petrillo S, 2018, CELL DEATH DIFFER, V25, P573, DOI 10.1038/s41418 017 0001 7
   Pla AF, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 939
   Pla AF, 2010, MOL CANCER RES, V8, P1466, DOI 10.1158/1541 7786.MCR 10 0002
   Ripamonti U, 2000, GROWTH FACTORS, V17, P269, DOI 10.3109/08977190009028971
   Roato I, 2019, INT ORTHOP, V43, P15, DOI 10.1007/s00264 018 4192 4
   Roato I, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/4126379
   Sabatino M, 2012, J TRANSL MED, V10, DOI 10.1186/1479 5876 10 23
   Samsonraj RM, 2017, STEM CELL TRANSL MED, V6, P2173, DOI 10.1002/sctm.17 0129
   Sanchez MBH, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0628 9
   Schipani E, 1997, P NATL ACAD SCI USA, V94, P13689, DOI 10.1073/pnas.94.25.13689
   Schipani E, 2009, J BONE MINER RES, V24, P1347, DOI [10.1359/JBMR.090602, 10.1359/jbmr.090602]
   Skovrlj B, 2015, SPINE, V40, P1862, DOI 10.1097/BRS.0000000000001126
   Suwa F, 1998, J Osaka Dent Univ, V32, P27
   Urist MR, 1997, J BONE MINER RES, V12, P343, DOI 10.1359/jbmr.1997.12.3.343
   van Gastel N, 2012, STEM CELLS, V30, P2460, DOI 10.1002/stem.1210
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092 8674(00)81169 1
   Wang DS, 1997, ENDOCRINOLOGY, V138, P2953, DOI 10.1210/en.138.7.2953
   Willette RN, 1999, J VASC RES, V36, P120, DOI 10.1159/000025634
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Zhang R, 2012, ARTIF ORGANS, V36, P1036, DOI 10.1111/j.1525 1594.2012.01529.x
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 58
TC 37
Z9 37
U1 0
U2 17
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD OCT 14
PY 2019
VL 10
AR 1291
DI 10.3389/fphys.2019.01291
PG 11
WC Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology
GA JO1UM
UT WOS:000497369900001
PM 31681005
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Su, Y
   Chen, X
   Zhou, HY
   Shaw, S
   Chen, J
   Isales, CM
   Zhao, J
   Shi, XM
AF Su, Yun
   Chen, Xing
   Zhou, Hongyan
   Shaw, Sean
   Chen, Jie
   Isales, Carlos M.
   Zhao, Jing
   Shi, Xingming
TI Expression of long noncoding RNA Xist is induced by
   glucocorticoids
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE glucocorticoid; Xist; MSC; differential expression; glucocorticoid
   receptor; long noncoding (lnc) RNA
ID MESENCHYMAL STEM CELL; X CHROMOSOME INACTIVATION; SUPPRESS
   BONE FORMATION; MARROW STROMAL CELLS; OSTEOBLAST DIFFERENTIATION;
   RHEUMATOID ARTHRITIS; OSTEOGENIC DIFFERENTIATION; FUNCTIONAL ANTAGONISM;
   RESPONSE ELEMENTS; THERAPY
AB Glucocorticoids (GCs) are potent anti inflammatory and immunosuppressive agents. However, their clinical usage is limited by severe multisystemic side effects. Glucocorticoid induced osteoporosis results in significant morbidity and mortality but the cellular and molecular mechanisms underlying GC induced bone loss are not clear. GC use results in decreased osteoblast differentiation with increased marrow adiposity through effects on bone marrow stem cells. GC effects are transduced through its receptor (GR). To identify novel GR regulated genes, we performed RNA sequencing (RNA Seq) analysis comparing conditional GR knockout mouse made by crossing the floxed GR animal with the Col I promoter Cre, versus normal floxed GR without Cre, and that testing was specific for Col I promoter active cells, such as bone marrow mesenchymal stem/osteoprogenitor cells (MSCs) and osteoblasts. Results showed 15 upregulated genes (3  to 10 fold) and 70 downregulated genes ( 2.7  to  10 fold), with the long noncoding RNA X inactive specific transcript (Xist) downregulated the most. The differential expression of genes measured by RNA Seq was validated by qRT PCR analysis of selected genes and the GC/GR signaling dependent expression of Xist was further demonstrated by GC (dexamethasone) treatment of GR deficient MSCs in vitro and by GC injection of C57BL/6 mice (wild type males and females) in vivo. Our data revealed that the long noncoding RNA Xist is a GR regulated gene and its expression is induced by GC both in vitro and in vivo. To our knowledge, this is the first evidence showing that Xist is transcriptionally regulated by GC/GR signaling.
C1 [Su, Yun; Zhou, Hongyan; Shaw, Sean; Isales, Carlos M.; Shi, Xingming] Augusta Univ, Dept Neurosci & Regenerat Med, Augusta, GA 30912 USA.
   [Chen, Xing] Logist Engn Univ, Dept Math, Chongqing, Peoples R China.
   [Zhou, Hongyan] Jianghan Univ, Sch Med, Dept Pathol & Pathophysiol, Wuhan, Peoples R China.
   [Chen, Jie] Augusta Univ, Div Biostat & Data Sci, Dept Populat Hlth Sci, Augusta, GA USA.
   [Isales, Carlos M.; Shi, Xingming] Augusta Univ, Dept Orthopaed Surg, Augusta, GA 30912 USA.
   [Zhao, Jing] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Complex Res, Shanghai, Peoples R China.
C3 University System of Georgia; Augusta University; Jianghan University;
   University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; Shanghai University of Traditional Chinese
   Medicine
RP Shi, XM (通讯作者)，Augusta Univ, Dept Neurosci & Regenerat Med, Augusta, GA 30912 USA.; Shi, XM (通讯作者)，Augusta Univ, Dept Orthopaed Surg, Augusta, GA 30912 USA.
EM xshi@augusta.edu
RI Isales, Carlos/J 9902 2013; Isales, Carlos/ABF 2983 2021; Zhao,
   Jing/S 3581 2019
OI Isales, Carlos/0000 0002 4480 3484; 
FU National Institute on Aging, National Institutes of Health (NIH)
   [R01AG046248]; National Institutes of Health (NIH); National Institute
   on Aging of the National Institutes of Health
FX This work was supported by grants from The National Institute on Aging
   (R01AG046248), National Institutes of Health (NIH). Research reported in
   this publication was supported in part by the National Institute on
   Aging of the National Institutes of Health under Award Numbers
   R01AG046248.
CR Brockdorff N, 1998, CELL MOL LIFE SCI, V54, P104, DOI 10.1007/s000180050129
   Brockdorff N, 2011, DEVELOPMENT, V138, P5057, DOI 10.1242/dev.065276
   Brown CJ, 2001, SEMIN REPROD MED, V19, P125, DOI 10.1055/s 2001 15392
   Chen SJ, 2020, AGING DIS, V11, P1058, DOI 10.14336/AD.2019.0724
   Chen X, 2019, EXP THER MED, V17, P803, DOI 10.3892/etm.2018.7033
   Chen X, 2021, INT J MOL MED, V48, DOI 10.3892/ijmm.2021.4970
   Corren J, 2001, ANN ALLERG ASTHMA IM, V87, P405, DOI 10.1016/S1081 1206(10)62922 5
   D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074 7613(00)80398 2
   DEQUEKER J, 1995, J RHEUMATOL, V22, P1013
   Feng YM, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.918932
   Fernandes A L, 2001, Sao Paulo Med J, V119, P169, DOI 10.1590/S1516 31802001000500004
   Gayen S, 2016, P NATL ACAD SCI USA, V113, pE309, DOI 10.1073/pnas.1515971113
   Gjaltema RAF, 2022, MOL CELL, V82, P190, DOI 10.1016/j.molcel.2021.11.023
   Herberg S, 2014, TISSUE ENG PT A, V20, P3212, DOI [10.1089/ten.tea.2013.0663, 10.1089/ten.TEA.2013.0663]
   JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092 8674(90)90395 U
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Kirwan JR, 2000, Z RHEUMATOL, V59, P85
   Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711
   Kumar R, 2005, J STEROID BIOCHEM, V94, P383, DOI 10.1016/j.jsbmb.2004.12.046
   Li GL, 2017, EUR REV MED PHARMACO, V21, P2829
   Linghu B, 2009, GENOME BIOL, V10, DOI 10.1186/gb 2009 10 9 r91
   Liu F, 2004, INT J DEV BIOL, V48, P645, DOI 10.1387/ijdb.041816fl
   Liu W, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm 21 1032
   LOCASCIO V, 1990, BONE MINER, V8, P39, DOI 10.1016/0169 6009(91)90139 Q
   Mak W, 2009, CALCIFIED TISSUE INT, V85, P538, DOI 10.1007/s00223 009 9303 1
   MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086 197110000 00021
   Minguell JJ, 2001, EXP BIOL MED, V226, P507, DOI 10.1177/153537020122600603
   MORRISON N, 1993, J BONE MINER RES, V8, P969
   PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Qin WP, 2014, BIOCHEM BIOPH RES CO, V450, P979, DOI 10.1016/j.bbrc.2014.06.080
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752
   SAAG KG, 1994, AM J MED, V96, P115, DOI 10.1016/0002 9343(94)90131 7
   SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092 8674(90)90397 W
   Sher LB, 2006, CALCIFIED TISSUE INT, V79, P118, DOI 10.1007/s00223 005 0297 z
   Sher LB, 2004, ENDOCRINOLOGY, V145, P922, DOI 10.1210/en.2003 0655
   Sonnhammer ELL, 2015, NUCLEIC ACIDS RES, V43, pD234, DOI 10.1093/nar/gku1203
   Sun X, 2019, INT J CLIN EXP PATHO, V12, P1507
   van Everdingen AA, 2002, ANN INTERN MED, V136, P1, DOI 10.7326/0003 4819 136 1 200201010 00006
   Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693
   Walsh LJ, 2001, THORAX, V56, P279, DOI 10.1136/thorax.56.4.279
   Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004 1050
   Wang W, 2019, ONCOL LETT, V17, P256, DOI 10.3892/ol.2018.9596
   Webster JC, 1999, TRENDS ENDOCRIN MET, V10, P396, DOI 10.1016/S1043 2760(99)00186 1
   Yang MB, 2010, BONE, V47, P573, DOI 10.1016/j.bone.2010.06.002
   Yu J, 2021, BIOENGINEERED, V12, P6057, DOI 10.1080/21655979.2021.1967711
   Zhang W, 2008, J BONE MINER RES, V23, P1118, DOI [10.1359/jbmr.080304, 10.1359/JBMR.080304]
   Zhang WX, 2008, J BIOL CHEM, V283, P4723, DOI 10.1074/jbc.M704147200
   Zheng CY, 2020, MECH DEVELOP, V162, DOI 10.1016/j.mod.2020.103612
   Zhou H, 2013, BONE RES, V1, DOI 10.4248/BR201302001
NR 53
TC 4
Z9 4
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD SEP 14
PY 2022
VL 13
AR 1005944
DI 10.3389/fendo.2022.1005944
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 4Z1SK
UT WOS:000861996700001
PM 36187119
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sanchez Rexach, E
   Meaurio, E
   Sarasua, JR
AF Sanchez Rexach, Eva
   Meaurio, Emilio
   Sarasua, Jose Ramon
TI Recent developments in drug eluting devices with tailored interfacial
   properties
SO ADVANCES IN COLLOID AND INTERFACE SCIENCE
LA English
DT Article
ID IMPREGNATED CEMENT; BONE CEMENT; IN VIVO; DELIVERY; RELEASE; STENTS;
   ANTIBIOTICS; GENTAMICIN; CELL; MICROROBOTS
AB Drug eluting devices have greatly evolved during past years to become fundamental products of great marketing importance in the biomedical field. There is currently a large diversity of highly specialized devices for specific applications, making the development of these devices an exciting field of research. The replacement of the former bare metal devices by devices loaded with drugs allowed the sustained and controlled release of drugs, to achieve the desired local therapeutic concentration of drug. The newer devices have been "engineered" with surfaces containing micro  and nanoscale features in a well controlled manner, that have shown to significantly affect cellular and subcellular function of various biological systems. For example, the topography can be structured to form an antifouling surface mimicking the defense mechanisms found in nature, like the skin of the shark. In the case of bone implants, well controlled nanostructured interfaces can promote osteoblast differentiation and matrix production, and enhance short term and long term osteointegration. In any case, the goal of current research is to design implants that induce controlled, guided, and rapid healing. This article reviews recent trends in the development of drug eluting devices, as well as recent developments on the micro/nanotechnology scales, and their future challenges. For this purpose medical devices have been divided according to the different systems of the body they are focused to: orthopedic devices, breathing stents, gastrointestinal and urinary systems, devices for cardiovascular diseases, neuronal implants, and wound dressings.
C1 [Meaurio, Emilio] Univ Basque Country UPV EHU, Dept Min Met Engn & Mat Sci, Alameda Urquijo S N, Bilbao 48013, Spain.
   POLYMAT, Sch Engn, Alameda Urquijo S N, Bilbao 48013, Spain.
C3 University of Basque Country; University of Basque Country; POLYMAT
RP Meaurio, E (通讯作者)，Univ Basque Country UPV EHU, Dept Min Met Engn & Mat Sci, Alameda Urquijo S N, Bilbao 48013, Spain.
EM emiliano.meaurio@chu.es
RI Sarasua, Jose Ramon/E 1819 2015; Meaurio, Emilio/E 1695 2015; Sarasua,
   Jose/E 1819 2015
OI Sarasua, Jose Ramon/0000 0002 7468 2417; Meaurio,
   Emilio/0000 0001 5132 0424; SANCHEZ REXACH, EVA
   GLORIA/0000 0001 7087 3286
FU Spanish Ministry of Innovation and Competitiveness MINECO
   [MAT2013 45559 P]; Basque Government, Department of Education,
   Universities and Research [GIC12/161 IT 632 13]; EU iPROMEDAI COST
   Action [TD1305]
FX The authors are thankful for funds from the Spanish Ministry of
   Innovation and Competitiveness MINECO (MAT2013 45559 P), the Basque
   Government, Department of Education, Universities and Research
   (GIC12/161 IT 632 13) and the EU iPROMEDAI COST Action TD1305.
CR Abidian MR, 2006, ADV MATER, V18, P405, DOI 10.1002/adma.200501726
   Aoyagi S, INT J PHARM
   Arsiwala A, 2014, J CONTROL RELEASE, V189, P25, DOI 10.1016/j.jconrel.2014.06.021
   Athanasiou KA, 1998, ARTHROSCOPY, V14, P726, DOI 10.1016/S0749 8063(98)70099 4
   BAKER AS, 1988, J BONE JOINT SURG AM, V70A, P1551, DOI 10.2106/00004623 198870100 00015
   Baro M, 2002, J CONTROL RELEASE, V83, P353, DOI 10.1016/S0168 3659(02)00179 7
   Bolin MH, 2009, SENSOR ACTUAT B CHEM, V142, P451, DOI 10.1016/j.snb.2009.04.062
   BOURQUE WT, 1992, LAB ANIM SCI, V42, P369
   Brammer KS, 2008, NANO LETT, V8, P786, DOI 10.1021/nl072572o
   Cabanillas PF, 2000, INT J PHARM, V209, P15
   Cardoso PFG, 2007, J THORAC CARDIOV SUR, V134, P974, DOI 10.1016/j.jtcvs.2007.05.040
   Chao YK, 2013, CHEST, V144, P193, DOI 10.1378/chest.12 2282
   Che E., 2012, AJPS, V7, P85
   Chiu FY, 2002, J BONE JOINT SURG AM, V84A, P759, DOI 10.2106/00004623 200205000 00009
   Cox G, 2010, J BONE JOINT SURG BR, V92B, P329, DOI 10.1302/0301 620X.92B3.22787
   Dash AK, 1998, J PHARMACOL TOXICOL, V40, P1, DOI 10.1016/S1056 8719(98)00027 6
   DIMAIO FR, 1994, J ORTHOPAED RES, V12, P79, DOI 10.1002/jor.1100120110
   Eberhart RC, 2003, J BIOMAT SCI POLYM E, V14, P299, DOI 10.1163/156856203321478838
   Edmiston C E., 2000, Handbook of bacterial adhesion, P599
   EINHORN T, 1991, HOSP PRACT, V26, P41
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   Fattahi P, 2014, ADV MATER, V26, P1846, DOI 10.1002/adma.201304496
   Fernández J, 2016, RSC ADV, V6, P22121, DOI 10.1039/c6ra01065b
   Fernández J, 2015, EUR POLYM J, V71, P585, DOI 10.1016/j.eurpolymj.2015.09.001
   Fisher LE, 2015, J CONTROL RELEASE, V202, P57, DOI 10.1016/j.jconrel.2015.01.037
   Gallo J, 2014, INT J MOL SCI, V15, P13849, DOI 10.3390/ijms150813849
   Garimella R, 2017, J ORTHOP, V14, P30, DOI 10.1016/j.jor.2016.10.026
   Green RA, 2012, MACROMOL BIOSCI, V12, P494, DOI 10.1002/mabi.201100490
   Gu WY, 2013, INT J NANOMED, V8, DOI 10.2147/IJN.S44393
   Gulati K, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556 276X 6 571
   Harper EJ, 1998, P I MECH ENG H, V212, P113, DOI 10.1243/0954411981533881
   Hendricks KJ, 2001, CLIN ORTHOP RELAT R, P418
   Hetrick EM, 2006, CHEM SOC REV, V35, P780, DOI 10.1039/b515219b
   Hindy Pierre, 2012, Gastroenterol Hepatol (N Y), V8, P526
   Hoffman AS, 2008, J CONTROL RELEASE, V132, P153, DOI 10.1016/j.jconrel.2008.08.012
   HOSEMANN W, 1991, EUR ARCH OTO RHINO L, V248, P390, DOI 10.1007/BF01463560
   Htay T, 2005, VASC HEALTH RISK MAN, V1, P263, DOI 10.2147/vhrm.2005.1.4.263
   Hu TZ, 2015, ACS APPL MATER INTER, V7, P11695, DOI 10.1021/acsami.5b01993
   Huang YY, 2014, J CONTROL RELEASE, V193, P188, DOI 10.1016/j.jconrel.2014.05.011
   Huang YY, 2001, J MICROENCAPSUL, V18, P457
   Indolfi C, 2003, TRENDS CARDIOVAS MED, V13, P142, DOI 10.1016/S1050 1738(03)00038 0
   Jin GZ, 2011, NEUROSCI LETT, V501, P10, DOI 10.1016/j.neulet.2011.06.023
   Kanellakopoulou K, 2000, DRUGS, V59, P1223, DOI 10.2165/00003495 200059060 00003
   Keefer EW, 2008, NAT NANOTECHNOL, V3, P434, DOI 10.1038/nnano.2008.174
   Kim S, 2013, ADV MATER, V25, P5863, DOI 10.1002/adma.201301484
   Kohn J, 2000, BIOMATERIALS SCI INT, V2000, P64
   Kukreja N, 2009, J INTERV CARDIOL, V22, pS96, DOI 10.1111/j.1540 8183.2009.00455.x
   LEVIN PD, 1975, J BONE JOINT SURG BR, V57, P234, DOI 10.1302/0301 620X.57B2.234
   Lochbihler H, 1997, J PEDIATR SURG, V32, P717, DOI 10.1016/S0022 3468(97)90013 0
   MICLAU T, 1993, J ORTHOPAED RES, V11, P627, DOI 10.1002/jor.1100110503
   Middleton JC, 2000, BIOMATERIALS, V21, P2335, DOI 10.1016/S0142 9612(00)00101 0
   Mitra A., 2013, Advanced Drug Delivery
   Nelson B.J., 2008, SPRINGER HDB ROBOTIC, P411, DOI DOI 10.1007/978 3 540 30301 519
   Nelson BJ, 2010, ANNU REV BIOMED ENG, V12, P55, DOI 10.1146/annurev bioeng 010510 103409
   Nir S, 2016, CURR OPIN BIOTECH, V39, P48, DOI 10.1016/j.copbio.2015.12.012
   Pillay S, 2009, INT J PHARMACEUT, V382, P277, DOI 10.1016/j.ijpharm.2009.08.021
   Planell JA, 2009, WOODHEAD PUBL MATER, P3, DOI 10.1533/9781845696610.1.3
   Prabu P, 2006, J BIOMED MATER RES A, V79A, P153, DOI 10.1002/jbm.a.30715
   Qi N, 2012, INT J PHARMACEUT, V427, P234, DOI 10.1016/j.ijpharm.2012.02.008
   Rafanan AL, 2000, RADIOL CLIN N AM, V38, P395, DOI 10.1016/S0033 8389(05)70170 6
   Ranganath SH, BIOMATERIALS
   Ricci J., 2000, BONE ENG, P332
   Robey TC, 2000, LARYNGOSCOPE, V110, P1936, DOI 10.1097/00005537 200011000 00032
   Rossi S, 2004, J ANTIMICROB CHEMOTH, V54, P1013, DOI 10.1093/jac/dkh477
   Rutledge B, 2003, CLIN ORTHOP RELAT R, P280, DOI 10.1097/01.bio.0000065836.93465.ed
   Sanchez Rexach E, 2016, EUR POLYM J, V83, P288, DOI 10.1016/j.eurpolymj.2016.08.029
   Santos A, 2014, J MATER CHEM B, V2, P6157, DOI 10.1039/c4tb00548a
   Schroeder JE, 2011, INJURY, V42, P609, DOI 10.1016/j.injury.2011.03.029
   Shaikh M, 2013, J CONTROL RELEASE, V172, P105, DOI 10.1016/j.jconrel.2013.08.010
   Shin JH, 2005, EUR RADIOL, V15, P1241, DOI 10.1007/s00330 004 2564 1
   SMILACK JD, 1976, ANTIMICROB AGENTS CH, V9, P169, DOI 10.1128/AAC.9.1.169
   Stengel D, 2001, Lancet Infect Dis, V1, P175, DOI 10.1016/S1473 3099(01)00094 9
   Tamburino C, 2009, CATHETER CARDIOVASC, V73, P293
   Teja SB, 2013, J EXCIP FOOD CHEM, V4, P70
   Trampuz A, 2006, CURR OPIN INFECT DIS, V19, P349, DOI 10.1097/01.qco.0000235161.85925.e8
   TRIPPEL SB, 1986, J BONE JOINT SURG AM, V68A, P1297, DOI 10.2106/00004623 198668080 00026
   Wang K, 2006, NANO LETT, V6, P2043, DOI 10.1021/nl061241t
   Westedt U, 2004, EUR J PHARM BIOPHARM, V58, P161, DOI 10.1016/j.ejpb.2004.03.009
   Wininger DA, 1996, ANTIMICROB AGENTS CH, V40, P2675, DOI 10.1128/AAC.40.12.2675
   Wu P, 2006, BIOMATERIALS, V27, P2450, DOI 10.1016/j.biomaterials.2005.11.031
   Yang J., Biomaterials
   Yaszemski M.J., 2004, Tissue Engineering and Novel Delivery Systems
   YU D, 1992, J PHARM SCI, V81, P529, DOI 10.1002/jps.2600810611
   Yue ZL, 2013, ADV DRUG DELIVER REV, V65, P559, DOI 10.1016/j.addr.2012.06.002
   Zhang L, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3079655
   Zhao N, 2014, ADV MATER, V26, P6994, DOI 10.1002/adma.201401718
   Zhou HH, 2013, ACTA BIOMATER, V9, P6439, DOI 10.1016/j.actbio.2013.01.042
   Zilberman M, 2008, J CONTROL RELEASE, V130, P202, DOI 10.1016/j.jconrel.2008.05.020
   Zilberman M, 2006, ANNU REV BIOMED ENG, V8, P153, DOI 10.1146/annurev.bioeng.8.013106.151418
NR 89
TC 13
Z9 13
U1 1
U2 40
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0001 8686
EI 1873 3727
J9 ADV COLLOID INTERFAC
JI Adv. Colloid Interface Sci.
PD NOV
PY 2017
VL 249
BP 181
EP 191
DI 10.1016/j.cis.2017.05.005
PG 11
WC Chemistry, Physical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA FQ4GU
UT WOS:000418316500012
PM 28532663
DA 2025 08 17
ER

PT J
AU MacLauchlan, S
   Zuriaga, MA
   Fuster, JJ
   Cuda, CM
   Jonason, J
   Behzadi, F
   Duffen, JP
   Haines, GK
   Aprahamian, T
   Perlman, H
   Walsh, K
AF MacLauchlan, Susan
   Zuriaga, Maria A.
   Fuster, Jose J.
   Cuda, Carla M.
   Jonason, Jennifer
   Behzadi, Fernanda
   Duffen, Jennifer Parker
   Haines, G. Kenneth, III
   Aprahamian, Tamar
   Perlman, Harris
   Walsh, Kenneth
TI Genetic deficiency of Wnt5a diminishes disease severity in a murine
   model of rheumatoid arthritis
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE Rheumatoid arthritis; Wnt5a; Inflammation; Osteoclast fusion
ID INFLAMMATORY ARTHRITIS; MICROBIAL STIMULATION; METABOLIC DYSFUNCTION;
   CHEMOKINE PRODUCTION; SIGNALING PATHWAY; ADIPOSE TISSUE; MOUSE MODEL;
   CELLS; PROTEIN; OBESITY
AB Background: Rheumatoid arthritis (RA) is a common autoimmune disease characterized by chronic inflammation of the joints, leading to bone erosion and joint dysfunction. Despite the recent successes of disease modifying antirheumatic drugs (DMARDs), there is still clinical need for understanding the development and molecular etiology of RA. Wnts are developmental morphogens whose roles in adult pathology are poorly characterized. Wnt5a is a member of the non canonical family of Wnts that modulates a wide range of cell processes, including differentiation, migration, and inflammation. Wnt5a has been implicated as a possible contributor to arthritis and it is upregulated in synovial fibroblasts from RA patients.
   Methods: We investigated the role of endogenous Wnt5a in RA. Tamoxifen inducible, Wnt5a knockout (Wnt5a cKO) mice and littermate controls were monitored for arthritis development and joint pathology using the K/BxN serum transfer induced arthritis (STIA) model. To explore a role of Wnt5a in osteoclast fusion, bone marrow derived monocytes (BMDMs) were differentiated in vitro.
   Results: Wnt5a cKO mice were resistant to arthritis development compared to control littermates as assessed by ankle thickness and histologic measurements. Some parameters of inflammation were reduced in the Wnt5a cKO mice, including the extent of polymononuclear cell infiltration and extra articular inflammation. Wnt5a cKO mice also exhibited less cartilage destruction and a reduction in osteoclast activity with concomitant reduction in tartrate resistant acid phosphatase (TRAP), cathepsin K (CTSK), macrophage colony stimulating factor (MCSF), matrix metalloproteinase (MMP) 2 and MMP9 in the arthritic joints. Treatment of BMDMs with Wnt5a enhanced osteoclast fusion and increased the expression of dendrocyte expressed seven transmembrane protein (DCSTAMP) and MMP9, that are necessary for osteoclast formation and activity.
   Conclusions: These data suggest that Wnt5a modulates the development of arthritis by promoting inflammation and osteoclast fusion, and provide the first mouse genetic evidence of a role for endogenous Wnt5a in autoimmune disease.
C1 [MacLauchlan, Susan; Zuriaga, Maria A.; Fuster, Jose J.; Behzadi, Fernanda; Duffen, Jennifer Parker; Walsh, Kenneth] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Mol Cardiol, 700 Albany St,W 611, Boston, MA 02118 USA.
   [Cuda, Carla M.; Perlman, Harris] Northwestern Univ, Dept Med, Div Rheumatol, 240 E Huron St McGaw M338, Chicago, IL 60611 USA.
   [Jonason, Jennifer] Univ Rochester, Med Ctr, Sch Med & Dent, 601 Elmwood Ave,Box 665, Rochester, NY USA.
   [Aprahamian, Tamar] Boston Univ, Sch Med, Renal Sect, 650 Albany St, Boston, MA 02215 USA.
   [Haines, G. Kenneth, III] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA.
C3 Boston University; Northwestern University; University of Rochester;
   Boston University; Icahn School of Medicine at Mount Sinai
RP Walsh, K (通讯作者)，Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Mol Cardiol, 700 Albany St,W 611, Boston, MA 02118 USA.
EM kxwalsh@bu.edu
RI ; Fuster, José/D 3685 2011; Zuriaga Herrero, Maria Angeles/P 4616 2017;
   Zuriaga, María/P 4616 2017
OI Duffen, Jennifer/0000 0001 7797 037X; MacLauchlan,
   Susan/0000 0001 9689 0826; Cuda, Carla/0000 0002 2022 8171; Fuster, Jose
   Javier/0000 0002 5970 629X; Zuriaga Herrero, Maria
   Angeles/0000 0003 0422 2965; , G. Kenneth Haines
   III/0009 0005 6401 7981; 
FU National Institutes of Health (NIH) [HL120160, HL131006, HL132564,
   AG052160]; NIH [K01AR064313, AR064546, AR050250, AR054796, AI092490,
   HL108795]; Mabel Green Myers Chair of Medicine;  [HL007224]
FX This work was funded by National Institutes of Health (NIH) grants
   HL120160, HL131006, HL132564, and AG052160 to KW. SM was funded by a T32
   grant HL007224. This work was supported by grants from the NIH to CMC
   (K01AR064313) and HP (AR064546, AR050250, AR054796, AI092490, HL108795),
   and funds provided to HP by the Mabel Green Myers Chair of Medicine.
   None of the funding bodies participated in the design of the study or in
   the collection, analysis, or interpretation of data or in writing the
   manuscript.
CR Archer AM, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 016 0912 y
   Asquith DL, 2010, ARTHRITIS RHEUM US, V62, P472, DOI 10.1002/art.27205
   Bellon M, 2013, BLOOD, V121, P5045, DOI 10.1182/blood 2012 07 439109
   Bilkovski R, 2010, J BIOL CHEM, V285, P6170, DOI 10.1074/jbc.M109.054338
   Blumenthal A, 2006, BLOOD, V108, P965, DOI 10.1182/blood 2005 12 5046
   Bokarewa M, 2005, J IMMUNOL, V174, P5789, DOI 10.4049/jimmunol.174.9.5789
   Bretón Romero R, 2016, ARTERIOSCL THROM VAS, V36, P561, DOI 10.1161/ATVBAHA.115.306578
   Catalán V, 2014, J CLIN ENDOCR METAB, V99, pE1407, DOI 10.1210/jc.2014 1191
   Chabot V, 2006, J LEUKOCYTE BIOL, V79, P767, DOI 10.1189/jlb.0804464
   Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808
   Del Prete A, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/425068
   del Rincón I, 2001, ARTHRITIS RHEUM US, V44, P2737, DOI 10.1002/1529 0131(200112)44:12<2737::AID ART460>3.0.CO;2 #
   Duffau P, 2015, ARTHRITIS RHEUMATOL, V67, P3146, DOI 10.1002/art.39321
   Farb MG, 2016, VASC MED, V21, P489, DOI 10.1177/1358863X16666693
   Feng J, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002859
   Fuster JJ, 2015, DIABETES, V64, P1235, DOI 10.2337/db14 1164
   Giles JT, 2011, ANN RHEUM DIS, V70, P1562, DOI 10.1136/ard.2011.150813
   Halleskog C, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742 2094 9 111
   Helming L, 2009, TRENDS CELL BIOL, V19, P514, DOI 10.1016/j.tcb.2009.07.005
   Jung YS, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.48
   Kikuchi R, 2014, NAT MED, V20, P1464, DOI 10.1038/nm.3703
   Koenders MI, 2015, TRENDS PHARMACOL SCI, V36, P189, DOI 10.1016/j.tips.2015.02.001
   Kurayoshi M, 2007, BIOCHEM J, V402, P515, DOI 10.1042/BJ20061476
   Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Long Courtney L, 2012, Bonekey Rep, V1
   MacLauchlan S, 2009, J LEUKOCYTE BIOL, V85, P617, DOI 10.1189/jlb.1008588
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   McInnes IB, 2010, ANN RHEUM DIS, V69, P1898, DOI 10.1136/ard.2010.134684
   Meune C, RHEUMATOLOGY OXFORD
   Misharin AV, 2014, CELL REP, V9, P591, DOI 10.1016/j.celrep.2014.09.032
   Monach PA, 2008, CURR PROTOC IMMUNOL
   Nakamura K, 2016, J BIOL CHEM, V291, P2566, DOI 10.1074/jbc.M115.693937
   Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470
   Olama SM, 2012, RHEUMATOL INT, V32, P683, DOI 10.1007/s00296 010 1698 5
   Otero M, 2006, ANN RHEUM DIS, V65, P1198, DOI 10.1136/ard.2005.046540
   Ouchi N, 2010, SCIENCE, V329, P454, DOI 10.1126/science.1188280
   Pereira C, 2008, ARTERIOSCL THROM VAS, V28, P504, DOI 10.1161/ATVBAHA.107.157438
   Perlman H, 2000, J IMMUNOL, V164, P5227, DOI 10.4049/jimmunol.164.10.5227
   Postigo J, 2011, ARTHRITIS RHEUM US, V63, P971, DOI 10.1002/art.30220
   Rajasekaran N, 2014, OPEN J RHEUMATOL AUT, V4, P22, DOI [10.4236/ojra.2014.41003, DOI 10.4236/OJRA.2014.41003.]
   Rauner M, 2012, J BONE MINER RES, V27, P575, DOI 10.1002/jbmr.1488
   Rose S, 2013, ANN RHEUM DIS, V72, P89, DOI 10.1136/annrheumdis 2012 201431
   Scatizzi JC, 2006, AM J PATHOL, V168, P1531, DOI 10.2353/ajpath.2006.050555
   Scatizzi JC, 2006, ARTHRITIS RHEUM, V54, P3182, DOI 10.1002/art.22133
   Scatizzi JC, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2204
   Scatizzi JC, 2009, EUR J IMMUNOL, V39, P820, DOI 10.1002/eji.200838683
   Sen M, 2000, P NATL ACAD SCI USA, V97, P2791, DOI 10.1073/pnas.050574297
   Sen M, 2001, ARTHRITIS RHEUM, V44, P772, DOI 10.1002/1529 0131(200104)44:4<772::AID ANR133>3.3.CO;2 C
   Tanaka Y, 2016, KOREAN J INTERN MED, V31, P210, DOI 10.3904/kjim.2015.137
   Versini M, 2014, AUTOIMMUN REV, V13, P981, DOI 10.1016/j.autrev.2014.07.001
   Wang BM, 2012, CELL IMMUNOL, V278, P103, DOI 10.1016/j.cellimm.2012.07.005
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Wipke BT, 2001, J IMMUNOL, V167, P1601, DOI 10.4049/jimmunol.167.3.1601
   WUCHERPFENNIG AL, 1994, J BONE MINER RES, V9, P549
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211
   Yoshino T, 2011, INTERNAL MED, V50, P269, DOI 10.2169/internalmedicine.50.4306
   Yu CH, 2014, EUR J IMMUNOL, V44, P1480, DOI 10.1002/eji.201343959
NR 59
TC 22
Z9 31
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD JUL 19
PY 2017
VL 19
AR 166
DI 10.1186/s13075 017 1375 0
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA FB0QE
UT WOS:000405848800004
PM 28724439
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Bedoya, DA
   Vasti, C
   Rojas, R
   Giacomelli, CE
AF Aristizabal Bedoya, Dariana
   Vasti, Cecilia
   Rojas, Ricardo
   Giacomelli, Carla E.
TI Risedronate functionalized layered double hydroxides nanoparticles with
   bone targeting capabilities
SO APPLIED CLAY SCIENCE
LA English
DT Article
DE Nanocarriers; pH responsive; Hydroxyapatite binding; Colloidal
   stability; Bisphosphonates
ID COLLOIDAL STABILITY; INTRACELLULAR TRAFFICKING; CHEMICAL STABILITY;
   CONTROLLED RELEASE; UPTAKE MECHANISM; CELLULAR UPTAKE; DRUG DELIVERY;
   CANCER; SIZE; BISPHOSPHONATE
AB Layered double hydroxides nanoparticles (LDH NPs) are increasingly studied as drug nanocarriers for cellular delivery. Nevertheless, stable functionalizations providing targeting capabilities without disrupting the size of the carriers are necessary to achieve optimized performance. Here, LDH NPs were functionalized with risedronate (Ris) to improve the osteotropicity of the nanocarriers without altering the nanosized distribution. Ris is a nitrogen containing bisphosphonate with rich acid base reactivity that can lead Ris functionalized LDH NPs also as pH responsive drug nanocarriers. The current work is focused on the strategy to synthesize functionalized LDH NPs with a maximum adsorption and a minimum intercalation of Ris while maintaining their nanosize. The speciation and interactions of Ris at the surface of LDH NPs were analyzed using Raman microscopy whereas the functionalization stability and size distribution were checked in simulated biological media. Finally, pH sensitivity and hydroxyapatite binding capacity of Ris functionalized LDH NPs were evaluated. HIRis(3 ) anions were incorporated to the LDH NPs surface with high affinity providing with a negative zeta potential that controlled the size at around 100 nm. The size of Ris functionalized LDH NPs was not affected by the high ionic strength or the presence of proteins in simulated biological media. Further, the functionalization was stable against protein adsorption and anionic exchange. As expected, Ris functionalized LDH NPs are bioresponsive with a high sensitivity for pH changes and specific affinity for hydroxyapatite, which makes them appealing drug nanocarriers for new bone therapies. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Aristizabal Bedoya, Dariana; Vasti, Cecilia; Rojas, Ricardo; Giacomelli, Carla E.] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Fisicoquim, INFIQC CONICET, RA 5000 Cordoba, Argentina.
C3 National University of Cordoba; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET)
RP Giacomelli, CE (通讯作者)，Univ Nacl Cordoba, Fac Ciencias Quim, Dept Fisicoquim, INFIQC CONICET, RA 5000 Cordoba, Argentina.
EM giacomel@fcq.unc.edu.ar
OI Giacomelli, Carla/0000 0003 4339 3943; Aristizabal Bedoya,
   Dariana/0000 0002 8312 9605; Rojas, Ricardo/0000 0001 5826 2036
FU SeCyT UNC [05/C585]; FONCyT [PICT 12/0634]; CONICET [PIP
   11220120100575]; ANPCyT
FX Economic supports by SeCyT UNC, project number 05/C585, FONCyT, project
   PICT 12/0634, and CONICET, PIP 11220120100575, are gratefully
   acknowledged. CV and DAB acknowledge fellowships of ANPCyT and CONICET.
   The SEM images were obtained at the Laboratorio de Microscopia
   Electronica y Analisis por Rayos X (LAMARX) and the Raman spectra at the
   Laboratorio de Nanoscopia y Nanofotonica, INFIQC CONICET/UNC, Servicio
   Nacional de Microscopia   MINCyT.
CR Al Kattan A, 2010, ADV ENG MATER, V12, pB224, DOI 10.1002/adem.200980084
   Chakraborti M, 2011, INT J PHARMACEUT, V416, P305, DOI 10.1016/j.ijpharm.2011.06.016
   Chaudhari KR, 2012, J CONTROL RELEASE, V158, P470, DOI 10.1016/j.jconrel.2011.11.020
   Chen M, 2013, J COLLOID INTERF SCI, V390, P275, DOI 10.1016/j.jcis.2012.09.033
   Choi SJ, 2011, NANOMEDICINE UK, V6, P803, DOI [10.2217/NNM.11.86, 10.2217/nnm.11.86]
   Chung HE, 2012, APPL CLAY SCI, V65 66, P24, DOI 10.1016/j.clay.2012.06.007
   Coleman RE, 2011, BONE, V49, P71, DOI 10.1016/j.bone.2011.02.003
   Conde J, 2014, FRONT CHEM, V2, DOI 10.3389/fchem.2014.00048
   Conterosito E, 2013, PHYS CHEM CHEM PHYS, V15, P13418, DOI 10.1039/c3cp51235e
   Costantino U, 2009, ACS APPL MATER INTER, V1, P668, DOI 10.1021/am8001988
   Rodrigues LAD, 2013, COLLOID SURFACE B, V103, P642, DOI 10.1016/j.colsurfb.2012.10.068
   Errassifi F, 2014, J COLLOID INTERF SCI, V420, P101, DOI 10.1016/j.jcis.2014.01.017
   Fahami A, 2016, MAT SCI ENG C MATER, V59, P78, DOI 10.1016/j.msec.2015.10.002
   Gu Z, 2015, J MATER CHEM B, V3, P3331, DOI 10.1039/c5tb00248f
   Hu H, 2013, BIOCONJUGATE CHEM, V24, P968, DOI 10.1021/bc300683y
   Kankala RK, 2017, J MATER CHEM B, V5, P1507, DOI 10.1039/c6tb03146c
   Knowles JC, 2000, BIOMATERIALS, V21, P1387, DOI 10.1016/S0142 9612(00)00032 6
   Kuo YM, 2015, J MATER CHEM B, V3, P3447, DOI 10.1039/c4tb01989j
   Kuthati Y, 2015, APPL CLAY SCI, V112, P100, DOI 10.1016/j.clay.2015.04.018
   Ladewig K, 2010, BIOMATERIALS, V31, P1821, DOI 10.1016/j.biomaterials.2009.10.058
   Lee ES, 2008, J CONTROL RELEASE, V132, P164, DOI 10.1016/j.jconrel.2008.05.003
   LeVasseur N, 2016, CANCER TREAT REV, V50, P183, DOI 10.1016/j.ctrv.2016.09.013
   Li DX, 2011, COLLOID SURFACE A, V384, P585, DOI 10.1016/j.colsurfa.2011.05.012
   Ma R, 2014, J MATER CHEM B, V2, P4868, DOI 10.1039/c4tb00645c
   Medina Kauwe LK, 2005, GENE THER, V12, P1734, DOI 10.1038/sj.gt.3302592
   Meloun M, 2012, CENT EUR J CHEM, V10, P338, DOI 10.2478/s11532 011 0150 3
   Nakayama H, 2003, J PHARM SCI US, V92, P2419, DOI 10.1002/jps.10498
   Oh JM, 2006, BIOCONJUGATE CHEM, V17, P1411, DOI 10.1021/bc0601323
   Oh JM, 2009, ADV FUNCT MATER, V19, P1617, DOI 10.1002/adfm.200801127
   Ossipov DA, 2015, EXPERT OPIN DRUG DEL, V12, P1443, DOI 10.1517/17425247.2015.1021679
   Parello ML, 2010, J COLLOID INTERF SCI, V351, P134, DOI 10.1016/j.jcis.2010.07.053
   Pascaud P, 2013, LANGMUIR, V29, P2224, DOI 10.1021/la3046548
   Ray S, 2015, RSC ADV, V5, P39482, DOI 10.1039/c5ra03546e
   Redman Furey N, 2005, J PHARM SCI US, V94, P893, DOI 10.1002/jps.20308
   Rives V, 2014, APPL CLAY SCI, V88 89, P239, DOI 10.1016/j.clay.2013.12.002
   Rojas R, 2012, APPL CLAY SCI, V62 63, P15, DOI 10.1016/j.clay.2012.04.004
   Saha S, 2017, APPL CLAY SCI, V135, P493, DOI 10.1016/j.clay.2016.09.030
   Tantra R, 2010, COLLOID SURFACE B, V75, P275, DOI 10.1016/j.colsurfb.2009.08.049
   Vasti C, 2016, J MATER CHEM B, V4, P2008, DOI 10.1039/c5tb02698a
   Vermonden T, 2001, LANGMUIR, V17, P3734, DOI 10.1021/la010162o
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang LM, 2011, NANO LETT, V11, P772, DOI 10.1021/nl103992v
   Wang XL, 2014, BIOMATER SCI UK, V2, P961, DOI [10.1039/c4bm00020j, 10.1039/C4BM00020J]
   Wong YY, 2010, BIOMATERIALS, V31, P8770, DOI 10.1016/j.biomaterials.2010.07.077
   Xu ZP, 2006, J PHYS CHEM B, V110, P16923, DOI 10.1021/jp062281o
   Zhang XQ, 2014, COLLOID SURFACE B, V117, P98, DOI 10.1016/j.colsurfb.2014.02.018
   Zhu RR, 2016, ACTA BIOMATER, V29, P320, DOI 10.1016/j.actbio.2015.10.029
   Zuo HL, 2015, J COLLOID INTERF SCI, V459, P10, DOI 10.1016/j.jcis.2015.07.063
NR 48
TC 14
Z9 14
U1 1
U2 44
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169 1317
EI 1872 9053
J9 APPL CLAY SCI
JI Appl. Clay Sci.
PD JUN
PY 2017
VL 141
BP 257
EP 264
DI 10.1016/j.clay.2017.03.001
PG 8
WC Chemistry, Physical; Materials Science, Multidisciplinary; Mineralogy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science; Mineralogy
GA ES8ZT
UT WOS:000399846400030
OA Green Published
DA 2025 08 17
ER

PT J
AU Yan, NY
   Zhou, H
   Jin, PH
   Li, TF
   Liu, Q
   Ning, H
   Ma, ZX
   Feng, LF
   Jin, T
   Deng, YW
   Wu, ZW
AF Yan, Nongyang
   Zhou, Hao
   Jin, Penghe
   Li, Tengfei
   Liu, Qi
   Ning, Hao
   Ma, Zhixin
   Feng, Linfei
   Jin, Tao
   Deng, Youwen
   Wu, Zhengwei
TI A Multifunctional Cobalt Containing Implant for Treating Biofilm
   Infections and Promoting Osteointegration in Infected Bone Defects
   Through Macrophage Mediated Immunomodulation
SO ADVANCED SCIENCE
LA English
DT Article
DE bone infection therapy; cobalt containing implants; immunomodulation;
   osteogenic differentiation; plasma immersion ion implantation (PIII)
ID BIOACTIVE GLASS SCAFFOLDS; REGENERATION; TITANIUM; THERAPY; IONS
AB Treating bone infections and ensuring bone recovery is one of the major global problems facing modern orthopedics. Prolonged antibiotic use may increase the risk of antimicrobial resistance, and inflammation caused by biofilms can obstruct tissue healing, making bone infection treatment even more challenging. The optimal treatment strategy combines immune response modification to promote osteogenesis with effective bacterial infection removal that does not require long term antibiotic use. A one step plasma immersion ion implantation approach is used to create titanium alloy implants incorporating cobalt. According to experimental findings, cobalt containing titanium implants exhibit improved antibacterial activity by efficiently disrupting biofilm formations and reducing Methicillin resistant Staphylococcus aureus adherence by over 80%. Additionally, the implants exhibit superior anti inflammatory and osseointegration properties. RNA sequencing analysis reveals the potential mechanism of Co2+ in regulating the polarization of macrophages toward the anti inflammatory M2 phenotype, which is crucial for creating an immune environment conducive to bone healing. Concurrently, these implants promote osteogenic differentiation while suppressing osteoclast activity, further supporting bone repair. Overall, without exogenous recombinant proteins or antibiotics, the implants effectively eradicate infections and expedite bone repair, offering a novel therapeutic strategy for complex skeletal diseases with clinical promise.
C1 [Yan, Nongyang; Li, Tengfei; Wu, Zhengwei] Univ Sci & Technol China, Inst Adv Technol, 5089 Wangjiang West Rd, Hefei 230031, Anhui, Peoples R China.
   [Zhou, Hao; Jin, Penghe; Ning, Hao; Deng, Youwen] Cent South Univ, Dept Spine, Xiangya Hosp 3, 138 Tongzi Rd, Changsha 410013, Hunan, Peoples R China.
   [Liu, Qi; Feng, Linfei; Jin, Tao; Wu, Zhengwei] Univ Sci & Technol China, Sch Nucl Sci & Technol, 96 Jinzhai Rd, Hefei 230026, Anhui, Peoples R China.
   [Ma, Zhixin] Anhui Provincial HlthCommiss, Comprehens Spervis Off, 435 Tunbrook Rd, Hefei 230032, Peoples R China.
   [Feng, Linfei] AnhMed Univ, Dept Oral & Maxillofacial Surg, Affiliated Hosp 1, Hefei 230032, Anhui, Peoples R China.
C3 Chinese Academy of Sciences; University of Science & Technology of
   China, CAS; Central South University; Chinese Academy of Sciences;
   University of Science & Technology of China, CAS
RP Wu, ZW (通讯作者)，Univ Sci & Technol China, Inst Adv Technol, 5089 Wangjiang West Rd, Hefei 230031, Anhui, Peoples R China.; Deng, YW (通讯作者)，Cent South Univ, Dept Spine, Xiangya Hosp 3, 138 Tongzi Rd, Changsha 410013, Hunan, Peoples R China.; Wu, ZW (通讯作者)，Univ Sci & Technol China, Sch Nucl Sci & Technol, 96 Jinzhai Rd, Hefei 230026, Anhui, Peoples R China.
EM drywdeng@csu.edu.cn; wuzw@ustc.edu.cn
RI Liu, Qi/KHZ 9738 2024; Zhixin, Ma/AAH 2224 2019
OI Liu, Qi/0000 0003 2860 2532; 
FU Joint Laboratory of Plasma Application Technology Funding [JL06120001H];
   Hunan Provincial Health High Level Talent Scientific Research Project
   [R2023063]
FX N.Y. and H.Z. contributed equally to this work. This work was supported
   by the Joint Laboratory of Plasma Application Technology Funding (grant
   number: JL06120001H) and Hunan Provincial Health High Level Talent
   Scientific Research Project (grant number: R2023063).
CR Andrews RE, 2011, BONE, V49, P717, DOI 10.1016/j.bone.2011.06.007
   Chapple ILC, 2007, PERIODONTOL 2000, V43, P160, DOI 10.1111/j.1600 0757.2006.00178.x
   Chen L, 2021, BIOACT MATER, V6, P191, DOI 10.1016/j.bioactmat.2020.08.001
   Chen ZT, 2015, BIOMATERIALS, V61, P126, DOI 10.1016/j.biomaterials.2015.04.044
   Cobb LH, 2020, J ORTHOP RES, V38, P2091, DOI 10.1002/jor.24689
   Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337
   de Araujo FP, 2021, J GLOB ANTIMICROB RE, V26, P29, DOI 10.1016/j.jgar.2021.03.030
   Deng CJ, 2018, THERANOSTICS, V8, P1940, DOI 10.7150/thno.23674
   Deng ZW, 2019, INT J BIOL SCI, V15, P1113, DOI 10.7150/ijbs.32358
   Ding Y, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202300722
   Nguyen DC, 2021, NANO ENERGY, V82, DOI 10.1016/j.nanoen.2021.105750
   Egrilmez S, 2020, CLIN OPHTHALMOL, V14, P287, DOI 10.2147/OPTH.S181997
   Fu S, 2020, CLIN BIOMECH, V79, DOI 10.1016/j.clinbiomech.2019.12.006
   Gao YT, 2024, POLYMER, V302, DOI 10.1016/j.polymer.2024.127091
   Gessner BD, 2019, J PATIENT SAF, V15, P97, DOI 10.1097/PTS.0000000000000220
   Hajduga MB, 2021, ACTA BIOENG BIOMECH, V23, P131, DOI 10.37190/ABB 01766 2020 03
   Huang JJ, 2022, J ELECTRON MATER, V51, P6626, DOI 10.1007/s11664 022 09909 9
   Huang ZQ, 2022, BIOMATERIALS, V291, DOI 10.1016/j.biomaterials.2022.121901
   Iglesias Fernandez M, 2022, BIOMATER ADV, V136, DOI 10.1016/j.bioadv.2022.212797
   Jian G., 2023, Adv. Healthcare Mater, V12
   Jiménez Holguín J, 2024, ACTA BIOMATER, V176, P445, DOI 10.1016/j.actbio.2024.01.003
   Kang SJ, 2018, NAT IMMUNOL, V19, P561, DOI 10.1038/s41590 018 0108 0
   Kavanagh N, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00084 17
   Laxminarayan R, 2022, LANCET, V399, P606, DOI 10.1016/S0140 6736(22)00087 3
   Li B, 2022, SMALL, V18, DOI 10.1002/smll.202203619
   Li HK, 2019, NEW ENGL J MED, V380, P425, DOI 10.1056/NEJMoa1710926
   Li JH, 2019, MATER HORIZ, V6, P1271, DOI 10.1039/c8mh01606b
   Li XZ, 2018, BIOMED MATER, V13, DOI 10.1088/1748 605X/aabe33
   Li YB, 2021, MATER DESIGN, V210, DOI 10.1016/j.matdes.2021.110049
   Lin HY, 2021, CHEM ENG J, V411, DOI 10.1016/j.cej.2021.128469
   Liu GQ, 2020, THERANOSTICS, V10, P1074, DOI 10.7150/thno.37931
   Liu Y, 2019, CHEM SOC REV, V48, P428, DOI 10.1039/c7cs00807d
   Madiwal V, 2024, ISCIENCE, V27, DOI 10.1016/j.isci.2024.108827
   Mandakhbayar N, 2024, BIOACT MATER, V31, P298, DOI 10.1016/j.bioactmat.2023.08.014
   Masters EA, 2022, NAT REV MICROBIOL, V20, P385, DOI 10.1038/s41579 022 00686 0
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mills EL, 2016, CELL, V167, P457, DOI 10.1016/j.cell.2016.08.064
   Mirza RE, 2014, DIABETES, V63, P1103, DOI 10.2337/db13 0927
   Oh SH, 2003, BIOMATERIALS, V24, P4011, DOI 10.1016/S0142 9612(03)00284 9
   Prabhoo R, 2019, ORTHOP REV, V11, P79, DOI 10.4081/or.2019.8070
   Qin DL, 2024, J NANOBIOTECHNOL, V22, DOI 10.1186/s12951 024 02593 3
   Rosenberg G, 2022, NAT MICROBIOL, V7, P497, DOI 10.1038/s41564 022 01080 5
   Sadowska JM, 2021, MATER TODAY, V46, P136, DOI 10.1016/j.mattod.2020.12.018
   Shen XK, 2019, BIOMATERIALS, V212, P1, DOI 10.1016/j.biomaterials.2019.05.008
   Si JY, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.919159
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580 020 0230 3
   Song ZL, 2024, ADV FUNCT MATER, V34, DOI 10.1002/adfm.202315382
   Spellberg B, 2012, CLIN INFECT DIS, V54, P393, DOI 10.1093/cid/cir842
   Sui JH, 2023, MATER DESIGN, V231, DOI 10.1016/j.matdes.2023.112066
   Sun Y, 2021, ACS APPL MATER INTER, V13, P59051, DOI 10.1021/acsami.1c16300
   Tian YJ, 2022, BIOACT MATER, V9, P428, DOI 10.1016/j.bioactmat.2021.07.033
   Turner NA, 2019, NAT REV MICROBIOL, V17, P203, DOI 10.1038/s41579 018 0147 4
   Wang DL, 2016, J HAZARD MATER, V308, P328, DOI 10.1016/j.jhazmat.2016.01.066
   Wang YL, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202208639
   Wei C, 2024, CHEM ENG J, V490, DOI 10.1016/j.cej.2024.151566
   Wu CT, 2012, BIOMATERIALS, V33, P2076, DOI 10.1016/j.biomaterials.2011.11.042
   Wu L, 2022, CHEM ENG J, V447, DOI 10.1016/j.cej.2022.137484
   Xiao SQ, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202208968
   Zhang D., 2024, ADV MATER, V36
   Zhang WD, 2015, MATER CHARACT, V106, P302, DOI 10.1016/j.matchar.2015.06.008
   Zheng YF, 2019, MAT SCI ENG C MATER, V99, P770, DOI 10.1016/j.msec.2019.02.020
   Zhou JH, 2016, ACTA BIOMATER, V43, P358, DOI 10.1016/j.actbio.2016.07.045
   Zhou LQ, 2022, BIOMATER ADV, V134, DOI 10.1016/j.msec.2021.112562
   Zhuang LH, 2017, ADV MATER, V29, DOI 10.1002/adma.201606793
NR 64
TC 8
Z9 8
U1 43
U2 61
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD JAN
PY 2025
VL 12
IS 3
AR 2409200
DI 10.1002/advs.202409200
EA NOV 2024
PG 19
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA 4UI3K
UT WOS:001362802600001
PM 39587976
OA gold
DA 2025 08 17
ER

PT J
AU Jia, HB
   Ma, JX
   Ma, XL
   Yu, JT
   Feng, R
   Xu, LY
   Wang, J
   Xing, D
   Zhu, SW
   Wang, Y
AF Jia, H. B.
   Ma, J. X.
   Ma, X. L.
   Yu, J. T.
   Feng, R.
   Xu, L. Y.
   Wang, J.
   Xing, D.
   Zhu, S. W.
   Wang, Y.
TI Estrogen alone or in combination with parathyroid hormone can decrease
   vertebral MEF2 and sclerostin expression and increase vertebral bone
   mass in ovariectomized rats
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bone mass; Estrogen; MEF2s; PTH; Sclerostin
ID VAN BUCHEM DISEASE; SERUM SCLEROSTIN; POSTMENOPAUSAL OSTEOPOROSIS; BMP
   ANTAGONIST; SOST GENE; WOMEN; OSTEOPENIA; TURNOVER; PROTEIN; MICE
AB The study is about the regulatory effects of estrogen and parathyroid hormone (PTH) on sclerostin, a protein that inhibits the Wnt/beta catenin pathway. The results indicate that estrogen may down regulate sclerostin expression and that estrogen displays synergistic action with PTH. These results provide a new perspective on the relationship between estrogen and bone.
   To investigate whether estrogen can down regulate SOST and MEF2 (myocyte enhancer factor 2) expression and whether co treatment with estrogen and PTH has a stronger effect on suppressing SOST than PTH applied alone in ovariectomized rats.
   Forty three month old virgin female Sprague Dawley (SD) rats were ovariectomized and divided into four groups (n = 10). Another ten age matched rats received sham operations as controls. After allowing 8 weeks for the development of vertebral osteopenia, the rats were administered the drug intervention. For this intervention, the estrogen group was subcutaneously injected with 17 beta estradiol at 25 mu g/kg body weight, the PTH group was injected with 80 mu g/kg synthetic human PTH (1 34), and the co treatment group was concurrently treated with PTH and estrogen at the above dosage. The OVX group and sham group were treated with vehicle. The drug treatment was conducted for 12 weeks. After the lumbar spine bone mineral density (BMD) was measured, the rats were sacrificed, and the lumbar spine and blood were collected for qPCR, Western blot, immunohistochemistry and other tests.
   Estrogen can down regulate MEF2 and sclerostin expression, and co treatment with estrogen and PTH has a stronger effect on suppressing MEF2 and SOST mRNA than PTH alone. The co treatment group displayed slightly higher bone mass and biomechanical properties than the PTH group, but the differences were not significant.
   Estrogen appears to be a regulator of sclerostin, and the effect may involve suppressing MEF2s. Combined treatment with PTH and estrogen is not more beneficial for vertebral bone mass and strength than treatment with PTH alone in ovariectomized rats.
C1 [Jia, H. B.; Ma, X. L.; Yu, J. T.; Feng, R.; Xu, L. Y.; Wang, J.; Xing, D.] Tianjin Med Univ, Gen Hosp, Tianjin 300052, Peoples R China.
   [Jia, H. B.; Ma, J. X.; Ma, X. L.; Zhu, S. W.; Wang, Y.] Tianjin Hosp, Heping Branch, Biomech Labs, Orthoped Res Inst, Tianjin 300050, Peoples R China.
C3 Tianjin Medical University
RP Ma, XL (通讯作者)，Tianjin Hosp, Heping Branch, Biomech Labs, Orthoped Res Inst, 122 MuNan St, Tianjin 300050, Peoples R China.
EM maxinlong2007@gmail.com
RI zhu, shao wen/AAG 2726 2019; Xing, Dan/MXM 0398 2025
FU National Natural Science Foundation of China [81102607]; Key
   Technologies & Program of Tianjin [13ZCZDSY01700, 11ZCGYSY01800];
   Scientific and Technological Project of Tianjin Public Health Bureau
   [11KG137, 12KG120]
FX This study was supported by grants from the National Natural Science
   Foundation of China (No. 81102607), the Key Technologies & Program of
   Tianjin (No. 13ZCZDSY01700 and 11ZCGYSY01800) and the Scientific and
   Technological Project of Tianjin Public Health Bureau (No. 11KG137 and
   No. 12KG120).
CR Ardawi MSM, 2011, J BONE MINER RES, V26, P2812, DOI 10.1002/jbmr.479
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Brand NJ, 1997, INT J BIOCHEM CELL B, V29, P1467, DOI 10.1016/S1357 2725(97)00084 8
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Canpolat S, 2010, J PHYSIOL BIOCHEM, V66, P23, DOI 10.1007/s13105 010 0008 8
   Drake MT, 2010, J CLIN ENDOCR METAB, V95, P5056, DOI 10.1210/jc.2010 0720
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009 1703
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Gatti D, 2012, J BONE MINER RES, V27, P2259, DOI 10.1002/jbmr.1681
   Gatti D, 2012, BONE, V50, P739, DOI 10.1016/j.bone.2011.11.028
   Genetos DC, 2010, J CELL BIOCHEM, V110, P457, DOI 10.1002/jcb.22559
   Gooi JH, 2010, BONE, V46, P1486, DOI 10.1016/j.bone.2010.02.018
   Henslee AM, 2011, ACTA BIOMATER, V7, P3627, DOI 10.1016/j.actbio.2011.06.043
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Jastrzebski S, 2013, J BONE MINER RES, V28, P618, DOI 10.1002/jbmr.1773
   Kobayashi S, 1999, BONE, V25, P703, DOI 10.1016/S8756 3282(99)00219 7
   Kramer I, 2010, TRENDS ENDOCRIN MET, V21, P237, DOI 10.1016/j.tem.2009.12.002
   Kramer I, 2010, J BONE MINER RES, V25, P178, DOI 10.1359/jbmr.090730
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Mirza FS, 2010, J CLIN ENDOCR METAB, V95, P1991, DOI 10.1210/jc.2009 2283
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P6741, DOI 10.1210/jc.2005 2370
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   QI H, 1995, J BONE MINER RES, V10, P948
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Rubin MR, 2005, DRUGS, V65, P2481, DOI 10.2165/00003495 200565170 00005
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   SHEN V, 1993, J CLIN INVEST, V91, P2479, DOI 10.1172/JCI116483
   SHEN V, 1995, J CLIN INVEST, V96, P2331, DOI 10.1172/JCI118289
   SHEN V, 1992, CALCIFIED TISSUE INT, V50, P214, DOI 10.1007/BF00296285
   Silvestrini G, 2007, J MOL HISTOL, V38, P261, DOI 10.1007/s10735 007 9096 3
   Sims NA, 2010, J BONE MINER RES, V25, P175, DOI 10.1002/jbmr.53
   Staehling Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   WRONSKI TJ, 1988, ENDOCRINOLOGY, V123, P681, DOI 10.1210/endo 123 2 681
   Xu HG, 2013, ORTHOP SURG, V5, P40, DOI 10.1111/os.12028
   Zhao M., 2006, Experimental Oncology, V28, P44
NR 42
TC 17
Z9 19
U1 0
U2 11
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD DEC
PY 2014
VL 25
IS 12
BP 2743
EP 2754
DI 10.1007/s00198 014 2818 y
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AT3BM
UT WOS:000344810100007
PM 25074352
DA 2025 08 17
ER

PT J
AU Bryant, AE
   Aldape, MJ
   Bayer, CR
   Katahira, EJ
   Bond, L
   Nicora, CD
   Fillmore, TL
   Clauss, TRW
   Metz, TO
   Webb Robertson, BJ
   Stevens, DL
AF Bryant, Amy E.
   Aldape, Michael J.
   Bayer, Clifford R.
   Katahira, Eva J.
   Bond, Laura
   Nicora, Carrie D.
   Fillmore, Thomas L.
   Clauss, Therese R. W.
   Metz, Thomas O.
   Webb Robertson, Bobbie Jo
   Stevens, Dennis L.
TI Effects of delayed NSAID administration after experimental eccentric
   contraction injury   A cellular and proteomics study
SO PLOS ONE
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SKELETAL MUSCLE INJURY; A
   STREPTOCOCCAL MYONECROSIS; SOFT TISSUE INFECTIONS; VIMENTIN EXPRESSION;
   GENE EXPRESSION; SATELLITE CELLS; PROTEIN; EXERCISE; APOPTOSIS
AB Background
   Acute muscle injuries are exceedingly common and non steroidal anti inflammatory drugs (NSAIDs) are widely consumed to reduce the associated inflammation, swelling and pain that peak 1 2 days post injury. While prophylactic use or early administration of NSAIDs has been shown to delay muscle regeneration and contribute to loss of muscle strength after healing, little is known about the effects of delayed NSAID use. Further, NSAID use following non penetrating injury has been associated with increased risk and severity of infection, including that due to group A streptococcus, though the mechanisms remain to be elucidated. The present study investigated the effects of delayed NSAID administration on muscle repair and sought mechanisms supporting an injury/NSAID/infection axis.
   Methods
   A murine model of eccentric contraction (EC) induced injury of the tibialis anterior muscle was used to profile the cellular and molecular changes induced by ketorolac tromethamine administered 47 hr post injury.
   Results
   NSAID administration inhibited several important muscle regeneration processes and down regulated multiple cytoprotective proteins known to inhibit the intrinsic pathway of programmed cell death. These activities were associated with increased caspase activity in injured muscles but were independent of any NSAID effect on macrophage influx or phenotype switching.
   Conclusions
   These findings provide new molecular evidence supporting the notion that NSAIDs have a direct negative influence on muscle repair after acute strain injury in mice and thus add to renewed concern about the safety and benefits of NSAIDS in both children and adults, in those with progressive loss of muscle mass such as the elderly or patients with cancer or AIDS, and those at risk of secondary infection after trauma or surgery.
C1 [Bryant, Amy E.; Aldape, Michael J.; Bayer, Clifford R.; Katahira, Eva J.; Stevens, Dennis L.] US Dept Vet Affairs, Off Res & Dev, Boise, ID USA.
   [Bryant, Amy E.; Stevens, Dennis L.] Univ Washington, Sch Med, Seattle, WA USA.
   [Aldape, Michael J.] Northwest Nazarene Univ, Nampa, ID USA.
   [Bond, Laura] Boise State Univ, Boise, ID 83725 USA.
   [Nicora, Carrie D.; Fillmore, Thomas L.; Clauss, Therese R. W.; Metz, Thomas O.; Webb Robertson, Bobbie Jo] Pacific Northwest Natl Lab, Richland, WA 99352 USA.
C3 University of Washington; University of Washington Seattle; Boise State
   University; United States Department of Energy (DOE); Pacific Northwest
   National Laboratory
RP Bryant, AE (通讯作者)，US Dept Vet Affairs, Off Res & Dev, Boise, ID USA.; Bryant, AE (通讯作者)，Univ Washington, Sch Med, Seattle, WA USA.
EM amy.bryant@va.gov
RI ; Webb Robertson, Bobbie Jo/K 8230 2019; Nicora, Carrie/JDC 7465 2023;
   Metz, Thomas/MNO 3842 2025
OI Fillmore, Thomas/0000 0002 3763 589X; Nicora,
   Carrie/0000 0003 2461 9548; Webb Robertson,
   Bobbie Jo/0000 0002 4744 2397; 
FU National Institute of Allergy and Infectious Diseases [R21A1101457];
   Office of Research and Development, Medical Research Service, U.S.
   Department of Veterans Affairs [1101BX000395]; National Institute of
   General Medical Sciences [P20GM103408]; Office of Biological and
   Environmental Research and located at Pacific Northwest National
   Laboratory (PNNL); PNNL [DE AC05 76RL01830]; National Institute of
   General Medical Sciences of the National Institutes of Health
   [P2OGM103408, P2OGM109095, 1U54GM104944]; National Science Foundation
   [0619793, 0923535]; Murdock Charitable Trust; Idaho State Board of
   Education
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases (Grant # R21A1101457, AEB), the Office of Research
   and Development, Medical Research Service, U.S. Department of Veterans
   Affairs (Grant # 1101BX000395, AEB), and an Institutional Development
   Award (IDeA) from the National Institute of General Medical Sciences
   (Grant #P20GM103408 AEB, MJA). Proteomics analyses were performed in the
   Environmental Molecular Sciences Laboratory, a U.S. Department of Energy
   (DOE) Office of Science User Facility supported by the Office of
   Biological and Environmental Research and located at Pacific Northwest
   National Laboratory (PNNL). PNNL is a multi program laboratory operated
   by Battelle for the U.S. DOE under contract DE AC05 76RL01830. Ingenuity
   Pathway Analysis and some statistical analyses were performed at the
   Biomolecular Research Center of Boise State University, Boise ID which
   is supported in part by Institutional Development Awards (IDeA) from the
   National Institute of General Medical Sciences of the National
   Institutes of Health under Grants #P2OGM103408, P2OGM109095, and
   1U54GM104944. We also acknowledge support from the National Science
   Foundation, Grants #0619793 and #0923535; the MJ Murdock Charitable
   Trust; and the Idaho State Board of Education. The funders had no role
   in study design, data collection and analysis, decision to publish or
   preparation of the manuscript.
CR Alleva DG, 2002, J LEUKOCYTE BIOL, V71, P677
   Amson R, 2012, NAT MED, V18, P91, DOI 10.1038/nm.2546
   [Anonymous], 2007, StatXact Software Version 8.0
   Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075
   Augusto V., 2004, BRAZ J MORPHOL SCI, V21, P89
   Barash IA, 2004, AM J PHYSIOL CELL PH, V286, pC355, DOI 10.1152/ajpcell.00211.2003
   Bean C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.525
   Belcastro AN, 1998, MOL CELL BIOCHEM, V179, P135, DOI 10.1023/A:1006816123601
   Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407
   Bommer UA, 2015, CELL SIGNAL, V27, P1557, DOI 10.1016/j.cellsig.2015.04.011
   Bondesen BA, 2004, AM J PHYSIOL CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004
   BROOKS PM, 1991, NEW ENGL J MED, V324, P1716
   Bryant AE, 2006, J INFECT DIS, V193, P1685, DOI 10.1086/504261
   Bryant AE, 2015, CURR OPIN INFECT DIS, V28, P231, DOI 10.1097/QCO.0000000000000160
   Cai CX, 2009, NAT CELL BIOL, V11, P56, DOI 10.1038/ncb1812
   Cao W, 2008, BBA GEN SUBJECTS, V1780, P873, DOI 10.1016/j.bbagen.2008.02.007
   Chargé SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003
   Cho DH, 2007, ONCOGENE, V26, P2809, DOI 10.1038/sj.onc.1210080
   Cho DH, 2004, J BIOL CHEM, V279, P39942, DOI 10.1074/jbc.M405747200
   Choi SJ, 2014, J EXERC REHABIL, V10, P344
   Dee K, 2002, CELL DEATH DIFFER, V9, P209, DOI 10.1038/sj.cdd.4400930
   Dial S, 2005, JAMA J AM MED ASSOC, V294, P2989, DOI 10.1001/jama.294.23.2989
   Ervasti JM, 2003, J BIOL CHEM, V278, P13591, DOI 10.1074/jbc.R200021200
   Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899
   FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.bi.63.070194.002021
   Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032
   Hakkarainen TW, 2015, JAMA SURG, V150, P223, DOI 10.1001/jamasurg.2014.2239
   Hamilton SM, 2008, J INFECT DIS, V198, P1692, DOI 10.1086/593016
   Hamilton SM, 2014, J INFECT DIS, V209, P1429, DOI 10.1093/infdis/jit594
   Jaitly N, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471 2105 10 87
   Kang W, 2014, P NATL ACAD SCI USA, V111, pE54, DOI 10.1073/pnas.1308768111
   Kiebel GR, 2006, PROTEOMICS, V6, P1783, DOI 10.1002/pmic.200500500
   Lamagni TL, 2008, EMERG INFECT DIS, V14, P202, DOI 10.3201/eid1402.070888
   Leroy S, 2010, CLIN DRUG INVEST, V30, P179, DOI 10.2165/11532890 000000000 00000
   Lieber Richard L, 2002, J Am Acad Orthop Surg, V10, P67
   Linares GR, 2009, BONE, V44, P795, DOI 10.1016/j.bone.2009.01.003
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mackey AL, 2012, SCAND J MED SCI SPOR, V22, pE8, DOI 10.1111/j.1600 0838.2012.01463.x
   Mackey AL, 2007, J APPL PHYSIOL, V103, P425, DOI 10.1152/japplphysiol.00157.2007
   Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223
   Martineau LC, 2001, J APPL PHYSIOL, V91, P693, DOI 10.1152/jappl.2001.91.2.693
   Mary C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052877
   Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200
   McDade JR, 2014, HUM MOL GENET, V23, P1677, DOI 10.1093/hmg/ddt557
   Mendias CL, 2004, MUSCLE NERVE, V30, P497, DOI 10.1002/mus.20102
   Messika J, 2014, J CRIT CARE, V29, P733, DOI 10.1016/j.jcrc.2014.05.021
   Mikkelsen UR, 2009, J APPL PHYSIOL, V107, P1600, DOI 10.1152/japplphysiol.00707.2009
   MISHRA DK, 1995, J BONE JOINT SURG AM, V77, P1510, DOI 10.2106/00004623 199510000 00005
   Monroe ME, 2007, BIOINFORMATICS, V23, P2021, DOI 10.1093/bioinformatics/btm281
   Nagano Ito M, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/204960
   Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916 922.2003
   Nuwayhid ZB, 2007, ANN EPIDEMIOL, V17, P878, DOI 10.1016/j.annepidem.2007.05.011
   Paulsen G, 2012, EXERC IMMUNOL REV, V18, P42
   Permpalung N, 2016, CAN J GASTROENTEROL, V2016, DOI 10.1155/2016/7431838
   Peters D, 2003, J PHYSIOL LONDON, V553, P947, DOI 10.1113/jphysiol.2003.048462
   Pette D, 2001, HISTOCHEM CELL BIOL, V115, P359, DOI 10.1007/s004180100268
   Polpitiya AD, 2008, BIOINFORMATICS, V24, P1556, DOI 10.1093/bioinformatics/btn217
   Posey AD, 2011, CURR TOP DEV BIOL, V96, P203, DOI 10.1016/B978 0 12 385940 2.00008 5
   Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200
   Rho SB, 2011, FEBS LETT, V585, P29, DOI 10.1016/j.febslet.2010.11.014
   Schulz Trieglaff O, 2009, BIODATA MIN, V2, DOI 10.1186/1756 0381 2 4
   SEJERSEN T, 1993, J CELL SCI, V106, P1291
   Sidney S., 1956, Nonparametric Statistics for the Behavioral Sciences
   Soukup T, 2014, HISTOCHEM CELL BIOL
   Souyri C, 2008, CLIN EXP DERMATOL, V33, P249, DOI 10.1111/j.1365 2230.2007.02652.x
   STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101
   Susini L, 2008, CELL DEATH DIFFER, V15, P1211, DOI 10.1038/cdd.2008.18
   TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092 8674(95)90410 7
   Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 41
   Tidball JG, 2005, AM J PHYSIOL REG I, V288, pR345, DOI 10.1152/ajpregu.00454.2004
   Tondera D, 2004, J BIOL CHEM, V279, P31544, DOI 10.1074/jbc.M404704200
   Trappe RA, 2002, AM J PHYSIOL ENDOC M, V282, pE551, DOI 10.1152/ajpendo.00352.2001
   Trappe TA, 2013, J APPL PHYSIOL, V115, P909, DOI 10.1152/japplphysiol.00061.2013
   US Food and Drug Administration, 2015, SAF ANN FDA STRENGTH
   Vafiadaki E, 2015, GENE, V566, P1, DOI 10.1016/j.gene.2015.04.077
   Vaittinen S, 2001, J NEUROPATH EXP NEUR, V60, P588, DOI 10.1093/jnen/60.6.588
   VATER R, 1994, HISTOCHEM J, V26, P916
   Volker D, 2000, LAB ANIM UK, V34, P423, DOI 10.1258/002367700780387732
   Walsh JG, 2008, P NATL ACAD SCI USA, V105, P12815, DOI 10.1073/pnas.0707715105
   Warren GL, 2007, J PHYSIOL LONDON, V582, P825, DOI 10.1113/jphysiol.2007.132373
   Webb Robertson BJM., 2010, J Proteome Res
   Webb Robertson BJM, 2014, MOL CELL PROTEOMICS, V13, P3639, DOI 10.1074/mcp.M113.030932
   Yang F, 2012, EXPERT REV PROTEOMIC, V9, P129, DOI [10.1586/EPR.12.15, 10.1586/epr.12.15]
   Zhang PP, 2015, BIOCHEM BIOPH RES CO, V463, P102, DOI 10.1016/j.bbrc.2015.05.032
   Zimmer JSD, 2006, MASS SPECTROM REV, V25, P450, DOI 10.1002/mas.20071
NR 85
TC 10
Z9 14
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD FEB 28
PY 2017
VL 12
IS 2
AR e0172486
DI 10.1371/journal.pone.0172486
PG 23
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EN4LY
UT WOS:000395980200021
PM 28245256
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Hollis, ER
   Zou, YM
AF Hollis, Edmund R., II
   Zou, Yimin
TI Reinduced Wnt signaling limits regenerative potential of sensory axons
   in the spinal cord following conditioning lesion
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE axon regeneration; axon retraction; Wnt signaling
ID GUIDANCE; IDENTIFICATION; INJURY; ADULT; CNS
AB Conditioning lesion of the peripheral branch of dorsal column axons is a well known paradigm enabling the central branch to regenerate after injury to the spinal cord. However, only a small number of regenerating axons enter grafted substrates, and they do not grow beyond the lesion. We found that conditioning lesion induces, in addition to growth stimulating genes, related to receptor tyrosine kinase (Ryk), a potent repulsive receptor for Wnts. Wnts are expressed around the site of spinal cord injury, and we found that grafted bone marrow stromal cells secreting the Wnt inhibitors secreted frizzled related protein 2 or Wnt inhibitory factor 1 enhanced regeneration of the central branch after peripheral conditioning lesion. Furthermore, we found that Wnt4 expressing grafts caused dramatic long range retraction of the injured central branch of conditioned dorsal root ganglion neurons. Macrophages accumulate along the path of receding axons but not around Wnt4 expressing cells, suggesting that the retraction of dorsal column axons is not a secondary effect of increased macrophages attracted by Wnt4. Therefore, Wnt Ryk signaling is an inhibitory force co induced with growth stimulating factors after conditioning lesion. Overcoming Wnt inhibition may further enhance therapies being designed on the basis of the conditioning lesion paradigm.
C1 [Hollis, Edmund R., II; Zou, Yimin] Univ Calif San Diego, Div Biol Sci, Neurobiol Sect, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego
RP Zou, YM (通讯作者)，Univ Calif San Diego, Div Biol Sci, Neurobiol Sect, La Jolla, CA 92093 USA.
EM yzou@ucsd.edu
RI Hollis, Edmund/ACI 8021 2022
OI Hollis, Edmund/0000 0002 4535 4668
FU Roman Reed Foundation; Wings for Life Foundation; National Institutes of
   Health/National Institute of Neurological Disorders and Stroke
   (NIH/NINDS) [R01 NS 047484, T32 NS007220 27]; Craig H. Neilsen
   Foundation
FX The authors thanks Kristine Tolentino for assistance with sample
   processing and Anna Tury, Keisuke Onishi, and Virginia Hazen for
   critical reading of the manuscript. This work was supported by the Roman
   Reed Foundation, the Wings for Life Foundation, and National Institutes
   of Health/National Institute of Neurological Disorders and Stroke
   (NIH/NINDS) Grant R01 NS 047484 (to Y.Z.), NIH/NINDS Neurobiology
   Training Grant T32 NS007220 27, and Craig H. Neilsen Foundation
   Fellowships (to E.R.H.).
CR Blakely BD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018373
   Fabes J, 2007, EUR J NEUROSCI, V26, P2496, DOI 10.1111/j.1460 9568.2007.05859.x
   Fenstermaker AG, 2010, J NEUROSCI, V30, P16053, DOI 10.1523/JNEUROSCI.4508 10.2010
   Goldshmit Y, 2004, J NEUROSCI, V24, P10064, DOI 10.1523/JNEUROSCI.2981 04.2004
   Hollis ER, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00005
   HOLSTEGE JC, 1987, NEUROSCIENCE, V23, P809, DOI 10.1016/0306 4522(87)90160 6
   Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488 08.2008
   Jordan LM, 2008, BRAIN RES REV, V57, P183, DOI 10.1016/j.brainresrev.2007.07.019
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257 09.2009
   Li L, 2009, J NEUROSCI, V29, P5873, DOI 10.1523/JNEUROSCI.0183 09.2009
   Liu YB, 2008, J NEUROSCI, V28, P8376, DOI 10.1523/JNEUROSCI.1939 08.2008
   Liu YB, 2005, NAT NEUROSCI, V8, P1151, DOI 10.1038/nn1520
   Löw K, 2008, J NEUROSCI, V28, P1099, DOI 10.1523/JNEUROSCI.4906 07.2008
   Lyuksyutova AI, 2003, SCIENCE, V302, P1984, DOI 10.1126/science.1089610
   Pasterkamp RJ, 1999, MOL CELL NEUROSCI, V13, P143, DOI 10.1006/mcne.1999.0738
   Pasterkarnp RJ, 2006, PHILOS T R SOC B, V361, P1499, DOI 10.1098/rstb.2006.1892
   RICHARDSON PM, 1984, NATURE, V309, P791, DOI 10.1038/309791a0
   Salinas PC, 2008, ANNU REV NEUROSCI, V31, P339, DOI 10.1146/annurev.neuro.31.060407.125649
   Stam FJ, 2007, EUR J NEUROSCI, V25, P3629, DOI 10.1111/j.1460 9568.2007.05597.x
NR 20
TC 50
Z9 64
U1 1
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 4
PY 2012
VL 109
IS 36
BP 14663
EP 14668
DI 10.1073/pnas.1206218109
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 007TZ
UT WOS:000308912600074
PM 22904192
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Kalyan, S
   Huebbe, P
   Esatbeyoglu, T
   Niklowitz, P
   Côté, HCF
   Rimbach, G
   Kabelitz, D
AF Kalyan, Shirin
   Huebbe, Patricia
   Esatbeyoglu, Tuba
   Niklowitz, Petra
   Cote, Helene C. F.
   Rimbach, Gerald
   Kabelitz, Dieter
TI Nitrogen Bisphosphonate Therapy Is Linked to Compromised Coenzyme Q10
   and Vitamin E Status in Postmenopausal Women
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID DELTA T CELLS; ALPHA TOCOPHEROL; GAMMA TOCOPHEROL; OSTEONECROSIS; BONE;
   OSTEOPOROSIS; DAMAGE; JAW; INFLAMMATION; OSTEOCLAST
AB Background: Nitrogen bisphosphonates (N BPs) are the most widely used drugs for bone fragility disorders. Long term or high dose N BP use is associated with unusual serious side effects such as osteonecrosis of the jaw, musculoskeletal pain, and atypical fractures of long bones. It has escaped notice that the pathway N BPs block is central for the endogenous synthesis of coenzyme Q10, an integralenzymeof the mitochondrial respiratory chain and an important lipid soluble antioxidant. Our objective was to assess the coenzyme Q10 and antioxidant status in relation to N BP exposure in women with postmenopausal osteoporosis.
   Methods: Seventy one postmenopausal women (age, 73.5 +/  5.5 y) with osteoporosis and no other malignancy were included in this cross sectional study. Seventeen were treatment naive, 27 were on oral N BP, and 27 were on iv N BP.
   Results: Vitamin E gamma tocopherol levels (mu mol/mL) were significantly reduced in N BP users [oral, H(2) = 18.5, P = .02; iv, H(2) = 25.2, P < .001; mean rank comparisons after Kruskal Wallis test). Length of time (days) of N BP exposure, but not age, was inversely associated with the coenzyme Q10/cholesterol ratio (mu mol/mol) (beta =  0.27; P = .025), which was particularly low for those on iv N BP (mean difference =  35.0 +/  16.9; 95% confidence interval,  65.2 to  4.9; P = .02).
   Conclusion: The degree of N BP exposure appears related to compromised coenzyme Q10 status and vitamin E gamma tocopherol levels in postmenopausalwomenwith osteoporosis. This phenomenon may link to certain adverse N BP associated effects. Confirmation of this would suggest that therapeutic supplementation could prevent or reverse certain complications of long term N BP therapy for at risk individuals.
C1 [Kalyan, Shirin; Kabelitz, Dieter] Univ Kiel, Inst Immunol, D 24105 Kiel, Germany.
   [Huebbe, Patricia; Esatbeyoglu, Tuba; Rimbach, Gerald] Univ Kiel, D 24105 Kiel, Germany.
   [Niklowitz, Petra] Univ Witten Herdecke, Childrens Hosp Datteln, D 45711 Datteln, Germany.
   [Cote, Helene C. F.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada.
C3 University of Kiel; University of Kiel; Witten Herdecke University;
   University of British Columbia
RP Kalyan, S (通讯作者)，Univ Kiel, Inst Immunol, Arnold Heller Str 3,Haus 17, D 24105 Kiel, Germany.
EM shirin.kalyan@uksh.de; Dietrich.kabelitz@uksh.de
RI Kalyan, Shirin/E 2130 2011; Rimbach, Gerald/A 7178 2011; Cote,
   Helene/K 7896 2012; Esatbeyoglu, Tuba/ABB 7997 2021; Kabelitz,
   Dieter/A 2757 2010
OI Kalyan, Shirin/0000 0002 7332 2225; Rimbach, Gerald/0000 0001 7888 4684;
   Esatbeyoglu, Tuba/0000 0003 2413 6925
FU Alexander von Humboldt Foundation of Germany; Faculty of Medicine Grant
   from Christian Albrechts University of Kiel; Deutsche
   Forschungsgemeinschaft [Ka 502/10 2]; Deutsche Forschungsgemeinschaft
   ("Inflammation at Interfaces" Cluster of Excellence)
FX S.K. was supported by a Fellowship from the Alexander von Humboldt
   Foundation of Germany and a Faculty of Medicine Grant from
   Christian Albrechts University of Kiel. D. K. acknowledges grant support
   from the Deutsche Forschungsgemeinschaft (Ka 502/10 2 and
   "Inflammation at Interfaces" Cluster of Excellence). The funding bodies
   had no role in the study analysis or interpretation.
CR Cook Mills Joan M., 2010, Endocrine Metabolic & Immune Disorders Drug Targets, V10, P348
   CRANE FL, 1957, BIOCHIM BIOPHYS ACTA, V25, P220, DOI 10.1016/0006 3002(57)90457 2
   Dallner G, 2000, FREE RADICAL BIO MED, V29, P285, DOI 10.1016/S0891 5849(00)00307 5
   Edwards BJ, 2008, LANCET ONCOL, V9, P1166, DOI 10.1016/S1470 2045(08)70305 X
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   GHIRLANDA G, 1993, J CLIN PHARMACOL, V33, P226, DOI 10.1002/j.1552 4604.1993.tb03948.x
   Halpner AD, 1998, ARCH BIOCHEM BIOPHYS, V359, P305, DOI 10.1006/abbi.1998.0914
   Hollick Rosemary J, 2011, Menopause Int, V17, P66, DOI 10.1258/mi.2011.011014
   Jiang Q, 2003, FASEB J, V17, P816, DOI 10.1096/fj.02 0877com
   Jiang Q, 2000, P NATL ACAD SCI USA, V97, P11494, DOI 10.1073/pnas.200357097
   Kalyan S, 2013, J BONE MINER RES, V28, P728, DOI 10.1002/jbmr.1769
   Kalyan S, 2013, CELL MOL IMMUNOL, V10, P21, DOI 10.1038/cmi.2012.44
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914
   Larsen S, 2013, J AM COLL CARDIOL, V61, P44, DOI 10.1016/j.jacc.2012.09.036
   Littarru GP, 2007, MITOCHONDRION, V7, pS168, DOI 10.1016/j.mito.2007.03.002
   Marx RE, 2007, J ORAL MAXIL SURG, V65, P2397, DOI 10.1016/j.joms.2007.08.003
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Meier R, 2003, J MOL BIOL, V331, P725, DOI 10.1016/S0022 2836(03)00724 1
   Menke T, 2000, ANAL BIOCHEM, V282, P209, DOI 10.1006/abio.2000.4579
   Miles MV, 2003, CLIN CHIM ACTA, V332, P123, DOI 10.1016/S0009 8981(03)00137 2
   Moon HJ, 2013, J FOOD SCI, V78, pH785, DOI 10.1111/1750 3841.12116
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Orozco C, 2012, RHEUM DIS CLIN N AM, V38, P681, DOI 10.1016/j.rdc.2012.09.001
   Palaska PK, 2009, ONCOLOGIST, V14, P1154, DOI 10.1634/theoncologist.2009 0115
   Pfeilschifter J, 2006, EXP CLIN ENDOCR DIAB, V114, P611
   Potgieter M, 2013, NUTR REV, V71, P180, DOI 10.1111/nure.12011
   Ravosa MJ, 2011, ARCH ORAL BIOL, V56, P491, DOI 10.1016/j.archoralbio.2010.11.003
   Sellmeyer DE, 2010, JAMA J AM MED ASSOC, V304, P1480, DOI 10.1001/jama.2010.1360
   Shetty Kishore, 2009, General Dentistry, V57, P130
   Steele Paul E, 2004, Am J Clin Pathol, V121 Suppl, pS113
   STOYANOVSKY DA, 1995, ARCH BIOCHEM BIOPHYS, V323, P343, DOI 10.1006/abbi.1995.9955
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   von Zglinicki T, 2005, CURR MOL MED, V5, P197
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Whayne TF, 2011, ANGIOLOGY, V62, P415, DOI 10.1177/0003319710395560
   Wolf G, 1997, NUTR REV, V55, P376, DOI 10.1111/j.1753 4887.1997.tb01566.x
   Wysowski DK, 2005, ARCH INTERN MED, V165, P346, DOI 10.1001/archinte.165.3.346 b
   Zanet DL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057787
NR 40
TC 18
Z9 20
U1 0
U2 11
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD APR
PY 2014
VL 99
IS 4
BP 1307
EP 1313
DI 10.1210/jc.2013 3648
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AP7UU
UT WOS:000342283500053
PM 24423355
OA Bronze
DA 2025 08 17
ER

PT J
AU Lezcano, V
   Morelli, S
   González Pardo, V
AF Lezcano, Virginia
   Morelli, Susana
   Gonzalez Pardo, Veronica
TI Molecular and cellular outcomes of quercetin actions on healthy and
   tumor osteoblasts
SO BIOCHIMIE
LA English
DT Article
DE Phytoestrogen; Osteogenesis; Signaling pathway; Cytotoxicity
ID INDUCED GROWTH INHIBITION; CANCER CELLS; IN VIVO; APOPTOSIS;
   DIFFERENTIATION; PROLIFERATION; GENISTEIN; PATHWAY; ERK; POLYPHENOLS
AB There is a global trend in the use of natural bioactive compounds to complement conventional therapies in bone diseases. In this work, we studied the effects of the phytoestrogen quercetin (QUE) in healthy and tumor osteoblasts. We found that QUE (1 mu M, 48 h) significantly increased the cell number and the viability of healthy human osteoblasts (hFOB cells) determined by a trypan blue and a MTS assay, respectively, among other concentrations tested. In addition, wound healing and cellular adhesion assays also demonstrated that 1 mu M of QUE significantly stimulated both parameters in osteoblasts. Moreover, osteoblast differentiation was also triggered by QUE in an osteogenic medium by measuring alkaline phosphatase activity, calcium deposition, and collagen levels. Herein, a concentration of 0.01 mu M of QUE showed an increment in these differentiation markers and an activation of AKT/GSK3 beta/beta catenin pathway, determined by a Western blot analysis. In addition, immunocytochemistry and subcellular fraction studies indicated an increase of beta catenin localization in the plasma membrane after QUE treatment. Otherwise, QUE (20 100 mu M) decreased the cell number and the viability in tumor osteo blasts (ROS 17/2.8 cells) after 48 h. Furthermore, QUE (100 mu M) decreased AKT(Ser473) and the pro apoptotic protein BAD(Ser136) phosphorylation. In addition, the ERK1/2 phosphorylation increased leading to osteosarcoma cell death since pre treatment with the MEK inhibitor PD98059 had reverted QUE effect. Altogether, these results indicate that low concentrations of QUE stimulate osteoblasto genesis but have no effect on the growth of tumor osteoblast cells, for which only high concentrations are efficient. (c) 2022 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.
C1 [Lezcano, Virginia; Morelli, Susana; Gonzalez Pardo, Veronica] Univ Nacl Sur UNS, Dept Biol Bioquim & Farm, San Juan 670, RA 8000 Bahia Blanca, Buenos Aires, Argentina.
   [Lezcano, Virginia; Morelli, Susana; Gonzalez Pardo, Veronica] Consejo Nacl Invest Cient & Tecn CONICET, Inst Ciencias Biol & Biomed Sur INBIOSUR, RA 8000 Bahia Blanca, Buenos Aires, Argentina.
C3 National University of the South; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET)
RP Lezcano, V (通讯作者)，Univ Nacl Sur UNS, Dept Biol Bioquim & Farm, San Juan 670, RA 8000 Bahia Blanca, Buenos Aires, Argentina.
EM vlezcano@criba.edu.ar
OI Gonzalez Pardo, Veronica/0000 0002 9934 2670
FU Agencia Nacional de Promoci?on Cientifica y Tecnol?ogica [ANPCYT PICT
   1749]; Universidad Nacional del Sur [24/B248]; Agencia Nacional de
   Promocion Cientifica y Tecnologica [ANPC] [ANPCYT PICT 1749];
   Universidad Nacional del Sur, Argentina [24/B248];  [PICT 1749]
FX This work was carried out due to the funds received from the Agencia
   Nacional de Promocion Cientifica y Tecnologica [ANPCYT PICT 1749] and
   Universidad Nacional del Sur [24/B248] , Argentina. Acknowledgements We
   wish to thank Dr. Pablo De Genaro (IBIOSUR CONICET) for his assistance
   in formatting Immunofluorescence images.
CR Aalinkeel R, 2008, PROSTATE, V68, P1773, DOI 10.1002/pros.20845
   Abbruzzese G, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9060545
   Abu N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105244
   Baghel S. S., 2012, World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS), V1, P146
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Barsky L, 2021, EUR J CLIN NUTR, V75, P829, DOI 10.1038/s41430 020 00800 6
   Berndt K, 2013, ANTICANCER RES, V33, P1297
   Boly R, 2011, INT J ONCOL, V38, P833, DOI 10.3892/ijo.2010.890
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742 4658.2009.07366.x
   Calvo N, 2019, MOL CELL ENDOCRINOL, V483, P50, DOI 10.1016/j.mce.2019.01.005
   Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399
   Crowley Lisa C, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.prot087155
   Dang ZC, 2005, TRENDS ENDOCRIN MET, V16, P207, DOI 10.1016/j.tem.2005.05.001
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092 8674(00)80405 5
   Desmawati Desmawati, 2019, Open Access Maced J Med Sci, V7, P495, DOI 10.3889/oamjms.2019.044
   Dhanaraj T, 2021, ARCH BIOCHEM BIOPHYS, V701, DOI 10.1016/j.abb.2021.108795
   Egert S, 2008, J NUTR, V138, P1615, DOI 10.1093/jn/138.9.1615
   Fayed HA, 2019, EUR J PHARMACOL, V865, DOI 10.1016/j.ejphar.2019.172785
   Guo C, 2017, CELL PHYSIOL BIOCHEM, V43, P1547, DOI 10.1159/000481978
   Harwood M, 2007, FOOD CHEM TOXICOL, V45, P2179, DOI 10.1016/j.fct.2007.05.015
   Hinenoya H., 2013, Kawasaki Medical Journal, V39, P21
   Ho MX, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00474
   Houschyar KS, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00170
   Huang L, 2021, BIOACT MATER, V6, P3074, DOI 10.1016/j.bioactmat.2021.02.015
   Kanner J, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9090797
   Kawabata K, 2015, FOOD FUNCT, V6, P1399, DOI [10.1039/C4FO01178C, 10.1039/c4fo01178c]
   Kiyga E, 2020, MOL BIOL REP, V47, P4957, DOI 10.1007/s11033 020 05641 x
   Lamson D W, 2000, Altern Med Rev, V5, P196
   Lee SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048791
   Lezcano V, 2013, BBA MOL CELL RES, V1833, P2834, DOI 10.1016/j.bbamcr.2013.06.029
   Li G, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11555 9
   Lin HK, 2014, CELL RES, V24, P785, DOI 10.1038/cr.2014.57
   MATTER WF, 1992, BIOCHEM BIOPH RES CO, V186, P624, DOI 10.1016/0006 291X(92)90792 J
   McCarthy AD, 2004, INT J BIOCHEM CELL B, V36, P840, DOI 10.1016/j.biocel.2003.09.006
   Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919
   Molinuevo MS, 2008, CANCER CHEMOTH PHARM, V61, P767, DOI 10.1007/s00280 007 0532 6
   Monga SPS, 2006, CELL TISSUE RES, V323, P71, DOI 10.1007/s00441 005 0045 8
   MORTON MS, 1994, J ENDOCRINOL, V142, P251, DOI 10.1677/joe.0.1420251
   Nguyen TTT, 2004, CARCINOGENESIS, V25, P647, DOI 10.1093/carcin/bgh052
   Nie FJ, 2020, LIFE SCI, V258, DOI 10.1016/j.lfs.2020.118143
   Notoya M, 2004, EUR J PHARMACOL, V485, P89, DOI 10.1016/j.ejphar.2003.11.058
   Paganga G, 1997, FEBS LETT, V401, P78, DOI 10.1016/S0014 5793(96)01442 1
   Pang XG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4178021
   Pinkas J, 2002, CANCER RES, V62, P4781
   Reyes Farias M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133177
   Robaszkiewicz A, 2007, CELL BIOL INT, V31, P1245, DOI 10.1016/j.cellbi.2007.04.009
   Rom William N, 2003, Methods Mol Med, V75, P3
   Ryu B, 2009, CHEM BIOL INTERACT, V179, P192, DOI 10.1016/j.cbi.2009.01.006
   Sakanashi Y, 2008, LIFE SCI, V83, P164, DOI 10.1016/j.lfs.2008.05.009
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Son YO, 2006, EUR J PHARMACOL, V529, P24, DOI 10.1016/j.ejphar.2005.10.041
   Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960 9822(02)70790 2
   Steinhart Z, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146589
   Su Y, 2009, CARCINOGENESIS, V30, P331, DOI 10.1093/carcin/bgn279
   Tapia C, 2020, TOXICOL IN VITRO, V63, DOI 10.1016/j.tiv.2019.104748
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Wang S, 2016, MOLECULES, V21, DOI 10.3390/molecules21111489
   Wu GJ, 2020, J AGR FOOD CHEM, V68, P10639, DOI 10.1021/acs.jafc.0c02830
   Wu YH, 2016, BIOMED REP, V4, P583, DOI 10.3892/br.2016.638
   Xia MY, 2017, FEBS OPEN BIO, V7, P759, DOI 10.1002/2211 5463.12220
   Yan DY, 2020, J CELL MOL MED, V24, P2330, DOI 10.1111/jcmm.14915
   Yao AJ, 2015, BIOCHEM BIOPH RES CO, V465, P696, DOI 10.1016/j.bbrc.2015.08.049
   Zhang XA, 2015, PHARMACOGN MAG, V11, P404, DOI 10.4103/0973 1296.153096
   Zhang XM, 2001, CLIN EXP METASTAS, V18, P415, DOI 10.1023/A:1010960615370
   Zhao FL, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 020 00854 w
NR 66
TC 7
Z9 8
U1 0
U2 13
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0300 9084
EI 1638 6183
J9 BIOCHIMIE
JI Biochimie
PD AUG
PY 2022
VL 199
BP 46
EP 59
DI 10.1016/j.biochi.2022.04.003
EA APR 2022
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 1D2GN
UT WOS:000793624400005
PM 35447220
DA 2025 08 17
ER

PT J
AU Lambova, SN
   Ivanovska, N
   Stoyanova, S
   Belenska Todorova, L
   Georgieva, E
   Batsalova, T
   Moten, D
   Apostolova, D
   Dzhambazov, B
AF Lambova, Sevdalina Nikolova
   Ivanovska, Nina
   Stoyanova, Stela
   Belenska Todorova, Lyudmila
   Georgieva, Elenka
   Batsalova, Tsvetelina
   Moten, Dzhemal
   Apostolova, Desislava
   Dzhambazov, Balik
TI Changes in the Subchondral Bone, Visfatin, and Cartilage Biomarkers
   after Pharmacological Treatment of Experimental Osteoarthritis with
   Metformin and Alendronate
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteoarthritis; metformin; alendronate; biomarkers; visfatin; COMP;
   MMP 13; CTX II; histopathology
ID OLIGOMERIC MATRIX PROTEIN; KNEE OSTEOARTHRITIS; MARROW LESIONS;
   ZOLEDRONIC ACID; SYNOVIAL FLUID; SERUM; COMP; BISPHOSPHONATES;
   HISTOPATHOLOGY; DEGENERATION
AB Subchondral bone that has intense communication with the articular cartilage might be a potential target for pharmacological treatment in the early stages of osteoarthritis (OA). Considering the emerging data about the role of adipokines in the pathogenesis of OA, the administration of drugs that influence their level is also intriguing. Metformin and alendronate were administered in mice with collagenase induced OA (CIOA) as a monotherapy and in combination. Safranin O staining was used for the assessment of changes in subchondral bone and articular cartilage. Before and after treatment, serum levels of visfatin and biomarkers of cartilage turnover (CTX II, MMP 13, and COMP) were assessed. In the current study, the combined administration of alendronate and metformin in mice with CIOA led to the protection against cartilage and subchondral bone damage. In mice with CIOA, metformin led to a decrease in visfatin level. In addition, treatment with metformin, alendronate, or their combination lowered the level of cartilage biomarkers (CTX II and COMP), while the level of MMP 13 was not influenced. In conclusion, personalized combination treatment in OA according to clinical phenotype, especially in the early stages of the disease, might lead to the identification of a successful disease modifying therapeutic protocol in OA.
C1 [Lambova, Sevdalina Nikolova] Med Univ Plovdiv, Fac Med, Dept Propaedeut Internal Dis, Plovdiv 4000, Bulgaria.
   [Ivanovska, Nina] Bulgarian Acad Sci, Stephan Angeloff Inst Microbiol, Dept Immunol, Sofia 1113, Bulgaria.
   [Stoyanova, Stela; Georgieva, Elenka; Batsalova, Tsvetelina; Moten, Dzhemal; Apostolova, Desislava; Dzhambazov, Balik] Paisii Hilendarski Univ Plovdiv, Dept Dev Biol, Plovdiv 4000, Bulgaria.
   [Belenska Todorova, Lyudmila] Sofia Univ St Kliment Ohridski, Fac Med, Sofia 1407, Bulgaria.
C3 Medical University Plovdiv; Bulgarian Academy of Sciences; Stephan
   Angeloff Institute of Microbiology, Bulgarian Academy of Sciences;
   Plovdiv University; Medical University Sofia; University of Sofia
RP Dzhambazov, B (通讯作者)，Paisii Hilendarski Univ Plovdiv, Dept Dev Biol, Plovdiv 4000, Bulgaria.
EM sevdalina_n@abv.bg; nina_ivanovska@abv.bg;
   stela.stoyanova@uni plovdiv.bg; lbelenska@uni sofia.bg;
   elenkageorgieva@uni plovdiv.bg; tsvetelina@uni plovdiv.bg;
   moten@uni plovdiv.bg; apostolova@uni plovdiv.bg; balik@uni plovdiv.bg
RI ; Georgieva, Elenka/GXG 8061 2022; Stoyanova, Stela/GYJ 7435 2022;
   Dzhambazov, Balik/H 1220 2015; Lambova, Sevdalina/I 2386 2019;
   Batsalova, Tsvetelina/W 6340 2018; Belenska   Todorova,
   Lyudmila/FHH 5459 2022; Apostolova, Desislava/HKO 1168 2023
OI Moten, Dzhemal/0000 0002 7998 5214; Batsalova,
   Tsvetelina/0000 0002 6560 1945; Dzhambazov, Balik/0000 0001 8052 5840;
   Apostolova, Desislava/0009 0006 5543 2718; 
FU Bulgarian National Science Fund [KP 06 N33/9]
FX This research was funded by the Bulgarian National Science Fund
   (KP 06 N33/9).
CR Acibadem E, 2023, J ORAL REHABIL, V50, P113, DOI 10.1111/joor.13396
   Aho OM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173726
   Allen KD, 2022, OSTEOARTHR CARTILAGE, V30, P184, DOI 10.1016/j.joca.2021.04.020
   ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   Belenska Todorova L, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9081017
   Blumenfeld O, 2013, OSTEOARTHR CARTILAGE, V21, P923, DOI 10.1016/j.joca.2013.04.009
   Bolbos RI, 2008, OSTEOARTHR CARTILAGE, V16, P1150, DOI 10.1016/j.joca.2008.02.018
   Buckland Wright JC, 2007, RHEUMATOLOGY, V46, P257, DOI 10.1093/rheumatology/kel213
   Cai GQ, 2020, JAMA J AM MED ASSOC, V323, P1456, DOI 10.1001/jama.2020.2938
   Catterall J, 2013, OSTEOARTHR CARTILAGE, V21, pS77, DOI 10.1016/j.joca.2013.02.168
   Cheng HB, 2020, CARTILAGE, V11, P512, DOI 10.1177/1947603518798884
   Cheng JY, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/3450672
   Christgau S, 2001, BONE, V29, P209, DOI 10.1016/S8756 3282(01)00504 X
   Cooles FAH, 2011, CURR OPIN RHEUMATOL, V23, P233, DOI 10.1097/BOR.0b013e32834518a3
   Crema MD, 2013, OSTEOARTHR CARTILAGE, V21, P306, DOI 10.1016/j.joca.2012.11.005
   Croucher LJ, 1999, J CLIN PATHOL MOL PA, V52, P323, DOI 10.1136/mp.52.6.323
   Danila MI, 2014, PATHOBIOLOGY OF HUMAN DISEASE: A DYNAMIC ENCYCLOPEDIA OF DISEASE MECHANISMS, P1912, DOI 10.1016/B978 0 12 386456 7.04301 X
   Donell S, 2019, EFORT OPEN REV, V4, P221, DOI 10.1302/2058 5241.4.180102
   Duan YH, 2012, RHEUMATOL INT, V32, P985, DOI 10.1007/s00296 010 1731 8
   Fernández Martín S, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 021 02446 6
   Foster NE, 2023, OSTEOARTHR CARTILAGE, V31, P876, DOI 10.1016/j.joca.2023.03.008
   Gao Y, 2014, ARQ BRAS ENDOCRINOL, V58, P42, DOI 10.1590/0004 2730000002840
   Garnero P, 2002, ARTHRITIS RHEUM US, V46, P2613, DOI 10.1002/art.10576
   Gheita TA, 2015, OSTEOARTHR CARTILAGE, V23, pA85, DOI 10.1016/j.joca.2015.02.787
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Gyurkovska V, 2014, INFLAMMATION, V37, P995, DOI 10.1007/s10753 014 9820 6
   Hao HQ, 2019, OSTEOARTHR CARTILAGE, V27, P726, DOI 10.1016/j.joca.2018.10.009
   Hayami T, 2004, ARTHRITIS RHEUM US, V50, P1193, DOI 10.1002/art.20124
   Huang XY, 2023, J MATER SCI TECHNOL, V149, P42, DOI 10.1016/j.jmst.2022.11.027
   Intema F, 2010, OSTEOARTHR CARTILAGE, V18, P691, DOI 10.1016/j.joca.2010.01.004
   Kay JP, 2001, METABOLISM, V50, P1457, DOI 10.1053/meta.2001.28078
   KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494
   Koelling S, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1922
   Laiguillon MC, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4467
   Lambova SN, 2023, LIFE BASEL, V13, DOI 10.3390/life13020437
   Lambova SN, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9081019
   Laslett LL, 2012, ANN RHEUM DIS, V71, P1322, DOI 10.1136/annrheumdis 2011 200970
   Mai QG, 2011, J CELL BIOCHEM, V112, P2902, DOI 10.1002/jcb.23206
   Man G S, 2014, J Med Life, V7, P37
   Mathieu S, 2022, JOINT BONE SPINE, V89, DOI 10.1016/j.jbspin.2022.105444
   Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475
   Monma Y, 2004, CALCIFIED TISSUE INT, V74, P115, DOI 10.1007/s00223 002 2156 5
   Morozzi G, 2007, CLIN RHEUMATOL, V26, P1335, DOI 10.1007/s10067 006 0520 y
   Moschen AR, 2007, J IMMUNOL, V178, P1748, DOI 10.4049/jimmunol.178.3.1748
   Neidhart M, 1997, BRIT J RHEUMATOL, V36, P1151
   Ozkaya M, 2010, FERTIL STERIL, V93, P880, DOI 10.1016/j.fertnstert.2008.10.058
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   Puenpatom RA, 2009, POSTGRAD MED, V121, P9, DOI 10.3810/pgm.2009.11.2073
   Quicke JG, 2022, OSTEOARTHR CARTILAGE, V30, P196, DOI 10.1016/j.joca.2021.10.003
   Richard MJ, 2023, OSTEOARTHR CARTILAGE, V31, P458, DOI 10.1016/j.joca.2022.11.005
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Schmitz N, 2010, OSTEOARTHR CARTILAGE, V18, pS113, DOI 10.1016/j.joca.2010.05.026
   Siebelt M, 2014, BONE, V66, P163, DOI 10.1016/j.bone.2014.06.009
   Tan Q., 2021, Med. Nov. Technol. Devices, V9, P100052, DOI [10.1016/j.medntd.2020.100052, DOI 10.1016/J.MEDNTD.2020.100052]
   Tseng S, 2009, BIOMARK INSIGHTS, V4, P33
   Vaysbrot EE, 2018, OSTEOARTHR CARTILAGE, V26, P154, DOI 10.1016/j.joca.2017.11.013
   Vieira JS, 2019, INT J ORAL MAX SURG, V48, P1494, DOI 10.1016/j.ijom.2019.04.002
   Vilím V, 2002, OSTEOARTHR CARTILAGE, V10, P707, DOI 10.1053/joca.2002.0819
   Yao Q, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01330 w
   Zhang CF, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.865370
   Zhang FJ, 2014, EXP THER MED, V8, P391, DOI 10.3892/etm.2014.1750
   Zhang L, 2011, CLIN EXP MED, V11, P235, DOI 10.1007/s10238 011 0131 z
   Zheng S, 2016, SCAND J RHEUMATOL, V45, P224, DOI 10.3109/03009742.2015.1083053
   Ziqubu K, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24032227
NR 64
TC 6
Z9 6
U1 3
U2 13
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2023
VL 24
IS 12
AR 10103
DI 10.3390/ijms241210103
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA K2NW1
UT WOS:001014868100001
PM 37373251
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liu, JJ
   Zhang, JS
AF Liu, Jane Jijun
   Zhang, Jingsong
TI Sequencing Systemic Therapies in Metastatic Castration Resistant
   Prostate Cancer
SO CANCER CONTROL
LA English
DT Article
ID HUMAN CYTOCHROME P450(17 ALPHA); ZOLEDRONIC ACID; DOUBLE BLIND;
   INCREASED SURVIVAL; CONTROLLED TRIAL; SIPULEUCEL T; IMMUNOTHERAPY;
   MITOXANTRONE; ABIRATERONE; PREDNISONE
AB Background: Men with prostate cancer will not die of the disease until it progresses to the metastatic castration resistant stage. At that stage, the median survival is 9 to 30 months.
   Methods: Recently approved and emerging treatments for metastatic castration resistant prostate cancer (mCRPC) were reviewed based on their mechanisms of action, as well as sequencing and combining these treatments with existing options.
   Results: Advances in androgen deprivation therapy, immunotherapy, bone targeted therapy, and chemotherapy have led to approvals of abiraterone acetate, sipuleucel T, denosumab, and cabazitaxel for the treatment of mCRPC. Despite improvements in patient survival and quality of life, mCRPC remains incurable.
   Conclusions: With the emerging new therapies, this is an unprecedented time in treating mCRPC. A better understanding of their mechanisms of action, the genetic makeup of each mCRPC, and the development of new prognostic and predictive biomarkers will help determine sequencing or different combination treatments for each individual patient.
C1 [Liu, Jane Jijun] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Div Hematol & Oncol, Tampa, FL 33612 USA.
   [Zhang, Jingsong] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Genitourinary Oncol Program, Tampa, FL 33612 USA.
C3 State University System of Florida; University of South Florida; H Lee
   Moffitt Cancer Center & Research Institute; State University System of
   Florida; University of South Florida; H Lee Moffitt Cancer Center &
   Research Institute
RP Zhang, JS (通讯作者)，H Lee Moffitt Canc Ctr & Res Inst, Genitourinary Oncol Program, MCC GME, 12902 Magnolia Dr, Tampa, FL 33612 USA.
EM Jingsong.Zhang@Moffitt.org
CR [Anonymous], EUR J CANC S2
   [Anonymous], AM SOC CLIN ONC 2010
   Araujo JC, 2013, J CLIN ONCOL, V31, DOI 10.1200/jco.2013.31.6_suppl.lba8
   Attard G, 2005, BJU INT, V96, P1241, DOI 10.1111/j.1464 410X.2005.05821.x
   Barrie SE, 1997, J STEROID BIOCHEM, V60, P347, DOI 10.1016/S0960 0760(96)00225 7
   Bauman G, 2005, RADIOTHER ONCOL, V75, P258, DOI 10.1016/j.radonc.2005.03.003
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Berthold DR, 2005, J CLIN ONCOL, V23, P8247, DOI 10.1200/JCO.2005.03.1435
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Burch PA, 2000, CLIN CANCER RES, V6, P2175
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140 6736(10)61389 X
   Dreicer R, 2010, J CLIN ONCOL S, V28, p254s
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Fong L, 2008, J CLIN ONCOL, V26, P5275, DOI 10.1200/JCO.2008.17.8954
   Goldstein NS, 2002, AM J CLIN PATHOL, V117, P471, DOI 10.1309/G6PR Y774 X738 FG2K
   Higano CS, 2009, CANCER AM CANCER SOC, V115, P3670, DOI 10.1002/cncr.24429
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Jarman M, 1998, J MED CHEM, V41, P5375, DOI 10.1021/jm981017j
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Kantoff PW, 2010, J CLIN ONCOL, V28, P1099, DOI 10.1200/JCO.2009.25.0597
   Kelly WK, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.18_suppl.lba4511
   Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742 1241.2011.02799.x
   Massard C, 2011, CLIN CANCER RES, V17, P3876, DOI 10.1158/1078 0432.CCR 10 2815
   O'Day SJ, 2007, CANCER AM CANCER SOC, V110, P2614, DOI 10.1002/cncr.23086
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   POTTER GA, 1995, J MED CHEM, V38, P2463, DOI 10.1021/jm00013a022
   Robert C, 2009, ONCOLOGIST, V14, P848, DOI 10.1634/theoncologist.2009 0028
   Rosen LS, 2001, CANCER J, V7, P377
   Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
   Siegel R, 2013, CA CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Small EJ, 2000, J CLIN ONCOL, V18, P3894, DOI 10.1200/JCO.2000.18.23.3894
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175
   Weber J, 2009, CANCER IMMUNOL IMMUN, V58, P823, DOI 10.1007/s00262 008 0653 8
NR 40
TC 11
Z9 15
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1073 2748
J9 CANCER CONTROL
JI Cancer Control
PD JUL
PY 2013
VL 20
IS 3
BP 181
EP 187
DI 10.1177/107327481302000306
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 178WZ
UT WOS:000321479400006
PM 23811702
DA 2025 08 17
ER

PT J
AU Morgan, GJ
   Davies, FE
   Gregory, WM
   Szubert, AJ
   Bell, SE
   Drayson, MT
   Owen, RG
   Ashcroft, AJ
   Jackson, GH
   Child, JA
AF Morgan, Gareth J.
   Davies, Faith E.
   Gregory, Walter M.
   Szubert, Alex J.
   Bell, Sue E.
   Drayson, Mark T.
   Owen, Roger G.
   Ashcroft, A. John
   Jackson, Graham H.
   Child, J. Anthony
CA Natl Canc Res Inst Haematological
TI Effects of induction and maintenance plus long term bisphosphonates on
   bone disease in patients with multiple myeloma: the Medical Research
   Council Myeloma IX Trial
SO BLOOD
LA English
DT Article
ID RANDOMIZED TRIAL; SKELETAL MORBIDITY; ZOLEDRONIC ACID; CLODRONIC ACID;
   THALIDOMIDE; THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIAGNOSIS
AB The Medical Research Council Myeloma IX Trial (ISRCTNG8454111) examined traditional and thalidomide based induction and maintenance regimens and IV zoledronic acid (ZOL) and oral clodronate (CLO) in 1960 patients with newly diagnosed multiple myeloma. Overall survival (OS) and skeletal related event (SRE) data have been reported for the overall trial population. The present analysis investigated optimal therapy regimens for different patient populations in Myeloma IX. Patients were assigned to intensive or nonintensive treatment pathways and randomized to induction cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) versus cyclophosphamide, thalidomide, and dexamethasone (CTD; intensive) or melphalan and prednisolone versus attenuated oral CTD (CTDa; nonintensive). Patients were also randomized to ZOL or CLO. In the nonintensive pathway, CTDa produced better responses and lower SRE rates than melphalan and prednisolone. ZOL improved OS compared with CLO independently of sex, stage, or myeloma subtype, most profoundly in patients with baseline bone disease or other SREs. In patients treated for >= 2 years, ZOL improved OS compared with CLO from randomization (median not reached for either; P = .02) and also from first on study disease progression (median, 34 months for ZOL vs 27 months for CLO; P = .03). Thalidomide containing regimens had better efficacy than traditional regimens, and ZOL demonstrated greater benefits than CLO. (Blood. 2012;119(23):5374 5383)
C1 [Morgan, Gareth J.] Royal Marsden Natl Hlth Serv Fdn Trust, Sect Haematooncol, Inst Canc Res, London SM2 5NG, Surrey, England.
   [Gregory, Walter M.; Szubert, Alex J.; Bell, Sue E.; Child, J. Anthony] Univ Leeds, Clin Trials Res Unit, Leeds, W Yorkshire, England.
   [Drayson, Mark T.] Univ Birmingham, Birmingham, W Midlands, England.
   [Owen, Roger G.] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England.
   [Ashcroft, A. John] Mid Yorkshire Hosp Natl Hlth Serv Trust, Wakefield, England.
   [Jackson, Graham H.] Univ Newcastle, Newcastle Upon Tyne, Tyne & Wear, England.
C3 University of London; Institute of Cancer Research   UK; Royal Marsden
   NHS Foundation Trust; University of Leeds; University of Birmingham;
   Saint James's University Hospital; Newcastle University   UK
RP Morgan, GJ (通讯作者)，Royal Marsden Natl Hlth Serv Fdn Trust, Sect Haematooncol, Inst Canc Res, Brookes Lawley Bldg,15 Cotswold Rd, London SM2 5NG, Surrey, England.
EM gareth.morgan@icr.ac.uk
RI Jackson, Graham/GMW 7638 2022; Morgan, Gareth/G 3603 2010
OI Drayson, Mark/0000 0002 1528 7564; Davies, Faith/0000 0002 3971 2393; el
   haj, mohamad/0000 0001 7635 7557; Bell, Sue/0000 0003 1494 980X; morgan,
   gareth/0000 0002 4271 6360
FU MRC; Biomedical Research Center at the Royal Marsden Hospital; Leukaemia
   & Lymphoma Research; Novartis; Schering Health Care; Chugai; Pharmion;
   Celgene; Ortho Biotech; OrthoBiotech; MRC [G0100132] Funding Source:
   UKRI; Medical Research Council [G0100132] Funding Source: researchfish
FX Financial support for the MRC Myeloma IX trial and linked studies was
   obtained from the MRC, the Biomedical Research Center at the Royal
   Marsden Hospital, and Leukaemia & Lymphoma Research, with additional
   funding in the form of unrestricted educational grants from Novartis,
   Schering Health Care, Chugai, Pharmion, Celgene, and Ortho Biotech,
   mainly to support trial coordination and laboratory studies. Financial
   support for medical editorial assistance was provided by Novartis.G.J.M.
   has participated in advisory boards for, received payment for lectures
   and development of educational presentations from, and received travel
   support from Celgene, Novartis, Merck, and Johnson & Johnson. F.E.D. has
   participated in advisory boards and spoken at meetings for Celgene,
   Ortho Biotech, and Novartis and has received travel support to attend
   meetings from Celgene and Ortho Biotech. R.G.O. has received speaker's
   fees and travel support from Celgene and Ortho Biotech to attend
   scientific meetings. G.H.J. has received honoraria from Celgene and
   Janssen Cilag for speaking at educational meetings. J.A.C. has received
   honoraria and travel support from SAN (Science Agency and Network) for
   presentations that included aspects of results from the MRC Myeloma IX
   trial. The Clinical Trials Research Unit, University of Leeds, Leeds,
   United Kingdom (W.M.G., A.J.S., and S.E.B.), and the Mid Yorkshire
   Hospitals National Health Service Trust, Wakefield, United Kingdom
   (A.J.A.), received support from Celgene and OrthoBiotech for
   investigator travel to meetings for this study. M.T.D. declares no
   competing financial interests.
CR ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976
   [Anonymous], 2010, Blood, DOI DOI 10.1182/BLOOD.V116.21.3028.3028
   [Anonymous], NCCN CLIN PRACT GUID
   Bird JM, 2011, BRIT J HAEMATOL, V154, P32, DOI 10.1111/j.1365 2141.2011.08573.x
   Brenner H, 2009, HAEMATOL HEMATOL J, V94, P270, DOI 10.3324/haematol.13782
   Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284
   Durie BGM, 2007, MAYO CLIN PROC, V82, P516, DOI 10.4065/82.4.516
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   Lacy MQ, 2006, MAYO CLIN PROC, V81, P1047, DOI 10.4065/81.8.1047
   McCloskey EV, 2001, BRIT J HAEMATOL, V113, P1035, DOI 10.1046/j.1365 2141.2001.02851.x
   McCloskey EV, 1998, BRIT J HAEMATOL, V100, P317
   Morgan GJ, 2012, HAEMATOL HEMATOL J, V97, P442, DOI 10.3324/haematol.2011.043372
   Morgan GJ, 2012, BLOOD, V119, P7, DOI 10.1182/blood 2011 06 357038
   Morgan GJ, 2011, BLOOD, V118, P1231, DOI 10.1182/blood 2011 02 338665
   Morgan GJ, 2011, LANCET ONCOL, V12, P743, DOI 10.1016/S1470 2045(11)70157 7
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Spencer Andrew, 2008, BMC Clin Pharmacol, V8, P2, DOI 10.1186/1472 6904 8 2
   Van Bennekom CM, 2008, 50 AM SOC HEM ANN M
   Weitzman R, 2007, CRIT REV ONCOL HEMAT, V62, P148, DOI 10.1016/j.critrevonc.2006.12.005
   Wu P, 2010, 52 AM SOC HEM ANN M
NR 21
TC 101
Z9 106
U1 0
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD JUN 7
PY 2012
VL 119
IS 23
BP 5374
EP 5383
DI 10.1182/blood 2011 11 392522
PG 10
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 987BM
UT WOS:000307391400011
PM 22498739
OA Bronze
DA 2025 08 17
ER

PT J
AU Nishiyama, H
   Inoue, T
   Koizumi, Y
   Kobayashi, Y
   Kitamura, H
   Yamamoto, K
   Takeda, T
   Yamamoto, T
   Yamamoto, R
   Matsubara, T
   Hoshino, J
   Yanagita, M
AF Nishiyama, Hiroyuki
   Inoue, Takamitsu
   Koizumi, Yuichi
   Kobayashi, Yusuke
   Kitamura, Hiroshi
   Yamamoto, Kazuhiro
   Takeda, Takashi
   Yamamoto, Takehito
   Yamamoto, Ryohei
   Matsubara, Takeshi
   Hoshino, Junichi
   Yanagita, Motoko
TI Chapter 2:indications and dosing of anticancer drug therapy in patients
   with impaired kidney function, from clinical practice guidelines for the
   management of kidney injury during anticancer drug therapy 2022
SO INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
DE Anticancer drug therapy; Chronic kidney disease; Hemodialysis; Kidney
   transplant
ID ADULT CANCER PATIENTS; RENAL FUNCTION; AMERICAN SOCIETY; ZOLEDRONIC
   ACID; PHASE I; IMMUNOSUPPRESSION; EVEROLIMUS; DENOSUMAB; DISEASE;
   TRANSPLANTATION
AB This comprehensive review discusses the dosing strategies of cancer treatment drugs for patients with impaired kidney function, specifically those with chronic kidney disease (CKD), undergoing hemodialysis, and kidney transplant recipients. CKD patients often necessitate dose adjustments of chemotherapeutic agents, e.g., platinum preparations, pyrimidine fluoride antimetabolites, antifolate agents, molecularly targeted agents, and bone modifying agents, to prevent drug accumulation and toxicity due to diminished renal clearance of the administered drugs and their metabolites. In hemodialysis patients, factors such as drug removal from hemodialysis and altered pharmacokinetics demand careful optimization of anticancer drug therapy, including dose adjustment and timing of administration. While free cisplatin is removed by hemodialysis, most of the tissue  and protein bound cisplatin remains in the body and rebound cisplatin elevations are observed after hemodialysis. It is not recommended hemodialysis for drug removal, regardless of timing. Kidney transplant patients encounter unique challenges in cancer treatment, as maintaining the balance between reduction of immunosuppression, switching to mTOR inhibitors, and considering potential drug interactions with chemotherapeutic agents and immunosuppressants are crucial for preventing graft rejection and achieving optimal oncologic outcomes. The review underscores the importance of personalized, patient centric approaches to anticancer drug therapy in patients with impaired kidney function.
C1 [Nishiyama, Hiroyuki] Univ Tsukuba, Fac Med, Dept Urol, Ibaraki, Japan.
   [Inoue, Takamitsu] Int Univ Hlth, Dept Renal & Urol Surg, Chiba, Japan.
   [Koizumi, Yuichi] Seichokai Fuchu Hosp, Dept Pharm, Izumi, Japan.
   [Kobayashi, Yusuke; Takeda, Takashi] Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan.
   [Kitamura, Hiroshi] Univ Toyama, Fac Med, Dept Urol, Toyama, Japan.
   [Yamamoto, Kazuhiro] Kobe Univ Hosp, Dept Pharm, Kobe, Japan.
   [Yamamoto, Takehito] Univ Tokyo Hosp, Dept Pharm, Tokyo, Japan.
   [Yamamoto, Ryohei] Akita Univ, Grad Sch Med, Dept Urol, Akita, Japan.
   [Matsubara, Takeshi; Yanagita, Motoko] Kyoto Univ, Grad Sch Med, Dept Nephrol, Kyoto, Japan.
   [Hoshino, Junichi] Tokyo Womens Med Univ, Dept Nephrol, Tokyo, Japan.
   [Yanagita, Motoko] Kyoto Univ, Inst Adv Study Human Biol ASHBi, Kyoto, Japan.
C3 University of Tsukuba; Keio University; University of Toyama; Kobe
   University; University of Tokyo; Akita University; Kyoto University;
   Tokyo Women's Medical University; Kyoto University
RP Nishiyama, H (通讯作者)，Univ Tsukuba, Fac Med, Dept Urol, Ibaraki, Japan.
EM nishiuro@md.tsukuba.ac.jp
RI ; Takeda, Takashi/AAB 1391 2019; Yanagita, Motoko/AAJ 7731 2021; Inoue,
   Takamitsu/H 8165 2019
OI Inoue, Takamitsu/0000 0002 1362 4344; Yanagita,
   Motoko/0000 0002 0339 9008; 
FU Grants in Aid for Scientific Research [23KK0159, 22K08350] Funding
   Source: KAKEN
CR Agarwal M, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912 018 0708 8
   Anderson K, 2018, J CLIN ONCOL, V36, P812, DOI 10.1200/JCO.2017.76.6402
   Ando Y, 2023, INT J CLIN ONCOL
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Booka E, 2016, GASTRIC CANCER, V19, P876, DOI 10.1007/s10120 015 0536 6
   CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748
   CHABNER BA, 1973, J CLIN INVEST, V52, P1804, DOI 10.1172/JCI107362
   Chang HM, 2017, J AM COLL CARDIOL, V70, P2552, DOI [10.1016/j.jacc.2017.09.1095, 10.1016/j.jacc.2017.09.1096]
   Chen JC, 2021, INT J CLIN PHARM NET, V43, P2, DOI 10.1007/s11096 020 01105 1
   Cheungpasitporn W, 2015, TRANSPLANTATION, V99, P2382, DOI 10.1097/TP.0000000000000750
   Chiurchiu C, 2010, TRANSPL P, V42, P277, DOI 10.1016/j.transproceed.2009.11.017
   Dave V, 2015, AM J NEPHROL, V41, P129, DOI 10.1159/000380960
   Dimopoulos MA, 2016, J CLIN ONCOL, V34, P1544, DOI 10.1200/JCO.2015.65.0044
   Eriksson T, 2003, J PHARM PHARMACOL, V55, P1701, DOI 10.1211/0022357022241
   European Medicines Agency, 2016, EV PHARM MED PROD PA
   Fujita K, 2019, CURR DRUG METAB, V20, P361, DOI 10.2174/1389200220666190402143125
   GIUSTI DL, 1973, DRUG INTEL CLIN PHAR, V7, P382, DOI 10.1177/106002807300700902
   Gomez Camarero J, 2007, TRANSPLANTATION, V84, P786, DOI 10.1097/01.tp.0000280549.93403.dd
   González E, 2009, TRANSPL P, V41, P2332, DOI 10.1016/j.transproceed.2009.06.040
   Gudowska Sawczuk M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228582
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Holdaas H, 2016, J TRANSPLANT, V2016, DOI 10.1155/2016/4369574
   Hope CM, 2015, TRANSPL INT, V28, P1332, DOI 10.1111/tri.12638
   Jamal SA, 2011, J BONE MINER RES, V26, P1829, DOI 10.1002/jbmr.403
   Janus N, 2013, ANN ONCOL, V24, P501, DOI 10.1093/annonc/mds344
   Kamath Amrita V, 2016, Drug Discov Today Technol, V21 22, P75, DOI 10.1016/j.ddtec.2016.09.004
   Kasherman L, 2021, CURR ONCOL, V28, P661, DOI 10.3390/curroncol28010064
   Krens SD, 2019, LANCET ONCOL, V20, pE200, DOI 10.1016/S1470 2045(19)30145 7
   Krisl JC, 2017, AM J TRANSPLANT, V17, P1974, DOI 10.1111/ajt.14238
   Kunizawa K, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 59143 8
   Labaki C, 2020, CRIT REV ONCOL HEMAT, V150, DOI 10.1016/j.critrevonc.2020.102947
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Rafael PM, 2016, NEFROLOGIA, V36, P446, DOI 10.1016/j.nefro.2016.02.007
   Müsri FY, 2015, J CANCER RES THER, V11, P1018, DOI 10.4103/0973 1482.168996
   Nguyen LS, 2021, EUR J CANCER, V148, P36, DOI 10.1016/j.ejca.2021.01.038
   Nishikawa Y, 2017, CANCER CHEMOTH PHARM, V79, P629, DOI 10.1007/s00280 017 3249 1
   Nolin TD, 2008, CLIN PHARMACOL THER, V83, P898, DOI 10.1038/clpt.2008.59
   Otley CC, 2006, BRIT J DERMATOL, V154, P395, DOI 10.1111/j.1365 2133.2005.07087.x
   Porta C, 2020, KIDNEY INT, V98, P1108, DOI 10.1016/j.kint.2020.06.046
   Rinaldi DA, 1999, CANCER CHEMOTH PHARM, V44, P372, DOI 10.1007/s002800050992
   Saleh L, 2016, CURR OPIN NEPHROL HY, V25, P94, DOI 10.1097/MNH.0000000000000197
   Sofue N., 2016, IRYO YAKUGAKU, V42, P381, DOI 10.5649/jjphcs.42.381
   Sparreboom A, 2003, DRUG RESIST UPDATE, V6, P71, DOI 10.1016/S1368 7646(03)00005 0
   TAIHO Phamaceutical Co. Ltd, TS 1 GUID PROP US
   Takeuchi M, 2021, CANCER SCI, V112, P751, DOI 10.1111/cas.14758
   Takimoto CH, 2003, J CLIN ONCOL, V21, P2664, DOI 10.1200/JCO.2003.11.015
   Takimoto CH, 2007, CLIN CANCER RES, V13, P4832, DOI 10.1158/1078 0432.CCR 07 0475
   The Japanese society of Nephrology and pharmacotherapy, JAPANESE J NEPHROLOG, V10, P216
   Thimonier E, 2014, CLIN TRANSPLANT, V28, P1339, DOI 10.1111/ctr.12430
   Tsai DE, 2001, TRANSPLANTATION, V71, P1076, DOI 10.1097/00007890 200104270 00012
   Umemura S, 2019, HYPERTENS RES, V42, P1235, DOI 10.1038/s41440 019 0284 9
   US Food and Drug Administration Center for Drug Evaluation and Research, 2020, Pharmacokinetics in patients with impaired renal function study design, data analysis, and impact on dosing.
   Velenosi TJ, 2014, EXPERT OPIN DRUG MET, V10, P1131, DOI 10.1517/17425255.2014.931371
   Venook AP, 2000, J CLIN ONCOL, V18, P2780, DOI 10.1200/JCO.2000.18.14.2780
   Wiebe S, 2017, EUR J DRUG METAB PH, V42, P461, DOI 10.1007/s13318 016 0359 9
   Wilson LM, 2017, ANN INTERN MED, V166, P649, DOI 10.7326/M16 2752
   Zamorano JL, 2016, EUR HEART J, V37, P2768, DOI [10.1093/eurheartj/ehw211, 10.1002/ejhf.654]
   Zhao BT, 2016, BRIT J CLIN PHARMACO, V82, P696, DOI 10.1111/bcp.12988
NR 59
TC 3
Z9 7
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 1341 9625
EI 1437 7772
J9 INT J CLIN ONCOL
JI Int. J. Clin. Oncol.
PD OCT
PY 2023
VL 28
IS 10
BP 1298
EP 1314
DI 10.1007/s10147 023 02377 z
EA AUG 2023
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA T0YC2
UT WOS:001046945900001
PM 37572198
DA 2025 08 17
ER

PT J
AU Uesato, N
   Kitagawa, Y
   Matsuo, Y
   Miyagawa, N
   Inagaki, K
   Kakefuda, R
   Yamaguchi, T
   Hata, T
   Ikegashira, K
   Matsushita, M
AF Uesato, Naofumi
   Kitagawa, Yoshihiro
   Matsuo, Yushi
   Miyagawa, Naoki
   Inagaki, Koji
   Kakefuda, Reina
   Yamaguchi, Takayuki
   Hata, Takahiro
   Ikegashira, Kazutaka
   Matsushita, Mutsuyoshi
TI Therapeutic Effect of Colony Stimulating Factor 1 Receptor Kinase
   Inhibitor, JTE 952, on Methotrexate Refractory Pathology in a Rat Model
   of Rheumatoid Arthritis
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE JTE 952; colony stimulating factor 1 receptor; joint damage; bone
   erosion; pain; adjuvant induced arthritis
ID ADJUVANT INDUCED ARTHRITIS; INTERLEUKIN 34; BONE; MECHANISMS;
   EXPRESSION; SYNOVITIS; CSF 1
AB Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation and the destruction of bone and cartilage in affected joints. One of the unmet medical needs in the treatment of RA is to effectively prevent the structural destruction of joints, especially bone, which progresses because of resistance to conventional drugs that mainly have anti inflammatory effects, and directly leads to a decline in the QOL of patients. We previously developed a novel and orally available type II kinase inhibitor of colony stimulating factor 1 receptor (CSF1R), JTE 952. CSF1R is specifically expressed by monocytic lineage cells, including bone resorbing osteoclasts, and is important for promoting the differentiation and proliferation of osteoclasts. In the present study, we investigated the therapeutic effect of JTE 952 on methotrexate (MTX) refractory joint destruction in a clinically established adjuvant induced arthritis rat model. JTE 952 did not suppress paw swelling under inflammatory conditions, but it inhibited the destruction of joint structural components including bone and cartilage in the inflamed joints. In addition, decreased range of joint motion and mechanical hyperalgesia after disease onset were suppressed by JTE 952. These results suggest that JTE 952 is expected to prevent the progression of the structural destruction of joints and its associated effects on joint motion and pain by inhibiting CSF1/CSF1R signaling in RA pathology, which is resistant to conventional disease modifying anti rheumatic drugs such as MTX.
C1 [Uesato, Naofumi; Kitagawa, Yoshihiro; Matsuo, Yushi; Miyagawa, Naoki; Inagaki, Koji; Kakefuda, Reina; Yamaguchi, Takayuki; Hata, Takahiro; Ikegashira, Kazutaka; Matsushita, Mutsuyoshi] Japan Tobacco Inc, Cent Pharmaceut Res Inst, 1 1 Murasaki Cho, Takatsuki, Osaka 5691125, Japan.
   [Matsuo, Yushi] Japan Tobacco Inc, Cent Pharmaceut Res Inst, Toxicol Res Labs, 1 13 2 Fukuura,Kanazawa Ku, Yokohama 2360004, Japan.
C3 Japan Tobacco Inc.; Japan Tobacco Inc.
RP Uesato, N (通讯作者)，Japan Tobacco Inc, Cent Pharmaceut Res Inst, 1 1 Murasaki Cho, Takatsuki, Osaka 5691125, Japan.
EM naofumi.uesato@jt.com
CR Barsante MM, 2008, BRIT J PHARMACOL, V153, P992, DOI 10.1038/sj.bjp.0707462
   Chemel M, 2012, ANN RHEUM DIS, V71, P150, DOI 10.1136/annrheumdis 2011 200096
   Chitu V, 2006, CURR OPIN IMMUNOL, V18, P39, DOI 10.1016/j.coi.2005.11.006
   Choudhary N, 2018, IMMUNOPHARM IMMUNOT, V40, P193, DOI 10.1080/08923973.2018.1434793
   Doan T, 2005, J CLIN PHARMACOL, V45, P751, DOI 10.1177/0091270005277938
   Garcia S, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 0973 6
   Granger B, 2016, RMD OPEN, V2, DOI 10.1136/rmdopen 2016 000245
   Guo QY, 2018, BAMBOO SILK, V1, P1, DOI [10.1163/24689246 00101001, 10.1038/s41413 018 0016 9]
   Hashmi JA, 2010, INFLAMM RES, V59, P667, DOI 10.1007/s00011 010 0179 3
   Hu X, 2019, CLIN EXP IMMUNOL, V195, P237, DOI 10.1111/cei.13220
   Ikegashira K, 2019, BIOORG MED CHEM LETT, V29, P873, DOI 10.1016/j.bmcl.2019.02.006
   Kalyoncu U, 2009, ANN RHEUM DIS, V68, P183, DOI 10.1136/ard.2007.084848
   Kawaji H, 1995, Nihon Ika Daigaku Zasshi, V62, P260
   King TJ, 2012, AM J PATHOL, V181, P121, DOI 10.1016/j.ajpath.2012.03.037
   Komano Y, 2011, J RHEUMATOL, V38, P1258, DOI 10.3899/jrheum.101009
   Komatsu N, 2022, NAT REV RHEUMATOL, V18, P415, DOI 10.1038/s41584 022 00793 5
   Magari K, 2003, J RHEUMATOL, V30, P2193
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Moon SJ, 2013, J RHEUMATOL, V40, P1842, DOI 10.3899/jrheum.130356
   Mun SH, 2020, EXP MOL MED, V52, P1239
   Myasoedova E, 2010, ARTHRITIS RHEUM US, V62, P1576, DOI 10.1002/art.27425
   PANAYI GS, 1992, ARTHRITIS RHEUM US, V35, P729, DOI 10.1002/art.1780350702
   Pezet S, 2001, PAIN, V90, P113, DOI 10.1016/S0304 3959(00)00393 6
   Pixley FJ, 2004, TRENDS CELL BIOL, V14, P628, DOI 10.1016/j.tcb.2004.09.016
   Ramiro S, 2017, ANN RHEUM DIS, V76, P1093, DOI 10.1136/annrheumdis 2016 210708
   RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409
   Shim JH, 2018, CALCIFIED TISSUE INT, V102, P533, DOI 10.1007/s00223 017 0373 1
   SMITHOLIVER T, 1993, CYTOKINE, V5, P298, DOI 10.1016/1043 4666(93)90060 I
   Smolen JS, 2006, ARTHRITIS RHEUM US, V54, P702, DOI 10.1002/art.21678
   Sousa KH, 2007, NURS RES, V56, P434, DOI 10.1097/01.NNR.0000299850.29558.db
   Strauss G, 2002, CLIN EXP IMMUNOL, V128, P255, DOI 10.1046/j.1365 2249.2002.01777.x
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tanimoto A, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0802 0
   Uesato N, 2020, BIOL PHARM BULL, V43, P1884, DOI 10.1248/bpb.b20 00517
   Uesato N, 2020, BIOL PHARM BULL, V43, P325, DOI 10.1248/bpb.b19 00694
   VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117
   Wei SW, 2010, J LEUKOCYTE BIOL, V88, P495, DOI 10.1189/jlb.1209822
   Winthrop KL, 2020, ANN RHEUM DIS, V79, P88, DOI 10.1136/annrheumdis 2019 216151
   Xiang CG, 2023, PHARMACOL RES, V187, DOI 10.1016/j.phrs.2022.106566
   Yamaguchi T, 2012, INFLAMM RES, V61, P445, DOI 10.1007/s00011 011 0431 5
   Yokota K, 2021, ARTHRITIS RHEUMATOL, V73, P1145, DOI 10.1002/art.41666
   Yoshihara Y, 2000, ANN RHEUM DIS, V59, P455, DOI 10.1136/ard.59.6.455
NR 42
TC 1
Z9 1
U1 0
U2 0
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
EI 1347 5215
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD SEP
PY 2023
VL 46
IS 9
BP 1223
EP 1230
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA W1IR4
UT WOS:001089238900010
PM 37661402
OA gold
DA 2025 08 17
ER

PT J
AU Lin, Z
   Navarro, VP
   Kempeinen, KM
   Franco, LM
   Jin, QM
   Sugai, JV
   Giannobile, WV
AF Lin, Zhao
   Navarro, Valeria Pontelli
   Kempeinen, Kathryn M.
   Franco, Leo M.
   Jin, Qiming
   Sugai, James V.
   Giannobile, William V.
TI LMP1 regulates periodontal ligament progenitor cell proliferation and
   differentiation
SO BONE
LA English
DT Article
DE LMP1; Periodontal diseases; Tissue engineering; Signal transduction;
   TGF beta 1
ID BONE FORMATION; GENE TRANSFER; TRANSFORMING GROWTH FACTOR BETA 1;
   ADAPTER PROTEIN; BETA; ENIGMA; EXPRESSION; ACTIVATION; PATHWAYS; THERAPY
AB LMP1 is an intracellular scaffold protein that contains a PDZ domain and three LIM domains. LMP1 has multiple functions including regulating mesenchymal stem cell (MSC) osteogenesis. Gene delivery of LMP1 induces bone formation in vivo in heterotopic and orthotopic sites. However, little is known about the physiological function and gene regulatory mechanisms of LMP1 in MSCs at the molecular level. Periodontal ligament (PDL) cells are a unique progenitor cell population that can differentiate into multiple cell types, including osteoblasts, adipocytes, or chondrocytes. This study sought to determine the physiological function and gene regulatory mechanisms of LMP1 in PDL cells at the molecular level. We show that LMP1 is upregulated in early stage of PDL cell osteogenic differentiation. Stable gene knockdown of LMP1 by shRNA inhibits DNA synthesis and corresponding cell proliferation in PDL cells, and further leads to decreased mineralization in vitro. Overexpression of LMP1 increases cell proliferation, and PDZ and ww interacting domains are not sufficient to mediate this effect. Further, we found that in PDL cells, LMP1 is a downstream target gene of TGF beta 1 that is an early signal critical in preosteoblast proliferation and differentiation. TGF beta 1 stimulates PDL cell proliferation, however, this effect is compromised when LMP1 is knocked down. We further identified that the activation of TAK1 JNK/p38 kinase cascade is involved in the LMP1 gene regulation by TGF beta 1. We conclude that LMP1 is a downstream gene of TGF beta 1, involved in PDL cell proliferation. Our findings advance the understanding of the physiological function of LMP1 and define a regulatory mechanism of LMP1 in PDL progenitor cells and other MSCs. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Lin, Zhao; Navarro, Valeria Pontelli; Kempeinen, Kathryn M.; Franco, Leo M.; Jin, Qiming; Sugai, James V.; Giannobile, William V.] Univ Michigan, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [Giannobile, William V.] Univ Michigan, Dept Biomed Engn, Coll Engn, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Giannobile, WV (通讯作者)，Univ Michigan, Dept Periodont & Oral Med, 1011 N Univ Ave,Room 3397, Ann Arbor, MI 48109 USA.
EM william.giannobile@umich.edu
OI Giannobile, William/0000 0002 7102 9746
FU NIH/NIDCR [DE13397]; ITI Foundation; Horace H. Rackham School of
   Graduate Studies, University of Michigan; FAPESP
FX This work is funded by NIH/NIDCR DE13397 and ITI Foundation to W.V.G.
   Z.L. is also funded by Predoctoral Fellowship from Horace H. Rackham
   School of Graduate Studies, University of Michigan. V.P.N. was funded by
   FAPESP.
CR Barrés R, 2005, EXP CELL RES, V308, P334, DOI 10.1016/j.yexcr.2005.05.008
   Barrès R, 2006, MOL ENDOCRINOL, V20, P2864, DOI 10.1210/me.2005 0455
   BECK LS, 1991, J BONE MINER RES, V6, P961
   Boden SD, 1998, SPINE, V23, P2486, DOI 10.1097/00007632 199812010 00003
   Boden SD, 1998, ENDOCRINOLOGY, V139, P5125, DOI 10.1210/en.139.12.5125
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298
   Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691
   Geiser AG, 1998, BONE, V23, P87, DOI 10.1016/S8756 3282(98)00078 7
   Gruber R, 2004, CLIN ORAL IMPLAN RES, V15, P575, DOI 10.1111/j.1600 0501.2004.01062.x
   Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Kanaan RA, 2006, MED SCI MONITOR, V12, pRA164
   Lattanzi W, 2008, GENE THER, V15, P1330, DOI 10.1038/gt.2008.116
   Lee MK, 2007, EMBO J, V26, P3957, DOI 10.1038/sj.emboj.7601818
   Liu Y, 2008, J BONE MINER RES, V23, pS382
   Liu Y, 2008, STEM CELLS, V26, P1065, DOI 10.1634/stemcells.2007 0734
   Liu YS, 2002, J BONE MINER RES, V17, P406, DOI 10.1359/jbmr.2002.17.3.406
   Liu Z, 1999, HISTOL HISTOPATHOL, V14, P587, DOI 10.14670/HH 14.587
   MACKIE EJ, 1990, BONE, V11, P295, DOI 10.1016/8756 3282(90)90083 B
   Mao JJ, 2006, J DENT RES, V85, P966, DOI 10.1177/154405910608501101
   Massagué J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033
   Minamide A, 2003, J BONE JOINT SURG AM, V85A, P1030, DOI 10.2106/00004623 200306000 00007
   Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554
   Ott EB, 2007, DEV DYNAM, V236, P3144, DOI 10.1002/dvdy.21346
   Pola E, 2004, GENE THER, V11, P683, DOI 10.1038/sj.gt.3302207
   Ramseier Christoph A, 2006, Dent Clin North Am, V50, P245, DOI 10.1016/j.cden.2005.12.001
   Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Sonoyama W, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000079
   Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780
   Strohbach CA, 2008, CALCIFIED TISSUE INT, V83, P202, DOI 10.1007/s00223 008 9163 0
   Tacheau C, 2008, J CELL PHYSIOL, V217, P759, DOI 10.1002/jcp.21551
   TAKEUCHI Y, 1995, J CELL PHYSIOL, V162, P315, DOI 10.1002/jcp.1041620303
   Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002
   Yoon ST, 2004, SPINE, V29, P2603, DOI 10.1097/01.brs.0000146103.94600.85
   Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814
   Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328
   Zhu Z, 2001, J DENT RES, V80, P892, DOI 10.1177/00220345010800030901
NR 39
TC 24
Z9 26
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2010
VL 47
IS 1
BP 55
EP 64
DI 10.1016/j.bone.2010.03.013
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 615QN
UT WOS:000279150400007
PM 20348040
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Hald, JD
   Keerie, C
   Weir, CJ
   Javaid, MK
   Lam, W
   Osborne, P
   Walsh, J
   Langdahl, BL
   Ralston, SH
AF Hald, Jannie D.
   Keerie, Catriona
   Weir, Christopher J.
   Javaid, Muhammad K.
   Lam, Wayne
   Osborne, Patricia
   Walsh, Jennifer
   Langdahl, Bente L.
   Ralston, Stuart H.
TI Protocol of a randomised trial of teriparatide followed by zoledronic
   acid to reduce fracture risk in adults with osteogenesis imperfecta
SO BMJ OPEN
LA English
DT Article
DE randomized controlled trial; internal medicine; rheumatology; calcium &
   bone
ID BONE; MINERALIZATION; CHILDREN
AB Introduction Osteogenesis imperfecta (OI) is a rare genetic disease associated with multiple fractures throughout life. It is often treated with osteoporosis medications but their effectiveness at preventing fractures is unknown. The Treatment of Osteogenesis Imperfecta with Parathyroid Hormone and Zoledronic Acid trial will determine if therapy with teriparatide (TPTD) followed by zoledronic acid (ZA) can reduce the risk of clinical fractures in OI.
   Methods and analysis Individuals aged >= 18 years with a clinical diagnosis of OI are eligible to take part. At baseline, participants will undergo a spine X ray, and have bone mineral density (BMD) measured by dual energy X ray absorptiometry (DXA) at the spine and hip. Information on previous fractures and previous bone targeted treatments will be collected. Questionnaires will be completed to assess pain and other aspects of health related quality of life (HRQoL). Participants will be randomised to receive a 2 year course of TPTD injections 20 mu g daily followed by a single intravenous infusion of 5mg ZA, or to receive standard care, which will exclude the use of bone anabolic drugs. Participants will be followed up annually, have a repeat DXA at 2 years and at the end of study. Spine X rays will be repeated at the end of study. The duration of follow up will range between 2 and 8years. The primary endpoint will be new clinical fractures confirmed by X ray or other imaging. Secondary endpoints will include participant reported fractures, BMD and changes in pain and HRQoL.
   Ethics and dissemination The study received ethical approval in December 2016. Following completion of the trial, a manuscript will be submitted to a peer reviewed journal. The results will inform clinical practice by determining if TPTD/ZA can reduce the risk of fractures in OI compared with standard care.
C1 [Hald, Jannie D.; Langdahl, Bente L.] Aarhus Univ, Dept Endocrinol & Internal Med, Aarhus, Denmark.
   [Keerie, Catriona; Weir, Christopher J.] Univ Edinburgh, Usher Inst, Edinburgh Clin Trials Unit, Edinburgh, Midlothian, Scotland.
   [Javaid, Muhammad K.] Univ Oxford, Oxford NIHR Musculoskeletal Biomed Res Unit, Oxford, England.
   [Lam, Wayne; Ralston, Stuart H.] Univ Edinburgh, Ctr Genom & Expt Med, Western Gen Hosp, Edinburgh, Midlothian, Scotland.
   [Osborne, Patricia] Brittle Bone Soc, Dundee, Scotland.
   [Walsh, Jennifer] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England.
C3 Aarhus University; University of Edinburgh; University of Oxford;
   University of Edinburgh; University of Sheffield
RP Ralston, SH (通讯作者)，Univ Edinburgh, Ctr Genom & Expt Med, Western Gen Hosp, Edinburgh, Midlothian, Scotland.
EM stuart.ralston@ed.ac.uk
OI Langdahl, Bente/0000 0002 8712 7199; Hald, Jannie
   Dahl/0000 0002 7907 3792; Weir, Christopher/0000 0002 6494 4903;
   Ralston, Stuart/0000 0002 2804 7586
FU Efficacy and Mechanism Evaluation (EME) Programme [EME 14/200/18]; UK
   Medical Research Council (MRC); National Institute of Health Research;
   National Institutes of Health Research (NIHR) [EME/14/200/18] Funding
   Source: National Institutes of Health Research (NIHR)
FX The study was funded by the Efficacy and Mechanism Evaluation (EME)
   Programme (reference EME 14/200/18) which is a partnership between the
   UK Medical Research Council (MRC) and the National Institute of Health
   Research. The teriparatide was kindly donated by Eli Lilly
   Pharmaceuticals. For the purpose of open access, the author has applied
   a Creative Commons Attribution (CC BY) licence to any author accepted
   manuscript version arising from this submission.
CR Adami S, 2003, J BONE MINER RES, V18, P126, DOI 10.1359/jbmr.2003.18.1.126
   Atkinson TM, 2010, PAIN MED, V11, P337, DOI 10.1111/j.1526 4637.2009.00774.x
   Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756 3282(00)00376 8
   Boyde A, 1999, CALCIFIED TISSUE INT, V64, P185, DOI 10.1007/s002239900600
   Braga V, 2004, BONE, V34, P1013, DOI 10.1016/j.bone.2004.02.023
   Bruce B, 2003, J RHEUMATOL, V30, P167
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165 1781(89)90047 4
   Dwan K, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005088.pub4
   Dwan K, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005088.pub3
   Forlino A, 2016, LANCET, V387, P1657, DOI 10.1016/S0140 6736(15)00728 X
   Fratzl Zelman N, 2010, BONE, V46, P820, DOI 10.1016/j.bone.2009.10.037
   Fratzl Zelman N, 2016, J CLIN ENDOCR METAB, V101, P3516, DOI 10.1210/jc.2016 1334
   Fratzl Zelman N, 2015, BONE, V73, P233, DOI 10.1016/j.bone.2014.12.023
   Fratzl Zelman N, 2014, BONE, V60, P122, DOI 10.1016/j.bone.2013.11.023
   Hald JD, 2015, J BONE MINER RES, V30, P929, DOI 10.1002/jbmr.2410
   Orwoll ES, 2014, J CLIN INVEST, V124, P491, DOI 10.1172/JCI71101
   Phillipi CA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005088.pub2
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Ralston SH, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00924
   Rauch F, 2000, BONE, V26, P581, DOI 10.1016/S8756 3282(00)00269 6
   Roschger P, 2008, CALCIFIED TISSUE INT, V82, P263, DOI 10.1007/s00223 008 9113 x
   Schulz KF, 2010, TRIALS, V11, DOI [10.1016/j.jclinepi.2010.03.004, 10.1186/1741 7015 8 18, 10.1016/j.jclinepi.2010.02.005, 10.1186/1745 6215 11 32, 10.1136/bmj.c332, 10.4103/0976 500X.72352, 10.1136/bmj.c869, 10.1016/j.ijsu.2011.10.001, 10.1097/AOG.0b013e3181d9d421]
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   Ware JE Jr, 1998, J CLIN EPIDEMIOL, V51, P903, DOI 10.1016/S0895 4356(98)00081 X
   Wekre LL, 2014, CLIN RESPIR J, V8, P437, DOI 10.1111/crj.12092
   Wekre Lena Lande, 2011, Arch Osteoporos, V6, P31, DOI 10.1007/s11657 011 0054 z
NR 26
TC 9
Z9 9
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044 6055
J9 BMJ OPEN
JI BMJ Open
PD NOV
PY 2023
VL 13
IS 11
AR e078164
DI 10.1136/bmjopen 2023 078164
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA KR3B3
UT WOS:001181643400067
PM 37993151
OA Green Published, Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Huang, CQ
   Li, RG
   Yang, CS
   Ding, R
   Li, QC
   Xie, DH
   Zhang, RK
   Qiu, YY
AF Huang, Caiqiang
   Li, Runguang
   Yang, Changsheng
   Ding, Rui
   Li, Qingchu
   Xie, Denghui
   Zhang, Rongkai
   Qiu, Yiyan
TI PAX8 AS1 knockdown facilitates cell growth and inactivates autophagy in
   osteoblasts via the miR 1252 5p/GNB1 axis in osteoporosis
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID OSTEOGENIC DIFFERENTIATION; BONE RESORPTION; APOPTOSIS; LOCALIZATION;
   INFLAMMATION; PATHWAY
AB Osteoporosis: An RNA molecule that suppresses bone building A recently identified regulatory RNA molecule contributes to osteoporosis by suppressing production of a protein that promotes survival of bone building osteoblast cells. These regulatory RNA molecules do not encode proteins, but instead regulate gene expression by binding and inactivating complementary RNA strands. Researchers led by Yiyan Qiu at Southern Medical University in Guangzhou, China, have now learned how one such RNA facilitates bone degeneration in osteoporosis. Qiu and colleagues show that this RNA interferes with the production of a protein that is essential to the metabolic health and survival of osteoblasts, promoting bone loss in a rat model of osteoporosis. Experimental techniques that selectively deplete this RNA help preserve the viability of the osteoblast population. This depletion could provide a useful approach for future drug development efforts.
   Osteoporosis (OP) is the most common systematic bone disorder among elderly individuals worldwide. Long noncoding RNAs (lncRNAs) are involved in biological processes in various human diseases. It has been previously revealed that PAX8 antisense RNA 1 (PAX8 AS1) is upregulated in OP. However, its molecular mechanism in OP remains unclear. Therefore, we specifically designed this study to determine the specific role of PAX8 AS1 in OP. We first established a rat model of OP and then detected PAX8 AS1 expression in the rats with RT qPCR. Next, to explore the biological function of PAX8 AS1 in osteoblasts, in vitro experiments, such as Cell Counting Kit 8 (CCK 8) assays, flow cytometry, western blotting and immunofluorescence (IF) staining, were conducted. Subsequently, we performed bioinformatic analysis and luciferase reporter assays to predict and identify the relationships between microRNA 1252 5p (miR 1252 5p) and both PAX8 AS1 and G protein subunit beta 1 (GNB1). Additionally, rescue assays in osteoblasts clarified the regulatory network of the PAX8 AS1/miR 1252 5p/GNB1 axis. Finally, in vivo loss of function studies verified the role of PAX8 AS1 in OP progression. The results illustrated that PAX8 AS1 was upregulated in the proximal tibia of OP rats. PAX8 AS1 silencing promoted the viability and inhibited the apoptosis and autophagy of osteoblasts. PAX8 AS1 interacted with miR 1252 5p. GNB1 was negatively regulated by miR 1252 5p. In addition, the impacts of PAX8 AS1 knockdown on osteoblasts were counteracted by GNB1 overexpression. PAX8 AS1 depletion suppressed OP progression by inhibiting apoptosis and autophagy in osteoblasts. In summary, PAX8 AS1 suppressed the viability and activated the autophagy of osteoblasts via the miR 1252 5p/GNB1 axis in OP.
C1 [Huang, Caiqiang; Yang, Changsheng; Ding, Rui; Li, Qingchu; Qiu, Yiyan] Southern Med Univ, Div Spine Surg, Sect 2,Dept Orthoped, Affiliated Hosp 3,Guangdong Prov Key Lab Bone & J, Guangzhou, Guangdong, Peoples R China.
   [Li, Runguang] Southern Med Univ, Div Foot & Ankle Surg, Dept Orthoped,Affiliated Hosp 3, Guangdong Prov Key Lab Bone & Joint Degenerat Dis, Guangzhou, Guangdong, Peoples R China.
   [Xie, Denghui; Zhang, Rongkai] Southern Med Univ, Div Joint Surg, Acad Orthoped Guangdong Prov,Dept Orthoped,Affili, Key Lab Bone & Joint Degenerat Dis Southern Med U, Guangzhou, Guangdong, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Southern Medical University   China
RP Qiu, YY (通讯作者)，Southern Med Univ, Div Spine Surg, Sect 2,Dept Orthoped, Affiliated Hosp 3,Guangdong Prov Key Lab Bone & J, Guangzhou, Guangdong, Peoples R China.
EM qiuyiy55@hotmail.com
RI DING, RUI/P 3018 2019
OI Runguang, Li/0000 0002 4703 7180
FU National Natural Science Foundation for Young Scientists of China
   [8180090642]; Natural Science Foundation of Guangdong Province, China
   [2020A151501711]
FX The authors thank all lab members involved in this study. This work was
   supported by the National Natural Science Foundation for Young
   Scientists of China (Grant No. 8180090642) and the Natural Science
   Foundation of Guangdong Province, China (Grant No. 2020A151501711).
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Rizzo ADB, 2019, J PEDIAT BRAZIL, V95, P567, DOI 10.1016/j.jped.2018.05.011
   Buencamino MCA, 2009, J WOMENS HEALTH, V18, P873, DOI 10.1089/jwh.2008.0897
   Chen K, 2014, HISTOCHEM CELL BIOL, V142, P285, DOI 10.1007/s00418 014 1194 1
   Cheng LX, 2018, J MOL CELL BIOL, V10, P130, DOI 10.1093/jmcb/mjy006
   Das S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098965
   Diemar SS, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 00715 6
   Fei JY, 2018, MICROBIOL SPECTR, V6, DOI 10.1128/microbiolspec.RWR 0024 2018
   Fei Q, 2018, INT J MOL MED, V41, P3537, DOI 10.3892/ijmm.2018.3575
   Florencio Silva R, 2017, REV ASSOC MED BRAS, V63, P173, DOI 10.1590/1806 9282.63.02.173
   FROST HM, 1990, ANAT RECORD, V226, P433, DOI 10.1002/ar.1092260405
   Fu L, 2019, J CELL MOL MED, V23, P7517, DOI 10.1111/jcmm.14620
   Gudenas BL, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34708 w
   He L, 2018, EPIGENOMICS UK, V10, P661, DOI 10.2217/epi 2017 0176
   He ZY, 2019, J CELL PHYSIOL, V234, P4627, DOI 10.1002/jcp.27260
   Huang BZ, 2019, J CELL BIOCHEM, V120, P19610, DOI 10.1002/jcb.29267
   Huang K, 2020, INT J CLIN EXP PATHO, V13, P1243
   Ji QB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08277 5
   Jiang M, 2019, J BONE MINER RES, V34, P361, DOI 10.1002/jbmr.3604
   Kanazawa I, 2017, ENDOCR J, V64, P1043, DOI 10.1507/endocrj.EJ17 0323
   Kemp JP, 2014, J BONE MINER RES, V29, P1015, DOI 10.1002/jbmr.2093
   Kim C, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2062384
   Kong F, 2019, BIOMED PHARMACOTHER, V109, P716, DOI 10.1016/j.biopha.2018.10.079
   Li M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0627 5
   Li Y, 2016, CELL CHEM BIOL, V23, P1325, DOI 10.1016/j.chembiol.2016.09.011
   Liu JW, 2019, DIGEST DIS SCI, V64, P1868, DOI 10.1007/s10620 019 05506 9
   Liu RG, 2020, NEUROSCI LETT, V731, DOI 10.1016/j.neulet.2020.135060
   Luo D, 2016, OSTEOPOROSIS INT, V27, P1093, DOI 10.1007/s00198 015 3325 5
   Mas Ponte D, 2017, RNA, V23, P1080, DOI 10.1261/rna.060814.117
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rivadeneira F, 2016, TRENDS ENDOCRIN MET, V27, P262, DOI 10.1016/j.tem.2016.03.006
   Saito Mitsuru, 2015, Clin Calcium, V25, P1301, DOI CliCa150913011306
   Sbrana FV, 2016, STEM CELL REV REP, V12, P621, DOI 10.1007/s12015 016 9690 4
   Shen Y, 2020, EUR REV MED PHARMACO, V24, P6864, DOI 10.26355/eurrev_202006_21676
   Shieh A, 2016, J CLIN ENDOCR METAB, V101, P2802, DOI 10.1210/jc.2015 4262
   Song N, 2017, CHEM BIOL INTERACT, V261, P11, DOI 10.1016/j.cbi.2016.10.020
   Song YX, 2019, BIOCHEM BIOPH RES CO, V509, P359, DOI 10.1016/j.bbrc.2018.12.139
   Suter B, 2018, BBA GENE REGUL MECH, V1861, P938, DOI 10.1016/j.bbagrm.2018.08.004
   Uchida S, 2015, CIRC RES, V116, P737, DOI 10.1161/CIRCRESAHA.116.302521
   Wan YX, 2017, BIOCHEM BIOPH RES CO, V488, P46, DOI 10.1016/j.bbrc.2017.05.004
   Wang L, 2015, MOL MED REP, V11, P2711, DOI 10.3892/mmr.2014.3099
   Wen X, 2018, DATABASE OXFORD, DOI 10.1093/database/bay085
   Weng R, 2018, STEM CELLS, V36, P325, DOI 10.1002/stem.2749
   Wu RY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1082 z
   Wu Y, 2019, BMC MOL CELL BIOL, V20, DOI 10.1186/s12860 019 0230 3
   Yang L, 2019, J ENDOCRINOL INVEST, V42, P1125, DOI 10.1007/s40618 019 01034 5
   Ye D, 2018, BIOMED PHARMACOTHER, V104, P825, DOI 10.1016/j.biopha.2018.04.124
   Yoda A, 2015, NAT MED, V21, P71, DOI 10.1038/nm.3751
   Zhan SF, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1986 8
   Zhang Y, 2020, J CELL MOL MED, V24, P521, DOI 10.1111/jcmm.14759
   Zhou RS, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 5983 8
   Zhuang QY, 2019, CELL DEATH DIFFER, V26, P1700, DOI 10.1038/s41418 018 0240 2
NR 52
TC 18
Z9 19
U1 0
U2 13
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1226 3613
EI 2092 6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD MAY
PY 2021
VL 53
IS 5
BP 894
EP 906
DI 10.1038/s12276 021 00621 y
EA MAY 2021
PG 13
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA SN4MU
UT WOS:000652085000001
PM 34012023
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU La Noce, M
   Mele, L
   Laino, L
   Iolascon, G
   Pieretti, G
   Papaccio, G
   Desiderio, V
   Tirino, V
   Paino, F
AF La Noce, Marcella
   Mele, Luigi
   Laino, Luigi
   Iolascon, Giovanni
   Pieretti, Gorizio
   Papaccio, Gianpaolo
   Desiderio, Vincenzo
   Tirino, Virginia
   Paino, Francesca
TI Cytoplasmic Interactions between the Glucocorticoid Receptor and HDAC2
   Regulate Osteocalcin Expression in VPA Treated MSCs
SO CELLS
LA English
DT Article
DE epigenetic drug; glucocorticoid receptor; HDAC2; human mesenchymal stem
   cells; osteogenic differentiation
ID PULP STEM CELLS; HUMAN DENTAL PULP; HISTONE DEACETYLASE INHIBITION;
   GENE EXPRESSION; BONE TISSUE; OSTEOGENIC DIFFERENTIATION;
   IDENTIFICATION; TRANSCRIPTION; ACETYLATION; OSTEOBLASTS
AB Epigenetic regulation has been considered an important mechanism for influencing stem cell differentiation. In particular, histone deacetylases (HDACs) have been shown to play a role in the osteoblast differentiation of mesenchymal stem cells (MSCs). In this study, the effect of the HDAC inhibitor, valproic acid (VPA), on bone formation in vivo by MSCs was determined. Surprisingly, VPA treatment, unlike other HDAC inhibitors, produced a well organized lamellar bone tissue when MSCs collagen sponge constructs were implanted subcutaneously into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice, although a decrease of osteocalcin (OC) expression was observed. Consequently, we decided to investigate the molecular mechanisms by which VPA exerts such effects on MSCs. We identified the glucocorticoid receptor (GR) as being responsible for that downregulation, and suggested a correlation between GR and HDAC2 inhibition after VPA treatment, as evidenced by HDAC2 knockdown. Furthermore, using co immunoprecipitation analysis, we showed for the first time in the cytoplasm, binding between GR and HDAC2. Additionally, chromatin immunoprecipitation (ChIP) assays confirmed the role of GR in OC downregulation, showing recruitment of GR to the nGRE element in the OC promoter. In conclusion, our results highlight the existence of a cross talk between GR and HDAC2, providing a mechanistic explanation for the influence of the HDAC inhibitor (namely VPA) on osteogenic differentiation in MSCs. Our findings open new directions in targeted therapies, and offer new insights into the regulation of MSC fate determination.
C1 [La Noce, Marcella; Mele, Luigi; Papaccio, Gianpaolo; Desiderio, Vincenzo; Tirino, Virginia] Univ Campania Luigi Vanvitelli, Dept Expt Med, I 80138 Naples, Italy.
   [Laino, Luigi; Pieretti, Gorizio] Univ Campania Luigi Vanvitelli, Multidisciplinary Dept Med Surg & Odontostomatol, I 80121 Naples, Italy.
   [Iolascon, Giovanni] Univ Campania Luigi Vanvitelli, Dept Med & Surg Specialties & Dent, I 80121 Naples, Italy.
   [Paino, Francesca] Univ Milan, Dept Biomed Surg & Dent Sci, I 20133 Milan, Italy.
C3 Universita della Campania Vanvitelli; Universita della Campania
   Vanvitelli; Universita della Campania Vanvitelli; University of Milan
RP Papaccio, G (通讯作者)，Univ Campania Luigi Vanvitelli, Dept Expt Med, I 80138 Naples, Italy.; Paino, F (通讯作者)，Univ Milan, Dept Biomed Surg & Dent Sci, I 20133 Milan, Italy.
EM marcella.lanoce@unicampania.it; luigi.mele@unicampania.it;
   luigi.laino@unicampania.it; giovanni.iolascon@unicampania.it;
   dott.goriziopieretti@gmail.com; gianpaolo.papaccio@unicampania.it;
   vincenzo.desiderio@unicampania.it; virginia.tirino@unicampania.it;
   francesca.paino@unimi.it
RI La Noce, Marcella/AAM 1750 2021; Iolascon, Giovanni/T 6220 2017;
   pieretti, gorizio/AAJ 8216 2020; paino, francesca/AAC 8150 2019;
   desiderio, vincenzo/K 4244 2018; LAINO, LUIGI/AAB 8203 2022; Mele,
   Luigi/AAC 9887 2019; Papaccio, Gianpaolo/B 7150 2014
OI La Noce, Marcella/0000 0002 8782 3821; Paino,
   Francesca/0000 0002 3186 1888; Mele, Luigi/0000 0002 6008 0802;
   desiderio, vincenzo/0000 0003 1819 6083; Papaccio,
   Gianpaolo/0000 0002 4014 5306
FU EU [PON01_02834]; MIUR PRIN 2010 2011 [20102M7T8X002]
FX This research was funded by EU PON01_02834 and MIUR PRIN 2010 2011 n.
   20102M7T8X002.
CR Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Cho HH, 2005, J CELL BIOCHEM, V96, P533, DOI 10.1002/jcb.20544
   Chrousos GP, 2009, NAT REV ENDOCRINOL, V5, P374, DOI 10.1038/nrendo.2009.106
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   d'Aquino R, 2007, CELL DEATH DIFFER, V14, P1162, DOI 10.1038/sj.cdd.4402121
   De Boer J, 2006, TISSUE ENG, V12, P2927
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Ehnert S, 2012, BMC MED, V10, DOI 10.1186/1741 7015 10 101
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Forbes SJ, 2002, CLIN SCI, V103, P355, DOI 10.1042/cs1030355
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Giannoudis PV, 2005, INJURY, V36, P20, DOI 10.1016/j.injury.2005.07.029
   Giuliani A, 2013, STEM CELL TRANSL MED, V2, P316, DOI 10.5966/sctm.2012 0136
   Göttlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Graves Dana T, 2011, J Oral Microbiol, V3, DOI 10.3402/jom.v3i0.5304
   GREEN E, 1990, EUR J BIOCHEM, V188, P147, DOI 10.1111/j.1432 1033.1990.tb15382.x
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Hayashi K, 2008, CELL STEM CELL, V3, P391, DOI 10.1016/j.stem.2008.07.027
   HEINRICHS AAJ, 1993, BIOCHEMISTRY US, V32, P11436, DOI 10.1021/bi00093a022
   Hu ED, 2003, J PHARMACOL EXP THER, V307, P720, DOI 10.1124/jpet.103.055541
   Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466
   Itoh M, 2002, MOL ENDOCRINOL, V16, P2382, DOI 10.1210/me.2002 0144
   Karantzali E, 2008, GENOME BIOL, V9, DOI 10.1186/gb 2008 9 4 r65
   Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779
   Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026
   Kretsovali A, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/184154
   Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521 1878(199808)20:8<615::AID BIES4>3.0.CO;2 H
   La Noce M, 2014, J DENT, V42, P761, DOI 10.1016/j.jdent.2014.02.018
   Laino G, 2005, J BONE MINER RES, V20, P1394, DOI 10.1359/JBMR.050325
   LAJEUNESSE D, 1991, BONE MINER, V14, P237, DOI 10.1016/0169 6009(91)90025 U
   Leclerc N, 2005, ARTHRITIS RHEUM US, V52, P929, DOI 10.1002/art.20872
   Lee HW, 2006, MOL ENDOCRINOL, V20, P2432, DOI 10.1210/me.2006 0061
   Lee S, 2009, CELL PROLIFERAT, V42, P711, DOI 10.1111/j.1365 2184.2009.00633.x
   Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Löscher W, 2002, CNS DRUGS, V16, P669
   Mangano C, 2010, BIOMATERIALS, V31, P3543, DOI 10.1016/j.biomaterials.2010.01.056
   Maroni P, 2012, BIOCHEM BIOPH RES CO, V428, P271, DOI 10.1016/j.bbrc.2012.10.044
   McCool KW, 2007, J BIOL CHEM, V282, P6696, DOI 10.1074/jbc.M609519200
   Meyer T, 1997, DNA CELL BIOL, V16, P919, DOI 10.1089/dna.1997.16.919
   Miyoshi N, 2011, CELL STEM CELL, V8, P633, DOI 10.1016/j.stem.2011.05.001
   MORRISON N, 1993, J BONE MINER RES, V8, P969
   Moutsatsou P, 2012, TRENDS MOL MED, V18, P348, DOI 10.1016/j.molmed.2012.04.005
   Naddeo P, 2015, DENT MATER, V31, P235, DOI 10.1016/j.dental.2014.12.015
   Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168 9525(03)00176 8
   Nicolaides NC, 2010, STEROIDS, V75, P1, DOI 10.1016/j.steroids.2009.09.002
   Oakley RH, 2013, J ALLERGY CLIN IMMUN, V132, P1033, DOI 10.1016/j.jaci.2013.09.007
   Ocker Matthias, 2010, World J Biol Chem, V1, P55, DOI 10.4331/wjbc.v1.i5.55
   OGATA Y, 1995, EUR J BIOCHEM, V230, P183
   Paino F, 2017, CLIN SCI, V131, P699, DOI 10.1042/CS20170047
   Paino F, 2014, STEM CELLS, V32, P279, DOI 10.1002/stem.1544
   Pico Michael J, 2016, Bone Rep, V5, P222, DOI 10.1016/j.bonr.2016.07.006
   Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898 6568(99)00064 9
   Rogers GF, 2012, J CRANIOFAC SURG, V23, P323, DOI 10.1097/SCS.0b013e318241dcba
   Rose AJ, 2010, J STEROID BIOCHEM, V122, P10, DOI 10.1016/j.jsbmb.2010.02.010
   Roukis TS, 2006, ADV THER, V23, P218, DOI 10.1007/BF02850128
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379
   Triantafyllou N, 2010, J NEUROL SCI, V290, P131, DOI 10.1016/j.jns.2009.12.015
   Vandevyver S, 2012, TRAFFIC, V13, P364, DOI 10.1111/j.1600 0854.2011.01288.x
   Ware CB, 2009, CELL STEM CELL, V4, P359, DOI 10.1016/j.stem.2009.03.001
   Watari S, 2012, BIOMATERIALS, V33, P128, DOI 10.1016/j.biomaterials.2011.09.058
   Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032
   Zhang WB, 2008, J TISSUE ENG REGEN M, V2, P117, DOI 10.1002/term.71
   Zhang WB, 2006, TISSUE ENG, V12, P2813, DOI 10.1089/ten.2006.12.2813
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
NR 67
TC 38
Z9 40
U1 1
U2 15
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD MAR 5
PY 2019
VL 8
IS 3
AR 217
DI 10.3390/cells8030217
PG 21
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA HS9OC
UT WOS:000464195600001
PM 30841579
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Matuszewski, L
   Matuszewska, A
   Mazurkiewicz, T
   Polkowska, I
   Jaszek, M
   Graz, M
   Gagala, J
AF Matuszewski, Lukasz
   Matuszewska, Anna
   Mazurkiewicz, Tomasz
   Polkowska, Izabela
   Jaszek, Magdalena
   Graz, Marcin
   Gagala, Jacek
TI DETERMINATION OF PAMIDRONATE IN BISPHOSPHONATE ENRICHED BONE CEMENT BY
   ION PAIR HPLC AND CAPILLARY ELECTROPHORESIS
SO BULLETIN OF THE VETERINARY INSTITUTE IN PULAWY
LA English
DT Article
DE rats; bisphosphonates; bone cement; ion pair HPLC; capillary
   electrophoresis
ID CELLS IN VITRO; LIQUID CHROMATOGRAPHY; AMINO BISPHOSPHONATE; CLODRONATE;
   RATS; PHARMACEUTICALS; ALENDRONATE; VALIDATION; IMPURITIES; MECHANISMS
AB The presence of pamidronate during local use of bisphosphonates (BP) enriched bone cement was determined. The question was whether pamidronate implanted into the bone cement is eluted. The study was performed on 10 probes of BP enriched bone cement located in 0.9% NaCl. The probes were incubated for 3 and 6 weeks. Ion pair HPLC was used for the detection of pamidronate. Then, capillary electrophoresis was applied for quantitative analysis of pamidronate in the 3rd and Oh week after incubation. The presence of pamidronate, eluted from BP enriched bone cement into 0.9% NaCl solution 3 and 6 weeks after incubation, was demonstrated. These results may explain the changes in the level of cytokine RANKL and bone turnover marker osteoprotegrin in rats' serum treated with BP enriched bone cement 3 and 6 weeks after surgery. The possibility of effective local use of BP enriched bone cement in veterinary medicine was underlined. The results, and the former conducted research, point out that the clinical applications of BP enriched bone cement in vivo may have some validity in the future.
C1 [Matuszewski, Lukasz] Med Univ Lublin, Paediat Orthoped & Rehabil Clin, PL 20093 Lublin, Poland.
   [Matuszewska, Anna; Jaszek, Magdalena; Graz, Marcin] Maria Curie Sklodowska Univ Lublin, Dept Biochem, PL 20033 Lublin, Poland.
   [Polkowska, Izabela] Univ Life Sci Lublin, Dept & Clin Anim Surg, Fac Vet Med, PL 20612 Lublin, Poland.
   [Mazurkiewicz, Tomasz; Gagala, Jacek] Med Univ Lublin, Orthopaed & Traumatol Dept, PL 20954 Lublin, Poland.
C3 Medical University of Lublin; Maria Curie Sklodowska University;
   University of Life Sciences in Lublin; Medical University of Lublin
RP Matuszewski, L (通讯作者)，Med Univ Lublin, Paediat Orthoped & Rehabil Clin, PL 20093 Lublin, Poland.
EM lukasz.matuszewski@am.lublin.pl
RI ; Matuszewski, Łukasz/M 8281 2014; Jaszek, Magdalena/N 3258 2018
OI Matuszewski, Lukasz/0000 0002 7733 0329; Matuszewska,
   Anna/0000 0002 5586 5568; Polkowska, Izabela/0000 0002 4751 8566;
   Jaszek, Magdalena/0000 0003 2609 1820; Graz, Marcin/0000 0002 9899 8707
CR Abu Amer Y, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2170
   Åstrand J, 2002, ACTA ORTHOP SCAND, V73, P24, DOI 10.1080/000164702317281369
   Bexheti D, 2006, J CHROMATOGR A, V1130, P137, DOI 10.1016/j.chroma.2006.06.110
   Bock O, 2012, BONE, V50, P317, DOI 10.1016/j.bone.2011.10.027
   DALEYYATES PT, 1989, J CHROMATOGR BIOMED, V490, P329, DOI 10.1016/S0378 4347(00)82791 7
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Gao Y, 2009, BIOMATERIALS, V30, P1790, DOI 10.1016/j.biomaterials.2008.12.025
   Geoffroy V, 2011, CALCIFIED TISSUE INT, V88, P464, DOI 10.1007/s00223 011 9480 6
   Goldring SR, 2004, ARTHRITIS RHEUM US, V50, P2044, DOI 10.1002/art.20383
   Goodship AE, 2008, J ORTHOP RES, V26, P693, DOI 10.1002/jor.20533
   Huikko K, 2000, J CHROMATOGR A, V893, P411, DOI 10.1016/S0021 9673(00)00753 6
   Jakobsen T, 2007, CLIN ORTHOP RELAT R, P195, DOI 10.1097/BLO.0b013e31813c6696
   Jia HJ, 2006, ANAL CHIM ACTA, V562, P171, DOI 10.1016/j.aca.2006.01.077
   KWONG E, 1990, J CHROMATOGR SCI, V28, P563, DOI 10.1093/chromsci/28.11.563
   Lewis G, 2006, CLIN ORTHOP RELAT R, P233, DOI 10.1097/01.blo.0000201162.59819.28
   Makkonen N, 1996, J PHARMACOL EXP THER, V277, P1097
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Matuszewski L, INT ORTHOPAEDICS
   Matuszewski L, 2011, J FAC AGR KYUSHU U, V56, P213
   Mazurkiewicz T, INT ORTHOP, DOI DOI 10.1007/S00264 013 1816 6.ACCESSED
   Migliorati CA, 2003, J CLIN ONCOL, V21, P4253, DOI 10.1200/JCO.2003.99.132
   Morris CD, 2005, J BONE JOINT SURG AM, V87A, P1609, DOI 10.2106/JBJS.D.03032
   Perjési P, 2003, J PHARMACEUT BIOMED, V31, P929, DOI 10.1016/S0731 7085(02)00673 8
   Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456
   Prieto Alhambra D, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d7222
   Rodríguez JAB, 2007, J PHARMACEUT BIOMED, V44, P305, DOI 10.1016/j.jpba.2007.02.021
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Schindeler A, 2011, J BONE JOINT SURG BR, V93B, P1134, DOI 10.1302/0301 620X.93B8.25940
   Siren H, 1997, J CHROMATOGR A, V767, P293, DOI 10.1016/S0021 9673(96)01036 9
   Sparidans RW, 1999, PHARM WORLD SCI, V21, P1, DOI 10.1023/A:1008646810555
   Tomlin JL, 2000, VET REC, V147, P129, DOI 10.1136/vr.147.5.129
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Wilkinson JM, 2011, BONE, V49, P95, DOI 10.1016/j.bone.2011.01.009
   Xie Z, 2006, J CHROMATOGR A, V1104, P173, DOI 10.1016/j.chroma.2005.11.113
   Xuenong Z., 2003, ACTA ORTHOP SCAND, V74, P596
   Zacharis CK, 2008, J PHARMACEUT BIOMED, V48, P483, DOI 10.1016/j.jpba.2008.05.028
NR 37
TC 2
Z9 2
U1 0
U2 18
PU NATL VETERINARY RESEARCH INST
PI PULAWY
PA C/O PUBICATIONS OFFICE, 24 100 PULAWY, POLAND
SN 0042 4870
J9 B VET I PULAWY
JI Bull. Vet. Inst. Pulawy
PY 2013
VL 57
IS 2
BP 257
EP 262
DI 10.2478/bvip 2013 0045
PG 6
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA 177ZL
UT WOS:000321413800020
OA gold
DA 2025 08 17
ER

PT J
AU Abou Elnour, FS
   El Habashy, SE
   Essawy, MM
   Abdallah, OY
AF Abou Elnour, Fatma S.
   El Habashy, Salma E.
   Essawy, Marwa M.
   Abdallah, Ossama Y.
TI Alendronate/lactoferrin dual decorated lipid nanocarriers for
   bone homing and active targeting of ivermectin and methyl
   dihydrojasmonate for leukemia
SO BIOMATERIALS ADVANCES
LA English
DT Article
DE Nanostructured lipid carrier; Phytotherapeutics; Drug repurposing; Bone
   marrow niche; In vivo biodistribution; Residual leukemia
ID MARROW MICROENVIRONMENT; ANTIPARASITIC AGENT; NANOPARTICLES;
   ALENDRONATE; ACID; CELLS; DRUG; BISPHOSPHONATES; BIOMATERIAL;
   LACTOFERRIN
AB Chronic myeloid leukemia is a hematological cancer, where disease relapse and drug resistance are caused by bone hosted residual leukemia cells. An innovative resolution is bone homing and selective active targeting of anticancer loaded nanovectors. Herein, ivermectin (IVM) and methyl dihydrojasmonate (MDJ) loaded nanostructured lipid carriers (IVM NLC) were formulated then dually decorated by lactoferrin (Lf) and alendronate (Aln) to optimize (Aln/Lf/IVM NLC) for active targeting and bone homing potential, respectively. Aln/Lf/IVMNLC (1 mg) revealed nano size (73.67 +/  0.06 nm), low PDI (0.43 +/  0.06), sustained release of IVM (62.75 % at 140 h) and MDJ (78.7 % at 48 h). Aln/Lf/IVM NLC afforded substantial antileukemic cytotoxicity on K562 cells (4.29 fold lower IC50), higher cellular uptake and nuclear fragmentation than IVM NLC with acceptable cytocompatibility on oral epithelial cells (as normal cells). Aln/Lf/IVM NLC effectively upregulated caspase 3 and BAX (4.53 and 15.9 fold higher than IVM NLC, respectively). Bone homing studies verified higher hydroxyapatite affinity of Aln/Lf/IVM NLC (1 mg; 22.88 +/  0.01 % at 3 h) and higher metaphyseal binding (1.5 fold increase) than untargeted NLC. Moreover, Aln/Lf/IVM NLC 1 mg secured 1.35 fold higher in vivo bone localization than untargeted NLC, with lower off target distribution. Ex vivo hemocompatibility and in vivo biocompatibility of Aln/Lf/IVM NLC (1 mg/mL) were established, with pronounced amelioration of hepatic and renal toxicity compared to higher Aln doses. The innovative Aln/Lf/IVM NLC could serve as a promising nanovector for bone homing, active targeted leukemia therapy.
C1 [Abou Elnour, Fatma S.; El Habashy, Salma E.; Abdallah, Ossama Y.] Alexandria Univ, Fac Pharm, Dept Pharmaceut, 1 Khartoum Sq,POB 21521, Alexandria, Egypt.
   [Essawy, Marwa M.] Alexandria Univ, Fac Dent, Dept Oral Pathol, Alexandria, Egypt.
   [Essawy, Marwa M.] Alexandria Univ, Fac Med, Ctr Excellence Res Regenerat Med & Applicat CERRMA, Alexandria, Egypt.
C3 Egyptian Knowledge Bank (EKB); Alexandria University; Egyptian Knowledge
   Bank (EKB); Alexandria University; Egyptian Knowledge Bank (EKB);
   Alexandria University
RP El Habashy, SE (通讯作者)，Alexandria Univ, Fac Pharm, Dept Pharmaceut, 1 Khartoum Sq,POB 21521, Alexandria, Egypt.
EM salma.elhaleem@alexu.edu.eg
RI El Habashy, Salma/HKW 8184 2023; Essam El Habashy, Salma/HKW 8184 2023
OI Essam El Habashy, Salma/0000 0003 3891 5049
CR Abou Elnour FS, 2024, INT J PHARMACEUT, V656, DOI 10.1016/j.ijpharm.2024.124086
   ACS) A.C.S, 2023, Cancer Facts & Figures 2023.
   Ahmed AA, 2023, RB Internet, V7, P1, DOI [10.21931/RB/2022.07.03.41, DOI 10.21931/RB/2022.07.03.41]
   Aly S, 2023, INT J PHARMACEUT, V642, DOI 10.1016/j.ijpharm.2023.123163
   Daddy JCKA, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020191
   Bae KH, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01683 4
   Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330
   Brandsma ME, 2011, BIOTECHNOL ADV, V29, P230, DOI 10.1016/j.biotechadv.2010.11.007
   Budzinska A, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 43377 3
   Chai FJ, 2017, INT J NANOMED, V12, P1791, DOI 10.2147/IJN.S130404
   Chiarella E, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10051146
   Diel Ingo J, 2007, J Support Oncol, V5, P475
   El Habashy S, 2021, INT J NANOMED, V16, P1103, DOI 10.2147/IJN.S298297
   El Habashy SE, 2021, MAT SCI ENG C MATER, V119, DOI 10.1016/j.msec.2020.111599
   Elzoghby AO, 2020, BIOMATERIALS, V263, DOI 10.1016/j.biomaterials.2020.120355
   Etman SM, 2020, INT J PHARMACEUT, V578, DOI 10.1016/j.ijpharm.2020.119097
   Evans KO, 2019, CHEM PHYS LIPIDS, V220, P49, DOI 10.1016/j.chemphyslip.2019.02.004
   Fan LH, 2020, INT J PHARMACEUT, V579, DOI 10.1016/j.ijpharm.2020.119179
   Fang ZG, 2021, INT J POLYM MATER PO, V70, P27, DOI 10.1080/00914037.2019.1685516
   Fingrut O, 2002, LEUKEMIA, V16, P608, DOI 10.1038/sj.leu.2402419
   Flescher E, 2007, CANCER LETT, V245, P1, DOI 10.1016/j.canlet.2006.03.001
   Fouda A, 2022, APPL SCI BASEL, V12, DOI 10.3390/app122412879
   Freag MS, 2016, NANOMEDICINE UK, V11, P2975, DOI 10.2217/nnm 2016 0236
   Gaafar A, 2023, AM J TRANSL RES, V15, P967
   Goicoechea C, 1999, JPN J PHARMACOL, V79, P433, DOI 10.1254/jjp.79.433
   Gundogdu E, 2022, NANOMATERIALS BASEL, V12, DOI 10.3390/nano12020250
   Guo DW, 2018, ARTIF CELL NANOMED B, V46, P255, DOI 10.1080/21691401.2017.1307207
   Haider M, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030288
   He F, 2017, P NATL ACAD SCI USA, V114, P10542, DOI 10.1073/pnas.1708161114
   Holsæter AM, 2022, EUR J PHARM SCI, V177, DOI 10.1016/j.ejps.2022.106267
   Houshmand M, 2019, WORLD J STEM CELLS, V11, P476, DOI 10.4252/wjsc.v11.i8.476
   Hu QY, 2016, ADV MATER, V28, P9573, DOI 10.1002/adma.201603463
   Huang JJ, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.904292
   Izak Nau E, 2015, RSC ADV, V5, P84172, DOI 10.1039/c5ra10187e
   Jara MA, 2022, BONE, V158, DOI 10.1016/j.bone.2021.115901
   Jarocka Karpowicz I, 2021, MOLECULES, V26, DOI 10.3390/molecules26102901
   Jedrzejczyk M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249390
   Jiang Y, 2022, MOLECULES, V27, DOI 10.3390/molecules27041310
   Juarez M, 2018, AM J CANCER RES, V8, P317
   Kamath PR, 2017, EUR J MED CHEM, V136, P442, DOI 10.1016/j.ejmech.2017.05.032
   Ke J, 2016, J PHARM ANAL, V6, P404, DOI 10.1016/j.jpha.2016.07.001
   Kedmi R, 2010, BIOMATERIALS, V31, P6867, DOI 10.1016/j.biomaterials.2010.05.027
   Khalafi Amir, 2020, Research in Molecular Medicine, V8, P107, DOI 10.32598/rmm.8.3.726.3
   Knudsen KB, 2015, NANOMED NANOTECHNOL, V11, P467, DOI 10.1016/j.nano.2014.08.004
   Kronick O, 2023, CANCERS, V15, DOI 10.3390/cancers15174354
   Leung HHW, 2022, J GASTROEN HEPATOL, V37, P1131, DOI 10.1111/jgh.15843
   Liu S, 2016, J PHARM SCI US, V105, P78, DOI 10.1016/j.xphs.2015.10.026
   Malhotra Himanshu, 2019, Cell Physiol Biochem, V52, P517, DOI 10.33594/000000037
   Metwally WM, 2023, INT J PHARMACEUT, V638, DOI 10.1016/j.ijpharm.2023.122920
   Miller K, 2011, MOL PHARMACEUT, V8, P1052, DOI 10.1021/mp200083n
   Morsy SAA, 2024, J NEUROIMMUNE PHARM, V19, DOI 10.1007/s11481 024 10099 w
   Mu CF, 2017, MOL PHARMACEUT, V14, P274, DOI 10.1021/acs.molpharmaceut.6b00872
   Nair RR, 2010, BIOCHEM PHARMACOL, V80, P602, DOI 10.1016/j.bcp.2010.04.003
   Nakamura Bencomo S, 2021, INVEST NEW DRUG, V39, P400, DOI 10.1007/s10637 020 01020 2
   Noori T, 2023, IRAN J BASIC MED SCI, V26, P1272, DOI 10.22038/IJBMS.2023.71309.15493
   Nour EM, 2023, DRUG DELIV TRANSL RE, V13, P2847, DOI 10.1007/s13346 023 01353 4
   Olejnik A, 2018, COLLOID SURFACE A, V558, P558, DOI 10.1016/j.colsurfa.2018.09.026
   Pan TL, 2012, FOOD CHEM TOXICOL, V50, P3892, DOI 10.1016/j.fct.2012.07.005
   Pascual J, 2007, OSTEOPOROSIS INT, V18, P1435, DOI 10.1007/s00198 007 0361 9
   Qiang MD, 2020, MOLECULES, V25, DOI 10.3390/molecules25030610
   Rahman HS, 2013, INT J NANOMED, V8, DOI 10.2147/IJN.S45313
   Sallam NG, 2024, INT J PHARMACEUT, V649, DOI 10.1016/j.ijpharm.2023.123637
   Savchenko T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232314627
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Montoto SS, 2018, COLLOID SURFACE B, V167, P73, DOI 10.1016/j.colsurfb.2018.03.052
   Sharmeen S, 2010, BLOOD, V116, P3593, DOI 10.1182/blood 2010 01 262675
   Shehata EMM, 2022, INT J PHARMACEUT, V619, DOI 10.1016/j.ijpharm.2022.121712
   Shi PJ, 2017, COLLOID SURFACE B, V155, P477, DOI 10.1016/j.colsurfb.2017.04.042
   Shi YP, 2013, MOL PHARMACEUT, V10, P2479, DOI 10.1021/mp4001266
   Sudo M, 2021, PREGNANCY HYPERTENS, V25, P75, DOI 10.1016/j.preghy.2021.05.015
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Tang MY, 2021, PHARMACOL RES, V163, DOI 10.1016/j.phrs.2020.105207
   Tian ML, 2019, IOP C SER EARTH ENV, V252, DOI 10.1088/1755 1315/252/2/022049
   Tiboni F., 2020, PREPRINT
   Tran TH, 2014, CARBOHYD POLYM, V114, P407, DOI 10.1016/j.carbpol.2014.08.026
   Van Acker HH, 2016, PHARMACOL THERAPEUT, V158, P24, DOI 10.1016/j.pharmthera.2015.11.008
   Wang F, 2020, COLLOID SURFACE B, V190, DOI 10.1016/j.colsurfb.2020.110925
   Wang JQ, 2018, BIOCHEM BIOPH RES CO, V497, P241, DOI 10.1016/j.bbrc.2018.02.063
   Wu H, 2022, REGEN BIOMATER, V9, DOI 10.1093/rb/rbac058
   YAMADA Y, 1987, BLOOD, V70, P264
   Yehia R, 2017, COLLOID SURFACE B, V155, P512, DOI 10.1016/j.colsurfb.2017.04.031
NR 81
TC 5
Z9 5
U1 6
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2772 9508
J9 BIOMATER ADV
JI Biomater. Adv.
PD SEP
PY 2024
VL 162
AR 213924
DI 10.1016/j.bioadv.2024.213924
EA JUN 2024
PG 16
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA WI8R7
UT WOS:001254339000001
PM 38875802
DA 2025 08 17
ER

PT J
AU Tortora, C
   Di Paola, A
   Creoli, M
   Argenziano, M
   Martinelli, M
   Miele, E
   Rossi, F
   Strisciuglio, C
AF Tortora, Chiara
   Di Paola, Alessandra
   Creoli, Mara
   Argenziano, Maura
   Martinelli, Massimo
   Miele, Erasmo
   Rossi, Francesca
   Strisciuglio, Caterina
TI Effects of CB2 and TRPV1 Stimulation on Osteoclast Overactivity Induced
   by Iron in Pediatric Inflammatory Bowel Disease
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE inflammatory bowel disease; osteoporosis; osteoclasts; iron metabolism;
   CB2; TRPV1
ID CANNABINOID RECEPTOR; EXTRAINTESTINAL MANIFESTATIONS; HEPCIDIN;
   ABSORPTION; AMLODIPINE; CHANNEL; TRIAL; RISK; AXIS
AB Background The reduction of bone mineral density and osteoporosis have high impacts on the health of patients with inflammatory bowel diseases (IBD). We have previously shown that a dysregulated iron metabolism occurs in IBD and leads to a decrease in circulating iron concentration and excessive intracellular sequestration of iron. Studies suggest that iron overload significantly affects the bone, accelerating osteoclast (OC) differentiation and activation, promoting bone resorption. Moreover, we demonstrated that iron overload causes OC overactivity. The cannabinoid receptor type 2 (CB2) and the transient receptor potential vanilloid type 1 (TRPV1) are potential therapeutic targets for bone diseases. The aim of this study was to evaluate the roles of CB2 and TRPV1 receptors and of iron in the development of osteoporosis in pediatric IBD. Methods We differentiated OCs from peripheral blood mononuclear cells of patients with IBD and healthy donors and evaluated CB2 and TRPV1 receptor expression; OC activity, and iron metabolism by Western blot, TRAP assays, bone resorption assays, and iron assays. Moreover, we analyzed the effects of the pharmacological modulation of CB2 and TRPV1 receptors on OC activity and on the iron metabolism. Results We confirmed the well known roles of CB2 and TRPV1 receptors in bone metabolism and suggested that their stimulation can reduce the OC overactivity induced by iron, providing new insights into the pathogenesis of pediatric IBD related bone resorption. Conclusions Stimulation of CB2 and TRPV1 could reduce IBD related osteoporosis due to their direct effects on OC activity and to modulating the iron metabolism.
   Lay Summary In this study, we provide new insights into the pathogenesis of inflammatory bowel disease (IBD) related bone resorption, suggesting a role for iron. Cannabinoid receptor type 2 and transient receptor potential vanilloid type 1 stimulation could reduce IBD related osteoporosis, directly affecting osteoclast activity and modulating iron metabolism.
C1 [Tortora, Chiara; Argenziano, Maura; Rossi, Francesca; Strisciuglio, Caterina] Univ Campania Luigi Vanvitelli, Dept Woman Child & Gen & Specialist Surg, Via Crecchio 4, I 80138 Naples, Italy.
   [Di Paola, Alessandra; Creoli, Mara] Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy.
   [Martinelli, Massimo; Miele, Erasmo] Univ Naples Federico II, Sect Pediat, Dept Translat Med Sci, Naples, Italy.
C3 Universita della Campania Vanvitelli; Universita della Campania
   Vanvitelli; University of Naples Federico II
RP Rossi, F (通讯作者)，Univ Campania Luigi Vanvitelli, Dept Woman Child & Gen & Specialist Surg, Via Crecchio 4, I 80138 Naples, Italy.
EM francesca.rossi@unicampania.it
RI ; Martinelli, Massimo/AAC 1954 2022; Strisciuglio,
   Caterina/ABD 2466 2020; Rossi, Francesca/HTP 5870 2023; Miele,
   Erasmo/A 1906 2010; Di Paola, Alessandra/LUA 0359 2024
OI STRISCIUGLIO, Caterina/0000 0002 9005 6571; Rossi,
   Francesca/0000 0003 2879 6277; CREOLI, MARA/0000 0003 3378 7869; 
CR ALCANTARA O, 1994, BIOCHEM J, V298, P421, DOI 10.1042/bj2980421
   Annese V, 2019, SAUDI J MED MED SCI, V7, P66, DOI 10.4103/sjmms.sjmms_81_18
   Argenziano M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235875
   Bab I, 2008, J NEUROENDOCRINOL, V20, P69, DOI 10.1111/j.1365 2826.2008.01675.x
   Basseri Robert J, 2013, J Crohns Colitis, V7, pe286, DOI 10.1016/j.crohns.2012.10.013
   Buckley MC, 2021, ADV THER, V38, P4152, DOI 10.1007/s12325 021 01805 8
   Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807
   Che JM, 2020, BIOL TRACE ELEM RES, V195, P353, DOI 10.1007/s12011 019 01867 4
   Chemaitilly W, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2017.76.3268
   Czuba LC, 2018, PHARMACOL THERAPEUT, V192, P88, DOI 10.1016/j.pharmthera.2018.06.013
   Defaye M, 2022, CELL MOL GASTROENTER, V13, P977, DOI 10.1016/j.jcmgh.2021.12.012
   Dragoni G, 2021, DIGEST DIS, V39, P190, DOI 10.1159/000511641
   Du Q, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01064
   Fernandes JL, 2016, BLOOD, V128, P1555, DOI 10.1182/blood 2016 06 721183
   Ginzburg YZ, 2019, VITAM HORM, V110, P17, DOI 10.1016/bs.vh.2019.01.002
   Guan QD, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/7247238
   Guz Mark A, 2017, DIGEST LIVER DIS, V49, P639, DOI 10.1016/j.dld.2017.01.151
   Isaacs JD, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4397
   Jia Y, 2020, NEUROSCI LETT, V720, DOI 10.1016/j.neulet.2020.134779
   Karaskova E, 2018, J PAEDIATR CHILD H, V54, P1362, DOI 10.1111/jpc.14093
   Khaled A, 2019, DRUG DES DEV THER, V13, P2427, DOI 10.2147/DDDT.S211630
   Kumfu S, 2021, J CELL PHYSIOL, V236, P5108, DOI 10.1002/jcp.30219
   Kumfu S, 2018, EUR J PHARMACOL, V822, P43, DOI 10.1016/j.ejphar.2018.01.015
   Kuznicki P, 2021, J CLIN MED, V10, DOI 10.3390/jcm10194623
   Ledesma Colunga MG, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115400
   Levine Y Y, 2016, Zhonghua Er Ke Za Zhi, V54, P728, DOI 10.3760/cma.j.issn.0578 1310.2016.10.003
   Ferreir PVDLS, 2019, J PEDIAT BRAZIL, V95, pS59, DOI 10.1016/j.jped.2018.11.002
   Martinelli M, 2016, J CROHNS COLITIS, V10, P566, DOI 10.1093/ecco jcc/jjv242
   Moazzami B, 2019, TURKISH J PEDIATR, V61, P637, DOI 10.24953/turkjped.2019.05.001
   Nasser Yasmin, 2020, Curr Treat Options Gastroenterol, V18, P519, DOI 10.1007/s11938 020 00323 w
   Nso N, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/cureus.18841
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Oudit GY, 2006, J MOL MED, V84, P349, DOI 10.1007/s00109 005 0029 x
   Pawlowska Kamieniak A, 2021, ADV CLIN EXP MED, V30, P465, DOI 10.17219/acem/130356
   Rodriguez R, 2014, INFECT IMMUN, V82, P745, DOI 10.1128/IAI.00983 13
   Rosen MJ, 2015, JAMA PEDIATR, V169, P1053, DOI 10.1001/jamapediatrics.2015.1982
   Rossi F, 2009, BONE, V44, P476, DOI 10.1016/j.bone.2008.10.056
   Rossi F, 2014, HAEMATOLOGICA, V99, P1876, DOI 10.3324/haematol.2014.104463
   Rossi F, 2013, PHARMACOL RES, V68, P7, DOI 10.1016/j.phrs.2012.10.017
   Rossi F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042259
   Rossi F, 2012, PHARMACOL RES, V66, P88, DOI 10.1016/j.phrs.2012.03.011
   Rossi F, 2011, BONE, V48, P997, DOI 10.1016/j.bone.2011.01.001
   Sato H, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 66945 3
   Semrin G, 2006, INFLAMM BOWEL DIS, V12, P1101, DOI 10.1097/01.mib.0000235097.86360.04
   Seo YA, 2016, BIOCHEM J, V473, P4243, DOI 10.1042/BCJ20160674
   Sgambato D, 2019, WORLD J CLIN CASES, V7, P1908, DOI 10.12998/wjcc.v7.i15.1908
   Shah YM, 2009, CELL METAB, V9, P152, DOI 10.1016/j.cmet.2008.12.012
   Lalosevic MS, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/8523205
   Strisciuglio C, 2018, J CLIN GASTROENTEROL, V52, pE37, DOI 10.1097/MCG.0000000000000755
   Talathi S, 2020, EUR J PEDIATR, V179, P1499, DOI 10.1007/s00431 020 03629 0
   Tortora C, 2020, J PEDIATR GASTR NUTR, V71, P633, DOI 10.1097/MPG.0000000000002863
   Vavricka SR, 2015, INFLAMM BOWEL DIS, V21, P1794, DOI 10.1097/MIB.0000000000000429
   Verma S, 2017, METALLOMICS, V9, P101, DOI [10.1039/c6mt00282j, 10.1039/C6MT00282J]
   Wang LJ, 2012, INFLAMM BOWEL DIS, V18, P112, DOI 10.1002/ibd.21675
   Xie WJ, 2016, CALCIFIED TISSUE INT, V98, P275, DOI 10.1007/s00223 015 0087 1
   Yanatori I, 2019, FREE RADICAL BIO MED, V133, P55, DOI 10.1016/j.freeradbiomed.2018.07.020
NR 56
TC 9
Z9 9
U1 0
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1078 0998
EI 1536 4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD AUG 1
PY 2022
VL 28
IS 8
BP 1244
EP 1253
DI 10.1093/ibd/izac073
EA APR 2022
PG 10
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology
GA 3K9AS
UT WOS:000787407300001
PM 35472140
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Abu Khader, A
   Law, KW
   Jahan, S
   Manesia, JK
   Pasha, R
   Hovey, O
   Pineault, N
AF Abu Khader, Ahmad
   Law, Kyle W.
   Jahan, Suria
   Manesia, Javed K.
   Pasha, Roya
   Hovey, Owen
   Pineault, Nicolas
TI Paracrine Factors Released by Osteoblasts Provide Strong Platelet
   Engraftment Properties
SO STEM CELLS
LA English
DT Article
DE Osteoblasts; Platelet engraftment; Progenitor expansion; Hematopoietic
   reconstitution; IGF 2; Cellular therapy
ID HEMATOPOIETIC STEM CELLS; UMBILICAL CORD BLOOD; GROWTH FACTOR I;
   MYELOID LEUKEMIA CELLS; EX VIVO EXPANSION; BONE MARROW; BETA CATENIN;
   PROGENITOR CELLS; IGF II; MAINTENANCE
AB Ex vivo expansion of hematopoietic stem cell (HSCs) and progenitors may one day overcome the slow platelet engraftment kinetics associated with umbilical cord blood transplantation. Serum free medium conditioned with osteoblasts (i.e., osteoblast conditioned medium [OCM]) derived from mesenchymal stromal cells (MSC) was previously shown to increase cell growth and raise the levels of human platelets in mice transplanted with OCM expanded progenitors. Herein, we characterized the cellular and molecular mechanisms responsible for these osteoblast derived properties. Limiting dilution transplantation assays revealed that osteoblasts secrete soluble factors that synergize with exogenously added cytokines to promote the production of progenitors with short term platelet engraftment activities, and to a lesser extent with long term platelet engraftment activities. OCM also modulated the expression repertoire of cell surface receptors implicated in the trafficking of HSC and progenitors to the bone marrow. Furthermore, OCM contains growth factors with prosurvival and proliferation activities that synergized with stem cell factor. Insulin like growth factor (IGF) 2 was found to be present at higher levels in OCM than in control medium conditioned with MSC. Inhibition of the IGF 1 receptor, which conveys IGF 2 intracellular signaling, largely abolished the growth promoting activity of OCM on immature CD34(+) subsets and progenitors in OCM cultures. Finally, IGF 1R effects appear to be mediated in part by the coactivator  catenin. In summary, these results provide new insights into the paracrine regulatory activities of osteoblasts on HSC, and how these can be used to modulate the engraftment properties of human HSC and progenitors expanded in culture. Stem Cells2019;37:345 356
C1 [Abu Khader, Ahmad; Law, Kyle W.; Jahan, Suria; Manesia, Javed K.; Pasha, Roya; Hovey, Owen; Pineault, Nicolas] Canadian Blood Serv, Ctr Innovat, 1800 Alta Vista, Ottawa, ON K1G 4J5, Canada.
   [Abu Khader, Ahmad] King Hussein Canc Ctr, Dept Cell Therapy & Appl Genom, Amman, Jordan.
   [Jahan, Suria; Hovey, Owen; Pineault, Nicolas] Univ Ottawa, Biochem Microbiol & Immunol Dept, Ottawa, ON, Canada.
C3 Canadian Blood Services; King Hussein Cancer Center; University of
   Ottawa
RP Pineault, N (通讯作者)，Canadian Blood Serv, Ctr Innovat, 1800 Alta Vista, Ottawa, ON K1G 4J5, Canada.
EM pineault@blood.ca
OI Pineault, Nicolas/0000 0002 0082 0944; Abu Khader,
   Ahmad/0000 0002 8940 8170; Jahan, Suria/0000 0002 3768 5512; Hovey,
   Owen/0000 0003 3623 9569
FU Canadian Blood Services (Canadian Blood Services/Canadian Institutes of
   Health Research operating grant program)   federal government (Health
   Canada); provincial ministry of health [RN210152]; territorial ministry
   of health [RN210152]
FX We thank the staff at Canadian Blood Services (CBS) Cord Blood for
   Research Program for their precious help and Geraldine Walsh for editing
   and proofreading the article. This research received funding support
   from Canadian Blood Services (Canadian Blood Services/Canadian
   Institutes of Health Research operating grant program), funded by the
   federal government (Health Canada) and the provincial and territorial
   ministries of health (RN210152). As a condition of this support, this
   article must contain the statement "The views expressed herein do not
   necessarily represent the views of the federal government".
CR Abu Khader A, 2016, CYTOTECHNOLOGY, V68, P2257, DOI 10.1007/s10616 016 0019 6
   Ahmed F, 2004, BLOOD, V103, P2079, DOI 10.1182/blood 2003 06 1770
   Ahmed N, 1999, STEM CELLS, V17, P92, DOI 10.1002/stem.170092
   Alsheikh M, 2017, EUR J HAEMATOL, V98, P542, DOI 10.1111/ejh.12865
   Barroca V, 2017, EBIOMEDICINE, V15, P150, DOI 10.1016/j.ebiom.2016.11.035
   Battiwalla M, 2009, CYTOTHERAPY, V11, P503, DOI 10.1080/14653240903193806
   Brahmkhatri VP, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/538019
   Buckley SM, 2011, EXP HEMATOL, V39, P114, DOI 10.1016/j.exphem.2010.09.010
   Cairo MS, 2016, BONE MARROW TRANSPL, V51, P27, DOI 10.1038/bmt.2015.196
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Caselli A, 2013, STEM CELLS, V31, P2193, DOI 10.1002/stem.1463
   Çelebi B, 2011, J IMMUNOL METHODS, V370, P93, DOI 10.1016/j.jim.2011.06.006
   Chen JC, 2018, J BIOL CHEM, V293, P3700, DOI 10.1074/jbc.M117.789503
   Cheung AMS, 2012, BLOOD, V119, P3431, DOI 10.1182/blood 2011 12 398024
   Chitteti BR, 2013, BONE, V54, P58, DOI 10.1016/j.bone.2013.01.038
   Chitteti BR, 2014, BLOOD, V124, P519, DOI 10.1182/blood 2014 03 565721
   Cortin V, 2005, EXP HEMATOL, V33, P1182, DOI 10.1016/j.exphem.2005.06.020
   Crane GM, 2017, NAT REV IMMUNOL, V17, P573, DOI 10.1038/nri.2017.53
   Cutler C, 2013, BLOOD, V122, P3074, DOI 10.1182/blood 2013 05 503177
   de Lima M, 2012, NEW ENGL J MED, V367, P2305, DOI 10.1056/NEJMoa1207285
   Delaney C, 2010, NAT MED, V16, P232, DOI 10.1038/nm.2080
   Doepfner KT, 2007, LEUKEMIA, V21, P1921, DOI 10.1038/sj.leu.2404813
   Dominici M, 2009, BLOOD, V114, P2333, DOI 10.1182/blood 2008 10 183459
   Dumont N, 2014, EXP HEMATOL, V42, P741, DOI 10.1016/j.exphem.2014.04.009
   Émond H, 2012, STEM CELLS DEV, V21, P3209, DOI 10.1089/scd.2012.0142
   Fares I, 2017, BLOOD, V129, P3344, DOI 10.1182/blood 2016 11 750729
   Fares I, 2014, SCIENCE, V345, P1509, DOI 10.1126/science.1256337
   Ferreira MSV, 2012, BIOMATERIALS, V33, P6987, DOI 10.1016/j.biomaterials.2012.06.029
   Frostad S, 1998, STEM CELLS, V16, P334, DOI 10.1002/stem.160334
   Fuentes R, 2010, J CLIN INVEST, V120, P3917, DOI 10.1172/JCI43326
   Gonçalves R, 2006, EXP HEMATOL, V34, P1353, DOI 10.1016/j.exphem.2006.05.024
   Gonsalves FC, 2011, P NATL ACAD SCI USA, V108, P5954, DOI 10.1073/pnas.1017496108
   Hoggatt J, 2009, BLOOD, V113, P5444, DOI 10.1182/blood 2009 01 201335
   Horwitz ME, 2014, J CLIN INVEST, V124, P3121, DOI 10.1172/JCI74556
   Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008
   Jeannet R, 2013, STEM CELLS, V31, P560, DOI 10.1002/stem.1309
   Kellner J, 2015, CYTOTHERAPY, V17, P418, DOI 10.1016/j.jcyt.2014.11.004
   Kokkaliaris KD, 2016, BLOOD, V128, P1181, DOI 10.1182/blood 2016 03 705590
   Li WS, 2013, BLOOD, V121, P4063, DOI 10.1182/blood 2012 12 473470
   Majeti R, 2007, CELL STEM CELL, V1, P635, DOI 10.1016/j.stem.2007.10.001
   Marquez Curtis LA, 2011, STEM CELL REV REP, V7, P590, DOI 10.1007/s12015 010 9212 8
   Mendelson A, 2014, NAT MED, V20, P833, DOI 10.1038/nm.3647
   Michalicka M, 2017, STEM CELLS DEV, V26, P1735, DOI 10.1089/scd.2017.0133
   Milano F, 2017, STEM CELL TRANSL MED, V6, P566, DOI 10.5966/sctm.2016 0112
   Miller PH, 2016, EXP HEMATOL, V44, P635, DOI 10.1016/j.exphem.2016.04.003
   Mishima S, 2010, EUR J HAEMATOL, V84, P538, DOI 10.1111/j.1600 0609.2010.01419.x
   Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660
   Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559
   Notta F, 2016, SCIENCE, V351, P139, DOI 10.1126/science.aab2116
   Notta F, 2011, SCIENCE, V333, P218, DOI 10.1126/science.1201219
   Oliver DC, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.46.46
   Oostendorp RAJ, 2005, STEM CELLS, V23, P842, DOI 10.1634/stemcells.2004 0120
   Pineault N, 2015, EXP HEMATOL, V43, P498, DOI 10.1016/j.exphem.2015.04.011
   Pineault N, 2011, CYTOTHERAPY, V13, P467, DOI 10.3109/14653249.2010.530651
   Popat U, 2015, BLOOD, V125, P2885, DOI 10.1182/blood 2015 01 607366
   Robinson SN, 2012, EXP HEMATOL, V40, P445, DOI 10.1016/j.exphem.2012.01.015
   Rocha V, 2004, NEW ENGL J MED, V351, P2276, DOI 10.1056/NEJMoa041469
   Salati S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053496
   Sanjuan Pla A, 2013, NATURE, V502, P232, DOI 10.1038/nature12495
   Schepers K, 2015, CELL STEM CELL, V16, P254, DOI 10.1016/j.stem.2015.02.014
   Schipper LF, 2012, STEM CELLS, V30, P988, DOI 10.1002/stem.1071
   Schwartz GN, 1996, STEM CELLS, V14, P337, DOI 10.1002/stem.140337
   Staal FJT, 2016, CANCERS, V8, DOI 10.3390/cancers8090078
   Szilvassy SJ, 2001, EXP HEMATOL, V29, P1494, DOI 10.1016/S0301 472X(01)00751 2
   Szilvassy Stephen J, 2002, Methods Mol Med, V63, P167, DOI 10.1385/1 59259 140 X:167
   Taichman RS, 1996, BLOOD, V87, P518, DOI 10.1182/blood.V87.2.518.bloodjournal872518
   Taichman RS, 1998, STEM CELLS, V16, P7, DOI 10.1002/stem.160007
   Tazzari PL, 2007, LEUKEMIA, V21, P886, DOI 10.1038/sj.leu.2404643
   Venkatraman A, 2013, NATURE, V500, P345, DOI 10.1038/nature12303
   Wagner E, 2006, TRANSFUSION, V46, P1190, DOI 10.1111/j.1537 2995.2006.00870.x
   Walenda T, 2011, EXP HEMATOL, V39, P617, DOI 10.1016/j.exphem.2011.02.011
   Xia LJ, 2004, BLOOD, V104, P3091, DOI 10.1182/blood 2004 02 0650
   Ye P, 2010, GLIA, V58, P1031, DOI 10.1002/glia.20984
   Zhang CC, 2005, BLOOD, V105, P4314, DOI 10.1182/blood 2004 11 4418
   Zhang CC, 2004, BLOOD, V103, P2513, DOI 10.1182/blood 2003 08 2955
   Zumkeller W, 1999, BLOOD, V94, P3653, DOI 10.1182/blood.V94.11.3653.423k42_3653_3657
NR 76
TC 6
Z9 7
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD MAR
PY 2019
VL 37
IS 3
BP 345
EP 356
DI 10.1002/stem.2956
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA HO1TB
UT WOS:000460692600005
PM 30520180
OA Bronze
DA 2025 08 17
ER

PT J
AU Gentleman, E
   Swain, RJ
   Evans, ND
   Boonrungsiman, S
   Jell, G
   Ball, MD
   Shean, TAV
   Oyen, ML
   Porter, A
   Stevens, MM
AF Gentleman, Eileen
   Swain, Robin J.
   Evans, Nicholas D.
   Boonrungsiman, Suwimon
   Jell, Gavin
   Ball, Michael D.
   Shean, Tamaryn A. V.
   Oyen, Michelle L.
   Porter, Alexandra
   Stevens, Molly M.
TI Comparative materials differences revealed in engineered bone as a
   function of cell specific differentiation
SO NATURE MATERIALS
LA English
DT Article
ID OSTEOGENIC CELLS; MOUSE CALVARIA; MINERALIZATION; SPECTROSCOPY;
   OSTEOBLASTS
AB An important aim of regenerative medicine is to restore tissue function with implantable, laboratory grown constructs that contain tissue specific cells that replicate the function of their counterparts in the healthy native tissue. It remains unclear, however, whether cells used in bone regeneration applications produce a material that mimics the structural and compositional complexity of native bone. By applying multivariate analysis techniques to micro Raman spectra of mineralized nodules formed in vitro, we reveal cell source dependent differences in interactions between multiple bone like mineral environments. Although osteoblasts and adult stem cells exhibited bone specific biological activities and created a material with many of the hallmarks of native bone, the 'bone nodules' formed from embryonic stem cells were an order of magnitude less stiff, and lacked the distinctive nanolevel architecture and complex biomolecular and mineral composition noted in the native tissue. Understanding the biological mechanisms of bone formation in vitro that contribute to cell source specific materials differences may facilitate the development of clinically successful engineered bone.
C1 [Gentleman, Eileen; Swain, Robin J.; Evans, Nicholas D.; Boonrungsiman, Suwimon; Jell, Gavin; Ball, Michael D.; Porter, Alexandra; Stevens, Molly M.] Univ London Imperial Coll Sci Technol & Med, Dept Mat, London SW7 2AZ, England.
   [Gentleman, Eileen; Evans, Nicholas D.; Boonrungsiman, Suwimon; Jell, Gavin; Ball, Michael D.; Stevens, Molly M.] Univ London Imperial Coll Sci Technol & Med, Inst Biomed Engn, London SW7 2AZ, England.
   [Shean, Tamaryn A. V.; Oyen, Michelle L.] Univ Cambridge, Dept Engn, Cambridge CB2 1PZ, England.
C3 Imperial College London; Imperial College London; University of
   Cambridge
RP Stevens, MM (通讯作者)，Univ London Imperial Coll Sci Technol & Med, Dept Mat, London SW7 2AZ, England.
EM m.stevens@imperial.ac.uk
RI ; Stevens, Martin/J 6495 2013; Jell, Gavin/B 7855 2010; Oyen,
   Michelle/M 8682 2019
OI Stevens, Molly/0000 0002 7335 266X; Boonrungsiman,
   Suwimon/0000 0002 9550 939X; Evans, Nicholas/0000 0002 3255 4388;
   Gentleman, Eileen/0000 0003 0447 5137; Ball,
   Michael/0000 0003 4139 0802; Jell, Gavin/0000 0001 8115 1609; Oyen,
   Michelle/0000 0002 3428 748X; 
FU Rothermere Foundation; National Science and Engineering Research Council
   Canada; Canadian Centennial Scholarship Fund; Medical Research Council,
   UK; EPSRC [EP/E007627/1] Funding Source: UKRI; MRC [G0500489] Funding
   Source: UKRI; Engineering and Physical Sciences Research Council
   [EP/E007627/1] Funding Source: researchfish; Medical Research Council
   [G0500489] Funding Source: researchfish
FX The authors would like to thank the EPSRC for funding, R. Carzaniga of
   the Electron Microscopy Centre, Imperial College London, for invaluable
   assistance with TEM and N.Walters for laboratory support. We are also
   grateful to R. Hill for help with the hydroxyapatite standard. R. J. S.
   gratefully acknowledges funding from the Rothermere Foundation, the
   National Science and Engineering Research Council Canada and the
   Canadian Centennial Scholarship Fund. N. D. E. was supported by a career
   development fellowship in stem cell research from the Medical Research
   Council, UK.
CR Akkus O, 2004, BONE, V34, P443, DOI 10.1016/j.bone.2003.11.003
   Alper J, 2009, NAT BIOTECHNOL, V27, P213, DOI 10.1038/nbt0309 213a
   AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792
   Bonewald LF, 2003, CALCIFIED TISSUE INT, V72, P537, DOI 10.1007/s00223 002 1057 y
   Boskey A, 2003, OSTEOPOROSIS INT, V14, pS16, DOI 10.1007/s00198 003 1468 2
   Boskey A, 2007, BIOMATERIALS, V28, P2465, DOI 10.1016/j.biomaterials.2006.11.043
   Boyan BD, 2000, BONE, V27, P341, DOI 10.1016/S8756 3282(00)00347 1
   Buttery LDK, 2001, TISSUE ENG, V7, P89, DOI 10.1089/107632700300003323
   Carden A, 2000, J BIOMED OPT, V5, P259, DOI 10.1117/1.429994
   CARTER EA, 2001, INFRARED RAMAN SPECT
   Diem M, 2004, ANALYST, V129, P880, DOI 10.1039/b408952a
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   ECAROTCHARRIER B, 1983, J CELL BIOL, V96, P639, DOI 10.1083/jcb.96.3.639
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   Fang JM, 1997, ANAT EMBRYOL, V196, P349, DOI 10.1007/s004290050104
   FRIEDLAENDER GE, 1983, CLIN ORTHOP RELAT R, P58
   Gadeleta SJ, 2000, BONE, V27, P541, DOI 10.1016/S8756 3282(00)00362 8
   Giannoudis PV, 2005, INJURY, V36, P20, DOI 10.1016/j.injury.2005.07.029
   Govindarajan V, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471 213X 6 7
   Gruen L, 2006, STEM CELLS, V24, P2162, DOI 10.1634/stemcells.2006 0105
   Hwang NS, 2008, P NATL ACAD SCI USA, V105, P20641, DOI 10.1073/pnas.0809680106
   Kim S, 2008, BIOMATERIALS, V29, P1043, DOI 10.1016/j.biomaterials.2007.11.005
   Krishna CM, 2004, APPL SPECTROSC, V58, P1128, DOI 10.1366/0003702041959460
   Lewandrowski KU, 2000, BIOMATERIALS, V21, P757, DOI 10.1016/S0142 9612(99)00179 9
   LITINSKI V, 2008, REGENERARIVE MED IND
   Notingher I, 2004, J CELL BIOCHEM, V92, P1180, DOI 10.1002/jcb.20136
   Patel R, 2004, NEW ENGL J MED, V350, P2544, DOI 10.1056/NEJMp048090
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Porter AE, 2004, BIOMATERIALS, V25, P3303, DOI 10.1016/j.biomaterials.2003.10.006
   SCHOETERS GER, 1988, CELL TISSUE KINET, V21, P363, DOI 10.1111/j.1365 2184.1988.tb00794.x
   Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05
   Shimko DA, 2004, TISSUE ENG, V10, P1386, DOI 10.1089/ten.2004.10.1386
   Sogo Y, 2007, J MATER SCI MATER M, V18, P1001, DOI 10.1007/s10856 006 0092 z
   Stevens MM, 2005, SCIENCE, V310, P1135, DOI 10.1126/science.1106587
   Swain RJ, 2007, BIOCHEM SOC T, V35, P544, DOI 10.1042/BST0350544
   SYFTESTAD GT, 1985, DEV BIOL, V110, P275, DOI 10.1016/0012 1606(85)90087 9
   Tarnowski CP, 2002, J BONE MINER RES, V17, P1118, DOI 10.1359/jbmr.2002.17.6.1118
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tzaphlidou M, 2004, J RADIOANAL NUCL CH, V259, P347, DOI 10.1023/B:JRNC.0000017316.20693.45
   Ushiki T, 2002, ARCH HISTOL CYTOL, V65, P109, DOI 10.1679/aohc.65.109
   Yerramshetty JS, 2008, BONE, V42, P476, DOI 10.1016/j.bone.2007.12.001
NR 42
TC 199
Z9 215
U1 1
U2 175
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476 1122
EI 1476 4660
J9 NAT MATER
JI Nat. Mater.
PD SEP
PY 2009
VL 8
IS 9
BP 763
EP 770
DI 10.1038/NMAT2505
PG 8
WC Chemistry, Physical; Materials Science, Multidisciplinary; Physics,
   Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science; Physics
GA 486RO
UT WOS:000269215500024
PM 19633661
DA 2025 08 17
ER

PT J
AU Yu, GY
   Corn, PG
   Shen, PF
   Song, JH
   Lee, YC
   Lin, SC
   Pan, J
   Agarwal, SK
   Panaretakis, T
   Pacifici, M
   Logothetis, CJ
   Yu Lee, L
   Lin, SH
AF Yu, Guoyu
   Corn, Paul G.
   Shen, Pengfei
   Song, Jian H.
   Lee, Yu Chen
   Lin, Song Chang
   Pan, Jing
   Agarwal, Sandeep K.
   Panaretakis, Theocharis
   Pacifici, Maurizio
   Logothetis, Christopher J.
   Yu Lee, Li Yuan
   Lin, Sue Hwa
TI Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer
   Bone Lesions by Blocking the Endothelial to Osteoblast Transition
SO CANCER RESEARCH
LA English
DT Article
ID HETEROTOPIC OSSIFICATION; CELL LINES; I RECEPTOR; BMP; DIFFERENTIATION;
   INDUCTION; GROWTH; LIMB; SKELETOGENESIS; IDENTIFICATION
AB ? Metastatic prostate cancer in the bone induces bone forming lesions that contribute to progression and therapy resistance. Prostate cancer induced bone formation originates from endothe lial cells (EC) that have undergone endothelial to osteoblast (EC to OSB) transition in response to tumor secreted BMP4. Current strategies targeting prostate cancer induced bone formation are lacking. Here, we show that activation of retinoic acid receptor (RAR) inhibits EC to OSB transition and reduces prostate cancer  induced bone formation. Treatment with palovarotene, an RARy agonist being tested for heterotopic ossification in fibrodysplasia ossificans progressiva, inhibited EC to OSB transition and oste oblast mineralization in vitro and decreased tumor induced bone formation and tumor growth in several osteogenic prostate cancer models, and similar effects were observed with the pan RAR agonist all trans retinoic acid (ATRA). Knockdown of RARa, (3, or y isoforms in ECs blocked BMP4 induced EC to OSB transition and osteoblast mineralization, indicating a role for all three isoforms in prostate cancer induced bone formation. Furthermore, treatment with palovarotene or ATRA reduced plasma Tenascin C, a factor secreted from EC OSB cells, which may be used to monitor treatment response. Mechanistically, BMP4 activated pSmad1 formed a complex with RAR in the nucleus of ECs to activate EC to OSB transition. RAR activation by palovarotene or ATRA caused pSmad1 degradation by recruiting the E3 ubiquitin ligase Smad ubiquitination regulatory factor1 (Smurf1) to the nuclear pSmad1/RARy complex, thus blocking EC to OSB transition. Collectively, these findings sug gest that palovarotene can be repurposed to target prostate cancer induced bone formation to improve clinical outcomes for patients with bone metastasis. Significance: This study provides mechanistic insights into how RAR agonists suppress prostate cancer induced bone formation and offers a rationale for developing RAR agonists for prostate cancer bone metastasis therapy. See related commentary by Bhowmick and Bhowmick, p. 2975
C1 [Yu, Guoyu; Shen, Pengfei; Lee, Yu Chen; Lin, Song Chang; Panaretakis, Theocharis; Logothetis, Christopher J.; Lin, Sue Hwa] Univ Texas M D Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA.
   [Corn, Paul G.; Song, Jian H.; Pan, Jing; Panaretakis, Theocharis; Logothetis, Christopher J.; Lin, Sue Hwa] Univ Texas M D Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA.
   [Agarwal, Sandeep K.; Yu Lee, Li Yuan] Baylor Coll Med, Dept Med, Sect Immunol Allergy & Rheumatol, Houston, TX USA.
   [Pacifici, Maurizio] Childrens Hosp Philadelphia, Translat Res Program Pediat Orthopaed, Philadelphia, PA USA.
   [Lin, Sue Hwa] Univ Texas, Grad Sch Biomed Sci Houston, Houston, TX USA.
   [Lin, Sue Hwa] Univ Texas M D Anderson Canc Ctr, Dept Translat Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine;
   University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia; University of Texas System; University of Texas System;
   UTMD Anderson Cancer Center
RP Lin, SH (通讯作者)，Univ Texas M D Anderson Canc Ctr, Dept Translat Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM yulee@bcm.edu
RI ; Panaretakis, Theocharis/A 9354 2010; pan, jing/KJL 2220 2024
OI Panaretakis, Theocharis/0000 0001 5754 6950; Corn,
   Paul/0000 0002 4106 6335
FU NIH [RO1 CA174798, P50 CA140388, P30 CA016672]; Cancer Prevention and
   Research Institute of Texas CPRIT [RP150179, RP190252]; Biology of
   Inflammation Center Arthritis Research Endowment [AR00108]
FX This work was supported by grants from the NIH RO1 CA174798 (to S. H.
   Lin and L. Y. Yu Lee) , P50 CA140388 (to C.J. Logothetis, S. .H Lin) ,
   P30 CA016672, Cancer Prevention and Research Institute of Texas CPRIT
   RP150179 and RP190252 (to S. H. Lin and L. Y. Yu Lee) , and the Biology
   of Inflammation Center Arthritis Research Endowment AR00108 (to L. Y.
   Yu Lee) .
CR Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861
   Cruz ACC, 2019, J APPL ORAL SCI, V27, DOI 10.1590/1678 7757 2018 0317
   Cao Y, 2014, SCI REP UK, V4, DOI 10.1038/srep04965
   Cash DE, 1997, J CELL BIOL, V136, P445, DOI 10.1083/jcb.136.2.445
   Chen MC, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/580736
   Corren J, 2019, NAT IMMUNOL, V20, P1603, DOI 10.1038/s41590 019 0524 9
   Dai JL, 2008, CANCER RES, V68, P5785, DOI 10.1158/0008 5472.CAN 07 6541
   Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008 5472.CAN 05 1891
   Engblom C, 2017, SCIENCE, V358, DOI 10.1126/science.aal5081
   Foster BA, 1997, CANCER RES, V57, P3325
   Gao M, 1999, J CELL PHYSIOL, V179, P336, DOI 10.1002/(SICI)1097 4652(199906)179:3<336::AID JCP11>3.0.CO;2 Q
   Glass CK, 2000, GENE DEV, V14, P121
   Hind M, 2009, CURR OPIN INVEST DR, V10, P1243
   Hoffman LM, 2006, J CELL BIOL, V174, P101, DOI 10.1083/jcb.200604150
   Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838
   Horwitz EM, 2010, NAT MED, V16, P1373, DOI 10.1038/nm1210 1373
   Kaplan J, 2012, GENE THER, V19, P786, DOI 10.1038/gt.2011.152
   Kini AR, 2001, BLOOD, V97, P3919, DOI 10.1182/blood.V97.12.3919
   Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200
   Larange A, 2016, ANNU REV IMMUNOL, V34, P369, DOI 10.1146/annurev immunol 041015 055427
   Lee YC, 2022, ONCOGENE, V41, P757, DOI 10.1038/s41388 021 02131 7
   Lee YC, 2015, CANCER RES, V75, P4949, DOI 10.1158/0008 5472.CAN 15 1215
   Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008 5472.CAN 10 4374
   Lin DPL, 2018, J PHARM PHARMACOL, V70, P307, DOI 10.1111/jphp.12862
   Lin E, 2014, CELL PHYSIOL BIOCHEM, V33, P1620, DOI 10.1159/000358724
   Lin SC, 2017, DEV CELL, V41, P467, DOI 10.1016/j.devcel.2017.05.005
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Medici D, 2010, NAT MED, V16, P1400, DOI 10.1038/nm.2252
   Midwood KS, 2011, CELL MOL LIFE SCI, V68, P3175, DOI 10.1007/s00018 011 0783 6
   Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156
   Montesano T, 2009, CLIN TER, V160, P193
   Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955 0674(98)80015 X
   Morrissey C, 2010, NEOPLASIA, V12, P192, DOI 10.1593/neo.91836
   Nordstrand A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041223
   PACIFICI M, 1980, EXP CELL RES, V129, P469, DOI 10.1016/0014 4827(80)90517 0
   Pacifici M, 2018, BONE, V109, P267, DOI 10.1016/j.bone.2017.08.010
   Pan TH, 2021, ONCOGENE, V40, P4592, DOI 10.1038/s41388 021 01874 7
   Pan TH, 2020, MOL CANCER THER, V19, P1266, DOI 10.1158/1535 7163.MCT 19 0174
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Pignolo R, 2020, ASBMR VIRTUAL M
   Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096
   Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02171 2
   Shimono K, 2011, NAT MED, V17, P454, DOI 10.1038/nm.2334
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Siddikuzzaman, 2011, IMMUNOPHARM IMMUNOT, V33, P241, DOI 10.3109/08923973.2010.521507
   Supakul S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051079
   Tabatabai TS, 2021, MOL BIOL RES COMMUN, V10, P93, DOI 10.22099/mbrc.2021.39354.1578
   Teixeira CC, 2010, J BIOL CHEM, V285, P31055, DOI 10.1074/jbc.M109.079962
   Trump DL, 1997, CANCER CHEMOTH PHARM, V39, P349, DOI 10.1007/s002800050582
   van Dinther M, 2010, J BONE MINER RES, V25, P1208, DOI [10.1002/jbmr.091110, 10.1359/jbmr.091110]
   Walter Yohrling J, 2004, CLIN CANCER RES, V10, P2179, DOI 10.1158/1078 0432.CCR 03 1013
   Watson PA, 2005, CANCER RES, V65, P11565, DOI 10.1158/0008 5472.CAN 05 3441
   Weston AD, 2000, J CELL BIOL, V148, P679, DOI 10.1083/jcb.148.4.679
   Weston AD, 2002, J CELL BIOL, V158, P39, DOI 10.1083/jcb.200112029
   Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109
   Yang J, 2013, AM J PHYSIOL LUNG C, V305, pL312, DOI 10.1152/ajplung.00054.2013
   Ye XC, 2007, FRONT BIOSCI, V12, P3273, DOI 10.2741/2311
   Yen YT, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003 021 02175 1
   Yu G, 2021, ISCIENCE, V24
   Yu Lee LY, 2018, CANCER RES, V78, P2911, DOI 10.1158/0008 5472.CAN 17 1051
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 61
TC 15
Z9 15
U1 2
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD SEP 1
PY 2022
VL 82
IS 17
BP 3158
EP 3171
DI 10.1158/0008 5472.CAN 22 0170
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 4V4GD
UT WOS:000859435900001
PM 35802768
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Wu, XH
   Zhao, KX
   Fang, XX
   Lu, F
   Cheng, P
   Song, XT
   Zhang, WK
   Yao, C
   Zhu, JL
   Chen, HX
AF Wu, Xinhui
   Zhao, Kangxian
   Fang, Xiaoxin
   Lu, Feng
   Cheng, Pu
   Song, Xiaoting
   Zhang, Weikang
   Yao, Can
   Zhu, Jiling
   Chen, Haixiao
TI Saikosaponin D Inhibited IL 1β Induced ATDC 5 Chondrocytes Apoptosis
   In Vitro and Delayed Articular Cartilage Degeneration in OA Model
   Mice In Vivo
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Saikosaponin D; osteoarthritis; Nrf2; HO 1; ROS; NF kappa B; therapy
ID SIGNALING PATHWAY; OSTEOARTHRITIS; ACTIVATION; SYSTEM; CELLS; RNA
AB Osteoarthritis (OA) is the most common joint disease in the elderly, characterized by cartilage degradation and proliferation of subchondral bone. The pathogenesis of OA involves a variety of inflammatory mediators, including nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor (TNF) alpha, and interleukin (IL) 1 beta. From the molecular mechanism, the nuclear factor erythroid 2 related factor (Nrf2)/heme oxygenase 1 (HO 1) pathway and the expression of ROS regulated the production of the above inflammatory mediators. Saikosaponin D (SSD), which is an active ingredient isolated from Bupleurum, has various biological functions. In this study, IL 1 beta was used as a pro inflammatory factor to create an in vitro OA model. According to the results of high density culture, qPCR, ROS measurement, Western blot, and immunofluorescence, SSD activated the Nrf2/HO 1/ROS axis, inhibited the production of inflammatory mediators, and protected against ECM destruction. The DMM mouse model was used as a model of OA in mice. From the results of safranin O/fast green staining, hematoxylin eosin staining, tartrate resistant acid phosphatase (TRAP) staining, and OARSI scores, SSD protected against the mice knee articular cartilage degeneration and reduced the number of osteoclasts in the subchondral bone. Experimental results found that SSD suppressed IL 1 beta induced differentiated ATDC 5 chondrocytes apoptosis via the Nrf2/HO 1/ROS axis in vitro. SSD delayed the progression of OA in DMMs model mice in vivo. Therefore, SSD has the potential to become a drug for clinical treatment of OA.
C1 [Wu, Xinhui; Zhao, Kangxian; Cheng, Pu; Song, Xiaoting; Zhang, Weikang; Yao, Can; Chen, Haixiao] Wenzhou Med Univ, Dept Orthoped, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China.
   [Wu, Xinhui; Zhao, Kangxian; Cheng, Pu; Song, Xiaoting; Zhang, Weikang; Zhu, Jiling; Chen, Haixiao] Wenzhou Med Univ, Wenzhou, Peoples R China.
   [Fang, Xiaoxin; Lu, Feng] Zhejiang Univ, Sch Med, Hangzhou, Peoples R China.
   [Fang, Xiaoxin; Lu, Feng; Chen, Haixiao] Zhejiang Univ, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Zhejiang
   University; Zhejiang University
RP Chen, HX (通讯作者)，Wenzhou Med Univ, Dept Orthoped, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China.; Chen, HX (通讯作者)，Wenzhou Med Univ, Wenzhou, Peoples R China.; Chen, HX (通讯作者)，Zhejiang Univ, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China.
EM drchx@126.com
FU Natural Science Foundation of Zhejiang Province [LY20H060006];
   Experimental Animal Science Project of Zhejiang Province [LGD19H310001]
FX Funding The research was funded by the Natural Science Foundation of
   Zhejiang Province (No. LY20H060006) and the Experimental Animal Science
   Project of Zhejiang Province (No. LGD19H310001).
CR Abella V, 2016, SCI REP UK, V6, DOI 10.1038/srep20356
   Amin A R, 2000, Curr Rheumatol Rep, V2, P447, DOI 10.1007/s11926 000 0019 5
   Martel Pelletier Johanne, 2016, Nat Rev Dis Primers, V2, P16072, DOI [10.1038/nrdp.2016.73, 10.1038/nrdp.2016.72]
   Azab A, 2016, MOLECULES, V21, DOI 10.3390/molecules21101321
   Bellezza Ilaria, 2010, Cancers (Basel), V2, P483, DOI 10.3390/cancers2020483
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140 6736(11)60243 2
   Cao PH, 2020, EXPERT OPIN PHARMACO, V21, P797, DOI 10.1080/14656566.2020.1732924
   Chu CR, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01209
   Cinelli MA, 2020, MED RES REV, V40, P158, DOI 10.1002/med.21599
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Gómez R, 2009, ARTHRITIS RHEUM US, V60, P1704, DOI 10.1002/art.24522
   Guilak F, 2018, MATRIX BIOL, V71 72, P40, DOI 10.1016/j.matbio.2018.05.008
   Ho FM, 2007, BIOCHEM PHARMACOL, V74, P298, DOI 10.1016/j.bcp.2007.04.008
   Hoshi H, 2017, CELL TISSUE RES, V368, P379, DOI 10.1007/s00441 016 2563 y
   Hosseinzadeh A, 2016, J PINEAL RES, V61, P411, DOI 10.1111/jpi.12362
   Huang CY, 2009, EUR J CLIN INVEST, V39, P417, DOI 10.1111/j.1365 2362.2009.02106.x
   Huang H, 2017, SCI REP UK, V7, DOI 10.1038/srep42294
   Jeon J, 2020, ANN RHEUM DIS, V79, P1635, DOI 10.1136/annrheumdis 2020 217904
   Jia YW, 2019, INFLAMMATION, V42, P1754, DOI 10.1007/s10753 019 01037 7
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Kim JH, 2014, CELL, V156, P730, DOI 10.1016/j.cell.2014.01.007
   Lai MR, 2020, ONCOTARGETS THER, V13, P9465, DOI 10.2147/OTT.S263322
   Latourte A, 2020, NAT REV RHEUMATOL, V16, P673, DOI 10.1038/s41584 020 00518 6
   Li C, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392 019 0037 x
   Li PZ, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2020.106288
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018 016 2223 0
   Lu MC, 2016, MED RES REV, V36, P924, DOI 10.1002/med.21396
   Ma HL, 2007, OSTEOARTHR CARTILAGE, V15, P695, DOI 10.1016/j.joca.2006.11.005
   Malemud CJ, 2019, BIOCHEM PHARMACOL, V165, P33, DOI 10.1016/j.bcp.2019.02.033
   Mehana ESE, 2019, LIFE SCI, V234, DOI 10.1016/j.lfs.2019.116786
   Morimoto H, 2013, CELL TISSUE RES, V351, P41, DOI 10.1007/s00441 012 1521 6
   Qin TT, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.243
   Rigoglou S, 2013, INT J BIOCHEM CELL B, V45, P2580, DOI 10.1016/j.biocel.2013.08.018
   Saha S, 2020, MOLECULES, V25, DOI 10.3390/molecules25225474
   Shi YF, 2022, PHYTOMEDICINE, V98, DOI 10.1016/j.phymed.2022.153928
   Sondergaard BC, 2010, OSTEOARTHR CARTILAGE, V18, P279, DOI 10.1016/j.joca.2009.11.005
   Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52
   Tong DL, 2018, CANCER METAST REV, V37, P355, DOI 10.1007/s10555 018 9752 y
   Wojdasiewicz P, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/561459
   Yamamoto M, 2018, PHYSIOL REV, V98, P1169, DOI 10.1152/physrev.00023.2017
   Yan ZJ, 2020, J CELL MOL MED, V24, P13046, DOI 10.1111/jcmm.15905
   Yuan BC, 2017, PHARM BIOL, V55, P620, DOI 10.1080/13880209.2016.1262433
   Zhai KF, 2018, J AGR FOOD CHEM, V66, P6073, DOI 10.1021/acs.jafc.8b02241
   Zhu XB, 2019, ANN RHEUM DIS, V78, P1420, DOI 10.1136/annrheumdis 2018 214940
NR 44
TC 9
Z9 12
U1 2
U2 17
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 18
PY 2022
VL 13
AR 845959
DI 10.3389/fphar.2022.845959
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 0Y1YO
UT WOS:000790191600001
PM 35370642
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wongthong, U
   Khemthong, P
   Youngjan, S
   Phanthasri, J
   Toso, M
   Rungnim, C
   Boonrungsiman, S
   Butburee, T
   Sriring, M
   Chanthad, C
   Sreearunothai, P
   Ikoma, T
   Nakajima, H
   Klysubun, W
   Supruangnet, R
   Singhatanadgit, W
AF Wongthong, Unchidtha
   Khemthong, Pongtanawat
   Youngjan, Saran
   Phanthasri, Jakkapop
   Toso, Montree
   Rungnim, Chompoonut
   Boonrungsiman, Suwimon
   Butburee, Teera
   Sriring, Manus
   Chanthad, Chalathorn
   Sreearunothai, Paiboon
   Ikoma, Toshiyuki
   Nakajima, Hideki
   Klysubun, Wantana
   Supruangnet, Ratchadaporn
   Singhatanadgit, Weerachai
TI Rational design for MgO modified porous carbon towards enhancing
   zoledronic acid adsorption
SO APPLIED SURFACE SCIENCE
LA English
DT Article
DE Bisphosphonate; NEXAFS; XPS; XANES; MgO; AC; Zoledronic acid adsorption;
   Cytotoxicity
ID REMOVAL; BISPHOSPHONATES; CYTOTOXICITY; CATALYSTS; COMPOSITE; IRON
AB Nitrogen containing bisphosphonates (N BPs), namely zoledronic acid (ZA), are typically used as antiresorptive drugs by inhibiting osteoclast formation and functions. However, the long term use of ZA may increase the risk of osteonecrosis of the jaw (ONJ) after tooth extraction. Hence, this study aims to develop a new sustainable adsorption material for capturing the exposed ZA. The porous activated carbon (AC) incorporated with MgO at various ratios was successfully developed and extensively characterized by several techniques. The adsorption behaviors correlated to their physicochemical properties for ZA removal were also carried out. Furthermore, density functional theory (DFT) was applied to investigate the adsorption mechanism of ZA adsorbed on a carbon surface functionalized with crystalline MgO. The results found that the well dispersed MgO/AC provided a good adsorption capacity for ZA. The MgO with 15 % wt loading shows the highest performance (73 mg/g) on adsorbing ZA under a neutral condition compared to a bare AC (14 mg/g). The MgO/AC adsorbents were cytocompatible with human monocytic cells in vitro. The DFT result demonstrated that the MgO cluster is an active site for ZA adsorption. This evidence could imply that MgO/AC is a potential adsorbent for ZA removal in preventing ZA related bone complications.
C1 [Wongthong, Unchidtha; Ikoma, Toshiyuki] Natl Sci & Technol Dev Agcy NSTDA, Thailand Adv Inst Sci & Technol TAIST, Pathum Thani 12120, Thailand.
   [Wongthong, Unchidtha; Ikoma, Toshiyuki] Natl Sci & Technol Dev Agcy NSTDA, Tokyo Inst Technol Tokyo Tech, Pathum Thani 12120, Thailand.
   [Wongthong, Unchidtha; Sreearunothai, Paiboon] Thammasat Univ, Sirindhorn Int Inst Technol, Pathum Thani 12120, Thailand.
   [Khemthong, Pongtanawat; Youngjan, Saran; Phanthasri, Jakkapop; Boonrungsiman, Suwimon; Butburee, Teera; Sriring, Manus; Chanthad, Chalathorn] Natl Sci & Technol Dev Agcy NSTDA, Natl Nanotechnol Ctr NANOTEC, Pathum Thani 12120, Thailand.
   [Toso, Montree] Stem Cell Life Res Ctr, Salaya 73170, Nakorn Pathom, Thailand.
   [Rungnim, Chompoonut] Natl Sci & Technol Dev Agcy NSTDA, Natl Elect & Comp Technol Ctr NECTEC, Pathum Thani 12120, Thailand.
   [Nakajima, Hideki; Klysubun, Wantana; Supruangnet, Ratchadaporn] Synchrotron Light Res Inst, Nakhon Ratchasima 30000, Thailand.
   [Singhatanadgit, Weerachai] Thammasat Univ Rangsit Campus, Fac Dent, Pathum Thani 12120, Thailand.
   [Singhatanadgit, Weerachai] Thammasat Univ Rangsit Campus, Res Unit Mineralized Tissue Reconstruct, Pathum Thani 12120, Thailand.
C3 National Science & Technology Development Agency   Thailand; National
   Science & Technology Development Agency   Thailand; Thammasat
   University; National Science & Technology Development Agency   Thailand;
   National Nanotechnology Center (NANOTEC); National Science & Technology
   Development Agency   Thailand; National Electronics & Computer
   Technology Center (NECTEC); Thammasat University; Thammasat University
RP Khemthong, P (通讯作者)，Natl Sci & Technol Dev Agcy NSTDA, Natl Nanotechnol Ctr NANOTEC, Pathum Thani 12120, Thailand.; Singhatanadgit, W (通讯作者)，Thammasat Univ Rangsit Campus, Fac Dent, Pathum Thani 12120, Thailand.; Singhatanadgit, W (通讯作者)，Thammasat Univ Rangsit Campus, Res Unit Mineralized Tissue Reconstruct, Pathum Thani 12120, Thailand.
EM pongtanawat@nanotec.or.th; s wrch@staff.tu.ac.th
RI NAKAJIMA, Hideki/O 7312 2015; Ikoma, Toshiyuki/E 4288 2012;
   Singhatanadgit, Weerachai/V 4967 2019; Khemthong,
   Pongtanawat/F 1118 2011; Sreearunothai, Dr.Paiboon/GLU 0083 2022;
   Phanthasri, Jakkapop/GSD 6456 2022; Nakajima, Hideki/O 7312 2015;
   Rungnim, Chompoonut/NKP 0291 2025
OI Phanthasri, Jakkapop/0000 0002 6479 2743; Boonrungsiman,
   Suwimon/0000 0002 9550 939X; Nakajima, Hideki/0000 0001 9167 1288; 
FU National Nanotechnology Center [P1752318, P2052530]; Thailand Science
   Research and Innovation Fundamental Fund [TUFF 83/2566]; Thammasat
   University Research Fund [TUFT FF 40/2565]; Sirindhorn International
   Institute of Technology (SIIT); National Science and Technology
   Development Agency (NSTDA) [S CA CO 2561  8185 TH]; National Sci  ence
   and Technology Development Agency (NSTDA) [SERE G S1Y18/010]; Thailand
   Advanced Institute of Science and Technology   Tokyo Institute of
   Technology: TAIST Tokyo Tech
FX This research project is supported by National Nanotechnology Center
   (Grant no. P1752318, P2052530), Thailand Science Research and Innovation
   Fundamental Fund (Contract Number TUFF 83/2566) and Thammasat University
   Research Fund (Contract Number TUFT FF 40/2565). Scholarship for
   Graduate Student Studying at SIIT by Sirindhorn International Institute
   of Technology (SIIT) and National Science and Technology Development
   Agency (NSTDA) (SERE G S1Y18/010) and Thailand Advanced Institute of
   Science and Technology   Tokyo Institute of Technology: TAIST Tokyo Tech
   (S CA CO 2561  8185 TH) are also appreciated for MS scholarship (Ms.
   Unchidtha Wongthong).
CR Alothaid H, 2022, SAUDI J BIOL SCI, V29, DOI 10.1016/j.sjbs.2022.103387
   Chen EYT, 2012, J BIOMED MATER RES A, V100A, P2006, DOI 10.1002/jbm.a.34201
   de Almeida AD, 2018, J BIOMED MATER RES B, V106, P1799, DOI 10.1002/jbm.b.33995
   de Sousa AF, 2012, CHEM ENG J, V210, P143, DOI 10.1016/j.cej.2012.08.080
   Eivazzadeh Keihan R, 2019, J ADV RES, V18, P185, DOI 10.1016/j.jare.2019.03.011
   Hallaji H, 2015, J TAIWAN INST CHEM E, V46, P109, DOI 10.1016/j.jtice.2014.09.007
   Hassan HS, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 12648 w
   Jia G, 2005, ENVIRON SCI TECHNOL, V39, P1378, DOI 10.1021/es048729l
   Kondo A, 2021, J PHYS CHEM C, V125, P10937, DOI 10.1021/acs.jpcc.1c01470
   Li MX, 2016, ENVIRON REV, V24, P319, DOI 10.1139/er 2015 0080
   LIPPENS BC, 1965, J CATAL, V4, P319, DOI 10.1016/0021 9517(65)90307 6
   Liu JW, 2019, J ENVIRON MANAGE, V250, DOI 10.1016/j.jenvman.2019.109438
   Mikhalovsky SV, 2012, NOVEL CARBON ADSORBENTS, P639, DOI 10.1016/B978 0 08 097744 7.00021 1
   Miksad RA, 2011, ONCOLOGIST, V16, P121, DOI 10.1634/theoncologist.2010 0183
   Najm MS, 2014, ORAL DIS, V20, P94, DOI 10.1111/odi.12080
   Nicolatou Galitis O, 2019, OR SURG OR MED OR PA, V127, P117, DOI 10.1016/j.oooo.2018.09.008
   Paulo S, 2020, MATERIALS, V13, DOI 10.3390/ma13081955
   Paulo S, 2019, MATERIALS, V12, DOI 10.3390/ma12111840
   Phanthasri J, 2018, APPL SURF SCI, V427, P545, DOI 10.1016/j.apsusc.2017.09.032
   Qayoom I, 2018, BONE JOINT RES, V7, P548, DOI 10.1302/2046 3758.710.BJR 2018 0015.R2
   Rasmusson L, 2014, INT J DENT, V2014, DOI 10.1155/2014/471035
   Ri MH, 2016, J MATER SCI, V51, P3125, DOI 10.1007/s10853 015 9622 8
   Ruggiero S.L., 2022, J ORAL MAXILLOFACIAL
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Saito N, 2009, CHEM SOC REV, V38, P1897, DOI 10.1039/b804822n
   Sedlmair J, 2012, J SOIL SEDIMENT, V12, P24, DOI 10.1007/s11368 011 0385 9
   Shahkarami S, 2016, IND ENG CHEM RES, V55, P5955, DOI 10.1021/acs.iecr.5b04824
   Siriwardane IW, 2017, MATER DESIGN, V136, P127, DOI 10.1016/j.matdes.2017.09.034
   Thomele D, 2021, CRYST GROWTH DES, V21, P4674, DOI 10.1021/acs.cgd.1c00535
   Walker M, 2013, J PHYS CHEM A, V117, P12590, DOI 10.1021/jp408166m
   Wall NA, 2005, APPL GEOCHEM, V20, P1704, DOI 10.1016/j.apgeochem.2005.04.004
   Wang SH, 2021, MATERIALS, V14, DOI 10.3390/ma14020441
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Zhao PF, 2016, ENERG FUEL, V30, P7543, DOI 10.1021/acs.energyfuels.6b01223
   Zu YH, 2010, ENERG FUEL, V24, P3810, DOI 10.1021/ef100419m
NR 35
TC 3
Z9 5
U1 1
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0169 4332
EI 1873 5584
J9 APPL SURF SCI
JI Appl. Surf. Sci.
PD APR 1
PY 2023
VL 615
AR 156359
DI 10.1016/j.apsusc.2023.156359
EA JAN 2023
PG 10
WC Chemistry, Physical; Materials Science, Coatings & Films; Physics,
   Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science; Physics
GA 8L1VI
UT WOS:000923576200001
DA 2025 08 17
ER

PT J
AU Watson, CJ
   Tang, WJ
   Rojas, MF
   Fiedler, IAK
   de Oca, EMM
   Cronrath, AR
   Callies, LK
   Swearer, AA
   Ahmed, AR
   Sethuraman, V
   Addish, S
   Farr, GH
   Gómez, AE
   Rai, J
   Monstad Rios, AT
   Gardiner, EM
   Karasik, D
   Maves, L
   Busse, B
   Hsu, YH
   Kwon, RY
AF Watson, Claire J.
   Tang, W. Joyce
   Rojas, Maria F.
   Fiedler, Imke A. K.
   de Oca, Ernesto Morfin Montes
   Cronrath, Andrea R.
   Callies, Lulu K.
   Swearer, Avery Angell
   Ahmed, Ali R.
   Sethuraman, Visali
   Addish, Sumaya
   Farr, Gist H.
   Gomez, Arianna Ericka
   Rai, Jyoti
   Monstad Rios, Adrian T.
   Gardiner, Edith M.
   Karasik, David
   Maves, Lisa
   Busse, Bjorn
   Hsu, Yi Hsiang
   Kwon, Ronald Young
TI wnt16 regulates spine and muscle morphogenesis through parallel
   signals from notochord and dermomyotome
SO PLOS GENETICS
LA English
DT Article
ID BONE MASS; NO TAIL; CELL; EXPRESSION; PROTEIN; SOMITE; REGENERATION;
   ASSOCIATION; INDUCTION; GENETICS
AB Bone and muscle are coupled through developmental, mechanical, paracrine, and autocrine signals. Genetic variants at the CPED1 WNT16 locus are dually associated with bone  and muscle related traits. While Wnt16 is necessary for bone mass and strength, this fails to explain pleiotropy at this locus. Here, we show wnt16 is required for spine and muscle morphogenesis in zebrafish. In embryos, wnt16 is expressed in dermomyotome and developing notochord, and contributes to larval myotome morphology and notochord elongation. Later, wnt16 is expressed at the ventral midline of the notochord sheath, and contributes to spine mineralization and osteoblast recruitment. Morphological changes in wnt16 mutant larvae are mirrored in adults, indicating that wnt16 impacts bone and muscle morphology throughout the lifespan. Finally, we show that wnt16 is a gene of major effect on lean mass at the CPED1 WNT16 locus. Our findings indicate that Wnt16 is secreted in structures adjacent to developing bone (notochord) and muscle (dermomyotome) where it affects the morphogenesis of each tissue, thereby rendering wnt16 expression into dual effects on bone and muscle morphology. This work expands our understanding of wnt16 in musculoskeletal development and supports the potential for variants to act through WNT16 to influence bone and muscle via parallel morphogenetic processes.
   Author summary
   In humans, genetic variants (DNA sequences that vary amongst individuals) have been identified that appear to influence two tissues, bone and skeletal muscle. However, how single genes and genetic variants exert dual influence on both tissues is not well understood. In this study, we found that the wnt16 gene is necessary for specifying the size and shape of both muscle and bone during development in zebrafish. We also disentangled how wnt16 affects both tissues: distinct cellular populations adjacent to muscle and bone secrete Wnt16, where it acts as a signal guiding the size and shape of each tissue. This is important because in humans, genetic variants near the WNT16 gene have effects on both bone  and muscle related traits. This study expands our understanding of the role of WNT16 in bone and muscle development, and helps to explain how genetic variants near WNT16 affect traits for both tissues. Moreover, WNT16 is actively being explored as a target for osteoporosis therapies, thus our study could have implications with regard to the potential of targeting WNT16 to treat bone and muscle simultaneously.
C1 [Watson, Claire J.; Tang, W. Joyce; Rojas, Maria F.; de Oca, Ernesto Morfin Montes; Cronrath, Andrea R.; Callies, Lulu K.; Swearer, Avery Angell; Ahmed, Ali R.; Sethuraman, Visali; Addish, Sumaya; Gomez, Arianna Ericka; Rai, Jyoti; Monstad Rios, Adrian T.; Gardiner, Edith M.; Kwon, Ronald Young] Univ Washington, Sch Med, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA.
   [Watson, Claire J.; Tang, W. Joyce; Rojas, Maria F.; de Oca, Ernesto Morfin Montes; Cronrath, Andrea R.; Callies, Lulu K.; Swearer, Avery Angell; Ahmed, Ali R.; Sethuraman, Visali; Addish, Sumaya; Gomez, Arianna Ericka; Rai, Jyoti; Monstad Rios, Adrian T.; Gardiner, Edith M.; Kwon, Ronald Young] Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98195 USA.
   [Fiedler, Imke A. K.; Busse, Bjorn] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Hamburg, Germany.
   [Farr, Gist H.; Maves, Lisa] Univ Washington, Sch Med, Dept Pediat, Div Cardiol, Seattle, WA 98195 USA.
   [Farr, Gist H.; Maves, Lisa] Seattle Childrens Res Inst, Ctr Dev Biol & Regenerat Med, Seattle, WA USA.
   [Karasik, David; Hsu, Yi Hsiang] Hebrew SeniorLife, Inst Aging Res, Boston, MA USA.
   [Hsu, Yi Hsiang] Harvard Med Sch, Dept Med, Boston, MA 02115 USA.
   [Hsu, Yi Hsiang] Broad Inst Harvard & Massachusetts Inst Technol, Boston, MA USA.
C3 University of Washington; University of Washington Seattle; University
   of Washington; University of Washington Seattle; University of Hamburg;
   University Medical Center Hamburg Eppendorf; University of Washington;
   University of Washington Seattle; Seattle Children's Hospital; Harvard
   University; Harvard University Medical Affiliates; Hebrew SeniorLife;
   Harvard University; Harvard Medical School; Harvard University;
   Massachusetts Institute of Technology (MIT); Broad Institute
RP Kwon, RY (通讯作者)，Univ Washington, Sch Med, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA.; Kwon, RY (通讯作者)，Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98195 USA.
EM ronkwon@uw.edu
RI ; Busse, Björn/AAC 4033 2020
OI Gomez, Arianna/0000 0002 9334 4130; RAI, JYOTI/0000 0001 6101 739X;
   Callies, LuLu/0000 0003 3866 0808; Karasik, David/0000 0002 8826 0530;
   Maves, Lisa/0000 0002 9798 790X; Ahmed, Ali/0000 0003 1122 5953; Rojas,
   Maria Fernanda/0000 0001 8344 4384
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of
   the National Institutes of Health [AR074417, AR072199]; UW Royalty
   Research Fund [A139347]; University of Washington Department of
   Orthopaedics and Sports Medicine; Institute for Stem Cell and
   Regenerative Medicine; Mary Gates Endowment
FX Research reported in this publication was supported by the National
   Institute of Arthritis and Musculoskeletal and Skin Diseases of the
   National Institutes of Health under Award Numbers AR074417 (R.Y.K.) and
   AR072199 (Y. H.H.). The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institutes of Health. The authors would also like to
   acknowledge support from UW Royalty Research Fund Grant A139347
   (R.Y.K.), a Seed Grant from the University of Washington Department of
   Orthopaedics and Sports Medicine (R.Y.K.), an Innovation Pilot Award
   from the Institute for Stem Cell and Regenerative Medicine (C.J.W.), and
   scholarships from the Mary Gates Endowment (A.R.A. and V.S.). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alam I, 2016, ENDOCRINOLOGY, V157, P722, DOI 10.1210/en.2015 1281
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Babaei F, 2016, ZEBRAFISH, V13, P310, DOI 10.1089/zeb.2016.1245
   Bagwell J, 2020, ELIFE, V9, DOI 10.7554/eLife.51221
   Berberoglu MA, 2017, DEV BIOL, V424, P162, DOI 10.1016/j.ydbio.2017.03.004
   Boudaoud A, 2014, NAT PROTOC, V9, P457, DOI 10.1038/nprot.2014.024
   Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936
   Brotto M, 2015, BONE, V80, P109, DOI 10.1016/j.bone.2015.02.010
   Bunis DG, 2020, BIOINFORMATICS, V36, P5535, DOI 10.1093/bioinformatics/btaa1011
   Busse B, 2020, J ORTHOP RES, V38, P925, DOI 10.1002/jor.24539
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Caetano Lopes J, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.181834
   Chatani M, 2011, DEV BIOL, V360, P96, DOI 10.1016/j.ydbio.2011.09.013
   Chesi A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09302 x
   Christ B, 2004, ANAT EMBRYOL, V208, P333, DOI 10.1007/s00429 004 0408 z
   Clements WK, 2011, NATURE, V474, P220, DOI 10.1038/nature10107
   Crepaldi G, 2005, J Endocrinol Invest, V28, P66
   Currie PD, 1996, NATURE, V382, P452, DOI 10.1038/382452a0
   Daane JM, 2019, NAT ECOL EVOL, V3, P1102, DOI 10.1038/s41559 019 0914 2
   DeLaurier A, 2010, GENESIS, V48, P505, DOI 10.1002/dvg.20639
   Dietrich K, 2021, J BONE MINER RES, V36, P436, DOI 10.1002/jbmr.4256
   El Brolosy MA, 2019, NATURE, V568, P193, DOI 10.1038/s41586 019 1064 z
   Ellis K, 2013, J CELL BIOL, V200, P667, DOI 10.1083/jcb.201212095
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   Farnsworth DR, 2020, DEV BIOL, V459, P100, DOI 10.1016/j.ydbio.2019.11.008
   Fiedler IAK, 2018, J BONE MINER RES, V33, P1489, DOI 10.1002/jbmr.3445
   Fleming A, 2004, DEVELOPMENT, V131, P873, DOI 10.1242/dev.00952
   Goeman JJ, 2004, BIOINFORMATICS, V20, P93, DOI 10.1093/bioinformatics/btg382
   Gros J, 2009, NATURE, V457, P589, DOI 10.1038/nature07564
   Grotmol S, 2005, J ANAT, V206, P427, DOI 10.1111/j.1469 7580.2005.00408.x
   Heilig AK, 2022, ELIFE, V11, DOI 10.7554/eLife.71845
   Hirschfeld HP, 2017, OSTEOPOROSIS INT, V28, P2781, DOI 10.1007/s00198 017 4151 8
   Hollway GE, 2007, DEV CELL, V12, P207, DOI 10.1016/j.devcel.2007.01.001
   Hunter CJ, 2003, J ANAT, V202, P279, DOI 10.1046/j.1469 7580.2003.00162.x
   Hur M, 2017, ELIFE, V6, DOI 10.7554/eLife.26014
   Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879
   JAYNE BC, 1994, J MORPHOL, V220, P185, DOI 10.1002/jmor.1052200207
   Judex S, 2010, METHODS, V50, P14, DOI 10.1016/j.ymeth.2009.05.017
   Kague E, 2022, GENES BASEL, V13, DOI 10.3390/genes13020279
   Kague E, 2019, FASEB J, V33, P9116, DOI 10.1096/fj.201802654RR
   Karasik D, 2008, J BONE MINER RES, V23, P788, DOI 10.1359/JBMR.080218
   Keenan SR, 2019, J DEV BIOL, V7, DOI 10.3390/jdb7020012
   Kelahmetoglu Y, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.591476
   Kemp C, 2005, DEV DYNAM, V233, P1064, DOI 10.1002/dvdy.20408
   Kiel DP, 2020, J BONE MINER RES, V35, P1626, DOI 10.1002/jbmr.4147
   KIMURA Y, 1995, DEV BIOL, V169, P347, DOI 10.1006/dbio.1995.1149
   Kirk B, 2020, J CACHEXIA SARCOPENI, V11, P609, DOI 10.1002/jcsm.12567
   Kwon RY, 2019, BONE, V126, P37, DOI 10.1016/j.bone.2019.02.009
   Lee SJ, 2020, P NATL ACAD SCI USA, V117, P23942, DOI 10.1073/pnas.2014716117
   Lim YW, 2017, CURR BIOL, V27, P1968, DOI 10.1016/j.cub.2017.05.067
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Ma RC, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007775
   Makita R, 1998, MECH DEVELOP, V71, P165, DOI 10.1016/S0925 4773(98)00013 6
   Maves L, 2007, DEVELOPMENT, V134, P3371, DOI 10.1242/dev.003905
   Maynard RD, 2018, GENE, V674, P127, DOI 10.1016/j.gene.2018.06.060
   McGowan LM, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10461
   McLaren S.B.P., 2021, DEVELOPMENT, V148, DOI [DOI 10.1242/DEV.199459, 10.1242/dev.199459]
   Medina Gomez C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00108 3
   Medina Gomez C, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002718
   Meijering EHW, 2001, MED IMAGE ANAL, V5, P111, DOI 10.1016/S1361 8415(00)00040 2
   Mitchell JA, 2015, J BONE MINER RES, V30, P1676, DOI 10.1002/jbmr.2508
   Movérare Skrtic S, 2015, P NATL ACAD SCI USA, V112, P14972, DOI 10.1073/pnas.1520408112
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Novotny SA, 2015, PHYSIOLOGY, V30, P8, DOI 10.1152/physiol.00033.2014
   Peck SH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10692 5
   Peng C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.643894
   Nguyen PD, 2014, NATURE, V512, P314, DOI 10.1038/nature13678
   Pipalia TG, 2016, DIS MODEL MECH, V9, P671, DOI 10.1242/dmm.022251
   Postlethwait JH, 2019, ZEBRAFISH, V16, P469, DOI 10.1089/zeb.2019.1760
   Pulit SL, 2019, HUM MOL GENET, V28, P166, DOI 10.1093/hmg/ddy327
   Qu XC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136673
   Recidoro AM, 2014, J BONE MINER RES, V29, P2346, DOI 10.1002/jbmr.2274
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schmidt U., Cell Detection with Star Convex Polygons
   SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021
   Seo HC, 1998, MECH DEVELOP, V70, P49, DOI 10.1016/S0925 4773(97)00175 5
   Takada R, 2006, DEV CELL, V11, P791, DOI 10.1016/j.devcel.2006.10.003
   Tang WJ, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2022.103784
   Tlili S, 2019, P NATL ACAD SCI USA, V116, P25430, DOI 10.1073/pnas.1900819116
   Tonelli F, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00489
   Trajanoska K, 2019, CURR OSTEOPOROS REP, V17, P86, DOI 10.1007/s11914 019 00505 1
   Tuladhar R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12028 5
   Urso K, 2019, BONE, V127, P104, DOI 10.1016/j.bone.2019.06.002
   van der Meulen T, 2005, J EXP BIOL, V208, P3675, DOI 10.1242/jeb.01826
   von Maltzahn J, 2012, TRENDS CELL BIOL, V22, P602, DOI 10.1016/j.tcb.2012.07.008
   Walker JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075422
   Wang X, 2021, APPL SCI BASEL, V11, DOI 10.3390/app112210510
   Watson CJ, 2020, CELL SYST, V10, P275, DOI 10.1016/j.cels.2020.02.007
   Weinberg ES, 1996, DEVELOPMENT, V122, P271
   Wopat S, 2018, CELL REP, V22, P2026, DOI 10.1016/j.celrep.2018.01.084
   Zheng HF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002745
NR 91
TC 9
Z9 10
U1 4
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553 7404
J9 PLOS GENET
JI PLoS Genet.
PD NOV
PY 2022
VL 18
IS 11
AR e1010496
DI 10.1371/journal.pgen.1010496
PG 30
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA 8N4ER
UT WOS:000925102700002
PM 36346812
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Murillo, G
   Blanquer, A
   Vargas Estevez, C
   Barrios, L
   Ibáñez, E
   Nogués, C
   Esteve, J
AF Murillo, Gonzalo
   Blanquer, Andreu
   Vargas Estevez, Carolina
   Barrios, Lleonard
   Ibanez, Elena
   Nogues, Carme
   Esteve, Jaume
TI Electromechanical Nanogenerator Cell Interaction Modulates Cell Activity
SO ADVANCED MATERIALS
LA English
DT Article
DE bioelectronics; cell activity modulation; electrical stimulation;
   nanogenerators; piezoelectronics
ID ELECTRICAL STIMULATION; OSTEOBLAST GROWTH; ACTIVATION; ADHESION;
   QUALITY; FORCES; ENERGY; LAYER
AB Noninvasive methods for in situ electrical stimulation of human cells open new frontiers to future bioelectronic therapies, where controlled electrical impulses could replace the use of chemical drugs for disease treatment. Here, this study demonstrates that the interaction of living cells with piezoelectric nanogenerators (NGs) induces a local electric field that self stimulates and modulates their cell activity, without applying an additional chemical or physical external stimulation. When cells are cultured on top of the NGs, based on 2D ZnO nanosheets, the electromechanical NG cell interactions stimulate the motility of macrophages and trigger the opening of ion channels present in the plasma membrane of osteoblast like cells (Saos 2) inducing intracellular calcium transients. In addition, excellent cell viability, proliferation, and differentiation are validated. This in situ cell scale electrical stimulation of osteoblast like cells can be extrapolated to other excitable cells such as neurons or muscle cells, paving the way for future bioelectronic medicines based on cell targeted electrical impulses.
C1 [Murillo, Gonzalo; Vargas Estevez, Carolina; Esteve, Jaume] IMB CNM CSIC, Inst Microelect Barcelona, Campus UAB, Bellaterra 08193, Spain.
   [Blanquer, Andreu; Barrios, Lleonard; Ibanez, Elena; Nogues, Carme] Univ Autonoma Barcelona, Dept Biol Cellular Fisiol & Immunol, Edifici C, Bellaterra 08193, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC   Instituto
   de Microelectronica de Barcelona (IMB CNM); Autonomous University of
   Barcelona; Autonomous University of Barcelona
RP Murillo, G (通讯作者)，IMB CNM CSIC, Inst Microelect Barcelona, Campus UAB, Bellaterra 08193, Spain.; Nogués, C (通讯作者)，Univ Autonoma Barcelona, Dept Biol Cellular Fisiol & Immunol, Edifici C, Bellaterra 08193, Spain.
EM gonzalo.murillo@csic.es; carme.nogues@uab.cat
RI Vargas Estevez, Carolina/B 3863 2015; Ibáñez, Elena/K 4320 2014;
   Barrios, Leonardo/L 3315 2014; Estevez, Carolina/B 3863 2015; Ibanez,
   Elena/K 4320 2014; Esteve, Jaume/O 6493 2016; Murillo,
   Gonzalo/AAE 1481 2020; Blanquer, Andreu/W 5541 2019; Nogues,
   Carme/A 2339 2009
OI Vargas Estevez, Carolina/0000 0002 0150 7976; Barrios,
   Leonardo/0000 0002 6151 8503; Ibanez, Elena/0000 0002 0275 6958; Esteve,
   Jaume/0000 0001 9440 7984; Murillo, Gonzalo/0000 0002 0368 1900;
   Blanquer, Andreu/0000 0002 3551 1885; Nogues, Carme/0000 0002 6361 8559
FU SiNERGY (Silicon Friendly Materials and Device Solutions for Microenergy
   Applications) [FP7 NMP 2013 SMALL 7]; MINAHE V project
   [TEC2013 41767 R/MINECO]; NG4Cell project [TEC2015 72461 EXP];
   ENV BIO PORAL project [MAT2014 57960 C3 3 R]; Spanish National Research
   Council (CSIC) under the "Junta para la Ampliacion de Estudios"
   Programme; European Social Fund (ESF);  [604169]
FX G.M. and A.B. contributed equally to this work. This work was supported
   by FP7 NMP 2013 SMALL 7, SiNERGY (Silicon Friendly Materials and Device
   Solutions for Microenergy Applications), Contract no. 604169, MINAHE V
   project (TEC2013 41767 R/MINECO), NG4Cell project (TEC2015 72461 EXP),
   and ENV BIO PORAL project (MAT2014 57960 C3 3 R). G.M. acknowledges his
   JAE Doc contract from the Spanish National Research Council (CSIC) under
   the "Junta para la Ampliacion de Estudios" Programme, cofunded by the
   "European Social Fund (ESF)". The authors would like to thank H. Lozano
   and N. Domingo for performing the piezoresponse measurements. In
   addition, the authors would like to show their gratitude to Hysitron,
   Inc. (www.hysitron.com) for carrying out the pico indentation
   characterization.
CR [Anonymous], 2013, Principles of Neural Science
   Birmingham K, 2014, NAT REV DRUG DISCOV, V13, P399, DOI 10.1038/nrd4351
   Cho MR, 2000, ANN BIOMED ENG, V28, P234, DOI 10.1114/1.263
   Ganz A, 2006, BIOL CELL, V98, P721, DOI 10.1042/BC20060039
   Hwang GT, 2014, ADV MATER, V26, P4880, DOI 10.1002/adma.201400562
   Jin Y, 2016, ADV MATER, V28, P7365, DOI 10.1002/adma.201601900
   Khatib L, 2004, FASEB J, V18, P1903, DOI 10.1096/fj.04 1814fje
   Lee JY, 2008, BIOMATERIALS, V29, P3743, DOI 10.1016/j.biomaterials.2008.05.029
   Li B, 2010, SENSORS BASEL, V10, P9948, DOI 10.3390/s101109948
   Marino A, 2015, ACS NANO, V9, P7678, DOI 10.1021/acsnano.5b03162
   Meng SY, 2011, J BONE MINER METAB, V29, P535, DOI 10.1007/s00774 010 0257 1
   Murillo G, 2017, NANOSCALE RES LETT, V12, DOI 10.1186/s11671 017 1838 x
   Murillo G, 2016, CRYST GROWTH DES, V16, P5059, DOI 10.1021/acs.cgd.6b00661
   Özkucur N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006131
   Park JK, 2010, ADV MATER, V22, P4857, DOI 10.1002/adma.201002255
   Quammen D, 2013, NATURE, V496, P165, DOI 10.1038/496165a
   ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013 4694(94)90029 9
   Wagner T, 2007, ANNU REV BIOMED ENG, V9, P527, DOI 10.1146/annurev.bioeng.9.061206.133100
   Wang XD, 2007, SCIENCE, V316, P102, DOI 10.1126/science.1139366
   Wang ZL, 2012, MRS BULL, V37, P814, DOI 10.1557/mrs.2012.186
   Wang ZL, 2010, MAT SCI ENG R, V70, P320, DOI 10.1016/j.mser.2010.06.015
   Wang ZL, 2006, SCIENCE, V312, P242, DOI 10.1126/science.1124005
   Weder G, 2009, BIOINTERPHASES, V4, P27, DOI 10.1116/1.3139962
   Yang R, 2009, NANO LETT, V9, P1201, DOI 10.1021/nl803904b
   Yue K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044040
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zhu G, 2012, NANO LETT, V12, P3086, DOI [10.1021/nl300972f1, 10.1021/nl300972f]
NR 27
TC 156
Z9 158
U1 8
U2 236
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935 9648
EI 1521 4095
J9 ADV MATER
JI Adv. Mater.
PD JUN 27
PY 2017
VL 29
IS 24
AR 1605048
DI 10.1002/adma.201605048
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA EY3YJ
UT WOS:000403911800005
PM 28437016
OA Green Published
DA 2025 08 17
ER

PT J
AU Serowoky, MA
   Patel, DD
   Hsieh, JW
   Mariani, FV
AF Serowoky, Maxwell A.
   Patel, Divya D.
   Hsieh, Jason W.
   Mariani, Francesca V.
TI Use of commercially available adhesive tapes to preserve cartilage and
   bone tissue integrity during cryosectioning
SO BIOTECHNIQUES
LA English
DT Article
DE bone; cartilage; chondrocytes; cryo sectioning; demineralization;
   fluorescent imaging; growth plate; histology; mouse; osteoblasts;
   transgenic
AB The use of fluorescent tags to monitor protein expression and to lineage trace cells has become a standard complement to standard histological techniques in the fields of embryology, pathology and regenerative medicine. Unfortunately, traditional paraffin embedding protocols can substantially diminish or abolish the native emission signal of the fluorophore of interest. To preserve the fluorescent signal, an alternative is to use cryosectioning; however, this can often result in undesirable artefacts such as tearing or shattering   particularly for mineralized tissues such as bone and cartilage. Here we present a method of using a commercially available tape to stabilize murine femur tissue, thus allowing for cryosectioning of cartilage and bone tissues carrying fluorescent tags without the need for demineralization.
C1 [Serowoky, Maxwell A.; Patel, Divya D.; Hsieh, Jason W.; Mariani, Francesca V.] Univ Southern Calif, Keck Sch Med, Broad Ctr Regenerat Med & Stem Cell Res, Dept Stem Cell Biol & Regenerat Med, Los Angeles, CA 90007 USA.
C3 University of Southern California
RP Mariani, FV (通讯作者)，Univ Southern Calif, Keck Sch Med, Broad Ctr Regenerat Med & Stem Cell Res, Dept Stem Cell Biol & Regenerat Med, Los Angeles, CA 90007 USA.
EM fmariani@usc.edu
RI Patel, Divya/JTS 9886 2023
OI Mariani, Francesca/0000 0003 1619 8763
FU NIH NIAMS [AR064462, AR069700]; USC STAR Program
FX This work was supported by NIH NIAMS AR064462 and AR069700 and by the
   USC STAR Program (to DP). This paper is subject to the NIH Public Access
   Policy. The authors have no other relevant affiliations or financial
   involvement with any organization or entity with a financial interest in
   or financial conflict with the subject matter or materials discussed in
   the manuscript apart from those disclosed.
CR Cardiff Robert D, 2014, Cold Spring Harb Protoc, V2014, P655, DOI 10.1101/pdb.prot073411
   Dyment NA, 2016, JOVE J VIS EXP, DOI 10.3791/54468
   Elefteriou F, 2011, BONE, V49, P1242, DOI 10.1016/j.bone.2011.08.021
   Hsu YC, 2015, STEM CELLS, V33, P3197, DOI 10.1002/stem.2123
   Jiang X, 2005, J HISTOCHEM CYTOCHEM, V53, P593, DOI 10.1369/jhc.4A6401.2005
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123
   Mack SA, 2014, METHODS MOL BIOL, V1130, P165, DOI 10.1007/978 1 62703 989 5_12
   Mangiavini Laura, 2016, Curr Protoc Mouse Biol, V6, P67, DOI 10.1002/9780470942390.mo150094
   MATTHEWS JB, 1984, HISTOCHEM J, V16, P771, DOI 10.1007/BF01095281
   Maye P, 2011, GENESIS, V49, P410, DOI 10.1002/dvg.20733
   Nakagawa A, 2015, BIOTECHNIQUES, V59, P153, DOI 10.2144/000114328
   Rowe DW, 2018, CURR OSTEOPOROS REP, V16, P77, DOI 10.1007/s11914 018 0421 4
   Srour MK, 2015, J BONE MINER RES, V30, P297, DOI 10.1002/jbmr.2326
   Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509
NR 15
TC 13
Z9 15
U1 0
U2 4
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 0736 6205
EI 1940 9818
J9 BIOTECHNIQUES
JI Biotechniques
PD OCT
PY 2018
VL 65
IS 4
BP 191
EP 196
DI 10.2144/btn 2018 0021
PG 5
WC Biochemical Research Methods; Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA GW5UY
UT WOS:000447006800004
PM 30284932
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Andreassen, CH
   Lorenzen, M
   Nielsen, JE
   Yahyavi, SK
   Toft, BG
   Ingerslev, LR
   Clemmensen, C
   Rasmussen, LJ
   Bokemeyer, C
   Juul, A
   Jorgensen, A
   Jensen, MB
AF Andreassen, Christine Hjorth
   Lorenzen, Mette
   Nielsen, John E.
   Yahyavi, Sam Kafai
   Toft, Birgitte Gronkaer
   Ingerslev, Lars R.
   Clemmensen, Christoffer
   Rasmussen, Lene Juel
   Bokemeyer, Carsten
   Juul, Anders
   Jorgensen, Anne
   Jensen, Martin Blomberg
TI RANKL regulates testicular cancer growth and Denosumab treatment has
   suppressive effects on GCNIS and advanced seminoma
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
ID CARCINOMA IN SITU; STEM CELL PLURIPOTENCY; KAPPA B LIGAND; DIFFERENTIAL
   EXPRESSION; CISPLATIN RESISTANCE; RECEPTOR ACTIVATOR; TUMOR CELLS;
   VITAMIN D; BONE; OSTEOPROTEGERIN
AB Background Testicular germ cell tumours (TGCTs) have a high sensitivity to chemotherapy and a high cure rate, although with serious adverse effects. In the search for tumour suppressive drugs, the RANKL inhibitor Denosumab, used to treat osteoporosis, came up as a candidate since RANKL signalling was recently identified in the testis. Methods Expression of RANKL, RANK and OPG, and the effects of RANKL inhibition were investigated in human TGCTs, TGCT derived cell lines, and TGCT xenograft models. Serum RANKL was measured in TGCT patients. Results RANKL, RANK, and OPG were expressed in germ cell neoplasia in situ (GCNIS), TGCTs, and TGCT derived cell lines. RANKL inhibition reduced proliferation of seminoma derived TCam 2 cells, but had no effect on embryonal carcinoma derived NTera2 cells. Pretreatment with Denosumab did not augment the effect of cisplatin in vitro. However, inhibition of RANKL in vivo reduced tumour growth exclusively in the TCam 2 xenograft model and Denosumab treatment decreased proliferation in human GCNIS cultures. In TGCT patients serum RANKL had no prognostic value. Conclusions This study shows that the RANKL signalling system is expressed in GCNIS and seminoma where RANKL inhibition suppresses tumour growth in vitro and in vivo. Future studies are needed to determine whether RANKL is important for the malignant transformation or transition from GCNIS to invasive tumours.
C1 [Andreassen, Christine Hjorth; Lorenzen, Mette; Yahyavi, Sam Kafai; Jensen, Martin Blomberg] Copenhagen Univ Hosp, Dept Growth & Reprod, Rigshosp, Grp Skeletal Mineral & Gonadal Endocrinol, Copenhagen, Denmark.
   [Nielsen, John E.; Juul, Anders; Jorgensen, Anne] Copenhagen Univ Hosp, Dept Growth & Reprod, Rigshosp, Copenhagen, Denmark.
   [Toft, Birgitte Gronkaer] Copenhagen Univ Hosp, Dept Pathol, Rigshosp, Copenhagen, Denmark.
   [Ingerslev, Lars R.; Clemmensen, Christoffer] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Rasmussen, Lene Juel] Univ Copenhagen, Ctr Hlth Aging, Copenhagen, Denmark.
   [Rasmussen, Lene Juel] Univ Copenhagen, Dept Cellular & Mol Med, Copenhagen, Denmark.
   [Bokemeyer, Carsten] Univ Med Ctr Hamburg Eppendorf, Sect Pneumol, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany.
   [Juul, Anders] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark.
   [Jensen, Martin Blomberg] Harvard Univ, Div Bone & Mineral Res, HSDM HMS, Boston, MA 02115 USA.
C3 University of Copenhagen; Copenhagen University Hospital;
   Rigshospitalet; University of Copenhagen; Copenhagen University
   Hospital; Rigshospitalet; Rigshospitalet; University of Copenhagen;
   Copenhagen University Hospital; University of Copenhagen; Novo Nordisk
   Foundation; University of Copenhagen; University of Copenhagen;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Copenhagen; Harvard University; Harvard School of Dental
   Medicine
RP Jensen, MB (通讯作者)，Copenhagen Univ Hosp, Dept Growth & Reprod, Rigshosp, Grp Skeletal Mineral & Gonadal Endocrinol, Copenhagen, Denmark.; Jensen, MB (通讯作者)，Harvard Univ, Div Bone & Mineral Res, HSDM HMS, Boston, MA 02115 USA.
EM Blombergjensen@gmail.com
RI ; Clemmensen, Christoffer/AAM 3347 2020; Andreassen,
   Christine/JZT 8157 2024; Clemmensen, Christoffer/N 4680 2017; Jorgensen,
   Anne/S 8681 2016; Juul, Anders/F 5864 2013; blomberg jensen,
   martin/U 3338 2017; Jensen, Martin Blomberg/U 3338 2017; Jørgensen,
   Anne/S 8681 2016
OI Juul, Anders/0000 0002 0534 4350; Rasmussen, Lene
   Juel/0000 0001 6864 963X; Clemmensen, Christoffer/0000 0003 2456 9667;
   Jorgensen, Anne/0000 0002 6409 198X; Hjorth Andreassen,
   Christine/0000 0002 3643 6426; Jensen, Martin
   Blomberg/0000 0003 3800 4253; Ingerslev, Lars Roed/0000 0002 4164 7690;
   Kafai Yahyavi, Sam/0000 0002 6658 5094; 
FU Novo Nordisk Fonden (Novo Nordisk Foundation); Danish Cancer Society;
   Candys Foundation; NNF Center for Basic Metabolic Research [SCOP
   Platform, Clemmensen Group] Funding Source: researchfish; Novo Nordisk
   Fonden [NNF17OC0026096] Funding Source: researchfish
FX Novo Nordisk Fonden (Novo Nordisk Foundation), The Danish Cancer
   Society, and Candys Foundation.
CR Abada PB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087444
   ANDREWS PW, 1986, DIFFERENTIATION, V31, P119, DOI 10.1111/j.1432 0436.1986.tb00392.x
   Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678
   Armstrong L, 2006, HUM MOL GENET, V15, P1894, DOI 10.1093/hmg/ddl112
   Bandak M, 2017, EUR J CANCER, V84, P9, DOI 10.1016/j.ejca.2017.07.006
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Chamoux E, 2008, J CELL PHYSIOL, V216, P536, DOI 10.1002/jcp.21430
   Chen LM, 2011, J CELL BIOCHEM, V112, P933, DOI 10.1002/jcb.23009
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Faget J, 2018, J THORAC ONCOL, V13, P387, DOI 10.1016/j.jtho.2017.11.121
   Feldman DR, 2008, JAMA J AM MED ASSOC, V299, P672, DOI 10.1001/jama.299.6.672
   Fenske AE, 2012, CANCER LETT, V324, P171, DOI 10.1016/j.canlet.2012.05.009
   Gonzalez Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495
   Gurney JK, 2019, EUR UROL, V76, P615, DOI 10.1016/j.eururo.2019.07.002
   Poulsen KH, 2020, BMC CANCER, V20, DOI 10.1186/s12885 020 06820 6
   Hase T, 2003, EUR J CANCER, V39, P2043, DOI 10.1016/S0959 8049(03)00485 4
   Hikim APS, 2003, ENDOCRINOLOGY, V144, P3167, DOI 10.1210/en.2003 0175
   Hoei Hansen CE, 2005, HISTOPATHOLOGY, V47, P48, DOI 10.1111/j.1365 2559.2005.02182.x
   Howe KL, 2021, NUCLEIC ACIDS RES, V49, pD884, DOI 10.1093/nar/gkaa942
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Ikeda T, 2001, ENDOCRINOLOGY, V142, P1419, DOI 10.1210/en.142.4.1419
   Jacobsen C, 2015, ANDROLOGY US, V3, P111, DOI 10.1111/andr.299
   Jensen MB, 2008, ANN ONCOL, V19, P1910, DOI 10.1093/annonc/mdn407
   Jensen MB, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22734 8
   Jensen MB, 2012, NEOPLASIA, V14, P952, DOI 10.1593/neo.121164
   Jiang YF, 2020, HUM REPROD, V35, P2439, DOI 10.1093/humrep/deaa233
   JOHNSON D E, 1976, Urology, V8, P234, DOI 10.1016/0090 4295(76)90374 5
   Jorgensen A, 2014, BRIT J CANCER, V110, P2604, DOI 10.1038/bjc.2014.160
   Jorgensen A, 2013, J STEROID BIOCHEM, V136, P238, DOI 10.1016/j.jsbmb.2012.10.008
   Jorgensen A, 2013, J PATHOL, V229, P588, DOI 10.1002/path.4154
   Jostes S, 2017, J CELL MOL MED, V21, P1300, DOI 10.1111/jcmm.13059
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 2 r29
   Lee J, 2006, J BIOL CHEM, V281, P33554, DOI 10.1074/jbc.M603937200
   Li XM, 2014, ONCOL REP, V32, P2605, DOI 10.3892/or.2014.3511
   Liang J, 2013, CANCER CELL, V23, P107, DOI 10.1016/j.ccr.2012.11.013
   Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Lorenzen M, 2020, CANCERS, V12, DOI 10.3390/cancers12061358
   Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   McKee CM, 2006, APOPTOSIS, V11, P2237, DOI 10.1007/s10495 006 0288 1
   Mikami S, 2009, J PATHOL, V218, P530, DOI 10.1002/path.2567
   Mizuno Y, 1993, Nihon Hinyokika Gakkai Zasshi, V84, P1211
   Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029
   Mortensen LJ, 2019, BONE, V123, P103, DOI 10.1016/j.bone.2019.03.022
   Mueller T, 2006, TUMOR BIOL, V27, P71, DOI 10.1159/000092324
   Oechsle K, 2012, J CANCER RES CLIN, V138, P947, DOI 10.1007/s00432 012 1169 3
   Paduch DA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216586
   Peters S, 2019, CLIN TRANSL ONCOL, V21, P977, DOI 10.1007/s12094 018 02023 5
   Pliarchopoulou K, 2010, CANCER TREAT REV, V36, P262, DOI 10.1016/j.ctrv.2009.12.011
   Rajpert De Meyts E, 2004, HUM REPROD, V19, P1338, DOI 10.1093/humrep/deh265
   Rajpert De Meyts E, 2006, HUM REPROD UPDATE, V12, P303, DOI 10.1093/humupd/dmk006
   Rajpert De Meyts E, 2016, LANCET, V387, P1762, DOI 10.1016/S0140 6736(15)00991 5
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Shang WQ, 2015, ONCOL REP, V34, P3007, DOI 10.3892/or.2015.4303
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   SKAKKEBAEK NE, 1972, LANCET, V2, P516
   SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365 2605.1987.tb00161.x
   Skakkebæk NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Sonne SB, 2009, CANCER RES, V69, P5241, DOI 10.1158/0008 5472.CAN 08 4554
   Steven A., 2018, UROL ONCOL, P1
   Swarnkar G, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12707 7
   Taylor Weiner A, 2016, NATURE, V540, P114, DOI 10.1038/nature20596
   van Dam PA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092183
   Wickham H., 2016, ggplot2: Elegant graphics for data analysis, DOI [10.1007/978 3 319 24277 4, DOI 10.1007/978 3 319 24277 4]
   Wu D, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks461
   Yi J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078144
   Yoldi G, 2016, CANCER RES, V76, P5857, DOI 10.1158/0008 5472.CAN 15 2745
   Yu CY, 2013, ASIAN PAC J CANCER P, V14, P4907, DOI 10.7314/APJCP.2013.14.8.4907
   Zhu YB, 2013, ASIAN PAC J CANCER P, V14, P4775, DOI 10.7314/APJCP.2013.14.8.4775
NR 75
TC 5
Z9 5
U1 0
U2 3
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0007 0920
EI 1532 1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD AUG 1
PY 2022
VL 127
IS 3
BP 408
EP 421
DI 10.1038/s41416 022 01810 w
EA APR 2022
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 3O1TG
UT WOS:000783462000002
PM 35418213
OA Green Published
DA 2025 08 17
ER

PT J
AU Drouin, A
   Wallbillich, N
   Theberge, M
   Liu, S
   Katz, J
   Bellovoda, K
   Cheon, SSY
   Gootkind, F
   Bierman, E
   Zavras, J
   Berberich, MJ
   Kalocsay, M
   Guastaldi, F
   Salvadori, N
   Troulis, M
   Fusco, DN
AF Drouin, Arnaud
   Wallbillich, Nicholas
   Theberge, Marc
   Liu, Sharon
   Katz, Joshua
   Bellovoda, Kamela
   Cheon, Scarlett Se Yun
   Gootkind, Frederick
   Bierman, Emily
   Zavras, Jason
   Berberich, Matthew J.
   Kalocsay, Marian
   Guastaldi, Fernando
   Salvadori, Nicolas
   Troulis, Maria
   Fusco, Dahlene N.
TI Impact of Zika virus on the human type I interferon osteoimmune response
SO CYTOKINE
LA English
DT Article
DE Zika; Interferon; Saos 2; Osteoblasts; Proteomics; HELZ2; KI20A; KIF20A
ID ONCOLYTIC ACTIVITY; BAX INHIBITOR 1; STEM CELLS; PROTEIN; EXPRESSION;
   SAOS 2; KIF20A; GENES; DIFFERENTIATION; OSTEOMYELITIS
AB Background: The developing field of osteoimmunology supports importance of an interferon (IFN) response pathway in osteoblasts. Clarifying osteoblast IFN interactions is important because IFN is used as salvage anti tumor therapy but systemic toxicity is high with variable clinical results. In addition, osteoblast response to systemic bursts and disruptions of IFN pathways induced by viral infection may influence bone remodeling. ZIKA virus (ZIKV) infection impacts bone development in humans and IFN response in vitro. Consistently, initial evidence of permissivity to ZIKV has been reported in human osteoblasts. Hypothesis: Osteoblast like Saos 2 cells are permissive to ZIKV and responsive to IFN.
   Methods: Multiple approaches were used to assess whether Saos 2 cells are permissive to ZIKV infection and exhibit IFN mediated ZIKV suppression. Proteomic methods were used to evaluate impact of ZIKV and IFN on Saos 2 cells.
   Results: Evidence is presented confirming Saos 2 cells are permissive to ZIKV and support IFN mediated suppression of ZIKV. ZIKV and IFN differentially impact the Saos 2 proteome, exemplified by HELZ2 protein which is upregulated by IFN but non responsive to ZIKV. Both ZIKV and IFN suppress proteins associated with microcephaly/pseudo TORCH syndrome (BI1, KI20A and UBP18), and ZIKV induces potential entry factor PLVAP.
   Conclusions: Transient ZIKV infection influences osteoimmune state, and IFN and ZIKV activate distinct proteomes in Saos 2 cells, which could inform therapeutic, engineered, disruptions.
C1 [Drouin, Arnaud; Wallbillich, Nicholas; Liu, Sharon; Fusco, Dahlene N.] Tulane Univ, Sch Med, Dept Med, 1430 Tulane Ave, New Orleans, LA 70114 USA.
   [Drouin, Arnaud] Tulane Univ, Sch Med, Dept Pathol, 1430 Tulane Ave, New Orleans, LA 70114 USA.
   [Theberge, Marc; Katz, Joshua] Tulane Univ, 6823 St Charles Ave, New Orleans, LA 70118 USA.
   [Bellovoda, Kamela; Cheon, Scarlett Se Yun] Massachusetts Gen Hosp, Dept Med, 55 Fruit St, Boston, MA 02114 USA.
   [Gootkind, Frederick; Bierman, Emily; Zavras, Jason; Guastaldi, Fernando; Troulis, Maria] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, 55 Fruit St, Boston, MA 02114 USA.
   [Berberich, Matthew J.; Kalocsay, Marian] Harvard Med Sch, Lab Syst Pharmacol, Armenise Bldg,200 Longwood, Boston, MA 02115 USA.
   [Salvadori, Nicolas] Inst Rech Dev IRD PHPT, Marseille, France.
   [Salvadori, Nicolas] Chiang Mai Univ, Fac Associated Med Sci, Chiang Mai, Thailand.
   [Bellovoda, Kamela] Queen Mary Univ London, London, England.
   [Zavras, Jason] Dartmouth Coll, Hanover, MA USA.
   [Berberich, Matthew J.] Dana Farber Canc Inst, Dept Prot Degradat, Boston, MA 02115 USA.
C3 Tulane University; Tulane University; Tulane University; Harvard
   University; Harvard University Medical Affiliates; Massachusetts General
   Hospital; Harvard University; Harvard University Medical Affiliates;
   Massachusetts General Hospital; Harvard University; Harvard Medical
   School; Chiang Mai University; University of London; Queen Mary
   University London; Dartmouth College; Harvard University; Harvard
   University Medical Affiliates; Dana Farber Cancer Institute
RP Fusco, DN (通讯作者)，JBJ 251a 333 S Liberty St, New Orleans, LA 70130 USA.
EM dfusco@tulane.edu
RI ; Kalocsay, Marian/ABH 5959 2020; Salvadori, Nicolas/L 1381 2019;
   Drouin, Arnaud/AAA 3390 2022
OI Theberge, Marc/0000 0002 1491 4538; Zavras, Jason/0000 0002 0958 5653;
   Salvadori, Nicolas/0000 0002 0820 5305; Kalocsay,
   Marian/0000 0002 4187 5829
FU Massachusetts General Hospital Oral Maxillofacial Surgery Education and
   Research Fund; NIH [P50 GM107618]; NIH NIAMS [P30 AR 066261]; Tulane
   University School of Medicine; Jean Foundation; W.C.Guralnick
   (Haleotes Bentas) Fund
FX Support for this work was provided by the Massachusetts General Hospital
   Oral Maxillofacial Surgery Education and Research Fund (DF), NIH P50
   GM107618 (DF), NIH NIAMS P30 AR 066261 (DF) and Tulane University School
   of Medicine(DF), The Jean Foundation (MT, FG) and the W.C.Guralnick
   (Haleotes Bentas) Fund (MT, FG). The funders had no role in study
   design, data collection, interpretation, or the decision to submit the
   work for publication.
CR Abernathy E, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.2006926
   [Anonymous], 2018, EUR J IMMUNOL, DOI DOI 10.1002/EJI.201847483
   Barakeh Duna, 2015, Hum Genome Var, V2, P15006, DOI 10.1038/hgv.2015.6
   Bayless NL, 2016, CELL HOST MICROBE, V20, P423, DOI 10.1016/j.chom.2016.09.006
   Best SM, 2017, J VIROL, V91, DOI [10.1128/JVI.01970 16, 10.1128/jvi.01970 16]
   Böhm G, 2015, J PROTEOME RES, V14, P2500, DOI 10.1021/acs.jproteome.5b00072
   Bowen JR, 2018, VIRUS RES, V254, P21, DOI 10.1016/j.virusres.2017.08.018
   Camargos VN, 2019, EBIOMEDICINE, V44, P516, DOI 10.1016/j.ebiom.2019.05.014
   Carvalho IF, 2019, J APPL ORAL SCI, V27, DOI 10.1590/1678 7757 2018 0276
   Chen JJ, 2011, AM J HUM GENET, V88, P827, DOI 10.1016/j.ajhg.2011.05.008
   Chen Q, 2018, MBIO, V9, DOI 10.1128/mBio.01683 18
   Colavita F, 2018, J RHEUMATOL, V45, P443, DOI 10.3899/jrheum.170835
   Corrêa Oliveira GE, 2017, REV BRAS PSIQUIATR, V39, P381, DOI 10.1590/1516 4446 2017 2308
   Cui YC, 2018, MICROB PATHOGENESIS, V122, P130, DOI 10.1016/j.micpath.2018.06.021
   Culjat M, 2016, CLIN INFECT DIS, V63, P805, DOI 10.1093/cid/ciw324
   Das NK, 2018, PHYS SCI REV, V3, DOI 10.1515/psr 2017 0081
   Duan J, 2016, ONCOTARGETS THER, V9, P6741, DOI 10.2147/OTT.S115974
   Elias JE, 2007, NAT METHODS, V4, P207, DOI 10.1038/nmeth1019
   ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044 0305(94)80016 2
   Ersing I, 2017, CELL REP, V19, P1479, DOI 10.1016/j.celrep.2017.04.062
   Fernandez Garcia MD, 2011, J VIROL, V85, P2980, DOI 10.1128/JVI.02483 10
   Folly BB, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471 2334 11 34
   Frost LS, 2014, EXP EYE RES, V124, P56, DOI 10.1016/j.exer.2014.04.010
   Fusco DN, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00240
   Fusco DN, 2013, GASTROENTEROLOGY, V144, P1438, DOI 10.1053/j.gastro.2013.02.026
   Horovitz DDG, 2016, NEUROLOGY, V87, P118, DOI 10.1212/WNL.0000000000002814
   Geng A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05152 1
   Goede JS, 2006, ANN HEMATOL, V85, P591, DOI 10.1007/s00277 006 0143 z
   Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009
   He W, 2018, INT J NANOMED, V13, P877, DOI 10.2147/IJN.S147849
   Hiragami S, 2016, STUD PERCEPT ACTION, P124
   Iannolo G, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1499 z
   Janisch KM, 2013, DEVELOPMENT, V140, P4672, DOI 10.1242/dev.093286
   Jirka I, 2017, MAT SCI ENG C MATER, V76, P775, DOI 10.1016/j.msec.2017.03.067
   Joob B, 2018, REV BRAS PSIQUIATR, V40, DOI 10.1590/1516 4446 2017 2561
   Kanazawa T, 2013, AM J MED GENET B, V162, P679, DOI 10.1002/ajmg.b.32164
   Kawai Y, 2018, ONCOL REP, V40, P195, DOI 10.3892/or.2018.6401
   Ke PY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123940
   Kikuchi R, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020263
   Krajewska M, 2011, BRAIN RES, V1370, P227, DOI 10.1016/j.brainres.2010.11.015
   Kumar A, 2016, EMBO REP, V17, P1766, DOI 10.15252/embr.201642627
   Lane WC, 2018, MBIO, V9, DOI 10.1128/mBio.00535 18
   Lee GH, 2011, INT J BIOCHEM CELL B, V43, P1305, DOI 10.1016/j.biocel.2011.05.004
   Lisak D, 2016, CELL DEATH DIFFER, V23, P358, DOI 10.1038/cdd.2015.115
   Little JN, 2019, HUM MOL GENET, V28, P434, DOI 10.1093/hmg/ddy350
   Liu JX, 2018, INT J MOL MED, V42, P2891, DOI 10.3892/ijmm.2018.3858
   Liu SL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169280
   Lu MQ, 2018, IUBMB LIFE, V70, P328, DOI 10.1002/iub.1726
   Lubin JA, 2018, NEUROSURGERY, V82, pE113, DOI 10.1093/neuros/nyy047
   Lui ELH, 2016, BIOCHEM BIOPH RES CO, V479, P766, DOI 10.1016/j.bbrc.2016.09.137
   Maffulli N, 2016, SURG J R COLL SURG E, V14, P345, DOI 10.1016/j.surge.2015.12.005
   McAlister GC, 2014, ANAL CHEM, V86, P7150, DOI 10.1021/ac502040v
   McNeely KC, 2017, NEURAL DEV, V12, DOI 10.1186/s13064 017 0082 5
   Meuwissen MEC, 2016, J EXP MED, V213, P1163, DOI 10.1084/jem.20151529
   Mumtaz N, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 35422 3
   Nandi SK, 2016, BIOTECHNOL ADV, V34, P1305, DOI 10.1016/j.biotechadv.2016.09.005
   Opal SM, 2003, CRIT CARE, V7, P23, DOI 10.1186/cc1854
   Paixao ES, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh 2017 000530
   Pankiv S, 2010, J CELL BIOL, V188, P253, DOI 10.1083/jcb.200907015
   Pardy RD, 2019, CYTOKINE, V119, P7, DOI 10.1016/j.cyto.2019.02.009
   Paulo JA, 2016, J PROTEOMICS, V148, P85, DOI 10.1016/j.jprot.2016.07.005
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Petribu Natacha Calheiros de Lima, 2018, Radiol Bras, V51, P366, DOI 10.1590/0100 3984.2017.0119
   Rawarak N, 2019, VIRUSES BASEL, V11, DOI 10.3390/v11020155
   Riemer J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017037
   Saad FA, 2011, INT ORTHOP, V35, P447, DOI 10.1007/s00264 010 1076 7
   Saito K, 2017, J NEURO ONCOL, V132, P63, DOI 10.1007/s11060 016 2360 1
   Shah NSM, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.635
   Shah NSM, 2016, BMC GENET, V17, DOI 10.1186/s12863 016 0345 x
   Sharma Bhandari A, 2015, INT J MOL MED, V36, P1664, DOI 10.3892/ijmm.2015.2384
   Shen TY, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/4863182
   Shi L, 2018, NEUROL RES, V40, P189, DOI 10.1080/01616412.2018.1424699
   Song YY, 2019, SCI DATA, V6, DOI 10.1038/sdata.2019.16
   Taniuchi K, 2005, CANCER RES, V65, P105
   Terrier CSP, 2017, J INFECTION, V75, P281, DOI 10.1016/j.jinf.2017.07.007
   Thompson J, 2019, DEV DYNAM, V248, P221, DOI 10.1002/dvdy.13
   Ting L, 2011, NAT METHODS, V8, P937, DOI [10.1038/NMETH.1714, 10.1038/nmeth.1714]
   Tsukasaki M., 2019, NAT REV IMMUNOL
   Tzschentke TM, 2021, BRIT J PHARMACOL, V178, P1973, DOI 10.1111/bph.14799
   Walker CL, 2018, AM J OBSTET GYNECOL, V219, DOI 10.1016/j.ajog.2018.04.047
   WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003 2697(84)90782 6
   Williams SE, 2015, DEVELOPMENT, V142, P3921, DOI 10.1242/dev.124271
   Woeckel VJ, 2012, J CELL PHYSIOL, V227, P2668, DOI 10.1002/jcp.23009
   Young JA, 2011, J BIOL CHEM, V286, P6521, DOI 10.1074/jbc.M110.172288
   Yu ZX, 2020, WORLD J PEDIATR, V16, P44, DOI 10.1007/s12519 019 00273 z
   Yuan S, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00402
   Zhang J, 2017, CURR STEM CELL RES T, V12, P357, DOI 10.2174/1574888X11666160921121555
   Zhang WJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167449
   Zhao C, 2005, P NATL ACAD SCI USA, V102, P10200, DOI 10.1073/pnas.0504754102
   Zhao X, 2018, CANCER MED US, V7, P4678, DOI 10.1002/cam4.1710
   Zhou YM, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/6581576
   Zhu Z, 2017, J EXP MED, V214, P2843, DOI 10.1084/jem.20171093
NR 92
TC 4
Z9 4
U1 1
U2 8
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 4666
EI 1096 0023
J9 CYTOKINE
JI Cytokine
PD JAN
PY 2021
VL 137
AR 155342
DI 10.1016/j.cyto.2020.155342
PG 93
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA PG6HM
UT WOS:000599834300007
PM 33130337
DA 2025 08 17
ER

PT J
AU Chen, W
   Gao, B
   Hao, L
   Zhu, G
   Jules, J
   MacDougall, MJ
   Wang, J
   Han, X
   Zhou, X
   Li, YP
AF Chen, W.
   Gao, B.
   Hao, L.
   Zhu, G.
   Jules, J.
   MacDougall, M. J.
   Wang, J.
   Han, X.
   Zhou, X.
   Li, Y.  P.
TI The silencing of cathepsin K used in gene therapy for periodontal
   disease reveals the role of cathepsin K in chronic infection and
   inflammation
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE adeno associated virus; alveolar bone loss; cathepsin K; gene therapy;
   periodontal diseases
ID PORPHYROMONAS GINGIVALIS; BONE DESTRUCTION; IMMUNE CELL; EXPRESSION;
   OSTEOCLASTS; MOUSE; MICE; ARTHRITIS; DIFFERENTIATION; PYCNODYSOSTOSIS
AB Background and Objective: Periodontitis is a severe chronic inflammatory disease and one of the most prevalent non communicable chronic diseases that affects the majority of the world's adult population. While great efforts have been devoted toward understanding the pathogenesis of periodontitis, there remains a pressing need for developing potent therapeutic strategies for targeting this dreadful disease. In this study, we utilized adeno associated virus (AAV) expressing cathepsin K (Ctsk) small hairpin (sh) RNA (AAV sh Ctsk) to silence Ctsk in vivo and subsequently evaluated its impact in periodontitis as a potential therapeutic strategy for this disease.
   Material and Methods: We used a known mouse model of periodontitis, in which wild type BALB/cJ mice were infected with Porphyromonas gingivalis W50 in the maxillary and mandibular periodontium to induce the disease. AAV sh Ctsk was then administrated locally into the periodontal tissues in vivo, followed by analyses to assess progression of the disease.
   Results: AAV mediated Ctsk silencing drastically protected mice (>80%) from P. gingivalis induced bone resorption by osteoclasts. In addition, AAV sh Ctsk administration drastically reduced inflammation by impacting the expression of many inflammatory cytokines as well as T cell and dendritic cell numbers in periodontal lesions.
   Conclusion: AAV mediated Ctsk silencing can simultaneously target both the inflammation and bone resorption associated with periodontitis through its inhibitory effect on immune cells and osteoclast function. Thereby, AAV sh Ctsk administration can efficiently protect against periodontal tissue damage and alveolar bone loss, establishing this AAV mediated local silencing of Ctsk as an important therapeutic strategy for effectively treating periodontal disease.
C1 [Chen, W.; Gao, B.; Hao, L.; Zhu, G.; Jules, J.; Wang, J.; Li, Y.  P.] Univ Alabama Birmingham, Dept Pathol, SHEL 810,1825 Univ Blvd, Birmingham, AL 35294 USA.
   [Gao, B.; Hao, L.; Zhou, X.] Sichuan Univ, West China Coll Stomatol, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China.
   [MacDougall, M. J.] Univ Alabama Birmingham, Sch Dent, Inst Oral Hlth Res, Birmingham, AL 35294 USA.
   [Han, X.] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA USA.
C3 University of Alabama System; University of Alabama Birmingham; Sichuan
   University; University of Alabama System; University of Alabama
   Birmingham; Harvard University; Harvard University Medical Affiliates;
   Forsyth Institute
RP Li, YP (通讯作者)，Univ Alabama Birmingham, Dept Pathol, SHEL 810,1825 Univ Blvd, Birmingham, AL 35294 USA.; Zhou, X (通讯作者)，Sichuan Univ, West China Coll Stomatol, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China.
EM zhouxd@scu.edu.cn; ypli@uab.edu
RI Zhou, Xuedong/LSL 0410 2024; Han, Xiaozhe/I 7532 2019; MacDougall,
   Mary/ABG 8212 2021
OI Zhou, Xuedong/0000 0002 9319 7302; Hao, Liang/0000 0003 2071 7044
FU UAB Department of Pathology;  [R01DE023813]
FX We thank Ms. Christie Paulson for her excellent assistance with this
   manuscript. We appreciate the assistance of the Center for Metabolic
   Bone Disease at The University of Alabama at Birmingham (P30 AR046031).
   We are also grateful for the assistance of the Small Animal Phenotyping
   Core (P30 DK079626), Metabolism Core, and Neuroscience Molecular
   Detection Core Laboratory at the University of Alabama at Birmingham
   (P30 NS0474666). This work was supported by R01DE023813 (Y.P.L.) and UAB
   Department of Pathology Start Up funding (Wei Chen).
CR Asagiri M, 2008, SCIENCE, V319, P624, DOI 10.1126/science.1150110
   Azuma MM, 2014, INT ENDOD J, V47, P615, DOI 10.1111/iej.12196
   Bankiewicz KS, 2006, MOL THER, V14, P564, DOI 10.1016/j.ymthe.2006.05.005
   Carter BJ, 2005, HUM GENE THER, V16, P541, DOI 10.1089/hum.2005.16.541
   Chen W, 2007, HUM MOL GENET, V16, P410, DOI 10.1093/hmg/ddl474
   Chen W, 2014, P NATL ACAD SCI USA, V111, P8482, DOI 10.1073/pnas.1310617111
   Chen W, 2013, P NATL ACAD SCI USA, V110, P7294, DOI 10.1073/pnas.1211383110
   Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337
   Delima AJ, 2001, J CLIN PERIODONTOL, V28, P233, DOI 10.1034/j.1600 051x.2001.028003233.x
   Ertugrul AS, 2013, INT J ORAL SCI, V5, P92, DOI 10.1038/ijos.2013.30
   Evans C, 2010, J RHEUMATOL, V37, P683, DOI 10.3899/jrheum.100055
   Feng SM, 2009, BIOCHEM J, V417, P195, DOI 10.1042/BJ20081073
   Fischer CL, 2013, INT J ORAL SCI, V5, P130, DOI 10.1038/ijos.2013.28
   Gao B, 2013, J DENT RES, V92, P180, DOI 10.1177/0022034512468757
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Goodson JM, 2012, J CLIN PERIODONTOL, V39, P526, DOI 10.1111/j.1600 051X.2012.01870.x
   Haffajee A D, 1994, Periodontol 2000, V5, P78, DOI 10.1111/j.1600 0757.1994.tb00020.x
   Hommel JD, 2003, NAT MED, V9, P1539, DOI 10.1038/nm964
   Irwin C R, 1998, Oral Dis, V4, P43
   Jiang HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058599
   Jönsson D, 2011, J PERIODONTAL RES, V46, P153, DOI 10.1111/j.1600 0765.2010.01331.x
   Kamolmatyakul S, 2004, J DENT RES, V83, P791, DOI 10.1177/154405910408301011
   Kamolmatyakul S, 2001, J DENT RES, V80, P351, DOI 10.1177/00220345010800011001
   Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140 6736(07)60982 9
   Lappin DF, 2001, CLIN EXP IMMUNOL, V123, P294, DOI 10.1046/j.1365 2249.2001.01448.x
   Li YP, 1999, J BONE MINER RES, V14, P487, DOI 10.1359/jbmr.1999.14.4.487
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   LI YP, 1995, J BONE MINER RES, V10, P1197
   Liu D, 2003, INT J MOL MED, V11, P17
   MANHART SS, 1994, J PERIODONTOL, V65, P807, DOI 10.1902/jop.1994.65.9.807
   Mease PJ, 2010, J RHEUMATOL, V37, P692, DOI 10.3899/jrheum.090817
   Miller CS, 2006, J AM DENT ASSOC, V137, P322, DOI 10.14219/jada.archive.2006.0181
   Musatov S, 2006, P NATL ACAD SCI USA, V103, P10456, DOI 10.1073/pnas.0603045103
   Nakashima T, 2009, J BONE MINER METAB, V27, P519, DOI 10.1007/s00774 009 0089 z
   O'Gradaigh D, 2004, RHEUMATOLOGY, V43, P122, DOI 10.1093/rheumatology/keg447
   Orozco A, 2006, ORAL MICROBIOL IMMUN, V21, P256, DOI 10.1111/j.1399 302X.2006.00292.x
   Ouyang WJ, 2011, ANNU REV IMMUNOL, V29, P71, DOI 10.1146/annurev immunol 031210 101312
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Sasaki H, 2004, J PERIODONTAL RES, V39, P432, DOI 10.1111/j.1600 0765.2004.00760.x
   Seymour GJ, 2007, CLIN MICROBIOL INFEC, V13, P3, DOI 10.1111/j.1469 0691.2007.01798.x
   Shirodaria S, 2000, J DENT RES, V79, P1864, DOI 10.1177/00220345000790110801
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tu QS, 2009, J CELL PHYSIOL, V218, P135, DOI 10.1002/jcp.21576
   Wang L, 2005, GENE THER, V12, P1453, DOI 10.1038/sj.gt.3302539
   Wilensky A, 2009, J CLIN PERIODONTOL, V36, P915, DOI 10.1111/j.1600 051X.2009.01464.x
   Yang S, 2013, BONE RES, V1, P260, DOI 10.4248/BR201303005
   Yang SY, 2007, GENE DEV, V21, P1803, DOI 10.1101/gad.1544107
   Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705
   Zhou Q, 2011, ARTHRITIS RHEUM US, V63, P2318, DOI 10.1002/art.30421
NR 49
TC 34
Z9 40
U1 1
U2 13
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD OCT
PY 2016
VL 51
IS 5
BP 647
EP 660
DI 10.1111/jre.12345
PG 14
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA ED7DX
UT WOS:000389023400011
PM 26754272
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Chiang, CW
   Chen, CH
   Manga, YB
   Huang, SC
   Chao, KM
   Jheng, PR
   Wong, PC
   Nyambat, B
   Satapathy, MK
   Chuang, EY
AF Chiang, Chih Wei
   Chen, Chih Hwa
   Manga, Yankuba B.
   Huang, Shao Chan
   Chao, Kun Mao
   Jheng, Pei Ru
   Wong, Pei Chun
   Nyambat, Batzaya
   Satapathy, Mantosh Kumar
   Chuang, Er Yuan
TI Facilitated and Controlled Strontium Ranelate Delivery Using GCS HA
   Nanocarriers Embedded into PEGDA Coupled with Decortication Driven
   Spinal Regeneration
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE strontium ranelate; drug formulation; nanoparticles; hyaluronic acid;
   glycol chitosan
ID MESENCHYMAL STEM CELLS; GLYCOL CHITOSAN NANOPARTICLES; HYALURONIC ACID;
   DRUG DELIVERY; BONE FORMATION; RODENT MODELS; GAIT ANALYSIS; RELEASE;
   EFFICACY; REPLICATION
AB Background and Purpose: Strontium ranelate (SrR) is an oral pharmaceutical agent for osteoporosis. In recent years, numerous unwanted side effects of oral SrR have been revealed. Therefore, its clinical administration and applications are limited. Hereby, this study aims to develop, formulate, and characterize an effective SrR carrier system for spinal bone regeneration.
   Methods: Herein, glycol chitosan with hyaluronic acid (HA) based nanoformulation was used to encapsulate SrR nanoparticles (SrRNPs) through electrostatic interaction. Afterward, the poly(ethylene glycol) diacrylate (PEGDA) based hydrogels were used to encapsulate presynthe sized SrRNPs (SrRNPs H). The scanning electron microscope (SEM), TEM, rheometer, Fourier transform infrared spectroscopy (FTIR), and dynamic light scattering (DLS) were used to characterize prepared formulations. The rabbit osteoblast and a rat spinal decortication models were used to evaluate and assess the developed formulation bio compatibility and therapeutic efficacy.
   Results: In vitro and in vivo studies for cytotoxicity and bone regeneration were conducted. The cell viability test showed that SrRNPs exerted no cytotoxic effects in osteoblast in vitro. Furthermore, in vivo analysis for new bone regeneration mechanism was carried out on rat decortication models. Radiographical and histological analysis suggested a higher level of bone regeneration in the SrRNPs H implanted groups than in the other experimental groups.
   Conclusion: Local administration of the newly developed formulated SrR could be a promising alternative therapy to enhance bone regeneration in bone defect sites in future clinical applications.
C1 [Chiang, Chih Wei; Chao, Kun Mao] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, Taipei 10617, Taiwan.
   [Chiang, Chih Wei] Taipei Med Univ Hosp, Dept Orthoped, Taipei 11031, Taiwan.
   [Chen, Chih Hwa] Taipei Med Univ, Dept Orthoped, Shuang Ho Hosp, New Taipei 23561, Taiwan.
   [Chen, Chih Hwa; Manga, Yankuba B.; Huang, Shao Chan; Jheng, Pei Ru; Wong, Pei Chun; Nyambat, Batzaya; Satapathy, Mantosh Kumar; Chuang, Er Yuan] Taipei Med Univ, Grad Inst Biomed Mat & Tissue Engn, Int PhD Program Biomed Engn, Sch Biomed Engn,Coll Biomed Engn, Taipei 11031, Taiwan.
   [Chen, Chih Hwa] Taipei Med Univ, Coll Med, Sch Med, Taipei 11031, Taiwan.
   [Chen, Chih Hwa] Taipei Med Univ, Res Ctr Biomed Device, Taipei 11031, Taiwan.
   [Chao, Kun Mao] Natl Taiwan Univ, Dept Comp Sci & Informat Engn, Taipei 10617, Taiwan.
   [Chuang, Er Yuan] Taipei Med Univ, Cell Physiol & Mol Image Res Ctr, Wan Fang Hosp, Taipei 116, Taiwan.
C3 National Taiwan University; Taipei Medical University; Taipei Medical
   University Hospital; Taipei Medical University; Shuang Ho Hospital;
   Taipei Medical University; Taipei Medical University; Taipei Medical
   University; National Taiwan University; Taipei Medical University;
   Taipei Municipal WanFang Hospital
RP Chuang, EY (通讯作者)，Taipei Med Univ, Grad Inst Biomed Mat & Tissue Engn, Int PhD Program Biomed Engn, Sch Biomed Engn,Coll Biomed Engn, Taipei 11031, Taiwan.; Chuang, EY (通讯作者)，Taipei Med Univ, Cell Physiol & Mol Image Res Ctr, Wan Fang Hosp, Taipei 116, Taiwan.
EM eychuang@tmu.edu.tw
RI ; Satapathy, Mantosh Kumar/AAE 2727 2021
OI Chen, Chih Hwa/0000 0002 2274 5789; Manga, Yankuba
   B./0000 0002 8750 3721; CHAO, KUN MA0/0000 0003 2837 1279; SATAPATHY,
   MANTOSH KUMAR/0000 0002 6646 7928
FU Ministry of Science and Technology (MOST), Taiwan [MOST
   108 2221 E 038 017 MY3, MOST 1082320 B 038 061 MY3]
FX This original paper was supported by a government project from the
   Ministry of Science and Technology (MOST), Taiwan (MOST
   108 2221 E 038 017 MY3; MOST 1082320 B 038 061 MY3). Chih Wei Chiang and
   Chih Hwa Chen are the first two co authors and made equal contributions.
CR Alsalahi A, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/829401
   Andrzejowski P, 2019, J ORTHOP TRAUMATOL, V20, DOI 10.1186/s10195 019 0528 0
   Barbosa AI, 2019, MOLECULES, V24, DOI 10.3390/molecules24020346
   BOUCHER HH, 1959, J BONE JOINT SURG BR, V41, P248
   Caló E, 2015, EUR POLYM J, V65, P252, DOI 10.1016/j.eurpolymj.2014.11.024
   Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756 3282(96)00080 4
   Caverzasio J, 2008, BONE, V42, P1131, DOI 10.1016/j.bone.2008.02.010
   Chattopadhyay N, 2007, BIOCHEM PHARMACOL, V74, P438, DOI 10.1016/j.bcp.2007.04.020
   Chiang CW, 2015, INT J MOL SCI, V16, P23318, DOI 10.3390/ijms161023318
   Choi KY, 2010, BIOMATERIALS, V31, P106, DOI 10.1016/j.biomaterials.2009.09.030
   Choudhary S, 2007, J BONE MINER RES, V22, P1002, DOI 10.1359/JBMR.070321
   Cianferotti L, 2013, THER ADV MUSCULOSKEL, V5, P127, DOI 10.1177/1759720X13483187
   Deepthi S, 2016, J MATER CHEM B, V4, P4092, DOI 10.1039/c6tb00684a
   Dhakar RC., 2012, J DRUG DELIV THER, V2
   Dhandayuthapani B, 2011, INT J POLYM SCI, V2011, DOI 10.1155/2011/290602
   Eskandar NG, 2009, INT J PHARMACEUT, V376, P186, DOI 10.1016/j.ijpharm.2009.04.036
   Felszeghy S, 2001, ARCH ORAL BIOL, V46, P939, DOI 10.1016/S0003 9969(01)00053 X
   Ferland CE, 2011, PHARMACOL BIOCHEM BE, V97, P603, DOI 10.1016/j.pbb.2010.11.003
   Fromigué O, 2009, J CELL MOL MED, V13, P2189, DOI 10.1111/j.1582 4934.2009.00673.x
   Frosch KH, 2003, J ORTHOP RES, V21, P213, DOI 10.1016/S0736 0266(02)00143 2
   Grumezescu AM, 2017, MULTIFUNCTIONAL SYSTEMS FOR COMBINED DELIVERY, BIOSENSING AND DIAGNOSTICS, pXV
   Guo XJ, 2016, INT J BIOL SCI, V12, P1511, DOI 10.7150/ijbs.16499
   Herbin M, 2007, BEHAV BRAIN RES, V181, P173, DOI 10.1016/j.bbr.2007.04.001
   Howell SB, 2001, CANCER J, V7, P219
   Huang YC, 2014, MAR DRUGS, V12, P4379, DOI 10.3390/md12084379
   Ishikawa G, 2014, EUR J PHARMACOL, V738, P111, DOI 10.1016/j.ejphar.2014.05.048
   Jia X, 2016, CARBOHYD POLYM, V152, P391, DOI 10.1016/j.carbpol.2016.06.109
   Katouzian I, 2016, TRENDS FOOD SCI TECH, V53, P34, DOI 10.1016/j.tifs.2016.05.002
   Key J, 2016, INT J NANOMED, V11, P4141, DOI 10.2147/IJN.S109494
   Kim JH, 2008, J CONTROL RELEASE, V127, P41, DOI 10.1016/j.jconrel.2007.12.014
   Lakes EH, 2016, OSTEOARTHR CARTILAGE, V24, P1837, DOI 10.1016/j.joca.2016.03.008
   Langdahl BL, 2018, OXFORD DESK REFERENC, P342
   Lee JH, 2013, TISSUE ENG REGEN MED, V10, P279, DOI 10.1007/s13770 013 1090 0
   Li YP, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957 4484/20/6/065104
   Li YH, 2015, SCI REP UK, V5, DOI 10.1038/srep16124
   Liao JH, 2018, J BIOMED NANOTECHNOL, V14, P496, DOI 10.1166/jbn.2018.2510
   Liu HZ, 2013, ACTA PHARM SIN B, V3, P86, DOI 10.1016/j.apsb.2013.02.003
   McAvoy K, 2018, PHARM RES DORDR, V35, DOI 10.1007/s11095 017 2298 9
   Miller VM, 2009, NANOMEDICINE UK, V4, P725, DOI [10.2217/nnm.09.61, 10.2217/NNM.09.61]
   Misra S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00201
   Mobasheri A, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926 013 0364 9
   Nair BP, 2016, COLLOID SURFACE B, V143, P423, DOI 10.1016/j.colsurfb.2016.03.033
   Nardone V, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/871863
   O'Neill CP, 2020, CELLS BASEL, V9, DOI 10.3390/cells9020521
   Orienti I, 2005, DRUG DELIV, V12, P15, DOI 10.1080/10717540590889574
   Ou CY, 2014, FORMOS J SURG, V47, P166, DOI 10.1016/j.fjs.2014.04.002
   Paillard A, 2010, PHARM RES DORDR, V27, P126, DOI 10.1007/s11095 009 9986 z
   Panmekiate S, 2015, DENTOMAXILLOFAC RAD, V44, DOI 10.1259/dmfr.20140322
   Papa S, 2018, J CONTROL RELEASE, V278, P49, DOI 10.1016/j.jconrel.2018.03.034
   Rao RD, 2007, SPINE J, V7, P61, DOI 10.1016/j.spinee.2006.03.004
   Ross AE, 2012, AAPS J, V14, P482, DOI 10.1208/s12248 012 9356 3
   Seo Jeongdeok, 2016, Journal of Pharmaceutical Investigation, V46, P317, DOI 10.1007/s40005 016 0251 2
   Sharifi S, 2012, CHEM SOC REV, V41, P2323, DOI 10.1039/c1cs15188f
   Sila Asna Monnipha, 2007, Kobe J Med Sci, V53, P25
   Sreekumar S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 23064 4
   Tian A, 2014, INT J ORAL MAX IMPL, V29, P1446, DOI 10.11607/jomi.3806
   Tomar L, 2013, INT J NANOMED, V8, P505, DOI 10.2147/IJN.S38011
   Tsai TT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0167296
   Tsolaki IN, 2009, J PROSTHODONT, V18, P309, DOI 10.1111/j.1532 849X.2008.00433.x
   Tuchman A, 2016, GLOB SPINE J, V6, P592, DOI 10.1055/s 0035 1570749
   Vasi AM, 2014, MAT SCI ENG C MATER, V38, P177, DOI 10.1016/j.msec.2014.01.052
   Wagh VD, 2014, J NANOTECHNOL, V2014, DOI 10.1155/2014/683153
   Wei WP, 2020, DRUG DELIV, V27, P460, DOI 10.1080/10717544.2020.1739171
   Wu T, 2020, BIOACT MATER, V5, P348, DOI 10.1016/j.bioactmat.2020.03.004
   Xue P, 2015, RSC ADV, V5, P75204, DOI 10.1039/c5ra09329e
   Yang YS, 2018, INT J NANOMED, V13, P4361, DOI 10.2147/IJN.S165359
   Yoo HS, 1999, PHARMACEUT RES, V16, P1114, DOI 10.1023/A:1018908421434
   Zaki SSO, 2015, J NANOTECHNOL, V2015, DOI 10.1155/2015/919658
   Zarins J., 2016, Acta Chir. Latv., V16, P17, DOI [10.1515/chilat 2017 0004, DOI 10.1515/CHILAT 2017 0004]
   Zariwala MG, 2013, INT J PHARMACEUT, V456, P400, DOI 10.1016/j.ijpharm.2013.08.070
   Zhao JB, 2020, BIORESOUR BIOPROCESS, V7, DOI 10.1186/s40643 019 0289 x
   Zhou D, 2017, INT J NANOMED, V12, P2673, DOI 10.2147/IJN.S131251
   Zhu LL, 2007, BIOCHEM BIOPH RES CO, V355, P307, DOI 10.1016/j.bbrc.2007.01.120
   Zwolak P, 2018, ARCH ORTHOP TRAUM SU, V138, P13, DOI 10.1007/s00402 017 2818 4
NR 74
TC 15
Z9 16
U1 1
U2 23
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2021
VL 16
BP 4209
EP 4224
DI 10.2147/IJN.S274461
PG 16
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA SW2AN
UT WOS:000664321800001
PM 34188470
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Inoue, T
   Nagatoya, K
   Kagitani, M
   Shibahara, N
   Ueda, H
   Katsuoka, Y
   Ohashi, S
   Kitagawa, Y
   Nishimoto, K
   Yasuda, H
AF Inoue, Toru
   Nagatoya, Katsuyuki
   Kagitani, Maki
   Shibahara, Nobuhisa
   Ueda, Haruhiko
   Katsuoka, Yoji
   Ohashi, Seiji
   Kitagawa, Yoshiyuki
   Nishimoto, Kazuhiko
   Yasuda, Hideaki
CA Hokusetsu Renal Osteodystrophy Stu
TI Influence of sevelamer on mineral metabolism and hyperparathyroidism in
   Japanese hemodialysis patients
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article
DE calcium x phosphate product; hemodialysis; hyperphosphatemia;
   parathyroid hormone; sevelamer hydrochloride
ID X PHOSPHATE PRODUCT; COMBINATION THERAPY; CALCIUM CARBONATE; MORTALITY
   RISK; HYPERPHOSPHATEMIA; HYDROCHLORIDE; CALCIFICATION; ASSOCIATION;
   CORONARY
AB In June 2003, sevelamer hydrochloride became widely available in Japan and was expected to control hyperphosphatemia in hemodialysis patients without inducing hypercalcemia. To evaluate the impact of sevelamer therapy on mineral metabolism, we recruited 954 hemodialysis patients from 21 renal units just before the general release of sevelamer in Japan. The serum calcium, phosphate, and parathyroid hormone levels determined on enrollment were compared with those later measured in June 2004. Sevelamer was prescribed for 169 of the 859 patients for whom data were available in 2004. The mean calcium level, phosphate level, and calcium x phosphate product were all significantly reduced during the 12 month study period, but the intact parathyroid hormone (iPTH) level did not change. As a result, the percentage of patients who achieved a calcium x phosphate product of < 55 mg(2)/dL(2) was significantly increased, but there were no changes in that of patients who achieved the target ranges for phosphate (3.5 5.5 mg/dL) or iPTH (150 300 pg/mL). Among sevelamer treated patients, iPTH significantly increased, and this change was more marked in the patients with an initial iPTH level < 150 pg/mL. Sevelamer was useful for reducing the serum calcium level and calcium x phosphate product, but hyperphosphatemia and hyperparathyroidism were not improved in our study population at 12 months after the release of sevelamer. A decrease in the calcium load might result in the exacerbation of hyperparathyroidism. However, among patients with relative hypoparathyroidism, sevelamer therapy may be beneficial for the prevention of adynamic bone disease.
C1 Osaka Med Coll, Blood Purificat Ctr, Osaka 5698686, Japan.
   Osaka Med Coll, Dept Urol, Osaka 5698686, Japan.
   Takatsuki Hosp, Osaka, Japan.
   Kitagawa Clin, Osaka, Japan.
   Nishimoto Clin, Osaka, Japan.
   Sanko Hosp, Osaka, Japan.
C3 Osaka Medical & Pharmaceutical University; Osaka Medical &
   Pharmaceutical University
RP Inoue, T (通讯作者)，Osaka Med Coll, Blood Purificat Ctr, 2 7 Daigaku Cho, Osaka 5698686, Japan.
EM t inoue@poh.osaka med.ac.jp
CR Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Chertow GM, 1999, NEPHROL DIAL TRANSPL, V14, P2907, DOI 10.1093/ndt/14.12.2907
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Guérin AP, 2000, NEPHROL DIAL TRANSPL, V15, P1014, DOI 10.1093/ndt/15.7.1014
   Koiwa F, 2005, THER APHER DIAL, V9, P340, DOI 10.1111/j.1744 9987.2005.00294.x
   McIntyre CW, 2002, NEPHROL DIAL TRANSPL, V17, P1643, DOI 10.1093/ndt/17.9.1643
   Nakai S, 2005, THER APHER DIAL, V9, P431
   Ogata H, 2005, THER APHER DIAL, V9, P11, DOI 10.1111/j.1774 9987.2005.00215.x
   PAYNE RB, 1973, BMJ BRIT MED J, V4, P643, DOI 10.1136/bmj.4.5893.643
   Qunibi WY, 2004, KIDNEY INT, V65, P1914, DOI 10.1111/j.1523 1755.2004.00590.x
   SHINZATO T, 1994, NEPHRON, V67, P280, DOI 10.1159/000187980
NR 14
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1744 9979
EI 1744 9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
PD JUN
PY 2007
VL 11
IS 3
BP 210
EP 214
DI 10.1111/j.1744 9987.2007.00468.x
PG 5
WC Hematology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Urology & Nephrology
GA 165EF
UT WOS:000246286000008
PM 17498003
DA 2025 08 17
ER

PT J
AU Houghton, TJ
   Tanaka, KSE
   Kang, T
   Dietrich, E
   Lafontaine, Y
   Delorme, D
   Ferreira, SS
   Viens, F
   Arhin, FF
   Sarmiento, I
   Lehoux, D
   Fadhil, I
   Laquerre, K
   Liu, J
   Ostiguy, V
   Poirier, H
   Moeck, G
   Parr, TR
   Far, AR
AF Houghton, Tom J.
   Tanaka, Kelly S. E.
   Kang, Ting
   Dietrich, Evelyne
   Lafontaine, Yanick
   Delorme, Daniel
   Ferreira, Sandra S.
   Viens, Frederic
   Arhin, Francis F.
   Sarmiento, Ingrid
   Lehoux, Dario
   Fadhil, Ibtihal
   Laquerre, Karine
   Liu, Jing
   Ostiguy, Valeric
   Poirier, Hugo
   Moeck, Gregory
   Parr, Thomas R., Jr.
   Far, Adel Rafai
TI Linking Bisphosphonates to the Free Amino Groups in Fluoroquinolones:
   Preparation of Osteotropic Prodrugs for the Prevention of Osteomyelitis
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID DELIVERY SYSTEM ODDS; IN VIVO CHARACTERIZATION; DRUG DELIVERY; BONE;
   INFECTION; AGENTS; CARBOXYFLUORESCEIN; PHARMACOKINETICS; CIPROFLOXACIN;
   LACTONIZATION
AB Osteomyelitis is an infection located in bone and a notoriously difficult disease to manage, requiring frequent and heavy doses of systemically administered antibiotics. Targeting antibiotics to the bone after systemic administration may provide both greater efficacy of treatment and less frequent administration. By taking advantage, of the affinity of the bisphosphonate group for bone mineral, we have prepared a set of 13 bisphosphonated antibacterial prodrugs based on eight different linkers tethered to the free amino functionality on fluoroquinolone antibiotics. While all but one of the prodrugs were shown in vitro to be effective and rapid bone binders (over 90% in 1 h), only eight of them demonstrated the capacity to significantly regenerate the parent drug. In a rat model of the disease, a selected group of agents demonstrated their ability to prevent osteomyelitis when used in circumstances under which the parent drug had already been cleared and is thus inactive.
C1 [Houghton, Tom J.; Tanaka, Kelly S. E.; Kang, Ting; Dietrich, Evelyne; Lafontaine, Yanick; Delorme, Daniel; Ferreira, Sandra S.; Viens, Frederic; Arhin, Francis F.; Sarmiento, Ingrid; Lehoux, Dario; Fadhil, Ibtihal; Laquerre, Karine; Liu, Jing; Ostiguy, Valeric; Poirier, Hugo; Moeck, Gregory; Parr, Thomas R., Jr.; Far, Adel Rafai] Targanta Therapeut Inc, St Laurent, PQ H4S 2A1, Canada.
RP Far, AR (通讯作者)，Targanta Therapeut Inc, 7170 Ave Frederick Banting, St Laurent, PQ H4S 2A1, Canada.
EM afar@targanta.com
RI Lehoux, Dario/MVW 5315 2025
OI Moeck, Greg/0000 0001 7827 7227; Lehoux, Dario/0009 0001 6516 6162;
   Rafai Far, Adel/0000 0001 5805 7833
CR ADAZAMLI IK, 1989, J MED CHEM, V32, P139, DOI 10.1021/jm00121a026
   Agarwal Suraj P., 1999, Indian Journal of Pharmaceutical Sciences, V61, P223
   ALEXANDER J, 1991, J MED CHEM, V34, P78, DOI 10.1021/jm00105a013
   ALEXANDER J, 1988, J MED CHEM, V31, P318, DOI 10.1021/jm00397a008
   Alexander J, 1996, J MED CHEM, V39, P480, DOI 10.1021/jm9506175
   AMSBERRY KL, 1990, J ORG CHEM, V55, P5867, DOI 10.1021/jo00310a019
   AMSBERRY KL, 1991, PHARMACEUT RES, V8, P455, DOI 10.1023/A:1015890809507
   Bansal G, 2005, ANGEW CHEM INT EDIT, V44, P3710, DOI 10.1002/anie.200500350
   Baro M, 2002, J CONTROL RELEASE, V83, P353, DOI 10.1016/S0168 3659(02)00179 7
   Castro C, 2003, J CONTROL RELEASE, V93, P341, DOI 10.1016/j.jconrel.2003.09.004
   DEGENHARDT CR, 1986, J ORG CHEM, V51, P3488, DOI 10.1021/jo00368a017
   Fujisaki J, 1996, J DRUG TARGET, V4, P117, DOI 10.3109/10611869609046270
   Fujisaki J, 1995, J DRUG TARGET, V3, P273, DOI 10.3109/10611869509015956
   Fujisaki J, 1998, J DRUG TARGET, V5, P129, DOI 10.3109/10611869808995866
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968 0896(99)00045 0
   Greenberg RN, 2000, ANTIMICROB AGENTS CH, V44, P164, DOI 10.1128/AAC.44.1.164 166.2000
   Henderson B, 2003, TRENDS MICROBIOL, V11, P570, DOI 10.1016/j.tim.2003.10.005
   Herczegh P, 2002, J MED CHEM, V45, P2338, DOI 10.1021/jm0105326
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Hirabayashi H, 2002, BIOPHARM DRUG DISPOS, V23, P307, DOI 10.1002/bdd.323
   Hirabayashi H, 2001, J CONTROL RELEASE, V70, P183, DOI 10.1016/S0168 3659(00)00355 2
   Kubícek V, 2005, J AM CHEM SOC, V127, P16477, DOI 10.1021/ja054905u
   Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140 6736(04)16727 5
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   Luke GP, 2002, SYNTHETIC COMMUN, V32, P2951, DOI 10.1081/SCC 120012983
   MADER JT, 1985, AM J MED, V78, P213, DOI 10.1016/0002 9343(85)90387 0
   MAKINEN TJ, 2005, BIOMATERIALS, V26, P5251
   Mandal S, 2002, J INFECTION, V44, P143, DOI 10.1053/jinf.2001.0952
   Mitscher LA, 2005, CHEM REV, V105, P559, DOI 10.1021/cr030101q
   *NAT COMM CLIN LAB, 1994, M100S5 NCCLS
   Nelson CL, 2002, J ORTHOP RES, V20, P643, DOI 10.1016/S0736 0266(01)00133 4
   Ogawa K, 2005, BIOCONJUGATE CHEM, V16, P751, DOI 10.1021/bc040249w
   OREILLY T, 1992, ANTIMICROB AGENTS CH, V36, P2693, DOI 10.1128/AAC.36.12.2693
   Page PCB, 2001, J ORG CHEM, V66, P3704, DOI 10.1021/jo001489h
   PETER K, 2005, ANN SURG, V241, P885
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   SAKAMOTO F, 1985, CHEM PHARM BULL, V33, P4870
   Shirtliff ME, 2002, ANTIMICROB AGENTS CH, V46, P231, DOI 10.1128/AAC.46.1.231 233.2002
   Shirtliff ME, 2001, J ANTIMICROB CHEMOTH, V48, P253, DOI 10.1093/jac/48.2.253
   SVAHN CM, 1986, J MED CHEM, V29, P445, DOI 10.1021/jm00154a004
   Tice AD, 2003, AM J MED, V114, P723, DOI 10.1016/S0002 9343(03)00231 6
   Tice AD, 2003, J ANTIMICROB CHEMOTH, V51, P1261, DOI 10.1093/jac/dkg186
   Uludag H, 2002, CURR PHARM DESIGN, V8, P1929, DOI 10.2174/1381612023393585
   Van Bambeke F, 2005, CLIN MICROBIOL INFEC, V11, P256, DOI 10.1111/j.1469 0691.2005.01131.x
   Vepsäläinen JJ, 2002, CURR MED CHEM, V9, P1201, DOI 10.2174/0929867023369998
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wright JEI, 2006, BIOMATERIALS, V27, P769, DOI 10.1016/j.biomaterials.2005.06.012
NR 48
TC 68
Z9 85
U1 0
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD NOV 13
PY 2008
VL 51
IS 21
BP 6955
EP 6969
DI 10.1021/jm801007z
PG 15
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 369YX
UT WOS:000260730900034
PM 18834106
DA 2025 08 17
ER

PT J
AU Brancaccio, D
   Bonimerz, J
   Coyne, D
AF Brancaccio, Diego
   Bonimerz, Juergen
   Coyne, Daniel
TI Vitamin D receptor activator selectivity in the treatment of secondary
   hyperparathyroidism
SO DRUGS
LA English
DT Article
ID CHRONIC KIDNEY DISEASE; PARATHYROID HORMONE SECRETION;
   1,25 DIHYDROXYVITAMIN D 3; D ANALOGS; HEMODIALYSIS PATIENTS; MINERAL
   METABOLISM; DIALYSIS PATIENTS; LONG TERM; 1 ALPHA HYDROXYVITAMIN D 2;
   RENAL OSTEODYSTROPHY
AB Secondary hyperparathyroidism (SHPT) is a common and serious consequence of chronic kidney disease (CKD). SHPT is a complex condition characterised by a decline in 1,25 dihydroxyvitamin D and consequent vitamin D receptor (VDR) activation, abnormalities in serum calcium and phosphorus levels, parathyroid gland hyperplasia, elevated parathyroid hormone (PTH) secretion, and systemic mineral and bone abnormalities. There are three classes of drugs used for treatment of SHPT: (i) nonselective VDR activators or agonists (VDRAs); (ii) selective VDRAs; and (iii) calcimimetics. The VDRAs act on the VDR, whereas the calcimimetics act on the calcium sensing receptor. Calcimimetics are commonly used in conjunction with VDRA therapy. By virtue of the differences in their chemical structure, the nonselective and selective VDRAs differ in their effects on gene expression, and ultimately parathyroid gland, bone and intestine function. Medications in all three classes are effective in suppression of PTH; however, clinical studies show that calcimimetics are associated with an unfavourable tolerability profile and hypocalcaemia, whereas nonselective VDRAs, and to a lesser extent selective VDRAs, are associated with dose limiting hypercalcaemia and hyperphosphataemia. Selective VDRAs also have minimal undesirable effects on calcium absorption in the intestine, and calcium and phosphorus mobilisation in the bone compared with nonselective VDRAs. Calcium load in patients with CKD can lead to vascular calcification, accelerated progression of cardiovascular disease and increased mortality. High serum phosphorus levels are also associated with adverse effects on cardiorenal function and survival. Recent evidence suggests that VDRAs are associated with a survival benefit in CKD patients, with a more favourable effect with selective VDRAs than nonselective VDRAs. Paricalcitol, a selective VDRA, is reported to exert specific effects on gene expression in various cell types that are involved in vascular calcification and the development of coronary artery disease. This article examines the molecular mechanisms that determine selectivity of VDRAs, and reviews the evidence for clinical efficacy, safety and survival associated with the three drug classes used for treatment of SHPT in CKD patients.
C1 Univ Milan, Div Renal, Milan, Italy.
   Med Univ Klin Heidelberg, Heidelberg, Germany.
   Washington Univ, Sch Med, Div Renal Dis, St Louis, MO USA.
C3 University of Milan; Ruprecht Karls University Heidelberg; Washington
   University (WUSTL)
RP Brancaccio, D (通讯作者)，Univ Milan, Osped San Paolo, Via Rudini 8, I 20142 Milan, Italy.
EM diego.brancaccio@tiscalinet.it
RI brancaccio, diego/AEP 3471 2022
CR *ABB LAB, 2005, ZEMPL PAR FULL PRESC
   Abboud H, 2006, AM J NEPHROL, V26, P105, DOI 10.1159/000092033
   ACHARYA M, 2004, 37 ANN M SCI EXP AM
   Alvarez Hernández D, 2003, J MOL ENDOCRINOL, V31, P255, DOI 10.1677/jme.0.0310255
   *AMG INC, 2004, SENS CIN HCI FULL PR
   Andress D, 2007, DRUGS, V67, P1999, DOI 10.2165/00003495 200767140 00003
   Andress DL, 2006, KIDNEY INT, V69, P33, DOI 10.1038/sj.ki.5000045
   Andress DL, 2005, SEMIN DIALYSIS, V18, P315, DOI 10.1111/j.1525 139X.2005.18408.x
   BAKER LRI, 1989, KIDNEY INT, V35, P661, DOI 10.1038/ki.1989.36
   Balint E, 2000, AM J KIDNEY DIS, V36, P789, DOI 10.1053/ajkd.2000.17667
   Barthel TK, 2007, J STEROID BIOCHEM, V103, P381, DOI 10.1016/j.jsbmb.2006.12.054
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2000, AM J KIDNEY DIS, V35, P1226, DOI 10.1016/S0272 6386(00)70064 3
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   BRANDI L, 1992, AM J NEPHROL, V12, P311, DOI 10.1159/000168465
   Brown Alex J, 2002, Treat Endocrinol, V1, P313, DOI 10.2165/00024677 200201050 00004
   Carlberg C, 2001, STEROIDS, V66, P213, DOI 10.1016/S0039 128X(00)00150 1
   Charytan C, 2005, AM J KIDNEY DIS, V46, P58, DOI 10.1053/j.ajkd.2005.04.013
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   Coburn JW, 2004, AM J KIDNEY DIS, V43, P877, DOI 10.1053/j.ajkd.2004.01.012
   Coen G, 2002, NEPHRON, V91, P103, DOI 10.1159/000057611
   Coyne D, 2006, AM J KIDNEY DIS, V47, P263, DOI 10.1053/j.ajkd.2005.10.007
   Coyne DW, 2002, AM J KIDNEY DIS, V40, P1283, DOI 10.1053/ajkd.2002.36899
   Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523 1755.2005.00596.x
   DESIRAJU B, 2006, AM SOC NEPHR ASN 39
   Dobrez DG, 2004, NEPHROL DIAL TRANSPL, V19, P1174, DOI 10.1093/ndt/gfh123
   Dusso AS, 2004, SEMIN NEPHROL, V24, P10, DOI 10.1053/j.semnephrol.2003.08.018
   Fryer RM, 2007, NEPHRON PHYSIOL, V106, P76, DOI 10.1159/000104875
   Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
   González EA, 2004, AM J NEPHROL, V24, P503, DOI 10.1159/000081023
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   HAMDY NAT, 1995, BRIT MED J, V310, P358, DOI 10.1136/bmj.310.6976.358
   Hammerland LG, 1998, MOL PHARMACOL, V53, P1083
   Hirata M, 2003, NEPHROL DIAL TRANSPL, V18, P1770, DOI 10.1093/ndt/gfg296
   Hirata M, 2002, NEPHROL DIAL TRANSPL, V17, P37, DOI 10.1093/ndt/17.suppl_10.37
   Hirata M, 2002, NEPHROL DIAL TRANSPL, V17, P41, DOI 10.1093/ndt/17.suppl_10.41
   Holliday LS, 2000, J AM SOC NEPHROL, V11, P1857, DOI 10.1681/ASN.V11101857
   Hough TA, 2004, P NATL ACAD SCI USA, V101, P13566, DOI 10.1073/pnas.0405516101
   Hudson JQ, 2006, ANN PHARMACOTHER, V40, P1584, DOI 10.1345/aph.1G724
   Indridason OS, 2000, KIDNEY INT, V57, P282, DOI 10.1046/j.1523 1755.2000.00819.x
   Issa LL, 2002, J BONE MINER RES, V17, P879, DOI 10.1359/jbmr.2002.17.5.879
   Joist HE, 2006, CLIN NEPHROL, V65, P335
   Jokihaara J, 2006, J BONE MINER RES, V21, P745, DOI 10.1359/JBMR.060114
   Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Kalpakian MA, 2007, SEMIN DIALYSIS, V20, P139, DOI 10.1111/j.1525 139X.2007.00261.x
   KROEGER PE, 2005, AM SOC PEHNR ASN 38
   LaClair RE, 2005, AM J KIDNEY DIS, V45, P1026, DOI 10.1053/j.ajkd.2005.02.029
   Li YC, 2002, J CLIN INVEST, V110, P229, DOI 10.1172/JCI0215219
   Lindberg J, 2001, CLIN NEPHROL, V56, P315
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Llach F, 2001, AM J KIDNEY DIS, V38, pS45, DOI 10.1053/ajkd.2001.28114
   London GM, 2007, J AM SOC NEPHROL, V18, P613, DOI 10.1681/ASN.2006060573
   LUND R, 2006, 43 EUR REN ASS EUR D
   MA JN, 2004, J AM SOC NEPHROL, V115, pA437
   Martin KJ, 1998, J AM SOC NEPHROL, V9, P1427
   Martin KJ, 2001, AM J KIDNEY DIS, V38, pS57, DOI 10.1053/ajkd.2001.28112
   Maung HM, 2001, AM J KIDNEY DIS, V37, P532
   MESSA P, 2006, 43 EUR REN ASS EUR D
   Mitsopoulos E, 2006, AM J KIDNEY DIS, V48, P114, DOI 10.1053/j.ajkd.2006.04.060
   Mittman N, 2006, KIDNEY INT, V70, pS64, DOI 10.1038/sj.ki.5001981
   Mizobuchi M, 2007, KIDNEY INT
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Moe SM, 2005, NEPHROL DIAL TRANSPL, V20, P2186, DOI 10.1093/ndt/gfh966
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   MORINIERE P, 1993, KIDNEY INT, V43, pS121
   Nakane M, 2006, J STEROID BIOCHEM, V98, P72, DOI 10.1016/j.jsbmb.2005.07.007
   Nakane M, 2007, J STEROID BIOCHEM, V103, P84, DOI 10.1016/j.jsbmb.2006.07.004
   NORDAL KP, 1988, J CLIN ENDOCR METAB, V67, P929, DOI 10.1210/jcem 67 5 929
   Peterlik M, 2005, EUR J CLIN INVEST, V35, P290, DOI 10.1111/j.1365 2362.2005.01487.x
   Petrie MS, 2004, J THROMB HAEMOST, V2, P2266, DOI 10.1111/j.1538 7836.2004.01038.x
   Qiao GL, 2005, J STEROID BIOCHEM, V96, P59, DOI 10.1016/j.jsbmb.2005.02.008
   Quack M, 1999, MOL PHARMACOL, V55, P1077, DOI 10.1124/mol.55.6.1077
   Rix M, 2004, NEPHROL DIAL TRANSPL, V19, P870, DOI 10.1093/ndt/gfg595
   *ROCH LAB INC, 2004, ROC CALC FULL PRESCR
   ROSS EA, 2006, AM SOC NEPHR ASN 39
   Ruef J, 1999, THROMB HAEMOSTASIS, V82, P109, DOI 10.1055/s 0037 1614638
   Slatopolsky E, 1998, AM J KIDNEY DIS, V32, pS40, DOI 10.1053/ajkd.1998.v32.pm9808142
   Slatopolsky E, 2002, KIDNEY INT, V62, P1277, DOI 10.1111/j.1523 1755.2002.kid573.x
   Slatopolsky E, 1999, KIDNEY INT, V56, pS14, DOI 10.1046/j.1523 1755.1999.07304.x
   Sprague SM, 2003, KIDNEY INT, V63, P1483, DOI 10.1046/j.1523 1755.2003.00878.x
   Takeyama KI, 1999, MOL CELL BIOL, V19, P1049
   Tan XY, 2006, J AM SOC NEPHROL, V17, P3382, DOI 10.1681/ASN.2006050520
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   Tentori F, 2006, KIDNEY INT, V70, P1858, DOI 10.1038/sj.ki.5001868
   *US FDA, ROCALTR CALC OR SOL
   VERVLOET MG, 2006, AM SOC NEPHR ASN 39
   Wu Wong JR, 2006, ATHEROSCLEROSIS, V186, P20, DOI 10.1016/j.atherosclerosis.2005.06.046
   YOUNG EW, 2005, J AM SOC NEPHROL, V16, pA278
   Zierold C, 2006, MOL PHARMACOL, V69, P1740, DOI 10.1124/mol.105.019851
   Zierold C, 2003, J CELL BIOCHEM, V88, P234, DOI 10.1002/jcb.10341
NR 91
TC 32
Z9 37
U1 0
U2 4
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012 6667
EI 1179 1950
J9 DRUGS
JI Drugs
PY 2007
VL 67
IS 14
BP 1981
EP 1998
DI 10.2165/00003495 200767140 00002
PG 18
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 222YK
UT WOS:000250334400002
PM 17883283
DA 2025 08 17
ER

PT J
AU Wang, L
   Zhang, HY
   Gao, B
   Shi, J
   Huang, Q
   Han, YH
   Hu, YQ
   Lu, WG
   Zhao, ZJ
   Liu, BH
   Jie, Q
   Yang, L
   Luo, ZJ
AF Wang, Long
   Zhang, Hong Yang
   Gao, Bo
   Shi, Jun
   Huang, Qiang
   Han, Yue Hu
   Hu, Ya Qian
   Lu, Wei Guang
   Zhao, Zhuo Jie
   Liu, Bao Hua
   Jie, Qiang
   Yang, Liu
   Luo, Zhuo Jing
TI Tetramethylpyrazine Protects Against Glucocorticoid Induced Apoptosis by
   Promoting Autophagy in Mesenchymal Stem Cells and Improves Bone Mass in
   Glucocorticoid Induced Osteoporosis Rats
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
DE tetramethylpyrazine; glucocorticoids; bone marrow derived mesenchymal
   stem cells; osteoporosis; autophagy
ID DIFFERENTIATION; ACTIVATION; DEXAMETHASONE; OSTEOBLASTS; INHIBITION;
   OSTEOCYTES; GROWTH; AGE
AB Glucocorticoid induced osteoporosis (GIOP) is a widespread clinical complication due to the common use of glucocorticoids. Excess glucocorticoids induce apoptosis of bone marrow derived mesenchymal stem cells (BMSCs), which have been shown to play an increasingly important role in the pathogenesis and therapy of osteoporosis. Tetramethylpyrazine (TMP), an extract from one of the most recognized herbs in traditional Chinese medicine (Chuanxiong), has been reported to have antiapoptotic properties. In this study, we tested whether TMP protects rat BMSCs following exposure to glucocorticoids in vitro and in vivo. We treated BMSCs with different concentrations of TMP (50, 100, or 200M) and exposed them to 10( 6) M dexamethasone (Dex) for 48h in vitro. Our data showed that TMP inhibited Dex induced cytotoxicity and protected BMSCs from apoptosis. Interestingly, further results demonstrated that TMP prevented apoptosis in BMSCs by promoting autophagy in an AMP activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) pathway dependent manner. In addition, calcein fluorescence double labeling and microcomputed tomography scanning indicated that 12 weeks of TMP administration augmented bone formation and protected trabecular bone mass in GIOP rats. We also discovered that first passage BMSCs isolated from the TMP treatment group had a lower rate of apoptosis and a higher light chain 3 (LC3) II/LC3 I ratio than the GIOP group. Our findings demonstrate for the first time that TMP can protect BMSCs from exposure to excess glucocorticoids by promoting autophagy through AMPK/mTOR pathway and might be an effective agent for the prevention and treatment of GIOP.
C1 [Wang, Long; Zhang, Hong Yang; Gao, Bo; Shi, Jun; Huang, Qiang; Han, Yue Hu; Hu, Ya Qian; Lu, Wei Guang; Zhao, Zhuo Jie; Jie, Qiang; Yang, Liu; Luo, Zhuo Jing] Fourth Mil Med Univ, Xijing Hosp, Inst Orthoped Surg, Xian 710032, Peoples R China.
   [Liu, Bao Hua] Shenzhen Univ, Hlth Sci Ctr, Shenzhen, Peoples R China.
C3 Air Force Medical University; Shenzhen University
RP Yang, L; Luo, ZJ (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Inst Orthoped Surg, Xian 710032, Peoples R China.
EM yangliu@fmmu.edu.cn; zjluofmmu@hotmail.com
RI ; Lu, Weiguang/HJA 2546 2022; Liu, Baohua/C 9594 2014; Zhang,
   Hongyang/IAR 1565 2023
OI Hu, Yaqian/0000 0002 1936 5478; Lu, Weiguang/0000 0002 3920 9667; Liu,
   Baohua/0000 0002 1599 8059; 
FU Program for Changjiang Scholars and Innovative Research Team in
   University [IRT13051]; National Natural Science Foundation of China
   [81572192, 81472043]
FX This work was supported by the Program for Changjiang Scholars and
   Innovative Research Team in University (no. IRT13051) and National
   Natural Science Foundation of China (81572192 and 81472043).
CR Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159 11
   [Anonymous], PLOS ONE
   Bonyadi M, 2003, P NATL ACAD SCI USA, V100, P5840, DOI 10.1073/pnas.1036475100
   Bouffi C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014247
   Burman C, 2010, SEMIN IMMUNOPATHOL, V32, P397, DOI 10.1007/s00281 010 0222 z
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Chen L, 2014, NEUROCHEM INT, V66, P27, DOI 10.1016/j.neuint.2014.01.006
   Chen TL, 2004, BONE, V35, P83, DOI 10.1016/j.bone.2004.03.019
   Cui L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034647
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Doria A, 2013, NEW ENGL J MED, V368, P1845, DOI 10.1056/NEJMc1303158
   Espert L, 2006, J CLIN INVEST, V116, P2161, DOI 10.1172/JCI26185
   Gao B, 2015, STEM CELLS DEV, V24, P781, DOI 10.1089/scd.2014.0367
   Gong XZ, 2015, ARCH TOXICOL, V89, P1057, DOI 10.1007/s00204 014 1302 y
   Hardy Rowan, 2011, Front Endocrinol (Lausanne), V2, P24, DOI 10.3389/fendo.2011.00024
   Hocking LJ, 2012, J BONE MINER RES, V27, P1439, DOI 10.1002/jbmr.1668
   Hong D, 2009, J STEROID BIOCHEM, V116, P86, DOI 10.1016/j.jsbmb.2009.05.007
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534 5807(04)00099 1
   Lu C, 2014, INT J BIOL SCI, V10, P350, DOI 10.7150/ijbs.8366
   Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427
   Muraglia A, 2000, J CELL SCI, V113, P1161
   Noh BK, 2011, BIOCHEM BIOPH RES CO, V414, P361, DOI 10.1016/j.bbrc.2011.09.077
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Oliver L, 2012, STEM CELLS DEV, V21, P2779, DOI 10.1089/scd.2012.0124
   Onal M, 2013, J BIOL CHEM, V288, P17432, DOI 10.1074/jbc.M112.444190
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036
   Rizzoli R, 2015, NAT REV RHEUMATOL, V11, P98, DOI 10.1038/nrrheum.2014.188
   Rodríguez Muela N, 2012, CELL DEATH DIFFER, V19, P162, DOI 10.1038/cdd.2011.88
   Sanchez CG, 2011, CARCINOGENESIS, V32, P964, DOI 10.1093/carcin/bgr029
   SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411
   Wang HY, 2012, CYTOTHERAPY, V14, P423, DOI 10.3109/14653249.2011.652735
   Wang L, 2015, MOL MED REP, V11, P2711, DOI 10.3892/mmr.2014.3099
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Weinstein RS, 2010, BONE, V46, P564, DOI 10.1016/j.bone.2009.06.030
   Xu DP, 2014, J NEUROIMMUNE PHARM, V9, P245, DOI 10.1007/s11481 013 9514 0
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yao W, 2013, BONE, V54, P279, DOI 10.1016/j.bone.2013.01.034
   Yi B, 2013, ONCOL LETT, V6, P583, DOI 10.3892/ol.2013.1403
   Zhang Q, 2012, STEM CELLS DEV, V21, P1321, DOI 10.1089/scd.2011.0684
NR 44
TC 45
Z9 49
U1 1
U2 32
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD MAR
PY 2017
VL 26
IS 6
BP 419
EP 430
DI 10.1089/scd.2016.0233
PG 12
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA EM8UC
UT WOS:000395585600004
PM 27917698
DA 2025 08 17
ER

PT J
AU Rennert, G
   Pinchev, M
   Rennert, HS
   Gruber, SB
AF Rennert, Gad
   Pinchev, Mila
   Rennert, Hedy S.
   Gruber, Stephen B.
TI Use of Bisphosphonates and Reduced Risk of Colorectal Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID BREAST CANCER; ZOLEDRONIC ACID; ORAL BISPHOSPHONATES; POSTMENOPAUSAL
   WOMEN; ANTITUMOR ACTIVITY; COLON CANCER; BONE MASS; METASTASES; STATINS;
   CLODRONATE
AB Purpose
   Bisphosphonates are commonly used for the treatment of osteoporosis and bone metastases caused by breast cancer and were recently reported to be associated with a reduced risk of breast cancer, possibly acting through the mevalonate pathway, but their association with risk of other cancers is unknown.
   Patients and Methods
   The Molecular Epidemiology of Colorectal Cancer study is a population based, case control study in northern Israel of patients with colorectal cancer and age , sex , clinic , and ethnic group matched controls. Long term use of bisphosphonates before diagnosis was assessed in a subset of 933 pairs of postmenopausal female patients and controls, enrolled in Clalit Health Services, using computerized pharmacy records.
   Results
   The use of bisphosphonates for more than 1 year before diagnosis, but not for less than 1 year, was associated with a significantly reduced relative risk (RR) of colorectal cancer (RR, 0.50; 95% CI, 0.35 to 0.71). This association remained statistically significant after adjustment in a model for vegetable consumption, sports activity, family history of colorectal cancer, body mass index, and use of low dose aspirin, statins, vitamin D, and postmenopausal hormones (RR, 0.41; 95% CI, 0.25 to 0.67). Concomitant use of bisphosphonates and statins did not further reduce the risk.
   Conclusion
   The use of oral bisphosphonates for more than 1 year was associated with a 59% relative reduction in the risk of colorectal cancer, similar to the recently reported association of this drug class with reduction in breast cancer risk. J Clin Oncol 29:1146 1150. (C) 2011 by American Society of Clinical Oncology
C1 [Rennert, Gad] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Carmel Med Ctr, Dept Community Med & Epidemiol, IL 34362 Haifa, Israel.
   Clalit Hlth Serv Natl Canc Control Ctr, Haifa, Israel.
   Univ Michigan, Ann Arbor, MI 48109 USA.
C3 Technion Israel Institute of Technology; Rappaport Faculty of Medicine;
   Clalit Health Services; Carmel Medical Center; Clalit Health Services;
   University of Michigan System; University of Michigan
RP Rennert, G (通讯作者)，Technion Israel Inst Technol, Bruce Rappaport Fac Med, Carmel Med Ctr, Dept Community Med & Epidemiol, 7 Michal St, IL 34362 Haifa, Israel.
EM rennert@tx.technion.ac.il
OI Rennert, Gad/0000 0002 8512 068X
FU National Cancer Institute, Bethesda, MD [1R01CA81488]
FX Supported by Grant No. 1R01CA81488 from the National Cancer Institute,
   Bethesda, MD.
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Bundred NJ, 2008, CANCER AM CANCER SOC, V112, P1001, DOI 10.1002/cncr.23259
   Cardwell CR, 2010, JAMA J AM MED ASSOC, V304, P657, DOI 10.1001/jama.2010.1098
   Celiloglu M, 2009, MENOPAUSE, V16, P689, DOI 10.1097/gme.0b013e318194cafd
   Center MM, 2009, CANCER EPIDEM BIOMAR, V18, P1688, DOI 10.1158/1055 9965.EPI 09 0090
   Chlebowski RT, 2010, J CLIN ONCOL, V28, P3582, DOI 10.1200/JCO.2010.28.2095
   Clézardin P, 2002, SEMIN ONCOL, V29, P33, DOI 10.1053/sonc.2002.37420
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Etminan M, 2009, ALIMENT PHARM THER, V29, P1188, DOI 10.1111/j.1365 2036.2009.03989.x
   Ganry O, 2008, EUR J EPIDEMIOL, V23, P467, DOI 10.1007/s10654 008 9256 0
   Gates MA, 2010, CANCER EPIDEM BIOMAR, V19, P1033, DOI 10.1158/1055 9965.EPI 09 0975
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Green J, 2000, ANN ONCOL, V11, P14
   Green J, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c4444
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Guney E, 2008, NEUROENDOCRINOL LETT, V29, P252
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   Loke YK, 2009, DRUG SAFETY, V32, P219, DOI 10.2165/00002018 200932030 00004
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   McGlynn KA, 2008, INT J CANCER, V122, P1879, DOI 10.1002/ijc.23290
   Montagnani A, 2003, BONE, V32, P15, DOI 10.1016/S8756 3282(02)00924 9
   Neville Webbe HL, 2002, CANCER TREAT REV, V28, P305, DOI 10.1016/S0305 7372(02)00095 6
   Newcomb PA, 2010, BRIT J CANCER, V102, P799, DOI 10.1038/sj.bjc.6605555
   Nobuyuki H, 2001, J BONE MINER RES, V16, pS191
   Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027
   Pischon T, 2006, J NATL CANCER I, V98, P920, DOI 10.1093/jnci/djj246
   Powles T, 2002, J CLIN ONCOL, V20, P3219, DOI 10.1200/JCO.2002.11.080
   Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792
   Rachner TD, 2010, CANCER LETT, V287, P109, DOI 10.1016/j.canlet.2009.06.003
   Rennert G, 2010, J CLIN ONCOL, V28, P3577, DOI 10.1200/JCO.2010.28.1113
   Rosen CJ, 2005, NEW ENGL J MED, V353, P595, DOI 10.1056/NEJMcp043801
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Sassa S, 2009, ANTICANCER RES, V29, P4615
   Shane E, 2010, NEW ENGL J MED, V362, P1825, DOI 10.1056/NEJMe1003064
   Solomon DH, 2009, CURR OPIN RHEUMATOL, V21, P363, DOI 10.1097/BOR.0b013e32832ca433
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Tanriverdi HA, 2005, EUR J OBSTET GYN R B, V120, P63, DOI 10.1016/j.ejogrb.2004.08.007
   Wiemer AJ, 2009, ANTI CANCER AGENT ME, V9, P526, DOI 10.2174/187152009788451860
   Winter MC, 2008, CANCER TREAT REV, V34, P453, DOI 10.1016/j.ctrv.2008.02.004
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Yizhaki D, 2008, OPEN NUTR J, V2, P9, DOI DOI 10.2174/1874288200802010009
   Zhang YQ, 2001, AM J EPIDEMIOL, V153, P31, DOI 10.1093/aje/153.1.31
NR 43
TC 75
Z9 78
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0732 183X
EI 1527 7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 20
PY 2011
VL 29
IS 9
BP 1146
EP 1150
DI 10.1200/JCO.2010.33.7485
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 736YZ
UT WOS:000288532500027
PM 21321296
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Niikura, K
   Nakajima, S
   Takano, M
   Yamazaki, H
AF Niikura, Kazuaki
   Nakajima, Satoko
   Takano, Mikiko
   Yamazaki, Harumi
TI FR177995, a novel vacuolar ATPase inhibitor, exerts not only an
   inhibitory effect on bone destruction but also anti immunoinflammatory
   effects in adjuvant induced arthritic rats
SO BONE
LA English
DT Article
DE adjuvant induced arthritis; anti immunoinflammatory effect; bone
   destruction; osteoclast; vacuolar ATPase
ID COLLAGEN INDUCED ARTHRITIS; RHEUMATOID ARTHRITIS; TNF ALPHA; OSTEOCLAST
   DIFFERENTIATION; JOINT DESTRUCTION; GENE TRANSFER; RESORPTION;
   CARTILAGE; CELLS; SPECIFICITY
AB There is considerable evidence that osteoclasts are involved in the pathogenesis of juxta articular bone destruction in rheumatoid arthritis. Vacuolar ATPases (V ATPases), which are highly expressed in the ruffled border membrane of osteoclasts, play a central role in the process of bone resorption, and V ATPase inhibitors are effective in preventing bone destruction in several animal models of lytic bone diseases. Here, we evaluated for the first time the effects of V ATPase inhibition in rats with adjuvant induced arthritis (AIA) using FRI 77995, a novel V ATPase inhibitor.
   FR177995 completely inhibited H+ transport driven by V ATPase, but exerted no effect on the H+ transport activities of F  and P ATPase, indicating that FRI 77995 is a specific inhibitor of V ATPase. FRI 77995 acted directly on osteoclastic bone resorption and equally inhibited in vitro bone resorption stimulated by IL 1, IL 6 or PTH. In addition, FR177995 dose dependently reduced retinoic acid induced hypercalcemia in thyroparathyroidectomized ovariectomized rats. When FR177995 was administered to AIA rats once a day, the loss of femoral bone mineral density was significantly improved. Moreover, indicators of cartilage damage (arthritis score and glycosaminoglycan content in the femoral condyles) and inflammation parameters (paw swelling volume, erythrocyte sedimentation rate and plasma sialic acid level) were found to be unexpectedly ameliorated.
   These results strongly suggest that V ATPase may be an interesting drug target in the treatment of rheumatoid arthritis. (c) 2006 Elsevier Inc. All rights reserved.
RP Niikura, K (通讯作者)，21 Miyukigaoka, Ibaraki 3058585, Japan.
EM kazuaki.niikura@jp.astellas.com
OI Niikura, Kazuaki/0000 0002 3003 723X
CR Aibe K, 1996, BIOL PHARM BULL, V19, P1026
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Harada H, 2004, INFLAMM RES, V53, P45, DOI 10.1007/s00011 003 1214 4
   Hata H, 2004, J CLIN INVEST, V114, P582, DOI 10.1172/JCI200421795
   Hu YW, 2005, FEBS LETT, V579, P4937, DOI 10.1016/j.febslet.2005.07.078
   Itoh F, 2004, INFLAMMATION, V28, P15, DOI 10.1023/B:IFLA.0000014707.49803.b6
   Joosten LAB, 1999, J IMMUNOL, V163, P5049
   KOIZUMI K, 1976, J BIOCHEM, V79, P739, DOI 10.1093/oxfordjournals.jbchem.a131126
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   LAITALA T, 1994, J CLIN INVEST, V93, P2311, DOI 10.1172/JCI117235
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Makarov SS, 1996, P NATL ACAD SCI USA, V93, P402, DOI 10.1073/pnas.93.1.402
   Mihara M, 2001, CLIN IMMUNOL, V98, P319, DOI 10.1006/clim.2000.4989
   Niikura K, 2005, J BONE MINER RES, V20, P1579, DOI 10.1359/JBMR.050517
   Niikura K, 2004, BRIT J PHARMACOL, V142, P558, DOI 10.1038/sj.bjp.0705812
   Niikura Kazuaki, 2005, J Toxicol Sci, V30, P297
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Piecyk M, 2001, BEST PRACT RES CL RH, V15, P789, DOI 10.1053/berh.2001.0194
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Suzuki Y, 1998, J RHEUMATOL, V25, P1154
   Szekanecz Z, 2000, ARTHRITIS RHEUM, V43, P1266, DOI 10.1002/1529 0131(200006)43:6<1266::AID ANR9>3.0.CO;2 P
   Takayanagi H, 1999, J CLIN INVEST, V104, P137, DOI 10.1172/JCI6093
   TETI A, 1987, Bollettino Societa Italiana Biologia Sperimentale, V63, P1075
   TOMOI M, 1988, FOLIA PHARMACOL JPN, V92, P105, DOI 10.1254/fpj.92.105
   TRECHSEL U, 1987, J CLIN INVEST, V80, P1679, DOI 10.1172/JCI113257
   Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106
   Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756 3282(99)00210 0
   UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo 125 4 1805
   van Boekel MAM, 2002, ARTHRITIS RES, V4, P87, DOI 10.1186/ar395
   VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117
   Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105 2896.2005.00338.x
   WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784
   WLODAWER P, 1966, BIOCHIM BIOPHYS ACTA, V128, P34, DOI 10.1016/0926 6593(66)90139 1
   Yamamoto N, 1996, J RHEUMATOL, V23, P1778
   Yamamoto N, 2003, J CLIN INVEST, V112, P181, DOI 10.1172/JCI200317778
NR 39
TC 14
Z9 20
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2007
VL 40
IS 4
BP 888
EP 894
DI 10.1016/j.bone.2006.10.015
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 153GI
UT WOS:000245419800011
PM 17157574
DA 2025 08 17
ER

PT J
AU Göbel, A
   Zinna, VM
   Dell'Endice, S
   Jaschke, N
   Kuhlmann, JD
   Wimberger, P
   Rachner, TD
AF Goebel, Andy
   Zinna, Valentina M.
   Dell'Endice, Stefania
   Jaschke, Nikolai
   Kuhlmann, Jan Dominik
   Wimberger, Pauline
   Rachner, Tilman D.
TI Anti tumor effects of mevalonate pathway inhibition in ovarian cancer
SO BMC CANCER
LA English
DT Article
DE Ovarian cancer; Statins; Amino bisphosphonates; Apoptosis; Mevalonate
   pathway
ID BISPHOSPHONATES INDUCE APOPTOSIS; ENDOTHELIAL GROWTH FACTOR;
   DISSEMINATED TUMOR CELLS; BREAST CANCER; ZOLEDRONIC ACID; MAINTENANCE
   THERAPY; BONE MARROW; MOLECULAR MECHANISMS; DOUBLE BLIND; STATINS
AB BackgroundOvarian cancer remains the most fatal gynecological malignancy. Current therapeutic options are limited due to late diagnosis in the majority of the cases, metastatic spread to the peritoneal cavity and the onset of chemo resistance. Thus, novel therapeutic approaches are required. Statins and amino bisphosphonates are inhibitors of the mevalonate pathway, which is a fundamental pathway of cellular metabolism, essential for cholesterol production and posttranslational protein farnesylation and geranylgeranylation. While this pathway has emerged as a promising treatment target in several human malignancies, its potential as a therapeutic approach in ovarian cancer is still not fully understood.MethodsHuman ovarian cancer cell lines (IGROV 1, A2780, A2780cis) were treated with increasing concentrations (0.5 100 mu M) of statins (simvastatin, atorvastatin, rosuvastatin) and zoledronic acid. Effects on cell vitality and apoptosis were assessed using Cell Titer Blue (R), Caspase 3/7 Glo (R), clonogenic assays as well as cleaved poly (ADP ribose) polymerase (cPARP) detection. The inhibition of the mevalonate pathway was confirmed using Western Blot of unprenylated Ras and Rap1a proteins. Quantitative real time PCR and ELISA were used to analyze modulations on several key regulators of ovarian cancer tumorigenesis.ResultsThe treatment of IGROV 1 and A2780 cells with statins and zoledronic acid reduced vitality (by up to 80%; p <0.001) and induced apoptosis by up to 8 folds (p <0.001) in a dose dependent fashion. Rescue experiments using farnesyl pyrophosphate or geranylgeranyl pyrophosphate evidenced that blocked geranylgeranylation is the major underlying mechanism of the pro apoptotic effects. Gene expression of the tumor promoting cytokines and mediators, such as transforming growth factor (TGF) beta 1, vascular endothelial growth factor (VEGF), interleukin (IL) 8, and IL 6 were significantly suppressed by statins and zoledronic acid by up to 90% (p <0.001). For all readouts, simvastatin was most potent of all agents used. Cisplatin resistant A2780cis cells showed a relative resistance to statins and zoledronic acid. However, similar to the effects in A2780 cells, simvastatin and zoledronic acid significantly induced caspase 3/7 activation (6 folds; p <0.001).ConclusionOur in vitro findings point to promising anti tumor effects of statins and zoledronic acid in ovarian cancer and warrant additional validation in preclinical and clinical settings.
C1 [Goebel, Andy; Dell'Endice, Stefania; Jaschke, Nikolai; Rachner, Tilman D.] Tech Univ, Dept Med 3, Div Endocrinol Diabet & Bone Dis, Fetscherstr 74, D 01307 Dresden, Germany.
   [Goebel, Andy; Kuhlmann, Jan Dominik; Wimberger, Pauline; Rachner, Tilman D.] German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany.
   [Goebel, Andy; Kuhlmann, Jan Dominik; Wimberger, Pauline; Rachner, Tilman D.] German Canc Res Ctr, Heidelberg, Germany.
   [Zinna, Valentina M.] Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Barcelona, Spain.
   [Jaschke, Nikolai; Rachner, Tilman D.] Tech Univ Dresden, Ctr Hlth Aging, Dresden, Germany.
   [Jaschke, Nikolai] Med Univ Innsbruck, Dept Internal Med Gastroenterol Hepatol Endocrino, Innsbruck, Austria.
   [Kuhlmann, Jan Dominik; Wimberger, Pauline] Tech Univ Dresden, Med Fac, Dept Gynecol & Obstet, Dresden, Germany.
   [Kuhlmann, Jan Dominik; Wimberger, Pauline] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany.
   [Kuhlmann, Jan Dominik; Wimberger, Pauline] Natl Ctr Tumor Dis NCT, Dresden, Germany.
   [Kuhlmann, Jan Dominik; Wimberger, Pauline] Tech Univ Dresden, Fac Med, Dresden, Germany.
   [Kuhlmann, Jan Dominik; Wimberger, Pauline] Helmholtz Zentrum Dresden Rossendorf HZDR, Dresden, Germany.
C3 Technische Universitat Dresden; Helmholtz Association; German Cancer
   Research Center (DKFZ); Helmholtz Association; German Cancer Research
   Center (DKFZ); Barcelona Institute of Science & Technology; Institute
   for Research in Biomedicine   IRB Barcelona; Technische Universitat
   Dresden; Medical University of Innsbruck; Technische Universitat
   Dresden; Technische Universitat Dresden; Carl Gustav Carus University
   Hospital; Helmholtz Association; German Cancer Research Center (DKFZ);
   Ruprecht Karls University Heidelberg; National Center for Tumor
   Diseases; Technische Universitat Dresden; Helmholtz Association;
   Helmholtz Zentrum Dresden Rossendorf (HZDR)
RP Göbel, A (通讯作者)，Tech Univ, Dept Med 3, Div Endocrinol Diabet & Bone Dis, Fetscherstr 74, D 01307 Dresden, Germany.; Göbel, A (通讯作者)，German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany.; Göbel, A (通讯作者)，German Canc Res Ctr, Heidelberg, Germany.
EM Andy.Goebel@ukdd.de
RI ; Zinna, Valentina/AFM 1167 2022
OI Zinna, Valentina M./0000 0002 1693 5914; 
FU Deutsche Forschungsgemeinschaft as part of the DFG [GO 3055/1 1, RA
   2151/4 1, RA 2151/5 1, 2084]; Deutsche Krebshilfe [70113573]; Projekt
   DEAL
FX The conduction and analysis of the study was funded by the Deutsche
   Forschungsgemeinschaft to AG (GO 3055/1 1) and to TDR (RA 2151/4 1 and
   5 1) as part of the DFG Schwerpunktprogramm 2084 mu Bone as well as by
   the Deutsche Krebshilfe to AG and TDR (#70113573 and as part of the
   Mildred Scheel Nachwuchszentrum). Open access funding provided by
   Projekt DEAL.
CR ABATE M., 2017, Scientific reports, V7, P1
   Abdullah MarwanIbrahim., 2017, Scientific reports, V7, P1
   Åberg M, 2008, THROMB RES, V122, P191, DOI 10.1016/j.thromres.2007.09.017
   Abubaker K, 2013, MOL CANCER, V12, DOI 10.1186/1476 4598 12 24
   Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256
   Alsina Sanchís E, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081658
   Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644
   Beckwitt CH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197422
   BEHRENS BC, 1987, CANCER RES, V47, P414
   BENARD J, 1985, CANCER RES, V45, P4970
   Berndt N, 2011, NAT PROTOC, V6, P1775, DOI 10.1038/nprot.2011.387
   Brennan DJ, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 125
   Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016
   Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390
   Byrne AT, 2003, CLIN CANCER RES, V9, P5721
   Cai J, 2012, CARCINOGENESIS, V33, P20, DOI 10.1093/carcin/bgr230
   Campbell MJ, 2006, CANCER RES, V66, P8707, DOI 10.1158/0008 5472.CAN 05 4061
   Casella C, 2014, GYNECOL ONCOL, V135, P333, DOI 10.1016/j.ygyno.2014.08.015
   Chang HL, 2013, BBA GEN SUBJECTS, V1830, P4053, DOI 10.1016/j.bbagen.2013.04.011
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Clendening JW, 2010, P NATL ACAD SCI USA, V107, P15051, DOI 10.1073/pnas.0910258107
   Clendening JW, 2010, BLOOD, V115, P4787, DOI 10.1182/blood 2009 07 230508
   Clezardin Philippe, 2013, Bonekey Rep, V2, P267, DOI 10.1038/bonekey.2013.1
   Cohen C, 2003, MODERN PATHOL, V16, P574, DOI 10.1097/01.MP.0000073868.31297.B0
   Coleman RL, 2017, LANCET, V390, P1949, DOI 10.1016/S0140 6736(17)32440 6
   Couttenier A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189233
   Coward J, 2012, CANCER, V17, P6083, DOI [10.1073/pnas.0502178102, DOI 10.1073/PNAS.0502178102]
   De Wolf E., 2017, SCI REP, V7, P1
   Demierre MF, 2005, NAT REV CANCER, V5, P930, DOI 10.1038/nrc1751
   Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126
   Duan SZ, 2015, ONCOTARGET, V6, P27651, DOI 10.18632/oncotarget.4753
   Fragni M, 2016, ANTICANCER RES, V36, P913
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384
   Gazzerro P, 2012, PHARMACOL REV, V64, P102, DOI 10.1124/pr.111.004994
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   Goc A, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 409
   Göbel A, 2020, BBA REV CANCER, V1873, DOI 10.1016/j.bbcan.2020.188351
   Göbel A, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1322 x
   Göbel A, 2016, CANCER LETT, V375, P162, DOI 10.1016/j.canlet.2016.03.004
   Goff BA, 2000, CANCER, V89, P2068, DOI 10.1002/1097 0142(20001115)89:10<2068::AID CNCR6>3.0.CO;2 Z
   Goldstein JL, 2015, CELL, V161, P161, DOI 10.1016/j.cell.2015.01.036
   Green JR, 2002, AM J CLIN ONCOL CANC, V25, pS3, DOI 10.1097/00000421 200212001 00002
   Greenaway JB, 2016, ONCOTARGET, V7, P47343, DOI 10.18632/oncotarget.10121
   Gronich N, 2013, NAT REV CLIN ONCOL, V10, P625, DOI 10.1038/nrclinonc.2013.169
   Gupta S, 2020, J ACAD MARKET SCI, V48, P941, DOI 10.1007/s11747 019 00639 9
   Hashimoto K, 2005, CANCER RES, V65, P540
   He SS, 2019, ENDOCR RELAT CANCER, V26, P659, DOI 10.1530/ERC 18 0572
   Hennessy BT, 2009, LANCET, V374, P1371, DOI 10.1016/S0140 6736(09)61338 6
   Herr D, 2012, GYNECOL ONCOL, V127, P210, DOI 10.1016/j.ygyno.2012.05.002
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Hoffmann O, 2015, ARCH GYNECOL OBSTET, V292, P1117, DOI 10.1007/s00404 015 3748 4
   Hoffmann O, 2011, ANTICANCER RES, V31, P3623
   Inan S, 2006, HISTOL HISTOPATHOL, V21, P1055, DOI 10.14670/HH 21.1055
   Jelovac D, 2011, CA CANCER J CLIN, V61, P183, DOI 10.3322/caac.20113
   Kampan NC, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/413076
   Kar R, 2007, CANCER BIOL THER, V6, P1101, DOI 10.4161/cbt.6.7.4329
   Karabulut B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756 9966 29 102
   Kassim SK, 1999, CLIN BIOCHEM, V32, P333, DOI 10.1016/S0009 9120(99)00026 0
   Kassim SK, 2004, CLIN BIOCHEM, V37, P363, DOI 10.1016/j.clinbiochem.2004.01.014
   Kato S, 2010, J CELL MOL MED, V14, P1180, DOI 10.1111/j.1582 4934.2009.00771.x
   Kim A, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756 9966 31 14
   Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432
   Kochuparambil ST, 2011, J PHARMACOL EXP THER, V336, P496, DOI 10.1124/jpet.110.174870
   Kulbe H, 2007, CANCER RES, V67, P585, DOI 10.1158/0008 5472.CAN 06 2941
   Kumar J, 2014, BBA REV CANCER, V1845, P117, DOI 10.1016/j.bbcan.2013.12.003
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lane D, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 210
   Lavie O, 2013, GYNECOL ONCOL, V130, P615, DOI 10.1016/j.ygyno.2013.05.025
   Ledermann J, 2014, LANCET ONCOL, V15, P852, DOI 10.1016/S1470 2045(14)70228 1
   Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748
   Liu HL, 2009, CANCER CHEMOTH PHARM, V63, P997, DOI 10.1007/s00280 008 0830 7
   Longo J, 2019, MOL METAB, V25, P119, DOI 10.1016/j.molmet.2019.04.003
   Longuespée R, 2012, CANCER METAST REV, V31, P713, DOI 10.1007/s10555 012 9383 7
   Mano Y, 1999, EUR J CANCER, V35, P1214, DOI 10.1016/S0959 8049(99)00124 0
   Marchetti C, 2019, ONCOTARGETS THER, V12, P1095, DOI 10.2147/OTT.S155425
   Markman M, 2004, J CLIN ONCOL, V22, P3120, DOI 10.1200/JCO.2004.05.195
   Markman M, 2000, Oncologist, V5, P26, DOI 10.1634/theoncologist.5 1 26
   Matte I, 2012, AM J CANCER RES, V2, P566
   McTaggart SJ, 2006, CELL MOL LIFE SCI, V63, P255, DOI 10.1007/s00018 005 5298 6
   Melani C, 2007, CANCER RES, V67, P11438, DOI 10.1158/0008 5472.CAN 07 1882
   Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310
   Mokady D, 2015, DRUG RESIST UPDATE, V19, P22, DOI 10.1016/j.drup.2015.01.001
   Moore K, 2018, NEW ENGL J MED, V379, P2495, DOI 10.1056/NEJMoa1810858
   Mor G, 2005, P NATL ACAD SCI USA, V102, P7677, DOI 10.1073/pnas.0502178102
   NAGY JA, 1995, CANCER RES, V55, P360
   Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908
   Nilsson MB, 2005, CANCER RES, V65, P10794, DOI 10.1158/0008 5472.CAN 05 0623
   Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f
   Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799
   Porter Andrew P, 2016, Small GTPases, V7, P123, DOI 10.1080/21541248.2016.1173767
   Pujade Lauraine E, 2017, LANCET ONCOL, V18, P1274, DOI 10.1016/S1470 2045(17)30469 2
   Rachner TD, 2010, CANCER LETT, V287, P109, DOI 10.1016/j.canlet.2009.06.003
   Raghu VK, 2018, BIOCHEM BIOPH RES CO, V495, P659, DOI 10.1016/j.bbrc.2017.11.065
   Rennert G, 2014, GYNECOL ONCOL, V133, P309, DOI 10.1016/j.ygyno.2014.02.014
   Robinson E, 2013, GYNECOL ONCOL, V129, P417, DOI 10.1016/j.ygyno.2013.02.003
   Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725
   Sawada K, 2002, CANCER RES, V62, P6015
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Stronach EA, 2015, ONCOTARGET, V6, P31593, DOI 10.18632/oncotarget.3415
   Tania M, 2010, CURR ONCOL, V17, P6
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Taylor Harding B, 2010, GYNECOL ONCOL, V119, P549, DOI 10.1016/j.ygyno.2010.08.017
   Thurnher M, 2013, BBA MOL CELL BIOL L, V1831, P1009, DOI 10.1016/j.bbalip.2013.03.003
   Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399
   Wheatley SP, 2019, J CELL SCI, V132, P1
   Wolfe AR, 2015, BREAST CANCER RES TR, V154, P495, DOI 10.1007/s10549 015 3645 3
   Wong WWL, 2002, LEUKEMIA, V16, P508, DOI 10.1038/sj.leu.2402476
   Yanae M, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756 9966 30 74
   Yin J, 2015, CLIN TRANSL ONCOL, V17, P365, DOI 10.1007/s12094 014 1240 4
   Zheng L, 2018, EXP BIOL MED, V243, P655, DOI 10.1177/1535370218760283
NR 111
TC 35
Z9 35
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD JUL 29
PY 2020
VL 20
IS 1
AR 703
DI 10.1186/s12885 020 07164 x
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA MX4KP
UT WOS:000557692600003
PM 32727400
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Komano, Y
   Nanki, T
   Hayashida, K
   Taniguchi, K
   Miyasaka, N
AF Komano, Yukiko
   Nanki, Toshihiro
   Hayashida, Kenji
   Taniguchi, Ken
   Miyasaka, Nobuyuki
TI Identification of a human peripheral blood monocyte subset that
   differentiates into osteoclasts
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID RHEUMATOID ARTHRITIS PATIENTS; NECROSIS FACTOR ALPHA; COLONY STIMULATING
   FACTOR; BONE RESORPTION; VITRONECTIN RECEPTOR; STROMAL CELLS; C SRC;
   MACROPHAGES; INTEGRINS; TNF
AB Increased bone resorption mediated by osteoclasts causes various diseases such as osteoporosis and bone erosion in rheumatoid arthritis (RA). Osteoclasts are derived from the monocyte/macrophage lineage, but the precise origin remains unclear. In the present study, we show that the purified CD16 human peripheral blood monocyte subset, but not the CD16+ monocyte subset, differentiates into osteoclast by stimulation with receptor activator of NF kappa B ligand (RANKL) in combination with macrophage colony stimulating factor (M CSF). Integrin beta 3 mRNA and the integrin alpha nu beta 3 heterodimer were only expressed on CD16 monocytes, when they were stimulated with RANKL + M CSF. Downregulation of beta 3 subunit expression by small interfering RNA targeting beta 3 abrogated osteoclastogenesis from the CD16 monocyte subset. In contrast, the CD16+ monocyte subset expressed larger amounts of tumor necrosis factor alpha and IL 6 than the CD16 subset, which was further enhanced by RANKL stimulation. Examination of RA synovial tissue showed accumulation of both CD16+ and CD16 macrophages. Our results suggest that peripheral blood monocytes consist of two functionally heterogeneous subsets with distinct responses to RANKL. Osteoclasts seem to originate from CD16 monocytes, and integrin beta 3 is necessary for osteoclastogenesis. Blockade of accumulation and activation of CD16 monocytes could therefore be a beneficial approach as an anti bone resorptive therapy, especially for RA.
C1 Tokyo Med & Dent Univ, Grad Sch, Dept Med & Rheumatol, Tokyo 1138519, Japan.
   Tokyo Med & Dent Univ, Excellence Program Frontier Res Mol Destruct Toot, 21st Century Ctr, Tokyo 1138519, Japan.
   Hoshigaoka Koseinenkin Hosp, Dept Orthoped Surg, Osaka 5738511, Japan.
   Tokyo Metropolitan Bolutoh Hosp, Div Rheumat Dis, Tokyo 1300022, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU)
RP Nanki, T (通讯作者)，Tokyo Med & Dent Univ, Grad Sch, Dept Med & Rheumatol, Tokyo 1138519, Japan.
EM nanki.rheu@tmd.ac.jp
CR Ancuta P, 2003, J EXP MED, V197, P1701, DOI 10.1084/jem.20022156
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Badger AM, 2001, ARTHRITIS RHEUM US, V44, P128, DOI 10.1002/1529 0131(200101)44:1<128::AID ANR17>3.0.CO;2 M
   Belge KU, 2002, J IMMUNOL, V168, P3536, DOI 10.4049/jimmunol.168.7.3536
   Blom AB, 2003, ARTHRITIS RHEUM, V48, P1002, DOI 10.1002/art.10871
   CHU CQ, 1991, ARTHRITIS RHEUM, V34, P1125, DOI 10.1002/art.1780340908
   Crotti T. N., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P335
   Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   FINGERLE G, 1993, BLOOD, V82, P3170
   FISHER JE, 1993, ENDOCRINOLOGY, V132, P1411, DOI 10.1210/en.132.3.1411
   Fujikawa Y, 1996, ANN RHEUM DIS, V55, P816, DOI 10.1136/ard.55.11.816
   Fujikawa Y, 1996, ENDOCRINOLOGY, V137, P4058, DOI 10.1210/en.137.9.4058
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074 7613(03)00174 2
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hayashida K, 2001, ARTHRITIS RES, V3, P118, DOI 10.1186/ar149
   HELFRICH MH, 1992, J BONE MINER RES, V7, P335
   Horton MA, 2003, BRIT J HAEMATOL, V122, P950, DOI 10.1046/j.1365 2141.2003.04530.x
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092 8674(02)00971 6
   Katayama K, 2000, CLIN EXP IMMUNOL, V121, P566, DOI 10.1046/j.1365 2249.2000.01321.x
   Kawanaka N, 2002, ARTHRITIS RHEUM, V46, P2578, DOI 10.1002/art.10545
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529 0131(200105)44:5<1003::AID ANR179>3.3.CO;2 R
   Kotake S, 1996, J BONE MINER RES, V11, P88
   Kruger M, 1996, IMMUNOLOGY, V89, P89, DOI 10.1046/j.1365 2567.1996.d01 707.x
   Krutzik SR, 2005, NAT MED, V11, P653, DOI 10.1038/nm1246
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Murphy MG, 2005, J CLIN ENDOCR METAB, V90, P2022, DOI 10.1210/jc.2004 2126
   Nakamura I, 1998, ENDOCRINOLOGY, V139, P5182, DOI 10.1210/en.139.12.5182
   Nanki T, 2004, J IMMUNOL, V173, P7010, DOI 10.4049/jimmunol.173.11.7010
   NESBITT S, 1993, J BIOL CHEM, V268, P16737
   Nimmerjahn F, 2006, IMMUNITY, V24, P19, DOI 10.1016/j.immuni.2005.11.010
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   SALEH MN, 1995, BLOOD, V85, P2910, DOI 10.1182/blood.V85.10.2910.bloodjournal85102910
   SEITZ M, 1994, BRIT J RHEUMATOL, V33, P613
   Shalhoub V, 2000, BRIT J HAEMATOL, V111, P501, DOI 10.1046/j.1365 2141.2000.02379.x
   Shigeyama Y, 2000, ARTHRITIS RHEUM, V43, P2523, DOI 10.1002/1529 0131(200011)43:11<2523::AID ANR20>3.0.CO;2 Z
   Shono T, 2001, EXP CELL RES, V268, P169, DOI 10.1006/excr.2001.5276
   Sunderkötter C, 2004, J IMMUNOL, V172, P4410, DOI 10.4049/jimmunol.172.7.4410
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Teitelbaum SL, 2000, J BONE MINER METAB, V18, P344, DOI 10.1007/s007740070007
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105 2896.2005.00338.x
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   ZieglerHeitbrock HWL, 1996, IMMUNOL TODAY, V17, P424, DOI 10.1016/0167 5699(96)10029 3
NR 55
TC 127
Z9 140
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2006
VL 8
IS 5
AR R152
DI 10.1186/ar2046
PG 14
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 114GW
UT WOS:000242655700022
PM 16987426
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lee, SY
   Kim, CS
   Cho, SH
   Chun, HS
   Kim, JK
   Kim, DK
AF Lee, Sook Young
   Kim, Chun Sung
   Cho, Seon Ho
   Chun, Hong Sung
   Kim, Jong Keun
   Kim, Do Kyung
TI The effects of Angelica decursiva extract in the inhibition of
   cell proliferation and in the induction of apoptosis in osteogenic
   sarcoma cells
SO JOURNAL OF MEDICINAL PLANTS RESEARCH
LA English
DT Article
DE Human osteogenic sarcoma cell; Angelica decursiva; apoptosis; caspases;
   anti cancer therapy
ID AMINO ACID TRANSPORTERS; LUNG CANCER CELLS; CARCINOMA; LEUKEMIA;
   THERAPY; PATHWAY; PROTEIN; ARREST; GROWTH; LINES
AB The Angelica decursiva has been used in Korean traditional medicine as an antitussive, an analgesic, an antipyretic and a cough remedy. However, its anticancer activity has been unknown. In this study, we have examined the cytotoxic activity of ethanol extract of A. decursiva root (EEAD), and the mechanism by which EEAD suppresses cell growth in Saos2 human osteogenic sarcoma cells. Treatment of EEAD in Saos2 cells induced the apoptic cell death in a concentration dependent manner as determined by MTT assay and DNA fragmentation analysis but not in FOB human normal osteoblast cells. Furthermore, the proteolytic processing and the activity of caspase 3 and  7 were increased by EEAD treatment in Saos2 cells. These results suggest that EEAD can induce the suppression of cell growth and cell apoptosis in Saos2 human osteogenic sarcoma cells, and therefore, it may have potential properties for anticancer drug discovery.
C1 [Kim, Chun Sung; Cho, Seon Ho; Kim, Do Kyung] Chosun Univ, Coll Dent, Dept Oral Physiol, Stage BK21 2, Kwangju 501759, South Korea.
   [Lee, Sook Young] Chosun Univ, Coll Dent, Res Ctr Oral Dis Regulat Aged, Kwangju 501759, South Korea.
   [Chun, Hong Sung] Chosun Univ, Coll Dent, Dept Biotechnol, Program BK21, Kwangju 501759, South Korea.
   [Kim, Jong Keun] Chonnam Natl Univ, Sch Med, Dept Pharmacol, Kwangju 501746, South Korea.
C3 Chosun University; Chosun University; Chosun University; Chonnam
   National University
RP Kim, DK (通讯作者)，Chosun Univ, Coll Dent, Dept Oral Physiol, Stage BK21 2, Kwangju 501759, South Korea.
EM kdk@chosun.ac.kr
RI Kim, Yon/J 2743 2012; , Do Kyung Kim/A 5289 2008
FU Korea Science and Engineering Foundation (KOSEF) [R13 2008 010 01002 0];
   Korea government (MOST) [20050301034463]
FX This work was supported by the Korea Science and Engineering Foundation
   (KOSEF) grant (R13 2008 010 01002 0) funded by the Korea government
   (MOST) and a grant (20050301034463) from Biogreen 21 Program, Rural
   Development Administration, Republic of Korea. We thank Prof. Su In Cho,
   School of Oriental Medicine, Pusan National University, Korea, for his
   kind support. We thank Su Young Kim for her helpful technical support.
CR ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223
   Cheng YL, 2005, CANCER LETT, V222, P183, DOI 10.1016/j.canlet.2004.10.015
   Chicca A, 2007, J ETHNOPHARMACOL, V110, P148, DOI 10.1016/j.jep.2006.09.013
   Christou L, 2001, EUR J HAEMATOL, V67, P51, DOI 10.1034/j.1600 0609.2001.067001051.x
   Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001
   Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Hoshino T, 1991, J Clin Lab Immunol, V36, P39
   Hostanska K, 2007, CANCER DETECT PREV, V31, P129, DOI 10.1016/j.cdp.2007.03.001
   Hu HB, 2002, INT J CANCER, V102, P250, DOI 10.1002/ijc.10707
   Hu W, 2003, LANCET ONCOL, V4, P721, DOI 10.1016/S1470 2045(03)01277 4
   Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962 8924(01)02173 0
   Kim CS, 2008, BIOL PHARM BULL, V31, P1096, DOI 10.1248/bpb.31.1096
   Kim SG, 2006, ANTICANCER RES, V26, P1989
   Lee MR, 2008, FOOD SCI BIOTECHNOL, V17, P308
   Lee SMY, 2002, LIFE SCI, V71, P2267, DOI 10.1016/S0024 3205(02)01962 8
   Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092 8674(00)80197 X
   Mukherjee AK, 2001, CURR MED CHEM, V8, P1467, DOI 10.2174/0929867013372094
   Park DI, 2005, PHARMACOL RES, V51, P437, DOI 10.1016/j.phrs.2004.11.003
   Pezzuto JM, 1997, BIOCHEM PHARMACOL, V53, P121, DOI 10.1016/S0006 2952(96)00654 5
   Tan ML, 2005, J ETHNOPHARMACOL, V96, P287, DOI 10.1016/j.jep.2004.09.025
   Tian Z, 2006, PHYTOMEDICINE, V13, P181, DOI 10.1016/j.phymed.2004.07.010
   vanPoppel G, 1997, CANCER LETT, V114, P195, DOI 10.1016/S0304 3835(97)04662 4
   Vickers A, 2002, CANCER INVEST, V20, P1069, DOI 10.1081/CNV 120005926
   Yang HL, 2006, FOOD CHEM TOXICOL, V44, P1978, DOI 10.1016/j.fct.2006.06.027
   YANO H, 1994, CANCER RES, V54, P448
NR 27
TC 18
Z9 19
U1 0
U2 3
PU ACADEMIC JOURNALS
PI VICTORIA ISLAND
PA P O BOX 5170 00200 NAIROBI, VICTORIA ISLAND, LAGOS 73023, NIGERIA
SN 1996 0875
J9 J MED PLANTS RES
JI J. Med. Plants Res.
PD APR
PY 2009
VL 3
IS 4
BP 241
EP 245
PG 5
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 438UJ
UT WOS:000265580600008
DA 2025 08 17
ER

PT J
AU Chan, BY
   Lau, KS
   Jiang, B
   Kennelly, EJ
   Kronenberg, F
   Kung, AWC
AF Chan, B. Y.
   Lau, K. S.
   Jiang, B.
   Kennelly, E. J.
   Kronenberg, F.
   Kung, A. W. C.
TI Ethanolic extract of Actaea racemosa (black cohosh) potentiates
   bone nodule formation in MC3T3 E1 preosteoblast cells
SO BONE
LA English
DT Article
DE Cimicifuga racemosa; Actaea racemosa; black cohosh; MC3T3 E1;
   osteoblast; ICI 182 780; estrogen receptor
ID BREAST CANCER CELLS; CIMICIFUGA RACEMOSA; ISOPROPANOLIC EXTRACT;
   ESTROGEN RECEPTOR; IN VITRO; CLIMACTERIC COMPLAINTS; HUMAN OSTEOBLASTS;
   PROSTATE CANCER; DOUBLE BLIND; EFFICACY
AB Aceaeu racemosa (formerly Cimicifuga racemosa, black cohosh, AR) extracts have been widely used as an alternative to hormonal replacement therapy for menopausal symptoms. Recent evidences suggest AR extracts are also effective in protecting against postmenopausal bone loss. To determine whether AR has any direct anabolic effect on osteoblasts, we investigated the ethanolic extract of AR on bone nodule formation in mouse MC3T3 E1 preosteoblast cells. AR did not stimulate osteoblast proliferation. Rather, at high doses of 1000 ng/mL for 48 h, AR suppressed (7.2 +/  0.9% vs. control) osteoblast proliferation. At 500 ng/mL, a significant increase in bone nodule formation was seen with Von Kossa staining. Using quantitative PCR analysis, AR was shown to enhance the gene expression of runx2 and osteocalcin. Co treatment with ICI 182,780, the selective estrogen receptor antagonist, abolished the stimulatory effect of AR on runx2 and osteocalcin gene induction, as well as on bone nodule formation in MC3T3 E1 cells. This is a first report of the direct effect of AR on enhancement of bone nodule formation in osteoblasts, and this action was mediated via an estrogen receptor dependent mechanism. The results provide a scientific rationale at the molecular level for the claim that AR can offer effective prevention of postmenopausal bone loss. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Jiang, B.; Kronenberg, F.] Columbia Univ, Dept Rehabil Med, Coll Phys & Surg, New York, NY 10032 USA.
   [Jiang, B.; Kennelly, E. J.] CUNY, Lehman Coll, Dept Biol Sci, Bronx, NY 10468 USA.
   [Chan, B. Y.; Lau, K. S.; Kung, A. W. C.] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.
C3 Columbia University; City University of New York (CUNY) System; Lehman
   College (CUNY); University of Hong Kong
RP Kronenberg, F (通讯作者)，Columbia Univ, Dept Rehabil Med, Coll Phys & Surg, 630 W 168th St,Box 75, New York, NY 10032 USA.
EM fk11@columbia.edu; awckung@hkucc.hku.hk
RI ; Kung, Annie/C 4294 2009
OI Kennelly, Edward/0000 0002 1682 2696; 
FU HKU Foundation Bone Health Fund CRCG; Osteoporosis Research Fund of The
   University of Hong Kong; NIH National Center for Complementary and
   Alternative Medicine [R21 AT01957]
FX This study is supported by HKU Foundation Bone Health Fund CRCG grant
   and Osteoporosis Research Fund of The University of Hong Kong. We would
   like to thank NIH National Center for Complementary and Alternative
   Medicine grant (R21 AT01957) for the Support of F Kronenbergg, EJ
   Kennelly and B Jiang.
CR Anderson JJB, 1998, BAILLIERE CLIN ENDOC, V12, P543, DOI 10.1016/S0950 351X(98)80003 7
   Bai WP, 2007, MATURITAS, V58, P31, DOI 10.1016/j.maturitas.2007.04.009
   Braidman IP, 2001, J BONE MINER RES, V16, P214, DOI 10.1359/jbmr.2001.16.2.214
   Byers BA, 2002, J BONE MINER RES, V17, P1931, DOI 10.1359/jbmr.2002.17.11.1931
   Cappuzzo KA, 2004, ANN PHARMACOTHER, V38, P294, DOI 10.1345/aph.1D353
   Cheng MZ, 2002, J BONE MINER RES, V17, P593, DOI 10.1359/jbmr.2002.17.4.593
   Cheung WMW, 2006, FEBS LETT, V580, P121, DOI 10.1016/j.febslet.2005.11.062
   Deniz G, 2007, ACTA CHIR BELG, V107, P263, DOI 10.1080/00015458.2007.11680053
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fitzpatrick LA, 1999, MAYO CLIN PROC, V74, P601, DOI 10.4065/74.6.601
   Gold Deborah T, 2007, Curr Osteoporos Rep, V5, P3, DOI 10.1007/BF02938616
   Hirschberg AL, 2007, MENOPAUSE, V14, P89, DOI 10.1097/01.gme.0000230346.20992.34
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   HOSTANSKA K, 2007, BIOL PHARM BULL, V27, P1970
   Hostanska K, 2007, IN VIVO, V21, P349
   Jarry H, 2007, PLANTA MED, V73, P184, DOI 10.1055/s 2006 957081
   Kanno S, 2004, TOXICOLOGY, V196, P137, DOI 10.1016/j.tox.2003.12.002
   Kung AWC, 2003, J CLIN ENDOCR METAB, V88, P3130, DOI 10.1210/jc.2002 021855
   Lai BMH, 2008, OSTEOPOROSIS INT, V19, P571, DOI 10.1007/s00198 007 0482 1
   Lee MH, 2005, J BIOL CHEM, V280, P35579, DOI 10.1074/jbc.M502267200
   Liske E, 1998, ADV THER, V15, P45
   Lupu R, 2003, INT J ONCOL, V23, P1407
   Nappi RE, 2005, GYNECOL ENDOCRINOL, V20, P30, DOI 10.1080/09513590400020922
   Nisslein T, 2003, J BONE MINER METAB, V21, P370, DOI 10.1007/s00774 003 0431 9
   Osmers R, 2005, OBSTET GYNECOL, V105, P1074, DOI 10.1097/01.AOG.0000158865.98070.89
   OURSLER MJ, 1993, ANN MED, V25, P361, DOI 10.3109/07853899309147298
   Qiu SX, 2007, CHEM BIOL, V14, P860, DOI 10.1016/j.chembiol.2007.06.010
   Raus K, 2006, MENOPAUSE, V13, P678, DOI 10.1097/01.gme.0000196813.34247.e2
   Rice S, 2006, ENDOCR RELAT CANCER, V13, P995, DOI 10.1677/erc.1.01159
   Seidlová Wuttke D, 2006, MATURITAS, V55, pS64, DOI 10.1016/j.maturitas.2006.06.018
   Seidlová Wuttke D, 2003, EUR J ENDOCRINOL, V149, P351, DOI 10.1530/eje.0.1490351
   Seidlová Wuttke D, 2006, PLANTA MED, V72, P521, DOI 10.1055/s 2006 931538
   Seldlová Wuttke D, 2005, MATURITAS, V51, P177, DOI 10.1016/j.maturitas.2004.07.007
   Shi YC, 2007, BONE, V41, P87, DOI 10.1016/j.bone.2007.04.174
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Uebelhack R, 2006, OBSTET GYNECOL, V107, P247, DOI 10.1097/01.AOG.0000196504.49378.83
   Viereck V, 2005, J BONE MINER RES, V20, P2036, DOI 10.1359/JBMR.050716
   Viereck V, 2005, TRENDS ENDOCRIN MET, V16, P214, DOI 10.1016/j.tem.2005.05.002
   Walji R, 2007, SUPPORT CARE CANCER, V15, P913, DOI 10.1007/s00520 007 0286 z
   Wuttke W, 2003, MATURITAS, V44, pS67, DOI 10.1016/S0378 5122(02)00350 X
   Zepelin HHHV, 2007, INT J CLIN PHARM TH, V45, P143
   Zhao ZR, 2005, MOL THER, V12, P247, DOI 10.1016/j.ymthe.2005.03.009
NR 42
TC 17
Z9 19
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2008
VL 43
IS 3
BP 567
EP 573
DI 10.1016/j.bone.2008.04.018
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 344UW
UT WOS:000258953800021
PM 18555764
DA 2025 08 17
ER

PT J
AU Reid, IR
AF Reid, Ian R.
TI A broader strategy for osteoporosis interventions
SO NATURE REVIEWS ENDOCRINOLOGY
LA English
DT Article
ID BONE MINERAL DENSITY; ZOLEDRONIC ACID TREATMENT; FRACTURE RISK;
   POSTMENOPAUSAL WOMEN; OLDER WOMEN; VERTEBRAL FRACTURE; DOUBLE BLIND;
   DIAGNOSIS; COMMUNITY; HIP
AB Osteoporosis interventions are currently recommended in a small proportion of postmenopausal women, of whom similar to 50% will experience bone fracture. This Perspectives proposes that broader use of generic bisphosphonates would result in reductions in total fracture numbers and suggests that the current bone density definition of osteoporosis requires reappraisal.
   Approximately 50% of women experience at least one bone fracture postmenopause. Current screening approaches target anti fracture interventions to women aged >60 years who satisfy clinical risk and bone mineral density criteria for osteoporosis. Intervention is only recommended in 7 25% of those women screened currently, well short of the 50% who experience fractures. Large screening trials have not shown clinically significant decreases in the total fracture numbers. By contrast, six large clinical trials of anti resorptive therapies (for example, bisphosphonates) have demonstrated substantial decreases in the number of fractures in women not identified as being at high risk of fracture. This finding suggests that broader use of generic bisphosphonates in women selected by age or fracture risk would result in a reduction in total fracture numbers, a strategy likely to be cost effective. The utility of the current bone density definition of osteoporosis, which neither corresponds with who suffers fractures nor defines who should be treated, requires reappraisal.
C1 [Reid, Ian R.] Univ Auckland, Fac Med & Hlth Sci, Dept Med, Auckland, New Zealand.
   [Reid, Ian R.] Auckland Dist Hlth Board, Auckland, New Zealand.
C3 University of Auckland; Auckland District Health Board
RP Reid, IR (通讯作者)，Univ Auckland, Fac Med & Hlth Sci, Dept Med, Auckland, New Zealand.; Reid, IR (通讯作者)，Auckland Dist Hlth Board, Auckland, New Zealand.
EM i.reid@auckland.ac.nz
OI Reid, Ian/0000 0001 6021 5458
CR Abrahamsen B, 2016, BMJ BRIT MED J, V353, DOI 10.1136/bmj.i3365
   Adams AL, 2018, J BONE MINER RES, V33, P2
   [Anonymous], 2019, LANCET, V394, P611, DOI 10.1016/S0140 6736(19)31964 6
   Black DM, 2015, J BONE MINER RES, V30, P934, DOI 10.1002/jbmr.2442
   Black DM, 2012, J BONE MINER RES, V27, P243, DOI 10.1002/jbmr.1494
   Cauley JA, 2003, JAMA J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729
   Compston J, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0324 5
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Crandall CJ, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10239
   Crandall CJ, 2019, J BONE MINER RES, V34, P1419, DOI 10.1002/jbmr.3717
   Crandall CJ, 2015, J CLIN ENDOCR METAB, V100, P4315, DOI 10.1210/jc.2015 2568
   CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445
   Ensrud KE, 2008, J BONE MINER RES, V23, P112, DOI 10.1359/JBMR.070904
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Geiger EJ, 2018, J BONE MINER RES, V33, P103
   Gnant M, 2015, LANCET, V386, P433, DOI 10.1016/S0140 6736(15)60995 3
   Grey A, 2017, CAN MED ASSOC J, V189, pE1130, DOI 10.1503/cmaj.161207
   Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148
   JONES G, 1994, OSTEOPOROSIS INT, V4, P277, DOI 10.1007/BF01623352
   Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198 007 0543 5
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Kanis JA, 2000, OSTEOPOROSIS INT, V11, P669, DOI 10.1007/s001980070064
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Lin TC, 2014, OSTEOPOROSIS INT, V25, P1503, DOI 10.1007/s00198 014 2624 6
   Mai H, 2019, J CLIN ENDOCR METAB, V104, P3514, DOI 10.1210/jc.2018 02614
   McCloskey EV, 2007, J BONE MINER RES, V22, P135, DOI 10.1359/JBMR.061008
   Merlijn T, 2019, J BONE MINER RES, V34, P1993, DOI 10.1002/jbmr.3815
   Merlijn T, 2018, J BONE MINER RES, V33, P436
   Nguyen ND, 2007, OSTEOPOROSIS INT, V18, P1109, DOI 10.1007/s00198 007 0362 8
   Papaioannou A, 2010, CAN MED ASSOC J, V182, P1864, DOI 10.1503/cmaj.100771
   Reid IR, 2019, J INTERN MED, V286, P221, DOI 10.1111/joim.12901
   Reid IR, 2013, J CLIN ENDOCR METAB, V98, P557, DOI 10.1210/jc.2012 2868
   Reid IR, 2018, NEW ENGL J MED, V379, P2407, DOI 10.1056/NEJMoa1808082
   Rubin KH, 2018, OSTEOPOROSIS INT, V29, P567, DOI 10.1007/s00198 017 4326 3
   Schilcher J, 2014, NEW ENGL J MED, V371, P974, DOI 10.1056/NEJMc1403799
   Shepstone L, 2018, LANCET, V391, P741, DOI 10.1016/S0140 6736(17)32640 5
   Siris ES, 2008, OSTEOPOROSIS INT, V19, P681, DOI 10.1007/s00198 007 0493 y
   Siris ES, 2004, ARCH INTERN MED, V164, P1108, DOI 10.1001/archinte.164.10.1108
   Tatangelo G, 2019, J BONE MINER RES, V34, P616, DOI 10.1002/jbmr.3640
   Tei RMH, 2019, CALCIFIED TISSUE INT, V104, P102, DOI 10.1007/s00223 018 0476 3
   The National Institute for Health and Care excellence, 2019, BISPH TREAT OST
   Trajanoska K, 2018, BONE, V114, P116, DOI 10.1016/j.bone.2018.06.004
   Turner DA, 2018, J BONE MINER RES, V33, P845, DOI 10.1002/jbmr.3381
   Wilson C, 2018, EUR J CANCER, V94, P70, DOI 10.1016/j.ejca.2018.02.004
NR 45
TC 192
Z9 213
U1 7
U2 60
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1759 5029
EI 1759 5037
J9 NAT REV ENDOCRINOL
JI Nat. Rev. Endocrinol.
PD JUN
PY 2020
VL 16
IS 6
BP 333
EP 339
DI 10.1038/s41574 020 0339 7
EA MAR 2020
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA LN5KH
UT WOS:000520394600002
PM 32203407
DA 2025 08 17
ER

PT J
AU Raimundo, M
   Crichton, S
   Lei, K
   Sanderson, B
   Smith, J
   Brooks, J
   Ng, J
   Smith, JL
   McKenzie, C
   Beale, R
   Dickie, H
   Ostermann, M
AF Raimundo, Mario
   Crichton, Siobhan
   Lei, Katie
   Sanderson, Barnaby
   Smith, John
   Brooks, John
   Ng, Josephine
   Smith, Joanna Lemmich
   McKenzie, Catherine
   Beale, Richard
   Dickie, Helen
   Ostermann, Marlies
TI Maintaining Normal Levels of Ionized Calcium during Citrate Based Renal
   Replacement Therapy Is Associated with Stable Parathyroid Hormone Levels
SO NEPHRON CLINICAL PRACTICE
LA English
DT Article
DE Citrate; Parathyroid hormone; Continuous renal replacement therapy;
   Acute kidney injury
ID CONTINUOUS VENOVENOUS HEMODIAFILTRATION; CRITICALLY ILL; HEPARIN
   ANTICOAGULATION; REGIONAL CITRATE; BONE RESORPTION; HEMOFILTRATION;
   SECRETION; SEVERITY; SURVIVAL
AB Background/Aims: Citrate is an effective anticoagulant during continuous renal replacement therapy (CRRT). Previous studies showed raised parathyroid hormone (PTH) levels when aiming for serum ionized calcium [Ca i] between 0.8 and 1.1 mmol/l. Our objective was to assess whether citrate based CRRT with physiologic target systemic [Ca i] between 1.12 and 1.20 mmol/l could maintain stable PTH levels. Methods: Measurement of intact PTH (PTHi) in 30 consecutive critically ill patients treated with citrate based CRRT. Results: Thirty patients [mean age: 70.4 (SD 11.3) years; 56.7% males] were enrolled. Mean serum [Ca i] was 1.16 mmol/l (SD 0.09), 1.13 mmol/l (SD 0.09), 1.17 mmol/l (SD 0.05) and 1.16 mmol/l (SD 0.04) at baseline, 12, 24 and 48 h, respectively (p = 0.29). Median PTHi levels (interquartile range) at baseline, 12, 24 and 48 h were 66.5 (43 111), 109 (59.5 151.5), 88.5 (47 133) and 85 pg/ml (53 140), respectively. The differences between baseline and 12 h and across all time points were statistically not significant (p = 0.16 and p = 0.49, respectively). In a mixed effects model, each 0.1 mmol/l increase in serum [Ca i] was associated with a 31.2% decrease in PTHi (p < 0.001). Results were unchanged after adjustment for age, gender, magnesium, phosphate, arterial pH and time spent on CRRT. Conclusions: Maintaining systemic [Ca i] within the physiologic range was associated with stable PTHi levels. (C) 2013 S. Karger AG, Basel
C1 [Raimundo, Mario; Lei, Katie; Sanderson, Barnaby; Smith, John; Brooks, John; Ng, Josephine; Smith, Joanna Lemmich; McKenzie, Catherine; Beale, Richard; Dickie, Helen; Ostermann, Marlies] Kings Hlth Partners, Guys & St Thomas Fdn Hosp, Dept Crit Care, London, England.
   [Crichton, Siobhan] Kings Coll London, Div Hlth & Social Care Res, London WC2R 2LS, England.
   [Raimundo, Mario] Hosp Santa Maria, Ctr Hosp Lisboa Norte, Lisbon, Portugal.
C3 University of London; King's College London; Guy's & St Thomas' NHS
   Foundation Trust; University of London; King's College London;
   Universidade de Lisboa; Hospital Santa Maria
RP Ostermann, M (通讯作者)，Guys & St Thomas Fdn Hosp, Kings Coll London, Dept Crit Care Med, London SE1 7EH, England.
EM Marlies.Ostermann@gstt.nhs.uk
RI Edgeworth, Cathrine/AAB 7428 2020; Ostermann, Marlies/B 8777 2015;
   Ostermann, Marlies/AAH 8160 2021; McKenzie, Cathrine/AAB 7428 2020
OI Ostermann, Marlies/0000 0001 9500 9080; Crichton,
   Siobhan/0000 0001 9962 083X; Raimundo, Mario/0000 0001 8068 717X;
   McKenzie, Cathrine/0000 0002 5190 9711
CR Apsner R, 2004, ANESTH ANALG, V99, P1199, DOI 10.1213/01.ANE.0000132780.87036.F5
   Aris RM, 1998, CHEST, V114, P954, DOI 10.1378/chest.114.4.954
   Betjes MGH, 2007, J NEPHROL, V20, P602
   Brain M, 2011, CRIT CARE RESUSC, V13, P72
   BROWN EM, 1977, ENDOCRINOLOGY, V100, P1703, DOI 10.1210/endo 100 6 1703
   BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371
   Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239
   Carlstedt F, 1998, EUR J CLIN INVEST, V28, P898
   Chen Y, 2011, BONE, V49, P506, DOI 10.1016/j.bone.2011.05.014
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Gabutti L, 2002, INTENS CARE MED, V28, P1419, DOI 10.1007/s00134 002 1443 y
   Haden ST, 2000, CLIN ENDOCRINOL, V52, P329, DOI 10.1046/j.1365 2265.2000.00912.x
   Hetzel GR, 2011, NEPHROL DIAL TRANSPL, V26, P232, DOI 10.1093/ndt/gfq575
   Hocher B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040242
   JOBORN H, 1990, CLIN PHYSIOL, V10, P37, DOI 10.1111/j.1475 097X.1990.tb00082.x
   Kutsogiannis DJ, 2005, KIDNEY INT, V67, P2361, DOI 10.1111/j.1523 1755.2005.00342.x
   Lind L, 2000, CRIT CARE MED, V28, P93, DOI 10.1097/00003246 200001000 00015
   Monchi M, 2004, INTENS CARE MED, V30, P260, DOI 10.1007/s00134 003 2047 x
   Morgera S, 2009, CRIT CARE MED, V37, P2018, DOI 10.1097/CCM.0b013e3181a00a92
   Nierman DM, 1998, CHEST, V114, P1122, DOI 10.1378/chest.114.4.1122
   Oudemans van Straaten HM, 2011, CRIT CARE, V15, DOI 10.1186/cc9358
   Oudemans van Straaten HM, 2009, CRIT CARE MED, V37, P545, DOI 10.1097/CCM.0b013e3181953c5e
   Oudemans van Straaten HM, 2006, INTENS CARE MED, V32, P188, DOI 10.1007/s00134 005 0044 y
   Oudemans Van Straaten HM, 2008, CONTROVERSIES INTENS, P153
   QUARLES LD, 1992, J CLIN ENDOCR METAB, V75, P145, DOI 10.1210/jc.75.1.145
   Smith LM, 2002, CRIT CARE MED, V30, P837, DOI 10.1097/00003246 200204000 00020
   van der Voort PHJ, 2007, BLOOD PURIFICAT, V25, P267, DOI 10.1159/000101853
   Wang PL, 2004, AM J KIDNEY DIS, V44, P1110, DOI 10.1053/j.ajkd.2004.09.001
   Zhang Z, 2006, INTENS CARE MED, V38, P20
NR 29
TC 14
Z9 14
U1 0
U2 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1660 2110
J9 NEPHRON CLIN PRACT
JI Nephron. Clin. Pract.
PY 2013
VL 124
IS 1 2
BP 124
EP 131
DI 10.1159/000355860
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 275UZ
UT WOS:000328704800019
PM 24192818
DA 2025 08 17
ER

PT J
AU Zhao, Y
   Zhai, QL
   Liu, H
   Xi, X
   Chen, S
   Liu, DX
AF Zhao, Yi
   Zhai, Qiaoli
   Liu, Hong
   Xi, Xun
   Chen, Shuai
   Liu, Dongxu
TI TRIM16 Promotes Osteogenic Differentiation of Human Periodontal Ligament
   Stem Cells by Modulating CHIP Mediated Degradation of RUNX2
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE TRIM16; CHIP; ubiquitination; osteogenic differentiation; hPDLSCs
ID E3 UBIQUITIN LIGASE; OSTEOBLAST DIFFERENTIATION; MOLECULAR MECHANISM;
   BONE FORMATION; PROTEIN; SMURF1; IDENTIFICATION; REGENERATION;
   HOMEOSTASIS; EXPRESSION
AB Bone regeneration is the ultimate goal of periodontal therapies, in which osteogenic differentiation of human periodontal ligament stem cells plays a critical role. The tripartite motif (TRIM)16, an E3 ubiquitin ligase, is downregulated in periodontal tissues of patients with periodontitis, while the role of TRIM16 in the osteogenic differentiation of human periodontal ligament stem cells (hPDLSCs) is largely unknown. Firstly, we found that TRIM16 was increased throughout the osteogenic media induced differentiation of hPDLSCs. Then overexpression plasmids and specific short hairpin RNAs (shRNAs) were constructed to manipulate the expression of target molecules. TRIM16 significantly promoted alkaline phosphatase activity, mineralized nodule formation, and positively regulated the expression of osteo specific markers RUNX2, COL1A1 and OCN except the mRNA of RUNX2. Mechanistically, TRIM16 serves as a pivotal factor that stabilizes RUNX2 protein levels by decreasing CHIP mediated K48 linked ubiquitination degradation of the RUNX2 protein. This study identified a novel mechanism of TRIM16 in regulating stability of the RUNX2 protein, which promoted the osteogenic differentiation of hPDLSCs. TRIM16 may be a potential target of stem cell based bone regeneration for periodontal therapies.
C1 [Zhao, Yi; Liu, Hong; Xi, Xun; Chen, Shuai; Liu, Dongxu] Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Dept Orthodont, Jinan, Peoples R China.
   [Zhao, Yi; Liu, Hong; Xi, Xun; Chen, Shuai; Liu, Dongxu] Shandong Key Lab Oral Tissue Regenerat, Jinan, Peoples R China.
   [Zhao, Yi; Liu, Hong; Xi, Xun; Chen, Shuai; Liu, Dongxu] Shandong Engn Lab Dent Mat & Oral Tissue Regenera, Jinan, Peoples R China.
   [Zhai, Qiaoli] Zibo Cent Hosp, Ctr Translat Med, Zibo, Shandong, Peoples R China.
C3 Shandong University
RP Liu, DX (通讯作者)，Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Dept Orthodont, Jinan, Peoples R China.; Liu, DX (通讯作者)，Shandong Key Lab Oral Tissue Regenerat, Jinan, Peoples R China.; Liu, DX (通讯作者)，Shandong Engn Lab Dent Mat & Oral Tissue Regenera, Jinan, Peoples R China.
EM liudongxu@sdu.edu.cn
RI Liu, D.X./I 2483 2019
FU National Natural Science Foundation of China [81571010]; Key Research
   and Development project of Shandong Province [2018GSF118199]; Graduate
   education outstanding achievement training program of Shandong
   University [ZY20190004]
FX This work was supported by the National Natural Science Foundation of
   China (grant no. 81571010), Key Research and Development project of
   Shandong Province (grant no. 2018GSF118199), and Graduate education
   outstanding achievement training program of Shandong University (grant
   no. ZY20190004).
CR Aral K, 2020, J PERIODONTOL, V91, P606, DOI 10.1002/JPER.19 0222
   Ballinger CA, 1999, MOL CELL BIOL, V19, P4535
   Bell JL, 2013, CELL CYCLE, V12, P889, DOI 10.4161/cc.23825
   Bell JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037470
   Chen WT, 2020, BONE, V131, DOI 10.1016/j.bone.2019.115059
   Choi WH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10963
   Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618
   Erpapazoglou Zoi, 2014, Cells, V3, P1027, DOI 10.3390/cells3041027
   Gomathi K, 2020, LIFE SCI, V245, DOI 10.1016/j.lfs.2020.117389
   Hatakeyama S, 2017, TRENDS BIOCHEM SCI, V42, P297, DOI 10.1016/j.tibs.2017.01.002
   Jena KK, 2019, AUTOPHAGY, V15, P924, DOI 10.1080/15548627.2019.1586251
   Jena KK, 2018, EMBO J, V37, DOI 10.15252/embj.201798358
   Jeon SA, 2018, BONE, V116, P248, DOI 10.1016/j.bone.2018.08.012
   Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200
   Kim HJ, 2020, MOL CELLS, V43, P160, DOI 10.14348/molcells.2019.0247
   Kim JM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 16038 6
   Kimura T, 2017, AUTOPHAGY, V13, P1084, DOI 10.1080/15548627.2017.1307486
   Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2020, MOL CELLS, V43, P168, DOI 10.14348/molcells.2019.0244
   Kumar S, 2017, AUTOPHAGY, V13, P1086, DOI 10.1080/15548627.2017.1307487
   Kumar Y, 2015, J BIOL CHEM, V290, P30975, DOI 10.1074/jbc.M115.669531
   Lee JS, 2014, CELL PHYSIOL BIOCHEM, V34, P1824, DOI 10.1159/000366381
   Li CH, 2018, SCI REP UK, V8, DOI 10.1038/s41598 017 18541 1
   Li JT, 2019, CELL DEATH DIFFER, V26, P2652, DOI 10.1038/s41418 019 0328 3
   Li XN, 2008, J CELL BIOL, V181, P959, DOI 10.1083/jcb.200711044
   Liang C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05974 z
   Loones MT, 1998, CELL STRESS CHAPERON, V3, P237, DOI 10.1054/csac.1998.0111
   Lui JCK, 2007, FEBS LETT, V581, P109, DOI 10.1016/j.febslet.2006.11.082
   Maruyama Z, 2007, DEV DYNAM, V236, P1876, DOI 10.1002/dvdy.21187
   Matsumoto Y, 2017, J CLIN INVEST, V127, P2612, DOI 10.1172/JCI92233
   Mokuda S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10177 1
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Ren XY, 2020, EXP CELL RES, V391, DOI 10.1016/j.yexcr.2020.111988
   Sayed S, 2019, MAT SCI ENG C MATER, V105, DOI 10.1016/j.msec.2019.110027
   Sculean A, 2015, PERIODONTOL 2000, V68, P182, DOI 10.1111/prd.12086
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shimazu J, 2016, CELL REP, V15, P27, DOI 10.1016/j.celrep.2016.03.003
   Shu L, 2013, J BONE MINER RES, V28, P1925, DOI 10.1002/jbmr.1938
   Song JY, 2021, NAT REV MOL CELL BIO, V22, P54, DOI 10.1038/s41580 020 00300 2
   Stock M, 2003, J BIOL CHEM, V278, P17360, DOI 10.1074/jbc.M207631200
   Sutton SK, 2019, J CANCER RES CLIN, V145, P2241, DOI 10.1007/s00432 019 02981 5
   Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39
   van Huizen M, 2020, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00392
   Wei FL, 2013, STEM CELLS DEV, V22, P1752, DOI 10.1089/scd.2012.0688
   Xin H, 2005, J BIOL CHEM, V280, P20842, DOI 10.1074/jbc.M412275200
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Yang F, 2014, J ENDODONT, V40, P1579, DOI 10.1016/j.joen.2014.04.010
   Zhao BJ, 2012, J PHYSIOL BIOCHEM, V68, P485, DOI 10.1007/s13105 012 0161 3
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
   Zhao Y, 2020, EXP CELL RES, V397, DOI 10.1016/j.yexcr.2020.112336
   Zhu W, 2017, J BIOL CHEM, V292, P11178, DOI 10.1074/jbc.M116.772277
   Zusev M, 2008, J CELL PHYSIOL, V217, P618, DOI 10.1002/jcp.21525
NR 53
TC 15
Z9 16
U1 2
U2 25
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD JAN 7
PY 2021
VL 8
AR 625105
DI 10.3389/fcell.2020.625105
PG 14
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA PU2NB
UT WOS:000609141600001
PM 33490087
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wimbauer, F
   Yang, CH
   Shogren, KL
   Zhang, MZ
   Goyal, R
   Riester, SM
   Yaszemski, MJ
   Maran, A
AF Wimbauer, Fritz
   Yang, Caihong
   Shogren, Kristen L.
   Zhang, Minzhi
   Goyal, Ribu
   Riester, Scott M.
   Yaszemski, Michael J.
   Maran, Avudaiappan
TI Regulation of interferon pathway in 2 methoxyestradiol treated
   osteosarcoma cells
SO BMC CANCER
LA English
DT Article
DE 2 Methoxyestradiol; osteosarcoma; Interferon; ISRE; GAS
ID TRANSLATIONAL CONTROL; GENE EXPRESSION; ANTITUMOR ACTIVITY;
   TUMOR GROWTH; IFN GAMMA; APOPTOSIS; ACTIVATION; ALPHA; ANGIOGENESIS;
   SENSITIVITY
AB Background: Osteosarcoma is a bone tumor that often affects children and young adults. Although a combination of surgery and chemotherapy has improved the survival rate in the past decades, local recurrence and metastases still develop in 40% of patients. A definite therapy is yet to be determined for osteosarcoma. Anti  tumor compound and a metabolite of estrogen, 2 methoxyestradiol (2 ME) induces cell death in osteosarcoma cells. In this report, we have investigated whether interferon (IFN) pathway is involved in 2 ME induced anti tumor effects in osteosarcoma cells.
   Methods: 2 ME effects on IFN mRNA levels were determined by Real time PCR analysis. Transient transfections followed by reporter assays were used for investigating 2 ME effects on IFN pathway. Western blot analyses were used to measure protein and phosphorylation levels of IFN regulated eukaryotic initiation factor 2 alpha (eIF 2 alpha).
   Results: 2 ME regulates IFN and IFN mediated effects in osteosarcoma cells. 2 ME induces IFN gene activity and expression in osteosarcoma cells. 2 ME treatment induced IFN stimulated response element (ISRE) sequence dependent transcription and gamma activated sequence (GAS) dependent transcription in several osteosarcoma cells. Whereas, 2 ME did not affect IFN gene and IFN pathways in normal primary human osteoblasts (HOB). 2 ME treatment increased the phosphorylation of eIF 2 alpha in osteosarcoma cells. Furthermore, analysis of osteosarcoma tissues shows that the levels of phosphorylated form of eIF 2 alpha are decreased in tumor compared to normal controls.
   Conclusions: 2 ME treatment triggers the induction and activity of IFN and IFN pathway genes in 2 ME sensitive osteosarcoma tumor cells but not in 2 ME resistant normal osteoblasts. In addition, IFN signaling is inhibited in osteosarcoma patients. Thus, IFN pathways play a role in osteosarcoma and in 2 ME mediated anti proliferative effects, and therefore targeted induction of IFN signaling could lead to effective treatment strategies in the control of osteosarcoma.
C1 [Wimbauer, Fritz; Yang, Caihong; Shogren, Kristen L.; Zhang, Minzhi; Goyal, Ribu; Riester, Scott M.; Yaszemski, Michael J.; Maran, Avudaiappan] Mayo Clin, Coll Med, Dept Orthoped, Rochester, MN 55906 USA.
   [Wimbauer, Fritz; Yaszemski, Michael J.; Maran, Avudaiappan] Paracelsus Med Univ, A 5020 Salzburg, Austria.
   [Yang, Caihong] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China.
C3 Mayo Clinic; Paracelsus Private Medical University; Huazhong University
   of Science & Technology
RP Maran, A (通讯作者)，Mayo Clin, Coll Med, Dept Orthoped, Rochester, MN 55906 USA.
EM maran.avudai@mayo.edu
RI Riester, Scott/K 7032 2015; Yang, Caihong/KYR 4363 2024
FU Mayo Clinic Cancer Center; Mayo Clinic
FX This work was supported by Mayo Clinic Cancer Center Bridging to Success
   Award (Fraternal order of Eagles) and the Mayo Clinic.
CR Balachandran Siddharth, 2007, V383, P277, DOI 10.1007/978 1 59745 335 6_18
   Benedikt MB, 2010, J CELL BIOCHEM, V109, P950, DOI 10.1002/jcb.22473
   Carrle D, 2006, INT ORTHOP, V30, P445, DOI 10.1007/s00264 006 0192 x
   Chawla Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040
   Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544
   Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121
   FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0
   Gale M Jr, 2000, MICROBIOL MOL BIOL R, V64, P239, DOI 10.1128/MMBR.64.2.239 280.2000
   GLASGOW LA, 1981, JNCI J NATL CANCER I, V67, P207
   Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618
   JIA SF, 1991, LYMPHOKINE CYTOK RES, V10, P281
   Jia SF, 1999, J INTERF CYTOK RES, V19, P617, DOI 10.1089/107999099313758
   Kubo T, 2011, J BONE JOINT SURG AM, V93A, P519, DOI 10.2106/JBJS.J.00198
   Maran A, 2002, BONE, V30, P393, DOI 10.1016/S8756 3282(01)00681 0
   Maran A, 2008, J CELL BIOCHEM, V104, P1937, DOI 10.1002/jcb.21758
   O'Reilly R, 1996, Oncology (Williston Park), V10, P1813
   Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478
   Ricker JL, 2004, CLIN CANCER RES, V10, P8665, DOI 10.1158/1078 0432.CCR 04 1393
   ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826
   Schumacher G, 1999, CLIN CANCER RES, V5, P493
   Shogren KL, 2007, J BONE MINER RES, V22, P29, DOI 10.1359/JBMR.060914
   SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092 8674(94)90357 3
   Sikorski K, 2011, AM J PHYSIOL CELL PH, V300, pC1337, DOI 10.1152/ajpcell.00276.2010
   Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227
   Strander H, 2007, CYTOKINE GROWTH F R, V18, P373, DOI 10.1016/j.cytogfr.2007.06.014
   Tsukahara T, 2006, COMPUT BIOL CHEM, V30, P134, DOI 10.1016/j.compbiolchem.2006.01.002
   WARD WG, 1994, J CLIN ONCOL, V12, P1849, DOI 10.1200/JCO.1994.12.9.1849
   Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007
   Wesoly J, 2007, ACTA BIOCHIM POL, V54, P27, DOI 10.18388/abp.2007_3266
   Whelan J, 2010, PEDIATR BLOOD CANCER, V54, P350, DOI 10.1002/pbc.22136
   Yuan XW, 2007, ACTA PHARMACOL SIN, V28, P1835, DOI 10.1111/j.1745 7254.2007.00662.x
NR 31
TC 18
Z9 21
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD MAR 19
PY 2012
VL 12
AR 93
DI 10.1186/1471 2407 12 93
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 987YK
UT WOS:000307454400001
PM 22429849
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yang, HL
   Xu, YZ
   Zhu, M
   Gu, Y
   Zhang, W
   Shao, HG
   Wang, YJ
   Ping, ZC
   Hu, XY
   Wang, LL
   Geng, DC
AF Yang, Huilin
   Xu, Yaozeng
   Zhu, Mo
   Gu, Ye
   Zhang, Wen
   Shao, Hongguo
   Wang, Yijun
   Ping, Zichuan
   Hu, Xuanyang
   Wang, Liangliang
   Geng, Dechun
TI Inhibition of titanium particle induced inflammatory osteolysis after
   local administration of dopamine and suppression of osteoclastogenesis
   via D2 like receptor signaling pathway
SO BIOMATERIALS
LA English
DT Article
DE Aseptic loosening; Wear debris; Osteoclast; Inflammation; Dopamine
ID SYMPATHETIC NERVOUS SYSTEM; FACTOR KAPPA B; BONE RESORPTION; TNF ALPHA;
   PARKINSONS DISEASE; CALVARIAL MODEL; POLYETHYLENE; MICE; GENE;
   DIFFERENTIATION
AB Chronic inflammation and extensive osteoclast formation play critical roles in wear debris induced perimplant osteolysis. We investigated the potential impact of dopamine on titanium particle induced inflammatory osteolysis in vivo and in vitro. Twenty eight C57BL/6J mice were randomly assigned to four groups: sham control (PBS treatment), titanium (titanium/PBS treatment), low  (titanium/2 mu g kg( 1) day( 1) dopamine) and high dopamine (titanium/10 mu g kg( 1) day( 1) dopamine). After 2 weeks, mouse calvariae were collected for micro computed tomography (micro CT) and histomorphometry analysis. Bone marrow derived macrophages (BMMs) were isolated to assess osteoclast differentiation. Dopamine significantly reduced titanium particle induced osteolysis compared with the titanium group as confirmed by micro CT and histomorphometric data. Osteoclast numbers were 34.9% and 59.7% (both p < 0.01) lower in the low  and high dopamine treatment groups, respectively, than in the titanium group. Additionally, low RANKL, tumor necrosis factor alpha, interleukin 1 beta and interleukin 6 immunochemistry staining were noted in dopamine treatment groups. Dopamine markedly inhibited osteoclast formation, osteoclastogenesis related gene expression and pro inflammatory cytokine expression in BMMs in a dose dependent manner. Moreover, the resorption area was decreased with 10( 9) M and 10( 8) M dopamine to 40.0% and 14.5% (both p < 0.01), respectively. Furthermore, the inhibitory effect of dopamine was reversed by the D2 like receptor antagonist haloperidol but not by the D1 like receptor antagonist SCH23390. These results suggest that dopamine therapy could be developed into an effective and safe method for osteolysis related disease caused by chronic inflammation and excessive osteoclast formation. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Yang, Huilin; Xu, Yaozeng; Gu, Ye; Shao, Hongguo; Wang, Yijun; Ping, Zichuan; Hu, Xuanyang; Wang, Liangliang; Geng, Dechun] Soochow Univ, Dept Orthoped, Affiliated Hosp 1, 188 Shizi Rd, Suzhou 215006, Peoples R China.
   [Zhu, Mo] Soochow Univ, Dept Radiol, Affiliated Hosp 1, Suzhou, Peoples R China.
   [Gu, Ye] Soochow Univ, Dept Orthoped, Peoples Hosp Changshou City 1, Suzhou, Peoples R China.
   [Zhang, Wen] Soochow Univ, Inst Orthoped, Suzhou, Peoples R China.
C3 Soochow University   China; Soochow University   China; Soochow
   University   China; Soochow University   China
RP Geng, DC (通讯作者)，Soochow Univ, Dept Orthoped, Affiliated Hosp 1, 188 Shizi Rd, Suzhou 215006, Peoples R China.
EM szgengdc@163.com
RI ; Zhang, Wen/CAA 2126 2022; Geng, Dechun/LMO 1733 2024
OI /0000 0003 1013 8495; GENG, Dechun/0000 0003 4375 2803
FU Jiangsu Province's Key Medical center; Jiangsu Provincial Special
   Program of Medical Science [BL2012004]; Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD); National
   Nature Science Foundation of China [81472077, 81372018, 81272018,
   81101399]; Jiangsu Six Peak of Talents Program [2013 WSW 042]
FX This work was supported by the Jiangsu Province's Key Medical center,
   Jiangsu Provincial Special Program of Medical Science (Grant no.
   BL2012004), a Project Funded by the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD), the
   National Nature Science Foundation of China (Grant nos. 81472077,
   81372018, 81272018 and 81101399), Jiangsu Six Peak of Talents Program
   (Grant no. 2013 WSW 042).
CR BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0
   Bessler H, 1999, BIOMED PHARMACOTHER, V53, P141, DOI 10.1016/S0753 3322(99)80079 1
   Bliziotes M, 2000, BONE, V26, P15, DOI 10.1016/S8756 3282(99)00232 X
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Costa ER, 2006, J ORTHOP TRAUMA, V20, P470, DOI 10.1097/00005131 200608000 00004
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dong L, 2008, J ORTHOP RES, V26, P1114, DOI 10.1002/jor.20607
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Elefteriou F, 2008, ARCH BIOCHEM BIOPHYS, V473, P231, DOI 10.1016/j.abb.2008.03.016
   Gallo J, 2013, ACTA BIOMATER, V9, P8046, DOI 10.1016/j.actbio.2013.05.005
   Geng DC, 2011, ACTA BIOMATER, V7, P3216, DOI 10.1016/j.actbio.2011.05.007
   Geng DC, 2010, BIOMATERIALS, V31, P1996, DOI 10.1016/j.biomaterials.2009.11.069
   Hanami K, 2013, BONE, V56, P1, DOI 10.1016/j.bone.2013.04.019
   Harris WH, 2001, CLIN ORTHOP RELAT R, P66
   Höglinger GU, 2004, NAT NEUROSCI, V7, P726, DOI 10.1038/nn1265
   Holding CA, 2006, BIOMATERIALS, V27, P5212, DOI 10.1016/j.biomaterials.2006.05.054
   Kauther MD, 2013, BIOMATERIALS, V34, P2911, DOI 10.1016/j.biomaterials.2013.01.034
   Kim JA, 2015, INT ORTHOP, V39, P173, DOI 10.1007/s00264 014 2596 3
   Liu X, 2014, ACTA BIOMATER, V10, P4912, DOI 10.1016/j.actbio.2014.07.025
   Meftah M, 2013, J BONE JOINT SURG AM, V95A, P1193, DOI 10.2106/JBJS.L.00432
   Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189
   Nakashioya H, 2011, MOD RHEUMATOL, V21, P260, DOI 10.1007/s10165 010 0387 2
   Nich C, 2013, BIOMATERIALS, V34, P641, DOI 10.1016/j.biomaterials.2012.10.030
   Ragab AA, 1999, J ORTHOPAED RES, V17, P803, DOI 10.1002/jor.1100170603
   Ren WP, 2003, BIOMATERIALS, V24, P4819, DOI 10.1016/S0142 9612(03)00384 3
   Sawyer A, 2003, BIOTECH HISTOCHEM, V78, P271, DOI 10.1080/10520290310001646668
   Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756 3282(99)00215 X
   Shao HG, 2015, BIOMATERIALS, V60, P92, DOI 10.1016/j.biomaterials.2015.04.048
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Tian B, 2014, BIOMATERIALS, V35, P8937, DOI 10.1016/j.biomaterials.2014.06.055
   von Knoch M, 2004, BIOMATERIALS, V25, P4675, DOI 10.1016/j.biomaterials.2004.02.069
   Wang LP, 2010, BONE, V46, P1369, DOI 10.1016/j.bone.2009.11.029
   Wedemeyer C, 2007, CALCIFIED TISSUE INT, V81, P394, DOI 10.1007/s00223 007 9077 2
   Wedemeyer C, 2007, J BONE MINER RES, V22, P1011, DOI 10.1359/JBMR.070408
   Yan YQ, 2015, CELL, V160, P62, DOI 10.1016/j.cell.2014.11.047
   Zawawi MSF, 2015, CALCIFIED TISSUE INT, V96, P565, DOI 10.1007/s00223 015 9982 8
   Zhai ZJ, 2014, BIOMATERIALS, V35, P6299, DOI 10.1016/j.biomaterials.2014.04.044
   Zhao Y, 2013, BONE, V52, P498, DOI 10.1016/j.bone.2012.09.013
NR 38
TC 77
Z9 79
U1 0
U2 81
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD FEB
PY 2016
VL 80
BP 1
EP 10
DI 10.1016/j.biomaterials.2015.11.046
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA DD7HS
UT WOS:000370094900001
PM 26695376
DA 2025 08 17
ER

PT J
AU Lee, KK
   Raja, N
   Yun, HS
   Lee, SC
   Lee, CS
AF Lee, Kyung Kwan
   Raja, Naren
   Yun, Hui suk
   Lee, Sang Cheon
   Lee, Chang Soo
TI Multifunctional bone substitute using carbon dot and 3D printed
   calcium deficient hydroxyapatite scaffolds for osteoclast inhibition and
   fluorescence imaging
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Tissue engineering; Carbon dots; Bone substitute; Anti osteoclastogenic
   effect; Fluorescence imaging
ID QUANTUM DOTS; COMPOSITE SCAFFOLDS; ALENDRONATE; ACID; ZEBRAFISH;
   DELIVERY; NANOPARTICLES; SODIUM
AB Multifunctional bone substitute materials (BSM) have gained considerable attention with the exponen tial increase in aging populations. The development of hybrid materials for diagnosis and therapy of bone related diseases and dysfunctions, especially, has been a significant challenge in the biological and the biomedical field, due to the shortage of agents with specificity and selectivity toward bone. In this study, a hybrid material, referred as Alen CDs@CDHA, fabricated from alendronate conjugated carbon dots (Alen CDs) and calcium deficient hydroxyapatite (CDHA, the mineral component of bones) scaffolds is of fered as a novel multifunctional BSM for in vivo osteoclasts deactivation and fluorescence imaging. The fluorescent Alen CDs were hydrothermally prepared using phytic acid as carbon source, followed by con jugating alendronate, for controlled alendronate release and fluorescent imaging under acidic conditions. As prepared fluorescent Alen CDs were consecutively immobilized on surfaces of CDHA scaffolds, exhibit ing high affinity by bisphosphonate group, easily fabricated from alpha tricalcium phosphate (alpha TCP) paste using three dimensional (3D) printing system. The resultant Alen CDs@CDHA caused a significant de crease (> 50%) in viability of osteoclasts at 7 days after in vitro treatment. Furthermore, when Alen CDs@CDHA was implanted in balb/c nude mice for in vivo evaluation, we found Alen CDs@CDHA to be suitable for bone imaging through fluorescence signals, without necrosis or inflammatory symptoms in the epidermal tissues. Thus, these observations offer new opportunities for a novel and revolutionary use of Alen CDs@CDHA as highly specific multifunctional BSM for bone diagnosis and imaging, and as bone specific drug delivery materials, eventually providing anti osteoclastogenic treatments solution for degenerative bone disorders.Statement of significanceAlen CDs@CDHA significantly reduced the viability of osteoclasts and fluorescently imaged in vivo after transplantation, releasing drug via pH modulation. The development of fluorescence materials for bone imaging remains still a major challenge in the biomedical field owing to the shortage of selectivity and specificity. The results could lead to improvements in bone treatment strategies, as it could reduce the invasiveness of procedures and the associated negative outcomes, and increase the precision of strategies. Further, we believe that this study will be of interest to the readership of your journal as clearly focuses on the advancement of a biomaterial, where we have engineered a substance to substitute bone and integrate with a living system.(c) 2023 The Author(s). Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
C1 [Lee, Kyung Kwan; Lee, Chang Soo] Korea Res Inst Biosci & Biotechnol KRIBB, Bionanotechnol Res Ctr, Daejeon 34141, South Korea.
   [Lee, Kyung Kwan] Kyung Hee Univ, Grad Sch, Dept Biomed & Nanopharmaceut Sci, Seoul 02447, South Korea.
   [Raja, Naren; Yun, Hui suk] Korea Inst Mat Sci KIMS, Dept Adv Biomat Res, Ceram Mat Div, Chang Won 51508, South Korea.
   [Yun, Hui suk] Univ Sci & Technol UST, Dept Adv Mat Engn, Daejeon 34113, South Korea.
   [Lee, Sang Cheon] Kyung Hee Univ, Sch Dent, Dept Maxillofacial Biomed Engn, Seoul 02447, South Korea.
   [Lee, Chang Soo] Univ Sci & Technol UST, Dept Biotechnol, Daejeon 34113, South Korea.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB); Kyung
   Hee University; Korea Institute of Materials Science (KIMS); University
   of Science & Technology (UST); Kyung Hee University; University of
   Science & Technology (UST)
RP Lee, CS (通讯作者)，Korea Res Inst Biosci & Biotechnol KRIBB, Bionanotechnol Res Ctr, Daejeon 34141, South Korea.
EM cslee@kribb.re.kr
RI Raja, Naren/AAA 4156 2022
OI Raja, Naren/0000 0001 6321 1671
FU Internal Research Program   Electronics and Telecommunications Research
   Institute (ETRI) [21YR1500]; Electronics and Telecommunications Re 
   search Institute (ETRI); National Research Council of Science &
   Technology (NST) grant by MSIT [CAP20 013 0 0 0]; Institute of
   Information & Communications Technology Planning & Evaluation (IITP)  
   MSIT [2021 0 00725]; Korea Research Institute of Bioscience and
   Biotechnology (KRIBB) Research Initiative Program [KGM5472221]; Korea
   Institute of Planning and Evaluation for Technology in Food, Agriculture
   and Forestry (IPET); Korea Smart Farm R&D Foundation   Ministry of
   Agriculture, Food and Rural Affairs (MAFRA); Ministry of Science and ICT
   (MSIT) , Rural Development Administration (RDA) [421042 04]
FX This research was supported by the Internal Research Program (21YR1500)
   funded by the Electronics and Telecommunications Research Institute
   (ETRI) , National Research Council of Science & Technology (NST) grant
   by MSIT (No. CAP20 013 0 0 0) , Institute of Information &
   Communications Technology Planning & Evaluation (IITP) grant funded by
   MSIT (No.2021 0 00725 , Development of Monitoring Intelligence System
   Technology based on Multimodal Sensing for Monitoring the Risk of
   Infectious Diseases in Confined Spaces) and the Korea Research Institute
   of Bioscience and Biotechnology (KRIBB) Research Initiative Program
   (KGM5472221) . Finally, the authors acknowledge funding by Korea
   Institute of Planning and Evaluation for Technology in Food, Agriculture
   and Forestry (IPET) and Korea Smart Farm R & D Foundation (KosFarm)
   through Smart Farm Innovation Technology Development Program, funded by
   Ministry of Agriculture, Food and Rural Affairs (MAFRA) and Ministry of
   Science and ICT (MSIT) , Rural Development Administra  tion (RDA)
   (421042 04) . The funding agencies had no role in study design; in the
   collection, analysis and interpretation of data; in the writing of the
   report; and in the decision to submit the article for publication.
CR Anani T, 2022, BONE, V154, DOI 10.1016/j.bone.2021.116223
   Benyettou F, 2015, J MATER CHEM B, V3, P7237, DOI 10.1039/c5tb00994d
   Bhaisare ML, 2015, MICROCHIM ACTA, V182, P2173, DOI 10.1007/s00604 015 1541 5
   Chai YC, 2012, ACTA BIOMATER, V8, P3876, DOI 10.1016/j.actbio.2012.07.002
   Chen BB, 2020, GREEN CHEM, V22, P4034, DOI 10.1039/d0gc01014f
   Chen XX, 2014, ANGEW CHEM INT EDIT, V53, P12542, DOI 10.1002/anie.201408422
   Choy CJ, 2016, BIOCONJUGATE CHEM, V27, P2206, DOI 10.1021/acs.bioconjchem.6b00422
   Cnudde V, 2008, J MICROSC OXFORD, V232, P476, DOI 10.1111/j.1365 2818.2008.02142.x
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Deepthi S, 2016, INT J BIOL MACROMOL, V93, P1338, DOI 10.1016/j.ijbiomac.2016.03.041
   Devescovi Valentina, 2008, Chir Organi Mov, V92, P161, DOI 10.1007/s12306 008 0064 1
   Dong XL, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00675 x
   Hayami T, 2004, ARTHRITIS RHEUM US, V50, P1193, DOI 10.1002/art.20124
   He YC, 2018, RSC ADV, V8, P16762, DOI 10.1039/c8ra01872c
   Huang YF, 2014, CHEM EUR J, V20, P5640, DOI 10.1002/chem.201400011
   Kang YF, 2015, SCI REP UK, V5, DOI 10.1038/srep11835
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Kolk A, 2012, J CRANIO MAXILL SURG, V40, P706, DOI 10.1016/j.jcms.2012.01.002
   Kumar GS, 2014, NANOSCALE, V6, P3384, DOI 10.1039/c3nr05376h
   Lesani P, 2022, CHEM ENG J, V433, DOI 10.1016/j.cej.2021.133668
   Li SH, 2016, J MATER CHEM B, V4, P7398, DOI 10.1039/c6tb02241c
   Li SH, 2016, COLLOID SURFACE B, V145, P251, DOI 10.1016/j.colsurfb.2016.05.007
   Li XM, 2014, SCI REP UK, V4, DOI 10.1038/srep04976
   Li Y, 2015, J ORTHOP TRANSL, V3, P95, DOI 10.1016/j.jot.2015.05.002
   Liu RL, 2009, ANGEW CHEM INT EDIT, V48, P4598, DOI 10.1002/anie.200900652
   Lv MM, 2016, BIOMATER SCI UK, V4, P1113, DOI 10.1039/c6bm00091f
   Lv Y, 2019, CHEM EUR J, V25, P954, DOI 10.1002/chem.201804419
   Mucha A, 2003, EUR J ORG CHEM, V2003, P4797, DOI 10.1002/ejoc.200300469
   Olatunji FP, 2019, BIOORG MED CHEM LETT, V29, P2571, DOI 10.1016/j.bmcl.2019.08.005
   Osahor A, 2017, ANAL BIOCHEM, V534, P46, DOI 10.1016/j.ab.2017.07.008
   Pan DY, 2010, CHEM COMMUN, V46, P3681, DOI 10.1039/c000114g
   Peng ZL, 2017, COORDIN CHEM REV, V343, P256, DOI 10.1016/j.ccr.2017.06.001
   Qian XS, 2014, MATERIALS, V7, P8105, DOI 10.3390/ma7128105
   Raja N, 2021, ACS BIOMATER SCI ENG, V7, P1123, DOI 10.1021/acsbiomaterials.0c01341
   Rohini N.A., 2013, J ANTIVIR ANTIRETROV, V15, P1948
   Saranti A., 2022, Smart Materials in Medicine, V3, P12, DOI [10.1016/smaim.2021.11.002, DOI 10.1016/J.SMAIM.2021.11.002]
   Saxena M, 2013, RSC ADV, V3, P22504, DOI 10.1039/c3ra44100h
   Shafiei S, 2019, MAT SCI ENG C MATER, V100, P564, DOI 10.1016/j.msec.2019.03.003
   Siddique A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 28021 9
   Stevens MM, 2008, MATER TODAY, V11, P18, DOI 10.1016/S1369 7021(08)70086 5
   Sun YP, 2006, J AM CHEM SOC, V128, P7756, DOI 10.1021/ja062677d
   Thamake SI, 2012, BIOMATERIALS, V33, P7164, DOI 10.1016/j.biomaterials.2012.06.026
   Vedhanayagam M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105378
   Walmsley GG, 2015, NANOMED NANOTECHNOL, V11, P1253, DOI 10.1016/j.nano.2015.02.013
   Wang GL, 2010, J DRUG TARGET, V18, P611, DOI 10.3109/10611861003622560
   Wei GB, 2004, BIOMATERIALS, V25, P4749, DOI 10.1016/j.biomaterials.2003.12.005
   WILLIAMS ATR, 1983, ANALYST, V108, P1067, DOI 10.1039/an9830801067
   Xi YH, 2019, INT J NANOMED, V14, P6425, DOI 10.2147/IJN.S211981
   Xu HHK, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.56
   Ye WL, 2015, SCI REP UK, V5, DOI 10.1038/srep14614
   Yu CM, 2013, CHEM COMMUN, V49, P403, DOI 10.1039/c2cc37329g
   Zhang JT, 2014, ACTA BIOMATER, V10, P1035, DOI 10.1016/j.actbio.2013.11.001
   Zhang PK, 2016, RSC ADV, V6, P56610, DOI 10.1039/c6ra06856a
   Zhang SY, 2013, MACROMOLECULES, V46, P5141, DOI 10.1021/ma400675m
   Zhou H, 2011, ACTA BIOMATER, V7, P2769, DOI 10.1016/j.actbio.2011.03.019
NR 55
TC 16
Z9 17
U1 4
U2 59
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD MAR 15
PY 2023
VL 159
BP 382
EP 393
DI 10.1016/j.actbio.2023.01.028
EA FEB 2023
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 9X3AY
UT WOS:000949645700001
PM 36669550
OA hybrid
DA 2025 08 17
ER

PT J
AU Seldeen, KL
   Halley, PG
   Volmar, CH
   Rodríguez, MA
   Hernandez, M
   Pang, M
   Carlsson, SK
   Suva, LJ
   Wahlestedt, C
   Troen, BR
   Brothers, SP
AF Seldeen, K. L.
   Halley, P. G.
   Volmar, C. H.
   Rodriguez, M. A.
   Hernandez, M.
   Pang, M.
   Carlsson, S. K.
   Suva, L. J.
   Wahlestedt, C.
   Troen, B. R.
   Brothers, S. P.
TI Neuropeptide Y Y2 antagonist treated ovariectomized mice exhibit greater
   bone mineral density
SO NEUROPEPTIDES
LA English
DT Article
DE Neuropeptide Y; Y2 receptor; Bone; Menopause; JNJ 31020028
ID SMALL MOLECULE ANTAGONIST; MESENCHYMAL STEM CELLS; RECEPTOR SUBTYPES;
   KNOCKOUT MICE; HYPOTHALAMIC REGULATION; POSTMENOPAUSAL WOMEN;
   HIP FRACTURES; Y 2 RECEPTORS; NPY RECEPTORS; YY2 RECEPTOR
AB Osteoporosis, a disease characterized by progressive bone loss and increased risk of fracture, often results from menopausal loss of estrogen in women. Neuropeptide Y has been shown to negatively regulate bone formation, with amygdala specific deletion of the Y2 receptor resulting in increased bone mass in mice. In this study, ovariectomized (OVX) mice were injected once daily with JNJ 31020028, a brain penetrant Y2 receptor small molecule antagonist to determine the effects on bone formation. Antagonist treated mice had reduced weight and showed increased whole body bone mineral density compared to vehicle injected mice. Micro computerized tomography (micro CT) demonstrated increased vertebral trabecular bone volume, connectivity density and trabecular thickness. Femoral micro CT analysis revealed increased bone volume within trabecular regions and greater trabecular number, without significant difference in other parameters or within cortical regions. A decrease was seen in serum P1NP, a measure used to confirm positive treatment outcomes in bisphosphonate treated patients. C terminal telopeptide 1 (CDC 1), a blood biomarker of bone resorption, was decreased in treated animals. The higher bone mineral density observed following Y2 antagonist treatment, as determined by whole body DEXA scanning, is indicative of either enhanced mineralization or reduced bone loss. Additionally, our findings that ex vivo treatment of bone marrow cells with the Y2 antagonist did not affect osteoblast and osteoclast formation suggests the inhibitor is not affecting these cells directly, and suggests a central role for compound action in this system. Our results support the involvement of Y2R signalling in bone metabolism and give credence to the hypothesis that selective pharmacological manipulation of Y2R may provide anabolic benefits for treating osteoporosis.
C1 [Halley, P. G.; Volmar, C. H.; Carlsson, S. K.; Wahlestedt, C.; Brothers, S. P.] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Ctr Therapeut Innovat, 1501 NW 10th Ave,BRB 416 M860, Miami, FL 33136 USA.
   [Seldeen, K. L.; Pang, M.; Troen, B. R.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Div Geriatr & Palliat Med, Buffalo, NY USA.
   [Rodriguez, M. A.; Hernandez, M.] Bruce W Carter VA Geriatr Res Educ & Clin Ctr GRE, Miami, FL USA.
   [Suva, L. J.] Univ Arkansas, Med Sch, Ctr Orthopaed Res, Dept Orthopaed Surg, Little Rock, AR 72204 USA.
   [Seldeen, K. L.; Troen, B. R.] Vet Affairs Western New York Healthcare Syst, Res Serv, Buffalo, NY USA.
   [Rodriguez, M. A.; Hernandez, M.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
C3 University of Miami; State University of New York (SUNY) System;
   University at Buffalo, SUNY; Geriatric Research Education & Clinical
   Center; University of Arkansas System; University of Arkansas Little
   Rock; University of Arkansas Fayetteville; University of Miami
RP Brothers, SP (通讯作者)，Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Ctr Therapeut Innovat, 1501 NW 10th Ave,BRB 416 M860, Miami, FL 33136 USA.
EM sbrothers@med.miami.edu
RI ; Volmar, C/AFR 7749 2022; Seldeen, Kenneth/AAI 1918 2020; Troen,
   Bruce/ABB 4959 2021
OI Volmar, Claude Henry/0000 0001 9437 051X; Suva,
   Larry/0000 0002 2892 9757; Troen, Bruce/0000 0002 3699 0021
FU National Institutes of Health [R01NS092671, R01MH110441, DA035592,
   DA035055, AA023781]; Sylvester Drug Discovery Core; Sylvester Cancer
   Center; Florida Department of Health grants [6AZ08, 7AZ26]
FX SPB received support from the National Institutes of Health (R01NS092671
   and R01MH110441), the Sylvester Drug Discovery Core and the Sylvester
   Cancer Center. CW received support by from the National Institutes of
   Health (DA035592, DA035055 and AA023781) and Florida Department of
   Health grants (6AZ08 and 7AZ26).
CR Aguila HL, 2005, IMMUNOL REV, V208, P7, DOI 10.1111/j.0105 2896.2005.00333.x
   Balasubramaniam A, 1997, PEPTIDES, V18, P445, DOI 10.1016/S0196 9781(96)00347 6
   Baldock PA, 2005, J BONE MINER RES, V20, P1851, DOI 10.1359/JBMR.050523
   Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI200214588
   Baldock PA, 2007, J BIOL CHEM, V282, P19092, DOI 10.1074/jbc.M700644200
   Baldock PA, 2006, J BONE MINER RES, V21, P1600, DOI 10.1359/JBMR.060705
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Beranger GE, 2014, ENDOCRINOLOGY, V155, P1340, DOI 10.1210/en.2013 1688
   Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166 2236(96)01057 0
   Bonaventure P, 2004, J PHARMACOL EXP THER, V308, P1130, DOI 10.1124/jpet.103.060459
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brothers SP, 2010, EMBO MOL MED, V2, P429, DOI 10.1002/emmm.201000100
   Brothers SP, 2010, MOL PHARMACOL, V77, P46, DOI 10.1124/mol.109.058677
   Chen G, 1996, J NEUROSCI, V16, P7711
   Chen XL, 1997, AM J PHYSIOL HEART C, V273, pH1737, DOI 10.1152/ajpheart.1997.273.4.H1737
   Cho HY, 2014, J CELL PHYSIOL, V229, P561, DOI 10.1002/jcp.24478
   Chung HJ, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 184
   Cippitelli A, 2011, ALCOHOL, V45, P567, DOI 10.1016/j.alcohol.2010.09.003
   CROUCHER PI, 1994, BONE MINER, V25, P111, DOI 10.1016/S0169 6009(08)80253 X
   Delahunty KM, 2009, J CLIN DENSITOM, V12, P89, DOI 10.1016/j.jocd.2008.10.008
   Doods H, 1999, EUR J PHARMACOL, V384, pR3, DOI 10.1016/S0014 2999(99)00650 0
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Driessler F, 2010, J MOL ENDOCRINOL, V45, P175, DOI 10.1677/JME 10 0015
   DUMONT Y, 1992, PROG NEUROBIOL, V38, P125, DOI 10.1016/0301 0082(92)90038 G
   Duque G, 2009, MINERVA MED, V100, P79
   Elefteriou F, 2006, CELL METAB, V4, P441, DOI 10.1016/j.cmet.2006.10.010
   Fetissov SO, 2004, NEUROPEPTIDES, V38, P175, DOI 10.1016/j.npep.2004.05.009
   Fetissov SO, 2004, J COMP NEUROL, V470, P256, DOI 10.1002/cne.11047
   Fowler TW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042967
   Gallagher JC, 2006, BONE, V39, P1268, DOI 10.1016/j.bone.2006.06.007
   GLENN TC, 1994, AGING CLIN EXP RES, V6, P277, DOI 10.1007/BF03324253
   Grouzmann E, 1997, J BIOL CHEM, V272, P7699, DOI 10.1074/jbc.272.12.7699
   Gu XC, 2016, NEUROPEPTIDES, V60, P61, DOI 10.1016/j.npep.2016.09.005
   Hale LV, 2007, BONE, V40, P1103, DOI 10.1016/j.bone.2006.11.027
   Heilig M, 2004, NEUROPEPTIDES, V38, P213, DOI 10.1016/j.npep.2004.05.002
   HEILIG M, 1995, CRIT REV NEUROBIOL, V9, P115
   Jacques D, 1997, NEUROSCIENCE, V79, P129, DOI 10.1016/S0306 4522(96)00639 2
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   King PJ, 1999, J NEUROCHEM, V73, P641, DOI 10.1046/j.1471 4159.1999.0730641.x
   LEUNG KS, 1993, J BONE JOINT SURG BR, V75, P288, DOI 10.1302/0301 620X.75B2.8444951
   Liu S, 2016, NEUROPEPTIDES, V56, P105, DOI 10.1016/j.npep.2015.12.008
   Lundberg P, 2007, J BIOL CHEM, V282, P19082, DOI 10.1074/jbc.M609629200
   MARTIRE M, 1995, NEUROSCI LETT, V188, P9, DOI 10.1016/0304 3940(95)11380 F
   MEDANIC M, 1993, BRAIN RES, V620, P281, DOI 10.1016/0006 8993(93)90166 K
   Naveilhan P, 2001, NATURE, V409, P513, DOI 10.1038/35054063
   Nozdrachev A D, 2011, Zh Evol Biokhim Fiziol, V47, P105
   PERNOW J, 1988, ACTA PHYSIOL SCAND, V134, P157, DOI 10.1111/j.1748 1716.1988.tb08474.x
   Perrien DS, 2007, ENDOCRINOLOGY, V148, P1654, DOI 10.1210/en.2006 0848
   Qi Y, 2016, NEUROPEPTIDES, V55, P91, DOI 10.1016/j.npep.2015.09.009
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Raisz LG, 1999, CLIN CHEM, V45, P1353
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Redrobe JP, 2004, J MOL NEUROSCI, V22, P159, DOI 10.1385/JMN:22:3:159
   Redrobe JP, 2002, LIFE SCI, V71, P2921, DOI 10.1016/S0024 3205(02)02159 8
   Rosen HN, 2000, CALCIFIED TISSUE INT, V66, P100, DOI 10.1007/PL00005830
   Sainsbury A, 2010, MOL CELL ENDOCRINOL, V316, P109, DOI 10.1016/j.mce.2009.09.025
   Sainsbury A, 2002, P NATL ACAD SCI USA, V99, P8938, DOI 10.1073/pnas.132043299
   Saldanha S., 2010, PROBE REPORTS NIH MO
   Sarto T, 1998, BRIT J CANCER, V78, P240, DOI 10.1038/bjc.1998.471
   Schnitzler CM, 2005, CALCIFIED TISSUE INT, V76, P79, DOI 10.1007/s00223 004 0053 9
   Shi YC, 2012, BONE, V50, P430, DOI 10.1016/j.bone.2011.10.001
   Shoblock JR, 2010, PSYCHOPHARMACOLOGY, V208, P265, DOI 10.1007/s00213 009 1726 x
   Silva AP, 2007, FASEB J, V21, P671, DOI 10.1096/fj.06 6163com
   Solway B, 2011, P NATL ACAD SCI USA, V108, P7224, DOI 10.1073/pnas.1017719108
   Swanson DM, 2011, BIOORG MED CHEM LETT, V21, P5552, DOI 10.1016/j.bmcl.2011.06.136
   TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0
   Thorsell A, 2000, P NATL ACAD SCI USA, V97, P12852, DOI 10.1073/pnas.220232997
   Troen BR, 2003, EXP GERONTOL, V38, P605, DOI 10.1016/S0531 5565(03)00069 X
   WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167 0115(86)90048 0
   Xiao J, 2016, NEUROPEPTIDES, V56, P97, DOI 10.1016/j.npep.2015.12.006
   Yannielli PC, 2001, PEPTIDES, V22, P547, DOI 10.1016/S0196 9781(01)00356 4
NR 72
TC 12
Z9 18
U1 0
U2 10
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0143 4179
EI 1532 2785
J9 NEUROPEPTIDES
JI Neuropeptides
PD FEB
PY 2018
VL 67
BP 45
EP 55
DI 10.1016/j.npep.2017.11.005
PG 11
WC Endocrinology & Metabolism; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA FW8DC
UT WOS:000425556500006
PM 29129406
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Richter, R
   Forssmann, W
   Henschler, R
AF Richter, Rudolf
   Forssmann, Wolfgang
   Henschler, Reinhard
TI Current Developments in Mobilization of Hematopoietic Stem and
   Progenitor Cells and Their Interaction with Niches in Bone Marrow
SO TRANSFUSION MEDICINE AND HEMOTHERAPY
LA English
DT Article
DE Hematopoietic stem cell; Bone marrow; Mobilization; Stem cell niche
ID COLONY STIMULATING FACTOR; STEM/PROGENITOR CELLS; G CSF; SELF RENEWAL;
   RAPID MOBILIZATION; ENDOTHELIAL CELLS; BLOOD STEM; IN VITRO; INNATE
   IMMUNITY; PROSTAGLANDIN E
AB The clinical application of hematopoietic stem and progenitor cells (HSPCs) has evolved from a highly experimental stage in the 1980s to a currently clinically established treatment for more than 20,000 patients annually who suffer from hematological malignancies and other severe diseases. Studies in numerous murine models have demonstrated that HSPCs reside in distinct niches within the bone marrow environment. Whereas transplanted HSPCs travel through the bloodstream and home to sites of hematopoiesis, HSPCs can be mobilized from these niches into the blood either physiologically or induced by pharmaceutical drugs. Firstly, this review aims to give a synopsis of milestones defining niches and mobilization pathways for HSPCs, including the identification of several cell types involved such as osteoblasts, adventitial reticular cells, endothelial cells, monocytic cells, and granulocytic cells. The main factors that anchor HSPCs in the niche, and/or induce their quiescence are vascular cell adhesion molecule(VCAM) 1, CD44, hematopoietic growth factors, e.g. stem cell factor (SCF) and FLT3 Ligand, chemokines including CXCL12, growth regulated protein beta and IL 8, proteases, peptides, and other chemical transmitters such as nucleotides. In the second part of the review, we revise the current understanding of HSPC mobilization. Here, we discuss which mechanisms found to be active in HSPC mobilization correspond to the mechanisms relevant for HSPC interaction with niche cells, but also deal with other mediators and signals that target individual cell types and receptors to mobilize HSPCs. A multitude of questions remain to be addressed for a better understanding of HSPC biology and its implications for therapy, including more comprehensive concepts for regulatory circuits such as calcium homeostasis and parathormone, metabolic regulation such as by leptin, the significance of autonomic nervous system, the consequences of alteration of niches in aged patients, or the identification of more easily accessible markers to better predict the efficiency of HSPC mobilization. (C) 2017 S. Karger GmbH, Freiburg
C1 [Richter, Rudolf; Forssmann, Wolfgang] Hannover Med Sch, Dept Internal Med, Clin Immunol, Hannover, Germany.
   [Richter, Rudolf] MVZ Lab PD Dr Volkmann & Kollegen, Karlsruhe, Germany.
   [Henschler, Reinhard] Swiss Red Cross Blood Transfus Serv Zurich & Chur, Zurich, Switzerland.
C3 Hannover Medical School
RP Henschler, R (通讯作者)，Blood Transfus Serv SRC Zurich & Chur, Ruttistr 19, CH 8952 Zurich, Switzerland.
EM reinhard.henschler@blutspende gr.ch
CR Abraham M, 2007, STEM CELLS, V25, P2158, DOI 10.1634/stemcells.2007 0161
   Acar M, 2015, NATURE, V526, P126, DOI 10.1038/nature15250
   Adamiak M, 2017, STEM CELL REV REP, V13, P92, DOI 10.1007/s12015 016 9693 1
   Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247
   Adams GB, 2007, NAT BIOTECHNOL, V25, P238, DOI 10.1038/nbt1281
   Adams GB, 2009, NATURE, V459, P103, DOI 10.1038/nature07859
   Anasetti C, 2012, NEW ENGL J MED, V367, P1487, DOI 10.1056/NEJMoa1203517
   Appelqvist H, 2013, J MOL CELL BIOL, V5, P214, DOI 10.1093/jmcb/mjt022
   Ara T, 2003, IMMUNITY, V19, P257, DOI 10.1016/S1074 7613(03)00201 2
   Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Asada N, 2013, CELL STEM CELL, V12, P737, DOI 10.1016/j.stem.2013.05.001
   Avigdor A, 2004, BLOOD, V103, P2981, DOI 10.1182/blood 2003 10 3611
   BENAYAHU D, 1989, J CELL PHYSIOL, V140, P1, DOI 10.1002/jcp.1041400102
   BENAYAHU D, 1992, CALCIFIED TISSUE INT, V51, P195, DOI 10.1007/BF00334547
   Bilgin YM, 2016, CURR OPIN HEMATOL, V23, P67, DOI 10.1097/MOH.0000000000000200
   Blackburn Michael R, 2009, Handb Exp Pharmacol, P215, DOI 10.1007/978 3 540 89615 9_8
   Boettcher S, 2014, BLOOD, V124, P1393, DOI 10.1182/blood 2014 04 570762
   Bonig H, 2007, EXP HEMATOL, V35, P326, DOI 10.1016/j.exphem.2006.09.017
   Boulais PE, 2015, BLOOD, V125, P2621, DOI 10.1182/blood 2014 09 570192
   Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385
   Bruns I, 2014, NAT MED, V20, P1315, DOI 10.1038/nm.3707
   Butler JM, 2010, CELL STEM CELL, V6, P251, DOI 10.1016/j.stem.2010.02.001
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Cancelas JA, 2005, NAT MED, V11, P886, DOI 10.1038/nm1274
   Cao B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11007
   Chen SY, 2016, STEM CELLS, V34, P1730, DOI 10.1002/stem.2348
   Chow A, 2011, J EXP MED, V208, P261, DOI 10.1084/jem.20101688
   Christopher MJ, 2011, J EXP MED, V208, P251, DOI 10.1084/jem.20101700
   Christopher MJ, 2009, BLOOD, V114, P1331, DOI 10.1182/blood 2008 10 184754
   Colmone A, 2008, SCIENCE, V322, P1861, DOI 10.1126/science.1164390
   Dao MA, 2007, BLOOD, V110, P74, DOI 10.1182/blood 2006 08 034447
   Dar A, 2011, LEUKEMIA, V25, P1286, DOI 10.1038/leu.2011.62
   Day RB, 2012, CELL MOL LIFE SCI, V69, P1415, DOI 10.1007/s00018 011 0870 8
   DEXTER TM, 1973, J CELL PHYSIOL, V82, P461, DOI 10.1002/jcp.1040820315
   Di Virgilio F, 2009, CURR OPIN PHARMACOL, V9, P507, DOI 10.1016/j.coph.2009.06.021
   Ding L, 2013, NATURE, V495, P231, DOI 10.1038/nature11885
   Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783
   Domingues MJ, 2017, INT J HEMATOL, V105, P141, DOI 10.1007/s12185 016 2156 2
   Ferraro F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002191
   Filippi MD, 2004, NAT IMMUNOL, V5, P744, DOI 10.1038/ni1081
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365 2184.1970.tb00347.x
   Fukuda S, 2007, BLOOD, V110, P860, DOI 10.1182/blood 2006 06 031401
   Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101
   Golan K, 2012, BLOOD, V119, P2478, DOI 10.1182/blood 2011 06 358614
   Gómez Moutón C, 2004, J CELL BIOL, V164, P759, DOI 10.1083/jcb.200309101
   Greenbaum AM, 2011, LEUKEMIA, V25, P211, DOI 10.1038/leu.2010.248
   Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926
   Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485
   Guan JL, 2004, SCIENCE, V303, P773, DOI 10.1126/science.1094376
   HAYNESWORTH SE, 1992, BONE, V13, P69, DOI 10.1016/8756 3282(92)90363 2
   Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092 8674(02)00754 7
   Himburg HA, 2012, CELL REP, V2, P964, DOI 10.1016/j.celrep.2012.09.002
   Hoggatt J, 2013, NATURE, V495, P365, DOI 10.1038/nature11929
   Hoggatt J, 2009, BLOOD, V113, P5444, DOI 10.1182/blood 2009 01 201335
   Hooper AT, 2009, CELL STEM CELL, V4, P263, DOI 10.1016/j.stem.2009.01.006
   Hu XB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13095
   Ito K, 2007, BIOCHEM BIOPH RES CO, V357, P212, DOI 10.1016/j.bbrc.2007.03.123
   Iwata M, 2004, BLOOD, V103, P4496, DOI 10.1182/blood 2004 01 0256
   Juarez JG, 2012, BLOOD, V119, P707, DOI 10.1182/blood 2011 04 348904
   Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365
   Karpova D, 2013, TRANSFUSIONSMEDIZIN, V3, P127, DOI 10.1055/s 0032 1325071
   Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Kim AG, 2016, BLOOD, V128, P2457, DOI 10.1182/blood 2016 06 723981
   Kim CH, 2012, LEUKEMIA, V26, P106, DOI 10.1038/leu.2011.185
   Kobayashi H, 2010, NAT CELL BIOL, V12, P1046, DOI 10.1038/ncb2108
   Kook S, 2013, J CLIN INVEST, V123, P3420, DOI 10.1172/JCI64060
   Kovtonyuk LV, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00502
   Kunisaki Y, 2013, NATURE, V502, P637, DOI 10.1038/nature12612
   Kwak H, 2016, J CLIN INVEST, V126, P4554, DOI 10.1172/JCI87848
   Lam BS, 2011, BLOOD, V117, P1167, DOI 10.1182/blood 2010 05 286294
   Lambris JD, 2008, NAT REV MICROBIOL, V6, P132, DOI 10.1038/nrmicro1824
   Lapid K, 2012, STEMBOOK
   Latchney SE, 2017, SEMIN HEMATOL, V54, P25, DOI 10.1053/j.seminhematol.2016.10.001
   Lee HM, 2009, LEUKEMIA, V23, P2052, DOI 10.1038/leu.2009.158
   Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976
   Lemoli RM, 2004, BLOOD, V104, P1662, DOI 10.1182/blood 2004 03 0834
   Lévesque JP, 2002, EXP HEMATOL, V30, P440, DOI 10.1016/S0301 472X(02)00788 9
   Lévesque JP, 2003, EXP HEMATOL, V31, P109, DOI 10.1016/S0301 472X(02)01028 7
   LICHTMAN MA, 1981, EXP HEMATOL, V9, P391
   Liu FL, 2000, BLOOD, V95, P3025, DOI 10.1182/blood.V95.10.3025.010k32_3025_3031
   Liu Jingjing, 2011, World J Biol Chem, V2, P1, DOI 10.4331/wjbc.v2.i1.1
   Lo Celso C, 2009, NATURE, V457, P92, DOI 10.1038/nature07434
   Massberg S, 2009, ANN NY ACAD SCI, V1176, P87, DOI 10.1111/j.1749 6632.2009.04609.x
   Méndez Ferrer S, 2008, NATURE, V452, P442, DOI 10.1038/nature06685
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Méndez Ferrer S, 2010, ANN NY ACAD SCI, V1192, P139, DOI 10.1111/j.1749 6632.2010.05390.x
   MICHELSEN K, 1969, ACTA PHYSIOL SCAND, V77, P28, DOI 10.1111/j.1748 1716.1969.tb04550.x
   Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038
   Nagasawa T, 2008, NAT IMMUNOL, V9, P345, DOI 10.1038/ni0408 345
   Nakamura Ishizu A, 2014, BIOCHEM BIOPH RES CO, V454, P353, DOI 10.1016/j.bbrc.2014.10.095
   Nie YC, 2008, J EXP MED, V205, P777, DOI 10.1084/jem.20072513
   Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293
   North TE, 2007, NATURE, V447, P1007, DOI 10.1038/nature05883
   Ogle ME, 2017, STEM CELLS, V35, P1040, DOI 10.1002/stem.2556
   Okajima F, 2013, CELL SIGNAL, V25, P2263, DOI 10.1016/j.cellsig.2013.07.022
   Omatsu Y, 2010, IMMUNITY, V33, P387, DOI 10.1016/j.immuni.2010.08.017
   Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221
   Pébay A, 2007, PROSTAG OTH LIPID M, V84, P83, DOI 10.1016/j.prostaglandins.2007.08.004
   Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296
   Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845
   Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615
   PELUS LM, 1979, J EXP MED, V150, P277, DOI 10.1084/jem.150.2.277
   PELUS LM, 1981, CELL TISSUE KINET, V14, P515, DOI 10.1111/j.1365 2184.1981.tb00557.x
   Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813
   Pinho S, 2013, J EXP MED, V210, P1351, DOI 10.1084/jem.20122252
   Pitchford SC, 2009, CELL STEM CELL, V4, P62, DOI 10.1016/j.stem.2008.10.017
   Poulos MG, 2013, CELL REP, V4, P1022, DOI 10.1016/j.celrep.2013.07.048
   Qian H, 2007, CELL STEM CELL, V1, P671, DOI 10.1016/j.stem.2007.10.008
   Ratajczak J, 2004, BLOOD, V103, P2071, DOI 10.1182/blood 2003 06 2099
   Ratajczak MZ, 2010, LEUKEMIA, V24, P1667, DOI 10.1038/leu.2010.162
   Ratajczak MZ, 2010, LEUKEMIA, V24, P976, DOI 10.1038/leu.2010.53
   Ratajczak MZ, 2006, EXP HEMATOL, V34, P986, DOI 10.1016/j.exphem.2006.03.015
   Ratajczak MZ, 2014, EXPERT OPIN THER TAR, V18, P95, DOI 10.1517/14728222.2014.851671
   Reca R, 2003, BLOOD, V101, P3784, DOI 10.1182/blood 2002 10 3233
   Richter R, 2014, STEM CELLS DEV, V23, P1959, DOI 10.1089/scd.2013.0524
   Rosario M, 2016, CLIN DRUG INVEST, V36, P913, DOI 10.1007/s40261 016 0437 4
   Rossi L, 2007, BLOOD, V109, P533, DOI 10.1182/blood 2006 01 035634
   Ryan MA, 2010, NAT MED, V16, P1141, DOI 10.1038/nm.2217
   Ryser MF, 2008, MOL IMMUNOL, V46, P166, DOI 10.1016/j.molimm.2008.07.016
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Sato Koichi, 2010, World J Biol Chem, V1, P327, DOI 10.4331/wjbc.v1.i11.327
   SCHOFIELD R, 1986, INT J RADIAT BIOL, V49, P1021, DOI 10.1080/09553008514553241
   SCHOFIELD R, 1978, BLOOD CELLS, V4, P7
   Scott MK, 2014, JOVE J VIS EXP, DOI 10.3791/51683
   Seitz G, 2005, ANN NY ACAD SCI, V1044, P84, DOI 10.1196/annals.1349.011
   Siena S, 1999, BEST PRACT RES CL HA, V12, P27, DOI 10.1053/beha.1999.0005
   Simmons P J, 1994, Prog Clin Biol Res, V389, P271
   SIMMONS PJ, 1991, BLOOD, V78, P55
   Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992
   Stier S, 2002, BLOOD, V99, P2369, DOI 10.1182/blood.V99.7.2369
   Sugiyama A, 2015, CHRONOBIOL INT, V32, P934, DOI 10.3109/07420528.2015.1053910
   Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016
   Szumilas P, 2005, CELL PROLIFERAT, V38, P47, DOI 10.1111/j.1365 2184.2005.00329.x
   TAETLE R, 1980, CANCER RES, V40, P1223
   Taichman RS, 1996, BLOOD, V87, P518, DOI 10.1182/blood.V87.2.518.bloodjournal872518
   TAICHMAN RS, 1994, J EXP MED, V179, P1677, DOI 10.1084/jem.179.5.1677
   Taichman RS, 2001, BRIT J HAEMATOL, V112, P438, DOI 10.1046/j.1365 2141.2001.02568.x
   Tay J, 2017, INT J HEMATOL, V105, P129, DOI 10.1007/s12185 016 2162 4
   Tesio M, 2011, BLOOD, V117, P419, DOI 10.1182/blood 2009 06 230359
   Tian DM, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 015 0761 0
   Tzeng YS, 2011, BLOOD, V117, P429, DOI 10.1182/blood 2010 01 266833
   Valenzuela Fernández A, 2002, J BIOL CHEM, V277, P15677, DOI 10.1074/jbc.M111388200
   van der Loo JCM, 1998, J CLIN INVEST, V102, P1051, DOI 10.1172/JCI3687
   van Pel M, 2006, P NATL ACAD SCI USA, V103, P1469, DOI 10.1073/pnas.0510192103
   Vermeulen M, 1998, BLOOD, V92, P894, DOI 10.1182/blood.V92.3.894.415k22_894_900
   Winkler IG, 2005, J EXP MED, V201, P1077, DOI 10.1084/jem.20042299
   Winkler IG, 2012, NAT MED, V18, P1651, DOI 10.1038/nm.2969
   Winkler IG, 2010, BLOOD, V116, P4815, DOI 10.1182/blood 2009 11 253534
   Worel N, 2012, TRANSFUSION, V52, P2395, DOI 10.1111/j.1537 2995.2012.03603.x
   Wu QL, 2009, J CELL MOL MED, V13, P3764, DOI 10.1111/j.1582 4934.2009.00691.x
   Wu W, 2012, LEUKEMIA, V26, P736, DOI 10.1038/leu.2011.252
   Wysoczynski M, 2009, LEUKEMIA, V23, P1455, DOI 10.1038/leu.2009.73
   Xie YC, 2009, NATURE, V457, P97, DOI 10.1038/nature07639
   Yamamoto K, 2012, BBA PROTEINS PROTEOM, V1824, P105, DOI 10.1016/j.bbapap.2011.05.022
   Yamazaki S, 2011, CELL, V147, P1146, DOI 10.1016/j.cell.2011.09.053
   Yang FC, 2001, P NATL ACAD SCI USA, V98, P5614, DOI 10.1073/pnas.101546898
   Yoshihara H, 2007, CELL STEM CELL, V1, P685, DOI 10.1016/j.stem.2007.10.020
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhao M, 2014, NAT MED, V20, P1321, DOI 10.1038/nm.3706
   Zirafi O, 2015, CELL REP, V11, P737, DOI 10.1016/j.celrep.2015.03.061
   Zoughlami Y, 2012, BLOOD, V119, P2024, DOI 10.1182/blood 2011 06 364828
NR 162
TC 21
Z9 23
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1660 3796
EI 1660 3818
J9 TRANSFUS MED HEMOTH
JI Transfus. Med. Hemother.
PY 2017
VL 44
IS 3
BP 151
EP 164
DI 10.1159/000477262
PG 14
WC Hematology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Immunology
GA EX6QD
UT WOS:000403366100004
PM 28626366
OA Green Published
DA 2025 08 17
ER

PT J
AU Lee, BEJ
   Shahin Shamsabadi, A
   Wong, MK
   Raha, S
   Selvaganapathy, PR
   Grandfield, K
AF Lee, Bryan E. J.
   Shahin Shamsabadi, Alireza
   Wong, Michael K.
   Raha, Sandeep
   Selvaganapathy, Ponnambalam Ravi
   Grandfield, Kathryn
TI A Bioprinted In Vitro Model for Osteoblast to Osteocyte Transformation
   by Changing Mechanical Properties of the ECM
SO ADVANCED BIOSYSTEMS
LA English
DT Article
DE bioprinting; bone; in vitro model; osteoblast; osteocyte
ID MATRIX METALLOPROTEINASES; CELL CULTURE; MIGRATION; SYSTEM
AB Osteocytes are key contributors to bone remodeling. During the remodeling process, trapped osteoblasts undergo a phenotypic change to become osteocytes. The specific mechanisms by which osteocytes work are still debatable and models that exist to study them are sparse. This work presents an in vitro, bioprinted model based on the previously developed technique, ExCeL, in which a cell embedded hydrogel is printed and immediately crosslinked using paper as a crosslinker storing substrate. This process mimics the phenotypical change of osteoblast to osteocyte by altering the mechanical properties of the hydrogel. By printing Saos 2, osteosarcoma cells, embedded in the alginate hydrogel with differing mechanical properties, their morphology, protein, and gene expression can be changed from osteoblast like to osteocyte like. The stiffer gel is 30 times stiffer and results in significantly smaller cells with reduced alkaline phosphatase activity and expression of osteoblast marker genes such as MMP9 and TIMP2. There is no change in viability between cells despite encapsulation in gels with different mechanical properties. The results show that the phenomenon of osteoblasts becoming encapsulated during the bone remodeling process can be replicated using the ExCeL bioprinting technique. This model has potential for studying how osteocytes can interact with external mechanical stimuli or drugs.
C1 [Lee, Bryan E. J.; Shahin Shamsabadi, Alireza; Selvaganapathy, Ponnambalam Ravi; Grandfield, Kathryn] McMaster Univ, Sch Biomed Engn, 1280 Main St West, Hamilton, ON L8S 4L7, Canada.
   [Wong, Michael K.; Raha, Sandeep] McMaster Univ, Grad Program Med Sci, 1280 Main St West, Hamilton, ON L8S 4K1, Canada.
   [Raha, Sandeep] McMaster Univ, Dept Pediat, 1280 Main St West, Hamilton, ON L8S 4K1, Canada.
   [Selvaganapathy, Ponnambalam Ravi] McMaster Univ, Dept Mech Engn, 1280 Main St West, Hamilton, ON L8S 4L7, Canada.
   [Grandfield, Kathryn] McMaster Univ, Dept Mat Sci & Engn, 1280 Main St West, Hamilton, ON L8S 4L7, Canada.
C3 McMaster University; McMaster University; McMaster University; McMaster
   University; McMaster University
RP Selvaganapathy, PR; Grandfield, K (通讯作者)，McMaster Univ, Sch Biomed Engn, 1280 Main St West, Hamilton, ON L8S 4L7, Canada.; Selvaganapathy, PR (通讯作者)，McMaster Univ, Dept Mech Engn, 1280 Main St West, Hamilton, ON L8S 4L7, Canada.; Grandfield, K (通讯作者)，McMaster Univ, Dept Mat Sci & Engn, 1280 Main St West, Hamilton, ON L8S 4L7, Canada.
EM selvaga@mcmaster.ca; kgrandfield@mcmaster.ca
RI ; Raha, Sandeep/AAF 3655 2020
OI Grandfield, Kathryn/0000 0002 0188 9580; Shahin Shamsabadi,
   Alireza/0000 0002 8145 2556; Raha, Sandeep/0000 0001 7307 3292; Lee,
   Bryan/0000 0002 8273 0618
FU Natural Sciences and Engineering Research Council of Canada (NSERC)
   [RGPIN 2014 06053]; Canada Research Chairs Program; NSERC Discovery
   Accelerator Supplement
FX B.E.J.L. and A.S. S. contributed equally to this work. The manuscript
   was written through contributions of all authors. All authors have given
   approval to the final version of the manuscript. The authors would like
   to acknowledge the support of the Natural Sciences and Engineering
   Research Council of Canada (NSERC) and the Discovery Grant Program
   (RGPIN 2014 06053). P.R.S. acknowledges support from the Canada Research
   Chairs Program and the NSERC Discovery Accelerator Supplement.
   Microscopy was carried out at the Faculty of Health Sciences Electron
   Microscopy Facility at McMaster University. In vitro studies were
   performed at the Biointerfaces Institute at McMaster University.
CR Abbott A, 2003, NATURE, V424, P870, DOI 10.1038/424870a
   Antoni D, 2015, INT J MOL SCI, V16, P5517, DOI 10.3390/ijms16035517
   Axpe E, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17121976
   Baker BM, 2012, J CELL SCI, V125, P3015, DOI 10.1242/jcs.079509
   Barragan Adjemian C, 2006, CALCIFIED TISSUE INT, V79, P340, DOI 10.1007/s00223 006 0107 2
   Boukhechba F, 2009, J BONE MINER RES, V24, P1927, DOI [10.1359/JBMR.090517, 10.1359/jbmr.090517]
   Capulli M, 2014, ARCH BIOCHEM BIOPHYS, V561, P3, DOI 10.1016/j.abb.2014.05.003
   Chen QZ, 2012, PROG BIOMATER, V1, DOI 10.1186/2194 0517 1 2
   Civitelli R, 2008, ARCH BIOCHEM BIOPHYS, V473, P188, DOI 10.1016/j.abb.2008.04.005
   Coskun F, 2009, PAK J BOT, V41, P1587
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   Dew G, 2000, CELL TISSUE RES, V299, P385, DOI 10.1007/s004419900166
   Duval K, 2017, PHYSIOLOGY, V32, P266, DOI 10.1152/physiol.00036.2016
   Feng Q, 2014, BIOMATERIALS, V35, P5028, DOI 10.1016/j.biomaterials.2014.03.012
   Franz Odendaal TA, 2006, DEV DYNAM, V235, P176, DOI 10.1002/dvdy.20603
   Gao GF, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701018
   HILL PA, 1993, BIOCHIM BIOPHYS ACTA, V1177, P71, DOI 10.1016/0167 4889(93)90159 M
   Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092 8674(00)80064 1
   Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727
   Jang J, 2016, ACS BIOMATER SCI ENG, V2, P1722, DOI 10.1021/acsbiomaterials.6b00129
   Kang HW, 2016, NAT BIOTECHNOL, V34, P312, DOI 10.1038/nbt.3413
   Karsdal MA, 2004, DNA CELL BIOL, V23, P155, DOI 10.1089/104454904322964751
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Khojasteh Arash, 2013, Iran Endod J, V8, P118
   Kostovski E, 2015, CALCIFIED TISSUE INT, V96, P145, DOI 10.1007/s00223 014 9947 3
   Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956
   Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955 0674(99)00022 8
   Nelson CM, 2008, NAT PROTOC, V3, P674, DOI 10.1038/nprot.2008.35
   Ozbolat IT, 2016, DRUG DISCOV TODAY, V21, P1257, DOI 10.1016/j.drudis.2016.04.006
   Paic F, 2009, BONE, V45, P682, DOI 10.1016/j.bone.2009.06.010
   PALUMBO C, 1986, CELL TISSUE RES, V246, P125
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Peng WJ, 2016, TRENDS BIOTECHNOL, V34, P722, DOI 10.1016/j.tibtech.2016.05.013
   Shahin Shamsabadi A, 2019, BIOFABRICATION, V11, DOI 10.1088/1758 5090/ab0798
   Sugawara Y, 2005, BONE, V36, P877, DOI 10.1016/j.bone.2004.10.008
   Uchihashi K, 2013, BONE, V52, P102, DOI 10.1016/j.bone.2012.09.001
   Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433
   Wong MK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199632
NR 40
TC 4
Z9 4
U1 1
U2 19
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
EI 2366 7478
J9 ADV BIOSYST
JI Adv. Biosyst.
PD OCT
PY 2019
VL 3
IS 10
AR 1900126
DI 10.1002/adbi.201900126
EA AUG 2019
PG 9
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA JD7IX
UT WOS:000482393400001
PM 32648722
DA 2025 08 17
ER

PT J
AU Pasqua, L
   De Napoli, IE
   De Santo, M
   Greco, M
   Catizzone, E
   Lombardo, D
   Montera, G
   Comandè, A
   Nigro, A
   Morelli, C
   Leggio, A
AF Pasqua, Luigi
   De Napoli, Ilaria Ester
   De Santo, Marzia
   Greco, Marianna
   Catizzone, Enrico
   Lombardo, Domenico
   Montera, Gabriella
   Comande, Alessandra
   Nigro, Alessandra
   Morelli, Catia
   Leggio, Antonella
TI Mesoporous silica based hybrid materials for bone specific drug delivery
SO NANOSCALE ADVANCES
LA English
DT Article
ID NANOPARTICLES; RELEASE; SYSTEM; BISPHOSPHONATES; ALENDRONATE; MCM 41
AB A mesoporous silica based drug delivery device potentially useful for bone specific drug delivery has been designed, developed and characterized starting from MSU type mesoporous silica. The proposed system consists of a mesoporous silica nanoparticles (MSN) based vehicle, presenting alendronate as a targeting functionality for bone tissue while ibuprofen is used as a model molecule for the drugs to be delivered. The particles are functionalized on the external surface using a propionitrile derivative that is successively hydrolyzed to a carboxylic group. Alendronate, one of the most used member of the diphosphonate drug class, is electrostatically bonded to the external carboxyl functionalities of mesoporous silica. The obtained material has been characterized by powder X ray diffraction, N 2 adsorption desorption porosimetry, UV vis spectrophotometry, FT IR spectrometry and MAS NMR C 13 and Si 29. Hydroxyapatite, which simulates the bone matrix, has been synthesized with the aim of testing the targeting activity of the obtained device. In a separate test, the MSNs have been loaded with ibuprofen, a non steroidal anti inflammatory drug (NSAID), and its release has been determined under neutral conditions by HPLC. Moreover, biological tests were carried out. The tested devices did not show any toxicity towards normal cells, confirming their high biocompatibility and the lack of off target effects.
C1 [Pasqua, Luigi; De Napoli, Ilaria Ester; De Santo, Marzia; Catizzone, Enrico; Montera, Gabriella] Univ Calabria, Dept Environm & Chem Engn, I 87036 Arcavacata Di Rende, Italy.
   [Greco, Marianna; Comande, Alessandra; Nigro, Alessandra; Morelli, Catia; Leggio, Antonella] Univ Calabria, Dept Pharm Hlth & Nutr Sci, I 87036 Arcavacata Di Rende, Italy.
   [Lombardo, Domenico] CNR, Ist Proc Chimicofis IPCF, Messina, Italy.
C3 University of Calabria; University of Calabria; Consiglio Nazionale
   delle Ricerche (CNR)
RP Pasqua, L (通讯作者)，Univ Calabria, Dept Environm & Chem Engn, I 87036 Arcavacata Di Rende, Italy.
EM luigi.pasqua@unical.it
RI ; Morelli, Catia/AAE 1886 2019; Catizzone, Enrico/F 1424 2018; Lombardo,
   Domenico/AAI 2816 2020
OI Morelli, Catia/0000 0002 9407 0805; Catizzone,
   Enrico/0000 0002 3962 9493; 
FU MIUR
FX The authors acknowledge the research fund from ex MIUR 60% 2014.
CR Acharya M, 2017, ACTA CHIM SLOV, V64, P45, DOI 10.17344/acsi.2016.2772
   [Anonymous], BISPHOSPHONATES BONE
   Balas F, 2006, J AM CHEM SOC, V128, P8116, DOI 10.1021/ja062286z
   Bansal G, 2005, ANGEW CHEM INT EDIT, V44, P3710, DOI 10.1002/anie.200500350
   Boanini E, 2008, BIOMATERIALS, V29, P790, DOI 10.1016/j.biomaterials.2007.10.040
   Bobo D, 2016, PHARM RES DORDR, V33, P2373, DOI 10.1007/s11095 016 1958 5
   Botella P, 2017, J CONTROL RELEASE, V247, P28, DOI 10.1016/j.jconrel.2016.12.023
   Casadonte F, 2010, CHEM EUR J, V16, P8998, DOI 10.1002/chem.201000120
   Cavallaro G, 2004, DRUG DELIV, V11, P41, DOI 10.1080/10717540490265252
   Ceresa C, 2013, CURR MED CHEM, V20, P2589, DOI 10.2174/0929867311320200007
   Colilla M, 2010, MICROPOR MESOPOR MAT, V135, P51, DOI 10.1016/j.micromeso.2010.06.010
   Erez R, 2008, BIOORG MED CHEM LETT, V18, P816, DOI 10.1016/j.bmcl.2007.11.029
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   Hirabayashi H, 2001, J CONTROL RELEASE, V70, P183, DOI 10.1016/S0168 3659(00)00355 2
   Kuljanin J, 2002, J PHARMACEUT BIOMED, V28, P1215, DOI 10.1016/S0731 7085(02)00021 3
   Morelli C, 2011, NANOSCALE, V3, P3198, DOI 10.1039/c1nr10253b
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nigro A, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040250
   Page PCB, 2001, TETRAHEDRON, V57, P1837
   Pang YX, 2003, J EUR CERAM SOC, V23, P1697, DOI 10.1016/S0955 2219(02)00413 2
   Pascaud P, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/5/054108
   Pasqua L, 2005, STUD SURF SCI CATAL, V158, P557
   Pasqua L, 2003, PHYS CHEM CHEM PHYS, V5, P640, DOI 10.1039/b209444d
   Pasqua L, 2007, MICROPOR MESOPOR MAT, V103, P166, DOI 10.1016/j.micromeso.2007.01.045
   Pasqua L, 2016, MINI REV MED CHEM, V16, P743, DOI 10.2174/1389557516666160321113620
   Pasqua L, 2013, J POROUS MAT, V20, P865, DOI 10.1007/s10934 012 9663 1
   Rehman F, 2017, MAT SCI ENG C MATER, V72, P34, DOI 10.1016/j.msec.2016.11.040
   Sarig S, 2002, J CRYST GROWTH, V237, P55, DOI 10.1016/S0022 0248(01)01850 4
   Terracciano R, 2010, TALANTA, V80, P1532, DOI 10.1016/j.talanta.2009.03.060
   Thoke S.B., 2013, J. Drug Delivery Therap., V3, P65, DOI [10.22270/jddt.v3i5.623, DOI 10.22270/JDDT.V3I5.623]
   Vall M, 2017, INT J PHARMACEUT, V524, P141, DOI 10.1016/j.ijpharm.2017.03.063
   Vallet Regi M, 2001, CHEM MATER, V13, P308, DOI 10.1021/cm0011559
NR 32
TC 31
Z9 31
U1 0
U2 26
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2516 0230
J9 NANOSCALE ADV
JI Nanoscale Adv.
PD AUG 1
PY 2019
VL 1
IS 8
BP 3269
EP 3278
DI 10.1039/c9na00249a
PG 10
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA IO0IE
UT WOS:000479061800042
PM 36133588
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tangri, S
   Hasan, N
   Kaur, J
   Fauziya
   Mohammad
   Maan, S
   Kesharwani, P
   Ahmad, FJ
AF Tangri, Sukhmeet
   Hasan, Nazeer
   Kaur, Jasmeet
   Fauziya, Saurabh
   Mohammad, Prashant
   Maan, Saurabh
   Kesharwani, Prashant
   Ahmad, Farhan Jalees
TI Drug loaded bioglass nanoparticles and their coating for efficient
   tissue and bone regeneration
SO JOURNAL OF NON CRYSTALLINE SOLIDS
LA English
DT Article
DE Bioglass nanoparticles; Coating; Tissue and bone regeneration; Drug
   delivery; Bioactive glass
ID BIOACTIVE GLASS NANOPARTICLES; IN VITRO BIOACTIVITY; HUMAN OSTEOBLASTS;
   BIOMEDICAL APPLICATIONS; SURFACE MODIFICATION; 45S5 BIOGLASS(R); IONIC
   PRODUCTS; GROWTH FACTOR; BIOMATERIALS; STRONTIUM
AB There has been a significant increase in the utilization of bioactive glass for delivery of drugs and bone tissue repair at a therapeutic norm. In this article, we illustrate recent developments in bioactive glass (BG) particles, sphere, fibre, and scaffold preparation. Mesoporous bioactive glasses (MBGs), which have advantageous qualities like superior bioactivity, better therapeutic efficacy, antimicrobial activity, biocompatibility and degradation rate, are emerging as promising standards for tissue regeneration. BG also provides the targeted delivery at site of action in a very controlled manner to increase its therapeutic efficacy with less side effects. This review aims to reporting the latest advancement in drug loaded BGNPs, which is efficiently applicable for the bone and tissue regeneration in diverse manner.
C1 [Tangri, Sukhmeet; Hasan, Nazeer; Fauziya, Saurabh; Mohammad, Prashant; Kesharwani, Prashant; Ahmad, Farhan Jalees] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmaceut, New Delhi 110062, India.
   [Kaur, Jasmeet] Jamia Hamdard, Sch Pharmaceut Educ & Res, Microbial & Pharmaceut Biotechnol Lab, New Delhi 110062, India.
   [Maan, Saurabh] BS Anangpuria Inst Pharm, Ballabhgarh Sohna Rd, Faridabad 121004, India.
   [Kesharwani, Prashant] Saveetha Univ, Saveetha Inst Med & Tech Sci, Saveetha Dent Coll, Dept Pharmacol, Chennai, India.
   [Kesharwani, Prashant; Ahmad, Farhan Jalees] Jamia Hamdard, Sch Pharmaceut Educ & Res, New Delhi 110062, India.
C3 Jamia Hamdard University; Jamia Hamdard University; Saveetha Institute
   of Medical & Technical Science; Saveetha Dental College & Hospital;
   Jamia Hamdard University
RP Kesharwani, P; Ahmad, FJ (通讯作者)，Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmaceut, New Delhi 110062, India.; Kesharwani, P; Ahmad, FJ (通讯作者)，Jamia Hamdard, Sch Pharmaceut Educ & Res, New Delhi 110062, India.
EM prashantdops@gmail.com; fjahmad@jamiahamdard.ac.in
RI ; Hassan, Nazia/ADD 3297 2022; Ahmad, Farhan/HMO 6565 2023
OI Kaur, Jasmeet/0000 0002 3438 2882; Hasan, Nazeer/0000 0002 0785 1735; 
FU Department of Science and Technology (DST), New Delhi, India; University
   Grants Commission (UGC) under the special assistance Programme II
   (SAP II); Indian Council of Medical Research (ICMR), New Delhi, India,
   through Extramural Research Grants
FX The authors would like to acknowledge the Department of Science and
   Technology (DST), New Delhi, India, for providing the financial
   assistance to Department of Pharmaceutics, Jamia Hamdard. The authors
   would also like to thank the University Grants Commission (UGC) for
   providing financial assistance under the special assistance Programme II
   (SAP II) to the department of pharmaceutics, SPER, Jamia Hamdard. The
   author (Prashant Kesharwani) acknowledges financial support from the
   Indian Council of Medical Research (ICMR), New Delhi, India, through
   Extramural Research Grants.
CR Adams CS, 2009, J ORTHOP RES, V27, P701, DOI 10.1002/jor.20815
   Ahamed J, 2023, EUR POLYM J, V193, DOI 10.1016/j.eurpolymj.2023.112111
   Ahmad S, 2022, J BIOMAT SCI POLYM E, V33, P2292, DOI 10.1080/09205063.2022.2099666
   Alcaide M, 2010, ACTA BIOMATER, V6, P892, DOI 10.1016/j.actbio.2009.09.008
   Alt V, 2011, ACTA BIOMATER, V7, P1274, DOI 10.1016/j.actbio.2010.11.012
   Amaral M, 2002, BIOMATERIALS, V23, P4897, DOI 10.1016/S0142 9612(02)00249 1
   [Anonymous], 2006, Wiley Encyclopedia of Biomedical Engineering
   Arcos D, 2010, ACTA BIOMATER, V6, P2874, DOI 10.1016/j.actbio.2010.02.012
   Asri RIM, 2017, MAT SCI ENG C MATER, V77, P1261, DOI 10.1016/j.msec.2017.04.102
   Baino F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030722
   Bekmurzayeva A, 2018, MAT SCI ENG C MATER, V93, P1073, DOI 10.1016/j.msec.2018.08.049
   Bellantone M, 2000, J BIOMED MATER RES, V51, P484, DOI 10.1002/1097 4636(20000905)51:3<484::AID JBM24>3.0.CO;2 4
   Bharati S, 2009, J EUR CERAM SOC, V29, P2527, DOI 10.1016/j.jeurceramsoc.2009.02.013
   Boccaccini AR, 2010, COMPOS SCI TECHNOL, V70, P1764, DOI 10.1016/j.compscitech.2010.06.002
   Bolelli G, 2009, J EUR CERAM SOC, V29, P2249, DOI 10.1016/j.jeurceramsoc.2009.01.032
   Bosetti M, 2005, BIOMATERIALS, V26, P3873, DOI 10.1016/j.biomaterials.2004.09.059
   Boyle KK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222034
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521 4095(199905)11:7<579::AID ADMA579>3.0.CO;2 R
   Browne M, 2000, BIOMATERIALS, V21, P385, DOI 10.1016/S0142 9612(99)00200 8
   Cannillo V, 2022, MATERIALS, V15, DOI 10.3390/ma15062194
   Carrow JK, 2015, MACROMOL CHEM PHYS, V216, P248, DOI 10.1002/macp.201400427
   Chen QZ, 2015, MAT SCI ENG R, V87, P1, DOI 10.1016/j.mser.2014.10.001
   Comesaña R, 2010, ACTA BIOMATER, V6, P953, DOI 10.1016/j.actbio.2009.08.010
   Cross LM, 2016, ACTA BIOMATER, V42, P2, DOI 10.1016/j.actbio.2016.06.023
   Dongsar TT, 2023, J DRUG DELIV SCI TEC, V82, DOI 10.1016/j.jddst.2023.104371
   Durgalakshmi D., 2014, Procedia Engineering, V92, P2, DOI 10.1016/j.proeng.2013.08.288
   Egawa S, 2020, J ORTHOP RES, V38, P843, DOI 10.1002/jor.24507
   El Kady AM, 2012, CERAM INT, V38, P177, DOI 10.1016/j.ceramint.2011.05.158
   El Sayed SAM, 2020, J DRUG DELIV SCI TEC, V57, DOI 10.1016/j.jddst.2020.101757
   Fan JP, 2014, MAT SCI ENG C MATER, V36, P206, DOI 10.1016/j.msec.2013.12.009
   Faridi AW, 2023, IND ENG CHEM RES, V62, P4494, DOI 10.1021/acs.iecr.2c00416
   Fassbender M, 2013, BONE, V55, P298, DOI 10.1016/j.bone.2013.04.018
   Fatima M, 2023, EUR POLYM J, V183, DOI 10.1016/j.eurpolymj.2022.111759
   Francis A, 2016, CERAM INT, V42, P15442, DOI 10.1016/j.ceramint.2016.06.195
   Gallardo J, 2001, J SOL GEL SCI TECHN, V21, P65, DOI 10.1023/A:1011257516468
   Gao GF, 2014, BIOTECHNOL J, V9, P1304, DOI 10.1002/biot.201400305
   García A, 2009, CHEM MATER, V21, P5474, DOI 10.1021/cm9022776
   García C, 2006, J NON CRYST SOLIDS, V352, P3488, DOI 10.1016/j.jnoncrysol.2006.02.110
   Green DL, 2003, J COLLOID INTERF SCI, V266, P346, DOI 10.1016/S0021 9797(03)00610 6
   Hasan N, 2023, INT J PHARMACEUT, V632, DOI 10.1016/j.ijpharm.2022.122580
   Hasan N, 2022, CURR ANAL CHEM, V18, P798, DOI 10.2174/1573411018666220304085236
   Hasan R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147736
   Hazari SA, 2023, INT J PHARMACEUT, V638, DOI 10.1016/j.ijpharm.2023.122938
   Hench L. L., 2015, BIOMEDICAL GLASSES, V1, P1, DOI [10.1515/bglass 2015 0001, DOI 10.1515/BGLASS 2015 0001]
   Hench L.L., 1971, Journal of Biomedical Materials Research Symposium, V36, P117, DOI DOI 10.1002/JBM.820050611
   Hench LL, 2006, J MATER SCI MATER M, V17, P967, DOI 10.1007/s10856 006 0432 z
   Hench LL, 2010, J R SOC INTERFACE, V7, pS379, DOI 10.1098/rsif.2010.0151.focus
   Hench LL, 2009, J EUR CERAM SOC, V29, P1257, DOI 10.1016/j.jeurceramsoc.2008.08.002
   Hench LL, 2002, SCIENCE, V295, P1014, DOI 10.1126/science.1067404
   Herman H, 2000, MRS BULL, V25, P17, DOI 10.1557/mrs2000.119
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Horcajada P, 2004, SOLID STATE SCI, V6, P1295, DOI 10.1016/j.solidstatesciences.2004.07.026
   Imran M, 2022, INT J PHARMACEUT, V621, DOI 10.1016/j.ijpharm.2022.121790
   Izquierdo Barba I, 2005, SOLID STATE SCI, V7, P983, DOI 10.1016/j.solidstatesciences.2005.04.003
   Jain D, 2023, J DRUG DELIV SCI TEC, V86, DOI 10.1016/j.jddst.2023.104555
   Jones JR, 2006, BIOMATERIALS, V27, P964, DOI 10.1016/j.biomaterials.2005.07.017
   Jones JR, 2016, INT J APPL GLASS SCI, V7, P423, DOI 10.1111/ijag.12252
   Jones Julian R, 2015, Acta Biomater, V23 Suppl, pS53, DOI 10.1016/j.actbio.2015.07.019
   Kargozar S, 2018, J BIOMED MATER RES B, V106, P61, DOI 10.1002/jbm.b.33814
   Kawish SM, 2022, J DRUG DELIV SCI TEC, V75, DOI 10.1016/j.jddst.2022.103693
   Kesharwani P, 2023, J DRUG DELIV SCI TEC, V80, DOI 10.1016/j.jddst.2023.104164
   Kesharwani P, 2022, BIOMIMETICS BASEL, V7, DOI 10.3390/biomimetics7040206
   Kesse X, 2020, ACS APPL BIO MATER, V3, P1312, DOI 10.1021/acsabm.0c00036
   Killinger A, 2006, SURF COAT TECH, V201, P1922, DOI 10.1016/j.surfcoat.2006.04.034
   Kim C.Y., 2005, SURFACE BIOMODIFICAT
   Kim JH, 2013, J BIOMED MATER RES A, V101, P1447, DOI 10.1002/jbm.a.34446
   KOKUBO T, 1987, J MATER SCI, V22, P4067, DOI 10.1007/BF01133359
   Labbaf S, 2011, BIOMATERIALS, V32, P1010, DOI 10.1016/j.biomaterials.2010.08.082
   Lakhkar NJ, 2009, J MATER SCI MATER M, V20, P1339, DOI 10.1007/s10856 008 3688 7
   Lanting B, 2016, JBJS REV, V4, DOI 10.2106/JBJS.RVW.15.00096
   Lao J, 2009, J MATER CHEM, V19, P2940, DOI 10.1039/b822214b
   Lemons J E, 1986, J Arthroplasty, V1, P143
   Leonova E, 2008, J PHYS CHEM C, V112, P5552, DOI 10.1021/jp7107973
   Li H, 2019, COLLOID SURFACE B, V175, P409, DOI 10.1016/j.colsurfb.2018.12.033
   LI R, 1991, J APPL BIOMATER, V2, P231, DOI 10.1002/jab.770020403
   Lusquiños F, 2005, APPL SURF SCI, V247, P486, DOI 10.1016/j.apsusc.2005.01.134
   Marie PJ, 2001, CALCIFIED TISSUE INT, V69, P121, DOI 10.1007/s002230010055
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Moojen DJF, 2009, J ORTHOP RES, V27, P710, DOI 10.1002/jor.20808
   Nadaf A, 2022, RSC ADV, V12, P23808, DOI 10.1039/d2ra02864f
   Neut D, 2015, EUR CELLS MATER, V29, P42, DOI 10.22203/eCM.v029a04
   Nie BE, 2017, COLLOID SURFACE B, V150, P183, DOI 10.1016/j.colsurfb.2016.11.034
   Nikhat A, 2022, J DRUG DELIV SCI TEC, V73, DOI 10.1016/j.jddst.2022.103447
   O'Donnell MD, 2010, ACTA BIOMATER, V6, P2382, DOI 10.1016/j.actbio.2010.01.006
   Pajares Chamorro N, 2020, ACS OMEGA, V5, P12716, DOI 10.1021/acsomega.0c00180
   Parveen N, 2023, EUR POLYM J, V190, DOI 10.1016/j.eurpolymj.2023.111993
   Parveen N, 2023, COLLOID SURFACE B, V225, DOI 10.1016/j.colsurfb.2023.113231
   Parveen N, 2023, EUR POLYM J, V184, DOI 10.1016/j.eurpolymj.2022.111781
   Rabiee SM, 2015, CERAM INT, V41, P7241, DOI 10.1016/j.ceramint.2015.02.140
   Rahaman MN, 2011, ACTA BIOMATER, V7, P2355, DOI 10.1016/j.actbio.2011.03.016
   Rau JV, 2016, MAT SCI ENG C MATER, V64, P362, DOI 10.1016/j.msec.2016.03.100
   Regi M V., 2020, Biomaterials Science, P955, DOI [10.1016/b978 0 12 816137 1.00064 7, DOI 10.1016/B978 0 12 816137 1.00064 7]
   Rehman U, 2023, EUR POLYM J, V184, DOI 10.1016/j.eurpolymj.2022.111784
   Saini M, 2015, WORLD J CLIN CASES, V3, P52, DOI 10.12998/wjcc.v3.i1.52
   Salinas AJ, 2018, WOODH PUBL SER BIOM, P337, DOI 10.1016/B978 0 08 100936 9.00014 9
   Silver IA, 2001, BIOMATERIALS, V22, P175, DOI 10.1016/S0142 9612(00)00173 3
   Sola A, 2011, SURF ENG, V27, P560, DOI 10.1179/1743294410Y.0000000008
   Soni R, 2019, MATER TODAY PROC, V15, P294, DOI 10.1016/j.matpr.2019.05.008
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021 9797(68)90272 5
   Su YC, 2019, ACTA BIOMATER, V98, P174, DOI 10.1016/j.actbio.2019.03.055
   Su YC, 2018, J MECH BEHAV BIOMED, V77, P90, DOI 10.1016/j.jmbbm.2017.08.035
   Su YC, 2016, ACS BIOMATER SCI ENG, V2, P818, DOI 10.1021/acsbiomaterials.6b00013
   Su YC, 2015, RSC ADV, V5, P56001, DOI 10.1039/c5ra10315k
   Syed M.R., 2019, BIOMED THER CLIN APP, P467, DOI [DOI 10.1016/B978 0 08 102196 5.00017 3, 10.1016/B978 0 08 102196 5.00017 3]
   Tang CY, 2006, J OPTOELECTRON ADV M, V8, P1194
   Tao J, 2020, INT J NANOMED, V15, P5855, DOI 10.2147/IJN.S247088
   Thibault MH, 2020, MAT SCI ENG C MATER, V110, DOI 10.1016/j.msec.2020.110674
   Tian XG, 2021, MAT SCI ENG C MATER, V121, DOI 10.1016/j.msec.2020.111807
   Tsigkou O, 2014, ADV HEALTHC MATER, V3, P115, DOI 10.1002/adhm.201300126
   Tsigkou O, 2009, BIOMATERIALS, V30, P3542, DOI 10.1016/j.biomaterials.2009.03.019
   Vallet Regi M, 2021, MATER TODAY BIO, V11, DOI 10.1016/j.mtbio.2021.100121
   Walter MS, 2014, DENT MATER, V30, P200, DOI 10.1016/j.dental.2013.11.006
   Wang DG, 2008, COLLOID SURFACE B, V66, P155, DOI 10.1016/j.colsurfb.2008.06.003
   Wang YD, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00283
   Wei GB, 2008, ADV FUNCT MATER, V18, P3568, DOI 10.1002/adfm.200800662
   Wu CT, 2016, ACS APPL MATER INTER, V8, P11342, DOI 10.1021/acsami.6b03100
   Wu CT, 2011, ACTA BIOMATER, V7, P1797, DOI 10.1016/j.actbio.2010.12.018
   Wu CT, 2010, BIOMATERIALS, V31, P3429, DOI 10.1016/j.biomaterials.2010.01.061
   Wu ZY, 2011, ACTA BIOMATER, V7, P1807, DOI 10.1016/j.actbio.2010.11.041
   Xie K., 2015, Biomed Glasses, V1, P80, DOI DOI 10.1515/BGLASS 2015 0008
   Xynos ID, 2000, BIOCHEM BIOPH RES CO, V276, P461, DOI 10.1006/bbrc.2000.3503
   Xynos ID, 2001, J BIOMED MATER RES, V55, P151, DOI 10.1002/1097 4636(200105)55:2<151::AID JBM1001>3.0.CO;2 D
   Yan XX, 2006, BIOMATERIALS, V27, P3396, DOI 10.1016/j.biomaterials.2006.01.043
   Yan XX, 2004, ANGEW CHEM INT EDIT, V43, P5980, DOI 10.1002/anie.200460598
   Zeng LL, 2023, MOL CANCER, V22, DOI 10.1186/s12943 022 01708 4
   Zhang T, 2020, BIOMATER SCI UK, V8, P3106, DOI 10.1039/c9bm01968e
   Zhang XD, 2016, SCI REP UK, V6, DOI 10.1038/srep19361
   Zhang Y, 2013, CERAM INT, V39, P6591, DOI 10.1016/j.ceramint.2013.01.094
   Zheng K, 2017, ADV COLLOID INTERFAC, V249, P363, DOI 10.1016/j.cis.2017.03.008
   Zheng K, 2016, RSC ADV, V6, P95101, DOI 10.1039/c6ra05548f
   Zhu M, 2014, MATER LETT, V115, P194, DOI 10.1016/j.matlet.2013.10.058
NR 131
TC 15
Z9 15
U1 9
U2 27
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022 3093
EI 1873 4812
J9 J NON CRYST SOLIDS
JI J. Non Cryst. Solids
PD SEP 15
PY 2023
VL 616
AR 122469
DI 10.1016/j.jnoncrysol.2023.122469
EA JUL 2023
PG 13
WC Materials Science, Ceramics; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA N4OJ7
UT WOS:001036822000001
OA Bronze
DA 2025 08 17
ER

PT J
AU Seefried, L
   Baumann, J
   Hemsley, S
   Hofmann, C
   Kunstmann, E
   Kiese, B
   Huang, Y
   Chivers, S
   Valentin, MA
   Borah, B
   Roubenoff, R
   Junker, U
   Jakob, F
AF Seefried, Lothar
   Baumann, Jasmin
   Hemsley, Sarah
   Hofmann, Christine
   Kunstmann, Erdmute
   Kiese, Beate
   Huang, Yue
   Chivers, Simon
   Valentin, Marie Anne
   Borah, Babul
   Roubenoff, Ronenn
   Junker, Uwe
   Jakob, Franz
TI Efficacy of anti sclerostin monoclonal antibody BPS804 in adult patients
   with hypophosphatasia
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID ENZYME REPLACEMENT THERAPY; BONE MASS; POSTMENOPAUSAL WOMEN;
   TERIPARATIDE; BISPHOSPHONATE; ROMOSOZUMAB; METABOLISM; MUTATIONS;
   REGULATOR; DOMINANCE
AB BACKGROUND. Hypophosphatasia (HPP) is a rare genetic disorder resulting in variable alterations of bone formation and mineralization that are caused by mutations in the ALPL gene, encoding the tissue nonspecific alkaline phosphatase (ALP) enzyme.
   METHODS. In this phase IIA open label, single center, intra patient, dose escalating study, adult patients with HPP received 3 ascending intravenous doses of 5, 10, and 20 mg/kg BPS804, a fully human anti sclerostin monoclonal antibody, on days 1, 15, and 29, respectively. Patients were followed for 16 weeks after the last dose. We assessed the pharmacodynamics, pharmacokinetics, preliminary efficacy, and safety of BPS804 administrations at specified intervals during treatment and follow up.
   RESULTS. Eight patients (mean age 47.8 years) were enrolled in the study (6 females, 2 males). BPS804 treatment increased mean ALP and bone specific ALP enzymatic activity between days 2 and 29. Transient increases in the bone formation markers procollagen type I N terminal propeptide (PINP), osteocalcin, and parathyroid hormone as well as a transient decrease in the bone resorption marker C telopeptide of type I collagen (CTX 1) were observed. Lumbar spine bone mineral density showed a mean increase by day 85 and at end of study. Treatment associated adverse events were mild and transient.
   CONCLUSION. BPS804 treatment was well tolerated and resulted in increases in bone formation biomarkers and bone mineral density, suggesting that sclerostin inhibition could be applied to enhance bone mineral density, stability, and regeneration in non life threatening clinical situations in adults with HPP.
C1 [Seefried, Lothar; Baumann, Jasmin; Jakob, Franz] Univ Wurzburg, Dept Orthoped, Orthoped Ctr Musculoskeletal Res, Brettreichstr 11, D 97074 Wurzburg, Germany.
   [Hemsley, Sarah; Huang, Yue; Chivers, Simon; Valentin, Marie Anne; Roubenoff, Ronenn; Junker, Uwe] Novartis Pharma AG, Novartis Inst BioMed Res, Basel, Switzerland.
   [Hofmann, Christine] Univ Wurzburg, Childrens Hosp, Wurzburg, Germany.
   [Kunstmann, Erdmute] Univ Wurzburg, Inst Human Genet, Wurzburg, Germany.
   [Kiese, Beate] Novartis Pharma AG, Basel, Switzerland.
   [Borah, Babul] Novartis Inst BioMed Res Inc, Cambridge, MA USA.
   [Huang, Yue] Merck Serono, Beijing, Peoples R China.
   [Chivers, Simon] ADC Therapeut, London, England.
   [Junker, Uwe] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Basel, Switzerland.
C3 University of Wurzburg; Novartis; University of Wurzburg; University of
   Wurzburg; Novartis; Novartis; Novartis USA; Merck KGaA; EMD Serono Inc.;
   Roche Holding
RP Seefried, L (通讯作者)，Univ Wurzburg, Dept Orthoped, Orthoped Ctr Musculoskeletal Res, Brettreichstr 11, D 97074 Wurzburg, Germany.
EM l seefried.klh@uni wuerzburg.de
RI Seefried, Lothar/AAU 2169 2021; Jakob, Franz/D 8526 2015
OI Roubenoff, Ronenn/0000 0002 3959 3179; Seefried,
   Lothar/0000 0003 1154 3388
CR Anderson HC, 2004, AM J PATHOL, V164, P841, DOI 10.1016/S0002 9440(10)63172 0
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Barvencik F, 2011, OSTEOPOROSIS INT, V22, P2667, DOI 10.1007/s00198 011 1528 y
   Benisch P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045142
   Camacho Pauline M, 2008, Endocr Pract, V14, P204
   Carroll SH, 2012, J BIOL CHEM, V287, P15718, DOI 10.1074/jbc.M112.344994
   Doshi KB, 2009, CLIN CASES MINER BON, V6, P266
   Fauvert D, 2009, BMC MED GENET, V10, DOI 10.1186/1471 2350 10 51
   Gagnon C, 2010, J CLIN ENDOCR METAB, V95, P1007, DOI 10.1210/jc.2009 1965
   He WJ, 2013, FASEB J, V27, P3446, DOI 10.1096/fj.13 231233
   Hofmann C, 2014, EUR J HUM GENET, V22, P1160, DOI 10.1038/ejhg.2014.10
   Kaunitz JD, 2008, J CELL BIOCHEM, V105, P655, DOI 10.1002/jcb.21885
   Laroche M, 2012, CALCIFIED TISSUE INT, V90, P250, DOI 10.1007/s00223 011 9562 5
   Lewiecki EM, 2014, THER ADV MUSCULOSKEL, V6, P48, DOI 10.1177/1759720X13510479
   Lewiecki EM, 2011, DISCOV MED, V12, P263
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lia Baldini AS, 2008, HUM GENET, V123, P429, DOI 10.1007/s00439 008 0480 1
   Lia Baldini AS, 2001, HUM GENET, V109, P99, DOI 10.1007/s004390100546
   Liedert A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103250
   Linder CH, 2009, BONE, V45, P987, DOI 10.1016/j.bone.2009.07.009
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McColm J, 2014, J BONE MINER RES, V29, P935, DOI 10.1002/jbmr.2092
   McKiernan FE, 2014, J BONE MINER RES, V29, P1651, DOI 10.1002/jbmr.2178
   Mentrup B, 2011, BONE, V48, P1401, DOI 10.1016/j.bone.2011.03.676
   Millán JL, 2008, J BONE MINER RES, V23, P777, DOI 10.1359/JBMR.071213
   Millán JL, 2016, CALCIFIED TISSUE INT, V98, P398, DOI 10.1007/s00223 015 0079 1
   Mornet E, 2008, BEST PRACT RES CL RH, V22, P113, DOI 10.1016/j.berh.2007.11.003
   Müller HL, 2000, J CLIN ENDOCR METAB, V85, P743, DOI 10.1210/jc.85.2.743
   Orriss IR, 2012, BONE, V51, P389, DOI 10.1016/j.bone.2012.06.013
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Schalin Jäntti C, 2010, J CLIN ENDOCR METAB, V95, P5174, DOI 10.1210/jc.2010 1168
   Seefried L, 2014, J BONE MINER RES S1, V29
   Silvent J, 2014, J BIOL CHEM, V289, P24168, DOI 10.1074/jbc.M114.576843
   Sutton RAL, 2012, J BONE MINER RES, V27, P987, DOI 10.1002/jbmr.1565
   Thouverey C, 2009, OSTEOARTHR CARTILAGE, V17, P64, DOI 10.1016/j.joca.2008.05.020
   Veverka V, 2009, J BIOL CHEM, V284, P10890, DOI 10.1074/jbc.M807994200
   Wang N, 2013, J BONE MINER RES, V28, P1446, DOI 10.1002/jbmr.1877
   Wehmeyer C, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aac4351
   Whyte MP, 2007, J CLIN ENDOCR METAB, V92, P1203, DOI 10.1210/jc.2006 1902
   Whyte MP, 2016, J CLIN ENDOCR METAB, V101, P333, DOI 10.1210/jc.2015 3462
   Whyte MP, 2012, NEW ENGL J MED, V366, P904, DOI 10.1056/NEJMoa1106173
   Whyte MP, 2012, B GROUP INT RECH SCI, V51, pe35
   Yorgan TA, 2015, J BONE MINER RES, V30, P1175, DOI 10.1002/jbmr.2461
NR 44
TC 56
Z9 59
U1 1
U2 11
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUN 1
PY 2017
VL 127
IS 6
BP 2148
EP 2158
DI 10.1172/JCI83731
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EW6LC
UT WOS:000402620800015
PM 28436937
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Shin, YK
   Heo, JH
   Lee, JY
   Park, YJ
   Cho, SR
AF Shin, Yoon Kyum
   Heo, Jeong Hyun
   Lee, Jue Yeon
   Park, Yoon Jeong
   Cho, Sung Rae
TI Collagen binding peptide reverses bone loss in a mouse model of cerebral
   palsy based on clinical databases
SO ANNALS OF PHYSICAL AND REHABILITATION MEDICINE
LA English
DT Article
DE Cerebral palsy; Bone loss; Osteopontin; Collagen binding peptide; Bone
   formation
ID OSTEOGENESIS IN VITRO; MINERAL DENSITY; RISK FACTORS; OSTEOPOROSIS;
   CHILDREN; ADULTS; OSTEOPONTIN; DIFFERENTIATION; TERIPARATIDE;
   BISPHOSPHONATES
AB Background: Individuals with cerebral palsy (CP) experience bone loss due to impaired weight bearing. Despite serious complications, there is no standard medication.
   Objective: To develop a new pharmacological agent, we performed a series of studies. The primary aim was to develop an animal model of CP to use our target medication based on transcriptome analysis of individuals with CP. The secondary aim was to show the therapeutic capability of collagen binding peptide (CBP) in reversing bone loss in the CP mouse model.
   Methods: A total of 119 people with CP and 13 healthy adults participated in the study and 140 mice were used for the behavioral analysis and discovery of therapeutic effects in the preclinical study. The mouse model of CP was induced by hypoxic ischemic brain injury. Inclusion and exclusion criteria were established for CBP medication in the CP mouse model with bone loss.
   Results: On the basis of clinical outcomes showing insufficient mechanical loading from non ambulatory function and that underweight mainly affects bone loss in adults with CP, we developed a mouse model of CP with bone loss. Injury severity and body weight mainly affected bone loss in the CP mouse model. Transcriptome analysis showed SPP1 expression downregulated in adults with CP who showed lower bone density than healthy controls. Therefore, a synthesized CBP was administered to the mouse model. Trabecular thickness, total collagen and bone turnover activity increased with CBP treatment as compared with the saline control. Immunohistochemistry showed increased immunoreactivity of runt related transcription factor 2 and osteocalcin, so the CBP participated in osteoblast differentiation.
   Conclusions: This study can provide a scientific basis for a promising translational approach for developing new anabolic CBP medication to treat bone loss in individuals with CP. (C) 2020 The Authors. Published by Elsevier Masson SAS.
C1 [Shin, Yoon Kyum; Heo, Jeong Hyun; Cho, Sung Rae] Yonsei Univ, Coll Med, Dept & Res Inst Rehabil Med, 50 1,Yonsei Ro, Seoul 03722, South Korea.
   [Shin, Yoon Kyum; Cho, Sung Rae] Yonsei Univ, Coll Med, Brain Korea 21 PLUS Project Med Sci, Seoul 03722, South Korea.
   [Heo, Jeong Hyun; Cho, Sung Rae] Yonsei Univ, Coll Med, Grad Program NanoSci & Technol, Seoul 03722, South Korea.
   [Cho, Sung Rae] Yonsei Univ, Coll Med, Rehabil Inst Neuromuscular Dis, Seoul 03722, South Korea.
   [Lee, Jue Yeon; Park, Yoon Jeong] Nano Intelligent Biomed Engn Corp NIBEC, Cent Res Inst, Seoul 03080, South Korea.
   [Park, Yoon Jeong] Seoul Natl Univ, Sch Dent, Dept Dent Regenerat Biotechnol, Seoul 03080, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System; Yonsei University; Yonsei University
   Health System; Yonsei University; Yonsei University Health System; Seoul
   National University (SNU)
RP Cho, SR (通讯作者)，Yonsei Univ, Coll Med, Dept & Res Inst Rehabil Med, 50 1,Yonsei Ro, Seoul 03722, South Korea.
EM srcho918@yuhs.ac
RI Lee, Sang Jin/S 4056 2019
OI Cho, Sung Rae/0000 0003 1429 2684
FU National Research Foundation   Ministry of Education, Republic of Korea
   [NRF 2017R1D1A1B03028855, 2020R1I1A1A01071167]
FX The study was supported by the National Research Foundation
   (NRF2017R1D1A1B03028855; 2020R1I1A1A01071167) funded by the Ministry of
   Education, Republic of Korea. The CBP was provided by Nano Intelligent
   Biomedical Engineering Corporation (NIBEC) , Seoul National University,
   Republic of Korea. The authors thank Medical Illustration & Design, a
   part of the Medical Research Support Services of Yonsei University
   College of Medicine, for helping with illustrations related to the
   graphical abstract.
CR Balkaya M, 2013, J CEREBR BLOOD F MET, V33, P330, DOI 10.1038/jcbfm.2012.185
   Boyce AM, 2014, PM&R, V6, P427, DOI 10.1016/j.pmrj.2013.10.009
   Cohen M, 2009, J CHILD NEUROL, V24, P959, DOI 10.1177/0883073809332401
   DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332
   Dwan K, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005088.pub3
   Gajdosik Carrie Giller, 2001, Physical and Occupational Therapy in Pediatrics, V21, P49, DOI 10.1300/J006v21n04_04
   Gatti D, 2013, CALCIFIED TISSUE INT, V93, P448, DOI 10.1007/s00223 013 9770 2
   Gennaro M, 2019, NEURAL PLAST, V2019, DOI 10.1155/2019/5089321
   Giachelli CM, 2000, MATRIX BIOL, V19, P615, DOI 10.1016/S0945 053X(00)00108 6
   Haas AV, 2018, J ENDOCR SOC, V2, P922, DOI 10.1210/js.2018 00118
   Henderson RC, 2004, DEV MED CHILD NEUROL, V46, P416, DOI 10.1017/S0012162204000672
   Henderson RC, 2002, J PEDIATR US, V141, P644, DOI 10.1067/mpd.2002.128207
   Henderson RC, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e5
   Houlihan CM, 2014, J PEDIATR REHAB MED, V7, P143, DOI 10.3233/PRM 140283
   Houlihan CM, 2009, PHYS MED REH CLIN N, V20, P493, DOI 10.1016/j.pmr.2009.04.004
   Jakob F, 2012, EUR J ENDOCRINOL, V166, P87, DOI 10.1530/EJE 11 0740
   Jilka RL, 2013, J GERONTOL A BIOL, V68, P1209, DOI 10.1093/gerona/glt046
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim M, 2017, JOVE J VIS EXP, DOI 10.3791/55838
   Kim W, 2015, BONE, V71, P89, DOI 10.1016/j.bone.2014.10.003
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Lee JY, 2007, BIOMATERIALS, V28, P4257, DOI 10.1016/j.biomaterials.2007.05.040
   Lee JY, 2007, BIOCHEM BIOPH RES CO, V357, P68, DOI 10.1016/j.bbrc.2007.03.106
   Manuele S, 2007, ARCH GERONTOL GERIAT, V44, P249, DOI 10.1016/j.archger.2007.01.034
   Marciniak C, 2016, OSTEOPOROSIS INT, V27, P1477, DOI 10.1007/s00198 015 3393 6
   Modlesky CM, 2015, OSTEOPOROSIS INT, V26, P505, DOI 10.1007/s00198 014 2873 4
   OOMS ME, 1993, J BONE MINER RES, V8, P669
   Park YS, 2014, BIOMATERIALS, V35, P9747, DOI 10.1016/j.biomaterials.2014.08.007
   Real J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118178
   Rumajogee P, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00057
   Saito K, 2016, J DENT RES, V95, P1034, DOI 10.1177/0022034516645333
   Scheinberg MA, 2015, EINSTEIN SAO PAULO, V13, P555, DOI 10.1590/S1679 45082015AO3321
   Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001
   Sheridan KJ, 2009, DEV MED CHILD NEUROL, V51, P38, DOI 10.1111/j.1469 8749.2009.03432.x
   Shin MK, 2008, CELL SIGNAL, V20, P613, DOI 10.1016/j.cellsig.2007.11.012
   Shin YK, 2017, BONE, V103, P302, DOI 10.1016/j.bone.2017.07.015
   Trinh A, 2018, BONE, V117, P1, DOI 10.1016/j.bone.2018.09.001
   van der Sluis IM, 2001, J PEDIATR ENDOCR MET, V14, P817
   Whitney DG, 2019, J BONE MINER RES, V34, P1240, DOI 10.1002/jbmr.3694
   Yoon YK, 2012, ANN REHABIL MED ARM, V36, P770, DOI 10.5535/arm.2012.36.6.770
   Zhang Ping, 2008, Genomics Proteomics & Bioinformatics, V6, P4, DOI 10.1016/S1672 0229(08)60016 9
   ZHANG RW, 1995, J BONE MINER RES, V10, P415
   Zhou J, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00103
   Zhou S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128846
NR 44
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 1877 0657
EI 1877 0665
J9 ANN PHYS REHABIL MED
JI Ann. Phys. Rehabil. Med.
PD MAY
PY 2021
VL 64
IS 3
SI SI
AR 101445
DI 10.1016/j.rehab.2020.09.009
EA MAY 2021
PG 9
WC Rehabilitation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rehabilitation
GA SF3NG
UT WOS:000652665400013
PM 33130040
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Nicol, L
   Wang, Y
   Smith, R
   Sloan, J
   Nagamani, SCS
   Shapiro, J
   Lee, B
   Orwoll, E
AF Nicol, Lindsey
   Wang, Ying
   Smith, Rosamund
   Sloan, John
   Nagamani, Sandesh C. S.
   Shapiro, Jay
   Lee, Brendan
   Orwoll, Eric
TI Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta:
   Comparison With Normal Individuals and Response to Teriparatide Therapy
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE SCLEROSTIN (SOST); OSTEOGENESIS IMPERFECTA; TERIPARATIDE
ID POSTMENOPAUSAL WOMEN; PARATHYROID HORMONE; CIRCULATING SCLEROSTIN; MOUSE
   MODEL; TRANSCRIPTION FACTORS; BONE; OSTEOPOROSIS; SOST; ANTIBODY;
   ASSOCIATION
AB Sclerostin (SOST), a glycoprotein primarily derived from osteocytes, is an important regulator of bone remodeling. Osteogenesis imperfecta (OI) is a heritable disorder of bone characterized by low bone mass, bone fragility, recurrent fractures, and bone deformities. Altered SOST mediated signaling may have a role in pathogenesis of type I collagen related OI; however, this has not been evaluated in humans. We measured serum SOST levels in adults with OI who were enrolled in a randomized, placebo controlled clinical trial that evaluated the effects of osteoanabolic therapy with teriparatide. Compared with age  and sex matched control participants, mean SOST levels were lower in those with type I or types III/VI OI (p<0.0001). Receiver operating curve analysis revealed that sclerostin alone or sclerostin plus bone mineral content discriminated patients with OI from controls (area under the curve 0.80 and 0.87, respectively). SOST levels increased in the group of patients with type I OI during therapy with teriparatide (compared with placebo, p=0.01). The increase was significant at 6, 12, and 24 months of therapy (p0.02) and was apparent as early as 3 months (p=0.06). The magnitude of increases in SOST levels during therapy was inversely correlated with increases in vertebral volumetric bone mineral density (vBMD). Overall, these results suggest that: 1) SOST regulation is fundamentally altered in osteogenesis imperfecta; 2) serum SOST levels could be a biomarker of OI in adults; and 3) alterations in SOST may help predict the response to anabolic therapies in OI. (c) 2017 American Society for Bone and Mineral Research.
C1 [Nicol, Lindsey] Oregon Hlth & Sci Univ, Div Endocrinol, Dept Pediat, Portland, OR 97201 USA.
   [Wang, Ying] Oregon Hlth & Sci Univ, Div Biostat, Dept Med, Portland, OR 97201 USA.
   [Smith, Rosamund; Sloan, John] Lilly Res Labs, Indianapolis, IN USA.
   [Nagamani, Sandesh C. S.; Lee, Brendan] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Nagamani, Sandesh C. S.; Lee, Brendan] Texas Childrens Hosp, Houston, TX 77030 USA.
   [Shapiro, Jay] Kennedy Krieger Inst, Dept Bone & Osteogenesis Imperfecta, Baltimore, MD USA.
   [Orwoll, Eric] Oregon Hlth & Sci Univ, Dept Med, Div Endocrinol, Portland, OR 97201 USA.
C3 Oregon Health & Science University; Oregon Health & Science University;
   Eli Lilly; Lilly Research Laboratories; Baylor College of Medicine;
   Baylor College of Medicine; Baylor College Medical Hospital; Kennedy
   Krieger Institute; Oregon Health & Science University
RP Nicol, L (通讯作者)，707 SW Gaines St, Portland, OR USA.
EM nicol@ohsu.edu
OI Nagamani, Sandesh/0000 0001 6818 7367
FU Mereo
FX Lindsey Nicol, Ying Wang, Sandesh Nagamani, and Brendan Lee have no
   conflicts of interest to disclose. Rosamund Smith is a former employee
   of Eli Lilly and owns Lilly stock. John Sloan is an employee of Eli
   Lilly and owns Lilly stock. Eric Orwoll is a research consultant for Eli
   Lilly and is a co investigator for a clinical study sponsored by Mereo.
   Jay Shapiro is a medical consultant for Mereo.
CR Amrein K, 2012, J CLIN ENDOCR METAB, V97, P148, DOI 10.1210/jc.2011 2152
   Arasu A, 2012, J CLIN ENDOCR METAB, V97, P2027, DOI 10.1210/jc.2011 3419
   Ardawi MSM, 2012, J BONE MINER RES, V27, P2592, DOI 10.1002/jbmr.1718
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Carriero A, 2014, BONE, V61, P116, DOI 10.1016/j.bone.2013.12.020
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Costa AG, 2017, BONE, V96, P24, DOI 10.1016/j.bone.2016.10.012
   Crawford RP, 2003, BONE, V33, P744, DOI 10.1016/S8756 3282(03)00210 2
   Delgado Calle J, 2017, BONE, V96, P29, DOI 10.1016/j.bone.2016.10.007
   Drake MT, 2017, BONE, V96, P8, DOI 10.1016/j.bone.2016.12.004
   Drake MT, 2010, J CLIN ENDOCR METAB, V95, P5056, DOI 10.1210/jc.2010 0720
   Durosier C, 2013, J CLIN ENDOCR METAB, V98, P3873, DOI 10.1210/jc.2013 2113
   Forlino A, 2016, LANCET, V387, P1657, DOI 10.1016/S0140 6736(15)00728 X
   Fujiwara M, 2016, BONE, V85, P91, DOI 10.1016/j.bone.2016.01.024
   Galea GL, 2017, BONE, V96, P38, DOI 10.1016/j.bone.2016.10.008
   Glorieux FH, 2017, J BONE MINER RES, V32, P1496, DOI 10.1002/jbmr.3143
   Grafe I, 2016, J BONE MINER RES, V31, P1030, DOI 10.1002/jbmr.2776
   Grafel I, 2014, NAT MED, V20, P670, DOI 10.1038/nm.3544
   Gudmann NS, 2014, INT J MOL SCI, V15, P18789, DOI 10.3390/ijms151018789
   Jacobsen CM, 2014, J BONE MINER RES, V29, P2297, DOI 10.1002/jbmr.2198
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Jones SJ, 1999, CALCIFIED TISSUE INT, V64, P8, DOI 10.1007/s002239900571
   Kalajzic I, 2002, ENDOCRINOLOGY, V143, P1594, DOI 10.1210/en.143.5.1594
   Keaveny TM, 2007, J BONE MINER RES, V22, P149, DOI 10.1359/JBMR.061011
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kirmani S, 2012, OSTEOPOROSIS INT, V23, P1123, DOI 10.1007/s00198 011 1669 z
   Kocijan R, 2014, J CLIN ENDOCR METAB, V99, pE311, DOI 10.1210/jc.2013 2244
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Li HT, 2010, AM J PATHOL, V176, P2405, DOI 10.2353/ajpath.2010.090704
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Little DG, 2017, BONE, V101, P96, DOI 10.1016/j.bone.2017.04.016
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Mirza FS, 2010, J CLIN ENDOCR METAB, V95, P1991, DOI 10.1210/jc.2009 2283
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Morse LR, 2012, J BONE MINER RES, V27, P352, DOI 10.1002/jbmr.546
   Ominsky MS, 2017, BONE, V96, P63, DOI 10.1016/j.bone.2016.10.019
   Orwoll ES, 2014, J CLIN INVEST, V124, P491, DOI 10.1172/JCI71101
   Palomo T, 2014, J CLIN ENDOCR METAB, V99, pE920, DOI 10.1210/jc.2013 3852
   Piemonte S, 2012, J ENDOCRINOL INVEST, V35, P866, DOI 10.3275/8522
   Rauch F, 2000, BONE, V26, P581, DOI 10.1016/S8756 3282(00)00269 6
   Reppe S, 2015, J BONE MINER RES, V30, P249, DOI 10.1002/jbmr.2342
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Sarathchandra P, 2000, J PATHOL, V192, P385
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   Sinder BP, 2013, J BONE MINER RES, V28, P73, DOI 10.1002/jbmr.1717
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   van Lierop AH, 2010, EUR J ENDOCRINOL, V163, P833, DOI 10.1530/EJE 10 0699
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Yu EW, 2011, J CLIN ENDOCR METAB, V96, pE1848, DOI 10.1210/jc.2011 1534
NR 51
TC 14
Z9 15
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2018
VL 33
IS 2
BP 307
EP 315
DI 10.1002/jbmr.3312
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FV9GS
UT WOS:000424896500014
PM 29044725
OA Bronze
DA 2025 08 17
ER

PT J
AU Shi, C
   Cheng, WN
   Wang, Y
   Li, DZ
   Zhu, YC
   Zhou, LN
   Zhou, XZ
AF Shi, Ce
   Cheng, Wei Nan
   Wang, Yin
   Li, Da Zhuang
   Zhu, Yu Cheng
   Zhou, Li Na
   Zhou, Xiao Zhong
TI p38γ overexpression promotes osteosarcoma cell progression
SO AGING US
LA English
DT Article
DE osteosarcoma; p38 gamma; molecularly targeted therapy
ID CYCLIN E1; IN VITRO; OSTEOBLASTS; EXPRESSION
AB Osteosarcoma (OS) is the most common primary bone malignancy in the adolescent population. Recent studies demonstrate that p38 gamma (p38 gamma) phosphorylates retinoblastoma (Rb) to promote cyclin expression, cell cycle entry and tumorigenesis. Studying the potential function of p38 gamma in human OS, we show that p38 gamma mRNA and protein expression are significantly elevated in OS tissues and OS cells, whereas its expression is relatively low in normal bone tissue and in human osteoblasts/osteoblastic cells. Knockdown of p38 gamma in established (U2OS) and primary human OS cells potently inhibited cell growth, proliferation, migration and invasion, while promoting cell apoptosis. Furthermore, CRISPR/Cas9 induced p38 gamma knockout inhibited human OS cell progression in vitro. Conversely, ectopic overexpression of p38 gamma in primary human OS cells augmented cell growth, proliferation and migration. Signaling studies show that retinoblastoma (Rb) phosphorylation and cyclin E1/cyclin A expression were decreased following p38 gamma shRNA knockdown and knockout, but increased after ectopic p38 gamma overexpression. Collectively, these results show that p38 gamma overexpression promotes human OS cell progression.
C1 [Shi, Ce; Li, Da Zhuang; Zhou, Xiao Zhong] Soochow Univ, Dept Orthoped, Affiliated Hosp 2, Suzhou, Peoples R China.
   [Shi, Ce; Zhu, Yu Cheng] Xuzhou Med Univ, Dept Orthoped, Affiliated Sugian Hosp, Sugian, Peoples R China.
   [Cheng, Wei Nan] Xiamen Univ, Dept Orthoped, Affiliated Hosp 1, Xiamen, Peoples R China.
   [Wang, Yin] Soochow Univ, Jiangsu Key Lab Neuropsychiat Dis, Suzhou, Peoples R China.
   [Wang, Yin] Soochow Univ, Inst Neurosci, Suzhou, Peoples R China.
   [Zhou, Li Na] Jiangsu Univ, Dept Radiotherapy & Oncol, Affiliated Kunshan Hosp, Kunshan, Peoples R China.
C3 Soochow University   China; Xuzhou Medical University; Xiamen
   University; Soochow University   China; Soochow University   China;
   Jiangsu University
RP Zhou, XZ (通讯作者)，Soochow Univ, Dept Orthoped, Affiliated Hosp 2, Suzhou, Peoples R China.; Zhu, YC (通讯作者)，Xuzhou Med Univ, Dept Orthoped, Affiliated Sugian Hosp, Sugian, Peoples R China.; Zhou, LN (通讯作者)，Jiangsu Univ, Dept Radiotherapy & Oncol, Affiliated Kunshan Hosp, Kunshan, Peoples R China.
EM zhusuqianor9@163.com; zhoulinaks@163.com; zhouxz@suda.edu.cn
FU National Natural Science Foundation of China [81171712, 81873995,
   81773192]; Social development program of Jiangsu province [BE2019662];
   Gusu medical talents program of Suzhou [20015]; Health commission of
   Jiangsu province [H2017066]; Foundation of Tumor Clinical and Basic
   Research Team of Affiliated Kunshan Hospital of Jiangsu University
   [KYC005]; Kunshan Science and Technology Program [KS1528, KS18057];
   Jiangsu University Clinical Medical Science and Technology Development
   Fund [JLY20180012]; Natural Science Foundation of Jiangsu Province
   [BK20171248, BK20151213, SBK2019040088]; Key laboratory of spinal cord
   injury repair of Suzhou [SZS201807]
FX The study was supported by the National Natural Science Foundation of
   China (81171712, 81873995 and 81773192), Social development program of
   Jiangsu province (BE2019662), Gusu medical talents program of Suzhou
   (20015), Health commission of Jiangsu province (H2017066), Foundation of
   Tumor Clinical and Basic Research Team of Affiliated Kunshan Hospital of
   Jiangsu University (KYC005), Kunshan Science and Technology Program
   (KS1528 and KS18057), Jiangsu University Clinical Medical Science and
   Technology Development Fund (JLY20180012), and by Natural Science
   Foundation of Jiangsu Province (BK20171248, BK20151213 and
   SBK2019040088), Key laboratory of spinal cord injury repair of Suzhou
   (SZS201807).
CR Anderson ME, 2016, ORTHOP CLIN N AM, V47, P283, DOI 10.1016/j.ocl.2015.08.022
   Anninga JK, 2011, EUR J CANCER, V47, P2431, DOI 10.1016/j.ejca.2011.05.030
   [Anonymous], 2019, CANC DISCOV, DOI DOI 10.1158/2159 8290.CD RW2019 061
   Bishop MW, 2016, CURR OPIN PEDIATR, V28, P26, DOI 10.1097/MOP.0000000000000298
   CARBONAROHALL D, 1993, ONCOGENE, V8, P1649
   Chen WZ, 2018, BIOCHEM BIOPH RES CO, V499, P913, DOI 10.1016/j.bbrc.2018.04.019
   Chen XF, 2019, BIOCHEM BIOPH RES CO, V516, P466, DOI 10.1016/j.bbrc.2019.06.056
   Cheng L, 2016, CURR PHARM DESIGN, V22, P4830, DOI 10.2174/1381612822666160512151028
   Cuenda A, 2017, TRENDS BIOCHEM SCI, V42, P431, DOI 10.1016/j.tibs.2017.02.008
   Denduluri Sahitya K, 2015, J Biomed Res, V30, DOI 10.7555/JBR.29.20150075
   Fan JB, 2019, MOL CELL BIOCHEM, V460, P113, DOI 10.1007/s11010 019 03575 y
   Fan JB, 2016, ONCOTARGET, V7, P70613, DOI 10.18632/oncotarget.12138
   Fei HD, 2017, ONCOTARGET, V8, P49646, DOI 10.18632/oncotarget.17911
   Guo SG, 2017, BIOCHEM BIOPH RES CO, V487, P660, DOI 10.1016/j.bbrc.2017.04.111
   He JP, 2014, ASIAN PAC J CANCER P, V15, P5967, DOI 10.7314/APJCP.2014.15.15.5967
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Li G, 2019, AGING US, V11, P8526, DOI 10.18632/aging.102336
   Li Z. W., 2016, Oncotarget, V5, P1, DOI DOI 10.18632/ONCOTARGET.10995
   Lockwood WW, 2011, J MOL DIAGN, V13, P289, DOI 10.1016/j.jmoldx.2010.11.020
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Molendini L, 1998, INT J ONCOL, V12, P1007
   Sayles LC, 2019, CANCER DISCOV, V9, P46, DOI 10.1158/2159 8290.CD 17 1152
   Su C, 2019, BIOCHEM BIOPH RES CO, V517, P172, DOI 10.1016/j.bbrc.2019.07.038
   Tomás Loba A, 2019, NATURE, V568, P557, DOI 10.1038/s41586 019 1112 8
   Wang J, 2014, TUMOR BIOL, V35, P4859, DOI 10.1007/s13277 014 1637 2
   Wu CC, 2010, PROTEIN CELL, V1, P573, DOI 10.1007/s13238 010 0075 1
   Yang K, 2013, SCI REP UK, V3, DOI 10.1038/srep02089
   Zhang XY, 2018, BIOCHEM BIOPH RES CO, V503, P2255, DOI 10.1016/j.bbrc.2018.06.146
   Zhao J, 2020, CANCER LETT, V474, P158, DOI 10.1016/j.canlet.2020.01.020
   Zhao LP, 2013, NEUROCHEM RES, V38, P705, DOI 10.1007/s11064 013 0968 5
   Zhao S, 2017, ONCOTARGET, V8, P104867, DOI 10.18632/oncotarget.20452
   Zhou LN, 2019, AGING US, V11, P11136, DOI 10.18632/aging.102515
   Zhou WY, 2014, DISCOV MED, V17, P301
   Zhu CY, 2019, BIOCHEM BIOPH RES CO, V516, P645, DOI 10.1016/j.bbrc.2019.06.073
   Zuo Y, 2018, CELL PHYSIOL BIOCHEM, V45, P1840, DOI 10.1159/000487875
NR 35
TC 8
Z9 9
U1 1
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD SEP 30
PY 2020
VL 12
IS 18
BP 18384
EP 18395
DI 10.18632/aging.103708
PG 12
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA OD4OV
UT WOS:000579832800001
PM 32970611
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, Y
   Chen, HY
   Zhang, HY
AF Wang, Yang
   Chen, Hongyu
   Zhang, Hanyang
TI 被撤回的出版物: Kaempferol promotes proliferation, migration and
   differentiation of MC3T3 E1 cells via up regulation of microRNA 101
   (Retracted article. See vol. 49, pg. 157, 2021)
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article; Retracted Publication
DE Fracture healing; osteoblast; Kaempferol; microRNA 101; Wnt/beta catenin
   pathway
ID CATENIN; EXPRESSION; OSTEOBLAST; MEMBRANE; MEDICINE; FRACTURE
AB Osteoblast has been found to exert indispensable functions during fracture healing. This study aimed to investigate the effects of kaempferol, a natural flavonoid compound, on osteoblast proliferation, migration and differentiation, as well as possible molecular mechanisms. qRT PCR was performed to measure the expression level of microRNA 101 (miR 101). Cell viability and migration were respectively assessed using cell counting kit 8 (CCK 8) assay and two chamber migration assay. Relative alkaline phosphatase (ALP) activity was evaluated using p nitrophenyl phosphate (pNPP) as substrate. Western blotting was used to detect the protein expression levels of key molecules involved in cell proliferation, migration, differentiation, and Wnt/beta catenin pathway. Kaempferol treatment significantly promoted MC3T3 E1 cell proliferation, migration, and differentiation. Mechanistically, kaempferol notably enhanced the expression level of miR 101 in MC3T3 E1 cells. Knockdown of miR 101 obviously weakened the promoting effects of kaempferol on MC3T3 E1 cell proliferation, migration, and differentiation. In addition, kaempferol remarkably activated Wnt/beta catenin pathway in MC3T3 E1 cells via up regulating miR 101. This research further confirmed the promoting effects of kaempferol on osteoblast proliferation, migration, and differentiation. The up regulation of miR 101 and activation of Wnt/beta catenin pathway caused by kaempferol play critical roles in the promoting effects of kaempferol on osteoblast proliferation, migration, and differentiation.
C1 [Wang, Yang] Jilin Univ, China Japan Union Hosp, Dept Orthopaed, Changchun, Jilin, Peoples R China.
   [Chen, Hongyu] Qingdao West Coast New Area Cent Hosp, Dept Orthopaed, Qingdao, Shandong, Peoples R China.
   [Wang, Yang; Zhang, Hanyang] Jilin Univ, Hosp 2, Dept Orthopaed, 218 Ziqiang St, Changchun, Jilin, Peoples R China.
C3 Jilin University; Jilin University
RP Wang, Y (通讯作者)，Jilin Univ, Hosp 2, Dept Orthopaed, 218 Ziqiang St, Changchun, Jilin, Peoples R China.
EM zhanghanyang0006@sina.com
RI ; chen, hongyu/HHS 4314 2022
OI Weeks, Jason/0000 0001 5537 6927; 
CR Al Numair KS, 2015, PHARM BIOL, V53, P1372, DOI 10.3109/13880209.2014.982301
   Chen MQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109214
   Chiou WF, 2011, LIFE SCI, V88, P335, DOI 10.1016/j.lfs.2010.12.009
   Chun Lei LI, 2014, CHINESE J CONSERV DE, V5, P1340
   Devi KP, 2015, PHARMACOL RES, V99, P1, DOI 10.1016/j.phrs.2015.05.002
   Fazzalari NL, 2011, OSTEOPOROSIS INT, V22, P2003, DOI 10.1007/s00198 011 1611 4
   Gewirtz AM, 2007, J CLIN INVEST, V117, P3612, DOI 10.1172/JCI34274
   Ghiasi Mohammad S, 2017, Bone Rep, V6, P87, DOI 10.1016/j.bonr.2017.03.002
   Giganti MG, 2014, FRONT BIOSCI LANDMRK, V19, P1162, DOI 10.2741/4273
   Guo AJ, 2012, CHIN MED UK, V7, DOI 10.1186/1749 8546 7 10
   Guo JM, 2007, CANCER BIOL THER, V6, P85, DOI 10.4161/cbt.6.1.3553
   Hammond SM, 2015, ADV DRUG DELIVER REV, V87, P3, DOI 10.1016/j.addr.2015.05.001
   He ZH, 2012, J AGR FOOD CHEM, V60, P11309, DOI 10.1021/jf304169j
   Heo JS, 2010, MOL CELLS, V30, P449, DOI 10.1007/s10059 010 0139 3
   Hofmann A, 2009, ORTHOPADE, V38, P1009, DOI 10.1007/s00132 009 1488 5
   Huh MI, 2007, J CELL BIOCHEM, V101, P1222, DOI 10.1002/jcb.21246
   Ish Shalom S, 2010, METHODS MOL BIOL, V638, P103, DOI 10.1007/978 1 60761 611 5_7
   Khedgikar V, 2016, LIFE SCI, V151, P207, DOI 10.1016/j.lfs.2016.03.009
   Kim K, 2015, MOL CELL BIOCHEM, V407, P143, DOI 10.1007/s11010 015 2464 5
   Kim W, 2013, BIOCHEM J, V450, P9, DOI 10.1042/BJ20121284
   Kumar DU, 2012, FOLIA BIOL PRAGUE, V58, P115
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Li DD, 2015, GENE, V572, P198, DOI 10.1016/j.gene.2015.07.010
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Mohammadi A, 2017, BIOMED PHARMACOTHER, V86, P262, DOI 10.1016/j.biopha.2016.12.023
   Papaioannou G, 2014, CELL MOL LIFE SCI, V71, P4747, DOI 10.1007/s00018 014 1700 6
   Vimalraj S, 2013, CURR ISSUES MOL BIOL, V15, P7
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
NR 30
TC 13
Z9 13
U1 0
U2 26
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2169 1401
EI 2169 141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PY 2019
VL 47
IS 1
BP 1050
EP 1056
DI 10.1080/21691401.2019.1591428
PG 7
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA HR5GG
UT WOS:000463174300002
PM 30942633
OA gold
DA 2025 08 17
ER

PT J
AU Simpson, CL
   Mosier, JA
   Vyavahare, NR
AF Simpson, Chartrisa LaShan
   Mosier, Jenna A.
   Vyavahare, Narendra R.
TI Osteoclast Mediated Cell Therapy as an Attempt to Treat Elastin Specific
   Vascular Calcification
SO MOLECULES
LA English
DT Article
DE cell therapy; diabetes mellutis; elastin; microbead; osteoclast; RANK;
   vascular calcification
ID EXTRACELLULAR CALCIUM; STEM CELLS; KAPPA B; OSTEOPROTEGERIN; MODEL;
   ENCAPSULATION; DEGRADATION; SURVIVAL; RECEPTOR; LIGAND
AB Inflammation and stiffness in the arteries is referred to as vascular calcification. This process is a prevalent yet poorly understood consequence of cardiovascular disease and diabetes mellitus, comorbidities with few treatments clinically available. Because this is an active process similar to bone formation, it is hypothesized that osteoclasts (OCs), bone resorbing cells in the body, could potentially work to reverse existing calcification by resorbing bone material. The receptor activator of nuclear kappa B ligand (RANKL) is a molecule responsible for triggering a response in monocytes and macrophages that allows them to differentiate into functional OCs. In this study, OC and RANKL delivery were employed to determine whether calcification could be attenuated. OCs were either delivered via direct injection, collagen/alginate microbeads, or collagen gel application, while RANKL was delivered via injection, through either a porcine subdermal model or aortic injury model. While in vitro results yielded a decrease in calcification using OC therapy, in vivo delivery mechanisms did not provide control or regulation to keep cells localized long enough to induce calcification reduction. However, these results do provide context and direction for the future of OC therapy, revealing necessary steps for this treatment to effectively reduce calcification in vivo. The discrepancy between in vivo and in vitro success for OC therapy points to the need for a more stable and time controlled delivery mechanism that will allow OCs not only to remain at the site of calcification, but also to be regulated so that they are healthy and functioning normally when introduced to diseased tissue.
C1 [Simpson, Chartrisa LaShan; Mosier, Jenna A.] Mississippi State Univ, Dept Biol Engn, 130 Creelman St, Mississippi State, MS 39762 USA.
   [Vyavahare, Narendra R.] Clemson Univ, Rhodes Res Ctr 301, Dept Bioengn, Clemson, SC 29634 USA.
C3 Mississippi State University; Clemson University
RP Simpson, CL (通讯作者)，Mississippi State Univ, Dept Biol Engn, 130 Creelman St, Mississippi State, MS 39762 USA.
EM clsimpson@abe.msstate.edu; jmosier243@gmail.com; narenv@clemson.edu
FU South Carolina EPSCOR BRIN Grant; NIH RO1 grant [2RO1 HL061652 05]
FX This work was supported in part by a South Carolina EPSCOR BRIN Grant
   (to NRV) and by NIH RO1 grant entitled "Elastin Calcification:
   Mechanisms and Prevention" (2RO1 HL061652 05, PI Vyavahare).
CR Aranguren XL, 2009, J MOL MED, V87, P3, DOI 10.1007/s00109 008 0394 3
   Bailey MT, 2003, J BIOMED MATER RES A, V66A, P93, DOI 10.1002/jbm.a.10543
   Basalyga DM, 2004, CIRCULATION, V110, P3480, DOI 10.1161/01.CIR.0000148367.08413.E9
   Bessueille L, 2015, CELL MOL LIFE SCI, V72, P2475, DOI 10.1007/s00018 015 1876 4
   Bessueille L, 2015, FEBS LETT, V589, P2797, DOI 10.1016/j.febslet.2015.07.045
   Boyce BF, 2005, J BONE MINER METAB, V23, P11, DOI 10.1007/BF03026317
   Byon CH, 2008, J BIOL CHEM, V283, P15319, DOI 10.1074/jbc.M800021200
   Chinetti Gbaguidi G, 2017, CIRC RES, V121, P19, DOI 10.1161/CIRCRESAHA.116.310262
   Collin Osdoby P, 2004, CIRC RES, V95, P1046, DOI 10.1161/01.RES.0000149165.99974.12
   Doherty TM, 2004, ENDOCR REV, V25, P629, DOI 10.1210/er.2003 0015
   Dufrane D, 2006, TRANSPLANTATION, V81, P1345, DOI 10.1097/01.tp.0000208610.75997.20
   Evrard S, 2015, CLIN CHIM ACTA, V438, P401, DOI 10.1016/j.cca.2014.08.034
   Hofbauer LC, 2007, OSTEOPOROSIS INT, V18, P251, DOI 10.1007/s00198 006 0282 z
   Hunt NC, 2010, BIOTECHNOL LETT, V32, P733, DOI 10.1007/s10529 010 0221 0
   Jeziorska M, 1998, VIRCHOWS ARCH, V433, P559, DOI 10.1007/s004280050289
   Kang YH, 2015, KOREAN J PHYSIOL PHA, V19, P111, DOI 10.4196/kjpp.2015.19.2.111
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Simpson CL, 2007, CARDIOVASC PATHOL, V16, P29, DOI 10.1016/j.carpath.2006.07.001
   Lee BR, 2012, BIOMATERIALS, V33, P837, DOI 10.1016/j.biomaterials.2011.10.014
   Lee JS, 2006, AM J PATHOL, V168, P490, DOI 10.2353/ajpath.2006.050338
   Lee KY, 2012, PROG POLYM SCI, V37, P106, DOI 10.1016/j.progpolymsci.2011.06.003
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Mayfield AE, 2014, BIOMATERIALS, V35, P133, DOI 10.1016/j.biomaterials.2013.09.085
   McArthur K.M., 2017, AIMS Cell Tissue Eng, V1, P165, DOI [10.3934/celltissue.2017.3.165, DOI 10.3934/CELLTISSUE.2017.3.165]
   McClung M, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2167
   Melo LG, 2004, FASEB J, V18, P648, DOI 10.1096/fj.03 1171rev
   Pai A, 2011, AM J PATHOL, V178, P764, DOI 10.1016/j.ajpath.2010.10.006
   Paloian NJ, 2016, KIDNEY INT, V89, P1027, DOI 10.1016/j.kint.2015.12.046
   Persy V, 2009, TRENDS MOL MED, V15, P405, DOI 10.1016/j.molmed.2009.07.001
   Reynolds JL, 2004, J AM SOC NEPHROL, V15, P2857, DOI 10.1097/01.ASN.0000141960.01035.28
   Schoppet M, 2004, J CLIN ENDOCR METAB, V89, P4104, DOI 10.1210/jc.2003 031432
   Simionescu A, 2005, BIOCHEM BIOPH RES CO, V334, P524, DOI 10.1016/j.bbrc.2005.06.119
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Timraz SBH, 2016, EXP CELL RES, V343, P168, DOI 10.1016/j.yexcr.2016.04.004
   Yagar H, 2008, PREP BIOCHEM BIOTECH, V38, P13, DOI 10.1080/10826060701774304
   Yahagi K, 2017, ARTERIOSCL THROM VAS, V37, P191, DOI 10.1161/ATVBAHA.116.306256
   Yang H, 2004, KIDNEY INT, V66, P2293, DOI 10.1111/j.1523 1755.2004.66015.x
   Zhou HZ, 2011, BIOMATERIALS, V32, P7503, DOI 10.1016/j.biomaterials.2011.06.045
   Zhu Dongxing, 2012, Front Endocrinol (Lausanne), V3, P95, DOI 10.3389/fendo.2012.00095
NR 41
TC 4
Z9 4
U1 0
U2 9
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD JUN
PY 2021
VL 26
IS 12
AR 3643
DI 10.3390/molecules26123643
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA SZ3VL
UT WOS:000666496900001
PM 34203711
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liu, ZB
   Wang, H
   He, JL
   Yuan, XQ
   Sun, WW
AF Liu, Zibo
   Wang, Hui
   He, Jialing
   Yuan, Xiaoqin
   Sun, Weiwei
TI Rictor ablation in BMSCs inhibits bone metastasis of TM40D cells by
   attenuating osteolytic destruction and CAF formation
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE BMSCs; mTOR complex 2; breast cancer bone metastasis; osteolytic bone
   destruction; CAFs
ID MESENCHYMAL STEM CELLS; BREAST CANCER; EXPRESSION; THERAPY;
   DIFFERENTIATION; PATHOGENESIS; PROGRESSION; RESISTANCE; PATHWAY; RANKL
AB The mTOR complex 2 (mTORC2) is recognized as a promising target for breast cancer treatment. As mTORC2 specific inhibitors do not yet exist, studies into the role of mTORC2 in cancer are performed by deleting Rictor or by RNAi mediated Rictor silencing. The purpose of this study was to explore the effects of Rictor ablation in bone mesenchymal stromal cells (BMSCs) on bone metastasis of breast cancer. First, female mice with the genotype of Prx1 Cre; Rictor(f/f) (hereafter RiCKO) or Rictor(f/f) (as control) were injected intratibially with cells of the breast cancer cell line (TM40D) at 4 months of age. Three weeks later, osteolytic bone destruction was detected in metastatic legs by X ray and micro CT. We found that Rictor ablation in BMSCs inhibited TM40D induced osteolytic bone destruction and resulted in greater bone volume maintenance in vivo. Lower CTX I serum level, a decreased number of TRAP+ osteoclasts and lower Cathepsin K expression observed at the tumor bone interface indicated that osteoclastogenesis was inhibited in RiCKO mice. Additionally, co culture experiments confirmed that Rictor deletion in BMSCs diminished osteoclast differentiation partly via down regulation of RANKL expression. Furthermore, Rictor deficiency was found to reduce the transition of BMSCs to CAFs coupled with decreased secretion of cytokines (IL 6, RANKL, TGF beta), which resulted in lower chemotaxis and less proliferation in TM40D cells. These results suggest that Rictor ablation in BMSCs plays dual roles in breast cancer bone metastasis: (1) repression of osteolytic bone destruction; (2) inhibition of tumor growth.
C1 [Liu, Zibo; Wang, Hui; He, Jialing; Yuan, Xiaoqin; Sun, Weiwei] Nanjing Med Univ, Res Ctr Bone & Stem Cells, Lab Reprod Med, Dept Anat Histol & Embryol, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Sun, WW (通讯作者)，Xuehai Bldg D509,Long Mian Ave 10, Nanjing 211166, Jiangsu, Peoples R China.
EM 344910724@qq.com
RI Liu, Zibo/D 4262 2019; 王, 辉/HPH 7285 2023; sun, weiwei/GQA 5041 2022
FU National Natural Science Foundation of China [81200431, 81572386,
   81774075]; Jiangsu Student's Platform for innovation and
   entrepreneurship training program [201810312011Z]
FX We thank Dr. Fanxin Long (Washington University in St. Louis) for
   providing the transgenic mice genotyped Prx1 Cre; Rictor<SUP>f/f</SUP>
   in this paper. This work is supported by the National Natural Science
   Foundation of China, Grant Number: 81200431, 81572386 and 81774075; and
   Jiangsu Student's Platform for innovation and entrepreneurship training
   program, Grant Number: 201810312011Z.
CR [Anonymous], 2017, COLD SPRING HARB PER
   [Anonymous], 2016, INT J MOL SCI
   Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159 8290.CD 13 0286
   Brook N, 2018, INT J BIOCHEM CELL B, V96, P63, DOI 10.1016/j.biocel.2018.01.003
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Carew JS, 2011, TARGET ONCOL, V6, P17, DOI 10.1007/s11523 011 0167 8
   Chen JQ, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0004 5
   Chen JQ, 2015, J BONE MINER RES, V30, P369, DOI 10.1002/jbmr.2348
   Chen S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.380
   Cirri P, 2012, CANCER METAST REV, V31, P195, DOI 10.1007/s10555 011 9340 x
   El Shamieh S, 2018, PHARMACOGENOMICS, V19, P757, DOI 10.2217/pgs 2018 0019
   Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008
   Esposito M, 2014, PHARMACOL THERAPEUT, V141, P222, DOI 10.1016/j.pharmthera.2013.10.006
   Gandellini P, 2015, SEMIN CANCER BIOL, V35, P96, DOI 10.1016/j.semcancer.2015.08.008
   García García C, 2012, CLIN CANCER RES, V18, P2603, DOI 10.1158/1078 0432.CCR 11 2750
   Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007
   Hatakeyama J, 2014, ENDOCR RELAT CANCER, V21, pR345, DOI 10.1530/ERC 14 0141
   He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183
   Hietakangas V, 2008, BMC CANCER, V8, DOI 10.1186/1471 2407 8 282
   Hong IS, 2014, MUTAT RES FUND MOL M, V768, P98, DOI 10.1016/j.mrfmmm.2014.01.006
   Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912
   Janku F, 2012, J CLIN ONCOL, V30, P777, DOI 10.1200/JCO.2011.36.1196
   Joly MM, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058 017 0868 8
   Joly MM, 2016, CANCER RES, V76, P4752, DOI 10.1158/0008 5472.CAN 15 3393
   Karakasheva TA, 2018, CANCER RES, V78, P4957, DOI 10.1158/0008 5472.CAN 17 2268
   Kiesel L, 2016, MATURITAS, V86, P10, DOI 10.1016/j.maturitas.2016.01.001
   Kim LC, 2017, ONCOGENE, V36, P2191, DOI 10.1038/onc.2016.363
   Li HY, 2012, BREAST CANCER RES TR, V134, P1057, DOI 10.1007/s10549 012 2036 2
   Liu Y, 2018, CELL PHYSIOL BIOCHEM, V45, P1759, DOI 10.1159/000487784
   Miller TW, 2009, CLIN CANCER RES, V15, P7266, DOI 10.1158/1078 0432.CCR 09 1665
   Morrison MM, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005291
   Nahta R, 2010, CLIN BREAST CANCER, V10, pS72, DOI 10.3816/CBC.2010.s.015
   Nakashima Tomoki, 2013, Clin Calcium, V23, P218, DOI CliCa1302218228
   Ney JT, 2012, GEBURTSH FRAUENHEILK, V72, P385, DOI 10.1055/s 0031 1298276
   Pan CH, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01538
   Park JH, 2017, MOL CELLS, V40, P706
   Rucci N, 2014, WORLD J CLIN ONCOL, V5, P335, DOI 10.5306/wjco.v5.i3.335
   Sisay M, 2017, ONCOTARGETS THER, V10, P3801, DOI 10.2147/OTT.S135867
   Sparks CA, 2010, ONCOGENE, V29, P3733, DOI 10.1038/onc.2010.139
   Sun WW, 2016, BONE, V85, P1, DOI 10.1016/j.bone.2016.01.013
   Tandon M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3611
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Wang Y, 2017, ONCOL LETT, V14, P7269, DOI 10.3892/ol.2017.7130
   Wazir U, 2013, ONCOL REP, V29, P1969, DOI 10.3892/or.2013.2346
   Werfel TA, 2018, CANCER RES, V78, P1845, DOI 10.1158/0008 5472.CAN 17 2388
   Yan J, 2012, AM J PATHOL, V181, P234, DOI 10.1016/j.ajpath.2012.03.038
   Yang X, 2016, STEM CELLS DEV, V25, P1629, DOI 10.1089/scd.2016.0217
   Zhang F, 2010, CANCER RES, V70, P9360, DOI 10.1158/0008 5472.CAN 10 0207
   Zhou YC, 2019, EXP MOL PATHOL, V107, P85, DOI 10.1016/j.yexmp.2018.11.014
NR 49
TC 11
Z9 11
U1 0
U2 6
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2019
VL 15
IS 11
BP 2448
EP 2460
DI 10.7150/ijbs.37241
PG 13
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA IX4KO
UT WOS:000485655300016
PM 31595162
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Chen, QC
   Zheng, CP
   Li, YQ
   Bian, SQ
   Pan, HB
   Zhao, XL
   Lu, WW
AF Chen, Qingchang
   Zheng, Chuping
   Li, Yanqun
   Bian, Shaoquan
   Pan, Haobo
   Zhao, Xiaoli
   Lu, William W.
TI Bone Targeted Delivery of SDF 1 via Alendronate Functionalized
   Nanoparticles in Guiding Stem Cell Migration
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE bone targeting; gene delivery; stem cell homing; SDF 1; osteoporosis
   therapy
ID POLY(ETHYLENE GLYCOL); MESENCHYMAL CELLS; GENE TRANSFER; FACTOR I;
   RESORPTION; THERAPY; PEPTIDE; REPAIR; TRANSPLANTATION; TRAFFICKING
AB Stem cells are well known for their great capacity for tissue regeneration. This provides a promising source for cell based therapies in treating various bone degenerative disorders. However, the major hurdles for their application in transplantation are the poor bone marrow homing and engraftment efficiencies. Stromal cell derived factor 1 (SDF 1) has been identified as a major stem cell homing factor. With the aims of bone targeted SDF 1 delivery and regulating MSCs migration, alendronate modified liposomal nanoparticles (Aln Lipo) carrying SDF 1 gene were developed in this study. Alendronate modification significantly increased the mineral binding affinity of liposomes, and facilitated the gene delivery to osteoblastic cells. Up regulated SDF 1 expression in osteoblasts triggered MSCs migration. Systemic infusion of Aln Lipo SDF 1 with fluorescence labeling in mice showed the accumulation in osseous tissue by biophotonic imaging. Corresponding to the delivered SDF 1, the transplanted GFP+ MSCs were attracted to bone marrow and contributed to bone regeneration. This study may provide a useful technique in regulating stem cell migration.
C1 [Chen, Qingchang; Zheng, Chuping; Li, Yanqun; Bian, Shaoquan; Pan, Haobo; Zhao, Xiaoli] Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Biomed & Biotechnol, Res Ctr Human Tissues & Organs Degenerat, Shenzhen 518055, Peoples R China.
   [Lu, William W.] Univ Hong Kong, Dept Orthopaed & Traumatol, 21 Sassoon Rd, Hong Kong 999077, Hong Kong, Peoples R China.
   [Zheng, Chuping] Guangzhou Med Univ, Sch Pharmaceut Sci, Guangzhou 511436, Guangdong, Peoples R China.
C3 Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology,
   CAS; University of Hong Kong; Guangzhou Medical University
RP Zhao, XL (通讯作者)，Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Biomed & Biotechnol, Res Ctr Human Tissues & Organs Degenerat, Shenzhen 518055, Peoples R China.
EM zhaoxltju@gmail.com
RI ; Zhao, Xiaoli/KMY 5545 2024; Lu, William Weijia/C 4358 2009; Pan,
   Haobo/LLK 2703 2024
OI , Xiaoli/0000 0003 1524 1993; Lu, William Weijia/0000 0002 5780 2886; 
FU National Natural Science Foundation of China [81672226]; Science and
   Technology Research Funding of Shenzhen [JCYJ20160531174634936,
   JCYJ20170413162540673]; Shenzhen Peacock Program [110811003586331];
   Science and technology project of Guangdong [2016A020222007]
FX This work was funded by National Natural Science Foundation of China
   (81672226), Science and Technology Research Funding of Shenzhen
   (JCYJ20160531174634936, JCYJ20170413162540673), Shenzhen Peacock Program
   (110811003586331) and Science and technology project of Guangdong
   (2016A020222007).
CR Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Antebi B, 2014, CURR OSTEOPOROS REP, V12, P41, DOI 10.1007/s11914 013 0184 x
   Appelman Dijkstra NM, 2015, DRUGS, V75, P1049, DOI 10.1007/s40265 015 0417 7
   Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140 6736(03)14232 8
   Balazs DA, 2011, J DRUG DELIV, V2011, DOI 10.1155/2011/326497
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330
   BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092 8674(91)90279 8
   Chapel A, 2003, J GENE MED, V5, P1028, DOI 10.1002/jgm.452
   Chen HY, 2012, BIOCONJUGATE CHEM, V23, P1915, DOI 10.1021/bc3003088
   Chen PF, 2015, BIOMATERIALS, V39, P114, DOI 10.1016/j.biomaterials.2014.10.049
   Chen Y, 2010, J CELL MOL MED, V14, P1494, DOI 10.1111/j.1582 4934.2009.00912.x
   Clementi C, 2011, MOL PHARMACEUT, V8, P1063, DOI 10.1021/mp2001445
   Cosman F, 2017, J BONE MINER RES, V32, P198, DOI 10.1002/jbmr.3051
   Descalzo DLM, 2014, REGEN MED, V9, P219, DOI 10.2217/rme.13.100
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Fong ELS, 2011, BIOMATERIALS, V32, P395, DOI 10.1016/j.biomaterials.2010.08.101
   Frangogiannis NG, 2005, TRENDS CARDIOVAS MED, V15, P163, DOI 10.1016/j.tcm.2005.06.005
   Ghadge SK, 2011, PHARMACOL THERAPEUT, V129, P97, DOI 10.1016/j.pharmthera.2010.09.011
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   Gutwald R, 2010, BRIT J ORAL MAX SURG, V48, P285, DOI 10.1016/j.bjoms.2009.06.226
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Inoh Y, 2017, EUR J PHARM SCI, V102, P230, DOI 10.1016/j.ejps.2017.03.023
   Jones CH, 2013, MOL PHARMACEUT, V10, P4082, DOI 10.1021/mp400467x
   Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]
   Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001
   Kiernan J, 2016, STEM CELL TRANSL MED, V5, P683, DOI 10.5966/sctm.2015 0231
   Kitaori T, 2009, ARTHRITIS RHEUM US, V60, P813, DOI 10.1002/art.24330
   Laird DJ, 2008, CELL, V132, P612, DOI 10.1016/j.cell.2008.01.041
   Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood 2005 04 1417
   Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301 472X(02)00883 4
   Lee Y, 2004, BIOORG MED CHEM LETT, V14, P2637, DOI 10.1016/j.bmcl.2004.02.061
   Lei Y, 2010, DIGEST DIS SCI, V55, P285, DOI 10.1007/s10620 009 0757 9
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Lien CY, 2009, J BONE MINER RES, V24, P837, DOI [10.1359/JBMR.081257, 10.1359/jbmr.081257]
   Liu J, 2015, BIOMATERIALS, V52, P148, DOI 10.1016/j.biomaterials.2015.02.007
   Low SA, 2015, BIOMACROMOLECULES, V16, P3145, DOI 10.1021/acs.biomac.5b00777
   Mobasheri A, 2014, MATURITAS, V78, P188, DOI 10.1016/j.maturitas.2014.04.017
   Morelli S, 2011, ARCH BIOCHEM BIOPHYS, V507, P248, DOI 10.1016/j.abb.2010.12.013
   Murphy MB, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.94
   Noble GT, 2014, TRENDS BIOTECHNOL, V32, P32, DOI 10.1016/j.tibtech.2013.09.007
   Patrulea V, 2015, EUR J PHARM BIOPHARM, V97, P417, DOI 10.1016/j.ejpb.2015.08.004
   Pignatello R, 2012, J FUNCT BIOMATER, V3, P79, DOI 10.3390/jfb3010079
   Rafii S, 2015, NAT CELL BIOL, V17, P123, DOI 10.1038/ncb3096
   Rüster B, 2006, BLOOD, V108, P3938, DOI 10.1182/blood 2006 05 025098
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Ryu TK, 2016, J CONTROL RELEASE, V232, P152, DOI 10.1016/j.jconrel.2016.04.025
   Sackstein R, 2008, NAT MED, V14, P181, DOI 10.1038/nm1703
   Schmidt A, 2006, EUR J CELL BIOL, V85, P1179, DOI 10.1016/j.ejcb.2006.05.015
   Shao ZX, 2012, BIOMATERIALS, V33, P3375, DOI 10.1016/j.biomaterials.2012.01.033
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Srinivas R, 2009, CHEM SOC REV, V38, P3326, DOI 10.1039/b813869a
   Sun XY, 2012, BIOMATERIALS, V33, P916, DOI 10.1016/j.biomaterials.2011.10.035
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Sundararaman S, 2011, GENE THER, V18, P867, DOI 10.1038/gt.2011.18
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Thamake SI, 2012, BIOMATERIALS, V33, P7164, DOI 10.1016/j.biomaterials.2012.06.026
   Tuljapurkar SR, 2011, J ANAT, V219, P574, DOI 10.1111/j.1469 7580.2011.01423.x
   Nguyen TDT, 2016, SCI REP UK, V6, DOI 10.1038/srep36707
   Unzek S, 2007, CELL TRANSPLANT, V16, P879, DOI 10.3727/096368907783338271
   Wang YC, 2017, ACS NANO, V11, P9445, DOI 10.1021/acsnano.7b05103
   Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood 2004 02 0526
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Yu Q, 2015, CELL J, V16, P440
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhu YX, 2016, J CONTROL RELEASE, V238, P114, DOI 10.1016/j.jconrel.2016.07.043
NR 69
TC 56
Z9 63
U1 2
U2 108
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD JUL 18
PY 2018
VL 10
IS 28
BP 23700
EP 23710
DI 10.1021/acsami.8b08606
PG 11
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA GN9NJ
UT WOS:000439528400031
PM 29939711
DA 2025 08 17
ER

PT J
AU Zheng, HL
   Xu, WN
   Zhou, WS
   Yang, RZ
   Chen, PB
   Liu, T
   Jiang, LS
   Jiang, SD
AF Zheng, Huo Liang
   Xu, Wen Ning
   Zhou, Wen Sheng
   Yang, Run Ze
   Chen, Peng Bo
   Liu, Tao
   Jiang, Lei Sheng
   Jiang, Sheng Dan
TI Beraprost ameliorates postmenopausal osteoporosis by regulating
   Nedd4 induced Runx2 ubiquitination
SO CELL DEATH & DISEASE
LA English
DT Article
ID CRANIOFACIAL DEVELOPMENT; OSTEOBLAST; LIGASE; DIFFERENTIATION;
   DEGRADATION
AB Bone health requires adequate bone mass, which is maintained by a critical balance between bone resorption and formation. In our study, we identified beraprost as a pivotal regulator of bone formation and resorption. The administration of beraprost promoted differentiation of mouse bone mesenchymal stem cells (M BMSCs) through the PI3K AKT pathway. In co culture, osteoblasts stimulated with beraprost inhibited osteoclastogenesis in a rankl dependent manner. Bone mass of p53 knockout mice remained stable, regardless of the administration of beraprost, indicating that p53 plays a vital role in the bone mass regulation by beraprost. Mechanistic in vitro studies showed that p53 binds to the promoter region of neuronal precursor cell expressed developmentally downregulated 4 (Nedd4) to promote its transcription. As a ubiquitinating enzyme, Nedd4 binds to runt related transcription factor 2 (Runx2), which results in its ubiquitination and subsequent degradation. These data indicate that the p53 Nedd4 Runx2 axis is an effective regulator of bone formation and highlight the potential of beraprost as a therapeutic drug for postmenopausal osteoporosis.
C1 [Zheng, Huo Liang; Xu, Wen Ning; Zhou, Wen Sheng; Yang, Run Ze; Chen, Peng Bo; Liu, Tao; Jiang, Lei Sheng; Jiang, Sheng Dan] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Clin Spine Ctr, Sch Med, Shanghai 200082, Peoples R China.
C3 Shanghai Jiao Tong University
RP Jiang, LS; Jiang, SD (通讯作者)，Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Clin Spine Ctr, Sch Med, Shanghai 200082, Peoples R China.
EM jiangleisheng@xinhuamed.com.cn
RI Yang, Runze/NXX 4657 2025
FU National Natural Science Foundation of China [81672206]
FX This study was supported by the National Natural Science Foundation of
   China [81672206].
CR Barrett Connor E, 2001, INT J EPIDEMIOL, V30, P423, DOI 10.1093/ije/30.3.423
   Bartelt A, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0006 3
   Bauer DC, 2019, JAMA J AM MED ASSOC, V322, P2344, DOI 10.1001/jama.2019.17671
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cooper LT, 2003, J AM COLL CARDIOL, V41, P1687, DOI 10.1016/S0735 1097(03)00308 5
   DEFTOS LJ, 1995, J CLIN INVEST, V95, P2433, DOI 10.1172/JCI117942
   DEMOLIS JL, 1993, J CARDIOVASC PHARM, V22, P711, DOI 10.1097/00005344 199311000 00007
   Diab DL, 2013, CURR OPIN ENDOCRINOL, V20, P501, DOI 10.1097/01.med.0000436194.10599.94
   Fang NN, 2014, NAT CELL BIOL, V16, P1227, DOI 10.1038/ncb3054
   Gao JF, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01684 w
   Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436
   Jewett KA, 2016, MOL BRAIN, V9, DOI 10.1186/s13041 016 0214 6
   Jiang YP, 2019, LIFE SCI, V228, P208, DOI 10.1016/j.lfs.2019.05.002
   Jin FJ, 2017, STEM CELLS, V35, P1760, DOI 10.1002/stem.2620
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim J, 2011, J IMMUNOL, V186, P3866, DOI 10.4049/jimmunol.1002170
   Kushioka J, 2020, BONE RES, V8, DOI 10.1038/s41413 020 00115 z
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Liu WQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12794
   Ma YG, 2021, SCI TOTAL ENVIRON, V750, DOI 10.1016/j.scitotenv.2020.141638
   McKean JS, 2015, CARDIOVASC RES, V107, P546, DOI 10.1093/cvr/cvv176
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Park YS, 2014, BIOMATERIALS, V35, P9747, DOI 10.1016/j.biomaterials.2014.08.007
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Shao R, 2016, CELL RES, V26, P699, DOI 10.1038/cr.2016.51
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Snyder S, 2020, JAMA J AM MED ASSOC, V323, P1096, DOI 10.1001/jama.2020.0602
   Starling S, 2021, NAT REV ENDOCRINOL, V17, P5, DOI 10.1038/s41574 020 00441 6
   Sun X, 2019, INT J BIOL MACROMOL, V129, P579, DOI 10.1016/j.ijbiomac.2019.02.022
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Teramachi J, 2020, HAEMATOLOGICA
   Tsourdi E, 2018, NEW ENGL J MED, V378, P195, DOI 10.1056/NEJMc1714810
   Wang XY, 2006, J CELL BIOL, V172, P115, DOI 10.1083/jcb.200507106
   Wang ZW, 2020, SEMIN CANCER BIOL, V67, P92, DOI 10.1016/j.semcancer.2020.03.006
   Yang YF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14324 x
   Yasar L, 2006, PROSTAG OTH LIPID M, V79, P199, DOI 10.1016/j.prostaglandins.2005.12.001
   Yu T, 2020, AGING US, V12, P10473, DOI 10.18632/aging.103271
   Yu T, 2020, AGING US, V12, P10359, DOI 10.18632/aging.103262
   Zhang PP, 2015, CELL RES, V25, P1093, DOI 10.1038/cr.2015.109
   Zhang Y, 2020, J CELL PHYSIOL, V235, P5511, DOI 10.1002/jcp.29261
   Zhou SY, 2020, EUR J MED CHEM, V197, DOI 10.1016/j.ejmech.2020.112313
   Zhu W, 2017, J BIOL CHEM, V292, P11178, DOI 10.1074/jbc.M116.772277
   Zou WG, 2011, NAT CELL BIOL, V13, P59, DOI 10.1038/ncb2134
NR 46
TC 22
Z9 24
U1 0
U2 15
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAY 15
PY 2021
VL 12
IS 5
AR 497
DI 10.1038/s41419 021 03784 8
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA SK5RX
UT WOS:000656273400003
PM 33993186
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kajiya, H
   Katsumata, Y
   Sasaki, M
   Tsutsumi, T
   Kawaguchi, M
   Fukushima, T
AF Kajiya, Hiroshi
   Katsumata, Yuri
   Sasaki, Mina
   Tsutsumi, Takashi
   Kawaguchi, Minoru
   Fukushima, Tadao
TI Photothermal stress triggered by near infrared irradiated carbon
   nanotubes up regulates osteogenesis and mineral deposition in
   tooth extracted sockets
SO INTERNATIONAL JOURNAL OF HYPERTHERMIA
LA English
DT Article
DE Carbon nanotubes; heat shock proteins; mineral deposition; osteogenesis;
   photothermal stress
ID HEAT SHOCK PROTEINS; MARROW STROMAL CELLS; MOLECULAR CHAPERONES;
   GENE EXPRESSION; CANCER CELLS; BONE; OSTEOBLASTS; DIFFERENTIATION;
   PROLIFERATION; INDUCTION
AB Purpose: The bone regenerative healing process is often prolonged, with a high risk of infection particularly in elderly and diseased patients. A reduction in healing process time usually requires mechanical stress devices, chemical cues, or laser/thermal therapies. Although these approaches have been used extensively for the reduction of bone healing time, the exact mechanisms involved in thermal stress induced bone regeneration remain unclear. Methods: Photothermal stress (PTS) stimulation was carried out using a novel photothermal device, composed of an alginate gel (AG) including carbon nanotubes (CNT AGs) and their irradiator with near infrared (NIR) light. We investigated the effects of optimal hyperthermia on osteogenesis, its signalling pathway in vitro and mineral deposition in tooth extracted sockets in vivo. Results: The PTS (10 min at 42 degrees C, every day), triggered by NIR induced CNT, increased the activity of alkaline phosphatase (ALP) in mouse osteoblast MC3T3 E1 cells in a time dependent manner compared with the non thermal stress control. PTS significantly induced the expression of osteogenic related molecules such as ALP, RUNX2 and Osterix in a time dependent manner with phosphorylated mitogen activated protein kinases (MAPK). PTS increased the expression of heat shock factor (HSF) 2, but not HSF1, resulting in activation of heat shock protein 27. PTS significantly up regulated mineral deposition in tooth extracted sockets in normal and ovariectomised osteoporotic model mice in vivo. Conclusions: Our novel CNT based PTS up regulated osteogenesis via activation of heat shock related molecules, resulting in promotion of mineral deposition in enhanced tooth extracted sockets.
C1 [Kajiya, Hiroshi; Katsumata, Yuri; Kawaguchi, Minoru; Fukushima, Tadao] Fukuoka Dent Coll, Ctr Regenerat Med, Fukuoka 8140193, Japan.
   [Kajiya, Hiroshi; Sasaki, Mina; Tsutsumi, Takashi] Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, Fukuoka 8140193, Japan.
   [Kawaguchi, Minoru] Fukuoka Dent Coll, Dept Dent Engn, Fukuoka 8140193, Japan.
C3 Fukuoka Dental College (FDC); Fukuoka Dental College (FDC); Fukuoka
   Dental College (FDC)
RP Kajiya, H (通讯作者)，Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, Sawara ku, 2 15 1 Tamura, Fukuoka 8140193, Japan.
EM kajiya@college.fdcnet.ac.jp
OI Kajiya, Hiroshi/0000 0003 3275 3632
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [24592823, 23390455]; Japan Society for the Promotion of Science
   [S1001059]; Grants in Aid for Scientific Research [23390455, 24592823]
   Funding Source: KAKEN
FX This work was supported by Grants in Aid for Scientific Research from
   the Ministry of Education, Culture, Sports, Science and Technology of
   Japan (Nos. 24592823 and 23390455) and by a Grant in Aid for Strategic
   Study Base Formation Support Business (S1001059) from the Japan Society
   for the Promotion of Science.
CR ANG D, 1991, J BIOL CHEM, V266, P24233
   Berber S, 2000, PHYS REV LETT, V84, P4613, DOI 10.1103/PhysRevLett.84.4613
   COOPER LF, 1994, J BIOL CHEM, V269, P7869
   DOYLE JR, 1960, J BONE JOINT SURG AM, V42, P1191, DOI 10.2106/00004623 196042070 00009
   Ebbesen TW, 1996, NATURE, V382, P54, DOI 10.1038/382054a0
   Eriksson M, 2000, INT J DEV BIOL, V44, P471
   Fernandes M, BIOL HEAT SHOCK PROT
   Fisher JW, 2010, CANCER RES, V70, P9855, DOI 10.1158/0008 5472.CAN 10 0250
   HAKEDA Y, 1987, ENDOCRINOLOGY, V121, P1966, DOI 10.1210/endo 121 6 1966
   Huang H, 2010, NAT NANOTECHNOL, V5, P602, DOI [10.1038/NNANO.2010.125, 10.1038/nnano.2010.125]
   JAKOB U, 1993, J BIOL CHEM, V268, P1517
   Jeyamohan P, 2013, INT J NANOMED, V8, P2653, DOI 10.2147/IJN.S46054
   Ji SR, 2010, BBA REV CANCER, V1806, P29, DOI 10.1016/j.bbcan.2010.02.004
   Kam NWS, 2005, P NATL ACAD SCI USA, V102, P11600, DOI 10.1073/pnas.0502680102
   Kawaguchi M, 2006, DENT MATER J, V25, P719, DOI 10.4012/dmj.25.719
   Kawamura H, 1999, AM J PHYSIOL ENDOC M, V277, pE1046, DOI 10.1152/ajpendo.1999.277.6.E1046
   Kozawa O, 2001, ARCH BIOCHEM BIOPHYS, V388, P237, DOI 10.1006/abbi.2000.2290
   Kozawa O, 1999, J BONE MINER RES, V14, P1761, DOI 10.1359/jbmr.1999.14.10.1761
   LAVOIE JN, 1993, J BIOL CHEM, V268, P3420
   LEON SA, 1993, INT J HYPERTHER, V9, P77, DOI 10.3109/02656739309061480
   Lim CL, 2008, ANN ACAD MED SINGAP, V37, P347
   LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215
   Marrs B, 2006, J BIOMED MATER RES A, V77A, P269, DOI 10.1002/jbm.a.30651
   Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657
   MEZGER V, 1994, DEV BIOL, V165, P627, DOI 10.1006/dbio.1994.1281
   Miyagawa H, 2005, J NANOSCI NANOTECHNO, V5, P1593, DOI 10.1166/jnn.2005.181
   Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788
   Pagona G, 2006, CURR MED CHEM, V13, P1789, DOI 10.2174/092986706777452524
   Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00 0294rev
   RUOFF RS, 1995, CARBON, V33, P925, DOI 10.1016/0008 6223(95)00021 5
   SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392
   SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334
   SHAKOORI AR, 1992, J CELL BIOCHEM, V48, P277, DOI 10.1002/jcb.240480308
   Sharp LA, 2009, ANN BIOMED ENG, V37, P445, DOI 10.1007/s10439 008 9632 7
   Shui CX, 2001, J BONE MINER RES, V16, P731, DOI 10.1359/jbmr.2001.16.4.731
   SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092 8674(91)90452 5
   Sun TP, 2010, INT J NANOMED, V5, P343
   Tiffee JC, 2000, TISSUE CELL, V32, P141, DOI 10.1054/tice.2000.0097
   Treacy MMJ, 1996, NATURE, V381, P678, DOI 10.1038/381678a0
   UDELSMAN R, 1993, J CLIN INVEST, V91, P465, DOI 10.1172/JCI116224
   van der Zee J, 2002, ANN ONCOL, V13, P1173, DOI 10.1093/annonc/mdf280
   Wang W, 2005, DENT MATER J, V24, P478, DOI 10.4012/dmj.24.478
   Weissleder R, 2005, NAT BIOTECHNOL, V23, P1418, DOI 10.1038/nbt1159
   Yoshida K, 2009, CLIN ORAL IMPLAN RES, V20, P782, DOI 10.1111/j.1600 0501.2008.01654.x
   Zanello LP, 2006, NANO LETT, V6, P562, DOI 10.1021/nl051861e
NR 45
TC 21
Z9 21
U1 3
U2 46
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0265 6736
EI 1464 5157
J9 INT J HYPERTHER
JI Int. J. Hyperthermia
PY 2015
VL 31
IS 6
BP 635
EP 642
DI 10.3109/02656736.2015.1041430
PG 8
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA CR4VA
UT WOS:000361336600008
PM 26000973
DA 2025 08 17
ER

PT J
AU Singh, AP
   Zhang, YH
   No, JH
   Docampo, R
   Nussenzweig, V
   Oldfield, E
AF Singh, Agam Prasad
   Zhang, Yonghui
   No, Joo Hwan
   Docampo, Roberto
   Nussenzweig, Victor
   Oldfield, Eric
TI Lipophilic Bisphosphonates Are Potent Inhibitors of Plasmodium
   Liver Stage Growth
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID FARNESYL DIPHOSPHATE SYNTHASE; MALARIA; TRIAL; PRIMAQUINE; FALCIPARUM
AB Nitrogen containing bisphosphonates, drugs used to treat bone resorption diseases, also have activity against a broad range of protists, including blood stage Plasmodium spp. Here, we show that new generation "lipophilic" bisphosphonates designed as anticancer agents that block protein prenylation also have potent activity against Plasmodium liver stages, with a high (> 100) therapeutic index. Treatment of mice with the bisphosphonate BPH 715 and challenge with Plasmodium berghei sporozoites revealed complete protection (no blood stage parasites after 28 days). There was also activity against blood stage forms in vitro and a 4 day delay in the prepatent period in vivo. The lipophilic bisphosphonates have activity against a Plasmodium geranylgeranyl diphosphate synthase (GGPPS), as well as low nM activity against human farnesyl and geranylgeranyl diphosphate synthases. The most active inhibitor in vitro and in vivo had enzyme inhibitory activity similar to that of the other, less active compounds but was more lipophilic. Lipophilic bisphosphonates are thus promising leads for novel antimalarials that target liver stage infection.
C1 [Singh, Agam Prasad] Natl Inst Immunol, New Delhi 110067, India.
   [Singh, Agam Prasad; Nussenzweig, Victor] NYU, Dept Pathol, Langone Med Ctr, New York, NY 10016 USA.
   [Zhang, Yonghui; Oldfield, Eric] Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
   [No, Joo Hwan; Oldfield, Eric] Ctr Biophys & Computat Biol, Urbana, IL 61801 USA.
   [Docampo, Roberto] Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA.
   [Docampo, Roberto] Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA.
C3 Department of Biotechnology (DBT) India; National Institute of
   Immunology (NII); New York University; NYU Langone Medical Center;
   University of Illinois System; University of Illinois Urbana Champaign;
   University System of Georgia; University of Georgia; University System
   of Georgia; University of Georgia
RP Singh, AP (通讯作者)，Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India.
EM singhap@nii.res.in; eo@chad.scs.uiuc.edu
RI Zhang, Yonghui/AGY 5688 2022; Singh, Agam/AAH 2031 2020; Singh,
   Agam/F 2532 2012
OI Singh, Agam/0000 0003 4262 2556
FU Dana Foundation; United States Public Health Service (NIH) [GM65307];
   Barbara and Sanford Orkin Chair in Tropical and Emerging Diseases
FX This work was supported by the Dana Foundation (for Victor Nussenzweig),
   the United States Public Health Service (NIH grant GM65307 to Eric
   Oldfield), and the Barbara and Sanford Orkin Chair in Tropical and
   Emerging Diseases (for Roberto Docampo).
CR Baird JK, 2001, CLIN INFECT DIS, V33, P1990, DOI 10.1086/324085
   Bruña Romero O, 2001, INT J PARASITOL, V31, P1499, DOI 10.1016/S0020 7519(01)00265 X
   Carraz M, 2008, BIOORGAN MED CHEM, V16, P6186, DOI 10.1016/j.bmc.2008.04.033
   Chen CKM, 2008, J MED CHEM, V51, P5594, DOI 10.1021/jm800325y
   Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859
   Ghosh S, 2004, J MED CHEM, V47, P175, DOI 10.1021/jm030084x
   Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   Mazier D, 2009, NAT REV DRUG DISCOV, V8, P854, DOI 10.1038/nrd2960
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Mukkamala D, 2008, J MED CHEM, V51, P7827, DOI 10.1021/jm8009074
   Mutabingwa TK, 2005, LANCET, V365, P1474, DOI 10.1016/S0140 6736(05)66417 3
   Rodan Gideon A., 2002, Current Molecular Medicine (Hilversum), V2, P571, DOI 10.2174/1566524023362104
   Sanders JM, 2005, J MED CHEM, V48, P2957, DOI 10.1021/jm040209d
   Singh AP, 2007, CELL, V131, P492, DOI 10.1016/j.cell.2007.09.013
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Valecha N, 2001, CURR SCI INDIA, V80, P561
   Walsh DS, 2004, CLIN INFECT DIS, V39, P1095, DOI 10.1086/424508
   Wells TNC, 2009, NAT REV DRUG DISCOV, V8, P879, DOI 10.1038/nrd2972
   Zhang YH, 2010, ANGEW CHEM INT EDIT, V49, P1136, DOI 10.1002/anie.200905933
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 22
TC 47
Z9 59
U1 0
U2 15
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
SN 0066 4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUL
PY 2010
VL 54
IS 7
BP 2987
EP 2993
DI 10.1128/AAC.00198 10
PG 7
WC Microbiology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology; Pharmacology & Pharmacy
GA 611TF
UT WOS:000278845100031
PM 20457823
OA Green Published
DA 2025 08 17
ER

PT J
AU Morikane, S
   Ishida, K
   Ashizawa, N
   Taniguchi, T
   Matsubayashi, M
   Kurita, N
   Kobashi, S
   Iwanaga, T
AF Morikane, Shota
   Ishida, Koichi
   Ashizawa, Naoki
   Taniguchi, Tetsuya
   Matsubayashi, Masaya
   Kurita, Naoki
   Kobashi, Seiichi
   Iwanaga, Takashi
TI Lead Acetate Injected Mice is an Animal Model for Extrapolation of
   Calcifying Response to Humans Due to Low Involvement of Bone Resorption
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Bone resorption; Calciprotein particle formation; Calcification;
   Bisphosphonate; Lead acetate induced calcergy model; Aorta transplanted
   calcification model
ID LOCAL SIMPLE CALCERGY; VASCULAR CALCIFICATION; ARTERY CALCIFICATION;
   AORTIC CALCIFICATION; BISPHOSPHONATES; ALLOGRAFT; RAT;
   HYPERPHOSPHATEMIA; DETERMINANTS; INHIBITION
AB Vascular calcification affects the prognosis of patients with renal failure. Bisphosphonates are regarded as candidate anti calcifying drugs because of their inhibitory effects on both calcium phosphate aggregation and bone resorption. However, calcification in well known rodent models is dependent upon bone resorption accompanied by excessive bone turnover, making it difficult to estimate accurately the anti calcifying potential of drugs. Therefore, models with low bone resorption are required to extrapolate anti calcifying effects to humans. Three bisphosphonates (etidronate, alendronate, and FYB 931) were characterised for their inhibitory effects on bone resorption in vivo and calcium phosphate aggregation estimated by calciprotein particle formation in vitro. Then, their effects were examined using two models inducing ectopic calcification: the site where lead acetate was subcutaneously injected into mice and the transplanted, aorta obtained from a donor rat. The inhibitory effects of bisphosphonates on bone resorption and calcium phosphate aggregation were alendronate > FYB 931 > etidronate and FYB 931 > alendronate = etidronate, respectively. In the lead acetate induced model, calcification was most potently suppressed by FYB 931, followed by alendronate and etidronate. In the aorta transplanted model, only FYB 931 suppressed calcification at a high dose. In both the models, no correlation was observed between calcification and bone resorption marker, tartrate resistant acid phosphatase (TRACP). Results from the lead acetate induced model showed that inhibitory potency against calcium phosphate aggregation contributed to calcification inhibition. The two calcification models, especially the lead acetate induced model, may be ideal for the extrapolation of calcifying response to humans because of calcium phosphate aggregation rather than bone resorption as its mechanism.
C1 [Morikane, Shota; Ishida, Koichi; Ashizawa, Naoki; Taniguchi, Tetsuya; Matsubayashi, Masaya; Kurita, Naoki; Iwanaga, Takashi] FUJI YAKUHIN CO LTD, Res Labs 2, 636 1 Iidashinden,Nishi Ku, Saitama, Saitama 3310068, Japan.
   [Kobashi, Seiichi] FUJI YAKUHIN CO LTD, Res Labs 1, 3936 2 Sashi,Nishi Ku, Saitama, Saitama 3310047, Japan.
RP Morikane, S (通讯作者)，FUJI YAKUHIN CO LTD, Res Labs 2, 636 1 Iidashinden,Nishi Ku, Saitama, Saitama 3310068, Japan.
EM s morikane@fujiyakuhin.co.jp
FX We thank Dr. Koji Matsumoto, and Ms. Noriko Chikamatsu in FUJI YAKUHIN
   CO., LTD. for their assistance in the in vivo evaluation.
CR Amann K, 2008, CLIN J AM SOC NEPHRO, V3, P1599, DOI 10.2215/CJN.02120508
   Ariyoshi T, 2006, CLIN DRUG INVEST, V26, P215, DOI 10.2165/00044011 200626040 00006
   Bressendorff I, 2018, CLIN J AM SOC NEPHRO, V13, P1373, DOI 10.2215/CJN.13921217
   Bressendorff I, 2017, KIDNEY INT REP, V2, P380, DOI 10.1016/j.ekir.2016.12.008
   BRIDGES JB, 1972, CALC TISS RES, V10, P136, DOI 10.1007/BF02012543
   Chen W, 2019, NEPHROL DIAL TRANSPL, V34, P992, DOI 10.1093/ndt/gfy117
   DOYLE DV, 1979, J PATHOL, V128, P63, DOI 10.1002/path.1711280203
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Ferrer MD, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07203 x
   HIRSCH RS, 1984, AUST J EXP BIOL MED, V62, P727, DOI 10.1038/icb.1984.69
   Ishida K, 2021, J PHARM PHARMACOL, V73, P947, DOI 10.1093/jpp/rgab019
   Ishida K, 2019, J BONE MINER METAB, V37, P796, DOI 10.1007/s00774 019 00987 0
   KATO Y, 1977, CALC TISS RES, V24, P41, DOI 10.1007/BF02223295
   Kawakami K, 2023, CALCIFIED TISSUE INT, V113, P216, DOI 10.1007/s00223 023 01086 z
   LEVY RJ, 1985, CIRCULATION, V71, P349, DOI 10.1161/01.CIR.71.2.349
   LEVY RJ, 1983, AM J PATHOL, V113, P143
   Lomashvili K, 2006, KIDNEY INT, V69, P1464, DOI 10.1038/sj.ki.5000297
   Mathieu P, 2003, J THORAC CARDIOV SUR, V126, P1449, DOI 10.1016/S0022 5223(03)00031 X
   MCCLURE J, 1982, J PATHOL, V137, P243, DOI 10.1002/path.1711370308
   MCCLURE J, 1976, CALC TISS RES, V22, P129
   Pasch A, 2012, J AM SOC NEPHROL, V23, P1744, DOI 10.1681/ASN.2012030240
   Pawade TA, 2021, CIRCULATION, V143, P2418, DOI 10.1161/CIRCULATIONAHA.121.053708
   Price PA, 2001, ARTERIOSCL THROM VAS, V21, P817, DOI 10.1161/01.ATV.21.5.817
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Sakaguchi Y, 2019, J AM SOC NEPHROL, V30, P1073, DOI 10.1681/ASN.2018111150
   SELYE H, 1964, J HISTOCHEM CYTOCHEM, V12, P563, DOI 10.1177/12.8.563
   SHANKAR R, 1984, ATHEROSCLEROSIS, V52, P191, DOI 10.1016/0021 9150(84)90117 5
   Shiota E., 1982, ORTHOP TRAUMATOL, V31, P141, DOI [10.5035/nishiseisai.31.141, DOI 10.5035/NISHISEISAI.31.141]
   Spiegel DM, 2009, HEMODIAL INT, V13, P453, DOI 10.1111/j.1542 4758.2009.00364.x
   Tamagaki K, 2006, NEPHROL DIAL TRANSPL, V21, P651, DOI 10.1093/ndt/gfi273
   Tamura K, 2005, J PHARMACOL SCI, V99, P89, DOI 10.1254/jphs.FPJ05019X
   Tyson J, 2020, BIOENGINEERING BASEL, V7, DOI 10.3390/bioengineering7030088
   Tzanakis IP, 2014, INT UROL NEPHROL, V46, P2199, DOI 10.1007/s11255 014 0751 9
   WEBB CL, 1992, AM J PATHOL, V141, P487
   Yamada S, 2017, BONE, V100, P87, DOI 10.1016/j.bone.2016.11.012
   Yamada S, 2014, AM J PHYSIOL RENAL, V306, pF1418, DOI 10.1152/ajprenal.00633.2013
   Yamauchi H, 2013, J THORAC CARDIOV SUR, V145, P522, DOI 10.1016/j.jtcvs.2012.03.010
NR 37
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD SEP
PY 2024
VL 115
IS 3
BP 315
EP 327
DI 10.1007/s00223 024 01245 w
EA JUL 2024
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA E6Z7I
UT WOS:001260371600002
PM 38951181
DA 2025 08 17
ER

PT J
AU Gass, M
   Dawson Hughes, B
AF Gass, M
   Dawson Hughes, B
TI Preventing osteoporosis related fractures: An overview
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE bone loss; calcium/vitamin D supplementation; fractures; menopause;
   osteoporosis; pharmacotherapeutic intervention
ID BONE MINERAL DENSITY; ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN;
   VERTEBRAL FRACTURES; CALCIUM SUPPLEMENTATION; RANDOMIZED TRIAL;
   BREAST CANCER; OLDER WOMEN; RISK; BISPHOSPHONATES
AB Osteoporosis is a skeletal disorder characterized by compromised bone strength, which predisposes a person to increased risk of fracture. In the United States, 26% of women aged >= 65 years and >50% of women aged >= 85 years have osteoporosis. Over 1.5 million fractures per year are attributable to osteoporosis; these fractures result in 500,000 hospitalizations, 800,000 emergency room visits, 2.6 million physician visits, 180,000 nursing home placements, and $12 billion to $18 billion in direct healthcare costs each year. Fracture also results in loss of function and has a negative impact on psychological status. In recognition of the importance of bone health, the US Surgeon General has, for the first time, issued a comprehensive report on bone health and treatment. The report recommends a pyramidal approach to osteoporosis treatment that includes calcium and vitamin D supplementation, physical activity, and fall prevention as the first line in fracture prevention. The second level consists of treating secondary causes of osteoporosis; the third and top level consists of pharmacotherapy. Pharmacotherapeutic interventions (e.g., bisphosphonates, selective estrogen receptor modulators, calcitonin, and teriparatide) in women with postmenopausal osteoporosis provide substantial reduction in fracture risk over and above risk reduction with calcium and vitamin D supplementation alone. Despite the effectiveness of therapy, most patients who receive treatment do not remain on treatment for > 1 year. An important approach to reducing the rate of fractures is first to target our treatments to patients at high risk for fracture and then to develop strategies to improve treatment continuation rates. (C) 2006 Elsevier Inc. All rights reserved.
C1 Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Cincinnati, OH 45267 USA.
   Tufts Univ, Sch Med, Div Endocrinol, Boston, MA 02111 USA.
C3 University System of Ohio; University of Cincinnati; Tufts University
RP Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.
EM margery.gass@UC.edu
CR ADACHI K, 1990, ANN OTO RHINOL LARYN, V99, P738, DOI 10.1177/000348949009900914
   [Anonymous], 2004, Bone Health and Osteoporosis: A report of the Surgeon General
   *AV PHARM INC, 2004, ACT RIS SOD TABL PRE
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   CARANO A, 1990, J CLIN INVEST, V85, P456, DOI 10.1172/JCI114459
   Cauley JA, 2003, JAMA J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729
   Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   Cramer JA, 2004, J BONE MINER RES, V19, pS448
   Cranney A, 2002, ENDOCR REV, V23, P540, DOI 10.1210/er.2001 6002
   Cummings SR, 1999, JAMA J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305
   Delaney MF, 2003, J CLIN DENSITOM, V6, P45, DOI 10.1385/JCD:6:1:45
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   *E LILL CO, 2004, FORT TER RDNA OR INJ
   Emkey Ronald, 2004, MedGenMed, V6, P6
   Empana JP, 2004, J AM GERIATR SOC, V52, P685, DOI 10.1111/j.1532 5415.2004.52203.x
   Ensrud KE, 2000, J AM GERIATR SOC, V48, P241, DOI 10.1111/j.1532 5415.2000.tb02641.x
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   FIATARONE MA, 1990, JAMA J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029
   Gallagher JC, 2002, MENOPAUSE, V9, P84
   Going S, 2003, OSTEOPOROSIS INT, V14, P637, DOI 10.1007/s00198 003 1436 x
   Gordon Michael S, 2002, Endocr Pract, V8, P202
   Greenspan SL, 2002, J BONE MINER RES, V17, P1988
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Hodgson Stephen F, 2003, Endocr Pract, V9, P544
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Järvinen TL, 2003, J BONE MINER RES, V18, P1921, DOI 10.1359/jbmr.2003.18.11.1921
   Kado DM, 1999, ARCH INTERN MED, V159, P1215, DOI 10.1001/archinte.159.11.1215
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   *MERCK CO INC, 2004, FOS AL SOD TABL OR S
   *NAT OST FDN, PHYS GUID PREV TREAT
   *NAT OST FDN, PAT INF FALL PREV
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nevitt MC, 1998, ANN INTERN MED, V128, P793, DOI 10.7326/0003 4819 128 10 199805150 00001
   *NIH OFF DIET S, DIET SUPPL FACT SHEE
   *NOV PHARM CORP, 2003, MIAC CALC SAL NAS SP
   OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681
   PARKER MJ, 2004, COCHRANE DB SYST REV, V3
   REID IR, 1995, AM J MED, V98, P331, DOI 10.1016/S0002 9343(99)80310 6
   *ROCH LAB INC, 2005, BON IB SOD TABL PRES
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   *WHO, 1994, WHO TECHN REP SER, V843
NR 47
TC 190
Z9 201
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002 9343
EI 1555 7162
J9 AM J MED
JI Am. J. Med.
PD APR
PY 2006
VL 119
IS 4
SU 1
BP 3S
EP 11S
DI 10.1016/j.amjmed.2005.12.017
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 025RN
UT WOS:000236284700002
PM 16563939
DA 2025 08 17
ER

PT J
AU Welch, RD
   Billon, C
   Valfort, AC
   Burris, TP
   Flaveny, CA
AF Welch, Ryan D.
   Billon, Cyrielle
   Valfort, Aurore Cecile
   Burris, Thomas P.
   Flaveny, Colin A.
TI Pharmacological inhibition of REV ERB stimulates differentiation,
   inhibits turnover and reduces fibrosis in dystrophic muscle
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DUCHENNE MUSCULAR DYSTROPHY; ARNT LIKE 1; CELL PROLIFERATION; NUCLEAR
   RECEPTORS; CLOCK GENES; ALPHA; EXPRESSION; ATALUREN; REGENERATION;
   STRATEGIES
AB Duchenne muscular dystrophy (DMD) is a debilitating X linked disorder that is fatal. DMD patients lack the expression of the structural protein dystrophin caused by mutations within the DMD gene. The absence of functional dystrophin protein results in excessive damage from normal muscle use due to the compromised structural integrity of the dystrophin associated glycoprotein complex. As a result, DMD patients exhibit ongoing cycles of muscle destruction and regeneration that promote inflammation, fibrosis, mitochondrial dysfunction, satellite cell (SC) exhaustion and loss of skeletal and cardiac muscle function. The nuclear receptor REV ERB suppresses myoblast differentiation and recently we have demonstrated that the REV ERB antagonist, SR8278, stimulates muscle regeneration after acute injury. Therefore, we decided to explore whether the REV ERB antagonist SR8278 could slow the progression of muscular dystrophy. In mdx mice SR8278 increased lean mass and muscle function, and decreased muscle fibrosis and muscle protein degradation. Interestingly, we also found that SR8278 increased the SC pool through stimulation of Notch and Wnt signaling. These results suggest that REV ERB is a potent target for the treatment of DMD.
C1 [Welch, Ryan D.; Billon, Cyrielle; Valfort, Aurore Cecile; Burris, Thomas P.; Flaveny, Colin A.] St Louis Univ, Sch Med, Dept Physiol & Pharmacol, St Louis, MO 63104 USA.
C3 Saint Louis University
RP Flaveny, CA (通讯作者)，St Louis Univ, Sch Med, Dept Physiol & Pharmacol, St Louis, MO 63104 USA.
EM colin.flaveny@health.slu.edu
RI Burris, Thomas/B 3886 2016; Welch, Ryan/KZU 5349 2024
OI Burris, Thomas/0000 0003 2922 4449; 
FU National Institutes of Health [MH093429]
FX We would like to thank Dr. Grant Kolar in the department of Pathology
   and Saint Louis University for providing assistance with the
   histological and immuno histochemical assays conducted herein. This work
   was supported by a grant from the National Institutes of Health
   (MH093429, T.P.B.).
CR Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075
   Bach JR, 2011, RESP CARE, V56, P744, DOI 10.4187/respcare.00831
   Bjornson CRR, 2012, STEM CELLS, V30, P232, DOI 10.1002/stem.773
   Bodine SC, 2014, AM J PHYSIOL ENDOC M, V307, pE469, DOI 10.1152/ajpendo.00204.2014
   Bonaldo P, 2013, DIS MODEL MECH, V6, P25, DOI 10.1242/dmm.010389
   Braun R, 2014, AM J PHYS MED REHAB, V93, pS97, DOI 10.1097/PHM.0000000000000138
   Burke L, 1996, NUCLEIC ACIDS RES, V24, P3481, DOI 10.1093/nar/24.18.3481
   Chalkiadaki A, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004490
   Chatterjee S, 2015, EXP CELL RES, V331, P200, DOI 10.1016/j.yexcr.2014.08.041
   Chatterjee S, 2013, J CELL SCI, V126, P2213, DOI 10.1242/jcs.120519
   Church JE, 2014, EXP PHYSIOL, V99, P675, DOI 10.1113/expphysiol.2013.077255
   Cirillo F, 2017, FASEB J, V31, P2146, DOI 10.1096/fj.201600878R
   Crumbley C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017290
   DOWNES M, 1995, MOL ENDOCRINOL, V9, P1666, DOI 10.1210/me.9.12.1666
   Eichenfield DZ, 2016, ELIFE, V5, DOI 10.7554/eLife.13024
   Figeac N, 2015, CELL SIGNAL, V27, P1652, DOI 10.1016/j.cellsig.2015.03.025
   Foletta VC, 2011, PFLUG ARCH EUR J PHY, V461, P325, DOI 10.1007/s00424 010 0919 9
   Garg K, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00087
   Gee P, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/8765154
   Han XH, 2011, J BIOL CHEM, V286, P10649, DOI 10.1074/jbc.M110.169391
   Huraskin D, 2016, DEVELOPMENT, V143, P3128, DOI 10.1242/dev.139907
   Khurana TS, 2003, NAT REV DRUG DISCOV, V2, P379, DOI 10.1038/nrd1085
   Kitamoto T, 2010, STEM CELLS, V28, P2205, DOI 10.1002/stem.547
   Kojetin D, 2011, ACS CHEM BIOL, V6, P131, DOI 10.1021/cb1002575
   Kojetin DJ, 2014, NAT REV DRUG DISCOV, V13, P197, DOI 10.1038/nrd4100
   Kole R, 2015, ADV DRUG DELIVER REV, V87, P104, DOI 10.1016/j.addr.2015.05.008
   Lam MTY, 2013, NATURE, V498, P511, DOI 10.1038/nature12209
   Lapidos KA, 2004, CIRC RES, V94, P1023, DOI 10.1161/01.RES.0000126574.61061.25
   Le Grand F, 2009, CELL STEM CELL, V4, P535, DOI 10.1016/j.stem.2009.03.013
   Lim KRQ, 2017, DRUG DES DEV THER, V11, P533, DOI 10.2147/DDDT.S97635
   Malik V, 2012, EXPERT OPIN EMERG DR, V17, P261, DOI 10.1517/14728214.2012.691965
   Mandillo S, 2008, PHYSIOL GENOMICS, V34, P243, DOI 10.1152/physiolgenomics.90207.2008
   McDearmon EL, 2006, SCIENCE, V314, P1304, DOI 10.1126/science.1132430
   McDonald CM, 2017, LANCET, V390, P1489, DOI 10.1016/S0140 6736(17)31611 2
   Migita H, 2004, FEBS LETT, V561, P69, DOI 10.1016/S0014 5793(04)00118 8
   Nakamura A., 2017, J HUM GENET
   Nakamura A, 2017, J HUM GENET, V62, P459, DOI 10.1038/jhg.2016.152
   Nakao R, 2015, CHRONOBIOL INT, V32, P486, DOI 10.3109/07420528.2014.1003350
   Nam D, 2015, SCI REP UK, V5, DOI 10.1038/srep11239
   Otto A, 2008, J CELL SCI, V121, P2939, DOI 10.1242/jcs.026534
   Pant M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123875
   Parisi A, 2015, J CELL BIOL, V210, P717, DOI 10.1083/jcb.201501053
   Perrin L, 2015, MOL METAB, V4, P834, DOI 10.1016/j.molmet.2015.07.009
   Peverelli L, 2015, NEUROLOGY, V85, P1886, DOI 10.1212/WNL.0000000000002147
   Pini V, 2017, CURR STEM CELL REP, V3, P137, DOI 10.1007/s40778 017 0076 6
   Proffitt KD, 2013, CANCER RES, V73, P502, DOI 10.1158/0008 5472.CAN 12 2258
   Ramakrishnan SN, 2005, J BIOL CHEM, V280, P8651, DOI 10.1074/jbc.M413949200
   Reinig AM, 2017, PHARMACOTHERAPY, V37, P492, DOI 10.1002/phar.1909
   Ricotti V, 2013, J NEUROL NEUROSUR PS, V84, P698, DOI 10.1136/jnnp 2012 303902
   Roy B, 2016, P NATL ACAD SCI USA, V113, P12508, DOI 10.1073/pnas.1605336113
   Rudolf A, 2016, CELL REP, V15, P1277, DOI 10.1016/j.celrep.2016.04.022
   Ryan NJ, 2014, DRUGS, V74, P1709, DOI 10.1007/s40265 014 0287 4
   Rybalka E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115763
   Ryder S, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023 017 0631 3
   Schiavone M, 2017, PHARMACOL RES, V125, P122, DOI 10.1016/j.phrs.2017.09.001
   Scotton C, 2016, J CELL SCI, V129, P1671, DOI 10.1242/jcs.175927
   Seale P, 2003, CELL CYCLE, V2, P418, DOI 10.4161/cc.2.5.498
   Sharma A, 2014, AM J CASE REP, V15, P128, DOI 10.12659/AJCR.890078
   Tanaka Shingo, 2011, J Mol Signal, V6, P12, DOI 10.1186/1750 2187 6 12
   Tidball JG, 2010, AM J PHYSIOL REG I, V298, pR1173, DOI 10.1152/ajpregu.00735.2009
   Vila MC, 2017, CELL DEATH DIFFER, V24, P330, DOI 10.1038/cdd.2016.127
   von Maltzahn J, 2012, P NATL ACAD SCI USA, V109, P20614, DOI 10.1073/pnas.1215765109
   von Maltzahn J, 2012, TRENDS CELL BIOL, V22, P602, DOI 10.1016/j.tcb.2012.07.008
   Welch RD, 2017, MOL METAB, V6, P703, DOI 10.1016/j.molmet.2017.05.001
   Woldt E, 2013, NAT MED, V19, P1039, DOI 10.1038/nm.3213
   Yin L, 2007, SCIENCE, V318, P1786, DOI 10.1126/science.1150179
   Zhang YX, 2015, SCIENCE, V348, P1488, DOI 10.1126/science.aab3021
NR 67
TC 32
Z9 36
U1 0
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD DEC 7
PY 2017
VL 7
AR 17142
DI 10.1038/s41598 017 17496 7
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FP1EI
UT WOS:000417353800011
PM 29215066
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ayora, AF
   Herion, F
   Rompen, E
   Reginster, JY
   Magremanne, M
   Lambert, F
AF Ayora, Alberto Fernandez
   Herion, Francine
   Rompen, Eric
   Reginster, Jean Yves
   Magremanne, Michele
   Lambert, France
TI Dramatic osteonecrosis of the jaw associated with oral bisphosphonates,
   periodontitis, and dental implant removal
SO JOURNAL OF CLINICAL PERIODONTOLOGY
LA English
DT Article
DE alendronate; implant; medication related osteonecrosis of the jaw;
   osteonecrosis; osteoporosis; periodontitis
ID PREVENTIVE MEASURES; RANDOMIZED TRIAL; RISK; RECONSTRUCTION; CANCER;
   FLAP; IMPLEMENTATION; OSTEOPOROSIS; DOXYCYCLINE; MECHANISMS
AB IntroductionOsteoporosis affects millions of elderly patients, and anti resorptive drugs (ARD) such as bisphosphonates (BP) represent the first line therapy. Despite the benefits related to the use of these medications, osteonecrosis of the jaw is a significant complication in a subset of patients receiving these drugs.
   Case presentationThis report documents a case of dramatic bisphosphonate related osteonecrosis associated with periodontitis and dental implant removal in an osteoporotic patient treated with per os bisphosphonates for an uninterrupted period of 15years.
   ConclusionThe aim of this report was to discuss the administration period of BP in the treatment of osteoporosis, the decision making and clinical management of severe MRONJ and the indications for dental implant placement in these specific patients.
C1 [Ayora, Alberto Fernandez; Herion, Francine; Rompen, Eric] Univ Liege, Fac Med, Dept Periodontol & Oral Surg, Liege, Belgium.
   [Reginster, Jean Yves] Univ Liege, Fac Med, Dept Publ Hlth Epidemiol & Hlth Econ, Liege, Belgium.
   [Magremanne, Michele] Catholic Univ Louvain, Fac Med & Dent, Louvain, Belgium.
   [Lambert, France] CHU Liege, Dept Periodontol & Oral Surg, B 4000 Liege, Belgium.
   [Lambert, France] Univ Liege, Fac Med, Dent Biomat Res Unit DBRU, Liege, Belgium.
C3 University of Liege; University of Liege; Universite Catholique Louvain;
   University of Liege; University of Liege
RP Lambert, F (通讯作者)，CHU Liege, Dept Periodontol & Oral Surg, Domaine Sart Tilman Bat B 35, B 4000 Liege, Belgium.
EM france.lambert@chu.ulg.ac.be
RI Reginster, Jean Yves/AGC 6097 2022
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Almazin SM, 2009, J PERIODONTOL, V80, P999, DOI 10.1902/jop.2009.080574
   American Dental Association Council on Scientific Affairs, 2006, J Am Dent Assoc, V137, P1144
   [Anonymous], AM ASS OR MAX SURG P
   Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Black DM, 2012, NEW ENGL J MED, V366, P2051, DOI 10.1056/NEJMp1202623
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Campisi G, 2014, FUTURE ONCOL, V10, P257, DOI [10.2217/FON.13.211, 10.2217/fon.13.211]
   Dimitrakopoulos I, 2006, INT J ORAL MAX SURG, V35, P588, DOI 10.1016/j.ijom.2006.02.022
   Dimopoulos MA, 2009, ANN ONCOL, V20, P117, DOI 10.1093/annonc/mdn554
   Engroff SL, 2007, J ORAL MAXIL SURG, V65, P2374, DOI 10.1016/j.joms.2006.07.012
   Ferrari S, 2008, J ORAL MAXIL SURG, V66, P999, DOI 10.1016/j.joms.2007.06.631
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   GREVSTAD HJ, 1995, EUR J ORAL SCI, V103, P156, DOI 10.1111/j.1600 0722.1995.tb00017.x
   Holmes SG, 2004, BONE, V35, P471, DOI 10.1016/j.bone.2004.02.028
   Kang B, 2013, J BONE MINER RES, V28, P1631, DOI 10.1002/jbmr.1894
   Kanis JA, 2013, OSTEOPOROSIS INT, V24, P23, DOI 10.1007/s00198 012 2074 y
   Madrid C, 2009, CLIN ORAL IMPLAN RES, V20, P87, DOI 10.1111/j.1600 0501.2009.01772.x
   Magopoulos C, 2007, AM J OTOLARYNG, V28, P158, DOI 10.1016/j.amjoto.2006.08.004
   Mariotti A, 2008, J DENT EDUC, V72, P919
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Marx RE, 2007, J ORAL MAXIL SURG, V65, P2397, DOI 10.1016/j.joms.2007.08.003
   Mücke T, 2009, J CRANIO MAXILL SURG, V37, P291, DOI 10.1016/j.jcms.2008.12.004
   Neuprez A, 2014, OSTEOPOROSIS INT, V25, P393, DOI 10.1007/s00198 013 2437 z
   Nocini PF, 2009, EJSO EUR J SURG ONC, V35, P373, DOI 10.1016/j.ejso.2008.05.002
   Ott SM, 2011, CLEV CLIN J MED, V78, P619, DOI 10.3949/ccjm.78a.11022
   Otto S, 2011, J CRANIO MAXILL SURG, V39, P272, DOI 10.1016/j.jcms.2010.05.009
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Ripamonti CI, 2009, ANN ONCOL, V20, P137, DOI 10.1093/annonc/mdn526
   ROMPEN EH, 1993, J DENT RES, V72, P607, DOI 10.1177/00220345930720030901
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Sacco R, 2011, J APPL ORAL SCI, V19, P293, DOI 10.1590/S1678 77572011000400001
   Seth R, 2010, LARYNGOSCOPE, V120, P2165, DOI 10.1002/lary.21062
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Whitaker M, 2012, NEW ENGL J MED, V366, P2048, DOI 10.1056/NEJMp1202619
NR 37
TC 17
Z9 19
U1 0
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0303 6979
EI 1600 051X
J9 J CLIN PERIODONTOL
JI J. Clin. Periodontol.
PD FEB
PY 2015
VL 42
IS 2
BP 190
EP 195
DI 10.1111/jcpe.12322
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CB7AF
UT WOS:000349777600010
PM 25327450
DA 2025 08 17
ER

PT J
AU Almelah, E
   Smith, DPT
   Mcgown, A
   Aziz, A
   Potgieter, HJ
   Ragazzon, P
AF Almelah, Eman
   Smith, David P. T.
   Mcgown, Andrew
   Aziz, Athar
   Potgieter, Herman J.
   Ragazzon, Patricia
TI Dibenzoyl methane Derivatives as a Potential and Exciting New Therapy
   for the Treatment of Childhood Bone Cancer
SO ANTICANCER RESEARCH
LA English
DT Article
DE Bone cancer; dibenzoylmethane; childhood
ID INDEPENDENT CELL DEATH; EWING SARCOMA; C MYC; CYCLE; APOPTOSIS;
   OSTEOSARCOMA; CISPLATIN; COHORT; TUMORS
AB Childhood bone cancer though rare, has very limited treatment choices, with poor survival rates and often involving amputation. We developed a novel molecule, 2',4' dihydroxy dithion dibenzoyl methane and tested it on hepatic, colon, lung and osteoblast cancer cell lines. Thionylation of 2',4' dihydroxydibenzoylmethane led to selective targeting of bone cancer cells, stopping their growth and leading to their death without affecting non cancerous cells within the bone marrow or other non malignant cells.
C1 [Almelah, Eman; Smith, David P. T.; Mcgown, Andrew; Aziz, Athar; Ragazzon, Patricia] Univ Salford, Coll Sci & Technol, Sch Environm & Life Sci, Manchester, Lancs, England.
   [Potgieter, Herman J.] Manchester Metropolitan Univ, Div Chem & Environm Sci, Manchester, Lancs, England.
C3 University of Manchester; University of Salford; Manchester Metropolitan
   University
RP Ragazzon, P (通讯作者)，Univ Salford, Sch Environm & Life Sci, Room G02,Cockcroft Bldg, Manchester M5 4WT, Lancs, England.
EM p.a.ragazzon@salford.ac.uk
RI ; Potgieter, Johannes/L 5835 2017; McGown, Andrew/IZP 5612 2023;
   Potgieter, Herman/L 5835 2017
OI McGown, Andrew/0000 0002 2187 3850; Potgieter,
   Johannes/0000 0003 2833 7986; Ragazzon, Patricia/0000 0003 0374 4569
FU University of Salford; Manchester Metropolitan University research
   budgets
FX This research was funded by the University of Salford as part of the MSc
   research projects and the Manchester Metropolitan University research
   budgets. We would like to express our gratitude to: Dr Nanda Puspita,
   Ms, Basma A l Sudani, Mr Omar Elaskani and Ms Nasrin Ahmed for their
   help in the tissue culture at the University of Salford.
CR ACCO, CAN IN CHILDR
   Aziz A, 2009, SCIENCE, V326, P867, DOI 10.1126/science.1176056
   BCRTOrgUK, TEEN BON CANC
   Bröker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078 0432.CCR 04 2223
   Cancer.org, BONC CANC KEY STAT
   Cancer.Org, BON CANC
   CRUK, BON CANC TREATM
   CRUK, STAG BON CANC
   CRUK, AB CANC TYP
   Eisenberg E, 2003, TRENDS GENET, V19, P362, DOI 10.1016/S0168 9525(03)00140 9
   Escalas C, 2015, B CANCER, V102, P684, DOI 10.1016/j.bulcan.2015.03.008
   Ferrari S, 2014, TUMORI J, V100, P612, DOI [10.1177/1778.19262, 10.1700/1778.19262]
   Guicciardi ME, 2013, COMPR PHYSIOL, V3, P977, DOI 10.1002/cphy.c120020
   Gupta A, 1999, CLIN EXP IMMUNOL, V117, P56
   Hassan M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/150845
   Huang MT, 1998, CARCINOGENESIS, V19, P1697, DOI 10.1093/carcin/19.9.1697
   Iwasaki R, 2008, CANCER SCI, V100, P346
   Jackson KM, 2002, CANCER LETT, V178, P161, DOI 10.1016/S0304 3835(01)00844 8
   Jain MV, 2013, J CELL MOL MED, V17, P12, DOI 10.1111/jcmm.12001
   Kim N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120104
   Kogel D., 2000, Madame Curie Bioscience Database
   LARSEN JK, 1986, CYTOMETRY, V7, P54, DOI 10.1002/cyto.990070108
   Le Deley MC, 2014, J CLIN ONCOL, V32, P2440, DOI 10.1200/JCO.2013.54.4833
   Mateyak MK, 1999, MOL CELL BIOL, V19, P4672
   NHS, CANC OF THE BON
   NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603
   Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749
   Plantaz D, 2014, REV PRACT, V649, P1284
   Promega.com, AP GLO MAN
   Ragazzon PA, 2009, ANTICANCER RES, V29, P2273
   RODAN SB, 1987, CANCER RES, V47, P4961
   Sarcoma UK, UND SARC
   SCULLEY DG, 1992, HUM GENET, V90, P195
   Shalaby MS, 2014, ARCH DIS CHILD, V99, P1009, DOI 10.1136/archdischild 2014 306414
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0321 5
   Sukumari Ramesh S, 2011, INT J DEV NEUROSCI, V29, P701, DOI 10.1016/j.ijdevneu.2011.06.002
   Tait SWG, 2008, ONCOGENE, V27, P6452, DOI 10.1038/onc.2008.311
   Tao ZM, 2007, MOL PHARMACEUT, V4, P583, DOI 10.1021/mp070002r
   Tsaniras SC, 2014, SEMIN CELL DEV BIOL, V30, P174, DOI 10.1016/j.semcdb.2014.03.013
   van Maldegem AM, 2015, PEDIATR BLOOD CANCER, V62, P40, DOI 10.1002/pbc.25230
   Yoon JH, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 622
NR 41
TC 6
Z9 7
U1 1
U2 10
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD NOV
PY 2016
VL 36
IS 11
SI SI
BP 6043
EP 6050
DI 10.21873/anticanres.11193
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA EC9TI
UT WOS:000388486700052
PM 27793931
OA Green Accepted, Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU El Shafey, EM
   Alsahow, AE
   Alsaran, K
   Sabry, AA
   Atia, M
AF El Shafey, Eid M.
   Alsahow, Ali E.
   Alsaran, Khalid
   Sabry, Alaa A.
   Atia, Mohamed
TI Cinacalcet Hydrochloride Therapy for Secondary Hyperparathyroidism in
   Hemodialysis Patients
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article
DE Cinacalcet HCl; K; DOQI guidelines; Secondary hyperparathyroidism;
   Hemodialysis; Outcomes
ID MINERAL METABOLISM; HCL; DIALYSIS; MORTALITY; DISEASE
AB This study compared the efficacy of a cinacalcet based regimen with unrestricted conventional therapy (vitamin D and phosphate binders) for achieving Kidney Disease Outcome Quality Initiative (K/DOQI) targets for dialysis patients. In this multicenter, prospective study, hemodialysis patients with poorly controlled secondary hyperparathyroidism (SHPT) were randomized to receive a cinacalcet based regimen (n = 55) or a conventional therapy (n = 27). Doses of cinacalcet, vitamin D sterols, and phosphate binders were adjusted during a 12 week dose titration phase to achieve intact parathyroid hormone (iPTH) levels <= 31.8 pmol/L. The primary end point was the percentage of patients with values in this range during a 24 week efficacy assessment phase. The clinical response to 36 week cinacalcet treatment was evaluated. A dual energy X ray absorptiometry was performed before and after 36 weeks of cinacalcet therapy. Fifty eight percent of the cinacalcet group reached the primary end point, as compared with 19% of the conventional therapy group (P = 0.001). A higher percentage of patients receiving the cinacalcet based regimen versus conventional therapy achieved the targets for calcium, phosphorus and Ca x P. Achievement of targets was greatest in patients with less severe disease (intact PTH range, 31.8 to 53 pmol/L). Cinacalcet therapy increased proximal femur bone mineral density (BMD), but did not affect the lumbar spine. Itching intensity decreased significantly. Cinacalcet based treatment facilitates achievement of the K/DOQI targets for iPTH and bone mineral metabolism compared with conventional therapy in hemodialysis patients. Suppression of iPTH with cinacalcet reverses bone loss in the proximal femur. Cinacalcet alleviated itching.
C1 [El Shafey, Eid M.] Tanta Univ, Dept Internal Med, Div Nephrol, Tanta, Egypt.
   [Atia, Mohamed] Tanta Univ, Fac Med, Clin Pathol Dept, Tanta, Egypt.
   [El Shafey, Eid M.; Alsahow, Ali E.] Jahra Hosp, Dept Internal Med, Div Nephrol, Kuwait, Kuwait.
   [Alsaran, Khalid; Sabry, Alaa A.] Prince Salman Ctr Kidney Dis, Riyadh, Saudi Arabia.
C3 Egyptian Knowledge Bank (EKB); Tanta University; Egyptian Knowledge Bank
   (EKB); Tanta University; Jahra Hosptial
RP El Shafey, EM (通讯作者)，Tanta Univ Hosp, Dept Internal Med, Tanta, Egypt.
EM shafey70@yahoo.com
RI Alsahow, Ali/ABE 2481 2021; Gawaly, Amr/AAJ 8519 2020; ELSHAFEY,
   EID/JWP 1290 2024; El Fahar, Mohammed/AAC 6629 2019
OI ALSARAN, KHALID/0000 0003 1140 3721; AlSahow, Ali/0000 0001 8081 3244;
   Sabry, Alaa/0000 0003 0151 7717; Attia, Mohamed/0000 0002 6931 6076
CR Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Chertow GM, 2006, CLIN J AM SOC NEPHRO, V1, P305, DOI 10.2215/CJN.00870805
   Colloton M, 2005, KIDNEY INT, V67, P467, DOI 10.1111/j.1523 1755.2005.67103.x
   Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523 1755.2005.00596.x
   Drüeke TB, 2004, NEPHROL DIAL TRANSPL, V19, P20, DOI 10.1093/ndt/gfh1052
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Lien YHH, 2005, NEPHROL DIAL TRANSPL, V20, P1232, DOI 10.1093/ndt/gfh829
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Marco MP, 2003, KIDNEY INT, V63, pS111, DOI 10.1046/j.1523 1755.63.s85.26.x
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Nagano N, 2005, J PHARMACOL SCI, V97, P355, DOI 10.1254/jphs.FMJ04007X6
   Owda A, 2003, RENAL FAILURE, V25, P595, DOI 10.1081/JDI 120022551
   Pasieka JL, 2000, SURGERY, V128, P531, DOI 10.1067/msy.2000.108117
   PIERGIORGIO M, 2008, CLIN J AM SOC NEPHRO, V3, P36
   Schober HC, 1998, J AM SOC NEPHROL, V9, P1225
   Smrzová J, 2010, KIDNEY BLOOD PRESS R, V33, P333, DOI 10.1159/000317935
   Sterrett JR, 2007, CLIN NEPHROL, V68, P10
   Wada M, 2003, J BONE MINER RES, V18, pS99
   Young EW, 2004, AM J KIDNEY DIS, V44, pS34, DOI 10.1053/j.ajkd.2004.08.009
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
NR 22
TC 29
Z9 30
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1744 9979
EI 1744 9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
PD DEC
PY 2011
VL 15
IS 6
BP 547
EP 555
DI 10.1111/j.1744 9987.2011.00994.x
PG 9
WC Hematology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Urology & Nephrology
GA 865RG
UT WOS:000298327400005
PM 22107691
OA Bronze
DA 2025 08 17
ER

PT J
AU Wang, WZ
   Azar, T
   Tseng, WJ
   Pei, SP
   Zhou, YL
   Jiang, X
   Dyment, N
   Liu, XS
AF Wang, Wenzheng
   Azar, Tala
   Tseng, Wei Ju
   Pei, Shaopeng
   Zhou, Yilu
   Jiang, Xi
   Dyment, Nathaniel
   Liu, X. Sherry
TI Distinct Responses of Modeling   and Remodeling Based Bone Formation to
   the Discontinuation of Intermittent Parathyroid Hormone Treatment in
   Ovariectomized Rats
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BONE HISTOMORPHOMETRY; BONE QCT; MICROCT; ANALYSIS; QUANTITATION OF
   BONE; PRECLINICAL STUDIES; ANABOLICS
ID POSTMENOPAUSAL WOMEN; ANABOLIC THERAPY; TERIPARATIDE TREATMENT;
   OSTEOPOROSIS; DENSITY; MICROSTRUCTURE; MECHANISMS
AB Anabolic agents, such as intermittent parathyroid hormone (PTH), exert their treatment efficacy through activation of two distinct bone formation processes, namely, remodeling based bone formation (RBF, bone formation coupled with prior bone resorption) and modeling based bone formation (MBF, bone formation without prior activation of bone resorption). However, if not followed by an antiresorptive agent, treatment benefit was quickly lost upon withdrawal from anabolic agents. By using in vivo micro computed tomography imaging and multiplex cryohistology with sequential immunofluorescence staining, we investigated the temporal response of newly formed bone tissue from MBF and RBF and the preexisting bone tissue to withdrawal from PTH treatment and the associated cellular activity in an ovariectomized (OVX) rat model. We first demonstrated continued mineral apposition at both RBF and MBF sites following PTH discontinuation, resulting in an extended anabolic effect after 1 week withdrawal from PTH. It was further discovered that MBF sites had a greater contribution than RBF sites to the extended anabolic effect upon early withdrawal from PTH, evidenced by a higher percentage of alkaline phosphatase positive (ALP+) surfaces and far greater bone formation activity at MBF versus RBF sites. Furthermore, significant bone loss occurred after 3 weeks of discontinuation from PTH, resulting from marked loss of newly formed bone tissue from RBF and preexisting bone tissue prior to treatment. In contrast, MBF surfaces had a delayed increase of tartrate resistant acid phosphatase activity following PTH discontinuation. As a result, newly formed bone tissue from MBF had greater resistance to PTH discontinuation induced bone loss than those from RBF and preexisting bone. Understanding various responses of two distinct bone formation types and preexisting bone to anabolic treatment discontinuation is critical to inform the design of follow up treatment or cyclic treatment strategies to maximize treatment benefit of anabolic agents. (c) 2022 American Society for Bone and Mineral Research (ASBMR).
C1 [Wang, Wenzheng; Azar, Tala; Tseng, Wei Ju; Pei, Shaopeng; Zhou, Yilu; Jiang, Xi; Dyment, Nathaniel; Liu, X. Sherry] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA.
   [Wang, Wenzheng] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Orthopaed Surg, Wuhan, Peoples R China.
C3 University of Pennsylvania; Huazhong University of Science & Technology
RP Liu, XS (通讯作者)，Univ Penn, Dept Orthopaed, McKay Orthopaed Res Lab, 332A Stemmler Hall,3450 Hamilton Walk, Philadelphia, PA 19104 USA.
EM xiaoweil@pennmedicine.upenn.edu
RI Pei, Shaopeng/AAZ 4395 2021; Dyment, Nathaniel/AAD 6747 2021; Liu,
   Xiaowei/H 1664 2017; Tseng, Wei Ju/AAC 2819 2022; ZHOU,
   YILU/HJZ 2613 2023
OI Wang, Wenzheng/0000 0002 0372 4173; 
FU Penn Center for Musculoskeletal Diseases (PCMD); National Institutes of
   Health (NIH)/National Institute of Arthritis and Musculoskeletal and
   SkinDiseases (NIAMS) [P30 AR069619]; NIH/NIAMS [R01 AR077598,
   T32 AR007132, K01 AR066743]; National Science Foundation [1661858]; Div
   Of Civil, Mechanical, & Manufact Inn; Directorate For Engineering
   [1661858] Funding Source: National Science Foundation; National
   Institute of Arthritis and Musculoskeletal and Skin Diseases
   [T32AR007132] Funding Source: NIH RePORTER
FX Research reported in this publication was supported by the Penn Center
   for Musculoskeletal Diseases (PCMD), National Institutes of Health
   (NIH)/National Institute of Arthritis and Musculoskeletal and
   SkinDiseases (NIAMS) P30 AR069619, NIH/NIAMS T32 AR007132, NIH/NIAMS
   K01 AR066743 (to XSL), NIH/NIAMS R01 AR077598 (to XSL), and National
   Science Foundation Award 1661858 (to XSL).
CR Abdelgawad ME, 2016, HISTOCHEM CELL BIOL, V145, P603, DOI 10.1007/s00418 016 1414 y
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Cohen A, 2015, J CLIN ENDOCR METAB, V100, P4208, DOI 10.1210/jc.2015 2829
   Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157
   Cosman F, 2020, ENDOCR PRACT, V26, P777, DOI 10.4158/EP 2019 0596
   Cosman F, 2019, BONE, V120, P246, DOI 10.1016/j.bone.2018.10.020
   Cosman F, 2015, J CLIN ENDOCR METAB, V100, P2769, DOI 10.1210/jc.2015 1715
   Dempster DW, 2021, J BONE MINER RES, V36, P644, DOI 10.1002/jbmr.4243
   Dempster DW, 2018, J BONE MINER RES, V33, P627, DOI 10.1002/jbmr.3350
   Dempster DW, 2018, J BONE MINER RES, V33, P298, DOI 10.1002/jbmr.3309
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dyment NA, 2016, JOVE J VIS EXP, DOI 10.3791/54468
   Ensrud KE, 2021, JAMA J AM MED ASSOC, V326, P350, DOI 10.1001/jama.2021.0233
   Erben RG, 1996, ANAT REC, V246, P39, DOI 10.1002/(SICI)1097 0185(199609)246:1<39::AID AR5>3.0.CO;2 A
   FROST HM, 1990, ANAT RECORD, V226, P403, DOI 10.1002/ar.1092260402
   HATTNER R, 1965, NATURE, V206, P489, DOI 10.1038/206489a0
   HODSMAN AB, 1993, BONE, V14, P523, DOI 10.1016/8756 3282(93)90190 L
   Ibanez L., 2013, The ITK Software Guide: The Insight Segmentation and Registration Toolkit (version 1.4)
   Jee W. S. S., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P232
   Kobayashi S, 2003, BONE, V32, P163, DOI 10.1016/S8756 3282(02)00947 X
   Lan SH, 2013, BONE, V56, P83, DOI 10.1016/j.bone.2013.05.014
   Lassen NE, 2017, J BONE MINER RES, V32, P1395, DOI 10.1002/jbmr.3091
   Leder BZ, 2009, J CLIN ENDOCR METAB, V94, P2915, DOI 10.1210/jc.2008 2630
   Lindsay R, 2006, J BONE MINER RES, V21, P366, DOI 10.1359/JBMR.051109
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   McClung MR, 2018, J BONE MINER RES, V33, P1397, DOI 10.1002/jbmr.3452
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ominsky MS, 2014, J BONE MINER RES, V29, P1424, DOI 10.1002/jbmr.2152
   Sengupta P, 2013, INT J PREVENTIVE MED, V4, P624
   Takahashi H., 1964, Henry Ford Hosp Med Bull, V12, P359
   Tseng WJ, 2022, J BONE MINER RES, V37, P616, DOI 10.1002/jbmr.4495
   Wang WZ, 2021, BIOMATERIALS, V276, DOI 10.1016/j.biomaterials.2021.121015
NR 34
TC 2
Z9 3
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2022
VL 37
IS 11
BP 2215
EP 2225
DI 10.1002/jbmr.4704
EA SEP 2022
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 6S6LX
UT WOS:000862158300001
PM 36093591
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Huang, W
   Fridman, Y
   Bonfil, RD
   Ustach, CV
   Conley LaComb, MK
   Wiesner, C
   Saliganan, A
   Cher, ML
   Kim, HRC
AF Huang, W.
   Fridman, Y.
   Bonfil, R. D.
   Ustach, C. V.
   Conley LaComb, M. K.
   Wiesner, C.
   Saliganan, A.
   Cher, M. L.
   Kim, H R C.
TI A novel function for platelet derived growth factor D: induction of
   osteoclastic differentiation for intraosseous tumor growth
SO ONCOGENE
LA English
DT Article
DE prostate cancer; bone responses; osteoclastic differentiation; PDGF D
ID PROSTATE CANCER; PLASMINOGEN ACTIVATOR; PDGF D; BONE; RANKL;
   METALLOPROTEINASE; THERAPY
AB Although increasing evidence suggests a critical role for platelet derived growth factor (PDGF) receptor beta (beta PDGFR) signaling in prostate cancer (PCa) progression, the precise roles of beta PDGFR and PDGF isoform specific cell signaling have not been delineated. Recently, we identified the PDGF D isoform as a ligand for beta PDGFR in PCa and showed that PDGF D is activated by serine protease mediated proteolytic removal of the CUB domain in a two step process, yielding first a hemidimer (HD) and then a growth factor domain dimer. Herein, we demonstrate that the expression of PDGF D in human PCa LNCaP cells leads to enhanced bone tumor growth and bone responses in immunodeficient mice. Histopathological analyses of bone tumors generated by PDGF D expressing LNCaP cells (LNCaP PDGF D) revealed osteolytic and osteoblastic responses similar to those observed in human PCa bone metastases. Importantly, we discovered a novel function of PDGF D in the regulation of osteoclast differentiation, independent of the RANKL/RANK signaling axis. Although both PDGF B and  D were able to activate beta PDGFR, only PDGF D was able to induce osteoclastic differentiation in vitro, and upregulate the expression and nuclear translocation of nuclear factor of activated T cells 1, a master transcription factor for osteoclastogenesis. Taken together, these results reveal a new function of PDGF D as a regulator of osteoclastic differentiation, an activity critical for the establishment of skeletal metastatic deposit in PCa patients.
C1 [Huang, W.; Fridman, Y.; Bonfil, R. D.; Ustach, C. V.; Conley LaComb, M. K.; Cher, M. L.; Kim, H R C.] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA.
   [Bonfil, R. D.; Wiesner, C.; Saliganan, A.; Cher, M. L.] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Urol, Detroit, MI 48201 USA.
C3 Wayne State University; Barbara Ann Karmanos Cancer Institute; Barbara
   Ann Karmanos Cancer Institute; Wayne State University
RP Kim, HRC (通讯作者)，Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.
EM hrckim@med.wayne.edu
RI ; Huang, Wei/O 2346 2013
OI Bonfil, R. Daniel/0000 0002 1605 8317; 
FU NIH/NCI [CA64139, CA123362, R01CA137280]; Ruth L. Kirschstein National
   Research Service Award [T32 CA009531]
FX This work was supported by NIH/NCI RO1 grants CA64139 and CA123362 (to
   H RCK), R01CA137280 (to MLC) as well as the Ruth L. Kirschstein National
   Research Service Award T32 CA009531 (to MKC L). We thank Dr. C J Kim for
   his help with IHC analysis.
CR Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140
   Blair JM, 2006, NAT CLIN PRACT ONCOL, V3, P41, DOI 10.1038/ncponc0381
   Bonfil RD, 2007, AM J PATHOL, V170, P2100, DOI 10.2353/ajpath.2007.060720
   Breccia M, 2009, LEUKEMIA RES, V33, P871, DOI 10.1016/j.leukres.2009.01.040
   Buijs JT, 2009, CANCER LETT, V273, P177, DOI 10.1016/j.canlet.2008.05.044
   Chaudhary LR, 2004, BONE, V34, P402, DOI 10.1016/j.bone.2003.11.014
   Chott A, 1999, AM J PATHOL, V155, P1271, DOI 10.1016/S0002 9440(10)65229 7
   Deininger MWN, 2003, PHARMACOL REV, V55, P401, DOI 10.1124/pr.55.3.4
   Ehnman M, 2009, ONCOGENE, V28, P534, DOI 10.1038/onc.2008.410
   Fredriksson L, 2004, EMBO J, V23, P3793, DOI 10.1038/sj.emboj.7600397
   Godwin SL, 1997, J BIOL CHEM, V272, P11307
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Guilhot F, 2004, ONCOLOGIST, V9, P271, DOI 10.1634/theoncologist.9 3 271
   Himeno M, 2002, J BONE MINER RES, V17, P1297, DOI 10.1359/jbmr.2002.17.7.1297
   Kerkelä R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kubota K, 2003, PROTEOMICS, V3, P616, DOI 10.1002/pmic.200300410
   Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257
   LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593
   Mathew P, 2007, CLIN CANCER RES, V13, P5816, DOI 10.1158/1078 0432.CCR 07 1269
   Mehrotra M, 2004, J CELL BIOCHEM, V93, P741, DOI 10.1002/jcb.20138
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Ng SSW, 2004, CLIN CANCER RES, V10, P4192, DOI 10.1158/1078 0432.CCR 03 0700
   Reigstad LJ, 2005, FEBS J, V272, P5723, DOI 10.1111/j.1742 4658.2005.04989.x
   Robbins JR, 1999, DEV BIOL, V212, P255, DOI 10.1006/dbio.1999.9373
   Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140
   Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535 6108(02)00030 2
   Taichman RS, 2007, J CLIN INVEST, V117, P2351, DOI 10.1172/JCI31791
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Ustach CV, 2010, CANCER RES, V70, P9631, DOI 10.1158/0008 5472.CAN 10 0511
   Ustach CV, 2005, MOL CELL BIOL, V25, P6279, DOI 10.1128/MCB.25.14.6279 6288.2005
   Ustach CV, 2004, CANCER RES, V64, P1722, DOI 10.1158/0008 5472.CAN 03 3047
   Uutela M, 2004, BLOOD, V104, P3198, DOI 10.1182/blood 2004 04 1485
   van der Poel HG, 2004, EUR UROL, V45, P1, DOI 10.1016/j.eururo.2003.08.011
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 37
TC 26
Z9 30
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950 9232
EI 1476 5594
J9 ONCOGENE
JI Oncogene
PD OCT
PY 2012
VL 31
IS 42
BP 4527
EP 4535
DI 10.1038/onc.2011.573
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 022SH
UT WOS:000309982100004
PM 22158043
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU McCutcheon, E
   Bowden, SA
   Wasserman, H
   Diaz Thomas, A
   Bijelic, V
   Bachrach, LK
   Robinson, ME
AF McCutcheon, Emma
   Bowden, Sasigarn A. A.
   Wasserman, Halley
   Diaz Thomas, Alicia
   Bijelic, Vid
   Bachrach, Laura K. K.
   Robinson, Marie Eve
TI Treatment Practices and Confidence in the Management of Pediatric
   Metabolic Bone Disorders
SO HORMONE RESEARCH IN PAEDIATRICS
LA English
DT Article
DE Metabolic bone disorders; Survey; Bisphosphonates; Clinical practice;
   Burosumab
ID ATTITUDES; CHILDREN; OSTEOPOROSIS; PREVENTION; GUIDELINES; KNOWLEDGE;
   THERAPY; CARE
AB Introduction: Pediatric metabolic bone and mineral disorders encompass a wide variety of disorders that can be challenging to diagnose and treat because of inadequate physician training about optimal management. Methods: As practice variation and confidence levels may impact clinical outcome, we sought to assess physician confidence in managing pediatric metabolic bone and mineral disorders and the spectrum of treatment practices among members of the Pediatric Endocrine Society (PES) and the Canadian Pediatric Endocrine Group (CPEG). Questionnaires were distributed via e mail to all members of the PES and CPEG and 244 were completed. Responses were summarized using descriptive statistics, and proportions were compared using chi(2) or Fisher's exact tests, as appropriate. Results: Variations were observed among the respondents' confidence in the management of bone disorders and in the criteria used to initiate/discontinue intravenous bisphosphonates or prescribe burosumab therapy. Respondents felt confident with the management of 4 out of 20 pediatric bone conditions (confidence was defined as >90% of respondents reporting feeling "somewhat confident" or "very confident"). Physicians working in a bone clinic were more confident in prescribing burosumab for the treatment of X linked hypophosphatemic rickets compared to those not working in a bone clinic (65% vs. 47%, p = 0.03). Most respondents (52%) reported having received inadequate training in pediatric metabolic bone and mineral disorders. Discussion/Conclusion: Dedicated training, knowledge acquisition, and education resources are needed to increase confidence and standardize the use of bone targeted therapies.
C1 [McCutcheon, Emma; Robinson, Marie Eve] Univ Ottawa, Dept Pediat, Div Endocrinol, Ottawa, ON, Canada.
   [Bowden, Sasigarn A. A.] Ohio State Univ, Nationwide Childrens Hosp, Dept Pediat, Div Endocrinol,Coll Med, Columbus, OH USA.
   [Wasserman, Halley] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Endocrinol,Coll Med, Cincinnati, OH USA.
   [Diaz Thomas, Alicia] Univ Tennessee Hlth Sci Ctr, Dept Pediat Endocrinol, Memphis, TN USA.
   [Bijelic, Vid] Eastern Ontario Res Inst, Clin Res Unit, Childrens Hosp, Ottawa, ON, Canada.
   [Bachrach, Laura K. K.] Stanford Univ, Dept Pediat, Sch Med, San Francisco, CA USA.
   [Robinson, Marie Eve] Eastern Ontario Res Inst, Childrens Hosp, Ottawa, ON, Canada.
C3 University of Ottawa; University System of Ohio; Ohio State University;
   Nationwide Childrens Hospital; University System of Ohio; University of
   Cincinnati; Cincinnati Children's Hospital Medical Center; University of
   Tennessee System; University of Tennessee Health Science Center;
   University of Ottawa; Children's Hospital of Eastern Ontario; Stanford
   University; University of Ottawa; Children's Hospital of Eastern Ontario
RP Robinson, ME (通讯作者)，Univ Ottawa, Dept Pediat, Div Endocrinol, Ottawa, ON, Canada.; Robinson, ME (通讯作者)，Eastern Ontario Res Inst, Childrens Hosp, Ottawa, ON, Canada.
EM mrobinson@cheo.on.ca
RI ; Bowden, Sasigam/J 7465 2013; Bowden, Sasigarn/J 7465 2013; Wasserman,
   Halley/IVH 2870 2023; Robinson, Marie Eve/M 1059 2019
OI Bachrach, Laura/0000 0001 7513 9339; Bowden,
   Sasigarn/0000 0001 6917 5333; diaz thomas, alicia/0000 0002 0168 6855;
   Robinson, Marie Eve/0000 0002 2539 227X
CR Birnkrant DJ, 2018, LANCET NEUROL, V17, P347, DOI 10.1016/S1474 4422(18)30025 5
   Bishop N, 2014, J CLIN DENSITOM, V17, P275, DOI 10.1016/j.jocd.2014.01.004
   Cardinal M, 2020, CALCIFIED TISSUE INT, V106, P494, DOI 10.1007/s00223 019 00655 5
   Carpenter TO, 2018, NEW ENGL J MED, V378, P1987, DOI 10.1056/NEJMoa1714641
   Dwan K, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005088.pub3
   Fleming R, 2002, PREV MED, V34, P411, DOI 10.1006/pmed.2002.1006
   Fogelman Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160661
   Glenn D, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882 016 0299 2
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hembree WC, 2018, J CLIN ENDOCR METAB, V103, P699, DOI [10.1210/jc.2017 02548, 10.1210/jc.2017 01658]
   Jay M, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472 6963 9 106
   Jirschele K, 2015, FEMALE PELVIC MED RE, V21, P273, DOI 10.1097/SPV.0000000000000165
   Librizzi Jamie, 2017, Hosp Pediatr, V7, P320, DOI 10.1542/hpeds.2016 0101
   Pai M, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874 019 0713 0
   Partington A, 2017, AUST HEALTH REV, V41, P104, DOI 10.1071/AH15101
   Ramalle Gómara E, 2015, J EVAL CLIN PRACT, V21, P198, DOI 10.1111/jep.12281
   Robinson ME, 2019, BONE, V126, P11, DOI 10.1016/j.bone.2019.04.021
   Rossi V, 2019, CURR OPIN PEDIATR, V31, P708, DOI 10.1097/MOP.0000000000000813
   Royal College of Physicians and Surgeons of Canada, 2013, OBJ TRAIN SUBSP END, V2nd
   Simm PJ, 2018, J PAEDIATR CHILD H, V54, P223, DOI 10.1111/jpc.13768
   SuarezAlmazor M, 1997, J BONE MINER RES, V12, P1100, DOI 10.1359/jbmr.1997.12.7.1100
   The American Board of Pediatrics, 2018, CONT OUTL PED END 20
   Weber DR, 2019, J CLIN DENSITOM, V22, P567, DOI 10.1016/j.jocd.2019.07.002
   Zhu J, 2020, ENDOCR PRACT, V26, P267, DOI 10.4158/EP 2019 0344
NR 24
TC 2
Z9 2
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1663 2818
EI 1663 2826
J9 HORM RES PAEDIAT
JI Horm. Res. Paediatr.
PD OCT
PY 2022
VL 95
IS 4
BP 354
EP 362
DI 10.1159/000524994
PG 9
WC Endocrinology & Metabolism; Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Pediatrics
GA 6R6VX
UT WOS:000892439700006
PM 35569443
DA 2025 08 17
ER

PT J
AU Roszko, KL
   Bi, R
   Gorvin, CM
   Bräuner Osborne, H
   Xiong, XF
   Inoue, A
   Thakker, RV
   Stromgaard, K
   Gardella, T
   Mannstadt, M
AF Roszko, Kelly L.
   Bi, Ruiye
   Gorvin, Caroline M.
   Brauner Osborne, Hans
   Xiong, Xiao Feng
   Inoue, Asuka
   Thakker, Rajesh V.
   Stromgaard, Kristian
   Gardella, Thomas
   Mannstadt, Michael
TI Knockin mouse with mutant Gα11 mimics human inherited
   hypocalcemia and is rescued by pharmacologic inhibitors
SO JCI INSIGHT
LA English
DT Article
ID CALCIUM SENSING RECEPTOR; OF FUNCTION MUTATION; PARATHYROID HORMONE;
   UVEAL MELANOMA; PROTEIN; HYPOPARATHYROIDISM; HYPERCALCEMIA; GNA11;
   ABNORMALITIES; ACTIVATION
AB Heterotrimeric G proteins play critical roles in transducing extracellular signals generated by 7 transmembrane domain receptors. Somatic gain of function mutations in G protein a subunits are associated with a variety of diseases. Recently, we identified gain of function mutations in G alpha(11) in patients with autosomal dominant hypocalcemia type 2 (ADH2), an inherited disorder of hypocalcemia, low parathyroid hormone (PTH), and hyperphosphatemia. We have generated knockin mice harboring the point mutation GNA11 c.C178T (p. Arg60Cys) identified in ADH2 patients. The mutant mice faithfully replicated human ADH2. They also exhibited low bone mineral density and increased skin pigmentation. Treatment with NPS 2143, a negative allosteric modulator of the calcium sensing receptor (CASR), increased PTH and calcium concentrations in WT and mutant mice, suggesting that the gain of function effect of GNA11(R6OC) is partly dependent on coupling to the CASR. Treatment with the G alpha(11/q) specific inhibitor YM 254890 increased blood calcium in heterozygous but not in homozygous GNA11(R60C) mice, consistent with published crystal structure data showing that Arg60 forms a critical contact with YM 254890. This animal model of ADH2 provides insights into molecular mechanism of this G protein related disease and potential paths toward new lines of therapy.
C1 [Roszko, Kelly L.; Bi, Ruiye; Gardella, Thomas; Mannstadt, Michael] Massachusetts Gen Hosp, Endocrine Unit, Thier 1123,50 Blossom St, Boston, MA 02114 USA.
   [Roszko, Kelly L.; Bi, Ruiye; Gardella, Thomas; Mannstadt, Michael] Harvard Med Sch, Boston, MA USA.
   [Bi, Ruiye] Sichuan Univ, West China Sch Stomatol, Chengdu, Sichuan, Peoples R China.
   [Gorvin, Caroline M.; Thakker, Rajesh V.] Univ Oxford, Churchill Hosp, Acad Endocrine Unit, Radcliffe Dept Med, Oxford, England.
   [Brauner Osborne, Hans; Xiong, Xiao Feng; Stromgaard, Kristian] Univ Copenhagen, Dept Drug Design & Pharmacol, Copenhagen, Denmark.
   [Inoue, Asuka] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi, Japan.
   [Inoue, Asuka] Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Saitama, Japan.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard Medical School; Sichuan
   University; University of Oxford; University of Copenhagen; Tohoku
   University; Japan Science & Technology Agency (JST)
RP Mannstadt, M (通讯作者)，Massachusetts Gen Hosp, Endocrine Unit, Thier 1123,50 Blossom St, Boston, MA 02114 USA.
EM mannstadt@mgh.harvard.edu
RI Inoue, Asuka/JRF 5484 2023; Gorvin, Caroline/T 2406 2019;
   Bräuner Osborne, Hans/S 3298 2019; Brauner Osborne, Hans/D 7260 2011;
   Stromgaard, Kristian/E 3380 2010; Mannstadt, Michael/AAO 1124 2020
OI Gorvin, Caroline/0000 0002 1361 9174; Brauner Osborne,
   Hans/0000 0001 9495 7388; Bi, Ruiye/0000 0002 8297 9691; Stromgaard,
   Kristian/0000 0003 2206 4737
FU NIH [R01 DK100584, T32DK007028]; Center for Skeletal Research Imaging
   and Biomechanical Testing Core; Center for Skeletal Research Core [NIH
   P30 AR066261]; UK Medical Research Council program [G9825289, G1000467];
   Wellcome Trust Investigator Award; NIH Research (NIHR) Oxford Biomedical
   Research Centre Programme; NIHR Senior Investigator Award; JST, PRESTO;
   China State Key Laboratory of Oral Diseases Open Funding
   [SKLOD2015OF01]; Lundbeck Foundation; MRC [G1000467, G9825289] Funding
   Source: UKRI; Medical Research Council [G1000467, G9825289] Funding
   Source: researchfish; Wellcome Trust [106995/Z/15/Z] Funding Source:
   researchfish
FX This work was supported by the NIH grants R01 DK100584 (to MM) and
   T32DK007028 (supporting KR), the Center for Skeletal Research Imaging
   and Biomechanical Testing Core and the Center for Skeletal Research Core
   (NIH P30 AR066261), the UK Medical Research Council program grants
   (G9825289 and G1000467; to CG and RT), Wellcome Trust Investigator Award
   (to RT), NIH Research (NIHR) Oxford Biomedical Research Centre Programme
   (to RT), NIHR Senior Investigator Award (to RT), grants by JST, PRESTO
   (to AI), China State Key Laboratory of Oral Diseases Open Funding
   SKLOD2015OF01 (to RB), and a grant from the Lundbeck Foundation (to KS
   and HBO). We thank the Harvard genome modification facility for
   generating mice, Michael Armanini, Daniel Brooks, and Mary Bouxsein for
   skeletal imaging; Han Xie, Braden Corbin, and Monica Reyes for help with
   in vitro assays; Marc Wein for advice using CRISPR Cas9; and Henry
   Kronenberg for comments on this manuscript.
CR Ayturk UM, 2016, AM J HUM GENET, V98, P1271, DOI 10.1016/j.ajhg.2016.05.010
   Babinsky VN, 2016, J BIOL CHEM, V291, P10876, DOI 10.1074/jbc.M115.696401
   Bi RY, 2016, J BONE MINER RES, V31, P975, DOI 10.1002/jbmr.2769
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Bouxsein ML, 2009, BEST PRACT RES CL RH, V23, P741, DOI 10.1016/j.berh.2009.09.008
   Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936
   Conigrave AD, 2013, BEST PRACT RES CL EN, V27, P315, DOI 10.1016/j.beem.2013.05.010
   Dong BZ, 2015, J BONE MINER RES, V30, P1980, DOI 10.1002/jbmr.2551
   Flock T, 2015, NATURE, V524, P173, DOI 10.1038/nature14663
   Gorvin CM, 2016, J BONE MINER RES, V31, P1200, DOI 10.1002/jbmr.2778
   Guo J, 2017, J BONE MINER RES, V32, P86, DOI 10.1002/jbmr.2917
   Hannan FM, 2015, ENDOCRINOLOGY, V156, P3114, DOI 10.1210/en.2015 1269
   HAPPLE R, 1986, CLIN GENET, V29, P321
   Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154
   IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0
   Kantham L, 2009, AM J PHYSIOL ENDOC M, V297, pE915, DOI 10.1152/ajpendo.00315.2009
   Li D, 2014, J CLIN ENDOCR METAB, V99, pE1774, DOI 10.1210/jc.2014 1029
   Mannstadt M, 2013, NEW ENGL J MED, V368, P2532, DOI 10.1056/NEJMc1300278
   Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323
   Nesbit MA, 2013, NEW ENGL J MED, V368, P2476, DOI 10.1056/NEJMoa1300253
   Nesbit MA, 2013, NAT GENET, V45, P93, DOI 10.1038/ng.2492
   Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550
   Newey PJ, 2013, NEW ENGL J MED, V369, P2012, DOI 10.1056/NEJMoa1307557
   Nishimura A, 2010, P NATL ACAD SCI USA, V107, P13666, DOI 10.1073/pnas.1003553107
   Ogata N, 2007, J BIOL CHEM, V282, P35757, DOI 10.1074/jbc.M611902200
   Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505
   Piret SE, 2016, J BONE MINER RES, V31, P1207, DOI 10.1002/jbmr.2797
   POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194 303
   Ramnitz M, 2015, J BONE MINER RES S1, V30
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Rubin MR, 2008, J BONE MINER RES, V23, P2018, DOI 10.1359/JBMR.080803
   Saggio I, 2014, J BONE MINER RES, V29, P2357, DOI 10.1002/jbmr.2267
   Schrage R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10156
   Shirley MD, 2013, NEW ENGL J MED, V368, P1971, DOI 10.1056/NEJMoa1213507
   Shoback D, 2008, NEW ENGL J MED, V359, P391, DOI 10.1056/NEJMcp0803050
   Shoback DM, 2016, J CLIN ENDOCR METAB, V101, P2300, DOI 10.1210/jc.2015 3909
   Spiegel AM, 2004, ANNU REV MED, V55, P27, DOI 10.1146/annurev.med.55.091902.103843
   Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200
   Tenhola S, 2016, EUR J ENDOCRINOL, V175, P211, DOI 10.1530/EJE 16 0109
   Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584
   Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586
   Van Raamsdonk CD, 2004, NAT GENET, V36, P961, DOI 10.1038/ng1412
   Xiong XF, 2016, NAT CHEM, V8, P1035, DOI [10.1038/NCHEM.2577, 10.1038/nchem.2577]
   Yang H, 2014, NAT PROTOC, V9, P1956, DOI 10.1038/nprot.2014.134
NR 44
TC 27
Z9 29
U1 0
U2 20
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 2379 3708
J9 JCI INSIGHT
JI JCI Insight
PD FEB 9
PY 2017
VL 2
IS 3
AR e91079
DI 10.1172/jci.insight.91079
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EK1TN
UT WOS:000393708800016
PM 28194446
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Burr, AM
   Zuckerman, PC
   Castillo, AB
   Partridge, NC
   Parekkadan, B
AF Burr, Alexandra M.
   Zuckerman, Pamela Cabahug
   Castillo, Alesha B.
   Partridge, Nicola C.
   Parekkadan, Biju
TI Bioactive, full length parathyroid hormone delivered using an
   adeno associated viral vector
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Hypoparathyroidism; AAV vector; AAV PTH; parathyroid hormone
ID VITAMIN D; HYPOPARATHYROIDISM; BIOSYNTHESIS; TERIPARATIDE; SCLEROSTIN;
   SECRETION; THERAPY; PEPTIDE; INSULIN; GROWTH
AB Delivering the parathyroid hormone (PTH) gene has been attempted preclinically in a handful of studies, but delivering full length PTH (1 84) using adeno associated viral (AAV) vectors has not. Given the difficulty in achieving therapeutic levels of secreted proteins using gene therapy, this study seeks to determine the feasibility of doing so with PTH. An AAV vector was used to deliver human PTH driven by a strong promoter. We demonstrate the ability to secrete full length PTH from various cell types in vitro. PTH secretion from hepatocytes was measured over time and a fluorescent marker was used to compare the secretion rate of PTH in various cell types. Potency was measured by the ability of PTH to act on the PTH receptors of osteosarcoma cells and induced proliferation. PTH showed potency in vitro by inducing proliferation in two osteosarcoma cell lines. In vivo, AAV was administered systemically in immunocompromised mice which received xenografts of osteosarcoma cells. Animals that received the highest dose of AAV PTH had higher liver and plasma concentrations of PTH. All dosing groups achieved measurable plasma concentrations of human PTH that were above the normal range. The high dose group also had significantly larger tumors compared to control groups on the final day of the study. The tumors also showed dose dependent differences in morphology. When looking at endocrine signaling and endogenous bone turnover, we observed a significant difference in tibial growth plate width in animals that received the high dose AAV as well as dose dependent changes in blood biomarkers related to PTH. This proof of concept study shows promise for further exploration of an AAV gene therapy to deliver full length PTH for hypoparathyroidism. Additional investigation will determine efficacy in a disease model, but data shown establish bioactivity in well established models of osteosarcoma.
C1 [Burr, Alexandra M.; Parekkadan, Biju] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA.
   [Zuckerman, Pamela Cabahug; Castillo, Alesha B.] NYU, NYU Langone Hlth, Dept Orthoped Surg, New York, NY 10016 USA.
   [Zuckerman, Pamela Cabahug; Castillo, Alesha B.] NYU, Tandon Sch Engn, Dept Biomed Engn, New York, NY 11201 USA.
   [Zuckerman, Pamela Cabahug; Castillo, Alesha B.] Vet Affairs New York Harbor Healthcare Syst, Rehabil Res & Dev, New York, NY 11209 USA.
   [Partridge, Nicola C.] NYU, Dept Mol Pathobiol, Coll Dent, New York, NY 10010 USA.
C3 Rutgers University System; Rutgers University New Brunswick; New York
   University; NYU Langone Medical Center; New York University; New York
   University Tandon School of Engineering; New York University
RP Parekkadan, B (通讯作者)，Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA.
EM biju.parekkadan@rutgers.edu
RI Castillo, Alesha/AAC 9961 2019
OI Cabahug Zuckerman, Pamela/0000 0003 2475 9604; Burr,
   Alexandra/0000 0002 7954 3619
FU National Institutes of Health: National Center for Advancing
   Translational Sciences of the National Institutes of Health
   [TL1TR003019]; National Institutes of Health: National Institute of
   General Medicine [T32GM135141]; National Institutes of Health: National
   Institute of Biomedical Imaging and Bioengineering [R01EB012521,
   R01EB028782]; National Center for Advancing Translational Sciences
   [TL1TR003019] Funding Source: NIH RePORTER; National Institute of
   Biomedical Imaging and Bioengineering [R01EB012521] Funding Source: NIH
   RePORTER
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: The
   research reported in this publication was supported by the National
   Institutes of Health: National Center for Advancing Translational
   Sciences of the National Institutes of Health (TL1TR003019), the
   National Institute of General Medicine (T32GM135141), and the National
   Institute of Biomedical Imaging and Bioengineering (R01EB012521 and
   R01EB028782). The content is solely the responsibility of the authors
   and does not necessarily represent the official views of the National
   Institutes of Health.
CR Adriaansen J, 2011, HUM GENE THER, V22, P84, DOI 10.1089/hum.2010.097
   Almirol EA, 2016, J CLIN TRANSL ENDOCR, V5, P7, DOI 10.1016/j.jcte.2016.05.004
   Bilezikian JP, 2011, J BONE MINER RES, V26, P2317, DOI 10.1002/jbmr.483
   Chou FF, 2009, HUM GENE THER, V20, P1344, DOI 10.1089/hum.2009.015
   Coen G, 2002, NEPHROL DIAL TRANSPL, V17, P233, DOI 10.1093/ndt/17.2.233
   Erickson P, 2021, ANAL BIOCHEM, V625, DOI 10.1016/j.ab.2021.114213
   GINSBERG H, 1975, P SOC EXP BIOL MED, V148, P942
   Hoang D, 2017, ANN SURG, V266, P1075, DOI 10.1097/SLA.0000000000002004
   Kuzmin DA, 2021, NAT REV DRUG DISCOV, V20, P173, DOI 10.1038/d41573 021 00017 7
   Lanske B, 2014, KIDNEY INT, V86, P1071, DOI 10.1038/ki.2014.316
   Leiker AJ, 2013, JAMA SURG, V148, P602, DOI 10.1001/jamasurg.2013.104
   Li SL, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108839
   Liu D, 2012, J ENDOCRINOL INVEST, V35, P479, DOI 10.3275/7966
   Lock M, 2010, HUM GENE THER, V21, P1259, DOI 10.1089/hum.2010.055
   Luboshitzky R, 2009, J ENDOCRINOL INVEST, V32, P317, DOI 10.1007/BF03345719
   MACGREGOR RR, 1978, CLIN ORTHOP RELAT R, P244
   Mannstadt Michael, 2017, Nat Rev Dis Primers, V3, P17080, DOI 10.1038/nrdp.2017.80
   Marsic D, 2015, MOL THER METH CLIN D, V2, DOI 10.1038/mtm.2015.41
   Marx SJ, 2000, NEW ENGL J MED, V343, P1863, DOI 10.1056/NEJM200012213432508
   Mazzocchi G, 2001, AM J PHYSIOL ENDOC M, V280, pE209, DOI 10.1152/ajpendo.2001.280.2.E209
   Nakazawa T, 2005, BONE, V37, P711, DOI 10.1016/j.bone.2005.06.013
   Ogard CG, 2005, CLIN ENDOCRINOL, V63, P493, DOI 10.1111/j.1365 2265.2005.02363.x
   Ogawa T, 2002, J BONE MINER METAB, V20, P83, DOI 10.1007/s007740200011
   Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004
   Powers J, 2013, J BONE MINER RES, V28, P2570, DOI 10.1002/jbmr.2004
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   SAGGESE G, 1993, ACTA PAEDIATR, V82, P54, DOI 10.1111/j.1651 2227.1993.tb12930.x
   Sakwe AM, 2002, J BIOL CHEM, V277, P17687, DOI 10.1074/jbc.M108576200
   Shoback D, 2008, NEW ENGL J MED, V359, P391, DOI 10.1056/NEJMcp0803050
   Sikjaer T, 2013, J BONE MINER RES, V28, P2232, DOI 10.1002/jbmr.1964
   Soares MJ, 2011, EUR J CLIN NUTR, V65, P1348, DOI 10.1038/ejcn.2011.111
   Tai K, 2008, NUTRITION, V24, P279, DOI 10.1016/j.nut.2007.11.006
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   van Lierop AH, 2010, EUR J ENDOCRINOL, V163, P833, DOI 10.1530/EJE 10 0699
   Verdera HC, 2020, MOL THER, V28, P723, DOI 10.1016/j.ymthe.2019.12.010
   Viapiana O, 2013, CALCIFIED TISSUE INT, V92, P324, DOI 10.1007/s00223 012 9665 7
   Wen JF, 2020, AMB EXPRESS, V10, DOI 10.1186/s13568 020 0949 4
   Winer KK, 2019, BONE, V120, P535, DOI 10.1016/j.bone.2018.09.018
   Zhang DF, 2017, ONCOL RES, V25, P763, DOI 10.3727/096504016X14772402056137
   Zhou Y, 2005, CHINESE MED J PEKING, V118, P204
   Zincarelli C, 2008, MOL THER, V16, P1073, DOI 10.1038/mt.2008.76
NR 42
TC 0
Z9 0
U1 1
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1535 3702
EI 1535 3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD NOV
PY 2022
VL 247
IS 21
BP 1885
EP 1897
AR 15353702221097087
DI 10.1177/15353702221097087
EA JUN 2022
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 7F8UT
UT WOS:000810074800001
PM 35666091
OA Green Published
DA 2025 08 17
ER

PT J
AU Abid, HA
   Inoue, A
   Gorvin, CM
AF Abid, Hasnat Ali
   Inoue, Asuka
   Gorvin, Caroline M.
TI Heterogeneity of G protein activation by the calcium sensing receptor
SO JOURNAL OF MOLECULAR ENDOCRINOLOGY
LA English
DT Article
DE calcium homeostasis; calcium signalling; G protein coupled receptor;
   parathyroid and bone; signal transduction
ID FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; BIASED AGONISM; MUTATIONS; RHO;
   LOCALIZATION; DISSOCIATION; EXPRESSION; SECRETION; DISCOVERY; COUPLES
AB The calcium sensing receptor (CaSR) is a G protein coupled receptor that plays a fundamental role in extracellular calcium (Ca e(2+)) homeostasis by regulating parathyroid hormone release and urinary calcium excretion. The CaSR has been described to activate all four G protein subfamilies (G alpha(q/11), G alpha(i/o), G alpha(12/13), G alpha(s)), and mutations in the receptor that cause hyper/hypocalcaemia, have been described to bias receptor signalling. However, many of these studies are based on measurements of second messengers or gene transcription that occurs many steps downstream of receptor activation and can represent convergence points of several signalling pathways. Therefore, to assess CaSR mediated G protein activation directly, we took advantage of a recently described NanoBiT G protein dissociation assay system. Our studies, performed in HEK293 cells stably expressing CaSR, demonstrate that Ca e(2+) stimulation activates all G alpha(q/11) family and several G alpha(i/o) family proteins, although G alpha(z) was not activated. CaSR stimulated dissociation of G alpha(12/13) and G alpha(s) from G beta subunits, but this occurred at a slower rate than that of other G alpha subunits. Investigation of cDNA expression of G proteins in three tissues abundantly expressing CaSR, the parathyroids, kidneys and pancreas, showed G alpha(11), G alpha(z), G alpha(i1) and G alpha(13) genes were highly expressed in parathyroid tissue, indicating CaSR most likely activates G alpha(11) and G alpha(i1) in parathyroids. In kidney and pancreas, the majority of G proteins were similarly expressed, suggesting CaSR may activate multiple G proteins in these cells. Thus, these studies validate a single assay system that can be used to robustly assess CaSR variants and biased signalling and could be utilised in the development of new pharmacological compounds targeting CaSR.
C1 [Abid, Hasnat Ali; Gorvin, Caroline M.] Univ Birmingham, Inst Metab & Syst Res, Birmingham, W Midlands, England.
   [Abid, Hasnat Ali; Gorvin, Caroline M.] Univ Birmingham, Ctr Endocrinol Diabet & Metab, Birmingham, W Midlands, England.
   [Inoue, Asuka] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi, Japan.
   [Gorvin, Caroline M.] Univ Birmingham, Ctr Membrane Prot & Receptors COMPARE, Birmingham, W Midlands, England.
   [Gorvin, Caroline M.] Univ Nottingham, Ctr Membrane Prot & Receptors COMPARE, Nottingham, England.
C3 University of Birmingham; University of Birmingham; Tohoku University;
   University of Birmingham; University of Nottingham
RP Gorvin, CM (通讯作者)，Univ Birmingham, Inst Metab & Syst Res, Birmingham, W Midlands, England.; Gorvin, CM (通讯作者)，Univ Birmingham, Ctr Endocrinol Diabet & Metab, Birmingham, W Midlands, England.; Gorvin, CM (通讯作者)，Univ Birmingham, Ctr Membrane Prot & Receptors COMPARE, Birmingham, W Midlands, England.; Gorvin, CM (通讯作者)，Univ Nottingham, Ctr Membrane Prot & Receptors COMPARE, Nottingham, England.
EM C.Gorvin@bham.ac.uk
RI Inoue, Asuka/JRF 5484 2023; Gorvin, Caroline/T 2406 2019
OI Gorvin, Caroline/0000 0002 1361 9174
FU Centre of Membrane Proteins and Receptors (COMPARE); Academy of Medical
   Sciences Springboard Award   British Heart Foundation, [SBF004\1034];
   Global Challenges Research Fund; Government Department of Business,
   Energy and Industrial Strategy; Wellcome Trust; PRIME from the Japan
   Agency for Medical Research and Development. [19gm5910013]; Leading
   Advanced Projects for Medical Innovation (LEAP) from the Japan Agency
   for Medical Research and Development [JP19gm0010004]; Diabetes UK
FX This work was funded by: start up funds to C M G from the Centre of
   Membrane Proteins and Receptors (COMPARE) and an Academy of Medical
   Sciences Springboard Award (Ref: SBF004 vertical bar 1034, to C M G),
   which is supported by the British Heart Foundation, Diabetes UK, the
   Global Challenges Research Fund, the Government Department of Business,
   Energy and Industrial Strategy and the Wellcome Trust. A I was funded by
   PRIME (19gm5910013) and Leading Advanced Projects for Medical Innovation
   (LEAP) (JP19gm0010004) from the Japan Agency for Medical Research and
   Development.
CR Balenga N, 2017, J BONE MINER RES, V32, P654, DOI 10.1002/jbmr.3023
   Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200
   Braun M, 2014, VITAM HORM, V95, P165, DOI 10.1016/B978 0 12 800174 5.00007 7
   BROWN EM, 1978, ENDOCRINOLOGY, V103, P2323, DOI 10.1210/endo 103 6 2323
   Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239
   Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814
   Conigrave AD, 2004, J BIOL CHEM, V279, P38151, DOI 10.1074/jbc.M406373200
   Conigrave AD, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00563
   Davies SL, 2006, AM J PHYSIOL CELL PH, V290, pC1543, DOI 10.1152/ajpcell.00482.2005
   Devost D, 2017, J BIOL CHEM, V292, P5443, DOI 10.1074/jbc.M116.763854
   Digby GJ, 2008, J PHYSIOL LONDON, V586, P3325, DOI 10.1113/jphysiol.2008.153965
   Goldsmith ZG, 2007, ONCOGENE, V26, P3122, DOI 10.1038/sj.onc.1210407
   Gorvin CM, 2018, HUM MOL GENET, V27, P3720, DOI 10.1093/hmg/ddy263
   Gorvin CM, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aan3714
   Gorvin CM, 2018, CELL REP, V22, P1054, DOI 10.1016/j.celrep.2017.12.089
   Gorvin CM, 2018, J BONE MINER RES, V33, P32, DOI 10.1002/jbmr.3241
   Gundry J, 2017, FRONT NEUROSCI SWITZ, V11, DOI 10.3389/fnins.2017.00017
   Hauser AS, 2017, NAT REV DRUG DISCOV, V16, P829, DOI 10.1038/nrd.2017.178
   Hofer AM, 2000, NAT CELL BIOL, V2, P392, DOI 10.1038/35017020
   Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154
   Huang CF, 2004, AM J PHYSIOL CELL PH, V286, pC22, DOI 10.1152/ajpcell.00229.2003
   Inoue A, 2019, CELL, V177, P1933, DOI 10.1016/j.cell.2019.04.044
   Kifor O, 1997, J BONE MINER RES, V12, P715, DOI 10.1359/jbmr.1997.12.5.715
   Kroeze WK, 2015, NAT STRUCT MOL BIOL, V22, P362, DOI 10.1038/nsmb.3014
   Kumar BA, 2017, METHOD CELL BIOL, V142, P27, DOI 10.1016/bs.mcb.2017.07.012
   Leach K, 2012, ENDOCRINOLOGY, V153, P4304, DOI 10.1210/en.2012 1449
   Lotta LA, 2019, CELL, V177, P597, DOI 10.1016/j.cell.2019.03.044
   Mamillapalli R, 2008, J BIOL CHEM, V283, P24435, DOI 10.1074/jbc.M801738200
   Mamillapalli R, 2010, J ENDOCRINOL, V204, P287, DOI 10.1677/JOE 09 0183
   Mannstadt M, 2013, NEW ENGL J MED, V368, P2532, DOI 10.1056/NEJMc1300278
   Maziarz M, 2020, CELL, V182, P770, DOI 10.1016/j.cell.2020.06.020
   Nesbit MA, 2013, NEW ENGL J MED, V368, P2476, DOI 10.1056/NEJMoa1300253
   Nesbit MA, 2013, NAT GENET, V45, P93, DOI 10.1038/ng.2492
   Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505
   Pi M, 2002, ENDOCRINOLOGY, V143, P3830, DOI 10.1210/en.2002 220240
   POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092 8674(93)90617 Y
   Regard JB, 2008, CELL, V135, P561, DOI 10.1016/j.cell.2008.08.040
   Riccardi D, 2010, AM J PHYSIOL RENAL, V298, pF485, DOI 10.1152/ajprenal.00608.2009
   Rosenzweig DH, 2007, J NEUROSCI, V27, P5484, DOI 10.1523/JNEUROSCI.1421 07.2007
   Rossol M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2339
   Shyamsundar R, 2005, GENOME BIOL, V6, DOI 10.1186/gb 2005 6 3 r22
   Siehler S, 2009, BRIT J PHARMACOL, V158, P41, DOI 10.1111/j.1476 5381.2009.00121.x
   Squires PE, 2000, DIABETES, V49, P409, DOI 10.2337/diabetes.49.3.409
   Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199
   Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200
   Thomsen ARB, 2012, CELL CALCIUM, V51, P107, DOI 10.1016/j.ceca.2011.11.009
   VARRAULT A, 1995, ENDOCRINOLOGY, V136, P4390, DOI 10.1210/en.136.10.4390
   Wingler LM, 2020, TRENDS CELL BIOL, V30, P736, DOI 10.1016/j.tcb.2020.06.002
   Yarova PL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0282
   Zietek T, 2015, CURR OPIN CLIN NUTR, V18, P381, DOI 10.1097/MCO.0000000000000187
NR 50
TC 14
Z9 16
U1 0
U2 10
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 0952 5041
EI 1479 6813
J9 J MOL ENDOCRINOL
JI J. Mol. Endocrinol.
PD AUG
PY 2021
VL 67
IS 2
BP 41
EP 53
DI 10.1530/JME 21 0058
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA SV6MA
UT WOS:000663933700002
PM 34077389
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Kastelan, D
   Vlak, T
   Lozo, P
   Gradiser, M
   Mijic, S
   Nikolic, T
   Miskic, B
   Car, D
   Tajsic, G
   Dusek, T
   Jajic, Z
   Grubisic, F
   Poljicanin, T
   Bakula, M
   Dzubur, F
   Strizak Ujevic, M
   Kadojic, M
   Radman, M
   Vugrinec, M
   Kuster, Z
   Pekez, M
   Radovic, E
   Labar, L
   Crncevic Orlic, Z
   Korsic, M
AF Kastelan, Darko
   Vlak, Tonko
   Lozo, Petar
   Gradiser, Marina
   Mijic, Sime
   Nikolic, Tatjana
   Miskic, Blazenka
   Car, Dolores
   Tajsic, Gordana
   Dusek, Tina
   Jajic, Zrinka
   Grubisic, Frane
   Poljicanin, Tamara
   Bakula, Miro
   Dzubur, Fedja
   Strizak Ujevic, Matilda
   Kadojic, Mira
   Radman, Maja
   Vugrinec, Maja
   Kuster, Zeljka
   Pekez, Marijeta
   Radovic, Endi
   Labar, Ljubica
   Crncevic Orlic, Zeljka
   Korsic, Mirko
TI Health Related Quality of Life Among Patients with Postmenopausal
   Osteoporosis Treated with Weekly and Monthly Bisphosphonates
SO ENDOCRINE RESEARCH
LA English
DT Article
DE Bisphosphonates; Osteoporosis; Quality of life; EQ 5D; OPTQoL
ID MONTHLY ORAL IBANDRONATE; ONCE MONTHLY IBANDRONATE; BONE MINERAL
   DENSITY; VERTEBRAL FRACTURES; WEEKLY ALENDRONATE; OPEN LABEL; WOMEN;
   RISEDRONATE; THERAPY; TRIAL
AB Objective. The present study was designed to assess the effect of monthly ibandronate on health related quality of life (HR QoL) in patients with postmenopausal osteoporosis previously treated with weekly bisphosphonates. Methods. HR QoL was assessed by Euroqol (EQ 5D) and Osteoporosis Targeted Quality of Life (OPTQoL) questionnaires. Results. The EQ 5D questionnaire showed significant improvement associated with ibandronate treatment, occurring in mobility (p < 0.01), usual activity (p < 0.01), pain/discomfort (p < 0.05), and anxiety/depression (p < 0.05). In addition, ibandronate treatment considerably improved patients' perceived health on a visual analog scale (p < 0.001). For the OPTQoL questionnaire, patients reported less physical difficulty (p < 0.001), fewer adaptations in their lives (p < 0.001), and less fear (p < 0.001) with ibandronate than with weekly bisphosphonates. Conclusion. The study demonstrated that patients who were transferred from weekly bisphosphonates to a monthly ibandronate experienced improved HR QoL.</.
C1 [Kastelan, Darko; Dusek, Tina; Dzubur, Fedja; Korsic, Mirko] Univ Hosp Zagreb, Dept Endocrinol, Zagreb 10000, Croatia.
   [Vlak, Tonko] Univ Hosp Split, Dept Rehabil Med & Rheumatol, Split, Croatia.
   [Lozo, Petar] Outpatient Clin Gynaecol Lozo, Zadar, Croatia.
   [Gradiser, Marina] Cty Hosp Cakovec, Dept Internal Med, Cakovec, Croatia.
   [Mijic, Sime] Hlth Med Ctr Phys Med & Rehabil, Jastrebarsko, Croatia.
   [Nikolic, Tatjana; Car, Dolores; Tajsic, Gordana] Univ Clin Traumatol, Zagreb, Croatia.
   [Miskic, Blazenka] Dr Josip Bencevic Gen Hosp, Dept Internal Med, Slavonski Brod, Croatia.
   [Jajic, Zrinka; Grubisic, Frane] Univ Hosp Sestre Milosrdnice, Dept Rheumatol Phys Med & Rehabil, Zagreb, Croatia.
   [Poljicanin, Tamara] Vuk Vrhovac Univ Clin Diabet Endocrinol & Metab D, Zagreb, Croatia.
   [Bakula, Miro] Gen Hosp Sv Duh, Dept Endocrinol Diabet & Metab Disorders, Zagreb, Croatia.
   [Strizak Ujevic, Matilda] Gen Hosp Sibenik, Shibenik, Croatia.
   [Kadojic, Mira] Univ Hosp Osijek, Dept Phys Med & Rehabil, Osijek, Croatia.
   [Radman, Maja] Univ Hosp Split, Dept Diabet Endocrinol & Metab, Split, Croatia.
   [Vugrinec, Maja; Kuster, Zeljka; Pekez, Marijeta] Univ Zagreb, Sch Med, Zagreb 41001, Croatia.
   [Radovic, Endi] Univ Hosp Rijeka, Dept Phys & Rehabil Med, Rijeka, Croatia.
   [Labar, Ljubica] Special Hosp Orthopaed, Biograd, Croatia.
   [Crncevic Orlic, Zeljka] Univ Hosp Rijeka, Dept Endocrinol, Rijeka, Croatia.
C3 University of Zagreb; UNIVERSITY ZAGREB HOSPITAL; University of Split;
   University of Split; University of Zagreb; University of Rijeka;
   University of Rijeka
RP Kastelan, D (通讯作者)，Univ Hosp Zagreb, Div Endocrinol, Dept Internal Med, Kispaticeva 12, Zagreb 10000, Croatia.
EM dkastelan@inet.hr
RI Mamić, Maja/H 6876 2016; Poljicanin, Tamara/AAO 4123 2021; Radman,
   Maja/H 2891 2017; Vlak, Tonko/H 4906 2017; Kastelan,
   Darko/AAJ 4740 2020; Miškić, Blaženka/F 5528 2012
OI Poljicanin, Tamara/0000 0003 2336 0861; Vlak, Tonko/0000 0001 5415 7124;
   
CR Bonnick SL, 2009, J WOMENS HEALTH, V18, P935, DOI 10.1089/jwh.2008.1064
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   COOK DJ, 1993, ARTHRITIS RHEUM, V36, P750, DOI 10.1002/art.1780360603
   Cotté FE, 2010, OSTEOPOROSIS INT, V21, P145, DOI 10.1007/s00198 009 0930 1
   Derman R, 2009, CLIN INTERV AGING, V4, P357
   Emkey R, 2005, CURR MED RES OPIN, V21, P1895, DOI 10.1185/030079905X74862
   Emkey R, 2009, CLIN THER, V31, P751, DOI 10.1016/j.clinthera.2009.04.018
   Ferreira ND, 2009, MATURITAS, V62, P85, DOI 10.1016/j.maturitas.2008.10.012
   Hadji P, 2008, JOINT BONE SPINE, V75, P303, DOI 10.1016/j.jbspin.2007.07.011
   Harris ST, 2009, BONE, V44, P758, DOI 10.1016/j.bone.2009.01.002
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Kastelan D, 2009, CLIN RHEUMATOL, V28, P321, DOI 10.1007/s10067 008 1039 1
   Lewiecki EM, 2008, CLIN THER, V30, P605, DOI 10.1016/j.clinthera.2008.04.009
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lydick E, 1997, J BONE MINER RES, V12, P456, DOI 10.1359/jbmr.1997.12.3.456
   Marquis P, 2008, OSTEOPOROSIS INT, V19, P503, DOI 10.1007/s00198 007 0464 3
   Martin AR, 2002, BONE, V31, P32, DOI 10.1016/S8756 3282(02)00787 1
   Maugeri D, 2009, ARCH GERONTOL GERIAT, V49, P35, DOI 10.1016/j.archger.2008.04.008
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Ringe JD, 2007, CLIN EXP RHEUMATOL, V25, P766
   Romagnoli E, 2004, OSTEOPOROSIS INT, V15, P975, DOI 10.1007/s00198 004 1633 2
   Sebba AI, 2004, CURR MED RES OPIN, V20, P2031, DOI 10.1185/030079904X16768
   Silverman SL, 2001, ARTHRITIS RHEUM, V44, P2611, DOI 10.1002/1529 0131(200111)44:11<2611::AID ART441>3.0.CO;2 N
   Yoh K, 2005, J BONE MINER METAB, V23, P167, DOI 10.1007/s00774 004 0556 5
NR 25
TC 9
Z9 9
U1 0
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0743 5800
J9 ENDOCR RES
JI Endocr. Res.
PY 2010
VL 35
IS 4
BP 165
EP 173
DI 10.3109/07435800.2010.505218
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 666YI
UT WOS:000283158500003
PM 20868288
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Ito, K
   Muraoka, H
   Hirahara, N
   Sawada, E
   Hirohata, S
   Otsuka, K
   Okada, S
   Kaneda, T
AF Ito, Kotaro
   Muraoka, Hirotaka
   Hirahara, Naohisa
   Sawada, Eri
   Hirohata, Shoya
   Otsuka, Kohei
   Okada, Shunya
   Kaneda, Takashi
TI Quantitative assessment of mandibular bone marrow using computed
   tomography texture analysis for detect stage 0 medication related
   osteonecrosis of the jaw
SO EUROPEAN JOURNAL OF RADIOLOGY
LA English
DT Article
DE Adverse drug reaction; Bisphosphonates; Bone marrow; Bone necrosis;
   Magnetic resonance imaging; Medication related osteonecrosis of the jaw
ID BISPHOSPHONATE RELATED OSTEONECROSIS; OSTEOMYELITIS; FEATURES; MRI;
   ASSOCIATION; GUIDELINES; RADIOMICS; DIAGNOSIS
AB Purpose: Medication related osteonecrosis of the jaw (MRONJ) is a serious complication of treatment with bisphosphonates or antiangiogenic inhibitors. MRONJ has four stages (0 3); however, stage 0 MRONJ is difficult to detect using computed tomography (CT). This study aimed to quantitatively assess the mandibular bone marrow using texture analysis to detect stage 0 MRONJ from CT images. Methods: This retrospective study included 25 patients with stage 0 MRONJ who had a history of treatment with bisphosphonates and underwent CT and magnetic resonance imaging (MRI). The mandibular bone marrow with abnormal signals (T1 weighted imaging: low, T2 weighted imaging: low or high, short tau inversion recovery: high) on MRI, and no qualitative characteristic CT and oral findings indicative of osteonecrosis (exposed bone, sequestrum, periosteal reaction, and osteolysis) was identified as 0 MRONJ. Texture features of the bone marrow of the mandible with MRONJ and the contralateral, normal mandibular bone marrow were extracted using an open access software, namely, LIFEx. The volumes of interest (VOIs) were manually placed on CT images by tracing the bilateral mandibular bone marrow regions, excluding the teeth, mandibular canal, and cortical bone. Thirty seven texture features were extracted from each VOI. Results: Six gray level run length matrix features and four gray level zone length matrix features exhibited significant differences between mandibular bone marrow with and without MRONJ. Conclusions: CT was able to quantitatively assess texture features of normal mandibular bone marrow and that with MRONJ. Texture analysis may be useful as a new method for detecting stage 0 MRONJ using CT.
C1 [Ito, Kotaro; Muraoka, Hirotaka; Hirahara, Naohisa; Sawada, Eri; Hirohata, Shoya; Otsuka, Kohei; Okada, Shunya; Kaneda, Takashi] Nihon Univ, Dept Radiol, Sch Dent Matsudo, 2 870 1 Sakaecho Nishi, Chiba 2718587, Japan.
C3 Nihon University
RP Ito, K (通讯作者)，Nihon Univ, Dept Radiol, Sch Dent Matsudo, 2 870 1 Sakaecho Nishi, Chiba 2718587, Japan.
EM itou.koutarou@nihon u.ac.jp
FU JSPS KAKENHI [JP21K17101]
FX This research was supported by JSPS KAKENHI Grant Number JP21K17101.
CR Alegro MD, 2012, MAGN RESON MED, V68, P1647, DOI 10.1002/mrm.24174
   An CH, 2012, OR SURG OR MED OR PA, V114, P118, DOI 10.1016/j.oooo.2012.01.009
   Ariji Y, 2008, ORAL SURG ORAL MED O, V105, P503, DOI 10.1016/j.tripleo.2007.04.029
   Avanzo M, 2017, PHYS MEDICA, V38, P122, DOI 10.1016/j.ejmp.2017.05.071
   Barry B, 2014, MAGN RESON IMAGING, V32, P84, DOI 10.1016/j.mri.2013.04.006
   Buch K, 2015, AM J NEURORADIOL, V36, P1343, DOI 10.3174/ajnr.A4285
   Castellano G, 2004, CLIN RADIOL, V59, P1061, DOI 10.1016/j.crad.2004.07.008
   Fujimoto K, 2011, RADIOLOGY, V258, P739, DOI 10.1148/radiol.10100853
   Fujita A, 2016, J COMPUT ASSIST TOMO, V40, P43, DOI 10.1097/RCT.0000000000000320
   Ida M, 2005, DENTOMAXILLOFAC RAD, V34, P86, DOI 10.1259/dmfr/23641620
   Jirák D, 2002, J MAGN RESON IMAGING, V15, P68, DOI 10.1002/jmri.10042
   KANEDA T, 1995, ORAL SURG ORAL MED O, V79, P634, DOI 10.1016/S1079 2104(05)80107 6
   Krishnan A, 2009, J COMPUT ASSIST TOMO, V33, P298, DOI 10.1097/RCT.0b013e31817e4986
   Kuno H, 2017, AM J NEURORADIOL, V38, P2334, DOI 10.3174/ajnr.A5407
   Lambin P, 2012, EUR J CANCER, V48, P441, DOI 10.1016/j.ejca.2011.11.036
   Leite AF, 2014, INT J DENT, V2014, DOI 10.1155/2014/784348
   Lifexsoft, 2019, GREY LEV ZON LENGTH
   Mayerhoefer ME, 2012, NMR BIOMED, V25, P866, DOI 10.1002/nbm.1803
   Mosquera Lopez Clara, 2015, IEEE Rev Biomed Eng, V8, P98, DOI 10.1109/RBME.2014.2340401
   Nioche C, 2018, CANCER RES, V78, P4786, DOI 10.1158/0008 5472.CAN 18 0125
   Querrer R, 2021, SUPPORT CARE CANCER, V29, P2811, DOI 10.1007/s00520 020 05855 6
   Risse F, 2012, NMR BIOMED, V25, P131, DOI 10.1002/nbm.1725
   Ruggiero SL, 2006, ORAL SURG ORAL MED O, V102, P433, DOI 10.1016/j.tripleo.2006.06.004
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Ruggiero SL, 2007, CLIN CASES MINER BON, V4, P37
   Tanaka R, 2008, DENTOMAXILLOFAC RAD, V37, P94, DOI 10.1259/dmfr/38320433
   Valdora F, 2018, BREAST CANCER RES TR, V169, P217, DOI 10.1007/s10549 018 4675 4
   Zwanenburg A., 2016, Radiology, DOI DOI 10.1148/RADIOL.2020191145
NR 28
TC 9
Z9 9
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0720 048X
EI 1872 7727
J9 EUR J RADIOL
JI Eur. J. Radiol.
PD DEC
PY 2021
VL 145
AR 110030
DI 10.1016/j.ejrad.2021.110030
EA NOV 2021
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA XA1UW
UT WOS:000720442100005
PM 34798536
DA 2025 08 17
ER

PT J
AU Gao, WJ
   Zhou, J
   Huang, JT
   Zhang, ZG
   Chen, WQ
   Zhang, RH
   Kang, TB
   Liao, D
   Zhong, L
AF Gao, Weijie
   Zhou, Jing
   Huang, Jintao
   Zhang, Zhiguang
   Chen, Wanqi
   Zhang, Ruhua
   Kang, Tiebang
   Liao, Dan
   Zhong, Li
TI Up regulation of RAN by MYBL2 maintains osteosarcoma cancer stem like
   cells population during heterogeneous tumor generation
SO CANCER LETTERS
LA English
DT Article
DE Single  cell transcriptomic; Osteosarcoma cancer stem like cell;
   Intratumor heterogeneity; MYBL2; RAN
ID HEPATOCELLULAR CARCINOMA; METASTASIS; PROGRESSION; PROTEIN
AB Intratumor heterogeneity is one of the major features of cancers, leading to aggressive disease and treatment failure. Cancer stem like cells (CSCs) are believed to give rise to the heterogeneous cell types within tumors. Hence, understanding the regulatory mechanism underlying the recurrence process of heterogeneous tumor by CSCs could facilitate the development of CSC targeted therapies. Here, utilizing single cell transcriptomics, we present the molecular profile of osteosarcoma CSCs derived heterogeneous tumors consisting of CSC clusters, osteoprogenitor and differentiated cell types, such as pre osteoblasts, osteoblasts and chondroblasts. Furthermore, by constructing the comprehensive map of modulated genes during CSCs self renewal and differentiation, we identify RAN exhibiting specific peak expression in osteosarcoma CSCs clusters which is transcriptionally upregulated by MYBL2. Functionality, MYBL2 RAN pathway promotes the CSCs self renewal by enhancing the nuclear accumulation of MYC protein, which in turn boosts the overexpression of RAN as a positive feedback. Importantly, blockage of MYBL2 RAN pathway sensitizes CSCs to cisplatin treatment and synergistically enhanced the cisplatin induced cytotoxicity. Both MYBL2 and RAN are highly expressed in clinical osteosarcoma tissues which indicate poor prognosis. Collectively, our study provides advanced insights into the regeneration process of heterogeneous tumor originating from CSCs and highlights the MYBL2 RAN pathway as a promising target for CSC based therapy in osteosarcoma.
C1 [Gao, Weijie; Zhang, Ruhua; Kang, Tiebang; Liao, Dan] Sun Yat sen Univ Canc Ctr, Guangdong Prov Clin Res Ctr Canc, State Key Lab Oncol South China, Guangzhou, Peoples R China.
   [Gao, Weijie] Hubei Univ, Sch Life Sci, State Key Lab Biocatalysis & Enzyme Engn, Wuhan, Peoples R China.
   [Zhou, Jing] Hubei Polytech Univ, Sch Med, Hubei Key Lab Kidney Dis Pathogenesis & Intervent, Huangshi, Peoples R China.
   [Huang, Jintao] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou, Peoples R China.
   [Zhang, Zhiguang] Sun Yat Sen Univ, Sch Med, Shenzhen, Peoples R China.
   [Chen, Wanqi; Zhong, Li] Sun Yat sen Univ, Affiliated Hosp 7, Ctr Digest Dis, Sci Res Ctr, Shenzhen, Peoples R China.
   [Liao, Dan] Seventh Affiliated Hosp, Sci Res Ctr, Ctr Digest Dis, Shenzhen 518107, Peoples R China.
C3 State Key Lab Oncology South China; Sun Yat Sen University; Hubei
   University; Hubei Polytechnic University; Sun Yat Sen University; Sun
   Yat Sen University; Sun Yat Sen University
RP Liao, D (通讯作者)，Sun Yat sen Univ Canc Ctr, Guangdong Prov Clin Res Ctr Canc, State Key Lab Oncol South China, Guangzhou, Peoples R China.; Zhong, L (通讯作者)，Sun Yat sen Univ, Affiliated Hosp 7, Ctr Digest Dis, Sci Res Ctr, Shenzhen, Peoples R China.
EM liaodan@sysucc.org.cn; zhongli@sysush.com
RI Weijie, Gao/JDW 6180 2023; Zhang, Zhiguang/H 5916 2011; liao,
   dan/LJM 5348 2024; Chen, Wanqi/IWU 6396 2023
OI Zhong, Li/0000 0002 1646 2862
FU Guangdong Natural Science Funds for Distinguished Young Scholar,
   Guangdong Province, China [2021B1515020033]; National Nature Science
   Foundation in China [82373026, 82322053, 32370819, 32070765]; Shenzhen
   Science and Technology Program, Shenzhen, China [JCYJ20220530144607017];
   Shenzhen Medical Research Funds, Shenzhen, China [A2303011]; Guangdong
   Basic and Applied Basic Research Foundation, Guangdong Province, China
   [2022A1515220110]; Science and Technology Planning Project of Guangdong
   Province, China [2021B1212040006]; Research Start up Fund of the Seventh
   Affiliated Hospital, Sun Yat sen University, Shenzhen, China
   [ZSQYRSF0012]
FX This work was supported by the Guangdong Natural Science Funds for
   Distinguished Young Scholar, Guangdong Province, China (2021B1515020033)
   to D Liao; National Nature Science Foundation in China (82373026 to L
   Zhong, 82322053, 32370819, 32070765 to D Liao) ; Shenzhen Science and
   Technology Program, Shenzhen, China (JCYJ20220530144607017) to L Zhong;
   Shenzhen Medical Research Funds, Shenzhen, China (Grant No. A2303011) ;
   Guangdong Basic and Applied Basic Research Foundation, Guangdong
   Province, China (2022A1515220110) to L Zhong; the Science and Technology
   Planning Project of Guangdong Province, China (No. 2021B1212040006) ;
   Research Start up Fund of the Seventh Affiliated Hospital, Sun Yat sen
   University, Shenzhen, China (ZSQYRSF0012) to L Zhong.
CR Abe H, 2008, INT J CANCER, V122, P2391, DOI 10.1002/ijc.23400
   Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]
   An ZJ, 2019, CELL REP, V29, P1986, DOI 10.1016/j.celrep.2019.10.026
   Baker SJ, 2014, P NATL ACAD SCI USA, V111, P3122, DOI 10.1073/pnas.1315464111
   Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409
   Bhaduri A, 2020, CELL STEM CELL, V26, P48, DOI 10.1016/j.stem.2019.11.015
   Bindhya S, 2021, INT J BIOCHEM CELL B, V138, DOI 10.1016/j.biocel.2021.106051
   Boudhraa Z, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00345
   Chen DJ, 2022, INT J BIOL SCI, V18, P360, DOI 10.7150/ijbs.66913
   Cicirò Y, 2021, ONCOGENESIS, V10, DOI 10.1038/s41389 021 00309 y
   Clara JA, 2020, NAT REV CLIN ONCOL, V17, P204, DOI 10.1038/s41571 019 0293 2
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008 5472.CAN 06 3126
   Clarke MF, 2019, NEW ENGL J MED, V380, P2237, DOI 10.1056/NEJMra1804280
   Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304
   Gao WJ, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0987 x
   Gehart H, 2019, CELL, V176, P1158, DOI 10.1016/j.cell.2018.12.029
   Gulati GS, 2020, SCIENCE, V367, P405, DOI 10.1126/science.aax0249
   Haggag YA, 2019, CANCERS, V11, DOI 10.3390/cancers11020222
   Hartmann E, 2008, J CLIN ONCOL, V26, P4966, DOI 10.1200/JCO.2007.12.0410
   Hovestadt V, 2019, NATURE, V572, P74, DOI 10.1038/s41586 019 1434 6
   Jiang JH, 2017, CANCER LETT, V404, P19, DOI 10.1016/j.canlet.2017.07.006
   Kanojia D, 2022, PHARMACOL RES, V185, DOI 10.1016/j.phrs.2022.106462
   Kawazoe A, 2020, CLIN CANCER RES, V26, P5887, DOI 10.1158/1078 0432.CCR 20 1803
   Kester L, 2018, CELL STEM CELL, V23, P166, DOI 10.1016/j.stem.2018.04.014
   Kinker GS, 2020, NAT GENET, V52, P1208, DOI 10.1038/s41588 020 00726 6
   Kovacs CS, 2021, NAT REV ENDOCRINOL, V17, P336, DOI 10.1038/s41574 021 00488 z
   LeBlanc VG, 2022, CANCER CELL, V40, P379, DOI 10.1016/j.ccell.2022.02.016
   Li QJ, 2021, THERANOSTICS, V11, P5794, DOI 10.7150/thno.56604
   Ma XS, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 01264 9
   Malta TM, 2018, CELL, V173, P338, DOI 10.1016/j.cell.2018.03.034
   Miranda A, 2019, P NATL ACAD SCI USA, V116, P9020, DOI 10.1073/pnas.1818210116
   Musa J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.244
   Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024
   Pan XW, 2020, INT J BIOL SCI, V16, P3149, DOI 10.7150/ijbs.46645
   Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253
   Praharaj PP, 2023, AUTOPHAGY, V19, P2196, DOI 10.1080/15548627.2023.2178876
   Praktiknjo SD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14777 0
   Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0600 4
   Qiu XJ, 2017, NAT METHODS, V14, P979, DOI [10.1038/NMETH.4402, 10.1038/nmeth.4402]
   Reiter JG, 2019, NAT REV CANCER, V19, P639, DOI 10.1038/s41568 019 0185 x
   Altaba ARI, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002540
   Saygin C, 2019, CELL STEM CELL, V24, P25, DOI 10.1016/j.stem.2018.11.017
   Schnepp RW, 2015, CANCER CELL, V28, P599, DOI 10.1016/j.ccell.2015.09.012
   Shirakawa K, 2006, MOL CELL BIOL, V26, P6105, DOI 10.1128/MCB.02429 05
   Silljé HHW, 2006, CURR BIOL, V16, P731, DOI 10.1016/j.cub.2006.02.070
   Sneha S, 2020, CELL ONCOL, V43, P601, DOI 10.1007/s13402 020 00504 w
   Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031
   Sun YF, 2021, CELL, V184, P404, DOI 10.1016/j.cell.2020.11.041
   Suresh B, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6705927
   Tan YP, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 020 00398 y
   Tang BW, 2015, STEM CELL REP, V4, P155, DOI 10.1016/j.stemcr.2014.11.002
   Tarasov KV, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002478
   Turajlic S, 2019, NAT REV GENET, V20, P404, DOI 10.1038/s41576 019 0114 6
   Wang JC, 2021, THERANOSTICS, V11, P5045, DOI 10.7150/thno.56369
   Wang L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 00248 x
   Wang S, 2019, THERANOSTICS, V9, P4342, DOI 10.7150/thno.34090
   Wang Y, 2019, MOL CANCER RES, V17, P1665, DOI 10.1158/1541 7786.MCR 18 0019
   Werwein E, 2019, NUCLEIC ACIDS RES, V47, P103, DOI 10.1093/nar/gky935
   Xia F, 2008, CANCER RES, V68, P1826, DOI 10.1158/0008 5472.CAN 07 5279
   Xie H, 2014, CELL METAB, V19, P795, DOI 10.1016/j.cmet.2014.03.003
   Ye J, 2023, BBA REV CANCER, V1878, DOI 10.1016/j.bbcan.2023.188866
   Yuen HF, 2013, JNCI J NATL CANCER I, V105, P475, DOI 10.1093/jnci/djt028
   Yuen HF, 2012, CLIN CANCER RES, V18, P380, DOI 10.1158/1078 0432.CCR 11 2035
   Zaouil K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10570 w
   Zhan M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042350
   Zhang HG, 2022, CELL DEATH DIFFER, V29, P351, DOI 10.1038/s41418 021 00858 0
   Zhang LG, 2019, CANCER CELL, V36, P302, DOI 10.1016/j.ccell.2019.07.009
   Zhang Z, 2022, GENOME MED, V14, DOI 10.1186/s13073 022 01050 w
   Zheng SY, 2022, GENOM PROTEOM BIOINF, V20, P587, DOI 10.1016/j.gpb.2022.01.004
   Zhou Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 20059 6
NR 70
TC 6
Z9 7
U1 4
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PD APR 1
PY 2024
VL 586
AR 216708
DI 10.1016/j.canlet.2024.216708
EA FEB 2024
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA KY5V7
UT WOS:001183551500001
PM 38336287
DA 2025 08 17
ER

PT J
AU Yazawa, H
   Zimmermann, B
   Asami, Y
   Bernimoulin, JP
AF Yazawa, H
   Zimmermann, B
   Asami, Y
   Bernimoulin, JP
TI Simvastatin promotes cell metabolism, proliferation, and osteoblastic
   differentiation in human periodontal ligament cells
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE cell differentiation; cells, periodontal; osteoblasts; periodontal
   ligament; periodontal regeneration; simvastatin/therapeutic use
ID NITROGEN CONTAINING BISPHOSPHONATES; COA REDUCTASE INHIBITORS; FARNESYL
   PYROPHOSPHATE SYNTHASE; IN VITRO; MINERALIZED NODULES;
   EXTRACELLULAR MATRIX; MEVALONATE PATHWAY; BONE FORMATION; RAT; STATINS
AB Background: Simvastatin is one of the cholesterol lowering drugs. Recent studies demonstrated that it has a bone stimulatory effect. Periodontal ligament (PDL) cells are believed to play an important role in periodontal regeneration; that is, they may differentiate into specific cells which make cementum, bone, and attachment apparatus. It would be of interest whether simvastatin has a positive effect on PDL cells. Therefore, effects of simvastatin on cell proliferation and osteoblastic differentiation in PDL cells were analyzed.
   Methods: Human PDL cells were cultured in monolayer with simvastatin for 24 and 72 hours and cell metabolism and proliferation were determined. To analyze osteoblastic differentiation, human PDL cells were cultured in organoid culture for 7, 14, and 21 days and alkaline phosphatase (ALP) activity, osteopontin (OPN), bone morphogenetic protein (BMP)  2, osteocalcin (OCN), and calcium contents were measured. They were co treated by simvastatin and mevalonate.
   Results: Simvastatin enhanced cell proliferation and metabolism dose dependently after 24 hours. Simvastatin also stimulated ALP activity of human PDL cells dose dependently, and maximum effect was obtained at the concentration of 10( 8) M. In time dependent analysis, 10( 8) M simvastatin stimulated ALP activity and osteopontin content after 7 days and calcium contents after 21 days. BMP 2 and OCN contents were not detected. Moreover this statin enhanced ALP activity was abolished by mevalonate.
   Conclusion: These results suggest that at low concentration, simvastatin exhibits positive effect on proliferation and osteoblastic differentiation of human PDL cells, and these effects may be caused by the inhibition of the mevalonate pathway.
C1 Univ Med Sch Berlin, Fac Dent, Dept Periodontol, Charite, D 13353 Berlin, Germany.
   Univ Med Sch, Charite, Inst Clin Pharmacol & Toxicol, Berlin, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin
RP Univ Med Sch Berlin, Fac Dent, Dept Periodontol, Charite, Campus Virchow Klinikum,Augustenburger Platz 1, D 13353 Berlin, Germany.
EM yazawa.peri@tmd.ac.jp
CR ARCEO N, 1991, J PERIODONTOL, V62, P499, DOI 10.1902/jop.1991.62.8.499
   Axel DI, 2000, J CARDIOVASC PHARM, V35, P619, DOI 10.1097/00005344 200004000 00016
   CHO MI, 1992, CALCIFIED TISSUE INT, V50, P459, DOI 10.1007/BF00296778
   Desager JP, 1996, CLIN PHARMACOKINET, V31, P348, DOI 10.2165/00003088 199631050 00003
   Fromigué O, 2002, J ENDOCRINOL INVEST, V25, P539, DOI 10.1007/BF03345497
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002 220682
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Meier CR, 2000, JAMA J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   MELCHER AH, 1976, J PERIODONTOL, V47, P256, DOI 10.1902/jop.1976.47.5.256
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Mundy GR, 2001, BONE, V29, P495, DOI 10.1016/S8756 3282(01)00606 8
   NegreAminou P, 1997, BBA LIPID LIPID MET, V1345, P259, DOI 10.1016/S0005 2760(96)00184 1
   NOJIMA N, 1990, J PERIODONTAL RES, V25, P179, DOI 10.1111/j.1600 0765.1990.tb01041.x
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Oxlund H, 2001, CALCIFIED TISSUE INT, V69, P299, DOI 10.1007/s00223 001 2027 5
   PICHE JE, 1989, J DENT RES, V68, P761, DOI 10.1177/00220345890680050201
   RAMAKRISHNAN PR, 1995, CALCIFIED TISSUE INT, V57, P52, DOI 10.1007/BF00298997
   SOMERMAN MJ, 1988, J DENT RES, V67, P66, DOI 10.1177/00220345880670011301
   Song CL, 2003, BIOCHEM BIOPH RES CO, V308, P458, DOI 10.1016/S0006 291X(03)01408 6
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Thylin MR, 2002, J PERIODONTOL, V73, P1141, DOI 10.1902/jop.2002.73.10.1141
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   vanVliet AK, 1996, BIOCHEM PHARMACOL, V52, P1387, DOI 10.1016/S0006 2952(96)00467 4
   Vincent L, 2001, FEBS LETT, V495, P159, DOI 10.1016/S0014 5793(01)02337 7
   Wang PS, 2000, JAMA J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211
   Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393
   Wong RWK, 2003, BRIT J ORAL MAX SURG, V41, P244, DOI 10.1016/S0266 4356(03)00081 0
   ZIMMERMANN B, 1988, CELL DIFFER DEV, V25, P145, DOI 10.1016/0922 3371(88)90007 X
   ZIMMERMANN B, 1992, CELL TISSUE RES, V267, P75, DOI 10.1007/BF00318693
NR 34
TC 68
Z9 86
U1 0
U2 11
PU AMER ACAD PERIODONTOLOGY
PI CHICAGO
PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611 2690 USA
SN 0022 3492
EI 1943 3670
J9 J PERIODONTOL
JI J. Periodont.
PD FEB
PY 2005
VL 76
IS 2
BP 295
EP 302
DI 10.1902/jop.2005.76.2.295
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 912NK
UT WOS:000228085500020
PM 15974856
DA 2025 08 17
ER

PT J
AU Ramesh, T
AF Ramesh, Thiyagarajan
TI Osteogenic differentiation potential of human bone marrow derived
   mesenchymal stem cells enhanced by bacoside A
SO CELL BIOCHEMISTRY AND FUNCTION
LA English
DT Article
DE bacoside A; mesenchymal stem cell; osteogenesis; osteoporosis;
   Wnt/beta catenin signalling
ID PROMOTES OSTEOBLAST DIFFERENTIATION; BACOPA MONNIERI; STROMAL CELLS;
   HORMONE THERAPY; P38 MAPK; IN VITRO; EXTRACT; SAPONINS; MODULATION;
   PREVENTION
AB Stem cell therapy is growing rapidly to treat numerous diseases including bone associated diseases. Mesenchymal stem cells (MSCs) are most commonly preferred to treat bone diseases because it possesses high osteogenic potency. Though, to obtain maximum osteogenic efficiency of MSCs is challenging. Therefore, this study was planned to evaluate the osteogenic efficiency of human bone marrow derived mesenchymal stem cells (hBMSCs) by bacoside A. This study was investigated the activity of alkaline phosphatase (ALP) and expressions of the genes specific to osteogenic regulation mainly runt related transcription factor 2 (Runx2), osterix (Osx), osteocalcin (OCN) and collagen type I alpha 1 (Col I alpha 1) in hBMSCs cultured under osteogenic conditions at different concentrations of bacoside A for 14 days. The results of this study depicted significant upregulation in the activity of ALP and expressions of osteogenic regulator genes in bacoside A treated cells when compared with control cells. Besides, expressions of glycogen synthase kinase 3 beta (GSK 3 beta) and Wnt/beta catenin were evaluated; these expressions were also significantly increased in bacoside A treated cells when compared with control cells. This result provides a further supporting evidence of bacoside A role on osteogenesis in hBMSCs. The present study suggest that bacoside A will be applied to ameliorate the process of osteogenesis in hBMSCs to repair damaged bone structure during MSC based therapy; this will be an excellent and auspicious treatment for bone associated disorders including osteoporosis.
   Significance of the study
   Osteoporosis is a bone metabolic disorder characterized by an imbalance between the activity of osteoblastic bone formation and osteoclastic bone resorption that disrupts the bone microarchitecture. Current anti osteoporotic drugs are inhibiting bone resorption, but they are unable to restore the bone structure due to extreme bone remodelling process and causes numerous side effects. The finding of natural bioactive compounds with osteogenic property is very essential for osteoporosis treatment. This study was reported that bacoside A ameliorated osteogenic differentiation of hBMSCs through upregulation of osteogenic differentiation genes and Wnt/beta catenin signalling pathway. This result is indicating that bacoside A may be useful for osteoporosis treatments.
C1 [Ramesh, Thiyagarajan] Prince Sattam Bin Abdulaziz Univ, Coll Med, Dept Basic Med Sci, Al Kharj 11942, Saudi Arabia.
C3 Prince Sattam Bin Abdulaziz University
RP Ramesh, T (通讯作者)，Prince Sattam Bin Abdulaziz Univ, Coll Med, Dept Basic Med Sci, Al Kharj 11942, Saudi Arabia.
EM thiyagaramesh@gmail.com
RI Ramesh, Thiyagarajan/AAH 2631 2021
OI Ramesh, Dr. Thiyagarajan/0000 0001 6478 0833
CR Anbarasi K, 2006, LIFE SCI, V78, P1378, DOI 10.1016/j.lfs.2005.07.030
   Annie S, 2006, PHYTOMEDICINE, V13, P43, DOI 10.1016/j.phymed.2004.01.011
   [Anonymous], P.L.
   Arjmandi BH, 2002, J NUTR BIOCHEM, V13, P130, DOI 10.1016/S0955 2863(02)00172 9
   Bellin G, 2019, APPL SCI BASEL, V9, DOI 10.3390/app9163426
   Bongio M, 2016, NANOMEDICINE UK, V11, P1073, DOI 10.2217/nnm 2015 0021
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Chen WK, 2020, FREE RADICAL BIO MED, V146, P92, DOI 10.1016/j.freeradbiomed.2019.10.412
   CHOMCZYNSKI P, 1995, BIOTECHNIQUES, V19, P942
   Chowdhuri DK, 2002, PHYTOTHER RES, V16, P639, DOI 10.1002/ptr.1023
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   De Martinis M, 2020, CURR MED CHEM, V27, P6356, DOI 10.2174/0929867326666190730113123
   Deepak A, 2004, PHYTOMEDICINE, V11, P264, DOI 10.1078/0944 7113 00351
   Egermann M, 2005, OSTEOPOROSIS INT, V16, pS120, DOI 10.1007/s00198 004 1817 9
   Enomoto H, 2004, J CELL SCI, V117, P417, DOI 10.1242/jcs.00866
   Feng QY, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180453
   Folwarczna J, 2016, ACTA BIOCHIM POL, V63, P287, DOI 10.18388/abp.2015_1095
   Fontalis A, 2020, BONE, V136, DOI 10.1016/j.bone.2020.115336
   Frey JL, 2015, MOL CELL BIOL, V35, P1979, DOI 10.1128/MCB.01343 14
   González Rodríguez A, 2016, AUST NZ J PSYCHIAT, V50, P1207, DOI 10.1177/0004867416649033
   Gu QH, 2015, PHARMACOL RES, V97, P70, DOI 10.1016/j.phrs.2015.04.004
   Gu YQ, 2016, SCI REP UK, V6, DOI 10.1038/srep25282
   HEUSER HP, 1973, ARZNEIMITTEL FORSCH, V23, P558
   Hickey M, 2016, MENOPAUSE, V23, P1287, DOI 10.1097/GME.0000000000000712
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hollick Rosemary J, 2011, Menopause Int, V17, P66, DOI 10.1258/mi.2011.011014
   Hsu A, 2009, AM J PUBLIC HEALTH, V99, P2184, DOI 10.2105/AJPH.2009.159889
   HWANG JH, 2015, EXP MOL MED, V47
   Janani P, 2010, J CANCER RES CLIN, V136, P759, DOI 10.1007/s00432 009 0715 0
   Janani P, 2009, CELL BIOL TOXICOL, V25, P425, DOI 10.1007/s10565 008 9096 4
   Jeong HM, 2010, FOOD CHEM TOXICOL, V48, P3362, DOI 10.1016/j.fct.2010.09.005
   Jiang HJ, 2017, CELL TISSUE RES, V367, P257, DOI 10.1007/s00441 016 2528 1
   Kaushik D, 2009, BRAZ J PHARM SCI, V45, P643, DOI 10.1590/S1984 82502009000400006
   Kim JK, 2007, WOMEN HEALTH ISS, V17, P338, DOI 10.1016/j.whi.2007.05.001
   Kisiel AH, 2012, AM J VET RES, V73, P1305, DOI 10.2460/ajvr.73.8.1305
   Lee HW, 2008, J BONE MINER RES, V23, P1227, DOI 10.1359/JBMR.080325
   Li G, 2010, PHYTOTHER RES, V24, P571, DOI 10.1002/ptr.2987
   Li X, 2015, J CELL BIOCHEM, V116, P2354, DOI 10.1002/jcb.25186
   Li XD, 2011, CELL PHYSIOL BIOCHEM, V28, P367, DOI 10.1159/000331753
   Li Z, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249 020 01739 4
   LIAN JB, 1992, CRIT REV ORAL BIOL M, V3, P269, DOI 10.1177/10454411920030030501
   Liao Han Tsung, 2014, World J Stem Cells, V6, P288, DOI 10.4252/wjsc.v6.i3.288
   Ma ZP, 2015, CELL TISSUE RES, V361, P467, DOI 10.1007/s00441 015 2115 x
   Madhu K, 2019, BIOMED PHARMACOTHER, V109, P1339, DOI 10.1016/j.biopha.2018.10.188
   Malishev R, 2017, ACS CHEM NEUROSCI, V8, P884, DOI 10.1021/acschemneuro.6b00438
   Malmir H, 2020, CRIT REV FOOD SCI, V60, P1722, DOI 10.1080/10408398.2019.1590800
   Matsushita Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14029 w
   Miller PD, 2020, OSTEOPOROSIS INT, V31, P181, DOI 10.1007/s00198 019 05233 x
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Niu YB, 2011, PHYTOTHER RES, V25, P1700, DOI 10.1002/ptr.3414
   Pawar R, 2001, PLANTA MED, V67, P752, DOI 10.1055/s 2001 18351
   Promsuban C, 2017, NEUROREPORT, V28, P1031, DOI [10.1097/WNR.0000000000000862, 10.1097/wnr.0000000000000862]
   Rastogi M, 2012, BIOGERONTOLOGY, V13, P183, DOI 10.1007/s10522 011 9367 y
   Roodenrys S, 2002, NEUROPSYCHOPHARMACOL, V27, P279, DOI 10.1016/S0893 133X(01)00419 5
   Santen RJ, 2014, J STEROID BIOCHEM, V142, P52, DOI 10.1016/j.jsbmb.2013.06.010
   Shen Y, 2010, J NAT MED TOKYO, V64, P336, DOI 10.1007/s11418 010 0416 7
   Stough C, 2001, PSYCHOPHARMACOLOGY, V156, P481, DOI 10.1007/s002130100815
   Tao K, 2016, TOXICOL LETT, V240, P68, DOI 10.1016/j.toxlet.2015.10.007
   Vishnubalaji R, 2012, CELL TISSUE RES, V350, P1, DOI 10.1007/s00441 012 1471 z
   Vishnubalaji R, 2012, CELL TISSUE RES, V347, P419, DOI 10.1007/s00441 011 1306 3
   Wang Y, 2016, BMC EVOL BIOL, V16, DOI 10.1186/s12862 016 0653 9
   Wu YW, 2013, ANAL BIOCHEM, V433, P48, DOI 10.1016/j.ab.2012.10.008
   Xu YX, 2012, CHIN J INTEGR MED, V18, P909, DOI 10.1007/s11655 012 1294 2
   Ying XZ, 2013, EUR J PHARMACOL, V721, P225, DOI 10.1016/j.ejphar.2013.09.031
   Yonezawa T, 2011, BIOCHEM BIOPH RES CO, V409, P260, DOI 10.1016/j.bbrc.2011.05.001
   Zhao XL, 2012, CHIN HERB MED, V4, P265, DOI 10.3969/j.issn.1674 6348.2012.04.001
NR 66
TC 13
Z9 13
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0263 6484
EI 1099 0844
J9 CELL BIOCHEM FUNCT
JI Cell Biochem. Funct.
PD JAN
PY 2021
VL 39
IS 1
BP 148
EP 158
DI 10.1002/cbf.3596
EA NOV 2020
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Biochemistry & Molecular Biology; Cell Biology
GA PO8UT
UT WOS:000583590700001
PM 33137853
DA 2025 08 17
ER

PT J
AU Krevvata, M
   Silva, BC
   Manavalan, JS
   Galan Diez, M
   Kode, A
   Matthews, BG
   Park, D
   Zhang, CA
   Galili, N
   Nickolas, TL
   Dempster, DW
   Dougall, W
   Teruya Feldstein, J
   Economides, AN
   Kalajzic, I
   Raza, A
   Berman, E
   Mukherjee, S
   Bhagat, G
   Kousteni, S
AF Krevvata, Maria
   Silva, Barbara C.
   Manavalan, John S.
   Galan Diez, Marta
   Kode, Aruna
   Matthews, Brya Grace
   Park, David
   Zhang, Chiyuan A.
   Galili, Naomi
   Nickolas, Thomas L.
   Dempster, David W.
   Dougall, William
   Teruya Feldstein, Julie
   Economides, Aris N.
   Kalajzic, Ivo
   Raza, Azra
   Berman, Ellin
   Mukherjee, Siddhartha
   Bhagat, Govind
   Kousteni, Stavroula
TI Inhibition of leukemia cell engraftment and disease progression in mice
   by osteoblasts
SO BLOOD
LA English
DT Article
ID HEMATOPOIETIC STEM CELLS; BONE MARROW NICHE; ACUTE
   LYMPHOBLASTIC LEUKEMIA; PROGENITOR CELLS; MYELOID LEUKEMIA; SEROTONIN;
   MICROENVIRONMENT; OSTEOPONTIN; CHILDREN; THERAPY
AB The bone marrow niche is thought to act as a permissive microenvironment required for emergence or progression of hematologic cancers. We hypothesized that osteoblasts, components of the niche involved in hematopoietic stem cell (HSC) function, influence the fate of leukemic blasts. We show that osteoblast numbers decrease by 55% in myelodysplasia and acute myeloid leukemia patients. Further, genetic depletion of osteoblasts in mouse models of acute leukemia increased circulating blasts and tumor engraftment in the marrow and spleen leading to higher tumor burden and shorter survival. Myelopoiesis increased and was coupled with a reduction in B lymphopoiesis and compromised erythropoiesis, suggesting that hematopoietic lineage/progression was altered. Treatment of mice with acute myeloid or lymphoblastic leukemia with a pharmacologic inhibitor of the synthesis of duodenal serotonin, a hormone suppressing osteoblast numbers, inhibited loss of osteoblasts. Maintenance of the osteoblast pool restored normal marrow function, reduced tumor burden, and prolonged survival. Leukemia preventionwas attributable to maintenance of osteoblast numbers because inhibition of serotonin receptors alone in leukemic blasts did not affect leukemia progression. These results suggest that osteoblasts play a fundamental role in propagating leukemia in the marrow and may be a therapeutic target to induce hostility of the niche to leukemia blasts.
C1 [Krevvata, Maria; Silva, Barbara C.; Manavalan, John S.; Galan Diez, Marta; Kode, Aruna; Zhang, Chiyuan A.; Kousteni, Stavroula] Columbia Univ, Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY USA.
   [Matthews, Brya Grace; Kalajzic, Ivo] Univ Connecticut, Ctr Hlth, Dept Reconstruct Sci, Farmington, CT USA.
   [Park, David; Teruya Feldstein, Julie] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA.
   [Galili, Naomi; Raza, Azra] Columbia Univ, Coll Phys & Surg, Myelodysplast Syndromes Ctr, New York, NY USA.
   [Nickolas, Thomas L.] Columbia Univ, Coll Phys & Surg, Dept Med, Div Nephrol, New York, NY USA.
   [Dempster, David W.] Helen Hayes Hosp, Reg Bone Ctr, New York, NY USA.
   [Dougall, William] Amgen Inc, Seattle, WA USA.
   [Economides, Aris N.] Regeneron Pharmaceut Inc, Bone & Cartilage Biol Grp, Genome Engn Technol Grp, Tarrytown, NY 10591 USA.
   [Berman, Ellin] Weill Cornell Med Coll, Dept Med, Mem Sloan Kettering Canc Ctr, New York, NY USA.
   [Mukherjee, Siddhartha] Columbia Univ, Coll Phys & Surg, Dept Med, Div Hematol & Oncol, New York, NY USA.
   [Bhagat, Govind] Columbia Univ, Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY USA.
C3 Columbia University; University of Connecticut; Memorial Sloan Kettering
   Cancer Center; Columbia University; Columbia University; Amgen;
   Regeneron; Memorial Sloan Kettering Cancer Center; Cornell University;
   Weill Cornell Medicine; Columbia University; Columbia University
RP Kousteni, S (通讯作者)，Russ Berrie Med Sci Pavil,1150 St Nicholas Ave, New York, NY 10032 USA.
EM sk2836@cumc.columbia.edu
RI Matthews, Brya/B 9812 2013; Bhagat, Govind/AAE 9493 2021; GALAN DIEZ,
   MARTA/A 7037 2019; Galan Diez, Marta/A 7037 2019; Krevvata,
   Maria/O 6178 2014
OI Matthews, Brya G./0000 0002 4145 4696; Dougall,
   William/0000 0001 9487 251X; GALAN DIEZ, MARTA/0000 0002 2092 3414;
   Silva, Barbara/0000 0001 7276 581X; Economides,
   Aris/0000 0002 6508 8942; Bhagat, Govind/0000 0001 6250 048X; 
FU National Institute of Diabetes and Digestive and Kidney Diseases
   [DK063608 07]; National Institutes of Health National Institute of
   Arthritis and Musculoskeletal and Skin Diseases [R01 AR054447, R01
   AR055931]; National Institute of Aging [P01 AG032959]; Division of
   Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York;
   Brazilian National Council of Technological and Scientific Development
FX The authors thank Drs Michael Moore and Renier Brentjens (Memorial Sloan
   Kettering Cancer Center, New York) for providing the WEHI 3B murine
   myelomonocytic leukemia cells and the EL4 GFP Luc lymphoblastic leukemia
   cells, respectively, and Dr Lorraine Fitzpatrick for providing the bone
   biopsies for the human healthy control subjects. The authors also thank
   Drs Suzanne Lentzsch and Gerard Karsenty for critical reading of the
   manuscript, Don McMahon for help with statistical analysis, and Elzbieta
   Dworakowski, Chiu Yi Liu, Yan Nikhami, Foxwell N. Emmons, and Janine
   Pichard for technical assistance. The histology and metabolic unit
   facility of the Diabetes and Endocrinology Research Center (DERC;
   National Institute of Diabetes and Digestive and Kidney Diseases grant
   DK063608 07) and the authors thank the Molecular Pathology facility of
   the Herbert Irving Cancer Center of Columbia University Medical Center
   for preparation of tissue samples for histopathological analysis.This
   work was supported by the National Institutes of Health National
   Institute of Arthritis and Musculoskeletal and Skin Diseases grants R01
   AR054447 and R01 AR055931, and the National Institute of Aging grant P01
   AG032959 (S.K.); the Division of Hematologic Oncology, Memorial Sloan
   Kettering Cancer Center, New York (E.B.); and the Brazilian National
   Council of Technological and Scientific Development (B.C.S.).
CR Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Boyerinas B, 2013, BLOOD, V121, P4821, DOI 10.1182/blood 2012 12 475483
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chan CKF, 2009, NATURE, V457, P490, DOI 10.1038/nature07547
   Clarke BL, 1996, J CLIN ENDOCR METAB, V81, P2264, DOI 10.1210/jc.81.6.2264
   Colmone A, 2008, SCIENCE, V322, P1861, DOI 10.1126/science.1164390
   Crofton PM, 1998, J CLIN ENDOCR METAB, V83, P3121, DOI 10.1210/jc.83.9.3121
   Dennis JE, 2002, STEM CELLS, V20, P205, DOI 10.1634/stemcells.20 3 205
   Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783
   El Ziny MA, 2005, HEMATOLOGY, V10, P327, DOI 10.1080/10245330500155598
   Fitter S, 2008, BLOOD, V111, P2538, DOI 10.1182/blood 2007 07 104281
   Fox MF, 2013, LEUKEMIA LYMPHOMA, V54, P2274, DOI 10.3109/10428194.2013.777067
   Frisch BJ, 2012, BLOOD, V119, P540, DOI 10.1182/blood 2011 04 348151
   Fulzele K, 2013, BLOOD, V121, P930, DOI 10.1182/blood 2012 06 437160
   Gonzalez Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495
   Haddy TB, 2001, ONCOLOGIST, V6, P278, DOI 10.1634/theoncologist.6 3 278
   HERBERMAN RB, 1972, JNCI J NATL CANCER I, V48, P265
   Holland PM, 2010, CANCER BIOL THER, V9, P539, DOI 10.4161/cbt.9.7.11266
   Inose H, 2011, J BONE MINER RES, V26, P2002, DOI 10.1002/jbmr.439
   Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350
   Janzen V, 2008, CELL STEM CELL, V2, P584, DOI 10.1016/j.stem.2008.03.012
   Kim YW, 2008, BLOOD, V112, P4628, DOI 10.1182/blood 2008 03 148999
   Kode A, 2014, NATURE, V506, P240, DOI 10.1038/nature12883
   Kode A, 2012, J CLIN INVEST, V122, P3490, DOI 10.1172/JCI64906
   Krause DS, 2013, NAT MED, V19, P1513, DOI 10.1038/nm.3364
   Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980
   Lane SW, 2011, BLOOD, V118, P2849, DOI 10.1182/blood 2011 03 345165
   Lévesque JP, 2010, LEUKEMIA, V24, P1979, DOI 10.1038/leu.2010.214
   Lichtman MA, 2000, STEM CELLS, V18, P304, DOI 10.1634/stemcells.18 5 304
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Meredith EJ, 2005, FASEB J, V19, P1187, DOI 10.1096/fj.04 3477fje
   Miyamoto K, 2011, J EXP MED, V208, P2761, DOI 10.1084/jem.2010189020813c
   Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543
   Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood 2004 11 4422
   Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293
   Oh IH, 2010, STEM CELLS, V28, P1243, DOI 10.1002/stem.453
   Pegram HJ, 2012, BLOOD, V119, P4133, DOI 10.1182/blood 2011 12 400044
   Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851
   ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421
   Sala A, 2007, CANCER AM CANCER SOC, V109, P1420, DOI 10.1002/cncr.22546
   Serafeim A, 2003, BLOOD, V101, P3212, DOI 10.1182/blood 2002 07 2044
   Sinigaglia R, 2008, J PEDIATR ORTHOPED, V28, P20, DOI 10.1097/BPO.0b13e31815ff350
   Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992
   Taichman RS, 1996, BLOOD, V87, P518, DOI 10.1182/blood.V87.2.518.bloodjournal872518
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   Walkley CR, 2007, CELL, V129, P1097, DOI 10.1016/j.cell.2007.05.014
   WARNER NL, 1969, J NATL CANCER I, V43, P963
   Wu JY, 2008, P NATL ACAD SCI USA, V105, P16976, DOI 10.1073/pnas.0802898105
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Yoshihara H, 2007, CELL STEM CELL, V1, P685, DOI 10.1016/j.stem.2007.10.020
   Yoshikawa Y, 2011, J BONE MINER RES, V26, P2012, DOI 10.1002/jbmr.417
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood 2006 08 041384
NR 54
TC 98
Z9 107
U1 0
U2 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD OCT 30
PY 2014
VL 124
IS 18
BP 2834
EP 2846
DI 10.1182/blood 2013 07 517219
PG 13
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA AY3BC
UT WOS:000347458500016
PM 25139351
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Zhu, YJ
   Liu, SC
   Mei, FF
   Zhao, MH
   Xia, GH
   Shen, XR
AF Zhu, Yujie
   Liu, Shucheng
   Mei, Fengfeng
   Zhao, Meihui
   Xia, Guanghua
   Shen, Xuanri
TI Tilapia nilotica Head Lipids Improved Bone Loss by Regulating
   Inflammation and Serum Metabolism Through Gut Microbiota in
   Ovariectomized Rats
SO FRONTIERS IN NUTRITION
LA English
DT Article
DE bone loss; Tilapia nilotica head lipids; gut microbiota; inflammation;
   metabonomics
ID OSTEOCLAST DIFFERENTIATION; MINERAL DENSITY; FATTY ACIDS; OSTEOPOROSIS;
   PATHOGENESIS; MECHANISMS; RECEPTOR; FISH; OIL
AB Osteoporosis is a global health problem, and it is of great significance to replace the drugs with natural functional factors. In this study, we investigated the antiosteoporotic activity of lipids prepared from Tilapia nilotica fish head lipids (THLs) in the ovariectomized osteoporosis rats. THLs are composed of neutral lipids (NL, 77.84%), phospholipids (PL, 11.86%), and glycolipids (GL, 6.47%). There were apparent differences in the fatty acid composition of disparate components, and PL contains the most abundant omega 3 polyunsaturated fatty acids. The results proved that THLs could improve bone microstructure, increase bone mineral density, and decrease bone resorption. To illustrate the antiosteoporotic mechanism, we analyzed the changes in gut microbial communities, proinflammation factors, serum metabolites, and metabolic pathways. Further study on gut microbiota showed that THLs significantly decreased the content of Alistipes in the gut and dramatically increased the beneficial bacteria such as Oscillospira, Roseburia, and Dubosiella. Meanwhile, proinflammation factors of serum in OVX rats decreased significantly, and metabolites were changed. Therefore, we speculated that THLs improved bone loss through reducing inflammation and changing the metabolites and metabolic pathways such as arachidonic acid metabolism and primary bile acid metabolism, etc., by altering gut microbiota. The results indicated that THLs could be a functional factor with antiosteoporotic activity.
C1 [Zhu, Yujie; Mei, Fengfeng; Zhao, Meihui; Xia, Guanghua; Shen, Xuanri] Hainan Univ, Hainan Engn Res Ctr Aquat Resources Efficient Uti, Key Lab Food Nutr & Funct Food Hainan Prov, Coll Food Sci & Technol,Key Lab Seafood Proc Haik, Haikou, Hainan, Peoples R China.
   [Zhu, Yujie; Liu, Shucheng; Xia, Guanghua] Guangdong Ocean Univ, Guangdong Prov Key Lab Aquat Prod Proc & Safety, Zhanjiang, Peoples R China.
   [Zhu, Yujie; Mei, Fengfeng; Zhao, Meihui; Xia, Guanghua; Shen, Xuanri] Dalian Polytech Univ, Collaborat Innovat Ctr Prov & Ministerial Coconst, Dalian, Peoples R China.
C3 Hainan University; Guangdong Ocean University; Dalian Polytechnic
   University
RP Xia, GH; Shen, XR (通讯作者)，Hainan Univ, Hainan Engn Res Ctr Aquat Resources Efficient Uti, Key Lab Food Nutr & Funct Food Hainan Prov, Coll Food Sci & Technol,Key Lab Seafood Proc Haik, Haikou, Hainan, Peoples R China.; Xia, GH (通讯作者)，Guangdong Ocean Univ, Guangdong Prov Key Lab Aquat Prod Proc & Safety, Zhanjiang, Peoples R China.; Xia, GH; Shen, XR (通讯作者)，Dalian Polytech Univ, Collaborat Innovat Ctr Prov & Ministerial Coconst, Dalian, Peoples R China.
EM xiaguanghua2011@126.com; 990497@hainannu.edu.cn
RI Xia, Guanghua/AAN 1812 2021; shuo, chen/AAJ 9411 2020
FU National Key R&D Programs of China [2018YFD0901103]; Hainan Provincial
   Natural Science Foundation of China [2019RC093]; Program of Hainan
   Association for Science and Technology Plans to Youth RD Innovation
   [QCXM202003]
FX Funding This work was supported by the National Key R&D Programs of
   China (Number 2018YFD0901103), Hainan Provincial Natural Science
   Foundation of China (Number 2019RC093), and the Program of Hainan
   Association for Science and Technology Plans to Youth R&D Innovation
   (Number QCXM202003).
CR Abou Saleh H, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112701
   Amin N, 2020, AGING CLIN EXP RES, V32, P363, DOI 10.1007/s40520 019 01223 5
   Benoit M, 2008, J IMMUNOL, V181, P3733, DOI 10.4049/jimmunol.181.6.3733
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brahe LK, 2015, NUTR DIABETES, V5, DOI 10.1038/nutd.2015.9
   Cauley JA, 2015, STEROIDS, V99, P11, DOI 10.1016/j.steroids.2014.12.010
   Che HX, 2021, MOL NUTR FOOD RES, V65, DOI 10.1002/mnfr.202000986
   Chen LP, 2015, J OLEO SCI, V64, P1273, DOI 10.5650/jos.ess15190
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   D'Amelio P, 2018, CALCIFIED TISSUE INT, V102, P415, DOI 10.1007/s00223 017 0331 y
   Dahabiyeh LA, 2020, METABOLITES, V10, DOI 10.3390/metabo10020042
   Ding K, 2020, AGING DIS, V11, P438, DOI 10.14336/AD.2019.0523
   Ejtahed HS, 2016, HORM METAB RES, V48, P349, DOI 10.1055/s 0042 107792
   Gong LX, 2019, J FUNCT FOODS, V60, DOI 10.1016/j.jff.2019.103453
   Gu ZP, 2021, INT IMMUNOPHARMACOL, V96, DOI 10.1016/j.intimp.2021.107802
   Gu ZP, 2020, FOOD FUNCT, V11, P3245, DOI [10.1039/d0fo00116c, 10.1039/D0FO00116C]
   Harris TB, 2015, AM J CLIN NUTR, V101, P947, DOI 10.3945/ajcn.114.087502
   Hsu E, 2018, CALCIFIED TISSUE INT, V102, P512, DOI 10.1007/s00223 017 0321 0
   Ionova Martin SS, 2011, OSTEOPOROSIS INT, V22, P2283, DOI 10.1007/s00198 010 1432 x
   Johnson CH, 2016, NAT REV MOL CELL BIO, V17, P451, DOI 10.1038/nrm.2016.25
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Knudsen JK, 2021, CURR OSTEOPOROS REP, V19, P462, DOI 10.1007/s11914 020 00629 9
   Kruger MC, 2010, PROG LIPID RES, V49, P438, DOI 10.1016/j.plipres.2010.06.002
   Lavoie B, 2017, ADV EXP MED BIOL, V1033, P35, DOI 10.1007/978 3 319 66653 2_3
   Lee SR, 2020, J ETHNOPHARMACOL, V258, DOI 10.1016/j.jep.2020.112874
   Lei L, 2012, J AGR FOOD CHEM, V60, P1857, DOI 10.1021/jf204584t
   Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017
   Li S, 2020, BONE JOINT RES, V9, P524, DOI 10.1302/2046 3758.98.BJR 2020 0089.R1
   Lieberthal J, 2015, OSTEOARTHR CARTILAGE, V23, P1825, DOI 10.1016/j.joca.2015.08.015
   Liu TT, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00324
   Lucas S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02490 4
   Mao L, 2019, J FUNCT FOODS, V52, P73, DOI 10.1016/j.jff.2018.10.027
   Mei FF, 2021, J AGR FOOD CHEM, V69, P246, DOI 10.1021/acs.jafc.0c06671
   Meng KK, 2021, J FUNCT FOODS, V84, DOI 10.1016/j.jff.2021.104598
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   Ohlsson C, 2015, TRENDS ENDOCRIN MET, V26, P69, DOI 10.1016/j.tem.2014.11.004
   Ohlsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092368
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Prather C, 2020, AM J HEALTH SYST PH, V77, P1949, DOI 10.1093/ajhp/zxaa285
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Rahman MM, 2009, J CELL MOL MED, V13, P1833, DOI 10.1111/j.1582 4934.2009.00649.x
   Rahman M, 2008, J CELL PHYSIOL, V214, P201, DOI 10.1002/jcp.21188
   Ren XB, 2020, J FOOD BIOCHEM, V44, DOI 10.1111/jfbc.13182
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Santos FFP, 2010, FUEL, V89, P275, DOI 10.1016/j.fuel.2009.05.030
   Schmidt S, 2012, J PEDIATR GASTR NUTR, V55, P511, DOI 10.1097/MPG.0b013e31825817a0
   Seeman E, 2002, LANCET, V359, P1841, DOI 10.1016/S0140 6736(02)08706 8
   Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533
   Shang JJ, 2021, PEERJ, V9, DOI 10.7717/peerj.11128
   Shemanko CS, 2016, J MOL ENDOCRINOL, V57, pR153, DOI 10.1530/JME 16 0150
   Sjogren K, 2012, BONE, V50, pS91, DOI [10.1016/j.bone.2012.02.272, 10.1002/jbmr.1588]
   Skjodt MK, 2019, BRIT J CLIN PHARMACO, V85, P1063, DOI 10.1111/bcp.13759
   Tabatabaei Malazy O, 2017, DARU, V25, DOI 10.1186/s40199 017 0167 z
   Tella SH, 2014, EUR J CLIN PHARMACOL, V70, P1291, DOI 10.1007/s00228 014 1735 5
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Vijay Kumar M, 2010, SCIENCE, V328, P228, DOI 10.1126/science.1179721
   Villa CR, 2017, CRIT REV FOOD SCI, V57, P1664, DOI 10.1080/10408398.2015.1010034
   Wang YM, 2018, BIOCHEM BIOPH RES CO, V498, P981, DOI 10.1016/j.bbrc.2018.03.093
   Xiao HH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00932
   Yan J, 2018, GUT MICROBES, V9, P84, DOI 10.1080/19490976.2017.1371893
   Yang G, 2016, ANAL BIOANAL CHEM, V408, P4275, DOI 10.1007/s00216 016 9524 x
   Zhai G, 2010, ANN RHEUM DIS, V69, P1227, DOI 10.1136/ard.2009.120857
   Zhan QP, 2020, FOOD FUNCT, V11, P7048, DOI [10.1039/d0fo00884b, 10.1039/D0FO00884B]
   Zhang AH, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00553
   Zhang ML, 2018, INT J BIOL MACROMOL, V112, P433, DOI 10.1016/j.ijbiomac.2018.01.204
   Zhang Z, 2021, METABOLISM, V119, DOI 10.1016/j.metabol.2021.154767
   Zhu WW, 2016, METABOLOMICS, V12, DOI 10.1007/s11306 016 0965 1
   Zolfaroli I, 2021, MATURITAS, V147, P41, DOI 10.1016/j.maturitas.2021.03.001
NR 69
TC 32
Z9 33
U1 6
U2 53
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 861X
J9 FRONT NUTR
JI Front. Nutr.
PD JAN 12
PY 2022
VL 8
AR 792793
DI 10.3389/fnut.2021.792793
PG 15
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA YO4RJ
UT WOS:000747928100001
PM 35096937
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Fei, WY
   Huo, Q
   Zhao, PQ
   Qin, LJ
   Li, T
AF Fei, Wen Yong
   Huo, Qiang
   Zhao, Pei Qing
   Qin, Long Juan
   Li, Tao
TI Magnolol prevents ovariectomy induced bone loss by suppressing
   osteoclastogenesis via inhibition of the nuclear factor κB and
   mitogen activated protein kinase pathways
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE magnolol; bone loss; osteoclastogenesis; nuclear factor kappa B pathway;
   mitogen activated protein kinase pathway
ID NF B; OSTEOPOROSIS; CELLS
AB Magnolol is the active component of the traditional Chinese medicine Magnolia officinalis, and has antioxidant, anti inflammatory and anticancer activities, as well as an effect on bone metabolism in vitro. In the present study, it is reported that magnolol suppresses osteoclastogenesis in vivo and in vitro. Magnolol prevented ovariectomy induced bone loss and osteoclastogenesis in vivo, and decreased the serum levels of C terminal telopeptide of type 1 collagen, interleukin 6, tumor necrosis factor (TNF) alpha and tartrate resistant acid phosphatase 5B. In vitro, magnolol inhibited the osteoclastogenesis induced by the receptor activator for nuclear factor kappa B ligand, and impaired the osteoclast function in bone marrow monocytes and RAW264.7 cells in a dose dependent manner. Furthermore, magnolol suppressed the expression levels of the osteoclastogenesis markers cathepsin K, calcitonin receptor, matrix metalloproteinase 9, TNF receptor associated factor 6 and tartrate resistant acid phosphatase by inhibiting the nuclear factor kappa B and mitogen activated protein kinase pathways. Therefore, magnolol is a promising agent for the treatment of osteoporosis and associated disorders.
C1 [Fei, Wen Yong] Yangzhou Univ, Northern Jiangsu Peoples Hosp, Dept Orthoped, Clin Med Coll, Yangzhou 225001, Jiangsu, Peoples R China.
   [Huo, Qiang; Zhao, Pei Qing; Li, Tao] Shandong Univ, Cent Hosp Zibo, Ctr Translat Med, 54 West Gongqingtuan Rd, Zibo 255036, Shandong, Peoples R China.
   [Qin, Long Juan] Orthoped Basic & Translat Res Ctr, Jiangyin 214400, Jiangsu, Peoples R China.
C3 Yangzhou University; Shandong University
RP Li, T (通讯作者)，Shandong Univ, Cent Hosp Zibo, Ctr Translat Med, 54 West Gongqingtuan Rd, Zibo 255036, Shandong, Peoples R China.
EM litaozhongguo@vip.163.com
RI Zhao, Peiqing/AAA 5961 2022
OI Zhao, Peiqing/0000 0002 9311 1927
FU Young Medical Key Talent Project of Jiangsu province [QNRC2016458];
   Jiangsu Provincial Medical Innovation Team [XTDB2017004]; Clinical Study
   of Jiangsu University [JLY20160005]
FX The present study was supported by funds from the Young Medical Key
   Talent Project of Jiangsu province (grant no. QNRC2016458), Jiangsu
   Provincial Medical Innovation Team (grant no. C XTDB2017004) and
   Clinical Study of Jiangsu University (grant no. JLY20160005).
CR Al Daghri NM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005780
   [Anonymous], 2004, US Health and Human Services, P437
   Bateman ME, 2017, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00171
   Chen P, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889 016 3712 7
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chen X, 2017, FASEB J, V31, P4855, DOI 10.1096/fj.201700316R
   Chen X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.394
   Dong J, 2017, VET MICROBIOL, V211, P119, DOI 10.1016/j.vetmic.2017.10.005
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Gielen E, 2017, CALCIFIED TISSUE INT, V101, P111, DOI 10.1007/s00223 017 0266 3
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   Jeong JH, 2017, WORLD NEUROSURG, V106, P964, DOI [10.1016/J.WNEU.2017.07.083, 10.1016/j.wneu.2017.07.083]
   Kanzaki H, 2017, FASEB J, V31, P781, DOI 10.1096/fj.201600826R
   Kwak EJ, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/829650
   Li ML, 2015, CANCER SCI, V106, P1341, DOI 10.1111/cas.12762
   Liu Q, 2016, SCI REP UK, V6, DOI 10.1038/srep36662
   Lu SH, 2013, EVID BASED COMPLEMEN, V2013
   McClung M, 2017, BONE, V98, P37, DOI 10.1016/j.bone.2017.02.013
   Noel SE, 2018, J BONE MINER RES, V33, P396, DOI 10.1002/jbmr.3315
   Okabe I, 2017, J CELL BIOCHEM, V118, P739, DOI 10.1002/jcb.25726
   Park JW, 2018, J CELL PHYSIOL, V233, P1481, DOI 10.1002/jcp.26035
   Park KR, 2017, ARCH PHARM RES, V40, P933, DOI 10.1007/s12272 017 0932 z
   Paschalis EP, 2017, BONE, V95, P41, DOI 10.1016/j.bone.2016.11.002
   Stoecker WV, 2017, J BONE MINER RES, V32, P1386, DOI 10.1002/jbmr.3145
   Ueno M, 2018, PHYTOTHER RES, V32, P452, DOI 10.1002/ptr.5988
   Wang W, 2015, INFLAMMATION, V38, P16, DOI 10.1007/s10753 014 0003 2
   Wang YZ, 2017, FEBS J, V284, P2501, DOI 10.1111/febs.14142
   Xu LJ, 2018, J CELL BIOCHEM, V119, P3819, DOI 10.1002/jcb.26332
   Yang BY, 2016, INFLAMM RES, V65, P81, DOI 10.1007/s00011 015 0894 x
   Yang XB, 2017, J CELL BIOCHEM, V118, P4479, DOI 10.1002/jcb.26105
   Zhou Y, 2017, CELLS TISSUES ORGANS, V204, P25, DOI 10.1159/000464461
NR 31
TC 10
Z9 10
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD APR
PY 2019
VL 43
IS 4
BP 1669
EP 1678
DI 10.3892/ijmm.2019.4099
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA HO7EO
UT WOS:000461099500010
PM 30816431
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Ying, XZ
   Chen, XW
   Liu, HX
   Nie, PF
   Shui, XL
   Shen, Y
   Yu, KH
   Cheng, SW
AF Ying, Xiaozhou
   Chen, Xiaowei
   Liu, Haixiao
   Nie, Pengfei
   Shui, Xiaolong
   Shen, Yue
   Yu, Kehe
   Cheng, Shaowen
TI Silibinin alleviates high glucose suppressed osteogenic differentiation
   of human bone marrow stromal cells via antioxidant effect and
   PI3K/Akt signaling
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Silibinin; High glucose (HG); PI3K/Akt pathway; Antioxidant;
   Osteoporosis
ID OSTEOBLAST DIFFERENTIATION; DIABETES MELLITUS; OXIDATIVE STRESS;
   IN VITRO; MECHANISMS; GROWTH; RATS; PROLIFERATION; OSTEOPOROSIS;
   PATHOGENESIS
AB High glucose is one of the possible causes for osteoporosis and fracture in diabetes mellitus. Our previous study showed that silibinin can increase osteogenic effect by stimulating osteogenic genes expression in human bone marrow stem cells (hBMSCs). However, no study has yet investigated the effect of silibinin on osteogenic differentiation of hBMSCs cultured with high glucose. The aim of this study was to evaluate the influence of high glucose on osteogenic differentiation of hBMSCs and to determine if silibinin can alleviate those effects. In this study, the hBMSCs were cultured in an osteogenic medium with physiological (normal glucose, NG, 5.5 mM) or diabetic (high glucose, HG, 30 mM). The effects of silibinin on HG induced osteogenic differentiation were evaluated by alkaline phosphatas (ALP) activity assay, Von Kossa staining and real time polymerase chain reaction. HG induced oxidative damage was also assessed. Western blot were performed to examine the role of PI3K/Akt pathway. We demonstrated that HG suppressed osteogenic differentiation of hBMSCs, manifested by a decrease in expression of osteogenic markers and an increase of oxidative damage markers including reactive oxygen species and lipid peroxide (MDA). Remarkably, all of the observed oxidative damage and osteogenic dysfunction induced by HG were inhibited by silibinin. Furthermore, the PI3K/Akt pathway was activated by silibinin. These results demonstrate that silibinin may attenuate HG mediated hBMSCs dysfunction through antioxidant effect and modulation of PI3K/Akt pathway, suggesting that silibinin may be a superior drug candidate for the treatment of diabetes related bone diseases. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Ying, Xiaozhou; Liu, Haixiao; Shui, Xiaolong; Yu, Kehe] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou 325000, Peoples R China.
   [Chen, Xiaowei] Wenzhou Med Univ, Affiliated Hosp 1, Dept Ultrasound Imaging, Wenzhou 325000, Peoples R China.
   [Nie, Pengfei] Beilun Peoples Hosp, Dept Orthopaed, Ningbo 315800, Zhejiang, Peoples R China.
   [Shen, Yue] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Orthopaed Surg, Hangzhou 310009, Zhejiang, Peoples R China.
   [Cheng, Shaowen] Hainan Med Coll, Affiliated Hosp, Ctr Trauma, Haikou 570100, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Zhejiang
   University; Hainan Medical University
RP Ying, XZ (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, 109 Xue Yuan Xi Rd, Wenzhou 325000, Peoples R China.
EM yingxiaozhou@sina.com
RI Shen, Yue/JHS 7510 2023
FU National Natural Science Foundation of China [81402980]; Wenzhou
   Technology Project [Y20140154]
FX The authors thank all the staff in the Laboratory of Orthopedic Research
   Institute and Scientific Research Center of Second Affiliated Hospital
   of Wenzhou Medical University. This work was supported by grants from
   the National Natural Science Foundation of China (81402980) and the
   Wenzhou Technology Project (Y20140154).
CR Agoston M, 2001, CLIN CHIM ACTA, V303, P87, DOI 10.1016/S0009 8981(00)00383 1
   Al Anati L, 2009, MOL NUTR FOOD RES, V53, P460, DOI 10.1002/mnfr.200800110
   Ali MH, 2006, AM J PHYSIOL LUNG C, V291, pL38, DOI 10.1152/ajplung.00287.2004
   Balint E, 2001, BONE, V28, P21, DOI 10.1016/S8756 3282(00)00426 9
   Botolin S, 2006, J CELL BIOCHEM, V99, P411, DOI 10.1002/jcb.20842
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Gopalakrishnan V, 2006, BIOCHEM CELL BIOL, V84, P93, DOI 10.1139/O05 163
   Gopalakrishnan V, 2006, BIOCHEM CELL BIOL, V84, P728, DOI 10.1139/O06 066
   GRONTHOS S, 1995, BLOOD, V85, P929, DOI 10.1182/blood.V85.4.929.bloodjournal854929
   Ha HL, 2010, WORLD J GASTROENTERO, V16, P6035, DOI 10.3748/wjg.v16.i48.6035
   Hakki SS, 2010, J TRACE ELEM MED BIO, V24, P243, DOI 10.1016/j.jtemb.2010.03.003
   Kavitha CV, 2014, MOL CARCINOGEN, V53, P169, DOI 10.1002/mc.21959
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kim JH, 2009, MOL CELLS, V28, P201, DOI 10.1007/s10059 009 0123 y
   Kim JL, 2012, EXP BIOL MED, V237, P417, DOI 10.1258/ebm.2011.011376
   Kim SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067504
   Kittur S, 2002, J MOL NEUROSCI, V18, P265, DOI 10.1385/JMN:18:3:265
   Lavery LA, 2003, DIABETES CARE, V26, P1435, DOI 10.2337/diacare.26.5.1435
   Lee KH, 2008, EUR J PHARMACOL, V591, P1, DOI 10.1016/j.ejphar.2008.06.004
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lipscombe LL, 2007, DIABETES CARE, V30, P835, DOI 10.2337/dc06 1851
   LOCATTO ME, 1993, BONE MINER, V23, P129, DOI 10.1016/S0169 6009(08)80049 9
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   McCabe LR, 2007, J CELL BIOCHEM, V102, P1343, DOI 10.1002/jcb.21573
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Ozgocmen S, 2007, MOL CELL BIOCHEM, V295, P45, DOI 10.1007/s11010 006 9270 z
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Schwartz AV, 2003, CALCIFIED TISSUE INT, V73, P515, DOI 10.1007/s00223 003 0023 7
   Singh RP, 2005, EUR J CANCER, V41, P1969, DOI 10.1016/j.ejca.2005.03.033
   Strotmeyer ES, 2005, ARCH INTERN MED, V165, P1612, DOI 10.1001/archinte.165.14.1612
   Sun HL, 2006, BIOMATERIALS, V27, P5651, DOI 10.1016/j.biomaterials.2006.07.027
   Sun HL, 2010, BIOMATERIALS, V31, P1133, DOI 10.1016/j.biomaterials.2009.10.030
   Terada M, 1998, BONE, V22, P17, DOI 10.1016/S8756 3282(97)00220 2
   Verhaeghe J, 2000, BONE, V27, P249, DOI 10.1016/S8756 3282(00)00308 2
   Wei JW, 2015, CURR OSTEOPOROS REP, V13, P180, DOI 10.1007/s11914 015 0267 y
   Whiting DR, 2011, DIABETES RES CLIN PR, V94, P311, DOI 10.1016/j.diabres.2011.10.029
   Ying XZ, 2013, EUR J PHARMACOL, V721, P225, DOI 10.1016/j.ejphar.2013.09.031
   Zhang Y, 2013, J CELL BIOCHEM, V114, P2595, DOI 10.1002/jcb.24607
NR 40
TC 41
Z9 44
U1 2
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD OCT 15
PY 2015
VL 765
BP 394
EP 401
DI 10.1016/j.ejphar.2015.09.005
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CV4PN
UT WOS:000364249100048
PM 26362750
DA 2025 08 17
ER

PT J
AU Huang, SJ
   Jiang, YJ
   Li, J
   Mao, LL
   Qiu, ZY
   Zhang, S
   Jiang, YH
   Liu, Y
   Liu, W
   Xiong, Z
   Zhang, WJ
   Liu, XL
   Zhang, Y
   Bai, XC
   Guo, B
AF Huang, Shijiang
   Jiang, Yuanjun
   Li, Jing
   Mao, Linlin
   Qiu, Zeyou
   Zhang, Sheng
   Jiang, Yuhui
   Liu, Yong
   Liu, Wen
   Xiong, Zhi
   Zhang, Wuju
   Liu, Xiaolin
   Zhang, Yue
   Bai, Xiaochun
   Guo, Bin
TI Osteocytes/Osteoblasts Produce SAA3 to Regulate Hepatic Metabolism of
   Cholesterol
SO ADVANCED SCIENCE
LA English
DT Article
DE bone liver crosstalk; hypercholesterolaemia; osteocytes/osteoblasts;
   SAA3
ID SERUM AMYLOID A; NF KAPPA B; HIGH DENSITY LIPOPROTEIN; C REACTIVE
   PROTEIN; ACTIVATION; EXPRESSION; BONE; GENE; INFLAMMATION; ELEVATION
AB Hypercholesterolaemia is a systemic metabolic disease, but the role of organs other than liver in cholesterol metabolism is unappreciated. The phenotypic characterization of the Tsc1Dmp1 mice reveal that genetic depletion of tuberous sclerosis complex 1 (TSC1) in osteocytes/osteoblasts (Dmp1 Cre) triggers progressive increase in serum cholesterol level. The resulting cholesterol metabolic dysregulation is shown to be associated with upregulation and elevation of serum amyloid A3 (SAA3), a lipid metabolism related factor, in the bone and serum respectively. SAA3, elicited from the bone, bound to toll like receptor 4 (TLR4) on hepatocytes to phosphorylate c Jun, and caused impeded conversion of cholesterol to bile acids via suppression on cholesterol 7 alpha hydroxylase (Cyp7a1) expression. Ablation of Saa3 in Tsc1Dmp1 mice prevented the CYP7A1 reduction in liver and cholesterol elevation in serum. These results expand the understanding of bone function and hepatic regulation of cholesterol metabolism and uncover a potential therapeutic use of pharmacological modulation of SAA3 in hypercholesterolaemia.
   Cholesterol homeostasis requires collaboration among organs; however, the involvement of bone is unappreciated. The present work elucidates a mechanism by which bone derived SAA3 inhibits the expression of CYP7A1 by binding to TLR4 on hepatocytes and thereby phosphorylates c Jun, which leads to hypercholesterolaemia in Tsc1Dmp1 mice. Together, they identify SAA3 as a novel bone derived factor that regulates hepatic metabolism of cholesterol. image
C1 [Huang, Shijiang; Jiang, Yuanjun; Mao, Linlin; Zhang, Sheng; Jiang, Yuhui; Liu, Yong; Liu, Wen; Xiong, Zhi; Zhang, Wuju; Liu, Xiaolin; Zhang, Yue; Bai, Xiaochun; Guo, Bin] Southern Med Univ, Sch Basic Med Sci, Dept Cell Biol, State Key Lab Organ Failure Res, Guangzhou 510515, Guangdong, Peoples R China.
   [Li, Jing] Southern Med Univ, Nanfang Hosp, Dept Obstet & Gynecol, Guangzhou 510515, Guangdong, Peoples R China.
   [Qiu, Zeyou] Southern Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Guangzhou 510515, Guangdong, Peoples R China.
   [Qiu, Zeyou] Sichuan Univ, West China Xiamen Hosp, Equipment Mat Dept, Xiamen 361000, Fujian, Peoples R China.
   [Zhang, Wuju] Southern Med Univ, Affiliated Hosp 5, Cent Lab, Guangzhou 510900, Guangdong, Peoples R China.
   [Bai, Xiaochun] Southern Med Univ, Affiliated Hosp 3, Guangdong Prov Key Lab Bone & Joint Degenerat Dis, Guangzhou 510630, Guangdong, Peoples R China.
   [Guo, Bin] Southern Med Univ, Affiliated Hosp 10, Dongguan 523018, Guangdong, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Southern Medical University   China; Sichuan University; Southern
   Medical University   China; Southern Medical University   China;
   Southern Medical University   China
RP Zhang, Y; Bai, XC; Guo, B (通讯作者)，Southern Med Univ, Sch Basic Med Sci, Dept Cell Biol, State Key Lab Organ Failure Res, Guangzhou 510515, Guangdong, Peoples R China.; Bai, XC (通讯作者)，Southern Med Univ, Affiliated Hosp 3, Guangdong Prov Key Lab Bone & Joint Degenerat Dis, Guangzhou 510630, Guangdong, Peoples R China.; Guo, B (通讯作者)，Southern Med Univ, Affiliated Hosp 10, Dongguan 523018, Guangdong, Peoples R China.
EM yugi@smu.edu.cn; baixc15@smu.edu.cn; bzg18@smu.edu.cn
RI Huang, Shijiang/JBJ 8815 2023
FU National Natural Science Foundation of China; Natural Science Foundation
   of Guangdong Province, China [2021A151501184]; China Postdoctoral
   Science Foundation [2023M731545];  [81991511];  [32300965];  [82202654]
FX S.H., Y.J., and J.L. contributed equally to this work. This work was
   supported by grants from the National Natural Science Foundation of
   China (Grant No.81991511, 32300965, 82202654), the Natural Science
   Foundation of Guangdong Province, China (Grant No. 2021A151501184), and
   China Postdoctoral Science Foundation (Grant No. 2023M731545).
CR Agoro R, 2023, NAT REV NEPHROL, V19, P185, DOI 10.1038/s41581 022 00665 x
   Aparicio Vergara M, 2017, METHODS MOL BIOL, V1639, P161, DOI 10.1007/978 1 4939 7163 3_16
   Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298
   Bing ZY, 2000, J BIOL CHEM, V275, P31616, DOI 10.1074/jbc.M005378200
   Chait A, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 66898 7
   Chambers KF, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112588
   Chu BB, 2015, CELL, V161, P291, DOI 10.1016/j.cell.2015.02.019
   den Hartigh LJ, 2023, FRONT CARDIOVASC MED, V10, DOI 10.3389/fcvm.2023.1197432
   den Hartigh LJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108564
   Djurec M, 2018, P NATL ACAD SCI USA, V115, pE1147, DOI 10.1073/pnas.1717802115
   Dong Z, 2011, MOL MED, V17, P1357, DOI 10.2119/molmed.2011.00186
   Ge MX, 2019, BIOCHEM PHARMACOL, V164, P152, DOI 10.1016/j.bcp.2019.04.008
   Goodman CA, 2019, J APPL PHYSIOL, V127, P581, DOI 10.1152/japplphysiol.01011.2018
   Hua S, 2009, REDOX REP, V14, P187, DOI 10.1179/135100009X12525712409490
   Huang B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13885
   Jacobsen S, 2006, VET J, V172, P315, DOI 10.1016/j.tvjl.2005.04.021
   Ji SY, 2019, DEV CELL, V48, P460, DOI 10.1016/j.devcel.2018.12.021
   Johnson BD, 2004, CIRCULATION, V109, P2993, DOI 10.1161/01.CIR.0000130642.79868.B2
   Kim SP, 2017, P NATL ACAD SCI USA, V114, pE11238, DOI 10.1073/pnas.1707876115
   KLUVEBECKERMAN B, 1991, DNA CELL BIOL, V10, P651, DOI 10.1089/dna.1991.10.651
   Kosuge M, 2007, CIRC J, V71, P186, DOI 10.1253/circj.71.186
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Li TG, 2007, GASTROENTEROLOGY, V133, P1660, DOI 10.1053/j.gastro.2007.08.042
   Li TG, 2006, HEPATOLOGY, V43, P1202, DOI 10.1002/hep.21183
   Lim J, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.49
   Lin CX, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0041 8
   Malle E, 2009, CELL MOL LIFE SCI, V66, P9, DOI 10.1007/s00018 008 8321 x
   Mayer FJ, 2019, EUR J CLIN INVEST, V49, DOI 10.1111/eci.13095
   Michos ED, 2019, NEW ENGL J MED, V381, P1557, DOI 10.1056/NEJMra1806939
   Mirams M, 2004, BONE, V35, P1192, DOI 10.1016/j.bone.2004.06.014
   Mo Chenglin, 2012, Recent Pat Biotechnol, V6, P223
   Moon SH, 2019, CELL, V176, P564, DOI 10.1016/j.cell.2018.11.011
   NUNOKAWA Y, 1993, J VET MED SCI, V55, P1011, DOI 10.1292/jvms.55.1011
   O'Brien Kevin D, 2006, Curr Atheroscler Rep, V8, P62, DOI 10.1007/s11883 006 0066 0
   Ogasawara K, 2004, ATHEROSCLEROSIS, V174, P349, DOI 10.1016/j.atherosclerosis.2004.01.030
   Ray A, 1999, J IMMUNOL, V163, P2143
   Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202
   Roberts MD, 2023, PHYSIOL REV, V103, P2679, DOI 10.1152/physrev.00039.2022
   Sack George H Jr, 2020, Subcell Biochem, V94, P421, DOI 10.1007/978 3 030 41769 7_17
   Sack GH, 2018, MOL MED, V24, DOI 10.1186/s10020 018 0047 0
   Schatz M, 2020, FRONT NEUROENDOCRIN, V59, DOI 10.1016/j.yfrne.2020.100861
   Shibuya Y, 2015, FUTURE MED CHEM, V7, P2451, DOI 10.4155/fmc.15.161
   SHIMIZU H, 1994, GENE, V149, P305
   Shridas P, 2019, CURR OPIN LIPIDOL, V30, P320, DOI 10.1097/MOL.0000000000000616
   Son DS, 2004, ENDOCRINOLOGY, V145, P2245, DOI 10.1210/en.2003 1261
   STEEL DM, 1993, GENOMICS, V16, P447, DOI 10.1006/geno.1993.1209
   Tagliaferri C, 2015, AGEING RES REV, V21, P55, DOI 10.1016/j.arr.2015.03.002
   Tangseefa P, 2018, J CELL PHYSIOL, V233, P3769, DOI 10.1002/jcp.26163
   Tannock LR, 2018, J LIPID RES, V59, P339, DOI 10.1194/jlr.M080887
   TAPE C, 1990, BIOCHIM BIOPHYS ACTA, V1043, P295, DOI 10.1016/0005 2760(90)90030 2
   Terasawa M, 2004, J BONE MINER METAB, V22, P430, DOI 10.1007/s00774 004 0504 4
   Thompson JC, 2015, J LIPID RES, V56, P286, DOI 10.1194/jlr.M054015
   Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432 1327.1999.00657.x
   UHLAR CM, 1994, GENOMICS, V19, P228, DOI 10.1006/geno.1994.1052
   Urieli Shoval S, 2010, J HISTOCHEM CYTOCHEM, V58, P1015, DOI 10.1369/jhc.2010.956821
   Wang YF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17363 6
   Xiao M, 2021, BLOOD, V137, P3533, DOI 10.1182/blood.2020007731
   Xiao M, 2017, BLOOD, V129, P3196, DOI 10.1182/blood 2016 11 749838
   Xu S, 2018, CELL DEATH DIFFER, V25, P1549, DOI 10.1038/s41418 017 0049 4
   Ye RD, 2015, J LEUKOCYTE BIOL, V98, P923, DOI 10.1189/jlb.3VMR0315 080R
   Yu XJ, 2005, CYTOKINE GROWTH F R, V16, P221, DOI 10.1016/j.cytogfr.2005.01.002
   Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019
   Zhang J., 2017, J VIROL, V91, P6
   Zhu DD, 2016, INT J CANCER, V138, P1175, DOI 10.1002/ijc.29850
NR 64
TC 3
Z9 3
U1 2
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD JUN
PY 2024
VL 11
IS 24
DI 10.1002/advs.202307818
EA APR 2024
PG 14
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA WS0Z3
UT WOS:001201441800001
PM 38613835
OA gold
DA 2025 08 17
ER

PT S
AU Shimada, T
   Fukumoto, S
AF Shimada, Takashi
   Fukumoto, Seiji
BE KuroO, M
TI FGF23 AS A NOVEL THE PEUTIC TARGET
SO ENDOCRINE FGFS AND KLOTHOS
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
ID FIBROBLAST GROWTH FACTOR 23; HEREDITARY HYPOPHOSPHATEMIC RICKETS;
   FAMILIAL TUMORAL CALCINOSIS; HOMOZYGOUS MISSENSE MUTATION; RENAL
   PHOSPHATE REABSORPTION; VITAMIN D METABOLISM; AUTOSOMAL DOMINANT;
   PARATHYROID HORMONE; DIETARY PHOSPHATE; PROTEOLYTIC CLEAVAGE
AB Fibroblast growth factor (FGF) 23 is a hormone that acts to decrease phosphate, 1,25 dihydroxyvitaminD and parathyroid hormone levels in circulation. Particularly, appropriate actions of FGF23 are essential for maintaining physiological phosphate and vitamin D metabolism. Therefore, either gain or loss of function of FGF23 can impair these homeostatic regulations, causing several metabolic bone diseases. The measurement of circulating levels of FGF23 in patients with various types of hypophosphatemic rickets and/or osteomalacia has revealed that several of them are FGF23 dependent diseases, highlighting a novel therapeutic concept that the inhibition of the excess activity of FGF23 could be beneficial for patients with these diseases. Indeed, preliminary studies with a mouse disease model have validated this concept. On the other hand, replacement therapy with recombinant FGF23 may he applied to the disease caused by loss of function of FGF23. Although these concepts still need to be proven with more detailed analyses, the latest knowledge on the FGF23 related diseases and the development of methods to appropriately regulate FGF23 actions may synergistically create novel therapeutic maneuvers.
C1 [Shimada, Takashi] Kyowa Hakko Kirin Co Ltd, Innovat Drug Res Labs, Tokyo, Japan.
   [Fukumoto, Seiji] Tokyo Univ Hosp, Dept Med, Japan Div Nephrol & Endocrinol, Tokyo 113, Japan.
C3 Kyowa Kirin Ltd; University of Tokyo
RP Shimada, T (通讯作者)，Kyowa Hakko Kirin Co Ltd, Innovat Drug Res Labs, Tokyo, Japan.
EM takashi.shimada@kyowa kirin.co.jp
RI Fukumoto, Seiji/B 7853 2015
OI Fukumoto, Seiji/0000 0003 3610 3469
CR Aono Y, 2009, J BONE MINER RES, V24, P1879, DOI [10.1359/JBMR.090509, 10.1359/jbmr.090509]
   Araya K, 2005, J CLIN ENDOCR METAB, V90, P5523, DOI 10.1210/jc.2005 0301
   Bai XY, 2004, ENDOCRINOLOGY, V145, P5269, DOI 10.1210/en.2004 0233
   Bai XY, 2003, J BIOL CHEM, V278, P9843, DOI 10.1074/jbc.M210490200
   Bastepe M, 2008, REV ENDOCR METAB DIS, V9, P171, DOI 10.1007/s11154 008 9075 3
   Baum M, 2005, KIDNEY INT, V68, P1148, DOI 10.1111/j.1523 1755.2005.00506.x
   Beck L, 1997, J CLIN INVEST, V99, P1200, DOI 10.1172/JCI119276
   Beck L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/pnas.95.9.5372
   Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792
   Ben Dov IZ, 2007, J CLIN INVEST, V117, P4003, DOI 10.1172/JCI32409
   Benet Pagès A, 2005, HUM MOL GENET, V14, P385, DOI 10.1093/hmg/ddi034
   Bergwitz C, 2006, AM J HUM GENET, V78, P179, DOI 10.1086/499409
   Bickle DA., 2008, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, P141
   Burnett SAM, 2006, J BONE MINER RES, V21, P1187, DOI 10.1359/JBMR.060507
   Chefetz I, 2005, HUM GENET, V118, P261, DOI 10.1007/s00439 005 0026 8
   DREZNER MK, 1977, J CLIN INVEST, V60, P1046, DOI 10.1172/JCI108855
   Drezner MK, 2000, KIDNEY INT, V57, P9, DOI 10.1046/j.1523 1755.2000.00807.x
   ECONS MJ, 1994, NEW ENGL J MED, V330, P1679, DOI 10.1056/NEJM199406093302310
   Endo I, 2008, BONE, V42, P1235, DOI 10.1016/j.bone.2008.02.014
   Favus MJ., 2006, PRIMER METABOLIC BON, P76
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Ferrari SL, 2005, J CLIN ENDOCR METAB, V90, P1519, DOI 10.1210/jc.2004 1039
   FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095 130
   Frishberg Y, 2007, J BONE MINER RES, V22, P235, DOI 10.1359/JBMR.061105
   Fukagawa M, 2005, CURR OPIN NEPHROL HY, V14, P325, DOI 10.1097/01.mnh.0000172717.49476.80
   Fukumoto S, 2008, INTERNAL MED, V47, P337, DOI 10.2169/internalmedicine.47.0730
   Gattineni J, 2009, AM J PHYSIOL RENAL, V297, pF282, DOI 10.1152/ajprenal.90742.2008
   Goetz R, 2007, MOL CELL BIOL, V27, P3417, DOI 10.1128/MCB.02249 06
   Grieff M, 1997, CURR OPIN NEPHROL HY, V6, P15, DOI 10.1097/00041552 199701000 00004
   Gutierrez O, 2005, J AM SOC NEPHROL, V16, P2205, DOI 10.1681/ASN.2005010052
   Ichikawa S., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P318
   Ichikawa S, 2006, J CLIN ENDOCR METAB, V91, P4022, DOI 10.1210/jc.2005 2840
   Ichikawa S, 2009, ENDOCRINOLOGY, V150, P2543, DOI 10.1210/en.2008 0877
   Inoue Y, 2005, BIOCHEM J, V390, P325, DOI 10.1042/BJ20041799
   Jaureguiberry G, 2008, AM J PHYSIOL RENAL, V295, pF371, DOI 10.1152/ajprenal.00090.2008
   Jonsson KB, 2003, NEW ENGL J MED, V348, P1656, DOI 10.1056/NEJMoa020881
   Kang Y, 2009, J BONE MINER RES, P24
   Kazama JJ, 2005, THER APHER DIAL, V9, P328, DOI 10.1111/j.1744 9987.2005.00291.x
   Krajisnik T, 2007, J ENDOCRINOL, V195, P125, DOI 10.1677/JOE 07 0267
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200
   Larsson T, 2005, ENDOCRINOLOGY, V146, P3883, DOI 10.1210/en.2005 0431
   Larsson T, 2005, J CLIN ENDOCR METAB, V90, P2424, DOI 10.1210/jc.2004 2238
   Larsson T, 2004, ENDOCRINOLOGY, V145, P3087, DOI 10.1210/en.2003 1768
   Levi M, 2008, AM J PHYSIOL RENAL, V295, pF369, DOI 10.1152/ajprenal.90327.2008
   Liu SG, 2006, AM J PHYSIOL ENDOC M, V291, pE38, DOI 10.1152/ajpendo.00008.2006
   Liu SG, 2008, J AM SOC NEPHROL, V19, P2342, DOI 10.1681/ASN.2007121301
   Lorenz Depiereux B, 2006, AM J HUM GENET, V78, P193, DOI 10.1086/499410
   Lorenz Depiereux B, 2006, NAT GENET, V38, P1248, DOI 10.1038/ng1868
   LYLES KW, 1985, J CLIN ENDOCR METAB, V60, P1093, DOI 10.1210/jcem 60 6 1093
   MEYER RA, 1989, J BONE MINER RES, V4, P493
   MEYER RA, 1989, J BONE MINER RES, V4, P523
   Mirams M, 2004, BONE, V35, P1192, DOI 10.1016/j.bone.2004.06.014
   Miyamoto KI, 2007, AM J NEPHROL, V27, P503, DOI 10.1159/000107069
   Nelson AE, 1997, MOL CELL ENDOCRINOL, V132, P1, DOI 10.1016/S0303 7207(97)00111 1
   NESBITT T, 1992, J CLIN INVEST, V89, P1453, DOI 10.1172/JCI115735
   Pfister MF, 1998, P NATL ACAD SCI USA, V95, P1909, DOI 10.1073/pnas.95.4.1909
   Riminucci M, 2003, J CLIN INVEST, V112, P683, DOI 10.1172/JC120031899
   Saito H, 2003, J BIOL CHEM, V278, P2206, DOI 10.1074/jbc.M207872200
   Segawa H, 2003, PFLUG ARCH EUR J PHY, V446, P585, DOI 10.1007/s00424 003 1084 1
   Segawa H, 2007, AM J PHYSIOL RENAL, V292, pF769, DOI 10.1152/ajprenal.00248.2006
   Segawa H, 2009, AM J PHYSIOL RENAL, V297, pF671, DOI 10.1152/ajprenal.00156.2009
   Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081
   Shimada T, 2004, BIOCHEM BIOPH RES CO, V314, P409, DOI 10.1016/j.bbrc.2003.12.102
   Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198
   Shimada T, 2002, ENDOCRINOLOGY, V143, P3179, DOI 10.1210/en.143.8.3179
   Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264
   Shimada T, 2005, AM J PHYSIOL RENAL, V289, pF1088, DOI 10.1152/ajprenal.00474.2004
   Sitara D, 2004, MATRIX BIOL, V23, P421, DOI 10.1016/j.matbio.2004.09.007
   SLAVIN RE, 1993, AM J SURG PATHOL, V17, P788, DOI 10.1097/00000478 199308000 00004
   Tenenhouse HS, 2007, J STEROID BIOCHEM, V103, P572, DOI 10.1016/j.jsbmb.2006.12.090
   Topaz O, 2004, NAT GENET, V36, P579, DOI 10.1038/ng1358
   Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   Weber TJ, 2003, J BONE MINER RES, V18, P1227, DOI 10.1359/jbmr.2003.18.7.1227
   White KE, 2001, J CLIN ENDOCR METAB, V86, P497, DOI 10.1210/jc.86.2.497
   White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664
   Yamamoto H, 2005, BBA GENE STRUCT EXPR, V1732, P43, DOI 10.1016/j.bbaexp.2005.11.003
   Yamamoto T, 2005, J BONE MINER METAB, V23, P231, DOI 10.1007/s00774 004 0589 9
   Yamamoto T, 2007, J BONE MINER METAB, V25, P407, DOI 10.1007/s00774 007 0776 6
   Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696
   Yamashita T, 2002, J BIOL CHEM, V277, P28265, DOI 10.1074/jbc.M202527200
   Yamazaki Y, 2002, J CLIN ENDOCR METAB, V87, P4957, DOI 10.1210/jc.2002 021105
   Yamazaki Y, 2008, J BONE MINER RES, V23, P1509, DOI 10.1359/JBMR.080417
   Yu XJ, 2005, ENDOCRINOLOGY, V146, P4647, DOI 10.1210/en.2005 0670
NR 84
TC 10
Z9 12
U1 0
U2 0
PU SPRINGER VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D 14197 BERLIN, GERMANY
SN 0065 2598
EI 2214 8019
BN 978 1 4614 0886 4; 978 1 4614 0887 1
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2012
VL 728
BP 158
EP 170
D2 10.1007/978 1 4614 0887 1
PG 13
WC Cell Biology; Genetics & Heredity
WE Book Citation Index– Science (BKCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Genetics & Heredity
GA BA3CR
UT WOS:000334109100011
PM 22396168
DA 2025 08 17
ER

PT J
AU Ndong, JD
   Stevens, DM
   Vignaux, G
   Uppuganti, S
   Perrien, DS
   Yang, XL
   Nyman, JS
   Harth, E
   Elefteriou, F
AF Ndong, Jean de la Croix
   Stevens, David M.
   Vignaux, Guillaume
   Uppuganti, Sasidhar
   Perrien, Daniel S.
   Yang, Xiangli
   Nyman, Jeffry S.
   Harth, Eva
   Elefteriou, Florent
TI Combined MEK Inhibition and BMP2 Treatment Promotes Osteoblast
   Differentiation and Bone Healing in
   Nf1Osx<SUP> / </SUP> Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE NEUROFIBROMATOSIS; GENETIC ANIMAL MODELS; PRECLINICAL STUDIES; BMPS;
   STROMAL; MESENCHYMAL STEM CELLS; OSTEOBLASTS; ANABOLICS
ID NEUROFIBROMATOSIS TYPE I; CONGENITAL PSEUDOARTHROSIS; MORPHOGENETIC
   PROTEIN 7; NF1; FRACTURE; CELLS; TIBIA; BISPHOSPHONATE; LOVASTATIN;
   DYSPLASIA
AB Neurofibromatosis type I (NF1) is an autosomal dominant disease with an incidence of 1/3000, caused by mutations in the NF1 gene, which encodes the RAS/GTPase activating protein neurofibromin. Non bone union after fracture (pseudarthrosis) in children with NF1 remains a challenging orthopedic condition to treat. Recent progress in understanding the biology of neurofibromin suggested that NF1 pseudarthrosis stems primarily from defects in the bone mesenchymal lineage and hypersensitivity of hematopoietic cells to TGF. However, clinically relevant pharmacological approaches to augment bone union in these patients remain limited. In this study, we report the generation of a novel conditional mutant mouse line used to model NF1 pseudoarthrosis, in which Nf1 can be ablated in an inducible fashion in osteoprogenitors of postnatal mice, thus circumventing the dwarfism associated with previous mouse models where Nf1 is ablated in embryonic mesenchymal cell lineages. An ex vivo based cell culture approach based on the use of Nf1(flox/flox) bone marrow stromal cells showed that loss of Nf1 impairs osteoprogenitor cell differentiation in a cell autonomous manner, independent of developmental growth plate derived or paracrine/hormonal influences. In addition, in vitro gene expression and differentiation assays indicated that chronic ERK activation in Nf1 deficient osteoprogenitors blunts the pro osteogenic property of BMP2, based on the observation that only combination treatment with BMP2 and MEK inhibition promoted the differentiation of Nf1 deficient osteoprogenitors. The in vivo preclinical relevance of these findings was confirmed by the improved bone healing and callus strength observed in Nf1(osx)( / ) mice receiving Trametinib (a MEK inhibitor) and BMP2 released locally at the fracture site via a novel nanoparticle and polyglycidol based delivery method. Collectively, these results provide novel evidence for a cell autonomous role of neurofibromin in osteoprogenitor cells and insights about a novel targeted approach for the treatment of NF1 pseudoarthrosis. (c) 2014 American Society for Bone and Mineral Research.
C1 [Ndong, Jean de la Croix; Vignaux, Guillaume; Uppuganti, Sasidhar; Perrien, Daniel S.; Yang, Xiangli; Nyman, Jeffry S.; Elefteriou, Florent] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Bone Biol, Nashville, TN 37232 USA.
   [Ndong, Jean de la Croix; Vignaux, Guillaume; Yang, Xiangli; Elefteriou, Florent] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA.
   [Stevens, David M.; Harth, Eva] Vanderbilt Univ, Med Ctr, Dept Chem, Nashville, TN 37232 USA.
   [Stevens, David M.; Yang, Xiangli; Elefteriou, Florent] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
   [Uppuganti, Sasidhar; Perrien, Daniel S.; Nyman, Jeffry S.] Vanderbilt Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, Nashville, TN 37232 USA.
   [Perrien, Daniel S.; Nyman, Jeffry S.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN USA.
   [Perrien, Daniel S.; Harth, Eva] Vanderbilt Univ, Med Ctr, Inst Imaging Sci, Nashville, TN 37232 USA.
   [Elefteriou, Florent] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University;
   Vanderbilt University; Vanderbilt University; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); VA Tennessee Valley
   Healthcare System; Vanderbilt University; Vanderbilt University
RP Elefteriou, F (通讯作者)，Vanderbilt Univ, Med Ctr, 2215 Garland Ave,Light Hall,Room 1255D, Nashville, TN 37232 USA.
EM florent.elefteriou@vanderbilt.edu
RI ; Nyman, Jeffry/L 5736 2013; Harth, Eva/AAN 4608 2020; Elefteriou,
   Florent/P 2586 2017; Perrien, Daniel/ISV 0029 2023
OI Nyman, Jeffry/0000 0001 7403 7605; Uppuganti,
   Sasidhar/0000 0002 0656 2122; Harth, Eva/0000 0001 5553 0365; Perrien,
   Daniel/0000 0002 5488 3932; Elefteriou, Florent/0000 0002 2972 5633;
   Elefteriou, Xiangli/0000 0002 2333 8747
FU Children's Tumor Foundation [2012 01 028]; National Institute of
   Arthritis and Musculoskeletal and Skin Diseases, part of the National
   Institutes of Health [5R01 AR055966]; National Institutes of Health [S10
   RR027631]
FX This work was funded by a Young Investigator Award (2012 01 028) from
   the Children's Tumor Foundation (JN) and by the National Institute of
   Arthritis and Musculoskeletal and Skin Diseases, part of the National
   Institutes of Health, under Award Number 5R01 AR055966 (FE). Support for
   the micro computed tomography equipment was provided by the National
   Institutes of Health, Award Number S10 RR027631 (DSP). Support for
   chemical synthesis was provided by the Department of Chemistry (EH).
CR Alam N, 2009, CLIN ORTHOP RELAT R, V467, P3190, DOI 10.1007/s11999 009 1065 6
   Anticevic D, 2006, J PEDIATR ORTHOP B, V15, P220, DOI 10.1097/01.bpb.0000194439.75378.ac
   Birke O, 2010, J CHILD ORTHOP, V4, P507, DOI 10.1007/s11832 010 0293 3
   Chen JQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085161, 10.1371/journal.pone.0101277]
   Crawford AH, 2007, ORTHOP CLIN N AM, V38, P553, DOI 10.1016/j.ocl.2007.03.008
   Doan TKP, 2012, TISSUE ENG REGEN MED, V9, P283, DOI 10.1007/s13770 012 0352 6
   Elefteriou F, 2006, CELL METAB, V4, P441, DOI 10.1016/j.cmet.2006.10.010
   Fabeck L, 2006, J BONE JOINT SURG BR, V88B, P116, DOI 10.1302/0301 620X.88B1.16619
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   Khong PL, 2003, AM J ROENTGENOL, V180, P413, DOI 10.2214/ajr.180.2.1800413
   Kolanczyk M, 2007, HUM MOL GENET, V16, P874, DOI 10.1093/hmg/ddm032
   Kolanczyk M, 2008, BMC MED, V6, DOI 10.1186/1741 7015 6 21
   Lee FYI, 2006, J BONE JOINT SURG AM, V88A, P627, DOI 10.2106/JBJS.D.02201
   Leskelä HV, 2009, BONE, V44, P243, DOI 10.1016/j.bone.2008.10.050
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159 8290.CD 13 0070
   Ndong J, 2014, NAT MED
   Ono K, 2013, HUM MOL GENET, V22, P3048, DOI 10.1093/hmg/ddt162
   Ramachandran M, 2004, J SPINAL DISORD TECH, V17, P483, DOI 10.1097/01.bsd.0000133466.97241.50
   Rhodes SD, 2013, J BONE MINER RES, V28, P2476, DOI 10.1002/jbmr.1992
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Schindeler A, 2011, J BONE JOINT SURG BR, V93B, P1134, DOI 10.1302/0301 620X.93B8.25940
   Schindeler A, 2008, J ORTHOP RES, V26, P65, DOI 10.1002/jor.20481
   Sharma R, 2013, HUM MOL GENET, V22, P4818, DOI 10.1093/hmg/ddt333
   Spears BR, 2013, CHEM COMMUN, V49, P2394, DOI 10.1039/c3cc38369e
   Stevens DM, 2014, POLYM CHEM UK, V5, P3551, DOI 10.1039/c4py00207e
   Stevens DM, 2013, POLYM CHEM UK, V4, P2470, DOI 10.1039/c3py21119c
   Stevenson DA, 2013, J PEDIATR ORTHOPED, V33, P269, DOI 10.1097/BPO.0b013e31828121b8
   TAN A M, 1990, Annals Academy of Medicine Singapore, V19, P286
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tsuji K, 2008, J BONE JOINT SURG AM, V90A, P14, DOI 10.2106/JBJS.G.01109
   Wang WG, 2012, DEVELOPMENT, V139, P601, DOI 10.1242/dev.069575
   Wang WX, 2011, HUM MOL GENET, V20, P3910, DOI 10.1093/hmg/ddr310
   Wang WX, 2010, J BONE MINER RES, V25, P1658, DOI 10.1002/jbmr.42
   Yamaguchi T, 2011, INT J ONCOL, V39, P23, DOI 10.3892/ijo.2011.1015
   Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101
NR 36
TC 36
Z9 43
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2015
VL 30
IS 1
BP 55
EP 63
DI 10.1002/jbmr.2316
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AX4PR
UT WOS:000346914600007
PM 25043591
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kim, KM
   Jang, WG
AF Kim, Kyeong Min
   Jang, Won Gu
TI NXNL1 negatively regulates osteoblast differentiation via GDF15 induced
   PP2A Ca dependent manner in MC3T3 E1 cells
SO BIOFACTORS
LA English
DT Article
DE GDF15; NXNL1; osteogenic differentiation; PP2A C alpha; preosteoblast
ID TGF BETA; BONE FORMATION; GDF15; EXPRESSION; ALPHA
AB Controlling the level of intracellular reactive oxygen species (ROS) is important for the survival and differentiation of osteoblasts. Intracellular ROS levels are controlled by antioxidant enzymes that modulate the redox state of the cell. Nucleoredoxin like 1 (NXNL1) is an antioxidant enzyme that increases the viability of rod and cone cells by protecting them from oxidative stress, and is a potential pharmacological target for the treatment of retinitis pigmentosa. The present study investigated the role of NXNL on osteoblast differentiation of MC3T3 E1 preosteoblast cells. Results from qPCR experiments demonstrated that growth differentiation factor 15 (GDF15) increased NXNL1 expression, and that GDF15 induced NXNL1 decreased the expression of osteogenic genes such as distal less homeobox 5 (Dlx5) and Runt related transcription factor 2. Furthermore, NXNL1 also inhibits bone morphogenetic protein 2 induced phosphorylation of Smad1/5/9 and alkaline phosphatase activity. The inhibitory effects of NXNL1 on osteoblast differentiation were mediated by protein phosphatase 2A C alpha (PP2A C alpha). The expression of PP2A C alpha was regulated by GDF15, and overexpression of PP2A Ca increased the expression of NXNL1. Taken together, our results demonstrate that NXNL1 inhibits osteoblast differentiation of MC3T3 E1 due to GDF15 induced expression of PP2A C alpha.
C1 [Kim, Kyeong Min; Jang, Won Gu] Daegu Univ, Sch Engn, Dept Biotechnol, Gyeongbuk, South Korea.
   [Kim, Kyeong Min; Jang, Won Gu] Daegu Univ, Res Inst Antiaging, Gyeongbuk, South Korea.
   [Kim, Kyeong Min] Daegu Gyeongbuk Med Innovat Fdn DGMIF, New Drug Dev Ctr, Daegu, South Korea.
C3 Daegu University; Daegu University
RP Jang, WG (通讯作者)，Daegu Univ, Coll Engn, Dept Biotechnol, Gyeongbuk 38453, South Korea.
EM jangwg@daegu.ac.kr
OI Kim, Kyeong Min/0000 0002 7748 9866
FU Basic Science Research Program through the National Research Foundation
   of Korea(NRF)   Ministry of Education [2021R1F1A1062502]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea(NRF) funded by the Ministry of
   Education (No.2021R1F1A1062502).
CR Ago T, 2006, CIRC RES, V98, P294, DOI 10.1161/01.RES.0000207919.83894.9d
   Bengtsson L, 2009, J CELL SCI, V122, P1248, DOI 10.1242/jcs.039552
   Chaturvedi R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084584
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351
   Corre J, 2012, CANCER RES, V72, P1395, DOI 10.1158/0008 5472.CAN 11 0188
   Cristóbal I, 2017, BBA REV CANCER, V1868, P435, DOI 10.1016/j.bbcan.2017.08.005
   Cronin T, 2010, CELL DEATH DIFFER, V17, P1199, DOI 10.1038/cdd.2010.2
   Gao J, 2018, CELL DEATH DIFFER, V25, P229, DOI 10.1038/cdd.2017.144
   Ha G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216602
   Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284
   Hinoi E, 2012, J BONE MINER RES, V27, P938, DOI 10.1002/jbmr.1538
   Huang CX, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/804260
   Jang WG, 2011, BIOCHEM BIOPH RES CO, V404, P1004, DOI 10.1016/j.bbrc.2010.12.099
   Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891 2905.2001
   Kempf T, 2012, EUR J ENDOCRINOL, V167, P671, DOI 10.1530/EJE 12 0466
   Kim KM, 2019, EXP MOL MED, V51, DOI 10.1038/s12276 019 0263 x
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lambrecht C, 2013, METHODS MOL BIOL, V1053, P283, DOI 10.1007/978 1 62703 562 0_17
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Léveillard T, 2004, NAT GENET, V36, P755, DOI 10.1038/ng1386
   Léveillard T, 2017, CELL MOL LIFE SCI, V74, P3649, DOI 10.1007/s00018 016 2318 7
   Li M, 2020, CARDIOVASC DIABETOL, V19, DOI 10.1186/s12933 020 01092 7
   Li S, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0744 0
   Macia L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034868
   Mazhar S, 2019, BBA MOL CELL RES, V1866, P51, DOI 10.1016/j.bbamcr.2018.08.020
   Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034
   Nader CP, 2019, RESP RES, V20, DOI 10.1186/s12931 019 1192 x
   Okamura H, 2013, FEBS LETT, V587, P48, DOI 10.1016/j.febslet.2012.10.041
   Okamura H, 2011, BONE, V49, P368, DOI 10.1016/j.bone.2011.06.004
   Olmedo ML, 1999, J ORTHOP TRAUMA, V13, P356, DOI 10.1097/00005131 199906000 00006
   Park H, 2016, ONCOTARGET, V7, P9634, DOI 10.18632/oncotarget.7457
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rucci N, 2008, CLIN CASES MINER BON, V5, P49
   Schindler K, 2012, OBESITY FACTS, V5, P270, DOI 10.1159/000338729
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   Tran T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201584
   Tsai VWW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055174
   Unsicker K, 2013, CYTOKINE GROWTH F R, V24, P373, DOI 10.1016/j.cytogfr.2013.05.003
   Wang XW, 2008, FREE RADICAL BIO MED, V45, P336, DOI 10.1016/j.freeradbiomed.2008.04.028
   Westermarck J, 2008, TRENDS MOL MED, V14, P152, DOI 10.1016/j.molmed.2008.02.001
   Westhrin M, 2015, HAEMATOLOGICA, V100, pE511, DOI 10.3324/haematol.2015.124511
   Wlodarchak N, 2016, CRIT REV BIOCHEM MOL, V51, P162, DOI 10.3109/10409238.2016.1143913
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
NR 45
TC 3
Z9 4
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 6433
EI 1872 8081
J9 BIOFACTORS
JI Biofactors
PD JAN
PY 2022
VL 48
IS 1
BP 239
EP 248
DI 10.1002/biof.1817
EA DEC 2021
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA YS2VL
UT WOS:000731976600001
PM 34932831
DA 2025 08 17
ER

PT J
AU Liu, YQ
   Han, XF
   Bo, JX
   Ma, HP
AF Liu, Yan Qiu
   Han, Xiao Fei
   Bo, Jun Xia
   Ma, Hui Peng
TI Wedelolactone Enhances Osteoblastogenesis but Inhibits
   Osteoclastogenesis through Sema3A/NRP1/PlexinA1 Pathway
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE osteoblastogenesis; osteoclastogenesis; wedelolactone; Sema3A; NRP1
ID MESENCHYMAL STEM CELLS; IN VITRO; BONE FORMATION; SEMAPHORIN 3A;
   DIFFERENTIATION; PROLIFERATION; SCLEROSTEOSIS; NEUROPILIN 1;
   PLC GAMMA 2; RESPONSES
AB Bone remodeling balance is maintained by tight coupling of osteoblast mediated bone formation and osteoclast mediated bone resorption. Thus, agents with the capacity to regulate osteoblastogenesis and osteoclastogenesis have been investigated for therapy of bone  related diseases such as osteoporosis. In this study, we found that wedelolactone, a compound isolated from Ecliptae herb4 and a 9 day incubation fraction of conditioned media obtained from wedelolactone treated bone marrow mesenchymal stem cell (BMSC) significantly inhibited tartrate  resistant acid phosphatase (TRAP) activity in RANKL stimulated osteoclastic RAVV264.7 cells. Addition of the semaphorin 3A (Sema3A) antibody to the conditioned media partially blocked the medium's inhibitory effects on the RAW264.7 cells. In BMSC, mRNA expression of Sema3A increased in the presence of different wedelolactone concentrations. Blocking Sema3A activity with its antibody reversed wedelolactone induced alkaline phosphatase activity in BMSC and concurrently enhanced wedelolactone reduced TRAP activity in osteoclastic RAW264.7 cells. Moreover, in BMSC, wedelolactone enhanced binding of Sema3A with cell  surface receptors, including neuropilin (NRP)1 and plexinAl. Furthermore, nuclear accumulation of 13 catenin, a transcription factor acting downstream of wedelolactone induced Sema3A signaling, was blocked by the Sema3A antibody. In osteoclastic RAW264.7 cells, conditioned media and wedelolactone promoted the formation of plexin Al  NRP1, but conditioned media also caused the sequestration of the plexin Al  DNAX activating protein 12 (DAP12) complex and suppressed the phosphorylation of phospholipase C (PLC)y2. These data suggest that wedelolactone promoted osteoblastogenesis through production of Sema3A, thus inducing the formation of a Sema3A plexinAl Nrp 1 complex and 1i catenin activation. In osteoclastic RAW264.7 cells, wedelolactone inhibited osteoclastogenesis through sequestration of the plexinAl  DAP12 complex, induced the formation of plexinAl  Nrp 1 complex, and suppressed PLCy2 activation.
C1 [Liu, Yan Qiu] Dalian Med Univ, Inst Coll Integrat Med, Dalian, Peoples R China.
   [Han, Xiao Fei; Bo, Jun Xia] Dalian Univ, Coll Life Sci & Technol, Glucose & Lipid Metab Lab Liaoning Prov, Dalian, Peoples R China.
   [Ma, Hui Peng] Dalian Med Univ, Coll Med Lab, Dalian, Peoples R China.
C3 Dalian Medical University; Dalian University; Dalian Medical University
RP Liu, YQ (通讯作者)，Dalian Med Univ, Inst Coll Integrat Med, Dalian, Peoples R China.
EM yqliu@dmu.edu.cn
OI liu, Yan Qiu/0000 0002 1905 7168
FU National Natural Science Foundation of China [81473545]; Scientific
   research general project from Liaoning Education Department [L2015150]
FX This work was supported by a grant from National Natural Science
   Foundation of China (81473545) and the Scientific research general
   project from Liaoning Education Department (L2015150).
CR Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Epple H, 2008, MOL CELL BIOL, V28, P3610, DOI 10.1128/MCB.00259 08
   Faccio R, 2010, ANN NY ACAD SCI, V1192, P124, DOI 10.1111/j.1749 6632.2009.05217.x
   Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115
   Goetzl EJ, 2000, ANN NY ACAD SCI, V905, P177
   Gomez C, 2005, DEV DYNAM, V234, P393, DOI 10.1002/dvdy.20512
   Goshima Y, 2012, EXPERT OPIN THER TAR, V16, P933, DOI 10.1517/14728222.2012.710201
   Gu CH, 2003, DEV CELL, V5, P45, DOI 10.1016/S1534 5807(03)00169 2
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Hens JR, 2005, J BONE MINER RES, V20, P1103, DOI 10.1359/JBMR.050210
   Hsieh CJ, 2015, INT J ONCOL, V46, P555, DOI 10.3892/ijo.2014.2769
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Kaneko S, 2006, NAT MED, V12, P1380, DOI 10.1038/nm1505
   Kikuchi K, 2003, J BIOL CHEM, V278, P42985, DOI 10.1074/jbc.M302395200
   Krebsbach PH, 1999, CRIT REV ORAL BIOL M, V10, P165, DOI 10.1177/10454411990100020401
   Liu YQ, 2014, J ETHNOPHARMACOL, V157, P206, DOI 10.1016/j.jep.2014.09.033
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Melo PA, 1999, TOXICON, V37, P199, DOI 10.1016/S0041 0101(98)00183 4
   Narazaki M, 2006, BLOOD, V107, P3892, DOI 10.1182/blood 2005 10 4113
   Negishi Koga Takako, 2012, Bonekey Rep, V1, P183, DOI 10.1038/bonekey.2012.183
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Sarveswaran S, 2012, INT J ONCOL, V41, P2191, DOI 10.3892/ijo.2012.1664
   Syed SD, 2003, PHYTOTHER RES, V17, P420, DOI 10.1002/ptr.1153
   Takahashi T, 2001, NEURON, V29, P429, DOI 10.1016/S0896 6273(01)00216 1
   Takegahara N, 2006, NAT CELL BIOL, V8, P615, DOI 10.1038/ncb1416
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   WAGNER H, 1986, PLANTA MED, P374, DOI 10.1055/s 2007 969189
   Worzfeld T, 2014, NAT REV DRUG DISCOV, V13, P603, DOI 10.1038/nrd4337
   Zhang JF, 2009, PHYTOMEDICINE, V16, P521, DOI 10.1016/j.phymed.2009.01.003
   Zhang ZG, 2013, MENOPAUSE, V20, P232, DOI 10.1097/gme.0b013e318265e7dd
NR 36
TC 41
Z9 46
U1 1
U2 33
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 18
PY 2016
VL 7
AR 375
DI 10.3389/fphar.2016.00375
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DZ5JB
UT WOS:000385896700001
PM 27803667
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, DW
   Wang, YH
   Xu, SH
   Wang, F
   Wang, BM
   Han, K
   Sun, DQ
   Li, LX
AF Wang, Dawei
   Wang, Yonghui
   Xu, Shihong
   Wang, Fu
   Wang, Bomin
   Han, Ke
   Sun, Daqing
   Li, Lianxin
TI Epigallocatechin 3 gallate Protects against Hydrogen Peroxide Induced
   Inhibition of Osteogenic Differentiation of Human Bone Marrow Derived
   Mesenchymal Stem Cells
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID GREEN TEA POLYPHENOLS; OXIDATIVE STRESS; STROMAL CELLS;
   ( ) EPIGALLOCATECHIN 3 GALLATE; REGENERATION; SUPPRESSES; MECHANISMS;
   OSTEOBLAST; CATECHIN; DAMAGE
AB Oxidative stress induces bone loss and osteoporosis, and epigallocatechin 3 gallate (EGCG) may be used to combat these diseases due to its antioxidative property. Herein, oxidative stress in human bone marrow derived mesenchymal stem cells (BM MSCs) was induced by H2O2, resulting in an adverse effect on their osteogenic differentiation. However, this H2O2 induced adverse effect was nullified when the cells were treated with EGCG. In addition, treatment of BM MSCs with EGCG alone also resulted in the enhancement of osteogenic differentiation of BM MSCs. After EGCG treatment, expressions of beta catenin and cyclin D1 were upregulated, suggesting that the Wnt pathway was involved in the effects of EGCG on the osteogenic differentiation of BMMSCs. This was also confirmed by the fact that the Wnt pathway inhibitor, Dickkopf 1 (DKK 1), can nullify the EGCG induced enhancement effect on BM MSC's osteogenic differentiation. Hence, our results suggested that EGCG can reduce the effects of oxidative stress on Wnt pathway in osteogenic cells, which supported a potentially promising therapy of bone disorders induced by oxidative stress. Considering its positive effects on BM MSCs, EGCG may also be beneficial for stem cell based bone repair.
C1 [Wang, Dawei; Wang, Yonghui; Xu, Shihong; Wang, Fu; Wang, Bomin; Han, Ke; Li, Lianxin] Shandong Univ, Shandong Prov Hosp, Dept Orthoped, Jinan 250021, Peoples R China.
   [Sun, Daqing] Shandong Univ, Hosp 2, Dept Vasc Surg, Jinan 250000, Peoples R China.
C3 Shandong University; Shandong First Medical University & Shandong
   Academy of Medical Sciences; Shandong University
RP Li, LX (通讯作者)，Shandong Univ, Shandong Prov Hosp, Dept Orthoped, Jinan 250021, Peoples R China.; Sun, DQ (通讯作者)，Shandong Univ, Hosp 2, Dept Vasc Surg, Jinan 250000, Peoples R China.
EM bigqsun@sina.com; lxli23@sina.com
RI Wang, Fu/P 9950 2019
OI Wang, Dawei/0000 0002 6151 5839
FU National Natural Science Foundation of China [81201392]; Natural Science
   Foundation of Shandong Province [ZR2012HQ025]
FX This work was supported by the National Natural Science Foundation of
   China (81201392) and the Natural Science Foundation of Shandong Province
   (ZR2012HQ025).
CR Akhtar N, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3368
   Brzóska MM, 2015, CHEM BIOL INTERACT, V229, P132, DOI 10.1016/j.cbi.2015.01.031
   D'Angelo L, 2014, CARCINOGENESIS, V35, P2314, DOI 10.1093/carcin/bgu173
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Gagliardi S, 2010, NEUROBIOL DIS, V39, P198, DOI 10.1016/j.nbd.2010.04.008
   Hu XF, 2012, BIOMATERIALS, V33, P8082, DOI 10.1016/j.biomaterials.2012.07.057
   Hu XF, 2010, BIOMATERIALS, V31, P8854, DOI 10.1016/j.biomaterials.2010.08.006
   Hua P, 2015, MOL MED REP, V11, P113, DOI 10.3892/mmr.2014.2649
   Jeong JY, 2015, CELL BIOL INT, V39, P52, DOI 10.1002/cbin.10343
   Jin P, 2014, CELL TISSUE RES, V356, P381, DOI 10.1007/s00441 014 1797 9
   Kang JS, 2010, J PHARMACOL EXP THER, V334, P619, DOI 10.1124/jpet.110.169391
   Kim WK, 2010, J CELL BIOCHEM, V111, P1199, DOI 10.1002/jcb.22846
   Konat GW, 2003, J BIOSCIENCES, V28, P57, DOI 10.1007/BF02970132
   Lee MJ, 2002, CANCER EPIDEM BIOMAR, V11, P1025
   Li YQ, 2014, INT J MOL MED, V33, P1507, DOI 10.3892/ijmm.2014.1705
   Liu H, 2015, BIOMATERIALS, V49, P103, DOI 10.1016/j.biomaterials.2015.01.017
   Liu H, 2014, J CELL PHYSIOL, V229, P1494, DOI 10.1002/jcp.24591
   Lorenz M, 2015, J CARDIOVASC PHARM, V65, P607, DOI 10.1097/FJC.0000000000000232
   Mauney JR, 2005, TISSUE ENG, V11, P787, DOI 10.1089/ten.2005.11.787
   Moghe SS, 2012, J MED FOOD, V15, P448, DOI 10.1089/jmf.2011.0234
   Pae M, 2013, FOOD FUNCT, V4, P1287, DOI 10.1039/c3fo60076a
   Pae M, 2010, J NUTR, V140, P1509, DOI 10.3945/jn.110.124743
   Pandir D, 2015, CYTOTECHNOLOGY, V67, P367, DOI 10.1007/s10616 014 9695 2
   Pompella A, 2003, BIOCHEM PHARMACOL, V66, P1499, DOI 10.1016/S0006 2952(03)00504 5
   Prosecká E, 2015, J BIOMED MATER RES A, V103, P671, DOI 10.1002/jbm.a.35216
   Shen CL, 2008, OSTEOPOROSIS INT, V19, P979, DOI 10.1007/s00198 007 0527 5
   Shen CL, 2011, OSTEOPOROSIS INT, V22, P327, DOI 10.1007/s00198 010 1209 2
   Sies H, 2014, J BIOL CHEM, V289, P8735, DOI 10.1074/jbc.R113.544635
   Singh BN, 2011, BIOCHEM PHARMACOL, V82, P1807, DOI 10.1016/j.bcp.2011.07.093
   Song QH, 2014, INT J CLIN EXP MED, V7, P262
   Tao GZ, 2013, J BIOL CHEM, V288, P17214, DOI 10.1074/jbc.M112.445965
   Tian J, 2014, TUMOR BIOL, V35, P9439, DOI 10.1007/s13277 014 2433 8
   VALENZUELA A, 1991, LIFE SCI, V48, P301, DOI 10.1016/0024 3205(91)90550 U
   Vali B, 2007, J NUTR BIOCHEM, V18, P341, DOI 10.1016/j.jnutbio.2006.06.005
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Wittrant Y, 2008, BONE, V42, P1122, DOI 10.1016/j.bone.2008.02.006
   Xu FF, 2014, TISSUE ENG PT A, V20, P2768, DOI [10.1089/ten.tea.2014.0007, 10.1089/ten.TEA.2014.0007]
   Yin F, 2014, STEM CELLS, V32, P1278, DOI 10.1002/stem.1638
   Yun JH, 2004, J PERIODONTAL RES, V39, P300, DOI 10.1111/j.1600 0765.2004.00743.x
NR 39
TC 26
Z9 28
U1 1
U2 34
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PY 2016
VL 2016
AR 7532798
DI 10.1155/2016/7532798
PG 10
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DE6JT
UT WOS:000370740600001
PM 26977159
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Oizumi, T
   Yamaguchi, K
   Funayama, H
   Kuroishi, T
   Kawamura, H
   Sugawara, S
   Endo, Y
AF Oizumi, Takefumi
   Yamaguchi, Kouji
   Funayama, Hiromi
   Kuroishi, Toshinobu
   Kawamura, Hiroshi
   Sugawara, Shunji
   Endo, Yasuo
TI Necrotic Actions of Nitrogen Containing Bisphosphonates and Their
   Inhibition by Clodronate, a Non Nitrogen Containing Bisphosphonate in
   Mice: Potential for Utilization of Clodronate as a Combination Drug with
   a Nitrogen Containing Bisphosphonate
SO BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
LA English
DT Article
ID ACUTE PHASE RESPONSE; HISTIDINE DECARBOXYLASE; BONE RESORPTION;
   IN VITRO; MOLECULAR MECHANISMS; INFLAMMATORY ACTIONS; PAGETS DISEASE;
   T CELLS; ALENDRONATE; OSTEONECROSIS
AB Nitrogen containing bisphosphonates (NBPs) exhibit powerful anti bone resorptive effects (ABREs) via inhibition of farnesyl pyrophosphate synthase during cholesterol biosynthesis. Clinical applications have disclosed an unexpected side effect, namely osteonecrosis of jaw bones, and although thousands of cases have been documented in the last few years the mechanism remains unclear. Since NBPs accumulate in bone hydroxyapatite, more jaw bone osteonecrosis cases may come to light if NBPs continue to be used as they are being used now. We have previously reported that in mice, systemic (intraperitoneal) injection of clodronate (a non NBP) prevents the inflammatory effects of NBPs. Here, we examined in mice the local necrotic actions of various NBPs and the anti  necrotic effects of clodronate. A single subcutaneous injection of an NBP into the ear pinna induced necrosis at the injection site (relative potencies of necrotic actions of NBPs: zoledronate >> pamidronate >= alendronate > risedronate), while non NBPs lacked this effect. Clodronate, when injected together with an NBP, reduced or prevented the necrosis induced by that NBP, but not its ABRE. Clodronate reduced the amount of each NBP retained within tissues. These results, together with those of previous studies, suggest that (i) clodronate inhibits the inflammatory and necrotic actions of NBPs by inhibiting their incorporation into cells related to inflammation and/or necrosis, (ii) clodronate could be useful as a combination drug with NBPs for preventing their necrotic actions while retaining their ABREs and (iii) clodronate could also be useful as a substitution drug for NBPs in patients at risk of osteonecrosis of jaw bones.
C1 [Oizumi, Takefumi; Kuroishi, Toshinobu; Sugawara, Shunji; Endo, Yasuo] Tohoku Univ, Grad Sch Dent, Dept Mol Regulat, Aoba Ku, Sendai, Miyagi 9808575, Japan.
   [Oizumi, Takefumi; Yamaguchi, Kouji; Kawamura, Hiroshi] Tohoku Univ, Grad Sch Dent, Dept Oral & Maxillofacial Surg, Aoba Ku, Sendai, Miyagi 9808575, Japan.
   [Funayama, Hiromi] Tohoku Univ, Grad Sch Dent, Dept Oral Microbiol, Aoba Ku, Sendai, Miyagi 9808575, Japan.
C3 Tohoku University; Tohoku University; Tohoku University
RP Endo, Y (通讯作者)，Tohoku Univ, Grad Sch Dent, Dept Mol Regulat, Aoba Ku, 4 1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
EM endo@pharmac.dent.tohoku.ac.jp
OI Kuroishi, Toshinobu/0000 0003 1633 8615
FU Novartis Pharma K. K; Dainippon Sumitomo Pharma Co. Ltd; Tohoku
   University; Japan Society for the promotion of Science [1879145,
   18591995]; Grants in Aid for Scientific Research [18591995] Funding
   Source: KAKEN
FX This work was supported by grants from Novartis Pharma K. K. (Tokyo,
   Japan), Dainippon Sumitomo Pharma Co. Ltd. (Tokyo, Japan), Tohoku
   University (Sendai, Japan) and Japan Society for the promotion of
   Science (1879145 and 18591995). We are grateful to Dr. Masanori
   Takahashi (Novartis Pharma K. K.) and Dr. Takashi Katsumata (Dainippon
   Sumitomo Pharma Co. Ltd.) for providing information and Dr. Robert Timms
   for editing the manuscript.
CR ADAMI S, 1987, CALCIFIED TISSUE INT, V41, P326, DOI 10.1007/BF02556671
   Caraglia M, 2006, ENDOCR RELAT CANCER, V13, P7, DOI 10.1677/erc.1.01094
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Deng X, 2007, INT IMMUNOPHARMACOL, V7, P152, DOI 10.1016/j.intimp.2006.09.009
   Deng X, 2006, TOXICOL APPL PHARM, V213, P64, DOI 10.1016/j.taap.2005.09.005
   Dieli F, 2007, CANCER RES, V67, P7450, DOI 10.1158/0008 5472.CAN 07 0199
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Endo Y, 1999, BRIT J PHARMACOL, V126, P903, DOI 10.1038/sj.bjp.0702367
   ENDO Y, 1993, CALCIFIED TISSUE INT, V52, P248, DOI 10.1007/BF00298728
   FLEISCH HA, 1997, ANAL MED, V29, P56
   Funayama H, 2000, ARCH ORAL BIOL, V45, P787, DOI 10.1016/S0003 9969(00)00039 X
   Funayama H, 2005, CALCIFIED TISSUE INT, V76, P448, DOI 10.1007/s00223 004 0180 3
   Geddes A D., 1994, Bone and Mineral Research, P265
   HARINCK HIJ, 1987, BMJ BRIT MED J, V295, P1301, DOI 10.1136/bmj.295.6609.1301
   Hellstein JW, 2005, J ORAL MAXIL SURG, V63, P682, DOI 10.1016/j.joms.2005.01.010
   Lacy MQ, 2006, MAYO CLIN PROC, V81, P1047, DOI 10.4065/81.8.1047
   LIN JH, 1992, DRUG METAB DISPOS, V20, P473
   Lipton A, 2004, ONCOLOGIST, V9, P38, DOI 10.1634/theoncologist.9 90004 38
   MACAROL V, 1994, AM J OPHTHALMOL, V118, P220, DOI 10.1016/S0002 9394(14)72902 2
   Migliorati CA, 2006, LANCET ONCOL, V7, P508, DOI 10.1016/S1470 2045(06)70726 4
   Monkkonen J, 1989, PHARMACOL TOXICOL, V65, P294
   Monma Y, 2004, CALCIFIED TISSUE INT, V74, P115, DOI 10.1007/s00223 002 2156 5
   Munns CF, 2004, BONE, V35, P231, DOI 10.1016/j.bone.2004.03.008
   Nakamura M, 1999, BRIT J HAEMATOL, V107, P779, DOI 10.1046/j.1365 2141.1999.01774.x
   Pazianas M, 2007, CLIN THER, V29, P1548, DOI 10.1016/j.clinthera.2007.08.008
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Ruggiero S, 2006, J ONCOL PRACT, V2, P7, DOI 10.1200/JOP.2.1.7
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Sauty A, 1996, BONE, V18, P133, DOI 10.1016/8756 3282(95)00448 3
   SCHWEITZER DH, 1995, J BONE MINER RES, V10, P956
   SHIMAHARA M, 2007, JAP J ORAL SURG, V53, P16
   SIRIS ES, 1993, LANCET, V341, P436, DOI 10.1016/0140 6736(93)93029 Z
   Thiebaud D, 1997, CALCIFIED TISSUE INT, V61, P386, DOI 10.1007/s002239900353
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Yamaguchi K, 2000, BRIT J PHARMACOL, V130, P1646, DOI 10.1038/sj.bjp.0703460
   Yu ZQ, 2005, BASIC CLIN PHARMACOL, V97, P222, DOI 10.1111/j.1742 7843.2005.pto_138.x
NR 39
TC 30
Z9 31
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1742 7835
EI 1742 7843
J9 BASIC CLIN PHARMACOL
JI Basic Clin. Pharmacol. Toxicol.
PD MAY
PY 2009
VL 104
IS 5
BP 384
EP 392
DI 10.1111/j.1742 7843.2008.00374.x
PG 9
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 431CK
UT WOS:000265038700007
PM 19413658
DA 2025 08 17
ER

PT J
AU Miura, T
   Etani, Y
   Noguchi, T
   Hirao, M
   Takami, K
   Goshima, A
   Kurihara, T
   Fukuda, Y
   Ochiai, N
   Kanamoto, T
   Nakata, K
   Okada, S
   Ebina, K
AF Miura, Taihei
   Etani, Yuki
   Noguchi, Takaaki
   Hirao, Makoto
   Takami, Kenji
   Goshima, Atsushi
   Kurihara, Takuya
   Fukuda, Yuji
   Ochiai, Nagahiro
   Kanamoto, Takashi
   Nakata, Ken
   Okada, Seiji
   Ebina, Kosuke
TI Iguratimod suppresses sclerostin and receptor activator of NF KB ligand
   production via the extracellular signal regulated kinase/early growth
   response protein 1/tumor necrosis factor alpha pathway in osteocytes and
   ameliorates disuse osteoporosis in mice
SO BONE
LA English
DT Article
DE Disuse osteoporosis; Early growth response protein 1; Iguratimod;
   Osteocytes; RANKL; Sclerostin
ID KAPPA B ACTIVATION; BONE LOSS; OSTEOSARCOMA CELLS; IN VITRO; EXPRESSION;
   T 614; INHIBITION; DENSITY
AB Disuse osteoporosis is a prevalent complication among patients afflicted with rheumatoid arthritis (RA). Although reports have shown that the antirheumatic drug iguratimod (IGU) ameliorates osteoporosis in RA patients, details regarding its effects on osteocytes remain unclear. The current study examined the effects of IGU on osteocytes using a mouse model of disuse  induced osteoporosis, the pathology of which crucially involves osteocytes. A reduction in distal femur bone mass was achieved after 3 weeks of hindlimb unloading in mice, which was subsequently reversed by intraperitoneal IGU treatment (30 mg/kg; five times per week). Histology revealed that hindlimb unloaded (HLU) mice had significantly increased osteoclast number and sclerostinpositive osteocyte rates, which were suppressed by IGU treatment. Moreover, HLU mice exhibited a significant decrease in osteocalcin positive cells, which was attenuated by IGU treatment. In vitro, IGU suppressed the gene expression of receptor activator of NF  KB ligand (RANKL) and sclerostin in MLO Y4 and Saos 2 cells, which inhibited osteoclast differentiation of mouse bone marrow cells in cocultures. Although IGU did not affect the nuclear translocation or transcriptional activity of NF  KB, RNA sequencing revealed that IGU downregulated the expression of early growth response protein 1 (EGR1) in osteocytes. HLU mice showed significantly increased EGR1  and tumor necrosis factor alpha (TNF alpha) positive osteocyte rates, which were decreased by IGU treatment. EGR1 overexpression enhanced the gene expression of TNF alpha, RANKL, and sclerostin in osteocytes, which was suppressed by IGU. Contrarily, small interfering RNA  mediated suppression of EGR1 downregulated RANKL and sclerostin gene expression. These findings indicate that IGU inhibits the expression of EGR1, which may downregulate TNF alpha and consequently RANKL and sclerostin in osteocytes. These mechanisms suggest that IGU could potentially be used as a treatment option for disuse osteoporosis by targeting osteocytes.
C1 [Miura, Taihei; Noguchi, Takaaki; Kurihara, Takuya; Fukuda, Yuji; Okada, Seiji; Ebina, Kosuke] Osaka Univ, Grad Sch Med, Dept Orthopaed Surg, 2 2 Yamada Oka, Suita, Osaka 5650871, Japan.
   [Etani, Yuki; Ochiai, Nagahiro; Ebina, Kosuke] Osaka Univ, Dept Musculoskeletal Regenerat Med, Grad Sch Med, 2 2 Yamada Oka, Suita, Osaka 5650871, Japan.
   [Hirao, Makoto] Natl Hosp Org, Osaka Minami Med Ctr, Dept Orthopaed Surg, 2 1 Kidohigashimachi, Kawachi Nagano, Osaka 5868521, Japan.
   [Takami, Kenji] Nippon Life Hosp, Dept Orthopaed Surg, 2 1 54 Enokojima,Nishi Ku, Osaka, Osaka 5500006, Japan.
   [Goshima, Atsushi] Osaka Rosai Hosp, Dept Orthopaed Surg, 1179 3 Nagasone cho,Kita Ku, Sakai, Osaka 5918025, Japan.
   [Kanamoto, Takashi; Nakata, Ken] Osaka Univ, Grad Sch Med, Dept Hlth & Sport Sci, 2 2 Yamada Oka, Suita, Osaka 5650871, Japan.
C3 University of Osaka; University of Osaka; Osaka Rosai Hospital;
   University of Osaka
RP Ebina, K (通讯作者)，Osaka Univ, Grad Sch Med, Dept Orthopaed Surg, 2 2 Yamada Oka, Suita, Osaka 5650871, Japan.
EM k ebina@ort.med.osaka u.ac.jp
RI ; ochiai, nagahiro/MGB 5431 2025; Fukuda, Yuji/AAU 3624 2021; Ebina,
   Kosuke/AAH 6171 2019; Takami, Kenji/ABG 3188 2020; Okada,
   Seiji/F 5785 2013
OI Ochiai, Nagahiro/0000 0001 7834 539X; Miura, Taihei/0000 0002 1270 9864;
   Fukuda, Yuji/0000 0002 3889 0999; 
FU Grants in Aid for Scientific Research [23K08651, 23K15741] Funding
   Source: KAKEN
CR Aikawa Y, 2002, INFLAMM RES, V51, P188, DOI 10.1007/PL00000291
   Aleshcheva G, 2015, FASEB J, V29, P2303, DOI 10.1096/fj.14 268151
   Baek K, 2014, J CELL PHYSIOL, V229, P640, DOI 10.1002/jcp.24487
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Delgado Calle J, 2022, PHYSIOL REV, V102, DOI 10.1152/physrev.00043.2020
   Delgado Calle J, 2017, BONE, V96, P29, DOI 10.1016/j.bone.2016.10.007
   Deng L, 2022, INT J CLIN PRACT, V2022, DOI 10.1155/2022/5684293
   Dubrovsky AM, 2018, CALCIFIED TISSUE INT, V102, P607, DOI 10.1007/s00223 018 0401 9
   Etani Y, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115525
   Fang YK, 2021, SCI TOTAL ENVIRON, V757, DOI 10.1016/j.scitotenv.2020.143753
   Hamar A, 2021, OSTEOPOROSIS INT, V32, P1621, DOI 10.1007/s00198 021 05871 0
   Heiland GR, 2010, ANN RHEUM DIS, V69, P2152, DOI 10.1136/ard.2010.132852
   Herchenhan A, 2020, J ORTHOP RES, V38, P173, DOI 10.1002/jor.24513
   Hunter RB, 2001, AM J PHYSIOL CELL PH, V281, pC1285, DOI 10.1152/ajpcell.2001.281.4.C1285
   Jin X, 2022, NPJ MICROGRAVITY, V8, DOI 10.1038/s41526 022 00210 x
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kobayashi Y, 2016, J BIOCHEM, V159, P387, DOI 10.1093/jb/mvv124
   Kohno M, 2001, J RHEUMATOL, V28, P2591
   Kuriyama K, 2002, BIOCHEM BIOPH RES CO, V299, P903, DOI 10.1016/S0006 291X(02)02754 7
   Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200
   Li CH, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107219
   Li XH, 2019, ELIFE, V8, DOI 10.7554/eLife.49631
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Ma YF, 1999, J BONE MINER RES, V14, P439, DOI 10.1359/jbmr.1999.14.3.439
   Metzger CE, 2020, NPJ MICROGRAVITY, V6, DOI 10.1038/s41526 020 00118 4
   Miyama A, 2021, J BONE MINER METAB, V39, P639, DOI 10.1007/s00774 021 01206 5
   Nagaraja MP, 2013, J CELL BIOCHEM, V114, P1001, DOI 10.1002/jcb.24454
   Naruse K, 2016, J BONE MINER METAB, V34, P615, DOI 10.1007/s00774 015 0714 y
   Noguchi T, 2017, OSTEOPOROSIS INT, V28, P1063, DOI 10.1007/s00198 016 3830 1
   Prideaux M, 2014, CALCIFIED TISSUE INT, V95, P183, DOI 10.1007/s00223 014 9879 y
   Qin L, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0099 y
   Rolvien T, 2022, CALCIFIED TISSUE INT, V110, P592, DOI 10.1007/s00223 021 00836 1
   Sebastian A, 2017, BONE, V96, P76, DOI 10.1016/j.bone.2016.10.009
   Shi L, 2002, AM J PHYSIOL CELL PH, V282, pC1205, DOI 10.1152/ajpcell.00511.2001
   Siu S, 2015, ARTHRIT CARE RES, V67, P754, DOI 10.1002/acr.22519
   Sun WJ, 2019, ELIFE, V8, DOI 10.7554/eLife.47454
   Tanaka KI, 2015, BIOCHEM BIOPH RES CO, V461, P193, DOI 10.1016/j.bbrc.2015.02.091
   Terpos E, 2011, CLIN EXP RHEUMATOL, V29, P921
   Thiel G, 2012, ENDOCRINOLOGY, V153, P4716, DOI 10.1210/en.2012 1343
   Uchida T, 2018, AM J PHYSIOL CELL PH, V314, pC721, DOI 10.1152/ajpcell.00184.2017
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wei Y, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/214683
   WRONSKI TJ, 1987, AVIAT SPACE ENVIR MD, V58, P63
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Wu YX, 2017, MOL MED REP, V16, P8200, DOI 10.3892/mmr.2017.7648
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yan YY, 2020, CURR OSTEOPOROS REP, V18, P67, DOI 10.1007/s11914 020 00564 9
   Yu LC, 2011, BONE, V49, P1131, DOI 10.1016/j.bone.2011.08.016
   Zhang JS, 2013, J BIOL CHEM, V288, P4310, DOI 10.1074/jbc.M112.351197
NR 50
TC 6
Z9 6
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2024
VL 181
AR 117026
DI 10.1016/j.bone.2024.117026
EA FEB 2024
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA KZ6C4
UT WOS:001183820600001
PM 38325651
DA 2025 08 17
ER

PT J
AU Liu, CH
   Ma, MM
   Zhang, JD
   Gui, SL
   Zhang, XH
   Xue, ST
AF Liu, Chunhong
   Ma, Mingming
   Zhang, Junde
   Gui, Shaoliu
   Zhang, Xiaohai
   Xue, Shuangtao
TI Galangin inhibits human osteosarcoma cells growth by inducing
   transforming growth factor β1 dependent osteogenic differentiation
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Osteosarcoma; Osteogenic differentiation; Galangin; TGF beta 1/Smad2/3;
   Therapy
ID TGF BETA; OSTEOBLASTIC DIFFERENTIATION; PROLIFERATION; ACTIVATION;
   APOPTOSIS; BAICALEIN; MEMBRANE; PROTEINS; NUCLEUS; PATHWAY
AB Osteosarcoma is the most common primary malignancy of the musculoskeletal system, and is associated with excessive proliferation and poor differentiation of osteoblasts. Currently, despite the use of traditional chemotherapy and radiotherapy, no satisfactory and effective agent has been developed to treat the disease. Herein, we found that a flavonoid natural product, galangin, could significantly attenuate human osteosarcoma cells proliferation, without causing obvious cell apoptosis. Moreover, galangin enhanced the expression of osteoblast differentiation markers (collagen type I, alkaline phosphatase, osteocalcin and osteopontin) remarkably and elevated the alkaline phosphatase activity in human osteosarcoma cells. And galangin could also attenuated osteosarcoma growth in vivo.
   These bioactivities of galangin resulted from its selective activation of the transforming growth factor (TGF) beta 1/Smad2/3 signaling pathway, which was demonstrated by pathway blocking experiments. These findings suggested that galangin could be a promising agent to treat osteosarcoma. In addition, targeting TGF beta 1 to induce osteogenic differentiation might represent a novel therapeutic strategy to treat osteosarcoma with minimal side effects. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Liu, Chunhong; Zhang, Junde; Gui, Shaoliu; Zhang, Xiaohai; Xue, Shuangtao] Second Peoples Hosp Wuhu, Dept Orthoped Surg, 259 Jiuhuazhong Rd, Wuhu 241000, Anhui, Peoples R China.
   [Ma, Mingming] Peoples Hosp Fuyang, Dept Orthoped Surg, Fuyang, Anhui, Peoples R China.
RP Xue, ST (通讯作者)，Second Peoples Hosp Wuhu, Dept Orthoped Surg, 259 Jiuhuazhong Rd, Wuhu 241000, Anhui, Peoples R China.
EM 18155317015@163.com; mz20100104@outlook.com; drjundezhang@126.com;
   guishaoliu@163.com; johnchan70@126.com; dr.shuangtaoxue@hotmail.com
CR [Anonymous], WATER
   Cao JY, 2016, MOL MED REP, V13, P4238, DOI 10.3892/mmr.2016.5042
   Cathcart MC, 2016, BMC CANCER, V16, DOI 10.1186/s12885 016 2740 0
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   Clark JCM, 2008, J CANCER RES CLIN, V134, P281, DOI 10.1007/s00432 007 0330 x
   Ferguson WS, 2001, CANCER INVEST, V19, P292, DOI 10.1081/CNV 100102557
   GERLIER D, 1986, J IMMUNOL METHODS, V94, P57, DOI 10.1016/0022 1759(86)90215 2
   Han MA, 2016, SCI REP UK, V6, DOI 10.1038/srep18642
   Haydon RC, 2007, CLIN ORTHOP RELAT R, P237, DOI 10.1097/BLO.0b013e31802b683c
   Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284
   Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   Huh Jeong Eun, 2013, Eur J Pharmacol, V698, P57, DOI 10.1016/j.ejphar.2012.08.013
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104
   Jung CH, 2012, J MED FOOD, V15, P959, DOI 10.1089/jmf.2012.2286
   Kumar S, 2013, PHARM BIOL, V51, P607, DOI 10.3109/13880209.2012.757327
   Li Y, 2016, J CELL PHYSL
   Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005
   Luo P, 2010, ONCOGENE, V29, P2772, DOI 10.1038/onc.2010.50
   Ongaro A., 2016, J CELL PHYSL
   Ouyang GL, 2002, WORLD J GASTROENTERO, V8, P1053, DOI 10.3748/wjg.v8.i6.1053
   Quist T, 2015, ONCOGENE, V34, P4278, DOI 10.1038/onc.2014.354
   Ravichandiran V., 2016, Curr Drug Deliv
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Shi SL, 2009, J CELL BIOCHEM, V108, P926, DOI 10.1002/jcb.22324
   Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Thomas D, 2006, J CELL BIOCHEM, V98, P757, DOI 10.1002/jcb.20850
   Turri A, 2016, BIOMATERIALS, V84, P167, DOI 10.1016/j.biomaterials.2016.01.034
   Wagner Eric R., 2011, Sarcoma, V2011, P325238, DOI 10.1155/2011/325238
   Wang XH, 2013, ENVIRON TOXICOL PHAR, V36, P288, DOI 10.1016/j.etap.2013.04.004
   Wang YJ, 2014, TOXICOLOGY, V326, P9, DOI 10.1016/j.tox.2014.09.010
   Yan M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4661
   Ye FF, 2015, TUMOR BIOL, V36, P4731, DOI 10.1007/s13277 015 3122 y
   Ying M., 2016, ONCOGENE
   Zhang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098973
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
NR 39
TC 22
Z9 23
U1 1
U2 19
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD MAY
PY 2017
VL 89
BP 1415
EP 1421
DI 10.1016/j.biopha.2017.03.030
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA EW4JQ
UT WOS:000402468200160
PM 28340520
DA 2025 08 17
ER

PT J
AU Tamura, H
   Maekawa, T
   Damon, H
   Hiyoshi, T
   Yonezawa, D
   Nagai, K
   Ochiai, A
   Taniguchi, M
   Tabeta, K
   Maeda, T
   Terao, Y
AF Tamura, Hikaru
   Maekawa, Tomoki
   Damon, Hisanori
   Hiyoshi, Takumi
   Yonezawa, Daisuke
   Nagai, Kosuke
   Ochiai, Akihito
   Taniguchi, Masayuki
   Tabeta, Koichi
   Maeda, Takeyasu
   Terao, Yutaka
TI Peptides from rice endosperm protein restrain periodontal bone loss in
   mouse model of periodontitis
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE Food peptide; Periodontitis; Inflammation; Bone loss; Osteoclastogenesis
ID NF KAPPA B; PORPHYROMONAS GINGIVALIS; OSTEOCLAST DIFFERENTIATION;
   ANTIMICROBIAL ACTIVITY; ENDOTOXIC ACTIVITIES; CYANATE LYASE; AMINO ACID;
   IN VITRO; INHIBITION; DODECAPEPTIDE
AB Objective: Food derived peptides have been reported to exhibit antibacterial activity against periodontal pathogenic bacteria. However, no effect has been shown on inflammation and bone resorption in periodontal pathology. The overall objective of the current study was to investigate how rice peptides influence biological defense mechanisms against periodontitis induced inflammatory bone loss, and identify their novel functions as a potential anti inflammatory drug.
   Design: The expression of inflammatory and osteoclast related molecules was examined in mouse macrophage derived RAW 264.7 cell cultures using qPCR. Subsequently, the effect of these peptides on inflammatory bone loss in mouse periodontitis was examined using a mouse model of tooth ligation. Briefly, periodontal bone loss was induced for 7 days in mice by ligating the maxillary second molar and leaving the contralateral tooth unligated (baseline control). The mice were microinjected daily with the peptide in the gingiva until the day before euthanization. One week after the ligation, TRAP positive multinucleated cells (MNCs) were enumerated from five random coronal sections of the ligated sites in each mouse.
   Results: Rice peptides REP9 and REP11 significantly inhibited transcription activity of inflammatory and osteoclast related molecules. Local treatment with the rice peptides, in mice subjected to ligature induced periodontitis, inhibited inflammatory bone loss, explaining the decreased numbers of osteoclasts in bone tissue sections.
   Conclusion: Therefore, these data suggested that the rice peptides possess a protective effect against periodontitis.
C1 [Tamura, Hikaru; Maekawa, Tomoki; Damon, Hisanori; Hiyoshi, Takumi; Nagai, Kosuke; Terao, Yutaka] Niigata Univ, Grad Sch Med & Dent Sci, Div Microbiol & Infect Dis, Niigata, Japan.
   [Tamura, Hikaru; Maekawa, Tomoki; Damon, Hisanori; Yonezawa, Daisuke; Maeda, Takeyasu; Terao, Yutaka] Niigata Univ, Grad Sch Med & Dent Sci, Res Ctr Adv Oral Sci, Niigata, Japan.
   [Tamura, Hikaru; Hiyoshi, Takumi; Tabeta, Koichi] Niigata Univ, Grad Sch Med & Dent Sci, Div Periodontol, Niigata, Japan.
   [Yonezawa, Daisuke] Niigata Univ, Grad Sch Med & Dent Sci, Div Oral Sci Hlth Promot, Niigata, Japan.
   [Ochiai, Akihito; Taniguchi, Masayuki] Niigata Univ, Grad Sch Sci & Technol, Dept Mat Sci & Technol, Niigata, Japan.
C3 Niigata University; Niigata University; Niigata University; Niigata
   University; Niigata University
RP Terao, Y (通讯作者)，Grad Sch Med & Dent Sci, Div Microbiol & Infect Dis, Chuo Ku, 2 5274 Gakkocho Dori, Niigata 9518514, Japan.
EM terao@dent.niigata u.ac.jp
RI TABTA, KOICHI/AAG 6481 2020; 秋人, 落合/IVH 8254 2023; Maeda,
   Takeyasu/K 3784 2014; Tamura, Hikaru/LCE 0280 2024; Maekawa,
   Tomoki/AAA 4673 2020
OI Terao, Yutaka/0000 0002 4450 5583; Maekawa, Tomoki/0000 0002 4597 1316
FU JSPS KAKENHI JAPAN [16H06272E, 17K19747, 17H04367, 18K19638]; Takeda
   Science Foundation JAPAN; Nakajima Foundation JAPAN; Young Investigator
   Research Seed Grant from JSP JAPAN; Grants in Aid for Scientific
   Research [17H04367, 17K19747, 18K19638] Funding Source: KAKEN
FX This work was supported by grants from JSPS KAKENHI JAPAN (16H06272E,
   17K19747) to T.M, (17H04367, 18K19638) to Y.T.Takeda Science
   Foundation JAPAN, Nakajima Foundation JAPAN and Young Investigator
   Research Seed Grant from JSP JAPAN to T.M.
CR Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002
   Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cai Y, 2015, INT IMMUNOPHARMACOL, V29, P839, DOI 10.1016/j.intimp.2015.08.033
   Chen FQ, 2018, BIOMED PHARMACOTHER, V100, P142, DOI 10.1016/j.biopha.2018.02.014
   da Cunha MG, 2017, J NAT PROD, V80, P1893, DOI 10.1021/acs.jnatprod.7b00194
   Fujie A, 2015, BIOCHEM BIOPH RES CO, V457, P451, DOI 10.1016/j.bbrc.2015.01.012
   Ha H, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 352
   Hajishengallis G, 2016, TRENDS MICROBIOL, V24, P477, DOI 10.1016/j.tim.2016.02.010
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Hajishengallis G, 2014, TRENDS IMMUNOL, V35, P3, DOI 10.1016/j.it.2013.09.001
   Ibrahim HR, 2017, J ADV RES, V8, P63, DOI 10.1016/j.jare.2016.12.002
   Jiang Y, 2018, FOOD RES INT, V105, P836, DOI 10.1016/j.foodres.2017.12.022
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Jin DX, 2016, FOOD CHEM, V204, P427, DOI 10.1016/j.foodchem.2016.02.119
   Jourdain ML, 2018, J CLIN PERIODONTOL, V45, P524, DOI 10.1111/jcpe.12879
   Kobayashi Y, 2009, CRIT REV EUKAR GENE, V19, P61, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.30
   Liang Y, 2018, J AGR FOOD CHEM, V66, P440, DOI 10.1021/acs.jafc.7b04036
   Limtrakul Pornngarm, 2015, Asian Pac J Cancer Prev, V16, P4277
   Lin MC, 2010, PEPTIDES, V31, P1262, DOI 10.1016/j.peptides.2010.04.004
   Maekawa T, 2017, J DENT RES, V96, P571, DOI 10.1177/0022034516687248
   Maekawa T, 2016, J CLIN PERIODONTOL, V43, P238, DOI 10.1111/jcpe.12507
   Maekawa T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9272
   Maekawa T, 2014, CELL HOST MICROBE, V15, P768, DOI 10.1016/j.chom.2014.05.012
   Maekawa T, 2014, J IMMUNOL, V192, P6020, DOI 10.4049/jimmunol.1400569
   Mah YJ, 2014, ARCH ORAL BIOL, V59, P539, DOI 10.1016/j.archoralbio.2014.02.011
   Miyauchi Y, 2010, J EXP MED, V207, P751, DOI 10.1084/jem.20091957
   Moreno Montoro M, 2017, FOOD FUNCT, V8, P2783, DOI [10.1039/c7fo00666g, 10.1039/C7FO00666G]
   Potempa J, 2017, NAT REV RHEUMATOL, V13, P606, DOI 10.1038/nrrheum.2017.132
   Quirós A, 2005, J DAIRY SCI, V88, P3480, DOI 10.3168/jds.S0022 0302(05)73032 0
   Sabharwal A, 2018, PERIODONTOL 2000, V78, P212, DOI 10.1111/prd.12226
   Serrano J, 2015, J CLIN PERIODONTOL, V42, pS106, DOI 10.1111/jcpe.12331
   Shin J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5380
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Steinberg D, 2017, EXPERT OPIN DRUG DEL, V14, P571, DOI 10.1080/17425247.2016.1213239
   Takayama S, 2016, MICROB PATHOGENESIS, V94, P2, DOI 10.1016/j.micpath.2015.08.011
   Takayama Saori, 2015, BMC Res Notes, V8, P531, DOI 10.1186/s13104 015 1527 8
   Takei N, 2013, PEPTIDES, V42, P55, DOI 10.1016/j.peptides.2012.12.015
   Taniguchi M, 2017, BIOPOLYMERS, V108, DOI 10.1002/bip.23023
   Taniguchi M, 2017, J FUNCT FOODS, V34, P287, DOI 10.1016/j.jff.2017.04.046
   Taniguchi M, 2017, J PEPT SCI, V23, P252, DOI 10.1002/psc.2983
   Taniguchi M, 2016, J BIOSCI BIOENG, V122, P652, DOI 10.1016/j.jbiosc.2016.05.008
   Taniguchi M, 2014, BIOPOLYMERS, V102, P379, DOI 10.1002/bip.22525
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Uraipong C, 2016, J SCI FOOD AGR, V96, P1101, DOI 10.1002/jsfa.7182
NR 45
TC 13
Z9 14
U1 0
U2 14
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003 9969
EI 1879 1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD FEB
PY 2019
VL 98
BP 132
EP 139
DI 10.1016/j.archoralbio.2018.11.021
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA HK1KO
UT WOS:000457664000021
PM 30485826
DA 2025 08 17
ER

PT J
AU Zuo, HL
   Xin, H
   Yan, XN
   Huang, J
   Zhang, YP
   Du, H
AF Zuo, H L
   Xin, H.
   Yan, X N
   Huang, J.
   Zhang, Y P
   Du, H.
TI 17β Estradiol improves osteoblastic cell function through the
   Sirt1/NF κB/MMP 8 pathway
SO CLIMACTERIC
LA English
DT Article
DE Postmenopausal osteoporosis; 17 beta estradiol; osteoblasts; matrix
   metalloproteinase 8; Sirtuin 1; nuclear transcription factor kappa B
ID SERUM ALKALINE PHOSPHATASE; MATRIX METALLOPROTEINASES; BONE RESORPTION;
   SIRT1; DIFFERENTIATION; INHIBITORS
AB Objective: This study aims to investigate the beneficial effects of 17 beta estradiol supplementation on the function of osteoblastic cells through the Sirtuin 1/nuclear transcription factor kappa B/matrix metalloproteinase 8 (Sirt1/NF kappa B/MMP 8) pathway. Methods: Mouse primary osteoblasts were obtained from neonatal mouse calvaria, and the cells were treated with or without 17 beta estradiol. We first detected the effect of 17 beta estradiol on the function of osteoblastic cells. Then, the changes in estrogen receptor alpha (ER alpha), Sirt1, NF kappa B, and MMP 8 were determined after the osteoblasts were treated with 17 beta estradiol. During supplementation with 17 beta estradiol, knockdown of Sirt1 in osteoblasts was used to further measure the changes of NF kappa B and MMP 8 and observe the cell function. Results: In primary osteoblastic cells, exposure to 17 beta estradiol improved cell viability and increased the levels of bone formation biomarkers, including osteocalcin, osteoprotegerin (OPG), procollagen type 1 N terminal propeptide (P1NP), and alkaline phosphatase (ALP). In addition, 17 beta estradiol supplement activated ER alpha and Sirt1 expression and inhibited NF kappa B and MMP 8 expression. Moreover, these effects induced by 17 beta estradiol were reversed by knockdown of Sirt1 in mouse primary osteoblasts. Conclusion: 17 beta Estradiol replacement therapy may treat postmenopausal osteoporosis by improving osteoblastic cell function via the Sirt1/NF kappa B/MMP 8 pathway.
C1 [Zuo, H L; Xin, H.; Huang, J.; Zhang, Y P; Du, H.] Hebei Med Univ, Dept Gynecol & Obstet, Hosp 2, 215 Heping West Rd, Shijiazhuang 050000, Hebei, Peoples R China.
   [Yan, X N] Hebei Med Univ, Dept Ultrason Diag & Treatment Obstet & Gynecol, Hosp 2, Shijiazhuang, Hebei, Peoples R China.
C3 Hebei Medical University; Hebei Medical University
RP Du, H (通讯作者)，Hebei Med Univ, Dept Gynecol & Obstet, Hosp 2, 215 Heping West Rd, Shijiazhuang 050000, Hebei, Peoples R China.
EM duhuiys2004@yeah.net
CR Bäckesjö CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415
   Bendale DS, 2013, BRIT J PHARMACOL, V170, P779, DOI 10.1111/bph.12290
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boonen S, 2012, J BONE MINER RES, V27, P963, DOI 10.1002/jbmr.1570
   Chen YB, 2018, CELL MOL LIFE SCI, V75, P1117, DOI 10.1007/s00018 017 2687 6
   Choi SE, 2013, MOL CELLS, V36, P385, DOI 10.1007/s10059 013 0297 1
   Cosman F, 2017, J BONE MINER RES, V32, P198, DOI 10.1002/jbmr.3051
   Diab DL, 2013, CURR OPIN ENDOCRINOL, V20, P501, DOI 10.1097/01.med.0000436194.10599.94
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Feng J, 2014, ACTA BIOCH BIOPH SIN, V46, P1024, DOI 10.1093/abbs/gmu103
   Gong K, 2017, MOL CELLS, V40, P393, DOI 10.14348/molcells.2017.0018
   Gürsoy M, 2014, OMICS, V18, P582, DOI 10.1089/omi.2014.0020
   Haigis MC, 2010, ANNU REV PATHOL MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250
   Holliday LS, 1997, J BIOL CHEM, V272, P22053, DOI 10.1074/jbc.272.35.22053
   Kauppinen A, 2013, CELL SIGNAL, V25, P1939, DOI 10.1016/j.cellsig.2013.06.007
   Kim J, 2017, BIOCHEM BIOPH RES CO, V493, P879, DOI 10.1016/j.bbrc.2017.09.129
   Kucukalic Selimovic E, 2013, BOSNIAN J BASIC MED, V13, P259
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Lenglet S, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/659282
   Levin VA, 2018, OSTEOPOROSIS INT, V29, P1049, DOI 10.1007/s00198 018 4414 z
   Liu LY, 2018, MOL MED REP, V17, P1609, DOI 10.3892/mmr.2017.8042
   Medina Estrada I, 2018, J IMMUNOL RES, V2018, P1
   Mieczkowska J, 2016, DIS MARKERS, V2016, P1
   Mukaiyama K, 2015, AGING CLIN EXP RES, V27, P413, DOI 10.1007/s40520 014 0296 x
   Munasinghe A, 2017, J PHYS CHEM B, V121, P9141, DOI 10.1021/acs.jpcb.7b06687
   Nadkarni S, 2013, CURR OPIN PHARMACOL, V13, P576, DOI 10.1016/j.coph.2013.05.007
   Paiva KBS, 2017, PROG MOL BIOL TRANSL, V148, P203, DOI 10.1016/bs.pmbts.2017.05.001
   PRICE CP, 1993, ANN CLIN BIOCHEM, V30, P355, DOI 10.1177/000456329303000403
   Sasano Y, 2002, J HISTOCHEM CYTOCHEM, V50, P325, DOI 10.1177/002215540205000304
   Varghese S, 2006, FRONT BIOSCI LANDMRK, V11, P2949, DOI 10.2741/2024
   Vassilev V, 2005, J CLIN ENDOCR METAB, V90, P5848, DOI 10.1210/jc.2005 0762
   Wang Y, 2011, FEBS LETT, V585, P986, DOI 10.1016/j.febslet.2010.11.047
   Yao HW, 2012, BIOCHEM PHARMACOL, V84, P1332, DOI 10.1016/j.bcp.2012.06.031
   Yeung F, 2011, FEBS LETT, V585, P986
   Zainabadi K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178520
   Zhou SH, 2003, MOL ENDOCRINOL, V17, P56, DOI 10.1210/me.2002 0210
NR 36
TC 12
Z9 14
U1 0
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1369 7137
EI 1473 0804
J9 CLIMACTERIC
JI Climacteric
PD JUL 3
PY 2020
VL 23
IS 4
SI SI
BP 404
EP 409
DI 10.1080/13697137.2020.1758057
EA MAY 2020
PG 6
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Obstetrics & Gynecology
GA MH9MZ
UT WOS:000536855500001
PM 32410477
DA 2025 08 17
ER

PT J
AU Cheng, S
   Shao, HW
   Yin, D
   Zhou, JL
   Jian, LJ
   Xie, JN
   Zhang, Y
   Wang, DH
   Peng, F
AF Cheng, Shi
   Shao, Hongwei
   Yin, Dong
   Zhou, Jielong
   Jian, Linjia
   Xie, Juning
   Zhang, Yu
   Wang, Donghui
   Peng, Feng
TI Molecular Mechanism Underlying the Action of a Celastrol Loaded Layered
   Double Hydroxide Coated Magnesium Alloy in Osteosarcoma Inhibition and
   Bone Regeneration
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE osteosarcoma therapy; magnesium alloy; celastrol; tumor suppression;
   bone regeneration
ID BIODEGRADABLE MAGNESIUM; IN VITRO; IMPLANTS; TITANIUM
AB Osteosarcoma (OS) is a malignant bone tumor that threatenshumanhealth. Surgical removal of the tumor and followed by implantationwith a graft is the golden standard for its clinical treatment. However,avoiding recurrence by enhancing the antitumor properties of the implantsand improving osteogenesis around the implants remain a challenge.Here, we developed a layered double hydroxide (LDH) coated magnesium(Mg) alloy and loaded it with celastrol. The celastrol loaded Mg alloyexhibited enhanced corrosion resistance and sustained release of celastrol. In vitro cell culture suggested that the modified Mg alloyloaded with an appropriate amount of celastrol significantly inhibitedthe proliferation and migration of bone tumor cells while having littleinfluence on normal cells. A mechanistic study revealed that the celastrol loadedMg alloy upregulated reactive oxygen species (ROS) generation in bonetumor cells, resulting in mitochondrial dysfunction due to reducedmembrane potential, thereby inducing bone tumor cell apoptosis. Furthermore,it was found that celastrol induced autophagy in tumor cells inhibitedcell apoptosis in the initial 6 h. After & GE;12 h of culture,inhibition of the PI3K Akt mTOR signaling pathway was noted, resultingin excessive autophagy in tumor cells, finally causing cell apoptosis.The celatsrol loaded Mg alloy also exhibited effective antitumor propertiesin a subcutaneous tumor model. In vitro tartrate resistantacid phosphatase (TRAP) staining and gene expression results revealedthat the modified Mg alloy reduced the viability of osteoclasts, inducinga potential pathway for the increased bone regeneration around themodified Mg alloy seen in vivo. Together, the resultsof our study show that the celatsrol loaded Mg alloy might be a promisingimplant for treating OS.
C1 [Cheng, Shi; Shao, Hongwei; Yin, Dong; Zhou, Jielong; Xie, Juning; Zhang, Yu; Peng, Feng] Southern Med Univ, Guangdong Prov Peoples Hosp, Med Res Inst, Guangdong Acad Med Sci,Dept Orthoped, Guangzhou 510080, Peoples R China.
   [Cheng, Shi; Zhang, Yu; Peng, Feng] GuangDong Engn Technol Res Ctr Funct Repair Bone, Guangzhou 510080, Peoples R China.
   [Jian, Linjia; Wang, Donghui] Hebei Univ Technol, Sch Hlth Sci & Biomed Engn, Tianjin 300130, Peoples R China.
C3 Southern Medical University   China; Guangdong Academy of Medical
   Sciences & Guangdong General Hospital; Hebei University of Technology
RP Zhang, Y; Peng, F (通讯作者)，Southern Med Univ, Guangdong Prov Peoples Hosp, Med Res Inst, Guangdong Acad Med Sci,Dept Orthoped, Guangzhou 510080, Peoples R China.; Zhang, Y; Peng, F (通讯作者)，GuangDong Engn Technol Res Ctr Funct Repair Bone, Guangzhou 510080, Peoples R China.; Wang, DH (通讯作者)，Hebei Univ Technol, Sch Hlth Sci & Biomed Engn, Tianjin 300130, Peoples R China.
EM zhangyu@gdph.org.cn; donghuiwang@hebut.edu.cn; pengfeng@gdph.org.cn
RI Wang, Donghui/A 8242 2019; shao, hongwei/GWC 1808 2022; YIN,
   DONG/AAF 2883 2020; Zhang, Ziyue/KSL 8395 2024; Cheng, Shi/F 5069 2011;
   Wang, Donghui/HMP 1218 2023; Peng, Feng/ABE 3834 2021
OI Wang, Donghui/0000 0002 1198 0978; Peng, Feng/0000 0003 2366 2253; 
FU GDPH Supporting Fund for Talent Program [KY012021462, KY0120220137];
   National Natural Science Foundation of China [52001076, 51901239];
   Natural Science Foundation of Guangdong Province, China
   [2021A1515110135]; NSFC Incubation Project of Guangdong Provincial
   People's Hospital [KY0120220044]; Medical Research Fund Project of
   Guangdong [A2022251]
FX This work was financially supported by the GDPH Supporting Fund for
   Talent Program (KY012021462 and KY0120220137), National Natural Science
   Foundation of China (Grant Nos. 52001076 and 51901239), Natural Science
   Foundation of Guangdong Province, China (Grant No. 2021A1515110135),
   NSFC Incubation Project of Guangdong Provincial People's Hospital (No.
   KY0120220044), and Medical Research Fund Project of Guangdong
   (A2022251).
CR Argenziano M, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14090923
   Bock FJ, 2020, NAT REV MOL CELL BIO, V21, P85, DOI 10.1038/s41580 019 0173 8
   Braicu C, 2022, SEMIN CANCER BIOL, V80, P218, DOI 10.1016/j.semcancer.2020.05.015
   Chen SR, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00104
   Chen X, 2020, THERANOSTICS, V10, P10290, DOI 10.7150/thno.46728
   Cheng S, 2021, ACS OMEGA, V6, P24575, DOI 10.1021/acsomega.1c03169
   Cheng S, 2021, BIOACT MATER, V6, P91, DOI 10.1016/j.bioactmat.2020.07.014
   Corson TW, 2007, CELL, V130, P769, DOI 10.1016/j.cell.2007.08.021
   Espiritu J, 2021, BIOACT MATER, V6, P4360, DOI 10.1016/j.bioactmat.2021.04.012
   Fang GH, 2020, J MATER CHEM B, V8, P10954, DOI 10.1039/d0tb01939a
   Geetha M, 2009, PROG MATER SCI, V54, P397, DOI 10.1016/j.pmatsci.2008.06.004
   Gill J, 2021, NAT REV CLIN ONCOL, V18, P609, DOI 10.1038/s41571 021 00519 8
   Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002
   Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615
   Idris AI, 2010, FASEB J, V24, P4545, DOI 10.1096/fj.10 164095
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Karaismailoglu B, 2021, KNEE, V33, P327, DOI 10.1016/j.knee.2021.10.014
   Lah NAC, 2019, PERTANIKA J SCI TECH, V27, P459
   Lee JW, 2016, P NATL ACAD SCI USA, V113, P716, DOI 10.1073/pnas.1518238113
   Li T, 2021, ACS BIOMATER SCI ENG, V7, P2774, DOI 10.1021/acsbiomaterials.1c00288
   Liu XH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1173 4
   Liu Y, 2020, NATURE, DOI 10.1038/s41586 020 1992 7
   Liu ZG, 2022, J THORAC CARDIOV SUR, V163, P469, DOI 10.1016/j.jtcvs.2020.10.137
   Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Luo Y, 2021, BIOACT MATER, V6, P3231, DOI 10.1016/j.bioactmat.2021.02.032
   Nanjundaiah SM, 2012, J BIOL CHEM, V287, P22216, DOI 10.1074/jbc.M112.356816
   Niinomi M, 2012, ACTA BIOMATER, V8, P3888, DOI 10.1016/j.actbio.2012.06.037
   Okazaki Y, 2005, MATER TRANS, V46, P1610, DOI 10.2320/matertrans.46.1610
   Pan B, 2020, CIRC RES, V127, P502, DOI 10.1161/CIRCRESAHA.119.316007
   Peng F, 2021, BIOMATER SCI UK, V9, P8202, DOI 10.1039/d1bm01075a
   Peng F, 2016, ACS APPL MATER INTER, V8, P35033, DOI 10.1021/acsami.6b12974
   Peng HZ, 2021, ACTA BIOMATER, V128, P514, DOI 10.1016/j.actbio.2021.04.051
   Perelman A, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.171
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Renda G, 2022, PHYTOCHEM REV, V21, P537, DOI 10.1007/s11101 021 09785 x
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276
   Shi JF, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.558741
   Shoaib Z, 2022, BRIT J PHARMACOL, V179, P201, DOI 10.1111/bph.15713
   Sumner DR, 2015, J BIOMECH, V48, P797, DOI 10.1016/j.jbiomech.2014.12.021
   Weng WJ, 2021, ACTA BIOMATER, V130, P80, DOI 10.1016/j.actbio.2021.06.004
   Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281
   Yao ZH, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 97090 0
   Ye SJ, 2020, CIRC RES, V126, P1007, DOI 10.1161/CIRCRESAHA.119.315861
   Yin ZZ, 2020, J MAGNES ALLOY, V8, P42, DOI 10.1016/j.jma.2019.09.008
   Yu YQ, 2018, ACTA BIOMATER, V71, P215, DOI 10.1016/j.actbio.2018.02.023
   Zan R, 2021, SCI CHINA MATER, V64, P1007, DOI 10.1007/s40843 020 1509 2
   Zhang DD, 2021, J ALLOY COMPD, V853, DOI 10.1016/j.jallcom.2020.157010
   Zhang L, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.758921
   Zhou Zilan, 2021, Nanotheranostics, V5, P321, DOI 10.7150/ntno.56401
   Zhu WG, 2019, J BUON, V24, P1181
NR 51
TC 9
Z9 10
U1 13
U2 61
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD AUG 2
PY 2023
VL 9
IS 8
BP 4940
EP 4952
DI 10.1021/acsbiomaterials.3c00357
EA AUG 2023
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA O8DV2
UT WOS:001041641700001
PM 37530388
DA 2025 08 17
ER

PT J
AU Liao, L
   Yang, X
   Su, X
   Hu, C
   Zhu, X
   Yang, N
   Chen, X
   Shi, S
   Shi, S
   Jin, Y
AF Liao, L.
   Yang, X.
   Su, X.
   Hu, C.
   Zhu, X.
   Yang, N.
   Chen, X.
   Shi, S.
   Shi, S.
   Jin, Y.
TI Redundant miR 3077 5p and miR 705 mediate the shift of mesenchymal stem
   cell lineage commitment to adipocyte in osteoporosis bone marrow
SO CELL DEATH & DISEASE
LA English
DT Article
DE mesenchymal stem cells; microRNA; osteoporosis; cell differentiation
ID OSTEOGENIC DIFFERENTIATION; TRANSCRIPTION FACTOR; HOXA10; RUNX2; FAT;
   OSTEOBLASTOGENESIS; ADIPOGENESIS; INHIBITION; PROTEINS; GENES
AB During the process of aging, especially for postmenopausal females, the cell lineage commitment of mesenchymal stem cells (MSCs) shift to adipocyte in bone marrow, resulting in osteoporosis. However, the cell intrinsic mechanism of this cell lineage commitment switch is poorly understood. As the post transcription regulation by microRNAs (miRNAs) has a critical role in MSCs differentiation and bone homeostasis, we performed comprehensive miRNAs profiling and found miR 705 and miR 3077 5p were significantly enhanced in MSCs from osteoporosis bone marrow. Both miR 705 and miR 3077 5p acted as inhibitors of MSCs osteoblast differentiation and promoters of adipocyte differentiation, by targeting on the 3'untranslated region (3'UTR) of HOXA10 and RUNX2 mRNA separately. Combined inhibition of miR 705 and miR 3077 5p rescued the cell lineage commitment disorder of MSCs through restoring HOXA10 and RUNX2 protein level. Furthermore, we found excessive TNF alpha and reactive oxygen species caused by estrogen deficiency led to the upregulation of both miRNAs through NF kappa B pathway. In conclusion, our findings showed that redundant miR 705 and miR 3077 5p synergistically mediated the shift of MSCs cell lineage commitment to adipocyte in osteoporosis bone marrow, providing new insight into the etiology of osteoporosis at the post transcriptional level. Moreover, the rescue of MSCs lineage commitment disorder by regulating miRNAs expression suggested a novel potential therapeutic target for osteoporosis as well as stem cell mediated regenerative medicine. Cell Death and Disease (2013) 4, e600; doi:10.1038/cddis.2013.130; published online 18 April 2013
C1 [Liao, L.; Hu, C.; Jin, Y.] Fourth Mil Med Univ, Res & Dev Ctr Tissue Engn, Xian 710032, Peoples R China.
   [Liao, L.; Jin, Y.] Fourth Mil Med Univ, Dept Oral Histol & Pathol, Sch Stomatol, Xian 710032, Peoples R China.
   [Yang, X.] Fourth Mil Med Univ, Dept Prosthet, Sch Stomatol, Xian 710032, Peoples R China.
   [Yang, X.] ZunYi Med Coll, Sch Stomatol, Dept Prosthet, Zunyi, Peoples R China.
   [Su, X.] Xi An Jiao Tong Univ, Stomatol Hosp, Dept Orthodont, Xian 710049, Peoples R China.
   [Hu, C.] Engn Technol Ctr Tissue Engn Xian, Xian, Peoples R China.
   [Zhu, X.] Yantai Stomatol Hosp, Dept Pediat Dent, Yantai, Peoples R China.
   [Yang, N.] PLA 309th Hosp, Dept Stomatol, Beijing, Peoples R China.
   [Chen, X.] Zhejiang Univ, Dept Orthodont, Stomatol Hosp, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China.
   [Shi, S.] Univ So Calif, Ctr Craniofacial Mol Biol, Ostrow Sch Dent, Los Angeles, CA 90033 USA.
   [Shi, S.] 306 Hosp PLA, Dept Stomatol, Beijing 100101, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University; Zunyi Medical University; Xi'an Jiaotong University;
   Zhejiang University; University of Southern California
RP Jin, Y (通讯作者)，Fourth Mil Med Univ, Res & Dev Ctr Tissue Engn, 145 West Changle Rd, Xian 710032, Peoples R China.
EM shishengen@sohu.com; yanjin@fmmu.edu.cn
RI Liao, Li/U 6866 2017; Jin, Yan/I 4204 2013; Hu, Cheng Hu/I 4210 2013
OI Liao, Li/0000 0003 0030 1009; Hu, Cheng Hu/0000 0003 2443 6485
FU National Major Scientific Research Program of China [2010CB944800,
   2011CB964700]; Nature Science Foundation of China [81020108019,
   31030033]
FX This work was supported by grants from the National Major Scientific
   Research Program of China (2010CB944800 and 2011CB964700) and the Nature
   Science Foundation of China (81020108019, 31030033).
CR Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035
   Chan GK, 2002, GERONTOLOGY, V48, P62, DOI 10.1159/000048929
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chen JR, 2012, FASEB J, V26, P1131, DOI 10.1096/fj.11 197822
   de la Fuente L, 2005, DEV BIOL, V282, P294, DOI 10.1016/j.ydbio.2005.03.036
   Edgar CM, 2007, BONE, V40, P1389, DOI 10.1016/j.bone.2007.01.001
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Guo WH, 2009, BIOMATERIALS, V30, P6708, DOI 10.1016/j.biomaterials.2009.08.034
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hassan MQ, 2007, MOL CELL BIOL, V27, P3337, DOI 10.1128/MCB.01544 06
   Hassan MQ, 2009, CELLS TISSUES ORGANS, V189, P122, DOI 10.1159/000151453
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kassem M, 2011, AGING CELL, V10, P191, DOI 10.1111/j.1474 9726.2011.00669.x
   Kawai M, 2010, NAT REV ENDOCRINOL, V6, P629, DOI 10.1038/nrendo.2010.155
   Kim M, 2011, LANCET ONCOL, V12, P319, DOI 10.1016/S1470 2045(11)70067 5
   Kirkland JL, 2002, EXP GERONTOL, V37, P757, DOI 10.1016/S0531 5565(02)00014 1
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Liu YL, 2011, STEM CELLS, V29, P1804, DOI 10.1002/stem.728
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Nishikawa K, 2010, J CLIN INVEST, V120, P3455, DOI 10.1172/JCI42528
   Rodríguez JP, 2008, CURR STEM CELL RES T, V3, P208, DOI 10.2174/157488808785740325
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   ROSEN CJ, 1994, J CELL BIOCHEM, V56, P348, DOI 10.1002/jcb.240560311
   Rosen CJ, 2009, CRIT REV EUKAR GENE, V19, P109, DOI 10.1615/CritRevEukarGeneExpr.v19.i2.20
   Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057
   Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Ye L, 2012, CELL STEM CELL, V11, P50, DOI 10.1016/j.stem.2012.04.009
   Yu JM, 2011, AGING CELL, V10, P66, DOI 10.1111/j.1474 9726.2010.00646.x
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
NR 37
TC 115
Z9 132
U1 0
U2 55
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD APR
PY 2013
VL 4
AR e600
DI 10.1038/cddis.2013.130
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 132NL
UT WOS:000318075500034
PM 23598412
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lou, SH
   Lv, HC
   Chen, YX
   Zhang, LC
   Tang, PF
AF Lou, Shenghan
   Lv, Houchen
   Chen, Yuxiang
   Zhang, Licheng
   Tang, Peifu
TI Use of combination therapy in the treatment of primary osteoporosis:
   protocol for a network meta analysis of randomised trials
SO BMJ OPEN
LA English
DT Article
ID BONE MINERAL DENSITY; PARATHYROID HORMONE 1 84; POSTMENOPAUSAL WOMEN;
   VERTEBRAL FRACTURE; TERIPARATIDE RHPTH(1 34); IBANDRONATE COMBINATION;
   NONVERTEBRAL FRACTURES; WORLDWIDE PREVALENCE; SEQUENTIAL ANALYSIS; RISK
   REDUCTION
AB Introduction: The existing medications approved for treatment of primary osteoporosis can be divided into antiresorptive drugs and anabolic drugs. According to the mechanisms of action, the combined therapy may produce a synergistic effect on bone mineral density (BMD) compared with monotherapy, and thus improves the efficacy of fracture resistance. This network meta analysis aims to compare the efficacies of different combined methods for the treatment of primary osteoporosis.
   Methods and analysis: MEDLINE, EMBASE and Cochrane databases will be searched to identify all randomised controlled trials (RCTs) and quasi RCTs that evaluate the effectiveness of combined therapy versus monotherapy for primary osteoporosis. The primary outcome will be the BMD changes at the lumbar spine and total hip, and the secondary outcome will be the risks of vertebral fracture and non vertebral fracture. The efficacies of different combined methods will be compared via traditional pairwise meta analysis, trial sequential analysis and Bayesian network meta analysis. Risk of bias will be assessed using the Cochrane tool and the quality of evidence will be assessed using the Grading of Recommendations Assessment, Development and Evaluation for network meta analysis.
   Ethics and dissemination: Ethical approval is not required because this is a protocol for a systematic review without including confidential personal data or data on interventions on patients. Our results will be published in a peer review journal.
C1 [Lou, Shenghan; Lv, Houchen; Chen, Yuxiang; Zhang, Licheng; Tang, Peifu] Chinese Peoples Liberat Army Gen Hosp, Dept Orthoped, Beijing, Peoples R China.
C3 Chinese People's Liberation Army General Hospital
RP Tang, PF (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Orthoped, Beijing, Peoples R China.
EM pftang301@163.com
RI Lyu, Houchen/AAW 3614 2020; Lou, Shenghan/LEM 4366 2024
OI Tang, Peifu/0000 0003 4279 1704; Lou, Shenghan/0000 0001 8826 3160;
   Chen, Yuxiang/0000 0003 1458 5743; 
CR Austin M, 2012, J BONE MINER RES, V27, P687, DOI 10.1002/jbmr.1472
   Black DM, 2012, NEW ENGL J MED, V366, P2051, DOI 10.1056/NEJMp1202623
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Brok J, 2009, INT J EPIDEMIOL, V38, P287, DOI 10.1093/ije/dyn188
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654
   Chen PQ, 2006, J BONE MINER RES, V21, P1785, DOI 10.1359/JBMR.060802
   Compston J, 2012, ENDOCRINE, V41, P11, DOI 10.1007/s12020 011 9554 2
   Cosman F, 2001, J BONE MINER RES, V16, P925, DOI 10.1359/jbmr.2001.16.5.925
   Cosman F, 1998, J BONE MINER RES, V13, P1051, DOI 10.1359/jbmr.1998.13.6.1051
   Cosman Felicia, 2014, Bonekey Rep, V3, P518, DOI 10.1038/bonekey.2014.13
   Cosman F, 2013, J BONE MINER RES, V28, P1328, DOI 10.1002/jbmr.1853
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Cosman F, 2009, J CLIN ENDOCR METAB, V94, P3772, DOI 10.1210/jc.2008 2719
   Cranney A, 2002, ENDOCR REV, V23, P524, DOI 10.1210/er.2001 4002
   Cranney A, 2002, ENDOCR REV, V23, P540, DOI 10.1210/er.2001 6002
   Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002 9343(01)01124 X
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Deal C, 2005, J BONE MINER RES, V20, P1905, DOI 10.1359/JBMR.050714
   Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767
   Finkelstein JS, 2006, J CLIN ENDOCR METAB, V91, P2882, DOI 10.1210/jc.2006 0190
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009 1703
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Fogelman I, 2008, CALCIFIED TISSUE INT, V83, P85, DOI 10.1007/s00223 008 9152 3
   Gelman A., 1992, STAT SCI, V7, P457, DOI DOI 10.1214/SS/1177011136
   Higgins JP., 2011, BMJ, V343, pd5928, DOI DOI 10.1136/BMJ.D5928
   Higgins JPT, 2003, BMJ BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hochberg MC, 2002, J CLIN ENDOCR METAB, V87, P1586, DOI 10.1210/jc.87.4.1586
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14 2385
   Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Johnell O, 2004, OSTEOPOROSIS INT, V15, P38, DOI 10.1007/s00198 003 1490 4
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914
   Li W, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001156
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Lu GB, 2006, J AM STAT ASSOC, V101, P447, DOI 10.1198/016214505000001302
   Moher D, 2010, INT J SURG, V8, P336, DOI [10.1371/journal.pmed.1000097, 10.1186/2046 4053 4 1, 10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.i4086]
   Morin SN, 2013, CURR OSTEOPOROS REP, V11, P263, DOI 10.1007/s11914 013 0168 x
   Muschitz C, 2013, J BONE MINER RES, V28, P196, DOI 10.1002/jbmr.1716
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Puhan MA, 2014, BMJ BRIT MED J, V349, DOI 10.1136/bmj.g5630
   Quesada Gómez JM, 2011, OSTEOPOROSIS INT, V22, P2529, DOI 10.1007/s00198 010 1460 6
   Reeve J, 2001, J BONE MINER METAB, V19, P102, DOI 10.1007/s007740170048
   Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016
   Schafer AL, 2013, OSTEOPOROSIS INT, V24, P2591, DOI 10.1007/s00198 013 2349 y
   Schafer AL, 2012, J CLIN ENDOCR METAB, V97, P3522, DOI 10.1210/jc.2012 1844
   Seibel MJ, 2004, J BONE MINER RES, V19, P323, DOI 10.1359/JBMR.0301231
   Shen LX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026267
   Song JF, 2014, MED SCI MONITOR, V20, P2624, DOI 10.12659/MSM.892581
   Spiegelhalter DJ, 2002, J R STAT SOC B, V64, P583, DOI 10.1111/1467 9868.00353
   Ste Marie LG, 2006, J BONE MINER RES, V21, P283, DOI 10.1359/JBMR.051020
   Thorsteinsson AL, 2014, OSTEOPOROSIS INT, V25, P1937, DOI 10.1007/s00198 014 2684 7
   Torgerson DJ, 2001, JAMA J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Walker MD, 2013, ENDOCRINE, V44, P237, DOI 10.1007/s12020 012 9819 4
   Wermers RA, 2008, OSTEOPOROSIS INT, V19, P1055, DOI 10.1007/s00198 007 0557 z
   Wetterslev J, 2008, J CLIN EPIDEMIOL, V61, P64, DOI 10.1016/j.jclinepi.2007.03.013
   Whitaker M, 2012, NEW ENGL J MED, V366, P2048, DOI 10.1056/NEJMp1202619
   Zhang QG, 2015, INT J CLIN EXP MED, V8, P3338
NR 63
TC 3
Z9 4
U1 0
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044 6055
J9 BMJ OPEN
JI BMJ Open
PY 2016
VL 6
IS 11
AR e012802
DI 10.1136/bmjopen 2016 012802
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA EG8JQ
UT WOS:000391303400117
PM 28186942
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Maung, WM
   Nakata, H
   Miura, M
   Miyasaka, M
   Kim, YK
   Kasugai, S
   Kuroda, S
AF Maung, Wai Myo
   Nakata, Hidemi
   Miura, Motoi
   Miyasaka, Munemitsu
   Kim, You Kyoung
   Kasugai, Shohei
   Kuroda, Shinji
TI Low Intensity Pulsed Ultrasound Stimulates Osteogenic Differentiation of
   Periosteal Cells In Vitro
SO TISSUE ENGINEERING PART A
LA English
DT Article
DE LIPUS; low intensity pulsed ultrasound; periosteum derived cells;
   osteogenic differentiation; BMP Smad cannonical pathway; gelatin
ID MESENCHYMAL STEM CELLS; OSTERIX EXPRESSION; UP REGULATION; BONE;
   CULTURE; LIPUS; DLX5
AB Adequate bone volume is required for osseointegrated implants to restore lost teeth and oral function. Several studies have demonstrated potential advantage of stem cells in regenerative medicine using osteoblasts. The periosteum is composed of osteoblasts, fibroblasts, and osteoprogenitor cells. It may be an alternative source for bone tissue engineering because of easy isolation and rapid proliferation in vivo and in vitro. Low intensity pulsed ultrasound (LIPUS) has proved successful in recoveries from nonunions, delayed unions, and fracture of the bone in both animal experiments and clinical treatments. The study was to investigate the influence of LIPUS on the osteogenic differentiation in murine periosteum derived cells (PDCs) and the underlying mechanism of LIPUS. PDCs were treated daily with LIPUS for 20 min up to 21 days with 3 MHz frequency, 30 mW/cm(2) intensity, and pulse repetition frequency of 1 kHz. The effects of LIPUS on cell proliferation and viability were investigated. Osteogenic differentiation was analyzed by alkaline phosphatase (ALP) positive cell staining, ALP activity assay, mineralized nodule formation, real time reverse transcription polymerase chain reaction, as well as western blotting. The results indicated that ultrasound stimulation did not significantly affect the proliferation of PDCs. But LIPUS significantly increased ALP activity on day 7 and markedly promoted formation of mineralized nodules on day 21. mRNA expression of ALP and osteocalcin was significantly upregulated by stimulation with LIPUS. LIPUS enhanced gene expression of both bone morphogenetic protein 2 (BMP 2) and osterix only in the presence of osteogenic medium. LIPUS stimulation did not affect Smad 1 and Smad 5 protein expression, but significantly upregulated protein levels of BMP 2 and phosphor Smad 1/5/9 in PDCs. Thus, LIPUS stimulation increased early osteogenic differentiation in a normal medium and further enhanced expression of BMP 2 and subsequent osterix expression through the canonical Smad signaling pathway in an osteogenic medium, leading to mineral apposition. Therefore, LIPUS might have potential to promote osteogenesis in PDCs.
   Impact statement
   There are few studies on periosteum derived cells (PDCs) because conventional methods of their isolation are relatively difficult to procure abundant cells for cell culture and the total cell numbers are limited. In this study, a modified isolation technique of murine calvarial PDCs using gelatin is described. PDCs were initiated to emerge as early as day 3 and showed increased proliferation, which can be used for further studies.
   Low intensity pulsed ultrasound stimulation increased early osteogenic differentiation in a normal medium and further enhanced expression of bone morphogenic protein 2 and subsequent osterix expression through the canonical Smad signaling pathway in an osteogenic medium, leading to mineral apposition.
C1 [Maung, Wai Myo; Nakata, Hidemi; Miura, Motoi; Miyasaka, Munemitsu; Kim, You Kyoung; Kasugai, Shohei; Kuroda, Shinji] Tokyo Med & Dent Univ TMDU, Oral Implantol & Regenerat Dent Med Dept, Tokyo, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU)
RP Nakata, H; Kuroda, S (通讯作者)，Tokyo Med & Dent Univ TMDU, Oral Implantol & Regenerat Dent Med Dept, Bunkyo Ku, Yushima 1 5 45, Tokyo 1138510, Japan.
EM hidemi.irm@tmd.ac.jp; skuroda.mfc@tmd.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT),
   Japan
FX This research was kindly supported by a research grant provided by the
   Ministry of Education, Culture, Sports, Science and Technology (MEXT),
   Japan.
CR An YX, 2018, AM J TRANSL RES, V10, P67
   Angle SR, 2011, ULTRASONICS, V51, P281, DOI 10.1016/j.ultras.2010.09.004
   Anjos Afonso F, 2004, J CELL SCI, V117, P5655, DOI 10.1242/jcs.01488
   Argadine HM, 2005, ULTRASON, P996
   Arikawa T, 2004, J CELL PHYSIOL, V200, P400, DOI 10.1002/jcp.20031
   Atherton P, 2017, J CELL SCI, V130, P2277, DOI 10.1242/jcs.192781
   Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978 1 61779 415 5_2
   Berebichez Fridman Roberto, 2018, Sultan Qaboos Univ Med J, V18, pe264, DOI 10.18295/squmj.2018.18.03.002
   Caroti CM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13477 y
   Chen XW, 2007, MOL CELL BIOL, V27, P3313, DOI 10.1128/MCB.01476 06
   Chenard KE, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/601549
   Cornelissen M., 2007, TRENDS BIOMATERIALS, P191
   de Lageneste OD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03124 z
   Debnath S, 2018, NATURE, V562, P133, DOI 10.1038/s41586 018 0554 8
   Fujii Y, 2017, J TOKYO WOMENS MED U, V87, P108, DOI DOI 10.24488/JTWMU.87.4_108
   Fung CH, 2014, ULTRASONICS, V54, P850, DOI 10.1016/j.ultras.2013.10.013
   Goitre Luca, 2012, J Signal Transduct, V2012, P807682, DOI 10.1155/2012/807682
   Gregg D, 2004, ANTIOXID REDOX SIGN, V6, P757, DOI 10.1089/1523086041361604
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Harrison A, 2016, ULTRASONICS, V70, P45, DOI 10.1016/j.ultras.2016.03.016
   Hemery X, 2011, ORTHOP TRAUMATOL SUR, V97, P51, DOI 10.1016/j.otsr.2010.09.016
   Horwitz M.E, 2007, CURRENT PROTOCOLS IM, p22A21
   Huang S, 2015, J ORTHOP TRANSL, V3, P26, DOI 10.1016/j.jot.2014.07.005
   Huang Z, 2010, CYTOKINE, V51, P305, DOI 10.1016/j.cyto.2010.06.002
   Inubushi T, 2008, J PERIODONTOL, V79, P1984, DOI [10.1902/jop.2008.080081, 10.1902/jop.2008.080081 ]
   Jiang XX, 2019, IEEE T BIO MED ENG, V66, P2704, DOI 10.1109/TBME.2018.2889669
   Kim YK, 2016, STEM CELL TRANSL MED, V5, P227, DOI 10.5966/sctm.2015 0013
   Kumagai K, 2012, J ORTHOP RES, V30, P1516, DOI 10.1002/jor.22103
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Li XY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01309
   Mandal CC, 2016, J BIOL CHEM, V291, P1148, DOI 10.1074/jbc.M115.668939
   Marvel S, 2010, IEEE T ULTRASON FERR, V57, P1977, DOI 10.1109/TUFFC.2010.1645
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Miyabe M., 2010, KITASATO MED, V40, P20
   Miyasaka M, 2015, TISSUE ENG PT A, V21, P2829, DOI [10.1089/ten.tea.2015.0234, 10.1089/ten.TEA.2015.0234]
   Nakanishi Y, 2011, J HARD TISSUE BIOL, V20, P139
   Parvizi J, 2002, J ORTHOPAED RES, V20, P51, DOI 10.1016/S0736 0266(01)00069 9
   Semenkov V, 2019, AIMS MOL SCI, V6, P38, DOI 10.3934/molsci.2019.2.38
   Shi KQ, 2016, INT J CLIN EXP PATHO, V9, P12581
   Shiraishi R, 2011, J PERIODONTOL, V82, P1498, DOI 10.1902/jop.2011.100627
   Suzuki Akito, 2009, J Oral Sci, V51, P29
   Tai H, 1997, ENDOCRINOLOGY, V138, P2372, DOI 10.1210/en.138.6.2372
   Takiguchi T, 1999, J PERIODONTAL RES, V34, P431
   Teoh Kar Hao, 2018, Foot (Edinb), V35, P52, DOI 10.1016/j.foot.2018.01.004
   Tropel P, 2004, EXP CELL RES, V295, P395, DOI 10.1016/j.yexcr.2003.12.030
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Xie SC, 2019, J CELL BIOCHEM, V120, P15823, DOI 10.1002/jcb.28853
   Xu WF, 2016, J ORTHOP RES, V34, P1725, DOI 10.1002/jor.23196
   Xue H, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0074366, 10.1371/journal.pone.0068926]
   Yagi K, 2003, J CELL BIOCHEM, V88, P1077, DOI 10.1002/jcb.10467
   Yoshida A, 2013, J HARD TISSUE BIOL, V22, P301, DOI 10.2485/jhtb.22.301
   Zeller KS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064897
   Zhang F, 2003, BLOOD, V102, P2115, DOI 10.1182/blood 2003 01 0049
   Zhang ZL, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180087
NR 55
TC 32
Z9 33
U1 2
U2 26
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD JAN 1
PY 2021
VL 27
IS 1 2
BP 63
EP 73
DI 10.1089/ten.tea.2019.0331
EA MAY 2020
PG 11
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA PT5YL
UT WOS:000536274900001
PM 32164486
DA 2025 08 17
ER

PT J
AU Tamura, H
   Maekawa, T
   Domon, H
   Hiyoshi, T
   Hirayama, S
   Isono, T
   Sasagawa, K
   Yonezawa, D
   Takahashi, N
   Oda, M
   Maeda, T
   Tabeta, K
   Terao, Y
AF Tamura, Hikaru
   Maekawa, Tomoki
   Domon, Hisanori
   Hiyoshi, Takumi
   Hirayama, Satoru
   Isono, Toshihito
   Sasagawa, Karin
   Yonezawa, Daisuke
   Takahashi, Naoki
   Oda, Masataka
   Maeda, Takeyasu
   Tabeta, Koichi
   Terao, Yutaka
TI Effects of Erythromycin on Osteoclasts and Bone Resorption via DEL 1
   Induction in Mice
SO ANTIBIOTICS BASEL
LA English
DT Article
DE macrolides; periodontitis; osteoclastogenesis; DEL 1
ID DEVELOPMENTAL ENDOTHELIAL LOCUS 1; EXPERIMENTAL PERIODONTITIS; MACROLIDE
   THERAPY; AZITHROMYCIN; PROTEIN; EXPRESSION; ELECTROPORATION;
   EXACERBATIONS; INFLAMMATION; ANTIBIOTICS
AB Macrolides are used to treat various infectious diseases, including periodontitis. Furthermore, macrolides are known to have immunomodulatory effects; however, the underlying mechanism of their action remains unclear. DEL 1 has emerged as an important factor in homeostatic immunity and osteoclastogenesis. Specifically, DEL 1 is downregulated in periodontitis tissues. Therefore, in the present study, we investigated whether the osteoclastogenesis inhibitory effects of erythromycin (ERM) are mediated through upregulation of DEL 1 expression. We used a ligature induced periodontitis model in C57BL/6Ncrl wild type or DEL 1 deficient mice and in vitro cell based mechanistic studies to investigate how ERM inhibits alveolar bone resorption. As a result of measuring alveolar bone resorption and gene expression in the tooth ligation model, ERM treatment reduced bone loss by increasing DEL 1 expression and decreasing the expression of osteoclast related factors in wild type mice. In DEL 1 deficient mice, ERM failed to suppress bone loss and gene expression of osteoclast related factors. In addition, ERM treatment downregulated osteoclast differentiation and calcium resorption in in vitro experiments with mouse bone marrow derived macrophages. In conclusion, ERM promotes the induction of DEL 1 in periodontal tissue, which may regulate osteoclastogenesis and decrease inflammatory bone resorption. These findings suggest that ERM may exert immunomodulatory effects in a DEL 1 dependent manner.
C1 [Tamura, Hikaru; Maekawa, Tomoki; Domon, Hisanori; Hiyoshi, Takumi; Hirayama, Satoru; Isono, Toshihito; Sasagawa, Karin; Terao, Yutaka] Niigata Univ, Div Microbiol & Infect Dis, Grad Sch Med & Dent Sci, Niigata 9518514, Japan.
   [Tamura, Hikaru; Maekawa, Tomoki; Domon, Hisanori; Maeda, Takeyasu; Terao, Yutaka] Niigata Univ, Ctr Adv Oral Sci, Grad Sch Med & Dent Sci, Niigata 9518514, Japan.
   [Tamura, Hikaru; Hiyoshi, Takumi; Sasagawa, Karin; Takahashi, Naoki; Tabeta, Koichi] Niigata Univ, Grad Sch Med & Dent Sci, Div Periodontol, Niigata 9518514, Japan.
   [Yonezawa, Daisuke] Niigata Univ, Div Oral Sci Hlth Promot, Grad Sch Med & Dent Sci, Niigata 9518514, Japan.
   [Oda, Masataka] Kyoto Pharmaceut Univ, Dept Microbiol & Infect Control Sci, Yamashita 6078414, Japan.
C3 Niigata University; Niigata University; Niigata University; Niigata
   University; Kyoto Pharmaceutical University
RP Maekawa, T; Domon, H (通讯作者)，Niigata Univ, Div Microbiol & Infect Dis, Grad Sch Med & Dent Sci, Niigata 9518514, Japan.; Maekawa, T; Domon, H (通讯作者)，Niigata Univ, Ctr Adv Oral Sci, Grad Sch Med & Dent Sci, Niigata 9518514, Japan.
EM h tamura@dent.niigata u.ac.jp; maekawa t@dent.niigata u.ac.jp;
   hisa domon@dent.niigata u.ac.jp; hiyoshi@dent.niigata u.ac.jp;
   shirayama@dent.niigata u.ac.jp; tisono@dent.niigata u.ac.jp;
   k sasagawa@dent.niigata u.ac.jp; yonezawa01@dent.niigata u.ac.jp;
   takahashi n@dent.niigata u.ac.jp; moda@mb.kyoto phu.ac.jp;
   maedat@dent.niigata u.ac.jp; koichi@dent.niigata u.ac.jp;
   terao@dent.niigata u.ac.jp
RI Maekawa, Tomoki/AAA 4673 2020; Domon, H/ADQ 4045 2022; Maeda,
   Takeyasu/K 3784 2014; Tamura, Hikaru/LCE 0280 2024
OI Maekawa, Tomoki/0000 0002 4597 1316; Sasagawa,
   Karin/0009 0006 0016 3848; Hirayama, Satoru/0000 0003 0965 8733; Domon,
   Hisanori/0000 0002 2911 826X; Terao, Yutaka/0000 0002 4450 5583;
   Takahashi, Naoki/0000 0001 8952 7260; Maeda,
   Takeyasu/0000 0001 5317 7510
FU JSPS KAKENHI [17KK0165, 17K19747, 19H03828, 19K22706]; Takeda Science
   Foundation; Uehara Memorial Foundation; Terumo Life Science Foundation;
   Kowa Life Science Foundation; AMED Interstellar Initiative;
   Grants in Aid for Scientific Research [17K19747, 17KK0165, 19H03828,
   19K22706, 20K21671, 20H03858] Funding Source: KAKEN
FX This research was funded by grants from JSPS KAKENHI (17KK0165,
   17K19747, 19H03828, 19K22706), the Takeda Science Foundation, the Uehara
   Memorial Foundation, the Terumo Life Science Foundation, Kowa Life
   Science Foundation, and AMED Interstellar Initiative to Tomoki Maekawa.
CR Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623
   Amsden GW, 2005, J ANTIMICROB CHEMOTH, V55, P10, DOI 10.1093/jac/dkh519
   Amsden GW, 2001, INT J ANTIMICROB AG, V18, pS11, DOI 10.1016/S0924 8579(01)00410 1
   Aoki Nonaka Y, 2019, J PERIODONTOL, V90, P1160, DOI [10.1002/WER.18 0630, 10.1002/JPER.18 0630]
   Arredondo A, 2019, ORAL DIS, V25, P860, DOI 10.1111/odi.13043
   Arsic B, 2018, INT J ANTIMICROB AG, V51, P283, DOI 10.1016/j.ijantimicag.2017.05.020
   Basu A, 2018, MOLECULES, V23, DOI 10.3390/molecules23071786
   Boyer E, 2020, J ORAL MICROBIOL, V12, DOI 10.1080/20002297.2020.1832837
   Cervin A, 2007, RHINOLOGY, V45, P259
   Chavakis E, 2009, THROMB HAEMOSTASIS, V102, P191, DOI 10.1160/TH08 12 0844
   Choi EY, 2015, MOL PSYCHIATR, V20, P880, DOI 10.1038/mp.2014.146
   Choi Eun Young, 2009, Immune Netw, V9, P153, DOI 10.4110/in.2009.9.5.153
   Cui YA, 2018, INT J CHRONIC OBSTR, V13, P3813, DOI 10.2147/COPD.S181246
   Dasgupta SK, 2012, CIRCULATION, V125, P1664, DOI 10.1161/CIRCULATIONAHA.111.068833
   Dinos GP, 2017, BRIT J PHARMACOL, V174, P2967, DOI 10.1111/bph.13936
   Gannon SC, 2013, J CELL PHYSIOL, V228, P1098, DOI 10.1002/jcp.24259
   Hajishengallis G, 2019, TRENDS MOL MED, V25, P444, DOI 10.1016/j.molmed.2019.02.010
   Hajishengallis G, 2015, J LEUKOCYTE BIOL, V98, P539, DOI 10.1189/jlb.3VMR1014 468R
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Hanayama R, 2004, J IMMUNOL, V172, P3876, DOI 10.4049/jimmunol.172.6.3876
   Hashimoto M, 2016, DEV BIOL, V418, P1, DOI 10.1016/j.ydbio.2016.07.017
   Hashimoto M, 2015, SCI REP UK, V5, DOI 10.1038/srep11315
   Heta Saimir, 2018, Med Sci (Basel), V6, DOI 10.3390/medsci6010006
   Hidai C, 1998, GENE DEV, V12, P21, DOI 10.1101/gad.12.1.21
   Hidai C, 2007, CELL TISSUE RES, V330, P83, DOI 10.1007/s00441 007 0456 9
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Hiyoshi T, 2020, ARCH ORAL BIOL, V112, DOI 10.1016/j.archoralbio.2020.104679
   Hyun YM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc4882
   Jelic D, 2016, ANTIBIOTICS BASEL, V5, DOI 10.3390/antibiotics5030029
   Jepsen K, 2016, PERIODONTOL 2000, V71, P82, DOI 10.1111/prd.12121
   Jiang M, 2018, COMPLEMENT THER MED, V38, P11, DOI 10.1016/j.ctim.2018.03.010
   Kang YY, 2014, BIOCHEM BIOPH RES CO, V445, P369, DOI 10.1016/j.bbrc.2014.02.009
   Kobuchi S, 2020, ANTIBIOTICS BASEL, V9, DOI 10.3390/antibiotics9040199
   Konstantinidis T, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8110502
   Kourtzelis I, 2019, NAT IMMUNOL, V20, P40, DOI 10.1038/s41590 018 0249 1
   Lamont RJ, 2015, TRENDS MOL MED, V21, P172, DOI 10.1016/j.molmed.2014.11.004
   Lin M, 2017, BRAZ ORAL RES, V31, DOI [10.1590/1807 3107BOR 2017.vol31.0063, 10.1590/1807 3107bor 2017.vol31.0063]
   Lin XF, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007716.pub4
   Maekawa T, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136706
   Maekawa T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9272
   Maekawa T, 2014, CELL HOST MICROBE, V15, P768, DOI 10.1016/j.chom.2014.05.012
   Maekawa T, 2014, J IMMUNOL, V192, P6020, DOI 10.4049/jimmunol.1400569
   Miyazaki T, 2011, ANAL BIOCHEM, V410, P7, DOI 10.1016/j.ab.2010.11.014
   Mizraji G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00785
   Nakamura I, 2007, J BONE MINER METAB, V25, P337, DOI 10.1007/s00774 007 0773 9
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   O'Rourke VJ, 2017, AUST DENT J, V62, P14, DOI 10.1111/adj.12448
   Ogrendik M, 2014, INT J GEN MED, V7, P43, DOI 10.2147/IJGM.S56957
   Ogrendik M, 2011, POSTGRAD MED, V123, P220, DOI 10.3810/pgm.2011.09.2478
   Oh SH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188749
   Otsu K, 2011, PHARMACOLOGY, V88, P327, DOI 10.1159/000334339
   Papathanasiou E, 2016, J DENT RES, V95, P1018, DOI 10.1177/0022034516645332
   Park HS, 2017, INT IMMUNOPHARMACOL, V47, P212, DOI 10.1016/j.intimp.2017.04.008
   Ren WP, 2004, J ORTHOP RES, V22, P21, DOI 10.1016/S0736 0266(03)00130 X
   Rollins DR, 2014, J ALLER CL IMM PRACT, V2, P511, DOI 10.1016/j.jaip.2014.06.002
   Saleh A, 2016, AUST DENT J, V61, P469, DOI 10.1111/adj.12415
   Shin J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5380
   SLOTS J, 1990, J CLIN PERIODONTOL, V17, P479
   Steel HC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/584262
   Tamura Hikaru, 2021, Methods Mol Biol, V2210, P237, DOI 10.1007/978 1 0716 0939 2_23
   Tamura H, 2019, ARCH ORAL BIOL, V98, P132, DOI 10.1016/j.archoralbio.2018.11.021
   Tsukasaki M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03147 6
   Villedieu A, 2004, ANTIMICROB AGENTS CH, V48, P2298, DOI 10.1128/AAC.48.6.2298 2301.2004
   Yan S, 2018, IMMUNOL CELL BIOL, V96, P526, DOI 10.1111/imcb.12023
   Yuh D, 2020, J BIOL CHEM, V295, P7261, DOI 10.1074/jbc.RA120.013024
   Zhang P, 2010, J CLIN PHARMACOL, V50, P858, DOI 10.1177/0091270009360535
   Zhang Z, 2016, J PERIODONTAL RES, V51, P275, DOI 10.1111/jre.12319
   Zimmermann P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00302
NR 68
TC 9
Z9 10
U1 1
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 2079 6382
J9 ANTIBIOTICS BASEL
JI Antibiotics Basel
PD MAR
PY 2021
VL 10
IS 3
AR 312
DI 10.3390/antibiotics10030312
PG 15
WC Infectious Diseases; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Infectious Diseases; Pharmacology & Pharmacy
GA RD2UG
UT WOS:000633339200001
PM 33803007
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Schmidmaier, R
   Simsek, M
   Baumann, P
   Emmerich, B
   Meinhardt, G
AF Schmidmaier, Ralf
   Simsek, Meral
   Baumann, Philipp
   Emmerich, Bertold
   Meinhardt, Gerold
TI Synergistic antimyeloma effects of zoledronate and simvastatin
SO ANTI CANCER DRUGS
LA English
DT Article
DE apoptosis; diphosphonates; drug resistance; hydroxymethyl glutaryl CoA
   reductase inhibitors; multiple myeloma; simvastatin; zoledronic acid
ID MYELOMA CELL LINES; COA REDUCTASE INHIBITOR; MULTIPLE MYELOMA;
   PLASMA CELLS; GROWTH INHIBITION; IN VIVO; APOPTOSIS; BISPHOSPHONATE;
   BONE; LOVASTATIN
AB Despite advances in the treatment of multiple myeloma, it remains an incurable disease because of primary and secondary drug resistance. Mevalonate pathway inhibitors like bisphosphonates and statins have antimyeloma activity in vitro at very high concentrations, which may probably not be reached in vivo. NCI H929, OPM 2, U266 and RPMI 8226 myeloma cell lines were treated in the presence or absence of bone marrow stromal cells with sirrivastatin or zoledronate in combination with classical antimyeloma drugs like melphalan or bortezomib. Zoledronate did not show substantial antimyeloma activity at low and intermediate concentrations, whereas sirrivastatin potently induced apoptosis in myeloma cells without signs of primary, cell adhesion mediated drug resistance. Furthermore, sequential blockage of the mevalonate pathway by zoledronate and sirrivastatin demonstrated synergistic induction of apoptosis and reversal of cell adhesion mediated drug resistance.
C1 Klinikum Univ Munchen, Dept Haematol & Oncol, Med Klin Innenstadt, D 80336 Munich, Germany.
C3 University of Munich
RP Schmidmaier, R (通讯作者)，Klinikum Univ Munchen, Dept Haematol & Oncol, Med Klin Innenstadt, Ziemssenstr 1, D 80336 Munich, Germany.
EM ralf.schmidmaier@med.uni muenchen.de
RI Schmidmaier, Ralf/AFN 2678 2022
CR Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892
   Berenson JR, 2005, BEST PRACT RES CL HA, V18, P653, DOI 10.1016/j.beha.2005.03.001
   Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593
   Cafforio P, 2005, CARCINOGENESIS, V26, P883, DOI 10.1093/carcin/bgi036
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Corsini A, 1999, PHARMACOL THERAPEUT, V84, P413, DOI 10.1016/S0163 7258(99)00045 5
   Corso A, 2005, CANCER, V104, P118, DOI 10.1002/cncr.21104
   Derenne S, 1999, J BONE MINER RES, V14, P2048, DOI 10.1359/jbmr.1999.14.12.2048
   Dhodapkar MV, 1998, BRIT J HAEMATOL, V103, P530, DOI 10.1046/j.1365 2141.1998.00976.x
   Dmoszynska A, 2004, POL J PHARMACOL, V56, P485
   Gordon S, 2002, BRIT J HAEMATOL, V119, P475, DOI 10.1046/j.1365 2141.2002.03824.x
   Gronich N, 2004, J INVEST MED, V52, P335, DOI 10.1136/jim 52 05 34
   HOLMBERG M, 1994, ANTI CANCER DRUG, V5, P598, DOI 10.1097/00001813 199410000 00012
   Iguchi T, 2003, CELL SIGNAL, V15, P719, DOI 10.1016/S0898 6568(03)00007 X
   Jánosi J, 2004, ANTICANCER RES, V24, P1817
   Liu Ze Lin, 2004, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V12, P340
   Otsuki T, 2004, ONCOL REP, V11, P1053
   Otsuki T, 2003, INT J ONCOL, V23, P763
   Salomo M, 2003, BRIT J HAEMATOL, V122, P202, DOI 10.1046/j.1365 2141.2003.04437.x
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Schmidmaier R, 2004, BLOOD, V104, P1825, DOI 10.1182/blood 2003 12 4218
   Sezer O, 2003, EUR J HAEMATOL, V71, P231, DOI 10.1034/j.1600 0609.2003.00116.x
   Shipman CM, 2000, BRIT J HAEMATOL, V111, P283, DOI 10.1046/j.1365 2141.2000.02310.x
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Takahashi R, 2001, LEUKEMIA RES, V25, P77, DOI 10.1016/S0145 2126(00)00087 4
   Tassone P, 2000, LEUKEMIA, V14, P841, DOI 10.1038/sj.leu.2401770
   Ural AU, 2003, INT J HEMATOL, V78, P443, DOI 10.1007/BF02983818
   van de Donk NWCJ, 2003, BLOOD, V102, P3354, DOI 10.1182/blood 2003 03 0970
   van de Donk NWCJ, 2002, LEUKEMIA, V16, P1362, DOI 10.1038/sj.leu.2402501
NR 29
TC 33
Z9 37
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3621 USA
SN 0959 4973
J9 ANTI CANCER DRUG
JI Anti Cancer Drugs
PD JUL
PY 2006
VL 17
IS 6
BP 621
EP 629
DI 10.1097/01.cad.0000215058.85813.02
PG 9
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 067FN
UT WOS:000239287300003
PM 16917207
DA 2025 08 17
ER

PT J
AU Esser, AK
   Schmieder, AH
   Ross, MH
   Xiang, JY
   Su, XM
   Cui, G
   Zhang, HY
   Yang, XX
   Allen, JS
   Williams, T
   Wickline, SA
   Pan, DPJ
   Lanza, GM
   Weilbaecher, KN
AF Esser, Alison K.
   Schmieder, Anne H.
   Ross, Michael H.
   Xiang, Jingyu
   Su, Xinming
   Cui, Grace
   Zhang, Huiying
   Yang, Xiaoxia
   Allen, John S.
   Williams, Todd
   Wickline, Samuel A.
   Pan, Dipanjan
   Lanza, Gregory M.
   Weilbaecher, Katherine N.
TI Dual therapy with αvβ3 targeted Sn2 lipase labile
   fumagillin prodrug nanoparticles and zoledronic acid in the Vx2 rabbit
   tumor model
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Fumagillin; Zoledronic acid; Cancer; Nanoparticle; MRI; Molecular
   imaging
ID ANGIOGENESIS INHIBITOR TNP 470; PHASE I; BISPHOSPHONATE ACTION;
   SELECTIVE INHIBITION; REGULATES BONE; DRUG DELIVERY; CANCER; GROWTH;
   LOCALIZATION; MACROPHAGES
AB Fumagillin, an unstable anti angiogenesis mycotoxin, was synthesized into a stable lipase labile prodrug and incorporated into integrin targeted lipid encapsulated nanoparticles (alpha(v)beta(3) Fum PD NP). Dual anti angiogenic therapy combining alpha(v)beta(3) Fum PD NP with zoledronic acid (ZA), a long acting osteoclast inhibitor with proposed anti angiogenic effects, was evaluated. In vitro, alpha(v)beta(3) Fum PD NP reduced (P < 0.05) endothelial cell viability without impacting macrophage viability. ZA suppressed (P < 0.05) macrophage viability at high dosages but not endothelial cell proliferation. 3DMR neovascular imaging of rabbit Vx2 tumors showed no effect with ZA, whereas alpha(v)beta(3) Fum PD NP alone and with ZA decreased angiogenesis (P < 0.05). Immunohistochemistry revealed decreased (P < 0.05) microvascularity with alpha(v)beta(3) Fum PD NP and ZA and further microvascular reduction (P < 0.05) with dual therapy. In vivo, ZA did not decrease tumor macrophage numbers nor cancer cell proliferation, whereas alpha(v)beta(3) Fum PD NPs reduced both measures. Dual therapy with ZA and alpha(v)beta(3) Fum PD NP may provide enhanced neo adjuvant utility if macrophage ZA uptake is increased.
   From the Clinical Editor: Although anti angiogenesis is one of the treatment modalities in the fight against cancer, many cancers become resistant to VEGF pathway inhibitors. In this article, the authors investigated the use of dual therapy using fumagillin, integrin targeted lipid encapsulated nanoparticles (alpha(v)beta(3) Fum PD NP) and zoledronic acid (ZA), in both in vitro and in vivo experiments. This combination approach may provide an insight to the design of future drugs against cancers. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Esser, Alison K.; Ross, Michael H.; Xiang, Jingyu; Su, Xinming; Weilbaecher, Katherine N.] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA.
   [Schmieder, Anne H.; Cui, Grace; Zhang, Huiying; Yang, Xiaoxia; Allen, John S.; Williams, Todd; Wickline, Samuel A.; Lanza, Gregory M.] Washington Univ, Sch Med, Dept Med, Div Cardiol, St Louis, MO 63110 USA.
   [Pan, Dipanjan] Univ Illinois, Dept Bioengn, Urbana, IL 61801 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); University
   of Illinois System; University of Illinois Urbana Champaign
RP Lanza, GM (通讯作者)，Campus Box 8215,330 South Euclid Ave, St Louis, MO 63110 USA.; Weilbaecher, KN (通讯作者)，Campus Box 8069,330 South Euclid Ave, St Louis, MO 63110 USA.
EM greg.lanza@mac.com; kweilbae@wustl.edu
RI wickline, samuel/I 2898 2015; Su, Xinming/G 1643 2012; Xiang,
   Jingyu/JMQ 3519 2023; Yang, Xiaoxia/G 2416 2014; Zhang,
   Zhen/GXH 3666 2022
OI Xiang, Jingyu/0000 0001 5524 0931; Pan, Dipanjan/0000 0003 0175 4704;
   Ross, Michael/0000 0002 5136 650X; Su, Xinming/0000 0003 0351 2928; 
FU NIH [CA154737, CA097250, AR067491, DK102691, HL073646, HL122471,
   HL112518, HL113392, HHSN26820140042C]; Washington University
   Musculoskeletal Research Center (NIH) [P30AR057235]; Washington
   University Digestive Diseases Research Core (NIH) [P30DK52574]; Hope
   Center Alafi Neuroimaging Lab [S10RR027552]; Barnes Jewish Research
   Foundation; St. Louis Men's Group Against Cancer;  [5T32CA113275 07]; 
   [5T32GM007067 39]
FX This research was supported in whole or part by grants from the NIH
   CA154737 (K.N.W./D.P./G.M.L.); CA097250 (K.N.W.); AR067491 (S.A.W.),
   DK102691 (S.A.W.), and HL073646 (S.A.W.), HL122471 (G.M.L.), HL112518
   (G.M.L.), HL113392 (G.M.L.), HHSN26820140042C (G.M.L.) and training
   grants 5T32CA113275 07 (A.K.E.) and 5T32GM007067 39 (M.H.R.). We
   appreciate the further support provided by the Washington University
   Musculoskeletal Research Center (NIH P30AR057235), Washington University
   Digestive Diseases Research Core (NIH P30DK52574), Hope Center Alafi
   Neuroimaging Lab (S10RR027552), The Barnes Jewish Research Foundation
   and The St. Louis Men's Group Against Cancer.
CR Aft R, 2010, LANCET ONCOL, V11, P421, DOI 10.1016/S1470 2045(10)70054 1
   Amend SR, 2015, J BONE MINER RES, V30, P106, DOI 10.1002/jbmr.2308
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Bhargava P, 1999, CLIN CANCER RES, V5, P1989
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Bruno A, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00131
   Castronovo V, 1996, EUR J CANCER, V32A, P2520, DOI 10.1016/S0959 8049(96)00388 7
   Clézardin P, 2011, BONE, V48, P71, DOI 10.1016/j.bone.2010.07.016
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Dezube BJ, 1998, J CLIN ONCOL, V16, P1444, DOI 10.1200/JCO.1998.16.4.1444
   Dirkx AEM, 2003, CANCER RES, V63, P2322
   Dirkx AEM, 2006, FASEB J, V20, P621, DOI 10.1096/fj.05 4493com
   Griffioen AW, 1999, INT J CANCER, V80, P315, DOI 10.1002/(SICI)1097 0215(19990118)80:2<315::AID IJC23>3.0.CO;2 L
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Heller E, 2012, CANCER RES, V72, P897, DOI 10.1158/0008 5472.CAN 11 2681
   Herbst RS, 2002, J CLIN ONCOL, V20, P4440, DOI 10.1200/JCO.2002.04.006
   Hirbe AC, 2009, BONE, V44, P908, DOI 10.1016/j.bone.2009.01.010
   INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0
   Junankar S, 2015, CANCER DISCOV, V5, P35, DOI 10.1158/2159 8290.CD 14 0621
   Konno H, 1996, CANCER AM CANCER SOC, V77, P1736
   Kudelka AP, 1998, NEW ENGL J MED, V338, P991, DOI 10.1056/NEJM199804023381412
   Lanza GM, 2002, CIRCULATION, V106, P2842, DOI 10.1161/01.CIR.0000044020.27990.32
   Liu SP, 1998, SCIENCE, V282, P1324, DOI 10.1126/science.282.5392.1324
   Logothetis CJ, 2001, CLIN CANCER RES, V7, P1198
   Lowther WT, 1998, P NATL ACAD SCI USA, V95, P12153, DOI 10.1073/pnas.95.21.12153
   Marra M, 2009, CURR CANCER DRUG TAR, V9, P791, DOI 10.2174/156800909789760285
   Marra M, 2012, BIOTECHNOL ADV, V30, P302, DOI 10.1016/j.biotechadv.2011.06.018
   Mathew A, 2014, NAT REV CLIN ONCOL, V11, P564, DOI 10.1038/nrclinonc.2014.152
   Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444
   Pan D, 2014, THERANOSTICS, V4, P565, DOI 10.7150/thno.7581
   Pan D, 2012, NANOMEDICINE UK, V7, P1507, DOI [10.2217/nnm.12.27, 10.2217/NNM.12.27]
   Pan D, 2011, FASEB J, V25, P875, DOI 10.1096/fj.10 171728
   Partlow KC, 2008, BIOMATERIALS, V29, P3367, DOI 10.1016/j.biomaterials.2008.04.030
   Rogers TL, 2013, CELL ONCOL, V36, P505, DOI 10.1007/s13402 013 0156 2
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Schmieder AH, 2013, RADIOLOGY, V268, P470, DOI 10.1148/radiol.13120789
   Schmieder AH, 2008, FASEB J, V22, P4179, DOI 10.1096/fj.08 112060
   Shusterman S, 2001, CLIN CANCER RES, V7, P977
   Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099
   Soman NR, 2008, NANO LETT, V8, P1131, DOI 10.1021/nl073290r
   Su XM, 2012, J CLIN INVEST, V122, P3579, DOI 10.1172/JCI38576
   Turk BE, 1999, CHEM BIOL, V6, P823, DOI 10.1016/S1074 5521(99)80129 X
   Uluçkan Ö, 2009, CANCER RES, V69, P3196, DOI 10.1158/0008 5472.CAN 08 3358
   Wang JY, 2000, J CELL BIOCHEM, V77, P465, DOI 10.1002/(SICI)1097 4644(20000601)77:3<465::AID JCB11>3.0.CO;2 M
   Wang KZ, 2015, NANOMED NANOTECHNOL, V11, P601, DOI 10.1016/j.nano.2014.12.009
   Wang KZ, 2015, NANOMED NANOTECHNOL, V11, P569, DOI 10.1016/j.nano.2014.12.008
   Winter PM, 2008, FASEB J, V22, P2758, DOI 10.1096/fj.07 103929
   Winter PM, 2006, ARTERIOSCL THROM VAS, V26, P2103, DOI 10.1161/01.ATV.0000235724.11299.76
   WORSLEY DF, 1993, J NUCL MED, V34, P1612
   Zhang RY, 2015, THERANOSTICS, V5, P124, DOI 10.7150/thno.10014
   Zhou HF, 2014, ACS NANO, V8, P7305, DOI 10.1021/nn502372n
   Zhou HF, 2012, BIOMATERIALS, V33, P8632, DOI 10.1016/j.biomaterials.2012.08.005
NR 52
TC 13
Z9 14
U1 1
U2 29
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD JAN
PY 2016
VL 12
IS 1
BP 201
EP 211
DI 10.1016/j.nano.2015.10.003
PG 11
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA DG1BR
UT WOS:000371800600019
PM 26515754
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Osman, L
   Chester, AH
   Amrani, M
   Yacoub, MH
   Smolenski, RT
AF Osman, Lana
   Chester, Adrian H.
   Amrani, Mohamed
   Yacoub, Magdi H.
   Smolenski, Ryszard T.
TI A novel role of extracellular nucleotides in valve calcification   A
   potential target for atorvastatin
SO CIRCULATION
LA English
DT Article; Proceedings Paper
CT 78th Annual Scientific Session of the American Heart Association
CY NOV 13 16, 2005
CL Dallas, TX
SP Amer Heart Assoc
DE adenosine; enzymes; statins; valves
ID AORTIC VALVE; INTERSTITIAL CELLS; INFLAMMATION; ADENOSINE; REDUCTASE;
   STENOSIS
AB Background   Calcific aortic valve disease is a common condition and is associated with inflammatory changes and expression of osteoblast like cell phenotypes, but the cellular mechanisms are unclear. Recent studies identified extracellular ATP and P2Y receptor cascade as important regulators of bone remodeling, whereas its breakdown product, adenosine, is known to have anti  inflammatory properties. We hypothesize that extracellular ATP and adenosine have important roles in regulating osteoblast differentiation in human valve interstitial cells, and that this can be a potential target for therapy.
   Method and Results   Primary cultures of human valve interstitial cells (ICs) treated for 21 days with osteogenic media, ATP, and ATP gamma S ( a stable agonist of the P2Y receptor) revealed a significant increase in alkaline phosphatase (ALP) (an osteoblast marker) activity and expression as measured using spectrophotometric assay and immunocytochemistry staining. Valve ICs treated with adenosine alone did not cause an increase in ALP activity; however, adenosine treatment decreased the ALP activity and expression induced by osteogenic media after 21 days of incubation. In addition, atorvastatin inhibited the activity of ALP induced by ATP in human valve ICs, and enzyme studies revealed that atorvastatin upregulated the breakdown of extracellular ATP into adenosine in human valve ICs after 24  hour treatment.
   Conclusion   These findings identify a novel role for extracellular nucleotides in inducing osteoblast differentiation in human valve ICs in vitro and provide a potential therapeutic target for preventing the disease progression.
C1 Harefield Hosp, Imperial Coll London,Natl Heart & Lung Inst, Heart Sci Ctr,Dept Cardiothorac Surg, Royal Brompton & Harefield Natl Hlth Serv Trust, Harefield UB9 6JH, Middx, England.
   Med Univ Gdansk, Dept Biochem, Gdansk, Poland.
C3 Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital;
   Imperial College London; Fahrenheit Universities; Medical University
   Gdansk
RP Yacoub, MH (通讯作者)，Harefield Hosp, Imperial Coll London,Natl Heart & Lung Inst, Heart Sci Ctr,Dept Cardiothorac Surg, Royal Brompton & Harefield Natl Hlth Serv Trust, Harefield UB9 6JH, Middx, England.
EM m.yacoub@imperial.ac.uk
RI Smolenski, Ryszard/AEV 2370 2022
OI Smolenski, Ryszard/0000 0002 0190 9414
CR Bowler WB, 2001, BONE, V28, P507, DOI 10.1016/S8756 3282(01)00430 6
   Chikwe J, 2003, BR J CARDIOL, V10, P453
   Cilla DD, 1996, CLIN PHARMACOL THER, V60, P687, DOI 10.1016/S0009 9236(96)90218 0
   Cowell SJ, 2005, NEW ENGL J MED, V352, P2389, DOI 10.1056/NEJMoa043876
   ELY SW, 1992, CIRCULATION, V85, P893, DOI 10.1161/01.CIR.85.3.893
   Gallagher J. A., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P432
   Gartland A, 2003, CRIT REV EUKAR GENE, V13, P243, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.160
   Kaden JJ, 2004, J MOL CELL CARDIOL, V36, P57, DOI 10.1016/j.yjmcc.2003.09.015
   Mathieu P, 2005, J HEART VALVE DIS, V14, P353
   Mohler ER, 2001, CIRCULATION, V103, P1522, DOI 10.1161/01.cir.103.11.1522
   Morikawa Shigeru, 2002, J Atheroscler Thromb, V9, P178
   MOURA ML, 2005, CIRCULATION S2, P112
   Novaro GM, 2001, CIRCULATION, V104, P2205, DOI 10.1161/hc4301.098249
   Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a
   Rajamannan NM, 2003, CIRCULATION, V107, P2181, DOI 10.1161/01.CIR.0000070591.21548.69
   Rajamannan NM, 2002, CIRCULATION, V105, P2660, DOI 10.1161/01.CIR.0000017435.87463.72
   SMOLENSKI RT, 1990, J CHROMATOGR BIOMED, V527, P414, DOI 10.1016/S0378 4347(00)82125 8
   Taylor PA, 2003, INT J BIOCHEM CELL B, V35, P113, DOI 10.1016/S1357 2725(02)00100 0
   Taylor PM, 2000, J HEART VALVE DIS, V9, P150
   Zimmermann H, 1999, TRENDS PHARMACOL SCI, V20, P231, DOI 10.1016/S0165 6147(99)01293 6
NR 20
TC 49
Z9 54
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009 7322
EI 1524 4539
J9 CIRCULATION
JI Circulation
PD JUL 4
PY 2006
VL 114
SU 1
BP I566
EP I572
DI 10.1161/CIRCULATIONAHA.105.001214
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Cardiovascular System & Cardiology
GA 058TT
UT WOS:000238688200092
PM 16820639
DA 2025 08 17
ER

PT J
AU López, MAV
   García, MNV
   Entrena, A
   Lopez, SO
   García Arranz, M
   García Olmo, D
   Zapata, A
AF Vicente Lopez, Maria A.
   Vazquez Garcia, Miriam N.
   Entrena, Ana
   Olmedillas Lopez, Susana
   Garcia Arranz, Mariano
   Garcia Olmo, Damian
   Zapata, Agustin
TI Low Doses of Bone Morphogenetic Protein 4 Increase the Survival of Human
   Adipose Derived Stem Cells Maintaining Their Stemness and Multipotency
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID OSTEOGENIC DIFFERENTIATION; ADIPOCYTE DIFFERENTIATION; GENE EXPRESSION;
   STROMAL CELLS; MARROW; OSTEOBLAST; PATHWAYS; GROWTH; TISSUE; IA
AB Mesenchymal stem cells (MSCs) have emerged as important tools for cell therapy; therefore, identification of factors capable of governing their ex vivo expansion become essential. In this study we demonstrate that human adipose derived stem cells (ASCs) express all components of the bone morphogenetic protein (BMP)/BMP receptor signaling pathway and respond to BMP4 inducing upregulated expression of its specific target genes Id1 Id4. Moreover, ASCs grown in a medium reduced in serum produce endogenous BMP4 that could affect autocrinely ASC growth. On the contrary, dorsomorphin, an inhibitor of BMP signaling pathway, decreases cell numbers yielded from ASC cultures in correlation with increased apoptosis and decreased cycling cells. Therefore, BMP4 emerges as a possible factor for ex vivo expanding human ASCs. Our results demonstrate that, as other morphogens, BMP4 effects on human MSCs are dose dependent. High doses significantly increased apoptosis and drastically reduced cell proliferation, whereas low doses of BMP4 (0.01 0.1 ng/mL) significantly increase culture cell content, reduce the number of apoptotic cells, and increase that of cycling cells. Further, treatment of human ASCs with low doses of BMP4 does not modify expression of Nanog and Oct4, two transcription factors involved in self renewal and pluripotency of stem cells or avoid their osteogenic or osteoblastic differentiation capacities when cultured in adequate inducing media, as shown by the induction of specific gene expression (CEBP, PPAR gamma, and RUNX2). Our results therefore support BMP4 as a promising factor for expanding human adipose tissue derived MSCs maintaining their properties of stemness and multipotency.
C1 [Vicente Lopez, Maria A.; Vazquez Garcia, Miriam N.; Entrena, Ana] Univ Complutense, Sch Med, Dept Cell Biol, E 28040 Madrid, Spain.
   [Olmedillas Lopez, Susana; Garcia Arranz, Mariano] La Paz Univ Hosp, Cell Therapy Unit, Madrid, Spain.
   [Garcia Olmo, Damian] La Paz Univ Hosp, Dept Surg, Madrid, Spain.
   [Zapata, Agustin] Univ Complutense, Fac Biol, Dept Cell Biol, E 28040 Madrid, Spain.
C3 Complutense University of Madrid; Hospital Universitario La Paz;
   Hospital Universitario La Paz; Complutense University of Madrid
RP López, MAV (通讯作者)，Univ Complutense, Sch Med, Dept Cell Biol, E 28040 Madrid, Spain.
EM avicente@bio.ucm.es
RI ; Garcia Arranz, Mariano/L 7884 2019; VAZQUEZ GARCIA, MIRIAM
   NOHEMI/G 8866 2017; Vicente, Angeles/B 7951 2015; GARCIA,
   MIRIAM/G 8866 2017
OI Zapata, Agustin G/0000 0003 0576 2672; Garcia Arranz,
   Mariano/0000 0002 6266 9055; Garcia Olmo, Damian/0000 0002 9369 2338;
   VAZQUEZ GARCIA, MIRIAM NOHEMI/0000 0002 9810 884X; Vicente,
   Angeles/0000 0002 9456 5541; 
FU Regional Government of Madrid [S BIO/0204/2006]; Ministry of Science and
   Innovation [BFU2006 00651, BFU2007 65520, BFU2009 10315]; Health
   Institute Carlos III [RD06/0010/0003]; Complutense University
   [GR58/08 910552]
FX This work was supported by grants S BIO/0204/2006 from Regional
   Government of Madrid; BFU2006 00651, BFU2007 65520, and BFU2009 10315
   from the Ministry of Science and Innovation; RD06/0010/0003 from the
   Health Institute Carlos III; and GR58/08 910552 from the Complutense
   University and Regional Government of Madrid.
CR AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871
   Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Cejalvo T, 2007, IMMUNOLOGY, V121, P94, DOI 10.1111/j.1365 2567.2007.02541.x
   Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295
   Chen DH, 2003, CURR BIOL, V13, P1786, DOI 10.1016/j.cub.2003.09.033
   Chen DH, 2003, DEVELOPMENT, V130, P1159, DOI 10.1242/dev.00325
   Chen HL, 2007, STEM CELLS, V25, P63, DOI 10.1634/stemcells.2006 0339
   Chen TL, 2001, J CELL BIOCHEM, V82, P187, DOI 10.1002/jcb.1145
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Edgar CM, 2007, BONE, V40, P1389, DOI 10.1016/j.bone.2007.01.001
   Farré J, 2007, GROWTH FACTORS, V25, P71, DOI 10.1080/08977190701345200
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365 2184.1970.tb00347.x
   Friedman MS, 2006, J CELL BIOCHEM, V98, P538, DOI 10.1002/jcb.20719
   García Olmo D, 2005, DIS COLON RECTUM, V48, P1416, DOI 10.1007/s10350 005 0052 6
   GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189
   GIMBLE JM, 1995, J CELL BIOCHEM, V58, P393, DOI 10.1002/jcb.240580312
   Goldman DC, 2009, BLOOD, V114, P4393, DOI 10.1182/blood 2009 02 206433
   Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681
   Herrera B, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471 2121 10 20
   Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838
   Ji XH, 2000, J BONE MINER METAB, V18, P132, DOI 10.1007/s007740050103
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Massagué J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753
   Mishina Y, 2004, J BIOL CHEM, V279, P27560, DOI 10.1074/jbc.M404222200
   Mishina Y, 2003, FRONT BIOSCI LANDMRK, V8, pD855, DOI 10.2741/1097
   Nilsson EE, 2003, BIOL REPROD, V69, P1265, DOI 10.1095/biolreprod.103.018671
   Noël D, 2004, STEM CELLS, V22, P74, DOI 10.1634/stemcells.22 1 74
   Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794
   Oreffo ROC, 1999, J CELL BIOCHEM, V75, P382, DOI 10.1002/(SICI)1097 4644(19991201)75:3<382::AID JCB4>3.0.CO;2 N
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pochampally RR, 2004, BLOOD, V103, P1647, DOI 10.1182/blood 2003 06 1967
   Riekstina U, 2009, STEM CELL REV REP, V5, P378, DOI 10.1007/s12015 009 9094 9
   Shivdasani AA, 2003, CURR BIOL, V13, P2065, DOI 10.1016/j.cub.2003.10.063
   Solmesky LJ, 2009, STEM CELLS DEV, V18, P1283, DOI 10.1089/scd.2009.0020
   Ulloa Montoya F, 2007, GENOME BIOL, V8, DOI 10.1186/gb 2007 8 8 r163
   YOUNG HE, 1995, DEV DYNAM, V202, P137, DOI 10.1002/aja.1002020205
   Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54
   Zhang JW, 2005, DEV BIOL, V284, P1, DOI 10.1016/j.ydbio.2005.05.009
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
   ZUK PA, 2004, INT FAT APPL TECHN S
NR 42
TC 46
Z9 47
U1 0
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD JUN
PY 2011
VL 20
IS 6
BP 1011
EP 1019
DI 10.1089/scd.2010.0355
PG 9
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 769GS
UT WOS:000291001000008
PM 20846028
DA 2025 08 17
ER

PT J
AU He, BC
   Gao, JL
   Luo, XJ
   Luo, JY
   Shen, JK
   Wang, LY
   Zhou, QX
   Wang, YT
   Luu, HH
   Haydon, RC
   Wang, CZ
   Du, W
   Yuan, CS
   He, TC
   Zhang, BQ
AF He, Bai Cheng
   Gao, Jian Li
   Luo, Xiaoji
   Luo, Jinyong
   Shen, Jikun
   Wang, Linyuan
   Zhou, Qixin
   Wang, Yi Tao
   Luu, Hue H.
   Haydon, Rex C.
   Wang, Chong Zhi
   Du, Wei
   Yuan, Chun Su
   He, Tong Chuan
   Zhang, Bing Qiang
TI Ginsenoside Rg3 inhibits colorectal tumor growth through the
   down regulation of Wnt/β catenin signaling
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE colon cancer; Wnt signaling; beta catenin; ginsenoside Rg3; ginseng;
   human colorectal cancer
ID PROSTATE CANCER CELLS; NF KAPPA B; BETA CATENIN; AMERICAN GINSENG;
   COLON CANCER; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION;
   PANAX QUINQUEFOLIUS; NATURAL PRODUCTS; CARCINOMA CELLS
AB Colorectal cancer (CRC) is one of the most common and deadly malignancies in the world. Most CRCs are initiated by aberrant activation of the Wnt/beta catenin signaling pathway. Despite the advances in its early diagnosis, optimized surgical approaches, and chemotherapies, the clinical management of advanced CRC requires effective adjuvant agents. Ginsenoside Rg3 is a single compound isolated from American ginseng (Panax quinquefolius L., Araliaceae) and Asian ginseng (Panax ginseng C. A. Meyer). We investigated the anticancer activity of Rg3 on colon cancer cells and its potential molecular mechanism behind Rg3's anticancer activity. We found that Rg3 inhibits cell proliferation and viability of cancer cells in vitro. This inhibitory effect of Rg3 is, at least in part, mediated by blocking nuclear translocation of the beta catenin protein and hence inhibiting beta catenin/Tcf transcriptional activity. Allelic deletion of the oncogenic beta catenin in HCT116 cells renders the cells more sensitive to Rg3 induced growth inhibition. Using the xenograft tumor model of human colon cancer, we have demonstrated that Rg3 effectively inhibits the growth of tumors derived from the human colon cancer cell line HCT116. Histologic examination revealed that Rg3 inhibits cancer cell proliferation, decreases PNCA expression and diminishes nuclear staining intensity of beta catenin. Taken together, our results strongly suggest that the anticancer activity of Rg3 may be in part caused by blocking the nuclear translocation of beta catenin in colon cancer cells. This line of investigation may lead to the development of novel therapies in which Rg3 can be used as an effective adjuvant agent for the clinical management of colorectal cancers.
C1 [He, Bai Cheng; Luo, Xiaoji; Luo, Jinyong; Shen, Jikun; Wang, Linyuan; Luu, Hue H.; Haydon, Rex C.; He, Tong Chuan; Zhang, Bing Qiang] Univ Chicago, Med Ctr, Mol Oncol Lab, Dept Surg, Chicago, IL 60637 USA.
   [He, Bai Cheng; Gao, Jian Li; Luo, Xiaoji; Luo, Jinyong; Zhou, Qixin; He, Tong Chuan; Zhang, Bing Qiang] Chongqing Med Univ, Dept Pharmacol, Chongqing 400016, Peoples R China.
   [He, Bai Cheng; Gao, Jian Li; Luo, Xiaoji; Luo, Jinyong; Zhou, Qixin; He, Tong Chuan; Zhang, Bing Qiang] Chongqing Med Univ, Key Lab Diagnost Med Chinese Minist Educ, Chongqing 400016, Peoples R China.
   [Wang, Yi Tao] Univ Macau, Inst Chinese Med Sci, SAR, Macau, Peoples R China.
   [Wang, Chong Zhi; Du, Wei; Yuan, Chun Su; He, Tong Chuan] Univ Chicago, Med Ctr, Tang Ctr Herbal Med Res, Chicago, IL 60637 USA.
   [Du, Wei] Univ Chicago, Med Ctr, Ben May Dept Canc Res, Chicago, IL 60637 USA.
C3 University of Chicago; University of Chicago Medical Center; Chongqing
   Medical University; Chongqing Medical University; University of Macau;
   University of Chicago; University of Chicago Medical Center; University
   of Chicago; University of Chicago Medical Center
RP He, TC (通讯作者)，Univ Chicago, Med Ctr, Mol Oncol Lab, Dept Surg, 5841 S Maryland Ave,MC 3079, Chicago, IL 60637 USA.
EM tche@surgery.bsd.uchicago.edu; zhbingqiang@gmail.com
RI Wang, Yitao/O 5184 2016; Wang, Chong Zhi/B 8337 2014; GAO,
   JianLi/J 4997 2017; GAO, Jian Li/J 4997 2017
OI GAO, JianLi/0000 0002 5977 0021; 
FU Brinson Foundation; NIH [AT004418]; University of Chicago Comprehensive
   Cancer Center
FX We thank Bert Vogelstein of Johns Hopkins University, Baltimore, MD, USA
   for the generous provision of HCT116 beta cateninwt/ko cell line. The
   reported study was supported in part by research grants from the Brinson
   Foundation (TCH), the NIH (AT004418 to TCH, CSY and WD), and an Animal
   Imaging Pilot Grant from The University of Chicago Comprehensive Cancer
   Center (RCH). We would like to apologize to those authors whose original
   study was not cited due to space constraints. The authors declare that
   they have no competing interests.
CR AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121
   [Anonymous], 2008, CHIN J INTEGR MED, V14, P33, DOI [10.1007/s11655 007 9002 6, 10.1007/s11655 007 9002]
   Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006 2952(99)00212 9
   Bae EA, 2006, PLANTA MED, V72, P627, DOI 10.1055/s 2006 931563
   Benetti R, 2005, J BIOL CHEM, V280, P22070, DOI 10.1074/jbc.M501810200
   Bi Y, 2009, J CELL BIOCHEM, V108, P295, DOI 10.1002/jcb.22254
   Block Keith I, 2003, Integr Cancer Ther, V2, P247, DOI 10.1177/1534735403256419
   Brocardo M, 2005, EMBO REP, V6, P184, DOI 10.1038/sj.embor.7400329
   Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999
   Chang Yuan S, 2003, Integr Cancer Ther, V2, P13, DOI 10.1177/1534735403251167
   CHEN L, J BONE MINE IN PRESS
   Cho SH, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 449
   Choi KT, 2008, ACTA PHARMACOL SIN, V29, P1109, DOI 10.1111/j.1745 7254.2008.00869.x
   Christensen LP, 2009, ADV FOOD NUTR RES, V55, P1, DOI 10.1016/S1043 4526(08)00401 4
   Cragg GM, 1997, J NAT PROD, V60, P52, DOI 10.1021/np9604893
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140 6736(10)60353 4
   da Rocha Adriana B., 2001, Current Opinion in Pharmacology, V1, P364
   de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453
   Fearnhead NS, 2002, BRIT MED BULL, V64, P27, DOI 10.1093/bmb/64.1.27
   Haydon RC, 2002, INT J CANCER, V102, P338, DOI 10.1002/ijc.10719
   Haydon RC, 2002, CLIN CANCER RES, V8, P1288
   He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078 0432.CCR 09 2499
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092 8674(00)81664 5
   Huang JY, 2009, LIVER INT, V29, P1569, DOI 10.1111/j.1478 3231.2009.02111.x
   Iishi H, 1997, CLIN EXP METASTAS, V15, P603, DOI 10.1023/A:1018491314066
   IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0
   Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518
   Jia WWG, 2004, CAN J PHYSIOL PHARM, V82, P431, DOI [10.1139/y04 049, 10.1139/Y04 049]
   Jiang W, 2001, J BIOL CHEM, V276, P45168, DOI 10.1074/jbc.M106924200
   Kang KS, 2007, FREE RADICAL RES, V41, P1181, DOI 10.1080/10715760701581740
   Keum YS, 2003, MUTAT RES FUND MOL M, V523, P75, DOI 10.1016/S0027 5107(02)00323 8
   Kim HS, 2004, ARCH PHARM RES, V27, P429, DOI 10.1007/BF02980085
   Kim ND, 2003, BRIT J PHARMACOL, V140, P661, DOI 10.1038/sj.bjp.0705490
   Kim SM, 2010, EUR J PHARMACOL, V631, P1, DOI 10.1016/j.ejphar.2009.12.018
   Kim SM, 2009, ARCH PHARM RES, V32, P755, DOI 10.1007/s12272 009 1515 4
   Kim YJ, 2008, BIOL PHARM BULL, V31, P826, DOI 10.1248/bpb.31.826
   King ML, 2010, PHYTOMEDICINE, V17, P261, DOI 10.1016/j.phymed.2009.06.008
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092 8674(00)81333 1
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Labianca R, 2010, CRIT REV ONCOL HEMAT, V74, P106, DOI 10.1016/j.critrevonc.2010.01.010
   Lee KY, 1997, ANTICANCER RES, V17, P1067
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Li BH, 2010, CANCER LETT, V289, P62, DOI 10.1016/j.canlet.2009.08.002
   LIU CX, 1992, J ETHNOPHARMACOL, V36, P27, DOI 10.1016/0378 8741(92)90057 X
   Liu TG, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 250
   Luo JY, 2007, LAB INVEST, V87, P97, DOI 10.1038/labinvest.3700509
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo XJ, 2008, CLIN ORTHOP RELAT R, V466, P2060, DOI 10.1007/s11999 008 0361 x
   Luo XJ, 2008, INT J ONCOL, V32, P975, DOI 10.1007/978 3 540 77385 6
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luu HH, 2005, CANCER LETT, V229, P135, DOI 10.1016/j.canlet.2005.02.015
   Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585 005 0365 9
   Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242
   Mann J, 2002, NAT REV CANCER, V2, P143, DOI 10.1038/nrc723
   Meng LH, 2004, CANCER RES, V64, P9086, DOI 10.1158/0008 5472.CAN 04 0313
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Ragnhammar P, 2001, ACTA ONCOL, V40, P282, DOI 10.1080/02841860151116367
   Rowley PT, 2005, ANNU REV MED, V56, P539, DOI 10.1146/annurev.med.56.061704.135235
   Senchina DS, 2009, EXERC IMMUNOL REV, V15, P66
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Song XM, 2009, VACCINE, V27, P4883, DOI 10.1016/j.vaccine.2009.06.033
   Sparks AB, 1998, CANCER RES, V58, P1130
   Spelman K, 2006, ALTERN MED REV, V11, P128
   Stepanovic S, 2000, J MICROBIOL METH, V40, P175, DOI 10.1016/S0167 7012(00)00122 6
   Su YX, 2009, CLIN EXP METASTAS, V26, P599, DOI 10.1007/s10585 009 9259 6
   Surh YJ, 2001, J KOREAN MED SCI, V16, pS38, DOI 10.3346/jkms.2001.16.S.S38
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   VAJGAND VJ, 1969, TALANTA, V16, P1311, DOI 10.1016/0039 9140(69)80007 X
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Wang CZ, 2008, ANTICANCER RES, V28, P2545
   Wang Y, 2008, ANAL CHEM, V80, P4680, DOI 10.1021/ac8002402
   Xie JT, 2009, BIOL PHARM BULL, V32, P1552, DOI 10.1248/bpb.32.1552
   Yoo JH, 2010, CANCER LETT, V289, P99, DOI 10.1016/j.canlet.2009.08.008
   Yue PYK, 2006, BIOCHEM PHARMACOL, V72, P437, DOI 10.1016/j.bcp.2006.04.034
   Zhang QY, 2008, CANCER BIOTHER RADIO, V23, P647, DOI 10.1089/cbr.2008.0532
   Zhang QY, 2006, BIOCHEM BIOPH RES CO, V342, P824, DOI 10.1016/j.bbrc.2006.02.044
   Zhou L, 2003, CANCER LETT, V193, P161, DOI 10.1016/S0304 3835(03)00013 2
   Zhou L, 2002, BIOTECHNIQUES, V33, P1126, DOI 10.2144/02335dd07
   Zhu GH, 2009, DIFFERENTIATION, V78, P195, DOI 10.1016/j.diff.2009.06.001
NR 81
TC 119
Z9 140
U1 1
U2 28
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019 6439
EI 1791 2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD FEB
PY 2011
VL 38
IS 2
BP 437
EP 445
DI 10.3892/ijo.2010.858
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 712YQ
UT WOS:000286702600016
PM 21152855
OA Bronze
DA 2025 08 17
ER

PT J
AU Xia, Y
   Ge, GR
   Xiao, HX
   Wu, MZ
   Wang, TH
   Gu, CY
   Yang, HL
   Geng, DC
AF Xia, Yu
   Ge, Gaoran
   Xiao, Haixiang
   Wu, Mingzhou
   Wang, Tianhao
   Gu, Chengyong
   Yang, Huilin
   Geng, Dechun
TI REPIN1 regulates iron metabolism and osteoblast apoptosis in
   osteoporosis
SO CELL DEATH & DISEASE
LA English
DT Article
ID BONE MINERAL DENSITY; GELATINASE ASSOCIATED LIPOCALIN; BODY INSULIN
   SENSITIVITY; MESENCHYMAL STEM CELLS; GENETIC HEMOCHROMATOSIS; BINDING
   PROTEIN; ADIPOSE TISSUE; DNA BINDING; OVERLOAD; THALASSEMIA
AB Osteoporosis is not well treated due to the difficulty of finding commonalities between the various types of it. Iron homeostasis is a vital component in supporting biochemical functions, and iron overload is recognized as a common risk factor for osteoporosis. In this research, we found that there is indeed evidence of iron accumulation in the bone tissue of patients with osteoporosis and REPIN1, as an origin specific DNA binding protein, may play a key role in this process. We revealed that sh Repin1 therapy can rescue bone loss in an iron overload induced osteoporosis mouse model. Knockdown of Repin1 can inhibit apoptosis and enhance the resistance of osteoblasts to iron overload toxicity. REPIN1 promoted apoptosis by regulating iron metabolism in osteoblasts. Mechanistically, knockdown of Repin1 decreased the expression of Lcn2, which ameliorated the toxic effects of intracellular iron overload. The anti iron effect of lentivirus sh Repin1 was partially reversed or replicated by changing LCN2 expression level via si RNA or plasmid, which indirectly verified the key regulatory role of LCN2 as a downstream target. Furthermore, the levels of BCL2 and BAX, which play a key role in the mitochondrial apoptosis pathway, were affected. In summary, based on the results of clinical specimens, animal models and in vitro experiments, for the first time, we proved the key role of REPIN1 in iron metabolism related osteoporosis.
C1 [Xia, Yu; Ge, Gaoran; Xiao, Haixiang; Wu, Mingzhou; Wang, Tianhao; Yang, Huilin; Geng, Dechun] Soochow Univ, Affiliated Hosp 1, Dept Orthoped, Suzhou, Jiangsu, Peoples R China.
   [Wu, Mingzhou] Nanjing Univ Chinese Med, Taicang TCM Hosp, Taicang, Peoples R China.
   [Gu, Chengyong] Nanjing Med Univ, Suzhou Hosp, Suzhou Municipal Hosp North Dist, Suzhou, Peoples R China.
C3 Soochow University   China; Nanjing University of Chinese Medicine;
   Nanjing Medical University
RP Yang, HL; Geng, DC (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthoped, Suzhou, Jiangsu, Peoples R China.; Gu, CY (通讯作者)，Nanjing Med Univ, Suzhou Hosp, Suzhou Municipal Hosp North Dist, Suzhou, Peoples R China.
EM gcygcy1979@163.com; suzhouspine@163.com; szgengdc@suda.edu.cn
RI Geng, Dechun/LMO 1733 2024; Xia, Yu/W 6150 2019
OI Gu, chengyong/0000 0002 1804 1367; GENG, Dechun/0000 0003 4375 2803
FU National Natural Science Foundation of China [82072425, 82072498,
   82272157]; Priority Academic Program Development of Jiangsu Higher
   Education Institutions (PAPD); Jiangsu Medical Research Project
   [ZD2022014]; Special Project of Diagnosis; the Program of Suzhou Health
   Commission [GSWS2022002]; National and Local Engineering Laboratory of
   New Functional Polymer Materials [SDGC2205]; Special Project of
   Diagnosis and Treatment Technology for Key Clinical Diseases in Suzhou
   [LCZX202003]
FX This study was supported by the National Natural Science Foundation of
   China (82072425, 82072498, 82272157), the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD), Jiangsu
   Medical Research Project (ZD2022014), Special Project of Diagnosis; the
   Program of Suzhou Health Commission (GSWS2022002), National and Local
   Engineering Laboratory of New Functional Polymer Materials (SDGC2205)
   and Special Project of Diagnosis and Treatment Technology for Key
   Clinical Diseases in Suzhou (LCZX202003).
CR Abshagen K, 2019, J ADV RES, V16, P99, DOI 10.1016/j.jare.2018.11.003
   Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607
   Barasch J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12973
   Bock FJ, 2020, NAT REV MOL CELL BIO, V21, P85, DOI 10.1038/s41580 019 0173 8
   CADDLE MS, 1990, MOL CELL BIOL, V10, P6236, DOI 10.1128/MCB.10.12.6236
   Carbonare LD, 2009, ARTHRITIS RHEUM US, V60, P3356, DOI 10.1002/art.24884
   Catalan V, 2009, J MOL MED, V87, P803, DOI 10.1007/s00109 009 0486 8
   Che JM, 2020, BIOL TRACE ELEM RES, V195, P353, DOI 10.1007/s12011 019 01867 4
   Chen B, 2015, EXP THER MED, V10, P7, DOI 10.3892/etm.2015.2484
   Corradini E, 2020, MOL ASPECTS MED, V75, DOI 10.1016/j.mam.2020.100896
   Costa D, 2013, J CELL PHYSIOL, V228, P2210, DOI 10.1002/jcp.24391
   Crownover BK, 2013, AM FAM PHYSICIAN, V87, P183
   DAILEY L, 1990, MOL CELL BIOL, V10, P6225, DOI 10.1128/MCB.10.12.6225
   Dev S, 2017, HEMODIAL INT, V21, pS6, DOI 10.1111/hdi.12542
   Devireddy LR, 2005, CELL, V123, P1293, DOI 10.1016/j.cell.2005.10.027
   Feng Y, 2021, CELL MOL BIOL LETT, V26, DOI 10.1186/s11658 021 00281 w
   Ferreira AC, 2015, PROG NEUROBIOL, V131, P120, DOI 10.1016/j.pneurobio.2015.06.005
   Flores Romero H, 2019, CELLS BASEL, V8, DOI 10.3390/cells8101176
   FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006 291X(05)81256 2
   Ganz T, 2015, NAT REV IMMUNOL, V15, P500, DOI 10.1038/nri3863
   Ganz T, 2013, PHYSIOL REV, V93, P1721, DOI 10.1152/physrev.00008.2013
   Gattermann N, 2021, DTSCH ARZTEBL INT, V118, P847, DOI 10.3238/arztebl.m2021.0290
   Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097 2765(02)00708 6
   Guggenbuhl P, 2005, OSTEOPOROSIS INT, V16, P1809, DOI 10.1007/s00198 005 1934 0
   Hesselbarth N, 2017, INT J OBESITY, V41, P1815, DOI 10.1038/ijo.2017.172
   Houchens CR, 2000, NUCLEIC ACIDS RES, V28, P570, DOI 10.1093/nar/28.2.570
   Hvidberg V, 2005, FEBS LETT, V579, P773, DOI 10.1016/j.febslet.2004.12.031
   Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev genet 102108 134850
   Jia P, 2012, J ORTHOP RES, V30, P1843, DOI 10.1002/jor.22133
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Ke JY, 2017, ORAL DIS, V23, P784, DOI 10.1111/odi.12662
   Kern M, 2014, DIABETES, V63, P3295, DOI 10.2337/db13 0933
   Kim BJ, 2013, OSTEOPOROSIS INT, V24, P2627, DOI 10.1007/s00198 013 2363 0
   Kim BJ, 2012, J BONE MINER RES, V27, P2279, DOI 10.1002/jbmr.1692
   KJELDSEN L, 1993, J BIOL CHEM, V268, P10425
   Klöting N, 2007, DIABETES METAB RES, V23, P406, DOI 10.1002/dmrr.713
   Kovács P, 2001, METABOLISM, V50, P458, DOI 10.1053/meta.2001.21698
   Kudo H, 2008, TOXICOLOGY, V246, P143, DOI 10.1016/j.tox.2008.01.004
   Li SZ, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.707138
   Lim WH, 2015, J BONE MINER RES, V30, P2078, DOI 10.1002/jbmr.2546
   Liu G, 2006, BIOMETALS, V19, P245, DOI 10.1007/s10534 005 6666 2
   Luo C, 2022, FREE RADICAL BIO MED, V188, P337, DOI 10.1016/j.freeradbiomed.2022.06.236
   Moreno Navarrete JM, 2014, DIABETES CARE, V37, P1092, DOI 10.2337/dc13 1602
   Merono T, 2011, MEDICINA BUENOS AIRE, V71, P566
   Miller RG, 2006, AM J HEMATOL, V81, P236, DOI 10.1002/ajh.20541
   Mitchell AL, 2012, NAT REV ENDOCRINOL, V8, P306, DOI [10.1038/nrendo.2012.74, 10.1038/nrendo.2012.186, 10.1038/nrendo.2012.127, 10.1038/nrendo.2012.200, 10.1038/nrendo.2011.245, 10.1038/nrendo.2012.56]
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rossi F, 2014, HAEMATOLOGICA, V99, P1876, DOI 10.3324/haematol.2014.104463
   Roudkenar MH, 2008, ARCH MED RES, V39, P402, DOI 10.1016/j.arcmed.2007.12.002
   Rucci N, 2015, J BONE MINER RES, V30, P357, DOI 10.1002/jbmr.2341
   Ruschke K, 2010, BIOCHEM BIOPH RES CO, V400, P246, DOI 10.1016/j.bbrc.2010.08.049
   Sadat Ali M, 2011, BIOMETALS, V24, P19, DOI 10.1007/s10534 010 9391 4
   Schapira AHV, 2012, LANCET, V379, P1825, DOI 10.1016/S0140 6736(11)61305 6
   SCHNITZLER CM, 1994, J BONE MINER RES, V9, P1865
   Siddiqui WA, 2015, ARCH TOXICOL, V89, P289, DOI 10.1007/s00204 014 1448 7
   Singh L, 2016, BONE, V85, P29, DOI 10.1016/j.bone.2016.01.014
   Sinigaglia L, 1997, J RHEUMATOL, V24, P1809
   Torti SV, 2018, ANNU REV NUTR, V38, P97, DOI 10.1146/annurev nutr 082117 051732
   Tsay J, 2010, BLOOD, V116, P2582, DOI 10.1182/blood 2009 12 260083
   Valenti L, 2009, OSTEOPOROSIS INT, V20, P549, DOI 10.1007/s00198 008 0701 4
   Villalvilla A, 2016, SCI REP UK, V6, DOI 10.1038/srep29243
   Vogiatzi MG, 2009, J BONE MINER RES, V24, P543, DOI 10.1359/JBMR.080505
   Vogiatzi MG, 2006, BONE, V38, P571, DOI 10.1016/j.bone.2005.10.001
   Vogt ACS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094591
   Wang X, 2015, J ENDOCRINOL, V226, P121, DOI 10.1530/JOE 14 0657
   Weizer Stern O, 2006, AM J HEMATOL, V81, P479, DOI 10.1002/ajh.20549
   Xiao X, 2017, ANNU REV NUTR, V37, P103, DOI 10.1146/annurev nutr 071816 064559
   Yang F, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12422
   Zhou YY, 2022, TOXICOLOGY, V465, DOI 10.1016/j.tox.2021.153050
   Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238
NR 70
TC 9
Z9 11
U1 0
U2 7
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD SEP 25
PY 2023
VL 14
IS 9
AR 631
DI 10.1038/s41419 023 06160 w
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA T2RB1
UT WOS:001076496400002
PM 37749079
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Khayati, M
   Manjili, HK
   Soleimani, M
   Hosseinzadeh, S
   Akrami, M
   Haririan, I
   Tafti, SHA
AF Khayati, Maryam
   Manjili, Hamidreza Kheiri
   Soleimani, Masoud
   Hosseinzadeh, Simzar
   Akrami, Mohammad
   Haririan, Ismaeil
   Tafti, Seyed Hossein Ahmadi
TI Microfluidic synthesis of zoledronic acid loaded chitosan nanoparticles
   used for osteogenic differentiation of mesenchymal cells
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Chitosan nanoparticles; Mesenchymal stem cells (MSCs); Microfluidics
   platform; Osteogenic differentiation; Zoledronic acid
ID STEM CELLS; POLYMERIC NANOPARTICLES; DELIVERY; BONE; BISPHOSPHONATES;
   COMMITMENT; PLATFORM; LADEN
AB Zoledronic acid (ZA) is known as a potent bisphosphonate in osteogenic differentiation, but at high doses, it possesses toxic effects and causes decreased proliferation and differentiation of osteoblasts. Therefore, encap sulation of ZA into nanoparticles and control of its release is expected to promote differentiation of stem cells into osteoblasts. The present work aimed to develop a simple method for synthesis of monodisperse ZA loaded chi tosan (CS) nanoparticles. In this regard, we proposed a microfluidic synthesis of nanoparticles through the ionic cross linking of CS in the presence of ZA without a crosslinker. The main advantages of these microfluidic generated nanoparticles were narrow size distribution and fine spherical shape. Conversely, the nanoparticles that were synthesized using a bulk mixing method had an irregular shape with a broad size distribution. Real  time PCR assay as well as alizarin red staining were used to evaluate the in vitro osteogenic potential of the nanoparticles. The results indicated that the controlled release of ZA from the microfluidic system generated uniform nanoparticles, improving the osteogenic differentiation of mesenchymal stem cells. Additionally, this microfluidic device provided the well controlled synthesis of novel nanoparticles with a modified CS macro molecular polymer for targeted drug delivery systems.
C1 [Khayati, Maryam; Manjili, Hamidreza Kheiri] Zanjan Univ Med Sci, Sch Pharm, Dept Pharmaceut Nanotechnol, Zanjan, Iran.
   [Khayati, Maryam; Manjili, Hamidreza Kheiri] Zanjan Univ Med Sci, Pharmaceut Nanotechnol Res Ctr, Zanjan, Iran.
   [Soleimani, Masoud; Hosseinzadeh, Simzar] Shahid Beheshti Univ Med Sci, Med Nanotechnol & Tissue Engn Res Ctr, Tehran, Iran.
   [Soleimani, Masoud; Hosseinzadeh, Simzar] Shahid Beheshti Univ Med Sci, Sch Adv Technol Med, Dept Tissue Engn & Appl Cell Sci, Tehran, Iran.
   [Akrami, Mohammad; Haririan, Ismaeil] Univ Tehran Med Sci, Fac Pharm, Dept Pharmaceut Biomat, Tehran, Iran.
   [Akrami, Mohammad; Haririan, Ismaeil] Univ Tehran Med Sci, Fac Pharm, Med Biomat Res Ctr, Tehran, Iran.
   [Akrami, Mohammad; Haririan, Ismaeil] Univ Tehran, Inst Biomat, Tehran, Iran.
   [Akrami, Mohammad; Haririan, Ismaeil] Tehran Univ Med Sci IBUTUMS, Tehran, Iran.
   [Haririan, Ismaeil] Univ Tehran Med Sci, Fac Pharm, Dept Pharmaceut, Tehran, Iran.
   [Tafti, Seyed Hossein Ahmadi] Univ Tehran Med Sci, Tehran Heart Ctr Hosp, Res Ctr Adv Technol Cardiovasc Med, Tehran, Iran.
C3 Shahid Beheshti University Medical Sciences; Shahid Beheshti University
   Medical Sciences; Tehran University of Medical Sciences; Tehran
   University of Medical Sciences; University of Tehran; Tehran University
   of Medical Sciences; Tehran University of Medical Sciences
RP Manjili, HK (通讯作者)，Zanjan Univ Med Sci, Sch Pharm, Dept Pharmaceut Nanotechnol, Zanjan, Iran.
EM h.kheiri@zums.ac.ir
RI hosseinzadeh, simzar/J 7304 2019; akrami, Mohammad/AAK 9374 2021;
   manjili, hamidreza/J 9876 2016
FU Zanjan University of Medical Sciences [A 12 966 18]; Iran National
   Science Foundation (INSF) [98022870]
FX We gratefully acknowledge the financial support from the Zanjan
   University of Medical Sciences (Project Number A 12 966 18) and the Iran
   National Science Foundation (INSF) (Project Number 98022870) .
CR Aderibigbe B, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9010002
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Bodnar M, 2005, BIOMACROMOLECULES, V6, P2521, DOI 10.1021/bm0502258
   Ebert R, 2009, BONE, V44, P858, DOI 10.1016/j.bone.2009.01.009
   Giacalone G, 2013, BIOMACROMOLECULES, V14, P737, DOI 10.1021/bm301832v
   Hasani Sadrabadi M.M., ADV MATER, V26
   Hasani Sadrabadi MM, 2015, NANOMED NANOTECHNOL, V11, P1809, DOI 10.1016/j.nano.2015.04.005
   Hasani Sadrabadi MM, 2012, J AM CHEM SOC, V134, P18904, DOI 10.1021/ja307751a
   Hengst V, 2007, INT J PHARMACEUT, V331, P224, DOI 10.1016/j.ijpharm.2006.11.024
   Hood RR, 2015, SMALL, V11, P5790, DOI 10.1002/smll.201501345
   Huang Y, 2012, NANOSCALE, V4, P2484, DOI 10.1039/c2nr12072k
   Kang XJ, 2013, MICROFLUID NANOFLUID, V15, P337, DOI 10.1007/s10404 013 1152 6
   Karnik R, 2008, NANO LETT, V8, P2906, DOI 10.1021/nl801736q
   Li X, 2019, ACS APPL MATER INTER, V11, P7311, DOI 10.1021/acsami.8b16588
   Lu MQ, 2014, ACS NANO, V8, P10026, DOI 10.1021/nn502549v
   Mahmoudi Z, 2020, CARBOHYD POLYM, V229, DOI 10.1016/j.carbpol.2019.115551
   Majedi FS, 2014, ADV FUNCT MATER, V24, P432, DOI 10.1002/adfm.201301628
   Majedi FS, 2013, LAB CHIP, V13, P204, DOI 10.1039/c2lc41045a
   Majedi FS, 2012, CHEM COMMUN, V48, P7744, DOI 10.1039/c2cc33253a
   Mao SR, 2010, ADV DRUG DELIVER REV, V62, P12, DOI 10.1016/j.addr.2009.08.004
   Marra M., BIOTECHNOL ADV
   Marra M, 2011, NANOMED NANOTECHNOL, V7, P955, DOI 10.1016/j.nano.2011.03.004
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Pessoa ACSN, 2017, LAB CHIP, V17, P2281, DOI 10.1039/c7lc00291b
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Reid IR, 2005, NEW ENGL J MED, V353, P898, DOI 10.1056/NEJMoa044241
   Sabourian P, 2020, J CONTROL RELEASE, V317, P216, DOI 10.1016/j.jconrel.2019.11.029
   Salzano G, 2011, INT J PHARMACEUT, V403, P292, DOI 10.1016/j.ijpharm.2010.10.046
   Schiraldi C, 2014, CANCER BIOL THER, V15, P1524, DOI 10.4161/15384047.2014.955989
   Shamsi M, 2017, INT J BIOL MACROMOL, V99, P433, DOI 10.1016/j.ijbiomac.2017.03.013
   Shi XT, 2012, ADV FUNCT MATER, V22, P3799, DOI 10.1002/adfm.201200914
   Shmeeda H, 2013, J CONTROL RELEASE, V167, P265, DOI 10.1016/j.jconrel.2013.02.003
   Sipoli CC, 2015, BIOCHEM ENG J, V103, P114, DOI 10.1016/j.bej.2015.06.017
   Wacker JB, 2012, LAB CHIP, V12, P3111, DOI 10.1039/c2lc40300e
   Wang YJ, 2015, BIOTECHNOL ADV, V33, P1626, DOI 10.1016/j.biotechadv.2015.08.005
   Wu GS, 2016, CARBOHYD POLYM, V138, P49, DOI 10.1016/j.carbpol.2015.11.044
   Yang D, 2021, INT J BIOL MACROMOL, V182, P639, DOI 10.1016/j.ijbiomac.2021.04.057
   Yuan Y, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 72552 z
   Zeisberger SM, 2006, BRIT J CANCER, V95, P272, DOI 10.1038/sj.bjc.6603240
   Zhao X, 2016, ADV FUNCT MATER, V26, P2809, DOI 10.1002/adfm.201504943
NR 40
TC 7
Z9 7
U1 2
U2 24
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD APR 15
PY 2023
VL 234
AR 123056
DI 10.1016/j.ijbiomac.2022.12.275
EA FEB 2023
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 9U8VH
UT WOS:000947982300001
PM 36587647
DA 2025 08 17
ER

PT J
AU Stewart, DL
AF Stewart, Devin L.
TI PROSTHODONTIC TREATMENT OF A PATIENT TAKING NITROGEN CONTAINING
   BISPHOSPHONATES TO PRESERVE THE INTEGRITY OF THE EPITHELIAL ATTACHMENT:
   A CLINICAL REPORT
SO JOURNAL OF PROSTHETIC DENTISTRY
LA English
DT Article
ID ZOLEDRONIC ACID; POSTMENOPAUSAL OSTEOPOROSIS; MULTIPLE MYELOMA;
   OSTEONECROSIS; ALENDRONATE; JAWS; PAMIDRONATE; INHIBITION;
   CALCIFICATION; PYROPHOSPHATE
AB Osteonecrosis of the jaw has been identified in recent years as an unfortunate potential side effect for patients taking nitrogen containing bisphosphonates. Many authors have attempted unsuccessfully to elucidate the mechanism behind this drug induced malady, leaving dentists with unclear guidelines on how to treat these patients. Recent literature suggests a threshold related impairment of epithelial cell migration over bone. A conservative, non invasive approach aimed at preserving the epithelial attachment in a patient on a long term oral alendronate protocol is described. The advantage of this approach is to prevent a highly destructive bone degenerative process that does not have a clear and predictable treatment protocol. (J Prosthet Dent 2011;106:350 354)
C1 [Stewart, Devin L.] Univ Calif Los Angeles, Sch Dent, Dept Removable Prosthodont, Los Angeles, CA 90024 USA.
C3 University of California System; University of California Los Angeles
RP Stewart, DL (通讯作者)，360 San Miguel Dr,Suite 204, Newport Beach, CA 92660 USA.
EM dlstewart@ncofi.org
CR Assouline Dayan Y, 2002, SEMIN ARTHRITIS RHEU, V32, P94, DOI 10.1053/sarh.2002.33724
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403
   Edwards BJ, 2008, J AM DENT ASSOC, V139, P1674, DOI 10.14219/jada.archive.2008.0110
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FLEISCH H, 1962, AM J PHYSIOL, V203, P671, DOI 10.1152/ajplegacy.1962.203.4.671
   FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264
   Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538 7836.2006.02259.x
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Marx RE, 2007, J ORAL MAXIL SURG, V65, P2397, DOI 10.1016/j.joms.2007.08.003
   Mavrokokki T, 2007, J ORAL MAXIL SURG, V65, P415, DOI 10.1016/j.joms.2006.10.061
   Mayor P, 2002, ONCOLOGIST, V7, P481
   Migliorati CA, 2005, J AM DENT ASSOC, V136, P1658, DOI 10.14219/jada.archive.2005.0108
   Migliorati CA, 2003, J CLIN ONCOL, V21, P4253, DOI 10.1200/JCO.2003.99.132
   Mitchell DY, 2001, PHARMACEUT RES, V18, P166, DOI 10.1023/A:1011024200280
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Reid IR, 2007, BONE, V41, P318, DOI 10.1016/j.bone.2007.04.196
   Reitemeier RF, 1940, J PHYS CHEM US, V44, P535, DOI 10.1021/j150401a001
   Reszka AA, 2001, MOL PHARMACOL, V59, P193, DOI 10.1124/mol.59.2.193
   Rosen LS, 2001, CANCER J, V7, P377
   Ruggiero S, 2006, J ONCOL PRACT, V2, P7, DOI 10.1200/JOP.2.1.7
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Sedghizadeh PP, 2009, J AM DENT ASSOC, V140, P61, DOI 10.14219/jada.archive.2009.0019
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Wallace JL, 1999, ALIMENT PHARM THER, V13, P1675
   Wang J, 2003, J ORAL MAXIL SURG, V61, P1104, DOI 10.1016/S0278 2391(03)00328 8
NR 34
TC 3
Z9 3
U1 0
U2 1
PU MOSBY ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0022 3913
J9 J PROSTHET DENT
JI J. Prosthet. Dent.
PD DEC
PY 2011
VL 106
IS 6
BP 350
EP 354
DI 10.1016/S0022 3913(11)60144 3
PG 5
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 871YK
UT WOS:000298773400002
PM 22133390
DA 2025 08 17
ER

PT J
AU Fu, FD
   Luo, H
   Du, Y
   Chen, YY
   Tian, K
   Pan, J
   Li, J
   Wang, NN
   Bao, RH
   Jin, HT
   Tong, PJ
   Ruan, HF
   Wu, CL
AF Fu, Fangda
   Luo, Huan
   Du, Yu
   Chen, Yuying
   Tian, Kun
   Pan, Jin
   Li, Jian
   Wang, Nani
   Bao, Ronghua
   Jin, Hongting
   Tong, Peijian
   Ruan, Hongfeng
   Wu, Chengliang
TI AR/PCC herb pair inhibits osteoblast pyroptosis to alleviate diabetes 
   related osteoporosis by activating Nrf2/Keap1 pathway
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE Anemarrhenae Rhizoma/Phellodendri Chinensis Cortex herb pair; diabetes;
   Nrf2/Keap1 signalling; osteoporosis; pyroptosis
ID NERVE FIBERS; KAPPA B; CELLS; METHYLGLYOXAL; ANGIOGENESIS; OSTEOGENESIS;
   EXPRESSION; ACID
AB Osteoporosis is a prevalent complication of diabetes, characterized by systemic metabolic impairment of bone mass and microarchitecture, particularly in the spine. Anemarrhenae Rhizoma/Phellodendri Chinensis Cortex (AR/PCC) herb pair has been extensively employed in Traditional Chinese Medicine to manage diabetes; however, its potential to ameliorate diabetic osteoporosis (DOP) has remained obscure. Herein, we explored the protective efficacy of AR/PCC herb pair against DOP using a strep tozotocin (STZ) induced rat diabetic model. Our data showed that AR/PCC could effectively reduce the elevated fasting blood glucose and reverse the osteoporotic phenotype of diabetic rats, resulting in significant improvements in vertebral trabecular area percentage, trabecular thickness and trabecular number, while reducing trabecular separation. Specifically, AR/PCC herb pair improved impaired osteogenesis, nerve ingrowth and angiogenesis. More importantly, it could mitigate the aberrant activation of osteoblast pyroptosis in the vertebral bodies of diabetic rats by reducing increased expressions of Nlrp3, Asc, Caspase1, Gsdmd and IL  1 beta. Mechanistically, AR/PCC activated antioxidant pathway through the upregulation of the antioxidant response protein Nrf2, while concurrently decreasing its negative feedback regulator Keap1. Collectively, our in vivo findings demonstrate that AR/PCC can inhibit osteoblast pyroptosis and alleviate STZ induced rat DOP, suggesting its potential as a therapeutic agent for mitigating DOP.
C1 [Fu, Fangda; Jin, Hongting; Tong, Peijian; Ruan, Hongfeng; Wu, Chengliang] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Tradit Chinese Med, Inst Orthopaed & Traumatol, Hangzhou, Peoples R China.
   [Luo, Huan] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Pharm, Hangzhou, Peoples R China.
   [Du, Yu] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Hangzhou, Peoples R China.
   [Chen, Yuying] Zhejiang Chinese Med Univ, Clin Med Coll 4, Hangzhou, Peoples R China.
   [Tian, Kun] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Orthopaed, Hangzhou, Peoples R China.
   [Pan, Jin] China Acad Art, Sch Architecture, Dept Architecture, Hangzhou, Peoples R China.
   [Li, Jian] Hangzhou Ninth Peoples Hosp, Dept Orthopaed, Hangzhou, Peoples R China.
   [Wang, Nani] Zhejiang Acad Tradit Chinese Med, Dept Med, Hangzhou, Peoples R China.
   [Bao, Ronghua] Hangzhou Fuyang Hosp TCM Orthoped & Traumatol, Hangzhou 311400, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang University; Zhejiang
   Chinese Medical University; Zhejiang Chinese Medical University;
   Zhejiang Chinese Medical University; China Academy of Art
RP Ruan, HF (通讯作者)，Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Tradit Chinese Med, Inst Orthopaed & Traumatol, Hangzhou, Peoples R China.; Wang, NN (通讯作者)，Zhejiang Acad Tradit Chinese Med, Dept Med, Hangzhou, Peoples R China.; Bao, RH (通讯作者)，Hangzhou Fuyang Hosp TCM Orthoped & Traumatol, Hangzhou 311400, Zhejiang, Peoples R China.
EM wnn8511@163.com; 13647516@qq.com; rhf@zcmu.edu.cn
RI ; Ruan, Hongfeng/HKO 1118 2023
OI Chen, YuYing/0009 0007 2192 6485; 
FU National Natural Science Foundation of China [82174140, 82174401,
   81973870, 81973881]; Natural Science Foundation of Zhejiang Province
   [LQ23H270003, LY22H270003]; Joint Funds of the Zhejiang Provincial
   Natural Science Foundation of China [LBY22H270008]; Traditional Chinese
   Medical Administration of Zhejiang Province [2023ZR019, 2023ZL128,
   2022ZX005, 2022ZB119, 2021ZB090]; Zhejiang Medical and Health Science
   and Technology Project [2023RC194, 2021KY222]; Research Project of
   Zhejiang Chinese Medical University [2021JKZDZC02, 2021JKZKTS036A];
   Research Project of Zhejiang Chinese Medical University Affiliated
   Hospital [2022FSYYZZ05, 2022FSYYZQ02]; Zhejiang Chinese Medical
   University School level Education and Teaching Reform Project [CY22001]
FX This work was financially supported by National Natural Science
   Foundation of China (no. 82174140, 82174401, 81973870, 81973881),
   Natural Science Foundation of Zhejiang Province (no. LQ23H270003 and
   LY22H270003), Joint Funds of the Zhejiang Provincial Natural Science
   Foundation of China (no. LBY22H270008), Traditional Chinese Medical
   Administration of Zhejiang Province (no. 2023ZR019, 2023ZL128,
   2022ZX005, 2022ZB119, 2021ZB090), Zhejiang Medical and Health Science
   and Technology Project (no. 2023RC194, 2021KY222), Research Project of
   Zhejiang Chinese Medical University (no. 2021JKZDZC02, 2021JKZKTS036A),
   Research Project of Zhejiang Chinese Medical University Affiliated
   Hospital (no. 2022FSYYZZ05 and 2022FSYYZQ02), Zhejiang Chinese Medical
   University School level Education and Teaching Reform Project (no.
   CY22001).
CR Arioz BI, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01511
   Athyros VG, 2018, HORM INT J ENDOCRINO, V17, P61, DOI 10.1007/s42000 018 0014 8
   Behera J, 2022, DIABETES, V71, P2777, DOI 10.2337/db21 0573
   Bortolin RH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125349
   Chen J, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.964808
   Chen XL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.651589
   Chen Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27563 3
   Chen YY, 2023, ECOTOX ENVIRON SAFE, V249, DOI 10.1016/j.ecoenv.2022.114376
   Choi EM, 2016, J AGR FOOD CHEM, V64, P226, DOI 10.1021/acs.jafc.5b05157
   Cipriani C, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00122
   Enríquez Pérez IA, 2017, NEUROSCI LETT, V655, P28, DOI 10.1016/j.neulet.2017.06.042
   Ferrari SL, 2018, OSTEOPOROSIS INT, V29, P2585, DOI 10.1007/s00198 018 4650 2
   Galliera E, 2017, IMMUN AGEING, V14, DOI 10.1186/s12979 017 0097 0
   Grässel S, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0485 1
   Han DD, 2019, FREE RADICAL BIO MED, V137, P1, DOI 10.1016/j.freeradbiomed.2019.04.014
   Hsu YH, 2014, J ETHNOPHARMACOL, V151, P635, DOI 10.1016/j.jep.2013.11.031
   Irie K, 2002, MICROSC RES TECHNIQ, V58, P85, DOI 10.1002/jemt.10122
   Jaasma MJ, 2007, J BIOMECH, V40, P1938, DOI 10.1016/j.jbiomech.2006.09.010
   Jeong SJ, 2003, BIOL PHARM BULL, V26, P1721, DOI 10.1248/bpb.26.1721
   Jiang N, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.752546
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim KR, 2022, PLANTS BASEL, V11, DOI 10.3390/plants11010023
   Kubo Y, 2019, CALCIFIED TISSUE INT, V105, P341, DOI 10.1007/s00223 019 00576 3
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lei LY, 2021, CHIN J NAT MEDICINES, V19, P112, DOI 10.1016/S1875 5364(21)60012 2
   Li HL, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906 019 2651 0
   Li J, 2015, GENET MOL RES, V14, P11292, DOI 10.4238/2015.September.22.23
   Li M, 2016, J ETHNOPHARMACOL, V185, P120, DOI 10.1016/j.jep.2016.03.023
   Lin F, 2020, J TRANSL MED, V18, DOI 10.1186/s12967 020 02467 w
   Liu F, 2021, EUR J PHARMACOL, V909, DOI 10.1016/j.ejphar.2021.174377
   Liu JM, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00778
   Liu XW, 2015, CHIN J NAT MEDICINES, V13, P145, DOI 10.1016/S1875 5364(15)60019 X
   Liu YW, 2018, PHYTOTHER RES, V32, P1574, DOI 10.1002/ptr.6088
   Ma HD, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9067610
   Ma RF, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/3218313
   Matsubara H, 2012, BONE, V51, P168, DOI 10.1016/j.bone.2012.02.017
   Mediero A, 2015, J BONE MINER RES, V30, P837, DOI 10.1002/jbmr.2421
   Mohsin S, 2019, EXPERT OPIN BIOL TH, V19, P937, DOI 10.1080/14712598.2019.1618266
   Peng J, 2016, CONNECT TISSUE RES, V57, P277, DOI 10.3109/03008207.2016.1171858
   Rios Arce ND, 2020, J CELL PHYSIOL, V235, P2350, DOI 10.1002/jcp.29141
   Schröder K, 2015, CELL MOL LIFE SCI, V72, P25, DOI 10.1007/s00018 014 1712 2
   Sharma BR, 2021, NAT IMMUNOL, V22, P550, DOI 10.1038/s41590 021 00886 5
   Shi JW, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.898360
   Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514
   Suh KS, 2016, CYTOTECHNOLOGY, V68, P2539, DOI 10.1007/s10616 016 9977 y
   Takafuji Y, 2019, J CELL PHYSIOL, V234, P9687, DOI 10.1002/jcp.27655
   Thounaojam MC, 2019, DIABETES, V68, P1014, DOI 10.2337/db18 0912
   Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725
   Tu WJ, 2019, AGING DIS, V10, P637, DOI 10.14336/AD.2018.0513
   Wada J, 2016, NAT REV NEPHROL, V12, P13, DOI 10.1038/nrneph.2015.175
   Wan LQ, 2022, INT J BIOL SCI, V18, P809, DOI 10.7150/ijbs.63219
   Wang NN, 2021, CARBOHYD POLYM, V271, DOI 10.1016/j.carbpol.2021.118438
   Wang NN, 2021, FREE RADICAL BIO MED, V171, P112, DOI 10.1016/j.freeradbiomed.2021.05.014
   Wang NN, 2020, PHYTOMEDICINE, V75, DOI 10.1016/j.phymed.2020.153247
   Watson EC, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031559
   Xian YF, 2011, J ETHNOPHARMACOL, V137, P1425, DOI 10.1016/j.jep.2011.08.014
   Xie HG, 2018, BIOMED PHARMACOTHER, V108, P280, DOI 10.1016/j.biopha.2018.08.131
   Xie YB, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00381
   Xu PC, 2022, J ETHNOPHARMACOL, V293, DOI 10.1016/j.jep.2022.115269
   Yang L, 2020, BIOCHEM BIOPH RES CO, V522, P471, DOI 10.1016/j.bbrc.2019.11.080
   Yin YK, 2020, SCI REP UK, V10, DOI 10.1038/s41598 019 57185 1
   Ying Y, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00774
   Yu H, 2021, J ETHNOPHARMACOL, V266, DOI 10.1016/j.jep.2020.113447
   Zhang HH, 2021, DRUG DES DEV THER, V15, P4911, DOI 10.2147/DDDT.S338439
   Zhao XN, 2018, BIOMED CHROMATOGR, V32, DOI 10.1002/bmc.4296
   Zhu CY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.898634
NR 66
TC 16
Z9 20
U1 3
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD NOV
PY 2023
VL 27
IS 22
BP 3601
EP 3613
DI 10.1111/jcmm.17928
EA AUG 2023
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA GP4F2
UT WOS:001082612000001
PM 37621124
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Jaarah, N
   Lam, CFJ
   Lodhia, N
   Dulnoan, D
   Moore, AE
   Hampson, G
AF Jaarah, N.
   Lam, C. F. J.
   Lodhia, N.
   Dulnoan, D.
   Moore, A. E.
   Hampson, G.
TI Differential effects of teriparatide, denosumab and zoledronate on hip
   structural and mechanical parameters in osteoporosis; a real life study
SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
LA English
DT Article
DE Osteoporosis; Teriparatide; Denosumab; Zoledronate; Hip geometry
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; PARATHYROID HORMONE;
   FEMORAL NECK; FRACTURES; STRENGTH; METAANALYSIS; GEOMETRY; FEMUR; RISK
AB Purpose The aim of this study was to evaluate changes in hip geometry parameters following treatment with teriparatide (TPD), denosumab (Dmab) and zoledronate (ZOL) in real life setting.
   Methods We studied 249 patients with osteoporosis (OP) with mean [SD] age of 71.5 [11.1] years divided into 3 treatment groups; Group A received TPD; n = 55, Group B (Dmab); n = 116 and Group C (ZOL); n = 78 attending a routine metabolic bone clinic. Bone mineral density (BMD) was measured by DXA at the lumbar spine (LS), total hip (TH) and femoral neck (FN) prior to treatment and after 2 years (Group A), after a mean treatment duration of 3.3 [1.3] years (Group B) and after 1, 2 and 3 doses of ZOL (Group C) to assess treatment response. Hip structural analysis (HSA) was carried out retrospectively from DXA acquired femur images at the narrow neck (NN), the intertrochanter (IT) and femoral shaft (FS).
   Results Changes in parameters of hip geometry and mechanical strength were seen in the following treatment. Percentage change in cross sectional area (CSA): 3.56[1.6] % p = 0.01 and cross sectional moment of inertia (CSMI): 4.1[1.8] % p = 0.029 increased at the NN only in Group A. Improvement in HSA parameters at the IT were seen in group B: CSA: 3.3[0.67]% p < 0.001, cortical thickness (Co Th): 2.8[0.78]% p = 0.001, CSMI: 5.9[1.3]% p < 0.001, section modulus (Z):6.2[1.1]% p < 0.001 and buckling ratio (BR):   3.0[0.86]% p = 0.001 with small changes at the FS: CSA: 1.2[ 0.4]% p = 0.005, Z:1.6 [0.76]%, p = 0.04. Changes at the IT were also seen in Group C (after 2 doses): CSA: 2.5[0.77]% p = 0.017, Co Th: 2.4[0.84]% p = 0.012, CSMI: 3.9[1.3]% p = 0.017, Z:5.2[1.16]% p < 0.001 and BR:   3.1[0.88]% p = 0.001 and at the NN (following 3 doses): outer diameter (OD): 4.0[1.4]% p = 0.0005, endocortical diameter(ED): 4.3[1.67% p = 0.009, CSA:5.2[1.8]% p = 0.003, CSMI: 9.3[3.8]% p = 0.019.
   Conclusions Analysis of the effect of OP therapies on hip geometry is useful in understanding the mechanisms of their antifracture effect and may provide additional information on their efficacy.
C1 [Jaarah, N.; Lam, C. F. J.; Lodhia, N.; Hampson, G.] St Thomas Hosp, Dept Chem Pathol & Metab Med, 5Th Floor,Lambeth Palace Rd, London, England.
   [Jaarah, N.; Lam, C. F. J.; Lodhia, N.; Dulnoan, D.; Moore, A. E.; Hampson, G.] Guys Hosp, Osteoporosis Unit, London SE1 7EH, England.
C3 Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS
   Foundation Trust
RP Hampson, G (通讯作者)，St Thomas Hosp, Dept Chem Pathol & Metab Med, 5Th Floor,Lambeth Palace Rd, London, England.; Hampson, G (通讯作者)，Guys Hosp, Osteoporosis Unit, London SE1 7EH, England.
EM geeta.hampson@kcl.ac.uk
OI Hampson, Geeta/0000 0001 8465 5247
CR Antonini S, 2024, J ENDOCRINOL INVEST, V47, P433, DOI 10.1007/s40618 023 02174 5
   Augoulea A, 2017, J MUSCULOSKEL NEURON, V17, P444
   Beck Thomas J, 2007, Curr Osteoporos Rep, V5, P49
   Beck TJ, 2000, J BONE MINER RES, V15, P2297, DOI 10.1359/jbmr.2000.15.12.2297
   Bilezikian JP, 2019, OSTEOPOROSIS INT, V30, P1855, DOI 10.1007/s00198 019 05020 8
   BLACK DM, 2007, NEW ENGL J MED, V356, P1809, DOI DOI 10.1056/NEJMOA067312
   Bonnick SL, 2009, OSTEOPOROSIS INT, V20, P911, DOI 10.1007/s00198 008 0762 4
   Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157
   Cianferotti L, 2023, J ENDOCRINOL INVEST, V46, P1283, DOI 10.1007/s40618 023 02056 w
   Crandall CJ, 2014, ANN INTERN MED, V161, P711, DOI 10.7326/M14 0317
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Danielson ME, 2013, OSTEOPOROSIS INT, V24, P1379, DOI 10.1007/s00198 012 2066 y
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   Díez Pérez A, 2019, BONE, V120, P1, DOI 10.1016/j.bone.2018.09.020
   Hampson G, 2021, ENDOCRINE, V73, P509, DOI 10.1007/s12020 021 02735 9
   Han SL, 2012, INT J CLIN PRACT, V66, P199, DOI 10.1111/j.1742 1241.2011.02837.x
   Hansen S, 2013, J BONE MINER RES, V28, P736, DOI 10.1002/jbmr.1784
   Kaptoge S, 2008, J BONE MINER RES, V23, P1892, DOI [10.1359/jbmr.080802, 10.1359/JBMR.080802]
   Keaveny TM, 2014, J BONE MINER RES, V29, P158, DOI 10.1002/jbmr.2024
   Kim Kwangkyoun, 2021, Hip Pelvis, V33, P45, DOI 10.5371/hp.2021.33.2.45
   LaCroix AZ, 2010, OSTEOPOROSIS INT, V21, P919, DOI 10.1007/s00198 009 1056 1
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Lyu HC, 2019, J CLIN ENDOCR METAB, V104, P1753, DOI 10.1210/jc.2018 02236
   Nakamura T, 2017, OSTEOPOROSIS INT, V28, P389, DOI 10.1007/s00198 016 3736 y
   Oswald AJ, 2014, CALCIFIED TISSUE INT, V94, P176, DOI 10.1007/s00223 013 9788 5
   Poole KES, 2015, J BONE MINER RES, V30, P46, DOI 10.1002/jbmr.2325
   Poole KES, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038466
   Ramamurthi K, 2012, OSTEOPOROSIS INT, V23, P543, DOI 10.1007/s00198 011 1578 1
   Sone Teruki, 2017, Bone Rep, V7, P164, DOI 10.1016/j.bonr.2017.11.002
   Stevens LA, 2007, J AM SOC NEPHROL, V18, P2749, DOI 10.1681/ASN.2007020199
   Unnanuntana A, 2011, CLIN ORTHOP RELAT R, V469, P2194, DOI 10.1007/s11999 010 1694 9
   Van Staa TP, 2001, BONE, V29, P517, DOI 10.1016/S8756 3282(01)00614 7
   Zebaze RM, 2014, BONE, V59, P173, DOI 10.1016/j.bone.2013.11.016
NR 33
TC 1
Z9 1
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0391 4097
EI 1720 8386
J9 J ENDOCRINOL INVEST
JI J. Endocrinol. Invest.
PD JUL
PY 2024
VL 47
IS 7
BP 1667
EP 1677
DI 10.1007/s40618 023 02280 4
EA JAN 2024
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA WE4M6
UT WOS:001137850900001
PM 38191946
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Sun, FM
   Cheng, Y
   Chen, JR
   Wanchai, V
   Mery, DE
   Xu, HW
   Gai, DZ
   Al Hadidi, S
   Schinke, C
   Thanendrarajan, S
   Zangari, M
   van Rhee, F
   Tricot, G
   Shaughnessy, JD 
   Zhan, FH
AF Sun, Fumou
   Cheng, Yan
   Chen, Jin Ran
   Wanchai, Visanu
   Mery, David E.
   Xu, Hongwei
   Gai, Dongzheng
   Al Hadidi, Samer
   Schinke, Carolina
   Thanendrarajan, Sharmilan
   Zangari, Maurizio
   van Rhee, Frits
   Tricot, Guido
   Shaughnessy, John D., Jr.
   Zhan, Fenghuang
TI BCMA  and CST6 specific CAR T cells lyse multiple myeloma cells and
   suppress murine osteolytic lesions
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID THERAPY; ANTIGEN; GENERATION; DKK1
AB We have previously demonstrated that cystatin E/M (CST6), which is elevated in a subset of patients with multiple myeloma (MM) lacking osteolytic lesions (OLs), suppresses MM bone disease by blocking osteoclast differentiation and function. CST6 is a secreted type 2 cystatin, a cysteine protease inhibitor that regulates lysosomal cysteine proteases and the asparaginyl endopeptidase legumain. Here, we developed B cell maturation antigen (BCMA) CST6 chimeric antigen receptor T cells (CAR T cells), which lysed MM cells and released CST6 proteins. Our in vitro studies show that these CAR T cells suppressed the differentiation and formation of tartrate resistant acid phosphatase positive (TRAP+) osteoclasts. Using xenografted MM mice, bioluminescence images showed that both BCMA CAR T and BCMA CST6 CAR T cells inhibited MM growth to a similar extent. Reconstructed micro computed tomography images revealed that BCMA CST6 CAR T cells, but not BCMA CAR T cells, prevented MM induced bone damage and decreased osteoclast numbers. Our results provide a CAR T strategy that targets tumor cells directly and delivers an inhibitor of bone resorption.
C1 [Sun, Fumou; Cheng, Yan; Wanchai, Visanu; Mery, David E.; Xu, Hongwei; Gai, Dongzheng; Al Hadidi, Samer; Schinke, Carolina; Thanendrarajan, Sharmilan; Zangari, Maurizio; van Rhee, Frits; Tricot, Guido; Shaughnessy, John D., Jr.; Zhan, Fenghuang] Univ Arkansas Med Sci UAMS, Winthrop P Rockefeller Inst, Dept Internal Med, Myeloma Ctr, Little Rock, AR USA.
   [Chen, Jin Ran] Univ Arkansas Med Sci UAMS, Arkansas Childrens Nutr Ctr, Little Rock, AR USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences
RP Zhan, FH (通讯作者)，Univ Arkansas Med Sci, Dept Internal Med, 4301 W Markham St, Little Rock, AR 72205 USA.
EM FZhan@uams.edu
RI ; Zhong, Wenzhao/C 3388 2008; Hadidi, Samer/ABB 9061 2020; Wanchai,
   Visanu/AAR 9992 2020
OI Mery, David/0000 0002 8327 9777; Sun, Fumou/0000 0003 2034 3492;
   Schinke, Carolina/0000 0002 2699 1741; Cheng, Yan/0000 0001 7877 9622; 
FU National Cancer Institute (NCI), NIH [1R01CA236814 01A1,
   3R01 CA236814 03S1, U54CA272691 01]; US Department of Defense
   [CA180190]; Myeloma Crowd Research Initiative Award; Paula and Rodger
   Riney Foundation; UAMS Winthrop P. Rockefeller Cancer Institute (WRCRI)
   Fund; Arkansas Breast Cancer Research Program
FX We are indebted to the clinicians of the Myeloma Institute for Research
   and Therapy for referring patients to this study and to all the patients
   who have helped us in our pursuit of a cure. This study was funded by
   National Cancer Institute (NCI), NIH grants 1R01CA236814 01A1 (to FZ),
   3R01 CA236814 03S1 (to FZ), and U54CA272691 01 (to FZ and JDS); by the
   US Department of Defense grant CA180190 (to FZ); the Myeloma Crowd
   Research Initiative Award (to FZ); the Paula and Rodger Riney Foundation
   (to FZ); the UAMS Winthrop P. Rockefeller Cancer Institute (WRCRI) Fund
   (to FZ); and the Arkansas Breast Cancer Research Program (to FS). We
   thank iCell Gene Therapeutics Inc. for constructing and providing the
   CAR vectors. We thank the UAMS Genomics Core for single cell RNA Seq and
   the Tissue Biorepository and Procurement Service (TBAPS) for providing
   primary samples.
CR Berdeja JG, 2021, LANCET, V398, P314, DOI 10.1016/S0140 6736(21)00933 8
   Cafforio P, 2014, J BONE MINER RES, V29, P55, DOI 10.1002/jbmr.2022
   Carpenter RO, 2013, CLIN CANCER RES, V19, P2048, DOI 10.1158/1078 0432.CCR 12 2422
   Chmielewski M, 2017, CELL REP, V21, P3205, DOI 10.1016/j.celrep.2017.11.063
   Chmielewski M, 2015, EXPERT OPIN BIOL TH, V15, P1145, DOI 10.1517/14712598.2015.1046430
   Chmielewski M, 2011, CANCER RES, V71, P5697, DOI 10.1158/0008 5472.CAN 11 0103
   Gai DZ, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI159527
   García Guerrero E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01128
   Giuliani N, 2002, BLOOD, V100, P4615, DOI 10.1182/blood 2002 04 1121
   Glass DA, 2003, NEW ENGL J MED, V349, P2479, DOI 10.1056/NEJMp038176
   Goltzman D, 2001, J CLIN INVEST, V107, P1219, DOI 10.1172/JCI13073
   Harmer D, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00788
   Jaspers JE, 2023, J CLIN INVEST, V133, DOI 10.1172/JCI166028
   Kong LB, 2019, J CELL MOL MED, V23, P3077, DOI 10.1111/jcmm.14277
   Kuehl WM, 2012, J CLIN INVEST, V122, P3456, DOI 10.1172/JCI61188
   Li JR, 2011, J CLIN INVEST, V121, P4655, DOI 10.1172/JCI46134
   Marino S, 2021, BRIT J PHARMACOL, V178, P1907, DOI 10.1111/bph.14889
   Martin T, 2023, J CLIN ONCOL, V41, P1265, DOI 10.1200/JCO.22.00842
   Matsumoto T, 2011, BONE, V48, P129, DOI 10.1016/j.bone.2010.05.036
   Munshi NC, 2021, NEW ENGL J MED, V384, P705, DOI 10.1056/NEJMoa2024850
   Okuma A, 2021, METHODS MOL BIOL, V2312, P3, DOI 10.1007/978 1 0716 1441 9_1
   Oyajobi BO, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2168
   Pegram HJ, 2012, BLOOD, V119, P4133, DOI 10.1182/blood 2011 12 400044
   Philip B, 2014, BLOOD, V124, P1277, DOI 10.1182/blood 2014 01 545020
   Raje N, 2019, NEW ENGL J MED, V380, P1726, DOI 10.1056/NEJMoa1817226
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470 2045(18)30072 X
   Raje NS, 2019, CLIN CANCER RES, V25, P12, DOI 10.1158/1078 0432.CCR 18 1537
   Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361
   Terpos E, 2009, ANN ONCOL, V20, P1303, DOI 10.1093/annonc/mdn796
   Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 017 0037 4
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Yang JR, 2023, CANCER LETT, V553, DOI 10.1016/j.canlet.2022.215949
   Yeku OO, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10940 8
   Zah E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 16160 5
   Zamagni E, 2019, BLOOD, V133, P644, DOI 10.1182/blood 2018 08 825356
NR 36
TC 2
Z9 2
U1 1
U2 6
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JAN 2
PY 2024
VL 134
IS 1
AR e171396
DI 10.1172/JCI171396
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA JD2S8
UT WOS:001171162100006
PM 37883186
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Costa, V
   Carina, V
   Fontana, S
   De Luca, A
   Monteleone, F
   Pagani, S
   Sartori, M
   Setti, S
   Faldini, C
   Alessandro, R
   Fini, M
   Giavaresi, G
AF Costa, Viviana
   Carina, Valeria
   Fontana, Simona
   De Luca, Angela
   Monteleone, Francesca
   Pagani, Stefania
   Sartori, Maria
   Setti, Stefania
   Faldini, Cesare
   Alessandro, Riccardo
   Fini, Milena
   Giavaresi, Gianluca
TI Osteogenic commitment and differentiation of human mesenchymal stem
   cells by low intensity pulsed ultrasound stimulation
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE low intensity pulsed ultrasound; mesenchymal stem cells; osteogenic
   commitment; osteoblast differentiation; proteomic analysis
ID THERAPEUTIC ULTRASOUND; OSTEOBLASTIC CELLS; BONE MARROW; LINEAGE
   COMMITMENT; EXPRESSION; OSTEONECTIN; MAINTENANCE; PROGENITORS;
   HYPOTHESIS; MATURATION
AB Low intensity pulsed ultrasound (LIPUS) as an adjuvant therapy in in vitro and in vivo bone engineering has proven to be extremely useful. The present study aimed at investigating the effect of 30mW/cm(2) LIPUS stimulation on commercially available human mesenchymal stem cells (hMSCs) cultured in basal or osteogenic medium at different experimental time points (7, 14, 21 days). The hypothesis was that LIPUS would improve the osteogenic differentiation of hMSC and guarantying the maintenance of osteogenic committed fraction, as demonstrated by cell vitality and proteomic analysis. LIPUS stimulation (a) regulated the balance between osteoblast commitment and differentiation by specific networks (activations of RhoA/ROCK signaling and upregulation of Ribosome constituent/Protein metabolic process, Glycolysis/Gluconeogenesis, RNA metabolic process/Splicing and Tubulins); (b) allowed the maintenance of a few percentage of osteoblast precursors (21 days CD73+/CD90+: 6%; OCT 3/4+/NANOG+/SOX2+: 10%); (c) induced the activation of osteogenic specific pathways shown by gene expression (early: ALPL, COL1A1, late: RUNX2, BGLAP, MAPK1/6) and related protein release (COL1a1, OPN, OC), in particular in the presence of osteogenic soluble factors able to mimic bone microenvironment. To summarize, LIPUS might be able to improve the osteogenic commitment of hMSCs in vitro, and, at the same time, enhance their osteogenic differentiation.
C1 [Costa, Viviana; Carina, Valeria; De Luca, Angela; Giavaresi, Gianluca] Rizzoli Orthoped Inst, Innovat Technol Platforms Tissue Engn Theranost &, Palermo, Italy.
   [Fontana, Simona; Monteleone, Francesca; Alessandro, Riccardo] Univ Palermo, Biol & Genet Unit, Dept Biopathol & Med Biotechnol, Palermo, Italy.
   [Pagani, Stefania; Fini, Milena; Giavaresi, Gianluca] Rizzoli Orthoped Inst, Lab Preclin & Surg Studies, Bologna, Italy.
   [Sartori, Maria; Fini, Milena] Rizzoli Orthoped Inst, Lab BITTA, Bologna, Italy.
   [Setti, Stefania] IGEA SpA, Modena, Italy.
   [Faldini, Cesare] Rizzoli Orthoped Inst, Orthopaed & Traumatol Clin 2, Bologna, Italy.
C3 IRCCS Istituto Ortopedico Rizzoli; University of Palermo; IRCCS Istituto
   Ortopedico Rizzoli; IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto
   Ortopedico Rizzoli
RP Costa, V (通讯作者)，Rizzoli Orthoped Inst, Via Divisi 83, I 90133 Palermo, Italy.
EM viviana.costa@ior.it
RI Sartori, Maria/K 3092 2018; Giavaresi, Gianluca/J 5583 2016; De Luca,
   Angela/ABD 3384 2020; costa, viviana/K 4084 2016; Fontana,
   Simona/AAI 9072 2020; COSTA, VIVIANA/K 4084 2016; Pagani,
   Stefania/C 7151 2019; deluca, angela/ABD 3384 2020; Fini,
   Milena/J 4808 2016; carina, valeria/K 2001 2016
OI Sartori, Maria/0000 0002 2123 9032; De Luca, Angela/0000 0001 5493 9441;
   costa, viviana/0000 0002 2425 6460; Giavaresi,
   Gianluca/0000 0001 7843 5969; Pagani, Stefania/0000 0002 4055 3828;
   Fini, Milena/0000 0002 3732 3570; carina, valeria/0000 0002 7323 8023;
   Fontana, Simona/0000 0003 4681 2170
FU Operational Programme ERDF [PON01_00829]; Piattaforme Tecnologiche per
   l'Ingegneria Tis [PON03_00011]; Potenziamento strutturale di una rete di
   eccell; Cinque per mille
FX Operational Programme ERDF 2007 2013; PON01_00829, Grant number:
   Piattaforme Tecnologiche per l'Ingegneria Tis; PON03_00011, Grant
   number: Potenziamento strutturale di una rete di eccell; Cinque per
   mille 2012
CR Alvarez R, 2015, INT J ORAL SCI, V7, P213, DOI 10.1038/ijos.2015.42
   Angle SR, 2011, ULTRASONICS, V51, P281, DOI 10.1016/j.ultras.2010.09.004
   Appleford MR, 2007, BIOMATERIALS, V28, P4788, DOI 10.1016/j.biomaterials.2007.06.010
   Aubin JE, 1996, J CELL PHYSIOL, V169, P468, DOI 10.1002/(SICI)1097 4652(199612)169:3<468::AID JCP7>3.0.CO;2 M
   Augat P, 2005, OSTEOPOROSIS INT, V16, pS36, DOI 10.1007/s00198 004 1728 9
   Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Baker N, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0225 8
   Carina V., 2017, J CELLULAR PHYSL
   Chen ZX, 2011, MOL CELL BIOCHEM, V358, P221, DOI 10.1007/s11010 011 0938 7
   Claes L, 2007, PROG BIOPHYS MOL BIO, V93, P384, DOI 10.1016/j.pbiomolbio.2006.07.021
   Delany AM, 2003, ENDOCRINOLOGY, V144, P2588, DOI 10.1210/en.2002 221044
   Di Maggio N, 2012, STEM CELLS, V30, P1455, DOI 10.1002/stem.1106
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   El Mowafi H, 2005, INT ORTHOP, V29, P121, DOI 10.1007/s00264 004 0625 3
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Fang BW, 2008, J CELL SCI, V121, P358, DOI 10.1242/jcs.017145
   FISCHELL TA, 1991, CIRCULATION, V84, P1783, DOI 10.1161/01.CIR.84.4.1783
   Folmes CDL, 2016, SEMIN CELL DEV BIOL, V52, P68, DOI 10.1016/j.semcdb.2016.02.010
   Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011
   Foster LJ, 2005, STEM CELLS, V23, P1367, DOI 10.1634/stemcells.2004 0372
   Frairia Roberto, 2011, Muscles Ligaments Tendons J, V1, P138
   Fung CH, 2014, ULTRASONICS, V54, P1358, DOI 10.1016/j.ultras.2014.02.003
   Gao QH, 2016, J ENDODONT, V42, P425, DOI 10.1016/j.joen.2015.12.019
   Griffin MF, 2015, WORLD J STEM CELLS, V7, P37, DOI 10.4252/wjsc.v7.i1.37
   Haasters F, 2009, J ANAT, V214, P759, DOI 10.1111/j.1469 7580.2009.01065.x
   Higuchi C, 2009, J BONE MINER METAB, V27, P158, DOI 10.1007/s00774 009 0037 y
   Hu B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095168
   Huang CY, 2013, TRENDS MOL MED, V19, P555, DOI 10.1016/j.molmed.2013.05.005
   Johns LD, 2002, J ATHL TRAINING, V37, P293
   JUNDT G, 1987, CELL TISSUE RES, V248, P409
   Kern SE, 2007, CANCER RES, V67, P8985, DOI 10.1158/0008 5472.CAN 07 1971
   Kessler CB, 2007, ENDOCRINOLOGY, V148, P1666, DOI 10.1210/en.2006 0443
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Kuhn NZ, 2010, J CELL PHYSIOL, V222, P268, DOI 10.1002/jcp.21940
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Kusuyama J., 2015, J ORTHOP TRAUMA, V29, pS2, DOI DOI 10.1097/01.BOT.0000462953.87235.74
   Lin WT, 2016, J CELL BIOCHEM, V117, P621, DOI 10.1002/jcb.25310
   Liu YSA, 2014, CELL TRANSPLANT, V23, P1, DOI 10.3727/096368912X659925
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MAXWELL L, 1994, ULTRASOUND MED BIOL, V20, P383, DOI 10.1016/0301 5629(94)90007 8
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   McNamara LE, 2010, J TISSUE ENG, V1, DOI 10.4061/2010/120623
   Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491
   Papadimitropoulos A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102359
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pricola KL, 2009, J CELL BIOCHEM, V108, P577, DOI 10.1002/jcb.22289
   Rawool NM, 2003, J ULTRAS MED, V22, P145, DOI 10.7863/jum.2003.22.2.145
   Ringdén O, 2006, BIOL BLOOD MARROW TR, V12, P693, DOI 10.1016/j.bbmt.2006.04.004
   Rutten S, 2009, BONE, V45, P862, DOI 10.1016/j.bone.2009.07.012
   Saalbach A, 2000, J INVEST DERMATOL, V115, P882, DOI 10.1046/j.1523 1747.2000.00104.x
   Salasznyk RM, 2005, STEM CELLS DEV, V14, P354, DOI 10.1089/scd.2005.14.354
   Sato M, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0798 8
   Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957
   Scherzed A, 2016, ONCOL REP, V35, P219, DOI 10.3892/or.2015.4383
   SCHOFIELD R, 1978, BLOOD CELLS, V4, P7
   Stolzing A, 2006, REJUV RES, V9, P31, DOI 10.1089/rej.2006.9.31
   Uddin SMZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073914
   Wang YY, 2014, ACTA BIOMATER, V10, P2518, DOI 10.1016/j.actbio.2013.12.052
   Wang Z, 2014, BIORESEARCH OPEN ACC, V3, P79, DOI 10.1089/biores.2014.0007
   Yoon DS, 2014, FASEB J, V28, P3273, DOI 10.1096/fj.13 248567
   Yoshimura H, 2007, CELL TISSUE RES, V327, P449, DOI 10.1007/s00441 006 0308 z
   Yoshimura K, 2006, J CELL PHYSIOL, V208, P64, DOI 10.1002/jcp.20636
   Yue Y, 2013, CELL PROLIFERAT, V46, P320, DOI 10.1111/cpr.12035
   Yun HM, 2016, BIOMATERIALS, V85, P88, DOI 10.1016/j.biomaterials.2016.01.035
   Ziros PG, 2002, J BIOL CHEM, V277, P23934, DOI 10.1074/jbc.M109881200
NR 65
TC 43
Z9 48
U1 1
U2 44
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD FEB
PY 2018
VL 233
IS 2
BP 1558
EP 1573
DI 10.1002/jcp.26058
PG 16
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA FL9RB
UT WOS:000414593500074
PM 28621452
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Terpos, E
AF Terpos, Evangelos
TI Antibodies to dickkopf 1 protein
SO EXPERT OPINION ON THERAPEUTIC PATENTS
LA English
DT Article
DE bone metastasis; dickkopf 1; multiple myeloma; osteoporosis; rheumatoid
   arthritis
ID ADULT STEM CELLS; MULTIPLE MYELOMA; HUMAN OSTEOBLASTS; BONE MARROW; WNT;
   ANTAGONIST; EXPRESSION; INHIBITOR; INDUCTION; MECHANISM
AB Patent WO2006015373 claims the development of anti dickkopf 1 (DKK 1) antibodies and immunologically functional fragments that neutralise DKK 1 function. These molecules can be used to detect DKK 1 in biological samples allowing the identification of pathological conditions in which DKK 1 alteration contributes to their pathophysiology. The use of anti DKK 1 antibodies is of high importance in the treatment of bone disorders characterised by the inhibition of osteoblast function and subsequent bone loss. Postmenopausal and steroid induced osteoporosis, myeloma bone disease and cancer bone metastases with lytic lesions are candidates for anti DKK 1 therapy, as DKK 1 is implicated in their pathogenesis. Furthermore, anti DKK 1 antibodies may be evaluated in conditions where promoting stem cell renewal is required, such as diabetes, inflammatory bowel disorders, chronic heart failure, muscle or neurological diseases.
C1 251 Gen Airforce Hosp, Dept Haematol & Med Res, GR 11525 Athens, Greece.
   Univ London Imperial Coll Sci & Technol, Fac Med, Dept Haematol, London, England.
C3 Imperial College London
RP Terpos, E (通讯作者)，251 Gen Airforce Hosp, Dept Haematol & Med Res, 3 Kanellopoulou St, GR 11525 Athens, Greece.
EM e.terpos@imperial.ac.uk
RI Terpos, Evangelos/AAD 3667 2019
OI Terpos, Evangelos/0000 0001 5133 1422
CR Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534 5807(02)00167 3
   Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Caricasole A, 2004, J NEUROSCI, V24, P6021, DOI 10.1523/JNEUROSCI.1381 04.2004
   Davidson G, 2002, DEVELOPMENT, V129, P5587, DOI 10.1242/dev.00154
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200
   Gregory CA, 2005, J BIOL CHEM, V280, P2309, DOI 10.1074/jbc.M406275200
   Gunn WG, 2006, STEM CELLS, V24, P986, DOI 10.1634/stemcells.2005 0220
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378 1119(99)00365 0
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025
   Politou MC, 2006, INT J CANCER, V119, P1728, DOI 10.1002/ijc.22033
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   van der Horst G, 2005, J BONE MINER RES, V20, P1867, DOI 10.1359/JBMR.050614
   Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503
   Wirths O, 2003, LAB INVEST, V83, P429, DOI 10.1097/01.LAB.0000059926.66359.BD
   Yamaguchi K, 2001, INTERNAL MED, V40, P1, DOI 10.2169/internalmedicine.40.1
NR 21
TC 1
Z9 6
U1 2
U2 3
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69 77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1354 3776
J9 EXPERT OPIN THER PAT
JI Expert Opin. Ther. Patents
PD OCT
PY 2006
VL 16
IS 10
BP 1453
EP 1458
DI 10.1517/13543776.16.10.1453
PG 6
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 091QK
UT WOS:000241043200009
DA 2025 08 17
ER

PT J
AU Koiwa, F
   Tokunaga, S
   Asada, S
   Endo, Y
   Fukagawa, M
   Akizawa, T
AF Koiwa, Fumihiko
   Tokunaga, Shin
   Asada, Shinji
   Endo, Yuichi
   Fukagawa, Masafumi
   Akizawa, Tadao
TI Efficacy of Evocalcet in Previously Cinacalcet Treated Secondary
   Hyperparathyroidism Patients
SO KIDNEY INTERNATIONAL REPORTS
LA English
DT Article
DE calcium; cinacalcet; evocalcet; parathyroid gland volume; parathyroid
   hormone; secondary hyperparathyroidism
ID PATIENTS RECEIVING HEMODIALYSIS; PARATHYROID HORMONE SECRETION;
   KIDNEY DISEASE; GUIDELINE; CKD
AB Introduction: Evocalcet is a recently approved calcimimetic agent for secondary hyperparathyroidism (SHPT). In this study, the efficacy and safety of once daily oral evocalcet were evaluated in patients without prior cinacalcet use (nonusers) and previously treated patients (users).
   Methods: This post hoc analysis of a previous phase III head to head comparison study included SHPT patients treated with evocalcet with or without prior cinacalcet use. Endpoints included trends in the median intact and whole parathyroid hormone (PTH), mean corrected calcium, phosphate, and bone metabolic markers, and whole to intact PTH ratios throughout the 30 week study period; proportions of patients achieving target intact PTH, corrected calcium, and phosphate at weeks 28 to 30; and adverse drug reactions (ADRs).
   Results: This study included 127 nonusers and 190 users with significant differences in age; duration of dialysis; use of intravenous vitamin D receptor activators; levels of intact PTH, corrected calcium, tartrate resistant acid phosphatase 5b, procollagen type 1 N terminal propeptide; and largest parathyroid gland volume (P < 0.05 for all characteristics) between 2 groups at baseline. Users required higher evocalcet dosages than nonusers. Similar efficacy results were found in the 2 groups except for a significantly higher proportion of nonusers achieving the intact PTH target (81.6% vs 67.1%, difference [95% confidence interval],  14.5% [ 24.59,  3.34]), and a significant reduction in largest parathyroid gland volume from week 0 to week 30 ( 120.6 [567.2] mm(3), P = 0.043). No difference was found in ADRs between the 2 groups.
   Conclusion: Treatment with evocalcet is effective and safe irrespective of prior cinacalcet treatment in SHPT patients.
C1 [Koiwa, Fumihiko] Showa Univ, Dept Internal Med, Div Nephrol, Fujigaoka Hosp, Yokohama, Kanagawa, Japan.
   [Tokunaga, Shin; Asada, Shinji] Kyowa Kirin Co Ltd, Med Affairs Dept, Tokyo, Japan.
   [Tokunaga, Shin; Endo, Yuichi] Kyowa Kirin Co Ltd, R&D Div, Tokyo, Japan.
   [Fukagawa, Masafumi] Tokai Univ, Dept Internal Med, Div Nephrol Endocrinol & Metab, Sch Med, Isehara, Kanagawa, Japan.
   [Akizawa, Tadao] Showa Univ, Dept Med, Div Nephrol, Sch Med, Tokyo, Japan.
C3 Showa University; Kyowa Kirin Ltd; Kyowa Kirin Ltd; Tokai University;
   Showa University
RP Koiwa, F (通讯作者)，Showa Univ, Fujigaoka Hosp, Div Nephrol, Dept Internal Med,Aoba Ku, 1 30 Fujigaoka, Yokohama, Kanagawa 2278501, Japan.
EM koiwa f@med.showa u.ac.jp
OI Asada, Shinji/0000 0002 7717 8945
FU KKC
FX This work was sponsored by KKC. The authors thank all the collaborators
   for their participation in the study (see Supplementary List of
   collaborators) , Ms. Shiori Yasui, Mr. Taichi Mizogui and Dr. Shinjo
   Yada of A2 Healthcare Cor poration for statistical analyses, and ASCA
   Corporation for assisting with the writing and editing of the
   manuscript. Clinical Trial Registration: ClinicalTrials.gov
   (NCT02549391) and JAPIC (JapicCTI 153013).
CR Akizawa T, 2020, THER APHER DIAL, V24, P248, DOI 10.1111/1744 9987.13434
   Akizawa T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204896
   Akizawa T, 2018, CLIN DRUG INVEST, V38, P945, DOI 10.1007/s40261 018 0687 4
   Block GA, 2010, KIDNEY INT, V78, P578, DOI 10.1038/ki.2010.167
   Cunningham J, 2011, CLIN J AM SOC NEPHRO, V6, P913, DOI 10.2215/CJN.06040710
   D'Amour P, 2002, EUR J ENDOCRINOL, V146, P407, DOI 10.1530/eje.0.1460407
   Fahrleitner Pammer A, 2008, J BONE MINER RES, V23, P1850, DOI 10.1359/JBMR.080610
   Fukagawa M, 2018, KIDNEY INT, V94, P818, DOI 10.1016/j.kint.2018.05.013
   Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744 9987.12058
   Gao P, 2001, J BONE MINER RES, V16, P605, DOI 10.1359/jbmr.2001.16.4.605
   Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Hall R, 2020, CLIN J AM SOC NEPHRO, V15, P1603, DOI 10.2215/CJN.04350420
   Kawata T, 2005, J CLIN ENDOCR METAB, V90, P5774, DOI 10.1210/jc.2005 0243
   Kawata T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195316
   Kazama JJ, 2004, NEPHROL DIAL TRANSPL, V19, P892, DOI 10.1093/ndt/gfh038
   Ketteler M, 2017, KIDNEY INT, V92, P26, DOI 10.1016/j.kint.2017.04.006
   Koda R, 2015, CLIN EXP NEPHROL, V19, P710, DOI 10.1007/s10157 014 1045 3
   Komaba H, 2011, CLIN EXP NEPHROL, V15, P797, DOI 10.1007/s10157 011 0502 5
   Komaba H, 2010, CLIN J AM SOC NEPHRO, V5, P2305, DOI 10.2215/CJN.02110310
   Lafrance JP, 2013, BMC NEPHROL, V14, DOI 10.1186/1471 2369 14 100
   Malberti F, 1999, NEPHROL DIAL TRANSPL, V14, P2398, DOI 10.1093/ndt/14.10.2398
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Murray TM, 2005, ENDOCR REV, V26, P78, DOI 10.1210/er.2003 0024
   Pereira L, 2018, CLIN KIDNEY J, V11, P80, DOI 10.1093/ckj/sfx125
   Reiss AB, 2018, ATHEROSCLEROSIS, V278, P49, DOI 10.1016/j.atherosclerosis.2018.08.046
   Shigematsu T, 2018, CLIN PHARMACOL ADV A, V10, P101, DOI 10.2147/CPAA.S171044
   Shigematsu T, 2019, CLIN EXP NEPHROL, V23, P258, DOI 10.1007/s10157 018 1635 6
   Tsuruya K, 2019, CLIN EXP NEPHROL, V23, P739, DOI 10.1007/s10157 019 01692 y
   Yokoyama K, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 42017 z
NR 29
TC 8
Z9 9
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2468 0249
J9 KIDNEY INT REP
JI Kidney Int. Rep.
PD NOV
PY 2021
VL 6
IS 11
BP 2830
EP 2839
DI 10.1016/j.ekir.2021.08.020
EA NOV 2021
PG 10
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA WW7RU
UT WOS:000718109600012
PM 34805635
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kyllönen, L
   D'Este, M
   Alini, M
   Eglin, D
AF Kylloenen, Laura
   D'Este, Matteo
   Alini, Mauro
   Eglin, David
TI Local drug delivery for enhancing fracture healing in osteoporotic bone
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Drug delivery; Osteoporotic fracture; Growth factors; Small molecules
ID FIBROBLAST GROWTH FACTOR; MESENCHYMAL STEM CELLS; CALCIUM PHOSPHATE
   CEMENT; PARATHYROID HORMONE 1 34; EP4 RECEPTOR AGONIST; STRONTIUM
   RANELATE TREATMENT; COLONY STIMULATING FACTOR; DIFFERENTIATION IN VITRO;
   POROUS IMPLANT SURFACES; COLLOIDAL GELATIN GELS
AB Fragility fractures can cause significant morbidity and mortality in patients with osteoporosis and inflict a considerable medical and socioeconomic burden. Moreover, treatment of an osteoporotic fracture is challenging due to the decreased strength of the surrounding bone and suboptimal healing capacity, predisposing both to fixation failure and non union. Whereas a systemic osteoporosis treatment acts slowly, local release of osteogenic agents in osteoporotic fracture would act rapidly to increase bone strength and quality, as well as to reduce the bone healing period and prevent development of a problematic non union. The identification of agents with potential to stimulate bone formation and improve implant fixation strength in osteoporotic bone has raised hope for the fast augmentation of osteoporotic fractures. Stimulation of bone formation by local delivery of growth factors is an approach already in clinical use for the treatment of non unions, and could be utilized for osteoporotic fractures as well. Small molecules have also gained ground as stable and inexpensive compounds to enhance bone formation and tackle osteoporosis. The aim of this paper is to present the state of the art on local drug delivery in osteoporotic fractures. Advantages, disadvantages and underlying molecular mechanisms of different active species for local bone healing in osteoporotic bone are discussed. This review also identifies promising new candidate molecules and innovative approaches for the local drug delivery in osteoporotic bone. (C) 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Kylloenen, Laura; D'Este, Matteo; Alini, Mauro; Eglin, David] AO Res Inst Davos, CH 7270 Davos, Switzerland.
C3 AO Foundation
RP Kyllönen, L (通讯作者)，AO Res Inst Davos, Clavadelerstr 8, CH 7270 Davos, Switzerland.
EM laura.kylloenen@aofoundation.org
RI Alini, Mauro/AAG 7961 2020; D'Este, Matteo/AAB 2835 2022
OI D'Este, Matteo/0000 0002 0424 8172
CR Aghaloo T, 2006, AM J PATHOL, V169, P903, DOI 10.2353/ajpath.2006.051210
   Aghaloo T, 2010, J ORAL MAXIL SURG, V68, P300, DOI 10.1016/j.joms.2009.03.066
   Aguirre JI, 2007, J BONE MINER RES, V22, P877, DOI 10.1359/JBMR.070313
   Al Zube L, 2009, J ORTHOP RES, V27, P1074, DOI 10.1002/jor.20842
   Alam S, 2009, ORAL SURG ORAL MED O, V107, P22, DOI 10.1016/j.tripleo.2008.06.025
   Alegre DN, 2012, RHEUMATOL INT, V32, P439, DOI 10.1007/s00296 010 1687 8
   Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Amanat N, 2007, J BONE MINER RES, V22, P867, DOI 10.1359/JBMR.070318
   Amosi N, 2012, ACTA BIOMATER, V8, P2466, DOI 10.1016/j.actbio.2012.04.003
   Anbinder Ana Lia, 2006, Braz. Dent. J., V17, P267, DOI 10.1590/S0103 64402006000400001
   Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   Arns S, 2012, BIOORGAN MED CHEM, V20, P2131, DOI 10.1016/j.bmc.2012.01.024
   Aro HT, 2011, J BONE JOINT SURG AM, V93A, P801, DOI 10.2106/JBJS.I.01763
   Arrighi I, 2009, BIOMATERIALS, V30, P1763, DOI 10.1016/j.biomaterials.2008.12.023
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Back DA, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 42
   Baek KH, 2005, J KOREAN MED SCI, V20, P438, DOI 10.3346/jkms.2005.20.3.438
   Baier M, 2013, J ORTHOP SURG RES, V8, DOI 10.1186/1749 799X 8 16
   Bakker AD, 2013, BONE, V53, P112, DOI 10.1016/j.bone.2012.11.044
   BARRIOS C, 1993, J ORTHOP TRAUMA, V7, P438, DOI 10.1097/00005131 199310000 00006
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Benisch P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045142
   Betts AM, 2010, J PHARMACOL EXP THER, V333, P2, DOI 10.1124/jpet.109.164129
   Blokhuis TJ, 2012, J ORTHOP RES, V30, P720, DOI 10.1002/jor.22013
   Boerckel JD, 2011, BIOMATERIALS, V32, P5241, DOI 10.1016/j.biomaterials.2011.03.063
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Boonen S, 2002, J CLIN ENDOCR METAB, V87, P1593, DOI 10.1210/jc.87.4.1593
   Bradley JD, 2007, J PERIODONTAL RES, V42, P267, DOI 10.1111/j.1600 0765.2006.00943.x
   Broderick JM, 2013, SCI WORLD J, DOI 10.1155/2013/515197
   Brouwers JEM, 2009, OSTEOPOROSIS INT, V20, P1823, DOI 10.1007/s00198 009 0882 5
   Brouwers JEM, 2008, CALCIFIED TISSUE INT, V83, P186, DOI 10.1007/s00223 008 9160 3
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Brown KV, 2011, TISSUE ENG PT A, V17, P1735, DOI [10.1089/ten.TEA.2010.0446, 10.1089/ten.tea.2010.0446]
   Cacoub P, 2013, OSTEOPOROSIS INT, V24, P1751, DOI 10.1007/s00198 013 2265 1
   Calixto JC, 2011, J CRANIO MAXILL SURG, V39, P215, DOI 10.1016/j.jcms.2010.03.009
   Calvo Fernández T, 2010, EUR CELLS MATER, V20, P260
   Calvo Guirado JL, 2014, CLIN ORAL IMPLAN RES, V00, P1
   Calvo Guirado JL, 2010, J PINEAL RES, V49, P356, DOI 10.1111/j.1600 079X.2010.00801.x
   Carofino BC, 2008, J BONE JOINT SURG AM, V90A, P99, DOI 10.2106/JBJS.G.01546
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Caudrillier A, 2010, MOL PHARMACOL, V78, P569, DOI 10.1124/mol.109.063347
   CHAMBERS TJ, 1983, J CLIN ENDOCR METAB, V57, P819, DOI 10.1210/jcem 57 4 819
   Chen BL, 2013, CALCIFIED TISSUE INT, V93, P481, DOI 10.1007/s00223 013 9765 z
   Chen B, 2007, BIOMATERIALS, V28, P1027, DOI 10.1016/j.biomaterials.2006.10.013
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Chen KM, 2007, PHARMAZIE, V62, P388, DOI 10.1691/ph.2007.5.6682
   Chen SH, 2013, ACTA BIOMATER, V9, P6711, DOI 10.1016/j.actbio.2013.01.024
   Chen SH, 2012, ACTA BIOMATER, V8, P3128, DOI 10.1016/j.actbio.2012.04.030
   Chen S, 2011, CHINESE MED J PEKING, V124, P3953, DOI 10.3760/cma.j.issn.0366 6999.2011.23.021
   Cheng CX, 2013, MOL IMAGING BIOL, V15, P336, DOI 10.1007/s11307 012 0592 9
   Chou J., 2013, J TISSUE ENG REGEN M, DOI 10.1002/term.1784
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Clafshenkel WP, 2012, J PINEAL RES, V53, P206, DOI 10.1111/j.1600 079X.2012.00989.x
   Coletta D J, 2014, Open Biomed Eng J, V8, P20, DOI 10.2174/1874120701408010020
   Colón Emeric C, 2011, OSTEOPOROSIS INT, V22, P2329, DOI 10.1007/s00198 010 1473 1
   Cornell Charles N, 2003, J Am Acad Orthop Surg, V11, P109
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Cunningham BW, 2009, J NEUROSURG SPINE, V10, P300, DOI 10.3171/2009.1.SPINE08565
   D'Este M, 2013, ACTA BIOMATER, V9, P5421, DOI 10.1016/j.actbio.2012.11.022
   D'Este M, 2012, CARBOHYD POLYM, V90, P1378, DOI 10.1016/j.carbpol.2012.07.007
   Doi Y, 2011, BONE, V49, P777, DOI 10.1016/j.bone.2011.07.005
   Downey ME, 2009, BONE, V44, P266, DOI 10.1016/j.bone.2008.10.041
   Du XL, 2012, J CELL PHYSIOL, V227, P3731, DOI 10.1002/jcp.24083
   Dumitriu RP, 2011, POLYM INT, V60, P222, DOI 10.1002/pi.2929
   Dunstan CR, 1999, J BONE MINER RES, V14, P953, DOI 10.1359/jbmr.1999.14.6.953
   Egermann M, 2005, OSTEOPOROSIS INT, V16, pS120, DOI 10.1007/s00198 004 1817 9
   Egermann M, 2006, HUM GENE THER, V17, P507, DOI 10.1089/hum.2006.17.507
   Egermann M, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 271
   Ellegaard M, 2013, J BONE MINER RES, V28, P2145, DOI 10.1002/jbmr.1957
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   European Medicines Agency, 2014, PRAC REC SUSP US PRO
   Evans CH, 2012, ADV DRUG DELIVER REV, V64, P1331, DOI 10.1016/j.addr.2012.03.013
   Ezirganli S, 2014, CLIN ORAL IMPLAN RES, V25, P969, DOI 10.1111/clr.12177
   Fan JJ, 2012, J MATER SCI MATER M, V23, P399, DOI 10.1007/s10856 011 4491 4
   Farra R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003276
   Fromigué O, 2009, J CELL MOL MED, V13, P2189, DOI 10.1111/j.1582 4934.2009.00673.x
   Fu DL, 2012, J ZHEJIANG UNIV SC B, V13, P364, DOI 10.1631/jzus.B1100381
   Fu LJ, 2013, ACTA PHARMACOL SIN, V34, P387, DOI 10.1038/aps.2012.170
   Fukui T, 2012, J BONE MINER RES, V27, P1118, DOI 10.1002/jbmr.1558
   Gao Y, 2009, J CONTROL RELEASE, V139, P15, DOI 10.1016/j.jconrel.2009.05.032
   Gao Y, 2009, BONE, V44, P225, DOI 10.1016/j.bone.2008.10.054
   Garbuz DS, 2008, J BONE JOINT SURG AM, V90A, P1090, DOI 10.2106/JBJS.G.00415
   Garrison KR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006950.pub2
   Gatti D, 2011, J CLIN ENDOCR METAB, V96, P1555, DOI 10.1210/jc.2010 2552
   Glazebrook M, 2013, FOOT ANKLE INT, V34, P1055, DOI 10.1177/1071100713481459
   Graham S, 2009, EXPERT OPIN INV DRUG, V18, P749, DOI [10.1517/13543780902893051 , 10.1517/13543780902893051]
   Greiner SH, 2008, ACTA ORTHOP, V79, P717, DOI 10.1080/17453670810016768
   Gruber HE, 2000, CALCIFIED TISSUE INT, V66, P29, DOI 10.1007/s002230010007
   Guo DG, 2005, BIOMATERIALS, V26, P4073, DOI 10.1016/j.biomaterials.2004.10.032
   Guo HF, 2010, J MED CHEM, V53, P1819, DOI 10.1021/jm901685n
   Habermann B, 2010, CALCIFIED TISSUE INT, V86, P82, DOI 10.1007/s00223 009 9317 8
   Hamdy RC, 2012, INT J WOMENS HEALTH, V4, P471, DOI 10.2147/IJWH.S24776
   Harding AK, 2011, ACTA ORTHOP, V82, P465, DOI 10.3109/17453674.2011.594231
   Harmankaya N, 2013, ACTA BIOMATER, V9, P7064, DOI 10.1016/j.actbio.2013.02.040
   Hayashi K, 2005, J BONE JOINT SURG BR, V87B, P1150, DOI 10.1302/0301 620X.87B8.15886
   Hayashi K, 2010, J BIOMED MATER RES A, V92A, P1202, DOI 10.1002/jbm.a.32444
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Ho ML, 2009, EUR J CLIN INVEST, V39, P296, DOI 10.1111/j.1365 2362.2009.02092.x
   Hollinger JO, 2008, J ORTHOP RES, V26, P83, DOI 10.1002/jor.20453
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Huang JG, 2013, MOL MED REP, V8, P1221, DOI 10.3892/mmr.2013.1624
   Hulsart Billström G, 2011, ACTA BIOMATER, V7, P3042, DOI 10.1016/j.actbio.2011.04.021
   Ishida K, 2010, TISSUE ENG PT A, V16, P3271, DOI 10.1089/ten.tea.2009.0268
   Ito M, 2006, BONE, V39, P453, DOI 10.1016/j.bone.2006.02.054
   Ito T, 2013, J PHARM PHARMACOL, V65, P494, DOI 10.1111/jphp.12008
   Ito T, 2012, J MATER SCI MATER M, V23, P1291, DOI 10.1007/s10856 012 4597 3
   Iwaniec UT, 2007, OSTEOPOROSIS INT, V18, P351, DOI 10.1007/s00198 006 0240 9
   Iwaniec UT, 2003, BONE, V33, P380, DOI 10.1016/S8756 3282(03)00118 2
   Jeon JH, 2008, PHARM DEV TECHNOL, V13, P505, DOI 10.1080/10837450802282488 
   Jeon JH, 2008, BIOMATERIALS, V29, P3591, DOI 10.1016/j.biomaterials.2008.05.011
   Jeon JH, 2007, INT J PHARMACEUT, V340, P6, DOI 10.1016/j.ijpharm.2007.03.007
   Jeon O, 2008, BIOCHEM BIOPH RES CO, V369, P774, DOI 10.1016/j.bbrc.2008.02.099
   Ji W, 2012, ADV DRUG DELIVER REV, V64, P1152, DOI 10.1016/j.addr.2012.03.003
   Jia M, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/364604
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jin QM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097035
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Jung RE, 2007, CLIN ORAL IMPLAN RES, V18, P319, DOI 10.1111/j.1600 0501.2007.01342.x
   Jung RE, 2007, INT J ORAL MAX IMPL, V22, P258
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kambe T, 2012, BIOORGAN MED CHEM, V20, P2235, DOI 10.1016/j.bmc.2012.02.018
   Kamolratanakul P, 2011, ARTHRITIS RHEUM US, V63, P1021, DOI 10.1002/art.30151
   Kato M, 2006, BIOMATERIALS, V27, P2035, DOI 10.1016/j.biomaterials.2005.10.007
   Kato S, 2011, MOL CELL BIOCHEM, V349, P97, DOI 10.1007/s11010 010 0664 6
   Kato T, 1998, J ORTHOP RES, V16, P654, DOI 10.1002/jor.1100160605
   Kawaguchi H, 2007, J ORTHOP RES, V25, P480, DOI 10.1002/jor.20315
   Kawaguchi H, 2010, J BONE MINER RES, V25, P2459, DOI 10.1002/jbmr.146
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   KELLER J, 1993, ACTA ORTHOP SCAND, V64, P59, DOI 10.3109/17453679308994530
   Kempen DHR, 2009, BIOMATERIALS, V30, P2816, DOI 10.1016/j.biomaterials.2009.01.031
   Khojasteh A, 2013, J CRANIOFAC SURG, V24, pE68, DOI 10.1097/SCS.0b013e31827009c5
   Kim I, 2013, INT J ORAL MAX IMPL, V28, P1194, DOI 10.11607/jomi.2685
   Kim J, 2010, J BIOMED MATER RES A, V95A, P673, DOI 10.1002/jbm.a.32884
   Kim M, 2012, MECH AGEING DEV, V133, P215, DOI 10.1016/j.mad.2012.03.014
   Kim WY, 2001, INT ORTHOP, V25, P360, DOI 10.1007/s002640100287
   King WJ, 2012, ADV DRUG DELIVER REV, V64, P1239, DOI 10.1016/j.addr.2012.03.004
   Kodera R, 2014, BONE, V58, P26, DOI 10.1016/j.bone.2013.09.021
   Kotlarczyk MP, 2012, J PINEAL RES, V52, P414, DOI 10.1111/j.1600 079X.2011.00956.x
   Koyama H, 2002, J BONE MINER RES, V17, P1219, DOI 10.1359/jbmr.2002.17.7.1219
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Kubo T, 1999, J STEROID BIOCHEM, V68, P197, DOI 10.1016/S0960 0760(99)00032 1
   Kupcsik L, 2009, J CELL MOL MED, V13, P4465, DOI 10.1111/j.1582 4934.2008.00545.x
   Kwak J, 2013, TISSUE ENG PT A, V19, P426, DOI [10.1089/ten.tea.2012.0042, 10.1089/ten.TEA.2012.0042]
   Ladizesky MG, 2001, LIFE SCI, V70, P557, DOI 10.1016/S0024 3205(01)01431 X
   Ladizesky MG, 2003, J PINEAL RES, V34, P143, DOI 10.1034/j.1600 079X.2003.00021.x
   Lee JH, 2012, SPINE J, V12, P239, DOI 10.1016/j.spinee.2012.01.013
   Lee JH, 2011, P SPIE BIOSENS NANOM, VIV, P8099
   Lencel P, 2011, MED HYPOTHESES, V76, P317, DOI 10.1016/j.mehy.2010.09.023
   Leucht P, 2013, J BONE JOINT SURG AM, V95A, P1278, DOI [10.2106/JBJS.L01502, 10.2106/JBJS.L.01502]
   Li B, 2009, BIOMATERIALS, V30, P6768, DOI 10.1016/j.biomaterials.2009.08.038
   Li DX, 2007, J MATER SCI MATER M, V18, P2225, DOI 10.1007/s10856 007 3084 8
   Li M, 2003, J BONE MINER RES, V18, P2033, DOI 10.1359/jbmr.2003.18.11.2033
   Li M, 2010, CLIN ORTHOP RELAT R, V468, P1978, DOI 10.1007/s11999 010 1321 9
   Li WM, 2010, TISSUE ENG PT A, V16, P2861, DOI 10.1089/ten.tea.2009.0550
   Li X, 2011, J BONE MINER METAB, V29, P396, DOI 10.1007/s00774 010 0231 y
   Li YF, 2010, OSTEOPOROSIS INT, V21, P1889, DOI 10.1007/s00198 009 1140 6
   Li YF, 2012, CLIN ORAL IMPLAN RES, V23, P1038, DOI 10.1111/j.1600 0501.2011.02252.x
   Li YF, 2010, BIOMATERIALS, V31, P9006, DOI 10.1016/j.biomaterials.2010.07.112
   Li YF, 2010, J ORTHOP RES, V28, P578, DOI 10.1002/jor.21050
   Liang K, 1999, ENDOCRINOLOGY, V140, P5780
   Lienemann PS, 2012, ADV DRUG DELIVER REV, V64, P1078, DOI 10.1016/j.addr.2012.03.010
   Lill CA, 2003, J ORTHOPAED RES, V21, P836, DOI 10.1016/S0736 0266(02)00266 8
   Liu X, 2007, BIOMATERIALS, V28, P4124, DOI 10.1016/j.biomaterials.2007.05.034
   Liu XQ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054077, 10.1371/journal.pone.0077367, 10.1371/journal.pone.0058489]
   Liu Y, 2012, J PINEAL RES, V52, P47, DOI 10.1111/j.1600 079X.2011.00917.x
   Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209
   Liu Y, 2007, BIOMATERIALS, V28, P2677, DOI 10.1016/j.biomaterials.2007.02.003
   Lopa S, 2013, J BIOMED MATER RES A, V101, P3396, DOI 10.1002/jbm.a.34649
   López Martínez F, 2012, INT J DENT, V2012, DOI 10.1155/2012/628406
   Lozano D, 2014, ACTA BIOMATER, V10, P3307, DOI 10.1016/j.actbio.2014.03.025
   Lu J, 2008, SPINE, V33, P242, DOI 10.1097/BRS.0b013e318162451b
   Calvo Guirado JL, 2010, J PINEAL RES, V48, P194, DOI 10.1111/j.1600 079X.2009.00743.x
   Calvo Guirado JL, 2009, J PINEAL RES, V47, P164, DOI 10.1111/j.1600 079X.2009.00696.x
   Negri AL, 2012, CLIN CASES MINER BON, V9, P166
   Lyon T, 2013, J BONE JOINT SURG AM, V95A, P2088, DOI 10.2106/JBJS.L.01545
   Manabe T, 2007, BONE, V40, P1475, DOI 10.1016/j.bone.2007.01.015
   Pino AM, 2012, BIOL RES, V45, P279, DOI 10.4067/S0716 97602012000300009
   MARIE PJ, 1993, J BONE MINER RES, V8, P607
   Mata A, 2010, BIOMATERIALS, V31, P6004, DOI 10.1016/j.biomaterials.2010.04.013
   McGuire MK, 2006, INT J PERIODONT REST, V26, P223
   Mehta M, 2012, ADV DRUG DELIVER REV, V64, P1257, DOI 10.1016/j.addr.2012.05.006
   Mero A, 2014, J CONTROL RELEASE, V187, P30, DOI 10.1016/j.jconrel.2014.05.008
   Meunier PJ, 2009, OSTEOPOROSIS INT, V20, P1663, DOI 10.1007/s00198 008 0825 6
   Miladi K, 2013, INT J PHARMACEUT, V445, P181, DOI 10.1016/j.ijpharm.2013.01.031
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   Ming LG, 2013, J CELL PHYSIOL, V228, P513, DOI 10.1002/jcp.24158
   Mitlak BH, 1996, J BONE MINER RES, V11, P238
   Moazzaz P, 2005, SPINE, V30, P1706, DOI 10.1097/01.brs.0000172230.01655.55
   Montagnani A, 2003, BONE, V32, P427, DOI 10.1016/S8756 3282(03)00034 6
   Montazerolghaem M, 2014, J BIOMED MATER RES A, V102, P340, DOI 10.1002/jbm.a.34702
   Morley P, 2001, CURR PHARM DESIGN, V7, P671, DOI 10.2174/1381612013397780
   Mukozawa A, 2011, CLIN ORAL IMPLAN RES, V22, P1327, DOI 10.1111/j.1600 0501.2010.02135.x
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Murphy CM, 2014, ACTA BIOMATER, V10, P2250, DOI 10.1016/j.actbio.2014.01.016
   Naik AA, 2009, J BONE MINER RES, V24, P251, DOI [10.1359/jbmr.081002, 10.1359/JBMR.081002]
   Nakamura K, 1998, INT ORTHOP, V22, P49, DOI 10.1007/s002640050207
   Nakamura K, 1997, J ORTHOPAED RES, V15, P307, DOI 10.1002/jor.1100150222
   NAKAMURA T, 1995, ENDOCRINOLOGY, V136, P1276, DOI 10.1210/en.136.3.1276
   Nakamura T, 1998, J BONE MINER RES, V13, P942, DOI 10.1359/jbmr.1998.13.6.942
   Namikawa T, 2007, SPINE, V32, P2294, DOI 10.1097/BRS.0b013e318154c5b6
   Namkung Matthai H, 2001, BONE, V28, P80, DOI 10.1016/S8756 3282(00)00414 2
   Narayanan D, 2012, J BIOMED NANOTECHNOL, V8, P98, DOI 10.1166/jbn.2012.1367
   Nardone V, 2012, INT J BIOMATER, V2012, DOI 10.1155/2012/865291
   Nevins M, 2005, J PERIODONTOL, V76, P2205, DOI 10.1902/jop.2005.76.12.2205
   Nevins M, 2007, INT J PERIODONT REST, V27, P421
   Nian H, 2009, PHYTOMEDICINE, V16, P320, DOI 10.1016/j.phymed.2008.12.006
   Nian Hua, 2006, Zhong Xi Yi Jie He Xue Bao, V4, P628, DOI 10.3736/jcim20060618
   Nikolaou VS, 2009, INJURY, V40, P663, DOI 10.1016/j.injury.2008.10.035
   Ninomiya T, 2011, EUR J PHARMACOL, V650, P396, DOI 10.1016/j.ejphar.2010.10.021
   Nyan M, 2009, CLIN ORAL IMPLAN RES, V20, P280, DOI 10.1111/j.1600 0501.2008.01639.x
   Oest ME, 2007, J ORTHOP RES, V25, P941, DOI 10.1002/jor.20372
   Okada M, 2009, CELL BIOCHEM FUNCT, V27, P526, DOI 10.1002/cbf.1615
   Okumura S, 2006, BONE, V39, P684, DOI 10.1016/j.bone.2006.04.010
   Oliver RA, 2013, OSTEOPOROSIS INT, V24, P2581, DOI 10.1007/s00198 013 2345 2
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Ostrowska Z, 2002, NEUROENDOCRINOL LETT, V23, P104
   Ostrowska Z, 2001, NEUROENDOCRINOL LETT, V22, P121
   Oxlund H, 2004, BONE, V34, P609, DOI 10.1016/j.bone.2003.12.014
   Özec I, 2007, J CRANIOFAC SURG, V18, P546
   Ozturan KE, 2011, J ORTHOP RES, V29, P138, DOI 10.1002/jor.21204
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Pan HZ, 2013, BIOMATERIALS, V34, P6528, DOI 10.1016/j.biomaterials.2013.05.003
   Panzavolta S, 2010, J INORG BIOCHEM, V104, P1099, DOI 10.1016/j.jinorgbio.2010.06.008
   Paralkar VM, 2003, P NATL ACAD SCI USA, V100, P6736, DOI 10.1073/pnas.1037343100
   Park JW, 2013, J BIOMED MATER RES A, V101, P298, DOI 10.1002/jbm.a.34433
   Park JW, 2010, ACTA BIOMATER, V6, P2843, DOI 10.1016/j.actbio.2010.01.017
   Park SB, 2013, SPINE J, V13, P1273, DOI 10.1016/j.spinee.2013.06.010
   Patil S, 2009, J ORTHOP RES, V27, P281, DOI 10.1002/jor.20572
   Patterson J, 2010, BIOMATERIALS, V31, P6772, DOI 10.1016/j.biomaterials.2010.05.047
   Peichl P, 2011, J BONE JOINT SURG AM, V93A, P1583, DOI 10.2106/JBJS.J.01379
   Pemmer B, 2011, J SYNCHROTRON RADIAT, V18, P835, DOI 10.1107/S090904951103038X
   Peng SL, 2013, BONE, V55, P230, DOI 10.1016/j.bone.2013.02.012
   Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939 6411(00)00090 4
   Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Phillips Frank M, 2006, Spine J, V6, P500, DOI 10.1016/j.spinee.2006.01.014
   Ramírez Fernández MP, 2013, CLIN ORAL INVEST, V17, P147, DOI 10.1007/s00784 012 0684 6
   Popelut A, 2010, BIOMATERIALS, V31, P9173, DOI 10.1016/j.biomaterials.2010.08.045
   Pountos I, 2010, J ORTHOP TRAUMA, V24, P552, DOI 10.1097/BOT.0b013e3181efa8fe
   Power RA, 2004, OSTEOPOROSIS INT, V15, P716, DOI 10.1007/s00198 004 1595 4
   Prall WC, 2013, BIOCHEM BIOPH RES CO, V440, P617, DOI 10.1016/j.bbrc.2013.09.114
   Pyo SW, 2014, INT J ORAL MAX IMPL, V29, P478, DOI 10.11607/jomi.3423
   Qi MC, 2012, BONE, V50, P119, DOI 10.1016/j.bone.2011.10.011
   Radomsky ML, 1998, CLIN ORTHOP RELAT R, pS283
   Radomsky ML, 1999, J ORTHOP RES, V17, P607, DOI 10.1002/jor.1100170422
   Raiche AT, 2004, BIOMATERIALS, V25, P677, DOI 10.1016/S0142 9612(03)00564 7
   Raschke M, 2002, BONE, V30, P144, DOI 10.1016/S8756 3282(01)00640 8
   Reginster JY, 2012, OSTEOPOROSIS INT, V23, P1115, DOI 10.1007/s00198 011 1847 z
   Rejnmark L, 2004, J BONE MINER RES, V19, P737, DOI 10.1359/JBMR.040209
   Reyes R, 2012, INJURY, V43, P334, DOI 10.1016/j.injury.2011.10.008
   Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101 1029
   Ripamonti U, 1997, J BONE MINER RES, V12, P1584, DOI 10.1359/jbmr.1997.12.10.1584
   Ripamonti U, 2009, J CRANIOFAC SURG, V20, P1544, DOI 10.1097/SCS.0b013e3181b09ca6
   Rizzoli Rene, 2011, Expert Rev Clin Pharmacol, V4, P593
   Rodríguez JP, 2000, J CELL BIOCHEM, V79, P557, DOI 10.1002/1097 4644(20001215)79:4<557::AID JCB40>3.0.CO;2 H
   Roelofs AJ, 2010, CURR PHARM DESIGN, V16, P2950
   Roth JA, 1999, J BIOL CHEM, V274, P22041, DOI 10.1074/jbc.274.31.22041
   Rybchyn MS, 2011, J BIOL CHEM, V286, P23771, DOI 10.1074/jbc.M111.251116
   Sabareeswaran A, 2013, BIOMATERIALS, V34, P9278, DOI 10.1016/j.biomaterials.2013.08.070
   Sachse A, 2005, BONE, V37, P699, DOI 10.1016/j.bone.2005.06.011
   Saito W, 2014, J BIOMED MATER RES A, V102, P3049, DOI 10.1002/jbm.a.34974
   Sandhu HS, 2001, EUR SPINE J, V10, pS122, DOI 10.1007/s005860100303
   Santini JT, 1999, NATURE, V397, P335, DOI 10.1038/16898
   Santo VE, 2013, TISSUE ENG PART B RE, V19, P327, DOI [10.1089/ten.TEB.2012.0727, 10.1089/ten.teb.2012.0727]
   Sarban S, 2009, CLIN ORTHOP RELAT R, V467, P3113, DOI 10.1007/s11999 009 1004 6
   Satomura K, 2007, J PINEAL RES, V42, P231, DOI 10.1111/j.1600 079X.2006.00410.x
   Schmidmaier G, 2003, ACTA ORTHOP SCAND, V74, P604, DOI 10.1080/00016470310018036
   Schwabe P, 2012, SCI WORLD J, DOI 10.1100/2012/560142
   Schwarz F, 2009, J PERIODONTOL, V80, P1315, DOI 10.1902/jop.2009.090034
   Sessa G, 2011, AGING CLIN EXP RES, V23, P69
   Shuid AN, 2013, CURR DRUG TARGETS, V14, P1558, DOI 10.2174/1389450114666131108153905
   Si XH, 1998, INT J ORAL MAX SURG, V27, P310, DOI 10.1016/S0901 5027(05)80622 8
   Simic P, 2006, J BIOL CHEM, V281, P25509, DOI 10.1074/jbc.M513276200
   Skoglund B, 2002, J BONE MINER RES, V17, P2004, DOI 10.1359/jbmr.2002.17.11.2004
   Smucker JD, 2008, SPINE, V33, P1324, DOI 10.1097/BRS.0b013e3181732a74
   Sörensen TC, 2013, J PHARM PHARMACOL, V65, P201, DOI 10.1111/j.2042 7158.2012.01588.x
   Sondergaard BC, 2006, OSTEOARTHR CARTILAGE, V14, P759, DOI 10.1016/j.joca.2006.01.014
   Song CL, 2003, BIOCHEM BIOPH RES CO, V308, P458, DOI 10.1016/S0006 291X(03)01408 6
   Stadelmann VA, 2008, EUR CELLS MATER, V16, P10, DOI 10.22203/eCM.v016a02
   Stadlinger B, 2013, EUR CELLS MATER, V25, P326, DOI 10.22203/eCM.v025a23
   Stefani C M, 2000, Implant Dent, V9, P126, DOI 10.1097/00008505 200009020 00004
   Stein D, 2005, J PERIODONTOL, V76, P1861, DOI 10.1902/jop.2005.76.11.1861
   Stoch SA, 2009, CLIN PHARMACOL THER, V86, P175, DOI 10.1038/clpt.2009.60
   Strohbach CA, 2008, CALCIFIED TISSUE INT, V83, P202, DOI 10.1007/s00223 008 9163 0
   Tai IC, 2013, INT J NANOMED, V8, P3895, DOI 10.2147/IJN.S48694
   Tami AE, 2009, BONE, V45, P1117, DOI 10.1016/j.bone.2009.07.090
   Tanaka M, 2004, BONE, V34, P940, DOI 10.1016/j.bone.2004.01.002
   Tang YC, 2008, CELL BIOL INT, V32, P1150, DOI 10.1016/j.cellbi.2008.06.005
   Tejwani NC, 2011, J ORTHOP TRAUMA, V25, pS56, DOI 10.1097/BOT.0b013e31821b8a52
   Thompson DD, 2010, BONE, V47, pS71
   Thormann U, 2013, BIOMATERIALS, V34, P8589, DOI 10.1016/j.biomaterials.2013.07.036
   Tikiz C, 2005, CLIN RHEUMATOL, V24, P447, DOI 10.1007/s10067 004 1053 x
   Toker H, 2012, ARCH ORAL BIOL, V57, P1545, DOI 10.1016/j.archoralbio.2012.06.013
   Trejo CG, 2010, BIOMATERIALS, V31, P8564, DOI 10.1016/j.biomaterials.2010.07.103
   Turgeman G, 2002, J CELL BIOCHEM, V86, P461, DOI 10.1002/jcb.10231
   Uchida K, 2014, J BIOMED MATER RES A, V102, P1737, DOI 10.1002/jbm.a.34841
   Uchiyama S, 2013, BONE JOINT J, V95B, P1544, DOI 10.1302/0301 620X.95B11.31652
   Valderrama P, 2010, J PERIODONTOL, V81, P737, DOI 10.1902/jop.2010.090562
   van de Watering FCJ, 2012, J CONTROL RELEASE, V164, P283, DOI 10.1016/j.jconrel.2012.07.007
   van der Stok J, 2013, TISSUE ENG PT A, V19, P2605, DOI [10.1089/ten.tea.2013.0181, 10.1089/ten.TEA.2013.0181]
   Van Tomme SR, 2008, INT J PHARMACEUT, V355, P1, DOI 10.1016/j.ijpharm.2008.01.057
   Verron E, 2010, BIOMATERIALS, V31, P7776, DOI 10.1016/j.biomaterials.2010.06.047
   Verron E, 2010, DRUG DISCOV TODAY, V15, P547, DOI 10.1016/j.drudis.2010.05.003
   Vonau RL, 2001, CLIN ORTHOP RELAT R, P243
   Wang HN, 2013, J CONTROL RELEASE, V166, P172, DOI 10.1016/j.jconrel.2012.12.015
   Wang XL, 2013, J ORTHOP RES, V31, P164, DOI 10.1002/jor.22188
   Wang YW, 2012, ADV DRUG DELIVER REV, V64, P1341, DOI 10.1016/j.addr.2011.09.002
   Wei H, 2011, INT J ORAL MAX SURG, V40, P413, DOI 10.1016/j.ijom.2010.10.015
   Wermelin K, 2007, ACTA ORTHOP, V78, P385, DOI 10.1080/17453670710013979
   Wölfle JV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086151
   Wong E, 2013, J BONE JOINT SURG AM, V95A, P454, DOI 10.2106/JBJS.L.00275
   Wronski TJ, 2001, J BONE MINER RES, V16, P1399, DOI 10.1359/jbmr.2001.16.8.1399
   Wu CC, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/3/035009
   Wu ZX, 2011, J ORTHOP SCI, V16, P99, DOI 10.1007/s00776 010 0019 x
   Xie XH, 2012, J TISSUE ENG REGEN M
   Xu Shao wen, 2003, Chin J Traumatol, V6, P160
   Yamaguchi M, 2012, MOL CELL BIOCHEM, V359, P399, DOI 10.1007/s11010 011 1034 8
   Yamano S, 2014, BIOMATERIALS, V35, P2446, DOI 10.1016/j.biomaterials.2013.12.006
   Yang GL, 2012, INT J ORAL MAX IMPL, V27, P1332
   Yang GL, 2012, INT J ORAL MAX IMPL, V27, P369
   Yoon BH, 2014, J BONE MINER RES, V29, P1950, DOI 10.1002/jbmr.2238
   Young S, 2009, TISSUE ENG PT A, V15, P2347, DOI 10.1089/ten.tea.2008.0510
   Yu NYC, 2014, EUR CELLS MATER, V27, P98, DOI 10.22203/eCM.v027a08
   Yu NYC, 2013, EUR CELLS MATER, V25, P190, DOI 10.22203/eCM.v025a14
   Yu NYC, 2010, EUR CELLS MATER, V20, P431
   Yu XH, 2012, J MATER SCI MATER M, V23, P2177, DOI 10.1007/s10856 012 4682 7
   Yu XH, 2011, J BIOMED MATER RES B, V97B, P345, DOI 10.1002/jbm.b.31820
   Zara JN, 2011, TISSUE ENG PT A, V17, P1389, DOI [10.1089/ten.TEA.2010.0555, 10.1089/ten.tea.2010.0555]
   Zarrinkalam MR, 2013, J ORTHOP RES, V31, P1390, DOI 10.1002/jor.22387
   Zhai YQ, 2009, J BIOTECHNOL, V142, P259, DOI 10.1016/j.jbiotec.2009.05.012
   Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405
   Zhang JF, 2010, MOL CELL ENDOCRINOL, V314, P70, DOI 10.1016/j.mce.2009.08.012
   Zhang LM, 2010, J PINEAL RES, V49, P364, DOI 10.1111/j.1600 079X.2010.00803.x
   Zhang LC, 2013, MED HYPOTHESES, V81, P713, DOI 10.1016/j.mehy.2013.07.034
   Zhang YF, 2012, BIOMATERIALS, V33, P6698, DOI 10.1016/j.biomaterials.2012.06.021
   Zhao JY, 2010, TISSUE ENG PT A, V16, P233, DOI [10.1089/ten.tea.2009.0165, 10.1089/ten.TEA.2009.0165]
   Zhao SH, 2010, INT J PHARMACEUT, V393, P268, DOI 10.1016/j.ijpharm.2010.04.034
   Zhu SS, 2011, INJURY, V42, P1467, DOI 10.1016/j.injury.2011.05.040
   Zupan J, 2012, J BIOMED SCI, V19, DOI 10.1186/1423 0127 19 28
NR 341
TC 139
Z9 157
U1 1
U2 142
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JAN 1
PY 2015
VL 11
BP 412
EP 434
DI 10.1016/j.actbio.2014.09.006
PG 23
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA AY7NZ
UT WOS:000347747900040
PM 25218339
DA 2025 08 17
ER

PT J
AU Feng, Y
   Zhu, SJ
   Antaris, AL
   Chen, H
   Xiao, YL
   Lu, XW
   Jiang, LL
   Diao, S
   Yu, K
   Wang, Y
   Herraiz, S
   Yue, JY
   Hong, XC
   Hong, GS
   Cheng, Z
   Dai, HJ
   Hsueh, AJ
AF Feng, Yi
   Zhu, Shoujun
   Antaris, Alexander L.
   Chen, Hao
   Xiao, Yuling
   Lu, Xiaowei
   Jiang, Linlin
   Diao, Shuo
   Yu, Kuai
   Wang, Yan
   Herraiz, Sonia
   Yue, Jingying
   Hong, Xuechuan
   Hong, Guosong
   Cheng, Zhen
   Dai, Hongjie
   Hsueh, Aaron J.
TI Live imaging of follicle stimulating hormone receptors in gonads and
   bones using near infrared II fluorophore
SO CHEMICAL SCIENCE
LA English
DT Article
ID POLYCYSTIC OVARY; IN VIVO; FLUORESCENCE; FERTILITY; WINDOW; CELLS;
   SPERMATOGENESIS; DISRUPTION; THERAPY; MICE
AB In vivo imaging of hormone receptors provides the opportunity to visualize target tissues under hormonal control in live animals. Detecting longer wavelength photons in the second near infrared window (NIR II, 1000 1700 nm) region affords reduced photon scattering in tissues accompanied by lower autofluorescence, leading to higher spatial resolution at up to centimeter tissue penetration depths. Here, we report the conjugation of a small molecular NIR II fluorophore CH1055 to a follicle stimulating hormone (FSH CH) for imaging ovaries and testes in live mice. After exposure to FSH CH, specific NIR II signals were found in cultured ovarian granulosa cells containing FSH receptors. Injection of FSH CH allowed live imaging of ovarian follicles and testicular seminiferous tubules in female and male adult mice, respectively. Using prepubertal mice, NIR II signals were detected in ovaries containing only preantral follicles. Resolving earlier controversies regarding the expression of FSH receptors in cultured osteoclasts, we detected for the first time specific FSH receptor signals in bones in vivo. The present imaging of FSH receptors in live animals using a ligand conjugated NIR II fluorophore with low cell toxicity and rapid clearance allows the development of non invasive molecular imaging of diverse hormonal target cells in vivo.
C1 [Feng, Yi; Lu, Xiaowei; Jiang, Linlin; Wang, Yan; Herraiz, Sonia; Hsueh, Aaron J.] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Program Reprod & Stem Cell Biol, Stanford, CA 94305 USA.
   [Zhu, Shoujun; Antaris, Alexander L.; Diao, Shuo; Yu, Kuai; Yue, Jingying; Hong, Guosong; Dai, Hongjie] Stanford Univ, Dept Chem, Stanford, CA 94305 USA.
   [Chen, Hao; Xiao, Yuling; Hong, Xuechuan] Wuhan Univ, Hubei Prov Engn & Technol Res Ctr Fluorinated Pha, Key Lab Virol, Sch Pharmaceut Sci, Wuhan 430071, Peoples R China.
   [Chen, Hao; Cheng, Zhen] Stanford Univ, Dept Radiol, BioX Program, MIPS, Stanford, CA 94305 USA.
   [Feng, Yi] Fudan Univ, Sch Basic Med Sci, Dept Integrat Med & Neurobiol, Shanghai 200032, Peoples R China.
   [Feng, Yi] Fudan Univ, Inst Acupuncture & Moxibust, State Key Lab Med Neurobiol,Fudan Inst Integrat M, Inst Brain Sci,Brain Sci Collaborat Innovat Ctr, Shanghai 200032, Peoples R China.
C3 Stanford University; Stanford University; Wuhan University; Stanford
   University; Fudan University; Fudan University
RP Hsueh, AJ (通讯作者)，Stanford Univ, Sch Med, Dept Obstet & Gynecol, Program Reprod & Stem Cell Biol, Stanford, CA 94305 USA.; Dai, HJ (通讯作者)，Stanford Univ, Dept Chem, Stanford, CA 94305 USA.; Cheng, Z (通讯作者)，Stanford Univ, Dept Radiol, BioX Program, MIPS, Stanford, CA 94305 USA.
EM zcheng@stanford.edu; hdai@stanford.edu; hdai@stanford.edu
RI Xiao, Yuling/NBX 6437 2025; YU, KUAI/B 8429 2017; Lu,
   xiaowei/MFJ 7274 2025; Cheng, Zhen/K 2843 2012; zhu,
   shoujun/S 8058 2017; Chen, Hao/KCK 5937 2024; Dai,
   Hongjie/ABC 4574 2021; Zhu, Shoujun/S 8058 2017; Hong,
   Guosong/A 7551 2013; Herraiz, Sonia/M 6119 2015; Feng, Yi/P 6817 2019
OI Jiang, Linlin/0000 0001 9636 2281; Feng, Yi/0000 0002 7156 6023; hong,
   xuechuan/0000 0001 6834 3278; Chen, Hao/0000 0002 8470 5467; Zhu,
   Shoujun/0000 0002 2412 6121; Hong, Guosong/0000 0002 8858 4471; Herraiz,
   Sonia/0000 0003 0703 6922; 
FU Office of Science (BER), U.S. Department of Energy [DE SC0008397]; NCI
   Cancer Center Nanotechnology Excellence Grant (CCNE TR) [U54 CA119367,
   CA151459]; NSFC [81573383, 81373254, 21390402, 477 21204069, 81402882,
   81673766]; PSTCS [SYG201521]; NSFJ [BK20160387]; National Institutes of
   Health/ National Institute of Child Health and Human Development [U54
   HD068158]; Chinese Postdoc Special Scientific Foundation [2014T70392];
   Development Project of Shanghai Peak Disciplines Integrated Chinese and
   Western Medicine
FX This work was partially supported by the Office of Science (BER), U.S.
   Department of Energy (DE SC0008397) (ZC), NCI Cancer Center
   Nanotechnology Excellence Grant (CCNE TR), U54 CA119367, CA151459 (to H.
   D.), NSFC (81573383, 81373254, 21390402, 477 21204069, 81402882) (X. H.,
   Y. X.), PSTCS (SYG201521) (Y. X.), NSFJ (BK20160387) (Y. X.), National
   Institutes of Health/ National Institute of Child Health and Human
   Development (U54 HD068158 as part of the Specialized Cooperative Centers
   Program in Reproduction and Infertility Research, to A. J. H.), Chinese
   Postdoc Special Scientific Foundation (2014T70392) NSFC (81673766) and
   Development Project of Shanghai Peak Disciplines Integrated Chinese and
   Western Medicine (to Y. F.). The authors declare no competing financial
   interests.
CR Allan CM, 2010, P NATL ACAD SCI USA, V107, P22629, DOI 10.1073/pnas.1012141108
   Antaris AL, 2016, NAT MATER, V15, P235, DOI [10.1038/NMAT4476, 10.1038/nmat4476]
   Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141
   Balen AH, 2003, HUM REPROD UPDATE, V9, P505, DOI 10.1093/humupd/dmg044
   Brown M, 2013, J MAGN RESON IMAGING, V38, P689, DOI 10.1002/jmri.23992
   Davis MR, 2012, MOL GENET METAB, V107, P635, DOI 10.1016/j.ymgme.2012.07.023
   DEKRETSE.DM, 1972, J CLIN ENDOCR METAB, V35, P392, DOI 10.1210/jcem 35 3 392
   Dierich A, 1998, P NATL ACAD SCI USA, V95, P13612, DOI 10.1073/pnas.95.23.13612
   DOBYNS BM, 1974, J CLIN ENDOCR METAB, V38, P976, DOI 10.1210/jcem 38 6 976
   Fauser BCJM, 1997, ENDOCR REV, V18, P71, DOI 10.1210/edrv.18.1.0290
   GAY VL, 1974, ENDOCRINOLOGY, V95, P1582, DOI 10.1210/endo 95 6 1582
   Griswold MD, 1998, SEMIN CELL DEV BIOL, V9, P411, DOI 10.1006/scdb.1998.0203
   Hodgson Stephen F, 2003, Endocr Pract, V9, P544
   Hong GS, 2014, NAT PHOTONICS, V8, P723, DOI [10.1038/nphoton.2014.166, 10.1038/NPHOTON.2014.166]
   Hong GS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5206
   Hong H, 2015, MOL PHARMACEUT, V12, P403, DOI 10.1021/mp500766x
   Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257
   Hsueh AJW, 2015, ENDOCR REV, V36, P1, DOI 10.1210/er.2014 1020
   HSUEH AJW, 1984, ENDOCR REV, V5, P76, DOI 10.1210/edrv 5 1 76
   Kawamura K, 2013, P NATL ACAD SCI USA, V110, P17474, DOI 10.1073/pnas.1312830110
   Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297 201
   La Marca A, 2010, HUM REPROD UPDATE, V16, P113, DOI 10.1093/humupd/dmp036
   LEE CW, 2015, J BIOTECHNOL BIOMATE, V5
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   Pan P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077095
   Radu A, 2010, NEW ENGL J MED, V363, P1621, DOI 10.1056/NEJMoa1001283
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   Rolf S., 1990, MOL ENDOCRINOL, V4, P525
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Suzuki N, 2015, HUM REPROD, V30, P608, DOI 10.1093/humrep/deu353
   Tabakman SM, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1477
   Tapanainen JS, 1997, NAT GENET, V15, P205, DOI 10.1038/ng0297 205
   Tourkova IL, 2015, ANN NY ACAD SCI, V1335, P100, DOI 10.1111/nyas.12502
   VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596
   Welsher K, 2011, P NATL ACAD SCI USA, V108, P8943, DOI 10.1073/pnas.1014501108
   Zhang B, 2014, NAT MED, V20, P948, DOI 10.1038/nm.3619
   Zhang B, 2013, NANO RES, V6, P113, DOI 10.1007/s12274 012 0286 2
   Zhu C, 2016, CONTRAST MEDIA MOL I, V11, P99, DOI 10.1002/cmmi.1662
   Zhu LL, 2012, P NATL ACAD SCI USA, V109, P14574, DOI 10.1073/pnas.1212806109
NR 39
TC 92
Z9 101
U1 1
U2 162
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2041 6520
EI 2041 6539
J9 CHEM SCI
JI Chem. Sci.
PD MAY 1
PY 2017
VL 8
IS 5
BP 3703
EP 3711
DI 10.1039/c6sc04897h
PG 9
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA ET8MH
UT WOS:000400553000048
PM 28626555
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Skowronska Józwiak, E
   Lewandowski, KC
   Adamczewski, Z
   Krawczyk Rusiecka, K
   Lewinski, A
AF Skowronska Jozwiak, Elzbieta
   Lewandowski, Krzysztof C.
   Adamczewski, Zbigniew
   Krawczyk Rusiecka, Kinga
   Lewinski, Andrzej
TI Mechanisms of Normalisation of Bone Metabolism during Recovery from
   Hyperthyroidism: Potential Role for Sclerostin and Parathyroid Hormone
SO INTERNATIONAL JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID SERUM SCLEROSTIN; MINERAL DENSITY; CIRCULATING SCLEROSTIN; FRACTURE
   RISK; MARKERS; THERAPY; GENDER; GENE
AB Sclerostin, a protein expressed by osteocytes, is a negative regulator of bone formation. The aim of the study was to investigate the relationship between parathyroid hormone (PTH) and markers of bone metabolism and changes of sclerostin concentrations before and after treatment of hyperthyroidism. Patients and Methods. The study involved 33 patients (26 women), age (mean +/  SD) 48 +/  15 years, with hyperthyroidism. Serum sclerostin, PTH, calcium, and bone markers [osteocalcin (OC) and collagen type I cross linked C telopeptide I (CTX)] were measured at diagnosis of hyperthyroidism and after treatment with thiamazole. Results. After treatment of hyperthyroidism a significant decrease in free T 3 (FT3) and free T 4 (FT4) concentrations was accompanied by marked decrease of serumsclerostin (from 43.7 +/  29.3 to 28.1 +/  18.4 pmol/L; P < 0.001), OC (from35.6 +/  22.0 to 27.0 +/  14.3 ng/ mL; P < 0.001), and CTX (from 0.49 +/  0.35 to 0.35 +/  0.23 ng/ dL; P < 0.005), accompanied by an increase of PTH (from 29.3 +/  14.9 to 39.8 +/  19.8; P < 0.001). During hyperthyroidism there was a positive correlation between sclerostin and CTX (r(s) = 0.41, P < 0.05) and between OC and thyroid hormones (with FT3 r(s) = 0.42, with FT4 r(s) = 0.45, P < 0.05). Conclusions. Successful treatment of hyperthyroidism results in a significant decrease in serum sclerostin and bonemarkers concentrations, accompanied by an increase of PTH.
C1 [Skowronska Jozwiak, Elzbieta; Lewandowski, Krzysztof C.; Adamczewski, Zbigniew; Krawczyk Rusiecka, Kinga; Lewinski, Andrzej] Med Univ Lodz, Dept Endocrinol & Metab Dis, PL 90338 Lodz, Poland.
C3 Medical University Lodz
RP Lewinski, A (通讯作者)，Med Univ Lodz, Dept Endocrinol & Metab Dis, 281 289 Rzgowska St, PL 90338 Lodz, Poland.
EM alewin@csk.umed.lo.dz.pl
RI Skowronska Jozwiak, Elzbieta/KTI 2908 2024; Lewinski,
   Andrzej/S 9985 2016; Lewandowski, Krzysztof/AAS 8803 2020; Adamczewski,
   Zbigniew/S 9826 2016; Krawczyk Rusiecka, Kinga/S 9828 2016;
   Skowronska Jozwiak, Elzbieta/I 7359 2015
OI Lewinski, Andrzej/0000 0002 8748 3337; Adamczewski,
   Zbigniew/0000 0001 8713 6936; Krawczyk Rusiecka,
   Kinga/0000 0002 5358 5706; Skowronska Jozwiak,
   Elzbieta/0000 0002 0019 4269; Lewandowski, Krzysztof/0000 0002 9113 2804
FU Medical University of Lodz, Poland [503/1 107 03/503 11 001]
FX The study was financially supported by funds from the Medical University
   of Lodz, Poland (Project no. 503/1 107 03/503 11 001).
CR Amrein K, 2012, J CLIN ENDOCR METAB, V97, P148, DOI 10.1210/jc.2011 2152
   Ardawi MSM, 2011, J BONE MINER RES, V26, P2812, DOI 10.1002/jbmr.479
   Armamento Villareal R, 2014, OSTEOPOROSIS INT, V25, P551, DOI 10.1007/s00198 013 2450 2
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   BOUILLON R, 1974, J CLIN ENDOCR METAB, V38, P999, DOI 10.1210/jcem 38 6 999
   Choi HJ, 2015, INT J CARDIOL, V184, P62, DOI 10.1016/j.ijcard.2015.01.072
   Costa AG, 2013, J CLIN ENDOCR METAB, V98, P4736, DOI 10.1210/jc.2013 2106
   Costa AG, 2011, J CLIN ENDOCR METAB, V96, P3804, DOI 10.1210/jc.2011 0566
   Gorka J, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/638727
   He JW, 2014, J CLIN ENDOCR METAB, V99, pE665, DOI 10.1210/jc.2013 2086
   Kobe N, 1999, ENDOCRINE, V10, P53, DOI 10.1385/ENDO:10:1:53
   Lewiecki EM, 2014, THER ADV MUSCULOSKEL, V6, P48, DOI 10.1177/1759720X13510479
   Mazziotti G, 2010, BONE, V46, P747, DOI 10.1016/j.bone.2009.10.031
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Nagasaka S, 1997, CLIN ENDOCRINOL, V47, P215, DOI 10.1046/j.1365 2265.1997.2401045.x
   O'Shea PJ, 2012, J BIOL CHEM, V287, P17812, DOI 10.1074/jbc.M111.311464
   Pantazi H, 2000, J CLIN ENDOCR METAB, V85, P1099, DOI 10.1210/jc.85.3.1099
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Silva BC, 2011, J ENDOCRINOL INVEST, V34, P801, DOI 10.3275/7925
   Skowronska Jozwiak E, 2012, THYROID RES, V5, DOI 10.1186/1756 6614 5 14
   Svare A, 2009, EUR J ENDOCRINOL, V161, P779, DOI 10.1530/EJE 09 0139
   Toulis KA, 2014, OSTEOPOROSIS INT, V25, P121, DOI 10.1007/s00198 013 2498 z
   Tsourdi E., 2015, ENDOCRINOLOGY
   Vestergaard P, 2000, THYROID, V10, P341, DOI 10.1089/thy.2000.10.341
   Vestergaard P, 2002, THYROID, V12, P411, DOI 10.1089/105072502760043503
   Viapiana O, 2013, CALCIFIED TISSUE INT, V92, P324, DOI 10.1007/s00223 012 9665 7
   Yu EW, 2011, J CLIN ENDOCR METAB, V96, pE1848, DOI 10.1210/jc.2011 1534
NR 27
TC 12
Z9 12
U1 1
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 8337
EI 1687 8345
J9 INT J ENDOCRINOL
JI Int. J. Endocrinol.
PY 2015
VL 2015
AR 948384
DI 10.1155/2015/948384
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CQ6TN
UT WOS:000360737000001
PM 26366174
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Clemons, MJ
   Cochrane, B
   Pond, GR
   Califaretti, N
   Chia, SKL
   Dent, RA
   Song, XN
   Robidoux, A
   Parpia, S
   Warr, D
   Rayson, D
   Pritchard, KI
   Levine, MN
AF Clemons, Mark J.
   Cochrane, Brandy
   Pond, Gregory R.
   Califaretti, Nadia
   Chia, Stephen K. L.
   Dent, Rebecca Alexandra
   Song, Xinni
   Robidoux, Andre
   Parpia, Sameer
   Warr, David
   Rayson, Daniel
   Pritchard, Kathleen I.
   Levine, Mark N.
TI Randomised, phase II, placebo controlled, trial of fulvestrant plus
   vandetanib in postmenopausal women with bone only or bone predominant,
   hormone receptor positive metastatic breast cancer (MBC): the OCOG
   ZAMBONEY study
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Fulvestrant; Vandetanib; Postmenopausal; Bone metastases; Breast cancer
ID ENDOTHELIAL GROWTH FACTOR; SKELETAL RELATED EVENT; ZOLEDRONIC ACID;
   SOLID TUMORS; DOUBLE BLIND; PALLIATIVE BENEFIT; THERAPY; INHIBITOR;
   ZD6474; BISPHOSPHONATES
AB Biomarkers of bone turnover, including urine N telopeptide (uNTx), have been used as surrogate measures of response to bone targeted therapies. Vascular endothelial growth factor (VEGF) levels correlate with extent of bone metastases. We assessed whether vandetanib, an inhibitor of VEGF, epidermal growth factor receptor and RET signalling, improved uNTx response when added to fulvestrant (F) in breast cancer patients with bone metastases. Postmenopausal patients with bone predominant, hormone receptor positive metastatic breast cancer were randomised to F (500 mg IM days 1, 15, 29, then monthly) with either vandetanib (100 mg PO OD) (FV) or placebo (FP). The primary objective was uNTx response. Secondary objectives included PFS, OS, RECIST response, pain scores and toxicity. Sixty one patients were allocated to FV and 68 to FP. Out of 127 analyzable patients, an uNTx response occurred in 66 % for FV and 54 % for FP (p = 0.21). No difference was detected between groups for PFS; HR = 0.95 (95 % CI 0.65 1.38) or OS HR = 0.69 (95 % CI 0.37 1.31). For the 62 patients with measurable disease, clinical benefit rates were 41 and 43 %, respectively (p = 0.47). Serious adverse events were similar, 3.3 % for FV versus 5.9 % for FP. Elevated baseline uNTx (> 65 nM BCE/mmol Cr) was prognostic for PFS, HR = 1.55 (95 % CI 1.04 2.30) and for OS, HR = 2.32 (95 % CI 1.25 4.33). The addition of vandetanib to fulvestrant did not improve biomarker response, PFS or OS in patients with bone metastases. Baseline bone turnover was prognostic for PFS and OS.
C1 [Clemons, Mark J.; Song, Xinni] Ottawa Hosp Res Inst, Ottawa Hosp Canc Ctr, Div Med Oncol, Ottawa, ON K1H 8L6, Canada.
   [Clemons, Mark J.; Song, Xinni] Univ Ottawa, Ottawa, ON K1H 8L6, Canada.
   [Cochrane, Brandy; Pond, Gregory R.; Parpia, Sameer; Levine, Mark N.] McMaster Univ, Ontario Clin Oncol Grp, Hamilton, ON, Canada.
   [Califaretti, Nadia] Grand River Reg Canc Ctr, Kitchener, ON, Canada.
   [Chia, Stephen K. L.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
   [Dent, Rebecca Alexandra] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
   [Robidoux, Andre] Ctr Hosp Univ Montreal, Montreal, PQ, Canada.
   [Warr, David] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
   [Rayson, Daniel] Queen Elizabeth 2 Hlth Sci Ctr, Nova Scotia Canc Ctr, Halifax, NS, Canada.
C3 University of Ottawa; Ottawa Hospital Research Institute; University of
   Ottawa; McMaster University; British Columbia Cancer Agency; University
   of Toronto; Sunnybrook Research Institute; Sunnybrook Health Science
   Center; Universite de Montreal; University of Toronto; University Health
   Network Toronto; Princess Margaret Cancer Centre; Queen Elizabeth II
   Health Sciences Centre
RP Clemons, MJ (通讯作者)，Ottawa Hosp Res Inst, Ottawa Hosp Canc Ctr, Div Med Oncol, Box 912,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
EM mclemons@toh.on.ca
RI ; Pritchard, Kathleen/I 2184 2014; Pond, Gregory/JOZ 2926 2023; Rayson,
   Daniel/W 2800 2019
OI Rayson, Daniel/0000 0002 2438 3128; Pond, Gregory/0000 0003 1033 0882;
   Parpia, Sameer/0000 0002 9407 5622; 
FU AstraZeneca
FX Funding for this study was received from AstraZeneca. The funding source
   had no role in the collection, analysis and interpretation of data; in
   the writing of the report; and in the decision to submit the paper for
   publication. We are grateful to the patients and research staff involved
   in this study and the members of the Data Safety Monitoring Committee:
   Dr. Joel Singer (University of British Columbia), Dr. Charles Geyer
   (CTNeT Statewide Clinical Trials Network of Texas), Dr. Frederick R.
   Rickles (The George Washington University) and Dr. P. J. Devereaux
   (McMaster University). Preliminary results were presented at the 2013
   ASCO meeting, abstract number 574. The following (and site) were
   co investigators on this study; Dr. Som Mukherjee (Juravinski Cancer
   Centre, Hamilton), Dr. Xinni Song (The Ottawa Hospital Regional Cancer
   Centre), Dr. Nadia Califaretti (Grand River Regional Cancer Centre), Dr.
   Jose Chang (R. S. McLaughlin Durham Regional Cancer Centre), Dr. Scott
   Young (Health Sciences North, Sudbury), Dr. Christine Brezden Masley St.
   Michael's Hospital, Toronto), Dr. Sunil Verma (Sunnybrook Odette Cancer
   Centre, Toronto), Dr. David Warr (Princess Margaret Hospital, Toronto),
   Dr. Stephen Chia (BCCA Vancouver), Dr. Sanraj Basi Cross Cancer
   Institute), Dr. Daniel Rayson (QE II HSC Nova Scotia Cancer Centre), Dr.
   Florence Plaza Arnold (Saskatoon Cancer Centre), Dr. Andre Robidoux
   (CHUM, Montreal).
CR Amir E, 2009, J CLIN PATHOL, V62, P474, DOI 10.1136/jcp.2008.062505
   Amir E, 2013, AM J CLIN ONCOL CANC, V36, P436, DOI 10.1097/COC.0b013e3182568f7a
   Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653
   Boér K, 2012, INVEST NEW DRUG, V30, P681, DOI 10.1007/s10637 010 9538 8
   Broom R, 2009, J PAIN SYMPTOM MANAG, V38, P244, DOI 10.1016/j.jpainsymman.2008.08.005
   Carlomagno F, 2002, CANCER RES, V62, P7284
   Chia S, 2008, J CLIN ONCOL, V26, P1664, DOI 10.1200/JCO.2007.13.5822
   Clemons M, 2008, BREAST CANCER RES TR, V108, P79, DOI 10.1007/s10549 007 9583 y
   Clemons MJ, 2006, J CLIN ONCOL, V24, P4895, DOI 10.1200/JCO.2006.05.9212
   Di Leo A, 2010, J CLIN ONCOL, V28, P4594, DOI 10.1200/JCO.2010.28.8415
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Gnant M, 2013, JNCI J NATL CANCER I, V105, P654, DOI 10.1093/jnci/djt026
   Kaufman B, 2009, J CLIN ONCOL, V27, P5529, DOI 10.1200/JCO.2008.20.6847
   Lipton A, 2013, CLIN ONCOL UK, V25, P217, DOI 10.1016/j.clon.2012.11.004
   Lipton Allan, 2011, Breast Dis, V33, P59, DOI 10.3233/BD 2010 0327
   Mayer EL, 2012, BREAST CANCER RES TR, V136, P169, DOI 10.1007/s10549 012 2256 5
   Miller KD, 2005, CLIN CANCER RES, V11, P3369, DOI 10.1158/1078 0432.CCR 04 1923
   Natale RB, 2011, J CLIN ONCOL, V29, P1059, DOI 10.1200/JCO.2010.28.5981
   Osborne CK, 2011, CLIN CANCER RES, V17, P1147, DOI 10.1158/1078 0432.CCR 10 1869
   Plaza Menacho I, 2010, ONCOGENE, V29, P4648, DOI 10.1038/onc.2010.209
   Poon RTP, 2001, J CLIN ONCOL, V19, P1207, DOI 10.1200/JCO.2001.19.4.1207
   Santini D, 2006, ONCOL REP, V15, P1351
   Simmons Christine, 2007, Support Cancer Ther, V4, P182, DOI 10.3816/SCT.2007.n.013
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tan G, 2004, J PAIN, V5, P133, DOI 10.1016/j.jpain.2003.12.005
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Vinholes J, 1999, BRIT J CANCER, V80, P221, DOI 10.1038/sj.bjc.6690506
   Wagner AD, 2012, COCHRANE DB SYST REV, V7
   Wang CY, 2012, BREAST CANCER RES TR, V133, P487, DOI 10.1007/s10549 011 1775 9
   Wedge SR, 2002, CANCER RES, V62, P4645
   Wells SA, 2012, J CLIN ONCOL, V30, P134, DOI 10.1200/JCO.2011.35.5040
NR 32
TC 38
Z9 39
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167 6806
EI 1573 7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUL
PY 2014
VL 146
IS 1
BP 153
EP 162
DI 10.1007/s10549 014 3015 6
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AK1ZW
UT WOS:000338219300016
PM 24924416
DA 2025 08 17
ER

PT J
AU Pascaud, P
   Errassifi, F
   Brouillet, F
   Sarda, S
   Barroug, A
   Legrouri, A
   Rey, C
AF Pascaud, P.
   Errassifi, F.
   Brouillet, F.
   Sarda, S.
   Barroug, A.
   Legrouri, A.
   Rey, C.
TI Adsorption on apatitic calcium phosphates for drug delivery: interaction
   with bisphosphonate molecules
SO JOURNAL OF MATERIALS SCIENCE MATERIALS IN MEDICINE
LA English
DT Article
ID IN VITRO; NANOCRYSTALLINE APATITES; HYDROXYAPATITE; RELEASE;
   ALENDRONATE; BONE; TILUDRONATE; MECHANISMS; SYSTEMS; BMP 2
AB Bisphosphonates (BPs) are well established as an important class of drugs for the treatment and prevention of several bone disorders including osteoporosis. This work investigated the interaction of two bisphosphonates, risedronate and tiludronate, with several apatitic supports, a well crystallised hydroxyapatite (HA) and nanocrystalline apatites with varying maturation times, chemical composition and surface characteristics. The purpose was to fully understand the adsorption mechanism and desorption process, by the evaluation of the effect of several physicochemical parameters (temperature, pH and concentration of calcium and phosphate ions). Whatever the nature of the BP and the structure and composition of the apatite, the adsorption of such anti resorptive agents can be well described as an ion exchange reaction between phosphates species on the apatitic surface and BP molecules in solution. However, the parameters of adsorption can vary depending on the physicochemical conditions of the adsorption reaction. In addition, the structure and composition of the apatitic surface also influence the adsorption properties. Finally, BPs molecules are slowly released from apatitic supports, because most of the adsorbed molecules are irreversibly bound and not spontaneously released by dilution or simple washing. Moreover, similar to their adsorption, the release of bisphosphonates is strongly affected not only by the chemical properties of the molecule, but also by the chemical and structural characteristics of the apatitic substrates. The understanding of the adsorption and release processes provides fundamental tools for the development of drug delivery systems using apatite materials.
C1 [Pascaud, P.; Errassifi, F.; Sarda, S.] Univ Toulouse 3, Univ Toulouse, CIRIMAT, INPT,CNRS,UPS, F 31062 Toulouse, France.
   [Brouillet, F.] Univ Toulouse, UPS, CNRS, CIRIMAT,INPT,Fac Sci Pharmaceut, F 31062 Toulouse, France.
   [Barroug, A.] Univ Cadi Ayyad, Fac Sci Semlalia, Dept Chim, LPCME,CNRST,URAC 20, Marrakech Isl 40001, Morocco.
   [Legrouri, A.] Al Akhawayn Univ, Sch Sci & Engn, Ifrane 53000, Morocco.
   [Rey, C.] Univ Toulouse, ENSIACET, UPS, CIRIMAT,INPT,CNRS, F 31030 Toulouse, France.
C3 Universite de Toulouse; Universite Federale Toulouse Midi Pyrenees
   (ComUE); Universite Toulouse III   Paul Sabatier; Institut National
   Polytechnique de Toulouse; Centre National de la Recherche Scientifique
   (CNRS); Universite de Toulouse; Universite Federale Toulouse
   Midi Pyrenees (ComUE); Universite Toulouse III   Paul Sabatier; Institut
   National Polytechnique de Toulouse; Centre National de la Recherche
   Scientifique (CNRS); Cadi Ayyad University of Marrakech; Centre National
   de la Recherche Scientifique & Technologique (CNRST); Al Akhawayn
   University; Universite de Toulouse; Universite Federale Toulouse
   Midi Pyrenees (ComUE); Universite Toulouse III   Paul Sabatier; Institut
   National Polytechnique de Toulouse; Centre National de la Recherche
   Scientifique (CNRS)
RP Sarda, S (通讯作者)，Univ Toulouse 3, Univ Toulouse, CIRIMAT, INPT,CNRS,UPS, F 31062 Toulouse, France.
EM stephanie.sarda@iut tlse3.fr
RI ; Legrouri, Ahmed/L 1647 2013; BROUILLET, fabien/HKO 3785 2023
OI Sarda, Stephanie/0000 0002 9525 4403; Legrouri,
   Ahmed/0000 0001 5439 2757; BROUILLET, Fabien/0000 0002 8860 9069; 
FU French Moroccan Volubilis integrated action [MA/05/122]
FX A part of this research was supported by the French Moroccan Volubilis
   integrated action MA/05/122. The authors thank Procter & Gamble and
   Sanofi Aventis for the generous donation of risedronate and tiludronate
   samples respectively.
CR Al Kattan A, 2010, ADV ENG MATER, V12, pB224, DOI 10.1002/adem.200980084
   Autefage H, 2009, J BIOMED MATER RES B, V91B, P706, DOI 10.1002/jbm.b.31447
   Barroug A, 2004, J ORTHOP RES, V22, P703, DOI 10.1016/j.orthres.2003.10.016
   Barroug A, 1998, J COLLOID INTERF SCI, V208, P147, DOI 10.1006/jcis.1998.5759
   Benaziz L, 2001, J COLLOID INTERF SCI, V238, P48, DOI 10.1006/jcis.2001.7450
   CHARLOT G, 1974, CHIM ANAL QUANTITATI
   Cukrowski I, 2007, BONE, V41, P668, DOI 10.1016/j.bone.2007.05.008
   Demerjian N, 1999, CLIN RHEUMATOL, V18, P349, DOI 10.1007/s100670050116
   DENISSEN H, 1994, BONE MINER, V25, P123, DOI 10.1016/S0169 6009(08)80254 1
   Eichert D., 2008, Nanocrystalline Apatite Based Biomaterials, P93
   Elliott SN, 1997, LIFE SCI, V62, P77, DOI 10.1016/S0024 3205(97)01040 0
   Errassifi F, 2014, J COLLOID INTERF SCI, V420, P101, DOI 10.1016/j.jcis.2014.01.017
   Errassifi F, 2010, CERAM TRANS, V218, P159
   Errassifi F, 2011, MECANISMES ADSORPTIO, P239
   Europe Co, 2011, EUROPEAN PHARMACOPOE, P2381
   Gómez Morales J, 2013, PROG CRYST GROWTH CH, V59, P1, DOI 10.1016/j.pcrysgrow.2012.11.001
   GORBUNOFF MJ, 1984, ANAL BIOCHEM, V136, P433, DOI 10.1016/0003 2697(84)90240 9
   Hoffman A, 2001, INT J PHARM, V220, P1, DOI 10.1016/S0378 5173(01)00654 8
   Iafisco M, 2008, LANGMUIR, V24, P4924, DOI 10.1021/la703381h
   Josse S, 2005, BIOMATERIALS, V26, P2073, DOI 10.1016/j.biomaterials.2004.05.019
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   Kos M., 2009, Biosci. Hypotheses, V2, P34, DOI [DOI 10.1016/J.BIHY.2008.08.004, 10.1016/j.bihy.2008.08.004]
   Lebugle A, 2002, BIOMATERIALS, V23, P3517, DOI 10.1016/S0142 9612(02)00082 0
   Liu Y, 2007, BIOMATERIALS, V28, P2677, DOI 10.1016/j.biomaterials.2007.02.003
   Lopez Macipe A, 1998, J COLLOID INTERF SCI, V200, P114, DOI 10.1006/jcis.1997.5343
   Midy V, 2001, J MATER SCI MATER M, V12, P293, DOI 10.1023/A:1011286818733
   Misra DN, 1998, COLLOID SURFACE A, V141, P173, DOI 10.1016/S0927 7757(98)00332 X
   Mönkkönen J, 1998, LIFE SCI, V62, pPL95, DOI 10.1016/S0024 3205(97)01178 8
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   OUIZAT S, 1999, MAT RES B, V34, P2279, DOI DOI 10.1016/S0025 5408(00)00167 7
   Palazzo B, 2007, ADV FUNCT MATER, V17, P2180, DOI 10.1002/adfm.200600361
   Panzavolta S, 2009, J INORG BIOCHEM, V103, P101, DOI 10.1016/j.jinorgbio.2008.09.012
   Pascaud P, 2012, BIOMED MATER, V7, P1
   Pascaud P, 2013, LANGMUIR, V29, P2224, DOI 10.1021/la3046548
   Rey C, 2007, MATERIALWISS WERKST, V38, P996, DOI 10.1002/mawe.200700229
   Rey C, 1995, CELL MATER, V5, P345
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Trombe JC, 1972, CONTRIBUTION ETUDE D
   Yin G, 2002, CHEM ENG J, V87, P181, DOI 10.1016/S1385 8947(01)00248 0
NR 40
TC 50
Z9 50
U1 1
U2 78
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957 4530
EI 1573 4838
J9 J MATER SCI MATER M
JI J. Mater. Sci. Mater. Med.
PD OCT
PY 2014
VL 25
IS 10
BP 2373
EP 2381
DI 10.1007/s10856 014 5218 0
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA AP9SX
UT WOS:000342421300017
PM 24789452
DA 2025 08 17
ER

PT J
AU Ulasevich, S
   Ryzhkov, NV
   Andreeva, DV
   Özden, DS
   Piskin, E
   Skorb, EV
AF Ulasevich, Sviatlana
   Ryzhkov, Nikolay V.
   Andreeva, Daria V.
   Ozden, Dilek Sura
   Piskin, Erhan
   Skorb, Ekaterina V.
TI Light to Heat Photothermal Dynamic Properties of Polypyrrole Based
   Coating for Regenerative Therapy and Lab on a Chip Applications
SO ADVANCED MATERIALS INTERFACES
LA English
DT Article
DE mesoporous titania; polyelectrolytes; polymer coating; polypyrrole;
   ultrasonic treatment
ID CONTROLLED RELEASE; ULTRASONIC CAVITATION; COMPOSITE SCAFFOLD; TITANIUM
   SURFACES; DRUG DELIVERY; GROWTH FACTOR; IN VITRO; NANOPARTICLES;
   MICROCAPSULES; FABRICATION
AB Targeted delivery and release of biomolecules, e.g., bone morphogenetic protein (BMP 2), are gaining high interest due to the application for tissue engineering, diagnostics, surface enhanced therapy and lab on a chip. Here, a new hybrid temperature responsive system consisting of polypyrrole (PPy) layer, mesoporous titania surface (TMS), and BMP 2 is proposed. The PPy layer has the light to heat photothermal property. Dynamic behavior of the PPy layer in response to light can regulate release of BMP 2. The PPy based coatings on TMS have shown to be efficient for storage of BMP 2 and can be tuned to release BMP 2 under irradiation. Moreover, the possibility of local delivery and generation of a gradual release of BMP 2 for regulated cell growth is shown. Furthermore, the fabricated surfaces possess excellent biocompatibility and low cytotoxicity for MC3T3 E1 cells. It is shown that the released BMP 2 can effectively promote osteogenic differentiation of MC3T3 E1 cells. Thus, the TMS/PPy BMP 2 is suggested to prolong targeted release of the BMP 2 for more than 25 days which stimulates osteoblasts' proliferation. The new stimuli responsive hybrid system is promising for targeted, localized, sustained drug release and application in bone tissue engineering.
C1 [Ulasevich, Sviatlana; Ryzhkov, Nikolay V.; Skorb, Ekaterina V.] ITMO Univ, Infochem Sci Ctr, Lomonosova Str 9, St Petersburg 191002, Russia.
   [Andreeva, Daria V.] Natl Univ Singapore, Dept Mat Sci & Engn, Singapore 117575, Singapore.
   [Ozden, Dilek Sura] Hacettepe Univ, Chem Engn Dept, TR 06800 Ankara, Turkey.
   [Ozden, Dilek Sura] Hacettepe Univ, Ctr Bioengn & Biyomedtek Nanobiyomedtek, Bioengn Div, TR 06800 Ankara, Turkey.
   [Piskin, Erhan] Bilkent Univ, Nanobiyomedtek Biyomed & Biyoteknol San Tic Ltd S, NanoBMT, 56 Cyberpk, TR 06800 Ankara, Turkey.
C3 ITMO University; National University of Singapore; Hacettepe University;
   Hacettepe University; Ihsan Dogramaci Bilkent University
RP Ulasevich, S; Skorb, EV (通讯作者)，ITMO Univ, Infochem Sci Ctr, Lomonosova Str 9, St Petersburg 191002, Russia.
EM saulasevich@itmo.ru; skorb@itmo.ru
RI PİSKİN, ERHAN/G 6109 2013; Andreeva, Daria/AAV 3091 2021; Özden,
   Dilek/JLL 1810 2023; Ryzhkov, Nikolay/ABH 6636 2020; Ulasevich,
   Sviatlana/F 6452 2019; Skorb, Ekaterina/J 1554 2017
OI Ryzhkov, Nikolay/0000 0002 6557 0018; Andreeva,
   Daria/0000 0003 0273 2064; 
FU Russian Science Foundation [19 79 10244]; ITMO University [08 08];
   Russian Science Foundation [19 79 10244] Funding Source: Russian Science
   Foundation
FX The authors acknowledge Russian Science Foundation Grant No. 19 79 10244
   for the financial support. ITMO University Fellowship and Professorship
   Program 08 08 is acknowledged for infrastructural support.
CR Abalymov A, 2020, ACS BIOMATER SCI ENG, V6, P3933, DOI 10.1021/acsbiomaterials.0c00119
   Aizenberg J, 2005, SCIENCE, V309, P275, DOI 10.1126/science.1112255
   Anderson A, 2015, ELECTROANAL, V27, P872, DOI 10.1002/elan.201400643
   Andreeva DV, 2006, MACROMOL RAPID COMM, V27, P931, DOI 10.1002/marc.200600111
   Andreeva DV, 2012, SMALL, V8, P820, DOI 10.1002/smll.201102365
   Andreeva DV, 2002, THIN SOLID FILMS, V406, P54, DOI 10.1016/S0040 6090(01)01719 9
   Asaumi Y, 2020, LANGMUIR, V36, P2695, DOI 10.1021/acs.langmuir.0c00061
   Au KM, 2013, CHEM COMMUN, V49, P10525, DOI 10.1039/c3cc46385k
   Belova V, 2010, ANGEW CHEM INT EDIT, V49, P7129, DOI 10.1002/anie.201002069
   Cha JN, 2003, J AM CHEM SOC, V125, P8285, DOI 10.1021/ja0279601
   Chen J, 2018, MAT SCI ENG C MATER, V89, P316, DOI 10.1016/j.msec.2018.04.031
   Chen SJ, 2000, J MATER SCI LETT, V19, P2157, DOI 10.1023/A:1026799415199
   Cherepanov PV, 2015, GREEN CHEM, V17, P2745, DOI 10.1039/c5gc00047e
   Chung RJ, 2016, SURF COAT TECH, V303, P283, DOI 10.1016/j.surfcoat.2016.03.081
   Collier JH, 2000, J BIOMED MATER RES, V50, P574, DOI 10.1002/(SICI)1097 4636(20000615)50:4<574::AID JBM13>3.0.CO;2 I
   Dinc DO, 2019, SURF INNOV, V7, P249, DOI 10.1680/jsuin.19.00013
   Elyashevich GK, 2005, J APPL POLYM SCI, V97, P1410, DOI 10.1002/app.21192
   Fang G., 2020, INT J BIOL MACROMOL, V151, P1126
   Gensel J, 2012, ADV MATER, V24, P985, DOI 10.1002/adma.201103786
   George PM, 2005, BIOMATERIALS, V26, P3511, DOI 10.1016/j.biomaterials.2004.09.037
   Guadarrama B., 2020, ACS APPL MATER INTER, V12
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Hosseini Nassab N, 2017, NANOSCALE, V9, P143, DOI 10.1039/c6nr08288b
   Kai D, 2011, J BIOMED MATER RES A, V99A, P376, DOI 10.1002/jbm.a.33200
   Kim DH, 2007, ADV FUNCT MATER, V17, P79, DOI 10.1002/adfm.200500594
   Kim S, 2018, ACS APPL MATER INTER, V10, P33032, DOI 10.1021/acsami.8b11546
   Kopf J, 2016, ADV ENG MATER, V18, P476, DOI 10.1002/adem.201500456
   Kumar AM, 2013, CERAM INT, V39, P5639, DOI 10.1016/j.ceramint.2012.12.080
   Kuvyrkov E, 2019, ULTRASON SONOCHEM, V52, P437, DOI 10.1016/j.ultsonch.2018.12.024
   Lendlein A, 2002, SCIENCE, V296, P1673, DOI 10.1126/science.1066102
   Li FG, 2007, J MATER CHEM, V17, P4309, DOI 10.1039/b708707a
   Liao JW, 2013, SURF COAT TECH, V228, pS41, DOI 10.1016/j.surfcoat.2012.09.023
   Liu M, 2016, RSC ADV, V6, P84269, DOI 10.1039/c6ra18261e
   Mdleleni MM, 1998, J AM CHEM SOC, V120, P6189, DOI 10.1021/ja9800333
   Mîndroiu M, 2013, APPL SURF SCI, V276, P401, DOI 10.1016/j.apsusc.2013.03.107
   Moquin A, 2019, CHEM COMMUN, V55, P9829, DOI 10.1039/c9cc04000e
   Muderrisoglu C, 2018, ADV MATER INTERFACES, V5, DOI 10.1002/admi.201800452
   Murray PS, 2014, BIOL OPEN, V3, P1183, DOI 10.1242/bio.20149761
   Okitsu K, 1996, ULTRASON SONOCHEM, V3, pS249, DOI 10.1016/S1350 4177(96)00033 8
   Parakhonskiy B, 2009, LANGMUIR, V25, P4780, DOI 10.1021/la804002x
   Park D, 2014, CHEM COMMUN, V50, P15014, DOI 10.1039/c4cc06349j
   Parthasarathy RV, 1997, CHEM MATER, V9, P560, DOI 10.1021/cm9604017
   Peterson AM, 2014, ACS APPL MATER INTER, V6, P1866, DOI 10.1021/am404849y
   Peterson AM, 2012, BIOMACROMOLECULES, V13, P3120, DOI 10.1021/bm300928s
   Qi W, 2008, ADV MATER, V20, P601, DOI 10.1002/adma.200702155
   Qi W, 2009, BIOMACROMOLECULES, V10, P1212, DOI 10.1021/bm801502r
   Rikhari B, 2018, CARBOHYD POLYM, V189, P126, DOI 10.1016/j.carbpol.2018.01.042
   Rosales Leal JI, 2010, COLLOID SURFACE A, V365, P222, DOI 10.1016/j.colsurfa.2009.12.017
   Sajesh KM, 2013, INT J BIOL MACROMOL, V62, P465, DOI 10.1016/j.ijbiomac.2013.09.028
   Samanta D, 2016, NANOSCALE, V8, P9310, DOI 10.1039/c6nr01884j
   Samanta D, 2015, NANOSCALE, V7, P9497, DOI 10.1039/c5nr02196k
   Sameni Reza, 2010, Open Pacing Electrophysiol Ther J, V3, P4
   Shi GX, 2008, BIOMATERIALS, V29, P3792, DOI 10.1016/j.biomaterials.2008.06.010
   Shi GX, 2004, BIOMATERIALS, V25, P2477, DOI 10.1016/j.biomaterials.2003.09.032
   Sirivisoot S, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/8/085101
   Skorb EV, 2010, NANOSCALE, V2, P722, DOI 10.1039/c0nr00074d
   Skorb EV, 2012, J MATER CHEM, V22, P13841, DOI 10.1039/c2jm30768e
   Song FX, 2016, RSC ADV, V6, P92804, DOI 10.1039/c6ra15267h
   Stauffer WR, 2006, BIOMATERIALS, V27, P2405, DOI 10.1016/j.biomaterials.2005.10.024
   STREET GB, 1985, MOL CRYST LIQ CRYST, V118, P137, DOI 10.1080/00268948508076201
   Tomczykowa M, 2019, POLYMERS BASEL, V11, DOI 10.3390/polym11020350
   Tretyakov Y. D., 2007, INORG CHEM, V3, P352
   Ulasevich SA, 2016, MACROMOL BIOSCI, V16, P1422, DOI 10.1002/mabi.201600127
   Vallet Regí M, 2006, CHEM EUR J, V12, P5934, DOI 10.1002/chem.200600226
   Venkatasubbu GD, 2013, ADV POWDER TECHNOL, V24, P947, DOI 10.1016/j.apt.2013.01.008
   Vidal JC, 2003, MICROCHIM ACTA, V143, P93, DOI 10.1007/s00604 003 0067 4
   Wang Y, 2014, CHEM EUR J, V20, P11826, DOI 10.1002/chem.201403480
   Wennerberg A, 2009, CLIN ORAL IMPLAN RES, V20, P172, DOI 10.1111/j.1600 0501.2009.01775.x
   Xu XW, 2019, NANOSCALE, V11, P21953, DOI 10.1039/c9nr07017f
   Yang K, 2012, ADV MATER, V24, P5586, DOI 10.1002/adma.201202625
   Yu CL, 2009, J SOLID STATE CHEM, V182, P1061, DOI 10.1016/j.jssc.2009.01.033
   Zhong Cheng, 2017, Int J Nanomedicine, V12, P1215, DOI 10.2147/IJN.S124040
   Zhukova Y, 2017, ULTRASON SONOCHEM, V36, P146, DOI 10.1016/j.ultsonch.2016.11.014
NR 73
TC 12
Z9 12
U1 0
U2 33
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2196 7350
J9 ADV MATER INTERFACES
JI Adv. Mater. Interfaces
PD NOV
PY 2020
VL 7
IS 21
AR 2000980
DI 10.1002/admi.202000980
EA SEP 2020
PG 11
WC Chemistry, Multidisciplinary; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science
GA OR6RH
UT WOS:000571142800001
OA Green Published
DA 2025 08 17
ER

PT J
AU Ma, WQ
   Sun, XJ
   Wang, Y
   Zhu, Y
   Han, XQ
   Liu, NF
AF Ma, Wen Qi
   Sun, Xue Jiao
   Wang, Ying
   Zhu, Yi
   Han, Xi Qiong
   Liu, Nai Feng
TI Restoring mitochondrial biogenesis with metformin attenuates
   β GP induced phenotypic transformation of VSMCs into an osteogenic
   phenotype via inhibition of PDK4/oxidative stress mediated apoptosis
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Metformin; Mitochondrial biogenesis; Phenotypic transformation;
   Apoptosis; Autophagy
ID ACTIVATED PROTEIN KINASE; VASCULAR CALCIFICATION; SKELETAL MUSCLE;
   AUTOPHAGY; MECHANISMS; MITOPHAGY
AB Mitochondrial abnormalities have long been observed in the development of vascular calcification. Metformin, a member of the biguanide class of antidiabetic drugs, has recently received attention owing to new findings regarding its protective role in cardiovascular disease. Since the precise control of mitochondrial quantity and quality is critical for the survival and function of vascular smooth muscle cells (VSMCs), maintaining mitochondrial homeostasis may be a potential protective factor for VSMCs against osteoblast like phenotypic transition. However, limited studies have been reported in this area. Here, we investigated the role of metformin in the phenotypic transformation of VSMCs, as well as its intracellular signal transduction pathways. We demonstrated that supplementation with metformin restored the beta glycerophosphate (beta GP) mediated impairment of mitochondrial biogenesis in VSMCs, as evidenced by an increased mitochondrial DNA copy number, a restored mitochondrial membrane potential (MMP), and upregulated mitochondrial biogenesis related gene expression, whereas the AMP activated protein kinase (AMPK) inhibitor compound C suppressed these effects. We also observed that overexpression of pyruvate dehydrogenase kinase 4 (PDK4), an important mitochondrial matrix enzyme in cellular energy metabolism, exacerbated beta GP induced oxidative stress and subsequent apoptosis in VSMCs but that these effects were suppressed by dichloroacetate, a widely reported PDK4 inhibitor. More importantly, enhanced mitochondrial biogenesis attenuated the beta GP induced phenotypic transformation of VSMCs into an osteogenic phenotype through inhibition of the PDK4/oxidative stress mediated apoptosis pathway, whereas disruption of mitochondrial biogenesis by zidovudine aggravated beta GP induced apoptosis in VSMCs. In addition, inhibition of autophagy by small interfering RNA targeting Atg5 reduced mitochondrial biogenesis in VSMCs. In summary, we uncovered a novel mechanism by which metformin attenuates the phenotypic transformation of VSMCs into an osteogenic phenotype via inhibition of the PDK4/oxidative stress mediated apoptosis pathway, and mitochondrial homeostasis is involved in this process.
C1 [Ma, Wen Qi; Sun, Xue Jiao; Wang, Ying; Zhu, Yi; Han, Xi Qiong; Liu, Nai Feng] Southeast Univ, Zhongda Hosp, Sch Med, Dept Cardiol, 87 Dingjiaqiao, Nanjing 210009, Jiangsu, Peoples R China.
C3 Southeast University   China
RP Liu, NF (通讯作者)，Southeast Univ, Zhongda Hosp, Sch Med, Dept Cardiol, 87 Dingjiaqiao, Nanjing 210009, Jiangsu, Peoples R China.
EM liunf@seu.edu.cn
RI Liu, Nai feng/AAM 7836 2020
OI Ma, Wen Qi/0000 0002 0287 8496
FU National Natural Science Foundation of China [81770451]; Fundamental
   Research Funds for the Central Universities; Postgraduate Research &
   Practice Innovation Program of Jiangsu Province [KYCX18_0170,
   KYCX17_0174]
FX This work was supported by National Natural Science Foundation of China
   (No. 81770451), the Fundamental Research Funds for the Central
   Universities, and the Postgraduate Research & Practice Innovation
   Program of Jiangsu Province (KYCX18_0170, KYCX17_0174).
CR An JH, 2010, BONE, V47, P140, DOI 10.1016/j.bone.2010.04.593
   Ballinger SW, 2002, CIRCULATION, V106, P544, DOI 10.1161/01.CIR.0000023921.93743.89
   Bardeesi ASA, 2017, J TRANSL MED, V15, DOI 10.1186/s12967 017 1190 z
   Bowker Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191
   Byon CH, 2008, J BIOL CHEM, V283, P15319, DOI 10.1074/jbc.M800021200
   Cao XR, 2013, ENDOCRINOLOGY, V154, P3680, DOI 10.1210/en.2013 1002
   Carchman EH, 2013, FASEB J, V27, P4703, DOI 10.1096/fj.13 229476
   Chiao YA, 2016, AGING US, V8, P314, DOI 10.18632/aging.100881
   Dai XY, 2013, KIDNEY INT, V83, P1042, DOI 10.1038/ki.2012.482
   De Meyer GRY, 2015, CIRC RES, V116, P468, DOI 10.1161/CIRCRESAHA.116.303804
   Ding Y, 2016, CIRC RES, V119, P718, DOI 10.1161/CIRCRESAHA.116.308689
   Durham AL, 2018, CARDIOVASC RES, V114, P590, DOI 10.1093/cvr/cvy010
   Gao Y, 2008, J PHARM PHARMACOL, V60, P1695, DOI 10.1211/jpp.60/12.0017
   Goldberg RB, 2017, CIRCULATION, V136, P52, DOI 10.1161/CIRCULATIONAHA.116.025483
   Hock MB, 2009, ANNU REV PHYSIOL, V71, P177, DOI 10.1146/annurev.physiol.010908.163119
   Jang WG, 2011, BIOCHEM BIOPH RES CO, V404, P1004, DOI 10.1016/j.bbrc.2010.12.099
   Jeong JY, 2012, DIABETES METAB J, V36, P328
   Jeoung NH, 2015, DIABETES METAB J, V39, P188, DOI 10.4093/dmj.2015.39.3.188
   Johnson RC, 2006, CIRC RES, V99, P1044, DOI 10.1161/01.RES.0000249379.55535.21
   Jornayvaz FR, 2010, ESSAYS BIOCHEM, V47, P69, DOI [10.1042/BSE0470069, 10.1042/bse0470069]
   Ju JS, 2016, J PHYSIOL SCI, V66, P417, DOI 10.1007/s12576 016 0440 9
   Kamarajugadda S, 2012, MOL CELL BIOL, V32, P1893, DOI 10.1128/MCB.06248 11
   Kim H, 2012, J CELL MOL MED, V16, P273, DOI 10.1111/j.1582 4934.2011.01294.x
   Lee SJ, 2015, SCI REP UK, V5, DOI 10.1038/srep16577
   Leem J, 2016, ENDOCRINOL METAB, V31, P52, DOI 10.3803/EnM.2016.31.1.52
   Leopold JA, 2015, TRENDS CARDIOVAS MED, V25, P267, DOI 10.1016/j.tcm.2014.10.021
   Loubiere C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05052 2
   Ma WQ, 2017, ONCOTARGET, V8, P112841, DOI 10.18632/oncotarget.22835
   Murphy E, 2016, CIRC RES, V118, P1960, DOI 10.1161/RES.0000000000000104
   Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074
   Palikaras K, 2014, EXP GERONTOL, V56, P182, DOI 10.1016/j.exger.2014.01.021
   Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Proudfoot D, 2000, CIRC RES, V87, P1055, DOI 10.1161/01.RES.87.11.1055
   Sergin I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15750
   Sobenin IA, 2013, ATHEROSCLEROSIS, V227, P283, DOI 10.1016/j.atherosclerosis.2013.01.006
   Stetler RA, 2013, J CEREBR BLOOD F MET, V33, P22, DOI 10.1038/jcbfm.2012.158
   Sugden Mary C., 2006, Archives of Physiology and Biochemistry, V112, P139, DOI 10.1080/13813450600935263
   Tai S, 2016, INT J CARDIOL, V211, P1, DOI 10.1016/j.ijcard.2016.02.128
   Wang SB, 2012, CLIN SCI, V122, P555, DOI 10.1042/CS20110625
   Wong ND, 2012, JACC CARDIOVASC IMAG, V5, P358, DOI 10.1016/j.jcmg.2011.12.015
   Xu MM, 2017, LIFE SCI, V179, P23, DOI 10.1016/j.lfs.2016.11.025
   Zhang XY, 2016, VASC PHARMACOL, V81, P83, DOI 10.1016/j.vph.2016.01.002
   Zhu JH, 2013, AUTOPHAGY, V9, P1663, DOI 10.4161/auto.24135
NR 44
TC 80
Z9 93
U1 1
U2 30
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD JAN 5
PY 2019
VL 479
BP 39
EP 53
DI 10.1016/j.mce.2018.08.012
PG 15
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA HB4EJ
UT WOS:000451005300005
PM 30170182
DA 2025 08 17
ER

PT J
AU Yue, B
   Zhang, W
   Li, M
   Xu, L
AF Yue, Bin
   Zhang, Wei
   Li, Ming
   Xu, Li
TI WTAP increases BMP2 expression to promote osteoblast differentiation and
   inhibit osteoblast senescence via m<SUP>6</SUP>A methylation of
   Sp1
SO MOLECULAR GENETICS AND GENOMICS
LA English
DT Article
DE WTAP; Sp1; m(6)A; Osteoblast differentiation; Osteoblast senescence
ID TRANSCRIPTION FACTOR; DOWN REGULATION; BONE; OSTEOPOROSIS; POLYMORPHISM;
   PROTEINS; DENSITY
AB Pro differentiation and anti senescence treatment may be potential strategies for senile osteoporosis therapy. However, the regulatory mechanism underlying osteoblast differentiation and senescence in senile osteoporosis remain to be clarified. In the present study, the preosteoblast cell line MC3T3 E1 was used to induce osteoblast differentiation. The H2O2 was applied to induce senescence. H2O2 treatment significantly inhibited the expression of Wilms tumor 1 associating protein (WTAP), runtrelated transcription factor 2 (Runx2), Osterix and specific protein 1 (Sp1), inhibited the alkaline phosphatase (ALP) activity, upregulated the senescence associated beta galactosidase (SA beta Gal), and increased the mRNA levels of p16 and p21. WTAP overexpression significantly reversed the effect of H2O2, during the osteoblast differentiation of MC3T3 E1 cells. The RIP qRT PCR and MeRIP qRT PCR assays confirmed that N6 methyladenosine (m(6)A) modification of Sp1 mRNA was significantly decreased by H2O2 treatment, but was increased by WTAP overexpression. The m(6)A modification of Sp1 mRNA significantly increased the stability of Sp1 mRNA. The ChIP qRT PCR assay and luciferase reporter gene assay showed that Sp1 could bind to the promoter of BMP2. BMP2 knockdown reversed the effect of Sp1 on osteoblast differentiation and senescence. In conclusion, WTAP increased BMP2 expression to promote osteoblast differentiation and inhibit osteoblast senescence via increasing m(6)A methylation of Sp1 mRNA. This study sheds new light on our understanding of mechanisms underlying osteoblast differentiation and senescence, and provides potential strategies for senile osteoporosis therapy.
C1 [Yue, Bin; Xu, Li] Staff Hosp Changqing Oilfield, Dept Endocrinol, Xian 710018, Peoples R China.
   [Zhang, Wei] Staff Hosp Changqing Oilfield, Dept Gen Internal Med, 20,Changqing West Rd,Jinghe Dev Zone, Xian 710018, Peoples R China.
   [Li, Ming] Staff Hosp Changqing Oilfield, Dept Orthoped, Xian 710018, Peoples R China.
RP Zhang, W (通讯作者)，Staff Hosp Changqing Oilfield, Dept Gen Internal Med, 20,Changqing West Rd,Jinghe Dev Zone, Xian 710018, Peoples R China.
EM wei_zhg0@163.com
CR Ambrosi TH, 2021, NATURE, V597, P256, DOI 10.1038/s41586 021 03795 7
   An HJ, 2016, MOL CELL BIOCHEM, V414, P201, DOI 10.1007/s11010 016 2672 7
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Castillo AB, 2014, AM J PHYSIOL ENDOC M, V306, pE937, DOI 10.1152/ajpendo.00458.2013
   Chatakun P, 2014, CELL MOL LIFE SCI, V71, P113, DOI 10.1007/s00018 013 1326 0
   Chen YH, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1053 8
   Choi LY, 2021, PHYTOTHER RES, V35, P7050, DOI 10.1002/ptr.7336
   Ding A, 2021, LAB INVEST, V101, P1458, DOI 10.1038/s41374 021 00649 8
   Duan Juan Li, 2022, Hepatology, V75, P584, DOI 10.1002/hep.32209
   Dun YY, 2020, ARAB J GASTROENTEROL, V21, P43, DOI 10.1016/j.ajg.2019.12.004
   Durbano HW, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186909
   Föger Samwald U, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052701
   Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096 203
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   Kim HJ, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 022 04186 5
   Kim J, 2017, BBA GEN SUBJECTS, V1861, P2663, DOI 10.1016/j.bbagen.2017.07.008
   Kim KM, 2019, EXP MOL MED, V51, DOI 10.1038/s12276 019 0263 x
   Kurt Sirin O, 2014, GENE, V540, P226, DOI 10.1016/j.gene.2014.02.028
   Lee SY, 2020, MOL THER, V28, P142, DOI 10.1016/j.ymthe.2019.08.014
   Li YJ, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13291
   Li YM, 2024, FRONT IMMUNOL, V15, DOI 10.3389/fimmu.2024.1423378
   Liu JC, 2023, STEM CELL TRANSL MED, V12, P307, DOI 10.1093/stcltm/szad020
   Moradifard S, 2020, MUTAT RES REV MUTAT, V786, DOI 10.1016/j.mrrev.2020.108339
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Oh JE, 2007, BIOCHEM BIOPH RES CO, V353, P86, DOI 10.1016/j.bbrc.2006.11.118
   Park Ji Hwan, 2021, Exp Mol Med, V53, P1092, DOI 10.1038/s12276 021 00643 6
   Park KR, 2022, PHARMACOL RES, V184, DOI 10.1016/j.phrs.2022.106423
   Pluijm SMF, 2004, ANN RHEUM DIS, V63, P71, DOI 10.1136/ard.2002.002287
   Qadir A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010349
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Son HE, 2018, LIFE SCI, V193, P34, DOI 10.1016/j.lfs.2017.12.008
   Swift ML, 2022, GEROSCIENCE, V44, P683, DOI 10.1007/s11357 021 00456 5
   Tang JY, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0706 6
   Wang HF, 2020, CALCIFIED TISSUE INT, V106, P486, DOI 10.1007/s00223 019 00654 6
   Wang J, 2021, AGING US, V13, P21134, DOI 10.18632/aging.203377
   Wu H, 2022, INT J BIOL SCI, V18, P661, DOI 10.7150/ijbs.65861
   Wu TL, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13234
   Xia CP, 2020, MOL CELL PROBE, V50, DOI 10.1016/j.mcp.2019.101504
   Xu JW, 2007, GENE, V392, P221, DOI 10.1016/j.gene.2006.12.032
   Xu XJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.653724
   Yang YM, 2022, J GENET GENOMICS, V49, P847, DOI 10.1016/j.jgg.2022.03.001
   You YH, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419 023 05565 x
   Yu SB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163277
   Zhang XY, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007555
   Zhou Y, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw104
NR 45
TC 2
Z9 2
U1 4
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1617 4615
EI 1617 4623
J9 MOL GENET GENOMICS
JI Mol. Genet. Genomics
PD DEC
PY 2024
VL 299
IS 1
AR 109
DI 10.1007/s00438 024 02203 9
PG 14
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA N7T6H
UT WOS:001366318300001
PM 39601917
DA 2025 08 17
ER

PT J
AU Moore, JB
   Hoang, TD
   Shwayhat, AF
AF Moore, John B.
   Hoang, Thanh D.
   Shwayhat, Alfred F.
TI Case Report of Clinical Vignette: Osteopetrosis
SO MILITARY MEDICINE
LA English
DT Article
ID AUTOSOMAL RECESSIVE OSTEOPETROSIS
AB Introduction: Osteopetrosis is a connective tissue disorder resulting from abnormally dense bone predisposing patients to fracture. The clinical pattern of fractures across time and space as well as suggestive radiographic findings usually raises diagnostic suspicion. Multiple genetic mutations resulting in dysfunctional osteoclasts have been implicated in the pathogenesis of osteopetrosis with variable inheritance patterns. In severe cases, usually inherited in an autosomal recessive pattern, the medullary cavity important in the production of normal blood cell progenitors is replaced by defective endochondral bone, leading to pancytopenia and consequential extramedullary hema topoiesis. Materials and methods: This is a case report from a patient presenting to Naval Medical Center San Diego, a large Military Treatment Facility constituting a regional referral center for Navy Medicine West and serving approximately 250,000 eligible patients with more than 6,200 military and civilian staff. The genetic analysis was performed by Connective Tissue Gene Tests (CTGT) using the CTGT Osteopetrosis NextGen sequencing panel, consisting of 13 genes associated with osteopetrosis. A literature review was performed using PUBMED and Google Scholar to identify information on osteopetrosis and mutation implications. Results: We present a 19 year old male with clinical osteopetrosis resulting from compound heterozygosity of several mutated alleles within the PLEKHM1 gene, which is important to endosomal and lysosomal vesicular function. To date, most mutations discovered involve genes coding for intracellular enzymes, like carbonic anhydrase, or cell surface transporters, such as the osteoclast H+ ATPase proton pump and the chloride channel, engaged in the acidification of bone at the interface of the osteoclastic ruffled border and the bone matrix. This case represents one of the few reports of inherited defects within the PLEKHM1 gene, resulting in defective osteoclastic ruffled border formation and consequential inadequate bone resorption. Conclusions: This patient's lack of hematologic deficiencies and survival into adulthood portend an improved long term prognosis and may infer prognostic insight in future cases with similar genetic abnormalities. In patients presenting with skeletal abnormalities and pathologic fractures in early adulthood, the clinician should consider osteopetrosis as a potential explanatory mechanism. Genetic characterization can elucidate cellular pathophysiology and potentially guide treatment modalities. Patients are typically managed with lifestyle adjustments limiting traumatic fracture and antiresorptive medications, typified by the bisphosphonate class. Since osteoclasts derive from a hematopoietic precursor, the only definitive curative therapy present is hematopoietic stem cell transplant. In the future, novel genomic level modulation may confer the ability to correct underlying point mutations and spare individuals from the morbidity associated with bone marrow transplant.
C1 [Moore, John B.; Hoang, Thanh D.; Shwayhat, Alfred F.] Naval Med Ctr San Diego, Dept Med, Div Endocrinol, 34800 Bob Wilson Dr, San Diego, CA 92134 USA.
C3 United States Department of Defense; United States Navy; Naval Medical
   Center San Diego
RP Moore, JB (通讯作者)，Naval Med Ctr San Diego, Dept Med, Div Endocrinol, 34800 Bob Wilson Dr, San Diego, CA 92134 USA.
RI HOANG, THANH/AAE 7724 2020
OI Moore, John/0000 0002 1196 5006
CR GERRITSEN EJA, 1994, PEDIATRICS, V93, P247
   Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Van Wesenbeeck L, 2007, J CLIN INVEST, V117, P919, DOI 10.1172/JCI30328
NR 4
TC 3
Z9 3
U1 0
U2 1
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026 4075
EI 1930 613X
J9 MIL MED
JI Milit. Med.
PD MAR APR
PY 2017
VL 182
IS 3 4
BP E1886
EP E1888
DI 10.7205/MILMED D 16 00234
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA ER6WA
UT WOS:000398948700057
PM 28290981
OA Bronze
DA 2025 08 17
ER

PT J
AU Liu, Y
   de Groot, K
   Hunziker, EB
AF Liu, Y
   de Groot, K
   Hunziker, EB
TI BMP 2 liberated from biomimetic implant coatings induces and sustains
   direct ossification in an ectopic rat model
SO BONE
LA English
DT Article
DE BMP 2; biomimetic coating; direct ossification; foreign body giant
   cells; osteoclasts
ID CALCIUM PHOSPHATE COATINGS; DIFFERENTIATION IN VITRO; PLASMA SPRAYED
   COATINGS; BOVINE SERUM ALBUMIN; BONE FORMATION; ENDOCHONDRAL
   OSSIFICATION; CELL DIFFERENTIATION; HYDROXYAPATITE; OSTEOCLAST; STRENGTH
AB Introduction. Using a rat model, we evaluated the kinetics and histomorphometry of ectopic bone formation in association with biomimetic implant coatings containing BMP 2.
   Materials and methods. One experimental and three control groups were set up: titanium alloy discs coated with a biomimetically co precipitated layer of calcium phosphate and BMP 2 [1.7 mu g per disc (incorporated BMP group)]; uncoated discs (control); discs biomimetically coated with a layer of calcium phosphate alone (control); and discs biomimetically coated with a layer of calcium phosphate beating superficially adsorbed BMP 2 [0.98 mu g per disc (control)]. Discs (n = 6 per group) were implanted subcutaneously in rats and retrieved at 7 day intervals over a period of 5 weeks for kinetic, histomorphometrical, morphological and histochemical analyses.
   Results. In the incorporated BMP 2 group, osteogenic activity was first observed 2 weeks after implantation and thereafter continued unabated until the end of the monitoring period. The net weekly rates of bone formation per disc were 5.8 mm(3) at 2 weeks and 3.64 mm(3) at 5 weeks. The total volumes of bone formed per disc at these junctures were 5.8 mm(3) and 10.3 mm(3), respectively. Bone tissue, which was formed by a direct ossification mechanism, was deposited at distances of up to 340 Inn from the implant surfaces. The biomimetic coatings were degraded gradually, initially by foreign body giant cells alone and then also by osteoclasts. Forty percent of the coating material (and thus presumably of the incorporated BMP 2) remained at the end of the monitoring period. Hence, 60% of the incorporated BMP 2 had been released. At this 5 week juncture, no bone tissue was associated with any of the control implants.
   Conclusion. BMP 2 incorporated into biomimetic calcium phosphate coatings is capable not only of inducing bone formation at an ectopic site in vivo but also of doing so with a very high potency at a low pharmacological level, and of sustaining this activity for a considerable period of time. The sustainment of osteogenic activity is of great clinical importance for the osseointegration of dental and orthopedic implants. (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ Bern, ITI Res Inst Dent & Skeletal Biol, CH 3010 Bern, Switzerland.
   Univ Twente, Biomat Res Grp, NL 7500 AE Enschede, Netherlands.
C3 University of Bern; University of Twente
RP Univ Bern, ITI Res Inst Dent & Skeletal Biol, Murtenstr 35,POB 54, CH 3010 Bern, Switzerland.
EM ernst.hunziker@iti.unibe.ch
RI Hunziker, Ernst B/GYA 1015 2022
CR Adamsons K, 1998, PROG ORG COAT, V34, P64, DOI 10.1016/S0300 9440(98)00022 8
   Alam MI, 2001, BIOMATERIALS, V22, P1643
   Ballanti P, 1997, OSTEOPOROSIS INT, V7, P39, DOI 10.1007/BF01623458
   Barrere F, 2002, BIOMATERIALS, V23, P1921, DOI 10.1016/S0142 9612(01)00318 0
   Barrère F, 1999, BONE, V25, p107S, DOI 10.1016/S8756 3282(99)00145 3
   Blom EJ, 2002, J BIOMED MATER RES, V59, P265, DOI 10.1002/jbm.1241
   Blom EJ, 2000, J BIOMED MATER RES, V50, P67, DOI 10.1002/(SICI)1097 4636(200004)50:1<67::AID JBM10>3.0.CO;2 E
   BRAGDON CR, 2003, CLIN ORTHOP RELAT R, V417, P50
   Cochran DL, 1999, J PERIODONTOL, V70, P139, DOI 10.1902/jop.1999.70.2.139
   CONNOR JR, 1995, J HISTOCHEM CYTOCHEM, V43, P1193, DOI 10.1177/43.12.8537635
   Consiglio R, 1998, THIN SOLID FILMS, V332, P151, DOI 10.1016/S0040 6090(98)00987 0
   Cruz Orive LM, 1999, J MICROSC OXFORD, V193, P182, DOI 10.1046/j.1365 2818.1999.00460.x
   CRUZORIVE LM, 1990, AM J PHYSIOL, V258, pL148, DOI 10.1152/ajplung.1990.258.4.L148
   de Groot K, 1998, P I MECH ENG H, V212, P137, DOI 10.1243/0954411981533917
   DEGROOT K, 1987, J BIOMED MATER RES, V21, P1375, DOI 10.1002/jbm.820211203
   ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019 2791(71)90454 X
   Filvaroff E, 1998, CURR BIOL, V8, pR679, DOI 10.1016/S0960 9822(98)70434 8
   FREEMAN MAR, 1992, J BONE JOINT SURG BR, V74, P933, DOI 10.1302/0301 620X.74B6.1447263
   GEESINK RGT, 1990, CLIN ORTHOP RELAT R, P39
   GLASS DA, 1989, J PERIODONTOL, V60, P121, DOI 10.1902/jop.1989.60.3.121
   GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699 0463.1988.tb05320.x
   GUNDERSEN HJG, 1987, J MICROSC OXFORD, V147, P229, DOI 10.1111/j.1365 2818.1987.tb02837.x
   Healy KE, 1999, ANN NY ACAD SCI, V875, P24, DOI 10.1111/j.1749 6632.1999.tb08491.x
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   KLEIN CPAT, 1994, J BIOMED MATER RES, V28, P961, DOI 10.1002/jbm.820280815
   KOKUBO T, 1990, J BIOMED MATER RES, V24, P721, DOI 10.1002/jbm.820240607
   Kokubo T., 1989, Bioceramics, V1, P157
   Lacefield W R, 1998, Implant Dent, V7, P315, DOI 10.1097/00008505 199807040 00010
   LAYROLLE P, 1998, BIOCERAMICS, V11, P465
   Liu Y, 2004, KEY ENG MATER, V254 2, P619, DOI 10.4028/www.scientific.net/KEM.254 256.619
   Liu Y, 2004, ANN BIOMED ENG, V32, P398, DOI 10.1023/B:ABME.0000017536.10767.0f
   Liu Y, 2003, BIOMATERIALS, V24, P65, DOI 10.1016/S0142 9612(02)00252 1
   Liu YL, 2004, TISSUE ENG, V10, P101, DOI 10.1089/107632704322791745
   Liu YL, 2001, J BIOMED MATER RES, V57, P327, DOI 10.1002/1097 4636(20011205)57:3<327::AID JBM1175>3.0.CO;2 J
   Liu YL, 2000, J MATER SCI MATER M, V11, P711, DOI 10.1023/A:1008971611885
   McNulty V, 2000, J COMPUT ASSIST TOMO, V24, P466, DOI 10.1097/00004728 200005000 00021
   Mostov K, 1997, SCIENCE, V276, P219, DOI 10.1126/science.276.5310.219
   ONO I, 1995, J CRANIOFAC SURG, V6, P238, DOI 10.1097/00001665 199505000 00011
   Ono I, 1998, J BONE MINER METAB, V16, P81, DOI 10.1007/s007740050030
   Reddi AH, 2001, J BONE JOINT SURG AM, V83A, pS1, DOI 10.2106/00004623 200100001 00001
   REDDI AH, 1990, BIOMATERIALS, V11, P33
   SAMPATH TK, 1992, J BIOL CHEM, V267, P20352
   SASANO Y, 1993, ANAT REC, V236, P373, DOI 10.1002/ar.1092360211
   Sasano Y, 1997, ANAT RECORD, V247, P472, DOI 10.1002/(SICI)1097 0185(199704)247:4<472::AID AR5>3.0.CO;2 T
   Schenk RK., 1984, METHODS CALCIFIED TI, P1
   Schmidmaier G, 2000, CHIRURG, V71, P1016, DOI 10.1007/s001040051176
   Stigter M, 2002, BIOMATERIALS, V23, P4143, DOI 10.1016/S0142 9612(02)00157 6
   Sumner DR, 2004, J ORTHOP RES, V22, P58, DOI 10.1016/S0736 0266(03)00127 X
   Uludag H, 1999, J BIOMED MATER RES, V46, P193, DOI 10.1002/(SICI)1097 4636(199908)46:2<193::AID JBM8>3.0.CO;2 1
   URIST MR, 1992, BONE GRAFTS BONE SUB, P70
   Wen HB, 1999, J BIOMED MATER RES, V46, P245, DOI 10.1002/(SICI)1097 4636(199908)46:2<245::AID JBM14>3.0.CO;2 A
   YUAN H, 1998, J MAT SCI MAT MED, V9
   Zamora PO, 2002, BIOCONJUGATE CHEM, V13, P920, DOI 10.1021/bc0155216
NR 53
TC 256
Z9 286
U1 0
U2 50
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2005
VL 36
IS 5
BP 745
EP 757
DI 10.1016/j.bone.2005.02.005
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 926QA
UT WOS:000229136500001
PM 15814303
DA 2025 08 17
ER

PT J
AU Kamal, R
   Bansal, SC
   Khandelwal, N
   Rai, DV
   Dhawan, DK
AF Kamal, Rozy
   Bansal, S. C.
   Khandelwal, N.
   Rai, D. V.
   Dhawan, D. K.
TI Moderate Zinc Supplementation During Prolonged Steroid Therapy
   Exacerbates Bone Loss in Rats
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Bone mineral content; Bone mineral density; Mineral metabolism; Calcium;
   Prednisolone; Zinc
ID INTESTINAL CALCIUM ABSORPTION; L HISTIDINATO ZINC; PARATHYROID HORMONE;
   VITAMIN D; MAGNESIUM; OSTEOPOROSIS; PREDNISOLONE; PHOSPHORUS;
   METABOLISM; MECHANISMS
AB The present study was conducted to understand the influence of zinc on bone mineral metabolism in prednisolone treated rats. Disturbance in bone mineral metabolism was induced in rats by subjecting them to prednisolone treatment for a period of 8 weeks. Female rats aged 6 8 weeks weighing 150 to 200 g were divided into four treatment groups, viz., normal control, prednisolone treated (40 mg/kg body weight orally, thrice a week), zinc treated (227 mg/L in drinking water, daily), and combined prednisolone + zinc treated groups. Parameters such as changes in mineral levels in the bone and serum, bone mineral density (BMD), bone mineral content (BMC), and bone 99m technetium labeled methylene diphosphonate (Tc 99m MDP) uptake were studied in various treatment groups. Prednisolone treatment caused an appreciable decrease in calcium levels both in the bone and serum and also in bone dry weight, BMC, and BMD in rats. Prednisolone treated rats when supplemented with zinc showed further reduction in calcium levels, bone dry weight, BMD, and BMC. The study therefore revealed that moderate intake of zinc as a nutritional supplement during steroid therapy could enhance calcium deficiency in the body and accelerate bone loss.
C1 [Kamal, Rozy; Dhawan, D. K.] Panjab Univ, UIEAST, Ctr Nucl Med, Chandigarh 160014, India.
   [Bansal, S. C.; Khandelwal, N.] Postgrad Inst Med Educ & Res PGIMER, Dept Radiol, Chandigarh 160012, India.
   [Rai, D. V.] Shobhit Univ Engn & Technol, Dept Biomed Engn, Meerut 250110, Uttar Pradesh, India.
   [Dhawan, D. K.] Panjab Univ, Dept Biophys, Chandigarh 160014, India.
C3 Panjab University; Post Graduate Institute of Medical Education &
   Research (PGIMER), Chandigarh; Shobhit University; Panjab University
RP Dhawan, DK (通讯作者)，Panjab Univ, Dept Biophys, Chandigarh 160014, India.
EM dhawan@pu.ac.in
OI Rai, Durg Vijay/0000 0001 8693 1620; Kamal, Rozy/0000 0002 3207 3250
CR Adachi JD, 2001, INT J FERTIL WOMEN M, V46, P190
   ADHAM NF, 1980, NUTR METAB, V24, P281
   BARRATT TM, 1994, ARCH DIS CHILD, V70, P151
   BELLORINFONT E, 1984, ENDOCRINOLOGY, V115, P544, DOI 10.1210/endo 115 2 544
   Bhardwaj P, 2013, MENOPAUSE, V20, P1184, DOI [10.1097/GME.0b013e31828a7f4e, 10.1097/gme.0b013e31828a7f4e]
   BIGI A, 1995, J INORG BIOCHEM, V58, P49, DOI 10.1016/0162 0134(94)00036 A
   BOGDEN JD, 1990, J AM COLL NUTR, V9, P214
   Canalis E, 2001, J CLIN ENDOCR METAB, V86, P5681, DOI 10.1210/jc.86.12.5681
   CHEN RW, 1977, J NUTR, V107, P805, DOI 10.1093/jn/107.5.805
   COSMAN F, 1994, J BONE MINER RES, V9, P1097
   DHAWAN DK, 1994, J TRACE ELEM EXP MED, V7, P1
   DURSUN N, 1994, JPN J PHYSIOL, V44, P157, DOI 10.2170/jjphysiol.44.157
   FONTAINE J, 1991, AGENTS ACTIONS, V33, P247, DOI 10.1007/BF01986570
   Gaby AR, 2006, ALTERN MED REV, V11, P188
   HAHN TJ, 1981, J CLIN ENDOCR METAB, V52, P111, DOI 10.1210/jcem 52 1 111
   HAHN TJ, 1979, J CLIN INVEST, V64, P655, DOI 10.1172/JCI109506
   HARDWICK LL, 1991, J NUTR, V121, P13, DOI 10.1093/jn/121.1.13
   JAGOX A, 1994, NEW ENGL J MED, V330, P651, DOI 10.1056/NEJM199403033300926
   Jorgensen RJ, 2001, J DAIRY SCI, V84, P609, DOI 10.3168/jds.S0022 0302(01)74514 6
   Kenney MA, 1997, BIOL TRACE ELEM RES, V58, P35, DOI 10.1007/BF02910664
   KISHI S, 1994, BIOCHEM PHARMACOL, V48, P1225, DOI 10.1016/0006 2952(94)90160 0
   KLEIN RG, 1977, J CLIN INVEST, V60, P253, DOI 10.1172/JCI108762
   KNOCHEL JP, 1992, AM J MED, V92, P455, DOI 10.1016/0002 9343(92)90739 X
   LURIE AG, 1976, J NUCL MED, V17, P688
   Moore AEB, 2012, EUR J NUCL MED MOL I, V39, P326, DOI 10.1007/s00259 011 1974 y
   Murray E. J., 1981, Nutrition Research, V1, P107, DOI 10.1016/S0271 5317(81)80013 9
   NAKASHIMA H, 1982, EUR J NUCL MED, V7, P531, DOI 10.1007/BF00571644
   NORDIN BEC, 1981, J STEROID BIOCHEM, V15, P171, DOI 10.1016/0022 4731(81)90272 7
   Ogoshi T, 2008, MOD RHEUMATOL, V18, P552, DOI 10.1007/s10165 008 0096 2
   PRASAD AS, 1995, NUTRITION, V11, P93
   Reid IR, 1997, EUR J ENDOCRINOL, V137, P209, DOI 10.1530/eje.0.1370209
   SADASIVAN V, 1952, BIOCHEM J, V52, P452, DOI 10.1042/bj0520452
   SADASIVAN V, 1951, BIOCHEM J, V49, P186, DOI 10.1042/bj0490186
   SADASIVAN V, 1951, BIOCHEM J, V48, P527, DOI 10.1042/bj0480527
   Saito N, 2004, J AM COLL NUTR, V23, p701S, DOI 10.1080/07315724.2004.10719412
   Salvatore A, 2012, GLUCOCORTICOID INDUC
   SANDSTEAD HH, 1995, NUTRITION, V11, P87
   SIMECKOVA A, 1985, PHYSIOL BOHEMOSLOV, V34, P155
   SOARES JH, 1987, NUTR RES, V7, P151, DOI 10.1016/S0271 5317(87)80027 1
   SONG MK, 1986, BIOL TRACE ELEM RES, V11, P75, DOI 10.1007/BF02795526
   SPENCER H, 1987, J AM COLL NUTR, V6, P47
   SUZUKI Y, 1983, METABOLISM, V32, P151, DOI 10.1016/0026 0495(83)90221 4
   THOMPSON A, 1959, J ANIM SCI, V18, P187, DOI 10.2527/jas1959.181187x
   Tipu MK, 2012, PAK J PHARM SCI, V25, P845
   Toba Y, 2000, J NUTR, V130, P216, DOI 10.1093/jn/130.2.216
   TOHMON M, 1988, J BONE MINER RES, V3, P325
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   YAMAGUCHI M, 1992, PHARMACOLOGY, V45, P292, DOI 10.1159/000139013
   YAMAGUCHI M, 1994, MOL CELL BIOCHEM, V136, P163, DOI 10.1007/BF00926077
   Yao W, 2008, ARTHRITIS RHEUM, V58, P3485, DOI 10.1002/art.23954
   YASUI M, 1991, BIOL TRACE ELEM RES, V31, P293, DOI 10.1007/BF02990198
   ZHOU JR, 1993, J NUTR, V123, P1383
NR 52
TC 2
Z9 2
U1 0
U2 7
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0163 4984
EI 1559 0720
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD SEP
PY 2014
VL 160
IS 3
BP 383
EP 391
DI 10.1007/s12011 014 0063 z
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA AN3PR
UT WOS:000340500900010
PM 25022244
DA 2025 08 17
ER

PT J
AU Jia, CY
   Shang, JC
   Wang, Y
   Bai, LJ
   Tong, C
   Chen, YJ
   Zhang, P
AF Jia, Chunyan
   Shang, Jingchuan
   Wang, Yi
   Bai, Lijuan
   Tong, Chao
   Chen, Yongjie
   Zhang, Pu
TI Copper(II) mediated sliver nanoclusters as a fluorescent platform for
   highly sensitive detection of alendronate sodium
SO SENSORS AND ACTUATORS B CHEMICAL
LA English
DT Article
DE Metal nanoclusters; Photoluminescence; Alendronate sodium; Osteoporosis;
   Pharmaceutical analysis
ID BISPHOSPHONATES DRUGS; HUMAN PLASMA; OSTEOPOROSIS; PROBE; TABLETS;
   URINE; BONE
AB Alendronate sodium (ALDS) is an important and regularly used medicine in clinical therapy of osteoporosis. In this work, a new analytical method is developed for the detection of ALDS based on a fluorescent platform of copper(II) mediated silver nanoclusters (AgNCs). Specifically, Cu2+ can selectively bind with DNA stabilized AgNCs and thus greatly quench their red fluorescence. In the presence of ALDS, their fluorescence can largely recover again owing to the stronger coordination of ALDS with Cu2+. On the basis of such a mechanism, fluorescence "on off on" mode of the nanoprobe is applied to detect ALDS in a wide linear range of 800 pM 200 mu M, with a detection limit of 100 pM. Compared with previously reported methods, the present approach has significant advantages regard to simplicity, high sensitivity, and a wide detectable concentration range. This method has been successfully applied in ALDS assay in tablets and human body fluids. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Jia, Chunyan; Shang, Jingchuan; Bai, Lijuan; Chen, Yongjie; Zhang, Pu] Chongqing Med Univ, Coll Pharm, Res Ctr Pharmacodynam Evaluat Engn Technol Chongq, Chongqing 400016, Peoples R China.
   [Wang, Yi] Chongqing Normal Univ, Coll Chem, Chongqing Key Lab Green Synth & Applicat, Chongqing 401331, Peoples R China.
   [Tong, Chao] Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet, Chongqing 400016, Peoples R China.
C3 Chongqing Medical University; Chongqing Normal University; Chongqing
   Medical University
RP Zhang, P (通讯作者)，Chongqing Med Univ, Coll Pharm, Res Ctr Pharmacodynam Evaluat Engn Technol Chongq, Chongqing 400016, Peoples R China.
EM zhangpu51@hotmail.com
RI ; Bai, Lijuan/JCE 3232 2023; ZHANG, PU/KZV 0280 2024; Wang,
   Yi/J 5439 2015
OI Bai, Lijuan/0000 0001 9450 4581; 
FU National Natural Science Foundation of China [81501837, 21505012,
   21775014]; Chongqing Research Program of Basic Research and Frontier
   Technology [cstc2017jcyjAX0368]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81501837, 21505012, and 21775014) and Chongqing Research
   Program of Basic Research and Frontier Technology (No.
   cstc2017jcyjAX0368).
CR Al Deeb SK, 2004, TALANTA, V64, P695, DOI 10.1016/j.talanta.2004.03.044
   Berti L, 2008, NAT NANOTECHNOL, V3, P81, DOI 10.1038/nnano.2007.460
   Chang Y, 2013, ANAL METHODS UK, V5, P6200, DOI 10.1039/c3ay41219a
   Chen MX, 2012, ANAL BIOANAL CHEM, V402, P791, DOI 10.1007/s00216 011 5467 4
   Cooper C, 2011, OSTEOPOROSIS INT, V22, P1277, DOI 10.1007/s00198 011 1601 6
   Eiken P, 2016, OSTEOPOROSIS INT, V27, P1, DOI 10.1007/s00198 015 3334 4
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Fu Y, 2011, J PHYS CHEM C, V115, P10370, DOI 10.1021/jp200132b
   Gatti Davide, 2015, Expert Opin Pharmacother, V16, P2409, DOI 10.1517/14656566.2015.1087506
   Guo WW, 2009, CHEM COMMUN, P3395, DOI 10.1039/b821518a
   Guo YM, 2012, ANALYST, V137, P301, DOI 10.1039/c1an15877e
   Iglesias JE, 2015, GERODONTOLOGY, V32, P169, DOI 10.1111/ger.12093
   Imai K, 2013, CLIN INTERV AGING, V8, P681, DOI 10.2147/CIA.S37199
   Invernizzi M, 2015, AGING CLIN EXP RES, V27, P107, DOI 10.1007/s40520 014 0256 5
   Kang HS, 2006, J LIQ CHROMATOGR R T, V29, P1589, DOI 10.1080/10826070600678308
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Koba M, 2008, ACTA POL PHARM, V65, P289
   Liu HY, 2011, CHEM COMMUN, V47, P4237, DOI 10.1039/c1cc00103e
   Lu TL, 2010, J LIQ CHROMATOGR R T, V33, P349, DOI 10.1080/10826070903525974
   Dolatabadi JEN, 2014, BIOIMPACTS, V4, P39, DOI 10.5681/bi.2014.005
   Ngozi RN, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0342 3
   Peng J, 2015, SENSOR ACTUAT B CHEM, V221, P708, DOI 10.1016/j.snb.2015.07.002
   Prutthiwanasan B, 2010, J SEP SCI, V33, P228, DOI 10.1002/jssc.200900518
   Razak OA, 2003, TALANTA, V59, P1061, DOI 10.1016/S0039 9140(03)00013 4
   Roschger P, 2001, BONE, V29, P185, DOI 10.1016/S8756 3282(01)00485 9
   Shang L, 2008, J MATER CHEM, V18, P4636, DOI 10.1039/b810409c
   Strampel W, 2007, DRUG SAFETY, V30, P755, DOI 10.2165/00002018 200730090 00003
   Walash MI, 2012, CHEM CENT J, V6, DOI 10.1186/1752 153X 6 25
   Wu D, 2015, J CHROMATOGR SCI, V53, P1794, DOI 10.1093/chromsci/bmv074
   Xie BG, 2014, J PHARMACEUT BIOMED, V93, P73, DOI 10.1016/j.jpba.2013.07.006
   Yuan X, 2013, CHEM ASIAN J, V8, P858, DOI 10.1002/asia.201201236
   Yun MH, 2006, J PHARMACEUT BIOMED, V40, P168, DOI 10.1016/j.jpba.2005.06.025
   Zhang L, 2016, ANAL CHEM, V88, P11460, DOI 10.1021/acs.analchem.6b02522
   Zhang M, 2011, ANALYST, V136, P5139, DOI 10.1039/c1an15891k
   Zhang P, 2013, BIOSENS BIOELECTRON, V49, P433, DOI 10.1016/j.bios.2013.05.056
   Zhou Y, 2014, ANALYST, V139, P3122, DOI 10.1039/c4an00487f
   Zhu LS, 2006, RAPID COMMUN MASS SP, V20, P3421, DOI 10.1002/rcm.2755
   Zhuang QF, 2014, BIOSENS BIOELECTRON, V55, P76, DOI 10.1016/j.bios.2013.12.003
NR 38
TC 15
Z9 15
U1 1
U2 111
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
EI 0925 4005
J9 SENSOR ACTUAT B CHEM
JI Sens. Actuator B Chem.
PD SEP 15
PY 2018
VL 269
BP 271
EP 277
DI 10.1016/j.snb.2018.04.127
PG 7
WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Electrochemistry; Instruments & Instrumentation
GA GH2DF
UT WOS:000433211100033
DA 2025 08 17
ER

PT J
AU Pham, CV
   Pham, TT
   Lai, TT
   Trinh, DC
   Nguyen, HVM
   Ha, TTM
   Phuong, TT
   Tran, LD
   Winkler, C
   To, TT
AF Pham, Cuong, V
   Pham, Thanh T.
   Lai, Thuy T.
   Trinh, Dat C.
   Nguyen, Huong V. M.
   Ha, Tam T. M.
   Phuong, Thuong T.
   Tran, Long D.
   Winkler, Christoph
   To, Thuy T.
TI Icariin reduces bone loss in a Rankl induced transgenic medaka
   (Oryzias latipes) model for osteoporosis
SO JOURNAL OF FISH BIOLOGY
LA English
DT Article
DE bisphosphonate; icariin; medaka; mineralized matrix; neural arch;
   osteoporosis
ID ANIMAL MODELS; ZEBRAFISH; BISPHOSPHONATES; OSTEOGENESIS; PHENOTYPE
AB Given the limitations and side effects of many synthetic drugs, natural products are an important alternative source for drugs and medications for many diseases. Icariin (ICA), one of the main flavonoids from plants of the Epimedium genus, has been shown to ameliorate osteoporosis and improve bone health in preclinical studies. Those studies have used different in vivo models, mostly rodents, but the underlying mechanisms remain unclear. The present study shows, for the first time, that ICA reduces bone damage in a Rankl induced medaka fish (Oryzias latipes), a non rodent osteoporosis model. Live imaging was previously performed in this model to characterize antiresorptive and bone anabolic properties of drugs. Here, a new quantification method (I M) was established based on the length of mineralized neural arches to quantify levels of bone mineralization damage and protection in early post embryonic fish. This method was validated by quantification of three levels of bone damage in three independent Rankl fish lines, and by the determination of different degrees of severity of osteoporosis like phenotypes in one Rankl line exposed to variable Rankl induction schemes. I M was also used to quantify the efficacy of alendronate and etidronate, two common anti osteoporotic bisphosphonates, and revealed comparable bone protective effects for ICA and alendronate in this fish osteoporosis model. This study's data support the value of the medaka fish model for bone research and establish a method to screen for novel osteoprotective compounds.
C1 [Pham, Cuong, V; Pham, Thanh T.; Lai, Thuy T.; Trinh, Dat C.; Nguyen, Huong V. M.; Ha, Tam T. M.; Tran, Long D.; To, Thuy T.] Vietnam Natl Univ, VNU Univ Sci, Fac Biol, 334 Nguyen Trai, Hanoi, Vietnam.
   [Phuong, Thuong T.] Vietnam Natl Inst Med Mat, Dept Herbal Anal & Standardizat, Hanoi, Vietnam.
   [Winkler, Christoph] Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore.
   [Winkler, Christoph] Natl Univ Singapore, Ctr Bioimaging Sci, Singapore, Singapore.
   [Tran, Long D.; To, Thuy T.] VNU Univ Sci, Key Lab Enzyme & Prot Technol, Hanoi, Vietnam.
   [To, Thuy T.] Dinh Tien Hoang Inst Med, Hanoi, Vietnam.
C3 Vietnam National University Hanoi (VNU Hanoi) System; National
   University of Singapore; National University of Singapore; Vietnam
   National University Hanoi (VNU Hanoi) System
RP To, TT (通讯作者)，Vietnam Natl Univ, VNU Univ Sci, Fac Biol, 334 Nguyen Trai, Hanoi, Vietnam.
EM tothanhthuy@hus.edu.vn
RI ; Winkler, Christoph/G 4822 2012
OI Pham, Van Cuong/0000 0003 4787 7013; TRINH, Cong
   Dat/0000 0002 8512 8243; Winkler, Christoph/0000 0003 4688 6241; Tran,
   Long D./0000 0001 9232 0244; TO, T. THUY/0000 0002 3885 420X; Lai, Thuy
   Thi/0000 0002 1892 9833; Nguyen Vuong Minh, Huong/0000 0003 4641 2011
FU Vietnam National Foundation for Science and Technology Development
   (NAFOSTED) [106 YS.06 2014 15]; Singapore Ministry of Education
   [MOE2016 T2 2 086]; National Research Foundation Singapore
   [NRF2017 NRF ISF002 2671]
FX This research was funded by the Vietnam National Foundation for Science
   and Technology Development (NAFOSTED) under the Grant number
   106 YS.06 2014 15. CW was supported by grants from the Singapore
   Ministry of Education (MOE2016 T2 2 086) and the National Research
   Foundation Singapore (NRF2017 NRF ISF002 2671).
CR Barrett Ruth, 2006, Biotechnology Journal, V1, P651, DOI 10.1002/biot.200600043
   Bergen DJM, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00006
   Blume SW, 2011, OSTEOPOROSIS INT, V22, P1835, DOI 10.1007/s00198 010 1419 7
   Charles JF, 2017, BONE, V101, P162, DOI 10.1016/j.bone.2017.05.001
   Chatani M, 2011, DEV BIOL, V360, P96, DOI 10.1016/j.ydbio.2011.09.013
   Che CT, 2016, MOLECULES, V21, DOI 10.3390/molecules21030239
   de Vrieze E, 2014, OSTEOPOROSIS INT, V25, P567, DOI 10.1007/s00198 013 2441 3
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Huang HX, 2018, ANIM MODEL EXP MED, V1, P53, DOI 10.1002/ame2.12000
   Hur M, 2017, ELIFE, V6, DOI 10.7554/eLife.26014
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015
   Inohaya K, 2007, DEV DYNAM, V236, P3031, DOI 10.1002/dvdy.21329
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Lin CY, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929 016 0236 5
   Lleras Forero L., 2019, DEV BIOL, DOI [10.1016/j.ydbio.2019.07.009, DOI 10.1016/J.YDBI0.2019.07.009]
   Mackay Eirinn W, 2013, Bonekey Rep, V2, P445, DOI 10.1038/bonekey.2013.179
   Mirza F, 2015, EUR J ENDOCRINOL, V173, pR131, DOI 10.1530/EJE 15 0118
   Moshiri A, 2017, CLIN REV BONE MINER, V15, P1, DOI 10.1007/s12018 016 9207 3
   Pasqualetti S, 2015, INT J EXP PATHOL, V96, P11, DOI 10.1111/iep.12106
   Pham T. K. O., 2018, VIETNAM J SCI TECHNO, V60, P52
   Renn J, 2013, DEV BIOL, V381, P134, DOI 10.1016/j.ydbio.2013.05.030
   Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361
   Russell RGG, 2015, CURR OPIN PHARMACOL, V22, P115, DOI 10.1016/j.coph.2015.05.005
   Singer A, 2015, MAYO CLIN PROC, V90, P53, DOI 10.1016/j.mayocp.2014.09.011
   Sze SCW, 2010, MOLECULES, V15, P7861, DOI 10.3390/molecules15117861
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   To TT, 2015, COMP BIOCHEM PHYS C, V178, P68, DOI 10.1016/j.cbpc.2015.08.007
   To TT, 2012, DEVELOPMENT, V139, P141, DOI 10.1242/dev.071035
   Walker MB, 2007, BIOTECH HISTOCHEM, V82, P23, DOI 10.1080/10520290701333558
   Wang Z, 2018, OSTEOPOROSIS INT, V29, P535, DOI 10.1007/s00198 017 4255 1
   Watson ATD, 2017, TOXICOL SCI, V155, P485, DOI 10.1093/toxsci/kfw229
   Witten PE, 2017, METHOD CELL BIOL, V138, P321, DOI 10.1016/bs.mcb.2016.09.001
   Witten PE, 2006, AQUACULTURE, V258, P164, DOI 10.1016/j.aquaculture.2006.05.005
   Wu L, 2017, CURR TOP MED CHEM, V17, P1670, DOI 10.2174/1568026617666161116141033
   Yu TS, 2017, DEVELOPMENT, V144, P265, DOI 10.1242/dev.139550
   Yu TS, 2016, DIS MODEL MECH, V9, P155, DOI 10.1242/dmm.019091
   Zhang WJ, 2018, BIOCHEM BIOPH RES CO, V496, P654, DOI 10.1016/j.bbrc.2017.12.172
NR 37
TC 12
Z9 13
U1 0
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 1112
EI 1095 8649
J9 J FISH BIOL
JI J. Fish Biol.
PD APR
PY 2021
VL 98
IS 4
SI SI
BP 1039
EP 1048
DI 10.1111/jfb.14241
EA JAN 2020
PG 10
WC Fisheries; Marine & Freshwater Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Fisheries; Marine & Freshwater Biology
GA RJ9DZ
UT WOS:000506293500001
PM 31858585
DA 2025 08 17
ER

PT J
AU Costa, V
   De Fine, M
   Carina, V
   Conigliaro, A
   Raimondi, L
   De Luca, A
   Bellavia, D
   Salamanna, F
   Alessandro, R
   Pignatti, G
   Fini, M
   Giavaresi, G
AF Costa, Viviana
   De Fine, Marcello
   Carina, Valeria
   Conigliaro, Alice
   Raimondi, Lavinia
   De Luca, Angela
   Bellavia, Daniele
   Salamanna, Francesca
   Alessandro, Riccardo
   Pignatti, Giovanni
   Fini, Milena
   Giavaresi, Gianluca
TI How miR 31 5p and miR 33a 5p Regulates SP1/CX43 Expression in
   Osteoarthritis Disease: Preliminary Insights
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteoarthritis; microRNAs; osteoblasts; chondrocytes; SP1; CX43
AB Osteoarthritis (OA) is a degenerative bone disease that involved micro and macro environment of joints. To date, there are no radical curative treatments for OA and novel therapies are mandatory. Recent evidence suggests the role of miRNAs in OA progression. In our previous studies, we demonstrated the role of miR 31 5p and miR 33a families in different bone regeneration signaling. Here, we investigated the role of miR 31 5p and miR 33a 5p in OA progression. A different expression of miR 31 5p and miR 33a 5p into osteoblasts and chondrocytes isolated from joint tissues of OA patients classified in based on different Kellgren and Lawrence (KL) grading was highlighted; and through a bioinformatic approach the common miRNAs target Specificity proteins (Sp1) were identified. Sp1 regulates the expression of gap junction protein Connexin43 (Cx43), which in OA drives the modification of (i) osteoblasts and chondrocytes genes expression, (ii) joint inflammation cytokines releases and (iii) cell functions. Concerning this, thanks to gain and loss of function studies, the possible role of Sp1 as a modulator of CX43 expression through miR 31 5p and miR 33a 5p action was also evaluated. Finally, we hypothesize that both miRNAs cooperate to modulate the expression of SP1 in osteoblasts and chondrocytes and interfering, consequently, with CX43 expression, and they might be further investigated as new possible biomarkers for OA.
C1 [Costa, Viviana; Carina, Valeria; Raimondi, Lavinia; De Luca, Angela; Bellavia, Daniele; Salamanna, Francesca; Fini, Milena; Giavaresi, Gianluca] IRCCS Ist Ortoped Rizzoli, SC Sci & Tecnol Chirurg, SS Piattaforma Sci Om Ortopedia Personalizzata, I 40136 Bologna, Italy.
   [De Fine, Marcello; Pignatti, Giovanni] IRCCS Ist Ortoped Rizzoli, I 40136 Bologna, Italy.
   [Conigliaro, Alice; Alessandro, Riccardo] Univ Palermo, Sect Biol & Genet, Dept Biomed Neurosci & Adv Diagnost BiND, I 90133 Palermo, Italy.
   [Alessandro, Riccardo] Ist Ric & Innovaz Biomed IRIB, I 90133 Palermo, Italy.
C3 University of Palermo; Consiglio Nazionale delle Ricerche (CNR);
   Istituto Ricerca l'Innovazione Biomedica (IRIB CNR)
RP Costa, V (通讯作者)，IRCCS Ist Ortoped Rizzoli, SC Sci & Tecnol Chirurg, SS Piattaforma Sci Om Ortopedia Personalizzata, I 40136 Bologna, Italy.
EM viviana.costa@ior.it; marcello.define@gmail.com; valeria.carina@ior.it;
   alice.conigliaro@unipa.it; lavinia.raimondi@ior.it;
   angela.deluca@ior.it; daniele.bellavia@ior.it;
   francesca.salamanna@ior.it; riccardo.alessandro@unipa.it;
   giovanni.pignatti@ior.it; milena.fini@ior.it; gianluca.giavaresi@ior.it
RI Conigliaro, Alice/ACW 5549 2022; Raimondi, Lavinia/K 4085 2016; carina,
   valeria/K 2001 2016; De Fine, Marcello/AAC 1333 2019; Salamanna,
   Francesca/J 6032 2016; costa, viviana/K 4084 2016; COSTA,
   VIVIANA/K 4084 2016; Bellavia, Daniele/H 9774 2019; De Luca,
   Angela/ABD 3384 2020; Conigliaro, Alice/J 8717 2016; deluca,
   angela/ABD 3384 2020; Giavaresi, Gianluca/J 5583 2016
OI De Fine, Marcello/0000 0003 3652 6306; Giavaresi,
   Gianluca/0000 0001 7843 5969; Raimondi, Lavinia/0000 0001 9394 2002;
   carina, valeria/0000 0002 7323 8023; Salamanna,
   Francesca/0000 0001 7402 4054; costa, viviana/0000 0002 2425 6460;
   Bellavia, Daniele/0000 0003 3308 9112; De Luca,
   Angela/0000 0001 5493 9441; Conigliaro, Alice/0000 0002 3037 835X; 
FU Fondi 5 per mille ANNO 2017  [Medicina rigenerativa e ricostruttiva per
   la chirurgia vertebrale: caratterizzazione biologica e strutturale di
   biomateriali funzionalizzati ed ingegnerizzati&quot;.] Funding Source:
   Medline
CR Beavers KR, 2015, ADV DRUG DELIVER REV, V88, P123, DOI 10.1016/j.addr.2014.12.006
   Bellavia D, 2019, BONE, V122, P52, DOI 10.1016/j.bone.2019.02.013
   Bivi N, 2012, J BONE MINER RES, V27, P374, DOI 10.1002/jbmr.548
   Buo AM, 2017, J BONE MINER RES, V32, P1727, DOI 10.1002/jbmr.3152
   Costa V, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121495
   Costa V, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071569
   Costa V, 2017, CYTOTHERAPY, V19, P1412, DOI 10.1016/j.jcyt.2017.09.007
   Costa V, 2017, ONCOTARGET, V8, P24292, DOI 10.18632/oncotarget.14464
   Feng X, 2000, J BIOL CHEM, V275, P8331, DOI 10.1074/jbc.275.12.8331
   Gago Fuentes R, 2015, MOL CELL PROTEOMICS, V14, P1831, DOI 10.1074/mcp.M115.050211
   Garnero P, 1998, J BONE MINER RES, V13, P813, DOI 10.1359/jbmr.1998.13.5.813
   Gibon E, 2017, J BIOMED MATER RES B, V105, P1685, DOI 10.1002/jbm.b.33676
   Goto T, 2006, J BONE MINER RES, V21, P661, DOI 10.1359/JBMR.020605
   Gu HJ, 2019, AM J TRANSL RES, V11, P2940
   Hantusch B, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471 2199 8 20
   Hunziker EB, 2002, OSTEOARTHR CARTILAGE, V10, P432, DOI 10.1053/joca.2002.0801
   Ortuño MJ, 2013, BONE, V52, P548, DOI 10.1016/j.bone.2012.11.007
   Kohn MD, 2016, CLIN ORTHOP RELAT R, V474, P1886, DOI 10.1007/s11999 016 4732 4
   Liu JZ, 2005, J CELL BIOCHEM, V96, P716, DOI 10.1002/jcb.20569
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo Dico A, 2016, THERANOSTICS, V6, P1105, DOI 10.7150/thno.14700
   Loiselle AE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081399
   Maneix L, 2014, J MOL MED, V92, P1179, DOI 10.1007/s00109 014 1195 5
   Mann V, 2001, J CLIN INVEST, V107, P899, DOI 10.1172/JCI10347
   Mayan MD, 2013, AM J PATHOL, V182, P1337, DOI 10.1016/j.ajpath.2012.12.018
   Moorer MC, 2017, J CELL SCI, V130, P531, DOI 10.1242/jcs.197285
   Murata K, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3013
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Negoro H, 2013, FEBS LETT, V587, P98, DOI 10.1016/j.febslet.2012.11.021
   Ntoumou E, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148 017 0428 1
   Pelletier JP, 2001, ARTHRITIS RHEUM US, V44, P1237, DOI 10.1002/1529 0131(200106)44:6<1237::AID ART214>3.0.CO;2 F
   Plotkin LI, 2015, CURR OSTEOPOROS REP, V13, P67, DOI 10.1007/s11914 015 0255 2
   R Core Team, 2020, LANG ENV STAT COMP
   Raimondi L, 2017, ONCOTARGET, V8, P100831, DOI 10.18632/oncotarget.19852
   Raimondo S, 2020, CANCERS, V12, DOI 10.3390/cancers12020449
   Stains JP, 2003, J BIOL CHEM, V278, P24377, DOI 10.1074/jbc.M212554200
   Wang SY, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3482751
   Yu SB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163277
NR 38
TC 15
Z9 15
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2021
VL 22
IS 5
AR 2471
DI 10.3390/ijms22052471
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA QV9FD
UT WOS:000628267200001
PM 33671114
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hayden, JB
   Hoang, BH
AF Hayden, JB
   Hoang, BH
TI Osteosarcoma: Basic science and clinical implications
SO ORTHOPEDIC CLINICS OF NORTH AMERICA
LA English
DT Article
ID HIGH GRADE OSTEOSARCOMA; GENE EXPRESSION; OSTEOBLAST DIFFERENTIATION;
   TRANSCRIPTION FACTOR; P GLYCOPROTEIN; METASTASIS; CELLS; TUMOR;
   CHEMOTHERAPY; PROGRESSION
AB Current therapy for osteosarcoma successfully treats 60% to 70%, of patients. Attempts to identify patients who will respond poorly to therapy has focused on the use of new biologic markers or microarray cluster analysis. New potential therapeutic targets, including growth factors, chemokines, transcription factors, and angiogenic factors, are being evaluated for their roles in osteosarcoma. These new targets may provide mechanisms to treat the patients who would respond poorly to standard therapy.
C1 Univ Calif Irvine, Med Ctr, Dept Orthopaed Surg, Orange, CA 92868 USA.
   Oregon Hlth Sci Univ, Dept Orthopaed & Rehabil, Portland, OR 97239 USA.
C3 University of California System; University of California Irvine; Oregon
   Health & Science University
RP Hoang, BH (通讯作者)，Univ Calif Irvine, Med Ctr, Dept Orthopaed Surg, 101 City Dr, Orange, CA 92868 USA.
EM bhhoang@uci.edu
CR Anninga JK, 2004, EUR J CANCER, V40, P963, DOI 10.1016/j.ejca.2003.10.025
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Buckley JD, 1998, CANCER, V83, P1440, DOI 10.1002/(SICI)1097 0142(19981001)83:7<1440::AID CNCR23>3.0.CO;2 3
   Cao Y, 2005, CANCER RES, V65, P1124, DOI 10.1158/0008 5472.CAN 04 2128
   Dhaini HR, 2003, J CLIN ONCOL, V21, P2481, DOI 10.1200/JCO.2003.06.015
   Ferrari S, 2004, CANCER, V100, P1936, DOI 10.1002/cncr.20151
   Fuchs B, 2002, CLIN ORTHOP RELAT R, P40
   Gorlick R, 2003, CLIN CANCER RES, V9, P5442
   Hauben EI, 2002, EUR J CANCER, V38, P1218, DOI 10.1016/S0959 8049(02)00037 0
   Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677
   Holzer G, 2005, PEDIATR BLOOD CANCER, V44, P163, DOI 10.1002/pbc.20217
   Inaba H, 2004, PEDIATR BLOOD CANCER, V43, P729, DOI 10.1002/pbc.20151
   Kaya M, 2004, J BONE JOINT SURG BR, V86B, P143, DOI 10.1302/0301 620X.86B1.14069
   Kempf Bielack B, 2005, J CLIN ONCOL, V23, P559, DOI 10.1200/JCO.2005.04.063
   Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982
   Khanna C, 2001, CANCER RES, V61, P3750
   Lafleur EA, 2004, CLIN CANCER RES, V10, P8114, DOI 10.1158/1078 0432.CCR 04 0353
   Laverdiere C, 2005, CLIN CANCER RES, V11, P2561, DOI 10.1158/1078 0432.CCR 04 1089
   Leonard P, 2003, BRIT J CANCER, V89, P2284, DOI 10.1038/sj.bjc.6601389
   Meyers PA, 2004, CURR OPIN ONCOL, V16, P120, DOI 10.1097/00001622 200403000 00006
   Mintz MB, 2005, CANCER RES, V65, P1748, DOI 10.1158/0008 5472.CAN 04 2463
   Nakano T, 2003, CLIN EXP METASTAS, V20, P665, DOI 10.1023/A:1027355610603
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nathan SS, 2005, CLIN CANCER RES, V11, P2389, DOI 10.1158/1078 0432.CCR 04 2048
   Ochi K, 2004, INT J ONCOL, V24, P647
   PICCI P, 1994, DRUGS, V47, P82, DOI 10.2165/00003495 199447010 00006
   Retz MM, 2005, INT J CANCER, V114, P182, DOI 10.1002/ijc.20729
   Ross J. A., 2001, Medical and Pediatric Oncology, V37, P55, DOI 10.1002/mpo.1164
   Serra M, 2003, J CLIN ONCOL, V21, P536, DOI 10.1200/JCO.2003.03.144
   Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187
   Tsunemi T, 2003, CLIN ORTHOP RELAT R, P159, DOI 10.1097/01.blo.0000038050.29678.7e
   Wolf M, 2000, CANCER GENET CYTOGEN, V123, P128, DOI 10.1016/S0165 4608(00)00319 8
   Wunder JS, 2005, J CLIN ONCOL, V23, P1483, DOI 10.1200/JCO.2005.04.074
   Zhou H, 2003, J PEDIAT HEMATOL ONC, V25, P27, DOI 10.1097/00043426 200301000 00007
   Zucchini C, 2004, BONE, V34, P672, DOI 10.1016/j.bone.2003.12.008
NR 35
TC 91
Z9 105
U1 0
U2 11
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0030 5898
EI 1558 1373
J9 ORTHOP CLIN N AM
JI Orthop. Clin. North Am.
PD JAN
PY 2006
VL 37
IS 1
BP 1
EP +
DI 10.1016/j.ocl.2005.06.004
PG 8
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 994WF
UT WOS:000234061200002
PM 16311106
DA 2025 08 17
ER

PT J
AU Zhao, YT
   Qin, Y
   Yang, JS
   Huang, DG
   Hu, HM
   Wang, XD
   Wu, SF
   Hao, DJ
AF Zhao, Y.  T.
   Qin, Y.
   Yang, J.  S.
   Huang, D.  G.
   Hu, H.  M.
   Wang, X.  D.
   Wu, S.  F.
   Hao, D.  J.
TI Wharton's Jelly derived mesenchymal stem cells suppress apoptosis of
   nucleus pulposus cells in intervertebral disc degeneration via
   Wnt pathway
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Mesenchymal stromal cell; Intervertebral disc degeneration; Wnt; Nucleus
   pulposus cell; Apoptosis
ID WNT/BETA CATENIN; MOLECULAR BASIS; BONE MARROW
AB OBJECTIVE: Aberrant apoptosis of nucleus pulposus cells (NPCs) is one of the most remarkable pathological changes in intervertebral disc degeneration (IDD) development. Albeit the advances in the application of stem cell based therapy in IDD treatment, the molecular mechanisms underlying the anti apoptotic actions of mesenchymal stem cell (MSC) remain poorly elucidated.
   PATIENTS AND METHODS: The expression patterns of apoptosis related proteins and Wnt/beta catenin related genes in NP samples isolated from patients with mild or severe IDD were compared by performing immunoblot assay and quantitative real time polymerase chain reaction (qRT PCR), respectively. NPCs were in vitro treated with compression to induce apoptosis and then co cultured with Wharton's Jelly derived MSCs without direct interaction. After that, flow cytometry was carried out to detect the apoptosis rate of NPCs and the activity of Wnt/beta catenin pathway was determined. DKK 1 was used to inhibit Wnt signaling, in prior to evaluation of the effects of WJ MSCs on apoptosis within the co cultured NPCs.
   RESULTS: Compared to the mild IDD group. there was a significant increase in the expression of Caspase 3 and Bax in the NP tissues from severe IDD patients, whereas Bcl 2 displayed an opposite result. In addition. the expression of Wnt 3a. Wnt 5a. Wnt 10a, GSK 3 beta. cyclinD1 and p catenin was notably augmented in parallel with IDD progression. After compression treatment, the proportion of apoptotic NPCs was increased. which was then dramatically reversed by WJ MSCs co culture. Likewise, WJ MSCs suppressed compression induced Wnt related gene expression and blocking Wnt/beta catenin pathway using DKK 1 enhanced the anti apoptotic impacts of WJ MSCs. In the presence of DKK 1, there was no significant difference between NPCs co cultured with WJ MSCs and those cells cultured alone.
   CONCLUSIONS: WJ MSCs attenuate the compression induced apoptosis in NPCs and inhibit the activation of Wnt/beta catenin signaling. Blocking Wnt/beta catenin pathway further facilitates the actions of WJ MSCs in anti apoptosis, indicating that Wnt/beta catenin signaling plays a crucial role in this process and may function as a potential therapeutic target for IDD treatment.
C1 [Zhao, Y.  T.; Yang, J.  S.; Huang, D.  G.; Hu, H.  M.; Wang, X.  D.; Hao, D.  J.] Xi An Jiao Tong Univ, Honghui Hosp, Dept Spine Surg, Xian, Peoples R China.
   [Qin, Y.] Xi An Jiao Tong Univ, Honghui Hosp, Xian, Peoples R China.
   [Wu, S.  F.] Xi An Jiao Tong Univ, Ctr Translat Med, Sch Med, Affiliated Hosp 1, Xian, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong
   University
RP Hao, DJ (通讯作者)，Xi An Jiao Tong Univ, Honghui Hosp, Dept Spine Surg, Xian, Peoples R China.
EM zytqy@163.com
RI WU, XUAN/ISS 8430 2023
FU China Postdoctoral Science Foundation [2016M602943XB]; Shaanxi
   Postdoctoral Research Fund [2017BSHQYXMZZ19]
FX China Postdoctoral Science Foundation (2016M602943XB); Shaanxi
   Postdoctoral Research Fund (2017BSHQYXMZZ19).
CR Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Batsali AK, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0555 9
   Ding F, 2013, APOPTOSIS, V18, P777, DOI 10.1007/s10495 013 0839 1
   Ding F, 2012, APOPTOSIS, V17, P579, DOI 10.1007/s10495 012 0708 3
   Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200
   Han ZH, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1677 x
   Hiyama A, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4379
   Hiyama A, 2011, J CELL PHYSIOL, V226, P1139, DOI 10.1002/jcp.22438
   Hiyama A, 2010, ARTHRITIS RHEUM US, V62, P3036, DOI 10.1002/art.27599
   Kadow T, 2015, CLIN ORTHOP RELAT R, V473, P1903, DOI 10.1007/s11999 014 3774 8
   Kepler CK, 2013, SPINE J, V13, P318, DOI 10.1016/j.spinee.2012.12.003
   Luoma K, 2000, SPINE, V25, P487, DOI 10.1097/00007632 200002150 00016
   Mathew J, 2013, INT J SPINE SURG, V7, DOI 10.1016/j.ijsp.2013.02.001
   Park JB, 2005, J BONE JOINT SURG AM, V87A, P1338, DOI 10.2106/JBJS.D.02527
   Pfirrmann CWA, 2001, SPINE, V26, P1873, DOI 10.1097/00007632 200109010 00011
   PHILLIPS KL, 2015, OSTEOARTHR CARTILAGE, V23, P1165
   Risbud MV, 2014, NAT REV RHEUMATOL, V10, P44, DOI 10.1038/nrrheum.2013.160
   Smolders LA, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4157
   Sun ZY, 2018, J PHARMACOL SCI, V138, P263, DOI 10.1016/j.jphs.2018.10.007
   Vadala G, 2008, SPINE, V33, P870, DOI 10.1097/BRS.0b013e31816b4619
   Vadalà G, 2016, WORLD J STEM CELLS, V8, P185, DOI 10.4252/wjsc.v8.i5.185
   Wang QS, 2016, HUM VACC IMMUNOTHER, V12, P85, DOI 10.1080/21645515.2015.1030549
   Xie HX, 2016, INT J MOL MED, V37, P859, DOI 10.3892/ijmm.2016.2470
   Zeng Y, 2015, BIOMATERIALS, V59, P53, DOI 10.1016/j.biomaterials.2015.04.029
NR 24
TC 18
Z9 23
U1 0
U2 4
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 19
BP 9807
EP 9814
DI 10.26355/eurrev_202010_23190
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA OG0EP
UT WOS:000581569100014
PM 33090383
DA 2025 08 17
ER

PT J
AU Zhu, ZL
   Wang, XY
   Wang, ZD
   Zhao, Z
   Zhou, PH
   Gao, XB
AF Zhu, Zhonglian
   Wang, Xuyi
   Wang, Zhaodong
   Zhao, Zhi
   Zhou, Pinghui
   Gao, Xubin
TI Neobavaisoflavone protects osteoblasts from dexamethasone induced
   oxidative stress by upregulating the CRNDE mediated Nrf2/HO 1 signaling
   pathway
SO DRUG DEVELOPMENT RESEARCH
LA English
DT Article
DE CRNDE; neobavaisoflavone; Nrf2/HO 1; osteoporosis; oxidative stress
ID MICE; DIFFERENTIATION; OSTEOPOROSIS; DAMAGE
AB Neobavaisoflavone (NBIF) is a flavonoid, which has a variety of pharmacological activities. However, the mechanism of NBIF in the treatment of osteoporosis still needs further exploration. The differentiation of osteoblast MC 3T3 E1 cells after treatment was observed by Alizarin red staining. Cell counting kit 8 and flow cytometry were used to detect viability, apoptosis, and reactive oxygen species (ROS) levels of treated MC 3T3 E1 cells, respectively. Malondialdehyde (MDA), lactate dehydrogenase (LDH), superoxide dismutase (SOD) and glutathione peroxidase (GSH Px) were tested by ELISA kits. The expressions of lncRNA MALAT1, MEG3, CRNDE, Runx2, osteocalcin (OCN), osteopontin (OPN), collagen I (col I), nuclear Nrf2, cytoplasm Nrf2, heme oxygenase 1 (HO 1) and quinone oxidoreductase 1 (NQO1) in treated MC 3T3 E1 cells were examined by Quantitative real time PCR or Western blot. Dexamethasone (Dex) inhibited the viability of MC 3T3 E1 cells, while the appropriate amount of NBIF had no significantly effect on cell viability. Dex downregulated CRNDE expression, whereas NBIF upregulated CRNDE. Overexpressed CRNDE and NBIF reversed the inhibitory effects of Dex on cell viability, differentiation and levels of SOD, GSH Px, Runx2, OCN, OPN, col I, nuclear Nrf2, HO 1 and NQO1 while reversing the promoting effect of Dex on apoptosis and the levels of ROS, MDA, LDH and cytoplasm Nrf2 in MC 3T3 E1 cells, respectively, but shCRNDE further reversed the effects of NBIF in MC 3T3 E1 cells. NBIF protected osteoblasts from Dex induced oxidative stress by upregulating the CRNDE mediated Nrf2/HO 1 signaling pathway.
C1 [Zhu, Zhonglian; Wang, Xuyi; Wang, Zhaodong; Zhao, Zhi; Zhou, Pinghui; Gao, Xubin] Bengbu Med Coll, Anhui Key Lab Tissue Transplantat, Dept Orthoped, Affiliated Hosp 1, Bengbu, Peoples R China.
C3 Bengbu Medical University
RP Zhu, ZL (通讯作者)，Bengbu Med Coll, Affiliated Hosp 1, Dept Orthoped, 287 Changhuai Rd, Bengbu 233000, Anhui, Peoples R China.
EM zhuzhonglian_zzl@163.com
FU Key Project of Education Department of Anhui [KJ2018A0229]; Bengbu
   Municipal Science and Technology Innovation Guidance Project [20180312];
   Swedish Heart Lung Foundation [20180312] Funding Source: Swedish
   Heart Lung Foundation
FX Key Project of Education Department of Anhui, Grant/Award Number:
   KJ2018A0229; 2018 Bengbu Municipal Science and Technology Innovation
   Guidance Project, Grant/Award Number: 20180312
CR Alejandro P, 2018, RHEUM DIS CLIN N AM, V44, P437, DOI 10.1016/j.rdc.2018.03.004
   Amantea D, 2009, FEBS J, V276, P13, DOI 10.1111/j.1742 4658.2008.06766.x
   García Gómez MC, 2020, CLIN INVEST ARTERIOS, V32, P33, DOI 10.1016/j.arteri.2019.03.008
   Chen HW, 2020, J CELL MOL MED, V24, P9067, DOI 10.1111/jcmm.15543
   de Oliveira MC, 2018, REV BRAS GINECOL OBS, V40, P251, DOI 10.1055/s 0038 1666856
   De Rosa A, 2021, THORAC CANCER, V12, P106, DOI 10.1111/1759 7714.13724
   Deng S, 2019, BIOMED PHARMACOTHER, V110, P602, DOI 10.1016/j.biopha.2018.11.103
   Du DJ, 2009, ANN BIOMED ENG, V37, P146, DOI 10.1007/s10439 008 9586 9
   Fang HQ, 2011, CELL RES, V21, P1295, DOI 10.1038/cr.2011.81
   Feng Y, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/7067619
   Gao Y, 2018, J CELL BIOCHEM, V119, P6986, DOI 10.1002/jcb.26907
   Goc Z, 2017, CHINESE J PHYSIOL, V60, P1, DOI 10.4077/CJP.2017.BAF435
   Heidari F, 2019, CYTOKINE, V120, P186, DOI 10.1016/j.cyto.2019.05.007
   Huang W, 2012, MOL CELL BIOCHEM, V360, P71, DOI 10.1007/s11010 011 1045 5
   Jung WW, 2014, INT J MOL MED, V33, P1327, DOI 10.3892/ijmm.2014.1666
   Kalyanaraman H, 2018, DIABETES, V67, P607, DOI 10.2337/db17 0965
   Kasher M, 2020, OSTEOPOROSIS INT, V31, P2197, DOI 10.1007/s00198 020 05504 y
   Kato S, 2009, LIFE SCI, V84, P302, DOI 10.1016/j.lfs.2008.12.011
   Li J, 2018, MOL MED REP, V18, P2581, DOI 10.3892/mmr.2018.9274
   Liang J, 2018, J CELL BIOCHEM, V119, P431, DOI 10.1002/jcb.26200
   Liu XN, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/7161592
   Mao WH, 2018, MOL MED REP, V17, P8369, DOI 10.3892/mmr.2018.8908
   Martins CM, 2018, INT ENDOD J, V51, P641, DOI 10.1111/iej.12876
   Mehdi M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/6039453
   Mulati M, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115076
   Newsholme P, 2016, BIOCHEM J, V473, P4527, DOI 10.1042/BCJ20160503C
   Park JS, 2020, TISSUE ENG REGEN MED, V17, P875, DOI 10.1007/s13770 020 00289 x
   Patel J, 2020, AM J MANAG CARE, V26, pS311, DOI 10.37765/ajmc.2020.88549
   Petelina T I, 2019, Klin Lab Diagn, V64, P417, DOI 10.18821/0869 2084 2019 64 7 417 423
   Roche Patricia, 2014, Cardiovascular & Hematological Disorders   Drug Targets, V14, P107
   Sajadimajd S, 2018, CURR CANCER DRUG TAR, V18, P538, DOI 10.2174/1568009617666171002144228
   Sato N, 2009, DENT MATER, V25, P1532, DOI 10.1016/j.dental.2009.07.006
   Shieh P, 2019, TOXICOLOGY, V417, P1, DOI 10.1016/j.tox.2019.02.004
   Sinha K, 2013, ARCH TOXICOL, V87, P1157, DOI 10.1007/s00204 013 1034 4
   Sun H, 2020, BIOMED REP, V13, P15, DOI 10.3892/br.2020.1305
   Takanche JS, 2020, PHYTOMEDICINE, V66, DOI 10.1016/j.phymed.2019.153107
   Tsikas D, 2017, ANAL BIOCHEM, V524, P13, DOI 10.1016/j.ab.2016.10.021
   Verardo Angela R, 2018, Nestle Nutr Inst Workshop Ser, V89, P47, DOI 10.1159/000486492
   Xu JJ, 2018, CELL PHYSIOL BIOCHEM, V48, P583, DOI 10.1159/000491887
   Xu Xiao Kun, 2016, Zhongguo Zhong Yao Za Zhi, V41, P2922, DOI 10.4268/cjcmm20161528
   Zheng S, 2019, EUR REV MED PHARMACO, V23, P4609, DOI 10.26355/eurrev_201906_18038
NR 41
TC 20
Z9 24
U1 6
U2 29
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0272 4391
EI 1098 2299
J9 DRUG DEVELOP RES
JI Drug Dev. Res.
PD NOV
PY 2021
VL 82
IS 7
BP 1044
EP 1054
DI 10.1002/ddr.21811
EA MAR 2021
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WW5BE
UT WOS:000628337900001
PM 33713471
DA 2025 08 17
ER

PT J
AU Wallimann, A
   Magrath, W
   Pugliese, B
   Stocker, N
   Westermann, P
   Heider, A
   Gehweiler, D
   Zeiter, S
   Claesson, MJ
   Richards, RG
   Akdis, CA
   Hernandez, CJ
   O'Mahony, L
   Thompson, K
   Moriarty, TF
AF Wallimann, Alexandra
   Magrath, Walker
   Pugliese, Brenna
   Stocker, Nino
   Westermann, Patrick
   Heider, Anja
   Gehweiler, Dominic
   Zeiter, Stephan
   Claesson, Marcus J.
   Richards, R. Geoff
   Akdis, Cezmi A.
   Hernandez, Christopher J.
   O'Mahony, Liam
   Thompson, Keith
   Moriarty, T. Fintan
TI Butyrate Inhibits Osteoclast Activity In Vitro and Regulates
   Systemic Inflammation and Bone Healing in a Murine Osteotomy Model
   Compared to Antibiotic Treated Mice
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID GUT MICROBIOME; B CELL; OSTEOPROTEGERIN; ACTIVATION; MONOCYTES;
   MIGRATION; HEALTH; TISSUE; RANKL
AB Short chain fatty acids (SCFAs) produced by the gut microbiota have previously been demonstrated to play a role in numerous chronic inflammatory diseases and to be key mediators in the gut bone signaling axis. However, the role of SCFAs in bone fracture healing and its impact on systemic inflammation during the regeneration process has not been extensively investigated yet. The aim of this study was to first determine the effects of the SCFA butyrate on key cells involved in fracture healing in vitro, namely, osteoclasts and mesenchymal stromal cells (MSCs), and second, to assess if butyrate supplementation or antibiotic therapy impacts bone healing, systemic immune status, and inflammation levels in a murine osteotomy model. Butyrate significantly reduced osteoclast formation and resorption activity in a dose dependent manner and displayed a trend for increased calcium deposits in MSC cultures. Numerous genes associated with osteoclast differentiation were differentially expressed in osteoclast precursor cells upon butyrate exposure. In vivo, antibiotic treated mice showed reduced SCFA levels in the cecum, as well as a distinct gut microbiome composition. Furthermore, circulating proinflammatory TNF alpha, IL 17a, and IL 17f levels, and bone preserving osteoprotegerin (OPG), were increased in antibiotic treated mice compared to controls. Antibiotic treated mice also displayed a trend towards delayed bone healing as revealed by reduced mineral apposition at the defect site and higher circulating levels of the bone turnover marker PINP. Butyrate supplementation resulted in a lower abundance of monocyte/macrophages in the bone marrow, as well as reduced circulating proinflammatory IL 6 levels compared to antibiotic  and control treated mice. In conclusion, this study supports our hypothesis that SCFAs, in particular butyrate, are important contributors to successful bone healing by modulating key cells involved in fracture healing as well as systemic inflammation and immune responses.
C1 [Wallimann, Alexandra; Magrath, Walker; Pugliese, Brenna; Gehweiler, Dominic; Zeiter, Stephan; Richards, R. Geoff; Thompson, Keith; Moriarty, T. Fintan] AO Res Inst Davos, Davos, Switzerland.
   [Wallimann, Alexandra; Stocker, Nino; Westermann, Patrick; Heider, Anja; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland.
   [Claesson, Marcus J.] SeqBiome Ltd, 3 Castleheights, Bandon, Cork, Ireland.
   [Hernandez, Christopher J.] Cornell Univ, Sibley Sch Mech & Aerosp Engn, Ithaca, NY USA.
   [Hernandez, Christopher J.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA.
   [O'Mahony, Liam] Univ Coll Cork, APC Microbiome Ireland, Dept Med, Coll Rd, Cork, Ireland.
   [O'Mahony, Liam] Univ Coll Cork, APC Microbiome Ireland, Dept Microbiol, Coll Rd, Cork, Ireland.
C3 AO Foundation; University of Zurich; Swiss Institute of Allergy & Asthma
   Research; Cornell University; University College Cork; University
   College Cork
RP Moriarty, TF (通讯作者)，AO Res Inst Davos, Davos, Switzerland.
EM alexandra.wallimann@aofoundation.org; wmagrat1@jhmi.edu;
   brenna.pugliese@gmail.com; nino.stocker@siaf.uzh.ch;
   patrick.westermann@siaf.uzh.ch; anja.heider@siaf.uzh.ch;
   dominic.gehweiler@aofoundation.org; stephan.zeiter@aofoundation.org;
   marcusclaesson@seqbiome.com; geoff.richards@aofoundation.org;
   akdisac@siaf.uzh.ch; cjh275@cornell.edu; liam.omahony@ucc.ie;
   keith.thompson@aofoundation.org; fintan.moriarty@aofoundation.org
RI Claesson, Marcus/K 7639 2015; Akdis, Cezmi/AAV 4844 2020; Zeiter,
   Stephan/AAI 1880 2021; Richards, Robert/I 8235 2015; O'Mahony,
   Liam/AAG 5838 2019; Hernandez, Christopher/B 5290 2009
OI Claesson, Marcus/0000 0002 5712 0623; Zeiter,
   Stephan/0000 0002 8155 4202; Stocker, Nino/0000 0003 3200 8982; Akdis,
   Cezmi/0000 0001 8020 019X; Thompson, Keith/0000 0002 9167 5147;
   Richards, Robert/0000 0002 7778 2480; Westermann,
   Patrick/0000 0003 2894 6140; Gehweiler, Dominic/0000 0001 7148 9569;
   Hernandez, Christopher John/0000 0002 0712 6533; Wallimann,
   Alexandra/0000 0001 6755 3679; Magrath, Walker/0000 0001 8576 1156;
   Heider, Anja/0000 0002 3448 4125; O'Mahony, Liam/0000 0003 4705 3583;
   Pugliese, Brenna/0000 0003 1636 2439; 
FU AO Trauma as part of the Clinical Priority Program Bone Infection
   [AR2017_06]
FX The authors would like to thank all the members of the preclinical
   facility at ARI Davos for their help with the animal study, in
   particular the animal caretakers, Caroline Constant for performing
   surgeries, Karen Mys for support in mu CT analysis, and Mauro Bluvol and
   Nora Goudsouzian for histological sample processing. Pamela Furlong, Ge
   Tan, Susanne Bartl, Ciara Ferris, and Samson Arveladze are also
   acknowledged for support in the performance of this study. This study
   was funded by AO Trauma as part of the Clinical Priority Program Bone
   Infection (AR2017_06).
CR Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726
   Bahney CS, 2019, J ORTHOP RES, V37, P35, DOI 10.1002/jor.24170
   Baht GS, 2018, CURR OSTEOPOROS REP, V16, P138, DOI 10.1007/s11914 018 0423 2
   Barcik W, 2020, IMMUNITY, V52, P241, DOI 10.1016/j.immuni.2020.01.007
   Berthelot JM, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen 2019 001037
   Britton RA, 2014, J CELL PHYSIOL, V229, P1822, DOI 10.1002/jcp.24636
   Dabke K, 2019, J CLIN INVEST, V129, P4050, DOI 10.1172/JCI129194
   Ding K, 2020, AGING DIS, V11, P438, DOI 10.14336/AD.2019.0523
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Flick LM, 2003, J ORTHOP RES, V21, P676, DOI 10.1016/S0736 0266(03)00011 1
   Franzosa EA, 2019, NAT MICROBIOL, V4, P293, DOI 10.1038/s41564 018 0306 4
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Guss JD, 2019, OSTEOARTHR CARTILAGE, V27, P129, DOI 10.1016/j.joca.2018.07.020
   Guss JD, 2017, J BONE MINER RES, V32, P1343, DOI 10.1002/jbmr.3114
   Hawrelak Jason A, 2004, Altern Med Rev, V9, P180
   Hernandez CJ, 2021, J ORTHOP RES, V39, P251, DOI 10.1002/jor.24927
   Houschyar KS, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00170
   Kaiser K, 2018, N S ARCH PHARMACOL, V391, P523, DOI 10.1007/s00210 018 1483 7
   Kim DS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01525
   Kindle L, 2006, J BONE MINER RES, V21, P193, DOI 10.1359/JBMR.051027
   Kotani M, 2013, J IMMUNOL, V190, P605, DOI 10.4049/jimmunol.1201345
   Kubota A, 2004, J RHEUMATOL, V31, P426
   Lasitschka F, 2017, IMMUN INFLAMM DIS, V5, P480, DOI 10.1002/iid3.184
   Liu H, 2018, ADV NUTR, V9, P21, DOI 10.1093/advances/nmx009
   Liu JH, 2020, DIS MODEL MECH, V13, DOI 10.1242/dmm.043620
   Lucas S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02490 4
   Lynch SV, 2016, NEW ENGL J MED, V375, P2369, DOI 10.1056/NEJMra1600266
   Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530
   Min SC, 2017, CLIN RHEUMATOL, V36, P2351, DOI 10.1007/s10067 017 3690 x
   Montalvany Antonucci CC, 2019, BONE, V125, P112, DOI 10.1016/j.bone.2019.05.016
   Nam D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040044
   Nevius E, 2015, J EXP MED, V212, P1931, DOI 10.1084/jem.20150088
   Ono T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10928
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prystaz K, 2018, AM J PATHOL, V188, P474, DOI 10.1016/j.ajpath.2017.10.011
   Rahman MM, 2003, BLOOD, V101, P3451, DOI 10.1182/blood 2002 08 2622
   Reid P, 2009, EUR J CELL BIOL, V88, P1, DOI 10.1016/j.ejcb.2008.06.004
   Reinke S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004754
   Rios Arce ND, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115269
   Roberts JL, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110831
   Rodrigues FC, 2012, J MED FOOD, V15, P664, DOI 10.1089/jmf.2011.0296
   Rosser EC, 2020, CELL METAB, V31, P837, DOI 10.1016/j.cmet.2020.03.003
   Rupp M, 2018, INT ORTHOP, V42, P247, DOI 10.1007/s00264 017 3734 5
   Schepper JD, 2019, J BONE MINER RES, V34, P681, DOI 10.1002/jbmr.3635
   Schepper JD, 2017, ADV EXP MED BIOL, V1033, P225, DOI 10.1007/978 3 319 66653 2_11
   Schlundt Claudia, 2015, J Exp Orthop, V2, P1, DOI 10.1186/s40634 014 0017 6
   Schulthess J, 2019, IMMUNITY, V50, P432, DOI 10.1016/j.immuni.2018.12.018
   Sun GJ, 2017, CLIN EXP PHARMACOL P, V44, P455, DOI 10.1111/1440 1681.12719
   Tang X, 2020, J AGR FOOD CHEM, V68, P6588, DOI 10.1021/acs.jafc.0c01820
   Tompkins KA, 2016, CONNECT TISSUE RES, V57, P69, DOI 10.3109/03008207.2016.1140152
   Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444
   Tsai YL, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929 018 0493 6
   Tzioupis C, 2007, INJURY, V38, pS3, DOI 10.1016/S0020 1383(07)80003 9
   Ulrich Vinther M, 2005, CALCIFIED TISSUE INT, V76, P280, DOI 10.1007/s00223 004 0126 9
   Voss JO, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/714230
   Wallimann A, 2021, EUR CELLS MATER, V40, P454, DOI 10.22203/eCM.v041a29
   Wallimann A, 2021, CALCIFIED TISSUE INT, V108, P654, DOI 10.1007/s00223 020 00790 4
   Wang TT, 2020, CURR DRUG TARGETS, V21, P213, DOI 10.2174/1389450120666190821161259
   Witkowski M, 2020, CIRC RES, V127, P553, DOI 10.1161/CIRCRESAHA.120.316242
   Wu T, 2020, MSYSTEMS, V5, DOI 10.1128/mSystems.00587 20
   Yang SF, 2015, APMIS, V123, P975, DOI 10.1111/apm.12439
   Zannettino ACW, 2005, J CELL PHYSIOL, V204, P714, DOI 10.1002/jcp.20354
   Zólkiewicz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12082189
NR 64
TC 32
Z9 34
U1 6
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0962 9351
EI 1466 1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PD DEC 10
PY 2021
VL 2021
AR 8817421
DI 10.1155/2021/8817421
PG 17
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Immunology
GA YG6JY
UT WOS:000742593500001
PM 34924815
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pichardo, SEC
   van Merkesteyn, JPR
AF Pichardo, Sarina E. C.
   van Merkesteyn, J. P. Richard
TI Bisphosphonate related osteonecrosis of the jaws: spontaneous or dental
   origin?
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
LA English
DT Article
ID RISK FACTORS; MULTIPLE MYELOMA; FOLLOW UP; CANCER; BONE; PREVENTION;
   OSTEOMYELITIS; MANAGEMENT; NECROSIS; THERAPY
AB Objective(s). Bisphosphonates are frequently used worldwide mostly in osteoporosis and skeletal bone metastases. However, a serious side effect is bisphosphonate related osteonecrosis of the jaws (BRONJ). The mechanism behind BRONJ remains unclear. In literature several origins are suggested. Presence of the teeth in the jaws may play an important role. Therefore in this study 45 patients were analyzed retrospectively.
   Study design. Files of 45 patients with a diagnosis of BRONJ were analyzed, meaning clinical features, bisphosphonate use, dental history including luxating moment and (previous) treatment.
   Results. In 97.5% (n = 44) a certain or presumable dental focus, such as extractions, a previous dental treatment or prosthesis complaints were found as initiating factor of BRONJ.
   Conclusion. In contrast to findings in literature, in our group of patients a dental focus was found in 44 of 45 cases. This implies a dentoalveolar start of BRONJ with subsequent spreading into the jaws in nearly all cases.
C1 [Pichardo, Sarina E. C.; van Merkesteyn, J. P. Richard] Leiden Univ, Med Ctr, Dept Oral & Maxillofacial Surg, NL 2300 RC Leiden, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University   Excl LUMC
RP van Merkesteyn, JPR (通讯作者)，Leiden Univ, Med Ctr, Dept Oral & Maxillofacial Surg, POB 9600, NL 2300 RC Leiden, Netherlands.
EM j.p.r.van_merkesteyn@lumc.nl
RI ; van Merkesteyn, Richard/ABE 2622 2021; Pichardo, Sarina/JQV 4729 2023
OI Pichardo, Sarina/0000 0002 6446 9655; 
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Alons K, 2009, ORAL SURG ORAL MED O, V107, pE1, DOI 10.1016/j.tripleo.2008.09.021
   American Dental Association Council on Scientific Affairs, 2006, J Am Dent Assoc, V137, P1144
   Badros A, 2008, J CLIN ONCOL, V26, P5904, DOI 10.1200/JCO.2008.16.9300
   Bagan JV, 2006, ORAL ONCOL, V42, P327, DOI 10.1016/j.oraloncology.2005.08.001
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Bedogni A, 2008, ORAL SURG ORAL MED O, V105, P358, DOI 10.1016/j.tripleo.2007.08.040
   Boonyapakorn T, 2008, ORAL ONCOL, V44, P857, DOI 10.1016/j.oraloncology.2007.11.012
   Dimopoulos MA, 2006, HAEMATOL HEMATOL J, V91, P968
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Estilo CL, 2008, ONCOLOGIST, V13, P911, DOI 10.1634/theoncologist.2008 0091
   Ficarra G, 2005, J CLIN PERIODONTOL, V32, P1123, DOI 10.1111/j.1600 051X.2005.00842.x
   Filleul O, 2010, J CANCER RES CLIN, V136, P1117, DOI 10.1007/s00432 010 0907 7
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kos M, 2010, J CRANIO MAXILL SURG, V38, P255, DOI 10.1016/j.jcms.2009.06.005
   Lugassy G, 2004, AM J MED, V117, P440, DOI 10.1016/j.amjmed.2004.04.015
   Manfredi M, 2011, INT J ORAL MAX SURG, V40, P277, DOI 10.1016/j.ijom.2010.11.002
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Marx RE, 2007, J ORAL MAXIL SURG, V65, P2397, DOI 10.1016/j.joms.2007.08.003
   Mavrokokki T, 2007, J ORAL MAXIL SURG, V65, P415, DOI 10.1016/j.joms.2006.10.061
   Melo MD, 2005, J AM DENT ASSOC, V136, P1675, DOI 10.14219/jada.archive.2005.0110
   Merigo Elisabetta, 2006, Acta Biomed, V77, P109
   Migliorati CA, 2005, CANCER, V104, P83, DOI 10.1002/cncr.21130
   Novince CM, 2009, CELLS TISSUES ORGANS, V189, P275, DOI 10.1159/000152915
   O'Ryan FS, 2012, J ORAL MAXIL SURG, V70, P1844, DOI 10.1016/j.joms.2011.08.033
   Otto S, 2012, J CRANIO MAXILL SURG, V40, P303, DOI 10.1016/j.jcms.2011.05.003
   Pires FR, 2005, ORAL DIS, V11, P365, DOI 10.1111/j.1601 0825.2005.01130.x
   Purcell PM, 2005, MED J AUSTRALIA, V182, P417, DOI 10.5694/j.1326 5377.2005.tb06762.x
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Then C, 2012, ONKOLOGIE, V35, P658, DOI 10.1159/000343950
   Thumbigere Math V, 2012, AM J CLIN ONCOL CANC, V35, P386, DOI 10.1097/COC.0b013e3182155fcb
   van Merkesteyn JPR, 1997, INT J ORAL MAX SURG, V26, P450, DOI 10.1016/S0901 5027(97)80012 4
   Vescovi P, 2012, J ORAL PATHOL MED, V41, P214, DOI 10.1111/j.1600 0714.2011.01091.x
   Vescovi P, 2011, ORAL ONCOL, V47, P191, DOI 10.1016/j.oraloncology.2010.11.007
   Voss PJ, 2012, J CRANIO MAXILL SURG, V40, P719, DOI 10.1016/j.jcms.2012.01.005
   Wang J, 2003, J ORAL MAXIL SURG, V61, P1104, DOI 10.1016/S0278 2391(03)00328 8
   Watters AL, 2013, OR SURG OR MED OR PA, V115, P192, DOI 10.1016/j.oooo.2012.05.017
   Wilde F, 2011, ORAL SURG ORAL MED O, V111, P153, DOI 10.1016/j.tripleo.2010.04.015
   Williamson RA, 2010, INT J ORAL MAX SURG, V39, P251, DOI 10.1016/j.ijom.2009.11.014
   Woo Sook Bin, 2007, Alpha Omegan, V100, P194, DOI 10.1016/j.aodf.2007.10.013
   Zarychanski R, 2006, AM J HEMATOL, V81, P73, DOI 10.1002/ajh.20481
NR 44
TC 31
Z9 34
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2212 4403
EI 2212 4411
J9 OR SURG OR MED OR PA
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
PD SEP
PY 2013
VL 116
IS 3
BP 287
EP 292
DI 10.1016/j.oooo.2013.05.005
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 205ZM
UT WOS:000323484300016
PM 23953415
OA hybrid
DA 2025 08 17
ER

PT J
AU Al Badr, W
   Martin, KJ
AF Al Badr, Wisam
   Martin, Kevin J.
TI Vitamin D and kidney disease
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID SUBTOTALLY NEPHRECTOMIZED RATS; SECONDARY HYPERPARATHYROIDISM;
   PARATHYROID HORMONE; HEMODIALYSIS PATIENTS; D RECEPTOR;
   1,25 DIHYDROXYVITAMIN D 3; D ANALOGS; 1,25(OH)(2) VITAMIN D 3; VASCULAR
   CALCIFICATION; MINERAL METABOLISM
AB Abnormalities in vitamin D metabolism play a major role in the pathogenesis of secondary hyperparathyroidism in chronic kidney disease. The gradual and progressive decline in 1,25 dihydroxyvitamin D in the course of chronic kidney disease is the result of several mechanisms that limit the ability of the failing kidney to maintain the levels of 1,25 dihydroxyvitamin D despite increasing levels of parathyroid hormone. Recent observations have indicated that chronic kidney disease seems to be associated with a high incidence of nutritional vitamin D insufficiency or deficiency as manifested by decreased levels of 25 hydroxyvitamin D. This contributes to the inability to maintain the levels of 1,25 dihydroxyvitamin D; therefore, current practice guidelines suggest repleting vitamin D status by the administration of native vitamin D as a first step in the therapy of the abnormalities of bone and mineral metabolism in chronic kidney disease. The efficacy of this therapy is extremely variable, and active vitamin D sterols may be required, especially as kidney disease progresses. The importance of the abnormal vitamin D metabolism is being investigated vigorously in view of the observations that vitamin D may have important biologic actions in many tissues in addition to bone and parathyroid. Thus, observational data have suggested potential survival benefits of vitamin D sterol administration in this clinical setting, and experimental data have suggested a potential beneficial effect of vitamin D sterols on the progression of kidney disease. Further work is required to define the mechanisms involved and to examine the effects of vitamin D therapy on outcomes in randomized, controlled trials.
C1 [Martin, Kevin J.] St Louis Univ, Med Ctr, Div Nephrol, Div Nephrol 9 FDT, St Louis, MO 63110 USA.
C3 Saint Louis University
RP Martin, KJ (通讯作者)，St Louis Univ, Med Ctr, Div Nephrol, Div Nephrol 9 FDT, 3635 Vista Ave, St Louis, MO 63110 USA.
EM martinkj@slu.edu
RI Martin, Kevin/AAA 3212 2021
CR Agarwal R, 2005, KIDNEY INT, V68, P2823, DOI 10.1111/j.1523 1755.2005.00755.x
   Akiba T, 1998, AM J KIDNEY DIS, V32, P238, DOI 10.1053/ajkd.1998.v32.pm9708607
   Al Aly Z, 2007, AM J KIDNEY DIS, V50, P59, DOI 10.1053/j.ajkd.2007.04.010
   Andress DL, 2006, KIDNEY INT, V69, P33, DOI 10.1038/sj.ki.5000045
   Aschenbrenner JK, 2001, J SURG RES, V100, P171, DOI 10.1006/jsre.2001.6221
   Bodyak N, 2007, P NATL ACAD SCI USA, V104, P16810, DOI 10.1073/pnas.0611202104
   Brandi L, 1998, J INTERN MED, V244, P121
   Cardus A, 2007, J BONE MINER RES, V22, P860, DOI 10.1359/JBMR.070305
   Chandra Prakash, 2008, Endocr Pract, V14, P10
   Coburn JW, 2004, AM J KIDNEY DIS, V43, P877, DOI 10.1053/j.ajkd.2004.01.012
   Coyne D, 2006, AM J KIDNEY DIS, V47, P263, DOI 10.1053/j.ajkd.2005.10.007
   Dusso AS, 2005, AM J PHYSIOL RENAL, V289, pF8, DOI 10.1152/ajprenal.00336.2004
   González EA, 2004, AM J NEPHROL, V24, P503, DOI 10.1159/000081023
   Hilpert J, 2002, KIDNEY INT, V62, P1672, DOI 10.1046/j.1523 1755.2002.00634.x
   Hirata M, 2003, NEPHROL DIAL TRANSPL, V18, P1770, DOI 10.1093/ndt/gfg296
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Krüger S, 2001, EXP NEPHROL, V9, P223
   Kuhlmann A, 2004, AM J PHYSIOL RENAL, V286, pF526, DOI 10.1152/ajprenal.00316.2003
   LaClair RE, 2005, AM J KIDNEY DIS, V45, P1026, DOI 10.1053/j.ajkd.2005.02.029
   Leheste JR, 1999, AM J PATHOL, V155, P1361, DOI 10.1016/S0002 9440(10)65238 8
   Li YC, 2004, J STEROID BIOCHEM, V89 90, P387, DOI 10.1016/j.jsbmb.2004.03.004
   London GM, 2007, J AM SOC NEPHROL, V18, P613, DOI 10.1681/ASN.2006060573
   Martin KJ, 2007, J AM SOC NEPHROL, V18, P875, DOI 10.1681/ASN.2006070771
   Martin KJ, 1998, J AM SOC NEPHROL, V9, P1427
   Mizobuchi M, 2007, KIDNEY INT, V72, P709, DOI 10.1038/sj.ki.5002406
   Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092 8674(00)80655 8
   Nykjaer A, 2001, P NATL ACAD SCI USA, V98, P13895, DOI 10.1073/pnas.241516998
   Perwad F, 2007, AM J PHYSIOL RENAL, V293, pF1577, DOI 10.1152/ajprenal.00463.2006
   Ritz E, 1995, NEPHROL DIAL TRANSPL, V10, P2228, DOI 10.1093/ndt/10.12.2228
   Schwarz U, 1998, KIDNEY INT, V53, P1696, DOI 10.1046/j.1523 1755.1998.00951.x
   Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264
   Sprague SM, 2003, KIDNEY INT, V63, P1483, DOI 10.1046/j.1523 1755.2003.00878.x
   Subramaniam N, 2001, J BIOL CHEM, V276, P15741, DOI 10.1074/jbc.M011033200
   Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   Tentori F, 2006, KIDNEY INT, V70, P1858, DOI 10.1038/sj.ki.5001868
   Tsukamoto Y, 2000, AM J KIDNEY DIS, V35, P458, DOI 10.1016/S0272 6386(00)70198 3
   Usatii M, 2007, KIDNEY INT, V72, P1330, DOI 10.1038/sj.ki.5002532
   Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909
   Willnow TE, 2002, CURR OPIN LIPIDOL, V13, P255, DOI 10.1097/00041433 200206000 00004
   Wolf M, 2007, KIDNEY INT, V72, P1004, DOI 10.1038/sj.ki.5002451
   Wu Wong JR, 2007, J CELL BIOCHEM, V100, P1395, DOI 10.1002/jcb.21133
   Wu Wong JR, 2006, ATHEROSCLEROSIS, V186, P20, DOI 10.1016/j.atherosclerosis.2005.06.046
   Xiang W, 2005, AM J PHYSIOL ENDOC M, V288, pE125, DOI 10.1152/ajpendo.00224.2004
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
   Zhang Z, 2008, KIDNEY INT, V73, P163, DOI 10.1038/sj.ki.5002572
   Zhu KJ, 2001, ACTA PHARMACOL SIN, V22, P62
   Zisman AL, 2007, AM J NEPHROL, V27, P36, DOI 10.1159/000098561
NR 48
TC 130
Z9 151
U1 0
U2 8
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555 9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD SEP
PY 2008
VL 3
IS 5
BP 1555
EP 1560
DI 10.2215/CJN.01150308
PG 6
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 342AR
UT WOS:000258757500049
PM 18450926
OA Green Published, Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Liu, SY
   Fang, T
   Yang, LY
   Chen, ZG
   Mu, S
   Fu, Q
AF Liu, Shengye
   Fang, Tao
   Yang, Liyu
   Chen, Zhiguang
   Mu, Shuai
   Fu, Qin
TI Gastrodin protects MC3T3 E1 osteoblasts from dexamethasone induced
   cellular dysfunction and promotes bone formation via induction of the
   NRF2 signaling pathway
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE dexamethasone; gastrodin; glucocorticoid induced osteoporosis; nuclear
   factor like 2; osteoblast
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; OSTEOGENIC DIFFERENTIATION;
   MITOCHONDRIAL FUNCTION; OXIDATIVE STRESS; UP REGULATION; IN VITRO;
   APOPTOSIS; DISEASE; CELLS; ACTIVATION
AB Glucocorticoid (GC) induced osteoporosis (GIO) is one of the most common secondary and iatrogenic forms of osteoporosis. GCs are widely used in clinical therapy and play a key role in the normal regulation of bone remodeling. However, the prolonged and high dose administration of GCs results in the occurrence of osteoporosis, which is partially due to the dysfunction and apoptosis of osteoblasts and osteocytes. The aim of the present study was to investigate the effects of gastrodin, a natural bioactive compound isolated from the traditional Chinese herbal agent Gastrodia elata, on GC treated MC3T3 E1 murine osteoblastic cells. MC3T3 E1 cells were exposed to dexamethasone (DEX), with or without gastrodin pretreatment, and cell viability was measured by the Cell Counting Kit 8 (CCK 8) assay. Quantitative polymerase chain reaction analysis was performed to evaluate osteogenic gene expression, and cellular alkaline phosphatase (ALP) activity was measured as well. Alizarin Red staining of calcium deposits was found to reflect the degree of osteoblast maturity. Western blotting was performed to determine the expression of osteogenic and adipogenic differentiation key proteins, as well as nuclear factor like 2 (NRF2) pathway related proteins. Annexin V fluorescein isothiocyanate/propidium iodide flow cytometric analysis was performed to determine osteoblast apoptosis. JC 1 staining was used to detect the changes of the mitochondrial membrane potential in cells. The results revealed that gastrodin prevented the decrease in cell viability caused by DEX induced MC3T3 E1 cell dysfunction, and that groups pretreated with gastrodin exhibited higher mRNA levels of osteogenic genes, such as Runx2, osterix, bone morphogenetic protein 2 and osteocalcin. Furthermore, treatment with both DEX and gastrodin was associated with increased ALP activity in MC3T3 E1 cells, as well as more calcium deposits, compared with cells treated with DEX alone. In addition, gastrodin increased osteogenic key marker protein Runx2 while activating NRF2 and downstream effector protein expression. Therefore, gastrodin may have the potential to reduce DEX induced cell apoptosis and increase the mitochondrial membrane potential against DEX. These results demonstrated that gastrodin was able to prevent and/ or delay DEX induced osteoporosis by improving osteoblast function, and these protective effects were verified in an animal model.
C1 [Liu, Shengye; Fang, Tao; Yang, Liyu; Mu, Shuai; Fu, Qin] China Med Univ, Shengjing Hosp, Dept Spine & Joint Surg, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China.
   [Chen, Zhiguang] China Med Univ, Emergency Dept, Shengjing Hosp, Shenyang 110004, Liaoning, Peoples R China.
C3 China Medical University; China Medical University
RP Fu, Q (通讯作者)，China Med Univ, Shengjing Hosp, Dept Spine & Joint Surg, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China.
EM CMU_FuQin@163.com
RI fang, tao/IQU 3074 2023; Liu, Shengye/HKE 2627 2023; 杨, 立宇/GZM 5725 2022
FU Outstanding Scientific Fund of Shengjing Hospital [MD31]; National
   Natural Science Foundation of China [81370981]
FX This study was sponsored by grants from the National Natural Science
   Foundation of China (no. 81370981) and the Outstanding Scientific Fund
   of Shengjing Hospital (MD31).
CR Angelova PR, 2016, FREE RADICAL BIO MED, V100, P81, DOI 10.1016/j.freeradbiomed.2016.06.005
   [Anonymous], 2015, EVID BASED COMPL ALT, DOI DOI 10.1155/2015/828427
   Buehring B, 2013, J ALLERGY CLIN IMMUN, V132, P1019, DOI 10.1016/j.jaci.2013.08.040
   Cao H, 2012, INT J MOL MED, V29, P435, DOI 10.3892/ijmm.2011.845
   Chan CKY, 2016, BRIT MED BULL, V119, P129, DOI 10.1093/bmb/ldw033
   Chen YY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133809
   Chen ZG, 2016, CLIN EXP PHARMACOL P, V43, P268, DOI 10.1111/1440 1681.12513
   Choi EM, 2016, J AGR FOOD CHEM, V64, P226, DOI 10.1021/acs.jafc.5b05157
   Choi EM, 2012, INFLAMMATION, V35, P1204, DOI 10.1007/s10753 012 9430 0
   de Vries F, 2007, J INTERN MED, V261, P170, DOI 10.1111/j.1365 2796.2006.01754.x
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Fang JX, 2016, EUR J ORAL SCI, V124, P241, DOI 10.1111/eos.12270
   Frenkel B, 2015, ADV EXP MED BIOL, V872, P179, DOI 10.1007/978 1 4939 2895 8_8
   Giusti A, 2010, BONE, V47, P169, DOI 10.1016/j.bone.2010.05.019
   Gómez Puerto MC, 2016, AUTOPHAGY, V12, P1804, DOI 10.1080/15548627.2016.1203484
   Hartmann K, 2016, PHYSIOL REV, V96, P409, DOI 10.1152/physrev.00011.2015
   Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006
   Huang Q, 2015, BONE, V73, P132, DOI 10.1016/j.bone.2014.12.059
   Kalak R, 2009, BONE, V45, P61, DOI 10.1016/j.bone.2009.03.673
   Kim J, 2015, J GINSENG RES, V39, P46, DOI 10.1016/j.jgr.2014.06.001
   Liang WN, 2012, INT J MOL MED, V30, P889, DOI 10.3892/ijmm.2012.1079
   Lin H, 2014, DRUG DES DEV THER, V8, P973, DOI 10.2147/DDDT.S65410
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018 016 2223 0
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Pellegrini GG, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070423
   Peng ZW, 2015, NEUROCHEM RES, V40, P661, DOI 10.1007/s11064 015 1513 5
   Qu LL, 2016, PHYTOTHER RES, V30, P402, DOI 10.1002/ptr.5541
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Sun YX, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929 015 0212 5
   Sun YX, 2015, BONE, V74, P1, DOI 10.1016/j.bone.2014.12.066
   Wang XL, 2014, LIFE SCI, V114, P77, DOI 10.1016/j.lfs.2014.08.004
   Yu SB, 2013, BONE, V56, P234, DOI 10.1016/j.bone.2013.06.019
   Yuan ZY, 2016, CURR STEM CELL RES T, V11, P216, DOI 10.2174/1574888X10666150519093429
   Zhang ZC, 2013, J ASIAN NAT PROD RES, V15, P619, DOI 10.1080/10286020.2013.791286
   Zhen YF, 2014, J CELL PHYSIOL, V229, P1475, DOI 10.1002/jcp.24589
   Zheng HF, 2014, CHINESE MED J PEKING, V127, P3926, DOI 10.3760/cma.j.issn.0366 6999.20141371
   Zhuang HL, 2016, CURR STEM CELL RES T, V11, P255, DOI 10.2174/1574888X10666150531173309
NR 38
TC 46
Z9 52
U1 0
U2 30
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD APR
PY 2018
VL 41
IS 4
BP 2059
EP 2069
DI 10.3892/ijmm.2018.3414
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FY9BQ
UT WOS:000427160600028
PM 29393365
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Glenjen, NI
   Hatfield, K
   Bruserud, O
AF Glenjen, NI
   Hatfield, K
   Bruserud, O
TI Coculture of native human acute myelogenous leukemia blasts with
   fibroblasts and osteoblasts results in an increase of vascular
   endothelial growth factor levels
SO EUROPEAN JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE acute myelogenous leukemia; angiogenesis; vascular endothelial growth
   factor
ID ACUTE MYELOID LEUKEMIA; IN VITRO CULTURE; OSTEOSARCOMA CELL LINE;
   SERUM FREE MEDIA; MYELODYSPLASTIC SYNDROMES; INCREASED ANGIOGENESIS;
   BONE MARROW; AML CELLS; PROLIFERATION; EXPRESSION
AB Objectives: Angiogenesis seems important in the development of acute myelogenous leukemia (AML). Proangiogenic vascular endothelial growth factor (VEGF) is constitutively secreted by the AML blasts for a subset of patients, but it can also be released by non leukemic bone marrow cells. Methods: VEGF levels were determined after coculture of native human AML blasts with fibroblast lines, osteoblastic sarcoma cell lines, normal bone marrow stromal cells and normal osteoblasts. Cultures were prepared with leukemic and non leukemic cells separated by a semipermeable membrane or in direct contact. Results: The non leukemic cells usually showed higher spontaneous VEGF release than AML cell populations. Coculture of AML blasts with HFL1 fibroblasts caused a supra additive increase of VEGF levels when the cell populations were cultured separately, and the increase was also observed when cells were cultured in direct contact. An increase was also observed when AML blasts were cultured with osteoblastic sarcoma cells, normal bone marrow stromal cells and normal osteoblasts. Coculture had divergent effects on VEGF mRNA levels both for leukemic and non leukemic cells, but increased mRNA levels were commonly observed especially for the non leukemic cells. Cytokine inhibition experiments suggest that IL1 is important for the VEGF increasing crosstalk, whereas the mechanisms are probably heterogeneous for coculture with osteoblasts. Conclusion: The bi directional crosstalk via local cytokine networks between AML blasts and non leukemic cells results in increased local VEGF levels, an observation suggesting that VEGF targeting antiangiogenic therapy should be considered as a general therapeutic strategy in AML.
C1 Haukeland Hosp, Dept Med, Div Hematol, N 5021 Bergen, Norway.
   Univ Bergen, Bergen, Norway.
C3 University of Bergen; Haukeland University Hospital; University of
   Bergen
RP Haukeland Hosp, Dept Med, Div Hematol, N 5021 Bergen, Norway.
EM oystein.bruserud@haukeland.no
CR Aguayo A, 2000, BLOOD, V96, P2240, DOI 10.1182/blood.V96.6.2240.h8002240_2240_2245
   Aguayo A, 1999, BLOOD, V94, P3717, DOI 10.1182/blood.V94.11.3717.423k09_3717_3721
   Aguayo A, 2002, CANCER AM CANCER SOC, V95, P1923, DOI 10.1002/cncr.10900
   Bautz F, 2000, EXP HEMATOL, V28, P700, DOI 10.1016/S0301 472X(00)00168 5
   Brunner B, 2002, J HEMATOTH STEM CELL, V11, P119, DOI 10.1089/152581602753448586
   Bruserud O, 2004, HAEMATOLOGICA, V89, P391
   Bruserud O, 2003, LEUKEMIA RES, V27, P455, DOI 10.1016/S0145 2126(02)00227 8
   Bruserud O, 2002, HAEMATOLOGICA, V87, P584
   BRUSERUD O, 1992, ACTA ONCOL, V31, P53, DOI 10.3109/02841869209088266
   Bruserud O, 2000, J HEMATOTH STEM CELL, V9, P923, DOI 10.1089/152581600750062372
   Bruserud O, 2001, STEM CELLS, V19, P1, DOI 10.1634/stemcells.19 1 1
   Chavakis E, 2002, ARTERIOSCL THROM VAS, V22, P887, DOI 10.1161/01.ATV.0000017728.55907.A9
   de Bont ESJM, 2002, CLIN CANCER RES, V8, P2856
   de Bont ESJM, 2001, MED PEDIATR ONCOL, V37, P511, DOI 10.1002/mpo.1244
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   Fiedler W, 1997, BLOOD, V89, P1870, DOI 10.1182/blood.V89.6.1870
   GLENJEN NI, IN PRESS INT J CANC
   Hussong JW, 2000, BLOOD, V95, P309
   Jeha S, 2002, LEUKEMIA RES, V26, P399, DOI 10.1016/S0145 2126(01)00149 7
   Lai B, 2002, CANCER, V94, P14, DOI 10.1002/cncr.10200
   Lee JJ, 2001, LEUKEMIA RES, V25, P1067, DOI 10.1016/S0145 2126(01)00082 0
   Litwin C, 2002, AM J HEMATOL, V70, P22, DOI 10.1002/ajh.10092
   Löwenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407
   Mesters RM, 2001, BLOOD, V98, P241, DOI 10.1182/blood.V98.1.241
   Nelissen JMDT, 2000, EXP HEMATOL, V28, P422, DOI 10.1016/S0301 472X(00)00127 2
   Padró T, 2002, LEUKEMIA, V16, P1302, DOI 10.1038/sj.leu.2402534
   Padró T, 2000, BLOOD, V95, P2637, DOI 10.1182/blood.V95.8.2637.008k07_2637_2644
   Rochet N, 2003, EUR J HAEMATOL, V70, P43, DOI 10.1034/j.1600 0609.2003.02766.x
   Rochet N, 1999, INT J CANCER, V82, P282, DOI 10.1002/(SICI)1097 0215(19990719)82:2<282::AID IJC20>3.0.CO;2 R
   Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169
   Weimar IS, 1998, LEUKEMIA, V12, P1195, DOI 10.1038/sj.leu.2401080
NR 32
TC 21
Z9 22
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0902 4441
EI 1600 0609
J9 EUR J HAEMATOL
JI Eur. J. Haematol.
PD JAN
PY 2005
VL 74
IS 1
BP 24
EP 34
DI 10.1111/j.1600 0609.2004.00333.x
PG 11
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 882RM
UT WOS:000225956000005
PM 15613103
DA 2025 08 17
ER

PT J
AU Ha, YJ
   Ma, XJ
   Li, SK
   Li, T
   Li, ZH
   Qian, YH
   Shafiq, M
   Wang, JW
   Zhou, XJ
   He, CL
AF Ha, Yujie
   Ma, Xiaojun
   Li, Shikai
   Li, Tao
   Li, Zhihui
   Qian, Yuhan
   Shafiq, Muhammad
   Wang, Jinwu
   Zhou, Xiaojun
   He, Chuanglong
TI Bone Microenvironment Mimetic Scaffolds with Hierarchical Microstructure
   for Enhanced Vascularization and Bone Regeneration
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE bone microenvironment; bone regeneration; dual drug delivery;
   hierarchical microstructures; vascularization
ID MESENCHYMAL STEM CELLS; FORMING PEPTIDE 1; TISSUE; OSTEOGENESIS;
   STIMULATION; NETWORKS; ANGIOGENESIS; CONSTRUCTION; PROMOTE; REPAIR
AB Microchannel networks within engineered 3D scaffold can allow nutrient exchange and rapid blood vessels formation. However, fabrication of a bone microenvironment mimicking scaffold with hierarchical micro/nanofibrous and microchannel structures is still a challenge. Herein, inspired by structural and functional cues of bone remodeling, a microchannel networks enriched nanofibrous scaffold by using 3D printing and thermally induced phase separation techniques, which can facilitate cells migration and nutrients transportation, is developed. The customizable vascular like structure of polycaprolactone within the nanofibrous gelatin silica scaffold is fabricated using 3D printed sacrificial templates, while dimethyloxalylglycine (DMOG) loaded mesoporous silica nanoparticles (MSNs) located on the scaffold surface and bone forming peptide 1 (BFP) loaded MSNs embedded in the scaffold are implemented for sequential release of DMOG and BFP. The cell experiments show that dual drug delivery scaffold (DBM/GP) promotes angiogenesis by stimulating migration, tube formation, and angiogenesis related genes/protein expression of endothelial cells, and osteogenesis by promoting osteo related genes expression and mineral deposition of osteoblasts. Additionally, DBM/GP scaffold facilitates the angiogenic activity of osteoblasts by activating phosphatidylinositol 3 kinase/protein kinase B/hypoxia inducible factor 1 alpha pathway. Furthermore, enhanced vascularization and bone regeneration of DBM/GP scaffold are demonstrated via subcutaneous and skull defect models. Overall, this study reveals that the bone microenvironment mimetic dual drug delivery scaffold provides a promising strategy for bone defects treatment.
C1 [Ha, Yujie; Li, Shikai; Li, Zhihui; Qian, Yuhan; Shafiq, Muhammad; Zhou, Xiaojun; He, Chuanglong] Donghua Univ, Coll Chem Chem Engn & Biotechnol, Shanghai Engn Res Ctr Nanobiomat & Regenerat Med, Shanghai 201620, Peoples R China.
   [Ma, Xiaojun] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Orthoped, Shanghai 200080, Peoples R China.
   [Li, Tao; Wang, Jinwu] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants,Dept Orthopae, Shanghai 200011, Peoples R China.
C3 Donghua University; Shanghai Jiao Tong University; Shanghai Jiao Tong
   University
RP Zhou, XJ; He, CL (通讯作者)，Donghua Univ, Coll Chem Chem Engn & Biotechnol, Shanghai Engn Res Ctr Nanobiomat & Regenerat Med, Shanghai 201620, Peoples R China.
EM zxj@dhu.edu.cn; hcl@dhu.edu.cn
RI Wang, Jinwu/AAG 4431 2021; He, Chuanglong/C 2976 2011; ma,
   xiaojun/MFH 4215 2025; li, shikai/B 9317 2009; Shafiq,
   Muhammad/AHE 0800 2022; Zhou, Xiaojun/ABA 5017 2020; Li,
   Tao/IYS 7077 2023
OI Zhou, Xiaojun/0000 0001 5040 8053; Shafiq, Muhammad/0000 0002 5887 5032;
   He, Chuanglong/0000 0001 8330 8542; 
FU National Natural Science Foundation of China [32071350, 32171404,
   81702124, 82072969]; Natural Science Foundation of Shanghai
   [21ZR1403100]; Fundamental Research Funds for the Central Universities
   [2232021D 10, 2232018A3 07, 2232019A3 06]; International Cooperation
   Fund of the Science and Technology Commission of Shanghai Municipality
   [19440741600]; Science and Technology Commission of Shanghai
   Municipality [20DZ2254900]; Shanghai Jiao Tong University School of
   Medicine [HKDL[2017]129]
FX Y.H. and X.M. contributed equally to this work. This study was supported
   by the National Natural Science Foundation of China (Nos. 32071350,
   32171404, 81702124, and 82072969), Natural Science Foundation of
   Shanghai (No. 21ZR1403100), Fundamental Research Funds for the Central
   Universities (Nos. 2232021D 10, 2232018A3 07, and 2232019A3 06),
   International Cooperation Fund of the Science and Technology Commission
   of Shanghai Municipality (No. 19440741600), and Science and Technology
   Commission of Shanghai Municipality (No. 20DZ2254900). Bone
   marrow derived mesenchymal stem cells (BMSCs) were isolated from femur
   and tibia of Sprague Dawley (SD) rats as previously reported
   procedures,[7] which was performed in compliance with the Institutional
   Animal Care and Use Committees (IACUC) guidelines. All the experimental
   animal procedures were performed in accordance with the Guidelines for
   Care and Use of Laboratory Animals and approved by the Animal Care and
   Welfare Committee of Shanghai Ninth People's Hospital, Shanghai Jiao
   Tong University School of Medicine (No: HKDL[2017]129).
CR Chen L, 2019, WIRES NANOMED NANOBI, V11, DOI 10.1002/wnan.1573
   Chu LY, 2018, J MATER CHEM B, V6, P1658, DOI 10.1039/c7tb03353b
   Cui HT, 2016, ADV SCI, V3, DOI 10.1002/advs.201600058
   Dai QY, 2021, BIOMATER SCI UK, V9, P5519, DOI 10.1039/d1bm00870f
   Du YY, 2019, BIOMATERIALS, V218, DOI 10.1016/j.biomaterials.2019.119334
   Feng C, 2021, ACTA BIOMATER, V119, P419, DOI 10.1016/j.actbio.2020.11.010
   Geng MR, 2021, BIOMATER SCI UK, V9, P2631, DOI 10.1039/d0bm02058c
   Grigoryan B, 2019, SCIENCE, V364, P458, DOI 10.1126/science.aav9750
   Gu JN, 2021, BIOACT MATER, V6, P3254, DOI 10.1016/j.bioactmat.2021.02.033
   Jahangir S, 2019, J MATER SCI MATER M, V30, DOI 10.1007/s10856 018 6202 x
   Kang MS, 2018, BIOMATERIALS, V162, P183, DOI 10.1016/j.biomaterials.2018.02.005
   Kim HK, 2012, BIOMATERIALS, V33, P7057, DOI 10.1016/j.biomaterials.2012.06.036
   Kinstlinger IS, 2020, NAT BIOMED ENG, V4, P916, DOI 10.1038/s41551 020 0566 1
   Kong N, 2014, J MATER CHEM B, V2, P1100, DOI 10.1039/c3tb21529f
   Lee SJ, 2019, J COLLOID INTERF SCI, V539, P468, DOI 10.1016/j.jcis.2018.12.097
   Lei B, 2012, J MATER CHEM, V22, P14133, DOI 10.1039/c2jm31290e
   Lei D, 2019, MATER HORIZ, V6, P1197, DOI 10.1039/c9mh00174c
   Li HY, 2013, ACTA BIOMATER, V9, P5379, DOI 10.1016/j.actbio.2012.10.019
   Li JK, 2020, NANO RES, V13, P2268, DOI 10.1007/s12274 020 2846 1
   Li S, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202102685
   Li S, 2019, MAT SCI ENG C MATER, V104, DOI 10.1016/j.msec.2019.109936
   Li Y, 2020, J BIOMED MATER RES B, V108, P2167, DOI 10.1002/jbm.b.34555
   Li Y, 2017, J MATER CHEM B, V5, P7153, DOI 10.1039/c7tb01732d
   Liang B, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1410 y
   Liang QF, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202001485
   Liu Y, 2016, SMALL, V12, P4611, DOI 10.1002/smll.201600626
   Luo YX, 2022, CHEM ENG J, V430, DOI 10.1016/j.cej.2021.132926
   Luo ZY, 2018, BIOMATERIALS, V163, P25, DOI 10.1016/j.biomaterials.2018.02.025
   Ma WP, 2021, BIOMATERIALS, V279, DOI 10.1016/j.biomaterials.2021.121225
   Ma YX, 2022, BIOACT MATER, V9, P475, DOI 10.1016/j.bioactmat.2021.07.016
   Martino MM, 2014, SCIENCE, V343, P885, DOI 10.1126/science.1247663
   Miller JS, 2012, NAT MATER, V11, P768, DOI [10.1038/NMAT3357, 10.1038/nmat3357]
   Noor N, 2019, ADV SCI, V6, DOI 10.1002/advs.201900344
   Palikuqi B, 2020, NATURE, V585, P426, DOI 10.1038/s41586 020 2712 z
   Qi X, 2017, SCI REP UK, V7, DOI 10.1038/srep42820
   Qu TJ, 2013, J MATER CHEM B, V1, P4764, DOI 10.1039/c3tb21002b
   Rafique M, 2021, BIOMATERIALS, V271, DOI 10.1016/j.biomaterials.2021.120746
   Ren XZ, 2018, ACTA BIOMATER, V70, P140, DOI 10.1016/j.actbio.2018.02.010
   Shang LL, 2021, BIOACT MATER, V6, P1175, DOI 10.1016/j.bioactmat.2020.10.010
   Shi MC, 2015, ACTA BIOMATER, V21, P178, DOI 10.1016/j.actbio.2015.04.019
   Szklanny AA, 2021, ADV MATER, V33, DOI 10.1002/adma.202102661
   Tang W, 2020, BIOMATERIALS, V232, DOI 10.1016/j.biomaterials.2019.119645
   Tayalia P, 2009, ADV MATER, V21, P3269, DOI 10.1002/adma.200900241
   Velasco Hogan A, 2018, ADV MATER, V30, DOI 10.1002/adma.201800940
   Wang HX, 2018, J BIOMED MATER RES A, V106, P1008, DOI 10.1002/jbm.a.36287
   Wang SJ, 2019, ADV MATER, V31, DOI 10.1002/adma.201904341
   Wang WH, 2017, BIOACT MATER, V2, P224, DOI 10.1016/j.bioactmat.2017.05.007
   Wang XT, 2021, CHEM ENG J, V413, DOI 10.1016/j.cej.2020.127413
   Wu L, 2020, BIOMATERIALS, V227, DOI 10.1016/j.biomaterials.2019.119555
   Wu Q, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120553
   Yu T, 2016, ADV FUNCT MATER, V26, P6719, DOI 10.1002/adfm.201602631
   Zhang JY, 2016, INT J BIOL SCI, V12, P639, DOI 10.7150/ijbs.14025
   Zhao PP, 2019, CHEM ENG J, V359, P1120, DOI 10.1016/j.cej.2018.11.071
   Zhou BJ, 2020, STEM CELL REV REP, V16, P702, DOI 10.1007/s12015 019 09947 7
   Zhou XJ, 2018, J MATER CHEM B, V6, P740, DOI 10.1039/c7tb01246b
NR 55
TC 155
Z9 162
U1 35
U2 522
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD MAY
PY 2022
VL 32
IS 20
AR 2200011
DI 10.1002/adfm.202200011
EA FEB 2022
PG 14
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA 1F2MN
UT WOS:000752966400001
DA 2025 08 17
ER

PT J
AU Komaba, H
   Fukagawa, M
AF Komaba, Hirotaka
   Fukagawa, Masafumi
CA KRN1493 Study Grp
TI Impact of Cinacalcet Hydrochloride on the Achievement of the Japanese
   Society for Dialysis Therapy (JSDT) Guideline Targets: A post hoc
   Analysis of the KRN1493 Study
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article
DE Calcimimetics; Cinacalcet; JSDT guidelines; PTH; Secondary
   hyperparathyroidism
ID PARATHYROID HORMONE LEVELS; STAGE RENAL DISEASE; SECONDARY
   HYPERPARATHYROIDISM; HEMODIALYSIS PATIENTS; CALCIMIMETIC AGENT;
   CARDIOVASCULAR EVENTS; MINERAL METABOLISM; BONE METABOLISM;
   COST UTILITY; CALCIUM
AB The Japanese Society for Dialysis Therapy (JSDT) released the Guidelines for the Management of Secondary Hyperparathyroidism in Chronic Dialysis Patients (JSDT guidelines), which set target ranges for calcium (8.4 10.0 mg/dL), phosphorus (3.5 6.0 mg/dL) and intact parathyroid hormone (PTH) (60 180 pg/mL); however, achieving the guideline targets is difficult and challenging. In this post hoc analysis, we evaluate the impact of cinacalcet on the achievement of the JSDT targets. After a treatment period of 74 weeks, 26% of the cinacalcet group achieved intact PTH levels within the target ranges (P < 0.001, compared with the control group). A significantly greater proportion achieved the targets for calcium and phosphorus, as compared with control patients (65 % vs. 45%, P=0.015; 68% vs. 47%. P=0.009, respectively). The proportion of patients in whom serum calcium and phosphorus were controlled to within the target ranges increased from 21% at baseline to 44% (P<0.001). The combined targets of three parameters were achieved by 17% of cinacalcet treated patients, while none of the control patients achieved these parameters simultaneously (P < 0.001). Cinacalcet treatment also efficaciously reduced elevated serum calcium and phosphorus levels. Even in patients with baseline intact PTH levels >500 pg/mL, where parathyroidectomy has been recommended in the JSDT guidelines. 20% of the cinacalcet group achieved the target intact PTH levels. Longer term cinacalcet treatment aimed at the JSDT targets may lead to further reductions in PTH secretion. Further studies are required to examine the potential benefit of cinacalcet and to revise the current guidelines relating to adequate use of cinacalcet.
C1 [Fukagawa, Masafumi] Kobe Univ, Sch Med, Div Nephrol, Chuo Ku, Kobe, Hyogo 6500017, Japan.
   Kobe Univ, Sch Med, Kidney Ctr, Kobe, Hyogo 6500017, Japan.
C3 Kobe University; Kobe University
RP Fukagawa, M (通讯作者)，Kobe Univ, Sch Med, Div Nephrol, Chuo Ku, 7 5 2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM fukagawa@med.kobe u.ac.jp
RI Komaba, Hirotaka/C 9199 2011
OI Komaba, Hirotaka/0000 0002 1704 4507; Fukagawa,
   Masafumi/0000 0002 7832 2339
FU Kirin Pharma Co., Ltd
FX We wish to thank the members of the KRN1493 Study Group listed
   previously (22,23). This study was supported by Kirin Pharma Co., Ltd.
CR Akiba T, 2008, THER APHER DIAL, V12, P117, DOI 10.1111/j.1744 9987.2008.00556.x
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Chertow GM, 2007, CLIN J AM SOC NEPHRO, V2, P898, DOI 10.2215/CJN.04381206
   Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523 1755.2005.00596.x
   Arenas MD, 2007, NEPHROL DIAL TRANSPL, V22, P1639, DOI 10.1093/ndt/gfl840
   Drüeke TB, 2000, J AM SOC NEPHROL, V11, P1141, DOI 10.1681/ASN.V1161141
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Eriguchi R, 2008, CLIN KIDNEY J, V1, P218, DOI 10.1093/ndtplus/sfn058
   Fox J, 1999, ENDOCRINE, V10, P97, DOI 10.1385/ENDO:10:2:97
   Fukagawa M, 2006, KIDNEY INT, V70, pS3, DOI 10.1038/sj.ki.5001594
   Fukagawa M, 2008, NEPHROL DIAL TRANSPL, V23, P328, DOI 10.1093/ndt/gfm534
   FUKUDA N, 1993, J CLIN INVEST, V92, P1436, DOI 10.1172/JCI116720
   Garside R, 2007, NEPHROL DIAL TRANSPL, V22, P1428, DOI 10.1093/ndt/gfl774
   Goodman WG, 2000, KIDNEY INT, V58, P436, DOI 10.1046/j.1523 1755.2000.00183.x
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Goodman WG, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341017
   JAPANESE S, THER APHER IN PRESS
   Jean G, 2007, NEPHROL DIAL TRANSPL, V22, P2102, DOI 10.1093/ndt/gfm172
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Kifor O, 1996, J CLIN ENDOCR METAB, V81, P1598, DOI 10.1210/jc.81.4.1598
   Kimata N, 2007, THER APHER DIAL, V11, pS62, DOI 10.1111/j.1744 9987.2007.00518.x
   Komaba H, 2008, THER APHER DIAL, V12, P42, DOI 10.1111/j.1744 9987.2007.00539.x
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Maung HM, 2001, AM J KIDNEY DIS, V37, P532
   Messa P, 2008, CLIN J AM SOC NEPHRO, V3, P36, DOI 10.2215/CJN.03591006
   Moe SM, 2005, NEPHROL DIAL TRANSPL, V20, P2186, DOI 10.1093/ndt/gfh966
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Nakai S, 2008, THER APHER DIAL, V12, P49, DOI 10.1111/j.1744 9987.2007.00540.x
   Nakai S, 2007, THER APHER DIAL, V11, P411, DOI 10.1111/j.1744 9987.2007.00523.x
   Narayan R, 2007, AM J KIDNEY DIS, V49, P801, DOI 10.1053/j.ajkd.2007.03.009
   Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040
   Peacock M, 2005, J CLIN ENDOCR METAB, V90, P135, DOI 10.1210/jc.2004 0842
   Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD
   Serra AL, 2007, NEPHROL DIAL TRANSPL, V22, P577, DOI 10.1093/ndt/gfl560
   Slatopolsky E, 1999, KIDNEY INT, V56, pS14, DOI 10.1046/j.1523 1755.1999.07304.x
   Srinivas TR, 2006, CLIN J AM SOC NEPHRO, V1, P323, DOI 10.2215/CJN.00500705
   Tominaga Y, 1997, SEMIN SURG ONCOL, V13, P78, DOI 10.1002/(SICI)1098 2388(199703/04)13:2<78::AID SSU3>3.0.CO;2 Z
   Tominaga Y, 2007, THER APHER DIAL, V11, P266, DOI 10.1111/j.1744 9987.2007.00489.x
NR 39
TC 15
Z9 15
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1744 9979
EI 1744 9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
PD OCT
PY 2008
VL 12
SU 1
BP S44
EP S49
DI 10.1111/j.1744 9987.2008.00631.x
PG 6
WC Hematology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Urology & Nephrology
GA 410GZ
UT WOS:000263566800009
PM 19032527
OA Bronze
DA 2025 08 17
ER

PT J
AU Kishiya, M
   Sawada, T
   Kanemaru, K
   Kudo, H
   Numasawa, T
   Yokoyama, T
   Tanaka, S
   Motomura, S
   Ueyama, K
   Harata, S
   Toh, S
   Furukawa, KI
AF Kishiya, Masaki
   Sawada, Toshitada
   Kanemaru, Kohta
   Kudo, Hitoshi
   Numasawa, Takuya
   Yokoyama, Toru
   Tanaka, Sunao
   Motomura, Shigeru
   Ueyama, Kazumasa
   Harata, Seiko
   Toh, Satoshi
   Furukawa, Ken Ichi
TI A functional RNAi screen for runx2 regulated genes associated with
   ectopic bone formation in human spinal ligaments
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE runx2/Cbfa1; angiopoletin 1; microarray; osteochondrogenesis;
   ossification of the posterior longitudinal ligament (OPLL)
ID POSTERIOR LONGITUDINAL LIGAMENT; IDIOPATHIC SKELETAL HYPEROSTOSIS;
   TRANSFORMING GROWTH FACTOR BETA 1 GENE; MESENCHYMAL STEM CELLS;
   OPEN DOOR LAMINOPLASTY; CERVICAL SPINE; OSTEOBLAST DIFFERENTIATION;
   MECHANICAL STRESS; OSTEOGENIC DIFFERENTIATION; PHARMACOLOGICAL RESEARCH
AB Ossification of the posterior longitudinal ligament of the spine (OPLL) is characterized by ectopic ossification in the spinal ligaments, which enlarges with time and compresses the spinal cord, resulting in serious neurological symptoms. We previously reported that Runx2 expression was enhanced in spinal ligament cells from OPLL patients (OPLL cells). To clarify genes regulated by Runx2, Runx2 expression was first enhanced by culturing primary OPLL cells in osteogenic medium (OS induction) and then inhibited by siRNAs targeted to Runx2. DNA microarray demonstrated that in addition to chondrogenic factors such as connective tissue growth factor and cartilage oligomeric matrix protein, anglopoictin 1 was also significantly increased by OS induction and decreased by siRNAs for Runx2 in OPLL cells, suggesting that these genes are regulated by Runx2. However, these changes were not observed in non OPLL control cells (from cervical spondylotic myelopathy patients). Furthermore, Runx2 was not decreased by siRNAs for angiopoletin 1. OS induction and RNAi inhibition of angiopoletin 1 expression was also observed in osteoblasts. Both siRNAs for Runx2 and angiopoletin 1 completely inhibited aggrecan 1 expression. These results suggest that anglopoietin 1 is downstream of Runx2 in both OPLL primary cells and osteoblasts. Angiopoietin 1 may play an important role in ectopic ossification.
C1 [Kishiya, Masaki; Sawada, Toshitada; Kanemaru, Kohta; Motomura, Shigeru; Furukawa, Ken Ichi] Hirosaki Univ, Grad Sch Med, Dept Pharmacol, Hirosaki, Aomori 0368562, Japan.
   [Kishiya, Masaki; Sawada, Toshitada; Kudo, Hitoshi; Numasawa, Takuya; Yokoyama, Toru; Tanaka, Sunao] Hirosaki Univ, Grad Sch Med, Dept Orthopaed Surg, Hirosaki, Aomori 0368562, Japan.
   [Ueyama, Kazumasa] Hirosaki Mem Hosp, Hirosaki, Aomori 0368076, Japan.
   [Harata, Seiko] Aomori Prefectural Cent Hosp, Aomori 0308553, Japan.
C3 Hirosaki University; Hirosaki University
RP Furukawa, KI (通讯作者)，Hirosaki Univ, Grad Sch Med, Dept Pharmacol, Hirosaki, Aomori 0368562, Japan.
EM furukawa@cc.hirosaki u.ac.jp
RI Furukawa, Ken Ichi/N 9244 2014; Toh, Satoshi/K 5737 2013
CR Chiba K, 2006, SPINE, V31, P2998, DOI 10.1097/01.brs.0000250307.78987.6b
   Collett GDM, 2005, CIRC RES, V96, P930, DOI 10.1161/01.RES.0000163634.51301.0d
   DUCY P, 1995, MOL CELL BIOL, V15, P1858
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   El Miedany YM, 2000, CLIN EXP RHEUMATOL, V18, P193
   Furukawa K, 2006, J PHARMACOL SCI, V100, P201, DOI 10.1254/jphs.FMJ05004X4
   Furushima K, 2002, J BONE MINER RES, V17, P128, DOI 10.1359/jbmr.2002.17.1.128
   Gibson G, 1998, MICROSC RES TECHNIQ, V43, P191, DOI 10.1002/(SICI)1097 0029(19981015)43:2<191::AID JEMT10>3.0.CO;2 T
   Goldring MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652
   Hall AP, 2006, TOXICOL PATHOL, V34, P131, DOI 10.1080/01926230600611836
   Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972
   Horikoshi T, 2006, HUM GENET, V119, P611, DOI 10.1007/s00439 006 0170 9
   Ikeda R, 2005, J BIOL CHEM, V280, P8523, DOI 10.1074/jbc.M409442200
   Inaba K, 1996, IN VIVO, V10, P445
   Inoue I, 2006, J PHARMACOL SCI, V100, P205, DOI 10.1254/jphs.FMJ05004X5
   Iwasaki K, 2004, CALCIFIED TISSUE INT, V74, P448, DOI 10.1007/s00223 002 0021 1
   Iwasawa T, 2006, CALCIFIED TISSUE INT, V79, P422, DOI 10.1007/s00223 006 0147 7
   Kamiya M, 2001, SPINE, V26, P1264, DOI 10.1097/00007632 200106010 00017
   Karsenty G, 1999, BONE, V25, P107, DOI 10.1016/S8756 3282(99)00111 8
   Kawaguchi Y, 2003, SPINE, V28, P1424, DOI 10.1097/00007632 200307010 00013
   Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200
   Li MQ, 2004, MICROSC RES TECHNIQ, V64, P330, DOI 10.1002/jemt.20088
   Mader R, 2005, RHEUMATOL INT, V26, P132, DOI 10.1007/s00296 004 0529 y
   Mader R, 2005, EXPERT OPIN PHARMACO, V6, P1313, DOI 10.1517/14656566.6.8.1313
   Mader R, 2004, J RHEUMATOL, V31, P620
   Mader R, 2003, ISRAEL MED ASSOC J, V5, P506
   Mader R, 2002, SEMIN ARTHRITIS RHEU, V32, P130, DOI 10.1053/sarh.2002.33726
   Maeda S, 2001, J BONE MINER RES, V16, P948, DOI 10.1359/jbmr.2001.16.5.948
   Meyer PR, 1999, CLIN ORTHOP RELAT R, P49, DOI 10.1097/00003086 199902000 00006
   Murata H, 2004, J CELL BIOCHEM, V92, P715, DOI 10.1002/jcb.20090
   Nakama S, 2006, MED MOL MORPHOL, V39, P198, DOI 10.1007/s00795 006 0338 3
   Nakamura I, 1999, HUM GENET, V104, P492, DOI 10.1007/s004390050993
   Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257
   Numasawa T, 1999, J BONE MINER RES, V14, P500, DOI 10.1359/jbmr.1999.14.4.500
   Ogawa Y, 2005, J NEUROSURG SPINE, V3, P198, DOI 10.3171/spi.2005.3.3.0198
   Ohishi H, 2003, J PHARMACOL EXP THER, V305, P818, DOI 10.1124/jpet.102.047142
   OHTSUKA K, 1986, Journal of the Japanese Orthopaedic Association, V60, P1087
   Okawa A, 1998, NAT GENET, V19, P271, DOI 10.1038/956
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   Radio NM, 2006, J PINEAL RES, V40, P332, DOI 10.1111/j.1600 079X.2006.00318.x
   RESNICK D, 1978, AM J ROENTGENOL, V130, P588, DOI 10.2214/ajr.130.3.588
   RESNICK D, 1976, RADIOLOGY, V119, P559, DOI 10.1148/119.3.559
   RESNICK D, 1978, AM J ROENTGENOL, V131, P1049, DOI 10.2214/ajr.131.6.1049
   Song J, 2006, SPINAL CORD, V44, P576, DOI 10.1038/sj.sc.3101881
   Sun LX, 2001, CANCER RES, V61, P4994
   Tahara M, 2005, SPINE, V30, P877, DOI 10.1097/01.brs.0000160686.18321.ad
   Tanaka T, 2003, AM J HUM GENET, V73, P812, DOI 10.1086/378593
   Tanno M, 2003, BONE, V33, P475, DOI 10.1016/S8756 3282(03)00204 7
   TAUKAHARA S, 2005, SPINE, V30, P2321
   Yamamoto Y, 2002, SPINE, V27, P1852, DOI 10.1097/00007632 200209010 00009
   Yamazaki Masashi, 2002, Clin Calcium, V12, P1109
NR 52
TC 22
Z9 31
U1 0
U2 4
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD MAR
PY 2008
VL 106
IS 3
BP 404
EP 414
DI 10.1254/jphs.FP0072043
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 281KN
UT WOS:000254495900012
PM 18319563
OA Bronze
DA 2025 08 17
ER

PT J
AU Eldridge, SE
   Barawi, A
   Wang, H
   Roelofs, AJ
   Kaneva, M
   Guan, ZY
   Lydon, H
   Thomas, BL
   Thorup, AS
   Fernandez, BF
   Caxaria, S
   Strachan, D
   Ali, A
   Shanmuganathan, K
   Pitzalis, C
   Whiteford, JR
   Henson, F
   McCaskie, AW
   De Bari, C
   Dell'Accio, F
AF Eldridge, Suzanne E.
   Barawi, Aida
   Wang, Hui
   Roelofs, Anke J.
   Kaneva, Magdalena
   Guan, Zeyu
   Lydon, Helen
   Thomas, Bethan L.
   Thorup, Anne Sophie
   Fernandez, Beatriz F.
   Caxaria, Sara
   Strachan, Danielle
   Ali, Ahmed
   Shanmuganathan, Kanatheepan
   Pitzalis, Costantino
   Whiteford, James R.
   Henson, Frances
   McCaskie, Andrew W.
   De Bari, Cosimo
   Dell'Accio, Francesco
TI Agrin induces long term osteochondral regeneration by supporting repair
   morphogenesis
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID AMP RESPONSE ELEMENT; ARTICULAR CARTILAGE; SYNOVIAL JOINT;
   GENE EXPRESSION; STEM CELLS; TGF BETA; OSTEOARTHRITIS; PROTEIN; LRP4;
   MAINTENANCE
AB Cartilage loss leads to osteoarthritis, the most common cause of disability for which there is no cure. Cartilage regeneration, therefore, is a priority in medicine. We report that agrin is a potent chondrogenic factor and that a single intraarticular administration of agrin induced long lasting regeneration of critical size osteochondral defects in mice, with restoration of tissue architecture and bone cartilage interface. Agrin attracted joint resident progenitor cells to the site of injury and, through simultaneous activation of CREB and suppression of canonical WNT signaling downstream of beta catenin, induced expression of the chondrogenic stem cell marker GDF5 and differentiation into stable articular chondrocytes, forming stable articular cartilage. In sheep, an agrin containing collagen gel resulted in long lasting regeneration of bone and cartilage, which promoted increased ambulatory activity. Our findings support the therapeutic use of agrin for joint surface regeneration.
C1 [Eldridge, Suzanne E.; Barawi, Aida; Kaneva, Magdalena; Guan, Zeyu; Thorup, Anne Sophie; Fernandez, Beatriz F.; Caxaria, Sara; Strachan, Danielle; Ali, Ahmed; Shanmuganathan, Kanatheepan; Pitzalis, Costantino; Dell'Accio, Francesco] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Ctr Expt Med & Rheumatol, London EC1M 6BQ, England.
   [Wang, Hui; Roelofs, Anke J.; De Bari, Cosimo] Univ Aberdeen, Aberdeen Ctr Arthrit & Musculoskeletal Hlth, Arthrit & Regenerat Med Lab, Aberdeen AB25 2ZD, Scotland.
   [Lydon, Helen; McCaskie, Andrew W.] Univ Cambridge, Addenbrookes Hosp, Dept Surg, Div Trauma & Orthopaed Surg, Cambridge CB2 2QQ, England.
   [Thomas, Bethan L.] Queen Mary Univ London, Ctr Biochem Pharmacol, Barts & London Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England.
   [Whiteford, James R.] Univ Cambridge, Dept Vet Med, Comparat Musculoskeletal Biol Grp, Madingley Rd, Cambridge CB3 0ES, England.
   [Henson, Frances] Queen Mary Univ London, Ctr Microvasc Res, Barts & London Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England.
C3 University of London; Queen Mary University London; University of
   Aberdeen; Cambridge University Hospitals NHS Foundation Trust;
   Addenbrooke's Hospital; University of Cambridge; University of London;
   Queen Mary University London; University of Cambridge; University of
   London; Queen Mary University London
RP Eldridge, SE; Dell'Accio, F (通讯作者)，Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Ctr Expt Med & Rheumatol, London EC1M 6BQ, England.
EM suzanne.e.eldridge@gmail.com; fdellaccio@gmail.com
RI ; Roelofs, Anke/ABG 5019 2021
OI Strachan, Danielle/0000 0002 9544 6341; Guan, Zeyu/0000 0003 3050 4210;
   Ali, Ahmed/0000 0002 2750 399X; Thorup, Anne Sophie/0000 0002 0435 4071;
   Whiteford, James/0000 0002 8967 7389; Caxaria, Sara/0000 0002 8434 8332;
   Fernandez, Beatriz F/0000 0002 8612 0251; Kaneva, Magdalena
   K/0000 0003 3822 749X; Eldridge, Suzanne/0000 0002 1630 6261; Pitzalis,
   Costantino/0000 0003 1326 5051; McCaskie, Andrew/0000 0001 6476 0832
FU MRC [MR/L022893/1, MR/N010973/1, MR/P026362/1]; Versus Arthritis [19667,
   21515, 20886, 21621]; Rosetrees Trust [A1205]; Medical College of St
   Bartholomew's Hospital Trust; William Harvey Research Foundation; Barts
   Charity [MGU0313] Funding Source: researchfish; Medical Research Council
   [MR/L022893/1, MC_PC_12009, 1095739, MR/K017047/1, MR/K013076/1,
   MR/N010973/1, MR/P026362/1] Funding Source: researchfish; Rosetrees
   [M380 F1] Funding Source: researchfish; Versus Arthritis [19654, 20886,
   19667] Funding Source: researchfish; MRC [MC_PC_17230, MR/R000956/1,
   MR/L022893/1, MR/N010973/1, MR/P026362/1, MR/R015635/1, MR/K013076/1]
   Funding Source: UKRI
FX We gratefully acknowledge funding support of this work by the MRC
   (MR/L022893/1, MR/N010973/1,and MR/P026362/1), Versus Arthritis (19667,
   21515, 20886, and 21621), Rosetrees Trust (A1205), the Medical College
   of St Bartholomew's Hospital Trust, and the William Harvey Research
   Foundation.
CR Altarejos JY, 2011, NAT REV MOL CELL BIO, V12, P141, DOI 10.1038/nrm3072
   Anraku Y, 2009, J BONE MINER METAB, V27, P272, DOI 10.1007/s00774 009 0038 x
   Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139
   Asai N, 2014, BIOCHEM BIOPH RES CO, V451, P302, DOI 10.1016/j.bbrc.2014.07.125
   Barth AIM, 1999, P NATL ACAD SCI USA, V96, P4947, DOI 10.1073/pnas.96.9.4947
   CAMPANELLI JT, 1991, CELL, V67, P909, DOI 10.1016/0092 8674(91)90364 5
   CAMPANELLI JT, 1992, COLD SPRING HARB SYM, V57, P461, DOI 10.1101/SQB.1992.057.01.051
   Chiamulera C, 2008, NEUROSCI LETT, V442, P234, DOI 10.1016/j.neulet.2008.07.025
   Choi HY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007930
   Comblain F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156902
   Corr M, 2008, NAT CLIN PRACT RHEUM, V4, P550, DOI 10.1038/ncprheum0904
   Curl WW, 1997, ARTHROSCOPY, V13, P456, DOI 10.1016/S0749 8063(97)90124 9
   Davidson ENB, 2006, ANN RHEUM DIS, V65, P1414, DOI 10.1136/ard.2005.045971
   Davidson ENB, 2015, ANN RHEUM DIS, V74, P1257, DOI 10.1136/annrheumdis 2013 204528
   De Bari C, 2001, ARTHRITIS RHEUM, V44, P85, DOI 10.1002/1529 0131(200101)44:1<85::AID ANR12>3.0.CO;2 6
   De Bari C, 2001, ARTHRITIS RHEUM US, V44, P1928, DOI 10.1002/1529 0131(200108)44:8<1928::AID ART331>3.0.CO;2 P
   Decker RS, 2017, SEMIN CELL DEV BIOL, V62, P50, DOI 10.1016/j.semcdb.2016.10.005
   Dell'accio F, 2010, EUR CELLS MATER, V20, P210
   Dell'Accio F, 2008, ARTHRITIS RHEUM US, V58, P1410, DOI 10.1002/art.23444
   Deshmukh V, 2019, OSTEOARTHR CARTILAGE, V27, P1347, DOI 10.1016/j.joca.2019.05.006
   Deshmukh V, 2018, OSTEOARTHR CARTILAGE, V26, P18, DOI 10.1016/j.joca.2017.08.015
   Eldridge S, 2016, ANN RHEUM DIS, V75, P1228, DOI 10.1136/annrheumdis 2015 207316
   Eltawil NM, 2009, OSTEOARTHR CARTILAGE, V17, P695, DOI 10.1016/j.joca.2008.11.003
   FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896 6273(93)90153 I
   Fitzgerald JB, 2004, J BIOL CHEM, V279, P19502, DOI 10.1074/jbc.M400437200
   GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595
   Gruber J, 2004, ARTHRITIS RHEUM US, V50, P2539, DOI 10.1002/art.20369
   Guo XZ, 2004, GENE DEV, V18, P2404, DOI 10.1101/gad.1230704
   Gwak J, 2012, CELL RES, V22, P237, DOI 10.1038/cr.2011.127
   Hartmann C, 2001, CELL, V104, P341, DOI 10.1016/S0092 8674(01)00222 7
   Hilgenberg LGW, 2004, J NEUROBIOL, V61, P289, DOI 10.1002/neu.20049
   Hiligsmann M, 2013, SEMIN ARTHRITIS RHEU, V43, P303, DOI 10.1016/j.semarthrit.2013.07.003
   Hjelle K, 2002, ARTHROSCOPY, V18, P730, DOI 10.1053/jars.2002.32839
   Koyama E, 2008, DEV BIOL, V316, P62, DOI 10.1016/j.ydbio.2008.01.012
   Long FX, 2001, DEVELOPMENT, V128, P541
   Lories RJU, 2007, ARTHRITIS RHEUM US, V56, P4095, DOI 10.1002/art.23137
   Loughlin J, 2004, P NATL ACAD SCI USA, V101, P9757, DOI 10.1073/pnas.0403456101
   LUYTEN FP, 1992, J BIOL CHEM, V267, P3691
   Monteagudo S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15889
   MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0
   Nalesso G, 2017, ANN RHEUM DIS, V76, P218, DOI 10.1136/annrheumdis 2015 208577
   Nalesso G, 2011, J CELL BIOL, V193, P551, DOI 10.1083/jcb.201011051
   PINEDA S, 1992, ACTA ANAT, V143, P335
   Pregizer SK, 2018, ANN RHEUM DIS, V77, P450, DOI 10.1136/annrheumdis 2017 212475
   Raker VK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00123
   Rapp J, 2017, RESP RES, V18, DOI 10.1186/s12931 017 0650 6
   Roelofs AJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15040
   Rountree RB, 2004, PLOS BIOL, V2, P1815, DOI 10.1371/journal.pbio.0020355
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shwartz Y, 2016, CELL REP, V15, P2577, DOI 10.1016/j.celrep.2016.05.055
   Simic P, 2004, PROG INFLAM RES, P73
   Später D, 2006, DEVELOPMENT, V133, P3039, DOI 10.1242/dev.02471
   STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0
   Thomas JT, 1997, NAT GENET, V17, P58, DOI 10.1038/ng0997 58
   Tian QB, 2006, EUR J NEUROSCI, V23, P2864, DOI 10.1111/j.1460 9568.2006.04846.x
   van Amerongen R, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007914
   van der Kraan PM, 2010, OSTEOARTHR CARTILAGE, V18, P735, DOI 10.1016/j.joca.2010.03.001
   Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960 9822(03)00240 9
   Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200
   Willert K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007864
   Xie FC, 2015, J MED CHEM, V58, P5075, DOI 10.1021/acs.jmedchem.5b00468
   Yan K, 2016, MOL MED REP, V13, P3715, DOI 10.3892/mmr.2016.5005
   Yasuhara R, 2011, LAB INVEST, V91, P1739, DOI 10.1038/labinvest.2011.144
   Yazici Y, 2017, OSTEOARTHR CARTILAGE, V25, P1598, DOI 10.1016/j.joca.2017.07.006
   Zhang B, 2008, NEURON, V60, P285, DOI 10.1016/j.neuron.2008.10.006
   Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102
NR 67
TC 45
Z9 47
U1 1
U2 34
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD SEP 2
PY 2020
VL 12
IS 559
AR eaax9086
DI 10.1126/scitranslmed.aax9086
PG 15
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA NL8HE
UT WOS:000567648800001
PM 32878982
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Cao, FM
   Yang, KD
   Qiu, S
   Li, J
   Jiang, W
   Tao, L
   Zhu, Y
AF Cao, Fangming
   Yang, Keda
   Qiu, Shui
   Li, Jie
   Jiang, Wen
   Tao, Lin
   Zhu, Yue
TI Metformin reverses oxidative stress induced mitochondrial dysfunction in
   pre osteoblasts via the EGFR/GSK 3β/calcium pathway
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE osteoporosis; metformin; mitochondrial dysfunction; GSK 3 beta; EGFR
ID POSTMENOPAUSAL OSTEOPOROSIS; BONE FORMATION; HOMEOSTASIS; DEFICIENCY;
   APOPTOSIS; BENEFITS
AB Oxidative stress is one of the main causes of osteoblast apoptosis induced by post menopausal osteoporosis. The authors previously found that metformin can reverse the loss of bone mass in post menopausal osteoporosis. The present study aimed to further clarify the effects and mechanisms of action of metformin in post menopausal osteoporosis under conditions of oxidative stress. Combined with an in depth investigation using the transcriptome database, the association between oxidative stress and mitochondrial dysfunction in post menopausal osteoporosis was confirmed. A pre osteoblast model of oxidative stress was constructed, and the apoptotic rate following the addition of hydrogen peroxide and metformin was detected using CCK 8 assay and Annexin V FITC/PI staining. Mitochondrial membrane potential was detected using the JC 1 dye, the intracellular calcium concentration was detected using Fluo 4 AM, the intracellular reactive oxygen species (ROS) level was observed using DCFH DA, and the mitochondrial superoxide level was observed using MitoSOX Red. Bay K8644 was used to increase the level of intracellular calcium. siRNA was used to interfere with the expression of glycogen synthase kinase (GSK) 3b. Western blot analysis was used to detect the expression of mitochondrial dysfunction related proteins. The results revealed that oxidative stress decreased mitochondrial membrane potential and increased intracellular ROS, mitochondrial superoxide and cytoplasmic calcium levels in pre osteoblasts; however, metformin improved mitochondrial dysfunction and reversed oxidative stress induced injury. Metformin inhibited mitochondrial permeability transition pore opening, suppressed the cytoplasmic calcium influx and reversed pre osteoblast apoptosis by promoting GSK 3b phosphorylation. Moreover, it was found that EGFR was the cell membrane receptor of metformin in pre osteoblasts, and the EGFR/GSK 3b/calcium axis played a key role in metformin reversing the oxidative stress response of pre osteoblasts in post menopausal osteoporosis. On the whole, these findings provide a pharmacological basis for the use of metformin for the treatment of post menopausal osteoporosis.
C1 [Cao, Fangming; Yang, Keda; Qiu, Shui; Li, Jie; Jiang, Wen; Tao, Lin; Zhu, Yue] China Med Univ, Dept Orthoped, Hosp 1, Shenyang 110001, Liaoning, Peoples R China.
   [Tao, Lin; Zhu, Yue] China Med Univ, Dept Orthoped, Hosp 1, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
C3 China Medical University; China Medical University
RP Tao, L; Zhu, Y (通讯作者)，China Med Univ, Dept Orthoped, Hosp 1, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
EM zhuyuedr@163.com; taolindr@163.com
RI Jiang, Wen/HJB 4471 2022; Cao, Fangming/KHC 6557 2024; Lin,
   Tao/KRO 9146 2024
OI Tao, Lin/0000 0002 1702 9833; 
FU National Natural Science Foundation of China [81472044]; Science and
   Technology Planning Project in Shenyang [20 205 2 045]
FX The present study was supported by the National Natural Science
   Foundation of China (grant no. 81472044) and the Science and Technology
   Planning Project in Shenyang (grant no. 20 205 2 045).
CR Abate M, 2020, SEMIN CELL DEV BIOL, V98, P139, DOI 10.1016/j.semcdb.2019.05.022
   Appelman Dijkstra NM, 2015, DRUGS, V75, P1049, DOI 10.1007/s40265 015 0417 7
   Arceo Mendoza R, 2021, ENDOCRIN METAB CLIN, V50, P167, DOI 10.1016/j.ecl.2021.03.009
   Bai JR, 2022, BIOMED PHARMACOTHER, V149, DOI 10.1016/j.biopha.2022.112847
   Bandeira L, 2017, ENDOCRIN METAB CLIN, V46, P207, DOI [10.1016/j.ec1.2016.11.001, 10.1016/j.ecl.2016.11.001]
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Buckley L, 2017, ARTHRITIS RHEUMATOL, V69, P1521, DOI [10.1002/art.40137, 10.1002/acr.23279]
   Cameron AR, 2016, CIRC RES, V119, P652, DOI 10.1161/CIRCRESAHA.116.308445
   Ding L, 2020, EXPERT OPIN THER TAR, V24, P417, DOI 10.1080/14728222.2020.1743681
   Ensrud Kristine E, 2021, JAMA, V325, P96, DOI 10.1001/jama.2020.2923
   Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018
   Hu ZY, 2016, CARDIOVASC RES, V110, P227, DOI 10.1093/cvr/cvw048
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Karch J, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw4597
   Kespohl B, 2021, CYTOKINE GROWTH F R, V60, P18, DOI 10.1016/j.cytogfr.2021.04.002
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim DH, 2021, PROG LIPID RES, V83, DOI 10.1016/j.plipres.2021.101115
   Kulkarni AS, 2020, CELL METAB, V32, P15, DOI 10.1016/j.cmet.2020.04.001
   Lal H, 2015, CIRC RES, V116, P138, DOI 10.1161/CIRCRESAHA.116.303613
   Li J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2159 z
   Lin JT, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9203934
   Liu GQ, 2019, FASEB J, V33, P11137, DOI 10.1096/fj.201900436RR
   Lv ZQ, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00191
   Mohamad NV, 2020, ENDOCR METAB IMMUNE, V20, P1478, DOI 10.2174/1871530320666200604160614
   Morciano G, 2021, BIOL REV, V96, P2489, DOI 10.1111/brv.12764
   Nagini S, 2019, SEMIN CANCER BIOL, V56, P25, DOI 10.1016/j.semcancer.2017.12.010
   NavaneethaKrishnan S, 2020, ONCOGENE, V39, P2797, DOI 10.1038/s41388 020 1188 5
   Panel M, 2018, AGING CELL, V17, DOI 10.1111/acel.12793
   Phukan S, 2010, BRIT J PHARMACOL, V160, P1, DOI 10.1111/j.1476 5381.2010.00661.x
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Roskoski R Jr, 2019, PHARMACOL RES, V139, P395, DOI 10.1016/j.phrs.2018.11.014
   Sanchez Rangel E, 2017, DIABETOLOGIA, V60, P1586, DOI 10.1007/s00125 017 4336 x
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580 020 0230 3
   Tseng CH, 2021, EUR J ENDOCRINOL, V184, P299, DOI 10.1530/EJE 20 0507
   Vatner SF, 2020, AGEING RES REV, V64, DOI 10.1016/j.arr.2020.101194
   Wang FS, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10091394
   Wang HY, 2022, CELL BIOL TOXICOL, V38, P531, DOI 10.1007/s10565 021 09644 7
   Wang SH, 2016, J BIOL CHEM, V291, P21085, DOI 10.1074/jbc.M116.717892
   Wang XP, 2021, MOLECULES, V26, DOI 10.3390/molecules26051460
   Wu Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.427
   Yang KD, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.829830
   Yang KD, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10751
   Yang TC, 2016, OSTEOPOROSIS INT, V27, P2281, DOI 10.1007/s00198 015 3470 x
   Zhang R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0641 7
   Zhang T, 2022, AUTOPHAGY, V18, P1216, DOI 10.1080/15548627.2021.1975914
   Zhang Z, 2020, INT J BIOL MACROMOL, V156, P730, DOI 10.1016/j.ijbiomac.2020.04.103
   Zhao FL, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 020 00854 w
   Zhu PJ, 2018, REDOX BIOL, V16, P157, DOI 10.1016/j.redox.2018.02.019
NR 48
TC 12
Z9 12
U1 3
U2 38
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD APR
PY 2023
VL 51
IS 4
AR 36
DI 10.3892/ijmm.2023.5239
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA C3GH5
UT WOS:000960836200001
PM 36999607
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU He, HQ
   Law, BYK
   Zhang, N
   Qiu, CL
   Qu, YQ
   Wu, AG
   Han, Y
   Song, Q
   Zheng, WL
   Liu, Y
   He, YZ
   Wong, VKW
AF He, Hu Qiang
   Law, Betty Yuen Kwan
   Zhang, Ni
   Qiu, Cong ling
   Qu, Yuan Qing
   Wu, An Guo
   Han, Yu
   Song, Qi
   Zheng, Wen Lu
   Liu, Yong
   He, Yan Zheng
   Wong, Vincent Kam Wai
TI Bavachin Protects Human Aortic Smooth Muscle Cells Against
   β Glycerophosphate Mediated Vascular Calcification and Apoptosis
   via Activation of mTOR Dependent Autophagy and Suppression of
   β Catenin Signaling
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE vascular calcification; autophagy; Wnt/beta catenin; Apoptosis; Atg7
ID OSTEOBLASTIC DIFFERENTIATION; OXIDATIVE STRESS; MATRIX VESICLES;
   DISEASE; UPDATE; HEALTH; ASSAY
AB Vascular calcification is a major complication of cardiovascular disease and chronic renal failure. Autophagy help to maintain a stable internal and external environment that is important for modulating arteriosclerosis, but its pathogenic mechanism is far from clear. Here, we aimed to identify the bioactive compounds from traditional Chinese medicines (TCM) that exhibit an anti arteriosclerosis effect. In beta glycerophosphate (beta GP) stimulated human aortic smooth muscle cells (HASMCs), the calcium level was increased and the expression of the calcification related proteins OPG, OPN, Runx2, and BMP2 were all up regulated, followed by autophagy induction and apoptosis. Meanwhile, we further revealed that beta GP induced apoptosis of human osteoblasts and promoted differentiation of osteoblasts through Wnt/beta catenin signaling. Bavachin, a natural compound from Psoralea corylifolia, dose dependently reduced the level of intracellular calcium and the expression of calcification related proteins OPG, OPN, Runx2 and BMP2, thus inhibiting cell apoptosis. In addition, bavachin increased LC3 II and beclin1 expression, along with intracellular LC3 II puncta formation, which autophagy induction is Atg7 dependent and is regulated by suppression of mTOR signaling. Furthermore, addition of autophagy inhibitor, wortmannin (WM) attenuated the inhibitory effect of bavachin on beta GP induced calcification and apoptosis in HASMCs. Collectively, the present study revealed that bavachin protects HASMCs against apoptosis and calcification by activation of the Atg7/mTOR autophagy pathway and suppression of the beta catenin signaling, our findings provide a potential clinical application for bavachin in the therapy of cardiovascular disease.
C1 [He, Hu Qiang; Law, Betty Yuen Kwan; Zhang, Ni; Qiu, Cong ling; Qu, Yuan Qing; Han, Yu; Song, Qi; Zheng, Wen Lu; Wong, Vincent Kam Wai] Macau Univ Sci & Technol, Fac Chinese Med, Macau, Peoples R China.
   [He, Hu Qiang; Law, Betty Yuen Kwan; Zhang, Ni; Qiu, Cong ling; Qu, Yuan Qing; Han, Yu; Song, Qi; Zheng, Wen Lu; Wong, Vincent Kam Wai] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.
   [He, Hu Qiang; Liu, Yong; He, Yan Zheng] Southwest Med Univ, Dept Vasc Surg, Affiliated Hosp, Luzhou, Peoples R China.
   [Zheng, Wen Lu] Southwest Med Univ, Sch Pharm, Lab Chinese Malaria Med, Dept Pharmacol, Luzhou, Peoples R China.
   [Zheng, Wen Lu] Southwest Med Univ, Inst Cardiovasc Res, Key Lab Med Bectrophysiol, Minist Educ China,Collaborat Innovat Ctr Prevent, Luzhou, Peoples R China.
   [Wu, An Guo] Southwest Med Univ, Dept Thorac & Cardial Surg, Affiliated Hosp, Luzhou, Peoples R China.
   [Wu, An Guo] Southwest Med Univ, Dept Nucl Med, Affiliated Hosp, Luzhou, Peoples R China.
   [Song, Qi] Southwest Med Univ, Nucl Med & Mol Imaging Key Lab Sichuan Prov, Affiliated Hosp, Luzhou, Peoples R China.
C3 Macau University of Science & Technology; Macau University of Science &
   Technology; Southwest Medical University; Southwest Medical University;
   Southwest Medical University; Southwest Medical University; Southwest
   Medical University; Southwest Medical University
RP Wong, VKW (通讯作者)，Macau Univ Sci & Technol, Fac Chinese Med, Macau, Peoples R China.; Wong, VKW (通讯作者)，Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.; He, YZ (通讯作者)，Southwest Med Univ, Dept Vasc Surg, Affiliated Hosp, Luzhou, Peoples R China.
EM heyanzheng_2018@163.com; kawwong@must.edu.mo
RI liu, yong/NUP 8048 2025; Wong, VKH/KRQ 3186 2024; Anguo,
   Wu/GRF 4136 2022
OI Wong, Vincent Kam Wai/0000 0002 2951 8108; Wu,
   An Guo/0000 0002 9850 7576
FU FDCT grant from the Macao Science and Technology Development Fund
   [0022/2018/A1]; Foshan Medicine Dengfeng Project of China [2019 2021]
FX This work was supported by a FDCT grant from the Macao Science and
   Technology Development Fund (Project code: 0022/2018/A1) and Foshan
   Medicine Dengfeng Project of China (2019 2021).
CR Abdel Mohsen MA, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010172
   Albanese I, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007356
   Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI [10.1161/CIR.0000000000000746, 10.1161/CIR.0000000000000659]
   Bowman MAH, 2012, TRENDS CARDIOVAS MED, V22, P93, DOI 10.1016/j.tcm.2012.07.002
   Cai T, 2016, EXP CELL RES, V345, P206, DOI 10.1016/j.yexcr.2016.06.007
   Cencioni C, 2013, INT J MOL SCI, V14, P17643, DOI 10.3390/ijms140917643
   Chellan B, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 30073 w
   Ciceri P, 2016, ATHEROSCLEROSIS, V254, P93, DOI 10.1016/j.atherosclerosis.2016.09.071
   Dai XY, 2013, KIDNEY INT, V83, P1042, DOI 10.1038/ki.2012.482
   Deshpande S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 25295 x
   Doria A, 2013, NEW ENGL J MED, V368, P1845, DOI 10.1056/NEJMc1303158
   Durham AL, 2018, CARDIOVASC RES, V114, P590, DOI 10.1093/cvr/cvy010
   Frauscher B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01866
   Giachelli CM, 2004, J AM SOC NEPHROL, V15, P2959, DOI 10.1097/01.ASN.0000145894.57533.C4
   Grootaert MOJ, 2018, CARDIOVASC RES, V114, P622, DOI 10.1093/cvr/cvy007
   Gudipaty SA, 2018, ANNU REV CELL DEV BI, V34, P311, DOI 10.1146/annurev cellbio 100616 060748
   Huang H, 2008, CURR OPIN CELL BIOL, V20, P119, DOI 10.1016/j.ceb.2008.01.009
   Kaiser SE, 2012, NAT STRUCT MOL BIOL, V19, P1242, DOI 10.1038/nsmb.2415
   Kapustin AN, 2011, CIRC RES, V109, pE1, DOI 10.1161/CIRCRESAHA.110.238808
   Kay AM, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/6809703
   Krzanowski M, 2018, THER APHER DIAL, V22, P519, DOI 10.1111/1744 9987.12681
   Leopold JA, 2015, TRENDS CARDIOVAS MED, V25, P267, DOI 10.1016/j.tcm.2014.10.021
   Li S, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578 018 0263 x
   Lin CH, 2018, ENVIRON TOXICOL, V33, P770, DOI 10.1002/tox.22564
   Liu Y, 2016, SCI REP UK, V6, DOI 10.1038/srep25578
   Lu W, 2016, ONCOL REP, V36, P3597, DOI 10.3892/or.2016.5134
   Mariño G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Metaxakis A, 2018, CELLS BASEL, V7, DOI 10.3390/cells7050037
   Mialet Perez J, 2017, ESSAYS BIOCHEM, V61, P721, DOI 10.1042/EBC20170022
   Peng X, 2016, ENVIRON TOXICOL, V31, P1113, DOI 10.1002/tox.22120
   Peng Y, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03044 w
   Qiao WW, 2014, CELL PHYSIOL BIOCHEM, V33, P1945, DOI 10.1159/000362971
   Qiu CT, 2017, MOL CELL BIOCHEM, V433, P149, DOI 10.1007/s11010 017 3023 z
   Rodriguez KJ, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471 2261 14 29
   Saadat YR, 2015, BIOIMPACTS, V5, P25, DOI 10.15171/bi.2015.01
   Shanahan CM, 2013, KIDNEY INT, V83, P984, DOI 10.1038/ki.2013.75
   Song HS, 2018, PHYTOMEDICINE, V40, P37, DOI 10.1016/j.phymed.2017.12.030
   Sun Y, 2012, CIRC RES, V111, P543, DOI 10.1161/CIRCRESAHA.112.267237
   Takeda T, 2018, BIOMED PHARMACOTHER, V100, P486, DOI 10.1016/j.biopha.2018.02.019
   Thompson B, 2012, NAT REV ENDOCRINOL, V8, P529, DOI 10.1038/nrendo.2012.36
   Torremadé N, 2016, J BONE MINER RES, V31, P1865, DOI 10.1002/jbmr.2852
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   Ullah A, 2016, SAUDI PHARM J, V24, P547, DOI 10.1016/j.jsps.2015.03.013
   Ulukaya E, 2008, TOXICOL IN VITRO, V22, P232, DOI 10.1016/j.tiv.2007.08.006
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Yahagi K, 2017, ARTERIOSCL THROM VAS, V37, P191, DOI 10.1161/ATVBAHA.116.306256
   Zhan JK, 2014, CAN J CARDIOL, V30, P568, DOI 10.1016/j.cjca.2013.11.005
   Zhang ZJ, 2019, J CELL MOL MED, V23, P177, DOI 10.1111/jcmm.13903
NR 48
TC 33
Z9 37
U1 1
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD DEC 19
PY 2019
VL 10
AR 1427
DI 10.3389/fphar.2019.01427
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA LH3VY
UT WOS:000528716400001
PM 31920640
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Trimarchi, H
   Lombi, F
   Forrester, M
   Elizondo, C
   Sawinski, D
   Pereyra, H
   Freixas, E
AF Trimarchi, Hernan
   Lombi, Fernando
   Forrester, Mariano
   Elizondo, Cristina
   Sawinski, Deirdre
   Pereyra, Horacio
   Freixas, Emilio
TI Disodium pamidronate for treating severe hypercalcemia in a hemodialysis
   patient
SO NATURE CLINICAL PRACTICE NEPHROLOGY
LA English
DT Article
DE bisphosphonates; hemodialysis; hypercalcemia; multiple myeloma;
   pamidronate
ID HORMONE RELATED PROTEIN; SECONDARY HYPERPARATHYROIDISM;
   MULTIPLE MYELOMA; BISPHOSPHONATES; MECHANISMS; DISEASE
AB Background A 48 year old man with a recent diagnosis of multiple myeloma and rapidly progressive oliguric end stage renal disease requiring hemodialysis, presented with a serum calcium concentration of 3.4 mmol/l (13.6 mg/dl).
   Investigations Serum laboratory analysis, electroencephalogram, MRI of the brain and bone marrow, and kidney biopsies.
   Diagnosis Hypercalcemia secondary to multiple myeloma.
   Management Short term intravenous disodium pamidronate therapy (30 mg daily) and daily monitoring of serum calcium concentration.
C1 Hosp Britan Buenos Aires, Dept Med, Renal Sect, RA 1280 Buenos Aires, DF, Argentina.
   Hosp Britan Buenos Aires, Dept Med, Renal Transplant Unit, RA 1280 Buenos Aires, DF, Argentina.
   Hosp Britan Buenos Aires, Dept Med, Renal Pancreas Transplant Unit, RA 1280 Buenos Aires, DF, Argentina.
   Hosp Britan Buenos Aires, Div Nephrol, Buenos Aires, DF, Argentina.
   Hosp Britan Buenos Aires, Internal Med Serv, Buenos Aires, DF, Argentina.
   Columbia Univ, Med Ctr, New York, NY USA.
C3 Hospital Britanico de Buenos Aires; Hospital Britanico de Buenos Aires;
   Hospital Britanico de Buenos Aires; Hospital Britanico de Buenos Aires;
   Hospital Britanico de Buenos Aires; Columbia University
RP Trimarchi, H (通讯作者)，Hosp Britan Buenos Aires, Dept Med, Renal Sect, Perdriel 74, RA 1280 Buenos Aires, DF, Argentina.
EM htrimarchi@hotmail.com
OI Elizondo, Cristina Maria/0000 0002 3262 2176
CR Barri YM, 1996, HEMATOL ONCOL CLIN N, V10, P775, DOI 10.1016/S0889 8588(05)70367 1
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Glass DA, 2003, NEW ENGL J MED, V349, P2479, DOI 10.1056/NEJMp038176
   Lindberg JS, 1999, SEMIN NEPHROL, V19, P115
   Lu KC, 2003, AM J KIDNEY DIS, V42, P1221, DOI 10.1053/j.ajkd.2003.08.023
   Major PP, 2002, AM J CLIN ONCOL CANC, V25, pS10, DOI 10.1097/00000421 200212001 00003
   Markowitz GS, 2001, J AM SOC NEPHROL, V12, P1164, DOI 10.1681/ASN.V1261164
   PEARCE CJ, 1991, ANN CLIN BIOCHEM, V28, P229, DOI 10.1177/000456329102800305
   POPOVTZER M, 1992, RENAL ELECTROLYTE DI, P287
   Rajkumar SV, 2005, MAYO CLIN PROC, V80, P1371, DOI 10.4065/80.10.1371
   RATCLIFFE WA, 1992, LANCET, V339, P164, DOI 10.1016/0140 6736(92)90220 W
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   SCHEINMAN SJ, 1991, AM J MED SCI, V301, P178, DOI 10.1097/00000441 199103000 00005
   Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306
   Torregrosa JV, 2003, KIDNEY INT, V63, pS88, DOI 10.1046/j.1523 1755.63.s85.21.x
NR 15
TC 10
Z9 12
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013 1917 USA
SN 1745 8323
J9 NAT CLIN PRACT NEPHR
JI Nat. Clin. Pract. Nephrol.
PD AUG
PY 2006
VL 2
IS 8
BP 459
EP 463
DI 10.1038/ncpneph0248
PG 5
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 067ZF
UT WOS:000239340600012
PM 16932480
DA 2025 08 17
ER

PT J
AU Baudry, A
   Bitard, J
   Mouillet Richard, S
   Locker, M
   Poliard, A
   Launay, JM
   Kellermann, O
AF Baudry, Anne
   Bitard, Juliette
   Mouillet Richard, Sophie
   Locker, Morgane
   Poliard, Anne
   Launay, Jean Marie
   Kellermann, Odile
TI Serotonergic 5 HT2B Receptor Controls Tissue nonspecific
   Alkaline Phosphatase Activity in Osteoblasts via Eicosanoids and
   Phosphatidylinositol specific Phospholipase C
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BONE FORMATION; INFANTILE HYPOPHOSPHATASIA; INHIBITION; CELL;
   5 HYDROXYTRYPTAMINE; DIFFERENTIATION; MINERALIZATION; ACTIVATION;
   EXPRESSION; PROTEIN
AB In previous studies, we observed that mice knocked out for the serotonin 2B receptor (5 HT2BR) show defects in bone homeostasis. The present work focuses on the downstream targets relaying the anabolic function of this receptor in osteoblasts. A functional link between the 5 HT2BR and the activity of the tissue nonspecific alkaline phosphatase (TNAP) is established using the C1 osteoprogenitor cell line. During C1 osteogenic differentiation, both 5 HT2BR and TNAP mRNA translations are delayed with respect to extracellular matrix deposition. Once the receptor is expressed, it constitutively controls TNAP activity at a post translational level along the overall period of mineral deposition. Indeed, pharmacological inhibition of the 5 HT2BR intrinsic activity or shRNA mediated 5 HT2BR knockdown prevents TNAP activation, but not its mRNA translation. In contrast, agonist stimulation of the receptor further increases TNAP activity during the initial mineralization phase. Building upon our previous observations that the 5 HT2BR couples with the phospholipase A2 pathway and prostaglandin production at the beginning of mineral deposition, we show that the 5 HT2BR controls leukotriene synthesis via phospholipase A2 at the terminal stages of C1 differentiation. These two 5 HT2BR dependent eicosanoid productions delineate distinct time windows of TNAP regulation during the osteogenic program. Finally, prostaglandins or leukotrienes are shown to relay the post translational activation of TNAP via stimulation of the phosphatidylinositol specific phospholipase C. In agreement with the above findings, primary calvarial osteoblasts from 5 HT2BR null mice exhibit defects in TNAP activity.
C1 [Baudry, Anne; Bitard, Juliette; Mouillet Richard, Sophie; Locker, Morgane; Poliard, Anne; Kellermann, Odile] Univ Paris 05, INSERM U747, F 75006 Paris, France.
   [Launay, Jean Marie] Hop Lariboisiere, INSERM U942, Serv Biochim, AP HP, F 75009 Paris, France.
   [Launay, Jean Marie] F Hoffmann La Roche & Co Ltd, Pharma Res Dept, CH 4070 Basel, Switzerland.
C3 Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite
   Paris Cite; Hopital Universitaire Lariboisiere Fernand Widal   APHP;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Roche Holding
RP Kellermann, O (通讯作者)，Univ Paris 05, INSERM U747, 45 Rue St Peres, F 75006 Paris, France.
EM odile.kellermann@parisdescartes.fr
RI MOUILLET RICHARD, Sophie/E 4960 2017; Locker, Morgane/LIF 6504 2024;
   Baudry, Anne/O 2624 2017; Mouillet, Sophie/E 4960 2017
OI MOUILLET RICHARD, Sophie/0000 0002 8950 1949; Baudry,
   Anne/0000 0002 7729 1753; BITARD, Juliette/0000 0001 6626 3522; 
FU Centre National de la Recherche Scientifique; Institut National de la
   Sante et de la Recherche Medicale
FX This work was supported by grants from Centre National de la Recherche
   Scientifique and the Institut National de la Sante et de la Recherche
   Medicale.
CR BAXTER G, 1995, TRENDS PHARMACOL SCI, V16, P105, DOI 10.1016/S0165 6147(00)88991 9
   Baxter GS, 1996, BEHAV BRAIN RES, V73, P149
   BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756
   Bliziotes MM, 2001, BONE, V29, P477, DOI 10.1016/S8756 3282(01)00593 2
   Ciancaglini P, 2006, BRAZ J MED BIOL RES, V39, P603, DOI 10.1590/S0100 879X2006000500006
   Collet C, 2008, FASEB J, V22, P418, DOI 10.1096/fj.07 9209com
   Fedde KN, 1999, J BONE MINER RES, V14, P2015, DOI 10.1359/jbmr.1999.14.12.2015
   Goridis C, 2002, NAT REV NEUROSCI, V3, P531, DOI 10.1038/nrn871
   Haney E. M., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P133
   Hennessy KM, 2009, BIOMATERIALS, V30, P1898, DOI 10.1016/j.biomaterials.2008.12.053
   HENTHORN PS, 1992, CLIN CHEM, V38, P2501
   Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399
   Hikiji H, 2008, PROG LIPID RES, V47, P107, DOI 10.1016/j.plipres.2007.12.003
   Jonnakuty C, 2008, J CELL PHYSIOL, V217, P301, DOI 10.1002/jcp.21533
   Kleven MS, 1997, J PHARMACOL EXP THER, V282, P747
   Kozak W, 2004, FRONT BIOSCI LANDMRK, V9, P3339, DOI 10.2741/1486
   Leysen JE, 2004, CNS NEUROL DISORD DR, V3, P11, DOI 10.2174/1568007043482598
   Locker M, 2006, CELL SIGNAL, V18, P628, DOI 10.1016/j.cellsig.2005.06.006
   MACGREGOR GR, 1995, DEVELOPMENT, V121, P1487
   Manivet P, 2000, J BIOL CHEM, V275, P9324, DOI 10.1074/jbc.275.13.9324
   Masferrer JL, 1999, ANN NY ACAD SCI, V889, P84, DOI 10.1111/j.1749 6632.1999.tb08726.x
   Millan MJ, 2008, TRENDS PHARMACOL SCI, V29, P454, DOI 10.1016/j.tips.2008.06.007
   Minamizaki T, 2009, BONE, V44, P1177, DOI 10.1016/j.bone.2009.02.010
   Mouillet Richard S, 2005, J BIOL CHEM, V280, P4592, DOI 10.1074/jbc.M406199200
   Murshed M, 2005, GENE DEV, V19, P1093, DOI 10.1101/gad.1276205
   Nakano Y, 2004, BONE, V35, P1077, DOI 10.1016/j.bone.2004.07.009
   Narisawa S, 1997, DEV DYNAM, V208, P432, DOI 10.1002/(SICI)1097 0177(199703)208:3<432::AID AJA13>3.0.CO;2 1
   POLIARD A, 1995, J CELL BIOL, V130, P1461, DOI 10.1083/jcb.130.6.1461
   Poliard A, 1999, EXP CELL RES, V253, P385, DOI 10.1006/excr.1999.4704
   Spyridakis S, 2010, AM J RESP CELL MOL, V42, P357, DOI 10.1165/rcmb.2009 0078OC
   Tesch W, 2003, J BONE MINER RES, V18, P117, DOI 10.1359/jbmr.2003.18.1.117
   VANBELLE H, 1976, CLIN CHEM, V22, P972
   Warden SJ, 2005, ENDOCRINOLOGY, V146, P685, DOI 10.1210/en.2004 1259
   Warden SJ, 2008, MENOPAUSE, V15, P1176, DOI 10.1097/gme.0b013e318173566b
   Warden SJ, 2010, BONE, V46, P4, DOI 10.1016/j.bone.2009.06.029
   Westbroek I, 2001, J BIOL CHEM, V276, P28961, DOI 10.1074/jbc.M101824200
   WHYTE MP, 1994, ENDOCR REV, V15, P439, DOI 10.1210/er.15.4.439
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
NR 38
TC 24
Z9 28
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 20
PY 2010
VL 285
IS 34
BP 26066
EP 26073
DI 10.1074/jbc.M109.073791
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 638UB
UT WOS:000280921000022
PM 20573958
OA Green Published, Green Accepted
DA 2025 08 17
ER

PT J
AU Santos, FM
   Costa, VRD
   de Araújo, S
   de Sousa, CDF
   Moreira, TP
   Gonçalves, MR
   dos Santos, ACPM
   Ferreira, HAS
   Costa, PAC
   Barrioni, BR
   Bargi Souza, P
   Pereira, MD
   Nogueira, ML
   Souza, DD
   Guimaraes, PPG
   Teixeira, MM
   Queiroz, CM Jr
   Costa, VV
AF Santos, Franciele Martins
   Costa, Victor Rodrigues de Melo
   de Araujo, Simone
   de Sousa, Carla Daiane Ferreira
   Moreira, Thaiane Pinto
   Goncalves, Matheus Rodrigues
   dos Santos, Anna Clara Paiva Menezes
   Ferreira, Heloisa Athayde Seabra
   Costa, Pedro Augusto Carvalho
   Barrioni, Breno Rocha
   Bargi Souza, Paula
   Pereira, Marivalda de Magalhaes
   Nogueira, Mauricio Lacerda
   Souza, Danielle da Gloria
   Guimaraes, Pedro Pires Goulart
   Teixeira, Mauro Martins
   Queiroz Junior, Celso Martins
   Costa, Vivian Vasconcelos
TI Essential role of the CCL2 CCR2 axis in Mayaro virus induced disease
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE Mayaro virus; alphavirus; CCR2 receptor; CCL2 chemokine; bone loss;
   inflammation
ID FIBROBLAST LIKE SYNOVIOCYTES; INDUCED ARTHRITIS; MOUSE MODEL; MURINE
   MODEL; INFECTION; IMMUNOPATHOLOGY; EXPRESSION; MYOSITIS; CCR2;
   INTERLEUKIN 6
AB Mayaro virus (MAYV) is an emerging arbovirus member of the Togaviridae family and Alphavirus genus. MAYV infection causes an acute febrile illness accompanied by persistent polyarthralgia and myalgia. Understanding the mechanisms involved in arthritis caused by alphaviruses is necessary to develop specific therapies. In this work, we investigated the role of the CCL2/CCR2 axis in the pathogenesis of MAYV induced disease. For this, wild type (WT) C57BL/6J and CCR2 /  mice were infected with MAYV subcutaneously and evaluated for disease development. MAYV infection induced an acute inflammatory disease in WT mice. The immune response profile was characterized by an increase in the production of inflammatory mediators, such as IL 6, TNF, and CCL2. Higher levels of CCL2 at the local and systemic levels were followed by the significant recruitment of CCR2+ macrophages and a cellular response orchestrated by these cells. CCR2 /  mice showed an increase in CXCL 1 levels, followed by a replacement of the macrophage inflammatory infiltrate by neutrophils. Additionally, the absence of the CCR2 receptor protected mice from bone loss induced by MAYV. Accordingly, the silencing of CCL2 chemokine expression in vivo and the pharmacological blockade of CCR2 promoted a partial improvement in disease. Cell culture data support the mechanism underlying the bone pathology of MAYV, in which MAYV infection promotes a pro osteoclastogenic microenvironment mediated by CCL2, IL 6, and TNF, which induces the migration and differentiation of osteoclast precursor cells. Overall, these data contribute to the understanding of the pathophysiology of MAYV infection and the identification future of specific therapeutic targets in MAYV induced disease.IMPORTANCEThis work demonstrates the role of the CCL2/CCR2 axis in MAYV induced disease. The infection of wild type (WT) C57BL/6J and CCR2 /  mice was associated with high levels of CCL2, an important chemoattractant involved in the recruitment of macrophages, the main precursor of osteoclasts. In the absence of the CCR2 receptor, there is a mitigation of macrophage migration to the target organs of infection and protection of these mice against bone loss induced by MAYV infection. Much evidence has shown that host immune response factors contribute significantly to the tissue damage associated with alphavirus infections. Thus, this work highlights molecular and cellular targets involved in the pathogenesis of arthritis triggered by MAYV and identifies novel therapeutic possibilities directed to the host inflammatory response unleashed by MAYV.
   This work demonstrates the role of the CCL2/CCR2 axis in MAYV induced disease. The infection of wild type (WT) C57BL/6J and CCR2 /  mice was associated with high levels of CCL2, an important chemoattractant involved in the recruitment of macrophages, the main precursor of osteoclasts. In the absence of the CCR2 receptor, there is a mitigation of macrophage migration to the target organs of infection and protection of these mice against bone loss induced by MAYV infection. Much evidence has shown that host immune response factors contribute significantly to the tissue damage associated with alphavirus infections. Thus, this work highlights molecular and cellular targets involved in the pathogenesis of arthritis triggered by MAYV and identifies novel therapeutic possibilities directed to the host inflammatory response unleashed by MAYV.
C1 [Santos, Franciele Martins; Costa, Victor Rodrigues de Melo; Goncalves, Matheus Rodrigues; Queiroz Junior, Celso Martins; Costa, Vivian Vasconcelos] Univ Fed Minas Gerais, Drug Res & Dev Ctr, Dept Morphol, Belo Horizonte, MG, Brazil.
   [de Araujo, Simone; Ferreira, Heloisa Athayde Seabra; Costa, Pedro Augusto Carvalho; Bargi Souza, Paula; Guimaraes, Pedro Pires Goulart] Univ Fed Minas Gerais, Dept Physiol & Biophys, Belo Horizonte, MG, Brazil.
   [de Sousa, Carla Daiane Ferreira; Moreira, Thaiane Pinto; dos Santos, Anna Clara Paiva Menezes; Souza, Danielle da Gloria] Univ Fed Minas Gerais, Dept Microbiol, Host Microorganism Interact Lab, Belo Horizonte, MG, Brazil.
   [Barrioni, Breno Rocha; Pereira, Marivalda de Magalhaes] Univ Fed Minas Gerais, Dept Met & Mat Engn, Belo Horizonte, MG, Brazil.
   [Nogueira, Mauricio Lacerda] Sao Jose do Rio Preto Sch Med FAMERP, Virol Res Lab, Sao Jose Do Rio Preto, SP, Brazil.
   [Teixeira, Mauro Martins] Univ Fed Minas Gerais, Drug Res & Dev Ctr, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil.
C3 Universidade Federal de Minas Gerais; Universidade Federal de Minas
   Gerais; Universidade Federal de Minas Gerais; Universidade Federal de
   Minas Gerais; Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP);
   Universidade Federal de Minas Gerais
RP Queiroz, CM Jr; Costa, VV (通讯作者)，Univ Fed Minas Gerais, Drug Res & Dev Ctr, Dept Morphol, Belo Horizonte, MG, Brazil.
EM cmqj@ufmg.br; vivianvcosta@gmail.com
RI ; Costa, Pedro/T 6813 2018; Costa, Vivian/I 2499 2018; Bargi Souza,
   Paula/J 5262 2015; Nogueira, Mauricio/B 7599 2012; Queiroz Junior,
   Celso/L 5438 2013; Barrioni, Breno/H 4769 2018; Teixeira,
   Mauro/A 4587 2008; , Marivalda/U 1142 2019
OI Rodrigues Goncalves, Matheus/0009 0008 0798 9778; Bargi Souza,
   Paula/0000 0001 7746 0636; Santos, Franciele/0000 0002 8768 610X;
   Teixeira, Mauro/0000 0002 6944 3008; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   [465425/2014 3]; Fundacao de Amparo a Pesquisa do Estado de Minas Gerais
   (FAPEMIG) [RED 00202 22, 25036/2014 3, APQ 02281 18]; L'Oreal UNESCO ABC
   'Para Mulheres na Ciencia; International Society of Neurochemistry
   [29344]; Centers for Research on Emerging Infectious Diseases (CREID)
   [1U01AI151807]
FX Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   465425/2014 3 Mauro Martins Teixeira Fundacao de Amparo a Pesquisa do
   Estado de Minas Gerais (FAPEMIG) RED 00202 22 Mauro Martins
   TeixeiraFundacao de Amparo a Pesquisa do Estado de Minas Gerais
   (FAPEMIG) 25036/2014 3 Mauro Martins Teixeira L'Oreal UNESCO ABC 'Para
   Mulheres na Ciencia' Vivian Vasconcelos Costa Fundacao de Amparo a
   Pesquisa do Estado de Minas Gerais (FAPEMIG) APQ 02281 18 Vivian
   Vasconcelos CostaInternational Society of Neurochemistry 29344 Vivian
   Vasconcelos Costa Centers for Research on Emerging Infectious Diseases
   (CREID) 1U01AI151807 Mauricio Lacerda Nogueira
CR Acosta Ampudia Y, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426 018 0163 5
   Amaral FA, 2012, ARTHRITIS RHEUM US, V64, P474, DOI 10.1002/art.33355
   Assunçao Miranda I, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/973516
   Bardina SV, 2015, J IMMUNOL, V195, P4306, DOI 10.4049/jimmunol.1500352
   Bengue M, 2019, VIRUSES BASEL, V11, DOI 10.3390/v11090797
   Chen CY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00513 0
   Chen WQ, 2015, TRENDS MICROBIOL, V23, P35, DOI 10.1016/j.tim.2014.09.005
   Chen W, 2014, VIROL J, V11, DOI 10.1186/s12985 014 0189 9
   Coury F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00679
   Culshaw A, 2017, CURR OPIN IMMUNOL, V48, P1, DOI 10.1016/j.coi.2017.07.001
   Damjanovic D, 2012, CLIN IMMUNOL, V144, P57, DOI 10.1016/j.clim.2012.05.005
   Mota MTD, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 62084 x
   Mota MTD, 2015, FUTURE VIROL, V10, P1109, DOI 10.2217/fvl.15.76
   Drevets DA, 2010, BRAIN BEHAV IMMUN, V24, P919, DOI 10.1016/j.bbi.2010.02.011
   Dussault AA, 2006, BIOL PROCED ONLINE, V8, P1, DOI 10.1251/bpo114
   Figueiredo CM, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02246
   Gardner J, 2010, J VIROL, V84, P8021, DOI 10.1128/JVI.02603 09
   Gschwandtner M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02759
   Gustine JN, 2021, AM J PATHOL, V191, P4, DOI 10.1016/j.ajpath.2020.08.009
   Haist KC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006748
   Halsey ES, 2013, EMERG INFECT DIS, V19, P1839, DOI 10.3201/eid1911.130777
   Haringman JJ, 2004, ARTHRITIS RES THER, V6, P93, DOI 10.1186/ar1172
   Herrero LJ, 2011, P NATL ACAD SCI USA, V108, P12048, DOI 10.1073/pnas.1101089108
   Hess A, 2011, P NATL ACAD SCI USA, V108, P3731, DOI 10.1073/pnas.1011774108
   Hiroki CH, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03108
   Hotez PJ, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005462
   Krohn Grimberghe M, 2020, NAT BIOMED ENG, V4, P1076, DOI 10.1038/s41551 020 00623 7
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   Kwiatkowski K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.615327
   Lidbury BA, 2008, J INFECT DIS, V197, P1585, DOI 10.1086/587841
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Longobardi L, 2017, OSTEOARTHR CARTILAGE, V25, P914, DOI 10.1016/j.joca.2016.11.004
   Miller RE, 2012, P NATL ACAD SCI USA, V109, P20602, DOI 10.1073/pnas.1209294110
   Morrison TE, 2006, J VIROL, V80, P737, DOI 10.1128/JVI.80.2.737 749.2006
   Mostafavi H, 2019, VIRUSES BASEL, V11, DOI 10.3390/v11030290
   Nanki T, 2001, J IMMUNOL, V167, P5381, DOI 10.4049/jimmunol.167.9.5381
   Neumark E, 2003, INT J CANCER, V106, P879, DOI 10.1002/ijc.11337
   Ng LFP, 2017, ANNU REV VIROL, V4, P413, DOI 10.1146/annurev virology 101416 041808
   Noret M, 2012, J INFECT DIS, V206, P455, DOI 10.1093/infdis/jis368
   Phuklia W, 2013, VIRUS RES, V177, P179, DOI 10.1016/j.virusres.2013.08.011
   Ponzetti M, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00236
   Poo YS, 2014, J VIROL, V88, P6862, DOI 10.1128/JVI.03364 13
   Proost P, 1996, J LEUKOCYTE BIOL, V59, P67, DOI 10.1002/jlb.59.1.67
   Quinones MP, 2005, J MOL MED, V83, P672, DOI 10.1007/s00109 005 0637 5
   Raghu H, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 210426
   Roy E, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00899 20
   Rulli NE, 2011, J INFECT DIS, V204, P1026, DOI 10.1093/infdis/jir470
   Rulli NE, 2009, ARTHRITIS RHEUM US, V60, P2513, DOI 10.1002/art.24682
   Santiago FW, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004104
   Santos FM, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007375
   Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070
   Slegers CAD, 2014, J CLIN VIROL, V60, P317, DOI 10.1016/j.jcv.2014.04.020
   Tappe D, 2016, EMERG INFECT DIS, V22, P750, DOI 10.3201/eid2204.151502
   Teng TS, 2015, J INFECT DIS, V211, P1925, DOI 10.1093/infdis/jiv049
   Theilacker C, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471 2334 13 369
NR 55
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
SN 0022 538X
EI 1098 5514
J9 J VIROL
JI J. Virol.
PD JAN 23
PY 2024
VL 98
IS 1
DI 10.1128/jvi.01102 23
EA JAN 2024
PG 24
WC Virology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Virology
GA FQ0B8
UT WOS:001135427900001
PM 38169294
OA Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Sapède, D
   Bahraoui, S
   Abou Nassif, L
   Barthelaix, A
   Mathieu, M
   Jorgensen, C
   Djouad, F
AF Sapede, Dora
   Bahraoui, Sarah
   Abou Nassif, Lea
   Barthelaix, Audrey
   Mathieu, Marc
   Jorgensen, Christian
   Djouad, Farida
TI Cartilage regeneration in zebrafish depends on Nrg1/ErbB signaling
   pathway
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE cartilage; regeneration; neuregulin 1; chrondrocytes; osteoarthritis
ID CARDIOMYOCYTE PROLIFERATION; HEART REGENERATION; NEUREGULIN 1; FIN;
   OSTEOBLASTS; REPAIR; CELLS; ERBB2; DEDIFFERENTIATION; CHONDROCYTES
AB Objective: Cartilage, as the majority of adult mammalian tissues, has limited regeneration capacity. Cartilage degradation consecutive to joint injury or aging then leads to irreversible joint damage and diseases. In contrast, several vertebrate species such as the zebrafish have the remarkable capacity to spontaneously regenerate skeletal structures after severe injuries. The objective of our study was to test the regenerative capacity of Meckel's cartilage (MC) upon mechanical injury in zebrafish and to identify the mechanisms underlying this process.
   Methods and Results: Cartilage regenerative capacity in zebrafish larvae was investigated after mechanical injuries of the lower jaw MC in TgBAC(col2a1a: mCherry), to visualize the loss and recovery of cartilage. Confocal analysis revealed the formation of new chondrocytes and complete regeneration of MC at 14 days post injury (dpi) via chondrocyte cell cycle re entry and proliferation of pre existing MC chondrocytes near the wound. Through expression analyses, we showed an increase of nrg1 expression in the regenerating lower jaw, which also expresses Nrg1 receptors, ErbB3 and ErbB2. Pharmacological inhibition of the ErbB pathway and specific knockdown of Nrg1 affected MC regeneration indicating the pivotal role of this pathway for cartilage regeneration. Finally, addition of exogenous NRG1 in an in vitro model of osteoarthritic (OA) like chondrocytes induced by IL1 beta suggests that Nrg1/ErbB pathway is functional in mammalian chondrocytes and alleviates the increased expression of catabolic markers characteristic of OA like chondrocytes.
   Conclusion: Our results show that the Nrg1/ErbB pathway is required for spontaneous cartilage regeneration in zebrafish and is of interest to design new therapeutic approaches to promote cartilage regeneration in mammals.
C1 [Sapede, Dora; Bahraoui, Sarah; Abou Nassif, Lea; Barthelaix, Audrey; Mathieu, Marc; Jorgensen, Christian; Djouad, Farida] Univ Montpellier, IRMB, INSERM, Montpellier, France.
   [Jorgensen, Christian] CHU Montpellier, Montpellier, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Montpellier; Universite de Montpellier; CHU de Montpellier
RP Djouad, F (通讯作者)，Univ Montpellier, IRMB, INSERM, Montpellier, France.
EM farida.djouad@inserm.fr
RI djouad, farida/P 1749 2017
FU University of Montpellier [ANR 18 CE18 0010 02]; Inserm; FOREUM
   Foundation for Research in Rheumatology; French National Research Agency
   (ANR) for "PPAROA" project [ANR 18 CE18 0010 02]; University of
   Montpellier, Inserm and by research grants from the FOREUM Foundation
   for Research in Rheumatology and the French National Research Agency
   (ANR) for the "PPAROA" project;  [ANR 18 CE18 0010 0]
FX This study was funded by the University of Montpellier, Inserm and by
   research grants from the FOREUM Foundation for Research in Rheumatology
   and the French National Research Agency (ANR) for the "PPAROA" project
   (ANR 18 CE18 0010 02).
CR Akiyama H, 2004, P NATL ACAD SCI USA, V101, P6502, DOI 10.1073/pnas.0401711101
   Ando K, 2017, DEV CELL, V43, P643, DOI 10.1016/j.devcel.2017.10.015
   Askary A, 2016, ELIFE, V5, DOI 10.7554/eLife.16415
   Bartus K, 2016, BRAIN, V139, P1394, DOI 10.1093/brain/aww039
   Bersell K, 2009, CELL, V138, P257, DOI 10.1016/j.cell.2009.04.060
   Brunt LH, 2016, OSTEOARTHR CARTILAGE, V24, P1940, DOI 10.1016/j.joca.2016.06.015
   Brunt LH, 2017, DEVELOPMENT, V144, P2798, DOI 10.1242/dev.153528
   CHAN WY, 1991, J EXP ZOOL, V260, P74, DOI 10.1002/jez.1402600110
   Cuervo R, 2012, P NATL ACAD SCI USA, V109, P3838, DOI 10.1073/pnas.1006619109
   D'Uva G, 2015, CELL CYCLE, V14, P2383, DOI 10.1080/15384101.2015.1063292
   D'Uva G, 2015, NAT CELL BIOL, V17, P627, DOI 10.1038/ncb3149
   Dutton JR, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471 213X 8 105
   El Soury M, 2019, NEURAL REGEN RES, V14, P1374, DOI 10.4103/1673 5374.253516
   Fisher MC, 2007, DEV GROWTH DIFFER, V49, P503, DOI 10.1111/j.1440 169x.2007.00941.x
   Fricker FR, 2011, FUTUR NEUROL, V6, P809, DOI 10.2217/FNL.11.45
   Gambarotta G, 2014, NEURAL REGEN RES, V9, P1183, DOI 10.4103/1673 5374.135324
   Gemberling M, 2013, TRENDS GENET, V29, P611, DOI 10.1016/j.tig.2013.07.003
   Geurtzen K, 2014, DEVELOPMENT, V141, P2225, DOI 10.1242/dev.105817
   Giovannone D, 2019, ELIFE, V8, DOI 10.7554/eLife.42736
   Gosset M, 2008, NAT PROTOC, V3, P1253, DOI 10.1038/nprot.2008.95
   Hammond CL, 2009, DEVELOPMENT, V136, P3991, DOI 10.1242/dev.042150
   Hao Q, 2021, LIFE SCI, V264, DOI 10.1016/j.lfs.2020.118283
   Huc Brandt S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113331
   Islam S, 2001, OSTEOARTHR CARTILAGE, V9, P684, DOI 10.1053/joca.2001.0465
   Jabbour A, 2011, TRANSPLANTATION, V91, P961, DOI 10.1097/TP.0b013e3182115b4b
   Jabbour A, 2011, EUR J HEART FAIL, V13, P83, DOI 10.1093/eurjhf/hfq152
   Kawakami A, 2004, DEV DYNAM, V231, P693, DOI 10.1002/dvdy.20181
   Kerber G, 2003, J MOL NEUROSCI, V21, P149, DOI 10.1385/JMN:21:2:149
   Knopf F, 2011, DEV CELL, V20, P713, DOI 10.1016/j.devcel.2011.04.014
   Laplace Builhé B, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 26422 5
   Lawrence EA, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0335
   Le HX, 2020, J TISSUE ENG, V11, DOI 10.1177/2041731420943839
   Liang X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.91
   Ling ITC, 2017, DEV BIOL, V421, P219, DOI 10.1016/j.ydbio.2016.11.016
   Londono R, 2018, CURR PATHOBIOL REP, V6, P61, DOI 10.1007/s40139 018 0161 2
   Ma EY, 2008, J NEUROSCI, V28, P2261, DOI 10.1523/JNEUROSCI.4372 07.2008
   Mahmoud AI, 2015, DEV CELL, V34, P387, DOI 10.1016/j.devcel.2015.06.017
   Mai NC, 2014, DIS MODEL MECH, V7, P871, DOI 10.1242/dmm.014498
   Marques IJ, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.167692
   Maumus M, 2013, STEM CELL RES, V11, P834, DOI 10.1016/j.scr.2013.05.008
   Mitchell RE, 2013, OSTEOARTHR CARTILAGE, V21, P269, DOI 10.1016/j.joca.2012.11.004
   Nawachi K, 2002, FEBS LETT, V528, P109, DOI 10.1016/S0014 5793(02)03263 5
   Nguyen Chi M, 2015, ELIFE, V4, DOI 10.7554/eLife.07288
   Ohgo S, 2019, DEV GROWTH DIFFER, V61, P419, DOI 10.1111/dgd.12625
   Paul S, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.81
   Paul S, 2016, DEVELOPMENT, V143, P2066, DOI 10.1242/dev.131292
   Polizzotti BD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa5171
   Porrello ER, 2011, SCIENCE, V331, P1078, DOI 10.1126/science.1200708
   Poss KD, 2002, SCIENCE, V298, P2188, DOI 10.1126/science.1077857
   Prasad MK, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471 213X 11 40
   Recher G, 2013, DEVELOPMENT, V140, P4860, DOI 10.1242/dev.099010
   Rojas Muñoz A, 2009, DEV BIOL, V327, P177, DOI 10.1016/j.ydbio.2008.12.012
   Ruiz M, 2020, BIOMATERIALS, V226, DOI 10.1016/j.biomaterials.2019.119544
   Singh SP, 2012, DEV CELL, V22, P879, DOI 10.1016/j.devcel.2012.03.006
   Smeeton J, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.777787
   Storer MA, 2020, DEV CELL, V52, P509, DOI 10.1016/j.devcel.2019.12.004
   Wadugu B, 2012, AM J PHYSIOL HEART C, V302, pH2139, DOI 10.1152/ajpheart.00063.2012
   Wang XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045380
   Wang Y, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.945206
   Wang ZH, 2022, BIOACT MATER, V11, P317, DOI 10.1016/j.bioactmat.2021.10.002
   Yan XH, 2011, CURR PHARM DESIGN, V17, P1808, DOI 10.2174/138161211796391010
   Yoon D, 2018, BIOMED MATER, V13, DOI 10.1088/1748 605X/aaac37
   Yoshida K, 2020, DEV BIOL, V463, P110, DOI 10.1016/j.ydbio.2020.04.010
NR 63
TC 5
Z9 5
U1 2
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD APR 4
PY 2023
VL 11
AR 1123299
DI 10.3389/fcell.2023.1123299
PG 12
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA I1GA9
UT WOS:001000317200001
PM 37215080
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Jiang, ZC
   Li, JY
   Chen, SJ
   Guo, Q
   Jing, ZC
   Huang, BY
   Pan, YX
   Wang, L
   Hu, YH
AF Jiang, Zichao
   Li, Jingyi
   Chen, Sijie
   Guo, Qi
   Jing, Zhaocheng
   Huang, Biying
   Pan, Yixiao
   Wang, Long
   Hu, Yihe
TI Zoledronate and SPIO dual targeting nanoparticles loaded with ICG for
   photothermal therapy of breast cancer tibial metastasis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INDOCYANINE GREEN; BONE METASTASIS; GOLD NANORODS; CELLS; MECHANISMS;
   ABLATION; BISPHOSPHONATES; MICELLES; FEATURES; PLATFORM
AB Currently, nanoparticles (NPs) for cancer photothermal therapy (PTT) have limited in vivo clearance, lack targeting ability and have unsatisfactory therapeutic efficiency. Herein, we report a dual targeting and photothermally triggered nanotherapeutic system based on superparamagnetic iron oxide (Fe3O4) and indocyanine green (ICG) entrapped poly lactide co glycolide modified by ZOL (PLGA ZOL) NPs (ICG/Fe3O4@PLGA ZOL) for PTT of breast cancer tibial metastasis, which occurs frequently in the clinic and causes challenging complications in breast cancer. In this system, both ICG and Fe3O4 can convert light into heat, while NPs with Fe3O4 and ZOL can be attracted to a specific location in bone under an external magnetic field. Specifically, the dual targeting and double photothermal agents guaranteed high accumulation in the tibia and perfect PTT efficiency. Furthermore, the in vivo studies showed that ICG/Fe3O4@PLGA ZOL NPs have extraordinary antitumor therapeutic effects and that these NPs can be accurately located in the medullary cavity of the tibia to solve problems with deep lesions, such as breast cancer tibial metastasis, showing great potential for cancer theranostics.
C1 [Jiang, Zichao; Li, Jingyi; Guo, Qi; Jing, Zhaocheng; Pan, Yixiao; Wang, Long; Hu, Yihe] Cent South Univ, Xiangya Hosp, Dept Orthoped, Changsha 410008, Hunan, Peoples R China.
   [Chen, Sijie; Huang, Biying] Cent South Univ, Xiangya Hosp 2, Dept Ultrasound Diag, Changsha 410011, Hunan, Peoples R China.
C3 Central South University; Central South University
RP Wang, L; Hu, YH (通讯作者)，Cent South Univ, Xiangya Hosp, Dept Orthoped, Changsha 410008, Hunan, Peoples R China.
EM dr_wanglong@csu.edu.cn; huyh1964@163.com
RI Guo, Qi/U 5576 2019; Huang, Biying/IAS 1015 2023
OI Wang, Long/0000 0002 2733 7370
FU National Natural Science Foundation of China [81601883, 81873988];
   Natural Science Foundation of Hunan Province [2018JJ3861]; Hunan
   Provincial Science and Technology Department [2017SK50106]
FX This work was supported by Grants from the National Natural Science
   Foundation of China (Grant nos. 81601883, 81873988), the Natural Science
   Foundation of Hunan Province (Grant no. 2018JJ3861) and Hunan Provincial
   Science and Technology Department (Grant no. 2017SK50106).
CR Alila S, 2009, CARBOHYD POLYM, V77, P553, DOI 10.1016/j.carbpol.2009.01.028
   Chanda D, 2009, CLIN CANCER RES, V15, P7175, DOI 10.1158/1078 0432.CCR 09 1938
   Chaudhari KR, 2012, J CONTROL RELEASE, V158, P470, DOI 10.1016/j.jconrel.2011.11.020
   Chen WS, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201605795
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Chen ZM, 2017, OPT EXPRESS, V25, P15093, DOI 10.1364/OE.25.015093
   Cheng L, 2012, BIOMATERIALS, V33, P2215, DOI 10.1016/j.biomaterials.2011.11.069
   Chu KF, 2014, NAT REV CANCER, V14, P199, DOI 10.1038/nrc3672
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Desmettre T, 2000, SURV OPHTHALMOL, V45, P15, DOI 10.1016/S0039 6257(00)00123 5
   Dong WJ, 2011, ADV MATER, V23, P5392, DOI 10.1002/adma.201103521
   Dong ZL, 2016, THERANOSTICS, V6, P1031, DOI 10.7150/thno.14431
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Eckhardt BL, 2012, NAT REV DRUG DISCOV, V11, P479, DOI 10.1038/nrd2372
   Futakuchi M, 2016, ADV DRUG DELIVER REV, V99, P206, DOI 10.1016/j.addr.2015.11.017
   Gao CJ, 2018, CHEM EUR J, V24, P12827, DOI 10.1002/chem.201802611
   Gerratana L, 2015, CLIN EXP METASTAS, V32, P125, DOI 10.1007/s10585 015 9697 2
   Guo LR, 2014, ACS NANO, V8, P5670, DOI 10.1021/nn5002112
   Hannah A, 2014, ACS NANO, V8, P250, DOI 10.1021/nn403527r
   He YF, 2017, J CONTROL RELEASE, V264, P76, DOI 10.1016/j.jconrel.2017.08.024
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Huang Peng, 2013, Angew Chem Int Ed Engl, V52, P13958, DOI 10.1002/anie.201308986
   Huober Jens, 2010, Crit Rev Oncol Hematol, V74 Suppl 1, pS7, DOI 10.1016/S1040 8428(10)70004 4
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   Khandare J, 2006, PROG POLYM SCI, V31, P359, DOI 10.1016/j.progpolymsci.2005.09.004
   Kirchherr AK, 2009, MOL PHARMACEUT, V6, P480, DOI 10.1021/mp8001649
   Li KC, 2016, ACS APPL MATER INTER, V8, P12082, DOI 10.1021/acsami.6b04579
   Li YB, 2010, NANOMEDICINE UK, V5, P1161, DOI 10.2217/NNM.10.85
   Liu Q, 2019, ACS NANO, V13, P4778, DOI 10.1021/acsnano.9b01444
   Lu GH, 2019, BIOMATERIALS, V195, P13, DOI 10.1016/j.biomaterials.2018.12.025
   Ma Y, 2013, BIOMATERIALS, V34, P7706, DOI 10.1016/j.biomaterials.2013.07.007
   Majd MH, 2013, J DRUG TARGET, V21, P328, DOI 10.3109/1061186X.2012.750325
   Niu CC, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06122 1
   Niu CC, 2013, BIOMATERIALS, V34, P2307, DOI 10.1016/j.biomaterials.2012.12.003
   Peng JR, 2014, THERANOSTICS, V4, P678, DOI 10.7150/thno.7869
   Qiao H, 2017, ACS NANO, V11, P7259, DOI 10.1021/acsnano.7b03197
   Qin JB, 2015, NANOSCALE, V7, P13991, DOI 10.1039/c5nr02521d
   Robinson JT, 2010, NANO RES, V3, P779, DOI 10.1007/s12274 010 0045 1
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Shen S, 2013, BIOMATERIALS, V34, P3150, DOI 10.1016/j.biomaterials.2013.01.051
   Tang K, 2018, RSC ADV, V8, P5407, DOI 10.1039/c7ra13091k
   Tian QW, 2011, ACS NANO, V5, P9761, DOI 10.1021/nn203293t
   Wan ZH, 2014, THERANOSTICS, V4, P399, DOI 10.7150/thno.8171
   Wang L, 2018, ACS APPL MATER INTER, V10, P42102, DOI 10.1021/acsami.8b16323
   Xu Y, 2017, RSC ADV, V7, P40791, DOI 10.1039/c7ra07024a
   Yang RH, 2019, NANOSCALE, V11, P5717, DOI 10.1039/c8nr10430a
   Yang W, 2018, BIOMATERIALS, V154, P48, DOI 10.1016/j.biomaterials.2017.10.043
   Yong M, 2011, BREAST CANCER RES TR, V129, P495, DOI 10.1007/s10549 011 1475 5
   Yu J, 2015, THERANOSTICS, V5, P931, DOI 10.7150/thno.11802
   Yue CX, 2013, BIOMATERIALS, V34, P6853, DOI 10.1016/j.biomaterials.2013.05.071
   Zhou FF, 2012, BIOMATERIALS, V33, P3235, DOI 10.1016/j.biomaterials.2011.12.029
NR 51
TC 28
Z9 31
U1 1
U2 54
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD AUG 13
PY 2020
VL 10
IS 1
AR 13675
DI 10.1038/s41598 020 70659 x
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA NF8MH
UT WOS:000563546400007
PM 32792593
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jing, D
   Luo, EP
   Cai, J
   Tong, SC
   Zhai, MM
   Shen, GH
   Wang, X
   Luo, ZJ
AF Jing, Da
   Luo, Erping
   Cai, Jing
   Tong, Shichao
   Zhai, Mingming
   Shen, Guanghao
   Wang, Xin
   Luo, Zhuojing
TI Mechanical Vibration Mitigates the Decrease of Bone Quantity and Bone
   Quality of Leptin Receptor Deficient Db/Db Mice by Promoting Bone
   Formation and Inhibiting Bone Resorption
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE LEPTIN; DB; DB MICE; WHOLE BODY VIBRATION; BONE QUALITY; BONE TURNOVER;
   WNT; LRP;  CATENIN SIGNALING; OPG; RANKL; RANK SYSTEM
ID WHOLE BODY VIBRATION; HORMONE REPLACEMENT THERAPY; LOW MAGNITUDE;
   DIABETES MELLITUS; MUSCLE STRENGTH; GENE EXPRESSION; MESSENGER RNA; LONG
   BONES; LOW LEVEL; IN VIVO
AB Leptin, a major hormonal product of adipocytes, is involved in regulating appetite and energy metabolism. Substantial studies have revealed the anabolic actions of leptin on skeletons and bone cells both in vivo and in vitro. Growing evidence has substantiated that leptin receptor deficient db/db mice exhibit decreased bone mass and impaired bone microstructure despite several conflicting results previously reported. We herein systematically investigated bone microarchitecture, mechanical strength, bone turnover and its potential molecular mechanisms in db/db mice. More importantly, we also explored an effective approach for increasing bone mass in leptin receptor deficient animals in an easy and noninvasive manner. Our results show that deterioration of trabecular and cortical bone microarchitecture and decreases of skeletal mechanical strength?including maximum load, yield load, stiffness, energy, tissue level modulus and hardness?in db/db mice were significantly ameliorated by 12 week, whole body vibration (WBV) with 0.5g, 45Hz via micro computed tomography (CT), three point bending, and nanoindentation examinations. Serum biochemical analysis shows that WBV significantly decreased serum tartrate resistant acid phosphatase 5b (TRACP5b) and CTx 1 levels and also mitigated the reduction of serum osteocalcin (OCN) in db/db mice. Bone histomorphometric analysis confirmed that decreased bone formation?lower mineral apposition rate, bone formation rate, and osteoblast numbers in cancellous bone?in db/db mice were suppressed by WBV. Real time PCR assays show that WBV mitigated the reductions of tibial alkaline phosphatase (ALP), OCN, Runt related transcription factor 2 (RUNX2), type I collagen (COL1), BMP2, Wnt3a, Lrp6, and  catenin mRNA expression, and prevented the increases of tibial sclerostin (SOST), RANK, RANKL, RANL/osteoprotegerin (OPG) gene levels in db/db mice. Our results show that WBV promoted bone quantity and quality in db/db mice with obvious anabolic and anticatabolic effects. This study not only enriches our basic knowledge about bone quality and bone turnover mechanisms in leptin receptor deficient animals, but also advances our understanding of the skeletal sensitivity of leptin resistant db/db mice in response to external mechanical stimulation. (c) 2016 American Society for Bone and Mineral Research.
C1 [Jing, Da; Luo, Zhuojing] Fourth Mil Med Univ, Inst Orthopaed, Xijing Hosp, 17 West Changle Rd, Xian, Peoples R China.
   [Jing, Da; Luo, Erping; Tong, Shichao; Zhai, Mingming; Shen, Guanghao] Fourth Mil Med Univ, Dept Biomed Engn, Xian, Peoples R China.
   [Cai, Jing] Fourth Mil Med Univ, Xijing Hosp, Dept Endocrinol, Xian, Peoples R China.
   [Wang, Xin] Fourth Mil Med Univ, Dept Prevent Med, Xian, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University; Air Force Medical University
RP Luo, ZJ (通讯作者)，Fourth Mil Med Univ, Inst Orthopaed, Xijing Hosp, 17 West Changle Rd, Xian, Peoples R China.
EM zjluo@fmmu.edu.cn
RI Cai, Jing/JXM 0087 2024
FU National Natural Science Foundation of China [81471806, 31270889,
   31500760]; Shaanxi Provincial Natural Science Foundation [2014JQ4139]
FX The authors acknowledge grant support from The National Natural Science
   Foundation of China (Nos. 81471806, 31270889, and 31500760) and Shaanxi
   Provincial Natural Science Foundation (No. 2014JQ4139).
CR Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bartell SM, 2011, J BONE MINER RES, V26, P1710, DOI 10.1002/jbmr.406
   Bellia A, 2014, INT J SPORTS MED, V35, P511, DOI 10.1055/s 0033 1354358
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Burguera B, 2001, ENDOCRINOLOGY, V142, P3546, DOI 10.1210/en.142.8.3546
   Caprio M, 2001, TRENDS ENDOCRIN MET, V12, P65, DOI 10.1016/S1043 2760(00)00352 0
   Carnevale V, 2014, NUTR METAB CARDIOVAS, V24, P1151, DOI 10.1016/j.numecd.2014.06.013
   Chan ME, 2012, FASEB J, V26, P4855, DOI 10.1096/fj.12 209841
   Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092 8674(00)81294 5
   Christiansen BA, 2006, ANN BIOMED ENG, V34, P1149, DOI 10.1007/s10439 006 9133 5
   Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596 585
   Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503
   Cooley J, 2015, J DIABETES METAB DIS, V14, DOI 10.1186/s40200 015 0141 6
   Cornish J, 2002, J ENDOCRINOL, V175, P405, DOI 10.1677/joe.0.1750405
   de Oliveira ML, 2010, BONE, V46, P1516, DOI 10.1016/j.bone.2010.02.009
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Ealey KN, 2006, REGUL PEPTIDES, V136, P9, DOI 10.1016/j.regpep.2006.04.013
   Ebrahimi A, 2015, INDIAN J MED RES, V142, P450, DOI 10.4103/0971 5916.169210
   Elmantaser M, 2012, J MUSCULOSKEL NEURON, V12, P144
   Emilsson V, 1997, DIABETES, V46, P313, DOI 10.2337/diabetes.46.2.313
   Fajardo RJ, 2014, J BONE MINER RES, V29, P1025, DOI 10.1002/jbmr.2210
   Farr JN, 2016, BONE, V82, P28, DOI 10.1016/j.bone.2015.07.027
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gilsanz V, 2006, J BONE MINER RES, V21, P1464, DOI 10.1359/JBMR.060612
   Hamrick MW, 2004, BONE, V34, P376, DOI 10.1016/j.bone.2003.11.020
   He HB, 2004, ENDOCRINOLOGY, V145, P447, DOI 10.1210/en.2003 1239
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hoggard N, 1997, BIOCHEM BIOPH RES CO, V232, P383, DOI 10.1006/bbrc.1997.6245
   Holloway WR, 2002, J BONE MINER RES, V17, P200, DOI 10.1359/jbmr.2002.17.2.200
   Jing D, 2014, J BONE MINER RES, V29, P2250, DOI 10.1002/jbmr.2260
   Jing D, 2014, FASEB J, V28, P1582, DOI 10.1096/fj.13 237578
   Jing D, 2013, BONE, V53, P531, DOI 10.1016/j.bone.2013.01.008
   Judex S, 2002, FASEB J, V16, P1280, DOI 10.1096/fj.01 0913fje
   Kalra SP, 2009, PEPTIDES, V30, P967, DOI 10.1016/j.peptides.2009.01.020
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Li KR, 2012, HEART, V98, P920, DOI 10.1136/heartjnl 2011 301345
   Mahavni V, 2001, CURR OPIN ONCOL, V13, P384, DOI 10.1097/00001622 200109000 00012
   Margetic S, 2002, INT J OBESITY, V26, P1407, DOI 10.1038/sj.ijo.0802142
   Martin A, 2005, ENDOCRINOLOGY, V146, P3652, DOI 10.1210/en.2004 1509
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564
   PATERSON CR, 1980, LANCET, V1, P1164
   Peelman F, 2004, PROG LIPID RES, V43, P283, DOI 10.1016/j.plipres.2004.03.001
   Pistoia W, 2003, BONE, V33, P937, DOI 10.1016/j.bone.2003.06.003
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Roosa SMM, 2011, J BONE MINER RES, V26, P100, DOI 10.1002/jbmr.193
   Rubin C, 2001, FASEB J, V15, P2225, DOI 10.1096/fj.01 0166com
   Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122
   Rubin C, 2004, J BONE MINER RES, V19, P343, DOI 10.1359/JBMR.0301251
   Sehmisch S, 2009, OSTEOPOROSIS INT, V20, P1999, DOI 10.1007/s00198 009 0892 3
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Swift JM, 2010, J BONE MINER RES, V25, P564, DOI 10.1359/jbmr.090811
   Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630
   Tsochatzis E, 2006, AM J GASTROENTEROL, V101, P2629, DOI 10.1111/j.1572 0241.2006.00848.x
   Turner RT, 2014, J ENDOCRINOL, V223, pM1, DOI 10.1530/JOE 14 0224
   Turner RT, 2013, J BONE MINER RES, V28, P22, DOI 10.1002/jbmr.1734
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Verschueren SMP, 2004, J BONE MINER RES, V19, P352, DOI 10.1359/JBMR.0301245
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wallner C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118823
   Wang MY, 2010, P NATL ACAD SCI USA, V107, P4813, DOI 10.1073/pnas.0909422107
   Williams GA, 2011, J BONE MINER RES, V26, P1698, DOI 10.1002/jbmr.367
   Xie LQ, 2006, BONE, V39, P1059, DOI 10.1016/j.bone.2006.05.012
   Yadav S, 2015, EUR J ORTHO IN PRESS
   Yeni YN, 1997, BONE, V21, P453, DOI 10.1016/S8756 3282(97)00173 7
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
NR 68
TC 32
Z9 37
U1 2
U2 20
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD SEP
PY 2016
VL 31
IS 9
BP 1713
EP 1724
DI 10.1002/jbmr.2837
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DW5WL
UT WOS:000383718100013
PM 26990203
OA Bronze
DA 2025 08 17
ER

PT J
AU Lai, LZ
   Wang, ZD
   Ge, YH
   Qiu, W
   Wu, BL
   Fang, FC
   Xu, HY
   Chen, Z
AF Lai, Lingzhi
   Wang, Zhaodan
   Ge, Yihong
   Qiu, Wei
   Wu, Buling
   Fang, Fuchun
   Xu, Huiyong
   Chen, Zhao
TI Comprehensive analysis of the long noncoding RNA associated competitive
   endogenous RNA network in the osteogenic differentiation of periodontal
   ligament stem cells
SO BMC GENOMICS
LA English
DT Article
DE Competing endogenous RNA; Long noncoding RNA; MicroRNA; osteogenic
   differentiation; Periodontal ligament stem cells
ID UNIQUE FEATURES; CERNA; PREDICTION
AB Backgroud The mechanism implicated in the osteogenesis of human periodontal ligament stem cells (PDLSCs) has been investigated for years. Previous genomics data analyses showed that long noncoding RNA (lncRNA), microRNA (miRNA) and messenger RNA (mRNA) have significant expression differences between induced and control human PDLSCs. Competing for endogenous RNAs (ceRNA), as a widely studied mechanism in regenerative medicine, while rarely reported in periodontal regeneration. The key lncRNAs and their ceRNA network might provide new insights into molecular therapies of periodontal regeneration based on PDLSCs. Results Two networks reflecting the relationships among differentially expressed RNAs were constructed. One ceRNA network was composed of 6 upregulated lncRNAs, 280 upregulated mRNAs, and 18 downregulated miRNAs. The other network contained 33 downregulated lncRNAs, 73 downregulated mRNAs, and 5 upregulated miRNAs. Functional analysis revealed that 38 GO terms and 8 pathways related with osteogenesis were enriched. Twenty four osteogenesis related gene centred lncRNA associated ceRNA networks were successfully constructed. Among these pathways, we highlighted MAPK and TGF beta pathways that are closely related to osteogenesis. Subsequently, subnetworks potentially linking the GO:0001649 (osteoblast differentiation), MAPK and TGF beta pathways were constructed. The qRT PCR validation results were consistent with the microarray analysis. Conclusion We construct a comprehensively identified lncRNA associated ceRNA network might be involved in the osteogenesis of PDLSCs, which could provide insights into the regulatory mechanisms and treatment targets of periodontal regeneration.
C1 [Lai, Lingzhi] Maoming Peoples Hosp, Dept Stomatol, Maoming 525000, Peoples R China.
   [Wang, Zhaodan; Ge, Yihong; Qiu, Wei; Wu, Buling; Fang, Fuchun; Xu, Huiyong] Southern Med Univ, Nanfang Hosp, Dept Stomatol, Guangzhou 510515, Guangdong, Peoples R China.
   [Wu, Buling; Chen, Zhao] Southern Med Univ, Shenzhen Stomatol Hosp Pingshan, 143 Dongzong Rd, Shenzhen 518118, Peoples R China.
C3 Southern Medical University   China; Southern Medical University   China
RP Xu, HY (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Stomatol, Guangzhou 510515, Guangdong, Peoples R China.; Chen, Z (通讯作者)，Southern Med Univ, Shenzhen Stomatol Hosp Pingshan, 143 Dongzong Rd, Shenzhen 518118, Peoples R China.
EM xhy581@163.com; tinycozy@163.com
RI Lai, Lingzhi/E 2585 2017
OI Wu, Buling/0000 0002 9678 6962
FU Medical Scientific Research Foundation of Guangdong Province [B2021074];
   Natural Science Foundation of Guangdong Province [2020A1515011453,
   2021A1515010854, 2020A1515011455, 2020A1515110027]; President Foundation
   of Nanfang Hospital, Southern Medical University [2020B024]; Highlevel
   Hospital Construction Research Project of Maoming People's Hospital
   [zx2020006]
FX This research was supported by the Medical Scientific Research
   Foundation of Guangdong Province (B2021074), the Natural Science
   Foundation of Guangdong Province (2020A1515011453, 2021A1515010854,
   2020A1515011455, 2020A1515110027), the President Foundation of Nanfang
   Hospital, Southern Medical University (2020B024) and the Highlevel
   Hospital Construction Research Project of Maoming People's Hospital
   (zx2020006).
CR Bunch H, 2018, MOL GENET GENOMICS, V293, P1, DOI 10.1007/s00438 017 1370 9
   Chen X, 2019, INT J MOL MED, V43, P1709, DOI 10.3892/ijmm.2019.4101
   Chen Z, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01622 w
   Deng LD, 2018, BIOCHEM BIOPH RES CO, V503, P2061, DOI 10.1016/j.bbrc.2018.07.160
   Fang FC, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1411 x
   Feng YM, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.918932
   Ghafouri Fard S, 2021, BIOMED PHARMACOTHER, V133, DOI 10.1016/j.biopha.2020.111093
   Gu XG, 2017, BMC GENET, V18, DOI 10.1186/s12863 017 0569 4
   Hao YL, 2017, J PERIODONTOL, V88, P1105, DOI 10.1902/jop.2017.170079
   He HX, 2010, STEM CELL REV REP, V6, P137, DOI 10.1007/s12015 009 9110 0
   Hu L, 2018, ORAL DIS, V24, P696, DOI 10.1111/odi.12703
   Huang YP, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 019 1519 z
   Huang YP, 2019, EUR J ORTHODONT, V41, P333, DOI 10.1093/ejo/cjy057
   Jiang H, 2017, MOL BIOSYST, V13, P1182, DOI 10.1039/c7mb00094d
   Kanehisa M, 2021, NUCLEIC ACIDS RES, V49, pD545, DOI 10.1093/nar/gkaa970
   Kanehisa M, 2019, PROTEIN SCI, V28, P1947, DOI 10.1002/pro.3715
   Karreth FA, 2014, METHODS MOL BIOL, V1167, P199, DOI 10.1007/978 1 4939 0835 6_13
   Kim BC, 2012, TISSUE ENG PART B RE, V18, P235, DOI [10.1089/ten.teb.2011.0642, 10.1089/ten.TEB.2011.0642]
   Li GC, 2021, LIFE SCI, V277, DOI 10.1016/j.lfs.2021.119419
   Li JJ, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 020 02123 6
   Li S, 2018, J PERIODONTAL RES, V53, P495, DOI 10.1111/jre.12539
   Li XM, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2581 2
   Li ZB, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01953 8
   Lin YF, 2021, J PERIODONTAL RES, V56, P679, DOI 10.1111/jre.12864
   Liu Y, 2019, AGING US, V11, P5334, DOI 10.18632/aging.102105
   Liu ZJ, 2020, J CELL PHYSIOL, V235, P3350, DOI 10.1002/jcp.29223
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   Qi XL, 2015, J MED GENET, V52, P710, DOI 10.1136/jmedgenet 2015 103334
   Qiu W, 2020, WORLD J STEM CELLS, V12, P251, DOI 10.4252/wjsc.v12.i4.251
   Qu Q, 2016, J PERIODONTOL, V87, pE127, DOI 10.1902/jop.2016.150592
   Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10
   Ransohoff JD, 2018, NAT REV MOL CELL BIO, V19, P143, DOI 10.1038/nrm.2017.104
   Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638
   Tay Y, 2014, CELL RES, V24, P259, DOI 10.1038/cr.2014.21
   Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986
   Tomokiyo A, 2019, STEM CELLS DEV, V28, P974, DOI 10.1089/scd.2019.0031
   Wang L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.125
   Wang Y, 2020, AGING US, V12, P24033, DOI 10.18632/aging.104095
   Wang Z, 2020, BMC DEV BIOL, V20, DOI 10.1186/s12861 019 0206 8
   Wu D, 2020, ARCH ORAL BIOL, V117, DOI 10.1016/j.archoralbio.2020.104814
   Wu H, 2019, ONCOL LETT, V17, P2457, DOI 10.3892/ol.2018.9831
   Wu WJ, 2018, MOL MED REP, V17, P7845, DOI 10.3892/mmr.2018.8846
   Xu SY, 2018, CANCER MED US, V7, P1019, DOI 10.1002/cam4.1315
   Yang J, 2021, ENDOCR CONNECT, P471
   Yang L, 2014, TRENDS BIOCHEM SCI, V39, P35, DOI 10.1016/j.tibs.2013.10.002
   Yang QL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00701
   Yi HZ, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4913
   Zhang C, 2017, ONCOTARGET, V8, P113543, DOI 10.18632/oncotarget.22708
   Zhang KY, 2020, INT J MOL MED, V46, P535, DOI 10.3892/ijmm.2020.4628
NR 49
TC 7
Z9 8
U1 0
U2 17
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2164
J9 BMC GENOMICS
JI BMC Genomics
PD JAN 3
PY 2022
VL 23
IS 1
AR 1
DI 10.1186/s12864 021 08243 4
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA XZ9IS
UT WOS:000737959800001
PM 34979896
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Qin, ZY
   Xie, HY
   Su, PC
   Song, ZS
   Xu, RY
   Guo, SS
   Fu, Y
   Zhang, P
   Jiang, HB
AF Qin, Ziyue
   Xie, Hanyu
   Su, Pengcheng
   Song, Zesheng
   Xu, Rongyao
   Guo, Songsong
   Fu, Yu
   Zhang, Ping
   Jiang, Hongbing
TI Targeting endoplasmic reticulum stress induced lymphatic dysfunction for
   mitigating bisphosphonate related osteonecrosis
SO CLINICAL AND TRANSLATIONAL MEDICINE
LA English
DT Article
DE autophagy; bisphosphonates; endoplasmic reticulum stress; lymphatic
   drainage; osteonecrosis
ID ZOLEDRONIC ACID; RHEUMATOID ARTHRITIS; CELL DEATH; AUTOPHAGY;
   VASCULATURE; APOPTOSIS; THERAPY; VESSELS; ROLES
AB BackgroundBisphosphonates (BPs) are the first line treatment to stop bone resorption in diseases, including osteoporosis, Paget's disease, multiple myeloma and bone metastases of cancer. However, BPs related osteonecrosis of the jaw (BRONJ), characterized by local inflammation and jawbone necrosis, is a severe intractable complication. The cumulative inflammatory burden often accompanies impaired lymphatic drainage, but its specific impact on BRONJ and the underlying mechanisms remain unclear.MethodsThe mouse BRONJ model was established to assess the integrity and drainage function of lymphatic vessels by tissue clearing techniques, injected indocyanine green lymphatic clearance assay, flow cytometry analysis and histopathological staining. RNA sequencing, metabolome analysis, transmission electron microscopy and Western blotting were utilized to analyze the impacts of Zoledronate acid (ZA) on endoplasmic reticulum stress (ERS) and function of lymphatic endothelial cells (LECs). By constructing Lyve1creERT; SIRT6f/f and Lyve1creERT; ATG5f/f mice, we evaluated the role of ERS induced LECs apoptosis in the progression of BRONJ. Additionally, we developed a nanoparticle loaded ZA and rapamycin (ZDPR) to enhance autophagy and evaluated its potential in mitigating BRONJ.ResultsThe mouse BRONJ model displayed impaired lymphatic drainage, accompanied by significant local inflammation and bone necrosis. The prolonged stimulation of ZA resulted in the extension of ERS and the inhibition of autophagy in LECs, ultimately leading to apoptosis. Mechanistically, ZA activated XBP1s through the NAD+/SIRT6 pathway, initiating ERS induced apoptosis in LECs. The conditional knockout mouse models demonstrated that the deletion of SIRT6 or ATG5 significantly worsened lymphatic drainage and inflammatory infiltration in BRONJ. Additionally, the innovative nanoparticle ZDPR alleviated ERS apoptosis in LECs and enhanced lymphatic function, facilitating inflammation resolution.ConclusionOur study has elucidated the role of the NAD+/SIRT6/XBP1s pathway in ERS induced apoptosis in ZA treated LECs, and further confirmed the therapeutic potential of ZDPR in restoring endothelial function and improving lymphatic drainage, thereby effectively mitigating BRONJ.Key points Bisphosphonate induced lymphatic drainage impairment exacerbates bone necrosis. Zoledronate acid triggers endoplasmic reticulum stress and apoptosis in lymphatic endothelial cells via the NAD+/SIRT6/XBP1s pathway. Novel nanoparticle loaded Zoledronate acid and rapamycin enhances autophagy, restores lymphatic function, and mitigates bisphosphonates related osteonecrosis of the jaw progression.
C1 [Qin, Ziyue; Xie, Hanyu; Su, Pengcheng; Song, Zesheng; Xu, Rongyao; Guo, Songsong; Fu, Yu; Zhang, Ping; Jiang, Hongbing] Nanjing Med Univ, Affiliated Hosp Stomatol, Dept Oral & Maxillofacial Surg, Nanjing, Peoples R China.
   [Qin, Ziyue; Xie, Hanyu; Su, Pengcheng; Song, Zesheng; Xu, Rongyao; Guo, Songsong; Fu, Yu; Zhang, Ping; Jiang, Hongbing] Nanjing Med Univ, State Key Lab Cultivat Base Res, Prevent & Treatment Oral Dis, Nanjing, Jiangsu, Peoples R China.
   [Jiang, Hongbing] Nanjing Med Univ, Jiangsu Prov Engn Res Ctr Stomatol Translat Med, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University
RP Jiang, HB (通讯作者)，Nanjing Med Univ, State Key Lab Cultivat Base Res, 140 Hanzhong Rd, Nanjing 210029, Peoples R China.
EM jhb@njmu.edu.cn
RI xie, hanyu/ISV 5855 2023; Xu, Rongyao/AHB 8403 2022; Jiang,
   Hongbing/AAQ 6331 2021; Qin, Ziyue/KTI 1804 2024
OI Jiang, Hongbing/0000 0002 3748 0381
FU National Natural Science Foundation of China; Jiangsu Province
   Capability Improvement Project through Science, Technology and
   Education Jiangsu Provincial Research Hospital Cultivation Unit
   [YJXYYJSDW4]; Jiangsu Provincial Medical Innovation Center [CXZX202227];
    [81771092];  [81970910]
FX This work was supported by the National Natural Science Foundation of
   China (81771092 and 81970910 to Hongbing Jiang), Jiangsu Province
   Capability Improvement Project through Science, Technology and
   Education Jiangsu Provincial Research Hospital Cultivation Unit
   (YJXYYJSDW4 to Hongbing Jiang) and Jiangsu Provincial Medical Innovation
   Center (CXZX202227 to Hongbing Jiang). We would like to thank Yongchu
   Pan, Mifang Yang, Zhibin Sun, Donglin Yan, Linlin Jiang, Kang Li and Lan
   Ma for their guidance in the utilization of experimental instruments
   (Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University).
   We thank Rui Gu, and Yatao Xu for their contribution to the preparation
   of ZDPR nanoparticles (Nanjing Tech University).
CR Adchariyasakulchai P, 2024, BIOMED PHARMACOTHER, V171, DOI 10.1016/j.biopha.2024.116142
   Ahmadi A, 2021, PHYTOTHER RES, V35, P5564, DOI 10.1002/ptr.7192
   Ahn JH, 2019, NATURE, V572, P62, DOI 10.1038/s41586 019 1419 5
   Arun MZ, 2016, DRUG DES DEV THER, V10, P1453, DOI 10.2147/DDDT.S103124
   Azizi M, 2023, LIFE SCI, V314, DOI 10.1016/j.lfs.2022.121341
   Bang In Hyuk, 2019, Exp Mol Med, V51, P1, DOI 10.1038/s12276 019 0309 0
   Bhardwaj M, 2020, SEMIN CANCER BIOL, V66, P116, DOI 10.1016/j.semcancer.2019.11.007
   Bhatia S, 2022, CHEM REV, V122, P8911, DOI 10.1021/acs.chemrev.1c00704
   Biswas L, 2023, CELL, V186, P382, DOI 10.1016/j.cell.2022.12.031
   Budzinska A, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 43377 3
   Chen XY, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01570 w
   Chen YF, 2023, NEW ENGL J MED, V388, pE69, DOI 10.1056/NEJMicm2209172
   Cybulsky AV, 2017, NAT REV NEPHROL, V13, P681, DOI 10.1038/nrneph.2017.129
   Du HN, 2024, ENVIRON INT, V184, DOI 10.1016/j.envint.2024.108445
   Emdad L, 2020, SEMIN CANCER BIOL, V66, P140, DOI 10.1016/j.semcancer.2019.07.013
   Ensrud Kristine E, 2021, JAMA, V325, P96, DOI 10.1001/jama.2020.2923
   Favus MJ, 2010, NEW ENGL J MED, V363, P2027, DOI 10.1056/NEJMct1004903
   Gadallah SH, 2021, ARCH PHYSIOL BIOCHEM, V127, P235, DOI 10.1080/13813455.2019.1628069
   Glimcher LH, 2020, NAT IMMUNOL, V21, P963, DOI 10.1038/s41590 020 0708 3
   Guo ZY, 2023, CLIN TRANSL MED, V13, DOI 10.1002/ctm2.1377
   Hetz C, 2020, NAT REV MOL CELL BIO, V21, P421, DOI 10.1038/s41580 020 0250 z
   Hsu M, 2022, NAT IMMUNOL, V23, P581, DOI 10.1038/s41590 022 01158 6
   Kara M, 2022, J BIOCHEM MOL TOXIC, V36, DOI 10.1002/jbt.23083
   Kataura T, 2024, CELL DEATH DIS, V15, DOI 10.1038/s41419 024 06770 y
   Kato M, 2014, ARTHRITIS RHEUMATOL, V66, P40, DOI 10.1002/art.38190
   Kessel D, 2020, AUTOPHAGY, V16, P2098, DOI 10.1080/15548627.2020.1783823
   Khandelwal VKM, 2014, PHYSIOL RES, V63, pS601, DOI 10.33549/physiolres.932934
   Kuroshima S, 2013, BONE, V56, P101, DOI 10.1016/j.bone.2013.05.013
   Li P, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.1039
   Lin JW., 2022, Int J Mol Sci, V23
   Liu KM, 2015, AM J PHYSIOL RENAL, V309, pF318, DOI 10.1152/ajprenal.00607.2014
   Lu Y, 2016, MOL MED REP, V14, P4747, DOI 10.3892/mmr.2016.5834
   Lund T, 2024, BLOOD CANCER J, V14, DOI 10.1038/s41408 024 01046 2
   Madhavan A, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28271 2
   Naama M, 2023, AUTOPHAGY, V19, P3014, DOI 10.1080/15548627.2023.2228191
   Okawa H, 2022, ELIFE, V11, DOI 10.7554/eLife.76207
   Oliver G, 2020, CELL, V182, P270, DOI 10.1016/j.cell.2020.06.039
   Otto S, 2018, CANCER TREAT REV, V69, P177, DOI 10.1016/j.ctrv.2018.06.007
   Park SY, 2022, BIOCHEM PHARMACOL, V199, DOI 10.1016/j.bcp.2022.115022
   Peng Y, 2017, LIFE SCI, V185, P63, DOI 10.1016/j.lfs.2017.07.024
   Phillips J, 2024, ANN RHEUM DIS, V83, P529, DOI 10.1136/ard 2023 224990
   Qu XZ, 2024, APPL BIOCHEM BIOTECH, V196, P7362, DOI 10.1007/s12010 024 04859 w
   Ramasamy SK, 2016, ANNU REV CELL DEV BI, V32, P649, DOI 10.1146/annurev cellbio 111315 124936
   Rigg N, 2022, NEUROTOXICOLOGY, V91, P321, DOI 10.1016/j.neuro.2022.06.004
   Roichman A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 23545 7
   Savino S, 2018, EUR J MED CHEM, V158, P184, DOI 10.1016/j.ejmech.2018.08.044
   Seo EH, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24065336
   Shah TS, 2022, J EXP MED, V220, DOI 10.1084/jem.20220618
   Shen X, 2022, JCI INSIGHT, V7, DOI 10.1172/jci.insight.159865
   Sim IW, 2020, J CLIN ONCOL, V38, P2971, DOI 10.1200/JCO.19.02192
   Sun ST, 2021, BRIT J PHARMACOL, V178, P2008, DOI 10.1111/bph.15251
   Vishlaghi N, 2024, CELL REP, V43, DOI 10.1016/j.celrep.2024.114049
   Wilson N, 2023, TRENDS CELL BIOL, V33, P788, DOI 10.1016/j.tcb.2023.02.004
   Wiseman RL, 2022, MOL CELL, V82, P1477, DOI 10.1016/j.molcel.2022.03.025
   Xia Y, 2018, CELL, V175, P1059, DOI 10.1016/j.cell.2018.08.070
   Xu Q, 2021, J CELL MOL MED, V25, P10126, DOI 10.1111/jcmm.16949
   Xu RY, 2023, ADV SCI, V10, DOI 10.1002/advs.202303946
   Xue Q, 2023, AUTOPHAGY, V19, P2175, DOI 10.1080/15548627.2023.2200554
   Yamashita J, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115611
   Yang YY, 2024, CELL DEATH DIS, V15, DOI 10.1038/s41419 024 06515 x
   Yu SW, 2024, KIDNEY INT, V106, P433, DOI 10.1016/j.kint.2024.04.015
   Zhang RJ, 2023, APOPTOSIS, V28, P977, DOI 10.1007/s10495 023 01858 w
   Zheng YK, 2024, J ORTHOP TRANSL, V45, P66, DOI 10.1016/j.jot.2024.02.001
   Zhou SR, 2024, THERANOSTICS, V14, P265, DOI 10.7150/thno.90940
   Zhu JH., 2017, Biomed Res Int, V2017
NR 65
TC 1
Z9 1
U1 4
U2 15
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2001 1326
J9 CLIN TRANSL MED
JI Clin. Transl. Med.
PD NOV
PY 2024
VL 14
IS 11
AR e70082
DI 10.1002/ctm2.70082
PG 22
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA O1G9Q
UT WOS:001368708200001
PM 39521624
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chakraborty, S
   Goswami, D
   Chakravarty, R
   Mohammed, SK
   Sarma, HD
   Dash, A
AF Chakraborty, Sudipta
   Goswami, Dibakar
   Chakravarty, Rubel
   Mohammed, Sahiralam Khan
   Sarma, Haladhar Deb
   Dash, Ashutosh
TI Syntheses and evaluation of <SUP>68</SUP>Ga  and
   <SUP>153</SUP>Sm labeled DOTA conjugated bisphosphonate ligand for
   potential use in detection of skeletal metastases and management of pain
   arising from skeletal metastases
SO CHEMICAL BIOLOGY & DRUG DESIGN
LA English
DT Article
DE Sm 153; Ga 68; bifunctional chelator; bisphosphonates; skeletal
   accumulation; skeletal metastases
ID BONE SEEKING; RADIOPHARMACEUTICAL THERAPY; BIFUNCTIONAL CHELATORS;
   OSSEOUS METASTASES; CANCER; LU 177 DOTMP; PALLIATION; AGENTS; BREAST
AB This article reports the syntheses and evaluation of Ga 68  and Sm 153 complexes of a new DOTA (1,4,7,10 tetraazacyclododecane 1,4,7,10 tetraacetic acid) conjugated geminal bisphosphonate, DOTA Bn SCN BP, for their potential uses in the early detection of skeletal metastases by imaging and palliation of pain arising from skeletal metastases, respectively. The conjugate was synthesized in high purity following an easily adaptable three step reaction scheme. Gallium 68  and Sm 153 complexes were prepared in high yield (>98%) and showed excellent in vitro stability in phosphate buffered saline (PBS) and human serum. Both the complexes showed high affinity for hydroxyapatite particles in in vitro binding study. In biodistribution studies carried out in normal Wistar rats, both the complexes exhibited rapid skeletal accumulation with almost no retention in any other major organ. The newly synthesized molecule DOTA Bn SCN BP would therefore be a promising targeting ligand for the development of radiopharmaceuticals for both imaging skeletal metastases and palliation of pain arising out of it in patients with cancer when radiolabeled with Ga 68 and Sm 153, respectively. A systematic comparative evaluation, however, showed that there was no significant improvement of skeletal accumulation of the Sm 153 DOTA Bn SCN BP complex over Sm 153 DOTMP (1,4,7,10 tetraazacyclododecane 1,4,7,10 tetramethylenephosphonic acid) as the later itself demonstrated optimal properties required for an agent for bone pain palliation.
C1 [Chakraborty, Sudipta; Chakravarty, Rubel; Mohammed, Sahiralam Khan; Dash, Ashutosh] Bhabha Atom Res Ctr, Radiopharmaceut Div, Bombay, Maharashtra, India.
   [Chakraborty, Sudipta; Goswami, Dibakar; Chakravarty, Rubel; Dash, Ashutosh] Homi Bhabha Natl Inst, Bombay, Maharashtra, India.
   [Goswami, Dibakar] Bhabha Atom Res Ctr, Bio Organ Div, Bombay, Maharashtra, India.
   [Sarma, Haladhar Deb] Bhabha Atom Res Ctr, Radiat Biol & Hlth Sci Div, Bombay, Maharashtra, India.
C3 Bhabha Atomic Research Center (BARC); Homi Bhabha National Institute;
   Bhabha Atomic Research Center (BARC); Bhabha Atomic Research Center
   (BARC)
RP Chakraborty, S (通讯作者)，Bhabha Atom Res Ctr, Radiopharmaceut Div, Bombay, Maharashtra, India.
EM sudipta@barc.gov.in
RI ; Sarma, Haladhar Dev/C 2350 2009; Sarma, Haladhar/C 2350 2009; goswami,
   dibakar/AAE 2672 2019
OI Chakraborty, Sudipta/0000 0002 8002 439X; Sarma, Haladhar
   Dev/0000 0001 7168 4487; 
CR Baum RP, 2012, THERANOSTICS, V2, P437, DOI 10.7150/thno.3645
   Bergmann R, 2016, EJNMMI RES, V6, DOI 10.1186/s13550 016 0161 3
   Chakraborty S, 2008, APPL RADIAT ISOTOPES, V66, P1196, DOI 10.1016/j.apradiso.2008.02.061
   Chakraborty S, 2017, J LABELLED COMPD RAD, V60, P410, DOI 10.1002/jlcr.3517
   Chakravarty R, 2013, NUCL MED BIOL, V40, P197, DOI 10.1016/j.nucmedbio.2012.11.001
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Correa González L, 2014, ARCH MED RES, V45, P301, DOI 10.1016/j.arcmed.2014.03.006
   desRosales R. T. M., 2009, CHEM COMMUN, V32, P4847
   Fellner M, 2012, NUCL MED BIOL, V39, P993, DOI 10.1016/j.nucmedbio.2012.04.007
   FRIEDELL HL, 1950, AM J ROENTGENOL, V64, P559
   Kantoci D, 1996, SYNTHETIC COMMUN, V26, P2037, DOI 10.1080/00397919608003560
   Kubícek V, 2005, J AM CHEM SOC, V127, P16477, DOI 10.1021/ja054905u
   Lam MGEH, 2007, ANTI CANCER AGENT ME, V7, P381
   Lange R, 2016, BONE, V91, P159, DOI 10.1016/j.bone.2016.08.002
   Lewington VJ, 2005, J NUCL MED, V46, p38S
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Liu S, 2001, BIOCONJUGATE CHEM, V12, P7, DOI 10.1021/bc000070v
   Meckel M., 2016, EJNMMI RADIOPHARM CH, V1, P14
   Meckel M, 2015, CANCER BIOTHER RADIO, V30, P94, DOI 10.1089/cbr.2014.1720
   Ogawa K, 2011, NUCL MED BIOL, V38, P631, DOI 10.1016/j.nucmedbio.2010.12.004
   Paes FM, 2010, SEMIN NUCL MED, V40, P89, DOI 10.1053/j.semnuclmed.2009.10.003
   Pandit Taskar N, 2004, J NUCL MED, V45, P1358
   Passah A, 2017, EUR J NUCL MED MOL I, V44, P41, DOI 10.1007/s00259 016 3469 3
   Pfannkuchen N, 2017, PHARMACEUTICALS BASE, V10, DOI 10.3390/ph10020045
   Rubens RD, 1998, EUR J CANCER, V34, P210, DOI 10.1016/S0959 8049(97)10128 9
   Suzuki K, 2011, NUCL MED BIOL, V38, P1011, DOI 10.1016/j.nucmedbio.2011.02.015
   Uludag H, 2000, BIOTECHNOL PROGR, V16, P258, DOI 10.1021/bp990154m
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
NR 28
TC 9
Z9 9
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1747 0277
EI 1747 0285
J9 CHEM BIOL DRUG DES
JI Chem. Biol. Drug Des.
PD SEP
PY 2018
VL 92
IS 3
BP 1618
EP 1626
DI 10.1111/cbdd.13327
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA GS1PP
UT WOS:000443302700004
PM 29729071
DA 2025 08 17
ER

PT J
AU Xiao, F
   Zhou, Y
   Liu, YF
   Xie, M
   Guo, GC
AF Xiao, Fei
   Zhou, Yun
   Liu, Yongfu
   Xie, Mian
   Guo, Guancheng
TI Inhibitory Effect of Sirtuin6 (SIRT6) on Osteogenic Differentiation of
   Bone Marrow Mesenchymal Stem Cells
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Osteosarcoma; Sirtuin 1; Sirtuins
ID GENE RELATED PEPTIDE; MICE LACKING; INTERNATIONAL SOCIETY; IMPAIRED
   NOCICEPTION; PAIN SENSATION; TRPV1; OSTEOPOROSIS; OSTEOCLASTOGENESIS;
   INVOLVEMENT; ACTIVATION
AB Background: The imbalance between bone resorption and formation is the basic mechanism underlying osteoporosis in the elderly. Osteogenesis is the differentiation of human mesenchymal stem cells (hMSCs) into osteoblasts. Sirtuin6 (SIRT6) regulates various biological functions, including differentiation. Transient receptor potential cation channel subfamily V member 1 (TRPV1) is a non selective cation channel that can be activated by physical and chemical stimulation. However, experimental data supporting the role of SIRT6 in osteogenic differentiation (OD) of hMSCs are lacking.
   Material/Methods: Differentiation of hMSCs was induced. The expressions of SIRT6, TRPV1, and CGRP were detected by Q PCR, Western blot, and ELISA, respectively. SIRT6 was overexpressed in hMSCs by transfection. ALP activity and Alizarin Red staining were utilized to detect the effect of SIRT6 on hMSC OD. Then, capsaicin and capsazepine, the TRPV1 agonist and antagonist, respectively, were administrated to assess the role of TRPV1.
   Results: SIRT6 expression was downregulated during hMSC differentiation. SIRT6 overexpression was accompanied by reduced expression of specific genes and alkaline phosphatase (ALP) activity in osteoblasts. Furthermore, TRPV1 channel was also reduced by SIRT6 overexpression via ubiquitinating TRPV1. Capsaicin was utilized in SIRT6 overexpressed cells. Capsaicin therapy counteracted the effect of SIRT6 overexpression on OD, and markedly decreased OD.
   Conclusion: The SIRT6 TRPV1 CGRP signal axis is the key to regulating OD in hMSCs, which could be a potential therapeutic target for osteoporosis and bone loss related diseases.
C1 [Xiao, Fei; Zhou, Yun; Liu, Yongfu; Xie, Mian; Guo, Guancheng] Zhengzhou Univ, Dept Emergency Surg, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
C3 Zhengzhou University
RP Guo, GC (通讯作者)，Zhengzhou Univ, Dept Emergency Surg, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
EM guanchengguoo@163.com
CR Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059
   Alm JJ, 2010, J ORTHOP RES, V28, P1634, DOI 10.1002/jor.21167
   Assas BM, 2014, FRONT NEUROSCI SWITZ, V8, DOI 10.3389/fnins.2014.00023
   Bareille P, 2013, INT J CLIN PHARM TH, V51, P576, DOI 10.5414/CP201890
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brain SD, 2004, PHYSIOL REV, V84, P903, DOI 10.1152/physrev.00037.2003
   Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fan JZ, 2014, MOL CELL BIOCHEM, V392, P85, DOI 10.1007/s11010 014 2021 7
   Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197
   FRANCOCERECEDA A, 1992, EUR J PHARMACOL, V221, P183, DOI 10.1016/0014 2999(92)90792 3
   Gomes RN, 2005, SHOCK, V24, P590, DOI 10.1097/01.shk.0000183395.29014.7c
   Green DP, 2016, MOL PAIN, V12, DOI 10.1177/1744806916661725
   Haigis MC, 2010, ANNU REV PATHOL MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250
   Han QJ, 2016, NEURON, V92, P1279, DOI 10.1016/j.neuron.2016.11.007
   Hanaka M, 2018, BONE, V110, P284, DOI 10.1016/j.bone.2018.02.006
   He LH, 2017, SCI REP UK, V7, DOI 10.1038/srep42385
   HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306 4522(88)90064 4
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Hu KZ, 2017, BIOMED PHARMACOTHER, V91, P841, DOI 10.1016/j.biopha.2017.04.094
   Idris AI, 2010, BONE, V46, P1089, DOI 10.1016/j.bone.2010.01.368
   Irie K, 2002, MICROSC RES TECHNIQ, V58, P85, DOI 10.1002/jemt.10122
   Jang Young Eun, 2015, Restor Dent Endod, V40, P223, DOI 10.5395/rde.2015.40.3.223
   Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654
   Lerner U. H., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P440
   Naot D, 2008, BONE, V43, P813, DOI 10.1016/j.bone.2008.07.003
   Negri L, 2006, J NEUROSCI, V26, P6716, DOI 10.1523/JNEUROSCI.5403 05.2006
   Park SJ, 2016, SCI REP UK, V6, DOI 10.1038/srep26186
   Pilgram TK, 2002, J PERIODONTOL, V73, P298, DOI 10.1902/jop.2002.73.3.298
   Pinho Ribeiro FA, 2017, TRENDS IMMUNOL, V38, P5, DOI 10.1016/j.it.2016.10.001
   Qiu WM, 2010, J BIOL CHEM, V285, P14438, DOI 10.1074/jbc.M109.052001
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Riera CE, 2014, CELL, V157, P1023, DOI 10.1016/j.cell.2014.03.051
   Rodríguez JP, 2000, J CELL BIOCHEM, V79, P557, DOI 10.1002/1097 4644(20001215)79:4<557::AID JCB40>3.0.CO;2 H
   Romanovsky AA, 2009, PHARMACOL REV, V61, P228, DOI 10.1124/pr.109.001263
   Rosenbaum Andrew J, 2008, Organogenesis, V4, P23
   Schinke T, 2004, J BONE MINER RES, V19, P2049, DOI 10.1359/JBMR.040915
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Song HY, 2018, ANTICANCER RES, V38, P647, DOI 10.21873/anticanres.12268
   Sugatani T, 2015, BONE, V81, P168, DOI 10.1016/j.bone.2015.07.018
   Takahashi N, 2016, SCI REP UK, V6, DOI 10.1038/srep29294
   Valentijn K, 1997, BONE, V21, P269, DOI 10.1016/S8756 3282(97)00142 7
   Wang LP, 2010, BONE, V46, P1369, DOI 10.1016/j.bone.2009.11.029
   Yao QP, 2014, INT J BIOCHEM CELL B, V49, P98, DOI 10.1016/j.biocel.2014.01.016
   Zhai XY, 2016, REJUV RES, V19, P373, DOI 10.1089/rej.2015.1770
   Zhang DM, 2016, INT J ORAL SCI, V8, P84, DOI 10.1038/ijos.2015.57
   Zhang P, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10323 z
   Zhao R, 2017, J CELL PHYSIOL, V232, P1957, DOI 10.1002/jcp.25704
NR 48
TC 18
Z9 23
U1 1
U2 8
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643 3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD NOV 8
PY 2019
VL 25
BP 8412
EP 8421
DI 10.12659/MSM.917118
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA JL7LP
UT WOS:000495710200002
PM 31701920
OA Green Published
DA 2025 08 17
ER

PT J
AU Misra, J
   Mohanty, ST
   Madan, S
   Fernandes, JA
   Ebetino, FH
   Russell, RGG
   Bellantuono, I
AF Misra, Juhi
   Mohanty, Sindhu T.
   Madan, Sanjeev
   Fernandes, James A.
   Ebetino, F. Hal
   Russell, R. Graham G.
   Bellantuono, Ilaria
TI Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem
   Cells and Protects Their Function
SO STEM CELLS
LA English
DT Article
DE Stem cells; DNA damage; Aging; Radiation; mTOR; Bisphosphonates
ID AGE RELATED CHANGES; BONE MARROW; STROMAL CELLS; ACID; STRESS; ATM;
   BISPHOSPHONATES; DIFFERENTIATION; IRRADIATION; MECHANISMS
AB Mesenchymal stem cells (MSCs) undergo a decline in function following ex vivo expansion and exposure to irradiation. This has been associated with accumulation of DNA damage and has important implications for tissue engineering approaches or in patients receiving radiotherapy. Therefore, interventions, which limit accumulation of DNA damage in MSC, are of clinical significance. We were intrigued by findings showing that zoledronate (ZOL), an anti resorptive nitrogen containing bisphosphonate, significantly extended survival in patients affected by osteoporosis. The effect was too large to be simply due to the prevention of fractures. Moreover, in combination with statins, it extended the lifespan in a mouse model of Hutchinson Gilford Progeria Syndrome. Therefore, we asked whether ZOL was able to extend the lifespan of human MSC and whether this was due to reduced accumulation of DNA damage, one of the important mechanisms of aging. Here, we show that this was the case both following expansion and irradiation, preserving their ability to proliferate and differentiate in vitro. In addition, administration of ZOL before irradiation protected the survival of mesenchymal progenitors in mice. Through mechanistic studies, we were able to show that inhibition of mTOR signaling, a pathway involved in longevity and cancer, was responsible for these effects. Our data open up new opportunities to protect MSC from the side effects of radiotherapy in cancer patients and during ex vivo expansion for regenerative medicine approaches. Given that ZOL is already in clinical use with a good safety profile, these opportunities can be readily translated for patient benefit.
C1 [Misra, Juhi; Mohanty, Sindhu T.; Russell, R. Graham G.; Bellantuono, Ilaria] Univ Sheffield, Sch Med, Mellanby Ctr Bone Res, Sheffield, S Yorkshire, England.
   [Misra, Juhi; Mohanty, Sindhu T.; Russell, R. Graham G.; Bellantuono, Ilaria] Univ Sheffield, Sch Med, Dept Human Metab, MRC Arthrit Res Ctr Integrated Res Musculoskeleta, Sheffield, S Yorkshire, England.
   [Madan, Sanjeev; Fernandes, James A.] Sheffield Childrens Hosp, Dept Paediat Orthopaed & Trauma Surg, Sheffield, S Yorkshire, England.
   [Ebetino, F. Hal] Univ Rochester, Dept Chem, Rochester, NY USA.
   [Ebetino, F. Hal] Univ Oxford, Struct Genom Consortium, Oxford, England.
   [Russell, R. Graham G.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Inst Musculoskeletal Sci,Oxford NIHR Biomed Res U, Oxford, England.
C3 University of Sheffield; University of Sheffield; Sheffield Children's
   NHS Foundation Trust; Sheffield Children's Hospital; University of
   Rochester; University of Oxford; University of Oxford
RP Bellantuono, I (通讯作者)，Univ Sheffield, Sch Med, Dept Human Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM i.bellantuono@shef.ac.uk
RI Russell, Robert Graham G/JEF 5877 2023; Bellantuono,
   Ilaria/ABF 2700 2021; Russell, R/JEF 5877 2023
OI Russell, Robert Graham G/0000 0002 4136 1828; Madan,
   Sanjeev/0000 0003 2604 3810; Bellantuono, Ilaria/0000 0001 9994 6987
FU University of Sheffield; MRC; Arthritis Research UK as part of the
   MRC Arthritis Research UK Centre for Integrated research into
   Musculoskeletal Ageing (CIMA); Medical Research Council [MR/K006312/1]
   Funding Source: researchfish; MRC [MR/K006312/1, MC_PC_13076] Funding
   Source: UKRI
FX We thank Susan Smith, Healthcare Gateway, for helpful discussions. The
   enantiomeric pair of pyrindine bisphosphonates was kindly provided by
   Prof. Robert Boeckman, University of Rochester, Rochester, NY. This work
   was supported by the proof of concept fund a studentship from the
   University of Sheffield (to J.M.) and by the MRC and Arthritis Research
   UK as part of the MRC Arthritis Research UK Centre for Integrated
   research into Musculoskeletal Ageing (CIMA).
CR Alves H, 2010, J CELL MOL MED, V14, P2729, DOI 10.1111/j.1582 4934.2009.00931.x
   Baxter MA, 2004, STEM CELLS, V22, P675, DOI 10.1634/stemcells.22 5 675
   Baxter NN, 2005, JAMA J AM MED ASSOC, V294, P2587, DOI 10.1001/jama.294.20.2587
   Cao X, 2011, P NATL ACAD SCI USA, V108, P1609, DOI 10.1073/pnas.1015350108
   Chowdhury D, 2013, NAT REV MOL CELL BIO, V14, P181, DOI 10.1038/nrm3523
   Cmielova J, 2012, INT J RADIAT BIOL, V88, P393, DOI 10.3109/09553002.2012.666001
   Coleman R, 2014, LANCET ONCOL, V15, P997, DOI 10.1016/S1470 2045(14)70302 X
   Coleman R, 2011, CANCER AM CANCER SOC, V117, P11, DOI 10.1002/cncr.25529
   Colón Emeric CS, 2010, J BONE MINER RES, V25, P91, DOI 10.1359/jbmr.090704
   COSTANTINO PD, 1995, OTOLARYNG CLIN N AM, V28, P1021
   Ebert R, 2009, BONE, V44, P858, DOI 10.1016/j.bone.2009.01.009
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Gharibi B, 2014, STEM CELLS, V32, P2256, DOI 10.1002/stem.1709
   Grayson WL, 2015, NAT REV ENDOCRINOL, V11, P140, DOI 10.1038/nrendo.2014.234
   Inomata K, 2009, CELL, V137, P1088, DOI 10.1016/j.cell.2009.03.037
   Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989
   Jegoux F, 2010, ORAL SURG ORAL MED O, V109, P173, DOI 10.1016/j.tripleo.2009.10.001
   Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861
   Lee CH, 2010, CANCER RES, V70, P1564, DOI 10.1158/0008 5472.CAN 09 3228
   Liu BH, 2005, NAT MED, V11, P780, DOI 10.1038/nm1266
   Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097 2765(02)00636 6
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Miyamoto K, 2008, BLOOD, V112, P4485, DOI 10.1182/blood 2008 05 159848
   Mohanty ST, 2012, STEM CELLS, V30, P1134, DOI 10.1002/stem.1065
   Naveiras O, 2009, NATURE, V460, P259, DOI 10.1038/nature08099
   Oliver L, 2013, STEM CELLS, V31, P800, DOI 10.1002/stem.1336
   Otto S, 2010, J ORAL MAXIL SURG, V68, P2837, DOI 10.1016/j.joms.2010.07.017
   Paik JH, 2009, CELL STEM CELL, V5, P540, DOI 10.1016/j.stem.2009.09.013
   Renault VM, 2009, CELL STEM CELL, V5, P527, DOI 10.1016/j.stem.2009.09.014
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Scaffidi P, 2006, SCIENCE, V312, P1059, DOI 10.1126/science.1127168
   Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002
   Takubo K, 2008, CELL STEM CELL, V2, P170, DOI 10.1016/j.stem.2007.10.023
   Tsai WB, 2008, NAT CELL BIOL, V10, P460, DOI 10.1038/ncb1709
   Varela I, 2008, NAT MED, V14, P767, DOI 10.1038/nm1786
   Wallin JJ, 2011, MOL CANCER THER, V10, P2426, DOI 10.1158/1535 7163.MCT 11 0446
   Wu X, 2000, BONE, V26, P21, DOI 10.1016/S8756 3282(99)00238 0
   Xue Q, 2008, CANCER RES, V68, P9551, DOI 10.1158/0008 5472.CAN 08 2058
   Zhang X, 2015, STEM CELLS, V33, P1915, DOI 10.1002/stem.2019
NR 42
TC 50
Z9 52
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD MAR
PY 2016
VL 34
IS 3
BP 756
EP 767
DI 10.1002/stem.2255
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA DH1NU
UT WOS:000372552600021
PM 26679354
OA Green Published, hybrid, Green Accepted
DA 2025 08 17
ER

PT J
AU Zhu, DL
   Chen, XF
   Zhou, XR
   Hu, SY
   Tuo, XM
   Hao, RH
   Dong, SS
   Jiang, F
   Rong, Y
   Yang, TL
   Yang, Z
   Guo, Y
AF Zhu, Dong Li
   Chen, Xiao Feng
   Zhou, Xiao Rong
   Hu, Shou Ye
   Tuo, Xiao Mei
   Hao, Ruo Han
   Dong, Shan Shan
   Jiang, Feng
   Rong, Yu
   Yang, Tie Lin
   Yang, Zhi
   Guo, Yan
TI An Osteoporosis Susceptibility Allele at 11p15 Regulates SOX6
   Expression by Modulating TCF4 Chromatin Binding
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE TRANSCRIPTION FACTORS; OSTEOBLAST; OSTEOPOROSIS; DISEASES AND DISORDERS
   OF/RELATED TO BONE; POPULATION STUDIES; EPIDEMIOLOGY; HUMAN ASSOCIATION
   STUDIES; GENETIC RESEARCH
ID GENOME WIDE ASSOCIATION; LOCI; EXPANSION; RISK
AB Osteoporosis is an age related complex disease clinically diagnosed with bone mineral density (BMD). Although several genomewide association studies (GWASs) have discovered multiple noncoding genetic variants at 11p15 influencing osteoporosis risk, the functional mechanisms of these variants remain unknown. Through integrating bioinformatics and functional experiments, a potential functional single nucleotide polymorphism (SNP; rs1440702) located in an enhancer element was identified and the A allele of rs1440702 acted as an allelic specificities enhancer to increase its distal target gene SOX6 (similar to 600 Kb upstream) expression, which plays a key role in bone formation. We also validated this long range regulation via conducting chromosome conformation capture (3C) assay. Furthermore, we demonstrated that SNP rs1440702 with a risk allele (rs1440702 A) could increase the activity of the enhancer element by altering the binding affinity of the transcription factor TCF4, resulting in the upregulation expression of SOX6 gene. Collectively, our integrated analyses revealed how the noncoding genetic variants (rs1440702) affect osteoporosis predisposition via long range gene regulatory mechanisms and identified its target gene SOX6 for downstream biomarker and drug development. (C) 2022 American Society for Bone and Mineral Research (ASBMR).
C1 [Zhu, Dong Li; Chen, Xiao Feng; Zhou, Xiao Rong; Tuo, Xiao Mei; Hao, Ruo Han; Dong, Shan Shan; Jiang, Feng; Rong, Yu; Yang, Tie Lin; Guo, Yan] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian 710049, Shaanxi, Peoples R China.
   [Zhu, Dong Li; Chen, Xiao Feng; Zhou, Xiao Rong; Tuo, Xiao Mei; Hao, Ruo Han; Dong, Shan Shan; Jiang, Feng; Rong, Yu; Yang, Tie Lin; Guo, Yan] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Biomed Informat & Genom Ctr, Xian 710049, Shaanxi, Peoples R China.
   [Hu, Shou Ye; Yang, Zhi; Guo, Yan] Xi An Jiao Tong Univ, Honghui Hosp, Xian 710049, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong
   University
RP Guo, Y (通讯作者)，Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian 710049, Shaanxi, Peoples R China.; Guo, Y (通讯作者)，Xi An Jiao Tong Univ, Sch Life Sci & Technol, Biomed Informat & Genom Ctr, Xian 710049, Shaanxi, Peoples R China.; Yang, Z (通讯作者)，Xi An Jiao Tong Univ, Honghui Hosp, Xian 710049, Shaanxi, Peoples R China.
EM xgcgfd@126.com; guoyan253@xjtu.edu.cn
RI Chen, Xiao Feng/AAN 8808 2020; Guo, Yan/G 8742 2014; Zhou,
   Xiaorong/M 3600 2014; Yang, Tie Lin/G 8365 2014; JIANG,
   Feng/HTP 2862 2023
OI Chen, Xiao Feng/0000 0002 5886 6427; Jiang, Feng/0000 0002 9726 5720; 
FU National Natural Science Foundation of China [31970569, 82170896,
   32000409, 32000394]; Natural Science Basic Research Program Shaanxi
   Province [2020JQ 026]; Science Fund for Distinguished Young Scholars of
   Shaanxi Province [2021JC 02]; Shaanxi Provincial Key Research and
   Development Project [2019ZDLSF01 09]; Innovation Capability Support
   Program of Shaanxi Province [2022TD 44]; China Postdoctoral Science
   Foundation [2019M650261]; Fundamental Research Funds for the Central
   Universities; High Performance Computing Platform and Instrument
   Analysis Center of Xi'an Jiaotong University
FX This study is supported by the National Natural Science Foundation of
   China (31970569, 82170896, 32000409, and 32000394); Natural Science
   Basic Research Program Shaanxi Province (2020JQ 026); Science Fund for
   Distinguished Young Scholars of Shaanxi Province (2021JC 02); Shaanxi
   Provincial Key Research and Development Project (2019ZDLSF01 09);
   Innovation Capability Support Program of Shaanxi Province (2022TD 44);
   China Postdoctoral Science Foundation (2019M650261); and the Fundamental
   Research Funds for the Central Universities. This study is also
   supported by the High Performance Computing Platform and Instrument
   Analysis Center of Xi'an Jiaotong University. Authors' roles: ZDL and GY
   performed study concept and design. ZDL performed development of
   methodology and writing. CXF, HRH, JF, and DSS provided acquisition,
   analysis and interpretation of data, and statistical analysis. ZDL, ZXR,
   and TXM performed experiments for every portion of the manuscript. ZDL,
   HSY, and RY performed drawing. YTL, YZ, and GY performed review and
   revision of the paper. All authors read and approved the final paper.
CR [Anonymous], 2012, NATURE, V489
   Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335
   Benner C, 2016, BIOINFORMATICS, V32, P1493, DOI 10.1093/bioinformatics/btw018
   Chen XF, 2018, AM J HUM GENET, V102, P776, DOI 10.1016/j.ajhg.2018.03.001
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   Feng GJ, 2021, J HUM GENET, V66, P251, DOI 10.1038/s10038 020 00835 4
   Glass DA, 2006, ANN NY ACAD SCI, V1068, P117, DOI 10.1196/annals.1346.015
   Hao R.H., 2020, 3D CHROMATIN ORG CHA
   Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106
   Hsu YH, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000977
   Jolma A, 2013, CELL, V152, P327, DOI 10.1016/j.cell.2012.12.009
   Kulakovskiy IV, 2016, NUCLEIC ACIDS RES, V44, pD116, DOI 10.1093/nar/gkv1249
   Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718
   Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176
   Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794
   Morris JA, 2019, NAT GENET, V51, P258, DOI 10.1038/s41588 018 0302 x
   Musunuru K, 2010, NATURE, V466, P714, DOI 10.1038/nature09266
   Pachkov M, 2007, NUCLEIC ACIDS RES, V35, pD127, DOI 10.1093/nar/gkl857
   Pouresmaeili F, 2018, THER CLIN RISK MANAG, V14, P2029, DOI 10.2147/TCRM.S138000
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Richards JB, 2012, NAT REV GENET, V13, P576, DOI 10.1038/nrg3228
   Rivadeneira F, 2009, NAT GENET, V41, P1199, DOI 10.1038/ng.446
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Styrkarsdottir U, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013217
   Thynn HN, 2020, J INVEST DERMATOL, V140, P348, DOI 10.1016/j.jid.2019.06.147
   Trajanoska K, 2019, BONE, V126, P2, DOI 10.1016/j.bone.2019.04.005
   Villalobos Comparán M, 2017, INT J GENOMICS, V2017, DOI 10.1155/2017/5831020
   Ward LD, 2012, NAT BIOTECHNOL, V30, P1095, DOI 10.1038/nbt.2422
   Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281
   Xu D, 2017, INT J CLIN EXP PATHO, V10, P5263
   Yang TL, 2012, OSTEOPOROSIS INT, V23, P781, DOI 10.1007/s00198 011 1626 x
   Zhang L, 2014, HUM MOL GENET, V23, P1923, DOI 10.1093/hmg/ddt575
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhang Y, 2015, OSTEOPOROSIS INT, V26, P553, DOI 10.1007/s00198 014 2882 3
   Zhu DL, 2018, J BONE MINER RES, V33, P1335, DOI 10.1002/jbmr.3419
NR 36
TC 3
Z9 3
U1 1
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2022
VL 37
IS 6
BP 1147
EP 1155
DI 10.1002/jbmr.4554
EA APR 2022
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 1X3LJ
UT WOS:000782998900001
PM 35373860
DA 2025 08 17
ER

PT J
AU Yoon, Y
   Khan, IU
   Choi, KU
   Jung, T
   Jo, K
   Lee, SH
   Kim, WH
   Kim, DY
   Kweon, OK
AF Yoon, Yongseok
   Khan, Imdad Ullah
   Choi, Kyeong Uk
   Jung, Taeseong
   Jo, Kwangrae
   Lee, Su Hyung
   Kim, Wan Hee
   Kim, Dae Yong
   Kweon, Oh Kyeong
TI Different Bone Healing Effects of Undifferentiated and Osteogenic
   Differentiated Mesenchymal Stromal Cell Sheets in Canine Radial Fracture
   Model
SO TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE MSCs sheet; Undifferentiation; Osteogenic differentiation; Bone healing;
   Dog
ID STEM CELLS; OSTEOBLAST DIFFERENTIATION; BIOLOGICAL CHARACTERISTICS;
   REGENERATIVE MEDICINE; TRANSCRIPTION FACTORS; OSTEOCLAST FORMATION;
   ECTOPIC SITE; TRANSPLANTATION; PERIOSTEUM; SCAFFOLD
AB Cell sheets technology is being available for fracture healing. This study was performed to clarify bone healing mechanism of undifferentiated (UCS) and osteogenic (OCS) differentiated mesenchymal stromal cell (MSC) sheets in the fracture model of dogs. UCS and OCS were harvested at 10 days of culture. Transverse fractures at the radius of six beagle dogs were assigned into three groups (n = 4 in each group) i.e. UCS, OCS and control. The fractures were fixed with a 2.7 mm locking plate and six screws. Cell sheets were wrapped around the fracture site. Bones were harvested 8 weeks after operation, then scanned by micro computed tomography (micro CT) and analyzed histopathologically. The micro CT revealed different aspects of bone regeneration among the groups. The percentages of external callus volume out of total bone volume in control, UCS, and OCS groups were 42.1, 13.0 and 4.9% (p < 0.05) respectively. However, the percentages of limbs having connectivity of gaps were 25, 12.5 and 75% respectively. In histopathological assessments, OCS group showed well organized and mature woven bone with peripheral cartilage at the fracture site, whereas control group showed cartilage formation without bone maturation or ossification at the fracture site. Meanwhile, fracture site was only filled with fibrous connective tissue without endochondral ossification and bone formation in UCS group. It was suggested that the MSC sheets reduced the quantity of external callus, and OCS induced the primary bone healing.
C1 [Yoon, Yongseok; Khan, Imdad Ullah; Choi, Kyeong Uk; Jung, Taeseong; Jo, Kwangrae; Kim, Wan Hee; Kweon, Oh Kyeong] Seoul Natl Univ, Dept Vet Surg, Coll Vet Med, 1 Gwanak Ro, Seoul 08826, South Korea.
   [Lee, Su Hyung; Kim, Dae Yong] Seoul Natl Univ, Dept Vet Pathol, Coll Vet Med, 1 Gwanak Ro, Seoul 08826, South Korea.
   [Yoon, Yongseok; Khan, Imdad Ullah; Choi, Kyeong Uk; Jung, Taeseong; Jo, Kwangrae; Lee, Su Hyung; Kim, Dae Yong; Kweon, Oh Kyeong] Seoul Natl Univ, PLUS Program Creat Vet Sci Res BK21, Res Inst Vet Sci, 1 Gwanak Ro, Seoul 08826, South Korea.
   [Yoon, Yongseok; Khan, Imdad Ullah; Choi, Kyeong Uk; Jung, Taeseong; Jo, Kwangrae; Lee, Su Hyung; Kim, Dae Yong; Kweon, Oh Kyeong] Seoul Natl Univ, Coll Vet Med, 1 Gwanak Ro, Seoul 08826, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University (SNU)
RP Kweon, OK (通讯作者)，Seoul Natl Univ, Dept Vet Surg, Coll Vet Med, 1 Gwanak Ro, Seoul 08826, South Korea.; Kweon, OK (通讯作者)，Seoul Natl Univ, PLUS Program Creat Vet Sci Res BK21, Res Inst Vet Sci, 1 Gwanak Ro, Seoul 08826, South Korea.; Kweon, OK (通讯作者)，Seoul Natl Univ, Coll Vet Med, 1 Gwanak Ro, Seoul 08826, South Korea.
EM ohkweon@snu.ac.kr
OI Choi, Kyeong Uk/0000 0003 2424 4352
FU National Research Foundation of Korea [NRF 2013R1A1A2004506]; Research
   Institute for Veterinary Science, Seoul National University
FX This work was supported by the National Research Foundation of Korea
   (NRF 2013R1A1A2004506) and the Research Institute for Veterinary
   Science, Seoul National University.
CR Aenlle KK, 2014, MOL ENDOCRINOL, V28, P722, DOI 10.1210/me.2013 1286
   Akahane M, 2008, J TISSUE ENG REGEN M, V2, P196, DOI 10.1002/term.81
   Akahane M, 2010, J TISSUE ENG REGEN M, V4, P404, DOI 10.1002/term.259
   Alves EG, 2014, BMC VET RES, V10, DOI 10.1186/s12917 014 0190 y
   ARO HT, 1993, CLIN ORTHOP RELAT R, P8
   Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886
   Dwek JR, 2010, SKELETAL RADIOL, V39, P319, DOI 10.1007/s00256 009 0849 9
   Egami M, 2014, ARCH PHARM RES, V37, P96, DOI 10.1007/s12272 013 0299 8
   Geng WX, 2013, BIOCHEM BIOPH RES CO, V433, P595, DOI 10.1016/j.bbrc.2013.03.034
   Gu HJ, 2014, CELL TISSUE RES, V358, P453, DOI 10.1007/s00441 014 1952 3
   Guo P, 2015, SCANNING, V37, P42, DOI 10.1002/sca.21177
   Huang S, 2015, CELL TRANSPLANT, V24, P2643, DOI 10.3727/096368915X687219
   Inagaki Y, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/842192
   Kassem M, 2008, CELL TISSUE RES, V331, P157, DOI 10.1007/s00441 007 0509 0
   Kim M, 2016, J VET MED SCI, V78, P619, DOI 10.1292/jvms.15 0361
   Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   Kuk M, 2016, CELL TRANSPLANT, V25, P1415, DOI 10.3727/096368915X689532
   Lacey DC, 2009, OSTEOARTHR CARTILAGE, V17, P735, DOI 10.1016/j.joca.2008.11.011
   Lin YC, 2013, ACTA BIOMATER, V9, P5243, DOI 10.1016/j.actbio.2012.09.028
   Matsuda W., 2008, CARDIOVASC REVASCULA, V9, P110
   Matsuura K, 2014, J CONTROL RELEASE, V190, P228, DOI 10.1016/j.jconrel.2014.05.024
   Nakamura A, 2010, BONE, V46, P418, DOI 10.1016/j.bone.2009.08.048
   Napimoga MH, 2015, INT IMMUNOPHARMACOL, V26, P378, DOI 10.1016/j.intimp.2015.04.033
   Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353
   Parekkadan B, 2010, ANNU REV BIOMED ENG, V12, P87, DOI 10.1146/annurev bioeng 070909 105309
   Rapp AE, 2015, EUR CELLS MATER, V29, P22, DOI 10.22203/eCM.v029a02
   Rifas L, 2009, ARTHRITIS RHEUM US, V60, P3324, DOI 10.1002/art.24877
   Ryu HH, 2009, J VET SCI, V10, P273, DOI 10.4142/jvs.2009.10.4.273
   Sabat R, 2010, CYTOKINE GROWTH F R, V21, P331, DOI 10.1016/j.cytogfr.2010.09.002
   Sanjabi S, 2009, CURR OPIN PHARMACOL, V9, P447, DOI 10.1016/j.coph.2009.04.008
   Shimizu T, 2015, INJURY, V46, P1457, DOI 10.1016/j.injury.2015.04.031
   Syed Picard FN, 2014, J ORAL MAXIL SURG, V72, P1078, DOI 10.1016/j.joms.2014.02.005
   Timmen M, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 184
   TOBIAS K.M., 2012, Veterinary Surgery: Small Animal, Chapter 41 Fracture Biology and Biomechanics Chapter 43 Internal Fracture Fixation Chapter 46 Delayed Unions, nonunions, and Malunions, P565
   Uchihara Y, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/629168
   Uchiyama H, 2006, J CRANIOMAXILLOFAC S, V34, P174
   Vaes BLT, 2002, J BONE MINER RES, V17, P2106, DOI 10.1359/jbmr.2002.17.12.2106
   Wang ZF, 2015, J BIOMED MATER RES B, V103, P1204, DOI 10.1002/jbm.b.33288
   Wei FL, 2012, J CELL PHYSIOL, V227, P3216, DOI 10.1002/jcp.24012
   Yang J, 2007, BIOMATERIALS, V28, P5033, DOI 10.1016/j.biomaterials.2007.07.052
   Yu JS, 2014, BIOMATERIALS, V35, P3516, DOI 10.1016/j.biomaterials.2014.01.015
NR 43
TC 9
Z9 9
U1 0
U2 12
PU KOREAN TISSUE ENGINEERING REGENERATIVE MEDICINE SOC
PI JONGRO GU
PA 199 1, DONGSUNG DONG,, JONGRO GU, SEOUL 110 810, SOUTH KOREA
SN 1738 2696
J9 TISSUE ENG REGEN MED
JI Tissue Eng. Regen. Med.
PD FEB
PY 2018
VL 15
IS 1
BP 115
EP 124
DI 10.1007/s13770 017 0092 8
PG 10
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA FT7RB
UT WOS:000423349200010
PM 30603539
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, XJ
   Li, Y
   Chen, YE
   Chen, JH
   Ma, PX
AF Zhang, Xiaojin
   Li, Yan
   Chen, Y. Eugene
   Chen, Jihua
   Ma, Peter X.
TI Cell free 3D scaffold with two stage delivery of miRNA 26a to regenerate
   critical sized bone defects
SO NATURE COMMUNICATIONS
LA English
DT Article
ID IN VIVO; GENE DELIVERY; OSTEOGENIC DIFFERENTIATION; PROTEIN ADSORPTION;
   NONVIRAL VECTORS; OSTEOCYTES; OSTEOBLAST; NANOPARTICLES; ARCHITECTURE;
   NANOCARRIER
AB MicroRNAs ( miRNAs) are being developed to enhance tissue regeneration. Here we show that a hyperbranched polymer with high miRNA binding affinity and negligible cytotoxicity can self assemble into nano sized polyplexes with a 'double shell' miRNA distribution and high transfection efficiency. These polyplexes are encapsulated in biodegradable microspheres to enable controllable two stage (polyplexes and miRNA) delivery. The microspheres are attached to cell free nanofibrous polymer scaffolds that spatially control the release of miR 26a. This technology is used to regenerate critical sized bone defects in osteoporotic mice by targeting Gsk 3b to activate the osteoblastic activity of endogenous stem cells, thus addressing a critical challenge in regenerative medicine of achieving cell free scaffold based miRNA therapy for tissue engineering.
C1 [Zhang, Xiaojin; Li, Yan; Ma, Peter X.] Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
   [Li, Yan; Chen, Jihua] Fourth Mil Med Univ, Sch Stomatol, Dept Prosthodont, State Key Lab Mil Stomatol, Xian 710032, Peoples R China.
   [Chen, Y. Eugene] Univ Michigan, Dept Cardiac Surg, Frankel Cardiovasc Ctr, Ann Arbor, MI 48109 USA.
   [Ma, Peter X.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Ma, Peter X.] Univ Michigan, Macromol Sci & Engn Ctr, Ann Arbor, MI 48109 USA.
   [Ma, Peter X.] Univ Michigan, Dept Mat Sci & Engn, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; Air Force Medical
   University; University of Michigan System; University of Michigan;
   University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan
RP Ma, PX (通讯作者)，Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.; Chen, JH (通讯作者)，Fourth Mil Med Univ, Sch Stomatol, Dept Prosthodont, State Key Lab Mil Stomatol, Xian 710032, Peoples R China.; Ma, PX (通讯作者)，Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.; Ma, PX (通讯作者)，Univ Michigan, Macromol Sci & Engn Ctr, Ann Arbor, MI 48109 USA.; Ma, PX (通讯作者)，Univ Michigan, Dept Mat Sci & Engn, Ann Arbor, MI 48109 USA.
EM jhchen@fmmu.edu.cn; mapx@umich.edu
RI X, Peter/E 4895 2011; Zhang, Xiaojin/O 3556 2017; Li, Yan/AAA 6908 2021
OI Zhang, Xiaojin/0000 0001 6624 2377; Chen, Ji hua/0000 0002 1151 0693; 
FU US National Institutes of Health [DE015384, DE017689, DE022327,
   HL114038]; US National Science Foundation [NSF DMR 1206575]; Program for
   Changjiang Scholars and Innovative Research Team in Universities
   [IRT13051]; National Natural Science Research Program of China
   [31501036]; CSC fellowship from the Chinese Scholarship Council; School
   of Stomatology of the Fourth Military Medical University of China;
   National Institute of Dental and Craniofacial Research [R01DE022327]
   Funding Source: NIH RePORTER
FX We acknowledge the financial support from the US National Institutes of
   Health (DE015384, DE017689 and DE022327: P.X.M.; HL114038: P.X.M. and
   Y.E.C.), the US National Science Foundation (NSF DMR 1206575: P.X.M.),
   Program for Changjiang Scholars and Innovative Research Team in
   Universities (Number IRT13051: J.C.) and National Natural Science
   Research Program of China (31501036). Y.L. was partially supported by a
   CSC fellowship from the Chinese Scholarship Council and the School of
   Stomatology of the Fourth Military Medical University of China.
CR Aagaard L, 2007, ADV DRUG DELIVER REV, V59, P75, DOI 10.1016/j.addr.2007.03.005
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990
   Chen VJ, 2006, BIOMATERIALS, V27, P3973, DOI 10.1016/j.biomaterials.2006.02.043
   Chiou GY, 2012, J CONTROL RELEASE, V159, P240, DOI 10.1016/j.jconrel.2012.01.014
   Dahlman JE, 2014, NAT NANOTECHNOL, V9, P648, DOI [10.1038/NNANO.2014.84, 10.1038/nnano.2014.84]
   Dalby B, 2004, METHODS, V33, P95, DOI 10.1016/j.ymeth.2003.11.023
   Eppler SM, 2002, CLIN PHARMACOL THER, V72, P20, DOI 10.1067/mcp.2002.126179
   Feng GJ, 2011, BIOMATERIALS, V32, P8182, DOI 10.1016/j.biomaterials.2011.07.049
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Fuhrmann K, 2012, ACS NANO, V6, P1667, DOI 10.1021/nn2046554
   Ge ZS, 2014, BIOMATERIALS, V35, P3416, DOI 10.1016/j.biomaterials.2013.12.086
   Hu J, 2008, BIOMATERIALS, V29, P3815, DOI 10.1016/j.biomaterials.2008.06.015
   Hwang DW, 2011, BIOMATERIALS, V32, P4968, DOI 10.1016/j.biomaterials.2011.03.047
   Ibrahim AF, 2011, CANCER RES, V71, P5214, DOI 10.1158/0008 5472.CAN 10 4645
   Icli B, 2013, CIRC RES, V113, P1231, DOI 10.1161/CIRCRESAHA.113.301780
   Johnell O, 2004, OSTEOPOROSIS INT, V15, P38, DOI 10.1007/s00198 003 1490 4
   KEITER RL, 1969, INORG CHEM, V8, P2115, DOI 10.1021/ic50080a015
   Kim K, 2015, MOL CELLS, V38, P75, DOI 10.14348/molcells.2015.2241
   Kirtane AR, 2013, NAT NANOTECHNOL, V8, P805, DOI 10.1038/nnano.2013.234
   Krützfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Kulkarni NH, 2007, J CELL BIOCHEM, V102, P1504, DOI 10.1002/jcb.21374
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Lee CH, 2010, LANCET, V376, P440, DOI 10.1016/S0140 6736(10)60668 X
   Li JB, 2014, CHEM SOC REV, V43, P506, DOI 10.1039/c3cs60312a
   Li Y, 2013, BIOMATERIALS, V34, P5048, DOI 10.1016/j.biomaterials.2013.03.052
   Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011
   Ma PX, 2008, ADV DRUG DELIVER REV, V60, P184, DOI 10.1016/j.addr.2007.08.041
   MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077
   Marquart TJ, 2010, P NATL ACAD SCI USA, V107, P12228, DOI 10.1073/pnas.1005191107
   Melnikova I, 2007, NAT REV DRUG DISCOV, V6, P863, DOI 10.1038/nrd2443
   Mintzer MA, 2009, CHEM REV, V109, P259, DOI 10.1021/cr800409e
   Miyazaki Y, 2012, NAT MED, V18, P1136, DOI 10.1038/nm.2791
   Nair LS, 2007, PROG POLYM SCI, V32, P762, DOI 10.1016/j.progpolymsci.2007.05.017
   Najafi Shoushtari SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/science.1189123
   Nayak S, 2010, GENE THER, V17, P295, DOI 10.1038/gt.2009.148
   Neffe AT, 2015, ADV MATER, V27, P1738, DOI 10.1002/adma.201404787
   Nomoto T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4545
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Pantazis Panayotis, 2012, Methods Mol Biol, V906, P311, DOI 10.1007/978 1 61779 953 2_25
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Pouton CW, 2001, ADV DRUG DELIVER REV, V46, P187, DOI 10.1016/S0169 409X(00)00133 2
   Press AT, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6565
   Radowski MR, 2007, ANGEW CHEM INT EDIT, V46, P1265, DOI 10.1002/anie.200603801
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862
   Smith LA, 2009, BIOMATERIALS, V30, P2516, DOI 10.1016/j.biomaterials.2009.01.009
   Stern AR, 2012, BIOTECHNIQUES, V52, P361, DOI 10.2144/0000113876
   Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511
   Tseng SJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7456
   URIST MR, 1979, P NATL ACAD SCI USA, V76, P1828, DOI 10.1073/pnas.76.4.1828
   Vacik T, 2011, GENE DEV, V25, P1783, DOI 10.1101/gad.17227011
   van Rooij E, 2012, CIRC RES, V110, P496, DOI 10.1161/CIRCRESAHA.111.247916
   Verma IM, 2013, SCIENCE, V341, P853, DOI 10.1126/science.1242551
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wei GB, 2007, BIOMATERIALS, V28, P2087, DOI 10.1016/j.biomaterials.2006.12.028
   Wei GB, 2006, J BIOMED MATER RES A, V78A, P306, DOI 10.1002/jbm.a.30704
   Whitehead KA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5277
   Wilson CE, 2002, J MATER SCI MATER M, V13, P1265, DOI 10.1023/A:1021139415528
   Woo KM, 2003, J BIOMED MATER RES A, V67A, P531, DOI 10.1002/jbm.a.10098
   Woo KM, 2007, BIOMATERIALS, V28, P2622, DOI 10.1016/j.biomaterials.2007.02.004
   Woo KM, 2009, TISSUE ENG PT A, V15, P2155, DOI 10.1089/ten.tea.2008.0433
   Wu W, 2012, NAT MED, V18, P1148, DOI 10.1038/nm.2821
   Xie J, 2012, NAT METHODS, V9, P403, DOI [10.1038/NMETH.1903, 10.1038/nmeth.1903]
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Yue YA, 2011, J CONTROL RELEASE, V155, P67, DOI 10.1016/j.jconrel.2010.10.028
NR 66
TC 249
Z9 271
U1 3
U2 222
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN
PY 2016
VL 7
AR 10376
DI 10.1038/ncomms10376
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DC2BL
UT WOS:000369022100013
PM 26765931
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Mohanty, ST
   Cairney, CJ
   Chantry, AD
   Madan, S
   Fernandes, JA
   Howe, SJ
   Moore, HD
   Thompson, MJ
   Chen, BN
   Thrasher, A
   Keith, WN
   Bellantuono, I
AF Mohanty, Sindhu T.
   Cairney, Claire J.
   Chantry, Andrew D.
   Madan, Sanjeev
   Fernandes, James A.
   Howe, Steven J.
   Moore, Harry D.
   Thompson, Mark J.
   Chen, Beining
   Thrasher, Adrian
   Keith, W. Nicol
   Bellantuono, Ilaria
TI A Small Molecule Modulator of Prion Protein Increases Human Mesenchymal
   Stem Cell Lifespan, Ex Vivo Expansion, and Engraftment to Bone Marrow in
   NOD/SCID Mice
SO STEM CELLS
LA English
DT Article
DE Marrow stromal cells; Aging; Osteoblast; Mesenchymal stem cell; Stem
   cell transplantation; Adult stem cells
ID SELF RENEWAL; OXIDATIVE STRESS; DNA DAMAGE; EXPRESSION; LIMIT
AB Human mesenchymal stem cells (hMSCs) have been shown to have potential in regenerative approaches in bone and blood. Most protocols rely on their in vitro expansion prior to clinical use. However, several groups including our own have shown that hMSCs lose proliferation and differentiation ability with serial passage in culture, limiting their clinical applications. Cellular prion protein (PrP) has been shown to enhance proliferation and promote self renewal of hematopoietic, mammary gland, and neural stem cells. Here we show, for the first time, that expression of PrP decreased in hMSC following ex vivo expansion. When PrP expression was knocked down, hMSC showed significant reduction in proliferation and differentiation. In contrast, hMSC expanded in the presence of small molecule 3/689, a modulator of PrP expression, showed retention of PrP expression with ex vivo expansion and extended lifespan up to 10 population doublings. Moreover, cultures produced a 300 fold increase in the number of cells generated. These cells showed a 10 fold increase in engraftment levels in bone marrow 5 weeks post transplant. hMSC treated with 3/689 showed enhanced protection from DNA damage and enhanced cell cycle progression, in line with data obtained by gene expression profiling. Moreover, upregulation of superoxide dismutase 2 (SOD2) was also observed in hMSC expanded in the presence of 3/689. The increase in SOD2 was dependent on PrP expression and suggests increased scavenging of reactive oxygen species as mechanism of action. These data point to PrP as a good target for chemical intervention in stem cell regenerative medicine. STEM CELLS2012;30:11341143
C1 [Bellantuono, Ilaria] Univ Sheffield, Sch Med Dent & Hlth, Acad Unit Bone Biol, Mellanby Ctr Bone Res,Dept Human Metab, Sheffield S10 2RX, S Yorkshire, England.
   [Cairney, Claire J.; Keith, W. Nicol] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland.
   [Madan, Sanjeev; Fernandes, James A.] Sheffield Childrens Hosp, Dept Paediat Orthopaed & Trauma Surg, Sheffield, S Yorkshire, England.
   [Howe, Steven J.; Thrasher, Adrian] UCL, Dept Infect & Immun, Mol Immunol Unit, London, England.
   [Moore, Harry D.] Univ Sheffield, Ctr Stem Cell Biol, Sheffield S10 2RX, S Yorkshire, England.
   [Thompson, Mark J.; Chen, Beining] Univ Sheffield, Dept Chem, Sheffield S10 2RX, S Yorkshire, England.
C3 University of Sheffield; University of Glasgow; Sheffield Children's NHS
   Foundation Trust; Sheffield Children's Hospital; University of London;
   University College London; University of Sheffield; University of
   Sheffield
RP Bellantuono, I (通讯作者)，Univ Sheffield, Sch Med Dent & Hlth, Acad Unit Bone Biol, Mellanby Ctr Bone Res,Dept Human Metab, Room DU19, Sheffield S10 2RX, S Yorkshire, England.
EM i.bellantuono@sheffield.ac.uk
RI Keith, Nicol/D 3325 2009; Cairney, Claire/H 6989 2012; Bellantuono,
   Ilaria/ABF 2700 2021; Chantry, Andrew/B 3065 2009
OI Keith, Nicol/0000 0001 7862 3580; Chantry, Andrew/0000 0002 2797 7626;
   Bellantuono, Ilaria/0000 0001 9994 6987; Madan,
   Sanjeev/0000 0003 2604 3810; Cairney, Claire/0000 0001 6531 245X; 
FU Biotechnology and Biological Sciences Research Council (BBSRC)
   [BB/E014119/1]; Cancer Research UK; BBSRC [BB/E014119/1, BB/D524908/1]
   Funding Source: UKRI; EPSRC [EP/I037296/1] Funding Source: UKRI; MRC
   [G0801059] Funding Source: UKRI; Biotechnology and Biological Sciences
   Research Council [BB/D524908/1, BB/E014119/1] Funding Source:
   researchfish; Engineering and Physical Sciences Research Council
   [EP/I037296/1] Funding Source: researchfish; Great Ormond Street
   Hospital Childrens Charity [V1223, V1259] Funding Source: researchfish;
   Medical Research Council [G0801059] Funding Source: researchfish;
   National Institute for Health Research [NF SI 0611 10001] Funding
   Source: researchfish
FX This study was supported by Biotechnology and Biological Sciences
   Research Council (BBSRC, BB/E014119/1). The gene expression profiling
   was funded by Cancer Research UK. We are grateful to Orla Gallagher,
   Daren Lough and Julia Hough (Department of Human Metabolism, University
   of Sheffield) for their expert technical assistance. We thank Peter
   Andrews, Paul Gokhale and Ramya Udayashankar (Centre for Stem Cell
   Biology, University of Sheffield) for helpful discussion and Sandra
   Knight (Department of Chemistry, University of Sheffield) for technical
   assistance.
CR Augello A, 2010, EUR CELLS MATER, V20, P121
   Baxter MA, 2004, STEM CELLS, V22, P675, DOI 10.1634/stemcells.22 5 675
   Brown DR, 2000, EMBO J, V19, P1180, DOI 10.1093/emboj/19.6.1180
   Brown DR, 1998, BIOCHEM J, V334, P423, DOI 10.1042/bj3340423
   Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505
   Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097 4644(199702)64:2<278::AID JCB11>3.0.CO;2 F
   Chen B, 2010, INDOLE DERIVATIVES S
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Chen SB, 2006, P NATL ACAD SCI USA, V103, P17266, DOI 10.1073/pnas.0608156103
   Demaison C, 2002, HUM GENE THER, V13, P803, DOI 10.1089/10430340252898984
   Galderisi U, 2009, STEM CELLS DEV, V18, P1033, DOI 10.1089/scd.2008.0324
   Gambardella A, 2011, J BONE MINER RES, V26, P811, DOI 10.1002/jbmr.266
   Goldrath AW, 2004, P NATL ACAD SCI USA, V101, P16885, DOI 10.1073/pnas.0407417101
   Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388
   Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989
   Ko E, 2011, STEM CELLS DEV
   Kyriakou C, 2008, HAEMATOL HEMATOL J, V93, P1457, DOI 10.3324/haematol.12553
   Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008 5472.CAN 06 4493
   Mandal PK, 2011, NAT REV MOL CELL BIO, V12, P198, DOI 10.1038/nrm3060
   Owusu Ansah E, 2009, NATURE, V461, P537, DOI 10.1038/nature08313
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Steele AD, 2006, P NATL ACAD SCI USA, V103, P3416, DOI 10.1073/pnas.0511290103
   Thompson MJ, 2011, CHEMMEDCHEM, V6, P115, DOI 10.1002/cmdc.201000383
   Thompson MJ, 2009, J MED CHEM, V52, P7503, DOI 10.1021/jm900920x
   Treiber N, 2011, AGING CELL, V10, P239, DOI 10.1111/j.1474 9726.2010.00658.x
   Trowbridge JJ, 2006, NAT MED, V12, P89, DOI 10.1038/nm1339
   Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003
   Wagner W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005846
   Wu X, 2000, BONE, V26, P21, DOI 10.1016/S8756 3282(99)00238 0
   Yew TL, 2011, AGING CELL, V10, P349, DOI 10.1111/j.1474 9726.2011.00676.x
   Zhang CC, 2006, P NATL ACAD SCI USA, V103, P2184, DOI 10.1073/pnas.0510577103
NR 33
TC 29
Z9 32
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD JUN
PY 2012
VL 30
IS 6
BP 1134
EP 1143
DI 10.1002/stem.1065
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 942YJ
UT WOS:000304087300010
PM 22367629
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Xu, Q
   Li, CH
   Tang, CH
   Huang, XL
   Wu, LF
   Zhou, X
   Lei, SF
   Deng, FY
AF Xu, Qing
   Li, Chun Hui
   Tang, Chang Hua
   Huang, Xiao Li
   Wu, Long Fei
   Zhou, Xu
   Lei, Shu Feng
   Deng, Fei Yan
TI PKM2 is a Novel Osteoporosis Associated Protein in Chinese
SO ENDOCRINE RESEARCH
LA English
DT Article
DE BMD; osteoporosis; osteoporotic fracture; PKM2; proteomics
ID PYRUVATE KINASE M2; PHOTOBIOMODULATION; CELLS
AB Purpose: Osteoporosis is characterized by low bone mineral density (BMD) and high risk of osteoporotic fracture (OF). Peripheral blood monocytes (PBM) can differentiate into osteoclasts to resorb bone. This study was to identify PBM expressed proteins significant for osteoporosis in Chinese Han elderly population (>65 years), and focused on two phenotypes of osteoporosis: low BMD and OF. Methods: Label free quantitative proteomics was employed to profile PBM proteome and to identify differentially expressed proteins (DEPs) between OF (N=27) vs. non fractured (NF, N=24) subjects and between low BMD (N=12) vs. high BMD (N=12) subjects in women. Western blotting (WB) was conducted to validate differential expression, and ELISA to evaluate translational value for secretory protein of interest. Results: We discovered 59 DEPs with fold change (FC)>1.3 (P<1x10 5), and validated the significant up regulation of pyruvate kinase isozyme 2 (PKM2) with osteoporosis (P<0.001). PKM2 protein upregulation with OF was replicated with PBM in men (P=0.04). Plasma PKM2 protein level was significantly elevated with OF in an independent sample (N=100, FC=1.68, P=0.01). Pursuant functional assays showed that extracellular PKM2 protein supplement not only promoted monocyte trans endothelial migration, growth, and osteoclast differentiation (marker gene expression), but also inhibited osteoblast growth, differentiation (ALP gene expression), and activity. Conclusion: The above findings suggest that PKM2 protein is a novel osteoporosis associated functional protein in Chinese Han elderly population. It may serve as a risk biomarker and drug target for osteoporosis.
C1 [Xu, Qing; Li, Chun Hui; Wu, Long Fei; Zhou, Xu; Lei, Shu Feng; Deng, Fei Yan] Collaborat Innovat Ctr Bone & Immunol Sihong Hosp, Sch Publ Hlth, Suzhou, Jiangsu, Peoples R China.
   [Xu, Qing; Li, Chun Hui; Wu, Long Fei; Zhou, Xu; Lei, Shu Feng; Deng, Fei Yan] Ctr Genet Epidemiol & Genom, Suzhou, Jiangsu, Peoples R China.
   [Tang, Chang Hua; Huang, Xiao Li] Collaborat Innovat Ctr Bone & Immunol Sihong Hosp, Sihong Hosp, Dept Orthoped, Suqian, Jiangsu, Peoples R China.
   [Lei, Shu Feng; Deng, Fei Yan] Soochow Univ, Suzhou Med Coll, Jiangsu Key Lab Prevent & Translat Med Geriatr Dis, Suzhou, Jiangsu, Peoples R China.
   [Lei, Shu Feng; Deng, Fei Yan] Soochow Univ, Suzhou Med Coll, MOE Key Lab Geriatr Dis & Immunol, Suzhou, Jiangsu, Peoples R China.
   [Lei, Shu Feng] Soochow Univ, Changzhou Geriatr Hosp, Dept Orthoped, Changzhou, Jiangsu, Peoples R China.
   [Deng, Fei Yan] Soochow Univ, Sch Publ Hlth, Suzhou Med Coll, Ctr Genet Epidemiol & Genom, 199 Renai Rd, Suzhou 215123, Jiangsu, Peoples R China.
C3 Soochow University   China; Soochow University   China; Soochow
   University   China; Soochow University   China
RP Deng, FY (通讯作者)，Soochow Univ, Sch Publ Hlth, Suzhou Med Coll, Ctr Genet Epidemiol & Genom, 199 Renai Rd, Suzhou 215123, Jiangsu, Peoples R China.
EM fdeng@suda.edu.cn
RI Li, Chunhui/Y 4731 2019; Wu, Longfei/I 8968 2018
FU Natural Science Foundation of China [81373010, 82173598, 82173529,
   82373587]; Science and Technology Project of Suzhou [SS202050,
   SYS2019024]; Project of the Priority Academic Program Development of
   Jiangsu Higher Education Institutions; QingLan Project of Higher
   Education of Jiangsu Province
FX The study was supported by the Natural Science Foundation of China
   81373010, 82173598, 82173529, and 82373587), the Science and Technology
   Project of Suzhou (SS202050, SYS2019024), the Project of the Priority
   Academic Program Development of Jiangsu Higher Education Institutions,
   and the QingLan Project of Higher Education of Jiangsu Province. The
   proteome wide protein expression profiling was con ducted/serviced by
   the Aptbiotech Company (Shanghai, China)
CR [Anonymous], 2008, Osteoporosis a summary statement of China
   Cheng C, 2020, ANNU REV MED, V71, P277, DOI 10.1146/annurev med 052218 020620
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   Cox J., 2014, MOL CELL PROTEOMICS
   Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Curtis EM, 2017, INT J ORTHOP TRAUMA, V26, P7, DOI [10.1016/j.bone.2017.01.024, 10.1016/j.ijotn.2017.04.004]
   Dai JL, 2019, J EXP MED, V216, P2883, DOI 10.1084/jem.20190158
   Dayton TL, 2016, EMBO REP, V17, P1721, DOI 10.15252/embr.201643300
   Deng Fei Yan, 2005, Acta Genetica Sinica, V32, P1003
   Dong GC, 2016, ONCOL LETT, V11, P1980, DOI 10.3892/ol.2016.4168
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Dy CJ, 2011, J BONE JOINT SURG AM, V93A, P1326, DOI [10.2106/JBJS.I.01132, 10.2106/JBJSJ.01132]
   Eliuk S, 2015, ANNU REV ANAL CHEM, V8, P61, DOI 10.1146/annurev anchem 071114 040325
   Fredoni M, 2017, LASER MED SCI, V32, P1545, DOI 10.1007/s10103 017 2278 7
   Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   Guo JC, 2020, AGING US, V12, P3976, DOI 10.18632/aging.102866
   Han DW, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 07667 6
   Hsu MC, 2016, AM J CANCER RES, V6, P628
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Hwang MH, 2016, LASER MED SCI, V31, P767, DOI 10.1007/s10103 016 1923 x
   Kim H, 2023, BONE RES, V11, DOI 10.1038/s41413 023 00251 2
   Liang J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12431
   Liu FB, 2017, NAT CELL BIOL, V19, P1358, DOI 10.1038/ncb3630
   Ly Tony, 2018, Wellcome Open Res, V3, P51, DOI 10.12688/wellcomeopenres.14392.1
   Macías I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051653
   Marques GS, 2018, BIOL PROCED ONLINE, V20, DOI 10.1186/s12575 018 0069 6
   Maycas M, 2017, J CELL PHYSIOL, V232, P3611, DOI 10.1002/jcp.25829
   Michalski A, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.011015
   Murakami K, 2017, BIOMETALS, V30, P335, DOI 10.1007/s10534 017 0009 y
   Nahnsen S, 2013, MOL CELL PROTEOMICS, V12, P549, DOI 10.1074/mcp.R112.025163
   Narni Mancinelli E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002457
   Padamsey Z, 2017, NEURON, V93, P132, DOI 10.1016/j.neuron.2016.11.013
   Parfitt AM, 1998, BONE, V23, P491, DOI 10.1016/S8756 3282(98)00140 9
   Pulkkinen P, 2004, OSTEOPOROSIS INT, V15, P274, DOI 10.1007/s00198 003 1556 3
   Sapkota M, 2015, EUR J PHARMACOL, V769, P100, DOI 10.1016/j.ejphar.2015.11.003
   Schurman L, 2001, EXP CLIN ENDOCR DIAB, V109, P340, DOI 10.1055/s 2001 17401
   Sharma R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093696
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wong N, 2015, CANCER LETT, V356, P184, DOI 10.1016/j.canlet.2014.01.031
   Yang WW, 2015, J CELL SCI, V128, P1655, DOI 10.1242/jcs.166629
   Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598
   Zhou X, 2019, J PROTEOMICS, V207, DOI 10.1016/j.jprot.2019.103440
   Zhou X, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194781
   Zhou Y, 2015, OSTEOPOROSIS INT, V26, P2561, DOI 10.1007/s00198 015 3250 7
NR 46
TC 1
Z9 1
U1 0
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0743 5800
EI 1532 4206
J9 ENDOCR RES
JI Endocr. Res.
PD APR 2
PY 2024
VL 49
IS 2
BP 92
EP 105
DI 10.1080/07435800.2024.2310818
EA FEB 2024
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA OK7H3
UT WOS:001154794000001
PM 38288985
DA 2025 08 17
ER

PT J
AU Kheifetz, Y
   Scholz, M
AF Kheifetz, Yuri
   Scholz, Markus
TI Modeling individual time courses of thrombopoiesis during multi cyclic
   chemotherapy
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID 3 WEEKLY CHOP CHEMOTHERAPY; HEMATOPOIETIC STEM CELLS; MEGAKARYOCYTE
   GROWTH; INDUCED THROMBOCYTOPENIA; HEMATOLOGICAL TOXICITY; AGGRESSIVE
   LYMPHOMAS; PLATELET PRODUCTION; MATHEMATICAL MODEL; ETOPOSIDE; TRIAL
AB Background Thrombocytopenia is a major side effect of cytotoxic cancer therapies. The aim of precision medicine is to develop therapy modifications accounting for the individual's risk.
   Methodology/Principle findings To solve this task, we develop an individualized bio mechanistic model of the dynamics of bone marrow thrombopoiesis, circulating platelets and therapy effects thereon. Comprehensive biological knowledge regarding cell differentiation, amplification, apoptosis rates, transition times and corresponding regulations are translated into ordinary differential equations. A model of osteoblast/osteoclast interactions was incorporated to mechanistically describe bone marrow support of quiescent cell stages. Thrombopoietin (TPO) as a major regulator is explicitly modelled including pharmacokinetics and dynamics of TPO injections. Effects of cytotoxic drugs are modelled by transient depletions of proliferating cells. To calibrate the model, we used population data from the literature and close meshed individual data of N = 135 high grade non Hodgkin's lymphoma patients treated with CHOP like chemotherapies. To limit the number of free parameters, several parsimony assumptions were derived from biological data and tested via Likelihood methods. Heterogeneity of patients was explained by a few model parameters. The over fitting issue of individual parameter estimation was successfully dealt with a virtual participation of each patient in population based experiments. The model qualitatively and quantitatively explains a number of biological observations such as the role of osteoblasts in explaining long term toxic effects, megakaryocyte mediated feedback on stem cells, bi phasic stimulation of thrombopoiesis by TPO, dynamics of megakaryocyte ploidies and non exponential platelet degradation. Almost all individual time series could be described with high precision. We demonstrated how the model can be used to provide predictions regarding individual therapy adaptations.
   Conclusions We propose a mechanistic thrombopoiesis model of unprecedented comprehensiveness in both, biological mechanisms considered and experimental data sets explained. Our innovative method of parameter estimation allows robust determinations of individual parameter settings facilitating the development of individual treatment adaptations during chemotherapy.
   Author summary Chemotherapy is ubiquitously used to treat cancer diseases. Due to general toxicity of the drugs, chemotherapy results in a number of side effects especially with respect to blood formation. Here we study the loss of platelets during chemotherapy which is dose limiting in many situations. However, this side effect greatly varies between patients with respect to both, severity and necessity of clinical countermeasures.We therefore developed a mathematical model to predict the time course of platelets of patients under chemotherapy and to propose possible treatment adaptations in cases of intolerable toxicity. The model is based on available biological knowledge and data of platelet formation and therapeutic effects thereon. As a major result, we could describe individual time series data of 135 patients under chemotherapy. Conversely, the model can be used to make predictions regarding alternative therapy schedules such as postponement of therapy or chemotherapy dose reductions. Our model is intended to support clinical decision making on an individual patient level.
C1 [Kheifetz, Yuri; Scholz, Markus] Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany.
C3 Leipzig University
RP Scholz, M (通讯作者)，Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany.
EM markus.scholz@imise.uni leipzig.de
OI Kheifetz, Yuri/0000 0002 8356 2724
FU German Federal Ministry of Research and Education [031A424]
FX This work was financed by the German Federal Ministry of Research and
   Education, Grant number 031A424 "HaematoOPT". The funders had no role in
   data collection, analysis or preparation of the manuscript.
CR Abkowitz JL, 1996, NAT MED, V2, P190, DOI 10.1038/nm0296 190
   [Anonymous], 2015, UK SUPREME COURT YB, V6, P175
   Basser RL, 2002, BLOOD, V99, P2599, DOI 10.1182/blood.V99.7.2599
   Bernard Samuel, 2006, Genome Inform, V17, P72
   Bernstein SH, 2002, J CLIN PHARMACOL, V42, P501, DOI 10.1177/00912700222011553
   Bruns I, 2014, NAT MED, V20, P1315, DOI 10.1038/nm.3707
   COHEN T, 1974, SCAND J HAEMATOL, V12, P9
   Cooper GM, 2000, MECH OXIDATIVE PHOSP, V2
   Crombag MRBS, 2016, CANCERS, V8, DOI 10.3390/cancers8010006
   Diehl V, 2003, NEW ENGL J MED, V348, P2386, DOI 10.1056/NEJMoa022473
   Engel C, 1999, BRIT J HAEMATOL, V105, P832, DOI 10.1046/j.1365 2141.1999.01459.x
   Faivre C, 2017, BRIT J CANCER, V116, P344, DOI 10.1038/bjc.2016.439
   Fielder PJ, 1997, BLOOD, V89, P2782, DOI 10.1182/blood.V89.8.2782
   FREEDMAN ML, 1975, BRIT J HAEMATOL, V31, P255, DOI 10.1111/j.1365 2141.1975.tb00855.x
   Friberg LE, 2003, INVEST NEW DRUG, V21, P183, DOI 10.1023/A:1023573429626
   Friberg LE, 2002, J CLIN ONCOL, V20, P4713, DOI 10.1200/JCO.2002.02.140
   Glauche I, 2007, STEM CELLS, V25, P1791, DOI 10.1634/stemcells.2007 0025
   GUERRIERO R, 1995, BLOOD, V86, P3725, DOI 10.1182/blood.V86.10.3725.bloodjournal86103725
   HANSON SR, 1985, BLOOD, V66, P1105
   Harker LA, 2000, BLOOD, V95, P2514
   Hersh JK, 1998, TRANSFUSION, V38, P637, DOI 10.1046/j.1537 2995.1998.38798346631.x
   Italiano JE, 1999, J CELL BIOL, V147, P1299, DOI 10.1083/jcb.147.6.1299
   Joerger M, 2007, CLIN CANCER RES, V13, P6410, DOI 10.1158/1078 0432.CCR 07 0064
   Kliem C, 2001, THESIS
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Kuhn E, 2005, COMPUT STAT DATA AN, V49, P1020, DOI 10.1016/j.csda.2004.07.002
   Kuter D J, 1996, Stem Cells, V14 Suppl 1, P88
   Lawson MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9983
   Leysi Derilou Y, 2011, THESIS
   Leysi Derilou Y, 2012, DIFFERENTIATION, V83, P200, DOI 10.1016/j.diff.2011.12.003
   Leysi Derilou Y, 2010, CELL CYCLE, V9, P2589, DOI 10.4161/cc.9.13.12078
   Li JZ, 2001, BLOOD, V98, P3241, DOI 10.1182/blood.V98.12.3241
   Minelli O, 2009, BONE MARROW TRANSPL, V43, P263, DOI 10.1038/bmt.2008.310
   Nakamura Ishizu A, 2014, BIOCHEM BIOPH RES CO, V454, P353, DOI 10.1016/j.bbrc.2014.10.095
   Pfreundschuh M, 2004, BLOOD, V104, P626, DOI 10.1182/blood 2003 06 2094
   Pfreundschuh M, 2004, BLOOD, V104, P634, DOI 10.1182/blood 2003 06 2095
   Roeder I, 2002, EXP HEMATOL, V30, P853, DOI 10.1016/S0301 472X(02)00832 9
   Santillán M, 2000, J THEOR BIOL, V206, P585, DOI 10.1006/jtbi.2000.2149
   Schirm S, 2014, BMC SYST BIOL, V8, DOI 10.1186/s12918 014 0138 7
   Scholz M, 2005, J MATH BIOL, V50, P397, DOI 10.1007/s00285 004 0295 1
   Scholz M, 2012, THEOR BIOL MED MODEL, V9, DOI 10.1186/1742 4682 9 32
   Scholz M, 2010, J THEOR BIOL, V264, P287, DOI 10.1016/j.jtbi.2009.12.032
   Shampine LF, 1997, SIAM J SCI COMPUT, V18, P1, DOI 10.1137/S1064827594276424
   Shampine LF, 1999, SIAM REV, V41, P538, DOI 10.1137/S003614459933425X
   Skomorovski K, 2003, BRIT J HAEMATOL, V123, P683, DOI 10.1046/j.1365 2141.2003.04696.x
   STENBERG PE, 1989, BLOOD CELLS, V15, P23
   TSAN MF, 1984, AM J HEMATOL, V17, P97, DOI 10.1002/ajh.2830170114
   van Kesteren C, 2005, INVEST NEW DRUG, V23, P225, DOI 10.1007/s10637 005 6730 3
   VONSCHULTHESS GK, 1986, SCAND J HAEMATOL, V36, P473
   Wallin JE, 2010, BASIC CLIN PHARMACOL, V106, P234, DOI 10.1111/j.1742 7843.2009.00520.x
   Wallin JE, 2009, COMPUT METH PROG BIO, V93, P283, DOI 10.1016/j.cmpb.2008.10.011
   Wichmann H.  E., 1985, Mathematical Modeling of Cell Proliferation: Stem Cell Regulation in Hemopoiesis
   Wichmann H E, 1984, REGULATIONSMODELLE I
   WICHMANN HE, 1979, CELL TISSUE KINET, V12, P551, DOI 10.1111/j.1365 2184.1979.tb00176.x
   Wright DE, 2001, BLOOD, V97, P2278, DOI 10.1182/blood.V97.8.2278
   Wunderlich A, 2003, ANN ONCOL, V14, P881, DOI 10.1093/annonc/mdg249
   Zenner A, 2007, CANCER RES, V67, P4767, DOI 10.1158/0008 5472.CAN 06 4303
   Ziepert M, 2008, ANN ONCOL, V19, P752, DOI 10.1093/annonc/mdm541
NR 58
TC 20
Z9 21
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
EI 1553 7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD MAR
PY 2019
VL 15
IS 3
AR e1006775
DI 10.1371/journal.pcbi.1006775
PG 32
WC Biochemical Research Methods; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA HS4YW
UT WOS:000463877900026
PM 30840616
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Do Nascimento, MHM
   Ambrosio, FN
   Ferraraz, DC
   Windisch Neto, H
   Querobino, SM
   Nascimento Sales, M
   Alberto Silva, C
   Christoffolete, MA
   Franco, MKKD
   Kent, B
   Yokaichiya, F
   Lombello, CB
   De Araujo, DR
AF Monteiro do Nascimento, Monica Helena
   Ambrosio, Felipe Nogueira
   Ferraraz, Debora Carajiliascov
   Windisch Neto, Hermann
   Querobino, Samyr Machado
   Nascimento Sales, Michelle
   Alberto Silva, Carlos
   Christoffolete, Marcelo Augusto
   Franco, Margareth K. K. D.
   Kent, Ben
   Yokaichiya, Fabiano
   Lombello, Christiane Bertachini
   de Araujo, Daniele Ribeiro
TI Sulforaphane loaded hyaluronic acid poloxamer hybrid hydrogel enhances
   cartilage protection in osteoarthritis models
SO MATERIALS SCIENCE AND ENGINEERING C MATERIALS FOR BIOLOGICAL
   APPLICATIONS
LA English
DT Article
DE Sulforaphane; Poloxamer; Hyaluronic acid; Hydrogels; Osteoarthritis
ID DRUG DELIVERY SYSTEMS; X RAY SCATTERING; IN VITRO; ARTICULAR CARTILAGE;
   GENE EXPRESSION; ONCOSTATIN M; KAPPA B; RHEOLOGICAL CHARACTERIZATION;
   INTRAARTICULAR TREATMENT; CHONDROSARCOMA CELLS
AB Sulforaphane (SFN) is an isothiocyanate with anti arthritic and immuno regulatory activities, supported by the downregulation of NF kappa B pathway, reduction on metalloproteinases expression and prevention of cytokineinduced cartilage degeneration implicated in OA progression. SFN promising pharmacological effects associated to its possible use, by intra articular route and directly in contact to the site of action, highlight SFN as promising candidate for the development of drug delivery systems. The association of poloxamers (PL) and hyaluronic acid (HA) supports the development of osteotrophic and chondroprotective pharmaceutical formulations. This study aims to develop PL HA hybrid hydrogels as delivery systems for SFN intra articular release and evaluate their biocompatibility and efficacy for osteoarthritis treatment. All formulations showed viscoelastic behavior and cubic phase organization. SFN incorporation and drug loading showed a concentrationdependent behavior following HA addition. Drug release profiles were influenced by both diffusion and relaxation of polymeric chains mechanisms. The PL407 PL338 HA SFN hydrogel did not evoke pronounced cytotoxic effects on either osteoblast or chondrosarcoma cell lines. In vitro/ex vivo pharmacological evaluation interfered with an elevated activation of NF kappa B and COX 2, increased the type II collagen expression, and inhibited proteoglycan depletion. These results highlight the biocompatibility and the pharmacological efficacy of PL HA hybrid hydrogels as delivery systems for SFN intra articular release for OA treatment.
C1 [Monteiro do Nascimento, Monica Helena; Querobino, Samyr Machado; Nascimento Sales, Michelle; Alberto Silva, Carlos; Christoffolete, Marcelo Augusto; de Araujo, Daniele Ribeiro] ABC Fed Univ, Human & Nat Sci Ctr, Santo Andre, SP, Brazil.
   [Monteiro do Nascimento, Monica Helena; de Araujo, Daniele Ribeiro] Fed Univ ABC, Drugs & Bioact Delivery Syst Res Grp SISLIBIO, Santo Andre, SP, Brazil.
   [Ambrosio, Felipe Nogueira; Ferraraz, Debora Carajiliascov; Windisch Neto, Hermann; Lombello, Christiane Bertachini] ABC Fed Univ, Engn Modelling & Appl Social Sci Ctr, Santo Andre, SP, Brazil.
   [Franco, Margareth K. K. D.] Inst Pesquisas Energet & Nucl IPEN, Sao Paulo, SP, Brazil.
   [Kent, Ben] Helmholtz Zentrum Berlin Mat, Inst Soft Matter & Funct Mat, Berlin, Germany.
   [Kent, Ben] Univ New South Wales, Sch Chem, Kensington, NSW, Australia.
   [Yokaichiya, Fabiano] Helmholtz Zentrum Berlin Mat, Dept Quantum Phenomena Novel Mat, Berlin, Germany.
   [Yokaichiya, Fabiano] Univ Fed Parana, Dept Phys, Curitiba, Parana, Brazil.
C3 Universidade Federal do ABC (UFABC); Universidade Federal do ABC
   (UFABC); Universidade Federal do ABC (UFABC); Comissao Nacional de
   Energia Nuclear (CNEN); Instituto de Pesquisas Energeticas e Nucleares
   (IPEN); University of New South Wales Sydney; Universidade Federal do
   Parana
RP De Araujo, DR (通讯作者)，ABC Fed Univ, Drug & Bioact Delivery Syst Res Grp SISLIBIO, Human & Nat Sci Ctr, Av Estados 5001,Bloco A,Torre 3,Lab 503 3, BR 09021058 Santo Andre, SP, Brazil.
EM daniele.araujo@ufabc.edu.br
RI Ribeiro de Araujo, Daniele/L 1153 2016; Ambrosio, Felipe/O 3461 2019;
   querobino, samyr/M 7894 2019; Yokaichiya, Fabiano/D 3620 2012; Kent,
   Ben/GQZ 9142 2022; Franco, Margareth/N 5506 2016; Alberto Silva,
   Carlos/F 2972 2012; de Araujo, Daniele/L 1153 2016; Lombello, Christiane
   Bertachini/G 4128 2014; Nascimento, Monica/LMO 8531 2024
OI Ribeiro de Araujo, Daniele/0000 0002 9289 4229; Ambrosio,
   Felipe/0000 0002 8005 3772; Alberto Silva, Carlos/0000 0003 4519 8930; 
FU Sao Paulo Research Foundation  FAPESP [2014/14457 5, 2015/14763 1,
   2019/20303 4]; National Council for Scientific and Technological
   Development  CNPq [402838/2016 5, 309207/2016 9, 307718/2019 0]
FX The Sao Paulo Research Foundation  FAPESP (Grant 2014/14457 5,
   2015/14763 1, 2019/20303 4), National Council for Scientific and
   Technological Development  CNPq (Grant 402838/2016 5, 309207/2016 9,
   307718/2019 0).
CR Abou Raya A, 2014, J RHEUMATOL, V41, P53, DOI 10.3899/jrheum.130199
   Aigner T, 2006, EUR CELLS MATER, V12, P49, DOI 10.22203/eCM.v012a06
   Akkari ACS, 2016, MAT SCI ENG C MATER, V68, P299, DOI 10.1016/j.msec.2016.05.088
   ALEXANDRIDIS P, 1994, MACROMOLECULES, V27, P2414, DOI 10.1021/ma00087a009
   Altman RD, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0775 z
   Angel MJ, 2003, SPORTS MED ARTHROSC, V11, P168, DOI 10.1097/00132585 200311030 00002
   Artzner F, 2007, LANGMUIR, V23, P5085, DOI 10.1021/la062622p
   Bjornland T, 2007, J ORAL REHABIL, V34, P583, DOI 10.1111/j.1365 2842.2007.01759.x
   Blalock D, 2015, CLIN MED INSIGHTS AR, V8, P15, DOI 10.4137/CMAMD.S22147
   Boileau C, 2005, ANN RHEUM DIS, V64, P891, DOI 10.1136/ard.2004.026906
   Brandt KD, 2000, ARTHRITIS RHEUM US, V43, P1192, DOI 10.1002/1529 0131(200006)43:6<1192::AID ANR2>3.0.CO;2 L
   BROCKLEHURST R, 1984, J BONE JOINT SURG AM, V66A, P95, DOI 10.2106/00004623 198466010 00013
   Butoescu N, 2009, EUR J PHARM BIOPHARM, V73, P205, DOI 10.1016/j.ejpb.2009.06.009
   CAWSTON TE, 1995, BIOCHEM BIOPH RES CO, V215, P377, DOI 10.1006/bbrc.1995.2476
   Chen YZ, 2015, INT J NANOMED, V10, DOI 10.2147/IJN.S86827
   Cho KY, 2003, INT J PHARM, V260, P83, DOI 10.1016/S0378 5173(03)00259 X
   Choi MC, 2019, CELLS BASEL, V8, DOI 10.3390/cells8070734
   Chung C, 2006, J BIOMED MATER RES A, V77A, P518, DOI 10.1002/jbm.a.30660
   Conrozier T, 2010, ANN RHEUM DIS, V69, P281
   Davidson RK, 2013, ARTHRITIS RHEUM US, V65, P3130, DOI 10.1002/art.38133
   de Araujo D. R., 2014, NANOTOXICOLOGY MAT M, V1
   de Figueirêdo ES, 2010, ARQ BRAS OFTALMOL, V73, P92, DOI 10.1590/S0004 27492010000100018
   de Klaver MJM, 2003, ANESTH ANALG, V97, P465, DOI 10.1213/01.ANE.0000073162.27208.E9
   Dumortier G, 2006, PHARM RES DORDR, V23, P2709, DOI 10.1007/s11095 006 9104 4
   Duran N, 2014, NANOMED NANOTOXICOL, P1, DOI 10.1007/978 1 4614 8993 1
   Edsman K, 1998, EUR J PHARM SCI, V6, P105, DOI 10.1016/S0928 0987(97)00075 4
   Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031 9422(00)00316 2
   Fan HW, 2015, GENET MOL RES, V14, P12872, DOI 10.4238/2015.October.21.7
   Fearon U, 2006, ARTHRITIS RHEUM US, V54, P3152, DOI 10.1002/art.22161
   Fong WK, 2016, J CONTROL RELEASE, V228, P67, DOI 10.1016/j.jconrel.2016.02.042
   Fotakis G, 2006, TOXICOL LETT, V160, P171, DOI 10.1016/j.toxlet.2005.07.001
   Fox AJS, 2009, SPORTS HEALTH, V1, P461, DOI 10.1177/1941738109350438
   Franco MKKD, 2020, CHEMISTRYSELECT, V5, P12853, DOI 10.1002/slct.202001116
   Freitas M. N., 2006, Revista de Ciencias Farmaceuticas Basica e Aplicada, V27, P113
   Mariano KCF, 2020, INT J POLYM MATER PO, V69, P592, DOI 10.1080/00914037.2019.1596909
   Garg H.G. Hales., 2004, CHEM BIOL HYALURONAN, V1st
   Gebauer M, 2005, OSTEOARTHR CARTILAGE, V13, P697, DOI 10.1016/j.joca.2005.04.004
   Goes AM, 2012, POLIMEROS, V22, P34, DOI 10.1590/S0104 14282012005000012
   GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823
   Gomis A, 2009, OSTEOARTHR CARTILAGE, V17, P798, DOI 10.1016/j.joca.2008.11.013
   Grenier S, 2014, J BIOMECH, V47, P645, DOI 10.1016/j.jbiomech.2013.11.050
   Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200
   Hsieh HY, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227784
   Hu PF, 2014, INT J CLIN EXP PATHO, V7, P6575
   Hui W, 1997, ANN RHEUM DIS, V56, P184, DOI 10.1136/ard.56.3.184
   Hui W, 2003, ARTHRITIS RHEUM US, V48, P3404, DOI 10.1002/art.11333
   Ifrah M, 1998, VIRAL IMMUNOL, V11, P49, DOI 10.1089/vim.1998.11.49
   International Standards Organization, 2009, 109935 ISO, P34
   Jeong HJ, 2012, MOL MED REP, V6, P1199, DOI 10.3892/mmr.2012.1057
   Kang ML, 2014, EXPERT OPIN DRUG DEL, V11, P269, DOI 10.1517/17425247.2014.867325
   Khansai M, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1183 0
   Kim HA, 2009, RHEUMATOLOGY, V48, P932, DOI 10.1093/rheumatology/kep132
   Kim HA, 2012, RHEUMATOLOGY, V51, P1006, DOI 10.1093/rheumatology/ker525
   Ko JY, 2013, BIOMATERIALS, V34, P5359, DOI 10.1016/j.biomaterials.2013.03.066
   Kogan G, 2007, BIOTECHNOL LETT, V29, P17, DOI 10.1007/s10529 006 9219 z
   Kulkarni CV, 2016, LANGMUIR, V32, P11907, DOI 10.1021/acs.langmuir.6b03300
   Leopold SS, 2002, J BONE JOINT SURG AM, V84A, P1619, DOI 10.2106/00004623 200209000 00015
   Liacini A, 2005, ARTHRITIS RES THER, V7, pR777, DOI 10.1186/ar1735
   Lippens E, 2013, J BIOMATER APPL, V27, P828, DOI 10.1177/0885328211427774
   Liu CC, 2017, MOL MED REP, V16, P1369, DOI 10.3892/mmr.2017.6698
   Liu ZH, 2011, INT J MOL SCI, V12, P1684, DOI 10.3390/ijms12031684
   Marques MRC, 2011, DISSOLUT TECHNOL, V18, P15, DOI 10.14227/DT180311P15
   Mayo L, 2008, EUR J PHARM BIOPHARM, V70, P199, DOI 10.1016/j.ejpb.2008.04.025
   Mayol L, 2011, BIOMACROMOLECULES, V12, P28, DOI 10.1021/bm1008958
   Mengshol JA, 2001, NUCLEIC ACIDS RES, V29, P4361, DOI 10.1093/nar/29.21.4361
   Mero A, 2014, POLYMERS BASEL, V6, P346, DOI 10.3390/polym6020346
   MILLER RR, 1991, ANAL BIOCHEM, V192, P380, DOI 10.1016/0003 2697(91)90552 5
   Moran EM, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2772
   Moreland LW, 2003, ARTHRITIS RES THER, V5, P54, DOI 10.1186/ar623
   Nascimento M.H.N., 2018, INT J BIOL MACROMOL, V1, P1
   Oshiro A, 2014, LANGMUIR, V30, P13689, DOI 10.1021/la503021c
   Palmer AW, 2009, OSTEOARTHR CARTILAGE, V17, P1029, DOI 10.1016/j.joca.2009.02.009
   Pattoli MA, 2005, J PHARMACOL EXP THER, V315, P382, DOI 10.1124/jpet.105.087569
   Pei Y, 2006, OSTEOARTHR CARTILAGE, V14, P749, DOI 10.1016/j.joca.2006.01.017
   Pereira GG, 2013, QUIM NOVA, V36, P1121, DOI 10.1590/S0100 40422013000800008
   Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75
   Ricci EJ, 2002, EUR J PHARM SCI, V17, P161, DOI 10.1016/S0928 0987(02)00166 5
   RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369
   Salim M, 2016, LANGMUIR, V32, P5552, DOI 10.1021/acs.langmuir.6b01007
   SCHMOLKA IR, 1972, J BIOMED MATER RES, V6, P571, DOI 10.1002/jbm.820060609
   Sharma PK, 2008, COLLOID SURFACE B, V63, P229, DOI 10.1016/j.colsurfb.2007.12.009
   Sosnik A, 2005, BIOMATERIALS, V26, P349, DOI 10.1016/j.biomaterials.2004.02.041
   Souza R. S., 2011, Arquivos Brasileiros de Ciencias da Saude, V36, P48, DOI [10.7322/abcs.v36i1.75, DOI 10.7322/ABCS.V36I1.75]
   Tani N, 1999, TOXICOL IN VITRO, V13, P175, DOI 10.1016/S0887 2333(98)00071 X
   Theocharis AD, 2010, FEBS J, V277, P3904, DOI 10.1111/j.1742 4658.2010.07800.x
   TYLER JA, 1988, COLLAGEN REL RES, V8, P393
   Vincenti MP, 2001, ARTHRITIS RES, V3, P381, DOI 10.1186/ar331
   Wang JY, 2002, P NATL ACAD SCI USA, V99, P14362, DOI 10.1073/pnas.222536599
   Xu CJ, 2005, ONCOGENE, V24, P4486, DOI 10.1038/sj.onc.1208656
   YARON I, 1989, ARTHRITIS RHEUM US, V32, P173, DOI 10.1002/anr.1780320210
   Ye LX, 2001, CARCINOGENESIS, V22, P1987, DOI 10.1093/carcin/22.12.1987
   Zeng L, 2014, INT IMMUNOPHARMACOL, V18, P175, DOI 10.1016/j.intimp.2013.11.021
   Zhang Y, 2005, J COLLOID INTERF SCI, V285, P74, DOI 10.1016/j.jcis.2004.12.033
   Zhang YS, 2001, CARCINOGENESIS, V22, P425, DOI 10.1093/carcin/22.3.425
   Zheng ZH, 2008, RHEUMATOLOGY, V47, P22, DOI 10.1093/rheumatology/kem284
NR 95
TC 29
Z9 29
U1 3
U2 44
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD SEP
PY 2021
VL 128
AR 112345
DI 10.1016/j.msec.2021.112345
EA AUG 2021
PG 15
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA UK2OG
UT WOS:000691813600007
PM 34474895
DA 2025 08 17
ER

PT J
AU Fuchs, AG
   Echeverría, CI
   Rojo, FGP
   González, EAP
   Roldán, EJA
AF Fuchs, A. G.
   Echeverria, C. I.
   Perez Rojo, F. G.
   Prieto Gonzalez, E. A.
   Roldan, E. J. A.
TI Proline modulates the effect of bisphosphonate on calcium levels and
   adenosine triphosphate production in cell lines derived from bovine
   Echinococcus granulosus protoscoleces
SO JOURNAL OF HELMINTHOLOGY
LA English
DT Article
ID NONSELECTIVE CATION CHANNEL; PLANAR LIPID BILAYERS; HYDATID CYST FLUID;
   MOLECULAR CHARACTERIZATION; MYOINOSITOL HEXAKISPHOSPHATE; BINDING
   PROTEIN; RAT BONE; MULTILOCULARIS; LOCALIZATION; MECHANISM
AB Bisphosphonates have been proposed as pharmacological agents against parasite and cancer cell growth. The effect of these compounds on helminthic cell viability and acellular compartment morphology, however, has not yet been studied. The effects of different types of bisphosphonates, namely etidronate (EHDP), pamidronate (APD), alendronate (ABP), ibandronate (IB) and olpadronate (OPD), and their interaction with amiloride, 1,25 dihydroxycholecalciferol (D 3) and proline were evaluated on a cell line derived from bovine Echinococcus granulousus protoscoleces (EGPE) that forms cystic colonies in agarose. The EGPE cell line allowed testing the effect of bisphosphonates alone and in association with other compounds that could modulate calcium apposition/deposition, and were useful in measuring the impact of these compounds on cell growth, cystic colony formation and calcium storage. Decreased cell growth and cystic colony formation were found with EHDP, IB and OPD, and increased calcium storage with EHDP only. Calcium storage in EGPE cells appeared to be sensitive to the effect of amiloride, D 3 and proline. Proline decreased calcium storage and increased colony formation. Changes in calcium storage may be associated with degenerative changes of the cysts, as shown in the in vitro colony model and linked to an adenosine triphosphate (ATP) decrease. In conclusion, bisphosphonates could be suitable tempering drugs to treat cestode infections.
C1 [Fuchs, A. G.; Echeverria, C. I.; Perez Rojo, F. G.; Prieto Gonzalez, E. A.; Roldan, E. J. A.] Univ Abierta Interamer, Ctr Altos Estudios Ciencias Humanas & Salud CAECI, Buenos Aires, DF, Argentina.
RP Fuchs, AG (通讯作者)，Univ Abierta Interamer, Ctr Altos Estudios Ciencias Humanas & Salud CAECI, Ave Montes de Oca 745,C127OAAH, Buenos Aires, DF, Argentina.
EM Alicia.Fuchs@uai.edu.ar
OI Perez Rojo, Fernando Gabriel/0000 0001 9513 5116
FU Universidad Abierta Interamericana grants
FX This work used the in vitro model for pharmacological studies in
   Echinococcus, applied patent P090102320 Argentina, by A. G. Fuchs,
   Universidad Abierta Interamericana. The work was supported by
   Universidad Abierta Interamericana grants. We thank Dr Gabriela Canziani
   for careful reading of the manuscript. The authors declare no conflicts
   of interest.
CR Cabezon C, 2008, MOL IMMUNOL, V45, P1431, DOI 10.1016/j.molimm.2007.08.022
   Casaravilla C, 2006, FEBS J, V273, P3192, DOI 10.1111/j.1742 4658.2006.05328.x
   CHOWDHURY N, 1993, J HELMINTHOL, V67, P112, DOI 10.1017/S0022149X00012980
   Cukrowski I, 2007, BONE, V41, P668, DOI 10.1016/j.bone.2007.05.008
   Cumino AC, 2010, INT J PARASITOL, V40, P651, DOI 10.1016/j.ijpara.2009.11.011
   Cumino AC, 2009, PARASITOL INT, V58, P270, DOI 10.1016/j.parint.2009.03.005
   Daryani A, 2009, TROP ANIM HEALTH PRO, V41, P1701, DOI 10.1007/s11250 009 9368 x
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Echeverría CI, 2010, IN VITRO CELL DEV AN, V46, P781, DOI 10.1007/s11626 010 9345 8
   Epping K, 2011, EXP PARASITOL, V129, P85, DOI 10.1016/j.exppara.2011.07.013
   Farach Carson MC, 1998, AM J KIDNEY DIS, V31, P729, DOI 10.1053/ajkd.1998.v31.pm9531195
   FRAYHA GJ, 1980, INT J PARASITOL, V10, P359, DOI 10.1016/0020 7519(80)90036 3
   GIORGIO A, 1992, RADIOLOGY, V184, P705, DOI 10.1148/radiology.184.3.1509053
   Grosman C, 1995, EXP PARASITOL, V81, P546, DOI 10.1006/expr.1995.1148
   Grosman C, 1997, J MEMBRANE BIOL, V158, P87, DOI 10.1007/s002329900246
   GUENTHER HL, 1981, BIOCHEM J, V196, P293, DOI 10.1042/bj1960293
   Guerret S, 1998, PARASITOL RES, V84, P657, DOI 10.1007/s004360050466
   Halder SK, 2011, J CLIN ENDOCR METAB, V96, pE754, DOI 10.1210/jc.2010 2131
   Heath DD, 2003, ACTA TROP, V85, P133, DOI 10.1016/S0001 706X(02)00219 X
   Hemphill A, 2007, PARASITOLOGY, V134, P1657, DOI 10.1017/S0031182007003198
   IBARRA C, 1994, EXP PARASITOL, V78, P400, DOI 10.1006/expr.1994.1044
   Irigoín F, 2004, J CELL BIOCHEM, V93, P1272, DOI 10.1002/jcb.20262
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kusters JMAM, 2005, BIOPHYS J, V89, P3741, DOI 10.1529/biophysj.105.062984
   LIDOR C, 1987, BIOCHEM J, V243, P75, DOI 10.1042/bj2430075
   Mahmoud Lily H., 2002, Journal of the Egyptian Society of Parasitology, V32, P647
   Masud T, 1998, ANN RHEUM DIS, V57, P346, DOI 10.1136/ard.57.6.346
   Moro P, 2006, PARASITOL INT, V55, pS181, DOI 10.1016/j.parint.2005.11.048
   Ortiz Gómez A, 2006, EUKARYOT CELL, V5, P1057, DOI 10.1128/EC.00034 06
   Panda DK, 2004, J BIOL CHEM, V279, P16754, DOI 10.1074/jbc.M310271200
   Phang JM, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00060
   Sanz Rodríguez CE, 2007, J BIOL CHEM, V282, P12377, DOI 10.1074/jbc.M607286200
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Shao WJ, 2005, AM J PHYSIOL CELL PH, V289, pC248, DOI 10.1152/ajpcell.00393.2004
   SMITH SA, 1993, PARASITOL RES, V79, P245, DOI 10.1007/BF00931900
   Spiliotis M, 2004, EXP PARASITOL, V107, P163, DOI 10.1016/j.exppara.2004.05.006
   Vazquez G, 2003, CALCIFIED TISSUE INT, V72, P215, DOI 10.1007/s00223 002 1070 1
   VIDOR E, 1986, ANN PARASIT HUM COMP, V61, P333, DOI 10.1051/parasite/1986613333
   Zurabian R, 2005, ARCH MED RES, V36, P4, DOI 10.1016/j.arcmed.2004.10.001
NR 39
TC 2
Z9 2
U1 0
U2 2
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0022 149X
EI 1475 2697
J9 J HELMINTHOL
JI J. Helminthol.
PD DEC
PY 2014
VL 88
IS 4
BP 459
EP 467
DI 10.1017/S0022149X13000436
PG 9
WC Parasitology; Zoology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Parasitology; Zoology
GA AS7ZH
UT WOS:000344469900012
PM 23742745
DA 2025 08 17
ER

PT J
AU Hosseinpour, S
   Walsh, LJ
   Xu, C
AF Hosseinpour, Sepanta
   Walsh, Laurence J.
   Xu, Chun
TI Modulating Osteoimmune Responses by Mesoporous Silica Nanoparticles
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE immunomodulation; osteoimmunomodulation; bone regeneration; mesoporous
   silica nanoparticles; macrophages
ID CERIUM DIOXIDE NANOPARTICLES; M2 MACROPHAGE POLARIZATION; PROTEIN KINASE
   PATHWAYS; FACTOR KAPPA B; IN VITRO; OSTEOBLAST DIFFERENTIATION;
   INFLAMMATORY RESPONSES; TRICALCIUM PHOSPHATE; CELLULAR RESPONSE;
   OXIDATIVE STRESS
AB The immune response plays an important role in biomaterial mediated osteogenesis. Nanomaterials may influence immune responses and thereby alter bone regeneration. Mesoporous silica nanoparticles (MSNs) have received much attention for drug delivery and bone regeneration. Recently, immunomodulatory effects of MSNs on osteogenesis have been reported. In this Review, we summarize the osteoimmunomodulation of MSNs, including the effects of MSN characteristics on immune cells and osteogenesis. Impacts of MSNs on immune cells vary according to nanoparticle properties, including surface topography and charge, particle size, and ion release. MSNs with suitable doses can inhibit inflammation and create an immune microenvironment beneficial for bone regeneration by activating immune cells and stimulating cytokine release. Further work is needed to explore and clarify the underlying mechanisms, including crosstalk between various types of immune cells and how to design MSNs to create a suitable immune environment for osteogenesis.
C1 [Hosseinpour, Sepanta; Walsh, Laurence J.; Xu, Chun] Univ Queensland, Sch Dent, Herston, Qld 4006, Australia.
C3 University of Queensland
RP Xu, C (通讯作者)，Univ Queensland, Sch Dent, Herston, Qld 4006, Australia.
EM chun.xu@uq.edu.au
RI Walsh, Laurence/F 1210 2010; Xu, Chun/C 3649 2017; Hosseinpour,
   Sepanta/K 8114 2019
OI Xu, Chun/0000 0001 8831 3607; 
FU University of Queensland; National Health and Medical Research Council
   of Australia (NHMRC)
FX S.H. acknowledges a graduate scholarship from The University of
   Queensland. C.X. acknowledges the support of the Early Career Fellowship
   from the National Health and Medical Research Council of Australia
   (NHMRC) .
CR Abbaraju PL, 2017, CHEM ASIAN J, V12, P1465, DOI 10.1002/asia.201700392
   Abbaraju PL, 2017, J AM CHEM SOC, V139, P6321, DOI 10.1021/jacs.6b12622
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Boraschi D, 2017, SEMIN IMMUNOL, V34, P33, DOI 10.1016/j.smim.2017.08.013
   Carson JS, 2007, INJURY, V38, pS33, DOI 10.1016/j.injury.2007.02.008
   Champion JA, 2006, P NATL ACAD SCI USA, V103, P4930, DOI 10.1073/pnas.0600997103
   Chen LJ, 2018, NANOMEDICINE UK, V13, P1939, DOI 10.2217/nnm 2018 0076
   Chen YP, 2017, ACS APPL MATER INTER, V9, P10254, DOI 10.1021/acsami.7b00240
   Chen ZT, 2018, APPL MATER TODAY, V10, P184, DOI 10.1016/j.apmt.2017.12.003
   Chen ZT, 2016, MATER TODAY, V19, P304, DOI 10.1016/j.mattod.2015.11.004
   Chiou WF, 2003, EUR J PHARMACOL, V458, P217, DOI 10.1016/S0014 2999(02)02733 4
   Chou CC, 2017, ACS APPL MATER INTER, V9, P22235, DOI 10.1021/acsami.7b05359
   Chung TH, 2007, BIOMATERIALS, V28, P2959, DOI 10.1016/j.biomaterials.2007.03.006
   Cook Emily A, 2009, Clin Podiatr Med Surg, V26, P589, DOI 10.1016/j.cpm.2009.07.003
   Cui W, 2018, ACS BIOMATER SCI ENG, V4, P211, DOI 10.1021/acsbiomaterials.7b00506
   Davison NL, 2014, EUR CELLS MATER, V27, P281, DOI 10.22203/eCM.v027a20
   Duan JC, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/s12989 014 0050 8
   Ekkapongpisit M, 2012, INT J NANOMED, V7, P4147, DOI 10.2147/IJN.S33803
   Encinas N, 2019, ACTA BIOMATER, V84, P317, DOI 10.1016/j.actbio.2018.12.012
   Franco S, 2020, CANCERS, V12, DOI 10.3390/cancers12102892
   Franz S, 2011, BIOMATERIALS, V32, P6692, DOI 10.1016/j.biomaterials.2011.05.078
   Geng HY, 2017, CHEM EUR J, V23, P10878, DOI 10.1002/chem.201701806
   Ghosh S, 2021, FRONT MATER, V8, DOI 10.3389/fmats.2021.692309
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Glenn Justin D, 2014, World J Stem Cells, V6, P526, DOI 10.4252/wjsc.v6.i5.526
   Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105
   Gu HJ, 2011, BIOMATERIALS, V32, P7023, DOI 10.1016/j.biomaterials.2011.06.003
   Gustafson HH, 2015, NANO TODAY, V10, P487, DOI 10.1016/j.nantod.2015.06.006
   Ha SW, 2014, ACS NANO, V8, P5898, DOI 10.1021/nn5009879
   Hachim D, 2017, BIOMATERIALS, V112, P95, DOI 10.1016/j.biomaterials.2016.10.019
   HAYMAN AR, 1994, J BIOL CHEM, V269, P1294
   Hosseinpour S, 2020, J MATER CHEM B, V8, P9863, DOI 10.1039/d0tb01868f
   Hosseinpour S, 2017, ORAL MAXILLOFAC SURG, V21, P109, DOI 10.1007/s10006 017 0608 3
   Humbert P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00663
   Hussain S, 2013, AUTOPHAGY, V9, P101, DOI 10.4161/auto.22266
   Hussain S, 2012, ACS NANO, V6, P5820, DOI 10.1021/nn302235u
   Izquierdo Barba I, 2008, J NANOMATER, V2008, DOI 10.1155/2008/106970
   Jia JB, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00404
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Kondo N, 2006, BIOMATERIALS, V27, P4419, DOI 10.1016/j.biomaterials.2006.04.016
   Kwon D, 2017, NANO LETT, V17, P2747, DOI 10.1021/acs.nanolett.6b04130
   Lee S, 2011, ACTA BIOMATER, V7, P2337, DOI 10.1016/j.actbio.2011.01.006
   Lei C, 2021, NANO RES, V14, P770, DOI 10.1007/s12274 020 3112 2
   Lesniak A, 2012, ACS NANO, V6, P5845, DOI 10.1021/nn300223w
   Li HM, 2019, ADV MATER, V31, DOI 10.1002/adma.201904535
   Liang H, 2019, ACS APPL MATER INTER, V11, P41758, DOI 10.1021/acsami.9b16848
   Liu F, 2013, J BONE MINER RES, V28, P2414, DOI 10.1002/jbmr.1971
   Liu K, 2015, AUTOPHAGY, V11, P271, DOI 10.1080/15548627.2015.1009787
   Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542
   Lu F, 2009, SMALL, V5, P1408, DOI 10.1002/smll.200900005
   Luo J, 2019, ACTA METALL SIN ENGL, V32, P1253, DOI 10.1007/s40195 019 00926 y
   Luo Z, 2014, J BIOMED MATER RES A, V102, P3781, DOI 10.1002/jbm.a.35049
   Mao LX, 2017, ACTA BIOMATER, V61, P217, DOI 10.1016/j.actbio.2017.08.015
   Meng H, 2011, ACS NANO, V5, P4434, DOI 10.1021/nn103344k
   Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166
   Montalvo Quirós S, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12121218
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Mühlfeld C, 2008, SWISS MED WKLY, V138, P387, DOI 2008/27/smw 12153
   Muhlfeld C., 2008, SWISS MED WKLY, V138, P256
   Mukherjee SP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00673
   Muszanska AK, 2011, BIOMATERIALS, V32, P6333, DOI 10.1016/j.biomaterials.2011.05.016
   Najar M, 2016, J IMMUNOTHER, V39, P45, DOI 10.1097/CJI.0000000000000108
   Niikura K, 2013, ACS NANO, V7, P3926, DOI 10.1021/nn3057005
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Nowak JS, 2014, TOXICOL LETT, V224, P84, DOI 10.1016/j.toxlet.2013.10.003
   Oberdörster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339
   Oliveira R, 2012, IMPLANT DENT, V21, P422, DOI 10.1097/ID.0b013e3182691873
   Owens DE, 2006, INT J PHARMACEUT, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Park EJ, 2009, TOXICOL LETT, V184, P18, DOI 10.1016/j.toxlet.2008.10.012
   Parodi A, 2014, ACS NANO, V8, P9874, DOI 10.1021/nn502807n
   Paul S, 2012, IMMUNITY, V36, P947, DOI 10.1016/j.immuni.2012.04.008
   Pettit AR, 2008, BONE, V43, P976, DOI 10.1016/j.bone.2008.08.128
   Pinna A, 2021, ACTA BIOMATER, V122, P365, DOI 10.1016/j.actbio.2020.12.029
   Polo Montalvo A, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13081152
   Primus CM, 2019, ACTA BIOMATER, V96, P35, DOI 10.1016/j.actbio.2019.05.050
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Schlundt C, 2018, BONE, V106, P78, DOI 10.1016/j.bone.2015.10.019
   Schröder HC, 2012, J CELL BIOCHEM, V113, P3197, DOI 10.1002/jcb.24196
   Shi MC, 2017, BIOMATERIALS, V144, P176, DOI 10.1016/j.biomaterials.2017.08.027
   Shi MC, 2016, ACTA BIOMATER, V30, P334, DOI 10.1016/j.actbio.2015.11.033
   Siednienko J, 2010, EUR J IMMUNOL, V40, P3150, DOI 10.1002/eji.201040547
   Sridharan R, 2015, MATER TODAY, V18, P313, DOI 10.1016/j.mattod.2015.01.019
   Stern ST, 2008, TOXICOL SCI, V106, P140, DOI 10.1093/toxsci/kfn137
   Sun X, 2021, BIOACT MATER, V6, P757, DOI 10.1016/j.bioactmat.2020.08.030
   Takayanagi H, 2005, J PERIODONTAL RES, V40, P287, DOI 10.1111/j.1600 0765.2005.00814.x
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tasia WD, 2020, NANOSCALE, V12, P2328, DOI 10.1039/c9nr08467c
   Teng RJ, 2012, AM J PHYSIOL LUNG C, V302, P1651, DOI 10.1152/ajplung.00177.2011
   Nguyen TL, 2019, ADV MATER, V31, DOI 10.1002/adma.201803953
   Torres M, 2003, FRONT BIOSCI, V8, pD369, DOI 10.2741/999
   Vallet Regi Maria, 2018, Enzymes, V43, P1, DOI 10.1016/bs.enz.2018.07.001
   Vallet Regí M, 2018, MOLECULES, V23, DOI 10.3390/molecules23010047
   Vallhov H, 2007, NANO LETT, V7, P3576, DOI [10.1021/nl0714785, 10.1021/nI0714785]
   Voicu SNP, 2015, INT J MOL SCI, V16, P29398, DOI 10.3390/ijms161226171
   Wang J, 2018, NAT NANOTECHNOL, V13, P1078, DOI 10.1038/s41565 018 0274 0
   Wang J, 2017, ACTA BIOMATER, V51, P447, DOI 10.1016/j.actbio.2017.01.059
   Wang XP, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201901432
   Wang XP, 2016, ADV HEALTHC MATER, V5, P1169, DOI 10.1002/adhm.201501013
   Wang XP, 2016, ANGEW CHEM INT EDIT, V55, P1899, DOI 10.1002/anie.201506179
   Wang Y, 2018, J MATER CHEM B, V6, P4089, DOI 10.1039/c8tb00544c
   Wiens M, 2010, BIOMATERIALS, V31, P7716, DOI 10.1016/j.biomaterials.2010.07.002
   Wu SH, 2011, CHEM COMMUN, V47, P9972, DOI 10.1039/c1cc11760b
   Xi C, 2016, INFLAMM RES, V65, P325, DOI 10.1007/s00011 016 0919 0
   Xu C, 2020, NANO RES, V13, P2323, DOI 10.1007/s12274 020 2783 z
   Xu C, 2020, ACS APPL NANO MATER, V3, P1457, DOI 10.1021/acsanm.9b02298
   Xu C, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00290
   Xu C, 2018, J MATER CHEM B, V6, P1899, DOI 10.1039/c7tb03201c
   Xu C, 2017, CHEM MATER, V29, P7725, DOI 10.1021/acs.chemmater.7b01804
   Xu C, 2015, SMALL, V11, P5949, DOI 10.1002/smll.201501449
   Xu C, 2014, J MATER CHEM B, V2, P253, DOI 10.1039/c3tb21431a
   Xu XW, 2019, NANOSCALE, V11, P21953, DOI 10.1039/c9nr07017f
   Yamashita M, 2008, J ENDOCRINOL, V196, P601, DOI 10.1677/JOE 07 0532
   Yu YB, 2014, J HAZARD MATER, V270, P176, DOI 10.1016/j.jhazmat.2014.01.028
   Yue H, 2010, EUR J PHARM SCI, V41, P650, DOI 10.1016/j.ejps.2010.09.006
   Zabirnyk O, 2007, AUTOPHAGY, V3, P278, DOI 10.4161/auto.3916
   Zhang HJ, 2015, J MATER CHEM B, V3, P6480, DOI 10.1039/c5tb00634a
   Zhang ML, 2012, J BIOMED MATER RES A, V100A, P2979, DOI 10.1002/jbm.a.34246
   Zhao Y, 2014, J BIOL CHEM, V289, P21028, DOI 10.1074/jbc.M113.546523
NR 119
TC 29
Z9 29
U1 9
U2 83
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD OCT 10
PY 2022
VL 8
IS 10
BP 4110
EP 4122
DI 10.1021/acsbiomaterials.1c00899
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 5I2IX
UT WOS:000868188200001
PM 34775744
DA 2025 08 17
ER

PT J
AU Niu, YM
   Wang, LT
   Yu, N
   Xing, PF
   Wang, ZZ
   Zhong, ZF
   Feng, YX
   Dong, L
   Wang, CM
AF Niu, Yiming
   Wang, Lintao
   Yu, Na
   Xing, Panfei
   Wang, Zhenzhen
   Zhong, Zhangfeng
   Feng, Yanxian
   Dong, Lei
   Wang, Chunming
TI An "all in one" scaffold targeting macrophages to direct endogenous bone
   repair in situ
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Bioactive scaffolds; Tissue regeneration; Macrophages; Polysaccharides;
   Bone
ID MESENCHYMAL STEM CELLS; TUMOR ASSOCIATED MACROPHAGES; KONJAC
   GLUCOMANNAN; MECHANICAL PROPERTIES; PARATHYROID HORMONE;
   ENDOTHELIAL CELLS; ADIPOSE TISSUE; GROWTH FACTORS; ONCOSTATIN M;
   REGENERATION
AB Scaffolds for tissue repair are designed in an increasingly complicated manner to meet multi facet biological needs during the healing process. However, overly sophisticated design, especially the use of multiple components and delivery of exogenous cells, hampers the bench to bedside translation. Here, a multi functional   yet mono compositional   bioactive scaffold is devised to mediate the full range, endogenous bone repair. Based on immunoactivity screening, a chemically modified glucomannan polysaccharide is selected and processed into an anisotropic porous scaffold, which accurately stimulates macrophages to produce pro regenerative cytokines. These cytokines effectively enhance the recruitment ("R") and induced osteogenesis ("IO") of the bone progenitor cells in situ. Meanwhile, the anisotropic porosity and carbohydrate signal of the scaffold facilitate differential adhesion ("A") and distribution ("D") of the macrophages and bone progenitor cells   enabling the former's accumulation at the surface while encouraging the latter's infiltration into the scaffold. Implanted in a rat calvarial defect model, this "RADIO" system effectively promotes healing over 12 weeks, with the obvious formation of hard callus through the scaffold. In summary, RADIO integrates multiple functions into one single scalable system ("all in one") to govern the dynamic bone repair process, by harnessing the power of host macrophages. RADIO represents an open platform to solving the long lasting complexity versus simplicity dilemma in biomaterials design.
   Statement of Significance
   Biomaterials as versatile tools for tissue repair are becoming increasingly complicated, yet overly sophisticated design   especially the use of multiple components, exogenous cells, and overdosed growth factors   hampers their clinical application. The pre requisite for designing a successful integrative scaffold is to identify an inherent biological target responding to biomaterial signals, thereby efficiently and safely promoting tissue repair via the endogenous healing capability instead of extra multifarious biochemical components. For bone regeneration, the pivotal regulator is macrophages. Through activating host macrophages, our single component scaffold system coordinates the entire bone regenerative cascade in situ and induces successful bone regeneration in a calvarial defect model. This scaffold represents a scalable and multi functional approach to effectively simplify the sophisticated design in regenerative medicine. (C) 2020 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Niu, Yiming; Xing, Panfei; Wang, Zhenzhen; Zhong, Zhangfeng; Feng, Yanxian; Wang, Chunming] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Ave Univ, Macau, Peoples R China.
   [Wang, Lintao; Dong, Lei] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Peoples R China.
   [Yu, Na] Natl Dent Ctr Singapore, 5 Second Hosp Ave, Singapore 168938, Singapore.
   [Yu, Na] Duke NUS Med Sch, 8 Coll Rd, Singapore 169857, Singapore.
C3 University of Macau; Nanjing University; National University of
   Singapore
RP Wang, CM (通讯作者)，Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Ave Univ, Macau, Peoples R China.
EM cmwang@umac.mo
RI Yanxian, Feng/ABC 1623 2021; Dong, Lei/J 3516 2013; Xing,
   Panfei/IAR 3006 2023; Wang, Chunming/I 3392 2013
OI Wang, Zhenzhen/0000 0003 4645 0958; Feng, Yanxian/0000 0003 2091 2632;
   Niu, Yiming/0000 0001 9845 8295; Wang, Chunming/0000 0001 9185 9678;
   Dong, Lei/0000 0002 2013 4191; Xing, Panfei/0009 0004 3738 7226
FU Science and Technology Development Fund, Macau SAR [FDCT 080/2016/A2,
   0018/2019/AFJ]; University of Macau [MYRG2017 00028 ICMS,
   MYRG2019 00080 ICMS]
FX This study was funded by The Science and Technology Development Fund,
   Macau SAR (File No. FDCT 080/2016/A2, 0018/2019/AFJ) and the University
   of Macau (MYRG2017 00028 ICMS, MYRG2019 00080 ICMS).
CR Abbaszadeh A, 2016, CARBOHYD POLYM, V144, P168, DOI 10.1016/j.carbpol.2016.02.026
   Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   Arrighi I, 2009, BIOMATERIALS, V30, P1763, DOI 10.1016/j.biomaterials.2008.12.023
   Bahney CS, 2019, J ORTHOP RES, V37, P35, DOI 10.1002/jor.24170
   Baht GS, 2018, CURR OSTEOPOROS REP, V16, P138, DOI 10.1007/s11914 018 0423 2
   Batoon L, 2017, CURR OSTEOPOROS REP, V15, P385, DOI 10.1007/s11914 017 0384 x
   Berendsen AD, 2015, BONE, V80, P14, DOI 10.1016/j.bone.2015.04.035
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Chandler EM, 2011, BIOTECHNOL BIOENG, V108, P1683, DOI 10.1002/bit.23079
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Chen JL, 2020, J MATER CHEM B, V8, P316, DOI 10.1039/c9tb02053e
   Cho SW, 2014, P NATL ACAD SCI USA, V111, P1545, DOI 10.1073/pnas.1315153111
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479
   de Grado GF, 2018, J TISSUE ENG, V9, DOI 10.1177/2041731418776819
   Dupont KM, 2010, P NATL ACAD SCI USA, V107, P3305, DOI 10.1073/pnas.0905444107
   Eggenhofer E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00148
   Feng YX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10354 2
   Feng YX, 2017, BIOMATERIALS, V134, P128, DOI 10.1016/j.biomaterials.2017.04.042
   Fermaintt CS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10319 5
   Gan JJ, 2018, BIOMATERIALS, V178, P95, DOI 10.1016/j.biomaterials.2018.06.015
   García Gareta E, 2015, BONE, V81, P112, DOI 10.1016/j.bone.2015.07.007
   Gbureck U, 2007, ADV MATER, V19, P795, DOI 10.1002/adma.200601370
   Guihard P, 2015, AM J PATHOL, V185, P765, DOI 10.1016/j.ajpath.2014.11.008
   Guihard P, 2012, STEM CELLS, V30, P762, DOI 10.1002/stem.1040
   Hasani Sadrabadi MM, 2019, ACS NANO, V13, P3830, DOI 10.1021/acsnano.8b09623
   Hocking AM, 2015, ADV WOUND CARE, V4, P623, DOI 10.1089/wound.2014.0579
   Holloway JL, 2015, MACROMOL BIOSCI, V15, P1218, DOI 10.1002/mabi.201500178
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603 685
   James AW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8362
   Julier Z, 2017, ACTA BIOMATER, V53, P13, DOI 10.1016/j.actbio.2017.01.056
   Jung UW, 2017, J CLIN PERIODONTOL, V44, P1172, DOI 10.1111/jcpe.12802
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Katsuraya K, 2003, CARBOHYD POLYM, V53, P183, DOI 10.1016/S0144 8617(03)00039 0
   Kaur G, 2019, MAT SCI ENG C MATER, V104, DOI 10.1016/j.msec.2019.109895
   Keaveny TM, 2001, ANNU REV BIOMED ENG, V3, P307, DOI 10.1146/annurev.bioeng.3.1.307
   Kleinhans C, 2015, BIOTECHNOL J, V10, P1727, DOI 10.1002/biot.201400813
   Ko E, 2018, ACS APPL MATER INTER, V10, P7614, DOI 10.1021/acsami.7b03328
   Li HX, 2019, 2019 3RD CONFERENCE ON VEHICLE CONTROL AND INTELLIGENCE (CVCI), P109, DOI 10.1109/cvci47823.2019.8951696
   Lin D, 2019, BIOMATERIALS, V196, P122, DOI 10.1016/j.biomaterials.2017.11.011
   Liu JY, 2012, CARBOHYD POLYM, V89, P158, DOI 10.1016/j.carbpol.2012.02.065
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007 0054
   Ma LM, 2018, ACS APPL MATER INTER, V10, P42146, DOI 10.1021/acsami.8b17495
   Misch CE, 1999, J ORAL MAXIL SURG, V57, P700, DOI 10.1016/S0278 2391(99)90437 8
   Mitchell AC, 2016, ACTA BIOMATER, V30, P1, DOI 10.1016/j.actbio.2015.11.007
   Molina ER, 2015, J CONTROL RELEASE, V219, P107, DOI 10.1016/j.jconrel.2015.08.038
   Moroni L, 2018, TRENDS BIOTECHNOL, V36, P384, DOI 10.1016/j.tibtech.2017.10.015
   Murphy CM, 2010, BIOMATERIALS, V31, P461, DOI 10.1016/j.biomaterials.2009.09.063
   Murphy SV, 2014, NAT BIOTECHNOL, V32, P773, DOI 10.1038/nbt.2958
   Nair A, 2011, ACTA BIOMATER, V7, P3887, DOI 10.1016/j.actbio.2011.06.050
   Nichol JW, 2010, BIOMATERIALS, V31, P5536, DOI 10.1016/j.biomaterials.2010.03.064
   Niu YM, 2017, BIOMATERIALS, V139, P39, DOI 10.1016/j.biomaterials.2017.05.042
   O'Brien FJ, 2011, MATER TODAY, V14, P88, DOI 10.1016/S1369 7021(11)70058 X
   Pacelli S, 2017, ADV DRUG DELIVER REV, V120, P50, DOI 10.1016/j.addr.2017.07.011
   Pajarinen J, 2019, BIOMATERIALS, V196, P80, DOI 10.1016/j.biomaterials.2017.12.025
   Papageorgiou DG, 2017, PROG MATER SCI, V90, P75, DOI 10.1016/j.pmatsci.2017.07.004
   Park SB, 2017, PROG POLYM SCI, V68, P77, DOI 10.1016/j.progpolymsci.2016.12.003
   Pashuck ET, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002717
   Prins HJ, 2016, STEM CELL TRANSL MED, V5, P1362, DOI 10.5966/sctm.2015 0369
   Roccuzzo M, 2017, CLIN ORAL IMPLAN RES, V28, P1577, DOI 10.1111/clr.13028
   Roosa SMM, 2010, J BIOMED MATER RES A, V92A, P359, DOI 10.1002/jbm.a.32381
   Seeherman HJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aar4953
   Shen XF, 2016, BIOMATERIALS, V106, P205, DOI 10.1016/j.biomaterials.2016.08.023
   Smith MH, 2007, INT J MED ROBOT COMP, V3, P207, DOI 10.1002/rcs.143
   Spicer PP, 2012, NAT PROTOC, V7, P1918, DOI 10.1038/nprot.2012.113
   Sridharan R, 2015, MATER TODAY, V18, P313, DOI 10.1016/j.mattod.2015.01.019
   Suárez González D, 2014, TISSUE ENG PT A, V20, P2077, DOI 10.1089/ten.tea.2013.0358
   Sultan S, 2018, NANOSCALE, V10, P4421, DOI 10.1039/c7nr08966j
   TOMODA M, 1974, CHEM PHARM BULL, V22, P2710
   Wang CM, 2006, BIOTECHNOL LETT, V28, P539, DOI 10.1007/s10529 006 0011 x
   Wang Y, 2017, J MATER CHEM B, V5, P7307, DOI 10.1039/c7tb01495c
   Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080
   Wofford KL, 2020, ACTA BIOMATER, V101, P237, DOI 10.1016/j.actbio.2019.11.021
   Wu Andy C, 2013, Bonekey Rep, V2, P373, DOI 10.1038/bonekey.2013.107
   Xiao M, 2015, CARBOHYD POLYM, V130, P1, DOI 10.1016/j.carbpol.2015.05.001
   Zhan XD, 2014, BIOMATERIALS, V35, P10046, DOI 10.1016/j.biomaterials.2014.09.007
   Zhang B, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau7411
   Zhang L, 2019, ACTA BIOMATER, V84, P16, DOI 10.1016/j.actbio.2018.11.039
   Zhang Y, 2017, CELL TISSUE RES, V369, P273, DOI 10.1007/s00441 017 2598 8
   Zhao HX, 2017, MATER LETT, V194, P220, DOI 10.1016/j.matlet.2017.02.059
NR 81
TC 14
Z9 15
U1 6
U2 86
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JUL 15
PY 2020
VL 111
BP 153
EP 169
DI 10.1016/j.actbio.2020.05.023
PG 17
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA MC7HH
UT WOS:000543452700012
PM 32447062
DA 2025 08 17
ER

PT J
AU Grosjean, F
   Nasi, S
   Schneider, P
   Chobaz, V
   Liu, A
   Mordasini, V
   Moullec, K
   Vezzoni, P
   Lavanchy, C
   Busso, N
   Acha Orbea, H
   Ehirchiou, D
AF Grosjean, Frederic
   Nasi, Sonia
   Schneider, Pascal
   Chobaz, Veronique
   Liu, Alexandra
   Mordasini, Vanessa
   Moullec, Kristell
   Vezzoni, Paolo
   Lavanchy, Christine
   Busso, Nathalie
   Acha Orbea, Hans
   Ehirchiou, Driss
TI Dendritic Cells Cause Bone Lesions in a New Mouse Model of Histiocytosis
SO PLOS ONE
LA English
DT Article
ID T CELLS; MALIGNANT HISTIOCYTOSIS; OSTEOCLASTS; TRANSDIFFERENTIATION;
   DIFFERENTIATION; ARTHRITIS; PATHWAY; MICE
AB Langerhans cell histiocytosis (LCH) is a rare disease caused by the clonal accumulation of dendritic Langerhans cells, which is often accompanied by osteolytic lesions. It has been reported that osteoclast like cells play a major role in the pathogenic bone destruction seen in patients with LCH and these cells are postulated to originate from the fusion of DCs. However, due to the lack of reliable animal models the pathogenesis of LCH is still poorly understood. In this study, we have established a mouse model of histiocytosis recapitulating human disease for osteolytic lesions seen in LCH patients. At 12 weeks after birth, severe bone lesions were observed in our multisystem histiocytosis (Mushi) model, when CD8 alpha conventional dendritic cells (DCs) are transformed (MuTuDC) and accumulate. Most importantly, our study demonstrates that bone loss in LCH can be accounted for the transdifferentiation of MuTuDCs into functional osteoclasts both in vivo and in vitro. Moreover, we have shown that injected MuTuDCs reverse the osteopetrotic phenotype of oc/oc mice in vivo. In conclusion, our results support a crucial role of DCs in bone lesions in histiocytosis patients. Furthermore, our new model of LCH based on adoptive transfer of MuTuDC lines, leading to bone lesions within 1 2 weeks, will be an important tool for investigating the pathophysiology of this disease and ultimately for evaluating the potential of anti resorptive drugs for the treatment of bone lesions.
C1 [Grosjean, Frederic; Schneider, Pascal; Liu, Alexandra; Mordasini, Vanessa; Moullec, Kristell; Lavanchy, Christine; Acha Orbea, Hans; Ehirchiou, Driss] Univ Lausanne, Dept Biochem CIIL, CH 1066 Epalinges, Switzerland.
   [Nasi, Sonia; Chobaz, Veronique; Busso, Nathalie] Univ Lausanne, DAL, Serv Rheumatol, Lab Rheumatol,CHUV, CH 1066 Epalinges, Switzerland.
   [Vezzoni, Paolo] CNR, Milan Unit, UOS IRGB, I 20138 Milan, Italy.
   [Vezzoni, Paolo] Humanitas Res Ctr, Rozzano, Italy.
C3 University of Lausanne; University of Lausanne; Centre Hospitalier
   Universitaire Vaudois (CHUV); Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Ricerca Genetica e Biomedica (IRGB CNR); IRCCS Humanitas
   Research Hospital
RP Acha Orbea, H (通讯作者)，Univ Lausanne, Dept Biochem CIIL, CH 1066 Epalinges, Switzerland.
EM Hans.Acha Orbea@unil.ch
RI ; Grosjean, Frederic/HNC 2871 2023; Vezzoni, Paolo/R 3416 2019; Nasi,
   Sonia/HJB 2860 2022
OI Nasi, Sonia/0000 0002 6625 8309; Schneider, Pascal/0000 0003 0677 9409;
   Vezzoni, Paolo/0000 0002 6382 3923; Grosjean,
   Frederic/0000 0003 4959 7517; 
FU Swiss National Science Foundation; Histiocytosis Research Trust; FIRB
   [RBAP11H2R9 OO4]; Progetto Invecchiamento
FX The work was supported by grants from the Swiss National Science
   Foundation to HAO and PS, the Histiocytosis Research Trust to HAO and
   FIRB RBAP11H2R9 OO4 and Progetto Invecchiamento to PV.
CR Allen CE, 2009, NAT MED, V15, P483, DOI 10.1038/nm0509 483
   Alnaeeli M, 2006, J IMMUNOL, V177, P3314, DOI 10.4049/jimmunol.177.5.3314
   Alnaeeli M, 2009, BLOOD, V113, P264, DOI 10.1182/blood 2008 09 180836
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Berres ML, 2013, ADV IMMUNOL, V120, P127, DOI 10.1016/B978 0 12 417028 5.00005 3
   Cantu MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043257
   Coury F, 2008, NAT MED, V14, P81, DOI 10.1038/nm1694
   da Costa CET, 2005, J EXP MED, V201, P687, DOI 10.1084/jem.20041785
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Duval A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00338
   Egeler RM, 2010, IMMUNOL REV, V234, P213, DOI 10.1111/j.0105 2896.2009.00883.x
   FRANZ T, 1985, NATURE, V315, P149, DOI 10.1038/315149a0
   Frattini A, 2005, P NATL ACAD SCI USA, V102, P14629, DOI 10.1073/pnas.0507637102
   Gallois A, 2010, J BONE MINER RES, V25, P661, DOI 10.1359/jbmr.090829
   Johansson M, 2006, EXP HEMATOL, V34, P242, DOI 10.1016/j.exphem.2005.11.010
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   LOHLER J, 1987, LEUKEMIA, V1, P58
   MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460 2075.1995.tb00146.x
   Marraco SAF, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00331
   Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev immunol 020711 074950
   Montella L, 2009, J BONE MINER METAB, V27, P110, DOI 10.1007/s00774 008 0001 2
   Morimoto A, 2010, PEDIATR BLOOD CANCER, V54, P98, DOI 10.1002/pbc.22224
   Peters TL, 2011, MOL THER, V19, P1433, DOI 10.1038/mt.2011.106
   Rivollier A, 2004, BLOOD, V104, P4029, DOI 10.1182/blood 2004 01 0041
   Ruggiero SL, 2011, ANN NY ACAD SCI, V1218, P38, DOI 10.1111/j.1749 6632.2010.05768.x
   Schneider P, 2003, J BIOL CHEM, V278, P5444, DOI 10.1074/jbc.M210783200
   SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092 8674(92)90029 C
   Speziani C, 2007, EUR J IMMUNOL, V37, P747, DOI 10.1002/eji.200636534
   Steiner OG, 2008, BLOOD, V111, P2073, DOI 10.1182/blood 2007 06 097576
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Wakkach A, 2008, BLOOD, V112, P5074, DOI 10.1182/blood 2008 01 132787
   Weitzmann MN, 2005, IMMUNOL REV, V208, P154, DOI 10.1111/j.0105 2896.2005.00324.x
   Weitzmann MN, 2001, J BONE MINER RES, V16, P328, DOI 10.1359/jbmr.2001.16.2.328
NR 34
TC 8
Z9 8
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD AUG 6
PY 2015
VL 10
IS 8
AR e0133917
DI 10.1371/journal.pone.0133917
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CO3MQ
UT WOS:000359062300023
PM 26247358
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Lan, Q
   Cao, JD
   Bi, XT
   Xiao, X
   Li, DS
   Ai, YL
AF Lan, Qian
   Cao, Jiadong
   Bi, Xueting
   Xiao, Xin
   Li, Dongsheng
   Ai, Yilong
TI Curcumin primed periodontal ligament stem cells derived extracellular
   vesicles improve osteogenic ability through the Wnt/β catenin pathway
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE curcumin; extracellular vesicles; periodontal ligament stem cells;
   oteogenesis; Wnt/beta catenin
ID EXOSOMES; DENSITY
AB Introduction: Curcumin has broad application prospects in the prevention and treatment of periodontal diseases. Periodontal ligament stem cell derived extracellular vesicles (PDLSC EV) can effectively promote periodontal tissue regeneration and possess good drug delivery capability. Superior pharmacological effects can be exerted using PDLSC EV as a curcumin carrier.Methods: In the present study, we constructed curcumin primed PDLSCs derived extracellular vesicles (Cur PDLSC EV) from cell culture supernatants of curcumin pretreated PDLSCs by ultracentrifugation and investigated their effects on the proliferation, migration, and osteogenic ability of PDLSCs and the corresponding downstream molecular pathways.Results: Both Cur PDLSC EV and PDLSC EV promoted osteoblast proliferation and migration. Compared with PDLSC EV, Cur PDLSC EV possessed a more potent pro osteogenic ability. Moreover, the improved osteogenesis of Cur PDLSC EV was related to the activation of the Wnt/beta catenin signaling pathway.Conclusion: This study suggests that Cur PDLSC EV can promote osteogenic differentiation by activating Wnt/beta catenin, providing reference bases for the treatment of periodontal diseases.
C1 [Lan, Qian; Cao, Jiadong; Bi, Xueting; Xiao, Xin; Ai, Yilong] Foshan Univ, Foshan Stomatol Hosp, Sch Med, Foshan, Guangdong, Peoples R China.
   [Li, Dongsheng] Deja Lab, Foshan, Guangdong, Peoples R China.
C3 Foshan University
RP Ai, YL (通讯作者)，Foshan Univ, Foshan Stomatol Hosp, Sch Med, Foshan, Guangdong, Peoples R China.; Li, DS (通讯作者)，Deja Lab, Foshan, Guangdong, Peoples R China.
EM dong614lds@126.com; aiyilong@126.com
OI Li, Dongsheng/0000 0002 1578 1239
FU Project of Foshan Science and Technology Innovation (Medical Science and
   Technology Research) [2120001008692]; Project of Foshan Engineering
   Technology Research Center
FX This study was supported by the Project of Foshan Science and Technology
   Innovation (Medical Science and Technology Research, No. 2220001004715)
   and the Project of Foshan Engineering Technology Research Center (No.
   2120001008692).
CR Amato M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232113419
   Calabrese EJ, 2021, PHARMACOL RES, V173, DOI 10.1016/j.phrs.2021.105914
   Chiricosta L, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00582
   Cho DC, 2013, J KOREAN NEUROSURG S, V54, P461, DOI 10.3340/jkns.2013.54.6.461
   Daily JW, 2016, J MED FOOD, V19, P717, DOI 10.1089/jmf.2016.3705
   Farooqi AA, 2018, BIOTECHNOL ADV, V36, P328, DOI 10.1016/j.biotechadv.2017.12.010
   Forouzanfar F, 2020, CURR PHARM DESIGN, V26, P4277, DOI 10.2174/1381612826666200513112607
   Hu L, 2018, ORAL DIS, V24, P696, DOI 10.1111/odi.12703
   Hua S, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11071858
   Huang HM, 2022, STEM CELL REP, V17, P1842, DOI 10.1016/j.stemcr.2022.06.006
   Iwasaki K, 2021, DENT J BASEL, V9, DOI 10.3390/dj9010009
   Kalani A, 2017, NEURAL REGEN RES, V12, P205, DOI 10.4103/1673 5374.200799
   Kang H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123843
   Keshtkar S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0791 7
   Kotha RR, 2019, MOLECULES, V24, DOI 10.3390/molecules24162930
   Lan Q, 2024, ORAL DIS, V30, P710, DOI 10.1111/odi.14375
   Lei FZ, 2022, ACTA BIOMATER, V141, P333, DOI 10.1016/j.actbio.2021.12.035
   Li Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.691013
   Liu HM, 2022, COLLOID SURFACE B, V209, DOI 10.1016/j.colsurfb.2021.112163
   Liu T, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8852307
   Nelson KM, 2017, J MED CHEM, V60, P1620, DOI 10.1021/acs.jmedchem.6b00975
   Oskouie MN, 2019, J CELL PHYSIOL, V234, P8182, DOI 10.1002/jcp.27615
   Rajan TS, 2016, SCI REP UK, V6, DOI 10.1038/srep38743
   Rezaie J, 2022, BIOCHEM PHARMACOL, V203, DOI 10.1016/j.bcp.2022.115167
   Riva A, 2017, EUR REV MED PHARMACO, V21, P1684
   Sanidad KZ, 2019, ANNU REV FOOD SCI T, V10, P597, DOI [10.1146/annurev food 032818 121738, 10.1146/annurcv food 032818 121738]
   Sculean A, 2015, PERIODONTOL 2000, V68, P182, DOI 10.1111/prd.12086
   Sharma AR, 2019, J NUTR BIOCHEM, V74, DOI 10.1016/j.jnutbio.2019.108228
   Slots J, 2017, PERIODONTOL 2000, V75, P7, DOI 10.1111/prd.12221
   Sun Y, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02629 7
   Tomokiyo A, 2019, STEM CELLS DEV, V28, P974, DOI 10.1089/scd.2019.0031
   Tsuda T, 2018, FOOD FUNCT, V9, P705, DOI [10.1039/c7fo01242j, 10.1039/C7FO01242J]
   Vashisht M, 2018, J CELL BIOCHEM, V119, P1488, DOI 10.1002/jcb.26309
   Vashisht M, 2017, APPL BIOCHEM BIOTECH, V183, P993, DOI 10.1007/s12010 017 2478 4
   Yang B, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.781378
   Yang MW, 2011, PHYTOMEDICINE, V18, P205, DOI 10.1016/j.phymed.2010.05.011
   Yeo RWY, 2013, ADV DRUG DELIVER REV, V65, P336, DOI 10.1016/j.addr.2012.07.001
   Yuan XG, 2022, J EXTRACELL VESICLES, V11, DOI 10.1002/jev2.12235
   Zhao Y, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14102189
NR 39
TC 13
Z9 13
U1 7
U2 25
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD SEP 28
PY 2023
VL 11
AR 1225449
DI 10.3389/fcell.2023.1225449
PG 9
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA U1FI7
UT WOS:001082327600001
PM 37842095
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jeong, C
   Lee, CH
   Seo, J
   Park, JHY
   Lee, KW
AF Jeong, Chanhyeok
   Lee, Chang Hyung
   Seo, Jiwon
   Park, Jung Han Yoon
   Lee, Ki Won
TI Catechin and flavonoid glycosides from the Ulmus genus: Exploring their
   nutritional pharmacology and therapeutic potential in osteoporosis and
   inflammatory conditions
SO FITOTERAPIA
LA English
DT Article
DE Ulmus genus; Bone health; Pharmacological activity; Natural compound;
   Glycosides
ID DAVIDIANA PLANCH ULMACEAE; VAR. JAPONICA; WALLICHIANA PLANCHON;
   ALKALINE PHOSPHATASE; PHENOLIC COMPOUNDS; NAKAI PROTECTS; CELL GROWTH; I
   COLLAGEN; ROOT BARK; EXTRACT
AB This review investigates the therapeutic effects of Ulmus species extracts, traditionally used as tea ingredients in East Asia, on bone health and inflammatory conditions. Through the analysis of 9757 studies, narrowing down to 56 pertinent ones, we evaluated the safety and efficacy of Ulmus extracts. The focus was on catechin glycosides (CG) and flavonoid glycosides (FG), key compounds identified for their potential benefits. The research highlights the extracts' role in enhancing bone mineral density (BMD) by stimulating osteoblast activity and suppressing osteoclast differentiation, suggesting a protective effect against osteoporosis. Furthermore, the extracts demonstrated significant anti inflammatory properties by modulating inflammatory markers and pathways. The findings confirm the historical use of Ulmus extracts in East Asia for health benefits and recommend further exploration into functional foods and nutraceuticals. The review calls for more rigorous research, including clinical trials, to establish optimal use and integration into modern health solutions. It underscores the potential of Ulmus extracts in promoting bone health and managing inflammation, advocating for a bridge between traditional practices and contemporary scientific validation. In conclusion, Ulmus extracts, a material long consumed as tea ingredients in East Asia, exhibit significant potential for improving bone health and reducing inflammation. This review calls for additional research to explore their full therapeutic capabilities, emphasizing the need for optimized extraction methods and clinical trials. It reinforces the importance of bridging traditional knowledge with contemporary scientific approaches to health and dietary solutions, promoting overall wellness.
C1 [Lee, Chang Hyung; Park, Jung Han Yoon; Lee, Ki Won] Seoul Natl Univ, Dept Agr Biotechnol, Seoul 08826, South Korea.
   [Lee, Chang Hyung; Park, Jung Han Yoon; Lee, Ki Won] Seoul Natl Univ, Res Inst Agr & Life Sci, Seoul 08826, South Korea.
   [Lee, Chang Hyung; Lee, Ki Won] Seoul Natl Univ, BioMAX Inst, Seoul 08826, South Korea.
   [Lee, Ki Won] Seoul Natl Univ, Adv Inst Convergence Technol, Suwon 16229, South Korea.
   [Lee, Ki Won] Seoul Natl Univ, Inst Green Bio Sci & Technol, Pyeongchang 25354, South Korea.
   [Lee, Ki Won] Seoul Natl Univ, Dept Agr Biotechnol, Seoul 08826, South Korea.
   [Lee, Ki Won] Seoul Natl Univ, Ctr Food & Bio convergence, Seoul 08826, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU)
RP Lee, KW (通讯作者)，Seoul Natl Univ, Dept Agr Biotechnol, Seoul 08826, South Korea.; Lee, KW (通讯作者)，Seoul Natl Univ, Res Inst Agr & Life Sci, Seoul 08826, South Korea.
EM kiwon@snu.ac.kr
RI ; Lee, Chang Hyung/MTD 8229 2025
OI Lee, Chang Hyung/0000 0002 1907 4400; 
FU Korea Institute of Marine Science & Technology Promotion (KIMST)  
   Ministry of Oceans and Fisheries, Republic of Korea [20220488]; Brain
   Korea 21 Plus Program of the Department of Agricultural Biotechnology,
   Seoul National University, Republic of Korea
FX This work was supported by the Korea Institute of Marine Science &
   Technology Promotion (KIMST) , which is funded by the Ministry of Oceans
   and Fisheries, Republic of Korea (20220488) , and Brain Korea 21 Plus
   Program of the Department of Agricultural Biotechnology, Seoul National
   University, Republic of Korea.
CR Abbasi S, 2018, APPL ECOL ENV RES, V16, P4955, DOI 10.15666/aeer/1604_49554968
   BARSETT H, 1992, CARBOHYD POLYM, V18, P125, DOI 10.1016/0144 8617(92)90134 C
   Bhola S, 2023, S AFR J BOT, V159, P51, DOI 10.1016/j.sajb.2023.06.004
   Cho AR, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/5690816
   Cho EJ, 2011, KOREAN J PHYSIOL PHA, V15, P339, DOI 10.4196/kjpp.2011.15.6.339
   Choi HG, 2013, PHYTOTHER RES, V27, P1376, DOI 10.1002/ptr.4882
   Choi S.I., 2017, Int. J. Mol. Sci., V18
   D'Angiolo M, 2022, PLANTA MED, V88, P762, DOI 10.1055/a 1787 1342
   Dou JZ, 2021, IND CROP PROD, V164, DOI 10.1016/j.indcrop.2021.113387
   Eom SY, 2006, J COSMET SCI, V57, P355
   FEUCHT W, 1992, TREE PHYSIOL, V10, P169, DOI 10.1093/treephys/10.2.169
   Ghazi S, 2022, RESULTS CHEM, V4, DOI 10.1016/j.rechem.2022.100428
   Ghosh C, 2012, FOOD CHEM TOXICOL, V50, P2009, DOI 10.1016/j.fct.2012.03.056
   Gupta P, 2019, NEUROTOXICOLOGY, V73, P100, DOI 10.1016/j.neuro.2019.02.017
   Hakim Ibn Sina, 1998, Canon of Medicine, Book II Materia Medica, VII, P284
   Halloran D, 2020, J DEV BIOL, V8, DOI 10.3390/jdb8030019
   Hamidullah, 2015, BIOCHIMIE, V119, P68, DOI 10.1016/j.biochi.2015.10.012
   Hartmann AM, 2011, ARCH GYNECOL OBSTET, V284, P1265, DOI 10.1007/s00404 010 1830 5
   Hong SO, 2017, J ETHNOPHARMACOL, V202, P1, DOI 10.1016/j.jep.2017.03.009
   Hosny M, 2014, ARCH PHARM RES, V37, P698, DOI 10.1007/s12272 013 0264 6
   Hwang T, 2022, INT J MED SCI, V19, P1131, DOI 10.7150/ijms.72241
   Irfan M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00698
   Jeong C., 2023, Sci. Rep., V13, P102
   Jeong C, 2024, J ETHNOPHARMACOL, V319, DOI 10.1016/j.jep.2023.117285
   Jiang WH, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00201 4
   Joo T, 2014, SAUDI J BIOL SCI, V21, P427, DOI 10.1016/j.sjbs.2014.04.003
   Villaverde JJ, 2016, BIORESOURCES, V11, P5618
   Jun CD, 1998, J ETHNOPHARMACOL, V62, P129, DOI 10.1016/S0378 8741(98)00063 4
   Jun Sung Park, 2005, Journal of Acupuncture Research, V22, P55
   Jung MJ, 2008, FOOD CHEM, V108, P482, DOI 10.1016/j.foodchem.2007.10.081
   Kang SK, 2006, IN VITRO CELL DEV AN, V42, P225, DOI 10.1290/0510068.1
   Khan MP, 2013, PHYTOMEDICINE, V20, P1256, DOI 10.1016/j.phymed.2013.07.007
   Kim EJ, 2010, J ACUPUNCT MERIDIAN, V3, P16, DOI 10.1016/S2005 2901(10)60003 9
   Kim I, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1138676
   Kim J. P., 1996, Korean J. Pharmacognosy, V27, P26
   Kim J, 2022, MEDICINA LITHUANIA, V58, DOI 10.3390/medicina58040466
   Kim Jong Pyung, 1996, Agricultural Chemistry and Biotechnology, V39, P89
   Kim KS, 2005, J ETHNOPHARMACOL, V97, P65, DOI 10.1016/j.jep.2004.10.011
   Kim K, 2021, J MICROBIOL, V59, P1150, DOI 10.1007/s12275 021 1329 8
   Kim KW, 2008, PHYTOTHER RES, V22, P511, DOI 10.1002/ptr.2366
   Kim TM, 2012, J VET SCI, V13, P7, DOI 10.4142/jvs.2012.13.1.7
   Ko JH, 2007, CELL BIOCHEM FUNCT, V25, P495, DOI 10.1002/cbf.1337
   Ko JH, 2006, J PHARMACOL SCI, V101, P205, DOI 10.1254/jphs.FP0051053
   Ko JH, 2005, J ETHNOPHARMACOL, V100, P339, DOI 10.1016/j.jep.2005.03.029
   Komori T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105776
   Koyama T., 1991, Obstet. Gynecol. Ther., V63, P203
   Kusiak W., 2022, Materials (Basel), V15, DOI [10.3390/ma151140.33, DOI 10.3390/MA151140.33]
   Kwon JH, 2011, ARCH PHARM RES, V34, P1459, DOI 10.1007/s12272 011 0907 4
   Kwon YE, 2022, MOLECULES, V27, DOI 10.3390/molecules27041419
   Lee EH, 2013, J ETHNOPHARMACOL, V146, P608, DOI 10.1016/j.jep.2013.01.035
   Lee HS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076716
   Lee JH, 2017, INT J BIOL MACROMOL, V104, P1124, DOI 10.1016/j.ijbiomac.2017.06.121
   Lee KeyongHo Lee KeyongHo, 2004, Korean Journal of Pharmacognosy, V35, P199
   Lee KM, 2016, INTEGR MED RES, V5, P131, DOI 10.1016/j.imr.2016.03.006
   Lee MY, 2010, J ETHNOPHARMACOL, V130, P61, DOI 10.1016/j.jep.2010.04.011
   Lee S, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9100981
   Lee UD, 2007, ENVIRON TOXICOL PHAR, V23, P154, DOI 10.1016/j.etap.2006.08.002
   Lee YL, 2022, FRONT MED LAUSANNE, V9, DOI 10.3389/fmed.2022.1000428
   Lee Y, 2007, J MED FOOD, V10, P118, DOI 10.1089/jmf.2006.078
   Lee YY, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/9358563
   Lyu J, 2013, J PHARMACOPUNCT, V16, P41, DOI 10.3831/KPI.2013.16.013
   Menon V, 2012, PROG ENERG COMBUST, V38, P522, DOI 10.1016/j.pecs.2012.02.002
   Metsämuuronen S, 2019, PHYTOCHEM REV, V18, P623, DOI 10.1007/s11101 019 09630 2
   Mi suk Kang, 2008, Journal of Acupuncture Research, V25, P119
   Mirsaidi A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02650 y
   Oh PS, 2006, PHARMACOL REP, V58, P67
   Pan JH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188381
   김경범, 2012, 한국식품저장유통학회지, V19, P909
   Park J, 2021, MOLECULES, V26, DOI 10.3390/molecules26040781
   Park KH, 2020, GENES GENOM, V42, P87, DOI 10.1007/s13258 019 00883 x
   Park YJ, 2020, CELLS BASEL, V9, DOI 10.3390/cells9010030
   Paschke D, 2009, EUR J CANCER PREV, V18, P162, DOI [10.1097/CEJ.0b013e32831bc546., 10.1097/CEJ.0b013e32831bc546]
   Pásztory Z, 2016, BIORESOURCES, V11, P7859, DOI 10.15376/biores.11.3.Pasztory
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Pratyusha S, 2022, PLANT STRESS PHYSL P, P125, DOI [DOI 10.5772/INTECHOPEN.102873, 10.5772/intechopen.102873]
   Qin X, 2021, J BONE MINER RES, V36, P2081, DOI 10.1002/jbmr.4386
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Rawat P, 2009, BIOORG MED CHEM LETT, V19, P4684, DOI 10.1016/j.bmcl.2009.06.074
   Sharan K, 2010, MENOPAUSE, V17, P393, DOI 10.1097/gme.0b013e3181bfae38
   Sharma C, 2014, INT J PHARM SCI RES, V5, P730, DOI 10.13040/IJPSR.0975 8232.5(3).730 41
   Shi X., 1983, Chinese English terminology of traditional Chinese medicine, P71
   Shin DY, 2000, CHEM PHARM BULL, V48, P1805, DOI 10.1248/cpb.48.1805
   Siddiqui JA, 2011, OSTEOPOROSIS INT, V22, P3013, DOI 10.1007/s00198 010 1519 4
   Siddiqui JA, 2011, MENOPAUSE, V18, P198, DOI 10.1097/gme.0b013e3181e84e67
   Simpson MG, 2010, PLANT SYSTEMATICS, 2ND EDITION, P1
   Son YO, 2004, MOL CELLS, V18, P163
   Song IK, 2007, ENVIRON TOXICOL PHAR, V23, P102, DOI 10.1016/j.etap.2006.07.013
   Suh SJ, 2007, J ETHNOPHARMACOL, V109, P480, DOI 10.1016/j.jep.2006.08.030
   Syed AA, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00510
   Syed AA, 2016, J ETHNOPHARMACOL, V193, P555, DOI 10.1016/j.jep.2016.10.008
   Szwajkowska Michalek L, 2020, APPL SCI BASEL, V10, DOI 10.3390/app10196907
   Taib M, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/1920683
   Tanase C, 2019, MOLECULES, V24, DOI 10.3390/molecules24061182
   Tsao YT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010159
   Tungmunnithum Duangjai, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030093
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Walker RI, 1932, SCIENCE, V75, P107, DOI 10.1126/science.75.1934.107 a
   Wang WH, 2022, ACS OMEGA, V7, DOI 10.1021/acsomega.1c05305
   Yang WK, 2013, MOL MED REP, V8, P726, DOI 10.3892/mmr.2013.1581
   Yin ML, 2022, PLANT SIGNAL BEHAV, V17, DOI 10.1080/15592324.2022.2138041
   You YO, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/269874
   Zhang YY, 2022, NAT PROD COMMUN, V17, DOI 10.1177/1934578X211069721
   Zheng MS, 2011, ARCH PHARM RES, V34, P1443, DOI 10.1007/s12272 011 0905 6
   Zheng MS, 2010, ARCH PHARM RES, V33, P1307, DOI 10.1007/s12272 010 0903 0
   Zhuang XM, 2016, AM J TRANSL RES, V8, P298
NR 105
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0367 326X
EI 1873 6971
J9 FITOTERAPIA
JI Fitoterapia
PD OCT
PY 2024
VL 178
AR 106188
DI 10.1016/j.fitote.2024.106188
EA AUG 2024
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA E3F9Y
UT WOS:001301904200001
PM 39153558
DA 2025 08 17
ER

PT J
AU Zhang, YJ
   Liu, Y
   Li, ZC
   Zhang, Q
   Li, JC
AF Zhang, Yijing
   Liu, Yue
   Li, Zichao
   Zhang, Qin
   Li, Jingchao
TI Breast Cancer Bone Metastasis Therapy and Tumor Associated Bone
   Destruction Repair by Versatile Semiconducting Nanointegrators with
   X Ray Adjuvant
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE bone destruction repair; bone metastasis therapy; osteogenesis;
   semiconducting nanomaterials; X ray adjuvants
ID METAL ORGANIC FRAMEWORK; NANOPARTICLES; CALCIUM; MECHANISMS;
   MICROENVIRONMENT; OVERLOAD
AB Tumor progress and tumor associated osteolysis are two key issues of breast cancer bone metastasis, which makes it challenging for bone metastasis treatment. To settle these two issues concurrently, a versatile semiconducting nanointegrator (termed as SPNCpG/Ca) containing semiconducting polymer nanoparticle (SPN), Ca2+ and cytosine phosphate guanine (CpG) oligonucleotides conjugated on the surface via a singlet oxygen (1O2) responsive linker, is designed. The antitumor effect can be triggered with X ray irradiation as an adjuvant, in which SPN works as a radiosensitizer to produce 1O2 for radiotherapy and controlled release of CpG via disrupting 1O2 responsive linkers. The Ca2+ accumulation via SPNCpG/Ca delivering causes tumor cell death and the released CpG activates immune response to realize immunotherapy. The combinational action of radiotherapy, Ca2+ overloading, and immunotherapy results in complete clearance of metastatic tumor cells in 4T1 breast cancer based bone metastasis mouse models. Furthermore, Ca2+ can accelerate osteogenesis of bone marrow mesenchymal stem cells while CpG inhibits osteoclast differentiation in the bone metastasis microenvironment to alleviate osteolysis, which synergistically contributes to repair of tumor associated bone destruction. SPNCpG/Ca represents a versatile therapeutic nanosystem with the abilities to treat bone metastasis and repair tumor associated bone destruction, providing a new tactic for bone metastasis therapy.
   A versatile semiconducting nanointegrator containing Ca2+ and cytosine phosphate guanine (CpG) oligonucleotide is fabricated for breast cancer bone metastasis therapy and tumor associated bone destruction repair. With X ray as an adjuvant, this nanointegrator combines radiotherapy, Ca2+ overloading, and immunotherapy for bone metastasis clearance, and also achieves tumor associated bone defect repair via Ca2+ promoted osteogenesis and CpG mediated osteoclast inhibition. image
C1 [Zhang, Yijing; Liu, Yue; Li, Zichao; Li, Jingchao] Donghua Univ, Coll Biol Sci & Med Engn, State Key Lab Modificat Chem Fibers & Polymer Mat, Shanghai 201620, Peoples R China.
   [Zhang, Qin] Shanghai Univ, Inst Translat Med, Shanghai 200444, Peoples R China.
C3 Donghua University; Shanghai University
RP Li, JC (通讯作者)，Donghua Univ, Coll Biol Sci & Med Engn, State Key Lab Modificat Chem Fibers & Polymer Mat, Shanghai 201620, Peoples R China.; Zhang, Q (通讯作者)，Shanghai Univ, Inst Translat Med, Shanghai 200444, Peoples R China.
EM Sabrina_1985@shu.edu.cn; jcli@dhu.edu.cn
FU National Natural Science Foundation of China; Science and Technology
   Commission of Shanghai Municipality [22490760700, 22ZR1401100,
   22ZR1424900, 20DZ2254900];  [32371441];  [52203155];  [52311530771]
FX This study was financially supported by the National Natural Science
   Foundation of China (32371441, 52203155, and 52311530771) and Science
   and Technology Commission of Shanghai Municipality (22490760700,
   22ZR1401100, 22ZR1424900, and 20DZ2254900). All animal experiments
   complied with the protocols of Donghua University institutional animal
   care and treatment committee with approval number DHUEC NSFC 2022 16.
CR Barradas AMC, 2012, BIOMATERIALS, V33, P3205, DOI 10.1016/j.biomaterials.2012.01.020
   Clézardin P, 2021, PHYSIOL REV, V101, P797, DOI 10.1152/physrev.00012.2019
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   Cox TR, 2023, NATURE, V617, P208, DOI 10.1038/s41586 023 06048 x
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Cui XW, 2019, NANO TODAY, V28, DOI 10.1016/j.nantod.2019.100773
   Deng W, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05118 3
   Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008
   Fan WP, 2018, ANGEW CHEM INT EDIT, V57, P8383, DOI 10.1002/anie.201800594
   Fu H, 2022, J AM CHEM SOC, V144, P8987, DOI 10.1021/jacs.2c00749
   Gao X, 2021, BIOMATERIALS, V265, DOI 10.1016/j.biomaterials.2020.120404
   Geng J, 2021, NAT CHEM, V13, P805, DOI 10.1038/s41557 021 00711 4
   González Vázquez A, 2014, ACTA BIOMATER, V10, P2824, DOI 10.1016/j.actbio.2014.02.004
   Gu CH, 2024, NAT NANOTECHNOL, V19, P1044, DOI 10.1038/s41565 024 01613 5
   He C, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202006214
   Hofbauer LC, 2021, NAT REV CLIN ONCOL, V18, P488, DOI 10.1038/s41571 021 00499 9
   Hu BB, 2022, J CONTROL RELEASE, V350, P377, DOI 10.1016/j.jconrel.2022.08.034
   Hu J. J., 2024, Angew. Chem., V63
   Huang C, 2022, ADV MATER, V34, DOI 10.1002/adma.202207593
   Huang JS, 2023, BIOMATERIALS, V302, DOI 10.1016/j.biomaterials.2023.122340
   Jiang YA, 2021, NANO TODAY, V39, DOI 10.1016/j.nantod.2021.101182
   Koo S, 2024, ANGEW CHEM INT EDIT, V63, DOI 10.1002/anie.202318459
   Li CY, 2017, ADV MATER, V29, DOI 10.1002/adma.201605754
   Li JC, 2023, ANGEW CHEM INT EDIT, V62, DOI 10.1002/anie.202305200
   Li M, 2023, NANO TODAY, V50, DOI 10.1016/j.nantod.2023.101833
   Liang HF, 2022, SMALL, V18, DOI 10.1002/smll.202107787
   Liao JF, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00139 z
   Liu H, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 31356 7
   Liu JS, 2024, ADV SCI, V11, DOI 10.1002/advs.202406750
   Liu J, 2020, NANO LETT, V20, P4882, DOI 10.1021/acs.nanolett.0c00893
   Liu XL, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adf3329
   Lu KD, 2018, NAT BIOMED ENG, V2, P600, DOI 10.1038/s41551 018 0203 4
   Luo ZY, 2023, NAT NANOTECHNOL, V18, P647, DOI 10.1038/s41565 023 01374 7
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Ni Kaiyuan, 2020, Angew Chem Int Ed Engl, V59, P1108, DOI 10.1002/anie.201911429
   Nierkens S, 2011, CANCER RES, V71, P6428, DOI 10.1158/0008 5472.CAN 11 2154
   Niu YM, 2022, ACS NANO, V16, P2209, DOI 10.1021/acsnano.1c08269
   Pang YC, 2021, BIOACT MATER, V6, P712, DOI 10.1016/j.bioactmat.2020.09.006
   Pang YC, 2020, NANO LETT, V20, P829, DOI 10.1021/acs.nanolett.9b02916
   Pederson L, 1999, CANCER RES, V59, P5849
   Qiao H, 2017, ACS NANO, V11, P7259, DOI 10.1021/acsnano.7b03197
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Satcher RL, 2022, NAT REV CANCER, V22, P85, DOI 10.1038/s41568 021 00406 5
   Sun PF, 2022, ADV SCI, V9, DOI 10.1002/advs.202204718
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Vanderburgh J, 2020, ACS NANO, V14, P311, DOI 10.1021/acsnano.9b04571
   Vanderburgh JP, 2019, J CONTROL RELEASE, V311, P257, DOI 10.1016/j.jconrel.2019.08.038
   Vermeulen S, 2022, BIOMATERIALS, V283, DOI 10.1016/j.biomaterials.2022.121431
   Wang BL, 2022, ADV SCI, V9, DOI 10.1002/advs.202201451
   Wang FS, 2024, SMALL, V20, DOI 10.1002/smll.202306378
   Wei JJ, 2022, ADV SCI, V9, DOI 10.1002/advs.202103689
   Xie C, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202100408
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
   Yip RKH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 26556 6
   Yu NY, 2024, ANGEW CHEM INT EDIT, V63, DOI 10.1002/anie.202405639
   Yu NY, 2023, NANO TODAY, V52, DOI 10.1016/j.nantod.2023.101944
   Yu NY, 2022, NANO TODAY, V46, DOI 10.1016/j.nantod.2022.101600
   Zhang M, 2019, CHEM US, V5, P2171, DOI 10.1016/j.chempr.2019.06.003
   Zhang WJ, 2021, CELL, V184, P2471, DOI 10.1016/j.cell.2021.03.011
   Zhang XD, 2021, MATTER US, V4, P2727, DOI 10.1016/j.matt.2021.05.019
   Zhang YJ, 2023, NANO LETT, DOI 10.1021/acs.nanolett.3c02414
   Zhang YJ, 2022, BIOMATERIALS, V291, DOI 10.1016/j.biomaterials.2022.121906
   Zhao HJ, 2019, ACS NANO, V13, P12553, DOI 10.1021/acsnano.9b03288
   Zhao PP, 2020, CHEM ENG J, V381, DOI 10.1016/j.cej.2019.122694
   Zhao YP, 2017, NANOSCALE, V9, P6264, DOI 10.1039/c7nr00962c
   Zheng P, 2022, ANGEW CHEM INT EDIT, V61, DOI 10.1002/anie.202204904
   Zheng P, 2021, NANO LETT, V21, P2088, DOI 10.1021/acs.nanolett.0c04778
   Zou BH, 2022, BIOMATERIALS, V285, DOI 10.1016/j.biomaterials.2022.121549
NR 70
TC 3
Z9 3
U1 23
U2 63
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD JAN
PY 2025
VL 35
IS 2
DI 10.1002/adfm.202412165
EA OCT 2024
PG 13
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA R6D5B
UT WOS:001326649300001
OA Bronze
DA 2025 08 17
ER

PT J
AU Li, ZH
   Liu, HR
   Wang, R
   Ji, CH
   Wei, Y
   Shi, MS
   Wang, YQ
   Du, YP
   Zhang, YF
   Yuan, Q
   Yan, CH
AF Li, Zhihao
   Liu, Haoran
   Wang, Rui
   Ji, Chenhui
   Wei, Yan
   Shi, Miusi
   Wang, Yingqian
   Du, Yaping
   Zhang, Yufeng
   Yuan, Quan
   Yan, Chunhua
TI Bioactive Core Shell CaF2 Upconversion Nanostructure for
   Promotion and Visualization of Engineered Bone Reconstruction
SO ACS NANO
LA English
DT Article
DE biomineralization; upconversion; bioactive glasses; fluoride; tissue
   engineering
AB Inorganic ion metabolism plays significant roles in various life processes including signal transduction, substance exchange, and cellular constructions. Regulation and monitoring of ion metabolism offer great promise to modulate biological activities and provide insights into related mechanisms. Here, a synergistic nanodepot based on a bioactive core shell CaF2 upconversion nanostructure that integrates multiple mineral ions for metabolic regulation was built for the acceleration and monitoring of the biomineralization process. Multiple mineral ions released from the nanodepots can accelerate the growth of inorganic crystals and enhance the production of organic matrixes, synergistically facilitating the regeneration of bone defects in vivo. During the process, such a nanodepot can be constructed to specifically recognize osteoblasts for the monitoring of biomineralization. This nanoprobe represents an efficient strategy to promote and monitor biomineralization related metabolic activities with applications in fundamental research, disease diagnosis, and regenerative medicine.
C1 [Li, Zhihao; Liu, Haoran; Wang, Yingqian; Yuan, Quan] Wuhan Univ, Coll Chem & Mol Sci, Key Lab Analyt Chem Biol Med, Minist Educ, Wuhan 430072, Peoples R China.
   [Wang, Rui; Wei, Yan; Shi, Miusi; Zhang, Yufeng] Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hu, Wuhan 430072, Peoples R China.
   [Ji, Chenhui; Yuan, Quan] Hunan Univ, Coll Chem & Chem Engn, Inst Chem Biol & Nanomed, State Key Lab Chemo Biosensing & Chemometr, Changsha 410082, Hunan, Peoples R China.
   [Du, Yaping; Yan, Chunhua] Nankai Univ, Ctr Rare Earth & Inorgan Funct Mat, Sch Mat Sci & Engn, Key Lab Adv Energy Mat Chem,Tianjin Key Lab Rare, Tianjin 300350, Peoples R China.
   [Du, Yaping; Yan, Chunhua] Nankai Univ, Ctr Rare Earth & Inorgan Funct Mat, Natl Inst Adv Mat, Key Lab Adv Energy Mat Chem,Tianjin Key Lab Rare, Tianjin 300350, Peoples R China.
C3 Wuhan University; Wuhan University; Hunan University; Nankai University;
   Nankai University
RP Yuan, Q (通讯作者)，Wuhan Univ, Coll Chem & Mol Sci, Key Lab Analyt Chem Biol Med, Minist Educ, Wuhan 430072, Peoples R China.; Zhang, YF (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hu, Wuhan 430072, Peoples R China.; Yuan, Q (通讯作者)，Hunan Univ, Coll Chem & Chem Engn, Inst Chem Biol & Nanomed, State Key Lab Chemo Biosensing & Chemometr, Changsha 410082, Hunan, Peoples R China.
EM zyf@whu.edu.cn; yuanquan@whu.edu.cn
RI ; Yuan, Quan/I 7822 2019; Shi, Miusi/AAA 8893 2021; Zhang,
   Yufeng/GZL 1973 2022; yan, ch/JCE 8484 2023
OI Li, Zhihao/0009 0008 6191 4806; Zhang, Yufeng/0000 0001 8702 5291; Shi,
   Miusi/0000 0001 8679 4013; Yuan, Quan/0000 0002 3085 431X
FU National Natural Science Foundation of China [21925401, 21675120,
   21904100]
FX This work was supported by the National Natural Science Foundation of
   China (21925401, 21675120, 21904100). Q.Y. thanks the large scale
   instrument and equipment sharing foundation of Wuhan University.
CR Ai Xiangzhao, 2017, Angew Chem Int Ed Engl, V56, P3031, DOI 10.1002/anie.201612142
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   Brauer DS, 2015, ANGEW CHEM INT EDIT, V54, P4160, DOI 10.1002/anie.201405310
   Busch S, 2001, CHEM MATER, V13, P3260, DOI 10.1021/cm0110728
   Chang HH, 2017, CHEM COMMUN, V53, P3838, DOI 10.1039/c6cc10114c
   Chen S, 2018, SCIENCE, V359, P679, DOI 10.1126/science.aaq1144
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Dirckx N, 2019, NAT REV ENDOCRINOL, V15, P651, DOI 10.1038/s41574 019 0246 y
   Dong NN, 2011, ACS NANO, V5, P8665, DOI 10.1021/nn202490m
   Du HL, 2016, LANGMUIR, V32, P1155, DOI 10.1021/acs.langmuir.5b04186
   Dudev T, 2014, CHEM REV, V114, P538, DOI 10.1021/cr4004665
   Fan WP, 2013, J AM CHEM SOC, V135, P6494, DOI 10.1021/ja312225b
   Fukao K, 2017, ACS NANO, V11, P12103, DOI 10.1021/acsnano.7b04942
   Hamm LM, 2014, P NATL ACAD SCI USA, V111, P1304, DOI 10.1073/pnas.1312369111
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Hu XX, 2017, ADV MATER, V29, DOI 10.1002/adma.201605235
   Jones JR, 2013, ACTA BIOMATER, V9, P4457, DOI 10.1016/j.actbio.2012.08.023
   Kim D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03041 1
   Li ZJ, 2016, THERANOSTICS, V6, P2380, DOI 10.7150/thno.15914
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Lin Y, 2019, ANGEW CHEM INT EDIT, V58, P17061, DOI 10.1002/anie.201910343
   Liu CL, 2016, ACS APPL MATER INTER, V8, P29997, DOI 10.1021/acsami.6b10374
   Liu YS, 2013, CHEM SOC REV, V42, P6924, DOI 10.1039/c3cs60060b
   Luo YJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9301
   Mirts EN, 2019, ACCOUNTS CHEM RES, V52, P935, DOI 10.1021/acs.accounts.9b00011
   Müller WEG, 2019, CHEM REV, V119, P12337, DOI 10.1021/acs.chemrev.9b00460
   Palm W, 2017, NATURE, V546, P234, DOI 10.1038/nature22379
   Pereira DD, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800700
   Peretó J, 2012, CHEM SOC REV, V41, P5394, DOI 10.1039/c2cs35054h
   Pols T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12287 2
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Rauch A, 2019, NAT GENET, V51, P716, DOI 10.1038/s41588 019 0359 1
   Reznikov N, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.41
   Riccardi L, 2018, NAT REV CHEM, V2, P100, DOI 10.1038/s41570 018 0018 6
   Shao CY, 2018, ADV MATER, V30, DOI 10.1002/adma.201704876
   Smeets PJM, 2015, NAT MATER, V14, P394, DOI [10.1038/NMAT4193, 10.1038/nmat4193]
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Thompson KH, 2003, SCIENCE, V300, P936, DOI 10.1126/science.1083004
   Tsoi KM, 2016, NAT MATER, V15, P1212, DOI [10.1038/NMAT4718, 10.1038/nmat4718]
   Veernala I, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 37327 7
   Wang YF, 2016, ACS NANO, V10, P9927, DOI 10.1021/acsnano.6b03835
   Wang YQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10761 5
   Wang Z, 2018, NANOSCALE, V10, DOI 10.1039/c8nr02078g
   Wang ZQ, 2009, J PHYS CHEM B, V113, P16393, DOI 10.1021/jp905846p
   Weichold V, 2016, ANGEW CHEM INT EDIT, V55, P6374, DOI 10.1002/anie.201509573
   Yang L, 2010, BIOMATERIALS, V31, P2976, DOI 10.1016/j.biomaterials.2010.01.002
   Yao SS, 2017, ADV MATER, V29, DOI 10.1002/adma.201605903
   Yu N, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801132
   Zheng W, 2013, ANGEW CHEM INT EDIT, V52, P6671, DOI 10.1002/anie.201302481
NR 50
TC 29
Z9 31
U1 3
U2 139
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD NOV 24
PY 2020
VL 14
IS 11
BP 16085
EP 16095
DI 10.1021/acsnano.0c08013
PG 11
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA PA3JK
UT WOS:000595533800149
PM 33151671
DA 2025 08 17
ER

PT J
AU Roche, B
   Vanden Bossche, A
   Malaval, L
   Normand, M
   Jannot, M
   Chaux, R
   Vico, L
   Lafage Proust, MH
AF Roche, Bernard
   Vanden Bossche, Arnaud
   Malaval, Luc
   Normand, Myriam
   Jannot, Martin
   Chaux, Robin
   Vico, Laurence
   Lafage Proust, Marie Helene
TI Parathyroid Hormone 1 84 Targets Bone Vascular Structure and Perfusion
   in Mice: Impacts of Its Administration Regimen and of Ovariectomy
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE PTH; BONE VASCULARIZATION; BONE PERFUSION; BONE REMODELING; VASCULAR
   REMODELING
ID BLOOD FLOW; INTERMITTENT PTH; TRABECULAR BONE; BETA BLOCKER; MOUSE BONE;
   ANGIOGENESIS; RATS; NEOVASCULARIZATION; METABOLISM; MIGRATION
AB Bone vessel functions during bone remodeling are poorly understood. They depend on both vessel network structure and vasomotor regulation. Parathyroid hormone (PTH) is a systemic vasodilator that may modulate microvascularization. Moreover, although intermittent PTH is anti osteoporotic, continuous PTH administration can be catabolic for bone. Finally, ovariectomy (OVX) reduces bone perfusion and vessel density in mice. We reasoned that the effects of PTH on bone vascularization might depend on its administration regimen and be impacted by ovariectomy. A 100 mu g/kg PTH 1 84 daily dose was administered for 15 days to 4 month old female C57BL/6 mice, either as daily sc injection (iPTH) or continuously (cPTH; ALZET minipump). Blood pressure (BP) and tibia bone perfusion were measured in vivo with a laser Doppler device. Histomorphometry of bone and barium contrasted vascular network were performed on the same tibia. Compared with untreated controls, both iPTH and cPTH increased bone formation but had opposite effects on resorption. Both iPTH and cPTH were slightly angiogenic. Intermittent PTH increased microvessel size (+48%, p < 0.001), whereas cPTH decreased it ( 29%, p = 0.009). iPTH increased bone perfusion (27%, p < 0.001) with no change in BP, whereas cPTH did not. The vascular effects of a 15 day iPTH treatment were analyzed in OVX mice and compared with sham operated and OVX untreated controls. Two other anti osteoporotic drugs, zoledronate (one injection, 70 mu g/kg) and propranolol, (5 mg/kg/d) were tested in OVX mice. Although no change in bone mass was observed, iPTH stimulated bone formation and prevented the OVX induced reduction in bone perfusion and vessel density. Both zoledronate and propranolol strongly lowered bone turnover, but surprisingly, zoledronate prevented OVX induced reduction in bone perfusion but propranolol did not. Our integrative approach thus demonstrates that the effects of PTH on bone vessel structure and function depend on its mode of administration as well as on the HPG axis hormonal status, and that OVX induced vascular changes are prevented by iPTH. c 2014 American Society for Bone and Mineral Research.
C1 [Roche, Bernard; Vanden Bossche, Arnaud; Malaval, Luc; Normand, Myriam; Jannot, Martin; Chaux, Robin; Vico, Laurence; Lafage Proust, Marie Helene] Univ Lyon, INSERM, U1059, Lab Biol Integree Tissu Osseux, St Etienne, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm)
RP Lafage Proust, MH (通讯作者)，INSERM, Fac Med, U1059, F 42023 St Etienne, France.
EM mh.lafage.proust@univ st etienne.fr
RI Vico, Laurence/O 1927 2018; Vico, Laurence/ABG 7239 2020; Malaval,
   Luc/K 3060 2019; Malaval, Luc/D 2206 2011
OI Vico, Laurence/0000 0002 2110 287X; Lafage Proust,
   Marie Helene/0000 0002 2091 3961; NORMAND, Myriam/0000 0002 7535 4888;
   Malaval, Luc/0000 0002 8640 2646
FU Societe Francaise de Rhumatologie
FX This work was supported by a grant from the Societe Francaise de
   Rhumatologie. We thank Nycomed for providing PTH 1 84.
CR Bianco P, 2011, BEST PRACT RES CL HA, V24, P37, DOI 10.1016/j.beha.2011.01.005
   Biver E, 2010, BONE, V46, P643, DOI 10.1016/j.bone.2009.10.034
   BOELKINS JN, 1976, ENDOCRINOLOGY, V98, P403, DOI 10.1210/endo 98 2 403
   Boerckel JD, 2011, P NATL ACAD SCI USA, V108, pE674, DOI 10.1073/pnas.1107019108
   Bonnet N, 2008, J CELL PHYSIOL, V217, P819, DOI 10.1002/jcp.21564
   Bouxsein ML, 2005, J BONE MINER RES, V20, P635, DOI 10.1359/JBMR.041204
   BRINDLEY GW, 1988, AM J PHYSIOL, V255, pH94, DOI 10.1152/ajpheart.1988.255.1.H94
   BRINKER MR, 1990, J BONE JOINT SURG AM, V72A, P964, DOI 10.2106/00004623 199072070 00002
   Brixen KT, 2004, BASIC CLIN PHARMACOL, V94, P260
   Brookes M., 1998, BLOOD SUPPLY BONE SC, P75
   Chim SM, 2013, CYTOKINE GROWTH F R, V24, P297, DOI 10.1016/j.cytogfr.2013.03.008
   Clausen JO, 2009, OSTEOPOROSIS INT, V20, P1631, DOI 10.1007/s00198 008 0812 y
   Clines GA, 2011, J BONE MINER RES, V26, P2523, DOI 10.1002/jbmr.450
   COCHRANE E, 1991, J ENDOCRINOL, V131, P359, DOI 10.1677/joe.0.1310359
   DEAN MT, 1992, J ORTHOPAED RES, V10, P104, DOI 10.1002/jor.1100100113
   Dhillon RS, 2013, J BONE MINER RES, V28, P586, DOI 10.1002/jbmr.1765
   Díaz Flores L, 2009, HISTOL HISTOPATHOL, V24, P909, DOI 10.14670/HH 24.909
   Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607
   DRIESSENS M, 1981, AM J PHYSIOL, V241, pH91, DOI 10.1152/ajpheart.1981.241.1.H91
   Frost ML, 2003, J BONE MINER RES, V18, P2215, DOI 10.1359/jbmr.2003.18.12.2215
   HADDY FJ, 1968, ANNU REV MED, V19, P167, DOI 10.1146/annurev.me.19.020168.001123
   Hård AL, 2011, ACTA PAEDIATR, V100, P1063, DOI 10.1111/j.1651 2227.2011.02330.x
   Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538 7836.2006.02259.x
   Jilka RL, 2010, J BONE MINER RES, V25, P2427, DOI 10.1002/jbmr.145
   Kaczmarczyk Sedlak I, 2007, PHARMACOL REP, V59, P58
   Kapitola J, 2003, Sb Lek, V104, P133
   Komrakova M, 2011, J ENDOCRINOL, V209, P9, DOI 10.1530/JOE 10 0353
   Kristensen HB, 2013, J BONE MINER RES, V28, P574, DOI 10.1002/jbmr.1760
   Lamy S, 2010, VASC PHARMACOL, V53, P200, DOI 10.1016/j.vph.2010.08.002
   Lavine JA, 2013, JAMA OPHTHALMOL, V131, P376, DOI 10.1001/jamaophthalmol.2013.1476
   Léauté Labrèze C, 2013, BRIT J DERMATOL, V169, P181, DOI 10.1111/bjd.12217
   Leblanc AJ, 2012, MICROCIRCULATION, V19, P676, DOI 10.1111/j.1549 8719.2012.00207.x
   Locklin RM, 2003, J CELL BIOCHEM, V89, P180, DOI 10.1002/jcb.10490
   Maes C, 2013, CALCIFIED TISSUE INT, V92, P307, DOI 10.1007/s00223 012 9689 z
   Maes C, 2010, EMBO J, V29, P424, DOI 10.1038/emboj.2009.361
   Malaval L, 2008, J EXP MED, V205, P1145, DOI 10.1084/jem.20071294
   Moore AEB, 2010, J BONE MINER RES, V25, P960, DOI 10.1359/jbmr.091108
   Napoli C, 2008, NAT CLIN PRACT CARD, V5, P571, DOI 10.1038/ncpcardio1214
   Pierroz DD, 2006, BONE, V39, P260, DOI 10.1016/j.bone.2006.01.145
   Prisby R, 2013, BONE, V54, P68, DOI 10.1016/j.bone.2013.01.028
   Prisby R, 2011, J BONE MINER RES, V26, P2583, DOI 10.1002/jbmr.459
   Roche B, 2013, BONE, V55, P418, DOI 10.1016/j.bone.2013.03.022
   Roche B, 2012, BONE, V50, P390, DOI 10.1016/j.bone.2011.09.051
   Schluter KD, 1998, CARDIOVASC RES, V37, P34, DOI 10.1016/S0008 6363(97)00194 6
   Soki FN, 2013, J CELL BIOCHEM, V114, P67, DOI 10.1002/jcb.24301
   Song HJ, 2012, BONE, V51, P1008, DOI 10.1016/j.bone.2012.08.126
   Stresing V, 2011, BONE, V48, P259, DOI 10.1016/j.bone.2010.09.035
   Thompson B, 2012, NAT REV ENDOCRINOL, V8, P529, DOI 10.1038/nrendo.2012.36
   TRAN MA, 1980, BRIT J PHARMACOL, V70, P363, DOI 10.1111/j.1476 5381.1980.tb08711.x
   Tsai SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041065
   UZAWA T, 1995, BONE, V16, P477
   Verhaar HJJ, 2009, ARCH GERONTOL GERIAT, V49, P130
   WANG HH, 1984, EUR J PHARMACOL, V97, P209
   Wang YM, 2006, J ENDOCRINOL, V189, P279, DOI 10.1677/joe.1.06351
   Weber K, 2009, J BONE MINER RES, V24, P22, DOI [10.1359/JBMR.0080904, 10.1359/jbmr.0080904]
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Yang SM, 2011, BONE, V48, P451, DOI 10.1016/j.bone.2010.10.170
   Yao ZQ, 2004, J BONE MINER RES, V19, P1471, DOI 10.1359/JBMR.040517
   Yu YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031771
   Zaruba MM, 2008, CARDIOVASC RES, V77, P722, DOI 10.1093/cvr/cvm080
   Zhou H, 2003, BONE, V32, P513, DOI 10.1016/S8756 3282(03)00057 7
NR 61
TC 38
Z9 41
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2014
VL 29
IS 7
BP 1608
EP 1618
DI 10.1002/jbmr.2191
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AN0AO
UT WOS:000340243600011
PM 24496950
OA Bronze
DA 2025 08 17
ER

PT J
AU Brechter, AB
   Persson, E
   Lundgren, I
   Lerner, UH
AF Brechter, Anna Bernhold
   Persson, Emma
   Lundgren, Inger
   Lerner, Ulf H.
TI Kinin B1 and B2 receptor expression in osteoblasts and fibroblasts is
   enhanced by interleukin 1 and tumour necrosis factor α.: Effects
   dependent on activation of NF κB and MAP kinases
SO BONE
LA English
DT Article
DE bradykinin; interleukin 1; tumour necrosis factor; prostaglandin; bone
   resorption
ID RECEPTOR GENE EXPRESSION; BRADYKININ B 1 RECEPTOR; SMOOTH MUSCLE;
   UP REGULATION; PROSTAGLANDIN BIOSYNTHESIS; PROTEIN KINASES;
   BONE RESORPTION; TRANSCRIPTION; MECHANISMS; INVOLVEMENT
AB Pro inflammatory mediators formed by the kallikrein kinin system can stimulate bone resorption and synergistically potentiate bone resorption induced by IL 1 and TNF alpha. We have shown that the effect is associated with synergistically enhanced RANKL expression and enhanced prostaglandin biosynthesis, due to increased cyclooxygenase 2 expression. In the present study, the effects of osteotropic cytokines and different kinins on the expression of receptor subtypes for bradykinin (BK), des Arg(10) Lys BK (DALBK), IL 1 beta and TNF alpha have been investigated. IL 1 beta and TNF alpha enhanced kinin B1 and B2 receptor binding in the human osteoblastic cell line MG 63 and the mRNA expression of B1 and B2 receptors in MG 63 cells, human gingival fibroblasts and intact mouse calvarial bones. Kinins did not affect mRNA expression of IL 1 or TNF receptors. EMSA showed that IL 1 beta and TNF alpha activated NF kappa B and AP 1 in MG 63 cells. IL 1 beta stimulated NF kappa B via a non canonical pathway (p52/p65) and TNF alpha via the canonical pathway (p50/p65). Activation of AP 1 involved c Jun in both IL 1 beta and TNF alpha stimulated cells, but c Fos only in TNF alpha stimulated cells. Phospho ELISA and Western blots showed that IL 1 beta activated JNK and p38, but not ERK 1/2 MAP kinase. Pharmacological inhibitors showed that NF kappa B, p38 and JNK were important for IL 1 beta induced stimulation of B1 receptors, and NF kappa B and p38 for B2 receptors. p38 and JNK were important for TNF alpha induced stimulation of B1 receptors, whereas NF kappa B, p38 and JNK were involved in TNF alpha induced expression of B2 receptors. These data show that IL 1 beta and TNF alpha upregulate B1 and B2 receptor expression by mechanisms involving activation of both NF kappa B and MAP kinase pathways, but that signal transduction pathways are different for IL 1 beta and TNF alpha. The enhanced kinin receptor expression induced by the pro inflammatory cytokines IL 1 beta and TNF alpha might be one important mechanism involved in the synergistic enhancement of prostaglandin formation caused by co treatment with kinins and one of the two cytokines. These mechanisms might help to explain the enhanced bone resorption associated with inflammatory disorders, including periodontitis and rheumatoid arthritis. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Brechter, Anna Bernhold; Persson, Emma; Lundgren, Inger; Lerner, Ulf H.] Umea Univ, Dept Oral Cell Biol, SE 90187 Umea, Sweden.
C3 Umea University
RP Lerner, UH (通讯作者)，Umea Univ, Dept Oral Cell Biol, SE 90187 Umea, Sweden.
EM UIf.Lerner@odont.umu.se
OI Lerner, Ulf/0000 0002 3579 1960
CR Bachvarov DR, 1996, GENOMICS, V33, P374, DOI 10.1006/geno.1996.0213
   Baptista HA, 2002, MOL PHARMACOL, V62, P1344, DOI 10.1124/mol.62.6.1344
   Brechter AB, 2002, REGUL PEPTIDES, V103, P39, DOI 10.1016/S0167 0115(01)00325 1
   Brechter AB, 2007, ARTHRITIS RHEUM US, V56, P910, DOI 10.1002/art.22445
   Campos MM, 1999, BRIT J PHARMACOL, V127, P1851, DOI 10.1038/sj.bjp.0702715
   CLOVER J, 1994, BONE, V15, P585, DOI 10.1016/8756 3282(94)90305 0
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   GANJU P, 2007, EUR J PHARMACOL, V421, P191
   Haddad EB, 2000, MOL PHARMACOL, V57, P1123
   Imai C, 2005, CLIN EXP HYPERTENS, V27, P59, DOI 10.1081/CEH 200044262
   Joseph K, 2005, ADV IMMUNOL, V86, P159, DOI 10.1016/S0065 2776(04)86005 X
   Larrivée JF, 1998, J IMMUNOL, V160, P1419
   Leeb Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2
   LERNER U, 1987, J PERIODONTAL RES, V22, P284, DOI 10.1111/j.1600 0765.1987.tb01586.x
   Lerner UH, 2006, J DENT RES, V85, P596, DOI 10.1177/154405910608500704
   Lerner U. H., 2002, PRINCIPLES BONE BIOL, P773
   LERNER UH, 1991, BIOCHEM BIOPH RES CO, V175, P775, DOI 10.1016/0006 291X(91)91633 N
   LERNER UH, 1991, INFLAMMATION, V15, P427, DOI 10.1007/BF00923340
   LERNER UH, 1987, J BONE MINER RES, V2, P375
   Lerner UH, 1997, KININ SYSTEM, P219
   LJUNGGREN O, 1991, J BONE MINER RES, V6, P443
   LJUNGGREN O, 1991, J BONE MINER RES, V6, P807
   LJUNGGREN O, 1990, BRIT J PHARMACOL, V101, P382, DOI 10.1111/j.1476 5381.1990.tb12718.x
   Lorenzo J.A., 2002, Princ. Bone Biol, VSecond, P961
   Madeddu P, 1997, BRIT J PHARMACOL, V121, P1763, DOI 10.1038/sj.bjp.0701255
   Marceau F, 2004, NAT REV DRUG DISCOV, V3, P845, DOI 10.1038/nrd1522
   Marceau F, 1998, PHARMACOL REV, V50, P357
   Medeiros R, 2004, CIRC RES, V94, P1375, DOI 10.1161/01.RES.0000128404.65887.08
   Moreau ME, 2005, J PHARMACOL SCI, V99, P6, DOI 10.1254/jphs.SRJ05001X
   Newton R, 2002, EUR J PHARMACOL, V441, P193, DOI 10.1016/S0014 2999(01)01624 7
   Ni AG, 1998, J BIOL CHEM, V273, P2784, DOI 10.1074/jbc.273.5.2784
   Pesquero JB, 2006, BIOL CHEM, V387, P119, DOI 10.1515/BC.2006.017
   Pesquero JB, 1996, IMMUNOPHARMACOLOGY, V33, P36, DOI 10.1016/0162 3109(96)00080 X
   Phagoo SB, 1999, MOL PHARMACOL, V56, P325, DOI 10.1124/mol.56.2.325
   Phagoo SB, 2001, J PHARMACOL EXP THER, V298, P77
   Phagoo SB, 2000, EUR J PHARMACOL, V397, P237, DOI 10.1016/S0014 2999(00)00323 X
   Sabourin T, 2002, AM J PHYSIOL HEART C, V283, pH227, DOI 10.1152/ajpheart.00978.2001
   Sabourin T, 2001, BRIT J PHARMACOL, V133, P1154, DOI 10.1038/sj.bjp.0704158
   Sardi SP, 2002, J PHARMACOL EXP THER, V301, P975, DOI 10.1124/jpet.301.3.975
   Schanstra JP, 1998, J CLIN INVEST, V101, P2080, DOI 10.1172/JCI1359
   Scherrer D, 1999, N S ARCH PHARMACOL, V359, P153, DOI 10.1007/PL00005337
   Schmidlin F, 1998, MOL PHARMACOL, V53, P1009
   Tsukagoshi H, 1999, BIOCHEM BIOPH RES CO, V259, P476, DOI 10.1006/bbrc.1999.0798
   Walsh NC, 2004, CURR OPIN RHEUMATOL, V16, P419, DOI 10.1097/01.bor.0000127824.42507.68
   Yang XG, 2001, J CELL BIOCHEM, V82, P163, DOI 10.1002/jcb.1116
   Zhou XF, 2000, J CELL BIOCHEM, V78, P351, DOI 10.1002/1097 4644(20000901)78:3<351::AID JCB1>3.0.CO;2 U
   Zhou XF, 1998, BIOCHEM J, V330, P361, DOI 10.1042/bj3300361
NR 47
TC 51
Z9 54
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2008
VL 43
IS 1
BP 72
EP 83
DI 10.1016/j.bone.2008.02.003
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 319GC
UT WOS:000257151100010
PM 18467203
DA 2025 08 17
ER

PT J
AU Yue, SJ
   An, JN
   Zhang, YF
   Li, JY
   Zhao, CZ
   Liu, JY
   Liang, LL
   Sun, HL
   Xu, Y
   Zhong, ZY
AF Yue, Shujing
   An, Jingnan
   Zhang, Yifan
   Li, Jiaying
   Zhao, Cenzhu
   Liu, Jingyi
   Liang, Lanlan
   Sun, Huanli
   Xu, Yang
   Zhong, Zhiyuan
TI Exogenous Antigen Upregulation Empowers Antibody Targeted
   Nanochemotherapy of Leukemia
SO ADVANCED MATERIALS
LA English
DT Article
DE CD38; combination strategy; exogenous stimulation; leukemia;
   nanomedicines; targeted therapy
ID ACUTE MYELOID LEUKEMIA; TRANS RETINOIC ACID; MULTIPLE MYELOMA;
   STEM CELLS; IMMUNOTHERAPY; VINCRISTINE; PROGENITORS; OSTEOCLASTS;
   EFFICACY; THERAPY
AB Acute myeloid leukemia (AML) is afflicted by a high mortality rate and few treatment options. The lack of specific surface antigens severely hampers the development of targeted therapeutics and cell therapy. Here, it is shown that exogenous all trans retinoic acid (ATRA) mediates selective and transient CD38 upregulation on leukemia cells by up to 20 fold, which enables high efficiency targeted nanochemotherapy of leukemia with daratumumab antibody directed polymersomal vincristine sulfate (DPV). Strikingly, treatment of two CD38 low expressing AML orthotopic models with ATRA and DPV portfolio strategies effectively eliminates circulating leukemia cells and leukemia invasion into bone marrow and organs, leading to exceptional survival benefits with 20 40% of mice becoming leukemia free. The combination of exogenous CD38 upregulation and antibody directed nanotherapeutics provides a unique and powerful targeted therapy for leukemia.
C1 [Yue, Shujing; Zhang, Yifan; Liu, Jingyi; Sun, Huanli; Zhong, Zhiyuan] Soochow Univ, Coll Chem Chem Engn & Mat Sci, Biomed Polymers Lab, Suzhou 215123, Peoples R China.
   [An, Jingnan; Zhao, Cenzhu; Xu, Yang] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Collaborat Innovat Ctr Hematol, Suzhou 215123, Peoples R China.
   [Li, Jiaying] Soochow Univ, Affiliated Hosp 1, Orthopaed Inst, Dept Orthopaed Surg, Suzhou 215007, Peoples R China.
   [Zhong, Zhiyuan] Soochow Univ, Coll Pharmaceut Sci, Suzhou 215123, Peoples R China.
C3 Soochow University   China; Soochow University   China; Soochow
   University   China; Soochow University   China
RP Sun, HL; Zhong, ZY (通讯作者)，Soochow Univ, Coll Chem Chem Engn & Mat Sci, Biomed Polymers Lab, Suzhou 215123, Peoples R China.; Xu, Y (通讯作者)，Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Collaborat Innovat Ctr Hematol, Suzhou 215123, Peoples R China.; Zhong, ZY (通讯作者)，Soochow Univ, Coll Pharmaceut Sci, Suzhou 215123, Peoples R China.
EM sunhuanli@suda.edu.cn; yangxu@suda.edu.cn; zyzhong@suda.edu.cn
RI ; Sun, Huanli/AAD 1768 2020; Xu, Yang/GOH 1228 2022; Zhong,
   Zhiyuan/D 8508 2011
OI Xu, Yang/0000 0003 4643 2098; Zhong, Zhiyuan/0000 0003 4175 4741
FU National Natural Science Foundation of China [52073196, 52273251,
   52233007, 82000157]; National Key Ramp;D Program of China
   [2021YFB3800900]; Natural Science Foundation of the Jiangsu Higher
   Education Institutions of China [21KJA150007]
FX This work was supported by the National Natural Science Foundation of
   China (52073196, 52273251, 52233007, and 82000157), the National Key R &
   D Program of China (2021YFB3800900), and the Natural Science Foundation
   of the Jiangsu Higher Education Institutions of China (21KJA150007). The
   authors thank Dr. Fengtao You from Persongen Bio Therapeutics (Suzhou)
   Co., Ltd. for providing Molm 13 Luc and human T cells. All the animal
   experiments were approved by the Animal Care and Use Committee of
   Soochow University (Suzhou, China), and all protocols of animal studies
   conformed to the Guide for the Care and Use of Laboratory Animals
   (approval no. SYXK 2021 0065). Samples from AML patients and healthy
   donors were obtained at Jiangsu Institute of Hematology, the First
   Affiliated Hospital of Soochow University, Suzhou, China. Informed
   consent was signed by patients and donors according to the guidelines
   given by the ethical committee of the First Affiliated Hospital of
   Soochow University (approval no. 2017169 2).
CR Akinduro O, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02376 5
   Bai HY, 2021, CHEM ENG J, V405, DOI 10.1016/j.cej.2020.126891
   Becker S, 2020, MOL CANCER RES, V18, P859, DOI 10.1158/1541 7786.MCR 19 1203
   Buteyn NJ, 2018, INT IMMUNOL, V30, P375, DOI 10.1093/intimm/dxy040
   Cai H, 2022, BLOOD, V139, P3040, DOI 10.1182/blood.2021011510
   Chao MW, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045 015 0176 7
   Choi Y, 2009, NAT REV RHEUMATOL, V5, P543, DOI 10.1038/nrrheum.2009.175
   Cui QY, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045 021 01092 4
   D'Agostino M, 2020, LANCET HAEMATOL, V7, pE355, DOI 10.1016/S2352 3026(19)30254 6
   Daver N, 2021, LEUKEMIA, V35, P1843, DOI 10.1038/s41375 021 01253 x
   Deng CF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22454 z
   DiNardo CD, 2019, BLOOD, V133, P7, DOI 10.1182/blood 2018 08 868752
   Dohner H, 2021, NAT REV CLIN ONCOL, V18, P577, DOI 10.1038/s41571 021 00509 w
   Frerichs KA, 2019, BLOOD, V134, DOI 10.1182/blood 2019 123383
   Gu WX, 2021, J CONTROL RELEASE, V329, P706, DOI 10.1016/j.jconrel.2020.10.005
   Gurney M, 2022, HAEMATOLOGICA, V107, P437, DOI 10.3324/haematol.2020.271908
   Hebbar N, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28243 6
   Hu QY, 2018, NAT BIOMED ENG, V2, P831, DOI 10.1038/s41551 018 0310 2
   Jyoti N., 2019, HAEMATOLOGICA, V104
   Katherine D. C., 2019, HAEMATOLOGICA, V104, P1302
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kuek V, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136888
   Kumar B, 2018, LEUKEMIA, V32, P575, DOI 10.1038/leu.2017.259
   Larrue C, 2016, BLOOD, V127, P882, DOI 10.1182/blood 2015 05 646497
   Lichtenegger FS, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045 017 0505 0
   Lima CSP, 2000, HAEMATOLOGIA, V30, P325, DOI 10.1163/156855900300109576
   Lokhorst HM, 2015, NEW ENGL J MED, V373, P1207, DOI 10.1056/NEJMoa1506348
   Löwenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407
   Marvin Peek J, 2022, CANCERS, V14, DOI 10.3390/cancers14030497
   Nijhof IS, 2015, LEUKEMIA, V29, P2039, DOI 10.1038/leu.2015.123
   Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192
   Schaefer J, 2020, NAT REV DRUG DISCOV, V19, P233, DOI 10.1038/d41573 019 00142 4
   Sheridan C, 2017, NAT BIOTECHNOL, V35, P696, DOI 10.1038/nbt0817 696
   Short NJ, 2020, CANCER DISCOV, V10, P506, DOI 10.1158/2159 8290.CD 19 1011
   Short NJ, 2018, LANCET, V392, P593, DOI 10.1016/S0140 6736(18)31041 9
   Siegal T, 2022, BLOOD REV, V53, DOI 10.1016/j.blre.2021.100910
   Tang XW, 2020, BLOOD, V136, DOI 10.1182/blood 2020 141602
   Tarighat SS, 2016, LEUKEMIA, V30, P789, DOI 10.1038/leu.2015.308
   Trujillo Alonso V, 2019, NAT NANOTECHNOL, V14, P616, DOI 10.1038/s41565 019 0406 1
   van de Donk NWCJ, 2018, BLOOD, V131, P13, DOI 10.1182/blood 2017 06 740944
   Veletic I, 2019, BLOOD, V133, P2320, DOI 10.1182/blood 2018 10 878926
   Wang XF, 2017, MOL CANCER, V16, DOI 10.1186/s12943 016 0574 7
   Wu GJ, 2021, NAT CANCER, V2, P1170, DOI 10.1038/s43018 021 00262 0
   Xia YF, 2023, BIOACT MATER, V21, P499, DOI 10.1016/j.bioactmat.2022.08.032
   Xie XL, 2021, NAT BIOMED ENG, V5, P414, DOI 10.1038/s41551 020 00624 6
   Yahara Y, 2020, NAT CELL BIOL, V22, P49, DOI 10.1038/s41556 019 0437 8
   Yamashita M, 2020, NAT REV CANCER, V20, P365, DOI 10.1038/s41568 020 0260 3
   Yang X, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045 017 0543 7
   Yoshida T, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.73
   Yu N, 2021, ADV MATER, V33, DOI 10.1002/adma.202007787
NR 50
TC 13
Z9 14
U1 12
U2 127
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935 9648
EI 1521 4095
J9 ADV MATER
JI Adv. Mater.
PD AUG
PY 2023
VL 35
IS 32
DI 10.1002/adma.202209984
EA JUN 2023
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA W7DV8
UT WOS:001020044500001
PM 37321606
DA 2025 08 17
ER

PT J
AU Li, XR
   Si, YH
   Liang, JX
   Li, MS
   Wang, ZW
   Qin, YY
   Sun, LT
AF Li, Xiaorong
   Si, Yunhui
   Liang, Jingxian
   Li, Mengsha
   Wang, Zhiwei
   Qin, Yinying
   Sun, Litao
TI Enhancing bone regeneration and immunomodulation via gelatin
   methacryloyl hydrogel encapsulated exosomes from osteogenic
   pre differentiated mesenchymal stem cells
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article
DE Exosomes; Osteogenesis; Mesenchymal stem cells; Immune mechanisms;
   Composite hydrogel
ID NF KAPPA B; DNA DAMAGE RESPONSE; EXTRACELLULAR VESICLES; ATM;
   PHOSPHORYLATION; CARTILAGE; PROLIFERATION; BIOMATERIALS; OSTEOBLASTS;
   ACTIVATION
AB Mesenchymal stem cell  derived exosomes (MSC Exos) have emerged as promising candidates for cell  free therapy in tissue regeneration. However, the native osteogenic and angiogenic capacities of MSC Exos are often insufficient to repair critical  sized bone defects, and the underlying immune mechanisms remain elusive. Furthermore, achieving sustained delivery and stable activity of MSC Exos at the defect site is essential for optimal therapeutic outcomes. Here, we extracted exosomes from osteogenically pre  differentiated human bone marrow mesenchymal stem cells (hBMSCs) by ultracentrifugation and encapsulated them in gelatin methacryloyl (GelMA) hydrogel to construct a composite scaffold. The resulting exosome encapsulated hydrogel exhibited excellent mechanical properties and biocompatibility, facilitating sustained delivery of MSC Exos. Osteogenic pre  differentiation significantly enhanced the osteogenic and angiogenic properties of MSC Exos, promoting osteogenic differentiation of hBMSCs and angiogenesis of human umbilical vein endothelial cells (HUVECs). Furthermore, MSC Exos induced polarization of Raw264.7 cells from a pro  inflammatory phenotype to an anti inflammatory phenotype under simulated inflammatory conditions, thereby creating an immune microenvironment conducive to osteogenesis. RNA sequencing and bioinformatics analysis revealed that MSC Exos activate the p53 pathway through targeted delivery of internal microRNAs and regulate macrophage polarization by reducing DNA oxidative damage. Our study highlights the potential of osteogenic exosome encapsulated composite hydrogels for the development of cell  free scaffolds in bone tissue engineering.
C1 [Li, Xiaorong; Liang, Jingxian; Qin, Yinying; Sun, Litao] Sun Yat Sen Univ, Sch Publ Hlth Shenzhen, Shenzhen 518107, Peoples R China.
   [Si, Yunhui] Sun Yat Sen Univ, Sch Biomed Engn, Shenzhen 518107, Peoples R China.
   [Li, Mengsha] Sun Yat Sen Univ, Sch Mat Sci & Engn, Guangzhou 510006, Peoples R China.
   [Li, Mengsha; Wang, Zhiwei] Southern Marine Sci & Engn Guangdong Lab Zhuhai, Zhuhai 519000, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   Southern Marine Science & Engineering Guangdong Laboratory; Southern
   Marine Science & Engineering Guangdong Laboratory (Zhuhai)
RP Sun, LT (通讯作者)，Sun Yat Sen Univ, Sch Publ Hlth Shenzhen, Shenzhen 518107, Peoples R China.; Si, YH (通讯作者)，Sun Yat Sen Univ, Sch Biomed Engn, Shenzhen 518107, Peoples R China.
EM siyh5@mail.sysu.edu.cn; sunlt@mail.sysu.edu.cn
RI ; Lin, Xiaorong/ABC 4163 2021
OI SUN, LITAO/0000 0002 8415 989X; 
FU National Key Research and Development Program of China [2021YFC2300100];
   Guangdong Natural Science Foundation [2021B1515020047]; National Natural
   Science Foundation of China [32271314]; Shenzhen Science and Technology
   Innovation Commission [JCYJ20200109142446804]; School of Materials, Sun
   Yat sen University
FX This work was supported by the National Key Research and Development
   Program of China (Grant No. 2021YFC2300100), the Guangdong Natural
   Science Foundation (Grant No. 2021B1515020047), the National Natural
   Science Foundation of China (Grant No. 32271314), and the Shenzhen
   Science and Technology Innovation Commission (Grant No.
   JCYJ20200109142446804). This work was also supported by the School of
   Materials, Sun Yat sen University.
CR Ahmed KM, 2009, FREE RADICAL BIO MED, V46, P1543, DOI 10.1016/j.freeradbiomed.2009.03.012
   Alvarez Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807
   Andres A, 2018, TRANSPLANTATION, V102, pS731, DOI 10.1097/01.tp.0000543713.98918.6e
   Bai JX, 2020, BIOMATERIALS, V255, DOI 10.1016/j.biomaterials.2020.120197
   Barascu A, 2012, EMBO J, V31, P1080, DOI 10.1038/emboj.2011.492
   Bialas N, 2021, BIOMATERIALS, V276, DOI 10.1016/j.biomaterials.2021.121013
   Bock O, 2005, BRIT J HAEMATOL, V130, P76, DOI 10.1111/j.1365 2141.2005.05573.x
   Breakefield XO, 2011, MOL THER, V19, P1574, DOI 10.1038/mt.2011.169
   Brennan MA, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909125
   Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035
   Chai CY, 2023, THERANOSTICS, V13, P3943, DOI 10.7150/thno.83178
   Chen CJ, 2023, ACS APPL MATER INTER, V15, P28891, DOI 10.1021/acsami.3c01539
   Cheng QQ, 2022, MOL THER, V30, P3066, DOI 10.1016/j.ymthe.2022.06.013
   Chibaya L, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2003193118
   Choi M, 2017, J AM SOC NEPHROL, V28, P3190, DOI 10.1681/ASN.2016060690
   Confalonieri D, 2018, TISSUE ENG PART B RE, V24, P155, DOI [10.1089/ten.teb.2017.0305, 10.1089/ten.TEB.2017.0305]
   Cui YZ, 2016, FEBS LETT, V590, P185, DOI 10.1002/1873 3468.12024
   Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545
   Dirckx N, 2019, NAT REV ENDOCRINOL, V15, P651, DOI 10.1038/s41574 019 0246 y
   Duan L, 2021, NANOSCALE, V13, DOI 10.1039/d0nr07622h
   Dunphy G, 2018, MOL CELL, V71, P745, DOI 10.1016/j.molcel.2018.07.034
   Elliott RO, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13010122
   Gannon HS, 2012, CANCER CELL, V21, P668, DOI 10.1016/j.ccr.2012.04.011
   Gao ZS, 2021, ACTA BIOMATER, V126, P211, DOI 10.1016/j.actbio.2021.03.018
   Ghosh M, 2023, MOL CELL, V83, P266, DOI 10.1016/j.molcel.2022.12.023
   Ghosh M, 2021, CANCER CELL, V39, P494, DOI 10.1016/j.ccell.2021.01.003
   Gou YN, 2024, BIOACT MATER, V34, P51, DOI 10.1016/j.bioactmat.2023.12.003
   Guo JW, 2023, CELL REP MED, V4, DOI 10.1016/j.xcrm.2022.100881
   Han DL, 2020, CHEM ENG J, V396, DOI 10.1016/j.cej.2020.125194
   Han Z, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12054
   Hao LZ, 2023, CHEM ENG J, V471, DOI 10.1016/j.cej.2023.144594
   Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478 811X 9 12
   He J, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202300395
   Hinderer S, 2016, ADV DRUG DELIVER REV, V97, P260, DOI 10.1016/j.addr.2015.11.019
   Hinz M, 2010, MOL CELL, V40, P63, DOI 10.1016/j.molcel.2010.09.008
   Hu MJ, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI139333
   Huang JH, 2021, NANOSCALE, V13, P8740, DOI 10.1039/d1nr01314a
   Imai T, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.26238
   Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Kang Y, 2022, BIOACT MATER, V18, P26, DOI 10.1016/j.bioactmat.2022.02.012
   Kozlov SV, 2016, MOL CELL PROTEOMICS, V15, P1032, DOI 10.1074/mcp.M115.055723
   Krishnan L, 2017, ACTA BIOMATER, V49, P101, DOI 10.1016/j.actbio.2016.12.012
   Kurian AG, 2022, BIOACT MATER, V8, P267, DOI 10.1016/j.bioactmat.2021.06.027
   Lamichhane TN, 2015, MOL PHARMACEUT, V12, P3650, DOI 10.1021/acs.molpharmaceut.5b00364
   Li FY, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01347 3
   Li JL, 2022, J COLLOID INTERF SCI, V612, P377, DOI 10.1016/j.jcis.2021.12.091
   Li P, 2017, THERANOSTICS, V7, P789, DOI 10.7150/thno.18133
   Li WC, 2023, ACS NANO, V17, P22106, DOI 10.1021/acsnano.3c09220
   Li WH, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01645 2
   Li XF, 2018, BIOMED PHARMACOTHER, V99, P622, DOI 10.1016/j.biopha.2018.01.103
   Liang WS, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.833840
   Liang Z, 2021, CHEM ENG J, V422, DOI 10.1016/j.cej.2021.130084
   Lin XF, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700660
   Lin Y, 2020, J DRUG TARGET, V28, P129, DOI 10.1080/1061186X.2019.1641508
   Liu AQ, 2021, BIOMATERIALS, V272, DOI 10.1016/j.biomaterials.2021.120718
   Liu CF, 2022, INT J BIOL MACROMOL, V202, P418, DOI 10.1016/j.ijbiomac.2022.01.083
   Liu C, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01273 4
   Liu TY, 2020, SAGE OPEN, V10, DOI 10.1177/2158244019899048
   Liu W, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 01015 y
   Liu Y, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20193531
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Lu GD, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.608521
   Lv Y, 2020, ADV SCI, V7, DOI 10.1002/advs.201901412
   Ma SY, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.1091360
   Mondal J, 2023, J CONTROL RELEASE, V353, P1127, DOI 10.1016/j.jconrel.2022.12.027
   Mori MA, 2019, CELL METAB, V30, P656, DOI 10.1016/j.cmet.2019.07.011
   Munive Olarte A, 2022, J COLLOID INTERF SCI, V607, P298, DOI 10.1016/j.jcis.2021.08.149
   Narayanan R, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3808674
   Nichol JW, 2010, BIOMATERIALS, V31, P5536, DOI 10.1016/j.biomaterials.2010.03.064
   Ofek P, 2003, J BIOL CHEM, V278, P14299, DOI 10.1074/jbc.M211699200
   Qazi TH, 2017, BIOMATERIALS, V140, P103, DOI 10.1016/j.biomaterials.2017.06.019
   Qi YM, 2021, J HAZARD MATER, V416, DOI 10.1016/j.jhazmat.2021.126177
   Qin YH, 2016, SCI REP UK, V6, DOI 10.1038/srep21961
   Ren SH, 2023, FRONT BIOENG BIOTECH, V11, DOI 10.3389/fbioe.2023.1136453
   Riazifar M, 2017, ANNU REV PHARMACOL, V57, P125, DOI 10.1146/annurev pharmtox 061616 030146
   SABOKBAR A, 1994, BONE MINER, V27, P57, DOI 10.1016/S0169 6009(08)80187 0
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Samsonraj RM, 2017, STEM CELL TRANSL MED, V6, P2173, DOI 10.1002/sctm.17 0129
   Schmidt AH, 2021, INJURY, V52, pS18, DOI 10.1016/j.injury.2021.01.043
   Schneider G, 2010, ONCOGENE, V29, P2795, DOI 10.1038/onc.2010.46
   Seenprachawong K, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00543
   Sharifi S, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 02830 x
   Sharma RB, 2019, DIABETES, V68, P975, DOI 10.2337/db18 0761
   Siler J, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25052462
   Spees JL, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0363 7
   Spiller KL, 2017, ADV DRUG DELIVER REV, V122, P74, DOI 10.1016/j.addr.2017.05.010
   Stahl A, 2021, TISSUE ENG PART B RE, V27, P539, DOI [10.1089/ten.teb.2020.0281, 10.1089/ten.TEB.2020.0281]
   Sun JR, 2023, COMPOS PART B ENG, V261, DOI 10.1016/j.compositesb.2023.110803
   Sun LN, 2021, BIOMATERIALS, V271, DOI 10.1016/j.biomaterials.2021.120761
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Tomé M, 2011, CELL DEATH DIFFER, V18, P985, DOI 10.1038/cdd.2010.167
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   van Dommelen SM, 2012, J CONTROL RELEASE, V161, P635, DOI 10.1016/j.jconrel.2011.11.021
   Wang XQ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193059
   Wang YW, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/652034
   Wang ZF, 2010, PROTEIN CELL, V1, P1063, DOI 10.1007/s13238 010 0140 9
   Weitering TJ, 2021, TRENDS IMMUNOL, V42, P350, DOI 10.1016/j.it.2021.02.001
   Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042
   Wu D, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00958 6
   Wu MH, 2024, ADV SCI, V11, DOI 10.1002/advs.202304641
   Xiao WQ, 2011, ACTA BIOMATER, V7, P2384, DOI 10.1016/j.actbio.2011.01.016
   Xie F, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0422 z
   Xu JF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114627
   Xue X, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202009432
   Yan GQ, 2020, INFLAMMATION, V43, P1279, DOI 10.1007/s10753 020 01207 y
   Yang ZJ, 2023, J NANOBIOTECHNOL, V21, DOI 10.1186/s12951 023 01871 w
   Yasuda H, 2021, J BONE MINER METAB, V39, P2, DOI 10.1007/s00774 020 01175 1
   Ying GL, 2018, BIO DES MANUF, V1, P215, DOI 10.1007/s42242 018 0028 8
   Yu WW, 2022, Eng. Regen, V3, P270, DOI [DOI 10.1016/J.ENGREG, 10.1016/j.engreg, DOI 10.1016/J.ENGREG.2022.06.004]
   Zakeri Z, 2024, BIOMATER SCI UK, V12, P2561, DOI 10.1039/d3bm01055d
   Zhai MM, 2020, ADV SCI, V7, DOI 10.1002/advs.202001334
   Zhang BJ, 2021, PROG NAT SCI MATER, V31, P883, DOI 10.1016/j.pnsc.2021.04.008
   Zhang JY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0417 0
   Zhang SP, 2018, BIOMATERIALS, V156, P16, DOI 10.1016/j.biomaterials.2017.11.028
   Zhang Y, 2022, J BIOL ENG, V16, DOI 10.1186/s13036 022 00301 z
   Zhang YT, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12570
   Zhao QG, 2015, P NATL ACAD SCI USA, V112, P530, DOI 10.1073/pnas.1423008112
   Zheng YY, 2022, BIOACT MATER, V14, P364, DOI 10.1016/j.bioactmat.2022.01.042
   Zhong WQ, 2023, CELL REP, V42, DOI 10.1016/j.celrep.2023.113224
   Zhu QH, 2023, PHARMACOL RES, V192, DOI 10.1016/j.phrs.2023.106798
NR 121
TC 15
Z9 15
U1 12
U2 73
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0021 9797
EI 1095 7103
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD OCT 15
PY 2024
VL 672
BP 179
EP 199
DI 10.1016/j.jcis.2024.05.209
EA JUN 2024
PG 21
WC Chemistry, Physical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA UR9I2
UT WOS:001249899700001
PM 38838627
DA 2025 08 17
ER

PT J
AU Popovic, KS
   Kocar, M
AF Popovic, Katarina Surlan
   Kocar, Miha
TI Imaging findings in bisphosphonate induced osteonecrosis of the jaws
SO RADIOLOGY AND ONCOLOGY
LA English
DT Article
DE bisphosphonates; osteonecrosis; jaw; CT; MRI
ID RISK FACTORS; MANAGEMENT; MRI
AB Background. Bisphosphonates are drugs used in the treatment of lytic bone metastases, multiple myeloma, hyper calcemia of malignant origin, osteoporosis, and diseases such as Paget's disease. Recently osteonecrosis of the jaw has been associated with the use of bisphosphonates. This study describes the imaging findings of bisphosphonate associated osteonecrosis of the jaws.
   Patients and methods. Eleven patients, receiving bisphosphonate medication for approximately 28 months, with pain on affected side, nonhealing extraction sockets, purulent discharge and swelling in soft tissue were examined. Imaging consisted of non contrast enhanced CT and contrast enhanced MRI. All patients underwent surgery of affected bone and histology confirmed osteonecrosis.
   Results. CT scan showed osteolytic and sclerotic lesions with cortical bone destruction in all patients. The osteonecrosis was identified as delimited focal lesions with reduction of the signal on T1  weighted imaging and T2  weighted imaging. All the patients had soft tissue involvement with enhancement in orbicular, buccinator muscle of the mouth or masticator space and adenopathy in submandibular and jugular digastric chain.
   Conclusions. Bisphosphonate related osteonecrosis of the jaw presents a variety of imaging findings that help to determine the extent of the disease and track the progression, however they are not specific for this disease.
C1 [Popovic, Katarina Surlan] Univ Med Ctr Ljubljana, Inst Radiol, Dept Neuroradiol, Ljubljana 1000, Slovenia.
   [Kocar, Miha] Univ Med Ctr Ljubljana, Dept Maxillofacial & Oral Surg, Ljubljana 1000, Slovenia.
C3 University Medical Centre Ljubljana; University Medical Centre Ljubljana
RP Popovic, KS (通讯作者)，Univ Med Ctr Ljubljana, Inst Radiol, Dept Neuroradiol, Zaloska 7, Ljubljana 1000, Slovenia.
EM katarina.surlan@gmail.com
CR Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Arce K, 2009, J ORAL MAXIL SURG, V67, P75, DOI 10.1016/j.joms.2008.12.002
   Bedogni A, 2008, ORAL SURG ORAL MED O, V105, P358, DOI 10.1016/j.tripleo.2007.08.040
   Bisdas S, 2008, CLIN RADIOL, V63, P71, DOI 10.1016/j.crad.2007.04.023
   Cheng A, 2005, AUST DENT J, V50, pS4, DOI 10.1111/j.1834 7819.2005.tb00384.x
   Chiandussi S, 2006, DENTOMAXILLOFAC RAD, V35, P236, DOI 10.1259/dmfr/27458726
   Debevec L, 2009, RADIOL ONCOL, V43, P47, DOI 10.2478/v10019 009 0008 x
   Elad S, 2010, CLIN ORAL INVEST, V14, P43, DOI 10.1007/s00784 009 0311 3
   García Ferrer L, 2008, AM J ROENTGENOL, V190, P949, DOI 10.2214/AJR.07.3045
   Hansen T, 2007, VIRCHOWS ARCH, V451, P1009, DOI 10.1007/s00428 007 0516 2
   Horvat AG, 2009, RADIOL ONCOL, V43, P213, DOI 10.2478/v10019 009 0038 4
   Krishnan A, 2009, J COMPUT ASSIST TOMO, V33, P298, DOI 10.1097/RCT.0b013e31817e4986
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Migliorati CA, 2005, ORAL SURG ORAL MED O, V99, P135, DOI 10.1016/j.tripleo.2004.10.001
   Migliorati CA, 2006, LANCET ONCOL, V7, P508, DOI 10.1016/S1470 2045(06)70726 4
   Naik NH, 2009, CLIN INFECT DIS, V49, P1729, DOI 10.1086/648075
   Orlandini F, 2009, J RADIOL, V90, P199, DOI 10.1016/S0221 0363(09)72470 9
   Phal PM, 2007, AM J NEURORADIOL, V28, P1139, DOI 10.3174/ajnr.A0518
   Podobnik J, 2010, RADIOL ONCOL, V44, P92, DOI 10.2478/v10019 010 0027 7
   Pogrel MA, 2004, J ORAL MAXIL SURG, V62, P391, DOI 10.1016/j.joms.2003.11.003
   Rajer M, 2008, RADIOL ONCOL, V42, P23, DOI 10.2478/v10019 007 0035 4
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Thumbigere Math V, 2009, J ORAL MAXIL SURG, V67, P1904, DOI 10.1016/j.joms.2009.04.051
   Williamson RA, 2010, INT J ORAL MAX SURG, V39, P251, DOI 10.1016/j.ijom.2009.11.014
NR 25
TC 16
Z9 17
U1 0
U2 1
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D 10785 BERLIN, GERMANY
SN 1318 2099
EI 1581 3207
J9 RADIOL ONCOL
JI Radiol. Oncol.
PD DEC
PY 2010
VL 44
IS 4
BP 215
EP 219
DI 10.2478/v10019 010 0032 x
PG 5
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 680VK
UT WOS:000284263900002
PM 22933918
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, JY
   Zhang, RX
   Dong, CS
   Jiao, LY
   Xu, L
   Liu, JY
   Wang, ZT
   Ying, QLM
   Fong, H
   Lao, LX
AF Wang, Juyong
   Zhang, Ruixin
   Dong, Changsheng
   Jiao, Liying
   Xu, Ling
   Liu, Jiyong
   Wang, Zhengtao
   Ying, Qi Liang Mao
   Fong, Harry
   Lao, Lixing
TI Topical treatment with Tong Luo San Jie gel
   alleviates bone cancer pain in rats
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Chinese herbs; Bone cancer pain; Tong Luo San Jie (TLSJ) gel; Type I
   collagen carboxy terminal telopeptide; Bone specific alkaline
   phosphatase; Osteoclast
ID BIOCHEMICAL MARKERS; MANAGEMENT; METABOLISM; MECHANISMS; MEDICINE;
   MORPHINE; EXTRACT
AB Ethnopharmacological relevance: The herbal analgesic gel Tong Luo San Jie (TLSJ) and its modifications are used in traditional Chinese medicine to manage cancer pain. However, its mechanisms are still unknown.
   Aim of the study: To investigate the effects and mechanisms of TLSJ gel on bone cancer pain in a rat model.
   Materials and methods: A bone cancer pain rat model was established by inoculating Walker 256 rat carcinoma cells directly into the right tibial medullary cavity of Sprague Dawley rats (150 170g): Phosphate buffered saline (PBS) tibial inoculation was used as control. Cancer bearing rats were treated twice a day with external TLSJ gel (0.5 g/cm(2)/day) or inert gel control for 21 day (n=10/group). Behavioral tests such as mechanical threshold and paw withdrawal latency (PWL) were carried out. Osteoclastic activities were determined and carboxyterminal pyridinoline cross linked type I collagen telopeptides (ICTP) and bone specific alkaline phosphatase (BAP) concentrations were detected with ELISA after treatment. Adverse effects were monitored, and biochemical and histological tests were performed in naive rats treated with local TLSJ gel for six weeks.
   Results: TLSJ treatment significantly restored bone cancer induced decrease of PWL and mechanical threshold compared to inert gel. It also decreased the level of blood serum ICTP and BAP and inhibited osteoclast activities. No adverse effects or abnormal biochemical and histological changes were detected after TLSJ treatment.
   Conclusion: The present study shows that TLSJ significantly inhibits bone cancer induced thermal and mechanical sensitization. It suggests that the gel may be useful in managing cancer pain and that it may act by inhibiting osteoclastic activity. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Zhang, Ruixin; Lao, Lixing] Univ Maryland, Ctr Integrat Med, Baltimore, MD 21201 USA.
   [Wang, Juyong; Dong, Changsheng; Jiao, Liying; Xu, Ling] Shanghai Univ Tradit Chinese Med, Tumor Inst Tradit Chinese Med, Longhua Hosp, Shanghai 200032, Peoples R China.
   [Liu, Jiyong; Wang, Zhengtao] Shanghai Univ Tradit Chinese Med, Key Lab Standardizat Chinese Med, Minist Educ, Shanghai 201210, Peoples R China.
   [Ying, Qi Liang Mao] Fudan Univ, Shanghai Med Coll, Dept Integrat Med & Neurobiol, Shanghai 200032, Peoples R China.
   [Fong, Harry] Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA.
C3 University System of Maryland; University of Maryland Baltimore;
   Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine; Fudan University; University of
   Illinois System; University of Illinois Chicago; University of Illinois
   Chicago Hospital
RP Lao, LX (通讯作者)，Univ Maryland, Ctr Integrat Med, 520 W Lombard St,Suite 204, Baltimore, MD 21201 USA.
EM xulq67@gmail.com; llao@compmed.umm.edu
RI Zhang, Ruixin/LBI 2317 2024; Dong, Chang Sheng/HCH 9181 2022; Lao,
   Lixing/P 9107 2019; Jiao, Liying/C 6307 2011; Wang,
   Zhengtao/AAH 7360 2019
OI Dong, Chang Sheng/0000 0001 8385 7904; Lao, Lixing/0000 0003 0198 9714;
   Wang, Zhengtao/0000 0003 2797 4625
FU National Institutes of Health [1R03TW008375 01A1]; National Natural
   Science Foundation of China [81173225]
FX This work was supported by the National Institutes of Health (No:
   1R03TW008375 01A1) and the National Natural Science Foundation of China
   (No: 81173225). We would like to thank Dr. Lyn Lowry for her editorial
   support.
CR Abildgaard N, 2003, BRIT J HAEMATOL, V120, P235, DOI 10.1046/j.1365 2141.2003.04050.x
   Adami S, 1997, CANCER, V80, P1674, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1674::AID CNCR18>3.0.CO;2 X
   [Anonymous], CLIN J TRADIT CHIN M
   BANNING A, 1991, PAIN, V45, P45, DOI 10.1016/0304 3959(91)90163 R
   BENSKY D., 1993, CHINESE HERBAL MED M
   Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018 199819030 00002
   Chen T., 2006, CHINESE J INFORM TCM, V13, P7
   Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542
   *CHIN STAT ADM TRA, 1999, TEST GUID SAF EV NEW
   Cleary JF, 2007, J PALLIAT MED, V10, P1369, DOI 10.1089/jpm.2007.9842
   Clohisy DR, 2000, CLIN ORTHOP RELAT R, P104
   Davies NM, 2004, J PHARM PHARM SCI, V7, P332
   Delaisse Jean Marie, 1992, P289
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Fan AY, 2005, J ALTERN COMPLEM MED, V11, P323, DOI 10.1089/acm.2005.11.323
   FDA CDER/FDA, 2004, GUID IND BOT DRUG PR
   Gad SC., 2002, DRUG SAFETY EVALUATI
   Ghilardi JR, 2005, J NEUROSCI, V25, P3126, DOI 10.1523/JNEUROSCI.3815 04.2005
   Gözüm S, 2003, CANCER NURS, V26, P230
   Gutgsell Terence, 2003, Am J Hosp Palliat Care, V20, P140, DOI 10.1177/104990910302000213
   He LH, 2011, ANAL SCI, V27, P433, DOI 10.2116/analsci.27.433
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   INTURRISI CE, 1989, CANCER, V63, P2308, DOI 10.1002/1097 0142(19890601)63:11<2308::AID CNCR2820631141>3.0.CO;2 D
   KOIZUMI M, 1995, J CANCER RES CLIN, V121, P542, DOI 10.1007/BF01197767
   Krishna LKR, 2010, ANN ACAD MED SINGAP, V39, P790
   Lao L., 1999, TRADITIONAL CHINESE, P216
   Li RW, 2003, J ETHNOPHARMACOL, V85, P61, DOI 10.1016/S0378 8741(02)00339 2
   Liu Jiyong, 2009, Zhongguo Zhong Yao Za Zhi, V34, P2730
   Luger NM, 2001, CANCER RES, V61, P4038
   Paqueron X, 2003, ANESTHESIOLOGY, V99, P199, DOI 10.1097/00000542 200307000 00030
   Pargeon KL, 1999, J PAIN SYMPTOM MANAG, V18, P358, DOI 10.1016/S0885 3924(99)00097 4
   PASTERNAK GW, 1988, JAMA J AM MED ASSOC, V259, P1362, DOI 10.1001/jama.259.9.1362
   Plebani M, 1996, CLIN BIOCHEM, V29, P67, DOI 10.1016/0009 9120(95)02001 2
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Sareen R, 2011, CURR DRUG DELIV, V8, P407, DOI 10.2174/156720111795768013
   Schaffer D, 2006, MED J AUSTRALIA, V185, P501, DOI 10.5694/j.1326 5377.2006.tb00665.x
   Scheiman JM, 2001, AM J MANAG CARE, V7, pS10
   Sevcik MA, 2004, PAIN, V111, P169, DOI 10.1016/j.pain.2004.06.015
   Sheu MJ, 2009, J ETHNOPHARMACOL, V126, P332, DOI 10.1016/j.jep.2009.08.019
   Smith MR, 2006, CANCER TREAT REV, V32, P23, DOI 10.1016/S0305 7372(06)80006 X
   Strang P, 1998, ACTA ONCOL, V37, P641, DOI 10.1080/028418698429973
   Su SL, 2012, J ETHNOPHARMACOL, V139, P649, DOI 10.1016/j.jep.2011.12.013
   Tamada T, 2001, J BONE MINER METAB, V19, P45, DOI 10.1007/s007740170059
   Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896 6273(00)80564 4
   Virik K, 2000, Aust Fam Physician, V29, P1027
   Wang CH, 2011, ANAL BIOANAL CHEM, V401, P275, DOI 10.1007/s00216 011 5075 3
   White House Commission on Complementary and Alternative Medicine Commission, 2002, WHIT HOUS COMM COMPL
   Wilson KG, 2007, J CLIN ONCOL, V25, P1691, DOI 10.1200/JCO.2006.08.6801
   Xie F, 2008, J ETHNOPHARMACOL, V117, P463, DOI 10.1016/j.jep.2008.02.025
   Xu L, 2007, INTEGR CANCER THER, V6, P208, DOI 10.1177/1534735407305705
   Yu S, 2009, CHINESE MED J PEKING, V122, P2027, DOI 10.3760/cma.j.issn.0366 6999.2009.17.013
   Yuan CS, 2004, J CLIN PHARMACOL, V44, P1323, DOI 10.1177/0091270004267809
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
NR 54
TC 21
Z9 27
U1 0
U2 31
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD OCT 11
PY 2012
VL 143
IS 3
BP 905
EP 913
DI 10.1016/j.jep.2012.08.026
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 022UT
UT WOS:000309990000018
PM 22960543
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Stiers, PJ
   Stegen, S
   van Gastel, N
   Van Looveren, R
   Torrekens, S
   Carmeliet, G
AF Stiers, Pieter Jan
   Stegen, Steve
   van Gastel, Nick
   Van Looveren, Riet
   Torrekens, Sophie
   Carmeliet, Geert
TI Inhibition of the Oxygen Sensor PHD2 Enhances Tissue Engineered
   Endochondral Bone Formation
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BIOENGINEERING; IMPLANTS; CHONDROCYTE AND CARTILAGE BIOLOGY; PARACRINE
   PATHWAYS; ANIMAL MODELS
ID STEM CELLS; MATURE OSTEOBLASTS; PROGENITOR CELLS; MICE LACKING;
   ANGIOGENESIS; VEGF; CARTILAGE; OSSIFICATION; HIF 1 ALPHA; HYPOXIA
AB Tissue engineering holds great promise for bone regenerative medicine, but clinical translation remains challenging. An important factor is the low cell survival after implantation, primarily caused by the lack of functional vasculature at the bone defect. Interestingly, bone development and repair initiate predominantly via an avascular cartilage template, indicating that chondrocytes are adapted to limited vascularization. Given these advantageous properties of chondrocytes, we questioned whether tissue engineered cartilage intermediates implanted ectopically in mice are able to form bone, even when the volume size increases. Here, we show that endochondral ossification proceeds efficiently when implant size is limited (<= 30 mm(3)), but chondrogenesis and matrix synthesis are impaired in the center of larger implants, leading to a fibrotic core. Increasing the level of angiogenic growth factors does not improve this outcome, because this strategy enhances peripheral bone formation, but disrupts the conversion of cartilage into bone in the center, resulting in a fibrotic core, even in small implants. On the other hand, activation of hypoxia signaling in cells before implantation stimulates chondrogenesis and matrix production, which culminates in enhanced bone formation throughout the entire implant. Together, our results show that induction of angiogenesis alone may lead to adverse effects during endochondral bone repair, whereas activation of hypoxia signaling represents a superior therapeutic strategy to improve endochondral bone regeneration in large tissue engineered implants. (c) 2018 American Society for Bone and Mineral Research.
C1 [Stiers, Pieter Jan; Stegen, Steve; van Gastel, Nick; Van Looveren, Riet; Torrekens, Sophie; Carmeliet, Geert] Katholieke Univ Leuven, Lab Clin & Expt Endocrinol, Dept Chron Dis Metab & Ageing, Leuven, Belgium.
   [Stiers, Pieter Jan; Stegen, Steve; van Gastel, Nick; Carmeliet, Geert] Katholieke Univ Leuven, Div Skeletal Tissue Engn, Prometheus, Leuven, Belgium.
C3 KU Leuven; KU Leuven
RP Carmeliet, G (通讯作者)，Lab Clin & Expt Endocrinol, Herestr 49 Bus 902, B 3000 Leuven, Belgium.
EM geert.carmeliet@kuleuven.be
RI ; van Gastel, Nick/P 7610 2018
OI Stegen, Steve/0000 0002 4471 6401; van Gastel, Nick/0000 0002 0563 3590
FU Hercules Foundation [AKUL/11/033]; Fund for Scientific Research Flanders
   [FWO: G.096414, G0A4216N]; Research Foundation Flanders [FWO/12H5917N];
   BOF KU Leuven GOA project [3M120209]
FX The TCS SP8 MP system used for intravital imaging at the VIB KU Leuven
   Centre for Cancer Biology was funded by a structural grant from the
   Hercules Foundation (AKUL/11/033). GC acknowledges funding support from
   the Fund for Scientific Research Flanders (FWO: G.096414, G0A4216N). PJS
   is a fellow from the Agency for Innovation by Science and Technology in
   Flanders (IWT). SS is financed by a postdoctoral grant of the Research
   Foundation Flanders (FWO/12H5917N). NvG is funded by BOF KU Leuven GOA
   project 3M120209. This work is part of Prometheus, the KU Leuven R&D
   Division of Skeletal Tissue Engineering. We thank Karen Moermans, Ingrid
   Stockmans, and Shauni Loopmans for excellent technical assistance. The
   collagen type I dsRed mouse and pJ320 plasmid were kindly provided by
   Sunichi Murakami. pWPXLd was a gift from Didier Trono (Addgene #12258).
CR Amarilio R, 2007, DEVELOPMENT, V134, P3917, DOI 10.1242/dev.008441
   Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Aragonés J, 2009, CELL METAB, V9, P11, DOI 10.1016/j.cmet.2008.10.001
   Aro E, 2015, J BIOL CHEM, V290, P16964, DOI 10.1074/jbc.M115.662635
   Aro E, 2012, J BIOL CHEM, V287, P37134, DOI 10.1074/jbc.M112.352872
   Becquart P, 2012, TISSUE ENG PT A, V18, P2084, DOI [10.1089/ten.TEA.2011.0690, 10.1089/ten.tea.2011.0690]
   Benders KEM, 2013, TRENDS BIOTECHNOL, V31, P169, DOI 10.1016/j.tibtech.2012.12.004
   Bose S, 2012, TRENDS BIOTECHNOL, V30, P546, DOI 10.1016/j.tibtech.2012.07.005
   Bourgine PE, 2014, P NATL ACAD SCI USA, V111, P17426, DOI 10.1073/pnas.1411975111
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Chaudhary NI, 2007, EUR RESPIR J, V29, P976, DOI 10.1183/09031936.00152106
   Colnot C, 2009, J BONE MINER RES, V24, P274, DOI 10.1359/JBMR.081003
   Dennis SC, 2015, TISSUE ENG PART B RE, V21, P247, DOI [10.1089/ten.teb.2014.0419, 10.1089/ten.TEB.2014.0419]
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   Freeman FE, 2017, TISSUE ENG PART B RE, V23, P128, DOI [10.1089/ten.teb.2016.0197, 10.1089/ten.TEB.2016.0197]
   Furuya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02541 w
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Geurtzen K, 2014, DEVELOPMENT, V141, P2225, DOI 10.1242/dev.105817
   Grayson WL, 2015, NAT REV ENDOCRINOL, V11, P140, DOI 10.1038/nrendo.2014.234
   Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   Laschke MW, 2006, TISSUE ENG, V12, P2093, DOI 10.1089/ten.2006.12.2093
   Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925 4773(01)00601 3
   Maes C, 2004, J CLIN INVEST, V113, P188, DOI 10.1172/JCI200419383
   Maes C, 2012, NAT REV RHEUMATOL, V8, P358, DOI 10.1038/nrrheum.2012.36
   Maes C, 2012, J BONE MINER RES, V27, P596, DOI 10.1002/jbmr.1487
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Maes C, 2010, EMBO J, V29, P424, DOI 10.1038/emboj.2009.361
   Marsano A, 2016, STEM CELL TRANSL MED, V5, P1730, DOI 10.5966/sctm.2015 0321
   Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020
   Provot S, 2007, J CELL BIOL, V177, P451, DOI 10.1083/jcb.200612023
   Rabie ABM, 2002, ANGLE ORTHOD, V72, P431
   Sakaguchi Y, 2005, ARTHRITIS RHEUM US, V52, P2521, DOI 10.1002/art.21212
   Schipani E, 2001, GENE DEV, V15, P2865
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366
   Smith BD, 2015, NAT REV RHEUMATOL, V11, P213, DOI 10.1038/nrrheum.2015.27
   Stegen S, 2016, BONE, V87, P176, DOI 10.1016/j.bone.2016.03.014
   Stegen S, 2016, CELL METAB, V23, P265, DOI 10.1016/j.cmet.2016.01.002
   Stegen S, 2015, BONE, V70, P19, DOI 10.1016/j.bone.2014.09.017
   Stiers PJ, 2018, JBMR PLUS, V2, P92, DOI 10.1002/jbm4.10028
   Stiers PJ, 2016, MOL CELL ENDOCRINOL, V432, P106, DOI 10.1016/j.mce.2015.12.024
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Tarkka T, 2003, J GENE MED, V5, P560, DOI 10.1002/jgm.392
   van Gastel N, 2014, STEM CELLS, V32, P2407, DOI 10.1002/stem.1783
   van Gastel N, 2012, STEM CELLS, V30, P2460, DOI 10.1002/stem.1210
   Zimmermann CE, 2011, TISSUE ENG PT A, V17, P1147, DOI [10.1089/ten.tea.2009.0577, 10.1089/ten.TEA.2009.0577]
NR 46
TC 15
Z9 19
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2019
VL 34
IS 2
BP 333
EP 348
DI 10.1002/jbmr.3599
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HL3ZC
UT WOS:000458653600014
PM 30452097
OA Bronze
DA 2025 08 17
ER

PT J
AU Wang, T
   Sun, CH
   Zhong, HB
   Gong, Y
   Cui, ZK
   Xie, J
   Wang, YP
   Liang, C
   Cao, HH
   Chen, XR
   Zou, ZP
   Li, SF
   Bai, XC
AF Wang, Ting
   Sun, Chun han
   Zhong, Hao bo
   Gong, Yan
   Cui, Zhong Kai
   Xie, Jing
   Wang, Yan peng
   Liang, Chuang
   Cao, He he
   Chen, Xiao rui
   Zou, Zhi peng
   Li, Sheng fa
   Bai, Xiao chun
TI N (3 methoxybenzyl) (9Z,12Z,15Z) octadecatrienamide promotes bone
   formation via the canonical Wnt/β catenin signaling pathway
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE bone metabolism; Maca;
   N (3 methoxybenzyl) (9Z,12Z,15Z) octadecatrienamide; postmenopausal
   osteoporosis; Wnt/beta catenin
ID MACA LEPIDIUM MEYENII; DIFFERENTIATION; PATHOGENESIS; PHOSPHORYLATION;
   POLYSACCHARIDE; OSTEOPOROSIS; OSTEOBLAST; RESORPTION; DIAGNOSIS; WALP.
AB Osteoporosis is characterized by low bone mineral density and microarchitectural deterioration of bone tissue. N (3 methoxybenzyl) (9Z,12Z,15Z) octadecatrienamide (MBOC) is one of the macamides isolated from Maca (Lepidium meyenii Walp.), a cruciferous plant from the Andes of Peru. In this study, C3H/10T1/2 mesenchymal stem cells were treated with MBOC in osteogenic induction medium. An ovariectomized (OVX) mouse model was used to investigate the effect of 1 month MBOC treatment on the prevention of postmenopausal osteoporosis. Remarkably, trabecular thickness, trabecular number, and bone volume/tissue volume of the distal femoral metaphysis were significantly increased in OVX+MBOC mice compared with OVX mice, as revealed by microcomputed tomography analysis. Trabecular separation was decreased in OVX+MBOC mice compared with OVX mice. Consistently, MBOC increased the levels of osteocalcin and runt related transcription factor 2 in OVX mice, as well as the expression of runt related transcription factor 2, osterix, and alkaline phosphatase in C3H/10T1/2 cells. Mechanistically, MBOC activates the canonical Wnt/beta catenin signaling pathway via inhibiting phosphorylation of GSK 3 beta at Tyr216 and maintaining beta catenin expression. Collectively, the current study demonstrates the robustness of MBOC in the induction of mesenchymal stem cells osteogenic differentiation and consequent bone formation, suggesting that MBOC may be a potentially effective drug to treat postmenopausal osteoporosis.
C1 [Wang, Ting; Gong, Yan; Cui, Zhong Kai; Xie, Jing; Wang, Yan peng; Liang, Chuang; Cao, He he; Chen, Xiao rui; Zou, Zhi peng; Bai, Xiao chun] Southern Med Univ, Sch Basic Med Sci, Minist Educ, Key Lab Mental Hlth,Dept Cell Biol, Guangzhou, Guangdong, Peoples R China.
   [Sun, Chun han; Zhong, Hao bo; Li, Sheng fa] Huizhou First Peoples Hosp, Dept Orthoped, 20 South Sanxin Ave, Huizhou 516000, Guangdong, Peoples R China.
   [Bai, Xiao chun] Southern Med Univ, Affiliated Hosp 3, Acad Orthoped, Guangdong Prov Key Lab Bone & Joint Degenerat Dis, Guangzhou, Guangdong, Peoples R China.
C3 Southern Medical University   China; Southern Medical University   China
RP Li, SF (通讯作者)，Huizhou First Peoples Hosp, Dept Orthoped, 20 South Sanxin Ave, Huizhou 516000, Guangdong, Peoples R China.; Zou, ZP; Bai, XC (通讯作者)，Southern Med Univ, Sch Basic Med Sci, Dept Cell Biol, 1838 North Guangzhou Ave, Guangzhou 510515, Guangdong, Peoples R China.
EM 40184665@qq.com; 759529552@qq.com; baixc15@smu.edu.cn
RI ; Cui, Zhong Kai/K 2051 2019; Li, Shengfa/KOD 4698 2024; Li (li),
   Shengfa (sheng fa)/KOD 4698 2024; Tamburini, jerome/LBH 1975 2024
OI Xie, Jing/0000 0001 5624 458X; Li (li), Shengfa (sheng
   fa)/0009 0005 6801 7102; Cui, Zhong Kai/0000 0003 3112 9379; Wang,
   Ting/0000 0002 1309 0194; 
FU Guangdong Provincial Bureau of Traditional Chinese Medicine [20161254];
   National Natural Science Foundation of China [81560213]; Huizhou Science
   and Technology Plan Project [2015B040010004]
FX Research project of Guangdong Provincial Bureau of Traditional Chinese
   Medicine, Grant/Award Number: 20161254; National Natural Science
   Foundation of China, Grant/Award Number: 81560213; Guangdong Provincial
   Bureau of Traditional Chinese Medicine, Grant/Award Number: 20161254;
   Huizhou Science and Technology Plan Project, Grant/Award Number:
   2015B040010004
CR Antika LD, 2017, J NUTR BIOCHEM, V49, P42, DOI 10.1016/j.jnutbio.2017.07.014
   BAIN SD, 1993, J BONE MINER RES, V8, P435
   CHAMBERS TJ, 1982, J PATHOL, V136, P27, DOI 10.1002/path.1711360104
   CHOW J, 1992, J CLIN INVEST, V89, P74, DOI 10.1172/JCI115588
   Cselenyi CS, 2008, P NATL ACAD SCI USA, V105, P8032, DOI 10.1073/pnas.0803025105
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Diab DL, 2012, ENDOCRIN METAB CLIN, V41, P487, DOI 10.1016/j.ecl.2012.04.007
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gonzales C, 2010, FORSCH KOMPLEMENTMED, V17, P137, DOI 10.1159/000315214
   Gonzales GF, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/193496
   GUEGUEN R, 1995, J BONE MINER RES, V10, P2017
   Hartigan JA, 1999, J BIOL CHEM, V274, P21395, DOI 10.1074/jbc.274.30.21395
   Hendrickx G, 2015, NAT REV RHEUMATOL, V11, P462, DOI 10.1038/nrrheum.2015.48
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Huang YJ, 2018, NAT PRODUCT BIOPROSP, V8, P405, DOI 10.1007/s13659 018 0185 7
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lee MS, 2016, MATURITAS, V92, P64, DOI 10.1016/j.maturitas.2016.07.013
   Li J, 2017, INT J BIOL MACROMOL, V95, P1305, DOI 10.1016/j.ijbiomac.2016.11.031
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Matsumoto Y, 2013, STEROIDS, V78, P513, DOI 10.1016/j.steroids.2013.02.011
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   McCollom MM, 2005, PHYTOCHEM ANALYSIS, V16, P463, DOI 10.1002/pca.871
   Piao S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004046
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Samuels A, 1999, J BONE MINER RES, V14, P178, DOI 10.1359/jbmr.1999.14.2.178
   Sandhu SK, 2011, J CLIN PATHOL, V64, P1042, DOI 10.1136/jcp.2010.077842
   Seeman E, 2002, LANCET, V359, P1841, DOI 10.1016/S0140 6736(02)08706 8
   Tang QQ, 2004, P NATL ACAD SCI USA, V101, P9607, DOI 10.1073/pnas.0403100101
   Valentová K, 2008, FOOD CHEM TOXICOL, V46, P1006, DOI 10.1016/j.fct.2007.10.031
   Valentova Katerina, 2003, Biomedical Papers (Olomouc), V147, P119
   Valerio Luis G Jr, 2005, Toxicol Rev, V24, P11, DOI 10.2165/00139709 200524010 00002
   Wu NN, 2010, ACTA BIOCH BIOPH SIN, V42, P699, DOI 10.1093/abbs/gmq075
   Zhang LJ, 2017, INT J BIOL MACROMOL, V99, P63, DOI 10.1016/j.ijbiomac.2017.01.125
   Zhang YZ, 2006, J ETHNOPHARMACOL, V105, P274, DOI 10.1016/j.jep.2005.12.013
NR 36
TC 10
Z9 11
U1 1
U2 34
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD APR
PY 2019
VL 33
IS 4
BP 1074
EP 1083
DI 10.1002/ptr.6301
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HW7XM
UT WOS:000466903300023
PM 30768733
DA 2025 08 17
ER

PT J
AU Kovrlija, I
   Panczyszyn, E
   Demir, O
   Laizane, M
   Corazzari, M
   Locs, J
   Loca, D
AF Kovrlija, Ilijana
   Panczyszyn, Elzbieta
   Demir, Oznur
   Laizane, Marta
   Corazzari, Marco
   Locs, Janis
   Loca, Dagnija
TI Doxorubicin loaded octacalcium phosphate particles as controlled release
   drug delivery systems: Physico chemical characterization, in
   vitro drug release and evaluation of cell death pathway
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Octacalcium phosphate; Doxorubicin; Drug delivery; Apoptosis;
   Osteosarcoma cells
ID BONE; DIFFERENTIATION; PROLIFERATION; INVOLVEMENT; OSTEOBLAST;
   RESISTANCE; MECHANISM; APOPTOSIS
AB Mastering new and efficient ways to obtain successful drug delivery systems (DDS) with controlled release became a paramount quest in the scientific community. Increase of malignant bone tumors and the necessity to optimize an approach of localized drug delivery require research to be even more intensified. Octacalcium phosphate (OCP), with a number of advantages over current counterparts is extensively used in bone engineering. The aim of the present research was to synthesize bioactive and biocompatible doxorubicin (DOX) containing OCP particles. DOX OCP was successfully obtained in situ in an exhaustive range of added drug (1 20 wt%, theoretical loading). Based on XRD, above 10 wt% of DOX, OCP formation was inhibited and the obtained product was low crystalline alpha TCP. In vitro drug release was performed in pH 7.4 and 6.0. In both pH environments DOX had a continuous release over six weeks. However, the initial drug burst for pH 7.4, in the first 24 h, ranged from 15.9 +/  1.3 % to 33.5 +/  12 % and for pH 6.0 23.7 +/  1.5 % to 36.2 +/  12 %.The DOX OCP exhibited an inhibitory effect on viability of osteosarcoma cell lines MG63, U2OS and HOS. In contrast, MC3T3 E1 cells (IC50 > 0.062 mu M) displayed increased viability and proliferation from 3rd to 7th day. Testing of the DDS on ferroptotic markers (CHAC1, ACSL4 and PTGS2) showed that OCP DOX does not induce ferroptotic cell death. Moreover, the evaluation of protein levels of cleaved PARP, by western blotting analysis, corroborated that apoptosis is the main pathway of programmed cell death in osteosarcoma cells induced by DOX OCP.
C1 [Kovrlija, Ilijana; Demir, Oznur; Laizane, Marta; Locs, Janis; Loca, Dagnija] Riga Tech Univ, Inst Biomat & Bioengn, Fac Nat Sci & Technol, Pulka 3, LV 1007 Riga, Latvia.
   [Kovrlija, Ilijana; Demir, Oznur; Laizane, Marta; Locs, Janis; Loca, Dagnija] Riga Tech Univ, Baltic Biomat Ctr Excellence, Headquarters, Riga, Latvia.
   [Panczyszyn, Elzbieta; Corazzari, Marco] Univ Piemonte Orientale, Dept Hlth Sci, I 28100 Novara, Italy.
   [Panczyszyn, Elzbieta; Corazzari, Marco] Univ Piemonte Orientale, Ctr Translat Res Autoimmune & Allerg Dis CAAD, I 28100 Novara, Italy.
   [Corazzari, Marco] Univ Piemonte Orientale, Interdisciplinary Res Ctr Autoimmune Dis IRCAD, Novara, Italy.
   [Loca, Dagnija] Riga Tech Univ, Inst Biomat & Bioengn, Pulka St 3, LV 1007 Riga, Latvia.
C3 Riga Technical University; Riga Technical University; University of
   Eastern Piedmont Amedeo Avogadro; University of Eastern Piedmont Amedeo
   Avogadro; University of Eastern Piedmont Amedeo Avogadro; Riga Technical
   University
RP Loca, D (通讯作者)，Riga Tech Univ, Inst Biomat & Bioengn, Pulka St 3, LV 1007 Riga, Latvia.
EM dagnija.loca@rtu.lv
RI ; Oğuz, Öznur/ABH 1286 2020; Corazzari, Marco/B 4631 2019; Corazzari,
   Marco/J 5825 2019
OI Demir, Oznur/0000 0002 1783 7582; Corazzari, Marco/0000 0002 6246 5968;
   Kovrlija, Ilijana/0000 0002 4796 0469
FU European Union [860462, 857287]
FX The authors acknowledge the financial support for granting Open Access
   and access to the infrastructure and expertise from the European Union's
   Horizon 2020 Research and Innovation programme under grant agreement
   [No. 857287 (BBCE) ] , as well as the European Union's Horizon 2020
   Research and Innovation programme under the Marie Sklodowska Curie grant
   agreement [No. 860462 (PREMUROSA) ] .
CR Akutsu M, 1995, EUR J CANCER, V31A, P2341, DOI 10.1016/0959 8049(95)00448 3
   Anada T, 2008, KEY ENG MATER, V361 363, P31, DOI 10.4028/www.scientific.net/KEM.361 363.31
   Banerjee D, 2019, MATER TODAY CHEM, V12, P200, DOI 10.1016/j.mtchem.2018.11.008
   Bordbar Khiabani A, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241713135
   Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478 811X 8 31
   Chen X, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.637162
   Chow L.C., 2001, Monographs in Oral Science, V18, DOI [10.1007/springerreference_39293, DOI 10.1007/SPRINGERREFERENCE_39293]
   Cree IA, 2017, BMC CANCER, V17, DOI 10.1186/s12885 016 2999 1
   Demir O, 2024, BIOMATER ADV, V157, DOI 10.1016/j.bioadv.2023.213731
   Dorozhkin SV, 2016, CERAM INT, V42, P6529, DOI 10.1016/j.ceramint.2016.01.062
   El Bayoumil T, 2009, CLIN CANCER RES, V15, P1973, DOI 10.1158/1078 0432.CCR 08 2392
   Fu JK, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120537
   Gagliardi M, 2023, CELL DEATH DISCOV, V9, DOI 10.1038/s41420 023 01394 1
   Gautier J, 2012, INT J PHARMACEUT, V423, P16, DOI 10.1016/j.ijpharm.2011.06.010
   Genin F.Y., 2004, United States Patent, Patent No. [1(12), 112]
   Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11 10 1121
   Honda Y, 2007, J BIOMED MATER RES B, V80B, P281, DOI 10.1002/jbm.b.30595
   Iafisco M, 2016, J MATER CHEM B, V4, P57, DOI 10.1039/c5tb01524c
   Ito N, 2014, MATER LETT, V120, P94, DOI 10.1016/j.matlet.2014.01.040
   Jablonska Trypuc A, 2017, MOLECULES, V22, DOI 10.3390/molecules22071106
   Ji P, 2015, ONCOL RES, V22, P185, DOI 10.3727/096504015X14343704124340
   Jiang XD, 2022, MATER CHEM PHYS, V276, DOI 10.1016/j.matchemphys.2021.125440
   Jiang XJ, 2021, NAT REV MOL CELL BIO, V22, P266, DOI 10.1038/s41580 020 00324 8
   Kovrlija I., 2023, Biomolecules, P13
   Kovrlija I, 2021, ACTA BIOMATER, V135, P40, DOI 10.1016/j.actbio.2021.08.021
   Lebugle A, 2002, BIOMATERIALS, V23, P3517, DOI 10.1016/S0142 9612(02)00082 0
   LEGEROS RZ, 1989, SCANNING MICROSCOPY, V3, P129
   Li J, 2016, ONCOTARGET, V7, P44763, DOI 10.18632/oncotarget.8206
   Li SZ, 2023, J CANCER RES CLIN, V149, P6785, DOI 10.1007/s00432 023 04614 4
   Lin RY, 2005, BIOMATERIALS, V26, P4476, DOI 10.1016/j.biomaterials.2004.11.014
   Liu X, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.1031779
   Liu Y, 2022, MATER TODAY BIO, V14, DOI 10.1016/j.mtbio.2022.100227
   Liu Y, 2021, ACTA BIOMATER, V131, P555, DOI 10.1016/j.actbio.2021.07.016
   Loca D, 2015, MAT SCI ENG C MATER, V49, P106, DOI 10.1016/j.msec.2014.12.075
   Martinez T, 2021, FUTURE ONCOL, V17, P3511, DOI 10.2217/fon 2021 0128
   MATHEW M, 1988, J CRYST SPECTROSC, V18, P235, DOI 10.1007/BF01194315
   Miotto G, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101328
   Modh H, 2021, INT J PHARMACEUT, V608, DOI 10.1016/j.ijpharm.2021.121073
   Mosina M, 2022, ACTA BIOMATER, V150, P48, DOI 10.1016/j.actbio.2022.07.063
   Nussinov R, 2021, DRUG RESIST UPDATE, V59, DOI 10.1016/j.drup.2021.100796
   OLSON RD, 1990, FASEB J, V4, P3076, DOI 10.1096/fasebj.4.13.2210154
   Parent M, 2017, J CONTROL RELEASE, V252, P1, DOI 10.1016/j.jconrel.2017.02.012
   Pelss J, 2011, ADV MATER RES SWITZ, V284 286, P1770, DOI 10.4028/www.scientific.net/AMR.284 286.1770
   Pfeffer CM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020448
   Pinski J, 2001, CANCER RES, V61, P6372
   Pisa R, 2020, NAT CHEM BIOL, V16, P817, DOI 10.1038/s41589 020 0596 8
   Pylostomou A, 2023, BIOMATER ADV, V148, DOI 10.1016/j.bioadv.2023.213367
   Qi C, 2015, CHEM ASIAN J, V10, P2503, DOI 10.1002/asia.201500667
   Qiu C, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.746030
   Roncuzzi L, 2014, ONCOL REP, V32, P389, DOI 10.3892/or.2014.3181
   Saito S, 2021, ACTA BIOMATER, V129, P309, DOI 10.1016/j.actbio.2021.05.017
   Shi HS, 2019, APPL MATER TODAY, V15, P100, DOI 10.1016/j.apmt.2019.01.002
   Siebler T, 2002, HORM RES, V58, P80, DOI 10.1159/000064769
   Singh V., 2022, Sci, V4, DOI [DOI 10.3390/SCI4020015, 10.3390/sci4020015]
   Sritharan S, 2021, LIFE SCI, V278, DOI 10.1016/j.lfs.2021.119527
   Suzuki O, 2020, WOODH PUBL SER BIOM, P1, DOI 10.1016/C2017 0 01051 0
   Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042 7158.2012.01567.x
   Tang QL, 2011, NANOMED NANOTECHNOL, V7, P428, DOI 10.1016/j.nano.2010.12.005
   Tani T, 2006, IN VIVO, V20, P55
   Nguyen TTT, 2016, GENES CELLS, V21, P226, DOI 10.1111/gtc.12346
   Thorn CF, 2011, PHARMACOGENET GENOM, V21, P440, DOI 10.1097/FPC.0b013e32833ffb56
   van der Zanden SY, 2021, FEBS J, V288, P6095, DOI 10.1111/febs.15583
   Wang AZ, 2012, ANNU REV MED, V63, P185, DOI 10.1146/annurev med 040210 162544
   Wang JW, 2009, J BIOMED MATER RES A, V90A, P664, DOI 10.1002/jbm.a.32128
   Wang SW, 2004, J BIOL CHEM, V279, P25535, DOI 10.1074/jbc.M400944200
   Wang X, 2022, ACTA PHARM SIN B, V12, P3567, DOI 10.1016/j.apsb.2022.03.020
   Wen SH, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935 018 0625 9
   Wilson BE, 2019, LANCET ONCOL, V20, P769, DOI 10.1016/S1470 2045(19)30163 9
   Yang XY, 2010, J PHYS CHEM C, V114, P6265, DOI 10.1021/jp911576f
   Yao ZT, 2020, CANCER RES, V80, P1171, DOI 10.1158/0008 5472.CAN 19 2348
   Yin J, 2018, TOXICOL IN VITRO, V51, P1, DOI 10.1016/j.tiv.2018.05.001
NR 71
TC 11
Z9 11
U1 2
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD MAR 25
PY 2024
VL 653
AR 123932
DI 10.1016/j.ijpharm.2024.123932
EA FEB 2024
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA NR9O9
UT WOS:001202300700001
PM 38387818
OA hybrid
DA 2025 08 17
ER

PT J
AU Campos, JF
   Mierzwa, AGH
   Freitas Jesus, M
   Lazaretti Castro, M
   Nonaka, KO
   Reginato, RD
AF Campos, Jenifer Freitas
   Hidalgo Mierzwa, Aline Gomes
   Freitas Jesus, Mariana
   Lazaretti Castro, Marise
   Nonaka, Keico Okino
   Reginato, Rejane Daniele
TI Mechanical Vibration Associated With Intermittent PTH Improves Bone
   Microarchitecture in Ovariectomized Rats
SO JOURNAL OF CLINICAL DENSITOMETRY
LA English
DT Article
DE Bone densitometry; bone histomorphometry; intermittent PTH; mechanical
   vibration; ovariec tomized rats
ID PARATHYROID HORMONE 1 34; WHOLE BODY VIBRATION; HIGH FREQUENCY;
   POSTMENOPAUSAL WOMEN; STRONTIUM RANELATE; LOW INTENSITY; SIGNALS;
   ALENDRONATE; PARAMETERS; FRACTURES
AB Introduction: Intermittent 1 34 parathyroid hormone (iPTH) administration, a bone forming treatment, is widely used as a therapy for severe osteoporosis. It can only be used for a maximum of 24 mo and must be followed by an antiresorptive drug to retain the new formed tissue. Mechanical load, in the form of low intensity and high frequency vibration, has received considerable attention due to its ability to prevent bone loss. Aim: To investigate the ability of whole body mechanical vibration (MV) to potentiate the anabolic effects of iPTH and to inhibit bone resorption following discontinuation of iPTH treatment in estrogen deficient rats. Methodology: Fifty four 6 month old female Wistar rats were ovariectomized (OVX) or sham operated. After 5 mo, they were divided into 7 groups: Sham   non OVX; Control   OVX, vehicle for 60 d; MV   OVX, submitted to MV for 60 d; PTH60d   OVX, injected with iPTH for 60 d; PTH+MV   OVX, injected with iPTH combined with MV for 60 d; PTH30d   OVX, injected with iPTH for 30 d, and untreated for 30 d; PTH30d/MV30d OVX, injected with iPTH for 30 d, followed by MV for 30 d. Bone mineral density (BMD) and body composition (lean mass and fat) were evaluated at OVX (T0), the beginning (T1), and at the end (T2) of treatments by dual X ray absorptiometry (DXA). Femurs were processed for histomorphometry (bone volume BV/TV and cortical thickness Ct.Th) and tibias for biomechanical test. Results: Body composition and BMD were similar among the groups at T0. In T2, MV presented higher fat than other groups (except PTH60d) and PTH30d/MV30d showed greater lean mass than Control. At T1, Sham presented the highest BMD, but between T1 vs T2 there was an increase in all iPTH treated groups. At T2, BMD was higher in PTH60d and PTH+MV than in the Control and MV groups. The highest BV/TV was observed in the PTH +MV group, followed by PTH60d. Cortical thickness was increased in PTH60d and PTH+MV compared to Sham. Vibration applied post iPTH (PTH30d/MV30d) improved the force at failure in tibias when compared to Sham and Control groups. Conclusion: MV potentiated iPTH anabolic effects in cancellous bone; however, MV was unable to maintain bone mass after stopping iPTH in ovariectomized rats.
C1 [Campos, Jenifer Freitas; Hidalgo Mierzwa, Aline Gomes; Freitas Jesus, Mariana; Reginato, Rejane Daniele] Univ Fed Sao Paulo, Dept Morphol & Genet, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Lazaretti Castro, Marise] Univ Fed Sao Paulo, Dept Med, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Nonaka, Keico Okino] Univ Fed Sao Carlos, Dept Physiol Sci, Sao Carlos, SP, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao
   Paulo (UNIFESP); Universidade Federal de Sao Carlos
RP Reginato, RD (通讯作者)，Univ Fed Sao Paulo, Sch Med, Dept Morphol & Genet, Mineralized Tissue & Histol Res Lab,UNIFESP, Rua Botucatu,740 Vila Clementino, BR 04023900 Sao Paulo, SP, Brazil.
EM rejanedr.morf@epm.br
RI Castro, Marise/U 4478 2017; Campos, Jenifer/GVU 2637 2022; REGINATO,
   REJANE/G 6579 2013; Nonaka, Keico/E 3679 2012
OI REGINATO, REJANE/0000 0002 4370 9111; 
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   Brazil
FX The authors are grateful to Dr Orivaldo Lopes Silva (Professor of
   Bioengineering Graduate Program, University of Sao Paulo USP Sao Carlos)
   and Dr Monica Longo de Oliveira (Federal University of Sao
   Paulo UNIFESP) for providing the vibration platform, to Patricia dos
   Reis Sousa Goncalves (Federal University of Sao Paulo  UNIFESP) and
   Victor Fabricio (Federal University of Sao Carlos   UFSCar) for
   technical assistance. This work was supported by Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazil.
CR Alexander JM, 2001, J BONE MINER RES, V16, P1665, DOI 10.1359/jbmr.2001.16.9.1665
   Alliston T, 2014, CURR OSTEOPOROS REP, V12, P366, DOI 10.1007/s11914 014 0213 4
   [Anonymous], TER FORTEO COLT PEN
   Sasso GRD, 2015, GYNECOL ENDOCRINOL, V31, P980, DOI 10.3109/09513590.2015.1075198
   Davis SR, 2012, CLIMACTERIC, V15, P419, DOI 10.3109/13697137.2012.707385
   de Oliveira ML, 2010, BONE, V46, P1516, DOI 10.1016/j.bone.2010.02.009
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dutra MC, 2016, MENOPAUSE, V23, P870, DOI 10.1097/GME.0000000000000644
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Fangel R, 2014, J APPL BIOMATER FUNC, V12, P271, DOI 10.5301/jabfm.5000198
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Florencio Silva R, 2013, CLIMACTERIC, V16, P709, DOI 10.3109/13697137.2013.769096
   Fox J, 2006, CALCIFIED TISSUE INT, V79, P262, DOI 10.1007/s00223 006 0108 1
   Gusi N, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 92
   Hagino H, 2001, J BONE MINER METAB, V19, P244, DOI 10.1007/s007740170027
   Hoffmann DB, 2017, J BONE MINER METAB, V35, P31, DOI 10.1007/s00774 016 0736 0
   Jepsen DB, 2018, TRIALS, V19, DOI 10.1186/s13063 018 2551 5
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Judex S, 2010, J MUSCULOSKEL NEURON, V10, P3
   Judex S, 2007, J BIOMECH, V40, P1333, DOI 10.1016/j.jbiomech.2006.05.014
   Kim CH, 2003, J BONE MINER RES, V18, P2116, DOI 10.1359/jbmr.2003.18.12.2116
   Kimura S, 2017, OSTEOPOROSIS INT, V28, P1109, DOI 10.1007/s00198 016 3812 3
   Kurland ES, 2004, OSTEOPOROSIS INT, V15, P992, DOI 10.1007/s00198 004 1636 z
   Li M, 1997, BONE, V20, P55, DOI 10.1016/S8756 3282(96)00317 1
   Matsumoto T, 2016, CALCIFIED TISSUE INT, V98, P520, DOI 10.1007/s00223 015 0104 4
   Mierzwa AGH, 2017, OSTEOARTHR CARTILAGE, V25, P1179, DOI 10.1016/j.joca.2017.02.793
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Pacheco Costa R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/454162
   Reyes ML, 2011, J BONE MINER RES, V26, P1759, DOI 10.1002/jbmr.402
   Rubin C, 2006, AGE AGEING, V35, P32, DOI 10.1093/ageing/afl082
   Sato M, 2004, J BONE MINER RES, V19, P623, DOI 10.1359/JBMR.040112
   Singer A, 2015, MAYO CLIN PROC, V90, P53, DOI 10.1016/j.mayocp.2014.09.011
   STENSTROM A, 1982, ANAT EMBRYOL, V164, P9, DOI 10.1007/BF00301875
   Tastekin N, 2017, ARTHRITIS RHEUMATOL, V62, P1837
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
NR 36
TC 1
Z9 1
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1094 6950
EI 1559 0747
J9 J CLIN DENSITOM
JI J. Clin. Densitom.
PD JUL SEP
PY 2020
VL 23
IS 3
BP 511
EP 519
DI 10.1016/j.jocd.2018.09.003
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA OA7KO
UT WOS:000577959700024
PM 30327242
DA 2025 08 17
ER

PT J
AU Schmidt, JR
   Adamowicz, K
   Arend, L
   Lehmann, J
   List, M
   Poh, PSP
   Baumbach, J
   Kalkhof, S
   Laske, T
AF Schmidt, Johannes R.
   Adamowicz, Klaudia
   Arend, Lis
   Lehmann, Joerg
   List, Markus
   Poh, Patrina S. P.
   Baumbach, Jan
   Kalkhof, Stefan
   Laske, Tanja
TI Meta analysis of proteomics data from osteoblasts, bone, and blood:
   Insights into druggable targets, active factors, and potential
   biomarkers for bone biomaterial design
SO JOURNAL OF TISSUE ENGINEERING
LA English
DT Article
DE biomaterial; bone regeneration; module mining; drug repurposing;
   biomarker; proteomics; osteoblasts; blood plasma; extracellular
   vesicles; network enrichment; meta analysis
ID MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION; PHENETHYL
   ISOTHIOCYANATE; EXTRACELLULAR VESICLES; COMPUTATIONAL PLATFORM; GENE;
   EXPRESSION; DIHYDROARTEMISININ; NANOPARTICLES; REGENERATION
AB Non healing bone defects are a pressing public health concern accounting for one main cause for decreased life expectancy and quality. An aging population accompanied with increasing incidence of comorbidities, foreshadows a worsening of this socio economic problem. Conventional treatments for non healing bone defects prove ineffective for 5% 10% of fractures. Those challenges not only increase the patient's burden but also complicate medical intervention, underscoring the need for more effective treatment strategies and identification of patients at risk before treatment selection. To address this, our proteomic meta analysis aims to identify universally affected proteins and functions in the context of bone regeneration that can be utilized as novel bioactive biomaterial functionalizations, drug targets or therapeutics as well as analytical endpoints, or biomarkers in implant design and testing, respectively. We compiled 29 proteomic studies covering cellular models, extracellular vesicles, extracellular matrix, bone tissue, and liquid biopsies to address different tissue hierarchies and species. An innovative, integrated framework consisting of data harmonization, candidate protein selection, network construction, and functional enrichment as well as drug repurposing and protein scoring metrics was developed. To make this framework widely applicable to other research questions, we have published a detailed tutorial of our meta analysis process. We identified 51 proteins that are potentially important for bone healing. This includes well known ECM components such as collagens, fibronectin and periostin, and proteins less explored in bone biology like YWHAE, HSPG2, CCN1, HTRA1, IGFBP7, LGALS1, TGFBI, C3, SERPINA1, and ANXA1 that might be utilized in future bone biomaterial development. Furthermore, we discovered the compounds trifluoperazine, phenethyl isothiocyanate, quercetin, and artenimol, which target key proteins such as S100A4, YWHAZ, MMP2, and TPM4 providing the option to manipulate undesired processes in bone regeneration. This may open new ways for treatment options to face the increasing socio economic pressure of non healing bone defects.
C1 [Schmidt, Johannes R.; Lehmann, Joerg; Kalkhof, Stefan] Fraunhofer Inst Cell Therapy & Immunol IZI, Dept Preclin Dev & Validat, Leipzig, Germany.
   [Adamowicz, Klaudia; Arend, Lis; Baumbach, Jan; Laske, Tanja] Univ Hamburg, Inst Computat Syst Biol, Hamburg, Germany.
   [Arend, Lis; List, Markus] Tech Univ Munich, TUM Sch Life Sci, Data Sci Syst Biol, Freising Weihenstephan, Germany.
   [Lehmann, Joerg; Kalkhof, Stefan] Fraunhofer Cluster Excellence Immune mediated Dis, Leipzig, Germany.
   [List, Markus] Tech Univ Munich, Munich Data Sci Inst, Garching, Germany.
   [Poh, Patrina S. P.] Charite Univ Med Berlin, Julius Wolff Inst, Berlin Inst Hlth, Berlin, Germany.
   [Baumbach, Jan] Univ Southern Denmark, Dept Math & Comp Sci, Computat Biomed Lab, Odense, Denmark.
   [Kalkhof, Stefan] Univ Appl Sci Coburg, Inst Bioanal, Coburg, Germany.
C3 Fraunhofer Gesellschaft; Fraunhofer Germany; Fraunhofer Cell Therapy &
   Immunology; University of Hamburg; Technical University of Munich;
   Technical University of Munich; Humboldt University of Berlin; Free
   University of Berlin; Charite Universitatsmedizin Berlin; Berlin
   Institute of Health; University of Southern Denmark; Hochschule Coburg
RP Laske, T (通讯作者)，Univ Hamburg, Inst Computat Syst Biol, Fac Math Informat & Nat Sci, Albert Einstein Ring 8 10, Hamburg, 22761, Germany.; Kalkhof, S (通讯作者)，Fraunhofer Inst Cell Therapy & Immunol, Dept Preclin Dev & Validat, Perlickstr 1, D 04103 Leipzig, Germany.
EM stefan.kalkhof@izi.fraunhofer.de; tanja.laske@uni hamburg.de
RI ; Poh, Patrina/AAQ 3975 2021; Kalkhof, Stefan/Z 2000 2019; List,
   Markus/I 2020 2019; Schmidt, Johannes/HIK 1379 2022
OI Schmidt, Johannes/0000 0002 2026 9715; Adamowicz,
   Klaudia/0000 0002 9418 4386; Arend, Lis/0000 0001 7990 8385; Laske,
   Tanja/0000 0002 7922 7595
FU German Federal Ministry of Education and Research (BMBF) [01ZX1910B,
   01ZX1910D, 01ZX2210B, 01ZX2210D]; Preclinical confirmatory study
   framework (REGAGforBone) [01KC2304C]; Excellence Strategy of the Federal
   Government; Lander
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by the German Federal Ministry of Education and Research
   (BMBF) within the framework of the "e:Med" research and funding concept
   ("grants 01ZX1910B, 01ZX1910D, 01ZX2210B, and 01ZX2210D") and
   preclinical confirmatory study framework (REGAGforBone, grant:
   01KC2304C). T.L. was awarded with a seed funding under the Excellence
   Strategy of the Federal Government and the Lander.
CR Abbaoui B, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201800079
   Adamowicz K, 2023, NPJ SYST BIOL APPL, V9, DOI 10.1038/s41540 023 00311 7
   Adamowicz K, 2022, BRIEF BIOINFORM, V23, DOI 10.1093/bib/bbac247
   Ahmed R., 2018, J Exp Algorithmics, V24
   Akbar MA, 2017, HUM GENE THER, V28, P179, DOI 10.1089/hum.2016.069
   Altenhoff AM, 2016, NAT METHODS, V13, P425, DOI [10.1038/NMETH.3830, 10.1038/nmeth.3830]
   Amberger JS, 2019, NUCLEIC ACIDS RES, V47, pD1038, DOI 10.1093/nar/gky1151
   Andersen H, 2003, J BONE MINER RES, V18, P195, DOI 10.1359/jbmr.2003.18.2.195
   Ansari S, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14040289
   Arinaitwe E, 2009, CLIN INFECT DIS, V49, P1629, DOI 10.1086/647946
   Aswamenakul K, 2020, MOL BIOL REP, V47, P7505, DOI 10.1007/s11033 020 05811 x
   Athanasopoulos AN, 2007, J BIOL CHEM, V282, P26746, DOI 10.1074/jbc.M705200200
   Baek D, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03517 x
   Barrio Hernandez I, 2020, GENOME RES, V30, P127, DOI 10.1101/gr.248286.119
   Bernett J, 2022, BIOINFORMATICS, V38, P1600, DOI 10.1093/bioinformatics/btab876
   Bigham Sadegh A, 2015, INT WOUND J, V12, P238, DOI 10.1111/iwj.12231
   Blair HC, 2016, LAB INVEST, V96, P763, DOI 10.1038/labinvest.2016.51
   Boteanu RM, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 75527 2
   Brandao AS, 2022, ELIFE, V11, DOI 10.7554/eLife.76987
   Braun KF, 2011, THESCIENTIFICWORLDJO, V11, P2348, DOI 10.1100/2011/471426
   Calciolari E, 2018, J PERIODONTAL RES, V53, P174, DOI 10.1111/jre.12498
   Calciolari E, 2017, CLIN ORAL IMPLAN RES, V28, pE101, DOI 10.1111/clr.12936
   Calciolari K, 2021, CIENC RURAL, V51, DOI 10.1590/0103 8478cr20200352
   Cao JJ., 2011, Ann N Y Acad Sci, V1240
   Chavanpatil MD, 2007, J PHARM SCI US, V96, P3379, DOI 10.1002/jps.20961
   Chen Y., 2022, FASEB J, V36
   Cheung KL, 2010, AAPS J, V12, P87, DOI 10.1208/s12248 009 9162 8
   Chitti SV, 2023, NUCLEIC ACIDS RES, V52, pD1694, DOI 10.1093/nar/gkad1007
   Chiu Yu Chieh, 2016, J Exp Orthop, V3, P25
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Cochran BJ, 2021, CURR ATHEROSCLER REP, V23, DOI 10.1007/s11883 021 00906 7
   Costa V, 2018, J CELL PHYSIOL, V233, P1558, DOI 10.1002/jcp.26058
   Csardi G., 2005, InterJournal, Complex Systems, V1695, P1
   Cunningham F., 2022, Nucleic Acids Res, V50, P95
   Davies OG, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00092
   Dec P, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24010529
   Del Gaudio P, 2015, CARBOHYD POLYM, V115, P629, DOI 10.1016/j.carbpol.2014.09.040
   Deutsch EW, 2020, NUCLEIC ACIDS RES, V48, pD1145, DOI 10.1093/nar/gkz984
   DeVito NJ, 2019, BMJ EVID BASED MED, V24, P53, DOI 10.1136/bmjebm 2018 111107
   Dong R, 2020, J TISSUE ENG, V11, DOI 10.1177/2041731420926918
   Doostmohammadi A, 2024, CELL COMMUN SIGNAL, V22, DOI 10.1186/s12964 024 01607 9
   Dou C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.69
   Ehrnthaller C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081341
   Fagard RH, 1996, J HYPERTENS, V14, pS9, DOI 10.1097/00004872 199609002 00004
   Fang F, 2024, BONE RES, V12, DOI 10.1038/s41413 023 00313 5
   Fang JY, 2023, INT J BIOL MACROMOL, V238, DOI 10.1016/j.ijbiomac.2023.124125
   Feng MX, 2016, SCI REP UK, V6, DOI 10.1038/srep19074
   Ferracini R, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030122
   Filliat G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181600
   Gao X, 2015, INT J NANOMED, V10, P7109, DOI 10.2147/IJN.S94045
   Ge XT, 2018, EXP BIOL MED, V243, P715, DOI 10.1177/1535370218769420
   Ghebes CA, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.640419
   Gillman CE, 2021, MAT SCI ENG C MATER, V130, DOI 10.1016/j.msec.2021.112466
   Griffanti G, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15041087
   Haddaway NR, 2022, CAMPBELL SYST REV, V18, DOI 10.1002/cl2.1230
   Haidich AB, 2010, HIPPOKRATIA, V14, P29
   Hamzic E, 2016, CLIN MED INVEST, V1, P1
   Hao DK, 2023, BIOACT MATER, V20, P179, DOI 10.1016/j.bioactmat.2022.05.027
   He Y, 2019, FASEB J, V33, P6069, DOI 10.1096/fj.201802195R
   Heo SC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116698
   Hopwood B, 2009, BONE, V44, P87, DOI 10.1016/j.bone.2008.08.120
   Hovey O, 2020, PROTEOMICS, V20, DOI 10.1002/pmic.202000036
   Hu Y, 2020, THERANOSTICS, V10, P2293, DOI 10.7150/thno.39238
   Huang D., 2020, PeerJ, V8
   Huang XY, 2022, INT J BIOL SCI, V18, P4088, DOI 10.7150/ijbs.69816
   Huo CH, 2019, ELECTROPHORESIS, V40, P1839, DOI 10.1002/elps.201900130
   Hussein AI, 2018, J ORTHOP RES, V36, P1153, DOI 10.1002/jor.23754
   Jain G, 2022, J FUNCT BIOMATER, V13, DOI 10.3390/jfb13010028
   Jassal B, 2020, NUCLEIC ACIDS RES, V48, pD498, DOI 10.1093/nar/gkz1031
   Jiang LJ, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.596783
   Jiao XY, 2007, J BIOL CHEM, V282, P1080, DOI 10.1074/jbc.M513414200
   Jourdan JP, 2020, J PHARM PHARMACOL, V72, P1145, DOI 10.1111/jphp.13273
   Khoswanto Christian, 2023, J Oral Biol Craniofac Res, V13, P539, DOI 10.1016/j.jobcr.2023.06.002
   Kim H, 2017, BMB REP, V50, P97, DOI 10.5483/BMBRep.2017.50.2.170
   Kim H, 2018, INT J BIOL MACROMOL, V120, P119, DOI 10.1016/j.ijbiomac.2018.07.159
   Klavert J, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.663357
   Kliemt S, 2013, J PROTEOME RES, V12, P378, DOI 10.1021/pr300640h
   Kotlyar M, 2019, NUCLEIC ACIDS RES, V47, pD581, DOI 10.1093/nar/gky1037
   Kurien T, 2013, BONE JOINT J, V95B, P583, DOI 10.1302/0301 620X.95B5.30286
   Lau KR, 2023, J BIOMED MATER RES A, V111, P825, DOI 10.1002/jbm.a.37525
   Lazareva O, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbab066
   Lee JM, 2015, CALCIFIED TISSUE INT, V96, P56, DOI 10.1007/s00223 014 9938 4
   Leoni G, 2015, J CLIN INVEST, V125, P1215, DOI 10.1172/JCI76693
   Li JJ, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 020 02123 6
   Li JY, 2021, J BONE MINER METAB, V39, P631, DOI 10.1007/s00774 020 01200 3
   Li M, 2020, BIOACT MATER, V5, P938, DOI 10.1016/j.bioactmat.2020.06.017
   Li ZX, 2022, J PERIODONTAL RES, V57, P1169, DOI 10.1111/jre.13054
   Liang W, 2011, EUR J PHARMACOL, V670, P317, DOI 10.1016/j.ejphar.2011.08.014
   Löffler J, 2023, COMMUN BIOL, V6, DOI 10.1038/s42003 023 04652 1
   Loureiro J, 2019, MAT SCI ENG C MATER, V104, DOI 10.1016/j.msec.2019.109847
   Luo Y, 2018, TOXICOL APPL PHARM, V341, P8, DOI 10.1016/j.taap.2018.01.002
   Maglott D, 2005, NUCLEIC ACIDS RES, V33, pD54, DOI 10.1093/nar/gki031
   Mahnavi A, 2023, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.1057699
   Maier A, 2024, NUCLEIC ACIDS RES, V52, pW481, DOI 10.1093/nar/gkae388
   Malashkevich VN, 2010, P NATL ACAD SCI USA, V107, P8605, DOI 10.1073/pnas.0913660107
   Martin TJ, 2014, J BONE MINER RES, V29, P1519, DOI 10.1002/jbmr.2276
   Martínez Aguilar MM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11122853
   Martino MM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002614
   Materozzi M, 2024, SCI REP UK, V14, DOI 10.1038/s41598 024 57898 y
   Mattinzoli D, 2016, BONE, V83, P35, DOI 10.1016/j.bone.2015.10.008
   McMichael BK, 2008, EXP CELL RES, V314, P564, DOI 10.1016/j.yexcr.2007.10.018
   Meinberg EG, 2019, INJURY, V50, pS62, DOI 10.1016/j.injury.2019.05.005
   Merker D, 2021, MAT SCI ENG C MATER, V128, DOI 10.1016/j.msec.2021.112289
   Migliorini F, 2021, EUR J MED RES, V26, DOI 10.1186/s40001 021 00593 9
   Min HW, 2020, J REHABIL MED, V52, DOI 10.2340/16501977 2622
   Mollazadeh S, 2015, J ORTHOP SURG RES, V10, DOI 10.1186/s13018 015 0152 5
   Montoya C, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00131 z
   Morhayim J, 2020, FASEB J, V34, P5435, DOI 10.1096/fj.201902610R
   Murakami A, 2007, BIOFACTORS, V30, P1, DOI 10.1002/biof.5520300101
   Nielson CM, 2017, J BONE MINER RES, V32, P1559, DOI 10.1002/jbmr.3125
   Nieuwoudt M, 2021, ANN BIOMED ENG, V49, P3621, DOI 10.1007/s10439 021 02872 2
   Nováková S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22157908
   Okamoto T, 2005, INT J MOL MED, V16, P275
   Othman Z, 2020, MATER TODAY BIO, V7, DOI 10.1016/j.mtbio.2020.100066
   Page MJ, 2021, BMJ BRIT MED J, V372, DOI [10.1136/bmj.n160, 10.1136/bmj.n71]
   Park DJ, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01656 7
   Pei SP, 2020, BONE, V131, DOI 10.1016/j.bone.2019.115078
   Piñero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Poh PSP, 2022, CURR OPIN BIOTECH, V74, P263, DOI 10.1016/j.copbio.2021.12.002
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Ramsay RR, 2018, CLIN TRANSL MED, V7, DOI 10.1186/s40169 017 0181 2
   Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369
   Reinke S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004754
   Rivero G, 2019, J MATER SCI MATER M, V30, DOI 10.1007/s10856 019 6302 2
   Rose JP., 2023, PLOS ONE, V18
   Ruiz M, 2019, OSTEOARTHR CARTILAGE, V27, P493, DOI 10.1016/j.joca.2018.11.005
   Sadegh S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27138 2
   Salbach Hirsch J, 2021, BIOL CHEM, V402, P1415, DOI 10.1515/hsz 2021 0174
   Saleh AK, 2024, LIFE SCI, V344, DOI 10.1016/j.lfs.2024.122566
   Sasaki K, 2001, ANAL CHIM ACTA, V447, P63, DOI 10.1016/S0003 2670(01)01290 9
   Sayers E W., 2021, Nucleic Acids Research, V50
   Schmidt JR, 2019, J CELL BIOCHEM, V120, P8706, DOI 10.1002/jcb.28158
   Schmidt JR, 2016, MOL CELL PROTEOMICS, V15, P558, DOI 10.1074/mcp.M115.049718
   Silva JC, 2019, GLYCOCONJUGATE J, V36, P141, DOI 10.1007/s10719 019 09858 2
   Simunovic F, 2019, J CELL BIOCHEM, V120, P396, DOI 10.1002/jcb.27394
   Sjöstedt E, 2020, SCIENCE, V367, P1090, DOI 10.1126/science.aay5947
   Song SJ, 2006, GENE, V379, P92, DOI 10.1016/j.gene.2006.04.029
   Spada S, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046 021 01908 8
   Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109
   Suleimenova D, 2017, CLIN ORAL IMPLAN RES, V28, P713, DOI 10.1111/clr.12868
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Szweras M, 2002, J BIOL CHEM, V277, P19991, DOI 10.1074/jbc.M112234200
   Tanios M, 2022, CURR OSTEOPOROS REP, V20, P229, DOI 10.1007/s11914 022 00740 z
   The UniProt Consortium, 2021, Nucleic Acids Res, V49
   Thiery J, 2024, PROTEOMICS, V24, DOI 10.1002/pmic.202300002
   Tiaden AN, 2012, STEM CELLS, V30, P2271, DOI 10.1002/stem.1190
   Tossetta G, 2022, BONE, V157, DOI 10.1016/j.bone.2022.116350
   Tyanova S, 2016, NAT PROTOC, V11, P2301, DOI 10.1038/nprot.2016.136
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]
   Ursu O, 2019, NUCLEIC ACIDS RES, V47, pD963, DOI 10.1093/nar/gky963
   Valainis D, 2019, BIOMED MATER, V14, DOI 10.1088/1748 605X/ab38c6
   Varughese R, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223 018 0254 9
   Vitali F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162407
   Wang JH, 2024, BIOMOLECULES, V14, DOI 10.3390/biom14050554
   Wang RX, 2023, ACS CENTRAL SCI, V9, P1927, DOI 10.1021/acscentsci.3c00794
   Wang Y, 2018, COLLOID SURFACE B, V172, P90, DOI 10.1016/j.colsurfb.2018.08.032
   Wang YJ, 2021, BIOENGINEERED, V12, P5386, DOI 10.1080/21655979.2021.1960766
   Wang ZP, 2021, TOXICOLOGY, V448, DOI 10.1016/j.tox.2020.152652
   Wangler S, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 020 02062 2
   Weerasinghe DK, 2023, FRONT CELL DEV BIOL, V11, DOI 10.3389/fcell.2023.1184550
   Wilkinson MD, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.18
   Williams JP, 2010, ANN NY ACAD SCI, V1192, P358, DOI 10.1111/j.1749 6632.2009.05242.x
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wolf B, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25042015
   Wong SK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176448
   Wu A M., 2021, Lancet Healthy Longev, V2
   Xia H, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.839035
   Xie Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12758
   Xiong T, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.832591
   Xu JJ, 2024, AGING CELL, V23, DOI 10.1111/acel.14035
   Xu WT, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 04272 y
   Yalcinkaya F, 2016, INT J POLYM SCI, V2016, DOI 10.1155/2016/4671658
   Yang J, 2021, J ORTHOP TRANSL, V27, P77, DOI 10.1016/j.jot.2020.10.004
   Yang X, 2018, REGEN BIOMATER, V5, P229, DOI 10.1093/rb/rby014
   Yang YJ, 2007, EUR J EPIDEMIOL, V22, P527, DOI 10.1007/s10654 007 9140 3
   Ye CY, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12752
   Yin PY, 2020, ARCH MED SCI, V16, P1419, DOI 10.5114/aoms.2019.89979
   Yoshikawa H., J R Soc Interface, V6
   Yu HR, 2012, CALCIFIED TISSUE INT, V91, P81, DOI 10.1007/s00223 012 9613 6
   Zeng YZ, 2019, ACTA BIOMATER, V93, P152, DOI 10.1016/j.actbio.2019.01.060
   Zhang SF, 2013, ACTA BIOMATER, V9, P7236, DOI 10.1016/j.actbio.2013.04.003
   Zhang W, 2018, FASEB J, V32, P2280, DOI 10.1096/fj.201700998RR
   Zhao LR, 2014, INT J MOL MED, V34, P1025, DOI 10.3892/ijmm.2014.1852
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
   Zhu YB, 2002, BIOMACROMOLECULES, V3, P1312, DOI 10.1021/bm020074y
NR 185
TC 3
Z9 3
U1 2
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2041 7314
J9 J TISSUE ENG
JI J. Tissue Eng.
PY 2024
VL 15
AR 20417314241295332
DI 10.1177/20417314241295332
PG 26
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA N8S6P
UT WOS:001366969100001
PM 39620099
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Ozeki, N
   Mogi, M
   Yamaguchi, H
   Hiyama, T
   Kawai, R
   Hase, N
   Nakata, K
   Nakamura, H
   Kramer, RH
AF Ozeki, Nobuaki
   Mogi, Makio
   Yamaguchi, Hideyuki
   Hiyama, Taiki
   Kawai, Rie
   Hase, Naoko
   Nakata, Kazuhiko
   Nakamura, Hiroshi
   Kramer, Randall H.
TI 被撤回的出版物: Differentiation of Human Skeletal Muscle Stem Cells into
   Odontoblasts Is Dependent on Induction of α1 Integrin Expression
   (Retracted article. See vol. 296, 2021)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
DE Bone Morphogenetic Protein (BMP); Cell Adhesion; Cell Motility;
   Integrins; Stem Cells; Muscle; BMP 4; Odontoblast; Retinoic Acid
ID DENTAL PULP; GENE EXPRESSION; NEURAL CREST; TOOTH; BONE; ADHESION;
   MATRIX; MINERALIZATION; SIALOPROTEIN; REGENERATION
AB Background: Human skeletal muscle stem cells (hSMSCs) can differentiate into bone and fat cells. Results: hSMSCs could also differentiate into odontoblasts but required an extracellular matrix scaffold and changes in their integrin profile. Conclusion: The present results identify an odontoblast differentiation pathway dependent on adhesion receptor expression. Significance: The data provide insight into how hSMSC adhesion receptors interact with the microenvironment to regulate lineage specification.
   Skeletal muscle stem cells represent an abundant source of autologous cells with potential for regenerative medicine that can be directed to differentiate into multiple lineages including osteoblasts and adipocytes. In the current study, we found that 7 integrin positive human skeletal muscle stem cells (7(+)hSMSCs) could differentiate into the odontoblast lineage under specific inductive conditions in response to bone morphogenetic protein 4 (BMP 4). Cell aggregates of FACS harvested 7(+)hSMSCs were treated in suspension with retinoic acid followed by culture on a gelatin scaffold in the presence of BMP 4. Following this protocol, 7(+)hSMSCs were induced to down regulate myogenic genes (MYOD and 7 integrin) and up regulate odontogenic markers including dentin sialophosphoprotein, matrix metalloproteinase 20 (enamelysin), dentin sialoprotein, and alkaline phosphatase but not osteoblastic genes (osteopontin and osteocalcin). Following retinoic acid and gelatin scaffold/BMP 4 treatment, there was a coordinated switch in the integrin expression profile that paralleled odontoblastic differentiation where 11 integrin was strongly up regulated with the attenuation of muscle specific 71 integrin expression. Interestingly, using siRNA knockdown strategies revealed that the differentiation related expression of the 1 integrin receptor positively regulates the expression of the odontoblastic markers dentin sialophosphoprotein and matrix metalloproteinase 20. These results strongly suggest that the differentiation of 7(+)hSMSCs along the odontogenic lineage is dependent on the concurrent expression of 1 integrin.
C1 [Ozeki, Nobuaki; Yamaguchi, Hideyuki; Hiyama, Taiki; Kawai, Rie; Hase, Naoko; Nakata, Kazuhiko; Nakamura, Hiroshi] Aichi Gakuin Univ, Sch Dent, Dept Endodont, Nagoya, Aichi 4648651, Japan.
   [Mogi, Makio] Aichi Gakuin Univ, Sch Pharm, Dept Med Biochem, Nagoya, Aichi 4648650, Japan.
   [Kramer, Randall H.] Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA.
C3 Aichi Gakuin University; Aichi Gakuin University; University of
   California System; University of California San Francisco
RP Kramer, RH (通讯作者)，Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA.
EM randall.kramer@ucsf.edu
FU National Institutes of Health [R01DE015404]; Ministry of Education,
   Culture, Sports, Science and Technology of Japan [24659849, 22791853,
   25253101]; Grants in Aid for Scientific Research [22791853, 24659849]
   Funding Source: KAKEN
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant R01DE015404 (to R. K.). This work was also supported by
   Grant in aid for Exploratory Research 24659849 (to H. N.), Grant in aid
   for Young Scientists (B) 22791853 (to N. O.), and Grant in aid for
   Scientific Research (A) 25253101 (to N. O.) from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan.
CR Aguiar MC, 2007, J ANAT, V210, P418, DOI 10.1111/j.1469 7580.2007.00708.x
   Alessandri G, 2004, LANCET, V364, P1872, DOI 10.1016/S0140 6736(04)17443 6
   Almushayt A, 2006, GENE THER, V13, P611, DOI 10.1038/sj.gt.3302687
   Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432 0436.2001.680412.x
   Atsawasuwan P, 2013, J DENT RES, V92, P622, DOI 10.1177/0022034513487906
   Bègue Kirn C, 1998, EUR J ORAL SCI, V106, P963, DOI 10.1046/j.0909 8836.1998.eos106510.x
   Brizzi MF, 2012, CURR OPIN CELL BIOL, V24, P645, DOI 10.1016/j.ceb.2012.07.001
   Casagrande L, 2010, J DENT RES, V89, P603, DOI 10.1177/0022034510364487
   Chen S, 2008, J BIOL CHEM, V283, P19359, DOI 10.1074/jbc.M709492200
   Cobourne MT, 2003, ARCH ORAL BIOL, V48, P1, DOI 10.1016/S0003 9969(02)00208 X
   DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Evans DJR, 2006, DEV DYNAM, V235, P1310, DOI 10.1002/dvdy.20663
   Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092 8674(04)00255 7
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Huo N, 2010, STEM CELLS DEV, V19, P93, DOI 10.1089/scd.2009.0048
   Huojia M, 2005, DEV GROWTH DIFFER, V47, P141
   Iohara K, 2004, J DENT RES, V83, P590, DOI 10.1177/154405910408300802
   Kawaguchi J, 2005, BONE, V36, P758, DOI 10.1016/j.bone.2004.07.019
   Lee HK, 2012, GENE EXPR PATTERNS, V12, P102, DOI 10.1016/j.gep.2012.02.002
   Lee JY, 2000, J CELL BIOL, V150, P1085, DOI 10.1083/jcb.150.5.1085
   MacDougall M, 1998, EUR J ORAL SCI, V106, P227, DOI 10.1111/j.1600 0722.1998.tb02180.x
   MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807
   Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100
   Mogi M, 2004, BONE, V35, P507, DOI 10.1016/j.bone.2004.03.003
   Mogi M, 2003, J BIOL CHEM, V278, P47477, DOI 10.1074/jbc.M307055200
   Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038
   Noden DM, 2005, J ANAT, V207, P575, DOI 10.1111/j.1469 7580.2005.00473.x
   Noden DM, 2006, DEV DYNAM, V235, P1194, DOI 10.1002/dvdy.20697
   Noguchi F, 2009, J ENDODONT, V35, P668, DOI 10.1016/j.joen.2009.01.016
   Oh SH, 2012, J DENT RES, V91, P1124, DOI 10.1177/0022034512461916
   Ozeki N, 2007, BIOCHEM BIOPH RES CO, V353, P54, DOI 10.1016/j.bbrc.2006.11.110
   Ozeki N, 2006, EXP CELL RES, V312, P4162, DOI 10.1016/j.yexcr.2006.09.017
   Pawlikowski B, 2009, DEV DYNAM, V238, P138, DOI 10.1002/dvdy.21833
   Qin CL, 2003, CONNECT TISSUE RES, V44, P179, DOI 10.1080/03008200390152296
   Reilly GC, 2010, J BIOMECH, V43, P55, DOI 10.1016/j.jbiomech.2009.09.009
   Rendl M, 2008, GENE DEV, V22, P543, DOI 10.1101/gad.1614408
   Roberts AI, 1999, IMMUNOLOGY, V97, P679
   Salmela E, 2012, CELLS TISSUES ORGANS, V195, P287, DOI 10.1159/000327529
   Schindeler A, 2009, DIFFERENTIATION, V77, P12, DOI 10.1016/j.diff.2008.09.007
   Simon S, 2009, BONE, V45, P693, DOI 10.1016/j.bone.2009.06.018
   Sinanan ACM, 2004, BIOTECHNOL APPL BIOC, V40, P25, DOI 10.1042/BA20030185
   Takada I, 2007, ANN NY ACAD SCI, V1116, P182, DOI 10.1196/annals.1402.034
   Takeda T, 2008, J DENT RES, V87, P676, DOI 10.1177/154405910808700716
   Tucker AS, 2000, DEVELOPMENT, V127, P4691
   Vizirianakis IS, 2001, ARCH BIOCHEM BIOPHYS, V385, P108, DOI 10.1006/abbi.2000.2134
   Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427
   Wei X, 2007, J ENDODONT, V33, P703, DOI 10.1016/j.joen.2007.02.009
   Xu HF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052209
   Yan ZB, 2006, CELLS TISSUES ORGANS, V183, P123, DOI 10.1159/000095986
   Yu JH, 2006, TISSUE ENG, V12, P3097, DOI 10.1089/ten.2006.12.3097
   Yu YC, 2011, MOL CELL BIOCHEM, V351, P85, DOI 10.1007/s11010 011 0714 8
   Zouvelou V, 2009, J EXP ZOOL PART B, V312B, P361, DOI 10.1002/jez.b.21262
NR 54
TC 24
Z9 24
U1 0
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 16
PY 2014
VL 289
IS 20
BP 14380
EP 14391
DI 10.1074/jbc.M113.526772
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA AH2XF
UT WOS:000335984600063
PM 24692545
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Lv, HH
   Wang, YJ
   Zhen, CX
   Liu, JY
   Chen, X
   Zhang, GJ
   Yao, W
   Guo, HJ
   Wei, YP
   Wang, SH
   Yang, JC
   Shang, P
AF Lv, Huanhuan
   Wang, Yijia
   Zhen, Chenxiao
   Liu, Junyu
   Chen, Xin
   Zhang, Gejing
   Yao, Wei
   Guo, Huijie
   Wei, Yunpeng
   Wang, Shenghang
   Yang, Jiancheng
   Shang, Peng
TI A static magnetic field improves bone quality and balances the function
   of bone cells with regulation on iron metabolism and redox status in
   type 1 diabetes
SO FASEB JOURNAL
LA English
DT Article
DE bone quality; bone remodeling; diabetic osteoporosis; iron metabolism;
   redox level; static magnetic field
ID HIGH GLUCOSE; PROMOTES; DETERIORATION; OSTEOPOROSIS; STRENGTH; HEALTH
AB Osteoporosis is one of the chronic complications of type 1 diabetes with high risk of fracture. The prevention of diabetic osteoporosis is of particular importance. Static magnetic fields (SMFs) exhibit advantages on improvement of diabetic complications. The biological effects and mechanism of SMFs on bone health of type 1 diabetic mice and functions of bone cells under high glucose have not been clearly clarified. In animal experiment, six week old male C57BL/6J mice were induced to type 1 diabetes and exposed to SMF of 0.4 0.7 T for 4 h/day lasting for 6 weeks. Bone mass, biomechanical strength, microarchitecture and metabolism were determined by DXA, three point bending assay, micro CT, histochemical and biochemical methods. Exposure to SMF increased BMD and BMC of femur, improved biomechanical strength with higher ultimate stress, stiffness and elastic modulus, and ameliorated the impaired bone microarchitecture in type 1 diabetic mice by decreasing Tb.Pf, Ct.Po and increasing Ct.Th. SMF enhanced bone turnover by increasing the level of markers for bone formation (OCN and Collagen I) as well as bone resorption (CTSK and NFAT2). In cellular experiment, MC3T3 E1 cells or primary osteoblasts and RAW264.7 cells were cultured in 25 mM high glucose stimulated diabetic marrow microenvironment under differentiation induction and exposed to SMF. SMF promoted osteogenesis with higher ALP level and mineralization deposition in osteoblasts, and it also enhanced osteoclastogenesis with higher TRAP activity and bone resorption in osteoclasts under high glucose condition. Further, SMF increased iron content with higher FTH1 expression and regulated the redox level through activating HO 1/Nrf2 in tibial tissues, and lowered hepatic iron accumulation by BMP6 mediated regulation of hepcidin and lipid peroxidation in mice with type 1 diabetes. Thus, SMF may act as a potential therapy for improving bone health in type 1 diabetes with regulation on iron homeostasis metabolism and redox status.
C1 [Lv, Huanhuan; Wang, Yijia; Zhen, Chenxiao; Liu, Junyu; Chen, Xin; Zhang, Gejing; Yao, Wei; Guo, Huijie; Wang, Shenghang; Shang, Peng] Northwestern Polytech Univ, Sch Life Sci, Xian, Peoples R China.
   [Lv, Huanhuan; Wang, Yijia; Zhen, Chenxiao; Liu, Junyu; Chen, Xin; Zhang, Gejing; Yao, Wei; Guo, Huijie; Wang, Shenghang; Shang, Peng] Northwestern Polytech Univ, Key Lab Space Biosci & Biotechnol, Xian, Peoples R China.
   [Lv, Huanhuan; Shang, Peng] Northwestern Polytech Univ Shenzhen, Res & Dev Inst, Shenzhen, Peoples R China.
   [Wang, Yijia] Zhejiang Univ, Med Ctr, Liangzhu Lab, Hangzhou, Peoples R China.
   [Wei, Yunpeng] Shenzhen Univ, Sch Med, Shenzhen, Peoples R China.
   [Wang, Shenghang] Shenzhen Longhua New Dist Peoples Hosp, Dept Spinal Surg, Shenzhen, Peoples R China.
   [Yang, Jiancheng] Honghui Hosp, Dept Osteoporosis, Xian, Peoples R China.
C3 Northwestern Polytechnical University; Northwestern Polytechnical
   University; Northwestern Polytechnical University; Liangzhu Laboratory;
   Zhejiang University; Shenzhen University
RP Lv, HH; Shang, P (通讯作者)，Northwestern Polytech Univ, Sch Life Sci, Xian, Peoples R China.; Lv, HH; Shang, P (通讯作者)，Northwestern Polytech Univ Shenzhen, Res & Dev Inst, Shenzhen, Peoples R China.
EM lvhh2017@nwpu.edu.cn; shangpeng@nwpu.edu.cn
RI Yang, Jiancheng/JPK 2205 2023; Wang, Yijia/MGV 6373 2025; Liu,
   Junyu/NRB 0328 2025
OI Lv, Huanhuan/0000 0002 4869 4908; 
FU MOST | National Natural Science Foundation of China (NSFC) [81803032,
   52037007]; Natural Science Foundation of Shanxi Province (Shanxi
   Province Natural Science Foundation) [2019JQ632]
FX MOST | National Natural Science Foundation of China (NSFC), Grant/Award
   Number: 81803032 and 52037007; Natural Science Foundation of Shanxi
   Province (Shanxi Province Natural Science Foundation), Grant/Award
   Number: 2019JQ632
CR Abdulameer SA, 2012, PATIENT PREFER ADHER, V6, P435, DOI 10.2147/PPA.S32745
   Adami S, 2009, CURR MED RES OPIN, V25, P1057, DOI [10.1185/03007990902801147, 10.1185/03007990902801147 ]
   Cai J, 2018, OSTEOPOROSIS INT, V29, P1177, DOI 10.1007/s00198 018 4392 1
   Cai ZY, 2018, BIOCHEM BIOPH RES CO, V503, P428, DOI 10.1016/j.bbrc.2018.04.052
   Carter CS, 2020, CELL METAB, V32, P561, DOI 10.1016/j.cmet.2020.09.012
   Chen GL, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02004 y
   Chen XR, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00128 8
   Cipriani C, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00122
   Cole JB, 2020, NAT REV NEPHROL, V16, P377, DOI 10.1038/s41581 020 0278 5
   Combs MD, 2011, DEVELOPMENT, V138, P1747, DOI 10.1242/dev.060996
   Cunha JS, 2014, CELL TISSUE RES, V358, P249, DOI 10.1007/s00441 014 1913 x
   Dong DD, 2019, J TISSUE ENG REGEN M, V13, P2181, DOI 10.1002/term.2973
   Dong W, 2018, BIOCHEM BIOPH RES CO, V505, P1195, DOI 10.1016/j.bbrc.2018.10.059
   Fonseca H, 2014, SPORTS MED, V44, P37, DOI 10.1007/s40279 013 0100 7
   García Hernández A, 2012, BONE, V50, P276, DOI 10.1016/j.bone.2011.10.032
   Guan CC, 2009, BONE, V45, P1146, DOI 10.1016/j.bone.2009.08.009
   Gürgül S, 2008, BONE, V42, P74, DOI 10.1016/j.bone.2007.08.040
   Han J, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.813057
   Jing D, 2011, OSTEOPOROSIS INT, V22, P1885, DOI 10.1007/s00198 010 1447 3
   Keenan HA, 2016, CURR OSTEOPOROS REP, V14, P351, DOI 10.1007/s11914 016 0338 8
   Kell DB, 2014, METALLOMICS, V6, P748, DOI 10.1039/c3mt00347g
   Komori T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207513
   Kwan RLC, 2015, ADV SKIN WOUND CARE, V28, P212, DOI 10.1097/01.ASW.0000462012.58911.53
   Li FJ, 2016, BIOMED ENG ONLINE, V15, DOI 10.1186/s12938 015 0121 6
   Lim PJ, 2019, NAT METAB, V1, P519, DOI 10.1038/s42255 019 0063 6
   Lv HH, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12982
   Ma W, 2021, FOOD FUNCT, V12, P4246, DOI [10.1039/D0FO03442H, 10.1039/d0fo03442h]
   Mert T, 2010, BIOELECTROMAGNETICS, V31, P39, DOI 10.1002/bem.20524
   Leao AAP, 2020, J DIABETES COMPLICAT, V34, DOI 10.1016/j.jdiacomp.2020.107573
   Sewing L, 2022, J BONE MINER RES, V37, P837, DOI 10.1002/jbmr.4517
   Shah VN, 2017, OSTEOPOROSIS INT, V28, P2601, DOI 10.1007/s00198 017 4097 x
   Soliman Ashraf T, 2017, Acta Biomed, V88, P112, DOI 10.23750/abm.v88i1.6049
   Starup Linde J, 2016, BONE, V82, P69, DOI 10.1016/j.bone.2015.02.019
   Takeno A, 2021, DIABETOL INT, V12, P171, DOI 10.1007/s13340 020 00463 5
   Toxqui L, 2015, NUTRIENTS, V7, P2324, DOI 10.3390/nu7042324
   Weber DR, 2016, CURR OSTEOPOROS REP, V14, P327, DOI 10.1007/s11914 016 0333 0
   Yang JC, 2021, CELLS BASEL, V10, DOI 10.3390/cells10123519
   Yang JC, 2021, INT J RADIAT BIOL, V97, P746, DOI 10.1080/09553002.2021.1900944
   Yang JC, 2021, BIOELECTROMAGNETICS, V42, P200, DOI 10.1002/bem.22324
   Yang JC, 2018, BIOL TRACE ELEM RES, V184, P214, DOI 10.1007/s12011 017 1161 5
   Yoshioka F, 2021, J DIABETES INVEST, V12, P1689, DOI 10.1111/jdi.13530
   Zhang H, 2018, BONE, V107, P36, DOI 10.1016/j.bone.2017.10.024
   Zhang J, 2017, ELECTROMAGN BIOL MED, V36, P8, DOI 10.3109/15368378.2016.1141362
   Zhang N, 2019, CELL BIOCHEM FUNCT, V37, P385, DOI 10.1002/cbf.3415
   Zhao J, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/6305370
   Zhou J, 2015, ENDOCRINE, V49, P258, DOI 10.1007/s12020 014 0439 z
NR 46
TC 13
Z9 13
U1 3
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD JUL
PY 2023
VL 37
IS 7
AR e22985
DI 10.1096/fj.202202131RR
PG 20
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA H8UG9
UT WOS:000998641000001
PM 37249350
DA 2025 08 17
ER

PT J
AU Wang, Q
   Wu, WC
   Han, XY
   Zheng, AY
   Lei, S
   Wu, J
   Chen, HQ
   He, CQ
   Luo, FM
   Liu, XJ
AF Wang, Qian
   Wu, Wenchao
   Han, Xiaoyu
   Zheng, Ai
   Lei, Song
   Wu, Jiang
   Chen, Huaiqing
   He, Chengqi
   Luo, Fengming
   Liu, Xiaojing
TI Osteogenic differentiation of amniotic epithelial cells: synergism of
   pulsed electromagnetic field and biochemical stimuli
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Amniotic epithelial cells; Osteogenic differentiation; Pulsed
   electromagnetic field; BMP 2; Wnt/beta catenin signaling; Reactive
   oxygen species; Integrin beta 1
ID MESENCHYMAL STEM CELLS; PROLIFERATION; EXPRESSION
AB Background: Pulsed electromagnetic field (PEMF) is a non invasive physical therapy used in the treatment of fracture nonunion or delayed healing. PEMF can facilitate the osteogenic differentiation of bone marrow mesenchymal stem cells in vitro. Amniotic epithelial cells (AECs) have been proposed as a potential source of stem cells for cell therapy. However, whether PEMF could modulate the osteogenic differentiation of AECs is unknown. In the present study, the effects of PEMF on the osteogenic differentiation of AECs were investigated.
   Methods: AECs were isolated from amniotic membrane of human placenta by trypsin digestion and were induced by PEMF and/or osteo induction medium. After 21 days we used real time RT PCR and immunocytochemistry to study the expression of osteoblast markers. The signal transduction of osteogenesis was further investigated.
   Results: The PEMF stimulation, or osteo induction medium alone could induce osteogenic differentiation of AECs, as shown by expression of osteoblast specific genes and proteins including alkaline phosphatase and osteocalcin. Furthermore, a combination of PEMF and osteo induction medium had synergy effects on osteogenic differentiation. In our study, the gene expression of BMP 2, Runx2, beta catenin, Nrf2, Keap1 and integrin beta 1 were up regulated in the osteogenic differentiation of AECs induced by PEMF and/or osteo induction medium.
   Conclusions: Combined application of PEMF and osteo induction medium is synergistic for the osteogenic differentiation of AECs. It might be a novel approach in the bone regenerative medicine.
C1 [Wang, Qian; He, Chengqi; Liu, Xiaojing] Sichuan Univ, West China Hosp, Ctr Rehabil Med, Chengdu 610064, Sichuan, Peoples R China.
   [Wang, Qian; He, Chengqi; Liu, Xiaojing] Rehabilitat Key Lab Sichuan Prov, Chengdu, Sichuan, Peoples R China.
   [Wang, Qian; Wu, Wenchao; Han, Xiaoyu; Chen, Huaiqing; Luo, Fengming; Liu, Xiaojing] Sichuan Univ, West China Hosp, Regenerat Med Res Ctr, Lab Cardiovasc Dis, Chengdu 610064, Sichuan, Peoples R China.
   [Wang, Qian; He, Chengqi] Sichuan Univ, Hong Kong Polytech Univ, Inst Disaster Management & Reconstruct, Chengdu 610041, Peoples R China.
   [Zheng, Ai] Sichuan Univ, West China Hosp, Dept Obstet & Gynecol, Chengdu 610064, Sichuan, Peoples R China.
   [Lei, Song] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu 610064, Sichuan, Peoples R China.
   [Wu, Jiang; Chen, Huaiqing] Sichuan Univ, West China Ctr Med Sci, Biomed Engn Lab, Chengdu 610064, Sichuan, Peoples R China.
   [Luo, Fengming] Sichuan Univ, West China Hosp, Golden Card Ward, Chengdu 610064, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University; Hong Kong Polytechnic
   University; Sichuan University; Sichuan University; Sichuan University;
   Sichuan University; Sichuan University
RP Liu, XJ (通讯作者)，Sichuan Univ, West China Hosp, Regenerat Med Res Ctr, Lab Cardiovasc Dis, Chengdu 610064, Sichuan, Peoples R China.
EM xiaojingliu67@gmail.com
FU National Natural Science Foundation of China [30470437, 30870596,
   11072163, 81171865, 30971325]; Department of Rehabilitation Medicine,
   West China Hospital, Sichuan University
FX This work was supported by grants from the National Natural Science
   Foundation of China, No. 30470437, 30870596 and 11072163 (XIAOJING LIU),
   No. 81171865 (CHENGQI HE), No. 30971325(FENGMING LUO). The PEMF system
   was support by the Department of Rehabilitation Medicine, West China
   Hospital, Sichuan University. We would like to acknowledge the
   assistance and critical advice provided by Dr. Jue Lin (University of
   California, San Francisco) and Dr. Rui Lin (Medimmune Inc.) in the
   preparation of this manuscript.
CR Assiotis A, 2012, J ORTHOP SURG RES, V7, DOI 10.1186/1749 799X 7 24
   Bai WF, 2013, CYTOTHERAPY, V15, P961, DOI 10.1016/j.jcyt.2013.03.001
   Barboni B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063256
   Barnaba S, 2013, PHYSIOTHER RES INT, V18, P109, DOI 10.1002/pri.1536
   Carbone A, 2014, CURR STEM CELL RES T, V9, P297, DOI 10.2174/1574888X0904140429142451
   Ceccarelli G, 2013, BIORESEARCH OPEN ACC, V2, P283, DOI 10.1089/biores.2013.0016
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Frahm J, 2010, TOXICOL LETT, V192, P330, DOI 10.1016/j.toxlet.2009.11.010
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Hochmuth CE, 2011, CELL STEM CELL, V8, P188, DOI 10.1016/j.stem.2010.12.006
   Ibiwoye MO, 2004, J ORTHOP RES, V22, P1086, DOI 10.1016/j.orthres.2003.12.017
   Kasten A, 2010, J CELL BIOCHEM, V111, P1586, DOI 10.1002/jcb.22890
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Miki T, 2007, CURR PROTOC STEM CEL, V12, P1
   Miki T, 2007, J REPROD IMMUNOL, V75, P91, DOI 10.1016/j.jri.2007.03.017
   Pan PX, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 36
   Parolini O, 2008, STEM CELLS, V26, P300, DOI 10.1634/stemcells.2007 0594
   Puklin Faucher E, 2009, J CELL SCI, V122, P179, DOI 10.1242/jcs.042127
   Regoli F, 2005, FREE RADICAL BIO MED, V39, P1620, DOI 10.1016/j.freeradbiomed.2005.08.004
   Satija NK, 2007, STEM CELLS DEV, V16, P7, DOI 10.1089/scd.2006.9998
   Schwartz Z, 2008, J ORTHOP RES, V26, P1250, DOI 10.1002/jor.20591
   Shi HF, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 35
   Song MY, 2014, CELL BIOCHEM BIOPHYS, V69, P47, DOI 10.1007/s12013 013 9764 8
   Sun LY, 2010, BIOELECTROMAGNETICS, V31, P209, DOI 10.1002/bem.20550
   Tsai MT, 2009, J ORTHOP RES, V27, P1169, DOI 10.1002/jor.20862
   van der Horst G, 2005, J BONE MINER RES, V20, P1867, DOI 10.1359/JBMR.050614
   Vincenzi F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065561
   Ward DF, 2007, STEM CELLS DEV, V16, P467, DOI 10.1089/scd.2007.0034
   Yanes O, 2010, NAT CHEM BIOL, V6, P411, DOI 10.1038/nchembio.364
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Yang Y, 2010, BIOELECTROMAGNETICS, V31, P277, DOI 10.1002/bem.20560
   Yim EKF, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt132
   Zhong C, 2012, PHYS THER, V92, P1208, DOI 10.2522/ptj.20110224
NR 33
TC 16
Z9 21
U1 1
U2 30
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD AUG 11
PY 2014
VL 15
AR 271
DI 10.1186/1471 2474 15 271
PG 10
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA AP5DC
UT WOS:000342098900001
PM 25112311
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Patil, S
   Tian, Y
   Chen, SY
   Stoma, LY
   Zhao, YP
   Zhang, J
   Yin, C
   Su, PH
   Deng, XD
   Qian, AR
AF Patil, Suryaji
   Tian, Ye
   Chen, Siyu
   Stoma, Laura Y.
   Zhao, Yipu
   Zhang, Jie
   Yin, Chong
   Su, Peihong
   Deng, Xudong
   Qian, Airong
TI SDSSD peptide modified polyvinylamine   A novel bone targeting RNA
   delivery system
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Bone targeting; RNA delivery; Non viral vector; Polyvinylamine;
   SDSSD PVAm
ID NANOPARTICLES; SURFACES; SIZE
AB Bone related disorders have become a prevailing concern in older men and postmenopausal women. Traditional methods of treatment, though have benefits, their inability to target specific cells or tissues increases their ineffectiveness and side effects. RNA therapy has emerged as an alternative to conventional therapy owing to its specific targeting ability. However, the lack of appropriate RNA vectors remains a major problem for successful RNA therapy. Here, we designed a delivery system, (SDSSD PVAm (PS)) based on a cationic polymer, polyvinylamine (PVAm), and a bone targeting peptide, SDSSD (Serine Aspartate Serine Serine Aspartate), to deliver a therapeutic RNA, anti miR 138 5p, to the bone tissue. The results showed that the SDSSD modification not only had no negative effect on the RNA carrying or protection abilities of PVAm but also improved targeting and RNA delivery to osteoblasts and improve osteogenic potential of the cells by improving the expression of osteogenic genes both at RNA and protein level. Recombinant anti miR 138 5p delivered through PS was highly enriched in the bone tissue, and the resultant nanoparticles could circulate for a longer time in the blood with negligible toxicity. The results showed that improved RNA delivery through PS significantly increased the rate of bone formation and improved trabecular and cortical bone microarchitecture, resulting in enhanced bone mass in ovariectomy (OVX) and hind limb unloading (HLU) model mice. These results demonstrate that SDSSD PVAm is a novel RNA delivery system for bone related disorders, such as osteoporosis.
C1 [Patil, Suryaji; Tian, Ye; Chen, Siyu; Stoma, Laura Y.; Zhao, Yipu; Zhang, Jie; Deng, Xudong; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, Xian Key Lab Special Med & Hlth Engn, Lab Bone Metab,Key Lab Space Biosci & Biotechnol, Xian, Shaanxi, Peoples R China.
   [Patil, Suryaji; Tian, Ye; Chen, Siyu; Stoma, Laura Y.; Zhao, Yipu; Zhang, Jie; Deng, Xudong; Qian, Airong] Northwestern Polytech Univ, Res Ctr Special Med & Hlth Syst Engn, Sch Life Sci, Xian, Shaanxi, Peoples R China.
   [Patil, Suryaji; Tian, Ye; Chen, Siyu; Stoma, Laura Y.; Zhao, Yipu; Zhang, Jie; Deng, Xudong; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, NPU UAB Joint Lab Bone Metab, Xian 710072, Shaanxi, Peoples R China.
   [Yin, Chong] North Sichuan Med Coll, Dept Clin Lab, Affiliated Hosp, Nanchong 637000, Peoples R China.
   [Su, Peihong] Xian Med Univ, Inst Basic & Translat Med, Shaanxi Prov Key Lab Ischem Cardiovasc Dis, Xian 710021, Shaanxi, Peoples R China.
C3 Northwestern Polytechnical University; Northwestern Polytechnical
   University; Northwestern Polytechnical University; North Sichuan Medical
   University; Xi'an Medical University
RP Tian, Y; Deng, XD; Qian, AR (通讯作者)，Northwestern Polytech Univ, Sch Life Sci, Xian Key Lab Special Med & Hlth Engn, Lab Bone Metab,Key Lab Space Biosci & Biotechnol, Xian, Shaanxi, Peoples R China.
EM tianye@nwpu.edu.cn; dengxd@nwpu.edu.cn; qianair@nwpu.edu.cn
RI Deng, Xudong/N 5407 2015; Patil, Suryaji/MIU 4121 2025; Chen,
   Siyu/R 9287 2019
FU National Natural Science Foundation of China [32371296, 82072106,
   32371371, 82204543]; Shaanxi Provincial Key RD Program [2021SF 293];
   Research Funds for the Central Universities [D5000230104]; Shaanxi
   Province Natural Science Foundation [2022JQ 822]; Natural Science
   Research Project of Shaanxi Provincial Education Department [22JS032]
FX This work was supported by the National Natural Science Foundation of
   China (32371296, 82072106, 32371371, and 82204543), the Shaanxi
   Provincial Key R&D Program (2021SF 293), Research Funds for the Central
   Universities (D5000230104), the Shaanxi Province Natural Science
   Foundation (2022JQ 822), and Natural Science Research Project of Shaanxi
   Provincial Education Department (22JS032).
CR Aliabadi HM, 2016, POLYM NANOMATERIALS, P55
   Boskey AL, 2010, J DENT RES, V89, P1333, DOI 10.1177/0022034510377791
   Chen ZH, 2022, INT J BIOL SCI, V18, P4837, DOI 10.7150/ijbs.71411
   Clogston JD, 2011, METHODS MOL BIOL, V697, P63, DOI 10.1007/978 1 60327 198 1_6
   Cui YZ, 2022, BIOACT MATER, V10, P207, DOI 10.1016/j.bioactmat.2021.09.015
   Dréan M, 2017, BIOMACROMOLECULES, V18, P440, DOI 10.1021/acs.biomac.6b01526
   Gao YG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158182
   Guo JW, 2023, CELL REP MED, V4, DOI 10.1016/j.xcrm.2022.100881
   Guo SJ, 2017, MOL THER NUCL ACIDS, V9, P399, DOI 10.1016/j.omtn.2017.10.010
   Hoshyar N, 2016, NANOMEDICINE UK, V11, P673, DOI 10.2217/nnm.16.5
   Huang LY, 2022, J ENVIRON MANAGE, V306, DOI 10.1016/j.jenvman.2022.114482
   Huang Xin, 2022, Biomater Transl, V3, P201, DOI 10.12336/biomatertransl.2022.03.004
   Kim HI, 2024, EXP MOL MED, V56, P836, DOI 10.1038/s12276 024 01201 6
   Kramer Martha F, 2011, Curr Protoc Mol Biol, VChapter 15, DOI 10.1002/0471142727.mb1510s95
   Li XM, 2022, J FOOD SCI, V87, P1708, DOI 10.1111/1750 3841.16116
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Lim JP, 2011, IMMUNOL CELL BIOL, V89, P836, DOI 10.1038/icb.2011.20
   Liu J, 2015, BIOMATERIALS, V52, P148, DOI 10.1016/j.biomaterials.2015.02.007
   Liu JL, 2024, NANO TODAY, V54, DOI 10.1016/j.nantod.2023.102074
   Liu L, 2010, BIOMATERIALS, V31, P1380, DOI 10.1016/j.biomaterials.2009.10.056
   Michael B, 2007, TOXICOL PATHOL, V35, P742, DOI 10.1080/01926230701595292
   Nielsen JJ, 2020, CURR OSTEOPOROS REP, V18, P449, DOI 10.1007/s11914 020 00604 4
   Patil S, 2023, FUTUR J PHARM SCI, V9, DOI 10.1186/s43094 023 00560 7
   Patil S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215491
   Saha K, 2014, MATER HORIZONS, V1, P102, DOI 10.1039/c3mh00075c
   Salave S, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15020608
   Shi C, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2020.107473
   Song HL, 2016, PHARM DEV TECHNOL, V21, P680, DOI 10.3109/10837450.2015.1045617
   Sophocleous A., 1914, Methods Mol Biol, V2019, P261
   Su PH, 2022, BONE, V154, DOI 10.1016/j.bone.2021.116238
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Tautzenberger A, 2012, INT J NANOMED, V7, P4545, DOI 10.2147/IJN.S34127
   Tavakol S, 2012, J NANOPART RES, V14, DOI 10.1007/s11051 012 1265 y
   Tian Y, 2022, J CONTROL RELEASE, V345, P20, DOI 10.1016/j.jconrel.2022.03.003
   Trivedi Shilpa, 2020, J Oral Biol Craniofac Res, V10, P158, DOI 10.1016/j.jobcr.2020.04.006
   van den Berg AIS, 2021, J CONTROL RELEASE, V331, P121, DOI 10.1016/j.jconrel.2021.01.014
   Venkatesan J, 2015, MATERIALS, V8, P5426, DOI 10.3390/ma8085253
   Wang Gen, 2023, Biomater Transl, V4, P27, DOI 10.12336/biomatertransl.2023.01.005
   Wang X, 2022, FOOD FUNCT, V13, P2913, DOI [10.1039/d1fo02755g, 10.1039/D1FO02755G]
   Yan J, 2024, J CONTROL RELEASE, V367, P620, DOI 10.1016/j.jconrel.2024.01.055
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhao LS, 2017, J FUNCT FOODS, V34, P159, DOI 10.1016/j.jff.2017.04.021
   Zhao YP, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202202143
   Zhou ZX, 2017, ADV DRUG DELIVER REV, V115, P115, DOI 10.1016/j.addr.2017.07.021
NR 44
TC 1
Z9 1
U1 13
U2 26
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD OCT 15
PY 2024
VL 498
AR 155188
DI 10.1016/j.cej.2024.155188
EA SEP 2024
PG 17
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA F9D3R
UT WOS:001312732400001
DA 2025 08 17
ER

PT J
AU Steinbeck, MJ
   Chernets, N
   Zhang, J
   Kurpad, DS
   Fridman, G
   Fridman, A
   Freeman, TA
AF Steinbeck, Marla J.
   Chernets, Natalie
   Zhang, Jun
   Kurpad, Deepa S.
   Fridman, Gregory
   Fridman, Alexander
   Freeman, Theresa A.
TI Skeletal Cell Differentiation Is Enhanced by Atmospheric Dielectric
   Barrier Discharge Plasma Treatment
SO PLOS ONE
LA English
DT Article
ID KINASE 1 ASK1; SIGNAL REGULATING KINASE 1; MESENCHYMAL STEM CELLS;
   HYDROGEN PEROXIDE; NITRIC OXIDE; CHONDROCYTE DIFFERENTIATION;
   MITOCHONDRIAL BIOGENESIS; SUPEROXIDE ANION; MAP KINASE; PATHWAY
AB Enhancing chondrogenic and osteogenic differentiation is of paramount importance in providing effective regenerative therapies and improving the rate of fracture healing. This study investigated the potential of non thermal atmospheric dielectric barrier discharge plasma (NT plasma) to enhance chondrocyte and osteoblast proliferation and differentiation. Although the exact mechanism by which NT plasma interacts with cells is undefined, it is known that during treatment the atmosphere is ionized generating extracellular reactive oxygen and nitrogen species (ROS and RNS) and an electric field. Appropriate NT plasma conditions were determined using lactate dehydrogenase release, flow cytometric live/dead assay, flow cytometric cell cycle analysis, and Western blots to evaluate DNA damage and mitochondrial integrity. We observed that specific NT plasma conditions were required to prevent cell death, and that loss of pre osteoblastic cell viability was dependent on intracellular ROS and RNS production. To further investigate the involvement of intracellular ROS, fluorescent intracellular dyes Mitosox (superoxide) and dihydrorhodamine (peroxide) were used to assess onset and duration after NT plasma treatment. Both intracellular superoxide and peroxide were found to increase immediately post NT plasma treatment. These increases were sustained for one hour but returned to control levels by 24 hr. Using the same treatment conditions, osteogenic differentiation by NT plasma was assessed and compared to peroxide or osteogenic media containing beta glycerolphosphate. Although both NT plasma and peroxide induced differentiation specific gene expression, neither was as effective as the osteogenic media. However, treatment of cells with NT plasma after 24 hr in osteogenic or chondrogenic media significantly enhanced differentiation as compared to differentiation media alone. The results of this study show that NT plasma can selectively initiate and amplify ROS signaling to enhance differentiation, and suggest this technology could be used to enhance bone fusion and improve healing after skeletal injury.
C1 [Steinbeck, Marla J.; Fridman, Gregory] Drexel Univ, Dept Biomed Engn, Philadelphia, PA 19104 USA.
   [Chernets, Natalie] Drexel Univ, Dept Elect Engn, Philadelphia, PA 19104 USA.
   [Zhang, Jun] Jilin Univ, Hosp 2, Dept Orthopaed, Changchun, Jilin, Peoples R China.
   [Zhang, Jun; Kurpad, Deepa S.; Freeman, Theresa A.] Thomas Jefferson Univ, Dept Orthopaed Surg, Philadelphia, PA 19107 USA.
   [Fridman, Alexander] Drexel Univ, Dept Mech Engn & Mech, Philadelphia, PA 19104 USA.
C3 Drexel University; Drexel University; Jilin University; Thomas Jefferson
   University; Drexel University
RP Freeman, TA (通讯作者)，Thomas Jefferson Univ, Dept Orthopaed Surg, Philadelphia, PA 19107 USA.
EM Theresa.freeman@jefferson.edu
RI ; Zhang, Donglei/AAB 7572 2022
OI Fridman, Gregory/0000 0003 4006 4722; Freeman,
   Theresa/0000 0002 5959 5884; 
FU NIH [1 R01 EB 013011   01, 5R03 DE020840 03]
FX This work was supported by NIH Grants 1 R01 EB 013011   01 (Freeman and
   Fridman) and 5R03 DE020840 03 (Freeman). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ahmad R, 2009, IMMUNOPHARM IMMUNOT, V31, P388, DOI 10.1080/08923970802709197
   Akterin S, 2006, CELL DEATH DIFFER, V13, P1454, DOI 10.1038/sj.cdd.4401818
   Arjunan K.P., 2011, Journal of the Royal Society Interface, prsif20110220
   Boota A, 1996, AM J PHYSIOL LUNG C, V271, pL932, DOI 10.1152/ajplung.1996.271.6.L932
   BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891 5849(94)00198 S
   Castagna R, 2009, TOXICOL IN VITRO, V23, P365, DOI 10.1016/j.tiv.2008.12.016
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Chen C, 2008, J EXP MED, V205, P2397, DOI 10.1084/jem.20081297
   Choe Y, 2011, J CELL BIOCHEM, DOI [10.1002/jcb.24017, DOI 10.1002/JCB.24017.[]
   Coulombe S, 2006, PURE APPL CHEM, V78, P1147, DOI 10.1351/pac200678061147
   Dobrynin D, 2009, NEW J PHYS, V11, DOI 10.1088/1367 2630/11/11/115020
   Faigle R, 2004, MOL CELL BIOL, V24, P280, DOI 10.1128/MCB.24.1.280 293.2004
   Forman HJ, 2010, BIOCHEMISTRY US, V49, P835, DOI 10.1021/bi9020378
   Fridman A, 2005, J PHYS D APPL PHYS, V38, pR1, DOI 10.1088/0022 3727/38/2/R01
   Fridman A., 2004, PLASMA PHYS ENG, P853
   Fridman G, 2008, PLASMA PROCESS POLYM, V5, P503, DOI 10.1002/ppap.200700154
   Fridman G, 2007, PLASMA PROCESS POLYM, V4, P370, DOI 10.1002/ppap.200600217
   Fridman G, 2006, PLASMA CHEM PLASMA P, V26, P425, DOI 10.1007/s11090 006 9024 4
   Ge C, 2011, J BONE MINER RES, DOI [10.1002/jbmr.561, DOI 10.1002/JBMR.561.[]
   Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200
   GLOVER J L, 1982, Lasers in Surgery and Medicine, V2, P101
   Gow AJ, 2001, J CELL PHYSIOL, V187, P277, DOI 10.1002/jcp.1085
   Hancock JT, 1997, BRIT J BIOMED SCI, V54, P38
   Hou YY, 2012, FREE RADICAL BIO MED, V52, P462, DOI 10.1016/j.freeradbiomed.2011.10.453
   Hsieh CC, 2006, FASEB J, V20, P259, DOI 10.1096/fj.05 4376com
   Ji AR, 2010, EXP MOL MED, V42, P175, DOI 10.3858/emm.2010.42.3.018
   Juarez JC, 2008, P NATL ACAD SCI USA, V105, P7147, DOI 10.1073/pnas.0709451105
   Kalghatgi S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016270
   Kalghatgi S, 2010, ANN BIOMED ENG, V38, P748, DOI 10.1007/s10439 009 9868 x
   Kamiya N, 2002, J BONE MINER RES, V17, P1832, DOI 10.1359/jbmr.2002.17.10.1832
   Kashiwase K, 2005, BIOCHEM BIOPH RES CO, V327, P136, DOI 10.1016/j.bbrc.2004.12.002
   Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893 901.2001
   Kushibiki T, 2010, J PHOTOCH PHOTOBIO B, V98, P211, DOI 10.1016/j.jphotobiol.2010.01.008
   Laroussi M, 2005, PLASMA PROCESS POLYM, V2, P391, DOI 10.1002/ppap.200400078
   Leduc M, 2009, NEW J PHYS, V11, DOI 10.1088/1367 2630/11/11/115021
   Li J, 2010, CELL PROLIFERAT, V43, P333, DOI 10.1111/j.1365 2184.2010.00682.x
   Lin IC, 2008, PLAST RECONSTR SURG, V121, P1554, DOI 10.1097/PRS.0b013e31816c3bd7
   Linnane AW, 2007, BIOGERONTOLOGY, V8, P445, DOI 10.1007/s10522 007 9096 4
   Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198 2208.2000
   Mandal CC, 2011, BIOCHEM J, V433, P393, DOI 10.1042/BJ20100357
   Matsuzawa A, 2008, BBA GEN SUBJECTS, V1780, P1325, DOI 10.1016/j.bbagen.2007.12.011
   Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028
   Motohashi H, 2010, BLOOD, V115, P677, DOI 10.1182/blood 2009 05 223107
   Mungrue IN, 2003, ACTA PHYSIOL SCAND, V179, P123, DOI 10.1046/j.1365 201X.2003.01182.x
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Nicco C, 2005, BIOMED PHARMACOTHER, V59, P169, DOI 10.1016/j.biopha.2005.03.009
   Parasassi T, 2010, THESCIENTIFICWORLDJO, V10, P1192, DOI 10.1100/tsw.2010.104
   Pervaiz S, 2007, INT J BIOCHEM CELL B, V39, P1297, DOI 10.1016/j.biocel.2007.04.007
   Tran P, 2012, J BIOL CHEM, V287, P11602, DOI 10.1074/jbc.M112.351601
   Rigoulet M, 2011, ANTIOXID REDOX SIGN, V14, P459, DOI 10.1089/ars.2010.3363
   Rosser J, 2012, METHODS MOL BIOL, V816, P67, DOI 10.1007/978 1 61779 415 5_6
   Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900
   Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200
   Shao JS, 2007, ANN NY ACAD SCI, V1117, P40, DOI 10.1196/annals.1402.075
   Shekhter AB, 2005, NITRIC OXIDE BIOL CH, V12, P210, DOI 10.1016/j.niox.2005.03.004
   Stanton LA, 2003, DEV BIOL, V263, P165, DOI 10.1016/S0012 1606(03)00321 X
   Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874
   Steinbeck MJ, 1998, J CELL PHYSIOL, V176, P574, DOI 10.1002/(SICI)1097 4652(199809)176:3<574::AID JCP14>3.0.CO;2 #
   Stone JR, 2006, ANTIOXID REDOX SIGN, V8, P243, DOI 10.1089/ars.2006.8.243
   Suy S, 1998, J BIOL CHEM, V273, P17871, DOI 10.1074/jbc.273.28.17871
   Takeda K, 2008, ANNU REV PHARMACOL, V48, P199, DOI 10.1146/annurev.pharmtox.48.113006.094606
   Teixeira CC, 2005, BONE, V37, P37, DOI 10.1016/j.bone.2005.03.010
   Terkhorn SP, 2007, J CELL PHYSIOL, V210, P257, DOI 10.1002/jcp.20873
   Vandamme M, 2010, PLASMA PROCESS POLYM, V7, P264, DOI 10.1002/ppap.200900080
   Vargo JJ, 2004, GASTROINTEST ENDOSC, V59, P81, DOI 10.1016/S0016 5107(03)02296 X
   Weng CC, 2009, INT J RADIAT BIOL, V85, P362, DOI 10.1080/09553000902781105
   Winterbourn CC, 2008, NAT CHEM BIOL, V4, P278, DOI 10.1038/nchembio.85
   Wu AS, 2013, J SURG RES, V179, pE1, DOI 10.1016/j.jss.2012.02.039
   Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511
   zur Nieden NI, 2007, J BIOTECHNOL, V129, P421, DOI 10.1016/j.jbiotec.2007.01.006
NR 70
TC 53
Z9 57
U1 0
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 12
PY 2013
VL 8
IS 12
AR e82143
DI 10.1371/journal.pone.0082143
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 276EU
UT WOS:000328731800040
PM 24349203
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Scavelli, C
   Di Pietro, G
   Cirulli, T
   Coluccia, M
   Boccarelli, A
   Giannini, T
   Mangialardi, G
   Bertieri, R
   Coluccia, AML
   Ribatti, D
   Dammacco, F
   Vacca, A
AF Scavelli, Claudio
   Di Pietro, Giulia
   Cirulli, Teresa
   Coluccia, Mauro
   Boccarelli, Angela
   Giannini, Teresa
   Mangialardi, Giuseppe
   Bertieri, Raffaello
   Coluccia, Addolorata Maria Luce
   Ribatti, Domenico
   Dammacco, Franco
   Vacca, Angelo
TI Zoledronic acid affects over angiogenic phenotype of endothelial cells
   in patients with multiple myeloma
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID BONE MARROW; GROWTH FACTOR; BISPHOSPHONATES INHIBIT; SUPPRESSION;
   PRENYLATION; EXPRESSION; PROSTATE; ADHESION; DISEASE; GENES
AB Therapeutic doses of zoledronic acid markedly inhibit in vitro proliferation, chemotaxis, and capillarogenesis of bone marrow endothelial cells of patients with multiple myeloma. Zoledronic acid also induces a sizeable reduction of angiogenesis in the in vivo chorioallantoic membrane assay. These effects are partly sustained by gene and protein inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in an autocrine loop. Mevastatin, a specific inhibitor of the mevalonate pathway, reverts the zoledronic acid antiangiogenic effect, indicating that the drug halts this pathway. Our results provide evidence of a direct antiangiogenic activity of zoledronic acid on multiple myeloma patient derived endothelial cells due to at least four different mechanisms identified either in vitro or in vivo. Tentatively, we suggest that the zoledronic acid antitumoral activity in multiple myeloma is also sustained by antiangiogenesis, which would partly account for its therapeutic efficacy in multiple myeloma.
C1 [Scavelli, Claudio; Di Pietro, Giulia; Cirulli, Teresa; Giannini, Teresa; Mangialardi, Giuseppe; Coluccia, Addolorata Maria Luce; Dammacco, Franco; Vacca, Angelo] Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, I 70124 Bari, Italy.
   [Coluccia, Mauro; Boccarelli, Angela] Univ Bari, Sch Med, Sect Gen Pathol, Bari, Italy.
   [Ribatti, Domenico] Univ Bari, Sch Med, Dept Human Anat & Histol, Bari, Italy.
   [Bertieri, Raffaello] Novartis Pharm, Origgio, Italy.
C3 Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari
   Aldo Moro; Universita degli Studi di Bari Aldo Moro; Novartis; Novartis
   Italy
RP Vacca, A (通讯作者)，Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, Piazza Giulio Cesare 11, I 70124 Bari, Italy.
EM a.vacca@dimo.uniba.it
RI Coluccia, Mauro/I 3533 2012; Vacca, Angelo/AAC 9558 2022; Angelina,
   Boccarelli/AAM 4813 2020; Dammacco, Franco/ABG 5728 2020
OI BOCCARELLI, Angelina/0000 0002 9514 2022; Vacca,
   Angelo/0000 0002 4567 8216; 
CR Beillard E, 2003, LEUKEMIA, V17, P2474, DOI 10.1038/sj.leu.2403136
   Bellamy WT, 1999, CANCER RES, V59, P728
   Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200
   Borset M, 1996, BLOOD, V88, P3998, DOI 10.1182/blood.V88.10.3998.bloodjournal88103998
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Clézardin P, 2002, SEMIN ONCOL, V29, P33, DOI 10.1053/sonc.2002.37420
   Corey E, 2003, CLIN CANCER RES, V9, P295
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630
   DURIE BGM, 1986, SEMIN ONCOL, V13, P300
   EDGELL CJ, 1983, P NATL ACAD SCI BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734
   Folkman J, 2001, THROMB HAEMOSTASIS, V86, P23
   Fournier P, 2002, CANCER RES, V62, P6538
   Guidolin D, 2004, MICROVASC RES, V67, P117, DOI 10.1016/j.mvr.2003.11.002
   Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538 7836.2006.02259.x
   Kyle RA, 2003, BRIT J HAEMATOL, V121, P749
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Podar K, 2005, BLOOD, V105, P1383, DOI 10.1182/blood 2004 07 2909
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Ria R, 2004, THROMB HAEMOSTASIS, V92, P1438, DOI 10.1160/TH04 06 0334
   Ribatti D, 2006, ONCOGENE, V25, P4257, DOI 10.1038/sj.onc.1209456
   Ribatti D, 2006, NAT PROTOC, V1, P85, DOI 10.1038/nprot.2006.13
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Tanaka Y, 2007, CLIN CANCER RES, V13, P816, DOI 10.1158/1078 0432.CCR 06 2258
   Vacca A, 2006, LEUKEMIA, V20, P193, DOI 10.1038/sj.leu.2404067
   Vacca A, 2005, J CLIN ONCOL, V23, P5334, DOI 10.1200/JCO.2005.03.723
   Vacca A, 2003, BLOOD, V102, P3340, DOI 10.1182/blood 2003 04 1338
   Vacca A, 2006, BLOOD, V108, P1661, DOI 10.1182/blood 2006 04 014563
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 31
TC 66
Z9 74
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD DEC
PY 2007
VL 6
IS 12
BP 3256
EP 3262
DI 10.1158/1535 7163.MCT 07 0311
PN 1
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 245HS
UT WOS:000251926300019
PM 18089719
OA Bronze
DA 2025 08 17
ER

PT J
AU Chen, L
   Lin, XY
   Wei, M
   Zhang, B
   Sun, YN
   Chen, X
   Zhang, ST
   Zhang, H
   Zhang, JY
   Yu, XJ
   Yao, BH
   Zhao, K
   Tang, YF
   Tan, QC
   Wu, ZX
AF Chen, Lei
   Lin, Xiuying
   Wei, Min
   Zhang, Bo
   Sun, Yani
   Chen, Xi
   Zhang, Shitong
   Zhang, Hao
   Zhang, Jieyu
   Yu, Xiaojiao
   Yao, Binghua
   Zhao, Kang
   Tang, Yufei
   Tan, Quanchang
   Wu, Zixiang
TI Hierarchical antibiotic delivery system based on calcium phosphate
   cement/montmorillonite gentamicin sulfate with drug release pathways
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE CPC/MMT GS; Drug release pathways; Release mechanism; Compressive
   strength; Antibacterial properties
ID BONE CEMENT; MONTMORILLONITE
AB Antibiotic loaded calcium phosphate cement (CPC) has emerged as a promising biomaterial for drug delivery in orthopedics. However, there are problems such as the burst release of antibiotics, low cumulative release ratio, inappropriate release cycle, inferior mechanical strength, and poor anti collapse properties. In this research, montmorillonite gentamicin (MMT GS) was fabricated by solution intercalation method and served as the drug release pathways in CPC to avoid burst release of GS, achieving promoted cumulative release ratios and a release cycle matched the time of inflammatory response. The results indicated that the highest cumulative release ratio and release concentration of GS in CPC/MMT GS was 94.1 +/  2.8 % and 1183.05 mu g/mL, and the release cycle was up to 504 h. In addition, the hierarchical GS delivery system was divided into three stages, and the kinetics followed the Korsmeyer Peppas model, the zero order model, and the diffusion dissolution model, respectively. Meanwhile, the compressive strength of CPC/MMT GS was up to 51.33 +/  3.62 MPa. Antibacterial results demonstrated that CPC/MMT GS exhibited excellent in vitro long lasting antibacterial properties to E. coli and S. aureus. Furthermore, CPC/MMT GS promoted osteoblast proliferation and exhibited excellent in vivo histocompatibility. Therefore, CPC/MMT GS has favorable application prospects in the treatment of bone defects with bacterial infections and inflammatory reactions.
C1 [Chen, Lei; Zhang, Jieyu; Yu, Xiaojiao; Yao, Binghua] Xian Univ Technol, Sch Sci, Xian 710054, Peoples R China.
   [Lin, Xiuying; Wei, Min; Zhang, Bo; Sun, Yani; Chen, Xi; Zhang, Shitong; Zhang, Hao; Zhao, Kang; Tang, Yufei] Xian Univ Technol, Sch Mat Sci & Engn, Xian 710048, Peoples R China.
   [Chen, Lei; Zhao, Kang; Tang, Yufei] Xian Univ Technol, Shaanxi Prov Key Lab Corros & Protect, Xian 710048, Peoples R China.
   [Tan, Quanchang; Wu, Zixiang] Fourth Mil Med Univ, Xijing Hosp, Inst Orthopaed, Xian 710032, Peoples R China.
C3 Xi'an University of Technology; Xi'an University of Technology; Xi'an
   University of Technology; Air Force Medical University
RP Tang, YF (通讯作者)，Xian Univ Technol, Sch Mat Sci & Engn, Xian 710048, Peoples R China.; Wu, ZX (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Inst Orthopaed, Xian 710032, Peoples R China.
EM yftang@xaut.edu.cn; wuzixiang@fmmu.edu.cn
RI Tan, QuanChang/HGA 0149 2022; Zhang, Bo/Q 7605 2018; Zhang,
   Shitong/AAX 9475 2021; Wu, Zixiang/MVX 5663 2025; tang,
   yufei/IST 8760 2023
FU National Natural Science Foundation of China [52172073, 22072114]; China
   Postdoctoral Science Foundation [2023MD734216]; Shaanxi Provincial
   Natural Science Basic Research Program [2023 JC QN 0382]; Shaanxi
   Provincial Department of Education Special Research Program Project
   [22JK0476]; Science and Technology Plan Projects in Beilin District
   [GX2238]; Research Initiation Fund of Xi'an University of Technology
   [109 451121010]
FX This work was supported by the National Natural Science Foundation of
   China (No. 52172073 and 22072114) , China Postdoctoral Science
   Foundation (No. 2023MD734216) , Shaanxi Provincial Natural Science Basic
   Research Program (No. 2023 JC QN 0382) , Shaanxi Provincial Department
   of Education Special Research Program Project (No. 22JK0476) , Science
   and Technology Plan Projects in Beilin District (No. GX2238) , Research
   Initiation Fund of Xi'an University of Technology (No. 109 451121010) .
CR Alkhraisat MH, 2008, BIOMATERIALS, V29, P4691, DOI 10.1016/j.biomaterials.2008.08.026
   Bakhsheshi Rad HR, 2019, J ALLOY COMPD, V773, P180, DOI 10.1016/j.jallcom.2018.08.310
   Balmayor ER, 2012, CARBOHYD POLYM, V87, P32, DOI 10.1016/j.carbpol.2011.06.078
   Bee SL, 2018, PROG POLYM SCI, V85, P57, DOI 10.1016/j.progpolymsci.2018.07.003
   BROWN WE, 1983, J DENT RES, V62, P672
   Chen L, 2023, J MECH BEHAV BIOMED, V147, DOI 10.1016/j.jmbbm.2023.106149
   Chen L, 2021, J MATER CHEM B, V9, P508, DOI 10.1039/d0tb01452d
   Cho Young Dan, 2018, J Bone Metab, V25, P9
   Cui ZK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11511 3
   Dolci LS, 2019, INT J PHARMACEUT, V554, P245, DOI 10.1016/j.ijpharm.2018.11.023
   Fan LJ, 2022, J MATER SCI TECHNOL, V111, P167, DOI 10.1016/j.jmst.2021.08.089
   Feng P, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202214726
   Fosca M, 2022, BIOACT MATER, V7, P341, DOI 10.1016/j.bioactmat.2021.05.032
   Haghbin Nazarpak M, 2010, CERAM SILIKATY, V54, P334
   Heinemann S, 2013, ACTA BIOMATER, V9, P6199, DOI 10.1016/j.actbio.2012.12.017
   Irbe Z, 2021, CERAM INT, V47, P24012, DOI 10.1016/j.ceramint.2021.05.110
   Jayrajsinh S, 2017, J DRUG DELIV SCI TEC, V39, P200, DOI 10.1016/j.jddst.2017.03.023
   Kar S, 2016, INT J BIOL MACROMOL, V82, P628, DOI 10.1016/j.ijbiomac.2015.10.060
   Ke Y, 2023, INT J BIOL MACROMOL, V243, DOI 10.1016/j.ijbiomac.2023.125330
   Khonsary SA., 2023, SURG NEUROL INT, V14, P91, DOI [10.25259/SNI1842023, DOI 10.25259/SNI1842023]
   Krüger R, 2012, BIOMATERIALS, V33, P5887, DOI 10.1016/j.biomaterials.2012.04.053
   Li W, 2021, COMPOS PART B ENG, V204, DOI 10.1016/j.compositesb.2020.108492
   Liu HL, 2023, COLLOID SURFACE B, V227, DOI 10.1016/j.colsurfb.2023.113382
   Losiewicz B, 2021, MATERIALS, V14, DOI 10.3390/ma14206142
   Mizuno K, 2022, J INORG BIOCHEM, V234, DOI 10.1016/j.jinorgbio.2022.111884
   Nandi SK, 2009, MAT SCI ENG C MATER, V29, P2478, DOI 10.1016/j.msec.2009.07.014
   Olad A, 2019, CERAM INT, V45, P15609, DOI 10.1016/j.ceramint.2019.05.071
   Pandey H, 2011, NANOSCALE, V3, P4104, DOI 10.1039/c1nr10661a
   Qi Q, 2023, WORLD NEUROSURG, V176, P10, DOI [10.1016/j.wneu.2023.04.048, 10.1016/j.wNEu.2023.04.048]
   Rapacz Kmita A, 2017, MAT SCI ENG C MATER, V70, P471, DOI 10.1016/j.msec.2016.09.031
   Ribeiro N, 2022, CERAM INT, V48, P33361, DOI 10.1016/j.ceramint.2022.07.279
   Roy A, 2016, MAT SCI ENG C MATER, V59, P92, DOI 10.1016/j.msec.2015.09.081
   Sang S, 2021, MAT SCI ENG C MATER, V124, DOI 10.1016/j.msec.2021.112069
   Shen YB, 2024, COMPOS PART B ENG, V271, DOI 10.1016/j.compositesb.2023.111159
   Shi MM, 2018, J INT MED RES, V46, P2803, DOI 10.1177/0300060518773023
   Shie MY, 2013, BIOMATERIALS, V34, P6589, DOI 10.1016/j.biomaterials.2013.05.075
   Song QX, 2024, BIOACT MATER, V32, P304, DOI 10.1016/j.bioactmat.2023.10.007
   Uchida K, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4560647
   Uskokovic V, 2017, J MATER CHEM B, V5, P6065, DOI [10.1039/c7tb01794d, 10.1039/C7TB01794D]
   Vorndran E, 2013, ACTA BIOMATER, V9, P9558, DOI 10.1016/j.actbio.2013.08.009
   Wei M, 2022, CERAM INT, V48, P35185, DOI 10.1016/j.ceramint.2022.08.117
   Xiang AS, 2011, J MEMBRANE SCI, V366, P104, DOI 10.1016/j.memsci.2010.09.052
   Yang Y, 2018, ACTA BIOMATER, V79, P265, DOI 10.1016/j.actbio.2018.08.015
   Zhu JJ, 2020, THERANOSTICS, V10, P6544, DOI 10.7150/thno.44428
NR 44
TC 4
Z9 4
U1 6
U2 25
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD JUN
PY 2024
VL 238
AR 113925
DI 10.1016/j.colsurfb.2024.113925
EA APR 2024
PG 11
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA SF8C7
UT WOS:001233123500001
PM 38657556
DA 2025 08 17
ER

PT J
AU Wu, XJ
   Ahn, EY
   McKenna, MA
   Yeo, H
   McDonald, JM
AF Wu, XJ
   Ahn, EY
   McKenna, MA
   Yeo, H
   McDonald, JM
TI Fas binding to calmodulin regulates apoptosis in osteoclasts
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID CHOLANGIOCARCINOMA CELLS; MEDIATED APOPTOSIS; KINASE ACTIVATION;
   CALCIUM CHANNELS; BONE RESORPTION; BREAST CANCER; IN VITRO; T CELLS;
   TAMOXIFEN; ANTAGONISTS
AB Promotion of osteoclast apoptosis is one therapeutic approach to osteoporosis. Calmodulin, the major intracellular Ca2+ receptor, modulates both osteoclastogenesis and bone resorption. The calmodulin antagonist, trifluoperazine, rescues bone loss in ovariectomized mice (Zhang, L., Feng, X., and McDonald, J. M. ( 2003) Endocrinology 144, 4536   4543). We show here that a 3 h treatment of mouse osteoclasts with either of the calmodulin antagonists, tamoxifen or trifluoperazine, induces osteoclast apoptosis dose  dependently. Tamoxifen, 10 mu M, and trifluoperazine, 10 mu M, induce 7.3 +/  1.8 fold and 5.3 +/  0.9 fold increases in osteoclast apoptosis, respectively. In Jurkat cells, calmodulin binds to Fas, the death receptor, and this binding is regulated during Fas mediated apoptosis (Ahn, E. Y., Lim, S. T., Cook, W. J., and McDonald, J. M. ( 2004) J. Biol. Chem. 279, 5661   5666). In osteoclasts, calmodulin also binds Fas. When osteoclasts are treated with 10 mu M trifluoperazine, the binding between Fas and calmodulin is dramatically decreased at 15 min and gradually recovers by 60 min. A point mutation of the Fas death domain in the Lpr (cg) mouse renders Fas inactive. Using glutathione S transferase fusion proteins, the human Fas cytoplasmic domain is shown to bind calmodulin, whereas a point mutation ( V254N) comparable with the Lpr cg mutation in mice has markedly reduced calmodulin binding. Osteoclasts derived from Lpr (cg) mice have diminished calmodulin/ Fas binding and are more sensitive to calmodulin antagonist induced apoptosis than those from wild type mice. Both tamoxifen and twrifluoperazine induced apoptosis are increased 1.6 +/  0.2 fold in Lpr( cg) derived osteoclasts compared with osteoclasts derived from wild type mice. In summary, calmodulin antagonists induce apoptosis in osteoclasts by a mechanism involving interference with calmodulin binding to Fas. The effects of calmodulin/ Fas binding on calmodulin antagonist induced apoptosis may open a new avenue for therapy for osteoporosis.
C1 Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.
   Vet Adm Med Ctr, Birmingham, AL 35233 USA.
C3 University of Alabama System; University of Alabama Birmingham; US
   Department of Veterans Affairs; Veterans Health Administration (VHA)
RP McDonald, JM (通讯作者)，Univ Alabama, Dept Pathol, 509 LHRB,1530 3rd Ave,Sd, Birmingham, AL 35294 USA.
EM mcdonald@uab.edu
CR ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756
   Ahn EY, 2004, J BIOL CHEM, V279, P5661, DOI 10.1074/jbc.M311040200
   Ahn EY, 2003, AM J PATHOL, V163, P2053, DOI 10.1016/S0002 9440(10)63563 8
   CHINNAIYAN AM, 1995, CELL, V81, P512
   Cohen P., 1988, CALMODULIN
   Evans J.S., 1988, CALMODULIN, P57
   FRANKFURT OS, 1995, CANCER LETT, V97, P149, DOI 10.1016/0304 3835(95)03970 8
   Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   ITOH N, 1993, J BIOL CHEM, V268, P10932
   KAMEDA T, 1995, BIOCHEM BIOPH RES CO, V207, P753, DOI 10.1006/bbrc.1995.1251
   Kimura M, 1994, Int Rev Immunol, V11, P193, DOI 10.3109/08830189409061727
   Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194
   Liao BR, 1999, P NATL ACAD SCI USA, V96, P6217, DOI 10.1073/pnas.96.11.6217
   LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302
   MAMARBACHI A, 1987, CELL CALCIUM, V8, P473, DOI 10.1016/0143 4160(87)90030 3
   Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Micoli KJ, 2000, J BIOL CHEM, V275, P1233, DOI 10.1074/jbc.275.2.1233
   Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143 4160(98)90116 6
   Pan G, 1999, AM J PATHOL, V155, P193, DOI 10.1016/S0002 9440(10)65113 9
   Pan G, 1998, IMMUNOPHARMACOLOGY, V40, P91, DOI 10.1016/S0162 3109(98)00018 6
   Radding W, 2000, AIDS RES HUM RETROV, V16, P1519, DOI 10.1089/088922200750006047
   Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499
   Rochat Steiner V, 2000, J EXP MED, V192, P1165, DOI 10.1084/jem.192.8.1165
   SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003 2697(91)90243 M
   SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343
   Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097 2765(02)00482 3
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   VANELDIK LJ, 1998, CALMODULIN SIGNAL T
   WATANABEFUKUNAG.R, 1992, NATURE, V356, P317
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Williams JP, 1996, J BIOL CHEM, V271, P12488, DOI 10.1074/jbc.271.21.12488
   Williams JP, 2000, BIOCHEM CELL BIOL, V78, P715, DOI 10.1139/bcb 78 6 715
   Wu XJ, 2005, J BONE MINER RES, V20, P107, DOI 10.1359/JBMR.041022
   Wu XJ, 2003, ENDOCRINOLOGY, V144, P5545, DOI 10.1210/en.2003 0296
   Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147
   Zhang L, 2003, ENDOCRINOLOGY, V144, P4536, DOI 10.1210/en.2003 0147
   Zühlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200
NR 39
TC 44
Z9 50
U1 0
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 19
PY 2005
VL 280
IS 33
BP 29964
EP 29970
DI 10.1074/jbc.M500710200
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 954SX
UT WOS:000231176200069
PM 15965236
OA hybrid, Green Accepted
DA 2025 08 17
ER

PT J
AU Saidova, AA
   Vorobjev, IA
AF Saidova, Aleena A.
   Vorobjev, Ivan A.
TI Lineage Commitment, Signaling Pathways, and the Cytoskeleton Systems in
   Mesenchymal Stem Cells
SO TISSUE ENGINEERING PART B REVIEWS
LA English
DT Article
DE MSC; cytoskeleton; signaling pathways; actin; microtubules;
   differentiation; mechanotransduction; nucleoskeleton
ID FOCAL ADHESION KINASE; HIPPO YAP PATHWAY; BONE MARROW; OSTEOGENIC
   DIFFERENTIATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; OSTEOBLAST
   DIFFERENTIATION; SURFACE CHEMISTRY; PRIMARY CILIA; REGULATES
   CHONDROGENESIS
AB Mesenchymal stem cells (MSCs) from adult tissues are promising candidates for personalized cell therapy and tissue engineering. Significant progress was achieved in our understanding of the regulation of MSCs proliferation and differentiation by different cues during the past years. Proliferation and differentiation of MSCs are sensitive to the extracellular matrix (ECM) properties, physical cues, and chemical signaling. Sheath stress, matrix stiffness, surface adhesiveness, and micro  and nanotopography define cell shape and dictate lineage commitment of MSCs even in the absence of specific chemical signals. We discuss mechanotransduction as the major route from ECM through the cytoskeleton toward signaling pathways and gene expression. All components of the cytoskeleton from primary cilium and focal adhesions (FAs) to actin, microtubules (MTs), and intermediate filaments (IFs) are involved in the mechanotransduction. Differentiation of MSCs is regulated via the complex network of interrelated signaling pathways, including RhoA/ROCK, Akt/Erk, and YAP/TAZ effectors of Hippo pathway. These pathways could be regulated both by chemical and mechanical stimuli. Attenuation of these pathways in MSCs results in specific changes in FAs and actin cytoskeleton. Besides, differentiation of MSCs affects MTs and IFs. Recent findings highlight the role of intranuclear actin in the regulation of transcription factors in response to mechanical environmental stimuli. Alterations of cytoskeletal components reflect the MSC senescence state and their migratory capacity. In this review, we discuss the relationships between the molecular interactions in signaling pathways and morphological response of cytoskeletal components and reveal the complex interrelations between cytoskeleton systems and signaling pathways during lineage commitment of MSCs. Impact Statement This review describes the complex network of relationships between mechanical and biochemical stimuli in mesenchymal stem cells (MSC) and their balance which defines the morphological changes of cell shape due to rearrangement of cytoskeletal systems during lineage commitment of MSCs.
C1 [Saidova, Aleena A.; Vorobjev, Ivan A.] Moscow MV Lomonosov State Univ, Biol Fac, Leninskiye Gori 1 12, Moscow 119991, Russia.
   [Saidova, Aleena A.] Ctr Expt Embryol & Reprod Biotechnol, Moscow, Russia.
   [Vorobjev, Ivan A.] Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow, Russia.
   [Vorobjev, Ivan A.] Nazarbayev Univ, Sch Sci & Humanities, Dept Biol, Nur Sultan, Kazakhstan.
   [Vorobjev, Ivan A.] Nazarbayev Univ, Natl Lab Astana, Nur Sultan, Kazakhstan.
C3 Lomonosov Moscow State University; Center for Experimental Embryology &
   Reproductive Biotechnologies; Lomonosov Moscow State University;
   Nazarbayev University; Nazarbayev University
RP Saidova, AA (通讯作者)，Moscow MV Lomonosov State Univ, Biol Fac, Leninskiye Gori 1 12, Moscow 119991, Russia.
EM saidova@mail.bio.msu.ru
RI ; Vorobjev, Ivan/B 2776 2015; Saidova, Aleena/AAQ 3962 2020
OI Saidova, Aleena/0000 0003 3294 7146; 
FU Russian Foundation for Basic Research [17 54 33009]; State Grant of the
   Republic of Kazakhstan [AP05134232]; Lomonosov Moscow State University
   Program of Development
FX This research was supported, in part, by the Russian Foundation for
   Basic Research (17 54 33009), State Grant of the Republic of Kazakhstan
   (AP05134232) to I.V. and through the Lomonosov Moscow State University
   Program of Development.
CR Alieva IB, 2004, CELL BIOL INT, V28, P139, DOI 10.1016/j.cellbi.2003.11.013
   Annabi B, 2004, J CELL BIOCHEM, V91, P1146, DOI 10.1002/jcb.10763
   Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042
   Arnsdorf EJ, 2009, J CELL SCI, V122, P546, DOI 10.1242/jcs.036293
   Aszodi A, 2003, GENE DEV, V17, P2465, DOI 10.1101/gad.277003
   Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<73::AID JCB11>3.0.CO;2 L
   Beloglazova IB, 2016, B EXP BIOL MED+, V161, P775, DOI 10.1007/s10517 016 3507 y
   Bernal A, 2018, CELL MOL LIFE SCI, V75, P2177, DOI 10.1007/s00018 018 2794 z
   Bershadsky AD, 2003, ANNU REV CELL DEV BI, V19, P677, DOI 10.1146/annurev.cellbio.19.111301.153011
   Bertolo A, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 38546 2
   Bertolo A, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 016 0452 7
   Born AK, 2009, EUR CELLS MATER, V18, P49
   Byron A, 2016, CURR OPIN CELL BIOL, V39, P93, DOI 10.1016/j.ceb.2016.02.013
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Cavalcanti Adam EA, 2008, HFSP J, V2, P276, DOI 10.2976/1.2976662
   Chahine NO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061651
   Chang SH, 1998, J BIOL CHEM, V273, P19213, DOI 10.1074/jbc.273.30.19213
   Chang TH, 2014, BIOMATERIALS, V35, P3934, DOI 10.1016/j.biomaterials.2014.01.028
   Chen B, 2015, ANNU REV BIOPHYS, V44, P1, DOI 10.1146/annurev biophys 051013 023102
   Chen JC, 2016, FASEB J, V30, P1504, DOI 10.1096/fj.15 276402
   Chen S, 2017, STEM CELL REP, V8, P773, DOI 10.1016/j.stemcr.2017.01.028
   Corrigan MA, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 22174 3
   Curran JM, 2006, BIOMATERIALS, V27, P4783, DOI 10.1016/j.biomaterials.2006.05.001
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Dalby MJ, 2014, NAT MATER, V13, P558, DOI [10.1038/NMAT3980, 10.1038/nmat3980]
   Darling EM, 2008, J BIOMECH, V41, P454, DOI 10.1016/j.jbiomech.2007.06.019
   Di Maggio N, 2017, SCI REP UK, V7, DOI 10.1038/srep44398
   Dopie J, 2012, P NATL ACAD SCI USA, V109, pE544, DOI 10.1073/pnas.1118880109
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Eckes B, 1998, J CELL SCI, V111, P1897
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Ersahin T, 2015, MOL BIOSYST, V11, P1946, DOI 10.1039/c5mb00101c
   Fazeli Z, 2016, J CELL COMMUN SIGNAL, V10, P273, DOI 10.1007/s12079 016 0334 x
   Ferreira RR, 2019, J CELL SCI, V132, DOI 10.1242/jcs.213496
   FRIEDENSTEIN AJ, 1966, J EMBRYOL EXP MORPH, V16, P381
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365 2184.1970.tb00347.x
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890 196803000 00009
   Frith JE, 2012, J CELL SCI, V125, P317, DOI 10.1242/jcs.087916
   Gao H, 2009, STEM CELLS, V27, P857, DOI 10.1002/stem.23
   Geissler S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052700
   Grassel S, 2007, FRONT BIOSCI, V12, P4946, DOI 10.2741/2440
   Graziano A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000496
   Gruber R, 2004, PLATELETS, V15, P29, DOI 10.1080/09537100310001643999
   Guan SP, 2018, FEBS OPEN BIO, V8, P15, DOI 10.1002/2211 5463.12330
   Guilak F, 2009, CELL STEM CELL, V5, P17, DOI 10.1016/j.stem.2009.06.016
   Guo M, 2013, BIOPHYS J, V105, P1562, DOI 10.1016/j.bpj.2013.08.037
   Gurkan UA, 2008, ANN BIOMED ENG, V36, P1978, DOI 10.1007/s10439 008 9577 x
   Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Hao LJ, 2016, COLLOID SURFACE B, V148, P549, DOI 10.1016/j.colsurfb.2016.09.027
   Hoey DA, 2012, STEM CELLS, V30, P2561, DOI 10.1002/stem.1235
   Hu KZ, 2017, BIOMED PHARMACOTHER, V91, P841, DOI 10.1016/j.biopha.2017.04.094
   Huang IH, 2014, J CELL SCI, V127, P4186, DOI 10.1242/jcs.150227
   Huang JH, 2009, NANO LETT, V9, P1111, DOI 10.1021/nl803548b
   Hwang JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135519
   Iihoshi S, 2004, BRAIN RES, V1007, P1, DOI 10.1016/j.brainres.2003.09.084
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Janson IA, 2015, J BIOMED MATER RES A, V103, P1246, DOI 10.1002/jbm.a.35254
   Jarocha D, 2015, CELL TRANSPLANT, V24, P661, DOI 10.3727/096368915X687796
   Johnson GP, 2018, J CELL SCI, V131, DOI 10.1242/jcs.222737
   Jung EM, 2011, BIOCHEM BIOPH RES CO, V404, P463, DOI 10.1016/j.bbrc.2010.12.003
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Kasper G, 2009, STEM CELLS, V27, P1288, DOI 10.1002/stem.49
   Keselowsky BG, 2003, J BIOMED MATER RES A, V66A, P247, DOI 10.1002/jbm.a.10537
   Keselowsky BG, 2004, BIOMATERIALS, V25, P5947, DOI 10.1016/j.biomaterials.2004.01.062
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Lan MA, 2005, BIOMATERIALS, V26, P4523, DOI 10.1016/j.biomaterials.2004.11.028
   Langelier E, 2000, J HISTOCHEM CYTOCHEM, V48, P1307, DOI 10.1177/002215540004801002
   Lavenus S, 2011, EUR CELLS MATER, V22, P84, DOI 10.22203/eCM.v022a07
   Lee JH, 2016, BIOCHEM BIOPH RES CO, V473, P752, DOI 10.1016/j.bbrc.2015.09.081
   Li H, 2015, CELL DEATH DIFFER, V22, P1935, DOI 10.1038/cdd.2015.99
   Li Wen Ge, 2005, Chin J Traumatol, V8, P349
   Li YJ, 2004, J ORTHOP RES, V22, P1283, DOI 10.1016/j.orthres.2004.04.002
   Lim YB, 2000, BIOCHEM BIOPH RES CO, V273, P609, DOI 10.1006/bbrc.2000.2987
   Liu J, 2005, CELL METAB, V2, P165, DOI 10.1016/j.cmet.2005.08.006
   Liu LN, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan2966
   Liu Y, 2014, NANO LETT, V14, P5539, DOI 10.1021/nl501912g
   Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006 3495(00)76279 5
   Lu ZF, 2008, BIOCHEM BIOPH RES CO, V372, P547, DOI 10.1016/j.bbrc.2008.05.063
   Lück S, 2013, COMPUTATION STAT, V28, P139, DOI 10.1007/s00180 011 0265 1
   Luo WJ, 2008, EXP CELL RES, V314, P3382, DOI 10.1016/j.yexcr.2008.07.003
   Makita R, 2008, AM J PHYSIOL RENAL, V294, pF542, DOI 10.1152/ajprenal.00201.2007
   Mathieu PS, 2012, TISSUE ENG PART B RE, V18, P436, DOI [10.1089/ten.teb.2012.0014, 10.1089/ten.TEB.2012.0014]
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   McGlashan SR, 2006, J HISTOCHEM CYTOCHEM, V54, P1005, DOI 10.1369/jhc.5A6866.2006
   McNamara LE, 2011, BIOMATERIALS, V32, P7403, DOI 10.1016/j.biomaterials.2011.06.063
   Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Menuki K, 2008, BONE, V43, P613, DOI 10.1016/j.bone.2008.04.022
   Meriane M, 2006, STEM CELLS, V24, P2557, DOI 10.1634/stemcells.2006 0209
   Mishra P, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 46682 y
   Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008 5472.CAN 08 0943
   MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896 6273(88)90124 9
   Mizuno M, 2001, J BIOCHEM TOKYO, V129, P133, DOI 10.1093/oxfordjournals.jbchem.a002824
   Mo JS, 2012, GENE DEV, V26, P2138, DOI 10.1101/gad.197582.112
   Moghaddam MM, 2019, ARTIF CELL NANOMED B, V47, P1022, DOI 10.1080/21691401.2019.1586718
   Morin Kensicki EM, 2006, MOL CELL BIOL, V26, P77, DOI 10.1128/MCB.26.1.77 87.2006
   Müller P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071283
   Nardone G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15321
   Nathan AS, 2011, ACTA BIOMATER, V7, P57, DOI 10.1016/j.actbio.2010.08.007
   Nauli SM, 2008, CIRCULATION, V117, P1161, DOI 10.1161/CIRCULATIONAHA.107.710111
   Nemeth CL, 2014, TISSUE ENG PT A, V20, P2817, DOI [10.1089/ten.tea.2013.0614, 10.1089/ten.TEA.2013.0614]
   Ng F, 2008, BLOOD, V112, P295, DOI 10.1182/blood 2007 07 103697
   Nobusue H, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4368
   Nöth U, 2002, J ORTHOP RES, V20, P1060, DOI 10.1016/S0736 0266(02)00018 9
   Ode A, 2011, EUR CELLS MATER, V22, P26, DOI 10.22203/eCM.v022a03
   Ofek G, 2009, BIOPHYS J, V97, P1873, DOI 10.1016/j.bpj.2009.07.050
   Oh S, 2009, P NATL ACAD SCI USA, V106, P2130, DOI 10.1073/pnas.0813200106
   Olivares Navarrete R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170312
   Oliver De La Cruz J, 2019, BIOMATERIALS, V205, P64, DOI 10.1016/j.biomaterials.2019.03.009
   Ono N, 2014, DEV CELL, V29, P330, DOI 10.1016/j.devcel.2014.03.014
   Ozkul Y, 2016, J CELL PHYSIOL, V231, P2393, DOI 10.1002/jcp.25371
   Pan JX, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0018 7
   Percipalle P, 2013, NUCLEUS AUSTIN, V4, P43, DOI 10.4161/nucl.22798
   Petrie TA, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001002
   Phillips JE, 2010, ACTA BIOMATER, V6, P12, DOI 10.1016/j.actbio.2009.07.023
   Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Plouffe SW, 2018, J BIOL CHEM, V293, P11230, DOI 10.1074/jbc.RA118.002715
   Plouffe SW, 2016, MOL CELL, V64, P993, DOI 10.1016/j.molcel.2016.10.034
   Price S. T., 2015, INT J STEM CELL RES, V2, P2, DOI [DOI 10.23937/2469 570X/1410014, 10.23937/2469 570x/1410014]
   Proulx Bonneau S, 2011, BIOMARK INSIGHTS, V6, P107, DOI 10.4137/BMI.S8247
   Razafiarison T, 2018, P NATL ACAD SCI USA, V115, P4631, DOI 10.1073/pnas.1704543115
   Reagan MR, 2011, STEM CELLS, V29, P920, DOI 10.1002/stem.645
   Roberts JN, 2016, ACS NANO, V10, P6667, DOI 10.1021/acsnano.6b01765
   Rodríguez JP, 2004, J CELL BIOCHEM, V93, P721, DOI 10.1002/jcb.20234
   Rotsch C, 2000, BIOPHYS J, V78, P520, DOI 10.1016/S0006 3495(00)76614 8
   Sackstein R, 2005, CURR OPIN HEMATOL, V12, P444, DOI 10.1097/01.moh.0000177827.78280.79
   Saidova, 2018, ANN RES REV BIOL, V29, P1, DOI [10.9734/ARRB/2018/45687, DOI 10.9734/ARRB/2018/45687]
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Schwarz US, 2006, BIOSYSTEMS, V83, P225, DOI 10.1016/j.biosystems.2005.05.019
   Sen B, 2017, STEM CELLS, V35, P1624, DOI 10.1002/stem.2617
   Sen B, 2015, STEM CELLS, V33, P3065, DOI 10.1002/stem.2090
   Sen B, 2014, J BONE MINER RES, V29, P78, DOI 10.1002/jbmr.2031
   Sethe S, 2006, AGEING RES REV, V5, P91, DOI 10.1016/j.arr.2005.10.001
   Sharma P, 2017, ANN BIOMED ENG, V45, P1365, DOI 10.1007/s10439 016 1787 z
   Song JP, 2017, HYPERTENSION, V70, P324, DOI 10.1161/HYPERTENSIONAHA.117.09584
   Sonowal H, 2013, J BIOMED SCI, V20, DOI 10.1186/1423 0127 20 71
   Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936
   SPIEGELMAN BM, 1982, CELL, V29, P53, DOI 10.1016/0092 8674(82)90089 7
   Squillaro T, 2016, CELL TRANSPLANT, V25, P829, DOI 10.3727/096368915X689622
   Stavenschi E, 2019, FASEB J, V33, P4178, DOI 10.1096/fj.201801474RR
   Sun MY, 2018, INT J MED SCI, V15, P257, DOI 10.7150/ijms.21620
   Takahashi I, 2003, EUR J CELL BIOL, V82, P182, DOI 10.1078/0171 9335 00307
   Tate MLK, 2008, INT J BIOCHEM CELL B, V40, P2720, DOI 10.1016/j.biocel.2008.05.011
   Taylor MD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000813
   Tew LS, 2018, RSC ADV, V8, P6551, DOI 10.1039/c7ra12234a
   Tondreau T, 2004, DIFFERENTIATION, V72, P319, DOI 10.1111/j.1432 0436.2004.07207003.x
   Trappmann B, 2012, NAT MATER, V11, P642, DOI [10.1038/NMAT3339, 10.1038/nmat3339]
   Trickey WR, 2004, J ORTHOPAED RES, V22, P131, DOI 10.1016/S0736 0266(03)00150 5
   Tumbar T, 2001, NAT CELL BIOL, V3, P134, DOI 10.1038/35055033
   Tvorogova A.A., 2018, INT J VET SCI RES, V4, P23, DOI DOI 10.17352/IJVSR.000032
   Ullah M, 2019, ISCIENCE, V15, P421, DOI 10.1016/j.isci.2019.05.004
   Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376
   Vertelov G, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt153
   WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161
   Wang N, 1998, HYPERTENSION, V32, P162, DOI 10.1161/01.HYP.32.1.162
   Wang ZY, 2014, P NATL ACAD SCI USA, V111, pE89, DOI 10.1073/pnas.1319190110
   Wei X, 2013, ACTA PHARMACOL SIN, V34, P747, DOI 10.1038/aps.2013.50
   Whitesides George M, 2005, Sci Prog, V88, P17, DOI 10.3184/003685005783238462
   Wiese C, 2004, CELL MOL LIFE SCI, V61, P2510, DOI 10.1007/s00018 004 4144 6
   Wong A, 2014, BMC VET RES, V10, DOI 10.1186/s12917 014 0173 z
   Woods A, 2005, J BIOL CHEM, V280, P11626, DOI 10.1074/jbc.M409158200
   Woods A, 2006, J BIOL CHEM, V281, P13134, DOI 10.1074/jbc.M509433200
   Xie J, 2018, ACTA BIOMATER, V79, P83, DOI 10.1016/j.actbio.2018.08.018
   Yang HS, 2016, ADV HEALTHC MATER, V5, P137, DOI 10.1002/adhm.201500003
   Yang YT, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0836 y
   Ye K, 2015, NANO LETT, V15, P4720, DOI 10.1021/acs.nanolett.5b01619
   Yeung T, 2005, CELL MOTIL CYTOSKEL, V60, P24, DOI 10.1002/cm.20041
   Yourek G, 2007, ASAIO J, V53, P219, DOI 10.1097/MAT.0b013e31802deb2d
   Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037
   Yu JH, 2011, HUM MOL GENET, V20, P1061, DOI 10.1093/hmg/ddq549
   Zamir E, 2001, J CELL SCI, V114, P3583
   Zhang T, 2018, CELL TISSUE RES, V373, P379, DOI 10.1007/s00441 018 2815 0
   Zhang WX, 2008, J BIOL CHEM, V283, P4723, DOI 10.1074/jbc.M704147200
   Zhang XC, 2009, NEURON, V64, P173, DOI 10.1016/j.neuron.2009.08.018
   Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303
   Zhou S, 2008, AGING CELL, V7, P335, DOI 10.1111/j.1474 9726.2008.00377.x
   Zhou Y, 2017, J CELL MOL MED, V21, P1073, DOI 10.1111/jcmm.12946
NR 182
TC 74
Z9 80
U1 7
U2 74
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3368
EI 1937 3376
J9 TISSUE ENG PART B RE
JI Tissue Eng. Part B Rev.
PD FEB 1
PY 2020
VL 26
IS 1
BP 13
EP 25
DI 10.1089/ten.teb.2019.0250
EA NOV 2019
PG 13
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering;
   Materials Science
GA KI1SM
UT WOS:000498899100001
PM 31663422
OA Bronze
DA 2025 08 17
ER

PT J
AU Cao, X
   Wu, XW
   Frassica, D
   Yu, B
   Pang, LJ
   Xian, LL
   Wan, M
   Lei, WQ
   Armour, M
   Tryggestad, E
   Wong, J
   Wen, CY
   Lu, WW
   Frassica, FJ
AF Cao, Xu
   Wu, Xiangwei
   Frassica, Deborah
   Yu, Bing
   Pang, Lijuan
   Xian, Lingling
   Wan, Mei
   Lei, Weiqi
   Armour, Michael
   Tryggestad, Erik
   Wong, John
   Wen, Chun Yi
   Lu, William Weijia
   Frassica, Frank J.
TI Irradiation induces bone injury by damaging bone marrow microenvironment
   for stem cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE CFU fibroblast; repopulation; differentiation; self renewal; angiography
ID TRANSPLANTATION; ANGIOGENESIS; OSTEOGENESIS; ORIGIN; DIFFERENTIATION;
   CHEMOTHERAPY; ENGRAFTMENT; MIGRATION; CAPACITY; THERAPY
AB Radiation therapy can result in bone injury with the development of fractures and often can lead to delayed and nonunion of bone. There is no prevention or treatment for irradiation induced bone injury. We irradiated the distal half of the mouse left femur to study the mechanism of irradiation induced bone injury and found that no mesenchymal stem cells (MSCs) were detected in irradiated distal femora or nonirradiated proximal femora. The MSCs in the circulation doubled at 1 week and increased fourfold after 4 wk of irradiation. The number of MSCs in the proximal femur quickly recovered, but no recovery was observed in the distal femur. The levels of free radicals were increased threefold at 1 wk and remained at this high level for 4 wk in distal femora, whereas the levels were increased at 1 wk and returned to the basal level at 4 wk in nonirradiated proximal femur. Free radicals diffuse ipsilaterally to the proximal femur through bone medullary canal. The blood vessels in the distal femora were destroyed in angiographic images, but not in the proximal femora. The osteoclasts and osteoblasts were decreased in the distal femora after irradiation, but no changes were observed in the proximal femora. The total bone volumes were not affected in proximal and distal femora. Our data indicate that irradiation produces free radicals that adversely affect the survival of MSCs in both distal and proximal femora. Irradiation injury to the vasculatures and the microenvironment affect the niches for stem cells during the recovery period.
C1 [Cao, Xu; Wu, Xiangwei; Yu, Bing; Pang, Lijuan; Xian, Lingling; Wan, Mei; Lei, Weiqi; Frassica, Frank J.] Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD 21205 USA.
   [Frassica, Deborah] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21205 USA.
   [Armour, Michael; Tryggestad, Erik; Wong, John] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol Med Phys, Baltimore, MD 21205 USA.
   [Wu, Xiangwei; Pang, Lijuan] Shihezi Univ, Shihezi Med Coll, Shihezi Xinjiang 832002, Peoples R China.
   [Wen, Chun Yi; Lu, William Weijia] Univ Hong Kong, Dept Orthopaed, Hong Kong 999777, Hong Kong, Peoples R China.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; Shihezi University; University of Hong Kong
RP Cao, X (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD 21205 USA.
EM xcao11@jhmi.edu; ffrassi@jhmi.edu
RI Lu, William Weijia/C 4358 2009; WEN, Chunyi/P 4168 2017
OI Lu, William Weijia/0000 0002 5780 2886; WEN, Chunyi/0000 0003 1949 7822
CR Baxter NN, 2005, JAMA J AM MED ASSOC, V294, P2587, DOI 10.1001/jama.294.20.2587
   COSTANTINO PD, 1995, OTOLARYNG CLIN N AM, V28, P1021
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Deng H, 2007, PHYS MED BIOL, V52, P2729, DOI 10.1088/0031 9155/52/10/007
   Dickhut A, 2005, ANN HEMATOL, V84, P722, DOI 10.1007/s00277 005 1067 8
   Epperly MW, 2004, RADIAT RES, V162, P233, DOI 10.1667/RR3224
   Garrett RW, 2009, CELL STEM CELL, V4, P503, DOI 10.1016/j.stem.2009.05.011
   Gerson SL, 1999, NAT MED, V5, P262, DOI 10.1038/6470
   Greenberger JS, 2007, IN VIVO, V21, P141
   Greenberger JS, 2009, SEMIN RADIAT ONCOL, V19, P133, DOI 10.1016/j.semradonc.2008.11.006
   HARRISON DE, 1978, J EXP MED, V147, P1526, DOI 10.1084/jem.147.5.1526
   HARRISON DE, 1982, J EXP MED, V156, P1767, DOI 10.1084/jem.156.6.1767
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Jegoux F, 2010, ORAL SURG ORAL MED O, V109, P173, DOI 10.1016/j.tripleo.2009.10.001
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kawada H, 2004, BLOOD, V104, P3581, DOI 10.1182/blood 2004 04 1488
   Koç ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307
   Koç ON, 1999, EXP HEMATOL, V27, P1675, DOI 10.1016/S0301 472X(99)00101 0
   Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092 8674(01)00328 2
   Lee KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   MAUCH P, 1995, INT J RADIAT ONCOL, V31, P1319, DOI 10.1016/0360 3016(94)00430 S
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Rieger K, 2005, EXP HEMATOL, V33, P605, DOI 10.1016/j.exphem.2005.02.004
   Schipani E, 2009, J BONE MINER RES, V24, P1347, DOI [10.1359/JBMR.090602, 10.1359/jbmr.090602]
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   WERTS ED, 1980, RADIAT RES, V81, P20, DOI 10.2307/3575360
   Yin T, 2006, J CLIN INVEST, V116, P1195, DOI 10.1172/JCI28568
NR 31
TC 200
Z9 228
U1 0
U2 24
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 25
PY 2011
VL 108
IS 4
BP 1609
EP 1614
DI 10.1073/pnas.1015350108
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 711MD
UT WOS:000286594800074
PM 21220327
OA Green Published
DA 2025 08 17
ER

PT J
AU Pujia, A
   Gazzaruso, C
   Montalcini, T
AF Pujia, Arturo
   Gazzaruso, Carmine
   Montalcini, Tiziana
TI An update on the potential role of C peptide in diabetes and
   osteoporosis
SO ENDOCRINE
LA English
DT Article
DE C peptide; Diabetes; Osteoporosis; Fractures; Intracellular signaling
ID BONE MINERAL DENSITY; GLYCEMIC CONTROL; RENAL FUNCTION; K+ ATPASE;
   GLUCOSE UTILIZATION; TUBULAR CELLS; TYPE 1; INSULIN; MELLITUS;
   PREVALENCE
AB Purpose C peptide secretion is deficient or absent in type 1 diabetes mellitus. It is well accepted that insulin replacement therapy cannot prevent the development of long term diabetes related complications, which can often be disabling or even life threatening. Several cross sectional investigations have suggested that residual C peptide production in patients with type 1 diabetes mellitus would help prevent a number of complications. In animal models of diabetes and in patients with type 1 diabetes mellitus, C peptide replacement improves renal function, skin and skeletal muscle blood flow, nerve conduction, glucose utilization, and other diabetes related complications. Recent investigations suggest a new beneficial effect of C peptide, which to date has never been studied. It is known that osteoporosis is the most prevalent short term complication in type 1 diabetes mellitus. This review will highlight new insights into the pathophysiology and future therapeutic modalities for osteoporosis in individuals with diabetes.
   Methods This review provides a concise summary of old and new insights into the role of C peptide in diabetes related complications.
   Results The data suggest that C peptide is a bioactive peptide, acting independently of insulin, which binds to a G protein coupled membrane binding site in different cell types. By triggering Ca2+ dependent intracellular signaling pathways, both Na+, K+ ATPase and endothelial nitric oxide synthase are activated. C peptide may act on osteoblast cells by ERK 1/2 pathway activation, modulate collagen biosynthesis and RANKL expression. Furthermore, C peptide deficient postmenopausal women, not affected by diabetes, have a lower bone mineral density than those with normal C peptide levels.
   Conclusion Taken together these studies encourage further investigations to elucidate the role of C peptide in preventing bone loss in type 1 diabetes mellitus and in those individuals with C peptide deficiency and osteoporosis.
C1 [Pujia, Arturo] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Clin Nutr Unit, I 88100 Catanzaro, Italy.
   [Gazzaruso, Carmine] Clin Inst Beato Matteo, Internal & Emergency Med, I 27029 Vigevano, Italy.
   [Gazzaruso, Carmine] Clin Inst Beato Matteo, Ctr Appl Clin Res Ce RCA, I 27029 Vigevano, Italy.
   [Montalcini, Tiziana] Magna Graecia Univ Catanzaro, Dept Clin & Expt Med, Clin Nutr Unit, Menopause Clin, I 88100 Catanzaro, Italy.
C3 Magna Graecia University of Catanzaro; Magna Graecia University of
   Catanzaro
RP Montalcini, T (通讯作者)，Magna Graecia Univ Catanzaro, Dept Clin & Expt Med, Clin Nutr Unit, Menopause Clin, I 88100 Catanzaro, Italy.
EM tmontalcini@unicz.it
RI Gazzaruso, Carmine/F 9072 2018; Montalcini, Tiziana/AGV 1479 2022
OI Gazzaruso, Carmine/0000 0001 9974 0735; 
CR Al Rasheed NM, 2004, DIABETOLOGIA, V47, P987, DOI 10.1007/s00125 004 1404 9
   BARRETTCONNOR E, 1992, JAMA J AM MED ASSOC, V268, P3333
   Brooks AM, 2015, DIABETES CARE, V38, P105, DOI 10.2337/dc14 1656
   CLARK JL, 1969, BIOCHEM BIOPH RES CO, V35, P456, DOI 10.1016/0006 291X(69)90367 2
   Clark PM, 1999, ANN CLIN BIOCHEM, V36, P541, DOI 10.1177/000456329903600501
   CLEMENTS RS, 1985, AM J MED, V79, P2, DOI 10.1016/0002 9343(85)90503 0
   Ekberg K, 2003, DIABETES, V52, P536, DOI 10.2337/diabetes.52.2.536
   Gunczler P, 1998, J PEDIATR ENDOCR MET, V11, P413
   HOUGH FS, 1987, S AFR MED J, V72, P116
   Ido Y, 1997, SCIENCE, V277, P563, DOI 10.1126/science.277.5325.563
   Johansson BL, 2000, DIABETIC MED, V17, P181, DOI 10.1046/j.1464 5491.2000.00274.x
   JOHANSSON BL, 1992, DIABETOLOGIA, V35, P1151, DOI 10.1007/BF00401369
   JOHANSSON BL, 1992, DIABETOLOGIA, V35, P121, DOI 10.1007/BF00402543
   Johansson BL, 1996, DIABETOLOGIA, V39, P687
   JOHANSSON BL, 1993, J CLIN ENDOCR METAB, V77, P976, DOI 10.1210/jcem.77.4.8408474
   Jones AG, 2013, DIABETIC MED, V30, P803, DOI 10.1111/dme.12159
   Kamikawa A, 2008, DIABETES METAB RES, V24, P331, DOI 10.1002/dmrr.810
   Kitamura T, 2001, BIOCHEM J, V355, P123, DOI 10.1042/0264 6021:3550123
   Kitamura T., 2002, BIOCHEM J, V366, P377
   Koivisto VA, 1996, DIABETES CARE, V19, P689, DOI 10.2337/diacare.19.7.689
   Kujath AS, 2015, DIABETES METAB RES, V31, P421, DOI 10.1002/dmrr.2627
   Lachin JM, 2014, DIABETES, V63, P739, DOI 10.2337/db13 0881
   LEVIN ME, 1976, NEW ENGL J MED, V294, P241, DOI 10.1056/NEJM197601292940502
   Li YJ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0070390, 10.1371/journal.pone.0080475]
   Lopez Ibarra P J, 2001, Endocr Pract, V7, P346
   Lunt M, 2001, OSTEOPOROSIS INT, V12, P688, DOI 10.1007/s001980170069
   MCNAIR P, 1979, ACTA ENDOCRINOL COP, V90, P463, DOI 10.1530/acta.0.0900463
   Montalcini T, 2015, OSTEOPOROSIS INT, V26, P1639, DOI 10.1007/s00198 015 3040 2
   Montalcini T, 2013, ENDOCRINE, V43, P59, DOI 10.1007/s12020 012 9813 x
   Nordquist L, 2010, DIABETES METAB RES, V26, P193, DOI 10.1002/dmrr.1071
   Ohtomo Y, 1998, DIABETOLOGIA, V41, P287, DOI 10.1007/s001250050905
   POLONSKY KS, 1986, J CLIN INVEST, V77, P98, DOI 10.1172/JCI112308
   Rigler R, 1999, P NATL ACAD SCI USA, V96, P13318, DOI 10.1073/pnas.96.23.13318
   RINGE JD, 1976, AM J ROENTGENOL, V126, P1300, DOI 10.2214/ajr.126.6.1300
   Russo C, 2017, MOL CELL ENDOCRINOL, V442, P134, DOI 10.1016/j.mce.2016.12.012
   Saito M, 2010, OSTEOPOROSIS INT, V21, P195, DOI 10.1007/s00198 009 1066 z
   SANTIAGO JV, 1977, J CLIN ENDOCR METAB, V45, P845, DOI 10.1210/jcem 45 4 845
   Schwartz AV, 2001, J CLIN ENDOCR METAB, V86, P32, DOI 10.1210/jc.86.1.32
   SJOBERG S, 1987, DIABETOLOGIA, V30, P208, DOI 10.1007/BF00270417
   Sjöquist M, 1998, KIDNEY INT, V54, P758, DOI 10.1046/j.1523 1755.1998.00074.x
   SUZUKI K, 1989, DIABETES RES CLIN PR, V6, P45, DOI 10.1016/0168 8227(89)90056 9
   VANDAELE PLA, 1995, ANN INTERN MED, V122, P409, DOI 10.7326/0003 4819 122 6 199503150 00002
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198 006 0253 4
   Wahren J, 2000, AM J PHYSIOL ENDOC M, V278, pE759, DOI 10.1152/ajpendo.2000.278.5.E759
   Wahren J, 2016, DIABETES CARE, V39, P596, DOI 10.2337/dc15 2068
   WINOCOUR PH, 1990, DIABETES RES CLIN PR, V9, P23, DOI 10.1016/0168 8227(90)90005 E
   Yamaguchi T, 2009, BONE, V45, P174, DOI 10.1016/j.bone.2009.05.003
   Zhang WX, 2007, DIABETES METAB RES, V23, P63, DOI 10.1002/dmrr.672
   Zhong Z, 2004, CELL MOL LIFE SCI, V61, P2782, DOI 10.1007/s00018 004 4258 x
NR 49
TC 16
Z9 20
U1 0
U2 19
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355 008X
EI 1559 0100
J9 ENDOCRINE
JI Endocrine
PD DEC
PY 2017
VL 58
IS 3
BP 408
EP 412
DI 10.1007/s12020 017 1286 5
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FN2XZ
UT WOS:000415861000002
PM 28374151
DA 2025 08 17
ER

PT J
AU Liu, LC
   Aronson, J
   Huang, SL
   Lu, YL
   Czernik, P
   Rahman, S
   Kolli, V
   Suva, LJ
   Lecka Czernik, B
AF Liu, Lichu
   Aronson, James
   Huang, Shilong
   Lu, Yalin
   Czernik, Piotr
   Rahman, Sima
   Kolli, Vipula
   Suva, Larry J.
   Lecka Czernik, Beata
TI Rosiglitazone Inhibits Bone Regeneration and Causes Significant
   Accumulation of Fat at Sites of New Bone Formation
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Rosiglitazone; Diabetes; Bone healing; Osteoblast; Angiogenesis;
   Adipocyte
ID TYPE 2 DIABETES MELLITUS; FIBROBLAST GROWTH FACTOR; MESENCHYMAL
   STEM CELLS; DISTRACTION OSTEOGENESIS; PPAR GAMMA; OSTEOBLAST
   DIFFERENTIATION; EXPRESSION; FRACTURES; RISK; MICE
AB Thiazolidinediones (TZDs), peroxisome proliferator activated receptor gamma activators, and insulin sensitizers represent drugs used to treat hyperglycemia in diabetic patients. Type 2 diabetes mellitus (T2DM) is associated with a twofold increase in fracture risk, and TZDs use increases this risk by an additional twofold. In this study, we analyzed the effect of systemic administration of the TZD rosiglitazone on new bone formation in two in vivo models of bone repair, a model of drilled bone defect regeneration (BDR) and distraction osteogenesis (DO) and a model of extended bone formation. Rosiglitazone significantly inhibited new endosteal bone formation in both models. This effect was correlated with a significant accumulation of fat cells, specifically at sites of bone regeneration. The diminished bone regeneration in the DO model in rosiglitazone treated animals was associated with a significant decrease in cell proliferation measured by the number of cells expressing proliferating cell nuclear antigen and neovascularization measured by both the number of vascular sinusoids and the number of cells producing proangiogenic vascular endothelial growth factor at the DO site. In summary, rosiglitazone decreased new bone formation in both BDR and DO models of bone repair by mechanisms which include both intrinsic changes in mesenchymal stem cell proliferation and differentiation and changes in the local environment supporting angiogenesis and new bone formation. These studies suggest that bone regeneration may be significantly compromised in T2DM patients on TZD therapy.
C1 [Huang, Shilong; Lu, Yalin; Czernik, Piotr; Rahman, Sima; Kolli, Vipula; Lecka Czernik, Beata] Univ Toledo, Dept Orthopaed Surg, Toledo, OH 43614 USA.
   [Lecka Czernik, Beata] Univ Toledo, Dept Physiol, Toledo, OH 43614 USA.
   [Lecka Czernik, Beata] Univ Toledo, Dept Pharmacol, Toledo, OH 43614 USA.
   [Liu, Lichu; Aronson, James] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Res Inst, Little Rock, AR 72205 USA.
   [Aronson, James; Suva, Larry J.] Univ Arkansas Med Sci, Dept Orthopaed Surg, Ctr Orthopaed Res, Little Rock, AR 72205 USA.
   [Rahman, Sima; Lecka Czernik, Beata] Univ Toledo, Ctr Diabet & Endocrine Res, Toledo, OH 43614 USA.
C3 University System of Ohio; University of Toledo; University System of
   Ohio; University of Toledo; University System of Ohio; University of
   Toledo; University of Arkansas System; University of Arkansas Medical
   Sciences; Arkansas Children's Hospital; University of Arkansas System;
   University of Arkansas Medical Sciences; University System of Ohio;
   University of Toledo
RP Lecka Czernik, B (通讯作者)，Univ Toledo, Dept Orthopaed Surg, Hlth Sci Campus,3000 Arlington Ave, Toledo, OH 43614 USA.
EM beata.leckaczernik@utoledo.edu
OI Suva, Larry/0000 0002 2892 9757
FU NIH/NIA AG [028935]; American Diabetes Association's Amaranth Diabetes
   Fund [1 09 RA 95]
FX This work was supported by the following funds (to B. L. C.): NIH/NIA AG
   028935 and the American Diabetes Association's Amaranth Diabetes Fund
   1 09 RA 95.
CR Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   ARONSON J, 1994, CLEFT PALATE CRAN J, V31, P473, DOI 10.1597/1545 1569(1994)031<0473:EACEWD>2.3.CO;2
   ARONSON J, 1994, CLIN ORTHOP RELAT R, P124
   Aronson J, 2004, CLIN ORTHOP RELAT R, P264, DOI 10.1097/01.blo.0000138186.53426.f9
   Aronson J, 1997, J ORTHOPAED RES, V15, P563, DOI 10.1002/jor.1100150412
   Aronson J, 1994, CLEFT PALATE CRAN J, V31, P481
   ARONSON J, 2002, J REGENERATIVE MED, V3, P7
   Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   Campbell TM, 2003, CALCIFIED TISSUE INT, V73, P49, DOI 10.1007/s00223 002 2120 4
   Caplan AI, 2011, J ORTHOP RES, V29, P1795, DOI 10.1002/jor.21462
   DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994 59
   Goetze S, 2002, BIOCHEM BIOPH RES CO, V293, P1431, DOI 10.1016/S0006 291X(02)00385 6
   Grey A, 2007, J CLIN ENDOCR METAB, V92, P1305, DOI 10.1210/jc.2006 2646
   Gruntmanis U, 2010, CALCIFIED TISSUE INT, V86, P343, DOI 10.1007/s00223 010 9352 5
   Habib ZA, 2010, J CLIN ENDOCR METAB, V95, P592, DOI 10.1210/jc.2009 1385
   Janghorbani M, 2007, AM J EPIDEMIOL, V166, P495, DOI 10.1093/aje/kwm106
   Kahn SE, 2008, DIABETES CARE, V31, P845, DOI 10.2337/dc07 2270
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Kumar S, 2010, MOL THER, V18, P1026, DOI 10.1038/mt.2009.315
   Lazarenko OP, 2007, ENDOCRINOLOGY, V148, P2669, DOI 10.1210/en.2006 1587
   Lecka Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Lecka Czernik Beata, 2010, Curr Osteoporos Rep, V8, P178, DOI 10.1007/s11914 010 0027 y
   Lecka Czernik Beata, 2010, Curr Osteoporos Rep, V8, P84, DOI 10.1007/s11914 010 0016 1
   Lewinson D, 2001, HISTOCHEM CELL BIOL, V116, P381, DOI 10.1007/s004180100331
   Lieu C, 2011, CLIN CANCER RES, V17, P6130, DOI 10.1158/1078 0432.CCR 11 0659
   Loke YK, 2009, CAN MED ASSOC J, V180, P32, DOI 10.1503/cmaj.080486
   Meier C, 2008, ARCH INTERN MED, V168, P820, DOI 10.1001/archinte.168.8.820
   Monfoulet L, 2010, CALCIFIED TISSUE INT, V86, P72, DOI 10.1007/s00223 009 9314 y
   Nadra K, 2010, ENDOCRINOLOGY, V151, P4969, DOI 10.1210/en.2010 0131
   Perrien DS, 2007, ENDOCRINOLOGY, V148, P1654, DOI 10.1210/en.2006 0848
   Perrien DS, 2002, J HISTOCHEM CYTOCHEM, V50, P567, DOI 10.1177/002215540205000414
   Shockley KR, 2009, J CELL BIOCHEM, V106, P232, DOI 10.1002/jcb.21994
   Sottile V, 2004, CALCIFIED TISSUE INT, V75, P329, DOI 10.1007/s00223 004 0224 8
   Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829
   Vestergaard P, 2009, CALCIFIED TISSUE INT, V84, P45, DOI 10.1007/s00223 008 9195 5
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Wolff GL, 1999, PHYSIOL GENOMICS, V1, P151, DOI 10.1152/physiolgenomics.1999.1.3.151
   Wren TAL, 2011, J CLIN ENDOCR METAB, V96, P782, DOI 10.1210/jc.2010 1922
   Zinman B, 2010, J CLIN ENDOCR METAB, V95, P134, DOI 10.1210/jc.2009 0572
NR 41
TC 36
Z9 43
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD AUG
PY 2012
VL 91
IS 2
BP 139
EP 148
DI 10.1007/s00223 012 9623 4
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 974LX
UT WOS:000306438100005
PM 22752619
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Macdonald, KK
   Cheung, CY
   Anseth, KS
AF Macdonald, Kelly K.
   Cheung, Charles Y.
   Anseth, Kristi S.
TI Cellular delivery of TGFβ1 promotes osteoinductive signalling
   for bone regeneration
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE TGF beta(1); nonviral gene therapy; bone tissue engineering
ID GROWTH FACTOR BETA; OSTEOBLAST LIKE CELLS; GENE DELIVERY; DNA DELIVERY;
   STIMULATION; THERAPY; REPAIR
AB Administration of osteoinductive growth factors to wound sites, alone or in conjunction with a delivery vehicle, is an appealing treatment option for critical bone defects. The delivery of cells transfected with genes encoding for osteoinductive growth factors, such as TGF beta(1), represents an attractive option to locally deliver constant levels of these growth factors to stimulate new bone formation at the defect site. Using non viral transfection methods, we showed that osteoblasts can be genetically modified in vitro to secrete sustained therapeutic levels of TGF beta(1) in its active form through control of the transfected cell environment. In addition, delivery of TGF beta(1) produced by genetically modified cells that contained the proper post translational modifications provided a more robust cellular response compared to administration of bacterially derived recombinant TGF beta(1). Migration and subsequent proliferation of osteoblasts are critical aspects of the initial steps in the cascade of new bone tissue formation. Exposure to mammalian derived TGF beta(1) induced a more pronounced chemotactic response upon administration of 10 pg/ml TGF beta(1), whereas osteoblasts showed enhanced levels of metabolic activity at 100 pg/ml, which is indicative of greater levels of cellular proliferation when compared to addition of the same levels of recombinant TGF beta(1). This increased efficacy of cell derived TGF beta(1) over recombinant forms of TGF beta(1), combined with provision of a continual source of TGF beta(1), highlights the advantages of delivering genetically modified cells over exogenous protein delivery for bone tissue engineering. Copyright (C) 2007 John Wiley & Sons, Ltd.
C1 [Macdonald, Kelly K.; Cheung, Charles Y.; Anseth, Kristi S.] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA.
C3 University of Colorado System; University of Colorado Boulder
RP Anseth, KS (通讯作者)，Univ Colorado, Dept Chem & Biol Engn, Campus Box 424, Boulder, CO 80309 USA.
EM kristi.anseth@colorado.edu
FU NIDCR NIH HHS [R01 DE016523] Funding Source: Medline
CR Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473
   Bonadio J, 2002, ANN NY ACAD SCI, V961, P71, DOI 10.1111/j.1749 6632.2002.tb03053.x
   Bonadio J, 2002, ANN NY ACAD SCI, V961, P58, DOI 10.1111/j.1749 6632.2002.tb03048.x
   Bostrom MPG, 1998, CLIN ORTHOP RELAT R, pS116, DOI 10.1097/00003086 199810001 00013
   Bostrom MPG, 1998, CLIN ORTHOP RELAT R, pS124, DOI 10.1097/00003086 199810001 00014
   Chen RR, 2003, PHARM RES DORDR, V20, P1103, DOI 10.1023/A:1025034925152
   Einhorn TA, 1999, CLIN ORTHOP RELAT R, pS59, DOI 10.1097/00003086 199910001 00007
   Fang JM, 1996, P NATL ACAD SCI USA, V93, P5753, DOI 10.1073/pnas.93.12.5753
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   HUGHES FJ, 1992, BONE MINER, V19, P63, DOI 10.1016/0169 6009(92)90844 4
   LAWRENCE DA, 1984, J CELL PHYSIOL, V121, P184, DOI 10.1002/jcp.1041210123
   MACKIE EJ, 1990, BONE, V11, P295, DOI 10.1016/8756 3282(90)90083 B
   Mahato RI, 1999, ADV GENET, V41, P95, DOI 10.1016/S0065 2660(08)60152 2
   MUNDY GR, 1995, BONE, V17, pS71, DOI 10.1016/8756 3282(95)00182 D
   PATIL P, 2000, T ORTHOP RES SOC, V25, P362
   Peter SJ, 2000, J BIOMED MATER RES, V50, P452, DOI 10.1002/(SICI)1097 4636(20000605)50:3<452::AID JBM20>3.0.CO;2 0
   PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P825
   Quick DJ, 2004, J CONTROL RELEASE, V96, P341, DOI 10.1016/j.jconrel.2004.01.021
   Quick DJ, 2004, J CONTROL RELEASE, V97, P333, DOI 10.1016/j.jconrel.2004.03.001
   Quick DJ, 2003, PHARM RES DORDR, V20, P1730, DOI 10.1023/B:PHAM.0000003368.66471.6a
   Reyes Botella C, 2002, CELL PHYSIOL BIOCHEM, V12, P353, DOI 10.1159/000067905
   Shea LD, 1999, NAT BIOTECHNOL, V17, P551, DOI 10.1038/9853
   Zhang H, 2003, BIOMATERIALS, V24, P2013, DOI 10.1016/S0142 9612(02)00616 6
NR 23
TC 15
Z9 18
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD JUL AUG
PY 2007
VL 1
IS 4
BP 314
EP 317
DI 10.1002/term.31
PG 4
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA 310HR
UT WOS:000256520000008
PM 18038422
DA 2025 08 17
ER

PT J
AU Limgala, RP
   Goker Alpan, O
AF Limgala, Renuka P.
   Goker Alpan, Ozlem
TI Effect of Substrate Reduction Therapy in Comparison to Enzyme
   Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher
   Disease
SO BIOMOLECULES
LA English
DT Article
DE Gaucher disease; bone involvement; enzyme replacement therapy; substrate
   reduction therapy; Osteoimmunology; RANK /RANKL; Osteopontin; MIP 1 beta
AB Gaucher disease (GD) is caused by mutations in the GBA gene, leading to deficient activity of the lysosomal enzyme glucocerebrosidase. Among all the symptoms across various organ systems, bone disease is a major concern as it causes high morbidity and reduces quality of life. Enzyme replacement therapy (ERT) is the most accepted treatment; however, there are still unmet needs. As an alternative, substrate reduction therapy (SRT) was developed using glucosylceramide synthase inhibitors. In the current study, the effects of ERT vs. SRT were compared, particularly the immunological and bone remodeling aspects. GD subjects were divided into three cohorts based on their treatment at initial visit: ERT, SRT, and untreated (UT). Immunophenotyping showed no significant immune cell alterations between the cohorts. Expression of RANK/RANKL/Osteoprotegerin pathway components on immune cells and the secreted markers of bone turnover were analyzed. In the ERT cohort, no significant changes were observed in RANK, RANKL or serum biomarkers. RANKL on T lymphocytes, Osteopontin and MIP 1 beta decreased with SRT treatment indicating probable reduction in osteoclast activity. Other secreted factors, Osteocalcin and RANKL /Osteoprotegerin did not change with the treatment status. Insights from the study highlight personalized differences between subjects and possible use of RANK pathway components as markers for bone disease progression.
C1 [Limgala, Renuka P.; Goker Alpan, Ozlem] Lysosomal & Rare Disorders Res & Treatment Ctr LD, Fairfax, VA 22030 USA.
RP Limgala, RP (通讯作者)，Lysosomal & Rare Disorders Res & Treatment Ctr LD, Fairfax, VA 22030 USA.
EM rlimgala@ldrtc.org; ogoker alpan@ldrtc.org
OI Limgala, Renuka/0000 0001 6957 6284
FU Sanofi Genzyme [GZ 2014 11295]
FX This study was supported by an investigator initiated research grant
   from Sanofi Genzyme (GZ 2014 11295). We thank Dr. Ravi S. Kamath
   (Fairfax Radiological consultants, Fairfax, VA, USA) for imaging of
   skeletal manifestations of GD patients. We appreciate Miriam Lopez and
   Chidima Ioanou (O&O Alpan, LLC, Fairfax, VA, USA) for their support in
   coordinating collection of samples.
CR Amato Dominick, 2018, J Med Case Rep, V12, P19, DOI 10.1186/s13256 017 1541 7
   Atkins GJ, 2006, J BONE MINER RES, V21, P1339, DOI 10.1359/JBMR.060604
   Bennett LL, 2013, ANN PHARMACOTHER, V47, P1182, DOI 10.1177/1060028013500469
   Ceravolo Ferdinando, 2017, J Med Case Rep, V11, P19, DOI 10.1186/s13256 016 1147 5
   Charrow J, 2015, AM J HEMATOL, V90, pS19, DOI 10.1002/ajh.24056
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Goker Alpan O, 2011, MOL GENET METAB, V104, P438, DOI 10.1016/j.ymgme.2011.08.004
   Goker Alpan O, 2010, THER CLIN RISK MANAG, V6, P315
   Gravallese EM, 2003, J CLIN INVEST, V112, P147, DOI 10.1172/JCI200310109
   Lacerda L, 1999, BLOOD CELL MOL DIS, V25, P130, DOI 10.1006/bcmd.1999.0237
   Leibbrandt A, 2010, ADV EXP MED BIOL, V658, P77, DOI 10.1007/978 1 4419 1050 9_9
   Limgala RP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168135
   Mucci JM, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/192761
   Mistry PK, 2010, P NATL ACAD SCI USA, V107, P19473, DOI 10.1073/pnas.1003308107
   Mistry PK, 2009, BRIT J HAEMATOL, V147, P561, DOI 10.1111/j.1365 2141.2009.07872.x
   Nagral A, 2014, J CLIN EXP HEPATOL, V4, P37, DOI 10.1016/j.jceh.2014.02.005
   Pandey Manoj Kumar, 2013, Critical Reviews in Oncogenesis, V18, P197
   Ponzetti M, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00236
   Smid BE, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023 016 0413 3
   Sonder SU, 2016, BLOOD CELL MOL DIS, V59, P8, DOI 10.1016/j.bcmd.2016.02.003
   Srivastava RK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00657
   van Breemen MJ, 2007, BBA MOL BASIS DIS, V1772, P788, DOI 10.1016/j.bbadis.2007.04.002
   van Dussen L, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023 014 0112 x
   Van Rossum Alison, 2016, Hosp Pharm, V51, P553, DOI 10.1310/hpj5107 553
   Weinreb N, 2008, AM J HEMATOL, V83, P890, DOI 10.1002/ajh.21280
   Weitzmann MN, 2017, TOXICOL PATHOL, V45, P911, DOI 10.1177/0192623317735316
   Zimran A, 2014, PEDIATR ENDOCR REV P, V12, P82
NR 27
TC 13
Z9 15
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2218 273X
J9 BIOMOLECULES
JI Biomolecules
PD APR
PY 2020
VL 10
IS 4
AR 526
DI 10.3390/biom10040526
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA LW9WG
UT WOS:000539492400032
PM 32244296
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Vesela, B
   Kratochvilova, A
   Svandova, E
   Benes, P
   Rihova, K
   Poliard, A
   Matalova, E
AF Vesela, Barbora
   Kratochvilova, Adela
   Svandova, Eva
   Benes, Petr
   Rihova, Kamila
   Poliard, Anne
   Matalova, Eva
TI Caspase 12 Is Present During Craniofacial Development and Participates
   in Regulation of Osteogenic Markers
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE caspase 12; bone; osteoblast; differentiation; alkaline phosphatase
ID ENDOPLASMIC RETICULUM STRESS; CELL DEATH; ACTIVATION; APOPTOSIS;
   EXPRESSION; CALPAIN
AB Caspases are evolutionary conserved proteases traditionally known as participating in apoptosis and inflammation but recently discovered also in association with other processes such as proliferation or differentiation. This investigation focuses on caspase 12, ranked among inflammatory caspases but displaying other, not yet defined functions. A screening analysis pointed to statistically significant (P < 0.001) increase in expression of caspase 12 in a decisive period of mandibular bone formation when the original mesenchymal condensation turns into vascularized bone tissue. Immunofluorescence analysis confirmed the presence of caspase 12 protein in osteoblasts. Therefore, the osteoblastic cell line MC3T3 E1 was challenged to investigate any impact of caspase 12 on the osteogenic pathways. Pharmacological inhibition of caspase 12 in MC3T3 E1 cells caused a statistically significant decrease in expression of some major osteogenic genes, including those for alkaline phosphatase, osteocalcin and Phex. This downregulation was further confirmed by an alkaline phosphatase activity assay and by a siRNA inhibition approach. Altogether, this study demonstrates caspase 12 expression and points to its unknown physiological engagement in bone cells during the course of craniofacial development.
C1 [Vesela, Barbora; Kratochvilova, Adela; Svandova, Eva; Matalova, Eva] Acad Sci, Inst Anim Physiol & Genet, Lab Odontogenesis & Osteogenesis, Brno, Czech Republic.
   [Benes, Petr; Rihova, Kamila] Masaryk Univ, Fac Sci, Dept Expt Biol, Brno, Czech Republic.
   [Poliard, Anne] Paris Univ, UFR Odontol Montrouge, Lab Orofacial Pathol Imaging & Biotherapies, Paris, France.
   [Matalova, Eva] Univ Vet & Pharmaceut Sci, Fac Vet Med, Dept Physiol, Brno, Czech Republic.
C3 Czech Academy of Sciences; Institute of Animal Physiology & Genetics of
   the Czech Academy of Sciences; Masaryk University Brno; Universite Paris
   Cite; University of Veterinary Sciences Brno
RP Vesela, B (通讯作者)，Acad Sci, Inst Anim Physiol & Genet, Lab Odontogenesis & Osteogenesis, Brno, Czech Republic.
EM veselab.lab@gmail.com
RI ; Svandova, Eva/AAX 3852 2020; Benes, Petr/K 6369 2016
OI , Barbora/0000 0001 8585 2082; Kratochvilova, Adela/0000 0002 3533 0953;
   Benes, Petr/0000 0002 8297 9675; 
FU Inter COST project by the Ministry of Education of the Czechia
   [LTC18081]; COST Action (integrative action for multidisciplinary
   studies on structural cellular networks) [CA15214]; Czech Science
   Foundation (GA CR) [19 14727 S]
FX The international research cooperation was supported by the Inter COST
   project LTC18081 (Caspases as novel regulators in osteogenic cellular
   networks) running under the InterExcellence program provided by the
   Ministry of Education of the Czechia (www.msmt.cz).The Inter COST
   project is associated with the core COST Action (CA15214, an integrative
   action for multidisciplinary studies on structural cellular networks,
   www.cost.eu).Masaryk University participated in frame of the Czech
   Science Foundation (GA CR) project 19 14727 S.
CR Bolivar BE, 2019, FEBS J, V286, P2628, DOI 10.1111/febs.14926
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Fedde KN, 1999, J BONE MINER RES, V14, P2015, DOI 10.1359/jbmr.1999.14.12.2015
   Francis F, 1997, GENOME RES, V7, P573, DOI 10.1101/gr.7.6.573
   de la Cadena SC, 2014, APOPTOSIS, V19, P414, DOI 10.1007/s10495 013 0930 7
   Kalai M, 2003, J CELL BIOL, V162, P457, DOI 10.1083/jcb.200303157
   Kratochvílová A, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 64294 9
   Liu L, 2015, BIOL TRACE ELEM RES, V164, P64, DOI 10.1007/s12011 014 0192 4
   Lorenz Depiereux B, 2006, NAT GENET, V38, P1248, DOI 10.1038/ng1868
   Minaríková M, 2014, CELLS TISSUES ORGANS, V200, P339, DOI 10.1159/000439165
   Mogi M, 2003, J BIOL CHEM, V278, P47477, DOI 10.1074/jbc.M307055200
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887
   Nakajima YI, 2017, CELL DEATH DIFFER, V24, P1422, DOI 10.1038/cdd.2017.36
   Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200
   Roy S, 2008, P NATL ACAD SCI USA, V105, P4133, DOI 10.1073/pnas.0706658105
   Saleh M, 2006, NATURE, V440, P1064, DOI 10.1038/nature04656
   Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451
   Salvamoser R, 2019, CELL DEATH DIFFER, V26, P1124, DOI 10.1038/s41418 018 0188 2
   Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216
   Shiraishi H, 2006, J CELL SCI, V119, P3958, DOI 10.1242/jcs.03160
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Svandova E, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.330
   Svandova E, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00174
   Tsapras P, 2017, CELL DEATH DIFFER, V24, P1369, DOI 10.1038/cdd.2017.43
   Van Opdenbosch N, 2019, IMMUNITY, V50, P1352, DOI 10.1016/j.immuni.2019.05.020
   Vande Walle L, 2016, NATURE, V534, pE1, DOI 10.1038/nature17649
   Veselá B, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00124
   Veselá B, 2015, CONNECT TISSUE RES, V56, P326, DOI 10.3109/03008207.2015.1040546
NR 29
TC 6
Z9 6
U1 0
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD OCT 15
PY 2020
VL 8
AR 589136
DI 10.3389/fcell.2020.589136
PG 10
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA OK7FZ
UT WOS:000584812900001
PM 33178702
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ali, M
   Kucko, N
   Jansen, JA
   Yang, F
   Walboomers, XF
AF Ali, Muhanad
   Kucko, Nathan
   Jansen, John A.
   Yang, Fang
   Walboomers, X. Frank
TI The effect of lipoxin A4 on E. coli LPS induced osteoclastogenesis
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Osteoclast; Inflammation; Bone resorption; Lipoxin A4; Periodontitis
ID PERIODONTAL LIGAMENT FIBROBLASTS; PRO RESOLVING MEDIATORS;
   TUMOR NECROSIS FACTOR; NITRIC OXIDE; GINGIVAL FIBROBLASTS; LIPID
   MEDIATORS; BONE LOSS; DIFFERENTIATION; INFLAMMATION; EXPRESSION
AB Objectives The objective of the present study was to investigate the effect of lipoxin type A4 (LXA4) on bacterial induced osteoclastogenesis. Material and methods Human periodontal ligament cells (PDLCs) in coculture with osteoclast precursors (RAW264.7 cells) were exposed to bacterial stimulation with lipopolysaccharide (LPS) to induce inflammation. After 24 h, cells were treated to 100 ng/ml of LXA4 and 50 ng/ml of forymul peptide receptor 2 (FPR2/ALX) receptor antagonist (Boc 2). After 5 days, osteoclastic resorptive activity was assessed on calcium phosphate (CaP) synthetic bone substitute. Additionally, osteoclastic differentiation was evaluated using tartrate resistant acid phosphatase (TRAP) staining, TRAP enzymatic activity assay, and on the expression of osteoclast specific genes. Results We found that stimulation of in the osteoclasts with LPS stimulated PDLCs induced a significant increase in tartrate resistant acid phosphatase (TRAP) positive cells, higher resorptive activity, and enhanced expression of specific genes. Meanwhile, LXA4 treatment exhibited strong anti inflammatory activity, and was able to reverse these inflammatory effects. Conclusions We conclude that (1) PDLCs are a potential target for treating bacterial induced bone resorption in patients with periodontal disease, and (2) LXA4 is a suitable candidate for such therapy.
C1 [Ali, Muhanad; Kucko, Nathan; Jansen, John A.; Yang, Fang; Walboomers, X. Frank] Radboud Univ Nijmegen, Dept Dent, Radboud Inst Mol Life Sci, Biomat,Med Ctr, Philips van Leydenlaan 25, NL 6525 EX Nijmegen, Netherlands.
C3 Philips; Radboud University Nijmegen
RP Walboomers, XF (通讯作者)，Radboud Univ Nijmegen, Dept Dent, Radboud Inst Mol Life Sci, Biomat,Med Ctr, Philips van Leydenlaan 25, NL 6525 EX Nijmegen, Netherlands.
EM frank.walboomers@radboudumc.nl
RI Yang, Fang/E 1937 2011; Kucko, Nathan/K 8589 2015; Walboomers,
   X.Frank/B 3692 2013
OI Kucko, Nathan/0000 0002 4904 8238; 
FU Netherlands Organization for Scientific Research (NWO) domain  Applied
   and Engineering Sciences [13844]
FX This study was supported by the Netherlands Organization for Scientific
   Research (NWO) domain  Applied and Engineering Sciences with project
   number 13844.
CR Aas JA, 2005, J CLIN MICROBIOL, V43, P5721, DOI 10.1128/JCM.43.11.5721 5732.2005
   Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Aldridge C, 2008, J SURG RES, V149, P296, DOI 10.1016/j.jss.2007.12.758
   Andrukhov O, 2014, ACTA ODONTOL SCAND, V72, P337, DOI 10.3109/00016357.2013.834535
   Arora Nupur, 2014, J Indian Soc Periodontol, V18, P9, DOI 10.4103/0972 124X.128192
   Beertsen W, 1997, PERIODONTOL 2000, V13, P20, DOI 10.1111/j.1600 0757.1997.tb00094.x
   Bloemen V, 2011, J CELL BIOCHEM, V112, P1890, DOI 10.1002/jcb.23109
   Bloemen V, 2010, J CELL PHYSIOL, V222, P565, DOI 10.1002/jcp.21971
   Boraschi D., 2016, Curr Bionanotechnol (Discontinued), V2, P71, DOI DOI 10.2174/2213529402666160601121721
   Bosshart H, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.08.53
   Buckley CD, 2001, TRENDS IMMUNOL, V22, P199, DOI 10.1016/S1471 4906(01)01863 4
   Burger D, 2002, ARTHRITIS RES THER, V4, pS169, DOI 10.1186/ar558
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4
   Chiang N, 2017, MOL ASPECTS MED, V58, P114, DOI 10.1016/j.mam.2017.03.005
   Chiang N, 2012, NATURE, V484, P524, DOI 10.1038/nature11042
   Cochran DL, 2008, J PERIODONTOL, V79, P1569, DOI 10.1902/jop.2008.080233
   Colombo APV, 2002, J PERIODONTOL, V73, P360, DOI 10.1902/jop.2002.73.4.360
   de Vries TJ, 2006, J CELL BIOCHEM, V98, P370, DOI 10.1002/jcb.20795
   Dong JS, 2018, BMC VET RES, V14, DOI 10.1186/s12917 018 1360 0
   Du AQ, 2016, J CELL MOL MED, V20, P1329, DOI 10.1111/jcmm.12819
   El Awady AR, 2010, J PERIODONTOL, V81, P1324, DOI 10.1902/jop.2010.100054
   Elisia I, 2018, J IMMUNOL METHODS, V452, P26, DOI 10.1016/j.jim.2017.10.004
   Gaudin A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 27194 7
   Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663
   Graves DT, 2003, J PERIODONTOL, V74, P391, DOI 10.1902/jop.2003.74.3.391
   Guzik TJ, 2003, J PHYSIOL PHARMACOL, V54, P469
   Tran HLB, 2014, IN VITRO CELL DEV AN, V50, P597, DOI 10.1007/s11626 014 9748 z
   Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923
   Herath TDK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058496
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Hormdee D, 2005, CLIN EXP IMMUNOL, V142, P490, DOI 10.1111/j.1365 2249.2005.02937.x
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Kanzaki H, 2001, J DENT RES, V80, P887, DOI 10.1177/00220345010800030801
   Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lerner UH, 2006, J DENT RES, V85, P596, DOI 10.1177/154405910608500704
   Li ZH, 2017, MOL MED REP, V16, P8380, DOI 10.3892/mmr.2017.7625
   Liu CY, 2017, EXP CELL RES, V352, P293, DOI 10.1016/j.yexcr.2017.02.018
   Ma MG, 2012, INT J NANOMED, V7, P1781, DOI 10.2147/IJN.S29884
   MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323
   Maria SM, 2014, J BIOMED MATER RES B, V102, P903, DOI 10.1002/jbm.b.33071
   Miyazaki T, 2011, ANAL BIOCHEM, V410, P7, DOI 10.1016/j.ab.2010.11.014
   Mustafa M, 2013, AM J PHYSIOL CELL PH, V305, pC673, DOI 10.1152/ajpcell.00242.2012
   Offenbacher S, 1996, Ann Periodontol, V1, P821, DOI 10.1902/annals.1996.1.1.821
   Page RC, 1997, PERIODONTOL 2000, V14, P9, DOI 10.1111/j.1600 0757.1997.tb00189.x
   Patntirapong S, 2009, BIOMATERIALS, V30, P548, DOI 10.1016/j.biomaterials.2008.09.062
   Prieto P, 2010, CELL DEATH DIFFER, V17, P1179, DOI 10.1038/cdd.2009.220
   Reddi K, 1998, J BONE MINER RES, V13, P1260, DOI 10.1359/jbmr.1998.13.8.1260
   Scheres N, 2010, J PERIODONTAL RES, V45, P262, DOI 10.1111/j.1600 0765.2009.01229.x
   Serhan CN, 2015, SEMIN IMMUNOL, V27, P200, DOI 10.1016/j.smim.2015.03.004
   Serhan CN, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016311
   Serhan CN, 2003, J IMMUNOL, V171, P6856, DOI 10.4049/jimmunol.171.12.6856
   SERHAN CN, 1990, J CLIN INVEST, V85, P772, DOI 10.1172/JCI114503
   Sodin Semrl S, 2000, J IMMUNOL, V164, P2660, DOI 10.4049/jimmunol.164.5.2660
   Sokos D, 2015, J PERIODONTAL RES, V50, P152, DOI 10.1111/jre.12197
   Souto R, 2006, BRAZ J MICROBIOL, V37, P208, DOI 10.1590/S1517 83822006000300002
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66
   Takayanagi H, 2002, ARTHRITIS RES THER, V4, pS227, DOI 10.1186/ar581
   Taubman MA, 2007, J CLIN PERIODONTOL, V34, P367, DOI 10.1111/j.1600 051X.2007.01065.x
   Teles R, 2013, PERIODONTOL 2000, V62, P95, DOI 10.1111/prd.12010
   Terrizzi AR, 2013, ARCH ORAL BIOL, V58, P1407, DOI 10.1016/j.archoralbio.2013.06.010
   Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756 3282(99)00210 0
   Van Dyke TE, 2003, J DENT RES, V82, P82, DOI 10.1177/154405910308200202
   Van Dyke TE, 2011, J CLIN PERIODONTOL, V38, P119, DOI 10.1111/j.1600 051X.2010.01662.x
   Wattanaroonwong N, 2011, ARCH ORAL BIOL, V56, P212, DOI 10.1016/j.archoralbio.2010.10.004
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
   Xu JJ, 2017, PHARM BIOL, V55, P2095, DOI 10.1080/13880209.2017.1357737
   Zou W, 2002, J BONE MINER RES, V17, P1211, DOI 10.1359/jbmr.2002.17.7.1211
NR 71
TC 14
Z9 17
U1 0
U2 13
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD MAR
PY 2021
VL 25
IS 3
BP 957
EP 969
DI 10.1007/s00784 020 03385 3
EA JUN 2020
PG 13
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA QG0TQ
UT WOS:000538357600005
PM 32506323
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Decusara, M
   Romila, A
   Pavel, L
   Andrei, LL
   Negraia, MR
   Macovei, LA
AF Decusara, Mioara
   Romila, Aurelia
   Pavel, Liliana
   Andrei, Lucian Laurentiu
   Negraia, Magdalena Rusu
   Macovei, Luana Andreea
TI Chemical Changes Caused by Calcium Deposition in Forestier   Rotes  
   Querrol's Disease
SO REVISTA DE CHIMIE
LA English
DT Article
DE hydroxyapatite; calcium deposits; Forestier's disease; hyperostosis
ID IDIOPATHIC SKELETAL HYPEROSTOSIS
AB Calcium is involved in many biological processes. Hydroxyapatite provides bone mineralization, maintains cellular signaling, enzyme activity, nerve impulse transmission, muscle contraction and regulates blood clotting and membrane permeability. Calcium depositions may be caused by necrosis following trauma, connective tissue diseases, metabolic diseases, sarcoidosis, myeloma, metastases, chondrocalcinosis or calcium pyrophosphate dihydrate crystal deposition disease, cervical spondylosis, ankylosing spondylitis, ossification of the posterior longitudinal ligament of the spine and Forestier's disease. Diffuse idiopathic skeletal hyperostosis (DISH) or Forestier Rotes Querrol's disease is characterized by calcification of ligaments and entheses of the anterior vertebrae in the thoracic spine and sacroiliac joint bridging caused by abnormal proliferation of osteoblasts. At least four consecutive thoracic vertebrae are affected and the intervertebral disc space is preserved. Peripheral joints of heels, knees, elbows and pelvis may be also affected. Diagnosis is confirmed by radiographic findings with a candlewax like appearance down the spine, on C2 C6 vertebrae. A total number of 37 patients with a median age of 63 years, of which 24 were male (64.86%) and 13 female (35.14%), were diagnosed with DISH at the Clinic of Geriatry of Galati County Emergency Clinical Hospital Si Apostol Andrei between 2006 2016. Differential diagnosis included ankylosing spondylitis and spondylosis deformans. DISH was found in patients aged over 50 years, with obesity and diabetes, based on radiographic findings. Drug therapy and physical therapy successfully provided pain relief, increased axial and peripheral mobility, improved physical function and optimal quality of life. None of our patients required surgery, as there were no cases with compromised airways and digestive tract involvement. Our study confirms that old age, obesity and type 2 diabetes are risk factors for diffuse idiopathic skeletal hyperostosis.
C1 [Decusara, Mioara; Romila, Aurelia; Pavel, Liliana; Negraia, Magdalena Rusu] Dunarea de Jos Univ Galati, Fac Med & Pharm, 47 Domneasca Str, Galati 800008, Romania.
   [Andrei, Lucian Laurentiu; Macovei, Luana Andreea] Gligore T Popa Univ Med & Pharm, Dept Rhetimatol Rehabil Phys Med & Balneol, 16 Univ Str, Iasi 700115, Romania.
C3 Dunarea De Jos University Galati; Grigore T Popa University of Medicine
   & Pharmacy
RP Romila, A (通讯作者)，Dunarea de Jos Univ Galati, Fac Med & Pharm, 47 Domneasca Str, Galati 800008, Romania.
EM aurelia.romila@yahoo.com
RI Decu, Mioara/HHD 2176 2022; macovei, luana/R 9354 2019; Rusu Negraia,
   Magdalena/MXM 0590 2025
OI MACOVEI, LUANA/0000 0002 4856 867X; 
CR Atzeni F, 2006, RHEUM DIS CLIN N AM, V32, P413, DOI 10.1016/j.rdc.2006.02.003
   BILEZIKIAN J.P., 2008, PRINCIPLES BONE BI 1, VI, P1697
   BURR D.B., 2014, BASIC APPL BONE BIOL, P261
   Carnevale V, 2014, NUTR METAB CARDIOVAS, V24, P1151, DOI 10.1016/j.numecd.2014.06.013
   Collins JF, 2017, MOLEC NUTRITION, P69, DOI 10.1016/B978 0 12 802168 2.00007 5
   DEVLIN V.J., 2012, SPINE SECRETS PLUS, P450
   HOCHBERG M.C., 2015, RHEUMATOLOGY, P1515
   Ii H, 2016, BONE, V90, P37, DOI 10.1016/j.bone.2016.05.008
   Kramer IM, 2016, SIGNAL TRANSDUCTION, 3RD EDITION, P1
   NORMAN A.W., 2015, HORMONES, P189
   Song L, 2017, ADV CLIN CHEM, V82, P1, DOI 10.1016/bs.acc.2017.06.005
   Stefan M, 2011, MED SURG J, V115, P1102
   Yayama T, 2018, J ORTHOP SCI, V23, P26, DOI 10.1016/j.jos.2017.09.024
NR 13
TC 9
Z9 9
U1 1
U2 6
PU CHIMINFORM DATA S A
PI BUCHAREST
PA CALEA PLEVNEI NR 139, SECTOR 6, BUCHAREST R 77131, ROMANIA
SN 0034 7752
J9 REV CHIM BUCHAREST
JI Rev. Chim.
PD MAY
PY 2018
VL 69
IS 5
BP 1254
EP 1256
PG 3
WC Chemistry, Multidisciplinary; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Engineering
GA GJ0OQ
UT WOS:000434954100046
DA 2025 08 17
ER

PT J
AU Zhao, YD
   Urganus, AL
   Spevak, L
   Shrestha, S
   Doty, SB
   Boskey, AL
   Pachman, LM
AF Zhao, Yongdong
   Urganus, Annette L.
   Spevak, Lyudmila
   Shrestha, Sheela
   Doty, Stephen B.
   Boskey, Adele L.
   Pachman, Lauren M.
TI Characterization of Dystrophic Calcification Induced in Mice by
   Cardiotoxin
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article; Proceedings Paper
CT 29th Annual Meeting of the
   American Society for Bone and Mineral Research
CY SEP 16 19, 2007
CL Honolulu, HI
SP Amer Soc Bone & Mineral Res
DE Osteogenesis; Mineral/matrix ratio; Dystrophic calcification;
   Mitochondria; Cell death
ID JUVENILE DERMATOMYOSITIS; SKELETAL MUSCLE; IN VIVO; BONE MINERALIZATION;
   TNF ALPHA; OSTEOPONTIN; VENOM; HYDROXYAPATITE; REGENERATION;
   INFLAMMATION
AB Dystrophic calcifications often occur after injury, infection, or onset of certain rheumatic diseases. Treatment has been limited to surgical removal following failure of medical therapy. In an attempt to establish a reproducible animal model for dystrophic calcification that permitted the screening of potential interventions, we evaluated cardiotoxin (injury) induced calcifications in three murine strains at both the cellular and ultrastructural levels. All osteopontin null mice and tumor necrosis factor receptor null mice on a C57B6 background had calcifications at days 3 and 7 after injury compared to 75% of wild type C57B6 mice. There was no difference in mineral content among calcifications from the three mouse strains. Osteogenesis was suggested by the expression of osteocalcin, osterix, and alkaline phosphatase in calcified murine muscle tissue. Osteoclast like cells facilitated the removal of transient dystrophic deposits (<28 days) in all models. However, none of the models showed an association of mineral crystals with collagen, suggesting that the deposits were not bone like. The dystrophic mechanism was validated as cell death, and mitochondrial calcifications occurred soon after skeletal muscle injury in the three murine strains.
C1 [Zhao, Yongdong; Pachman, Lauren M.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Spevak, Lyudmila; Doty, Stephen B.; Boskey, Adele L.] Hosp Special Surg, Weill Cornell Med Coll, New York, NY 10021 USA.
   [Zhao, Yongdong; Urganus, Annette L.; Shrestha, Sheela; Pachman, Lauren M.] Childrens Mem Res Ctr, Ctr Excellence Clin Immunol, Chicago, IL 60614 USA.
C3 Northwestern University; Feinberg School of Medicine; Cornell
   University; Weill Cornell Medicine
RP Pachman, LM (通讯作者)，Childrens Mem Res Ctr, Ctr Excellence Clin Immunol, 2300 Childrens Plaza,Box 212, Chicago, IL 60614 USA.
EM yongdong.zhao@cchmc.org; aurganus@childrensmemorial.org;
   spevakm@hss.edu; shshrestha@childrensmemorial.org; dotys@hss.edu;
   boskey@hss.edu; pachman@northwestern.edu
RI ; Pachman, Lauren/AAZ 6061 2021
OI zhao, yongdong/0000 0003 3618 1379; Pachman, Lauren/0000 0001 8117 574X;
   Boskey, Adele/0000 0002 6181 2219
FU NIAMS NIH HHS [P30 AR046121, R0 1AR48289, AR046121, R01 AR048289]
   Funding Source: Medline
CR BOCCIARELLI DS, 1970, CALC TISS RES, V5, P261, DOI 10.1007/BF02017554
   Boskey AL, 2003, J BONE MINER RES, V18, P1005, DOI 10.1359/jbmr.2003.18.6.1005
   Boskey AL, 2005, VIB SPECTROSC, V38, P107, DOI 10.1016/j.vibspec.2005.02.015
   Brunnert SR, 1997, LAB ANIM SCI, V47, P11
   Chen SE, 2005, AM J PHYSIOL CELL PH, V289, pC1179, DOI 10.1152/ajpcell.00062.2005
   de la Peña LS, 2005, J BONE MINER RES, V20, P1168, DOI 10.1359/JBMR.050305
   Doherty TM, 2003, P NATL ACAD SCI USA, V100, P11201, DOI 10.1073/pnas.1932554100
   Faccio R, 1998, BIOCHEM BIOPH RES CO, V249, P522, DOI 10.1006/bbrc.1998.9180
   FLETCHER JE, 1987, TOXICON, V25, P1003, DOI 10.1016/0041 0101(87)90164 4
   FLETCHER JE, 1991, TOXICON, V29, P1489, DOI 10.1016/0041 0101(91)90005 C
   FOURIE AM, 1983, BIOCHEM INT, V6, P581
   Giachelli CM, 2005, CIRC RES, V96, P717, DOI 10.1161/01.RES.0000161997.24797.c0
   HUANG JL, 1991, TOXICON, V29, P31, DOI 10.1016/0041 0101(91)90037 R
   HUSSMANN J, 1995, ANN PLAS SURG, V34, P138, DOI 10.1097/00000637 199502000 00005
   JACKSON SA, 1978, CALC TISS RES, V25, P217, DOI 10.1007/BF02010772
   Ling YF, 2005, J BONE MINER RES, V20, P2169, DOI 10.1359/JBMR.050815
   Nakamura I, 2003, J ELECTRON MICROSC, V52, P527, DOI 10.1093/jmicro/52.6.527
   OWNBY CL, 1993, TOXICON, V31, P697, DOI 10.1016/0041 0101(93)90376 T
   Pachman LM, 2006, ARTHRITIS RHEUM US, V54, P3345, DOI 10.1002/art.22158
   Pampena DA, 2004, BIOCHEM J, V378, P1083, DOI 10.1042/BJ20031150
   Stock SR, 2004, CONNECT TISSUE RES, V45, P248, DOI 10.1080/03008200490903066
   Urganus AL, 2009, ARTHRIT RHEUM ARTHR, V61, P501, DOI 10.1002/art.24391
   Verdelis K, 2008, BONE, V43, P983, DOI 10.1016/j.bone.2008.08.110
   Wei BPC, 2003, ANZ J SURG, V73, P556, DOI 10.1046/j.1445 1433.2003.02665.x
   Woo JT, 2005, BIOCHEM PHARMACOL, V69, P87, DOI 10.1016/j.bcp.2004.08.036
   Zhao P, 2006, J BIOL CHEM, V281, P429, DOI 10.1074/jbc.M507440200
   Zhao Y, 2007, CLIN IMMUNOL, V125, P165, DOI 10.1016/j.clim.2007.06.011
   Zhu BQ, 2004, J CELL PHYSIOL, V198, P155, DOI 10.1002/jcp.10394
NR 28
TC 22
Z9 26
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD SEP
PY 2009
VL 85
IS 3
BP 267
EP 275
DI 10.1007/s00223 009 9271 5
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Endocrinology & Metabolism
GA 488UF
UT WOS:000269374900008
PM 19690791
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Nomura, Y
   Fukui, C
   Morishita, Y
   Haishima, Y
AF Nomura, Yusuke
   Fukui, Chie
   Morishita, Yuki
   Haishima, Yuji
TI A biological study establishing the endotoxin limit for osteoblast and
   adipocyte differentiation of human mesenchymal stem cells
SO REGENERATIVE THERAPY
LA English
DT Article
DE Endotoxin limit; Regenerative medicine products; Human mesenchymal stem
   cells; Bone differentiation
ID FIBROBLAST GROWTH FACTOR; OSTEOGENIC DIFFERENTIATION; BONE REGENERATION;
   PROLIFERATION; LIPOPOLYSACCHARIDE; CONTAMINATION; RECEPTORS; DELIVERY;
   SCAFFOLD
AB Introduction: Multipotent mesenchymal stem cells (MSCs) are widespread in adult organisms and are implicated in tissue maintenance and repair, regulation of hematopoiesis, and immunologic responses. Human (h) MSCs have applications in tissue engineering, cell based therapy, and medical devices but it is unclear how they respond to unfavorable conditions, such as hypoxia or inflammation after transplantation in vivo. Although endotoxin testing is required for evaluating the quality and safety of transplanted MSCs, no reports on their dose response to endotoxins are available to establish the limits for in vitro MSC culture systems. In the present study, we aimed to accurately quantify the risk of endotoxin contamination in cell culture systems to establish an acceptable endotoxin limit for the differentiation of hMSC osteoblasts and adipocytes.
   Methods: Three types of bone marrow derived hMSCs (hMSC 1: 21 year old, M/B; hMSC 2: 36 year old, M/B; hMSC 3: 43 year old, M/C) and adipose derived stem cells (ADSCs; StemPro Human) were cultured in osteogenic or adipogenic differentiation media, respectively, from commercial kits, containing various concentrations of endotoxin (0.01 100 ng/ml). The degree of adipocyte and osteoblast differentiation was estimated by fluorescent staining of lipid droplets and hydroxyapatite, respectively. To clarify the molecular mechanism underlying the effect of endotoxin on hMSC differentiation, cellular proteins were extracted from cultured cells and subjected to liquid chromatograph tandem mass spectrometry shotgun proteomics analysis.
   Results: Although endotoxin did not effect the adipocyte differentiation of hMSCs, osteoblast differentiation was enhanced by various endotoxin concentrations: over 1 ng/ml, for hMSC 1; 10 ng/ml, for hMSC 2; and 100 ng/ml, for hMSC 3. Proteomic analysis of hMSC 1 cells revealed up regulation of many proteins related to bone formation. These results suggested that endotoxin enhances the osteoblast differentiation of MSCs depending on the cell type.
   Conclusions: Since endotoxins can affect various cellular functions, an endotoxin limit should be established for in vitro MSC cultures. Its no observed adverse effect level was 0.1 ng/ml based on the effect on the hMSC osteoblast differentiation, but it may not necessarily be the limit for ADSCs. (C) 2018, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.
C1 [Nomura, Yusuke; Fukui, Chie; Morishita, Yuki; Haishima, Yuji] Natl Inst Hlth Sci, Div Med Devices, Setagaya Ku, 1 18 1 Kamiyoga, Tokyo 1588501, Japan.
C3 National Institute of Health Sciences   Japan
RP Haishima, Y (通讯作者)，Natl Inst Hlth Sci, Div Med Devices, Setagaya Ku, 1 18 1 Kamiyoga, Tokyo 1588501, Japan.
EM nomura@nihs.go.jp; hasegaw@nihs.go.jp; y morishita@nihs.go.jp;
   haishima@nihs.go.jp
OI Morishita, Yuki/0000 0001 5482 9701
CR Arahira T, 2014, J MECH BEHAV BIOMED, V39, P218, DOI 10.1016/j.jmbbm.2014.07.013
   Avila HM, 2014, APPL MICROBIOL BIOT, V98, P7423, DOI 10.1007/s00253 014 5819 z
   Chen GB, 2015, CURR STEM CELL RES T, V10, P99, DOI 10.2174/1574888X09666140812112631
   Cho HH, 2006, TISSUE ENG, V12, P111, DOI 10.1089/ten.2006.12.111
   Cho HH, 2006, STEM CELLS, V24, P2744, DOI 10.1634/stemcells.2006 0189
   Crisostomo PR, 2008, AM J PHYSIOL CELL PH, V294, pC675, DOI 10.1152/ajpcell.00437.2007
   CUNNINGHAM NS, 1995, GROWTH FACTORS, V12, P99, DOI 10.3109/08977199509028956
   Curtin CM, 2015, ADV HEALTHC MATER, V4, P223, DOI 10.1002/adhm.201400397
   Daly KA, 2012, TISSUE ENG PT A, V18, P1293, DOI [10.1089/ten.TEA.2011.0597, 10.1089/ten.tea.2011.0597]
   Haishima Y, 2001, J BIOMED MATER RES, V55, P424, DOI 10.1002/1097 4636(20010605)55:3<424::AID JBM1032>3.0.CO;2 S
   Haishima Y, 2017, J BIOMED MATER RES B, V105, P1514, DOI 10.1002/jbm.b.33692
   Hanada K, 1997, J BONE MINER RES, V12, P1606, DOI 10.1359/jbmr.1997.12.10.1606
   Hayakawa T, 2015, REGEN THER, V2, P57, DOI 10.1016/j.reth.2015.05.002
   He XQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149876
   Hino J, 2004, FRONT BIOSCI LANDMRK, V9, P1520, DOI 10.2741/1355
   Hiwatashi N, 2015, ANN OTO RHINOL LARYN, V124, P116, DOI 10.1177/0003489414546396
   Ho TY, 2007, BIOMATERIALS, V28, P4370, DOI 10.1016/j.biomaterials.2007.07.005
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Kadono H, 1999, INFECT IMMUN, V67, P2841, DOI 10.1128/IAI.67.6.2841 2846.1999
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Liu TJ, 2007, J CELL PHYSIOL, V211, P728, DOI 10.1002/jcp.20988
   Nomura Y, 2017, REGEN THER, V7, P45, DOI 10.1016/j.reth.2017.08.004
   Osyczka AM, 2005, ENDOCRINOLOGY, V146, P3428, DOI 10.1210/en.2005 0303
   Pevsner Fischer M, 2007, BLOOD, V109, P1422, DOI 10.1182/blood 2006 06 028704
   RIETSCHEL E.T., 1984, BACTERIAL ENDOTOXIN, P11
   Rietschel ETBL, 1990, ENDOTOXIN PATHOPHYSI, P5
   Sapir Yulia, 2014, Methods Mol Biol, V1181, P83, DOI 10.1007/978 1 4939 1047 2_8
   Schutte RJ, 2009, BIOMATERIALS, V30, P160, DOI 10.1016/j.biomaterials.2008.09.026
   Scutt A, 1999, CALCIFIED TISSUE INT, V64, P69, DOI 10.1007/s002239900581
   Shi Liang, 2007, Zhonghua Xue Ye Xue Za Zhi, V28, P828
   Snyder TN, 2014, J BIOL ENG, V8, DOI 10.1186/1754 1611 8 10
   Sun Kai, 2015, Eur J Orthop Surg Traumatol, V25, P243, DOI 10.1007/s00590 014 1515 z
   van Putten SM, 2011, J BIOMED MATER RES A, V98A, P527, DOI 10.1002/jbm.a.33144
   Wang ZJ, 2009, CELL BIOL INT, V33, P665, DOI 10.1016/j.cellbi.2009.03.006
   WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83
   Yang H, 2002, PHYTOTHER RES, V16, P43, DOI 10.1002/ptr.912
   Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191
NR 37
TC 11
Z9 11
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD JUN
PY 2018
VL 8
BP 46
EP 57
DI 10.1016/j.reth.2018.01.002
PG 12
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA GK1TG
UT WOS:000435903700007
PM 30271865
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Maruhashi, T
   Kaifu, T
   Yabe, R
   Seno, A
   Chung, SH
   Fujikado, N
   Iwakura, Y
AF Maruhashi, Takumi
   Kaifu, Tomonori
   Yabe, Rikio
   Seno, Akimasa
   Chung, Soo Hyun
   Fujikado, Noriyuki
   Iwakura, Yoichiro
TI DCIR Maintains Bone Homeostasis by Regulating IFN γ Production in T
   Cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID NECROSIS FACTOR ALPHA; ANKYLOSING SPONDYLITIS; DENDRITIC CELLS;
   OSTEOCLAST FORMATION; INTERFERON GAMMA; AUTOIMMUNE DISEASES; INHIBITORY
   MOTIF; DEFICIENT MICE; MOUSE MODEL; TNF ALPHA
AB Dendritic cell immunoreceptor (DCIR) is a C type lectin receptor mainly expressed in DCs. Dcir( / ) mice spontaneously develop autoimmune enthesitis and ankylosis accompanied by fibrocartilage proliferation and ectopic ossification. However, the mechanisms of new bone/cartilage formation in Dcir( / ) mice remain to be elucidated. In this study, we show that DCIR maintains bone homeostasis by regulating IFN gamma production under pathophysiological conditions. DCIR deficiency increased bone volume in femurs and caused aberrant ossification in joints, whereas these symptoms were abolished in Rag2( / ) Dcir( / ) mice. IFN gamma producing T cells accumulated in lymph nodes and joints of Dcir( / ) mice, and purified Dcir( / ) DCs enhanced IFN gamma(+) T cell differentiation. The ankylotic changes and bone volume increase were suppressed in the absence of IFN gamma. Thus, IFN gamma is a positive chondrogenic and osteoblastogenic factor, and DCIR is a crucial regulator of bone metabolism; consequently, both factors are potential targets for therapies directed against bone metabolic diseases.
C1 [Maruhashi, Takumi; Kaifu, Tomonori; Yabe, Rikio; Seno, Akimasa; Chung, Soo Hyun; Fujikado, Noriyuki; Iwakura, Yoichiro] Univ Tokyo, Ctr Expt Med & Syst Biol, Inst Med Sci, Tokyo 1088639, Japan.
   [Maruhashi, Takumi; Iwakura, Yoichiro] Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130032, Japan.
   [Maruhashi, Takumi; Kaifu, Tomonori; Yabe, Rikio; Chung, Soo Hyun; Iwakura, Yoichiro] Tokyo Univ Sci, Res Inst Biomed Sci, Noda, Chiba 2780022, Japan.
   [Kaifu, Tomonori; Fujikado, Noriyuki; Iwakura, Yoichiro] Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Saitama 3320012, Japan.
   [Yabe, Rikio; Seno, Akimasa; Iwakura, Yoichiro] Chiba Univ, Med Mycol Res Ctr, Chiba 2508673, Japan.
C3 University of Tokyo; University of Tokyo; Tokyo University of Science;
   Japan Science & Technology Agency (JST); Chiba University
RP Iwakura, Y (通讯作者)，Tokyo Univ Sci, Res Inst Biomed Sci, 2669 Yamazaki, Noda, Chiba 2780022, Japan.
EM iwakura@rs.tus.ac.jp
RI ; Kaifu, Tomonori/ABF 9491 2021; iwakura, yoichiro/E 5457 2011; Seno,
   Akimasa/I 1512 2019; Iwakura, Yoichiro/E 5457 2011
OI Chung, Soo Hyun/0000 0003 2808 1327; Fujikado,
   Noriyuki/0000 0002 3183 5866; Maruhashi, Takumi/0000 0003 2944 1611;
   Seno, Akimasa/0000 0002 9664 9490; iwakura,
   yoichiro/0000 0002 9934 5775; KAIFU, Tomonori/0000 0003 3668 5366;
   Kaifu, Tomonori/0000 0002 2614 1472; Fujikado,
   Noriyuki/0000 0002 0415 5929
FU Japan Society for the Promotion of Science [24220011, 23500489]; Japan
   Science and Technology Agency; Science and Technology Research Promotion
   Program for Agriculture, Forestry, Fisheries, and Food Industry;
   Grants in Aid for Scientific Research [23500489, 26430095] Funding
   Source: KAKEN
FX This work was supported by Grant in Aid for Scientific Research (S)
   24220011 (to Y.I.) and Grant in Aid for Scientific Research (C) 23500489
   (to T.K.) from the Japan Society for the Promotion of Science; a Core
   Research for Evolutional Science and Technology Grant from the Japan
   Science and Technology Agency (to Y.I.); the Science and Technology
   Research Promotion Program for Agriculture, Forestry, Fisheries, and
   Food Industry (to Y.I.); and by a fellowship from the Japan Society for
   the Promotion of Science (to T.M.).
CR Abe Y, 2009, MOD RHEUMATOL, V19, P316, DOI 10.1007/s10165 009 0166 0
   Abram CL, 2013, IMMUNITY, V38, P489, DOI 10.1016/j.immuni.2013.02.018
   Adamopoulos IE, 2011, J IMMUNOL, V187, P951, DOI 10.4049/jimmunol.1003986
   Aoki K, 1999, BONE, V25, P261, DOI 10.1016/S8756 3282(99)00174 X
   Armaka M, 2008, J EXP MED, V205, P331, DOI 10.1084/jem.20070906
   Australo Anglo American Spondyloarthritis Consortium (TASC) and the Wellcome Trust Case Control Consortium 2 (WTCCC2), 2011, NAT GENET, V43, P761
   Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Bates EEM, 1999, J IMMUNOL, V163, P1973
   Benjamin M, 2007, ARTHRITIS RHEUM, V56, P224, DOI 10.1002/art.22290
   BRAUN J, 1995, ARTHRITIS RHEUM, V38, P499, DOI 10.1002/art.1780380407
   Braun J, 2007, LANCET, V369, P1379, DOI 10.1016/S0140 6736(07)60635 7
   Crew MD, 1998, J INTERF CYTOK RES, V18, P219, DOI 10.1089/jir.1998.18.219
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Duque G, 2011, J BONE MINER RES, V26, P1472, DOI 10.1002/jbmr.350
   Duque G, 2009, STEM CELLS, V27, P550, DOI 10.1634/stemcells.2008 0886
   Finnegan A, 2002, J IMMUNOL, V169, P3345, DOI 10.4049/jimmunol.169.6.3345
   Fowler MJ Jr, 1998, BIOCHEM BIOPH RES CO, V248, P450, DOI 10.1006/bbrc.1998.8988
   Fujikado N, 2008, NAT MED, V14, P176, DOI 10.1038/nm1697
   Fukui N, 2003, J BONE JOINT SURG AM, V85A, P59, DOI 10.2106/00004623 200300003 00011
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Giltay EJ, 1999, ANN NY ACAD SCI, V876, P340, DOI 10.1111/j.1749 6632.1999.tb07658.x
   Goldring MB, 2008, ANN RHEUM DIS, V67, P75, DOI 10.1136/ard.2008.098764
   Gosset M, 2008, NAT PROTOC, V3, P1253, DOI 10.1038/nprot.2008.95
   IKEBE T, 1988, J IMMUNOL, V140, P827
   Kanazawa N, 2002, J INVEST DERMATOL, V118, P261, DOI 10.1046/j.0022 202x.2001.01633.x
   Kaneko T, 2012, J IMMUNOL, V188, P5397, DOI 10.4049/jimmunol.1103210
   Lee YM, 2010, INT IMMUNOL, V22, P805, DOI 10.1093/intimm/dxq431
   Li TF, 2005, FRONT BIOSCI LANDMRK, V10, P681, DOI 10.2741/1563
   Limón Camacho L, 2012, J RHEUMATOL, V39, P830, DOI 10.3899/jrheum.110862
   Lories RJU, 2007, ARTHRITIS RHEUM, V56, P489, DOI 10.1002/art.22372
   Lories RJU, 2005, J CLIN INVEST, V115, P1571, DOI 10.1172/JCI23738
   Lories RJU, 2003, ARTHRITIS RHEUM, V48, P2807, DOI 10.1002/art.11389
   Mathieu A, 2009, AUTOIMMUN REV, V8, P420, DOI 10.1016/j.autrev.2009.01.003
   Matthys P, 2003, ARTHRITIS RHEUM US, V48, P2983, DOI 10.1002/art.11273
   Mei Y, 2011, CLIN RHEUMATOL, V30, P269, DOI 10.1007/s10067 010 1647 4
   Meyer Wentrup F, 2008, BLOOD, V111, P4245, DOI 10.1182/blood 2007 03 081398
   Meyer Wentrup F, 2009, J LEUKOCYTE BIOL, V85, P518, DOI 10.1189/jlb.0608352
   Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074 7613(02)00391 6
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Newport M, 2007, NAT GENET, V39, P1329, DOI 10.1038/ng.2007.17
   Osorio F, 2011, IMMUNITY, V34, P651, DOI 10.1016/j.immuni.2011.05.001
   Pao LI, 2007, ANNU REV IMMUNOL, V25, P473, DOI 10.1146/annurev.immunol.23.021704.115647
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Redlich K, 2004, ARTHRITIS RHEUM, V50, P1001, DOI 10.1002/art.20194
   Reveille JD, 2010, NAT GENET, V42, P123, DOI 10.1038/ng.513
   Richard M, 2006, MOL IMMUNOL, V43, P1716, DOI 10.1016/j.molimm.2005.10.006
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Sherlock JP, 2012, NAT MED, V18, P1069, DOI 10.1038/nm.2817
   Shin HS, 2015, J IMMUNOL, V194, P316, DOI 10.4049/jimmunol.1401013
   Tagawa Y, 1997, J IMMUNOL, V159, P1418
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Taniguchi T, 1997, LAB INVEST, V77, P647
   Thomas GP, 2010, IMMUNOL REV, V233, P162, DOI 10.1111/j.0105 2896.2009.00852.x
   van der Heijde D, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2794
   VERBRUGGEN G, 1993, J RHEUMATOL, V20, P1020
   WILL R, 1990, J RHEUMATOL, V17, P1649
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Xu Y, 2007, BIOCHEM BIOPH RES CO, V359, P311, DOI 10.1016/j.bbrc.2007.05.098
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 64
TC 36
Z9 40
U1 0
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022 1767
EI 1550 6606
J9 J IMMUNOL
JI J. Immunol.
PD JUN 15
PY 2015
VL 194
IS 12
BP 5681
EP 5691
DI 10.4049/jimmunol.1500273
PG 11
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA CJ8MY
UT WOS:000355757800015
PM 25926676
DA 2025 08 17
ER

PT J
AU Davis, HE
   Case, EM
   Miller, SL
   Genetos, DC
   Leach, JK
AF Davis, Hillary E.
   Case, Erin M.
   Miller, Stephanie L.
   Genetos, Damian C.
   Leach, J. Kent
TI Osteogenic Response to BMP 2 of hMSCs Grown on Apatite Coated Scaffolds
SO BIOTECHNOLOGY AND BIOENGINEERING
LA English
DT Article
DE scaffold; osteoconductivity; osteoinductive; bone morphogenetic protein;
   simulated body fluid
ID BONE REGENERATION; POLYMER MICROSPHERES; ACID) MICROSPHERES; CERAMIC
   COMPOSITES; DRUG DELIVERY; IN VITRO; HYDROXYAPATITE; CELL; OSTEOBLAST;
   DIFFERENTIATION
AB Osteoconductive materials play a critical role in promoting integration with surrounding bone tissue and resultant bone repair in vivo. However, the impact of 3D osteoconductive substrates coupled with soluble signals on progenitor cell differentiation is not clear. In this study, we investigated the influence of bone morphogenetic protein 2 (BMP 2) concentration on the osteogenic differentiation of human mesenchymal stem cells (hMSCs) when seeded in carbonated apatite coated polymer scaffolds. Mineralized scaffolds were more hydrophilic and adsorbed more BMP 2 compared to non mineralized scaffolds. Changes in alkaline phosphatase (ALP) activity within stimulated hMSCs were dependent on the dose of BMP 2 and the scaffold composition. We detected more cell secreted calcium on mineralized scaffolds at all time points, and higher BMP 2 concentrations resulted in increased ALP and calcium levels. RUNX2 and IBSP gene expression within hMSCs was affected by both substrate and soluble signals, SP7 by soluble factors, and SPARC by substrate mediated cues. The present data indicate that a combination of apatite and BMP 2 do not simply enhance the osteogenic response of hMSCs, but act through multiple pathways that may be both substrate and growth factor mediated. Thus, multiple signaling strategies will likely be necessary to achieve optimal bone regeneration. Biotechnol. Bioeng. 2011; 108: 2727 2735. (C) 2011 Wiley Periodicals, Inc.
C1 [Davis, Hillary E.; Case, Erin M.; Miller, Stephanie L.; Genetos, Damian C.; Leach, J. Kent] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA.
C3 University of California System; University of California Davis
RP Leach, JK (通讯作者)，Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA.
EM jkleach@ucdavis.edu
RI ; Genetos, Damian/A 6480 2012; davis, hillary/LDF 9279 2024
OI Genetos, Damian/0000 0002 8599 2867; Davis, Hillary/0000 0001 5363 2587;
   
FU AO Foundation [F 06 98L]; NASA [NNX08AY31G]; NIH [NIAMS AR057547]; NASA
   [93064, NNX08AY31G] Funding Source: Federal RePORTER
FX Contract grant sponsor: AO FoundationContract grant number:
   F 06 98LContract grant sponsor: NASA Harriett G. Jenkins Predoctoral
   FellowshipContract grant number: NNX08AY31GContract grant sponsor:
   NIHContract grant number: NIAMS AR057547
CR Autefage H, 2009, J BIOMED MATER RES B, V91B, P706, DOI 10.1002/jbm.b.31447
   Bauer TW, 2007, ARCH PATHOL LAB MED, V131, P217
   Bauer TW, 1999, SKELETAL RADIOL, V28, P483, DOI 10.1007/s002560050552
   Bauer TW, 2000, CLIN ORTHOP RELAT R, P10
   Bhumiratana S, 2011, BIOMATERIALS, V32, P2812, DOI 10.1016/j.biomaterials.2010.12.058
   Celil AB, 2005, J CELL BIOCHEM, V95, P518, DOI 10.1002/jcb.20429
   COHEN S, 1991, PHARMACEUT RES, V8, P713, DOI 10.1023/A:1015841715384
   COHEN SA, 1979, CLIN CHEM, V25, P1519
   Davis HE, 2009, J BIOMED MATER RES A, V90A, P1021, DOI 10.1002/jbm.a.32169
   Dong XL, 2007, BIOPHYS J, V93, P750, DOI 10.1529/biophysj.106.103168
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Habraken WJEM, 2007, ADV DRUG DELIVER REV, V59, P234, DOI 10.1016/j.addr.2007.03.011
   He JW, 2010, TISSUE ENG PT A, V16, P127, DOI [10.1089/ten.tea.2009.0255, 10.1089/ten.TEA.2009.0255]
   Jongpoiboonkit L, 2009, ADV MATER, V21, P1960, DOI 10.1002/adma.200801808
   Jorgensen NR, 2004, STEROIDS, V69, P219, DOI 10.1016/j.steroids.2003.12.005
   Kang SW, 2008, J BIOMED MATER RES A, V85A, P747, DOI 10.1002/jbm.a.31572
   Kay S, 2002, TISSUE ENG, V8, P753, DOI 10.1089/10763270260424114
   Kim HJ, 2008, BONE, V42, P1226, DOI 10.1016/j.bone.2008.02.007
   Kim SS, 2007, J BIOMED MATER RES A, V80A, P206, DOI 10.1002/jbm.a.30836
   Kim SS, 2006, BIOMATERIALS, V27, P1399, DOI 10.1016/j.biomaterials.2005.08.016
   Kimelman N, 2007, TISSUE ENG, V13, P1135, DOI 10.1089/ten.2007.0096
   Komatsu DE, 2010, J CELL BIOCHEM, V109, P302, DOI 10.1002/jcb.22418
   Kretlow JD, 2007, TISSUE ENG, V13, P927, DOI 10.1089/ten.2006.0394
   Liu Y, 2007, J DENT RES, V86, P84, DOI 10.1177/154405910708600114
   Murphy WL, 2005, BIOMATERIALS, V26, P303, DOI 10.1016/j.biomaterials.2004.02.034
   Murphy WL, 2004, J DENT RES, V83, P204, DOI 10.1177/154405910408300304
   Murphy WL, 2002, J AM CHEM SOC, V124, P1910, DOI 10.1021/ja012433n
   Mygind T, 2007, BIOMATERIALS, V28, P1036, DOI 10.1016/j.biomaterials.2006.10.003
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   O'hEireamhoin Sven, 2011, Orthop Surg, V3, P40, DOI 10.1111/j.1757 7861.2010.00119.x
   Osyczka AM, 2004, CELLS TISSUES ORGANS, V176, P109, DOI 10.1159/000075032
   Porter JR, 2009, BIOTECHNOL PROGR, V25, P1539, DOI 10.1002/btpr.246
   Smith LL, 2007, INT J NANOMED, V2, P383
   Tsuruga E, 1997, J BIOCHEM TOKYO, V121, P317
   Whang K, 1999, TISSUE ENG, V5, P35, DOI 10.1089/ten.1999.5.35
   Whang K, 2000, BIOMATERIALS, V21, P2545, DOI 10.1016/S0142 9612(00)00122 8
   Zhang PB, 2009, BIOMATERIALS, V30, P58, DOI 10.1016/j.biomaterials.2008.08.041
   Zhang RY, 1999, J BIOMED MATER RES, V44, P446
NR 39
TC 30
Z9 40
U1 0
U2 18
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0006 3592
J9 BIOTECHNOL BIOENG
JI Biotechnol. Bioeng.
PD NOV
PY 2011
VL 108
IS 11
BP 2727
EP 2735
DI 10.1002/bit.23227
PG 9
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA 831GP
UT WOS:000295717700022
PM 21656707
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Khajuria, DK
   Karuppagounder, V
   Nowak, I
   Sepulveda, DE
   Lewis, GS
   Norbury, CC
   Raup Konsavage, WM
   Vrana, KE
   Kamal, F
   Elbarbary, RA
AF Khajuria, Deepak Kumar
   Karuppagounder, Vengadeshprabhu
   Nowak, Irena
   Sepulveda, Diana E.
   Lewis, Gregory S.
   Norbury, Christopher C.
   Raup Konsavage, Wesley M.
   Vrana, Kent E.
   Kamal, Fadia
   Elbarbary, Reyad A.
TI Cannabidiol and Cannabigerol, Nonpsychotropic Cannabinoids, as
   Analgesics that Effectively Manage Bone Fracture Pain and Promote
   Healing in Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE FRACTURE HEALING; BONE REGENERATION; ANALGESIC; CANNABIDIOL;
   CANNABIGEROL
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GENE EXPRESSION; RECEPTOR; CELLS;
   INHIBITION; NONUNION; MASS; CB2; HEALTHY; OSTERIX
AB Bone fractures are among the most prevalent musculoskeletal injuries, and pain management is an essential part of fracture treatment. Fractures heal through an early inflammatory phase, followed by repair and remodeling. Nonsteroidal anti inflammatory drugs (NSAIDs) are not recommended for fracture pain control as they potently inhibit the inflammatory phase and, thus, impair the healing. Opioids do not provide a better alternative for several reasons, including abuse potential. Accordingly, there is an unmet clinical need for analgesics that effectively ameliorate postfracture pain without impeding the healing. Here, we investigated the analgesic efficacy of two nonpsychotropic cannabinoids, cannabidiol (CBD) and cannabigerol (CBG), in a mouse model for tibial fracture. Mice with fractured tibiae exhibited increased sensitivity to mechanical, cold, and hot stimuli. Both CBD and CBG normalized pain sensitivity to all tested stimuli, and their analgesic effects were comparable to those of the NSAIDs. Interestingly, CBD and CBG promoted bone healing via multiple mechanisms during the early and late phases. During the early inflammatory phase, both cannabinoids increased the abundance of periosteal bone progenitors in the healing hematoma and promoted the osteogenic commitment of these progenitors. During the later phases of healing, CBD and CBG accelerated the fibrocartilaginous callus mineralization and enhanced the viability and proliferation of bone and bone marrow cells. These effects culminated in higher bone volume fraction, higher bone mineral density, and improved mechanical quality of the newly formed bone. Together, our data suggest CBD and CBG as therapeutic agents that can replace NSAIDs in managing postfracture pain as both cannabinoids exert potent analgesic effects and, at the same time, promote bone healing. & COPY; 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
C1 [Khajuria, Deepak Kumar; Karuppagounder, Vengadeshprabhu; Nowak, Irena; Lewis, Gregory S.; Kamal, Fadia; Elbarbary, Reyad A.] Penn State Univ, Coll Med, Dept Orthopaed & Rehabil, Hershey, PA USA.
   [Khajuria, Deepak Kumar; Karuppagounder, Vengadeshprabhu; Nowak, Irena; Lewis, Gregory S.; Kamal, Fadia; Elbarbary, Reyad A.] Penn State Univ, Coll Med, Ctr Orthopaed Res & Translat Sci CORTS, Hershey, PA USA.
   [Sepulveda, Diana E.; Raup Konsavage, Wesley M.; Vrana, Kent E.; Kamal, Fadia] Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA USA.
   [Sepulveda, Diana E.] Penn State Coll Med, Dept Anesthesiol & Perioperat Med, Hershey, PA USA.
   [Norbury, Christopher C.] Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA USA.
   [Elbarbary, Reyad A.] Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA USA.
   [Elbarbary, Reyad A.] Penn State Univ, Ctr RNA Mol Biol, University Pk, PA USA.
   [Kamal, Fadia; Elbarbary, Reyad A.] Penn State Univ, Dept Orthopaed & Rehabil, Coll Med, Hershey, PA 17033 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Penn State Health; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); Pennsylvania State University; Penn State
   Health; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Penn State Health; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); Pennsylvania State University; Penn State
   Health; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Pennsylvania State University  
   University Park; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Pennsylvania State University; Penn State Health
RP Kamal, F; Elbarbary, RA (通讯作者)，Penn State Univ, Dept Orthopaed & Rehabil, Coll Med, Hershey, PA 17033 USA.
EM fkamal@pennstatehealth.psu.edu; relbarbary@pennstatehealth.psu.edu
RI Elbarbary, Reyad/LCD 6398 2024; Khajuria, Deepak/A 5993 2019; Kamal,
   Fadia/AAP 1798 2021; Raup Konsavage, Wesley/ABB 1910 2020; Khajuria,
   Deepak Kumar/A 5993 2019; Sepúlveda, Diana/HDL 8091 2022
OI Lewis, Gregory/0000 0002 3673 0182; Khajuria, Deepak
   Kumar/0000 0002 3737 8504; Kamal, Fadia/0000 0003 2408 4061
FU Analysis of the plasma concentrations of CBD and CBG was performed at
   the Mass Spectrometry Core Facility (small molecules) (RRID no. is
   SCR_017831), and the FC analysis was performed at the Flow Cytometry and
   Cell Sorting core (RRID no. SCR_021134) at the [SCR_017831, SCR_021134];
   Penn State University College of Medicine; (Penn State College of
   Medicine); PA Options for Wellness [R01 DK121327, R01 AR071968]
FX Analysis of the plasma concentrations of CBD and CBG was performed at
   the Mass Spectrometry Core Facility (small molecules) (RRID no. is
   SCR_017831), and the FC analysis was performed at the Flow Cytometry and
   Cell Sorting core (RRID no. SCR_021134) at the Penn State University
   College of Medicine. Kent E. Vrana (and the Penn State College of
   Medicine) is the recipient of research support from PA Options for
   Wellness (a state approved medical marijuana clinical registrant). The
   funding sources were not involved in study design, providing any
   experimental materials, data collection, data analysis and
   interpretation, writing of the report, or the decision to submit the
   article for publication. The authors would like to acknowledge members
   of the state approved medical marijuana academic clinical research
   center at Penn State for insights and comments on the data and study
   design. This work was supported by National Institutes of Health (NIH)
   grants R01 DK121327 to Reyad A. Elbarbary and R01 AR071968 to Fadia
   Kamal.
CR Alves CJ, 2016, BONE, V85, P107, DOI 10.1016/j.bone.2016.01.026
   Baht GS, 2018, CURR OSTEOPOROS REP, V16, P138, DOI 10.1007/s11914 018 0423 2
   Bergenstock M, 2005, J ORTHOP TRAUMA, V19, P717, DOI 10.1097/01.bot.0000184144.98071.5d
   Bhattacharyya T, 2005, ARTHRIT RHEUM ARTHR, V53, P364, DOI 10.1002/art.21170
   Brown Matthew L, 2014, PLoS One, V9, pe99656, DOI 10.1371/journal.pone.0099656
   Carlson EL, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.aau8491
   Carrillo Salinas FJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094733
   Chau DL, 2008, CLIN INTERV AGING, V3, P273, DOI 10.2147/CIA.S1847
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   De Filippis D, 2008, NEUROGASTROENT MOTIL, V20, P919, DOI 10.1111/j.1365 2982.2008.01114.x
   Devinsky O, 2018, NEUROLOGY, V90, pE1204, DOI 10.1212/WNL.0000000000005254
   FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376
   Feinberg SD, 2000, GERIATRICS, V55, P44
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   Giannoudis PV, 2000, J BONE JOINT SURG BR, V82B, P655, DOI 10.1302/0301 620X.82B5.9899
   Henriquez JE, 2017, JAIDS J ACQ IMM DEF, V75, P588, DOI 10.1097/qai.0000000000001449
   HOGEVOLD HE, 1992, ACTA ORTHOP SCAND, V63, P607
   Hsu WY, 2019, ADDICTION, V114, P2008, DOI 10.1111/add.14732
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Jain N, 2018, SPINE J, V18, P1659, DOI 10.1016/j.spinee.2018.04.012
   Ortuño MJ, 2013, BONE, V52, P548, DOI 10.1016/j.bone.2012.11.007
   Kaplan BLF, 2008, BIOCHEM PHARMACOL, V76, P726, DOI 10.1016/j.bcp.2008.06.022
   Karuppagounder V, 2023, CANNABIS CANNABINOID, V8, P1030, DOI 10.1089/can.2021.0244
   Karuppagounder V, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23147933
   Kegelman CD, 2021, J BONE MINER RES, V36, P143, DOI 10.1002/jbmr.4166
   Khajuria DK, 2023, BONE RES, V11, DOI 10.1038/s41413 022 00236 7
   Khajuria DK, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115436
   Khuja I, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030668
   Koester MC, 2006, CLIN SPORT MED, V25, P63, DOI 10.1016/j.csm.2005.08.004
   Koester Michael C, 2005, Curr Sports Med Rep, V4, P289
   Kogan NM, 2021, MOLECULES, V26, DOI 10.3390/molecules26185601
   Kogan NM, 2015, J BONE MINER RES, V30, P1905, DOI 10.1002/jbmr.2513
   Laprairie RB, 2015, BRIT J PHARMACOL, V172, P4790, DOI 10.1111/bph.13250
   Legare CA, 2022, PHARMACOLOGY, V107, P131, DOI 10.1159/000521683
   Li DH, 2017, EUR J PHARMACOL, V809, P13, DOI 10.1016/j.ejphar.2017.05.011
   Lozano Ondoua AN, 2013, J BONE MINER RES, V28, P92, DOI 10.1002/jbmr.1732
   Mantyh PW, 2014, EUR J NEUROSCI, V39, P508, DOI 10.1111/ejn.12462
   Martínez Pinilla E, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00744
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0
   McVeigh LG, 2020, CURR OSTEOPOROS REP, V18, P460, DOI 10.1007/s11914 020 00617 z
   Minville V, 2008, ANESTHESIOLOGY, V108, P467, DOI 10.1097/ALN.0b013e3181649333
   Mitchell SAT, 2018, CURR OSTEOPOROS REP, V16, P325, DOI 10.1007/s11914 018 0446 8
   MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0
   Murnaghan M, 2006, J BONE JOINT SURG AM, V88A, P140, DOI 10.2106/JBJS.F.00454
   Nakamichi Y, 2017, J BONE MINER RES, V32, P1297, DOI 10.1002/jbmr.3096
   Navarro G, 2018, BIOCHEM PHARMACOL, V157, P148, DOI 10.1016/j.bcp.2018.08.046
   Navarro G, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00632
   Nichols JM, 2020, CANNABIS CANNABINOID, V5, P12, DOI 10.1089/can.2018.0073
   O'Connor JP, 2009, ACTA ORTHOP, V80, P597, DOI 10.3109/17453670903316769
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Ofek O, 2011, J BONE MINER RES, V26, P308, DOI 10.1002/jbmr.228
   Pinamont WJ, 2020, JOVE J VIS EXP, DOI 10.3791/60991
   Rock EM, 2011, PSYCHOPHARMACOLOGY, V215, P505, DOI 10.1007/s00213 010 2157 4
   Pazos MR, 2013, NEUROPHARMACOLOGY, V71, P282, DOI 10.1016/j.neuropharm.2013.03.027
   Sepulveda DE, 2022, EUR J PAIN, V26, P1950, DOI 10.1002/ejp.2016
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Tam J, 2008, FASEB J, V22, P285, DOI 10.1096/fj.06 7957com
   Tam J, 2006, MOL PHARMACOL, V70, P786, DOI 10.1124/mol.106.026435
   Tham M, 2019, BRIT J PHARMACOL, V176, P1455, DOI 10.1111/bph.14440
   Thapa D, 2018, CANNABIS CANNABINOID, V3, P11, DOI 10.1089/can.2017.0041
   Wee H, 2022, JOVE J VIS EXP, DOI 10.3791/64262
   Wheeler P, 2005, BRIT J SPORT MED, V39, P65, DOI 10.1136/bjsm.2004.012492
   Xing WR, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0064 9
   Xiong W, 2012, J EXP MED, V209, P1121, DOI 10.1084/jem.20120242
   Xu JJ, 2022, BONE RES, V10, DOI 10.1038/s41413 021 00176 8
   Yoshioka NK, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 13062 y
NR 68
TC 8
Z9 8
U1 3
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2023
VL 38
IS 11
BP 1560
EP 1576
DI 10.1002/jbmr.4902
EA SEP 2023
PG 17
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA LG9O8
UT WOS:001070057600001
PM 37597163
OA hybrid
DA 2025 08 17
ER

PT J
AU Maurizi, A
AF Maurizi, Antonio
TI Experimental therapies for osteopetrosis
SO BONE
LA English
DT Article
DE Osteopetrosis; Experimental therapy; Rare bone disease; Gene therapy;
   HSCT; siRNA
ID STEM CELL TRANSPLANTATION; GENE THERAPY; BONE; GENERATION; PHENOTYPE;
   RESCUE; BLOOD; MODEL
AB The medical treatment of osteopetrosis is an ongoing clinical problem. There are no effective and safer thera peutic approaches for all its forms. However, recent discoveries concerning the etiology and the pathogenesis of osteopetrosis, the development of dedicated cellular and animal models, and the advent of new technologies are paving the way for the development of targeted and safer therapies for both lethal and milder osteopetrosis. This review summarizes the huge effort and successes made by researchers to identify and develop new experimental approaches with this objective, such as the use of non genotoxic myeloablation, gene correction of inducible Pluripotent Stem Cells (iPSCs), lentiviral based gene therapy, protein replacement, prenatal treatment, osteoclast precursors transplantation and RNA Interference.
C1 [Maurizi, Antonio] Univ Aquila, Dept Biotechnol & Appl Clin Sci, I 67100 Laquila, Italy.
   [Maurizi, Antonio] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio Coppito 2, I 67100 Laquila, Italy.
C3 University of L'Aquila; University of L'Aquila
RP Maurizi, A (通讯作者)，Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio Coppito 2, I 67100 Laquila, Italy.
EM antoniomaurizi@outlook.com
RI ; Maurizi, Antonio/AAI 7728 2020
OI Maurizi, Antonio/0000 0002 7027 4694; 
FU Piano Operativo Nazionale (PON) Ricerca Innovazione [FSE REACT EU
   DM.1062]; Fondazione Telethon [GGP20074]; American Society for Bone and
   Mineral Research (ASBMR Rising Star 2021); Department of
   Biotechnological and Applied Clinical Sciences, University of L'Aquila
   [2022_07_DG_2022_13]
FX AM is supported by the "Piano Operativo Nazionale (PON) Ricerca
   Innovazione" (FSE REACT EU DM.1062), he is a member of the Cost Action
   CA18139 GEMSTONE consortium and he received funding from Fondazione
   Telethon (GGP20074), the American Society for Bone and Mineral Research
   (ASBMR Rising Star 2021) and from the Department of Biotechnological and
   Applied Clinical Sciences, University of L'Aquila (intramural "DISCAB
   GRANT 2022_07_DG_2022_13").
CR Abadir E., CLARK TARGETING NICH
   Agarwal R, 2020, BLOOD, V136, DOI 10.1182/blood 2020 137762
   Agarwal Rajni, 2019, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, V25
   Alam I, 2015, J BONE MINER RES, V30, P2005, DOI 10.1002/jbmr.2545
   Alam I, 2014, BONE, V59, P66, DOI 10.1016/j.bone.2013.10.021
   Anderson RH, 2018, MOL CELL PROBE, V40, P52, DOI 10.1016/j.mcp.2018.01.001
   Barruet E, 2016, METHODS MOL BIOL, V1353, P101, DOI 10.1007/7651_2014_171
   Capo V, 2021, HAEMATOLOGICA, V106, P74, DOI 10.3324/haematol.2019.238261
   Cappariello A, 2015, BIOMATERIALS, V46, P58, DOI 10.1016/j.biomaterials.2014.12.033
   Cappariello A, 2010, J BONE MINER RES, V25, P106, DOI 10.1359/jbmr.090715
   Capulli M, 2015, MOL THER NUCL ACIDS, V4, P1, DOI 10.1038/mtna.2015.21
   Castiello MC, 2021, J ALLERGY CLIN IMMUN, V147, P309, DOI 10.1016/j.jaci.2020.04.033
   Chen IP, 2014, J CLIN MED, V3, P1490, DOI 10.3390/jcm3041490
   Chen WL, 2019, J BONE JOINT SURG AM, V101, P1939, DOI 10.2106/JBJS.19.00558
   Cohen S, 2020, LANCET HAEMATOL, V7, pE134, DOI 10.1016/S2352 3026(19)30202 9
   Czechowicz A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08201 x
   Even Or E, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.28841
   Frattini A, 2005, P NATL ACAD SCI USA, V102, P14629, DOI 10.1073/pnas.0507637102
   Hennig AF, 2019, STEM CELL RES, V35, DOI 10.1016/j.scr.2018.101367
   Imel EA, 2019, J BONE MINER RES, V34, P1436, DOI 10.1002/jbmr.3715
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Jeon OH, 2016, SCI REP UK, V6, DOI 10.1038/srep26761
   Johansson MK, 2007, BLOOD, V109, P5178, DOI 10.1182/blood 2006 12 061382
   KEY L, 1984, NEW ENGL J MED, V310, P409, DOI 10.1056/NEJM198402163100701
   KEY LL, 1995, NEW ENGL J MED, V332, P1594, DOI 10.1056/NEJM199506153322402
   Le Blanc K, 2006, CURR OPIN IMMUNOL, V18, P586, DOI 10.1016/j.coi.2006.07.004
   Lo Iacono N, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/412768
   Löfvall H, 2019, HUM GENE THER, V30, P1395, DOI 10.1089/hum.2019.047
   Magnani A, 2019, BLOOD ADV, V3, P237, DOI 10.1182/bloodadvances.2018023176
   Maurizi A, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0055 x
   Maurizi A, 2018, BONE, V110, P343, DOI 10.1016/j.bone.2018.02.031
   Menale C, 2019, STEM CELL TRANSL MED, V8, P22, DOI 10.1002/sctm.18 0085
   Moscatelli I, 2018, HUM GENE THER, V29, P938, DOI 10.1089/hum.2017.053
   Moscatelli I, 2013, BONE, V57, P1, DOI 10.1016/j.bone.2013.07.026
   Neri T, 2015, STEM CELL REP, V5, P558, DOI 10.1016/j.stemcr.2015.08.005
   Norwood I, 2021, BONE, V144, DOI 10.1016/j.bone.2020.115828
   Orchard PJ, 2015, BLOOD, V126, P270, DOI 10.1182/blood 2015 01 625541
   Palchaudhuri R, 2016, NAT BIOTECHNOL, V34, P738, DOI 10.1038/nbt.3584
   Penna S, 2021, DIS MODEL MECH, V14, DOI 10.1242/dmm.048940
   Penna S, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00085
   Saito A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 017 0754 4
   Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756 3282(99)00278 1
   Shadur B, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.27010
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Stepensky P, 2019, BLOOD ADV, V3, P862, DOI 10.1182/bloodadvances.2018025890
   Straathof KC, 2009, LANCET, V374, P912, DOI 10.1016/S0140 6736(09)60945 4
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   Teti A., 2013, HAEMATOPOIETIC STEM, P265
   Teti A, 2017, BONE, V102, P50, DOI 10.1016/j.bone.2017.02.002
   Thrasher AJ, 2017, MOL THER, V25, P1132, DOI 10.1016/j.ymthe.2017.03.018
   Tondelli B, 2009, AM J PATHOL, V174, P727, DOI 10.2353/ajpath.2009.080688
   Wu CC, 2017, J CLIN ENDOCR METAB, V102, P3111, DOI 10.1210/jc.2017 01127
   Xian XJ, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01701 y
   Zhu GH, 2021, ORPHANET J RARE DIS, V16, DOI 10.1186/s13023 021 01955 6
NR 54
TC 4
Z9 5
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2022
VL 165
AR 116567
DI 10.1016/j.bone.2022.116567
EA SEP 2022
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 5D1FI
UT WOS:000864695400004
PM 36152941
DA 2025 08 17
ER

PT J
AU Liu, Y
   Sebastian, S
   Huang, JT
   Corbascio, T
   Engellau, J
   Lidgren, L
   Tägil, M
   Raina, DB
AF Liu, Yang
   Sebastian, Sujeesh
   Huang, Jintian
   Corbascio, Tova
   Engellau, Jacob
   Lidgren, Lars
   Tagil, Magnus
   Raina, Deepak Bushan
TI Longitudinal in vivo biodistribution of nano and micro sized
   hydroxyapatite particles implanted in a bone defect
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE nano hydroxyapatite; micro hydroxyapatite; biodistribution; drug
   delivery; osteosarcoma
ID TARGETED DRUG DELIVERY; NANOPARTICLES; BISPHOSPHONATES; MICROPARTICLES;
   PENETRATION; GENTAMICIN; MECHANISM
AB Hydroxyapatite (HA) has been widely used as a bone substitute and more recently as a carrier for local delivery of bone targeted drugs. Majority of the approved HA based biomaterials and drug carriers comprise of micrometer sized particulate HA (mHA) or granules and can therefore only be used for extracellular drug release. This shortcoming could be overcome with the use of cell penetrating HA nanoparticles (nHA) but a major concern with the clinical use of nHA is the lack of data on its in vivo biodistribution after implantation. In this study, we aimed to study the in vivo biodistribution of locally implanted nHA in a clinically relevant tibial void in rats and compare it with mHA or a combination of mHA and nHA. To enable in vivo tracking, HA particles were first labelled with C 14 zoledronic acid (C 14 ZA), known to have a high binding affinity to HA. The labelled particles were then implanted in the animals and the radioactivity in the proximal tibia and vital organs was detected at various time points (Day 1, 7 and 28) post implantation using scintillation counting. The local distribution of the particles in the bone was studied with micro CT. We found that majority (> 99.9%) of the implanted HA particles, irrespective of the size, stayed locally at the implantation site even after 28 days and the findings were confirmed using micro CT. Less than 0.1% radioactivity was observed in the kidney and the spleen at later time points of day 7 and 28. No pathological changes in any of the vital organs could be observed histologically. This is the first longitudinal in vivo HA biodistribution study showing that the local implantation of nHA particles in bone is safe and that nHA could potentially be used for localized drug delivery.
C1 [Liu, Yang; Sebastian, Sujeesh; Huang, Jintian; Corbascio, Tova; Lidgren, Lars; Tagil, Magnus; Raina, Deepak Bushan] Lund Univ, Fac Med, Orthoped, Dept Clin Sci Lund, Lund, Sweden.
   [Engellau, Jacob] Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden.
C3 Lund University; Lund University; Skane University Hospital
RP Liu, Y; Raina, DB (通讯作者)，Lund Univ, Fac Med, Orthoped, Dept Clin Sci Lund, Lund, Sweden.
EM liu.yang@med.lu.se; deepak.raina@med.lu.se
RI Liu, Yang/HOH 2214 2023; Sebastian, Sujeesh/AAD 8175 2020; Tagil,
   Magnus/N 1778 2019
FU Swedish Research Council (Vetenskapsradet) [2021 03447]; Fru Berta
   Kamprad foundation [FBKS 2020 23 (269)]; Maggie Stephens foundation
   [20202004]; China Scholarship Council [201806940015]; Swedish Research
   Council [2021 03447] Funding Source: Swedish Research Council
FX Swedish Research Council (Vetenskapsradet, Grant number: 2021 03447),
   Fru Berta Kamprad foundation (Grant number: FBKS 2020 23 (269)), Maggie
   Stephens foundation (Grant number: 20202004) and China Scholarship
   Council (grant number: 201806940015) are deeply thanked for the
   financial support to conduct this research.
CR Ajdary M, 2018, NANOMATERIALS BASEL, V8, DOI 10.3390/nano8090634
   Bae YH, 2011, J CONTROL RELEASE, V153, P198, DOI 10.1016/j.jconrel.2011.06.001
   Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020
   Byrne James D, 2008, Mcgill J Med, V11, P43
   Chen BH, 2018, CRIT REV BIOTECHNOL, V38, P1003, DOI 10.1080/07388551.2018.1426555
   Cheng H, 2017, DRUG DISCOV TODAY, V22, P1336, DOI 10.1016/j.drudis.2017.04.021
   Cui YZ, 2022, ACS NANO, V16, P11076, DOI 10.1021/acsnano.2c03781
   Cui YZ, 2022, BIOACT MATER, V10, P207, DOI 10.1016/j.bioactmat.2021.09.015
   de Grado GF, 2018, J TISSUE ENG, V9, DOI 10.1177/2041731418776819
   Deng ZJ, 2011, NAT NANOTECHNOL, V6, P39, DOI [10.1038/nnano.2010.250, 10.1038/NNANO.2010.250]
   Dogra P, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06730 z
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Fadia BS, 2022, ACS OMEGA, V7, P20656, DOI 10.1021/acsomega.2c00727
   Ferdous Z, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072375
   Garazzino S, 2011, INT J INFECT DIS, V15, pE415, DOI 10.1016/j.ijid.2011.03.003
   Golombek SK, 2018, ADV DRUG DELIVER REV, V130, P17, DOI 10.1016/j.addr.2018.07.007
   Hong J, 2014, J AGR FOOD CHEM, V62, P6871, DOI 10.1021/jf501428w
   Horstmann PF, 2018, J ORTHOP SURG HONG K, V26, DOI 10.1177/2309499018774929
   Hussain S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/923475
   Iranpour P, 2016, ULTRASONOGRAPHY, V35, P3, DOI 10.14366/usg.15020
   Jelvehgari M, 2010, IRAN J BASIC MED SCI, V13, P85
   Kim M, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf4398
   Kollenda SA, 2020, ACTA BIOMATER, V109, P244, DOI 10.1016/j.actbio.2020.03.031
   Lara Ochoa S, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13101642
   Lawric CM, 2020, BONE JOINT J, V102B, P163, DOI 10.1302/0301 620X.102B6.BJJ 2019 1639.R1
   Lee JH, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743 8977 10 36
   Liu GW, 2020, PHYSIOL REP, V8, DOI 10.14814/phy2.14545
   Liu Y, 2022, MATER TODAY BIO, V14, DOI 10.1016/j.mtbio.2022.100227
   Ma P., 2013, J NANOMEDICINE NANOT, V4, P1000164, DOI [DOI 10.4172/2157 7439.1000164, 10.4172/2157 7439.1000164]
   Marques MRC, 2019, ADV DRUG DELIVER REV, V151, P23, DOI 10.1016/j.addr.2019.06.003
   MOGHIMI SM, 1993, BIOCHIM BIOPHYS ACTA, V1157, P233, DOI 10.1016/0304 4165(93)90105 H
   Montoya C, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00131 z
   Mukherjee S, 2008, J AM CHEM SOC, V130, P1264, DOI 10.1021/ja0759949
   Najahi Missaoui W, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010385
   Newman MR, 2016, CURR OPIN BIOTECH, V40, P125, DOI 10.1016/j.copbio.2016.02.029
   Ng CT, 2016, ACS BIOMATER SCI ENG, V2, P1959, DOI 10.1021/acsbiomaterials.6b00358
   Niemann M, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12051207
   Pascual B, 1996, BIOMATERIALS, V17, P509, DOI 10.1016/0142 9612(96)82725 6
   Porsio B, 2018, ACS APPL MATER INTER, V10, P165, DOI 10.1021/acsami.7b14992
   Qi HZ, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.775682
   Raina DB, 2020, ACTA ORTHOP, V91, P126, DOI 10.1080/17453674.2019.1686865
   Raina DB, 2019, ACTA BIOMATER, V96, P619, DOI 10.1016/j.actbio.2019.07.009
   Salamanna F, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11020530
   Salles S, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10543
   Sang XZ, 2013, J AGR FOOD CHEM, V61, P5590, DOI 10.1021/jf3035989
   Sebastian S, 2022, BONE JOINT RES, V11, P787, DOI 10.1302/2046 3758.1111.BJR 2022 0101.R1
   Sheng L, 2013, J BIOMED MATER RES A, V101, P3238, DOI 10.1002/jbm.a.34634
   Stevens MM, 2008, MATER TODAY, V11, P18, DOI 10.1016/S1369 7021(08)70086 5
   Swallow EA, 2018, OSTEOPOROSIS INT, V29, P2139, DOI 10.1007/s00198 018 4589 3
   Tabernero J, 2013, CANCER DISCOV, V3, P406, DOI 10.1158/2159 8290.CD 12 0429
   Torkington MS, 2017, BONE JOINT J, V99B, P358, DOI [10.1302/0301 620X.99B3.BJJ 2016 0328.R1, 10.1302/0301 620x.99b3.bjj 2016 0328.r1]
   Tsoi KM, 2016, NAT MATER, V15, P1212, DOI [10.1038/NMAT4718, 10.1038/nmat4718]
   Ventola C Lee, 2012, P T, V37, P582
   Verhulst A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121861
   Wang ZY, 2021, NANOSCALE RES LETT, V16, DOI 10.1186/s11671 021 03522 1
   Wei J, 2015, J MATER CHEM B, V3, P8162, DOI 10.1039/c5tb01268f
   Wilhelm S, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.14
   Zhang K, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax6946
   Zhao CY, 2018, MOLECULES, V23, DOI 10.3390/molecules23040826
   Zhao Na, 2018, J Nanomed Nanotechnol, V9, DOI 10.4172/2157 7439.1000519
NR 60
TC 8
Z9 8
U1 2
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD DEC 19
PY 2022
VL 10
AR 1076320
DI 10.3389/fbioe.2022.1076320
PG 15
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA 7M1GD
UT WOS:000906402900001
PM 36601389
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yun, HY
   Ku, B
   Lee, HS
   Shin, HC
   Park, JB
   Kim, CH
   Kim, SJ
AF Yun, Hye Yeoung
   Ku, Bonsu
   Lee, Hye Seon
   Shin, Ho Chul
   Park, Jun Beom
   Kim, Chang Hyen
   Kim, Seung Jun
TI The Discovery of Novel Protein Tyrosine Phosphatase ε Inhibitors Using a
   High throughput Screening Approach
SO BULLETIN OF THE KOREAN CHEMICAL SOCIETY
LA English
DT Article
DE Protein tyrosine phosphatase; High throughput screening; Chemical
   library; Inhibitor; Osteoporosis
ID OSTEOCLASTS; TURNOVER; DISEASE
AB Protein tyrosine phosphatase epsilon (PTP epsilon) is important for signal transduction in osteoclasts, and is considered to be an attractive drug target for the treatment of osteoporosis. We identified 11 potent PTP epsilon inhibitors based on three chemical scaffolds through the high throughput screening of a chemical library. As these compounds are structurally diverse with high bioavailability, they warrant further investigation in the near future. The discovery of these inhibitors and the relationship between their structure and inhibitory activity toward PTP epsilon is discussed in detail.
C1 [Yun, Hye Yeoung; Ku, Bonsu; Lee, Hye Seon; Shin, Ho Chul; Kim, Seung Jun] Korea Res Inst Biosci & Biotechnol, Dis Target Struct Res Ctr, Daejeon 34141, South Korea.
   [Yun, Hye Yeoung; Ku, Bonsu; Kim, Seung Jun] Univ Sci & Technol, Dept Bioanalyt Sci, Daejeon 34113, South Korea.
   [Park, Jun Beom] Catholic Univ Korea, Seoul St Marys Hosp, Dept Periodont, Seoul 137701, South Korea.
   [Kim, Chang Hyen] Catholic Univ Korea, Seoul St Marys Hosp, Dept Oral & Maxillofacial Surg, Seoul 137701, South Korea.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB);
   University of Science & Technology (UST); Seoul St. Mary's Hospital;
   Catholic University of Korea; Seoul St. Mary's Hospital; Catholic
   University of Korea
RP Kim, SJ (通讯作者)，Korea Res Inst Biosci & Biotechnol, Dis Target Struct Res Ctr, Daejeon 34141, South Korea.; Kim, SJ (通讯作者)，Univ Sci & Technol, Dept Bioanalyt Sci, Daejeon 34113, South Korea.; Kim, CH (通讯作者)，Catholic Univ Korea, Seoul St Marys Hosp, Dept Oral & Maxillofacial Surg, Seoul 137701, South Korea.
EM omfskim1@catholic.ac.kr; ksj@kribb.re.kr
RI Shin, Eui/P 8725 2019; Park, Jun Beom/I 8201 2019; Ku,
   Bonsu/LZE 8247 2025
OI Ku, Bonsu/0000 0003 1784 8975; 
FU National Research Foundation of Korea   Ministry of Science, ICT and
   Future Planning [2015M3A9B5030308]; KRIBB Research Initiative Program
FX The authors thank the staff of the Korea Chemical Bank for help with
   selecting the chemical library. This work was supported by a grant (no.
   2015M3A9B5030308) from the National Research Foundation of Korea, funded
   by the Ministry of Science, ICT and Future Planning. We were also
   supported by the KRIBB Research Initiative Program.
CR Chiusaroli R, 2004, MOL BIOL CELL, V15, P234, DOI 10.1091/mbc.e03 04 0207
   Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02 07 0389
   Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235
   Gil Henn H, 2000, ONCOGENE, V19, P4375, DOI 10.1038/sj.onc.1203790
   Granot Attas S, 2009, MOL BIOL CELL, V20, P4324, DOI 10.1091/mbc.E08 11 1158
   Hendriks WJAJ, 2013, FEBS J, V280, P708, DOI 10.1111/febs.12000
   Luxenburg C, 2006, J CELL SCI, V119, P4878, DOI 10.1242/jcs.03271
   Miyamoto Takeshi, 2003, Keio J Med, V52, P1
   Otto S, 2011, J CRANIO MAXILL SURG, V39, P272, DOI 10.1016/j.jcms.2010.05.009
   Reddy SV, 2004, J CELL BIOCHEM, V93, P688, DOI 10.1002/jcb.20256
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068
   Sheng MHC, 2009, CELL MOL LIFE SCI, V66, P1946, DOI 10.1007/s00018 009 8811 5
NR 13
TC 1
Z9 1
U1 0
U2 5
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0253 2964
EI 1229 5949
J9 B KOREAN CHEM SOC
JI Bull. Korean Chem. Soc.
PD JAN
PY 2017
VL 38
IS 1
BP 44
EP 53
DI 10.1002/bkcs.11044
PG 10
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA EK1QN
UT WOS:000393700800007
DA 2025 08 17
ER

PT J
AU Ye, DM
   Chen, C
   Wang, QW
   Zhang, Q
   Li, S
   Liu, HW
AF Ye, Dongmei
   Chen, Chen
   Wang, Qiwen
   Zhang, Qi
   Li, Sha
   Liu, Hongwei
TI Short wave enhances mesenchymal stem cell recruitment in fracture
   healing by increasing HIF 1 in callus
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Mesenchymal stem cells; Short Wave therapy; Recruitment; Fracture; HIF 1
ID STROMAL CELLS; IN VIVO; BONE; MIGRATION; HYPERTHERMIA; EXPRESSION;
   PROMOTES; MOBILIZATION; THRESHOLDS; REPAIR
AB BackgroundAs a type of high frequency electrotherapy, a short wave can promote the fracture healing process; yet, its underlying therapeutic mechanisms remain unclear.PurposeTo observe the effect of Short Wave therapy on mesenchymal stem cell (MSC) homing and relative mechanisms associated with fracture healing.Materials and methodsFor in vivo study, the effect of Short Wave therapy to fracture healing was examined in a stabilized femur fracture model of 40 SD rats. Radiography was used to analyze the morphology and microarchitecture of the callus. Additionally, fluorescence assays were used to analyze the GFP labeled MSC homing after treatment in 20 nude mice with a femoral fracture. For in vitro study, osteoblast from newborn rats simulated fracture site was first irradiated by the Short Wave; siRNA targeting HIF 1 was used to investigate the role of HIF 1. Osteoblast culture medium was then collected as chemotaxis content of MSC, and the migration of MSC from rats was evaluated using wound healing assay and trans well chamber test. The expression of HIF 1 and its related factors were quantified by q RT PCR, ELISA, and Western blot.ResultsOur in vivo experiment indicated that Short Wave therapy could promote MSC migration, increase local and serum HIF 1 and SDF 1 levels, induce changes in callus formation, and improve callus microarchitecture and mechanical properties, thus speeding up the healing process of the fracture site. Moreover, the in vitro results further indicated that Short Wave therapy upregulated HIF 1 and SDF 1 expression in osteoblast and its cultured medium, as well as the expression of CXCR 4, beta  catenin, F actin, and phosphorylation levels of FAK in MSC. On the other hand, the inhibition of HIF 1 alpha was significantly restrained by the inhibition of HIF 1 alpha in osteoblast, and it partially inhibited the migration of MSC.ConclusionsThese results suggested that Short Wave therapy could increase HIF 1 in callus, which is one of the crucial mechanisms of chemotaxis MSC homing in fracture healing.
C1 [Ye, Dongmei; Wang, Qiwen; Zhang, Qi; Li, Sha; Liu, Hongwei] Dalian Univ, Affiliated Zhongshan Hosp, Dept Rehabil, Dalian 116001, Peoples R China.
   [Chen, Chen] Dalian Univ, Med Coll, Dept Anat, Dalian, Peoples R China.
   [Wang, Qiwen] Peoples Hosp Longhua Dist, Dept Rehabil, Shenzhen, Peoples R China.
C3 Dalian University; Dalian University; The People's Hospital of Longhua,
   Shenzhen
RP Ye, DM (通讯作者)，Dalian Univ, Affiliated Zhongshan Hosp, Dept Rehabil, Dalian 116001, Peoples R China.
EM shuiyan_1980@163.com
OI Ye, Dongmei/0000 0003 0247 3891
FU National Natural Science Foundation of China [81601982]
FX The National Natural Science Foundation of China (grant number 81601982)
   supported this study.
CR Annabi B, 2003, STEM CELLS, V21, P337, DOI 10.1634/stemcells.21 3 337
   Azevedo MM, 2015, TISSUE ENG PT A, V21, P382, DOI [10.1089/ten.tea.2014.0083, 10.1089/ten.TEA.2014.0083]
   Banks TA, 2015, INTEGR BIOL UK, V7, P693, DOI 10.1039/c4ib00297k
   Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075
   Chen Jun Qiu, 2018, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V26, P1858, DOI 10.7534/j.issn.1009 2137.2018.06.047
   Chen QF, 2018, BIOTECHNOL LETT, V40, P215, DOI 10.1007/s10529 017 2446 7
   Cotoia A, 2018, TRIALS, V19, DOI 10.1186/s13063 018 2556 0
   Cui YY, 2013, BIOMATERIALS, V34, P9373, DOI 10.1016/j.biomaterials.2013.08.060
   De Becker A, 2016, WORLD J STEM CELLS, V8, P73, DOI 10.4252/wjsc.v8.i3.73
   Dewhirst MW, 2003, INT J HYPERTHER, V19, P267, DOI 10.1080/0265673031000119006
   Freeman TA, 2009, J ORTHOP RES, V27, P673, DOI 10.1002/jor.20771
   Fuseler JW, 2012, BIOMATERIALS, V33, P1032, DOI 10.1016/j.biomaterials.2011.10.029
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Griffin M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023404
   Guo XQ, 2017, CELL TISSUE RES, V367, P197, DOI 10.1007/s00441 016 2535 2
   Herberg S, 2013, TISSUE ENG PT A, V19, P1, DOI [10.1089/ten.tea.2012.0085, 10.1089/ten.TEA.2012.0085]
   Ishii M, 2019, MOL CELL BIOCHEM, V455, P185, DOI 10.1007/s11010 018 3481 y
   Ito H, 2011, MOD RHEUMATOL, V21, P113, DOI 10.1007/s10165 010 0357 8
   Kim YS, 2013, MOL NEUROBIOL, V47, P811, DOI 10.1007/s12035 012 8393 3
   Kitaori T, 2009, ARTHRITIS RHEUM US, V60, P813, DOI 10.1002/art.24330
   Kumar S, 2012, BONE, V50, P1012, DOI 10.1016/j.bone.2012.01.027
   LEON SA, 1993, INT J HYPERTHER, V9, P69, DOI 10.3109/02656739309061479
   LEON SA, 1993, INT J HYPERTHER, V9, P77, DOI 10.3109/02656739309061480
   Lin F, 2018, EXP THER MED, V16, P3504, DOI 10.3892/etm.2018.6634
   Liu HB, 2010, BIOCHEM BIOPH RES CO, V401, P509, DOI 10.1016/j.bbrc.2010.09.076
   Liu LZ, 2016, CELL PHYSIOL BIOCHEM, V38, P1605, DOI 10.1159/000443101
   Liu TL, 2015, EUR J MED RES, V20, DOI 10.1186/s40001 015 0084 x
   Liu YZ, 2018, CLIN INTERV AGING, V13, P1465, DOI 10.2147/CIA.S167431
   Mannavola F, 2019, J TRANSL MED, V17, DOI 10.1186/s12967 019 1982 4
   Martinez VG, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0659 2
   Mattinzoli D, 2014, JOVE J VIS EXP, DOI 10.3791/51465
   Mediero A, 2015, ARTHRITIS RHEUMATOL, V67, P849, DOI 10.1002/art.38971
   Meng SS, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1031 x
   Moisley KM, 2019, J ORTHOP RES, V37, P1329, DOI 10.1002/jor.24261
   Obermeyer TS, 2012, J ORTHOP TRAUMA, V26, P712, DOI 10.1097/BOT.0b013e3182724298
   Ostberg JR, 2006, CANCER IMMUNOL IMMUN, V55, P292, DOI 10.1007/s00262 005 0689 y
   Ostberg JR, 2000, CELL STRESS CHAPERON, V5, P458, DOI 10.1379/1466 1268(2000)005<0458:ROIABM>2.0.CO;2
   Pang CJ, 2013, SYNAPSE, V67, P637, DOI 10.1002/syn.21669
   Periyasamy Thandavan S, 2008, KIDNEY INT, V74, P631, DOI 10.1038/ki.2008.214
   Riddle SR, 2000, AM J PHYSIOL LUNG C, V278, pL407, DOI 10.1152/ajplung.2000.278.2.L407
   Rui YF, 2010, TISSUE ENG PT A, V16, P1549, DOI [10.1089/ten.tea.2009.0529, 10.1089/ten.TEA.2009.0529]
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Sangani R, 2014, STEM CELL RES, V12, P354, DOI 10.1016/j.scr.2013.11.002
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   SEKINS KM, 1984, ARCH PHYS MED REHAB, V65, P1
   Shields Nora, 2002, Physiother Res Int, V7, P191, DOI 10.1002/pri.259
   Sotkis A, 2001, CELL COMMUN ADHES, V8, P277, DOI 10.3109/15419060109080737
   Su PH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082343
   Tsai LK, 2011, STROKE, V42, P2932, DOI 10.1161/STROKEAHA.110.612788
   Wan J, 2016, ACTA BIOCH BIOPH SIN, V48, P371, DOI 10.1093/abbs/gmw005
   Wang Guan Jie, 2012, Zhongguo Gu Shang, V25, P572
   Wei FY, 2016, EUR CELLS MATER, V31, P341, DOI 10.22203/eCM.v031a22
   Wei FY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106722
   Wei N, 2013, CELL TRANSPLANT, V22, P977, DOI 10.3727/096368912X657251
   Wu YJ, 2012, STEM CELL REV REP, V8, P243, DOI 10.1007/s12015 011 9293 z
   Xu Heng, 1999, Hunan Yike Daxue Xuebao, V24, P125
   YATVIN MB, 1977, INT J RADIAT BIOL, V32, P513, DOI 10.1080/09553007714551301
   Yu XF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062703
   Zhao Zhiqiang, 2011, Eur Cell Mater, V22, P344
   Zhou M, 2017, MOL MED REP, V15, P3186, DOI 10.3892/mmr.2017.6348
   Zimolag E, 2017, BBA MOL CELL RES, V1864, P267, DOI 10.1016/j.bbamcr.2016.11.011
NR 61
TC 12
Z9 13
U1 1
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD SEP 7
PY 2020
VL 11
IS 1
AR 382
DI 10.1186/s13287 020 01888 0
PG 16
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA NQ6GM
UT WOS:000570968600002
PM 32894200
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Behr, B
   Panetta, NJ
   Longaker, MT
   Quarto, N
AF Behr, Bjoern
   Panetta, Nicholas J.
   Longaker, Michael T.
   Quarto, Natalina
TI Different endogenous threshold levels of Fibroblast Growth
   Factor ligands determine the healing potential of frontal and parietal
   bones
SO BONE
LA English
DT Article
DE FGF; Calvarial healing; Embryonic origin; Bone regeneration; Neural
   crest cell contribution
ID DURA MATER; CELL PROLIFERATION; FRACTURE REPAIR; PROTEIN KINASE; FGF 2;
   EXPRESSION; OSTEOGENESIS; STIMULATION; OSTEOBLAST; NOGGIN
AB In the skull vault, neural crest derived frontal bones have an increased healing capacity and higher expression levels of Fibroblast Growth Factor ligands as compared to mesoderm derived parietal bones. Thus, we asked whether Fibroblast Growth Factor ligands are responsible for the superior healing potential of frontal bones. Parietal defects in juvenile and adult mice treated with Fibroblast Growth Factor 2,  9 and  18 showed increased bone regeneration, comparable to frontal defects. Immunohistochemistry revealed increased recruitment of osteoprogenitors and activation of FGF signaling pathways in FGF treated parietal defects. Conversely, calvarial defects in Fgf 9(+/ ) and Fgf 18(+/ ) mice showed impaired calvarial healing which could be rescued by exogenous Fibroblast Growth Factor ligands. Moreover, by utilizing Wnt1Cre/R26R mice, the migration and contribution of dura mater and pericranium cells to calvarial healing could be demonstrated. Taken together our results demonstrated that different endogenous threshold levels of Fibroblast Growth Factor ligands in frontal and parietal bones have a profound impact on calvarial regeneration. The present study thereby opens new avenues for translational medicine. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Behr, Bjoern; Panetta, Nicholas J.; Longaker, Michael T.; Quarto, Natalina] Stanford Univ, Sch Med, Dept Surg, Childrens Surg Res Program, Stanford, CA 94305 USA.
   [Behr, Bjoern] Heidelberg Univ, Dept Plast & Handsurg, BG Unfallklin Ludwigshafen, D 6900 Heidelberg, Germany.
   [Quarto, Natalina] Univ Naples Federico II, Dept Struct & Funct Biol, Naples, Italy.
C3 Stanford University; Ruprecht Karls University Heidelberg; University of
   Naples Federico II
RP Longaker, MT (通讯作者)，257 Campus Dr, Stanford, CA 94305 USA.
EM longaker@stanford.edu; quarto@unina.it
RI Behr, Björn/AAS 1877 2021; Panetta, Nicholas/JTS 7656 2023
FU Oak Foundation; NIH [R21DE019274, 1R01DE019434]; German Research
   Foundation [DFG BE 4169 1]
FX The authors would like to thank Dr. David Ornitz (Washington University,
   St. Louis, MO) for providing Fgf 9<SUP>+/ </SUP> and
   Fgf 18<SUP>+/ </SUP> and Dr Yang Chai (University of Southern
   California, CA) for Wnt1 Cre/R26R mice. This work was supported by the
   Oak Foundation, NIH R21DE019274 and NIH 1R01DE019434 to M.T.L. and the
   German Research Foundation (DFG BE 4169 1) to B.B.
CR Abbaspour A, 2008, BONE, V42, P98, DOI 10.1016/j.bone.2007.08.031
   CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490
   Chaudhary LR, 2004, BONE, V34, P402, DOI 10.1016/j.bone.2003.11.014
   Chaudhary LR, 2000, J CELL BIOCHEM, V76, P354, DOI 10.1002/(SICI)1097 4644(20000301)76:3<354::AID JCB2>3.3.CO;2 L
   Chen WJ, 2004, J BONE MINER METAB, V22, P303, DOI 10.1007/s00774 004 0487 6
   COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861
   Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007
   de Oliveira RS, 2007, CHILD NERV SYST, V23, P1097, DOI 10.1007/s00381 007 0413 7
   Debiais F, 2004, EXP CELL RES, V297, P235, DOI 10.1016/j.yexcr.2004.03.032
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Fakhry A, 2005, BONE, V36, P254, DOI 10.1016/j.bone.2004.10.003
   Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163
   Greenwald JA, 2000, PLAST RECONSTR SURG, V106, P630, DOI 10.1097/00006534 200009030 00016
   Hung IH, 2007, DEV BIOL, V307, P300, DOI 10.1016/j.ydbio.2007.04.048
   Jackson RA, 2006, GENE, V379, P79, DOI 10.1016/j.gene.2006.04.028
   Jiang XB, 2002, DEV BIOL, V241, P106, DOI 10.1006/dbio.2001.0487
   KAWAGUCHI H, 1994, ENDOCRINOLOGY, V135, P774, DOI 10.1210/en.135.2.774
   Kawaguchi H, 2001, J CLIN ENDOCR METAB, V86, P875, DOI 10.1210/jc.86.2.875
   Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200
   Kim SJ, 2007, GROWTH FACTORS, V25, P77, DOI 10.1080/08977190701398977
   Li S, 2007, AM J PHYSIOL CELL PH, V293, pC1834, DOI 10.1152/ajpcell.00135.2007
   Liang K, 1999, ENDOCRINOLOGY, V140, P5780
   Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602
   Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297
   MAYAHARA H, 1993, GROWTH FACTORS, V9, P73, DOI 10.3109/08977199308991583
   Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641
   NAGAI H, 1995, BONE, V16, P367, DOI 10.1016/8756 3282(94)00049 2
   Nakamura K, 1997, J ORTHOPAED RES, V15, P307, DOI 10.1002/jor.1100150222
   NAKAMURA T, 1995, ENDOCRINOLOGY, V136, P1276, DOI 10.1210/en.136.3.1276
   Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702
   Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702
   Pintucci G, 2003, J CELL BIOCHEM, V90, P1015, DOI 10.1002/jcb.10721
   Pintucci G, 2006, FASEB J, V20, P398, DOI 10.1096/fj.05 4114fje
   Quarto N, 2009, J BONE MINER RES
   Quarto N, 2006, TISSUE ENG, V12, P1405, DOI 10.1089/ten.2006.12.1405
   Quarto N, 2009, CELLS TISSUES ORGANS, V190, P158, DOI 10.1159/000202789
   REID CA, 1981, PLAST RECONSTR SURG, V67, P591, DOI 10.1097/00006534 198105000 00002
   Reinhold MI, 2007, J BIOL CHEM, V282, P3653, DOI 10.1074/jbc.M608995200
   Reinhold MI, 2004, J BIOL CHEM, V279, P38209, DOI 10.1074/jbc.M404855200
   RODAN SB, 1989, J BIOL CHEM, V264, P19934
   Rodriguez JES, 2009, J BONE MINER RES, V24, P1917, DOI [10.1359/JBMR.090507, 10.1359/jbmr.090507]
   Schmid GJ, 2009, DEV DYNAM, V238, P766, DOI 10.1002/dvdy.21882
   Shimoaka T, 2002, J BIOL CHEM, V277, P7493, DOI 10.1074/jbc.M108653200
   Spector JA, 2002, PLAST RECONSTR SURG, V109, P645, DOI 10.1097/00006534 200202000 00035
   Tokuda H, 2000, J BONE MINER RES, V15, P2371, DOI 10.1359/jbmr.2000.15.12.2371
   Wan DC, 2007, J BIOL CHEM, V282, P26450, DOI 10.1074/jbc.M703282200
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
NR 47
TC 51
Z9 56
U1 1
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD AUG
PY 2010
VL 47
IS 2
BP 281
EP 294
DI 10.1016/j.bone.2010.05.008
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 632SW
UT WOS:000280449300015
PM 20472108
DA 2025 08 17
ER

PT J
AU Chen, N
   Meng, Y
   Zhan, HX
   Li, G
AF Chen, Ning
   Meng, Yuan
   Zhan, Huixian
   Li, Gang
TI Identification and Validation of Potential Ferroptosis Related Genes in
   Glucocorticoid Induced Osteonecrosis of the Femoral Head
SO MEDICINA LITHUANIA
LA English
DT Article
DE glucocorticoid induced osteonecrosis of the femoral head; ferroptosis;
   bioinformatics analysis; gene expression omnibus
ID STEROID INDUCED OSTEONECROSIS; MESENCHYMAL STEM CELLS; IRON;
   DIFFERENTIATION; OSTEOBLASTS; INHIBITION; APOPTOSIS; HIP
AB Background and Objectives. Glucocorticoid induced osteonecrosis of the femoral head (GIONFH) is a serve complication of long term administration of glucocorticoids. Previous experimental studies have shown that ferroptosis might be involved in the pathological process of GIONFH. The purpose of this study is to identify the ferroptosis related genes and pathways of GIONFH by bioinformatics to further illustrate the mechanism of ferroptosis in SONFH through bioinformatics analysis. Materials and Methods. The GSE123568 mRNA expression profile dataset, including 30 GIONFH samples and 10 non GIONFH samples, was downloaded from the Gene Expression Omnibus (GEO) database. Ferroptosis related genes were obtained from the FerrDb database. First, differentially expressed genes (DEGs) were identified between the serum samples from GIONFH cases and those from controls. Ferroptosis related DEGs were obtained from the intersection of ferroptosis related genes and DEGs. Only ferroptosis DEGs were used for all analyses. Then, we conducted a Kyoto encyclopedia of genome (KEGG) and gene ontology (GO) pathway enrichment analysis. We constructed a protein protein interaction (PPI) network to screen out hub genes. Additionally, the expression levels of the hub genes were validated in an independent dataset GSE10311. Results. A total of 27 ferroptosis related DEGs were obtained between the peripheral blood samples of GIONFH cases and non GIONFH controls. Then, GO, and KEGG pathway enrichment analysis revealed that ferroptosis related DEGs were mainly enriched in the regulation of the apoptotic process, oxidation reduction process, and cell redox homeostasis, as well as HIF 1, TNF, FoxO signaling pathways, and osteoclast differentiation. Eight hub genes, including TLR4, PTGS2, SNCA, MAPK1, CYBB, SLC2A1, TXNIP, and MAP3K5, were identified by PPI network analysis. The expression levels of TLR4, TXNIP and MAP3K5 were further validated in the dataset GSE10311. Conclusion. A total of 27 ferroptosis related DEGs involved in GIONFH were identified via bioinformatics analysis. TLR4, TXNIP, and MAP3K5 might serve as potential biomarkers and drug targets for GIONFH.
C1 [Chen, Ning] Shandong Univ Tradit Chinese Med, Postdoctoral Res Ctr, Jinan 250355, Peoples R China.
   [Meng, Yuan; Zhan, Huixian] Guangzhou Univ Chinese Med, Coll Clin Med, Guangzhou 510006, Peoples R China.
   [Li, Gang] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Orthopaed Microsurg, Jinan 250014, Peoples R China.
   [Li, Gang] Shandong Univ Tradit Chinese Med, Clin Med Sch 1, Jinan 250355, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Guangzhou
   University of Chinese Medicine; Shandong University of Traditional
   Chinese Medicine; Shandong University of Traditional Chinese Medicine
RP Li, G (通讯作者)，Shandong Univ Tradit Chinese Med, Affiliated Hosp, Orthopaed Microsurg, Jinan 250014, Peoples R China.; Li, G (通讯作者)，Shandong Univ Tradit Chinese Med, Clin Med Sch 1, Jinan 250355, Peoples R China.
EM sdszylg@163.com
RI Chen, Ning/IVH 6535 2023
FU National Natural Science Foundation of China [82074453]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 82074453).
CR Almeida Maria, 2012, Bonekey Rep, V1
   Anesi A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194925
   Bai R, 2015, EXP THER MED, V10, P591, DOI 10.3892/etm.2015.2521
   Balogh E, 2016, BBA MOL BASIS DIS, V1862, P1640, DOI 10.1016/j.bbadis.2016.06.003
   Cai JJ, 2021, CELL METAB, V33, P258, DOI 10.1016/j.cmet.2021.01.002
   Chen GY, 2019, PEERJ, V7, DOI 10.7717/peerj.6306
   Chen JZ, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/3182368
   Chen L, 2020, FASEB J, V34, P5208, DOI 10.1096/fj.201901864RR
   Cui SA, 2022, PEERJ, V10, DOI 10.7717/peerj.13983
   DeHart DN, 2018, BIOCHEM PHARMACOL, V148, P155, DOI 10.1016/j.bcp.2017.12.022
   den Uyl D, 2011, CURR RHEUMATOL REP, V13, P233, DOI 10.1007/s11926 011 0173 y
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Erken HY, 2012, INT ORTHOP, V36, P1523, DOI 10.1007/s00264 012 1497 6
   Evans Jay T, 2003, Expert Rev Vaccines, V2, P219, DOI 10.1586/14760584.2.2.219
   Gangji V, 2003, J RHEUMATOL, V30, P348
   Guerado E, 2016, INJURY, V47, pS16, DOI 10.1016/S0020 1383(16)30835 X
   Hadian K, 2020, CELL, V181, P1188, DOI 10.1016/j.cell.2020.04.039
   Jeney V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00077
   Jia P, 2012, J ORTHOP RES, V30, P1843, DOI 10.1002/jor.22133
   Jiang XJ, 2021, NAT REV MOL CELL BIO, V22, P266, DOI 10.1038/s41580 020 00324 8
   Jing XZ, 2020, J CELL PHYSIOL, V235, P9864, DOI 10.1002/jcp.29799
   Kang JS, 2009, J ARTHROPLASTY, V24, P1178, DOI 10.1016/j.arth.2009.05.022
   Kapoor K, 2016, P NATL ACAD SCI USA, V113, P4711, DOI 10.1073/pnas.1603735113
   Latunde Dada GO, 2017, BBA GEN SUBJECTS, V1861, P1893, DOI 10.1016/j.bbagen.2017.05.019
   Lekva T, 2012, EUR J ENDOCRINOL, V166, P1039, DOI 10.1530/EJE 11 1082
   Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037030
   Li TX, 2019, BONE, V122, P199, DOI 10.1016/j.bone.2019.03.008
   Li Z, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.881914
   Lin TY, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02464 9
   McGettrick AF, 2007, BRIT J HAEMATOL, V139, P185, DOI 10.1111/j.1365 2141.2007.06802.x
   Mo YL, 2021, LIFE SCI, V266, DOI 10.1016/j.lfs.2020.118938
   Mont MA, 2015, J BONE JOINT SURG AM, V97A, P1604, DOI 10.2106/JBJS.O.00071
   Moutsatsou P, 2012, TRENDS MOL MED, V18, P348, DOI 10.1016/j.molmed.2012.04.005
   Moya Angeler J, 2015, WORLD J ORTHOP, V6, P590, DOI 10.5312/wjo.v6.i8.590
   Petrigliano FA, 2007, CLIN ORTHOP RELAT R, P53, DOI 10.1097/BLO.0b013e3181591c92
   Rochette L, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24010449
   Seguro LPC, 2013, AUTOIMMUN REV, V12, P629, DOI 10.1016/j.autrev.2012.12.002
   Shi WK, 2022, BMC GENOMICS, V23, DOI 10.1186/s12864 022 08996 6
   Singh Lalit P, 2013, J Clin Exp Ophthalmol, V4, DOI 10.4172/2155 9570.1000287
   Singh Lalit Pukhrambam, 2021, JOJ Ophthalmol, V8, P77
   Sun F, 2022, PEERJ, V10, DOI 10.7717/peerj.13319
   Sun F, 2022, BIOCHEM BIOPH RES CO, V602, P149, DOI 10.1016/j.bbrc.2022.02.112
   Tian L, 2014, J HUAZHONG U SCI MED, V34, P679, DOI 10.1007/s11596 014 1336 7
   Tsukanaka M, 2016, ACTA ORTHOP, V87, P479, DOI 10.1080/17453674.2016.1212180
   Vergely C, 2003, ARCH BIOCHEM BIOPHYS, V420, P209, DOI 10.1016/j.abb.2003.07.007
   Vink A, 2002, CIRCULATION, V106, P1985, DOI 10.1161/01.CIR.0000032146.75113.EE
   Wang C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096361
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wu ZX, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 03958 7
   Xu K, 2021, ENVIRON TOXICOL, V36, P2123, DOI 10.1002/tox.23327
   Yang N, 2021, INT J MED SCI, V18, P3697, DOI 10.7150/ijms.61080
   Zakaria NA, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11050755
   Zhang XX, 2022, CELL TRANSPLANT, V31, DOI 10.1177/09636897221082687
   Zhu CY, 2019, BIOCHEM BIOPH RES CO, V516, P645, DOI 10.1016/j.bbrc.2019.06.073
   Zhu KY, 2021, EXP NEUROL, V345, DOI 10.1016/j.expneurol.2021.113828
NR 56
TC 10
Z9 11
U1 0
U2 17
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1010 660X
EI 1648 9144
J9 MEDICINA LITHUANIA
JI Med. Lith.
PD FEB
PY 2023
VL 59
IS 2
AR 297
DI 10.3390/medicina59020297
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 9J2GN
UT WOS:000940012200001
PM 36837498
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tao, ZS
   Zhou, WS
   Xu, HG
   Yang, M
AF Tao, Zhou Shan
   Zhou, Wan Shu
   Xu, Hong Guang
   Yang, Min
TI Intermittent administration sodium valproate has a protective effect on
   bone health in ovariectomized rats
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Osteoporosis; Bone mass; Bone mineral density; Bone strength; Valproic
   acid
ID CHILDREN RECEIVING CARBAMAZEPINE; PARATHYROID HORMONE 1 34;
   ANTIEPILEPTIC DRUGS; ACID; METABOLISM; DENSITY; ACTIVATION; EXPRESSION;
   INHIBITORS; TURNOVER
AB The present work was aimed to evaluate the effect of different administration modes of sodium valproate (VPA) on bone strength, bone mass and bone mineral density in ovariectomized (OVX) rats and further investigation of the possible mechanism. 60 female SD rats were randomly divided into 4 groups: Sham group (Sham, n = 15), OVX group (OVX, n = 15), OVX rats received intermittent VPA treatment group (IVPA, n = 15) and OVX rats received daily VPA treatment group (EVPA, n = 15). After 12 weeks of treatment, the rats were sacrificed, and serum and femur samples were harvested. DEXA, Micro CT, history, biomechanical testing, biochemical index and western blot analysis were used to observe the therapeutic effect and explore the possible mechanism. MicroCT and DEXA analysis of bones revealed better BMD and higher BV/TV, Tb. Th, Tb. N, Conn. D and lower Tb. Sp at femoral metaphysis evaluated in IVPA when compared with OVX and EVPA group (P < 0.05). Histological, fluorescent analysis and biological strength revealed more trabecular bone and higher relative mineral apposition rate, maximal load, elastic modulus and energy at break with evaluated in IVPA when compared with OVX and EVPA group (P < 0.05). The levels of P1NP, estrogen, CTX, TRAP 5b and RANKL of the IVPA group showed a significant increase when compared with the OVX and EVPA group (P < 0.05). We confirm adverse effects on protein expressions including Notch1, Jagged1, HEY1, Wnt 1, 8 catenin and RUNX2 following daily VPA treatment in OVX female rats. Our current study demonstrated that intermittent administration of sodium valproate has a protective effect on bone health in OVX rats and these effects may be achieved by activating Notch/ Wnt/8 catenin/RUNX2 signal axis.
C1 [Tao, Zhou Shan; Yang, Min] Yijishan Hosp, Wannan Med Coll, Affiliated Hosp 1, Dept Trauma Orthoped, 2 Zhe Shan Xi Rd, Wuhu 241001, Anhui, Peoples R China.
   [Zhou, Wan Shu] Wannan Med Coll, Affiliated Hosp 2, Dept Geriatr, 123 Kangfu Rd, Wuhu 241001, Anhui, Peoples R China.
   [Xu, Hong Guang] Yijishan Hosp, Wannan Med Coll, Affiliated Hosp 1, Dept Spinal Orthoped, 2 Zhe Shan Xi Rd, Wuhu 241001, Peoples R China.
C3 Wannan Medical College; Wannan Medical College; Wannan Medical College
RP Tao, ZS (通讯作者)，Yijishan Hosp, Wannan Med Coll, Affiliated Hosp 1, Dept Trauma Orthoped, 2 Zhe Shan Xi Rd, Wuhu 241001, Anhui, Peoples R China.
EM tzs19900327@126.com
RI Xu, Hong Guang/F 1731 2010
FU National Natural Science Foundation of China [82002322]; "Peak" Training
   Program and "Panfeng" Innovation Team Project for Scientific Research of
   Yijishan Hospital, Wannan Medical College [PF2019005, GF 2019T02,
   PF2019007]; Young and Middle aged Key Project of Wannan Medical College
   [WK2020ZF16]
FX This study was supported by a grant from National Natural Science
   Foundation of China (82002322), Funding of "Peak" Training Program and
   "Panfeng" Innovation Team Project for Scientific Research of Yijishan
   Hospital, Wannan Medical College (grant no. GF 2019G04, PF2019005, GF
   2019T02 and PF2019007) and Young and Middle aged Key Project of Wannan
   Medical College(WK2020ZF16).
CR Akhoundi MSA, 2018, INT ORTHOD, V16, P73, DOI [10.1016/j.ortho.2018.01.022, 10.1016/j.ortho.2018.01.021]
   Akin R, 1998, PEDIATR NEUROL, V19, P129, DOI 10.1016/S0887 8994(98)00039 3
   Aksoy A, 2011, J PEDIATR ENDOCR MET, V24, P703, DOI 10.1515/JPEM.2011.019
   AlMuraikhi N, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/3041262
   Altay EE, 2000, J PEDIATR ENDOCR MET, V13, P933
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cabrera D, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03362 7
   Cui J, 2019, LAB INVEST, V99, P58, DOI 10.1038/s41374 018 0087 7
   Fabre S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113439
   Fan HC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081242
   Farrokhi Effat, 2015, Iranian Biomedical Journal, V19, P160, DOI 10.7508/ibj.2015.03.005
   Gabet Y, 2008, J BONE MINER RES, V23, P48, DOI 10.1359/JBMR.070901
   Guerra JM, 2019, J BONE MINER METAB, V37, P780, DOI 10.1007/s00774 018 0983 3
   Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160
   Ji YT, 2017, AM J TRANSL RES, V9, P2933
   Lee HS, 2013, BMC PEDIATR, V13, DOI 10.1186/1471 2431 13 211
   Li B, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0090 7
   Li YF, 2013, OSTEOPOROSIS INT, V24, P1063, DOI 10.1007/s00198 012 2258 5
   Li ZL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020526
   McCorry DJP, 2004, NEUROLOGY, V62, P342, DOI 10.1212/WNL.62.2.342 a
   Nissen Meyer LSH, 2008, SEIZURE EUR J EPILEP, V17, P187, DOI 10.1016/j.seizure.2007.11.024
   Ortinau LC, 2017, BONE, V103, P188, DOI 10.1016/j.bone.2017.07.010
   Ozaki D, 2021, OSTEOPOROSIS INT, V32, P145, DOI 10.1007/s00198 020 05728 y
   Paino F, 2014, STEM CELLS, V32, P279, DOI 10.1002/stem.1544
   Parveen B, 2018, BONE, V113, P57, DOI 10.1016/j.bone.2018.05.011
   Rabadiya S, 2018, BIOMED PHARMACOTHER, V97, P919, DOI 10.1016/j.biopha.2017.10.137
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rocha S, 2019, J CELL PHYSIOL, V234, P19691, DOI 10.1002/jcp.28569
   Sreedharan M, 2018, INDIAN PEDIATR, V55, P307, DOI 10.1007/s13312 018 1273 9
   Stockhausen MT, 2005, BRIT J CANCER, V92, P751, DOI 10.1038/sj.bjc.6602309
   Sun LC, 2016, J DRUG TARGET, V24, P169, DOI 10.3109/1061186X.2015.1066794
   Tanaka S., 2020, J BONE MINER METABOL
   Tao Z.S., BIOMED PHARMACOTHER, V132
   Tao Z.S., BIOMED PHARMACOTHER, V132
   Tao ZS, 2021, J ORTHOP TRANSL, V27, P67, DOI 10.1016/j.jot.2020.10.006
   Tao ZS, 2020, Z GERONTOL GERIATR, V53, P671, DOI 10.1007/s00391 019 01659 4
   Tao ZS, 2019, J BONE MINER METAB, V37, P1026, DOI 10.1007/s00774 019 01008 w
   Tao ZS, 2019, Z GERONTOL GERIATR, V52, P139, DOI 10.1007/s00391 018 1376 x
   Tao ZS, 2016, Z GERONTOL GERIATR, V49, P423, DOI 10.1007/s00391 015 0949 1
   Thijs RD, 2019, LANCET, V393, P689, DOI 10.1016/S0140 6736(18)32596 0
   Voudris KA, 2005, J CHILD NEUROL, V20, P513
   Yuan XM, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6869452
   Zhang RT, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 020 02151 1
   Zhang ST, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.106014
   Zhong R, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01171
   Zhou D, 2018, INT J MOL MED, V41, P3433, DOI 10.3892/ijmm.2018.3534
NR 46
TC 18
Z9 20
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 5
PY 2021
VL 906
AR 174268
DI 10.1016/j.ejphar.2021.174268
EA JUN 2021
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA UJ8TH
UT WOS:000691551500007
PM 34166702
DA 2025 08 17
ER

PT J
AU Suh, J
   Kim, NK
   Lee, SH
   Eom, JH
   Lee, Y
   Park, JC
   Woo, KM
   Baek, JH
   Kim, JE
   Ryoo, HM
   Lee, SJ
   Lee, YS
AF Suh, Joonho
   Kim, Na Kyung
   Lee, Seung Hoon
   Eom, Je Hyun
   Lee, Youngkyun
   Park, Joo Cheol
   Woo, Kyung Mi
   Baek, Jeong Hwa
   Kim, Jung Eun
   Ryoo, Hyun Mo
   Lee, Se Jin
   Lee, Yun Sil
TI GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a
   MSTN/GDF11 inhibitor, increases muscle mass but weakens bone
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE GDF11; myostatin; follistatin; osteogenesis; BMP
ID DIFFERENTIATION FACTOR 11; DEVELOPING MOUSE LIMB; BETA SUPERFAMILY;
   MYOSTATIN ACTIVITY; GENE THERAPY; ACTIVIN; GROWTH; AGE; EXPRESSION;
   MUTATION
AB Growth and differentiation factor 11 (GDF11) and myostatin ( MSTN) are closely related transforming growth factor beta (TGF beta) family members, but their biological functions are quite distinct. While MSTN has been widely shown to inhibit muscle growth, GDF11 regulates skeletal patterning and organ development during embryogenesis. Postnatal functions of GDF11, however, remain less clear and controversial. Due to the perinatal lethality of Gdf11 null mice, previous studies used recombinant GDF11 protein to prove its postnatal function. However, recombinant GDF11 and MSTN proteins share nearly identical biochemical properties, and most GDF11 binding molecules have also been shown to bind MSTN, generating the possibility that the effects mediated by recombinant GDF11 protein actually reproduce the endogenous functions of MSTN. To clarify the endogenous functions of GDF11, here, we focus on genetic studies and show that Gdf11 null mice, despite significantly down regulating Mstn expression, exhibit reduced bone mass through impaired osteoblast (OB) and chondrocyte ( CH) maturations and increased osteoclastogenesis, while the opposite is observed in Mstn null mice that display enhanced bone mass. Mechanistically, Mstn deletion up regulates Gdf11 expression, which activates bone morphogenetic protein (BMP) signaling pathway to enhance osteogenesis. Also, mice overexpressing follistatin (FST), a MSTN/GDF11 inhibitor, exhibit increased muscle mass accompanied by bone fractures, unlike Mstn null mice that display increased muscle mass without fractures, indicating that inhibition of GDF11 impairs bone strength. Together, our findings suggest that GDF11 promotes osteogenesis in contrast to MSTN, and these opposing roles of GDF11 and MSTN must be considered to avoid the detrimental effect of GDF11 inhibition when developing MSTN/GDF11 inhibitors for therapeutic purposes.
C1 [Suh, Joonho; Kim, Na Kyung; Eom, Je Hyun; Woo, Kyung Mi; Baek, Jeong Hwa; Ryoo, Hyun Mo; Lee, Yun Sil] Seoul Natl Univ, Sch Dent, Dept Mol Genet, Seoul 08826, South Korea.
   [Suh, Joonho; Kim, Na Kyung; Eom, Je Hyun; Park, Joo Cheol; Woo, Kyung Mi; Baek, Jeong Hwa; Ryoo, Hyun Mo; Lee, Yun Sil] Seoul Natl Univ, Dent Res Inst, Seoul 08826, South Korea.
   [Lee, Seung Hoon; Kim, Jung Eun] Kyungpook Natl Univ, Cell & Matrix Res Inst, Sch Med, Dept Mol Med, Daegu 41566, South Korea.
   [Lee, Youngkyun] Kyungpook Natl Univ, Sch Dent, Dept Biochem, Daegu 41566, South Korea.
   [Park, Joo Cheol] Seoul Natl Univ, Sch Dent, Dept Oral Histol Dev Biol, Seoul 08826, South Korea.
   [Lee, Se Jin] Jackson Lab Genom Med, Farmington, CT 06032 USA.
   [Lee, Se Jin] Univ Connecticut, Sch Med, Dept Genet & Genome Sci, Farmington, CT 06030 USA.
C3 Seoul National University (SNU); Seoul National University (SNU);
   Kyungpook National University (KNU); Kyungpook National University
   (KNU); Seoul National University (SNU); Jackson Laboratory; University
   of Connecticut
RP Lee, YS (通讯作者)，Seoul Natl Univ, Sch Dent, Dept Mol Genet, Seoul 08826, South Korea.; Lee, YS (通讯作者)，Seoul Natl Univ, Dent Res Inst, Seoul 08826, South Korea.
EM yunlee@snu.ac.kr
RI ; Woo, Kyung/A 2793 2009; Park, Joo Cheol/AGU 5020 2022; Baek,
   Jeong Hwa/A 8628 2012; Ryoo, Hyun Mo/D 5839 2012; Woo, Kyung
   Mi/A 2793 2009
OI Kim, Na Kyung/0000 0001 7675 5141; Ryoo, Hyun Mo/0000 0001 6769 8341;
   Woo, Kyung Mi/0000 0002 2782 1189
FU CreativePioneering Researchers Program through Seoul National University
   (SNU); Basic Research Laboratory Program of the National Research
   Foundation (NRF)   Korean government [NRF 2017R1A4A1014584]
FX We thank Suzanne M. Sebald for assistance with shipping and handling
   mice; and Je Yong Choi, Hong Hee Kim, and MinSung Kim for helpful
   discussions. This work was supported by CreativePioneering Researchers
   Program through Seoul National University (SNU) and Basic Research
   Laboratory Program (Grant NRF 2017R1A4A1014584) of the National Research
   Foundation (NRF) funded by the Korean government (to Y. S.L.).
CR Acosta J, 2005, J BIOTECHNOL, V119, P324, DOI 10.1016/j.jbiotec.2005.04.023
   Al Zaidy Samiah A, 2015, J Neuromuscul Dis, V2, P185
   Alves RDAM, 2013, MOL CELL PROTEOMICS, V12, P2890, DOI 10.1074/mcp.M112.024927
   Andersson O, 2006, EMBO REP, V7, P831, DOI 10.1038/sj.embor.7400752
   Chantry AD, 2010, J BONE MINER RES, V25, P2357, DOI 10.1002/jbmr.142
   Clop A, 2006, NAT GENET, V38, P813, DOI 10.1038/ng1810
   Dankbar B, 2015, NAT MED, V21, P1085, DOI 10.1038/nm.3917
   Dussiot M, 2014, NAT MED, V20, P398, DOI 10.1038/nm.3468
   Egerman MA, 2015, CELL METAB, V22, P164, DOI 10.1016/j.cmet.2015.05.010
   Esquela AF, 2003, DEV BIOL, V257, P356, DOI 10.1016/S0012 1606(03)00100 3
   Gaddy Kurten D, 2002, ENDOCRINOLOGY, V143, P74, DOI 10.1210/en.143.1.74
   Gamer LW, 1999, DEV BIOL, V208, P222, DOI 10.1006/dbio.1998.9191
   Haidet AM, 2008, P NATL ACAD SCI USA, V105, P4318, DOI 10.1073/pnas.0709144105
   Hamrick MW, 2007, BONE, V40, P1544, DOI 10.1016/j.bone.2007.02.012
   Harmon EB, 2004, DEVELOPMENT, V131, P6163, DOI 10.1242/dev.01535
   Katsimpardi L, 2014, SCIENCE, V344, P630, DOI 10.1126/science.1251141
   Kota J, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000112
   Lach Trifilieff E, 2014, MOL CELL BIOL, V34, P606, DOI 10.1128/MCB.01307 13
   Lee SJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000789
   Lee SJ, 2005, P NATL ACAD SCI USA, V102, P18117, DOI 10.1073/pnas.0505996102
   Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098
   Lee YS, 2013, P NATL ACAD SCI USA, V110, pE3713, DOI 10.1073/pnas.1309907110
   Li WW, 2019, FASEB J, V33, P3317, DOI 10.1096/fj.201801375RR
   Liu WQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12794
   Loffredo FS, 2013, CELL, V153, P828, DOI 10.1016/j.cell.2013.04.015
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Lu Q, 2016, CALCIFIED TISSUE INT, V99, P500, DOI 10.1007/s00223 016 0173 z
   McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0
   McPherron AC, 1999, NAT GENET, V22, P260, DOI 10.1038/10320
   McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457
   McPherron AC, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471 213X 9 24
   Mendell JR, 2017, MOL THER, V25, P870, DOI 10.1016/j.ymthe.2017.02.015
   Mendell JR, 2015, MOL THER, V23, P192, DOI 10.1038/mt.2014.200
   Mosher DS, 2007, PLOS GENET, V3, P779, DOI 10.1371/journal.pgen.0030079
   Nakamichi Y, 2012, P NATL ACAD SCI USA, V109, P10006, DOI 10.1073/pnas.1207361109
   Nakashima M, 1999, MECH DEVELOP, V80, P185, DOI 10.1016/S0925 4773(98)00205 6
   Qin YW, 2017, J BIOL CHEM, V292, P11021, DOI 10.1074/jbc.M116.770941
   Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230 7242.2003
   Rodgers BD, 2015, ENDOCRINOLOGY, V156, P3885, DOI 10.1210/en.2015 1628
   Rodgers BD, 2014, ENDOCRINOLOGY, V155, P670, DOI 10.1210/en.2013 2107
   Rodino Klapac LR, 2013, HUM MOL GENET, V22, P4929, DOI 10.1093/hmg/ddt342
   Sakai R, 1999, BONE, V25, P191, DOI 10.1016/S8756 3282(99)00152 0
   Schneyer AL, 2008, ENDOCRINOLOGY, V149, P4589, DOI 10.1210/en.2008 0259
   Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933
   Sinha M, 2014, SCIENCE, V344, P649, DOI 10.1126/science.1251152
   Suh J, 2019, J CELL PHYSIOL, V234, P23360, DOI 10.1002/jcp.28904
   Suragani RNVS, 2014, NAT MED, V20, P408, DOI 10.1038/nm.3512
   Thompson TB, 2005, DEV CELL, V9, P535, DOI 10.1016/j.devcel.2005.09.008
   Walker RG, 2018, P NATL ACAD SCI USA, V115, pE866, DOI 10.1073/pnas.1714622115
   Walker RG, 2017, BMC BIOL, V15, DOI 10.1186/s12915 017 0350 1
   Wang WH, 2019, INFLAMMATION, V42, P319, DOI 10.1007/s10753 018 0895 3
   Wei K, 2016, J NEPHROL, V29, P349, DOI 10.1007/s40620 016 0284 7
   Wu HH, 2003, NEURON, V37, P197, DOI 10.1016/S0896 6273(02)01172 8
   Zhang Y, 2015, GENE, V557, P209, DOI 10.1016/j.gene.2014.12.039
   Zhang YH, 2016, ONCOTARGET, V7, P12063, DOI 10.18632/oncotarget.7642
NR 55
TC 48
Z9 56
U1 3
U2 22
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 3
PY 2020
VL 117
IS 9
BP 4910
EP 4920
DI 10.1073/pnas.1916034117
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA KS7FX
UT WOS:000518473500066
PM 32071240
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Duchesne, E
   Dufresne, SS
   Dumont, NA
AF Duchesne, Elise
   Dufresne, Sebastien S.
   Dumont, Nicolas A.
TI Impact of Inflammation and Anti inflammatory Modalities on Skeletal
   Muscle Healing: From Fundamental Research to the Clinic
SO PHYSICAL THERAPY
LA English
DT Article
ID SATELLITE CELLS; SYSTEMIC INFLAMMATION; COX 2 PATHWAY; DRUGS NSAIDS;
   ELDERLY MEN; MAST CELLS; REGENERATION; INJURY; PROLIFERATION;
   HYPERTROPHY
AB Anti inflammatory modalities are commonly used for the treatment of various musculoskeletal injuries. Although inflammation was originally believed to interfere with skeletal muscle regeneration, several recent studies have highlighted the beneficial effects of inflammatory cells on muscle healing. This discrepancy is attributable to an evolving understanding of the complex inflammatory process. To better appreciate the paradoxical roles of inflammation, clinicians must have a better comprehension of the fundamental mechanisms regulating the inflammatory response. In this perspective article, cellular, animal, and human studies were analyzed to summarize recent knowledge regarding the impact of inflammation on muscle regeneration in acute or chronic conditions. The effect of anti inflammatory drugs on the treatment of various muscle injuries was also considered. Overall, this work aims to summarize the current state of the literature on the inflammatory process associated with muscle healing in order to give clinicians the necessary tools to have a more efficient and evidence based approach to the treatment of muscle injuries and disorders.
C1 [Duchesne, Elise; Dufresne, Sebastien S.] Univ Quebec Chicoutimi, Dept Sci Sante, Saguenay, PQ, Canada.
   [Duchesne, Elise] Ctr Integre Univ Sante, Grp Rech Interdisciplinaire Malad Neuromusculaire, Saguenay, PQ, Canada.
   [Duchesne, Elise] Serv Sociaux Saguenay Lac St Jean, Saguenay, PQ, Canada.
   [Dufresne, Sebastien S.] CHU Quebec Res Ctr, Quebec City, PQ, Canada.
   [Dufresne, Sebastien S.] Univ Laval, Fac Med, Quebec City, PQ, Canada.
   [Dumont, Nicolas A.] Ste Justine Hosp Res Ctr, Musculoskeletal Dis & Rehabil Dept, Montreal, PQ, Canada.
   [Dumont, Nicolas A.] Univ Montreal, Fac Med, Dept Rehabil, Montreal, PQ, Canada.
C3 University of Quebec; University of Quebec Chicoutimi; Laval University;
   Universite de Montreal
RP Dumont, NA (通讯作者)，Ste Justine Hosp Res Ctr, Musculoskeletal Dis & Rehabil Dept, Montreal, PQ, Canada.; Dumont, NA (通讯作者)，Univ Montreal, Fac Med, Dept Rehabil, Montreal, PQ, Canada.
EM nicolas.dumont.1@umontreal.ca
RI ; Dufresne, Sebastien/AAL 7005 2021
OI Dufresne, Sebastien S./0000 0001 5924 7962; Duchesne,
   Elise/0000 0002 9953 8315
FU Pole of Excellence in musculoskeletal diseases and rehabilitation;
   Ste Justine Foundation; Fonds de recherche du Quebec   Sante (FRQS)
FX N.A. Dumont is supported by the Pole of Excellence in musculoskeletal
   diseases and rehabilitation from the Ste Justine Foundation and from the
   Fonds de recherche du Quebec   Sante (FRQS).
CR Abdel Salam E, 2009, Acta Myol, V28, P94
   Ambrosio F, 2010, PHYS THER, V90, P1807, DOI 10.2522/ptj.20100030
   Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075
   Batsis JA, 2016, CLIN NUTR, V35, P1472, DOI 10.1016/j.clnu.2016.03.028
   Bentzinger CF, 2013, EMBO REP, V14, P1062, DOI 10.1038/embor.2013.182
   Berenbaum F, 2013, OSTEOARTHR CARTILAGE, V21, P16, DOI 10.1016/j.joca.2012.11.012
   Bonaldo P, 2013, DIS MODEL MECH, V6, P25, DOI 10.1242/dmm.010389
   Bondesen BA, 2006, AM J PHYSIOL CELL PH, V290, pC1651, DOI 10.1152/ajpcell.00518.2005
   Bondesen BA, 2004, AM J PHYSIOL CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004
   Braund R, 2011, PHYSIOTHER RES INT, V16, P43, DOI 10.1002/pri.472
   Buono R, 2012, STEM CELLS, V30, P197, DOI 10.1002/stem.783
   CARLSON BM, 1989, AM J PHYSIOL, V256, pC1262
   Chazaud B, 2016, IMMUNOL CELL BIOL, V94, P140, DOI 10.1038/icb.2015.97
   Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873
   Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260
   Crystal NJ, 2013, EUR J APPL PHYSIOL, V113, P2577, DOI 10.1007/s00421 013 2693 9
   Dadgar S, 2014, J CELL BIOL, V207, P139, DOI 10.1083/jcb.201402079
   Department of Health, ALL HLTH PROF PRESCR
   Dessem D, 2011, PAIN RES TREAT, V2011, DOI 10.1155/2011/647967
   Dideriksen K, 2016, EXP GERONTOL, V83, P120, DOI 10.1016/j.exger.2016.07.016
   Dideriksen K, 2016, EXP GERONTOL, V82, P8, DOI 10.1016/j.exger.2016.05.009
   Duchesne E, 2013, MUSCLE NERVE, V48, P403, DOI 10.1002/mus.23758
   Duchesne E, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 235
   Dufresne SS, 2016, M S MED SCI, V32, P591, DOI 10.1051/medsci/20163206022
   Dumont N, 2007, J APPL PHYSIOL, V103, P97, DOI 10.1152/japplphysiol.01132.2006
   Dumont N, 2008, AM J PHYSIOL REG I, V295, pR1831, DOI 10.1152/ajpregu.90318.2008
   Dumont NA, 2015, COMPR PHYSIOL, V5, P1027, DOI 10.1002/cphy.c140068
   Ershler WB, 2000, ANNU REV MED, V51, P245, DOI 10.1146/annurev.med.51.1.245
   Franceschi C, 2014, J GERONTOL A BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Frontera WR, 2015, CALCIFIED TISSUE INT, V96, P183, DOI 10.1007/s00223 014 9915 y
   Fry CS, 2014, FASEB J, V28, P1654, DOI 10.1096/fj.13 239426
   Gao HGL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071875
   Gaudenzio N, 2016, J CLIN INVEST, V126, P3981, DOI 10.1172/JCI85538
   Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550
   Green M, 2016, PHYSIOTHER CAN, V68, P230, DOI 10.3138/ptc.2015 25
   Grimmer K, 2002, AUST J PHYSIOTHER, V48, P82, DOI 10.1016/S0004 9514(14)60202 6
   Guo S, 2010, J DENT RES, V89, P219, DOI 10.1177/0022034509359125
   Haddad F, 2005, J APPL PHYSIOL, V98, P911, DOI 10.1152/japplphysiol.01026.2004
   Hall Chris, 2009, V546, P255, DOI 10.1007/978 1 60327 977 2_16
   Heiderscheit BC, 2010, J ORTHOP SPORT PHYS, V40, P67, DOI 10.2519/jospt.2010.3047
   Kasuga K, 2008, J IMMUNOL, V181, P8677, DOI 10.4049/jimmunol.181.12.8677
   Kim OY, 2012, AGE, V34, P415, DOI 10.1007/s11357 011 9244 2
   Kumar Saravana, 2005, Ther Clin Risk Manag, V1, P69, DOI 10.2147/tcrm.1.1.69.53596
   Langen RCJ, 2004, FASEB J, V18, P227, DOI 10.1096/fj.03 0251com
   Lemos DR, 2015, NAT MED, V21, P786, DOI 10.1038/nm.3869
   Lepper C, 2011, DEVELOPMENT, V138, P3639, DOI 10.1242/dev.067595
   Londhe P, 2015, BONE, V80, P131, DOI 10.1016/j.bone.2015.03.015
   Mackey AL, 2007, J APPL PHYSIOL, V103, P425, DOI 10.1152/japplphysiol.00157.2007
   Mann CJ, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044 5040 1 21
   Manzur AY, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003725.pub3
   Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460
   McCarthy JJ, 2011, DEVELOPMENT, V138, P3657, DOI 10.1242/dev.068858
   Michalaki V, 2004, BRIT J CANCER, V90, P2312, DOI 10.1038/sj.bjc.6601814
   Mikkelsen UR, 2009, J APPL PHYSIOL, V107, P1600, DOI 10.1152/japplphysiol.00707.2009
   Nguyen TVV, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478 016 0371 y
   Norland R, 2016, PHYS THER, V96, P550, DOI 10.2522/ptj.20150057
   Novak ML, 2009, AM J PHYSIOL REG I, V296, pR1132, DOI 10.1152/ajpregu.90874.2008
   Oishi Y, 2016, NPJ AGING MECH DIS, V2, DOI 10.1038/npjamd.2016.18
   Passamano Luigia, 2012, Acta Myol, V31, P121
   Petersen SG, 2011, MED SCI SPORT EXER, V43, P425, DOI 10.1249/MSS.0b013e3181f27375
   Peterson JM, 2003, MED SCI SPORT EXER, V35, P892, DOI 10.1249/01.MSS.0000069917.51742.98
   Powers SK, 2016, MED SCI SPORT EXER, V48, P2307, DOI 10.1249/MSS.0000000000000975
   Qin J, 2013, RES VET SCI, V94, P84, DOI 10.1016/j.rvsc.2012.07.018
   Relaix F, 2012, DEVELOPMENT, V139, P2845, DOI 10.1242/dev.069088
   Remels AH, 2007, CLIN CHEST MED, V28, P537, DOI 10.1016/j.ccm.2007.06.003
   REYNOLDS JF, 1995, S AFR MED J, V85, P517
   Sali A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034204
   Sambasivan R, 2011, DEVELOPMENT, V138, P3647, DOI 10.1242/dev.067587
   Scott HA, 2016, INTEGR BIOL UK, V8, P869, DOI 10.1039/c6ib00084c
   Serhan CN, 2008, PROSTAG LEUKOTR ESS, V79, P157, DOI 10.1016/j.plefa.2008.09.012
   Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276
   Sin DD, 2008, THORAX, V63, P95, DOI 10.1136/thx.2007.088575
   Smith C, 2008, SPORTS MED, V38, P947, DOI 10.2165/00007256 200838110 00005
   Soltow QA, 2006, MED SCI SPORT EXER, V38, P840, DOI 10.1249/01.mss.0000218142.98704.66
   St Pierre SJG, 2004, FASEB J, V18, P1937, DOI 10.1096/fj.04 1859fje
   Summan M, 2006, AM J PHYSIOL REG I, V290, pR1488, DOI 10.1152/ajpregu.00465.2005
   te Pas MFW, 2000, MOL BIOL REP, V27, P87, DOI 10.1023/A:1007120921064
   Teixeira CFP, 2003, MUSCLE NERVE, V28, P449, DOI 10.1002/mus.10453
   Tidball JG, 2005, AM J PHYSIOL REG I, V288, pR345, DOI 10.1152/ajpregu.00454.2004
   Tierney MT, 2014, NAT MED, V20, P1182, DOI 10.1038/nm.3656
   Toumi H, 2006, J ANAT, V208, P459, DOI 10.1111/j.1469 7580.2006.00543.x
   Vella L, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00086
   Wåhlin Larsson B, 2014, AGE, V36, DOI 10.1007/s11357 014 9718 0
   Zhang LP, 2011, FASEB J, V25, P1653, DOI 10.1096/fj.10 176917
   Zhou J, 2016, TRENDS ENDOCRIN MET, V27, P335, DOI 10.1016/j.tem.2016.03.002
   Zweifach BW, 2014, INFLAMMATORY PROCESS, VI
NR 86
TC 53
Z9 61
U1 0
U2 22
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0031 9023
EI 1538 6724
J9 PHYS THER
JI Phys. Ther.
PD AUG
PY 2017
VL 97
IS 8
BP 807
EP 817
DI 10.1093/ptj/pzx056
PG 11
WC Orthopedics; Rehabilitation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rehabilitation
GA FC8FP
UT WOS:000407077500005
PM 28789470
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Chen, C
   Zheng, LL
   Zeng, G
   Chen, YB
   Liu, WZ
   Song, WD
AF Chen, Chen
   Zheng, Linli
   Zeng, Gang
   Chen, Yanbo
   Liu, Wenzhou
   Song, Weidong
TI Identification of potential diagnostic biomarkers for tenosynovial giant
   cell tumour by integrating microarray and single cell RNA sequencing
   data
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Tenosynovial giant cell tumour; Osteoclast; Bioinformatics analysis;
   Gene Expression Omnibus
ID PIGMENTED VILLONODULAR SYNOVITIS; OSTEOCLAST DIFFERENTIATION; EXPRESS
AB PurposeTenosynovial giant cell tumour (TGCT) is a benign hyperplastic and inflammatory disease of the joint synovium or tendon sheaths, which may be misdiagnosed due to its atypical symptoms and imaging features. We aimed to identify biomarkers with high sensitivity and specificity to aid in diagnosing TGCT.MethodsTwo scRNA seq datasets (GSE210750 and GSE152805) and two microarray datasets (GSE3698 and GSE175626) were downloaded from the Gene Expression Omnibus (GEO) database. By integrating the scRNA seq datasets, we discovered that the osteoclasts are abundant in TGCT in contrast to the control. The single sample gene set enrichment analysis (ssGSEA) further validated this discovery. Differentially expressed genes (DEGs) of the GSE3698 dataset were screened and the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of DEGs were conducted. Osteoclast specific up regulated genes (OCSURGs) were identified by intersecting the osteoclast marker genes in the scRNA seq and the up regulated DEGs in the microarray and by the least absolute shrinkage and selection operator (LASSO) regression algorithm. The expression levels of OCSURGs were validated by an external dataset GSE175626. Then, single gene GSEA, protein protein interaction (PPI) network, and gene drug network of OCSURGs were performed.Result22 seurat clusters were acquired and annotated into 10 cell types based on the scRNA seq data. TGCT had a larger population of osteoclasts compared to the control. A total of 159 osteoclast marker genes and 104 DEGs (including 61 up regulated genes and 43 down regulated genes) were screened from the scRNA seq analysis and the microarray analysis. Three OCSURGs (MMP9, SPP1, and TYROBP) were finally identified. The AUC of the ROC curve in the training and testing datasets suggested a favourable diagnostic capability. The PPI network results illustrated the protein protein interaction of each OCSURG. Drugs that potentially target the OCSURGs were predicted by the DGIdb database.ConclusionMMP9, SPP1, and TYROBP were identified as osteoclast specific up regulated genes of the tenosynovial giant cell tumour via bioinformatic analysis, which had a reasonable diagnostic efficiency and served as potential drug targets.
C1 [Chen, Chen; Zeng, Gang; Chen, Yanbo; Liu, Wenzhou; Song, Weidong] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped, Yingfeng Rd 33rd, Guangzhou 510000, Guangdong, Peoples R China.
   [Zheng, Linli] Sun Yat Sen Univ, Affiliated Hosp 1, Joint Surg, 58 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University
RP Liu, WZ; Song, WD (通讯作者)，Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped, Yingfeng Rd 33rd, Guangzhou 510000, Guangdong, Peoples R China.
EM liuwzh23@mail.sysu.edu.cn; songwd@mail.sysu.edu.cn
RI Song, Weidong/LWI 3629 2024
FU National Natural Science Foundation of China
FX We appreciate the reviewers' effort and time in reviewing the
   manuscript.
CR Bruno F, 2019, RADIOL MED, V124, P243, DOI 10.1007/s11547 019 01035 7
   Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019
   Chou CH, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 67730 y
   Coxon FP, 2008, SEMIN CELL DEV BIOL, V19, P424, DOI 10.1016/j.semcdb.2008.08.004
   Dai BY, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 021 27683 w
   Darling JM, 1997, AM J PATHOL, V150, P1383
   De Fusco C, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/4045238
   de St Aubain Somerhausen N., 2020, WHO CLASSIFICATION T, P133
   Depalle B, 2021, ACTA BIOMATER, V120, P194, DOI 10.1016/j.actbio.2020.04.040
   Fields GB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01278
   Finis K, 2006, ARTHRITIS RHEUM US, V54, P1009, DOI 10.1002/art.21641
   Gounder MM, 2018, J CLIN ONCOL, V36, P202, DOI 10.1200/JCO.2017.75.8482
   Hänzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 7
   Hao YH, 2021, CELL, V184, P3573, DOI 10.1016/j.cell.2021.04.048
   Haure Mirande JV, 2022, MOL NEURODEGENER, V17, DOI 10.1186/s13024 022 00552 w
   HUGHES TH, 1995, SKELETAL RADIOL, V24, P7, DOI 10.1007/BF02425937
   Humphrey MB, 2006, J BONE MINER RES, V21, P237, DOI 10.1359/JBMR.051016
   Humphrey MB, 2004, J BONE MINER RES, V19, P224, DOI 10.1359/JBMR.0301234
   KAJI H, 1994, ENDOCRINOLOGY, V135, P484, DOI 10.1210/en.135.1.484
   Kim JH, 2023, ACAD RADIOL, V30, P2616, DOI 10.1016/j.acra.2023.01.012
   Kluger MA, 2013, KIDNEY INT, V83, P865, DOI 10.1038/ki.2012.483
   Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592 019 0619 0
   Lacombe J, 2013, CELL CYCLE, V12, P2744, DOI 10.4161/cc.25825
   Lantos JE, 2013, SKELETAL RADIOL, V42, P589, DOI 10.1007/s00256 012 1533 z
   McGinnis CS, 2019, CELL SYST, V8, P329, DOI 10.1016/j.cels.2019.03.003
   Murthy S, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04507 3
   Neale SD, 1997, J CLIN PATHOL, V50, P605, DOI 10.1136/jcp.50.7.605
   Nguyen M, 2001, INT J BIOCHEM CELL B, V33, P960, DOI 10.1016/S1357 2725(01)00007 3
   O'Keefe R J, 1998, Iowa Orthop J, V18, P26
   Paloneva J, 2003, J EXP MED, V198, P669, DOI 10.1084/jem.20030027
   Plotkin B, 2016, RADIOGRAPHICS, V36, P1688, DOI 10.1148/rg.2016160014
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robert M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.820046
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 77
   Rubin BP, 2007, SKELETAL RADIOL, V36, P267, DOI 10.1007/s00256 006 0249 3
   Sandborn WJ, 2016, ALIMENT PHARM THER, V44, P157, DOI 10.1111/apt.13653
   Schreiber S, 2018, J CROHNS COLITIS, V12, P1014, DOI 10.1093/ecco jcc/jjy070
   Stacchiotti S, 2023, CANCER TREAT REV, V112, DOI 10.1016/j.ctrv.2022.102491
   Stenbeck G, 2002, SEMIN CELL DEV BIOL, V13, P285, DOI 10.1016/S1084952102000587
   Takeuchi A, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1050 7
   Tosun B, 2022, J BONE MINER RES, V37, P1761, DOI 10.1002/jbmr.4629
   van IJzendoorn DGP, 2022, CLIN CANCER RES, V28, P4934, DOI 10.1158/1078 0432.CCR 22 1898
   Verslegers M, 2013, PROG NEUROBIOL, V105, P60, DOI 10.1016/j.pneurobio.2013.03.004
   Verspoor FGM, 2013, FUTURE ONCOL, V9, P1515, DOI 10.2217/fon.13.124
   Wan JMC, 2010, RADIOL MED, V115, P141, DOI 10.1007/s11547 010 0515 2
   Wang QH, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.846421
   Wu TZ, 2021, INNOVATION AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100141
   Xu YT, 2021, PHARMACOL RES, V165, DOI 10.1016/j.phrs.2021.105458
   Yasmin, 2005, ARTERIOSCL THROM VAS, V25, P372, DOI 10.1161/01.ATV.0000151373.33830.41
   Yoshida W, 2003, HUM PATHOL, V34, P65, DOI 10.1053/hupa.2003.52
   Zhang DN, 2022, J OVARIAN RES, V15, DOI 10.1186/s13048 022 01059 0
   Zhao HL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0391 6
   Zhao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.665442
   Zhao ZM, 2017, ACTA CYTOL, V61, P160, DOI 10.1159/000457828
NR 54
TC 0
Z9 0
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD NOV 29
PY 2023
VL 18
IS 1
AR 905
DI 10.1186/s13018 023 04279 2
PG 13
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA Z1SK5
UT WOS:001109947900001
PM 38017559
OA gold
DA 2025 08 17
ER

PT J
AU Bischoff, I
   Tsaryk, R
   Chai, F
   Fürst, R
   Kirkpatrick, CJ
   Unger, RE
AF Bischoff, Iris
   Tsaryk, Roman
   Chai, Feng
   Fuerst, Robert
   Kirkpatrick, Charles James
   Unger, Ronald E.
TI In vitro evaluation of a biomaterial based anticancer drug
   delivery system as an alternative to conventional post surgery bone
   cancer treatment
SO MATERIALS SCIENCE AND ENGINEERING C MATERIALS FOR BIOLOGICAL
   APPLICATIONS
LA English
DT Article
DE Doxorubicin; Cancer cells; Healthy cells; Polycyclodextrin
   hydroxyapatite; Drug delivery; Hypoxia
ID CHEMOTHERAPEUTIC AGENTS; ENDOTHELIAL CELLS; CYCLODEXTRIN; RELEASE;
   OSTEOSARCOMA; HYPOXIA; MECHANISMS; EXPERIENCE; APOPTOSIS; CYCLE
AB Patients diagnosed with osteosarcoma are currently treated with intravenous injections of anticancer agents after tumor resection. However, due to remaining neoplastic cells at the site of tumor removal, cancer recurrence often occurs. Successful bone regeneration combined with the control of residual cancer cells presents a challenge for tissue engineering. Cyclodextrins loaded with chemotherapeutic drugs reversibly release the drugs over time. Hydroxyapatite bone biomaterials coated with doxorubicin loaded cyclodextrin should release the drug with time after implantation directly at the original tumor site and may be a way to eliminate residual neoplastic cells. In the present study, we have carried out in vitro studies to evaluate such a drug delivery system and have shown that doxorubicin released from cyclodextrin coated hydroxyapatite retained biological activity and exhibited longer and higher cytotoxic effects on both cancer (osteosarcoma cells) and healthy cells (primary osteoblasts and endothelial cells) compared to biomaterials without cyclodextrin loaded with doxorubicin. Furthermore, doxorubicin released from biomaterials with cyclodextrin moderately induced the expression of tumor suppressor protein p53 whereas p21 expression was similar to control cells. In addition, hypoxic conditions, which occur after implantation until blood flow to the area is regenerated, protected endothelial cells and primary osteoblasts from doxorubicin induced cytotoxicity. This chemo protective effect was far less prominent for the osteosarcoma cells. These findings indicate that a hydroxyapatite cyclodextrin doxorubicin chemotherapeutic strategy may enhance the drug targeting effect on tumor cells while protecting the more sensitive healthy cells for a period of time after implantation. A successful integration of such a drug delivery system might allow healthy cells to initially survive during the doxorubicin exposure period, while eliminating residual neoplastic cells.
C1 [Bischoff, Iris; Tsaryk, Roman; Kirkpatrick, Charles James; Unger, Ronald E.] Johannes Gutenberg Univ Mainz, Inst Pathol, Mainz, Germany.
   [Chai, Feng] Univ Lille, Fac Med, Lille, France.
   [Fuerst, Robert] Goethe Univ, Inst Pharmaceut Biol, Frankfurt, Germany.
C3 Johannes Gutenberg University of Mainz; Universite de Lille; Goethe
   University Frankfurt
RP Bischoff, I (通讯作者)，Johannes Gutenberg Univ Mainz, Inst Pathol, Mainz, Germany.
EM i.bischoff@em.uni frankfurt.de
RI Fürst, Robert/HLX 5006 2023
OI Kirkpatrick, Charles James/0000 0002 0088 418X; Furst,
   Robert/0000 0002 9926 7578
FU Federal Ministry of Education and Research (ERA Net EuroTransBio 4:
   AnCaBoR) [BMBF 0315771B]
FX This work was supported by a grant of the Federal Ministry of Education
   and Research (ERA Net EuroTransBio 4: AnCaBoR, Funding number: BMBF
   0315771B).
CR Arsenault D, 2012, J CELL PHYSIOL, V227, P789, DOI 10.1002/jcp.22792
   Bernhardt A, 2011, CLIN ORAL IMPLAN RES, V22, P651, DOI 10.1111/j.1600 0501.2010.02015.x
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Boyle Robert George, 2006, Anti Cancer Agents in Medicinal Chemistry, V6, P281
   Cazzalini O, 2010, MUTAT RES REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009
   Chai F, 2014, J BIOMED MATER RES B, V102, P1130, DOI 10.1002/jbm.b.33094
   Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438
   Davies JH, 2003, J CLIN ENDOCR METAB, V88, P6088, DOI 10.1210/jc.2003 030712
   Davies JH, 2002, CALCIFIED TISSUE INT, V70, P408, DOI 10.1007/s002230020039
   de Oliveira RL, 2012, CANCER CELL, V22, P263, DOI 10.1016/j.ccr.2012.06.028
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   DORFMAN HD, 1995, CANCER, V75, P203, DOI 10.1002/1097 0142(19950101)75:1+<203::AID CNCR2820751308>3.0.CO;2 V
   Duchêne D, 1999, J CONTROL RELEASE, V62, P263, DOI 10.1016/S0168 3659(99)00046 2
   DUCHEYNE P, 1981, J BIOMED MATER RES, V15, P441, DOI 10.1002/jbm.820150315
   Ehrhart N, 1999, AM J VET RES, V60, P1347
   Fratino L, 2013, ANTI CANCER AGENT ME, V13, P1419, DOI 10.2174/18715206113136660357
   Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008 5472.CAN 04 3995
   HAIDLE CW, 1986, CANCER BIOCHEM BIOPH, V8, P327
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   Hines DJ, 2013, CRIT REV THER DRUG, V30, P257, DOI 10.1615/CritRevTherDrugCarrierSyst.2013006475
   HIRAYAMA F, 1993, YAKUGAKU ZASSHI, V113, P425, DOI 10.1248/yakushi1947.113.6_425
   Hofmann A, 2003, J BIOMED MATER RES A, V67A, P191, DOI 10.1002/jbm.a.10594
   Hu B, 2014, DRUG DELIV, V21, P204, DOI 10.3109/10717544.2013.843609
   Iyer L, 1998, EUR J CANCER, V34, P1493, DOI 10.1016/S0959 8049(98)00230 5
   JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470
   Lee DD, 1999, CLIN ORTHOP RELAT R, pS396, DOI 10.1097/00003086 199910001 00038
   LEE JSY, 1995, CANCER, V76, P2253, DOI 10.1002/1097 0142(19951201)76:11<2253::AID CNCR2820761112>3.0.CO;2 8
   Leprêtre S, 2009, BIOMATERIALS, V30, P6086, DOI 10.1016/j.biomaterials.2009.07.045
   Longhi A, 2012, CANCER AM CANCER SOC, V118, P5050, DOI 10.1002/cncr.27493
   MOORE AS, 1991, J VET INTERN MED, V5, P227, DOI 10.1111/j.1939 1676.1991.tb00953.x
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022 1759(91)90198 O
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Prives C, 1999, J PATHOL, V187, P112
   Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395
   RUBANYI GM, 1994, PHARMACOL REV, V46, P325
   Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955 0674(00)00216 7
   Stella VJ, 1999, ADV DRUG DELIVER REV, V36, P3, DOI 10.1016/S0169 409X(98)00052 0
   Suzuki E, 2000, J BIOL CHEM, V275, P3637, DOI 10.1074/jbc.275.5.3637
   Swift LP, 2006, CANCER RES, V66, P4863, DOI 10.1158/0008 5472.CAN 05 3410
   Thabet MH, 2000, OTOLARYNG HEAD NECK, V123, P482, DOI 10.1067/mhn.2000.105062
   Wittig JC, 2002, AM FAM PHYSICIAN, V65, P1123
   Wouessidjewe D, 1996, STP PHARMA SCI, V6, P21
   Zhang Z, 2013, POLYM CHEM UK, V4, P3265, DOI 10.1039/c3py00141e
   Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192
NR 44
TC 13
Z9 13
U1 0
U2 69
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD DEC 1
PY 2018
VL 93
BP 115
EP 124
DI 10.1016/j.msec.2018.07.057
PG 10
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA GX2SC
UT WOS:000447569400013
PM 30274043
DA 2025 08 17
ER

PT J
AU Pant, A
   Singh, G
   Barnwal, RP
   Sharma, T
   Singh, B
AF Pant, Anjali
   Singh, Gurpal
   Barnwal, Ravi Pratap
   Sharma, Teenu
   Singh, Bhupinder
TI QbD driven development and characterization of superparamagnetic iron
   oxide nanoparticles (SPIONS) of a bone targeting peptide for early
   detection of osteoporosis
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Bone disorders; Nanocarriers; Drug targeting; D aspartic acid
   octapeptide; Surface functionalization
ID MAGNETIC NANOPARTICLES; IN VITRO; FORMULATION DEVELOPMENT; SYSTEMATIC
   DEVELOPMENT; DESIGN; RESONANCE; DELIVERY; CONJUGATION; RELEASE; QUALITY
AB Osteoporosis is a metabolic disorder that leads to deterioration of bones. The major challenges confronting osteoporosis therapy include early stage detection and regular disease monitoring. The present studies employed D aspartic acid octapeptide ( D Asp )8 as bone targeting peptide for evaluating osteoporosis manifestation, and superparamagnetic iron oxide nanoparticles (SPIONs) as nanocarriers for MRI aided diagnosis. Thermal decomposition technique was employed to synthesize SPIONs, followed by surface functionalization with hydrophilic ligands. Failure mode effect analysis and factor screening studies were performed to identify concentrations of SPIONs and ligand as critical material attributes, and systematic optimization was subsequently conducted employing face centered cubic design. The optimum formulation was delineated using desirability function, and design space demarcated with 178.70 nm as hydrodynamic particle size,  24.40 mV as zeta potential, and 99.89 % as hydrophilic iron content as critical quality attributes. XRD patterns ratified lattice structure and SQUID studies corroborated superparamagnetic properties of hydrophilic SPIONs. Bioconjugation of ( D Asp )8 with SPIONs (1:1) was confirmed using UV spectroscopy, FTIR and NMR studies. Cell line studies indicated successful targeting of SPIONs to MG 63 human osteoblasts, ratifying enormous bone targeting and safety potential of peptide tethered SPIONs as MRI probes. In vivo MRI imaging studies in rats showcased promising contrast ability and safety of peptide conjugated SPIONs.
C1 [Pant, Anjali; Singh, Gurpal; Singh, Bhupinder] Panjab Univ, Univ Inst Pharmaceut Sci, Chandigarh 160014, India.
   [Barnwal, Ravi Pratap] Panjab Univ, Dept Biophys, Chandigarh 160014, India.
   [Sharma, Teenu; Singh, Bhupinder] Chitkara Univ, Chitkara Coll Pharm, Rajpura 140401, Punjab, India.
C3 Panjab University; Panjab University; Chitkara University, Punjab
RP Singh, G; Singh, B (通讯作者)，Panjab Univ, Univ Inst Pharmaceut Sci, Chandigarh 160014, India.; Barnwal, RP (通讯作者)，Panjab Univ, Dept Biophys, Chandigarh 160014, India.; Singh, B (通讯作者)，Chitkara Univ, Chitkara Coll Pharm, Rajpura 140401, Punjab, India.
EM gurpalsingh.ips@gmail.com; barnwal@pu.ac.in; bsbhoop@yahoo.com
RI Sharma, Dr Teenu/JHT 3919 2023
FU Department of Science & Technology, New Delhi, India [IF170942]
FX Funding Department of Science & Technology, New Delhi, India, for the
   requisite funding to the first author (A.P.) to perform the present work
   as a DST INSPIRE Research Fellow (IF170942) , availing the facilities of
   the University Institute of Pharmaceutical Sciences for the present
   research work.
CR Aghanejad A, 2022, INT J BIOL MACROMOL, V207, P592, DOI 10.1016/j.ijbiomac.2022.03.057
   Anastasilakis AD, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010152
   Atrei A, 2021, APPL SCI BASEL, V11, DOI 10.3390/app11156974
   Beg S, 2016, POWDER TECHNOL, V294, P93, DOI 10.1016/j.powtec.2016.02.023
   Bendersky LA, 2001, J RES NATL INST STAN, V106, P997, DOI 10.6028/jres.106.051
   Binkley N, 2014, CURR OSTEOPOROS REP, V12, P403, DOI 10.1007/s11914 014 0242 z
   Chen YL, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.909408
   CPCSEA, 2018, Compendium of CPCSEA, P1
   de Oliveira MA, 2022, MED ENG PHYS, V108, DOI 10.1016/j.medengphy.2022.103887
   Esmaili M, 2021, J BIOMOL STRUCT DYN, V39, P977, DOI 10.1080/07391102.2020.1722751
   Fahmy R, 2012, AAPS PHARMSCITECH, V13, P1243, DOI 10.1208/s12249 012 9844 x
   Fan Y, 2023, MATER DESIGN, V229, DOI 10.1016/j.matdes.2023.111862
   Fang C, 2009, J MATER CHEM, V19, P6258, DOI 10.1039/b902182e
   Fu YC, 2014, ACTA BIOMATER, V10, P4583, DOI 10.1016/j.actbio.2014.07.015
   Galli M, 2017, RSC ADV, V7, P15500, DOI 10.1039/C7RA00519A
   Garg B, 2016, COLLOID SURFACE B, V141, P611, DOI 10.1016/j.colsurfb.2016.02.012
   Garg NK, 2017, INT J PHARMACEUT, V517, P413, DOI 10.1016/j.ijpharm.2016.12.010
   Gürer F, 2021, CARBOHYD POLYM, V267, DOI 10.1016/j.carbpol.2021.118226
   Harman CLG, 2022, MATER ADV, V3, P6007, DOI 10.1039/d2ma00369d
   Hauser AK, 2016, NANOMEDICINE UK, V11, P1769, DOI 10.2217/nnm 2016 0050
   Hu SY, 2018, J TISSUE ENG REGEN M, V12, pE2085, DOI 10.1002/term.2641
   Jain A, 2022, DRUG DELIV TRANSL RE, V12, P1136, DOI 10.1007/s13346 021 00990 x
   Jain A, 2019, J LIQ CHROMATOGR R T, V42, P502, DOI 10.1080/10826076.2019.1626742
   Jana NR, 2004, CHEM MATER, V16, P3931, DOI 10.1021/cm049221k
   Jarockyte G, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081193
   Jiang T, 2014, INT J PHARMACEUT, V475, P547, DOI 10.1016/j.ijpharm.2014.08.067
   Justin C, 2017, APPL NANOSCI, V7, P463, DOI 10.1007/s13204 017 0583 x
   Kadri A, 2022, OSTEOPOROSIS INT, V33, P861, DOI 10.1007/s00198 021 06129 5
   Kanis J.A., 2007, ASSESSMENT OSTEOPORO
   Kesharwani P, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13020250
   Khajuria DK, 2012, REV BRAS REUMATOL, V52, P462
   Khalil IR, 2016, MATERIALS, V9, DOI 10.3390/ma9010028
   Kim TK, 2015, KOREAN J ANESTHESIOL, V68, P540, DOI 10.4097/kjae.2015.68.6.540
   Kumar M, 2012, INT J NANOMED, V7, P3503, DOI 10.2147/IJN.S32694
   Lam T, 2016, NANOMATERIALS BASEL, V6, DOI 10.3390/nano6060100
   Lattuada M, 2007, LANGMUIR, V23, P2158, DOI 10.1021/la062092x
   Lee MS, 2016, INT J NANOMED, V11, P4583, DOI 10.2147/IJN.S112415
   Lewiecki EM, 2019, J DRUG ASSESS, V8, P25, DOI 10.1080/21556660.2019.1579728
   Liu JS, 2017, INT J NANOMED, V12, P3561, DOI 10.2147/IJN.S133787
   Lo Muzio L, 2013, EUR J INFLAMM, V11, P797
   Marshall SK, 2022, NANOMATERIALS BASEL, V12, DOI 10.3390/nano12193517
   Ogawa K, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14149 7
   Olszta MJ, 2007, MAT SCI ENG R, V58, P77, DOI 10.1016/j.mser.2007.05.001
   Onak G, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 36109 5
   Pandit C, 2022, SCI TOTAL ENVIRON, V831, DOI 10.1016/j.scitotenv.2022.154857
   Pant A, 2023, BIOMED CHROMATOGR, V37, DOI 10.1002/bmc.5641
   Pant A, 2023, CRIT REV THER DRUG, V40, P95, DOI 10.1615/CritRevTherDrugCarrierSyst.2022043413
   Pant A, 2022, J WATER HEALTH, V20, P1673, DOI 10.2166/wh.2022.293
   Piazza RD, 2020, MATER RES EXPRESS, V7, DOI 10.1088/2053 1591/ab6700
   Poonia N, 2019, COLLOID SURFACE B, V181, P756, DOI 10.1016/j.colsurfb.2019.06.004
   Pucci C, 2022, BIOMATER SCI UK, V10, P2103, DOI 10.1039/d1bm01963e
   Puiu RA, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13091356
   Saad MM., 2019, Egypt J Radiol Nuclear Med, V50, P1, DOI [10.1186/s43055 019 0046 3, DOI 10.1186/S43055 019 0046 3]
   Safari B, 2022, COLLOID SURFACE B, V211, DOI 10.1016/j.colsurfb.2021.112284
   Saha I, 2022, J DRUG DELIV SCI TEC, V71, DOI 10.1016/j.jddst.2022.103272
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Saville SL, 2013, NANOSCALE, V5, P2152, DOI 10.1039/c3nr32979h
   Saxena N, 2017, J MAGN MAGN MATER, V429, P166, DOI 10.1016/j.jmmm.2017.01.031
   Schuetze B, 2016, J MATER CHEM B, V4, P2179, DOI 10.1039/c5tb02443a
   Shah B, 2016, J DRUG DELIV SCI TEC, V33, P37, DOI 10.1016/j.jddst.2016.03.008
   Shah ST, 2017, NANOMATERIALS BASEL, V7, DOI 10.3390/nano7100306
   Shan L., 2009, Molecular Imaging and Contrast Agent Database (MICAD), P2004
   Sharma T, 2021, COLLOID SURFACE B, V197, DOI 10.1016/j.colsurfb.2020.111429
   Siminzar P, 2023, MOL IMAGING BIOL, V25, P464, DOI 10.1007/s11307 022 01795 1
   Singh B, 2020, CRIT REV THER DRUG, V37, P229, DOI 10.1615/CritRevTherDrugCarrierSyst.2020032040
   Singh B, 2017, NANOTECHNOLOGY BASED APPROACHES FOR TARGETING AND DELIVERY OF DRUGS AND GENES, P110, DOI 10.1016/B978 0 12 809717 5.00003 8
   Singh B, 2009, ACTA PHARMACEUT, V59, P1, DOI 10.2478/v10007 009 0005 z
   Sollmann N, 2021, J MAGN RESON IMAGING, V54, P12, DOI 10.1002/jmri.27260
   Sophocleous Antonia, 2014, Bonekey Rep, V3, P614, DOI 10.1038/bonekey.2014.109
   Thakor AS, 2016, J NUCL MED, V57, P1833, DOI 10.2967/jnumed.116.181362
   Torras M, 2020, MICROCHIM ACTA, V187, DOI 10.1007/s00604 020 04454 w
   Wu SY, 2018, AM J TRANSL RES, V10, P1431
   Wyss PP, 2016, ACS OMEGA, V1, P182, DOI 10.1021/acsomega.6b00088
   Xiao PL, 2022, OSTEOPOROSIS INT, V33, P2137, DOI 10.1007/s00198 022 06454 3
   Xu W, 2012, RSC ADV, V2, P10907, DOI 10.1039/c2ra21052e
   Yang J, 2015, ACS APPL MATER INTER, V7, P5420, DOI 10.1021/am508983n
   Yin CC, 2020, ACTA BIOMATER, V102, P416, DOI 10.1016/j.actbio.2019.11.025
   Yu Q, 2018, CURR MED SCI, V38, P1096, DOI 10.1007/s11596 018 1989 8
   Zakir F, 2020, NANOMEDICINE UK, V15, P1167, DOI 10.2217/nnm 2020 0079
   Zeng YY, 2022, MATER DESIGN, V221, DOI 10.1016/j.matdes.2022.110967
   Zhang N, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00325
   Zheng SW, 2014, J BIOMATER APPL, V28, P1051, DOI 10.1177/0885328213493486
   Zhu Y, 2011, J ALLOY COMPD, V509, P8549, DOI 10.1016/j.jallcom.2011.05.115
NR 83
TC 4
Z9 4
U1 4
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD APR 10
PY 2024
VL 654
AR 123936
DI 10.1016/j.ijpharm.2024.123936
EA MAR 2024
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA PY0T9
UT WOS:001217530100001
PM 38417727
DA 2025 08 17
ER

PT J
AU Chu, YS
   Wong, PC
   Jang, JSC
   Chen, CH
   Wu, SH
AF Chu, Yun Shin
   Wong, Pei Chun
   Jang, Jason Shian Ching
   Chen, Chih Hwa
   Wu, Si Han
TI Combining Mg Zn Ca Bulk Metallic Glass with a Mesoporous Silica
   Nanocomposite for Bone Tissue Engineering
SO PHARMACEUTICS
LA English
DT Article
DE mesoporous silica nanoparticles; Mg Zn Ca bulk metallic glass; bone
   tissue engineering; osteogenic growth peptide; osteogenic
   differentiation; osteoinduction; osteoconduction; osseointegration
ID OSTEOGENIC GROWTH PEPTIDE; NANOPARTICLES; MAGNESIUM; OSSEOINTEGRATION;
   DEGRADATION; COMPOSITES; PAXILLIN; FAK; ERK
AB Mg Zn Ca bulk metallic glass (BMG) is a promising orthopedic fixation implant because of its biodegradable and biocompatible properties. Structural supporting bone implants with osteoinduction properties for effective bone regeneration have been highly desired in recent years. Osteogenic growth peptide (OGP) can increase the proliferation and differentiation of mesenchymal stem cells and enhance the mineralization of osteoblast cells. However, the short half life and non specificity to target areas limit applications of OGP. Mesoporous silica nanoparticles (MSNs) as nanocarriers possess excellent properties, such as easy surface modification, superior targeting efficiency, and high loading capacity of drugs or proteins. Accordingly, we propose a system of combining the OGP containing MSNs with Mg Zn Ca BMG materials to promote bone regeneration. In this work, we conjugated cysteine containing OGP (cgOGP, 16 a.a.) to interior walls of channels in MSNs and maintained the dispersity of MSNs via PEGylation. An in vitro study showed that metal ions released from Mg Zn Ca BMG promoted cell proliferation and migration and elevated alkaline phosphatase (ALP) activity and mineralization. On treating cells with both BMG ion containing Minimum Essential Medium Eagle alpha modification (alpha MEM) and OGP conjugated MSNs, enhanced focal adhesion turnover and promoted differentiation were observed. Hematological analyses showed the biocompatible nature of this BMG/nanocomposite system. In addition, in vivo micro computed tomographic and histological observations revealed that our system stimulated osteogenesis and new bone formation around the implant site.
C1 [Chu, Yun Shin] Taipei Med Univ, Grad Inst Biomed Mat & Tissue Engn, Taipei 11031, Taiwan.
   [Wong, Pei Chun] Taipei Med Univ Hosp, Dept Orthoped, Taipei 11031, Taiwan.
   [Wong, Pei Chun] Taipei Med Univ, Coll Med, Sch Med, Dept Orthoped, Taipei 11031, Taiwan.
   [Wong, Pei Chun] Taipei Med Univ Hosp, Orthoped Res Ctr, Taipei 11031, Taiwan.
   [Jang, Jason Shian Ching] Natl Cent Univ, Grad Inst Mat Sci & Engn, Taoyuan 32001, Taiwan.
   [Jang, Jason Shian Ching] Natl Cent Univ, Dept Mech Engn, Taoyuan 32001, Taiwan.
   [Chen, Chih Hwa] Taipei Med Univ, Coll Biomed Engn, Sch Biomed Engn, Taipei 11031, Taiwan.
   [Chen, Chih Hwa] Taipei Med Univ, Dept Orthoped, Shuang Ho Hosp, New Taipei 11031, Taiwan.
   [Chen, Chih Hwa] Taipei Med Univ, Coll Med, Sch Med, Taipei 11031, Taiwan.
   [Chen, Chih Hwa] Taipei Med Univ, Res Ctr Biomed Device, Taipei 11031, Taiwan.
   [Wu, Si Han] Taipei Med Univ, Grad Inst Nanomed & Med Engn, Taipei 11031, Taiwan.
   [Wu, Si Han] Taipei Med Univ, Coll Biomed Engn, Int PhD Program Biomed Engn, Taipei 11031, Taiwan.
C3 Taipei Medical University; Taipei Medical University Hospital; Taipei
   Medical University; Taipei Medical University; Taipei Medical
   University; Taipei Medical University Hospital; National Central
   University; National Central University; Taipei Medical University;
   Taipei Medical University; Taipei Medical University; Taipei Medical
   University; Taipei Medical University; Taipei Medical University
RP Wu, SH (通讯作者)，Taipei Med Univ, Grad Inst Nanomed & Med Engn, Taipei 11031, Taiwan.; Wu, SH (通讯作者)，Taipei Med Univ, Coll Biomed Engn, Int PhD Program Biomed Engn, Taipei 11031, Taiwan.
EM shinshinjoyce@gmail.com; s0925135546@gmail.com; jscjang@ncu.edu.tw;
   chihhwache@tmu.edu.tw; smilehanwu@tmu.edu.tw
RI ; Wu, Si Han/A 2814 2013; Wu, Si Han/AAN 6416 2021
OI Wong, Pei Chun/0000 0001 8357 5616; Chu, Yun Shin/0000 0002 4650 7881;
   Wu, Si Han/0000 0002 2586 7538; 
FU National Health Research Institutes [NHRI EX111 10911EC]; Ministry of
   Science and Technology of Taiwan [MOST110 2113 M038 004]
FX This study was supported by research grants from the National Health
   Research Institutes (NHRI EX111 10911EC) and the Ministry of Science and
   Technology of Taiwan (MOST110 2113 M038 004).
CR Bai JX, 2020, BIOMATERIALS, V255, DOI 10.1016/j.biomaterials.2020.120197
   Bin SJB, 2022, J MAGNES ALLOY, V10, P899, DOI 10.1016/j.jma.2021.10.010
   Chaya A, 2015, ACTA BIOMATER, V18, P262, DOI 10.1016/j.actbio.2015.02.010
   Chen BJ, 2020, CHEM ENG J, V396, DOI 10.1016/j.cej.2020.125335
   Chen YC, 2002, J MED CHEM, V45, P1624, DOI 10.1021/jm010479l
   Chen YP, 2020, ACS APPL MATER INTER, V12, P56741, DOI 10.1021/acsami.0c16728
   Chen ZA, 2019, ACS APPL MATER INTER, V11, P4790, DOI 10.1021/acsami.8b18434
   Deng GY, 2018, INT J NANOMED, V13, P103, DOI 10.2147/IJN.S148487
   Fan JX, 2017, BIOMATERIALS, V139, P116, DOI 10.1016/j.biomaterials.2017.06.007
   Galli S, 2017, OSTEOPOROSIS INT, V28, P2195, DOI 10.1007/s00198 017 4004 5
   Gu XN, 2010, BIOMATERIALS, V31, P1093, DOI 10.1016/j.biomaterials.2009.11.015
   He LY, 2016, BRAZ J MED BIOL RES, V49, DOI [10.1590/1414 431X20165257, 10.1590/1414 431x20165257]
   Huang DM, 2008, TOXICOL APPL PHARM, V231, P208, DOI 10.1016/j.taap.2008.04.009
   Ishibe S, 2004, MOL CELL, V16, P257, DOI 10.1016/j.molcel.2004.10.006
   Janjua TI, 2021, NAT REV MATER, V6, P1072, DOI 10.1038/s41578 021 00385 x
   Ji W, 2012, ADV DRUG DELIVER REV, V64, P1152, DOI 10.1016/j.addr.2012.03.003
   Kao KC, 2013, MICROPOR MESOPOR MAT, V169, P7, DOI 10.1016/j.micromeso.2012.09.030
   Kim YH, 2015, ADV DRUG DELIVER REV, V94, P28, DOI 10.1016/j.addr.2015.06.003
   Koidou VP, 2018, BIOMATER SCI UK, V6, P1936, DOI 10.1039/c8bm00300a
   Lashgari HR, 2022, J MATER SCI TECHNOL, V119, P131, DOI 10.1016/j.jmst.2021.09.068
   Liu J, 2019, BIOMATER SCI UK, V7, P1463, DOI 10.1039/c8bm01611a
   Liu J, 2018, J BIOMED MATER RES A, V106, P3021, DOI 10.1002/jbm.a.36491
   Liu L, 2019, BIOMATERIALS, V192, P523, DOI 10.1016/j.biomaterials.2018.11.007
   López Colomé AM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045 017 0418 y
   Miron RJ, 2012, J DENT RES, V91, P736, DOI 10.1177/0022034511435260
   Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549
   Ouyang D, 2021, APPL MATER TODAY, V23, DOI 10.1016/j.apmt.2021.100988
   Ouyang SH, 2019, BIOACT MATER, V4, P37, DOI 10.1016/j.bioactmat.2018.12.001
   Pigossi SC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111885
   Pillow TH, 2017, CHEM SCI, V8, P366, DOI 10.1039/c6sc01831a
   Policastro GM, 2016, WIRES NANOMED NANOBI, V8, P449, DOI 10.1002/wnan.1376
   Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005
   Salvati A, 2018, NANOIMPACT, V9, P42, DOI 10.1016/j.impact.2017.10.004
   San Miguel SM, 2005, J BIOL CHEM, V280, P37495, DOI 10.1074/jbc.M503861200
   Setyawati MI, 2017, ACS APPL MATER INTER, V9, P6690, DOI 10.1021/acsami.6b12524
   Song MS, 2019, J MATER SCI TECHNOL, V35, P535, DOI 10.1016/j.jmst.2018.10.008
   Tang W, 2014, J AM CHEM SOC, V136, P16357, DOI 10.1021/ja508946h
   Turecek PL, 2016, J PHARM SCI US, V105, P460, DOI 10.1016/j.xphs.2015.11.015
   Vanella L, 2010, BONE, V46, P236, DOI 10.1016/j.bone.2009.10.012
   Vedadghavami A, 2020, NANO TODAY, V34, DOI 10.1016/j.nantod.2020.100898
   Wang Q, 2020, MATER DESIGN, V193, DOI 10.1016/j.matdes.2020.108811
   Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094
   Wessels V, 2012, ADV ENG MATER, V14, pB357, DOI 10.1002/adem.201180200
   Wittkowske C, 2016, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00087
   Wong CC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092191
   Wong PC, 2016, METALS BASEL, V6, DOI 10.3390/met6050116
   Wong PC, 2017, J ALLOY COMPD, V699, P914, DOI 10.1016/j.jallcom.2017.01.010
   Wu SH, 2013, CHEM SOC REV, V42, P3862, DOI 10.1039/c3cs35405a
   Wu SH, 2011, CHEM COMMUN, V47, P9972, DOI 10.1039/c1cc11760b
   Yang YW, 2020, MATER DESIGN, V185, DOI 10.1016/j.matdes.2019.108259
   Zberg B, 2009, NAT MATER, V8, P887, DOI [10.1038/NMAT2542, 10.1038/nmat2542]
   Zhang C, 2021, MAT SCI ENG R, V145, DOI 10.1016/j.mser.2021.100625
   Zhang DY, 2019, BIOMATER SCI UK, V7, P3984, DOI 10.1039/c9bm00746f
   Zhang RL, 2020, ACS APPL MATER INTER, V12, P42472, DOI 10.1021/acsami.0c07917
   Zhang ZZ, 2019, AM J SPORT MED, V47, P954, DOI 10.1177/0363546518820076
   Zheng YF, 2014, MAT SCI ENG R, V77, P1, DOI 10.1016/j.mser.2014.01.001
   Zhou WH, 2021, BIOMATER SCI UK, V9, P807, DOI 10.1039/d0bm01584a
NR 57
TC 8
Z9 9
U1 1
U2 37
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1999 4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD MAY
PY 2022
VL 14
IS 5
AR 1078
DI 10.3390/pharmaceutics14051078
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 1S9KR
UT WOS:000804361600001
PM 35631664
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, MR
   Fukushima, Y
   Nozaki, K
   Nakanishi, H
   Deng, J
   Wakabayashi, N
   Itaka, K
AF Zhang, Maorui
   Fukushima, Yuta
   Nozaki, Kosuke
   Nakanishi, Hideyuki
   Deng, Jia
   Wakabayashi, Noriyuki
   Itaka, Keiji
TI Enhancement of bone regeneration by coadministration of angiogenic and
   osteogenic factors using messenger RNA
SO INFLAMMATION AND REGENERATION
LA English
DT Article
DE Bone regeneration; Angiogenesis; mRNA medicine; Vascular endothelial
   growth factor; Runt related transcription factor 2; Mandible bone
   defect; Polyplex nanomicelle
ID OSTEOBLAST DIFFERENTIATION; GENE TRANSFER; COLLAGEN; THERAPY; REPAIR;
   CELLS
AB BackgroundBone defects remain a challenge today. In addition to osteogenic activation, the crucial role of angiogenesis has also gained attention. In particular, vascular endothelial growth factor (VEGF) is likely to play a significant role in bone regeneration, not only to restore blood supply but also to be directly involved in the osteogenic differentiation of mesenchymal stem cells. In this study, to produce additive angiogenic osteogenic effects in the process of bone regeneration, VEGF and Runt related transcription factor 2 (Runx2), an essential transcription factor for osteogenic differentiation, were coadministered with messenger RNAs (mRNAs) to bone defects in the rat mandible.MethodsThe mRNAs encoding VEGF or Runx2 were prepared via in vitro transcription (IVT). Osteogenic differentiation after mRNA transfection was evaluated using primary osteoblast like cells, followed by an evaluation of the gene expression levels of osteogenic markers. The mRNAs were then administered to a bone defect prepared in the rat mandible using our original cationic polymer based carrier, the polyplex nanomicelle. The bone regeneration was evaluated by micro computerized tomography (& mu;CT) imaging, and histologic analyses.ResultsOsteogenic markers such as osteocalcin (Ocn) and osteopontin (Opn) were significantly upregulated after mRNA transfection. VEGF mRNA was revealed to have a distinct osteoblastic function similar to that of Runx2 mRNA, and the combined use of the two mRNAs resulted in further upregulation of the markers. After in vivo administration into the bone defect, the two mRNAs induced significant enhancement of bone regeneration with increased bone mineralization. Histological analyses using antibodies against the Cluster of Differentiation 31 protein (CD31), alkaline phosphatase (ALP), or OCN revealed that the mRNAs induced the upregulation of osteogenic markers in the defect, together with increased vessel formation, leading to rapid bone formation.ConclusionsThese results demonstrate the feasibility of using mRNA medicines to introduce various therapeutic factors, including transcription factors, into target sites. This study provides valuable information for the development of mRNA therapeutics for tissue engineering.
C1 [Zhang, Maorui; Fukushima, Yuta; Nakanishi, Hideyuki; Deng, Jia; Itaka, Keiji] Tokyo Med & Dent Univ TMDU, Inst Biomat & Bioengn, Dept Biofunct Res, Tokyo 1010062, Japan.
   [Zhang, Maorui; Nozaki, Kosuke; Wakabayashi, Noriyuki] Tokyo Med & Dent Univ TMDU, Grad Sch Med & Dent Sci, Dept Adv Prosthodont, Tokyo 1138549, Japan.
   [Zhang, Maorui] Southwest Med Univ, Dept Oral Implantol, Affiliated Stomatol Hosp, Luzhou 646000, Peoples R China.
   [Deng, Jia] Tokyo Med & Dent Univ TMDU, Grad Sch Med & Dent Sci, Dept Masticatory Funct & Hlth Sci, Tokyo 1138549, Japan.
   [Itaka, Keiji] Osaka Univ, Ctr Infect Dis Educ & Res CiDER, Clin Biotechnol Team, Osaka 5650871, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Southwest Medical University; Institute of Science Tokyo; Tokyo Medical
   & Dental University (TMDU); University of Osaka
RP Itaka, K (通讯作者)，Tokyo Med & Dent Univ TMDU, Inst Biomat & Bioengn, Dept Biofunct Res, Tokyo 1010062, Japan.; Itaka, K (通讯作者)，Osaka Univ, Ctr Infect Dis Educ & Res CiDER, Clin Biotechnol Team, Osaka 5650871, Japan.
EM itaka.bif@tmd.ac.jp
RI Wakabayashi, Noriyuki/ABA 2063 2020; Itaka, Keiji/KXQ 4687 2024; Nozaki,
   Kosuke/AAB 3729 2021; Nakanishi, Hideyuki/Q 5855 2017
OI Wakabayashi, Noriyuki/0000 0002 0517 6756; Nakanishi,
   Hideyuki/0000 0003 1159 3676
FU Japan Agency for Medical Research and Development (AMED), Japan
   [22fk0310515s0501, 22ak0101173s0202]; Japan Science and Technology
   Agency (JST ) [G4304]; Japan China Sasakawa Medical Fellowship
   [2110?II?031]; Axcelead, Inc; Grants in Aid for Scientific Research
   [21K16603, 23K11843] Funding Source: KAKEN
FX This research was financially supported in part by the Japan Agency for
   Medical Research and Development (AMED), Japan, under Grant Number
   22fk0310515s0501 (K.I.) and 22ak0101173s0202 (K.I.), TMDU WISE II
   Program from Japan Science and Technology Agency (JST ), under Grant
   Number G4304 (M.Z.), and Japan China Sasakawa Medical Fellowship, under
   Grant Number 2110?II?031 (M.Z.). This research was also supported in
   part by Axcelead, Inc.
CR Aini H, 2016, SCI REP UK, V6, DOI 10.1038/srep18743
   Alameh MG, 2021, IMMUNITY, V54, P2877, DOI 10.1016/j.immuni.2021.11.001
   Baba M, 2015, J CONTROL RELEASE, V201, P41, DOI 10.1016/j.jconrel.2015.01.017
   Balmayor ER, 2016, BIOMATERIALS, V87, P131, DOI 10.1016/j.biomaterials.2016.02.018
   Basyuni S, 2020, BRIT J ORAL MAX SURG, V58, P632, DOI 10.1016/j.bjoms.2020.03.016
   Carlsson L, 2018, MOL THER METH CLIN D, V9, P330, DOI 10.1016/j.omtm.2018.04.003
   Crowley ST, 2019, MOL THER NUCL ACIDS, V17, P465, DOI 10.1016/j.omtn.2019.06.016
   Sasso GRD, 2021, DEV BIOL, V478, P133, DOI 10.1016/j.ydbio.2021.07.001
   Das A, 2016, CELL TISSUE RES, V364, P125, DOI 10.1007/s00441 015 2301 x
   Deng J, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14091785
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Fukushima Y, 2021, BIOMATERIALS, V270, DOI 10.1016/j.biomaterials.2021.120681
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Götz C, 2015, OR SURG OR MED OR PA, V120, P315, DOI 10.1016/j.oooo.2015.05.022
   Han XX, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27493 0
   Hashimoto Y, 2022, PROG NEUROBIOL, V216, DOI 10.1016/j.pneurobio.2022.102288
   Hojo H, 2022, CELL REP, V40, DOI 10.1016/j.celrep.2022.111315
   Hu K, 2016, BONE, V91, P30, DOI 10.1016/j.bone.2016.06.013
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Itaka K, 2007, MOL THER, V15, P1655, DOI 10.1038/sj.mt.6300218
   Itaka K, 2011, CURR GENE THER, V11, P457, DOI 10.2174/156652311798192879
   KABAN LB, 1981, J DENT RES, V60, P1356, DOI 10.1177/00220345810600071201
   Kanayama N, 2006, CHEMMEDCHEM, V1, P439, DOI 10.1002/cmdc.200600008
   Kawamoto T, 2014, METHODS MOL BIOL, V1130, P149, DOI 10.1007/978 1 62703 989 5_11
   Kim I, 2019, MACROMOL BIOSCI, V19, DOI 10.1002/mabi.201800460
   Li CF, 2022, NAT IMMUNOL, V23, P543, DOI 10.1038/s41590 022 01163 9
   Lin CY, 2019, MOL THER NUCL ACIDS, V16, P162, DOI 10.1016/j.omtn.2019.02.012
   Liu K, 2020, REGEN BIOMATER, V7, P435, DOI 10.1093/rb/rbaa022
   Lu CH, 2013, BIOTECHNOL ADV, V31, P1695, DOI 10.1016/j.biotechadv.2013.08.015
   Maes C, 2010, EMBO J, V29, P424, DOI 10.1038/emboj.2009.361
   Marcucio RS, 2023, J DENT RES, V102, P13, DOI 10.1177/00220345221125401
   Matsui A, 2018, J CONTROL RELEASE, V285, P1, DOI 10.1016/j.jconrel.2018.06.033
   Matsui A, 2015, SCI REP UK, V5, DOI 10.1038/srep15810
   Oyama N, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13111810
   Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278
   Schott NG, 2021, TISSUE ENG PART B RE, V27, P199, DOI [10.1089/ten.teb.2020.0132, 10.1089/ten.TEB.2020.0132]
   Tahtinen S, 2022, NAT IMMUNOL, V23, P532, DOI 10.1038/s41590 022 01160 y
   Uchida H, 2014, J AM CHEM SOC, V136, P12396, DOI 10.1021/ja506194z
   Uchida S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056220
   Wang PP, 2021, J CONTROL RELEASE, V334, P188, DOI 10.1016/j.jconrel.2021.04.021
   Wang ZH, 2020, J CELL BIOCHEM, V121, P2394, DOI 10.1002/jcb.29462
   Wani TU, 2021, J CONTROL RELEASE, V339, P143, DOI 10.1016/j.jconrel.2021.09.029
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Winn SR, 2000, ADV DRUG DELIVER REV, V42, P121, DOI 10.1016/S0169 409X(00)00057 0
   Zangi L, 2013, NAT BIOTECHNOL, V31, P898, DOI 10.1038/nbt.2682
   Zhang MR, 2019, J ORAL MAXIL SURG, V77, P1293, DOI 10.1016/j.joms.2019.01.017
NR 47
TC 18
Z9 18
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1880 8190
J9 INFLAMM REGEN
JI Inflamm. Regen.
PD JUN 20
PY 2023
VL 43
IS 1
AR 32
DI 10.1186/s41232 023 00285 3
PG 16
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Research & Experimental Medicine
GA J8KY7
UT WOS:001012069700002
PM 37340499
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zeller, AN
   Selle, M
   Gong, Z
   Winkelmann, M
   Krettek, C
   Bundkirchen, K
   Neunaber, C
   Noack, S
AF Zeller, A.  N.
   Selle, M.
   Gong, Z.
   Winkelmann, M.
   Krettek, C.
   Bundkirchen, K.
   Neunaber, C.
   Noack, S.
TI OSTEOPOROSIS IS ACCOMPANIED BY REDUCED CD274 EXPRESSION IN HUMAN BONE
   MARROW DERIVED MESENCHYMAL STEM CELLS
SO EUROPEAN CELLS & MATERIALS
LA English
DT Article
DE Osteoporosis; mesenchymal stem cells; CD274; osteoblasts; gene
   expression
ID MEDICATION RELATED OSTEONECROSIS; STROMAL CELLS; OVARIECTOMIZED MICE;
   MINERAL DENSITY; CLASS II; DIFFERENTIATION; GENE; WNT; ASSOCIATION;
   PREVENTION
AB Underlying pathomechanisms of osteoporosis are still not fully elucidated. Cell based therapy approaches pose new possibilities to treat osteoporosis and its complications. The aim of this study was to quantify differences in human bone marrow derived mesenchymal stem cells (hBMSCs) between healthy donors and those suffering from clinically manifest osteoporosis.
   Cell samples of seven donors for each group were selected retrospectively from the hBMSC cell bank of the Trauma Department of Hannover Medical School. Cells were evaluated for their adipogenic, osteogenic and chondrogenic differentiation potential, for their proliferation potential and expression of surface antigens. Furthermore, a RT2 Osteoporosis Profiler PCR array, as well as quantitative real time PCR were carried out to evaluate changes in gene expression.
   Cultivated hBMSCs from osteoporotic donors showed significantly lower cell surface expression of CD274 (4.98 % +/  2.38 %) than those from the control group (26.03 % +/  13.39 %; p = 0.007), as assessed by flow cytometry. In osteoporotic patients, genes involved in inhibition of the anabolic WNT signalling pathway and those associated with stimulation of bone resorption were significantly upregulated. Apart from these changes, no significant differences were found for the other cell surface antigens, adipogenic, osteogenic and chondrogenic differentiation ability as well as proliferation potential.
   These findings supported the theory of an influence of CD274 on the regulation of bone metabolism. CD274 might be a promising target for further investigations of the pathogenesis of osteoporosis and of cell based therapies involving MSCs.
C1 [Zeller, A.  N.; Selle, M.; Gong, Z.; Winkelmann, M.; Krettek, C.; Bundkirchen, K.; Neunaber, C.; Noack, S.] Hannover Med Sch, Trauma Dept, Carl Neuberg Str 1, D 30625 Hannover, Germany.
   [Zeller, A.  N.] Hannover Med Sch, Dept Craniomaxillofacial Surg, Carl Neuberg Str 1, D 30625 Hannover, Germany.
C3 Hannover Medical School; Hannover Medical School
RP Zeller, AN (通讯作者)，Hannover Med Sch, Trauma Dept, Carl Neuberg Str 1, D 30625 Hannover, Germany.
EM zeller.alexander@mh hannover.de
RI Neunaber, Claudia/AAJ 1490 2021
OI Bundkirchen, Katrin/0000 0002 5256 3732
FU German Research Foundation (DFG); Open Access Publication Fund of
   Hannover Medical School (MHH); Hannover Medical School; Else
   KronerFreseniusStiftung [2016A188]
FX We would like to thank the donors and surgeons of the Trauma Department
   at Hannover Medical School for providing us with bone marrow samples and
   Claudia Pitz, Melanie Weiss and Johanna Ehlers for their valuable
   assistance. The Institute of Functional and Applied Anatomy at Hannover
   Medical School generously made it possible for us to use their flow
   cytometer for this study. We acknowledge support by the German Research
   Foundation (DFG) and the Open Access Publication Fund of Hannover
   Medical School (MHH) . The underlying study was financed solely by
   Hannover Medical School and Else KronerFreseniusStiftung [Grant No.
   2016A188] .
CR Aghebati Maleki L, 2019, J CELL PHYSIOL, V234, P8570, DOI 10.1002/jcp.27833
   Antebi B, 2014, CURR OSTEOPOROS REP, V12, P41, DOI 10.1007/s11914 013 0184 x
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Banas A, 2007, HEPATOLOGY, V46, P219, DOI 10.1002/hep.21704
   Bara JJ, 2014, STEM CELLS, V32, P1713, DOI 10.1002/stem.1649
   Baron R, 2018, CURR OPIN PHARMACOL, V40, P134, DOI 10.1016/j.coph.2018.04.011
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bocelli Tyndall C, 2015, ANN RHEUM DIS, V74, P260, DOI 10.1136/annrheumdis 2013 204235
   Bocelli Tyndall C, 2010, ARTHRITIS RHEUM US, V62, P3815, DOI 10.1002/art.27736
   Bundkirchen K, 2018, J TRAUMA ACUTE CARE, V85, P359, DOI 10.1097/TA.0000000000001952
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Camernik K, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01657 z
   Cecconi E, 2006, EUR J ENDOCRINOL, V155, P41, DOI 10.1530/eje.1.02181
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Chan LC, 2019, J CLIN INVEST, V129, P3324, DOI 10.1172/JCI126022
   Cheishvili D, 2018, J BONE MINER RES, V33, P1980, DOI 10.1002/jbmr.3527
   Crane JL, 2014, J MOL MED, V92, P107, DOI 10.1007/s00109 013 1084 3
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   DeMambro VE, 2015, ENDOCRINOLOGY, V156, P4129, DOI 10.1210/en.2014 1452
   di Filippo L, 2020, PITUITARY, V23, P314, DOI 10.1007/s11102 020 01041 3
   Docheva D, 2007, J CELL MOL MED, V11, P21, DOI 10.1111/j.1582 4934.2007.00001.x
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Eriksson E, 2019, J IMMUNOL, V202, P787, DOI 10.4049/jimmunol.1800717
   Fajar JK, 2017, J TAIBAH UNIV MED SC, V12, P212, DOI 10.1016/j.jtumed.2016.07.010
   Fliefel R, 2015, INT J ORAL MAX SURG, V44, P568, DOI 10.1016/j.ijom.2015.01.026
   Franki AS, 2005, MOL IMMUNOL, V42, P413, DOI 10.1016/j.molimm.2004.07.020
   Freedman BI, 2009, J BONE MINER RES, V24, P1719, DOI [10.1359/JBMR.090501, 10.1359/jbmr.090501]
   Gibon E, 2017, J ORTHOP TRANSL, V10, P28, DOI 10.1016/j.jot.2017.04.002
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Golob AL, 2015, MED CLIN N AM, V99, P587, DOI 10.1016/j.mcna.2015.01.010
   Haasters F, 2014, BIOCHEM BIOPH RES CO, V452, P118, DOI 10.1016/j.bbrc.2014.08.055
   Haddouti EM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218309
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Jin YH, 2013, J VIROL, V87, P11538, DOI 10.1128/JVI.01967 13
   Johnell O, 2005, OSTEOPOROSIS INT, V16, pS3, DOI 10.1007/s00198 004 1702 6
   Kassem M, 2004, BASIC CLIN PHARMACOL, V95, P209, DOI 10.1111/j.1742 7843.2004.pto950502.x
   Kassem M, 2011, AGING CELL, V10, P191, DOI 10.1111/j.1474 9726.2011.00669.x
   Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985
   Kling JM, 2014, J WOMENS HEALTH, V23, P563, DOI 10.1089/jwh.2013.4611
   Kretlow JD, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471 2121 9 60
   Larghero J, 2008, ANN RHEUM DIS, V67, P443, DOI 10.1136/ard.2007.071233
   Lee HJ, 2007, BONE, V41, P979, DOI 10.1016/j.bone.2007.08.034
   Lemound J, 2018, J ORAL MAXIL SURG, V76, P877, DOI 10.1016/j.joms.2017.09.021
   Li XH, 2019, INT J CLIN EXP PATHO, V12, P4077
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Lin CS, 2012, CYTOTHERAPY, V14, P1159, DOI 10.3109/14653249.2012.729817
   Machado Cíntia de Vasconcellos, 2013, Rev. Bras. Hematol. Hemoter., V35, P62, DOI 10.5581/1516 8484.20130017
   Pino AM, 2012, BIOL RES, V45, P279, DOI 10.4067/S0716 97602012000300009
   Mikami Y, 2014, ANAT SCI INT, V89, P1, DOI 10.1007/s12565 013 0208 8
   Moffett SP, 2009, BONE, V44, P999, DOI 10.1016/j.bone.2008.12.024
   Nagahama K, 2004, BONE, V35, P1059, DOI 10.1016/j.bone.2004.06.018
   Nicoletti G, 2013, PRS GLOB OPEN, V1, P32
   Ogata K, 2015, BONE, V74, P95, DOI 10.1016/j.bone.2015.01.011
   Paccou J, 2015, J CLIN ENDOCR METAB, V100, P3613, DOI 10.1210/jc.2015 2338
   Pichardo SEC, 2013, J CRANIO MAXILL SURG, V41, pE65, DOI 10.1016/j.jcms.2012.10.014
   Pietschmann P, 2016, GERONTOLOGY, V62, P128, DOI 10.1159/000431091
   Prall WC, 2013, BIOCHEM BIOPH RES CO, V440, P617, DOI 10.1016/j.bbrc.2013.09.114
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rodríguez JP, 1999, J CELL BIOCHEM, V75, P414, DOI 10.1002/(SICI)1097 4644(19991201)75:3<414::AID JCB7>3.3.CO;2 3
   Rodríguez Sanz M, 2015, J MOL ENDOCRINOL, V55, P69, DOI 10.1530/JME 15 0079
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Schäck LM, 2013, STEM CELLS DEV, V22, P3226, DOI 10.1089/scd.2013.0290
   Siegel G, 2013, BMC MED, V11, DOI 10.1186/1741 7015 11 146
   Tarte K, 2010, BLOOD, V115, P1549, DOI 10.1182/blood 2009 05 219907
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Ueland T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122896
   Wang SH, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756 8722 5 19
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Wein MN, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031237
   Xu XH, 2010, ENDOCR REV, V31, P447, DOI 10.1210/er.2009 0032
   Yan K, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12778
   Zhao RCH, 2004, J LAB CLIN MED, V143, P284, DOI 10.1016/j.lab.2003.11.009
   Zhou S, 2008, AGING CELL, V7, P335, DOI 10.1111/j.1474 9726.2008.00377.x
NR 75
TC 3
Z9 4
U1 0
U2 1
PU AO RESEARCH INSTITUTE DAVOS ARI
PI DAVOS
PA CLAVADELERSTRASSE 8, DAVOS, CH 7270, SWITZERLAND
SN 1473 2262
J9 EUR CELLS MATER
JI Eur. Cells Mater.
PD JAN JUN
PY 2021
VL 41
BP 603
EP 615
DI 10.22203/eCM.v041a39
PG 13
WC Cell & Tissue Engineering; Engineering, Biomedical; Materials Science,
   Biomaterials; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science; Orthopedics
GA SL4SR
UT WOS:000656909800001
PM 34056703
DA 2025 08 17
ER

PT J
AU Kihara, T
   Ichikawa, S
   Yonezawa, T
   Lee, JW
   Akihisa, T
   Woo, JT
   Michi, Y
   Amagasa, T
   Yamaguchi, A
AF Kihara, Tasuku
   Ichikawa, Saki
   Yonezawa, Takayuki
   Lee, Ji Won
   Akihisa, Toshihiro
   Woo, Je Tae
   Michi, Yasuyuki
   Amagasa, Teruo
   Yamaguchi, Akira
TI Acerogenin A, a natural compound isolated from Acer nikoense
   Maxim, stimulates osteoblast differentiation through bone morphogenetic
   protein action
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Acerogenin A; Natural compound; Osteoblast; BMP; Runx2; Noggin
ID JAPANESE FOLK MEDICINE; IN VITRO; CYCLIC DIARYLHEPTANOIDS; CELL LINES;
   INHIBITORS; CBFA1; BMP; CONSTITUENTS; DELIVERY; AGONIST
AB We investigated the effects of acerogenin A, a natural compound isolated from Acer nikoense Maxim, on osteoblast differentiation by using osteoblastic cells. Acerogenin A stimulated the cell proliferation of MC3T3 E1 osteoblastic cells and RD C6 osteoblastic cells (Runx2 deficient cell line). It also increased alkaline phosphatase activity in MC3T3 E1 and RD C6 cells and calvarial osteoblastic cells isolated from the calvariae of newborn mice. Acerogenin A also increased the expression of mRNAs related to osteoblast differentiation, including Osteocalcin, Osterix and Runx2 in MC3T3 E1 cells and primary osteoblasts: it also stimulated Osteocalcin and Osterix mRNA expression in RD C6 cells. The acerogenin A treatment for 3 days increased Bmp 2, Bmp 4, and Bmp 7 mRNA expression levels in MC3T3 E1 cells. Adding noggin, a BMP specific antagonist, inhibited the acerogenin A induced increase in the Osteocalcin, Osterix and Runx2 mRNA expression levels. These results indicated that acerogenin A stimulates osteoblast differentiation through BMP action, which is mediated by Runx2 dependent and Runx2 independent pathways. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Yamaguchi, Akira] Tokyo Med & Dent Univ, Sect Oral Pathol, Grad Sch Med & Dent Sci, Bunkyo Ku, Tokyo 1138549, Japan.
   [Kihara, Tasuku; Michi, Yasuyuki; Amagasa, Teruo] Tokyo Med & Dent Univ, Sect Maxillofacial Surg, Grad Sch Med & Dent Sci, Tokyo 1138549, Japan.
   [Kihara, Tasuku; Yamaguchi, Akira] Tokyo Med & Dent Univ, Global Ctr Excellence GCOE Program, Int Res Ctr Mol Sci Tooth & Bone Dis, Tokyo 1138549, Japan.
   [Yonezawa, Takayuki; Lee, Ji Won; Woo, Je Tae] Chubu Univ, Res Inst Biol Funct, Kasugai, Aichi 487, Japan.
   [Akihisa, Toshihiro] Nihon Univ, Coll Sci & Technol, Tokyo 101, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Chubu University; Nihon University
RP Yamaguchi, A (通讯作者)，Tokyo Med & Dent Univ, Sect Oral Pathol, Grad Sch Med & Dent Sci, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138549, Japan.
EM akira.mpa@tmd.ac.jp
RI LEE, Ji/C 2295 2009; YONEZAWA, Takayuki/O 3047 2019; Yamaguchi,
   Akinobu/E 4265 2016
OI Michi, Yasuyuki/0000 0003 1574 1218; YONEZAWA,
   Takayuki/0000 0001 8060 0839
FU Japan Society for the Promotion of Science [22249061, 21659420];
   Ministry of Health, Labour, and Welfare [21040101]; Global Center of
   Excellence (GCOE) Program; international Research Center for Molecular
   Science in Tooth and Bone Diseases, Tokyo Medical and Dental University;
   Grants in Aid for Scientific Research [22249061, 11F01113, 21659420]
   Funding Source: KAKEN
FX This work was supported by a Grant in Aid for Scientific Research from
   the Japan Society for the Promotion of Science (Nos. 22249061 and
   21659420) and Health and Labour Sciences Research Grants from the
   Ministry of Health, Labour, and Welfare (No. 21040101) to A.Y., and by
   the Global Center of Excellence (GCOE) Program; international Research
   Center for Molecular Science in Tooth and Bone Diseases, Tokyo Medical
   and Dental University.
CR Awad HA, 2007, TISSUE ENG, V13, P1973, DOI 10.1089/ten.2006.0107
   Baron R, 2006, CURR TOP DEV BIOL, V76, P103, DOI 10.1016/S0070 2153(06)76004 5
   BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874
   Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P81, DOI 10.1002/term.74
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Garrett IR, 2007, CURR TOP DEV BIOL, V78, P127, DOI 10.1016/S0070 2153(06)78004 8
   Hojo H, 2008, BIOCHEM BIOPH RES CO, V376, P375, DOI 10.1016/j.bbrc.2008.08.167
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Liu TJ, 2007, J CELL PHYSIOL, V211, P728, DOI 10.1002/jcp.20988
   Luisetto G, 2009, J Endocrinol Invest, V32, P32
   Morikawa T, 2003, CHEM PHARM BULL, V51, P62, DOI 10.1248/cpb.51.62
   Morikawa T, 2003, J NAT PROD, V66, P86, DOI 10.1021/np020351m
   Morita H, 2010, BIOORG MED CHEM LETT, V20, P1070, DOI 10.1016/j.bmcl.2009.12.036
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   NAGAI M, 1978, CHEM PHARM BULL, V26, P2805
   NAGAI M, 1976, J CHEM SOC CHEM COMM, P338, DOI 10.1039/c39760000338
   Nakagawa K, 2007, BONE, V41, P543, DOI 10.1016/j.bone.2007.06.013
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Namikawa T, 2007, SPINE, V32, P2294, DOI 10.1097/BRS.0b013e318154c5b6
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Rosen V, 2006, ANN NY ACAD SCI, V1068, P19, DOI 10.1196/annals.1346.005
   SAMPATH TK, 1992, J BIOL CHEM, V267, P20352
   Shinoda M., 1986, SHOYAKUGAKU ZASSHI, V40, P177
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   White AP, 2007, INT ORTHOP, V31, P735, DOI 10.1007/s00264 007 0422 x
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681
   Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
NR 31
TC 14
Z9 14
U1 0
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 11
PY 2011
VL 406
IS 2
BP 211
EP 217
DI 10.1016/j.bbrc.2011.02.017
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 738CF
UT WOS:000288616200010
PM 21303661
DA 2025 08 17
ER

PT J
AU Tian, X
   Zhang, JZ
   Guo, Q
   Wang, GY
   Wang, H
   Li, ZY
   Dong, JM
AF Tian, Xu
   Zhang, Jizheng
   Guo, Qiang
   Wang, Guangyu
   Wang, He
   Li, Zhiyong
   Dong, Jingming
TI CHLOROGENIC ACID IMPROVED HIGH GLUCOSE INDUCED APOPTOSIS AND OSTEOGENIC
   DIFFERENTIATION IN MC3T3 E1 CELLS THROUGH ELIMINATING OXIDATIVE STRESS
SO ACTA POLONIAE PHARMACEUTICA
LA English
DT Article
DE anti oxidative; apoptosis; chlorogenic acid; diabetic osteoporosis;
   MC3T3 E1 cells; osteoblast viability
ID HYDROGEN PEROXIDE; GENE EXPRESSION; INHIBITION; MECHANISMS; ESTROGEN
AB Long term hyperglycemia affects bone metabolism and causes osteoporosis, the prevalence of diabetes induced osteoporosis has prompted researchers to develop new biological therapies for its management. Chlorogenic acid (CGA) as an anti oxidative, anti inflammatory component has been found in lots of traditional Chinese medicine. In this study, we found that CGA improves high glucose (HG) induced inhibition of osteoblast differentiation and apoptosis of MC3T3 E1 cells through regulating oxidative stress. Detailly. phosphatase (ALP) activity and osteoblast viability of MC3T3 E1 cells were decreased but reactive oxygen species (ROS) production was increased by HG, and CGA increased ALP activity, osteoblast viability, and superoxide dismutase (SOD) activity but decreased ROS, the transcription of the genes ALP, Runx2, osteocalcin (OCN) and protein of RUNX2 regulated osteogenic differentiation were also decreased by HG but increased by CGA supplementation. Protein and mRNA of Bcl 2 were decreased, but Bax and caspase 3 were increased by HG, CGA further improved apoptosis of MC3T3 E1 cells through increasing expression of Bcl 2, but decreasing expression of Bax and caspase 3. These indicated that CGA improves the proliferation and differentiation of osteoblasts inhibited by high glucose. which may provide a perspective on the therapeutic role in the treatment of diabetic osteoporosis.
C1 [Tian, Xu; Zhang, Jizheng; Wang, Guangyu; Dong, Jingming] Tianjin Hosp, Dept Orthopaed Inst, 406 Jiefangnan St, Tianjin 300211, Peoples R China.
   [Guo, Qiang; Wang, He; Li, Zhiyong] Tianjin Med Univ, Orthopaed Dept, Baodi Clin Coll, 8 Guangchuan Rd, Tianjin 301800, Peoples R China.
C3 Tianjin Medical University
RP Dong, JM (通讯作者)，Tianjin Hosp, Dept Orthopaed Inst, 406 Jiefangnan St, Tianjin 300211, Peoples R China.
EM Huntertianxu@163.com
RI LI, ZHIYONG/AAE 3158 2019
CR Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Bafana A, 2011, J MOL CATAL B ENZYM, V68, P129, DOI 10.1016/j.molcatb.2010.11.007
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Balint E, 2001, BONE, V28, P21, DOI 10.1016/S8756 3282(00)00426 9
   Banfi G, 2008, CLIN CHEM LAB MED, V46, P1550, DOI 10.1515/CCLM.2008.302
   Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1
   Botolin S, 2006, J CELL BIOCHEM, V99, P411, DOI 10.1002/jcb.20842
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Choi EM, 2008, CELL BIOL TOXICOL, V24, P225, DOI 10.1007/s10565 007 9031 0
   Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004
   Dandona P, 1996, LANCET, V347, P444, DOI 10.1016/S0140 6736(96)90013 6
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Fatokun AA, 2006, BONE, V39, P542, DOI 10.1016/j.bone.2006.02.062
   Hamada Y, 2009, BONE, V44, P936, DOI 10.1016/j.bone.2008.12.011
   Kwon MJ, 2012, J DERMATOL SCI, V67, P81, DOI 10.1016/j.jdermsci.2012.06.003
   Lean JM, 2005, ENDOCRINOLOGY, V146, P728, DOI 10.1210/en.2004 1021
   Liu YJ, 2013, MOL MED REP, V8, P1106, DOI 10.3892/mmr.2013.1652
   Maalik A, 2016, ACTA POL PHARM, V73, P851
   Mann V, 2007, BONE, V40, P674, DOI 10.1016/j.bone.2006.10.014
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Mohsin S, 2019, EXPERT OPIN BIOL TH, V19, P937, DOI 10.1080/14712598.2019.1618266
   Morikawa D, 2013, J BONE MINER RES, V28, P2368, DOI 10.1002/jbmr.1981
   Napoli N, 2017, NAT REV ENDOCRINOL, V13, P208, DOI 10.1038/nrendo.2016.153
   Omori K, 2008, J LEUKOCYTE BIOL, V84, P292, DOI 10.1189/jlb.1207832
   Shi HT, 2013, TOXICOLOGY, V303, P107, DOI 10.1016/j.tox.2012.10.025
   Ueno T, 2011, J BIOMED MATER RES A, V99A, P523, DOI 10.1002/jbm.a.33211
   Upadhyay R, 2013, CRIT REV FOOD SCI, V53, P968, DOI 10.1080/10408398.2011.576319
   Vitaglione P, 2004, CRIT REV FOOD SCI, V44, P575, DOI 10.1080/10408690490911701
   Wan CW, 2013, PHYTOTHER RES, V27, P545, DOI 10.1002/ptr.4751
   Ye HY, 2016, ARCH PHARM RES, V39, P989, DOI 10.1007/s12272 016 0771 3
   Zhang Lan tao, 2011, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V33, P281, DOI 10.3881/j.issn.1000 503X.2011.03.015
   Zhang Y, 2013, J CELL BIOCHEM, V114, P2595, DOI 10.1002/jcb.24607
   Zhao YY, 2012, HYPERTENS RES, V35, P370, DOI 10.1038/hr.2011.195
   Zhou NA, 2015, CELL PHYSIOL BIOCHEM, V36, P44, DOI 10.1159/000374052
NR 34
TC 0
Z9 0
U1 3
U2 25
PU POLSKIE TOWARZYSTWO FARMACEUTYCZNE
PI WARSAW
PA DLUGA 16, 00 238 WARSAW, POLAND
SN 0001 6837
EI 2353 5288
J9 ACTA POL PHARM
JI ACTA POL. PHARM.
PD NOV DEC
PY 2020
VL 77
IS 6
BP 881
EP 887
DI 10.32383/appdr/130824
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA PS6EN
UT WOS:000608019200007
OA hybrid
DA 2025 08 17
ER

PT J
AU Hortobagyi, GN
   Zheng, M
   Mohanlal, R
AF Hortobagyi, Gabriel N.
   Zheng, Ming
   Mohanlal, Ramon
TI Indirect Evaluation of Bone Saturation with Zoledronic Acid After
   Long Term Dosing
SO ONCOLOGIST
LA English
DT Article
DE Zoledronic acid; Long term dosing; Bone saturation; Pharmacokinetics;
   OPTIMIZE 2
ID METASTATIC BREAST CANCER; BISPHOSPHONATES; EFFICACY; PHARMACODYNAMICS;
   PHARMACOKINETICS; INHIBITION; MECHANISM; SYNTHASE; SAFETY; RISK
AB Background Zoledronic acid (ZA), a potent bisphosphonate used for treatment of bone metastasis, has high bone affinity. This post hoc analysis evaluated the effects of long term treatment and reduction in dosing frequency of ZA on bone saturation. Materials and Methods Pharmacokinetic data from three independent studies, OPTIMIZE 2 (patients receiving >= 9 doses of bisphosphonates) and two phase I studies, CZOL4460503 and CZOL4460506 (patients who were bisphosphonate naive/bisphosphonate free for >= 1 year after previous dosing), were pooled. Serial urine and plasma samples were used as surrogate markers to determine ZA plasma area under the curve (AUC) over 6 hours (AUC(0 6h)) and dose excreted in urine over 6 hours (urine(0 6h)). Potential relationships between the number of years for which patients had been treated previously at time of study entry and AUC(0 6h) or urine(0 6h) were analyzed graphically. Results Creatinine clearances for patients were similar across the three studies and at all time points analyzed. The levels of AUC(0 6h) ZA in plasma at week 0 in every (q) 4 and q12 weekly arms of OPTIMIZE 2 were 0.366 h x mg/L and 0.397 h x mg/L compared with 0.345 h x mg/L and 0.356 h x mg/L in CZOL4460503 and CZOL4460506, respectively. In OPTIMIZE 2, the AUC(0 6h) ZA plasma levels were the same (0.428 h x mg/L) at week 36 in both q4 and q12 arms. The levels of ZA urine(0 6h) at week 36 in OPTIMIZE 2 (q4 and q12 week arms), CZOL4460503, and CZOL4460506 were 36.6%, 30.8%, 26.5%, and 27.3%, respectively. Conclusion Long term ZA treatment may not impact bone saturation, and ZA dosing frequency does not seem to influence drug retention rates.
C1 [Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA.
   [Zheng, Ming; Mohanlal, Ramon] Novartis Pharmaceut, E Hanover, NJ USA.
C3 University of Texas System; UTMD Anderson Cancer Center; Novartis;
   Novartis USA
RP Hortobagyi, GN (通讯作者)，UTMDACC, Dept Breast Med Oncol, Div Canc Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM ghortoba@mdanderson.org
FU Novartis Pharmaceuticals Corporation
FX We thank William Sallas for his significant contribution toward data
   analyses and drafting of this manuscript. This study was sponsored by
   Novartis Pharmaceuticals Corporation, who also provided financial
   support for medical editorial assistance. We thank Sweta Rathore from
   Novartis Healthcare Pvt Ltd for medical editorial assistance with this
   manuscript. R.M. is currently affiliated with AstraZeneca and
   BeyondSpring Pharmaceuticals.
CR Amadori D, 2013, LANCET ONCOL, V14, P663, DOI 10.1016/S1470 2045(13)70174 8
   Body JJ, 1999, J BONE MINER RES, V14, P1557, DOI 10.1359/jbmr.1999.14.9.1557
   Body JJ, 1997, CANCER, V80, P1699, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1699::AID CNCR23>3.3.CO;2 A
   Brown JE, 2007, CLIN CANCER RES, V13, P5406, DOI 10.1158/1078 0432.CCR 07 0247
   Brufsky AM, 2013, BREAST J, V19, P504, DOI 10.1111/tbj.12152
   Carteni G, 2006, ONCOLOGIST, V11, P841, DOI 10.1634/theoncologist.11 7 841
   Cecchini MG., 2005, EAU Update Series, V3, P214
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Coleman RE, 2008, BRIT J CANCER, V98, P1736, DOI 10.1038/sj.bjc.6604382
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Gnant Michael, 2011, Ther Adv Med Oncol, V3, P293, DOI 10.1177/1758834011420599
   Greenberg MS, 2004, ORAL SURG ORAL MED O, V98, P259, DOI 10.1016/j.tripleo.2004.08.001
   Holen I, 2010, CURR PHARM DESIGN, V16, P1262, DOI 10.2174/138161210791034003
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   Idrees ASM, 2013, CANCER SCI, V104, P536, DOI 10.1111/cas.12124
   Kajizono M, 2015, BIOL PHARM BULL, V38, P1850, DOI 10.1248/bpb.b15 00385
   Kim YS, 2012, J BREAST CANCER, V15, P261, DOI 10.4048/jbc.2012.15.2.261
   Legay F, 2002, J PHARMACEUT BIOMED, V30, P897, DOI 10.1016/S0731 7085(02)00218 2
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Mukherjee S, 2009, J AM CHEM SOC, V131, P8374, DOI 10.1021/ja902895p
   Polascik Thomas J, 2008, Ther Clin Risk Manag, V4, P261
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   Tracy TS, 2004, DRUG ABSORPTION DIST
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Van Poznak C, 2017, J CLIN ONCOL, V35, P3978, DOI 10.1200/JCO.2017.75.4614
NR 29
TC 5
Z9 5
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1083 7159
EI 1549 490X
J9 ONCOLOGIST
JI Oncologist
PD FEB
PY 2019
VL 24
IS 2
BP 178
EP 184
DI 10.1634/theoncologist.2018 0218
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA HL7OM
UT WOS:000458930900012
PM 30297386
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Yang, FB
   Zhang, X
   Song, T
   Li, XD
   Lv, H
   Li, TT
   Zhao, J
   Liu, Z
   Zhang, XF
   Hou, YL
   Xu, XL
AF Yang, Fubiao
   Zhang, Xin
   Song, Tao
   Li, Xiaodong
   Lv, Hang
   Li, Tongtong
   Zhao, Jun
   Liu, Zhao
   Zhang, Xiaofeng
   Hou, Yunlong
   Xu, Xilin
TI Huogu injection alleviates SONFH by regulating adipogenic
   differentiation of BMSCs via targeting the miR 34c 5p/MDM4 pathway
SO GENE
LA English
DT Article
DE Huogu injection; BSMCs; Adipogenic differentiation; miR 34c 5p; MDM4
   pathway; SONFH
ID STEROID INDUCED OSTEONECROSIS; MESENCHYMAL STEM CELLS; OSTEOBLAST
   DIFFERENTIATION; MICRORNA EXPRESSION; FEMORAL HEAD; MDM2
AB Although the precise pathogenesis of steroid induced osteonecrosis of femoral head (SONFH) is not yet fully understood, evidence shows miRNAs mediated posttranscription control directs the adipogenesis of bone marrow mesenchymal stem cells (BMSCs) and plays a pivotal role in the SONFH processes. Huogu injection formulated according to traditional Chinese medicine (TCM) theory has been used to treat SONFH by intra articular injection. In this study, we asked whether the therapeutic effects of Huogu injection might depend on the inhibition of adipogenic differentiation of BMSCs, and if so, the pathway might be a therapeutic target to promote bone repair. Consequently, miR 34c 5p was upregulated in the dexamethasone (DEX) treated BMSCs and might participate in the adipogenesis of BMSCs. TargetScan database and the luciferase reporter assay showed miR 34c 5p targeted on the MDM4 and negatively regulated its expression. Huogu injection in vitro inhibited the adipogenesis in the DEX treated BMSCs by inhibiting the expression levels of PPAR gamma and C/EBP alpha, as well as reducing miR 34c 5p to prevent the degradation of MDM4. Moreover, miR 34c 5p mimic or MDM4 knockdown using shRNA neutralized the anti adipogenesis of Huogu injection in BMSCs. In vivo, the results of X ray imaging confirmed that Huogu injection alleviated the bone loss in rat SONFH. Consistent with results in vitro, Huogu injection reduced the lipid accumulation, removed the suppression of MDM4 by downregulating the expression of miR 34c 5p, and inhibited the expression of C/EBP alpha and PPAR gamma in bone tissues. When the lenti virus encoding miR 34c 5p was conducted by intra articular injection, the overexpression of miR 34c 5p antagonized the therapeutic effects of Huogu injection. Our results underline the critical importance of the miR 34c 5p/MDM4 pathway in regulating the adipogenic outcome of BMSCs, suggesting the miR 34c 5p as a potentially effective therapeutic target in SONFH. These results further reinforce the potential of Huogu injection as an alternative approach in SONFH.
C1 [Yang, Fubiao; Zhang, Xiaofeng] Heilongjiang Univ Tradit Chinese Med, Harbin 150000, Heilongjiang, Peoples R China.
   [Zhang, Xin; Liu, Zhao] Heilongjiang Univ Tradit Chinese Med, Grad Sch, Harbin 150000, Heilongjiang, Peoples R China.
   [Song, Tao; Li, Tongtong; Hou, Yunlong] Hebei Univ Chinese Med, Coll Integrated Tradit Chinese & Western Med, Shijiazhuang 050000, Hebei, Peoples R China.
   [Li, Xiaodong; Lv, Hang; Xu, Xilin] Heilongjiang Univ Tradit Chinese Med, Affiliated Hosp 2, Harbin 150000, Heilongjiang, Peoples R China.
   [Zhao, Jun] Zhuhai Hosp Integrated Tradit Chinese & Western Me, Zhuhai 510000, Guangdong, Peoples R China.
   [Hou, Yunlong] Natl Key Lab Collateral Dis Res & Innovat Chinese, Shijiazhuang 050000, Hebei, Peoples R China.
C3 Heilongjiang University of Chinese Medicine; Heilongjiang University of
   Chinese Medicine; Hebei University of Chinese Medicine; Heilongjiang
   University of Chinese Medicine
RP Hou, YL (通讯作者)，Hebei Univ Chinese Med, Coll Integrated Tradit Chinese & Western Med, Shijiazhuang 050000, Hebei, Peoples R China.; Xu, XL (通讯作者)，Heilongjiang Univ Tradit Chinese Med, Affiliated Hosp 2, Harbin 150000, Heilongjiang, Peoples R China.
EM houyunlonghrb@hotmail.com
RI ; Hou, Yunlong/C 4885 2014
OI Zhang, Xin/0000 0001 5249 2084; 
FU National Natural Science Foundation of China [81774343]; Heilongjiang
   University of traditional Chinese Medicine Foundation [2019MS20];
   Heilongjiang Province Traditional Chinese Medicine Research Project
   [ZHY2020 147]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81774343) , Talent training support plan of the central
   support fund for the reform and development of local colleges and
   universities (high level talent training support project) , Heilongjiang
   University of traditional Chinese Medicine Foundation project (No.
   2019MS20) , Heilongjiang Province Traditional Chinese Medicine Research
   Project (No. ZHY2020 147) .
CR Boregowda SV, 2018, CELL DEATH DIFFER, V25, P677, DOI 10.1038/s41418 017 0004 4
   Boregowda SV, 2012, STEM CELLS, V30, P975, DOI 10.1002/stem.1069
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Crompton J, 2020, ACTA ORTHOP, V91, P687, DOI 10.1080/17453674.2020.1795598
   Gu CX, 2016, SCI REP UK, V6, DOI 10.1038/srep38491
   Han LZ, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1498 0
   Itoh T, 2009, J BIOL CHEM, V284, P19272, DOI 10.1074/jbc.M109.014001
   Jang SA, 2019, MOLECULES, V24, DOI 10.3390/molecules24173051
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Karni Schmidt O, 2016, ANNU REV PATHOL MECH, V11, P617, DOI 10.1146/annurev pathol 012414 040349
   King VM, 2017, METHODS MOL BIOL, V1617, P27, DOI 10.1007/978 1 4939 7046 9_2
   Kuang MJ, 2019, CHEM BIOL INTERACT, V304, P97, DOI 10.1016/j.cbi.2019.03.008
   Lee EJ, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9060648
   Li QQ, 2017, PROTEIN CELL, V8, P439, DOI 10.1007/s13238 017 0385 7
   Li Z., 2021, Mol. Med. Rep., V24
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Liu LH, 2017, CHINESE MED J PEKING, V130, P2601, DOI 10.4103/0366 6999.217094
   Liu QH, 2010, ANNU REV BIOCHEM, V79, P295, DOI 10.1146/annurev.biochem.052208.151733
   Majidinia M, 2020, BIOGERONTOLOGY, V21, P275, DOI 10.1007/s10522 020 09862 2
   Meermans G, 2017, BONE JOINT J, V99B, P732, DOI 10.1302/0301 620X.99B6.38053
   Mizuno Y, 2008, BIOCHEM BIOPH RES CO, V368, P267, DOI 10.1016/j.bbrc.2008.01.073
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Singh AK, 2020, DIAB MET SYND CLIN R, V14, P971, DOI 10.1016/j.dsx.2020.06.054
   Song K, 2014, MOL MED REP, V10, P755, DOI 10.3892/mmr.2014.2264
   Sun CJ, 2020, PHYTOTHER RES, V34, P1704, DOI 10.1002/ptr.6652
   Taipaleenmäki H, 2018, CURR OSTEOPOROS REP, V16, P1, DOI 10.1007/s11914 018 0417 0
   Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430
   Wang A, 2018, GENE, V671, P103, DOI 10.1016/j.gene.2018.05.091
   Wang BQ, 2015, MOL MED REP, V12, P7447, DOI 10.3892/mmr.2015.4386
   Wang T, 2010, BIOCHEM BIOPH RES CO, V402, P186, DOI 10.1016/j.bbrc.2010.08.031
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Xiang S, 2020, INT J MOL MED, V45, P805, DOI 10.3892/ijmm.2020.4455
   Yu HC, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03225 1
   Zhang SY, 2021, J MED CHEM, V64, P10621, DOI 10.1021/acs.jmedchem.1c00940
   Zhao DW, 2020, J ORTHOP TRANSL, V21, P100, DOI 10.1016/j.jot.2019.12.004
   Zhu WW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2496 y
   Zhu ZX, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/8759642
NR 37
TC 12
Z9 12
U1 0
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 1119
EI 1879 0038
J9 GENE
JI Gene
PD SEP 5
PY 2022
VL 838
AR 146705
DI 10.1016/j.gene.2022.146705
EA JUL 2022
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA 3Q2GZ
UT WOS:000838052700003
PM 35772657
OA hybrid
DA 2025 08 17
ER

PT J
AU Gan, Q
   Pan, H
   Zhang, WJ
   Yuan, Y
   Qian, JC
   Liu, CS
AF Gan, Qi
   Pan, Hao
   Zhang, Wenjing
   Yuan, Yuan
   Qian, Jiangchao
   Liu, Changsheng
TI Fabrication and evaluation of a BMP 2/dexamethasone co loaded gelatin
   sponge scaffold for rapid bone regeneration
SO REGENERATIVE BIOMATERIALS
LA English
DT Article
DE BMP 2; dexamethasone; Runx2; pre clinical; bone regeneration
ID MESENCHYMAL STEM CELLS; MORPHOGENETIC PROTEIN 2; IN VITRO; OSTEOBLAST
   DIFFERENTIATION; DEXAMETHASONE; BMP 2; RUNX2; COOPERATION; INDUCTION;
   FAMILY
AB Improving the osteogenic activity of BMP 2 in vivo has significant clinical application value. In this research, we use a clinical gelatin sponge scaffold loaded with BMP 2 and dexamethasone (Dex) to evaluate the osteogenic activity of dual drugs via ectopic osteogenesis in vivo. We also investigate the mechanism of osteogenesis induced by BMP 2 and Dex with C2C12, a multipotent muscle derived progenitor cell. The results show that the gelatin scaffold with Dex and BMP 2 can significantly accelerate osteogenesis in vivo. It is indicated that compared with the BMP 2 or Dex alone, 100 nM of Dex can dramatically enhance the BMP 2 induced alkaline phosphatase activity (ALP), ALP mRNA expression and mineralization. Further studies show that 100 nM of Dex can maintain the secondary structure of BMP 2 and facilitate recognition of BMP 2 with its receptors on the surface of C2C12 cells. We also find that in C2C12, Dex has no obvious effect on the BMP 2 induced Smad1/5/8 protein expression and the STAT3 dependent pathway, but Runx2 dependent pathway is involved in the Dex stimulated osteoblast differentiation of BMP 2 both in vitro and in vivo. Based on these results, a potential mechanism model about the synergistic osteoinductive effect of Dex and BMP 2 in C2C12 cells via Runx2 activation is proposed. This may provide a theoretical basis for the pre clinical application of Dex and BMP 2 for bone regeneration.
C1 [Gan, Qi; Yuan, Yuan; Liu, Changsheng] East China Univ Sci & Technol, Key Lab Ultrafine Mat, Minist Educ, Shanghai 200237, Peoples R China.
   [Gan, Qi; Qian, Jiangchao] East China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China.
   [Pan, Hao; Zhang, Wenjing; Liu, Changsheng] East China Univ Sci & Technol, Engn Res Ctr Biomed Mat, Minist Educ, Shanghai 200237, Peoples R China.
   [Liu, Changsheng] East China Univ Sci & Technol, Frontiers Sci Ctr Materiobiol & Dynam Chem, Shanghai 200237, Peoples R China.
C3 East China University of Science & Technology; East China University of
   Science & Technology; East China University of Science & Technology;
   East China University of Science & Technology
RP Yuan, Y; Liu, CS (通讯作者)，East China Univ Sci & Technol, Key Lab Ultrafine Mat, Minist Educ, Shanghai 200237, Peoples R China.; Liu, CS (通讯作者)，East China Univ Sci & Technol, Engn Res Ctr Biomed Mat, Minist Educ, Shanghai 200237, Peoples R China.; Liu, CS (通讯作者)，East China Univ Sci & Technol, Frontiers Sci Ctr Materiobiol & Dynam Chem, Shanghai 200237, Peoples R China.
EM yyuan@ecust.edu.cn; liucs@ecust.edu.cn
RI Zhang, Wenjing/B 5983 2019
FU Natural Science Foundation of China for Innovative Research Groups
   [51621002]; National Natural Science Foundation of China [32071337];
   Shanghai Pujiang Program [20PJ1402600]; 111 Project [B14018];
   Fundamental Research Funds for the Central Universities
FX This work was supported by the Natural Science Foundation of China for
   Innovative Research Groups (No. 51621002), the National Natural Science
   Foundation of China (No. 32071337), Shanghai Pujiang Program
   (20PJ1402600) and the 111 Project (B14018). This study was also
   supported by `the Fundamental Research Funds for the Central
   Universities'.
CR Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809
   Bolland BJRF, 2007, EXPERT REV MED DEVIC, V4, P393, DOI 10.1586/17434440.4.3.393
   Briquez PS, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abh4302
   Carpenter RS, 2010, J ORTHOP RES, V28, P1330, DOI 10.1002/jor.21126
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen X, 2021, BIOMATERIALS, V277, DOI 10.1016/j.biomaterials.2021.121117
   Freeman FE, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb5093
   Gan Q, 2015, J MATER CHEM B, V3, P2281, DOI 10.1039/c5tb00219b
   Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577
   Herberg S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax2476
   Hettiaratchi MH, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay1240
   Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551
   Holyoak DT, 2019, REGEN BIOMATER, V6, P211, DOI 10.1093/rb/rbz013
   Ishihara K, 2002, BBA MOL CELL RES, V1592, P281, DOI 10.1016/S0167 4889(02)00321 X
   Itoh S, 2006, BONE, V39, P505, DOI 10.1016/j.bone.2006.02.074
   Jäger M, 2008, J ORTHOP RES, V26, P1440, DOI 10.1002/jor.20565
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Johnson CT, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw1228
   Jorgensen NR, 2004, STEROIDS, V69, P219, DOI 10.1016/j.steroids.2003.12.005
   Jun JH, 2010, J BIOL CHEM, V285, P36410, DOI 10.1074/jbc.M110.142307
   Kawaski T, 2010, BIOMATERIALS, V31, P1191, DOI 10.1016/j.biomaterials.2009.10.048
   Kim HJ, 2021, ADV THER GERMANY, V4, DOI 10.1002/adtp.202000245
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Li L, 2015, BIOMATERIALS, V37, P218, DOI 10.1016/j.biomaterials.2014.10.015
   Lian H, 2020, REGEN BIOMATER, V7, P71, DOI 10.1093/rb/rbz038
   Lin D, 2016, AM J TRANSL RES, V8, P1379
   Liu HB, 2020, BIOMATER SCI UK, V8, P3871, DOI 10.1039/d0bm00581a
   Liu K, 2020, REGEN BIOMATER, V7, P435, DOI 10.1093/rb/rbaa022
   Martins A, 2010, BIOMATERIALS, V31, P5875, DOI 10.1016/j.biomaterials.2010.04.010
   Matsumoto Y, 2010, MOL CELL ENDOCRINOL, V325, P118, DOI 10.1016/j.mce.2010.05.004
   McDermott AM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav7756
   Mikami Y, 2007, BIOCHEM BIOPH RES CO, V362, P368, DOI 10.1016/j.bbrc.2007.07.192
   Mikami Y, 2010, J CELL PHYSIOL, V223, P123, DOI 10.1002/jcp.22017
   Phillips JE, 2006, J CELL SCI, V119, P581, DOI 10.1242/jcs.02758
   Raina DB, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc1779
   Ruckh TT, 2010, ACTA BIOMATER, V6, P2949, DOI 10.1016/j.actbio.2010.02.006
   Sanchez Casanova S, 2020, BIOMATERIALS, V241, DOI 10.1016/j.biomaterials.2020.119909
   Seeherman HJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aar4953
   Walsh S, 2001, RHEUMATOLOGY, V40, P74, DOI 10.1093/rheumatology/40.1.74
   Wang Q, 2007, J BIOL CHEM, V282, P10742, DOI 10.1074/jbc.M610997200
   Xu TT, 2020, REGEN BIOMATER, V7, P91, DOI 10.1093/rb/rbz040
   Zhang B, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau7411
   Zhang YY, 2012, MOL ENDOCRINOL, V26, P798, DOI 10.1210/me.2011 1287
   Zhou HJ, 2009, BIOMATERIALS, V30, P1715, DOI 10.1016/j.biomaterials.2008.12.016
NR 44
TC 15
Z9 15
U1 8
U2 68
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2056 3418
EI 2056 3426
J9 REGEN BIOMATER
JI Regen. Biomater.
PD APR 8
PY 2022
VL 9
AR rbac008
DI 10.1093/rb/rbac008
EA MAY 2022
PG 11
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 1T1VS
UT WOS:000804525800001
PM 35592142
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sanchez, CP
   He, YZ
AF Sanchez, CP
   He, YZ
TI Daily or intermittent calcitriol administration during growth hormone
   therapy in rats with renal failure and advanced secondary
   hyperparathyroidism
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID OSTEOBLAST LIKE CELLS; 1 ALPHA,25 DIHYDROXYVITAMIN D 3;
   SIGNAL TRANSDUCTION; PLATE CHONDROCYTES; FACTOR RECEPTOR 3; IMPROVES
   GROWTH; ADYNAMIC BONE; VITAMIN D; PROLIFERATION; CHILDREN
AB Growth hormone (GH) improves growth in children with chronic renal failure. The response to GH may be affected by the degree of secondary hyperparathyroidism and concurrent treatment with vitamin D. Forty six rats underwent 5/6 nephrectomy (Nx) and were given a high phosphorus diet (Nx Phos) to induce advanced secondary hyperparathyroidism and divided into the following groups: (1) Nx Phos (n = 10) received saline, (2) GH at 10 IU/kg per d (Nx Phos+GH; n = 9), (3) GH and daily calcitriol (D) at 50 ng/kg per d (Nx Phos+GH+daily D; n = 8), (4) GH and intermittent D (three times weekly) at 350 ng/kg per wk (Nx Phos+GH+int D; n = 9), and (5) intact control (n = 10). Serum parathyroid hormone (PTH) levels were elevated in Nx Phos, but IGF I levels did not change with growth hormone. Body length, tibial length, and growth plate width did not increase with either GH or calcitriol. Proliferating cell nuclear antigen staining, PTH/PTHrP receptor, bone morphogenetic protein 7, and fibroblast growth factor receptor 3 expression increased with GH alone or with intermittent calcitriol but were slightly diminished during daily calcitriol administration. GH enhanced IGF I, IGF binding receptor 3, and GH receptor but declined with daily and intermittent calcitriol. Overall, there was no improvement in body length, tibial length, and growth plate width at the end of GH therapy, but selected markers of chondrocyte proliferation and chondrocyte differentiation increased, although these changes were attenuated by calcitriol. The combination of GH and calcitriol that is frequently used in children with renal failure and secondary hyperparathyroidism require further studies to evaluate the optimal dose and frequency of administration to increase linear growth and prevent bone disease.
C1 Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Sanchez, CP (通讯作者)，Univ Wisconsin, Sch Med, Dept Pediat, 3590 MSC Pediat,1300 Univ Ave, Madison, WI 53706 USA.
EM cpsanchez@wisc.edu
RI Sanchez, Cheryl/AAF 6973 2020
FU NIDDK NIH HHS [DK 56688 01] Funding Source: Medline
CR Amizuka N, 2004, BONE, V34, P13, DOI 10.1016/j.bone.2003.08.009
   Ardissino G, 2000, PEDIATR NEPHROL, V14, P664, DOI 10.1007/s004670000365
   Carter Su C, 2000, PEDIATR NEPHROL, V14, P550, DOI 10.1007/s004670000366
   Cozzolino M, 2001, KIDNEY INT, V60, P2109, DOI 10.1046/j.1523 1755.2001.00042.x
   Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092 8674(00)81069 7
   DYCK MV, 2001, EUR J PEDIATR, V160, P359
   Gevers EF, 1996, J BONE MINER RES, V11, P1103
   González EA, 2002, KIDNEY INT, V61, P1322, DOI 10.1046/j.1523 1755.2002.00258.x
   GOODMAN WG, 1994, KIDNEY INT, V46, P1160, DOI 10.1038/ki.1994.380
   Jensen SS, 2001, MOL ENDOCRINOL, V15, P1370, DOI 10.1210/me.15.8.1370
   KASSEM M, 1993, CALCIFIED TISSUE INT, V52, P222, DOI 10.1007/BF00298723
   Klaus G, 1998, KIDNEY INT, V53, P1152, DOI 10.1046/j.1523 1755.1998.00884.x
   KLAUS G, 1991, PEDIATR NEPHROL, V5, P461, DOI 10.1007/BF01453682
   Kuizon BD, 1998, KIDNEY INT, V53, P205, DOI 10.1046/j.1523 1755.1998.00724.x
   Lund RJ, 2004, J AM SOC NEPHROL, V15, P359, DOI 10.1097/01.ASN.0000109671.99498.08
   Mehls O, 2000, PEDIATR NEPHROL, V14, P658, DOI 10.1007/s004670000346
   Morales O, 2002, J BIOL CHEM, V277, P34879, DOI 10.1074/jbc.M204819200
   Nifuji A, 1999, J BONE MINER RES, V14, P2057, DOI 10.1359/jbmr.1999.14.12.2057
   REICHEL H, 1993, KIDNEY INT, V44, P1259, DOI 10.1038/ki.1993.377
   Sanchez CP, 1998, KIDNEY INT, V54, P1879, DOI 10.1046/j.1523 1755.1998.00199.x
   Sanchez CP, 2002, BONE, V30, P692, DOI 10.1016/S8756 3282(02)00696 8
   Schaefer F, 2001, J CLIN INVEST, V108, P467, DOI 10.1172/JCI200111895
   Schmitt CP, 2003, PEDIATR NEPHROL, V18, P440, DOI 10.1007/s00467 003 1091 7
   Schmitt CP, 2000, KIDNEY INT, V57, P1484, DOI 10.1046/j.1523 1755.2000.00993.x
   Segev O, 2000, HUM MOL GENET, V9, P249, DOI 10.1093/hmg/9.2.249
   Slatopolsky E, 2000, KIDNEY INT, V58, P753, DOI 10.1016/S0085 2538(15)47156 X
   Wu LNY, 1997, J CELL BIOCHEM, V67, P498, DOI 10.1002/(SICI)1097 4644(19971215)67:4<498::AID JCB8>3.0.CO;2 N
   Wuhl E, 1996, PEDIATR NEPHROL, V10, P294
NR 28
TC 4
Z9 4
U1 1
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046 6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD APR
PY 2005
VL 16
IS 4
BP 929
EP 938
DI 10.1681/ASN.2003100878
PG 10
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 910MO
UT WOS:000227935800015
PM 15728789
OA Bronze
DA 2025 08 17
ER

PT J
AU Palmini, G
   Brandi, ML
AF Palmini, Gaia
   Brandi, Maria Luisa
TI microRNAs and bone tumours: Role of tiny molecules in the development
   and progression of chondrosarcoma, of giant cell tumour of bone and of
   Ewing's sarcoma
SO BONE
LA English
DT Article
DE Bone sarcoma; miRNAs; Chondrosarcoma; Giant cell tumour of bone; Ewing's
   sarcoma
ID GROWTH FACTOR EXPRESSION; MESENCHYMAL STEM CELLS; DOWN REGULATION;
   UP REGULATION; VEGF A; PROMOTES ANGIOGENESIS; LUNG CANCER; OSTEOBLAST
   DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; HEPATOCELLULAR CARCINOMA
AB The increasing interest on microRNAs (miRNAs), small non coding RNA molecules containing about 22 nucle otides, about their biological functions led researchers to discover that they are actively involved in several biological processes. In the last decades, miRNAs become one of the most topic of cancer research. miRNAs, thanks to their function, are the perfect molecules to modulate multiple signaling pathways and gene expression in cancer, with the consequent capacity to modulate cancerous processes, such as cellular proliferation, invasion, metastasis and chemoresistance in various tumours. In the last years, several studies have demonstrated the role of miRNAs in their pathophysiology, but little we know about the underlying mechanism that lead to bone tu mours like chondrosarcoma (COS), giant cell tumour of bone (GCTB) and Ewing sarcoma (EWS) to still be highly aggressive and resistant tumours. An exploration of the role of miRNAs in the biology of them will permit to researchers to find new molecular mechanisms that can be used to develop new and more effective therapies against these bone tumours. Here we present a comprehensive study of the latest discoveries which have been performed in relation to the role of miRNAs in the neoplastic processes which characterize COS, EWS and GCTB, demonstrating how these tiny molecules can act as tumour promoters or as tumour suppressors and how they can be used for improving therapeutic approaches.
C1 [Palmini, Gaia; Brandi, Maria Luisa] Univ Florence, Dept Expt & Clin Biomed Sci, Florence, Italy.
   [Brandi, Maria Luisa] Fdn Italiana Ric Malattie Osso, FIRMO Onulus, Florence, Italy.
C3 University of Florence
RP Brandi, ML (通讯作者)，Univ Florence, Dept Expt & Clin Biomed Sci, Florence, Italy.; Brandi, ML (通讯作者)，Fdn Italiana Ric Malattie Osso, FIRMO Onulus, Florence, Italy.
EM gaia.palmini@unifi.it; marialuisa.brandi@unifi.it
RI ; Palmini, Gaia/AAE 3211 2021
OI brandi, maria luisa/0000 0002 8741 0592; 
CR Achkar NP, 2016, TRENDS PLANT SCI, V21, P1034, DOI 10.1016/j.tplants.2016.09.003
   Ahn S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 20371 8
   Aldinucci D, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/292376
   Alvarez Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073
   Amer KM, 2020, J ORTHOP RES, V38, P311, DOI 10.1002/jor.24463
   [Anonymous], 1999, Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975 1995, DOI DOI 10.1037/E407432005 001
   [Anonymous], 2017, EUR REV
   Barrett SP, 2016, DEVELOPMENT, V143, P1838, DOI 10.1242/dev.128074
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Bertoni F, 2003, CANCER, V97, P2520, DOI 10.1002/cncr.11359
   Boehme KA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010311
   Cai QY, 2017, AM J TRANSL RES, V9, P3282
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623 198769010 00018
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Casali PG, 2014, ANN ONCOL, V25, P113, DOI 10.1093/annonc/mdu256
   Chang HP, 2015, BIOCHEM BIOPH RES CO, V464, P45, DOI 10.1016/j.bbrc.2015.05.092
   Chang SS, 2004, CLIN ORTHOP RELAT R, P103, DOI 10.1097/01.blo.0000141372.54456.80
   Charlier E, 2019, BIOCHEM PHARMACOL, V165, P49, DOI 10.1016/j.bcp.2019.02.036
   Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178
   Chen D, 2015, CANCER LETT, V362, P208, DOI 10.1016/j.canlet.2015.03.041
   Chen FY, 2018, BIOMED PHARMACOTHER, V103, P1092, DOI 10.1016/j.biopha.2018.04.100
   Chen JJ, 2018, HUM CELL, V31, P42, DOI 10.1007/s13577 017 0183 9
   Chen JM, 2019, INT J MOL MED, V43, P1513, DOI 10.3892/ijmm.2018.4042
   Chen JC, 2015, ONCOTARGET, V6, P11434, DOI 10.18632/oncotarget.3397
   Chen LY, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658 019 0144 2
   Chen SS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 018 1241 2
   Chen Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1574 5
   Cheng JW, 2016, ONCOTARGET, V7, P30702, DOI [10.16632/oncotarget.8930, 10.18632/oncotarget.8930]
   Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672
   Christiansen Ailsa, 2011, Genes Cancer, V2, P1146, DOI 10.1177/1947601911423028
   Chuang JY, 2015, ONCOTARGET, V6, P4239, DOI 10.18632/oncotarget.2978
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008 5472.CAN 06 3126
   Cornelis F, 2014, BONE, V58, P11, DOI 10.1016/j.bone.2013.10.004
   Cortez MA, 2011, NAT REV CLIN ONCOL, V8, P467, DOI 10.1038/nrclinonc.2011.76
   Cotterill SJ, 2000, J CLIN ONCOL, V18, P3108, DOI 10.1200/JCO.2000.18.17.3108
   Cowan RW, 2013, BONE, V52, P238, DOI 10.1016/j.bone.2012.10.002
   Crist CG, 2009, P NATL ACAD SCI USA, V106, P13383, DOI 10.1073/pnas.0900210106
   Dai LH, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4114
   Daniel R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061281
   DENEKAMP J, 1993, BRIT J RADIOL, V66, P181, DOI 10.1259/0007 1285 66 783 181
   Dudek KA, 2010, J BIOL CHEM, V285, P24381, DOI 10.1074/jbc.M110.111328
   Elmen J, 2008, NUCLEIC ACIDS RES, V36, P1153, DOI 10.1093/nar/gkm1113
   Errani C, 2018, J BONE JOINT SURG AM, V100, P496, DOI 10.2106/JBJS.17.00057
   Errani C, 2010, CANCER TREAT REV, V36, P1, DOI 10.1016/j.ctrv.2009.09.002
   Esposito F, 2012, J CLIN ENDOCR METAB, V97, pE710, DOI 10.1210/jc.2011 3068
   EVANS HL, 1977, CANCER AM CANCER SOC, V40, P818, DOI 10.1002/1097 0142(197708)40:2<818::AID CNCR2820400234>3.0.CO;2 B
   Fang YT, 2019, GENE, V699, P37, DOI 10.1016/j.gene.2019.03.004
   Federman N, 2014, PEDIATR DRUGS, V16, P21, DOI 10.1007/s40272 013 0051 3
   Feng Y, 2019, HISTOL HISTOPATHOL, V34, P275, DOI 10.14670/HH 18 044
   Ferrer Santacreu EM, 2012, J ONCOL, V2012, DOI 10.1155/2012/437958
   Fong YC, 2012, J CELL PHYSIOL, V227, P223, DOI 10.1002/jcp.22720
   Frantz C, 2010, J CELL SCI, V123, P4195, DOI 10.1242/jcs.023820
   Fujii S, 2018, ANAL CHEM, V90, P10217, DOI 10.1021/acs.analchem.8b01443
   Gao P, 2011, MOL CANCER RES, V9, P1509, DOI 10.1158/1541 7786.MCR 11 0336
   Gao XN, 2011, LEUKEMIA RES, V35, P1226, DOI 10.1016/j.leukres.2011.06.010
   Gaspar N, 2015, J CLIN ONCOL, V33, P3036, DOI 10.1200/JCO.2014.59.5256
   Gelderblom H, 2008, ONCOLOGIST, V13, P320, DOI 10.1634/theoncologist.2007 0237
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Goldring MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652
   Gong LH, 2012, VIRCHOWS ARCH, V460, P327, DOI 10.1007/s00428 012 1198 y
   Han L, 2013, ACTA PHARM SIN B, V3, P65, DOI 10.1016/j.apsb.2013.02.006
   Hanna JA, 2012, BIOTECHNIQUES, V52, P235, DOI 10.2144/000113837
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   Harata K, 2010, ONCOL LETT, V1, P685, DOI 10.3892/ol_00000120
   Hariharan V S, 1937, Ind Med Gaz, V72, P151
   Hasanifard L, 2019, J CELL PHYSIOL, V234, P8162, DOI 10.1002/jcp.27612
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   Havens MA, 2012, NUCLEIC ACIDS RES, V40, P4626, DOI 10.1093/nar/gks026
   Hébert SS, 2008, P NATL ACAD SCI USA, V105, P6415, DOI 10.1073/pnas.0710263105
   Herbert SP, 2011, NAT REV MOL CELL BIO, V12, P551, DOI 10.1038/nrm3176
   Herr I, 2017, CANCER LETT, V409, P49, DOI 10.1016/j.canlet.2017.08.029
   Hombach S, 2016, ADV EXP MED BIOL, V937, P3, DOI 10.1007/978 3 319 42059 2_1
   Hu N, 2015, INT J MOL SCI, V16, P10491, DOI 10.3390/ijms160510491
   Huang CY, 2016, CLIN SCI, V130, P1523, DOI 10.1042/CS20160117
   Huang J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10753 5
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681
   Hwang WL, 2014, NAT CELL BIOL, V16, P268, DOI 10.1038/ncb2910
   Jee YH, 2018, ENDOCRINOLOGY, V159, P1469, DOI 10.1210/en.2017 00780
   Jensen ED, 2008, J BONE MINER RES, V23, P361, DOI 10.1359/JBMR.071104
   Jeong W, 2018, J CLIN PATHOL, V71, P579, DOI 10.1136/jclinpath 2018 205071
   Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816
   Ji Q, 2008, BMC CANCER, V8, DOI 10.1186/1471 2407 8 266
   Jiang ZY, 2018, BIOCHEM BIOPH RES CO, V505, P1003, DOI 10.1016/j.bbrc.2018.10.025
   John Anitha, 2001, Pathology and Oncology Research, V7, P14
   Kawano M, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935 018 0536 9
   Kawano M, 2017, INT J ONCOL, V51, P1842, DOI 10.3892/ijo.2017.4155
   Kenyon JD, 2019, TISSUE ENG PT A, V25, P80, DOI [10.1089/ten.tea.2017.0440, 10.1089/ten.TEA.2017.0440]
   Khan N, 2016, ANAL BIOANAL CHEM, V408, P2891, DOI 10.1007/s00216 015 9277 y
   Ko JY, 2019, TISSUE ENG PT A, V25, P990, DOI [10.1089/ten.tea.2018.0189, 10.1089/ten.TEA.2018.0189]
   Kundu ZS, 2018, INDIAN J ORTHOP, V52, P45, DOI 10.4103/ortho.IJOrtho_216_17
   Kuramochi H, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 88
   Lai VK, 2012, CELL CYCLE, V11, P767, DOI 10.4161/cc.11.4.19211
   Lee HP, 2015, ONCOTARGET, V6, P36746, DOI 10.18632/oncotarget.5479
   Lee S, 2014, STEM CELLS DEV, V23, P1798, DOI 10.1089/scd.2013.0609
   Lee SWL, 2019, J CONTROL RELEASE, V313, P80, DOI 10.1016/j.jconrel.2019.10.007
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476
   Lei SL, 2014, ONCOL LETT, V8, P1768, DOI 10.3892/ol.2014.2328
   Li CF, 2018, AM J MED SCI, V355, P477, DOI 10.1016/j.amjms.2018.01.004
   Li GJ, 2015, BIOMED PHARMACOTHER, V73, P154, DOI 10.1016/j.biopha.2015.05.010
   Li GS, 2021, CONNECT TISSUE RES, V62, P313, DOI 10.1080/03008207.2019.1702650
   Li HY, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058 017 0918 2
   Li J, 2015, BIOCHEM BIOPH RES CO, V460, P482, DOI 10.1016/j.bbrc.2015.03.059
   Li MA, 2012, BIOESSAYS, V34, P670, DOI 10.1002/bies.201200019
   Li S, 2015, INT J CLIN EXP PATHO, V8, P11854
   Li W, 2009, ANAL BIOANAL CHEM, V394, P1117, DOI 10.1007/s00216 008 2570 2
   Li XP, 2018, ONCOTARGETS THER, V11, P8445, DOI 10.2147/OTT.S172393
   Li YY, 2017, ONCOTARGET, V8, P10274, DOI 10.18632/oncotarget.14394
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359
   Lin CY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.354
   Lin CY, 2017, ONCOTARGET, V8, P39571, DOI 10.18632/oncotarget.17142
   Lin CY, 2014, BIOCHEM PHARMACOL, V91, P522, DOI 10.1016/j.bcp.2014.08.008
   Lin Patrick P., 2011, Sarcoma, V2011, P276463, DOI 10.1155/2011/276463
   Lin RJ, 2010, CANCER RES, V70, P7841, DOI 10.1158/0008 5472.CAN 10 0970
   Linabery AM, 2008, CANCER AM CANCER SOC, V113, P2575, DOI 10.1002/cncr.23866
   Liu B, 2019, ONCOL LETT, V17, P781, DOI 10.3892/ol.2018.9711
   Liu C, 2017, ONCOL LETT, V13, P2631, DOI 10.3892/ol.2017.5778
   Liu CH, 2016, MOL CELL ENDOCRINOL, V419, P217, DOI 10.1016/j.mce.2015.10.021
   Liu GT, 2015, CANCER LETT, V357, P476, DOI 10.1016/j.canlet.2014.11.015
   Liu W, 2016, TUMOR BIOL, V37, P6331, DOI 10.1007/s13277 015 4480 1
   Liu YZ, 2019, ARTIF CELL NANOMED B, V47, P2114, DOI 10.1080/21691401.2019.1620760
   Lobry C, 2011, J EXP MED, V208, P1931, DOI 10.1084/jem.20111855
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   Long XH, 2015, TUMOR BIOL, V36, P3799, DOI 10.1007/s13277 014 3021 7
   López Pousa A, 2015, CLIN TRANSL ONCOL, V17, P419, DOI 10.1007/s12094 014 1268 5
   Lu J, 2014, ONCOTARGET, V5, P11319, DOI 10.18632/oncotarget.2435
   Lu QS, 2018, MOL MED REP, V18, P3577, DOI 10.3892/mmr.2018.9365
   Ordóñez JL, 2009, CANCER RES, V69, P7140, DOI 10.1158/0008 5472.CAN 08 4041
   Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599
   Luo AH, 2015, BIOMED PHARMACOTHER, V73, P75, DOI 10.1016/j.biopha.2015.05.014
   Ma CY, 2016, ONCOL LETT, V12, P2538, DOI 10.3892/ol.2016.4939
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   Matin F, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 24424 w
   Mavrogenis AF, 2017, SICOT J, V3, DOI 10.1051/sicotj/2017041
   MCCARTHY EF, 1980, CLIN ORTHOP RELAT R, P14
   McCarthy JJ, 2007, J APPL PHYSIOL, V102, P306, DOI 10.1152/japplphysiol.00932.2006
   Melo SA, 2010, CANCER CELL, V18, P303, DOI 10.1016/j.ccr.2010.09.007
   Mendoza Naranjo A, 2013, EMBO MOL MED, V5, P1087, DOI 10.1002/emmm.201202343
   Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785
   Yamada M, 2008, CLIN CANCER RES, V14, P2351, DOI 10.1158/1078 0432.CCR 07 4499
   Miyaki S, 2010, GENE DEV, V24, P1173, DOI 10.1101/gad.1915510
   Montgomery C, 2019, J KNEE SURG, V32, P331, DOI 10.1055/s 0038 1675815
   Moore C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178028
   Müller DA, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957 016 1034 y
   Nakamura Y, 2012, APPL BIOCHEM BIOTECH, V166, P64, DOI 10.1007/s12010 011 9404 y
   Narayanan A, 2019, LIFE SCI, V232, DOI 10.1016/j.lfs.2019.116676
   Newcomb B., 2015, BIOACTIVE SPHINGOLIP, P81, DOI [10.1007/978 3 319 20750 6, DOI 10.1007/978 3 319 20750 6]
   Nishida N, 2006, VASC HEALTH RISK MAN, V2, P213, DOI 10.2147/vhrm.2006.2.3.213
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   Packer AN, 2008, J NEUROSCI, V28, P14341, DOI 10.1523/JNEUROSCI.2390 08.2008
   Paduch R, 2016, CELL ONCOL, V39, P397, DOI 10.1007/s13402 016 0281 9
   Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232
   Pescador D, 2012, INT J SURG CASE REP, V3, P134, DOI 10.1016/j.ijscr.2011.11.009
   Qin L, 2005, J BIOL CHEM, V280, P3974, DOI 10.1074/jbc.M409807200
   Ren YQ, 2013, ANAL CHEM, V85, P4784, DOI 10.1021/ac400583e
   Roberto GM, 2019, CANCER GENET NY, V230, P21, DOI 10.1016/j.cancergen.2018.11.003
   Rohini M, 2018, BIOCHIMIE, V154, P10, DOI 10.1016/j.biochi.2018.07.023
   Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005
   Rupaimoole R, 2016, ONCOGENE, V35, P4312, DOI 10.1038/onc.2015.492
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Sanchez Saba JE, 2020, MEDICINA BUENOS AIRE, V80, P23
   Sang S, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3173547
   Sarkar S, 2010, MOL BIOL CELL, V21, P2138, DOI 10.1091/mbc.E10 01 0062
   Sasahira T, 2012, BRIT J CANCER, V107, P700, DOI 10.1038/bjc.2012.330
   Satterfield L, 2017, INT J CANCER, V141, P2062, DOI 10.1002/ijc.30909
   Schetter AJ, 2008, JAMA J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425
   Schmittgen TD, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh040
   Scott KL, 2011, CANCER CELL, V20, P92, DOI 10.1016/j.ccr.2011.05.025
   Shen J, 2013, NATURE, V497, P383, DOI 10.1038/nature12080
   Shida D, 2008, CURR DRUG TARGETS, V9, P662, DOI 10.2174/138945008785132402
   Sibley CR, 2012, NUCLEIC ACIDS RES, V40, P438, DOI 10.1093/nar/gkr722
   Siegel R. L., 2018, CA CANCER J CLIN, V68, P30, DOI [10.3322/caac.v69.110.3322/caac.21551, DOI 10.3322/CAAC.21442, 10.3322/caac.21442]
   Singh S, 2017, FEBS LETT, V591, P1371, DOI 10.1002/1873 3468.12655
   Soheilyfar S, 2018, J BUON, V23, P1290
   Stewart FW, 1938, AM J PATHOL, V14, P515
   Su CM, 2018, BIOCHEM PHARMACOL, V154, P234, DOI 10.1016/j.bcp.2018.05.001
   Sui JP, 2019, J CELL BIOCHEM, V120, P9631, DOI 10.1002/jcb.28241
   Sun H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0565 2
   Sun XJ, 2019, MOL CANCER THER, V18, P2021, DOI 10.1158/1535 7163.MCT 18 1020
   Takeda A, 2008, PLANT CELL PHYSIOL, V49, P493, DOI 10.1093/pcp/pcn043
   Tang CH, 2010, BIOCHEM PHARMACOL, V79, P209, DOI 10.1016/j.bcp.2009.08.006
   Tang DG, 2012, CELL RES, V22, P457, DOI 10.1038/cr.2012.13
   Tang JF, 2018, BONE, V114, P137, DOI 10.1016/j.bone.2018.06.010
   Tang XF, 2016, ONCOL REP, V35, P2963, DOI 10.3892/or.2016.4647
   Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299
   Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033
   Tokumaru S, 2008, CARCINOGENESIS, V29, P2073, DOI 10.1093/carcin/bgn187
   Traub F, 2016, EUR J CANCER, V59, P1, DOI 10.1016/j.ejca.2016.01.006
   Tsai CH, 2017, MOL ONCOL, V11, P1380, DOI 10.1002/1878 0261.12106
   Tsai CH, 2015, ONCOTARGET, V6, P258, DOI 10.18632/oncotarget.2724
   Tumminia A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122863
   Urdinez J, 2020, J BONE MINER RES, V35, P1077, DOI 10.1002/jbmr.3976
   Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c
   van Praag VM, 2018, SURG ONCOL, V27, P402, DOI 10.1016/j.suronc.2018.05.009
   Wang CQ, 2017, CANCER LETT, V385, P261, DOI 10.1016/j.canlet.2016.10.010
   Wang HT, 2015, ONCOL REP, V34, P1203, DOI 10.3892/or.2015.4085
   Wang JC, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1309 7
   Wang P, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935 019 1014 8
   Wang XL, 2015, ONCOTARGET, V6, P32737, DOI 10.18632/oncotarget.5355
   Wang XW, 2013, SCI REP UK, V3, DOI 10.1038/srep01942
   Weber Kristy L, 2002, Iowa Orthop J, V22, P75
   Wei Jun Qiang, 2012, Nan Fang Yi Ke Da Xue Xue Bao, V32, P291
   Weiner Scott D, 2004, Instr Course Lect, V53, P645
   Wojciechowska A, 2017, ADV CLIN EXP MED, V26, P865, DOI 10.17219/acem/62915
   Wu YF, 2017, BIOMED PHARMACOTHER, V96, P7, DOI 10.1016/j.biopha.2017.09.043
   Wy Z., 2014, INT J CLIN EXP PATHO, V7
   Xiao YY, 2015, J CELL MOL MED, V19, P2172, DOI 10.1111/jcmm.12597
   Xie XB, 2011, CLIN CANCER RES, V17, P5901, DOI 10.1158/1078 0432.CCR 11 0660
   Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038
   Yang WH, 2014, BBA GEN SUBJECTS, V1840, P3483, DOI 10.1016/j.bbagen.2014.09.012
   Ye CL, 2018, ONCOL LETT, V15, P4390, DOI 10.3892/ol.2018.7900
   Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803
   Yoshida A, 2018, ACTA MED OKAYAMA, V72, P165, DOI 10.18926/AMO/55857
   Yuan CW, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046 016 0294 2
   Zenali MJ, 2009, ANN CLIN LAB SCI, V39, P160
   Zhang GP, 2017, J CELL MOL MED, V21, P254, DOI 10.1111/jcmm.12961
   Zhang HP, 2017, ONCOL LETT, V13, P463, DOI 10.3892/ol.2016.5408
   Zhang P, 2017, CELL PHYSIOL BIOCHEM, V42, P242, DOI 10.1159/000477323
   Zhang S, 2018, ONCOTARGETS THER, V11, P7967, DOI 10.2147/OTT.S167771
   Zhang SX, 2018, CANCER BIOMARK, V21, P179, DOI 10.3233/CBM 170620
   Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007
   Zhou X, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171017
   Zhu XD, 2021, MED SCI MONITOR, V27, DOI 10.12659/MSM.929154
   Zoni E, 2015, CANCER RES, V75, P2326, DOI 10.1158/0008 5472.CAN 14 2155
NR 227
TC 8
Z9 8
U1 1
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD AUG
PY 2021
VL 149
AR 115968
DI 10.1016/j.bone.2021.115968
EA APR 2021
PG 20
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA TF0MX
UT WOS:000670402800009
PM 33892177
DA 2025 08 17
ER

PT J
AU Ahn, GY
   Kim, SE
   Yun, TH
   Choi, I
   Park, D
   Choi, SW
AF Ahn, Guk Young
   Kim, Sung Eun
   Yun, Tae Hoon
   Choi, Inseong
   Park, Daewon
   Choi, Sung Wook
TI Enhanced osteogenic differentiation of alendronate conjugated
   nanodiamonds for potential osteoporosis treatment
SO BIOMATERIALS RESEARCH
LA English
DT Article
DE Alendronate; Nanodiamond; Proliferation; Osteogenic differentiation
ID GENE EXPRESSION ANALYSIS; BONE MINERAL DENSITY; OSTEOBLAST
   DIFFERENTIATION; DRUG DELIVERY; STROMAL CELLS; PROLIFERATION;
   BISPHOSPHONATES; NANOPARTICLES; MATURATION; HYDROGEL
AB Background Alendronate (Alen) is promising material used for bone targeted drug delivery due to its high bone affinity and therapeutic effects on bone diseases. In addition, Alen can enhance the osteogenic differentiation of osteoblastic cell. Recently, nanodiamonds (NDs) with hardness, non toxicity, and excellent biocompatibility are employed as promising materials for carrier systems and osteogenic differentiation. Therefore, we prepared Alen conjugated NDs (Alen NDs) and evaluated their osteogenic differentiation performances. Methods Alen NDs were synthesized using DMTMM as a coupling reagent. Morphological change of Mouse calvaria derived preosteoblast (MC3T3 E1) treated with Alen NDs was observed using the confocal microscope. The osteogenic differentiation was confirmed by cell proliferation, alkaline phosphatase (ALP), calcium deposition, and real time polymerase chain reaction assay. Results Alen NDs were prepared to evaluate their effect on the proliferation and differentiation of osteoblastic MC3T3 E1 cells. The Alen NDs had a size of about 100 nm, and no cytotoxicity at less than 100 mu g/mL of concentration. The treatment of NDs and Alen NDs reduced the proliferation rate of MC3T3 E1 cells without cell death. Confocal microscopy images confirmed that the treatment of NDs and Alen NDs changed the cellular morphology from a fibroblastic shape to a cuboidal shape. Flow cytometry, alkaline phosphatase (ALP) activity, calcium deposition, and real time polymerase chain reaction (RT PCR) confirmed the higher differentiation of MC3T3 E1 cells treated by Alen NDs, compared to the groups treated by osteogenic medium and NDs. The higher concentration of Alen ND treated in MC3T3 E1 resulted in a higher differentiation level. Conclusions Alen NDs can be used as potential therapeutic agents for osteoporosis treatment by inducing osteogenic differentiation.
C1 [Ahn, Guk Young; Yun, Tae Hoon; Choi, Inseong; Choi, Sung Wook] Catholic Univ Korea, Dept Biotechnol, Biomed & Chem Engn, 43 Jibong Ro, Gyeonggi Do 14662, Bucheon Si, South Korea.
   [Kim, Sung Eun] Korea Univ, Dept Orthopaed Surg, Med Ctr, Guro Hosp, 80 Guro Dong, Seoul 152703, South Korea.
   [Kim, Sung Eun] Korea Univ, Rare Dis Inst, Med Ctr, Guro Hosp, 80 Guro Dong, Seoul 152703, South Korea.
   [Park, Daewon] Univ Colorado Denver, Dept Bioengn, Anschulz Med Campus,12800 E 19th Ave, Aurora, CO 80045 USA.
C3 Catholic University of Korea; Korea University; Korea University
   Medicine (KU Medicine); Korea University; Korea University Medicine (KU
   Medicine); University of Colorado System; University of Colorado
   Anschutz Medical Campus; Children's Hospital Colorado
RP Choi, SW (通讯作者)，Catholic Univ Korea, Dept Biotechnol, Biomed & Chem Engn, 43 Jibong Ro, Gyeonggi Do 14662, Bucheon Si, South Korea.
EM choisw@catholic.ac.kr
RI Kim, Miyoung/C 8316 2012
OI kim, sung eun/0000 0001 9445 2451; Choi, Sung Wook/0000 0002 5075 8798
FU Korea Medical Device Development Fund   Korea government (Ministry of
   Science and ICT) [202012D21 02]; Korea Medical Device Development Fund  
   Korea government (Ministry of Trade, Industry and Energy)
   [202012D21 02]; Korea Medical Device Development Fund   Korea government
   (Ministry of Health Welfare) [202012D21 02]; Korea Medical Device
   Development Fund   Korea government (Ministry of Food and Drug Safety)
   [202012D21 02]; Research Fund, 2021 of The Catholic University of Korea;
   National Research Foundation of Korea (NRF)   Korea government (MIST)
   [2021R1A2C1003865]
FX This work was supported by the Korea Medical Device Development Fund
   grant funded by the Korea government (the Ministry of Science and ICT,
   the Ministry of Trade, Industry and Energy, the Ministry of Health &
   Welfare, the Ministry of Food and Drug Safety) (Project Number:
   202012D21 02), the Research Fund, 2021 of The Catholic University of
   Korea, and the National Research Foundation of Korea (NRF) grant funded
   by the Korea government (MIST) (No. 2021R1A2C1003865).
CR Asafo Adjei TA, 2016, CURR OSTEOPOROS REP, V14, P226, DOI 10.1007/s11914 016 0321 4
   Bahrambeigi Vahid, 2012, Adv Biomed Res, V1, P8, DOI 10.4103/2277 9175.94431
   Boncel S, 2009, NUCLEOS NUCLEOT NUCL, V28, P103, DOI 10.1080/15257770902736467
   Bongiorno T, 2014, J BIOMECH, V47, P2197, DOI 10.1016/j.jbiomech.2013.11.017
   Cha Sung Ho, 2017, Biomater Res, V21, P1
   Chen CS, 2020, SURF COAT TECH, V399, DOI 10.1016/j.surfcoat.2020.126125
   Chiba K, 2021, BONE, V144, DOI 10.1016/j.bone.2020.115770
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   D'Este M, 2014, CARBOHYD POLYM, V108, P239, DOI 10.1016/j.carbpol.2014.02.070
   Fukumoto Seiji, 2017, F1000Res, V6, P625, DOI 10.12688/f1000research.10682.1
   Gao XL, 2021, APPL MATER TODAY, V22, DOI 10.1016/j.apmt.2020.100922
   GERTZ BJ, 1993, OSTEOPOROSIS INT, V3, pS13
   Giner M, 2011, EUR J PHARMACOL, V650, P682, DOI 10.1016/j.ejphar.2010.10.058
   Hong D, 2010, EXP CELL RES, V316, P2291, DOI 10.1016/j.yexcr.2010.05.011
   Huang Y, 2020, J MATER CHEM B, V8, P9794, DOI 10.1039/d0tb01948h
   Hwang SJ, 2016, MACROMOL RES, V24, P623, DOI 10.1007/s13233 016 4094 5
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Kim HK, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.40
   Kim HK, 2009, CLIN ORTHOP RELAT R, V467, P3121, DOI 10.1007/s11999 008 0409 y
   Kim SE, 2015, J TISSUE ENG REGEN M, V9, pE219, DOI 10.1002/term.1668
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Li DW, 2020, BIOMATER SCI UK, V8, P3138, DOI 10.1039/d0bm00376j
   Liu DD, 2010, ACS NANO, V4, P2185, DOI 10.1021/nn901479w
   Manzano Moreno FJ, 2015, J CRANIO MAXILL SURG, V43, P396, DOI 10.1016/j.jcms.2014.12.008
   Marini F, 2014, BEST PRACT RES CL EN, V28, P783, DOI 10.1016/j.beem.2014.07.004
   Martins CA, 2015, J ENDODONT, V41, P45, DOI 10.1016/j.joen.2014.07.010
   Masaki H, 2020, J BONE MINER METAB, V38, P405, DOI 10.1007/s00774 019 01073 1
   Mochalin VN, 2012, NAT NANOTECHNOL, V7, P11, DOI [10.1038/nnano.2011.209, 10.1038/NNANO.2011.209]
   Mora Raimundo P, 2017, AIMS BIOENG, V4, P259, DOI 10.3934/bioeng.2017.2.259
   Nakata J, 2020, BIOCHEM BIOPH RES CO, V526, P547, DOI 10.1016/j.bbrc.2020.03.033
   Pan L, 2014, TOXICOL LETT, V225, P34, DOI 10.1016/j.toxlet.2013.11.029
   Qi SD, 2020, ANALYST, V145, P3871, DOI 10.1039/d0an00052c
   Qiao XY, 2016, SCI REP UK, V6, DOI 10.1038/srep18732
   Ryu TK, 2016, J CONTROL RELEASE, V232, P152, DOI 10.1016/j.jconrel.2016.04.025
   Sun HL, 2006, BIOMATERIALS, V27, P5651, DOI 10.1016/j.biomaterials.2006.07.027
   Techaniyom P, 2020, APPL SURF SCI, V526, DOI 10.1016/j.apsusc.2020.146646
   Tu Kristie N, 2018, P T, V43, P92
   Valenti MT, 2008, BONE, V43, P1084, DOI 10.1016/j.bone.2008.07.252
   Wang XL, 2015, CURR PHARM DESIGN, V21, P1575, DOI 10.2174/1381612821666150115152841
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Xie GH, 2018, DESALINATION, V447, P147, DOI 10.1016/j.desal.2018.09.014
   Xu X, 2020, AM J TRANSL RES, V12, P4251
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   Zhang JY, 2012, J ORTHOP RES, V30, P47, DOI 10.1002/jor.21485
   Zhang QW, 2011, BIOMATERIALS, V32, P87, DOI 10.1016/j.biomaterials.2010.08.090
   Zhang Y, 2011, J BONE MINER RES, V26, P604, DOI 10.1002/jbmr.225
NR 47
TC 15
Z9 15
U1 2
U2 39
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1226 4601
EI 2055 7124
J9 BIOMATER RES
JI Biomater. Res.
PD SEP 23
PY 2021
VL 25
IS 1
AR 28
DI 10.1186/s40824 021 00231 9
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA UU2TL
UT WOS:000698653600001
PM 34556181
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Xi, JC
   Li, QG
   Luo, XB
   Li, JL
   Guo, LX
   Xue, HB
   Wu, GS
AF Xi, Jiancheng
   Li, Qinggui
   Luo, Xiaobo
   Li, Jinlong
   Guo, Lixin
   Xue, Haibin
   Wu, Guangsen
TI Epigallocatechin 3 gallate protects against secondary osteoporosis in a
   mouse model via the Wnt/β catenin signaling pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE epigallocatechin 3 gallate; secondary osteoporosis; Wnt; beta catenin
ID OSTEOGENIC DIFFERENTIATION; IDIOPATHIC OSTEOPOROSIS; POSTMENOPAUSAL
   WOMEN; STROMAL CELLS; BONE DENSITY; DISEASE; TRANSCRIPTION; OSTEOBLASTS;
   INHIBITION; INDUCTION
AB Epigallocatechin 3 gallate (EGCG) is a polyphenolic compound extracted and isolated from green tea, which has a variety of important biological activities in vitro and in vivo, including anti tumor, anti oxidation, anti inflammation and lowering blood pressure. The aim of the present study was to investigate the protective effect of EGCG against secondary osteoporosis in a mouse model via the Wnt/beta catenin signaling pathway. Reverse transcription quantitative polymerase chain reaction (RT qPCR) and western blotting were used to analyze runt related transcription factor 2 and osterix mRNA expression, and the protein expression of cyclin D1, Wnt and beta catenin, and suppressed peroxisome proliferator activated receptor protein expression. The protective effect of EGCG against secondary osteoporosis was examined and its potential mechanism was analyzed. Treatment with EGCG significantly decreased serum calcium, urinary calcium, body weight and body fat, and increased leptin levels in mice with secondary osteoporosis. In addition, EGCG treatment significantly inhibited the structure score of articular cartilage and cancellous bone in proximal tibia metaphysis in mice with secondary osteoporosis. Treatment also significantly decreased alkaline phosphatase activity, runt related transcription factor 2 and osterix mRNA expression. EGCG also significantly induced the protein expression of cyclin D1, Wnt and beta catenin, and suppressed peroxisome proliferator activated receptor gamma protein expression in mice with secondary osteoporosis. Taken together, these results suggest that EGCG may be a possible new drug in clinical settings.
C1 [Xi, Jiancheng; Luo, Xiaobo; Li, Jinlong; Guo, Lixin; Xue, Haibin; Wu, Guangsen] Peoples Liberat Army, Hosp 309, Dept Minimally Invas Spinal Surg, Beijing 100091, Peoples R China.
   [Li, Qinggui] Hebei Univ, Affiliated Hosp 4, Dept Orthoped, 212 Yuhua East Rd, Baoding 071000, Hebei, Peoples R China.
C3 Hebei University
RP Li, QG (通讯作者)，Hebei Univ, Affiliated Hosp 4, Dept Orthoped, 212 Yuhua East Rd, Baoding 071000, Hebei, Peoples R China.
EM xijcjcbj@163.com
CR Cohen A, 2015, J CLIN ENDOCR METAB, V100, P4208, DOI 10.1210/jc.2015 2829
   Colaianni G, 2014, WORLD J ORTHOP, V5, P242, DOI 10.5312/wjo.v5.i3.242
   de Oliveira MR, 2016, PHARMACOL RES, V104, P70, DOI 10.1016/j.phrs.2015.12.027
   Duque G, 2013, J BONE MINER RES, V28, P639, DOI 10.1002/jbmr.1782
   Feagan BG, 2016, NEW ENGL J MED, V375, P1946, DOI 10.1056/NEJMoa1602773
   Frediani B, 2013, CLIN DRUG INVEST, V33, P193, DOI 10.1007/s40261 013 0062 4
   Fujita M, 2002, BIOCHEM BIOPH RES CO, V299, P222, DOI 10.1016/S0006 291X(02)02640 2
   Ge CX, 2016, J CELL PHYSIOL, V231, P587, DOI 10.1002/jcp.25102
   Ge WS, 2011, STEM CELLS, V29, P1112, DOI 10.1002/stem.663
   Halse J, 2014, J CLIN ENDOCR METAB, V99, pE2207, DOI 10.1210/jc.2013 4009
   Hampson G, 2013, BONE, V56, P42, DOI 10.1016/j.bone.2013.05.010
   Hasegawa T, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471 213X 8 71
   Hosking Sarah M, 2015, BMC Res Notes, V8, P33, DOI 10.1186/s13104 015 0985 3
   Jiang Y, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/4927035
   Lee H, 2013, J NUTR BIOCHEM, V24, P1232, DOI 10.1016/j.jnutbio.2012.09.007
   Leslie WD, 2009, INFLAMM BOWEL DIS, V15, P39, DOI 10.1002/ibd.20541
   Li XY, 2017, CLIN CHIM ACTA, V471, P177, DOI 10.1016/j.cca.2017.06.007
   Liou SF, 2015, J CELL PHYSIOL, V230, P2038, DOI 10.1002/jcp.24904
   Liu HF, 2015, TRIALS, V16, DOI 10.1186/s13063 015 0780 4
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marupanthorn K, 2017, INT J MOL MED, V39, P654, DOI 10.3892/ijmm.2017.2872
   Meng JR, 2016, STEM CELL REP, V6, P633, DOI 10.1016/j.stemcr.2016.03.010
   Nishiyama KK, 2014, J CLIN ENDOCR METAB, V99, P2418, DOI 10.1210/jc.2014 1041
   Pae M, 2013, FOOD FUNCT, V4, P1287, DOI 10.1039/c3fo60076a
   Peter B, 2017, EUR BIOPHYS J BIOPHY, V46, P1, DOI 10.1007/s00249 016 1141 2
   Renaud J, 2015, REJUV RES, V18, P257, DOI 10.1089/rej.2014.1639
   Wang DW, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7532798
   Wang F, 2016, J AGR FOOD CHEM, V64, P2875, DOI 10.1021/acs.jafc.5b06132
   Xu S, 2016, J BONE MINER RES, V31, P1320, DOI 10.1002/jbmr.2800
   Yan ZX, 2018, EXP THER MED, V15, P2589, DOI 10.3892/etm.2018.5723
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Zhang JF, 2010, MOL CELL ENDOCRINOL, V314, P70, DOI 10.1016/j.mce.2009.08.012
   Zheng XF, 2015, EXP THER MED, V10, P541, DOI 10.3892/etm.2015.2553
NR 33
TC 24
Z9 24
U1 1
U2 36
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD NOV
PY 2018
VL 18
IS 5
BP 4555
EP 4562
DI 10.3892/mmr.2018.9437
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GV9PW
UT WOS:000446493000043
PM 30221714
OA Bronze
DA 2025 08 17
ER

PT J
AU Liu, WD
   Mao, L
   Ji, F
   Chen, FL
   Hao, YD
   Liu, G
AF Liu, Weidong
   Mao, Li
   Ji, Feng
   Chen, Fengli
   Hao, Yuedong
   Liu, Gang
TI Targeted activation of AMPK by GSK621 ameliorates
   H2O2 induced damages in osteoblasts
SO ONCOTARGET
LA English
DT Article
DE osteonecrosis; osteoblasts; AMPK; GSK621; oxidative stress
ID SMALL MOLECULE ACTIVATOR; PROTEIN KINASE; INDUCED APOPTOSIS;
   CELL GROWTH; COMPOUND 13; MALIGNANT MELANOMA; HYDROGEN PEROXIDE;
   OXIDATIVE STRESS; UNITED STATES; DEXAMETHASONE
AB GSK621 is a novel AMP activated protein kinase (AMPK) activator. This study tested its potential cytoprotective effect in hydrogen peroxide (H2O2) treated osteoblasts. In cultured MC3T3 E1 osteoblastic cells and primary murine osteoblasts, GSK621 significantly attenuated H2O2 induced cell death and apoptosis. AMPK activation was required for GSK621 induced osteoblast cytoprotection. Inhibition of AMPK, by AMPK alpha 1 T172A mutation or shRNA silence, almost completely blocked GSK621 induced osteoblast cytoprotection. Reversely, introduction of a constitutively active AMPK alpha 1 (T172D) alleviated H2O2 injuries in MC3T3 E1 cells. Further, GSK621 increased nicotinamide adenine dinucleotide phosphate (NADPH) content in osteoblasts to inhibit H2O2 induced reactive oxygen species (ROS) production. Meanwhile, GSK621 activated cytoprotective autophagy in the osteoblasts. On the other hand, pharmacological inhibition of autophagy alleviated GSK621 mediated osteoblast cytoprotection against H2O2. These results suggest that targeted activation of AMPK by GSK621 ameliorates H2O2 induced osteoblast cell injuries.
C1 [Liu, Weidong; Ji, Feng; Hao, Yuedong; Liu, Gang] Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Orthoped, Huaian, Peoples R China.
   [Mao, Li] Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Endocrinol, Huaian, Peoples R China.
   [Chen, Fengli] Nanjing Med Univ, Huaian Peoples Hosp 1, Clin Lab, Huaian, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University
RP Ji, F (通讯作者)，Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Orthoped, Huaian, Peoples R China.
EM huaiaifengjidr@163.com
FU National Natural Science Foundation
FX This work is supported by the National Natural Science Foundation.
CR [Anonymous], BIOCH BIOPHYS RES CO
   [Anonymous], AM J PHYSL HEART CIR
   [Anonymous], BIOCH BIOPHYS RES CO
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Carling D, 2012, BIOCHEM J, V445, P11, DOI 10.1042/BJ20120546
   Chen LZ, 2016, BIOCHEM BIOPH RES CO, V480, P515, DOI 10.1016/j.bbrc.2016.10.040
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Fan JB, 2016, ONCOTARGET, V7, P70613, DOI 10.18632/oncotarget.12138
   Fan JB, 2015, MOL CELL BIOCHEM, V398, P105, DOI 10.1007/s11010 014 2210 4
   Faubert B, 2015, CANCER LETT, V356, P165, DOI 10.1016/j.canlet.2014.01.018
   Guo SG, 2016, BIOCHEM BIOPH RES CO, V471, P545, DOI 10.1016/j.bbrc.2016.02.036
   Guo SG, 2016, BIOCHEM BIOPH RES CO, V469, P281, DOI 10.1016/j.bbrc.2015.11.104
   Hardie DG, 2012, CHEM BIOL, V19, P1222, DOI 10.1016/j.chembiol.2012.08.019
   Herbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041
   Himburg HA, 2010, NAT MED, V16, P475, DOI 10.1038/nm.2119
   Hu XQ, 2016, TUMOR BIOL, V37, P1071, DOI 10.1007/s13277 015 3854 8
   Huo HZ, 2014, BIOCHEM BIOPH RES CO, V443, P406, DOI 10.1016/j.bbrc.2013.11.099
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066
   Ji F, 2015, BIOCHEM BIOPH RES CO, V458, P568, DOI 10.1016/j.bbrc.2015.02.007
   Jiang H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161017
   Kim IY, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00175
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306
   Liang D, 2013, CELL SIGNAL, V25, P1126, DOI 10.1016/j.cellsig.2013.02.003
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Rigel DS, 1996, J AM ACAD DERMATOL, V34, P839, DOI 10.1016/S0190 9622(96)90041 9
   SALOPEK TG, 1995, DERMATOL SURG, V21, P301, DOI 10.1111/j.1524 4725.1995.tb00177.x
   She C, 2014, CELL SIGNAL, V26, P1, DOI 10.1016/j.cellsig.2013.08.046
   Souttou B, 2001, J CELL PHYSIOL, V187, P59, DOI 10.1002/1097 4652(2001)9999:9999<00::AID JCP1051>3.0.CO;2 F
   Sujobert P, 2015, CELL REP, V11, P1446, DOI 10.1016/j.celrep.2015.04.063
   Talasila KM, 2013, ACTA NEUROPATHOL, V125, P683, DOI 10.1007/s00401 013 1101 1
   Tare RS, 2002, BIOCHEM BIOPH RES CO, V298, P324, DOI 10.1016/S0006 291X(02)02456 7
   Wang B, 2013, BIOCHEM BIOPH RES CO, V437, P1, DOI 10.1016/j.bbrc.2013.05.090
   Wang SB, 2012, CLIN SCI, V122, P555, DOI 10.1042/CS20110625
   Zhao HY, 2015, BIOCHEM BIOPH RES CO, V463, P510, DOI 10.1016/j.bbrc.2015.05.059
   Zhao S, 2016, BIOCHEM BIOPH RES CO, V481, P212, DOI 10.1016/j.bbrc.2016.10.104
   Zheng B, 2015, CANCER LETT, V357, P468, DOI 10.1016/j.canlet.2014.11.012
   Zhu YL, 2014, INT J MOL SCI, V15, P11190, DOI 10.3390/ijms150611190
NR 39
TC 38
Z9 43
U1 0
U2 18
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 7
PY 2017
VL 8
IS 6
BP 10543
EP 10552
DI 10.18632/oncotarget.14454
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA EK8NX
UT WOS:000394181800132
PM 28060740
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Sally, ML
   Richelle, SG
   Aina, H
   Carla, T
   Helena, M
   Sarah, EH
   Philip, JT
   Mark, N
   Gregory, FS
   Cecilia, MP
   Steven, EM
AF Sally, Lansley M.
   Richelle, Searles G.
   Aina, Hoi
   Carla, Thomas
   Helena, Moneta
   Sarah, Herrick E.
   Philip, Thompson J.
   Mark, Newman
   Gregory, Sterrett F.
   Cecilia, Prele M.
   Steven, Mutsaers E.
TI Mesothelial cell differentiation into osteoblast  and adipocyte like
   cells
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE mesothelial cell; malignant mesothelioma; progenitor cell; osteoblast;
   bone; adipocyte; cell differentiation; epithelial to mesenchymal
   transition; tissue engineering
ID CARTILAGINOUS DIFFERENTIATION; MALIGNANT MESOTHELIOMA; MESENCHYMAL
   TRANSITION; PERITONEAL DIALYSIS; AVIAN EMBRYOS; STROMAL CELLS; IN VITRO;
   BONE; TRANSFORMATION; RAT
AB Serosal pathologies including malignant mesothelioma (MM) can show features of osseous and/or cartilaginous differentiation although the mechanism for its formation is unknown. Mesothelial cells have the capacity to differentiate into cells with myofibroblast, smooth muscle and endothelial cell characteristics. Whether they can differentiate into other cell types is unclear. This study tests the hypothesis that mesothelial cells can differentiate into cell lineages of the embryonic mesoderm including osteoblasts and adipocytes. To examine this, a functional assay of bone formation and an adipogenic assay were performed in vitro with primary rat and human mesothelial cells maintained in osteogenic or adipogenic medium (AM) for 0 26 days. Mesothelial cells expressed increasing levels of alkaline phosphatase, an early marker of the osteoblast phenotype, and formed mineralized bone like nodules. Mesothelial cells also accumulated lipid indicative of a mature adipocyte phenotype when cultured in AM. All cells expressed several key osteoblast and adipocyte markers, including osteoblast specific runt related transcription factor 2, and demonstrated changes in mRNA expression consistent with epithelial to mesenchymal transition. In conclusion, these studies confirm that mesothelial cells have the capacity to differentiate into osteoblast and adipocyte like cells, providing definitive evidence of their multipotential nature. These data strongly support mesothelial cell differentiation as the potential source of different tissue types in MM tumours and other serosal pathologies, and add support for the use of mesothelial cells in regenerative therapies.
C1 [Sally, Lansley M.; Richelle, Searles G.; Aina, Hoi; Carla, Thomas; Helena, Moneta; Philip, Thompson J.; Cecilia, Prele M.; Steven, Mutsaers E.] Univ Western Australia, Lung Inst Western Australia, Nedlands, WA 6009, Australia.
   [Sally, Lansley M.; Richelle, Searles G.; Aina, Hoi; Carla, Thomas; Helena, Moneta; Philip, Thompson J.; Cecilia, Prele M.; Steven, Mutsaers E.] Univ Western Australia, Ctr Asthma Allergy & Resp Res, Nedlands, WA 6009, Australia.
   [Helena, Moneta] Murdoch Univ, Div Vet & Biomed Sci, Murdoch, WA 6150, Australia.
   [Sarah, Herrick E.] Univ Manchester, Fac Med & Human Sci, Sch Med, Manchester, Lancs, England.
   [Mark, Newman] Sir Charles Gairdner Hosp, Dept Cardiothorac Surg, Perth, WA, Australia.
   [Gregory, Sterrett F.] Univ Western Australia, Dept Pathol, Nedlands, WA 6009, Australia.
C3 University of Western Australia; University of Western Australia;
   Murdoch University; University of Manchester; Sir Charles Gairdner
   Hospital; University of Western Australia; University of Western
   Australia
RP Steven, EM (通讯作者)，Sir Charles Gairdner Hosp, Lung Inst Western Australia, Ground Floor E Block, Perth, WA 6009, Australia.
EM mutsaers@liwa.uwa.edu.au
RI Prele, Cecilia/H 5664 2014; Herrick, Sarah/A 3121 2015; herrick,
   sarah/A 3121 2015
OI Mutsaers, Steven/0000 0002 2615 8338; Herrick,
   Sarah/0000 0002 9085 5664; 
FU Heart Foundation; National Health and Medical Research Council of
   Australia [353554]; Lung Institute of Western Australia
FX We thank Mr. Pierre Filion (PathWest Laboratory Medicine WA) for help
   with the TEM, Dr. Kathy Heel, Centre for Microscopy, Characterization
   and Analysis, University of Western Australia, for assistance with cell
   sorting and Dr. Stuart Hodgetts, University of Western Australia for
   provision of the CD90 antibody. This work was supported by grants from
   the Heart Foundation and National Health and Medical Research Council
   (grant no. 353554) of Australia and S. M. L. was supported by an
   Australian Commonwealth Postgraduate Award (and Lung Institute of
   Western Australia top up award).
CR Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<73::AID JCB11>3.0.CO;2 L
   Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874
   Cheng SL, 1998, J BONE MINER RES, V13, P633, DOI 10.1359/jbmr.1998.13.4.633
   Decologne N, 2007, J IMMUNOL, V179, P6043, DOI 10.4049/jimmunol.179.9.6043
   Demirag F, 2007, LUNG CANCER, V57, P233, DOI 10.1016/j.lungcan.2007.01.033
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   DONNA A, 1981, HISTOPATHOLOGY, V5, P31, DOI 10.1111/j.1365 2559.1981.tb01764.x
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fadare O, 2002, MODERN PATHOL, V15, P777, DOI 10.1097/01.MP.0000017565.19341.63
   Foley Comer AJ, 2002, J CELL SCI, V115, P1383
   Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783
   HANSEN O, 1983, PATHOL RES PRACT, V176, P125, DOI 10.1016/S0344 0338(83)80004 1
   Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972
   Hay ED, 1995, ACTA ANAT, V154, P8
   Herrick SE, 2004, INT J BIOCHEM CELL B, V36, P621, DOI 10.1016/j.biocel.2003.11.002
   KATOH J, 1994, FOLIA HISTOCHEM CYTO, V32, P235
   Kawaguchi M, 2007, DEV DYNAM, V236, P2973, DOI 10.1002/dvdy.21334
   Kiyozuka Y, 1999, DIGEST DIS SCI, V44, P1626, DOI 10.1023/A:1026627413715
   Klebe S, 2008, MODERN PATHOL, V21, P1084, DOI 10.1038/modpathol.2008.125
   Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634
   Margetts PJ, 2005, J AM SOC NEPHROL, V16, P425, DOI 10.1681/ASN.2004060436
   Muñoz Chápuli R, 1999, DIFFERENTIATION, V64, P133, DOI 10.1046/j.1432 0436.1999.6430133.x
   Mutsaers SE, 2002, RESPIROLOGY, V7, P171, DOI 10.1046/j.1440 1843.2002.00404.x
   Nakazato Y, 2002, NEPHROL DIAL TRANSPL, V17, P1293, DOI 10.1093/ndt/17.7.1293
   Nasreen N, 2009, AM J PHYSIOL LUNG C, V297, pL115, DOI 10.1152/ajplung.90587.2008
   Pérez Pomares JM, 2004, DEV DYNAM, V229, P465, DOI 10.1002/dvdy.10455
   Pérez Pomares JM, 2002, INT J DEV BIOL, V46, P1005
   RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069
   Rigby RJ, 1998, NEPHROL DIAL TRANSPL, V13, P154, DOI 10.1093/ndt/13.1.154
   RITTINGHAUSEN S, 1992, EXP TOXICOL PATHOL, V44, P55, DOI 10.1016/S0940 2993(11)80138 7
   Rodgers UR, 2009, MATRIX BIOL, V28, P263, DOI 10.1016/j.matbio.2009.04.006
   Rosen ED, 2000, GENE DEV, V14, P1293
   Sherwood AL, 2008, CELL PROLIFERAT, V41, P894, DOI 10.1111/j.1365 2184.2008.00560.x
   Simsir A, 1999, DIAGN CYTOPATHOL, V20, P125, DOI 10.1002/(SICI)1097 0339(199903)20:3<125::AID DC3>3.0.CO;2 V
   Stewart K, 1999, J BONE MINER RES, V14, P1345, DOI 10.1359/jbmr.1999.14.8.1345
   Tanjore H, 2009, AM J RESP CRIT CARE, V180, P657, DOI 10.1164/rccm.200903 0322OC
   Wada AM, 2003, CIRC RES, V92, P525, DOI 10.1161/01.RES.0000060484.11032.0B
   Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378 1119(98)00227 3
   Yañez Mó M, 2003, NEW ENGL J MED, V348, P403, DOI 10.1056/NEJMoa020809
   Yang AH, 2003, KIDNEY INT, V63, P1530, DOI 10.1046/j.1523 1755.2003.00861.x
   YANNOPOULOS K, 1992, AM J GASTROENTEROL, V87, P230
   YOUSEM SA, 1987, ARCH PATHOL LAB MED, V111, P62
NR 43
TC 56
Z9 63
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD OCT
PY 2011
VL 15
IS 10
BP 2095
EP 2105
DI 10.1111/j.1582 4934.2010.01212.x
PG 11
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 824RD
UT WOS:000295218800008
PM 21070599
OA Green Published
DA 2025 08 17
ER

PT J
AU Kode, JA
   Mukherjee, S
   Joglekar, MV
   Hardikar, AA
AF Kode, Jyoti A.
   Mukherjee, Shayanti
   Joglekar, Mugdha V.
   Hardikar, Anandwardhan A.
TI Mesenchymal stem cells: immunobiology and role in immunomodulation and
   tissue regeneration
SO CYTOTHERAPY
LA English
DT Article; Proceedings Paper
CT 9th Indo/United States Cytometry Workshop   Application of Stem Cell
   Biology and Regenerative Medicine
CY JUL 21 25, 2008
CL Manipal Inst Regenerat Med & Natl Ctr Biol Sci, Bangalore, INDIA
HO Manipal Inst Regenerat Med & Natl Ctr Biol Sci
DE Cell therapy; immunobiology; immunomodulation; mesenchymal stem cells;
   tissue regeneration
ID MARROW STROMAL CELLS; VERSUS HOST DISEASE; BONE MORPHOGENETIC PROTEINS;
   ENDOTHELIAL GROWTH FACTOR; TOLL LIKE RECEPTORS; IN VITRO; PROGENITOR
   CELLS; MYOCARDIAL INFARCTION; COSTIMULATORY PATHWAY; THERAPEUTIC
   STRATEGY
AB Mesenchymal stem cells ( MSC) are multipotent cells that differentiate into osteoblasts, myocytes, chondrocytes and adipocytes as well as insulin producing cells. The mechanism underlying their in vivo differentiation is not clear and is thought to be caused by spontaneous cell fusion or factors present in the microenvironment. However, their ease of isolation, high 'ex vivo' expansion potential and ability to differentiate into multiple lineages make them attractive tools for potential use in cell therapy. MSC have been isolated from several tissues, including bone/bone marrow, fat, Wharton's jelly, umbilical cord blood, placenta and pancreas. The 'immunosuppressive' property of human MSC makes them an important candidate for cellular therapy in allogeneic settings. Use of allogeneic MSC for repair of large defects may be an alternative to autologous and allogeneic tissue grafting procedures. An allogeneic approach would enable MSC to be isolated from any donor, expanded and cryopreserved, providing a readily available source of progenitors for cell replacement therapy.
C1 [Kode, Jyoti A.; Mukherjee, Shayanti] Tata Mem Hosp, Chiplunkar Lab, ACTREC, Kharghar 410210, Navi Mumbai, India.
   [Joglekar, Mugdha V.; Hardikar, Anandwardhan A.] Natl Ctr Cell Sci, Stem Cells & Diabet Sect, Lab 12, Pune, Maharashtra, India.
C3 Tata Memorial Centre (TMC); Tata Memorial Hospital; Advance Centre for
   Treatment, Research & Education in Cancer (ACTREC); Department of
   Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)
RP Kode, JA (通讯作者)，Tata Mem Hosp, Chiplunkar Lab, ACTREC, Kharghar 410210, Navi Mumbai, India.
EM jkode@actrec.gov.in
RI Hardikar, Anandwardhan/ACF 7730 2022; Kode, Jyoti/C 9757 2017; Joglekar,
   Mugdha/AFP 0659 2022
OI Kode, Jyoti Anand/0000 0001 6907 2449; Joglekar,
   Mugdha/0000 0001 5346 2266; Mukherjee, Shayanti/0000 0001 9995 002X; 
CR Abarrategi A, 2008, TISSUE ENG PT A, V14, P1305, DOI 10.1089/ten.tea.2007.0229
   Abdi R, 2008, DIABETES, V57, P1759, DOI 10.2337/db08 0180
   Alhadlaq A, 2004, STEM CELLS DEV, V13, P436, DOI 10.1089/scd.2004.13.436
   Arinzeh TL, 2003, J BONE JOINT SURG AM, V85A, P1927, DOI 10.2106/00004623 200310000 00010
   Beyer Nardi N, 2006, HANDB EXP PHARM, V174, P249
   Bochkov NP, 2007, B EXP BIOL MED+, V143, P122, DOI 10.1007/s10517 007 0031 0
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Conget PA, 1999, J CELL PHYSIOL, V181, P67, DOI 10.1002/(SICI)1097 4652(199910)181:1<67::AID JCP7>3.0.CO;2 C
   Devine SM, 2002, J CELL BIOCHEM, P73, DOI 10.1002/jcb.10046
   Fan HB, 2006, BIOMATERIALS, V27, P4573, DOI 10.1016/j.biomaterials.2006.04.013
   Fang BJ, 2004, TRANSPLANTATION, V78, P83, DOI 10.1097/01.TP.0000128326.95294.14
   FRIEDENSTEIN AJ, 1974, TRANSPLANTATION, V17, P331, DOI 10.1097/00007890 197404000 00001
   Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856
   Grinnemo KH, 2004, J THORAC CARDIOV SUR, V127, P1293, DOI 10.1016/j.jtcvs.2003.07.037
   HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756 3282(92)90364 3
   Haynesworth SE, 1996, J CELL PHYSIOL, V166, P585, DOI 10.1002/(SICI)1097 4652(199603)166:3<585::AID JCP13>3.0.CO;2 6
   Herrera MB, 2004, INT J MOL MED, V14, P1035
   Honczarenko M, 2006, STEM CELLS, V24, P1030, DOI 10.1634/stemcells.2005 0319
   Hosseinkhani H, 2006, BIOMATERIALS, V27, P5836, DOI 10.1016/j.biomaterials.2006.08.003
   Hurst DR, 2007, NAT MED, V13, P1289, DOI 10.1038/nm1107 1289
   ILIC D, 2008, REGEN MED, P257
   Iwamoto S, 2007, J CLIN INVEST, V117, P1049, DOI 10.1172/JCI30235
   Jacobsohn DA, 2002, EXPERT OPIN INV DRUG, V11, P1271, DOI 10.1517/13543784.11.9.1271
   Jacobsohn DA, 2002, DRUGS, V62, P879, DOI 10.2165/00003495 200262060 00002
   Jo JI, 2007, TISSUE ENG, V13, P313, DOI 10.1089/ten.2006.0133
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Keilhoff G, 2006, TISSUE ENG, V12, P1451, DOI 10.1089/ten.2006.12.1451
   Kim DH, 2005, CYTOKINE, V31, P119, DOI 10.1016/j.cyto.2005.04.004
   Kim MS, 2005, STEM CELLS, V23, P113, DOI 10.1634/stemcells.2004 0110
   Kirker Head CA, 2000, ADV DRUG DELIVER REV, V43, P65, DOI 10.1016/S0169 409X(00)00078 8
   Klyushnenkova E, 2005, J BIOMED SCI, V12, P47, DOI 10.1007/s11373 004 8183 7
   Koç ON, 2002, BONE MARROW TRANSPL, V30, P215, DOI 10.1038/sj.bmt.1703650
   Kraus KH, 2006, VET SURG, V35, P232, DOI 10.1111/j.1532 950X.2006.00142.x
   Kurozumi K, 2005, MOL THER, V11, P96, DOI 10.1016/j.ymthe.2004.09.020
   Kyriakou CA, 2006, J GENE MED, V8, P253, DOI 10.1002/jgm.840
   Lama VN, 2007, J CLIN INVEST, V117, P989, DOI 10.1172/JCI29713
   Le Blanc K, 2005, CYTOTHERAPY, V7, P36, DOI 10.1080/14653240510018118
   Le Blanc K, 2003, CYTOTHERAPY, V5, P485, DOI 10.1080/14653240310003611
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Le Blanc K, 2006, CURR OPIN IMMUNOL, V18, P586, DOI 10.1016/j.coi.2006.07.004
   Lee RH, 2006, P NATL ACAD SCI USA, V103, P17438, DOI 10.1073/pnas.0608249103
   Li A, 2006, GENE THER, V13, P1178, DOI 10.1038/sj.gt.3302741
   Li XK, 2007, COLLOID SURFACE B, V57, P198, DOI 10.1016/j.colsurfb.2007.02.010
   Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304 3940(01)02384 9
   Liotta F, 2008, STEM CELLS, V26, P279, DOI 10.1634/stemcells.2007 0454
   Liu B, 2008, J MATER SCI MATER M, V19, P1127, DOI 10.1007/s10856 007 3224 1
   Lu L, 1996, CRIT REV ONCOL HEMAT, V22, P61, DOI 10.1016/1040 8428(96)88370 3
   Mishra PJ, 2009, CANCER RES, V69, P1255, DOI 10.1158/0008 5472.CAN 08 3562
   Morishita T, 2006, ARTIF ORGANS, V30, P115, DOI 10.1111/j.1525 1594.2006.00190.x
   Moviglia GA, 2006, CYTOTHERAPY, V8, P202, DOI 10.1080/14653240600736048
   NASEF A, 2007, LIBYAN J MED    0907
   Nauta AJ, 2006, BLOOD, V108, P2114, DOI 10.1182/blood 2005 11 011650
   Noiseux N, 2006, MOL THER, V14, P840, DOI 10.1016/j.ymthe.2006.05.016
   Ouyang HW, 2003, TISSUE ENG, V9, P431, DOI 10.1089/107632703322066615
   Pevsner Fischer M, 2007, BLOOD, V109, P1422, DOI 10.1182/blood 2006 06 028704
   Poh KK, 2007, INT J CARDIOL, V117, P360, DOI 10.1016/j.ijcard.2006.04.092
   Ramasamy R, 2007, LEUKEMIA, V21, P304, DOI 10.1038/sj.leu.2404489
   Reiser J, 2005, EXPERT OPIN BIOL TH, V5, P1571, DOI 10.1517/14712598.5.12.1571
   Ren C, 2008, GENE THER, V15, P1446, DOI 10.1038/gt.2008.101
   Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014
   Ries C, 2007, BLOOD, V109, P4055, DOI 10.1182/blood 2006 10 051060
   Sato K, 2007, BLOOD, V109, P228, DOI 10.1182/blood 2006 02 002246
   Seeherman H, 2005, CYTOKINE GROWTH F R, V16, P329, DOI 10.1016/j.cytogfr.2005.05.001
   Shibata T, 2008, DIABETES, V57, P3099, DOI 10.2337/db08 0031
   Shih HN, 2005, J ORTHOP RES, V23, P1293, DOI 10.1016/j.orthres.2005.04.005
   Shlomchik WD, 2007, NAT REV IMMUNOL, V7, P340, DOI 10.1038/nri2000
   Shlomchik WD, 2007, BIOL BLOOD MARROW TR, V13, P2, DOI 10.1016/j.bbmt.2006.10.020
   Sonoyama W, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000079
   Spaggiari GM, 2008, BLOOD, V111, P1327, DOI 10.1182/blood 2007 02 074997
   Tamada K, 2000, NAT MED, V6, P283
   Thomas E D, 1999, Biol Blood Marrow Transplant, V5, P341
   Tolar J, 2007, STEM CELLS, V25, P371, DOI 10.1634/stemcells.2005 0620
   Tomchuck SL, 2008, STEM CELLS, V26, P99, DOI 10.1634/stemcells.2007 0563
   TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065 2776(08)60664 1
   Tse WT, 2003, TRANSPLANTATION, V75, P389, DOI 10.1097/01.TP.0000045055.63901.A9
   Tyndall A, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2103
   Uematsu K, 2005, BIOMATERIALS, V26, P4273, DOI 10.1016/j.biomaterials.2004.10.037
   Vojtassák J, 2006, NEUROENDOCRINOL LETT, V27, P134
   Von Lüttichau I, 2005, STEM CELLS DEV, V14, P329, DOI 10.1089/scd.2005.14.329
   Wu M, 2006, BRIT J DERMATOL, V155, P282, DOI 10.1111/j.1365 2133.2006.07357.x
   Xu KL, 2007, INT J HEMATOL, V86, P84, DOI 10.1532/IJH97.A10613
   Xu L, 2007, EUR J HAEMATOL, V78, P235, DOI 10.1111/j.1600 0609.2006.00804.x
   Yang JF, 2007, CARDIOLOGY, V107, P17, DOI 10.1159/000093609
   Yoshikawa T, 2008, PLAST RECONSTR SURG, V121, P860, DOI 10.1097/01.prs.0000299922.96006.24
   Zachos T, 2007, MOL THER, V15, P1543, DOI 10.1038/sj.mt.6300192
   Zhang DG, 2007, TRANSPL INT, V20, P174, DOI 10.1111/j.1432 2277.2006.00407.x
   Zhang N, 2008, EXP CLIN ENDOCR DIAB, V116, P104, DOI 10.1055/s 2007 985154
   Zhang SH, 2006, J CELL BIOCHEM, V99, P1132, DOI 10.1002/jcb.20949
   Zhao MZ, 2006, J CEREBR BLOOD F MET, V26, P1176, DOI 10.1038/sj.jcbfm.9600273
NR 91
TC 308
Z9 366
U1 1
U2 65
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1465 3249
EI 1477 2566
J9 CYTOTHERAPY
JI Cytotherapy
PY 2009
VL 11
IS 4
BP 377
EP 391
DI 10.1080/14653240903080367
PG 15
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research
   & Experimental Medicine
GA 465GC
UT WOS:000267569600002
PM 19568970
DA 2025 08 17
ER

PT J
AU Srinivasan, PP
   Parajuli, A
   Price, C
   Wang, LY
   Duncan, RL
   Kirn Safran, CB
AF Srinivasan, Padma P.
   Parajuli, Ashutosh
   Price, Christopher
   Wang, Liyun
   Duncan, Randall L.
   Kirn Safran, Catherine B.
TI Inhibition of T Type Voltage Sensitive Calcium Channel Reduces
   Load Induced OA in Mice and Suppresses the Catabolic Effect of Bone
   Mechanical Stress on Chondrocytes
SO PLOS ONE
LA English
DT Article
ID SUBCHONDRAL BONE; CARTILAGE DEGENERATION; ARTICULAR CARTILAGE;
   SHEAR STRESS; ION CHANNEL; OSTEOARTHRITIS; EXPRESSION;
   MECHANOTRANSDUCTION; CELLS; TRPV4
AB Voltage sensitive calcium channels (VSCC) regulate cellular calcium influx, one of the earliest responses to mechanical stimulation in osteoblasts. Here, we postulate that T type VSCCs play an essential role in bone mechanical response to load and participate in events leading to the pathology of load induced OA. Repetitive mechanical insult was used to induce OA in Ca(v)3.2 T VSCC null and wild type control mouse knees. Osteoblasts (MC3T3 E1) and chondrocytes were treated with a selective T VSCC inhibitor and subjected to fluid shear stress to determine how blocking of T VSCCs alters the expression profile of each cell type upon mechanical stimulation. Conditioned media (CM) obtained from static and sheared MC3T3 E1 was used to assess the effect of osteoblast derived factors on the chondrocyte phenotype. T VSCC null knees exhibited significantly lower focal articular cartilage damage than age matched controls. In vitro inhibition of T VSCC significantly reduced the expression of both early and late mechanoresponsive genes in osteoblasts but had no effect on gene expression in chondrocytes. Furthermore, treatment of chondrocytes with CM obtained from sheared osteoblasts induced expression of markers of hypertrophy in chondrocytes and this was nearly abolished when osteoblasts were pre treated with the T VSCC specific inhibitor. These results indicate that T VSCC plays a role in signaling events associated with induction of OA and is essential to the release of osteoblast derived factors that promote an early OA phenotype in chondrocytes. Further, these findings suggest that local inhibition of T VSCC may serve as a therapy for blocking load induced bone formation that results in cartilage degeneration.
C1 [Srinivasan, Padma P.; Duncan, Randall L.; Kirn Safran, Catherine B.] Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA.
   [Parajuli, Ashutosh; Price, Christopher; Duncan, Randall L.; Kirn Safran, Catherine B.] Univ Delaware, Biomed Engn Program, Newark, DE 19716 USA.
   [Wang, Liyun; Duncan, Randall L.] Univ Delaware, Dept Mech Engn, Newark, DE 19716 USA.
C3 University of Delaware; University of Delaware; University of Delaware
RP Kirn Safran, CB (通讯作者)，Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA.
EM ckirn@udel.edu
RI Price, Christopher/I 4851 2018; Duncan, Randall/AAK 3888 2020;
   Kirn Safran, Catherine/AAB 9089 2022; Srinivasan, Padma/F 8134 2016
OI Duncan, Randall/0000 0001 5733 6603; 
FU National Institutes of Health (USA)
FX This work was supported by National Institutes of Health (USA): CBKS RLD
   LW. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abed E, 2009, MOL MEMBR BIOL, V26, P146, DOI 10.1080/09687680802612721
   Alford AI, 2003, BONE, V33, P64, DOI 10.1016/S8756 3282(03)00167 4
   [Anonymous], THESIS U DELAWARE
   Bergink AP, 2005, BONE, V37, P446, DOI 10.1016/j.bone.2005.05.001
   Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P81, DOI 10.1002/term.74
   CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493
   Chen CC, 2003, SCIENCE, V302, P1416, DOI 10.1126/science.1089268
   Choi S, 2007, GENES BRAIN BEHAV, V6, P425, DOI 10.1111/j.1601 183X.2006.00268.x
   Clark AL, 2010, ARTHRITIS RHEUM US, V62, P2973, DOI 10.1002/art.27624
   D'Angelo M, 2000, J CELL BIOCHEM, V77, P678, DOI 10.1002/(SICI)1097 4644(20000615)77:4<678::AID JCB15>3.3.CO;2 G
   DUNCAN R, 1989, FEBS LETT, V251, P17, DOI 10.1016/0014 5793(89)81420 6
   DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070
   Duncan RL, 1998, SEMIN NEPHROL, V18, P178
   Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Goldring MB, 2010, ANN NY ACAD SCI, V1192, P230, DOI 10.1111/j.1749 6632.2009.05240.x
   Hayami T, 2004, ARTHRITIS RHEUM US, V50, P1193, DOI 10.1002/art.20124
   Herman BC, 2010, BONE, V47, P766, DOI 10.1016/j.bone.2010.07.006
   Huang HD, 2004, AM J PHYSIOL CELL PH, V287, pC1, DOI 10.1152/ajpcell.00559.2003
   Huang LP, 2004, J PHARMACOL EXP THER, V309, P193, DOI 10.1124/jpet.103.060814
   HUNG CT, 1995, CLIN ORTHOP RELAT R, P256
   Hunter David J, 2003, Curr Rheumatol Rep, V5, P15, DOI 10.1007/s11926 003 0078 5
   Kapur S, 2010, J BIOL CHEM, V285, P37607, DOI 10.1074/jbc.M110.169714
   Kennedy OD, 2012, BONE, V50, P1115, DOI 10.1016/j.bone.2012.01.025
   Ko FC, 2013, ARTHRITIS RHEUM US, V65, P1569, DOI 10.1002/art.37906
   Krakow D, 2009, AM J HUM GENET, V84, P307, DOI 10.1016/j.ajhg.2009.01.021
   Li JL, 2002, J BONE MINER RES, V17, P1795, DOI 10.1359/jbmr.2002.17.10.1795
   Lu XL, 2012, J BONE MINER RES, V27, P563, DOI 10.1002/jbmr.1474
   Martel Pelletier J, 2010, EKLEM HAST CERRAHISI, V21, P2
   McDonald J, 2009, Handbook of biological statistics, DOI DOI 10.1017/CBO9781107415324.004
   Mohtai M, 1996, J ORTHOP RES, V14, P67, DOI 10.1002/jor.1100140112
   Muramatsu S, 2007, J BIOL CHEM, V282, P32158, DOI 10.1074/jbc.M706158200
   Ohba S, 2010, OSTEOARTHR CARTILAGE, V18, P1620, DOI 10.1016/j.joca.2010.09.006
   Pan J, 2012, BONE, V51, P212, DOI 10.1016/j.bone.2011.11.030
   Pavalko FM, 1998, AM J PHYSIOL CELL PH, V275, pC1591
   Phan MN, 2009, ARTHRITIS RHEUM US, V60, P3028, DOI 10.1002/art.24799
   Pitsillides AA, 2011, NAT REV RHEUMATOL, V7, P654, DOI 10.1038/nrrheum.2011.129
   Poulet B, 2011, ARTHRITIS RHEUM US, V63, P137, DOI 10.1002/art.27765
   Prasadam I, 2010, ARTHRITIS RHEUM US, V62, P1349, DOI 10.1002/art.27397
   Price C, 2011, J BONE MINER RES, V26, P277, DOI 10.1002/jbmr.211
   RADIN EL, 1986, CLIN ORTHOP RELAT R, P34
   Robling AG, 2002, BONE, V31, P562, DOI 10.1016/S8756 3282(02)00871 2
   Rubin J, 2006, GENE, V367, P1, DOI 10.1016/j.gene.2005.10.028
   Ryder KD, 2001, J BONE MINER RES, V16, P240, DOI 10.1359/jbmr.2001.16.2.240
   Shao Y, 2005, DEV DYNAM, V234, P54, DOI 10.1002/dvdy.20517
   Smalt R, 1997, AM J PHYSIOL ENDOC M, V273, pE751, DOI 10.1152/ajpendo.1997.273.4.E751
   Srinivasan PP, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/2/024109
   Suzuki T, 2013, BONE, V54, P172, DOI 10.1016/j.bone.2013.01.001
   Tat SK, 2010, BEST PRACT RES CL RH, V24, P51, DOI 10.1016/j.berh.2009.08.004
   Todorovic SM, 2011, BRIT J PHARMACOL, V163, P484, DOI 10.1111/j.1476 5381.2011.01256.x
   Todorovic SM, 2001, MOL PHARMACOL, V60, P603
   Truong LH, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2101
   Westacott C., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P507
   Zhou XZ, 2010, J BIOMECH, V43, P1598, DOI 10.1016/j.jbiomech.2009.12.028
NR 54
TC 22
Z9 30
U1 0
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 26
PY 2015
VL 10
IS 5
AR e0127290
DI 10.1371/journal.pone.0127290
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CJ0QZ
UT WOS:000355183900079
PM 26011709
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Suzuki, Y
   Nishiyama, T
   Hasuda, K
   Fujishiro, T
   Niikura, T
   Hayashi, S
   Hashimoto, S
   Kurosaka, M
AF Suzuki, Yoshihiro
   Nishiyama, Takayuki
   Hasuda, Keiichiro
   Fujishiro, Takaaki
   Niikura, Takahiro
   Hayashi, Shinya
   Hashimoto, Shingo
   Kurosaka, Masahiro
TI Effect of etidronate on COX 2 expression and PGE2 production
   in macrophage like RAW 264.7 cells stimulated by titanium particles
SO JOURNAL OF ORTHOPAEDIC SCIENCE
LA English
DT Article
ID TOTAL HIP ARTHROPLASTY; PROSTAGLANDIN E 2 PRODUCTION; OSTEOBLASTIC
   MC3T3 E1 CELLS; PERIPROSTHETIC BONE LOSS; FACTOR KAPPA B; IN VITRO;
   MINERAL DENSITY; BISPHOSPHONATES; RECEPTOR; OSTEOCLASTOGENESIS
AB Background. The most common failure of total joint replacement is aseptic loosening in association with osteolysis. Previous reports have shown that prostaglandin E 2 (PGE(2)) secreted from macrophages that phagocytosed wear debris induced periprosthetic osteolysis. Many clinical studies have reported that bisphosphonate therapy reduced periprosthetic bone loss and loosening of the implants after total joint replacements. Bisphosphonates are synthetic compounds with the ability to decrease bone resorption. In addition, some bisphosphonates have been reported to have anti inflammatory effects by reducing the secretion of pro inflammatory cytokines. However, the mechanism of bisphosphonates that reduces periprosthetic bone resorption remains unclear. The purpose of this study was to investigate one of the mechanisms by which etidronate (EHDP) inhibits periprosthetic bone resorption.
   Methods. Macrophage like RAW 264.7 cells were treated with EHDP at concentrations of 0.001, 0.01, 0.1, 1, 10, and 100 mu M together with the titanium particles at a concentration of 1 mg/ml. After a 24 h culture period, total mRNA was isolated and reverse transcription polymerase chain reaction (RT PCR) was done to examine the expression of cyclooxygenase 2 (COX 2). The supernatants were also collected and production of PGE(2), interleukin 1 beta (IL 1 beta), interleukin 6 (IL 6), and tumor necrosis factor alpha (TNF alpha) were quantified using an enzyme linked immunosorbent assay (ELISA).
   Results. Analyses showed that COX 2 expression and PGE(2) production were suppressed by EHDP in a dose dependent manner. By 100 mu M of EHDP, PGE(2) production of the cells was suppressed approximately to the level of the nonstimulated cells. Production of IL 1 beta, IL 6, and TNF alpha in the supernatant was also suppressed by EHDP.
   Conclusions. The blockage effect of pro inflammatory cytokines is a possible etidronate mechanism that reduces bone resorption around implants.
C1 Kobe Univ, Grad Sch Med, Dept Orthopaed Surg, Chuo Ku, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Suzuki, Y (通讯作者)，Kobe Univ, Grad Sch Med, Dept Orthopaed Surg, Chuo Ku, 7 5 1 Kusunoki cho, Kobe, Hyogo 6500017, Japan.
RI ; Hayashi, Shinya/KFR 1295 2024
OI Hayashi, Shinya/0000 0003 4308 9845; 
CR Bauer DC, 1996, J BONE MINER RES, V11, P29
   Bhandari M, 2005, J BONE JOINT SURG AM, V87A, P293, DOI 10.2106/JBJS.D.01772
   Brändström H, 2001, BIOCHEM BIOPH RES CO, V280, P831, DOI 10.1006/bbrc.2000.4223
   CECCHINI MG, 1987, J BONE MINER RES, V2, P135
   Chang MC, 2006, INT ENDOD J, V39, P819, DOI 10.1111/j.1365 2591.2006.01156.x
   FLEISCH H, 2000, BISPHOSPHONATES BONE, P43
   Fokter SK, 2006, WIEN KLIN WOCHENSCHR, V118, P23, DOI 10.1007/s00508 006 0556 7
   Fujishiro T, 2004, J BIOMED MATER RES A, V68A, P531, DOI 10.1002/jbm.a.20098
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Kanematsu M, 2000, J BONE MINER RES, V15, P1321, DOI 10.1359/jbmr.2000.15.7.1321
   KIM KJ, 1994, J BONE JOINT SURG AM, V76A, P172, DOI 10.2106/00004623 199402000 00002
   Li XD, 2000, ENDOCRINOLOGY, V141, P2054, DOI 10.1210/en.141.6.2054
   Lo CJ, 1998, J TRAUMA, V45, P19, DOI 10.1097/00005373 199807000 00004
   Makkonen N, 1999, EUR J PHARM SCI, V8, P109, DOI 10.1016/S0928 0987(98)00065 7
   MURRAY DW, 1990, J BONE JOINT SURG BR, V72, P988, DOI 10.1302/0301 620X.72B6.2246303
   NAVARRA P, 1992, NEUROENDOCRINOLOGY, V56, P61, DOI 10.1159/000126209
   Niikura Takahiro, 2002, Kobe Journal of Medical Sciences, V48, P115
   PENNANEN N, 1995, PHARMACEUT RES, V12, P916, DOI 10.1023/A:1016281608773
   PILBEAM CC, 1993, J BIOL CHEM, V268, P25643
   SHANBHAG AS, 1995, J ARTHROPLASTY, V10, P498, DOI 10.1016/S0883 5403(05)80152 4
   Shanbhag AS, 1997, CLIN ORTHOP RELAT R, P33
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Suda M, 1998, CALCIFIED TISSUE INT, V62, P327, DOI 10.1007/s002239900440
   THOMPSON DD, 1988, J BONE MINER RES, V3, P409
   Tuominen OM, 2006, METHOD FIND EXP CLIN, V28, P361, DOI 10.1358/mf.2006.28.6.1003551
   Venesmaa PK, 2001, J BONE MINER RES, V16, P2126, DOI 10.1359/jbmr.2001.16.11.2126
   Yamaguchi K, 2005, J ORTHOP SCI, V10, P32, DOI 10.1007/s00776 004 0854 8
   Yamaguchi K, 2003, BONE, V33, P144, DOI 10.1016/S8756 3282(03)00085 1
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 29
TC 17
Z9 21
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0949 2658
EI 1436 2023
J9 J ORTHOP SCI
JI J. Orthop. Sci.
PD NOV
PY 2007
VL 12
IS 6
BP 568
EP 577
DI 10.1007/s00776 007 1180 8
PG 10
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 235HY
UT WOS:000251225600009
PM 18040640
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Xu, SY
   Xia, TS
   Zhang, JW
   Jiang, YP
   Wang, NN
   Xin, HL
AF Xu, Shengyan
   Xia, Tianshuang
   Zhang, Jingwen
   Jiang, Yiping
   Wang, Nani
   Xin, Hailiang
TI Protective effects of bitter acids from Humulus lupulus L. against
   senile osteoporosis via activating Nrf2/HO 1/NQO1 pathway in D galactose
   induced aging mice
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Bitter acids; Hops; Senescence; Osteoporosis; D galactose; Nrf2
ID INDUCED BONE LOSS; ISO ALPHA ACIDS; OXIDATIVE STRESS; HOP; APOPTOSIS;
   DAMAGE; RATS
AB Bitter acids (BA) from Humulus lupulus L. (hops) are known for beer brewing and have been proved to have activities on reliving oxidative stress and osteoporosis. This study firstly determined the effects of BA on senile osteoporosis (SOP) in D galactose induced aging mice. BA significantly increased femoral bone mineral density, serum levels of alkaline phosphatase, osteocalcin as well as decreased serum tartrate resistant acid phosphatase contents in D galactose induced mice. BA also promoted proliferation, differentiation, mineralization and inhibited cell senescence, apoptosis in D galactose treated osteoblasts. Furthermore, BA attenuated D galactose induced oxidative stress through the activation of nuclear translocation of Nrf2 and the increase of intracellular HO 1, NQO1 expressions. In conclusion, BA might attenuate osteoporosis in aged mice through activating Nrf2/ HO 1/NQO1 signaling pathway. As important components in beer, BA have potential in the development of drugs for SOP treatment.
C1 [Xu, Shengyan; Xia, Tianshuang; Zhang, Jingwen; Jiang, Yiping; Xin, Hailiang] Naval Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.
   [Wang, Nani] Zhejiang Acad Tradit Chinese Med, Dept Med, Hangzhou 310007, Zhejiang, Peoples R China.
C3 Naval Medical University
RP Xin, HL (通讯作者)，Naval Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.; Wang, NN (通讯作者)，Zhejiang Acad Tradit Chinese Med, Dept Med, Hangzhou 310007, Zhejiang, Peoples R China.
EM wnn8511@163.com; hailiangxin@163.com
FU National Natural Science Foundation of China [82174079, U1603283,
   82004015]; Project of Science and Technology Commission of Shanghai
   Municipality [21S21902600]; Natural Science Foundation of Zhejiang
   Province [LY21H280001, LY20H280003]; Hangzhou agricultural and social
   development project [20201203B130]
FX This work was supported by the National Natural Science Foundation of
   China (82174079, U1603283, 82004015) , Project of Science and Technology
   Commission of Shanghai Municipality (21S21902600) , Natural Science
   Foundation of Zhejiang Province (LY21H280001, LY20H280003) and Hangzhou
   agricultural and social development project (20201203B130) .
CR Bhutia SK, 2022, J NUTR BIOCHEM, V99, DOI 10.1016/j.jnutbio.2021.108841
   Chen WJ, 2004, J AGR FOOD CHEM, V52, P55, DOI 10.1021/jf034737u
   Cummings SR, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115411
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   El Amrousy D, 2021, PEDIATR RES, V89, P878, DOI 10.1038/s41390 020 01197 5
   Feng H, 2020, INT J CLIN EXP PATHO, V13, P382
   González Burgos E, 2012, J NAT PROD, V75, P1750, DOI 10.1021/np300418m
   Gorjanovic S, 2013, J AGR FOOD CHEM, V61, P9089, DOI 10.1021/jf401718z
   Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00 0764fje
   Gu G, 2005, APOPTOSIS, V10, P583, DOI 10.1007/s10495 005 1893 0
   Hadzi Petrushev N, 2015, PHYSIOL RES, V64, P61, DOI 10.33549/physiolres.932786
   Hall AJ, 2008, PHYTOCHEMISTRY, V69, P1534, DOI 10.1016/j.phytochem.2008.02.001
   Hsu YY, 2019, J FOOD SCI TECH MYS, V56, P1939, DOI 10.1007/s13197 019 03660 6
   Jung KA, 2010, MOLECULES, V15, P7266, DOI 10.3390/molecules15107266
   Kannan S, 2020, BIOL OPEN, V9, DOI 10.1242/bio.053280
   Kao TH, 2013, FOOD CHEM, V141, P1218, DOI 10.1016/j.foodchem.2013.04.032
   Lamb JJ, 2011, NUTR RES, V31, P347, DOI 10.1016/j.nutres.2011.03.016
   Lewiecki EM, 2010, THER ADV CHRONIC DIS, V1, P115, DOI 10.1177/2040622310374783
   Lu J, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6301433
   Mahmoud MAA, 2021, TOXICOL REP, V8, P366, DOI 10.1016/j.toxrep.2021.02.007
   Mishra AK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010233
   Nagybakay NE, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10060918
   Naruphontjiralcul P, 2018, ACTA BIOMATER, V66, P67, DOI 10.1016/j.actbio.2017.11.008
   Perez Amodio S, 2006, CALCIFIED TISSUE INT, V78, P248, DOI 10.1007/s00223 005 0185 6
   Rana T, 2012, FREE RADICAL BIO MED, V53, P2298, DOI 10.1016/j.freeradbiomed.2012.10.536
   Siegel L, 2008, ANTICANCER RES, V28, P289
   Sun XL, 2022, J BONE MINER METAB, V40, P375, DOI 10.1007/s00774 021 01295 2
   Takashi Y, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23042376
   Taniguchi Y, 2013, J AGR FOOD CHEM, V61, P3121, DOI 10.1021/jf3047187
   Tobe H, 1997, BIOSCI BIOTECH BIOCH, V61, P158, DOI 10.1271/bbb.61.158
   Tobe H, 1997, BIOSCI BIOTECH BIOCH, V61, P1027, DOI 10.1271/bbb.61.1027
   Trius Soler M, 2020, MOLECULES, V25, DOI 10.3390/molecules25173910
   Tsay J, 2010, BLOOD, V116, P2582, DOI 10.1182/blood 2009 12 260083
   Van Cleemput M, 2009, MOL NUTR FOOD RES, V53, P1143, DOI 10.1002/mnfr.200800493
   Wang S, 2022, CHEM BIOL DRUG DES, V99, P46, DOI 10.1111/cbdd.13904
   Wawrzyniak Anna, 2008, Pol Arch Med Wewn, V118 Suppl, P59
   Xia T. S., 2021, J PHARM PRACTICE, V39, P509
   Xia TS, 2021, CHIN J INTEGR MED, V27, P31, DOI 10.1007/s11655 019 2700 z
   Xia TianShuang Xia TianShuang, 2019, Academic Journal of Second Military Medical University, V40, P25
   Xu WM, 2020, J ETHNOPHARMACOL, V261, DOI 10.1016/j.jep.2020.112992
   Yamamoto K, 2000, FEBS LETT, V465, P103, DOI 10.1016/S0014 5793(99)01727 5
   Ye Y, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/185716
   Zhang QL, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9281481
NR 43
TC 9
Z9 10
U1 6
U2 46
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1756 4646
EI 2214 9414
J9 J FUNCT FOODS
JI J. Funct. Food.
PD JUL
PY 2022
VL 94
AR 105099
DI 10.1016/j.jff.2022.105099
EA MAY 2022
PG 10
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA 1T6DQ
UT WOS:000804817600001
OA gold
DA 2025 08 17
ER

PT J
AU Fan, SJ
   Tan, YD
   Yuan, XC
   Liu, C
   Wu, XY
   Dai, T
   Ni, S
   Wang, JF
   Weng, YP
   Zhao, HB
AF Fan, Shijie
   Tan, Yadong
   Yuan, Xiuchen
   Liu, Chun
   Wu, Xiaoyu
   Dai, Ting
   Ni, Su
   Wang, Jiafeng
   Weng, Yiping
   Zhao, Hongbin
TI Regulation of the immune microenvironment by pioglitazone loaded
   polylactic glycolic acid nanosphere composite scaffolds to promote
   vascularization and bone regeneration
SO JOURNAL OF TISSUE ENGINEERING
LA English
DT Article
DE 3D printing; pioglitazone; macrophage polarization; osteogenesis;
   vascularization
ID OSTEOGENIC DIFFERENTIATION; NANO ATTAPULGITE; MINERAL DENSITY;
   MACROPHAGES; HYDROGEL; POLARIZATION; NANOFIBERS; M1
AB Osteogenesis is caused by multiple factors, and the inflammatory response, osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs), regeneration of blood vessels, and other factors must be considered in bone tissue engineering. To effectively repair bone defect, it is important to decrease excessive inflammation, enhance the differentiation of mesenchymal stem cells into osteoblasts, and stimulate angiogenesis. Herein, nano attapulgite (ATP), polyvinyl alcohol (PVA), and gelatin (GEL) scaffolds were produced using 3D printing technology and pioglitazone (PIO) containing polylactic acid glycolic acid (PLGA) nanospheres were added. In both in vitro and in vivo studies, material scaffolds with PIO loaded polylactic acid glycolic acid nanospheres could reduce the inflammatory response by encouraging macrophage polarization from M1 to M2 and promoting the osteogenic differentiation of BMSCs by activating the BMP2/Smad/RUNX2 signal pathway to repair bone defects. The vascularization of human umbilical vein endothelial cells (HUVECs) through the PI3K/AKT/HIF1 /VEGF pathway was also encouraged. In vivo research using PIO containing PLGA nanospheres revealed massive collagen deposition in skin models. These findings indicate a potentially effective scaffold for bone healing, when PLGA nanospheres which contain the drug PIO are combined with ATP/PVA/GEL scaffolds.
   Graphical abstract
C1 [Fan, Shijie; Tan, Yadong; Yuan, Xiuchen; Liu, Chun; Wu, Xiaoyu; Dai, Ting; Ni, Su; Wang, Jiafeng; Weng, Yiping; Zhao, Hongbin] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Orthoped, Changzhou, Peoples R China.
   [Fan, Shijie; Tan, Yadong; Yuan, Xiuchen; Liu, Chun; Wu, Xiaoyu; Dai, Ting; Ni, Su; Wang, Jiafeng; Weng, Yiping; Zhao, Hongbin] Nanjing Med Univ, Changzhou Med Ctr, Changzhou, Peoples R China.
   [Weng, Yiping] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Orthoped, Changzhou 213164, Peoples R China.
   [Zhao, Hongbin] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Orthoped, Gehu Middle 68, Changzhou 213164, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University; Nanjing Medical University
RP Weng, YP (通讯作者)，Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Orthoped, Changzhou 213164, Peoples R China.; Zhao, HB (通讯作者)，Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Orthoped, Gehu Middle 68, Changzhou 213164, Peoples R China.
EM czeywengyiping@163.com; zhao761032@163.com
RI Ni, Su/KOX 1297 2024; wu, 晓煜/HIK 3475 2022; Zhao, Hongbin/A 4166 2019;
   Wang, Jiafeng/LZE 8700 2025
OI Weng, Yiping/0009 0004 3807 8636; chun, liu/0000 0001 9875 0544
FU Changzhou Clinical Medicine Center of Nanjing Medical University Program
   [CMCC202216]; Technology of Jiangsu Province [BE2018644]; Changzhou
   SciTech Program [CE20215020]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: Changzhou
   Clinical Medicine Center of Nanjing Medical University Program
   (CMCC202216), Technology of Jiangsu Province (BE2018644), and Changzhou
   Sci & Tech Program (CE20215020) all provided funding for this study.
CR Abaricia JO, 2020, BIOMATERIALS, V243, DOI 10.1016/j.biomaterials.2020.119920
   Abdelhafez AT, 2021, LIFE SCI, V280, DOI 10.1016/j.lfs.2021.119706
   Adlerz KM, 2016, EUR BIOPHYS J BIOPHY, V45, P301, DOI 10.1007/s00249 015 1096 8
   Allafchian A, 2020, INT J BIOL MACROMOL, V163, P1780, DOI 10.1016/j.ijbiomac.2020.09.129
   Andrukhov O, 2020, DENT MATER, V36, pE194, DOI 10.1016/j.dental.2020.04.003
   Appel EA, 2010, J AM CHEM SOC, V132, P14251, DOI 10.1021/ja106362w
   Asano M, 1999, BRIT J PHARMACOL, V128, P673, DOI 10.1038/sj.bjp.0702818
   Azarian MH, 2019, MAT SCI ENG C MATER, V103, DOI 10.1016/j.msec.2019.109829
   Bittner SM, 2018, MATER TODAY, V21, P861, DOI 10.1016/j.mattod.2018.02.006
   Cam ME, 2021, MAT SCI ENG C MATER, V119, DOI 10.1016/j.msec.2020.111586
   Cao JL, 2022, CARBOHYD POLYM, V287, DOI 10.1016/j.carbpol.2022.119318
   Chim SM, 2013, CYTOKINE GROWTH F R, V24, P297, DOI 10.1016/j.cytogfr.2013.03.008
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Dong XY, 2020, J CELL PHYSIOL, V235, P9933, DOI 10.1002/jcp.29808
   Duarte LRF, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12010075
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   El Rashidy AA, 2017, ACTA BIOMATER, V62, P1, DOI 10.1016/j.actbio.2017.08.030
   Gauthier O, 1998, BIOMATERIALS, V19, P133, DOI 10.1016/S0142 9612(97)00180 4
   Han J, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.888267
   He XY, 2019, INT J BIOL MACROMOL, V127, P665, DOI 10.1016/j.ijbiomac.2019.01.202
   Hill GR, 2009, BIOL BLOOD MARROW TR, V15, P139, DOI 10.1016/j.bbmt.2008.11.008
   Hotchkiss KM, 2016, ACTA BIOMATER, V31, P425, DOI 10.1016/j.actbio.2015.12.003
   Huang JH, 2019, J MATER CHEM B, V7, P7690, DOI 10.1039/c9tb02072a
   Jaitin DA, 2019, CELL, V178, P686, DOI 10.1016/j.cell.2019.05.054
   Ji HZ, 2021, ACTA BIOMATER, V135, P274, DOI 10.1016/j.actbio.2021.08.050
   Jiang GY, 2021, ACTA BIOMATER, V128, P150, DOI 10.1016/j.actbio.2021.04.010
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lei YT, 2022, BIOACT MATER, V16, P472, DOI 10.1016/j.bioactmat.2022.02.016
   Li ZY, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.680328
   Lien SM, 2009, ACTA BIOMATER, V5, P670, DOI 10.1016/j.actbio.2008.09.020
   Lin HX, 2022, PHYTOTHER RES, V36, P3584, DOI 10.1002/ptr.7525
   Liu C, 2021, INT J NANOMED, V16, P8417, DOI 10.2147/IJN.S339500
   Liu F, 2021, MACROMOL BIOSCI, V21, DOI 10.1002/mabi.202000398
   Liu J, 2017, AGING CELL, V16, P360, DOI 10.1111/acel.12566
   Liu J, 2022, INT J NANOMED, V17, P4087, DOI 10.2147/IJN.S372247
   Lu LY, 2017, J ORTHOP RES, V35, P2378, DOI 10.1002/jor.23553
   Luo M, 2021, J MATER CHEM B, V9, P1867, DOI 10.1039/d0tb02333g
   Ma JY, 2022, BIOMATER SCI UK, V10, P4635, DOI 10.1039/d2bm00547f
   Mahon OR, 2020, BIOMATERIALS, V239, DOI 10.1016/j.biomaterials.2020.119833
   Momotori N, 2019, REGEN THER, V11, P131, DOI 10.1016/j.reth.2019.06.008
   Ng KW, 2012, TISSUE ENG PT A, V18, P1273, DOI [10.1089/ten.tea.2011.0276, 10.1089/ten.TEA.2011.0276]
   Nikoubashman O, 2018, MACROMOL BIOSCI, V18, DOI 10.1002/mabi.201700292
   Oishi Y, 2018, INT IMMUNOL, V30, P511, DOI 10.1093/intimm/dxy054
   Okabe Y, 2016, NAT IMMUNOL, V17, P9, DOI 10.1038/ni.3320
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   Pop LM, 2017, OSTEOPOROSIS INT, V28, P3261, DOI 10.1007/s00198 017 4164 3
   Przekora A, 2017, MAT SCI ENG C MATER, V73, P225, DOI 10.1016/j.msec.2016.12.081
   Qiu PC, 2020, BIOMATERIALS, V227, DOI 10.1016/j.biomaterials.2019.119552
   Ryan KE, 2007, ATHEROSCLEROSIS, V194, pE123, DOI 10.1016/j.atherosclerosis.2006.11.007
   Schlundt C, 2018, BONE, V106, P78, DOI 10.1016/j.bone.2015.10.019
   Shen YF, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2485 1
   Shuai CJ, 2020, MAT SCI ENG C MATER, V108, DOI 10.1016/j.msec.2019.110486
   Stigler RG, 2018, NANOMATERIALS BASEL, V8, DOI 10.3390/nano8070524
   Sun MH, 2020, DRUG DELIV, V27, P632, DOI 10.1080/10717544.2020.1756985
   Tsirella E, 2012, J PHYSIOL PHARMACOL, V63, P201
   Vachliotis ID, 2022, DIABETES OBES METAB, V24, P1702, DOI 10.1111/dom.14774
   Viscoli CM, 2017, J CLIN ENDOCR METAB, V102, P914, DOI 10.1210/jc.2016 3237
   Wahab AHA, 2019, J MECH BEHAV BIOMED, V91, P406, DOI 10.1016/j.jmbbm.2018.12.033
   Wang J, 2019, INT J NANOMED, V14, P7987, DOI 10.2147/IJN.S216182
   Wang Q, 2022, BONE, V154, DOI 10.1016/j.bone.2021.116211
   Wang ZH, 2020, INT J NANOMED, V15, P6945, DOI 10.2147/IJN.S254094
   Wilkinson AC, 2019, NATURE, V571, P117, DOI 10.1038/s41586 019 1244 x
   Wilson K, 2022, ANNU REV CHEM BIOMOL, V13, P481, DOI 10.1146/annurev chembioeng 092220 015404
   Wu SY, 2022, ACS APPL MATER INTER, V14, P15942, DOI 10.1021/acsami.1c24748
   Wubneh A, 2018, ACTA BIOMATER, V80, P1, DOI 10.1016/j.actbio.2018.09.031
   Xu XW, 2019, ACTA BIOMATER, V86, P235, DOI 10.1016/j.actbio.2019.01.001
   Xue Y, 2022, INT J BIOL SCI, V18, P572, DOI 10.7150/ijbs.63505
   Yang DB, 2019, SEMIN IMMUNOPATHOL, V41, P551, DOI 10.1007/s00281 019 00754 3
   Zhang CY, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7404038
   Zhang J., 2020, Cell Prolif, V53
   Zhang L, 2019, ACTA BIOMATER, V84, P16, DOI 10.1016/j.actbio.2018.11.039
   Zhang YS, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.735824
   Zhao BA, 2022, ACTA BIOMATER, V151, P235, DOI 10.1016/j.actbio.2022.08.009
   Zhao HB, 2020, BIOMED MATER, V15, DOI 10.1088/1748 605X/ab843f
   Zhao SJ, 2020, THERANOSTICS, V10, P17, DOI 10.7150/thno.36930
   Zheng MT, 2021, BIOMED MATER, V16, DOI 10.1088/1748 605X/abdbdc
NR 76
TC 5
Z9 5
U1 5
U2 28
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2041 7314
J9 J TISSUE ENG
JI J. Tissue Eng.
PY 2024
VL 15
AR 20417314241231452
DI 10.1177/20417314241231452
PG 22
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA HV7R2
UT WOS:001162353300001
PM 38361536
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Bateman, ME
   Strong, AL
   Hunter, RS
   Bratton, MR
   Komati, R
   Sridhar, J
   Riley, KE
   Wang, GD
   Hayes, DJ
   Boue, SM
   Burow, ME
   Bunnell, BA
AF Bateman, Marjorie E.
   Strong, Amy L.
   Hunter, Ryan S.
   Bratton, Melyssa R.
   Komati, Rajesh
   Sridhar, Jayalakshmi
   Riley, Kevin E.
   Wang, Guangdi
   Hayes, Daniel J.
   Boue, Stephen M.
   Burow, Matthew E.
   Bunnell, Bruce A.
TI Osteoinductive effects of glyceollins on adult mesenchymal stromal/stem
   cells from adipose tissue and bone marrow
SO PHYTOMEDICINE
LA English
DT Article
DE Glyceollin; Mesenchymal stem cells; Adipose tissue; Bone marrow;
   Osteogenesis; Tissue scaffolds
ID STEM CELLS; RECEPTOR ALPHA; DAIDZEIN; DIFFERENTIATION; ESTROGEN; BREAST;
   GENISTEIN; REPLACEMENT; OSTEOBLASTS; METABOLISM
AB Background: While current therapies for osteoporosis focus on reducing bone resorption, the development of therapies to regenerate bone may also be beneficial. Promising anabolic therapy candidates include phytoestrogens, such as daidzein, which effectively induce osteogenesis of adipose derived stromal cells (ASCs) and bone marrow stromal cells (BMSCs).
   Purpose: To investigate the effects of glyceollins, structural derivatives of daidzein, on osteogenesis of ASCs and BMSCs.
   Study Design: Herein, the osteoinductive effects of glyceollin I and glyceollin II were assessed and compared to estradiol in ASCs and BMSCs. The mechanism by which glyceollin II induces osteogenesis was further examined.
   Methods: The ability of glyceollins to promote osteogenesis of ASCs and BMSCs was evaluated in adherent and scaffold cultures. Relative deposition of calcium was analyzed using Alizarin Red staining, Bichinchoninic acid Protein Assay, and Alamar Blue Assay. To further explore the mechanism by which glyceollin II exerts its osteoinductive effects, docking studies of glyceollin II, RNA isolation, cDNA synthesis, and quantitative RT PCR (qPCR) were performed.
   Results: In adherent cultures, ASCs and BMSCs treated with estradiol, glyceollin I, or glyceollin II demonstrated increased calcium deposition relative to vehicle treated cells. During evaluation on PLGA scaffolds seeded with ASCs and BMSCs, glyceollin II was the most efficacious in inducing ASC and BMSC osteogenesis compared to estradiol and glyceollin I. Dose response analysis in ASCs and BMSCs revealed that glyceollin II has the highest potency at 10 nM in adherent cultures and 1 mu M in tissue scaffold cultures. At all doses, osteoinductive effects were attenuated by fulvestrant, suggesting that glyceollin II acts at least in part through estrogen receptor mediated pathways to induce osteogenesis. Analysis of gene expression demonstrated that, similar to estradiol, glyceollin II induces upregulation of genes involved in osteogenic differentiation.
   Conclusion: The ability of glyceollin II to induce osteogenic differentiation in ASCs and BMSCs indicates that glyceollins hold the potential for the development of pharmacological interventions to improve clinical outcomes of patients with osteoporosis. (C) 2017 Elsevier GmbH. All rights reserved.
C1 [Bateman, Marjorie E.; Strong, Amy L.; Hunter, Ryan S.; Bunnell, Bruce A.] Tulane Univ, Sch Med, Ctr Stem Cell Res & Regenerat Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Bratton, Melyssa R.] Xavier Univ Louisiana, Cell & Mol Biol Core Facil, New Orleans, LA USA.
   [Komati, Rajesh; Sridhar, Jayalakshmi; Riley, Kevin E.; Wang, Guangdi] Xavier Univ Louisiana, Dept Chem, New Orleans, LA USA.
   [Hayes, Daniel J.] Louisiana State Univ, Dept Biol & Agr Engn, Baton Rouge, LA 70803 USA.
   [Hayes, Daniel J.] Ctr Agr, Baton Rouge, LA USA.
   [Boue, Stephen M.] USDA, Southern Reg Res Ctr, 1100 Robert E Lee Blvd, New Orleans, LA USA.
   [Burow, Matthew E.] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70118 USA.
   [Bunnell, Bruce A.] Tulane Univ, Sch Med, Dept Pharmacol, New Orleans, LA 70118 USA.
   [Bunnell, Bruce A.] Tulane Univ, Tulane Natl Primate Res Ctr, Div Regenerat Med, Covington, LA USA.
C3 Tulane University; Xavier University of Louisiana; Xavier University of
   Louisiana; Louisiana State University System; Louisiana State
   University; United States Department of Agriculture (USDA); Tulane
   University; Tulane University; Tulane University
RP Bunnell, BA (通讯作者)，Tulane Univ, Sch Med, Ctr Stem Cell Res & Regenerat Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.
EM bbunnell@tulane.edu
RI ; Komati, Rajesh/K 7497 2019; Bratton, Melyssa/G 9431 2019; Riley,
   Kevin/HGB 2912 2022; Burow, Matthew/D 6351 2013
OI Komati, Rajesh/0000 0002 9940 0690; Strong, Amy/0000 0002 2581 2481;
   Bratton, Melyssa/0000 0001 9063 2025; Hayes, Daniel/0000 0001 9499 4111;
   Bunnell, Bruce/0000 0001 6196 3722; 
FU NIGMS NIH HHS [R15 GM113193] Funding Source: Medline
CR Bernotas RC, 2010, BIOORG MED CHEM LETT, V20, P209, DOI 10.1016/j.bmcl.2009.10.132
   Burow ME, 2001, J CLIN ENDOCR METAB, V86, P1750, DOI 10.1210/jc.86.4.1750
   Calkin AC, 2012, NAT REV MOL CELL BIO, V13, P213, DOI 10.1038/nrm3312
   De Wilde A, 2004, J CELL PHYSIOL, V200, P253, DOI 10.1002/jcp.20008
   Emadedin M, 2015, ARCH IRAN MED, V18, P336, DOI 015186/AIM.003
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Gercel Taylor C, 2004, ANTICANCER RES, V24, P795
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   Hess K, 2009, BONE, V45, P367, DOI 10.1016/j.bone.2009.04.252
   Hong L, 2006, TISSUE ENG, V12, P2747, DOI 10.1089/ten.2006.12.2747
   Jin S, 2010, ANN ONCOL, V21, P263, DOI 10.1093/annonc/mdp499
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kha HT, 2004, J BONE MINER RES, V19, P830, DOI 10.1359/JBMR.040115
   Kim HJ, 2010, J MED FOOD, V13, P382, DOI 10.1089/jmf.2009.1281
   König MA, 2016, CYTOTHERAPY, V18, P41, DOI 10.1016/j.jcyt.2015.10.002
   Lamartiniere CA, 2002, TOXICOL SCI, V65, P228, DOI 10.1093/toxsci/65.2.228
   Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341
   Levi B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011177
   Liu TM, 2007, STEM CELLS, V25, P750, DOI 10.1634/stemcells.2006 0394
   Marini H, 2007, ANN INTERN MED, V146, P839, DOI 10.7326/0003 4819 146 12 200706190 00005
   Matsui Y, 2015, BIOORG MED CHEM LETT, V25, P3914, DOI 10.1016/j.bmcl.2015.07.047
   Peterson B, 2005, TISSUE ENG, V11, P120, DOI 10.1089/ten.2005.11.120
   Picherit C, 2000, J NUTR, V130, P1675, DOI 10.1093/jn/130.7.1675
   Prawitt J, 2011, BONE, V48, P339, DOI 10.1016/j.bone.2010.08.018
   Qureshi AT, 2014, METHOD ENZYMOL, V538, P67, DOI 10.1016/B978 0 12 800280 3.00005 0
   Robertson KM, 2006, J BONE MINER RES, V21, P1276, DOI 10.1359/JBMR.060503
   RODAN G A, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P85
   Salvo VA, 2006, CLIN CANCER RES, V12, P7159, DOI 10.1158/1078 0432.CCR 06 1426
   Schairer C, 2000, JAMA J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485
   Seo JB, 2004, MOL CELL BIOL, V24, P3430, DOI 10.1128/MCB.24.8.3430 3444.2004
   Strong AL, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/412467
   Strong AL, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt493
   Weiderpass E, 1999, J NATL CANCER I, V91, P1131, DOI 10.1093/jnci/91.13.1131
   Yadav DK, 2011, BIOORG MED CHEM LETT, V21, P677, DOI 10.1016/j.bmcl.2010.12.008
NR 34
TC 13
Z9 15
U1 0
U2 19
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
J9 PHYTOMEDICINE
JI Phytomedicine
PD APR 15
PY 2017
VL 27
BP 39
EP 51
DI 10.1016/j.phymed.2017.02.003
PG 13
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA EP3EW
UT WOS:000397266600006
PM 28314478
DA 2025 08 17
ER

PT J
AU Tang, L
   Lv, SJ
   Wu, ZP
   Qian, M
   Xu, YD
   Gao, X
   Wang, T
   Guo, W
   Hou, TH
   Li, X
   Li, ZX
   Zhao, J
   Xiao, JR
   Wei, HF
AF Tang, Liang
   Lv, Shu Jun
   Wu, Zhipeng
   Qian, Ming
   Xu, Yuduo
   Gao, Xin
   Wang, Tao
   Guo, Wen
   Hou, Tianhui
   Li, Xiu
   Li, Zhenxi
   Zhao, Jian
   Xiao, Jianru
   Wei, Haifeng
TI Role of betulinic acid derivative SH 479 in triple negative breast
   cancer and bone microenvironment
SO ONCOLOGY LETTERS
LA English
DT Article
DE betulinic acid derivative; breast cancer; bone metastasis
ID SUPPRESSOR CELLS; CHECKPOINT BLOCKADE; CLINICAL FEATURES; PRIMARY TUMOR;
   METASTASIS; SURVIVAL; PATHWAY; GROWTH; EXPRESSION; INVASION
AB Breast cancer has a high prevalence in the general population and is often associated with bone metastasis. Specific therapeutic targets are missing for triple negative breast cancer (TNBC), which presents some immunogenic characteristics. Betulinic acid (BA) has been reported to have some anti tumor properties, and its modified derivative SH 479 was demonstrated to inhibit TNBC bone metastasis. The present study aimed to investigate the effect of the BA derivative SH 479 on breast cancer and bone microenvironment. The effect of BA and its derivative SH 479 on MDA MB 231 cell proliferation was determined with the MTS method. The cytotoxicity effect of SH 479 was evaluated using the Live and Dead assay. Cell microfilament changes were observed by F actin staining. The effects of SH 479 on PARP protein expression and cell cycle were detected by western blotting and flow cytometry, respectively. The migratory ability of breast cancer cells treated with SH 479 was determined by migration assay. The effect of SH 479 on osteoclast differentiation induced by breast cancer cells was observed using the osteoclast differentiation assay and tartrate resistant acid phosphatase staining. The effects of SH 479 on T lymphocytes and bone marrow derived suppressor cells (MDSCs) in bone marrow from mice were observed by flow cytometry. The results demonstrated that SH 479 significantly inhibited the proliferation of the TNBC cell line MDA MB 231 at lower concentrations but had no significant effect on normal cells and other types of breast cancer cells for the same concentration. Furthermore, SH 479 significantly interfered with actin microfilaments in breast cancer cells but had no effect on cell apoptosis and cell cycle. In addition, SH 479 inhibited the migratory ability of breast cancer cells and the differentiation of osteoclasts induced by breast cancer cells. In bone marrow immune microenvironment, addition of SH 479 could promote the proliferation of CD4+T lymphocytes and inhibit the proliferation of MDSCs. Taken together, the findings from this study demonstrated that SH 479 inhibited the activity and migratory ability of TNBC cells and the differentiation of osteoclasts induced by TNBC and affected the bone marrow immune microenvironment. SH 479 may therefore inhibit breast cancer metastasis to bones, indicating that SH 479 may be considered as a promising drug to inhibit bone metastasis in patients with breast cancer.
C1 [Tang, Liang; Wu, Zhipeng; Qian, Ming; Xu, Yuduo; Gao, Xin; Wang, Tao; Hou, Tianhui; Li, Xiu; Li, Zhenxi; Zhao, Jian; Xiao, Jianru; Wei, Haifeng] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Spine Tumor Ctr, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
   [Lv, Shu Jun] Haian Peoples Hosp, Dept Orthoped, Haian 226600, Jiangsu, Peoples R China.
   [Guo, Wen] Taizhou Peoples Hosp, Dept Orthoped, Taizhou 225300, Jiangsu, Peoples R China.
C3 Naval Medical University
RP Xiao, JR; Wei, HF (通讯作者)，Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Spine Tumor Ctr, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
EM xiaojianrumail@yeah.net; weihaifengmai@yeah.net
RI Li, Xiu/IIP 2983 2023; Wu, Zhi Peng/AAZ 4873 2021
OI Li, Xiu/0009 0008 4823 9025
FU Science and Technology Commission of Shanghai Municipality [17ZR1439000]
FX This study was funded by the Science and Technology Commission of
   Shanghai Municipality (grant no. 17411950301) and the Science and
   Technology Commission of Shanghai Municipality (grant no. 17ZR1439000).
CR Aisha AF, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 168
   Akhshi TK, 2014, CYTOSKELETON, V71, P1, DOI 10.1002/cm.21150
   Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042
   Beiki O, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3086
   Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845
   Buijs JT, 2009, CANCER LETT, V273, P177, DOI 10.1016/j.canlet.2008.05.044
   Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078 0432.CCR 06 1109
   Chowdhury Arnab Roy, 2002, Med Sci Monit, V8, pBR254
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   de Melo CL, 2009, J AGR FOOD CHEM, V57, P8776, DOI 10.1021/jf900768w
   de Sá MS, 2009, PARASITOL RES, V105, P275, DOI 10.1007/s00436 009 1394 0
   Fang J, 2015, CLIN TRANSL ONCOL, V17, P173, DOI 10.1007/s12094 014 1247 x
   Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016
   Fulda S, 2009, MOL NUTR FOOD RES, V53, P140, DOI 10.1002/mnfr.200700491
   Genet C, 2010, J MED CHEM, V53, P178, DOI 10.1021/jm900872z
   Goode BL, 2007, ANNU REV BIOCHEM, V76, P593, DOI 10.1146/annurev.biochem.75.103004.142647
   Harries M, 2014, CANCER EPIDEMIOL, V38, P427, DOI 10.1016/j.canep.2014.05.005
   Hou TH, 2018, ONCOL LETT, V16, P2255, DOI 10.3892/ol.2018.8935
   Ji HF, 2009, EMBO REP, V10, P194, DOI 10.1038/embor.2009.12
   Katz H, 2018, MED ONCOL, V35, DOI 10.1007/s12032 017 1071 6
   Kovar DR, 2006, CURR OPIN CELL BIOL, V18, P11, DOI 10.1016/J.CEB.2005.12.011
   Kuchuk I, 2013, J BONE ONCOL, V2, P137, DOI 10.1016/j.jbo.2013.09.001
   Li ZX, 2019, J BONE MINER RES, V34, P765, DOI 10.1002/jbmr.3652
   Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147
   Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241
   McArthur HL, 2016, CLIN ADV HEMATOL ONC, V14, P922
   Morris GJ, 2007, CANCER AM CANCER SOC, V110, P876, DOI 10.1002/cncr.22836
   Mullauer FB, 2010, ANTI CANCER DRUG, V21, P215, DOI 10.1097/CAD.0b013e3283357c62
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Oakman C, 2010, BREAST, V19, P312, DOI 10.1016/j.breast.2010.03.026
   Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Petrie RJ, 2012, J CELL SCI, V125, P5917, DOI 10.1242/jcs.093732
   Pusztai L, 2016, CLIN CANCER RES, V22, P2105, DOI 10.1158/1078 0432.CCR 15 1315
   Rakha EA, 2007, CANCER AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381
   Sawant A, 2013, CANCER RES, V73, P4606, DOI 10.1158/0008 5472.CAN 13 0305
   Sawant A, 2012, J IMMUNOL, V189, P4258, DOI 10.4049/jimmunol.1101855
   Schalper KA, 2014, CLIN CANCER RES, V20, P2773, DOI 10.1158/1078 0432.CCR 13 2702
   Sinha P, 2005, J IMMUNOL, V174, P636, DOI 10.4049/jimmunol.174.2.636
   Sung B, 2008, BLOOD, V111, P4880, DOI 10.1182/blood 2007 10 117994
   Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078 0432.CCR 05 0883
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001
   van der Heide V, 2016, ANESTHESIOLOGY, V124, P908, DOI 10.1097/ALN.0000000000001031
   Viji V, 2011, BRIT J PHARMACOL, V162, P1291, DOI 10.1111/j.1476 5381.2010.01112.x
   Xu J, 2012, J MED CHEM, V55, P3122, DOI 10.1021/jm201540h
   Yoneda T, 1999, CANCER TREAT REV, V25, P293, DOI 10.1053/ctrv.1999.0133
   Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112
   Zhang YL, 2019, J FOOD SCI, V84, P904, DOI 10.1111/1750 3841.14484
   Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210
NR 50
TC 10
Z9 11
U1 1
U2 16
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD AUG
PY 2021
VL 22
IS 2
AR 605
DI 10.3892/ol.2021.12866
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA TA4YO
UT WOS:000667256000001
PM 34188707
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhao, X
   Alqwbani, M
   Luo, Y
   Chen, CJ
   Ge, A
   Wei, Y
   Li, DH
   Wang, QR
   Tian, M
   Kang, PD
AF Zhao, Xin
   Alqwbani, Mohammed
   Luo, Yue
   Chen, Changjun
   Ge, A.
   Wei, Yang
   Li, Donghai
   Wang, Qiuru
   Tian, Meng
   Kang, Pengde
TI Glucocorticoids decreased Cx43 expression in osteonecrosis of femoral
   head: The effect on proliferation and osteogenic differentiation of rat
   BMSCs
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE bone marrow mesenchymal stem cells; connexin43; dexamethasone; ERK1; 2
   signalling pathway; osteonecrosis of femoral head
ID MARROW STROMAL CELLS; STEROID INDUCED OSTEONECROSIS; MESENCHYMAL
   STEM CELLS; INTRAOSSEOUS PRESSURE; BONE; CONNEXIN 43; ERK; HEMICHANNELS;
   OSTEOBLASTS; LIGAMENT
AB Glucocorticoid (GC) induced osteonecrosis of the femoral head (GC ONFH) is considered as one of the most serious side effects of long term or over dose steroid therapy. However, the underlying cause mechanisms are still not fully investigated. We firstly established a rat model of GC ONFH and injected lipopolysaccharide (LPS) and methylprednisolone (MPS). We found that the expressions of Cx43, Runx2, ALP and COLROMAN NUMERAL ONE were more decreased than the normal group. Secondly, the isolated rat bone marrow stem cells (BMSCs) were treated with dexamethasone (Dex) in vitro, and the expressions of Cx43, Runx2, ALP and COLROMAN NUMERAL ONE were decreased significantly. Moreover, the results of immunofluorescence staining, alizarin red staining, EdU assay and CCK8 showed that the osteogenic differentiation and the proliferation capacity of BMSCs were decreased after induced by Dex. A plasmid of lentivirus mediated Cx43 (Lv Cx43) gene overexpression was established to investigate the function of Cx43 in BMSCs under the Dex treatment. Findings demonstrated that the proliferation and osteogenic differentiation abilities were enhanced after Lv Cx43 transfected to BMSCs, and these beneficial effects of Lv Cx43 were significantly blocked when PD988059 (an inhibitor of ERK1/2) was used. In conclusion, the overexpression of Cx43 could promote the proliferation and osteogenic differentiation of BMSCs via activating the ERK1/2 signalling pathway, which provide a basic evidence for further study on the detailed function of Cx43 in GC ONFH.
C1 [Zhao, Xin; Alqwbani, Mohammed; Luo, Yue; Chen, Changjun; Ge, A.; Li, Donghai; Wang, Qiuru; Kang, Pengde] Sichuan Univ, West China Hosp, Dept Orthopaed Surg, 37 Wainan Guoxue Rd, Chengdu 610041, Peoples R China.
   [Wei, Yang; Tian, Meng] Sichuan Univ, West China Hosp, Neurosurg Res Lab, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University
RP Kang, PD (通讯作者)，Sichuan Univ, West China Hosp, Dept Orthopaed Surg, 37 Wainan Guoxue Rd, Chengdu 610041, Peoples R China.; Tian, M (通讯作者)，Sichuan Univ, West China Hosp, Neurosurg Res Lab, Chengdu 610041, Sichuan, Peoples R China.
EM tianmong007@gmail.com; kangpengde1969@163.com
RI Changjun, Chen/JVO 3592 2024; Xin, Zhao/MHQ 3521 2025; ALQWBANI,
   MOHAMMED/AAB 6157 2022; Chen, Changjun/P 7573 2017
OI yue, luo/0000 0002 1931 2181; Chen, Changjun/0000 0002 4198 7177
FU National Natural Science Foundation of China [81672165, 81974333,
   81401528]
FX National Natural Science Foundation of China (Grant/Award Number:
   81672165, 81974333, 81401528).
CR Bastidas Coral AP, 2019, J CELL PHYSIOL, V234, P20520, DOI 10.1002/jcp.28652
   Bennett MVL, 2012, BRAIN RES, V1487, P3, DOI 10.1016/j.brainres.2012.08.042
   Bivi N, 2012, J BONE MINER RES, V27, P374, DOI 10.1002/jbmr.548
   Buo AM, 2017, J BONE MINER RES, V32, P1727, DOI 10.1002/jbmr.3152
   Cao HJ, 2016, J ORTHOP TRANSL, V4, P57, DOI 10.1016/j.jot.2015.09.005
   Chen DC, 2016, CELL TISSUE RES, V363, P765, DOI 10.1007/s00441 015 2277 6
   Chen XJ, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108746
   Chen YH, 2019, J CELL PHYSIOL, V234, P19824, DOI 10.1002/jcp.28581
   Civitelli R, 2008, ARCH BIOCHEM BIOPHYS, V473, P188, DOI 10.1016/j.abb.2008.04.005
   De Maio A, 2002, J CELL PHYSIOL, V191, P269, DOI 10.1002/jcp.10108
   Deng S, 2019, BIOMED PHARMACOTHER, V110, P602, DOI 10.1016/j.biopha.2018.11.103
   Donahue HJ, 2018, NAT REV RHEUMATOL, V14, P42, DOI 10.1038/nrrheum.2017.204
   Fu LJ, 2008, BONE, V43, P40, DOI 10.1016/j.bone.2008.03.008
   Fu XR, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080784
   Gong LL, 2013, STEROIDS, V78, P401, DOI 10.1016/j.steroids.2013.01.004
   Hervé JC, 2013, CELL TISSUE RES, V352, P21, DOI 10.1007/s00441 012 1485 6
   HUNGERFORD DS, 1985, ORTHOP CLIN N AM, V16, P635
   Kang H, 2016, OSTEOPOROSIS INT, V27, P1493, DOI 10.1007/s00198 015 3381 x
   Keating A, 2012, CELL STEM CELL, V10, P709, DOI 10.1016/j.stem.2012.05.015
   Kerachian MA, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3062
   Kerachian MA, 2009, J STEROID BIOCHEM, V114, P121, DOI 10.1016/j.jsbmb.2009.02.007
   Kong LC, 2020, INT J BIOL SCI, V16, P655, DOI 10.7150/ijbs.38713
   Laird DW, 2014, FEBS LETT, V588, P1339, DOI 10.1016/j.febslet.2013.12.022
   Leithe E, 2018, BBA BIOMEMBRANES, V1860, P48, DOI 10.1016/j.bbamem.2017.05.008
   Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348
   Li J, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1431 6
   Li P, 2019, J NAT MED TOKYO, V73, P104, DOI 10.1007/s11418 018 1249 z
   Li SN, 2015, J ORTHOP RES, V33, P1008, DOI 10.1002/jor.22830
   Li ZH, 2020, KAOHSIUNG J MED SCI, V36, P35, DOI 10.1002/kjm2.12134
   Lin FX, 2018, CELL PHYSIOL BIOCHEM, V47, P161, DOI 10.1159/000489763
   Liu BY, 2019, MAT SCI ENG C MATER, V99, P1123, DOI 10.1016/j.msec.2019.02.072
   Liu G, 2016, EXP MOL PATHOL, V101, P89, DOI 10.1016/j.yexmp.2016.07.009
   Liu ZS, 2020, CELL BIOCHEM FUNCT, V38, P87, DOI 10.1002/cbf.3457
   Luo P, 2018, INT ORTHOP, V42, P1747, DOI 10.1007/s00264 018 3994 8
   Miyanishi K, 2002, BONE, V30, P185, DOI 10.1016/S8756 3282(01)00663 9
   Moorer MC, 2017, CURR OSTEOPOROS REP, V15, P24, DOI 10.1007/s11914 017 0345 4
   Plotkin LI, 2016, BMC CELL BIOL, V17, DOI 10.1186/s12860 016 0088 6
   Riquelme MA, 2015, J BIOL CHEM, V290, P28321, DOI 10.1074/jbc.M115.683417
   Stains JP, 2016, SEMIN CELL DEV BIOL, V50, P31, DOI 10.1016/j.semcdb.2015.12.017
   Stains JP, 2014, CALCIFIED TISSUE INT, V94, P55, DOI 10.1007/s00223 013 9742 6
   Wang N, 2019, J CELL MOL MED, V23, P3683, DOI 10.1111/jcmm.14272
   Wang N, 2019, EUR J PHARMACOL, V849, P11, DOI 10.1016/j.ejphar.2019.01.064
   Wang YL, 2020, IUBMB LIFE, V72, P296, DOI 10.1002/iub.2165
   Wei Z, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/1340252
   Weinstein RS, 2012, ENDOCRINE, V41, P183, DOI 10.1007/s12020 011 9580 0
   Wu XJ, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8140595
   Xia XC, 2010, MOL CELL BIOL, V30, P206, DOI 10.1128/MCB.01844 08
   Xiao JJ, 2015, MOL CELL BIOCHEM, V409, P113, DOI 10.1007/s11010 015 2517 9
   Xu ZH, 2012, MOL BIOL REP, V39, P7271, DOI 10.1007/s11033 012 1557 4
   Yang HS, 2016, CELL PHYSIOL BIOCHEM, V38, P237, DOI 10.1159/000438625
   Zhang QK, 2018, J INT MED RES, V46, P2141, DOI 10.1177/0300060517700299
   Zhang QW, 2018, CURR PROTEIN PEPT SC, V19, P1049, DOI 10.2174/1389203719666180709103515
   Zhao X, 2019, CALCIFIED TISSUE INT, V105, P506, DOI 10.1007/s00223 019 00592 3
   Zhao Y, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/637415
   Zhou DA, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 239
NR 55
TC 18
Z9 21
U1 2
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JAN
PY 2021
VL 25
IS 1
BP 484
EP 498
DI 10.1111/jcmm.16103
EA NOV 2020
PG 15
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA PS3LO
UT WOS:000589906600001
PM 33205619
OA Green Published
DA 2025 08 17
ER

PT J
AU Jiang, SG
   Liu, ZG
   Wu, L
   Yuan, YJ
   Hu, Y
   Zhang, XY
   Wei, L
   Zu, YG
AF Jiang, Shougang
   Liu, Zhiguo
   Wu, Lei
   Yuan, Yingjie
   Hu, Yan
   Zhang, Xingyao
   Wei, Liang
   Zu, Yuangang
TI Tumor targeting with docosahexaenoic acid conjugated docetaxel for
   inhibiting lung cancer metastasis to bone
SO ONCOLOGY LETTERS
LA English
DT Article
DE docosahexaenoic acid conjugated docetaxel; tumor vascular endothelium
   targeting; lung cancer metastasis to bone; antitumor activity
ID SERUM ALBUMIN NANOPARTICLES; DHA PACLITAXEL TAXOPREXIN; II OPEN LABEL;
   1ST LINE TREATMENT; PROSTATE CANCER; BREAST CANCER; FATTY ACIDS;
   THERAPY; EFFICACY; PHOSPHATIDYLETHANOLAMINE
AB Docetaxel (DTX) is currently used as a first  or second line drug treatment for patients with lung cancer, however, it is less effective for the treatment of patients with bone metastasis of lung cancer. This is primarily due to the fact that docetaxel is nonspecific. In the present study, docosahexaenoic acid (DHA) was selected as a tumor targeting ligand, and DHA conjugated DTX (DTX DHA) was prepared for inhibiting lung cancer metastasis to bone. The anti cancer activity assay revealed that DTX DHA exhibited a similar antitumor efficacy to DTX in vitro. The maximum tolerated dose of DTX DHA was increased compared with that of DTX. The present study results indicated that DTX DHA exhibited an improved inhibition efficacy of lung cancer metastasis to bone in comparison with DTX in vivo. Encouragingly, the mean survival time of the DTX DHA group (30.60 days) was increased compared with the DTX group (26.10 days; P<0.01). Furthermore, the results of cell migration and osteoclast induced formation assays suggested that DTX DHA inhibited lung cancer metastasis to bone primarily by affecting lung cancer cell migration. These results indicate that DTX DHA may exhibit a potential therapeutic effect against lung cancer metastasis to bone.
C1 [Jiang, Shougang; Liu, Zhiguo; Wu, Lei; Yuan, Yingjie; Hu, Yan; Zhang, Xingyao; Wei, Liang; Zu, Yuangang] Northeast Forestry Univ, Minist Educ, Key Lab Forest Plant Ecol, 26 Hexing Rd, Harbin 150040, Heilongjiang, Peoples R China.
   [Jiang, Shougang; Liu, Zhiguo; Wu, Lei; Yuan, Yingjie; Hu, Yan; Zhang, Xingyao; Wei, Liang; Zu, Yuangang] Northeast Forestry Univ, State Engn Lab Bioresources Ecoutilizat, Harbin 150040, Heilongjiang, Peoples R China.
C3 Northeast Forestry University   China; Northeast Forestry University  
   China
RP Zu, YG (通讯作者)，Northeast Forestry Univ, Minist Educ, Key Lab Forest Plant Ecol, 26 Hexing Rd, Harbin 150040, Heilongjiang, Peoples R China.
EM cpu127@126.com
RI ; Zhang, Xingyao/AAX 1727 2021; liu, zhiguo/IUQ 7631 2023
OI Wei, Liang/0000 0001 7660 3471; 
FU Fundamental Research Funds for the Central Universities [2572018BU03];
   Science Foundation of Heilongjiang Province, China [H2018001];
   Heilongjiang [LBH Z10282]
FX The present study was funded by the Fundamental Research Funds for the
   Central Universities (grant no. 2572018BU03), the Science Foundation of
   Heilongjiang Province, China (grant no. H2018001) and the Heilongjiang
   Postdoctoral (grant no. LBH Z10282).
CR Bedikian AY, 2011, ANN ONCOL, V22, P787, DOI 10.1093/annonc/mdq438
   Bölükbas DA, 2015, NANOMEDICINE UK, V10, P3203, DOI 10.2217/nnm.15.155
   Bradley MO, 2001, CLIN CANCER RES, V7, P3229
   Chauvin L, 2016, BBA MOL CELL BIOL L, V1861, P380, DOI 10.1016/j.bbalip.2016.01.012
   Chu J.J., 2014, MED INNOV CHINA, V11, P11
   Fahrmann JF, 2016, CANCER BIOMARK, V16, P609, DOI 10.3233/CBM 160602
   Gligorov J, 2004, ONCOLOGIST S, V9, pS3, DOI 10.1634/theoncologist.9 suppl_2 3
   Harries M, 2004, BRIT J CANCER, V91, P1651, DOI 10.1038/sj.bjc.6602196
   Hoang B, 2017, CANCER LETT, V410, P169, DOI 10.1016/j.canlet.2017.09.029
   Jiang SG, 2015, DRUG DELIV, V22, P206, DOI 10.3109/10717544.2013.879964
   Jones RJ, 2008, CANCER CHEMOTH PHARM, V61, P435, DOI 10.1007/s00280 007 0486 8
   Kan C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101674
   Kenmotsu H, 2015, CANCER SCI, V106, P497, DOI 10.1111/cas.12647
   Lazzari C, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00004
   LeVasseur N, 2016, CANCER TREAT REV, V50, P183, DOI 10.1016/j.ctrv.2016.09.013
   Li SW, 2014, ONCOTARGET, V5, P3622, DOI 10.18632/oncotarget.1969
   Liu FX, 2013, INT J PHARMACEUT, V451, P41, DOI 10.1016/j.ijpharm.2013.04.020
   Luo QQ, 2016, MOL CLIN ONCOL, V5, P227, DOI 10.3892/mco.2016.917
   Mai JH, 2014, J CONTROL RELEASE, V187, P22, DOI 10.1016/j.jconrel.2014.04.057
   Merendino N, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/310186
   Murphy RA, 2011, CANCER AM CANCER SOC, V117, P3774, DOI 10.1002/cncr.25933
   Payne M, 2006, J THORAC ONCOL, V1, P984, DOI 10.1097/01243894 200611000 00011
   Popper HH, 2016, CANCER METAST REV, V35, P75, DOI 10.1007/s10555 016 9618 0
   Rahman MM, 2013, BREAST CANCER RES TR, V141, P341, DOI 10.1007/s10549 013 2703 y
   Ray A, 2011, MOL PHARMACEUT, V8, P1090, DOI 10.1021/mp100402n
   Riediger ND, 2009, J AM DIET ASSOC, V109, P668, DOI 10.1016/j.jada.2008.12.022
   Roato I, 2014, WORLD J CLIN ONCOL, V5, P149, DOI 10.5306/wjco.v5.i2.149
   Sánchez Lara K, 2014, CLIN NUTR, V33, P1017, DOI 10.1016/j.clnu.2014.03.006
   Siddiqui RA, 2011, BIOFACTORS, V37, P399, DOI 10.1002/biof.181
   Socinski MA, 2014, CURR ONCOL, V21, pE691, DOI 10.3747/co.21.1997
   Sparreboom A, 2003, CLIN CANCER RES, V9, P151
   Stafford JH, 2011, NEOPLASIA, V13, P299, DOI 10.1593/neo.101366
   Vicent S, 2015, AM J RESP CRIT CARE, V192, P799, DOI 10.1164/rccm.201503 0440SO
   Yared JA, 2012, DRUG DES DEV THER, V6, P371, DOI 10.2147/DDDT.S28997
   Yates CM, 2011, J NUTR, V141, P1331, DOI 10.3945/jn.111.139287
   Zu YG, 2017, ANTI CANCER AGENT ME, V17, P542, DOI 10.2174/1871520616666160817143656
NR 36
TC 10
Z9 14
U1 0
U2 19
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD SEP
PY 2018
VL 16
IS 3
BP 2911
EP 2920
DI 10.3892/ol.2018.9047
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA GQ7TE
UT WOS:000441948400019
PM 30127879
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Srouji, S
   Ben David, D
   Fromigué, O
   Vaudin, P
   Kuhn, G
   Müller, R
   Livne, E
   Marie, PJ
AF Srouji, Samer
   Ben David, Dror
   Fromigue, Olivia
   Vaudin, Pascal
   Kuhn, Gisela
   Mueller, Ralph
   Livne, Erella
   Marie, Pierre J.
TI Lentiviral Mediated Integrin α5 Expression in Human Adult Mesenchymal
   Stromal Cells Promotes Bone Repair in Mouse Cranial and Long Bone
   Defects
SO HUMAN GENE THERAPY
LA English
DT Article
ID STEM CELLS; GENE THERAPY; DIFFERENTIATION; APOPTOSIS; PLATFORM
AB Adult human mesenchymal stromal cells (hMSCs) are an important source for tissue repair in regenerative medicine. Notably, targeted gene therapy in hMSCs to promote osteogenic differentiation may help in the development of novel therapeutic approaches for bone repair. We recently showed that alpha 5 integrin (ITGA5) promotes osteoblast differentiation in bone marrow derived hMSCs. Here, we determined whether lentiviral (LV) mediated expression of ITGA5 in hMSCs derived from the bone marrow stroma of healthy individuals may promote bone repair in vivo in two relevant critical size bone defects in the mouse. In a first series of experiments, control or LV ITGA5 transduced hMSCs were seeded on collagen based gelatin sponge and transplanted in a cranial critical size defect (5mm) in Nude Foxn1nu mice. Microcomputed tomography and quantitative histological analyses after 8 weeks showed no or little de novo bone formation in defects implanted with collagen sponge alone or with hMSCs, respectively. In contrast, implantation of collagen sponge with LV ITGA5 transduced hMSCs showed greater bone formation compared with control hMSCs. We also tested the bone repair potential of LV mediated ITGA5 expression in hMSCs in a critical size long bone defect (2 mm) in femur in Nude Foxn1nu mice. Bone remnants were stabilized with external fixation, and control or LV ITGA5 transduced hMSCs mixed with coral/hydroxyapatite particles were transplanted into the critical size long bone defect. Histological analysis after 8 weeks showed that LV ITGA5 transduced hMSCs implanted with particles induced 85% bone regeneration and repair. These results demonstrate that repair of critical size mouse cranial and long bone defects can be induced using LV mediated ITGA5 gene expression in hMSCs, which provides a novel gene therapy for bone regeneration.
C1 [Srouji, Samer] Carmel Hosp, Oral & Maxillofacial Surg Dept, IL 32000 Haifa, Israel.
   [Srouji, Samer; Ben David, Dror; Livne, Erella] Technion Israel Inst Technol, Dept Anat & Cell Biol, Rappaport Fac Med, IL 32000 Haifa, Israel.
   [Fromigue, Olivia; Marie, Pierre J.] INSERM, Lab Osteoblast Biol & Pathol, U606, F 75475 Paris, France.
   [Fromigue, Olivia; Marie, Pierre J.] Univ Paris Diderot, UMR 606, F 75475 Paris, France.
   [Vaudin, Pascal] INSERM, U966, F 75475 Paris, France.
   [Vaudin, Pascal] Univ Tours, F 37032 Tours, France.
   [Kuhn, Gisela; Mueller, Ralph] ETH, Inst Biomech, CH 8093 Zurich, Switzerland.
C3 Clalit Health Services; Carmel Medical Center; Technion Israel Institute
   of Technology; Rappaport Faculty of Medicine; Institut National de la
   Sante et de la Recherche Medicale (Inserm); Universite Paris Cite;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Tours; Swiss Federal Institutes of Technology Domain; ETH
   Zurich
RP Marie, PJ (通讯作者)，Hop Lariboisiere, INSERM, U606, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM pierre.marie@inserm.fr
RI Fromigue, Olivia/B 8225 2013; Müller, Ralph/A 1198 2008; Vaudin,
   Pascal/J 1870 2014; Muller, Ralph/A 1198 2008
OI Fromigue, Olivia/0000 0002 3050 6155; Srouji, Samer/0000 0001 8837 2391;
   Muller, Ralph/0000 0002 5811 7725
FU Fondation de l'Avenir pour la Recherche Appliquee, Paris, France
   [ET9 521]
FX The authors thank Dr. S. Kuwada (University of Utah, Salt Lake City, UT)
   for the gift of the ITGA5 plasmid. This work was supported in part by
   the Fondation de l'Avenir pour la Recherche Appliquee, Paris, France
   (no. ET9 521). The use of ITGA5 agonists for applications in tissue
   regeneration is covered by European patent no. 08290752.8 and U.S.
   patent no. US 2011 0182916.
CR Aslan H, 2006, TISSUE ENG, V12, P877, DOI 10.1089/ten.2006.12.877
   Augello A, 2010, HUM GENE THER, V21, P1226, DOI 10.1089/hum.2010.173
   Bianco P, 2000, J CLIN INVEST, V105, P1663, DOI 10.1172/JCI10413
   Bianco P, 2010, HUM GENE THER, V21, P1057, DOI 10.1089/hum.2010.136
   Charbord P, 2010, HUM GENE THER, V21, P1045, DOI 10.1089/hum.2010.115
   Delorme Bruno, 2007, V140, P67
   Dufour C, 2007, EXP CELL RES, V313, P394, DOI 10.1016/j.yexcr.2006.10.021
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   Evans CH, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001493
   Franceschi RT, 2005, J DENT RES, V84, P1093, DOI 10.1177/154405910508401204
   Gazit D, 1999, J GENE MED, V1, P121, DOI 10.1002/(SICI)1521 2254(199903/04)1:2<121::AID JGM26>3.0.CO;2 J
   GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092 8674(90)90098 Y
   Hamidouche Z, 2008, FASEB J, V22, P3813, DOI 10.1096/fj.08 106302
   Hamidouche Z, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 44
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Heyde M, 2007, J PHARM PHARMACOL, V59, P329, DOI 10.1211/jpp.59.3.0002
   Hou Z, 1999, P NATL ACAD SCI USA, V96, P7294, DOI 10.1073/pnas.96.13.7294
   Kaabeche K, 2005, J CELL SCI, V118, P1223, DOI 10.1242/jcs.01679
   Kassem M, 2004, CLONING STEM CELLS, V6, P369, DOI 10.1089/clo.2004.6.369
   Lian J. B., 2003, Current Pharmaceutical Design, V9, P2677, DOI 10.2174/1381612033453659
   Lutolf MR, 2003, NAT BIOTECHNOL, V21, P513, DOI 10.1038/nbt818
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   Muller Ralph, 2006, Curr Osteoporos Rep, V4, P80, DOI 10.1007/s11914 006 0007 4
   Oreffo ROC, 2005, STEM CELL REV, V1, P169, DOI 10.1385/SCR:1:2:169
   Peterson B, 2005, TISSUE ENG, V11, P120, DOI 10.1089/ten.2005.11.120
   Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449
   Prockop DJ, 2009, MOL THER, V17, P939, DOI 10.1038/mt.2009.62
   Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100
   Ruegsegger P, 1996, CALCIFIED TISSUE INT, V58, P24, DOI 10.1007/s002239900006
   Srouji S, 2011, TISSUE ENG PART C ME, V17, P597, DOI [10.1089/ten.TEC.2010.0501, 10.1089/ten.tec.2010.0501]
   Turgeman G, 2001, J GENE MED, V3, P240
   Vilquin JT, 2006, REGEN MED, V1, P589, DOI 10.2217/17460751.1.4.589
NR 32
TC 27
Z9 30
U1 0
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043 0342
EI 1557 7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD FEB
PY 2012
VL 23
IS 2
BP 167
EP 172
DI 10.1089/hum.2011.059
PG 6
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 895UN
UT WOS:000300522200006
PM 21958321
DA 2025 08 17
ER

PT J
AU Gui, LY
   Ye, QY
   Yu, L
   Dou, G
   Zhou, Y
   Liu, Y
   Zhang, YQ
   Yang, XS
   Jin, F
   Liu, SY
   Jin, Y
   Ren, LL
AF Gui, Linyuan
   Ye, Qingyuan
   Yu, Lu
   Dou, Geng
   Zhou, Yang
   Liu, Yang
   Zhang, Yanqi
   Yang, Xiaoshan
   Jin, Fang
   Liu, Shiyu
   Jin, Yan
   Ren, Lili
TI Bone Targeting Peptide and RNF146 Modified Apoptotic Extracellular
   Vesicles Alleviate Osteoporosis
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE osteoporosis; mesenchymal stem cells; apoptotic extracellular vesicles;
   bone targeting; bone regeneration
ID STEM CELLS; BISPHOSPHONATES; OSTEONECROSIS; MANAGEMENT; DIAGNOSIS;
   EXOSOMES; BENEFITS; JAW
AB Background: Osteoporosis is a highly prevalent disease that causes fractures and loss of motor function. Current drugs targeted for osteoporosis often have inevitable side effects. Bone marrow mesenchymal stem cell (BMSCs) derived apoptotic extracellular vesicles (ApoEVs) are nanoscale extracellular vesicles, which has been shown to promote bone regeneration with low immunogenicity and high biological compatibility. However, natural ApoEVs cannot inherently target bones, and are often eliminated by macrophages in the liver and spleen. Thus, our study aimed to reconstruct ApoEVs to enhance their bone targeting capabilities and bone promoting function and to provide a new method for osteoporosis treatment. Methods: We conjugated a bone targeting peptide, (Asp Ser Ser)6 ((DSS)6), onto the surface of ApoEVs using standard carbodiimide chemistry with DSPE PEG COOH serving as the linker. The bone targeting ability of (DSS)6 ApoEVs was determined using an in vivo imaging system and confocal laser scanning microscopy (CLSM). We then loaded ubiquitin ligase RING finger protein146 (RNF146) into BMSCs via adenovirus transduction to obtain functional ApoEVs. The bone promoting abilities of (DSS)6 ApoEVs and (DSS)6 ApoEVsRNF146 were measured in vitro and in vivo. Results: Our study successfully synthesized bone targeting and gained functional (DSS)6 ApoEVsRNF146 and found that engineered ApoEVs could promote osteogenesis in vitro and exert significant bone targeting and osteogenesis promoting effects to alleviate osteoporosis in a mouse model. Conclusion: To promote the bone targeting ability of natural ApoEVs, we successfully synthesized engineered ApoEVs, (DSS)6ApoEVs, which holds great promise for the treatment of osteoporosis.
C1 [Gui, Linyuan; Dou, Geng; Zhou, Yang; Yang, Xiaoshan; Liu, Shiyu; Jin, Yan; Ren, Lili] Fourth Mil Med Univ, Natl Clin Res Ctr Oral Dis, Shaanxi Int Joint Res Ctr Oral Dis, Ctr Tissue Engn,Sch Stomatol,State key Lab Oral &, Xian 710032, Shaanxi, Peoples R China.
   [Ye, Qingyuan] Fourth Mil Med Univ, Sch Stomatol, State Key Lab Oral & Maxillofacial Reconstruct & R, Natl Clin Res Ctr Oral Dis,Shaanxi Key Lab Stomato, Xian 710032, Shaanxi, Peoples R China.
   [Yu, Lu; Liu, Yang] Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Jinan 250012, Shandong, Peoples R China.
   [Yu, Lu] Shandong Key Lab Oral Tissue Regenerat, Jinan 250012, Shandong, Peoples R China.
   [Yu, Lu] Shandong Engn Lab Dent Mat & Oral Tissue Regenerat, Jinan 250012, Shandong, Peoples R China.
   [Yu, Lu] Shandong Prov Clin Res Ctr Oral Dis, Jinan 250012, Shandong, Peoples R China.
   [Zhou, Yang] Fourth Mil Med Univ, Xijing Hosp, Dept Anesthesiol & Perioperat Med, Xian 710032, Shaanxi, Peoples R China.
   [Zhang, Yanqi; Jin, Fang] Fourth Mil Med Univ, Natl Clin Res Ctr Oral Dis, State Key Lab Oral & Maxillofacial Reconstruct & R, Shaanxi Clin Res Ctr Oral Dis,Dept Orthodont,Sch S, Xian 710032, Shaanxi, Peoples R China.
   [Yang, Xiaoshan] Southern Med Univ, Stomatol Hosp, Sch Stomatol, Guangzhou 510280, Guangdong, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Shandong
   University; Air Force Medical University; Air Force Medical University;
   Southern Medical University   China
RP Jin, Y; Ren, LL (通讯作者)，Fourth Mil Med Univ, Natl Clin Res Ctr Oral Dis, Shaanxi Int Joint Res Ctr Oral Dis, Ctr Tissue Engn,Sch Stomatol,State key Lab Oral &, Xian 710032, Shaanxi, Peoples R China.
EM yanjin@fmmu.edu.cn; lanyangddgy@qq.com
RI Dou, Geng/LUW 9667 2024; JIN, YAN/HPC 7389 2023
OI Ye, Qingyuan/0000 0001 7804 9726; Ren, Lili/0009 0002 2999 251X
FU National Key Research and Development Program of China [2022YFA1104400];
   National Natural Science Foundation of China [81930025, 82202341]
FX Funding This study was supported by the National Key Research and
   Development Program of China (2022YFA1104400 to Yan Jin) and The
   National Natural Science Foundation of China (81930025 to Yan Jin,
   82202341 to Xiaoshan Yang) .
CR ALBERT A, 1956, NATURE, V177, P433, DOI 10.1038/177433a0
   Bergmann A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3145re8
   Brown JP, 2014, CAN FAM PHYSICIAN, V60, P324
   Caruso S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01486
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dell RM, 2012, J BONE MINER RES, V27, P2544, DOI 10.1002/jbmr.1719
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Estell EG, 2021, NAT REV ENDOCRINOL, V17, P31, DOI 10.1038/s41574 020 00426 5
   GAMBRELL RD, 1982, FERTIL STERIL, V37, P457
   Hatzenbuehler J, 2011, AM FAM PHYSICIAN, V84, P1027
   Jain S, 2021, MAT SCI ENG C MATER, V121, DOI 10.1016/j.msec.2020.111832
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Khan M, 2017, ENDOCRIN METAB CLIN, V46, P181, DOI 10.1016/j.ecl.2016.09.009
   Lawson MA, 2010, J BIOMED MATER RES B, V92B, P149, DOI 10.1002/jbm.b.31500
   Li M, 2022, J DENT RES, V101, P714, DOI 10.1177/00220345211068338
   Li ZH, 2022, MOL THER, V30, P3193, DOI 10.1016/j.ymthe.2022.05.006
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Liao W, 2019, ACTA BIOMATER, V86, P1, DOI 10.1016/j.actbio.2018.12.045
   Liu DW, 2018, CELL RES, V28, P918, DOI 10.1038/s41422 018 0070 2
   Liu M, 2018, J DENT RES, V97, P859, DOI 10.1177/0022034518764411
   Lorentzon M, 2019, J INTERN MED, V285, P381, DOI 10.1111/joim.12873
   Ma L, 2023, BIOACT MATER, V19, P626, DOI 10.1016/j.bioactmat.2022.04.022
   MARUYAMA K, 1995, BBA BIOMEMBRANES, V1234, P74, DOI 10.1016/0005 2736(94)00263 O
   Parada N, 2021, J ADV RES, V31, P61, DOI 10.1016/j.jare.2021.01.001
   Poon IKH, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1608786
   Ravindran S, 2013, J BIOL CHEM, V288, P16098, DOI 10.1074/jbc.M113.450585
   Reichert JC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003720
   Reyes C, 2016, J CELL BIOCHEM, V117, P20, DOI 10.1002/jcb.25266
   Rotman SG, 2018, J CONTROL RELEASE, V269, P88, DOI 10.1016/j.jconrel.2017.11.009
   Sánchez A, 2017, OSTEOPOROSIS INT, V28, P1145, DOI 10.1007/s00198 016 3840 z
   Santavanond Jascinta P, 2021, Subcell Biochem, V97, P61, DOI 10.1007/978 3 030 67171 6_4
   Shi C, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2020.107473
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Tang HX, 2022, CELLS BASEL, V11, DOI 10.3390/cells11233879
   Valentn S, 2009, CLIN COSMET INVESTI, V2, P129
   Wang JT, 2010, J COLLOID INTERF SCI, V349, P578, DOI 10.1016/j.jcis.2010.04.081
   Wiklander OPB, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.26316
   Xiao Y, 2010, INT J ORAL SCI, V2, P127, DOI 10.4248/IJOS10045
   Yamashita T, 2016, EUR J PHARM BIOPHARM, V98, P1, DOI 10.1016/j.ejpb.2015.10.017
   Yang K, 2018, BONE, V114, P40, DOI 10.1016/j.bone.2018.06.003
   Yang YS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10809 6
   Ye QY, 2023, INT J ORAL SCI, V15, DOI 10.1038/s41368 022 00205 0
   Ye QY, 2022, J PERIODONTOL, V93, P1738, DOI 10.1002/JPER.21 0657
   Zernecke A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000610
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang Y, 2011, NAT CELL BIOL, V13, P623, DOI 10.1038/ncb2222
   Zheng CX, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12109
   Zhou X, 2021, NANO LETT, V21, P7998, DOI 10.1021/acs.nanolett.1c02150
   Zimmermann CE, 2011, TISSUE ENG PT A, V17, P1147, DOI [10.1089/ten.tea.2009.0577, 10.1089/ten.TEA.2009.0577]
NR 49
TC 12
Z9 13
U1 8
U2 31
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2024
VL 19
BP 471
EP 488
DI 10.2147/IJN.S433511
PG 18
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA GA7B7
UT WOS:001149991900001
PM 38250192
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Carmona Sarabia, L
   Vélez, GQ
   Escalera Joy, AM
   Mojica Vázquez, D
   Esteves Vega, S
   Peterson Peguero, EA
   López Mejías, V
AF Carmona Sarabia, Lesly
   Velez, Gabriel Quinones
   Escalera Joy, Andrea M.
   Mojica Vazquez, Darilys
   Esteves Vega, Solimar
   Peterson Peguero, Esther A.
   Lopez Mejias, Vilmali
TI Design of Extended Bisphosphonate Based Coordination Polymers as
   Bone Targeted Drug Delivery Systems for Breast Cancer Induced Osteolytic
   Metastasis and Other Bone Therapies
SO INORGANIC CHEMISTRY
LA English
DT Article
ID METAL ORGANIC FRAMEWORKS; CONTROLLED RELEASE; 5 FLUOROURACIL; ZINC;
   PHOSPHONATES; CRYSTALLINE; ALGINATE
AB Extended bisphosphonate basedcoordination polymers (BPCPs)present higher binding (>2.5x) than commercialBPsto the main constituent of bone, comparable drug loading/release (similar to 30wt % 5 fluorouracil) relative to other network coordination polymers(i.e., MIL 53), and the ability to effect cytotoxicity against a triple negativehuman breast cancer cell line (MDA MB 231) known to metastasize tothe bone without disrupting viability in human osteoblast like hFOB1.19 cells. Collectively, these results demonstrate the potentialof BPCPs as bone targeted drug delivery systems to treat bone relateddiseases such as osteolytic metastases.
   The coordination between benzene 1,4 bis(bisphosphonicacid) (BBPA),the bisphosphonate (BP) analogue of benzene 1,4 dicarboxylic acid(BDC), and bioactive metals led to the formation of extended bisphosphonate basedcoordination polymers (BPCPs). Four distinct crystalline phases wereobtained, namely, BBPA Ca forms I and II, BBPA Zn, and BBPA Mg. Amongthese, BBPA Ca forms I (7 x 9 angstrom(2)) and II (8 x12 angstrom(2)) possess channels large enough to encapsulate5 fluorouracil (5 FU), a drug prescribed in combination with BPs totreat breast cancer induced osteolytic metastases (OM). Dissolutioncurves show a 14% release of BBPA from BBPA Ca form II in phosphate bufferedsaline, while similar to 90% was released in fasted state simulated gastricfluid. These results suggest that this material is relatively stablein neutral environments yet collapses in acidic conditions. Moreover,the phase inversion temperature method decreased the particle sizeof BBPA Ca form II, resulting in nano Ca@BBPA (similar to 134 d.nm).Binding assays showed a higher affinity of nano Ca@BBPA (similar to 97%)to hydroxyapatite than BBPA (similar to 70%) and significantly higherbinding than commercial BPs, zolendronic (3.0x), and risedronic(2.4x) acids after 24 h. Furthermore, both BBPA Ca form II andnano Ca@BBPA presented comparable drug loading and release (similar to 30wt % 5 FU) relative to BDC based CCs (UiO 66, MIL 53, and BDC Zr)where other pharmaceutical compounds (caffeine, ibuprofen, aspirin,and alpha cyano 4 hydroxycinnamic acid) have been encapsulated.Cell viability assays established that drug loaded nano Ca@BBPA increasesthe cytotoxicity of a triple negative human breast cancer cell line(MDA MB 231) when compared to 5 FU (%RCV = 8 +/  5 vs 75 +/  1% at a 100 mu M). At the same concentration, no significant decreasein cell viability was observed for normal human osteoblast like hFOB1.19 cells (%RCV = 85 +/  1%). Collectively, these results demonstratethe feasibility of nano Ca@BBPA as a potential drug delivery system(DDS), with high affinity to bone tissue, to treat bone related diseasessuch as OM.
C1 [Carmona Sarabia, Lesly; Velez, Gabriel Quinones; Escalera Joy, Andrea M.; Mojica Vazquez, Darilys; Lopez Mejias, Vilmali] Univ Puerto Rico, Dept Chem, San Juan, PR 00931 USA.
   [Carmona Sarabia, Lesly; Velez, Gabriel Quinones; Escalera Joy, Andrea M.; Mojica Vazquez, Darilys; Esteves Vega, Solimar] Univ Puerto Rico, Crystallizat Design Inst, Mol Sci Res Ctr, San Juan, PR 00926 USA.
   [Esteves Vega, Solimar] Univ Puerto Rico, Interdisciplinary Sci Program, San Juan, PR 00931 USA.
   [Peterson Peguero, Esther A.] Univ Puerto Rico, Dept Biol, San Juan, PR 00931 USA.
C3 University of Puerto Rico; University of Puerto Rico Medical Sciences
   Campus; University of Puerto Rico; University of Puerto Rico; University
   of Puerto Rico; University of Puerto Rico Medical Sciences Campus
RP López Mejías, V (通讯作者)，Univ Puerto Rico, Dept Chem, San Juan, PR 00931 USA.
EM vilmali.lopez@upr.edu
OI Quinones Velez, Gabriel/0000 0001 8789 1616; Peterson Peguero, Esther
   A/0000 0001 7497 0980; Carmona Sarabia, Lesly/0000 0002 1733 319X;
   Esteves Vega, Solimar/0000 0002 0035 826X
CR Bailone RL, 2022, COMPARATIVE MED, V72, P342, DOI 10.30802/AALAS CM 22 000009
   Ban JZ, 2021, CELLS BASEL, V10, DOI 10.3390/cells10112944
   Beg S, 2017, DRUG DISCOV TODAY, V22, P625, DOI 10.1016/j.drudis.2016.10.001
   Boedtkjer E, 2020, ANNU REV PHYSIOL, V82, P103, DOI 10.1146/annurev physiol 021119 034627
   Bray F, 2018, CA CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   BURDETT JK, 1978, INORG CHEM, V17, P2553, DOI 10.1021/ic50187a041
   Cai MR, 2020, RSC ADV, V10, P36862, DOI 10.1039/d0ra06106a
   Capietto AH, 2021, CANCER IMMUNOL RES, V9, P1400, DOI 10.1158/2326 6066.CIR 21 0232
   Case DR, 2020, MOLECULES, V25, DOI 10.3390/molecules25143172
   Castiglioni S, 2013, NUTRIENTS, V5, P3022, DOI 10.3390/nu5083022
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Croset M, 2015, BONE CANCER: PRIMARY BONE CANCER AND BONE METASTASES, 2ND EDITION, P479, DOI 10.1016/B978 0 12 416721 6.00041 8
   Cunha D, 2013, CHEM MATER, V25, P2767, DOI 10.1021/cm400798p
   Egorov M, 2011, EUR J ORG CHEM, V2011, P7148, DOI 10.1002/ejoc.201101094
   FIROR RL, 1978, INORG CHEM, V17, P2144, DOI 10.1021/ic50186a021
   Freire E, 2010, ACTA CRYSTALLOGR C, V66, pM166, DOI 10.1107/S0108270110017634
   Fu RB, 2016, CRYST GROWTH DES, V16, P5074, DOI 10.1021/acs.cgd.6b00669
   Gandara Loe J, 2019, ACS APPL MATER INTER, V11, P1924, DOI 10.1021/acsami.8b20222
   Giger EV, 2013, J CONTROL RELEASE, V167, P175, DOI 10.1016/j.jconrel.2013.01.032
   Guenin E, 2005, ANTICANCER RES, V25, P1139
   Guenin E, 2004, EUR J ORG CHEM, V2004, P2983
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   Hart NH, 2018, TRIALS, V19, DOI 10.1186/s13063 018 3091 8
   Jaiswal A. K., 2020, INDIAN J FORENSIC CO, V7, P51, DOI [10.18231/j.ijfcm.2020.013, DOI 10.18231/J.IJFCM.2020.013]
   Jiang ZL, 2020, J MATER CHEM B, V8, P7189, DOI 10.1039/d0tb00599a
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Khan MA, 2022, GELS BASEL, V8, DOI 10.3390/gels8010047
   Lecouvey M, 2001, TETRAHEDRON LETT, V42, P8475, DOI 10.1016/S0040 4039(01)01844 5
   Lei BQ, 2018, ACS APPL MATER INTER, V10, P16698, DOI 10.1021/acsami.7b19693
   Li RR, 2018, Z ANORG ALLG CHEM, V644, P317, DOI 10.1002/zaac.201800003
   Lima AC, 2016, ADV HEALTHC MATER, V5, P1687, DOI 10.1002/adhm.201600219
   Liu DM, 2012, CHEM COMMUN, V48, P2668, DOI 10.1039/c2cc17635a
   Liu XB, 2021, ACS APPL MATER INTER, V13, P9643, DOI 10.1021/acsami.0c21486
   Ma KR, 2013, SYNTHETIC MET, V182, P40, DOI 10.1016/j.synthmet.2013.09.004
   Mutalik S, 2014, DRUG DELIV, V21, P44, DOI 10.3109/10717544.2013.845861
   Hanh NT, 2019, VIETNAM J CHEM, V57, P16, DOI 10.1002/vjch.201960002
   Nogués X, 2018, MED CLIN BARCELONA, V150, P479, DOI 10.1016/j.medcli.2017.10.019
   Orellana Tavra C, 2020, ACS APPL MATER INTER, V12, P5633, DOI 10.1021/acsami.9b21692
   Orellana Tavra C, 2016, J MATER CHEM B, V4, P7697, DOI 10.1039/c6tb02025a
   Patel K, 2007, BBA PROTEINS PROTEOM, V1774, P1247, DOI 10.1016/j.bbapap.2007.07.010
   Pham H, 2020, ACS OMEGA, V5, P3418, DOI 10.1021/acsomega.9b03696
   Plum LM, 2010, INT J ENV RES PUB HE, V7, P1342, DOI 10.3390/ijerph7041342
   Raja DS, 2015, INORG CHEM, V54, P4268, DOI 10.1021/ic5029993
   Renfrew AK, 2014, METALLOMICS, V6, P1324, DOI 10.1039/c4mt00069b
   Rezic I, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14224961
   Rojas S, 2021, EUR J INORG CHEM, V2021, P1325, DOI 10.1002/ejic.202001134
   Rojas S, 2018, ACS OMEGA, V3, P2994, DOI 10.1021/acsomega.8b00185
   Ryu M. S., 2020, Present Knowl. Nutr. Elev. Ed., VEleventh, P393, DOI DOI 10.1016/B978 0 323 66162 1.00023 8
   Siegel RL, 2022, CA CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708
   Song BH, 2019, J IRAN CHEM SOC, V16, P333, DOI 10.1007/s13738 018 1520 y
   Stapleton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071345
   Stavgianoudaki N, 2012, CRYSTENGCOMM, V14, P5385, DOI 10.1039/c2ce25632k
   Su PY, 2020, ONCOTARGETS THER, V13, P5207, DOI 10.2147/OTT.S242820
   Tekuri S. K., 2021, ADV ANIM VET SCI, V9, P393, DOI 10.17582/journal.aavs/2021/9.3.393.399
   Tummala S, 2015, SAUDI PHARM J, V23, P308, DOI 10.1016/j.jsps.2014.11.010
   Uchtman V. A., 1972, J PHYS CHEM A, V1262, P1304
   Vassaki M, 2020, CHEM COMMUN, V56, P5166, DOI 10.1039/d0cc00439a
   Vélez GQ, 2023, ACS APPL BIO MATER, DOI 10.1021/acsabm.2c00648
   Vélez GQ, 2023, INORG CHEM, V62, P201, DOI 10.1021/acs.inorgchem.2c03203
   Vélez GQ, 2023, NANOSCALE ADV, V5, P425, DOI 10.1039/d2na00390b
   Vélez GQ, 2022, MATER ADV, V3, P3251, DOI 10.1039/d1ma01127h
   Vélez GQ, 2020, J MATER CHEM B, V8, P2155, DOI 10.1039/c9tb01857c
   Welsh J, 2013, ANIMAL MODELS FOR THE STUDY OF HUMAN DISEASE, P997, DOI 10.1016/B978 0 12 415894 8.00040 3
   Yamaguchi M, 2010, MOL CELL BIOCHEM, V338, P241, DOI 10.1007/s11010 009 0358 0
   YONEDA T, 1994, BREAST CANCER RES TR, V32, P73, DOI 10.1007/BF00666208
   Zhang XL, 2014, DALTON T, V43, P285, DOI 10.1039/c3dt52159a
NR 67
TC 9
Z9 9
U1 2
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0020 1669
EI 1520 510X
J9 INORG CHEM
JI Inorg. Chem.
PD JUN 6
PY 2023
VL 62
IS 24
BP 9440
EP 9453
DI 10.1021/acs.inorgchem.3c00542
EA JUN 2023
PG 14
WC Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA J2TG5
UT WOS:001008139000001
PM 37278598
DA 2025 08 17
ER

PT J
AU Kim, NH
   Cha, YH
   Kim, HS
   Lee, SE
   Huh, JK
   Kim, JK
   Kim, JM
   Ryu, JK
   Kim, HJ
   Lee, Y
   Lee, SY
   Noh, I
   Li, XY
   Weiss, SJ
   Jahng, TA
   Yook, JI
AF Kim, Nam Hee
   Cha, Yong Hoon
   Kim, Hyun Sil
   Lee, Soo Eon
   Huh, Jong Ki
   Kim, Jung Kook
   Kim, Jeong Moon
   Ryu, Joo Kyung
   Kim, Hee Jin
   Lee, Yoonmi
   Lee, Su Yeon
   Noh, Insup
   Li, Xiao Yan
   Weiss, Stephen J.
   Jahng, Tae Ahn
   Yook, Jong In
TI A platform technique for growth factor delivery with novel mode of
   action
SO BIOMATERIALS
LA English
DT Article
DE Protein transduction domain (PTD); Mode of action (MoA); Growth factors;
   Regenerative medicine
ID BONE MORPHOGENETIC PROTEINS; TAT FUSION PROTEINS; MESENCHYMAL
   TRANSITION; LIVER FIBROSIS; TRANSDUCTION; SNAIL1; SPINE; CELL;
   REGENERATION; SURGERY
AB Though growth factors allow tissue regeneration, the trade off between their effectiveness and adverse effects limits clinical application. The key issues in current growth factor therapy largely derive from initial burst pharmacokinetics, rapid clearance, and proteolytic cleavage resulting in clinical ineffectiveness and diverse complications. While a number of studies have focused on the development of carriers, issues arising from soluble growth factor remain. In this study, we report a prodrug of growth factors constituting a novel mode of action (MoA). To mimic endogenous protein processing in cells, we developed a recombinant BMP 2 polypeptide based on a protein transduction domain (PTD) to transduce the protein into cells followed by furin mediated protein cleavage and secretion of active growth factor. As proof of concept, a few micrograms scale of PTD BMP 2 polypeptide sufficed to induce bone regeneration in vivo. As a simple platform, our technique can easily be ektended to delivery of BMP 7 and DKK 1 as therapeutics for TGF beta and canonical Wnt signaling, respectively, to suppress the epithelial mesenchymal transition (EMT), which constitutes a fundamental biological mechanism of many diseases. This technique largely overcomes the limitations of current soluble growth factors and opens the door to next generation growth factor therapeutics. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Kim, Nam Hee; Cha, Yong Hoon; Kim, Hyun Sil; Ryu, Joo Kyung; Lee, Yoonmi; Yook, Jong In] Yonsei Univ, Coll Dent, Oral Canc Res Inst, Dept Oral Pathol, Seoul 120752, South Korea.
   [Lee, Soo Eon; Jahng, Tae Ahn] Seoul Natl Univ, Coll Med, Dept Neurosurg, Seoul 110799, South Korea.
   [Huh, Jong Ki] Yonsei Univ, Coll Dent, Dept Oral & Maxillofacial Surg, Seoul 120752, South Korea.
   [Kim, Jung Kook; Kim, Jeong Moon] Ortholution, Songnam 462725, Kyunggi Do, South Korea.
   [Kim, Hee Jin] Yonsei Univ, Coll Dent, Dept Anat, Seoul 120752, South Korea.
   [Lee, Su Yeon; Noh, Insup] Seoul Natl Univ Sci & Technol, Dept Chem Engn, Seoul 139743, South Korea.
   [Lee, Su Yeon; Noh, Insup] Seoul Natl Univ Sci & Technol, Convergence Inst Biomed Engn & Biomat, Seoul 139743, South Korea.
   [Li, Xiao Yan; Weiss, Stephen J.] Univ Michigan, Div Mol Med & Genet, Dept Internal Med, Ann Arbor, MI 48109 USA.
   [Li, Xiao Yan; Weiss, Stephen J.] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.
C3 Yonsei University; Yonsei University Health System; Seoul National
   University (SNU); Yonsei University; Yonsei University Health System;
   Yonsei University; Yonsei University Health System; Seoul National
   University of Science & Technology; Seoul National University of Science
   & Technology; University of Michigan System; University of Michigan;
   University of Michigan System; University of Michigan
RP Jahng, TA (通讯作者)，Seoul Natl Univ, Coll Med, Dept Neurosurg, Seoul 110799, South Korea.
EM taj@snu.ac.kr; jiyook@yuhs.ac
RI Kim, Kunhong/C 1304 2008; Kim, Nam Hee/GVU 3400 2022; kim,
   sanghyo/G 8523 2012; Noh, Insup/S 4467 2019; Kim, Hee/AAU 6368 2021
OI Kim, Hyun Sil/0000 0003 3614 1764; lee, suyeon/0000 0002 1468 3768;
   Yook, Jong In/0000 0002 7318 6112; Huh, Jong Ki/0000 0002 7381 3972;
   Cha, Yong Hoon/0000 0003 1761 3260; Kim, Nam Hee/0000 0002 3087 5276
FU Ortholution; National Research Foundation of Korea
   [NRF 2012M3A9B2052523, NRF 2013R1A1A1011652, NRF 2014R1A2A 1A05004670];
   Seoul RBD Program [PA110028]
FX We thank E. Tunkle for preparation of the manuscript and professor S. G.
   Ahn at Chosun University for helpful discussion of PTD technique. This
   work was supported by grants from the Ortholution and from the National
   Research Foundation of Korea (NRF 2012M3A9B2052523,
   NRF 2013R1A1A1011652, NRF 2014R1A2A 1A05004670) and from the Seoul R&BD
   Program (PA110028).
CR Becker Hapak M, 2003, CURR PROTOC CELL BIO
   Boon MR, 2011, CYTOKINE GROWTH F R, V22, P221, DOI 10.1016/j.cytogfr.2011.08.001
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Constam DB, 1999, J CELL BIOL, V144, P139, DOI 10.1083/jcb.144.1.139
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092 8674(88)90263 2
   Garrison KR, 2007, HEALTH TECHNOL ASSES, V11, P1
   Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434
   He WC, 2009, J AM SOC NEPHROL, V20, P765, DOI 10.1681/ASN.2008060566
   Henderson WR, 2010, P NATL ACAD SCI USA, V107, P14309, DOI 10.1073/pnas.1001520107
   Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293
   Jo S, 2012, MACROMOL RES, V20, P968, DOI 10.1007/s13233 012 0138 7
   Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304 189
   Kim NH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001744
   Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097
   Kinoshita K, 2007, GUT, V56, P706, DOI 10.1136/gut.2006.092460
   Leighton M, 2003, J BIOL CHEM, V278, P18478, DOI 10.1074/jbc.M213021200
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Lo KWH, 2012, ADV DRUG DELIVER REV, V64, P1277, DOI 10.1016/j.addr.2012.03.014
   Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108
   Moatz Bradley, 2013, Surg Neurol Int, V4, pS67, DOI 10.4103/2152 7806.109444
   Mroz TE, 2010, SPINE, V35, pS86, DOI 10.1097/BRS.0b013e3181d81ef2
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054
   Park SY, 2010, EMBO J, V29, P3787, DOI 10.1038/emboj.2010.254
   PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0
   Poynton AR, 2002, SPINE, V27, pS40, DOI 10.1097/00007632 200208151 00010
   Ren SY, 2013, P NATL ACAD SCI USA, V110, P1440, DOI 10.1073/pnas.1211179110
   Rowe RG, 2011, MOL CELL BIOL, V31, P2392, DOI 10.1128/MCB.01218 10
   Samavarchi Tehrani P, 2010, CELL STEM CELL, V7, P64, DOI 10.1016/j.stem.2010.04.015
   Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Seeherman H, 2005, CYTOKINE GROWTH F R, V16, P329, DOI 10.1016/j.cytogfr.2005.05.001
   Smucker JD, 2006, SPINE, V31, P2813, DOI 10.1097/01.brs.0000245863.52371.c2
   URIST MR, 1977, CLIN ORTHOP RELAT R, P251
   van den Berg A, 2011, CURR OPIN BIOTECH, V22, P888, DOI 10.1016/j.copbio.2011.03.008
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wang SN, 2006, J AM SOC NEPHROL, V17, P2504, DOI 10.1681/ASN.2006030278
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200
   Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508
   Zeisberg M, 2005, J BIOL CHEM, V280, P8094, DOI 10.1074/jbc.M413102200
   Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888
NR 42
TC 13
Z9 14
U1 0
U2 36
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 2014
VL 35
IS 37
BP 9888
EP 9896
DI 10.1016/j.biomaterials.2014.08.005
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA AR5QX
UT WOS:000343639700014
PM 25218859
DA 2025 08 17
ER

PT J
AU Medina, C
AF Medina, Carolina
TI Shockwave Therapy in Veterinary Rehabilitation
SO VETERINARY CLINICS OF NORTH AMERICA SMALL ANIMAL PRACTICE
LA English
DT Article
DE Extracorporeal shockwave therapy; Shockwave; Shockwave therapy
ID WAVE THERAPY; CALCIFYING TENDINITIS; BONE; URETEROLITHIASIS;
   NEPHROLITHIASIS; OSTEOARTHRITIS; SUPRASPINATUS; LITHOTRIPSY; INDUCTION;
   DESMITIS
AB Extracorporeal shockwave therapy (ESWT) is a noninvasive treatment that involves the transcutaneous delivery of high energy sound waves into tissue creating therapeutic effects. Shockwaves are nonlinear, high pressure, high velocity acoustic waves characterized by low tensile amplitude, short rise time to peak pressure, and a short duration (less than 10 milliseconds). ESWT has been shown to increase the expression of cytokines and growth factors leading to decreased inflammation, neovascularization, and cellular proliferation; activation of osteogenesis by osteoblast differentiation and then by increased proliferation; inhibition of cartilage degeneration and rebuilding of subchondral bone; and increased serotonin in the dorsal horn and descending inhibition of pain signals. Musculoskeletal conditions that can benefit from ESWT include osteoarthritis, tendinopathies, fracture/bone healing, and wound healing.
C1 [Medina, Carolina] Elanco Anim Hlth, 2500 Innovat Way, Greenfield, IN 46140 USA.
RP Medina, C (通讯作者)，Elanco Anim Hlth, 2500 Innovat Way, Greenfield, IN 46140 USA.
EM carolina.medina@elancoah.com
RI Medina, Carolina/KVY 1752 2024
CR Aicher A, 2006, CIRCULATION, V114, P2823, DOI 10.1161/CIRCULATIONAHA.106.628623
   Alvarez L, 2022, VET CLIN N AM SMALL, V52, P1033, DOI 10.1016/j.cvsm.2022.03.007
   BAILEY G, 1995, J AM VET MED ASSOC, V207, P592
   Barnes K, 2015, VET COMP ORTHOPAED, V28, P207, DOI 10.3415/VCOT 14 10 0156
   Barnes K, 2019, VET SURG, V48, P1382, DOI 10.1111/vsu.13320
   Becker W, 2015, J AM ANIM HOSP ASSOC, V51, P15, DOI 10.5326/JAAHA MS 6175
   Block G, 1996, J AM VET MED ASSOC, V208, P531
   Chung B, 2002, SPORTS MED, V32, P851, DOI 10.2165/00007256 200232130 00004
   Crowe OM, 2004, EQUINE VET J, V36, P313, DOI 10.2746/0425164044890562
   Császár NBM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140541
   Dahlberg J, 2005, VET COMP ORTHOPAED, V18, P147
   Dahlberg JA, 2006, JAVMA J AM VET MED A, V229, P100, DOI 10.2460/javma.229.1.100
   Danova NA, 2003, VET REC, V152, P208, DOI 10.1136/vr.152.7.208
   Frisbie DD, 2009, AM J VET RES, V70, P449, DOI 10.2460/ajvr.70.4.449
   Gallagher A, 2012, VET SURG, V41, P482, DOI 10.1111/j.1532 950X.2012.00958.x
   Gerdesmeyer L, 2003, JAMA J AM MED ASSOC, V290, P2573, DOI 10.1001/jama.290.19.2573
   HAUPT G, 1992, UROLOGY, V39, P529, DOI 10.1016/0090 4295(92)90009 L
   JOHANNES EJ, 1994, J SURG RES, V57, P246, DOI 10.1006/jsre.1994.1139
   Kearney CJ, 2011, J ORTHOP RES, V29, P1536, DOI 10.1002/jor.21346
   Kieves NR, 2015, VET COMP ORTHOPAED, V28, P425, DOI 10.3415/VCOT 15 05 0084
   Koolen MKE, 2018, J ORTHOP RES, V36, P76, DOI 10.1002/jor.23615
   Leeman JJ, 2016, VET REC, V179, P385, DOI 10.1136/vr.103487
   McClure SR, 2004, VET SURG, V33, P40, DOI 10.1111/j.1532 950x.2004.04013.x
   Moretti B, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 16
   Mueller M, 2007, VET REC, V160, P762, DOI 10.1136/vr.160.22.762
   Niebaum K., 2018, Canine Sports Medicine and Rehabilition, VSecond, P136
   ROMPE JD, 1995, CLIN ORTHOP RELAT R, P196
   Schaden W, 2001, CLIN ORTHOP RELAT R, P90
   Sems A, 2006, J AM ACAD ORTHOP SUR, V14, P195, DOI 10.5435/00124635 200604000 00001
   van der Jagt OP, 2009, J ORTHOP RES, V27, P1528, DOI 10.1002/jor.20910
   Wang CJ, 2003, J ORTHOP RES, V21, P984, DOI 10.1016/S0736 0266(03)00104 9
   Wang CJ, 2005, J BONE JOINT SURG AM, V87A, P2380, DOI 10.2106/JBJS.E.00174
   Wang FS, 2004, J BIOL CHEM, V279, P10331, DOI 10.1074/jbc.M308013200
   Wang FS, 2002, J BONE JOINT SURG BR, V84B, P457, DOI 10.1302/0301 620X.84B3.11609
   Wang G., 2002, J FOOT ANKLE SURG, V41, P16, DOI DOI 10.1016/S1067 2516(02)80005 9
NR 35
TC 0
Z9 0
U1 0
U2 4
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0195 5616
EI 1878 1306
J9 VET CLIN N AM SMALL
JI Vet. Clin. N. Am. Small Anim. Pract.
PD JUL
PY 2023
VL 53
IS 4
BP 775
EP 781
DI 10.1016/j.cvsm.2023.02.009
EA MAY 2023
PG 7
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA Q1DG1
UT WOS:001054984700001
PM 36964030
DA 2025 08 17
ER

PT J
AU Avril, P
   Le Nail, LR
   Brennan, MA
   Rosset, P
   De Pinieux, G
   Layrolle, P
   Heymann, D
   Perrot, P
   Trichet, V
AF Avril, Pierre
   Le Nail, Louis Romee
   Brennan, Meadhbh A.
   Rosset, Philippe
   De Pinieux, Gonzague
   Layrolle, Pierre
   Heymann, Dominique
   Perrot, Pierre
   Trichet, Valerie
TI Mesenchymal stem cells increase proliferation but do not change
   quiescent state of osteosarcoma cells: Potential implications according
   to the tumor resection status
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Mesenchymal stem cell; Osteosarcoma; Adipose tissue transfer; Cell
   cycle; Quiescence
ID AUTOLOGOUS FAT TRANSPLANTATION; BIPHASIC CALCIUM PHOSPHATE; STROMAL
   CELLS; PULMONARY METASTASIS; OSTEOGENIC SARCOMA; RAT OSTEOSARCOMA;
   BREAST CANCER; THERAPY; GROWTH; OSTEOCLASTS
AB Conventional therapy of primary bone tumors includes surgical excision with wide resection, which leads to physical and aesthetic defects. For reconstruction of bone and joints, allografts can be supplemented with mesenchymal stem cells (MSCs). Similarly, adipose tissue transfer (ATT) is supplemented with adipose derived stem cells (ADSCs) to improve the efficient grafting in the correction of soft tissue defects. MSC like cells may also be used in tumor targeted cell therapy. However, MSC may have adverse effects on sarcoma development. In the present study, human ADSCs, MSCs and pre osteoclasts were co injected with human MNNG HOS osteosarcoma cells in immunodeficient mice. ADSCs and MSCs, but not the osteoclast precursors, accelerated the local proliferation of MNNG HOS osteosarcoma cells. However, the osteolysis and the metastasis process were not exacerbated by ADSCs, MSCs, or pre osteoclasts. In vitro proliferation of MNNG HOS and Saos 2 osteosarcoma cells was increased up to 2 fold in the presence of ADSC conditioned medium. In contrast, ADSC conditioned medium did not change the dormant, quiescent state of osteosarcoma cells cultured in oncospheres. Due to the enhancing effect of ADSCs/MSCs on in vivo/in vitro proliferation of osteosarcoma cells, MSCs may not be good candidates for osteosarcoma targeted cell therapy. Although conditioned medium of ADSCs accelerated the cell cycle of proliferating osteosarcoma cells, it did not change the quiescent state of dormant osteosarcoma cells, indicating that ADSC secreted factors may not be involved in the risk of local recurrence. (C) 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY NC ND license.
C1 [Avril, Pierre; Le Nail, Louis Romee; Brennan, Meadhbh A.; Rosset, Philippe; De Pinieux, Gonzague; Layrolle, Pierre; Heymann, Dominique; Perrot, Pierre; Trichet, Valerie] INSERM, UMR 957, Equipe Labellisee LIGUE 2012, F 44035 Nantes, France.
   [Avril, Pierre; Le Nail, Louis Romee; Brennan, Meadhbh A.; Rosset, Philippe; De Pinieux, Gonzague; Layrolle, Pierre; Heymann, Dominique; Perrot, Pierre; Trichet, Valerie] Univ Nantes, Nantes Atlantique Univ, Fac Med, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, 1 Rue Gaston Veil, F 44035 Nantes, France.
   [Le Nail, Louis Romee; Rosset, Philippe] Univ Hosp, Serv Chirurg Orthoped & Traumatol, F 37044 Tours, France.
   [Le Nail, Louis Romee; Rosset, Philippe; De Pinieux, Gonzague] Univ Tours, Fac Med, F 37044 Tours, France.
   [Perrot, Pierre] Univ Hosp, Serv Chirurg Plast & Brutes, F 44093 Nantes, France.
   [De Pinieux, Gonzague] Univ Hosp, Serv Anat Pathol, F 37044 Tours, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Nantes Universite; CHU Tours; Universite de Tours; Nantes Universite;
   CHU de Nantes; CHU Tours
RP Trichet, V (通讯作者)，Fac Med, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, 1 Rue Gaston Veil, F 44035 Nantes, France.
EM valerie.trichet@univ nantes.fr
RI ; Brennan, Meadhbh/L 2068 2015; Layrolle, Pierre/K 9257 2015; Heymann,
   Dominique/AAC 6014 2019; Trichet, Valérie/L 1553 2015; Le Nail,
   Louis Romée/CAH 0851 2022
OI Le Nail, Louis Romee/0000 0003 1642 4935; Heymann,
   Dominique/0000 0001 7777 0669; Trichet, Valerie/0000 0003 4183 9032;
   Brennan, Meadhbh A/0000 0002 1532 9760; Layrolle,
   Pierre/0000 0001 9800 5210; 
FU INSERM; "Ligue Contre le Cancer" (Equipe Labellisee LIGUE)
   [EL2012NCC/DH]; Federation Nationale Enfants et Sante; "Societe
   Francaise de lutte contre les Cancers et les leucemies de l'Enfant et de
   l'Adolescent("appel a projet")
FX This work was supported by INSERM, the "Ligue Contre le Cancer" (Equipe
   Labellisee LIGUE 2012; grant EL2012NCC/DH), the "Federation Nationale
   Enfants et Sante" and the "Societe Francaise de lutte contre les Cancers
   et les leucemies de l'Enfant et de l'Adolescent("appel a projet 2013").
CR Aanstoos M.E., 2015, CLIN ORTHOP RELAT RE
   Avril P., 2015, PLAST RECON IN PRESS
   Bian ZY, 2010, CANCER SCI, V101, P2554, DOI 10.1111/j.1349 7006.2010.01731.x
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Bochet L, 2013, CANCER RES, V73, P5657, DOI 10.1158/0008 5472.CAN 13 0530
   Brennan MA, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/4/045019
   Brennan MA, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt504
   Burns JS, 2012, CANCER LETT, V325, P1, DOI 10.1016/j.canlet.2012.05.027
   Bus M P A, 2014, J Bone Joint Surg Am, V96, pe26, DOI 10.2106/JBJS.M.00655
   Carrière A, 2009, ARTERIOSCL THROM VAS, V29, P1093, DOI 10.1161/ATVBAHA.109.188318
   Centeno CJ, 2011, CURR STEM CELL RES T, V6, P368
   Chevalier S, 1996, J BIOL CHEM, V271, P14764, DOI 10.1074/jbc.271.25.14764
   COLEMAN SR, 1995, AESTHET PLAST SURG, V19, P421, DOI 10.1007/BF00453875
   Cordonnier T, 2011, TISSUE ENG PART C ME, V17, P249, DOI [10.1089/ten.tec.2010.0387, 10.1089/ten.TEC.2010.0387]
   Covarrubias P, 2013, AESTHET PLAST SURG, V37, P778, DOI 10.1007/s00266 013 0126 0
   David M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009741
   Delay E, 2009, AESTHET SURG J, V29, P360, DOI 10.1016/j.asj.2009.08.010
   Dirat B, 2011, CANCER RES, V71, P2455, DOI 10.1158/0008 5472.CAN 10 3323
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Donati D, 2008, CLIN ORTHOP RELAT R, V466, P459, DOI 10.1007/s11999 007 0055 9
   Duplomb L, 2008, ENDOCRINOLOGY, V149, P3688, DOI 10.1210/en.2007 1719
   Endo Munoz L, 2012, BBA REV CANCER, V1826, P434, DOI 10.1016/j.bbcan.2012.07.003
   Endo Munoz L, 2010, CANCER RES, V70, P7063, DOI 10.1158/0008 5472.CAN 09 4291
   Ferrari S, 1997, ANN ONCOL, V8, P765, DOI 10.1023/A:1008221713505
   Gamblin AL, 2014, BIOMATERIALS, V35, P9660, DOI 10.1016/j.biomaterials.2014.08.018
   Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394
   Gobin B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090795
   Grisendi G, 2015, STEM CELLS, V33, P859, DOI 10.1002/stem.1903
   Grisendi G, 2011, AM J CANCER RES, V1, P787
   HERNIGOU P, 1993, J BONE JOINT SURG BR, V75, P904, DOI 10.1302/0301 620X.75B6.8245080
   Hernigou P, 2014, INT ORTHOP, V38, P1825, DOI 10.1007/s00264 014 2384 0
   Hernigou P, 2013, J BONE JOINT SURG AM, V95A, P2215, DOI 10.2106/JBJS.M.00261
   Heymann D, 2005, BONE, V37, P74, DOI 10.1016/j.bone.2005.02.020
   Hilven PH, 2015, BONE JOINT J, V97B, P853, DOI 10.1302/0301 620X.97B6.34692
   Hsu WK, 2008, J BONE JOINT SURG AM, V90A, P1043, DOI 10.2106/JBJS.G.00292
   Nguyen Ngoc KV, 2012, P NATL ACAD SCI USA, V109, pE2595, DOI 10.1073/pnas.1212834109
   Klopp AH, 2011, STEM CELLS, V29, P11, DOI 10.1002/stem.559
   Kolle SFT, 2012, J PLAST SURG HAND SU, V46, P59, DOI 10.3109/2000656X.2012.668326
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   Levings PP, 2009, CANCER RES, V69, P5648, DOI 10.1158/0008 5472.CAN 08 3580
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu F, 2009, PLAST RECONSTR SURG, V124, P1437, DOI 10.1097/PRS.0b013e3181babbb6
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   MEYERS PA, 1992, J CLIN ONCOL, V10, P5, DOI 10.1200/JCO.1992.10.1.5
   Mohr A, 2008, J CELL MOL MED, V12, P2628, DOI 10.1111/j.1582 4934.2008.00317.x
   Motrescu ER, 2008, ONCOGENE, V27, P6347, DOI 10.1038/onc.2008.218
   Pérez Cano R, 2012, EJSO EUR J SURG ONC, V38, P382, DOI 10.1016/j.ejso.2012.02.178
   Perrot P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010999
   Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750 1172 2 6
   Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1
   Rousseau J, 2010, CANCER GENE THER, V17, P387, DOI 10.1038/cgt.2009.89
   Rousseau J, 2011, J BONE MINER RES, V26, P2452, DOI 10.1002/jbmr.455
   Shimizu T, 2012, MOL CANCER RES, V10, P454, DOI 10.1158/1541 7786.MCR 11 0347
   Sterodimas A, 2011, AESTHET SURG J, V31, P682, DOI 10.1177/1090820X11415976
   Tsukamoto S, 2012, INT J ONCOL, V40, P163, DOI 10.3892/ijo.2011.1220
   Waterman RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045590
   Wilson H, 2008, VET J, V175, P69, DOI 10.1016/j.tvjl.2007.07.025
   Xu WT, 2009, CANCER LETT, V281, P32, DOI 10.1016/j.canlet.2009.02.022
   Yoshimura K, 2008, AESTHET PLAST SURG, V32, P48, DOI 10.1007/s00266 007 9019 4
   Zhang P, 2013, ONCOL REP, V30, P1753, DOI 10.3892/or.2013.2619
   Zhang YB, 2012, ANN PLAS SURG, V68, P111, DOI 10.1097/SAP.0b013e31822d9e04
   Zimel MN, 2009, CLIN ORTHOP RELAT R, V467, P2813, DOI 10.1007/s11999 009 1024 2
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 64
TC 30
Z9 30
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD MAR
PY 2016
VL 5
IS 1
BP 5
EP 14
DI 10.1016/j.jbo.2015.11.002
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DO3UY
UT WOS:000377708900002
PM 26998421
OA Green Published, Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Halvorson, KG
   Kubota, K
   Sevcik, MA
   Lindsay, TH
   Sotillo, JE
   Ghilardi, JR
   Rosol, TJ
   Boustany, L
   Shelton, DL
   Mantyh, PW
AF Halvorson, KG
   Kubota, K
   Sevcik, MA
   Lindsay, TH
   Sotillo, JE
   Ghilardi, JR
   Rosol, TJ
   Boustany, L
   Shelton, DL
   Mantyh, PW
TI A blocking antibody to nerve growth factor attenuates skeletal pain
   induced by prostate tumor cells growing in bone
SO CANCER RESEARCH
LA English
DT Article
ID NEUROTROPHIN RECEPTOR P75; PRIMARY SENSORY NEURONS; GENE RELATED
   PEPTIDE; CANCER PAIN; SUBSTANCE P; INDUCED HYPERALGESIA; BREAKTHROUGH
   PAIN; INNERVATION; EXPRESSION; NGF
AB Prostate cancer is unique in that bone is often the only clinically detectable site of metastasis. Prostate tumors that have metastasized to bone frequently induce bone pain which can be difficult to fully control as it seems to be driven simultaneously by inflammatory, neuropathic, and tumorigenic mechanisms. As nerve growth factor (NGF) has been shown to modulate inflammatory and some neuropathic pain states in animal models, an NGF sequestering antibody was administered in a prostate model of bone cancer where significant bone formation and bone destruction occur simultaneously in the mouse femur. Administration of a blocking antibody to NGF produced a significant reduction in both early and late stage bone cancer pain related behaviors that was greater than or equivalent to that achieved with acute administration of 10 or 30 mg/kg of morphine sulfate. In contrast, this therapy did not influence tumor induced bone remodeling, osteoblast proliferation, osteoclastogenesis, tumor growth, or markers of sensory or sympathetic innervation in the skin or bone. One rather unique aspect of the sensory innervation of bone, that may partially explain the analgesic efficacy of anti NGF therapy in relieving prostate cancer induced bone pain, is that nearly all nerve fibers that innervate the bone express trkA and p75, and these are the receptors through which NGF sensitizes and/or activates nociceptors. The present results suggest that anti NGF therapy may be effective in reducing pain and enhancing the quality of life in patients with prostate tumor induced bone cancer pain.
C1 Univ Minnesota, Dept Diagnost & Biol Sci, Minneapolis, MN 55455 USA.
   Univ Minnesota, Neurosyst Ctr, Minneapolis, MN 55455 USA.
   Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA.
   Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA.
   Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA.
   Vet Affairs Med Ctr, Res Serv, Minneapolis, MN 55417 USA.
   Ohio State Univ, Coll Vet Med, Columbus, OH 43210 USA.
   Ohio State Univ, Res Off, Columbus, OH 43210 USA.
   Rinat Neurosci Corp, Palo Alto, CA USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Minneapolis VA Health Care System; University System of Ohio; Ohio State
   University; University System of Ohio; Ohio State University
RP Mantyh, PW (通讯作者)，Univ Minnesota, Dept Diagnost & Biol Sci, 18 208 Moos Tower,515 Delaware St SE, Minneapolis, MN 55455 USA.
EM manty001@umn.edu
RI Rosol, Thomas/G 9585 2011
OI Rosol, Thomas/0000 0003 3737 1190
CR Adler C.P., 2000, Bone Diseases: Macroscopic, Histological, and Radiological Diagnosis of Structural Changes in the Skeleton
   ANDREEV NY, 1995, PAIN, V63, P109, DOI 10.1016/0304 3959(95)00024 M
   Averill S, 2004, EUR J NEUROSCI, V19, P1437, DOI 10.1111/j.1460 9568.2004.03241.x
   AVERILL S, 1995, EUR J NEUROSCI, V7, P1484, DOI 10.1111/j.1460 9568.1995.tb01143.x
   Bergmann I, 1998, NEUROSCI LETT, V255, P87, DOI 10.1016/S0304 3940(98)00713 7
   Berruti A, 2000, J UROLOGY, V164, P1248, DOI 10.1016/S0022 5347(05)67149 2
   BJURHOLM A, 1988, PEPTIDES, V9, P165, DOI 10.1016/0196 9781(88)90023 X
   BODY JJ, 2000, TUMOR BONE DIS OSTEO, P561
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165 0270(94)90144 9
   Clohisy DR, 2003, CANCER AM CANCER SOC, V97, P866, DOI 10.1002/cncr.11144
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Corey E, 2002, PROSTATE, V52, P20, DOI 10.1002/pros.10091
   Cornelissen BPM, 1998, AM J VET RES, V59, P1378
   Davies NM, 2004, J PHARM PHARM SCI, V7, P332
   Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200
   DONNERER J, 1992, NEUROSCIENCE, V49, P693, DOI 10.1016/0306 4522(92)90237 V
   FAWCETT DW, 1986, BONE, P211
   Foster PA, 2002, J PATHOL, V197, P245, DOI 10.1002/path.1111
   Gould HJ, 2000, BRAIN RES, V854, P19, DOI 10.1016/S0006 8993(99)02216 7
   GRONBLAD M, 1984, ANAT RECORD, V209, P297, DOI 10.1002/ar.1092090306
   Guise TA, 2003, SEMIN ONCOL, V30, P717, DOI 10.1016/S0093 7754(03)00347 6
   HEUMANN R, 1987, J CELL BIOL, V104, P1623, DOI 10.1083/jcb.104.6.1623
   Hongo JAS, 2000, HYBRIDOMA, V19, P215, DOI 10.1089/02724570050109611
   Jemal A, 2005, CA CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896 6273(02)00908 X
   Koltzenburg M, 1999, PAIN, pS93, DOI 10.1016/S0304 3959(99)00142 6
   LeRoy BE, 2002, PROSTATE, V50, P104
   LEWIN GR, 1994, EUR J NEUROSCI, V6, P1903, DOI 10.1111/j.1460 9568.1994.tb00581.x
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Luger NM, 2001, CANCER RES, V61, P4038
   Mach DB, 2002, NEUROSCIENCE, V113, P155, DOI 10.1016/S0306 4522(02)00165 3
   Mamet J, 2003, J BIOL CHEM, V278, P48907, DOI 10.1074/jbc.M309468200
   MCCARTHY BG, 1995, NEUROLOGY, V45, P1848, DOI 10.1212/WNL.45.10.1848
   Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304 3959(01)00437 7
   Mendell LM, 1999, MICROSC RES TECHNIQ, V45, P252, DOI 10.1002/(SICI)1097 0029(19990515/01)45:4/5<252::AID JEMT9>3.0.CO;2 N
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305 7372(98)90005 6
   Mercadante S, 1999, PAIN, V79, P1, DOI 10.1016/S0304 3959(98)00118 3
   Mukherjee D, 2001, JAMA J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954
   Olson KB, 1999, ONCOLOGY NY, V13, P1537
   OLSON KB, 1999, ONCOLOGY, V13, P49
   Petersen M, 1998, NEUROSCIENCE, V83, P161, DOI 10.1016/S0306 4522(97)00374 6
   PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304 3959(90)90004 W
   Portenoy RK, 1999, ONCOLOGY NY, V13, P25
   Ramer MS, 2001, J NEUROCHEM, V77, P864, DOI 10.1046/j.1471 4159.2001.00288.x
   Revilla M, 1998, PROSTATE, V35, P243
   Rueff A, 1996, PAIN, V66, P359, DOI 10.1016/0304 3959(96)03060 6
   Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19 24 10886.1999
   SEIKE W, 1976, Yonago Acta Medica, V20, P192
   Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022
   Sevcik MA, 2004, PAIN, V111, P169, DOI 10.1016/j.pain.2004.06.015
   Shelton DL, 2005, PAIN, V116, P8, DOI 10.1016/j.pain.2005.03.039
   Shu XQ, 1999, P NATL ACAD SCI USA, V96, P7693, DOI 10.1073/pnas.96.14.7693
   Susaki Y, 1996, BLOOD, V88, P4630, DOI 10.1182/blood.V88.12.4630.bloodjournal88124630
   TOKUNAGA J, 1967, J ANAT, V101, P125
   VERGE VMK, 1990, J NEUROSCI, V10, P2018
   Walsh GS, 1999, J NEUROSCI, V19, P258, DOI 10.1523/JNEUROSCI.19 01 00258.1999
   Walsh T D, 1990, J Pain Symptom Manage, V5, P362
   Zahn PK, 2004, J PAIN, V5, P157, DOI 10.1016/j.jpain.2004.02.538
NR 59
TC 184
Z9 243
U1 0
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD OCT 15
PY 2005
VL 65
IS 20
BP 9426
EP 9435
DI 10.1158/0008 5472.CAN 05 0826
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 974BR
UT WOS:000232566800045
PM 16230406
OA Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Joiner, DM
   Tayim, RJ
   Kadado, A
   Goldstein, SA
AF Joiner, Danese M.
   Tayim, Riyad J.
   Kadado, Allen
   Goldstein, Steven A.
TI Bone marrow stromal cells from aged male rats have delayed
   mineralization and reduced response to mechanical stimulation through
   nitric oxide and ERK1/2 signaling during osteogenic differentiation
SO BIOGERONTOLOGY
LA English
DT Article
DE Age; Marrow stromal cell; Mechanotransduction; ERK1/2; Nitric oxide;
   Osteoporosis
ID MESENCHYMAL STEM CELLS; TRABECULAR BONE; FLUID FLOW; OSTEOPROGENITOR
   CELLS; COMPRESSIVE STRENGTH; TRANSCRIPTION FACTOR; FRACTURE INCIDENCE;
   CANCELLOUS BONE; IN VITRO; OSTEOPOROSIS
AB Bone marrow stromal cells (MSCs) are a source of osteoblast precursors that can be recruited during bone remodeling or injury, both important processes in aging populations. With advancing age, alterations in bone structure and mineralization are often associated with an increase in osteoporosis and fracture risk. Changes in the number of osteoprogenitor cells and their osteogenic potential may occur with advancing age; however few studies have considered the influence of mechanical conditions. Here, we investigated the ability of bone MSCs from mature and aged rats to differentiate into osteoblasts and to respond to short and long periods of mechanical stimulation through signaling by ERK1/2, nitric oxide (NO), and prostaglandin E 2 (PGE(2)) during differentiation. Mineralization was delayed and reduced, but extracellular matrix production appeared less affected by increased age. Differentiating MSCs from aged animals had a decreased response to short and long periods of mechanical stimulation through ERK1/2 signaling, and to long periods of mechanical loading through NO signaling early and late during differentiation. Increases in relative PGE(2) signaling were higher in MSCs from aged animals, which could compensate for reduced ERK1/2 and NO signaling. The decreased mineralization may decrease the ability of cells from aged animals to respond to mechanical stimulation through ERK1/2 and NO signaling, with increased impairment over differentiation time. Decreasing the delay in mineralization of MSCs from aging animals might improve their ability to respond to mechanical stimulation during bone remodeling and injury, suggesting therapies for bone fragility diseases and tissue engineering treatments in elderly populations.
C1 [Joiner, Danese M.] Van Andel Res Inst, Lab Cell Signaling & Carcinogenesis, Grand Rapids, MI 49503 USA.
   [Joiner, Danese M.; Tayim, Riyad J.; Kadado, Allen; Goldstein, Steven A.] Univ Michigan, Dept Orthopaed Surg, Orthopaed Res Labs, Ann Arbor, MI 48109 USA.
C3 Van Andel Institute; Van Andel Research Institute; University of
   Michigan System; University of Michigan
RP Joiner, DM (通讯作者)，Van Andel Res Inst, Lab Cell Signaling & Carcinogenesis, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.
EM danese.joiner@vai.org
FU NSF; NIH [RO1 AR51504]
FX The authors would like to thank to XiXi Wang, Sharon Reske, Kathy Sweet,
   and Bonnie Nolan for animal care and Dennis Kayner and Charles Roehm
   with their assistance with the oscillatory fluid shear system. This work
   was supported by NSF Graduate Student Research Fellowship (DMJ) and NIH
   Grant RO1 AR51504 (SAG).
CR Bakker AD, 2006, OSTEOPOROSIS INT, V17, P827, DOI 10.1007/s00198 006 0072 7
   Ben Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013
   Bergman RJ, 1996, J BONE MINER RES, V11, P568
   BROCKBANK KGM, 1983, MECH AGEING DEV, V22, P11, DOI 10.1016/0047 6374(83)90003 9
   Cao JJ, 2005, J BONE MINER RES, V20, P1659, DOI 10.1359/JBMR.050503
   Ciarelli TE, 2000, J BONE MINER RES, V15, P32, DOI 10.1359/jbmr.2000.15.1.32
   Cole JH, 2011, CLIN ORTHOP RELAT R, V469, P2139, DOI 10.1007/s11999 011 1784 3
   COWIN SC, 1995, J BIOMECH, V28, P1281, DOI 10.1016/0021 9290(95)00058 P
   Ding DC, 2011, CELL TRANSPLANT, V20, P5, DOI 10.3727/096368910X
   Donahue SW, 2001, AM J PHYSIOL CELL PH, V281, pC1635, DOI 10.1152/ajpcell.2001.281.5.C1635
   EGRISE D, 1992, BONE, V13, P355, DOI 10.1016/8756 3282(92)90451 2
   ERIKSEN EF, 1985, BONE, V6, P141, DOI 10.1016/8756 3282(85)90046 8
   FEDARKO NS, 1992, J CELL PHYSIOL, V151, P215, DOI 10.1002/jcp.1041510202
   Fong ELS, 2011, BIOMATERIALS, V32, P395, DOI 10.1016/j.biomaterials.2010.08.101
   FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488
   Quiroz FG, 2010, CYTOTECHNOLOGY, V62, P109, DOI 10.1007/s10616 010 9265 1
   HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523
   Justesen J, 2002, CALCIFIED TISSUE INT, V71, P36, DOI 10.1007/s00223 001 2059 x
   Kajkenova O, 1997, J BONE MINER RES, V12, P1772, DOI 10.1359/jbmr.1997.12.11.1772
   Kassem M, 2011, AGING CELL, V10, P191, DOI 10.1111/j.1474 9726.2011.00669.x
   Katsara O, 2011, STEM CELLS DEV, V20, P1550, DOI 10.1089/scd.2010.0280
   Katzburg S, 1999, BONE, V25, P667, DOI 10.1016/S8756 3282(99)00225 2
   Kostenuik PJ, 1997, AM J PHYSIOL ENDOC M, V273, pE1133
   Kretlow JD, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471 2121 9 60
   KUFAHL RH, 1990, J BIOMECH, V23, P171, DOI 10.1016/0021 9290(90)90350 C
   Liedert A., 2005, MECHANOSENSITIVITY H
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Majumdar S, 1997, J BONE MINER RES, V12, P111, DOI 10.1359/jbmr.1997.12.1.111
   MARIE PJ, 1989, J CLIN ENDOCR METAB, V69, P272, DOI 10.1210/jcem 69 2 272
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   McCalden RW, 1997, J BONE JOINT SURG AM, V79A, P421, DOI 10.2106/00004623 199703000 00016
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   MOSEKILDE L, 1986, BONE, V7, P207, DOI 10.1016/8756 3282(86)90019 0
   Muschler GF, 2001, J ORTHOP RES, V19, P117, DOI 10.1016/S0736 0266(00)00010 3
   Nishida S, 1999, J BONE MINER METAB, V17, P171, DOI 10.1007/s007740050081
   Orwig DL, 2011, RHEUM DIS CLIN N AM, V37, P401, DOI 10.1016/j.rdc.2011.08.004
   Owan I, 1997, AM J PHYSIOL CELL PH, V273, pC810, DOI 10.1152/ajpcell.1997.273.3.C810
   Oxlund H, 1996, BONE, V19, P479, DOI 10.1016/S8756 3282(96)00283 9
   Paschalis EP, 1997, CALCIFIED TISSUE INT, V61, P487, DOI 10.1007/s002239900372
   PIEKARSKI K, 1977, NATURE, V269, P80, DOI 10.1038/269080a0
   Price C, 2011, J BONE MINER RES, V26, P277, DOI 10.1002/jbmr.211
   QUARTO R, 1995, CALCIFIED TISSUE INT, V56, P123, DOI 10.1007/BF00296343
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003 4819 114 11 919
   ROSS PD, 1990, CALCIFIED TISSUE INT, V46, P149, DOI 10.1007/BF02555036
   Schraufstatter IU, 2011, FRONT BIOSCI LANDMRK, V16, P2271, DOI 10.2741/3853
   Schuit SCE, 2004, BONE, V34, P195, DOI 10.1016/j.bone.2003.10.001
   Sethe S, 2006, AGEING RES REV, V5, P91, DOI 10.1016/j.arr.2005.10.001
   Smalt R, 1997, ADV EXP MED BIOL, V433, P311
   Stenderup K, 2001, J BONE MINER RES, V16, P1120, DOI 10.1359/jbmr.2001.16.6.1120
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Stolzing A, 2006, AGING CELL, V5, P213, DOI 10.1111/j.1474 9726.2006.00213.x
   Strube P, 2009, BONE, V45, P1065, DOI 10.1016/j.bone.2009.08.005
   Swan CC, 2003, J BIOMECH ENG T ASME, V125, P25, DOI 10.1115/1.1535191
   Tullberg Reinert H, 1999, HISTOCHEM CELL BIOL, V112, P271, DOI 10.1007/s004180050447
   Urist MR, 1997, J BONE MINER RES, V12, P343, DOI 10.1359/jbmr.1997.12.3.343
   WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021 9290(94)90010 8
   Wilson A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471 2164 11 229
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   XU CX, 1983, J CELL SCI, V61, P453
   Zhang W, 2008, J BONE MINER RES, V23, P1118, DOI [10.1359/jbmr.080304, 10.1359/JBMR.080304]
NR 63
TC 22
Z9 22
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389 5729
J9 BIOGERONTOLOGY
JI Biogerontology
PD OCT
PY 2012
VL 13
IS 5
BP 467
EP 478
DI 10.1007/s10522 012 9391 6
PG 12
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology
GA 014AI
UT WOS:000309347000001
PM 22944913
DA 2025 08 17
ER

PT J
AU Alansari, S
   Sangsuwon, C
   Vongthongleur, T
   Kwal, R
   Teo, MC
   Lee, YB
   Nervina, J
   Teixeira, C
   Alikhani, M
AF Alansari, Sarah
   Sangsuwon, Chinapa
   Vongthongleur, Thapanee
   Kwal, Rachel
   Teo, Miang Chneh
   Lee, Yoo B.
   Nervina, Jeanne
   Teixeira, Cristina
   Alikhani, Mani
TI Biological principles behind accelerated tooth movement
SO SEMINARS IN ORTHODONTICS
LA English
DT Article
ID INTENSITY LASER THERAPY; CYTOKINE EXPRESSION; ORTHODONTIC FORCE; PAIN;
   OSTEOCLASTOGENESIS; PROSTAGLANDINS; CURRENTS; LIGAND; CELLS; TIME
AB Understanding the biology of tooth movement has great importance for developing techniques that increase the rate of tooth movement. Based on interpretations of data on the biology of tooth movement, the resulting accelerating techniques can be divided into two main groups: one group stimulates upstream events to indirectly activate downstream target cells, while the other group bypasses the upstream events and directly stimulates downstream target cells. In both approaches, there is a general consensus that the rate of tooth movement is controlled by the rate of bone resorption, which in turn is controlled by osteoclast activity. Therefore, to increase the rate of tooth movement, osteoclasts should be the target of treatment. In this article, both approaches will be reviewed and the biological limitations of each group will be discussed. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Alikhani, Mani] NYU, Coll Dent, Consortium Translat Orthodont Res, New York, NY 10010 USA.
   NYU, Coll Dent, Dept Orthodont, New York, NY 10010 USA.
   Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA.
C3 New York University; New York University; Harvard University; Harvard
   School of Dental Medicine
RP Alikhani, M (通讯作者)，NYU, Coll Dent, Consortium Translat Orthodont Res, 345 E 24th St, New York, NY 10010 USA.
EM mani.alikhani@nyu.edu
RI Sangsuwon, Chinapa/OBO 0895 2025
CR Alikhani M, 2015, ORTHOD CRANIOFAC RES, V18, P8, DOI 10.1111/ocr.12090
   Alikhani M, 2014, AM J ORTHOD DENTOFAC, V145, P273, DOI 10.1016/j.ajodo.2014.01.004
   Andrade I, 2007, J DENT RES, V86, P1089, DOI 10.1177/154405910708601113
   Andrade I, 2009, J DENT RES, V88, P1037, DOI 10.1177/0022034509346230
   Angeli A, 2002, ANN NY ACAD SCI, V966, P97, DOI 10.1111/j.1749 6632.2002.tb04207.x
   ASHCRAFT MB, 1992, AM J ORTHOD DENTOFAC, V102, P310, DOI 10.1016/0889 5406(92)70046 D
   BEESON DC, 1975, J DENT RES, V54, P251
   Bjordal JM, 2006, PHOTOMED LASER SURG, V24, P533
   Bjordal JM, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 75
   Bjordal JM, 2003, AUST J PHYSIOTHER, V49, P107, DOI 10.1016/S0004 9514(14)60127 6
   Blechman AM, 1998, AM J ORTHOD DENTOFAC, V113, P379, DOI 10.1016/S0889 5406(98)70246 X
   DAVIDOVITCH Z, 1980, AM J ORTHOD DENTOFAC, V77, P33, DOI 10.1016/0002 9416(80)90222 5
   Taddei SRD, 2013, BONE, V52, P259, DOI 10.1016/j.bone.2012.09.036
   Taddei SRD, 2012, AM J ORTHOD DENTOFAC, V141, P153, DOI 10.1016/j.ajodo.2011.07.019
   Doshi Mehta G, 2012, AM J ORTHOD DENTOFAC, V141, P289, DOI 10.1016/j.ajodo.2011.09.009
   Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063
   Fischer TJ, 2007, ANGLE ORTHOD, V77, P417, DOI 10.2319/0003 3219(2007)077[0417:OTAWCE]2.0.CO;2
   Fuller K, 2006, ENDOCRINOLOGY, V147, P1979, DOI 10.1210/en.2005 1340
   Garlet TP, 2007, EUR J ORAL SCI, V115, P355, DOI 10.1111/j.1600 0722.2007.00469.x
   Gurton AU, 2004, ANGLE ORTHOD, V74, P526
   Haruyama N, 2002, J DENT RES, V81, P406, DOI 10.1177/154405910208100610
   Hashimoto F, 2001, EUR J ORTHODONT, V23, P535, DOI 10.1093/ejo/23.5.535
   Knop LAH, 2012, EUR J ORTHODONT, V34, P531, DOI 10.1093/ejo/cjq173
   Huang YY, 2009, DOSE RESPONSE, V7, P358, DOI 10.2203/dose response.09 027.Hamblin
   Jimi E, 1996, J BIOL CHEM, V271, P4605
   Kale S, 2004, AM J ORTHOD DENTOFAC, V125, P607, DOI 10.1016/j.ajodo.2003.06.002
   Kalia S, 2004, Orthod Craniofac Res, V7, P26, DOI 10.1111/j.1601 6343.2004.00278.x
   Karu TI, 2008, PHOTOCHEM PHOTOBIOL, V84, P1091, DOI 10.1111/j.1751 1097.2008.00394.x
   Kawasaki K, 2000, LASER SURG MED, V26, P282, DOI 10.1002/(SICI)1096 9101(2000)26:3<282::AID LSM6>3.0.CO;2 X
   Krishnan V., 2006, AM J ORTHOD DENTOFAC, V129, p469., DOI [10.1016/j.ajodo.2005.10.007, DOI 10.1016/J.AJODO.2005.10.007]
   LANYON LE, 1984, J BIOMECH, V17, P897, DOI 10.1016/0021 9290(84)90003 4
   LEIKER BJ, 1995, AM J ORTHOD DENTOFAC, V108, P380, DOI 10.1016/S0889 5406(95)70035 8
   Lundy FT, 2004, CRIT REV ORAL BIOL M, V15, P82, DOI 10.1177/154411130401500203
   Madan MS, 2007, AM J ORTHOD DENTOFAC, V131, DOI 10.1016/j.ajodo.2006.06.014
   Marquezan M, 2010, PHOTOMED LASER SURG, V28, P757, DOI 10.1089/pho.2009.2694
   Miyoshi K, 2001, EUR J ORTHODONT, V23, P329, DOI 10.1093/ejo/23.4.329
   MOHAMMED AH, 1989, AM J ORTHOD DENTOFAC, V95, P231, DOI 10.1016/0889 5406(89)90053 X
   O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301
   Ong CKL, 2000, ANGLE ORTHOD, V70, P118
   Perkins DJ, 1997, PROSTAG OTH LIPID M, V54, P727, DOI 10.1016/S0090 6980(97)00144 5
   Potts JT, 2007, ANN NY ACAD SCI, V1117, P196, DOI 10.1196/annals.1402.088
   Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449
   Sekhavat AR, 2002, AM J ORTHOD DENTOFAC, V122, P542, DOI 10.1067/mod.2002.126153
   Soma S, 1999, J BONE MINER RES, V14, P546, DOI 10.1359/jbmr.1999.14.4.546
   Soma S, 2000, J DENT RES, V79, P1717, DOI 10.1177/00220345000790091301
   STARK TM, 1987, AM J ORTHOD DENTOFAC, V91, P91, DOI 10.1016/0889 5406(87)90465 3
   Suda T, 2003, J CELL BIOCHEM, V88, P259, DOI 10.1002/jcb.10331
   Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554
   Tafur J, 2008, PHOTOMED LASER SURG, V26, P323, DOI 10.1089/pho.2007.2184
   TAKANOYAMAMOTO T, 1992, J DENT RES, V71, P1487, DOI 10.1177/00220345920710080501
   Teixeira CC, 2010, J DENT RES, V89, P1135, DOI 10.1177/0022034510373764
   Tengku BS, 2000, EUR J ORTHODONT, V22, P475, DOI 10.1093/ejo/22.5.475
   TWEEDLE J A, 1965, Angle Orthod, V35, P218
   Verna C, 2000, EUR J ORTHODONT, V22, P343, DOI 10.1093/ejo/22.4.343
   Wilcko MT, 2009, J ORAL MAXIL SURG, V67, P2149, DOI 10.1016/j.joms.2009.04.095
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoshimatsu M, 2006, J BONE MINER METAB, V24, P20, DOI 10.1007/s00774 005 0641 4
NR 57
TC 19
Z9 24
U1 1
U2 11
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 1073 8746
EI 1558 4631
J9 SEMIN ORTHOD
JI Semin. Orthod.
PD SEP
PY 2015
VL 21
IS 3
BP 151
EP 161
DI 10.1053/j.sodo.2015.06.001
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CQ2OY
UT WOS:000360442000002
DA 2025 08 17
ER

PT J
AU Yang, G
   Singh, S
   McDonough, CW
   Lamba, JK
   Hamadeh, I
   Holliday, LS
   Wang, DX
   Katz, J
   Lakatos, PA
   Balla, B
   Kosa, JP
   Pelliccioni, GA
   Price, DK
   Van Driest, SL
   Figg, WD
   Langaee, T
   Moreb, JS
   Gong, Y
AF Yang, Guang
   Singh, Sonal
   McDonough, Caitrin W.
   Lamba, Jatinder K.
   Hamadeh, Issam
   Holliday, L. Shannon
   Wang, Danxin
   Katz, Joseph
   Lakatos, Peter A.
   Balla, Bernadett
   Kosa, Janos P.
   Pelliccioni, Gian Andrea
   Price, Douglas K.
   Van Driest, Sara L.
   Figg, William D.
   Langaee, Taimour
   Moreb, Jan S.
   Gong, Yan
TI Genome wide Association Study Identified Chromosome 8 Locus Associated
   with Medication Related Osteonecrosis of the Jaw
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID BISPHOSPHONATE INDUCED OSTEONECROSIS; POLYMORPHISM; MUTATIONS
AB Medication related osteonecrosis of the jaw (MRONJ) is a rare but serious drug related adverse event. To identify pharmacogenomic markers of MRONJ associated with bisphosphonate therapy, we conducted a genomewide association study (GWAS) meta analysis followed by functional analysis of 5,008 individuals of European ancestry treated with bisphosphonates, which includes the largest number of MRONJ cases to date (444 cases and 4,564 controls). Discovery GWAS was performed in randomly selected 70% of the patients with cancer and replication GWAS was performed in the remaining 30% of the patients with cancer treated with intravenous bisphosphonates followed by meta analysis of all 3,639 patients with cancer. GWAS was also performed in 1,369 patients with osteoporosis treated with oral bisphosphonates. The lead single nucleotide polymorphism (SNP), rs2736308 on chromosome 8, was associated with an increased risk of MRONJ with an odds ratio (OR) of 2.71 and 95% confidence interval (CI) of 1.90 3.86 (P = 3.57*10( 8)) in the meta analysis of patients with cancer. This SNP was validated in the MRONJ GWAS in patients with osteoporosis (OR: 2.82, 95% CI: 1.55 4.09, P = 6.84*10( 4)). The meta analysis combining patients with cancer and patients with osteoporosis yielded the same lead SNP rs2736308 on chromosome 8 as the top SNP (OR: 2.74, 95% CI: 2.09 3.39, P = 9.65*10( 11)). This locus is associated with regulation of the BLK, CTSB, and FDFT1 genes, which had been associated with bone mineral density. FDFT1 encodes a membrane associated enzyme, which is implicated in the bisphosphonate pathway. This study provides insights into the potential mechanism of MRONJ.
C1 [Yang, Guang; Singh, Sonal; McDonough, Caitrin W.; Lamba, Jatinder K.; Hamadeh, Issam; Wang, Danxin; Langaee, Taimour; Gong, Yan] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32610 USA.
   [Yang, Guang; Singh, Sonal; McDonough, Caitrin W.; Lamba, Jatinder K.; Hamadeh, Issam; Wang, Danxin; Langaee, Taimour; Gong, Yan] Univ Florida, Coll Pharm, Ctr Pharmacogen & Precis Med, Gainesville, FL 32610 USA.
   [Lamba, Jatinder K.; Gong, Yan] UF Hlth Canc Ctr, Gainesville, FL 32610 USA.
   [Hamadeh, Issam] Levine Canc Inst, Canc Pharmacol Dept, Charlotte, NC USA.
   [Holliday, L. Shannon] Univ Florida, Coll Dent, Dept Orthodont, Gainesville, FL USA.
   [Katz, Joseph] Univ Florida, Coll Dent, Dept Oral Med, Gainesville, FL USA.
   [Lakatos, Peter A.; Balla, Bernadett; Kosa, Janos P.] Semmelweis Univ, Dept Internal Med & Oncol, Budapest, Hungary.
   [Pelliccioni, Gian Andrea] Alma Mater Studiorum Univ Bologna, Dept Biomed & Neuromotor Sci, Sect Dent, Bologna, Italy.
   [Price, Douglas K.; Figg, William D.] NCI, Genitourinary Malignancies Branch, Bethesda, MD 20892 USA.
   [Van Driest, Sara L.] Vanderbilt Univ, Med Ctr, Dept Pediat & Med, Nashville, TN USA.
   [Moreb, Jan S.] Novant Hlth Canc Inst, Hematol Transplantat & Cellular Therapy Dept, Winston Salem, NC USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida; State University System of
   Florida; University of Florida; Semmelweis University; University of
   Bologna; National Institutes of Health (NIH)   USA; NIH National Cancer
   Institute (NCI); Vanderbilt University
RP Gong, Y (通讯作者)，Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32610 USA.; Gong, Y (通讯作者)，Univ Florida, Coll Pharm, Ctr Pharmacogen & Precis Med, Gainesville, FL 32610 USA.; Gong, Y (通讯作者)，UF Hlth Canc Ctr, Gainesville, FL 32610 USA.
EM gong@cop.ufl.edu
RI ; Moreb, Jan/HJG 6455 2022; Figg Sr, William/M 2411 2016; Wang,
   Danxin/I 5810 2019; Gong, Yan/LBH 7198 2024; Katz, Joseph/A 7624 2010;
   Holliday, Lexie/GYQ 4972 2022; McDonough, Caitrin/AES 1698 2022
OI Wang, Danxin/0000 0002 7134 3065; katz, joseph/0000 0002 0741 8149;
   Holliday, Lexie/0000 0002 0844 1965; McDonough,
   Caitrin/0000 0001 6393 7288
FU University of Florida College or Pharmacy, University of Florida Health
   Cancer Center, University of Florida Informatics Institute; University
   of Florida Clinical and Translational Science Institute; NIH National
   Center for Advancing Translational Sciences [UL1 TR001427]; Vanderbilt
   University Medical Center's BioVU; NIH funded Shared Instrumentation
   Grant [S10RR025141]; CTSA [UL1TR002243, UL1TR000445, UL1RR024975,
   U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378,
   U19HL065962, R01HD074711]
FX Y.G. is supported by University of Florida College or Pharmacy,
   University of Florida Health Cancer Center, University of Florida
   Informatics Institute, and University of Florida Clinical and
   Translational Science Institute, which is supported in part by the NIH
   National Center for Advancing Translational Sciences under award number
   UL1 TR001427. Some of the dataset(s) used for the analyses described
   were obtained from Vanderbilt University Medical Center's BioVU which is
   supported by numerous sources: institutional funding, private agencies,
   and federal grants. These include the NIH funded Shared Instrumentation
   Grant S10RR025141; and CTSA grants UL1TR002243, UL1TR000445, and
   UL1RR024975. Genomic data are also supported by investigator led
   projects that include U01HG004798, R01NS032830, RC2GM092618,
   P50GM115305, U01HG006378, U19HL065962, R01HD074711; and additional
   funding sources listed at https://victr.vumc.org/biovu funding/.
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Belinky Frida, 2015, Database (Oxford), V2015, DOI 10.1093/database/bav006
   Borowiec M, 2009, P NATL ACAD SCI USA, V106, P14460, DOI 10.1073/pnas.0906474106
   Brakspear Karen S, 2012, Front Endocrinol (Lausanne), V3, P97, DOI 10.3389/fendo.2012.00097
   Byeon S.E., 2012, MEDIAT INFLAMM, V2012, P18, DOI DOI 10.1155/2012/512926
   Carvalho Silva D, 2019, NUCLEIC ACIDS RES, V47, pD1056, DOI 10.1093/nar/gky1133
   Covarrubias Pazaran G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156744
   de Leeuw CA, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004219
   de Mingo A, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.368
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Esfahanizadeh Nasrin, 2013, Dent Res J (Isfahan), V10, P460
   Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194
   Goldman M, 2013, NUCLEIC ACIDS RES, V41, pD949, DOI 10.1093/nar/gks1008
   Gong L, 2011, PHARMACOGENET GENOM, V21, P50, DOI 10.1097/FPC.0b013e328335729c
   Holden AL, 2014, NAT REV DRUG DISCOV, V13, P795, DOI 10.1038/nrd4441
   Huang DD, 2018, NUCLEIC ACIDS RES, V46, pW114, DOI 10.1093/nar/gky407
   Katz J, 2011, INT J ORAL MAX SURG, V40, P605, DOI 10.1016/j.ijom.2011.02.002
   Kim C, 2019, J BONE ONCOL, V14, DOI 10.1016/j.jbo.2018.100215
   Langemeyer L, 2018, TRENDS CELL BIOL, V28, P957, DOI 10.1016/j.tcb.2018.06.007
   Lawson CD, 2018, J CELL BIOL, V217, P447, DOI 10.1083/jcb.201612069
   Linder M, 2018, CELL DEATH DIFFER, V25, P1094, DOI 10.1038/s41418 017 0054 7
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Nedergaard M, 2002, NAT REV NEUROSCI, V3, P748, DOI 10.1038/nrn916
   Nicoletti P, 2012, ONCOLOGIST, V17, P279, DOI 10.1634/theoncologist.2011 0202
   Porcu E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10936 0
   Qin L, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10177
   Roden DM, 2008, CLIN PHARMACOL THER, V84, P362, DOI 10.1038/clpt.2008.89
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Sarasquete ME, 2008, BLOOD, V112, P2709, DOI 10.1182/blood 2008 04 147884
   Sharma MK, 2010, BIOCHEM BIOPH RES CO, V391, P91, DOI 10.1016/j.bbrc.2009.10.168
   Such E, 2011, HAEMATOL HEMATOL J, V96, P1557, DOI 10.3324/haematol.2011.042572
   Sutherland A, 2016, JNCI J NATL CANCER I, V108, DOI 10.1093/jnci/djv338
   Tang CH, 2010, BIOCHEM PHARMACOL, V79, P1648, DOI 10.1016/j.bcp.2010.01.025
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   von Moos R, 2019, CANCER TREAT REV, V76, P57, DOI 10.1016/j.ctrv.2019.05.003
   Wan Jason T, 2020, [Bone Research, 骨研究], V8, P14
   Wang YM, 2018, GENOME BIOL, V19, DOI [10.1186/s13059 018 1445 x, 10.1186/s13059 018 1519 9]
   Warde Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537
   Watanabe K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01261 5
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Writzl K, 2017, AM J HUM GENET, V101, P844, DOI 10.1016/j.ajhg.2017.09.017
   Yang G, 2021, J BONE MINER RES, V36, P347, DOI 10.1002/jbmr.4185
   Yang G, 2019, BONE, V124, P75, DOI 10.1016/j.bone.2019.04.010
   Yang G, 2018, J BONE MINER RES, V33, P91, DOI 10.1002/jbmr.3285
   Zhou Xin, 2012, Curr Protoc Bioinformatics, VChapter 10, DOI 10.1002/0471250953.bi1010s40
NR 50
TC 10
Z9 11
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0009 9236
EI 1532 6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD DEC
PY 2021
VL 110
IS 6
BP 1558
EP 1569
DI 10.1002/cpt.2397
EA AUG 2021
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WW6NM
UT WOS:000691391400001
PM 34390503
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Zolochevska, O
   Figueiredo, ML
AF Zolochevska, Olga
   Figueiredo, Marxa L.
TI Cell Cycle Regulators cdk2ap1 and Bicalutamide Suppress Malignant
   Biological Interactions Between Prostate Cancer and Bone Cells
SO PROSTATE
LA English
DT Article
DE cdk2ap1; bicalutamide; cell cycle regulation; prostate cancer; therapy;
   bone interaction
ID NF KAPPA B; ANDROGEN RECEPTOR; PC 3 CELLS; EXPRESSION; DIFFERENTIATION;
   GROWTH; P12(DOC 1); PROLIFERATION; APOPTOSIS; DNA
AB INTRODUCTION. We examined whether the novel cell cycle regulator cdk2 associated protein 1 (p12(cdk2ap1) or cdk2ap1), recently shown to regulate prostate cancer cell cycle and apoptosis, could have the capacity to reduce invasiveness and/or reduce malignant biological interactions between prostate cancer and bone cells. We also examined whether combining two cell cycle arrest stimuli, cdk2ap1 plus bicalutamide (or casodex, CDX), could help enhance inhibition of prostate cancer cell phenotypes.
   METHODS. We stably expressed cdk2ap1 in prostate cancer cell lines using lentiviral vectors, as well as several different co culture assays to quantify cellular invasion, migration, and the effect of the treatments on interaction with the bone microenvironment.
   RESULTS. We have determined that cdk2ap1 can further augment the effects of CDX on cell cycle arrest, growth inhibition, and cellular invasion. Using a coculture model, we observed that either cdk2ap1 or cdk2ap1/CDX combination were able to reduce chemotaxis towards osteoblasts, and also reduce the osteoblastic proliferative response to prostate cancer. Also modified by cdk2ap1 and CDX were several signaling pathways associated with prostate cancer/bone crosstalk mechanisms involved in prostate cancer progression.
   CONCLUSIONS. These results suggest that either cdk2ap1 or the cdk2ap1/CDX combination hold promise in regulating prostate cancer growth and malignant phenotypes, and potentially also in reducing procarcinogenic interactions with a bone microenvironment model, restoring malignant phenotypes and signaling to a more benign state. Prostate 71: 353 367, 2011. (C) 2010 Wiley Liss, Inc.
C1 [Zolochevska, Olga; Figueiredo, Marxa L.] Louisiana State Univ, Dept Comparat Biomed Sci, Sch Vet Med, Baton Rouge, LA 70803 USA.
C3 Louisiana State University System; Louisiana State University; Louisiana
   State University School of Veterinary Medicine
RP Figueiredo, ML (通讯作者)，Louisiana State Univ, Dept Comparat Biomed Sci, Sch Vet Med, 1909 Skip Bertman Dr, Baton Rouge, LA 70803 USA.
EM mfigueiredo@vetmed.lsu.edu
CR Arencibia JM, 2009, INT J ONCOL, V34, P457, DOI 10.3892/ijo_00000170
   CULIG Z, 1993, PROSTATE, V22, P11, DOI 10.1002/pros.2990220103
   Cwikla SJ, 2000, J ORAL MAXIL SURG, V58, P406, DOI 10.1016/S0278 2391(00)90924 8
   Dai JL, 2004, CANCER RES, V64, P994, DOI 10.1158/0008 5472.CAN 03 1382
   Davis JN, 2006, CANCER RES, V66, P11897, DOI 10.1158/0008 5472.CAN 06 2497
   Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463 8471.1998
   Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903
   Figueiredo ML, 2005, CLIN CANCER RES, V11, P3939, DOI 10.1158/1078 0432.CCR 04 2085
   Fisher JL, 2002, CELL TISSUE RES, V307, P337, DOI 10.1007/s00441 001 0503 x
   Floryk D, 2005, CANCER RES, V65, P11588, DOI 10.1158/0008 5472.CAN 05 1831
   Floryk D, 2004, CANCER RES, V64, P9049, DOI 10.1158/0008 5472.CAN 04 1553
   GRAHAM TR, CANC SCI, V101, P103
   Hall CL, 2006, J CELL BIOCHEM, V97, P661, DOI 10.1002/jcb.20735
   Katner AL, 2002, PROSTATE, V53, P77, DOI 10.1002/pros.10124
   Kent TS, 2004, ANN SURG ONCOL, V11, P192, DOI 10.1245/ASO.2004.03.056
   Kohno Y, 2002, ORAL ONCOL, V38, P274, DOI 10.1016/S1368 8375(01)00055 0
   Koponen JK, 2003, GENE THER, V10, P459, DOI 10.1038/sj.gt.3301889
   Lampen A, 2005, BBA MOL CELL BIOL L, V1735, P30, DOI 10.1016/j.bbalip.2005.01.007
   Libertini SJ, 2006, PROSTATE, V66, P70, DOI 10.1002/pros.20314
   Lin BY, 2005, CANCER RES, V65, P3081, DOI 10.1158/0008 5472.CAN 04 3218
   Matsuo K, 2000, FASEB J, V14, P1318, DOI 10.1096/fj.14.10.1318
   Mori K, 2007, BONE, V40, P981, DOI 10.1016/j.bone.2006.11.006
   Nanni S, 2006, MOL CANCER RES, V4, P79, DOI 10.1158/1541 7786.MCR 05 0098
   Oldak M, 2010, J VIROL, V84, P1376, DOI 10.1128/JVI.01220 09
   Pluta K, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472 6750 7 41
   Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398
   Rigas AC, 2007, ONCOGENE, V26, P7611, DOI 10.1038/sj.onc.1210586
   Ritchie CK, 1997, ENDOCRINOLOGY, V138, P1145, DOI 10.1210/en.138.3.1145
   Sastry L, 2002, GENE THER, V9, P1155, DOI 10.1038/sj.gt.3301731
   SCHRODER FH, 1993, BRIT J UROL, V71, P633, DOI 10.1111/j.1464 410X.1993.tb16056.x
   Shintani S, 2001, CLIN CANCER RES, V7, P2776
   Shintani S, 2000, MOL CELL BIOL, V20, P6300, DOI 10.1128/MCB.20.17.6300 6307.2000
   Sitcheran R, 2003, GENE DEV, V17, P2368, DOI 10.1101/gad.1114503
   SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628
   Tao K, 2008, BMC CANCER, V8, DOI 10.1186/1471 2407 8 228
   Tyagi A, 2002, CELL CYCLE, V1, P137, DOI 10.4161/cc.1.2.115
   Wagner EF, 2010, ANN RHEUM DIS, V69, P86, DOI 10.1136/ard.2009.119396
   Wu Z, 2007, CARCINOGENESIS, V28, P1393, DOI 10.1093/carcin/bgm050
   Yin JJ, 2007, MOL CELL BIOL, V27, P7538, DOI 10.1128/MCB.00955 07
   Yuan ZQ, 2003, ONCOGENE, V22, P6304, DOI 10.1038/sj.onc.1206609
   Zhan P, 2002, J STEROID BIOCHEM, V83, P101, DOI 10.1016/S0960 0760(02)00275 3
   Zolochevska O, 2009, PROSTATE, V69, P1586, DOI 10.1002/pros.21007
NR 42
TC 13
Z9 14
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0270 4137
EI 1097 0045
J9 PROSTATE
JI Prostate
PD MAR 1
PY 2011
VL 71
IS 4
BP 353
EP 367
DI 10.1002/pros.21249
PG 15
WC Endocrinology & Metabolism; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Urology & Nephrology
GA 728SE
UT WOS:000287894000003
PM 20812223
DA 2025 08 17
ER

PT J
AU Meng, JH
   Zhou, CH
   Hu, B
   Luo, MM
   Yang, YT
   Wang, YX
   Wang, W
   Jiang, GY
   Hong, JQ
   Li, SH
   Wu, HB
   Yan, SG
   Yan, WQ
AF Meng, Jiahong
   Zhou, Chenhe
   Hu, Bin
   Luo, Mengmeng
   Yang, Yute
   Wang, Yangxin
   Wang, Wei
   Jiang, Guangyao
   Hong, Jianqiao
   Li, Sihao
   Wu, Haobo
   Yan, Shigui
   Yan, Weiqi
TI Stevioside Prevents Wear Particle Induced Osteolysis by Inhibiting
   Osteoclastogenesis and Inflammatory Response via the Suppression of TAK1
   Activation
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE aseptic loosening; osteoclast; NF kappa B   nuclear factor kappa B;
   MAPK; TAK1
ID NF KAPPA B; RANKL INDUCED OSTEOCLASTOGENESIS; P38 SIGNALING PATHWAY;
   TOTAL HIP; IN VITRO; PERIPROSTHETIC OSTEOLYSIS; OSTEOGENIC ACTIVITY;
   TITANIUM PARTICLES; NFATC1 INDUCTION; F ACTIN
AB Aseptic loosening and periprosthetic osteolysis are the leading causes of total joint arthroplasty failure, which occurs as a result of chronic inflammatory response and enhanced osteoclast activity. Here we showed that stevioside, a natural compound isolated from Stevia rebaudiana, exhibited preventative effects on titanium particle induced osteolysis in a mouse calvarial model. Further histological assessment and real time PCR analysis indicated that stevioside prevented titanium particle induced osteolysis by inhibiting osteoclast formation and inflammatory cytokine expression in vivo. In vitro, we found that stevioside could suppress RANKL induced osteoclastogenesis and titanium particle induced inflammatory response in a dose dependent manner. Mechanistically, stevioside achieved these effects by disrupting the phosphorylation of TAK1 and subsequent activation of NF kappa B/MAPKs signaling pathways. Collectively, our data suggest that stevioside effectively suppresses osteoclastogenesis and inflammatory response both in vitro and in vivo, and it might be a potential therapy for particle induced osteolysis and other osteolytic diseases.
C1 [Meng, Jiahong; Zhou, Chenhe; Hu, Bin; Yang, Yute; Wang, Yangxin; Wang, Wei; Jiang, Guangyao; Hong, Jianqiao; Li, Sihao; Wu, Haobo; Yan, Shigui; Yan, Weiqi] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Orthoped Surg, Hangzhou, Zhejiang, Peoples R China.
   [Meng, Jiahong; Zhou, Chenhe; Hu, Bin; Yang, Yute; Wang, Yangxin; Wang, Wei; Jiang, Guangyao; Hong, Jianqiao; Li, Sihao; Wu, Haobo; Yan, Shigui; Yan, Weiqi] Zhejiang Univ, Orthoped Res Inst, Hangzhou, Zhejiang, Peoples R China.
   [Luo, Mengmeng] Zhejiang Univ, Sch Med, Dept Plast Surg, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University
RP Wu, HB; Yan, SG; Yan, WQ (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Orthoped Surg, Hangzhou, Zhejiang, Peoples R China.; Wu, HB; Yan, SG; Yan, WQ (通讯作者)，Zhejiang Univ, Orthoped Res Inst, Hangzhou, Zhejiang, Peoples R China.
EM 2505014@zju.edu.cn; zrjwsj@zju.edu.cn; wyan@zju.edu.cn
RI ; Zhou, Chenhe/AAI 9226 2020
OI Yan, Weiqi/0000 0002 3298 7677; 
FU National Natural Science Foundation of China [81772360, 31771106]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Nos. 81772360 and 31771106).
CR Abu Amer Y, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2170
   Akisaka T, 2001, J BONE MINER RES, V16, P1248, DOI 10.1359/jbmr.2001.16.7.1248
   Bechtel CP, 2016, J BONE JOINT SURG AM, V98, P285, DOI 10.2106/JBJS.O.00736
   Beck RT, 2012, J ORTHOP RES, V30, P541, DOI 10.1002/jor.21554
   Bi FG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139793
   Boonkaewwan C, 2013, J SCI FOOD AGR, V93, P3820, DOI 10.1002/jsfa.6287
   Bozic KJ, 2009, J BONE JOINT SURG AM, V91A, P128, DOI 10.2106/JBJS.H.00155
   Caughey GE, 2001, J IMMUNOL, V167, P2831, DOI 10.4049/jimmunol.167.5.2831
   Chauhan SD, 2003, FASEB J, V17, P773, DOI 10.1096/fj.02 0668fje
   Cheng T, 2010, J BIOMED MATER RES A, V93A, P1493, DOI [10.1002/jbm.a.326.18, 10.1002/jbm.a.32618]
   Feng SM, 2009, BIOCHEM J, V417, P195, DOI 10.1042/BJ20081073
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Greenfield EM, 2002, J ORTHOPAED RES, V20, P1, DOI 10.1016/S0736 0266(01)00070 5
   Helfrich MH, 2005, ARCH ORAL BIOL, V50, P115, DOI 10.1016/j.archoralbio.2004.11.016
   Hirakawa K, 1996, J BIOMED MATER RES, V31, P257, DOI 10.1002/(SICI)1097 4636(199606)31:2<257::AID JBM13>3.0.CO;2 I
   Hirayama T, 2002, RHEUMATOLOGY, V41, P1232, DOI 10.1093/rheumatology/41.11.1232
   Holding CA, 2006, BIOMATERIALS, V27, P5212, DOI 10.1016/j.biomaterials.2006.05.054
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Idris AI, 2010, FASEB J, V24, P4545, DOI 10.1096/fj.10 164095
   Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014 5793(00)01146 7
   Landgraeber S, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/185150
   Lee SS, 2012, BIOMATERIALS, V33, P4251, DOI 10.1016/j.biomaterials.2012.03.005
   Li FY, 2012, INFLAMMATION, V35, P1669, DOI 10.1007/s10753 012 9483 0
   Masui T, 2005, BIOMATERIALS, V26, P1695, DOI 10.1016/j.biomaterials.2004.05.017
   Millett PJ, 2002, J BONE JOINT SURG AM, V84A, P236, DOI 10.2106/00004623 200202000 00011
   Nam JS, 2017, J BIOMED MATER RES A, V105, P912, DOI 10.1002/jbm.a.36004
   Nie YK, 2013, INFLAMMATION, V36, P242, DOI 10.1007/s10753 012 9540 8
   Noordin S, 2012, CAN J SURG, V55, P408, DOI 10.1503/cjs.003711
   Noosud J, 2017, AVICENNA J PHYTOMEDI, V7, P101
   Obando Pereda GA, 2014, LIFE SCI, V97, P96, DOI 10.1016/j.lfs.2013.11.008
   Parvizi J, 2017, AM J INFECT CONTROL, V45, P1267, DOI 10.1016/j.ajic.2017.06.027
   Pioletti DP, 2004, BIOMATERIALS, V25, P5803, DOI 10.1016/j.biomaterials.2004.01.053
   Purdue PE, 2007, CLIN ORTHOP RELAT R, P251, DOI 10.1097/01.blo.0000238813.95035.1b
   Ragone MI, 2017, PHYTOMEDICINE, V35, P18, DOI 10.1016/j.phymed.2017.08.022
   Shao HG, 2015, BIOMATERIALS, V60, P92, DOI 10.1016/j.biomaterials.2015.04.048
   Stevenson DA, 2011, CLIN GENET, V80, P566, DOI 10.1111/j.1399 0004.2010.01619.x
   Sumiya E, 2015, BIOCHEM BIOPH RES CO, V463, P1284, DOI 10.1016/j.bbrc.2015.06.105
   Suzuki Y, 2007, J ORTHOP SCI, V12, P568, DOI 10.1007/s00776 007 1180 8
   Takagi M, 2007, J BIOMED MATER RES A, V81A, P1017, DOI 10.1002/jbm.a.31235
   Teeny SM, 2003, J ARTHROPLASTY, V18, P954, DOI 10.1016/j.arth.2003.09.001
   Tian B, 2014, BIOMATERIALS, V35, P8937, DOI 10.1016/j.biomaterials.2014.06.055
   von Knoch M, 2004, J ORTHOP RES, V22, P237, DOI 10.1016/j.orthres.2003.08.013
   Wang WG, 2014, INT J MOL SCI, V15, P21913, DOI 10.3390/ijms151221913
   Wang ZQ, 2012, BIOCHEM BIOPH RES CO, V417, P1280, DOI 10.1016/j.bbrc.2011.12.130
   Wedemeyer C, 2005, BIOMATERIALS, V26, P3719, DOI 10.1016/j.biomaterials.2004.09.026
   Wedemeyer C, 2007, CALCIFIED TISSUE INT, V81, P394, DOI 10.1007/s00223 007 9077 2
   Wooley PH, 2002, BIOMATERIALS, V23, P517, DOI 10.1016/S0142 9612(01)00134 X
   Wu CL, 2015, BIOCHEM PHARMACOL, V93, P59, DOI 10.1016/j.bcp.2014.10.019
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
   Zhai ZJ, 2014, BIOMATERIALS, V35, P6299, DOI 10.1016/j.biomaterials.2014.04.044
   Zhang XP, 2001, J BONE MINER RES, V16, P660, DOI 10.1359/jbmr.2001.16.4.660
   Zhou CH, 2018, BRIT J PHARMACOL, V175, P859, DOI 10.1111/bph.14092
NR 54
TC 9
Z9 9
U1 0
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 26
PY 2018
VL 9
AR 1053
DI 10.3389/fphar.2018.01053
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GU9EM
UT WOS:000445647500001
PM 30319406
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Aripirala, S
   Gonzalez Pacanowska, D
   Oldfield, E
   Kaiser, M
   Amzel, LM
   Gabelli, SB
AF Aripirala, Srinivas
   Gonzalez Pacanowska, Dolores
   Oldfield, Eric
   Kaiser, Marcel
   Amzel, L. Mario
   Gabelli, Sandra B.
TI Structural and thermodynamic basis of the inhibition of Leishmania
   major farnesyl diphosphate synthase by nitrogen containing
   bisphosphonates
SO ACTA CRYSTALLOGRAPHICA SECTION D BIOLOGICAL CRYSTALLOGRAPHY
LA English
DT Article
ID PROTEIN STRUCTURES; PRODUCT; MECHANISM; REFINEMENT; FEATURES; BINDING;
   DESIGN; ENZYME; ERRORS; DRUGS
AB Farnesyl diphosphate synthase (FPPS) is an essential enzyme involved in the biosynthesis of sterols (cholesterol in humans and ergosterol in yeasts, fungi and trypanosomatid parasites) as well as in protein prenylation. It is inhibited by bisphosphonates, a class of drugs used in humans to treat diverse bone related diseases. The development of bisphosphonates as antiparasitic compounds targeting ergosterol biosynthesis has become an important route for therapeutic intervention. Here, the X ray crystallographic structures of complexes of FPPS from Leishmania major (the causative agent of cutaneous leishmaniasis) with three bisphosphonates determined at resolutions of 1.8, 1.9 and 2.3 angstrom are reported. Two of the inhibitors, 1 (2 hydroxy 2,2 diphosphonoethyl) 3 phenylpyridinium (300B) and 3 butyl 1 (2,2 diphosphonoethyl)pyridinium (476A), co crystallize with the homoallylic substrate isopentenyl diphosphate (IPP) and three Ca2+ ions. A t hird inhibitor, 3 fluoro 1 (2 hydroxy 2,2 diphosphonoethyl)pyridinium (46I), was found to bind two Mg2+ ions but not IPP. Calorimetric studies showed that binding of the inhibitors is entropically driven. Comparison of the structures of L. major FPPS (LmFPPS) and human FPPS provides new information for the design of bisphosphonates that will be more specific for inhibition of LmFPPS. The asymmetric structure of the LmFPPS 46I homodimer indicates that binding of the allylic substrate to both monomers of the dimer results in an asymmetric dimer with one open and one closed homoallylic site. It is proposed that IPP first binds to the open site, which then closes, opening the site on the other monomer, which closes after binding the second IPP, leading to the symmetric fully occupied FPPS dimer observed in other structures.
C1 [Aripirala, Srinivas] Johns Hopkins Univ, Inst Multiscale Modeling Biol Interact, Baltimore, MD 21210 USA.
   [Aripirala, Srinivas] Johns Hopkins Univ, Dept Biophys & Biophys Chem, Baltimore, MD 21210 USA.
   [Gonzalez Pacanowska, Dolores] Lopez Neyra Inst Parasitol & Biomed, Granada 18001, Spain.
   [Oldfield, Eric] Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
   [Kaiser, Marcel] Univ Basel, CH 4003 Basel, Switzerland.
   [Amzel, L. Mario; Gabelli, Sandra B.] Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA.
   [Gabelli, Sandra B.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   [Gabelli, Sandra B.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins University; Consejo Superior de
   Investigaciones Cientificas (CSIC); CSIC   Instituto de Parasitologia y
   Biomedicina Lopez Neyra (IPBLN); University of Illinois System;
   University of Illinois Urbana Champaign; University of Basel; Johns
   Hopkins University; Johns Hopkins University; Johns Hopkins University
RP Amzel, LM (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, 725 N Wolfe St WBSB 604, Baltimore, MD 21205 USA.
EM mamzel@jhmi.edu; gabelli@jhmi.edu
RI ; Gabelli, Sandra/A 3705 2008
OI Gonzalez Pacanowska, Dolores/0000 0002 4303 5209; Kaiser,
   Marcel/0000 0003 1785 7302; Gabelli, Sandra/0000 0003 1205 5204; Amzel,
   L. Mario/0000 0002 0129 9572
FU National Institutes of Health [GM065307, CA158191]; Plan Nacional
   [SAF2010 20059]; United States Department of Energy [DE AC0206CH11357]
FX This work was supported by National Institutes of Health grants GM065307
   and CA158191 to EO and in part by the Plan Nacional SAF2010 20059 to
   DGP. Use of the Advanced Photon Source at Argonne National Laboratory
   was supported by the United States Department of Energy under contract
   DE AC0206CH11357. Use of the Lilly Research Laboratory collaborative
   access team LRL CAT beamline at sector 31 of the Advanced Photon Source
   was provided by Eli Lilly Co., who operate the facility.
CR [Anonymous], 2014, Leishmaniasis
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754
   Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0
   Hooft RWW, 1996, J APPL CRYSTALLOGR, V29, P714, DOI 10.1107/S0021889896008631
   Huang CH, 2010, PROTEINS, V78, P888, DOI 10.1002/prot.22614
   JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   LASKOVICS FM, 1981, BIOCHEMISTRY US, V20, P1893, DOI 10.1021/bi00510a027
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022 2836(71)90324 X
   Montalvetti A, 2003, J BIOL CHEM, V278, P17075, DOI 10.1074/jbc.M210467200
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Narita K, 1999, J BIOCHEM TOKYO, V126, P566, DOI 10.1093/oxfordjournals.jbchem.a022487
   NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597
   Ohnuma S, 1996, J BIOL CHEM, V271, P30748, DOI 10.1074/jbc.271.48.30748
   Ortiz Gómez A, 2006, EUKARYOT CELL, V5, P1057, DOI 10.1128/EC.00034 06
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076 6879(97)76066 X
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rodriguez N, 2002, J INFECT DIS, V186, P138, DOI 10.1086/341074
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Sanders JM, 2005, J MED CHEM, V48, P2957, DOI 10.1021/jm040209d
   Szkopinska A, 2005, ACTA BIOCHIM POL, V52, P45
   TARSHIS LC, 1994, BIOCHEMISTRY US, V33, P10871, DOI 10.1021/bi00202a004
   Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736
   Zhang Y, 2006, J MED CHEM, V49, P5804, DOI 10.1021/jm060280e
NR 31
TC 19
Z9 20
U1 0
U2 8
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1399 0047
J9 ACTA CRYSTALLOGR D
JI Acta Crystallogr. Sect. D Biol. Crystallogr.
PD MAR
PY 2014
VL 70
BP 802
EP 810
DI 10.1107/S1399004713033221
PN 3
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biophysics; Crystallography
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Crystallography
GA AC3HC
UT WOS:000332406600019
PM 24598749
OA Green Published
DA 2025 08 17
ER

PT J
AU Yu, M
   Wang, D
   Yang, W
   Xu, MJ
   Liu, Y
   Xu, SY
   Yao, P
   Yan, H
   Liu, LG
AF Yu, Miao
   Wang, Di
   Yang, Wei
   Xu, Mengjing
   Liu, Yang
   Xu, Siyuan
   Yao, Ping
   Yan, Hong
   Liu, Liegang
TI Mechanisms of Nrf2/HO 1 pathway up regulation induced by pu erh black
   tea extract supplementation for quinocetone treated Sprague Dawley rats
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Pu erh tea; BTE; QCT; Nrf2/HO 1; Oxidative stress; ERK
ID DNA OXIDATIVE DAMAGE; HEME OXYGENASE 1; EPIGALLOCATECHIN GALLATE; HUMAN
   OSTEOBLASTS; GENE EXPRESSION; COMET ASSAY; IN VIVO; GREEN; FERMENTATION;
   STRESS
AB Pu erh tea is a special post fermented tea product that contains various compounds. Quinocetone (QCT) has been used as a veterinary drug in P.R. China. However, QCT has been proven to cause oxidative DNA damage, inflammation, and apoptosis. We have used Puerh black tea extract (BTE) as an intervention for QCT treated SD rats and analyzed its protective effect. Our data demonstrated that BTE improved QCT induced functional and organic liver damage. This protective effect was accomplished by activating the Nrf2/HO 1 pathway expression and the potential mechanism consisted in the activation of the extracellular signal regulated kinase (ERK) pathway by polyphenols contained in BTE. Moreover, some flavonoids and quinone (also contained in BTE) might effectively activate Nrf2/HO 1 pathway expression and protect SD rats from oxidative stress. Thus, the protective effect of BTE against QCT induced oxidative damage demonstrated new insights into the antioxidative mechanisms of Pu erh tea. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Yu, Miao; Wang, Di; Yang, Wei; Xu, Mengjing; Liu, Yang; Yao, Ping; Liu, Liegang] Huazhong Univ Sci & Technol, Sch Publ Hlth, Dept Nutr & Food Hyg, Tongji Med Coll,Hubei Key Lab Food Nutr & Safety, Wuhan 430030, Peoples R China.
   [Yu, Miao; Wang, Di; Yang, Wei; Xu, Mengjing; Liu, Yang; Yao, Ping; Yan, Hong; Liu, Liegang] Huazhong Univ Sci & Technol, Sch Publ Hlth, Tongji Med Coll, Minist Educ,Key Lab Environm & Hlth, Wuhan 430030, Peoples R China.
   [Xu, Siyuan] Hubei Prov Acad Prevent Med, Hubei Key Lab Appl Toxicol, Wuhan 430079, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology
RP Yan, H (通讯作者)，Huazhong Univ Sci & Technol, Sch Publ Hlth, Tongji Med Coll, Minist Educ,Key Lab Environm & Hlth, 13 Hangkong Rd, Wuhan 430030, Peoples R China.
EM yanhong@mails.tjmu.edu.cn; lgliu@mails.tjmu.edu.cn
RI li, yan/GXH 7943 2022
FU National Natural Science Foundation of China [NSFC81373042,
   NSFC81202210]; Open Fund of Hubei Provincial Key Laboratory for Applied
   Toxicology, Hubei Provincial Academy for Preventive Medicine
FX This work was supported by the National Natural Science Foundation of
   China (NSFC81373042 and NSFC81202210) and the Open Fund of Hubei
   Provincial Key Laboratory for Applied Toxicology, Hubei Provincial
   Academy for Preventive Medicine. We would like to thank all the
   participants for their contribution to this study.
CR Azqueta A, 2007, CHEM BIOL INTERACT, V168, P95, DOI 10.1016/j.cbi.2007.02.013
   CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253
   Chan MMY, 1997, BIOCHEM PHARMACOL, V54, P1281, DOI 10.1016/S0006 2952(97)00504 2
   Chen HX, 2013, J FOOD SCI, V78, pC1665, DOI 10.1111/1750 3841.12288
   Chen ZJ, 2014, TOXICOL LETT, V226, P314, DOI 10.1016/j.toxlet.2014.02.020
   Duh PD, 2004, J AGR FOOD CHEM, V52, P8169, DOI 10.1021/jf0490551
   Ehnert S, 2012, FOOD CHEM, V132, P724, DOI 10.1016/j.foodchem.2011.11.008
   Fan JP, 2013, FOOD CHEM TOXICOL, V59, P527, DOI 10.1016/j.fct.2013.06.047
   Halliwell B, 1996, BIOCHEM SOC T, V24, P1023, DOI 10.1042/bst0241023
   HELLMAN B, 1995, MUTAT RES DNA REPAIR, V336, P123, DOI 10.1016/0921 8777(94)00047 A
   Holzer N, 2012, LANGENBECK ARCH SURG, V397, P467, DOI 10.1007/s00423 011 0882 8
   Jozkowicz A, 2007, ANTIOXID REDOX SIGN, V9, P2099, DOI 10.1089/ars.2007.1659
   Khuri FR, 2008, J CLIN ONCOL, V26, P345, DOI 10.1200/JCO.2007.14.0913
   Lee Hilz YY, 2006, CHEM RES TOXICOL, V19, P1499, DOI 10.1021/tx060157q
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109
   Na HK, 2008, ARCH BIOCHEM BIOPHYS, V476, P171, DOI 10.1016/j.abb.2008.04.003
   Nesslany F, 2007, MUTAT RES GEN TOX EN, V630, P28, DOI 10.1016/j.mrgentox.2007.02.010
   Ogborne RM, 2004, BIOCHEM SOC T, V32, P1003, DOI 10.1042/BST0321003
   Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006 2952(02)01137 1
   Qin JH, 2012, J AGR FOOD CHEM, V60, P1213, DOI 10.1021/jf204844g
   Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320 344.2004
   Sasaki YF, 1997, MUTAT RES GEN TOX EN, V391, P215, DOI 10.1016/S1383 5718(97)00073 9
   Shen JZ, 2010, RAPID COMMUN MASS SP, V24, P375, DOI 10.1002/rcm.4399
   Snyder SH, 2001, NEUROPSYCHOPHARMACOL, V25, P294, DOI 10.1016/S0893 133X(01)00275 5
   Subramanian P, 2015, J FUNCT FOODS, V13, P89, DOI 10.1016/j.jff.2014.12.035
   Torres M, 2003, BIOFACTORS, V17, P287, DOI 10.1002/biof.5520170128
   Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960
   Wang D, 2012, FOOD CHEM TOXICOL, V50, P147, DOI 10.1016/j.fct.2011.10.069
   Wang D, 2011, FOOD CHEM TOXICOL, V49, P477, DOI 10.1016/j.fct.2010.11.028
   Wang D, 2010, J AGR FOOD CHEM, V58, P1350, DOI 10.1021/jf902171h
   Wang WN, 2014, FOOD CHEM, V152, P539, DOI 10.1016/j.foodchem.2013.10.117
   Wang X, 2010, REGUL TOXICOL PHARM, V58, P421, DOI 10.1016/j.yrtph.2010.08.008
   Wu CC, 2006, LIFE SCI, V78, P2889, DOI 10.1016/j.lfs.2005.11.013
   Yu M, 2014, FOOD CHEM TOXICOL, V69, P210, DOI 10.1016/j.fct.2014.04.026
   Yu M, 2013, REGUL TOXICOL PHARM, V66, P279, DOI 10.1016/j.yrtph.2013.04.005
   Zhao X, 2013, J ENVIRON PATHOL TOX, V32, P275, DOI 10.1615/JEnvironPatholToxicolOncol.2013007074
   Zhong Y, 2012, J FUNCT FOODS, V4, P323, DOI 10.1016/j.jff.2011.12.011
   Zuo YG, 2002, TALANTA, V57, P307, DOI 10.1016/S0039 9140(02)00030 9
NR 40
TC 8
Z9 9
U1 1
U2 24
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1756 4646
J9 J FUNCT FOODS
JI J. Funct. Food.
PD APR
PY 2015
VL 14
BP 767
EP 778
DI 10.1016/j.jff.2015.03.004
PG 12
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA CV8AX
UT WOS:000364500000078
DA 2025 08 17
ER

PT J
AU Sun, ZQ
   Lin, C
   Wu, KL
   Wang, MY
AF Sun, Zhaoqi
   Lin, Chao
   Wu, Kailiu
   Wang, Mingyi
TI Dual mechanism design to enhance bone formation by overexpressed SDF 1
   ADSCs in magnesium doped calcium phosphate scaffolds
SO MATERIALS & DESIGN
LA English
DT Article
DE SDF 1; Lentivirus; Cell migration; Magnesium doped calcium phosphate;
   cement; Bone defect
ID MESENCHYMAL STEM CELLS; IN VITRO; CALVARIAL DEFECTS; TISSUE REPAIR;
   STROMAL CELLS; MIGRATION; MARROW; REGENERATION; CEMENT; OSTEOGENESIS
AB Background: SDF 1/CXCR4 axis plays a critical role in the mobilization and regeneration of host derived cells. Little is known around the role of SDF 1 gene on bone regeneration. This study was conceptualized to create a 2 in 1 strategy by identifying potential role of SDF 1 on promoting endogenous osteoblast migration and synergizing with magnesium doped calcium phosphate scaffold (MCPC) on osteogenic differentiation. Method: ADSCs were transfected with Lenti SDF 1. Cell proliferation, osteogenic gene expression and ALP/ARS staining were investigated. Osteoblast migration was studied. MCPC construct was employed as carrier of Lenti SDF 1 ADSCs. Osteogenic gene expressions of BMSCs were determined in MCPC + ADSCs medium. MCPC + Lenti SDF 1 ADSCs scaffolds were implanted into rats and bone regeneration efficacy was evaluated by micro CT and histological analysis. Result: SDF 1 transduction neither impacted ADSCs' proliferation, nor osteogenic differentiation. LentiSDF 1 ADSCs promoted migration of BMSCs/osteoblasts. MCPC facilitated osteogenic differentiation of BMSCs. Bone formation was significantly increased in MCPC + Lenti SDF 1 group. Conclusion: Overexpressed SDF 1 gene promotes the homing of endogenous osteoblasts. MCPC + LentiSDF 1 facilitated robust in situ bone regeneration via dual mechanisms by recruiting endogenous BMSCs' and enhancing homing cell's differentiation. This advanced design combines gene therapy and osteoinductive tissue scaffolds, which is proved to be a promising strategy to achieve satisfied clinical bone repair efficacy. (c) 2021 Published by Elsevier Ltd. This is an open access article under the CC BY NC ND license (http:// creativecommons.org/licenses/by nc nd/4.0/).
C1 [Sun, Zhaoqi; Wu, Kailiu; Wang, Mingyi] Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Oral & Maxillofacial Head & Neck Oncol, Sch Med, Shanghai 200011, Peoples R China.
   [Sun, Zhaoqi; Wu, Kailiu; Wang, Mingyi] Natl Clin Res Ctr Oral Dis, Shanghai 200011, Peoples R China.
   [Sun, Zhaoqi; Wu, Kailiu; Wang, Mingyi] Shanghai Key Lab Stomatol, Shanghai 200011, Peoples R China.
   [Sun, Zhaoqi; Wu, Kailiu; Wang, Mingyi] Shanghai Res Inst Stomatol, Shanghai 200011, Peoples R China.
   [Lin, Chao] Weifang Med Univ, Sch Stomatol, Weifang 261053, Peoples R China.
C3 Shanghai Jiao Tong University; Shandong Second Medical University
RP Wang, MY (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Oral & Maxillofacial Head & Neck Oncol, Sch Med, Shanghai 200011, Peoples R China.; Wang, MY (通讯作者)，Natl Clin Res Ctr Oral Dis, Shanghai 200011, Peoples R China.; Wang, MY (通讯作者)，Shanghai Key Lab Stomatol, Shanghai 200011, Peoples R China.; Wang, MY (通讯作者)，Shanghai Res Inst Stomatol, Shanghai 200011, Peoples R China.
EM Mingyiwang2020@163.com
FU Ninth People's Hospital [JYZZ104]
FX Authors would also like to acknowledge financial support from
   fundamental research program funding of Ninth People's Hospital
   affiliated to Shanghai Jiao Tong University School of Medicine (JYZZ104)
   .
CR Abueva CDG, 2018, MATER DESIGN, V141, P142, DOI 10.1016/j.matdes.2017.12.040
   Augello A, 2010, EUR CELLS MATER, V20, P121
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Bose S, 2018, MATER DESIGN, V151, P102, DOI 10.1016/j.matdes.2018.04.049
   Bunpetch V, 2019, BIOMATERIALS, V196, P67, DOI 10.1016/j.biomaterials.2017.11.023
   Cao J, 2013, BRIT J ORAL MAX SURG, V51, P937, DOI 10.1016/j.bjoms.2013.05.003
   D'Mello S, 2017, AAPS J, V19, P43, DOI 10.1208/s12248 016 9982 2
   Edwards PC, 2005, GENE THER, V12, P75, DOI 10.1038/sj.gt.3302386
   Galipeau J, 2013, CYTOTHERAPY, V15, P2, DOI 10.1016/j.jcyt.2012.10.002
   Ghadge SK, 2011, PHARMACOL THERAPEUT, V129, P97, DOI 10.1016/j.pharmthera.2010.09.011
   Hu CJ, 2013, J SURG RES, V183, P427, DOI 10.1016/j.jss.2013.01.019
   Jiang XQ, 2009, BIOMATERIALS, V30, P4522, DOI 10.1016/j.biomaterials.2009.05.021
   Jin W, 2018, PEERJ, V6, DOI 10.7717/peerj.6072
   Jones GN, 2012, STEM CELL TRANSL MED, V1, P70, DOI 10.5966/sctm.2011 0007
   Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001
   Kawecki F, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700919
   Khatua C, 2019, MATER DESIGN, V167, DOI 10.1016/j.matdes.2019.107628
   Kim J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032350
   Li Q, 2016, EXP THER MED, V12, P45, DOI 10.3892/etm.2016.3309
   Liu NM, 2013, J CELL BIOCHEM, V114, P2677, DOI 10.1002/jcb.24615
   Liu XL, 2011, PROTEIN CELL, V2, P845, DOI 10.1007/s13238 011 1097 z
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Padalhin AR, 2018, MATER DESIGN, V158, P172, DOI 10.1016/j.matdes.2018.08.029
   Paula ACC, 2020, MAT SCI ENG C MATER, V107, DOI 10.1016/j.msec.2019.110301
   Petit I, 2007, TRENDS IMMUNOL, V28, P299, DOI 10.1016/j.it.2007.05.007
   Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211
   Shimaya M, 2010, OSTEOARTHR CARTILAGE, V18, P1300, DOI 10.1016/j.joca.2010.06.005
   Shin L, 2013, STEM CELL TRANSL MED, V2, P33, DOI 10.5966/sctm.2012 0041
   Solovyeva VV, 2020, APPL BIOCHEM BIOTECH, V190, P773, DOI 10.1007/s12010 019 03128 5
   Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005 0271
   Stich S, 2009, CELL TISSUE RES, V336, P225, DOI 10.1007/s00441 009 0768 z
   Wang SY, 2009, BIOMATERIALS, V30, P2489, DOI 10.1016/j.biomaterials.2008.12.067
   Wang Y, 2008, BRAIN RES, V1195, P104, DOI 10.1016/j.brainres.2007.11.068
   Wei FY, 2016, EUR CELLS MATER, V31, P341, DOI 10.22203/eCM.v031a22
   Xia HM, 2018, NAT REV MATER, V3, P174, DOI 10.1038/s41578 018 0027 6
   Xinaris C, 2013, CELL TRANSPLANT, V22, P423, DOI 10.3727/096368912X653246
   Xu FF, 2020, J MECH BEHAV BIOMED, V103, DOI 10.1016/j.jmbbm.2019.103532
   Yamada Y, 2013, STEM CELLS, V31, P572, DOI 10.1002/stem.1300
   Yang M, 2005, CYTOTHERAPY, V7, P273, DOI 10.1080/14653240510027244
   Yi T, 2012, ARCH PHARM RES, V35, P213, DOI 10.1007/s12272 012 0202 z
   Yu J, 2010, J CARDIOVASC PHARM, V55, P496, DOI 10.1097/FJC.0b013e3181d7a384
   Zhang J, 2015, BIOMATERIALS, V53, P251, DOI 10.1016/j.biomaterials.2015.02.097
   Zhang LX, 2015, INT J CLIN EXP PATHO, V8, P10261
   Zhang Q, 2019, MAT SCI ENG C MATER, V103, DOI 10.1016/j.msec.2019.109858
   Zhang WJ, 2011, BIOMATERIALS, V32, P9415, DOI 10.1016/j.biomaterials.2011.08.047
   Zhao J, 2012, TISSUE ENG PT A, V18, P185, DOI [10.1089/ten.tea.2011.0297, 10.1089/ten.TEA.2011.0297]
   Zimowska M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093302
   Zou DH, 2011, BIOMATERIALS, V32, P9707, DOI 10.1016/j.biomaterials.2011.09.005
NR 48
TC 6
Z9 6
U1 1
U2 30
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264 1275
EI 1873 4197
J9 MATER DESIGN
JI Mater. Des.
PD OCT
PY 2021
VL 208
AR 109884
DI 10.1016/j.matdes.2021.109884
EA JUN 2021
PG 13
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA UA0LY
UT WOS:000684858300006
OA gold
DA 2025 08 17
ER

PT J
AU Portero Muzy, NR
   Chavassieux, PM
   Bouxsein, ML
   Gineyts, E
   Garnero, P
   Chapurlat, RD
AF Portero Muzy, N. R.
   Chavassieux, P. M.
   Bouxsein, M. L.
   Gineyts, E.
   Garnero, P.
   Chapurlat, R. D.
TI Early effects of zoledronic acid and teriparatide on bone
   microarchitecture, remodeling and collagen crosslinks: Comparison
   between iliac crest and lumbar vertebra in ewes
SO BONE
LA English
DT Article
DE Iliac crest; Vertebra; Ewe; Zoledronic acid; Teriparatide
ID AGE RELATED CHANGES; TRABECULAR BONE; POSTMENOPAUSAL WOMEN;
   HISTOMORPHOMETRIC PARAMETERS; BIOMECHANICAL PROPERTIES; NONENZYMATIC
   GLYCATION; MECHANICAL PROPERTIES; COMPUTED TOMOGRAPHY;
   PARATHYROID HORMONE; SKELETAL FRAGILITY
AB Iliac crest bone biopsies are used to assess the mechanism of action of drug treatments, yet there are little data comparing this site to sites prone to fracture. The purpose of this study was to compare the delay and the amplitude of responses to treatment in two different bone sites. The short term effects of zoledronic acid and teriparatide on microarchitecture, collagen crosslinks and bone remodeling were evaluated in iliac crest and lumbar vertebrae. Aged ewes (n = 8/gr) received either vehicle (CTRL) or a single injection of zoledronic acid (ZOL, 10 mg) or daily injections of teriparatide (TPTD, 20 mu g/d) for 3 months. Blood samples were collected monthly for assessing bone turnover markers. At the end of the study, a transiliac bone biopsy (IC) and L1 lumbar vertebrae (LV1) were collected to assess bone microarchitecture; pyridinoline (PYD), deoxypyridinoline (DPD), pentosidine (PEN) content, static and dynamic parameters of bone remodeling. In CTRL Tb BV/TV was significantly higher in LV1 than IC (p<0.0001). This was associated with a trend of higher Tb.N, Tb.Th, DA, an inferior Conn.D and a lower bone turnover as shown by the decreases of osteoid parameters, MS/BS, Ac.f in LV1 when compared to IC. In addition, the ratio PYD/DPD was 4 times higher in LV1 than IC. After 3 months, significant decreases of sALP (p<0.001) and sCTX (p<0.001) were observed in the ZOL group whereas in TPTD group, after transient increases, they returned to baseline values. When compared to their respective CTRL, ZOL induced significant increases in Tb.BV/TV, Conn.D, Tb.N and Tb.Sp, in IC but not in LV1. Regardless of the site, ZOL markedly depressed the bone turnover: The static parameters of bone formation significantly decreased and the diminution of MS/BS, BFR/BS and Ac.f varied from  94 to   98% vs CTRL (p<0.01 to 0.001). It was associated with a diminution of the DPD content and the PYD/DPD ratio mainly in IC cortices. In contrast, after 3 months, TPTD did not modify the 3D structure and microarchitecture in IC and LV1, except a trend of higher Conn.D in IC, compared to IC CTRL. TPTD treatment induced a significant increase in cortical porosity in LV1 (p<0.05) when compared to LV1 CTRL. Static parameters of bone formation and resorption were augmented in both sites, significantly only in LV1 (p<0.05) with a trend of increases in MS/BS and BFR/BS, compared to LV1 CTRL. In conclusion, in adult ewes, the bone mass, microarchitecture, remodeling and collagen crosslink content differ according to the bone site (iliac crest and vertebra). Furthermore, after 3 months, the responses to ZOL and TPTD were of different magnitude and delay between the two bone sites. The distinction of bone sites to study the early effects of anti osteoporotic therapies appears meaningful in order to approach their site specific anti fracture efficacy. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Portero Muzy, N. R.; Chavassieux, P. M.; Gineyts, E.; Garnero, P.; Chapurlat, R. D.] Fac Med Lyon Est, INSERM, UMR 1033, F 69372 Lyon 08, France.
   [Portero Muzy, N. R.; Chavassieux, P. M.; Gineyts, E.; Garnero, P.; Chapurlat, R. D.] Univ Lyon, Lyon, France.
   [Bouxsein, M. L.] Beth Israel Deaconess Med Ctr, Orthoped Biomech Lab, Boston, MA 02215 USA.
   [Bouxsein, M. L.] Harvard Univ, Sch Med, Boston, MA USA.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Claude Bernard Lyon 1; Harvard University; Harvard University
   Medical Affiliates; Beth Israel Deaconess Medical Center; Harvard
   University; Harvard Medical School
RP Portero Muzy, NR (通讯作者)，Fac Med Lyon Est, INSERM, UMR 1033, Rue Guillaume Paradin, F 69372 Lyon 08, France.
EM Nathalie.Portero Muzy@univ lyon1.fr
RI Chavassieux, Pascale/L 9071 2018; CHAPURLAT, ROLAND/AAU 1165 2021
OI Gineyts, Evelyne/0000 0003 3868 5810; 
FU NCRR NIH HHS [S10 RR017868] Funding Source: Medline
CR Allen MR, 2008, OSTEOPOROSIS INT, V19, P329, DOI 10.1007/s00198 007 0533 7
   Allen MR, 2008, OSTEOPOROSIS INT, V19, P95, DOI 10.1007/s00198 007 0451 8
   Amling M, 1996, J BONE MINER RES, V11, P36, DOI 10.1002/jbmr.5650110107
   AMLING M, 1994, BONE MINER, V27, P193, DOI 10.1016/S0169 6009(08)80193 6
   Arlot M, 2005, J BONE MINER RES, V20, P1244, DOI 10.1359/JBMR.050309
   Bauer DC, 2006, J BONE MINER RES, V21, P292, DOI 10.1359/JBMR.051018
   Binkley N, 1998, J BONE MINER RES, V13, P1775, DOI 10.1359/jbmr.1998.13.11.1775
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Bouxsein ML, 2009, BEST PRACT RES CL RH, V23, P741, DOI 10.1016/j.berh.2009.09.008
   Bouxsein ML, 2005, BEST PRACT RES CL RH, V19, P897, DOI 10.1016/j.berh.2005.07.004
   CHAVASSIEUX P, 1991, BONE, V12, P421, DOI 10.1016/8756 3282(91)90031 D
   CHAVASSIEUX P, 1993, OSTEOPOROSIS INT, V3, P97, DOI 10.1007/BF01623380
   CHAVASSIEUX P, 1990, Journal of Bone and Mineral Research, V5, pS95
   Chavassieux P, 2001, J BONE MINER RES, V16, P89, DOI 10.1359/jbmr.2001.16.1.89
   Chavassieux P, 1997, BONE, V20, P451, DOI 10.1016/S8756 3282(97)00016 1
   Chavassieux P, 2001, OSTEOPOROSIS, V2nd, P501
   Davison KS, 2006, SEMIN ARTHRITIS RHEU, V36, P22, DOI 10.1016/j.semarthrit.2006.04.002
   DELMAS PD, 1995, BONE, V16, P603, DOI 10.1016/8756 3282(95)00113 R
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Dobnig H, 2005, J CLIN ENDOCR METAB, V90, P3970, DOI 10.1210/jc.2003 1703
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   EYRE DR, 1988, BIOCHEM J, V252, P495, DOI 10.1042/bj2520495
   Follet H, 2011, J ORTHOP RES, V29, P481, DOI 10.1002/jor.21275
   GARNERO P, 1993, J CLIN ENDOCR METAB, V77, P1046, DOI 10.1210/jc.77.4.1046
   GOULET RW, 1994, J BIOMECH, V27, P375, DOI 10.1016/0021 9290(94)90014 0
   Hodsman AB, 2000, BONE, V27, P311, DOI 10.1016/S8756 3282(00)00316 1
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Libouban H, 2008, MICRON, V39, P998, DOI 10.1016/j.micron.2007.09.006
   MELLISH RWE, 1991, J BONE MINER RES, V6, P689
   Meunier P, 1973, Clin Endocrinol Metab, V2, P239, DOI 10.1016/S0300 595X(73)80042 8
   Meunier P, 1973, P 1 WORKSH BON MORPH, P100
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Mitton D, 1998, BONE, V22, P651, DOI 10.1016/S8756 3282(98)00036 2
   MOSEKILDE L, 1988, BONE, V9, P195, DOI 10.1016/8756 3282(88)90030 0
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   PODENPHANT J, 1986, BONE, V7, P427, DOI 10.1016/8756 3282(86)90002 5
   Portero NR, 2005, CALCIFIED TISSUE INT, V77, P195, DOI 10.1007/s00223 004 1260 0
   Recker RR, 2008, J BONE MINER RES, V23, P6, DOI 10.1359/JBMR.070906
   Roux JP, 2010, J BONE MINER RES, V25, P356, DOI 10.1359/jbmr.090803
   Saito M, 2008, OSTEOPOROSIS INT, V19, P1343, DOI 10.1007/s00198 008 0585 3
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Silva MJ, 1997, BONE, V21, P191, DOI 10.1016/S8756 3282(97)00100 2
   Sorensen OH, 2003, BONE, V32, P120, DOI 10.1016/S8756 3282(02)00946 8
   Tang SY, 2007, BONE, V40, P1144, DOI 10.1016/j.bone.2006.12.056
   Thomas T, 1996, J APPL PHYSIOL, V80, P198, DOI 10.1152/jappl.1996.80.1.198
   Turner CH, 2002, OSTEOPOROSIS INT, V13, P97, DOI 10.1007/s001980200000
   Vashishth D, 2001, BONE, V28, P195, DOI 10.1016/S8756 3282(00)00434 8
   Viguet Carrin S, 2009, J CHROMATOGR B, V877, P1, DOI 10.1016/j.jchromb.2008.10.043
   Viguet Carrin S, 2006, BONE, V39, P1073, DOI 10.1016/j.bone.2006.05.013
   Viguet Carrin S, 2010, BONE, V46, P342, DOI 10.1016/j.bone.2009.10.001
   Wegrzyn J, 2010, J BONE MINER RES, V25, P2324, DOI 10.1002/jbmr.164
   Zioupos P, 1999, J BIOMECH, V32, P209, DOI 10.1016/S0021 9290(98)00146 8
NR 54
TC 12
Z9 14
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2012
VL 51
IS 4
BP 714
EP 719
DI 10.1016/j.bone.2012.07.004
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 005DH
UT WOS:000308730200011
PM 22796591
DA 2025 08 17
ER

PT J
AU Saffie Siebert, S
   Alam, I
   Sutera, FM
   Dehsorkhi, A
   Torabi Pour, N
   Baran Rachwalska, P
   Iamartino, L
   Teti, A
   Maurizi, A
   Gerard O'Riley, RL
   Acton, D
   Econs, MJ
AF Saffie Siebert, Suzanne
   Alam, Imranul
   Sutera, Flavia Maria
   Dehsorkhi, Ashkan
   Torabi Pour, Nissim
   Baran Rachwalska, Paulina
   Iamartino, Luca
   Teti, Anna
   Maurizi, Antonio
   Gerard O'Riley, Rita L.
   Acton, Dena
   Econs, Michael J.
TI Effect of Allele Specific Clcn7<SUP>G213R</SUP> siRNA Delivered
   Via a Novel Nanocarrier on Bone Phenotypes in ADO2 Mice on 129S
   Background
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Autosomal dominant osteopetrosis; Gene therapy; siRNA;
   Silicon stabilised hybrid lipid nanoparticles
ID AUTOSOMAL DOMINANT OSTEOPETROSIS; GENE MUTATIONS; DISEASE; OSTEOPOROSIS;
   OSTEOCLASTS; SEVERITY
AB Autosomal dominant osteopetrosis type 2 (ADO2) is a rare inherited bone disorder characterised by dense but brittle bones. It displays striking phenotypic variability, with the most severe symptoms, including blindness and bone marrow failure. Disease management largely relies on symptomatic treatment since there is no safe and effective treatment. Most ADO2 cases are caused by heterozygous loss of function mutations in the CLCN7 gene, which encodes an essential Cl /H+ antiporter for proper bone resorption by osteoclasts. Thus, siRNA mediated silencing of the mutant allele is a promising therapeutic approach, but targeting bone for first in human translation remains challenging. Here, we demonstrate the utility of silicon stabilised hybrid lipid nanoparticles (sshLNPs) as a next generation nucleic acid nanocarrier capable of delivering allele specific siRNA to bone. Using a Clcn7(G213R) knock in mouse model recapitulating one of the most common human ADO2 mutations and based on the 129S genetic background (which produces the most severe disease phenotype amongst current models), we show substantial knockdown of the mutant allele in femur when siRNA targeting the pathogenic variant is delivered by sshLNPs. We observed lower areal bone mineral density in femur and reduced trabecular thickness in femur and tibia, when siRNA loaded sshLNPs were administered subcutaneously (representing the most relevant administration route for clinical adoption and patient adherence). Importantly, sshLNPs have improved stability over conventional LNPs and enable 'post hoc loading' for point of care formulation. The treatment was well tolerated, suggesting that sshLNP enabled gene therapy might allow successful clinical translation of essential new treatments for ADO2 and potentially other rare genetic bone diseases.
C1 [Saffie Siebert, Suzanne; Sutera, Flavia Maria; Dehsorkhi, Ashkan; Torabi Pour, Nissim; Baran Rachwalska, Paulina; Iamartino, Luca] SiSaf Ltd, Guildford GU2 7RE, Surrey, England.
   [Alam, Imranul; Gerard O'Riley, Rita L.; Acton, Dena; Econs, Michael J.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
   [Econs, Michael J.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
   [Teti, Anna; Maurizi, Antonio] Univ Aquila, Dept Biotechnol & Appl Clin Sci, I 67100 Laquila, Italy.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; University of
   L'Aquila
RP Saffie Siebert, S (通讯作者)，SiSaf Ltd, Guildford GU2 7RE, Surrey, England.; Alam, I (通讯作者)，Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
EM saffie@sisaf.com; ialam@iu.edu
RI Sutera, Flavia/H 1714 2016; Maurizi, Antonio/AAI 7728 2020
OI Econs, Michael/0000 0003 0940 1911; 
FU Piano Operativo Nazionale (PON) Ricerca Innovazione [FSE REACT EU
   D.M.1062]
FX A.M. is supported by the 'Piano Operativo Nazionale (PON) Ricerca
   Innovazione' (FSE REACT EU D.M.1062).
CR Ahn I, 2023, EXP MOL MED, V55, P1283, DOI 10.1038/s12276 023 00998 y
   Aigner A, 2019, NANOMEDICINE UK, V14, P2777, DOI 10.2217/nnm 2019 0321
   Akinc A, 2010, MOL THER, V18, P1357, DOI 10.1038/mt.2010.85
   Alam I, 2017, BONE, V94, P34, DOI 10.1016/j.bone.2016.10.016
   Alam I, 2015, J BONE MINER RES, V30, P2005, DOI 10.1002/jbmr.2545
   Alam I, 2014, BONE, V59, P66, DOI 10.1016/j.bone.2013.10.021
   Baran Rachwalska P, 2020, J CONTROL RELEASE, V326, P192, DOI 10.1016/j.jconrel.2020.07.004
   Capulli M, 2015, MOL THER NUCL ACIDS, V4, P1, DOI 10.1038/mtna.2015.21
   Chen Y, 2023, FRONT PEDIATR, V11, DOI 10.3389/fped.2023.1096770
   Cohen Solal M, 2023, BONE, V167, DOI 10.1016/j.bone.2022.116635
   Coudert AE, 2014, LAB INVEST, V94, P275, DOI 10.1038/labinvest.2013.140
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Desai AS, 2023, NEW ENGL J MED, V389, P228, DOI 10.1056/NEJMoa2208391
   Dohrn MF, 2021, NEUROL RES PRACT, V3, DOI 10.1186/s42466 021 00155 8
   Friedrich M, 2022, BIODRUGS, V36, P549, DOI 10.1007/s40259 022 00549 3
   Gandell DL, 2019, PATIENT PREFER ADHER, V13, P351, DOI 10.2147/PPA.S187120
   Garnero P, 2017, MOL DIAGN THER, V21, P401, DOI 10.1007/s40291 017 0272 1
   Henriksen K, 2004, AM J PATHOL, V164, P1537, DOI 10.1016/S0002 9440(10)63712 1
   Imel EA, 2019, J BONE MINER RES, V34, P1436, DOI 10.1002/jbmr.3715
   Kasper D, 2005, EMBO J, V24, P1079, DOI 10.1038/sj.emboj.7600576
   Ladd LM, 2021, SKELETAL RADIOL, V50, P903, DOI 10.1007/s00256 020 03625 3
   Liu XL, 2016, J BIOMED RES, V30, P264, DOI 10.7555/JBR.30.20150110
   Malcolm DW, 2020, CURR OSTEOPOROS REP, V18, P312, DOI 10.1007/s11914 020 00587 2
   Maurizi A, 2023, MOL THER NUCL ACIDS, V33, P925, DOI 10.1016/j.omtn.2023.08.020
   Maurizi A, 2022, BONE, V165, DOI 10.1016/j.bone.2022.116567
   Maurizi A, 2018, BONE, V110, P343, DOI 10.1016/j.bone.2018.02.031
   Miller VM, 2003, P NATL ACAD SCI USA, V100, P7195, DOI 10.1073/pnas.1231012100
   Nguyen A, 2022, JBMR PLUS, V6, DOI 10.1002/jbm4.10597
   Nicoli ER, 2019, AM J HUM GENET, V104, P1127, DOI 10.1016/j.ajhg.2019.04.008
   Saffie Siebert R.S., 2023, WIPO Patent, Patent No. [2023/002222A1, 2023002222]
   Salam S, 2018, J AM SOC NEPHROL, V29, P1557, DOI 10.1681/ASN.2017050584
   Schulz A, 2023, BONE, V167, DOI 10.1016/j.bone.2022.116634
   Seong S, 2023, BIOMATER SCI UK, V11, P2581, DOI 10.1039/d2bm02038f
   Sherk VD, 2013, J CLIN DENSITOM, V16, P104, DOI 10.1016/j.jocd.2012.07.009
   Sobacchi C., 2022, GENEREVIEWS
   Solberg LB, 2014, CALCIFIED TISSUE INT, V94, P510, DOI 10.1007/s00223 013 9834 3
   Teti A, 2022, BONE, V164, DOI 10.1016/j.bone.2022.116512
   The Human Protein Atlas, 2023, CLCN7 TISSUE
   Torabi Pour N, 2020, WIPO Patent Application, Patent No. [2020/193995A1, 2020193995]
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Uijl E, 2019, HYPERTENSION, V73, P1249, DOI 10.1161/HYPERTENSIONAHA.119.12703
   Waguespack SG, 2003, J BONE MINER RES, V18, P1513, DOI 10.1359/jbmr.2003.18.8.1513
   Waguespack SG, 2007, J CLIN ENDOCR METAB, V92, P771, DOI 10.1210/jc.2006 1986
   Wartosch L, 2009, FASEB J, V23, P4056, DOI 10.1096/fj.09 130880
   Wu CC, 2017, J CLIN ENDOCR METAB, V102, P3111, DOI 10.1210/jc.2017 01127
   Xiong Q, 2016, JOINT BONE SPINE, V83, P276, DOI 10.1016/j.jbspin.2015.07.010
NR 46
TC 1
Z9 1
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD JUL
PY 2024
VL 115
IS 1
BP 85
EP 96
DI 10.1007/s00223 024 01222 3
EA MAY 2024
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA TU0N7
UT WOS:001220873900001
PM 38733412
DA 2025 08 17
ER

PT J
AU Uhl, C
   Nyirenda, T
   Siegel, DS
   Lee, WY
   Zilberberg, J
AF Uhl, Christopher
   Nyirenda, Themba
   Siegel, David S.
   Lee, Woo Y.
   Zilberberg, Jenny
TI Natural killer cells activity against multiple myeloma cells is
   modulated by osteoblast induced IL 6 and IL 10 production
SO HELIYON
LA English
DT Article
DE NK cells; Multiple myeloma; Cytotoxicity; Osteoblasts; Microenvironment
ID MEDIATED DRUG RESISTANCE; TUMOR MICROENVIRONMENT; EXTRACELLULAR MATRIX;
   NK CELLS; THERAPY; MODEL; NK 92; LINE
AB Background: Natural killer (NK) cells are part of the innate arm of the immune system; as such NK cells can be activated rapidly to target virus infected cells and tumor cells without prior sensitization. The human NK 92MI cell line is among the most widely used NK cell in preclinical research studies and has also been approved for clinical applications. Previous studies have shown that osteoblasts (OSB) confer drug resistance in multiple myeloma (MM) and other cancers that metastasize to the bone marrow.
   Aim: We evaluated here how OSB, which are bone forming cells and a key cellular component of the bone marrow microenvironment, modulate the cytotoxic activity of NK 92MI cells against the MM.1S multiple myeloma cell line.
   Methods: The osteoblastic niche was recapitulated with either the osteoblastic cell line hFOB 1.19 (hFOB) or primary osteoblasts (P OSB) derived from surgical resections. Time lapse imaging was utilized to quantify changes in MM.1S cell viability under different conditions, including: (1) Co culture of MM.1S with NK92MI cells, (2) triple culture of hFOB or P OSB with MM.1S and NK 92MI, and (3) MM.1S or NK 92MI cells primed with OSB derived supernatant. Cytokine analysis was conducted to quantify potential secreted factors associated with the protective effects of OSB.
   Results: The physical presence of OSB hindered the activity of NK 92MI cells, resulting in the increased viability of MM.1S compared to co cultures which lacked OSB. This observation was accompanied by reduced perforin and granzyme A secretion from NK 92MI cells. Contact of OSB and NK 92MI cells also induced interleukin 6 (IL 6) and interleukin 10 (IL 10) production; two cytokines which are known to impair the NK cell immunity against MM and other cancers. OSB supernatant also conferred cytoprotection to MM.1S, suggesting a dual mechanism by which OSB may modulate both NK and MM cells.
   Conclusions: We demonstrated here that OSB can negatively impact the activity of NK cells against MM. As NK cells and their chimeric antigen receptor modified versions become more widely used in the clinic, our results suggest that understanding the role of OSB as potential immunoregulators of the NK cell mediated cytotoxic response in the bone marrow tumor microenvironment may provide new opportunities for enhancing the effectiveness of this potent immunotherapeutic approach.
C1 [Uhl, Christopher; Siegel, David S.; Zilberberg, Jenny] Ctr Discovery & Innovat, 111 Ideation Way,Bldg 102, Nutley, NJ 07110 USA.
   [Nyirenda, Themba; Siegel, David S.] John Theurer Canc Ctr, 92 2nd St Ste 301, Hackensack, NJ 07601 USA.
   [Lee, Woo Y.] Stevens Inst Technol, Dept Chem & Chem Biol, 1 Castle Point Hudson, Hoboken, NJ 07030 USA.
C3 Stevens Institute of Technology
RP Zilberberg, J (通讯作者)，Ctr Discovery & Innovat, 111 Ideation Way,Bldg 102, Nutley, NJ 07110 USA.
EM jenny@discordia.org
OI Zilberberg, Jenny/0000 0002 4139 2616; Uhl,
   Christopher/0009 0008 7816 0721
FU National Institutes of Health [1R33CA212806 01A1]
FX Funding statement This work was supported by the National Institutes of
   Health, grant#: 1R33CA212806 01A1.
CR Adomako A, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1460 1
   Asimakopoulos F, 2017, J LEUKOCYTE BIOL, V102, P265, DOI 10.1189/jlb.3MR1116 468R
   Bascetin R, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120610
   Bussard KM, 2010, J CELL BIOCHEM, V111, P1138, DOI 10.1002/jcb.22799
   Chen WC, 2020, CURR OPIN PHARMACOL, V54, P36, DOI 10.1016/j.coph.2020.08.006
   Chen ZH, 2019, LAB CHIP, V19, P254, DOI 10.1039/c8lc00872h
   Clark SE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02087
   Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658
   Ehlers FAI, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.622896
   Fontana F, 2021, CLIN CANCER RES, V27, P1974, DOI 10.1158/1078 0432.CCR 20 2839
   GOLDMANLEIKIN RE, 1989, J LAB CLIN MED, V113, P335
   GONG JH, 1994, LEUKEMIA, V8, P652
   Gonzalez Rodriguez AP, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101557
   Greenstein S, 2003, EXP HEMATOL, V31, P271, DOI 10.1016/S0301 472X(03)00023 7
   Iyoda T, 2018, CLIN IMMUNOL, V187, P76, DOI 10.1016/j.clim.2017.10.007
   Kirshner J, 2008, BLOOD, V112, P2935, DOI 10.1182/blood 2008 02 142430
   Krasnova Y, 2017, CLIN IMMUNOL, V177, P50, DOI 10.1016/j.clim.2015.10.001
   Lawson MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9983
   Meyaard L, 2008, J LEUKOCYTE BIOL, V83, P799, DOI 10.1189/jlb.0907609
   Mitwasi N, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 59082 4
   Musolino C, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/1852517
   Nair Gupta P, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408 020 0331 4
   Nakamura A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910761
   Pappa C, 2007, CYTOKINE, V37, P171, DOI 10.1016/j.cyto.2007.02.022
   Pittari G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01444
   Quatromoni JG, 2012, AM J TRANSL RES, V4, P376
   Rajkumar SV, 2020, AM J HEMATOL, V95, P548, DOI 10.1002/ajh.25791
   Rossi GR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00073
   Shimasaki N, 2020, NAT REV DRUG DISCOV, V19, P200, DOI 10.1038/s41573 019 0052 1
   Sun QL, 2017, BONE, V105, P245, DOI 10.1016/j.bone.2017.09.012
   Szkaradkiewicz A, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/901564
   Toscani D, 2015, ANN NY ACAD SCI, V1335, P45, DOI 10.1111/nyas.12578
   Wu J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1310 0
   Xia JF, 2020, BIOSCI TRENDS, V14, P354, DOI 10.5582/bst.2020.03308
   Xu LJ, 2018, MOL ONCOL, V12, P269, DOI 10.1002/1878 0261.12135
   Zhang JW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102418
NR 36
TC 6
Z9 6
U1 1
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2405 8440
J9 HELIYON
JI Heliyon
PD MAR
PY 2022
VL 8
IS 3
AR e09167
DI 10.1016/j.heliyon.2022.e09167
EA MAR 2022
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 0Z3MU
UT WOS:000790985900010
PM 35846441
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yan, Z
   Tian, XX
   Zhu, JY
   Lu, ZF
   Yu, LF
   Zhang, DW
   Liu, YW
   Yang, CF
   Zhu, QS
   Cao, XR
AF Yan, Zhao
   Tian, Xiaoxi
   Zhu, Jinyu
   Lu, Zifan
   Yu, Lifeng
   Zhang, Dawei
   Liu, Yanwu
   Yang, Chongfei
   Zhu, Qingsheng
   Cao, Xiaorui
TI Metformin suppresses UHMWPE particle induced osteolysis in the mouse
   calvaria by promoting polarization of macrophages to an
   anti inflammatory phenotype
SO MOLECULAR MEDICINE
LA English
DT Article
DE Inflammation; Osteoclasts; AMPK; Macrophage; Osteolysis
ID SKELETAL MUSCLE; BONE TURNOVER; IN VIVO; KINASE; CELLS; DIFFERENTIATION;
   ACTIVATION; AMPK; ALENDRONATE; INHIBITION
AB Background: Implant failure remains a major obstacle to successful treatment via TJA. Periprosthetic osteolysis arid aseptic loosening are considered as proof of wear debris induced disruption of local regulatory mechanisms related to excessive bone resorption associated with osteolysis and the damage at the bone prosthesis interface. Therefore, there is an immediate need to explore strategies for limiting and curing periprosthetic osteolysis and aseptic loosening.
   Methods: We analyzed the in vitro cytokine production by primary mouse bone marrow macrophages (BMMs) that were exposed to ultra high molecular weight polyethylene (UHMWPE) particles and treated with metformin at different concentrations with or without 5 aminoimidazole 4 carboxamide ribonucleoside to activate or inhibit AMPK A mouse calvarial model was used to examine the in vivo effects of metformin on UHMWPE particle induced osteolysis.
   Results: With particles, primary mouse BMMs secreted more pro inflammatory cytokines tumor necrosis factor alpha and interleukin (IL) 6. Treatment with metformin inhibited these variations and promoted the release of cytokine IL 10 with anti inflammatory capability. In vivo, metformin reduced the production of pro inflammatory cytokines, osteoclastogenesis, and osteolysis, increasing IL 10 production. Metformin also promoted the polarization of macrophages to an anti inflammatory phenotype in vivo via AMPK activation.
   Discussion: A crucial point in limiting and correcting the periprosthetic osteolysis and aseptic loosening is the inhibition of inflammatory factor production and osteoclast activation induced by activated macrophages. The ability of metformin to attenuate osteolysis induced in mouse calvaria by the particles was related to a reduction in osteoclast number and polarization of macrophages to an anti inflammatory functional phenotype.
   Conclusions: Metformin could limit the osteolysis induced by implant debris. Therefore, we hypothesized that metformin could be a potential drug for osteolysis induced by implant debris.
C1 [Yan, Zhao; Zhu, Jinyu; Yu, Lifeng; Zhang, Dawei; Liu, Yanwu; Yang, Chongfei; Zhu, Qingsheng; Cao, Xiaorui] Fourth Mil Med Univ, Xijing Hosp, PLA Inst Orthopaed, Xian 710032, Shaanxi, Peoples R China.
   [Tian, Xiaoxi] Fourth Mil Med Univ, Tangdu Hosp, Emergency Dept, Xian 710038, Shaanxi, Peoples R China.
   [Zhu, Jinyu] Fourth Mil Med Univ, Dept Pharmacogen, State Key Lab Canc Biol, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University
RP Zhu, QS; Cao, XR (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, PLA Inst Orthopaed, Xian 710032, Shaanxi, Peoples R China.
EM zhuqsh@fmmu.edu.cn; caoxiaorui.810428@aliyun.com
RI ; Zhang, Dawei/C 5981 2008
OI Yan, Zhao/0000 0002 5491 1227; ZHU, JINYU/0000 0002 7811 752X; 
FU Project of Natural Science Foundation of Shaanxi Province [2014JQ4142];
   National Natural Science Foundation of China [81501936, 31571215]
FX This work was supported by the Project of Natural Science Foundation of
   Shaanxi Province (2014JQ4142) and the National Natural Science
   Foundation of China (81501936) and (31571215). The authors thank Xiaorui
   Cao and Qingsheng Zhu from the PLA Institute of Orthopaedics, Xijing
   Hospital, and the Fourth Military Medical University, China as well as
   Zifan Lu of the State Key Laboratory of Cancer Biology, Fourth Military
   Medical University, China, for their technical help and advice.
CR Atkins GJ, 2009, BIOMATERIALS, V30, P3672, DOI 10.1016/j.biomaterials.2009.03.035
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Cantatore FP, 1999, J RHEUMATOL, V26, P2318
   Davies LC, 2015, IMMUNOLOGY, V144, P541, DOI 10.1111/imm.12451
   FROKJAER J, 1995, ACTA ORTHOP SCAND, V66, P303, DOI 10.3109/17453679508995549
   GLANT TT, 1993, J BONE MINER RES, V8, P1071
   Hamann C, 2012, NAT REV ENDOCRINOL, V8, P297, DOI 10.1038/nrendo.2011.233
   Inzucchi SE, 2014, JAMA J AM MED ASSOC, V312, P2668, DOI 10.1001/jama.2014.15298
   Jiang JH, 2016, AM J PATHOL, V186, P57, DOI 10.1016/j.ajpath.2015.09.006
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kang H, 2013, J BIOL CHEM, V288, P12187, DOI 10.1074/jbc.M112.430389
   Kostenuik PJ, 2015, J BONE MINER RES, V30, P657, DOI 10.1002/jbmr.2401
   KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513
   Kurtz S, 2007, J BONE JOINT SURG AM, V89A, P780, DOI 10.2106/JBJS.F.00222
   La Fontaine J, 2016, J FOOT ANKLE SURG, V55, P955, DOI 10.1053/j.jfas.2016.04.012
   Lee YS, 2010, BONE, V47, P926, DOI 10.1016/j.bone.2010.08.001
   Li DJ, 2015, ACTA PHYSIOL, V213, P711, DOI 10.1111/apha.12421
   Malyshev I, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/341308
   Martinez FO, 2008, FRONT BIOSCI LANDMRK, V13, P453, DOI 10.2741/2692
   Minghetti Luisa, 2007, Subcell Biochem, V42, P127
   Monami M, 2008, DIABETES CARE, V31, P199, DOI 10.2337/dc07 1736
   Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074
   Nich Christophe, 2011, Arthritis Res Ther, V13, pR100, DOI 10.1186/ar3381
   Patel VA, 2015, J BIOL CHEM, V290, P22352, DOI 10.1074/jbc.M115.667345
   Purdue P Edward, 2006, HSS J, V2, P102, DOI 10.1007/s11420 006 9003 6
   Quinn JMW, 2010, FASEB J, V24, P275, DOI 10.1096/fj.09 137158
   Ren PG, 2011, CLIN ORTHOP RELAT R, V469, P113, DOI 10.1007/s11999 010 1645 5
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Sag D, 2008, J IMMUNOL, V181, P8633, DOI 10.4049/jimmunol.181.12.8633
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Singh A, 2014, J CONTROL RELEASE, V190, P515, DOI 10.1016/j.jconrel.2014.04.021
   Tsoyi K, 2011, BRIT J PHARMACOL, V162, P1498, DOI 10.1111/j.1476 5381.2010.01126.x
   Vasamsetti SB, 2015, DIABETES, V64, P2028, DOI 10.2337/db14 1225
   Voronov I, 1998, J BIOMED MATER RES, V39, P40, DOI 10.1002/(SICI)1097 4636(199801)39:1<40::AID JBM6>3.3.CO;2 Y
   Wang YG, 2016, CELL SIGNAL, V28, P1270, DOI 10.1016/j.cellsig.2016.06.004
   Zhang Q, 2005, ARTHRITIS RHEUM US, V52, P2708, DOI 10.1002/art.21236
NR 36
TC 39
Z9 41
U1 0
U2 20
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1076 1551
EI 1528 3658
J9 MOL MED
JI Mol. Med.
PD MAY 9
PY 2018
VL 24
AR 20
DI 10.1186/s10020 018 0013 x
PG 12
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA GG3XM
UT WOS:000432627000001
PM 30134793
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Brunetti, G
   Faienza, MF
   Piacente, L
   Ventura, A
   Oranger, A
   Carbone, C
   Di Benedetto, A
   Colaianni, G
   Gigante, M
   Mori, G
   Gesualdo, L
   Colucci, S
   Cavallo, L
   Grano, M
AF Brunetti, Giacomina
   Faienza, Maria Felicia
   Piacente, Laura
   Ventura, Annamaria
   Oranger, Angela
   Carbone, Claudia
   Di Benedetto, Adriana
   Colaianni, Graziana
   Gigante, Margherita
   Mori, Giorgio
   Gesualdo, Loreto
   Colucci, Silvia
   Cavallo, Luciano
   Grano, Maria
TI High dickkopf 1 levels in sera and leukocytes from children with
   21 hydroxylase deficiency on chronic glucocorticoid treatment
SO AMERICAN JOURNAL OF PHYSIOLOGY ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE dickkopf 1; 21 hydroxylase deficiency patients; glucocorticoid induced
   osteoporosis; leukocytes; glucocorticoids
ID BONE MINERAL DENSITY; YOUNG ADULT PATIENTS; CONGENITAL
   ADRENAL HYPERPLASIA; REPLACEMENT THERAPY; CIRCULATING DICKKOPF 1;
   RECEPTOR ACTIVATOR; BODY COMPOSITION; GENE EXPRESSION; ANTAGONIST DKK1;
   PAGETS DISEASE
AB High dickkopf 1 levels in sera and leukocytes from children with 21 hydroxylase deficiency on chronic glucocorticoid treatment. Am J Physiol Endocrinol Metab 304: E546 E554, 2013. First published January 8, 2013; doi:10.1152/ajpendo.00535.2012. Children with 21 hydroxylase deficiency (21 OHD) need chronic glucocorticoid (cGC) therapy to replace congenital deficit of cortisol synthesis, and this therapy is the most frequent and severe form of drug induced osteoporosis. In this study, we enrolled 18 patients (9 females) and 18 sex  and age matched controls. We found in 21 OHD patients high serum and leukocyte levels of dickkopf 1 (DKK1), a secreted antagonist of the Wnt/beta catenin signaling pathway known to be a key regulator of bone mass. In particular, we demonstrated by flow cytometry, confocal microscopy, and real time PCR that monocytes, T lymphocytes, and neutrophils from patients expressed high levels of DKK1, which may be related to the cGC therapy. In fact, we showed that dexamethasone treatment markedly induced the expression of DKK1 in a dose and time dependent manner in leukocytes. The serum from patients containing elevated levels of DKK1 can directly inhibit in vitro osteoblast differentiation and receptor activator of NF kappa B ligand (RANKL) expression. We also found a correlation between both DKK1 and RANKL or COOH terminal telopeptides of type I collagen (CTX) serum levels in 21 OHD patients on cGC treatment. Our data indicated that DKK1, produced by leukocytes, may contribute to the alteration of bone remodeling in 21 OHD patients on cGC treatment.
C1 [Brunetti, Giacomina; Oranger, Angela; Carbone, Claudia; Di Benedetto, Adriana; Colaianni, Graziana; Colucci, Silvia; Grano, Maria] Univ Bari, Dept Basic Med Sci Neurosci & Sense Organs, Sect Human Anat & Histol, I 70124 Bari, Italy.
   [Faienza, Maria Felicia; Piacente, Laura; Ventura, Annamaria; Cavallo, Luciano] Univ Bari A Moro, Dept Biomed Sci & Human Oncol, Bari, Italy.
   [Gigante, Margherita; Mori, Giorgio] Univ Foggia, Dept Biomed Sci, Foggia, Italy.
   [Gesualdo, Loreto] Univ Bari, Dept Emergency & Organ Transplantat, Nephrol Dialysis & Transplantat Unit, I 70124 Bari, Italy.
C3 Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari
   Aldo Moro; University of Foggia; Universita degli Studi di Bari Aldo
   Moro
RP Brunetti, G (通讯作者)，Univ Bari, Dept Basic Med Sci Neurosci & Sense Organs, Sect Human Anat & Histol, Piazza Giulio Cesare 11, I 70124 Bari, Italy.
EM giacomina.brunetti@uniba.it
RI ; Brunetti, Giacomina/J 7692 2016; cavallo, luigi/C 7272 2015; Gesualdo,
   Loreto/K 7751 2016; Mori, Giorgio/P 1370 2014; Faienza, Maria
   Felicia/K 6779 2016; Faienza, Maria/K 6779 2016; Giacomina,
   Brunetti/J 7692 2016
OI Colaianni, Graziana/0000 0001 8501 5399; Grano,
   Maria/0000 0002 7121 5899; Brunetti, Giacomina/0000 0002 0681 1432;
   Gesualdo, Loreto/0000 0002 4861 0911; Colucci,
   Silvia/0000 0001 9970 3539; cavallo, luciano/0000 0003 4787 8681; Mori,
   Giorgio/0000 0001 6731 0247; oranger, angela/0000 0003 0881 6840;
   Faienza, Maria Felicia/0000 0002 1899 8337; 
CR Aicher A, 2008, CIRC RES, V103, P796, DOI 10.1161/CIRCRESAHA.107.172718
   Berenbaum S, 2002, J CLIN ENDOCR METAB, V87, P4048, DOI 10.1210/jc.2002 020611
   CAMERON FJ, 1995, J CLIN ENDOCR METAB, V80, P2238, DOI 10.1210/jc.80.7.2238
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Canalis E, 2004, BONE, V34, P593, DOI 10.1016/j.bone.2003.11.026
   Christiansen P, 2004, HORM RES, V61, P133, DOI 10.1159/000075588
   Colucci S, 2004, BLOOD, V104, P3722, DOI 10.1182/blood 2004 02 0474
   Dalbeth N, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3123
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Faienza MF, 2009, J CLIN ENDOCR METAB, V94, P2269, DOI 10.1210/jc.2008 2446
   Freire POD, 2003, J BONE MINER METAB, V21, P396, DOI 10.1007/s00774 003 0434 6
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Girgis R, 1997, J CLIN ENDOCR METAB, V82, P3926, DOI 10.1210/jc.82.12.3926
   Guo CY, 1996, CLIN ENDOCRINOL, V45, P535, DOI 10.1046/j.1365 2265.1996.00851.x
   Gussinye M, 1997, PEDIATRICS, V100, P671, DOI 10.1542/peds.100.4.671
   Hagenfeldt K, 2000, EUR J ENDOCRINOL, V143, P667, DOI 10.1530/eje.0.1430667
   Jaaskelainen J, 1996, CLIN ENDOCRINOL, V45, P707, DOI 10.1046/j.1365 2265.1996.8620871.x
   Jang WG, 2012, J BIOL CHEM, V287, P905, DOI 10.1074/jbc.M111.253187
   Kanis JA, 2000, OSTEOPOROSIS INT, V11, P192, DOI 10.1007/s001980050281
   King JA, 2006, J CLIN ENDOCR METAB, V91, P865, DOI 10.1210/jc.2005 0745
   Koch S, 2011, GASTROENTEROLOGY, V141, P259, DOI 10.1053/j.gastro.2011.03.043
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lajic S, 2011, ENDOCR DEV, V20, P96, DOI 10.1159/000321228
   Lee N, 2007, BRIT J CANCER, V97, P1552, DOI 10.1038/sj.bjc.6604069
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Mak W, 2009, CALCIFIED TISSUE INT, V85, P538, DOI 10.1007/s00223 009 9303 1
   Marshall MJ, 2009, CLIN BIOCHEM, V42, P965, DOI 10.1016/j.clinbiochem.2009.04.007
   Mazziotti G, 2010, EUR J ENDOCRINOL, V163, P15, DOI 10.1530/EJE 10 0125
   Mora S, 1996, BONE, V18, P337, DOI 10.1016/8756 3282(96)00003 8
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Naot D, 2007, J BONE MINER RES, V22, P298, DOI 10.1359/JBMR.061108
   New MI, 2004, ANN NY ACAD SCI, V1038, P14, DOI 10.1196/annals.1315.009
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025
   Paganini C, 2000, HORM RES, V54, P164, DOI 10.1159/000053253
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Rippo MR, 2010, INT J IMMUNOPATH PH, V23, P1153, DOI 10.1177/039463201002300419
   Rivkees SA, 2009, INT J PEDIATR ENDOCR, DOI 10.1155/2009/274682
   Roato I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003627
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Schaeffer TL, 2010, INT J PEDIATR ENDOCR, DOI 10.1155/2010/692439
   Sciannamblo M, 2006, J CLIN ENDOCR METAB, V91, P4453, DOI 10.1210/jc.2005 2823
   Senolt L, 2012, ANN RHEUM DIS, V71, P71, DOI 10.1136/annrheumdis 2011 200357
   Speiser Phyllis W., 1993, Pediatric Research, V33, pS81, DOI 10.1203/00006450 199305001 00466
   Stikkelbroeck NMML, 2003, J CLIN ENDOCR METAB, V88, P1036, DOI 10.1210/jc.2002 021074
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Terpos E, 2006, BRIT J HAEMATOL, V135, P688, DOI 10.1111/j.1365 2141.2006.06356.x
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Wang SY, 2011, J RHEUMATOL, V38, P821, DOI 10.3899/jrheum.100089
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
   ZELISSEN PMJ, 1994, ANN INTERN MED, V120, P207, DOI 10.7326/0003 4819 120 3 199402010 00005
NR 54
TC 38
Z9 41
U1 0
U2 5
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193 1849
EI 1522 1555
J9 AM J PHYSIOL ENDOC M
JI Am. J. Physiol. Endocrinol. Metab.
PD MAR
PY 2013
VL 304
IS 5
BP E546
EP E554
DI 10.1152/ajpendo.00535.2012
PG 9
WC Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Physiology
GA 100EB
UT WOS:000315677500011
PM 23299503
DA 2025 08 17
ER

PT J
AU Guillem Llobat, P
   Marín, M
   Rouleau, M
   Silvestre, A
   Blin Wakkach, C
   Ferrándiz, ML
   Guillén, MI
   Ibáñez, L
AF Guillem Llobat, Paloma
   Marin, Marta
   Rouleau, Matthieu
   Silvestre, Antonio
   Blin Wakkach, Claudine
   Ferrandiz, Maria Luisa
   Guillen, Maria Isabel
   Ibanez, Lidia
TI New Insights into the Pro Inflammatory and Osteoclastogenic Profile of
   Circulating Monocytes in Osteoarthritis Patients
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE bone remodeling; monocyte; osteoclast progenitor; osteoarthritis;
   inflammation
ID TNF ALPHA; M CSF; CELLS; BONE; DECTIN 1; ACTIVATION; CARTILAGE;
   RECEPTOR; SUBSETS; ZYMOSAN
AB Osteoarthritis (OA) is a degenerative condition of the articular cartilage with chronic low grade inflammation. Monocytes have a fundamental role in the progression of OA, given their implication in inflammatory responses and their capacity to differentiate into bone resorbing osteoclasts (OCLs). This observational experimental study attempted to better understand the molecular pathogenesis of OA through the examination of osteoclast progenitor (OCP) cells from both OA patients and healthy individuals (25 OA patients and healthy samples). The expression of osteoclastogenic and inflammatory genes was analyzed using RT PCR. The OA monocytes expressed significantly higher levels of CD16, CD115, TLR2, Mincle, Dentin 1, and CCR2 mRNAs. Moreover, a flow cytometry analysis showed a significantly higher surface expression of the CD16 and CD115 receptors in OA vs. healthy monocytes, as well as a difference in the distribution of monocyte subsets. Additionally, the OA monocytes showed a greater osteoclast differentiation capacity and an enhanced response to an inflammatory stimulus. The results of this study demonstrate the existence of significant differences between the OCPs of OA patients and those of healthy subjects. These differences could contribute to a greater understanding of the molecular pathogenesis of OA and to the identification of new biomarkers and potential drug targets for OA.
C1 [Guillem Llobat, Paloma] Cardenal Herrera CEU Univ, Dept Biomed Sci, Valencia 46115, Spain.
   [Marin, Marta; Guillen, Maria Isabel; Ibanez, Lidia] Cardenal Herrera CEU Univ, Dept Pharm, Valencia 46115, Spain.
   [Rouleau, Matthieu; Blin Wakkach, Claudine] Cote Azur Univ, Natl Ctr Sci Res, Lab Mol Physiomed, UMR 7370, F 06107 Nice, France.
   [Silvestre, Antonio] Univ Clin Hosp, Serv Orthoped Surg & Traumatol, Valencia 46010, Spain.
   [Ferrandiz, Maria Luisa; Guillen, Maria Isabel] Univ Politecn Valencia, Interuniv Res Inst Mol Recognit & Technol Dev IDM, Valencia 46022, Spain.
   [Ferrandiz, Maria Luisa; Guillen, Maria Isabel] Univ Valencia, Valencia 46022, Spain.
C3 Universidad CEU Cardenal Herrera; Universidad CEU Cardenal Herrera;
   Centre National de la Recherche Scientifique (CNRS); CNRS   National
   Institute for Biology (INSB); Universite Cote d'Azur; Universitat
   Politecnica de Valencia; University of Valencia
RP Guillén, MI; Ibáñez, L (通讯作者)，Cardenal Herrera CEU Univ, Dept Pharm, Valencia 46115, Spain.; Guillén, MI (通讯作者)，Univ Politecn Valencia, Interuniv Res Inst Mol Recognit & Technol Dev IDM, Valencia 46022, Spain.; Guillén, MI (通讯作者)，Univ Valencia, Valencia 46022, Spain.
EM paloma.guillemllobat@uchceu.es; marta.marin1@uchceu.es;
   matthieu.rouleau@univ cotedazur.fr; antonio.silvestre@uv.es;
   claudine.blin@univ cotedazur.fr; luisa.ferrandiz@uv.es;
   iguillen@uchceu.es; lidia.ibanez@uchceu.es
RI Rouleau, Matthieu/D 5774 2016; Blin Wakkach, Claudine/I 1263 2016;
   Ibáñez, Lidia/P 6952 2015; Ferrandiz/K 9323 2017; Silvestre,
   Antonio/AAL 1966 2021; Guillem Llobat, Paloma/NDS 0323 2025
OI Rouleau, Matthieu/0000 0002 0075 9880; Blin Wakkach,
   Claudine/0000 0002 2621 3907; Silvestre, Antonio/0000 0002 6561 8704;
   Ferrandiz/0000 0003 4059 0175; Guillem Llobat,
   Paloma/0000 0001 9043 562X; Ibanez, Lidia/0000 0002 2217 8817; 
FU Conselleria de Innovacin, Universidades, Ciencia y Sociedad Digital
FX The authors would like to acknowledge all participants for their
   contribution to the study.
CR Andreev D, 2020, J CLIN INVEST, V130, P4811, DOI 10.1172/JCI134214
   Bao HN, 2023, SCI CHINA LIFE SCI, DOI 10.1007/s11427 023 2305 0
   Berenbaum F, 2013, OSTEOARTHR CARTILAGE, V21, P16, DOI 10.1016/j.joca.2012.11.012
   Chiu YG, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2915
   Chung PL, 2014, J CELL BIOCHEM, V115, P1412, DOI 10.1002/jcb.24792
   Dayyani F, 2003, J LEUKOCYTE BIOL, V74, P33, DOI 10.1189/jlb.1202612
   Dillon S, 2006, J CLIN INVEST, V116, P916, DOI 10.1172/JCI27203
   Durand M, 2013, ARTHRITIS RHEUM US, V65, P148, DOI 10.1002/art.37722
   Elson A, 2022, BONE, V164, DOI 10.1016/j.bone.2022.116538
   Elsori DH, 2011, J LEUKOCYTE BIOL, V90, P599, DOI 10.1189/jlb.0610376
   Flegar D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.767231
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787
   Garcia S, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 0973 6
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Gómez Aristizábal A, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 018 1798 2
   Greene MA, 2015, OSTEOARTHR CARTILAGE, V23, P1966, DOI 10.1016/j.joca.2015.01.008
   Haubruck P, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.763702
   Hirose S, 2019, INT IMMUNOL, V31, P687, DOI 10.1093/intimm/dxz036
   Hodge JM, 2007, J CELL BIOCHEM, V102, P759, DOI 10.1002/jcb.21331
   Hofer TP, 2015, BLOOD, V126, P2601, DOI 10.1182/blood 2015 06 651331
   Hu Y, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00147 z
   Ibáñez L, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23094693
   Ibáñez L, 2016, J BONE MINER RES, V31, P1899, DOI 10.1002/jbmr.2868
   Kiesel JR, 2009, J IMMUNOL, V182, P5477, DOI 10.4049/jimmunol.0803897
   Komano Y, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2046
   Kumar RA, 2018, INT IMMUNOPHARMACOL, V65, P348, DOI 10.1016/j.intimp.2018.10.016
   Li X, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01502 8
   Loukov D, 2018, OSTEOARTHR CARTILAGE, V26, P255, DOI 10.1016/j.joca.2017.10.018
   Lu XY, 2018, INT IMMUNOL, V30, P233, DOI 10.1093/intimm/dxy028
   Madel MB, 2020, ELIFE, V9, DOI 10.7554/eLife.54493
   Madel MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01408
   Mata Martínez P, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.812148
   Mori G, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/720504
   Motta F, 2023, CLIN REV ALLERG IMMU, V64, P222, DOI 10.1007/s12016 022 08941 1
   Ozanska A, 2020, SCAND J IMMUNOL, V92, DOI 10.1111/sji.12883
   Pers YM, 2018, THERANOSTICS, V8, P5519, DOI 10.7150/thno.27674
   Pippenger BE, 2015, OSTEOARTHR CARTILAGE, V23, P1865, DOI 10.1016/j.joca.2015.07.021
   Plantinga TS, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2933
   Rea IM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00586
   Rezus E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030614
   Rivollier A, 2004, BLOOD, V104, P4029, DOI 10.1182/blood 2004 01 0041
   Sato M, 2003, J IMMUNOL, V171, P417, DOI 10.4049/jimmunol.171.1.417
   Scanzello CR, 2017, J ORTHOP RES, V35, P735, DOI 10.1002/jor.23471
   Sharma AR, 2013, INT J MOL SCI, V14, P19805, DOI 10.3390/ijms141019805
   Shi T, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/4291689
   Sims NA, 2021, CYTOKINE, V146, DOI 10.1016/j.cyto.2021.155655
   Sprangers S, 2016, J CELL PHYSIOL, V231, P1249, DOI 10.1002/jcp.25220
   Toh ML, 2014, ARTHRITIS RHEUMATOL, V66, P2989, DOI 10.1002/art.38624
   Tsai Jefferson, 2023, J Bone Metab, V30, P127, DOI 10.11005/jbm.2023.30.2.127
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   van den Bosch MHJ, 2019, CLIN EXP IMMUNOL, V195, P153, DOI 10.1111/cei.13237
   Wang TT, 2020, CURR DRUG TARGETS, V21, P213, DOI 10.2174/1389450120666190821161259
   Weiskopf D, 2009, TRANSPL INT, V22, P1041, DOI 10.1111/j.1432 2277.2009.00927.x
   Wong KL, 2012, IMMUNOL RES, V53, P41, DOI 10.1007/s12026 012 8297 3
   Xue JM, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02308 7
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
   Ziegler Heitbrock L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00423
   Ziegler Heitbrock L, 2014, CELL IMMUNOL, V289, P135, DOI 10.1016/j.cellimm.2014.03.019
   Ziegler Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood 2010 02 258558
   Zimmermann HW, 2014, CURR TOP MED CHEM, V14, P1539, DOI 10.2174/1568026614666140827144115
NR 61
TC 4
Z9 4
U1 3
U2 9
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2024
VL 25
IS 3
AR 1710
DI 10.3390/ijms25031710
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HM8V6
UT WOS:001160023000001
PM 38338988
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Phillips, EG
   Beggs, LA
   Ye, F
   Conover, CF
   Beck, DT
   Otzel, DM
   Ghosh, P
   Bessit, ACF
   Borst, SE
   Yarrow, JF
AF Phillips, Ean G.
   Beggs, Luke A.
   Ye, Fan
   Conover, Christine F.
   Beck, Darren T.
   Otzel, Dana M.
   Ghosh, Payal
   Bessit, Anna C. F.
   Borst, Stephen E.
   Yarrow, Joshua F.
TI Effects of pharmacologic sclerostin inhibition or testosterone
   administration on soleus muscle atrophy in rodents after spinal cord
   injury
SO PLOS ONE
LA English
DT Article
ID SKELETAL MUSCLE; BONE LOSS; REPLACEMENT THERAPY; HYPOGONADAL MEN; CAST
   IMMOBILIZATION; HYBRID FIBERS; PREVENTS BONE; SHORT TERM; RATS; MODEL
AB Sclerostin is a circulating osteocyte derived glycoprotein that negatively regulates Wnt signaling after binding the LRP5/LRP6 co receptors. Pharmacologic sclerostin inhibition produces bone anabolic effects after spinal cord injury (SCI), however, the effects of sclerostin antibody (Scl Ab) on muscle morphology remain unknown. In comparison, androgen administration produces bone antiresorptive effects after SCI and some, but not all, studies have reported that testosterone treatment ameliorates skeletal muscle atrophy in this context. Our purposes were to determine whether Scl Ab prevents hindlimb muscle loss after SCI and compare the effects of Scl Ab to testosterone enanthate (TE), an agent with known myotrophic effects. Male Sprague Dawley rats aged 5 months received: (A) SHAM surgery (T8 laminectomy), (B) moderate severe contusion SCI, (C) SCI+TE (7.0 mg/wk, im), or (D) SCI+Scl Ab (25 mg/kg, twice weekly, sc). Twenty one days post injury, SCI animals exhibited a 31% lower soleus mass in comparison to SHAM, accompanied by >50% lower soleus muscle fiber cross sectional area (fCSA) (p<0.01 for all fiber types). Scl Ab did not prevent soleus atrophy, consistent with the relatively low circulating sclerostin concentrations and with the 91 99% lower LRP5/LRP6 gene expressions in soleus versus tibia (p<0.001), a tissue with known anabolic responsiveness to Scl Ab. In comparison, TE partially prevented soleus atrophy and increased levator ani/bulbocavernosus (LABC) mass by 30 40% (p<0.001 vs all groups). The differing myotrophic responsiveness coincided with a 3 fold higher androgen receptor gene expression in LABC versus soleus (p<0.01). This study provides the first direct evidence that Scl Ab does not prevent soleus muscle atrophy in rodents after SCI and suggests that variable myotrophic responses in rodent muscles after androgen administration are influenced by androgen receptor expression.
C1 [Phillips, Ean G.; Beggs, Luke A.; Ye, Fan; Conover, Christine F.; Yarrow, Joshua F.] North Florida South Georgia Vet Hlth Syst, Malcom Randall VA Med Ctr, Res Serv, Gainesville, FL 32608 USA.
   [Beck, Darren T.] Auburn Univ, Sch Kinesiol, Auburn, AL 36849 USA.
   [Beck, Darren T.] Edward Via Coll Osteopath Med, Dept Cell Biol & Physiol, Auburn Campus, Auburn, AL USA.
   [Otzel, Dana M.] North Florida South Georgia Vet Hlth Syst, Malcom Randall VA Med Ctr, Brain Rehabil Res Ctr, Gainesville, FL USA.
   [Ghosh, Payal] Florida State Univ, Dept Nutr Food & Exercise Sci, Tallahassee, FL 32306 USA.
   [Bessit, Anna C. F.] Shriners Hosp Children, Orthoped Dept, Montreal, PQ, Canada.
   [Borst, Stephen E.] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL USA.
   [Yarrow, Joshua F.] Univ Florida, Coll Med, Div Endocrinol Diabet & Metab, Gainesville, FL 32611 USA.
C3 Auburn University System; Auburn University; State University System of
   Florida; Florida State University; State University System of Florida;
   University of Florida; State University System of Florida; University of
   Florida
RP Yarrow, JF (通讯作者)，North Florida South Georgia Vet Hlth Syst, Malcom Randall VA Med Ctr, Res Serv, Gainesville, FL 32608 USA.; Yarrow, JF (通讯作者)，Univ Florida, Coll Med, Div Endocrinol Diabet & Metab, Gainesville, FL 32611 USA.
EM jfyarrow@ufl.edu
OI Yarrow, Joshua/0000 0002 2727 8649; BECK, DARREN/0000 0002 1674 9839
FU Office of Research and Development, Rehabilitation Research and
   Development, Department of Veterans Affairs SPiRE [I21RX001371 01];
   Presidential Early Career Award for Scientist and Engineers (PECASE)
   [B9280 0]
FX This work was supported by the Office of Research and Development,
   Rehabilitation Research and Development, Department of Veterans Affairs
   SPiRE (#I21RX001371 01) and Presidential Early Career Award for
   Scientist and Engineers (PECASE #B9280 0) to JFY, and by resources
   provided by the North Florida/South Georgia Veterans Health System. The
   sclerostinneutralizing monoclonal antibody (Scl AbIII) was generously
   provided by Amgen, Inc. and UCB through a Department of Veterans Affairs
   Cooperative Research and Development Agreement (CRADA). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript. The work reported herein does
   not represent the views of the US Department of Veterans Affairs of the
   US government.
CR Battaglino RA, 2012, BONE, V51, P600, DOI 10.1016/j.bone.2012.04.019
   Bauman WA, 2011, HORM METAB RES, V43, P574, DOI 10.1055/s 0031 1280797
   Bauman WA, 2015, J SPINAL CORD MED, V38, P38, DOI 10.1179/2045772314Y.0000000206
   Bauman WA, 2014, J SPINAL CORD MED, V37, P32, DOI 10.1179/2045772313Y.0000000122
   Beck DT, 2014, J BONE MINER RES, V29, P2405, DOI 10.1002/jbmr.2265
   Beggs LA, 2015, J BONE MINER RES, V30, P681, DOI 10.1002/jbmr.2396
   Borst SE, 2007, AM J PHYSIOL ENDOC M, V293, pE507, DOI 10.1152/ajpendo.00130.2007
   Borst SE, 2014, AM J PHYSIOL ENDOC M, V306, pE433, DOI 10.1152/ajpendo.00592.2013
   Brotto M, 2015, BONE, V80, P109, DOI 10.1016/j.bone.2015.02.010
   Byers JS, 2012, J COMP NEUROL, V520, P2683, DOI 10.1002/cne.23066
   Dalbo VJ, 2017, ANDROLOGIA, V49, DOI 10.1111/and.12622
   Giangregorio L, 2006, J SPINAL CORD MED, V29, P489, DOI 10.1080/10790268.2006.11753898
   Graham ZA, 2016, J NEUROTRAUM, V33, P1128, DOI 10.1089/neu.2015.4058
   Gregory CM, 2003, CAN J APPL PHYSIOL, V28, P491, DOI 10.1139/h03 036
   Gregory CM, 2003, SPINAL CORD, V41, P23, DOI 10.1038/sj.sc.3101370
   Huang J, 2017, JBMR PLUS, V1, P86, DOI 10.1002/jbm4.10015
   Hutchinson KJ, 2001, J NEUROTRAUM, V18, P1075, DOI 10.1089/08977150152693764
   Karczewska Kupczewska M, 2016, J CLIN ENDOCR METAB, V101, P3079, DOI 10.1210/jc.2016 1594
   Khuyagbaatar B, 2015, J NEUROTRAUM, V32, P1987, DOI 10.1089/neu.2015.3875
   Liu M, 2010, EUR J APPL PHYSIOL, V109, P709, DOI 10.1007/s00421 010 1392 z
   Moore PD, 2016, WORLD J CLIN CASES, V4, P172, DOI 10.12998/wjcc.v4.i7.172
   Park S, 2014, J APPL PHYSIOL, V116, P797, DOI 10.1152/japplphysiol.00955.2013
   Qin W, 2016, OSTEOPOROSIS INT, V27, P3627, DOI 10.1007/s00198 016 3700 x
   Qin WP, 2015, J BONE MINER RES, V30, P1994, DOI 10.1002/jbmr.2549
   Qin WP, 2013, J BIOL CHEM, V288, P13511, DOI 10.1074/jbc.M113.454892
   Rogerson S, 2007, J STRENGTH COND RES, V21, P354
   Rudnicki MA, 2015, BONE, V80, P60, DOI 10.1016/j.bone.2015.02.009
   Spatz JM, 2013, J BONE MINER RES, V28, P865, DOI 10.1002/jbmr.1807
   Stevens JE, 2006, J NEUROTRAUM, V23, P1671, DOI 10.1089/neu.2006.23.1671
   Sun L, 2013, J SPINAL CORD MED, V36, P616, DOI 10.1179/2045772312Y.0000000020
   Tagliaferri C, 2015, AGEING RES REV, V21, P55, DOI 10.1016/j.arr.2015.03.002
   Takeda I, 2014, PATHOBIOLOGY, V81, P94, DOI 10.1159/000357238
   TALMADGE RJ, 1995, J APPL PHYSIOL, V78, P1256, DOI 10.1152/jappl.1995.78.4.1256
   Talmadge RJ, 1999, ANAT RECORD, V255, P188, DOI 10.1002/(SICI)1097 0185(19990601)255:2<188::AID AR9>3.0.CO;2 H
   Tian XY, 2011, BONE, V48, P197, DOI 10.1016/j.bone.2010.09.009
   Tran TH, 2012, J BIOL CHEM, V287, P32651, DOI 10.1074/jbc.M112.353243
   Wu Y, 2012, SPINAL CORD, V50, P57, DOI 10.1038/sc.2011.91
   Wu Y, 2012, J NEUROTRAUM, V29, P1663, DOI 10.1089/neu.2011.2203
   Yarrow JF, 2014, J MUSCULOSKEL NEURON, V14, P255
   Yarrow JF, 2017, J NEUROTRAUM, V34, P2972, DOI 10.1089/neu.2016.4814
   Yarrow JF, 2014, J NEUROTRAUM, V31, P834, DOI 10.1089/neu.2013.3155
   Yarrow JF, 2012, MED SCI SPORT EXER, V44, P818, DOI 10.1249/MSS.0b013e31823bfcbf
   Ye F, 2013, EXP PHYSIOL, V98, P1038, DOI 10.1113/expphysiol.2012.070722
   Ye F, 2013, J NEUROTRAUM, V30, P227, DOI 10.1089/neu.2012.2504
   Zhang DY, 2016, BONE, V87, P161, DOI 10.1016/j.bone.2016.02.005
NR 45
TC 25
Z9 26
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAR 26
PY 2018
VL 13
IS 3
AR e0194440
DI 10.1371/journal.pone.0194440
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GA5DH
UT WOS:000428351800030
PM 29579075
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Thillard, EM
   Sade, P
   Michot, J
   Bres, V
   Jonville Bera, AP
AF Thillard, Eve Marie
   Sade, Paula
   Michot, Joelle
   Bres, Virginie
   Jonville Bera, Annie Pierre
TI Drug related hypophosphatemia: Descriptive study and case/non case
   analysis of the French national pharmacovigilance database
SO THERAPIE
LA English
DT Article
DE Hypophosphatemia; Adverse drug reaction; Tenofovir; Carboxymaltose iron;
   Pharmacovigilance
ID NEPHROTOXICITY
AB Phosphorus is an essential element for all living organisms and is involved in various biological pathways. A severe hypophosphatemia can lead to serious complications (acute heart or respiratory failure, rhabdomyolysis, hemolysis . . . ) and increases mortality in patients at risk. Various drugs are known to induce hypophosphatemia through various mechanisms. The aim of this study was to highlight the main drugs associated with hypophosphatemia and to deduce the underlying mechanisms based on a descriptive analysis and a case/non case analysis using the cases of drug induced hypophosphatemia reported to the French Pharmacovigilance Network. A total of 368 cases of hypophosphatemia were included in the study. Patients' mean age was 52 +/  18 years. One hundred and ninety one cases (52%) were serious including 131 (36%) hospitalizations. The median value of serum phosphorus level was 0.54 mmol/L [0.40 0.66] ( n = 309). Those 368 cases corresponded to 185 different suspected substances among which the most frequent drugs were tenofovir disoproxil ( n = 175; 48%), ferric carboxymaltose ( n = 29; 8%), denosumab ( n = 16; 4%), zoledronic acid ( n = 14; 4%) and hydrochlorothiazide ( n = 10; 3%). For these five drugs, a significant disproportionality was found. Tenofovir disoproxil related hypophosphatemia occurred more than one year after its introduction, and a renal tubulopathy (Fanconi's syndrome) was reported in 44 cases (25%). Hypophosphatemia related to iron carboxymaltose occurred within a median of 20 days after injection and was mostly severe. Mechanism included the fibroblast growth factor 23 which can be measured to confirm drug origin. Concerning anti  osteoporosis treatments, hypophosphatemia could be explained by their mechanism of action (abrupt increase of parathormone induced by hypocalcemia) but the patient history (malignancy condition) was a major bias. For hydrochlorothiazide, hyphosphatemia was often moderate, associated with other electrolytic disturbances and occurred during a long term treatment. Awareness of healthcare professionals is essential to detect as soon as possible hypophosphatemia and its complications related to these drugs. (c) 2023 Societe franc , aise de pharmacologie et de therapeutique. Published by Elsevier Masson SAS. All rights reserved.
C1 [Thillard, Eve Marie; Sade, Paula; Jonville Bera, Annie Pierre] Univ Hosp Tours, Pharmacovigilance Reg Ctr Ctr Val De Loire, Dept Pharmacosurveillance, F 37044 Tours, France.
   [Michot, Joelle] Univ Sorbonne, Pharmacovigilance Reg Ctr Paris St Antoine, AP HP, F 75012 Paris, France.
   [Bres, Virginie] CHU Montpellier, Pharmacovigilance Reg Ctr Montpellier, Dept Med Pharmacol & Toxicol, F 34000 Montpellier, France.
C3 CHU Tours; Assistance Publique Hopitaux Paris (APHP); Sorbonne
   Universite; Universite de Montpellier; CHU de Montpellier
RP Thillard, EM (通讯作者)，Univ Hosp Tours, Pharmacovigilance Reg Ctr Ctr Val De Loire, Dept Pharmacosurveillance, F 37044 Tours, France.
EM evemarie.thillard@gmail.com
RI Jonville Bera, Annie Pierre/L 9019 2015; bres, virginie/AAS 2010 2020
CR Adhikari S, 2021, CLIN KIDNEY J, V14, P2304, DOI 10.1093/ckj/sfab078
   Aloy B, 2016, AIDS REV, V18, P184
   Arimone Y, 2013, THERAPIE, V68, P69, DOI 10.2515/therapie/2013016
   BEGAUD B, 1985, THERAPIE, V40, P111
   Bégaud B, 2002, JAMA J AM MED ASSOC, V288, P1588, DOI 10.1001/jama.288.13.1588
   Bihan K, 2020, THERAPIE, V75, P591, DOI 10.1016/j.therap.2020.02.022
   Chiam P, 2017, Med Case Rep, V3
   EMA, 2023, Serious adverse reaction
   Faillie JL, 2019, THERAPIE, V74, P225, DOI 10.1016/j.therap.2019.01.006
   Foreman JW, 2019, PEDIATR CLIN N AM, V66, P159, DOI 10.1016/j.pcl.2018.09.002
   Gaasbeek A, 2005, AM J MED, V118, P1094, DOI 10.1016/j.amjmed.2005.02.014
   Gupta SK, 2005, CLIN INFECT DIS, V40, P1559, DOI 10.1086/430257
   Herlitz LC, 2010, KIDNEY INT, V78, P1171, DOI 10.1038/ki.2010.318
   Lecoq AL, 2021, THERAPIE, V76, P705, DOI 10.1016/j.therap.2021.04.008
   Liamis G, 2010, QJM INT J MED, V103, P449, DOI 10.1093/qjmed/hcq039
   Mateo L, 2016, CLIN RHEUMATOL, V35, P1271, DOI 10.1007/s10067 014 2627 x
   Megapanou E, 2020, DRUG SAFETY, V43, P197, DOI 10.1007/s40264 019 00888 1
   Ministere des solidarites et de la sante, 2023, Base de donnees publique des medicaments
   Montastruc JL, 2006, JOINT BONE SPINE, V73, P629, DOI 10.1016/j.jbspin.2006.09.002
   Montastruc JL, 2022, THERAPIE, V77, P261, DOI 10.1016/j.therap.2022.03.001
   Nguyen Anton, 2018, J Adv Pract Oncol, V9, P601
   OKADA M, 1983, KLIN WOCHENSCHR, V61, P99, DOI 10.1007/BF01496662
   Padelli M, 2017, PRESSE MED, V46, P987, DOI 10.1016/j.lpm.2017.09.002
   Percy L, 2017, BEST PRACT RES CL OB, V40, P55, DOI 10.1016/j.bpobgyn.2016.09.007
   Rifkin BS, 2004, AM J MED, V117, P282, DOI 10.1016/j.amjmed.2004.03.025
   Sato K, 1997, BONE, V21, P57, DOI 10.1016/S8756 3282(97)00084 7
   Schouten BJ, 2009, J CLIN ENDOCR METAB, V94, P2332, DOI 10.1210/jc.2008 2396
   vih.org, 2014, Les chiffres du VIH en France
   Watkins KR, 2015, SUPPORT CARE CANCER, V23, P1657, DOI 10.1007/s00520 014 2521 8
   Wolf M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.124486
   Zoller H, 2023, GUT, V72, P644, DOI 10.1136/gutjnl 2022 327897
NR 31
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0040 5957
EI 1958 5578
J9 THERAPIE
JI Therapie
PD MAY JUN
PY 2024
VL 79
IS 3
BP 371
EP 378
DI 10.1016/j.therap.2023.07.007
EA MAY 2024
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA UO8A3
UT WOS:001249078700001
PM 37634954
DA 2025 08 17
ER

PT J
AU Wang, LL
   Chen, DD
   Lee, JH
   Gu, XH
   Alaaeddine, G
   Li, JM
   Wei, L
   Yu, SP
AF Wang, Li Li
   Chen, Dongdong
   Lee, Jinhwan
   Gu, Xiaohuan
   Alaaeddine, Ghina
   Li, Jimei
   Wei, Ling
   Yu, Shan Ping
TI Mobilization of Endogenous Bone Marrow Derived Endothelial Progenitor
   Cells and Therapeutic Potential of Parathyroid Hormone after Ischemic
   Stroke in Mice
SO PLOS ONE
LA English
DT Article
ID FOCAL CEREBRAL ISCHEMIA; STEM CELLS; ENHANCES ANGIOGENESIS;
   MYOCARDIAL INFARCTION; FUNCTIONAL RECOVERY; BARREL CORTEX; NEUROGENESIS;
   RECEPTOR; BLOOD; BRAIN
AB Stroke is a major neurovascular disorder threatening human life and health. Very limited clinical treatments are currently available for stroke patients. Stem cell transplantation has shown promising potential as a regenerative treatment after ischemic stroke. The present investigation explores a new concept of mobilizing endogenous stem cells/progenitor cells from the bone marrow using a parathyroid hormone (PTH) therapy after ischemic stroke in adult mice. PTH 1 34 (80 mu g/kg, i.p.) was administered 1 hour after focal ischemia and then daily for 6 consecutive days. After 6 days of PTH treatment, there was a significant increase in bone marrow derived CD 34/Fetal liver kinase 1 (Flk 1) positive endothelial progenitor cells (EPCs) in the peripheral blood. PTH treatment significantly increased the expression of trophic/regenerative factors including VEGF, SDF 1, BDNF and Tie 1 in the brain peri infarct region. Angiogenesis, assessed by co labeled Glut 1 and BrdU vessels, was significantly increased in PTH treated ischemic brain compared to vehicle controls. PTH treatment also promoted neuroblast migration from the subventricular zone (SVZ) and increased the number of newly formed neurons in the peri infarct cortex. PTH treated mice showed significantly better sensorimotor functional recovery compared to stroke controls. Our data suggests that PTH therapy improves endogenous repair mechanisms after ischemic stroke with functional benefits. Mobilizing endogenous bone marrow derived stem cells/progenitor cells using PTH and other mobilizers appears an effective and feasible regenerative treatment after ischemic stroke.
C1 [Wang, Li Li; Chen, Dongdong; Lee, Jinhwan; Gu, Xiaohuan; Alaaeddine, Ghina; Wei, Ling; Yu, Shan Ping] Emory Univ Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA.
   [Wang, Li Li; Li, Jimei] Capital Med Univ, Beijing Friendship Hosp, Dept Neurol, Beijing, Peoples R China.
   [Wei, Ling] Emory Univ Sch Med, Dept Neurol, Atlanta, GA USA.
C3 Emory University; Capital Medical University; Emory University
RP Yu, SP (通讯作者)，Emory Univ Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA.
EM spyu@emory.edu
RI Chen, DongDong/ADS 0885 2022; Alaaeddine, Ghina/HHN 7143 2022; Li,
   Jiarong/ABG 6750 2022
FU NIH [NS0458710, NS075338, NS062097]; AHA Established Investigator Award;
   AHA [12GRNT12060222]; National Natural Science Foundation of China
   [81350012]; NIH from the Extramural Research Facilities Program of the
   National Center for Research Resources [C06 RR015455]; American Heart
   Association (AHA) [12GRNT12060222] Funding Source: American Heart
   Association (AHA)
FX This work is supported by NIH grants NS0458710 (SPY), NS075338 (LW),
   NS062097 (LW), AHA Established Investigator Award (LW), AHA Grant in Aid
   grant 12GRNT12060222 (SPY) and by a grant 81350012 (JL) from National
   Natural Science Foundation of China. This work was also supported by the
   NIH grant C06 RR015455 from the Extramural Research Facilities Program
   of the National Center for Research Resources. The funders had no role
   in interfering with study design, data collection and analysis, decision
   to publish, or preparation of the manuscript.
CR Adams GB, 2007, NAT BIOTECHNOL, V25, P238, DOI 10.1038/nbt1281
   AKMAL M, 1984, P SOC EXP BIOL MED, V176, P434
   Arai K, 2009, FEBS J, V276, P4644, DOI 10.1111/j.1742 4658.2009.07176.x
   Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Ballen KK, 2007, BIOL BLOOD MARROW TR, V13, P838, DOI 10.1016/j.bbmt.2007.03.007
   Bensinger W, 2009, BONE MARROW TRANSPL, V43, P181, DOI 10.1038/bmt.2008.410
   Bieglmayer C, 2002, CLIN CHEM, V48, P1731
   Borlongan CV, 2011, PROG NEUROBIOL, V95, P213, DOI 10.1016/j.pneurobio.2011.08.005
   Bouët V, 2007, EXP NEUROL, V203, P555, DOI 10.1016/j.expneurol.2006.09.006
   Brines ML, 1999, NEUROSCI LETT, V274, P13, DOI 10.1016/S0304 3940(99)00664 3
   Brunner S, 2008, EXP HEMATOL, V36, P1157, DOI 10.1016/j.exphem.2008.03.014
   Brunner S, 2007, AM J PHYSIOL ENDOC M, V293, pE1670, DOI 10.1152/ajpendo.00287.2007
   CHAUBAL A, 1994, ACTA NEUROPATHOL, V88, P454
   Chizh BA, 2007, J PSYCHOPHARMACOL, V21, P259, DOI 10.1177/0269881105062484
   Coppolino G, 2011, J INVEST MED, V59, P823, DOI 10.2310/JIM.0b013e318214edf8
   Couillard Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460 9568.2004.03813.x
   Dunac A, 2007, J NEUROL, V254, P327, DOI 10.1007/s00415 006 0362 1
   Espinera AR, 2013, NEUROSCIENCE, V247, P1, DOI 10.1016/j.neuroscience.2013.04.011
   Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919
   FEOLA M, 1986, SURG GYNECOL OBSTET, V163, P523
   Freret T, 2009, BEHAV NEUROSCI, V123, P224, DOI 10.1037/a0014157
   Ghani U, 2005, STROKE, V36, P151, DOI 10.1161/01.STR.0000149944.15406.16
   Hess DC, 2008, CELL PROLIFERAT, V41, P94, DOI 10.1111/j.1365 2184.2008.00486.x
   Horn T, 2010, NEUROCHEM INT, V57, P940, DOI 10.1016/j.neuint.2010.09.014
   Huber BC, 2011, CARDIOVASC RES, V90, P529, DOI 10.1093/cvr/cvr014
   Huber BC, 2010, AM J PHYSIOL HEART C, V298, pH1466, DOI 10.1152/ajpheart.00033.2010
   Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902
   Lemoli RM, 2008, HAEMATOLOGICA, V93, P321, DOI 10.3324/haematol.12616
   Lemoli RM, 2006, STEM CELLS, V24, P2817, DOI 10.1634/stemcells.2006 0333
   Li WL, 2013, NEUROSCIENCE, V244, P16, DOI 10.1016/j.neuroscience.2013.03.045
   Li WL, 2008, DEV NEUROBIOL, V68, P1474, DOI 10.1002/dneu.20674
   Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417
   Liang Z, 2007, BIOCHEM BIOPH RES CO, V359, P716, DOI 10.1016/j.bbrc.2007.05.182
   Lin TN, 2000, J CEREBR BLOOD F MET, V20, P387, DOI 10.1097/00004647 200002000 00021
   Lubjuhn J, 2009, J NEUROSCI METH, V184, P95, DOI 10.1016/j.jneumeth.2009.07.029
   Manzerra P, 2001, P NATL ACAD SCI USA, V98, P11055, DOI 10.1073/pnas.191353598
   Misra V, 2012, NEUROLOGY, V79, pS207, DOI 10.1212/WNL.0b013e31826959d2
   Moubarik C, 2011, STEM CELL REV REP, V7, P208, DOI 10.1007/s12015 010 9157 y
   Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735
   Navarro Sobrino M, 2010, MICROVASC RES, V80, P317, DOI 10.1016/j.mvr.2010.05.008
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ogle ME, 2012, NEUROBIOL DIS, V45, P733, DOI 10.1016/j.nbd.2011.10.020
   Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323 06.2006
   Ovbiagele B, 2008, STROKE, V39, P2231, DOI 10.1161/STROKEAHA.107.513499
   Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0
   Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172
   Roger VL, 2012, CIRCULATION, V125, pE2, DOI [10.1161/CIR.0b013e31823ac046, 10.1161/CIR.0b013e3182456d46]
   Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050
   Schwarzkopf TM, 2013, EXP BIOL MED, V238, P84, DOI 10.1258/ebm.2012.012261
   Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505
   Sigler A, 2009, P NATL ACAD SCI USA, V106, P11759, DOI 10.1073/pnas.0812695106
   Strong K, 2007, LANCET NEUROL, V6, P182, DOI 10.1016/S1474 4422(07)70031 5
   Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622
   Taylor CW, 2012, BIOCHEM SOC T, V40, P147, DOI 10.1042/BST20110615
   Usdin TB, 1997, ENDOCRINOLOGY, V138, P831, DOI 10.1210/en.138.2.831
   Usdin TB, 2003, TRENDS ENDOCRIN MET, V14, P14, DOI 10.1016/S1043 2760(02)00002 4
   USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455
   WEI L, 1995, STROKE, V26, P1459, DOI 10.1161/01.STR.26.8.1459
   Wei L, 2012, NEUROBIOL DIS, V46, P635, DOI 10.1016/j.nbd.2012.03.002
   WEISS SW, 1993, AM J SURG PATHOL, V17, P1039, DOI 10.1097/00000478 199310000 00009
   Whitaker VR, 2007, J CEREBR BLOOD F MET, V27, P57, DOI 10.1038/sj.jcbfm.9600318
   Yang JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020219
   Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475
   Zaruba MM, 2008, CARDIOVASC RES, V77, P722, DOI 10.1093/cvr/cvm080
   Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460
NR 65
TC 34
Z9 38
U1 0
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD FEB 4
PY 2014
VL 9
IS 2
AR e87284
DI 10.1371/journal.pone.0087284
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 302VA
UT WOS:000330631800026
PM 24503654
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Sandstedt, M
   Vukusic, K
   Johansson, M
   Jonsson, M
   Magnusson, R
   Hultén, LM
   Dellgren, G
   Jeppsson, A
   Lindahl, A
   Synnergren, J
   Sandstedt, J
AF Sandstedt, Mikael
   Vukusic, Kristina
   Johansson, Markus
   Jonsson, Marianne
   Magnusson, Rasmus
   Hulten, Lillemor Mattsson
   Dellgren, Goran
   Jeppsson, Anders
   Lindahl, Anders
   Synnergren, Jane
   Sandstedt, Joakim
TI Regional transcriptomic profiling reveals immune system enrichment in
   nonfailing atria and all chambers of the failing human heart
SO AMERICAN JOURNAL OF PHYSIOLOGY HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE heart failure; immune system; normal heart; transcriptomics; upstream
   regulators
ID FAILURE; INTERLEUKIN 1; MACROPHAGES; PATHWAYS; THERAPY
AB The different chambers of the human heart demonstrate regional physiological traits and may be differentially affected during pathological remodeling, resulting in heart failure. Few previous studies, however, have characterized the different chambers at a transcriptomic level. We, therefore, conducted whole tissue RNA sequencing and gene set enrichment analysis of biopsies collected from the four chambers of adult failing (n = 8) and nonfailing (n = 11) human hearts. Atria and ventricles demonstrated distinct transcriptional patterns. When compared with nonfailing ventricles, the transcriptional pattern of nonfailing atria was enriched for many gene sets associated with cardiogenesis, the immune system and bone morphogenetic protein (BMP), transforming growth factor beta (TGF beta), MAPK/JNK, and Wnt signaling. Differences between failing and nonfailing hearts were also determined. The transcriptional pattern of failing atria was distinct compared with that of nonfailing atria and enriched for gene sets associated with the innate and adaptive immune system, TGF beta/SMAD signaling, and changes in endothelial, smooth muscle cell, and cardiomyocyte physiology. Failing ventricles were also enriched for gene sets associated with the immune system. Based on the transcriptomic patterns, upstream regulators associated with heart failure were identified. These included many immune response factors predicted to be similarly activated for all chambers of failing hearts. In summary, the heart chambers demonstrate distinct transcriptional patterns that differ between failing and nonfailing hearts. Immune system signaling may be a hallmark of all four heart chambers in failing hearts and could constitute a novel therapeutic target.
C1 [Sandstedt, Mikael; Vukusic, Kristina; Jonsson, Marianne; Lindahl, Anders; Sandstedt, Joakim] Univ Gothenburg, Inst Biomed, Sahlgrenska Acad, Dept Lab Med, Gothenburg, Sweden.
   [Sandstedt, Mikael; Jonsson, Marianne; Hulten, Lillemor Mattsson; Lindahl, Anders; Sandstedt, Joakim] Sahlgrens Univ Hosp, Dept Clin Chem, Reg Vastra Gotaland, Gothenburg, Sweden.
   [Johansson, Markus; Magnusson, Rasmus; Synnergren, Jane] Univ Skovde, Sch Biosci, Dept Biol & Bioinformat, Skovde, Sweden.
   [Hulten, Lillemor Mattsson; Dellgren, Goran; Jeppsson, Anders; Synnergren, Jane] Univ Gothenburg, Inst Med, Sahlgrenska Acad, Dept Mol & Clin Med, Gothenburg, Sweden.
   [Dellgren, Goran; Jeppsson, Anders] Sahlgrens Univ Hosp, Dept Cardiothorac Surg, Reg Vastra Gotaland, Gothenburg, Sweden.
C3 University of Gothenburg; Sahlgrenska University Hospital; University of
   Skovde; University of Gothenburg; Sahlgrenska University Hospital
RP Sandstedt, M (通讯作者)，Univ Gothenburg, Inst Biomed, Sahlgrenska Acad, Dept Lab Med, Gothenburg, Sweden.; Sandstedt, M (通讯作者)，Sahlgrens Univ Hosp, Dept Clin Chem, Reg Vastra Gotaland, Gothenburg, Sweden.
EM mikael.sandstedt@gu.se
RI ; Johansson, Markus/GRO 6785 2022; Sandstedt, Mikael/GRO 7230 2022;
   Lindahl, Anders/H 9550 2014; Synnergren, Jane/T 4247 2018
OI Johansson, Markus/0000 0002 5134 4749; Mattsson Hulten,
   Lillemor/0000 0003 1273 3466; Jeppsson, Anders/0000 0003 2356 2295;
   Lindahl, Anders/0000 0003 2871 5166; Magnusson,
   Rasmus/0000 0001 9395 6025; Synnergren, Jane/0000 0003 4697 0590
FU The Swedish Society of Medicine
FX We thank the Cell and Tissue laboratory and the coordinators at the
   centrum for transplantation, Sahlgrenska University Hospital, for
   assistance with the logistics and the administration of the donor
   tissues and the nurses and surgeons at the Department of Cardiothoracic
   Surgery, Sahlgrenska University Hospital, for skillful handling of the
   biopsies. Graphical abstract was created with a licensed version of
   BioRender.com.
CR Abbate A, 2020, CIRC RES, V126, P1260, DOI 10.1161/CIRCRESAHA.120.315937
   Ajoolabady A, 2022, J AM COLL CARDIOL, V79, P2349, DOI 10.1016/j.jacc.2022.03.379
   Aurora AB, 2014, J CLIN INVEST, V124, P1382, DOI 10.1172/JCI72181
   Balatskyi VV, 2023, ACTA PHYSIOL, V237, DOI 10.1111/apha.13912
   Brennecke P, 2013, NAT METHODS, V10, P1093, DOI [10.1038/NMETH.2645, 10.1038/nmeth.2645]
   Buckley LF, 2018, J CARDIOVASC PHARM, V72, P68, DOI 10.1097/FJC.0000000000000591
   Carlisle MA, 2019, JACC HEART FAIL, V7, P447, DOI 10.1016/j.jchf.2019.03.005
   Chung ES, 2003, CIRCULATION, V107, P3133, DOI 10.1161/01.CIR.0000077913.60364.D2
   Everett BM, 2019, CIRCULATION, V139, P1289, DOI 10.1161/CIRCULATIONAHA.118.038010
   Fermin DR, 2008, CIRC CARDIOVASC GENE, V1, P117, DOI 10.1161/CIRCGENETICS.108.802652
   Flores ROR, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.019667
   Frangogiannis NG, 2022, NAT REV CARDIOL, V19, P435, DOI 10.1038/s41569 021 00646 w
   Fujiu K, 2022, INT IMMUNOL, V34, P81, DOI 10.1093/intimm/dxab036
   Gillers BS, 2015, CIRC RES, V116, P398, DOI 10.1161/CIRCRESAHA.116.304731
   Goumans MJ, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a022210
   Hanna A, 2020, CARDIOVASC DRUG THER, V34, P849, DOI 10.1007/s10557 020 07071 0
   Hulsmans M, 2017, CELL, V169, P510, DOI 10.1016/j.cell.2017.03.050
   InanlooRahatloo K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183874
   Johnson EK, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 32154 2
   Kawano H, 2003, HEART VESSELS, V18, P32, DOI 10.1007/s003800300005
   Levick S, 2014, HEART FAIL REV, V19, P227, DOI 10.1007/s10741 013 9393 8
   Li DL, 2022, CURR CARDIOL REP, V24, P1425, DOI 10.1007/s11886 022 01756 8
   Li ZY, 2022, KOREAN J PHYSIOL PHA, V26, P469, DOI 10.4196/kjpp.2022.26.6.469
   Litvinukova M, 2020, NATURE, V588, P466, DOI 10.1038/s41586 020 2797 4
   Luo X, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 91214 2
   Mann DL, 2004, CIRCULATION, V109, P1594, DOI 10.1161/01.CIR.0000124490.27666.B2
   McDonagh TA, 2021, EUR HEART J, V42, P3599, DOI [10.1093/eurheartj/ehab670, 10.1093/eurheartj/ehab368, 10.1002/ejhf.2333]
   Olsen MB, 2022, JACC BASIC TRANSL SC, V7, P84, DOI 10.1016/j.jacbts.2021.08.006
   Putko BN, 2021, EUR HEART J CARD IMG, V22, P220, DOI 10.1093/ehjci/jeaa041
   Reimand J, 2019, NAT PROTOC, V14, P482, DOI 10.1038/s41596 018 0103 9
   Rowton M, 2021, SEMIN CELL DEV BIOL, V118, P94, DOI 10.1016/j.semcdb.2021.06.002
   Sandstedt J, 2019, CYTOKINE, V113, P319, DOI 10.1016/j.cyto.2018.09.021
   Sandstedt M, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0269985
   Sandstedt M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202693
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sorensen DW, 2020, CURR HEART FAIL REP, V17, P225, DOI 10.1007/s11897 020 00470 2
   Steffens S, 2022, EUR HEART J, V43, P1533, DOI 10.1093/eurheartj/ehab842
   Tham YK, 2015, ARCH TOXICOL, V89, P1401, DOI 10.1007/s00204 015 1477 x
   Tucker NR, 2020, CIRCULATION, V142, P466, DOI 10.1161/CIRCULATIONAHA.119.045401
   Vukusic K, 2019, STEM CELLS DEV, V28, P1078, DOI 10.1089/scd.2019.0075
   Wang L, 2020, NAT CELL BIOL, V22, P108, DOI 10.1038/s41556 019 0446 7
   Wu J, 2018, ACTA BIOCH BIOPH SIN, V50, P323, DOI 10.1093/abbs/gmy007
   Zhang M, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 36117 0
NR 43
TC 1
Z9 1
U1 0
U2 0
PU AMER PHYSIOLOGICAL SOC
PI Rockville
PA 6120 Executive Blvd, Suite 600, Rockville, MD, UNITED STATES
SN 0363 6135
EI 1522 1539
J9 AM J PHYSIOL HEART C
JI Am. J. Physiol. Heart Circul. Physiol.
PD DEC 13
PY 2023
VL 325
IS 6
BP H1430
EP H1445
DI 10.1152/ajpheart.00438.2023
PG 16
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
   Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology; Physiology
GA EF7X1
UT WOS:001137584100002
PM 37830984
DA 2025 08 17
ER

PT J
AU Adchariyasakulchai, P
   Sakunrangsit, N
   Chokyakorn, S
   Suksanong, C
   Ketchart, W
AF Adchariyasakulchai, Patthamapon
   Sakunrangsit, Nithidol
   Chokyakorn, Sarun
   Suksanong, Chayanin
   Ketchart, Wannarasmi
TI Anticancer effect of zoledronic acid in endocrine resistant breast
   cancer cells via HER 2 signaling
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE AKT; Breast cancer; Endocrine resistance; ERK; HER 2; Zoledronic acid
ID ESTROGEN RECEPTOR; ADJUVANT THERAPY; BISPHOSPHONATES; ANTITUMOR;
   PROGRESSION; EXPRESSION; KINASE; CDK4/6; LUNG
AB HER  2 overexpression is a major mechanism involved in endocrine  resistant breast cancer, which has very limited treatment options. Zoledronic acid (ZA) is a drug in the bisphosphonate group used to treat osteoporosis. ZA was reported to exhibit activity in various cancers, with higher efficacy associated with estrogen  deprivation states. ZA inhibits cell proliferation in lung cancer through the epidermal growth factor receptor signaling pathway. Because endocrine  resistant breast cancer cells overexpress HER  2 and grow independently without estrogen, ZA may exert anticancer effects in these cell types. The inhibitory effects and mechanisms of ZA in endocrine  resistant cells through HER  2 signaling were investigated. The efficacy of ZA was higher in the endocrine  resistant breast cancer cells when compared with the wild  type cells. ZA also exhibited a synergistic effect with fulvestrant and may circumvent fulvestrant resistance. ZA decreased phosphorylated ERK (pERK) levels in resistant cell lines and attenuated HER  2 signaling in tamoxifen  and fulvestrant resistant cells. ZA significantly decreased HER  2 levels and its downstream signaling molecules, including pAKT and pNF KB in fulvestrant resistant breast cancer cells. This inhibitory effect may explain the lower IC50 values of ZA in fulvestrant resistant cells compared with tamoxifen resistant cells. Moreover, ZA inhibited the migration and invasion in the resistant cell lines, suggesting an ability to inhibit tumor metastasis. The results indicate that ZA has potential for repurposing as an adjuvant treatment for patients with endocrine  resistant breast cancer.
C1 [Adchariyasakulchai, Patthamapon; Sakunrangsit, Nithidol; Chokyakorn, Sarun; Suksanong, Chayanin; Ketchart, Wannarasmi] Chulalongkorn Univ, Fac Med, Dept Pharmacol, Bangkok 10330, Thailand.
   [Ketchart, Wannarasmi] Chulalongkorn Univ, Fac Med, Dept Pharmacol, 1873 Rama IV Rd, Bangkok 10330, Thailand.
C3 Chulalongkorn University; Chulalongkorn University
RP Ketchart, W (通讯作者)，Chulalongkorn Univ, Fac Med, Dept Pharmacol, 1873 Rama IV Rd, Bangkok 10330, Thailand.
EM wannarasmi.k@chula.ac.th
OI chokyakorn, sarun/0000 0001 5764 071X
FU Ratchadapiseksompotch Fund, Chulalongkorn University [RCU_H_64_017_30]
FX <STRONG> </STRONG>This research project was supported by the
   Ratchadapiseksompotch Fund, Chulalongkorn University [grant number
   RCU_H_64_017_30] .
CR Ayyagari R, 2018, CLIN THER, V40, P628, DOI 10.1016/j.clinthera.2018.03.004
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008 5472.CAN 09 1947
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Dagher OK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216908
   Di Salvatore M, 2011, CELL PROLIFERAT, V44, P139, DOI 10.1111/j.1365 2184.2011.00745.x
   Fanale D, 2016, ONCOTARGET, V7, P29321, DOI 10.18632/oncotarget.8722
   Foucquier J, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.149
   Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992
   García Becerra R, 2013, INT J MOL SCI, V14, P108, DOI 10.3390/ijms14010108
   Gralow JR, 2020, JNCI J NATL CANCER I, V112, P698, DOI 10.1093/jnci/djz215
   Gschwantler Kaulich D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185566
   Harnden K, 2015, J NATL COMPR CANC NE, V13, P480, DOI 10.6004/jnccn.2015.0061
   Herrera Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008 5472.CAN 15 0728
   Hosford SR, 2014, PHARMACOGEN PERS MED, V7, P203, DOI 10.2147/PGPM.S52762
   Hurvitz SA, 2008, CANCER AM CANCER SOC, V113, P2385, DOI 10.1002/cncr.23875
   Ibrahim T, 2012, CANCER CELL INT, V12, DOI 10.1186/1475 2867 12 48
   Kharwadkar N, 2017, BONE JOINT RES, V6, P144, DOI 10.1302/2046 3758.63.BJR 2016 0125.R1
   Li XY, 2012, MED ONCOL, V29, P714, DOI 10.1007/s12032 011 9904 1
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Migliorati CA, 2003, J CLIN ONCOL, V21, P4253, DOI 10.1200/JCO.2003.99.132
   Neville Webbe HL, 2010, BRIT J CANCER, V102, P1010, DOI 10.1038/sj.bjc.6605579
   Osborne CK, 2003, BREAST, V12, P362, DOI 10.1016/S0960 9776(03)00137 1
   Pandey K, 2019, INT J CANCER, V145, P1179, DOI 10.1002/ijc.32020
   Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568
   Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097 0215(19990719)82:2<268::AID IJC18>3.3.CO;2 W
   Sakunrangsit N, 2020, EUR J PHARMACOL, V868, DOI 10.1016/j.ejphar.2019.172878
   Sakunrangsit N, 2016, PHYTOTHER RES, V30, P1968, DOI 10.1002/ptr.5702
   Stachnik A, 2014, P NATL ACAD SCI USA, V111, P17995, DOI 10.1073/pnas.1421422111
   Verdijk R, 2007, CANCER LETT, V246, P308, DOI 10.1016/j.canlet.2006.03.011
   Wang L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1109 z
   Yin L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107369
   Yuen T, 2014, P NATL ACAD SCI USA, V111, P17989, DOI 10.1073/pnas.1421410111
   Zekri J, 2014, J BONE ONCOL, V3, P25, DOI 10.1016/j.jbo.2013.12.001
NR 33
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD FEB
PY 2024
VL 171
AR 116142
DI 10.1016/j.biopha.2024.116142
EA JAN 2024
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA GW1O7
UT WOS:001155620600001
PM 38198953
OA gold
DA 2025 08 17
ER

PT J
AU Quattrocchi, CC
   Santini, D
   Dell'Aia, P
   Piciucchi, S
   Leoncini, E
   Vincenzi, B
   Grasso, RF
   Tonini, G
   Zobel, BB
AF Quattrocchi, Carlo C.
   Santini, Daniele
   Dell'Aia, Paola
   Piciucchi, Sara
   Leoncini, Emanuele
   Vincenzi, Bruno
   Grasso, Rosario Francesco
   Tonini, Giuseppe
   Zobel, Bruno Beomonte
TI A prospective analysis of CT density measurements of bone metastases
   after treatment with zoledronic acid
SO SKELETAL RADIOLOGY
LA English
DT Article
DE bone metastases; computed tomography; zoledronic acid
ID BREAST CANCER; SKELETAL COMPLICATIONS; MULTIPLE MYELOMA; DOUBLE BLIND;
   PAMIDRONATE; BISPHOSPHONATES; RADIOTHERAPY; EFFICACY; MULTICENTER;
   MECHANISMS
AB Objective The objective was to prospectively determine CT density changes in bone metastases, before and after intravenous zoledronic acid for a maximum period of 12 months.
   Patients and methods Twenty three consecutive patients presented with bone metastases and underwent therapy with zoledronic acid from December 2004. All patients underwent CT of the chest, abdomen, and pelvis. Bone density, measured in Hounsfield units (HU), was determined by segmenting lesions in the same anatomical area of the metastasis sites on the axial images of the sequential series of CT examinations. The effects of zoledronic acid were evaluated by calculating absolute and relative increases in bone density.
   Results The patients presented with multiple metastases in 65% of the cases. When compared with the baseline, all groups demonstrated a significant increase in bone density, which significantly (p < 0.01) correlated with the number of zoledronic acid administrations. There was increased bone density of at least 100% in 57%, and an increase of at least 50% in 87% of the patients. This increase was significant in both lytic and sclerotic metastases after 3 months of therapy. No significant bone density difference was found in normal appearing bone.
   Conclusions Bone density measured by CT increases at metastatic sites after zoledronic acid treatment, regardless of the type of metastasis, in contrast to apparently normal bone.
C1 Ctr Interdisciplinare Ric Biomed, Dept Radiol, I 00155 Rome, Italy.
   Univ Campus Biomed Roma, Dept Oncol, I 00155 Rome, Italy.
   Univ Roma La Sapienza, I 00185 Rome, Italy.
C3 University Campus Bio Medico   Rome Italy; Sapienza University Rome
RP Quattrocchi, CC (通讯作者)，Ctr Interdisciplinare Ric Biomed, Dept Radiol, Via longoni 47, I 00155 Rome, Italy.
EM c.quattrocchi@unicampus.it
RI Zobel, Bruno/C 2676 2013; Tonini, Giuseppe/ISA 1908 2023; Quattrocchi,
   Carlo Cosimo/HOH 7116 2023; , emanuele/A 5466 2010; Beomonte Zobel,
   Bruno/C 2676 2013
OI Grasso, Rosario Francesco/0000 0001 8660 7070; Santini,
   Daniele/0000 0002 9118 3337; Tonini, Giuseppe/0000 0003 4442 8677;
   Vincenzi, Bruno/0000 0001 8222 9025; Quattrocchi, Carlo
   Cosimo/0000 0001 6823 7707; , emanuele/0000 0002 7669 8535; Beomonte
   Zobel, Bruno/0000 0001 9227 5535
CR Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Body J J, 1995, Can J Oncol, V5 Suppl 1, P16
   Body JJ, 2003, EXPERT OPIN PHARMACO, V4, P567, DOI 10.1517/eoph.4.4.567.22227
   Body JJ, 1996, CANCER TREAT REV, V22, P265, DOI 10.1016/S0305 7372(96)90020 1
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Chow E, 2004, RADIOTHER ONCOL, V70, P291, DOI 10.1016/j.radonc.2004.01.009
   CLARKE NW, 1991, BRIT J UROL, V68, P74, DOI 10.1111/j.1464 410X.1991.tb15260.x
   Fromigue O, 2003, BRIT J CANCER, V89, P178, DOI 10.1038/sj.bjc.6601009
   Garnero P, 2000, BRIT J CANCER, V82, P858, DOI 10.1054/bjoc.1999.1012
   Hamaoka T, 2004, J CLIN ONCOL, V22, P2942, DOI 10.1200/jco.2004.08.181
   HAYWARD JL, 1977, BRIT J CANCER, V35, P292, DOI 10.1038/bjc.1977.42
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Huber S, 2002, ANTICANCER RES, V22, P1279
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   KIDO DK, 1978, RADIOLOGY, V128, P371, DOI 10.1148/128.2.371
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   LAHTINEN R, 1992, LANCET, V340, P1049, DOI 10.1016/0140 6736(92)93075 X
   Lipton Allan, 2000, Cancer, V88, P3033, DOI 10.1002/1097 0142(20000615)88:12+<3033::AID CNCR20>3.3.CO;2 3
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Martini G, 2006, HAEMATOLOGICA, V91, P1720
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   O'Connor SD, 2007, RADIOLOGY, V242, P811, DOI 10.1148/radiol.2423060260
   OKEN MM, 1982, AM J CLIN ONCOL CANC, V5, P649, DOI 10.1097/00000421 198212000 00014
   Pan BQ, 2004, J BONE MINER RES, V19, P147, DOI 10.1359/jbmr.2004.19.1.147
   PATERSON AHG, 1993, J CLIN ONCOL, V11, P59, DOI 10.1200/JCO.1993.11.1.59
   PUROHIT OP, 1994, BRIT J CANCER, V70, P554, DOI 10.1038/bjc.1994.344
   QUATTROCCHI CC, 2007, IN PRESS RADIOL MED
   REINBOLD WD, 1989, SKELETAL RADIOL, V18, P517, DOI 10.1007/BF00351751
   Roodman GD, 2004, NEW ENGL J MED, V351, P195
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Saad F, 2005, BJU INT, V96, P964, DOI 10.1111/j.1464 410X.2005.05740.x
   Shapiro CL, 1999, CANCER INVEST, V17, P566, DOI 10.3109/07357909909032841
   Shih LY, 2004, J ORTHOP RES, V22, P1161
   Vassiliou V, 2007, INT J RADIAT ONCOL, V67, P264, DOI 10.1016/j.ijrobp.2006.08.022
   Yi B, 2002, CANCER RES, V62, P917
NR 37
TC 29
Z9 30
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0364 2348
EI 1432 2161
J9 SKELETAL RADIOL
JI Skeletal Radiol.
PD DEC
PY 2007
VL 36
IS 12
BP 1121
EP 1127
DI 10.1007/s00256 007 0388 1
PG 7
WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
GA 224JR
UT WOS:000250443800003
PM 17912514
DA 2025 08 17
ER

PT J
AU Wu, W
   Ye, ZY
   Zhou, Y
   Tan, WS
AF Wu, Wei
   Ye, Zhaoyang
   Zhou, Yan
   Tan, Wen Song
TI AICAR, a small chemical molecule, primes osteogenic differentiation of
   adult mesenchymal stem cells
SO INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS
LA English
DT Article
DE AICAR; Mesenchymal stem cells; Differentiation; Osteogenesis; Small
   molecule
ID ANTIDIABETIC DRUG METFORMIN; ACTIVATED PROTEIN KINASE; APOPTOSIS;
   PATHWAY; MINERALIZATION; PROLIFERATION; STIMULATION; ADIPONECTIN;
   OSTEOBLASTS; INHIBITION
AB The chemical approach to controlling stem cell fates is emerging as a powerful tool, holding great promise in tissue engineering and regenerative medicine. Various small molecules have been demonstrated capable of modulating stem cell differentiation. In this paper, we studied the effects of 5 aminoimidazole 4 carboxamide 1 beta riboside (AICAR), an activator of AMP activated protein kinase (AMPK), on mesenchymal stem cells (MSCs). AICAR at high concentrations (1.0 2.0 mM) significantly inhibited proliferation of both human amnion derived MSCs (hAMSCs) and rabbit bone marrow derived MSCs (BM MSCs). Most importantly, AICAR efficiently promoted the osteogenic differentiation of hAMSCs and BM MSCs in both growth medium and osteogenic medium. However, Metformin, another AMPK activator, showed no such effects. Meanwhile, AICAR significantly inhibited adipogenic differentiation of hAMSCs and BM MSCs. Our data suggests that AICAR represents a potent molecule, which can be applied in bone tissue regeneration.
C1 [Wu, Wei; Ye, Zhaoyang; Zhou, Yan; Tan, Wen Song] E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China.
C3 East China University of Science & Technology
RP Zhou, Y (通讯作者)，E China Univ Sci & Technol, State Key Lab Bioreactor Engn, 130 Mei Long Rd,POB 309, Shanghai 200237, Peoples R China.
EM zhouyan@ecust.edu.cn
RI yan, zhou/AEX 8535 2022
OI Zhou, Yan/0000 0002 9205 9936
FU Fundamental Research Funds for Central Universities; National Special
   Fund for the State Key Laboratory of Bioreactor Engineering [2060204];
   Shanghai Natural Science Foundation [10ZR1407100]; Shanghai Pujiang
   Program [10PJ1402200]; National Natural Science Foundation of China
   [31000424]
FX Grants from the Fundamental Research Funds for Central Universities, the
   National Special Fund for the State Key Laboratory of Bioreactor
   Engineering (2060204), Shanghai Natural Science Foundation
   (10ZR1407100), Shanghai Pujiang Program (10PJ1402200) and National
   Natural Science Foundation of China (31000424) are gratefully
   acknowledged.
CR Adamo Luigi, 2009, BMC Pharmacology, V9, P2, DOI 10.1186/1471 2210 9 2
   Borowiak M, 2009, CELL STEM CELL, V4, P348, DOI 10.1016/j.stem.2009.01.014
   Chen TH, 2007, BIOCHEM BIOPH RES CO, V355, P913, DOI 10.1016/j.bbrc.2007.02.057
   Chen T, 2009, CELL BIOL TOXICOL, V25, P573, DOI 10.1007/s10565 008 9113 7
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   De Boer J, 2006, TISSUE ENG, V12, P2927
   Di Bernardo G, 2010, J CELL PHYSIOL, V225, P537, DOI 10.1002/jcp.22236
   Di Bernardo G, 2009, STEM CELLS DEV, V18, P573, DOI 10.1089/scd.2008.0172
   Ding S, 2003, P NATL ACAD SCI USA, V100, P7632, DOI 10.1073/pnas.0732087100
   Gao Y, 2010, EUR J PHARMACOL, V635, P231, DOI 10.1016/j.ejphar.2010.02.051
   Giri S, 2006, NUTR METAB, V3, DOI 10.1186/1743 7075 3 31
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Jhun BS, 2004, BIOCHEM BIOPH RES CO, V318, P372, DOI 10.1016/j.bbrc.2004.04.035
   Kanazawa I, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471 2121 8 51
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kasai T, 2009, J CELL PHYSIOL, V221, P740, DOI 10.1002/jcp.21917
   Kefas BA, 2003, DIABETOLOGIA, V46, P250, DOI 10.1007/s00125 002 1030 3
   Kefas BA, 2003, J MOL ENDOCRINOL, V30, P151, DOI 10.1677/jme.0.0300151
   Kim JE, 2008, BONE, V43, P394, DOI 10.1016/j.bone.2008.03.021
   Lim S, 2011, STEM CELLS DEV, V20, P415, DOI 10.1089/scd.2010.0071
   Liu QH, 2009, TISSUE ENG PT A, V15, P3487, DOI [10.1089/ten.tea.2009.0175, 10.1089/ten.TEA.2009.0175]
   López JM, 2003, BIOCHEM J, V370, P1027, DOI 10.1042/BJ20021053
   Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021
   Martins A, 2010, BIOMATERIALS, V31, P5875, DOI 10.1016/j.biomaterials.2010.04.010
   Roche E, 2006, BIOORGAN MED CHEM, V14, P6466, DOI 10.1016/j.bmc.2006.06.015
   SABINA RL, 1985, J BIOL CHEM, V260, P6107
   Salasznyk RM, 2004, CELL COMMUN ADHES, V11, P137, DOI 10.1080/15419060500242836
   Santiago Mora R, 2011, OSTEOPOROSIS INT, V22, P675, DOI 10.1007/s00198 010 1270 x
   Sartipy P, 2008, PHARMACOL RES, V58, P152, DOI 10.1016/j.phrs.2008.06.002
   Wang M, 2010, BIOTECHNOL BIOPROC E, V15, P1047, DOI 10.1007/s12257 009 3147 4
   Wu X, 2002, J AM CHEM SOC, V124, P14520, DOI 10.1021/ja0283908
   Xu Y, 2008, NATURE, V453, P338, DOI 10.1038/nature07042
   Zang Y, 2008, J BIOL CHEM, V283, P6201, DOI 10.1074/jbc.M708619200
   Zang Y, 2009, J BIOL CHEM, V284, P6175, DOI 10.1074/jbc.M806887200
   Zhu ST, 2009, CELL STEM CELL, V4, P416, DOI 10.1016/j.stem.2009.04.001
NR 35
TC 32
Z9 35
U1 0
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0391 3988
EI 1724 6040
J9 INT J ARTIF ORGANS
JI Int. J. Artif. Organs
PD DEC
PY 2011
VL 34
IS 12
BP 1128
EP 1136
DI 10.5301/ijao.5000007
PG 9
WC Engineering, Biomedical; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Transplantation
GA 896LN
UT WOS:000300567900002
PM 22198598
DA 2025 08 17
ER

PT J
AU Dickson, PV
   Hamner, JB
   Cauthen, LA
   Ng, CYC
   McCarville, MB
   Davidoff, AM
AF Dickson, Paxton V.
   Hamner, John B.
   Cauthen, Lindsey A.
   Ng, Catherine Y. C.
   McCarville, M. Beth
   Davidoff, Andrew M.
TI Efficacy of zoledronate against neuroblastoma
SO SURGERY
LA English
DT Article; Proceedings Paper
CT 67th Annual Meeting of the Society of University Surgeons/1st Annual
   Academic Surgical Congress
CY FEB 07 11, 2006
CL San Diego, CA
SP Assoc Acad Surg, Soc Univ Surg
ID BISPHOSPHONATE TARGETS; RECEPTOR ACTIVATOR; ACID; CELLS; PROGRESSION;
   METASTASES; APOPTOSIS; INHIBIT; PATHWAY; MODEL
AB Background. We investigated the antitumor and antiosteoclastic effects of zoledronate against human neuroblastoma in vitro and in a marine model of bone metastasis.
   Methods. Antitumor activity of zoledronate against neuroblastoma cell lines was assessed by evaluating proliferation, apoptosis, and cell cycle progression. A marine model of bone invasion was used to assess antiosteoclastic and antitumor activity in vivo. Mice were followed by radiographic and bioluminescence imaging.
   Results. Treatment of human neuroblastoma cells resulted in a decrease in cell count, increase in apoptosis, and arrest of cell cycle progression. In the model of bone invasion, mice were treated weekly with zoledronate or vehicle control 10 days after tumor cell inoculation. Five weeks later, radiographs revealed a large degree of osteolytic disease in control mice. Impressively, mice treated with zoledronate demonstrated minimal radiographic changes at this time. Bioluminescence imaging of these mice revealed a significant restriction of tumor growth during the course of therapy.
   Conclusions. Zoledronate exhibits significant antitumor activity against human neuroblastoma cells in vitro, prevents development of osteolytic lesions, and restricts tumor growth in a marine model of bone metastasis. These results suggest that clinical investigation of zoledronate or similar bisphosphonates as adjuvant therapy in neuroblastoma patients is warranted.
C1 St Jude Childrens Res Hosp, Dept Surg, Memphis, TN 38105 USA.
   St Jude Childrens Res Hosp, Dept Radiol Sci, Memphis, TN 38105 USA.
   Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA.
C3 St Jude Children's Research Hospital; St Jude Children's Research
   Hospital; University of Tennessee System; University of Tennessee Health
   Science Center
RP Davidoff, AM (通讯作者)，St Jude Childrens Res Hosp, Dept Surg, 332 N Lauderdale St, Memphis, TN 38105 USA.
EM andrew.davidoff@stjude.org
RI McCarville, M Beth/N 2471 2018; McCarville, M/N 2471 2018
OI McCarville, M Beth/0000 0002 2888 443X; 
FU NCI NIH HHS [P30 CA 21765, R25 CA023944] Funding Source: Medline
CR Bukowski JF, 2005, BIOCHEM BIOPH RES CO, V328, P746, DOI 10.1016/j.bbrc.2004.11.075
   Dickson PV, 2005, J AM COLL SURGEONS, V201, pS53, DOI 10.1016/j.jamcollsurg.2005.06.117
   Forsea AM, 2004, BRIT J CANCER, V91, P803, DOI 10.1038/sj.bjc.6602052
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Granchi D, 2004, INT J CANCER, V111, P829, DOI 10.1002/ijc.20308
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Iguchi T, 2003, CELL SIGNAL, V15, P719, DOI 10.1016/S0898 6568(03)00007 X
   Kang MA, 2000, J GENE MED, V2, P289
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Michaelson MD, 2005, J CLIN ONCOL, V23, P8219, DOI 10.1200/JCO.2005.02.9579
   Michigami T, 2001, CANCER RES, V61, P1637
   NINANE J, 1998, PEDIAT SURG ONCOLOGY, P175
   Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f
   Ohtsuka Y, 2005, BLOOD, V106, P3134, DOI 10.1182/blood 2005 03 0972
   Perry CM, 2004, DRUGS, V64, P1197, DOI 10.2165/00003495 200464110 00004
   Roodman GD, 2001, J CLIN ONCOL, V19, P3562, DOI 10.1200/JCO.2001.19.15.3562
   ROSEN LS, 2004, CANCER, V1700, P2613
   Senaratne SG, 2002, BREAST CANCER RES, V4, P18, DOI 10.1186/bcr412
   Smith Matthew R, 2005, Cancer Treat Rev, V31 Suppl 3, P19, DOI 10.1016/j.ctrv.2005.09.004
   Wardley A, 2005, BRIT J CANCER, V92, P1869, DOI 10.1038/sj.bjc.6602551
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Xiao WG, 2002, EXP HEMATOL, V30, P1238, DOI 10.1016/S0301 472X(02)00930 X
NR 24
TC 9
Z9 9
U1 0
U2 0
PU MOSBY ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0039 6060
J9 SURGERY
JI Surgery
PD AUG
PY 2006
VL 140
IS 2
BP 227
EP 235
DI 10.1016/j.surg.2006.02.004
PG 9
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Surgery
GA 077PX
UT WOS:000240043200014
PM 16904974
DA 2025 08 17
ER

PT J
AU Jia, LL
   Xiong, YX
   Zhang, WJ
   Ma, XN
   Xu, X
AF Jia, Linglu
   Xiong, Yixuan
   Zhang, Wenjing
   Ma, Xiaoni
   Xu, Xin
TI Metformin promotes osteogenic differentiation and protects against
   oxidative stress induced damage in periodontal ligament stem cells via
   activation of the Akt/Nrf2 signaling pathway
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Metformin; Periodontal ligament stem cells; Osteogenesis; Oxidative
   stress
ID PROLIFERATION; ATHEROSCLEROSIS; INFLAMMATION; INHIBITION; OSTEOBLAST
AB Periodontal ligament stem cell (PDLSC) based tissue engineering is an important method for regenerating lost bone in periodontitis. Maintaining or enhancing the osteogenic differentiation of PDLSCs, as well as enhancing the resistance of PDLSCs to oxidative stress, is necessary in this process. As a common hypoglycemic drug, metformin has been reported to have multiple effects on cell functions. This study found that low concentrations of metformin did not affect cell proliferation but did inhibit adipogenic differentiation and promote osteogenic differentiation of PDLSCs. This positive effect was associated with activation of Akt signaling by metformin. Moreover, applying metformin as either a pretreatment or co treatment could reduce the amount of reactive oxygen species, enhance antioxidant capacity, and rescue the cell viability and osteogenic differentiation that were negatively affected by H2O2 induced oxidative stress in PDLSCs. In addition, metformin was found to activate the Nrf2 signaling pathway in PDLSCs, and knockdown of Nrf2 by siRNA impaired the protective effect of metformin. Taken together, these results indicate that metformin not only promotes osteogenic differentiation of PDLSCs, but also protects PDLSCs against oxidative stress induced damage, suggesting that metformin could be potentially useful in promoting PDLSC based bone regeneration in the treatment of periodontitis.
C1 [Jia, Linglu; Xiong, Yixuan; Zhang, Wenjing; Ma, Xiaoni; Xu, Xin] Shandong Univ, Sch Stomatol, Jinan, Peoples R China.
   [Jia, Linglu; Xiong, Yixuan; Zhang, Wenjing; Ma, Xiaoni; Xu, Xin] Shandong Prov Key Lab Oral Tissue Regenerat, Jinan, Peoples R China.
C3 Shandong University
RP Ma, XN; Xu, X (通讯作者)，44 1 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
EM maxiaoni0@126.com; xinxu@sdu.edu.cn
RI zhang, wenjing/AAE 7146 2019; LINGLU, JIA/HGA 3173 2022
OI Jia, Linglu/0000 0002 7074 8861; 
FU Construction Engineering Special Fund of Taishan Scholars [ts201511106];
   Natural Science Foundation of Shandong Province [ZR2017MH031]; Shandong
   medical and health science and technology development plan [2017WS112];
   Youth scientific research funds of School of Stomatology, Shandong
   University [2018QNJJ01]
FX This work was supported by the Construction Engineering Special Fund of
   Taishan Scholars (grant number ts201511106), Natural Science Foundation
   of Shandong Province (grant number ZR2017MH031), Shandong medical and
   health science and technology development plan (grant number 2017WS112)
   and the Youth scientific research funds of School of Stomatology,
   Shandong University(grant number 2018QNJJ01).
CR Al Jofi FE, 2018, CYTOTHERAPY, V20, P650, DOI 10.1016/j.jcyt.2018.02.369
   Amable G, 2019, INT J BIOCHEM CELL B, V112, P88, DOI 10.1016/j.biocel.2019.05.004
   Atashi F, 2015, STEM CELLS DEV, V24, P1150, DOI 10.1089/scd.2014.0484
   Bao XF, 2018, ACS NANO, V12, P8882, DOI 10.1021/acsnano.8b04022
   Barreto Torres G, 2015, AM J PHYSIOL HEART C, V308, pH749, DOI 10.1152/ajpheart.00414.2014
   Bhamra GS, 2008, BASIC RES CARDIOL, V103, P274, DOI [10.1007/s00395 007 0691 y, 10.1007/s00395 008 0736 x]
   Bullon P, 2014, PERIODONTOL 2000, V64, P139, DOI 10.1111/j.1600 0757.2012.00455.x
   Chen FM, 2012, BIOMATERIALS, V33, P6320, DOI 10.1016/j.biomaterials.2012.05.048
   Dai G, 2007, CIRC RES, V101, P723, DOI 10.1161/CIRCRESAHA.107.152942
   Dai XZ, 2017, CIRC RES, V120, pE7, DOI 10.1161/CIRCRESAHA.117.310619
   Denu RA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2989076
   Ding G, 2010, STEM CELLS, V28, P1829, DOI 10.1002/stem.512
   Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018
   Gao Y, 2008, J PHARM PHARMACOL, V60, P1695, DOI 10.1211/jpp.60/12.0017
   Graves DT, 1999, CLIN INFECT DIS, V28, P482, DOI 10.1086/515178
   Gu QL, 2017, TOHOKU J EXP MED, V241, P13, DOI 10.1620/tjem.241.13
   Hajishengallis G, 2014, TRENDS IMMUNOL, V35, P3, DOI 10.1016/j.it.2013.09.001
   Han YY, 2018, DRUG DES DEV THER, V12, P137, DOI 10.2147/DDDT.S148457
   Hernández Ríos P, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00869
   Houshmand B, 2018, ARCH ORAL BIOL, V95, P44, DOI 10.1016/j.archoralbio.2018.07.012
   Jang WG, 2011, BONE, V48, P885, DOI 10.1016/j.bone.2010.12.003
   Kang WY, 2017, J PERIODONTOL, V88, pE169, DOI 10.1902/jop.2017.170168
   Khallaghi B, 2016, LIFE SCI, V148, P286, DOI 10.1016/j.lfs.2016.02.024
   Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38
   Kitson SJ, 2019, CANCERS, V11, DOI 10.3390/cancers11050653
   Knani L, 2019, J PINEAL RES, V67, DOI 10.1111/jpi.12597
   Koch CA, 2018, REV ENDOCR METAB DIS, V19, P363, DOI 10.1007/s11154 018 9478 8
   Koh SJ, 2014, J GASTROEN HEPATOL, V29, P502, DOI 10.1111/jgh.12435
   Li SMH, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929 018 0478 5
   Ling SB, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045 017 0424 0
   Liu CC, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00439
   Liu Y, 2008, STEM CELLS, V26, P1065, DOI 10.1634/stemcells.2007 0734
   Lu CC, 2019, INT J ONCOL, V54, P1271, DOI 10.3892/ijo.2019.4704
   Ma J, 2018, EUR REV MED PHARMACO, V22, P7962, DOI 10.26355/eurrev_201811_16424
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev pharmtox 011112 140320
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Marycz K, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9785890
   Mogavero A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16149 z
   Montazersaheb S, 2018, BIOMED PHARMACOTHER, V108, P1328, DOI 10.1016/j.biopha.2018.09.135
   Mu W, 2018, PHARMACOL RES, V129, P462, DOI 10.1016/j.phrs.2017.11.020
   Ould Brahim F, 2018, STEM CELLS DEV, V27, P1085, DOI 10.1089/scd.2018.0055
   Park CH, 2010, BIOMATERIALS, V31, P5945, DOI 10.1016/j.biomaterials.2010.04.027
   Pernicova I, 2014, NAT REV ENDOCRINOL, V10, P143, DOI 10.1038/nrendo.2013.256
   Qin W, 2018, J ENDODONT, V44, P576, DOI 10.1016/j.joen.2017.11.017
   Qin X, 2018, J CELL BIOCHEM, V119, P1074, DOI 10.1002/jcb.26275
   Rivera Gonzalez GC, 2016, CELL STEM CELL, V19, P738, DOI 10.1016/j.stem.2016.09.002
   Saita M, 2016, BIOMATERIALS, V76, P292, DOI 10.1016/j.biomaterials.2015.10.077
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev biochem 061516 045037
   Smieszek A, 2018, J CLIN MED, V7
   Smieszek A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/769402
   Wang P, 2018, J TISSUE ENG REGEN M, V12, P437, DOI 10.1002/term.2470
   Wu WC, 2018, MOL PHARMACEUT, V15, P3272, DOI 10.1021/acs.molpharmaceut.8b00332
   Würth R, 2013, CELL CYCLE, V12, P145, DOI 10.4161/cc.23050
   Yamamoto M, 2018, PHYSIOL REV, V98, P1169, DOI 10.1152/physrev.00023.2017
   Yu CX, 2017, INT J BIOL SCI, V13, P1560, DOI 10.7150/ijbs.18830
   Zhang S, 2016, MOL CELL ENDOCRINOL, V422, P243, DOI 10.1016/j.mce.2015.12.018
   Zhao X, 2019, J CELL PHYSIOL, V234, P16619, DOI 10.1002/jcp.28337
NR 58
TC 56
Z9 57
U1 2
U2 44
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD JAN 15
PY 2020
VL 386
IS 2
AR 111717
DI 10.1016/j.yexcr.2019.111717
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA KD2QO
UT WOS:000507716000007
PM 31715142
DA 2025 08 17
ER

PT J
AU Tang, YH
   Yue, ZS
   Li, GS
   Zeng, LR
   Xin, DW
   Hu, ZQ
   Xu, CD
AF Tang, Yang Hua
   Yue, Zhen Shuang
   Li, Guo Song
   Zeng, Lin Ru
   Xin, Da Wei
   Hu, Zhong Qing
   Xu, Can Da
TI Effect of  ecdysterone on glucocorticoid induced apoptosis and autophagy
   in osteoblasts
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE steoporosis;  ecdysterone; apoptosis; autophagy; mammalian target of
   rapamycin
ID OSTEOGENIC DIFFERENTIATION; IN VITRO; CELLS; INVOLVEMENT; EXPRESSION;
   OSTEOCYTES; PROMOTION
AB The aim of the present study was to investigate the effect of glucocorticoids in osteoblasts and to examine the role of  ecdysterone in the pathogenesis of glucocorticoid induced osteoporosis. Osteoblasts were induced from bone marrow mesenchymal stem cells, which were isolated from C57BL/6 mice. Cell viability and apoptosis of osteoblasts were measured by Cell Counting Kit 8 and flow cytometry analysis, respectively. The expression of related genes and proteins was measured by reverse transcription quantitative polymerase chain reaction and western blot analysis respectively. Dose dependent decreases in the cell proliferation and differentiation were observed in dexamethasone (Dex) treated osteoblasts, evidenced by downregulation in the activity of alkaline phosphatasedecreased expression levels of Runt related transcription factor 2 and osteocalcin, and upregulated expression of RANK ligand. Dex also induced apoptosis and inhibited autophagy of osteoblasts, evidenced by upregulated B cell lymphoma 2 (Bcl 2) associated X protein/Bcl 2 ratio and the activation of mammalian target of rapamycin (mTOR), and decreased expression levels of Beclin 1, autophagy protein 5 and microtubule associated protein 1 light chain 3 II. The effects on cell proliferation, apoptosis and autophagy induced by Dex were reversed by  ecdysterone in a dose dependent manner. Therefore,  ecdysterone may be a promising candidate drug for the treatment of osteoporosis through inducing osteoblast autophagic activity by inactivating mTOR.
C1 [Tang, Yang Hua; Yue, Zhen Shuang; Zeng, Lin Ru; Xin, Da Wei; Hu, Zhong Qing; Xu, Can Da] Xiaoshan TCM Hosp, Dept Orthoped, Hangzhou 311201, Zhejiang, Peoples R China.
   [Li, Guo Song] Xiaoshan TCM Hosp, Dept Anesthesiol, 156 Yucai Rd, Hangzhou 311201, Zhejiang, Peoples R China.
RP Li, GS (通讯作者)，Xiaoshan TCM Hosp, Dept Anesthesiol, 156 Yucai Rd, Hangzhou 311201, Zhejiang, Peoples R China.
EM guosonglil@126.com
FU Science and Technology Project from Traditional Chinese Medicine of
   Zhejiang Province [2015ZA174]; Social Development Major Scientific and
   Technological Projects in Xiaoshan District of Hangzhou City [2014207]
FX This study was supported by the Science and Technology Project from
   Traditional Chinese Medicine of Zhejiang Province (grant no. 2015ZA174)
   and the Social Development Major Scientific and Technological Projects
   in Xiaoshan District of Hangzhou City (grant no. 2014207).
CR Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Buehring B, 2013, J ALLERGY CLIN IMMUN, V132, P1019, DOI 10.1016/j.jaci.2013.08.040
   Cahlíková L, 2011, NAT PROD COMMUN, V6, P707
   Canu N, 2005, J NEUROCHEM, V92, P1228, DOI 10.1111/j.1471 4159.2004.02956.x
   Choo MK, 2009, BONE, V45, P579, DOI 10.1016/j.bone.2009.05.009
   Compston J, 2010, NAT REV RHEUMATOL, V6, P82, DOI 10.1038/nrrheum.2009.259
   Conradie MM, 2007, J ENDOCRINOL, V195, P229, DOI 10.1677/JOE 07 0217
   Dai WW, 2015, BONE, V74, P48, DOI 10.1016/j.bone.2015.01.001
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Fiorini C, 2013, APOPTOSIS, V18, P337, DOI 10.1007/s10495 012 0790 6
   Fukushima W, 2010, CLIN ORTHOP RELAT R, V468, P2715, DOI 10.1007/s11999 010 1292 x
   Gao L, 2008, BIOL PHARM BULL, V31, P2245, DOI 10.1248/bpb.31.2245
   Hamidouche Z, 2008, FASEB J, V22, P3813, DOI 10.1096/fj.08 106302
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037030
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Pan Z, 2016, NEUROTOX RES, V30, P453, DOI 10.1007/s12640 016 9631 7
   Pantovic A, 2013, BONE, V52, P524, DOI 10.1016/j.bone.2012.10.024
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Syrov V. N., 1992, Eksperimental'naya i Klinicheskaya Farmakologiya, V55, P61
   Wander SA, 2011, J CLIN INVEST, V121, P1231, DOI 10.1172/JCI44145
   Whittier X, 2016, RHEUM DIS CLIN N AM, V42, P177, DOI 10.1016/j.rdc.2015.08.005
   Xia XC, 2010, J BONE MINER RES, V25, P2479, DOI 10.1002/jbmr.160
   Yang YH, 2013, APOPTOSIS, V18, P1363, DOI 10.1007/s10495 013 0867 x
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910 814
   Yun SI, 2009, J BONE MINER METAB, V27, P140, DOI 10.1007/s00774 008 0019 5
   Zhu FB, 2015, INT J CLIN EXP MED, V8, P12337
   Zou Y, 2015, TOXICOL SCI, V147, P28, DOI [10.1093/toxsci/kfv111, 10.1093/toxsci/kfv1]
NR 32
TC 32
Z9 37
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JAN
PY 2018
VL 17
IS 1
BP 158
EP 164
DI 10.3892/mmr.2017.7840
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FT8WG
UT WOS:000423433300019
PM 29115419
OA Green Submitted, Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Isahaya, E
   Hara, N
   Nishiyama, T
   Hoshii, T
   Takizawa, I
   Takahashi, K
AF Isahaya, Etsuko
   Hara, Noboru
   Nishiyama, Tsutomu
   Hoshii, Tatsuhiko
   Takizawa, Itsuhiro
   Takahashi, Kota
TI Bone Metabolic Disorder in Patients With Prostate Cancer Receiving
   Androgen Deprivation Therapy (ADT): Impact of ADT on the Growth
   Hormone/Insulin Like Growth Factor 1/Parathyroid Hormone Axis
SO PROSTATE
LA English
DT Article
DE androgen deprivation therapy; insulin like growth factor 1; bone
   metabolism
ID FACTOR I; MEN; AGONISTS; SERUM; RISK; FRACTURE; CELLS
AB BACKGROUND. Although androgen deprivation therapy (ADT) has been associated with bone loss in patients with prostate cancer, its mechanism remains unclear. The growth hormone (GH)/insulin like growth factor 1 (IGF) 1/parathyroid hormone (PTH) axis plays a critical role in bone synthesis, but its activity during ADT is also unknown.
   METHODS. Seventy one patients with localized prostate cancer, who received ADT, were prospectively studied based on their bone mineral density (BMD) and blood and urine samples at the baseline and after ADT for 6 months.
   RESULTS. The IGF 1 level was correlated with BMD before ADT (rs = 0.325, P = 0.007), but such a relationship disappeared after ADT (P = 0.565). Following ADT, the serum IGF 1 level increased compared with that at the baseline (22 +/  6 nmol/L vs. 19 +/  5 nmol/L, respectively, P < 0.001). The serum PTH level was reduced after ADT (41 +/  33 ng/L) compared with the baseline (55 +/  44 ng/L) (P < 0.001), but no change was observed in the serum GH level (P = 0.691). Bone resorption markers such as blood N telopeptide (NTx), urinary NTx, calcium, and inorganic phosphorus levels increased after ADT (P < 0.001 in all). The ratio of the IGF 1 level after ADT/before ADT was associated with the ratio of the value after ADT/before ADT of alkaline phosphatase (rs = 0.266, P = 0.025) and calcium (rs = 0.242, P = 0.042).
   CONCLUSION. Despite the unaffected GH and upregulated bone resorption, the serum IGF 1 level was elevated by ADT. The IGF 1 level was correlated with BMD before ADT, but the relationship was disrupted after ADT. IGF 1 or its receptor in the bone may be functionally inactivated during ADT. Prostate 70: 155 161, 2070. (C) 2009 Wiley Liss, Inc.
C1 [Isahaya, Etsuko; Hara, Noboru; Nishiyama, Tsutomu; Hoshii, Tatsuhiko; Takizawa, Itsuhiro; Takahashi, Kota] Niigata Univ, Div Urol, Dept Regenerat & Transplant Med, Grad Sch Med & Dent Sci, Niigata, Japan.
   [Hara, Noboru] Niigata Univ, Div Mol Oncol, Dept Signal Transduct Res, Grad Sch Med & Dent Sci, Niigata, Japan.
C3 Niigata University; Niigata University
RP Hara, N (通讯作者)，Asahimachi 1, Niigata 9518510, Japan.
EM harasho@med.niigata u.ac.jp
CR Agnusdei D, 2005, J Endocrinol Invest, V28, P32
   Anawalt BD, 2001, ENDOCRIN METAB CLIN, V30, P647, DOI 10.1016/S0889 8529(05)70206 1
   DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv 10 1 68
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   Greenspan SL, 2005, J CLIN ENDOCR METAB, V90, P6410, DOI 10.1210/jc.2005 0183
   Greenspan SL, 2007, ANN INTERN MED, V146, P416, DOI 10.7326/0003 4819 146 6 200703200 00006
   Gutiérrez S, 2007, CELL TISSUE RES, V327, P121, DOI 10.1007/s00441 006 0283 4
   Higano CS, 2004, UROL CLIN N AM, V31, P331, DOI 10.1016/j.ucl.2004.01.001
   Huang YS, 1998, J ENDOCRINOL, V159, P43, DOI 10.1677/joe.0.1590043
   Janssen JAMJL, 2004, J CLIN ENDOCR METAB, V89, P4391, DOI 10.1210/jc.2004 0232
   Kamel HK, 2005, DRUG AGING, V22, P741, DOI 10.2165/00002512 200522090 00003
   Léger J, 2007, EUR J ENDOCRINOL, V157, P685, DOI 10.1530/EJE 07 0402
   Michaelson MD, 2008, CA CANCER J CLIN, V58, P196, DOI 10.3322/CA.2008.0002
   Nishiyama T, 2005, J CLIN ENDOCR METAB, V90, P657, DOI 10.1210/jc.2004 1611
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Smith MR, 2005, J CLIN ONCOL, V23, P7897, DOI 10.1200/JCO.2004.00.6908
   Smith MR, 2001, NEW ENGL J MED, V345, P948, DOI 10.1056/NEJMoa010845
   Sommers Marilyn Sawyer, 2005, J Forensic Nurs, V1, P28
   Stoch SA, 2001, J CLIN ENDOCR METAB, V86, P2787, DOI 10.1210/jc.86.6.2787
   Thorner MO, 1999, J CLIN ENDOCR METAB, V84, P2098, DOI 10.1210/jc.84.6.2098
   Townsend MF, 1997, CANCER, V79, P545, DOI 10.1002/(SICI)1097 0142(19970201)79:3<545::AID CNCR17>3.0.CO;2 3
   Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003 0003
NR 22
TC 10
Z9 11
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0270 4137
EI 1097 0045
J9 PROSTATE
JI Prostate
PD FEB 1
PY 2010
VL 70
IS 2
BP 155
EP 161
DI 10.1002/pros.21047
PG 7
WC Endocrinology & Metabolism; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Urology & Nephrology
GA 550ZJ
UT WOS:000274173500006
PM 19760629
DA 2025 08 17
ER

PT J
AU Curtis, JR
   Xi, J
   Westfall, AO
   Cheng, H
   Lyles, K
   Saag, KG
   Delzell, E
AF Curtis, Jeffrey R.
   Xi, Juan
   Westfall, Andrew O.
   Cheng, Hong
   Lyles, Kenneth
   Saag, Kenneth G.
   Delzell, Elizabeth
TI Improving the Prediction of Medication Compliance The Example of
   Bisphosphonates for Osteoporosis
SO MEDICAL CARE
LA English
DT Article
DE bisphosphonate; adherence; compliance; osteoporosis
ID POSTMENOPAUSAL OSTEOPOROSIS; INSTRUMENTAL VARIABLES; CLINICAL PRACTICE;
   ADHERENCE; PERSISTENCE; THERAPY; ALENDRONATE; WOMEN; DETERMINANTS;
   HYPERTENSION
AB Introduction: Administrative claims data have a limited ability to identify persons with high compliance to oral bisphosphonates. We tested whether adding information on compliance with other drugs used to treat chronic, asymptomatic conditions would improve the predictive ability of administrative data to identify adherent individuals.
   Methods: Using data from a large, US healthcare organization, we identified new bisphosphonate users and their 1 year compliance to oral bisphosphonates, quantified by the Medication Possession Ratio (MPR). Multivariable logistic regression models evaluated the relationship between high bisphosphonate compliance (MPR >= 80%) and patient demographics, comorbidities, and health services utilization. To these logistic regression models, we evaluated the incremental change in the area under the receiver operator curve (AUC) after adding information regarding compliance with other drug classes. These included antihyperlipidemics (statins), antihypertensives, antidepressants, oral diabetes agents, and glaucoma medications. Results from the logistic regression models were evaluated in parallel using recursive partitioning trees with 10 fold cross validation.
   Results: Among 101,038 new bisphosphonate users, administrative data identified numerous nonmedication factors (eg, age, gender, use of preventive services) significantly associated with high bisphosphonate compliance at I year. However, all these factors in aggregate had low discriminant ability to identify persons highly adherent with bisphosphonates (AUC = 0.62). For persons who were new users of >= 1 of the other asymptomatic condition drugs, MPR data on the other drugs substantially improved the prediction of high bisphosphonate compliance. The impact on prediction was largest for concomitant statin users (AUC = 0.70).
   Conclusions: Information on compliance with drugs used to treat chronic asymptomatic conditions improves the prediction of compliance with oral bisphosphonates. This information may help identify persons who should receive targeted interventions to promote compliance to osteoporosis medications.
C1 [Curtis, Jeffrey R.] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, CERTs, Birmingham, AL 35294 USA.
   [Curtis, Jeffrey R.; Saag, Kenneth G.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
   [Westfall, Andrew O.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
   [Cheng, Hong; Saag, Kenneth G.; Delzell, Elizabeth] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA.
   [Lyles, Kenneth] Duke Univ, Dept Med, Durham, NC USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham; Duke
   University
RP Curtis, JR (通讯作者)，Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, CERTs, UAB FOT 840,510 20th St S, Birmingham, AL 35294 USA.
EM jcurtis@uab.edu
RI Xi, Juan/KFR 3679 2024; Curtis, Jeffrey/I 6723 2015
OI Westfall, Andrew/0000 0002 0468 4695; Curtis, Jeffrey
   R/0000 0002 8907 8976
FU Pharma Foundation Research Grant in Health Outcomes and Novartis
   Pharmaceuticals; National Institutes of Health [AR053351, AR052361];
   Arthritis Foundation
FX This project was funded by a Pharma Foundation Research Grant in Health
   Outcomes and Novartis Pharmaceuticals. Some of the investigators
   (J.R.C., K.G.S.) also receive support from the National Institutes of
   Health (AR053351, AR052361) and the Arthritis Foundation (J.R.C.). The
   authors independently developed the analysis plan, extracted the data,
   conducted the analysis, and interpreted the results.
CR Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629
   Beest FJAPV, 2008, OSTEOPOROSIS INT, V19, P511, DOI 10.1007/s00198 007 0466 1
   Briesacher BA, 2008, PHARMACOTHERAPY, V28, P437, DOI 10.1592/phco.28.4.437
   Brookhart MA, 2007, AM J EPIDEMIOL, V166, P348, DOI 10.1093/aje/kwm070
   Brookhart MA, 2007, ARCH INTERN MED, V167, P847, DOI 10.1001/archinte.167.8.847
   Caro JJ, 1999, CAN MED ASSOC J, V160, P31
   Clowes JA, 2004, J CLIN ENDOCR METAB, V89, P1117, DOI 10.1210/jc.2003 030501
   Curtis JR, 2006, OSTEOPOROSIS INT, V17, P1268, DOI 10.1007/s00198 006 0136 8
   Curtis JR, 2008, J BONE MINER RES, V23, P1435, DOI 10.1359/JBMR.080418
   Delmas PD, 2007, J CLIN ENDOCR METAB, V92, P1296, DOI 10.1210/jc.2006 1526
   DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895 4356(92)90133 8
   Gibson TB, 2006, AM J MANAG CARE, V12, P509
   Gold Deborah T, 2006, Curr Osteoporos Rep, V4, P21, DOI 10.1007/s11914 006 0011 8
   Greenland S, 2000, INT J EPIDEMIOL, V29, P722, DOI 10.1093/ije/29.4.722
   Hosmer J.W., 2000, APPL LOGISTIC REGRES
   Huybrechts KF, 2006, BONE, V38, P922, DOI 10.1016/j.bone.2005.10.022
   LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284
   Lo JC, 2006, OSTEOPOROSIS INT, V17, P922, DOI 10.1007/s00198 006 0085 2
   MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650 198601000 00007
   Parris ES, 2005, DIABETES CARE, V28, P595, DOI 10.2337/diacare.28.3.595
   Penning van Beest FJA, 2006, CLIN THER, V28, P236, DOI 10.1016/j.clinthera.2006.01.002
   Perreault S, 2005, ANN PHARMACOTHER, V39, P1401, DOI 10.1345/aph.1E548
   Rizzo JA, 1997, CLIN THER, V19, P1446, DOI 10.1016/S0149 2918(97)80018 5
   Rossini M, 2006, OSTEOPOROSIS INT, V17, P914, DOI 10.1007/s00198 006 0073 6
   Sikka R, 2005, AM J MANAG CARE, V11, P453
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   Solomon DH, 2005, ARCH INTERN MED, V165, P2414, DOI 10.1001/archinte.165.20.2414
   Turbi C, 2004, CLIN THER, V26, P245, DOI 10.1016/S0149 2918(04)90023 9
   Weycker D, 2006, OSTEOPOROSIS INT, V17, P1645, DOI 10.1007/s00198 006 0179 x
NR 29
TC 78
Z9 84
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7079
EI 1537 1948
J9 MED CARE
JI Med. Care
PD MAR
PY 2009
VL 47
IS 3
BP 334
EP 341
DI 10.1097/MLR.0b013e31818afa1c
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 412VT
UT WOS:000263753000010
PM 19194337
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Li, YM
   Tang, L
AF Li, Yongming
   Tang, Lin
TI Local delivery of osteoprotegerin may be a way of reinforcing
   orthodontic anchorage
SO MEDICAL HYPOTHESES
LA English
DT Article
ID KAPPA B LIGAND; RECEPTOR ACTIVATOR; BONE RESORPTION; RANKL; MICE
AB One of the most challenging problems in orthodontics is anchorage. The traditional mechanical methods of reinforcing anchorage are limited by multiple factors, but a pharmacological approach aimed at utilizing the known biological mechanisms underlying tooth movement may provide an ideal way of reinforcing orthodontic anchorage. So we make the hypotheses that if the resorptive process of modeling during tooth movement can be inhibited, tooth movement may be inhibited as well. Since osteoprotegerin (OPG) has been found to be a key factor in the inhibition of osteoclast differentiation and activation, and involved in mechano modulation of bone modeling, its local delivery adjacent to the anchorage teeth may provide a novel pharmacological approach for preventing unneeded tooth movement that is highly desirable for reinforcing orthodontic anchorage. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Li, Yongming; Tang, Lin] Fourth Mil Med Univ, Dept Orthodont, Xian 710032, Shaanxi Prov, Peoples R China.
C3 Air Force Medical University
RP Li, YM (通讯作者)，Fourth Mil Med Univ, Dept Orthodont, 145 Changle Xi Rd, Xian 710032, Shaanxi Prov, Peoples R China.
EM liyongming@fmmu.edu.cn
CR Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Capparelli C, 2003, J BONE MINER RES, V18, P852, DOI 10.1359/jbmr.2003.18.5.852
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Kostenuik PJ, 2004, BONE, V34, P656, DOI 10.1016/j.bone.2003.12.006
   Morony S, 1999, J BONE MINER RES, V14, P1478, DOI 10.1359/jbmr.1999.14.9.1478
   Schett G, 2003, ARTHRITIS RHEUM, V48, P2042, DOI 10.1002/art.11150
   Shiotani A, 2001, J ELECTRON MICROSC, V50, P365, DOI 10.1093/jmicro/50.4.365
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   Tang L, 2006, BIOCHEM BIOPH RES CO, V344, P122, DOI 10.1016/j.bbrc.2006.03.123
   Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763
NR 12
TC 3
Z9 4
U1 0
U2 3
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306 9877
J9 MED HYPOTHESES
JI Med. Hypotheses
PD FEB
PY 2009
VL 72
IS 2
BP 178
EP 179
DI 10.1016/j.mehy.2008.09.022
PG 2
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 398KH
UT WOS:000262730500020
PM 18951727
DA 2025 08 17
ER

PT J
AU Hirata, W
   Itatani, Y
   Masui, H
   Kawada, K
   Mizuno, R
   Yamamoto, T
   Okamoto, T
   Ogawa, R
   Inamoto, S
   Maekawa, H
   Okamura, R
   Kiyasu, Y
   Hanada, K
   Okamoto, M
   Nishikawa, Y
   Sugimoto, N
   Tamura, T
   Hatano, E
   Sakai, Y
   Obama, K
AF Hirata, Wataru
   Itatani, Yoshiro
   Masui, Hideyuki
   Kawada, Kenji
   Mizuno, Rei
   Yamamoto, Takamasa
   Okamoto, Takuya
   Ogawa, Ryotaro
   Inamoto, Susumu
   Maekawa, Hisatsugu
   Okamura, Ryosuke
   Kiyasu, Yoshiyuki
   Hanada, Keita
   Okamoto, Michio
   Nishikawa, Yasuyo
   Sugimoto, Naoko
   Tamura, Takuya
   Hatano, Etsuro
   Sakai, Yoshiharu
   Obama, Kazutaka
TI Downregulation of osteoprotegerin in colorectal cancer cells promotes
   liver metastasis via activating tumor associated macrophage
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; EXPRESSION; SMAD4; OPG;
   ACCUMULATION; THP 1
AB Osteoprotegerin (OPG) is a secreted cytokine that functions as a decoy receptor for receptor activator of nuclear factor kappa B (RANK) ligand (RANKL). Anti RANKL treatment for bone metastasis has been widely accepted for solid tumors. However, the mechanism of OPG RANKL RANK signaling in systemic colorectal cancer (CRC) metastasis remains unclear. In this study, we investigated the relevance and function of OPG expression in CRC liver metastasis. First, we performed in silico analysis using The Cancer Genome Atlas public database and found that lower OPG expression in CRC was associated with poor overall survival. Immunohistochemistry analyses using resected specimen from patients with CRC in our institute confirmed the result. Patient matched primary CRC and liver metastases showed a significant downregulation of OPG expression in metastatic lesions. In CRC cell lines, OPG expression did not suppress cell proliferation and migration. However, OPG expression inhibited macrophage migration by suppressing the RANKL RANK pathway. Moreover, in vivo mouse liver metastasis models showed that OPG expression in CRC cells suppressed liver metastases. In addition, treatment with an anti RANKL neutralizing antibody also suppressed liver metastases. These results showed that downregulation of OPG expression in CRC cells promotes liver metastasis by activating tumor associated macrophage, which can become a candidate for targeted therapy with anti RANKL neutralizing antibody for CRC liver metastasis.
C1 [Hirata, Wataru; Itatani, Yoshiro; Masui, Hideyuki; Kawada, Kenji; Mizuno, Rei; Yamamoto, Takamasa; Okamoto, Takuya; Ogawa, Ryotaro; Maekawa, Hisatsugu; Okamura, Ryosuke; Kiyasu, Yoshiyuki; Hanada, Keita; Okamoto, Michio; Nishikawa, Yasuyo; Sugimoto, Naoko; Tamura, Takuya; Hatano, Etsuro; Sakai, Yoshiharu; Obama, Kazutaka] Kyoto Univ, Grad Sch Med, Dept Surg, 54 Shogoin Kawaharacho,Sakyo ku, Kyoto 6068507, Japan.
   [Kawada, Kenji] Kurashiki Cent Hosp, Dept Surg, Okayama 7108602, Japan.
   [Mizuno, Rei] NHO Kyoto Med Ctr, Dept Surg, Kyoto 6110041, Japan.
   [Inamoto, Susumu; Sakai, Yoshiharu] Japanese Red Cross Osaka Hosp, Dept Surg, Osaka 5438555, Japan.
   [Kiyasu, Yoshiyuki] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA.
C3 Kyoto University; Kurashiki Central Hospital; University of Michigan
   System; University of Michigan
RP Itatani, Y (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Surg, 54 Shogoin Kawaharacho,Sakyo ku, Kyoto 6068507, Japan.
EM itatani@kuhp.kyoto u.ac.jp
RI Kiyasu, Yoshiyuki/MGV 1571 2025; Maekawa, Hisatsugu/MSW 9355 2025;
   Okamoto, Michio/MEO 9630 2025; Hatano, Etsuro/AAX 2407 2020; OBAMA,
   KAZUTAKA/AAW 8263 2021; Kawada, Kenji/AFO 5018 2022
OI Masui, Hideyuki/0000 0002 0771 540X; 
FU JSPS KAKENHI; Center for Anatomical, Pathological and Forensic Medical
   Research
FX We thank the Center for Anatomical, Pathological and Forensic Medical
   Research, Graduate School of Medicine, Kyoto University for preparing
   microscope slides. We also thank Naoya Fujita for providing MC38 cell
   line. We thank Editage (www.editage.com) for English language editing.
CR Ahern E, 2018, NAT REV CLIN ONCOL, V15, P676, DOI 10.1038/s41571 018 0095 y
   [Anonymous], About us
   Augestad KM, 2015, CANCER EPIDEMIOL, V39, P734, DOI 10.1016/j.canep.2015.07.009
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Corey E, 2005, CANCER RES, V65, P1710, DOI 10.1158/0008 5472.CAN 04 2033
   Fujimura T, 2015, J INVEST DERMATOL, V135, P2884, DOI 10.1038/jid.2015.209
   Genin M, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1546 9
   Gómez Aleza C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 20138 8
   Gong B, 2019, J EXP MED, V216, P982, DOI 10.1084/jem.20180870
   Gyori DS, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00507
   Holen I, 2005, BREAST CANCER RES TR, V92, P207, DOI 10.1007/s10549 005 2419 8
   Inamoto S, 2016, CLIN CANCER RES, V22, P492, DOI 10.1158/1078 0432.CCR 15 0726
   Itatani Y, 2020, P NATL ACAD SCI USA, V117, P21598, DOI 10.1073/pnas.2008112117
   Itatani Y, 2013, GASTROENTEROLOGY, V145, P1064, DOI 10.1053/j.gastro.2013.07.033
   Jimenez Duran G, 2020, EBIOMEDICINE, V61, DOI 10.1016/j.ebiom.2020.103039
   Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626
   Kim HS, 2016, ONCOTARGET, V7, P15187, DOI 10.18632/oncotarget.7885
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Li DQ, 2022, CANCER RES, V82, P3321, DOI 10.1158/0008 5472.CAN 22 0507
   Li LW, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1435250
   Lian GH, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819849068
   Liang Q, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03642 7
   Lu TY, 2009, J CELL BIOCHEM, V108, P315, DOI 10.1002/jcb.22256
   Moon A, 2016, ONCOTARGET, V7, P79305, DOI 10.18632/oncotarget.12686
   Neamatallah Thikryat, 2019, J Microsc Ultrastruct, V7, P53, DOI 10.4103/JMAU.JMAU_68_18
   Palafox M, 2012, CANCER RES, V72, P2879, DOI 10.1158/0008 5472.CAN 12 0044
   Park EK, 2007, INFLAMM RES, V56, P45, DOI 10.1007/s00011 007 6115 5
   Park JH, 2017, MOL CELLS, V40, P706
   Peddi P, 2013, CANCER TREAT REV, V39, P97, DOI 10.1016/j.ctrv.2012.07.002
   Renema N, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160150
   Sandra F, 2006, ORAL ONCOL, V42, P415, DOI 10.1016/j.oraloncology.2005.09.009
   Schneeweis LA, 2005, J BIOL CHEM, V280, P41155, DOI 10.1074/jbc.M506366200
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385
   Stokes RW, 1999, CELL IMMUNOL, V197, P1, DOI 10.1006/cimm.1999.1554
   Sun F, 2021, METHODS MOL BIOL, V2366, P213, DOI 10.1007/978 1 0716 1669 7_13
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Tsukamoto S, 2011, CLIN CANCER RES, V17, P2444, DOI 10.1158/1078 0432.CCR 10 2884
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wan X, 2020, CLIN TRANSL MED, V9, DOI 10.1186/s40169 019 0249 2
   Weichhaus M, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0390 5
   Xenabrowser, About Us
   Yamamoto T, 2017, CLIN CANCER RES, V23, P833, DOI 10.1158/1078 0432.CCR 16 0520
   Zang LY, 2015, SCI REP UK, V5, DOI 10.1038/srep18324
NR 44
TC 1
Z9 1
U1 0
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD DEC 14
PY 2023
VL 13
IS 1
AR 22217
DI 10.1038/s41598 023 49312 w
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CL2L3
UT WOS:001125340600065
PM 38097649
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kirkpatrick, JE
   Kirkwood, KL
   Woster, PM
AF Kirkpatrick, Joy E.
   Kirkwood, Keith L.
   Woster, Patrick M.
TI Inhibition of the histone demethylase KDM4B leads to activation of
   KDM1A, attenuates bacterial induced pro inflammatory cytokine release,
   and reduces osteoclastogenesis
SO EPIGENETICS
LA English
DT Article
DE Periodontitis; periodontal disease; KDM4B; JMJD2B; KDM1A; H3K9;
   inflammation; immunity
ID AGGREGATIBACTER ACTINOMYCETEMCOMITANS; GENE EXPRESSION; BONE LOSS;
   PERIODONTITIS; METHYLATION; CELLS; DIFFERENTIATION; TRIMETHYLATION;
   TRANSCRIPTION; MACROPHAGES
AB Periodontal disease (PD) afflicts 46% of Americans with no effective adjunctive therapies available. While most pharmacotherapy for PD targets bacteria, the host immune response is responsible for driving tissue damage and bone loss in severe disease. Herein, we establish that the histone demethylase KDM4B is a potential drug target for the treatment of PD. Immunohistochemical staining of diseased periodontal epithelium revealed an increased abundance of KDM4B that correlates with inflammation. In murine calvarial sections exposed to Aggregatibacter actinomycetemcomitans lipopolysaccharide (Aa LPS), immunohistochemical staining revealed a significant increase in KDM4B protein expression. The 8 hydroxyquinoline ML324 is known to inhibit the related demethylase KDM4E in vitro, but has not been evaluated against any other targets. Our studies indicate that ML324 also inhibits KDM4B (IC50: 4.9 M), and decreases the pro inflammatory cytokine response to an Aa LPS challenge in vitro. Our results suggest that KDM4B inhibition induced immunosuppression works indirectly, requiring new protein synthesis. In addition, fluorescence stained macrophages exhibited a significant decrease in global monomethyl histone 3 lysine 4 (H3K4me) levels following an Aa LPS challenge that was prevented by KDM4B inhibition, suggesting this effect is produced through KDM1A mediated demethylation of H3K4. Finally, ML324 inhibition of KDM4B in osteoclast progenitors produced a significant reduction in Aa LPS induced osteoclastogenesis. These data link histone methylation with host immune response to bacterial pathogens in PD, and suggest a previously unreported, alternative mechanism for epigenetic control of the host inflammatory environment. As such, KDM4B represents a new therapeutic target for treating hyper inflammatory diseases that result in bone destruction.
C1 [Kirkpatrick, Joy E.; Woster, Patrick M.] Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
   [Kirkwood, Keith L.] Univ Buffalo, Dept Oral Biol, Buffalo, NY USA.
C3 Medical University of South Carolina; State University of New York
   (SUNY) System; University at Buffalo, SUNY
RP Woster, PM (通讯作者)，Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
EM woster@musc.edu
RI ; Woster, Patrick/A 5604 2010; Kirkwood, Keith/L 4728 2018; Gerasco,
   Joy/JCE 8689 2023
OI Kirkwood, Keith/0000 0003 4519 8973; Woster,
   Patrick/0000 0002 9471 1916; 
FU South Carolina Clinical & Translational Research (SCTR) Institute; NIH  
   NCATS [TL1 TR001451, UL1 TR001450]; NIH [R01 DE021423, F30 DE027290, RO1
   CA149095]; Medical University of South Carolina
FX This project was supported by the South Carolina Clinical &
   Translational Research (SCTR) Institute, with an academic home at the
   Medical University of South Carolina, NIH   NCATS Grant Number [UL1
   TR001450]; and NIH   NCATS Grant number [TL1 TR001451]; Additional
   support was received from NIH grant numbers [R01 DE021423]; (KLK), [F30
   DE027290]; (JEK), and [RO1 CA149095]; (PMW).
CR Berghaus LJ, 2010, COMP IMMUNOL MICROB, V33, P443, DOI 10.1016/j.cimid.2009.07.001
   Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008 5472.CAN 12 4300
   Binda O, 2010, EPIGENETICS US, V5, P767, DOI 10.4161/epi.5.8.13278
   Choi JY, 2017, SCI REP UK, V7, DOI 10.1038/srep45005
   Dunmyer J, 2012, MOL ORAL MICROBIOL, V27, P397, DOI 10.1111/j.2041 1014.2012.00656.x
   Eke PI, 2012, J DENT RES, V91, P914, DOI 10.1177/0022034512457373
   Eke PI, 2015, J PERIODONTOL, V86, P611, DOI 10.1902/jop.2015.140520
   El Gazzar M, 2008, J BIOL CHEM, V283, P32198, DOI 10.1074/jbc.M803446200
   Fu X, 2015, ANAT REC, V298, P1431, DOI 10.1002/ar.23172
   G Kawamura A Rai, 2012, PROBE REPORTS NIH MO
   Ginder GD, 2015, TRANSL RES, V165, P115, DOI 10.1016/j.trsl.2014.05.002
   Gottesfeld JM, 2009, FUTUR NEUROL, V4, P775, DOI 10.2217/FNL.09.55
   Hachiya R, 2016, SCI REP UK, V6, DOI 10.1038/srep28845
   Herbert BA, 2016, MOL ORAL MICROBIOL, V31, P207, DOI 10.1111/omi.12119
   Herbert BA, 2016, INFECT IMMUN, V17, P2016
   Herbert BA, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00552 16
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Janzer A, 2012, BIOCHEM BIOPH RES CO, V421, P665, DOI 10.1016/j.bbrc.2012.04.057
   Kim TW, 2016, ONCOTARGET, V7, P4195, DOI 10.18632/oncotarget.6549
   Krayer Joe W, 2010, Dent Clin North Am, V54, P13, DOI 10.1016/j.cden.2009.08.010
   Labbé RM, 2014, AM J TRANSL RES, V6, P1
   Lakowski B, 2006, J MOL NEUROSCI, V29, P227, DOI 10.1385/JMN:29:3:227
   Li MF, 2016, J INTERF CYTOK RES, V36, P48, DOI 10.1089/jir.2014.0172
   Liang Y, 2013, MBIO, V4, DOI 10.1128/mBio.00558 12
   LOE H, 1967, J PERIODONTOL, V38, P610, DOI 10.1902/jop.1967.38.6.610
   Meng S, 2014, J DENT RES, V93, P657, DOI 10.1177/0022034514534261
   Mishra M, 2014, FREE RADICAL BIO MED, V75, P129, DOI 10.1016/j.freeradbiomed.2014.07.001
   Madeira MFM, 2012, MICROBES INFECT, V14, P198, DOI 10.1016/j.micinf.2011.09.005
   Noh MK, 2013, EXP THER MED, V6, P847, DOI 10.3892/etm.2013.1222
   Pachaiyappan B, 2014, BIOORG MED CHEM LETT, V24, P21, DOI 10.1016/j.bmcl.2013.11.001
   Pan DN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066294
   Papadopoulos G, 2013, J IMMUNOL, V190, P1148, DOI 10.4049/jimmunol.1202511
   Park SR, 2014, INFECT IMMUN, V82, P1914, DOI 10.1128/IAI.01226 13
   Ponnaluri VKC, 2009, BIOCHEM BIOPH RES CO, V390, P280, DOI 10.1016/j.bbrc.2009.09.107
   Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108
   Shi LH, 2013, NAT MED, V19, P291, DOI 10.1038/nm.3101
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Silva N, 2015, J APPL ORAL SCI, V23, P329
   Su ZL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13387
   Valerio MS, 2017, J PERIODONTAL RES, V52, P377, DOI 10.1111/jre.12401
   Valerio MS, 2015, CYTOKINE, V71, P71, DOI 10.1016/j.cyto.2014.08.007
   Vazquez D, 1974, FEBS LETT, V40, pS48
   Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Woster PM, 2017, COMPREHENSIVE MEDICINAL CHEMISTRY III, VOL 2: DRUG DISCOVERY TECHNOLOGIES, P297, DOI 10.1016/B978 0 12 409547 2.12325 X
   Xu GL, 2015, J BIOL CHEM, V290, P5414, DOI 10.1074/jbc.M114.610345
   Yang IV, 2015, TRANSL RES, V165, P48, DOI 10.1016/j.trsl.2014.03.011
   Yates A, 2016, NUCLEIC ACIDS RES, V44, pD710, DOI 10.1093/nar/gkv1157
   Ye L, 2012, CELL STEM CELL, V11, P50, DOI 10.1016/j.stem.2012.04.009
   Zhang X., 2008, CURR PROTOC IMMUNOL, VChapter 14, pUnit 14.1
   Zhang XY, 2014, CANCER RES, V74, P7191, DOI 10.1158/0008 5472.CAN 14 1379
NR 51
TC 27
Z9 29
U1 0
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559 2294
EI 1559 2308
J9 EPIGENETICS US
JI Epigenetics
PY 2018
VL 13
IS 5
BP 557
EP 572
DI 10.1080/15592294.2018.1481703
PG 16
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA GS7GF
UT WOS:000443868300007
PM 29927684
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Takai, H
   Nakayama, Y
   Kim, DS
   Arai, M
   Arakiil, S
   Mezawa, M
   Nakajima, Y
   Kato, N
   Masunaga, H
   Ogata, Y
AF Takai, Hideki
   Nakayama, Youhei
   Kim, Dong Soon
   Arai, Masato
   Arakiil, Shouta
   Mezawa, Masaru
   Nakajima, Yu
   Kato, Naoko
   Masunaga, Hiroshi
   Ogata, Yorimasa
TI Androgen receptor stimulates bone sialoprotein (BSP) gene transcription
   via cAMP response element and activator protein 1/Glucocorticoid
   response elements
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE androgen; androgen receptor; bone sialoprotein; cAMP response element;
   activator protein 1; osteoblasts; transcription
ID INVERTED CCAAT BOX; TESTOSTERONE THERAPY; PROXIMAL PROMOTER; HYPOGONADAL
   MEN; MINERAL DENSITY; TATA BOX; EXPRESSION; IDENTIFICATION; CELLS;
   FIBROBLAST GROWTH FACTOR 2
AB Bone sialoprotein (BSP) is an early marker of osteoblast differentiation. Androgens are steroid hormones that are essential for skeletal development. The androgen receptor (AR) is a transcription factor and a member of the steroid receptor superfamily that plays an important role in male sexual differentiation and prostate cell proliferation. To determine the molecular mechanism involved in the stimulation of bone formation, we have analyzed the effects of androgens and AR effects on BSP gene transcription. AR protein levels were increased after AR overexpression in ROS17/ 2.8 cells. BSP mRNA levels were increased by AR overexpression. However, the endogenous and overexpressed BSP mRNA levels were not changed by DHT (10( 8) M, 24 h). Whereas luciferase (LUC) activities in all constructs, including a short construct (nts  116 to +60), were increased by AR overexpression, the basal and LUC activities enhanced by Ak overexpression were not induced by DHT(10( 8)M, 24 h). The effect of AR overexpression was abrogated by 2 bp mutations in either the cAMP response element (CRE) or activator protein 1 (AP1)/glucocorticoid response element (GRE). Gel shift analyses showed that AR overexpression increased binding to the CRE and AP1/GRE elements. Notably, the CRE protein complexes were supershifted by phospho CREB antibody, and CREB, c Fos, c Jun, and AR antibodies disrupted the complexes formation. The AP1/GRE protein complexes were supershifted by c Fos antibody and c Jun, and AR antibodies disrupted the complexes formation. These studies demonstrate that AR stimulates BSP gene transcription by targeting the CRE and AP1/GRE elements in the promoter of the rat BSP gene. J. Cell. Biochem. 102: 240 251, 2007. (C) 2007 Wiley Liss, Inc.
C1 Nihon Univ, Sch Dent, Dept Periodontol, Chiba 2718587, Japan.
   Nihon Univ, Sch Dent, Res Inst Oral Sci, Chiba 2718587, Japan.
C3 Nihon University; Nihon University
RP Ogata, Y (通讯作者)，Nihon Univ, Sch Dent, Dept Periodontol, Chiba 2718587, Japan.
EM ogata.yorimasa@nihon u.ac.jp
RI Kato, Naoko/B 9416 2016
CR Abu EO, 1997, J CLIN ENDOCR METAB, V82, P3493, DOI 10.1210/jcem.82.10.4319
   Anderson FH, 1997, J BONE MINER RES, V12, P472, DOI 10.1359/jbmr.1997.12.3.472
   BARAN DT, 1978, CALC TISS RES, V26, P103, DOI 10.1007/BF02013243
   Behre HM, 1997, J CLIN ENDOCR METAB, V82, P2386, DOI 10.1210/jc.82.8.2386
   BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995
   Benson MD, 2000, J BIOL CHEM, V275, P13907, DOI 10.1074/jbc.275.18.13907
   Benson MD, 1999, J BONE MINER RES, V14, P396, DOI 10.1359/jbmr.1999.14.3.396
   CHEN JK, 1992, J BONE MINER RES, V7, P987
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   FINKELSTEIN JS, 1992, NEW ENGL J MED, V326, P600, DOI 10.1056/NEJM199202273260904
   Ganss B, 1999, CRIT REV ORAL BIOL M, V10, P79, DOI 10.1177/10454411990100010401
   HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562
   Kang GJ, 2004, TAPPI J, V3, P19
   Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498
   Katznelson L, 1996, J CLIN ENDOCR METAB, V81, P4358, DOI 10.1210/jc.81.12.4358
   KERR JM, 1993, GENOMICS, V17, P408, DOI 10.1006/geno.1993.1340
   Kim RH, 1999, CANCER RES, V59, P565
   Kim RH, 1996, BIOCHEM J, V318, P219, DOI 10.1042/bj3180219
   KIM RH, 1994, MATRIX BIOL, V14, P31, DOI 10.1016/0945 053X(94)90027 2
   Lee DK, 2002, BIOCHEM BIOPH RES CO, V294, P408, DOI 10.1016/S0006 291X(02)00504 1
   LI JJ, 1995, BIOCHEM J, V310, P33, DOI 10.1042/bj3100033
   LI JJ, 1993, BIOCHEM J, V289, P625, DOI 10.1042/bj2890625
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092 8674(95)90199 X
   MIZUNO Y, 1994, CALCIFIED TISSUE INT, V54, P325, DOI 10.1007/BF00295958
   Nakayama Y, 2006, J CELL PHYSIOL, V208, P326, DOI 10.1002/jcp.20664
   Ogata Y, 2000, MATRIX BIOL, V19, P395, DOI 10.1016/S0945 053X(00)00085 8
   OGATA Y, 1995, EUR J BIOCHEM, V230, P183
   Ogata Y, 1997, J CELL BIOCHEM, V65, P501, DOI 10.1002/(SICI)1097 4644(19970615)65:4<501::AID JCB6>3.0.CO;2 S
   OLDBERG A, 1988, J BIOL CHEM, V263, P19430
   Ongphiphadhanakul B, 1995, CLIN ENDOCRINOL, V43, P727, DOI 10.1111/j.1365 2265.1995.tb00542.x
   ORWOLL ES, 1995, ENDOCR REV, V16, P87, DOI 10.1210/er.16.1.87
   Pak TR, 2006, ENDOCRINOLOGY, V147, P1924, DOI 10.1210/en.2005 1297
   Pak TR, 2005, ENDOCRINOLOGY, V146, P147, DOI 10.1210/en.2004 0871
   Samoto H, 2003, J BIOL CHEM, V278, P28659, DOI 10.1074/jbc.M300671200
   Samoto H, 2002, J CELL BIOCHEM, V87, P313, DOI 10.1002/jcb.10301
   Shimizu E, 2004, J CELL BIOCHEM, V91, P1183, DOI 10.1002/jcb.20002
   Shimizu E, 2005, J PERIODONTOL, V76, P1482, DOI 10.1902/jop.2005.76.9.1482
   Shimizu E, 2004, J PERIODONTOL, V75, P260, DOI 10.1902/jop.2004.75.2.260
   Shimizu E, 2002, J CELL BIOCHEM, V86, P35, DOI 10.1002/jcb.10194
   Shimizu E, 2006, BONE, V39, P42, DOI 10.1016/j.bone.2005.12.011
   Shimizu Sasaki K, 2001, J BIOL CHEM, V276, P5459, DOI 10.1074/jbc.M008971200
   Sih R, 1997, J CLIN ENDOCR METAB, V82, P1661, DOI 10.1210/jc.82.6.1661
   Vanderschueren D, 1996, HORM RES, V46, P95, DOI 10.1159/000185003
   VANDERSCHUEREN D, 1995, CALCIFIED TISSUE INT, V56, P341, DOI 10.1007/BF00301598
   Waltregny D, 2000, J BONE MINER RES, V15, P834, DOI 10.1359/jbmr.2000.15.5.834
   Wiren KM, 2004, ENDOCRINOLOGY, V145, P3507, DOI 10.1210/en.2003 1016
   Yamauchi M, 1996, MATRIX BIOL, V15, P119, DOI 10.1016/S0945 053X(96)90153 5
   Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517
NR 48
TC 19
Z9 26
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD SEP 1
PY 2007
VL 102
IS 1
BP 240
EP 251
DI 10.1002/jcb.21297
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 207PM
UT WOS:000249263100020
PM 17372929
DA 2025 08 17
ER

PT J
AU Oteri, G
   Campisi, G
   Panzarella, V
   Morreale, I
   Nucera, R
   Di Fede, O
   Picone, A
   Marcianò, A
AF Oteri, Giacomo
   Campisi, Giuseppina
   Panzarella, Vera
   Morreale, Ilaria
   Nucera, Riccardo
   Di Fede, Olga
   Picone, Antonio
   Marciano, Antonia
TI Could the Combined Administration of Bone Antiresorptive Drug, Taxanes,
   and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws
   in Cancer Patients?
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID BISPHOSPHONATE RELATED OSTEONECROSIS; METASTATIC BREAST CANCER;
   QUALITY OF LIFE; RISK FACTORS; TARGETED AGENTS; MULTICENTER;
   COMBINATION; DOCETAXEL; DENOSUMAB; DISEASE
AB The study presents a report of 58 metastatic cancer patients who developed osteonecrosis of the jaws after being treated with zoledronic acid and taxanes, plus corticosteroids. A retrospective analysis of data registered in the archives of two Italian osteonecrosis of the jaws treatment centers, who are based at the University of Messina and at the University of Palermo, was performed in order to study, in these patients, demographic data and characteristics such as frequency of cancer location, lines of therapy, frequency of cancer drugs, presence/absence of oral trigger, number, location, and stage of jaw osteonecrosis. It was found that the majority of patients developed advanced stages of osteonecrosis, frequently complicated with infection. It was hypothesized that the concurrent administration of chemotherapeutic agents could be eventually considered as a factor able to allow a faster worsening of the clinical manifestation through the exacerbation of soft tissue defects, due to chemotherapy drugs.
C1 [Oteri, Giacomo] AOU Policlin G Martino, Unit Dent, Messina, Italy.
   [Oteri, Giacomo; Nucera, Riccardo; Marciano, Antonia] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy.
   [Campisi, Giuseppina; Panzarella, Vera; Di Fede, Olga] Univ Palermo, Dept Surg Oncol & Oral Sci, Palermo, Italy.
   [Morreale, Ilaria] Univ Palermo, Azienda Osped Univ Policlin P Giaccone, Sicilian Reg Ctr Pharmacovigilance, Clin Pharmacol Unit, Palermo, Italy.
   [Picone, Antonio; Marciano, Antonia] Humanitas Ctr Catanese Oncol, Catania, Italy.
C3 University of Messina; University Messina Policlin; AOU Policlinico
   Gaetano Martino; University of Messina; University of Palermo;
   University of Palermo; Policlinico Paolo Giaccone
RP Oteri, G (通讯作者)，AOU Policlin G Martino, Unit Dent, Messina, Italy.; Oteri, G (通讯作者)，Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy.
EM giacomo.oteri@unime.it
RI ; Marcianò, Antonia/HLV 8624 2023; Nucera, Riccardo/AAQ 8644 2020;
   Panzarella, Vera/L 3162 2013; di fede, olga/K 7836 2016
OI Oteri, Giacomo/0000 0002 0941 1645; campisi,
   giuseppina/0000 0002 9443 0495; Marciano, Antonia/0000 0001 5664 3118;
   Panzarella, Vera/0000 0001 6339 6020; di fede, olga/0000 0002 5562 7420
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Alberto B, 2014, BRIT J ORAL MAX SURG, V52, P603, DOI 10.1016/j.bjoms.2014.04.009
   Ascani G, 2014, INT J DENT, V2014, DOI 10.1155/2014/565743
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Bettie NF, 2015, J PHARM BIOALLIED SC, V7, P414, DOI 10.4103/0975 7406.163473
   Bi YM, 2010, AM J PATHOL, V177, P280, DOI 10.2353/ajpath.2010.090592
   Campisi G, 2014, FUTURE ONCOL, V10, P257, DOI [10.2217/FON.13.211, 10.2217/fon.13.211]
   Christodoulou C, 2009, ONCOLOGY BASEL, V76, P209, DOI 10.1159/000201931
   Di Fede O, 2016, ORAL DIS, V22, P543, DOI 10.1111/odi.12490
   Dunstan CR, 2007, NAT CLIN PRACT ONCOL, V4, P42, DOI 10.1038/ncponc0688
   Fedele S, 2015, BRIT J ORAL MAX SURG, V53, P13, DOI 10.1016/j.bjoms.2014.09.001
   Franchina T, 2012, CANCER BIOL THER, V13, P472, DOI 10.4161/cbt.19593
   Fung PPL, 2017, ORAL DIS, V23, P477, DOI 10.1111/odi.12632
   Fusco V, 2017, SUPPORT CARE CANCER, V25, P345, DOI 10.1007/s00520 016 3147 9
   Fusco V, 2016, JNCI J NATL CANCER I, V108, DOI 10.1093/jnci/djw155
   Fusco V, 2016, EXPERT OPIN DRUG SAF, V15, P925, DOI 10.1080/14740338.2016.1177021
   Fusco V, 2015, CLIN GENITOURIN CANC, V13, P287, DOI 10.1016/j.clgc.2014.12.002
   Fusco V, 2014, SUPPORT CARE CANCER, V22, P1737, DOI 10.1007/s00520 014 2159 6
   Gasparini G, 2010, INT J IMMUNOPATH PH, V23, P619, DOI 10.1177/039463201002300224
   Gradishar WJ, 2012, BREAST CANCER BASIC, V6, P159, DOI 10.4137/BCBCR.S8205
   Grant DS, 2003, INT J CANCER, V104, P121, DOI 10.1002/ijc.10907
   Kuehn BM, 2006, JAMA J AM MED ASSOC, V295, P2833, DOI 10.1001/jama.295.24.2833
   Kyrgdis A, 2012, ANTICANCER RES, V32, P3527
   Lyseng Williamson KA, 2005, DRUGS, V65, P2513, DOI 10.2165/00003495 200565170 00007
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   McGowan K., 2017, ORAL DIS
   Miksad RA, 2011, ONCOLOGIST, V16, P121, DOI 10.1634/theoncologist.2010 0183
   Oteri G., 2017, DRUG SAFETY, P1
   Otto S, 2015, J BONE MINER RES, V30, P1113, DOI 10.1002/jbmr.2525
   Patel V, 2015, Br Dent J, V219, P203, DOI 10.1038/sj.bdj.2015.680
   Ramírez L, 2015, ORAL HLTH PREV DENT, V13, P385, DOI 10.3290/j.ohpd.a34055
   Rosella D, 2016, J INT SOC PREV COMMU, V6, P97, DOI 10.4103/2231 0762.178742
   Ruggiero Salvatore L, 2008, Dent Clin North Am, V52, P111, DOI 10.1016/j.cden.2007.09.002
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Vigarios E, 2017, SUPPORT CARE CANCER, V25, P1713, DOI 10.1007/s00520 017 3629 4
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Yoneda T, 2017, J BONE MINER METAB, V35, P6, DOI 10.1007/s00774 016 0810 7
NR 37
TC 8
Z9 8
U1 1
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2018
VL 2018
AR 4021952
DI 10.1155/2018/4021952
PG 6
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA GH6FC
UT WOS:000433537900001
PM 30003097
OA Green Submitted, hybrid, Green Published
DA 2025 08 17
ER

EF